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Susceptibility testing and detection of
resistance
P573 Comparison of ceftriaxone susceptibility rates of
Enterobacteriaceae in the TEST programme using EUCAST
vs. 2009 and 2010 CLSI breakpoints
R. Badal °, S. Bouchillon, B. Johnson, M. Hackel, M. Dowzicky
(Schaumburg, Collegeville, US)
Objective: EUCAST and CLSI have different breakpoints (bp) for
many drugs, including cephalosporins, complicating the process of
evaluating global data from surveillance studies. In 2010, CLSI will
lower susceptibility bp for several cephalosporins and aztreonam vs.
Enterobacteriaceae by as much as 2 doubling dilutions. The TEST
program has been monitoring susceptibility levels of tigecycline and
other drugs since 2004. This report evaluates the impact of the CLSI bp
change on reported susceptibility of Enterobacteriaceae to ceftriaxone
(Cax), both in Europe and globally.
Methods: 59,644 isolates of Enterobacteriaceae were tested from 2004–
2009 using broth microdilution following CLSI guidelines. Susceptibility
to Cax was compared using 2009 and 2010 CLSI (<8mcg/ml and
<1mcg/ml, respectively) and EUCAST (<1) bp.
Results: See the table.
Isolate Source BP Used % Susceptible
Enterob. E. coli K. pneumoniae K. oxytoca
ESBL+ ESBL− ESBL+ ESBL− ESBL+ ESBL−
Europe EUCAST/CLSI 2010 72 2 93 1 89 3 82
CLSI 2009 79 8 96 11 93 17 90
Rest of World EUCAST/CLSI 2010 75 2 91 2 88 6 88
CLSI 2009 82 9 94 13 92 39 94
ESBL= extended spectrum beta-lactamase.
Conclusions: Although the convergence of the EUCAST and CLSI Cax
bp in 2010 will eliminate discrepancies in susceptibility levels due to
different bp used in Europe and rest of world, analyses using CLSI will
see some large declines in %S values in some organism types (e.g.,
ESBL+ K. oxytoca). The new bp does a good job of classifying most
ESBL+ isolates as non-susceptible to Cax.
P574 Belgium goes EUCAST: critical aspects in a national move
from CLSI to EUCAST breakpoints
J. Van Eldere °, P. Melin, J. Verhaegen, K. Magerman for the
BVIKM-SBIMC EUCAST working party
Objectives: In 2008 − at a national meeting of the Belgian society
of clinical microbiology and infectious diseases (BVIKM-SBIMC) −
the members voted to switch from CLSI to EUCAST breakpoints from
the 1st of January 2010. Belgium till now had no national antibiogram
committee and almost all labs used CLSI breakpoints and methodology.
Here we report on some of the critical aspects of a wholesale nationwide
shift towards EUCAST breakpoints.
Method: the BVIKM-SBIMC decided to install a EUCAST working
party to promote and facilitate the transition from CLSI to EUCAST.
Members from the working party have had numerous meetings and
interviews with clinical microbiologists but also with antimicrobial
susceptibility testing (AST) manufacturers, drug manufacturers, ofﬁcial
organizations involved in clinical microbiology and also with clinicians.
Results:
1. A local committee to take the lead in the shift towards EUCAST
breakpoints is absolutely necessary. Although most microbiologists −
thanks to several national and local meetings − are by now aware of
EUCAST, most take a ‘wait and see’ attitude.
2. A ‘translation’ of EUCAST guidelines into ‘national’ EUCAST
guidelines is needed. The EUCAST website is not user-friendly and
most labs expect clear and practical advice on how to implement
EUCAST. In addition, speciﬁc national peculiarities still need
a local input (eg use of temocillin in Belgium for which no
EUCAST breakpoints are available). AST manufacturers and drug
manufacturers also have expressed the need for national guidance on
matters related to AST.
3. Microbiologists want advice on practical issues related to imple-
mentation of EUCAST breakpoints and in particular issues related
to quality control. In this context it is important for national
committees to seek collaboration and endorsement of all stakeholders
including the manufacturers but also national quality control and/or
accreditation agencies, reference labs, professional organizations etc.
Conclusion: Successful implementation of EUCAST breakpoints
necessitates an concerted effort. We believe that it takes a sufﬁcient
time (2 years) to prepare this shift and a substantial and sustained
communication effort to all stakeholders. To achieve this, the institution
of a national antibiogram committee is felt to be vital.
P575 EUCAST breakpoints in automated susceptibility testing:
evaluation of Vitek® 2
R. Smyth °, L. Bjelkenbrant, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: To evaluate the performance of VITEK® 2 with software
version 04.02 for susceptibility testing and SIR-category interpretation
for clinical isolates using the breakpoints developed by the European
Committee on Antimicrobial Susceptibility Testing (EUCAST).
Methods: 211 clinical isolates of known identities and susceptibility
patterns were tested in VITEK® 2 using cards AST-GP68 for
S. pneumoniae and AST-P592 for staphylococci and enterococci. The
isolates were stored strains comprising 131 staphylococci, 44 enterococci
and 37 S. pneumoniae.
SIR-category for all strains had previously been established using
the Swedish Reference Group for Antibiotics (SRGA) disc diffusion
method, calibrated to EUCAST breakpoints. Antibiotics evaluated were
cefoxitin, oxacillin, ciproﬂoxacin, clindamycin, erythromycin, fusidic
acid, gentamicin, linezolid, moxiﬂoxacin, penicillin, tetracycline and
vancomycin for the staphylococci. Ampicillin, gentamicin, imipenem,
linezolid, teicoplanin and vancomycin were evaluated for the enterococci
and cefotaxime, erythromycin, moxiﬂoxacin, penicillin and tetracycline
for the S. pneumoniae.
Reference strains Staph. aureus ATCC 29213, ATCC BAA-1026, ATCC
BAA-976, ATCC BAA-977, E. faecalis ATCC 29212, ATCC 51299 and
S. pneumoniae ATCC 49619 were included as appropriate on each day
of testing. Discordant results were resolved using Etest.
Results: Overall category agreement was obtained in 98.4% of
tests. Minor errors (mE) for 7 strains of CNS to tetracycline, three
S. pneumoniae to cefotaxime and one S. pneumoniae to moxiﬂoxacin.
One VME for S. pneumoniae to erythromycin. One strain of E. faecium
was falsely reported to be HLGR and one CNS strain falsely negative
in the test for inducible clindamycin resistance. Two strains of
S. pneumoniae failed to grow in AST-GP68 and are excluded from the
results table.
Conclusion: This ﬁrst evaluation of EUCAST breakpoints in VITEK® 2
indicates it to be a reliable tool for susceptibility testing of common
Gram positive organisms.
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Bacterial group/characteristic Total number
of strains (n)
Total number
of tests (n)
Category
agreement
(CA)
CA %
MSSA 64 768 768 100
MRSA 30 360 360 100
CNS 28 336 329 97.9
Staph. lugdunensis 9 108 108 100
ICR 10 10 9 90
E. faecalis 15 90 90 100
E. faecium 10 60 59 98.3
HLGR 9 9 9 100
VRE 10 10 10 100
Str. pneumoniae 37 148 143 96.6
PNSSP 21 21 21 100
P576 Evaluation of new ATB EU (08) panels compliant with
EUCAST guidelines
R. Martelin °, G. Zambardi, M. Albertini-Balland, E. Pillon,
M. Pompilio, J. Oliger, N. Carboni, P. Dufour (La Balme-les-Grottes, FR)
Objectives: In 2009, EUCAST breakpoints and expert rules will be
implemented through Europe to reach the unique goal of European har-
monization. As a consequence, bioMe´rieux has updated both the reagents
and software of its semi-automated antimicrobial susceptibility testing
system for being compliant with EUCAST 2008 recommendations. The
aim of this study was to determine the performances of these new panels.
Methods: To evaluate the accuracy, each of the 8 panels was tested
with a set of 64 to 120 strains. ATB G- EU (08), ATB UR EU (08)
and rapid ATB UR EU (08) were tested with Enterobacteriaceae,
ATB PSE EU (08) with non-fermentative Gram-negative bacilli, ATB
STAPH EU (08) with Staphylococci, ATB STREP EU (08) with
Enterococci, Pneumococci, b-haemolytic and other Streptococci, ATB
HAEMO EU (08) with Haemophilus and Moraxella catarrhalis, and
ATB ANA EU (08) with Anaerobes. Category agreements and error rates
were determined in comparison to the reference agar dilution method (or
Etest for Anaerobes). To evaluate the reproducibility, a minimum of 10
strains were tested 3 times on each reference and the rates of identical
interpretations were calculated.
Results: Average, minimum and maximum agreement and error
percentages respectively were as follows:
– category agreements: 93.2, 89.4 (ATB PSE EU 08) and 96.0 (ATB
STREP EU 08)
– major errors: 2.4, 1.2 (ATB HAEMO EU 08) and 3.1 (ATB UR EU
08)
– very major errors: 2.2, 0.5 (ATB STREP EU 08) and 4.6 (ATB PSE
EU 08)
The average reproducibility was 96.2%, with a minimum of 93.7% (ATB
PSE EU 08) and a maximum of 97.6% (ATB STAPH EU 08).
Conclusions: Overall performances of the new ATB EU panels are
satisfactory and are not negatively impacted by the use of the breakpoints
deﬁned by EUCAST, with few exceptions for non-fermentative species
and for Haemophilus. These new ATB panels and software will help
hospital and private laboratories to safety switch from CLSI or CA-SFM
recommendations to EUCAST.
P577 Assessment of the Phoenix system and EUCAST breakpoints
for antimicrobial susceptibility testing against contemporary
isolates expressing relevant resistance mechanisms
M.I. Morosini, M. Garcı´a-Castillo °, R. Canto´n (Madrid, ES)
Objective: To evaluate the accuracy of the PHOENIX system (BD,
USA) in combination with the EUCAST breakpoints for antimicrobial
susceptibility testing (AST) against contemporary clinical isolates
expressing relevant resistance mechanisms.
Methods: A total of 393 isolates were included: i) 200 fresh consecu-
tively recovered isolates (51 Enterobacteriaceae, EB; 40 P. aeruginosa,
PA; 30 S. aureus, SA; and 29 Enterococcus spp., E) and ii) 193 stored
(−80ºC) isolates with characterized resistance mechanism [96 extended-
spectrum-(ESBL) and 50 metalo-(MBL) b-lactamase producing EB,
10 MBL-producing PA, 20 methicillin-resistant SA, MRSA, and 17
vancomycin-resistant E, VRE]. Comparator AST results were either
routine or historical data obtained following CLSI guidelines (broth
microdilution). Discrepancies were resolved using Etest. Quality control
ATCC strains were used to assure MIC reproducibility. MBL- and
ESBL-coding genes and mecA and van determinants were conﬁrmed
by PCR and sequencing. PHOENIX performance was assessed based
on MICs concordances (essential agreement, EA, ±1 log2 dilution) and
percentage of interpretive category error rates (ER) (minor, mi; major,
M; very major, VM).
Results: An overall EA of 96% (3,283 organism-antimicrobial
combinations) and global 2.4% mi, 1.2% M and 1.1% VM errors were
observed. Among fresh isolates, EA was: 97% (97% EB; 94% PA; 98%
SA; and 98% E). Global ER in these isolates were: 0.8% mi; 0.6% M;
and 2.3% VM, being this latter value mainly due to discrepancies in
the combination gentamicin-PA. In isolates with characterized resistance
mechanisms, EA was: 95% (99% ESBL-EB; 94% MBL-EB; 100%
MBL-PA; 97% SARM; and 91% EVR) Overall ER in this subset of
isolates were: 3.5% mi; 2.0% M; and 0.8% VM. In these isolates, mi
errors were mainly due to discrepancies in ciproﬂoxacin and ESBL-EB
as well as in imipenem, meropenem and ciproﬂoxacin and MBL-EB
whereas M errors were mainly attributed to amoxicillin–clavulanic acid-
ESBL-EB discrepancies.
Conclusion: This study indicates reliable AST results of PHOENIX
system and accurate interpretive categorization when using EUCAST
breakpoints in contemporary isolates expressing relevant resistance
mechanisms. Interpretive category discrepancies were mainly due
to particular organism-antimicrobial combinations due to speciﬁc
breakpoint deﬁnition such as gentamicin and PA or heterogeneous
expression of resistance mechanisms such MBL affecting carbapenems
in EB.
P578 EUCAST disc diffusion antimicrobial susceptibility testing
method
E. Matuschek °, R. Smyth, D. Brown, G. Kahlmeter (Va¨xjo¨, SE;
Peterborough, UK)
Objective: The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) was recently tasked with developing a European
disk diffusion method calibrated to the harmonized European MIC
breakpoints. Method descriptions, quality control tables and zone
diameter breakpoints are to be developed by the end of 2009.
Methods: The method is based on Mueller-Hinton agar without supple-
ments (MH) for Enterobacteriaceae, Pseudomonas, Stenotrophomonas,
staphylococci and enterococci, and Mueller-Hinton agar with 5%
horse blood and 20mg/L b-NAD (MH-F) for Haemophilus, Moraxella
catarrhalis, Streptococcus pneumoniae, a- and b-haemolytic streptococci
and other fastidious organisms. The inoculum is McFarland 0.5 and
the plates are incubated at 35ºC for 16−20 h. MH plates are incubated
in air and MH-F in 5% CO2. Data for quality control strains and
clinical isolates was gathered during 2009 at the Swedish External
Reference Laboratory for Antimicrobial Susceptibility Testing, Va¨xjo¨
Central Hospital.
Results: For MH, the disk diffusion method was, when appropriate,
calibrated to quality control acceptable ranges established by Clinical
and Laboratory Standards Institute (CLSI). Repeated testing of a number
of antimicrobial agents resulted in reproducible results; with 64/75 mean
values targeting the mean of the CLSI range with a maximum of 1mm
difference for E. coli ATCC 25922, S. aureus ATCC 25923 and P. aerugi-
nosa ATCC 27853. There were no mean values differing more than 2mm
from the target. For reference strains and antibiotics/disks not represented
in CLSI tables, as well as for all data on MH-F, quality control ranges
were calculated from repeated testing by EUCAST on Mueller-Hinton
agar from several manufacturers. Clinical zone diameter breakpoints
were established by inhibition zone histogram analysis and by correlation
of inhibition zone diameters with corresponding MIC values.
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Conclusions: The main part of the EUCAST disk diffusion antimicrobial
susceptibility testing method is now developed and published on the
EUCAST website www.eucast.org where method descriptions, quality
control tables and clinical breakpoints are now freely available.
P579 EUCAST: validation of Mueller-Hinton agar with 5% horse
blood and 20mg/L b-NAD (MH-F) for gradient tests on
fastidious micro-organisms
C. Karlsson °, E. Matuschek, G. Kahlmeter (Va¨xjo¨, SE)
Objectives: The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) is currently developing a European standard method
for antimicrobial susceptibility testing by disk diffusion on Mueller-
Hinton agar (MH). The medium for fastidious organisms is MH
supplemented with 5% horse blood and 20mg/L b-NAD (MH-F). The
objective of this study was to validate MH-F for MIC determination
using gradient tests (Etest® and M.I.C.Evaluator™) for Haemophilus
inﬂuenzae (HI), Streptococcus pneumoniae (PN) and Streptococcus
pyogenes (GAS).
Methods: MIC values were determined using Etest® (bioMe´rieux) and
M.I.C.Evaluator™ (Oxoid) on MH-F and on media recommended by
the manufacturers; i.e. Haemophilus test medium (HTM) for HI and
MH with 5% sheep blood (MHstr) for PN and GAS. MIC determination
was repeated ten times for reference strains and ﬁve times for clinical
isolates. MIC values were read after 20 hours incubation at 35−36ºC
in 5% CO2. Susceptibility to amoxicillin–clavulanic acid, ampicillin,
ciproﬂoxacin, tetracycline and trimethoprim-sulfamethoxazole (SXT)
(Etest only) was determined for HI ATCC 49247 and HI NCTC 8468 and
benzylpenicillin, erythromycin, moxiﬂoxacin (E-test only), tetracycline
and SXT (Etest only) for PN ATCC 49619 and GAS CCUG 25571.
Additionally, for HI and PN, three clinical isolates with known resistance
and borderline MIC values for b-lactam antibiotics were tested. Etest and
M.I.C.Evaluator were validated separately.
Results: On MH-F and respective reference media for b-lactams,
ﬂuoroquinolones, erythromycin and tetracycline, identical MIC values
were obtained for 69% of Etest readings and 72% of M.I.C.Evaluator
readings, with another 31% (Etest) and 27% (M.I.C.Evaluator)
readings±one dilution respectively. Corresponding numbers for SXT
were 30% identical MIC values, 44% of readings±one dilution and 25%
differing by two dilutions. Results were easily read on both media.
Conclusion: MH-F showed excellent agreement with reference media
(HTM and MHstr) for gradient test MIC determination of HI, PN and
GAS. We recommend that the manufacturers further validate the use of
MH-F as an alternative to the currently recommended media. This will
allow the use of MH-F for both disk diffusion and gradient tests. For
SXT, further investigation is needed.
P580 MH-F: a common medium for fastidious organisms in the
EUCAST disk diffusion antimicrobial susceptibility testing
method
E. Matuschek °, D. Brown, G. Kahlmeter (Va¨xjo¨, SE; Peterborough, UK)
Objective: The European Committee on Antimicrobial Susceptibility
Testing (EUCAST) was recently tasked with developing a European disk
diffusion method. One important part of the method was to develop a
common medium for fastidious organisms, with focus on Haemophilus
inﬂuenzae (HI), Streptococcus pneumoniae (SP) and other streptococci.
Methods: Mueller-Hinton agar (MH) with different supplements was
investigated as the medium for testing HI and SP with a McFarland 0.5
inoculum and incubation at 35ºC and 5% CO2 for 16−20 h. The proposed
medium, MH with 5% horse blood and 20mg/L b-NAD (MH-F), was
then evaluated for growth of a number of fastidious organisms under the
described conditions.
Results: Supplementation of MH with 20mg/L b-NAD and 5%
horse blood resulted in good growth of SP and HI. When MH was
supplemented with sheep blood instead of horse blood, much more
b-NAD (>100mg/L) was needed for growth of HI. MH plates with
5% horse blood were further evaluated with b-NAD (purity ranging
from 95 to >99%) from seven different manufacturers. With 20mg/L
b-NAD, all products tested gave similar growth of both HI and SP. MH-F
supported good growth of a number of additional fastidious organisms
including streptococcus groups A, B, C and G, a-haemolytic streptococci
(S. anginosus, S. bovis, S. constellatus, S. gordonii, S. intermedius,
S. mitis, S. mutans, S. oralis, S. salivarius, S. sanguinis, S. vestibularis),
Moraxella catarrhalis, Haemophilus parainﬂuenzae, Aggregatibacter
aphrophilus, Pasteurella spp., Corynebacterium spp., Listeria monocyto-
genes, Arcanobacterium haemolyticum, Burkholderia cepacia, Eikenella
corrodens, Kingella kingae and Neisseria meningitidis.
Conclusions: Mueller-Hinton agar with 5% horse blood and 20mg/L
b-NAD (Mueller Hinton-Fastidious, MH-F) incubated in 5% CO2 was
chosen as the medium and atmosphere for fastidious organisms in the
EUCAST disk diffusion antimicrobial susceptibility test. Good growth
on MH-F was shown for a number of fastidious organisms. Anaerobes
and Neisseria gonorrhoeae will be further investigated.
P581 Screening for high-level aminoglycoside resistance in
enterococci. The EUCAST standard disc diffusion method
E. Matuschek, J. A˚hman °, C. Claesson, L. Nilsson, G. Kahlmeter
(Va¨xjo¨, Linko¨ping, SE)
Objective: The presence of high-level aminoglycoside resistance
(HLAR) in enterococci continues to increase and it is important to
differentiate strains without acquired resistance mechanisms from those
with HLAR. EUCAST recommends screening with gentamicin for
detection of HLAR in vitro. The objective of this study was to investigate
which gentamicin disk strength most reliably predicts HLAR, using
EUCAST breakpoints and standard disk diffusion method on Mueller-
Hinton agar.
Methods: A total of 125 clinical isolates of Enterococcus faecalis
(107) and Enterococcus faecium (18) were selected from Va¨xjo¨ Central
Hospital (n = 82) and Linko¨ping University Hospital (n = 43). All isolates
had gentamicin MIC values ranging from 16–1024mg/L, conﬁrmed with
Etest. Disk diffusion was performed on Mueller-Hinton agar without
supplements according to the EUCAST disk diffusion method, using
disks containing 10, 30 and 120 ug gentamicin. The inoculum suspension
was equivalent to McFarland 0.5 and plates were incubated at 35ºC for
18±2 h.
Results: HLAR was detected with gentamicin Etest (MIC> 128mg/L,
as deﬁned by EUCAST) in 50/102 E. faecalis and 18/18 E. faecium.
For E. faecalis, HLAR strains were clearly separated from those
without acquired resistance mechanisms and with gentamicin 10- and
30-ug disks inhibition zones were absent (= 6mm) for all HLAR
strains. For gentamicin 120-ug, three HLAR strains had inhibition
zones of 7−10mm. Separation of HLAR strains was less distinct for
E. faecium, when gentamicin 120 ug was used; ﬁve HLAR strains had
inhibition zones of 8−15mm. When comparing these results with data
on E. faecalis from routine laboratory work in Va¨xjo¨, the gentamicin
30-ug disk (n = 686) shows a clear separation, whereas discrimination
may become a problem with the gentamicin 10-ug disk (n = 237).
Conclusions: All gentamicin disks predicted high-level aminoglycoside
resistance in the E. faecalis investigated, whereas the results were
less conclusive for E. faecium. The results of this study suggest that
gentamicin 30-ug disks are more reliable than gentamicin 10- and 120-ug
disks for predicting HLAR in enterococci, using EUCAST breakpoints
and methodology.
P582 Amoxicillin–clavulanate and piperacillin–tazobactam:
comparison of different susceptibility testing methods
S. Persson °, C.G. Giske, V. O¨zenci (Stockholm, SE)
Objectives: To analyse the susceptibility of clinical Escherichia coli
isolates against amoxicillin–clavulanate and piperacillin–tazobactam and
compare the performance of three susceptibility testing methods.
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Methods: A total of 179 clinical Escherichia coli isolates were included.
Species identiﬁcation was performed with Vitek2, and susceptibility
testing was performed with disc diffusion, Etest and Vitek2. Etest-results
were considered the gold standard. EUCAST breakpoints were used for
both antibiotics when analyzing the MIC and Vitek2 data. Disc diffusion
breakpoints for piperacillin–tazobactam were derived from the Swedish
Reference Group for Antibiotics. The results from the three methods
were compared using Pearson correlation coefﬁcient (r). Discrepancies
between the methods were describes as minor, major and very major.
Results: The correlation for MICs for amoxicillin–clavulanate by Etest
and Vitek2 was relatively high (r = 0.82). Seventeen major (9.49%) and
one very major (0.56%) errors were observed with Vitek2. In contrast
there was poor correlation for the MICs for piperacillin/tazobactam by
Etest and Vitek2 (r = 0.37). As many as forty-seven (26.26%) major
and seven (3.91%) minor discrepancies were observed between the
two methods. In all major discrepancies observed in testing both
antibiotics, Vitek2 result was resistant whereas the Etest result was
susceptible. When disc diffusion method is considered, the breakpoint for
amoxicillin–clavulanate was estimated at 18mm in the wild type E. coli
population studied. Results from disc diffusion tests were signiﬁcantly
correlated with Etest for amoxicillin–clavulanate (r = 0.79). There were
twenty-three (12.85%) major discrepancies between the two methods. In
contrast, relatively poor correlation between Etest and disc diffusion
results was observed when piperacillin/tazobactam tested (r = 0.49).
There were twenty-eight (15.64%) minor discrepancies between the two
methods.
Conclusion: The susceptibility testing results for amoxicillin–
clavulanate obtained by three methods were highly correlated. However
there was poor correlation in piperacillin/tazobactam testing in the
studied material. The discrepancies observed for susceptibility testing
of piperacillin/tazobactam might be clinically important. Especially the
major errors observed with Vitek2 are of potential great concern.
P583 Evaluation of E-test to determine tigecycline MICs in
Enterobacter sp. from blood culture isolates
J.W. Cohen Stuart °, J.W. Mouton, N. Al Naiemi, A.C. Fluit, N. Arents,
B.M. Diederen, S. Thijsen, B. Vlamincx, M. Leverstein-Van Hall
(Utrecht, Nijmegen, Amsterdam, Veldhoven, Haarlem, Nieuwegein, NL)
Introduction: Tigecycline is often one of the last therapeutic options
for infections by multi-drug resistant Gram-negative bacteria. Therefore,
accurate MIC testing is critical. Previous studies have however shown
that tigecycline MICs determined by Etest may be inﬂuenced by the
brand of Muller-Hinton (MH) agar, hypothetically due to variations in
concentrations of manganese. Furthermore, for Acinetobacter spp. with
MICs 2mg/L by Etest, the MIC was at least two doubling-dilutions
lower using broth micro-dilution (BMD). The aim of this study was
to evaluate the Etest as a method to determine tigecycline MICs for
Enterobacter spp.
Methods: Tigecycline MICs were determined in 271 Enterobacter
bloodculture isolates from 12 laboratories throughout the Netherlands,
using Becton Dickinson (BD) MH II medium for BMD (Merlin,
Germany) according to the ISO-guideline 20776−1 (reference method
EUCAST and CLSI). The Etest (Biomerieux, France) was performed
using the same MH medium as well as an Iso-sensitest agar (Oxoid,
UK). In each experiment, E. coli ATCC 25922 was used as control
strain. EUCAST clinical breakpoints were used (susceptible(S)1mg/L),
as well as FDA breakpoints (S2mg/L).
Results: Compared to BMD, MICs determined by Etest were
signiﬁcantly higher using either MH agar or Iso-sensitest agar (see
Table). In 84% of the isolates, tigecycline MICs were 2 or more
doubling dilutions higher by Etest on MH agar compared to BMD. MICs
determined by Etest on MH agar were signiﬁcantly higher than on Iso-
sensitest agar. Susceptibility rates were signiﬁcantly higher when using
the BMD method compared to Etest, using either EUCAST or FDA
breakpoints (see Table). When EUCAST breakpoints were used, 97% of
isolates were S in the BMD method, whereas only 30% were S with Etest
on MH agar. Almost all isolates (96%) that tested non-S (EUCAST) by
Etest on MH agar, were S in the BMD method.
The MICs of the E. coli control strain were within the speciﬁed range
(0.03mg/L-0.25mg/L) for all three methods, although in the BMD
method the value was 0.0325mg/L and using Etest on MH agar, the
value was 0.25mg/L..
Conclusion: In Enterobacter spp., tigecycline MICs determined by Etest
are signiﬁcantly higher than MICs determined by BMD. Therefore,
Etest should not be used for tigecycline susceptibility testing in
Enterobacter spp. The misclassiﬁcation as tigeclycline non-susceptible
may incorrectly deny patients an important antibiotic option.
Method MIC (mg/L) % S
MIC50 MIC90 Geometric mean
±SD
EUCAST
(S 1)
FDA
(S 2)
BMD 0.25 1 0.42±0.41* 97%* 100%
Etest
BD MH agar 1.5 3 1.94±1.6* 30%* 82%*
Iso-sensitest Agar 0.5 1.5 0.88±1.2* 88%* 94%*
*p< 0.001 for comparisons between each method using t-test (comparisons of
means) or Fisher-Exact test (comparisons of susceptibility rates).
P584 A simple colourimetric method for antimicrobial
susceptibility testing of bacteria in bioﬁlms
S. Kim °, H.Y. Kang, S.M. Kim, D.T. Cho, J. Kim (Daegu, KR)
Objective: Bacteria in bioﬁlms are protected from antibiotics. For some
antibiotics, the concentration required to kill bioﬁlm cells may be greater
than a thousand times that required to kill planktonic cells of exactly
the same strain. Therefore, standard antimicrobial susceptibility test
has limited relevance for determining antimicrobial susceptibility of
bacteria in bioﬁlms. We here developed a simple colorimetric method for
antimicrobial susceptibility testing of bacteria in bioﬁlms using trimethyl
tetrazolium chloride (TTC) as an indicator of viable bacteria in bioﬁlms.
Method: Bioﬁlms were formed on 96-well polystyrene microtiter plate
for 1 day, treated with antibiotics for additional 1 day and reacted
with 0.02% TTC for 1 hr. The optical density at 540nm (OD540)
was measured on a microtiter plate colorimeter. The OD540 value
of bioﬁlms after treatment of antibiotics was compared with that of
bioﬁlms before treatment of antibiotics. Results were expressed as
reduction (%) of OD540 value in respect to controls. Using this new
method, bioﬁlms formed by Staphylococcus aureus, Escherichia coli
and Klebsiella pneumonia were tested for their susceptibility to several
antibiotics. Minimum inhibitory concentration (MIC) was determined by
the standardized CLSI method.
Ampicillin/
Sulbactam
Cefotaxime Amikacin Ciproﬂoxacin
E. coli ATCC 25922 MIC
MBIC
MBEC50
MBEC90
4
4
16
>512
0.5
0.5
8
>512
0.5
1
8
>512
0.0078
0.0078
1
>8
K. pneumoniae B170 MIC
MBIC
MBEC50
MBEC90
2
2
64
256
0.5
0.5
16
128
0.5
0.5
2
>512
0.0625
0.0156
1
>8
K. pneumoniae 172 MIC
MBIC
MBEC50
MBEC90
16
64
128
256
0.5
16
64
>512
0.5
8
>512
>512
0.125
0.25
>8
>8
Methicillin Vancomycin Teicoplanin Azithromycin
S. aureus ATCC 25913 MIC
MBIC
MBEC50
MBEC90
4
0.5
8
>512
1
4
8
>512
1
0.5
8
>256
2
0.5
>512
>512
S. aureus WS-3 MIC
MBIC
MBEC50
MBEC90
64
4
>512
>512
2
4
8
>512
2
0.25
8
>256
4
1
>512
>512
S. aureus WS-8 MIC
MBIC
MBEC50
MBEC90
8
2
>512
>512
1
4
16
>512
2
1
16
>256
4
2
>512
>512
S. aureus WS-22 MIC
MBIC
MBEC50
MBEC90
8
0.5
4
>512
2
1
8
>512
1
0.5
8
>256
4
0.5
32
>512
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Results: Reduction of TTC by viable bacteria produced red formazan
that could be measured quantitatively by colorimetric absorbance at
540 nm. The minimum bioﬁlm inhibitory concentration (MBIC) was
determined as the concentration at which the % of OD540 value
is 100%. Minimum bioﬁlm eradication concentration (MBEC) was
assessed such as MBEC50 and MBEC90, which was termed as the
concentration of drugs that kill 50% and 90% of bacteria in pre-
formed bioﬁlms, respectively. MBEC50 and MBEC90 were determined
as the concentration at which the % of OD540 value is 50% and
10%, respectively. The results were summarized in Table 1. Estimation
of the efﬁcacy of antibiotics for bacterial bioﬁlms was enabled by
comparing MBIC, MBEC50 and MBEC90 of drugs. In addition,
prominent differences in susceptibility for drugs between bioﬁlm cells
and their planktonic counterparts of the same strain (MBIC versus MIC)
were observed.
Conclusion: We developed a new simple colorimetric antimicrobial
susceptibility testing of bacteria in bioﬁlms using TTC as a viable
cell indicator. This method may be useful to screen the effectiveness
of antibiotics or biocides at eradicating bacterial bioﬁlms.
P585 Evaluation of performances of the Phoenix automated system
in the antimicrobial susceptibility testing using EUCAST
breakpoints
T. Giani, V. Conte, M.M. D’Andrea, G.M. Rossolini ° (Siena, IT)
Objectives: The objective of this work was to evaluate the performances
of the PHOENIX (PHX) system for antimicrobial susceptibility testing
(AST) and detection of clinically relevant resistance mechanisms
following the EUCAST guidelines.
Methods: 362 isolates, including routine clinical and collection isolates
with known MICs data, were used in this study. Gram-negatives (69%)
were represented by Enterobacteriaceae (including KPC and ESBL
producers), A. baumannii/calcoaceticus complex (IMP producers and
representative of the major nosocomial European clones), P. aeruginosa
(including metallo-carbapenemase producers) and S. maltophilia. Gram-
positives (31%) were Enterococcus spp (including VRE and high-level
aminoglycoside resistant strains), Staphylococcus spp (including MRSA)
and Streptococcus spp (including penicillin- and macrolide-resistant
strains). ASTs were performed using PHX using 3 ad hoc panels able to
determine the appropriate MICs in line with the EUCAST breakpoints.
Experimental Concordance (EC), deﬁned as MIC agreement ±1 log2
dilution and Category Concordance (CC) to determine Very Major Error
(VME), Major Error (ME) and minor Error (mE), were used to analyze
raw data obtained with PHX. Occurrences of discrepancies were resolved
ﬁrst by retesting and ultimately by Etest and/or micro-dilution method.
Results: Overall EC was 99.1% and CC was 96.2%. In total VME
accounted for 1.3%, ME 0.8% and mE 2.8%. For Enterobacteriaceae no
ME were seen, VME were 0.4% and mE 2.6%. All ESBL and KPC
producers were correctly identiﬁed as resistant isolates. Less agreement
was found for non-fermenting isolates. For this group VME were 2.6%,
ME 2.3% and mE 5%. The majority of the errors were observed for
P. aeruginosa and gentamicin (n = 6 VME), meropenem (n = 14 mE) and
piperacillin/tazobactam (n = 3 VME, n = 5 ME). For Staphylococci VME
were 1.7%, ME 1.8% and mE 1.6%. All MRSA were correctly identiﬁed
as such. No ME or VME were seen for Streptococcus and Enterococcus
spp and mE 1.7% and 1.3% respectively.
Conclusions: PHX showed excellent performances in the assessment
of MICs of clinical isolates using EUCAST compliant panels, as
demonstrated by the very high EC and CC. Accurate interpretative
categorization and detection of main resistance mechanisms was also
obtained using EUCAST breakpoints. Discrepancies observed for
speciﬁc species/antibiotic combinations will be further investigated.
P586 Ability of ciproﬂoxacin 1mg discs and British Society
for Antimicrobial Chemotherapy (BSAC) zone diameter
breakpoints to detect plasmid-mediated quinolone resistance
determinants in urinary enterobacterial isolates
A. Amin, D. Wareham ° (London, UK)
Objectives: Plasmid-mediated quinolone resistance (PMQR) genes have
been increasingly reported amongst members of the Enterobacteriaceae
worldwide. In London we recently reported an incidence of 53% in a
set of ciproﬂoxacin resistant urinary isolates collected at our centre. As
PMQR genes confer only low-level resistance it has been suggested that
modiﬁcation of screening procedures and breakpoints may be required in
order to optimize their detection (Cavaco & Aarustrup, JCM 2009). The
aim of this study was therefore to determine any correlation between
carriage of PMQR genes and zone of inhibition to 1mg ciproﬂoxacin
discs using BSAC susceptibility testing methodology and breakpoints.
Methods: Consecutive non-duplicate enterobacterial isolates obtained
from nosocomial and community-acquired urinary tract infections were
screened for PMQR genes using primers speciﬁc for qnrA,B and S,
qepA, and aac(6′)-Ib-cr and oqxA,B genes. Antimicrobial susceptibility
testing was performed for using the BSAC method with a zone size of
16mm considered resistant.
Results: 167 isolates were included, of which 76.0% were identiﬁed as
Escherichia coli. PMQR genes were found in 37.1% of isolates. qnrS
was present in 13.2% of isolates, qnrA in 0.6%, qepA in 2.4%, and
aac(6′)-Ib-cr in 32.9%. The oqxAB genes were detected in 18 isolates,
all of which were identiﬁed as K. pneumoniae, in which these genes are
located chromosomally Of the isolates harbouring PMQR genes, 98.4%
had a zone diameter of 16mm to 1mg ciproﬂoxacin discs.
Conclusions: These results suggest that the BSAC zone diameter
breakpoint for 1mg ciproﬂoxacin discs is adequate to detect isolates with
PMQR genes, although a very small proportion of such isolates may be
missed.
P587 Comparison of disc diffusion, E-test and Vitek2 for detection
of carbapenemase-producing Klebsiella pneumoniae with
various breakpoint systems
M. Vading °, Ø. Samuelsen, B. Haldorsen, A. Sundsfjord, C.G. Giske
(Stockholm, SE; Tromsø, NO)
Objectives: Carbapenem resistance among Klebsiella pneumoniae has
increased over the last years and their detection is challenging. The aim
of this study was to compare detection of carbapenemase producing
strains with the current CLSI and EUCAST breakpoints.
Methods: K. pneumoniae (n = 51) with known carbapenemases (KPC
n= 31, VIM n= 20) were collected from laboratories in Sweden, USA,
Greece and Norway. Disk diffusion (DD; Oxoid) and Etest (bioMe´rieux)
with imipenem (IPM), meropenem (MEM), and ertapenem (ERT) were
performed. Further, all strains were tested with the VITEK2-system with
5 different antibiotic cards containing either IPM or MEM or ERT,
and various combinations of these. ESBL-testing was performed with
VITEK2, ESBL combination disks (Becton Dickinson) and ESBL Etest.
Results: With current CLSI and EUCAST clinical MIC breakpoints,
respectively 11 and 7 of the strains were susceptible to IPM and
MEM, but none to ERT. Using the EUCAST epidemiological cut-
off value (ECOFF) all strains were resistant to both MEM and ERT,
but 5 strains were susceptible to IPM. All carbapenemase-producing
strains were detected with DD when using a cut-off value of 22mm for
IPM, MEM and ERT. The VITEK2 expert system failed in detecting
3 carbapenemase producers when using a card with IPM as the only
carbapenem. One failure was observed with ERT as the only carbapenem,
and one failure when using a card containing both IPM and MEM.
Antibiotic cards containing MEM or IPM plus ERT recognized all strains
as carbapenemase-producing. Many of the strains were ESBL-positive
both in VITEK2 and with combination disks (CDT), but not with ESBL
Etest.
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Conclusion: Both MEM and ERT performed better than IPM in
separating between wild-type isolates and carbapenemase-producers. For
MEM it was possible to detect all carbapenemases in K. pneumoniae
with the EUCAST ECOFF, but not with clinical breakpoints. All
carbapenemase producers were identiﬁed with the ERT clinical
breakpoints. Tentative disk diffusion cut-offs could be deﬁned, but should
be compared to EUCAST disk diffusion ECOFFs when these become
available. Strains with positive ESBL tests according to CDT method or
VITEK2 can still be carbapenemase producers, and this should be tested
if one or several carbapenem MICs are above the ECOFFs. To detect
carbapenemases with the VITEK2 system one should use antibiotic cards
containing more than one carbapenem, and always ERT.
P588 Two-centre evaluation of a microarray for rapid detection
of antibiotic resistance genes in Gram-negative species that
cause community and healthcare-associated infections
J-C. Zhang ° (London, UK)
Objectives: To evaluate a DNA extraction and microarray procedure for
rapid and accurate detection of resistance genes in Enterobacteriaceae,
Pseudomonas spp. and Acinetobacter spp.
Methods: The panel of 32 test strains comprised A. baumannii,
Escherichia coli, Klebsiella pneumoniae, Klebsiella spp., Enterobac-
ter spp., Citrobacter freundii, Morganella morganii, Hafnia alvei,
P. aeruginosa, and Salmonella; all had partially-deﬁned resistance
genotypes, as determined previously by PCR analysis. All strains
were tested in two centres. DNA was extracted using a simple lysis
method; resistance genes were ampliﬁed in a multiplex labelling
reaction and hybridized against a Clondiag strip-format array chip. The
array comprised 159 probes in triplicate, representing genes encoding:
aminoglycoside-modifying enzymes; acquired AmpC b-lactamases, ES-
BLs, and carbapenemases (the latter including metallo-enzymes, OXA-
48, KPC, and SME enzymes); plasmidic ﬂuoroquinolone resistances; and
resistance to chloramphenicol, macrolides, rifampicin, sulphonamides,
tetracyclines and trimethoprim. Results were analysed with an Arraymate
reader and IconoClust software. PCR and DNA sequencing were used
to verify results and to establish criteria for interpreting array data.
Results: The test strains allowed 113/159 (70%) probes to be validated;
46 probes did not hybridize with test DNA. The simple extraction
protocol yielded DNA suitable for analysis from diverse species,
including multiple genera of Enterobacteriaceae, P. aeruginosa and
A. baumannii. Generally there was good agreement between the
genotypes assigned at the two centres and, using a threshold of >0.4,
92% of array ‘hits’ were conﬁrmed by PCR. The beneﬁt was illustrated
by detection by array of rmtC and armA genes, subsequently conﬁrmed
by PCR and sequencing, in several clinical isolates that produced NDM-1
metallo-carbapenemase.
Conclusion: This simple array technology is able to detect resistance
genes in a broader range of host species than previously studied, and
shows good agreement with PCR-based detection strategies. The current
array needs further validation against a larger panel of strains, and
reﬁnement to replace non-speciﬁc probes. However, this initial work
clearly shows the potential of arrays as reference microbiology tools
and highlights the beneﬁts of the approach to detect antibiotic resistance
genes.
P589 Development of a real-time multiplex PCR assay for the
detection of CTX-M type ESBLs directly from blood cultures
G.L. Vanstone °, L. Wilkie, B.M. Charalambous, I. Balakrishnan
(London, UK)
The rapid detection of Extended-spectrum b-Lactamase (ESBL) pro-
ducing Enterobacteriaceae, particularly the CTX-M types, is critical
to implementing optimal antibiotic therapy and appropriate infection
control procedures. Currently, detection is based on phenotypic methods
that can take 48 hours to complete.
Objectives: To evaluate the novel combination of a rapid DNA extraction
method directly from blood cultures with a real-time multiplex PCR
(RT-PCR) that can detect the ﬁve-phylogenetic groups (CTX-M-1, CTX-
M-2, CTX-M-8, CTX-M-9 and CTX-M25) of CTX-M type ESBLs
(Birkett et al. 2007).
Methods: Five control organisms representing the CTX-M groups were
spiked into negative blood cultures to give concentrations of between
103 to 107 bacteria/ml. A bead-beating DNA extraction method (BD
Diagnostics) and RT-PCR was performed on all of the blood cultures.
The RT-PCR was performed as described previously (Birkett et al.
2007) on a RotorGene 6000 (Qiagen) using a commercially available
master mix (Lightcycler 480 Probes Master, Roche), following the
manufacturer’s instructions.
Results: All 5 strains were detected directly from blood cultures in 3.5
hours, with a detection limit of 104 bacteria/ml. This is signiﬁcantly
lower than the average number of bacteria found in blood cultures when
they ﬂag positive (>107 bacteria/ml) on our currently used, automated
blood culture detection system (Bactec FX, BD Diagnostics).
Conclusion: The detection time of the 5 CTX-M ESBL groups directly
from blood cultures was reduced by >10 fold compared with standard
methods. This rapid methodology is currently being evaluated on actual
blood cultures from patients. This simple and rapid technique has
the potential to dramatically improve patient outcome and facilitate
rationalisation of both antibiotic use and infection control practices much
earlier than currently possible.
P590 Pre-real-time PCR steps standardization for appropriate
interpretation of mexA and mexX gene expression by mex
Q-Test in P. aeruginosa
L. Avrain, D. Hocquet, T. Laurent, T. Leclipteux, P. Mertens °
(Gembloux, BE; Besanc¸on, FR)
Background: Absolute and relative gene expression analysis by Real-
Time PCR may be dependent on pre-Real-Time PCR steps, including
bacteria culture and cDNA synthesis. The successful completion of these
preliminary steps may affect the ﬁnal interpretation of the Real-Time
PCR results. The aim of the present study was to examine the impact of
culture phase, reverse transcription kits and Sybr Green mix kits on the
absolute and relative gene expression of mexAB-oprM and mexXY-oprM
pumps in P. aeruginosa.
Methods: Bacterial pellets were obtained by harvesting growing bacteria
at OD from 0.5 to 1.25 at 620 nm, for control strains (PAO1, PT629 and
mutGR1 respectively for wild type, mexAB and mexXY over-expressing
strains) and for 9 clinical strains overproducing one or both efﬂux
systems. Five reverse transcription kits and ﬁve Sybr Green mix kits were
compared on puriﬁed total RNA. The mexA and mexX genes absolute
and relative expressions were detected by mex Q-Test Real-Time PCR
kit (Coris BioConcept) with cut-off of signiﬁcant over-expression at 2
and 5 for mexA and mexX genes (relative to PAO1), respectively.
Results: Analysis of mexA and mexX genes expression during bacterial
growth revealed an increase in relative expression of mexA at higher OD
particularly for strains over-expressing mexA. The best discrimination
between wild-type and mexA or mexX overexpressing strains was
obtained at OD 1.0. Analysis of the ﬁve reverse transcription kits showed
important variations (more than 2 orders of magnitude) in absolute
expression of mexA and mexX. Some Reverse transcriptases showed
higher transcription of mRNA in high copies as for mexA while others
perform better on the mRNA with lower copy numbers like mexX. Table
1 lists the reverse transcriptase kits to the best (rank 1) to least efﬁcient
(rank 5). This observation is less perceptible when working in relative
expression. No major differences were observed with the Sybr Green
mix kits.
Conclusions: For robust and reproducible mex expression analysis with
the mex Q-TesT Real-Time PCR (Coris BioConcept), we recommend to
harvest bacterial pellets at an OD of 1±0.1 at 620 nm and to choose
the best Reverse Transcription kit. Though the list of tested kits is not
exhaustive, we recommend suppliers able to identify both genes in low
copies number (as the basal level of mexX in wild type strains) and
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genes with a low ratio of over-expression compared to PAO1, as strains
overexpressing mexA.
Table: Efﬁcacy rank of Reverse Transcription Kits for mexA and mexX
genes
Reverse Transcription Kits mexA mexX
First Strand cDNA Synthesis Kit (Roche Diagnostics) 1 3
Superscript III Reverse Transcriptase (Invitrogen) 2 2
Multiscribe Reverse transcriptase (Applied Biosystems) 3 4
RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas) 4 1
Reverse Transcription System (Promega) 5 5
P591 Comparative evaluation of disc synergy tests with EDTA
and dipicolinic acid for detection of MBL production in
Pseudomonas aeruginosa
E. Skleenova, J. D’Souza, N. Ivanchik, M. Edelstein °, R. Kozlov
(Smolensk, RU)
Objectives: Production of acquired metallo-b-lactamases (MBLs) is one
of the most clinically and epidemiologically signiﬁcant mechanisms of
resistance to carbapenems in P. aeruginosa. The aim of our study was
to compare the effectiveness of the double-disk synergy tests (DDSTs)
using two different inhibitors: EDTA and dipicolinic acid (DPA) for
detection of MBLs in P. aeruginosa.
Materials and Methods: Ten reference strains producing the known
MBLs: IMP-1, IMP-2, IMP-4, IMP-12, IMP-13, VIM-1, VIM-2, VIM-7,
VIM-10, SPM-1, and 480 clinical P. aeruginosa isolates non-susceptible
to imipenem and/or meropenem (MICs >4mg/L) were used in this
study. The clinical isolates were collected from 36 hospitals of diverse
geographic locations. DDSTs were performed by placing the disks
containing inhibitors (5 mkl of 0.5M EDTA or 5 mkl of 0.5M DPA)
15mm (center-to-center) from disks with imipenem. A clearly visible
extension of the inhibition zone of any b-lactam disk towards the
inhibitor disk was interpreted as positive result for MBL production. PCR
for the most common VIM- and IMP-type MBL genes was used as a
reference method and imipenem-hydrolysis assay was used as additional
method to resolve discrepant results of phenotypic and genotypic tests.
Results: Both the DDST-EDTA and DDST-DPA correctly detected the
presence of MBLs in all the control strains and all clinical isolates
(n = 159) that demonstrated positive PCR results for MBL genes. True
negative results were obtained by both assays for 306 isolates; false
positive results − for 15 isolates, of which 5 revealed extension of the
inhibition zones with both inhibitors, 5 with EDTA only, and 5 with DPA
only.
Conclusion: In our study, DDSTs with DPA and EDTA demonstrated
equal performance with 100% sensitivity, 96.9% speciﬁcity, 100% NPV,
and 94.1% PPV for detection of MBLs in P. aeruginosa. The speciﬁcity
of phenotypic MBL detection could be increased to 98.4% if positive
results are conﬁrmed by both assays.
P592 A novel screening agar for the detection of vancomycin
non-susceptible Staphylococcus aureus
C.D. Burnham °, K. Anderson, C.J. Weber, W.M. Dunne Jr. (Saint
Louis, Atlanta, US)
Objectives: The ability to accurately identify isolates of Staphylococcus
aureus with reduced susceptibility to vancomycin is of critical clinical
importance. Guidance for susceptibility testing for S. aureus has recently
been in ﬂux. In January 2006, CLSI updated breakpoints for vancomycin
susceptibility testing for S. aureus such that a minimum inhibitory
concentration (MIC) greater than 2mg/L was considered to be non-
susceptible to vancomycin. In 2009, the CLSI deemed that disk diffusion
was no longer an acceptable means for susceptibility testing for
vancomycin in staphylococci. The objective of this study was to design
a cost-effective medium to detect vancomycin non-susceptible S. aureus.
Methods: A medium consisting of brain heart infusion agar with
3mg/L vancomycin (BHI-V3) was created to screen for isolates of
S. aureus with reduced susceptibility to vancomycin. The agar was
inoculated with 10 uL of a 0.5 McFarland standard suspension of
organism and incubated at 35 C for 24 h. Any growth on BHI-
V3 was interpreted as positive. This agar was validated using a
collection of 100 S. aureus strains previously characterized by the
CDC using broth microdilution. This collection included 55 vancomycin
susceptible isolates and 45 vancomycin intermediate (VISA) isolates.
Once validated, BHI-V3 was incorporated into routine use in the Barnes-
Jewish Hospital Microbiology Laboratory. The vancomycin MIC of
all isolates growing on BHI-V3 was also determined using multiple
methods.
Results: All of the VISA isolates (45) and 19 of the vancomycin
susceptible isolates in the challenge set grew on BHI-V3, for 100%
sensitivity and 65% speciﬁcity. In the ﬁrst 60 days the agar was
implemented in clinical practice, we identiﬁed 17 potential VISA isolates
out of 421 S. aureus strains tested. Thirteen of these isolates were
conﬁrmed as VISA. The MIC of the conﬁrmed VISA isolates was
determined using four different methods. The Microscan Pos MIC Panel
26 had the highest sensitivity of VISA detection (92%), followed by
Etest (85%), and Sensititre GPALL (54%). Vitek2 GP67 was the least
sensitive, detecting only 1 of the 13 VISA isolates.
Conclusions: BHI-V3 has excellent sensitivity for detection of VISA.
We recommend that clinical laboratories use this media to screen all
isolates of S. aureus for reduced susceptibility to vancomycin. Isolates
that do not grow on the agar can be considered vancomycin susceptible.
P593 Wild type MIC distribution and epidemiological cut-off
values in clinical Legionella pneumophila serogroup 1 isolates
J.P. Bruin °, E. Ijzerman, J.W. den Boer, J.W. Mouton, B.M. Diederen
(Haarlem, Nijmegen, NL)
Objectives: Surveillance studies on the in vitro activity of antibiotics
used for Legionnaires’ disease are necessary to identify changes in
susceptibility rates. Wild type distribution and epidemiological cut off
values (ECOFF) used to detect resistance have not been described for
Legionella pneumophila. The goal of this study was to determine MICs
in clinical L. pneumophila isolates collected from patient materials and
to determine ECOFF.
Methods: 187 clinical L. pneumophila serogroup 1 isolates collected
from unique patients were tested. All patients were included as part of
a national outbreak detection programme. All strains were typed using
AFLP typing and/ or SBT according to the European Working Group
on Legionella Infections (EWGLI) guidelines. E-tests for ciproﬂoxacin,
levoﬂoxacin, moxiﬂoxacin, erythromycin, azithromycin, clarithromycin,
cefotaxim, rifampicin, tigecycline, and doxycycline (AB Biodisk, Solna,
Sweden) were performed. Buffered yeast extract agar supplemented with
a-ketoglutarate (BCYE-a; Oxoid, Basingstoke, UK) was used in the
testing procedure. The MICs were read after culture at 35ºC after 2 days
of incubation. ECOFF were determined according to EUCAST criteria
and expressed as WTXmg/L.
Results: The MIC90 and wild-type cut-off values were determined at
0.50 (range 0.5−2) and 1.0mg/l for ciproﬂoxacin, 0.25 (range 0.064−1.0)
and 0.50mg/l for levoﬂoxacin, 0.50 (range 0.25−1.0) and 1.0mg/l for
moxiﬂoxacin, 0.25 (range 0.032−2) and 1.0mg/l for erythromycin, 0.25
(range 0.032−8) and 1.0mg/l for azithromycin, 0.25 (range 0.064−1)
and 0.50mg/l for clarithromycin, 0.50 (range 0.016−1.0) and 1.0mg/l
for cefotaxim, 0.032 (range 0.016–0.032) and 0.032mg/l for rifampicin,
8 (range 2−16) and 16mg/l for tigecycline, 8 (range 1−8) and 16mg/l
for doxycycline.
Conclusion: All isolates were inhibited by low concentrations of the
quinolones and macrolides tested, with somewhat higher MICs for the
ﬂuoroquinolones. Rifampicin was found to be the most active against
L. pneumophila isolates. Only one isolate (0.5%) showed a MIC outside
the WT distribution for the ﬂuorochinolones and macrolide antibiotics
(MIC 2mg/l for ciproﬂoxacin and 6mg/l for azithromycin). These data
can be used as a reference for the detection of resistance in clinical
L. pneumophila isolates.
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P594 Correlation of MICs and diskzone diameters in clinical
Legionella pneumophila serogroup 1 isolates
J.P. Bruin °, E.P. Yzerman, B.M. Diederen, J.W. Den Boer, J.W. Mouton
(Haarlem, Nijmegen, NL)
Objectives: Routine use of disk diffusion tests for detecting antibiotic
susceptibility for Legionella pneumophila in relation with MICs have not
been described. The goal of this study was to determine the correlation
of MICs and zone diameter (MDcorr) in clinical L. pneumophila isolates
collected from patient materials for 10 antibiotics. We used BCYE agar
because this is most commonly used for culturing legionella.
Methods: 194 L. pneumophila serogroup 1 isolates collected from
unique patients were tested. All patients were included as part of a
national outbreak detection program. All strains were typed using AFLP
typing and/ or SBT according to the European Working Group on
Legionella Infections (EWGLI) guidelines. E-tests (AB Biodisk, Solna,
Sweden) and disk diffusion tests (Becton, Dickinson and Company,
USA) for ciproﬂoxacin (Cip), levoﬂoxacin (Lev), moxiﬂoxacin (Mox),
erythromycin (Ery), azithromycin (Azi), clarithromycin (Cla), cefotaxim
(Cef), rifampicin (Rif) and doxycycline (Dox) were performed. Buffered
yeast extract agar supplemented with a-ketoglutarate (BCYE-a; Oxoid,
Basingstoke, UK) was used in the testing procedure. The MICs and zone
diameter were read after culture at 35ºC and 2 days of incubation.
Results: Of the three ﬂuoroquinolones Cip showed the best MDcorr and
no major or minor errors were observed in differentiating susceptible
and resistant strains. All three macrolides Ery, Azi and Cla showed a
wide MIC distribution and good MDcorr. MICs also correlated well
with each other with R> 0.7. The disk zones were relatively wide,
22−56mm for Azi and Ery, and less for Cla (35−55mm). Resistance
could be differentiated from susceptible for Azi and Ery, but not for
Cla. Depending on the diskzone criterium there was one minor or one
major error for Cla. The MDcorr for cefotaxim was good, while for
rifampicin, doxycyclin and tigecyclin they were not (<0.4). However, as
there were no clearly resistant strains these were difﬁcult to interpret.
Conclusion: Good MIC-diskzone size correlates were found for the
quinolones, macrolides and cefotaxim. For quinolones the ciproﬂoxacin
and for macrolides either azithromycin or erythromycin could be used
as an indicator for class resistance.
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P595 Inducible clindamycin resistance should not be neglected
in erythromycin intermediate Staphylococcus aureus blood
isolates
D. Gu¨lmez °, B. Sener, G. Hasc¸elik (Ankara, TR)
Objectives: Detecting inducible clindamycin resistance is a challenge for
laboratories which use automated systems for antibiotic suscebtibility
testing. BD Phoenix system is used for antimicrobial testing of
Staphylococcus aureus isolates and BDXpert system is used for reporting
the susceptibility results in our laboratory. BDXpert System warns the
laboratory to perform a D-test for all erythromycin resistant isolates
(Rule 335) and does not report clindamycin susceptibility results.
Clindamycin susceptibility results of erythromycin intermediate isolates
are reported according to the detected minimum inhibitory concentration.
Since the panels to detect inducible clindamycin resistance are not yet
available in Turkey, this study was conducted to determine inducible
clindamycin resistance in erythromycin resistant and intermediate
S. aureus isolates.
Methods: S. aureus strains isolated from blood from January 2004 to
October 2009 were included. Phoenix system detected 67 erythromycin
resistant and 9 intermediate isolates. D-test was performed for all isolates
and compared with Phoenix results.
Results: Distribution of S. aureus isolates according to D-test results and
erythromycin susceptibility is given in the Table. Of the 67 erythromycin
resistant isolates, 8 (11.9) were D-zone negative and all were clindamycin
susceptible by the Phoenix system. Of the 9 erythromycin intermediate
isolates, 3 (33.3%) were D-zone positive and falsely reported as
clindamycin susceptible.
Conclusions: BDXpert system does not report clindamycin suscep-
tibility results for erythromycin resistant S. aureus isolates, however
inducible clindamycin resistance in erythromycin intermediate isolates
may be overlooked. Therefore all erythromycin intermediate S. aureus
strains should also be tested for inducible clindamycin resistance.
Table. Distribution of S. aureus isolates according to D-test results and
erythromycin susceptibility
Erythromycin R, n (%) Erythromycin I, n (%) Total, n (%)
D-zone positive 59 (88.1) 3 (33.3) 62 (81.6)
D-zone negative 8 (11.9) 6 (66.7) 14 (18.4)
Total 67 (100) 9 (100) 76 (100)
P596 Evaluation of spiral gradient endpoint technique for
rapid detection of vancomycin intermediate-resistant
Staphylococcus aureus
V. Doddangoudar °, M. O’Donoghue, M. Boost, P. Appelbaum
(Kowloon, HK; Hershey, US)
Objectives: Emergence of Staphylococcus aureus strains which are non-
susceptible to vancomycin has made treatment of infections by these
strains more difﬁcult. Their non-susceptibility cannot be easily and
rapidly determined by current methods as they lack sensitivity and
reproducibility or are slow and/or tedious to perform, thereby delaying
appropriate therapy for the patient. This study evaluated the spiral
gradient endpoint (SGE) technique for determination of vancomycin
MIC, aiming to provide an economical, rapid, and simple method for
the detection of vancomycin non-susceptible S. aureus.
Method: Using a spiral plater, vancomycin stock solution (2076mg/L)
was deposited on an agar plate in a spiral pattern to produce a
concentration gradient. Three agar media were evaluated: Mueller Hinton
(MH), Brain heart infusion (BH) and 5% Glucose Brain heart infusion
(GBH). Three isolates were inoculated in duplicate on each plate across
the spiral to expose them to the exponential concentration gradient and
then incubated at 37ºC for 24 h. SGE was determined by measuring the
distance from the centre of the plate to the endpoint of growth. The
antibiotic concentration at this point, which represents the MIC, was
calculated using SGE software. Results for 30 isolates were compared
to standard agar dilution method (SAD).
Results: The intra-batch, inter-batch and inter-observer reproducibilities
of SGE method were excellent for all media with best results being
obtained for BH. The ranges of standard deviation and coefﬁcients
of variation for BH were: 0.35–0.83 & 6.89–12.14% for intra-batch;
0.35–0.53 & 5.77–9.62% for inter-batch, and 0.58 & 8.66–13.3% for
inter-observer. There was excellent correlation between MICs generated
by the SGE method using BH and SAD (r2 = 0.961) over the range
0.5−20mg/ml.
Conclusion: In the era of increasing antibiotic resistance, early detection
of non-susceptibility can lead to improved therapy of multidrug resistant
infections and shorten expensive hospitalization stays. This study has
shown SGE technique to be a simple, rapid, and cost-effective alternative
for the routine laboratory. The cost of consumables is low when
compared to other recommended methods. Although there is an initial
outlay for purchase of a spiral plater (US$12,500), this investment can
be rapidly recovered by savings in consumables and labour, as well as
possible reduced hospitalisation costs as a result of rapid susceptibility
reporting made possible by SGE.
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P597 Methicillin-resistance detection in 5 minutes: novel rapid
immunochromatographic kit directly from Staphylococcus
aureus primary isolates
J-P. Rasigade, O. Raulin, A.M. Freydiere, L. Parmeland,
C. Roure-Sobas, H. Salord, J. Etienne, S. Tigaud, F. Laurent ° (Lyon, FR)
Objective: Rapid detection of methicillin resistance in Staphylococ-
cus spp., especially S. aureus, is crucial in patient management. The
availability of fast molecular diagnostics has strengthened infection
control strategies by providing results in hours rather than days, as the
time required for culture-based methods. However, costs and equipment
requirements have limited the widespread use of such molecular
methods. In this context, we evaluated a novel rapid detection kit
(Dipstick PLP2a, Inverness Medical) using immunochromatography for
sensitive and speciﬁc detection of the PLP2A protein causing methicillin
resistance. This method is performed in 5 minutes directly from primary
isolates, and is similar to the strep throat test routinely used for
diagnosing streptococcal sore throat.
Methods: A total of 222 strains of Staphylococcus spp. were grown
for 24 h on Columbia blood agar and trypticase soy blood agar plates
(bioMe´rieux, Lyon, France): 153 S. aureus (102 methicillin resistant
and 51 methicillin susceptible S. aureus) and 69 coagulase-negative
staphylococci (CoNS) (50 methicillin resistant and 19 methicillin
susceptible CoNS). Each strain was tested for methicillin resistance
using Dipstick PLP2A assay. The assay was also performed after PLP2A
induction in colonies harvested near the inhibition zone of oxacillin
and cefoxitin discs on Mueller-Hinton agar plates (bioMe´rieux, Lyon,
France).
Results:Methicillin resistance detection in S. aureus had 96% sensitivity,
100% speciﬁcity, 100% positive predictive value (PPV) and 98%
negative predictive value (NPV). The same detection in CoNS had
86% sensitivity, 100% speciﬁcity, 100% PPV and 73% NPV. In both
S. aureus and CoNS, sensitivity and speciﬁcity reached 100% after
PLP2A induction or an additional 24 h incubation.
Conclusions: Our ﬁndings demonstrate that the Dipstick PLP2A rapid
immunochromatographic kit allows sensitive and speciﬁc detection of
methicillin resistance directly from primary isolates of S. aureus and
CoNS. In the light of the importance of early adaptation of antibiotic
therapy in patients with staphylococcal infections, this rapid diagnostic
kit could soon play a routine part in microbiology laboratory testing.
P598 Performance of a new MicroScan WalkAway panel for
detection of oxacillin resistance in a French nationwide set
of Staphylococcus aureus isolated from community-acquired
skin and soft tissue infections
O. Gallon, P. Pina, F. Laurent, B. Lamy, X. Palette, F. Doucet-Populaire,
J.W. Decousser ° on behalf of the College de Bacte´riologie Virologie
Hygie`ne Study Group
Objectives: Detection of Oxacillin resistance (OR) in Staphylococcus
aureus is a daily challenge for clinical laboratories. Cefoxitin testing is
now currently recommended and used for this purpose. We evaluated
the performance of a new MicroScan WalkAway panel (Siemens,
Sacramento) including this compound for the detection of OR.
Methods: During 2006 203 S. aureus isolates were collected from
a nationwide study through the French College de Bacteriologie
Virologie Hygiene network interesting in community-acquired skin and
soft tissue infections. OR was detected by a mecA PCR, cefoxitin
(FOXdm) and moxalactam (MOXdm) disk diffusion method according
to French criteria (susceptible to oxacillin if diameter >26 and 23mm,
respectively), and the new MicroScan WalkAway panel PC30. This
panel contains oxacillin in doubling dilution from 0.25 to 2 mg/mL
and an additional cefoxitin test (4 mg/mL); each strain was categorized
as oxacillin resistant if its oxacillin MIC was superior to 2 mg/mL or
if the cefoxitin test was positive (i.e. yielded a growth). The panels
was automatically run according to the manufacturer’s instructions.
ATCC25923 and 43300 were used. In addition the Panton-Valentine
leukocidin coding gene (pvl) was detected by PCR. Very Major (VMe,
false susceptible) and Major errors (Me, false resistance) were reported.
Results: OR was detected in 15.3% of isolates (31/203) by PCR.
Considering the mecA PCR as the gold standard, the sensibility,
speciﬁcity, Positive Predictive and Negative Predictive Value were
respectively 96.8%, 100%, 100% and 99.4% for the FOXdm, 93.5%,
100%, 100% and 98.8% for the MOXdm, 100%, 99.4%, 96.9% and
100% for the PC30 panel. VMe and Me were identiﬁed for respectively
1 and 0 isolate for the FOXdm, 2 and 0 isolates for the MOXdm
and 0 and 1 isolates for the PC30 panel. Comparing to the oxacillin
MIC determination, the cefoxitin test detected true OR in two additional
isolates (mecA PCR positive). Among the 18 pvl PCR positive isolates,
only the PC30 panel accurately identiﬁed the oxacillin susceptibility for
the totality of this subgroup (17 oxacillin-susceptible and 1 oxacillin-
resistant isolates), the FOX and MOX diffusion method misidentifying
the OR in the only one mecA and pvl PCR positive isolate.
Conclusions: Both FOXdm or MOXdm and the PC30 panel are highly
accurate methods for OR detection in clinical relevant S. aureus, the later
method belonging to an automated antimicrobial susceptibility testing
system.
P599 Resistance to macrolides and licosamides. Comparison of
ICR test from Vitek-2C AST-577 card to D-test
R. Soloaga °, N. Carrion, M. Vazquez, A. Procopio, P. Amaya,
M. Giovanakis, A. Sujemecki, A. Rossetti, D. Lanzetta, S. Guaycochea,
L. Biblieri, J. Pares, S. Scorza, R. Pereda, A. Fernandez, A. Meo,
L. Derdoy, L. Guelfand (Buenos Aires, AR)
Objectives: Resistance to macrolides and lincosamides in Staphylococ-
cus strains isolated in Argentina is mainly due to efﬂux mechanisms
(E) or to the modiﬁed target (ribosome23s); the latter could occur by
induction (MLSi) or constitutive resistance (MLSc). Clindamycin may
select intratreatment resistance if MLSi is present. The objective was to
compare the ICR test performance (inducible clyndamycin resistance)
of the Vitek 2C AST-P577 card (bioMe´rieux, Marcy l’Etoile, France)
to the D-test suggested by the CLSI (Clinical and Laboratory Standards
Institute) to differenciate E from MLSi..
Materials: 372 isolated Staphylococcus strains were studied at 8
hospitals in Buenos Aires, Argentina. They correspond to S. aureus
(n:197), S. epidermidis (n: 86); S. hominis (n:30); S. haemolyticus (n:21),
S. capitis (n:6), S. saprophyticus (n:4), S. simulans (n:4), S. cohnii (n:4),
S. warneri (n:3), S. lugdunensis (n:3), S. auricularis (n:1), S. xylosus
(n:1), Staphylococcus spp (n:12).
The strains were identiﬁed using the Vitek 2C GPI card.
Resistance to macrolides and lincosamides, and the ICR test were
determined using the Vitek 2C AST-P577 card, considering breakpoints
and D-test methods suggested by the CLSI (CLSI 2009, M2 and M7,
Table 2C).
Results: 172 strains (46.3%) were erythromycin and clindamycin
susceptible, 97 (26%) were only resistant to erythromycin and 103
(27.7%) were resistant to both antibiotics.
According to the erythromycin and clindamycin MIC result, to the
AES Vitek 2C suggestions, to the IRC test and D-test, 23% of the
erythromycin resistant strains displayed efﬂux compatible mechanism,
51.5% MLSc and 25.5% MLSi.
Susceptibility, speciﬁcity, positive predictive value, negative predictive
value and essential correlation of the IRC test as regards the D-test were
100%.
Conclusions: The IRC test together with the Vitek 2 Advanced
Expert System (AES) offer an excellent correlation with the D-test to
differenciate MLSi from E.
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P600 Comparative evaluation of BD Phoenix system and
conventional agar dilution method for detection of oxacillin
resistance in Staphylococcus spp.
A. Nikulin °, M. Sukhorukova, M. Edelstein, R. Kozlov, A. Dekhnich
(Smolensk, RU)
Objectives: To evaluate the performance of the BD Phoenix system and
conventional phenotypic methods for the detection of oxacillin resistance
in clinical isolates of Staphylococcus spp.
Methods: In total, 299 clinical non-duplicate isolates of Staphylococ-
cus spp. collected from patients with different types of invasive infections
in different regions of Russia were included in the study.
Minimum inhibitory concentrations (MICs) of oxacillin were determined
using the agar dilution method on Mueller-Hinton agar (Becton
Dickinson). Staphylococcus aureus strain ATCC® 29213 and strains
carrying the SCCmec cassettes of types I-IV were used for quality
control. The results of agar dilution susceptibility testing were interpreted
according to the EUCAST clinical breakpoints. The combination panels
PMIC/ID-60 were used with the BD Phoenix system. Real-time PCR
(RT-PCR) assay for the mecA and internal 23S rRNA staphylococcal
gene sequences was used as a reference method to which the phenotypic
methods were compared.
Results: The results of oxacillin susceptibility testing by agar dilution
method and BD Phoenix system compared to those of RT-PCR are
presented in the table. The sensitivity, speciﬁcity, positive predictive
value (PPV) and negative predictive value (NPV) for both methods were
calculated. In three series of repetitive tests, the BD Phoenix system did
not yield any susceptibility results for 11 isolates of coagulase-negative
staphylococci (CNS) which were therefore excluded from analysis. Most
of the isolates that showed discrepant results of oxacillin susceptibility
testing and mecA status had the oxacillin MICs differing by no more
than one two-fold dilution from the breakpoint value.
Conclusion: Using the molecular test for mecA detection as a reference
method, the BD Phoenix system demonstrated higher sensitivity and
speciﬁcity than the agar dilution method for detection of oxacillin
resistance in S. aureus and CNS.
Number of isolates Percent
True
positive
False
positive
True
negative
False
negative
Sensitivity Speciﬁcity PPV NPV
S. aureus (n = 200)
RT-PCR 78 122
Phoenix 72 2 120 6 92.3 98.4 97.3 95.2
Agar dilution 66 30 92 12 84.6 75.4 68.8 88.5
CNS (n = 99)
RT-PCR 43 (35*) 56 (53*)
Phoenix* 33 15 38 2 94.3 71.7 68.8 95
Agar dilution 41 17 39 2 95.3 69.6 70.7 95.1
*Excluding isolates which did not yield any susceptibility result with BD Phoenix.
P601 Detection of inducible macrolide-lincosamide-streptogramin
B resistance in Staphylococcus species: Vitek2 Advanced
Expert system versus double disc method (D-zone test)
I. Geerts °, A. Smismans, J. Frans (Bonheiden, BE)
Objective: The double disk induction test (CLSI, M100-S19) is rec-
ommended to determine inducible macrolide-lincosamide-streptogramin
B (iMLSB) resistance in Staphylococcus species. The Advanced Expert
System (AES) of Vitek 2 (bioMe´rieux) claims to detect this resistance
mechanism as well. To evaluate the reliability of the AES, we compared
Vitek 2 with the double disk method.
Methods: On 125 consecutive Staphylococci spp. (52 Staphylococcus
aureus en 73 coagulase negative Staphylococci), collected in Imelda Hos-
pital Bonheiden (27/10/2008–28/07/2009), we retested erythromycin-
resistant Staphylococci on Vitek card AST-P549 (bioMe´rieux) for which
the AES reported a “resistant” clindamycin result (Vitek expert rule:
‘Therapeutic interpretation suggests corrections to clindamycin’), apply-
ing the CLSI double disk induction protocol. Staphylococcus strains were
suspended to a 0.5 McFarland turbidity before inoculation on a Mueller-
Hinton agar (Biorad). Subsequently, the erythromycin and clindamycin
disks (Biorad) were placed exactly 15mm edge to edge and the plates
were incubated for 16 to 18 h at 35±2ºC. Flattening of the zone of inhibi-
tion adjacent to the erythromycin disk conﬁrmed the presence of iMLSB.
Results: Each isolate resistant for erythromycin and susceptible to
clindamycin was inferred by the AES to harbour an iMLSB phenotype.
These data are inconsistent with surveillance data of methicillin suscepti-
ble S. aureus strains obtained by our reference center in Belgium (2007)
showing a resistance for clindamycin and erythromycin of respectively
26% and 7%. In the same survey methicillin resistant S. aureus expressed
62% resistance to erythromycin and 43% to clindamycin.
We obtained equal results between the AES and the double disk induction
in only 58.4% of our isolates. The results were discordant for 21.1% of
the S. aureus strains and 56.1% of the coagulase negative Staphylococci.
During our evaluation, Vitek 2 reported two major errors for clindamycin
and erythromycin susceptibility in two strains: one with conﬁrmed
constitutive MLSB for clindamycin (0.8%) and another found susceptible
for erythromycin (0.8%).
Conclusion: The high false positive rate excludes the application of the
AES for the reliable detection of iMLSB in Staphylococcus species. The
company announced to provide an improved iMLSB detection method
in the near future.
P602 Evaluation of MicroScan WalkAway for identiﬁcation and
antimicrobial susceptibility testing of Gram-positive cocci
H. Poupet °, J.M. Adam, N. Dmytruk, A. Billoet, C. Poyart (Paris, FR)
Objectives: The aim of this study was to evaluate MicroScan WalkAway
(Siemens) automated system for the identiﬁcation and antimicrobial
susceptibility testing (AST) of Gram-positive cocci. A total of 335 non-
redundant clinical isolates including 100 Staphylococcus aureus (SA),
50 coagulase-negative staphylococci (CNS), 55 Streptococcus agalactiae
(GBS), 71 Enterococcus sp (En), 20 b-hemolytic streptococci (BHS), 40
a-hemolytic streptococci (AHS) were tested.
Methods: MicroScan identiﬁcations were compared to: (i) phenotypic
routine tests for SA, GBS, and BHS; (ii) Vitek2 system (bioMe´rieux)
for CNS and En; and (iii) sodA sequencing for AHS. AST results were
compared to the agar dilution method according to the 2007 CA-SFM
recommendations.
Results: MicroScan correctly identiﬁed: 98% of SA, 98% of CNS,
94.5% of GBS, 96% of En, and 100% of BHS (identiﬁed as ﬁrst choice
>85% probability: 96% of SA, 71% of CNS, 84% of GBS, 89% of
En, and 90% of BHS, identiﬁed with low-level discrimination <85%:
2% SA, 27% SCN, 8% SGB, 7% En, and 10% BHS). Nine strains
were misidentiﬁed: SA (2%), CNS (2%), GBS (9%), En (4%). Using
sodA sequence determination as the gold standard, 72% of AHS were
correctly identiﬁed by MicroScan among which 15% were identiﬁed with
low-level discrimination. However 28% AHS were misidentiﬁed.
AST results were as follows:
i. SA: methicillin resistance was detected in 98% of the strains.
Two strains expressing low level methicillin resistance were not
detected. Very Major Error (VME) (susceptible (S) for resistant
(R)) were observed for penicillin G (2.5%), quinolones (1.2%), and
trimethoprim/sulfamethoxazol (1.2%).
ii. CNS: methicillin resistance was detected in 98% (1 major error
R for S). 2% VME were observed for quinolones, tobramycin, and
trimethoprim/sulfamethoxazol; 14% VME for fucidic acid; and 10%
for fosfomycin.
iii. Streptococci: 100% agreement was observed between the two
methods concerning b-lactams. Among GBS, 28 strains were
resistant to erythromycin (Ery) and/or clindamycin (Cli). Ery and
Cli resistance was not detected by MicroScan in 18% and 4%,
respectively.
iv. En: all strains resistant to glycopeptides were detected by
MicroScan. 1 VME was observed for kanamycin.
Conclusion: This study shows that the MicroScan system is an
acceptable system for identiﬁcation and AST of Gram-positive cocci
in routine laboratory. However, macrolide resistance detection in
streptococcal species remains to be improved.
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P603 Multicentre evaluation of the MicroScan Dried Overnight
cefoxitin screen test for coagulase-negative staphylococci
J. Hindler, K. Ward, D. Bruckner, K. Sei, M. Bacsafra, H. Bains,
L. Mann, B. Zimmer ° (Los Angeles, West Sacramento, US)
Objectives: Accurate detection of methicillin resistance in clinically
signiﬁcant coagulase-negative staphylococci (CNS) is essential. CLSI
recently introduced disk diffusion testing with cefoxitin (FOX) as an
alternate method to determine mecA-mediated methicillin resistance in
CNS. Interpretive criteria using FOX broth microdilution have not yet
been established for CNS. A multicenter study was performed to evaluate
the MicroScan broth microdilution Cefoxitin Screen (CfxS) Test used
in combination with the 18 hour oxacillin MIC. Results obtained were
compared with mecA or FOX disk results.
Methods: MicroScan panels were evaluated at three sites with 184
efﬁcacy and 32 challenge isolates (114 S. epidermidis and 102 other CNS
including 16 S. lugdunensis). Isolates were tested on a MicroScan Dried
Overnight Gram Positive Panel containing a single well with 4 ug/ml
cefoxitin and oxacillin concentrations of 0.12 to 8 ug/ml. MicroScan
results were compared to FOX disk and to mecA PCR. Panels were
inoculated using the turbidity standard method and read visually at 18 h.
FOX disk diffusion was performed as described and interpreted by CLSI.
MecA PCR was performed using primers described by Murakami et al.
(J. Clin. Microbiol. 29: 2240–2244).
Results: Sensitivity and speciﬁcity of the MicroScan panel using CfxS
and the 18 h OX MIC for detection of OX resistance compared to mecA
PCR were 99.2% and 95.9%. The MicroScan panel had 0.8% VME
(1/118) and 4.1% ME (4/98). Two of the 4 ME triggered a software
Alert rule indicating that CNS with OX MICs of 1 or 2 and negative
CfxS results may still be mecA negative and that additional testing might
be performed to resolve the mecA status. Sensitivity and speciﬁcity for
CfxS and 18 h OX MIC compared to FOX disk were 96.6% and 92.8%.
Sensitivity and speciﬁcity of the FOX disk results compared to mecA
PCR were 95.8% and 93.9%.
Conclusion: This multicenter study showed the MicroScan Dried
Overnight panel Cefoxitin Screen (CfxS) results correlate well with
mecA PCR testing for CNS.
Diagnosis and susceptibility testing of
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P604 Validation of the MicroScan WalkAway®-96 for the species
identiﬁcation and susceptibility testing of clinically signiﬁcant
coagulase-negative staphylococci
L. Patteet, L. Peeters, H. Goossens, M. Ieven ° (Antwerp, BE)
Objectives: Because of their increasing importance Coagulase Negative
Staphylococci(CNS)should be identiﬁed to the species level and
susceptibility testing be performed in clinically signiﬁcant specimens by
a reliable method. Whereas S. epidermidis is usually easily identiﬁed
with a high accuracy, some less prevalent species among the CNS
are identiﬁed with much lower accuracy by some commercial systems.
The aim of this study was to validate an automatic system, MicroScan
WalkAway®-96 in conjugation with the MicroScan®–Pos BP Combo
Panel Type 28 (Siemens Healthcare Diagnostics, Sacramento CA) for
the identiﬁcation and methicillin susceptibility of CNS.
Methods: The MicroScan system was evaluated on a collection of 428
CNS isolated in the University Hospital Antwerp. Identiﬁcation to the
same species level by a validated in-house method (J. Clin. Microbiol.
1995; 33: 1060), 2 commercial methods (API ID 32 Staph® and Staph-
zym®) and the biochemical reference method was considered the gold
standard. Methicillin susceptibility was compared to MICs for oxacillin
combined with PCR for the mecA gene.
Results: 413/428 (96.5%) of isolates could be identiﬁed correctly by
the MicroScan WalkAway®-96 system: S. epidermidis 292/296 (99%),
S. haemolyticus 48/50 (96%), S. hominis 33/34 (97%), S. capitis 13/14
(93%), S. warneri 9/14 (64%), S. lugdunensis 4/5 (80%), S. schleiferi
6/6, S. cohnii 2/2, S. saprophyticus 2/2, S. hyicus 1/1, S. intermedius 1/1,
S. sciuri 1/1, S. xylosis 1/1, S. lentus 0/1.
Of the 15/428 (3.5%) strains not correctly identiﬁed, 5 were S. warneri:
3 were identiﬁed at the genus level, 2 were misidentiﬁed; the 12 other
species were misidentiﬁed as other CNS.
The MicroScan system determines the methicillin susceptibility by
interpreting the susceptibility for oxacillin and cefoxitin, both integrated
in the Combo Pos panel. The correlation between the oxacillin
and cefoxitin susceptibility results was 98%. When the methicillin
susceptibility of the CNS determined by MicroScan was compared with
the MecA PCR method, the correlation was 97.6% both with oxacillin
and cefoxitin: 10/406 (2.5%) isolates showed a discrepant result, 8 were
reported false resistant in mecA negative strains, 2 were reported false
susceptible in MecA positive strains.
Conclusion: From this study, we concluded that, except for S. warneri,
the MicroScan WalkAway®-96 system is a simple and reliable method
for the identiﬁcation and methicillin susceptibility testing of CNS.
P605 Rapid detection of Staphylococcus aureus strains with reduced
susceptibility to vancomycin by isothermal microcalorimetry
A. Bizzini °, A. Trampuz (Lausanne, CH)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is an
increasing cause of morbidity and mortality. Vancomycin (VAN) is
the ﬁrst-line antibiotic for serious and invasive MRSA infections.
However, MRSA can exhibit heterogeneous (hVISA) or homogeneous
(VISA) intermediate susceptibility to VAN, which has been associated
with treatment failure. Therefore, the detection of VAN intermediate
resistance is of high importance in the clinical setting. Current
microbiological techniques, such as population analysis proﬁle (PAP),
are laborious and time-consuming. We investigated the potential of
microcalorimetry as a rapid and simple method to detect subpopulations
of reduced susceptibility to VAN by detection of growth-related heat
production in the presence of VAN.
Methods: CLIN, a clinical MRSA isolate (VAN MIC 1mg/L) was used
as a VAN susceptible control (VSSA). S. aureusMu3 (VANMIC 2mg/L)
was the representative strain for hVISA and S. aureus Mu50 (VAN MIC
8mg/L) for VISA. PAP was performed according to standard techniques.
Microcalorimetry was performed by inoculating 107 CFU of overnight
cultures into vials containing 2ml of brain heart infusion broth with serial
dilutions of VAN (from 0 to 8mg/L). Heat production was measured at
37ºC under static conditions for 48 hours. Detection of heat (representing
bacterial growth) was set at 20 microWatts, and the time to detection
(TTD, in hours) was determined.
Results: Table 1 shows the calorimetric TTD of the tested S. aureus
strains at various VAN concentrations. No heat production was detected
in the VSSA MRSA isolate at VAN concentration 1mg/L during the 48
hours of incubation. The Mu3 (hVISA) showed heat production with a
dose-proportional delay to 3.5 h (VAN 2mg/L) and 28.5 h (VAN 4mg/L).
The Mu50 (VISA) produced heat up to VAN 8mg/L.
Conclusions: Microcalorimetry was able to detect the presence of the
VAN resistant subpopulations in hVISA and VISA within 4 h. Measuring
of bacterial heat production may represent a simple and rapid method for
detection of various heteroresistant bacterial phenotypes. The accuracy
and reproducibility need to be tested with clinical strains and validated
with PAP.
Table 1
VAN concentration (mg/L) TTD
VSSA (CLIN) hVISA (Mu3) VISA (Mu50)
0 0.8 0.1 0.1
1 − 0.1 0.1
2 − 3.5 0.1
4 − 28.5 7.1
8 − − 37.5
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P606 Gram staining and recovery capacity of methicillin-resistant
Staphylococcus aureus by the Copan Eswab™ system versus
the Copan dry swab system
V. Saegeman °, J. Flamaing, J. Muller, W. Peetermans, J. Verhaegen
(Leuven, BE)
Objectives: The Copan ﬂocked swab system supplied with liquid Amies
medium (Eswab™) is getting established in a growing number of
hospitals. The aim of this study was to compare the performance of
the methicillin resistant Staphylococcus aureus (MRSA) Eswab™ with
that of the traditional Copan dry swab in terms of Gram staining, total
recovery capacity and MRSA detection.
Methods: Swabs were taken from 70 patients hospitalised in the
University Hospitals Leuven (geriatric medicine, internal medicine,
intensive care unit burn wounds). Nose and perineum were sampled
both with two conventional dry swabs and with the MRSA Eswab™.
The Eswab™ and the dry swab were alternate used ﬁrst.
Gram stains were performed by rolling the dry swabs over a slide and by
placing a drop of the vortexed Amies medium of the Eswab™on a slide.
Gram staining was performed with a Mirastainer® (Merck KGaA).
Recovery capacity was evaluated based on the recommendations of
CLSI document M40-A. More speciﬁcally, the swab elution method was
used to provide quantitative comparisons. The dry swabs were vortexed
in 1mL sterile physiologic saline. Three serial 10-fold dilutions were
prepared from each swab medium (saline/Amies). From each dilution,
100 ml was plated with the spiral plater (Spiral Biotech, autoplate 4000)
on mannitol-salt agar and MRSA chromogenic agar plate. Bacterial
counts were performed by means of the IUL Countermat Flash 4.2
automatic reader system.
Statistics: paired t-test and McNemar c2.
Results: Gram stains from the Eswab™ had a better quality than those
from the dry swab: more bacteria per high-power ﬁeld (67% vs 7%),
more bacterial species (51% vs 9%), and more epithelial cells (17% vs
13%) were noticed on the Eswab™ slide.
The total recovery capacity (CFU/mL) on average was 0.35 log higher
with the Eswab™. This was signiﬁcantly higher than the recovery with
the dry swab (paired t-test of log-transformed data, p< 0.01).
MRSA was detected only with Eswab™ in 3/70 samples. In 1/70
samples, MRSA was detected only with the dry swab. This difference
was statistically signiﬁcant (McNemar c2, p< 0.01).
Conclusion: This study showed that the higher recovery capacity of the
Eswab™ system also entails a higher chance of detecting MRSA. A
more extensive study should conﬁrm this hypothesis. Implementation of
this Eswab™ will require a cost-beneﬁt analysis. The extra costs of the
Eswab™ should be compared with the savings of detecting more MRSA
carriers.
P607 Isolation of MRSA: a comparison of direct plating
on Brilliance™ MRSA agar and broth enrichment on
Chromagar MRSA agar
S. Jobbitt, E. Scopes ° (Dunedin, NZ; Basingstoke, UK)
Objective: Standard laboratory procedures at Southern Community
Laboratories, NZ, for MRSA isolation currently involve broth enrich-
ment prior to plating onto CHROMagar MRSA Agar (BD). This study
compares the standard laboratory procedures to direct inoculation onto
Brilliance™ MRSA Agar (Oxoid).
Method: 362 swabs were collected from patients undergoing screening
for MRSA. Swabs were directly inoculated onto Brilliance MRSA
Agar and plates were incubated at 37ºC for 24 h. The swabs were
then tested according to standard laboratory procedures. Procedures
involve swab inoculation into an MRSA enrichment broth and incubation
at 37ºC for 24 h. Post-enrichment the broth was subcultured onto
CHROMagar MRSA Agar and plates were incubated at 37ºC for
24 h. Growth of presumptive MRSA on Brilliance MRSA Agar and
CHROMagar MRSA Agar was conﬁrmed by Gram stain, coagulase test,
latex agglutination, and cefoxitin-resistance testing. This conﬁrmation
algorithm was considered to be the gold standard.
Results: Eight of the 362 swabs were conﬁrmed as MRSA positive
(2% prevalence rate). The direct plating method on Brilliance MRSA
Agar gave a sensitivity and negative predictive value (NPV) of 100%
and speciﬁcity of 99%. The broth enrichment method on CHROMagar
MRSA Agar gave a sensitivity and NPV of 100% and speciﬁcity of
98%. Direct inoculation of Brilliance MRSA Agar yielded fewer false
positive results than broth enrichment onto CHROMagar MRSA Agar.
Conclusions: Direct inoculation of Brilliance™ MRSA Agar is a highly
effective technique for the screening of patients for MRSA, showing
high sensitivity, speciﬁcity and NPV. Although the number of positives
was low, the study indicates that MRSA can be isolated on Brilliance
MRSA Agar without the need for additional, time-consuming and costly
steps such as broth enrichment. Brilliance MRSA Agar also successfully
inhibits the growth of most non-MRSA organisms, reducing the need
for conﬁrmation procedures. Early presumptive MRSA identiﬁcation
by Brilliance MRSA Agar allows appropriate treatment and infection
control procedures to be adopted earlier, improving both treatment
outcomes and the effectiveness of infection control measures.
Table 1. Performance of direct plating and broth enrichment methods for
detection of MRSA
Performance Direct plating
onto Brilliance
MRSA Agar
Broth enrichment
onto CHROMagar
MRSA Agar
Sensitivity (%) 100 100
Speciﬁcity (%) 99 98
NPV (%) 100 100
Time to result (h) 18−24 42−48
P608 Optical mapping reveals a genetic insertion in colonizing
Staphylococcus aureus isolated from diabetic foot ulcers
A. Sotto, G. Lina, J.L. Richard, G. Skorski, C.W. Dykes °, J. Etienne,
J-P. Lavigne (Nıˆmes, Lyon, Bernis, FR; Gaithersburg, US)
Objective: Recently we highlighted the coexistence of two Staphylococ-
cus aureus populations in diabetic foot ulcers (DFU): one colonizing with
low virulence potential and one infecting with high virulence potential.
The purpose of this study was to assess the epidemiological links and
genomic rearrangements between these 2 S. aureus populations with
the goal of developing a tool to discriminate non-infected from infected
DFU.
Methods: Diabetic patients hospitalized in a diabetic foot department
with a foot ulcer were prospectively enrolled if they had been free of
antibiotic treatment over the previous 6 months. At admission, ulcers
were classiﬁed as infected or noninfected on the basis of clinical
examination, according to the International Working Group on the
Diabetic Foot system. Only patients carrying S. aureus as the sole
pathogen were included. Twenty-two patients harboring DFU (8 Grade
1, 4 Grade 2, 7 Grade 3 and 3 Grade 4) were enrolled. Strains were
subjected to analysis by Pulsed Field Gel Electrophoresis (BioRad),
using restriction endonuclease SmaI, and by Optical Mapping (OpGen
Inc., Gaithersburg, USA) to examine their genomic organization and
to search for shared features. Optical Maps were grouped according to
similarity using the UPGMA method.
Results: Using PFGE, no clonal link was detected between the different
strains, notably those isolated from Grade 1 ulcers (~70% homology).
Using Optical Maps, we identiﬁed that colonizing S. aureus (Grade 1)
belonged to a clonal group (CI) near to USA300 and infecting S. aureus
(Grade 2−4) to three clonal groups (CI, CII near to USA800, CIII
near to USA200). Four infecting strains also belonged to the same CI
clone as the colonizing strains, with more than 90% homology between
these strains. Optical Mapping identiﬁed the presence, and approximate
location, of an inserted DNA element in colonizing strains that was not
present in infecting strains. This insertion was exclusively present in all
Diagnosis and susceptibility testing of Staphylococcus and Enterococcus S145
Grade 1 strains and served to distinguish between the 2 populations. The
possibility that the insertion disrupts a gene related to virulence is under
investigation.
Conclusion: Optical Mapping provides considerably greater resolving
power than PFGE for distinguishing between colonizing and infecting
S. aureus in DFU and could contribute to more appropriate use of
antibiotics in these patients.
P609 Evaluation of chromogenic and selective media for the
detection of Pseudomonas aeruginosa and Staphylococcus
aureus in respiratory samples from cystic ﬁbrosis patients
E. Andre °, P. Lebecque, A. Simon, T.D. Huang (Brussels, BE)
Objectives: Early detection of Pseudomonas aeruginosa (PA) and
Staphylococcus aureus (SA) infection in cystic ﬁbrosis (CF) patients
remains a challenge for the microbiology lab. The aim of this study was
to compare commercial selective media to standard culture media for
the recovery and the presumptive identiﬁcation of PA and of SA directly
from sputum collected in these patients.
Methods: 67 sputa from 67 ambulatory CF patients were cultured
onto 6 selective media including MacConkey agar (MC; home-made),
Pseudomonas Isolation Agar (PABD; Becton-Dickinson), ChromID PA
agar (PABM; bioMe´rieux), a colistin aztreonam blood agar plate (CAP,
Oxoid), CHROMagar SA medium (SABD; BD) and ChromID SA
agar (SABM; bioMe´rieux). After up to 7 days of incubation at 35ºC,
colonies suggestive of PA or SA according to the plates reading
guidelines provided by the manufacturers were selected for phenotypic
identiﬁcation. Isolates showing atypical testing results were further
submitted for 16S rRNA sequencing.
Results: PA isolates were found in 14 samples (21%) growing at least on
one of the three selective media for PA. No signiﬁcant difference could be
observed between the three media in terms of the median time of growth
which ranged from 48 to 72 hours for both PA and SA. For PA, the
sensitivities were 71% (n = 10), 93% (n = 13) and 78% (n = 11) for MC,
PABD and for PABM respectively. The speciﬁcities of the two selective
media calculated on the basis of interpretative criteria provided by the
manufacturers were 69% for PABD and 85% for PABM. 29 patients
(43%) were found positive for SA and SABM showed signiﬁcantly
higher sensitivity (96%; n = 28; p< 0.05) compared to those obtained
for CAP (52%; n = 15) and SABD (79%; n = 23). The speciﬁcities of
the two chromogenic media were 58% for SABD and 72% for PABM
according to the recommended interpretative criteria. 46% (n = 13) of
the total SA isolates recovered by this method displayed small colony
variants phenotype.
Conclusion: The use of speciﬁc selective media could increase the
recovery of PA and SA isolates in CF respiratory samples and could lead
to an earlier management and antimicrobial therapy for these colonized
or infected patients. However, the identiﬁcation of the isolates should be
conﬁrmed as suggested by the low speciﬁcity of these media.
P610 Rapid detection of Staphylococcus aureus from blood culture
with SaSelect or MRSASelect
A. Decoster °, E. Dehecq (Lomme, FR)
Objectives: Only few hours incubation time are necessary to identify
Staphylococcus aureus and differentiate methicillin resistant (MRSA)
from blood culture by using SaSelect and MRSASelect.
Methods: After Gram staining, all blood cultures containing Gram
positive cocci in clusters were subcultured on SaSelect and MRSASelect
(Bio-Rad). In parallel, 10 blood culture bottles were spiked with 8 MRSA
strains and 2 methicillin resistant coagulase negative staphylococci. The
readings were performed from 6 h until 32 h of incubation (in general,
the readings were performed at 6, 8, 24 and 32 h at 35−37ºC). The
identiﬁcation of S. aureus was conﬁrmed by Pastorex Staph (Bio-Rad).
Results: 103 blood cultures positive to Gram positive cocci in clusters
were collected from February to June 2009, 44 of them containing
Staphylococcus aureus (17 MRSA and 27 MSSA), 58 holding coagulase
negative staphylococci, in one culture was identiﬁed a Micrococcus. All
the S. aureus have grown on SaSelect, all the MRSA have grown on
MRSASelect. The percentage of detection of S. aureus is described in
the following table according to the incubation time.
Even though about 13% of them were slightly pinkish, no coagulase
negative staphylococci showed the typical coloration of S. aureus even
after 32 h incubation time. The spiked specimens have conﬁrmed the
prospective data.
Conclusion: From 6 to 32 h incubation time, as soon as pink colonies
are detected on SaSelect or MRSASelect, the microbiologist can report
the presence of a S. aureus or more precisely of a MRSA.
Time after incubation Percentage of detection of S. aureus
Sa Select MRSA Select
6 h 43% 8%
8 h 93% 27%
10 h 98% 75%
P611 An evaluation of different methods to recover methicillin-
resistant Staphylococcus aureus from hospital environmental
surfaces
A. Dolan °, M. Bartlett, B. McEntee, E. Creamer, O. Sherlock,
H. Humphreys (Dublin, IE)
Objective: Due to the increased costs and clinical importance of
healthcare-associated infections (HCAI), there is a need for evidence-
based approaches to environmental sampling and its evaluation. We
compared the recovery of MRSA from two hospital surfaces using
different sampling methods, with a wild-type patient strain of methicillin-
resistant Staphylococcus aureus (MRSA).
Methods: One-hundred cm2 sections of mattress cover and laboratory
bench surface were contaminated with known inocula of MRSA. Bacteria
were recovered at three different time intervals (0 h, 24 h and 72 h)
using either saline moistened cotton swabs, neutralising buffer swabs
(Technical Service Consultants, U.K.), eSwabs (Copan, Italy), or direct
contact plates (MRSA Brilliance, Oxoid, U.K.). Swabs were enriched
in tryptone soya broth (Oxoid), nutrient broth (Oxoid), Amies solution
(Copan) or brain heart infusion (Oxoid) at 37ºC. Ten microlitres of
enrichment media were transferred to MRSASelect chromogenic agar
plates (BIO-RAD, France) after 18 h and incubated along with the
contact plates for 24 h at 37ºC. The sensitivity of each method cm−2
was determined for all time intervals and surfaces.
Results: The most sensitive method was eSwabs enriched in Amies
solution, which required 1.1 bacteria cm−2 to generate a positive result.
The least sensitive method was saline moistened cotton swabs, which
required 8.0×104 bacteria cm−2. MRSA Brilliance contact plates were
the quickest (24 h for a presumptive positive) and least labour intensive
method, and were highly sensitive, requiring 2.4 bacteria cm−2 to
generate a positive result. All sampling methods required less bacteria
cm−2 from the laboratory bench surface (ﬂat) than the mattress cover
surface (highly undulated) to generate a positive result. All sampling
methods showed a signiﬁcant reduction in sensitivity at the 72 h time
interval.
Conclusions: The recovery of bacteria from environmental samples
varies with the swabs, methodology used and the surface. Negative
culture results may not exclude a pathogen-free environment. Greater
standardisation in environmental sampling is required to facilitate the
assessment of and monitor improvements in the cleanliness of healthcare
institutions.
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P612 How many lumens should be cultured in the conservative
diagnosis of catheter-related bloodstream infections?
M. Guembe °, M. Rodrı´guez-Cre´ixems, C. Sa´nchez-Carrillo,
A. Pe´rez-Parra, P. Martı´n-Rabada´n, E. Bouza (Madrid, ES)
Objectives: Recent practice guidelines for the diagnosis of catheter-
related bloodstream infection (CRBSI) describe as an “unresolved issue”
the number of lumens from which blood cultures should be drawn to
make a conservative diagnosis of CRBSI. Our objective was to determine
how many CRBSI episodes would be missed if not all catheter lumens
were sampled.
Methods: We performed a retrospective study in patients with
microbiologically proven CRBSI in which all available catheter lumens
were used to drawn blood cultures. We artiﬁcially and randomly
eliminated the information and laboratory results of 1 or more lumens in
order to recalculate the number of episodes that would have been missed
in double and triple-lumen catheters.
Results: We collected 171 episodes of proven CRBSI corresponding
to 154 patients. Overall, if 1 lumen culture had been eliminated in
both double-lumen and triple-lumen catheters, we would have missed
37.5% and 25.4% episodes of CRBSI, respectively. If we had eliminated
2 cultures in triple-lumen catheters, 47.5% episodes would have been
missed.
Conclusion: Samples for blood culture should be obtained through all
catheter lumens in order to establish a diagnosis of CRBSI.
P614 Comparison of two chromogenic media for detection of
vancomycin-resistant enterococci from South Australian
patients
E. Scopes °, H. Henry (Basingstoke, UK; Adelaide, AU)
Objective: To compare the performance of two chromogenic media for
detecting vancomycin-resistant enterococci (VRE) from faecal samples
and rectal swabs sourced from patients undergoing VRE-screening at a
South Australian hospital.
Method: 114 VRE isolates previously isolated from clinical samples
were streaked onto Brilliance VRE Agar (Oxoid) and chromID™ VRE
Agar (bioMe´rieux). 222 faecal samples and 370 rectal swabs were
inoculated onto Brilliance VRE Agar and chromID VRE Agar. Plates
were incubated at 35ºC and read at 20−24 h and 48 h. Presumptive
VRE colonies on Brilliance VRE Agar and chromID VRE Agar were
identiﬁed by Gram stain or biochemical identiﬁcation and susceptibility
testing. Isolates identiﬁed biochemically and phenotypically as VRE
were conﬁrmed by RT-PCR. The gold standard was deemed to be the
identiﬁcation of VRE by RT-PCR.
Results: 108 and 105 VRE isolates grew on Brilliance VRE Agar and
chromID VRE Agar respectively at 24 h. At 48 h, both agars showed
growth of all 114 isolates. For clinical samples, Brilliance VRE Agar
showed sensitivity and speciﬁcity comparable to or exceding that of
chromID VRE Agar at 20−24 h and 48 h incubation, although both agars
showed a reduction in speciﬁcity at 48 h. Both agars showed consistently
high NPV at both 20−24 h and 48 h.
Table 1. Performance of Brillance VRE Agar and chromID VRE Agar
for detection of VRE
Product Incubation
time (h)
Sensitivity (%) Speciﬁcity (%) NPV (%)
Brilliance VRE Agar 20−24 96.2
(95%CI 97.4–97.7)
96.5
(95%CI 95.0–98.0)
99.8
(95%CI 99.5–100)
chromiD VRE Agar 20−24 75.0
(95%CI 71.5–78.5)
94.8
(95%CI 93.0–96.6)
99.5
(95%CI 98.3–100)
Brilliance VRE Agar 48 100
(95%CI 100)
86.2
(95%CI 83.4−89)
100
(95%CI 100)
chromID VRE Agar 48 97.9
(95%CI 96.7–99.1)
67.1
(95%CI 63.3–70.9)
99.7
(95%CI 98.8–100)
Conclusions: Brilliance™ VRE Agar showed exceptionally better
sensitivity at 24 h than chromID™ VRE Agar and has proven to be
a highly sensitive and speciﬁc medium for the presumptive detection of
VRE from clinical samples. Brilliance VRE Agar produced signiﬁcantly
fewer false positive results (non-VRE) than chromID VRE Agar, thus
reducing the number of unnecessary further conﬁrmation procedures.
Reliable and accurate results were available within 24 h when using
Brilliance VRE Agar, allowing rapid initiation of infection control
measures and patient treatment.
P615 Evaluation of Brilliance™ VRE Agar for detection of
vancomycin-resistant enterococci from four geographically
different hospitals in the United States
E. Scopes °, M.A. Silvius (Basingstoke, UK; Lenexa, US)
Objective: To evaluate the performance of Brilliance VRE Agar for
detecting vancomycin-resistant enterococci (VRE) from stool samples
and rectal swabs sourced from four geographically different hospitals in
the United States.
Method: 398 stool samples and 250 rectal swabs were collected from
asymptomatic patients undergoing screening for VRE colonization.
Stools/swabs were streaked onto Brilliance VRE Agar and Bile Aesculin
Azide Agar containing 6mg vancomycin (BAAV). Plates were incubated
at 35±2ºC; Brilliance VRE Agar was read at 24 h and BAAV was
read at 24 h and 48 h. Presumptive VRE colonies on Brilliance VRE
Agar and BEAV were identiﬁed to species level and their antibiotic
susceptibility determined using laboratory standard methods. The gold
standard was deemed to be identiﬁcation of an enterococcus with a
vancomycin MIC> 6mg/ml.
Results: 221 vancomycin-resistant Enterococcus faecalis and E. faecium
(>256 mg/ml) were recovered from 208 specimens (34% prevalence).
Overall performance (sensitivity, speciﬁcity and negative predictive value
(NPV)) of Brilliance VRE Agar was greater than BAAV. Performance of
Brilliance VRE Agar was equivalent to the gold standard (McNemar’s c2
test P = 0.6171) whereas performance of BAAV was signiﬁcantly lower
(P 0.0001).
Conclusions: Brilliance™ VRE Agar is a highly effective product
for the screening of gastrointestinal colonization of VRE. Brilliance
VRE Agar detects the most clinically relevant enterococci, allowing
clear differentiation of E. faecalis and E. faecium while inhibiting
growth of intrinsically resistant E. gallinarum and E. casseliﬂavus,
whereas BEAV is unable to distinguish between Enterococcus species.
Early presumptive identiﬁcation of E. faecium and E. faecalis allows
appropriate treatment and infection control procedures to be adopted
earlier, improving treatment outcomes and the effectiveness of infection
control measures.
Table 1. Performance of Brilliance VRE Agar and BAAV for detection
of VRE
Performance Brilliance VRE Agar BAAV
True positive 218 238
True negative 435 336
False positive 1 73
False negative 3 10
Sensitivity (%) 98.6 (95%CI 97.4–99.8) 96.0 (95%CI 93.9–98.1)
Speciﬁcity (%) 99.8 (95%CI 99.3–100) 82.2 (95%CI 78.2–86.2)
NPV (%) 99.3 (95%CI 98.4–100) 97.1 (95%CI 95.3–98.9)
P616 CAMP-inhibition-like phenomenon: a novel character for
identiﬁcation of Enterococcus faecalis
W. Laolert °, P. Santanirand (Bangkok, TH)
Objectives: Various bacteria such as Streptococcus agalactiae, Listeria
monocytogenes are known to produce CAMP factor which shows
synergism with Staphylococcus hemolysin to enhance hemolysis on
sheep blood agar. On the other hand, organisms like Arcanobacterium
haemolyticum and some Corynebacterium spp. produce factor which
inhibits CAMP-reaction (so called reverse CAMP). These characters
have also been used as parts of bacterial identiﬁcation key. This study
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was aimed to establish the CAMP and inhibition of CAMP phenomenon
among Enterococcus spp.
Method: Four hundred and twenty three isolates of Enterococcus species
including E. faecalis (n = 225), E. faecium (n = 182), E. casseliﬂavus
(n = 8), E. gallinarum (n = 6) and E. rafﬁnosus (n = 2) were tested for
CAMP and CAMP-inhibition factors with S. aureus ATCC 25923
on sheep versus human blood agar. Group B streptococcus and
A. haemolyticum were used as positive control for CAMP and CAMP-
inhibition test, respectively.
Result: Interestingly, among tested organisms, one hundred and ﬁfty
three isolates (36.17%) were found to produce CAMP-inhibition-like
factor. This inhibition of CAMP phenomenon was observed only when
tested on human blood agar but not on sheep blood agar. Furthermore, all
CAMP-inhibition-like positive isolates were E. faecalis (68% of tested
E. faecalis isolates). Incubation conditions such as temperature (room
temperature versus 37ºC) or atmosphere (ambient air versus 5% CO2)
showed minimal effect on this phenomenon.
Conclusion: To our knowledge, this is the ﬁrst report of CAMP-
inhibition-like phenomenon in Enterococcus faecalis. Since the test
is easily performed and can distinguished between the most two
common clinical isolated Enterococcus spp. (E. faecalis and E. faecium),
therefore, it would be worth adding this test as a part of identiﬁcation
key for Enterococcus species.
P617 Comparative study of selective chromogenic (chromID VRE)
and bile esculine agar for isolation and identiﬁcation of
vanA-containing glycopeptide-resistant enterococci using a
mice model
G. Birgand °, F. Wallet, M. Simonet, R.J. Courcol, R. Leclercq,
B. Grandbastien (Lille, Caen, FR)
Objectives: Since the early 90’s, several French hospitals are affected
by the emergence of Enterococcus faecium resistant to Glycopeptides
(GRE). This study compared qualities of microbiological techniques in
order to set up the most efﬁcient screening method for GRE control.
Methods: This experimental study was performed with the inoculation
of various quantities (102 to108 CFU/L) of 2 GRE strains with vanA
gene (vancomycin MIC=32mg/L and >256mg/L) to 8 groups of 4 CF1
mice. Drinking water was constituted of suspensions of vancomycin.
Techniques compared were bile esculine agar containing 6mg/liter
vancomycin (BEV), BEV after enrichment (ECE) and the chromogenic
medium chromID VRE® (CID; bioMe´rieux®). A quantiﬁcation of the
colonization was assessed after dilutions of feces in sterile water. Mice
feces were collected at J0, J6 and J9 after colonization and inoculated
on each medium. Qualitative and quantitative microbiological data were
collected after 24 to 72 hours of incubation. Data analysis was performed
with epidemiological tools in reference to a Gold standard (GS).
Results: Before inoculation, none mouse was colonized with GRE. The
number of CFU of GRE in mice feces was varying from 0 to 9.5 106/ml
according to the technique and delays of incubation and colonization.
The rate of GRE isolated varied from 15 to 21/29 mice at J6 and from 5
to 23/32 mice at J9. Overall, at J6, the interpretation was easier with the
CID than with the BEV or ECE. This difference between medium was
reduced at J9. The isolation and the interpretation were easier in feces
from mice colonized with GRE owning the high MIC to vancomycin.
Sensitivity was varying from 16.7 for the BEV to 87.5% for the CID
and the speciﬁcity from 57.1 for the ECE to 100% in several techniques
according to the length of incubation and the delay after colonization.
The rate LR+/LR− varied from 1.14 for BEV to plus inﬁnity. The
Youden’s index varied from 0.5 for BEV to 0.96 for CID.
Conclusion: The CID after 48 h of incubation appeared as the best
technique in term of quality and delay of analysis. During an outbreak of
GRE carriage, the inclusion of the CID in ﬁrst intention in a screening
strategy could allow getting a quick view of the situation. During this
study, the enrichment didn’t increase the sensibility of BEV. These
techniques will be compared with molecular methods based on simplex
and multiplex PCR.
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P618 Evaluation of four fully-automated immunoassays for
diagnosis of syphilis
T.D. Ly °, C. Marcenaro, M. Dautigny (Ivry-sur-Seine, FR)
Background: Serology is central to the screening and diagnosis
of syphilis infection. The serologic diagnosis of syphilis has for
many years been carried out mainly with Venereal Disease Research
Laboratory (VDRL) or rapid plasma reagin (RPR) test, Treponemal
Haemagglutination Assay (TPHA) or Fluorescent Treponemal Antibody
Absorption test (FTA-ABS). Since there were limitations of these tests
(i.e. their lack of sensitivity in early dark-ﬁeld positive primary cases
and the relatively high incidence of false-positive reactions), the quest
for a speciﬁc serologic test for syphilis began many years ago and still
continues. In recent years, immunoassays using puriﬁed recombinant
proteins have been developed to this aim.
Objectives: In this study, the performance of four automated tests:
Architect Syphilis TP (Abbott), BioPlex 2200 Syphilis IgM, IgG (Bio-
Rad), Immulite 2000 Syphilis Screen (Siemens) and Liaison Treponema
Screen (DiaSorin), using recombinant proteins, was compared to that of
TPHA (Syphagen TPHA, Biokit Barcelona, Spain).
Methods: 392 unselected sera and seven selected samples from patients
with primary syphilis were tested by TPHA as well as these four assays.
Whenever one assay scored reactive, IgG and IgM Line Immunoblot
(Virotech) was used for conﬁrmation.
Results: The Architect, BioPlex, Immulite and Liaison tests had an
overall agreement of 96.7%, 96.4%, 96.9% and 96.4% with 95.2%,
94.3%, 94.4% and 94.4% negative agreement, and 97.4%, 97.4%, 98.1%
and 97.4% positive agreement respectively versus TPHA (equivocal
results were excluded). Immunoblot IgG conﬁrmed positive 3/12, 3/13,
3/14 and 3/14 discrepant Immulite, Architect, BioPlex and Liaison
results versus TPHA respectively. In addition, seven primary syphilis
specimens (i.e., TPHA-negative) scored positive by Architect, Immulite,
Liaison and BioPlex IgM. By contrast two patients scored negative by
Bioplex IgG.
Conclusion: Architect Syphilis TP, Liaison Treponema Screen and
Immulite 2000 Syphilis screen with their suitability of automation are
an ideal screening test. However, the BioPlex IgM helps to differentiate
past infections from recent as demonstrated from the negative BioPlex
IgG results for 2 of the 7 primary samples.
P619 Diagnostic speciﬁcity of rTPN17 chemiluminescence
immunoassay or CLIA (Liaison®) in comparison with
TPN15-TPN45 Elisa on true and false-positive syphilis tests
A. Rossi °, A. Tamborini, L. Pinese, E. Canali, A. Milano, A. Berrone,
A. Bassani, D. Rossi, A. Toniolo (Varese, IT)
Objectives: The aim of this study was to compare the diagnostic per-
formance of rTPN17 chemiluminescence assay LIAISON® Treponema
screen (DiaSorin, Saluggia, Italy) with TpN17-TpN45 ELISA routinely
performed on clinical patients and on blood donors syphilis screening.
Positive tests were analyzed with both methods and with rapid plasma
reagin (RPR), with hemoagglutination treponemal tests (TPPA) and
immunoblot.
Methods: The routinely performed ELISA test (ETI-Treponema Plus,
DiaSorin) was an automated indirect immunoassay based on TpN17 and
TpN45 antigens and detection time was 3 hours.
The chemiluminesce assay (LIAISON® Treponema screen, DiaSorin)
was an automated immunoassay based on recombinant speciﬁc
Treponema pallidum antigen rTpN17, which was used for coating
magnetic particles (solid phase) and the same antigen was linked to
an isoluminol derivative (isoluminol-antigen conjugate). Detection time
of CLIA syphilis test was 1 hour. Between October 2007 and May 2008
syphilis screenings were done on 18533 clinical specimens.
S148 20th ECCMID, Posters
Results: The positive syphilis ELISA tests were 2.6% (N= 481) and of
these 0.29% (N= 53) were “possible false positive”; the tests of these
patients were repeated 3 weeks and 3 months later with ELISA, RPR,
TPPA and immunoblot and no “relevant” syphilis clinical signs emerged.
All the positive syphilis ELISA tests were also analyzed with rTPN17
chemiluminescence assay and “true positive” were conﬁrmed.
But of the 53 “false positive” 35 became “true negative” and of the 26
ELISA “false positive” tests with low index values (OD/CO < 2.0) only
2 remained positives; thus CLIA diagnostic test performance was more
signiﬁcant [p< 0.0001] with low index values. Diagnostic speciﬁcity of
ELISA and of CLIA syphilis tests were 99.71 and 99.90%.
Conclusions:
1. ELISA and CLIA syphilis tests were highly speciﬁc (CLIA was only
signiﬁcantly more speciﬁc for “false positives” with low index values)
2. CLIA syphilis test had a shorter time of detection: it might be usefull
for solid organ/tissue donor tests.
3. The lower number of “false positive” tests performed with CLIA
might be usefull in blood donors screening.
P620 Evaluation of indeterminate or low-level positive results
with the LIASON chemiluminescence immunoassay for
laboratory diagnosis of syphilis
M. Gozalo °, R. Balbas, M.A. Martinez-Bernal, M.A. Rodriguez,
L. Martinez-Martinez (Santander, ES)
Objective: Positive and negative results for laboratory diagnosis
of syphilis with the LIASON Treponema Screen (Diasorin, Italy)
chemiluminescence immunoassay (CLIA) are considered for index
values of >1.1 and <0.9, respectively, with indeterminate results for
index values of 0.9 to 1.1. Additionally, low-level positive results (index
value <10) are occasionally obtained. The objective of this study was to
compare indeterminate and low-level positive results obtained with the
LIASON assay with those obtained with a second CLIA, with reagin
test and with two treponemal tests.
Methods: Thirty-eight sera obtained from different patients in the period
February to October 2008 for which index values of [>0.9 to 1.1]
(n = 6) or [>1.1 and <10] (n = 32) were obtained with LIASON were
also tested with the CLIA Architect Syphilis TP (Abbott), a reagin test
(RPR, Spinreact), indirect hemagglutination (TPHA, Spinreact) and a
line immunoassay (Inno-LIA Syphilis Score, Innogenetics). The assays
and interpretation of results were done according to the corresponding
manufacturer’s instructions. Clinical charts of the patients were also
reviewed.
Results: Thirteen out the 38 tested sera were from pregnant women
without any clinical suspicion of syphilis, while the remaining 25
samples corresponded to patients in whom a serologic diagnosis of
syphilis was requested. Positive/indeterminate/negative results were as
follows: 16/0/22 (Architect), 1/0/37 (RPR), 8/0/30 (TPHA) and 11/4/23
(Inno-LIA). The RPR assay was positive in only 1/38 (2.6%) samples,
which was also positive for all other tests. Both treponemal tests
TPHA and Inno-LIA were positive in 8 (21.0%) samples. The 3
additional positive and 3 out the 4 indeterminate results with Inno-LIA
corresponded to patients without any clinical evidence of syphilis (one
of them was HIV-positive), while the remaining indeterminate case was
in patient with a suspicion of syphilitic chancre. Overall, 23 (60.5%)
samples positive with LIASON were negative with both the reagin test
and the two treponemic assays.
Conclusion: Indeterminate and positive low index values (>1.1 and <10)
obtained with the LIASON Treponema Screen assay should be conﬁrmed
with a treponemal test for avoiding false serologic diagnosis of syphilis.
P621 Evaluation of nine Mycoplasma pneumoniae ELISAs using
latent class analysis: circumventing the lack of a gold standard
C.W. Ang °, D.I. Van ’t Oever, N. Al Naiemi, J.A. Bogaards (Amsterdam,
NL)
Objectives: To compare nine commercially available assays for detection
of IgM and IgG antibodies against Mycoplasma pneumoniae.
Methods: 92 serum samples from clinically well deﬁned patients (in-
cluding healthy controls and cross-reactivity controls) were tested in nine
ELISA systems (Fujirebio, Anilabsystems, Biorad, Diacheck, Medac,
Novagnost, Savyon, Serion, Viro-Immun) for either total Ig or IgM and
IgG antibodies. As there is no gold standard for detecting recentM. pneu-
moniae infections, we used a latent-class model with three classes (un-
infected, recently infected, past infection). Latent class analysis (LCA)
involves ﬁtting a statistical model using all available diagnostic tests to
deﬁne an internal reference standard. This is the ﬁrst report of the use of a
latent-class model with three classes in the evaluation of serological tests.
Results: Using the cut-offs of the manufacturers, LCA resulted in
a probability for each serum sample to belong to one of the three
classes (uninfected, recently infected, past infection). 9/92 samples had
a probability of >0.95, only 1/92 samples had a probability of 0.69 and
the other 82 samples had a probability of <0.05 to be in the “recently
infected” class. 19/92 had a probability of >0.95 to be in the “past
infection” class, and only 4/92 had a probability between 0.05–0.95 to
be in the “past infection” class. Based on the probabilities for each serum
sample, sensitivity and speciﬁcity for each ELISA could be determined.
The sensitivities of the IgM ELISA’s for detecting a recent infection
ranged from 61% (Novagnost) to 96% (Anilabsystems). The speciﬁcities
ranged from 60% (Fujirebio) to 99% (Viro-Immun).
Conclusion: LCA using three classes allows to categorize samples based
on their infection status and can be widely applied in serological studies.
LCA allows comparing sensitivity and speciﬁcity of diagnostic tests even
without a gold standard.
P622 Direct latex agglutination for group B streptococcus carriage
detection
M. Martı´nez °, P. Ferrer, M.R. Vicente, E. Riquelme, M. Pariente,
L. Moreno, M.D. Crespo (Albacete, ES)
Objectives: The purpose of this study was to compare direct latex
agglutination on incubated selective broth with the CDC recommended
method for group B streptococcus (GBS) detection in pregnant women.
Methods: 242 vaginorectal swabs submitted to our laboratory during
1 month were tested by both methods. The swabs were immersed in
SBM broth (Todd-Hewitt with gentamicin, nalidixic acid, 5% blood;
Biomedics®) and incubated at 35ºC in an ambient atmosphere. After
overnight incubation they were subcultured onto 5% blood agar and
incubated for 24 h at 35ºC with 5% CO2. In addition, group B latex
testing (Slidex® Strepto Plus, bioMe´rieux®) was performed on all SBM
adapting the protocol to broth. Subcultures were examined and GBS
colonies were conﬁrmed by catalase reaction, Gram stain and latex
assay (also hippurate hydrolysis test when colonies were non-hemolytic).
Negative plates were reincubated and examined on the following day.
Subcultures were repeated when we obtained discrepant results.
Results: The results are shown in Table 1. Only in 1 of the 16 repeated
subcultures (positive latex samples with negative culture) GBS colonies
were recovered. All of them revealed heavy growth of Enterococcus spp.,
which can mask the presence of GBS in subcultures, especially when
the initial load is low. In 8 of them we also detected polyagglutinating
colonies (usually non-hemolytic streptococci) that could have given
false-positive latex results. Despite this limitation, there is a possibility
that these specimens could be in fact true positive ones according
to previous studies with molecular methods. Unfortunately, we cannot
conﬁrm this. The method had a sensitivity and speciﬁcity of 94.3% and
92.8%, respectively; and the predictive values were 99% for a negative
test and 68.8% for a positive one. Speciﬁcity and positive predictive value
could improve if some of the latex-positive culture-negative samples were
conﬁrmed as true positive. Turnaround time in days was signiﬁcantly
lower for the latex method (0.94±0.03) compared to the standard one
(4.71±1.05).
Conclusion: Our results show that direct latex agglutination on overnight
incubated selective broth is at least as sensitive as the CDC recommended
method and it decreases the turnaround time and the laboratory workload.
Although further investigation is needed to conﬁrm its real sensitivity,
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these data suggest that it is a useful method to give reliable negative
results in less than one day.
Table 1. Results of CDC culture and GBS antigen detection methods
Subculture Latex No. of specimens
+ + 32
+ − 2
− + 16
− − 192
34 (14.1%) 48 (19.8%) 242
P623 Evaluation of two chromogenic media for screening of
group B Streptococcus in pregnant women
L. Book °, G. Al-Rawahi, E. Thomas (Vancouver, CA)
Objectives: To compare the performance of StrepB Select (SBB)
(BioRad) and chromID™ Strepto B agar (STRB) (bioMe´rieux) media to
that of our routine method for group B Streptococcus (GBS) detection
in women at 35 to 37 weeks gestation.
Methods: Five hundred consecutive vaginal/anal swabs were submitted
directly to our microbiology laboratory for routine GBS screen between
January and July 2009. Swabs were immediately emulsiﬁed in 0.5mL
of sterile saline and processed as follows:
1. Routine: Blood agar plates (BAP) (PML) + Streptococcus Selective
broth, Group B (GBS broth) (PML). The BAP:s and the GBS broths
were inoculated, then incubated at 35ºC. BAP:s were examined for
colonies with typical GBS morphology. Negative BAP:s were re-
incubated for an additional 24 hrs and the corresponding GBS broths
were sub-cultured to a BAP. All suspect colonies were conﬁrmed by
Prolex™ Streptococcal grouping latex reagents (Group B) (Pro-Lab
Diagnostics).
2. 2. Study: SBB plates + STRB plates + GBS broth. The SBB, STRB
plates and GBS broths were incubated for 24 hours at 35ºC, then
processed as follows: all plates were examined for the presence of
GBS (SBB: blue colonies; STRB: pale pink/red colonies) followed by
group B Strep latex agglutination on all suspicious colonies. Negative
SSB/STRB plates were reincubated for an additional 24 hours and the
GBS broth was subcultured to SBB and STRB. Conﬁrmation by latex
agglutination was considered the gold standard.
Results: A total of 109/500 samples (22%) were positive for GBS
as follows: Our routine method detected 88/109 (80%); SBB detected
90/109 (83%) at 24 hrs, 99/109 (91%) at 48 hrs, 107/109 (98%) after
selective broth culture; STRB detected 85/109 (78%) at 24 hrs, 95/109
(87%) at 48 hrs, 104/109 (95%) after selective broth culture.
Conclusion: Both chromogenic media were more sensitive than our
routine method for detection of GBS. The SBB was easier to read and
more sensitive whilst the STRB was more speciﬁc after direct reading.
However, the speciﬁcity becomes less of an issue if all suspect colonies
are conﬁrmed by latex agglutination.
Media Direct plate at 24 hrs Direct plate at 48 hours Broth enrichment
Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
BioRad 83% 95% 91% 89% 98% 91%
bioMe´rieux 78% 98% 87% 91% 95% 95%
P624 Evaluation of the performance of chromID™ Strepto B,
a new chromogenic medium, to search for Streptococcus
agalactiae in pregnant women
R. Soloaga °, S. Montibello, L. Guelfand, M. Machain, N. Carrion,
D. Ferreira, J. Pidone, E. Ceregido, S. Kaufman (Buenos Aires, AR)
Objectives: Streptococcus agalactiae (EGB) may colonize the perineal
area and genital tract. This is important in pregnant women since the
transmission rate to newly born children is 50%, from which 1−2% of
colonized ones develop clinical infection with a 10% mortality rate. The
Center for Disease Control and Prevention (CDC) suggests rectal and
vaginal exudate culture be performed within 35−37 weeks of pregnancy
and prophylaxis intrapartum be provided to all EGB carriers in order
to reduce incidence of neonatal disease. The objective was to determine
the usefulness of bioMe´rieux chromogenic medium chromID Strepto B
(CR) for detecting Streptococcus agalactiae in pregnant women from
the Todd Hewitt broth (THB) relating to the methods proposed by the
CDC.
Methods: 1924 swabs were analyzed, 962 from vaginal introitus (VI)
and 962 rectal (RS) belonging to 962 women within 35−37 weeks.
Both samples were referred to the laboratory in Stuart medium. VI
and RS swabs were directly seeded in CR and incubated at 37ºC in
aerobiosis for 48hs. Both swabs were later placed in THB with 15
ug/ml supplement of nalidixic acid and 10 ug/ml of colistin. After 24hs
incubation, subcultures in CR medium and agar were performed with
5% sheep blood (ASO). Suspicious colonies, red in CR and gray±b
hemolysis in ASO were identiﬁedd by conventional test such as Gram
stain, catalase, bile-aesculin, CAMP, hippurate hydrolysis and group B
serology.
Results: EGB was isolated in 168 patients, with a prevalence of 17.4%.
Sensitivity, speciﬁcity, positive and negative predictive value of THB
subcultures with CR supplement and 48 hs incubation was 98.8, 100,
100 and 99.7% respectively. The corresponding values of direct harvest
of the sample were 57.8, 100, 100 and 90% respectively. Sensitivity of
THB in ASO was 85%.
Conclusions: THB subculture performance in CR was outstanding as
regards the method proposed by the CDC. Furthermore, laboratory work
and the possibility of false negative results due to the absence of colonies
with b hemolysis is decreased by CR.
P625 Evaluation of different culture media, swabs and sampling
techniques for rapid detection of vaginal and rectal group B
streptococci in pregnant women
N. El Aila °, I. Tency, G. Claeys, B. Saerens, M. Temmerman,
R. Verhelst, M. Vaneechoutte (Ghent, BE)
Objectives: The aim of this study was to compare different selective
media for group B Streptococcus (GBS) detection in pregant women, to
compare different sampling techniques, i.e. combined vaginorectal swabs
with separate vaginal and rectal swabs and to compare two different types
of swabs.
Methods: Seventy women were included, and four swabs were collected
from each. Three Eswabs were used, one for vaginal, one for rectal
and one for combined vaginorectal sampling. In addition, a classical
swab was used for vaginal sampling. All four swabs were inoculated
indirectly onto chromID Strepto B agar, Granada agar and Columbia
CNA after overnight incubation in Lim broth. The vaginorectal swab
was also inoculated directly on chromID Strepto B agar, Granada agar
and Columbia CNA. Red colonies on chromID Strepto B agar, orange
pigmented colonies on Granada agar or hemolytic colonies on Columbia
CNA, were conﬁrmed as GBS using the CAMP test and GBS speciﬁc
PCR.
Results: Fourteen women (20%) were colonized with GBS. Of these, 13
were positive after direct culture and one after enrichment. Six harbored
GBS in both rectum and vagina, six only in the rectum and for two
only the vaginorectal swab was positive. For chromID Strepto B agar
three women were false positive with red colonies identiﬁed as other
streptococcal and enterococcal species.
One false-negative result on Granada agar corresponded to a non-
haemolytic and non-pigmented GBS strain which was correctly identiﬁed
on chromID Strepto B agar. No differences could be observed between
the Eswab and the classical swab for sampling the vagina.
Conclusion: chromID Strepto B agar correctly identiﬁed one more strain
than Granada agar, but yielded false positive results for three women.
GBS colonies can be easily visualized and are clearly apparent in 24 h
after direct inoculation. Unexpectedly, vaginorectal swabbing was most
sensitive, since it detected GBS in two additional women, compared
to separate swabbing of rectum and vagina. No difference was found
S150 20th ECCMID, Posters
between Eswab and classical swab for vaginal sampling. In conclusion,
Granada agar may be prone to false negative results whereas chromID
Strepto B agar may be prone to false positive results but both of them are
superior to Columbia CNA and excellent for rapid detection of group B
streptococci in vaginal, rectal and vaginorectal samples.
P626 Kingella kingae culture: comparative study among different
BacT/Alert haemoculture bottles
A. Gene´ °, A.C. Aguilar (Barcelona, ES)
Objectives: Kingella kingae isolation has increased since osteoarticular
samples from children are cultured in hemoculture bottles.
The aim of this study was to compare the ability to support K. kingae
growth of three different bottles of BacT/Alert hemoculture system
(Biomerieux®), taking into account the bacterial concentration of the
sample and the addition of blood supply in the culture medium.
Methods: The hemoculture bottles used were: SA (Standard aerobic),
FA (FAN aerobic, containing activate charcoal) and PF (Pediatric FAN,
containing activate charcoal).
Eighteen strains of K. kingae isolated in our hospital from osteoarticular
infection in 7–23 month old patients were studied.
Each strain was progressively diluted to obtain six different concentra-
tions (A − F) of approximately 108, 104, 103, 102, 10 and 1 colony
forming units / ml. Quantitative cultures in blood agar plates were done
to control the ﬁnal concentration of each dilution.
In two SA, FA and PF bottles, 0.4ml of each dilution was inoculated.
In one bottle of each type 1ml of sterile human blood was added. The
bottles were processed in the BacT/Alert automatic incubator. Negative
cultures were discarded after seven days. All strains were double tested
(Series a and b).
Results: Including both series, in the bottles SA, FA and PF with blood
supply growth was detected in 84%, 25% and 38% and without blood
supply in 34%, 6% and 6% respectively.
A direct correlation between bacterial concentration of the inoculums and
bacterial growth, and inverse correlation between bacterial concentration
and incubation time to detect growth were observed.
Conclusion: According to our results, BacT/Alert SA bottles, in
combination with blood supply, is a good method to isolate K. kingae
from inoculums with low bacterial concentration. The ability to support
K. kingae growth is higher in SA than in SF and PF bottles. Addition of
blood supply in the culture medium increases the growth capacity, mainly
in those with low bacterial concentration, and decreases the incubation
time to isolate this microorganism.
Type of bottle Series Dilutions. No. of growing strains (Range of hours to detect growth)
A B C D E F
SA+ blood a
b
18 (9−13)
18 (7−14)
18(15−26)
18 (14−28)
18 (18−29)
18 (16−38)
18 (20−34)
18 (18−50)
14 (22−43)
16 (20−58)
4 (22−29)
3 (27−41)
SA a
b
16 (11−96)
17 (10−74)
7 (27–115)
7 (32–101)
4 (42–113)
5 (35–125)
3 (61−84)
6 (40–118)
2 (80−94)
4 (44−98)
0
2 (58−74)
FA+ blood a
b
14 (9–113)
11 (9–103)
5 (24−82)
6 (25–115)
5 (29–106)
4 (28–139)
4 (31–130)
1 (34−)
3 (35−89)
1 (42−)
0
0
FA a
b
5 (17−77)
3 (39−94)
2 (48−50)
0
1 (67−)
1 (96–)
1 (60–)
0
0
0
0
0
PF + blood a
b
17 (8−65)
14 (8–132)
9 (31–127)
6 (21−60)
9 (31–118)
7 (24–168)
6 (33–146)
3 (24−96)
6 (39−91)
3 (29–110)
2 (37−96)
0
PF a
b
8 (9–146)
5 (36–108)
0
0
0
0
0
0
0
0
0
0
P627 Clinical relevance of rapid identiﬁcation of Gram-negative
pathogens causing bloodstream infections using a new
peptide nucleic acid ﬂuorescent hybridization assay
P. Della-Latta °, S. Whittier, F. Wu (New York, US)
Objectives: Gram-negative bacilli (GNB) causing bloodstream infec-
tions (BSI) can be life threatening in hospitalized patients. Rapid
identiﬁcation (ID) of common GNB pathogens can impact appropriate
empiric therapy and infection control precautions, and is therefore
critical to improve patient care. This study evaluated the performance
of the ﬁrst rapid assay to identify 3 major GNB, Escherichia coli (EC),
Klebsiella pneumoniae (KP) and Pseudomonas aeruginosa (PA), from
newly positive BC. Empiric therapy for PA differs from that for EC or
KP and rapid detection of KPC carbapenemase by real-time PCR further
impacts prudent empiric therapy and infection control decisions.
Methods: From Oct. to Nov. 2009, 76 BC bottles (28 patients)
newly smear-positive for GNB were tested with a new rapid tri-color
ﬂuorescence in situ hybridization (FISH) assay, the GNR Trafﬁc Light
PNA FISH (GNRTL) (AdvanDx). The peptide nucleic acid ﬂuorescent
(PNA) probes that target rRNA sequences of EC, KP and PA appear as
green, yellow or red cells, respectively, when examined by ﬂuorescent
microscopy. Culture ID was performed using the Vitek 2 system
(bioMe´rieux). KPC production was tested directly from BC by real-
time PCR. Patient charts were reviewed retrospectively for therapeutic
changes based on pathogen ID.
Results: Of 76 GNB from BC, 29 were EC, 12 KC, 2 PA and 5 had
both EC and KP. Of 28 patients with BSI due to GNB, 73% were
infected with the targeted pathogens. The sensitivity, speciﬁcity, positive
and negative predictive values for GNRTL ID compared to culture were
100%. No false-positives or false-negatives occurred and co-infection
(EC and KP) was rapidly detected in 3 patients. One KP was KPC-
producing, which resulted in a therapeutic change from piperacillin–
tazobactam to polymyxin B. PA detection resulted in the addition of
tobramycin to regimens.
Conclusions: GNRTL is a highly sensitive and speciﬁc assay for
identifying speciﬁc GNB from BC in real-time. The ability to distinguish
PA from enteric GNB is clinically useful in targeting appropriate
pathogen speciﬁc therapy. GNB were identiﬁed within 1.5 hrs compared
to 1−3 days with culture.
P628 Identiﬁcation of Burkholderia pseudomallei from 2 types of
media using Vitek 2 software version 4.03
T. Urbanski °, M. Costello, P. O’Loughlin (Brisbane, AU)
Objectives: Burkholderia pseudomallei, the causative agent of Melioido-
sis is listed as a Category B agent that could potentially be used in a Bio-
terrorist attack. Melioidosis is potentially fatal. It is important that this
disease is quickly diagnosed and treated. The resistance to a wide range
of antibiotics makes early detection important for therapeutic manage-
ment. Failure to Identify has been reported due to lack of knowledge and
inadequate test-systems for this organism. The Vitek 2 is rapidly becom-
ing integrated into microbiology laboratories with a requirement for reli-
able identiﬁcation. Vitek 2 GN cards and an upgraded software database
to version 4.03 and above are now in use. A follow up study of work done
by Lowe, Haswell and Lewis, 2006 was required to assess Vitek 2 perfor-
mance to identify the same collection of isolates from clinical specimens
within Australia and a PCR method was used to validate this work.
Methods: 100 B. pseudomallei isolates, were recovered from −70ºC
storage. Sub-cultures on columbia horse blood and sheep blood
agar were analysed on the Vitek 2 using GN cards and standard
procedures. Identiﬁcation results were assessed for the numbers of
correct identiﬁcations from the 2 agar types. PCR was used for
identiﬁcation as described by Novak et al., 2006.
Results: Isolates growing on horse blood and sheep blood agar gave
84 and 82 correct identiﬁcations; 9 and 10 low discrimination; 7
and 7 incorrect identiﬁcations; and 0 and 1 inconclusive identiﬁcation
respectively and no statistical signiﬁcant difference of identiﬁcation
using the 2 media types (p> 0.05). The 7 misidentiﬁed isolates gave
an identiﬁcation of Burkholderia cepacia. All 10 low discrimination
isolates were between B. pseudomallei and B. cepacia with the exception
of one isolate that could not be discriminated between B. pseudomallei,
B. cepacia and Pseudomonas aeruginosa. All isolates were conﬁrmed
as B. pseudomallei by PCR testing.
Conclusions: No statistical signiﬁcant difference could be attributed
to the 2 media types. An improvement in Vitek 2 database has
been demonstrated. A lower rate of incorrect identiﬁcations was seen
compared to previously published data. However, users should still
be aware of potential misidentiﬁcations with B. cepacia. Conﬁrmatory
testing by PCR offers a fast, reliable method for discrimination.
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P629 Analysis of recombination events in DNA mismatch repair
genes among Escherichia coli strains belonging to different
phylogroups with different mutation frequencies
J.M. Gonzalez, M.C. Turrientes, M.R. Baquero, R. Canto´n, J.C. Gala´n °,
F. Baquero (Madrid, ES)
Objective: The genetic load imposed by the high frequency of mutations
might lead to long-term deleterious effects for the mutator population.
In this work, we analyze another possibility, “recombinational rescue”
rate for wild-type mismatch repair (MMR) genes.
Methods:MMR genes including mutS, mutL, and mutH, as well as those
involved in oxidative damage (GO) mutT and mutY, and two housekeep-
ing genes (arcA and fumC) were sequenced in 66 human Escherichia-
coli isolates with different mutation frequencies (17 hipo-mutators; 23
normo-mutators; 21 weak-mutators; 5 strong-mutators) and different
phylogenetic groups B2 (17), D (16); A (19); and B1 (14). Sixty-nine se-
quences (including 3 reference sequences) were aligned using ClustalW
program, and the best-ﬁt model of nucleotide substitution was selected
using jModelTest program. Alignments were analyzed using PhyML,
software that estimates maximum likelihood phylogenies. Recombination
among aligned sequences was detected using RDPv.3.27 program.
Results: No evidences of recombinational events were found analyzing
the housekeeping genes, nor in mutH (MMR) and mutT (GO repair
system). Although recombination events were detected in mutY gene
(26%) the highest frequency of these events (p< 0.001) was detectable
in the MMR genes: mutS (55.07% of sequences analyzed) and mutL
(44.93%). Recombination events in mutS gene were higher in weak
mutators (71.43%), but interestingly in mutL gene weak mutators showed
the lowest rate of recombination (p< 0.05). To avoid phylogenetic noise
the sequences with recombination events were eliminated. In this new
scenario, D group is still extremely heterogeneous suggesting that new
phylogenetic groups must potentially be accepted. Phylogenetic trees
of non-recombination events showed higher number of incongruences
(when a gene was not clustering with its phylogenetic group) among
mutator strains (p< 0.05).
Conclusions: High rates of intragenic recombination occur for the
MMR gene mutS, and mutL (high recombination in mutS with
low recombination in mutL seems to be a particular feature of
weak-mutators). Mutator strains showed signiﬁcantly higher genetic
incongruence. These results suggest that recombinational variation of
MMR genes might provide alterations in the mutation frequencies of
human E. coli isolates, including “recombinational rescue” of hyper-
mutable strains. The classiﬁcation into four major groups appears to be
an oversimpliﬁcation of a more complex reality.
P630 The use of commercial system in the identiﬁcation of
Gram-negative non-fermenting bacilli isolated from cystic
ﬁbrosis patients
C.R. Saraiva, L.V. da Silva Filho, D. de Oliveira Garcia ° (Sa˜o Paulo, BR)
Cystic ﬁbrosis (CF) is characterised by chronic lung infections. Respi-
ratory tract of CF patients are often colonised or infected by speciﬁc
microorganisms. Gram-negative non-fermenting (NF) bacilli, such as,
Pseudomonas aeruginosa, B. cepacia complex and Stenotrophomonas
maltophilia are the most prevalent microorganisms and other NF,
including some atypical or of difﬁcult identiﬁcation, are occasionally
isolated. NF differ in the potential pathogenic and transmissibility, so,
the correct identiﬁcation of the species is critical for the treatment.
Objectives: This study evaluated the API 20 NE system and classical
phenotypic and genotypic (PCR) method in the identiﬁcation of NF
isolated from CF outpatients being seen at Pediatric Pulmonology Unit
(Uiversity of Sa˜o Paulo Medical School).
Methods: Sixty-seven NF with inconclusive results by classical
phenotypic methods using an extensive biochemical serie were analysed
by API 20NE system. S. maltophilia and Achromobacter spp were
conﬁrmed by PCR using speciﬁc primers to 23S rRNA and 16S rRNA
genes, respectively.
Results: The identiﬁcation by API 20NE system showed 34.3%
Achromobacter spp, 10.4% Ochrobactrum anthropi, 10.4% S. mal-
tophilia, 9% Ralstonia pickettii, 6% Acinetobacter spp, 6% Burkholderia
cepacia, 4.5% Comamonas testosteroni, 4.5% P. aeruginosa, 3% Alcali-
genes faecalis, 3% Delftia acidovorans, 3% P. stutzeri, 1.5% Moraxella
spp, 1.5% Rhizobium radiobacter, 1.5% Wautersia paucula 0.6% Borde-
tella bronchiseptica, 0.6% Brevundimonas vesicularis. PCR conﬁrmed
90% Achromobacter spp and 42% S. maltophilia. All the other identiﬁca-
tions were compared with the morphological characteristics and comple-
mentary biochemical tests and all of them showed inconclusive results.
Conclusion: API 20NE system was unable to identify correctly microor-
ganisms atypical or rarely isolated from respiratory tract of CF patients
according to the morphological characteristics and complementary
biochemical tests. The identiﬁcation needs to be conﬁrmed by 16S rRNA
sequencing. An association of phenotypic and genotypic methods is more
efﬁcient to identify correctly rare or atypical NF.
Financial support: FAPESP no 2005/01625−8 and PPG/CCD/SES.
P631 Using an optimized protocol of the Corbett CAS1200
automated liquid handling system as a fast PCR setup
platform, reduces hands-on and process time signiﬁcantly
E. van Zanten °, S. Hofs, A.M. Kooistra-Smid (Groningen, NL)
Objectives: In the past few years our laboratory has witnessed an
increase in the number of samples analyzed, and the number of pathogens
screened for, using molecular methods. Manual performance of the PCR
setup has put a strain on the laboratory technicians performing these
PCR assays, for both workload and quality maintenance. We therefore
implemented an optimized protocol of the CAS1200 liquid handling
system to automate the entire PCR setup process reducing workload,
hands-on time and increasing quality control.
Methods: The Corbett Robotics4 software has two important features
that can speed up the PCR setup signiﬁcantly: the option to re-use
tips and the possibility to implement a “sample bank duplication step”
(SbDS). These features reduce the number of robotic movements, and
allow the platform to multi-dispense small volumes from a single large
volume uptake. The re-use of a single tip and SbDS were investigated for
the possibility of carry over of primer/probe from one well to the next,
regarding false positive results. We validated the CAS1200 platform by
prospectively analyzing 180 clinical samples in our internally controlled
triple-multiplex real-time PCR assays, screening for 8 enteric pathogens,
and comparing the results with manual PCR setup. The automated PCR
setup dispenses three different PCR master mixes in a PCR tray, then
adds DNA isolate directly from DNA isolation vessels, using a single
tip per DNA isolate, to the PCR mix using SbDS, and ﬁnally dispenses
the remainder of the DNA isolate in a storage vessel.
Results: No carry-over contamination was observed using the automated
PCR setup. Re-using tips for both apportioning the PCR mix and DNA
isolates yielded reproducible volumes. Of the 180 samples, 43 samples
were positive in both methods. Manual setup yielded one (Ct 38.7)
and automated setup two (Ct 36.6 and 38.7) additional positive samples
respectively. The mean difference in Ct values was 0.1 (range −3.4 to
2.5) in favour of manual PCR setup. Automated PCR preparation setup
could be completed within approximately 17 minutes, where as a trained
technician performs the manual PCR setup in approximately 45 minutes.
Conclusion: The use of the optimized protocol of the CAS1200 liquid
handling system results in a fast PCR setup that signiﬁcantly reduces
hands on time and workload. Moreover, the risk on human errors
decreases when dealing with large sample quantities and complex PCR
setups.
P632 Evaluation of a chromogenic medium for extended-spectrum
b-lactamase-producing Enterobacteriaceae
P. Lagace´-Wiens °, F. Tailor, P. Baudry, D. Hoban, G. Zhanel for the
Canadian Antimicrobial Resistance Alliance
Objectives: ESBL-producers are increasingly considered an infection
control problem worldwide. Simple and speciﬁc means of screening for
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ESBL-producing Escherichia coli and Klebsiella sp. are complicated
by the fact that cephalosporin resistance in Enterobacteriaceae may
be mediated by other mechanisms. The purpose of this study was
to evaluate the performance of a differential chromogenic screening
medium selective for ESBL-producers with a large library of genetically
characterised cephalosporin-resistant E. coli and K. pneumoniae.
Methods: Isolates were from 12 medical centers across Canada.
213 E. coli and 17 K. pneumoniae with ESBL or AmpC mediated
cephalosporin resistance were studied. E. coli and K. pneumoniae
were screened using ceftazidime and/or ceftriaxone MIC1 ug/ml.
ESBL genes (CTX-M, SHV, TEM, OXA), AmpC promoter/attenuator
alterations and presence of acquired AmpC-type genes (ACT-1/MIR-1-
related, DHA-related, FOX-related and CMY-2-related) were detected by
PCR and, where needed, sequencing. CHROMagar-ESBL (CHROMagar,
Paris, France) was inoculated with 150 cfu of each test organism. Growth
characteristics, including colour and colony counts were obtained.
Results: 114 ESBL-E. coli (1 each of CTX-M-1, 9, -24 and -65, 2 CTX-
M-2, 24 CTX-M-14, 77 CTX-M-15, 4 CTX-M-27, and 3 SHV-2a), 92
AmpC-E. coli (46 CMY-2 and 45 promoter/attenuator mutants), 8 co-
expressing ESBL and AmpC-E. coli (4 CTX-M-15, 2 CTX-M-14, 1 each
of CTX-M-3 and -12, all with promoter/attenuator mutations), 17 ESBL-
K. pneumoniae (co-expression of CTX-M and SHV-type ESBLs) and 50
wild-type E. coli were studied. Growth on medium is described in Table
1. 2.3% of E. coli had an atypical chomogenic reaction with no colour
produced. All K. pneumoniae had a typical chromogenic reaction. All
uninhibited AmpC hyperproducing organisms had >100 colonies/plate
and for 7/10, the mechanism of cephalosporin resistance was the CMY-2
gene. One ESBL-E. coli was inhibited by the medium. This isolate
expressed the TEM-12 gene and had a ceftriaxone MIC of 0.12 ug/ml
and a ceftazidime MIC of 8 ug/ml.
Conclusions: For E. coli with ceftriaxone and/or ceftazidime
MIC 1 ug/mL, sensitivity for ESBL-producers is 99.2%, speciﬁcity is
89.0%. Sensitivity for K. pneumoniae was 100%, but numbers were
small. This medium may facilitate the screening of ESBL-carriers,
particularly in areas where prevalence of ESBL producers is relatively
low compared to AmpC or other class C cephalosporinase-producing
organisms.
Organism (n) Any growth on
medium, n (%)
Sensitivity
(for ESBL)
Speciﬁcity
(for ESBL)
ESBL-E. coli (114) 114 (100) 99.2% 89%
AmpC E. coli (91) 10 (11.0) 99.2% 89%
ESBL and AmpC E. coli (8) 7 (87.5) 99.2% 89%
ESBL1 K. pneumoniae (17) 171 (100) 100% N/A
Wild-type E. coli (50) 0 (0)
13 K. pneumoniae were phenotypically ESBL-producers but had only SHV-1 b-
lactamase.
P633 Extended-spectrum b-lactamase-producing
Enterobacteriaceae: diagnostic performance of the
chromogenic medium Brilliance®-ESBL
Y. Gil °, A. Burillo, J. Go´mez-Garce´s (Madrid, ES)
Objectives: The rapid spread of extended-spectrum b-lactamases
(ESBL) among the Enterobacteriaceae (EB) is currently a cause
of concern for the management of infections caused by these
microorganisms.
In this study, the use of Brilliance®-ESBL (Oxoid) to detect clinical
isolates of ESBL-producing EB was compared to a reference test (E-test
strips, bioMe´rieux). We also tested the method on urine samples spiked
with different concentrations of ESBL-producing EB.
Methods: Sixty clinical isolates of ESBL-producing EB, as determined
by an automated system (Vitek2®, bioMe´rieux), and 20 clinical isolates
of non ESBL-producing EB were plated on Brilliance®-ESBL plates
at ﬁnal concentrations of 105 cfu/ml and ESBL production checked in
parallel using ceftazidime or cefotaxime E-test strips with or without
clavulanic acid. Klebsiella pneumoniae ATCC 700603 was used as a
positive control and Escherichia coli ATCC 25922 was used as a negative
control. The isolates were also used to inoculate culture-negative urine
samples at three different ﬁnal concentrations, 105, 103 and 10 cfu/ml,
which were simultaneously plated on Brilliance®-ESBL and blood agar.
Results: After 24 h of incubation, the growth of 100% of the ESBL+
strains on Brillance® medium was detected. All strains of E. coli
produced night blue colonies, while non-E. coli EB were light green
(K. pneumoniae or Enterobacter cloacae) or tan (Proteus vulgaris).
Of the non ESBL-producers (20), 7 strains of E. coli presumably
producing TEM-1, TEM-2 or SHV-1 and 4 strains of E. coli expressing
AmpC did not grow on Brilliance®, while the remaining 8 strains of
E. cloacae and 1 of E. coli, derepressed which overexpressed AmpC,
did grow in the chromogenic medium. At each concentration tested in
the urine samples, similar counts were obtained to those rendered by
standard media such as blood agar.
Conclusions:
1. The performance of Brilliance®-ESBL was excellent for isolating
ESBL-producing EB strains.
2. Derepressed E. cloacae strains hyperproducing cephalosporins are
able to grow in this medium.
3. Brilliance®-ESBL correctly identiﬁed both groups of bacterial species
examined (E. coli vs. non-E. coli), although it was unable to
distinguish between the latter (K. pneumoniae or E. cloacae).
4. Brilliance®-ESBL showed the same detection limits as non-speciﬁc
media, yielding similar counts to those obtained on blood agar.
P634 The potential of phenotypic methods for detecting ESBL-
and AmpC-type broad-spectrum b-lactamases
M. Htoutou Sedlakova °, V. Hanulik, M. Chroma, K. Hricova, M. Kolar,
R. Schaumann, A.C. Rodloff (Olomouc, CZ; Leipzig, DE)
Objectives: At present, enterobacteria producing broad-spectrum
b-lactamases belong to the feared bacterial pathogens. Of particular
clinical importance are ESBL and AmpC enzymes increasing the risk
of failure of antibiotic therapy and related morbidity and mortality.
The reliable laboratory detection of these enyzmes is still challenging,
especially in the case of AmpC enzymes. The aim of the work was
to compare the sensitivity of selected phenotypic methods for detecting
ESBL and AmpC production.
Methods: A total of 106 strains of the Enterobacteriaceae family
were tested, in which molecular biology methods conﬁrmed the
presence of genes encoding for ESBL (85 strains) or for AmpC
(21 strains). The strains were identiﬁed using the Phoenix automated
system (Becton Dickinson). In ESBL-positive strains, the sensitivity
of the ESBL E-test (AB Biodisk) and the modiﬁed double-disk
synergy test (DDST) was evaluated. AmpC strains were tested by
the modiﬁed AmpC disk method using 3-aminophenylboronic acid.
For simultaneous detection of ESBL and AmpC, the microdilution
method and determination of minimum inhibitory concentrations (MICs)
with a modiﬁed set of antimicrobial agents, including combinations
with sulbactam, tazobactam and 3-aminophenylboronic acid, were used.
Furthermore, the accuracy of determination of ESBL and AmpC
production by the Phoenix automated system was tested.
Results: The sensitivity of detection of ESBL by the Phoenix automated
system was high (99%); however, it only reached 38% in the group
of AmpC-positive strains. High sensitivity was also achieved by
tests speciﬁc for particular types of broad-spectrum b-lactamases:
the sensitivity of the ESBL E-test was 95%; the modiﬁed DDST
yielded 100% sensitivity for ESBL producers and the AmpC test
correctly detected 95% of AmpC-positive strains. The sensitivity of the
modiﬁed microdilution method was 94% and 95% for ESBL and AmpC
b-lactamases, respectively.
Conclusion: It is clear that the detection of broad-spectrum b-lactamases
must be based on speciﬁc phenotypic methods such as, in particular, the
modiﬁed DDST, ESBL E-test and AmpC disk method. The microdilution
method with a modiﬁed set of antibiotic agents and the comparison of
relevant MIC values seem also suitable as high sensitivity in the detection
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of the ESBL and AmpC enzymes can be achieved with easy to perform
methodology.
Supported by the projects MSM 6198959223 and IGA 9950−3.
P635 A selective screening broth for rapid detection of
extended-spectrum b-lactamases
G. Wilson, K. Irvine °, H. Hanaki, R. Kubo (Stirling, UK; Tokyo, JP)
Objectives: The objective was to develop a rapid method of screening
hospital patients for ESBL carriage. Development of a selective ESBL
broth, which changes colour (red to yellow) in the presence of an
ESBL, enables the detection and presumptive identiﬁcation of an ESBL-
producing organism.
Methods: A total of 264 controls were used to evaluate the screening
broth. This included; 160 phenotypically conﬁrmed ESBL-producing
organisms and 104 negative controls. In addition, 5 NCTC and ATCC
organisms were also tested against the broth.
The broth was tested against 510 unknown clinical samples (groin
swabs). After overnight incubation positive broths were subcultured
in order to test for ESBL production. The broth was centrifuged
and the deposit tested with the chromogenic cephalosporin HMRZ-
86 (Kanto Chemical Company, Japan). A coloured reaction (yellow
to red) is produced in the presence of an ESBL enzyme within
15 min. A positive result was then followed by neutralisation with
clavulanic acid to presumptively conﬁrm ESBL. The Jarlier test was
used to detect ESBL production and all isolates were identiﬁed by the
VITEK2 (bioMe´rieux, France). Groin swabs were also cultured onto
a growth control (MacConkey agar, Oxoid, England) for isolation of
any Enterobacteriaceae; all isolates were identiﬁed by the VITEK2, and
checked for ESBL production. A subset of 139 clinical samples were
incubated and examined after a 4 h period.
Results: A total of 48 ESBL-producing isolates were detected from
the clinical samples. The broth alone detected all 48 ESBL-producing
isolates, resulting in 100% sensitivity, however the speciﬁcity of the
broth was low (84.2%) due to 73 false positives. This resulted in a low
positive predictive value (PPV) of 39.6%. The combined use of the broth
and HMRZ-86 neutralisation test improved the speciﬁcity (98.9%), and
PPV (89%) of the test. The resulting sensitivity of the test was reduced
to 85.4%. Clinical samples tested at a 4 h incubation period showed
that 40% of positive broths contained an ESBL-producing organism,
conﬁrmed by the HMRZ-86 neutralisation test.
Conclusion: The combined use of the ESBL broth with the HMRZ-86
neutralisation test provides a speciﬁc and relatively sensitive method for
the presumptive detection of ESBL-producing organisms. There is also
the potential for the ESBL broth to be used as a rapid 4 h test.
P636 Evaluation of four screening protocols for detection
of extended-spectrum b-lactamase-producing
Enterobacteriaceae
B.M. Diederen °, C. Cheung, S. Euser, J.W. Cohen Stuart (Haarlem,
Utrecht, NL)
Objective: We evaluated the use of four different screening protocols
for the detection of extended-spectrum b-lactamase producing (ESBL)
Enterobacteriaceae.
Methods: From January 2009 to May 2009, surveillance culture samples
from ICU patients at two teaching hospitals were included. In addition,
random fecal samples obtained from GP and nursing home (NH)
residents were tested. Specimens were obtained with an Amies swab
and subsequently, each specimen was homogenized in a liquid Amies
medium (Eswab, Copan). Ten microliter suspension was inoculated in
a single session onto four culture media: directly on a chromogenic
medium (Method A. ESBL-ID; bioMe´rieux), and into the three different
enrichment broth regimens: trypticase soy broth (TSB) supplemented
with 1mg/l ceftazidime (Method B), TSB supplemented with 1mg/l
cefotaxim (Method C), and non-selective TSB (Method D). After
incubation for 24 h at 36ºC, 10 ml of broth was streaked on a ESBL
ID plate in the same way. All plates were incubated for 24 h at 36ºC.
All oxidase negative colonies presenting different morphological aspects
and growing on ESBL-ID after 18 to 24 h were identiﬁed with Vitek2.
Conﬁrmation of ESBL-producing isolates was performed by combined
double disks according to national guidelines.
Results: A total of 514 samples obtained from 384 patients was tested
(ICU patients: 202 samples, 72 patients; GP: 208 samples, 208 patients;
NH: 94 samples, 94 patients). A total of 23 samples obtained from 21
patients tested positive for ESBL producing Enterobacteriaceae (overall
prevalence 5.5%; 21 E. coli, 1 K. pneumoniae, 1 E. cloacae). Sensitivity
of method A, B, C, and D on a sample level were estimated as
70% (16/23; 95%CI, 49 to 85%), 82% (19/23; 95%CI, 62 to 94%),
82%(19/23; 95%CI, 62 to 94%), and 74% (17/23; 95%CI, 62 to 94%),
respectively. On a patient level, sensitivity of method A, B, C, and D were
estimated as 71% (15/21; 95%CI, 50 to 86%), 86% (18/21; 95%CI, 65
to 96%), 81%(17/21; 95%CI, 59 to 93%), and 76% (16/21; 95%CI, 62
to 94%), respectively. There were no statistically signiﬁcant differences
between speciﬁcities and sensitivities using the McNemar test for paired
samples or Fisher’s exact test.
Conclusions: From this clinical comparison, we conclude that a direct
inoculation on a chromogenic medium is a simple, rapid, and acceptable
accurate method for performing active surveillance for ESBL in a variety
of health care populations.
P637 Use of an HMRZ-86 supplemented broth for the direct
detection of extended-spectrum b-lactamase producing
Enterobacteriaceae in clinical samples
N. Gordon °, A. Sivaramakrishnan, R. Kubo, D. Wareham (London,
UK; Tokyo, JP)
Objectives: HMRZ-86 is a novel cephalosporin susceptible to hydrolysis
by extended spectrum and metallo-b-lactamases, resulting in an easily
observed colour change from yellow to red. It has previously been used
for the detection of ESBL production from bacterial colonies taken from
agar plates (Cica-b-Test). In this study we evaluated the use of an HMRZ-
86 based broth for the direct detection of ESBL producers from clinical
specimens.
Methods: the ability of nutrient broth supplemented with cefpodoxime,
vancomycin and HMRZ-86 to detect ESBL production by a number of
type strains was ﬁrst evaluated using inocula from 10e7−10e3 CFU/ml.
The broth was then assessed for the detection of ESBL producers in
perineal swabs (n = 94) obtained for routine MRSA screening. After
inoculation and incubation for 18 h at 37ºC, broths were inspected for
colour changes, subcultured to CHROMagar Orientation and compared
with growth obtained by inoculating swabs directly onto CHROMagar
Orientation supplemented with cefpodoxime. Isolates were identiﬁed by
oxidase testing and API20E, with ESBL production conﬁrmed by double
disc tests containing cefpodoxime or ceﬁpime ± clavulanate.
Results: Using type strains NCTC 13353 (Escherichia coli blaCTX-
M15), ATCC 700603 (Klebsiella pneumonia blaSHV-18) and ATCC
25922 (E. coli, ESBL negative), a red colour change was detectable down
to 10e4 CFU/ml. 13 broths were positive following direct inoculation
with perineal swabs. Of these, 9 were identiﬁed as Pseudomonas spp. The
remaining 4 were K. pneumoniae, E. coli and Enterobacter cloacae, 3 of
which were conﬁrmed as ESBL producers. One of the E. cloacae isolates
was ESBL negative but phenotypically appeared to be a hyperproducer
of AmpC. The sensitivity of the HMRZ broth for detection of ESBLs
was 100% with a speciﬁcity of 89%. To control for the possibility
of AmpC production resulting in false positives, all thirteen isolates
were re-inoculated into broth containing HMRZ-86 supplemented with
cloxacillin. The conﬁrmed ESBL producers gave a positive result at 18 h,
while the remaining isolates caused no colour change.
Conclusions: HMRZ-86 was highly sensitive for the detection of ESBLs
from perineal swabs, but lacked speciﬁcity due to the presence of AmpC
producers. This was improved by the addition of the AmpC inhibitor
cloxacillin. HMRZ-86 may be a useful substrate for the rapid detection
of high prevalence class A ESBLs directly in clinical samples.
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P638 Evaluation of Brilliance ESBL, a novel chromogenic agar for
the detection of extended-spectrum b-lactamases producing
Enterobacteriaceae
T.D. Huang °, P. Bogaerts, C. Berhin, A. Guisset, Y. Glupczynski
(Brussels, Yvoir, BE)
Objective: To evaluate the performance of Brilliance ESBL® (OX;
Oxoid) selective chromogenic agar for the detection and the presumptive
identiﬁcation of extended-spectrum b-lactamases (ESBL)-producing
Enterobacteriaceae (EB).
Methods: In a preliminary study, we challenged a collection of
200 Gram-negative bacterial including 156 EB strains with well-
deﬁned resistance mechanisms against OX and ChromID ESBL® (BM;
bioMe´rieux) chromogenic agar to evaluate the growth selectivity and
the chromogenic features of the media. In a second part, 528 clinical
samples (including 344 fecal specimens) obtained from 424 ambulatory
and hospitalized patients were plated onto OX, BM and MacConkey agar
to which a disk of ceftazidime was added (MCC) for the screening of
ESBL-producing EB. All colonies growing on any of the three media
after full 24-hour incubation were identiﬁed and tested for susceptibility
by Phoenix® System (Becton-Dickinson). ESBL conﬁrmation was
performed by combination disks method. Characterization of resistance
mechanisms was determined by PCR of TEM, SHV, CTX-M, OXA, and
AmpC genes with amplicon sequencing.
Results: Of the 156 EB isolates from the collection isolates, all 98 ESBL
producers were detected but 50 strains harbouring various non-ESBL
resistance mechanisms were also recovered on both OX and BM; 8 fully
susceptible isolates did not grow on any of the two selective media. Of
the 528 clinical samples screened, 144 (27%) yielded growth on at least
one of the three media. A total of 182 isolates including 109 (60%) EB
were recovered and 70 of these (from 59 specimens) were conﬁrmed
as ESBL-producing isolates. The sensitivities were 74.6%, 94.9% and
94.9% for MCC, BM and OX respectively. The speciﬁcities calculated
for the ESBL-negative samples reached 94.9%, 95.5% and 95.7% for
MCC, BM and OX respectively when only chromogenic enterobacterial
colonies were considered on the two chromogenic media.
Conclusions: OX and BM yielded comparable performances and had a
higher sensitivity than MCC for the detection of ESBL-producing EB
from clinical specimens. The high negative predictive value (99.3%)
found for OX suggested that this medium could represent an excellent
screening tool for rapid exclusion of carriage of ESBL producers. The
selection of enterobacterial isolates only for ESBL conﬁrmation based
on chromogenic features could limit the unnecessary workout.
P639 Evaluation of the UF1000i ﬂow cytometer as a means of
reducing urine cultures and predicting the micro-organisms
involved in urinary tract infections
J.M. Acedo, C. Artaza, M. Morito, J. Ferna´ndez, J. Valverde,
A. Delgado-Iribarren ° (Madrid, ES)
Objectives: The gold standard method for diagnosis of UTI is urine
culture but it is time-consuming and fewer than 25−30 percent of urine
samples sent to the laboratory are proven positive. Rapid screening
methods such as the UF-1000i ﬂow cytometer have been introduced
to reduce the number of urine samples requiring culture. This method
may also give an approximation of the microorganisms involved in UTI
because the scattergram B1 differs with bacilli and cocci. We evaluated
these two interesting topics of ﬂow cytometry for diagnosis of UTI.
Methods: Testing with the UF1000i system was done following
the instructions provided by the supplier (bioMe´rieux, France). The
reference method used was the semi-quantitative urine culture on
CLED agar (bioMe´rieux, France). Bacterial identiﬁcation was performed
automatically with MicroScan WalkAway (Siemens). A total of 500 urine
samples from general practice patients representing all age groups were
collected and analyzed. Culture results were reported as no growth;
contaminated (if there were 3 or more colony types without a dominant
species); positive (culture with 105 or 104 to <105 colony-forming
units/mL (cfu/mL) of a urinary pathogen in pure culture, two or more
potentially pathogenic bacterial species were isolated when the individual
counts were 104 cfu, or when the count for one organism was 104
cfu/mL and was clearly predominant).
Bacterial orientation: 2 independent observers classiﬁed the scattergram
B1 in samples with more than 25.000 cfu/ml into four groups: Bacilli,
Cocci, Both, Not classiﬁable.
If there were discrepancies between the observers, a third observer
revised the scattergram and determined how to classify the sample. If
there were discrepancies between the three observers the sample was
excluded (2 samples). Finally 125 out of 127 urine samples with more
than 25.000 cfu/ml were evaluated.
Results: The NPV and sensitivity calculated during this study are in
accordance with data obtained during previous studies, they are more
than 92% and 95% respectively.
Conclusions: The good NPV obtained allowed reporting of negative
results without culture being performed, reducing the urine cultures by
35% and reducing the turnaround time for these samples from 24 h to
same-day reporting.
Bacterial orientation of the microorganisms involved in UTI may
be achieved with UF1000i, especially with Staphylococci and Gram-
negative rods.
Bacterial orientation n Correct Not classiﬁable Wrong
n % n % n %
Cocci and bacilli 39 23 59 7 17.9 9 23.00
Bacilli 69 52 75.3 3 43.5 14 20.3
Cocci 17 8 47.00 0 0 9 53
Streptococci 11 2 18.2 0 0 9 81.8
Staphylococci 6 6 100 0 0 0 0
P640 Antibiotic screening of urine culture − a useful quality audit
W. Godwin °, S. Badarudeen, A. Godwin (Doha, QA)
Interpretation of urine cultures depends on various factors. Antibiotic
history is an important factor that affects the performance of urine
cultures in the laboratory. We decided to test the urine specimens for
antibiotics and compare it with the request forms sent to our laboratory.
The technique, incidence, implications, involved in processing of
specimens with incomplete antibiotic history received in the laboratory
are discussed. This internal audit practice stresses the need for quality
requests which play a major role in the clinical interpretation of culture
specimens.
Material and Method: Detection of antibacterial substance in the
urine. We modiﬁed the Urine Antibacterial Substance Assay (UABA),
a technique described by Sombrero L et al by using two Muller
Hinton agars each inoculated with a lawn culture of standard strains of
Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923.
Results: A total of 14680 consecutive urine specimens for culture and
sensitivity received in the laboratory during the study period from 1st
July 2008−30th June 2009 were tested with the UABA assay. 2494
(16.99%) samples yielded positive cultures. 388 (2.64%) samples were
positive for UABA of which 165 (42.53%) were received from the out
patient departments (OPD) and 223 (57.5%) from the wards. Of the
positive samples of UABA 222 (57.22%) had antibiotic history written on
the requisition form and 208 (93.7%) of the samples reported no growth.
Compliance to writing antibiotic history in the wards 183 (82.1%) was
higher than OPD’s 39 (23.64%). 115 (29.6%) of the positive UABA had
pus cells >5/HPF.
Conclusion: A periodic internal audit of antibiotic assay in urine
cultures provides baseline data permitting blind assessment of areas of
culture based clinical diagnostic work that are not readily amenable
to other quality assurance methods. It raises awareness to the
importance of quality and patient safety issues involved with history
taking using an evidence-based protocol and aids in the review of
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validating physicians’ compliance with an established protocol. Reaudit
interventional strategies can be planned, as part of a continuous quality
improvement program to affect change in physicians’ practices when
there is a drop from established benchmark. This can lead to overall
quality improvement in the process of care and save valuable ﬁnancial
resources.
P641 Evaluation of the Sysmex UF1000i urineﬂowcytometer in the
diagnostic work-up of urinary tract infection
W. van der Zwet °, F. Canbolat, J. Hessels, M. Deckers (Deventer, NL)
Objectives: Automation and standardisation of sediment analysis of
urine samples by ﬂow-cytometry might serve as an alternative to
traditional labour-intensive laboratory methods such as microscopic
examination and bacterial culture. We evaluated the Sysmex-UF1000i
urine ﬂowcytometer and compared results to standard laboratory
methods. Special interest was focused on the negative predictive value
and percentage of cultures that could be left undone.
Methods: The Sysmex UF1000i is a urine ﬂow-cytometer that uses two
separate channels for counting blood cells and bacteria. Two ﬂuorescent
dyes, one binding to cell membranes and one binding to nucleic acids,
are added to uncentrifuged urine. The urine is subsequently ﬂushed as
a laminar ﬂow through the two analytical channels in which the emitted
pulses, light scattering and ﬂuorescence are measured by a photodiode
and enhanced by a photomultiplier. Urine samples were investigated with
the Sysmex-UF1000i, manual microscopy of urine sediment, Gram-stain
and bacterial culture (golden standard).
Results: Three hundred ﬁfty eight urine samples were analyzed.
Reproducibility for detection of white (WBC) and red blood cells and
bacteria with the UF1000i was good, whereas detection of yeasts proved
unreliable. Depending on the deﬁnition of urinary tract infection (UTI)
used, the negative predictive value and the percentage of false-negative
results were 100% and 0% (UTI deﬁned as >105 Colony Forming
Units (CFU)/ml) and 99% and 1.3%, (UTI deﬁned as >104 CFU/ml)
respectively. Pre-screening with the Sysmex UF 1000i results in a
reduction of bacterial cultures of 42%.
Carry-over of bacteria between consecutive samples due to a ﬁxed
sample needle was observed, but did not result in false-positive
interpretation of Sysmex UF 1000i results. Evidently, because of the
occurrence of carry-over, samples that have been analyzed in the Sysmex
UF 1000i cannot be used for subsequent urine culture.
Conclusion: In conclusion, the Sysmex-UF1000i offers the possibility
of screening high numbers of urine samples in a fast and standardized
way resulting in a reduction in workload and speeding up the diagnostic
process. As in other non-culture methods, the UF 1000i should not be
applied in patients in whom yeast infection is suspected or patients that
are leukopenic.
P642 Preliminary evaluation of Sysmex UF1000i ﬂow cytometer
in discriminating Gram-negative and Gram-positive
micro-organisms in urine
R. De Rosa °, M. Avolio, P. Stano, S. Grosso, G. Bruschetta,
A. Camporese (Pordenone, IT)
Objectives: Urine culture test is the gold standard to identify the
aetiological agent of UTI, however it does not supplie same-day results.
Sysmex UF 1000i urine cytometer provides results in a few minutes;
we aimed to explore preliminary B_FSC and B_FLH parameters in
discriminating Gram negatives and Gram positives respect of bacterial
identiﬁcation by urine culture.
Methods: Sysmex UF1000i (Sysmex Co. Japan) a new ﬂuorescence
ﬂow cytometer intended for urinalysis purpose has a speciﬁc analitical
channel for bacteria counting. From this channel two parameters, the
B_FSC (Bacteria Forward Scatter) and the B_FLH (Bacteria Fluorescent
Light Intensity), expressed in arbitrary units (analytical channel, ch),
provide informations on the size and the nucleic acid content of bacteria
particles. 1349 samples from inpatients and outpatients were examined
by Sysmex UF1000i and cultured on CLED and CNA agar plates
(Kima, Padua, Italy); in the positive samples bacterial identiﬁcation was
performed by Vitek 2 system (bioMe´rieux, Florence, Italy). Data between
Gram-negative and Gram-positive bacteria were evaluated, comparing
the distribution of B_FSC and B_FLH values in the two groups.
Results:1003 samples were negative (74.4%). Out of 346 bacterial
culture positive (25.6%), 229 samples presented a growth of Gram
negatives, 45 samples growth of Gram positive bacteria and 72 samples
showed mixed growth (a Gram positive and a Gram negative or
contamination). The median B_FSC in Gram-negatives was 22.1 ch.,
in Gram-positive bacteria 44.6 ch. (p< 0.0001). The 95% distribution
of B_FSC was 11.5–70.4 ch. in Gram-negatives, 17.6–127.5 in Gram-
positives. Out of 274 samples, 168 (61.3%) had a B_FSC value <30 ch.:
163 (97.0%) were from samples with Gram-negatives, 5 (3.0%) from
samples with Gram-positives. The median B_FLH in Gram-negative
bacteria group was 85.5 ch., in Gram-positives 94.6 ch. (p = 0.027); the
95% distribution of B_FLH in the two groups were: 72.3–177.8 ch. in
Gram-negatives, 75.2–178.8 in Gram-positives. B_FSC value showed at
a cut-off value of 30 ch. a high discriminating power between the two
groups.
Conclusion: In this preliminary evaluation the B_FSC and B_FLH seem
to be interesting parameters in morphological assessment of bacteria
allowing to obtain in few minutes information as well as on bacterial
counting also on aetiological agent of urinary tract infection, needing
however to be further investigated in more extensive studies.
P643 Use of a polymerase chain reaction assay for rapid detection
and identiﬁcation of V. vulniﬁcus
I. Can˜igral, Y. Moreno °, A. Adrados, A. Gonzalez, M.A. Ferru´s
(Valencia, ES)
Objectives: Vibrio vulniﬁcus is a Gram-negative bacterium found in
warm seawater.
The bacterium is a worldwide highly invasive human pathogen with
highest mortality rates (up to 50%). Human infection are acquired though
consumption of contaminated seafood or though skin wounds. The main
symptoms are gastroenteritis, wound infection and septicemia, frequently
leading to limb amputation and fatality. It is considered as an important
emerging environmental and food safety issue around the world.
The objectives are optimize and to test Polymerase Chain reaction (PCR)
method for rapid detection and identiﬁcation Vibrio vulniﬁcus in clinical
and environmental samples.
Methods: Primers vvh785 and vvh 990, that amplify a fragment with
205bp of a haemolysin A gen (vvhA) were used. PCR conditions
were optimized and annealing temperature was established at 56ºC. The
reaction was applied to 20 Vibrio vulniﬁcus clinical and environmental
strains. It was applied directly to inoculated saline, water and seafood
samples too in order to test its potential for rapid detection. 10 sea
water samples obtained from Valencia coasts and 40 seafood samples,
including oysters, clams, mussels and goose barnacle, were analyzed.
Results: PCR protocol yielded a fragment of 205 bp. Reaction identiﬁed
all the Vibrio vulniﬁcus strains tested. Detection limit in inoculated
samples was 102 c.f.u in saline water and 104 c.f.u in complex matrix
such as seafood. Among the 50 samples ten samples were positive by
PCR and 2 strains of Vibrio vulniﬁcus were isolated.
Conclusion: This PCR method allows for rapid and speciﬁc detection
and identiﬁcation of V. vulniﬁcus and could be useful for diagnostic and
epidemiological purposes, determining the potential health risk due to
contaminated seafood and water.
P644 Long-term tigecycline therapy (6 weeks) for complications
of E. coli bacteremia
S. Hagenauer-Drektraan °, C. Wenisch, G. Seiberl (Vienna, AT)
Introduction: E. coli is one of the most common organisms associated
with bacteremia, but rarely causes complications under sufﬁcient therapy.
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We report a case of bacteremia with fully susceptible E. coli complicated
by discitis despite treatment with b-lactam antibiotics.
Case report: A 70 year old male patient was admitted due to sudden
onset of generalized weakness. On admission he had hypotension,
tachycardia, and scleral icterus. A few hours after admission the patient
became febrile. Laboratory test results revealed biliary obstruction and
elevated erythrocyte sedimentation and CRP as well as leucocyturia.
Abdominal ultrasound showed cholecystolithiasis and three layered
gallbladder wall suggestive for cholecystitis but without signs of
intrahepatic dilatation of the biliary tract.
Piperacillin/tazobactam 3.5g tid was started. On day 3 the patient
developed septic shock. Blood cultures grew Gram negative rods and
the antibiotic regimen was changed to ertapenem, presuming an ESBL
producing organism. Blood cultures subsequently grew fully susceptible
E. coli, but aspiration culture of a subcutaneous pustule, which developed
during the 1st week of therapy revealed ESBL producing E. coli and
Staphylococcus aureus (MSSA). The urine was sterile. The patient’s
condition improved and antibiotic treatment was stopped after 2 weeks.
The following day the patient became febrile and complained about
severe pain at palpation of the lower lumbar spine. An MRI scan showed
contrast enhancement of L4 and L5 and the L4-L5 intervertebral disc
(Figure 1.). The disc was punctured, but aspiration cultures were sterile.
Due to the ESBL producing E. coli and Staphylococcus aureus in a
pustule, antibiotic treatment was started with tigecyclin. The patient
was placed in a thoracic lumbar sacral orthosis. Intravenous therapy
with tigecyclin was continued for 6 weeks, followed by oral therapy
with ciproﬂoxacin and clindamycin for additional 6 weeks. Orthopaedic
training resulted in 100% rehabilitation.
Conclusions: E. coli is the second most common causative agent of
septic discitis. Therefore any prolonged episode of fever and elevated
CRP and erythrocyte sedimentation following E. coli bacteremia should
raise the suspicion of septic discitis and must be followed by directed
physical examination, diagnostic imaging and aspiration.
Figure 1. Contrast enhancement of L4 and L5, intervertebral disc,
and paravertebral soft tissue and also paraspinal muscles lateral to the
p. spinosi.
P645 Tigecycline activity tested against infrequently recovered
clinical species of non-enteric Gram-negative bacilli
R. Mendes, H. Sader °, M. Stilwell, R. Jones (North Liberty, US)
Objectives: To assess tigecycline (TIG) activity and potency against
non-enteric Gram-negative bacilli (NEGNB) clinical isolates. NEGNB
usually display multidrug-resistance (MDR) phenotype due to upregu-
lated efﬂux and chromosomal b-lactamases belonging to Classes A, B,
C or D, limiting the therapeutic options for treating infections caused
by these organisms. TIG has demonstrated a broad spectrum of activity
against Gram-positive and -negative bacterial pathogens, including many
MDR isolates.
Methods: A total of 2,996 clinically-signiﬁcant isolates of NEGNB
(23 species) were collected from 142 hospitals in 32 countries as part
of the SENTRY Antimicrobial Surveillance Program over a ten year
sampling period (2000–2009; North America [32.1%], Europe [26.8%],
Asia-Paciﬁc region [23.4%] and Latin America [17.7%]). Isolates were
submitted to a coordinator laboratory where species identiﬁcations
were conﬁrmed using standard algorithms and Vitek 2, and tested
for susceptibility (S) against TIG and comparators by reference CLSI
methods (M07-A8, 2009). CLSI and EUCAST interpretative criteria
were applied when available.
Results: Isolates were recovered mostly from bacteremia (58.1%),
pneumonia (29.7%) or skin and skin structure infections (10.4%). TIG
was most active against Pasteurella multocida (MIC90, 0.12mg/L) and
various Acinetobacter spp. (MIC90, 0.5mg/L). Aeromonas spp., Rhizo-
bium radiobacter, Ralstonia pickettii and Sphingomonas paucimobilis
were also very susceptible to TIG (MIC90, 0.5mg/L). In contrast,
Burkholderia cepacia, P. ﬂuorescens/putida, Chryseobacterium spp. and
Elizabethkingia spp. (MIC90, 4−>4mg/L) generally exhibited elevated
TIG MIC values. TIG (MIC50/90, 0.5/2mg/L; 95.5% inhibited at
2mg/L) and trimethoprim/sulfamethoxazole (TMP/SMX) (MIC50/90,
0.5/1mg/L; 96.1% S) were the most active compounds tested
against Stenotrophomonas maltophilia; while ceftazidime (MIC50/90,
16/>16mg/L; 45.1% S), levoﬂoxacin (MIC50/90, 1/4mg/L; 83.3% S)
and ticarcillin/clavulanate (MIC50/90, 32/>128mg/L; 38.7% S) showed
more limited activity against this organism.
Conclusions: TIG showed potent in vitro activity against many NEGNB
for which there are very limited therapeutic options and S data to guide
therapy. Against S. maltophilia, TIG activity was comparable to that of
TMP/SMX. The results of this study indicated that TIG may have an
important role in the treatment of infections caused by these species.
Organism (no. tested) MIC (mg/L)
50% 90%
Achromobacter xylosoxidans (130) 0.5 2
Acinetobacter haemolyticus (13) 0.12 0.5
A. junii (47) 0.12 0.5
A. lwofﬁi (216) 0.25 0.5
Aeromonas spp.a (211) 0.25 0.5
Alcaligenes faecalis (23) 0.5 2
Burkholderia cepacia (198) 1 4
Chryseobacterium indologenes (26) 4 >4
Elizabethkingia meningosepticum (39) 2 >4
Ochrobactrum anthropi (14) 0.5 1
Pasteurella multocida (53) 0.06 0.12
Pseudomonas spp. (83)b 0.25 2
P. ﬂuorescens/putida (191) 2 >4
Ralstonia pickettii (17) 0.25 0.5
Rhizobium radiobacter (18) 0.12 0.5
Sphingomonas paucimobilis (32) 0.12 0.5
Stenotrophomonas maltophilia (1685) 0.5 2
aIncludes A. caviae (34), A. hydrophila (118), A. salmonicida (1),
A. sobria (15), A. veronii (6) and Aeromonas spp. (37).
bIncludes P. mendocina (14), P. oryzihabitans (27) and P. stutzeri (42).
P646 In vitro activity of daptomycin combined with other
antimicrobial agents against Gram-negative bacteria
B. Ko¨rber-Irrgang °, M. Kresken (Rheinbach, DE)
Objectives: Daptomycin (DAP), a cyclic lipopeptide, exerts rapid
bactericidal activity against clinically important Gram-positive bacteria.
Combination therapy might be beneﬁcial to cover also Gram-negative
pathogens in mixed infections. We evaluated the in vitro activities of
DAP in combination with 11 other relevant drugs against clinical isolates
of Escherichia coli (ECO), Klebsiella pneumoniae (KPN), Klebsiella
oxytoca (KOX), Enterobacter cloacae (ECL), Pseudomonas aeruginosa
(PAE) and Acinetobacter baumannii (ABA).
Methods: A total of 50 organisms including strains with various
resistance phenotypes were studied. Synergy testing was performed
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by using the checkerboard broth microdilution method. DAP in
combination with amikacin (AMK), tobramycin (TOB), ceftazidime
(CAZ), ceftriaxone (CRO), piperacillin–tazobactam (P/T), meropenem
(MEM), imipenem (IMP), ciproﬂoxacin (CIP), moxiﬂoxacin (MOX) or
fosfomycin (FOS) were tested against strains of ECO (n = 10), ECL
(n = 10), KPN (n = 6) and KOX (n = 4) (in total 300 drug combination
tests), while DAP in combination with AMK, TOB, CAZ, P/T, MEM,
IMP, CIP, MOX or colistin (COL) was tested against 10 strains
each of PAE and ABA (in total 180 drug combination tests). The
fractional inhibitory concentration indices (FICIs) were calculated to
interpret the results. Synergism was deﬁned as FICI 0.5, indifference
as FICI> 0.5 to 4, and antagonism as FICI> 4.
Results: Antagonism was not detected with any combination. Of the
300 drug tests performed with the enterobacterial strains, 284 revealed
an indifferent effect, while synergism of DAP plus CIP, CRO, MEM
or MOX was observed for 10, 3, 2 and 1 strain, respectively. For
non-fermenting bacteria indifference was observed for nearly all drug
combinations, while synergism was seen for 2 ABA with COL and 1
ABA with TOB.
Conclusion: DAP did not antagonise the activity of antibacterial agents
directed to Gram-negative bacteria and may thus be combined with these
drugs for the treatment of bacterial mixed infections.
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P647 Real-time, random access detection of inﬂuenza A/B and
RSV A/B in respiratory specimens using nanoparticle probes
P.J. Jannetto, K.A. Vaughan, N.A. Ledeboer ° (Milwaukee, US)
Introduction: Multiplexed molecular detection of inﬂuenza A, in-
ﬂuenza B, and respiratory syncytial virus (RSV) is becoming increas-
ingly available with a number of commercial assays on the market.
Numerous studies have demonstrated increased sensitivity of these
techniques compared to culture and antigen-based detection methods.
This study evaluated the sensitivity and speciﬁcity of Nanosphere’s
Verigene System for the detection of respiratory viruses.
Methods: Nasopharyngeal specimens were collected prospectively at
multiple sites during the 2008−9 and 2009−10 respiratory seasons. The
presence of inﬂuenza A/B and RSV was determined using culture/DFA
and the residual samples frozen. The culture/DFA results for the samples
were blinded to the investigators until the conclusion of the study.
Discrepant results were resolved using bi-directional sequencing. Further
studies were conducted comparing the analytical sensitivity and percent
agreement between the Verigene (VG) and automated Verigene SP (SP)
system. Finally, studies were conducted evaluating performance of the
SP for detection of 2009 novel H1N1.
Results: Of the 720 specimens enrolled in the clinical trial, 123 were
culture/DFA positive for Inﬂuenza A, 31 were positive for inﬂuenza B,
49 were positive for RSV, and 517 specimens were culture negative.
In comparison to culture, the VG assay was 96.6% sensitive, 93.6%
speciﬁc. There were 133 discrepant specimens between VG and culture.
Bidirectional sequencing revealed that the VG assay yielded 108
additional positives otherwise negative by culture/DFA. After discrepant
resolution the VG sensitivity was 98.7% and speciﬁcity was 99.3%
with a positive and negative predictive value of 94.2% and 99.7%
respectively. A sample set representing inﬂuenza A/B, and RSV was
prepared to compare the semi-automated VG with the automated SP. A
total of 62 unique samples were obtained and tested at three sites. The
sites demonstrated overall positive agreement of 97.9% and negative
agreement of 100%. The SP assay has also successfully detected 2009
novel H1N1 from clinical specimens with high sensitivity and speciﬁcity,
compared to the CDC PCR.
Conclusion: Data from the study demonstrates that the VG assay and
its automated SP successor are highly sensitive and speciﬁc alternatives
to culture. The beneﬁt of this system over others is complete automation
of the test, including extraction, ampliﬁcation, and detection.
P648 Subtyping (H1/H3) of seasonal inﬂuenza A viruses by
multiplex real-time PCR assay
J. Acosta °, S. Vazquez, J.R. Otero, L. Folgueira (Madrid, ES)
Objectives: The emergence of seasonal inﬂuenza A H1N1 viruses
resistant to oseltamivir points out the need for rapid and sensitive
subtyping methods, in order to prescribe appropriated antiviral treatment.
The aim of this study was to identify the subtypes of seasonal inﬂuenza A
circulating in our patients over a period of three respiratory viruses
seasons and to assess the utility of a multiplex real-time PCR as a routine
method for subtyping Inﬂuenza A viruses.
Methods: From January 2007 to May 2009, 162 inﬂuenza A positive
respiratory samples by means of antigen detection or rapid culture
in shell vial, were collected and stored in aliquots at −70ºC until
RNA extraction. RNA was isolated from 200ml of respiratory samples
(nasal aspirates and nasopharyngeal swabs) by nucliSENS easyMAG®
instrument (Biomerieux). After retrotranscription, real-time PCR was
performed in a LightCycler® instrument version 2.0 (Roche Molecular
Biochemicals). A region of the matrix (M1) gene of inﬂuenza A virus,
two speciﬁc sequences of subtype H1 and H3 hemagglutinin (HA), and
an internal control were ampliﬁed in independent capillary reactions by
uniform cycling parameters: 10 min at 95ºC and 50 cycles of 15 s at 95ºC
and 60 s at 60ºC. The PCR product was detected by speciﬁc TaqMan
probes. H1/H3 subtyping assay was performed in a multiplex format,
using probes labeled with two different ﬂuorescent reporter dyes.
Results: The number of specimens studied during the respiratory virus
seasons of three calendar years, 2007, 2008 and 2009 were 98, 34 and 30
respectively. All the samples showed M1 gene ampliﬁcation. The results
demonstrated subtype H1 in 41 samples (25.3%) and subtype H3 in 117
samples (72.2%); in 4 samples subtype could not be determined (2.5%).
H1 subtype represents almost one third of inﬂuenza A positive samples
during years 2007 and 2008, whereas it was detected in less than 5% of
samples collected during 2009.
Conclusions: The assay based on a multiplex real-time PCR used in
this study provides a rapid, feasible and cost-effective approach for
subtyping (H1/H3) of seasonal inﬂuenza A viruses. This laboratory
diagnostic tool provides information relevant to make optimal drug
treatment recommendations.
P649 Detection and discrimination of inﬂuenza A and B, and
respiratory syncytial viruses using the 3M integrated cycler
M. Aye °, J. Chen, Y. Xie, S. Dempsey, H. Mai, E. Eleazar, M. Exner
(Cypress, US)
Objective: Recently, it has become evident that many rapid tests
designed to detect respiratory viruses lack sensitivity. As a result, a
clinical need has arisen for more sensitive tests that will detect and
discriminate inﬂuenza viruses. Molecular techniques have been shown
to be more sensitive than culture or rapid lateral ﬂow methodologies.
Therefore, a multiplex RT-PCR assay was designed to detect inﬂuenza A
viruses (of all hemagglutinin and neuraminidase types), inﬂuenza B
viruses, and Respiratory Syncytial virus (RSV).
Methods: Primers were designed to target conserved regions of
inﬂuenza A, B, and RSV. Speciﬁcity of the assay was tested by running a
panel of known inﬂuenza strains and against a set of clinical specimens
that were veriﬁed to be positive for the target viruses. In addition, a
panel of other respiratory specimens was tested to determine whether
there was any cross reactivity with these organisms. Assay sensitivity
was determined analytically by limit of detection studies, and sensitivity
was compared to culture and DFA methods.
Results: The assay was able to detect multiple inﬂuenza types and strains
including seasonal H1 and H3 strains, H1N1 (2009), and H5N1. All
inﬂuenza B strains tested were detected, as were all strains of RSV-A
and RSV-B that were tested. The assay sensitivity was excellent, and it
was shown to be more sensitive than culture and DFA for all viruses.
Conclusions: The use of this assay on the 3M integrated cycler
provides a sensitive, rapid and high throughput method for detecting
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and discriminating inﬂuenza A, B, and RSV viruses. The portability
and ease of use of the instrument make it useful as a ﬁrst line tool for
diagnosis of respiratory infections.
P650 Multiplex molecular diagnostics of respiratory infections
during the 2009 H1N1 pandemic: what else is out there?
A. Dumoulin °, H.H. Hirsch (Basel, CH)
Objectives: The aim of this study was to investigate the causes
of respiratory infections in samples from patients with suspected
H1N1v(2009) infection, using RespiﬁnderPLUS (RF), a commer-
cial multiplex assay detecting Inﬂuenza-A/B, Inﬂuenza-H5N1, RSV-
A/B, Parainﬂuenza-1−4, Coronavirus-OC43/229E/NL63, Rhinovirus,
Adenovirus, Metapneumovirus, Chlamydia pneumoniae, Mycoplasma
pneumoniae, Legionella pneumophila and Bordetella pertussis.
Methods: Samples collected during the initial wave (spring and summer)
of the 2009 H1N1v pandemic (n = 141) as well as during the second wave
(autumn and winter 2009) were analysed in parallel with a home-brew,
validated H1N1v real-time PCR. Turnaround time of the RF analysis
was 24 h. Hands-on time was 3 h.
Results: In the 141 samples collected during the initial wave of
the 2009 H1N1v pandemic, the proportion of positive samples was
63%: 40 Rhinovirus (28%), 25 Inﬂuenza-A (18%, all H1N1v), 5
Adenovirus, 5 Metapneumovirus, 3 Inﬂuenza-B, 2 Parainﬂuenza, 2
Coronavirus, 1 RSV-B, 1 Mycoplasma pneumonia, 52 negative. The
analysis results of the samples collected during the second wave will
be presented. Preliminary results indicate a much larger proportion of
H1N1v positive samples (PCR positivity rate 34%), as well as an increase
in Parainﬂuenza positive samples (10%).
Conclusion: RF analysis of respiratory samples collected during the
initial phase of the 2009 H1N1v pandemic revealed a high incidence
of Rhinovirus during spring and summer, whereas H1N1v was present
in only 8% of the samples. A strongly increased proportion of positive
H1N1v samples is expected in the samples of the second phase.
P651 Detection of six groups of human adenoviruses by quantitative
real-time polymerase chain reaction with one set of primers
C.Y. Lee °, Y.J. Chan, C.H. Chang, J.C. Lin, C.L. Lee, T.Y. Chou (Taipei
City, TW)
Objective: Human adenoviruses (HAdVs) are associated with a broad
spectrum of clinical illnesses and are endemic in the pediatric population
in particularly. At least 51 serotypes of adenoviruses has been identiﬁed
and classiﬁed into six groups (A to F) at present. Because of few cluster
homologies within AdVs species and between species, it is challenging
to develop real-time quantitative AdVs polymerase chain reaction (PCR)
assays effectively covering all AdVs types in one reaction. In this study,
a real-time PCR assay to quantitatively detect all six groups of human
adenoviruses is presented.
Methods: One set of designed primers was constructed to target the
relative conserved region of AdV hexon region with 130bp in size after
alignment. Real time PCR was performed with an ABI Prism 7000
sequence detection system. Six representative AdV strains of each group
(AdV-C1, AdV-E4, AdV-B7, AdV-D9, AdV-A12, AdV-F40) and stored
culture AdV isolates in Taipei Veterans General Hospital during 2004–
2008 were tested. For speciﬁcity testing, herpes simplex virus type 1
and 2 (HSV-1, 2), cytomegalovirus (CMV), BK and JC virus as negative
controls were tested for cross-reaction. For comparison, two published
real time quantitative PCR assays were conducted as well.
Results: A total of 119 clinical AdV isolates during the 5-year-period,
comprising 100 respiratory specimens, 11 stool or rectal specimens,
3 urine specimens, 1 blood specimen, 1 vaginal specimen and 1
cerebrospinal ﬂuid specimen, were analyzed. The serotypes distribution
of these clinical isolates, which were identiﬁed by Taiwan Center of
Diseases Control, belonged to serotypes -C1, -C2, -B3, -E4, -C5, -C6
and -B7. The detection rate of the designed primers of this study for the
DNA of six representative strains and the 119 culture isolates is 100%,
as effectively as the published methods. There was no cross reactivity
against HSV-1 and 2, CMV, BK and JC virus.
Conclusions: A potential effective real time quantitative PCR assay is
important for rapid clinical diagnosis of adenovirus infection, especially
amongst the immunocompromised hosts. The new developed real time
PCR assay allows rapid and sensitive quantiﬁcation of all deﬁned groups
of human adenoviruses to date. In addition, this assay is non-inferior to
the published methods.
P652 Comparison of two mega-multiplex-PCR respiratory
pathogen panels: the FilmArray™ 20-pathogen panel versus
Luminex xTAG® 12-pathogen panel
R. Selvarangan °, G. Metzler (Kansas City, US)
Background: FilmArray RP is a user friendly multiplex-PCR system for
comprehensive detection of 20 different bacterial and viral respiratory
pathogens and subtypes in clinical specimens within one hour from
receipt. Pathogens detected are inﬂuenza A (Flu A, H1 or H3),
inﬂuenza B (Flu B), Respiratory syncytial virus (RSV), Adenovirus
(AdV), Parainﬂuenza viruses (PIV 1, PIV1, PIV3, PIV4), human
metapneumovirus (hMPV) Rhinovirus (RhV), Coronaviruses (NL63,
HKU1, OC43, 299E), human BoCa virus (BV), M. pneumoniae (Mpne),
C. pneumoniae and B. pertussis.
Objective: To evaluate performance of FilmArray RP using respiratory
specimens from children that were previously tested by Luminex xTAG
multiplex PCR (xTAG RVP) capable of detecting 12 different respiratory
viruses and their subtypes.
Method: Frozen aliquots of xTAG RVP-tested specimens (n = 67) were
used for the comparison study. About 250 ul of respiratory specimen
was processed and inoculated into a hydrated FilmArray RP pouch and
loaded on the instrument. Five realtime PCR-tested pertussis specimens
were also used for evaluation.
Results: FilmArray RP results agreed with 63/67 (94%) specimens tested
by xTAG RVP. In the 67 specimens tested, xTAG RVP detected a total
of 81 viruses while FilmArray RP detected 98 pathogens (see Table 1);
12 of these pathogens are either not reportable (NL63 = 4, HKU1 = 1,
229E = 1) or absent on xTAG RVP panel (BV =4, PIV4=1, Mpne=1).
Co-infection with more than one pathogen was detected in 18% and
42% of the specimens tested by xTAG and FilmArray RP respectively.
FilmArray RP detected B. pertussis accurately in 3 positive specimens
and detected HKU1 and OC43 in 1 of 2 pertussis-negative specimens.
Conclusion: FilmArray RP had a higher detection rate for pathogens
when compared to xTAG RVP; this may be attributed to the use of
highly sensitive nested PCR and addition of new pathogens. Limitation
of the current FilmArray RP is low-throughput of one sample per hour
on a single instrument; however hands-on-time of less than ﬁve minutes
and rapid turn-around-time (TAT) of about 1 hour makes this assay user
friendly and rapid compared to the >1hr set-up time and 8 hr TAT for
xTAG RVP. A cluster of 4 FilmArray instruments may allow processing
of 28 to 84 specimens in one to three laboratory shifts making it a
suitable option for medium to large sized laboratories. The FilmArray RP
assay is easy to setup and provides rapid and highly sensitive detection
of respiratory pathogens.
Table 1: xTAG-RVP and FA-RVP results from 67 respiratory specimens
Results FluA FluB RSV AdV hMPV PIV RhV/EV CoV
xTAG-RVP 5 9 10 6 10 18 21 NR*
FA-RVP 5 9 13 7 10 20 23 6
* Not reportable in FDA approved xTAG version.
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P653 Validation of a pre-market version of the Idaho Technology
Inc. FilmArray™ Respiratory Panel for the detection
of respiratory pathogens in well-characterized human
respiratory specimens
R.S. Buller °, J. Jimenez, M. Poritz, K. Nilsson, K. Ririe, G.A. Storch
(Saint Louis, Salt Lake City, US)
Objectives: Respiratory infections are a major cause of illness
worldwide. Unbiased molecular detection of respiratory pathogens is
complicated by the fact that multiple agents sharing few conserved
sequences cause respiratory infections. Massive multiplexed PCR assays
for respiratory pathogens exist but are labor intensive and there is a
prolonged time to produce a result. Idaho Technology Inc.(ITI) has
developed a real-time PCR instrument called the FilmArray and an
associated reagent pouch which together are capable of simultaneously
detecting multiple organisms in a sample. The FilmArray pouch
contains freeze-dried reagents to perform nucleic acid extraction
ampliﬁcation, reverse transcription, and nested, multiplex real-time PCR.
The Respiratory Panel (RP) pouch identiﬁes 20 common and emerging
viral and bacterial pathogens and results are available in less than an
hour. Our objective was to help validate the RP by testing a set of well-
characterized specimens.
Methods: 86 specimens positive for adenoviruses, inﬂuenza A,
inﬂuenza B, parainﬂuenza virus, rhinovirus, respiratory syncytial
virus, coronavirus, human metapneumovirus, Bordetella pertussis, or
Mycoplasma pneumonia, as determined by PCR and conventional
methods or PCR alone, were tested by the RP assay and the results
compared to the earlier testing.
Results: 68 specimens positive for a respiratory virus were tested. 9 of
68 (13%) produced invalid FilmArray results due to control failures. Of
the valid runs, 58/59 (98%) agreed with the previous results. Additional
viruses were detected in 16 (28%) of the positive specimens, including
11 with 1 extra virus and 5 with 2 additional viruses. 18 specimens
positive for either B. pertussis or M. pneumoniae were also evaluated by
the FilmArray. 3 of these 18 (17%) specimens produced invalid results
due to control failures with 10/15 (67%) valid runs yielding results that
agreed with previous testing. Detection of individual agents and data
from the ongoing resolution of discrepant and FilmArray failed results
will be presented.
Conclusion: The ITI FilmArray RP is simple to use with minimal hands-
on time and has the ability to quickly detect a wide variety of viral and
bacterial agents of respiratory disease. The majority of instances where
the FilmArray RP failed to detect the expected agent were due to one
or more control failures, an issue that ITI is working to resolve prior to
formal clinical studies.
P654 Rapid and sensitive detection of viral infection and
co-infections in upper respiratory tract of patients with
ﬂu-like illness symptoms using PCR DNA microarray systems
F. Renois, N. Leveque, L. Andreoletti ° (Reims, FR)
Background: In France, a speciﬁc molecular diagnosis for the detection
for the new pandemic inﬂuenza A/H1N1v strain is recommended for
4 categories of patients with symptoms of ﬂu-like illness including
infants aged less than 12 months, symptomatic pregnant women,
symptomatic infants or adults suffering from chronic cardio-respiratory
pathologies or diabetes or for medical workers in daily contact with
immunocompromised patients.
Objective: In the present study, we determined the presence of
inﬂuenza A/H1N1v and 17 other respiratory viruses in nasopharyngeal
samples of the four above described categories of patients visiting
the Reims (Champagne-Ardenne) university hospital for symptoms of
inﬂuenza ﬂu-like illness.
Patients and Methods: From the 1st to 15th October 2009, we
prospectively tested 95 nasal swabs or nasopharyngeal aspirates taken
from adults (n = 57; 40.2y, SD=20.3y) or infants (n = 38; 5.3y, SD=4.3y)
suffering from acute ﬂu-like illness symptoms using two commercially
available PCR-DNA microarray detection systems (Pneumovir and
Fluavir detection assays, Genomica, Spain).
Results: Of the 95 respiratory samples tested by PCR-DNA microarray
systems, 30 (31%) were positive for the detection of inﬂuenza A/H1N1v
infection. Among these cases of inﬂuenza A/H1N1v infections, 25
(83%) were mono-infections whereas 5 cases (17%) were multiple
infections associating inﬂuenza A/H1N1v with Coronavirus, Bocavirus
(BoV), RSV or Human rhinoviruses (HRVs). Of the 95 respiratory
samples tested, 35 (37%) were positive for other respiratory viruses
than inﬂuenza A/H1N1v. Among these patients, we observed 30
mono-infection cases [HRVs (60%), PIV (20%), A/H3N2 (6%),
Coronavirus (4%), BoV (4%)] and 5 multiple infection cases where
HRVs were the most frequently virus detected. No speciﬁc viral mono-
infection or mixed viral infections appeared to be signiﬁcantly associated
with the severity of the disease or secondary hospitalization in intensive
care unit (P> 0.5).
Conclusion: The use of PCR-DNA microarray systems in clinical
virology practice allows a rapid and accurate detection of conventional
and newly discovered viral respiratory pathogens in infants and adults
suffering from ﬂu symptoms potentially related to an inﬂuenza A/H1N1v
infection. Moreover these molecular assays are of major interest
to develop new reliable weekly epidemiological survey systems for
respiratory viral infections in hospitalized and non hospitalized infants
and adults.
P655 Timely diagnosis of respiratory tract infections: evaluation
of the performance of the Respiﬁnder assay compared to the
RVP assay
M. Raymaekers °, B. De Rijke, I. Pauli, A-M. Van den Abeele,
R. Cartuyvels (Hasselt, Ghent, BE)
Objective: Lower respiratory tract infections are a common cause of
hospitalization in infants and young children and are typically caused
by viral or bacterial pathogens. Diagnostic methods such as culture and
serology are time consuming and have several other drawbacks such as
limited sensitivity, long turn-a-round time and limited number of detected
pathogens. Nucleic acid ampliﬁcation methods can increase sensitivity
and enable the initiation of appropriate interventions without delay.
Broad-spectrum detection and identiﬁcation circumvent the use of
individual diagnostic DNA or RNA based assays. At present, several
commercial assays are available for broad-spectrum detection. We
compared the performance of the Respiratory Virus Panel assay (RVP)
(Luminex Molecular Diagnostics) with that of the Respiﬁnder assay
(Pathoﬁnder) for the detection of respiratory pathogens.
Methods: A total of 106 EQC samples of 9 QCMD Quality Control
panels were analysed, of which 95 samples were expected to be positive.
Extraction was performed with easyMag (Biome´rieux) using the generic
2.0.1 protocol. The panels were analysed with the Respiﬁnder assay and
the RVP assay according to the manufacturer’s instructions.
Results: RVP was positive in only 31 samples. For 8 samples an
inconclusive result was obtained. All samples containing adenovirus,
Coronavirus NL63, Coronavirus OC43 and Coronavirus 229E were
false negative with RVP. No false positive results were found. Hence,
sensitivity was 32.6% and speciﬁcity 100%.
A positive result was found with the Respiﬁnder assay in 75 samples.
For 3 weak positive samples an inconclusive result was obtained. For 2
adenovirus type 31 samples the analysis was also false negative. No false
positive results were found. Hence, sensitivity was 79% and speciﬁcity
100%.
Conclusion: Both the RVP and Respiﬁnder assay have an excellent
speciﬁcity. Sensitivity was 32.6% and 79% for the RVP assay and
Respiﬁnder assay respectively. In conclusion, the results of our study
seem to indicate a better sensitivity for the Respiﬁnder.
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P656 PCR and microarray-based Prove-it™ Herpes assay for
rapid herpesvirus diagnostics from clinical samples
A-K. Ja¨rvinen, M. Ma¨ki °, L. Mannonen, R. Vainionpa¨a¨, J. Kauppinen,
R. Lienhard, M. Tritten, G. Cannon, K. Moilanen, M. Ha¨kkinen,
M. Lappalainen (Helsinki, Turku, Kuopio, FI; La Chaux-de-Fonds,
CH; Dublin, IE)
Objective: We conducted an evaluation study for the Prove-it™ Herpes
assay (Mobidiag) to compare results to those of current PCR-based
herpes diagnostics. Prove-it™ Herpes identiﬁes seven herpesviruses
(HSV-1, HSV-2, VZV, EBV, CMV, HHV-6, HHV-7) in a single assay in
three hours, whereas most current PCR-based commercial or homebrew
methods search for only one or few viruses at a time.
Methods: Altogether, 497 cerebrospinal ﬂuid samples were analyzed
by both methods in ﬁve laboratories in Finland, Ireland, and
Switzerland. Furthermore, one of the laboratories analyzed Quality
Control for Molecular Diagnostics (QCMD) 2009 proﬁciency sample
panels for VZV, HSV, EBV, CMV, and HHV-6. In Prove-it Herpes
standard workﬂow, extracted DNA was ampliﬁed by PCR followed by
hybridization and detection by Prove-it™ Advisor software according to
manufacturer’s instructions. Reference PCR assays were performed as
determined by individual laboratories. Discordant results were studied
by additional reference PCRs and DNA sequencing.
Results: The results for QCMD samples were excellent with over
90% of the samples identiﬁed correctly. In cerebrospinal ﬂuid material,
Prove-it™ Herpes revealed multiple additional viral targets, either alone
or in combinations, when compared to reference PCR workﬂows. In 12
conﬁrmed multi-infections combinations such as HSV-2 with HHV-7
were detected. HHV-7 was observed in nine cases together with other
herpesviruses and in eight cases alone. Prove-it™ Herpes revealed
also individual targets not suspected initially by patient’s proﬁle such
as HHV-6, EBV and CMV. The ﬁnal sensitivity and speciﬁcity for
Prove-it™ Herpes assay were 92% and 98%. These results, especially
HHV-7 cases, yield also interesting data for further investigations.
Conclusions: Prove-it™ Herpes was considered as a rapid and
robust diagnostic platform that was easily implemented into laboratory
workﬂow. As a qualitative screening assay, Prove-it™ Herpes was
deemed especially suitable for diagnostics of cerebrospinal ﬂuid samples.
However, the results from other sample types have also been promising.
The broad target coverage and small sample volume required by the assay
could beneﬁt diagnostics, and especially, the treatment of life-threatening
infections of the central nervous system.
P657 Evaluation of a commercial real-time hepatitis B assay in
combination with NucliSens easyMAG nucleic acid extraction
K. Bergs °, D. Ursi, H. Goossens, M. Ieven (Edegem, BE)
Introduction: The Abbott RealTime Hepatitis B virus (HBV) assay, is
a quantitative assay, to be used with the Abbott m2000sp extraction
module. The NucliSens easyMAG (bioMe´rieux) is an open system for
automated isolation of nucleic acids, based upon the BOOM technology.
Objectives: To evaluate the performance of the easyMAG nucleic acid
extraction system for routine use with the Abbott RealTime HBV assay.
Materials and Methods: Serum samples were extracted using the
easyMAG Speciﬁc B protocol with a proteı¨nase K pre-treatment, with
an input volume of 200 ml serum and 3 ml internal control (IC) and an
elution volume of 110 ml.
Precision was evaluated by intrarun and interrun testing according to
Rabenau et al. (JCV 2007;40:93−98) using the HBV low positive control
(HBVLP) and HBV high positive control (HBVHP). Linearity was
determined by a 10-fold dilution series of a strong positive sample.
To test accuracy, 31 samples (6 negatives, 25 positives) were sent to
another laboratory that used the standard Abbott m2000 extraction and
ampliﬁcation protocol and results were compared.
Results: For all samples the Ct values of the IC were within
the speciﬁcations of the assay. Mean intrarun variationcoefﬁcient for
HBVLP and HBVHP was 1.95% and 0.24% respectively. Mean interrun
variationcoefﬁcient was 5.03% and 1.27% respectively. These are within
the limits of the manufacturer.
The linearity resulted in a correlation coefﬁcient of 0.999. Concerning
the accuracy experiments, the 6 negative samples were also negative after
easyMAG extraction. Twenty-four out of 25 positive samples (96%) did
not differ more than 0.5 log IU/ml.
Conclusion: The Abbott RealTime HBV assay can be used in
combination with easyMAG extraction.
P658 Evaluation of a new commercial PCR-DNA microarray for
rapid and simultaneous detection of 9 viruses responsible for
central nervous system infections
N. Leveque °, A. Van Haecke, F. Renois, L. Andreoletti (Reims, FR)
Objectives: Viruses are the main etiological cause of central nervous
system infections. Rapid testing is recommended in order to improve
therapeutic management in case of viral infection. In the present work,
we evaluated a new PCR-DNA microarray system allowing the rapid
and simultaneous detection of 9 neurotropic viruses: HSV-1 and -2,
VZV, EBV, HCMV, HHV-6, -7, -8 and enteroviruses.
Methods: Clart® Entherpex kit (Genomica, Madrid, Spain) is based
on viral genome-speciﬁc fragments ampliﬁcation by multiplex PCR and
its subsequent detection via hybridization with microorganism-speciﬁc
binding probe arrays. Evaluation of the kit was ﬁrst carried out using
the 2009 samples of the Quality Control for Molecular Diagnostics
(Glasgow, Scotland). Four quality controls for HSV-1 and -2, VZV, EBV,
HCMV, HHV-6 and enteroviruses ranging from 102 to 103 copies/ml
were independently tested 4 times each in order to assess the sensitivity
and the reproducibility of the assay. Moreover, 20 cerebrospinal ﬂuids
(CSF) tested positive for enteroviruses and 27 tested positive for an
herpesvirus (7 HSV1, 2 HSV2, 8 VZV, 4 EBV, and 6 HHV6) were
retrospectively analyzed. The viral load in the CSF was also determined.
Results: Clart® Entherpex kit detected in all cases (4/4) the quality
controls >500 copies/ml for HHV6 and >1000 copies/ml for the other
Herpesviruses tested. The sensitivity was estimated from 166 copies/ml
for HHV6 to 220 copies for the HSV1. For enteroviruses, quality controls
corresponding to 280 and 390 copies/ml were never detected during the
4 analyzes performed while a viral load of 1480 copies/ml was detected
in 3 times of 4. These results placed Clart® Entherpex kit on the same
level of sensitivity that the other commercially available kits evaluated
by the QCMD. From the clinical samples, Clart® Entherpex kit detected
26 of the 27 herpesvirus infections of the central nervous system and
all the 20 enterovirus positive CSFs selected. Only one infection due to
EBV characterized by an undetectable viral load (<500 copies/ml) was
not diagnosed.
Conclusion: This new PCR-DNA microarray system is a sensitive
and speciﬁc test allowing rapid (in one day’s work) and simultaneous
detection from the CSF of the main RNA (enteroviruses) and DNA
(Herpesviridae) neurotropic viruses.
P659 Comparison of two fully automated QIAGEN extractors
for a range of viral targets, including swine lineage
inﬂuenza A H1N1v
A.V. Lee °, R.J. Manuel, D.A. Clark (London, UK)
Objectives: Automated DNA/RNA extractors are becoming increasingly
common and 2 such platforms from Qiagen are the QIAsymphony SP
and BioRobot MDx. Here we compare these automated platforms for
use in routine laboratories.
Methods: A range of sample types were used and the nucleic acid
extracts tested on “in-house” PCR assays. Four real time PCR tests were
used: quantitative assay for cytomegalovirus (CMV) on 80 positive and
negative stored samples; 108 stored positive respiratory samples for an
inﬂuenza multiplex, including swine lineage sH1 (3 targets) and swine
lineage speciﬁc sN1 targets; 48 stored positive samples were tested using
a herpes simplex virus (HSV) type 1, HSV type 2 and varicella zoster
virus (VZV) multiplex.
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Results: Overall the two platforms gave similar results for each assay.
For CMV viral loads, 66/80 positive and negative stored samples had
a mean difference (QIAsymphony − MDx) of 0.083 log10 c/ml (s.d.
0.365) with a correlation of 0.944. For the inﬂuenza multiplex and swine
speciﬁc H1 and N1 assays, 130/157 positive PCR targets showed a mean
difference of −0.595 cycles (s.d. 2.563) with a correlation of 0.873. For
HSV1/HSV2/VZV, 48/48 samples showed a mean difference of 1.741
cycles (s.d. 3.425) with a correlation of 0.777.
Conclusions: In total, 244/285 (85.6%) samples tested gave concordant
results between the QIAsymphony® SP and BioRobot MDx extractors,
with 6 previously negative PCR targets being detected as positive by the
BioRobot MDx.
Both extractors have a load and walk-away system, full sample and
reagent barcode tracking and intuitive software that is easily operated.
The QIAsymphony® SP has a continuous loading system that enables
24−96 samples to be loaded compared to the batch-based system of
the BioRobot MDx which processes 32−96 samples in each run. Both
instruments are present in our laboratory and in routine use, with the
advantages of each system being utilised for different requirements.
Our comparison shows that both extractors can be used interchangeably
which will prove beneﬁcial in outbreak situations.
P660 New SmartFinder assay for the real-time detection of 19
respiratory pathogens
M. Reijans °, M. Noben, J. Ossel, G. Simons (Maastricht, NL)
Objective: Molecular diagnostics play an increasingly important role in
the detection of infectious agents. Up to now, multiplex realtime PCR
assays are able to detect up to 5 targets in one reaction.
Here we present a new SmartFinder assay which enables the detection
of 19 respiratory infectious agents in one realtime PCR reaction.
Method: The SmartFinder assay makes use of MultiFinder probes. In
a MultiFinder assay the different probes are identiﬁed based upon the
speciﬁc length of each probe by size-fractionation. The SmartFinder
assay uses realtime PCR as detection platform. Fluorescent labelled
hybridization probes detect the different MultiFinder probes using a
realtime PCR machine. The combination of different ﬂuorescent labels
and speciﬁc melting temperatures allow the development of highly
complex realtime PCR assays. The assay detects 19 pathogens in one
reaction thereby differentiating between Inﬂuenza A, Inﬂuenza B, RSV
A, RSV B, Adeno, Rhino, Parainﬂuenza 1−4, Coronavirus 229E +
NL63 + OC43, Human metapneumovirus, BOCA virus, M. pneumoniae,
C. pneumoniae, L. pneumophila, and B. pertussis.
Results: The proof of principle was demonstrated using 70 QCMD
samples and selected clinical samples. The results were compared with
a standard RespiFinder assay based upon detection using capillary
electrophoresis. All 19 different targets were detected. The two assays
showed a high degree of correlation. Mixed etiologies were mimicked
by combining different targets. Most of the mixed infections could be
readily detected.
In addition, a large cohort of more than 80 clinical samples was tested
with the SmartFinder assay and RespiFinder. Samples positive for any
of the two assays where retested with speciﬁc realtime PCR’s. The two
assays showed a high concordance. Most of the positive samples could
be conﬁrmed by realtime PCR.
All analyses were done on a LightCycler 480 machine.
Conclusions: The new SmartFinder assay shows a high concordance
with realtime PCR and RespiFinder. Post PCR handling and analysis
time in the SmartFinder assay were reduced compared to the RespiFinder
generating a faster outcome. In addition, the closed, realtime detection
reduces contamination risk. This study proves that the SmartFinder
technology shows great potential in fast and easy multiparameter
screening of clinical samples for infectious agents.
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P661 Comparison between an opa-based real-time PCR and the
Cobas Amplicor test for the detection of N. gonorrhoeae
M.V. Elzi °, M. Gorgievski-Hrisoho (Berne, CH)
Objectives: Aim of this study was to compare the performance of a
real-time PCR targeting a 90-bp region on the N. gonorrhoeae opa gene
(Tabrizi et al. 2005) with the COBAS AMPLICOR test for detection of
N. gonorrhoeae.
Methods: 421 clinical samples were analysed using an opa-based
PCR (Tib Molbiol, Berlin, Germany) on the COBAS TaqMan
Analyzer (Roche Diagnostics, Rotkreuz, Switzerland), and the COBAS
AMPLICOR CT/NG test (Roche Diagnostics). DNA extraction was
performed using the AMPLICOR CT/NG sample preparation kit
(Roche Diagnostics) for swabs, and the NucliSENS easyMAG system
(bioMe´rieux, Marcy l’Etoile, France) for urine, ascites and synovial
ﬂuid. Analysis of COBAS TaqMan data was performed using the Utility
Channel Data Analyzer Software (Roche Diagnostics). Positive samples
were submitted to a conﬁrmatory laboratory (Institute of Medical
Microbiology, Zu¨rich, Switzerland) for further testing (PCR targets: 16S
rRNA gene, cppB gene and porA gene).
Results: We analysed 421 clinical samples (161 urines, 120 pharynx,
78 rectal swabs, 57 urogenital swabs, 4 intraabdominal samples, 1
synovial ﬂuid) and 10 samples of QCMD 2009. Overall, N. gonorrhoeae
was detected in 5/421 (1.2%) clinical samples using the opa-based
method, and in 82/421 (19.5%) clinical samples using the COBAS
AMPLICOR test. According to the conﬁrmatory laboratory, all positive
samples detected with the opa-based method, compared to only 5 of
82 (6.1%) positive samples from the COBAS AMPLICOR test were
correct. Agreement between the COBAS AMPLICOR NG test and the
opa-based test was noted in 81.7% of clinical samples (339 tests negative
and 5 positive using both methods). False positive results were detected
in 77 of 82 (93.9%) clinical samples using the COBAS AMPLICOR
NG test and in 0 of 5 clinical samples using the opa-based method.
We detected no additional positive clinical samples with the opa-based
method. However, in contrast to the COBAS AMPLICOR test, the opa-
based method allowed us to correctly identify 2 QCMD samples as
positive.
Conclusions: The opa-based PCR allowed a signiﬁcant reduction in
the number of false positive results. In comparison to the COBAS
AMPLICOR NG test, that is known to cross-react with some non-
pathogenic Neisseria species, the opa-based PCR showed an increased
speciﬁcity without impairment of sensitivity.
COBAS AMPLICOR NG test opa-based PCR
Negative Positive Total
Negative 339 0 339
Positive 77 5 82
Total 416 5 421
P662 Screening for Neisseria gonorrhoeae in urine samples using
real-time PCR
C. Berglund °, L. Carlsson, M. Ba¨ckman (Ta¨by, Stockholm, SE)
Objectives: In Sweden, an increase of Neisseria gonorrhoeae (NG)
cases has been observed during recent years, especially among young
women. However, the sexually transmitted disease Chlamydia, caused
by Chlamydia trachomatis (CT), still remains more prevalent. NG is
routinely diagnosed by culturing methods whereas CT generally is
detected in urine by nucleic acid tests. A screening method for both
CT and NG has been requested since sampling for NG is invasive and
painful.
Methods: The Abbott RealTime m2000 CT/NG assay was evaluated
on ten serological variants of NG as well as on four culture collection
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strains that were diluted in urine (approximately 1×108, 2.5×105, 800
or 2 organisms per 400 ml input). In addition, the QCMD 2008 NG EQA
Programme and dilutions of the AmpliTrol CT/GC DNA control (Bio-
Rad Laboratories) were tested. All runs were repeated at least twice and
in both presence and absence of CT.
Results: All included serological variants could be detected at expected
concentrations (1×108: mean CT = 19.4 (+++), 2.5×105: mean CT =
27.7 (++), 800: mean CT = 35.8 (+), 2: CT> 40 (−). Analysis of the
2008 QCMD panel resulted in a performance of 96.7%. One of the low
positive samples had a CT of 40.44 and was regarded as negative in one
of three runs.
Conclusion: Abbott RealTime m2000 CT/NG provided rapid, effective
and safe testing for NG in our study. The major advantages included:
(i) testing on urine which simpliﬁes sampling and subsequently may
lead to increasing sample volumes, (ii) Abbott multi-collect Specimen
Collection Kit allow long sample storage (14 days) prior to analysis,
which is in contrast to culturing methods where NG is extremely sensitive
for storage, (iii) a large amount (96) samples could be analysed in
a short time allowing negative results to be released within one day.
Disadvantages include: lack of bacterial isolates in order to perform
epidemiological typing and susceptibility testing, (ii) the method is
validated only for genital and urine samples.
P663 Comparison of the Roche prototype Cobas® 4800 CT/NG
assay to the Cobas Amplicor CT/NG assay
G. Tyrrell °, K. Kalan, G. Yung, J. Fuller (Edmonton, CA)
Objective: The Medical Microbiology Laboratory at the University
of Alberta Hospital routinely assays urine and dry swab specimens
using the MagNA Pure instrument for sample preparation and COBAS
AMPLICOR CT/NG test for the detection of Chlamydia trachomatis
(CT) and Neisseria gonorrhoea (NG). The cobas® 4800 is a highly
automated system that performs sample preparation; real-time PCR
ampliﬁcation; and simultaneous detection of CT and NG as well as
an internal control in a single tube. This study compares the current
COBAS AMPLICOR CT and NG test with the new cobas® 4800 system
for detection of CT and NG from cervical swabs and urine specimens
to evaluate the performance of these two tests in terms of sensitivity,
speciﬁcity, PPV, and NPV.
Methods: 541 CT and 279 NG banked specimens of urine or dry swabs,
were retested with the cobas® 4800 CT/NG test. An aliquot of the frozen
specimen (400ml) previously tested by the COBAS AMPLICOR CT/NG
test was diluted with 450ml saline solution and mixed with 850ml of the
cobas® PCR Media, before being loaded onto the cobas 4800 system.
The volume adjustment was to ensure equal amounts of specimen were
present in the PCR reactions using two the different assays. Correlation
of the CT and NG test results between the two assay systems is presented.
Results: Of the 541 CT specimens assayed, 7 specimens were excluded
from the data analysis due to samples precipitating out of the solution
or unknown COBAS AMPLICOR results. 536 specimens were assayed
for CT. The CT results showed 98.3% concordance (527/536 samples,
kappa=0.861) between the two tests. Banked CT-positive samples without
COBAS AMPLICOR NG ordered were excluded from the NG analysis.
Of the 279 remaining specimens which also had NG results, 9 mixed CT
and NG infections were observed with the COBAS AMPLICOR CT/NG
test, whereas 17 mixed CT/NG infections were observed with the cobas®
4800 CT/NG test. A concordant rate of 96.8% was observed (270/279,
kappa=0.603) for NG results from banked CT positive samples.
Conclusion: The cobas® 4800 CT/NG test and the COBAS AMPLICOR
CT/NG assays correlated well in this analysis. The cobas® 4800 system
is highly automated and easy to use for high volume testing of CT/NG.
P664 Performance of the Aptima CT and GC assays on the
Panther instrument
M.K. Vi °, J. Pham, C. Nguyen, B. Vinluan, C. Clark, A. Worlock
(San Diego, US)
Objectives: To evaluate the analytical performance of the Panther
Instrument, a new, fully automated molecular diagnostic analyzer under
development at Gen-Probe.
Methods: Reproducibility was assessed for the Gen-Probe APTIMA
COMBO 2 (AC2), APTIMA CT (ACT), and APTIMA GC (AGC)
Assays on the Panther Instrument. Positive reproducibility panels were
made using pooled naturally infected positive urine specimens diluted
1:1000 with pooled negative urine specimens. Panels consisted of a
Chlamydia trachomatis (CT), Neisseria gonorrhoeae (GC) and dual
positive panel members, as well as a negative panel member. Each
panel member was tested in replicates of 3 on two prototype Panther
Instruments over 10 days, giving a total of 60 replicates for each assay.
Platform comparison panels were made using individual positive
specimens diluted into individual negative specimens. The positive panel
member dilutions ranged from 1:100 to 1:1,000,000 for the AC2 and
AGC Assays and 1:100 to 1:10,000,000 for the ACT Assay. The total
number of positive panel members was 42 for the AC2 Assay (CT),
62 for the AC2 Assay (GC), 51 for the ACT Assay, and 60 for the
AGC Assay. The positive panels were run on both a prototype Panther
Instrument and Gen-Probe’s TIGRIS System in replicates of one, along
with between 84 and 92 individual known negative specimens.
Results: Total precision for reproducibility panels as measured by %CV
was 4% for CT, 2% for GC and 6% for dual positive samples using the
AC2 Assay, 4% for GC positive samples using the AGC Assay, and 11%
for CT positive samples using the ACT Assay. The % agreement between
the Panther Instrument and TIGRIS System results for the platform
comparison panels was 95% (41 of 43) for CT positive panels, 100%
(62/62) for GC positive panels and 100% (92/92) for negative panel
members using the AC2 Assay. The % agreement was 100% (60/60) for
GC positive panels and 100% (84/84) for negative panels using the AGC
Assay. The % agreement was 100% (51/51) for CT positive panels and
100% (92/92) for negative panels using the ACT Assay.
Conclusions: The fully automated Panther molecular diagnostic analyzer
under development at Gen-Probe provides precise results comparable to
the TIGRIS System when running the AC2, ACT and AGC Assays. In
addition to superior assay performance, the Panther Instrument offers
the optimum throughput, workﬂow and turn around time that is ideal for
the low-to-mid volume molecular testing laboratory.
P665 A multiplexed isothermal ampliﬁcation assay for the
detection of Chlamydia trachomatis and Neisseria gonorrhoeae
D. O’Neil °, V. Doseeva, T. Forbes, J. Wolff, K. Upton, K. McPartland,
D. Loeffert, I. Nazarenko (Gaithersburg, US)
Objectives: Our objective was to develop a sensitive, highly speciﬁc,
multiplexed assay for the detection of Chlamydia trachomatis (CT) and
Neisseria gonorrhoeae (NG). We have combined Qiagen’s proprietary
Hybrid Capture® (HC) technology for sample processing with isothermal
helicase dependent ampliﬁcation (tHDA) and endpoint ﬂuorescence
detection to develop a multiplex assay for the detection of CT and NG in
clinical samples. This product is currently at a research prototype stage
and is not yet commercially available.
Methods: Hybrid Capture sample preparation involved hybridization of
sequence-speciﬁc oligoribonucleotide probes to target DNA. RNA:DNA
hybrids were captured by HC antibodies conjugated to magnetic beads,
which can be placed directly into the ampliﬁcation reaction without prior
elution.
Captured target is ampliﬁed by tHDA, an isothermal technology
which utilizes a thermostable helicase to unwind double-stranded DNA,
followed by priming of the single-stranded target and extension by
DNA polymerase. This ampliﬁcation technology eliminates the need for
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thermocycling. tHDA products are detected in a closed-tube format by
endpoint ﬂuorescence detection with dual-labeled probes.
Our model assay has two CT ampliﬁcation targets, including the cryptic
plasmid and the outer membrane protein (omp) gene. Dual targets
ensures against deletion or mutation of the target sequence causing false
negative results. NG ampliﬁcation target is the outer membrane opacity
protein (opa), a multi-copy gene.
Results: Using this research prototype test system, we detected as little
as two CT elementary bodies, and less than ten NG cells per mL
of sample. Targets were detectable in multiplex, and each target was
detectable in the presence of an excess (105) of the other. All CT serovars
A-K, and L1-L3 were ampliﬁed and detected at equivalent sensitivity.
The method is suitable for the processing of samples in many different
media, among them: urine, PreservCyt®, STM and SurePath. The clinical
utility of this assay was demonstrated on a limited number of clinical
samples.
Conclusions: The combination of sequence-speciﬁc sample preparation
and isothermal target ampliﬁcation allows for a multiplex CT/NG
assay which delivers high analytical sensitivity and speciﬁcity. The
combination of short turn-around time (under three hours), isothermal
reaction conditions, and closed-tube format make the assay well suited
to adaptation for future high-throughput automation.
P666 Evaluation of automated DNA extraction and real-time
PCR detection of Chlamydia trachomatis and Neisseria
gonorrhoeae with the Abbott m2000 assay
C. Visser °, J. de Haan, A. de Cuijper, B. Duim (Amsterdam, NL)
Objectives: For routine diagnostics of Chlamydia trachomatis (Ct) and
Neisseria gonorrhoeae (Ng) commercial assays have been developed.
One is the Abbott m2000 assay that allows DNA extraction from 90
clinical specimens and real-time PCR detection of Ct and Ng. The assay
targets the cryptic plasmid of C. trachomatis and allows detection of the
recently developed deletion variant, and for N. gonorrhoeae detects the
opaA gen.
Methods: A total of 618 specimens consisting of male and female urines
and endocervical swabs collected in M4RT medium, were tested for the
presence of Ct and Ng nucleic acids using Abbott RealTime CT/NG
reagents on an m2000 platform and the in our lab routinely performed
Roche Cobas Amplicor test. Samples positive for Ng were conﬁrmed
with a real-time assay targeting the opaA gene. The evaluation assessed
the performance characteristics of the Abbott m2000 assay and the ability
of the assay to improve laboratory workﬂow and throughput.
Results: 44 specimens were Ct positive with the Abbott real-time test.
Of these samples 3 were negative with the Cobas Amplicor test. For
detection of CT the Abbott real-time showed a sensitivity of 100%
(44/44) and a speciﬁcity of 99% (551/554). 12 specimens were Ng
positive with the Abbott real-time test. Without conﬁrmation of the
positive Ng specimens detected with the Cobas Amplicor with the opaA
real-time assay, the sensitivity and speciﬁcity of the Abbott real-time test
were 27% (12/44) and 100% (438/438), respectively. After conﬁrmation
of the positive Cobas Amplicor samples, the sensitivity of the Abbott
real-time improved to 100%.
Conclusions: The Abbott m2000sp demonstrated greater sensitivity than
the Cobas Amplicor, and no conﬁrmation of Ng positive specimens is
required. Abbott m2000 combines high throughput with minimal labor
and supports a procedure that is easily learned. This makes it a suitable
system for routine detection of Ct/Ng in endocervical swabs and urine.
P667 Comparison of the new Versant® CT/GC DNA 1.0 Assay
(kPCR) and Roche Cobas® TaqMan® (CTM) assay for the
detection of Chlamydia trachomatis in urine samples
A. Lindauer °, K. Beyser, G. Warnat (Weiden, Eschborn, DE)
Objectives: Performance of the VERSANT® CT/GC DNA 1.0 Assay
(kPCR), which can simultaneously detect Chlamydia trachomatis (CT)
and Neisseria gonorrhoeae (GC) in swab and urine specimens, was
evaluated and compared with the Roche COBAS® TaqMan® CT Test
(CTM). Secondarily, the stability of urine samples in the presence or
absence of the Siemens VERSANT Urine Transport Kit (UTK) was
also evaluated.
Methods: 372 samples from preselected CTM positive pool urine
samples (pools of 5) were transferred into Siemens VERSANT® Urine
Transport Kits (UTK) and tested on the VERSANT® kPCR Molecular
System with the VERSANT assay. The Roche COBAS TaqMan assay
was used as a comparative method. Specimens with results that were
discrepant by the two assays were subjected to repeat testing in replicates
of two in both methods. Ten (10) low positive urine samples with late
CTM cycle threshold values (Ct 35−40) were also subjected to elevated
temperature (37ºC) for up to 96 hours stored in the VERSANT UTK or
neat urine and then tested in the VERSANT assay to determine effects
on Ct values.
Results: A total of 367 samples were evaluable of which 86 were
CT-positive and 281 were CT-negative. After resolution testing, the
VERSANT assay detected 85 of 86 of the positive samples and 279
of the 281 negative samples resulting in a sensitivity and speciﬁcity
of 98.83% and 99.28%, respectively. In comparison, the CTM assay
detected 83 of 86 of the positive samples and 276 of 281 of the
negative samples resulting in a sensitivity and speciﬁcity of 96.51%
and 98.22%, respectively. Furthermore, the VERSANT assay detected
positive samples 7 to 10 Ct’s earlier than the CTM assay in urine samples
undergoing stability testing. CT positive urine samples stored in the
presence of VERSANT UTK and subjected to temperatures of 37ºC for
up to 96 hours were shown to be stable. Also for the native urine samples
nearly the same stability could be shown.
Conclusion: These results indicate that the automated VERSANT assay
detects more true positive and true negative samples than the CTM
assay even when using CTM preselected urine samples from a screening
population. The VERSANT UTK, which requires no off-line processing
steps, offers the advantage of stable transport and storage for urine
samples up to 37ºC. The sensitivity of the VERSANT CT/GC DNA
1.0 Assay combined with automated throughput establishes this assay as
a quality diagnostic tool including the detection of urine pool samples.
P668 The role of the microbiology laboratory in the diagnosis
of lymphogranuloma venereum illustrated in 4 cases at a
university hospital, Basel, Switzerland
D. Goldenberger, M. de Roche, U. Flu¨ckiger, A. Blaich, R. Frei °
(Basel, CH)
Objectives: In context with the ongoing epidemic of lymphogranuloma
venereum (LGV) and its unspeciﬁc clinical presentation, there is a need
for a fast and reliable diagnosis of LGV. We applied a simple laboratory-
based algorithm for detection of Chlamydia trachomatis L1, L2, and L3
and performed a retrospective search for LGV cases at our clinics.
Methods: We established a duplex real-time PCR for simultaneous
detection of C. trachomatis L1, L2, L3 targeting the pmpH gene
and L2/L2b targeting the omp1 gene, respectively. For routine LGV
diagnosis, we ﬁrst performed a commercially available C. trachomatis
PCR (cryptic plasmid, Cobas Amplicor) in anorectal swabs or biopsies.
If the PCR was positive, we then routinely tested for the LGV agents. To
identify LGV cases retrospectively, we ran a search for C. trachomatis-
positive, non-urogenital and non-occular specimens in our laboratory
information system.
Results: We identiﬁed two LGV cases in the year 2008. Patient 1
presented with ulcer and inguinal lymphadenopathy. Patient 2 suffered
from severe ulcerative proctitis with delayed clinical diagnosis of
LGV. A total of 7 parafﬁn-embedded tissue specimens of these
patients were analyzed. All samples showed C. trachomatis L2/L2b-
DNA. The two diagnoses were completed with the omp1 genotyping
result of C. trachomatis L2b and positive serology ﬁndings. Applying
our laboratory algorithm, we additionally detected 2 cases with
C. trachomatis L2/L2b from 3 C. trachomatis-positive anorectal samples.
The 4 patients were between 41 to 50 years old and men who have sex
with men, one of whom was HIV-positive.
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Conclusion: Our laboratory-based approach is a promising tool to detect
LGV in a rapid and reliable way. This is crucial for the clinician to
initiate an appropriate antibiotic therapy. We also show that our tests can
be applied successfully to formalin-ﬁxed biopsies.
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P669 Clinical and laboratory evaluation of a real-time PCR for
Clostridium difﬁcile
E. de Jong °, A. de Jong, C. Bartels, C. van de Rijt, W.J. Melchers,
P.D. Sturm (Nijmegen, NL)
Objective: C. difﬁcile associated diarrhea (CDAD) is the major cause of
nosocomial diarrhea. A rapid and sensitive diagnostic test is necessary
to make the diagnosis. Many laboratories use enzyme immunoassays
(EIAs) for rapid diagnosis of CDAD since cell cytotoxicity test(CTT)
and toxigenic culture (TC) take 24 hours and more. The performance
EIAs vary widely with sensitivity and speciﬁcity ranging from 50 to
99% and 70 to 100%, respectively. Few studies have described PCR
with sensitivity ranging from 86 to 97% and speciﬁcity from 96 to
98%. A real-time PCR detecting Clostridium difﬁcile toxin A and B was
evaluated prospectively in hospitalized patients with diarrhea and healthy
volunteers.
Methods: Stool samples from 150 consecutive hospitalized adult patients
were included. PCR was compared to CTT of stool samples, TC,
immunochromatography (ICT) (Meridian), and ELISA (Vidas). Clinical
data were collected prospectively using a standardized questionnaire.
PCR was performed on the stool samples from 75 healthy volunteers.
Results: The median age of the patients was 61 yrs and 49% were male.
TC was positive in 17 (11%) patients. Using TC as the gold standard,
sensitivity/speciﬁcity of PCR, CTT, ICT, and ELISA was 100/99.2,
70/100, 47/99.2, and 58.8/89.4%, respectively.
Patients were categorized as positive CCT/TC/PCR (12); positive
TC/PCR only (5); negative TC (133). All patients with positive TC/PCR
had clinical diarrhea. No differences were present with respect to
current or prior antibiotic use, type of antibiotic, presence of diarrhea
deﬁned as >2 loose stools per day for a duration of >48 or >24
hrs, aspect of stool, fever, abdominal pain, tube feeding, proton
pump inhibitors, chemotherapy, immunocompetency, admission ward,
inﬂammatory bowel disease, leucocytes, and CRP. The median age of
the volunteers was 21 yrs and 29% were male. None of the healthy
volunteers were positive on PCR evaluation.
Conclusion: PCR is rapid and sensitive for the detection of C. difﬁcile.
The sensitivity of CTT was only 70% and cannot be used as gold
standard. EIAs had low sensitivity and speciﬁcity and were not
complementary to other tests. Clinical prediction of CDAD was not
possible. Clinical signiﬁcance of a positive result for TC/PCR only could
not be established, however all healthy volunteers had negative PCR
results.
P670 Evaluation of real-time PCR tcdC gene detection assay for
the diagnosis of Clostridium difﬁcile infection
T. Wong °, M. Romney, G. Ritchie, S. Pengilly, S. Champagne
(Vancouver, CA)
Objectives: The tcdC gene within the Clostridium difﬁcile pathogenicity
cassette is a negative regulator for toxins A and B expression.
Deletions in the tcdC gene are associated with more virulent strains
of C. difﬁcile including ribotype 027. In this prospective study,
a C. difﬁcile GDH antigen enzyme-linked immunoassay (Techlab,
Blacksburg, VA), a C. difﬁcile Toxin A/B enzyme-linked immunoassay
(Techlab, Blacksburg, VA), cell cytotoxicity assay, C. difﬁcile culture and
an in-house real-time PCR amplifying the tcdC gene were evaluated.
Methods: Faecal samples from hospitalised patients with a query
diagnosis of C. difﬁcile infection (CDI) were collected for two
consecutive months at St. Paul’s Hospital, Vancouver, Canada. In total,
430 faecal samples were obtained from 343 patients. Samples were
ﬁrst tested according to the hospital’s three step “standard operating
protocol” (SOP), which consists of (1) GDH antigen EIA, (2) Toxin A/B
EIA and (3) cell cytotoxicity assay. All faecal samples were cultured
on C. difﬁcile agar and then frozen for further studies. Samples were
then tested with an in-house tcdC gene real-time PCR for performance
evaluation. Discordant results were resolved by performing an ethanol
shock treatment; recovered isolates underwent toxigenic culture assay,
which is considered the gold standard for statistical analysis.
Results: There were 329 concordantly-positive, 57 concordantly-
negative, and 44 discordant results for a total concordance/discordance
rate of 89.8% / 10.2%. After resolution of discordant results, the
sensitivity for culture, SOP, and PCR were 87.4%, 85.5%, and
98.8%, respectively. The speciﬁcity for culture, SOP, and PCR were
96.8%, 99.1%, and 97.4%. The positive and negative predictive values
for culture, SOP, and PCR were 87.4%/96.8%, 95.6%/94.0%, and
90.5%/99.7%. For the 44 discordant results, agreement with the gold
standard for culture, SOP and PCR was 50.0%, 43.2%, and 77.3%.
Conclusion: We concluded that this in house real-time PCR for the
detection of C. difﬁcile tcdC gene is both sensitive and speciﬁc in our
hospital setting for patients with a query diagnosis of CDI. For resolving
discordant results, C. difﬁcile tcdC gene real-time PCR had the highest
concordance rates when compared to toxigenic culture.
Performance evaluation of C. difﬁcile culture, SOP* and tcdC gene PCR
Sensitivity
%
Speciﬁcity
%
PPV
%
NPV
%
Culture 87.4 96.8 87.4 96.8
SOP* 85.5 99.1 95.6 94.0
tcdC gene PCR 98.9 97.4 90.5 99.7
*SOP=St. Paul’s Hospital three step standard operating protocol
involving (1) GDH antigen EIA (2) toxin A/B EIA (3) cytotoxicity assay.
P671 Comparative evaluation of Clostridium difﬁcile detection by
three distinct real-time PCR techniques
C.W. Knetsch °, D. Bakker, R.F. de Boer, S. Hofs, A.M. Kooistra-Smid,
K. Eastwood, M. Wilcox, E.J. Kuijper (Leiden, Groningen, NL; Leeds,
UK)
Objectives: Incidence of Clostridium difﬁcile infections (CDI) has
increased in the past decade. Assays for the rapid diagnosis of CDI
are preferable. Previously, we have developed a real-time PCR, which
targets the C. difﬁcile toxin B gene. The aim of this study was to compare
this toxin B real-time PCR with two other real-time PCR techniques that
detect the presence of C. difﬁcile toxin genes and determine their utility
as rapid diagnostic test to diagnose CDI.
Methods: In total, 535 routine diagnostic diarrheal samples were tested
prospectively using cytotoxin assay (CYT) and cytotoxigenic culture
(CYTGC) and retrospectively using 2 in house developed real-time PCRs
(LUMC, LvI) and a commercially available PCR (GeneOhm, Becton
and Dickenson). Specimens were stored at 4ºC for 1 week and then
frozen at −20ºC. For the in-house developed real-time PCRs, faecal
samples were pre-treated with STAR buffer and chloroform to optimize
DNA extraction. DNA was extracted from faeces using automated DNA
extraction procedures. For each real-time PCR technique sensitivity,
speciﬁcity, positive predictive value (PPV) and negative predictive value
(NPV) were determined by using two gold standards; cytotoxigenic
culture and cytotoxicity assay.
Results: Compared with CYTGC, sensitivity, speciﬁcity, PPV and NPV
values were: for real-time PCR LUMC 96.0%, 88.0%, 66.0% and 98.9%,
for real-time PCR LvI 100.0%, 89.4%, 69.7% and 100.0% and for
BD GeneOhm 88.3%, 96.9%, 86.5% and 97.4%. Compared with CYT,
sensitivity, speciﬁcity, PPV and NPV values were: for real-time PCR
LUMC 96.7%, 85.9%, 59.2% and 99.2%, for real-time PCR LvI 98.9%,
87.3%, 62.7% and 99.7% and for BD GeneOhm 90.7%, 95.8%, 81.3%
and 98.1%.
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Conclusion: The three real-time PCRs have similar performances but
BD GeneOHM real-time PCR had the best PPV. Due to the high NPVs
all three real-time PCRs can be applied as a ﬁrst screening test for CDI.
However, the low PPVs of all PCRs require a second conﬁrmation test.
P672 Comparison of real-time polymerase chain reaction (Cepheid
GeneXpert) with enzyme-immunoassay (Meridian Premier
A/B) for the laboratory diagnosis of toxigenic Clostridium
difﬁcile
S. Goldenberg °, T. Dieringer, G. French (London, UK; Rochester, US)
There is increasing concern over the performance of Enzyme Immunoas-
say (EIA) tests for the laboratory diagnosis of Clostridium difﬁcile
Infection (CDI). The optimal method for diagnosis is yet to be deﬁned
and may vary from centre to centre, however there is a move towards
the use of newer Polymerase Chain Reaction (PCR) based tests.
We compared the Cepheid Genxpert PCR test (which detects Toxin B
gene and is able to give a presumptive identiﬁcation of ribotype 027)
with the Meridian Premier EIA for Toxin B in 224 consecutive diarrhoeal
stool samples. Results were validated against a gold standard of toxigenic
culture (TGC).
57 specimens were TGC positive. This 25.4% positivity rate (created
by stratiﬁcation) was much higher than our institution’s background rate
and we therefore used a modiﬁed method for calculating performance
characteristics in order not to distort ﬁgures for sensitivity and speciﬁcity.
Overall agreement between EIA and TGC was 92% (206/224) and
between PCR and TGC was 97.3% (218/224). The EIA had a sensitivity
of 65.7%, speciﬁcity of 98.0%, positive predictive value (PPV) of 84.2%
and negative predictive value (NPV) of 94.6% compared with TGC. The
PCR had a sensitivity of 100%, speciﬁcity of 96.7%, PPV of 90.5% and
NPV of 100% compared with TGC. (See table.)
6 specimens gave a PCR positive result but were EIA negative and failed
to yield C. difﬁcile. These may have been false-positives but it is possible
that toxigenic C. difﬁcile was present in the sample but in insufﬁcient
quantities or condition to be detected by other methods. (The number of
viable bacteria within the sample may have reduced during transportation
or storage).
The PCR assay identiﬁed 10 samples (17.5% of the samples that yielded
toxigenic C. difﬁcile) as ribotype 027. 9 of these were indistinguishable
from ribotype 027 by PCR-ribotyping, however one was a different
ribotype.
In our hands the Cepheid GeneXpert had a signiﬁcantly improved
sensitivity and speciﬁcity compared with the Meridan Premier EIA for
detection of toxigenic C. difﬁcile in diarrhoeal stool samples.
It is clear that suboptimal diagnostic C. difﬁcile assays undermine the
effectiveness of control measures and the usefulness of surveillance
systems.
Further research is warranted to determine the most accurate method of
diagnosis possibly including a PCR test as part of multistep procedure.
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Meridian Premier A/B EIA 65.7 98 84.2 94.6
Cepheid GeneXpert RT-PCR 100 96.7 90.5 100
P673 Performance comparison of Xpert C. difﬁcile, ImmunCard
enzyme immunoassay, and culture for the detection of
C. difﬁcile in stool
P. Legrand, Z. Ould Hocine, N. Launay, F. Maillebuau, J.M. Le
Glaunec, L. Deforges, N. Finnstro¨m °, M. Marmiesse (Creteil,
Maurens-Scopont, FR)
Objective: Various tests can detect the presence of C. difﬁcile and/or its
toxins in feces to establish the diagnosis in diarrhea following the use of
antibiotics. Many laboratories routinely use a rapid enzyme immunoassay
(EIA). Recently the Xpert C. difﬁcile test was developed. It runs on the
automated real-time PCR instrument GeneXpert (Cepheid). The assay
is very simple and easy to use and has proven to have an excellent
sensitivity (at least as good as the cytotoxicity assay). It allows the
detection of the toxin B gene, binary toxin gene and the nt117-deletion
in the tcdC gene.
We wanted to evaluate the added value provided by the diagnostic test
Xpert C. difﬁcile compared to the EIA ImmunoCard Toxins A & B
(IC) (Meridian Bioscience) in routine laboratory work. A CCFA culture
(bioMe´rieux) was also performed and the toxigenic nature of the strain
was determined by enzyme immunoassay.
Methods: 172 post-antibiotic diarrhoeal stool samples were tested
consecutively over a period of four months by Xpert, IC and culture
according to the manufacturers’ instructions.
Results: For 34 stool samples (19.8%), at least one of the techniques
detected a toxigenic C. difﬁcile. No other enteropathogenic organisms
were detected. The detection of C. difﬁcile was made in 19.2% of the
stool samples (33/172) by Xpert, 15.7% (27/172) by IC and 16.9%
(29/172) by culture.
Seven stool samples were positive by Xpert and negative by IC
(diagnostic gain of 20.6%). Three of them had a positive culture for
toxigenic C. difﬁcile Strain. Only one positive stool sample by culture
and IC was initially interpreted by Xpert as negative, but was positive
after a second test performed after the stool had been homogenized.
Toxigenic C. difﬁcile strain could not be isolated from any stool samples
determined negative by Xpert.
For one sample Xpert detected the binary toxin and the tcdC deletion,
characteristic of the PCR-ribotype O27. This was conﬁrmed by PCR-
ribotyping of the strain.
Conclusion: The Xpert C. difﬁcile test is much more sensitive than the
IC test. It is easy to use, gives a result in less than an hour and can
detect the ribotype O27. It may therefore contribute to a better diagnosis
of C. difﬁcile infections and hence limit the spread.
P674 Molecular analysis of toxigenic Clostridium difﬁcile isolates
from patients with nosocomial diarrhoea
M. Salari ° (Tehran, IR)
Objective:Clostridium difﬁcile is an identiﬁed cause of antibiotic-
associated diarrhea, antibiotic-associated colitis, pseudomembranous
colitis and nosocomial diarrhea. the objectiveof this survey was to
determine molecular analysis of toxigenic C. difﬁcile solates from
patients with nosocomial diarrhea in Tehran tertiary medical centers.
Methods: In this study, 1822 specimans of patients with nosocomial
diarrhea that were hospitalized in Emam khomeini hospital, Shariati
hospital and Children medical center and also100 hospital environmantal
specimens were collected. The specimens were cultured on a selective
cycloserine cefoxitin fructose agar (CCFA) and incubated in anaerobic
conditions, at 37ºC for 2 days. C. difﬁcile Isolates were characterized
by conventional biochemical tests. Bacterial cytotoxicity was assayed on
tissue culture and also all strains were typed by PCR-ribotyping method.
Results: Of the total specimens of patients and hospital enviroment,
124 and 17 toxigenic C. difﬁcile were isolated, respectively. Results of
statistical analysis show no signiﬁcant differences between the rate of
isolated toxigenic C. difﬁcile from patients, sex and age group of patients
(P> 0.05). A total of 28 different ribotypes was detected among the
clinical isolates by PCR ribotyping method. The predominant ribotypes
of isolated toxigenic C. difﬁcile were 13, 14, and 15. Ribotypes 13−17
were ﬁve distinct clones that were circulating in all three hospitals.
Conclusion: Findings of this study show that the toxigenic C. difﬁcile
isolates in Iran have different PCR-ribotyping patterns. Therefore, further
studies to evaluate PCR-typing are suggested.
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P675 A comparison of the dominant strains of Clostridium difﬁcile
in Scotland: growth rate, toxin production and sporulation
P. Vohra °, I.R. Poxton (Edinburgh, UK)
Objectives: To determine the differences in potential virulence of
Clostridium difﬁcile ribotypes most prevalent in Scotland (106, 001 and
027) using phenotypic traits and genomic analysis.
Methods: The growth of C. difﬁcile ribotypes 106, 001 and 027 was
observed along with 2 reference strains, 630 and VPI10463, over a
24 h period by measurement of OD600 every 4 h. Corresponding toxin
production was studied by ELISA using the C. difﬁcile TOX A/B II™
kit (Techlab) and associated spore production was determined by viable
counts for the same time points. The expression of the genes coding for
the C. difﬁcile toxins, tcdA and tcdB, and the initiator of sporulation,
spo0A, was analysed by Real-Time RT-PCR.
Results: The growth of all ribotypes was similar, but 106 and 001
appeared to have accelerated growth at 4 h compared to 027. Toxin
production was markedly different between the strains. By the stationary
phase, 027 produced at least 10-fold more total toxin (A and B) than
the others. 106 produced the most spores during the stationary phase,
followed by 027 and 001. Transcriptional analysis revealed that tcdA
expression was the highest in 027, almost double that observed in
106 and 001, but that of tcdB was markedly higher in 106. spo0A
transcription was the highest in 001, followed by 027 and 106.
Conclusions: Ribotypes 106, 001 and 027 are currently the most
prevalent in Scotland. The growth of these strains demonstrates that
greater cell numbers do not contribute to greater virulence. However,
higher spore production, as seen in 106, 001 and 027, is signiﬁcant in
terms of spread in the environment. Large amounts of toxin production,
however, can lead to greater virulence, as seen in 027 and even in 106 and
001 that do not produce as much toxin as 027, but produce signiﬁcantly
more toxin than reference strain 630. It is of interest to note that in 027,
tcdA transcription was signiﬁcantly higher than that of tcdB. This was
also observed in 001 and 106, though not as prominently. This suggests
that even though toxin B is essential for virulence, production of larger
amounts of toxin A may increase virulence. spo0A transcription was
also higher in the epidemic strains and this is also a good indicator
of differences between the strains. The epidemic ribotypes 106, 001
and 027, therefore, appear to have increased potential to spread in the
environment and cause more severe disease.
P676 Quantitative real-time PCR measurement of the impact of
ﬁdaxomicin or vancomycin treatment of Clostridium difﬁcile
infection on the intestinal microbiome, compared with
normal controls
T. Louie °, K. Cannon, M.St. Denis, B. Byrne, L. Ward (Calgary, CA)
Objective: The extent of impairment of the normal intestinal micro-
biome in patients with Clostridium difﬁcile infection (CDI) is not well
described. Selective bacterial killing of C. difﬁcile (Cd) with sparing of
the normal ﬂora is hypothesized to produce better treatment outcomes.
Persistence and regeneration of the normal ﬂora is thought to prevent
recurrence of disease. qPCR was performed to measure shifts in major
component organisms in fecal samples obtained during the conduct of
a phase 3 clinical trial which showed that ﬁdaxomicin was equally as
effective as vancomycin for disease resolution, but recurrence of CDI
was reduced by ~50%.
Methods: Treatment naı¨ve patients (n = 20) with ﬁrst episode or ﬁrst
recurrence of CDI were randomized to receive ﬁdaxomicin (Fdx) 200mg
BID or vancomycin (Van) 125mg QID p.o. for 10 days. Fecal samples
(>5 g) were retrieved at study entry and days 10, 14, 21 and 28. Patients
did not receive other antimicrobials. Bacterial DNA was extracted
from 2–300mg samples with a QIAamp DNA Mini Kit. Bacteroides
/Prevotella (Bact), Clostridium coccoides (Cc), C. leptum (Clep), E. coli,
Lactobacillus and Enterococcus group speciﬁc primers were used to
examine 10−20 ng of gDNA using the BioRad iQ5 / SYBR green master
mix RT-PCR method with melting point assessment. The accuracy of
qPCR quantitation was determined by testing normal stool controls
(n = 10), spiked known quantitative samples and quantitative cultures
for Cd, B. fragilis group, and coliforms.
Results: In normal stool controls, CFU/gm (SD) of Bact, Cc and Clep
were 10.2(0.6), 9.0(0.5), and 7.5 (1.2), respectively, 2−3 log10 higher
than counts at diagnosis of CDI. Fdx and Van were equally effective in
reducing C. difﬁcile counts from 7 to <2 log10 CFU/g during treatment.
In CDI patients, Fdx allowed the major components to persist, whereas
Van had an enduring suppression of Bact, and temporary suppression
of both Cc and Clep. Coliform and enterococcal counts were increased
1−2 log10/g compared to controls; vancomycin temporarily suppressed
enterococcal counts.
Conclusion: Compared to normal controls, CDI patients had a 100 to
1000 fold reduction in microbiome counts at CDI diagnosis. Vancomycin
suppressed Bacteroides/prevotella group organisms throughout the 4
week observation, and also affected C. coccoides and C. leptum
group bacteria. The relative preservation of components of the normal
microbiome during and after Fdx treatment may account for reduced
recurrences.
Log10 CFU/gm ± SD by qPCR, N= 10/group
Day 0 Day 10 Day 14 Day 21 Day 28
Bact/prev
Van 8.0±2.5 5.3±0.9** 5.8±1.8** 7.0± 2.3* 6.8± 2.8a
Fdx 8.3±1.9 9.3±1.3 9.4±1.2 9.3±1.4 9.2±1.3
C. coccoides
Van 7.8±1.7 4.7±0.7** 6.7±2.2* 8.5±0.8 8.6±1.1
Fdx 8.2±0.7 8.4±0.5 8.6±0.5 8.7±0.6 8.7±0.4
C. leptum
Van 5.1±2.2 2.1±1.2* 3.7±1.6 5.9±1.0 6.2±1.1
Fdx 5.2±2.8 4.9±2.4 4.7±2.3 5.7±2.2 5.9±1.3
**p 0.0001, *p 0.03, ap = 0.04 compared to Fdx.
P677 Development of unique one-step lateral ﬂow test for the
detection of Clostridium difﬁcile toxin A and B in faeces
S. Rameil °, D. Burghardt, J. Winkle, P. Schubert (Darmstadt, DE)
Objectives: Clostridium difﬁcile (C. diff.) is the predominant cause
of antibiotic-associated colitis and the leading cause of diarrhoea at
hospitalised patients. The toxicity of C. diff. is caused by its toxin A
and B. As early and rapid diagnosis is associated with better prognosis,
rapid, sensitive and easy to handle test systems are highly desirable.
Considering these demands we choose the Lateral ﬂow (LF) test format
as it is highly convenient for the operator. Furthermore it reduces the
liquid handling steps, sample preparation steps and hands-on time to a
minimum. Results of a comparative study performed with 181 clinical
stool samples tested by four commercially available ELISAs and PCR
as gold standard demonstrate an excellent performance and high quality
of the C. diff.-LF prototype. Sencondly we analysed the analytical
sensitivity of the C. diff.-LF prototype for both Toxins A and B of
C. diff..
Methods: LF-Assay: Test procedure of the C. diff.-LF prototype was as
follows:
1. mix stool with mobile solvent (ready to use) thoroughly (1:20)
2. 5 min sedimentation of prepared stool suspension at room temperature
3. transfer 150 mL supernatant (of 2.) on the application area of the LF
strip and read result after 15 min
ELISAs: ProSpecT® C. difﬁcile Toxin A/B Microplate Assay (Oxoid),
Premier™ Toxins A and B (Meridian), Serazym® Clostridium difﬁcile
Toxin A+B (Seramun) and C. DIFFICILE TOX A/B II™ (Inverness).
PCR: Fast Clostridium difﬁcile A/B Realtime (IFP).
All commercially available assays were used according manufacturers
instruction.
Samples: 181 (116 PCR negative and 65 PCR positive) stool specimens
of hospitalised diarrhoea patients were tested. Samples were stored at
−20ºC until analysed.
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The pure C. diff. Toxins A and B were obtained from tgcBIOMICS
GmbH (Mainz, Germany).
Results: See the tables.
Conclusion: Sensitivity and speciﬁcity of the LF-test (60%; 97%) is
comparable to the results of the Oxoid ELISA (62%; 100%) which was
the best of the used immunoassays. This is especially remarkable as the
LF-test takes only 20 min until result. It does not require any washing
step and needs only a minimum of liquid handling steps. Furthermore
the LF test demonstrated a great analytical sensitivity for Toxin A (0.2
ng/mL) and Toxin B (0.1 ng/mL) in stool matrix without particular
sample preparation.
Table 1: Sensitivity and speciﬁcity of four ELISAs and LF-test (PCR as
standard)
Test Sensitivity (%) Speciﬁcity (%)
ELISA, Oxoid 62 95
LF-test, R-Biopharm 60 96
ELISA, Seramun 46 92
ELISA, Inverness 46 100
ELISA, Meridian 42 97
Table 2: Analytical sensitivity of the LF-test for C. diff. Toxin A and B
in stool matrix
ng·mL−1 0 0.05 0.1 0.2 0.4 0.8
Toxin A − − − + + +
Toxin B − − + + + +
P678 Evaluation of a chromogenic culture medium for detection
of Clostridium difﬁcile
J.D. Perry °, K. Asir, D. Halimi, S. Orenga, R. Carlton, J. Evans,
F.K. Gould (Newcastle upon Tyne, UK; La Balme-les-Grottes, FR)
Objectives: To evaluate a novel prototype chromogenic medium for
detection of Clostridium difﬁcile from stool samples from patients with
hospital acquired diarrhoea.
Methods: A prototype chromogenic medium for C. difﬁcile (chromID™
C. difﬁcile prototype = IDCd) was evaluated with 268 diarrhoeal samples
positive for C. difﬁcile toxin by VIDAS immunoassay and 100 diarrhoeal
samples negative for C. difﬁcile toxin by VIDAS immunoassay. 10
microlitres of stool suspension was inoculated onto IDCd and a
commercially available selective medium (CLO medium; bioMe´rieux).
All media were incubated anaerobically at 37ºC for a full 24 h period
and then removed into air for interpretation and selection of colonies
for testing. After a maximum of 30 minutes in air, culture plates were
re-incubated anaerobically for a further 24 h and re-examined. Alcohol
treatment was avoided to assess the selectivity of the media. All suspect
strains of C. difﬁcile were identiﬁed using standard biochemical tests
and were further conﬁrmed by ribotyping.
Results: C. difﬁcile was recovered from 230 ‘toxin-positive’ stool
specimens (86%) using a combination of both media and all isolates
were recovered on IDCd after 24 h incubation. 97% of isolates generated
black colonies after 24 h incubation and only 1% remained colourless
after 48 h incubation. Occasional strains of Clostridium clostridioforme
and Bacteroides spp. also formed black colonies. On CLO medium,
only 59% of isolates could be recovered after 24 h incubation and after
48 h incubation, 24% of isolates remained uncultured. From 100 ‘toxin-
negative’ samples, six isolates of C. difﬁcile were recovered on IDCd
compared with only two on CLO medium.
Conclusions: There is increasing interest in the routine culture of
C. difﬁcile either as part of a diagnostic algorithm or to obtain isolates
for epidemiological typing. Chromogenic media have proven efﬁcacy for
the enhanced recovery of clinical pathogens such as methicillin-resistant
S. aureus. The chromID™ C. difﬁcile prototype medium is the ﬁrst
chromogenic medium described for isolation of C. difﬁcile and shows
good potential for detection of this increasingly important pathogen
within only 24 hours.
P679 ChromID™ C. difﬁcile, the ﬁrst chromogenic medium for
detection and direct identiﬁcation of Clostridium difﬁcile.
Comparison with three commercially available selective media
D. Halimi °, M.P. Bourguignon, V. Sauvonnet, J.D. Perry (La Balme
Les Grottes, Newcastle, FR)
Objective: To evaluate the performances of a novel chromogenic
medium for detection and direct identiﬁcation of C. difﬁcile in
comparison with 3 commercially available selective media. On the new
medium, the strains of C. difﬁcile produce grey to black colonies.
Methods: chromID™ C. difﬁcile prototype medium was compared to
CDSA (BD), CDA (Oxoid) and CLO (bioMe´rieux). A total of 96 strains
(47 C. difﬁcile and 49 non-C. difﬁcile strains) were inoculated directly
onto the media which were incubated in anaerobic conditions. After
24H the plates were examined and were re-incubated anaerobically for
a further 24H and re-examined.
Results: After 24 h of incubation, sensitivity of detection of C. difﬁcile
(growth and colour or growth and characteristic morphology) was higher
with the prototype medium (94% of strains generated black colonies)
than with CLO medium (85%), CDSA (13%) and CDA (45%). After
48 h, the sensitivity increased to 98% on the prototype medium and
respectively to 96%, 38% and 6% (loss of the characteristic aspect) for
the other media. After respectively 24 and 48 h of incubation, speciﬁcity
was 92 and 92% with the prototype medium, 96 and 96% with CDSA,
86 and 78% with CLO, and 61 and 41% with CDA.
Conclusion: chromID™ C. difﬁcile prototype medium is a chromogenic
medium that is accurate and easy to use for the detection of C. difﬁcile.
The high speciﬁcity and sensitivity of this prototype medium, after
only 24 h of incubation, make it the medium of choice for the direct
identiﬁcation of C. difﬁcile.
P680 A two-step algorithm for the diagnosis of Clostridium difﬁcile
infection: screening with a rapid immunoassay for the
detection of glutamatedehydrogenase and toxins A and B
followed by a real-time PCR for C. difﬁcile
J. Van Broeck °, C. Hubert, M. Vast, M. Delme´e (Brussels, BE)
Introduction: The Techlab ® C. diff Quik Chek Complete™ (Techlab
Blacksburg, VA, USA) is a rapid immunoassay for the detection of
Glutamatedehydrogenase and toxins A and B in fecal specimens, using
speciﬁc antibodies. The BD Gene-Ohm™ Cdiff (BD Diagnostics, San
Diego, CA, USA) is a real-time PCR assay targeting the toxin B
gene (TcdB) of Clostridium difﬁcile with a ﬂuorogenic target-speciﬁc
hybridization probe for the detection of the ampliﬁed DNA. With
toxigenic culture (TC) as gold standard, we evaluated the performances
of the combination of these tests for the diagnosis of C. difﬁcile
infections (CDI) on stool specimens.
Materials and Methods: Stools were from inpatients of the St Luc-
UCL University hospital (890 beds), older than 2 years and suffering
from diarrhoea. Cell cytotoxicity (CTA) was performed on MRC5
cells. Cultures were performed on CCFA. In case of positive culture
and negative CTA, colonies were tested for ‘in vitro’ toxin production
(TC). Some cultures were repeated on CCFA with added taurocholate
(TCCFA). Real-time PCR and the rapid immunoassay were performed
according to the manufacturer’s instructions.
Results: A total of 607 stool specimens collected in 2008 were tested.
Eighty four samples were shown to contain toxigenic C. difﬁcile by CTA
and/or toxigenic culture (prevalence: 13.9%). The sensitivity, speciﬁcity,
PPV and NPV of BD Gene-Ohm Cdiff™ were respectively: 91.7%,
96.5%, 81.1% and 98.5%. Those of CTA were 69.0%, 100%, 100%
and 95.3%. Unresolved result was recorded in 2 instances. PCR tests
were repeated, the two results remained unresolved and were excluded
from our calculation. Screening with C. diff Quik Chek Complete™
followed by the BD Gene-Ohm Cdiff™ on GDH positive, toxins A
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and B negative samples gave sensitivity, speciﬁcity, PPV and NPV of
respectively: 91.5%, 99.0%, 93.8% and 98.7%.
Conclusion: The combination of theTechlab ® C. diff Quik Chek
Complete™ and the BD Gene-Ohm Cdiff™ demonstrated a very good
sensitivity much superior to that of CTA and a good speciﬁcity. It is a
rapid method allowing result in less than two hours.
P681 Validation of Copan faecal swab for the detection of
Clostridium difﬁcile from faecal specimens with multiple
diagnostic assays
S. Castriciano °, J. Kafka, J. Padman, C. Lee (Hamilton, CA)
Objective: Clostridium difﬁcile (CD) infection is the leading cause
of nosocomial antibiotic-associated diarrhoea in adult, and paediatric
patients. There are a number of commercially available tests to detect
the CD toxin A and/or B and the common antigen.
A collection device with a liquid base transport medium compatible
with different laboratory methods for the collection and storage of faecal
specimen would be beneﬁcial. This study was conducted to determine
the compatibility of the Fecal Swab kit (FS) (Copan Italia) with tests,
which detect CD toxins A/B and the common antigen, CD glutamate
dehydrogenase.
Methods: 35 frozen faecal specimens, which tested positive previously
for toxin A/B by CD TOX A/B® II EIA, were used to validate the Fecal
Swab (FS) kit, which consists of a ﬂocked swab for the collection of the
faecal sample and a 2ml tube of semi-solid Cary Blair for transportation.
The swab was tested to determine the amount of faecal material collected,
and to ensure that the concentration of faecal material required in each
testing method was not affected by the dilution factor introduced by
the medium. The ﬂocked swab of the FS kit was used to prepare the
assimilated clinical specimens. The kits used in this validation were:
C. DIFF QUIK CHECK®, C. DIFF TOX A/B II®, TOX A/B QUIK
CHECK™, C. DIFF QUIK CHEK COMPLETE™, CD Toxin/Antitoxin
test (TechLab), ImmunoCard CD Toxin A&B (Meridian), ProGastro™
Cd (Prodesse, Inc.), and an in-house CD real-time PCR. Testing of
commercial kits was done according to the manufacturers’ speciﬁcations.
A negative FS kit was tested with each kit to check for interference. For
the in-house real-time PCR, nucleic acid was extracted from 140 ul of
FS sample to a 55ml elution buffer with the easyMAG (bioMe´rieux); 2
ul of puriﬁed nucleic acid was tested by real time PCR on the RotorGene
6000 (Corbett).
Results: The ﬂocked swab collects ~150mg of faecal material and no
interference was found when uninoculated FS kits were tested with all
methods. Out of 35 samples 33 were positive and 2 were negative with
all methods including the two PCR methods. 2 samples which tested
positive originally with the CD Tox A/B® II when retested were negative
for the toxin.
Conclusions: Copan Fecal Swab kit, a Liquid Based Microbiology pre-
analytic device, can be used to collect faecal specimens for the detection
of CD toxin A/B, CD glutamate dehydrogenase, toxin A, B, cytotoxin
in cell culture and nucleic acid by PCR.
P682 Comparison of a Clostridium difﬁcile antigen detection test
with toxigenic culture by PCR for the laboratory diagnosis
of community-acquired C. difﬁcile infections
K. Tan °, C. Pienaar, M. Kelly (Vancouver, Burnaby, CA)
Objective: Fifty percent of Clostridium difﬁcile (CD) infections (CDI)
are community acquired (CA CDI), and accurate laboratory diagnosis of
CA CDI is essential. Laboratory diagnosis is based on detection of CD
toxins in stool specimens and/or by toxigenic culture. CD toxins may
be detected by cell culture cytotoxin assay or by enzyme immunoassay
(EIA); however, both tests are less sensitive than toxigenic culture. Due
to the high proportion of CD-negative specimens, screening for the
CD speciﬁc antigen, glutamate dehydrogenase (GDH) before proceeding
with toxin testing may provide a rapid and cost-effective approach to the
laboratory diagnosis of CDI. In this study we evaluated a commercially
available antigen-EIA test (C. DIFF CHEK, TechLab) compared to
toxigenic culture by PCR as the gold standard.
Methods: The evaluation was performed over a 21-day period at a
large community laboratory. To insure an adequate number of positive
specimens in the evaluation, all stool specimens submitted for CD testing
were ﬁrst assessed by an automated toxin-EIA (VIDAS Clostridium
difﬁcile A & B, Biomerieux). 50 consecutive toxin EIA positive
specimens and 150 consecutive toxin EIA negative specimens were tested
by toxigenic culture and the antigen EIA test. The antigen-EIA test
was performed according to manufacturer’s recommendations. Toxigenic
culture was performed by inoculating the specimens on selective CD
agar, followed by a validated in-house PCR assay for conﬁrmatory
identiﬁcation of CD and the presence of toxin A and B genes.
Results: Of the 200 specimens included in the study, 55 were positive
and 145 were negative by toxigenic culture. Compared to toxigenic
culture, the antigen EIA test demonstrated 89% sensitivity, 94%
speciﬁcity, 79% positive predictive value (PPV) and 97% negative
predictive value (NPV). Results of the antigen EIA test could be reported
the same day that the test was performed, and the test was not technically
demanding.
Conclusions: With sensitivity of 89% and NPV of 97% compared to
the toxigenic culture gold standard, the CD antigen detection test may
provide an acceptable screening test for the laboratory diagnosis of CDI.
However, the low speciﬁcity and PPV of the CD antigen detection test
indicate that conﬁrmatory toxin testing of antigen positive specimens is
required.
P683 Evaluation of an ELFA assay for direct detection of toxins
from Clostridium difﬁcile colonies
V. Lalande °, B. Burghoffer, C. Eckert, F. Barbut, J.C. Petit (Paris, FR)
Toxigenic culture is considered to be a very sensitive method for the
diagnosis of Clostridium difﬁcile infections. However, this technique is
labor-intensive when using the cytotoxicity assay with a ﬁltrate of a
ﬁve-day broth culture.
Objective: To evaluate an ELFA assay, originally designed for toxins A
and B detection in stools (VIDAS® CD A&B; bioMe´rieux, France), for
toxin detection directly from colonies.
Methods: In the ﬁrst part of the study, we used a collection of 18
toxigenic strains previously characterized by toxinotyping (14 A+B+
strains, 2 A−B− strains, and 2 A−B+ strains). These strains were
subcultured on three selective media: taurocholate cycloserine cefoxitin
agar routinely used by the site (TCCA), CLO® (bioMe´rieux) and
chromID (bioMe´rieux), a new chromogenic medium under development.
Colonies were tested on the VIDAS system according to the
manufacturer’s recommendations.
In the second part of the study, we collected 25 positive prospective fresh
stools from hospitalized patients. Stools were selected on the positivity
of the cytotoxicity assay or toxigenic culture.
The stools were then subcultured on the three media (TCCA, CLO
and chrom ID) and toxins were detected on the VIDAS directly from
an inoculum obtained with 5 colonies (3 McFarland) taken from each
medium.
Results: Among the 16 toxigenic A+B+ and A−B+ strains no negative
results were obtained. For all media, equivocal results were found
independently of the toxinotype. Based on the cut off used for the stools,
the sensitivity on the VIDAS is 86.6% with CLO and chromID and 80%
with TCCA culture.
In the second part of the study using stool specimens, VIDAS testing
performed on colonies showed concordant results in 48% of cases for
the three media. The positivity rate for toxin detection was respectively
60%, 65% and 82.6% for TCCA, CLO and chromID. Equivocal results
were founded respectively for 30%, 15% and 4% for TCCA, CLO and
chromID. For 3 stool specimens, CLO medium did not enable growth of
C. difﬁcile.
Conclusion: The TCCA and chromID media showed very good
performance for the growth of C. difﬁcile. The VIDAS CD A&B assay
can be used to detect toxins directly from colonies isolated on the 3
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media tested. Further analysis are needed to establish the level of cut off
for toxin detection on colonies.
P684 Clostridium difﬁcile associated diarrhea uncertainties in
testing algorithms and the role of Toxin gene detection
G. Smith, H. Reddy, P. Dexter, N. Clarke, C. Tremlett, A. Johnson,
V. Sivaprakasam ° (Hereford, Norwich, UK)
Objectives: The Department of health of UK launched mandatory
surveillance for clostridium difﬁcile associated diarrhea (CDAD) in
January 2004, in response to notable increase in morbidity and mortality
linked to CDAD becoming more apparent since 1999. This resulted in an
increasing array of assays for the laboratory diagnosis of CDAD. Against
this background we set to deﬁne an optimum testing algorithm for the
laboratory diagnosis of CDAD with the use of clostridium difﬁcile gene
detection system (PCR assay) by GeneXpert (Cepheid), with the single
objective to achieve zero tolerance to hospital acquired CDAD.
Methods: 261 Stool samples from patients with loose stools attending
Hereford hospitals NHS trust in UK, between January and August 2009
were tested for the presence of Clostridium difﬁcile toxin by VIDAS
assay (Biomerieux) and cell culture cytotoxin assay (CTA) and the
clostridium difﬁcile toxin gene by PCR assay.
Results: With reference to CTA as the gold standard the sensitivity and
speciﬁcity of the VIDAS assay was 83.92% and 75.72 and that of PCR
assay was 100% and 77.66% respectively. The negative predictive value
and positive predictive value of VIDAS was 94.54% and 48.45% and
that of PCR was 100% and 54% respectively. In 37 samples VIDAS and
PCR were coherently positive where CTA was negative.
Conclusion: The superiority of the GeneXpert gene detection assay over
VIDAS in terms of efﬁcacy though signiﬁcant is not exceptional. In terms
of efﬁciency (user comfort, turn around time and no equivocal results)
we feel the PCR assay is far more superior. The ability to identify the
ribotype 027 strain at the same time is beneﬁcial to prevent harmful
cohorting. The CTA performance disappointed, given the coherence of
VIDAS and PCR for 37 “false-positive”. Since our patient population
had a high pre-test probability of CDAD, we feel that the PCR assay has
outperformed the CTA and we wonder whether it is time to crown the
PCR assay as the gold standard. Future similar studies could reafﬁrm
our suggestion using toxinogenic culture as a comparator instead of CTA
alone.
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P685 Biological ﬁtness effects of integrons in the absence of
antibiotic-selective pressure
S.S. Domingues °, P. Vieira, I. Starikova, G.J. da Silva, K.M. Nielsen
(Coimbra, Aveiro, PT; Tromsø, NO)
Objective: The biological cost of antibiotic resistance is the key
parameter determining the emergence, spread and stability of resistant
bacteria. The aim of this study was to assess the in vitro ﬁtness cost
conferred by class 1 integrons in Acinetobacter.
Methods: Acinetobacter baylyi BD413 was used as recipient bacterium
in natural transformation assays with integron-carrying donor DNA.
Acquisition of classical class 1 integrons was conﬁrmed by PCR and
the antimicrobial susceptibility of transformants was evaluated by E-test.
The ﬁtness of integron-carrying transformants was estimated by pairwise
competition experiments with the recipient bacterium in a minimal
medium during 24 h. Four competition replicates were done for each
transformant. The relative ﬁtness (W) was calculated as the ratio of the
Malthusian parameter of each competitor. The resistance genes confer a
disadvantage if W< 1 and an advantage when W< 1.
Results: Four distinct integrons that carried the following resistance
genes were evaluated: blaOXA-30+aadA1 (transformants 2.26.1, 11.1.1,
I2.1.1); dfrA12+aadA2 (transformant I3.1.1); aacA4+blaPSE+aadA2
(transformant I8.1.1); aadB (transformants 4.10.1, 10.1.1). Accordingly
to the CLSI guidelines, 11.1.1 and I2.1.1 were susceptible (S), 2.26.1
was intermediate and I8.1.1 was resistant (R) to ampicillin; I8.1.1 was
S and 4.10.1 and 10.1.1 were R to gentamicin; 4.10.1 and 10.1.1 were
R to kanamycin; 2.26.1, 11.1.1, I2.1.1 and I3.1.1 were S and I8.1.1 was
R to spectinomycin; all transformants were R to sulfamethoxazole. The
mean W of integron-carrying strains ranged from 0.99 to 1.17. However,
only one of the mean ﬁtness changes was statistically signiﬁcant. More
replicates are necessary to establish any (if) minor but signiﬁcant
changes.
Conclusion: Intervention policies aimed at combating antibiotic
resistance often rely on the assumption that resistance genes are costly
and will be lost from pathogenic bacterial populations when antibiotic
pressure is removed. Although our results are only statistically signiﬁcant
for 1 transformant, they clearly point out that the acquired integrons and
resulting changes in resistance proﬁles did not lead to major relative
ﬁtness reductions in Acinetobacter. These results might help to explain
integron’s wide dissemination and persistence. To our knowledge, this
is the ﬁrst time that a ﬁtness study of integrons is conducted in
transformants acquired by natural transformation.
P686 Plasmid addiction systems targeting DNA gyrase: drivers of
ﬂuoroquinolone resistance?
M. Doumith °, M.J. Ellington, P. Hawkey, N. Woodford (London,
Birmingham, UK)
Objectives: Plasmid addiction toxin-antitoxin (TA) systems enforce
plasmid retention at cell division. Like ﬂuoroquinolones, some toxins,
including CcdB, target DNA gyrase. Toxin resistance can be mediated
via mutations in the gyrase, which led us to hypothesize that: (i) some of
these changes might contribute to, or predispose towards ﬂuoroquinolone
resistance, and (ii) Qnr determinants might protect DNA gyrase against
these toxins. We tested these hypotheses.
Methods: The CcdAB TA system was used as model. The pBAD
and pBBR1MCS-2 vectors were used for dose-dependent L-arabinose-
induced CcdB expression and for Qnr protein expression in E. coli Top10
strain, respectively. MICs were determined by agar dilution or by Etest.
DNA manipulations and sequencing were by standard methods.
Results: Induction of CcdB expression led to colonies being smaller and
slow-growing than normal. Sub-inhibitory expression of CcdB selected
mutants of variable colonial sizes able to withstand expression of the
toxin at different levels. The mechanism of CcdB resistance in these
mutants did not involve mutations in GyrA, GyrB, ParC or ParE, and
ﬂuoroquinolone MICs were unaffected. Co-expression in trans of CcdB
and a Qnr determinant (A, B or S-type) did not allow the E. coli strain
to withstand higher expression levels of CcdB, indicating no protection
against its toxic effects. The glutamine residue at position two was shown
to play a critical role in toxicity of CcdB.
Conclusions: Our results show that resistance to the CcdB TA systems
can be attenuated by mechanisms other than changes in the gyrase.
Furthermore, resistance had no effects on ﬂuoroquinolone MICs, and
was not enhanced in the presence of Qnr proteins.
P687 Tn21-like transposons found in non-typhoidal Salmonella
enterica isolates of clinical origin carrying class 1 integrons
I. Rodrı´guez °, P. Garcı´a, I. Montero, A. Herrero, N. Martı´nez,
J. Beutlich, M.C. Martı´n, R. Rodicio, B. Guerra, M.C. Mendoza,
M.R. Rodicio (Berlin, DE; Oviedo, Villaviciosa, ES)
Objectives: In clinical isolates of Salmonella enterica belonging to
different serotypes, the structures of class 1 integrons inserted within
Tn21-like transposons and their involvement in multidrug resistance were
established.
Methods: The variable regions of class 1 integrons were ampliﬁed by
PCR using speciﬁc primers, and subsequently sequenced to identify the
gene cassettes inserted therein. PCR mapping, cloning and sequencing
were used to ascertain the organization of the Tn21-like transposons
carrying class 1 integrons.
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Results: Different conﬁgurations of class 1 integrons inserted within
Tn21-like transposons were detected: (a) multidrug resistant S.
Brandenburg and S. Ohio isolates positive for tet(B) contained a
defective class 1 integron with the 1600 bp/dfrA1-aadA1 variable region,
lacking IS1326, IS1353, tniBD1 and tniA (all carried by In2, the integron
of Tn21). This integron was included within a Tn2670-like transposon
(created by incorporation of Tn21 into Tn9), interrupted by a defective
Tn10; (b) multidrug resistant S. Brandenburg isolates, positive for a
Tn1721-like transposon carrying tet(A), harboured a class 1 integron
with the variable region 1600 bp/dfrA1-aadA1, which lacked IS1326
and IS1353, and was located within Tn21-like transposons not always
inserted into Tn9; (c) multidrug resistant S. Virchow isolates contained a
class 1 integron with the 1000 bp/aadA1 variable region, lacking IS1353,
and located within a Tn2670-like transposon; (d) in multiresistant S.
Panama and S. Virchow isolates, the class 1 integron 2300 bp/estX-
smr-aadA1, without IS1353, was also part of a Tn2670-like transposon;
(e) in multidrug resistant isolates of S. Typhimurium, a 2000 bp/blaOXA-
1-aadA1 integron, carrying IS1326, IS1353 and the tni module, was
inserted within a Tn2670-like transposon adjacent to a defective Tn10;
(f) in multidrug resistant S. Typhimurium monophasic isolates (antigenic
formula [4,5,12:i:−]) a class 1 integron 1000 bp/aadA1 (lacking IS1326,
IS1353 and the tni genes) was associated with a defective Tn21-like
transposon without the transposase gene tnpA.
Conclusion: All class 1 integrons reported in this work were part
of Tn21-like structures carried by large plasmids. These transposable
elements are often associated with other transposons, creating new
and more complex structures responsible for the multidrug resistance
phenotype of the analyzed isolates.
P688 Detection and characterization of class 1 integrons of
Gram-negative bacteria isolates from domestic, wild and
food-producing animals
S.S. Domingues °, C. Dias, M.J. Saavedra, G.J. da Silva (Coimbra,
Vila Real, PT)
Objective: Several antimicrobial agents used in animal and human
medicine belong to the same antibiotic families and occurrence of cross-
linked resistances has been identiﬁed. The aim of this study was to detect
and characterise class 1 integron in Gram-negative bacteria collected
from animal samples of different origin.
Methods: 76 samples were isolated from caecum, faeces, intestine,
oviduct, skin or vaginal ﬂuid of cats, dogs, jennies, deer, eagles, emus,
fox, owls, snake, squirrels, chickens, gilthead breams, rabbits and trouts.
The bacterial species were grown in selective culture media and identiﬁed
by API20E, API20NE or by sequence of the 16S rDNA or gyrB
genes. Antimicrobial susceptibility was determined by the disc diffusion
method. Strains intermediate or resistant to co-trimoxazole (SXT), one
of the most widely association of antibiotics used in animal husbandry,
were screened by PCR for intI gene presence. Positive isolates were
subject to PCR for detection of classic class 1 integrons. Gene cassettes
were identiﬁed by genomic sequencing.
Results: 57% of the isolates were intermediate or resistant to SXT. Of
these, 67% (29) were positive for intI and 37% (16) for class 1 integrons.
Integrons were detected in strains of 2 chickens, 7 rabbits, 1 dog, 1
fox and 5 owls. 8 gene cassettes were identiﬁed in 4 different integron
arrangements: dfrA12+orfF+aadA2, in 1 Citrobacter braakii (1 rabbit),
2 Citrobacter freundi (1 owl and 1 rabbit), 3 Enterobacter cloacae (3
rabbits) and 3 Escherichia coli (2 chickens and 1 rabbit); dfrA1+aadA1,
in 1 Aeromonas hydrophila/caviae (1 owl), 1 Aeromonas salmonicida (1
owl), 1 Escherichia fergusonii (1 owl) and 2 Pseudomonas ﬂuorescens
(1 fox and 1 owl); aadA6+orfD, in 1 Pseudomonas aeruginosa (1 dog);
and dfrA7, in 1 Escherichia coli (1 rabbit).
Conclusion: The results show that the same integron is present in
different bacterial species suggesting the horizontal genetic transfer of
the whole structure. The same gene cassette arrays have also been
reported in human isolates. Moreover, these were isolated from animals
that inhabit in diverse environments, highlighting that class 1 integrons
are well disseminated among wild and domestic animal isolates, acting
as integron-borne resistance gene reservoirs. These may have serious
implications in human health, not only because integrons can end up in
food products but also because manure is often used as a fertilizer with
possible contamination of soil and water.
P689 Occurrence and dissemination of class 1 integrons in
Klebsiella pneumoniae isolates in a hospital in Aveiro, Portugal
S. Ferreira °, C. Santos, E. Ramalheira, S. Mendo (Aveiro, PT)
Objective: Klebsiella pneumoniae is a common nosocomial agent
responsible for infections difﬁcult to treat. In the hospital environment,
resistant strains are not conﬁned to the patient but they can also colonize
inanimate surfaces, thus spreading resistance. The aim of the present
work was to evaluate the presence of class 1 integrons in K. pneumoniae
strains collected from different sources, in the Hospital Infante D. Pedro
EPE, Portugal.
Methods: The isolates were recovered from inpatients and inanimate
surfaces within the hospital wards. Inpatients samples were collected
from different biological products (urine, sputum and blood) analyzed
in the laboratory. Inanimate surfaces samples were collected with sterile
cotton swabs rubbed in the facility surfaces (toilet, lavatory and door
knob) and placed in rich medium, at 37ºC for 24 h. Dilutions were plated
in appropriate media and incubated as previously. Individual colonies
were identiﬁed using the automatic VITEK 2 system and Advanced
Expert System (VITEK 2 AES) (bioMe´rieux, Marcy L’E´toile, France).
Susceptibility testing was carried out according to guidelines of CLSI
standards. The presence of the integrons was detected by PCR, using
speciﬁc primers. Resulting nucleotide sequence of the PCR amplicons
was analyzed with the Blast and Clustal W programs.
Results: Class 1 integrons were detected in 59% of the K. pneumoniae
isolates collected from both sources. A total of 18 gene cassettes
occurring in 3 different arrays were identiﬁed; the variants aadA and dfrA
genes were the most frequently found. A particular array (dfrA17:aadA2)
was found in isolates from both sources.
Conclusions: These results suggest that new measures should be
implemented to control the dissemination of antibiotic resistance genes
in the hospital environment.
P690 Distribution of the gene cassette promoter variants of class
1 integrons in Escherichia coli strains isolated from clinical
and community samples in Spain and France
L. Vinue´, T. Jove´, C. Torres, M.C. Ploy ° (Logron˜o, ES; Limoges, FR)
Background: Class 1 integrons are widespread genetic elements that
capture gene cassettes (GC) that mainly encode antibiotic resistance
genes, by an integrase-mediated site-speciﬁc recombination. They play a
major role in the dissemination of antibiotic resistance in Gram-negative
bacteria. Integrated genes are usually promoterless and are expressed
from a common promoter Pc. Our previousin silico analysis showed
that 13 variants of Pc exist, providing a wide range of gene cassettes
expression levels. However, the Pc variants distribution in clinical strains
is unknown. Furthermore, there is a negative correlation between Pc
strength and integrase excision activity: the weaker the Pc variant is, the
more active the IntI1 is.
Methods: We studied 86 E. coli strains containing class 1 integrons,
isolated from clinical samples (n = 59) or from stools in the general
population (n = 27) either in Spain or France. The phylogenetic groups,
GC arrays and Pc variants were characterized by PCR and sequencing.
Results: From the 88 integrons detected (two strains carried two
different class 1 integrons), we identiﬁed only 4 Pc variants with
a wide distribution range. The weaker Pc variants, PcW and PcH1
were predominant (n = 50 and 30, respectively), the stronger variants,
PcWTGN-10 and PcS, remaining rare (n = 6 and 2, respectively). There
was no clear correlation between the Pc variant and the isolates’ origin
or phylogenetic group, nor between the Pc variant and the GC arrays.
Conclusion: Interestingly, the weak PcW was the most frequent variant
in both the E. coli clinical and community isolates. This suggests that
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the presence of an efﬁcient integrase for GC exchange may be more
beneﬁcial for the adaptation to often varying conditions rather than an
efﬁcient Pc promoter leading to a high level of resistance.
P691 Characterization of a novel class 3 multi-resistant integron
isolated from a hospital efﬂuent
O. Barraud, M. Casellas, B. Mayjonade, D. Chainier, C. Dagot,
M.C. Ploy ° (Limoges, FR)
Objectives: Integrons are bacterial genetic elements able to capture
and express antibiotic resistance genes contained within mobile gene
cassettes. Three main classes of multiresistant integrons (MRI) have
been described: class 1 and class 2 are the most prevalent but little is
known concerning class 3. We described a new class 3 integron with a
novel gene cassette array from an Enterobacter cloacae retrieved from
an hospital efﬂuent.
Methods: An efﬂuent sample was collected in April 2009 from
the Limoges University Hospital Center, France, and inoculated onto
Drigalski agar plates. Total DNA of the isolated strains was extracted by
boiling. Class 1, 2 and 3 MRI were detected from each strain using
real-time-PCR. Susceptibility testing was determined using Mueller-
Hinton agar according to the recommendations of the French Society
for Microbiology. Class 3 MRI cassette content was determined by PCR
and sequencing.
Results: Forty one different bacterial strains were isolated from the
efﬂuent sample: 27 harbored class 1 MRI, no strain harbored class 2
MRI and one strain of Enterobacter cloacae harbored a class 3 MRI.
This strain expressed a high-level penicillinase and was resistant to
tobramycin, netilmicin and amikacin. Cassette content revealed a new
array with two cassettes: blaOXA10 and aac(6′)-Ib.
Conclusion: This study describes the ﬁrst class 3 MRI detected in
France. Its cassette array has never been previously described, with a
functional blaOXA10 gene encoding an oxacillinase, followed by an
aac(6′)-Ib gene conferring resistance to aminoglycosides. This study
suggests that efﬂuents could be a reservoir of class 3 MRI.
P692 Association of the extended-spectrum b-lactamase blaTLA-1
gene to a novel ISCR element, ISCR20
B. Bercot °, L. Poirel, J. Silva, P. Nordmann (Le Kremlin-Bicetre,
FR; Morelos, MX)
Objective: TLA-1 is an Ambler class A extended-spectrum b-lactamase
reported from an Escherichia coli R170 clinical isolate described from
Mexico City in 2000. The aim of the study was to characterize the
genetic elements associated with of the blaTLA-1 gene from E. coli R170
and from a collection of TLA-1-producing Enterobacteriaceae recovered
from various hospitals from Mexico City.
Methods: The 150-kb plasmid RZA92 (pRZA92) of E. coli R170
was extracted by using the Qiaﬁlter Maxi plasmid puriﬁcation kit
and sequenced. The blaTLA-1 gene initiation site of transcription was
mapped using a 5’ rapid ampliﬁcation of cDNA ends PCR technique.
TLA-1-producing enterobacterial isolates were typed by the PFGE
technique. Plasmids were transferred by conjugation to azide-resistant
E. coli J53 strain. Plasmids were extracted from the tranconjugants by
the Kieser technique, transferred and hybridized with a TLA-1 probe.
Their incompatibility group (Inc) were determined by PCR.
Results: Analysis of the nucleotide sequence (5,925 bp) of pRZA92
surrounding the blaTLA-1 gene did not contain any insertion sequence
forming a transposon or any class 1 integron structure but evidenced a
novel ISCR element, ISCR20, coding a 406 amino-acids transposase. A
third of the transposase has respectively 33%, 30% and 27% of identity
with that of the ISCR1, ISCR2 and ISCR3. This element is inserted
232 bp upstream of the initiation start codon of the blaTLA-1 gene and
brings it its own promoter. An open reading frame (orf) encoding a
methyl-accepting chemotaxis protein element, but no ISCR20 element,
was evidenced upstream of the blaTLA-1 gene. An orf encoding a reverse
transcriptase/maturase (group II intron) preceded the ISCR20 element.
After PFGE analysis, eight non-clonal clinical isolates TLA-1-producing
Enterobacteriaceae were identiﬁed. For seven isolates, the blaTLA-1 gene
was located on conjugative plasmids of various sizes (ca. 110 kb to 150
kb) belonging to various group of incompatibility (IncA/C, IncF, IncL/M
or IncN). The blaTLA-1 gene was transferred from the seven isolates
to E. coli J53 by conjugation. The same ISCR20 element was identiﬁed
upstream of the blaTLA-1 genes in seven isolates.
Conclusion: The transposase encoded by the ISCR element may
transpose an adjacent DNA via a rolling-circle (RC) transposition
mechanism. Our study highlights a novel element, ISCR20, which is
involved in the expression of the blaTLA-1 gene and may allow its
transfer.
P693 A novel type of IncQ plasmid harbouring a class 3 integron
from Escherichia coli
L. Poirel °, A. Carattoli, T. Bruderer, R. Frei, S. Bernabeu, P. Nordmann
(Le Kremlin Bicetre, FR; Rome, IT; Basel, CH)
Objectives: The genes encoding the extended-spectrum b-lactamases
(ESBLs) of the GES type are usually part of class 1 integron structures.
Those integrons are themselves usually identiﬁed onto Tn21/Tn402
transposon structures. Our study was initiated by the identiﬁcation of
a blaGES-1 gene inside a peculiar class 3 integron structure.
Methods: Escherichia coli isolate TB7 had been isolated in 1998 in
Switzerland from an hospitalized patient. Genomic DNA E. coli TB7 was
extracted and used for PCR screening of known ESBL genes. Plasmids
were extracted using the Kieser technique. Whole sequencing of the
natural plasmid harbouring the blaGES-1 gene was achieved by a primer-
walking approach.
Results: E. coli TB7 harboured a blaGES-1 gene that was not bracketed
by class 1 integron features. Whole sequence analysis of plasmid pTB7
identiﬁed a gene encoding the class 3 integrase Int3 upstream of the
blaGES-1 gene cassette, sharing 60% amino acid identity with the class
1 integrase Int1. Downstream of blaGES-1, the blaOXA-10/aac(6′)-
Ib fused gene cassette was identiﬁed. The extremities of the class
3 integron were not clearly deﬁned, but suggested that a deletion
of those extremities had occurred during evolution. The backbone of
plasmid pQ7 contained ﬁve open reading frames; RepC, RepA, a fused
relaxase-primase protein, MobC, and an hypothetical protein, showing
a replication machinery similar to that of other IncQ-type plasmids,
including the oriV and the iteron-based incompatibility determinant.
However, plasmid pTB7 exhibited replicase genes and iteron sequences
that signiﬁcantly differed from those of all the previously reported IncQ
plasmid. The comparative analysis of the replication proteins of pQ7
showed it was homologous to two other plasmids; pGNB2 recovered
from a wastewater treatment plant from an unknown host strain and
harbouring the quinolone resistance gene qnrS2, and pWES-1 identiﬁed
from Salmonella entericaWesthampton in France and carrying the ESBL
gene blaCTX-M-53.
Conclusion: We propose here that pQ7 and its two related plasmids may
be classiﬁed into a novel sub-family of IncQ plasmids, deﬁned as IncQ-2
type, that correspond to non-conjugative and broad-host range resistance
plasmids.
P694 Spread and evolution of ST131 and IncFII-blaCTX-M-15 and
emergence of IncA/C-blaCTX-M-15 and IncN-blaCTX-M-28
plasmids in widespread Escherichia coli clones
Aˆ. Novais °, D. Viana, F. Baquero, R. Canto´n, T.M. Coque (Madrid, ES)
Objectives: Widespread IncFII plasmids and the ST131 Escherichia
coli (EC) clone have determined the global expansion of CTX-M-15.
Nevertheless, IncA/C and IncHI2 plasmids and other enterobacterial
hosts are being increasingly involved in the secondary spread of this
ESBL. Comprehensive molecular characterization of recent isolates
and plasmids harbouring blaCTX-M-15 and related blaCTX-M-28 was
performed.
Methods: Thirty CTX-M-15 and three CTX-M-28 (differing from CTX-
M-15 in the aminoacid change D288N) EC producers recovered in our
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institution in 2008 were studied. Population structure was established
by PFGE, MLST and phylogroup identiﬁcation. blaESBL genes and its
genetic environments were identiﬁed by PCR and sequencing. Transfer
of bla was carried out by broth/ﬁlter matings. Plasmid characterization
included S1-PFGE, comparison of RFLP patterns and Inc group
identiﬁcation (PCR-sequencing-hybridization). Genes associated with
blaCTX-M-15-IncFII plasmids (blaOXA-1, blaTEM-1, aac(6′)-Ib-cr) and
quinolone resistance (qnrA, qnrB, qnrS) were also investigated.
Results: Isolates were mostly recovered from urine (n = 26/33, 79%)
in outpatients (n = 19/33, 58%) or inpatients located at medical wards
(n = 9/33, 27%). Isolates were identiﬁed as B2-ST131 (n = 21, 64%;
3 PFGE-types), widespread clones of phylogroups A (4 ST410, 3
ST1284, 1 ST167) and D (1 ST405) and non-widespread clones of
group B1 (n = 2). Plasmid content varies within ST131, ST410 and
ST1284 clones (IncFII and/or IncA/C or IncN plasmids). blaCTX-
M-15 gene was transferred by conjugation in 91% of the cases, being
located in IncFII (n = 23, 70–110 Kb, reppC15−1a, 3 related RFLP) or
IncA/C plasmids (n = 2, 230 Kb, repp2039) among ST131, A-EC or
B1-EC clones. Identical genetic environments (ISEcp1-blaCTX-M-15-
orf477) and the presence of blaOXA-1, blaTEM-1 and aac(6′)-Ib-
cr were detected in IncFII and IncA/C plasmids. The blaCTX-M-28
(deltaISEcp1-IS5-blaCTX-M-28) was located in a 50kb-IncN plasmid
(n = 3, repR64) recovered from B2-ST131, A-ST410 and D-ST405.
qnrS1 was identiﬁed in 45% of CTX-M-15 producers, mainly ST131
isolates, and located in blaCTX-M-15-IncFII or co-existing IncA/C
(repp2039) and IncN (reppKP96) types.
Conclusion: Current spread of blaCTX-M-15 and blaCTX-M-28 in our
setting is associated with a variety of genetic platforms within prevalent
EC clones. This study highlights the evolution of ST131 by acquisition
of different plasmids and antibiotic resistance mechanisms.
P695 Contemporary spread of CTX-M-14-Escherichia coli in
Spain is mainly associated with persistent IncK and IncI1
and emerging IncN plasmids
Aˆ. Novais °, D. Viana, F. Baquero, R. Canto´n, T.M. Coque (Madrid, ES)
Objectives: CTX-M-14 represents one of the most frequent ESBLs in
different countries, including Spain, where it is increasingly detected.
Spread of an epidemic IncK-blaCTX-M-14a plasmid among E. coli (EC)
strains was documented until 2005. The aim of this study was to evaluate
the current epidemiological scenario to understand persistence and the
steady increase of CTX-M-14-EC producers.
Methods: Thirty-six CTX-M-14 E. coli producers collected in 2008
were studied. Relationship among isolates was established by XbaI-
PFGE and identiﬁcation of phylogenetic groups. blaESBL genes were
identiﬁed by PCR and sequencing. Transfer of bla was carried out by
broth/ﬁlter matings. Plasmid analysis included determination of size and
content (S1-PFGE), incompatibility group [characterization of replicases
(rep) and relaxases (rel) by PCR, sequencing and hybridization] and
comparison of RFLP patterns.
Results: Most isolates were recovered from urines (n = 32/26, 89%) of
outpatients (56%) or inpatients located at medical wards (33.3%). A high
clonal diversity was detected with 36 PFGE-types corresponding to B1
(n = 17, 47%), A (n = 10, 28%; 5 A1, 5 A0), D (n = 8, 22%) and B2
(n = 1, 3%) phylogroups. Conjugative transfer was achieved in 61% of
the cases. Two blaCTX-M-14 variants (34 blaCTX-M-14a and 2 blaCTX-
M-14b) were identiﬁed in 1 IncK (n = 13, blaCTX-M-14a), 2 IncI1 (n = 2,
blaCTX-M-14a/b), 1 IncB/O (n = 1, blaCTX-M-14b, reppEI545) and 1
IncN (n = 3, 35kb, blaCTX-M-14a, repR64) plasmids. IncK plasmids
comprise the epidemic pRYC105 ﬁrst detected in our institution in 2001
(75−85kb, blaCTX-M-14a, repR64+repR387+relpSERB1) which was
found in 36% of the isolates corresponding to A, B1 and D EC-clones;
and a closely related variant (80–100kb, blaCTX-M-14a, repR387 and
relpSERB1) identiﬁed in A and B1 isolates (n = 8), which consistently
contained 2 additional plasmids positive for FII+FIB (120–230kb) or
N replicons (30−60kb). Two IncI1 plasmids of 85kb (blaCTX-M-14a,
repR64+relpSC138) and 110kb (blaCTX-M-14b, repR64+rel R64) were
detected.
Conclusion: We described contemporary spread and persistence of the
epidemic pRYC105-IncK and IncI1 plasmids and the emergence of other
plasmid types (IncN, IncB/O) harbouring blaCTX-M-14 variants. This
study illustrates the impact of multiple acquisition events, recombination
and plasmidic selection for the successful spread of a particular antibiotic
resistance gene.
P696 Genetic environment of blaSHV-12 ESBL in three E. coli
clinical isolates: an IS26 structure truncated by a Tn1721
M. Ferna´ndez Va´zquez °, H. Iglesias de Sena, J.A. Garcı´a Rodrı´guez,
J.L. Mun˜oz Bellido (Salamanca, ES)
Objectives: SHV-12 is one of the most prevalent enzymes within the
SHV family. It has been reported all over the world in K. pneumoniae
and in E. coli, and has been shown to be the most frequent ESBL in
enterobacteria other than Escherichia coli and Klebsiella spp. blaSHV-
12 gene usually appears bracketed by two IS26, and has been associated
with genetic elements conferring resistance to ﬂuoroquinolones (qnr).
Here we describe a newer genetic environment (GE) of blaSHV-12 in
three clinical isolates of E. coli, previously undescribed for this ESBL.
Methods: MICs were determined according CLSI guidelines. Conjuga-
tion was performed by the ﬁlter mating method. ESBLs genes were
characterized by PCR and sequencing. The GE of blaSHV-12 was
determined by using a gene-walking strategy. Genetic diversity was
determined by RAPD.
Results: RAPD showed the three isolates were not genetically related.
All three yield a transconjugant strain (TS) harbouring the same structure
(Figure). Isolate 3 also harboured a blaCTX-M-14. MICs of ceftazidime,
cefotaxime and cefepime were respectively: for isolate 1: >16mg/l,
>8mg/l and 1mg/l; TS-1: >16mg/l, 4mg/l and 1mg/l; isolate 2:
>16mg/l, >8mg/l and 2mg/l; TS-2: 16mg/l, 1mg/l and 1mg/l;
isolate 3: >16mg/l, >8mg/l and 16mg/l; and TS-3: 8mg/l, 1mg/l
and 1mg/l. The analysis of plasmid incompatibility groups present
in the six strains revealed that the group I1/Ig was the common group
for all of them. blaSHV-12 was associated to an IS26 upstream, but
137 pb downstream deoR gene, the structure was truncated by an
Tn1721. This organization has been described previously only in two
P. aeruginosa isolates harbouring a blaSHV-2a (Access. No. AF74954
and AM988779). There is no information in these cases about plasmidic
behaviour, or incompatibility groups.
Conclusions: New genetic environments associated to ESBLs are being
progresively described. The diversity of these genetic environments and
their association to insertion sequences, transposons and other mobile
genetic elements are probably associated to the wide diffusion of these
enzymes.
P697 Characterization of plasmids carrying CMY-2-like genes in
Escherichia coli from the United Kingdom
J. Curry °, N. Woodford, P.D. Stapleton (London, UK)
Objectives: CMY-2-like b-lactamases, in common with other class C
cephalosporinases, confer resistance to third-generation cephalosporins,
cefoxitin and are refractory to inhibition by clavulanate. They are
encoded by blacmy-2 genes that originate from ampC found on the
chromosome of Citrobacter freundii. Mobilisation of the ampC gene on
to plasmids has led to its dissemination into a number of hosts including
Salmonella spp., Klebsiella spp. and Escherichia coli. This study aimed
to characterise the plasmids encoding CMY-2-like enzymes in the UK by
investigating a deﬁned set of E. coli isolates from diverse geographical
locations.
Extended-spectrum b-lactamases S173
Methods: Single E. coli isolates from each of nineteen different hospitals
in the UK were investigated; all were known to carry blaCMY2-like
genes. Plasmids harbouring these genes were identiﬁed by a combination
of plasmid proﬁling, DNA:DNA hybridisation with a blaCMY-2 probe,
and plasmid transfer studies. PCR-based replicon typing and plasmid
multi-locus sequence typing (pMLST) was used to classify the plasmids.
Results: Most (17) of the 19 isolates carried blaCMY-2, and 2 carried
its close relative, blaCMY-23. Insertion sequence element ISEcp1 was
identiﬁed 116 bp upstream from the initiation codon of the blaCMY-2-
like genes in 16 of 19 isolates indicating a common insertion point.
ISEcp1 from one of the isolates carrying the blaCMY-23 gene was
interrupted by IS5. The isolates each carried multiple plasmids with sizes
ranging from 1.1 to 168 Kb. Plasmids of incompatibility groups I1 (16/19
isolates) and F (16/19 isolates) were the most common followed by the
A/C2 subgroup (4/19 isolates). The blaCMY-2 genes were transferable
by conjugation to an E. coli recipient from 16 donor isolates. All
transconjugants carried IncI1 plasmids; 6 also acquired IncF or IncA/C2
types present in their parental donor; no transfer was detected from three
isolates, including those carrying blaCMY-23. Classiﬁcation of 10 IncI1
plasmids by pMLST revealed two isolates had identical proﬁles (ST2),
but the other eight plasmids all had unique sequence types; all ten carried
blaCMY-2.
Conclusions: A diverse set of IncI1 plasmids is responsible for the
spread of blaCMY-2-like genes in E. coli from the UK. This study
illustrates the power of pMLST for differentiating IncI1 plasmids
responsible for the spread of antimicrobial resistance genes.
P698 Comparison of fully sequenced plasmids harbouring
different CTX-M variants in German clinical isolates of
Escherichia coli
A. Cullik °, W. Witte (Wernigerode, DE)
Objectives: In recent years the number of outbreak and community
associated extended-spectrum b-lactamases (ESBL) producing Enter-
obacteriaceae is constantly increasing. In Europe the CTX-M type ESBL
of subgroups 1 and 9 are primarily found. They are often located on
large low-copy plasmids belonging to incompatibility groups F, I1, N,
HI, A/C and L/M. In order to learn about the mechanisms of acquisition
and dissemination of blaCTX-M in enterics, we sequenced two IncN
plasmids, pKC394 and pKC396, harbouring each one blaCTX-M gene
of the CTX-M subgroups 1 and 9, respectively.
Methods and Results: By PCR sequencing blaCTX-M-1 and blaCTX-
M-65, respectively, were identiﬁed in two 3rd generation cephalosporin
resistant E. coli and found to be located on IncN plasmids. The plasmids
obtained by conjugation were sequenced on a 454 Sequencer. They
were approximately 45 000 (pKC396, blaCTX-M-65) and 50 000bp
(pKC394, blaCTX-M-1) in size showing identical backbone regions,
similar to previously sequenced antibiotic IncN plasmids R46, pMUR050
and pC15−1a. The integration of blaCTX-M was probably mediated
by different insertion sequences (IS903 for blaCTX-M 65; IS26 for
blaCTX-M-1) and occurred at different sites of the plasmid backbone.
These sites are the same in R46 and pKP96, but they harbour different
antibiotic resistance cassettes. Unexpectedly, the pKC394 sequences
showed the blaCTX-M-1 as well as blaCTX-M-65 gene which was
conﬁrmed by PCR and southern hybridization experiments. The blaCTX-
M-65 integration site in pKC394 and pKC396 was identical.
Conclusions: The CTX-M/IS mobilization units seem to have different
targets sites for integration in the plasmid backbone. This is probably
due to their association of different IS elements and their corresponding
DNA recognition sequences. The integration of two different blaCTX-M
genes into the plasmid pKC394 is a new phenomenon that could entail
a increased resistance rates to cephalosporins, especially with inhibitor,
or ﬁtness beneﬁt like described for another b-lactamase, blaTEM.
P699 Occurrence and dissemination of genetic resistance
determinants among Gram-negative isolates collected from
inanimate surfaces in a hospital in Aveiro, Portugal
C. Santos °, T. Caetano, E. Ramalheira, S. Ferreira, S. Mendo (Aveiro,
PT)
Objective: In hospital environment, the arising of antibiotic resistant
strains is not only conﬁned to patients but also to the surrounding
environment. This is a serious problem worldwide given the selective
pressure exerted by overuse of antibiotics. The present study aimed to
assess the occurrence of antibiotic resistance determinants in bacterial
strains collected from inanimate surfaces.
Methods: Samples were collected with sterile cotton swabs rubbed
in the toilet, lavatory and door knob and placed in rich medium,
37ºC o/n. Dilutions were plated in McK agar and incubated as
previously. Phenotypically different colonies were selected and their
clonal relationship was determined by rep-PCR. Individual clones
were identiﬁed using VITEK2 system and VITEK2 AES (bioMe´rieux,
Marcy L’E´toile, France). Susceptibilities were determined according to
guidelines of CLSI standards. Class 1, class 2 integrons and b-lactamases
were screened by PCR, using speciﬁc primers. Nucleotide and deduced
aminoacid sequences were analyzed with Blast and ClustalW programs
and compared to others in the database.
Results: Eighty-ﬁve genetically different strains belonging to gen-
era Escherichia, Pseudomonas, Enterobacter, Klebsiella, Citrobacter,
Acinetobacter, Serratia, Proteus, Alcaligenes, Stenotrophomonas and
Morganella, were identiﬁed. The intI1 gene was ampliﬁed in 29% of
the isolates and intI2 gene was not detected. A total of 15 different
arrays identiﬁed: 35% were novel combinations of gene cassettes, never
described before; 65% were already described in different countries and
species, but in biological samples of patients or animals. Screening
for b-lactamases and metallo-b-lactamases (MBLs) enzymes revealed
the presence of CTX-M (7.05%), OXA (9.41%), SHV (18.82%), TEM
(87.06%), VIM (5.88%) and IMP (1.17%) variants. The most prevalent
b-lactamases were TEM-1 and SHV-12 variants, followed by MBL of
VIM-2 type that appeared always associated with class 1 integron.
Conclusions: Class 1 integrons are widely spread in the hospital
environment, particularly among opportunistic strains, as well as the
b-lactamases. These results are worrisome, since the studied isolates
were collected from inanimate surfaces, and possess different resistance
determinants that were described worldwide. The results show that
antibiotic resistance genes can be easily disseminated within the hospital
environment, and may be a possible source of infection in compromised
patients.
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P700 New genetic environment of quinolone resistance gene qnrA,
in a qnrA1 and double ESBL-producing K. oxytoca clinical
isolate
M. Ferna´ndez Va´zquez °, N. Gutie´rrez Zuﬁaurre, J.A. Garcı´a Rodrı´guez,
J.L. Mun˜oz Bellido (Salamanca, ES)
Objective: We describe the genetic environment (GE) of qnrA1 and
ESBLs in a K. oxytoca harbouring qnrA and two ESBLs.
Methods: MICs were determined according CLSI guidelines. Conju-
gation was performed by the ﬁlter mating method. qnrA1 and ESBLs
genes were characterized by PCR and sequencing. The GE of qnrA1 and
ESBLs genes were determined by using a gene-walking strategy. gyrA,
gyrB, parC and parE genes were sequenced.
Results: MICs of the K. oxytoca isolate were: amoxicillin, >16mg/l;
cefoxitin >8mg/l; ceftazidime, >16mg/l; cefotaxime, >8mg/l; nalidixic
acid, 16mg/l; ciproﬂoxacin, 0.12mg/l. gyrA, gyrB, parC and parE genes
were wild-type. The isolate harboured qnrA1, CTX-M-9 and SHV-12.
Transconjugant MICs were: ceftazidime, >16mg/l; cefotaxime, >8mg/l;
nalidixic acid, 8mg/l; ciproﬂoxacin, 0.1mg/l. There was an unique
plasmid sized >29,950 pb (incompatibility group HI2). SHV-12 was
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associated to a IS26, with a GE described in pMUB9 (Access. No.
EF370423). CTX-M 9 was included in a In60 class-1 integron (Access.
No. AF174129.3). qnrA1 was included in a structure similar to the
In36 (Access. No. AY259085.1) downstream from the ISCR1, excepting
because IS6100 was not found downstream orf6. Nevertheless, the
ISCR1 3′ end is truncated in its ﬁrst 144 bases by a IS26, probably
displacing the elements upstream of ISCR1 in the In36 backbone.
Conclusions: K. oxytoca harbouring both ESBLs and qnr simultaneously
have been infrequently reported. The GE reported for qnrA1 has not been
reported previously.
P701 Identiﬁcation of extended-spectrum b-lactamase producing
Enterobacteriaceae using the Hyplex® ESBL-ID multiplex
PCR-ELISA system
A. Senok °, M. Al-Zarouni, N. Al-Zarooni, D. Panigrahi (Sharjah, AE)
Objectives: Rapid detection and genotyping of extended-spectrum
b-lactamase (ESBL) types is required particularly in high prevalence
settings. This study was carried out assess the use of Hyplex® ESBL ID
multiplex PCR-ELISA system (h-ES-ID) in our setting and compare
it with conventional methods. In addition, the antibiotic resistance
proﬁle of identiﬁed ESBL isolates to carbapenems and tigecycline was
determined.
Methods: ESBL Enterobacteriaceae identiﬁed from seven secondary
and tertiary hospitals in the United Arab Emirates from June 2008-
March 2009 were included in the study. Screening for ESBL phenotype
was by double disk diffusion method according to CLSI guidelines and
conﬁrmed using the VITEK-2 (bioMe´rieux) and MicroScan Walk-Away
automated methods as well as ESBL-Etest. All isolates were tested using
the h-ES-ID which is designed to amplify TEM, blaSHV, blaCTX-M and
blaOXA bacterial DNA by multiplex PCR and subsequent hybridisation
of the PCR products to speciﬁc oligonucleotide probes. These consist
of a consensus probe for TEM, SHV, CTX-M and OXA and a
CTX-M speciﬁc probe for identiﬁcation of ESBL isolates with CTX-M
gene. The pattern of antibiotic susceptibility of CTX-M isolates to a
panel of antibiotics including ciproﬂoxoacin, imipenem, meropenem and
tigecycline was determined.
Results: A total of 292 ESBL-producing Enterobacteriaceae were
identiﬁed during the study period using the double disk diffusion
and automated methods. Majority of these were E. coli (n = 228)
and K. pneumoniae (n = 63). Of these 288 (98.6.%) exhibited the
ESBL phenotype using the Etest. The h-ES-ID assay identiﬁed 287
(98.2%) ESBL isolates of which 95% (n/N= 272/287) were CTX-M
types. Four isolates identiﬁed as ESBL positive by the double disk
and automated methods were negative by both E-test and PCR. All
isolates were sensitive to imipenem and meropenem. Ciproﬂoxacin
resistance was 80% among CTX-M positive isolates compared to 37.5%
among CTX-M negative isolates. Four CTX-M positive isolates showed
resistance to tigecyline. These included two K. pneumoniae and one
Enterobacter cloacae with MIC90: >4mg/ml, and one K. pneumoniae
with MIC90: 3mg/ml.
Conclusion: The h-ES-ID is a reliable test for the rapid detection of
ESBL isolates with the additional advantage of detecting those harboring
the CTX-M gene. The emergence of resistance to tigecycline among the
CTX-M isolates is of clinical signiﬁcance and should be monitored.
P702 Identiﬁcation of CTX-M-15-producing O25b-ST131
Escherichia coli isolates on the basis of distinct antibiotic
susceptibility and metabolic proﬁles
T. Gibreel °, F. Bolton, J. Cheesbrough, A. Fox, A. Dodgson, M. Upton
(Manchester, Preston, UK)
Objectives: The recent global dissemination of O25:H4-ST131 CTX-
M-15 producing uropathogenic E. coli (UPEC) isolates with a high
virulence potential represents a major health problem. The aim of this
study was to assess the possible association of key UPEC strains with
phenotypic proﬁles and to recognize putative predictor markers for
identiﬁcation of the ST131 clone.
Methods: A total of 310 isolates representing the UPEC population in
the northwest region of England were collected in the period 2006–2009.
Genotyping using multilocus sequence typing (MLST) and phylogenetic
group PCR was carried out in addition to determination of biochemical
activity and antibiotic susceptibility proﬁles using Vitek® system. ST131
isolates were screened using an O25b-ST131 CTX-M-15 allele speciﬁc
multiplex PCR.
Results: A nine-digit numerical code was generated using the results
of 27 biochemical tests. A total of 144 different proﬁles were detected,
of which 22 were solely associated with ST131 isolates. Aggregative
bioscores were signiﬁcantly higher among ST131 isolates (median 19
range 14−23) than among other commonly detected clonal groups.
Isolates were grouped based on the biochemical proﬁles and clusters
were examined for associations with ST and antibiogram proﬁles. This
revealed a large ST131 cluster comprising of 69 (90%) isolates that were
characterized as having a multiple resistance antibiogram.
Stepwise multivariate logistic regression analysis revealed resistance
to ﬂuoroquinolones as the strongest predictor of ST131, in addition
to three biochemical tests (production of a-galactosidase, 5-keto-D-
glucosnate and fermentation of saccharose) with an overall accuracy of
94.2%. Among the ST131 clonal group isolates, production of tyrosine
arylamidase appeared to be the only signiﬁcant predictor of CTX-M-15
producing O25b-ST131 strains with an over all accuracy of 94%.
Conclusion: ST131 clonal group in general, and O25b-ST131 CTX-
M-15 producing stains in particular, are characterized by unique
biochemical activities that can, to a certain extent, be used to predict
multiple drug resistant ST 131 clonal group strains.
P703 Characterization and location of the blaCTX-M-15 gene in en-
teroaggregative Escherichia coli causing traveller’s diarrhoea
E. Guiral °, S. Soto, E. Me´ndez-Arancibia, P. Salvador, J. Vila
(Barcelona, ES)
Objectives: Enteroaggregative Escherichia coli (EAEC) are one of
the most important bacteria causing traveller’s diarrhoea. Although
multiresistant EAEC clinical isolates have been shown, no EAEC isolates
resistant to third generation cephalosporins have been reported up to
now. In a previous study, 5 out of 51 EAEC isolates causing traveller’s
diarrhoea from patients who had travelled to India were found to be
resistant to these cephalosporins. The aim of this study was to investigate
the mechanisms of resistance to the third-generation cephalosporins in
these 5 EAEC clinical isolates.
Methods: Five E. coli strains were collected from stool samples from
patients with traveller’s diarrhoea. The presence of SHV, TEM, CTXM
ESBL and an Insertion Sequence (IS) related to those genes was
determined by PCR and sequenced using speciﬁc primers. Genetic
location of the gene encoding an ESBL was determined by reverse PCR
and conjugation. Conjugation was performed using both the K7 759
lac- kanamycin-resistant and J53 rifampicin-resistant E. coli strains. The
epidemiological relationship among these ﬁve EAEC strains was studied
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by PFGE, REP-PCR and MLST. The phylotype of the ﬁve strains was
determined by multiplex PCR.
Results: A blaCTX-M-15 gene was detected in all EAEC strains. By
reverse PCR, it was found that the gene could be related to the ISecp1
upstream, which was comﬁrmed by a combined PCR. Transconjugants
were obtained for three out of ﬁve strains. The PFGE and the REP-
PCR showed that these strains were non-epidemiologically related. Three
strains belonged to phylotype D and the other two to phylotype B2. The
MSLT study showed that the three strains belonging to phylotype D were
included in the Clonal Complex ST38.
Conclusion: This is the ﬁrst time that the blaCTX-M-15 gene has
been detected in EAEC clinical isolates causing traveller’s diarrhoea.
This gene was found in ﬁve epidemiologically unrelated EAEC strains
although three of them were from the same Clonal Complex and had the
same phylotype. The ﬁve strains had the ISecp1 element upstream of
the gene blaCTX-M-15. This gene was located in a transferable plasmid
in three of the strains.
P704 Prevalence of CTX-M extended-spectrum b-lactamase
Escherichia coli in chickens and turkeys in Great Britain
between 2006 and 2009
L.P. Randall °, C.S. Clouting, H. Wearing, M.J. Toszeghy, R. Horton,
N. Coldham, F.A. Clifton-Hadley, C.J. Teale, R.H. Davies (New Haw, UK)
Objectives: In recent years E. coli strains carrying CTX-M genes have
been isolated from chickens in Belgium, China, France, Japan, Portugal
and Spain. In view of the detection of such strains in poultry in a
number of different countries, two separate surveys for CTX-M E. coli
in chickens and turkeys were performed in Great Britain in 2006−7
(turkeys) and 2008−9 (chickens) to determine the prevalence of CTX-M
E. coli in poultry.
Methods: For the chicken survey, caecal contents from 388 chickens
from 22 abattoirs were sampled. For the turkey survey, 442 turkey
ﬂocks comprising 125 breeder and 317 meat ﬂocks from 337 farms
were sampled. Potential CTX-M positive isolates were recovered on
CHROM agar ECC (CHROMagar France) with addition of 1 or
2mg/L cephalosporin antibiotic or, for chicken samples only, also on
CHROMagar CTX (CHROMagar, France). Presumptive ESBLs were
tested for the presence of blaCTX-M gene by PCR and CTX-M positive
isolates were sequenced to determine the CTX-M type, PFGE typed,
tested for the ability to conjugation and tested for the presence of the O
25 serotype.
Table 1. Farms (Turkeys only) or abattoirs (chickens only) positive for
CTX-M E. coli showing CTX-M types
Samples collected from
Turkey Farms
Samples collected from
broiler chickens at slaughter
Type of farm Farm code CTX-M types Abattoir code CTX-M-types
Meat 2 14 AC 1
Meat 3 14 AE 1 & 15
Meat 4 14 AG 1
Meat 5 14 AH 1 & 15
Breeder 6 14 AI 1 & 3
Meat 7 14 AL 15
Meat 8 14 AM 3
Breeder 9 14 AS 1
Meat 10 14 AW 15
Meat 14 1 BB 1
Meat 11 14 BD 1
Meat 13 55 BJ 1
Meat 1 1 and 15
Meat 16 14
Meat 15 1
Meat 18 1
Meat 17 1
Meat 12 1 and 15
Results: Only 3.6% of individual chickens, 6.9% of turkey breeding
ﬂocks and 5.2% of turkey meat ﬂocks were found to have CTX-M
positive E. coli. CTX-M types 1, 3 and 15 were isolated from chickens,
with CTX-M type 1 being predominant. CTX-M types 1, 14, 15 and
55 were isolated from turkeys with CTX-M types 1 and 14 being
predominant (Table 1). In turkeys in particular, there was an association
of some CTX-M types with some of the shared ownerships. CTX-M
positive isolates from both chickens and turkeys were shown to be
clonally diverse by PFGE and most isolates readily transferred their
CTX-M gene to Salmonella by conjugation. None of the CTX-M positive
isolates was serogroup O 25. In the chicken survey, CHROMagar CTX
was the most effective agar for isolating CTX-M strains compared to
other agars used.
Conclusion: There was a suggestion of different CTX-M enzymes
circulating within chicken populations compared to those in turkeys
and the plasmids carrying these enzymes appeared to have spread into
clonally diverse E. coli strains. The prevalence of CTX-M E. coli in
individual chickens and in turkey ﬂocks was low, and on the basis of
strains being negative for serogroup O 25, none of the CTX-M 15 isolates
were O25-ST131 CTX-M 15, a human epidemic strain. Further work is
planned to investigate MLST and replicon types of CTX-M isolates.
P705 Molecular analysis of CTX-M-15 producing Escherichia coli
Belgian epidemic clone
I. Montesinos °, P. Bogaerts, R. De Mendonc¸a, A. Deplano, H. Rodriguez-
Villalobos, M.J. Struelens, Y. Glupczynski (Brussels, BE; Stockholm, SE)
Objectives: Pandemic clones of ST 131 CTX-M-15 producing E. coli
have been identiﬁed worldwide and represents a major public health
problem. Previous studies showed the dissemination of a major clone of
the virulent B2 group CTX-M-15 producing E. coli (CTX-M-15-EC) in
a large number of Belgian hospitals. We analysed this clone to elucidate
its phylogenetic origin and CTX-M-15 plasmid structure.
Methods: Ten CTX-M-15-EC isolates of Belgian epidemic clone (PFGE
type 6) were analyzed. Strains were genotyped by MLST. Plasmids were
extracted and transformed into E. coli TOPO10 electrocompetent cells.
MICs were determined by E-test. The presence of extended spectrum-
b-lactamases was conﬁrmed by double combination disk test (DDT) and
by PCR. The genetic environments of blaCTX-M-15 were analysed by
PCR mapping and sequencing.
Results: MLST analysis showed that CTX-M-15-EC isolates from
Belgian clone 6 belong to the ST131 lineage. Transformants were
obtained from all isolates. We found two groups of plasmids harbouring
blaCTX-M-15 as determined by PCR mapping. In the ﬁrst group (n = 8),
sequencing of a 5kb fragment showed 100% sequence identity to the
plasmid pEK516 (64 Kb), containing the transposase of the insertion
sequence ISEcp1, tnpA, tnpR and blaTEM upstream of blaCTX-M-15.
The second group (n = 2) showed 100% sequence identity over 7kb to
the plasmid pEK499 (117 Kb) which encompasses an upstream region
containing the transposase of the insertion sequence IS26 instead of
ISEcp1, tnpM, int, dfrhVII, addA and sulI. Both plasmids share a
truncated ORF 477 downstream of blaCTX-M-15. The transformants
harbouring pEK499 showed negative DDT test and lower MIC values
to ceftazidime, cefepime and cefotaxime (<2mg/l), contrasting to the
clinical isolates.
Conclusions: Molecular analysis of Belgian epidemic B2 CTX-M-15
producing E. coli strains showed its link to the international E. coli
ST131 lineage. Different plasmids were observed in the same genetic
lineage ST 131. This may contribute to the epidemiological success of
this clone.
P706 Multicentre study extended-spectrum b-lactamase
producing Escherichia coli in Spain: wide dissemination of
CTX-M-15-producing O25b-B2 strains
J. Oteo °, V. Bautista, N. Lara, M. Arroyo, S. Ferna´ndez,
M. Pe´rez-Va´zquez, O. Cuevas, S. Garcı´a-Cobos, B. Aracil, J. Campos
and the ESBL-REVERA-EARSS Study Group (REIPI)
Objectives: ESBL-producing E. coli isolates have increased in last years
in Spain. Recently, the local spread of the CTX-M-15-producing O25b-
phylogroup B2-ST131 strain has been also described in Spain. The aim
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of this study is to characterize the ESBL production in Spanish E. coli
isolates, mainly focussed on the distribution of O25b-phylogroup B2
strains.
Methods: A national prospective multicenter study was designed to
collect ESBL-producing E. coli from clinical samples between February
2008-May 2008. The 28 participant hospitals (representatives of the
main Spanish geographic areas) were asked to collect up to 10
consecutive, non-duplicated isolates. Antibiotic susceptibility testing and
ESBL detection was performed following CLSI guidelines. ESBLs were
characterized by PCR and sequenciation. Phylogroups were determined
by a multiplex PCR assay. The O25b type detection was carried out by
an allele-speciﬁc PCR.
Results: A collection of 229 ESBL-producing isolates was studied. 181
(79%) were from urine, 135 (58.9%) were from community-acquired
infections, and 153 (66.8%) were from patients >65 years old. Most
prevalent ESBL types were: CTX-M-15 (41.5%), SHV-12 (31%) and
CTX-M-14 (23.1%). Two different ESBLs were detected in 11 isolates:
CTX-M-15 + SHV-12 (5), CTX-M-14 + SHV-12 (5), CTX-M-15 + CTX-
M-14 (1). Seventy-six isolates (33.2%) belonged to phylogroup A, 47
(20.5%) to group B1, 75 (32.7%) to group B2, and 31 (13.5%) to
group D. The most frequent phylogroup in CTX-M-15 producers was
B2 (57.9%), in CTX-M-14 producers was B1 (34%) and in SHV-12
producers was A (49.3%). Resistance to ciproﬂoxacin, cotrimoxazole
and gentamicin was 81%, 60% and 12.6%, respectively, in CTX-M-15
producers; 80.3%, 63.4% and 9.9% in SHV-12 producers; and 71.7%,
77.4% and 17% in CTX-M-14 producers. A total of 53 CTX-M-15-
producing O25b-phylogroup B2 isolates were detected, but also 12 SHV-
12, 2 CTX-M-14, 1 CTX-M-9 and 1 SHV-2 producers were O25b-B2.
O25b-B2 E. coli producing CTX-M-15 were detected in 19 hospitals of
9 different geographic areas.
Conclusions: ESBLs more frequent in clinical E. coli isolates in
Spain were CTX-M-15, CTX-M-14 and SHV-12. CTX-M-15 isolates
belonged mainly to virulent phylogroup B2 while CTX-M-14 and SHV-
12 belonged mainly to phylogroups A and B1. The 55.8% of CTX-M-15
isolates were O25b-B2 isolates. O25b-B2 E. coli isolates also carried
other ESBLs. O25b-B2 E. coli producing CTX-M-15 is spreading in
different Spanish geographic areas.
P707 Identiﬁcation and characterization of epidemic CTX-
M-producing Enterobacteriaceae in a United Kingdom
region of 10-million population
L. Xu °, S. Shabir, T. Bodah, C. McMurray, K. Hardy, P. Hawkey,
K. Nye (Birmingham, UK)
Objective: An epidemic strain (strain A) of E. coli was identiﬁed by a
previous national survey of CTX-M producing ESBLs, conducted by the
UK Health Protection Agency. The aim of this study was to establish
the incidence of strain A and the prevalence of other epidemic strains
harbouring bla-CTX-M using a regional survey in the West Midlands.
Methods: A 2 month survey of CTX-M-producing ESBLs in Enter-
obacteriaceae was carried out. A total of 370 consecutive non-duplicate
isolates were collected from 13 loboratories which serve a population
of 10 million. The 345 conﬁrmed ESBL isolates were screened for the
presence of blaCTX-M by mutiplex PCR. Genotypes were identiﬁed
using Denaturing High-Performance Liquid Chromatography (DHPLC).
Insertion sequence typing of IS26 was performed. Clonal relationships
were studied by PFGE. A duplex PCR method was used to identify the
O25b-ST131 E. coli clone isolates.
Results: Of the 294 (85.2%) isolates carrying blaCTX-M 175 (59.5%)
were from hospital and 119 (40.5%) were from community patients.
These comprised 232 E. coli, 58 Klebsiella spp., 2 E. aerogenes, 1
E. cloacae and 1 P. vulgaris. The majority of isolates were from urinary
tract infections (241, 82.0%). Multiplex PCR showed that 284 isolates
(96.6%) expressed CTX-M group 1 enzymes. The remaining 10 isolates
harboured group 9, 2 and group 25/26 genes. All group 1 isolates
had blaCTX-M-15 proﬁles. IS26 was identiﬁed in 62 isolates (21%).
PFGE analysis found 23 clusters (RE 1−23) containing 213/225 (95%)
blaCTX-M positive E. coli which were distributed between hospital and
community isolates, 55% and 45% respectively. Of the clustered strains,
102 (60%) constituted the largest clone RE1 and shared the epidemic
strain A PFGE proﬁle; all harboured blaCTX-M-15 except one which
carried blaCTX-M-9. A total of 66% E. coli (154/232) were O25b-ST131
positive. The majority of the strains, clustered in the largest PFGE clone
RE1 (99 of 102) belonged to O25b-ST131.
Conclusion: Our survey shows for the ﬁrst time that the largest cluster
in the West Midland is the CTX-M-15 producing RE1 clone (strain
A). This clone has not only persisted for more than two years after
it emerged in one of local hospitals, but has also spread throughout
the region. Almost all RE1 strains belong to the O25b-ST131 lineage
(99/102) providing further evidence that this lineage plays a pivotal role
in the clonal dispersal of CTX-M-15-producing ESBLs worldwide.
P708 Sequence analysis of extended-spectrum b-lactamase genes
harboured by invasive isolates of Escherichia coli in Kuwait
G. Al Hashem, N. Al-Sweih, W. Jamal, M. Shahin, V.O. Rotimi ° (Safat,
KW)
Objective: This study was undertaken to analysis the genes encoding
ESBL phenotypes in invasive isolates of Escherichia coli obtained from
patients managed in Kuwait hospitals.
Methods: One hundred and thirteen ESBL-positive E. coli were
studied. ESBL production was conﬁrmed by PCR. DNA ex-
tracts of ESBL-positive isolates were screened for the pres-
ence of blaCTX-M, blaTEM and blaSHV genes using the
following primers: MA-1 − 5′-SCSATGTGCAGYACCAGTAA-3′
and MA-2 5′-CCGCRATATGRTTGGTGGTG-3′ (blaCTX-M), Cf-
TCGGGGAAATGTGCGCG and Dr-TGCTTAATCAGTGAGGCACC
(blaTEM) and OS-5f TTATCTCCCTGTTAGCCACC and OS-6r
GATTTGCTGATTTCGCTCGG (blaSHV). Strains with PCR amplicons
positive for these bla genes were sequenced using Applied Biosystems
sequencer and the nucleotides analyzed with software available at website
http://www.ncbi.nlm.nih.gov/blast. Selected CTX-M-, TEM- and SHV-
positive strains were evaluated for transfer of genetic determinants by
conjugation experiments and associated plasmid DNA extracted and
analyzed by agarose gel electrophoresis.
Results: Out of the 113 ESBL-positive isolates, 88 (77.9%), 46 (40.7%),
8 (7.1%) and 59 (52.2%) harbored blaCTX-M, blaTEM, blaSHV,
and blaISEp1, respectively. Forty-four (50%) of the CTX-M-positives
harbored blaTEM and 5 harbored blaSHV., but only 4 carried the 3
genes simultaneously. Sequence analysis showed that the most common
CTX-M-type was CTX-M-15 representing 84.1%, followed by CTXM-
14 (6.8%), CTX-M-14b (5.7%) and TOHO-1 (3.4%). Of these, 66
(89.2%) were found in isolates from the 3 predominant nationalities;
Kuwaitis (36.5%), Egyptians (32.4%) and Indians (20.3%). The CTX-M
phenotypes were easily transferrable to E. coli J53 (rifr) recipeint. Three
of the SHV-producing harboured blaSHV-1 and the remaining blaSHV-
11 while 27 of the TEM-producing strains harboured blaTEM-1, 2
blaTEM-170, 1 blaTEM-174 and remaining contained no sequence.
Conclusions: A large proportion of the invasive ESBL-positive E. coli
isolates in Kuwait produced the CTX-M-type b-lactamases and about
half of them also produced the TEM-type enzymes simultaneously.
SHV ESBL is relatively rare. However, all these ESBL phenotypes are
transferable by conjugal plasmids.
P709 Characterization of extended-spectrum b-lactamase types
produced by clinical isolates of Escherichia coli and
Klebsiella pneumoniae from Turkey: results of a multicentre
surveillance study (Hitit 2)
Z. Gulay °, D. Gur, M. Bicmen on behalf of The Hitit 2 Study Group
Objective: (i) to investigate speciﬁc ESBL types produced by clinical
E. coli (Ec) and K. pneumoniae (Kp) isolates in order to understand
their prevalence and distribution in Turkey (ii) to detect new ESBLs
that has a potential for spread (iii) to understand the epidemiology of
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multiresistant ST131:O25b clone which contributes to the increasing
prevalence of CTX-M-15.
Methods: A total of 319 clinical isolates which were conﬁrmed as
ESBL producers by E Test, were collected from 12 centers located
in 10 different cities. bla genes were ampliﬁed by PCR, cloned if
necessary and sent for sequence analysis. E. coli ST131:O25b clone was
investigated among CTX-M-15 producers by a PCR method developed
by Clermont et al. Plasmid analysis and in some cases ERIC-PCR were
also performed.
Results: CTX-M b-lactamases were detected in 97.4% of Ec and 95.1%
of Kp. Among CTX-Ms, CTX-M- 15 predominated in both species
(77.7% in Ec and 68.2% in Kp), followed by CTX-M-3 and CTX-
M-1(overall prevalances 22.5% and 3.1%). CTX-M-14 was detected in
an Ec isolate for the ﬁrst time in Turkey. SHV-type ESBLs were found
in 14.8% in Kp and 2.6% in Ec. The ESBLs with higher prevalances
were SHV-12 and SHV-5 in Kp. The only TEM type ESBL was TEM-
15 found in a Kp isolate. 5.3% of Kp SHV producers also produced a
CTX-M (15 or 3). Several SHV-type enzymes belonging to group 2be
(SHV-31, SHV-38) and group 2b (SHV-11, SHV-33, SHV-62, SHV-65)
were detected for the ﬁrst time in Turkey. Carbapenem resistance which is
due to OXA-48 production was found in 3.1% of Kp isolates and a small
outbreak caused by OXA-48 producing Kp was detected in one of the
centers. Among 119 Ec isolates which produce CTX-M-15, 51 (42.8%)
belonged to the ST131:025b clone. 86.3% of these isolates possessed an
identical ERIC-PCR pattern although collected from 10 different centers.
ESBLs were carried on plasmids with sizes 91−16 kb sometimes along
with quinolone resistance.
Conclusions: (i) CTX-M-15 clearly predominates among ESBLs de-
tected in Enterobacteriaceae isolated in Turkey. (ii) Several b-lactamases
including CTX-M-14 that are new for Turkey were identiﬁed.(iii)
Carbapenem resistance due to OXA-48 may become an emerging
problem.(iv) The international pandemic clone Ec ST131:O25b which
produces CTX-M-15 is widely disseminated in Turkey.
P710 Prevalence of extended-spectrum b-lactamases in Escherichia
coli strains isolated from Peruvian infants
S.G. Mosquito °, M.J. Pons, R. Maves, Y. Saenz, E. Mercado,
M. Vargas, L.J. Del Valle, C. Torres, T. Ochoa, J. Ruiz (Lima, PE;
Barcelona, ES; Logron˜o, ES)
Objectives: To determine the frequency of extended spectrum
b-lactamases (ESBLs) in diarrhoeagenic Escherichia coli strains isolated
from children under one year of age with and without diarrhoea in Peru.
Methods: A total of 293 ampicillin-resistant E. coli isolates were
obtained between October 2006 and July 2008 as part of a prospective
cohort study of diarrhoea in 1,034 children under one year of age.
Specimens were tested for the presence of ESBLs by double disk synergy
testing with cefotaxime (CTX), ceftazidime (CAZ) and, amoxicillin–
clavulanic acid (AMC). From these, 230 isolates were classiﬁed as
diarrhoeagenic E. coli (DEC) and 63 as non-DEC by multiplex real-
time PCR testing for diarrhoea virulence factors. The b-lactamase genes
blaTEM, blaSHV, blaOXA-1-like, and blaCTX-M were identiﬁed by
PCR. Posterior sequencing was performed for ESBL-positive isolates.
Additionally, 95 ampicillin-resistant but ESBL-negative isolates were
analysed by PCR in order to determine the prevalence of blaTEM,
blaSHV, blaOXA-1-like and blaCARB.
Results: Only two ESBL-positive isolates (0.7%) were identiﬁed, both
enteropathogenic E. coli (EPEC). The ﬁrst isolate was CAZ-resistant,
CTX-intermediate, and positive for the blaTEM and blaSHV genes. The
second isolate was CTX-intermediate and CAZ-susceptible; this isolate
only harboured blaSHV-12. Neither blaOXA-1-like nor blaCTX-M were
detected in these isolates.
The prevalence of blaTEM, blaSHV, and blaOXA-1-like among non
ESBL isolates was 48%, 42%, and 5%, respectively. No blaCARB
genes were detected. The presence of blaTEM (34%[12/35] vs.
57%[34/60])differed between control and diarrhoea groups respectively.
No differences were observed in the presence of b-lactamase genes
among DEC or non-DEC isolates from control participants.
Conclusion: There is a low prevalence of ESBL-positive E. coli
isolates in Peruvian children but a high frequency of blaTEM and
blaSHV genes among non-ESBL isolates. The blaTEM gene is most
prevalent in specimens from diarrhoea samples. Continued surveillance
of the prevalence of ESBL-positive isolates is necessary to monitor the
evolution of drug resistance in DEC.
P711 First description of Escherichia coli producing CTX-M-15
extended-spectrum b-lactamase in outpatients from
south-eastern Nigeria
I. Iroha °, S. Neumann, L. Marlinghaus, M. Korte, F. Szabados,
S. Gatermann, M. Kaase (Bochum, DE)
Objectives: The prevalence of extended-spectrum b-lactamases (ESBL)
in E. coli is increasing worldwide, mainly due to the spread of ESBLs of
type CTX-M-15. Plasmids with CTX-M-15 often also carry aac(6′)-Ib-cr
and OXA-1 b-lactamase genes.
Methods: A total of 44 single patient ESBL E. coli strains collected
from two hospitals located in Enugu (n = 28) and Abakaliki (n = 16)
in south-eastern Nigeria were used in this study. Conﬁrmation of the
ESBL phenotype was done by a double-disk synergy test. Initial species
identiﬁcation was conﬁrmed by MALDI-TOF analysis. Identiﬁcation
of ESBL genes was performed by speciﬁc PCR tests and subsequent
sequencing. In addition, PCR for OXA-1 b-lactamase was performed.
Screening for aac(6′)-Ib-cr was done by a speciﬁc PCR followed by
restriction with BseGI.
Results: Of the 44 ESBL E. coli strains 34 (77.2%) were isolated from
urine, 6 (13.6%) from vaginal swabs and 4 (9.0%) from wound swabs.
30 (68.1%) strains were isolated from female patients and 16 (36.4%)
strains were from outpatients. The age range of patients was 7 to 72 years,
but the majority of patients (n = 42; 95.5%) were under the age of 30.
Using speciﬁc PCRs we could demonstrate CTX-M-1 cluster enzymes
in 43 (97.7%) of strains, three of which were selected for sequencing
and found to be CTX-M-15. A positive PCR for OXA-1 was found in
40 (90.9%) strains and aac(6′)-Ib-cr could be demonstrated in 40 (90%)
strains.
Conclusion: For the ﬁrst time we could demonstrate CTX-M-15, found
almost always in association with OXA-1 and aac(6′)-Ib-cr, as the
dominant ESBL type in E. coli strains from south eastern Nigeria.
Remarkably a high proportion of the tested strains were from outpatients.
For the ﬁrst time aac(6′)-Ib-cr was detected in E. coli strains from Africa.
P712 Characterization of b-lactamase and plasmid content of
nosocomial and community Escherichia coli from Rio de
Janeiro, Brazil
M. Queiroz, P. Antunes, J. Moura˜o, E. Machado, L. Peixe ° (Rio de
Janeiro, BR; Porto, PT)
Objectives: Extended spectrum b-lactamases (ESBL) in Enterobacte-
riaceae are recognized as a major public health problem worldwide.
Particularly in Latin America, CTX-M ESBLs are endemic and largely
distributed. Our aim was to characterize the b-lactamase and plasmid
content of Escherichia coli isolates recovered from different community
sources and a hospital setting (1998–2001) in Rio de Janeiro, Brazil.
Methods: We analysed a total of 44 E. coli isolates obtained from
community, including raw vegetables (n = 14) and food handlers hands
(n = 6), and hospital, including fecal isolates of hospitalized patients
(n = 4), clinical specimens (n = 9) and hospital diets (n = 11). Clonality
was established by PFGE (XbaI). Susceptibility to antimicrobial agents
and b-lactamase characterization was performed. Resistance genes and
class 1 integrons were detected by PCR and sequencing. Plasmid
analysis included conjugation assays, determination of size (S1-PFGE)
and content (incompatibility groups by rep-PCR typing, hybridization
and sequencing).
Results: A positive synergism test was observed for 9 isolates
and 7 ESBL-producing human isolates were detected. All produced
b-lactamases with a pI of 5.4 and 7.3 to 8.2 and gave rise to positive
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amplicons for blaCTX-M groups and blaTEM being negative for blaSHV.
By sequencing, CTX-M-2 was detected in isolates from rectal swab of
hospitalized patients (n = 4), CTX-M-59 (n = 1) and CTX-M-9 (n = 2)
in clinical specimens and TEM-1 was detected in all all (n = 7). We
identiﬁed different clones among all ESBL-producing E. coli, which
were multidrug-resistant (MDR) and contained different plasmid types
(IncI1, IncA/C, IncFrepB, IncK, IncP and/or IncFIB). Among commu-
nity isolates, only 3 isolates from vegetables were MDR (ampicillin,
tetracycline, chloramphenicol, sulfametoxazol, streptomycin), though
non ESBL-producers, and one isolate carried a 1000 bp (aadA1) in-
tegron. Interestingly, these isolates also harboured several plasmid types
(IncI1, IncFrepB, IncK, IncFIIs, IncY, Inc FIA and/or IncFIB), providing
genetic platforms for acquisition of diferent antibiotic resistance genes.
Conclusion: Our results corroborate the previously reported prevalence
of CTX-M group 2 in ESBL-producing E. coli isolates from the hospital
environment (colonization and infection) in Brazil. Furthermore, we
found a diversity of plasmids that might act as substracts for the
acquisition and transfer of antibiotic resistance genes and elements.
P713 High rates of intestinal colonization with extended-spectrum
b-lactamase-producing Enterobacteriaceae in patients at a
tertiary-care hospital in Israel
M. Gazin °, J. Vervoort, M. Kazma, C. Lammens, R. Lameir, Y. Carmeli,
H. Goossens, S. Malhotra-Kumar (Antwerp, BE; Tel-Aviv, IL)
Objectives: Nosocomial infections caused by extended-spectrum
b-lactamase producing Enterobacteriaceae (ESBL-En) are increasing
worldwide. The inﬂux of these bacteria into hospitals has major
implications for infection-control. We studied the prevalence and
molecular epidemiology of ESBL-En isolated from stool samples of
hospitalized patients at the Tel-Aviv Sourasky Medical Center, Israel.
Methods: Stool samples (n = 121) were screened for presence of ESBL-
En on the BLSE bi-plate (MacConkey/Drigalski agar supplemented with
ceftazidime and cefotaxime, respectively). Isolates growing on BLSE
agar were puriﬁed and phenotypic presence of ESBLs conﬁrmed by
the double disc synergy test (DDST; cefotaxime, ceftazidime, cefepime,
and amoxicillin/clavulanate). Isolates were identiﬁed by conventional
and semi-automated (Api20NE/E, bioMe´rieux) biochemical testing.
b-lactamase genes (blaTEM, blaSHV and blaCTX-M) were detected
by consensus PCRs. blaCTX-M amplicons were typed by bidirectional
sequencing.
Results: Forty-three (35.5%) stool samples showed presence of ESBL-
En. CTX-M, TEM, and SHV genes were found in 38 (88.4%), 30
(69.8%), and 13 (30.2%) stool samples, respectively. Upto 4 different
ESBL-En species could be recovered from a single stool sample. One, 2,
3, and 4 different ESBL-En species were recovered from 27, 12, 2, and 2
stool samples, respectively. Of the 63 ESBL-En isolates studied, majority
were E. coli (n = 20, 31.7%) Klebsiella pneumoniae (n = 17, 27.0%), and
Enterobacter cloacae (n = 7, 11.1%). CTX-M genes were present either
alone or in combination with another bla gene in 51 (81.0%) of the 63
ESBL-En analyzed. Of the 51 CTX-M genes, 35 (68.6%) were identiﬁed
as CTX-M group 1 (CTX-M 15/28/3), 5 (9.8%) as CTX-M group 2
(CTX-M 2/20), 3 (5.9%) as CTX-M group 9 (CTX-M14/21/17/27), and
1 (2.0%) as CTX-M group 25 (CTX-M 25/26), while 7 (13.7%) genes
could not be assigned to any CTX-M group.
Conclusions: Our results show that CTX-M group 1 enzymes are the
predominant ESBL type present in commensal ESBL-En in Israel. The
high rates of intestinal colonization with ESBL-En in Israeli patients
underscore the importance of screening for ESBL-En carriage on
hospital admission.
P714 Identiﬁcation and dissemination of b-lactamases in
Gram-negative enteric bacteria in Nigerian hospitals
D.O. Ogbolu °, M.A. Webber (Ogbomosho, NG)
Objective: b-lactamases are the predominant cause of resistance to
b-lactam antibiotics in Gram negative bacteria and are a major cause of
nosocomial infections associated with high mortality all over the world
particularly in developing countries. This study however investigated the
dissemination of different b-lactamases in Gram negative enteric bacteria
isolated from clinical specimens of patients attending tertiary hospitals
in Nigeria.
Methods: One hundred and thirty-four Gram-negative enteric bacilli (of
13 species) were analysed for antimicrobial susceptibility, phenotypic
and genotypic detection of various b-lactamases and analysis of plasmids
carrying Extended Spectrum b-lactamase (ESBL) enzymes.
Results: Of the 134 isolates, 111 (82.8%) were found to be b-lactamase
positive while 28 (20.9%) were found to carry an ESBL. PCR revealed
that TEM was present in 109 of 134 isolates (81.3%), SHV in 33
(24.6%), OXA in 15 (11.2%) and CTX-M in 25 isolates (18.7%), while
all the genes were present in 6 (4.5%) of the isolates. AmpC enzymes
were present in 29 of 44 ESBL producing isolates (65.9%). Multiplex
PCR showed that 6 isolates were positive for ampC and these genes
were only found in isolates with CTX-M genes. Sequencing identiﬁed
these genes as ACT-1, DHA-1 and CMY-2. Of 13 representative
plasmids investigated 9 (69.2%) were self transferable when selected
by a b-lactam and the plasmids once transferred coded for b-lactam
resistance. Restriction enzymes revealed transformants all carried an
identical plasmid of approximately108 kb (Inc F).
Conclusion: There is diversity of b-lactamases genes in Gram-negative
enteric bacilli; TEM, SHV, OXA, CTX-M-1(15), CTX-M-1(3) and
AmpC types; ACT-1, DHA-1 and CMY-2. These genes are disseminated
by a dominant conjugative plasmid.
P715 Diversity of b-lactamase families in Enterobacteriaceae
isolates of Portuguese healthcare facilities
D. Jones-Dias, V. Manageiro, D. Louro, E. Ferreira, M. Canic¸a ° for
the ARSIP (Antimicrobial Resistance Surveillance Program in Portugal)
Objectives: b-lactamases are one of the most important mechanisms
of resistance in Gram negative bacteria. We aimed to investigate
b-lactamase producing-Enterobacteriaceae recovered from health care
facilities in Portugal, to evaluate how the use of b-lactams is
compromised in Portugal, due to this resistance mechanism.
Methods: A total of 125 strains of Enterobacteriaceae were characterized
as ESBL producers over a 4 year period (2004 to 2008) in 12 health
care facilities and tested for susceptibility to 32 antibiotics. Detection
of TEM, SHV, OXA, CTX-M, GES and AmpC encoding genes was
carried out by PCR. All positive isolates for CTX-M, GES and AmpC
enzymes were submitted to gene sequencing. TEM and SHV encoding
genes were identiﬁed when CTX-M was negative. Isoelectric focusing
was performed to determine the expression and pI of chromossomal
AmpC b-lactamases.
Results: A total of 118 isolates were non-susceptible to cefotaxime,
ceftriaxone, ceftazidime, cefpodoxime and ceﬁxime; 120 isolates were
non-susceptible to aztreonam and 27 to cefoxitine. Regarding carbapen-
ems, only one isolate revealed to be non-susceptible to imipenem. Only
19 isolates presented susceptibility to amoxicillin/clavulanic acid and
41 to piperacillin/tazobactam combinations. A total of 103 isolates were
multidrug resistant. Although all the isolates presented ESBL phenotype,
this was conﬁrmed only in 109 of them. Indeed, molecular methods
identiﬁed 99 strains possessing bla-CTX-M (blaCTX-M-1, blaCTX-
M-9, blaCTX-M-14, blaCTX-M-15 and blaCTX-M-32 genes), 5 strains
possessing bla-SHV-12, 5 with bla-TEM (blaTEM-10, blaTEM-24 and
blaTEM-52) and one with blaGES-1 gene, all encoding ESBL enzymes;
additionally, we also found 9 strains with hyperproduced penicillinases
like SHV-28, SHV-1 and TEM-1, probably responsible for false positive
ESBL phenotypes. The IEF method revealed that 11 strains possessed a
chromossomal AmpC enzyme and we also detected 2 plasmid-mediated
AmpC enzymes (DHA-1 and CMY-2). Overall, CTX-M-15 b-lactamases
were predominant and detected in multiple hospital wards, distinct
hospitals and various regions of the country.
Conclusion: In conclusion, the frequent co-production of two or more
b-lactamases, the diversity of the enzymes identiﬁed and the high level
of resistance to extended spectrum cephalosporins detected suggests real
threat and the need to take action.
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P716 Five-year trends in the prevalence and types of ESBLs and
antimicrobial susceptibility of ESBL-producing nosocomial
strains of Enterobacteriaceae in Russia
M. Sukhorukova, V. Kozyreva, N. Ivanchik, M. Edelstein, R. Kozlov °
on behalf of the ROSNET Study Group
Objectives: To determine the trends in prevalence of ESBLs of
different types and antimicrobial susceptibility of ESBL-producing
Enterobacteriaceae in Russian hospitals over the period of 2002–2007.
Materials and Methods: A total of 1,373 and 1,035 non-duplicate
nosocomial isolates of Enterobacteriaceae were collected, respectively,
from 31 and 36 hospitals of various geographic regions of Russia in
2002–2004 and 2006–2007. Antibiotic susceptibilities were determined
by agar dilution method and interpreted according to EUCAST clinical
breakpoints. All isolates were screened for ESBL-production using MIC
and disk synergy tests with cefotaxime, ceftazidime, cefepime and
clavulanate. Isolates with ESBL phenotype were tested for class A ESBL
genes using three real-time PCR assays: one for detection of CTX-M-1,
-2, -8 and -9/25 cluster enzymes, and the other two targeting ESBL
mutations in the genes for TEM (E104K, R164C/H/S, A237T, G238S,
E240K) and SHV (D179A/N/G, G238A/S, E240K) b-lactamases. ESBL
genes from 100 selected isolates were characterised by sequencing.
Results: Between 2002–2004 and 2006–2007, the prevalence of ESBLs
in nosocomial Enterobacteriaceae increased from 52.3% to 69.3%; from
81.2% to 90.0% in K. pneumoniae; and from 49.2% to 67.4% in E. coli.
The species distribution of ESBL producers remained fairly constant
with K. pneumoniae and E. coli being predominant species: 47.5%-
46.3% and 26.6%-28.6%, respectively. The changes in frequency of
ESBL groups were: 41.7% to 60.2% for CTX-M-1-cluster (mainly CTX-
M-15 and -3); 18.4% to 14.1% for SHVs (mainly SHV-12 and -2); 2.6%
to3.6% for CTX-M-9 cluster (CTX-M-14); 0.4% to 0.2% for CTX-M-2
cluster (CTX-M-5); and 0.1% to 0.1% for TEMs (TEM-29 and -143).
The resistance rates of ESBL producers in two study periods were,
correspondingly: 87.6% and 85.2% to amoxicillin–clavulanate, 40.4%
and 32.8% to piperacillin-tazabactam, 4.3% and 6.7% to ertapenem,
0.0% and 0.0% to imipenem and meropenem, 39.1% and 44.4%
to amikacin, 89.0% and 84.7% to gentamicin, 54.8% and 73.6% to
ciproﬂoxacin, 73.1% and 66.0% to co-trimoxazole.
Conclusions: To our knowledge, this study documents one of the
highest rates of ESBL production reported in national surveillance
studies that increased signiﬁcantly between 2002–2004 and 2006–2007.
The dominance of CTX-M-1 cluster ESBLs, the increase in resistance
to ciproﬂoxacin and consistency of carbapenem activity against ESBL
producers are the main trends identiﬁed in this study.
P717 Clonal spread of CTX-M producing Klebsiella pneumoniae
in a Croatian hospital
M. Vranic-Ladavac °, N. Beader, Z. Bosnjak, N. Barisic, S. Kalenic,
B. Bedenic (Pula, Zagreb, HR)
Objectives: Study was conducted to analyze the presence of extended-
spectrum b-lactamase (ESBL)-producing Klebsiella pneumoniae asso-
ciated with nosocomial outbreak at Croatian Hospital Pula. During
2007, 162 K. pneumoniae isolates with reduced susceptibility to third
generation cephalosporins were collected from hospital. Sixty of these
strains were chosen for further analysis.
Methods: Double-disk synergy test was used to detect ESBLs.
Minimum inhibitory concentrations (MICs) were determined by broth
microdilution method according to CLSI. The transferability of
ceftazidime resistance was tested by conjugation (broth mating method).
PCR was used to detect alleles encoding ESBL enzymes. The genotypes
of the strains were compared by analysis of banding patterns generated
by pulsed-ﬁeld gel electrophoresis (PFGE) of Xba I-digested genomic
DNA.
Results: ESBLs were found by DDST in all isolates. All strains
were resistant to cefuroxime, ceftazidime, cefotaxime, ceftriaxone,
aztreonam, piperacillin/tazobactam and ciproﬂoxacin. There was variable
susceptibility/resistance to cefepime and gentamicin. No resistance to
ceftazidime/clavulanate and carbapenems was observed. Only six strains
transferred resistant to E. coli recipient strain with low frequency.
Resistance to tetracycline was cotransfered to recipient strain alongside
with cefotaxime resistance from six strains and to sulphametoxazole
from four strains. Resistance to cefoxitin and ciproﬂoxacin was not
transferable.
All isolates yielded an amplicon of 545 bp with consensus MA primers.
Multiplex PCR was positive for group 1 of CTX-M b-lactamases.
Sequencing of selected amplicons revealed the presence of blaCTX-
15/28 with coding regions containing identical nucleotide sequences.
Our isolates contained ISEcpI insertion sequence located upstream of the
blaCTX-M-15 gene, which has been recently demonstrated to mobilize
3’adjacent genes to transfer between DNA replicons.
Conclusion: The results of this work provided insights into the molecular
epidemiology of the spread of ESBLs in Klebsiella pneumoniae involved
in an outbreak at Croatian Hospital. The hospital antibiotic policy
results in ceftriaxone being most heavily prescribed third generation
cephalosporin which might be expected to select for cefotaximases such
as CTX-M-15.
The spread of CTX-M producing Enterobacteriaceae in Croatia may
indicate difﬁculty in controlling this emerging resistance determinance
whatever the antibiotic policy is.
P718 Increase of extended-spectrum b-lactamase-producing
Escherichia coli in the Tyrol − a matter of clonality?
L. Bruder °, K. Grif, D. Orth, C. Lass-Flo¨rl, R. Wu¨rzner (Innsbruck, AT)
Introduction: b-lactamases represent a major defence mechanism
of Gram-negative bacteria against b-lactamase antibiotics. With the
development of b-lactamase resistant antibiotics bacteria developed
new mechanisms to overcome these new agents and responded with
the production of extended-spectrum b-lactamases (ESBLs). ESBL
producing E. coli are increasing dramatically nowadays and have become
a public health concern due to limited antibiotic options.
The aim of our study was to characterize ESBL producing E. coli in
the Tyrol by investigating clonality via two different molecular typing
methods and by determining the b-lactamase proﬁle.
Methods: One hundred twenty two ESBL producing E. coli, mostly
from urine samples (n = 97), from patients of the University hospital
Innsbruck (n = 60), district hospitals (n = 20) and practitioners (n = 41)
in the Tyrol (Austria) were collected from January to April 2009.
Molecular comparison of the ESBL producing E. coli strains was done
by repetitive PCR method (repPCR) (DiversiLab™) and Pulsed-Field
Gel-Electrophoresis (PFGE). Serotyping of representative strains was
performed according to the method of Ørskov & Ørskov. Characterisation
of b-lactamases was done by microarray analysis (Identibac®).
Results: Among 121 ESBL producing strains repPCR revealed one
main clone comprising 99 isolates, twenty-two isolates showed different
band patterns. PFGE corroborated these ﬁnding, but was even more
discriminatory and could distinguish within the main clone, consisting
of 90 of the 99 repPCR main clone isolates, between two subclones
with subclone I consisting of 37 isolates and subclone II of 53 isolates.
Serotyping of representative strains of both subclones showed, that
they all belonged to the serotype O25:H4. Data of microarray revealed
different combinations of b-lactamases in ESBL producing strains of
the main clone with TEM and CTX-M-type b-lactamases being most
prevalent.
Conclusion: ESBL producing E. coli in patients from hospitals and
outpatients in the Tyrol show clonal distribution. Thus transmission of
the same ESBL producing strain among patients might be the reason for
the dramatic increase in this region in recent time.
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P719 Variability and stability of bacteriologic and molecular traits
within Escherichia coli isolates of clone ST131
O. Boulet, L. Landraud, E. Frapy, V. Leﬂon-Guibout, E. Marcon,
X. Nassif, M. Nicolas-Chanoine ° (Clichy, Nice, Paris, FR)
Objective: E. coli phylogenetic group B2 clone ST131 producing CTX-
M-15 has been reported worldwide. However, isolates non extended-
spectrum b-lactamase (ESBL) producers have also been identiﬁed
recently. The purpose of this study was to compare different bacteriologic
and molecular traits in CTX-M-15- and non ESBL-producing isolates of
clone ST131.
Methods: Fifteen isolates [3 CTX-M-15 producers from the international
collection (IC) previously published, 7 from stools (S) of healthy subjects
and 5 from bacteremia (B)] were studied. Antibiotic susceptibility
[amoxicillin (AMX), nalidixic acid (NAL), cotrimoxazole (SXT) and
fosfomycin (FOS)] was determined by the agar diffusion method.
b-lactamase content and mutations in gyrA and parC were determined
by PCR and sequencing. Bioﬁlm production was quantiﬁed by crystal
violet assay. Virulence factor (VF) genes were identiﬁed by PCR and
the presence of 2289 sequences issued from the ﬂexible gene pool of 2
UPEC reference strains, strain RS218 and strain K2 were analyzed by
macroarray.
Results: Of the 15 isolates, 1 (S) was susceptible to AMX, 5 (3 S,
2 B) to NAL, 10 (2 IC, 6 S, 2 B) to SXT and all but one (IC) to
FOS. Five isolates (3 IC, 2 B) had CTX-M-15 with the chromosomal
cephalosporinase hyper-production in 1 case. Eight (5 S, 3 B) isolates
had TEM-1 and 1 (S) OXA-1. NAL resistance was related to GyrA
substitutions S82L-D87N alone in 3 S isolates and associated with ParC
substitutions S80I-E84V in 7 isolates (3 IC, 1 S, 3 B). Rate of bioﬁlm
production varied from 0.02 to 2.2. All isolates but one (B) had no
adhesin coded by pap genes and no hemolysin gene but all had ﬁmH and
2 siderophore related genes. Macroarray conﬁrmed the small number of
VF in all isolates (about 33% of the 204 VF sequences tested) whereas it
showed a higher proportion of the other sequences tested (more than 50%
of the structure proteins, IS/transposases, and metabolic enzymes tested).
Conclusions: Isolates of clone ST131 show variable bacteriologic traits
such as antibiotic susceptibility, b-lactamase content, bioﬁlm production.
Inversely, their genetic background evaluated on more than 2200 gene
sequences shows a certain stability. A noticeable common trait of these
isolates is the small number of VF genes in comparison with strains of
group B2 and the absence of pap and cnf1 genes in the great majority
of them.
P720 Phenotypic and genotypic analysis of a novel ESBL
phenotype (cefepimase)
F. Boyle °, D. Morris, S. Kariuki, G. Revathi, G. Healey, M. Cormican
(Galway, IE; Kenya, KE)
Objectives: We have reported a novel ESBL phenotype (cefepimase)
characterised by greater resistance to cefepime (FEP) than to cefotaxime
with signiﬁcant inhibition by clavulanic acid (CA). This phenotype
was observed in 19 isolates of S. Typhimurium − 17 from patients in
Kenya, 1 from an Irish patient and 1 from a patient from Malawi. The
isolates have b-lactamases with isoelectric points (pI’s) of 5.2 and 7.2.
BlaTEM-1, blaOXA-1 and ISCR1 were identiﬁed on an IncHI2/ IncW
multi replicon 39kb plasmid (pFEP39) present in all isolates. All isolates
harboured a c. 2kb Class 1 integron (C1I). Transfer of the phenotype by
electroporation of plasmid pFEP39 to S. Dublin was achieved.
Methods: Shot gun cloning of BamH1/ Xba1 digested 39kb plasmid
(pFEP39) into the corresponding sites of pBK-CMV was carried out
and transformed into Top10 cells selected on FEP containing agar.
Sequencing of a c. 5kb insert from recombinant plasmid (pFEP39−1dr)
was performed using T3 and T7 primers which ﬂanked the multiple
cloning site of the pBK-CMV expression vector, which was carried
out on an ABI 3730 capillary sequencer by Sequiserve, Vaterstetten,
Germany.
Results: Shotgun cloning resulted in a c. 5kb insert (pFEP39−1dr)
conferring resistance to cefepime (MIC 16mg/ml) with signiﬁcant
inhibition by CA (MIC 0.38 mg/ml) compared to a FEP MIC
of <0.25mg/ml for native Top10 cells. Sequencing results identi-
ﬁed a Pant/Pc (TGGACA17TAAGCT, −35/−10 sequence), promoter
combination directly upstream of blaOXA-1 in the c. 5kb insert,
downstream of which there was an activated P2 promoter combination
(TTGTTA17TACAGT −35/−10 sequence) due to the presence of a
‘GGG’ triplet immediately upstream of the −10 signal within the 17
nucleotide spacer region. No other b-lactamases identiﬁed in the insert.
Conclusions: OXA-1 is reported as having capacity to hydrolyse
cefepime but is not inhibitable by clavulanic acid. However the
“cefepimase” phenotype inhibited by clavulanic acid is transferred with
a plasmid construct in which blaOXA-1 (with the hybrid Pant/c/P2
promoter immediately upstream) is the only b-lactamase gene present.
This promoter combination has been shown to dramatically increase
expression of the proximal gene in the cassette.
P721 Mutational changes in different CTX-M b-lactamases able
to confer resistance to amoxicillin–clavulanate combination
A. Ripoll °, M. Rodrı´guez-Domı´nguez, A. Novais, M.C. Turrientes,
F. Baquero, R. Canto´n, J.C. Gala´n (Madrid, ES)
Objectives: The aim of this work is to test the possibility of emergence
of mutational resistance to amoxicillin–clavulanate (AMC) combination
in CTX-M b-lactamases in an in vitro evolution assay using an
Eschericha coli hypermutable strain carrying different blaCTX-M genes
and challenged by increasing AMC concentrations.
Methods: Six different blaCTX-M genes (blaCTX-M-1; -2; -3; -9;
-10; and -14) representing the three more frequent groups of CTX-M
(CTX-M-1; CTX-M-2; and CTX-M-9) were cloned in the same plasmid
vector (pBG18) and expressed in a non-mutator strain (MI1443, ampC
defective) and its isogenic strong-mutator derivative GB20 (MI1443
mutS::Tn10). GB20 carrying the different blaCTX-M genes, was
submitted to increasing concentrations of amoxicillin (1–128mg/L) and
a ﬁxed concentration of clavulanate (2mg/L) in 12 replicate cultures.
Then, cultures growing at 128/2 were exposed to growing concentrations
of clavulanate (128/2 to 128/64). Plasmid pools from 53 independent
cultures at different AMC concentrations (128/64, 128/8 and 64/2mg/l)
were extracted, transformed into MI1443 using as selector agent 2x the
original MIC to AMC. Finally 158 clones were selected, retransformed
and sequenced. MIC for AMC, ampicillin, cefuroxime, cefotaxime,
ceftazidime, cefepime and imipenem were determined for each wild-
type b-lactamase and their derivative mutants according CLSI guideline.
Results: Three types of AMC-resistant mutants were obtained: i) at
128/64mg/L a single S130G change was only found in CTX-M-1; ii) at
128/8mg/L S130G and K234R changes were detected as single changes
in CTX-M-1 and CTX-M-9 groups; iii) at 64/2mg/L three independent
mutants were detected, containing S130G and S237G in CTX-M-1 group
or S130G and K234R in CTX-M-9 group. For each CTX-M group, two
independent mutants were obtained, except in CTX-M-2, that not yielded
any AMC-resistant mutant in this assay. S130G mutation increased 8−32
times the MIC to AMC and was detected in 88% of all AMC-resistant
mutants. This mutation drastically decreased cephalosporin resistance.
K234R and S237G mutations conferred increased to 4x MIC to AMC,
although S237G change not affect to activity against cephalosporins.
Conclusion: Reduced susceptibility to AMC is shown to be caused by
S130G, S237G, and K234R mutations in CTX-M b-lactamases. CTX-
M-1 group might be prone to produce AMC-resistant variants than other
groups.
P722 Characterization of the new inhibitor-resistant SHV-107
b-lactamase in a clinical isolate of Klebsiella pneumoniae
V. Manageiro °, L. Albuquerque, M. Canic¸a (Lisbon, Coimbra, PT)
Objectives: b-lactamase inhibition is used as clinically strategy to ﬁght
the problem of b-lactam resistance. However, more than 30 inhibitor
resistant (IR) b-lactamases from TEM and SHV families have been
detected so far. In this study we performed a phenotypic, molecular,
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and biochemical characterization of the IR SHV-107 carrying the amino
acid substitution Thr235Ala.
Methods: K. pneumoniae INSRA6884 was isolated from sputum of a
92 years old female in an internal medicine service of a Portuguese
hospital, in 2006. Antimicrobial susceptibility was determined by
an agar dilution method. b-lactamase encoding genes were screened
by PCR and identiﬁed, using speciﬁc primers. Transformant E. coli
BL21 (DE3) harbouring the recombinant SHV-encoding plasmid was
obtained by electroporation. SHV-107 was extracted and puriﬁed by ion
exchange and gel ﬁltration. The kinetic constants were obtained by a
computerized microacidimetric method. Isoelectric point was estimated
by isoelectrofocusing.
Results: The clinical K. pneumoniae strain exhibited non-susceptibility
to all penicillins tested (MICs of 64 to >2048 ug/ml). The MICs of
penicillins were weakly reduced by clavulanic acid (from 2048 to 512
ug/ml), while tazobactam totally restored the piperacillin susceptibility.
Molecular characterisation identiﬁed a blaGES-7 gene, and the new
blaSHV-107, which sequence presented, according to Ambler numbering,
the amino acid substitutions L35Q and T235A, in relation with
SHV-1. The E. coli BL21 (pBK-SHV-107) transformant, producing a
b-lactamase with a pI of 7.6, exhibited a b-lactam resistance phenotype
similar to that of the clinical strain with respect to penicillins and
amoxicillin/clavulanic acid combination. The kinetic parameters of
the puriﬁed SHV-107 enzyme revealed strong afﬁnity to penicillins.
However, catalytic efﬁciency for these antibiotics was lower for SHV-107
than for SHV-1. No hydrolysis was detected against extended-spectrum
cephalosporins. The IC50 for SHV-107 was 1.53 uM for clavulanic acid,
9-fold higher than for SHV-1 (0.17 uM).
Conclusion: In this study we characterized a clinical K. pneumoniae
strain co-expressing two b-lactamases: ESBL GES-7 and the new IR
SHV-107. As evaluated by the kinetic data of SHV-107 b-lactamase,
T235A mutation in SHV enzymes not only is responsible for the loss
of the cephalosporinase activity, but is also important to the interaction
with the b-lactamase inhibitors.
P723 PER-6, an expanded-spectrum b-lactamase from Aeromonas
allosaccharophila
L. Poirel °, D. Girlich, P. Nordmann (Le Kremlin Bicetre, FR)
Objectives: Screening for potential expanded-spectrum b-lactamase
(ESBL)-producing bacteria in aquatic environments.
Methods: Water samples (n = 3) were recovered in January 2009 from
the Seine river, Paris, France, ﬁltrated, resuspended in sterile water and
then plated onto MacConkey agar plates containing ceftazidime (2 mg/
ml). Isolates were identiﬁed by the API 32GN system and by sequencing
the 16S rDNA genes. Cloning was performed by partial digestion of
total DNA, followed by ligation into plasmid pBKCMV and expression
into E. coli DH10B. Biochemical characterization was performed by UV
spectrophotometry.
Results: Aeromonas allosaccharophila isolate AL-1, resistant to broad-
spectrum cephalosporins but susceptible to cefoxitin and moxalactam,
was recovered. A typical synergy image between discs containing
clavulanic acid and ceftazidime suggested the production of an
ESBL. Cloning and sequencing identiﬁed blaPER-6 encoding a novel
ESBL, that was chromosomally-located. No integron nor transposon
was identiﬁed in the close vicinity of the blaPER-6 gene. PER-6
possessed 86% and 92% amino acid identity with PER-1 and PER-2,
respectively, known to be widespread among clinically-relevant Gram
negative isolates (P. aeruginosa, A. baumannii...). PER-6 possessed
hydrolytic properties of an ESBL, together with the ability to hydrolyse
carbapenems (imipenem, meropenem, and ertapenem) slightly, whereas
PER-1 and PER-2 did not. The identiﬁcation downstream of both
blaPER-6 and blaPER-1 genes of similar glutathion S-transferase
encoding genes suggests a common ancestor origin for these two ESBL
genes.
Conclusion: This study emphasises the spread of PER-type ESBLs in
Aeromonas species. In addition, it indicates that a PER-type b-lactamase,
through some speciﬁc amino acid substitutions, may possess a weak
ability to hydrolyse carbapenems. Finally, the recent identiﬁcation of
PER-1 in Aeromonas media from a Swiss alpine lake together with that
of PER-6 in A. allosaccharophila from the Seine river here underlines
the spread of these PER-type determinants in the environment on the
European continent, with a reservoir being likely a waterborne bacterial
species.
P724 Detection of ESBL presence in carbapenem-resistant
K. pneumoniae strains in the clinical laboratory
H. Moraitou °, I. Galani, M. Makarona, A. Mavrommati, P. Tsarpali,
P. Grillas, N. Souﬂa, A. Georgousi, V. Spyropoulos, S. Kanavaki
(Athens, GR)
Objectives: The aim of this study was to evaluate phenotypical
methods of detection of ESBL presence in carbapenemase-producing
K. pneumoniae isolates.
Materials and Methods: A total of 27 multidrug resistant K. pneu-
moniae strains were collected from January to September 2009, from
various units of our Hospital. All isolates had a resistance phenotype
compatible with carbapenemase production. Susceptibility testing was
performed by Kirby Bauer, E-test and Vitek2 automated system, accord-
ing to CLSI guidelines. All strains were further tested phenotypically
for the production of metallo-b lactamase by imipenem/EDTA test
and KPC by boronic acid/imipenem disc test. ESBL production was
tested both by DDST (ceftazidime-CAZ, cefotaxime-CTX, aztreonam-
ATM, ceftriaxone-CRO at 20mm distance from a disk containing
amoxicillin/clavulanate) and CLSI ESBL conﬁrmatory test using both
clavulanic acid (CA) and boronic acid (BA). The latter was performed
by placing disks containing CAZ with or without CA, with the addition
of a ﬁnal amount of 400 micrograms BA on each disk. The test was
considered positive when an increase in inhibitory zone around CAZ/CA
disk was 5mm or greater than CAZ alone. All strains were subjected to
PCR for the detection of blaVIM, blaKPC and SHV-type genes.
Results: Molecular methods proved that 3/27 strains (11.1%) harbored
blaVIM, 24/27 blaKPC (88.9%). SHV-type ESBLs were detected in all
isolates.
DDST was positive in all 3 VIM(+) strains (speciﬁcity and sensitivity
100%), and in 6/24 (25.0%) of KPC(+) strains. The CLSI ESBL
conﬁrmatory test with CA and BA was negative in VIM(+) strains and
positive in 23/24 KPC(+) strains (95.8%). As all K. pneumoniae harbored
ESBLs, no false positive results were detected by phenotypic methods.
Conclusions: Phenotypical methods of detection of resistance mech-
anisms are of great importance in a routine clinical microbiology
laboratory, where no molecular conﬁrmation methods are any time
available. Our results show that in the case of multidrug resistant
K. pneumoniae isolates, both DDST and the CLSI ESBL conﬁrmatory
test with CA and BA can safely detect ESBL production. These tests are
both included in our routine methodology, together with imipenem/EDTA
test and imipenem/BA test, in order to rapidly identify resistance
mechanisms and evaluate epidemiology of resistance in our Hospital.
P725 Molecular detection of SHV and AmpC (CITM, FOX)-type
b-lactamase in clinical isolates of Escherichia coli
A. Sabbaghi °, J. Fallah Mehrabadi, H. Molla agha Mirzaei, F. Fard
Saneei, M.M. Soltan Dallal (Zanjan, Tehran, IR)
Objective: Co-production of extended spectrum b-lactamase (ESBLs)
and AmpC enzymes has been detected as one of the most important
mechanism of resistance to b-lactam antibiotics among some pathogens
especially E. coli. In recent years, the prevalence of b-lactamase producer
organisms is increased and it led to a problem for diagnosis via Disk
diffusion method. On the other hand, SHV, CITM and FOX genes have
several subfamilies, and designing universal primers could be valuable
to detect all of them. Therefore, the aim of this study was to detection of
SHV and AmpC (CITM, FOX)-type b-lactamase genes by using speciﬁc
primers through PCR.
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Materials and Methods: More than 500 clinical samples were collected
from hospitals of Tehran and 265 E. coli isolates were detected by
standard biochemical tests such as IMVIC. Subsequently, these isolates
were screened for b-lactamase production by Disk diffusion method and
conﬁrmatory test (Combined Disk). Resistant isolates was evaluated for
molecular assessing with PCR.
Results: In Disk Agar Diffusion test, 128 (64%) E. coli isolates which
resistant to ceftazidime and cefotaxim were selected and followed by
Combined Disk (ceftazidime, cefotaxim and clavulanic acid) assay.
In Combined Disk, among 128 screened isolates, 115(89.8%) and 13
(10.2%) isolates were as ESBLs and AmpC producers, respectively. PCR
was performed on all 128 resistant isolates and results were showed
among 115 and 13 isolates, 7 (6.1%) and 13 (100%) to have bla SHV
and bla CITM, respectively. Fox Gene was not detected in any samples.
Conclusion: According to the recommendation of the Clinical and
Laboratory Standards Institute (CLSI), isolates which showed negative
conﬁrmatory test are potentially producer of AmpC. This survey
improved CLSI recommendation because among 13 AmpC producer
isolates, the result of CITM PCR was 100% positive. SHV gene was
detected in just 6.1% of isolates and others b-lactamase genes may be
have a role in b-lactam antibiotics along with other isolates.
AmpC b-lactamases and carbapenemases in
Enterobacteriaceae
P726 Inhibitor-based methods using boronic acid compounds for
detection of AmpC b-lactamases and extended-spectrum
b-lactamases-producing Escherichia coli and Klebsiella spp.
N. Yilmaz °, N. Agus, E. Bozcal, O. Oner, A. Uzel (Izmir, TR)
Objectives: The increasing prevalence of extended-spectrum b-lactam-
ase (ESBL) and plasmid-mediated AmpC (pAmpC) enzyme is of clinical
concern. Methods for the identiﬁcation of strains that produce ESBL
have been developed and applied for routine use, but no practical
methods for identiﬁcation of pAmpC b-lactamases producers have been
established to date. It has been stated that the AmpC b-lactamases when
present along with ESBL can mask the phenotype of the latter. We
evaluated highly sensitive methods using boronic acid (BA), an AmpC
enzyme inhibitor, to detect ESBL and p-AmpC production
Material and Methods: A total of 273 clinical isolates of
Klebsiella spp. (n: 82) and Escherichia coli (n:191) were analyzed.
Antibiotic susceptibility testing was performed by the Kirby-Bauer
method according to CLSI protocols. An organism demonstrating a zone
diameter around the cefoxitin (FOX), and/or ceftazidime (CAZ), and/or
cefotaxime (CTX) disk containing with BA 5mm than containing
alone these disks were considered an AmpC producer (BA test). The
CLSI conﬁrmatory method using CAZ and CTX disks with and without
clavulanic acid (CLA) was also carried out. Similar to the CLSI
conﬁrmatory test, an organism exhibiting 5mm zone size increase
around the CAZ-CLA or CTX-CLA disk combination with BA compared
to the CAZ or CTX disk alone was considered positive for ESBL
production (CLSI conﬁrmatory test with BA).
Results: A total of 102 isolates harbored only ESBLs, 112 harbored both
ESBLs and pAmpC, and 17 harbored only pAmpC enzyme. Sixty-six
of the 127 FOX resistant clinical isolates yielded positive AmpC by BA
test. The majority of AmpC isolates co-produced (84%) ESBL enzyme.
The CLSI conﬁrmatory test detected 215 (78%) ESBL-positive isolates.
In the test with both CLA and BA detected 228 ESBL-positive (83%)
isolates. In this test population 11 (65%), 10 (59%), and 12 (70%) AmpC
producing clinical isolates were susceptible by routine testing to CAZ,
CTX and cefepime, respectively.
Conclusion: The exact detection of ESBLs and pAmpC in isolates
is important for both treatment and epidemiology. The BA disk test
accurately detects the isolates that harbor both AmpCs and ESBLs.
In particular, the method allowed detection of an ESBL even when
potentially masked by a pAmpC.
P727 Prevalence and molecular characterization of plasmid-
mediated AmpC b-lactamases among clinical isolates of Es-
cherichia coli and Klebsiella spp. in Rhone-Alpes area, France
Z. Driche, H. Salord, A. Carricajo, M. Perouse de Montclos, O. Raulin,
C. Roure-Sobas, F. Laurent, S. Tigaud ° (Lyon, Saint Etienne, FR)
Objectives: The aim of this study was i) to investigate the prevalence of
plasmid-mediated AmpC b-lactamase in E. coli and Klebsiella spp from
ﬁve different hospitals in Rhone-Alpes area, France, ii) to determine
which types of plasmid-mediated AmpC-b-lactamases were harbored.
Methods: Between January 1st and May 31, 2009, a total of 3460
consecutive clinical isolates of E. coli and Klebsiella spp were screened
for resistance to cefoxitin (I or R) by phenotypic methods. A method
using a double diffusion test on cloxacillin plates was used to screen
isolates possibly harbouring the plasmid-mediated AmpC b-lactamase.
The plasmid-mediated resistance determinants in these isolates were
screened by multiplex PCR (CMY, DHA, MOX, EBC, FOX, ACC).
When positive, sequencing was performed to accurately identify the
genes.
Results: A total of 205 E. coli and 54 Klebsiella spp cefoxitin-R or
I isolates were initially included. Seventy-eight isolates were selected
by the cloxacillin methods and in 26 of those isolates (E. coli,
n = 22; Klebsiella spp, n = 4) a plasmid-mediated AmpC b-lactamase was
detected by PCR (9.6%). In E. coli (n = 22), we detected 20 CMY-2
or CMY-2 like AmpC b-lactamase, one ACT-6 and one DHA-1. In
Klebsiella spp (n = 4), we detected were detected two DHA-1, one ACT-6
and one ACT-1.
Conclusion: Our study demonstrated the occurrence (0.75% prevalence)
of plasmid-mediated AmpC b-lactamases in E. coli and Klebsiella spp in
Rhoˆne Alpes area. The CMY-2 AmpC b-lactamase types in E. coli are
the most prevalent and this may be the ﬁrst evidence of a dissemination
of this threatening mechanism. On the contrary, Klebsiella genus seemed
to be more rare but more diverse. Hence, continuous surveillance of the
prevalence and evolution of emerging AmpC b-lactamase is of major
concern.
P728 Multilocus sequence typing of DHA-1-producing Klebsiella
pneumoniae isolates in a Spanish hospital
K. Diestra °, E. Miro´, C. Martı´, D. Navarro, J. Cuquet, P. Coll,
F. Navarro (Barcelona, ES)
Objective: Klebsiella pneumoniae is an important opportunistic
pathogen with the ability to spread rapidly and cause nosocomial
outbreaks. The objective of this study was to investigate the molecular
epidemiology of K. pneumoniae isolates with plasmid mediated AmpC
type cephalosporinase that were isolated in a Spanish hospital.
Methods: A total of 26 K. pneumoniae isolates with induced resistance
to extended spectrum cephalosporinase were cultured from patients
hospitalized in the Granollers Hospital (Barcelona, Spain), between June
2007 and January 2008. bla genes were characterized by multiplex PCR
and sequencing. Isolates were typed by pulsed-ﬁeld gel electrophoresis
(PFGE) and multilocus sequence typing (MLST) according to the Institut
Pasteur scheme for K. pneumoniae. Only one isolate of each PFGE
pattern was selected for MLST.
Results: PCR and sequencing studies revealed that the bla gene encoding
the DHA-1 AmpC-like b-lactamase was present in all 26 isolates. Three
of them had also the blaCTX-M-15 ESBL gene. The 26 isolates were
classiﬁed into 11 PFGE patterns and ﬁve clusters: one cluster with seven
isolates (A), one with four isolates (B) and three clusters with three
strains (C, E and J).
By MLST the clusters A, B, and C were classiﬁed to sequence type
ST17, cluster J (carrying both blaCTX-M-15 and blaDHA-1 genes) to
ST326 and cluster E to a novel ST. Others PFGE patterns corresponded
to ST13, ST37 and four others new STs (numbers pending from Institut
Pasteur MLST Database).
ST326 carrying a CTX-M-15 ESBL alone was previously found in two
different hospitals from Barcelona.
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Conclusion: This study reports the ﬁrst detection and characterization of
ST for K. pneumoniae carrying blaDHA-1 gene in Spain. K. pneumoniae
ST326 seems to have acquired blaDHA-1, blaCTX-M-15 or both genes
in a limited period of time and geographical area.
P729 Plasmids carrying AmpC b-lactamases in Enterobacteriaceae
lacking inducible chromosomal ampC genes: ﬁndings from
a Spanish hospital, 1999–2007
C. Mata °, E. Miro´, B. Mirelis, P. Coll, F. Navarro (Barcelona, ES)
Objective: This study aimed to determine the plasmid families involved
in the dissemination of ampC genes.
Methods: In a study conducted at a Spanish hospital from 1999 to 2007
we found a total of 117 Enterobacteriaceae with acquired ampC genes
among 27,119 isolates lacking inducible chromosomal ampC genes.
Plasmid analysis was carried out in the transconjugants, when possible,
or in the donors’ strains by PCR-based replicon typing, S1-PFGE
analysis and Southern hybridization. Plasmid sizes were calculated by
using Fingerprinting II Informatix™ software.
Results: Among the 117 isolates studied, 97 transconjugants were
obtained (83%). Southern hybridization analysis was only possible in
94 strains, and in 8 strains a chromosomal location was suggested.
The remaining 15 were unresolved, 3 of them being lysed. The 94
solved strains showed that ampC genes were located on large plasmids
of different sizes. The predominant plasmids present in the 78 strains
harbouring CMY-2 or CMY-2 plus an ESBL belonged to: A/C (33.3%:
plasmid sizes ranged from 150 to 170kb in 66.7% of cases), I1 (20.5%:
sizes from 82 to 100kb in 81.2%) and K/B (10.3%: from 81 to 86kb
in 81.2%). bla(CMY-2) gene was also found in multireplicon plasmids
(12.8%) and in one case in an IncF group (1.3%). However, all but one of
the plasmids associated with DHA-1 or DHA-1 plus ESBL belonged to
the L/M group. In most cases, L/M was the only replicon present (63.3%:
with plasmids ranging in size from 70 to 80kb in 55.5% of cases) or
forming multireplicon plasmids (20%). Genes codifying ACC-1, CMY-4
and CMY-27 were harboured by I1, IncF group or non-typeable plasmids
while a chromosomal location was suggested in CMY-25 and CMY-40
(Table 1).
Table 1. Plasmid families associated with ampC genes in Enterobacte-
riaceae lacking inducible chromosomal ampC genes:
Enzymes (No.) Repliconsa Species (No.)
CMY-2 / CMY-2+ESBL (78) A/C E. coli (15), K. pneumoniae (2), P. mirabilis (8), S. enterica (1)
I1 E. coli (13), P. mirabilis (2), S. enterica (1)
K/B E. coli (7), P. mirabilis (1)
I1-K/B E. coli (3)
I1-F E. coli (3)
A/C-F E. coli (3)
A/C-I1 E. coli (1)
F E. coli (1)
CL P. mirabilis (4)
NS E. coli (4), K. pneumoniae (1), P. mirabilis (6)
L E. coli (2)
DHA-1 / DHA-1+ESBL (30) L/M K. pneumoniae (8), E. coli (7), K. oxytoca (3), P. mirabilis (1)
L/M-F E. coli (2), K. pneumoniae (1), K. oxytoca (1)
N E. coli (1)
L/M-N P. mirabilis (1)
L/M-NT K. pneumoniae (1)
NS E. coli (2)
CL E. coli (1)
L E. coli (1)
ACC-1 (3) I1 E. coli (1)
NT E. coli (1), K. pneumoniae (1)
CMY-4 (2) F E. coli (1)
NT E. coli (1)
CMY-27 (2) F E. coli (1)
NT E. coli (1)
CMY-25 and CMY-40 (2) CL K. pneumoniae (1), E. coli (1)
aF: includes one or more rep of the IncF group; CL: possible chromosomal location; NS: not solved; L: lysed;
NT: not typeable by the PCR-based replicon typing described by Carattoli et al.
Conclusions: Genes were mobilized by conjugation in 83% of strains
with acquired ampC genes. The results showed a relationship between
each ampC gene and the plasmid involved. Plasmids belonging to
the A/C, I1 and K/B incompatibility group were the most prevalent
plasmids carrying the bla(CMY-2) gene, while plasmids of the L/M
incompatibility group were associated to the bla(DHA-1) gene. In
addition, ampC genes were located on large plasmids of different sizes,
the incompatibility group A/C being the most heterogeneous group. The
present study corroborates that vectors involved in the mobilization of
ampC genes have a great ability to spread between species.
P730 Plasmid-mediated AmpC b-lactamases in Enterobacteriaceae
lacking inducible chromosomal ampC genes: prevalences at
a university hospital, Basel, Switzerland 2006–2009
H. Adler °, D. Hohler, E. Schultheiss, R. Frei (Basel, CH)
Objectives: Enterobacteriaceae producing plasmid-mediated AmpC
b-lactamases have emerged worldwide. However, European data on
prevalence and development over years are still rare. The aim of the
study was to determine the prevalence of plasmid-mediated AmpC
b-lactamases in clinical isolates of Enterobacteriaceae naturally lacking
an inducible chromosomal ampC gene (i.e. Klebsiella spp., Proteus
mirabilis, Salmonella enterica, Shigella spp. and E. coli).
Methods: Between January 2006 and August 31, 2009 a total of
10,777 consecutive, non repetitive clinical isolates of Enterobacteriaceae
were screened for ESBLs. Using CLSI procedures, at least 3 of the
following substances were tested: ceftazidime, cefpodoxime, aztreonam,
ceftriaxone or cefotaxime. In a second step, organisms naturally lacking
an inducible chromosomal ampC gene that were positive in the initial
screen assay were tested for resistance to cefoxitin. Cefoxitin resistant
isolates were considered suspicious for possessing a plasmid-mediated
AmpC b-lactamase. They were subsequently tested by ampC multiplex
PCR (Perez-Perez and Hanson, 2002, J Clin Microbiol 40:2153−62) and
the amplicons were sequenced.
Results: In the years 2006, 2007, 2008 and in the ﬁrst 8 months of
2009, prevalences of plasmid-mediated AmpC b-lactamases were 0.17%,
0.18%, 0.24% and 0.23%, respectively. Results are shown in table 1.
Molecular types were as follows: 4 CMY-2 in 2006, 4 CMY-2 and 1
DHA-1 in 2007, 4 CMY-2 and 3 DHA-1 in 2008, 3 CMY-2, 2 DHA-1
and one ACC-1 in 2009.
Conclusion: The prevalence of plasmid-mediated AmpC b-lactamases
in Enterobacteriaceae lacking an inducible chromosomal ampC gene has
remained very low. However, between 2006 and 2009 the diversity of
molecular types increased.
Table 1: Prevalence of plasmid-mediated AmpC b-lactamases in
Enterobacteriaceae lacking inducible chromosomal ampC genes
Organism Organisms with plasmid-mediated AmpC/Organisms without plasmid-mediated AmpC (%)
2006 2007 2008 2009* 2006–2009*
Escherichia coli 4/1776 (0.23) 4/2124 (0.19) 5/2202 (0.23) 3/1977 (0.15) 16/8079 (0.20)
Proteus mirabilis 0/115 (0) 0/132 (0) 0/142 (0) 1/148 (0.68) 1/537 (0.19)
Klebsiella spp. 0/484 (0) 1/561 (0.18) 2/562 (0.36) 2/514 (0.39) 5/2121 (0.24)
Salmonella 0/7 (0) 0/6 (0) 0/10 (0) 0/3 (0) 0/26 (0)
Shigella spp. 0/1 (0) 0/2 (0) 0/7 (0) 0/4 (0) 0/14 (0)
All 4/2383 (0.17) 5/2825 (0.18) 7/2923 (0.24) 6/2646 (0.23) 22/10,777 (0.2)
*January 1 to August 31, 2009.
P731 The sequence type ST131 covers half of the ESBL-producing
Escherichia coli strains in Southwest Finland
J. Jalava °, K. Vuorenoja, H. Marttila, A. Hakanen, O. Meurman,
K. Rantakokko-Jalava (Turku, FI)
Objectives: Extended-spectrum b-lactamase (ESBL)-producing Es-
cherichia coli strains are increasing rapidly in Southwest Finland. The
purpose of this work was to study the role of internationally recognized
ESBL-producing clones, like E. coli ST131, in the emergence of ESBL-
positive strains.
Methods: Altogether 58 ESBL-producing E. coli strains isolated
between the years 2004 and 2008 were typed with repetitive sequence-
based PCR assay (rep-PCR) using DiversiLab system. A portion of the
strains analysed with the rep-PCR were further analysed with MLST
in order to identify the sequence type of rep-PCR clusters. The most
important ESBL genes (CTX-M, TEM and SHV) were detected by PCR.
Results: In this study a cluster was deﬁned as strains that showed more
than 96% similarity in rep-PCR. Altogether 24 rep-PCR clusters were
identiﬁed. The biggest rep-PCR cluster included 28 (48%) strains and the
relative proportion of this cluster increased during the study period. Eight
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strains belonging to this rep-PCR cluster were typed with MLST and they
all were of sequence type 131. Twenty-four (86%), three (11%) and one
(3%) of these strains had CTX-M-1-type, CTX-M-9-type and SHV-type
ESBL gene, respectively. Each of the other rep-PCR clusters covered
only 2 to 5% of all isolates. Thus far MLST has been performed for
eight strains belonging to seven different minor REP-PCR clusters and
seven different sequence types have been identiﬁed. Among these CTX-
M-1, CTX-M-9, CTX-M-2, and SHV-type ESBL genes were detected in
13 (43%), 10 (33%), 1 (3%) and 6 (20%) strains, respectively.
Conclusions: When studied with rep-PCR and MLST, ESBL-producing
E. coli strains in Southwest Finland showed polyclonal origin. However,
also a single rep-PCR cluster covering almost half of the strains was
identiﬁed. This large rep-PCR cluster equals to E. coli sequence type
ST131, which is known to be widely spread. A great majority of these
strains had CTX-M-1-type ESBL-genes, and although CTX-M-9-type
and SHV-type genes were also detected, the distribution of ESBL genes
differed in this main clone compared to minor clones. Our data indicates
that the spread of ESBL-carrying clone ST131 plays a major role in
the emergence of ESBL-positive strains in Southwest Finland. Further
studies on the prevalence of ST131 strains among ESBL-negative isolates
of clinical origin are also needed to conﬁrm this ﬁnding.
P732 Prevalence study of b-lactamase genes TEM-1, SHV-1
and CTX-M in strains of extended-spectrum b-lactamases
producing Enterobacteriaceae by multiplex PCR
M. Moosavian °, B. Deiham (Ahvaz, IR)
Objective: Study of antimicrobial resistance patterns of Enterobacte-
riaceae isolated from clinical samples to seven of different antibiotics
during a 14 month period and also survey of Extended Spectrum
b-Lactamases (ESBLs) phenotype production and TEM, SHV and
CTX-M genes by Multiplex PCR method.
Methods: In this study 420 Enterobacteriaceae strains isolated from
8000 clinical specimens (except stool) were examined. The isolates
were identiﬁed by biochemical tests and then primary antimicrobial
susceptibility test was performed by Kirby-Bauer disk diffusion method.
Seven antibiotic disks used in this test, such as Cefotaxime, Ceftriaxone,
Ceftazidim, Cefepim, Cefepirom, Imipenem and Meropenem. ESBLs
producing strains detected by phenotypic conﬁrmatory test using single
or combined Ceftazidim/ Cefotaxime − Clavulanic acid disks. Then
DNA extraction was done by DNP kit procedure and ﬁnally presence of
blaTEM, blaSHV and bla CTX_M genes were evaluated by Multiplex
PCR Method.
Results: We identiﬁed 420 bacterial strains of Enterobacteriaceae which
were isolated from clinical specimens, such as blood, wound and
eye samples. Escherichia coli (E. coli) and Klebsiella pneumoniae
(Kl. Pneumoniae) were the most common isolates with frequency of
64.5 and 20 percent, respectively. Drug resistance patterns of these
strains showed that resistance to Cefotaxime, Ceftriaxone, Ceftazidim,
Cefepim, Cefepirom were 44, 44, 42, 39.5 and 39 percent, respectively.
Conﬁrmatory test showed 128 strains (30.5%) produced ESBLs,
including Klebsiella 45.4 and E. coli 28.8 percent. Multiplex PCR of
the genes among positive ESBLs bacteria (73 strains) showed TEM
gene in 65.5% and SHV in 15% strains. Also, 14 isolates (19%) had
both TEM & SHV b-lactamase genes, but CTX-M was not detected in
isolated bacteria.
Conclusion: Results from our study showed that the prevalence of
ESBLs, b-lactamase genes and antibiotic resistance patterns were
noticeable among of Enterobacteriaceae isolates, especially E. coli and
Kl. pneumoniae. So, we suggest that combined therapeutic regimens such
as b-lactamase antibiotics and b-lactamase inhibitors or carbapenems be
limited only to patients with serious infections and be designed based
on the antibacterial susceptibility test.
P733 Identiﬁcation of a blaCTX-M-15 duplication in a nosocomial
Escherichia coli isolate from Germany
A. Cullik °, W. Witte (Wernigerode, DE)
Objectives: The CTX-M type enzymes are the most prevalent group
of extended spectrum b-lactamases (ESBL) in Enterobacteriaceae.
Especially blaCTX-M-15 and blaCTX-M-1 are spread worldwide which
is due to horizontal transfer of the blaCTX-M genes by different
plasmids. During distribution analysis of nosocomial ESBL-producing
E. coli an isolate carrying two blaCTX-M-15 copies was found.
Methods: The plasmids of E. coli transconjugants obtained after
conjugation on cefotaxime/sodium azide selection agar were checked by
PCR sequencing of blaCTX-M genes and replicon typing. To investigate
the closer blaCTX-M environment gene walking and Sanger sequencing
of cloned PCR products were performed.
Results: The E. coli isolate 390/06 harboured blaCTX-M-15 on a
plasmid of IncI1 group. Upstream of a blaCTX-M-15 gene an ISEcp1
remnant, disrupted by an intact IS26 was identiﬁed. A second blaCTX-
M-15 copy was directly attached upstream of the IS26 element.
Conclusions: A tandem conﬁguration of blaCTX-M-15 has not been
reported so far. These two blaCTX-M-15 copies seem to lead to increased
resistance rates and can easily be distributed by conjugation. Both are
important criteria for the successful spread and stable inheritance of the
blaCTX-M-15 gene in a population under selective antibiotic pressure.
P734 Identiﬁcation of CMY-4 AmpC b-lactamase-producing
Proteus mirabilis clinical strains in Bulgaria
S. Sabtcheva °, T. Saga, T. Kantardjiev, M. Kaku (Soﬁa, BG; Sendai, JP)
Objective: To characterize bla genes responsible for acquired AmpC-
type b-lactamase resistance of Proteus mirabilis clinical isolates
recovered in Bulgaria.
Methods: Four epidemiologically unrelated Proteus mirabilis strains,
resistant to cephalosporins, cephamycins and b-lactam/b-lactamase
inhibitor combinations, were isolated from urine specimens at a
Bulgarian cancer hospital between 2000 and 2005. The disk potentiation
test using a Kirby-Bauer cefotaxime disk in combination with
3-aminophenylboronic acid was performed to conﬁrm the production of
AmpC-type enzymes. Multiplex polymerase chain reaction (PCR) using
six sets of ampC-speciﬁc primers (MOXMF/R, CITMF/R, DHAMF/R,
ACCMF/R, EBCMF/R, FOXMF/R) followed by sequence analysis of
PCR amplicons were used to identify ampC genes. Genotyping, by
pulsed-ﬁeld gel electrophoresis (PFGE) of genomic DNA digested with
SﬁI was performed to determine genetic relatedness of isolates. The
transferability of cefoxitin resistance was examined by conjugation. The
genetic basis of AmpC determinants was study by using the endonuclease
I-CeuI technique.
Results: CMY-4 AmpC-type b-lactamase was identiﬁed in all isolates.
Genotyping showed that one of the isolates was genetically different,
while the remaining three isolates were clonally related. The blaCMY-4
gene was not transferable to Escherichia coli by conjugation. In all
isolates it was chromosomally located and associated with an ISEcp1-
like element.
Conclusion: This is the ﬁrst report of CMY-4-producing Enterobacteri-
aceae in Bulgaria and the ﬁrst characterization of an acquired AmpC-type
b-lactamase in Bulgarian isolates.
P735 Diversity of plasmid-mediated AmpC b-lactamases among
clinical isolates of Enterobacteriaceae lacking inducible
chromosomal ampC gene from Portuguese hospitals
V. Manageiro °, D. Jones-Dias, G.A. Domingues, E. Ferreira, D. Louro,
M. Canic¸a for the Antimicrobial Resistance Surveillance Program
in Portugal (ARSIP)
Objectives: In Portugal, little is known on plasmid-mediated AmpC
b-lactamases. Hence, we purpose with this study to investigate plasmid-
AmpC b-lactamases and carbapenemases in Enterobacteriaceae S185
mediated AmpC b-lactamases (PMAB) in clinical Enterobacteriaceae
isolates lacking inducible chromosomal ampC genes in Portugal.
Methods: A total of 2576 clinical isolates of various species of
Enterobacteriaceae lacking inducible chromosomal ampC genes were
collected between January–June 1999 and March 2004–August 2009
from patients in Portuguese hospitals. Screening of antimicrobial
susceptibility of clinical isolates was performed by disc diffusion
method. Clinical isolates with resistance or with decreased susceptibility
to cefoxitin (inhibition zone diameter <18mm), showing synergism
between boronic acid and clavulanic acid and/or between cloxacillin and
ceftazidime (and/or cefoxitin) were considered presumptively PMAB.
The presence of acquired ampC genes was conﬁrmed by multiplex PCR.
Positive results were sequenciated. Transconjugants were achieved by
conjugation experiments.
Results: Among the 2576 isolates tested, 6.4% (109 E. coli, 43
K. pneumoniae, 11 K. oxytoca, 2 P. mirabilis and 1 Pantoea agglomerans)
were assumed to be PMAB and were selected for further analysis.
Seventy-six of the 166 positive isolates (45.8%) were conﬁrmed to be
PMAB-producers by multiplex PCR (52 blaDHA-, 24 blaCMY-2-, 5
blaMIR-, 1 blaACT- and 1 blaFOX-type genes). From that, 5 E. coli
strains and 1 P. mirabilis co-produced more than one PMAB. The
sequence of one CMY-type b-lactamase encoding gene differed from
blaCMY-2 by nine mutations, leading to the A49T, R105S, R125T,
H153R, T143A, Q213K, P208A, A236V and H262R amino acid
substitutions. This new PMAB was designated CMY-46.
Conclusion: AmpC b-lactamases are a major group of enzymes of
clinical importance (along with Class A b-lactamases). This study
documents for the ﬁrst time the occurrence and dissemination of these
enzymes in Portuguese hospitals. As noticed in other countries, PMAB
was described mostly in K. pneumoniae and E. coli isolates, with DHA-1
b-lactamase predominant, followed by CMY-2. Our work suggests that
reduced susceptibility to cefoxitin in the Enterobacteriaceae may be
an indicator of AmpC activity, but it should be conﬁrmed by other
tests, namely multiplex PCR. Infection with AmpC producing bacteria
is of great concern, and detection of such enzymes is consequently of
epidemiological importance.
P736 Emergence of KPC-producing Klebsiella pneumoniae in
Germany
Y. Pfeifer °, C. Wendt, R. Schiller, M. Ho¨ck, R. Podschun,
T.A. Wichelhaus, K.P. Hunfeld, W. Witte (Wernigerode, Heidelberg,
Berlin, Kiel, Frankfurt/M., DE)
Objectives: The dissemination of multidrug-resistant Klebsiella pneu-
moniae producing KPC carbapenemase is an increasing problem
worldwide. Since the ﬁrst emergence of KPC in 2001 in New York
(USA) these enzymes were described in K. pneumoniae from many
countries like Israel, China, France, Italy, Greece and the UK. In 2008
the ﬁrst isolates occurred in Germany. Here we report on molecular-
epidemiological analysis of KPC-producing K. pneumoniae isolated in
different German hospitals 2008–2009.
Methods: Twelve multidrug-resistant isolates of K. pneumoniae from
seven different hospitals were analysed. Among them were two isolates
from an outbreak in spring 2008 in one hospital.
PCR ampliﬁcation and sequencing of various b-lactamase, carbapen-
emase and porin genes was performed. The clonal relatedness of
all isolates was analysed by molecular typing using PFGE (Xba1
restriction).
Results: All above mentioned isolates were resistant to ﬂuoroquinolones,
sulfonamides and b-lactams including carbapenems. They remained
susceptible only to gentamicin and colistin and showed intermedia MIC
values for tigecyclin. PCR and sequencing revealed the presence of
KPC-2 (n = 7) and KPC-3 (n = 5). All isolates contained SHV-11 and the
KPC-3 producer additionally the TEM-1 b-lactamase. Sequence analysis
of the porin genes showed in all isolates a typical g-insertion in the
ompK35 gene leading to a premature stop of translation. The similarity
of PFGE-macrorestriction patterns of the isolates were more than 80%.
Three KPC-3 isolates from two hospitals located in the region were
identical and they were closely related to two KPC-3 isolates from
another region, respectively. The KPC-2 producing K. pneumoniae were
closely related as well as probably related to the KPC-3 producers.
All outbreak isolates contained KPC-2. The index patient was found to be
hospitalized in Greece before. Because of severe courses of infection and
several cases of death strict precautions like isolation were implemented
and a screening system was established in this hospital.
Conclusion: Infections with multidrug-resistant K. pneumoniae are
still rare in Germany. Probably one or more strains were introduced
from other countries and now occur sporadically in the whole of
Germany. Because of limited therapeutic options a surveillance of
multidrug-resistant Enterobacteriaceae is an urgent need to prevent
further dissemination.
P737 Emergence and prevalence of KPC-producing Klebsiella
pneumoniae isolates in a tertiary Greek hospital
S. Tsiplakou, A. Stylianakis, V. Papaioannou, F. Zoubouloglou,
D. Paraskevopoulou, P. Giakkoupi, A. Vatopoulos, A. Koutsoukou °
(Athens, GR)
Objectives: KPC-producing Klebsiella pneumoniae isolates are increas-
ingly encountered and result in carbapenem resistance, thereby posing
a major problem for treating multidrug resistant isolates. The aim of
the present study was to determine the emergence and spread of KPC
producers in our hospital.
Methods: From 2006 to 2008 a total of 238 Klebsiella pneumoniae
isolates exhibiting MIC values >1mg/L to imipenem and/or meropenem
were screened by the imipenem-EDTA MBL Etest and cloverleaf
(modiﬁed Hodge) test. PCR analysis and sequencing was performed
for those isolates that were phenotypically positive for carbapenemase
production, yielded a positive cloverleaf test and were negative for
metallo-b-lactamase (MBL) production. Klebsiella pneumoniae clinical
isolates were collected from blood (55), urine (41), pus (58), catheters
(49) and bronchial secretions (35) cultures of patients hospitalised in
different wards of our hospital, mainly in ICUs, and were tested for
susceptibility via the Vitek 2 system (Biomerieux, France) and Etest
strips (AB Biodisc, Sweden).
Results: All isolates were multidrug resistant to b-lactams, especially
to extended spectrum cephalosporins, quinolones and aminoglycosides,
but the majority was susceptible to gentamicin, tetracycline, tigecycline
and colistin. The MIC values of imipenem and meropenem ranged from
susceptible to non-susceptible. The imipenem-EDTA MBL Etest was
positive for MBL production for 181 isolates. PCR and sequencing
revealed the presence of KPC-2 gene in 57 isolates. The distribution
of isolates during the three-year period was the following: in 2006 all 80
isolates were MBL producers. In 2007 89 out of 90 isolates produced
MBL and one was KPC positive. In 2008 12 out of 68 isolates produced
MBL and 56 of 68 were KPC-producers.
Conclusions: Considering the fact that in the ﬁrst two years of the
study all carbapenem non susceptible isolates were MBL producers,
the emergence and signiﬁcant increase of KPC-producing Klebsiella
pneumoniae isolates not previously identiﬁed in our hospital poses a
signiﬁcant problem for the treatment of serious infections.
P738 First clinical isolate of blaIMI-2-producing Enterobacter
asburiae in France
G. Cuzon, D. Tande´, D. Le Nen, R. Le Berre, G. Le Lay, P. Nordmann,
T. Naas ° (Le Kremlin Bicetre, Brest, FR)
Objectives: Carbapenem resistance in Enterobacteriaceae is mainly
related to acquired carbapenem-hydrolyzing b-lactamases (1). These
b-lactamases can be either metallo b-lactamases (IMP, VIM), expanded-
spectrum oxacillinases (OXA-48), or Ambler class A enzymes (NMCA,
IMI, SME, GES, and KPC). Genes encoding IMI-2 b-lactamases were
found on plasmids in Enterobacter asburiae from United States rivers
and in one clinical isolate of E. cloacae from China. Here we describe
a single clinical isolate of IMI-2-producing E. asburiae.
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Methods: Bacterial isolates were characterized by standard biochemical
methods, susceptibility testing (disk diffusion), by Pulsed Field Gel
Electrophoresis, and plasmid analysis. Antibiotic resistance genes were
sought by PCR and sequencing.
Results: A 23 year old man, was hospitalized for an open dislocation
of the left index ﬁnger, subsequent to a tumble into a river. The
wound was disinfected, the ﬁnger reinserted, and was discharged the
next day with only local desinfections. Twenty days later he was
rehospitalized for cutaneous necrosis of the scare, and an osteotitis
requiring amputation of the left index ﬁnger. Bacterial cultures of pus,
soft skin tissu and bone revealed the presence of Aeromonas hydrophila
and Enterobacter asburiae. The patient was treated successfully with
ceftazidime (one week) and ciproﬂoxacin for three months. E. asburiae
isolate Bre-1 displayed reduced imipenem susceptibility, a synergy
image between carbapenems and with clavulanate, and crude extracts
displayed signiﬁcant Imipenem hydrolysis. A clavulanic acid-inhibited
b-lactamase IMI-2 was identiﬁed. The blaIMI-2 gene was located on
a self-transferable 66-kb plasmid, of similar size as the one initially
characterized by Aubron et al. (EID, 11, 2005). PCR analysis identiﬁed
an upstream LysR-type regulator gene that explained inducibility of
IMI-2 expression. Futhermore, the genetic environment of blaIMI-2
identiﬁed two IS2-like elements.
Conclusion: This is the ﬁrst description of an inducible and plasmid-
encoded IMI-2-producing E. asburiae clinical isolate. This study raises
the question of the importance of this reservoir in Enterobacteriaceae as
well as the origin of this plasmid-located carbapenemase gene that may
be transferred among other enterobacterial pathogens.
P739 Prevalence of extended-spectrum b-lactamases and of
carbapenemases in Gram-negative clinical isolates from
Belgian ICUs
Y. Glupczynski °, P. Bogaerts, T.D. Huang, C. Lammens, C. Berhin,
J. Van Eldere, H. Goossens (Yvoir, Antwerp, Leuven, BE)
Objectives: The objectives were to determine the prevalence and to
characterize the genotypes of ESBLs and of carbapenemases in a
collection of Gram-negative isolates recovered from patients hospitalized
in ICU in 14 Belgian hospitals in 2008–2009.
Methods: Non-duplicate, consecutive Gram-negative clinical isolates
were collected from patients hospitalized in ICUs for 48 h and with a
suspicion of deep-seated infections. MICs to 8 antimicrobials including
extended spectrum cephalosporins and carbapenems were determined by
microbroth dilution method according to CLSI guidelines. ESBLs were
screened by double combination disk test on all Enterobacteriaceae (EB)
isolates with ceftazidime (CAZ) MICs >1mg/L and were characterized
genotypically by IEF and by Ligase Detection Reaction and low-
density DNA micro-array (Check-Points®, The Netherlands). CAZ-R
non-ESBL E. coli and K. pneumoniae isolates were further analyzed
by multiplex PCR for plasmidic AmpC coding genes. Pseudomonas
and Acinetobacter spp. isolates with an imipenem (IMI) or meropenem
(MERO) MIC 8mg/L and EB with IMI or MERO MIC 1mg/L
were tested by PCR-sequencing for the presence of class A, B, and D
carbapenemases.
Results: ESBLs were detected by double combination discs in 55/571
(9.6%) EB (range of ESBL by centre: 2.1–23.8%), being mostly found
in E. coli (n = 24), E. aerogenes (n = 14) and in E. cloacae (n = 10).
CTX-M-groups (mainly CTX-M-15 and CTX-M-9) accounted for nearly
50% of ESBLs followed by SHV (SHV-4, SHV-5/-12) and TEM
types (TEM-24/TEM-52) in 30% and 20% of the isolates, respectively.
Four plasmidic AmpC were detected in 3 E. coli (CMY-2) and 1
K. pneumoniae (DHA-1) strains. No carbapenemase was found in any
of the 7 carbapenem-non susceptible EB isolates, while MBLs (VIM-2
like) were detected by PCR-sequencing in 5/174 (2.9%) P. aeruginosa
and OXA-23 or OXA-40 carbapenemases were found in 3/21 (14.3%)
A. baumannii.
Conclusion: The prevalence of ESBLs among EB averaged 10% in
Belgian ICUs but showed wide variations between centres. E. coli
accounted for more than 40% of all ESBL-producing EB and CTX-M
types were the most prevalent. Acquired transferable carbapenemases
were detected albeit at a low frequency in Pseudomonas spp (4
centres) and in Acinetobacter spp. (1 centre). Further epidemiological
surveillance is needed to monitor trends in the resistance mechanisms
of Gram-negative bacteria in Belgian ICUs.
P740 Further identiﬁcation of Klebsiella pneumoniae producing
carbapenem-hydrolyzing b-lactamase OXA-48 from Tunisia
G. Cuzon °, T. Naas, A. Lesenne, M. Benhamou, P. Nordmann (Le
Kremlin Bicetre, Antony, FR)
Objectives: Emergence and dissemination of Enterobacteriaceae isolates
harboring carbapenemases in various geographic regions represents a
signiﬁcant threat to the management of nosocomial infections. The
Ambler class D OXA-48 b-lactamase has initially been identiﬁed from a
carbapenem-resistant K. pneumoniae isolate from Istanbul, Turkey and
subsequently from Lebanon, Belgium, UK, and Israel. Here, we report
an OXA-48 producing K. pneumoniae isolate from Tunisia.
Methods: Bacterial isolates were characterized by standard biochemical
methods, disc diffusion susceptibility testing, by Pulsed Field Gel
Electrophoresis, and plasmid analysis, Carbapenemase expression was
studied spectrophotometrically. Antibiotic resistance genes were sought
by PCR and sequencing.
Results: On August 31, an 86-year-old man with severe chronic
obstructive pulmonary disease, was hospitalized in Tunisia for fever,
polypnea, and bronchiectasis. His state of health worsened and he
was transferred to the Intensive Care Unit of the hospital Prive´
d’Antony (Paris Suburbs), France, for sepsis syndrome. Five days after
imipenem treatment started, sputum and blood culture revealed an
ESBL-producing K. pneumoniae HPA-1 with reduced susceptibility to
imipenem. K. pneumoniae HPA-1 was resistant to expanded-spectrum
cephalosporins, ﬂuoroquinolones, rifampin, all aminoglycosides (except
amikacin), tetracycline and to ertapenem, but was of intermediate
susceptibility to meropenem and imipenem. The patient was successfully
treated with amikacin. Crude b-lactamase extract of K. pneumoniae
HPA-1 showed signiﬁcant imipenem hydrolysis activity. PCR experi-
ments followed by sequencing identiﬁed b-lactamase genes blaOXA-48,
bla TEM-1, blaSHV-1 and blaCTX-M--15. Plasmid analysis revealed a
ca. 70-kb self-conjugative plasmid harboring blaOXA-48. Two IS1999
elements were found surrounding the blaOXA-48 gene in a similar
manner to that found in the prototype K. pneumoniae 11978 strain from
Turkey.
Conclusion: This is the ﬁrst evidence of OXA-48-mediated carbapenem-
resistance in Enterobacteriaceae in Tunisia, and further evidence
of spread of this novel and powerful resistance determinant in
Mediterranean countries.
P741 Molecular characterization of the ﬁrst carbapenem-resistant
Klebsiella pneumoniae isolate Va22038 expressing blaOXA48
b-lactamase in Germany
J. Weinberg °, A. Heisig, P. Heisig (Hamburg, DE)
Objectives: The increasing frequency of Enterobacteriaceae resistant
to carbapenems is a major cause of concern and demands detailed
understanding of the molecular basis and epidemiology of carbapenem
resistance. Thus, this work, aims at identifying the molecular mech-
anism(s) of carbapenem resistance in a clinical isolate of Klebsiella
pneumoniae from Germany in 2004.
Methods: Clinical isolate K. pneumoniae Va22038 has been described
[1]. Susceptibilities to antimicrobial drugs were determined as minimal
inhibitory concentrations (MICs) according to guidelines of the CLSI.
Plasmid-DNA was isolated by both, the Crosa method and alkaline
lysis method and analysed after agarose gel electrophoresis. The outer
membrane proteins (OMPs) of the clinical isolate were isolated by
ultrasonic and sodium lauroyl sarcosine (sarcosyl) treatment, separated
on an SDS-PAGE gel, stained and visualized by a coomassie brilliant
AmpC b-lactamases and carbapenemases in Enterobacteriaceae S187
blue. Screening for genes encoding b-lactamases has been accomplished
by gene family-speciﬁc PCRs.
Sequencing of respective amplicons has been done by means of dye-
terminator sequencing.
Results: The MIC values of different b-lactam-antibiotics were elevated,
including imipenem, ertapenem, and meropenem (16, 32, and 8,
respectively). The plasmid analysis revealed a single 65kb plasmid. The
OMP proﬁle lacked characteristic bands of OmpK35 and OmpK36. A
PCR using primers speciﬁc for blaOXA resulted in a characteristic 744nt
fragment. DNA sequence analysis of an internal blaOXA-gene fragment
yielded 100 per cent homology to that of blaOXA-48. Further sequence
analysis of the adjacent regions of blaOXA-48 revealed two ﬂanking
putative transposase-genes.
Conclusion: This is the ﬁrst report of a clinical isolate expressing the
OXA-48 b-lactamase in Germany. The MIC proﬁle of carbapenems
indicates an interplay of this carbapenemase with a reduced expression
of the major OMPs OmpK35 and OmpK36.
The blaOXA-48 gene location between two transposase genes implies
that it is part of a composite transposon. This view is suppoorted by
results of PCR fragment analysis and sequencing of the corresponding
genetic context which resembles that of K. pneumoniae 11978, the ﬁrst
isolate reported to harbour an blaOXA-48 gene as part of the composite
transposon Tn1999.
P742 First report of the co-existence of blaOXA-48 or blaOXA-48-
like gene with blaNDM-1 in Enterobacteriaceae from India
K. Karthikeyan °, M. Toleman, C.G. Giske, M. Thirunarayan,
K. Kumaraswamy, N. Narayam, P. Krishnan, T. Walsh (Chennai, IN;
Cardiff, UK; Stockholm, SE; Haryana, IN)
Objectives: Carbapenemases are rapidly emerging in Enterobacteriaceae
in India causing serious treatment problems. This is probably due to the
combination of poor antibiotic prescription control, poor sanitation and a
large population. This project was initiated to determine the mechanism
responsible for the carbapenem resistance in four enteric clinical isolates
obtained from the ICU of a tertiary care hospital in Chennai in 2009.
Methods: Speciation and antibiotic testing was determined using a
Phoenix automated machine. Double disc synergy tests and Modiﬁed
Hodge tests were used for detection of metallo-b-lactamases (MBL) and
non-MBL carbapenemases, respectively. PCR screening involved using
custom primers for all known carbapenemases. Transconjugations were
performed using Escherichia coli J53 as the recipient. Pulsed ﬁeld gel
electrophoresis with partial S1 nuclease digestion and probing of agarose
gels with radio-labeled 32P blaNDM-1 and blaOXA48 gene DNA probes
was used to detect the genomic location of the respective carbapenemase
genes. blaOXA-48 and blaNDM-1 genes were sequenced and their local
genetic environment investigated with speciﬁc custom designed primers.
Plasmid replicon typing was employed to determine the Inc types.
Results: The four isolates; 3 Klebsiella pneumoniae and an E. coli
strain, displayed a multi-drug resistant proﬁle including resistance to
all the b-lactam antibiotics, aminoglycosides and quinolones and was
only sensitive to tigecycline and colistin. All isolates gave positive
DDST and MHT results and gave PCR products of expected sizes for
both blaOXA-48 and blaNDM-1. In-gel hybridization of PFGE gels
following partial S1 digestion determined that blaOXA-48 was found on
250kb plasmid, whereas blaNDM-1 was found on plasmids of varying
sizes (50kb-145kb) in the different strains. Transconjugants harboured
plasmids of identical size to the blaOXA-48 and blaNDM-1 plasmids
and the blaNDM-1 plasmids were determined to be of rep A/C type.
blaOXA-48 (100% ID) was found in the E. coli strain whereas a novel
variant of the blaOXA-48 gene (94% ID and 4 amino acid substitutions)
was found in the Klebsiella strains.
Conclusion: K. pneumoniae and E. coli isolates have been found in an
ICU in Chennai that carry two carbapenemase genes giving very broad
spectrum antibiotic resistance proﬁles. The emergence of these powerful
resistance mechanisms in India is a cause for great concern as treatment
options are virtually exhausted.
P743 First isolation of VIM-5 producing Enterobacter cloacae in
Chennai, India
K. Karthikeyan, T. Walsh, M. Thirunarayan, P. Krishnan, M. Toleman °
(Chennai, IN; Cardiff, UK)
Objectives: The emergence of enteric organisms harbouring carbapen-
emases is a signiﬁcant threat in the control of hospital infections as
carbapenems are the reserved for serious infections when other options
are depleted. Two carbapenem resistant Enterobacter cloacae clinical
isolates were obtained from the ICU of a tertiary care hospital in
Chennai in 2009. This project was initiated to determine the mechanism
responsible for the carbapenem resistance.
Methods: Speciation and susceptibility testing was determined by
automated systems (Phoenix). The presence of a metallo-b-lactamase
(MBL) was determined using the Hodge double disc synergy test
(DDST). Genomic DNA was screened for known MBL genes by
PCR using custom designed primers based on sequences of all known
MBL genes. The local genetic locus of the blaVIM-5 gene was
determined by PCR mapping and sequencing with primers designed
to genes commonly found in the class1 integron and the transposon,
Tn5090. The genetic location was further determined by pulsed ﬁeld gel
electrophoresis combined with S1 nuclease digestion and probing with
radio-labelled DNA probes and a random ﬂanking primer PCR approach.
Transconjugation and transformation experiments utilized Escherichia.
coli J53 and Top10 cells as recipients.
Results: Both isolates were classiﬁed as E. cloacae displayed a multi-
drug resistant phenotype; were resistant to all b-lactams, aminoglycosides
and quinolones and were sensitive to only tigecycline and colistin. The
carbapenemase gene blaVIM-5 was found in an unusual Class 1 integron
that lacked the usual 3′ conserved sequence and was found on a complete
Tn5090-like transposon. Two copies of this transposon were found on a
large 325kb plasmid. The transposons were inserted at two points within
this plasmid both near resolvase genes. The integron variable region
contained an additional aac6′II gene cassette in the second position.
Transconjugants and transformants had similar resistance patterns and in
both cases the blaVIM-5 gene was located on a plasmid of identical size.
The frequency of transconjugation was low i.e. approximately 1X10−8.
Conclusion: This is the ﬁrst report of VIM producing Enterobacteriaceae
in India. MBL producing pathogens are emerging rapidly in India and
their spread is likely to be facilitated by the large population, poor
sanitary conditions and little or no antibiotic prescription control.
P744 High-resolution crystal structures of SFC-1 and
acyl-intermediate in complex with meropenem: structural
basis for carbapenemase activity in class A b-lactamases
F. Fonseca °, A. Correia, J. Spencer (Aveiro, PT; Bristol, UK)
Objectives: Carbapenems are resistant to hydrolysis by most
b-lactamases and are used as last resort antibiotics in treatment of
multidrug resistant bacteria. SFC-1 is a class A serine carbapenemase
from Serratia fonticola, an environmental bacterium and occasional
pathogen. Unlike the majority of such enzymes, SFC-1 also efﬁciently
hydrolyzes third generation cephalosporins and is only weakly inhibited
by clinically useful inhibitors. Here we present crystal structures of
wild-type SFC-1 and of complexes of site-directed mutants with the
carbapenem meropenem in unhydrolysed and acylenzyme intermediate
forms.
Methods: S70A and E166A active site mutants were generated using the
QuikChange Site-Directed Mutagenesis kit. SFC-1 and mutant proteins
were puriﬁed from induced cultures of E. coli BL21 (DE3). Crystals of
SFC-1 were obtained by hanging drop vapour diffusion from 18−22%
w/v polyethylene glycol 3350, 0.2M sodium acetate. Crystals of SFC-1
mutants were obtained by seeding using crystals of the wild-type SFC-1.
Acylenzyme-intermediates and unhydrolysed complexes were prepared
by soaking crystals in the mother liquor solution containing meropenem
and ethylene glycol as cryoprotectant. X-ray data were collected at SRS
and DLS beamlines. Molecular replacement was performed with Phaser
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using KPC-2 or wild-type structures as search models. Model building
and reﬁnement were carried out using CCP4.
Results: Wild-type SFC-1 crystallised in space group P21 with 2
molecules in the asymmetric unit. SFC-1 mutants crystallized in space
group P212121 with 1 (E166A; acylenzyme) or 2 (S70A; substrate
complex) molecules in the asymmetric unit. SFC-1 has the disulﬁde bond
and other conserved features of the class A carbapenemase active-site.
Meropenem is oriented in the active site by Thr-236 and Thr-238, placing
it close to Ser-130 for proton transfer. In the carbapenem-inhibited
class A enzymes (e.g. SHV-1) interaction with Arg-244 imposes a
different orientation on bound meropenem, resulting in ﬂexible binding
at a distance from Ser-130, impairing proton transfer.
Conclusion: The overall structure of SFC-1 closely resembles those
of other known class A b-lactamases. However, these ﬁrst structures
of a class A carbapenemase with bound carbapenem reveal that these
enzymes change the orientation of bound meropenem to promote
catalysis, without gross distortion of overall structure.
P745 Detection of AmpC producers: comparison and evaluation of
phenotypic methods in Klebsiella pneumoniae clinical isolates
A. Paradela °, S. Ferreira, E. Ramalheira, S. Mendo (Aveiro, PT)
Objectives: This study aims to evaluate the performance of 3 phenotypic
methods for AmpC detection in K. pneumoniae: cefoxitin Hodge-test,
Induction test and Etest strips.
Methods: Strains resistant to extended-spectrum cephalosporins and/or
broad spectrum penicillins and susceptible to carbapenems, were
selected. E. coli ATCC 25922 and a S. marcescens were used as AmpC
non-producer and producer, respectively. Strains were identiﬁed and
antibiotic susceptibilities determined by Vitek2 system and Vitek2 AES
(bioMe´rieux, Marcy L’E´toile, France). ESBL producers were conﬁrmed
by Etest™ (AB Biodisk) ESBL with CT/CTL, TZ/TZL and PM/PML
strips, according to manufacturer’s instructions. Additionally, all isolates
were screened with Etest™ (AB Biodisk) AmpC strips CN/CNI. For the
Hodge test, a Mueller–Hinton (MH) agar plate was swab inoculated with
E. coli ATCC 25922 adjusted to 0.5 McFarland. A cefoxitin disk was
placed at the center of the plate and the test strains were heavily streaked
outwards from the disk. After incubation, the radius of the inhibition
zone of the indicator strain, and the decreased radius of the inhibition
zone along the growth of test strain were measured. In the induction
test, aztreonam, cefotaxime and amoxicillin–clavulanic acid disks were
placed 10mm apart from margin to margin in a MH plate inoculated
with the test strain. After incubation the plate was observed and the
presence of a truncated inhibition zone was interpreted as a positive.
Results: 7 isolates were determined as ESBL positive and 5 negative
by Vitek2 compact AES. The phenotype consistent with both ESBL
and AmpC was detected in 2 isolates. 7 and 5 isolates were positive
for AmpC production by strips CN/CNI strips and Induction test,
respectively. Hodge test results showed 6 isolates were positive, whereas
1 isolate showed minimal distortion. All AmpC producers were found to
be resistance to cefoxitin. Discrepancies between the different methods
were observed in 3 isolates. These results were conﬁrmed by PCR and
nucleotide sequence determination.
Conclusion: Although cefoxitin sensitive AmpC producers have been
reported, these results indicate that screening methods using cefoxitin are
still useful standardized tests. Etest CN/CNI strips was an easy, reliable
and rapid method of AmpC producers detection. These results highlight
the need of implementation of routine screening for AmpC producers by
phenotypic methods.
P746 New DNA microarray test for rapid detection of KPC,
OXA-48, VIM, IMP carbapenemase and TEM, SHV, CTX-M
ESBL-producers
T. Naas °, G. Cuzon, S. Gardin, P. Nordmann (Le Kremlin Bicetre, FR)
Background: Extended-spectrum b-lactamases (ESBLs) have rapidly
emerged worldwide. More recently also various carbapenemases have
spread in many regions. Rapid identiﬁcation of bacteria expressing these
enzymes therefore becomes more and more important. We evaluated a
new qualitative in vitro molecular diagnostic test “Check-CARBA ESBL”
for speciﬁc identiﬁcation of TEM and SHV-type ESBLs, and detection
of CTX-M, KPC, OXA-48, VIM, IMP producers.
Methods: We evaluated the new micro-array based “Check-CARBA
ESBL” test (Check-Points, Wageningen, Netherlands) that employs
highly speciﬁc DNA markers to identify the b-lactamase genes of
TEM, SHV, CTX-M, KPC, OXA-48, VIM and IMP, and discriminates
ESBL and non-ESBL TEM and SHV-genes. We used 67 well-
characterized Gram-negative rods (Enterobacteriaceae, Pseudomonas sp.,
Acinetobacter sp.) expressing various b-lactamases: 4 SHV, 5 TEM, 6
CTX-M, 10 OXA-48, 20 KPC, 10 VIM-, 10 IMP. 32 wild-type isolates
or isolates harbouring other b-lactamase genes were used as controls.
Total DNAs were extracted using Qiagen DNA mini kit.
Results: The Check-CARBA ESBL assay allowed fast and unambiguous
detection of all TEM, SHV and CTX-M ESBL genes present. In addition,
the clinically most relevant carbapenemases were also reliably detected.
The assay enabled easy distinction between non ESBL TEM and SHV
variants and their ESBL derivatives. None of the other tested b-lactamase
genes were detected (OXA-18, VEB, PER, GES) underlining a good
speciﬁcity. The assay was performed with several enterobacterial isolates,
but also on non-fermenting Gram negative rods, such as P. aeruginosa
and A. baumannii. A 1/10 dilution of the total DNA was required for
optimal results for non-fermenting isolates.
Conclusion: The Check-CARBA ESBL test represents a powerful high-
throughput tool for rapid identiﬁcation of carbapenemases and ESBLs
in all the clinical isolates tested. Results were obtained within the same
working day, allowing rapid implementation of isolation measures and
appropriate antibiotic treatment.
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P747 NaCl and clonazepam induce low-levels of multidrug
resistance in Escherichia coli strains through sdiA and soxS
overexpression
M.M. Tavı´o °, V. Aquili, M. Perilli, G. Amicosante, G. Celenza,
J.B. Poveda (Las Palmas G.C., ES; L’Aquila, IT)
Objectives: Low-levels of multidrug resistance (LL MDR) can serve as
intermediate steps for the development of increased clinically relevant
resistances. The aim of this study was to analyze the induction of
LL MDR by NaCl and clonazepam, which is one of the commonest
benzodiazepines in clinical treatments, in E. coli strains and regulator
genes involved. Results were compared with those previously described
utilizing diazepam, another benzodiazepine, in order to explain LL MDR
induced by non-antimicrobial drugs.
Methods: The effect of concentration ranges of NaCl (10.7–342 mM)
and clonazepam (0.0002–0.0625 mM) on antimicrobial agent MICs,
outer membrane protein expression analyzed by SDS-PAGE, 10%
cyclohexane tolerance by liquid-medium assay, and transcript levels of
acrB, marA, soxS, and sdiA genes by reverse transcription of total RNA
and PCR of cDNA, were evaluated in the wild type AG100 strain and
three susceptible E. coli clinical isolates. AG100 (induced with 5 mM
salicylate or 0.2 mM paraquat) was used as control.
Results: LL MDR induced by NaCl or clonazepam in the four E. coli
studied strains were characterized by OmpF loss, maintenance of
bacterial growth in the presence of 10% cyclohexane, and increased
transcript levels of acrB, sdiA, and soxS, but not marA. Such changes
occurred in a reversible and concentration-dependent manner. Thus, the
highest concentrations of NaCl or clonazepam that the studied strains
tolerated, induced the highest cyclohexane tolerance levels and transcript
levels of the analyzed genes, increasing 10.4−16 fold sdiA, 4.2−9 fold
soxS, and 3.8−4.5 fold acrB compared with their respective transcript
levels in non-induced AG100.
Conclusion: NaCl and clonazepam induced LL MDR, OmpF loss,
increased cyclohexane tolerance, and overexpression of the RND
transporter acrB, the quorum-sensing regulator sdiA, and soxS gene
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in the four studied E. coli strains, in a reversible and concentration-
dependent manner, ﬁtting with those described for diazepam.
P748 Real-time PCR analyses of ramA expression in tigecycline
non-susceptible isolates
M. Hackel °, C. Lascols, S. Bouchillon, B. Johnson, D. Hoban,
J. Johnson, R. Badal, S. Hawser, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Objectives: Tigecycline is a synthetic analogue of the tetracyclines
which exhibits signiﬁcant antibacterial activity against Gram-negative
and Gram-positive bacteria and is active against strains carrying
either one or both of the two major forms of tetracycline resistance:
tetracycline-speciﬁc efﬂux pumps and ribosomal protection. While
Klebsiella pneumoniae (KPN) is generally susceptible to tigecycline,
decreased susceptibility has been associated with the multidrug efﬂux
pump AcrAB. RamA belongs to a family of transcriptional activators
which are known to have a role in the up-regulation of this pump.
Overexpression of ramA or its close homologs has been correlated
with increased expression of the AcrAB efﬂux pump in several
Gram-negative species. This study evaluates the expression of ramA
in 42 tigecycline non-susceptible KPN isolates from the Tigecycline
Evaluation Surveillance Trial (TEST).
Methods: MICs were performed by broth microdilution following CLSI
guidelines. 42 clinical isolates with tigecycline MICs 8 mcg/ml were
analyzed for the expression of ramA by RT-PCR using previously
published primers and probes. Expression of the target gene was
normalized to that of housekeeping gene rrsE, a 16S rRNA gene.
Results: 4 of the 42 KPN tested had MICs of 16, while 38 had MICs
of 8. The average normalized level of expression of the ramA gene was
11.87, using a tigecycline susceptible strain as the reference condition
with an expression of 1. Overexpression was found in all these non-
susceptible isolates, with no differences between those with MICs of 8
or 16.
Conclusions: These results conﬁrm the previously established role of
ramA in reduced tigecycline susceptibility in Klebsiella pneumoniae.
As the expression of acrAB has been shown to be subject to multiple
levels of regulation, the exact function of ramA will require further
experiments.
P749 Energetics, pH and intrinsic efﬂux pump systems of
Gram-negative pathogens
G. Spengler °, M. McCusker, M. Martins, A. Martins, L. Rodrigues,
J. Ramos, M. Viveiros, I. Couto, J. Pa`ges, S. Fanning, L. Amaral
(Lisbon, PT; Dublin, IE; Marseille, FR)
Objectives:Multidrug resistant Gram-negative clinical isolates owe their
resistance primarily to over-expressed efﬂux pumps (EPs). Although in
recent years EPs of these bacteria have received increasing attention,
surprisingly, few studies are conducted under physiological conditions.
Furthermore, physiological parameters that normally effect enzyme
function including pH, metabolic energy, etc., are rarely explored
for possible effects on EP activity. The question of whether these
physiological parameters impact the activity of EPs of important Gram-
negative pathogens is partially answered by the study to be described.
Methods: The ability of wild-type reference strains of Salmonella
Enteritidis, Escherichia coli and Enterobacter aerogenes to extrude the
common substrate ethidium bromide (EB) in saline at varying pH or
in deionised water was assessed using the semi-automated ﬂuorometric
method. The capacity of each isolate to extrude EB in liquid medium
and on solid medium at varying pHs was similarly assessed using a
novel microplate-based EB method and the EB agar cartwheel method,
respectively.
Results: The capacity of each strain to extrude EB is consistently
affected by pH. At pH 5, extrusion of EB measured by any
method is shown to be optimized, is independent of metabolic energy
and is increasingly affected by concentrations of carbonyl cyanide
m-chlorophenylhydrazone (CCCP) which uncouples the proton motive
force (PMF). In contrast, at pH 8, extrusion is dependent upon metabolic
energy, and is affected by inhibitors of ABC transporters orthovanadate
and verapamil. In deionised water, efﬂux is exclusively dependent upon
metabolic energy (glucose or ethanol).
Conclusions: Gram-negative bacteria contain two general EP systems −
one that functions at low pH (represented by the RND superfamily
of transporters) and one that functions at high pH (a putative ABC
transporter). These data are consistent with those obtained by others
using puriﬁed AcrB which demonstrate a high dissociation of a substrate
at low pH and low dissociation at high pH, and for the stable association
of the EP itself that is greatest at low pH and unstable at high pH. The
relationship of efﬂux to pH and the relationship of the latter to the PMF,
the activity of F1F0-ATPase, and the protons required to energize the
efﬂux pump systems will be presented.
P750 The role of mar mutations for the ﬁtness cost and its
compensation in ﬂuoroquinolone-resistant Escherichia coli
B. Arntjen °, A. Heisig, P. Heisig (Hamburg, DE)
Objective: Selection of highly ﬂuoroquinolone resistant mutants with
ciproﬂoxacin from a quinolone susceptible isolate of E. coli (WT) has
yielded mutants MIII and MIVa carrying target mutations in genes gyrA
and parC in addition to a marR knock out deletion. This combination
of mutations is assumed to be responsible for the multiple-antibiotic
resistance (mar) phenotype and a distinct loss of ﬁtness of mutants MIII
and MIVa. Growing these mutants over 300 generations in the absence of
selective pressure resulted in mutants MIII-300-S16 and MIVa-300-S32
characterized by a restored ﬁtness and a partial loss of the mar phenotype.
DNA sequence analysis revealed a different marA point mutation in each
mutant. The aim of this study was to investigate the impact of these marA
mutations on ﬂuoroquinolone resistance and the restoration of the ﬁtness.
Methods: Individual marA point mutations were introduced into the
chromosome of parent strains WT and its marR deletion derivative WTIII
by site-directed mutagenesis. MICs were determined in the absence and
presence of sodium salicylate. The measurement of ﬁtness in vitro was
performed as a pairwise growth competition experiment. Expression
rates of genes marA and acrA were determined by qRT-PCR.
Results: MICs of novobiocin, ciproﬂoxacin, tetracycline, nalidixic acid
and cloramphenicol were decreased by fourfold for marA mutants of
WTIII, but only twofold for marA mutants of WT in the presence of
sodium salicylate as a known activator of marA expression. In a pairwise
competition experiment with WT, WTIII showed a signiﬁcantly reduced
ﬁtness (delta logCFU= 3). Introducing the marA mutations into WTIII
completely compensated this loss of ﬁtness (delta logCFU= 0). Gene
expression analysis revealed a more than twenty fold overexpression of
marA in WTIII and its marA mutants compared to WT. However, the
gene acrA encoding the multiple drug resistance efﬂux pump AcrAB
was overexpressed only in WTIII (fourfold). In marA mutants of WTIII
acrA expression was comparable to the level determined for WT. These
data support the idea of the marA mutations confering a loss of function.
Conclusions: The mar operon plays an essential role not only for the
development of high-level ﬂuoroquinolone resistance in E. coli, but also
for the ﬁtness of such isolates. These results stress the importance of a
balanced regulation of the mar operon.
P751 Characterization of a proposed RamR binding site involved
in regulation of multiple drug resistance in Salmonella Typhi-
murium and Salmonella Hadar using a reporter gene assay
F. Pott °, A. Heisig, P. Heisig (Hamburg, DE)
Objectives: In vitro-selected second-step mutants of Salmonella
Typhimurium (CII) and S. Hadar (DIIa) express a multiple drug
resistance (MDR) phenotype associated with overexpression of AcrAB-
TolC efﬂux pump and its activator RamA. This study aimed at analyzing
the regulation of ramA by characterizing a postulated stem-loop-structure
of the putative binding site of the repressor RamR upstream of ramA.
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Methods: The DNA sequence of ramR and the ramR-ramA intergenic
region (IGR) was determined by cycle-sequencing. To study the impact
of mutations on the ramA overexpression a set of plasmids was
constructed with promoter pramA and the adjacent RamR-binding
site fused to the b-lactamase blaTEM-1a reporter gene. Mutations
in the putative binding site were introduced into the plasmids by
replacing the wildtype IGR by those of mutants CII and DIIa to yield
plasmids pHPFP10−11 and -12, respectively. Variants were generated
by site-directed mutagenesis (pHPFP10−13 to -16). Gene expression
was assayed by determining minimal inhibitory concentrations (MICs)
of ampicillin (AMP) for salmonellae carrying the different reporter
gene plasmids. A ramR-knockout mutant was generated by inserting
a kanamycin resistance-cassette into ramR.
Results: Mutants CII and DIIa show deletions upstream ramA of 22
basepairs (bp) and 1bp, respectively. This deletes 15bp of the 20bp-
sized RamR binding site in CII and 1bp in DIIa. Cells carrying the
corresponding plasmids pHPFP10−11 and -12 showed an 8-fold increase
in MIC of AMP whereas knockout of the ramR gene only leads to
a 4-fold increase. Reconstituting the number of bases in the loop
(pHPFP10−13) does not alter the MIC compared to pHPFP10−12. A
different 1bp-deletion in the loop (pHPFP10−14) and deletions altering
the stem (pHFP10−15, -16) show increases in MIC of 7- and 6-fold,
respectively.
Conclusions: The results of the reporter gene assay (pHPFP10−11 and
-12) indicate that both deletions in CII and DIIa increase the ramA-
expression (8-fold MIC). Any other alteration (pHPFP10−13 to -16)
including the restoration of the loop size by a different bp, deletion of
another nucleotide or variations of the stem yielded comparable MIC
increases (6- to 8-fold), while inactivation of the ramR gene had a
reduced effect (MIC increase 4-fold). These results indicate that the
binding of repressor RamR to its binding site is strictly sequence-
dependent. Furthermore, the existence of ramA-regulators besides RamR
is likely.
Strain Plasmid Ampicillin MIC
(mg/ml)
Relative increase in MIC
compared to plasmid
pHPFP10-10
S. Typhimurium CI pHPFP10-10 512 1
S. Typhimurium CI ramR::kanR pHPFP10-10 2048 4
S. Typhimurium CI pHPFP10-11 4096 8
S. Typhimurium CI pHPFP10-12 4096 8
S. Typhimurium CI pHPFP10-13 4096 8
S. Typhimurium CI pHPFP10-14 3584 7
S. Typhimurium CI pHPFP10-15 3072 6
S. Typhimurium CI pHPFP10-16 3072 6
P752 Metabolomic proﬁling of the multidrug resistance
transcription regulator, RamA, in Klebsiella pneumoniae
T. Schneiders °, M. Abu Oun (Belfast, Surrey, UK)
Objectives: RamA is an AraC/XylS family transcriptional activator
where it’s over expression is associated with a multidrug resistance
phenotype via the acrAB efﬂux pump. In Salmonella it has been
shown that a deletion of the ramA renders the bacterium susceptible
to the effects of the putative efﬂux pump inhibitor chlorpromazine.
Whilst it has been repeatedly shown that RamA overexpression and
its effect on AcrAB results in the efﬂux of a variety of compounds
there has been no data on the effect of RamA overexpression on the
metabolomic proﬁle of these pathogenic bacteria. Therefore in order
to understand the role of this key regulator in the development of
antibiotic resistance, metabolomic analyses of RamA overexpression was
undertaken in K. pneumoniae.
Methods: Genetically modiﬁed mutants in the ramA locus (delta ramA
and delta ramR which is a ramA overexpresser) and the parental
Klebsiella pneumoniae strain Ecl8 were used in the Biolog analyses.
The three bacterial strains were analysed using the OmniLog Phenotype
Microarray System a high-throughput assay that allows the analyses of
carbon, nitrogen, phosphorus, sulphur and dipeptide substrate utilisation
of bacterial cells. All ﬂuids, reagents and PM panels were supplied by
Biolog and used according to the manufacturer’s instructions. Data was
analysed using the Genespring software.
Results: Generally the delta ramA mutant produced a similar
biochemical proﬁle to the parental wild type Ecl8. The biochemical
tests where the lack of ramA impacted signiﬁcantly on were in the
presence of osmolytes and growth in high pH. Approximately 43
signiﬁcant differences in substrate metabolism were found when the
ramA overexpresser was compared to either the delta ramA or parental
wildtype. The ramA overexpresser was particularly impaired when grown
in the presence of several nitrogen sources. Interestingly the ramA
overexpresser exhibited less pH sensitivity than the delta ramA mutant.
Conclusion: In this study the metabolomic impact of ramA overex-
pression, was determined in the nosocomial pathogen K. pneumoniae.
Our transcriptomic analyses shows that various membrane components
are up and down regulated in response to ramA overexpression which
supports the effects noted in the efﬂux/inﬂux of the different metabolic
substrates identiﬁed in the Biolog screen. These data clearly underscore
the metabolic cost of ramA overexpression and its effect on multidrug
resistance.
P753 Novel AraC regulator in mediating the multidrug-resistant
phenotype via the OqxAB efﬂux pump in clinical and
environmental isolates of Klebsiella pneumoniae
M. Veleba, T. Schneiders ° (Belfast, UK)
Objectives: AraC/XylS family consists of transcriptional regulators
that are involved in a myriad of cellular functions. A subset of these
transcriptional regulators typiﬁed by the MarA/SoxS and RamA proteins
confer a multidrug resistance phenotype via the upregulation of the
acrAB efﬂux pump. In this study we have identiﬁed another AraC type
regulator within the Klebsiella pneumoniae genome that may be involved
in conferring a multidrug resistant phenotype via the OqxAB pump.
Methods: RNA was extracted from a combination of isogenic mutants
and clinical isolates using the Qiagen RNaeasy Kit. RNA integrity was
assessed using nanodrop and Agilent Nanochip systems. The RNA was
transcribed into double stranded cDNA prior to labelling with Cy3.
The cDNA was hybridised to the Nimblegen expression array platform
designed from the K. pneumoniae MGH 78578 genome.
Results: Our microarray results demonstrated that the novel AraC
regulator was overexpressed in isogenic strains that differed only
in ramA expression levels. However ramA overexpression was not
linked to the upregulation of this novel AraC regulator. Bioinformatic
analyses of the genomic organisation of the area surrounding the novel
regulator indicated that it controls an efﬂux pump annotated as oqxAB.
RT-PCR analyses of clinical and environmental isolates demonstrated
that upregulation of the novel AraC regulator is linked to the upregulation
of the oqxAB efﬂux pumps. Bioinformatic and RT-PCR analyses support
this association as mutations within the AraC regulator also result in the
upregulation of the oqxAB pump.
Conclusion: In this study we have identiﬁed a previously uncharacterised
transcriptional regulator of the efﬂux pump oqxAB in Klebsiella
pneumoniae. A combination of factors underscore the importance of
understanding the regulation of the oqxAB gene by this novel AraC
regulator; ﬁrstly oqxAB has been previously identiﬁed as a signiﬁcant
efﬂux mechanism in conferring resistance to the growth promoter
olaquindox and ciproﬂoxacin and secondly is chromosomally encoded in
nosocomial pathogens such as Klebsiella spp. and Burkholderia spp. but
has acquired genetic mobility as a plasmid in E. coli. Therefore the role
of oqxAB and its novel AraC regulator represent an emerging mechanism
of resistance to clinically relevant antibiotics in K. pneumoniae.
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P754 Aac(6′)-Ib-cr genotyping by simultaneous high-resolution
melting analysis of an unlabelled probe and full length
amplicon
P. Andersson °, J.M. Bell, J. Turnidge (North Adelaide, AU)
Objectives: There are several variants of the gene encoding aminogly-
coside acetyltransferase aac(6′)-Ib, and of greatest clinical concern is
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the aac(6′)-Ib-cr variant which extends the enzyme targets to include
ﬂuoroquinolones in addition to aminoglycosides. The aac(6′)-Ib-cr
variant is characterised by amino acid changes at codon 102 (Trp→Arg)
and codon 179 (Asp→Tyr). There are two described aac(6′)-Ib-cr
variants which differ from the wild type aac(6′)-Ib (wt) at nucleotide
304 by a T→C (cr-C) or T→A (cr-A) change. Both nucleotide changes
result in a Trp→Arg amino acid substitution. We sought to design a
rapid and simple assay able to distinguish between the three known
alleles found in the aac(6′)-Ib gene at codon 102.
Methods: A 58bp fragment was ampliﬁed using asymmetrical primer
concentrations in the presence of a 25bp unlabelled probe with a perfect
match to the wt allele. The combined information from simultaneously
acquired high resolution melting data of the full length amplicon and
the unlabelled probe, allows unambiguous genotyping, even of discrete
T→A nucleotide changes.
Results: Two melting events were observed: one around 65−75ºC,
describing the probe disassociation and one around 79−84ºC, describing
whole amplicon melting (see ﬁgure). In brief, the probe and amplicon
melting points were: 72.0ºC and 81.9ºC for wt; 69.7ºC and 82.7ºC for
cr-C; 68.8ºC and 81.7ºC for cr-A. Heterozygote isolates containing both
wt and cr alleles showed a distinct shoulder on the amplicon melting
peak, due to the melting of heteroduplex fragments. The probe melting
event for heterozygotes showed two distinctive peaks representative of
the two individual allele probe peaks.
The assay was validated using 211 isolates with known aac(6′)-Ib status
and genotype, and further tested on 732 isolates with unknown aac(6′)-Ib
status and genotype. The assay performed reliably in all tests.
Conclusion: We have developed a one-step closed-tube assay for the
detection and genotyping of aac(6′)-Ib-cr, capable of differentiating
between the two genetic variants responsible for the aac(6′)-Ib-cr
phenotype, which from an epidemiological perspective is of importance.
The assay is rapid at <2 hours, costs less than US $1 per isolate and
addresses the need of an efﬁcient detection system for the monitoring
of the growing prevalence of clinically signiﬁcant aac-Ib-cr variants.
P755 Diffusion of plasmid-mediated quinolone resistance determi-
nants in CTX-M-type extended-spectrum b-lactamases in hos-
pitals and the community in the Saint-Etienne region, France
N. Filippa °, A. Carricajo, G. Aubert (Saint Etienne, FR)
Objectives: Fluoroquinolone resistance has been widely reported due to
unbridled clinical use of these compounds and is usually chromosomally
mediated. However, plasmid-mediated resistance has emerged and is
now described worldwide. The aim of this study was to evaluate the
prevalence of determinants of plasmid-mediated quinolone resistance
(PMQR) (qnrA, qnrB, qnrS, aac(6′)-Ib-cr, and qepA) among clinical
isolates of CTX-M type strains in the Saint-Etienne region (population:
600 000) comprising 11 analytical laboratories between October 2007
and March 2008.
Methods: A total of 103 non-duplicated isolates of CTX-M-positive
Enterobacteriaceae were screened using speciﬁc primers for qepA and
aac(6′)-Ib-cr and multiplex PCR for qnrA, qnrB and qnrS genes; The
aac(6′)-Ib-cr variant was further identiﬁed by digestion with BstCI.
PMQR-positive isolates were analyzed for antimicrobial susceptibility
and presence of mutations in the quinolone-resistance determining region
(QRDR) of gyrA gene.
Results: During the study period, 103 isolates were analyzed comprising
87 E. coli and 16 K. pneumoniae mostly CTX-M15 (36.9%), CTX-
M1 (28.2%), CTX-M14 (20.4%) but also CTX-M2 (5.8%), CTX-M57
(2.9%), CTX-M32 (2.9%), CTX-M27 (2.6%) and CTX-M8 (0.9%).
Twenty-seven isolates (26.2%) were positive for aac(6′)-Ib gene and
25/27 (92.6%) were aac(6′)-Ib-cr mutant. Of these 25 aac(6′)-Ib-cr, 23
were detected in CTX-M15 (19 E. coli and 4 K. pneumoniae), 1 in CTX-
M14 (E. coli) and 1 in CTX-M54 (E. coli). 29.6% of hospitals isolates
were positive for aac(6′)-Ib-cr compared to 21.6% in the community
and 8.3% in tertiary care units. Of 103 isolates, only 1 qnrS (0.9%) was
identiﬁed in a K. pneumoniae CTX-M15 isolate (in association with
aac(6′)-Ib-cr), whereas no qnrA-like or qnrB-like genes were detected.
Two qepA (1.9%) E. coli were isolated: 1 CTX-M14 and 1 CTX-M57,
respectively alone and associated with aac(6′)-Ib-cr. Analysis of the
gyrA chromosomal QRDR region revealed the presence of at least one
mutation in all PMQR bacteria identiﬁed.
Conclusions: Our results show that isolates with aac(6′)-Ib-cr,
often associated with the blaCTX-M-15 gene, are emerging among
ﬂuoroquinolone-resistant E. coli in the Saint-Etienne region, both in
hospitals and in the community. Diffusion of other PMQR determinants
such as qnr and qepA remains rare but is often associated with aac(6′)-
Ib-cr, suggesting that plasmid diffusion of these resistance determinants
may develop rapidly in the future.
P756 Additive effect of qnr genes, Ser83Leu substitution in
DNA gyrase and Ser80Arg in topoisomerase IV on the
ﬂuoroquinolone resistance in E. coli
A. Briales °, J.M. Rodriguez-Martinez, C. Velasco, P. Dı´az de Alba,
J. Pacho´n, J. Dominguez-Herrera, A. Pascual (Seville, ES)
Objectives: The aim of this study was to evaluate the impact of qnrA,
qnrB and qnrS in E. coli wild type strain and E. coli harbouring the most
frequent substitutions in the QRDR regions of GyrA and ParC, against
four different ﬂuoroquinolones (FQ).
Methods: E. coli ATCC 25922 was used as a background strain.
E. coli (GyrA Ser83Leu), E. coli (ParC Ser80Arg) and E. coli (GyrA
Ser83Leu/ParC Ser80Arg) were obtained by gene replacement, and
the respective derivatives carrying qnrA1, qnrB1 or qnrS1 into pBK-
CMV vector by transfromation. In total twelve isogenic strains were
investigated. MICs and MBCs of 4 ﬂuoroquinolones were determined.
Time killing curves were performed for each strain at 1 and 4 times MIC
values, and at ciproﬂoxacin 1 and 2mg/L.
Results: The effect on FQ resistance of the qnr genes was similar for CIP,
LEV, MXF and NFX in the different genetic backgrounds. MICs of CIP
against E. coli wild-type, E. coli (GyrA Ser83Leu) and E. coli (GyrA
Ser83Leu/ParC Ser80Arg) were 0.002, 0.125, 0.25mg/L, respectively.
In presence of qnrA, qnrB or qnrS, MICs increased from 4 to 64-fold
against this FQ. E. coli (gyrA Ser83Leu/parC Ser80Arg) harboring qnr
genes showed MICs for CIP, LEV, MXF and NFX that ranging from
1−2, 1−4, 1−2 and 4−8mg/L, respectively. MBCs of the four FQ were
the same or 1−2 dilutions higher than the corresponding MICs in all the
cases. In the time-killing assays, viable bacteria recovered for E. coli
wild-type harbouring qnr genes were at least 100-fold higher compared
to E. coli wild-type at 4xMIC of CIP at 24 h. In the time-killing assay at
1−2mg/L of CIP, no viable bacteria were recovered for E. coli wild-type
at 8 h, while 102–104 CFU/ml were recovered in presence of qnr. Those
values were observed to 24 h for qnrA, qnrB and qnrS. At 1mg/L of CIP,
a marked re-growth is observed in E. coli (gyrA Ser83Leu) harbouring
qnrA and qnrS. This re-growth was not observed for qnrB under the
same conditions.
Conclusions: The additive effect of the qnr genes, Ser83Leu in the GyrA
and Ser80Arg in ParC lead to intermediated susceptibility or resistance
to FQs. Expression of qnr genes in Enterobacteriaceae, at least in E. coli,
may have an important role to select one-step mutants with high level
of FQ resistance with additional substitutions in the QRDR region of
GyrA and ParC.
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P757 AAC-(6′)-Ib-cr, QnrC and QnrS determinants among bacte-
rial isolates from wild and food-producing animals in Portugal
E. Ferreira, L. Clemente, D. Jones-Dias, V. Manageiro, P. Themudo,
T. Albuquerque, A. Amado, M. Canic¸a ° (Lisbon, PT)
Objectives: Plasmid-mediated quinolone resistance (PMQR) is increas-
ingly identiﬁed worldwide in Enterobacteriaceae of human origin.
However, few reports describe their occurrence among bacteria from
animal origin. The aim of this study was to evaluate the extension of
PMQR in animals.
Methods: We screened two collections of Enterobacteriaceae isolates
(n = 140) for the presence of PMQR determinants, identiﬁed at National
Laboratory of Veterinary Research (LNIV, Lisbon), during a period
of two years (2008–2009). A total of 51 Salmonella isolates from
different serotypes were isolated from layers, and 89 Escherichia
coli were isolated from farm animals, birds and mammals. PCR and
nucleotide sequencing were used with speciﬁc primers to screen for
the presence of the following genes: qnrA, qnrB, qnrC, qnrD, qnrS,
aac-(6′)-Ib-cr and qepA genes. Susceptibility testing of isolates carrying
PMQR determinants was performed against quinolones (nalidixic acid,
ciproﬂoxacin, norﬂoxacin, peﬂoxacin, orbiﬂoxacin, marboﬂoxacin and
enroﬂoxacin) by disk diffusion and MIC methods, and interpreted
according to SFM veterinary and EFSA guidelines, respectively.
Results: We identiﬁed a qnrC-positive Salmonella enteritidis isolated in
a layer chicken. Three qnr genes were identiﬁed as qnrS1 and were
detected in E. coli isolates from a broiler, a dog and a turtle-dove.
The aac-(6′)-Ib-cr gene was detected in an E. coli isolated from a
dolphin. None of the isolates, from both collections, carried qnrA,
qnrB, qnrD or qepA genes. The isolates with aac-(6′)-Ib-cr and the
other two QnrS1 determinants showed diminished susceptibility to all
ﬂuoroquinolones tested and to nalidixic acid but one of the isolates with
QnrS1 determinant was susceptible to all antibiotics. Isolates with QnrC
determinant showed susceptibility to peﬂoxacin and marboﬂoxacin.
Conclusions: This survey showed that PMQR determinants are present
in animals from different environments in Portugal, including food-
producing animals. To our knowledge this is the ﬁrst report of a qnrC
gene in isolates from animal origin. The study highlights the need of
surveillance of this resistance mechanism and reinforces a more careful
use of ﬂuoroquinolones.
P758 Occurrence of plasmid-mediated quinolone resistance genes
and extended-spectrum b-lactamases encoding genes among
Gram-negative isolates from drinking and environmental
waters
N. Mendonc¸a °, J. Ramalho, P. Vieira, A. Tavares, P. Pereira, G.J. da
Silva (Coimbra, Leiria, PT)
Background: Water constitutes a way of dissemination of antimicrobial
resistance genes from bacteria of human and animal sources especially
if they are inserted in mobile genetic elements.
Objective: The aim of the work was to search for plasmid-mediated
quinolone resistance (qnr) genes and extended-spectrum b-lactamase
(ESBL)-encoding genes among coliform and non-fermentative bacilli
isolated from water of different origin.
Methods: Between May and October 2009, 187 isolates were recovered
from drinking, recreational, superﬁcial and underground waters. The
antimicrobial susceptibilities were determined by the disc diffusion
method. ESBL-phenotype was determined by double-disc synergy
method with ceftazidime and cefotaxime. blaTEM and blaSHV genes
were screened in ESBL-producers by PCR. Multiplex-PCR for the qnrA,
qnrB and qnrS genes was performed in nalidixic acid resistant isolates.
The amplicons detected were sequenced.
Results: Fifty three percent of the strains were isolated from
underground water, 24% from drinking water, 14% from superﬁcial water
and 10% in recreational water. Among consumption and recreational
water isolates, 2% were resistant to b-lactams. Furthermore, 3% of
resistance to nalidixic acid was also detected among isolates from
recreational water, where swimming pools were a major contributor.
Underground water isolates showed higher level of resistance to
amoxicillin/clavulanate (12%) and to nalidixic acid (7%) and a decrease
of susceptibility to ciproﬂoxacin (1%). Imipenem and gentamicin showed
good bacterial inhibitory activity with 99% and 79% of susceptibility,
respectively. Among the 187 strains, 11% showed resistance to nalidixic
acid of which only 15% presented qnrB. qnrB genes were found in
a Citrobacter spp. isolated from water of an artesian well (33%) and
Escherichia coli isolates from beach’s waters (67%). It is important
to highlight the levels of resistance detected to ceftazidime (4%) and
cefotaxime (5%), mostly among the recreational waters. Although results
from disc diffusion synergy method suggested that 3% of isolates were
ESBL-producers, we didn’t detect blaTEM or blaSHV genes by PCR.
Conclusions: The study showed the presence of antibiotic resistance
in aquatic environment, mostly in consumption, recreational and
underground waters and shows the presence of qnrB genes with potential
lateral transfer which may act in synergy with other quinolone resistance
mechanisms.
P759 Molecular analysis of ﬂuoroquinolone-resistant extra-
intestinal Escherichia coli isolates from dogs and humans in
Australia
J.L. Platell °, R.N. Cobbold, M.L. Menard, C.R. Clabots, M.A. Kuskowski,
D.J. Trott, J.R. Johnson (Brisbane, AU; Minneapolis, US)
Objectives: To assess the origins canine and human ﬂuoroquinolone-
resistant (FQr) phylogenetic group B2 FQr E. coli isolates in Australia.
Methods: Overall, 707 FQr extra-intestinal E. coli isolates (123
canine, 584 human) from Australian diagnostic laboratories (2007–2008)
underwent PCR-based phylotyping. Group B2 isolates were selectively
tested for single-nucleotide polymorphisms (SNPs) indicating sequence
type ST131, sepsis-associated O types (rfb PCR), susceptibility to 19
antimicrobials, extended virulence genotypes (53 traits), pulsed-ﬁeld gel
electrophoresis (PFGE) proﬁles, and partial multi-locus sequence typing
(MLST; fumC, gyrB, and recA).
Results: Group B2 accounted for 37% (263/707) of study isolates,
including 11% (13/123) of canine but 43% (250/584) of human isolates
(P< 0.001). 58% of group B2 isolates were multi-drug resistant (i.e.,
resistant to 4 antimicrobials), regardless of host. ST131 accounted
for the majority of both human (205/250, 82%) and canine (9/13,
69%) group B2 isolates. PFGE analysis showed several instances of
94% similarity among ST131 isolates across host species both within
Australia and compared with an international ST131 E. coli library. An
O75:K+ clonal group (ST1193), which likewise included canine and
human isolates, accounted for nearly 50% (24/49) of the non-ST131
group B2 isolates. Its two main pulsotypes were 90% similar; each
exhibiting human-canine commonality. Group B2 isolates’ virulence
proﬁles differed signiﬁcantly by clonal group, but not by host species.
Conclusions: Group B2 was signiﬁcantly more prevalent among human
than canine-source FQr E. coli in Australia, suggesting that dogs are
a less important reservoir for such strains than are humans. Two
clonal groups, ST131 (81%) and ST1193 (9%), accounted for 90%
of FQr group B2 isolates. Across-species strain similarity (by ST,
virulence genotype, and PFGE proﬁle) supports human-dog exchange
of FQr E. coli within Australia. Likewise, PFGE commonality with
international ST131 isolates suggests that dogs and humans in Australia
are participants in the intercontinental emergence and dissemination of
ST131. This, plus Australia’s unique banned use of FQs in production
animals, argues against the local food supply as a source for Australian
FQr group B2 strains.
Quinolone resistance in Enterobacteriaceae S193
P760 Antibiotic resistance of Salmonella enterica isolates from
Greece mediated by tetA, qnrA and qnrB resistant genes
G. Filioussis °, N. Tzimotoudis, E. Petridou, A. Zdragas,
K. Papageorgiou, S.K. Kritas (Thessaloniki, GR)
Objectives: The antibiotic resistance of ﬁfty Salmonella enterica strains,
isolated from animal and food sources in Greece and its association with
resistance genes and plasmids were investigated.
Methods: Antibiotic susceptibility of the Salmonella enterica isolates
was determined by dilution antimicrobial susceptibility tests in
accordance to the M100-S16 method and the interpretive criteria of
the Clinical and Laboratory Standards Insitute (CLSI, 2006). The MICs
were determined as the lowest concentrations of antimicrobial agents
that inhibited visible growth. PCR assays were performed to identify
the presence of genes conferring resistances. Nucleotide sequences of
PCR products were aligned and compared to GenBank homologue
sequences (www.ncbi.nlm.nih.gov). The plasmid content of the resistant
isolates was investigated by pulsed ﬁeld gel electrophoresis (PFGE) after
cleavage with Sau3AI restriction enzyme.
Results: Twelve isolates were resistant to tetracycline (MIC >128mg/ml),
ﬁve to ampicillin (MIC >128mg/ml) and three to nalidixic acid (MIC
>128mg/ml) and ciproﬂoxacin (MIC >128 mg/ml). The tetA gene was
highly prevalent in Salmonella strains of our study, being detected in
nine tetracycline-resistant isolates. Meanwhile qnrA and qnrB genes were
detected in the three quinolone resistant strains. The extended sequence
analysis of the products beard high identities when compared to GenBank
sequences. Finally no speciﬁc bands in pulsed-ﬁeld gel electrophoresis
(PFGE) patterns could be attributed to plasmid DNA.
Conclusions: This is to the best of our knowledge the ﬁrst report of
tetA, qnrA and qnrB resistant genes in Salmonella enterica isolates in
Greece. Plasmids and transposons carrying resistant genes have been
isolated from salmonellas in many countries. As they seem to be more
broadly distributed among enterobacteria than ﬁrst assumed, our further
work would be focused on the distribution of these DNA elements among
resistant Salmonella enterica serovars.
P761 Plasmid-mediated quinolone resistance genes in Enterobac-
teriaceae isolates of human and animal origin in Lithuania
J. Povilonis °, V. Seputiene, M. Jurenaite, M. Ruzauskas,
R. Siugzdiniene, M. Virgailis, A. Pavilonis, E. Suziedeliene (Vilnius,
Kaisiadorys, Kaunas, LT)
Objectives: Plasmid-mediated quinolone resistance (PMQR) caused
by qnr, qepA and aac(6′)-Ib-cr genes is emerging worldwide in
Enterobacteriaceae. The aim of this study was to evaluate the prevalence
of PMQR determinants in a collection of quinolone-resistant bacterial
isolates of human and animal origin in Lithuania (2005–2008) and
to investigate their association with extended-spectrum b-lactamase
(ESBL)-producing isolates.
Methods: A total of 265 non-repetitive quinolone-resistant (Nal, Cip
or Nor) bacterial isolates from human infections (n = 65 E. coli, n = 41
K. pneumoniae, n = 5 K. oxytoca) and from farm animals (n = 99
E. coli, n = 55 S. enterica) were studied. Screening of qnr (qnrA, qnrB,
qnrS), qepA and aac(6′)-Ib-cr genes was carried out by multiplex and
conventional PCR. Restriction analysis of PCR products was used to
distinguish between aac(6′)-Ib-cr and aac(6′)-Ib alleles.
Results: Of 265 isolates, 61 (23%) harboured PMQR genes (clinical
isolates: n = 30/65 (46%) E. coli, n = 18/41 (44%) K. pneumoniae, n = 2/5
(40%) K. oxytoca, animal isolates: n = 11/99 (11%) E. coli). The most
prevalent was aac(6′)-Ib-cr gene, found in 57 (22%) isolates (clinical
isolates: n = 29 E. coli, n = 17 K. pneumoniae, n = 1 K. oxytoca, animal
isolates: n = 10 E. coli). The qnr genes were detected in 8 (3%) isolates
and were represented by qnrB (clinical isolates: n = 1 E. coli, n = 1
K. pneumoniae, n = 1 K. oxytoca) and qnrS (clinical isolates: n = 1
K. oxytoca, animal isolates: n = 4 E. coli). qnr and aac(6′)-Ib-cr genes
coexisted in three E. coli animal isolates and one K. oxytoca clinical
isolate. No PMQR genes were observed in S. enterica animal isolates.
Among 71 E. coli, K. pneumoniae and K. oxytoca clinical isolates
producing CTX-M type b-lactamases, four (5.6%) harboured qnr genes:
qnrB (n = 1 CTX-M-3 E. coli, n = 1 CTX-M-15 K. pneumoniae, n = 1
CTX-M-15 K. oxytoca) and qnrS (n = 1 CTX-M-3 K. oxytoca). Thirty
three (46%) isolates carried aac(6′)-Ib-cr gene (n = 14 CTX-M-15 E. coli,
n = 18 CTX-M-15 K. pneumoniae, n = 1 K. oxytoca).
Conclusion: The aac(6′)-Ib-cr determinant is more prevalent than
other PMQR genes (P< 0.01) in quinolone resistant K. pneumoniae,
K. oxytoca and E. coli clinical isolates and E. coli animal isolates.
A strong association (P< 0.01) between CTX-M15 and aac(6′)-Ib-
cr determinants in CTX-M-producing E. coli, K. pneumoniae and
K. oxytoca clinical isolates was determined.
P762 Prevalence of plasmid-mediated quinolone resistance
determinants in Enterobacteriaceae strains isolated in
north-eastern Italy
A. Mazzariol °, R. Koncan, B. Kocsis, R. Aschbacher, P. Lanzafame,
R. Fontana, M. Rassu, M. Schinella, G. Cornaglia (Verona, Bolzano,
Trento, Vicenza, Rovereto, IT)
Objectives: To investigate the prevalence of plasmid-mediated quinolone
resistance determinants among Enterobacteriaceae isolated in North-East
Italy.
Materials and Methods: We collected 756 Enterobacteriaceae, non-
susceptible to ﬂuoroquinolones and/or resistant to third-generation
cephalosporins, isolated during 2007 and 2008 in ﬁve different
microbiology laboratories (namely Verona, Vicenza, Bolzano, Trento and
Rovereto). All isolates were screened by PCR for the presence of three
qnr determinants − namely A, B, and S − for the qepA efﬂux pump and
for aac(6′)-Ib-cr. These non-duplicate isolates included 497 Escherichia
coli, 69 Proteus spp., 52 Enterobacter spp., 68 Klebsiella spp., 24
Morganella morganii, 18 Citrobacter spp, 21 Providencia spp, and 7
Serratia spp.
Results: Of 756 strains tested 36 (4.76%) presented either qnrS (28
strains) or qnrB (8 strains). No qnr A was detected. Of 497 E. coli only
12 (2.41%) carried a qnr determinant (namely qnrS). The prevalence
of qnr determinants was higher in other species, namely 3.8% in
Enterobacter spp. (two qnr B), 33.33% in Citrobacter spp. (six qnr B),
and 22.05% in Klebsiella spp. (15 qnr S). The qep A gene was detected
in four K. oxytoca. strains. (0.53% of the total isolates). The aac(6′)-Ib-cr
determinant was detected in 66 strains (8.73% of the total), namely 56
E. coli, 8 Klebsiella, one P. mirabilis and one M. morganii. Five strains
harboured more than one PMQR, i.e. four E. coli carried a qnrS plus
aac(6′)-Ib-cr, and one Klebsiella harboured a qnrS plus a qepA). The
ciproﬂoxacin resistance of strains carrying one of the plasmid-mediated
determinants ranged between 0.25mg/L and 256mg/L. Out of 108
strains carrying a PMQR, 67 produced at least one ESBL and 6 strains
produced an MBL (VIM-1).
Conclusions: The prevalence of PMQR determinants in North-
Eastern Italy proved low among E. coli but much higher in other
Enterobacteriaceae genera such as Klebsiella and Citrobacter. The
aac(6′)-Ib-cr variant was also frequently detected, whilst the prevalence
of the qepA efﬂux pump is was very low. More often than not the PMQR
determinants were found to be associated with ESBLs.
P763 Prevalance and diversity of plasmid-mediated quinolone
resistance genes in extended-spectrum b-lactamase positive
Escherichia coli and Klebsiella pneumoniae: ﬁrst report of
qepA from Turkey
Z. Gulay °, M. Bicmen, D. Gur on behalf of the Hitit-2 Study Group
Objective: Plasmid-mediated quinolone resistance (PMQR) seem to be
emerging in Turkey as in the other parts of the world. However, previous
studies have not included some of the newer members of the PMQR
genes. In this study, we screened the PMQR determinants (qnr A, B, C,
S, qepA and aac(6′)-Ib-cr) in ESBL-positive invasive E. coli (Ec) and
K. pneumoniae (Kp) in order to update existing data.
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Method: The isolates were collected from 12 centers in Turkey as a
part of The Hitit-2 Surveillance Study. A total of 151 isolates (67 Ec,
84 Kp) were taken into the study. Of these, 105 (69.5%) were resistant
to nalidixic acid (Nal) and 95 to both Nal and CIP. PMQR genes were
detected by PCR. aac(6′)-Ib-cr variant is identiﬁed by digestion with
BseG1. All positive results were conﬁrmed by sequencing.
Results: Of the Nal(r) isolates 77 (73.3%) possessed one of the PMQR
genes. Among these 13 (16.8%) carried more than one PMQR gene.
The prevalance of PMQR genes was 12.5%-100% according to the
centers. Qnr A(A1), B(B1, B2, B5, B6/9) and S (S1) were detected in
1.9%, 10.5% and 1.9% of the isolates respectively. These were colected
in 5 different centers. None of the isolates carried qnrC. aac(6′)-Ib-
cr was detected in 69.5% of the Nal(r) isolates and was found in all
collaborating centers. 89% of aac(6′)-Ib-cr-positive isolates (43 Ec, 22
Kp) produced CTX-M-15 ESBL and of the Ec isolates 46.5% belonged
to the ST131:O25b clone. PMQR genes were carried on plasmids with
sizes 16−91 kb along with CTX-M b-lactamases in most cases. In two Ec
isolates qepA gene is detected for the ﬁrst time in Turkey. The isolates
came from one center and also possessed aac(6′)-Ib-cr and qnrB2. They
had identical ERIC-PCR patterns.
Conclusion: The results of this study show that both the prevalance
and the diversity of PMQR genes are increasing in ESBL positive
Enterobacteriaceae in Turkey. As a high number of isolates belong to
the multiresistant ST 131:O25b clone which caused epidemics in the
community, this study also indicates a potential risk of multiresistance
in community acquired infections.
P764 ESBL carrying Salmonella isolates with reduced
ﬂuoroquinolone susceptibility in Finnish travellers returning
from Asia
M. Gunell, P. Kotilainen, P. Huovinen, A-M. Rissanen, M. Korkeila,
A. Siitonen, M. O¨sterblad, J. Jalava, A. Hakanen ° (Turku, Kuopio,
Lappeenranta, Helsinki, FI)
Objectives: Fluoroquinolones and 3rd generation cephalosporins are
drugs of choice to treat severe Salmonella infections. Reduced
ﬂuoroquinolone susceptibility among Salmonella enterica isolates has
increased since late 1990’s. Furthermore, proportion of ESBL producing
strains of Escherichia coli and other species of Enterobacteriaceae
has increased world wide. So far Salmonella isolates acquiring
resistance determinant against both ﬂuoroquinolones and 3rd generation
cephalosporins have not been reported in Finland. This paper describes a
series of ESBL carrying Salmonella isolates among travellers returning
from Asia to Finland.
Methods: We included in this study four S. enterica isolates collected
from two different hospitals in Finland during March and April 2009.
The isolates were sent to the reference laboratory for ESBL gene
determination. We performed an ESBL screening using a disk diffusion
test with ampicillin (AMP) (10 mg), cefotaxime (CTX) (30 mg),
ceftazidime (CAZ) (30 mg), cefotaxime/clavulanic acid (CD03) (30/10
mg) and ceftazidime/clavulanic acid (CD02) (30/10 mg) disks. These
isolates were also screened for ESBL resistance genes of TEM-, SHV-
and CTX-M families by PCR and sequencing. In addition, one strain
from our earlier Salmonella collection showed ESBL phenotype and
was taken into this study.
Results: All Salmonella isolates tested showed an ESBL phenotype:
AMP disk 6mm, CTX disk 6mm, cefotaxime/clavulanic acid disk
25−29mm, CAZ 6−16mm and ceftazidime/clavulanic acid disk
23−28mm. The one strain from the earlier collection had AMP MIC
>128mg/L, CTX MIC 16mg/L, CAZ MIC >64mg/L and cefurox-
ime MIC 32mg/L. In addition, all of these isolates showed reduced
ciproﬂoxacin susceptibility (MIC 0.125mg/L). PCR results revealed
that one of the isolates was simultaneously TEM-1 and CTX-M positive,
three of the strains carried CTX-M-15 gene and the one strain from the
earlier collection had TEM-1 gene.
Conclusions: To date, this is the ﬁrst report on ESBL producing
Salmonella strains in Finland. The rapid emergence of ESBL carrying
Salmonella isolates with decreased ciproﬂoxacin susceptibility among
travellers returning to Finland needs more attention. These ﬁndings
suggest that ESBL screening is important not only with E. coli and
Klebsiella, but also with Salmonella strains, especially with isolates
showing the reduced ﬂuoroquinolone susceptibility.
P765 Analysis of the mechanisms of ﬂuoroquinolone resistance in
clonal group ST 131 uropathogenic Escherichia coli
T. Gibreel °, F. Bolton, J. Cheesbrough, M. Upton, A. Fox, A. Dodgson
(Manchester, Preston, UK)
Objectives: Recent studies have reported the widespread emergence of
the O25:H4-ST131 clone of uropathogenic Escherichia coli (UPEC)
which is characterized by CTX-M-15 ESBL production and has fre-
quently been associated with ﬂuoroquinolone resistance, this resistance
has increasingly been traced to plasmid medicated factors such as the
aac (6”)-Ib-cr gene and different Qnr genes that offer topoisomerase
protection. In this study we explore the prevalence of different quinolone
resistance mechanisms among ST131 strains within a deﬁned UPEC
population.
Methods: 32 E. coli isolates were examined representing the total of
ST 131 found among 250 non-duplicate isolates recovered from patients
with urinary tract infection, in the northwest region of England between
September 2007 and December 2008. All isolates were screened for
mutations in quinolone resistance determinant regions (QRDRs) of gyrA
and parC genes by sequencing the respective targets. A PCR-based
restriction fragment length polymorphism (PCR-RFLP) assay was used
to identify the aac (6’)-lb-cr variants and screening for the three known
qnr genes was carried out using Multiplex PCR.
Results: Of the 32 tested ST131 isolates 20 (62%) showed resistance
to quinolones (nalidixic acid) and 19 (59%) expressed additional
resistance to ﬂuoroquinolones (ciproﬂoxacin). All ciproﬂoxacin resistant
isolates had multiple mutations in both gyrA and parC genes while
the one nalidixic acid resistant isolate that failed to show resistance
to ciproﬂoxacin had a single gyrA mutation at codon 83 (Ser-Leu). On
the other hand only nine isolates carried the aac (6’)-lb-cr gene, which
represents 50% of ciproﬂoxacin resistant isolates. Of the 20 isolates
tested, none carried any of the targeted qnr genes.
Conclusion: The strong linkage between the ST131 clone and quinolone
resistance has been suggested to be the result of the high prevalence of
aac (6)-lb-cr among isolates of this clone. However, our study shows
that ﬂuoroquinolone resistance occurs in ST131 UPEC as a result of
accumulated point mutations in both gyrA and parC genes, irrespective
of their acquisition of any plasmid mediated resistance.
P766 Antimicrobial resistance of Gram-negative bacteria isolated
from domestic and food-producing animals: potential
reservoirs of plasmid-mediated quinolone resistance genes
N. Mendonc¸a, P. Vieira, J. Ramalho, M.J. Saavedra, G.J. da Silva °
(Coimbra, Vila Real, PT)
Objective: The aim of the study was to evaluate the antimicrobial
resistance of domestic and food-producing animals’ Gram negative
bacteria and to screen for the presence of plasmid-mediated quinolone
resistance genes (qnr) as few data on the prevalence of these determinants
in strains from animals are available.
Methods: Gram negative bacteria were isolated from domestic (cat, dog
and jennet) and food-producing (chicken, rabbit, trout and gilt-head
bream) animals. Antimicrobial susceptibility was performed using the
disc diffusion method according to CLSI guidelines. The presence of
qnr genes was determined by Multiplex-PCR and DNA sequencing.
Results: Of the 53 strains studied, 22 were isolated from domestic
animals (DA) and 31 from food-producing animals (FPA). The majority
of isolates were Enterobacteria (70%) and 46% were Escherichia coli.
Isolates of both groups showed high resistance to amoxicillin: 87% for
FPA and 91% for DA, whose activity were recovered in the presence of
clavulanic acid (26 and 67% of resistance, respectively). All FPA isolates
were susceptible to ceftazidime, cefotaxime and imipenem. In contrast,
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23%, 45% and 9% of DA isolates showed decrease susceptibility or
resistance to these b-lactams, respectively. Isolates were more susceptible
to gentamicin (100 and 91% for FPA and DA isolates, respectively) than
to kanamycin (32 and 23% for FPA and DA isolates, respectively). For
cloramphenicol and SXT, FPA and DA isolates showed 35% and 41%
of resistance, respectively, while tetracycline resistance was higher for
FPA (52%) than for DA group (41%). Both groups were more resistant
to nalidixic acid (55% for FPA and 59% for DA) than to ciproﬂoxacin
(19 for FPA and 27% for DA). In DA isolates were found 3 isolates with
QnrB and 1 with QnrS, none susceptible to quinolones. One isolate with
QnrB (quinolone resistant) and 6 with QnrS were found in FPA group,
susceptible to quinolones. The six isolates were collected from rabbits.
Conclusion: This work shows differences in antibiotic resistance
between isolates of DA and FPA. Noteworthy is the appearance of
resistant isolates to broad spectrum b-lactams, including imipenem in
isolates from DA group. qnr genes were detected in both groups,
suggesting that animals may act as reservoirs of these genes, even in
strains susceptible to nalidixic acid. Resistant bacteria present in DA
and FPA can be transmitted to humans by contact or food-chain, an
increasing risk for human health.
P767 Quinolone resistance mechanisms in Escherichia coli isolated
from children (with or without diarrhoea) under 1 year in
Lima, Peru
M.J. Pons °, S.G. Mosquito, E. Mercado, P. Rivera, R. Maves, L.J. Del
Valle, M. Vargas, T. Ochoa, J. Ruiz (Barcelona, ES; Lima, PE)
Objectives: The objective was to analyse the quinolone resistance
mechanisms (gyrA, parC, aac(6′)Ib-cr, qnrA,B,S) in Escherichia coli
isolated from children (with or without diarrhoea) in a periurban area of
Lima, Peru´.
Method: Strains: A total of 85 E. coli isolates (11 Enteropathogenic −
EPEC, 11 Diffussely adherent − DAEC, 27 Enteroaggregative − EAEC,
2 Enterotoxigenic − ETEC − and 34 non-diarrheogenic − non DEC)
exhibiting resistance or diminished susceptibility to quinolones were
analyzed. Antimicrobial susceptibility to nalidixic acid (NAL) and
ciproﬂoxacin (CIP) was established by disk diffusion in accordance with
CLSI. Presence of mutations in gyrA and parC genes was determined
by PCR and sequencing.
Table 1. Quinolone resistance patterns
Nal Cip GyrA parC QnrB AAC(6′)lb-cr NDEC DEC
I S wt wt + − 1 1
I S wt wt − + 0 1
I S wt wt − − 0 2
I S Leu 83 wt − − 0 2
R S wt wt + − 2 1
R S wt wt − − 1 5
R S wt wt − + 0 7
R S Leu 83 wt + + 1 0
R S Leu 83 wt − + 2 11
R S Leu 83 wt − − 6 19
R S Leu 83 Ile 80 − − 4 0
R S Leu 83 Ile 80 − + 1* 1
R S Leu 83-Asn 87 Ile 80 − − 1 0
R S Leu 83-Asn 87 Ile 80-Gly 84 − − 1 0
R R Leu 83 Ile 80 − − 1 0
R R Leu 83-Asn 87 Ile 80 − − 8 0
R R Leu 83-Asn 87 Ile 80-Val 84 − − 3 2
*This strain was PCR positive for QnrS.
Results: Attending to the resistance patterns and the mechanisms
involved were described 18 resistance proﬁles (Table 1).
Among DEC isolates the most frequent resistance pattern was NalR,
CipS followed by NalI CipS. No NalR CipR phenotype was detected
among DEC isolates. Meanwhile NalR CipS phenotype was the most
frequently detected in non-DEC isolates. All but 1 isolate, with one
substitution in GyrA and one in ParC presents the phenotype NalR Cip
S, while isolates with three or more substitutions in the targets were
full resistant to both quinolones. The unusual phenotype NalI or NalR
without target mutation was detected in 21 isolates, although in 13 cases
presence of the searched plasmidic mechanisms was detected (QnrB in
3 cases and AAC(6′)Ib-cr in the remaining10).
Interesting the aac(6′)Ib-cr gene was mainly detected in DEC isolates
that in non-DEC (20 vs 4 isolates).
Conclusions: A high frequency of isolates without identiﬁed mechanism
of quinolone-resistance has been observed, suggesting an high relevance
in the area of unusual mechanisms of resistance (such as hyperexpression
of chromosomal efﬂux pumps or the plasmid encoded efﬂux pumps
QepA or OqxAB).
Full characterization of these isolates is need to be performed in order
to identify the involved mechanism of quinolone-resistance.
P768 Presence of different resistance determinants conferring
plasmid-mediated quinolone resistance in Salmonella isolates
from reptiles in Germany
B. Guerra, K. Thomas, J. Beutlich, S. Jahn, L. Cavaco, R. Helmuth,
A. Schroeter, K. Veldman ° (Berlin, DE; Copenhagen, DK; Lelystad, DE)
Objective: Molecular characterization of antimicrobial resistance (R) in
Salmonella (S.) isolates originating from reptiles showing a plasmid-
mediated quinolone resistance (PMQR)- phenotype, in Germany.
Methods: Among the S. enterica isolates from animal and food
origin (2000–2008) obtained in the National Reference Laboratory for
Salmonella (NRL-Salm) strain collection, all epidemiologically unrelated
isolates showing a MIC for nalidixic acid = 8−32mg/L and for
ciproﬂoxacin 0.125−1mg/L, were selected. Twelve isolates originated
from reptiles. Molecular methods like PCR ampliﬁcations/sequencing,
PFGE with XbaI, plasmid proﬁle analysis and Southern-hybridization
were used to characterize the resistance determinants and epidemiologi-
cal relationship of the isolates.
Results: Nine isolates were positive for PMQR-genes. The qnrB19 gene
was present in seven strains, two S. Urbana, two S. subsp. I rough,
one S. subsp. II and two S. subsp. IV, isolated from different reptiles
(i.e. iguana, bearded dragon, turtle, gecko, snake) in different German
regions. The two S. Urbana and one of the rough isolates were isolated
from different animals in the same zoo, and showed by XbaI-PFGE and
plasmid analyses very similar patterns, suggesting the clonal spread of
a qnrB19-postive strain. The qnrB6 and acc(6′)-Ib-cr were both found
in one S. Lichtﬁeld isolated from a turtle. The qnrS1 gene was found
in a S. Pomona strain also isolated from a turtle in a different German
region. Plasmid location of the genes was conﬁrmed. No qnrA, qnrC,
qnrD or qepA genes were detected among the isolates analysed.
Conclusions: Our results show that various determinants conferring
PMQR are present in Salmonella isolates originating from different
reptiles. These animals could be a reservoir for the further spread of these
determinants, and thus they must be seen as a Public Health concern.
Pseudomonas
P769 A new pathway involved in cross-resistance to antibiotics in
Pseudomonas aeruginosa
C. Muller, K. Jeannot °, P. Ple´siat (Besanc¸on, FR)
Objectives: Constitutive overproduction of the multidrug efﬂux system
MexXY/OprM provides P. aeruginosa with a moderate resistance to
ﬂuoroquinolones, aminoglycosides, and cefepime. In mutants named
agrZ, MexXY/OprM upregulation results from inactivation of gene
mexZ, the product of which represses the meXY operon. However, other
efﬂux mutants (agrW) have been reported among clinical strains, that
exhibit an intact mexZ gene. This study investigates a subclass of this
latter type of mutants, dubbed agrW2.
Methods: Spontaneous MexXY/OprM overproducing mutants from
reference strain PAO1 were selected on amikacin in vitro. Their
drug susceptibility proﬁles were determined with the conventional
agar dilution method according to standard guidelines. Search for
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mexZ mutations was performed by DNA sequencing and BLAST
alignement analysis. Transript levels of genes mexY, mexZ, oprD,
PA5470, and PA5471 together with production of transporter MexY were
assessed by quantitative Real Time PCR (RT-qPCR) and immunoblotting,
respectively. The point mutation in a selected agrW2 mutant was
identiﬁed by whole genome sequencing (6.3 Mbp) by using an Illumina
Genome Analyser.
Results: Analysis of spontaneous amikacin resistant clones from strain
PAO1 led to identiﬁcation of a new type of MexXY/OprM overproducing
mutants (agrW2). Unlike previously reported agrW mutants, the agrW2
mutants exhibited increased resistance to carbapenems (imipenem 8
mg/mL) in addition to cefepime (16 mg/mL), ciproﬂoxacin (1 mg/mL),
and aminoglycosides (amikacin 16−32 mg/mL). Upregulation of MexY
gene (15−17 fold) and downregulation of porin OprD gene (0.06–0.07
fold) were in full agreement with this new resistance phenotype. Gene
deletion experiments demonstrated that neither repressor gene mexZ nor
the PA5471-PA5470 locus known as essential for mexXY drug induction
were involved in MexXY/OprM derepression in the agrW2 mutants.
Whole genome sequence analysis of a selected agrW2 clone revealed
a single nucleotide change (G→A) inactivating a yet uncharacterized
signal transduction system. Alteration of this system was recognized in
clinical multidrug resistant strains.
Conclusion: This study provides new insight into the complex regulation
of the MexXY/OprM pump. Importantly, it shows that aminoglycosides
are able to select porin-deﬁcient mutants of P. aeruginosa cross-resistant
to carbapenems.
P770 Surveillance of Pseudomonas aeruginosa isolates resistant
to carbapenems over a 7-year period (2003–2009) in Aveiro,
Portugal
S. Ferreira °, L. Tortas, E. Ramalheira, S. Mendo (Aveiro, PT)
Background: Pseudomonas aeruginosa is an important pathogen
responsible for nosocomial infections, mainly among immunocom-
promised patients. In the last years, several studies describing the
occurrence of metalo-b-lactamases and their association with an increase
on antibiotic resistance have been largely discussed. The aim of this work
was to investigate the incidence and prevalence of carbapenem resistant
P. aeruginosa since 2003, in a Hospital in the central region of Portugal
(Hospital Infante D. Pedro, Aveiro).
Methods: P. aeruginosa isolates were recovered from patients of
different wards admitted to the hospital during a 7 years period.
The isolates were identiﬁed by the automatic VITEK 2 system and
Advanced Expert System (VITEK 2 AES) (bioMe´rieux, Marcy L’E´toile,
France). The antibiotic susceptibilities were determined by disk diffusion
according to CLSI guidelines. The detection of metallo-b-lactamases was
determined by double disk test IMP/IMP+EDTA and conﬁrmed by PCR
followed by nucleotide sequence determination. Nucleotide and predicted
aminoacid sequences were analysed by Clustal W and Blast programs
and compared with others deposited in the databases.
Results: According to susceptibilities proﬁles, resistance to imipenem
in the timeframe studied was higher than resistance to meropenem.
During 2003 and until 2006 the number of resistance strains isolated was
constant. Nevertheless resistance to both antibiotics has been markedly
increasing in the last 3 years. The presence of blaVIM-2 emerged in
2007 as part of two distinct gene cassette arrays of class 1 integrons.
Both integrons revealed to be present in the hospital since 2007 in non-
related isolates and may be contributing for the increasing of resistance
observed.
Conclusion: This study demonstrates the increase of carbapenem
resistant strains in the last 3 years. These results may reﬂect the
intensive use of carbapenems, namely imipenem in the recent years,
thus compromising therapy of P. aeruginosa infections in this hospital.
P771 Molecular analysis and antimicrobial susceptibility
of Pseudomonas aeruginosa clinical isolates producing
metallo-b-lactamases
A. Bisiklis, C. Manolopoulos, E. Protonotariou °, S. Arampatzi,
E. Diza, F. Frantzidou (Thessaloniki, GR)
Objectives: The aim of this study was to determine the prevalence
of metallo-b-lactamases (MBLs) in clinical isolates of P. aeruginosa,
exhibiting resistance to carbapenems in a tertiary care Greek hospital.
Materials and Methods: The period 2002–2005 a total of 101 non-
repetitive clinical isolates of P. aeruginosa resistant to carbapenems
(MIC> 16 mg/ml) recovered from clinical specimens were studied.
Bacterial identiﬁcation and susceptibility testing were performed using
the VITEK2 automated system (bioMe´rieux, France). The MICs of
imipenem and meropenem were determined by the E-test (AB Biodisk,
Solna, Sweeden). All strains were screened for MBL production using
the IMP-EDTA double disk synergy test. The isolates with positive
the IMP-EDTA test were subjected to Real-time PCR (RT-PCR) using
speciﬁc primers for the detection of blaVIM and blaIMP. Moreover, all
MBL positive strains were studied for the presence of class 1 integron
and sequencing analysis for the possible presence of other genes that
coexist in the variable region of the integron.
Results: Among the 101 carbapenem-resistant P. aeruginosa isolates,
36 were positive by RT-PCR for blaVIM genes. Sequencing analysis
revealed the exist of blaVIM-2 gene. Susceptibility testing showed
that the isolates harboring blaVIM-2 had higher MICs in ceftazidime,
cefepime, amikacin, tobramycin, ciproﬂoxacin, and lower MICs in
pipercillin, piperacillin/tazobactam, aztreonam, gentamicin, netilmicin,
and colistin than those that no gene was identiﬁed. Integron class 1
was found in 30 out of 36 strains tested. Sequencing analysis of the
variable region of the integron 1 revealed that (a) 4 isolates harbored only
blaVIM-2 and confered resistance to all b-lactams and aminoglycocides,
(b) in 16 isolates blaVIM-2 coexisted with blaaacA29a which confers
resistance to tobramycin and amikacin while (c) in 10 isolates blaVIM-2
coexisted with blaaadB which confer resistance to the aminoglycosides,
gentamicin, tobramicin, netilmicin and amikacin, (d) the last 26 isolates
did not confer resistance to all b-lactams.
Conclusions: (a) 35.6% of the studied P. aeruginosa carbapenem
resistant isolates harbored a metallo-b-lactamase enzyme, VIM-2.
(b) In a percentage of 86.1% blaVIM-2 was detected as a part of the gene
cassette in the variable region of integron class 1. (c) In a percentage of
83.8%, blaVIM-2 coexisted with other gene cassettes (aminoglycosides)
within the variable region of the integron 1.
P772 MBL’s in Enterobacter cloacae and Pseudomonas spp. in a
medical university hospital, Warsaw
J. Patzer °, A. Rokosz, A. Sawicka-Grzelak, D. Dzierzanowska,
T. Walsh, M. Toleman (Warsaw, PL; Cardiff, UK)
Objectives: To analyse genetic structures containing metallo-b-lactamase
(MBL) genes in 32 multiresistant isolates collected in the Warsaw
Medical University Hospital, Poland during 2001–2005.
Methods: 25 Pseudomonas aeruginosa, ﬁve P. putida, one P. stutzeri
and one Enterobacter cloacae isolates, positive by Etest MBL strips
and carbapenem hydrolysis assays, were collected. The MBL positive
strains were further tested by a combination of genetic techniques
including PCR, RFLP of integron structures, sequencing, genomic
location experiments using S1 and Spe-1 digests and sequencing.
Results: All isolates were positive by hybridization with the blaVIM-1
and blaVIM-2 radio-labelled probes. Digestion of the class-1 integron
PCR products with HincII produced seven different integron RFLP types
(Types A-G). Type A was found in six P. aeruginosa, four P. putida and
one P. stutzeri strains and consisted of a class-1 integron harbouring
the aacA4 and blaVIM-4 gene cassettes. Type B was found in 12
P. aeruginosa and one E. cloacae strains, harbouring an integron with the
aacC4, blaVIM-4 gene cassettes and the insertion sequence ISpolnew.
Seven strains harboured the blaVIM-2 gene cassette in several different
Pseudomonas S197
gene arrays and one strain of P. aeruginosa harboured the blaVIM-1
gene. Other genes cassettes commonly found are aadA6, aadA10 and
aadB, conferring resistance to aminoglycosides. The blaVIM-4 genes
were mostly located on chromosome whereas all blaVIM-2 genes were
located on plasmids of various sizes ranging from 50kb to 350kb. There
was also evidence of the blaVIM-2 gene on multiple plasmids in two of
P. aeruginosa isolates.
Conclusions: The most commonly isolated MBL genes in Warsaw
are the blaVIM-4 fused gene cassette and blaVIM-2 gene cassette.
Of interest is the fact that blaVIM-2 gene is more often found on
plasmids than on the chromosome which is the reverse for blaVIM-4.
This observation may partly explain the fact that the blaVIM-2 gene is
found more often than any other MBL gene.
P773 Rare occurrence of carbapenem-resistant Pseudomonas
aeruginosa isolates carrying VIM-2 metallo-b-lactamase
S. Sardelic °, B. Bedenic, C. Colinon, Z. Bosnjak, G.M. Rossolini,
S. Kalenic (Split, Zagreb, HR; Villeurbanne, FR; Siena, IT)
Objectives: Reports of resistance to carbapenems in P. aeruginosa
caused by acquired metallo-b-lactamases (MBL) are increasing world-
wide. Following the ﬁrst report of two VIM-2-producing P. aeruginosa
strains in Croatia, we determined the occurence of MBL-producing
strains among imipenem resistant P. aeruginosa isolated from 2001 to
2007.
Methods: MICs to antipseudomonal antibiotics were determined by
broth microdilution. O-serotypes were determined by slide-agglutination.
Strain typing was achieved by PFGE of genomic DNA using the
XbaI enzyme and analysis of electrophoretic proﬁles with GelCompare
software. MBL genes were screened by PCR using speciﬁc primers
amplifying VIM and IMP genes. Variable arrays of MBL-carrying
integrons were determined by PCR-sequencing.
Results: Among 169 P. aeruginosa isolates studied, 138 (82%)
were multiresistant, ie. resistant to at least three drugs of following
classes of antibiotics: b-lactams, carbapenems, aminoglycosides, and
ﬂuoroquinolones. The most potent antibiotic was amikacin (83%
susceptible isolates; MIC90 32mg/L), followed by colistin (50%
susceptible; MIC90 8mg/L), and ceftazidime (31% susceptible; MIC90
64mg/L), respectively. EDTA signiﬁcantly lowered MICs to imipenem
in 3.5% of isolates whereas boronic acid signiﬁcantly lowered MICs
to ceftazidime and imipenem in 60% of isolates. The most common
serotype was O12 (59% of isolates) followed by O11 (17%) and O1
(4%). Most of O12 (85% of isolates) and O11 (69%) isolates were
multiresistant. PFGE analysis determined 9 main clonal lineages. O12
isolates belonged mainly to predominant clone A and O11 isolates to
the second most prevalent, clone B. Six strains (3.5% of strains) carried
the blaVIM-2 MBL gene. blaVIM-2 was located within the ﬁrst gene
cassette of a novel class 1 integron sized 3.3 kb, followed by blaOXA-10,
partial qacF, aacA4, and qacEdelta1 gene cassettes. All MBL positive
strains except one (being O12) were O11. Four MBL positive strains
belonged to the clone B, whilst remaining two were clonally unrelated.
Conclusion: Carbapenem resistance mediated by MBLs remains
infrequent in Croatia. The blaVIM-2 genes were found located in a novel
class 1 integron. Most of strains were signiﬁcantly inhibited by boronic
acid suggesting derepression of ampC enzyme as a main mechanism of
resistance to b-lactams and possibly, to carbapenems.
P774 Nosocomial spread of multidrug-resistant Pseudomonas
aeruginosa strain, producing the novel metallo-b-lactamase
variant VIM-20, in a Spanish hospital
X. Mulet °, M.D. Ocete, C. Juan, M.R. Guna, M. Jime´nez, M. Chanza´,
N. Tormo, J.L. Pe´rez, C. Gimeno, A. Oliver (Palma, Valencia, ES)
Objectives: The increasing prevalence of infections by imipenem (IMP)
and meropenem (MER) resistant Pseudomonas aeruginosa over the last
years (2007–2009) in a Spanish hospital, prompted us to characterize
the underlying resistance mechanisms and molecular epidemiology.
Methods: MicroScan panels were used for identiﬁcation and initial
susceptibility testing. MICs for selected strains were additionally
determined by Etest. Etest MBL strips were used for metallo-b-lactamase
(MBL) production screening, followed by conﬁrmation through PCR
and sequencing. Clonal relatedness was assessed by pulsed ﬁeld
gel electrophoresis (PFGE). blaVIM genes were cloned in plasmid
pUCP24, and the conferred resistance proﬁles were determined after
transformation into reference strain PAO1.
Results: The overall prevalence of infections by IMP and MER resistant
isolates increased from 5% in 2007 to 22% in 2009. The increase
was particularly noteworthy in the Intensive Care Unit (ICU), reaching
76% in 2009. Most of the isolates showed the same multidrug-
resistance (MDR) phenotype, including ceftazidime (CAZ), cefepime
(FEP), piperacillin–tazobactam (PTZ), ciproﬂoxacin (CIP), gentamicin
(GEN), tobramycin (TOB), and amikacin (AMK), whereas aztreonam
(ATM) susceptibility was variable. PFGE, performed in 6 representative
isolates, conﬁrmed the involvement of a single clone. All isolates yielded
a positive result with Etest MBL screening and blaVIM-2 PCR. DNA
sequencing of the PCR products revealed in all cases the presence
of a new MBL variant, designated VIM-20, differing from VIM-2 in
a single residue (H229R). blaVIM-2 and blaVIM-20 were cloned in
parallel in pUCP24 and transformed into PAO1. The conferred resistance
proﬁles were almost identical for both enzymes: MICs of IMP and MER
>32mg/L, MICs of CAZ, FEP, and PTZ 24−32mg/L, suggesting similar
hydrolytic properties that need to be conﬁrmed through biochemical
studies.
Conclusion: The increasing prevalence and diversity of MBLs produced
by P. aeruginosa calls for active surveillance to control the dissemination
of these highly concerning MDR determinants.
P775 Molecular characterization of genetic structures surrounding
blaVIM-2 gene identiﬁed in Pseudomonas aeruginosa clinical
isolates from Romania
M. Straut °, S. Dinu, S. Cretoiu, B. Lixandru, M. Surdeanu (Bucuresti,
RO)
Objectives: Our laboratory has been monitoring the presence of metallo-
b-lactamases (MBL) producing Pseudomonas aeruginosa (PAE) clinical
isolates since 2001. In 2007 and 2008, the ﬁrst ﬁve VIM producing
strains, resistant to imipenem and meropenem, were identiﬁed in
Bucharest. The aim of this study was to characterise the genetic
structures associated with the blaVIM genes harboured by these strains.
Methods: The presence of MBL and MBL encoding genes was
conﬁrmed by analytical isoelectric focusing and by PCR with speciﬁc
primers for blaVIM-like genes. Characterisation of the MBL gene and
its genetic environment, including its association with integrons and
transposons, was performed using PCR and DNA sequencing. The
location of blaVIM genes was determined using the endonuclease I-CeuI
technique. Serotyping was performed by 17 monovalent antisera against
the O antigen according to the International Antigenic Typing Scheme.
Clonal relationships were established by PFGE of SpeI-digested DNA
and MLST.
Results: Five out of 84 multidrug resistant clinical isolates harboured
blaVIM-2 gene. Four strains carried two blaVIM-2 gene copies,
chromosomally located. One copy was identiﬁed on an unusual class 1
integron containing a complete tni module, similar to Tn402, at the 3′
end, and the gene cassette array: aacA7 −blaVIM-2 −dhfrB. The structure
of this integron was similar to other TniC-like integrons described
in several countries. Each of three strains harboured additionally a
different standard class 1 integron. One integron of 4200 bp contained
ﬁve antibiotic resistance genes, including blaVIM-2. MLST analysis
showed that all these four strains belonged to sequence type ST233,
which is a singleton. The remaining blaVIM-2 positive strain was
assigned to the wide-spread sequence type ST235, which is the founder
of an international clonal complex containing MBL isolates. In this
particular strain, several blaVIM-2-carrying integrons were detected,
with blaVIM-2 as the second gene cassette. For all ﬁve isolates, a
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correlation between PFGE analysis proﬁles and serotyping results was
noticed.
Conclusion: In Romania, the prevalence of MBL-producing PAE strains
is still very low. This report is the ﬁrst molecular characterisation
of genetic environment of blaVIM-2 genes identiﬁed in PAE clinical
isolates from Bucharest. It highlights the epidemiological importance
of TniC-like integrons in connection with the global dissemination of
blaVIM-2.
P776 Detection of metallo-b-lactamase blaVIM and blaIMP type
genes in clinical isolates of Pseudomonas aeruginosa in
north-western Iran
S. Farajnia °, S. Youseﬁ, M.R. Nahaei, M.T. Akhi, R. Ghotasslou,
M. Soroush (Tabriz, IR)
Background: Pseudomonas aeruginosa is an important causative of
nosocomial infections, particularly in intensive care units (ICUs) and
burns units. The treatment of infections with this pathogen is considered
a major clinical problem due to its high antimicrobial resistance.
Production of metallo b-lactamases (MBLs) and deﬁciency of the outer-
membrane protein OprD are basic mechanisms of resistance to imipenem
in Pseudomonas aeruginosa. The acquired MBLs belong to two major
types, IMP and VIM, each comprising multiple allelic variants. The aim
of this study was to determine the prevalence of VIM-type and IMP type
metallo b-lactamases among clinical isolates of Pseudomonas aeroginosa
isolates.
Materials and Methods: A total of 324 non-duplicates, isolates of
Pseudomonas aeruginosa were collected from two educational hospitals
of Tabriz and Orumieh cities during September 2007 until September
2008. All isolates were identiﬁed as Pseudomonas aeruginosa by using
conventional bacteriologic tests. The antimicrobial susceptibility test
was carryed out by disc diffusion agar method. DNA extraction was
conducted by SDS-proteinas K and CTAB method. Ampliﬁcation of
blaVIM and blaIMP type genes was performed by using speciﬁc primers
in PCR reaction.
Results: Among 324 Pseudomonas aeruginosa isolates, 104(32.0%)
isolates were non-susceptible to imipenem, where 89(27.47%) were
resistant to imipenem and 15 (4.63%) isolates had intermediate resistance
to imipenem. Genotypic experiments revealed that 18 (17.31%) of
imipenem non-susceptible isolates had blaVIM type gene and 6 (5.77%)
isolates had blaIMP type gene.
Conclusion: This study was the ﬁrst report on isolation of MBLs
producing Pseudomonas aeruginosa strains from North-west of Iran.
The results of this study showed that both blaVIM and blaIMP type
metallo b-lactamase producing Pseudomonas aeruginosa are present in
study area. Therefore rapid and accurate detection of these isolates is
vital for treatment and control the spread of such strains.
P777 Clonal dissemination of IMP-6 producing multidrug-resistant
Pseudomonas aeruginosa in South Korea
J.S. Yoo °, J. Byeon, J. Yang, J.I. Yoo, G. Chung, Y.S. Lee (Seoul, KR)
Objectives: Carbapenem resistant P. aeruginosa (PA) has increased in
Korea, among them, VIM, IMP types of metallo-b lactamase(MBL)
were identiﬁed. Although increasing IMP types of MBL producing
PA were recently reported in tertiary-care hospitals, there were few
other reports. Thus we aim to describe the prevalence of MBLs and
molecular epidemiology of MBL-producing PA isolated from various
hospital settings.
Methods:We collected 851 non-duplicated PA isolates from non-tertiary
hospitals and long-term care facilities from 2008 to 2009, and from
tertiary-care hospitals from 2006 to 2007. Antimicrobial susceptibility
tests were performed according to CLSI methods and an imipenem disk
synergy test was performed on meropenem or imipenem non-susceptible
PA. PFGE types were determined by Xba-I restriction and integron
restriction types were analyzed by Mbo-I enzyme cutting.
Results: Carbapenem non-susceptible isolates were 310 (36.4%). MBLs
were detected in 57 isolates (IMP-1(2), IMP-6(48), VIM-2(7)) and
48(84.2%) of them were isolated from urine. All of MBL producing
isolates had class I integron, VIM-2 carrying integron of 2.5kb~7kb
and IMP carrying integron of 4.5kb were also detected. The integron
restriction proﬁle of IMP types showed only two types, moreover
49 (98%) were of the same type (Type I) which includes blaIMP-6,
qac, cmlA, blaoxa10, and aadA1. All IMP-6 producing PA were
resistant to ceftazidime, cefepime, gentamycin, tobramycin, amikacin,
and ciproﬂoxacin. PFGE analysis indicated all IMP-6 producing PA
isolates had nearly identical patterns corresponding to >85% similarity,
indicating clonality.
Conclusion: IMP-6 was the predominant type of MBL in this study, it
was found in >80% of MBL in all hospital settings. It is suspected that
IMP-6 producing PA which showed multi-drug resistant phenotypes has
been disseminated in all kinds of hospitals in South Korea. Therefore,
suitable intervention methods should be used to prevent the further
spread of IMP-6 carrying PA.
P778 Characterization of carbapenem resistance mechanisms and
integrons in Pseudomonas aeruginosa strains from a Spanish
hospital
B. Rojo-Bezares °, C. Seral, F.J. Castillo, S. Salvo, V. Estepa, M. de
Toro, C. Torres, Y. Sa´enz (Logrono, Zaragoza, ES)
Objective: To characterize metallo-b-lactamases (MBLs) and integrons
in imipenem-resistant P. aeruginosa (IRPA) strains from a Spanish
hospital.
Methods: 42 IRPA isolates were recovered from different samples
of 36 patients: surgical wound (14), urine (8), blood (7), bronchial
aspirate (6), skin lesion (4), peritoneal ﬂuid (2), and intraabdominal
abscess (1) from June 2008 to June 2009. Susceptibility testing to
22 antibiotics was performed by WIDER microdilution system. MBL
phenotype was determined by E-test and double disc method. Detection
and characterization of MBLs and class 1 and 2 integrons were
studied by PCR and sequencing. The oprD gene was analyzed by PCR
and sequencing in non-producing MBL isolates, and mutations were
determined by comparison with the sequence of control P. aeruginosa
PAO1. Clonal relationship among IRPA was performed by PFGE using
SpeI enzyme.
Results: A total of 32 indistinguishable PFGE patterns were detected
among the 42 IRPA isolates. All IRPA showed a multirresistance
phenotype, and the MBL phenotype was detected in 25 strains (60%) of
23 patients in which the blaVIM-2 gene was found. Class 1 integrons
were detected in 32 IRPA (76%), 19 of them showed two different
integrons, and another isolate ampliﬁed three class 1 variable regions.
Class 2 integrons were not found in our strains. All 25 MBL-producing
strains harboured the blaVIM-2 gene inside class 1 integrons, and in
addition, 17 of them presented a second class 1 integron containing
aminoglycoside resistance gene cassettes such as aadA1 and aac(3′)-I.
Seven non-MBL-producing strains contained class 1 integrons that
presented the following arrangements: aadB (2), aadA6+orfD (3), aadA7
(1), and aac(6′)-Ib+blaOXA-46 (1). Variations in oprD gene were
detected in 14 of 17 non-MBL-producing strains that could have effect
on the levels of carbapenem resistance.
Conclusions: High prevalence of MBL-producing P. aeruginosa
(60%) has been found among the clinical IRPA. VIM-2 b-lactamase
dissemination through mobile elements, like class 1 integrons, and the
inclusion of other resistance genes is a cause of great concern because
constitutes an effective way for dissemination of multiple antibiotic
resistance. In addition, chromosomal variations of the oprD gene have
been identiﬁed in our clinical IRPA.
P779 Prevalence of class A extended-spectrum b-lactamases in clin-
ical isolates of Pseudomonas aeruginosa in Belgian hospitals
Y. Glupczynski °, P. Bogaerts, A. Deplano, C. Berhin,
H. Rodriguez-Villalobos (Yvoir, Brussels, BE)
Objectives: Class A ESBLs are occasionally reported in non-fermenting
genera but their real prevalence has only rarely been investigated.
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The aims of this study were to display phenotypic evidence of ESBL
production, to determine the prevalence of class A ESBLs and to
characterize the genotypes of P. aeruginosa (PA) strains referred to two
Belgian reference laboratories.
Methods: Antimicrobial susceptibility by disc diffusion and Etest MIC
determination was performed on all PA clinical isolates referred from
January 2005 to December 2008. PA isolates resistant to cefazidime
(MIC> 8mg/L) and with a positive double-disc synergy test were
screened by PCR for the production of blaBEL, blaPER, blaGES and
blaVEB alleles. Genes encoding metallo-b-lactamases were also sought
in isolates with positive imipenem/EDTA synergy tests. Selected PCR
products were sequenced. PFGE of SpeI-digested genomic DNA was
used to compare isolates and selected isolates with deﬁned resistance
mechanisms were further characterized by MLST.
Results: 58 (2.7%) of 2150 PA isolates were considered potential ESBL
producers, among these 48 were conﬁrmed by molecular testing (39
blaBEL-1, 10 blaPER-1; and 2 isolates carried both genes). These PA
originated from 16 Belgian hospitals located throughout the country. All
but one of the 48 isolates clustered in one single major PFGE type
(called ZT). The majority of the isolates were serotype O11, (serotype
O15 and O4 were occasionally found). Five centers referred 15 BEL-
or PER-positive P. aeruginosa strains which also co-produced VIM-2 or
VIM-4 metallo-b-lactamases. MLST of seven representative PA isolates
revealed the presence of the ST235 sequence type which belongs to the
international clonal complex CC11.
Conclusion: Class A BEL-1 ESBL-producing PA isolates are now
widespread in Belgian hospitals and their emergence apparently results
from the clonal expansion and dissemination of the international ST235
clone. Of great concern was the ﬁnding that BEL and PER ESBLs
often coexisted with VIM carbapenemases and caused outbreaks in four
hospitals. Further surveillance studies are warranted since the spread of
these pan-resistant PA strains may compromise the efﬁcacy of current
anti-PA regimens in Belgian hospitals.
P780 Inﬂuence of antibiotic treatments on gene expression of RND
efﬂux pumps in successive isolates of Pseudomonas aeruginosa
collected from patients with nosocomial pneumonia hospital-
ized in intensive care units from Belgian teaching hospitals
M. Riou, L. Avrain, F. El Garch, Y. Glupczynski, J.P. Pirnay, D. De
Vos, P.M. Tulkens °, F. Van Bambeke (Brussels, Gembloux, Yvoir, BE)
Background: Emergence of resistance during therapy is a worrisome
problem that must be addressed in life-threatening infections such
as nosocomial pneumonia (NP). The contribution of efﬂux in this
phenomenon remains largely undeﬁned because undetected in routine.
Our aim was to evaluate the impact of antibiotic treatment on the
expression of genes coding for RND efﬂux pumps in P. aeruginosa (P.a)
isolated from patients with NP.
Methods: Samples: 62 pairs of P.a. collected from NP pts in 5 ICUs
(a) at the time of NP diagnosis (day 0) and (b) during treatment (day x).
Analyses: clonality delineated by REP-PCR and phylogenetic analysis
(Diversilab™; >95% identity). Gene expression evaluated by Real Time
PCR (mex Q-Test Kit, Coris BioConcept) for mexA (constitutively
expressed) and mexX (inducible with low expression level in WT
strains), and by PCR on cDNA for mexC and mexE (repressed in WT
strains). Antipseudomonal antibiotics prescribed: as from the clinical
records of each patient.
Results: The table shows (a) a high prevalence of genes encoding RND
efﬂux pumps in the initial isolates with mexA and mexX, alone or
in combination, being most prevalent, (b) a further, highly signiﬁcant
increase of prevalence between day 0 and day x when considering
all genes globally (Fisher’s Exact Test 2-sided P = 0.0028) or mexA,
mexX and mexA+mexX only (c2 Test for Independence P = 0.024). The
most used antibiotics were piperacillin–tazobactam (26 pts), amikacin
(22 pts), meropenem (20 pts), cefepime (19 pts), and ciproﬂoxacin (6
pts), but in combination for 69% of pts. No simple correlation could
be established between overexpression of a speciﬁc gene pump and
the corresponding antibiotics administered to the patient. However, the
predominant overexpressions seen (mexA, mexX) matched well with the
global use of the anti-pseudomonal antibiotics at the population level (see
note in Table for substrate speciﬁcities).
Conclusion: The study points to a high initial prevalence of genes
coding for efﬂux mechanisms towards the main antipseudomonal
antibiotics in P.a. isolates from patients with NP and its further increase
during treatment. An early detection of the genomic and functional
overexpression of these efﬂux transporters may be useful for both
epidemiological and therapeutic purposes. These observations also
point to the interest of developing efﬂux inhibitors as complementary
therapeutic agents.
Table. overexpression of genes coding for Mex pumps (total isolates: 62
pairs)
Day of collection None mexA mexX mexA+mexX Othersa
0b 37 7 6 6 6
xc 20 13 12 9 8
amexC, mexE, mexA+mexC, mexX+mexE, mexX+mexC+mexE, mexA+
mexX+mexC+mexE.
bBefore initiation of the treatment.
cDuring treatment (last sample available; mean: 23 days; median: 17.5
days; extremes: 1–123 days).
Preferential substrates: MexAB-OprM: b-lactams and ﬂuoroquinolones;
MexXY-OprM: aminoglycosides, cefepime, ﬂuoroquinolones.
P781 Prevalence of hypermutation in bloodstream isolates of
multidrug-resistant Pseudomonas aeruginosa
V.H. Tam °, C.G. Brioso, K.T. Chang, L.A. McCaskey, J.S. Weston
(Houston, US)
Objectives: Hypermutation is a well-recognized mechanism leading
to multidrug resistance in Pseudomonas aeruginosa (PA) from cystic
ﬁbrosis patients. However, its prevalence is not well established in the
non-cystic ﬁbrosis cohort. We examined the prevalence of hypermutation
in clinical isolates of multidrug resistant (MDR) PA obtained in our
hospital.
Methods: All bloodstream PA isolates obtained from 2005 to 2008 were
screened for multidrug resistance (deﬁned as resistance to 3 classes
of antipseudomonal agents). The clonality of the MDR isolates was
assessed by rep-PCR. The presence of hypermutation was assessed by
quantitatively plating 10x serial dilutions of an overnight culture on
media plates (with or without rifampin supplementation at 300mg/l).
Colony counts were numerated after up to 48 hours of incubation.
The experiments were repeated at least once on a different day.
Hypermutation was deﬁned as 20x increase in resistance mutation
frequency, compared to wild types. In addition, the mutS genetic
sequence was determined by PCR. For comparison, a standard wild type
(PAO1) and an isogenic known hypermutable derivative (PAO1-delta-
mutS) were used as negative and positive controls, respectively.
Results: Among 306 non-repeat PA isolates (from 254 episodes)
screened, 40 isolates (from 26 episodes) were found to be MDR. None of
the patient from which isolates were obtained had cystic ﬁbrosis. Using
the ﬁrst available isolate for each bacteremia episode (n = 23), 17 distinct
clones were revealed. Hypermutation was found in 3 isolates (prevalence
rate = 1.2% of total and 13.0% of MDR isolates). Point mutations in
mutS (D40N and G697S in 1 isolate, and M623K in another) were found
in 2 isolates.
Conclusion: In contrast to cystic ﬁbrosis patients, hypermutation was
not a common mechanism leading to MDR PA. Understanding the
prevalence and mechanism of resistance in PA may guide the choice
of empiric therapy for nosocomial infections in our hospital.
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P782 Susceptibility of bacteraemic Pseudomonas aeruginosa: a
55-country analysis from 2004 to 2008
D. Hoban °, M. Hackel, M. Renteria, R. Badal, S. Bouchillon,
B. Johnson, J. Johnson, S. Hawser, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Background: Pseudomonas aeruginosa (PA) blood stream infections
remain a therapeutic challenge worldwide and both empiric and directed
therapy continues to evolve as antimicrobial resistance increases.
The Tigecycline Evaluation Surveillance Trial (TEST) examines the
susceptibility of pathogens isolated from patients in countries worldwide
annually since 2004.
Methods: A large number of PA (2251) from blood culture from 1258
cumulative sites in various countries during 2004–2008 was tested.
MICs were determined using supplied broth microdilution panels and
interpreted according to FDA / CLSI guidelines.
Results: The % susceptible for those 2251 PA versus comparative
antimicrobial agents is shown in the table.
Conclusions: Piperacillin–Tazobactam and amikacin were the most
active agents overall during 2004–2008. However, both antimicrobials
exhibited diminished activity in 2008 as compared to 2004. Resistance
to meropenem, ceftazidime, cefepime and levoﬂoxacin continued to
increase. All studied antimicrobials displayed 7−20% less in vitro activity
in 2008 as compared to 2004. The continued monitoring of susceptibility
of PA globally is warranted as resistance continues to increase in all
antimicrobial classes.
%Susceptible/year: 2004–2008 (N)
Drug 2004
(322)
2005
(341)
2006
(431)
2007
(621)
2008
(536)
Amikacin 97.2 92.7 89.8 89.4 83.6
Cefepime 79.2 72.7 76.6 76.2 68.5
Ceftazidime 82.6 78.0 77.7 76.5 63.8
Ceftriaxone 22.7 14.1 15.6 12.1 10.8
Levoﬂoxacin 68.0 62.7 70.3 66.5 61.0
Meropenem 83.8 80.3 81.3 82.4 72.8
Pip-Tazo 90.1 86.8 88.2 87.1 75.9
P783 Activity of piperacillin/tazobactam and comparators against
Pseudomonas aeruginosa and Acinetobacter baumannii from
South Africa, 2004–2009
M. Renteria °, S. Bouchillon, R. Badal, B. Johnson, J. Johnson,
D. Hoban, M. Hackel, S. Hawser, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Background: Piperacillin–tazobactam (PTZ) continues to be useful for
the treatment of patients with polymicrobial infections caused by aerobic
or anaerobic b-lactamase-producing bacteria. PTZ is indicated for severe
community and hospital acquired infections including Pseudomonas
aeruginosa as well as Acinetobacter baumannii. In the Tigecycline
Evaluation and Surveillance Trial (T.E.S.T.), a comprehensive global
surveillance study, we have monitored the in vitro activity of PTZ and
comparators for 6 years.
Methods:We evaluated 435 A. baumannii (183) and P. aeruginosa (252)
isolates from 21 cumulative sites in South Africa between 2004 and 2009.
Isolates were identiﬁed at each study site and conﬁrmed by the central
lab following CLSI guidelines.
Results: The table shows MIC90 and % susceptible of PTZ and
comparators against P. aeruginosa and A. baumannii.
Conclusions: Since the approval of PTZ in 1993, PTZ continues to
demonstrate potent in vitro activity against P. aeruginosa. The activity
of PTZ is comparable to that of amikacin, imipenem and meropenem.
Only tigecycline demonstrated signiﬁcant activity against A. baumannii
with MIC90 values more than 8- to 128-fold lower than any other study
drug.
P. aeruginosa
(n = 252)
A. baumannii
(n = 183)
MIC90 %S MIC90 %S
Piperacillin–Tazobactam 128 88 >128 28
Amikacin 64 85 >64 38
Cefepime 32 77 >32 24
Ceftazidime 16 84 >32 24
Ceftriaxone >64 15 >64 15
Imipenem 8 86 >16 68
Meropenem >16 80 >16 24
Levoﬂoxacin >8 64 >8 32
Tigecycline >16 na 1 na
P784 In vitro activity of the ceftazidime/NXL104 combination
against Pseudomonas aeruginosa clinical isolates
C. Miossec °, A.M. Girard, A. Malavieille, M. Claudon, H. Goossens,
M. Black, P. Levasseur (Romainville, FR; Antwerp, BE)
Objectives: NXL104 is a new, non-b-lactam, b-lactamase inhibitor
currently under Phase 2 clinical development in combination with
ceftazidime (CAZ). NXL104 displays potent inhibition of both
class A and class C enzymes, including CTX-M and KPC variants.
CAZ/NXL104 activity has been demonstrated both in vitro and in vivo
against CAZ-resistant Enterobacteriaceae species. The aim of the study
was to evaluate the in vitro antibacterial activity of CAZ/NXL104 against
P. aeruginosa clinical strains.
Methods: 126 P. aeruginosa strains were collected as consecutive
isolates in a French hospital between December 2006 and April
2007. MIC determination was performed using NXL104 at 4 mg/mL
ﬁxed concentration, with variable concentrations of CAZ. Reference
compounds included piperacillin/tazobactam (PIP/TZP), imipenem
(IPM) and aztreonam (AZT). Clonal diversity of isolates was evaluated
by Pulsed-Field Gel Electrophoresis (PFGE). Resistant strains were
characterized according to presence / expression of b-lactamases, porins
and efﬂux system components.
Results: The susceptibilities of the P. aeruginosa strains were: 65%
to CAZ, 86% to IPM, 48% to AZT and 75% to PIP/TZP. The
addition of NXL104 to CAZ resulted in lowering of the MICs to
below susceptibility breakpoints in 86% of the resistant P. aeruginosa
strains; NXL104 protection of CAZ rendered 94% of isolates of the
whole panel susceptible to the combination. PFGE indicated high clonal
diversity among the strains intermediate or resistant to CAZ (29 different
pulsotypes in 44 strains). AmpC production was found to be the major
cause of resistance in the strains non-susceptible to CAZ.
Conclusion: CAZ/NXL104 combination showed excellent in vitro
activity against a recently collected panel of P. aeruginosa clinical
isolates, reﬂecting the potent inhibitory activity of NXL104 against
class C b-lactamases.
P785 In vitro activity of tigecycline against Enterobacteriaceae and
Acinetobacter baumannii
V. Papaioannou, S. Tsiplakou, A. Stylianakis, P. Petraki, C. Karra,
P. Papanikolaou, A. Panagopoulou, A. Koutsoukou ° (Athens, GR)
Objectives: Tigecycline is a member of the glycylcycline class of
antibiotics with a broad spectrum of activity which includes several
Gram-positive and Gram-negative bacteria. The aim of this study was
to evaluate the in vitro activity of this agent against Enterobacteriaceae
and Acinetobacter baumannii.
Methods: A total of 1405 strains of Enterobacteriaceae (K. pneumoniae
442, K. oxytoca 25, E. coli 669, E. cloacae 165, E. aerogenes 22,
C. freundii 27, C. koseri 15, S. marcescens 40), and of 347 strains
of A. baumannii were studied. Isolates were recovered from blood
cultures, body ﬂuids, catheters tips, pus, bronchial secretions and
urine samples in a one year period, from 01/11/08 to 31/10/09. The
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identiﬁcation and susceptibility testing was performed via the Vitek II
system (Biomerieux, France), and when necessary susceptibility results
were conﬁrmed with the use of Etest strips (AB Biodisc, Sweden)
according to CLSI guidelines. EUCAST Enterobacteriaceae breakpoints
were used to interpret Tigecycline MIC results for Enterobacteriaceae
and A. baumannii.
Results: Susceptibility testing revealed susceptibility to tigecycline at
83% for K. pneumoniae, 100% for K. oxytoca, 99.8% for E. coli, 94%
for E. cloacae, 95% for E. aerogenes, 96% for C. freundii, 100%
for C. koseri, 92% for S. marcescens, and 57% for A. baumannii.
Susceptibility to amikacin for K. pneumoniae and A. baumannii was at
59% and 21%, to cefepime at 26% and 0.6%, to imipenem at 36% and
7.8% and to levoﬂoxavin at 30% and 0.9% respectively. K. pneumoniae
and A. baumannii were multidrug resistant to a great extend.
Conclusion: Tigecycline maintains potent in vitro activity against most
strains of Enterobacteriaceae. Sensitivity percentages were similar to
those noted to other European countries. As for A. baumannii, there is
a decreased susceptibility but it may be an alternative treatment option
when other agents are excluded due to multidrug resistance. Due to the
possibility of gaining resistance, it is essential for a hospital to remain
aware of the susceptibility patterns of this new agent.
Acinetobacter
P786 Genetic and functional variability of AmpC-type b-lactamase
from Acinetobacter baumannii
J.M. Rodriguez-Martinez °, L. Poirel, P. Nordmann (Le Kremlin Bicetre,
FR)
Objectives: AmpC cephalosporinases with broadened substrate activity
(toward third/fourth-generation cephalosporins and/or carbapenems)
have been reported in Enterobacteriaceae and Pseudomonas aeruginosa.
Those “Extended-Spectrum AmpCs” (ESACs) have amino acids
substitutions mostly located into four regions in the vicinity of the
active site: the omega loop, the H-10 helix, the H-2 helix and the
C-terminal end. The study was aimed to characterize the ampC genes
from Acinetobacter baumannii isolates and to evaluate whether ESACs
enzymes might be identiﬁed in that species and may contribute to
resistance to broad-spectrum b-lactams.
Methods: Seventeen non-repetitive A. baumannii clinical isolates
recovered in 2007–2008 from Bicetre Hospital and being resistant to
ceftazidime (CAZ) were studied. MICs were determined by agar dilution
and E-test. Pulsed-ﬁeld gel electrophoresis was performed for molecular
strain typing. PCR and sequencing were used to characterize the blaampC
genes. Overexpression of AmpC was evaluated by using Mueller-Hinton
agar plates containing 200mg/L of cloxacillin (AmpC inhibitor). All the
ADC variants were cloned in the pTOPO vector and expressed in E. coli
TOP10 and E. coli HB4 (lacking OmpC and OmpF porins).
Results: Using cloxacillin containing plates, the susceptibility to
ceftazidime was restored for 11 out of 17 isolates. Colinearity
between the insertion sequence ISAba1 (providing strong promoter
sequences) and the blaampC gene was observed in 10 out of those
11 isolates. Genotyping performed using PFGE revealed an important
clonal diversity, with 7 distinct clones identiﬁed among the 17
isolates. Cloning and sequencing identiﬁed 5 distinct AmpC b-lactamase
variants among the 17 isolates. Recombinant plasmids harbouring those
different blaampC genes were transformed into E. coli TOP10 and
E. coli HB4 recipient strains. A variability in the resistance to broad-
spectrum cephalosporins (CAZ and CTX) was observed. Higher levels
of resistance (4 to 64-fold) to CAZ and CTX were observed with
recombinant E. coli strains expressing AmpC b-lactamases that had
substitutions Val236Ala in the omega-loop or N311S in the helix H-10.
These differences were observed both in E. coli Top10 or E. coli HB4.
Conclusions: Variants of A. baumannii-speciﬁc AmpC with extended
activity torward ceftazidime and cefotaxime have been ﬁrstly identiﬁed.
They might play a signiﬁcant role in term of resistance to broad-spectrum
cephalosporins.
P787 Extended-spectrum cephalosporinases hydrolyzing
fourth-generation cephalosporins in Acinetobacter baumannii
J.M. Rodriguez-Martinez °, P. Nordmann, L. Poirel (Le Kremlin Bicetre,
FR)
Objectives: AmpC cephalosporinases with broadened substrate activity
(ESACs) have been reported in Enterobacteriaceae and Pseudomonas
aeruginosa, which mainly present changes in four regions in the vicinity
of the active site: the omega loop, the H-10 helix, the H-2 helix and
the C-terminal end of the protein. Here, we characterized a new AmpC
variant from Acinetobacter baumannii presenting a broadened substrate
activity toward broad-spectrum cephalosporins.
Methods: Screening for ESAC production was performed using the
Mueller-Hinton agar plates containing cloxacillin (AmpC inhibitor).
MICs were determined by agar dilution and E-test techniques. PCR and
sequencing were used to characterize the blaampC genes. The blaampC
genes were cloned in vector pTOPO and expressed in E. coli TOP10 and
E. coli HB4 (lacking OmpC and OmpF porins). Identiﬁed ESACs were
puriﬁed and their Km and kcat values for b-lactams determined by UV
spectrophotometry.
Results: One isolate was resistant to ticarcillin, piperacillin–tazobactam,
ceftazidime, cefepime and aztreonam, and of intermediate susceptibility
to imipenem. Using cloxacillin-containing plates, the susceptibility to
ceftazidime and cefepime was restored, suggesting overproduction of
an ESAC AmpC. Cloning and sequencing identiﬁed a new ADC
AmpC b-lactamase variant presenting several amino acid substitutions,
including the substitution Pro238Arg together with a duplication
of the Ala residue at position 243 located inside the omega-loop.
Recombinant plasmid harbouring this blaampC gene was transformed
into E. coli TOP10 and E. coli HB4. A broadened hydrolytic activity
was observed against ceftazidime, cefotaxime, cefepime, cefpirome and
aztreonam, increasing the level of resistance of 8- to 512-fold, depending
of the b-lactam molecule and the E. coli strain background. The
catalytic efﬁciencies (kcat/Km) of the AmpC variants possessing these
substitutions were increased against ceftazidime, cefotaxime, cefepime,
cefpirome and against monobactams (aztreonam).
Conclusions: This is the ﬁrst description of an ESAC-type b-lactamase
from A. baumannii.
P788 Mechanisms of resistance to imipenem and extended-
spectrum cephalosporins in Acinetobacter baumannii clinical
isolates
H.Y. Lee °, C.L. Chen, C.H. Chuang, T.Y. Lin, C. Wu, C. Chiu
(Taoyuan, TW)
Objectives: Nosocomial infections caused by multidrug-resistant (MDR)
Acinetobacter baumannii have been increasing in recent years. In order
to elucidate the current resistance mechanisms, 27 A. baumannii clinical
isolates from a regional hospital in Taiwan in 2009 were examined in
this study.
Methods: E-test analysis was employed to test the minimum inhibitory
concentrations (MIC) to these isolates of 8 antibiotics. Primers speciﬁc
for resistance genes (blaOXA-23, blaOXA-24, blaOXA-40, blaOXA-54,
blaOXA-58, blaOXA-51, blaADC, blaIMP-1, blaVIM-1) were designed
for PCR ampliﬁcation and sequence identiﬁcation. The upstream regions
of the resistance genes were tested for ISAba1 as well.
Results: A. baumannii isolates showed the highest rate of susceptibility
(100%) to colistin, followed by tigecycline (63.0%), ampicillin/sulbactam
(55.6%), imipenem (51.9%), amikacin (30.0%), ceftazidime (22.2%),
gentamicin (18.5%), and ceftriaxone (0%). PCR ampliﬁcation and
sequence analysis identiﬁed blaOXA-23 in 9 isolates, blaOXA-51-like
in 22 isolates, blaOXA-58 in 2 isolates and blaADC-25 in all isolates.
Most blaOXA-51-like resistance genes were similar to blaOXA-138.
The upstream ISAba1 was found in 6 isolates with blaOXA-23 and
5 isolates with blaOXA-51-like and offered these 11 isolates with
full resistance to imipenem (all MIC >32) (Table 1). The upstream
ISAba1 was also found in 21 isolates with blaADC-25 and offered
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these isolates with full resistance to both ceftriaxone and ceftazidime. In
the opposite, all other 6 isolates carried blaADC-25 without upstream
ISAba1 showed intermediately resistant to ceftriaxone but susceptible
to ceftazidime. Isolates with combination of upstream ISAba1 and
OXA-type b-lactamases or Acinetobacter-derived cephalosporinases had
signiﬁcant full resistant ability to imipenem or extended-spectrum
cephalosporins than those without such combination (both p< 0.001).
None of isolates carried blaIMP-1. Therefore, the resistant mechanisms
were quite different from previous study in which the major resistant
gene contributing to imipenem resistance in A. baumannii clinical
isolates in 2006 was metallo-b-lactamase blaIMP-1.
Conclusion: Resistant mechanisms of A. baumannii changed rapidly.
Current results showed the upstream ISAba1 combined with OXA-
type b-lactamases or Acinetobacter-derived cephalosporinases offered
A. baumannii isolates in 2009 with full resistance to imipenem or
extended-spectrum cephalosporins, individually.
Table 1. Imipenem minimum inhibitory concentrations (MICs) of
A. baumannii with different carbapenemase genes and insertion
sequences
Carbapenemase genes and
insertion sequences
Total
number
No. of isolates
MIC (mg/mL)
>32
R
8−16
I
0.25−4
S
ISAba1–blaOXA-23 + blaOXA-51-like 5 5 0 0
ISAbal–blaOXA-23 1 1 0 0
ISAbal–blaOXA-51-like 5 5 0 0
blaOXA-23 + blaOXA-51-like 3 1 0 2
blaOXA-58 + blaOXA-51-like 2 0 1 1
blaOXA-51-like only 7 0 0 7
None 4 0 0 4
P789 OXA-58 in carbapenem-resistant Acinetobacter baumannii
Z. Aktas °, M. Isin, C. Kayacan (Istanbul, TR)
Objective: The aim of this study was to analyse the emergence
of carbapenem resistance among hospital strains of Acinetobacter
baumannii.
Methods: Twenty seven imipenem and meropenem non-susceptible
clinical isolates of A. baumannii were identiﬁed using the API 20NE
system. Antibiotic susceptibilities of these isolates were determined by
disk diffusion; followed by imipenem, ertapenem and meropenem MICs
by agar dilution, using CLSI interpretative criteria. Metallo-b-lactamase
(MBL) production was tested phenotypically using MBL E-tests.
Carbapenemase-encoding genes (blaIMP, blaVIM, blaOXA-48, blaOXA-
23-like, blaOXA-24-like, blaOXA-58) were sought by PCR using
consensus primers that were speciﬁc for each enzyme group. The isolates
were also screened for intrinsic blaOXA-51-like carbapenemase gene.
Sequencing reactions were performed with an automated sequencer
(Beckman Coulter CEQ 8000 Genetic Analysis System). Isolates were
genotyped by random ampliﬁed polymorphism (RAPD) DNA.
Results: Imipenem, meropenem and ertapenem MICs for the 27 clinical
isolates ranged between 4 and 64mg/L. MBL E-tests were positive for
11 of the 27 of isolates; however, PCRs revealed that all isolates were
negative for the MBL genes (blaIMP and blaVIM, as well as for blaOXA-
48, blaOXA-23-like and blaOXA-24-like genes. A blaOXA-58-like gene
and A. baumannii-speciﬁc intrinsic blaOXA-51-like gene were ampliﬁed
from all 27 clinical isolates. The results of RAPD analyses indicated that
all isolates belonged to the same clone.
Conclusion: OXA-58 carbapenemase showed an intra-hospital spread
in A. baumannii and its further spread has to be surveyed among
carbapenem resistant strains.
P790 OXA-24-like carbapenemase genes among carbapenem-
resistant Acinetobacter baumannii isolates from a clinical
hospital centre in Zagreb, Croatia
I. Marekovic °, L. Dijkshoorn, T. van der Reijden, A. Budimir,
Z. Bosnjak, S. Kalenic (Zagreb, HR; Leiden, NL)
Objectives: Carbapenem resistance in Acinetobacter baumannii has
emerged worldwide as a signiﬁcant problem leaving few therapeutic
options for treatment of infections. A major problem regarding
carbapenem resistance mechanisms are the acquired oxacillinases with
carbapenemase activity (OXA enzymes). Recently, in the Clinical
Hospital Centre Zagreb (Croatia) emergence of carbapenem-resistant
A. baumannii isolates was noticed. The aim of the study was to
investigate strain relatedness and carbapenemase encoding genes in
carbapenem-resistant isolates.
Methods: Seventy A. baumannii isolates were collected from December
2008 to April 2009 in Clinical Hospital Centre Zagreb. Susceptibility
tests were carried out by disc diffusion and E test. Carbapenems
tested included meropenem and imipenem. Identiﬁcation and genotypic
analysis of the Acinetobacter isolates was assessed by AFLP genomic
ﬁngerprinting. Detection of genes coding for OXA-23-like, OXA-24-
like, OXA-51-like and OXA-58-like carbapenemases was performed
with multiplex PCR. The presence of the ISAba1 insertion sequence
gene was also determined with PCR.
Results: All 70 isolates were identiﬁed as A. baumannii by AFLP
analysis. Thirty-four (48.6%) isolates were either intermediate or
resistant to at least one carbapenem. Intrinsic blaOXA-51-like gene was
expectedly detected in all isolates. BlaOXA-24-like gene was detected
in 30 (42.9%) isolates and blaOXA-58-like in one (1.4%) isolate. All
blaOXA-24-like positive isolates were resistant to both carbapenems,
while blaOXA-58-like positive isolate was intermediate. ISAbaI insertion
sequence gene was detected in all but two isolates. These two were
susceptible to carbapenems. With AFLP, 8 genotypes were distinguished.
These were distributed over 2 single strains and 6 clusters with multiple
isolates indicating the occurrence of multiple endemic strains. One major
cluster (genotype 3) comprised 35 isolates most of which containing
OXA-24-like carbapenemase genes and being carbapenem resistant.
Genotype 6 (14 isolates), 7 (2 isolates) and 8 (one isolate) corresponded
with EU clone I.
Conclusion: So far, the genes encoding OXA-24-like enzyme were
conﬁned to isolates from Spain and Portugal, and recently one isolate
was reported from Czech Republic. Here we report occurrence of a
major cluster of A. baumannii strains in our hospital in Zagreb in which
carbapenem-resistance was associated with OXA-24-like carbapenemase
genes.
P791 First report of OXA-72 − carbapenemase in clinical isolate
of Acinetobacter baumannii in Colombia
S.Y. Saavedra, A.L. Leal, C.H. Saavedra, J.S. Castillo London˜o °
(Bogota´, CO)
Objective: Characterization of a clinical isolate of A. baumannii resistant
to carbapenems expressing OXA-72.
Methods: The isolate was recovered of a sample surgical wound site
from a 47 years old male patient, hospitalized at Intensive Care Unit of
a third level hospital in Bogota. The isolate was re-identiﬁed with API
20NE, the determination of antimicrobial susceptibility was performed
by E-Test and the detection of genes encoding OXA carbapenemases was
performed by PCR using speciﬁc primers, ampliﬁcation products were
evaluated by sequentiation. To determined the location of the OXA-
72 gene, was analyzed genomic DNA digested with the endonuclease
I-Ceu-I and plasmid DNA, which were separated by electrophoresis
pulsed-ﬁeld gel, followed by a Southerm blot and a double hybridization
with probes 16S rRNA and blaOXA-24 for genomic DNA and with
the latest probe to plasmid DNA. The probe was labeled by PCR
with digoxigenin 11-dUTP (Roche), and detection was performed by
immunodetection with an antibody anti-digoxigenin and was visualized
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with a colorimetric substrate (NBT/BCIP). The transfer of resistance was
evaluated by conjugation and electroporation using as recipient strain
E. coli TOP10 the transconjugants and transformants were selected on
Bertani Luria plates supplemented with streptomycin (50mg/mL) and
ampicillin (50mg/mL).
Results: The isolate was resistant to meropenem, aztreonam and ceftriax-
one with MIC> 32mg/mL for each antimicrobial, showed intermediate
resistance to imipenem with MIC 8mg/mL and was sensitive to
amikacin, ceftazidime, cefepime, ciproﬂoxacin, piperacillin/tazobactam,
ampicillin/sulbactam, cefoperazone/sulbactam and colistin. PCR gene
detection from OXA carbapenems gene suggested presence from gene
blaOXA-51-like and blaOXA-24-like, and the sequencing ampliﬁcation
products conﬁrmed the presence from OXA-72 carbapenemase in the
isolate. In studies of location of the genomic DNA only hybridized
with probe for the 16S rRNA gene, while the plasmid DNA gave
three hybridization signals with the blaOXA24 probe, demonstrating
that the OXA-72 gene is on plasmid. Attempts to transfer resistance
by conjugation or transformation of plasmid DNA were unsuccessful.
Conclusions: In isolation analyzed the results suggest that blaOXA-72
gene is located on plasmid, however it is not possible to establish if in
multiple plasmids or a plasmid present in different forms.
P792 Frequent occurrence of genomic resistance islands among
Acinetobacter spp.
L. Poirel °, R. Bonnin, P. Nordmann (Le Kremlin Bicetre, FR)
Objectives: Genomic islands have been recently identiﬁed in Acineto-
bacter baumannii (AbaR) from diverse isolates being either multidrug
resistant or not. In A. baumannii strain AYE, the AbaR1 island was 86-
kb in size, and harbored 45 resistance genes. Whole genome sequencing
of a couple of A. baumannii strains from diverse geographical origins
and distinct clonal lineages identiﬁed other AbaR elements, varying in
size and content. Analysis of the AbaR surrounding sequences identiﬁed
an hotspot for integration, corresponding to the ATPase encoding gene.
AbaR elements are often bracketed by 5-bp duplications suggesting their
acquisition through a transposition-based event. Our objective was to
evaluate the distribution of AbaR-like islands among a collection of
A. baumannii isolates from worldwide origin, to identify their content
and their integration site. Additionally, transposition experiments were
attempted to evaluate the mobility of one AbaR element.
Methods: Forty-seven clinical Acinetobacter spp. isolates were collected
from worldwide origin, including 41 A. baumannii, 3 A. junii, 2 A. john-
sonii, and 1 A. lwofﬁi. Detection of the AbaR elements was performed by
PCR mapping followed by sequence analysis. Transposition/conjugation
assays have been conducted with A. baumannii BM4547 (Rif-R) as
recipient and A. baumannii B1190 possessing an AbaR10 element and
harbouring a conjugative plasmid used as donor.
Results: Our collection consisted of strains belonging to the three
different European clonal lineages (I, II, and III). 36 out of the 47 isolates
possessed a truncated ATPase gene, being all A. baumannii. 30 out of
those 36 isolates possessed the same ATPase-AbaR left-junction than
that originally identiﬁed with AbaRI, and 28 possessed the same ATPase-
AbaR right-junction. PCR mapping revealed that all the AbaR elements
identiﬁed were heterogeneous in size and genetic content. Attempts to
demonstrate the transposition of one AbaR from its original host failed.
Attemps to demonstrate a circular form of those AbaR elements using
an inverse-PCR approach did not identify any circular intermediate for
all these structures.
Conclusion: This study showed that dissemination of AbaR elements
among A. baumannii is widely spread, being identiﬁed among isolates
from distinct clonal lineages. The variety of those AbaR elements
suggests a capacity to evoluate and accumulate foreign genes, including
resistance genes.
P793 A 63-kb genomic resistance island in an Acinetobacter
baumannii isolate from 1977
L. Krizova °, B. Berger-Ba¨chi, A. Nemec (Prague, CZ; Zurich, CH)
Objective: Multidrug resistance in Acinetobacter baumannii has been
signiﬁcantly associated with a few international clonal lineages.
Multidrug-resistant (MDR) strains of two of these lineages (EU clones I
and II) have occurred in European hospitals since at least the 1980s.
Three large (86 kb, 63 kb and 56 kb), stucturally related genomic
resistance islands (AbaR1, AbaR3 and AbaR5, respectively) integrated
into the ATPase gene were recently found in EU clone I strains isolated
between 1997 and 2004. The aim of this study was to assess whether
a MDR outbreak strain of EU clone I isolated in 1977 harbours an
AbaR-like resistance island.
Methods: Strain HK302 was isolated during a hospital outbreak in
Switzerland in 1977 (Antimicrob Agents Chemother 1982; 22: 323) and
later was allocated to EU clone I. Strain AYE harbouring AbaR1 was
used as a positive control for the detection of AbaR1-associated genes
and PCR mapping. Disruption of the ATPase gene was determined using
PCR with primers derived from both ends of the gene. The presence of 29
AbaR1-associated genes was investigated by PCR using primers inferred
from the sequence of AbaR1. PCR mapping using the Long Range PCR
kit (Qiagen) was performed, followed by RFLP analysis of amplicons.
The regions different from those of AbaR1 were sequenced.
Results: A genomic region inserted into the ATPase gene at the same
position as known for AbaR1 was found in HK302. In addition, 18
AbaR1-associated genes were identiﬁed in this strain. PCR mapping
combined with RFLP analysis revealed that HK302 harboured a 63-kb
resistance island which shared regions of a total size of 57 kb with
AbaR1. Two segments (sized 4 kb and 2 kb) different from those of
AbaR1 were sequenced and found to correspond to the regions described
in AbaR3, i.e. one comprising the topoisomerase topA gene and the other
a transposon carrying blaTEM-1.
Conclusion: An AbaR3-like resistance island was identiﬁed in HK302,
which indicates that highly complex resistance islands existed in EU
clone I strains already in the late 1970s.
Supported by grant 310/08/1747 of the Grant Agency of the Czech
Republic.
P794 Multidrug resistance phenotype associated with presence of
integrons and speciﬁc clonal types of Acinetobacter spp.
E.C. Clı´maco °, M.O. Gomes, A.L. Darini (Ribeira˜o Preto, Juiz de
Fora, BR)
Objective: The main objective of this study was to determinate the
presence of class 1, 2 and 3 integrons in Acinetobacter spp. and the
association of these elements with multidrug resistance phenotype and
with clonal proﬁle of the strains.
Methods: Firstly, 63 Acinetobacter spp., isolated from inpatients of
University Hospital of Juiz de Fora, Minas Gerais State, Brazil,
from 2006 to 2007, were classiﬁed as multidrug resistant (MDR) or
non-multidrug resistant (n-MDR). Class 1, 2 and 3 integrons were
investigated by speciﬁc PCR ampliﬁcation of intI1, 2 and 3 genes
fragments and by RFLP obtained by RsaI and HinfI digestion of intI1,
2 and 3 fragments, ampliﬁed with consensus primers. The prevalence
of integrons were compared among MDR and n-MDR groups, and
statistical signiﬁcance was estimated applying Fisher‘s exact. PFGE was
performed and types were deﬁned by clusters formed at 85% Dice
similarity cutoff on a dendrogram constructed by UPGMA.
Results: 48 (76.1%) out of 63 Acinetobacter spp. were considered
MDR isolates. Class 1 integrons were detected in 11 (17.5%)
Acinetobacter spp. isolates, by speciﬁc PCR and by RFLP, all of
them were MDR. Class 2 integrons were found in 30 (47.6%)
Acinetobacter spp. isolates, by RFLP and, in 23 of them, by speciﬁc
PCR. 96.7% (29) of these isolates were MDR. Class 1 and 2 integrons
relationship with MDR Acinetobacter spp. isolates was statistically
signiﬁcant. No class 3 integrons was found. PFGE analysis revealed
S204 20th ECCMID, Posters
7 clonal types and two of them were prevalent. B type was prevalent
among the strains isolated up to September 2006, and A type among the
strains isolated after this period. 16 out of the 17 B type strains were
MDR and 50% of them harboured class 1 integrons. All the 30 A type
strains harboured class 2 integrons and 29, out of them, were considered
MDR isolates.
Conclusions: The incidence of MDR phenotype was high among the
studied strains. Class 2 integrons were more prevalent than class 1 ones in
Acinetobacter spp. isolates. Although both classes of integrons seem to
be associated with MDR isolates, this phenotype was statistically related
with A and B clonal types and it might be consequence of accumulation
of different resistance mechanisms in speciﬁcs clonal types.
P795 Aminoglycoside resistance in a clinical isolate of
Acinetobacter genomic species 13TU is associated with the
up-regulation of its AdeABC-like efﬂux system
A. Nemec °, P.G. Higgins, P. Jezek, L. Krizova (Prague, CZ; Cologne,
DE; Pribram, CZ)
Objectives: Acinetobacter genomic species (GS) 13TU is a member
of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Although commonly isolated from hospitalized patients, this species,
unlike A. baumannii, is usually well susceptible to antibiotics. In a
Czech hospital, two isolates of a GS 13TU strain differing in their
susceptibilities to aminoglycosides were obtained from the same patient.
The aim of this study was to assess whether the difference is associated
with the up-regulation of the GS 13TU efﬂux system related to the
AdeABC system in A. baumannii.
Methods: The two isolates, NIPH 952 and NIPH 953, were obtained,
respectively, from the sputum and gastric juice of an ICU patient.
Compared to NIPH 952, NIPH 953 showed elevated MICs to
aminoglycosides, in particular to gentamicin (1 versus 8mg/l) and
netilmicin (2 versus 16mg/l). The presence of the genes encoding
putative efﬂux components was tested by PCR using primers derived
from the AdeABC genes. The ability of NIPH 952 to produce
aminoglycoside-resistant variants was assessed by challenging it with
4 or 8mg/l of gentamicin. The adeB gene was partially sequenced and
its expression level was examined by real-time reverse transcription PCR
(RT-PCR).
Results: PCR amplicons of expected sizes were obtained with primers
targeting adeA, adeB and adeS in both NIPH 952 and NIPH 953. The
sequences of the adeB-like amplicons were identical in both isolates and
were 84−89% identical to the known adeB sequences in A. baumannii.
Variants with gentamicin MICs of more than 4mg/l were obtained from
NIPH 952 at frequencies of ~5×10−9. Two of these variants were further
investigated, i.e. NIPH 952-I (gentamicin MIC 8mg/l) and NIPH 952-
IV (gentamicin MIC 24mg/l). Compared to NIPH 952, the susceptibility
patterns of NIPH 952-I, NIPH 952-IV and NIPH 953 shared elevated
MICs to aminoglycosides, tetracycline, tigecycline and ciproﬂoxacin,
whereas no changes in MICs were observed for piperacillin, cefotaxime,
sulphonamides or polymyxins. Consistently, RT-PCR identiﬁed 27-fold,
214-fold and 38-fold increases in mRNA transcripts for adeB in NIPH
952-I, NIPH 952-IV and NIPH 953, respectively, as compared to NIPH
952.
Conclusion: The aminoglycoside resistance of the gastric GS 13TU
isolate is likely to result from the up-regulation of its efﬂux system
homologous to the AdeABC system in A. baumannii.
Supported by grant 310/08/1747 of the Grant Agency of the Czech
Republic.
P796 Involvement of pmrA/B in colistin resistance in clinical
isolates of Acinetobacter baumannii
A. Beceiro °, M. Doumith, M. Hornsey, H. Dhanji, G. Bou,
D. Livermore, N. Woodford (London, UK; A Coruna, ES)
Objectives: Colistin (Col) resistance is rare in A. baumannii and little is
known about its mechanism, although the pmrA/B genes which encode
a two-component regulatory system have been implicated in laboratory
mutants. We investigated the role of pmrA/B using a small panel of
international clinical A. baumannii strains and laboratory mutants.
Methods: Clinical isolates included 5 that were Col-R (MIC 8−64mg/L)
and 5 Col-S (MIC 1mg/L). We raised Col-R mutants of both ATCC
19606 and clinical isolate ABRIM (MICs for parent/mutant: 1 vs. 64 and
1 vs. 16, respectively), and also used a pair of clinical isolates, Ab133
and Ab132, belonging to a single strain and isolated from the same
patient (MICs, 2 and 64mg/L). Isolates were identiﬁed by phenotype
and species-speciﬁc PCR. PFGE was used to determine relatedness.
MICs were determined by agar dilution and Etest. Expression of pmrA/B
was monitored by RT-PCR. Nucleotide sequences of pmrA/B were
determined.
Results: Nucleotide sequences of pmrA/B were identical to reference
sequences (e.g. CP000521) in all Col-S clinical isolates, whereas 4/5
Col-R clinical isolates harboured single mutations in PmrB (either
S14L, L87F, M145K or P233S); the ﬁfth had both F387Y and
S403F. No mutations were found in PmrA. Single mutations in PmrB
were also found in Col-R mutants of strains ATCC 19606 (A227V),
ABRIM (N353Y) and in the Col-R clinical isolate Ab132 (L87F).
RT-PCR identiﬁed mean 20.6 and 7.4-fold increases in pmrA and
pmrB expression, respectively, in Col-R vs. Col-S isolates. Likewise,
expression of pmrA was higher in the Col-R mutants of ATCC 19606,
ABRIM and in isolate Ab132 (6.4, 19.5 and 4.2 fold, respectively),
compared with their parents. Expression of pmrB was not elevated in
the Col-R mutant of ATCC 19606 or in Ab132, but there was a 10.5
fold increase in the mutant of strain ABRIM.
Conclusions: Colistin is one of the few options for treating multi-
resistant A. baumannii infections. Resistance requires at least two distinct
genetic events: isolates must acquire at least one point mutation in PmrB
(which are not localized to a speciﬁc domain) and up-regulation (at least)
of pmrA. The functional signiﬁcance of the individual PmrB mutations
and the precise genetic events causing pmrAB up-regulation remain to
be deﬁned. Prompt detection and effective infection control measures
are critical to prevent spread of resistant strains.
P797 Molecular characterization and outbreak analysis of
multidrug-resistant Acinetobacter baumannii from German
hospitals
Y. Pfeifer °, S.H. Cho, P.G. Higgins, A.M. Fahr, T.A. Wichelhaus,
K.P. Hunfeld, M. Martin, W. Witte (Wernigerode, DE; Seoul, KR;
Cologne, Heidelberg, Frankfurt/M., Lubeck, DE)
Objectives: Emergence and dissemination of multidrug-resistant Acine-
tobacter baumannii are of special concern because of limited therapeutic
options and increased mortality. In many cases colistin is the
only antimicrobial substance for an adequate treatment. In Germany
A. baumannii outbreaks were observed mainly in the summer months.
Here we report on molecular-epidemiological analysis of A. baumannii
from different German hospitals.
Methods: The strain collection includes 22 isolates from two outbreaks
in one hospital (A) in 2007 as well as 42 outbreak isolates collected
in a surgical ICU (hospital B) in 2006–2008. Furthermore 32 isolates
(2005–2009) from two diagnostic laboratories were analysed. Molecular
typing by PFGE and sequence-based multiplex PCR to identify isolates
belonging to members of the European clonal complexes I-III were
performed. Relevant resistance genes (blaOXA, blaVIM and blaIMP)
were identiﬁed by PCR and sequencing.
Results: All above mentioned isolates were resistant to ﬂuoroquinolones,
aminoglycosides, sulfonamides and b-lactams including carbapenems.
PCR and sequencing of resistance genes revealed the presence of
OXA-b-lactamases in all isolates, with OXA-23 (n = 45) and OXA-58
(n = 47) as the most prevalent types. In several outbreak-independent
isolates the genes blaOXA-72 (n = 1), blaOXA-58+blaOXA-23 (n = 1) or
blaOXA-66 + insertion sequence ISAba1 were identiﬁed. In one single
carbapenem-resistant isolate no carbapenemase gene was found.
Multiplex-PCR analysis for identiﬁcation of clonal lineages revealed that
nearly all isolates are related to the European clones I (n = 19), II (n = 51)
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and III (n = 2). Outbreak analysis of hospital A showed three different
clones (PFGE-macrorestriction patterns) whereby eight identical isolates
with OXA-23 are related to the European clone II (multiplex-typing).
The index-patients were repatriated from hospitals in Turkey and Egypt.
In hospital B the 27 isolates from 2006 and 2007 had identical PFGE
patterns and contained OXA-58. However, in 2008 a new A. baumannii
clone with OXA-23 was detected. Two patients died from an infection
with this strain.
Conclusion: Infections with multidrug-resistant A. baumannii are still
rare in Germany. The strains were imported by patients after return from
abroad and further spread was probably due to transmission by staff
or contaminated medical equipment. This highlights the need for the
implementation of strict hygiene control measures or even isolation.
P798 Paradoxical amikacin susceptibility in a multidrug-resistant
strain of Acinetobacter baumannii
D. Krahe´ °, N. Gordon, B. David, D. Wareham (London, UK)
Objectives: A multi-drug resistant isolate of A. baumannii recovered
from a blood culture of a patient with multi-organ failure showed an
‘Eagle’-like phenomenon in amikacin susceptibility testing, with growth
inhibited at low concentrations but supported at concentrations above
pharmacodynamic breakpoints. We investigated this ﬁnding and carried
out molecular analysis of the strain.
Methods: The isolate was identiﬁed as A. baumannii by API 20NE
and molecular detection of the blaOXA-51-like gene instrinsic to the
species. Susceptibility to amikacin was carried out by disc diffusion
testing according to BSAC methodology, by E-test and by determination
of MICs by microtitre dilution. Multiplex PCRs were carried out to
detect carriage of aminoglycoside acetyltransferases [aac(6′)-Ib, aac(6′)-
Ih, aac(3)-II], nucleotidyltransferases [ant(2′′)-I], phosphotransferases
[aph(3′)-I, aph(3′)-VI, straA, straB] and 16S rDNA methyltransferases
[armA, rmtA-D, npmA]. The effect of the generic RND efﬂux pump
inhibitor PABA on the phenomenon was also assessed.
Results: In disc diffusion tests, growth was observed around 30 mg
discs within a zone of bacterial inhibition. E-tests conﬁrmed inhibition
of growth between 0.5 and 2mg/L of amikacin (Figure 1). In broth
microtitre dilution tests − non turbid ‘skipped’ wells were observed in
the dilution range 2–16mg/L but only when an inoculum of 1 x 10(3)
CFU / ml was used. PCR detected the carriage Of 3 aminoglycoside
resistance genes, straB, aac(6′)-Ib and the armA methyltransferase known
to mediate high level amikacin resistance. The addition of PABA at
50mg/L did not inﬂuence the effects observed.
Conclusion: Treatment options for serious MDR Acinetobacter in-
fections are extremely limited. We describe paradoxical susceptibility
to amikacin analogous to that described by Eagle in Gram-positive
bacteria in 1947 and by Lorian in the Enterobacteriaceae in 1979. Eagle
demonstrated correlation of this effect in vitro with adverse effects
in vivo. Further work is needed to characterize the exact mechanism,
especially the regulation and contribution of ArmA, and to evaluate
whether amikacin may have a role as a synergistic antibiotic at lower
concentrations.
P799 Clinical and microbiological characterization of 20
carbapenem-resistant Acinetobacter baumannii bloodstream
infections
J.Y. Song °, H.J. Cheong, W. Choi, Y.M. Jo, I. Hwang, J. Heo, J. Noh,
W.J. Kim (Seoul, KR)
Objectives: The incidence of carbapenem-resistant Acinetobacter bau-
mannii infection is increasing, which might be associated with increased
morbidity and mortality among critically ill patients with limited
therapeutic options. This study was conducted to evaluate the clinical
and microbiological features of carbapenem-resistant A. baumannii
bacteremia.
Methods: The medical records of 20 adult patients with carbapenem-
resistant A. baumannii bacteremia admitted to Korea University Guro
Hospital, from September 2005 through August 2009, were reviewed.
With 20 bloodstream isolates, we intended to detect genes producing
carbapenemases, and investigate inoculum effect on each antimicrobial
agent (rifampicin, imipenem, colistin and tigecycline). With one blood
isolate from patients with pneumonia, rifampicin-inducible resistance
was examined using experimental mouse pneumonia model.
Results: Out of 20 carbapenem-resistant A. baumannii bloodstream
infection (BI), most common primary focus was the catheter-related
infection (45%), followed by pneumonia (25%), surgical site infection
(15%), intra-abdominal infection (10%) and unknown sources (5%).
Preceding colonization was found in just four patients (20%). Seventeen
patients displayed BI by A. baumannii alone and three with polymicrobial
BI. The 30-day overall mortality was 55%; inappropriate antimicrobial
therapy (81.8% vs. 33.3%, p = 0.04) and high Pitt bacteremia score
(p = 0.04) were statistically signiﬁcant risk factors of mortality. All
20 isolates had blaOXA-51-like gene, two of which additionally had
blaOXA-58-like gene and blaOXA-23-like gene respectively. Inoculum
effect and rifampicin inducible resistance were not detected.
Conclusion: Low-level carbapenem-resistant A. baumannii strains with
OXA-51-like carbapenemase were prevalent. Most BI by carbapenem-
resistant A. baumannii strains developed in patients without known
preceding colonization, resulting in delayed appropriate antibiotic
therapy with high mortality rate.
P800 In vitro activity of biocides against predominant clones of
Acinetobacter baumannii in Spain
M.A. Gala´n, F. Ferna´ndez Cuenca °, S. Ballesta, M.C. Go´mez-Sa´nchez,
J. Vila, L. Martı´nez-Martı´nez, G. Bou, J. Rodrı´guez-Ban˜o, A. Pascual
(Badajoz, Seville, Barcelona, Santander, La Corun˜a, ES)
Objectives: Reduced susceptibility to biocides may contribute to the
persistence of some Acinetobacter baumannii (Ab) clones in hospitals.
The aim of this study was to determinate the susceptibilities of prevalent
clones of Ab to ﬁve biocides commony used in hospitals.
Methods: 8 clonally unrelated Ab with different antimicrobial sus-
ceptibility patterns corresponding to the most prevalent clones in
Spain (Ab-GEIH), 1 pan-drug-resistant Ab (resistant to all commonly
used antimicrobials: ﬂuoroquinolones, aminoglycosides, carbapenems
and other b-lactams, tygecycline and colistin) and 3 type strains
(A. baumannii ATCC 19606, Pseudomonas aeruginosa ATCC 27853
and Staphylococcus aureus ATCC 29213) were included. The biocides
assayed were: domestic bleach (sodium hypochlorite), sterillium (propan-
2-ol, propan-1-ol, mecetronium ethyl sulfate), ethanol, orsan (povidone-
iodine) and clorhexidine digluconate. The antimicrobial activity of these
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biocides was determined by microdilution and by disc diffusion. The
maximum dilution of biocide at which there is no visible growth
(MID, microdilution) and the diameter of growth inhibition (GID: disc
diffusion) were determined.
Results: MID and GID results are presented in the table. By
microdilution the Ab-GEIH clones were less susceptible to clorhexidine
digluconate than pan-drug-resistant Ab clone, but more susceptible
(6/8) than Ab ATCC. These Ab-GEIH clones were also slightly less
susceptible to sterillium than pan-drug-resistant Ab clone and the ATCC
strains. Five out of 8 Ab-GEIH clones were more susceptible to
ethanol than pan-drug-resistant Ab clone. No signiﬁcant differences were
observed for domestic bleach and orsan when Ab-GEIH clones were
compared with pan-drug-resistant Ab clone and the ATCC strains. Using
the disc diffusion assay the Ab-GEIH clones were much less susceptible
to clorhexidine digluconate than pan-drug-resistant Ab clone. The other
biocides showed no signiﬁcant differences in their activities when Ab-
GEIH clones were compared with pan-drug-resistant Ab clone and the
ATCC strains.
Conclusion: for sterillium and ethanol there was poor correlation
between microdilution and disc diffusion. Susceptibility to biocides
among Ab-GEIH clones was more variable for ethanol and clorhexidine
digluconate than for domestic bleach, sterillium and orsan. The pan-
drug-resistant Ab clone is more susceptible to clorhexidine digluconate
than Ab-GEIH clones. New studies with more Ab clones are warranted.
Isolates or strains Domestic
bleach Sterillium Ethanol
Chlorhexidine
digluconate Orsan
MID GID MID GID MID GID MID GID MID GID
Ab GEIH 1/64
1/128
37−42 1/32 9−11 1/128–
1/4096
6−8 1/8000–
1/120000
18−20 1/32 10−12
Ab PanR 1/64 40 1/128 10 1/128 6 1/240000 34 1/32 11
A. baumannii ATCC 19606 1/128 42 1/64 12 1/128 9 1/16000 18 1/16 11
P. aeruginosa ATCC 27853 1/32 30 1/64 11 1/4096 6 1/120000 20 1/16 8
S. aureus ATCC 29213 1/32 36 1/128 14 1/16384 7 <1/960000 34 1/32 11
P801 Acinetobacter spp. susceptibility to tigecycline determined by
E-test and microdilution
L. Robles °, J. Lozano, E. Riquelme, J.J. Blas, E. Simarro, M. Martı´nez,
M.D. Crespo (Albacete, ES)
Objective: To compare susceptibility to tigecycline through Etest and
broth microdilution in Acinetobacter baumannii strains resistant to
imipenem.
Methods: Isolates from patients admitted to our hospital between
January 2007 and October 2009 were studied, considering only one
isolate per patient. Identiﬁcation and study of susceptibility were
conducted with Vitek-2 system (Biomerieux®) and, in parallel, the
susceptibility to tigecycline was studied with Etest® (AB BIODISK)
in Mueller-Hinton agar (BioMedics). BSAC (British Society for
Antimicrobial Chemoterapy) breakpoints were used − susceptible 1,
intermediate = 2, and resistant 2mg/l. The values read were rounded
up to the upper dilution in base-2 system. We considered different MICs
where variation existed in at least 1 dilution.
Results: 52 imipenem-resistant A. baumannii were isolated − 15 in 2007
(28.85%), 15 in 2008 (28.85%), and 22 in 2009 (42.3%). The allocation
among services was 44.2% ICU, 23.1% Reanimation, 9.6% Internal
Medicine, 7.7% Surgery, and 15.4% in other services. 36 (69.2%)
isolates were susceptible to tigecycline by Etest (MIC: 0.5−1mg/l) −
amongst them, 13 (36.1%) shown a MIC value similar to the one
obtained by microdilution, 14 (38.9%) a greater MIC value, and 9 (25%)
a lesser value − 2mg/l by microdilution. The remaining 16 (30.8%)
strains shown an intermediate susceptibility to tigecycline (MIC=2mg/l)
by Etest. In 7 (43.75%) isolates, this value was similar to the one obtained
by microdilution, whereas in 2 cases (12.5%) we obtained a greater MIC
value by Etest − with the interpretation changing from intermediate
to susceptible. We could not found any strain with MIC> 2 by Etest.
A correlation between both methods was found (r = 0.73 p0.05). The
percentages of intermediate or tigecycline-resistant strains were 30.8%
by Etest and 27% by microdilution. As to the evolution in time, in 2007
a 33.3% of intermediate or resistant strains is found, 6.6% in 2008 and
45% in 2009.
Conclusions:
1. The greatest percentage of isolates was found in the critical care units.
2. Even though microdilution is the reference method, we realized
that 17.3% strains found susceptible by Etest were intermediate by
microdilution, which suggests that using Etest as the only study
method for susceptibility might lead to mistaken interpretations and
result in therapeutic failure.
3. We observed a signiﬁcant increase of resistance to tigecycline in our
hospital during the last year.
P802 In vitro activity of colistin sulfate in combination with other
antimicrobials against Acinetobacter baumannii
M.E. Steed °, K. Kaye, H. Salimnia, D. Marchaim, T. Chopra, M. Rybak
(Detroit, US)
Objective: Evaluate the synergy of colistin sulfate (CS) based
combination regimens against multi-drug resistant (MDR) Acinetobacter
baumannii.
Methods: The activity of CS, imipenem (IMP), ampicillin/sulbactam
(AS), rifampin (RIF), and tobramycin (TOB) was evaluated against eight
clonally unique strains of MDR A. baumannii from a multi-hospital
system in Detroit, MI, USA. Minimum inhibitory concentrations were
determined by broth microdilution according to CLSI guidelines. Time-
kill experiments were performed with CS (1 and 0.5× MIC) alone and
in combination with the other antimicrobials (0.5× MIC) at a starting
inoculum of 106 CFU/mL and bacterial killing was evaluated at 4, 8,
and 24 hours. Antimicrobial regimens included CS + IMP, CS + AS,
CS + RIF, CS + TOB, CS + TOB + RIF, and IMP + AS. Synergy and
bactericidal activity were deﬁned as a 2 log10 kill and a 3 log10 kill,
respectively.
Results: Colistin sulfate MICs ranged from 0.5mg/L (7 strains) to
1mg/L (1 strain). All strains were resistant to IMP and AS. Four strains
were TOB susceptible (MIC 1−2mg/L) and 4 strains were TOB resistant
(MIC 16 to 2038mg/L). RIF MICs ranged from 2 to 128mg/L. For
CS at 1x MIC, synergy and bactericidal activity was observed for CS +
RIF (1 strain), CS + TOB (1 strain), COL + IMP + RIF (1 strain), and
COL + TOB + RIF (2 strains). At 0.5× the MIC for all antimicrobials
tested, synergistic and bactericidal activity was observed for COL + IMP
(7 & 5 strains), COL + AS (6 & 5 strains), COL + RIF (7 & 4 strains),
COL + TOB (5 & 4 strains), and COL + TOB + RIF (8 & 6 strains).
The combination of IMP + AS was synergistic against 7 strains.
Conclusions: Synergistic activity was observed for all combinations
against some of the isolates tested. The combination of COL + IMP
and COL + TOB + RIF displayed the most consistent synergistic and
bactericidal activity against the tested strains.
P803 Evaluation of antibiotic synergy against multidrug-resistant
Acinetobacter baumannii: comparison of three methods
T.Y. Tan °, T.P. Lim, W. Lee, L. Ng, A.L. Kwa (Singapore, SG)
Objectives: Acinetobacter baumannii has emerged as a pathogen with
the potential to develop multi-drug resistance (MDR), leaving few
therapeutic options. Combination antibiotic therapy may be considered
for infections with MDR strains of A. baumannii. However, there is
scanty data on in vitro testing for antibiotic combinations, and the most
appropriate antibiotics to use in combination. This study evaluated two
antibiotic combinations for MDR A. baumannii, using three different
testing methods.
Methods: Twelve strains of MDR A. baumannii were collected from ﬁve
hospitals. Minimum inhibitory concentrations (MIC) to polymyxin B,
rifampicin and tigecycline were determined by microbroth dilution,
and clonal relatedness was determined by molecular strain typing.
All strains were tested for the presence of in vitro synergy to
polymyxin B-rifampicin and polymyxin B-tigeycline combinations by
time-kill assays, Etest and chequerboard methods. The deﬁnition of
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synergy for time-kill assays used was 2log10 decrease in cfu/ml for
the antibiotic combination compared with its more active constituent.
The deﬁnition of synergy for Etest and chequerboard methods was a
fractional inhibitory concentration index of 0.5.
Results: All isolates were susceptible to polymyxin B (MIC=0.5mg/l),
while the distribution of MIC was more variable for rifampicin
(2−32mg/l) and tigecycline (2−>256mg/l). All study isolates were
shown to be unrelated by molecular strain typing. In vitro synergy
was demonstrated in 7 (58%) isolates to polymyxin B-rifampicin and
polymyxin B-tigeycline combinations, when tested by time-kill assay.
None of the isolates demonstrated in vitro synergy against the same an-
tibiotic combinations when synergy testing was performed by Etest. Only
one isolate demonstrated in vitro synergy to polymyxin B-tigecycline
when tested by chequerboard assay.
Conclusion: The results of in vitro antibiotic synergy testing for
combinations of polymyxin B, tigecycline and rifampicin against
A. baumannii vary according to the testing method used. Time-kill
assays demonstrated in vitro synergy in over half of the study isolates,
but equivalent results were not obtained by the other two methods.
Further work is required to clarify the role of in vitro synergy testing,
in particular, by correlation with clinical outcome measures.
P804 Multidrug-resistant Acinetobacter baumannii blood isolates:
in vitro activity of colistin and tigecycline, existence of
metallo-b-lactamase production and heteroresistance
A. Ergin °, O. Koseoglu Eser, G. Hasc¸elik (Ankara, TR)
Objectives: The aims of the study were to determine the in vitro
susceptibility of colistin and tigecycline, metallo b-lactamase(MBL)
production and heteroresistance among multi-drug resistant(MDR)
Acinetobacter baumannii strains isolated from blood samples between
2004–2009.
Methods: Sixty MDR A. baumannii blood isolates that were fully
resistant to piperacillin (PIP), amikacin (AN), gentamicin (GM),
imipenem (IMP), meropenem (MER), cefotaxime (CTX), cef-
tazidime (CAZ), ciproﬂoxacin (CIP), levoﬂoxacin (LEV) detected by
BD Phoenix and were tested for colistin (CL) and tigecycline (TGC)
susceptibility by E-test. Heteroresistant colonies searched by E-test
for colistin and by disk diffusion test for IMP. MBL production was
determined by the combined disk test with IMP-0.1 M EDTA and
IMP-0.5M EDTA. An increase in zone diameter of 4 for 0.1M IMP-
EDTA disks and 7mm for 0.5 M IMP-EDTA disks was considered
positive for MBL production.
Results: Thirty-two (53.3%) of the invasive isolates were from intensive
care units (ICUs). MIC90 values for the isolates were >64mg/ml for
PIP, >32mg/ml for AN, >8mg/ml for GM, >8mg/ml for IMP, >8mg/ml
for MER, >32mg/ml for CTX, >16 mg/ml for CAZ, >2 mg/ml for CIP,
>4mg/ml for LEV, respectively. Resistance rate for colistin was 1.6%.
There were two separate probable heteroresistant isolates for colistin.
The MIC values for these heteroresistant strains were 8 and 24 mg/ml,
respectively. There was 12 fold increase in MICs among heteroresistant
isolates compared to the original MIC (0.094 and 0.25 mg/ml) levels.
Tigecycline resistance rate was 6.7%. Sixteen (26.6%) of the isolates
were susceptible to IMP. No heteroresistant strains were determined
among IMP susceptible isolates. Among 60 A. baumannii isolates, 18
(30%) yielded positive results by 0.1M IMP-EDTA disk test whereas
46(76.6%) of the isolates were positive by 0.5M IMP-EDTA disk test.
None of the imipenem susceptible strains gave positive MBL results by
both of the disk tests.
Conclusion: In this study, randomly selection of invasive MDR
A. baumannii isolates gave us an excellent view of colistin and
tigecycline, appearing as the only susceptible antimicrobials in ﬁve years
time but their limited usage in the clinical setting, existence of resistant
and heteroresistant isolates indicate that new antimicrobials should be
investigated against this important pathogen.
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P805 Fungiscope − a global database for rare fungal infections
M. Ru¨ping, A. Kindo, W. Heinz, A. Hamprecht, G. Fischer,
O.A. Cornely °, J.J. Vehreschild on behalf of the ISHAM Working
Group Fungiscope
Objectives: We are coordinating a global registry for cases of rare
invasive fungal diseases (IFD). Our objective is to broaden the knowledge
on epidemiology, to determine the clinical pattern of disease, to describe
and improve diagnostic procedures and therapeutic regimens, as well as
to facilitate exchange of clinical isolates among the contributors.
Methods: Fungiscope™ − A Global Rare Fungal Infection Registry
is an international university-based case registry that collects data of
patients with rare IFD, using a web-based electronic case form at
www.fungiscope.net. For inclusion in the registry cases have to have
positive cultures or histopathological, antigen or molecular genetic
evidence of IFD and the associated clinical symptoms and signs of
invasive infection. The data that are entered onto the registry include
demographics, underlying conditions, neutrophil count, concomitant
immunosuppressive medications, clinical signs and symptoms of IFD,
site of infection, diagnostic tests performed, pathogen identiﬁcation,
antifungal treatment, surgical procedures performed, response to
treatment, overall survival and attributable mortality.
Results: Overall, 134 cases have been completed. Results from
17 additional cases are pending. Chemotherapy or allogeneic stem
cell transplantation for a haematological malignancy was the most
predominant risk factor (n = 47; 35%), as well as diabetes mellitus
(n = 36; 27%), stay at an intensive care unit (n = 22; 16%) and chronic
renal failure (n = 17; 13%). In 47 patients (35%) the lung was the
organ of ﬁrst diagnosis, followed by the sino-nasal region in 22 (16%)
and deep soft tissue infections in 20 (15%) patients. For 74 (55%)
patients, a favourable outcome, deﬁned as a complete or partial response
to treatment of IFD was documented. Overall mortality and mortality
attributable to IFD was 38% (n = 51) and 23% (n = 31), respectively.
Conclusion: The clinical relevance of rare IFD is increasing steadily. In a
short period of time, a wide varietyof cases from Europe, Asia and South
America could be documented. Further investigators and coordinators are
cordially invited to contribute to Fungiscope.
P806 Multicentre prospective monitoring for empirical treatment
of invasive fungal infection using high negative predictive
value diagnostic strategies
L. Hasseine °, P. Marty, S. Cassaing, F. Robert-Gangneux, L. Gaudron,
R. Knecht, L. Bonesso, M-D. Linas, A. Berry, J-P. Gangneux (Nice,
Toulouse, Rennes, FR)
Objectives: In order to overcome moderate sensitivity of various
diagnostic tests during invasive fungal infections (IFI), early treatment
strategies such as empirical antifungal therapy (EAT) have been assessed.
EAT showed efﬁcacy in improving the outcome of infected patients
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but remains costly. The aim of this work was to standardize in 3
teaching hospitals the radiological and biological monitoring of EAT,
among which a new panfungal PCR assay (PF-PCR), and to evaluate
prospectively their negative predictive value (NPV).
Methods: 108 patients from Nice, Toulouse and Rennes University
hospitals (France) were enrolled at day 0 of their EAT prescription.
They beneﬁted from a radiological and biological monitoring to conﬁrm
or exclude an IFI. The biological screening consisted of mycological
analysis of various samples (blood culture, bronchoalveolar ﬂuid, . . . ),
galactomannan (GM) antigen assay in blood samples twice a week, and
a weekly whole blood PF-PCR assay that was developed for this study.
Results: Among the 108 patients treated, 53 were considered non
infected (according to EORTC/MSG 2008 criteria) and 55 patients were
infected: 37 invasive aspergillosis (5 proven, 28 probable and 4 possible),
16 candidemia, 1 fusariosis and 1 cryptococcosis.
(i) We ﬁrst evaluated the performance of our PF-PCR assay on the
whole population: SEN= 65%, SPE=83%, PPV=80% and NPV=70%.
Our results associated to other recently published data underlined the
limited sensitivity of PCR for the diagnosis of IFI and incite to optimize
the design and the standardization of molecular tools.
(ii) We then focused on ﬁlamentous IFI in order to evaluate the NPV
of different diagnostic strategies. From our results, we can draw that
a combination of 2 negative diagnostic tests allows the exclusion of
most IFI with a NPV of (i) 96% when combining negative CT scan and
2 consecutive PF-PCR; (ii) 90% when combining 2 consecutive PF-PCR
and 2 consecutive GM; (iii) 88% when combining negative CT scan and
2 consecutive GM.
Conclusion: Efforts must still be done to increase the sensitivity of the
diagnosis of IFI, and early therapeutic strategies such as EAT remain
useful. But in parallel, radiological and biological results should rapidly
allow the exclusion of non-infected patients in order to reduce its cost.
In this work, we show that the combination of a negative CT scan with
a negative PF-PCR detection has the highest NPV and allows the stop
of EAT within the ﬁrst ﬁfteen days.
P807 Impact of a multidisciplinary approach of invasive fungal
infections from diagnosis to treatment
F. Lieutier, V. Mondain °, M. Gari-Toussaint, L. Hasseine, A. Sirvent,
M. Poire´e, T. Dantin, N. Mounier, A. Mousnier (Nice, FR)
Invasive fungal infections (IFI) are severe diseases affecting immuno-
compromised patients. In France, since 2007, the cost of expensive
recommended antifungal treatments (AFT) is not included in the
normal per-case payment and each suspected IFI must be systematically
documented during interdisciplinary team meetings (ITM) including
an infectious disease specialist, a haematologist, a mycologist and a
pharmacist, when AFT are discussed.
Objective: to evaluate the impact of our ITM.
Methods: in 2008, 179 advices were provided in real time to prescribing
doctors concerning 109 patients receiving AFT. This was done during
31 ITM. From January to September 2009, 192 advices were provided
during 27 ITM, Each patient’s condition was documented according
to clinical presentation including emergency high resolution computed
tomography (CT) of the chest and abdomen and microbiological data
as Aspergillus galactomannan antigen assay twice a week, pan-fungal
PCR, and mycological analysis of various samples (Bronchoalveolar
ﬂuid, blood culture . . . ).
Results: in 2008, 8 cases of probable and 2 of possible invasive
aspergillosis (IA) were diagnosed (all in a haematology department,
with one paediatric case). Four patients died: in one case IA may have
been a causative factor. Incidence rate for IA was 4.7% among patients
with acute leukaemia and stem-cell transplantation, which seems low
compared to the literature. Advices were followed in 90% of cases. In
2008 and 2009 (until september), 95% of treatments involving added
costs, were in line with provisions for marketing authorization.
Number of empirical AFT:
First half the year 2003 19/41 (46%)
First half the year 2008 7/23 (30%)
First half the year 2009 9/39 (23%)
To conclude, currently, 100% of patients beneﬁt from a radiological
and biological monitoring, in order to optimize the diagnosis and AFT.
Thus, the empirical’s antifungal (AF) number has been reduced from 46
to 23%. Indeed, we observed a 17% drop in added AF costs and 12%
for other systemic AF (2007 versus 2008). A good compliance with the
suggested advices shows that prescribing doctors are in favour of the
scheme. The consumption of AF expressed in Daily Deﬁned Dose will
allow further assessment of practice trends.
P808 Real-life comparison of empirical and prophylactic
antifungal strategies in high-risk AML patients at a tertiary
cancer centre
D. Gutmann, J. Kersten, P. Schafhausen, T. Bru¨mmendorf, M. Trepel,
C. Bokemeyer, J. Panse ° (Hamburg, Aachen, DE)
Objectives: Invasive fungal infections (IFI) remain a major threat for
patients with acute myelogenious leukemia (AML) during induction
chemotherapy neutropenia 10 days. Two studies demonstrating reduc-
tion in morbidity and mortality through prophylaxis with posaconazole
lead to an AI recommendation in various guidelines. However, prompt
empirical or pre-emptive therapies are still used alternatives as real life
data about posaconazole prophylaxis are scarce and overtreatment and
increasing costs are of concern. We compared clinical and economic
parameters of empirical and prophylactic strategies at a tertiary cancer
center during intensive building (re-) construction.
Methods: Retrospective chart review study of 104 patients with primary
or secondary AML treated between January 2005 and February 2009.
Each induction chemotherapy or consolidation therapy with neutropenia
10 days was counted as an episode (n = 222). Patients were stratiﬁed
according to their antifungal approach: primary prophylaxis (n = 35, 51
episodes, group 1), empirical therapy (n = 63, 111 indices, group 2),
secondary prophylaxis (n = 41, 60 episodes, group 3, comprised of
patients from groups 1 and 2).
Results: Demographics, AML subtypes, co-morbidities and neutropenic
days (median = 13) were comparable in all three groups; no patient
received G-CSF support. Logistic regression analysis revealed days
of neutropenia, performance status, use of antibiotics and secondary
AML as risk factors for development of IFI, while primary prophylaxis
reduced the risk for possible/probable/proven IFI by 86.7% compared to
empirical therapy (p = 0.001). Incidences of probable/proven IFI were 3%
in group 1, 29% in group 2 and 7% in group 3 (p = 0.001) and 17%, 69%
and 37% (p< 0.001) when possible IFIs were included. Mortality during
observation period was similar (4%, 6.4%, 7%, NS). Also similar were
isolated pathogens, additional antifungals, change of antibiotics, days at
intensive care unit (ICU), bacterial infections except for enterocolitis
(45% group 2 vs 18% and 28% in groups 1 and 3). Side effects were
slightly higher in group 2 (8% vs 2% and 5%, NS). Days of hospital-
ization, antifungal, antibiotic, and antiviral costs were comparable, while
imaging costs were signiﬁcantly higher in group 2 (p = 0.006).
Conclusion: Posaconazole prophylaxis signiﬁcantly reduces incidences
of IFI in high risk AML patients, while mortality rates, days of
hospitalization, anti-infective and overall costs are not reduced.
P809 Prophylaxis drug monitoring of itraconazole and
voriconazole in the paediatric onco-haematological setting
F.G. De Rosa °, L. Baietto, A. D’Avolio, G. Ventimiglia, M. Siccardi,
E. Biasin, F. Carraro, F. Nesi, M. Simiele, M. Sciandra, G. Di Perri
(Turin, IT)
Objectives: There is a growing knowledge of the clinical importance of
therapeutic drug monitoring of azoles such as itraconazole, voriconazole
in the treatment of invasive fungal disease (IFI) due to variations in
absorption, metabolism and individual factors such as heterogeneity of
hepatic enzymes. In this paper we report our data based on a regional-
referral laboratory for the measurement of plasma concentration of
azoles in a variety of patients to illustrate the usefulness of Prophylaxis
Drug Monitoring (PDM).
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Methods: Paediatric patients with onco-haematological diseases in oral
antifungal prophylaxis for more than ﬁve days with Itraconazole (ITC)
(oral solution) or voriconazole (VRC), were included in the study.
Blood samples were collected at steady state, immediately before drug
administration (Ctrough). Plasma drug measurement was performed by
HPLC-MS validated method. The evaluated Ctrough were compared
with previously reported concentrations effective in the prevention or
treatment of IFI: 250 ng/mL for ITC and 1000 ng/mL for VRC.
Results: 10 patients received ITC (mean age 15.4±5.8 years old; mean
body weight 59.3±27.9 Kg) and 11 patients were treated with VRC
(mean age 14.9±6.4 years old, mean body weight 51±24.8 Kg). ITC was
administered daily at 4mg/Kg in 5 patients, 5mg/Kg in 3 patients and at
lower dosages in the others. VRC was administered at a dosage ranging
from 2 to 14mg/Kg daily. Mean Ctrough values were 158.2±131.5
ng/mL and 2855.8±2068.3 ng/mL for ITC and VRC, respectively.
The percentage of patients receiving ITC having a Ctrough 250 ng/ml
was 20%. The percentage of patients receiving VRC having a Ctrough
1000 ng/ml was 91%. There was a signiﬁcant correlation (p = 0.025)
between plasma Ctrough and VRC dosage (mg/Kg) but not for ITC.
Conclusion: Our data show that the administration of ITC as antifungal
prophylaxis for IFI is almost always associated with reduced plasma
concentrations, with reported ineffectiveness in the prevention of IFI. The
administration of VRC is more frequently associated with therapeutic
drug levels. In the setting of antifungal prophylaxis, VRC should
be preferred to ITC. Efforts should be made to pursue PDM when
prophylaxis with ITC is chosen in high-risk patients. Future studies are
needed to illustrate the value of PDM of azoles to ensure that optimal
plasma levels are achieved in at-risk patients.
P810 Distribution of zygomycetes species in France, 2003–2008
E. Dannaoui °, D. Garcia-Hermoso, K. Sitbon, D. Hoinard,
O. Lortholary, F. Dromer for the French Mycoses Study Group
Objectives: We have recently shown an increased incidence of
zygomycosis over a 10-year period in France (Bitar et al. Emerg Infect
Dis 2009). Here, we describe the diversity of zygomycetes species
responsible for invasive fungal infection in France (2003–2008) and their
relationship with infection characteristics and outcome.
Methods: Cases were recorded during the nationwide survey of
“emerging” mycoses through the electronic secured database called
RESOMYC. The causative species were identiﬁed at the NRCMA by
morphology and by sequencing the ITS region.
Results: Among the 110 cases (65% males, mean age±SD=47±21 yrs),
the distribution of the species was as follow: 36 (37%) Lichtheimia
spp. (formerly Absidia spp.), 25 (21%) Rhizopus oryzae, 12 Rhizomucor
pusillus, 13 Rhizopus microsporus, 6 Mucor circinelloides, 5 Saksenaea
vasiformis, and 13 isolates accounting for 8 other species.
The main characteristics of the cases involving the 5 major species are
summarized in Table 1.
Lichtheimia
spp.
R. oryzae Rhizomucor
pusillus
R. microsporus M. circinelloides
Underlying diseases*
Hematol. malignancies 14/23 (61%) 8/20 7/10 (70%) 5/9 0/6
Diabetes 0/23 10/20 (50%) 2/10 1/9 0/6
Solid organ transplant 5/23 0/20 1/10 2/9 0/6
Polytraumatisms 4/23 2/20 0/10 1/9 6/6 (100%)
Infections
Rhinocerebral* 5/32 14/25 (56%) 0/10 1/13 0/6
Pulmonary* 14/33 6/23 11/12 (92%) 10/13 (77%) 0/6
Cutaneous* 16/33 (49%) 5/24 2/11 1/13 4/6
Disseminated** 6/36 2/25 2/12 0/13 0/6
Death at 90 days** 10/27 6/17 6/12 6/11 0/5
*P< 0.01; **NS.
Denominators correspond to cases with available information.
Conclusion: The distribution of the main species involved in France
differs from that reported in other countries/geographical areas. In
particular, a high proportion of cases were due to Lichtheimia spp.
Since the proportions of underlying factors, infection localizations and
outcome differ according to zygomycetes species, accurate identiﬁcation
is important for a better understanding of the epidemiology and
pathophysiology of these infections.
P811 Estimation of the number of mucormycosis infections in
France through combined datasets, 2005–2007: preliminary
results
D. Van Cauteren, G. Morizot, F. Lanternier, E. Dannaoui, F. Dromer,
O. Lortholary °, D. Bitar (Paris, FR)
Introduction: A retrospective study of mucormycosis cases (Retrozygo)
is undergoing in order to describe these severe infections and their
outcome in France. Cases were identiﬁed through 2 sources: the French
hospital information system (PMSI) and the National Reference Center
for Mycoses and Antifungals (NRCMA). The PMSI is a managerial
tool based on the systematic collection of information for any new
hospital admission and the NRCMA coordinates a recently established
voluntary network of French mycologists. Using these two sources of
data we applied a capture-recapture approach to estimate the number of
mucormycosis cases in France between 2005 and 2007.
Methods: Cases identiﬁed through the datasets were included in the
Retrozygo study after veriﬁcation of their clinical symptoms and
biological conﬁrmation. Under the hypothesis of independence between
sources and equal catchability in each source, estimates of the total
expected numbers were calculated through a capture-recapture method.
By matching several sources of information coming from the same
population, the capture-recapture method allows to estimate the number
of cases not identiﬁed by any of the sources, the total number of cases
(N) in the population and the sensitivity of each source.
Preliminary results: Among 175 mucormycosis cases identiﬁed by the
two sources, 94 cases were excluded and 87 conﬁrmed: 31 cases were
identiﬁed in both sources, 28 were reported through the NRCMA only
and 22 through the PMSI only.
After capture-recapture analysis, the total number of expected cases was
100.9 (95% Conﬁdence interval: 0–228). Based on these results, the
sensitivity is 52% for PMSI, 58% for NRCMA and 87% when both data
are combined together.
Discussion: As zygomycosis is a rare disease, the wide conﬁdence
intervals obtained around (N) may be due to the small numbers of
cases in each source of data. The respective yield of each dataset
is fairly satisfactory and the combination of both sources provides a
good sensitivity. We may therefore consider that the present Retrozygo
study will capture the majority of cases which occured in France within
the study period, providing an accurate description of cases and their
outcome.
P812 Fungal rhinosinusitis in Kuwait: a 14-year retrospective
analysis of the aetiologic spectrum
Z. Khan °, S. Ahmad, R. Chandy, L. Joseph, D. Farhat, S. Al-Hajri
(Safat, Jabriya, Jabrya, KW)
Objective: Fungal rhinosinusitis, once considered an uncommon
disorder, is now being increasingly recognized worldwide. In the present
study, we have analyzed the etiologic spectrum of fungi isolated from
clinical material obtained from patients with rhinosinusitis over a 14-year
period (January 1996 – October 2009) in Kuwait.
Methods: All the clinical specimens (nasal tissues, curettages/washings
and swabs) received from different hospitals in Kuwait were cultured on
Sabouraud dextrose agar supplemented with chloramphenicol. The iden-
tity of the isolates was established by typical phenotypic characteristics
following the standard procedures. The molecular identiﬁcation of the
isolates was carried out by PCR ampliﬁcation using panfungal primers
and sequencing of the ampliﬁed products. Repeated isolations of the
same fungus from an individual patient were excluded from the analysis.
Results: Fungal isolates from 83 patients with rhinosinusitis were
analyzed. The age of these patients ranged between 3−70-years, 7%
of them were <12 years of age. Forty (48%) of the patients were males
and 63% of them were Kuwaiti nationals. Of the 83 fungal isolates,
36 (43%) were identiﬁed as Aspergillus ﬂavus, 30 (36%) as Bipolaris
hawaiensis, 6 as Aspergillus niger, 4 as Aspergillus terreus, 3 as
Aspergillus fumigatus, and one each as Bipolaris specifera, Paecilomyces
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lilacinus and Alternaria alterans. Of the total 30 isolates of B. hawaiensis,
26 (87%) came from Kuwaiti patients. The distribution of 36 A. ﬂavus
isolates between Kuwaiti and non-Kuwaiti patient was 13 (36%) and 23
(64%), respectively.
Conclusions: The ﬁndings suggest that A. ﬂavus and B. hawaiensis
are the two major species associated with the etiology of fungal
rhinosinusitis in Kuwait. The isolation rate of A. ﬂavus from Kuwaiti
patients was only 25% (13 of 52), but much higher from non-
Kuwaiti patients (23 of 31, 74%). Furthermore, the isolation of
B. hawaiensis predominantly from the Kuwaiti patients is also an
interesting observation warranting further studies on aerobiological and
immunological aspects of rhinosinusitis in Kuwait.
P814 A retrospective evaluation of the efﬁcacy of voriconazole in
24 ocular Fusarium infections
G. Obenga °, T. Gaujoux, O. Lortholary, P.F. Troke for the French
Mycosis Study Group
Objective: Fusarium spp. cause problematic ophthalmic infections as
they have low susceptibility to many antifungal agents and are, thus,
difﬁcult to treat. We examined the potential efﬁcacy of voriconazole
(VCZ) for therapy of Fusarium infections of the eye.
Methods: VCZ-treated patients (pts) with proven or probable keratitis
or endophthalmitis were identiﬁed from the Pﬁzer VCZ database (9 pts)
and 6 French ophthalmology departments (15 pts). Sociodemographic
features, predisposing factors, history of corneal trauma, associated
ocular conditions, other systemic diseases and prior therapies were anal-
ysed. Investigator-determined success was deﬁned as infection resolution
and/or ulcer healing. Failure was no response or persistent infection. In
some pts adjunctive surgery was also required (penetrating keratoplasty,
vitrectomy in emergency, evisceration) to resolve the infection.
Results: Most pts were Caucasian (83%) and male (71%). The site
of infection was keratitis (63%) or endophthalmitis (37%) with proven
infection in 23 (96%). Prior therapy was topical and/or systemic
amphotericin (46%), ﬂuconazole (17%) or others (33%), often in
combination. Fungal pathogens isolated were F. solani (14, 58%),
F. moniliforme (1), F. oxysporum (1) and Fusarium spp (8). VCZ was
administered systemically, topically and/or by intraocular injection, with
16 pts (66%) receiving VCZ as salvage and 8 as primary therapy.
Response by site of infection was 73% for keratitis and 66% for
endophthalmitis. Overall response was 71% and 7pts required adjunctive
surgery. However, response was 88% for 8 primary VCZ therapy pts and
64% for 16 salvage therapy pts. Response by species was, F. solani 9/14
(55%) and all others 8/10 (80%). In 13 pts (77%) VCZ was used in
combination (response 77% Vs 64% alone) with topical [amphotericin
B 10/24 (42%) caspofungin 5 (21%), natamycin 1 (4%)] and systemic
agents [caspofungin 3 (13%), amphotericin 2 (8%)].
Conclusions: Topical and systemic VCZ is effective alone or in
combination with other antifungal agents for therapy of Fusarium
keratitis or endophthalmitis. This therapy appears promising and a larger,
prospective study is warranted.
Underlying condition (n) Response by site n/N (%) Median VCZ therapy
Keratitis Endophthalmitis (days)
Steroids (2) 0/1 (0) 1/1 (100) 43–110
Surgery, trauma, burns (16) 9/11 (82) 4/5 (80) 47 (7–213)
Immune normal/unknown 2/3 (66) 1/3 (33) 92 (11–145)
Total (24) 11/15 (73) 6/9 (66) 54 (7–213)
P815 Fatal mycotic aneurysms due to Scedosporium apiospermum
A.T. Ong °, R. Bency, C.C. Blyth, M. Vicaretti, A. Harun, W. Meyer,
N. Gilroy, S.C. Chen (Westmead, AU)
Objectives: Scedosporium are emergent pathogens in both immuno-
compromised and immunocompetent patients that are difﬁcult to
treat. Mycotic aneurysms due to Scedosporium have been infrequently
reported. Two cases are presented and the literature reviewed.
Results: Case 1: A 48-yr-old diabetic male developed headache, left-
sided visual loss and cranial nerve palsies 3 weeks post left partial
mastoidectomy for cholesteatoma. Magnetic resonance imaging (MRI)
showed extensive skull base osteomyelitis. Intravenous antibacterial
agents were commenced and functional endoscopic sinus surgery
performed. Scedosporium apiospermum was cultured. The patient
received 12 weeks of antibacterials and voriconazole with clinical
response. Repeat imaging was performed two weeks post ceasing therapy
due to worsening headache. This demonstrated persistent osteomyelitis
with extension into the right petrous temporal bone and a superior
cerebellar artery aneurysm. Despite surgical clipping, he died from
aneurysmal rupture and massive cerebellar infarction.
Case 2: A 55-year-old living-related renal transplant recipient developed
an index ﬁnger lesion. Fungal culture grew S. apiospermum. Voricona-
zole was given for 3 months with apparent complete response. He
represented three months later with bilateral ﬂank and lower back pain.
MRI of the spine, abdomen and pelvis showed inﬂammatory aortitis
with lumbar osteomyelitis and a paravertebral abscess. A subcutaneous
nodule became evident on the right wrist. S. apiospermum was
cultured from both the paravertebral abscess and subcutaneous nodule.
Voriconazole treatment was initiated. Rapid progressive dilatation
of the aorta prompted surgical resection and replacement with a
polytetraﬂuoroethylene graft. Histopathology of the aorta revealed
granulomatous mycotic vasculitis and culture yielded S. apiospermum.
The patient initially clinically responded to surgery/voriconazole but
four months post surgery, developed refractory abdominal pain from
an occluded superior mesenteric artery graft and died.
Conclusions: Angioinvasive complications following Scedosporium
infection are rare. Eight cases have been described with a mortality
of 88%. Early diagnosis is essential for optimal management which
requires aggressive surgical resection and prolonged antifungal therapy.
High risk patients with localized infection should be carefully monitored
for delayed complications.
P816 Performance of the Vitek 2 yeast antifungal susceptibility
card compared to broth microdilution for Candida and
Cryptococcus sp.
W.W. Chan °, C. Sand, B. Jansen, R. Rennie, J. Fuller (Edmonton, CA)
Objectives: Standardized broth microdilution (BMD) for yeast sus-
ceptibility testing (CLSI M27) is a well-characterized reference assay
but is reliant on visual growth endpoint determination. The AST-YS01
card for the VITEK 2 platform (bioMe´rieux, Marcy l’Etoile, France)
provides an automated susceptibility test for yeasts that determines
growth spectrophotometrically. We compared the performance of the
AST-YS01 to BMD for Candida spp. and Cryptococcus spp. using
stringent agreement criteria.
Methods: Testing was performed on 172 archived clinical isolates
of Candida spp. (70 C. albicans, 49 C. glabrata, 17 C. krusei,
12 C. tropicalis, 11 C. parapsilosis, 13 others) and 37 isolates of
Cryptococcus spp. (32 C. neoformans, 4 C. gattii, 1 C. albidus),
including 44 resistant strains. MIC values for all isolates were determined
for ﬂuconazole (FLUC), voriconazole (VORI), amphotericin B (AMB),
and 5-ﬂucytosine (5FC) using BMD (CLSI M27-A3) at 24 & 48
hours of incubation. Except for Cryptococcus spp. with VORI, AST-
YS01 MIC values of all four drugs were determined for all isolates.
Essential agreement (EA) was calculated using±1 and±2 log2 dilution
boundary limits relative to the BMD MIC. Categorical agreement was
determined using available CLSI interpretive breakpoints and 2 for
AMB. Discordant MIC pairs (>2 log2 dilution discrepancy) were retested
with both methods.
Results: EA exceeded 90% in all scenarios when using ±2 log2 dilution
boundary limits, which has been previously reported. The AST-YS01
card showed better EA for all drugs to the 24 h BMD MIC, except
for 5FC. However, VORI versus Candida spp. was the only test
scenario that achieved an EA value >90% using ±1 dilution threshold.
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Notwithstanding, EA for 5FC against Candida and Cryptococcus, and
AMB against Candida were 88.6%, 89.8%, and 88.2%, respectively.
Categorical agreement was >90% for all drugs except FLUC against
Candida.
Conclusion: The VITEK 2 AST-YS01 yeast susceptibility test is
a standardized and reproducible system. However, its performance
compared to the reference BMD (CLSI) is suboptimal when we apply
the same EA criteria used routinely for antibacterial test performance
studies (±1 dilution). Unlike EUCAST, CLSI BMD methods do not use
spectrophotometry for endpoint determination. In the future, this level of
standardization may be all that is required to improve test performance
interpretations, while maintaining stringent criteria for test agreement.
Table 1. Essential agreement (EA) between VITEK 2 Yeast Card & broth
microdilution
Genus Drug EA at 24 h (%) EA at 48 h (%) CA at 48 h (%)
+/−1 dil +/−2 dil +/−1 dil +/−2 dil
Candida 5FC 88.6 94.0 93.4 98.2 95.2
AMB 89.8 98.8 80.1 98.2 98.8
FLUC 86.2 93.4 83.8 93.4 86.8
VORI 91.0 95.8 83.1 91.6 93.4
Cryptococcus 5FC 88.2 97.1 79.4 97.1 100
AMB 85.3 100 76.5 100 100
FLUC 82.4 97.1 73.5 97.1 100
dil: dilution.
P817 Risk factors for mortality of central nervous system
cryptococcosis in patients with AIDS
A. Cabello, C. Isea, M. Arsuaga, M. Go´rgolas, M. Ferna´ndez
Guerrero ° (Madrid, ES)
To determine prognosis and risk factors for therapeutic failure in the
short term( mortality and relapses)in HIV-positive patients with CNS
cryptococcosis.
Methods: retrospective review of consecutive cases of CNS cryptococ-
cosis complicating HIV-infection seen in a single institution since 1996.
Patients with CNS involvement and isolation of C. neoformans from CSF
and/or blood cultures were analyzed. Medical records and microbiologic
charts were reviewed according to a deﬁned protocol.
Results: 26 (1.4%) patients from a cohort of 1,800 patients with an
AIDS-deﬁning condition patients were assessed. Cryptococcosis was the
AIDS-deﬁning condition in 20 of these cases (77%). The mean age was
34.4±9.7 years; 92% were men and 73% were MSM. Most patients
followed a subacute course (<4 weeks) characterized by fever (70%),
headache (60%) and lethargy (30%). The mean CD4+ T cell count
was 61.6±65 (median 38.5). Brain CT-scans showed hypodense lesions
(cryptococcomas)in 4 cases. India ink stain showed yeast in 23 cases
(88%) and they were considered abundant in 16(66.6%). CSF cultures
were positive in 24 (92%) and fungemia was determined in 15 out of
19 patients in whom blood cultures were taken(79%). Crypto antigen in
CSF was positive 23 patients (88%) and the levels were >1024 in 18
(78%). Patients with crypto antigen titers >1024 had CD4+ T cell counts
signiﬁcantly lower than their counterparts with titers <1024 (43±38 vs
115±102; p< 0.05). Patients were treated with liposomal anfotericin B
with or without 5-ﬂucytosine for a mean of 2.7±1.3 weeks generally
followed by ﬂuconazole for long periods. Failures were observed in 7
patients (31%): 2 patients died and 6 had a clinical relapse within 3
months after diagnosis. Both patients who died and 5 out of 6 relapses
were patients with crypto antigen titers >1024 and low CD4+ T cell
counts.
Conclusions: Although rare, CNS cryptococcosis continues to produce
signiﬁcant morbidity and mortality in the HAART’s era. Profound
immunosuppression and high titers of crypto antigen in CSF are
associated with greater risk of mortality and treatment failures.
P818 Clinical epidemiology of cryptococcal infections in Singapore
M. Chan °, D. Lye, A. Chow, Y.S. Leo, T. Barkham (Singapore, SG)
Objective: Cryptococcosis has been reported in Singapore however
prevalence of subtypes, difference in clinical presentation, underlying
host status and treatment outcome are unknown.
Methods: All patients with laboratory conﬁrmed cryptococcal infections
admitted from June 1999 to March 2007 to Tan Tock Seng Hospital, a
1200 bed tertiary care centre in Singapore were retrospectively reviewed.
Stored isolates were cultured on canavanine-glycine-bromothymol blue
agar and subtyping was done by polymerase chain reaction restriction
fragment length polymorphism. Demographic, clinical, laboratory and
treatment outcome were analysed.
Results: Of 62 patients with cryptococcosis, only 3 (5%) were infected
with Cryptococcus gattii and all were immunocompetent. In contrast,
Cryptococcus neoformans infected mainly immunocompromised hosts
(91%) with AIDS being the underlying risk factor in 80%. Median
age was 39 years and 79% were male. Median duration of symptoms
was 14 days with main complaints of fever (79%), headache (71%)
and cough (45%). Abnormal ﬁndings of meningism occurred in 19%,
cranial neuropathy 10% and papilloedema 6%. Chest radiographs were
abnormal in one third. Brain imaging showed meningeal enhancement in
13% and hydrocephalus in 6%. Cerebrospinal ﬂuid india ink smears and
fungal cultures were positive in 73% and 85% respectively. Median CSF
cryptococcal antigen titre was 512 compared to 2048 in serum. Blood
cultures were positive in 47%. Total duration of treatment was 15 months
with median 14 days initial treatment with intravenous amphotericin B.
Neurosurgical shunt insertion was required in 15%. Mortality at 30 days
was 15%. Patients with Cryptococcus gattii were more likely to have
pneumonia, pulmonary cryptococcoma and were all immunocompetent.
Patients with Cryptococcus neoformans were younger and likely to have
AIDS. Clinical features and outcome were otherwise similar.
Conclusions: Cryptococcus neoformans was the predominant subtype
in Singapore and infected younger, mainly immunocompromised hosts
with AIDS. Cryptococcus gattii was uncommon, causing pulmonary
manifestations in older, immunocompetent patients.
P819 Serotypes distribution and antifungal susceptibility of
Cryptococcus neoformans in Spain
A. Gomez-Lopez °, O. Zaragoza, M.J. Buitrago, J.L. Rodriguez-Tudela,
M. Cuenca-Estrella (Majadahonda, ES)
The aetiological agent of cryptococcosis is classiﬁed in two species;
Cryptococcus gattii and C. neoformans. This species includes two
varieties: var. grubii (serotype A) and var. neoformans (serotype D),
as well as an AD hybrid.
Objective: The aim of this study was to evaluate the distribution and
susceptibility proﬁle of varieties of C. neoformans in a collection of
clinical isolates, to provide insights on the epidemiology and clinical
management.
Methods: A total of 45 isolates received in our institution was evaluated.
The isolates were ﬁrstly identiﬁed as Cryptococcus neoformans by
routine morphological and physiological tests. A multiplex PCR (pending
of patent) to identify both Cryptococcus neoformans varieties and
C. gattii, was used for serotyping. MICs for amphotericin B (AMB),
5-ﬂucytosine (5FC), ﬂuconazole (FLC), itraconazole (ITC), voriconazole
(VRC), ravuconazole (RVC) and posaconazole (POS) were determined
according to the recommendations proposed by the European Committee
on Antifungal Susceptibility Testing (EUCAST-deﬁnitive document),
with minor modiﬁcation to improve the growth of the strains.
Results: C. neoformans var. grubii (serotype A) was the predominant
(31/45, 69%) variety, following by C. neoformans var. neoformans
(serotype D, 7/45, 15.5%). The remaining 7 isolates were identiﬁed as
AD hybrids. The table displays susceptibility results.
Conclusions: (i) Our ﬁndings are consistent with previous studies, which
indicate that var. grubii is the most prevalent cryptococcal isolate.
(ii) The new multiplex PCR assay was useful for typing. (iii) The
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prevalence of AD hybrids in clinical isolates may be higher than the
current available estimations due to improper identiﬁcation of this
serotype. AD hybrids may be more common in clinical sources than was
previously thought (iv) C. neoformans AD hybrid showed signiﬁcantly
lower MICs to 5FC (ANOVA, p< 0.01).
Antifungal
agent
C. neoformans var. grubii,
serotype A (n = 31)
C. neoformans var. neoformans,
serotype D (n = 7)
C. neoformans AD hybrid
(n = 7)
GM (range) MIC90 GM (range) MIC90 GM (range) MIC90
AMB 0.18 (0.03−4) 0.5 0.09 (0.03–0.25) 0.25 0.07 (0.03–0.25) 0.25
5FC 14.3 (4−64) 32 9.7 (1−32) 32 1.4 (0.5−4) 4
FLC 18.3 (2–>64) >64 9.7 (0.5–>64) >64 6.5 (1−16) 16
ITC 0.19 (0.03–>8) 1 0.25 (0.06−2) 2 0.10 (0.03−0.5) 0.5
VRC 0.18 (0.02–>8) 0.5 0.25 (0.13−1) 1 0.22 (0.03−4) 4
RVC 0.14 (0.03−0.5) 0.5 0.27 (0.06−2) 2 0.12 (0.02−1) 1
POS 0.17 (0.03−8) 0.5 0.22 (0.13−0.5) 0.5 0.11 (0.02−1) 1
P820 A 12-year review of Candida spp. meningitis in patients
following neurosurgery
D. O’Brien °, D. Hughes, N. Stevens, F. Fitzpatrick, E. Smyth,
H. Humphreys (Dublin, IE)
Objective:To review all cases of Candida spp. meningitis in patients
following a neurosurgical procedure over a 12 year period in a tertiary
care hospital in Dublin, Ireland.
Methods: From September 1998 to July 2009 all cases of Candida spp.
meningitis in patients following a neurosurgical procedure were
identiﬁed using a computer search. A retrospective chart review
was performed to analyse patient demographics, outcome, nature of
neurosurgical procedure, underlying co-morbidities, species of Candida
implicated and type of antifungal agent used for treatment. In addition,
time to removal of any neurosurgical device and resolution of infection
following isolation of Candida spp. from the cerebrospinal ﬂuid (CSF)
was recorded.
Results: Twelve cases of Candida spp. meningitis were identiﬁed.
The majority of isolates were associated with external ventricular
drains (EVDs), one was associated with a lumbar drain and one
case followed insertion of Gliadel wafers (a bioploymer wafer to
deliver chemotherapy). Candida albicans was the predominant species
recovered and amphotericin B the antifungal agent most commonly
prescribed. Infection was associated with patients who were on treatment
for antecendent bacterial CNS infection and those who underwent
multiple EVD or ventriculo-peritoneal shunt revisions. All patients had
received broad spectrum antibiotics prior to Candida spp. meningitis. An
increase in mortality was seen in those patients who had an underlying
malignancy.
Conclusion: Candida spp. neurosurgical infection remains a rare
occurrence. Prior antibiotic use, recent or current bacterial CNS infection
and multiple neurosurgical device revisions are associated with Candida
app. meningitis. An awareness ot these factors may lead to improved
management and better outcome in these cases.
P821 Searching risk factors for developing serologically proven
candidiasis in ICU patients
J. Pema´n °, R. Zaragoza, G. Quindo´s, M. Alkorta, M.S. Cue´tara,
J. Camarena, P. Ramı´rez, M.J. Gimenez, E. Martı´n-Mazuelos,
M. Linares-Sicilia, J. Ponto´n for the Candida albicans Germ Tube
Antibody Detection in Critically Ill Patients (CAGTAUCI) Study Group
Objectives: A prospective, cohort, observational multicentre study was
carried out in six intensive care units (ICU) of tertiary-care Spanish
hospitals to identify the patients who could develop serologically proven
candidiasis in critical care setting.
Methods: Candida albicans Germ Tube Antibody (CAGTA) test was
performed twice a week if predetermined risk factors were present,
and serologically demonstrated candidiasis was considered if the testing
serum dilution was 1:160 in at least one sample.
Results: Fifty-three critically ill non-neutropenic patients were included.
Twenty-two patients (41.5%) had CAGTA-positive results. Neither
corrected colonization index nor antifungal treatment had inﬂuence on
CAGTA results. No statistical diferences were found in the rate of highly
colonized patients between positive- and negative-CAGTA results at the
end of the study (77.2% vs. 89.6%, respectively; p = 0.26). The presence
of acute renal failure at the beginning of the study was more frequent in
CAGTA-negative patients (p = 0.02). Previous surgery was more frequent
in CAGTA-positive patients (p = 0.03).
Conclusions: This study identiﬁed previous surgery patients as the
principal risk factor associated with serologically proven candidiasis.
The use of CAGTA technique should be mandatory in surgical patient
admitted in ICU. This technique could help to identify occult invasive
Candida infection in ICU population.
P822 A number of diverse human pathogenic fungi produce
proteases that can degrade immune proteins in the central
nervous system
G. Rambach °, I. Mohsenipour, C. Lass-Flo¨rl, J. Rainer, R. Wu¨rzner,
C. Speth (Innsbruck, AT)
Objectives: In invasive fungal infections, the high lethality rate of more
than 90% in cases of the affection of the central nervous system (CNS)
indicates an insufﬁciency of the local immunity. We studied the capacity
of diverse pathogenic fungi to degrade components of the complement
system and functional surface proteins of immune cells in the CNS.
Methods: Pathogenic species of Aspergillus, the Pseudallescheria/
Scedosporium cluster and some members of Zygomycetes were grown
in medium or cerebrospinal ﬂuid (CSF), with or without supplements.
Degradation of soluble complement proteins was evaluated by Western
Blot. Hyphal opsonization was examined by immunoﬂuorescence;
cellular expression of surface proteins was quantiﬁed by FACS.
Results: The growth of Aspergillus spp in CSF resulted in secretion
of proteolytic factors which degraded various complement proteins.
The extent of the proteolysis was dependent on the time period of
fungal growth and the Aspergillus species. A. fumigatus, the predominant
cause of cerebral aspergillosis, induced a rather quick and strong
degradation. The fungal secretion of proteases correlated with a
diminished opsonization of Aspergillus hyphae by complement proteins
and proteolytic destruction of complement receptor CR3 (CD11b/CD18)
on the surface of immune cells. Both opsonization of pathogens and
recognition of deposited complement proteins by receptors are crucial
for an efﬁcient antifungal attack.
Other Aspergillus species and further pathogenic fungi could also be
shown to secrete proteolytic factors. Compared to environmental isolates,
patient isolates of Aspergillus terreus seemed to destroy complement
more rapid. Within the Pseudallescheria/Scedosporium cluster, the
asexual form Scedosporium generally appears to be more active in this
regard than the perfect stadium Pseudallescheria. Among Zygomycetes,
we found complement-degrading isolates of Rhizomucor pusillus and
Rhizopus microsporus. Candida spp. and Cryptococcus neoformans will
be tested next.
Conclusions: Aspergillus spp and other pathogenic fungi secrete
proteases which can efﬁciently degrade complement proteins. This may
represent a pivotal evasion mechanism especially in the CNS that is
separated from the peripheral immune weapons by the blood-brain-
barrier. On the other hand, these proteases represent an interesting
therapeutic target to decrease the lethality of cerebral fungal infections.
P823 Prostaglandins as modulation of phagocitosis by Histoplasma
capsulatum-infected alveolar macrophages
P. Pereira °, C.S. Bitencourt, D.F. Santos, R. Nicolete, L. Faccioli
(Ribeira˜o Preto, BR)
Introduction: Prostaglandins (PGs) are importants mediators of
the inﬂammation and immune response, beyond participating as
immunomodulators in some experimental models. Recents studies have
demonstrated the role of the PGE(2) on the inhibition of Fcg-receptor-
mediated phagocytosis and microbial killing by alveolar macrophages
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(AMs). However, nothing is known about the effect of PGD(2) in
mediating phagocytosis. In histoplasmosis, the pulmonary injury occurs
after inhalation of Histoplasma capsulatum (Hc), In this context, AMs
are the ﬁrst cells to encounter and phagocyte Hc in the host.
Objectives: To investigated the effects of exogenous and endogenous
PGE(2) and PGD(2) on FcgRI-mediated phagocytosis.
Methods and Results:Mice were infected (i.t.) with 1×106 yeast/animal
(lethal inoculum) and daily treated or not with celecoxib (0.5, 1 or
5mg/kg). The administration of celecoxib reduced 30-days mortality
from 100% to 20% (0.5 or 1mg/kg) to 58% (5mg/kg) in lethal Hc-
infected mice. The mouse resident AMs were collected from BALF.
The counts of the number of phagocited yeasts were conducted as
phagocytic index in Hc-infected AMs using or not the inhibitors of PGs.
To verify which prostaglandin it could be involved in the suppression of
the phagocitosis, AMs rats were obtained via ex vivo lung lavage and
ressuspended in RPMI to a ﬁnal concentration of 2 ×106 cells/ml. After
the incubations the cells had following pretreatment for 30 min inhibitor
of PGs (celecoxib and indomethacin), and then for 5 min PGE(2) or
PGD(2). The adherent cells were infected in vitro with FITC labeled-Hc
IgG opsonized (Hc-ops) or not (Hc-non). Phagocytosis was determined
2 h after, as established: at a ratio of 1:1 (macrophages/ yeast), using
celecoxib and indomethacin (10uM) or PGD(2) and PGE(2) (1uM). Our
ﬁndings showed that PGD(2) induced greater phagocytic of Hc-ops than
PGE(2).
Conclusion: The results suggest an antagonistic effect elicited by the two
evaluated prostaglandins during phagocytosis process. Further studies
will be necessary in order to understand the mechanisms involved in the
phagocytosis of Hc yeasts.
Acknowledgements: FAPESP, CNPq.
P825 Voriconazole serum levels measured by high-performance
liquid chromatography: a single-centre study in 14 patients
A. Gomez-Lopez °, E. Cendejas, J. Garcia Rodriguez, A. Gutierrez-Altes,
J.L. Rodriguez-Tudela, M. Cuenca-Estrella (Majadahonda, Madrid, ES)
Background: Recent data have suggested that efﬁcacy and tolerance of
Voriconazole (VRC) could be increased with therapeutic drug monitoring
(TDM).
Objective: We show results of a retrospective study involving patients
receiving VRC for fungal infection treatment whose through serum levels
were monitored.
Method: A simple/fast high-permormance liquid chromatography
(HPLC) assay for VRC measurement in serum samples was used.
Results: A total of 14 patients were included, 10 men and 4 women with
a mean age of 46.8 years (4−87). The most frequent underlying condition
was malignant haematological disease (6/14, 43%) following by solid
organ transplantation (4/14, 29%), EPOC (2/14, 14%) and others (2/14,
14%). Among patients evaluated, 8 (57%) were treated for aspergillosis
(1 proven, 6 probable, and 1 possible), 2 (14%) were treated for
Aspergillus infection in a prosthesis, 2 (14%) for Scedosporium infection
(1 proven arthritis, 1 probable pulmonary infection), 1 (7%) for proven
invasive fusariosis, and 1 (7%) for an open wound infection caused by
A. fumigatus. A total of 59 through serum levels were performed, with a
median number of 4.2 per patient (1−15 determinations). Median VRC
through levels was 1.54 (range 0.0−6.4mg/L). Twelve patients had more
than one drug concentration determination. Low/high VRC serum levels
was deﬁned according to a recent paper by Pascual et al. (1−5.5mg/L).
Twenty ﬁve out of 59 (42%) of measurements from 9 different patients
were below 1mg/L, range 0.0–0.91mg/L. In 6 out of these 9 patients
VRC serum levels reached the therapeutic range (1−5.5mg/L) after the
ﬁrst monitoring. Most of them (5 out of 6) experienced microbiological
response (described as proven or presumed eradication of the fungal
pathogen). The remaining 3 patients had persistent VRC levels below
1mg/L (2 out of them had experienced a hepatic transplantation). Two of
them experienced a positive microbiological response. In the other hand,
3 patients had VRC levels persistently into the proposed therapeutic
range (media 2.6mg/L, range 1.3−6.4mg/L). All of them had complete
resolution of their fungal infection episode. Only one patient had VRC
measurement higher than 5.5mg/L, but no toxicity was reported.
Conclusions: (i) Lack of response to therapy was more frequent in
patients with VRC levels persistently lower than 1mg/L (ii) Detection
of VOR trough levels outside the therapeutic interval may lead to adjust
dosage and improve patient’s outcome. (iii) Prospective trials including
VRC TDM are needed.
P826 Onychomycosis by Paecilomyces lilacinus in a patient with
leukonychia
P. Innocenti °, E. Pagani, D. Vigl, V. Pasquetto, C. Cemin, K. Scalzo,
H.P. Huemer, C. Larcher (Bolzano, IT; Innsbruck, AT)
Introduction: Paecilomyces lilacinus (P.I.) is a ﬁlamentous fungus
living saprophytic in the environment. Very rarely it causes infection
in immunocompetent humans, mostly ocular infections (after lens
implantation) or cutaneous and sub-cutaneous infections. P.I. isolates
usually show low susceptibility to conventional antifungal drugs in vitro,
and variable susceptibility to novel triazoles.
Methods: During a period of 2 years 4 cultures of nail fragments
were grown from a 41 y old female on modiﬁed Sabouraud/Dextrose
agar (CAF bioMe´rieux, CAF+CEX Biolife). Cultures were continued
in suspension and the hyphae stained with lactophenole blue analysed
microscopically. 2 samples were tested with molecular methods, i.e.
automated DNA extraction with easyMAG (bioMe´rieux), ampliﬁcation
of the fungal internal transcribed spacer (ITS) region by PCR and
automated DNA sequencing of the ITS 1 and 2 regions (ABI3130).
The sequence results were evaluated using TraceEdit Pro (RIDOM
Bioinformatics) and a validated reference database for humanpathogenic
fungi. Additionally NIH database GenBank and the BLAST algorithm
was used.
Results: Growth of a ﬁlamentous hyaline fungus with white colonies
with lila shade developing in 4−5 days was observed in all samples.
The presence of Penicillium like conidiophores with divergent long
terminal phialides was seen with little elliptical conidia. DNA sequencing
conﬁrmed the genus Paecilomyces determining the species as P. lilacinus
with 99% homology of the ITS1 and 2 regions with GenBank isolate
accession number AY213667 and other P.I. entries.
Conclusion: P.I. infection of the nails is a very rare event in healthy, not
immunocompromised persons and it is unclear whether the precedent
pregnancy of the patient had triggered the onset. The infection of
the right hallux did not improve by systemic (Lamisil/terbinaﬁne)
and local treatment (Locetar/amorolﬁn nail lacquer). Also change to
Sporanox/itraconazol only led to deterioriation, so ﬁnally the extraction
of the nail had to be performed given the known difﬁculties with
treatment against P.I. described in the literature. This case highlights
the usefulness of molecular techniques, especially use of the highly
discriminative ITS region for fungal typing.
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P827 Comparison of diagnostic methods in the evaluation of
onychomycosis in patients referred to a hospital and
dermatology outpatients clinics in Sari, Iran
T. Shokohi °, Z. Haj Heydari, I. Haghani, A. Khalilian, R. Agilli,
S. Mayahi (Sari, IR)
Objectives: Onychomycosis is common nail problem, accounting for
up to half of all nail diseases. Onychomycosis requires administration
of antifungal agents for long periods. Nail disorders may mimic to
onychomycosis clinically. Therefore sensitive, quick and inexpensive test
is essential for screening nail specimens. Recently, It has been reported
that KONCPA (KOH treated Nail clipping + PAS) test might be a useful
complementary method with high positive rate and excellent view for
making the diagnosis of onychomycosis. The aims of this study were
to compare culture, KOH preparation, calcoﬂuor white stain (CFW),
and KONCPA in the diagnosis of onychomycosis and to determine their
sensitivity, speciﬁcity, positive predictive value and negative predictive
value.
Methods: In the present study, nail specimens were collected from
101 patients suspected to onychomycosis during 14 months. Nail
specimens were examined by potassium hydroxide 20%, KONCPA,
calcoﬂuor white stain and culturing on Sabouraud’s dextrose agar
containing chloramphenicol (SC), Sabouraud’s dextrose agar containing
cyclohexamide and chloramphenicol (SCC). Culture was chosen as the
gold standard for statistical analysis.
Results: Of the patients, 100 had at least 1 of the 4 diagnostic methods
positive for the presence of organisms. The following were calculated
for each test: sensitivity; speciﬁcity; positive predictive value; and
negative predictive value. The positive rates of fungal culture, KOH
preparation, CFW and KONCPA were 74.2%, 85.1%, 91.09%, and
99.01%, respectively. The sensitivities of each of the techniques were
as follows: KOH 92%; CFW 96%; and KONCPA 100%. KONCPA
method were more sensitive than KOH preparation (P = 0.00002) and
CFW (P= 0.0008). The speciﬁcities were as follows: KOH 38%; CFW
23%; and KONCPA 3.8%. The positive predictive value calculated for
the different techniques were: KOH 81%; CFW 78%; and KONCPA
75%. In terms of negative predictive value, the results were: KOH 66%;
CFW 66%; and KONCPA 100%.
Conclusion: KONCPA was the most sensitive among the tests. It is also
superior to the other methods in its negative predictive value. It was
easy to perform, rapid, gave signiﬁcantly higher rates of detection of
onychomycosis compared to the standard methods, namely KOH mount
and mycological culture and potentially is the single method of choice
for the evaluation of onychomycosis.
P828 Detection of dermatophyte infections in nail samples by PCR
targeting the DNA topoisomerase II genes
M. Hui °, M. Eastel, D. Jin, L.H. Fu, N.M. Luk, A.K. Chan, K.K. Lo,
C.Y. Chan (Shatin, Hong Kong, HK)
Objectives: Dermatophytic infections of nails can be caused by Tri-
chophyton species, Epidermophyton species and Microsporum species.
However, establishment of the etiological agents are often difﬁcult
due to the lack of sensitivity with traditional microscopic and culture
techniques. Therefore, we aimed to develop a direct detection method
by PCR targeting the dermatophyte DNA topoisomerase II genes.
Methods: Primers pair targeting the dermatophytes DNA topoiso-
merase II genes TopII-F (5’-GAGTTGATGGAGTATAGAGAGGT-3’)
and TopII-R (5’-GCTTTGGTGTACATTTCCATGT-3’) was designed.
The ampliﬁed DNA product size was approximately 690bp. Type strains
of Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton
ﬂoccosum, Microsporum canis, 2 Aspergillus species and 5 Candida
species were tested for sensitivity and speciﬁcity. Clinical nail samples
were collected from patients suspected to have dermatophytic nail
infections. These samples were subjected to microscopic examination for
fungal ﬁlaments, culture for dermatophytes, and PCR detection. DNA
was extracted from 30−50mg nail pieces by incubating in extraction
buffer for 10min at 95ºC. The reaction mixtures comprised of 1uL of
DNA, 2.5uL of 10X buffer, 0.375uL of dNTPs, 1uL of each primer, and
0.125uL Taq polymerase. The PCR cycles comprised of denaturation at
95ºC for 10min, followed by 35 cycles of 30s at 94ºC, 30s at 58ºC and
30s at 72ºC. The PCR products were visualised by gel electropheresis
on 1.5% agarose gel.
Results: A total of 112 nail samples were collected. Microscopic
examination was positive for fungal ﬁlaments in 13 (11.6%) samples.
Culture was positive for dermatophytes in 14 (12.5%) samples. Ten of
which were Trichophyton rubrum, 2 were Trichophyton mentagrophytes,
1 was Trichophyton verrucosum and another one was Trichophyton
tonsurans. PCR detection were positive in 42 (37.5%) samples. Four
culture positive cases were negative for PCR detection. 28 PCR positive
cases were microscopy- and culture-negative.
Conclusion: Traditional diagnostic methods by microscopy and culture
were technically simpler than molecular detection method. However, the
former method was time-consuming and crippled with low recovery rate.
Direct detection of targeted DNA topoisomerase II genes was rapid and
sensitive. Improved detection of dermatophytes was observed with the
additional use of PCR technique.
Antifungal resistance
P829 Dihydropteroate synthase-gene mutations decreased in
Pneumocystis jirovecii isolated from Spanish patients
R. Morilla, C. De La Horra °, V. Friaza, M.A. Montes-Cano,
E. Campano, L. Rivero, S. Gutierrez, N. Respaldiza, J. Medrano,
J.M. Varela, E. Calderon (Seville, ES)
Background: Sulfa drugs, trimethoprim-sulfamethoxazole and dapsone,
are mainstays for prophylaxis and treatment of Pneumocystis pneumonia
(PcP), a life-threatening disease in immunosuppressed patients. The
inability to culture Pneumocystis has led to develop molecular
techniques based on identiﬁcation of punctual mutations on the
Dihidropteroate Synthase gene (DHPS) that cause sulfa resistance in
other microorganisms. A key issue is whether the emergence of DHPS
mutations is result of transmission between patients or arises from
selection by the pressure of sulfa drugs, two possibilities are not
mutually exclusive. The role of Pneumocystis colonized subjects in
transmission of DHPS mutations still unknown. The aim is to provide
epidemiological data of P. jirovecii DHPS mutations among PcP patients
and immunocompetent colonized subjects.
Methods: The study included 47 PcP patients and 75 Pneumocystis
colonized subjects during 2001–2007 identiﬁed by nested PCR at
mtLSUrRNA gene. DHPS mutations were studied by Restriction
Fragment Length Polymorphism using Acc I and Hae III at nucleotide
positions 165 and 171 respectively.
Results: The analysis showed a 19.7% prevalence of DHPS gene
mutations in the overall population. All possible polymorphisms
described were identiﬁed. There were not difference between the
frequency of DHPS mutations in PcP patients and colonized subjects
(23.4% vs 17.3%; p = 0.75). A trend towards decreased frequency was
observed during this period in the Spanish population (from 31.3%
of DHPS-mutations during 2001 to 11.6% at 2007). The use of
sulfamethoxazole was also measure in this area showing a 41% of
decreasing.
Conclusions: Similar DHPS pattern was observed in PcP patients
and immunocompetent colonized subjects suggests that both group
could share a common transmission cycles of mutated strains. This
arise question about the role that colonized subjects could represent
as reservoir for DHPS mutations with ability to transmit them to
immunocompromised hosts susceptible to PCP. The reduction of
DHPS-mutations could be due to the diminuish of trimethoprim-
sulfamethoxazole comsum.
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P830 Comparison of EUCAST and CLSI M27-A3 broth
microdilution methods for testing susceptibilities of 144
Candida spp. to anidulafungin
S. Algarate, C. Seral °, J. Gil, R. Benito, F.J. Castillo, C. Rubio-Calvo
(Zaragoza, ES)
Objective: The aim of this study was to compare MICs of anidulafungin
obtained by the European Committee on Antibiotic Susceptibility Testing
(EUCAST) and CLSI (formely NCCLS) methods for 53 C. albicans,
32 C. glabrata, 20 C. parapsilosis, 18 C. tropicalis, 11 C. krusei, 7
C. famata, 2 C. lusitaniae and 1 C. guilliermondii isolates obtained
from clinical samples.
Methods: A total of 144 isolates of Candida spp. included 53 C. albicans
(36.81%), 32 C. glabrata (22.22%), 20 C. parapsilosis (13.89%), 18
C. tropicalis (12.5%), 11 C. krusei (7.64%), 7 C. famata (4.86%), 2
C. lusitaniae (1.39%) y 1 C. guilliermondii (0.69%) isolates identiﬁed
by Chromagar medium and API® 20C AUX system were tested. These
isolates were recovered from blood culture (38), catheter (16), respiratory
sources (27), urines (29), biological ﬂuids (17) and other sources (17) of
different hospitalized patients. MICs of anidulafungin were determined
by broth microdilution methods following the recommendations of
EUCAST and CLSI-M27-A2. In addition, correlation between the
methods was determined.
Results: Table lists the MIC50, MIC90 and range (mg/L) of
anidulafungin determined by the two reference methods.
All the isolates but C. parapsilosis showed a high intrinsic activity
(MIC90, mg/L) against anidulafungin, and the rank order of activity
was 0.125 for C. albicans and C. krusei, 0.25 for C. glabrata and
C. famata by the two methods tested. In C. tropicalis was 0.25 by
CLSI and 0.125 by EUCAST method. The percentages of correlation:
CLSI/ EUCAST±2 dilutions were between 82.88–100%, according to
the species. Six C. parapsilosis isolates showed the higher MICs of
anidulafungin, 8mg/L (1 strain (5%)) y 4mg/L (5 strains, 20%) by the
two methods.
Conclusions: Anidulafungin showed a high intrinsic activity against
Candida spp. being lower to C. parapsilosis. Our prospective surveil-
lance reveals no evidence of emerging anidulafungin resistance among
C. albicans, the most frecuent specie isolated. The variability observed
(MICs range 0.03−8mg/L) in C. parapsilosis could be inﬂuenced by
the lack of discrimination of species within the complex. Comparison
of both methods indicates that EUCAST and CLSI standards for yeast
result in essentially equivalent MICs of anidulafungin.
Microorganism Anidulafungin (CLSI-M27-A3) Anidulafungin (EUCAST)
MIC50
(mg/L)
MIC90
(mg/L)
Range
(mg/L)
MIC50
(mg/L)
MIC90
(mg/L)
Range (mg/L)
C. albicans (53) 0.06 0.125 <0.015−2 0.03 0.125 <0.015−1
C. glabrata (32) 0.125 0.25 <0.015−1 0.125 0.25 <0.015−1
C. parapsilosis (20) 1 4 0.03−8 1 4 <0.015−8
C. tropicalis (18) 0.06 0.25 <0.015−0.5 0.03 0.125 <0.015−0.5
C. krusei (11) 0.125 0.125 <0.015–0.25 0.06 0.125 <0.015–0.125
C. famata (7) 0.125 0.25 0.03−0.5 0.06 0.25 <0.015–0.25
C. lusitaniae (2) − − 0.03–0.06 − − <0.015
C. guilliermondii (1) − − 1 − − 1
P831 The increase of chitin content in the cell wall accounts for
the reduced echinocandin susceptibility displayed by clinical
isolates of C. parapsilosis
A. Silva °, S. Costa-de-Oliveira, M.M. Azevedo, I. Miranda, R. Rocha,
R. Silva, C. Pina-Vaz, A.G. Rodrigues (Porto, Vila Nova de Famalica˜o,
PT)
Objectives: Given the potential for decreased susceptibility of C. para-
psilosis to echinocandins, it is advisable to gather additional information
regarding this opportunistic fungal pathogen. Thus, the objective of this
study was to determine the mechanism of the reduced echinocandin
susceptibility showed by C. parapsilosis.
Methods: Ten C. parapsilosis clinical isolates were included in this
study. The susceptibility proﬁle to three echinocandins (caspofungin,
micafungin and anidulafungin) was determined according to CLSI M27-
A3 protocol. Comparative DNA sequence analysis of the hot spot 1
(HS1) region of FKS1 gene was also performed. For this, the FKS1 HS1
was ampliﬁed by PCR and sequenced in an ABI PRISM 3130 Genetic
Analyzer (Applied Biosystems). Additionally, the amount of chitin was
measured using two methodologies: classical, through quantiﬁcation
of glucosamine release by acid hydrolysis of puriﬁed cell walls; and
a ﬂow cytometry (FC) method, using a speciﬁc ﬂuorescent chitin
marker, calcoﬂuor white (CFW). Blastonidia suspensions (106 cells/mL)
in sterile water were stained with 2.5 mg/mL CFW; the intensity of
ﬂuorescence of cells was evaluated by FC in a BD FACSCANTO II
(Becton Dickiinson, Madrid, Spain). The ﬂuorescence emitted by fungal
cells is directly proportional to chitin amount.
Results: Four isolates were considered susceptible to echincandins and
other six were non-susceptible to at least one of the three antifungals
tested. Alignment of the deduced amino acid HS1 sequences from
susceptible and non-susceptible C. parapsilosis isolates did not reveal
any polymorphism involving amino acid changes, neither among the
C. parapsilosis studied nor with the previously reported sequence. The
amount of chitin in the cell wall was much higher on non-susceptible
strains by both methods.
Conclusion: Overall, this study provides evidence that no sense-to-sense
mutations are present in FKS1 HS1 gene of these isolates and that the
increase in MIC values to echinocandin drugs may be due to an increase
of the chitin cell wall content. Flow cytometric method described seems
to be a new and excellent toll for chitin content determination.
P832 Two different mechanisms for reduced C. glabrata
susceptibility to echinocandins after anidulafungin treatment
S. Costa-de-Oliveira °, A. Silva, M.M. Azevedo, I. Miranda, R. Rocha,
R. Silva, E. Ricardo, A.G. Rodrigues, C. Pina-Vaz (Porto, Vila Nova
de Famalica˜o, PT)
Objectives: Echinocandin resistance in candidiasis has been rare,
however only caspofungin has been extensively used. Some case
reports described FKS gene point mutation as responsible for acquired
echinocandin resistance during treatment. Further than glucan synthesis,
the increase in chitin content also plays a role in maintaining fungal cell
integrity against echinocandins. This is a case report of a 71 year old
female that was admitted in the Intensive Care Unit with a diagnostic of
pancreatitis. Her hospital course was complicated by multiple Candida
infections. She was treated with anidulafungin during 27 days. Candida
glabrata isolates from blood and other body sites were recovered before
and after anidulafungin treatment. To clarify the underlined resistance
mechanisms the chitin content and the hot spot region 1 (HS1) of the
FKS1 gene were assessed.
Methods: Antifungal susceptibility tests to azoles, amphotericin B
(AMB), caspofungin (CAS) and anidulafungin (AND) were performed,
according to CLSI M27 A3 protocol. Chitin content was determined
by measuring the glucosamine release by acid hydrolysis of puriﬁed cell
walls. Calcoﬂuor white (CFW) resistance was determined by inoculating
serial cell dilutions in YPD + CFW and AND. After DNA extraction a
random ampliﬁcation of polymorphic DNA was performed using primers
OPE-18 and OPA-18. The HS1 of the FKS1 gene was ampliﬁed from
Candida glabrata isolates and sequenced in an ABI PRISM 3130 Genetic
Analyzer.
Results: The isolates recovered at the beginning of the AND treatment
were S to all antifungals tested. However the isolates recovered during
treatment (from blood and peritoneal ﬂuid) showed a non susceptible
(NS) pattern to echinocandins. Pre and postreatment isolates were
conﬁrmed to be isogenic. In the NS blood isolate the chitin content
was 5 times higher than the peritoneal ﬂuid isolate and in susceptible
strains. A C-T mutation of FKS1 gene was found in the isolate recovered
from peritoneal ﬂuid (NS isolate), at position 1975, which results in the
substitution of serine by proline in the 659 position of the amino acid
sequence. This was the only isolate that was able to grow on the CFW
+ 2mg/ml AND YPD plates.
Conclusions: Point mutations in the HS1 of the FSK1 gene of
C. glabrata peritoneal ﬂuid isolates or and an increased in the chitin
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cell wall content on C. glabrata blood isolate were responsible for the
development of echinocandin resistance during anidulafungin therapy.
P833 Echinocandin E-test endpoint for Aspergillus shows poor
essential agreement with the reference minimum effective
concentration
J. Fuller °, A. Schoﬁeld, S. Jiwa, B. Jansen, C. Sand, R. Rennie
(Edmonton, CA)
Objective: The Clinical and Laboratory Standards Institute (CLSI) M38-
A2 broth microdilution (BMD) method for antifungal susceptibility
testing of ﬁlamentous fungi now includes guidelines for testing
echinocandin activity using the minimum effective concentration (MEC)
as the endpoint measurement. The objective of this study was to
determine if the caspofungin Etest could accurately and reliably measure
the MEC of a large collection of clinical Aspergillus isolates.
Methods: Caspofungin activity against Aspergillus isolates was tested by
BMD (CLSI M38-A2) for MEC (visual and microscopic) determination
and by Etest for MIC using both a RPMI agar and Mueller-Hinton
agar (supplemented with glucose and methylene blue [MGM]). Etest
was performed using a modiﬁcation of the CLSI M44-A disk diffusion
method and the inocula prepared for BMD. All tests were incubated
for 24 h. Etest MICs were recorded as the lowest concentration of
caspofungin where the zone of growth inhibition intersected with the
Etest strip. MICs were rounded up to the next even log2 concentration
for the evaluation. Etest values + 1 log2 dilution of the reference BMD
MEC were considered to be in essential agreement (EA).
Results: BMD MEC was determined for 345 clinical Aspergillus
isolates, including 105 A. fumigatus, 62 A. ﬂavus, 104 A. niger, 50
A. nidulans, and 24 A. terreus. Regardless of the Aspergillus species
or agar medium tested, the caspofungin Etest consistently produced a
markedly lower growth inhibition endpoint (MIC). The EA of the Etest
on MGM and RPMI to BMD MEC was 18% and 26%, respectively. The
geometric mean values for BMD MEC vs MGM Etest were 0.137 mg/ml
and 0.024 mg/ml, respectively, and the geometric mean values for BMD
vs RPMI were 0.128 mg/ml and 0.031 mg/ml, respectively. Comparatively,
91% of paired MGM and RPMI Etest results were within 2 log2 dilutions
of each other and consistently produced clearly deﬁned endpoints.
Conclusion: BMD for ﬁlamentous fungi is not an ideal test format
for many clinical laboratories and the simplicity of the Etest may
make it a more viable option. Although the results from this study
demonstrate a clear discordance between the absolute values generated
by the caspofungin BMD and Etest, it is difﬁcult to dismiss the consistent
performance of the Etest. An expanded optimization of test conditions
will hopefully improve Etest concordance with BMD MEC without
compromising consistency.
P834 A characterization of mean inhibitory concentrations and
patient outcomes in patients failing to respond to ﬂuconazole
treatment of severe infections caused by Candida sp.
B. Footer °, S. Monte, L. Podkulski, G. Prescott, C. Rotstein, J. Brown,
J. Paladino, J. Schentag (Buffalo, US; Toronto, CA)
Objectives: The goal of this study was to determine if ﬂuconazole
failures are more frequently associated with ﬂuconazole-resistant or
ﬂuconazole-susceptible strains of Candida, and to compare the calculated
AUIC values of patients with ﬂuconazole-susceptible verses ﬂuconazole-
resistant isolates.
Methods: This study was a retrospective, case series of adult patients
(>18 years) with an index Candida bloodstream infection and sufﬁcient
demographic, laboratory and microbiologic data to calculate serial
AUICs and determine clinical and microbiologic outcome. Patients
had to have received at least three days of ﬂuconazole and organism
susceptibility had to be available prior to enrolment. Although all had to
initially fail ﬂuconazole, both failures and successes were enrolled and
analysed.
Results: 97 cases were enrolled with 52 (54%) being culture positive
for Candida albicans. Although 98% of C. albicans isolates were
susceptible, clinical success was achieved in only 58% of cases and
the organism persisted at day 10 in 27% of the cases. 8 cases (15%)
were found to have an AUIC< 100. The AUIC< 100 group tended to
have a higher median MIC compared to the AUIC> 100 (0.56 vs. 0.19,
p = 0.47). Compared to C. albicans, more intermediate and resistant
organisms were observed in the non-albicans species group as 80%
of isolates were susceptible (p = 0.005). Clinical success rates differed
signiﬁcantly between susceptible and non-susceptible isolates (53% vs.
11%, p = 0.039), while bacterial eradication tended to occur less often
in nonsusceptible compared to susceptible organisms (44% vs. 61%,
p = 0.461). A total of 18 cases (40%) had AUICs <100 with median
MICs in those cases being higher compared to cases with AUIC> 100
(2.26 vs. 0.29, p = 0.058).
Conclusion: Fluconazole failure is almost always associated with
susceptible organisms, particularly for C. albicans. For non-albicans
species more intermediate or resistant organisms were observed, and
the overall MIC was higher than for C. albicans. Failure in susceptible
organisms occurs because ﬂuconazole dosing does not achieve a blood
concentration high enough to eradicated organisms with susceptible
but somewhat higher MICs. Lowering the breakpoint would rationalize
failure in some but not all of these patients. If the breakpoints are not
lowered, further research is needed to determine the ﬂuconazole dosing
necessary to achieve success in those patients with susceptible but higher
MICs.
P835 Fungaemia by Candida parapsilosis: in vivo induction of
azole resistance due to prolonged therapeutic exposure
A. Silva °, S. Costa-de-Oliveira, I. Miranda, C. Pina-Vaz,
A.G. Rodrigues (Porto, PT)
Objectives: A patient with C. parapsilosis fungaemia was submitted
to ﬂuconazole during eleven days, after which he died. Several
C. parapsilosis isolates had been collected before, during and after
initiation of ﬂuconazole therapeutics. A microbiological characterization
of the ﬁrst and the last isolate was performed.
Methods: In vitro antifungal susceptibility testing to four azoles (ﬂu-
conazole, itraconazole, voriconazole and posaconazole) was performed
according to CLSI protocols. Molecular typing of the C. parapsilosis
isolates was carried out by RAPD. The stability of resistant phenotype
(acquired in vivo) was assessed in vitro through repeated incubation of
the isolate without antifungal. The role of active efﬂux pumps in drug
resistance was evaluated using ﬂow cytometric analysis with rhodamine
6G (Rh-6G), a speciﬁc substrate for efﬂux pumps.
Results: The initial isolate was susceptible to all azoles, while the last
recovered isolate was resistant to all four tested azoles, displaying high
MIC values. Molecular typing of isolates demonstrated that the last
isolate and pre-treatment isolate were isogenic. Therefore, we report,
the in vivo C. parapsilosis acquisition of antifungal resistance, which
maintained stable after incubation without antifungal. No difference in
Rh-6G staining was found between the susceptible and the resistant
isolate, suggesting that in vivo azole resistance did not involve increase
in efﬂux pumps activity.
Conclusion: We report a clinical case of fungaemia by C. parapsilosis
which acquired resistance to azoles after exposure to ﬂuconazole. The
resistance was characterized by an increase of ﬂuconazole, itraconazole,
voriconazole and posaconazole MIC values, which kept stable.
Interestingly, azole resistance due to overexpression of eﬂlux pumps was
not conﬁrmed. Continued ﬂuconazole pressure was associated with the
development of multi-resistance.
P836 In vitro susceptibilities of invasive fungi isolated from Austrian
patients against echinocandins and commonly used azoles
B. Willinger °, L. Sittenthaler, E. Steiner, A.M. Hirschl, C. Lass-Flo¨rl
(Vienna, Innsbruck, AT)
Objective: The aim of the study was to determine the in vitro
susceptibilities of invasive fungal isolates collected since June 2008 by
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20 different Austrian medical centres against commonly used azoles and
the three available echinocandins.
Methods: The clinical samples yielding the growth of fungi included
blood cultures and other sterile specimens such as intravascular catheters,
biopsies or aspirates, samples from the lower respiratory tract. Antifungal
susceptibility for yeasts was assessed using a broth microdilution method
following the Clinical Laboratory Standards Institute M27-A3 guidelines
whereas moulds were tested as described by the European Committee
on Antimicrobial Susceptibility Testing. For moulds also amphotericin
B was tested.
Results: So far 552 yeast isolates have been collected. C. albicans,
followed by C. glabrata, C. parapsilosis and C. tropicalis were the most
common isolated species. In addition we tested 35 strains of ﬁlamentous
fungi including 26 strains of different Aspergillus species and 5 strains
of zygomycetes.
For Candida species, the MIC50 and MIC90 were 0.5mg/l and
8mg/l for ﬂuconazole, 0.03mg/l and 0.25mg/l for voriconazole,
0.25mg/l and 1.0mg/l for caspofungin, 0.03mg/l and 0.25mg/l for
anidulafungin, 0.25mg/l and 0.5mg/l for micafungin, respectively.
Thus, the agent with the best in vitro activities for the azoles was
voriconazole and for the echinocandins anidulafungin. Only 4.6% of
Candida isolates were resistent to ﬂuconazole, 2.0% to voriconazole,
0.5% to anidulafungin, 0.4% to caspofungin and 0.7% to micafungin
respectively. 15.5% of C. glabrata strains were resistant to ﬂuconazole,
and 10.9% to voriconazole. Concerning the echinocandins elevated
MICs were observed for C. glabrata, C. parapsilosis, C. guilliermondii
and C. lusitaniae. For Aspergillus species, the MIC50 and MIC90
were 1.0mg/l and 8mg/l for amphotericin B, 0.5mg/l and 2mg/l for
voriconazole, 0.5mg/l and 1.0mg/l for posaconzole. Concerning the
echinocandins, only ﬁve strains showed MICs below 8mg/l. For the
zygomycetes, the MICs were within the expected range.
Conclusion: Up to date our multicenter study reveals no evidence
of emerging azole or echinocandin resistance among invasive clinical
isolates of Candida spp. The MICs assessed for mould were within the
expected range.
P837 Susceptibility testing of anidulafungin against clinical isolates
of Candida parapsilosis in comparison with caspofungin and
micafungin
M. Ghannoum °, J. Herbert, N. Isham (Cleveland, US)
Objectives: Anidulafungin may have better in vitro activity against
C. parapsilosis compared to the other echinocandins, as suggested
by published case reports. C. parapsilosis isolates from burn unit
patients who failed caspofungin were found to have elevated minimum
inhibitory concentration (MIC) to caspofungin and micafungin but not
to anidulafungin. To expand upon this observation, we conducted a
comparative study of the in vitro activity of anidulafungin, caspofungin,
and micafungin against a large number of C. parapsilosis clinical
isolates.
Methods: MIC’s for anidulafungin, caspofungin and micafungin for
100 clinical isolates of C. parapsilosis were determined, following the
CLSI M27-A3 standard for the susceptibility testing of yeasts. Minimum
fungicidal concentration (MFC) determinations were also determined by
subculturing the total contents of each clear well from the MIC assay
for colony count.
Results: The MIC range and MIC90 (deﬁned as the lowest concentration
to inhibit 90% of isolates tested) were 0.06−4.0 and 2.0 micrograms/ml,
respectively, for all three echinocandins. In contrast, the MFC90 of
anidulafungin was 8.0 micrograms/ml, compared to >64 micrograms/ml
for both caspofungin and micafungin.
Conclusion: Although there were no differences in MIC across the three
echinocandins, anidulafungin had more potent cidal activity compared to
caspofungin and micafungin against a large number of clinical isolates
of C. parapsilosis. This observation suggests that anidulafungin may
be more effective in eradicating C. parapsilosis in clinical infections.
Comparative trials are needed to conﬁrm this observation.
P838 Antifungal susceptibility of yeasts isolated from patients with
fungaemia: comparison of the E-test on direct blood samples
and CLSI M27-A3
J. Guinea °, S. Recio, P. Escribano, T. Pela´ez, M. Torres-Narbona,
M. Rodrı´guez-Cre´ixems, C. Sa´nchez-Carrillo, E. Bouza (Madrid, ES)
Objectives: We prospectively performed antifungal susceptibility testing
using the E-test (ETdir) on direct blood samples from 163 patients (225
strains), and on 63 strains artiﬁcially inoculated in BACTEC. ETdir
MICs (24 h of incubation) of amphotericin B, ﬂuconazole, voriconazole,
posaconazole, isavuconazole, and caspofungin were compared with
results using CLSI M27-A3.
Methods: Strains were from highly ﬂuconazole-susceptible species
(FLUCO-S: 93 C. albicans, 77 C. parapsilosis, 18 C. tropicalis, 6
C. dubliniensis, 1 C. neoformans, 1 C. kefyr), or less ﬂuconazole-
susceptible species (FLUCO R: 52 C. glabrata, 29 C. krusei, 8
C. guilliermondii, 2 R. mucilaginosa, 1 T. mucoides). Voriconazole
breakpoints were used for posaconazole and isavuconazole (R 4
mg/mL). Strains were classiﬁed as susceptible (S) or resistant (R)
following the CLSI procedure. The percentage of strains correctly
classiﬁed by ETdir was calculated.
Results: Major discrepancies (M: R by ETdir and S by CLSI) were
found mostly for C. glabrata, C. krusei and the triazoles. Very major
discrepancies (VM: S by ETdir and R by CLSI) were found for
ﬂuconazole in C. krusei (n = 2), and for voriconazole in C. glabrata
(n = 1) and T. mucoides (n = 1) (see table).
Conclusions: ETdir in yeast-positive blood cultures is rapid (24 h) and
easy, and reliably determines the antifungal susceptibility to triazoles and
caspofungin of yeasts (especially highly ﬂuconazole-susceptible species)
from fungemic patients.
J. Guinea (CA08/00384) and M. Torres-Narbona (CM08/00277) are
contracted by FIS. This study received ﬁnancial support from Basilea
Pharmaceutica.
Overall
(correct/VM/M)
FLUCO-S
(correct/VM/M)
FLUCO-R
(correct/VM/M)
% of strains with
MIC discrepancies
±2-fold dilutions
Fluconazole 90.9/0.7/8.4 100/0/0 71.7/2.2/26.1 78.8
Voriconazole 98.3/0.7/1 100/0/0 94.6/2.2/3.3 83.7
Posaconazole 88.5/0/11.5 100/0/0 64.1/0/35.9 63.5
Isavuconazole 96.5/0/3.5 99.5/0/0.5 90.2/0/9.8 71.9
Amphotericin B 31.7/66.5/1.8 25.3/73.7/1 45.5/51.1/3.4 62
Caspofungin 100/0/0 100/0/0 100/0/0 88.2
P839 Can isavuconazole MICs for yeasts be read after 24 hours
of incubation?
J. Guinea °, P. Escribano, S. Recio, T. Pela´ez, E. Bouza (Madrid, ES)
Objectives: CLSI M27-A3 has mostly been validated for determination
of the MIC after 48 hours of incubation, except in the case of ﬂuconazole
(24 h). The activity of isavuconazole has mostly been determined against
yeast isolates after 48 h of incubation. Using the M27-A3 methodology,
we studied the activity of isavuconazole against Candida spp and other
yeast isolates and determined the correlation between MICs after 24 and
48 h.
Methods: A total of 297 recent clinical yeast blood isolates (n = 193) or
other clinical specimen sites (n = 104) were studied: C albicans (n = 82);
C glabrata (n = 67); C krusei (n = 31); C parapsilosis (n = 63); C tropicalis
(n = 17); Candida spp (n = 7); and other yeast isolates (n = 30). The
antifungal activity of isavuconazole was determined according to M27-
A3. MIC (50% inhibition of growth) was read after 24 h and 48 h
incubation. The MICs at 24 h and 48 h were considered to agree (essential
agreement) when the value recorded after each incubation time was
within ±2 or fewer 2-fold dilutions of the other, considering 48 h as the
gold standard. In the absence of breakpoints for isavuconazole, we chose
voriconazole breakpoints (1 mg/mL, susceptible; 2 mg/mL susceptible–
dose dependent; 4 mg/mL, resistant) to evaluate the categorical
agreement between MICs determined at 24 h and 48 h.
Results: MICs after 24 h of incubation were not determined for 6/297
(2%) isolates (1 C krusei and 5 other) due to poor growth. Overall, the
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antifungal activity (in mg/mL) of isavuconazole obtained after 24/48 h of
incubation was: MIC50 (0.015/0.031), MIC90 (0.125/0.25), and MIC
range (0.015−>16). Although the overall essential agreement between
both procedures was 87.6% (Figure), inter-speciﬁc differences were
noted with C parapsilosis and C tropicalis showing the highest agreement
(100%) and C glabrata the lowest (67.2%). Strains were classiﬁed (after
24/48 h of incubation) as susceptible (99%/97.9%), susceptible–dose
dependent (0.3%/1.4%), and resistant (0.7%, C tropicalis). Categorical
agreement was 98.9%, and only 3 strains (2 C glabrata and 1 C tropicalis)
showed minor errors.
Conclusions: The antifungal activity of isavuconazole against Candida
and other yeasts can be obtained after 24 hours of incubation with no
major or very major discrepancies. Validation of this procedure in future
studies including a higher number of ﬂuconazole/isavuconazole-resistant
isolates is warranted. J. Guinea (CA08/00384) is contracted by FIS.
P840 In vitro activity of isavuconazole against clinical non-Candida
yeast isolates determined by E-test and CLSI M27-A3
J. Guinea °, S. Recio, P. Escribano, T. Pela´ez, E. Bouza (Madrid, ES)
Objectives: Isavuconazole is a new triazole undergoing phase III study
for the treatment of patients with fungemia. The antifungal activity of
isavuconazole against non-Candida yeast isolates causing fungemia has
only been assessed for a limited number of isolates. We determined
the antifungal activity of isavuconazole against rare non-Candida yeast
isolates and compared it with that of other marketed triazoles.
Methods: We studied 29 clinical non-Candida strains: Dipodascus
capitatus (n = 9; 31%), Rhodotorula mucilaginosa (n = 2; 6.9%), Sac-
charomyces cerevisiae (n = 15; 51.7%), and Trichosporon spp. (n = 3;
10.3%). All isolates were identiﬁed by amplifying and sequencing
the ITS1-5.8S–ITS2 region (White et al). The antifungal activity
of ﬂuconazole, voriconazole, posaconazole, and isavuconazole was
determined using the CLSI M27-A3 microdilution procedure. That of
isavuconazole was also determined using the E-test. Each CLSI and
corrected (two-fold scale) E-test MIC was further converted to a log2
MIC. The methods agreed when the log2 MIC measured by each was
within ±2 or fewer twofold dilutions of the other.
Results: The MIC50, MIC90, and range of MICs (in mg/ml) for each
antifungal were as follows: posaconazole (0.5/2/0.062−2); ﬂuconazole
(4/32/1−>128); voriconazole (0.125/0.5/0.031−1); and isavuconazole
(CLSI: 0.125/0.5/<0.015−1; E-test: 0.125−1/0.031−2). For isavucona-
zole, CLSI M27-A3 and the E-test agreed for 51.7% (±1 twofold
dilutions) and 75.8% (±2 twofold dilutions) of strains. According
to the breakpoints suggested, the strains were classiﬁed as follows:
ﬂuconazole (susceptible, 72.4%; susceptible-dose dependent, 20.6%;
resistant, 6.9%) and voriconazole (susceptible, 100%). The only two
strains of R. mucilaginosa showing ﬂuconazole resistance (>128 mg/ml)
were voriconazole-susceptible and had MICs for isavuconazole 0.125
mg/ml.
Conclusions: The non-Candida isolates of Dipodascus capitatus,
Rhodotorula mucilaginosa, Saccharomyces cerevisiae, and Trichosporon
spp. studied were highly susceptible to isavuconazole (MICs 1 mg/ml),
even the ﬂuconazole-resistant strains. The E-test is an alternative means
of determining the antifungal activity of isavuconazole against non-
Candida isolates. J. Guinea (CA08/00384) is contracted by FIS.
P841 Detection of amphotericin B resistance in Candida
haemulonii and closely related species, using Etests, Vitek-2
Yeast Susceptibility Test, and CLSI M27 broth microdilution
J.H. Shin °, S.H. Kim, B.J. Oh, M.N. Kim, S.J. Jang, M.G. Shin,
S.P. Suh, D.W. Ryang (Gwangju, Seoul, KR)
Objectives: The emerging fungal pathogen Candida haemulonii and
closely related species often show high-level resistance to amphotericin B
(AMB). This study compared the utility of four antifungal susceptibility
testing methods in the detection of AMB-resistant isolates of these fungi.
Methods: A total of 51 clinical isolates (eight isolates of C. haemulonii,
10 isolates of Candida pseudohaemulonii, and 33 isolates of Candida
auris) were obtained from eight Korean hospitals during 2004–2009. For
each isolate, AMB susceptibility Etests (AB Biodisk, Solna, Sweden)
were performed on Mueller-Hinton agar supplemented with glucose
and methylene blue (Etest-MH), and on RPMI agar supplemented with
glucose (Etest-RPMI). Isolates were also examined in Vitek-2 yeast
susceptibility tests, and by the CLSI M27 broth microdilution method
(CLSI-BMD).
Results: Of the four methods, Etest-MH generated the broadest
distribution of AMB minimum inhibitory concentrations (MICs), ranging
from 0.125 to 32 ug/ml for all 51 isolates. MICs ranged from 4 to 32
ug/ml in the 18 isolates of C. haemulonii and C. pseudohaemulonii,
which we categorized as resistant. All 33 isolates of C. auris were
susceptible, with MICs ranging from 0.125 to 0.38 ug/ml. When AMB
MIC values from the other three test methods were compared to those
produced by Etest-MH, the essential agreements (within 2 dilutions) of
Etest-RPMI, Vitek-2, and CLSI-BMD were 88.2%, 92.2%, and 72.5%,
respectively. Etest-RPMI and CLSI-BMD produced two very major
errors (5.9%), while Vitek-2 produced no major errors, but two minor
errors (5.9%).
Conclusion: Of the four methods evaluated, Etest-MH appears to provide
the best discrimination between AMB-resistant and susceptible isolates
of C. haemulonii and closely related species; Vitek 2 can be a useful
screening method for detecting AMB resistance in these isolates.
P842 Investigation of efﬂux pumps and ERG11 gene expression
levels in Candida albicans isolates by semi-quantitative
reverse transcription-polymerase chain reaction
O. Irmak, M. Doluca Yu¨cesoy ° (Izmir, TR)
Objective: Widespread and repeated use of ﬂuconazole resulted
in resistance problem in Candida albicans strains. In this study,
investigation of the expression of efﬂux pump encoding genes, CDR1,
CDR2, and MDR1 and lanosterol 14 a-demethylase enzyme encoding
gene, ERG11 in ﬂuconazole (Flu) susceptible (S)/resistant(R)/dose
dependent susceptible (DDS) C. albicans isolates was aimed in order
to determine the role of these two mechanisms in ﬂuconazole resistance.
Methods: Four Flu R/DDS, seven Flu S and three tailing effect showing
S C. albicans strains which were isolated from clinical specimens in
three University hospitals in Turkey were included. Relative expression
of CDR1, CDR2, MDR1 and ERG11 transcripts were determined by
semi-quantitative reverse transcription polymerase chain reaction and
compared with drug susceptible C. albicans ATCC 14053 strain. The
expression of these genes was normalized with their ACT1 expression
levels.
Results: CDR1 and CDR2 transcripts were 3.12–7.16 and 1.83–18.0
fold upregulated, respectively in Flu R/DDS C. albicans isolates when
compared to C. albicans ATCC strain. Trailing isolates showed 0.64–
2.06 and 0.9−3.1 fold CDR1 and CDR2 expression while the sensitive
isolates expressed low levels of these genes or didn’t seem to express
at all. When MDR1 and ERG11 expressions were examined, it was
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observed that three and all Flu R/DDS as well as six and four Flu S
isolates expressed these two genes at various levels, respectively.
Conclusion: As a result, it can be concluded that overexpression of
efﬂux pumps especially CDR1 and CDR2 can be important mechanisms
of Flu resistance in our C. albicans isolates.
P844 Growth-related heat production of Aspergillus fumigatus
in presence of liposomal amphotericin B − a novel rapid
real-time method for evaluation of antifungals
U. Furustrand °, E. Seiler, A. Trampuz (Lausanne, CH)
Objectives: Current detection and susceptibility testing of moulds have
insufﬁcient sensitivity, require up to 72 h of incubation and carries
considerable risk of cross-contamination. We evaluated a closed-system
method for real-time detection of growth-related heat production of
Aspergillus fumigatus. Measurements were performed with liposomal
amphotericin B (AMB) (AmBisome) to evaluate the potential of
microcalorimetry for rapid, accurate and easy-to-perform susceptibility
testing of moulds.
Methods: A. fumigatus strain ATCC 204305 was used. Microcalorimetry
was performed in duplicate by adding 0.05ml of A. fumigatus suspension
containing 104 cells (determined in a haematocytometer by microscopy)
in 2.95ml Sabouraud Dextrose Broth containing serial 2-fold dilutions
of AMB. Heat production was measured at 37ºC under static conditions
and detection time (in h), peak heat ﬂow (in microwatt) and total heat
produced (in Joules) were determined. The lower detection limit of
heat production was deﬁned at 20 microW. The minimal heat inhibition
concentration (MHIC) was deﬁned as the lowest antifungal concentration
inhibiting heat production during 24 h of incubation.
Results: Heat production of A. fumigatus without AMB (positive
control) was detected after 11.3 h, with a peak of 220 microW and a total
heat of 5 J. Growth media with AMB but without A. fumigatus (negative
control) showed no detectable heat production. With increasing AMB
concentration, the detection time was proportionally delayed (Figure) by
3.9 h (at 0.5 ug/ml), 8.8 h (at 1 ug/ml), 11.8 h (at 2 ug/ml), 16.8 h (at 4
ug/ml), 20.8 h (at 8 ug/ml), 28.2 h (at 16 ug/ml), 35.7 h (at 32 ug/ml)
and 39.2 h (at 64 ug/ml). The MHIC of AMB was 4 ug/ml. The peak of
heat ﬂow gradually decreased from 220 microW (without AMB) to 120
microW (with 64 ug/ml AMB), while the total heat produced remained
similar at about 5 J.
Conclusion: Microcalorimetry allowed evaluation of activity of li-
posomal AMB against A. fumigatus by inhibiting its growth-related
heat production. This method has the potential for rapid (12−24 h),
accurate and real-time susceptibility testing of various moulds and for
evaluation of new antifungals. In further steps, systematic optimization
and standardization of calorimetric conditions are needed.
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P845 Candida colonization among paediatric cancer patients and
its impact on (1−3)-b-D-glucan, C. mannan and Candida
DNA detection in serum samples
E. Mokaddas °, M. Burhama, Z. Khan, S. Ahmed (Dasma, KW)
Objective: An 18-month prospective surveillance study was undertaken
to determine the extent of Candida colonization among pediatric cancer
patients and its possible impact on detection of (1−3)-b-D-glucan (BDG),
Candida mannan and Candida DNA in serum samples.
Methods: A total of 972 swabs originating from throat (n = 294),
nostrils (n = 600), anus (n = 28), and groin (n = 50) from 63 pediatric
cancer patients were cultured on Sabouraud dextrose agar supplemented
with chloramphenicol. Serum samples were collected from the patients
colonized with Candida species at a single or multiple sites for the
detection of BDG by Fungitell kit (Associates of Cape Cod Inc., USA),
Candida mannan by Platelia Candida Ag (BioRad, Marnes La Coquette,
France) and Candida DNA by using panfungal and/or species-speciﬁc
primers and DNA sequencing.
Results: Seventy-four (7.6%) swab cultures from 35 (55.5%) patients
yielded Candida species. The isolates included 61 of C. albicans, 8
of C. dubliniensis, 2 each of C. glabrata and C. tropicalis and one of
C. krusei. Eleven patients were colonized at three or more sites. None
of the serum samples from the colonized patients yielded BDG and/or
Candida mannan levels higher than the currently recommended cut-
off values of >80 pg/ml and >0.5 ng/ml used for the two diagnostic
tests, respectively. The geometric means of BDG and Candida mannan
levels were 31.6 + 12.98 pg/ml and 0.17 + 0.04 ng/ml, respectively.
Likewise, none of the serum samples (n = 36) of patients who were
colonized with Candida species yielded a positive PCR test for Candida
DNA. During the study period, only two colonized patients subsequently
developed candidemia due to C. tropicalis. Besides positive blood
cultures, C. tropicalis DNA, BDG (119.3 and 203 pg/ml), and Candida
mannan (0.77 and 0.28 ng/ml) were also detected in serum samples
during the candidemic episode.
Conclusions: The present study demonstrates that while mucosal
colonization with Candida species in cancer patients is not uncommon,
it may not give rise to diagnostically signiﬁcant levels of BDG, Candida
mannan or to Candida DNA in serum specimens. The study reinforces
the diagnostic utility of these markers in the diagnosis of invasive
candidiasis.
P846 Candida albicans interferes with galactomannan
antigenaemia in human bronchoalveolar lavage ﬂuids
F. Persat °, P. Vanon, S. Ranque, S. Picot (Lyon, Marseille, FR)
Objective: Galactomannan (GM) detection in bronchoalveolar lavage
(BAL) is often described as an adjunctive diagnostic tool for the
diagnosis of aspergillosis. Candida albicans infections are not a
recognized cause of false-positive GM assay when performed on serum.
However yeasts can be present in much larger amounts in BAL ﬂuid than
in serum. This study aimed at testing whether the presence of C. albicans
would inﬂuence the GM assay results in patient BAL ﬂuid.
Methods: 70 BAL samples, originating from 66 patients hospitalized
in various wards (haematology, intensive care units, pneumology),
were routinely analyzed with direct microscopic examination (ME) by
Giemsa and Gomori-Grocott stainings and culture. Platelia®-Aspergillus
(BioRad) GM ELISA assay was performed retrospectively. BALs were
splitted into four groups: (1) ME negative and culture negative (n = 20);
(2) ME with pseudomycelia-yeasts and pure C. albicans culture (n = 23);
(3) ME with hyphae and pure Aspergillus fumigatus culture (n = 10); (4)
ME negative and A. fumigatus pure culture (n = 17). Platelia®-Aspergillus
was performed as indicated by the manufacturer; the results were index
values, a 0.5 positivity threshold was used as recommended in serum.
Data were then analysed using increasing positivity threshold values.
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Results: Index values signiﬁcantly differed among the four groups
(p< 0.05, Kruskall-Wallis test). In the group 3 (hyphae and A. fumigatus
culture) 9 BAL index values were >1.5, and 6 (60.0%) were >8. In the
group 4 (negative ME and A. fumigatus culture), 12 (70.6%) were >0.5.
In the control groups 1 & 2, 15 were >0.5; 13 (86.6%) of those belonged
to group 2 (pseudomycelia-yeasts and C. albicans).
Conclusions: The presence of numerous pseudomycelia and yeasts in
ME was associated with increased GM index values that were similar
to those obtained for BALs with negative ME and A. fumigatus culture.
In this case, GM results in BAL should be more cautiously interpreted.
Whether a speciﬁc positivity threshold should be used when numerous
yeasts and pseudomycelia are detected in the BAL ﬂuid remains to be
addressed.
BAL groups N ELISA GM index positivity thresholds
Number of positive (%)
0.5 0.7 1.0 1.5
ME with hyphae + A. fumigatus culture 10 9 (90.0) 9 (90.0) 9 (90.0) 9 (90.0)
Negative ME + A. fumigatus culture 17 12 (70.6) 9 (52.9) 8 (47.1) 6 (35.3)
ME with pseudomycelia and yeasts + C. albicans culture 23 13 (56.5) 11 (47.8) 8 (34.8) 5 (21.7)
Negative ME + sterile culture 20 2 (10.0) 2 (10.0) 1 (5.0) 1 (5.0)
P847 Effects of three different topical antimicrobial dressings on
Candida albicans-contaminated full-thickness burns in rats
A. Acar °, F. Uygur, H. Diktas, R. Evinc, E. Ulkur, O. Oncul,
L. Gorenek (Istanbul, TR)
Background: In this experimental animal study, the effects of
three different topical antimicrobial dressing on Candida albicans
contaminated full-thickness burn in rats were analyzed.
Methods: Totally 32 adult Wistar rats (body weight 200–220 gr)
were used. Acticoat TM® (Smith and Nephew, Istanbul, Turkey),
chlorhexidine acetate 0.5% (Bactrigrass® and Mycostatine (Nystatin®)
were compared to assess the antifungal effect of a once-daily application
on experimental rat 15% full-skin thickness burn wound seeded 24 hours
earlier with a 108 CFU/mL standard strain of Candida albicans ATCC
90028. All the animals were scariﬁed at post burn day 7. The quantitative
counts of seeded organism in burn eschar and subjacent muscle were
determined, beside the cultures of left ventricle blood and lung biopsies.
Results:While there were signiﬁcant differences between Acticoat TM®
group (4±1x102) and control group (5±6x104), and between Mycostatin
group (4±4x102) and control group (P = 0.01, P = 0.01), there were
no signiﬁcant differences between chlorhexidine acetate 0.5% group
(2±3x104) and control group (P = 0.7) respectively. Acticoat TM® and
Mycostatin were sufﬁcient to prevent to C. albicans from invading to
the muscle and from causing systemic infection.
Conclusions: The animal data suggest that Mycostatin is the most
effective agents in the treatment of C. albicans-contaminated burn
wounds, and Acticoat TM® is a choice of treatment on fungal burn
wound infection with antibacterial effect and the particular advantage of
limiting the frequency of replacement of the dressing.
P848 Prevalence and antimycotic susceptibility of Candida sp.
causing vulvovaginitis
E. Krstevska-Kelepurovska °, E. Krsteva, I. Kelepurovski, O. Jankova,
A. Delova (Bitola, MK)
Objectives: The aim of this study was to ascertain the prevalence
and species representation of pathogenic yeasts in patients with clinical
symptoms of vulvovaginitis. Determination of in vitro susceptibility of
yeast isolates to clinically used antimycotic agents.
Methods: This study was conducted in six-months period and included
1058 sexually active women with clinical symptoms of vulvovaginitis.
Identiﬁcation of the yeast isolates was performed using Chromatic
Candida agar (Lioﬁlhem). Speciation of the yeasts was done using a
standardized biochemical commercial system API ID 32 C (bioMe´rieux,
France). In vitro susceptibilities were determined using API ATB
FUNGUS 3 (bioMe´rieux, France).
Results: A total of 1058 women were included in the study and in
181 (17.1%) yeasts were isolated. Candida albicans was the most
common species among the isolates 94 (51.9%) followed by C. glabrata
39 (21.5%). Other Candida spp. isolated were C. kefyr 17 (9.4%),
C. tropicalis, C. krusei and Sach. cerevisiae 9 (5.0%) each, C. sache
and C. parapsilosis 2 (1.1%) each. Thus the overall prevalence of non-
albicans Candida species was 87 (48.1%). Resistance to Amphotericin B
was detected in 42 (23.2%) of all analysed strains (in 16% of C. albicans,
25.6% − C. glabrata, 17.6% − C. kefyr). Resistance to Fluconazole
was seen in 25 (13.8%) of strains (in 18% strains of C. albicans,
11.8% − C. glabrata). Resistance to Itraconazole was detected in
59 (32.6%) isolates (in 18% strains of C. albicans, 76.9% − C. glabrata,
11.8% − C. kefyr). Resistance to Voriconazole was identiﬁed in 15 (8.3%)
strains (in 7.4% − C. albicans, 12.8% − C. glabrata, 11.8% − C. kefyr).
We also found 7 (3.9%) strains resistant to Flucitosine (C. albicans,
C. tropicalis, Sach. cerevisiae).
Conclusion: In this study, we observed that C. albicans (51.9%) was
the most frequent etiologic agent associated with mycotic vulvovaginitis.
Thus, in recent years, there has been a signiﬁcant increase of infections
caused by non-albicans species of Candida, particularly C. glabrata
(21.5%) and C. kefyr (9.4%). Most non-albicans Candida species have
higher percent of resistance to the antifungal agents, and infections they
cause are difﬁcult to treat. This phenomenon emphases the importance
of identiﬁcation and surveillance of the Candida species in the clinical
settings.
P849 Distribution of Candida sp. of colonized patients in intensive
care units
F. Ergin, M. Yetkin, C. Bulut, B. Oral, G. Ertem, N. Tulek °,
A.P. Demiroz (Ankara, TR)
Objectives: Candida infections mainly evolve from endogenous
colonization. Candida albicans remains the most frequent cause of
candida colonization. In this study we evaluated the epidemiology of
candida species of colonizated patients in intensive care unit.
Methods: The study was carried out between September 2008 and
February 2009 with the patients older than 18 years of age in a
medical/surgical intensive care unit. Throat, nose, skin (axilla), urine
and rectal swab cultures were taken at admission and weekly from
each patient. Candida colonies were identiﬁed by using germ tube test,
CHROMagar Candida Medium (Becton Dickinson, Germany) and ID
32 C (BioMeriux, France) yeast identiﬁcation kit.
Results: A total of 1691 samples were taken over the study period. 815
samples were belonging to the colonized patients. Of the 815 samples
collected from 42 patients, 143 (18%) yielded Candida species. These
included 66 (46%) C. albicans, 39 (27%) C. glabrata, 11 (8%) C. kefyr,
10 (7%) C. tropicalis, 8 (6%) C. krusei, 4 (3%) C. lusitaniae, 3 (%2)
C. sake and 2 (%1) C. holmii isolates.
Candida colonization was found with the highest percentage from throat,
urine and rectal swab samples. C. albicans and non-albicans Candida
species are similar rate in throat and urine samples, but non-albicans
Candida species are most common in rectal samples.
Of these colonized patients, invazive candida infection developed in nine
patients; ﬁve of them candidemia and four of them urinary tract infection.
C. albicans (3) and C. glabrata (2) were the cause of candidemia. Urinary
tract infections were developed by C. albicans, C. glabrata, C. tropicalis
and C. krusei.
Conclusion: Candida species are increasingly causing nosocomial
infections in intensive care units. Although Candida albicans is still
major pathogen, rate of non albicans Candida species are increasing
also.
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P850 Antifungal susceptibility patterns of Candida isolates
originated from invasive candidiasis
A. Stylianakis, V. Papaioannou, S. Tsiplakou, P. Papanikolaou,
K. Tsopelas, A. Panagopoulou, C. Karra, A. Koutsoukou ° (Athens, GR)
Objectives: The aim of our study was to evaluate the antifungal proﬁles,
against commonly used and newer antifungal agents of Candida isolates,
causing invasive candidiasis.
Methods: During one year period (11/2008–10/2009) we examined
forty three Candida isolates responsible for thirty seven distinct
cases of candidaemia and six other invasive candidiasis. The latter
isolates derived from surgical wounds (n = 3), lower respiratory tract
specimens (n = 2) and normally sterile samples (n = 1, ascitic ﬂuid)
each of them represented a unique infectious episode. The fungal
identiﬁcation procedure to species level included germ tube production
and the use of the automated compact system VITEK 2 (Biomerieux).
The antifungal susceptibility testing was performed by using E-test
strips (Biomerieux) and RPMI 1640 agar with 2% glucose according
to the manufacturer’s instructions. MIC was evaluated according to
CLSI criteria for 5-ﬂucytocine (FC), ﬂuconazole (FL), voriconazole
(VO), micafungin (MCF) and anidulafungin (AND) while a provisional
susceptibility breakpoint of 1mg/L was used for amphotericin B (AP)
and posaconazole (POS).
Results: C. parapsilosis was the predominant species (n = 31, 72%),
followed by C. albicans (n = 12, 28%). All isolates were inhibited at
MICs 1mg/L of amphotericin B, posaconazole and micafungin. Only
5 out of 31 (17%) C. parapsilosis isolates were susceptible to AND while
all C. albicans isolates were susceptible to the same agent. 37 isolates
were examined and found susceptible to the new echinocandins AND,
MCF, and to triazoles POS and VO. The susceptibility percentage of
the examined C. parapsilosis / C. albicans isolates to the rest antifungal
agents, was 88.4% / 83.7% for FC against C. parapsilosis / C. albicans,
and 34.9% / 30.2% for FL against the same isolates, respectively.
Conclusion: C. parapsilosis prevails among the isolates responsible to
invasive candidiasis, in our hospital. The more recent antifungal agents
POS and MCF as well as AP, VO were active against all Candida
isolates tested, FC possessed a satisfactory antifungal activity and AND
was active against all the C. albicans isolates. The low degree of
susceptibility to FL and AND observed against some Candida isolates
highlights the necessity of administrating antifungal agents in accordance
to the susceptibility test of the responsible isolates.
P851 Epidemiological trends in albicans and non-albicans
nosocomial candidaemia
J. Esperalba °, I. Rebollo, M.P. Mendaza, M.L. Go´mez-Lus,
S. Alca´ntara, M.F. Portero, D. Da´maso (Majadahonda, Madrid, ES)
Objectives: To evaluate the incidence, risk factors and mortality rate
of candidemia, as well as, determine differences of albicans and non-
albicans candidemia.
Methods: Retrospective and observational study conducted from June
2008 to May 2009 at the Puerta de Hierro Majadahonda University
Hospital in Madrid, Spain. It is a 613-bed hospital that covers a
population of approximately 5 hundred thousand people from 20 towns
in the northwest of Madrid. Candidemia was deﬁned as being found in at
least one positive blood culture yielding Candida. For the isolation and
identiﬁcation of Candida we used the routine methods: the BACTEC
9240 system and CHROMagar Candida Medium, Auxacolor or Api 20
C Aux systems. For each episode of candidemia, once we had identiﬁed
the specie, we collected clinical and demographic data, predisposing
disease and risk factors according to the scientiﬁc knowledge reviewed.
We used either the c2-test or the Fisher Exact-test to compare categorical
variables and to observe the factors associated with albicans and non-
albicans candidemias.
Results: A total of 28 cases of candidemia were documented, ranging 1.6
cases per 1.000 admissions. Overall, 36.7% of the episodes were due to
C. albicans, followed by C. parapsilosis (30%), C. tropicalis (13.33%),
C. krusei (10%) and C. glabrata, C. dublinensis and C. lusitaniae with
one isolate each (3.33% each). Candidemia was predominant (35.7%) in
the intensive care unit (ICU). The ICU patients had a signiﬁcant higher
risk to suffer a non-albicans than albicans candidemia (p = 0.057). The
rest of demographic data, risk factors, underline diseases and outcome
rates between the two groups did not reach statistical signiﬁcance (table).
Mostly, we identiﬁed that the risk factors more frequently associated were
intravascular catheter management, previous antimicrobial therapy and
being in an immunosuppressive situation. The attributed outcome rate
was 44.4%.
Conclusions: Candidemia is an important infection in terms of incidence
and mortality that occurs mainly in critical care and haematology
units. Although Candida albicans was still the predominant species,
we observed a high rate of non-albicans strains that currently are less
susceptible to ﬂuconazole. The results of this survey help us to establish
the pertinent epidemiological, diagnostic and therapeutic measures for
the control of this nosocomial illness.
Table. Candidemia in Puerta de Hierro Majadahonda University Hospital,
Madrid
Characteristic Total
patients
(27)
C. albicans
(11)
Candida
non-albicans
(19)
p value
Male (%) 15 (55.5) 5 (45.5) 12 (63.2)
Female (%) 12 (44.4) 6 (54.5) 7 (36.8)
Age (years), mean 63 (22−83) 59.45 (38−81) 65.4 (22−83) 0.282
Neoplasia (%) 13 (48.2) 7 (63.6) 7 (36.8) 0.389
HIV infection (%) 1 (3.7) 1 (9.1) 0
PDA (%) 1 (3.7) 1 (9.1) 0
COPD (%) 0 0 0
Diabetes mellitus (%) 6 (22.2) 2 (18.2) 4 (21.1) 1
Ischemic cardiopathy (%) 4 (14.8) 2 (18.2) 2 (10.5) 0.970
Cardiovascular accident (%) 1 (3.7) 1 (9.1) 0
Central venous catheter (%) 20 (74.1) 7 (63.6) 15 (78.9) 0.627
Urinary catheter (%) 16 (59.3) 4 (36.4) 12 (63.2) 0.299
Endotracheal intubation (%) 6 (22.2) 2 (18.2) 4 (21.1) 1
Nasogastric intubation (%) 4 (14.8) 1 (9.1) 3 (15.8) 1
Corticosteroid therapy (%) 12 (44.4) 4 (36.4) 8 (42.1) 1
Immunosuppression (%) 19 (70.4) 7 (63.6) 14 (73.7) 0.869
Antimicrobial therapy (%) 24 (88.9) 9 (81.8) 17 (89.5) 0.970
Surgery (%) 19 (70.4) 7 (63.6) 12 (63.1) 1
ICU (%) 13 (48.2) 2 (18.2) 11 (57.9) 0.057
Transplant (%) 5 (18.5) 0 5 (26.3)
Mortality (%) 12 (44.4) 5 (45.5) 7 (36.8) 0.712
HIV: Human immunodeﬁciency virus; PDA: Parenteral drug addicts;
COPD: Chronic obstructive pulmonary disease; ICU: Intensive care unit.
P852 Risk factors and the incidence of candidaemia in the
intensive care unit: a 5-year cross-sectional study
N. Yapar °, M. Akan, V. Avkan-Oguz, C. Ergon, M. Hancer, M. Doluca
Yu¨cesoy (Izmir, TR)
Objective: In recent years, an increase in the frequency of candidemia
has been observed. In this study we aimed to investigate the incidence of
candidemia and risk factors associated with this infection in our Intensive
Care Unit (ICU).
Methods: A cross sectional study in the ICU of a university hospital was
conducted from 1 January 2004 to 31 December 2008. Candidemia was
deﬁned as isolation of any species of Candida from at least one blood
culture of patients. For all patients demographic and clinical data were
collected from medical reports and medical microbiology laboratory
retrospectively. All statistical analyses were performed with Statistical
Package for the Social Sciences (SPSS, Version 15.0). For the variables
that had signiﬁcance in the c2 tests, logistic regression analysis was
performed. P values of <0.05 were considered as statistically signiﬁcant.
Results: In ﬁve years period, 66 candidemia cases were identiﬁed among
1076 cases. Overall incidence of candidemia was 3.38 per 1000 patient
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days. Of the cases 35 (53%) were male and 31 (47%) were female. Mean
age was 54.39±23.89 in case group and 53.25±23.01 in control group.
Risk factors of candidemia were given in the table.
Conclusion: In this study, we observed that important risk factors for
candidemia were red blood cell (RBC) transfusion, total parenteral
nutrition (TPN) and previous usage of antibiotics and antifungals.
Important risk factors such as central catheterization and mechanical
ventilation were not found signiﬁcant in this study, because of very
commonly implementation of those procedures in the ICU. We concluded
that a great number of candida blood stream infections were preventable
by reducing of unnecessary invasive procedures or antimicrobials.
Acknowledgement: We would like to thank Reyhan Ucku, MD, Prof. for
her statistical review of results.
Table. Risk factors of candidemia
Risk factor P value Logistic regression analysis
(c2 tests) P value OR (95%CI)
Gender 0.103 0.02 1.83 (1.07–3.12)
Tracheostomy <0.01
RBC transfusion <0.01 0.05 1.86 (0.99–3.50)
Abdominal surgery 0.02
TPN <0.01 0.09 1.63 (0.92–2.87)
CVC (Lower extremity) 0.01
Antibiotic use <0.01
Piperacillin–tazobactam <0.01
Glycopeptides <0.001 <0.001 4.10 (2.27–7.41)
Aminoglycosides <0.001 <0.01 2.20 (1.26–3.82)
Carbapenems <0.001 0.02 1.94 (1.06–3.54)
Antifungal use 0.46 0.06 0.40 (0.15–1.04)
P853 Adult and neonatal intensive care unit candidaemia:
retrospective analysis
A. Spiliopoulou °, S. Vamvakopoulou, C. Bartzavali,
G. Dimitracopoulos, E.D. Anastassiou, M. Christoﬁdou (Patras, GR)
Objectives: To investigate the isolation and distribution rate of
Candida spp. in blood cultures and to evaluate antifungal susceptibility
during a 12-year period (1997–2009) in a tertiary care hospital’s adult
(AICU) and neonatal (NICU) intensive care units.
Methods: Positive blood cultures (BacT/Alert, Organon Teknika) were
examined microscopically directly for yeasts or pseudohyphae and
subcultured on Sabouraud dextrose agar (Difco). Candida isolates were
screened by germ tubes test and identiﬁed using API 20CAUX and
automated VITEK system (both Biomerieux). Antifungal susceptibility
was carried out by E-test (AB Biodisk) on RPMI -2% glucose agar. MIC
was evaluated according to CLSI criteria for the following antifungal
agents: amphotericin B (AM), 5-ﬂuorocytocin (FC), ketoconazole (KE),
itraconazole (IT), ﬂuconazole (FL), voriconazole (VO), posaconazole
(PO) and caspofungin (CF). According to European Organization for
Research and Treatment of Cancer, an episode of candidaemia was
deﬁned as one or more positive blood cultures for Candida species
isolated from patients with clinical signs of infection. Subsequent
positive cultures were deﬁned as new episode, only if there was an
interval of at least 12 weeks between the two episodes.
Results: During the study period there were 285 candidemia cases.
Thirty three (33) cases were identiﬁed in AICU and sixty ﬁve (65) cases
in NICU The causative species in AICU / NICU were: C. albicans 22
strains (67%) / 39 strains (60%), C. parapsilosis 6 (18%)/18(27.7%),
C. glabrata 3 (9%)/5 (7.7%), C. tropicalis 2 (6%)/2 (3.1%) and
C. guilliermondii 0 (0%)/1 (1.5%). In terms of susceptibility to
antifungals, C. albicans isolates demonstrated excellent sensitivity rates
to AM, FC and CF, whereas the highest resistance rates were observed
to azoles, especially IT (27% and 16% in AICU and NICU respectively),
FL (18% and 8%) and KE (14% and 16%). C. parapsilosis isolates were
sensitive to all antifungals with the exception of IT (11% resistance in
NICU). C. glabrata and C. tropicalis demonstrated the higher resistance
rates to azoles among all Candida.
Conclusions: ICU Candidemia is predominantly caused by C. albicans.
Parenteral alimentation and use of central venous catheters seem to be
associated with high incidence of C. parapsilosis, which is the second
predominant specie in both ICUs. C. glabrata is the third more often
isolate and its identiﬁcation is clinically important due to high resistance
to azoles.
P854 A 9-year species and antifungal susceptibility study of
bloodstream Candida isolates in a Greek trauma hospital
A. Stylianakis, S. Tsiplakou, V. Papaioannou, K. Tsopelas, P. Petraki,
A. Panagopoulou, K. Ntetsika, A. Koutsoukou ° (Athens, GR)
Objectives: To study the epidemiology of candidaemias, the species
distribution among Candida isolates recovered from blood cultures and
their antifungal susceptibility proﬁles in a trauma Hospital in Greece,
during a nine year time period (11/2000–10/2009).
Methods: During the examined period 316 candidaemias were studied,
corresponding to equal numbered patients. The blood cultures were in-
cubated in the automated blood culture system BACTEC9240(Becton &
Dickinson). The fungal identiﬁcation procedure to species level
included microscopic examination of the yeast colonies, germ-tube
test, assimilation test of carbohydrates by API20AUX(Biomerieux)
and/or using the automated system VITEK2(Biomerieux). The antifungal
susceptibility testing (MIC) was performed by E-test strips(AB, Biodisk)
according to the manufacturer’s instructions. MIC was evaluated
according to CLSI criteria for 5-ﬂucytocine(FC), ﬂuconazole(FL),
ketokonazole(KE), itraconazole(IT), voriconazole(VO). As susceptible
to amphotericin B(AP) considered the isolates possessing MIC values of
1mg/L.
Results: The 66.1%(209/316) of candidaemias occurred in the ICUs, the
23.4%(74/316) in the surgical wards and the rest 10.4%(33/316) in the
medical wards. The crude fatal rate was 34.5%. All candidemia episodes
were caused by a single Candida species. The species distribution
was C. parapsilosis (n = 159, 50.3%), C. albicans (n = 67, 21.2%),
C. glabrata (n = 24, 7.6%), C. tropicalis (n = 20, 6.3%), C. lusitaniae
(n = 14, 4.4%), C. famata (n = 14, 4.4%), C. guilliermondii (n = 11,
3.5%), C. intermedie (n = 4, 1.3%) and C. utilis (n = 3, 1.0%). All isolates
were susceptible to AP. A decreased susceptibility (DD-S) to VO was
found in two C. parapsilosis isolates and in one C. albicans isolate
while two C. albicans isolates were resistant to the same agent. The
number and the susceptibility percentage of the two most common,
C. parapsilosis(n)/C. albicans(n1) isolates to the rest antifungal agents
were: n = 152, 95.4%/n1=62, 91.9% for FC, n = 79, 68.4%/n1=33, 60.6%
for FL, n = 63, 84.1%/n1=33, 30.3% for KE, n = 62, 64.5%/n1=23, 43.5%
for IT, respectively.
Conclusion: C. parapsilosis was the predominant cause of candidaemias
in our Hospital. The crude mortality rate was high. The low susceptibility
to triazoles and the dose-dependent susceptibility or resistance emerged
to VO, weak the armamentarium against this serious infection. Present
study shows that AP remains the drug of choice against bloodstream
Candida isolates.
P855 The characteristics of candidaemia at a tertiary care
cancer centre in Japan, with special interest in the type of
malignancies
N. Kishida °, Y. Gu, F. Takahiro, K. Okinaka, T. Sato, N. Ohmagari
(Sunto-gun, Tokyo, JP)
Objectives: One of the most important risk factors for candidemia is
malignancy, especially in the gastrointestinal tract. However, the details
of the type of gastrointestinal tract malignancies or the anatomic site
of origin of the malignancies associated with this risk are not well
documented. Also reports on the characteristics of candidemia among
cancer patients in Japan are scarce.
Methods: The records of all consecutive patients with candidemia
diagnosed between January 2006 and December 2008 at the Shizuoka
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cancer centre, a 557-bedded tertiary care cancer centre in Japan, were
reviewed.
Results: There were 85 episodes of candidemia during the study period.
Fifty-four episodes (64%) involved male patients, and 31 (36%) involved
female patients. The median of age of the patients was 62 years (range,
40−83). Eighty-three episodes (98%) occurred in patients with solid
tumours, and only 2 in patients with haematological malignancies. Of the
85 episodes, 62 (73%) occurred in patients with upper gastrointestinal
tract malignancies, including pharyngeal, oesophageal, gastric or hepato-
biliary-pancreatic cancer, while the remaining occurred in the patients
with other malignancies. The leading type of malignancy is gastric
cancer (25 out of 85 episodes; 29%). Fifty-two out of the 85 episodes
(61%), occurred in patients with a history of steroid use, and 49 (58%)
occurred in patients with peritoneal metastasis. Seventy-seven (91%)
of the episodes occurred in patients with insertion of a central venous
catheter or other port devices. Of the patients with a central venous
catheter or other port devices, 73 (95%) episodes had hyperalimentation.
Only seven of the episodes (8.2%) occurred in patients with documented
neutropenia. The 30-day mortality was 29%.
The distribution of the candida species was: 32%, Candida albicans;
31%, Candida grabrata; 22%, Candida parapsilosis; 7%, Candida
tropicalis; 1%, Candida krusei.
Conclusion: These data suggests that gastric cancer may be one of the
most important risk factors for candidemia. In addition, other upper
gastrointestinal tract malignancies are also potential risk factors for
candidemia. Therefore, one of typical clinical pictures of candidemia in
Japan would be a non-neutropenic and non-haematological patient who
has upper gastrointestinal tract malignancies especially gastric cancer
with peritoneal metastasis, using a central venous catheter or other port
devices for hyperalimentation.
P856 Prospective diagnostic performance of the (1−3)-Beta-D-
glucan assay in haematological patients with invasive
candidiasis
A. Alhambra °, M.S. Cue´tara, M. Catala´n, M.E. Alvarez,
M.D. Moragues, J. Ponto´n, A. del Palacio (Madrid, Legane´s, Bilbao, ES)
Objectives: Diagnosis of invasive candidiasis (IC) is challenging.
Invasive diagnostic procedures are precluded in haematological patients
and traditional microbiologic techniques have low sensitivity. (1−3)-b-D-
glucan (BG) assay is a non-invasive diagnostic tool that may increase
the diagnosis of IC.
Methods: BG detection was performed at the discretion of the clinical
haematological team. We prospectively assessed the serum levels of
BG assay in patients with a compatible clinical syndrome or either at
risk for IC. Conventional microbiologic methods, tissue biopsies, blood
cultures and necropsies together with the assessment of risk factors,
signs, symptoms and radiologic imaging were used for the diagnosis of
IC as deﬁned by De Pauw et al (Clin Infect Dis 2008; 46: 1813). Patients
were stratiﬁed as proposed by Prentice et al (Br J Haematol 2000; 110:
273). ROC curves were used for deﬁning the best BG cutoff.
Results: 98 patients (181 episodes) were included in the study. The
distribution of episodes in relationship with the risk group was: high
risk (n = 72); intermediate high (n = 21); intermediate low (n = 71) and
low (n = 17). The prevalence of IC was 5.10%. With a BG cutoff of 80
pg/mL the sensitivity, speciﬁcity, positive and negative predictive values
were 80, 64.52, 10.81 and 98.36% respectively.
Conclusions: The high negative predictive value of BG can exclude
reasonably IC in haematological patients even though 80% of patients
in our cohort were treated prophylactically with antifungals. In our
population the best cutoff for the diagnosis of IC was 80 pg/mL.
Acknowledgments: This investigation was supported by grants Fondo
de Investigacion Sanitaria, Instituto de Salud Carlos III, Proyecto
Investigacion PI 070134 (to MSC), PI 070107 (to A d P) and PI 070376
(to JP), grant IT-26407 of Departamento de Educacion, Universidades e
Investigacion del Gobierno Vasco (to JP) and Saiotek from Departamento
de Industria, Comercio y Turismo del Gobierno Vasco (to JP) and an
Educational grant from Pﬁzer (to A d P) and Gilead Spain (to A d P).
Characteristics of 5 patients with proven IC
No. Risk group Underlying
disease1
Site of
isolation
Candida spp. Prophylaxis No. of
serum
samples
No. of
+ve sera
Highest
BG
level
1 High intermediate AML Blood C. albicans Fluconazole 23 1 80
2 High NHL Blood C. albicans Fluconazole 5 2 134
3 High BL Blood C. krusei Itraconazole 16 6 158
4 Low intermediate CLL Blood/liver C. parapsilosis None 5 0 45
5 Low CLS Blood C. albicans None 4 4 1216
1AML: Acute myeloid leukemia; NHL: Non-Hodgkin’s lymphoma; BL: Burkitt lymphoma; CLL: Chronic
lymphocytic leukemia; CLS: Chronic lymphocytic syndrome.
P857 Trends in frequency, species distribution and antifungal
susceptibility of fungal bloodstream isolates of paediatric
patients, 2000–2009
E. Romanowska °, P. Nadkowska, B. Garczewska, D. Dzierzanowska
(Warsaw, PL)
Objectives: In the last decade we have observed a decrease of infections
caused by Candida albicans, and a shift towards non albicans species and
occurrence of other fungal genus. The aim of this study was to determine
the aetiology, frequency and antifungal susceptibility of clinical fungal
strains isolated from blood samples of paediatric patients hospitalized in
The Children’s Memorial Health Institute.
During a 10-year period time from 2000 to 20 November 2009 were
analized 158 isolates obtained from positive blood cultures of 127
patients.
Methods: The clinical material was peripheral blood directly incubated
in automated Bact/Alert system (bioMe´rieux). After receiving positive
cultures of blood specimens, fungal isolates were identiﬁed by their
morphological and biochemical features by using ID 32C (bioMe´rieux)
and microscoping (moulds). Antifungal susceptibility was assessed using
ATB Fungus tests (bioMe´rieux).
Results: Mycological assays conﬁrmed in 158 cases candidiases with
fungemia. The highest number of these infections occurred in the
oncological ward (27.2%), nutrition and paediatrics ward (19.5%),
intensive care unit (18.3%), transplantology and surgery ward (9.4%
and 8.2% respectively). Other wards with a lower than 3% occurrence
of fungemia were: cardiology, immunology, urology, neonates and
intensive care neonates ward. The main aetiological factor was Candida
parapsilosis (40%) followed by C. albicans (35.5%), C. tropicalis
(5.7%), C. glabrata (3.8%) and Saccharomyces cerevisiae (3.8%). Other
identiﬁed fungal species: C. famata, C. intermedia, C. lusitaniae,
C. guilliermondii, C. kefyr, C. krusei, C. dubliniensis, Trichosporon
asahii, Fusarium chlamydosporum. Majority of C. albicans strains were
sensitive to amphotericin B (100%) and ﬂuconazole (96.4%). Among
non-albicans strains increasing resistance to ﬂuconazole was found:
C. parapsilosis (11.1%) and C. tropicalis (22%). One from 150 clinical
Candida spp strains was resistant to voriconazole (C. glabrata).
Conclusions:
– Candida albicans was a predominant etiological factor of fungemia
till year 2005.
– Increasing prevalence of non albicans candidiemias was observed with
a beneﬁt towards C. parapsilosis.
– Received isolates show increasing occurrence of Candida species with
genetical resistance to ﬂuconazole and amphotericin B and appearance
of other fungal genus: Saccharomyces, Trichosporon, Fusarium.
– Candida blood infections showed increasing resistance to ﬂuconazole
and itraconazole.
P858 Epidemiology of candidaemia in an Italian tertiary hospital
during a 5-year period: January 2004-December 2008
A.M. Azzini, A. Tedesco °, G. Lo Cascio, F. Soldani, P. Sette,
M. Cordioli, E. Concia (Verona, San Bonifacio, IT)
Objective: To evaluate trends in candidaemia (CA) between 2004 and
2008.
Methods: All CA episodes were retrospectively identiﬁed and
demographic/clinical characteristics, data about systemic antifun-
gal/antibacterial drugs and others predisposing factors within the 2
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weeks before its onset were collected, including catheter-related CA.
The antifungal susceptibility patterns of isolated species were collected.
Results: 170 episodes of CA were identiﬁed, 91.2% hospital acquired.
The average incidence of CA was 1.72/10000 patient-days, ranging from
1.71 in 2004 to 1.31 in 2008, with a peak of 2.53 in 2005. 29.4% of
CA occurred in ICUs, followed by surgical and medical wards (both
28.2%) and neonatal intensive care unit (NICU) (14.1%). Table 1 shows
demographic characteristics, comorbidities and predisposing factors of
the studied population. C. parapsilosis was isolated in 41.8% of cases,
followed by C. albicans (34.1%), C. glabrata (14.7%), C. tropicalis
(2.9%) and C. krusei (1.8%). Non-albicans species exceeded C. albicans
during the entire study period.
29.6% of CA was persistent. CVC-related CA were 31.2%, in 74.6%
of them CVC was removed but in 26.2% later than 48 hours from the
diagnosis.
84.4% of patients received antifungal therapy: in 59.2% of cases
it started within 48 hours from the diagnosis. It was adequate in
62.5% for posology and in 56.6% for the susceptibility pattern of the
isolated mycete. Fluconazole was employed in 67.8%, followed by any
amphotericin B lipid-formulation (44.8%) and caspofungin (13.2%). No
azole-resistant C. albicans was isolated, 2.8% of C. parapsilosis was
ﬂuconazole-resistant. The 30-day crude mortality rate was 34.6%.
Table 1
Characteristics Ward
Total
(n = 170)
NICU
(n = 24)
ICU (n = 50) Surgical
(n = 48)
Medical
(n = 48)
Age (range) 53.9 (0−92) 20.3
(7−74)a
63.6 (17−86) 63.9
(21−92)
60.5 (7−92)
Sex (male) 105 (61.8) 12 (50.0) 28 (56.0) 33 (68.7) 32 (66.7)
Illness severity
McCabe 1 40 (23.5) 3 (12.5) 9 (18.0) 12 (25.0) 16 (34.8)
McCabe 2 98 (57.6) 5 (20.8) 28 (58.0) 35 (72.9) 27 (58.7)
McCabe 3 32 (18.8) 16 (66.7) 12 (24.0) 1 (2.1) 3 (6.5)
Severe sepsis/shock 34 (20.0) 4 (16.6) 22 (44.0) 5 (10.4) 8 (6.3)
WBC/neutrophils 11587/9073 15265/− 12522/10629 11213/9307 8939/6870
Comorbidities 143 (84.1) 24 (100.0) 43 (86.0) 40 (83.4) 38 (79.2)
Diabetes 27 (15.9) 0 (0.0) 12 (24.0) 9 (18.8) 6 (12.5)
Solid neoplasm 63 (37.1) 0 (0.0) 19 (38.0) 32 (66.7) 12 (25.0)
Haematological neoplasm 18 (10.6) 0 (0.0) 5 (10.0) 1 (2.1) 8 (16.7)
Transplant 1 (0.6) 0 (0.0) 0 (0.0) 1 (2.1) 0 (0.0)
HIV/AIDS 5 (2.9) 0 (0.0) 1 (2.0) 0 (0.0) 4 (8.3)
Rheumatic disease 10 (5.9) 0 (0.0) 4 (8.0) 1 (2.1) 5 (10.4)
VLBW 19 (11.2) 19 (79.1)b 0 (0.0) 0 (0.0) 0 (0.0)
Chronic liver disease/
chronic renal failure/COPD
81 (47.6) 5 (20.8) 35 (70.0) 19 (39.6) 25 (52.1)
Risk factors 170 (100.0) 24 (100.0) 50 (100.0) 48 (100.0) 48 (100.0)
TPN 119 (70.0) 23 (95.8) 28 (56.0) 33 (68.7) 35 (72.9)
CVC 154 (90.6) 24 (100.0) 48 (96.0) 38 (79.1) 44 (91.7)
CVC non tunnelled 119 (70.0) 6 (25.0) 46 (92.0) 34 (70.8) 35 (72.9)
CVC tunnelled 16 (9.4) 1 (4.2) 7 (14.0) 5 (10.4) 11 (22.9)
PICC 12 (7.1) 12 (50.0) 0 (0.0) 0 (0.0) 0 (0.0)
umbilical 17 (10.0) 17 (70.8) 0 (0.0) 0 (0.0) 0 (0.0)
Urethral catheter 109 (64.1) 3 (12.5) 47 (94.0) 32 (66.7) 27 (56.2)
VM 81 (47.6) 21 (87.5) 38 (76.0) 13 (27.0) 9 (18.7)
Neutropenia 10 (5.8) 0 (0.0) 3 (6.0) 0 (0.0) 7 (14.6)
Steroids 36 (21.2) 0 (0.0) 11 (22.0) 8 (16.7) 17 (35.4)
Chemotherapy 11 (6.5) 0 (0.0) 3 (6.0) 0 (0.0) 8 (16.7)
Immunosuppressors 7 (4.1) 0 (0.0) 1 (2.0) 3 (6.2) 3 (6.3)
GVHD 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Transplantation 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Dialysis 9 (5.2) 0 (0.0) 8 (16.0) 0 (0.0) 1 (2.1)
Surgery 93 (54.7) 4 (16.7) 32 (64.0) 40 (83.3) 18 (37.5)
abdominal 72 (42.3) 3 (12.5) 26 (52.0) 34 (70.8) 10 (20.8)
pancreatic 23 (13.5) 0 (0.0) 9 (18.0) 22 (45.8) 1 (2.1)
Re-intervention 29 (17.1) 1 (4.2) 14 (28.0) 9 (18.7) 4 (8.3)
Stay in intensive care 98 (57.6) 24 (100.0) 50 (100.0) 16 (33.3) 13 (27.0)
Length of stay (range)a 17.6 (1−84) 20.2 (7−74) 20.2 (1−74) 9.1 (1−39) 14.1 (1−84)
3 days 87 (51.2) 24 (100.0) 44 (88.0) 14 (29.1) 10 (20.8)
Antibiotic therapyc 150 (88.2) 22 (91.6) 43 (86.0) 44 (91.6) 41 (85.4)
Antimycotic prophylaxisc 43 (25.3) 6 (33.3) 14 (28.0) 9 (18.7) 14 (29.1)
With azolics 34 (20.0) 4 (16.6) 13 (26.0) 8 (16.7) 13 (27.0)
WBC, white blood cell; TPN, total parenteral nutrition; CVC, central venous catheter; PICC, peripheral inserted
central catheter; VM, mechanical ventilation; GVHD, Graft versus host diseases; NICU, neonatal intensive care
unit; ICU, intensive care unit.
a In days. b18 (75.0%) premature infants with ELBW (extremely low birth weight). cDuring previous 2 weeks for
at least 3 consecutive days.
Conclusions: The annual incidence of CA was high but in decline
after a peak in 2005. CA was more frequent in ICU and NICU (24.7
and 6.5/10000 patient-days), followed by surgical and medical wards.
Incidence rates in surgical wards was slightly higher than that in medical
ones: in the ﬁrst ones there was a greater frequency of abdominal and
pancreatic surgery, but in the second a wider use of CVC, TPN and
steroids. CVC related CA was about 30% (44.2% by C. albicans;37.2%
by C. parapsilosis)despite of the use of this device. Of interest is the
high frequency of non albicans species due to a relative greater number
of C. parapsilosis and C. glabrata.Worrisome is their frequent resistance
or S-DD susceptibility to ﬂuconazole, related to a wider use of the drug
the year before the peak in reduced susceptibility.
P859 Should fungi be monitored in hospital-related
drinking-water?
M.L. Pedro-Botet °, I. Sanchez, M. Batlle, L. Mateu, C. Barrenetxea,
A. Sanchez, R. Duarte, M. Rovira, J. Estella, A. Llorente, D. Gallardo,
I. Jarque, D. Serrano, J. Sanchez de Toledo, L. Vazquez, M. Sabria
for the Proiﬁ Study Group CIBERes), Spain
Drinking-water, although potable, may contain a range of microorgan-
isms including non-fermentors gramnegative bacilli,Mycobacterium spp.
and fungi not suitable for some patients within health care facilities.
Speciﬁc regulation on hospital potable water does not exist.
Objective: To investigate fungi in drinking-water of Departments of
Hematology (DH).
Methods: Annual fungal investigation (since July 2008) of cold (CW)
and hot (HW) water from DH and 3-yr surveillance of hospital-acquired
invasive fungal infection (IFI) in patients undergoing hematopoietic
progenitor transplantation (HPT) or leukemic patients on intensive
chemotherapy (LPIC).
Results: 12 DH were included. The mean follow-up was 10.5 months
(6−16m). Fungi were isolated in 119 (54%) of 220 water samples,
cold water samples (62/118;74%) were colonized signiﬁcantly more
frequently than hot water samples (45/102; 44.1%). Analysis of different
types of fungi showed that septated molds were the most prevalent (73,
33.1%) with Penicilium spp., Cladosporium spp. and Alternaria spp.
being of note. Aspergillus and Fusarium were found in 2 (1 in hot and
1 in cold) and 6 (2 in hot and 4 in cold) water samples, respectively.
Zygomycetes were isolated in 10 (2 hot and 8 cold) water samples with
Rhizopus spp. being the most prevalent. The prevalence of yeasts was
16.4% (36/220). Only 2 cases of hospital-acquired probable invasive
aspergillosis were detected. Aspergillus was not recovered in patient-
related water samples.
Conclusions: Fungal colonization amongst water samples in DH is high
(54%). CW in DH is colonized signiﬁcantly more frequently than HW.
Regulations on hospital potable water are warranted.
Pulmonary mycoses
P860 The diagnosis of pulmonary mycoses: histomorphological
criteria contra immunohistochemical reactivity
H.E. Jensen ° (Frederiksberg, DK)
Objectives: As a consequence of even suspecting the presence of
pulmonary mycoses clinically, cases are often not diagnosed until
histopathology is applied. Distinctive morphological details may provide
a tentative identiﬁcation, but the appearance of fungi in tissue sections
is affected by steric orientation and age of the fungus. Moreover, sharing
of morphological similarities and the presence of sparse and/or atypical
fungal elements will hamper a clear-cut diagnosis. In the present study,
the histomorphological diagnosis in 55 cases of pulmonary mycoses was
compared with the diagnosis obtained immunohistochemically.
Methods: In order to obtain a second opinion, a total of 55
pulmonary mycosis cases were received from 1996 to 2009. The
suspected diagnoses were as follows: aspergillosis: 29; aspergillosis
and candidosis: 6; zygomycosis: 8; and unidentiﬁed: 12. All cases
were immunohistochemically screened with three commercial available
antibodies from AbD Serotec reacting speciﬁcally with agents of
aspergillosis (MCA 2576), candidosis (1750–5557), and zygomycosis
(MCA 2577). Difﬁculties for obtaining a correct histomorphological
diagnosis were evaluated, too.
Results: A correct diagnosis of aspergillosis and zygomycosis was
upheld in 76% and 88%, respectively. The suspicion of a dual
infection of aspergillosis and candidosis was only conﬁrmed in 1 case,
whereas aspergillosis and candidosis alone was diagnosed in 4 and 1
cases, respectively. Aspergillosis was confused with zygomycosis in
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4 cases, and aspergillosis and candidosis in 2 cases. Only 1 case of
zygomycosis was misdiagnosed as aspergillosis. Unidentiﬁed cases were
identiﬁed as aspergillosis (n = 4). Zygomycosis (n = 1), aspergillosis and
candidosis (n = 1), candidosis (n = 2). Four cases remained unidentiﬁed
together with one suspected aspergillosis case, which failed to react
immunohistochemically. Diagnostic histomorphological criteria were
especially challenged in chronic lesions which contained massive
necrosis, and when only few fungal elements were present.
Conclusion: The application of immunohistochemistry changes the
histomorphological diagnoses in 28% of the cases. Moreover, the
technique diagnosed 67% of 12 unidentiﬁed causes of pulmonary
mycoses. Therefore, the application of the present series of antibodies in
immunohistochemical techniques will be advantageous for achieving a
more complete identiﬁcation of fungi, which is mandatory for an optimal
treatment strategy.
P861 Yeasts and mycelial fungi in lung cavities of tuberculosis
patients
A. Kulko °, P. Dreval (Moscow, RU)
Objective: To analyze the outcomes of seven-year mycology studies of
lung cavities contents of pulmonary tuberculosis (TB) patients.
Methods: Microscopy and culture (Sabouraud medium with chloram-
phenicol) of samples from lung cavities (aspirates, materials of biopsies
and resections); species identiﬁcation of isolated strains of yeasts
(morphological properties on chromogenic media: CandiSelect® 4,
Bio-Rad Labs. and chromID® Candida, bioMe´rieux; biochemical
properties: Auxacolor® 2 test-system, Bio-Rad Labs.) and mycelial fungi
(conventional methods, identiﬁcation media: Czapek-Dox and potato
dextrose agar).
Results: In 2002–2009 we studied samples from lung cavities (caverns,
tuberculomas, cysts, aspergillomas) of 264 pulmonary TB patients.
Cultural studies revealed fungi in 59 patients. The isolated strains
belonged to 18 species of 9 genera: yeasts − Candida (4 species),
Geotrichum (1); mycelial fungi − Alternaria (1), Aspergillus (6),
Cladosporium (1), Fusarium (1), Paecilomyces (1), Penicillium (2),
Rhizopus (1). The fungi from the genus Aspergillus were found in lung
cavities of 36 patients: A. fumigatus − in 23 patients, A. ﬂavus − in 3,
A. niger − in 4, A. restrictus − in 2, A. terreus − in 3, A. versicolor −
in 1. The fungi from the genus Candida were found in 10 patients:
C. albicans − in 5 patients, C. glabrata − in 3, C. kefyr − in 1,
C. tropicalis − in 1. It is important to note, that the fungi isolated from
lung cavities of 21 out of 59 (35.6%) patients were also revealed from
bronchoalveolar lavage ﬂuid (BAL) and/or sputum.
Conclusions: Lung cavities in TB patients represent an essential risk
factor for opportunistic pulmonary mycosis. Development of secondary
pulmonary aspergillosis (aspergilloma, other forms of pulmonary
aspergillosis) is very likely in such patients. If fungi are found in a
lung cavity, it is advisable to perform additional mycology studies of
sputum and BAL.
P862 First quantitative data on Pneumocystis jirovecii spread in
the air surrounding PCP patients
F. Choukri °, J. Menotti, C. Sarfati, J.C. Lucet, G. Nevez, Y. Garin,
F. Derouin, A. Totet (Paris, Brest, Amiens, FR)
Objectives: Airborne transmission of Pneumocystis has been demon-
strated in animal models and is strongly suspected between humans.
However, information concerning the fungal burden of Pneumocystis
in the environment is still lacking. Our objectives were to quantify
P. jirovecii (the human-derived Pneumocystis species) and estimate its
diffusion in the air surrounding patients with Pneumocystis pneumonia
(PCP), using a high-volume sampler combined with a real-time PCR
assay for P. jirovecii detection and quantiﬁcation.
Methods: Hospitalized patients with conﬁrmed PCP were prospectively
enrolled from January 2008 to July 2009. As early as possible after
diagnosis of PCP, air samples were collected at different distances from
PCP patients’ heads (1, 3, 5 and 8 m) i.e. inside and outside the
patient room. Control samples were collected away from patient wards
and outdoors. At each place, 1,500 L of air were collected using the
Coriolis air sampler (Bertin technologies) which ﬁnally delivers a 10mL
liquid sample. Detection and quantiﬁcation of P. jirovecii DNA in the
collected liquid medium were performed using a real-time PCR assay
targeting the mitochondrial large subunit rRNA gene of P. jirovecii.
Plasmid suspensions were used as standards for quantiﬁcation, giving
the correspondence between threshold cycle (Ct) values and the copy
number per microL of extracted DNA. The detection limit was estimated
at 7 copies/microL of extracted DNA.
Results: Air samples were collected in the environment of 19 PCP
patients. At a 1-meter distance from patients’ heads, P. jirovecii DNA was
detected in 15/19 (79.8%) cases, with fungal burdens ranging between
7.5 103 and 4.5 106 gene copies/m3. These levels decreased with distance
from the patients (p< 0.002), but 4/12 (33.3%) of the samples taken at
8 meters (i.e. in the corridor adjacent to their room) were positive. The
forty control samples were PCR negative for P. jirovecii detection.
Conclusion: Our method is efﬁcient to quantify P. jirovecii fungal
burdens in the air and to estimate its diffusion in the environment of
patients with PCP. This study provides the ﬁrst quantitative data on
the spread of P. jirovecii in the air, and supports the risk of direct
transmission in the proximity of patients with PCP. These results make
it possible to estimate hazard exposure, and open the ﬁeld for PCP
microbial quantitative risk assessment.
P863 Risk factors for Pneumocystis jirovecii pneumonia in kidney
transplant recipients and appraisal of strategies for selective
use of prophylaxis
M.G. de Boer °, F.P. Kroon, S. le Cessie, J.W. de Fijter, J.T. van Dissel
(Leiden, NL)
Selective use of Trimethoprim-Sulfamethoxazole (TMP-SMX) or alter-
native chemoprophylaxis for Pneumocystis pneumonia (PcP) in kidney
transplant recipients based on risk factor analysis is not a universally
adapted strategy and evidence based sources are limited. In a large
retrospective case–controlled study, potential risk factors for PcP in
kidney transplant recipients were investigated to deﬁne parameters for
use in clinical prediction rules and guidelines that could optimize PcP
prophylaxis in this population. Fifty-two cases were identiﬁed between
January 1983 and September 2008; PcP incidence was 2.7% per 1000
transplantations and developed between 60 days and 24 months post
transplantation in 85% of cases. For each case two time-matched controls
were enrolled. The complete analysis was performed in a time-matched
statistical model (using STATA) to prevent periodical bias. At baseline,
age >55 years and use of basiliximab were predictive for development
of PcP (adjusted odds ratio’s 2.7 and 0.2). CMV infection within 3
months prior to PcP (OR 3.0 95%CI 1.2−7.8) and treatment for rejection
(OR 5.8 95%CI 1.9–17.5) were independently associated with PcP
in a multivariate analysis. Increasing numbers of rejection treatments
correlated with higher risks and shorter times between transplantation
and PcP. A prediction model derived from the data indicated that
incidences between 1.0% and 5.0% and low mortality, allow a choice
for selective prophylaxis targeting the ﬁrst 6 months for all- and the ﬁrst
year post transplantation for patients >55 years of age and those treated
for rejection to avoid unneeded TMP-SMX side effects while achieving
a PcP incidence <1.0%. Furthermore, a strategy of not prescribing
prophylaxis, except to those at extremer risk (e.g. after 3 or more
treatments for rejection), can be pursued when PcP incidence is <1.0%
over a prolonged period of time. Caveats however still exist: in case of
sudden rises in incidence or ‘outbreak’, this strategy should be readily
abandoned and replaced by more intense use of prophylaxis. Current
guidelines may be reﬁned accordingly although validation of selective
risk based strategies for PcP prophylaxis requires prospective evaluation.
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P864 Different protein expression pattern induced by Pneumocystis
jirovecii colonization in idiopathic interstitial pneumonia
patients
V. Friaza °, R. Morilla, C. De La Horra, N. Respaldiza,
M.A. Montes-Cano, S. Gutierrez, J. Martin Juan, J.M. Varela,
J. Medrano, E. Calderon (Seville, ES)
Background: It has been describe the presence of Pneumocystis jirovecci
colonization in Idiopathic Interstitial Pneumonia (IIP) patients. However
the role of Pneumocystis play in the physiopathology of these diseases
remains still unknown. Pneumocystis colonization could induce changes
on the protein expression in its host. To identify these alterations could
help to understand the role of Pneumocystis in IIP.
Aim: To determinate difference induced by Pneumocystis colonization
in protein expression in IIP patients.
Methods: BALF from 10 well characterized NII patiens (5 colonizated
and 5 non-colonized by P jirovecii) were collected and centrifuged
to 600xg during ten minutes and supernatant were pooled separately.
Supernatant pooled were concentrated with Microcon Ultracel YM-3
(Millipore) and 200 ug of total proteins was Albumin and IgG depleted
using the Depletion Spin Trap Kit of GE Healthcare. Resultant proteins
were methanol:chloroform precipitated and following resuspended in
0.1% SDS to proceed trypsin digest, ITRAQ Labelling and LC-MS/MS
analysis.
Results: 136 different proteins were detected in BAL ﬂuid. High conﬁ-
dence sequence information and expression level for 65 polypeptides,
including metabolic enzymes, immunity-related proteins, surfactant
associated protein, calcium-binding proteins, redox protein, peptidases
and proteases. Thirty-four proteins displayed higher levels of expression
in colonized patients and twenty-eight presented lower levels in colonized
patients.
Conclusion: There are difference protein expression pattern probably
related with P. jirovecii colonization in IIP patients. These data deserve
further researches for unravelling the role of P. jirovecii colonization.
This study was supported by ERA-NET PathoGenoMic GEN2006–
27760-E/pat, Consejeria de Salud Junta de Andalucia PI 0391/2007 &
FIS PI080983.
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P865 Preliminary study on antifungal susceptibility and molecular
relatedness of Candida glabrata in intensive care units
M.E. Fadda, M. Deplano, M.B. Pisano, R. Podda, G.S. Podda,
S. Cosentino ° (Monserrato, Cagliari, IT)
Objectives: Candida glabrata is now emerging as an important human
pathogen responsible for candidemia. The prevalence of C. glabrata has
increased in the last decade and this species has recently emerged as
signiﬁcant pathogen in critically ill patients in Intensive Cure Units
(ICU).
The objective of this preliminary study was to deﬁne antifungal
susceptibility and molecular relatedness of C. glabrata isolates recovered
from colonizing and invasive sites of patients hospitalized in the ICUs
of two hospitals during a 12 month period.
Methods: Antifungal susceptibility proﬁle to amphotericin B, ﬂucona-
zole, itraconazole, ketoconazole, voriconazole, and caspofungine was
determined by disk diffusion method. Polymerase Chain Reaction (PCR)
ﬁngerprinting with the oligonucleotide 5′-GAGGGTGGCGGTTCT-3′
(M13) as single primer was used for a rapid molecular genotyping. A
total of 53 C. glabrata isolates from 22 patients were considered.
Results:Most of C. glabrata isolates were observed in pharyngeal swabs
and in feces or rectal swabs. A good sensibility to amphotericin B was
observed among isolates from both ICUs. All the strains were resistant
or DDS to itraconazole and ketoconazole. Among the 31 C. glabrata
isolates that were resistant or SDD to ﬂuconazole, 18 (58%) had a low
sensibility to voriconazole. At a 60% similarity the isolates were grouped
in two clusters. Several patients were colonized by similar isolates
in different anatomic sites supporting an endogenous transmission.
Similar RAPD-PCR proﬁles found from isolates from different patients
suggesting an exogenous acquisition.
Conclusions: Our preliminary study has contributed to monitor trends
of resistance to antifungal drugs. Caution is advised when considering
voriconazole therapy for C. glabrata candidemia in setting that predict
“older” (ﬂuconazole, itraconazole, ketoconazole) azoles resistance.
RAPD with the M13 primer was effective for C. glabrata typing as
it differentiated multiple isolates from different patients and was able
to ﬁnd colonization with similar isolates in different anatomic sites
of the same patient. Our results suggest a possible cross transmission
of C. glabrata strains and support the importance of a continued
epidemiological surveillance, particularly in the ICUs.
P866 Identiﬁcation of Candida by the PCR and microarray-based
Prove-it™ Sepsis assay
A. Aittakorpi, P. Kuusela, P. Koukila-Ka¨hko¨la¨, M. Vaara, M. Petrou,
V. Gant, M. Ma¨ki ° (Helsinki, FI; London, UK)
Objective: Prove-it™ Sepsis assay is a rapid, broad-range PCR and
microarray-based assay designed to identify the majority of sepsis-
causing bacteria. The pathogen panel covers 50 Gram-negative and
Gram-positive bacterial species. It also reports meticillin resistance by
detecting the mecA gene. The assay has been clinically validated using
positive blood cultures (speciﬁcity 99%, sensitivity 95%). After the
validation, the test has been further developed to identify 8 Candida spp.
This study aims to evaluate the performance of yeast identiﬁcation of
the Prove-it™ Sepsis assay.
Methods: 3318 blood samples from patients with suspected sepsis were
collected in Helsinki University Central Hospital Laboratory (HUSLAB;
Finland) and in University College London Hospital (UK). Blood culture
bottles of BacT/ALERT 3D (bioMe´rieux) and BACTEC 924 (Becton
Dickinson) were incubated for a total of 6 days or until ﬂagged
as positive. DNA was extracted from blood cultures using the DNA
extraction instrument easyMAG (bioMe´rieux) and stored at −20ºC prior
to the Prove-it™ Sepsis assay. Conventional identiﬁcation was done for
all positive samples and DNA extracts of positive yeast samples were
selected for the Prove-it™ Sepsis analysis of 3 hours assay time.
Results: Of the analyzed 3318 blood cultures, 2107 were positive by
conventional identiﬁcation methods. Of these, yeast was detected in
44 (2.1%) samples. Prove-it™ Sepsis assay identiﬁed Candida species
from 43 samples, having yeast coverage of 97.8%. Prevalence of
identiﬁed Candida spp. were: 73% C. albicans, 14% C. glabrata, 5%
C. tropicalis, 5% C. lusitaniae, and 2% C. parapsilosis. From two
samples containing two different Candida species, only one of them was
identiﬁed. Otherwise there was no discordance between identiﬁcation
results obtained by conventional methods and the Prove-it™ Sepsis assay.
No cross-hybridizations with bacterial capture oligonucleotides of the
assay, leading to false bacterial identiﬁcation, were observed.
Conclusions: The rapid and accurate Candida identiﬁcation from
positive blood cultures by modiﬁed Prove-it™ Sepsis provides a novel
tool for a faster and more evidence-based patient management which
is known to contribute to a positive outcome. Currently, the evaluation
of Prove-it™ Sepsis assay is continued blindfold with higher amount of
clinical yeast samples.
P867 The challenges and feasibility of validating molecular
diagnostic kits on multiple real-time PCR platforms
S.A. Follett °, R. O’Neill, K. Radej, A. Moody (Manchester, UK)
Purpose: The MycAssay family of molecular diagnostic real-time PCR
assays are designed to enhance the speed, sensitivity and speciﬁcity of
fungal diagnosis and are initially validated on the Cepheid SmartCycler.
However, for broad application across the fungal community, they need to
run on multiple platforms, thus offering a commercial, standardised assay
suitable for all potential users with their existing laboratory equipment.
Although the chemistry of the assays are designed to work with the
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majority of real-time PCR instruments, the reality of conducting platform
transfer studies for an in vitro diagnostic assay is not simple.
Methods: Common commercially available real-time PCR platforms
were assessed and prioritised for platform transfer. The MycAssay
Aspergillus assay was tested on a number of different platforms during
assay optimisation. Each platform was assessed for suitability by
determining efﬁciency, as well as the ability to reliably distinguish
negative samples. Replicate runs were performed to check that threshold
and other analysis settings were robust. Platforms satisfying these criteria
were then used for validation studies to satisfy the requirements for
in vitro diagnostic devices.
Results: The list of PCR platforms that can support the MycAssay family
of products includes; AB7500, RotorGene Q, Stratagene MX3005P,
Roche LightCycler 2.0 and Bio-Rad CFX96. Initial formulation testing
with the MycAssay Aspergillus product showed acceptable results for
both the Aspergillus and internal ampliﬁcation control reactions on all
platforms, allowing use in the research setting. However, the ability to
consistently reproduce results, as required for a CE-marked diagnostic,
varied between platforms. The source of this variation appears to be
in the platform speciﬁc interpretative software. In addition, while very
similar, Ct (or equivalents) results were not 100% comparable across
platforms.
Conclusions: Initial tests with molecular diagnostic assays may indicate
suitability on multiple real-time PCR platforms. However, the work
required to ensure long-term robustness can be far more complex than
expected. While raw data can look normal, analysis algorithms within
each manufacturer’s software programs can cause the generation of
discrepant ampliﬁcation curves and false positive results. Therefore,
before a molecular diagnostic kit can reliably be used on multiple
platforms it must undergo the meticulous testing required for CE-
marking standards.
P868 Puriﬁcation of cell-bound and free circulating bacterial,
fungal and viral nucleic acids from large blood volumes
using the QIAamp® pure pathogen nucleic acid kit
T. Doedt °, S. Martsch, D. Heckel (Hilden, DE)
Objective: The objective of this study was to develop a chemistry and
protocol for copuriﬁcation of bacterial, fungal and viral nucleic acids
from large volumes of whole blood (5ml) with the capability to elute
in small volumes (100 ml). To obtain maximal sensitivity, microbial
cell-bound as well as free circulating nucleic acids should be puriﬁed
with parallel depletion of the human DNA background.
Method: Human whole blood was spiked with various viruses, bacterial
and fungal cells as well as puriﬁed microbial DNA to mimic free
circulating DNA. The protocol was evaluated by determination of
pathogen nucleic acids by quantitative real time (rt)PCR, as well as
total DNA by UV/Vis spectroscopy. Performance was further compared
to commercially available reference kits.
Results: The QIAamp® Pure Pathogen Nucleic Acid Kit showed highest
yield of cell-bound and free circulating bacterial, fungal and viral
nucleic acids when compared to reference kits, which were either limited
in blood input volume or not capable of depleting the human DNA
background. These results could be obtained by splitting the blood
sample into plasma and a cellular fraction. The latter is partially lysed to
release the human genomic DNA, which in a subsequent centrifugation
is separated from the non-lysed microbial cells. The microbial nucleic
acids are released in a second, mechanical lysis step and combined
with the previously collected plasma, which is then subjected to a high-
volume silica-membrane based sample preparation. The QIAamp® Pure
Pathogen Nucleic Acid Kit was the only kit in this study, which was able
to deplete the human DNA background (90%) while concentrating viral
and free circulating nucleic acids in addition to cell-bound microbial
nucleic acids.
Conclusions:
• The QIAamp® Pure Pathogen Nucleic Acid Kit is the ﬁrst published
protocol enabling highly sensitive puriﬁcation of bacterial, fungal and
viral nucleic acids with parallel depletion of human DNA.
• The silica membrane based protocols enable high input volumes
(3−8ml whole blood) and elution in volumes as small as 20ml allowing
enrichment of pathogen nucleic acids by a factor of 400.
• The copuriﬁcation of microbial cell-bound and free circulating nucleic
acids allow for maximal sensitivity.
• The protocol provides nucleic acids that perform well in sensitive
downstream applications such as real-time PCR and RT-PCR.
P869 Species identiﬁcation of non-sporulating moulds
characterized as Mycelia sterilia isolated from clinical
specimens by molecular methods
D.W. Santos, V.R. Azevedo, S.S. Gonc¸alves, S. Mesquita, A.S. Melo °,
A.L. Colombo (Sao Paulo, BR)
In the last years, phaeohyphomycosis are increasing as subcutaneous
infections, with potential for blood and visceral dissemination. Some
dark moulds isolates cannot growth and sporulate on different media,
making impossible the identiﬁcation by conventional methods.
Objective: Our goal was to identify the species of isolates characterized
as Mycelia sterilia obtained from clinical samples using ITS region
sequencing.
Methods: Clinical samples were obtained from 9 patients: eight kidney
recipient patients who developed subcutaneous fungal infections and
one case of keratitis. All fungal infections had the diagnosis conﬁrmed
by histopathology using speciﬁc dyes for fungal detection (Grocott and
Fontana-Masson) and conventional culture (growth of Mycelia sterilia).
Since the histopathology showed septated demaceatious hyphae and the
culture identiﬁed nonsporulating fungi for all of these clinical samples,
the mycelia of these cultures were submitted to DNA extraction using
PrepMan Ultra kit. PCR assays were run to amplify the ITS region
of rDNA gene and the amplicons were sequenced. The sequences
were submitted for comparison on genebanks (National Center for
Biotechnology Information and Centraalbureau voor Schimmelcultures)
for species identiﬁcation.
Results: All culture results exhibited nonsporulating mycelia despite
using different speciﬁc media for inducing sporulation. After ITS region
ampliﬁcation and sequencing, the amplicon sequences were submitted to
the genebank sites for comparison to the databases. The basic alignment
search tool demonstrated high identity values (>98%) for all the isolates
tested. We obtained the following species identiﬁcation: Alternaria
alternata (2), Alternaria tenuissima (1), Cochliobolus lunatus (2),
Cochliobolus australiensis (1), Botryosphaeria dothidea (1), Ochroconis
gallopava (1) and Ascomycetes sp (1).
Conclusions: Mycelia sterilia isolates were frequently found in culture
recovered from kidney recipient patients under immunosupression with
calcineurin inhibitors. It is not clear whether calcineurin could have
any impact on inhibiting sporulation of ﬁlamentous fungi. ITS region
ampliﬁcation and sequencing was a helpful tool for species identiﬁcation
ofMycelia sterilia isolates and could allow deﬁning the best treatment for
the patients. One isolate was not identiﬁed at the species level, possibly
it may represent a species which ITS reference sequence is not deposited
in genebanks.
P870 Multilocus sequence typing of 156 bloodstream isolates of
Candida albicans from 10 university hospitals in Korea
J.H. Shin °, S. Kim, S.H. Park, M.N. Kim, H.S. Lee, Y. Uh, C.J. Moon,
M. Joo, M.G. Shin, S.P. Suh, D.W. Ryang (Gwangju, Seoul, Jeonju,
Wonju, KR)
Objectives: This study was performed to investigate the clonality of
Candida albicans bloodstream isolates from 10 Korean hospitals, and
to validate Multilocus Sequence Typing (MLST) against pulsed-ﬁeld gel
electrophoresis (PFGE) in the genotyping of C. albicans strains of multi-
institutional origin.
Methods: A total of 156 bloodstream isolates from 156 patients
were obtained from a Korean nationwide surveillance study, conducted
between September 2006 and August 2007. Partial internal sequences of
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seven housekeeping genes (AAT1a, ACC1, ADP1, MPIb, SYA1, VPS13,
and ZWF1b) were determined. PFGE typing was performed as part
of restriction endonuclease analysis of genomic DNAs using BssHII
(REAG-B). Clonal strains were deﬁned by the isolation of more than
two strains of the same diploid sequence type (DST), with the same or
similar REAG-B pattern.
Results: The 156 isolates yielded 114 unique DSTs by MLST. Ninety-
six isolates belonged to new sequence types (89 distinct DSTs), whereas
60 isolates belonged to previously described types (25 DSTs). MLST
revealed that 58 isolates (37.2%) shared 16 distinct DSTs. When the
MLST results were combined with REAG-B, 35 (22.4%) isolates shared
11 genotypes, suggesting clonal strains. Among the 35 clonal isolates, 8
(two isolates from each of four genotypes) came from the same hospitals,
but other genotype isolates came from different hospitals.
Conclusion: The present study shows that C. albicans candidemia
in Korea may frequently involve clonal strains. Additionally, MLST
is needed to clarify genotyping by REAG in clonality analysis of
C. albicans strains of multi-institutional origin.
P871 Lodderomyces elongisporus: ﬁrst report on its isolation and
characterization from clinical specimens in Kuwait
Z. Khan °, S. Ahmad (Safat, KW)
Objective: Lodderomyces elongisporus, is a recently recognized blood-
stream pathogen with phenotypic similarities with Candida parapsilosis
and other members of C. parapsilosis complex. So far, only little
information is available about the geographic distribution of this
species. The aim of this study was to determine its occurrence among
phenotypically identiﬁed C. parapsilosis strains isolated from a variety
of clinical specimens in Kuwait.
Methods: A total of 165 strains identiﬁed as C. parapsilosis by Vitek2
yeast identiﬁcation system were studied. All the isolates were cultured
on BBLTM CHROMagar Candida for development of turquoise blue
color colonies for provisional identiﬁcation of L. elongisporus. The
identity of the isolates was further studied on BBLTM Corn Meal
agar for the formation of ascospores. The unequivocal identiﬁcation of
L. elongisporus was conﬁrmed by direct DNA sequencing of internally
transcribed spacer (ITS)-1 and ITS-2 regions of rDNA.
Results: Of the 165 isolates cultured on Chromagar Candida, two strains
produced turquoise blue color colonies and also formed ascospores on
Corn Meal agar as well as on Malt extract agar. They were tentatively
identiﬁed as L. elongisporus. The isolates originated from the tip of
central venous catheter and sputum. Direct DNA sequencing of the
ITS region of rDNA conﬁrmed the identiﬁcation of both the isolates
as L. elongisporus. Of the remaining isolates, 158 and ﬁve strains
were identiﬁed as C. parapsilosis and C. orthopsilosis, respectively.
The rDNA sequence data of all ﬁve C. orthopsilosis and four randomly
selected C. parapsilosis strains were consistent with their species-speciﬁc
identiﬁcation.
Conclusions: The isolation of L. elongisporus has been reported from
the Middle East for the ﬁrst time. The identity of the two isolates
was conﬁrmed by phenotypic characteristics and DNA sequencing of
rDNA. This report suggests that L. elongisporus may be masquerading
as C. parapsilosis in some cases of invasive candidiasis.
Supported by KURA grant No. MI 01/08.
P872 Rapid detection and identiﬁcation of fungal pathogens by
rolling circle ampliﬁcation using Fonsecaea as a model
M. Najafzadeh °, J. Sun, V. Vicente, S. de Hoog (Utrecht, NL; Parana, BR)
We describe a rapid and sensitive assay for detection and identiﬁcation
of pathogenic fungi without sequencing. The method is presented with
species of Fonsecaea, agents of human chromoblastomycosis, as a model.
The ITS rDNA region of 103 Fonsecaea strains were sequenced and
aligned in view of designing three speciﬁc padlock probes to be used for
the detection of single nucleotide polymorphisms (SNPs) of Fonsecaea
species. The 38 strains included to test the speciﬁcity of rolling circle
ampliﬁcation (RCA) comprised 17 isolates of Fonsecaea pedrosoi, 13
of F. monophora and 8 of F. nubica. The assay proved to successfully
amplify DNA of the target fungi at the level of species; while no cross
reactivity was observed. The ampliﬁcation product was visualized on
a 1% agarose gel to verify the speciﬁcity of probe-template binding.
Amounts of reagents were minimized to avoid the generation of false
positive results. The simplicity, sensitivity, robustness and low costs
provide RCA a distinct position as highly practical method among
isothermal techniques for DNA diagnostics.
P873 Prevalence of C. albicans and dermatophytes in
onychomycosis
G.J. Wisselink °, E. van Zanten, A.M. Kooistra-Smid (Groningen, NL)
Objectives: Onychomycosis is predominantly caused by dermatophytes
with Trichophyton rubrum being the primary causative organism.
However, recent studies report yeast and molds not only as contaminants,
but are increasingly reporting them as pathogens in onychomycosis.
Candida albicans is the most frequently reported cause of candidal
onychomycosis. The aim of this study was to determine the prevalences
of C. albicans and dermatophytes in ﬁnger- and toenail onychomycosis.
Methods: Sixty-three ﬁnger- and 68 toenail clippings were collected
from patients suspected of onychomycosis in our mycology department.
As a control group, 86 ﬁnger- and toenail clippings were collected from
people not suspected of suffering onychomycosis. Culture for C. albicans
was only performed on the nail clippings collected from the patient
group. On all specimens EasyMag DNA extraction (Biomerieux, Boxtel,
The Netherlands) was performed, using overnight pre-lysis. Internallly
controlled multiplex real-time PCR was performed for the following
targets: T. rubrum, T. interdigitale and C. albicans.
Results: Culture for C. albicans yielded 13% and 0% positives in
samples of ﬁnger- and toenail samples respectively.
Fingernails: Of all 63 patient samples real-time PCR yielded 60%
C. albicans, 27% T. rubrum and 3% T. interdigitale. Of all 86 samples
of the control group real-time PCR yielded C. albicans, T. rubrum and
T. interdigitale in 16%, 4% and 2% respectively.
Toenails: In all 68 samples in the patient group real-time PCR detected
C. albicans, T. rubrum and T. interdigitale in 21%, 53% and 24%
respectively. Using real-time PCR, the samples in the control group
yielded C. albicans, T. rubrum and T. interdigitale in 13%, 8% and
14% respectively.
Double infections: Double infections of a dermatophyte and C. albicans
in the patient group detected by real-time PCR were observed in 13% of
the samples of the toenails and in 18% of the samples of the ﬁngernails.
Conclusion: C. albicans is signiﬁcantly more prevalent in ﬁngernails
of the patient group compared to the control group, odds ratio: 7.82
(p = 5×10−8), suggesting that C. albicans plays an important role in
ﬁngernail onychomycosis. T. rubrum is signiﬁcantly more prevalent
in both ﬁnger- and toenails of the patient group compared to the
control group, odds ratios: 12.70 (p< 10−8) and 10.22 (p = 7.2×10−5)
respectively.
Furthermore, this study showed a large increase in sensitivity using PCR
for the detection of C. albicans over culture.
P874 The impact of bronchoalveolar lavage ﬂuid sampling
analyzed by molecular methods for the diagnosis of invasive
fungal infections
N. Kokturk, A. Kalkanci °, S.Z. Aki, Z.A. Yegin, Z.N. Ozkurt,
O. Tunccan, S. Ozyegen Aslan, B. Yalcin, E. Senol, G. Turkoz Sucak,
M. Yagci, S. Kustimur (Ankara, TR)
Objectives: Polymerase chain reaction (PCR) from bronchoalveolar
lavage (BAL) clinical samples has been used to assist in the diagnosis
of invasive fungal infections (IFI). Culture and histopathological
examination of BAL ﬂuid are useful but have suboptimal sensitivity and
in the case of culture may require several days for fungal growth to be
evident. As a part of the diagnostic procedure for suspected pulmonary
Molecular mycology S229
infections in 30 patients with haematological malignancy, bronchoscopy
with BAL were performed.
Methods: Between January and November 2009, we prospectively
followed up 30 patients with pulmonary inﬁltrates suggestive of
pneumonia. Fungal stains, cultures, galactomannan detection and PCR
for Aspergillus, Candida and Pneumocystis were performed on all
patients. All patients had fever and pulmonary inﬁltrates on the
chest roentgenogram on the day that the BAL ﬂuid was obtained.
Galactomannan antigen detection was also performed with serum
samples.
Results: The 30 patients consisted of 6 patients with probable IFI
(microbiologic culture or galactomannan), 24 patients with possible IFI
(consistent clinical and radiologic ﬁndings). The sensitivity, speciﬁcity,
positive predictive value, and negative predictive value of PCR were
93%, 100%, 38%, and 99%, respectively, for probable IFI, and 64%,
93%, 52%, and 96%, respectively, for possible IFI.
Asergillus DNA was detected by real time PCR or Aspergillus
galactomannan ELISA were positive with BAL ﬂuid or blood samples
from three of 24 patients who had radiological evidence of aspergillosis.
Candida DNA was detected with BAL or blood samples from ﬁve of
30 patients, while Pneumocystis DNA was not detected in patients who
had radiological evidence of pulmonary infection.
Patients diagnosed with probable IFI according to traditional microbi-
ological methods had signiﬁcantly higher mortality rates compared to
their counterparts who had in addition a PCR-based diagnosis (80 vs
30%, p< 0.003).
Conclusion: This study demonstrates that PCR-based DNA detection for
a diagnosis of IFI from BAL ﬂuid has a signiﬁcant effect on the outcome
of patients with fungal infections, probably related to earlier diagnosis.
The use of bronchoscopy with BAL allowed correct identiﬁcation
of seven microorganisms involved. Four patients’ pneumonias had a
multiple etiology. The bronchoscopy methods used were well tolerated
even by patients whose condition was poor.
P875 Usefulness of real-time PCR and direct sequencing in the
diagnosis of invasive mycoses − in the case of six leukaemic
patients with proven/probable aspergillosis
U. Nawrot °, M. Ussowicz, K. Wlodarczyk, M. Pajaczkowska,
K. Kalwak, A. Chybicka (Wroclaw, PL)
The development of the new diagnostics methods enabling early
diagnosis of invasive mycoses (IFI) and early, targeting antifungal
therapy represent a task of primer importance.
In this paper we present the results of retrospectively performed
molecular examinations of blood and tissue samples collected from six
patients with either proven (1 patients) or probable (5) IFI. The patients
were treated in the Dept of Pediatric Hematology and Oncology, BMT
Unit of Wroclaw Medical University, in years 2006–2009. Investigated
material included a series of weakly taken blood samples (6−20 samples
per patient), which were available for four patients, and biopsy from
lungs (2 patients), liver (1 patient), and gallbladder (1 patient). All
patients were previously tested with Platelia Aspergillus tests (Bio Rad)
for Aspergillus galactomannan and showed at last two positive results.
No fungi were cultured from tested biopsies, however microscopic
examination revealed presence of fungal elements, except of gallbladder,
which were negative. DNA from clinical samples was extracted with the
use of QIAmpDNA Mini kit (Qiagen) and mechanical cells disruption
by beads beating (blood, tissues). qPCR was performed on Rotor-Gene
6000 (Corbett Life Science) system using either Aspergillus-speciﬁc
primers and hydrolysis probe ASP 28P (Williamson 2000, White 2006),
targeting the 28S rRNA gene, or panfungal primers Fungi 5.8f and ITS4
(Bergman 2007, White 1990), amplifying the ITS2 region of rDNA, and
the intercalating dye SYBR-Green I. Selected amplicons were sequenced
on both strands and obtained sequences were analysed using the Blast
software and Genbank-EMBL database.
The Aspergillus-speciﬁc qPCR correlated good with the Platelia
Aspergillus tests. A total of 16 GM-positive blood samples were
positive in qPCR, however among 22 GM-negative samples 6 were
positive in qPCR. The amplicons obtained from 8 blood samples (2
samples per patient) and two lung biopsies showed 98−99% sequence
similarity to A. fumigatus, thus A. fumigatus can be regarded as likely
causative agent of infection. Surprisingly, the liver sample from patient
with suspected reactivation of aspergillosis revealed the presence of
DNA of C. dubliniensis. The sequence analysis indicated that PCR
product obtained with DNA from gallbladder was probably a result of
contamination with Cladosporium.
The DNA-based methods seems to be valuable tool for improving
mycological diagnosis in immunocompromised patients.
P876 Molecular approaches to fungal infections in high-risk
haematology patients
A. Kalkanci °, S.Z. Aki, Z.A. Yegin, E. Suyani, O. Tunccan, N. Kokturk,
B. Yalcin, S. Ozyegen Aslan, E. Senol, G. Turkoz Sucak, S. Kustimur
(Ankara, TR)
Objectives: In high-risk patient cohorts, such as patients after allogeneic
stem-cell transplantation, or patients with acute leukaemia, early
diagnosis of invasive fungal infections (IFIs) is essential, as delayed or
missing diagnosis of IFI results in increasing rates of mortality. Current
non-culture based, diagnostic tests for systemic fungal infections include
measurement of Aspergillus galactomannan (GM) and polymerase chain
reaction (PCR) assays for Pneumocystis, Aspergillus or Candida DNA.
The aim of this study was to investigate the diagnostic utility of both
the aspergillus galactomannan (GM) antigen and the fungal PCR assays
in the diagnosis of IFI in high risk febrile neutropenic cancer patients.
Methods: During one year period, 40 febrile neutropenic (FN) cases
at high risk for developing IFI while receiving chemotherapy were
investigated at Gazi University Faculty of Medicine. These patients
were subjected to clinical evaluation, chest CT scan, conventional
blood cultures for bacterial and fungal pathogens, aspergillus GM
antigen detection and PCR assay utilizing Pneumocystis, Candida and
Aspergillus primers. Patients were screened twice a week by PCR and
antigen testing during fever and were followed-up for a minimum of 1
year.
Of the 40 cases, 3 were proven IFI; whereas 7 cases were probable and
30 cases were possible IFI.
Results: Aspergillus antigen test showed a sensitivity of 75%, speciﬁcity
of 60%, positive and negative predictive values of 50% and 85%;
respectively. Based on positive results for proven/probable IFI and
compared to culture results, Candida, Aspergillus and Pneumocystis PCR
assays showed sensitivity, speciﬁcity, positive and negative predictive
values of between 70−75%, 90−92%, 80−84% and 80−87%; respectively.
Conclusions: The introduction of a comprehensive diagnostic strategy
to exclude invasive fungal infection in high-risk patients with haemato-
logical malignancy can result in improvements in clinical management.
These molecular assays provide high potential in terms of sensitivity
and speciﬁcity, but vary widely in their feasibility and up to now have
not been standardised. The results of PCR assay was reasonably speciﬁc
but not very sensitive and had a chance of missing the diagnosis of
IFI. The PCR assay seems a promising test for objectively deﬁning IFI,
but is not recommended as the only tool for diagnosing IFI. Combining
microscopy, culture, and PCR may improve the diagnostic outcome.
P877 The protein “mycoarray”: a novel immunoassay for the
serological diagnosis of primitive invasive mycoses
A. Ardizzoni, M.C. Baschieri, L. Manca, C. Farina, C. Cermelli,
M. Meacci, C. Venturelli, E. Blasi ° (Modena, Milan, IT)
Objectives: Invasive fungal infections are an important cause of
morbidity and mortality in an increasingly higher number of patients,
also because of difﬁculties in providing a rapid and appropriate diagnosis.
In some cases, detection of a speciﬁc antibody response is a crucial
diagnostic tool; however, the available serological assays often provide
qualitative results only, their sensitivity and speciﬁcity are poor and
long time procedures are required. In addition, patients who suffer from
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an invasive mycosis may have multiple infections likely underestimated
by conventional diagnostic approaches. In order to couple the serology
of primitive invasive mycoses to the protein microarray technology, a
“mycoarray” assay has been designed and set up.
Methods: Four antigen extracts (histoplasmin, coccidioidin, Coccid-
ioides “TP” antigen and aspergillin) and the appropriate controls were
spotted in various conditions onto a restricted area of a microscope
slide. The arrays were then incubated with immune sera produced in
goat against each single antigen or, subsequently, with human sera (6
from patients affected by primitive invasive mycoses and 7 from healthy
individuals). The occurring immunocomplexes were detected by indirect
immunoﬂuorescence.
Results: The pilot experiments, conducted using the goat immune sera,
allowed to establish the optimal spotting conditions for each antigen in
terms of both spotting buffer and extracts’ dilution. The “mycoarrays”,
obtained by spotting each of the fungal antigens in its best condition,
were then processed with sera either from patients or control subjects. In
all the cases, the serological reactivity detected by the arrays processed
with the patients’ samples was in agreement with the clinical and
microbiological diagnosis; no reactivity was ever observed in the arrays
processed with the negative control sera.
Conclusions: The “protein mycoarray” is sensitive enough to discrimi-
nate between healthy individuals and patients affected by histoplasmosis
or coccidioidomycosis. Because of its intrinsic features, miniaturization
and multiparametricity, this novel diagnostic tool allows to cut out costs
and to shorten times-to-results. It follows that the “mycoarray” has all
the potentialities to be included in the daily clinical practice in the near
future.
Aspergillosis
P878 A phase II dose escalation study of caspofungin for invasive
aspergillosis
O.A. Cornely °, J.J. Vehreschild, M. Ru¨ping, D. Arenz, S. Schwartz,
C.P. Heussel, G. Silling, M. Mahne, J. Franklin, U. Harnischmacher,
A. Wilkens, F. Farowski, M. Karthaus, T. Lehrnbecher, A.J. Ullmann,
M. Hallek, A. Groll (Cologne, Berlin, Heidelberg, Mu¨nster, Munich,
Frankfurt, Mainz, DE)
Objectives: Treatment of invasive aspergillosis (IA) fails in up to 50%
and mortality is at least 30%. Antifungal combination treatment has
not been proven to be beneﬁcial and dose escalation with liposomal
amphotericin B did not improve outcome. New approaches are needed.
Methods: High dose caspofungin was investigated in an escalating
Fibonacci approach in IA deﬁned according to modiﬁed EORTC/MSG
criteria. In cohorts at 70mg, 100mg, 150mg, or 200mg QD, 8 patients
each were to receive caspofungin ﬁrst-line treatment for proven/probable
IA for up to 28 days. Dose limiting toxicity was deﬁned as 2 of 8
patients in the same cohort with the same grade 4 non-haematological
treatment-related adverse event (TRAE), or 4 of 8 patients with a grade
3 non-haematological TRAE. If no dose-limiting toxicity was reached,
12 additional patients were enrolled in the 200mg cohort. Patients
unevaluable for toxicity or pharmacokinetic analysis were replaced.
Results: A total of 46 patients were treated in the 4 cohorts (9, 8,
9, 20 pts). IA was proven in 2.2% and probable in 97.8%. Patient
characteristics were as follows: Median age 61 years (min 18.3, max
73.7); 21/46 (45.7%) female. Underlying diseases distribution was: AML
50%, ALL 8.7%, lymphoma 19.6%, chronic lymphocytic leukaemia
10.9%, other 10.9%. Median duration of treatment was 24.5 days. Two
(4.3%) patients with treatment durations 5 days were replaced for
pharmacokinetic analysis, but evaluated for safety and efﬁcacy. No dose-
limiting toxicity was found by investigator or DSMB assessment. At end
of treatment (EOT) complete plus partial response, was achieved in the
4 cohorts in 4/9, 3/8, 6/9, 12/20 patients, i.e. 25/46 (54.3%) of the
total population. Stable disease was achieved in 4 patients (8.7%), 17
(37%) patients failed treatment. Overall survival at 12 weeks was 76.1%.
After a 12 week follow-up attributable mortality was 8.7%. Death due
to malignancy occurred in 10.9%, to sepsis in 8.7%.
Conclusions: In the ﬁrst-line treatment of proven or probable invasive
aspergillosis no dose-limiting toxicity of caspofungin at doses up to
200mg QD was found. Complete plus partial response rates at EOT were
54.3% after dose-escalated caspofungin treatment, and thus in the range
of the success rates previously reported with voriconazole and liposomal
amphotericin B. Twelve weeks after start of treatment the 23.9% overall
mortality was lower than found in the literature.
Caspofungin MTD: Overall survival with 95% conﬁdence intervals.
Censored at 112 days (= 28 days treatment + 12 weeks follow-up).
P879 Invasive aspergillosis increases the risk of death in acute
myeloid leukaemia patients
M. Michallet, S. Kraghel, T. Be´net, M. Sobh, N. Voirin, M. El
Hamri, G. Cannas, F. Nicolini, E. Nicolas-Virelizier, H. Labussie`re,
S. Ducastelle, R. Crocchiolo, F. Barraco, X. Thomas, Y. Chelghoum,
M. Nicolle, A. Bienvenu, F. Persat, F. de Monbrison, N. Fanari,
S. Madene, P. Vanhems ° (Lyon, FR)
Objectives: To study the impact of invasive aspergillosis (IA) incidence
during induction therapy for acute myeloid leukemia (AML) patients on
short and long term overall survival.
Methods: A retrospective cohort study was performed in the Hematol-
ogy department of the Edouard Herriot Hospital, Lyon (France). Patients
with newly diagnosed AML between 01/01/2004 and 31/12/2007 were
retrospectively included and the follow-up was censored at 30/06/2009.
Data were extracted from medical charts and from the prospective
surveillance of IA (EORTC diagnosis criteria). The patients with IA after
post induction evaluation were excluded (N= 5). A Cox proportional
hazard model with diagnosis of IA and post induction evaluation
(complete remission [CR] of AML or failure of chemotherapy) as the
main exposure besides age, year of inclusion, WHO status, cytogenetic
group, kind of induction chemotherapy, and hematopoietic stem cell
transplantation, was ﬁtted.
Results: Overall, 262 patients counting for 149 370 patient-days were
analysed, the median age at diagnosis was 56.6 years (47.9–64.2 years),
and 196 (75%) had CR. There were 58 (22%) IA cases with a median
interval between induction and IA of 30 days (range, 16−27 days); 29
(50%) IA were possible, 24 (41%) probable, and 5 (9%) proven. At the
last follow-up, 165 (63%) patients died with a median overall survival
of 18 months (95% conﬁdence interval [95%CI] 14−23 months). The 4
year-survival of patients having had IA was 14%, and without IA 32%
(P = 0.01). The 2 year-survival of patients achieving of CR was 54%
vs. 5% for patients with failure of chemotherapy was 5% (P< 0.001).
Cox multivariate analysis (cf. Table) showed that patients in CR with
IA presented a higher risk of death compared to patients in CR without
IA (Hazard ratio=1.66, 95%CI 1.05–2.65, P = 0.031). In addition, IA
was associated with a higher risk of death in patients with failure
of chemotherapy compared to patients in CR without IA (Hazard
ratio=6.43, 95%CI 3.72–11.10, P< 0.001). The WHO status, cytogenetic
group and kind of induction chemotherapy were associated with lower
survival.
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Conclusion: IA was associated with a high risk of death in AML
patients whether they were in CR or failure after induction chemotherapy.
Cytogenetic group or WHO status are not modiﬁable risk factors for
death in this population while prevention of IA with environmental
procedures or using individual prophylaxis will improve survival
outcome.
Table. Factors independently associated with the survival in acute
myeloid leukemia patients in induction chemotherapy, multivariate Cox
proportional hazard model
Characteristics Hazard ratio 95%CI P
Invasive aspergillosis and post-induction evaluation
No invasive aspergillosis, and CR 1.00 (Ref.) − −
Invasive aspergillosis, and CR 1.66 (1.05–2.65) 0.031
No invasive aspergillosis, and failure 6.19 (4.11–9.29) <10−3
Invasive aspergillosis, and failure 6.43 (3.72–11.10) <10−3
WHO status
<2 1.00 (Ref.) − −
2 1.84 (1.30–2.60) 0.001
Cytogenetic group
Favorable 1.00 (Ref.) − −
Intermediary 4.52 (1.62–12.62) 0.004
Unfavorable 5.46 (1.98–15.07) 0.001
Not possible to classify or not done 8.14 (2.82–23.50) <10−3
Induction chemotherapy
Intensive 1.00 (Ref.) − −
Standard 2.04 (1.40–2.99) <10−3
CR, complete remission.
P880 Five-year surveillance of invasive aspergillosis in a German
tertiary care hospital
K. Graf °, S. Mohammad Khani, E. Ott, Z. Demir, F. Mattner,
P. Gastmeier, S. Ziesing, I. Chaberny on behalf of the Institute for
Medical Microbiology and Hospital Epidemiology
Objectives: Invasive aspergillus infections (IA) are a severe complication
in immuncompromised, especially transplantated, patients. Unfortunately
diagnosis can be difﬁcult in multimorbide patients and one must assume
that several patients die failing diagnosis and special treatment. The
aim of this study was to detect high risk patients to introduce special
preventive measures and to get information about quick diagnosis of
infection.
Methods: After implementation of a surveillance protocol in 2003,
we surveyed all hospitalized patients by positive microbiological
cultures, pathologic diagnoses and/ or pharmacologic informations
about antifungal treatment in 2003–2007: Cases were reviewed and
were classiﬁed according to international consensus criteria (EORTC).
Possible nosocomial acquisition was determined.
Results: Among the 704 alerts, 214 IA cases were observed: 56 proven
cases (26%), 25 (12%) probable cases and 133 (62%) possible cases.
The incidence was 1.6%. Among the proven and probable IA cases, we
observed 56% nosocomial cases (45/81) and 21% cases of undetermined
origin (17/81). Many patients (37/81) had organ transplantation, followed
by bone marrow transplantated patients (8/81), but we also found a
high number of other patient groups. We detected 10 malignancy tumor
patients and 26 other patients with chronical organ diseases. Among
the proven and probable cases we detected 53 patients undergoing
immunsuppressive therapy. 45% of the proven patients died during their
hospital stay. 11 of the proven patients did not get any antifungal
treatment, seven of those patients died. Overall 32 patients (57%)
were diagnosed by pathologic results, 16 patients were diagnosed by
autopsy and seven patients (13%) would not have been diagnosed without
autopsy.
Conclusion: High risk patients are not only patients undergoing
transplantation, but all patients undergoing immunsuppressive therapy.
Diagnosis is difﬁcult and 13% of all cases are diagnosed by autopsy
only. Thus, this study shows the importance of IA surveillance in all
high-risk units to improve infection prevention measures.
P881 Invasive infections caused by non-Aspergillus moulds
identiﬁed by sequencing analysis at a tertiary care hospital
in Taiwan, 2000–2008
M.S. Hsu °, Y.T. Huang, P.R. Hsueh (Panchiao, Taipei City, TW)
Objectives: The purpose of this study is to describe the clinical and
microbiological characteristics of 103 patients with cultures positive for
non-Aspergillus molds from 2000 to 2009 were described.
Methods: Invasive mold infections were deﬁned in accordance with the
EORTC/MSG criteria. The mold isolates were identiﬁed to the species
level by sequence comparison analysis of the internal transcribed spacer
(ITS) regions using primers ITS1 and ITS4. For Fusarium species,
sequence analysis of the translation elongation factor 1 a (EF1 a) region
was also performed with primers EF1 and EF2.
Results: Among the 103 patients, 27 cases (26.2%) met the criteria
for proven or probable IMI. The etiologic pathogens were Fusarium
species in 12 (44.4%) patients, Paecilomyces species in 7 (25.9%),
Zygomycetes in 5 (18.5%), and Scedopsorium species in 3 (11.1%)
(Table 1). Predisposing factors included hematological malignancies
(48%), steroid use (40%), solid organ tumor (12%), hematopoietic stem
cell (4%) or solid organ transplantation (12%), AIDS (8%), diabetes
mellitus (8%) and myelodysplastic syndrome (4%). The lung was the
most common main infection site (33%), followed by orbito-sinus-
facial (18.5%), skin and soft tissue (18.5%), blood (11.1%), and bile
(7.4%). Mortality was highest in patients with zygomycosis (4 out
of 5 patients died [80%]), followed by fusariosis (41.7%). 100% of
Fusarium were inhibited by2 umg/ml of amphotericin B. Paecilomyces
isolates showed different susceptibility patterns among species. For the
Zygomycetes, amphotericin B was the most active agent. Scedosporium
apiospermum was relatively susceptible to the newer azoles.
Conclusions: Non-Aspergillus invasive mold infections occurred pre-
dominantly in immunocompromised patients. Patients with underlying
hematological disorders were associated with increased risk of dis-
seminated disease and high mortality. Antifungal susceptibility varied
considerably between these species. This emphasized the importance
of identifying infecting mold organisms to the species level, which is
seldom achieved at standard clinical laboratories.
P882 Burden of invasive aspergillosis in COPD non-traditional
host: a hospital database analysis
D. Patel, X. Gao, J. Stephens, M. Forshag, M. Tarallo ° (Bethesda,
New York, US)
Objectives: Although invasive aspergillosis (IA) occurs predominantly
in immunocompromised hosts, it has been reported in patients with
chronic obstructive pulmonary disease (COPD). The aim of this study
was to estimate the excess clinical and economic burden of IA in COPD
patients compared to COPD patients without IA using a US inpatient
claims database (Premier Perspective™ Comparative Database).
Methods: Adults diagnosed with COPD (ICD-9 code = 491, 492,
493.2x, 496) + aspergillosis (117.3x) + pneumonia (484.1, 484.6, 484.7,
487.0) were identiﬁed in the Premier database(2005 to 2008). Patients
were excluded if ICD-9 codes were present for malignancies, HIV, or
conditions that would put them at risk for IA aside from COPD. Patients
with a charge for antifungal therapy during the admission were included.
To estimate the excess resource utilization and mortality, COPD+IA
patients (Cases) were compared to the matched COPD patients without
aspergillosis (Controls) by univariate analyses. Cases and controls were
matched (1:2) based on age, gender, race, payer, hospital characteristics,
geographical area, comorbidity index, and disease severity. Mortality,
length of stay (LOS), and costs were compared between groups.
Results: We identiﬁed 475 COPD+IA patients, with a mean age of 69
years, 50% male and 76% Caucasian. 85% patients were on a high dose
corticosteroid therapy, with 55% exposed to this therapy for more than
14 days. On average, antifungal therapy was initiated on the 6th day
of hospital stay, with a mean length of therapy being 15 days. 35%
of patients required mechanical ventilation, 56% had some ICU stay,
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and 31% were in the ICU when their antifungal therapy was initiated.
Occurrence and mortality rates were higher among COPD inpatients with
an ICU stay compared to those without an ICU stay (1.2% vs.0.7% and
45.2% vs. 29%, respectively). Compared to controls, COPD+IA cases
incurred signiﬁcantly higher costs ($48,163 vs. $30,210, p< 0.001),
longer LOS (23 vs. 14 days, p< 0.001), longer ICU stay (14 vs. 7 days,
p< 0.001), and higher mortality (29 vs. 23%, p = 0.016). Findings in
subgroup analyses were consistent.
Conclusion: COPD+IA patients have signiﬁcantly higher resource
utilization, costs and mortality compared to COPD patients without
IA. Consideration of IA as a cause of infection in hospitalized COPD
patients, followed by appropriate treatment, has the potential to impact
important clinical and economic outcomes.
P883 Is liver cirrhosis a predisposing condition to invasive
aspergillosis?
J. Guinea °, M. Torres-Narbona, P. Mun˜oz, R. Ban˜ares, M. Giannella,
M. Valerio, E. Bouza (Madrid, ES)
Objectives: Liver cirrhosis has recently been described as a risk
factor for invasive aspergillosis, particularly in critically ill patients.
We determined the clinical presentation and outcome of invasive
aspergillosis in patients with liver cirrhosis.
Methods: From January 1999 to March 2009, we recorded all proven
or probable cases of culture-documented invasive aspergillosis (EORTC
criteria) in patients with liver cirrhosis. Patients with malignancy, solid
organ transplantation and chronic obstructive pulmonary disease were
excluded.
Results: We documented 122 cases of proven or probable invasive
aspergillosis and 9 (7%) had of liver cirrhosis. Liver cirrhosis was due
to idiopathic autoimmune hepatitis (n = 7), alcoholism (n = 1), and HCV
and alcoholism (n = 1). The mean age of the patients was 53.8 y (range
30−79 y) and 6 were male. Overall, 7 patients required admission to
intensive care units when invasive aspergillosis was diagnosed. Three
patients developed acute liver failure before diagnosis. All patients were
receiving corticosteroids and broad-spectrum antibiotics on diagnosis.
The disease was always nosocomially acquired and the lung was
involved in all patients (one patient also had probable brain involvement,
and another probable ocular involvement) with nonspeciﬁc radiological
ﬁndings and bilateral inﬁltrates. Aspergillus fumigatus was isolated in
sputum (n = 2), bronchial aspirate (n = 8), and bonchoalveolar lavage
(n = 3). Galactomannan determination was performed in 5 patients
and was positive in 4 (1 ng/mL). Eight patients received antifungal
therapy [amphotericin B (n = 2), voriconazole + caspofungin (n = 4),
amphotericin B + caspofungin (n = 2)], but only 2 survived (voriconazole
+ caspofungin). Overall mortality was 77.7% (n = 7).
Conclusions: Cirrhotic patients receiving corticosteroids and broad-
spectrum antimicrobial agents should be considered potential invasive
aspergillosis patients (7% of all cases of invasive aspergillosis in our
institution). Lung and extra-pulmonary structures could be involved. The
yield of galactomannan was very high. M. Torres-Narbona is contracted
by Fondo de Investigacio´n Sanitaria (FIS) CM08/00277. Jesu´s Guinea is
contracted by FIS (CA08/00384).
P884 Retrospective analysis of invasive aspergillosis in
haemato-oncological department, 2005–2008
B. Weinbergerova, Z. Racil, I. Kocmanova °, E. Sevcikova, M. Toskova,
J. Winterova, M. Lengerova, J. Mayer (Brno, CZ)
Background: Invasive aspergillosis (IA) is a serious infectious
complication in immunocompromised patients (pts.). Particularly pts.
with hematological malignancies are at high risk of IA.
Methods: The goal of our retrospective analysis was to evaluate
incidence, early diagnostic possibilities and effect of antifungal therapy
in proven and probable IA in immunocompromised pts. in our institution
during 2005–2008. We followed EORTC/MSG criteria in evaluation of
IA diagnosis (2002) and therapy response (2008).
Results: In the mentioned period we documented 54 probable and 7
proven isolated pulmonary IA. Prolonged profound neutropenia (56%)
and long-term use of corticosteroids (34%) were identiﬁed as the
major risk factors of IA. 20 cases (33%) had normal ﬁnding on
pulmonary X-ray. 54 cases (89%) had abnormality on pulmonary
CT with “halo” sign as the most frequent ﬁnding (34%). 93% pts.
had consecutive positivity of serum-galactomannan (S-GM). In 38
cases (62%) consecutive positivity of S-GM occured before (3 days
in avg.) pathologic scan. These drugs or combination were used as
primary therapy: 41% voriconazole (VORI), 7% itraconazole (ITRA),
5% caspofungin (CASPO), 38% VORI+CASPO, 3% amphotericine B
deoxycholate (AMB) and 6% none. Overall RR to primary therapy was
56% (VORI 60%, VORI+CASPO 78%, ITRA 25%, CASPO 0% and
AMB 0%). In 9 cases we have to use salvage therapy (VORI+CASPO
in 7 pts., posaconazole+CASPO in 1 pt. and VORI in 1 pt.). Overall RR
to salvage therapy was 78%. The overall mortality rate was 44%, with
11% attributable to IA.
Conclusions: On the basis of our analysis we conﬁrm common risk
factors of IA and major role of S-GM and CT for early diagnosis and
prompt start of antifungal therapy of IA. We reached good results in RR
with using both VORI and combination of VORI+CASPO in primary
therapy of IA. Antifungal combination had excellent effect also if used
as salvage treatment of this infection.
NS10441–3/2009.
NS10442–3/2009.
P885 Value of combined use of bronchoalveolar lavage and
galactomannan antigen in the management of pneumonias
in haematological patients
L. Verga °, F. Farina, F. Rossini, I. Casaroli, E. Pogliani (Monza, IT)
Objectives: In our retrospective study we investigated the optimal timing
of bronchoalveolar lavage (BAL) and the comparison of galactomannan
antigen (GM) determined on BAL and serum in patients (pts) with
pneumonia.
Methods: From January 2007 to June 2009, 130 consecutive pts
with haematological disease were investigated for the presence of 175
pneumonias in our Unit.
At the onset of fever, blood cultures and assay GM were perfomed for
3 days. A chest computerized tomography (CT) was performed if pt
was still febrile after 4 days. Pts began antifungal drugs if there was a
possible or probable fungal infection. The decision to perform a BAL
was made on the basis of CT images and response to therapy (tp). Pts
characteristics and results are summarized in Table 1.
Results: The time between the onset of neutropenia and fever, the onset
of fever and CT, the CT and BAL and between the start of antifungal
tp and the BAL was 8, 5.5, 5, 5.38 days respectively. Among 148
serum GM, 31 were positive with a mean value of 1.35 (range 0.6−4.8).
We performed 75 BAL (average 11 days after the onset of fever). At
the time of procedure, 25 pts were already receiving broad-spectrum
antibiotic tp and 32 antibiotic and antifungal tp at therapeutic doses
(76% patients were in tp). 25 BAL demonstrated a pathogen by culture,
immunoﬂuorescence or RT-PCR or by direct microscopic examination.
GM in BAL was performed in 52 samples. GM was positive on BAL
in 15 pts: mean value of 2.06 (range 0.54–4.47); in 4 cultures were
positive for fungus. 9/15 were on antifungal tp from an average of 7
days. In 9/15 also serum GM was positive at the time of BAL. Of the
31 events with positive serum GM, BAL was performed in 16: among
them, 9 conﬁrmed GM BAL positivity, while 3 were negative for GM.
2 showed Aspergillus culture positive without GM. We found 6 pts with
BAL GM positive and serum GM negative. 36 BAL have provided an
etiological diagnosis. The diagnostic power was 48%. We changed tp in
38% of patients thanks to BAL. However, there was no difference in
mortality rate between patients with a positive and negative BAL.
Conclusion: In our experience, when BAL is used late, pt’s clinical
conditions and the great number of antibacterial and antifungal therapies
may negatively inﬂuence its results. We noticed that if we perform it early
during the course of disease we could improve the outcome and avoid
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unnecessary therapies. We must keep on comparing the sensibility of
GM on serum and on BAL.
Table 1: Characteristics of patients in study
No. of patients (%)
Age (years)
65 98 (75%)
>65 32 (25%)
Gender
Male 72 (55%)
Female 58 (45%)
Haematological disease
AML 69 (54%)
ALL 11 (8%)
Lymphoproliferative disorders 37 (28%)
Myeloproliferative disorders 7 (5%)
Others 6 (5%)
State of illness during the event
Onset 66 (39%)
RC 45 (25%)
RP 25 (14%)
PR 35 (20%)
Not classiﬁable 4 (2%)
Antifungal prophylaxis
Yes 54 (31%)
No 121 (69%)
Neutropenia
Yes 115 (66%)
No 60 (34%)
Hyperpyrexia
Yes 159 (91%)
No 16 (9%)
Chest CT
Yes 161 (92%)
No (only chest X-ray) 14 (8%)
BAL
Yes 75 (43%)
No 100 (57%)
Died:
Yes 36 (28%)
No 94 (72%)
P886 Invasive aspergillosis in haemato-oncological patients − 40
cases from a single centre
V. Kaplanova °, M. Krizo, M. Kouba, P. Cetkovsky for CELL, the Czech
Leukemia Study Group for Life
Objectives: Invasive aspergillosis (IA) is a major opportunistic infection
in patients with haematological malignancies. The incidence of IA has
increased signiﬁcantly in the past years. The high mortality reﬂects both
the invasivity of the pathogen and the profound immunosuppression of
the host organism. There has been a major development in diagnostic
and treatment options for IA within the past few years.
Methods: We retrospectively searched documentation of the patiens
treated in our tertiary haematlogical centre in the period 2005–2009 to
identify the cases of IA and describe their pattern of diagnosis, clinical
picture, treatment and outcome.
Results: We identiﬁed 40 cases (average age 53 years) of IA (according
to EORTC-MSG criteria: 3 proven, 31 probable and 6 possible but
clinically apparent cases). 38 patients suffered from pulmonary IA,
1 patient had blood stream infection and one patient had IA of
the paranasal sinuses. In one patient was the diagnosis of IA based
on autopsy, 39 patients were diagnosed to have IA while alive.
The underlying diagnosis was acute leukemia in 32 (80%) patients,
22 (55%) cases developed IA after remission induction therapy for
acute leukemia, 7 (18%) after allogeneic haematopoietic stem cell
transplantation (aloSCT). The microbiological criterion for diagnosis
was galactomannan detection in 36 of 37 probable and possible cases.
32 patients (80%) died and 8 patients (20%) are alive at follow-up
(9/2009). In 22 (55%) patients IA was either direct cause of death in 13
(32%) or it was an important factor contributing to death in 9 (23%).
Of the surviving patients 4 were initially treated by voriconazole, 2 by
combination of voriconazole and echinocandin and two (low risk) by
itraconazole. Of the 10 patients initially treated by different amphotericin
B formulations only 1 patient reached partial remission, all the others
were switched to other therapy due tu ineffectivity or died.
Conclusions: Our analysis shows that IA is an extremely severe
complication of treatment of acute leukemias and aloSCT with high
mortality. Galactomannan assay has a central role in diagnosis of IA.
Voriconazole, a current therapy of choice, was more efﬁcacious than
amphotericin B formulations in our analysis.
P887 Compartmental pharmacokinetics and pharmacodynamics
of amphotericin B in an in vitro model of invasive pulmonary
aspergillosis
J.M. Lestner °, S.J. Howard, J. Goodwin, L. Gregson, J. Majithiya,
T.J. Walsh, G.M. Jensen, W.W. Hope (Manchester, UK; Maryland,
San Dimas, US)
Objectives: To deﬁne the extent of tissue penetration and antifungal
effect of three clinical formulations of amphotericin B (AmB) in cellular
and ﬂuid compartments of the lung using an in vitro model of invasive
pulmonary aspergillosis (IPA).
Methods: An in vitro model, which utilised a cellular bilayer and
air-ﬂuid interface, was developed to examine the PK-PD of AmB.
Lipid formulations (liposomal (LAmB) and lipid-complex (ABLC))
were compared with AmB deoxycholate (DAmB). Concentrations
of galactomannan (GM) were used to deﬁne PD relationships in
endovascular and alveolar compartments, and concentrations of AmB
within cellular and ﬂuid compartments were measured by HPLC.
A mathematical model was used to calculate the area under the
concentration time curve (AUC) within compartments and estimate
the extent of drug penetration. Fungal biomass and drug-hyphal-host
cell interactions were visualised by confocal microscopy using an
A. fumigatus transformant expressing green ﬂuorescent protein and
sulforhodamine-labelled liposomes.
Results: In the absence of treatment hyphal penetration occurred at
14−16 hours post-inoculation, mirrored by a progressive rise in GM. The
presence of AmB signiﬁcantly altered fungal growth; DAmB induced
a steep exposure-response relationship in alveolar and endovascular
compartments; whereas LAmB and ABLC induced more languid
concentration-response relationships, with incomplete suppression of
galactomannan in the alveolar compartment. Concentrations of AmB
progressively declined in the endovascular ﬂuid as the drug distributed
throughout the compartments. High concentrations of AmB were
observed in the cellular bilayer: AUCs for AmB were 10–300 times
higher within the cells compared to those within endovascular ﬂuid. The
E50 in the endovascular compartment was 0.12, 1.03, and 4.41mg/L for
DAmB, LAmB and ABLC, respectively; and in the alveolar compartment
was 0.17, 7.76 and 39.34mg/L, respectively. Confocal microscopy
demonstrated that liposomes engaged directly with hyphae and host cells.
Conclusion: The PK-PD relationships of 3 clinical formulations of AmB
differ markedly within this model of IPA. Drug distribution within ﬂuid
and cellular sub-compartments within target tissues is of importance in
understanding pharmacological effect.
P888 Aspergillus-derived metabolites contribute to tissue damage
in cerebral aspergillosis
C. Speth °, M. Hagleitner, G. Rambach, C. Lass-Flo¨rl, K. Pfaller,
I. Mohsenipour (Innsbruck, AT)
Objective: The pathogenesis of cerebral aspergillosis is as yet
insufﬁciently clariﬁed and urgently needs further examination to develop
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adequate counterstrategies. Since neural damage occurs not only in close
proximity to the fungal hyphae our studies concentrate on a putative
contribution of fungal metabolites to the induction of tissue lesions.
Application of reducing agents was tested as therapeutic approach as the
biochemical structure of the toxins indicate a putative neutralization of
the toxins by these compounds.
Methods: Astrozytic and neuronal cell lines as well as primary microglia
were incubated with various fungal toxins, including gliotoxin, patulin
and citrinin. Toxicity was controlled by measuring mitochondrial activity
(MTS test), immunological competence was quantiﬁed as phagocytic
activity. Electron microscopy studies completed the examination of toxic
effects.
Results: The fungal metabolites gliotoxin, patulin and citrinin were all
able to affect the viability of astrocytes, neurons and microglia in a dose-
dependent manner. Gliotoxin was the most potent toxin, damaging the
cells already in nanomolar concentrations. Electron microscopy studies
showed changes in morphology and explicit signs of apoptosis for
gliotoxin-treated cells compared to mock-treated control cells. Staining
with annexin and propidium iodide conﬁrmed the dose-dependent
induction of the apoptotic program by gliotoxin as well as by patulin.
Furthermore, phagocytic activity of the cells incubated with gliotoxin
and patulin was depressed already in subtoxic concentrations.
The reducing components glutathione and DTT were both capable
to neutralize the deleterious effect of gliotoxin and patulin. All cells
survived otherwise toxic concentrations of the metabolites in the
presence of those substances and retained their phagocytic capacity.
Conclusions: Fungal metabolites were identiﬁed as putatively potent
inducers of tissue damage in cerebral aspergillosis since they signif-
icantly interfere with viability of all brain cell types tested. Being
secreted by Aspergillus they might affect extended regions of brain
tissue. Beside direct damage the metabolites reduce the immunologic
capacity of the cells by reducing their phagocytic activity. Both
effects might act synergistically and contribute to the pathogenesis of
cerebral aspergillosis. Reducing agents constitute promising therapeutic
components as they neutralize the toxic effect of at least some of the
metabolites.
P889 Effect of amphotericin B on Aspergillus terreus conidia and
hyphae of different growth stages using growth curves analysis
K. Krompa °, L. Zerva, J. Meletiadis (Athens, GR)
Background: Delayed administration and suboptimal exposure to
antifungal drugs may be detrimental for infections caused by A. terreus.
Therefore, we studed the pharmacodynamic characteristics of supra
and sub MIC (minimal inhibitory concentrations) concentrations of
amphotericin B to A. terreus conidia and hyphae of different growth
stages using growth curves analysis.
Methods: Inocula of 104CFU/ml from three clinical isolates of
A. terreus were prepared in 200ml RPMI1640+0.165M MOPS and
incubated in a 96-well ﬂatbottom microplates at 37ºC for 96 h. The
MIC of AMB was 1−2mg/l for all isolates. AMB was added into
corresponding wells at ﬁnal concentrations of 0.25×, 1×, and 4× MIC
after 0 h, 24 h, 48 h and 72 h of incubation. A. terreus was in form of
conidia at 0 h, of hyphae at 24 h and of mycelia at 48 h and 72 h. The
turbidity of each well was monitored continuously by measuring the
optical density at 630nm every 15min. Growth curves were constructed
and fungal growth before and after addition of the drugs was compared at
each time point and for each concentration. Reduction of fungal growth
was calculated as 100%x(ODo-ODf)/ODo where ODo and ODf are the
initial and ﬁnal optical densities after drug addition, respectively. Time
to regrowth after drug addition was also determined. All tests were
performed in duplicate.
Results: AMB completely inhibited fungal growth at 4× MIC when
added at 0 h for all three stains. When 1×MIC and 0.25×MIC of
AMB was added at 0 h there was complete inhibition of growth only
for 51 h (43−58 h) (median and range) and 32 h (21−39 h), respectively
for all strains. When 4×MIC of AMB was added at 24 h, 48 h and
72 h, fungal growth was reduced by 19% (17−20%), 27% (25−29%) and
31% (27−35%), respectively without regrowth being observed. When
1×MIC of AMB was added at 24 h, 48 h and 72 h, fungal growth was
reduced by 18% (14−20%), 30% (21−31%) and 23% (22−30%) with
subsequent regrowth being observed after 8−28 h, 4−6 h, and 3−6 h,
respectively. When 0.25×MIC of AMB was added at 24 h, 48 h and
72 h, fungal growth was reduced by 14% (14−15%), 25% (25−26%) and
21% (21−22%) with subsequent regrowth being observed after 8−12 h,
4−8 h, and 3−7 h, respectively.
Conclusion: AMB reduced fungal growth at supra and sub MIC
concentrations but regrowth being observed at 1× and 0.25× but not
at 4×MIC. Growth curves analysis revealed important concentration
and time dependent pharmacodynamic characteristics of AMB against
A. terreus.
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P890 Investigation of prevalence of major antibiotic resistance and
enterotoxin genes among clinical Bacteroides strains from a
European antibiotic susceptibility survey
J. So´ki, Z. Eitel, E. Urba´n, G. Terhes, E. Nagy ° on behalf of the
ESGARAB
Objective: Our aims were to examine the prevalence of common
antibiotic resistance genes of Bacteroides in a large set of isolates,
to compare their genotypes with their resistance patterns and to gain
information on the potential of the emergence of multiply resistant
strains.
Methods: Antibiotic susceptibility was previously measured by agar
dilution. The genotypes for the cepA, cfxA, cﬁA, ermF, nim, tetQ and
bft genes were examined by RealTime PCR using 96 well plate platform
and ﬂuorescent dye (SybrGreen) detection. The cepA, cfxA, ermF and
tetQ patterns were detected for 184 strains while the presence of the
cﬁA, nim and bft genes were recorded for 693 strains.
Results: The most common gene was the tetracycline resistance, tetQ
gene with the prevalence 78.5 and 85% among B. fragilis and non-
fragilis Bacteroides (NFB) strains, respectively. Similar high frequency
was found for the cepA gene with 74.3% among B. fragilis and with
57.5% among NFB strains. The presence of cepA and ermF genes was in
the same range as phenotypic resistance for cefoxitin and clindamycine,
respectively, but also differentially distributed between B. fragilis and
NFB strains. The differences of prevalence were statistically signiﬁcant.
The presence of cﬁA and bft genes among B. fragilis strains were 8.7
and 14.2%, respectively. However, some (7) bft genes were detected
among NFB strains, and the coincidence of cﬁA and bft genes were
found among B. fragilis (4) strains. The statistical analysis conﬁrmed
the independent occurrence of the bft and cﬁA genes in the B. fragilis
strains. As regards the four other genes examined, a similar analysis
demonstrated that the occurrence of the cepA and cﬁA genes negatively
correlate with a high level of signiﬁcance among B. fragilis strains. For
cfxA and ermF a clear conclusion could not be drawn because of the
low number of strains involved, and for tetQ the test was not signiﬁcant.
Out of the 693 Bacteroides strains examined only two harboured nim
genes.
Conclusion: The analysis of a high number of Bacteroides strains for
antibiotic and virulence genes opened an unseen view of complexity of
the interactions of these genes and taxa. An alarming coincidence of
bft and cﬁA genes, previously regarded as nonexistent, was observed.
Further investigations should reveal the factors behind the differential
occurrence of the genes between B. fragilis and between B. fragilis and
NFB species.
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P891 ACI-1 b-lactamase of Acidaminococcus intestini is carried in
a highly modular mobile genetic island
M. Rodrı´guez-Alcayna °, G. D’Auria, A. Latorre, R. Canto´n,
J.C. Gala´n, F. Baquero (Madrid, Valencia, ES)
Objective: To characterize the genetic environment of blaACI-1 gene
present in the chromosome of human Acidaminococcus intestini and the
possible events involved in its horizontal gene transfer.
Methods: b-lactam resistant RYC-MR95, RYC-MR02, RYC-MR88,
RYC-MR24, RYC-MR37 strains of A. intestini were collected from
clinical samples at our Hospital. Genome extraction, pyrosequenciation
and inverse PCR plus sequenciation were used in the characterization
process. Bioinformatics analysis included BLAST, Artemis, database
search and neighbour-joining (NJ) for phylogenetic trees.
Results: A 55,797 bp DNA sequence ﬂanked by 67 bp direct repeats
(DRs), carrying blaACI-1 gene and presenting two large serine-
recombinases was detected in RYC-MR95. This sequence constitutes
the core element. Such element was found to be inserted into a
greater one (100,778 bp), also ﬂanked by 54 bp DRs, carrying a
single recombinase. Southern blot assays using several orfs as probes
revealed the presence of 2 copies of the core element in A. intestini
chromosome. The second copy, of 55.8 Kb, lacking the blaACI-1 gene,
had an insertion of 55,131 bp, and the complex was ﬂanked by the
same 67 bp DRs than the ﬁrst core element. The Acidaminococcus sp.
D21 complete genome sequence (EMBL), has only one copy of the
core element, which was inserted in the same site that the second copy
in A. intestini RYC-MR95, whereas the speciﬁc site of insertion for
the ﬁrst copy was empty in Acidaminococcus sp D21. These results
suggest horizontal gene transfer events. To conﬁrm this point several
housekeeping and ACI-1 element genes were sequenced in all the
strains of the study, belonging to different Acidaminococcus species. The
phylogenetic tree obtained by NJ discriminated the branches for different
species, while the phylogenetic trees obtained using genes from core
element showed a mixture between branches, suggesting horizontal gene
transfer. Such element shows modules from different origins, including
genes of ﬁve different functional groups: recombinases, polymerases and
endonucleases, virulence, transcriptional regulation and methylases and
phage origin genes.
Conclusions: Amobile sequence of 55.8 Kb was found in two sites in the
chromosome of A. intestini RYC-MR95. According to known sequence
in Acidaminococcus sp. D21 these sites are site-speciﬁc suggesting
mobilization by site-speciﬁc recombinases. Different functional modules
from different origins suggest a modular evolution.
P892 Prevalence of primary clarithromycin resistance in
Helicobacter pylori strains over a 15-year period in Spain
S. Agudo °, T. Alarco´n, P. Urruzuno, A´. Somodevilla, M. Lo´pez-Brea
(Madrid, ES)
Introduction: Clarithromycin is one of the most important antibiotics
for H. pylori treatment and it is the most important factor to
predict eradication failure. This study will analyze the progression of
clarithromycin resistance and the most common point of mutations over
a 15 year period in Spain.
Methods: We studied 64 biopsies from H. pylori-positive patients from
four different regions from Spain in 1994 and 118 biopsies between
June 2008 to January 2009 from Madrid. Clarithromycin resistance was
determined by E-test, strains were considered resistant if MIC> 1mg/L.
DNA extraction was carried out with phenol/chloroform/isoamil alcohol
(25:24:1) in 1994 and by the NucliSens easyMAG platform with the
NucliSens magnetic extraction reagents (bioMe´rieux). Clarithromycin
resistant and sensitive strains were by PCR and DNA sequencing for
mutations in the 23S rRNA gene.
Results: In the 2008 period, we found 42 out of 118 (35.6%) strains
resistant to clarithromycin by E-test. E-test results were conﬁrmed for
the presence of point mutation in 34 (88.1%) of these strains. There were
8 H. pylori strains resistant to clarithromycin by E-test but without point
of mutation in the 23S rRNA gene. Point mutation A2143G was found
in 85.3% of the strains, A2142G was found in 8.8% of the strains and
T2182C was found in 5.9% of the strains. Dual mutations were found
in 8.8% of the strains. On the other hand in 1994, 10 out of 64 (15.6%)
strains were resistant to clarithromycin by E-test and molecular biology.
7 out of 10 (70%) resistant strains were from Madrid patients. 9 strains
had the point of mutation in the position A2143G and one in the position
A2142G.
Conclusions: Clarithromycin resistance was higher in Madrid than in
the rest of Spain in 1994. However, in Madrid there has been the same
level of resistance to clarithromycin and the same type of mutation in
the last ﬁfteen years.
P893 Mutant ribosomal protein S5 discovered in spectinomycin-
resistant Neisseria gonorrhoeae
E. Ilina °, N. Oparina, M. Malakhova, A. Borovskaya, I. Demina,
M. Serebryakova, M. Rogova, V. Govorun (Moscow, RU)
Objectives: Spectinomycin (SPC) is an antibiotic recommended for
gonorrhea treatment. The only mechanism described for the Neisseria
gonorrhoeae (NG) resistance to SPC are mutations in 16S rRNA
which are rare in clinical population. The other probable ways for SPC
resistance formation was investigated by in vitro selection of two SPC
resistant strains from different NG serovars. The possibility of SPC
resistance in NG due to isolated mutation T24P in ribosomal protein
(RP) S5 was demonstrated.
Methods: Two resistant NG strains were obtained from parent
susceptible ones by in vitro selection on GC agar supplemented with
1% IsoVitaleX and increasing concentrations of SPC (32 mkg/ml −
256 mkg/ml). Sequence analysis of 16S rRNA as well as RPs S5,
S4 and S8 were performed with dedicated primers using the BigDye
Terminator kit and the ABI Prism 3100 Genetic Analyser (Applera,
USA). The 2D electrophoresis of CHAPS soluble fraction of NG and
protein identiﬁcation were done as described earlier [Demina I. A.,
2009].
Results: SPC-resistant mutants were obtained from parent strains
belonged to P1A and P1B serovars after a month of selection. No
substitutions presumably associated with SPC resistance were found
in four copies of 16S rRNA genes analyzed independently. RPs S5,
S4 and S8 located nearby the SPC binding site were studied too. The
only mutation Thr24Pro was observed in RP S5 for both mutants. In
accordance with alignment this position matched to Ser22 of E. coli RP
S5, whose mutations were previously reported to result in SPC resistance
[Itoh, 1973].
Comparative proteomics of mutant strains vs. parent ones demonstrated
the multiple changes in the mobility of the same proteins. Several
genes encoding such proteins were sequenced, and no shift-explanating
substitutions were found. Such effect may be explained by disorders in
the protein synthesis by mutant ribosome because of similar inﬂuence
of RP S5 mutations was also found for E. coli [Kirthi, 2006].
Conclusion: For the ﬁrst we have shown that the SPC resistance of NG
could be generated by RPs5 mutation. Basing on proteomic research
data we have suggested that SPC-resistant NGs are rare due to disorders
in translation related to such phenotype.
P894 Molecular characterization of penicillin-binding-protein-3
in clinical isolates of Haemophilus inﬂuenzae with reduced
susceptibility to cefotaxime, taken from the British Society
for Antimicrobial Chemotherapy respiratory resistance
surveillance study 20
D. Knight, K. Maher, J. Blackman Northwood, R. Reynolds,
I. Morrissey ° (Fordham, Birmingham, UK)
Objective: The British Society for Antimicrobial Chemotherapy
(BSAC) respiratory resistance surveillance study monitors resistance in
community-acquired lower respiratory infections in the United Kingdom
and Ireland. The objective of this study was to identify the mechanism of
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cefotaxime non-susceptibility in three non-b-lactamase producing strains
of Haemophilus inﬂuenzae collected from 2004/05–2007/08.
Methods: MIC determination was achieved by using the BSAC agar
dilution susceptibility testing method. To determine the mechanism
of cefotaxime non-susceptibility, penicillin-binding-protein 3 (PBP3)
sequencing was performed as previously described (Straker et al,
J.Antimicrob. Chemotherapy 51:523. 2003).
Results: Minimum inhibitory concentration (MIC) was determined for
3740 clinical isolates of H. inﬂuenzae collected as part of the BSAC
Respiratory Resistance Surveillance Study 2004/05–2007/08. Of 3740
clinical H. inﬂuenzae isolates, 3205 (86%) were b-lactamase negative.
Of these, 3115 (97%) had cefotaxime MICs of 0.06mg/L, 66 (2.1%)
had MICs of 0.12mg/L and 19 (0.6%) were resistant to cefotaxime with
MICs of 0.25mg/L. We identiﬁed two isolates (HI040610 and HI062032)
with a cefotaxime MIC of 0.5mg/L and one (HI072003) with MIC
of 1mg/L. The table shows the amino acid substitutions found in the
PBP3 of these three isolates, with two highly susceptible isolates and
two reference strains for comparison.
Conclusion: Reduced susceptibility to cefotaxime, requiring MICs
>0.25mg/L is rare in non-b-lactamase producing strains of H. inﬂuenzae.
We have shown that the presence of amino acid substitutions within the
region adjacent to the PBP3 active site appear to cause raised cefotaxime
MIC. A substitution at amino acid 350 may cause a moderate increase
in cefotaxime MIC (0.12mg/L), but a combination of one or more
mutations between amino acid positions 490 and 517 confer isolates
with the highest cefotaxime MIC (0.5mg/L).
Isolate Cefotaxime MIC PBP3 Amino Acid positions
(mg/L) 350 490 502 511 517 526
HI072031 0.008 D G A V R N
H1072049 0.008 D G A V R N
ATCC 49247 0.015 D G A V R K
NCTC 11931 0.12 N G A V R N
HI040610 0.5 D E V V R K
HI062032 0.5 D G A V H N
HI072003 1 D G A A H N
P895 High-level trimethoprim-resistant Haemophilus inﬂuenzae
is due to multiple changes in the dfr gene and its promoter
plus the possession of plasmidic dfrA17 gene
B. Aracil °, S. Garcı´a-Cobos, M. Pe´rez-Va´zquez, F. Roma´n, J. Oteo,
V. Bautista, J. Campos (Madrid, ES)
Objective: Haemophilus inﬂuenzae (Hi) is an important human
pathogen. Cotrimoxazol has been used for the treatment of respiratory
and urinary infections caused by this and other pathogens and is still
being used in many countries; however, although trimethoprim (T)
resistance is broadly distributed in Hi, only limited data are available on
the mechanisms responsible of T resistance. Therefore, the aim of study
was to describe the modiﬁcations found in the constitutive dihydrofolate
reductase gene (dfr) and to study plasmidic dihydrofolate reductase genes
(dfrA) associated with highly T resistant Hi.
Methods: We studied 58 clinical Hi strains (21 T susceptible and 37
T highly resistant, 42 of them were capsulated of types b, e and f, and
16 were non-capsulated. A DNA fragment of 535 bp containing the dfr
gene and its promoter region, was ampliﬁed by PCR and sequenced.
An in vitro mutation model was also developed. Single nucleotide
polymorphisms (SNPs) of dfr and its promoter were analysed in the
same bacterial collection and in vitro T resistant mutants. In addition,
the plasmidic genes: dfrA7, dfrA9, dfrA12, dfrA13, dfrA14, dfrA17 were
identically ampliﬁed and sequenced.
Results: No aminoacid changes were detected in the dfr protein of 12
T susceptible strains (7 clinical isolates and 5 susceptible controls); 9
additional Ts isolates had 1 to 4 changes. T resistant Hi strains had
an average of 6 amino acid substitutions (range 1−13). The two most
frequent substitutions in T resistant strains were Lys107 to Gln (56.7%),
and Met21 Ile (48.6%). In addition, all T resistant strains had changes in
the dfr promoter region while none of the T susceptible strains did. SNPs
analysis showed that T resistant strains were highly polymorphic (average
of SNPs patterns 12, range 0−24) in comparison with T susceptible ones
(average of SNPs patterns 1, range 0−3). T resistant isogenic mutants
reproduced in part the aminoacid changes found in the wild T resistant
strains. Besides we found the dfrA17 plasmidic gen in all T resistant and
none T susceptible strains. Another plasmidic dfr genes studied, were not
found.
Conclusions: (1) Highly T resistant in Hi is due to multiple aminoacid
substitutions in the dfr enzyme plus the possession of dfrA17 gene.
(2) Resistant strains also show nucleotide changes in the promoter region
of dfr.(3) Dfr gene is genetically much more diverse in resistant strains.
P896 Expression of Moraxella catarrhalis outer membrane porin
M35 − regulation by exposure to aminopenicillins and cold
shock
M. Jetter °, R. Troller, C. Aebi (Berne, CH)
Objectives: The outer membrane protein M35 of Moraxella catarrhalis
is an antigenically highly conserved porin and involved in the uptake of
essential nutrients, but also in the susceptibility to aminopenicillins. M35
knock-out mutants show a signiﬁcantly higher MIC (minimal inhibition
concentration) for aminopenicillins than their respective wild-types. The
aim of this study is to determine the biological mechanism of this
potentially new antimicrobial resistance mechanism of M. catarrhalis
and the possibility of M35 as a cold shock regulated protein.
Methods: PCR using m35 speciﬁc primers was used to detect the
m35 gene in clinical isolates. The m35 mRNA expression of the
strains 300, O35E and 415 after exposure to amoxicillin or cold shock
treatment was measured by real time PCR and normalized to their 16S
mRNA expression. The expression of the M35 protein after growth with
amoxicillin respectively at 26ºC vs. 37ºC was analyzed by SDS-PAGE
and Western Blot.
Results: The screening of 52 clinical middle ear isolates resulted in
positive PCR products for all tested isolates. The analysis of the m35
mRNA expression after amoxicillin treatment showed an up to 80%
down regulation compared to the amoxicillin-free control in all three
strains tested. To demonstrate that this down regulation is not only a
transcriptional phenomenon, OMP of all three strains were isolated and
protein expression was analyzed by Western Blot. In-deed, all three
strains showed a lower M35 expression after growth with amoxicillin
than without amoxicillin. The cold shock analysis resulted in the same
effect as amoxicillin treatment. All three strains grown at 26ºC showed
an up to 80% down regulation of m35 mRNA expression compared
to 37ºC and protein expression of M35 after cold shock treatment was
reduced as well.
Conclusion: The altered expression of M35 after aminopenicillin
exposure indicates that this is a new resistance mechanism against
aminopenicillins in M. catarrhalis. In addition to the production of
b-lactamases, down regulation of porin expression is a well known
resistance mechanism in other bacteria. The differences in the expression
after cold shock treatment demonstrates that M35 is an additional
cold shock-regulated protein of Moraxella catarrhalis whose biological
function needs further investigation.
P897 Frequency and molecular characterization of macrolide and
ﬂuoroquinolone resistance in Helicobacter pylori isolates
identiﬁed at a university hospital, Karachi, Pakistan
S. Rajper °, E. Khan, Z. Ahmad, Z. Alam, R. Hasan (Karachi, PK)
Background: Helicobacter pylori (H. pylori) is the major infectious
cause for gastritis, peptic ulcer disease, gastric MALTomas and gastric
adenocarcinoma. Prevalence of H. pylori in Pakistan is upto 80% in
adult population alone and antibiotic susceptibility data for H. pylori
in Pakistan is virually non-existant. Treatment is based empirically
following international guidelines. In this study we determined the
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susceptibility of H. pylori against two frequently used antibiotics i.e
clarithromycin and ﬂuoroquinolones in biopsy samples by Reverse
Hybridization. To the best of our knowledge this is the ﬁrst study
reporting resistance pattern and molecular characterization of H. pylori
isolates from Pakistan.
Objectives: To determine the frequency and molecular characterization
of clarithromycin and ﬂuoroquinolones resistance in H. pylori isolates
at Aga Khan University Hospital, Karachi.
Materials and Methods: gastric antral biopsies(n = 115) positive for
H. pylori on histological ﬁndings were included in this study. DNA
extraction was done from parafﬁn embedded tissue biopsy samples
followed by ampliﬁcation and hybridization. Resistance to antibiotics
was determined by detecting mutations in the known genomic sites.
Fluoroquinolone resistance was determined by detecting mutations
in gyrA while clarithromycin resistance was detected by 23S rRNA
mutation on hybridization strip.
Results: Of the 115 isolates processed, ﬂuoroquinolone resistance was
noted in 49.13%(57/115) with GyrA 87 mutation being the most
common, where as clarithromycin resistance was noted in 34.78%
(40/115) with A2147G being the commonest mutation observed. Overall
25.21% (29/115) showed mutations suggestive of resistance to both
drugs. Heteroresistance was also observed in 36.52%(42/115) isolates.
Conclusion: Resistance to ﬂuoroquinolone and clarithromycin is
common in H. pylori isolates yielded at Aga Khan University. This
alerts towards the risk of treatment failure in patients who are treated
empirically. Susceptibility tests are needed to improve patient care by
providing targeted therapy especially in Pakistan where burden of disease
is high and no data is available to guide clinicians to choose appropriate
therapy.
P898 Mutations of gyrA and parC in Neisseria gonorrhoeae
clinical isolates in Hong Kong
L.K. Chan °, M. Hui, Z.K. Liu, L.Y. Lam, N.M. Luk, A.K. Chan,
K.K. Lo, C.Y. Chan (Hong Kong, CN)
Objective: The antimicrobial susceptibility of Neisseria gonorrhoeae
against ﬂuoroquniolones has shown regional differentiation with regard
to the mutations in the gyrA and parC subunits. With different mutation
sites in gyrA and parC reported worldwide, we studied the phenotypic
and genotypic resistance to ﬂuoroquinolones in Neisseria gonorrhoeae
in Hong Kong and compared that with other regions.
Methods: 86 clinical isolates of Neisseria gonorrhoeae had been
collected from the Yaumatei Social Hygiene Clinic in Hong Kong.
Detection of mutations in the gyrA and parC genes was performed by
sequence analysis. MIC values were determined by agar dilution method
according to the NCCLS.
Results: None of the strains were susceptible to ﬂuoroquiniolones. 95%
of the clinical isolates demonstrated resistance to ciproﬂoxacin and had
MIC 1mg/L. Four of the isolates fell into the intermediate range with
MIC of 0.12–0.25mg/L.
The result of sequence analysis showed that 98.8% of the isolates had
mutations due to amino acid changes both at position 91 and 95 in
the gyrA gene. All isolates demonstrated a change of Ser-91→ Phe, 23
isolates (26.7%) showed a change of Asp-95→Gly, 56 isolates (65.1%)
showed a change of Asp-95→Ala and 6 isolates (7%) showed a change
of Asp-95→Asn. Only one isolate showed mutations at Ser-91→ Phe
and Ala-92→ Pro with no mutation at position 95. Mutation in parC gene
mainly appeared at amino acid positions 86 to 91: 6 isolates (7%) had
mutation at Asp-86, 58 isolates (67.4%) had mutation at Ser-87 and 10
isolates (11.6%) had mutation at Glu-91. The 84 strains were categorized
into 22 types as shown in the table. Our results concurred with most of
the ﬁndings reported in other regions worldwide and in addition we
had found 3 new mutation sites of Gly-35→Asp, Asp-86→Gly and
Glu-91→Ala in the parC gene. One silent mutation in gyrA and four
silent mutations in parC were found which gave no amino acid change.
Conclusion: The multiple mutation sites found in the Quinolone-
resistant determining regions (QRDR) suggest that they are important in
the development of quinolone resistance. Most of the mutation proﬁles
were consistent with previously reported categories. Accumulation of
mutation in gyrA and parC is now of common occurrence.
Table. Amino acid substitutions in gyrA and parC genes in relation to
ciproﬂoxacin MICs
Mutations No. of strains MIC (mg/L)
gyrA parC
Ser-91 Ala-92 Asp-95 Gly-35 Asp-86 Ser-87 Ser-88 Glu-91
Phe Pro 1 1
Phe Gly 1 2
Phe Gly Asn 4 4−16
Phe Gly Gly 1 4
Phe Gly Arg 11 1−32*
Phe Gly Ala 1 2
Phe Gly Gly 2 4−16
Phe Gly Asp Arg 1 32
Phe Gly Arg Pro 1 32
Phe Gly Asn Gln 1 4
Phe Ala 10 0.25−4**
Phe Ala Gly 1 4
Phe Ala Arg 26 1−32
Phe Ala Asn 12 0.12−16***
Phe Ala Cys 1 4
Phe Ala Ile 1 32
Phe Ala Pro 1 4
Phe Ala Gly 2 4−16
Phe Ala Ala 1 4
Phe Ala Arg Pro 1 8
Phe Asn Ile 3 32
Phe Asn Gly 3 1
*Only one isolate exhibited a MIC of 1 mg/L; all others had MIC 4 mg/L.
**Only two isolates exhibited MICs of 0.25mg/L; all others had MIC 1 mg/L.
***One isolate exhibited MIC of 0.12mg/L and one exhibited MIC of 0.25mg/L; all the others had MICs 2mg/L.
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P899 PNU-100480, PNU-101244 and PNU-101603: preliminary
broth microdilution quality control ranges versus bacterial
reference strains and in vitro antibacterial effect studies
S. McCurdy °, M. Huband (Groton, US)
Objective: PNU-100480 is an orally active oxazolidinone being
developed for the treatment of susceptible, multi-drug and extensively
drug resistant strains of Mycobacterium tuberculosis. PNU-101603 and
PNU-101244 are primary metabolites of PNU-100480. This study was
undertaken to determine preliminary broth microdilution quality control
ranges for these compounds against Clinical and Laboratory Standards
Institute (CLSI) bacterial reference strains. In addition, the effects of
various experimental parameters on MICs were determined including:
inoculum size, pH, cation concentration, temperature, incubation
atmosphere, and human serum (in vitro effects).
Methods: PNU-100480, PNU-101244 and PNU-101603 broth microdi-
lution plates were prepared and tested according to CLSI guidelines and
included linezolid as a control. Two lots of cation-adjusted Mueller-
Hinton broth [CAMHB] (BD and Remel) and two lots of CAMHB
+3% lysed horse blood (Remel) were included. On separate days, each
reference strain and lot of media was tested. At the study completion, the
MIC for each organism/compound and lot of medium was determined
and preliminary QC ranges proposed and in vitro effects determined.
CLSI reference strain QC range
MIC,
mg/mL
Preliminary distribution
of MICs
PNU-100480
Staphylococcus aureus ATCC 29213 2−4 2 (18)a; 4 (10)
Enterococcus faecalis ATCC 29212 2 2 (28)
Streptococcus pneumoniae ATCC 49619 1 1 (14)
PNU-101244
Staphylococcus aureus ATCC 29213 2−4 2 (26); 4 (2)
Enterococcus faecalis ATCC 29212 1−2 1 (23); 2 (5)
Streptococcus pneumoniae ATCC 49619 0.5 0.5 (14)
PNU-101603
Staphylococcus aureus ATCC 29213 4 4 (28)
Enterococcus faecalis ATCC 29212 2−4 2 (27)
Streptococcus pneumoniae ATCC 49619 0.5−1 0.5 (11); 1 (3)
aNumber of tests with this MIC.
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Conclusions: Preliminary QC ranges for PNU-100480, PNU-101244
and PNU-101603 were determined and in vitro effects were examined.
No signiﬁcant lot to lot variability was observed for compound MICs in
CAMHB or CAMHB +3% LHB and no in vitro effects were found.
P900 In vitro and in vivo activity of PF-03315011: a new oxazo-
lidinone antibacterial versus recent bacterial clinical isolates
M. Huband °, L.M. Mullins, P.J. Pagano, J.B. Penzien, S. McCurdy,
M.M. Lemmon, G.W. Gibson, K. Leach, L. Qiu, J. Vara Prasad (Groton,
Ann Arbor, US)
Objective: Antibacterial resistance in Gram-positive bacterial species
continues to develop in both nosocomial and community settings (multi-
drug resistant Streptococcus pneumoniae, MRSA {USA 100, USA 300,
cfr}, vancomycin-intermediate Staphylococcus aureus). PF-03315011
is a new oxazolidinone being developed to treat infections caused
by susceptible and multi-drug resistant Gram-positive bacteria. This
study investigated the in vitro antibacterial activity of PF-03315011 and
comparator compounds by MIC, MBC, time-kill, and in vitro toxicity
assays. In vivo testing (PD50 determinations) was performed in CD1
female mice using protocols approved by the Pﬁzer Animal Care and Use
Committee in compliance with National Institute of Health guidelines
for proper care and use of laboratory animals.
Methods: MICs, MBCs, and time-kill assays followed Clinical and
Laboratory Standards Institute (CLSI) guidelines.
Results: In a Staphylococcus aureus (MRSA) acute systemic murine
infection model, PD50s (oral dosing, QD) for PF-03315011 and linezolid
were 0.52 and 1.52mg/kg, respectively; similarly, in a pneumococcal
pneumonia mouse model, (oral dosing, BID), PF-03315011 and linezolid
PD50s were 2.0 and 2.6mg/kg, respectively.
Conclusions: This study conﬁrms the in vitro antibacterial activity and
in vivo potency of PF-03315011 against clinically signiﬁcant Gram-
positive bacteria.
Organism (n) MIC, mg/mL
PF-03315011 Linezolid Levoﬂoxacin
Staphylococcus aureus oxacillin-S (20) 4 4 0.25
Staphylococcus aureus MRSA (118)a 4 4 32
Staphylococcus epidermidis (36)b 2 2 64
Coagulase negative staphylococci (54)c 4 4 32
Streptococcus pyogenes (28) 4 2 2
Streptococcus agalactiae (21) 4 2 1
Streptococcus pneumoniae (116)d 2 2 16
aIncludes 47 MRSA, 33 community acquired MRSA, 34 levoﬂoxacin-R MRSA,
and 4 VISA.
bIncludes 13 oxacillin-resistant S. epidermidis and 23 oxacillin-susceptible
S. epidermidis strains.
cIncludes 18 Staphylococcus haemolyticus, 13 S. lugdunensis, 10 S. saprophyticus,
and 13 S. warneri.
d Includes penicillin-susceptible, -intermediate, -resistant, and levoﬂoxacin-R
Streptococcus pneumoniae strains.
P901 CEM-101, a novel ﬂuoroketolide, tested against European
clinical isolates from 2009 (ﬁrst-year surveillance results)
R. Jones °, D. Farrell, H. Sader, M. Stilwell, M. Castanheira (North
Liberty, US)
Objectives: To determine the potency and spectrum of CEM-101, a
new ﬂuoroketolide, tested against contemporary (2009) European (EU)
pathogens. Preliminary results suggest that CEM-101 has expanded
activity against multidrug-resistant (MDR) pathogens associated with
community-acquired bacterial pneumonia (CABP), and skin and skin
structure infections (SSSI) when compared to macrolides (erythromycin
[ER], azithromycin [AZ], clarithromycin [CL]), clindamycin (CC) and
telithromycin (TE).
Methods: EU CEM-101 surveillance study collected 3,531 strains,
as following: S. aureus (SA; 1,398), coagulase-negative staphylococci
(CoNS; 454), enterococci (ENT; 613), S. pneumoniae (SPN; 485),
viridans group (VGS; 98) and b-haemolytic (BHS; 212) streptococci,
H. inﬂuenzae (HI; 242) and M. catarrhalis (MCAT; 29). These
consecutive strains were susceptibility (S) tested by CLSI methods
and results were interpreted by EUCAST breakpoints; TE interpretive
criteria were applied to CEM-101 for comparison purposes only. Thirteen
countries and nearly 30 medical centers were sampled.
Results: CEM-101 was very active against SPN (MIC90, 0.06mg/L),
VGS and BHS (MIC90, 0.03mg/L) with 100.0 and 98.1–100.0% of
isolates inhibited at 1 and 0.25mg/L, respectively. This potency was
 two fold greater than TE, and CEM-101 inhibited at 3.7% more
SPN at 0.25mg/L. The tested SPN was only 72.0, 74.2 and 82.1%
S to penicillin (PEN), ER and CC, respectively. Against HI and MCAT,
CEM-101 was quite active (MIC90/% inhibited at 4mg/L): 2/99.6 and
0.06/100.0, respectively (two-fold more active than TE). This activity
against Gram-negative CABP pathogens was most like AZ. SA and
CoNS (MIC50, 0.06mg/L for both) were generally S to CEM-101 (92.1
and 71.2% S versus 90.5 and 70.5% S for TE). ENT was only moderately
S to CEM-101 (MIC50/90, 1/2mg/L), but was two-fold more potent than
TE. E. faecalis (EF) isolates were usually more S (MIC50 at 0.25mg/L)
than other ENT. The EU collection sampled had 22.7% MRSA, 82.8%
MRCoNS, 1.7% vancomycin-resistant (VR) EF, 36.8% VR E. faecium,
41% PEN-R VGS, 4.8% TE-R S. pyogenes and 16.9% ampicillin-R HI.
Conclusions: CEM-101 clearly exhibited greater potency than currently
available MLSB agents (including TE, another ketolide) against
potentially indicated pathogens causing CABP or SSSI. Expanded
clinical investigations of CEM-101 appear warranted for oral and
parenteral route coverage of emerging MDR strains.
Organism (no.) % occurrences at CEM-101 MIC (mg/L):
0.03 0.06 0.12 0.25 0.5 1 2 4 >4
S. aureus (1,398) 16.0 71.7 3.5 0.4 0.3 0.3 <0.1 <0.1 7.7
CoNS (454) 31.7 28.0 9.9 0.9 0.7 − − 0.2 28.6
Enterococci (613) 32.6 2.3 1.8 1.6 8.7 20.1 28.2 4.6 0.2
S. pneumoniae (485) 92.8 2.5 1.4 2.7 0.4 0.2 − − −
VGS (98) 93.9 6.1 − − − − − − −
BHS (212) 90.6 3.8 2.4 1.4 1.9 − − − −
H. inﬂuenzae (242) − − 0.4 1.2 23.6 61.6 12.4 0.4 0.4
M. catarrhalis (29) 20.7 72.4 6.9 − − − − − −
a − = no occurrences, 0.0%; boldface value at MIC90.
P902 Multiple dose pharmacokinetics and safety of CEM-101, a
new ﬂuoroketolide, in healthy subjects
J. Still °, K. Clark, T. Degenhardt, D. Scott, P. Fernandes, S. Sharples
(Chapel Hill, Tempe, US)
Objectives: CEM-101 is a potent new ﬂuoroketolide under development
for treatment of bacterial respiratory tract and other infections. CEM-
101 pharmacokinetics (PK) and safety at single doses to 1600mg have
been reported previously. Safety and PK following escalating multiple
oral doses were investigated in this study.
Methods: This was a randomized, double-blind, placebo-controlled,
dose escalation study. Escalating doses (200, 400, and 600mg) were
administered once daily for 7 days to healthy adult subjects (5:2,
active:placebo; 200mg [n = 7], 400mg [n = 14] and 600mg [n = 14]).
Physical examinations, vital signs, ECGs, clinical laboratory tests, and
adverse events were monitored throughout the study. Blood samples for
CEM-101 concentrations and PK assessments were collected pre-dose
and frequently to 24 h post-dose on Day 1 and to 72 h post-dose on Day
7.
Results: CEM-101 mean Cmax values on Days 1 and 7 were 0.113
and 0.248 mcg/mL for the 200mg group, 0.579 and 1.09 mcg/mL for
the 400mg group, and 0.862 and 1.50 mcg/mL for the 600mg group.
Corresponding AUC(0−24) values were 0.888 and 2.31 mcg·h/mL, 4.85
and 13.30 mcg·h/mL, and 7.64 and 18.40 mcg·h/mL on Days 1 and 7.
Increases in Cmax and AUC(0−24) were more than dose proportional
from 200 to 400mg and then approximately dose proportional from 400
to 600mg. At all doses CEM-101 exposures were higher on Day 7 than
New antimicrobials: oxazolidinones, ﬂuoroketolides and pleuromutilins S239
Day 1, indicating that accumulation occurred over the dosing period.
Across the dose range the mean Tmax increased from 3.0 to 4.0 hours
on Day 1 and from 3.5 to 4.0 hours on Day 7 and the mean T1/2
increased from 3.64 to 5.06 hours on Day 1 and from 5.39 to 7.64 hours
on Day 7. All doses of CEM-101 were safe and generally well tolerated.
Gastrointestinal AEs, mostly mild, occurred in each dose group. ALT or
AST increases occurred in 4 of 10 subjects that received 600mg CEM-
101; all were low-level, transient, reversible, and not associated with
signs or symptoms of toxicity.
Conclusion: Over the 200 to 600mg dose range, multiple doses of
CEM-101 were safe and generally well tolerated in healthy male and
female subjects. Cmax and AUC0-inf increases were more than dose
proportional across the dose range and moderate accumulation of CEM-
101 was noted after 7 days of administration.
P903 CEM-101, a novel ketolide; in vitro activity against Legionella
pneumophila
J. Dubois °, P. Fernandes (Sherbrooke, CA; Chapel Hill, US)
Objective: CEM-101 is a new ﬂuoroketolide that has potent activity
against respiratory tract pathogens. The activity against a variety of
Legionella pneumophila serogroup was investigated.
Methods: The in vitro activity of CEM-101 was compared with that of
telithromycin, azithromycin, erythromycin, levoﬂoxacin and doxycycline
against a total of 300 Legionella pneumophila by a standard agar dilution
procedure using buffered yeast extract agar. The species tested included
L. pneumophila serogroup 1 (125 isolates), serogroup 2 (28), 3 (25), 4
(36), 5 (25), 6 (50) and serogroup 7, 8, 9, 12 (11).
Results: CEM-101 (MIC90 0.016mg/L) was as active as levoﬂoxacin
(MIC90 0.016mg/L) against L. pneumophila and was more active than
telithromycin (MIC90 0.06mg/L), azithromycin (MIC90 0.25mg/L),
erythromycin (MIC90 1mg/L) and doxycycline (MIC90 1mg/L).
Against the most frequent L. pneumophila such as serogroup 1,
the MIC90 of CEM-101 (0.03mg/L) was superior to telithromycin
(0.06mg/L), azithromycin (0.5mg/L), erythromycin (1mg/L) and
doxycycline (1mg/L). Against L. pneumophila serogroup 1, the MIC90
of CEM-101 (0.03mg/L) was similar to levoﬂoxacin (0.016mg/L).
CEM-101 was less active against L. pneumophila serogroup 1, 2, 3, 4,
5, and 6 strains (MIC90 0.016mg/L) than L. pneumophila serogroup 7,
8, 9 and 12 (MIC90 0.008mg/L).
Conclusions: These data conﬁrm the interesting activity of this new
ﬂuoroketolide CEM-101 against Legionella pneumophila.
P904 CEM-101, a novel ketolide: in vitro activity against resistant
strains of Streptococcus pneumoniae and Haemophilus
inﬂuenzae
J. Dubois °, P. Fernandes (Sherbrooke, CA; Chapel Hill, US)
Objective: CEM-101 is a promising ﬂuoroketolide that has potent
activity against respiratory tract pathogens resistant to other macrolide
agents. Its activity against a variety of resistant strains of Streptococcus
pneumoniae and Haemophilus inﬂuenzae was investigated.
Methods: The in vitro activity of CEM-101 was compared with that of
telithromycin, azithromycin, erythromycin, levoﬂoxacin and doxycycline
against a total of 199 resistant S. pneumoniae and 191 resistant
H. inﬂuenzae by agar dilution procedures (CLSI, M7-A7, M100-S18).
The tested strains included S. pneumoniae erythromycin-resistant (erm
B genotype; 107 isolates and mefE genotype; 54) and ciproﬂoxacin-
resistant (gyrA and parC genotype; 38) and also H. inﬂuenzae ery-
resistant (ermA,B,C genotype; 138) and cipro-resistant (gyrA and parC
genotype; 53).
Results: Against S. pneumoniae ery-resistant strains (ermB geno-
type), the activity of CEM-101 (MIC90 1mg/L) and levoﬂoxacin
(MIC90 2mg/L) was superior to the macrolides tested: telithromycin
(MIC90 4mg/L), azithromycin (MIC90 64mg/L), erythromycin
(MIC90 64mg/L)) and doxycycline (MIC90 32mg/L). Against
S. pneumoniae ery-resistant (mefE genotype) group, CEM-101 (MIC90
0.25mg/L) was the most active agent followed by levoﬂoxacin
(MIC90 2mg/L), telithromycin (MIC90 8mg/L), doxycycline (MIC90
16mg/L), azithromycin (MIC90 64mg/L) and erythromycin (MIC90
64mg/L). Against S. pneumoniae cipro-resistant (gyrA and parC
genotype) group, CEM-101 (MIC90 0.25mg/L) was also the most active
agent tested followed by telithromycin (MIC90 1mg/L), levoﬂoxacin
(MIC90 2mg/L), doxycycline (MIC90 16mg/L), azithromycin (MIC90
64mg/L) and erythromycin (MIC90 64mg/L). Against H. inﬂuenzae
ery-resistant (ermA,B,C genotype) strains, CEM-101 (MIC90 4mg/L)
was the most active macrolide tested followed by telithromycin (MIC90
16mg/L), azithromycin (MIC90 16mg/L) and erythromycin (MIC90
64mg/L). Against H. inﬂuenzae cipro-resistant (gyrA and parC
genotype) group, CEM-101 (MIC90 2mg/L) was slightly more active
than telithromycin (MIC90 4mg/L) and levoﬂoxacin (MIC90 4mg/L).
Conclusions: These data conﬁrm the interesting activity of the new
ﬂuoroketolide CEM-101 against resistant Streptococcus pneumoniae and
Haemophilus inﬂuenzae.
P905 Expanded studies of CEM-101, a novel ﬂuoroketolide,
tested against invasive isolates of N. meningitidis, including
ﬂuoroquinolone-non-susceptible resistant strains
R. Jones °, D. Biedenbach, L. Woosley, G. Gerken, M. Castanheira
(North Liberty, Iowa City, US)
Objectives: To evaluate the potential role/potency of CEM-101 tested
against N. meningitidis (NM) as a decolonizing regimen. More than
100 invasive clinical isolates were screened, including three cases of
ciproﬂoxacin-non-susceptible NM (C-NSNM) provided by the CDC
(Drs. H. Wu and M. Warton) occurring in North Dakota and California
(2007–2008).
Methods: 62 isolates were previously studied and that collection
was expanded to 103, including the C-NSNM (ciproﬂoxacin MICs,
0.06–0.25mg/L). The strains (>90% blood cultures) were collected
in 1997–2009 from 43 medical centers in North (58 strains) and
South (13) America, Europe (31) and Asia-Paciﬁc (1). Strains were
tested by CLSI broth microdilution methods for susceptibility (S) to
CEM-101 and 11 comparators, including b-lactams, ﬂuoroquinolones
(FQs), macrolides and three other classes. Serological identiﬁcation was
performed for serogroups (SGs) B, C, Y and W135. NM displaying
elevated ciproﬂoxacin MIC values (0.06mg/L) were evaluated for
mutations on gyrA or B and parC or E, and in the efﬂux pump gene
mtrR.
Antimicrobial agent MIC (mg/L) %Sa %Ra
50% 90% Range
CEM-101 0.015 0.015 0.015–0.06 − b −
Telithromycin 0.015 0.03 0.015–0.12 − −
Azithromycin 0.06 0.12 0.015–0.25 100.0 −
Clarithromycin 0.03 0.12 0.015–0.25 − −
Erythromycin 0.12 0.25 0.03−0.5 − −
Penicillin 0.03 0.12 0.015–0.25 84.5 0.0
Ceftriaxone 0.015 0.015 0.015 100.0 −
Ciproﬂoxacin 0.008 0.008 0.008–0.25 97.1 1.9
Levoﬂoxacin 0.008 0.008 0.008–0.25 97.1 1.9
Minocycline 0.12 0.25 0.008–0.25 100.0 −
Rifampin 0.015 0.03 0.008–0.12 100.0 0.0
Trimethoprim/sulfamethoxazole 0.12 2 0.06−4 50.5 47.6
aSusceptibility criteria based on CLSI M100-S19 (2009).
b − No susceptibility criteria have been proposed, but azithromycin at 2mg/L has
been considered susceptible (active); CLSI M100-S19.
Results: Penicillin-S was 84.5% with no resistant (R) strains detected.
All isolates were S to ceftriaxone, azithromycin, minocycline and
rifampin. 97.1% of NM were S to ciproﬂoxacin and levoﬂoxacin
(0.015mg/L); however, about one-quarter of the strains had reduced S
to nalidixic acid (MIC, 8mg/L), which can correlate with diminished
S to FQs, and 3 isolates (CDC strains) were frankly non-S. R to
trimethoprim/sulfamethoxazole (T/S) was 47.6%. Of MLSB agents,
CEM-101 was the most active (MIC90, 0.015mg/L) compared to
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telithromycin (0.03mg/L), azithromycin and clarithromycin (0.12mg/L)
and erythromycin (0.25mg/L). The prevalence rates (%) of SGs were:
B (41.7), C (37.9), Y (12.6) and W135 (2.9); only 5 were not typeable.
Three strains with ciproﬂoxacin MIC values at 0.06mg/L harbored
gyrA mutations that generated the amino acid substitution T91l. These
strains carried no alterations on the remaining tested genes (gyrB, parC,
parE and mtrR).
Conclusions: CEM-101 was the most active MLSB agent tested against
NM strains (all MICs 0.06mg/L), with a potency two-to 16 fold
greater than any other in class drug. CEM-101 was active against NM
isolates non-S to b-lactams, T/S and especially FQs. Further studies
should determine if CEM-101 can eradicate NM from the nasopharynx
of at-risk patients in cases where R to other potential decolonizing agents
has emerged.
P906 Safety, tolerance and pharmacokinetics of single and repeat
doses of BC-3781, a novel antimicrobial
W.T. Prince °, W.W. Wicha, F. Obermayr, V. Moschetti, R. Novak
(Vienna, AT; Dusseldorf, DE)
Background: BC-3781 is a new pleuromutilin which is in clinical
development for the treatment of skin and skin structure infections
and pneumonia. BC-3781 shows excellent antimicrobial activity against
relevant bacteria including methicillin-resistant Staphylococcus aureus
(MRSA). Reported here are the results of the ﬁrst two studies
investigating the safety, tolerance and pharmacokinetics (PK) of BC-
3781.
Methods: In a double-blind, placebo randomized, single intravenous
(i.v.) dose escalation study BC-3781 was given to 2 cohorts of 6 healthy
subjects each. Each subject in Cohort 1 received 25, 50 and 100mg
BC-3781 and placebo and in cohort 2, 200, 300 and 400mg BC-3781
and placebo. In a second double-blind, placebo-controlled, randomized
study 2 cohorts of 12 subjects were given single and repeat doses of
BC-3781 or placebo. Cohort 1 received 75mg BC-3781 or placebo:
Day 1 single dose, days 3−14 twice daily (q12) and day 15 single
dose. Cohort 2 received 150mg BC-3781 or placebo. In both studies
vital signs, laboratory safety parameters, adverse events and ECG were
recorded and samples taken for PK.
Results: No adverse events of clinical concern were reported. Also, there
were no clinically signiﬁcant changes in vital signs or safety laboratory
parameters in any subject at any session. At expected therapeutic doses
BC-3781 was well tolerated but at the highest single doses tested (300
and 400mg) some subjects showed signs of local intolerance. The plasma
concentration of BC-3781 after i.v. administration shows a multi-phasic
decline. After single doses the terminal half life is 8.6–12.0 h and AUC
increases linearly with dose supporting q12 dosing. After repeat dosing
of BC-3781 to steady state the AUC increased and no signiﬁcant increase
of Cmax was seen. The large volume of distribution indicates BC-3781
is well distributed.
Conclusions: BC-3781 was safe and well tolerated up to the maximum
doses tested, 400mg single dose and 150mg q12. The PK of BC-3781
show that it behaves in a predictable manner in humans and the plasma
levels indicate it has therapeutic potential for the treatment of Gram
positive infections. BC-3781 is being progressed into phase 2 studies.
P907 In vivo pharmacodynamic activity of BC-3781
W.A. Craig, D. Andes, Z. Ivezic-Schoenfeld, W.W. Wicha °, R. Novak
(Madison, US; Vienna, AT)
Background: BC-3781 is an antimicrobial agent of the pleuromutilin
class inhibiting the prokaryotic protein synthesis. BC-3781 is in clinical
development for intravenous and oral treatment of skin and skin
structure infections (SSSI) and community-acquired pneumonia (CAP).
We examined the pharmacodynamics of BC-3781 against clinical isolates
of Staphylococcus aureus (including methicillin-resistant S. aureus) and
Streptococcus pneumoniae (including penicillin-resistant S. pneumoniae)
in a neutropenic murine thigh and lung infection model.
Methods: Animals were treated either with single doses of 5 to
160mg/kg or alternatively fractionated doses of 2, 4 or 8 applications
per day were given to determine the PK/PD index most relevant for
efﬁcacy. To investigate in vivo killing and post-antibiotic effects, single
doses of 10, 20 and 40mg/kg were administered subcutaneously. At start
of therapy CFU/thigh or lung of either SA or SP in infected mice varied
from 105 to 107. The 12 hour dose required for a net bacteriostatic effect
was determined using the Emax dose-response model. Plasma protein
binding was determined using equilibrium dialysis.
Results: BC-3781 exhibited time-dependent killing with moderate post-
antibiotic effects (PAE) of about 3.5 hours for S. pneumoniae and around
1.5 hours for S. aureus. The 24 h AUC/MIC and Time>MIC were
identiﬁed as the PK/PD indices most important for efﬁcacy. There was
only a slightly enhanced activity of the drug in the presence of white
blood cells. The drug appeared to have 3- to 6-fold higher potency in
the lung than the thigh. The in vitro plasma protein binding in mice was
80%.
Conclusions: The bacteriostatic free 24 h AUC/MIC ratio required for
a selection of clinical isolates of S. aureus and S. pneumoniae strains
ranged from 8.04 to 16.50. This range provides the basis for the 24 h
fAUC/MIC target ratio required for efﬁcacy in SSSI and CAP patients.
P908 Pharmacokinetic, mass balance and tissue distribution of
[14C]-BC-3205 in non-pigmented rats
W.W. Wicha °, Z. Ivezic-Schoenfeld, R. Novak (Vienna, AT)
Background: BC-3205, a pleuromutilin antibiotic, is a new oral
development compound for human use. It has ﬁnished four Phase I
studies demonstrating good oral bioavailability in combination with a
favorable safety and tolerability proﬁle. Current clinical development
targets the indications skin and skin structure infections (SSSI) and
community-acquired pneumonia (CAP). BC-3205 has demonstrated both
in vitro activity and in vivo efﬁcacy in animal models against a broad
range of bacteria often encountered in SSSI and CAP. Target pathogens
include among others methicillin-resistant Staphylococcus aureus
(MRSA), multi-drug resistant Streptococcus pneumoniae, atypicals and
Haemophilus inﬂuenzae.
Methods: [14C]-labeled BC-3205 was administered to non-pigmented
male and female rats as single oral dose of 30mg/kg via gavage.
The substance-associated radioactivity of whole blood, plasma, expired
air, urine, feces, and carcasses was detected using liquid scintillation
counting techniques. The tissue distribution was investigated by
quantitative whole-body autoradiography (QWBA).
Results: Following a single oral administration of [14C]-BC-3205 to
male and female rats Cmax was reached within 3 h after administration.
QWBA showed rapid and uniform tissue distribution with peak tissue
concentrations around Cmax. Within the investigated time all intra-organ
radioactivites approached the lower limit of quantiﬁcation, indicating a
total elimination of the BC-3205 associated radioactivity. This was in line
with the results of the excretion balance, showing 96% total recovery of
radioactivity after 7 days in males and females. No differences in gender
could be observed.
Conclusions: BC-3205 showed a rapid and homogeneous tissue
distribution of radioactivity from blood to tissues. The excretion of
BC-3205 related radioactivity was rapid with 92.5% of material being
excreted within 48 h. Following an oral dose of [14C]-BC-3205, the
majority of the radioactivity was excreted via the fecal route (93.1%).
P909 Pharmacokinetic, mass balance and tissue distribution of
[14C]-BC-3781 in non-pigmented rats
W.W. Wicha °, Z. Ivezic-Schoenfeld, R. Novak (Vienna, AT)
Background: BC-3781 is a new antimicrobial agent of the pleuromutilin
class. BC-3781 ﬁnished successfully four Phase I studies demonstrating
a favorable safety and tolerability proﬁle. Current clinical development
targets the indications skin and skin structure infections (SSSI) and
community-acquired pneumonia (CAP) for the oral and intravenous
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route of application. BC-3781 exhibits excellent antimicrobial activity
against an entire set of different bacterial pathogens often encountered in
skin and skin-structure and respiratory tract infections. Target pathogens
include among others methicillin-resistant Staphylococcus aureus
(MRSA), multi-drug resistant Streptococcus pneumoniae, atypicals and
Haemophilus inﬂuenzae. In various murine efﬁcacy models BC-3781
demonstrated very good potency characterized by a concentration-
dependent killing and a moderate post-antibiotic effect.
Methods: [14C]-labeled BC-3781 was administered to non-pigmented
male and female rats as single i.v. dose of 10mg/kg. The substance-
associated radioactivity of whole blood, plasma, expired air, urine, feces,
and carcasses was detected using liquid scintillation counting techniques.
The tissue distribution was investigated by quantitative whole-body
autoradiography (QWBA).
Results: The plasma concentration-time curve of i.v. administered [14C]-
BC-3781 described a multi-phasic decline, with a rapid initial distribu-
tional phase followed by a terminal elimination phase. Drug concentra-
tions measured in the majority of tissues including skin, soft tissues and
lungs were substantially higher compared to plasma levels. Within the in-
vestigated time all intra-organ concentrations of BC-3781 approached the
lower limit of quantiﬁcation, being in line with a 96% total recovery of
radioactivity after 7 days. No differences in gender could be determined.
Conclusions: BC-3781 showed a high tissue afﬁnity and a rapid and
homogeneous distribution of radioactivity from blood to tissues. The
excretion of BC-3781 and/or its metabolites was rapid with 92% of the
material being excreted within 48 h via the urinary (13%) and fecal route
(79%).
P910 Antimicrobial activity of the investigational pleuromutilin
compound BC-3781 against Gram-positive organisms
commonly associated with cutaneous infections
S. Putnam, D. Biedenbach, H. Sader °, Z. Ivezic-Schoenfeld, S. Paukner,
R. Novak, R. Jones (North Liberty, US; Vienna, AT)
Objective: To determine the antimicrobial activity of BC-3781
against recent clinical isolates of Gram-positive cocci. BC-3781 is an
investigational semi-synthetic pleuromutilin derivative, which inhibits
ribosomal protein synthesis. BC-3781 binds to 50S ribosomal subunit
and cross resistance with other antimicrobial classes is very uncommon.
Methods: Antimicrobial activity of BC-3718 and comparator agents
was determined against 827 non-duplicate Gram-positive organisms,
including staphylococci (413), streptococci (302) and enterococci (112).
Susceptibility (S) testing used the CLSI reference broth microdilution
method (M07-A8, 2009) for MIC determinations with BC-3781 and
comparator drugs (azithromycin [AZ], clindamycin [CL] and linezolid
[LZ]). Interpretation of MIC values were based on CLSI (M100-S19,
2009) and EUCAST (2009) S criteria.
Results: Staphylococcal isolates were very S to BC-3781 with highest
MIC value being 0.25 and 1mg/L for S. aureus (SA) and coagulase-
negative staphylococci (CoNS), respectively. BC-3781 was eight- to 16-
fold more potent than LZ and also showed greater potency compared to
AZ and CL when tested against staphylococci (Table). Methicillin-S and
-resistant (R) staphylococci showed similar BC-3781 MIC distributions.
Highest BC-3781 MIC value among b-haemolytic streptococci (BHS)
was 0.12mg/L. BC-3781 was slightly more active than CL and eight- to
16-fold more active than LZ when tested against BHS. Viridans group
streptococci (VGS) was also BC-3781-S, but MIC values were slightly
elevated compared to BHS. BC-3781 showed potent activity against
vancomycin-S and -R E. faecium (EFM), and it was signiﬁcantly more
active than comparators against EFM. However, 28.6% of EFM exhibited
higher (2mg/L) BC-3781 MIC values (mechanism unknown).
Conclusions: BC-3781 was very active against a contemporary
(2008–2009) collection of staphylococci, streptococci and enterococci,
organisms commonly associated with cutaneous infections. BC-3781
activity was not adversely inﬂuenced by R to methicillin among
staphylococci or vancomycin among enterococci. Further studies are
warrant to determine the role of this novel pleuromutilin for the treatment
skin and skin structure infections.
Table. Activity of BC-3781 and comparator agents tested against selected
Gram-positive cocci
Organism BC-3781 Azithromycin Clindamycin Linezolid
(no. tested) MIC50/90 %Sa MIC50/90 %Sa MIC50/90 %Sa MIC50/90 %Sa
SA (314) 0.12/0.12 100.0a 16/>16 34.1 0.12/>16 77.1 2/2 100.0
CoNS (99) 0.06/0.12 100.0a >16/>16 47.5 0.12/>16 76.8 1/1 99.0
BHS (202) 0.03/0.06 100.0a 0.12/8 84.7 0.06/0.12 94.1 1/1 100.0
VGS (100) 0.12/0.5 98.0a 0.25/8 − a 0.03/0.12 91.0 1/1 − a
EFM (112) 0.12/16 71.4a >16/>16 − a >16/>16 − a 2/2 97.3
aAn ECV of 1mg/L was applied for comparison purposes only; breakpoint
criteria published by EUCAST; and − = no breakpoint has been established.
P911 Activity of BC-3205 when tested against Gram-positive
organisms responsible from skin and skin structure infections
S. Putnam, D. Biedenbach, D. Farrell, R. Novak, S. Paukner, Z. Ivezic-
Schoenfeld, H. Sader °, R. Jones (North Liberty, US; Vienna, AT)
Objective: To assess the in vitro activity for BC-3205, a novel semi-
synthetic pleuromutilin, against a contemporary collection of Gram-
positive cocci. Pleuromutilins inhibit bacterial protein synthesis by
binding to the 50S ribosomal subunit. BC-3205 is in early stage clinical
development for oral treatment of multidrug-resistant (R) skin and skin
structure infections (SSSI).
Methods: Over 800 unique contemporary clinical isolates of Gram-
positive organisms tested for susceptibility (S) by broth microdilution
methods (CLSI, M07-A8) to BC-3205 and comparator agents, including
azithromycin (AZ), clindamycin (CL) and linezolid (LZ). The organisms
tested were S. aureus (SA; 314), coagulase-negative staphylococci
(CoNS; 99), E. faecium (EFM; 112), b-haemolytic streptococci (BHS;
202) and viridans group streptococci (VGS; 100). Interpretation of results
was guided by CLSI (M100-S19, 2009) and EUCAST criteria.
Results: BC-3205 was very active against SA (MIC50/90, 0.12/0.12
mg/L) and showed similar potency against methicillin-S (MSSA)
and -R (MRSA) strains. Against MRSA, BC-3205 (MIC50/90,
0.06/0.12mg/L) showed signiﬁcantly greater activity than CL
(MIC50/90, 0.12/>16mg/L), LZ (MIC50/90, 2/2mg/L) and AZ
(MIC50/90, >16/>16mg/L). Methicillin-S (MSCoNS) and -R CoNS
(MRCoNS) were also very S to BC-3205 (see Table). LZ (MIC50/90,
1/1mg/L) was also very potent against CoNS, but eight- to 16-
fold less active than BC-3205. CL and AZ showed more limited
activity against CoNS, especially MRCoNS strains (MIC50/90, 0.12/>16
and >16/>16mg/L, respectively). BC-3205 was highly active against
vancomycin-S (VS) and vancomycin-R (VR) EFM (MIC50, 0.12mg/L
for both). BHS strains were very S to BC-3205 (MIC50/90,
0.06/0.06mg/L). BC-3205 (MIC50/90, 0.06/0.12mg/L) was four- and
16-fold more active than AZ (MIC50/90, 0.25/8mg/L) and LZ
(MIC50/90, 1/1mg/L); but slightly less potent than CL (MIC50/90,
0.03/0.12mg/L), when tested against VGS.
Conclusions: BC-3205 was very active against a representative collec-
tion of contemporary pathogens associated with SSSI. Pending further
pharmacokinetic/pharmacodynamic and early clinical trial studies, BC-
3205 appears to be a promising treatment for cutaneous infections caused
by R Gram-positive organisms.
Organism Number (cumulative percentage) of strains inhibited at BC-3205 MIC (mg/L) of:
(no. tested) 0.03 0.06 0.12 0.25 0.5 1 2 4 8 16
MSSA (102) 2 (2.0) 14 (15.7) 81 (95.1) 5 (100.0)
MRSA (212) 18 (8.5) 106 (58.5) 88 (100)
MSCoNS (50) 1 (2.0) 25 (52.0) 21 (94.0) 1 (96.0) 1 (98.0) 1 (100.0)
MRCoNS (49) 3 (5.9) 11 (28.6) 29 (87.8) 6 (100)
VS-EFM (78) 1 (1.3) 20 (26.9) 18 (50.0) 9 (61.5) 1 (62.8) 1 (64.1) 1 (65.4) 6 (73.1) 3 (76.9) 18 (100.0)
VR-EFM (34) 1(2.9) 13 (41.2) 10 (70.6) 5 (85.3) 1 (88.2) 1 (88.2) 1 (88.2) 2 (94.1) 2 (94.1) 2 (100.0)
BHS (202) 99 (49.0) 98 (97.5) 5 (100.0)
VGS (100) 37 (37.0) 41 (78.0) 16 (94.0) 4 (98.0) 2 (100.0)
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P912 Disc diffusion and MIC quality control ranges for BC-3205,
a novel pleuromutilin class antimicrobial
J. Ross, S. Putnam, R. Novak, S. Paukner, Z. Ivezic-Schoenfeld,
H. Sader, R. Jones ° (North Liberty, US; Vienna, AT)
Objectives: To establish the disk diffusion (DD) and MIC quality
control (QC) ranges for BC-3205, a novel semi-synthetic pleuromutilin
derivative in the early stage clinical development for oral treatment of
skin and skin structure infections (SSSI).
Methods: These QC studies for the 20-mcg BC-3205 disk and broth
microdilution method follow the CLSI M02-A10 (2009), M07-A8 (2009)
and M23-A3 (2008) document using eight laboratories, two lots of BC-
3205 disks, three or more different medium lots. The results are presented
as proposed QC ranges for four ATCC strains: S. aureus ATCC 25923,
H. inﬂuenzae ATCC 49247, S. pneumoniae ATCC 49619 and S. aureus
ATCC 29213 (MIC only). BC-3205 DD and MIC QC ranges were
established per a CLSI M23-A3 study design. Ten replicates with each
of 3 QC strains produced 1,440 zone diameters for two disk lots of
BC-3205 (20-mcg disk) provided by the Mast Group. Clindamycin (CL;
2-mcg disk), azithromycin (AZ; 15-mcg disk) and linezolid (LZ; 30-mcg
disk) were utilized as control agents for DD, while retapamulin, AZ and
levoﬂoxacin were the control agents for MIC testing.
Results: Proposed QC ranges are listed in the Table. No signiﬁcant
differences (>1mm) were noted between media or disk lots when testing
either BC-3205 or control agents. S. aureus ATCC 25923 produced larger
variations between laboratories with the most extreme laboratory modes
having a 7mm difference. One laboratory submitted signiﬁcantly larger
zone diameters for H. inﬂuenzae ATCC 49247 and was excluded from
evaluation leaving seven laboratories for a valid CLSI QC study. MIC
values for H. inﬂuenzae 49247 showed trailing endpoints of at least
one dilution step. One laboratory was excluded from analysis due to
outlier values. A 7mm zone diameter is proposed for S. pneumoniae
ATCC 49619 which includes 99.7% of all results. Excluding one aberrant
laboratory from the MIC testing analysis produced all seven participant
results within the proposed 0.06–0.25mg/L range. All but one MIC result
for the control agents were within expected ranges, when applicable. The
control disks (LZ, AZ, CL) provided a valid internal control for the study,
with 97.7 to 100.0% of zones within CLSI published QC ranges.
Conclusions: An acceptable QC range was established for the four QC
organisms that will guide clinical and reference laboratories involved in
clinical trials and facilitate the regulatory review process of BC-3205.
QC organism MIC/Disk diffusion zone diameters for BC-3205:
Proposed range (mg/L /mm) % in range
S. aureus ATCC 29213/25923 0.03–0.25 / 25−33 100.0 / 95.4
H. inﬂuenzae ATCC 49247 1−4 / 18−24 81.8 / 91.6
Excludes one participant 1−4 / 18−24 87.6a / 100.0a
S. pneumoniae ATCC 49619 0.06–0.25 / 20−26 100.0a / 99.7
aOne laboratory was excluded from evaluation, H. inﬂuenzae QC range for MICs
was not acceptable.
P913 Correlation of in vitro susceptibility testing results for an
investigational pleuromutilin (BC-3781) using MIC and disc
diffusion methods against Gram-positive pathogens
D. Biedenbach, H. Sader, S. Putnam, S. Paukner, R. Novak,
Z. Ivezic-Schoenfeld, R. Jones ° (North Liberty, US; Vienna, AT)
Objective: To establish the intermethod agreements for testing BC-
3781 using the CLSI reference broth microdilution (BMD) MIC and
disk diffusion (DD) tests for staphylococci, streptococci and enterococci.
This pleuromutilin agent has a unique mode of action which interferes
with bacterial protein synthesis without cross-resistance (R) to other
antimicrobial classes.
Methods: Strains with pleuromutilin-R phenotypes were included
to deﬁne the epidemiologic cutoff value (ECV)/susceptibility (S)
breakpoints for this agent. These strains included 11 non-wildtype (WT)
staphylococcal isolates that carried either cfr or vga(A). The enterococcal
population also included strains with non-WT BC-3781 MICs and
vancomycin-R isolates. The overall collection was dominated by recent
(2008–2009) clinical isolates of staphylococci (316), streptococci (302)
and E. faecium (EFM; 112). Isolates were tested by BMD and DD,
using a 20-mcg disk concentration and CLSI methods (M07-A8, 2009;
M02-A10, 2009). Media used were Mueller-Hinton broth or agar
supplemented with blood products (horse or sheep blood). Comparator
agents included azithromycin, linezolid and clindamycin.
Results: Using an ECV MIC of 1mg/L and a correlate zone diameter
at 20mm for the BC-3781 DD, resulted in no intermethod discords
for the staphylococci. One organism was noted at a BC-3781 MIC of
1mg/L (methicillin-S CoNS; zone diameter at 24mm) and one strain
with a MIC of 2mg/L (methicillin-R S. aureus; zone diameter at 15mm).
All non-WT strains had zone diameters around the 20-mcg BC-3781
disk of 6−17mm. The WT population of EFM contained MIC values
at 1mg/L and zone diameters at 21mm and excellent separation
between WT and non-WT enterococci was observed. All streptococci
would be considered S or WT at MICs of 1mg/L and zone diameters
of 20mm, except for two isolates in the S. bovis group (2 of 10
strains tested; 20%). Cross-R or -S with other agents (macrolides,
oxazolidnones, lincosamides) was not demonstrated.
Conclusions: The proposed/tentative ECV breakpoints (1mg/L and
20mm) proposed were without intermethod error for any organism
group. If an intermediate category (2mg/L, 17−19mm) was applied,
intermethod correlations would also be very acceptable with extremely
rare (0.4%) minor error. This study demonstrates that accurate
breakpoints can be selected and should be considered for use in the
early clinical trials for BC-3781, a promising agent for the cutaneous
infections.
Organism/MIC interpretationa (no.) No. at DD interpretation:
S or WT
(20mm)
R or non-WT
(19mm)
Staphylococcus spp. (316)
S or WT (1mg/L) 305 0
R or non-WT (2mg/L) 0 11
Enterococcus faecium (112)
S or WT (1mg/L) 80 0
R or non-WT (2mg/L) 0 32
Streptococcus spp. (302)
S or WT (1mg/L) 300 0
R or non-WT (2mg/L) 0 2
P914 Correlations of broth microdilution MIC and disc diffusion
results for an investigational agent, BC-3205 among
potentially indicated species
D. Biedenbach, H. Sader °, Z. Ivezic-Schoenfeld, R. Novak, S. Paukner,
S. Putnam, R. Jones (North Liberty, US; Vienna, AT)
Objective: To determine the correlation between the CLSI reference
broth microdilution (BMD) MIC (mg/L) and the zone diameter diffusion
(mm) results obtained for BC-3205 when tested against targeted Gram-
positive pathogens. BC-3205 is semi-synthetic pleuromutilin derivative
that interferes with bacterial protein synthesis. Cross resistance with
other antimicrobial classes has not been observed with BC-3205 and it
is being developed for the treatment of skin and skin structure infections
(SSSI) including multidrug-resistant (R) species.
Methods: Recent (2006–2009) clinical isolates of S. aureus (214),
coagulase-negative staphylococci. (102), E. faecium (EFM; 112),
b-haemolytic streptococci (202) and viridans group streptococci (100)
were tested by CLSI BMD and disk diffusion (20-mcg) using reference
methods and appropriate media (M07-A8, 2009; M02-A10, 2009).
Staphylococcal strains with non-wildtype (WT; 2mg/L) MIC values
for other pleuromutilin compounds (carrying vga[A] or cfr) were
included in the study to determine tentative epidemiologic cutoff values
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(ECV) for MIC and disk diffusion tests with BC-3205. Comparator
agents included azithromycin (AZ), linezolid (LZ) and clindamycin (CL).
Results: Using tentative ECV breakpoints (1mg/L and 20mm)
BC-3205 produced rare intermethod errors (see Figure). Excellent
discrimination by BMD between WT and non-WT populations were
evident among staphylococci, regardless of methicillin susceptibility. A
single non-WT MRSA strain (MIC, 1mg/L) fell below the proposed
ECV (1mg/L) introducing a major interpretive error (0.1%). The
WT EFM population contained MIC values at 1mg/L and zone
diameters 20mm with no zones between 16−19mm, enabling excellent
separation between WT and non-WT EFM (MICs, 2mg/L). BC-3205
scattergrams for the streptococci demonstrated dominant susceptibility
(MICs, 0.5mg/L and zone diameters at 21mm). Intermethod
interpretive agreement for the control agents ranged from 98.6 (AZ,
CL) to 100.0% (LZ).
Conclusions: Correlations of 20-mcg BC-3205 zone diameters with
the CLSI reference MIC values were excellent and extremely rare
intermethod error (0.1%) was noted when using a susceptible or
ECV breakpoints of 1mg/L and 20mm. These tentative criteria
should be considered for use in the early clinical trials. Signiﬁcant
cross-R or -susceptibility with other agents (macrolides, oxazolidinones,
lincosamides) was not observed.
Table. BC3205 scattergram comparing MIC and zone diameter results for
all Staphylococcus spp.a (316 strains). aIncludes Staphylococcus aureus
(214) and coagulase-negative staphylococci (102).
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P915 High prevalence of amikacin susceptibility in
aac(6′)-Ib-positive Enterobacter cloacae
S.Y. Kim °, Y.J. Park, J.K. Yu (Suwon, Seoul, KR)
Objectives: The aac(6′)-Ib gene encodes aminoglycoside 6′-N-
acetyltransferase. This gene confers resistance to amikacin, tobramycin,
kanamycin, netilmicin but not to gentamicin. The EUCAST recommends
reporting amikacin as intermediate for Enterobacteriaceae which is
intermediate or resistant to tobramycin and susceptible to gentamicin
and amikacin, because production of acquired aac(6′)-I may not confer
phenotypic amikacin resistance. The single amino-acid substitution in
aac(6′)-Ib (Leu119Ser) results in decrease in amikacin MIC and increase
in gentamicin MIC. We investigated correlation between the aac(6′)-Ib
and aminoglycoside MICs.
Methods: This study included 73 aac(6′)-Ib-positive E. cloacae
isolates from 12 laboratories between March and July 2005. All
isolates had been screened previously by PCR for the presence of
aac(6′)-Ib. Susceptibility to amikacin (2–256mg/L), kanamycin (2–
256mg/L), tobramycin (0.5−64mg/L), and gentamicin (0.5−64mg/L)
were determined by an agar dilution method. To determine the presence
of Leu119Ser mutation, sequencing was performed in isolates with
amikacin MIC 16mg/L.
Results: Of 73 aac(6′)-Ib-positive isolates, 64 (87.7%) were susceptible
to amikacin, 16 (21.9%) to kanamycin, 17 (23.3%) to tobramycin, and
32 (43.8%) to gentamicin by the CLSI guideline; 47 (64.4%) were
susceptible to amikacin, 16 (21.9%) to tobramycin, and 25 (34.2%)
to gentamicin by the EUCAST. Of amikacin-susceptible isolates, 15 of
64 (23.4%) and 6 of 47 (12.8%) were non-susceptible to tobramycin
and susceptible to gentamicin by the CLSI and EUCAST, respectively.
Only 4 of 64 isolates with amikacin MIC 16mg/L had single amino-
acid susbstitution on aac(6′)-Ib (Leu119Ser); three isolates had amikacin
MICs 2mg/L and one an MIC of 4mg/L.
Conclusion: Although the EUCAST breakpoint instead of the CLSI
breakpoint was used, many E. cloacae isolates with the aac(6′)-Ib
were susceptible to amikacin. Further investigations are required to
determine whether amikacin-susceptible isolates carrying the aac(6′)-Ib
are associated with therapeutic failure.
P916 Loop-mediated isothermal ampliﬁcation method for rapid
and simple detection of 16S rRNA methylase genes, rmtA,
rmtB and armA, and detection situation in Japan
M. Nagasawa °, M. Kaku, K. Yamaguchi, K. Kamachi, J. Wachino,
K. Yamane, Y. Arakawa (Miyagi, Tokyo, JP)
Background: Recently, a series of special methylases that protect
microbial 16S rRNA, the main target of aminoglycosides, was identiﬁed
in nosocomial pathogens, e.g., Pseudomonas aeruginosa, Klebsiella
pneumoniae and Serratia marcescens. To prevent and control the spread
of such resistant bacteria in hospitals, there is a need for a rapid
and simple detection method for the aminoglycoside-resistance genes.
Moreover, no exact isolation frequency of such microbes was determined
in Japan after the report of Yamane et al., EID, 13:642–646, 2007.
Methods: For speciﬁc detection of 16S rRNA methylase genes, rmtA,
rmtB and armA, a set of LAMP primes (F3, B3, FIP, BIP, LF and LB)
was designed for each gene by targeting their speciﬁc region using Primer
Explorer V4 software, respectively. The length of targeting rmtA, rmtB
and armA genes was 211, 226, and 259bp, respectively. The LAMP
reactions were carried out with the Loopamp DNA ampliﬁcation kit
(Eiken Co. Ltd., Japan) at 65ºC, and directly detected with the naked
eye using Loopamp ﬂuorescent detection reagent. The template DNA
was extracted from each aminoglycoside-resistant isolate (12 bacterial
species, 68 isolates) by a simple boiling method, and subjected to
the LAMP methods. Strains used were collected from 33 nationwide
hospitals.
Results: The rmtA-LAMP speciﬁcally detected all P. aeruginosa isolates
harboring rmtA in a 40-min reaction, but no ampliﬁcation was found in
strains harboring rmtB or armA. Similarly, the rmtB- and armA-LAMP
exclusively detected strains harboring only rmtB and armA, respectively.
The 16S rRNA methylase genes were found in various bacterial species.
The detection frequency in each species was from 0.07 to 3.51% of all
the clinical isolates tested and from 3.8 to 66% of the aminoglycoside-
resintant isolates.
Conclusions: The rmtA-, rmtB-, and armA-LAMP assay would promise
rapid and simple identiﬁcation of 16S rRNA methylase-producing
strains among aminoglycoside-resistant clinical isolates in ordinary
microbiology laboratories without using any speciﬁc and expensive
equipments.
P917 Molecular characterization and antimicrobial susceptibility
of Escherichia coli isolates from faeces of healthy humans
M. Citar, B. Jesenko, Z. Petkovsek, S. Markovic, M. Kuzmic,
V. Krizan-Hergouth, D. Zgur-Bertok, M. Starcic Erjavec ° (Ljubljana, SI)
Objectives: The bacterium Escherichia coli (E. coli) is the prototypic
commensal species of the facultative anaerobic microﬂora in the lower
intestine of healthy warm-blooded organisms. Usually, E. coli and its host
coexist in mutual beneﬁt but there are several highly adapted E. coli
strains that have acquired speciﬁc virulence factors and can cause an
impressive variety of different types of intestinal and extraintestinal
diseases. In order to screen for the prevalence of several virulence
(related) genes, a collection of 90 commensal E. coli strains isolated
from feces of healthy humans was studied.
Methods: Isolates were collected at the Department of Biology,
Biotechnical Faculty, University of Ljubljana, during the time period
from 01.03 to 04.09.2009. Strains were isolated from feces of healthy
men and women of different ages that were not any antimicrobial
medicines for therapeutic and prophylactic purposes.
Using the method of PCR ampliﬁcation with speciﬁc primers all isolates
were screened for the following virulence related genes: cnf1 (cytotoxic
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necrotising factor 1), hlyA (haemolysin), papGII (class II PapG adhesin),
papGIII (class III PapG adhesin), sfaDE (S ﬁmbriae), afa/draBC (Afa/Dr
adhesins), iucD (aerobactin), usp (uropathogenic-speciﬁc protein), tcpC
(a new Toll/interleukin-1 receptor domain), traJ (transfer region), and
rmoA (modulator of gene expression); two plasmid replication regions,
RepFIB and RepFIIA; and phylogenetic groups (A1, B1, B2 and D).
Further, the strains were tested for their susceptibility to three widely
used antibiotics: tetracycline, ciproﬂoxacine and ampicillin.
Results: Our results showed that 33% of the studied E. coli isolates
belonged to the B2 group, 30% to the D group, 22% to the A group,
and 14% to the B1 group. The cnf1 gene sequence was detected in 6%
of the strains, hlyA in 8%, papGII in 8%, papGIII in 3%, sfaDE in
17%, afa/draBC in 4%, iucD in 39%, usp in 24%, tcpC in 8%, traJ in
26%, rmoA in 27%, RepFIB in 33% and RepFIIA in 37% of the tested
isolates.
Of all the tested strains 73% were susceptible to ampicillin, 98% to
ciproﬂoxacine and 82% to tetracycline.
Conclusion: Our results indicate that among the gut microbiota
individual commensal E. coli strains exhibit the virulence potential to
instigate extraintestinal infections.
Prevalence
no. of strains (%)
Phylogenetic group
A 20 (22)
B1 13 (14)
B2 30 (33)
D 27 (30)
Virulence factor
cnﬂ 5 (6)
hlyA 7 (8)
papGII 7 (8)
PapGIII 3 (3)
sfaDE 15 (17)
afa/draBC 4 (4)
tucD 35 (39)
usp 22 (24)
tcpC 7 (8)
traJ 23 (26)
rmoA 24 (27)
RepFIB 30 (33)
RepFIIA 33 (37)
Antibiotic resistance
ampicillin 66 (73)
tetracycline 74 (32)
ciproﬂoxacin 88 (98)
P918 Faecal carriage of antibiotic-resistant Escherichia coli in
healthy children and home-raised chickens: a household
study in a resource-limited setting
E. Riccobono °, A. Mantella, F. Bartalesi, H. Gamboa, A. Bartoloni,
G.M. Rossolini, L. Pallecchi (Siena, Florence, IT; Camiri, BO)
Objective: In resource-limited countries (RLCs), home-raised domestic
animals live in close contact with household members, and exposure
to animal intestinal ﬂora is favored by condition of poor sanitation. In
a previous study carried out with healthy children in urban areas of
Bolivia and Peru, we evidenced high rates of acquired resistance in
commensal E. coli, including to drugs not routinely used in childhood
(e.g. tetracycline and quinolones). Here we studied resistant commensal
E. coli from healthy children and home-raised chickens in households
from one of the previously surveyed urban area.
Methods: Fecal carriage of resistant E. coli was studied in 21 healthy
children aged 6−72 months and 21 home-raised chickens, from 12
households in Villa Montes (Tarija Dept., Bolivia). Molecular analysis
(population structure of resistant bacteria, nature of acquired resistance
genes and their mobile genetic supports) was performed with isolates
exhibiting resistance to tetracycline-TET (n = 66) or nalidixic acid-NAL
(n = 30), collected from 6 children and 6 chickens from 3 selected
households.
Results: Except for resistance to (ﬂuoro)quinolones, which was higher
in chickens (P< 0.05), resistance rates in children and chickens were
overall high and comparable. TET- and NAL-resistant isolates belonged
to phylogenetic group A (67%) (signiﬁcantly more prevalent in children),
B1 (18%) (only in chickens) and D (15%) (equally distributed). Identical
RAPD-types were found in children or chickens living in the same
household, but in neither case human-animal sharing of the same
resistant clone was observed. TET-resistant isolates carried tet(A) or
tet(B) genes (equally distributed in isolates of human and animal
origin), often located on conjugative plasmids with different replicon
combinations. 2 NAL-resistant clones from children carried the qnrB19
gene, located on small non transferable ColE-type plasmids. Plasmid
transfer in different clones was never observed.
Conclusions: Household animals-humans transmission of resistant
bacteria in RLCs might not represent a major risk factor for fecal carriage
of resistant bacteria.
P919 Prevalence of sul genes in Escherichia coli causing urinary
tract infection in the community
R. Diaz °, S. Ferreira, A. Freitas, S. Mendo (Aveiro, PT)
Objectives: Urinary tract infections (UTI) are increasing signiﬁcantly
among the community. Escherichia coli is the main microorganism
responsible for urinary infections (UTI) and shows a signiﬁcant
percentage of resistance to Sulfamethoxazole + Trimethoprim (SxT).
Antimicrobial resistance is a major problem in the clinical context and
it represents a signiﬁcant threat for the general healthy public. The aim
of the present study was to evaluate the prevalence of antibiotic resistant
strains, namely to SxT, collected in a health care unit in Aveiro, central
region of Portugal.
Methods: 547 E. coli isolates were collected, between October and
December 2008, from community patients with suspected UTI. From
those, 25 were resistant to SxT and therefore selected for the study. The
presence of int1, sul1, sul2, sul3 genes and dfr variants was investigated
by PCR. Nucleotide sequence of the amplicon products was determined
in both strands and compared to others deposited in the Genebank
databases.
Results: Antibiotic resistance proﬁle of the 25 isolates, revealed a high
rate of resistance to Amoxicilin, Cefatrizin, Norﬂoxacin and SxT.
Nineteen isolates were positive for the presence of the int1 gene,
indicating the presence of class 1 integron(s); 13 were positive for sul1,
16 for sul2 and 2 for the sul3 gene. Variants of the dfr genes were
predominant in the ampliﬁed variable regions.
sul3 gene was found associated with class1 integron which is quite
unusual.
Conclusions: The percentage of resistance to SxT in the E. coli strains
was high. The presence of class 1 integrons in a high rate was also
surprising considering a community population. These results are of
major concern since they can compromise the use of antibiotics usually
employed in the treatment of UTI, namely the empiric treatment with
SxT.
P920 Plasmid dissemination of sul2 among non-typhoidal
Salmonella isolates in Portugal
T. Curiao °, P. Antunes, R. Matias, L. Peixe, T.M. Coque (Madrid,
ES; Porto, PT)
Objectives: Sulfonamide resistance is increasingly reported among
Salmonella isolates from different European countries, sul2 being the
most widespread sul gene. Our aim was to characterize the plasmids and
the genetic environment associated to sul2 among Portuguese multidrug-
resistant Salmonella isolates.
Methods: We studied 22 sul2-Salmonella isolates representatives for
different sources (hospital, food, piggeries), serotypes (Typhimurium,
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Enteritidis, Brikama, Saintpaul) and PFGE-clones (2002–2007). Iden-
tiﬁcation of sul genes (sul1, sul2, sul3) and sequences related to
their platforms (ISCR2, repCpRSF1010, strAB) were done by PCR.
Genetic environment was characterized by PCR mapping, long-PCR-
RFLP and sequencing. Conjugation assays were performed by standard
procedure. Plasmid analysis included size determination (S1 nuclease),
incompatibility grouping (PCR, hybridization and sequencing) and
comparison of RFLP patterns (PstI and ClaI).
Results: Most sul2 isolates were resistant to ampicilin, streptomycin,
tetracycline and trimethoprim and they also contained either sul1 (n = 10)
or sul3 (n = 2). Conjugative transfer of sul2 was achieved for 50% of the
isolates. sul2-plasmids ranged from 7 to 250 Kb, some containing two
copies of the gene. Conjugative plasmids corresponded to IncI1 (n = 3,
same RFLP type), IncFIIa (n = 2), IncN (n = 3, same RFLP type), IncA/C,
(n = 2), or IncHI1 (n = 1). IncI1, IncN, IncA/C and IncFII plasmids were
recovered from food and clinical isolates in different years. The sul2
gene was associated with strAB (n = 14) and also with ISCR2 (n = 6,
ISCR2-strB-strA-sul2, both platforms being located in a diverse range
of plasmids. Some plasmids were untypeble by the method used (n = 7).
Conclusions: sul2 is located in a diversity of plasmids among Salmonella
from Portugal. The identiﬁcation of widespread elements in both clinical
and community settings is of concern since they might fuel the
dissemination of antibiotic resistance in other hosts.
P921 Co-dispersion of copper and antibiotic resistance genes
among enterococci from different ecological niches, Portugal
E. Silveira °, A.R. Freitas, T.M. Coque, L. Peixe, C. Novais (Porto,
PT; Madrid, ES)
Objectives: In Europe, copper compounds are used in industry,
agriculture and animal production. Evidences concerning copper effect
on the selection of antibiotic (AB) resistant strains are scarce and
limited to enterococci from the animal production setting. Our goal
was to analyze the occurrence of tcrB among enterococci from different
ecological niches and to assess the co-transference of tcrB with several
AB resistance genes.
Methods: Representative enterococci from hospitalized patients (H,
n = 90), healthy humans (HV, n = 92), poultry (P, n = 127), piggeries-
animals/environment (PE, n = 197); sewage/river (SR, n = 43) collected
from North, Centre and South Portugal (1996–2007) were analyzed.
They belonged to different species and presented diverse antibiotic
resistant patterns. tcrB was searched by PCR as described. Mating assays
using E. faecium GE1/BM4105RF or E. faecalis JH2−2 as recipients
were accomplished for representative tcrB+ isolates (n = 47) using
BHI supplemented with rifampicin, fusidic acid plus tetracycline (Te),
erythromycin (Er), vancomycin (Vc) or gentamicin (Gm). Susceptibility
to nine AB was determined by disk diffusion (CLSI). Presence of genes
coding for antibiotic resistance (tetM,L; ermB, vanA, aac6-aph2) was
screened by PCR.
Results: tcrB was detected in 20% (109/549) of the isolates studied
including PE (26%; n = 52/197), H (21%-n = 19/90), SR (21%; n = 9/43),
HV (20%; n = 18/92) and P (9%; n = 11/127)]. They correspond to
E. faecium (25%, 56/224), E. faecalis (16%, 30/183) and Enterococcus
spp (24%, 24/142). tcrB+ transconjugants were selected in plates
supplemented with Er, Te, Vc (93%, 25/27 of positive matings;
53%, 8/15, 67%, 2/3, respectively) and co-transferred with variable AB
resistance patterns: Er-80% (20/25, ermB), Te-64% (16/25, 5 tetM, 9
tetML; 2 tetL), Vc-28% (7/25, vanA) high level of resistance (HLR)
streptomycin-20% (5/25), cloramphenicol-8% (2/25) or HLR-Gm-4%
(1/25; aac6-aph2).
Conclusions: Several Portuguese settings seem to be reservoir of
enterococci harbouring tcrB and AB resistance genes, both located in
common platforms or co-transferred during the same genetic event.
Horizontal dissemination of AB resistance mobile elements might be
favoured by the selective pressures exercised by the use of both AB and
copper compounds.
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P922 Respective contribution of PatA/PatB and PmrA in
ﬂuoroquinolone resistance in clinical isolates of Streptococcus
pneumoniae
A. Lismond, M.I. Garvey, F. El Garch, S. Delvigne, P.M. Tulkens,
L.J. Piddock, F. Van Bambeke ° (Brussels, BE; Birmingham, UK)
Background: Two efﬂux systems have been identiﬁed so far for
ﬂuoroquinolones (FQ) in S. pneumoniae (SP), namely PmrA (MFS
superfamily), and PatA/PatB (ABC transporters). Previous studies
suggest a predominant role of PatA/PatB in FQ resistance of laboratory
strains. The aim of the present study was to determine which of these
two systems could be primarily involved in the resistance of clinical
isolates to FQ.
Methods: 5 strains showing a phenotype suggestive of efﬂux were
selected from a large collection of SP isolates obtained from CAP
patients, and compared to ATCC49619. MICs were measured in
Mueller Hinton II agar supplemented with 5% deﬁbrinated horse
blood (±reserpine [efﬂux inhibitor]). Expression levels of patA, patB,
and pmrA genes were evaluated by real-time PCR. Gene inactivation
was obtained by transformation using genomic DNA of ATCC49619
disrupted in one of the genes under study (spectinomycin-resistance
cassette inserted in the middle of the gene of interest).
Results: Reserpine or gene disruption had no effect in ATCC49619.
Disruption of patA or patB was as effective as reserpine to reduce FQ
MIC in all clinical isolates, irrespective of the pump(s) overexpressed
(SP13 did not revert to wild-type MIC because of the presence of target
mutations). Disruption of pmrA had only a modest effect on NOR MIC
in SP257.
Conclusions: Disruption of patA or patB is sufﬁcient to reduce MIC to
the value measured in the presence of reserpine. PatA/PatB, even when
expressed at a basal level, contribute to resistance to FQ in the clinical
isolates analyzed while PmrA has almost no impact.
Strains Gene expressiona CIP MIC (mg/L)b,c NOR MIC (mg/L)b,c
patA patB pmrA w/o R with R patA− patB− pmrA− w/o R with R patA− patB− pmrA−
ATCC 49619 basal basal basal 0.5 0.5 0.5 0.5 0.5 4 2 4 2 4
SP13 + + + 16 4 2 2 16 256 16 16 16 128
SP207 + + + 4 0.5 1 0.5 nod 32 2 4 2 nod
SP295 + + basal 2 0.5 0.5 0.5 1 16 2 2 2 8
SP257 basal basal + 1 0.5 0.5 0.5 1 8 2 2 2 4
SP298 basal basal + 2 0.5 0.5 1 2 8 2 4 4 16
a + denotes a value >2-fold that measured in ATCC49619 (basal level).
b In control conditions (without reserpine ([w/o R]); + reserpine 10mg/L [with R]; in strain disrupted for patA [patA−], patB [patB−], or pmrA
[pmrA−].
cFigures in bold denote MICs brought back to those measured with reserpine (+/− 1 dilution).
dDisruptant non obtained so far (no).
P923 Development and stability of non-susceptibility to
vancomycin in methicillin-resistant Staphylococcus aureus
V. Doddangoudar °, M. Boost, M. O’Donoghue, P. Appelbaum
(Kowloon, HK; Hershey, US)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) with
non-susceptibility to vancomycin (VISA) was ﬁrst documented in 1997,
but the underlying mechanisms remain unclear. Reduced susceptibility
is typically reported in isolates from patients who have received
vancomycin therapy, usually lasting several weeks. We induced and
tracked hVISA/VISA development in MRSA clinical isolates by
exposure to sub-inhibitory levels of vancomycin and determined the
stability of these non-susceptible phenotypes.
Method: 30 clinical isolates of MRSA were subjected to increasing
concentrations of vancomycin based on their initial and subsequent MIC
to vancomycin for 60 days. Strains were incubated with vancomycin at
50% MIC for 48 h at 370C. The MICs were then determined by standard
agar dilution and spiral gradient endpoint (SGE) methods and strains
passaged to fresh media. After 60 days, stability of non-susceptibility
was determined by transferring the strains to fresh drug-free broth every
48 h and determining MIC weekly for a further 60 days. Development
and loss of resistance patterns were plotted.
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Results: All isolates developed non-susceptibility, with ﬁnal MICs by
60 days ranging from 6−20mg/ml (mean 10mg/ml, MIC90 20mg/ml).
Time required for the VISA development varied from 24−54 days and
several distinct patterns of MIC increase were observed. Removal of
drug pressure led to loss of non-susceptibility (mean MIC of 2.1mg/ml
(range 0.5−5)) in all but one strain (20mg/ml) after 4 weeks.
Conclusion: It is important to recognize the strong potential for MRSA
strains to become vancomycin non-susceptible, as currently there is
general belief that hVISA/VISA development are rare events. All
isolates became vancomycin non-susceptible by 60 days. Of 6 strains
reaching an MIC 20mg/ml, equivalent to CLSI resistance deﬁnition, one
converted to a stable phenotype. Current terminology may need to be
re-addressed, as hVISA/VISA can reach 20mg/ml though not having
vanA. Whilst non-susceptibility is clearly linked to selective pressure,
the rapid development within the period of regular therapy demonstrates
that treatment failure could easily occur. Use of SGE provided exact
MICs rather than the large stepwise increments of doubling dilutions,
allowing patterns of non-susceptibility development to be determined.
Further work on non-susceptibility development is continuing, examining
the mutations in regulator genes during development and loss of non-
susceptibility.
P924 Total genome sequencing and complete genetic analysis
of all SNP-linked phenotypes reveals novel clues to the
emergence of low-level glycopeptide intermediate resistance
in Staphylococcus aureus
A. Renzoni °, D. Andrey, C. Barras, A. Monod, P. Vaudaux, D. Lew,
W. Kelley (Geneva, CH)
The precise mechanisms leading to the emergence of low level
glycopeptide resistance in S. aureus are poorly understood. In this
study, we used high throughput whole genome sequencing to detect
differences between two isogenic strains: a parental strain (ISP794)
and a stable derivative (AR376) selected for growth on 4 mg/ml
teicoplanin. Surprisingly, we uncovered only three single nucleotide
polymorphisms (SNPs) mapping to three separate genes which could
account for the observed alteration in antibiotic sensitivity. Nonsense
mutations occurred in stp1 encoding a serine/threonine phosphatase
and in yjbH, encoding a putative negative regulator of the redox
sensor and global transcriptional regulator, Spx. A missense mutation
in vraS resulted in the non-conservative amino acid change G45R in
the histidine kinase sensor of cell wall stress, VraS. Using genetic
methods, all single, pairwise, and reconstructed triple SNP combinations
were subsequently evaluated for their contribution to emergence of low
level glycopeptide resistance. We found that the mutations within stp1
and vraS contributed partially alone and acted together synergistically
to evoke reduced teicoplanin sensitivity. Mutation within yjbH was
found to have no detectable effect on glycopeptide resistance under
our experimental conditions. Our results are the ﬁrst to report both the
combined complete genome sequencing and complete genetic analysis
leading to enhanced understanding of antibiotic resistance emergence
in this major human pathogen. The signiﬁcantly low cost and high
beneﬁt of applying high throughput sequencing to obtain clues to genetic
changes underlying drug resistance argues for the broader application
of this method in the near future. Previous work in our laboratory
(Renzoni, A et al 2009 AAC 53:903–911) using the reduced glycopeptide
sensitivity strain AR376 revealed that disruption of either of two
previously uncharacterized adjacent genes named trfA and trfB (for
teicoplanin resistance factor) could restore sensitivity to teicoplanin in
this background. The mechanisms of action of trfA and trfB remain to
be determined, but our present study now indicates they must function
to disrupt the effects of dual phosphosignalling pathways.
Supported by Swiss National Science Foundation grants 3100A0–120428
to W.L.K. and 310030–125109 to D.L.
P925 VanM gene cluster − a new glycopeptide resistance gene
cluster found in a clinical isolate of Enterococcus faecium
X. Xu, D. Lin, Y. Guo, S. Wu, X. Ye, D. Zhu, M. Wang ° (Shanghai, CN)
Objectives: Since the glycopeptide-resistant clinical isolates of Entero-
coccus species were reported in 1988, glycopeptide-resistant Enterococci
(GRE) are now encountered in hospitals in most countries. Seven types of
gene clusters (vanA, vanB, vanC, vanD, vanE, vanG and vanL) contribute
to glycopeptide resistance in Enterococcus spp. worldwide. A novel
glycopeptide-resistant determinant, vanM gene cluster, was cloned from
a clinical isolate of E. faecium.
Methods: Antimicrobial susceptibility testing and conjugation experi-
ment were carried out in a glycopeptide-resistant clinical isolate from
a teaching hospital in Shanghai, China. By PCR ampliﬁcation, walking
sequencing, and restriction fragment cloning, the glycopeptide-resistant
gene and its ﬂanking sequences were determined. The obtained sequence
was compared with known glycopeptide resistance gene clusters for
sequence identity by clustal W method.
Results: A clinical strain of E. faecium Efm-HS0661 was isolated from
an inpatient with an intra-abdominal infection and was resistant to most
antimicrobials, including vancomycin and teicoplanin. Its glycopeptides
resistance could be transferred to E. faecium BM4105RF by conjugation.
The donor and its transconjugant were negative by PCR for the known
van genes. With cloning method and primer walk sequencing, we found
a novel gene cluster, designated vanM gene cluster. The D-Ala:D-Lac
gene, vanM, was 1032bp in length and encoded a 343-amino-acid
protein, which shared 79.9%, 70.8%, 66.3%, and 78.8% amino acid
identity with VanA, VanB, VanD, and VanF, respectively. Though vanM
DNA sequence was most close to vanA, the organization of vanM gene
cluster was most similar to vanD gene cluster. Upstream of vanM gene
cluster there was an IS1216-like element, which may play an important
role in the dissemination of resistance determinant. Of 10 GRE strains
isolated from the teaching hospital from 2005 to 2008, 6 strains had
vanM genotype and 4 strains were vanA genotype.
Conclusion: A new glycopeptide resistance determinant, vanM gene
cluster, was characterized from a clinical isolate of glycopeptide-resistant
E. faecium. The vanM gene cluster was more common than vanA gene
cluster at a teaching hospital in Shanghai.
P926 VanN, a novel type of transferable vancomycin resistance in
Enterococcus faecium 08-174
F. Lebreton °, N. Bourdon, P. Berger, M. Fines-Guyon, R. Leclercq,
V. Cattoir (Caen, Marseille, FR)
Objectives: Vancomycin-resistant enterococci are recognized as a major
cause of nosocomial infections. To date, seven vancomycin resistance
determinants have been characterized: vanA, vanB, vanC1/C2, vanD,
vanE, vanG and vanL genes. The aim of this study was to investigate the
mechanism of vancomycin resistance in Enterococcus faecium 08-174,
a clinical isolate devoid of known vancomycin resistance gene.
Methods: Vancomycin-resistant E. faecium 08-174 was isolated from
a rectal swab in 2008 in Marseille, France. DNA ampliﬁcation of a
putative van gene was carried out by using degenerated primers V1
and V2 designed to amplify an internal fragment of ligase genes. The
PCR product was then cloned and sequenced. Thermal asymmetric
interlaced PCR (TAIL-PCR) assays were performed to determine the
entire sequence of the novel van gene. Transfer of vancomycin resistance
from E. faecium 08-174 to E. faecium BM4107 and Enterococcus
faecalis JH2−2 was attempted by ﬁlter mating experiments. Plasmid
analysis was performed by using a modiﬁed Kieser technique.
Results: E. faecium 08-174 displayed low-level resistance to vancomycin
(MIC, 12mg/L) and susceptibility to teicoplanin (MIC, 2mg/L). A ca.
600-bp PCR product was obtained with V1 and V2 primers and sequence
analysis revealed signiﬁcant similarities with van genes. TAIL-PCR
allowed us to determine the entire sequence of this novel ligase
gene designated vanN. The deduced protein shared the highest amino
acid identity with the D-Ala-D-Ser VanL, VanC2, VanC1 and VanE
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ligases (65%, 56%, 55% and 53%, respectively). Attempts to transfer
vancomycin resistance from E. faecium 08-174 to E. faecalis JH2−2 were
unsuccessful whereas a transconjugant was obtained with E. faecium
BM4107 used as a recipient. vanN sequence could be ampliﬁed by PCR
from the transconjugant. Analysis of plasmid content in E. faecium
08-174 and its transconjugant revealed the presence of a ca. 75-kb
plasmid.
Conclusion: We identiﬁed a previously unknown type of glycopeptide
resistance and demonstrated its transferability to another E. faecium
strain. Phenotypic (low-level resistance to vancomycin) and genotypic
(homology with VanL, VanC and VanE) traits suggest that VanN may be
a novel D-Ala-D-Ser ligase. Further investigations are being conducted
to conﬁrm this hypothesis. This would constitute the ﬁrst case of
transferable D-Ala-D-Ser type resistance and would increase the burden
of transferable vancomycin resistance.
Staphylococcus
P927 Vancomycin minimum bactericidal concentration analysis
of methicillin-resistant Staphylococcus aureus bacteraemia
isolates and correlation with daptomycin and vancomycin
minimum inhibitory concentrations
C. Doern °, H. Honda, W.M. Dunne Jr., D. Warren ° (St. Louis, US)
Objectives: The objective of this study was to analyze the relationship
between vancomycin minimum inhibitory concentrations (MIC) and
minimum bactericidal concentrations (MBC) for methicillin-resistant
S aureus (MRSA) bacteraemia isolates collected in a U.S. academic
hospital from 2005 to 2007. We also assessed the correlation between
vancomycin MIC/MBCs and daptomycin MIC.
Methods: MICs were determined for MRSA bacteraemia isolates using
the MicroScan − Pos MIC Panel Type 26. MicroScan panels were
inoculated from overnight growth on blood agar plates and incubated
at 35 degrees Celsius for 24 hr. Vancomycin MBCs were calculated by
plating 20 ul (in duplicate) of broth from the vancomycin MIC well
through the vancomycin 16 ug/ml well. The MBC was deﬁned as 99.9%
killing of the initial inoculum at 24 hr. Two-tailed Spearman’s rho was
used to calculate correlation coefﬁcients.
Results: 174 MRSA isolates were tested. The MIC-50 of daptomycin and
vancomycin were 0.5 (range 0.25−4 ug/ml) and 2.0 ug/ml (range 0.5−4
ug/ml), respectively. The MIC-90 of daptomycin was 1.0 ug/ml and the
MIC-90 of vancomycin was 2.0 ug/ml. The MBC-50 of vancomycin was
2.0 ug/ml and the MBC-90 was 8.0 ug/ml. Increased vancomycin MIC
correlated with increased daptomycin MIC among isolates in our cohort
(r = 0.334; p< 0.001) Increased vancomycin MBC also correlated with
increased daptomycin MIC (r = 0.366; p< 0.001). Vancomycin MIC and
MBC were highly correlated (r = 0.714; p< 0.001); in 124/174 (71%) of
isolates tested the vancomycin MBC was the same as the MIC. 12 (6.9%)
MRSA isolates were vancomycin-intermediate S. aureus (VISA) and 5
(2.9%) were non-susceptible to daptomycin (deﬁned as MIC> 1 ug/ml).
VISA strains were more likely to be non-susceptible to daptomycin [2/12
(17%) of VISA vs. 3/162 (2%) non-VISA isolates; p = 0.039].
Conclusions: In this cohort of MRSA bacteraemia specimens the
vancomycin MBC and MIC were identical in almost three-quarters of
isolates. Decreased susceptibility to vancomycin correlated to decreased
susceptibility to daptomycin.
P928 Activity proﬁle of tigecycline and comparator agents against
skin and wound isolates collected across Europe, 2006–2009
N.P. Brown, C.M. Pillar °, C. Thornsberry, D.F. Sahm, M. Dowzicky
(Chantilly, Collegeville, US)
Objective: TIG was approved in 2006 for the treatment of complicated
skin and skin structure infections. The spectrum of activity of TIG
includes both Gram-positive and Gram-negative pathogens, including
those with commonly encountered resistance phenotypes. It is important
to continue to monitor the activity of commonly utilized agents,
in particular recently approved agents, for resistance among targeted
pathogens. This study reports the current activity proﬁle of TIG and
comparators against recent Gram-positive and Gram-negative pathogens
collected in Europe focusing on skin and wound isolates.
Methods: 955 skin/wound and 2299 non-skin/wound Gram-positive
and Gram-negative organisms collected from 2006–2009 were centrally
tested by broth microdilution (CLSI M7-A8). Isolates were obtained from
sites distributed across 12 European countries. EUCAST breakpoints
(BP) were used to interpret TIG MIC results and CLSI (M100-S19) BP
were used to interpret all other agents.
Results: Against Gram-positive skin/wound isolates consisting of S. au-
reus (including MRSA), group A streptococci (GAS), and vancomycin
susceptible E. faecalis (VSE), TIG displayed potent in vitro activity
with MIC50s of 0.03mg/L (GAS) and 0.12mg/L (MSSA/MRSA/VSE)
and MIC90s of 0.06mg/L (GAS) and 0.25mg/L (MSSA/MRSA/VSE),
several fold lower than evaluated comparators. Over 99% of Gram-
positive skin and wound isolates were susceptible to TIG and to other
Gram-positive agents (linezolid, daptomycin, vancomycin). TIG was also
potent against Gram-negative enteric skin/wound isolates, with MIC50s
ranging from 0.12 to 0.5mg/L and MIC90s from 0.5 to 1mg/L. No TIG
resistance was detected among skin/wound isolates across the evaluated
Enterobacteriaceae spp., as was the case with imipenem. In contrast,
resistance was readily detected at varying levels among the evaluated
cephalosporins, gentamicin, ciproﬂoxacin, and piperacillin/tazobactam.
There was no notable difference in TIG activity proﬁle between that
observed with skin/wound isolates and non-skin/wound isolates.
Conclusions: TIG was potent against both Gram-positive and Gram-
negative skin/wound pathogens in Europe. Excluding S. aureus where
<1% of isolates were TIG resistant, no TIG was observed among the
evaluated isolates. The broad spectrum potency and overall lack of
resistance highlights the therapeutic potential of TIG, however continued
surveillance is warranted to monitor for emerging resistance among
primary pathogens.
P929 CEM-102 (fusidic acid) in vitro activity and evaluation
of molecular resistance mechanisms among European
Gram-positive isolates, 2008–2009
M. Castanheira, D. Farrell, M. Janechek, R. Jones ° (North Liberty, US)
Objectives: To evaluate the activity of fusidic acid (FA) among Gram-
positive bacteria collected in European medical centers in the 2008–2009
period and to analyze the prevalence of FA resistance (R) mechanisms
among staphylococci (2008).
Methods: A total of 7,504 strains collected from 29 European (EU)
medical sites located in 13 countries were susceptibility (S) tested by
CLSI reference broth microdilution against FA and comparator agents.
336 Staphylococcus spp. (2008 only) displaying FA MIC at 2mg/L
were tested for the presence of fusB, fusC and fusD and mutations on
fusA and fusE (FA primary and secondary active site).
Results: FA was very active against all staphylococci displaying a
MIC50 of 0.12mg/L regardless of methicillin-resistant (MR) proﬁle.
Applying EUCAST breakpoints (none available for CLSI), 90.7% of
S. aureus (SA) strains were S to FA, with lower rates observed among
MRSA (77.9%). Coagulase-negative staphylococci (CoNS) demonstrated
36.7% R against FA (14/867 S. saprophyticus with intrinsically elevated
FA MIC). MRCoNS displayed 40.5% of FA-R. FA demonstrated
marginal activity against enterococci and streptococci, with MIC50
values for b-haemolytic, group A, B and viridians group streptococci,
S. pneumoniae and enterococci ranging from 4 to 8mg/L. Among 336
staphylococci (FA MIC, 2mg/L), the presence of acquired FA-R genes
was detected in 64.9% of the strains (36.6% fusB and 28.3% fusC). fusB
and fusC rates among FA-R strains were 10.4 and 17.3% for SA and 26.1
and 11.3% for CoNS, respectively. fusA mutations were detected in 57 of
62 FA-R SA, most common being aminoacid alterations on position 461
(Leu to Lys/Ser). One SA showed a mutation on fusE (Q140L). Ireland
and Greece showed the highest SA FA-R rates with high prevalence of
L461K fusA mutation (clinical outbreaks). Low staphylococci FA-R rates
(1.4−3.1%) were observed in Israel, Italy, Poland, Spain and Sweden.
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Conclusions: FA appears to be a valuable alternative to other anti-MRSA
oral agents in the treatment of serious staphylococci infections. Despite
the long term of FA clinical use in European countries, staphylococci R
rates are still remarkably low except in clonal occurrences in a minority
of institutions.
Organism (no. tested) MIC (mg/L) EUCASTa
50% 90% S% R%
S. aureus (3,898) 0.12 0.5 90.7 9.3
MSSA (2,894) 0.12 0.25 95.1 4.9
MRSA (1,004) 0.12 >8 77.9 22.1
CONS (867) 0.12 >8 63.3 36.7
MSCoNS (176) 0.12 8 78.4 21.6
MRCoNS (691) 0.25 >8 59.5 40.5
Beta-haemolytic streptococci (374) 8 >8 − −
Group A streptococci (137) 4 8 − −
Group B streptococci (160) 8 >8 − −
Viridans Group streptococci (167) >8 >8 − −
S. pneumoniae (930) 8 >8 − −
Enterococcus spp. (1,268) 4 4 − −
a −: no interpretative criteria have been established.
P930 Antimicrobial activity of ceftaroline tested against Staphylo-
coccus aureus from the United States and Europe, 2008–2009
H. Sader °, G. Moet, R. Mendes, R. Jones (North Liberty, US)
Objectives: To evaluate the potency and spectrum of ceftaroline against
contemporary S. aureus strains and the correlation between SCCmec type
and ceftaroline MICs. Ceftaroline is a novel, parenteral cephalosporin
in late-stage clinical development for treatment of community-
acquired pneumonia and complicated skin and skin structure infections.
Ceftaroline exhibits broad-spectrum activity against Gram-negative and
-positive organisms, including methicillin-resistant S. aureus (MRSA)
and multidrug-resistant S. pneumoniae.
Methods: A total of 8742 unique clinical S. aureus strains were
consecutively collected in 2008–2009 from 29 hospitals located in
Europe (EU; 3899 strains) and 27 in the USA (4843 strains). Strains were
tested for susceptibility (S) to ceftaroline and numerous comparators by
CLSI broth microdilution methods. Additionally, 100 strains for which
SCCmec types had been previously characterized by PCR were tested
for S to ceftaroline and selected b-lactams.
Results: MRSA rates were 55.2% in the USA and 25.8% in EU,
ranging from 0.8% in Sweden to 59.5% in Greece. Ceftaroline (MIC50,
0.25mg/L) was 16-fold more active than ceftriaxone (MIC50, 4mg/L)
against methicillin-S S. aureus (MSSA) and showed potent activity
against MRSA (MIC50 1mg/L and MIC90, 1−2mg/L; see Table). All
MRSA were inhibited at 2mg/L of ceftaroline except 4 clonally
related strains from a Greek hospital and one strain from Italy (MIC
4mg/L for all). In EU and the USA, 37.1% and 34.6% of MRSA
strains were resistant (R) to clindamycin, and 85.9% and 65.9% were R
to levoﬂoxacin, respectively. In contrast, trimethoprim/sulfamethoxazole
(98.4–98.6% S), linezolid (100.0% S), and vancomycin (100.0% S)
remained very active against MRSA. Ceftaroline MIC values were lowest
among MRSA strains with SCCmec type IV, followed by those with
SCCmec types II, III, and I.
Organism (no. of strains) Cumulative % inhibited at ceftaroline MIC (mg/L) of:
0.06 0.12 0.25 0.5 1 2 4
MSSA
Europe (2895) 0.9 5.9 88.3 99.9 100.0 − −
USA (2169) 0.7 4.5 88.4 99.9 100.0 − −
MRSA
Europe (1004) 0.0 0.0 2.2 31.6 83.9 99.5 100.0a
USA (2674) 0.0 0.1 1.1 34.3 94.7 100.0 −
aOnly 5 strains (Greece and Italy).
Conclusions: Ceftaroline was very active against a large collection of
MSSA and MRSA strains recently (2008–2009) isolated in EU and USA
hospitals. Based on its favourable antimicrobial proﬁle, ceftaroline is a
very promising anti-staphylococcal therapeutic option widely applicable
to EU and the USA. MRSA isolates with SCCmec type IV, which are
found in USA pandemic clone USA300 and several clones circulating
in EU, exhibited the lowest ceftaroline MIC results.
P931 Activity of oritavancin and comparators in vitro against
standard and high inocula of Staphylococcus aureus
F. Arhin °, I. Sarmiento, T. Parr Jr., G. Moeck (Ville Saint Laurent, CA)
Objective: Inoculum size-dependent increases in minimum inhibitory
concentrations (MICs) of some antibiotics have been linked with
therapeutic failures. We studied the impact of inoculum size on
the growth-inhibitory and killing activities of oritavancin (ORI) and
comparators in vitro against S. aureus by broth microdilution and time-
kill assays at clinically-relevant concentrations of drugs.
Methods: MIC determinations and time-kill assays followed CLSI
guidelines. Tests were performed at standard inocula (105 CFU/mL)
and high inocula (107 CFU/mL). Drugs tested were ORI, vancomycin
(VAN), daptomycin (DAP) and linezolid. In time-kill assays, drugs were
tested at static concentrations approximating their free peak (fCmax)
and free trough (fCmin) in plasma when administered at approved doses
for complicated skin and skin structure infections. ORI fCmax and
fCmin were based on a single 1200mg dose. The S. aureus (SA) strains
used were ATCC 29213 (VAN susceptible), ATCC 43300 (methicillin-
resistant SA [MRSA]), ATCC 700699 (VAN-intermediate SA [VISA])
and NRS 402 (VISA).
Results: ORI MICs were 16-fold higher for all strains at the higher
inoculum relative to standard inoculum. MICs of comparators were 2-
to 8-fold higher when tested at the higher inoculum. In time-kill assays,
when tested at its fCmin and fCmax, ORI was bactericidal against ATCC
29213 and ATCC 43300 at standard and high inocula. At its fCmax, ORI
was bactericidal at standard inoculum but had no effect at the higher
inoculum against both VISA strains. At fCmin, ORI had no effect on
the VISA strains at either inoculum size. VAN was bactericidal against
ATCC 29213 and ATCC 43300 at both inoculum sizes at both fCmax and
fCmin. VAN had no effect on the VISA strains at both inoculum sizes at
its fCmin but was bactericidal and bacteriostatic at fCmax against both
strains at standard and high inocula, respectively. DAP had no effect on
all strains at its fCmin at both inoculum sizes. At its fCmax, DAP was
bactericidal against ATCC 29213 and ATCC 43300 at both inoculum
sizes. Against the VISA strains, DAP at both fCmax and fCmin had no
effect at both inoculum sizes.
Conclusions: ORI activity was diminished against all S. aureus
strains at high inoculum size. The activity of comparator antibiotics
was also diminished butto a lesser extent. In infections with a
high anticipated bacterial burden, alternative dosing of oritavancin or
synergistic combinations with additional agents may be warranted.
Agent Fold increase in MIC at higher inoculum relative to
lower inoculum
ATCC 29213 ATCC 43300 ATCC 700699 NRS 402
Oritavancin 16 16 16 16
Vancomycin 2 2 2 2
Daptomycin 8 8 2 2
Linezolid 2 2 2 4
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P932 Antimicrobial spectrum of activity of telavancin and
comparator agents tested against methicillin-resistant
Staphylococcus aureus recovered from United States and
European hospitals over a 3-year sampling period (2007–2009)
R. Mendes, H. Sader °, M. Janechek, R. Jones (North Liberty, US)
Objectives: To monitor the activities of telavancin (TLV) and
comparators against methicillin-resistant S. aureus (MRSA) collected
from the United States (US) and Europe (EU) including Turkey, over a
three year period (2007–2009). TLV was recently approved in the US
and Canada for the treatment of adult patients with complicated skin and
skin structure infections (cSSSI) caused by susceptible Gram-positive
pathogens. This new lipoglycopeptide has shown potent in vitro activity
against staphylococci, including multidrug-resistant (MDR) strains.
Methods: A total of 4,077 and 1,334 MRSA isolates were collected
respectively from 42 and 29 hospitals in the US and EU (13 different
countries). All isolates were submitted to a coordinator laboratory.
Species identiﬁcations were conﬁrmed by standard algorithms and, when
necessary, by Vitek 2. Antimicrobial susceptibility testing was performed
by CLSI methods (M07-A8, 2009). Interpretive criteria were those from
EUCAST (2009), except for TLV where the susceptibility breakpoint
approved by the US-FDA for S. aureus (1mg/L) was applied.
Results: MRSA were recovered from bacteremia (38.5%), pneumonia
(18.0%), SSSI (36.2%) and other infection sites (7.3%). MRSA rates
ranged from 56.2% in 2007 to 52.0% in 2009 in the US and from
28.3% in 2007 to 22.7% in 2008 in EU. Among EU countries, the
MRSA rates varied considerably, ranging from 0.6% in Sweden to 64.7%
in Greece. Overall TLV was consistently active against MRSA over
the study period (MIC90, 0.25mg/L; 100.0% susceptible; see table).
Resistance to teicoplanin was noted among isolates from both regions,
and resistance rates were highest in Turkey (19.5%) and Italy (4.1%).
Daptomycin (DAP; MIC90, 0.5mg/L), linezolid (LZD; MIC90, 2mg/L)
and trimethoprim/sulfamethoxazole (TMP/SMX; MIC90, 0.5mg/L)
were also active against MRSA. Quinupristin/dalfopristin (Q/D) MIC90
values increased one doubling dilution among US and EU MRSA.
Susceptibility rates to gentamicin were higher in the US (95.6%)
compared to EU (80.8%-86.9%).
Conclusions: Over a three year surveillance period TLV exhibited
sustained potency against MRSA isolates from the US and EU. While
vancomycin, DAP, LZD and Q/D were also active against these
strains, overall TLV MIC90 values were at least 2-fold lower when
compared to these agents. These data emphasize the importance of
continued longitudinal surveillance to monitor the activities of marketed
antimicrobial agents, mainly against MDR strains.
Antimicrobial agent MIC90 (mg/L) / % susceptible
a
US (no. tested by year) Europe (no. tested by year) Overall
2007 2008 2009 2007 2008 2009
(1,560) (1,277) (1,240) (366) (650) (318) (5,411)
Telavancin 0.25/100.0 0.25/100.0 0.25/100.0 0.25/100.0 0.25/100.0 0.25/100.0 0.25/100.0
Vancomycin 1/>99.9 1/100.0 1/100.0 1/100.0 1/100.0 1/100.0 1/>99.9
Teicoplanin 2/99.6 2/99.6 2/99.6 2/98.6 2/98.1 2/97.8 2/99.3
Daptomycin 0.5/99.9 0.5/99.6 0.5/100.0 0.5/100.0 0.5/100.0 0.5/100.0 0.5/99.9
Linezolid 2/99.9 2/100.0 2/99.8 2/100.0 2/100.0 2/100.0 2/99.9
Q/D 0.5/99.8 0.5/99.4 1/99.6 0.5/98.9 1/98.9 1/99.7 0.5/99.5
TMP/SMX 0.5/97.4 0.5/99.0 0.5/98.3 0.5/99.5 0.5/98.9 0.5/98.1 0.5/98.3
Clindamycin >2/63.0 >2/62.3 >2/67.3 >2/72.1 >2/62.9 >2/69.5 >2/64.8
Gentamicin 2/95.6 2/97.8 2/97.4 >8/86.9 >8/80.8 >8/86.8 2/93.6
Tetracycline 2/93.9 2/94.9 2/93.3 2/92.9 2/80.9 2/93.4 2/92.3
a Interpretive criteria were those from EUCAST (2009), except for telavancin where the susceptibility breakpoint
approved by the US-FDA for S. aureus (1mg/L) was applied.
P933 Increased vancomycin MIC among MRSA isolates in
Malaysia: truth or myth?
N. Ahmad °, S. Nawi, G. Rajasekaran, A. Husin, N. Rahman, N. Maning,
M. Aziz (Kuala Lumpur, Selangor, Johor, Sabah, Penang, Kelantan, MY)
Vancomycin has been the drug of choice for the treatment of methicillin-
resistant Staphylococcus aureus (MRSA). Susceptible Staphylococcus
aureus strains normally have vancomycin MIC values that ranged
between 0.5 and 2 mg/mL. Even though methicillin-resistant Staphylo-
coccus aureus (MRSA) with vancomycin MIC of 2 mg/mL is considered
susceptible to vancomycin, treatment failures for strains with this MIC
have been reported. The prevalence of Staphylococcus aureus clinical
strains with high MICs is not known in Malaysian hospitals.
Objective: This study was conducted to determine the vancomycin MIC
of Staphylococcus aureus isolates obtained from clinical samples from
6 major Malaysian hospitals.
Methodology: Methicillin-susceptible and methicillin resistant Staphy-
lococcus aureus (MSSA and MRSA) strains isolated from invasive
infections and non-colonizers were included in this study. The strains
were collected sequentially between March and July 2009 from 6
major Malaysian hospitals. Vancomycin MICs were determined by broth
microdilution method (CLSI) and E-test method.
Result: A total of 600 strains were included in this study, in which 300
were MSSA and 300 were MRSA. By both microdilution method, 87%
of the MSSA isolates have vancomycin MIC of 0.5 mg/mL and 13%
with MIC 1 mg/mL. No isolates showed MIC value of 2 mg/mL. Using
E-test method, the vancomycin MIC of the MSSA ranged from 0.75 to
2 mg/mL, where 16% of the isolates have vancomycin MIC of 2 mg/mL.
For MRSA isolates, using broth microdilution, the vancomycin MIC
ranged from 0.25 to 1 mg/mL where 41% of the isolates showed MIC of
1 mg/mL. Using E-test method, the vancomycin MIC ranged from 0.5
to 2 mg/mL, where 31% of the strains showed MIC of 2 mg/mL.
Conclusion: Using broth microdilution test, all the MSSA and MRSA
strains in this study showed MIC values of 1 mg/mL. However, the
percentage of isolates with vancomycin MIC 1 mg/mL was higher among
MRSA compared to MSSA isolates. Using E-test method, two-fold
higher vancomycin MIC values was observed, where MIC of 2 mg/mL
was detected in both the MSSA and MRSA strains. However, the strains
with MIC 2 mg/mL were much higher among MRSA compared to the
MSSA strains. The clinical implication of dilution difference between
these two methods is unknown. Further studies need to be carried out
to determine which method can be relied on when making therapeutic
recommendations.
P934 Is there a relationship between oritavancin in vitro
microbiological parameters and clinical outcome in
a 2007–2008 phase 2 study of complicated skin and
skin-structure infections?
A. Belley °, T. McClure, I. Sarmiento, F. Arhin, T. Parr Jr., G. Moeck
(St. Laurent, CA)
Objective: Oritavancin (ORI) is an investigational lipoglycopeptide in
clinical development for complicated skin and skin structure infections
(cSSSI) caused by Gram-positive organisms. A previous study has
demonstrated a relationship between vancomycin minimal inhibitory
concentration (MIC) or bactericidal activity with clinical outcome in
the treatment of Staphylococcus aureus bacteraemia (J Clin Micro 2004;
42:2398–2402). We explored whether ORI MIC or a microbiological
parameter from in vitro time-kill studies could distinguish S. aureus
clinical isolates from patient cure or failure outcome groups in a recent
Phase 2 study assessing ORI efﬁcacy in cSSSI.
Methods: ORI MIC determinations and time-kill studies were performed
on S. aureus isolates (n = 87) from the clinically-evaluable population of
patients enrolled in a Phase 2, multicenter, double-blind, randomized
study of ORI treatment of cSSSI. Time-kill kinetics were determined
at 0.12 and 0.5mg/L ORI to monitor rebound growth characteristics
and assess killing at a bactericidal concentration, respectively. Logistic
regression modeling (outcome = microbiological parameter) was
performed on the following microbiological parameters: area under the
bactericidal curve (AUBC) of log-transformed cfu/ml from 0 to 4 h
(AUBC0−4 h) or 4 to 24 h (AUBC4−24 h), rate of kill between 0 and 4 h
(Slope0−4 h) or mean of log-transformed cfu/ml at 0.5 h (CFU0.5 h) or
12 h (CFU12 h) to determine if isolates from the cure and failure clinical
outcome groups demonstrated signiﬁcantly different results. Mean values
from isolates of each clinical outcome group are presented with standard
deviation (SD).
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Results: S. aureus isolates from both clinical cure and failure groups had
ORI MIC distributions that were not signiﬁcantly different using Fisher’s
exact test. Logistic regression modeling revealed that the AUBC0−4 h,
AUBC4−24 h, Slope0−4 h, CFU0.5 h and CFU12 h derived from time-kill
studies using either 0.12mg/L or 0.5mg/L ORI were not signiﬁcantly
different between these groups.
Conclusions: In vitro microbiological parameters derived from MIC and
time-kill studies could not distinguish between isolates of S. aureus from
the cure and failure clinical outcome groups in a recent cSSSI study. We
propose that in the absence of resistance to ORI, underlying patient
heterogeneity likely accounts for the therapeutic failure to ORI observed
in the Phase 2 study.
Microbiological parameter Concentration of oritavancin used Clinical outcome, mean (SD)
derived from time-kill studies (mg/L) Cure, n = 43 Failure, n = 44
AUBC0−4 h (log cfu/ml)·h 0.12 4.8 (1.3) 4.6 (1.3)
AUBC4−24 h (log cfu/ml)·h 0.12 51.2 (19.8) 43.7 (25.7)
CFU12 h (log cfu/ml) 0.12 4.2 (0.6) 4.2 (0.5)
AUBC0−4 h (log cfu/ml)·h 0.5 1.8 (0.6) 1.9 (0.6)
Slope0−4 h (log cfu/ml)/h 0.5 −3.4 (1.4) −3.4 (1.5)
CFU0.5 h (log cfu/ml) 0.5 4.3 (1.5) 4.3 (1.5)
P935 Antimicrobial susceptibility of Staphylococcus capitis from
two Scandinavian hospitals
L. Buarø °, T. Monsen, J. Afset, K. Bergh (Trondheim, NO; Umea˚, SE)
Objective: The aim of the study was to examine the antimicrobial
susceptibility of clinical Staphylococcus capitis isolates from one
Norwegian and one Swedish hospital.
Methods: A total of 54 clinical S. capitis isolates, 22 Norwegian and
32 Swedish, were identiﬁed by standard methods and examined for
susceptibility to 15 antibiotics using agar disk diffusion (n = 11) and Etest
(n = 4). Breakpoints applied were deﬁned by the Norwegian Working
Group for Antibiotics except for vancomycin (VA) and teicoplanin (TP)
for which EUCAST breakpoints were used. Inducible clindamycin (CM)
resistance was examined by double disk diffusion, and oxacillin (OX)
resistance by mecA PCR. Screening for glycopeptide resistance was done
by Etest macro method, brain heart infusion agar supplemented with
VA 6mg/L or TP 5mg/L and Mueller-Hinton agar with TP 5mg/L.
Molecular typing was done by PFGE.
Results: Rates of reduced susceptibility among the Norwegian isolates
were: chloramphenicol 4.5%, CM 36.4%, erythromycin 36.4%, fusidic
acid 13.6%, gentamicin (GM) 40.9%, norﬂoxacin 31.8%, OX 50%,
tetracycline 13.6%, co-trimoxazole 9.1%, and VA 13.6%. In the Swedish
isolates reduced susceptibility was detected to the following antibiotics:
GM 100%, OX 100%, TP 75%, and VA 90.6%. All isolates from
both hospitals were susceptible to linezolid, rifampicin, tigecycline and
quinupristin-dalfopristin. A positive glycopeptide resistance screening
result was obtained in 78.1%-100% of the Swedish and 0–45.5% of
the Norwegian isolates depending on the method used. Divergent results
were observed between different glycopeptide resistance screening meth-
ods in 16 of the isolates. The Norwegian isolates showed considerable
heterogeneity both with respect to antimicrobial susceptibility (16
different proﬁles) and genotype (16 PFGE patterns). In contrast, a
high degree of homogeneity was observed with only three different
susceptibility proﬁles and PFGE patterns in the Swedish collection of
isolates.
Conclusion: The S. capitis strains studied showed considerable hetero-
geneity in antimicrobial susceptibility, but were uniformly susceptible
to four of the drugs tested. Reduced susceptibility to vancomycin
was detected in isolates from both hospitals. Discrepant results were
observed between different glycopeptide resistance screening methods.
Species speciﬁc antimicrobial susceptibility data for a larger collection
of epidemiologically unrelated S. capitis strains are warranted.
P936 Comparison of oritavancin activity against Staphylococcus
aureus isolates from a 2007–2008 phase 2 study and from
1999–2002 phase 3 studies of complicated skin and skin
structure infection
G. Moeck °, F. Arhin, J. Milata, T. McClure, K.J. Walker, T. Parr Jr.
(Saint-Laurent, CA; Indianapolis, US)
Objective: Oritavancin is an investigational lipoglycopeptide under
study for treatment of serious Gram-positive infections. Its spectrum
of activity includes methicillin-resistant S. aureus (MRSA). We
compared oritavancin susceptibilities of Staphylococcus aureus from a
phase 2 complicated skin and skin structure infection (cSSSI) study
(single/infrequent oritavancin dosing; conducted between 2007–2008)
to those from two phase 3 cSSSI studies (once-daily oritavancin
dosing for 3−7 days; conducted between 1999–2002) to assess whether
oritavancin potency was affected by concurrent changes in prevalence
and epidemiology of MRSA between the studies.
Methods: Pathogens were isolated locally from patient specimens.
A single isolate with the highest oritavancin minimum inhibitory
concentration (MIC) per patient was studied, yielding a total of 682
strains (252 MRSA, 430 methicillin-susceptible S. aureus [MSSA]).
Susceptibilities to oritavancin, vancomycin, teicoplanin, daptomycin,
linezolid, oxacillin, quinupristin-dalfopristin, tetracycline, tigecycline,
and trimethoprim-sulfamethoxazole were tested centrally by broth
microdilution following CLSI M7-A7 guidelines. Oritavancin assays
used 0.002% polysorbate-80 (as per 2009 CLSI M7-A8 guidelines).
Results: In the microbiologic intent-to-treat populations, MRSA
incidence increased dramatically over time, from 30% in the phase 3
studies conducted in 1999–2002 to 57% in the phase 2 study conducted
in 2007–2008. Oritavancin MIC90 against MRSA from the phase 2
study (0.12mg/L; n = 103) was 2-fold lower than that from the
phase 3 studies (0.25mg/L; n = 149); oritavancin MIC90 values against
MSSA (0.12mg/L) were unchanged over time. Oritavancin potency was
identical against MRSA and MSSA isolates from the Phase 2 study, with
an MIC90 of 0.12mg/L for both phenotypes.
Conclusion: Whereas the incidence of MRSA nearly doubled between
1999–2002 and 2007–2008 in studies of cSSSI, oritavancin exhibited
equivalent or greater in vitro potency against recent isolates, regardless
of methicillin resistance phenotype. This ﬁnding provides evidence of
sustained anti-MRSA activity of oritavancin over time and suggests a
potential role for oritavancin in treating serious MRSA infections in a
contemporary hospital setting.
Study (years) Organism (n) MIC90 Cumulative % inhibited at oritavancin MIC (mg/L)
(mg/L) 0.03 0.06 0.12 0.25 0.5 1 2
Phase 3 (1999–2002) MRSA (149) 0.25 14.8 48.3 82.6 99.3 99.3 99.3 100
MSSA (352) 0.12 18.5 57.7 91.2 100
Phase 2 (2007–2008) MRSA (103) 0.12 58.2 83.5 97.1 100
MSSA (78) 0.12 51.3 85.9 97.4 98.7 100
P937 Evaluation of oritavancin and comparators against Staphy-
lococcus aureus with varying susceptibility to vancomycin
C. Vidaillac °, J. Parra-Ruiz, M. Rybak (Detroit, US)
Objectives: Oritavancin (ORI) is a novel lipoglycopeptide antibiotic
with activity against Gram-positive pathogens including glycopeptide-
resistant isolates. In an effort to understand whether ORI could represent
a therapeutic option for infections caused by resistant strains, we assessed
the in vitro activity of ORI and relevant comparator agents against a
collection of clinical isolates of heterogeneous vancomycin intermediate
S. aureus (hVISA) and vancomycin resistant S. aureus (VRSA).
Methods: A collection of non-redundant clinical isolates of hVISA
(n = 100) and VRSA (n = 10) strains were evaluated in this study. All
hVISA isolates were previously characterized by population analysis
and Macro Etest, as previously recommended by Wootton et al. All
VRSA were selected from the NARSA collection. Susceptibility testing
was performed in duplicate by broth microdilution following CLSI
M7-A8 guidelines using vancomycin (VAN), ORI, daptomycin (DAP),
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teicoplanin (TEC), cefoxitin (CFX) and oxacillin (OXA). Quality control
was performed using S. aureus ATCC 29213. Four isolates, including 1
vancomycin intermediate S. aureus (VISA), 1 VRSA, 1 hVISA and 1
methicillin-resistant S. aureus DAP non susceptible were evaluated by
time kill experiments (TK) against VAN, DAP, TEC and ORI at 4 and
8× MIC using a starting inoculum of 5−6 log CFU/mL. Bactericidal
activity was deﬁned as 3 log10 kill compared to the starting inoculum.
Results: Susceptibility results are reported in Table 1. Overall, ORI MIC
ranges were lower than other lipo/glycopeptide comparators. MIC values
of the 4 isolates used in TK ranged between 0.12 to 1mg/L for ORI,
1 to 64mg/L for VAN, 2 to 8mg/L for TEC and 0.25 to 2mg/L for
DAP. DAP and ORI were the most effective drugs against all tested
isolates, exhibiting cidal activity within 8 h at either 4× and 8× the
MIC. In contrast, neither TEC nor VAN were cidal against the VRSA
and the MRSA daptomycin non susceptible isolates at 24 h. VAN was
bacteriostatic at either 4× and 8× MIC against the hVISA strain. All
tested antimicrobials exhibited cidal activity at 24 h against the VISA
isolate.
Conclusions: Both ORI and DAP exhibited potent in vitro activity
against isolates with reduced susceptibility to VAN. In TK, ORI and
DAP at 4× and 8× MIC demonstrated rapid cidal activity against
all tested isolates. Further investigations are warranted to better deﬁne
the therapeutic value of ORI in the treatment of multi-drug resistant
S. aureus infections.
Table 1. In vitro susceptibility of isolates in a large collection of
hVISA/VRSA to oritavancin and comparators
Antimicrobials Susceptibility values (in mg/L) of
hVISA (n = 100) VRSA (n = 10)
ORI MIC50 0.25 0.5
MIC90 0.5 1
Range 0.03−1 0.25−2
VAN MIC50 1 512
MIC90 2 512
Range 0.5−2 64–1024
DAP MIC50 0.25 0.25
MIC90 0.5 1
Range 0.12−1 0.12−2
TEC MIC50 1 64
MIC90 2 512
Range 0.12−16 16–1024
OXA MIC50 128 64
MIC90 512 128
Range 4–512 64–256
CFX MIC50 128 64
MIC90 256 256
Range 8−>512 32–256
P938 Activity of ceftaroline against selected clinical isolates of
Staphylococcus aureus from the Canadian Bacterial Sentinel
Network
D. Farrell °, A. McGeer, K. Green, D. Low (Toronto, CA)
Objective: To evaluate the activities of ceftaroline against contemporary
clinical isolates of Staphylococcus aureus collected in Canadian medical
centres as part of the Canadian Bacterial Surveillance Network (CBSN).
Ceftaroline is a novel, parenteral cephalosporin exhibiting bacterici-
dal activity against Gram-positive organisms, including methicillin-
susceptible and -resistant S. aureus (MSSA and MRSA), and common
Gram-negative pathogens. CBSN has conducted cross-Canada S. aureus
surveillance since 1987.
Methods: Susceptibility testing for ceftaroline and comparator antimi-
crobials was performed using CLSI broth microdilution methods on
591 isolates obtained from the CBSN (1999–2009) supplemented with
42 strains from the Network of Antimicrobial Resistance in S. aureus
(NARSA) program. Community-acquired (CA) and hospital-acquired
(HA) MRSA, MSSA, and vancomycin-intermediate S. aureus (VISA)
isolates were included. Where possible, the most recent CBSN isolates
were selected; number of isolates per year (year/n): 1999/1; 2002/92;
2003/62; 2004/40; 2005/56; 2006/25; 2007/195; 2008/110; 2009/10.
Results: Ceftaroline exhibited activity against all 633 strains and all
MRSA, MSSA, and VISA subgroups (highest ceftaroline MIC, 2mg/L)
(Table). Ceftaroline had a lower MIC90 against MSSA strains (n = 105;
MIC90, 0.25mg/L) than against MRSA strains (n = 528, MIC90,
1mg/L). Resistance to mupirocin, tetracycline, gentamicin, fusidic
acid, erythromycin, or cotrimoxazole, and decreased susceptibility to
vancomycin, did not affect ceftaroline activity against S. aureus.
Conclusions: Ceftaroline demonstrated potent in vitro activity against
selected contemporary CBSN and NARSA S. aureus isolates, including
strains with resistance to methicillin and/or reduced susceptibility to
vancomycin. S. aureus resistance to commonly used antimicrobials did
not adversely affect ceftaroline activity. These data highlight the potential
utility of ceftaroline in treating S. aureus infections, including MSSA,
MRSA, and VISA, in both community and hospital settings.
n Cumulative % at ceftaroline MIC
(mg/L)
MIC
(mg/L)
0.12 0.25 0.5 1 2 MIC50 MIC90
All 633 2.1 17.9 75.8 95.1 100 0.5 1
CA-MRSA 214 − 1.8 89.7 99.5 100 0.5 1
CA-MSSA 86 14 98.8 100 − − 0.25 0.25
HA-MRSA 275 − 2.2 60.4 90.2 100 0.5 1
HA-MSSA 14 7.1 85.7 100 − − 0.25 0.25
MR-VISA 39 − 2.6 43.6 92.3 100 1 1
MS-VISA 5 − 100 − − − − −
MR = methicillin resistant; MS = methicillin susceptible.
P939 Trends in ceftobiprole susceptibility among 2001–2008
consecutive methicillin-resistant Staphylococcus aureus blood
isolates
Y. Golan °, L. McDermott, D.R. Snydman (Boston, US)
Objective: Treatment options for MRSA blood-stream infections remain
limited. Resistance to the macrolides, ﬂuoroquinolones, and tetracyclins
is common and a recent MIC creep to vancomycin has been described.
Ceftobiprole is an investigational cephalosporin with extended activity
against MRSA. We describe trends in ceftobiprole susceptibility among
consecutive blood isolates of MRSA from a tertiary-care hospital.
Methods: All 2001 through 2008 MRSA blood isolates were saved.
Susceptibility to vancomycin and ceftobiprole was tested in duplicate
using broth microdilution according to recommended CLSI methodology.
CLSI reference strains S. aureus 29213 and E. faecalis 29212 served
as quality controls. Ceftobiprole powder was supplied by Johnson &
Johnson. Only the ﬁrst isolate from each bacteremia episode was tested.
Results: A total of 385 MRSA isolates were included of which 32%
were isolated from ICU patients and 68% from ward patients. Culture
sources included peripheral blood (71%), central vascular catheter (25%)
and arterial line (4%). Ceftobiprole MIC distribution was narrow with
99% of isolates exhibiting an MIC of 0.5−2mg/ml. Ceftobiprole MIC
range, MIC50, and MIC 90 were 0.25−4mg/ml, 1micog/ml, and 2mg/ml,
respectively. Ceftobiprole geometric mean MIC decreased during the
study period from 1.02mg/ml in 2001−4 to 0.84mg/ml in 2005−8.
In comparison, vancomycin geometric mean MIC has increased from
1.10mg/ml in 2001−4 to 1.22mg/ml in 2004−8. Higher vancomycin
MICs were not associated with higher Ceftobiprole MICs. Ceftobiprole
geometric mean MICs for isolates with a vancomycin MIC of 1mg/ml
and 2mg/ml were 0.93mg/ml and 0.97mg/ml, respectively. Ceftobiprole
geometric MICs were higher among isolates from ICU patients as
compared to ward patients (1.15mg/ml vs 0.94mg/ml, respectively)
and similar among isolates from peripheral blood and central lines
(1.00mg/ml and 0.97mg/ml, respectively).
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Conclusions: Ceftobiprole susceptibility among MRSA blood isolates
is within a tight MIC range and has not increased from 2001 to 2008.
Ceftobiprole’s activity is not affected by vancomycin MIC and it remains
as active against isolates with a vancomycin MIC of 2mg/ml. Slightly
higher Ceftobiprole MICs were observed in isolates from patients in the
ICU.
P940 Effect of tigecycline against methicillin-resistant coagulase-
negative staphylococci, with reduced susceptibility to
glycopeptides, growing as planktonic and adherent cells
A. Grossato °, C. Boldrin, A. Di Gabriele (Padua, IT)
Objectives: In the present study the activity of tigecycline (Wyeth), a
recently introduced drug, was investigated against a signiﬁcant number
of methicillin-resistant coagulase-negative staphylococci (CoNS-MR),
belonging to different species: 58 S. epidermidis, 30 S. haemolyticus,
8 S. hominis. The majority of them showed reduced susceptibility to
glycopeptides (2 S. haemolyticus were resistant to teicoplanin) and
showed ability to produce bioﬁlm (BF).
Methods: Non repetitive isolates of CoNS-MR, collected from high-risk
units (Neonatal ICU, Surgery’s Units, Burns Unit etc) and obtained from
clinically signiﬁcant specimens, were identiﬁed with API ID32 (Bio-
Me´rieux). PCR tests were performed to conﬁrm methicillin-resistance
(mecA) and to examine the presence of ica gene cluster, often found in
adhesive strains. MICs and MBCs were determined traditionally by broth
micro-dilutuion method. The MICs of BF forming bacteria were tested
in a pre-formed 24hBF, using the static microtiter model. To quantify
BF, before and after treatment with tigecycline, OD570 of stained BF
were determined colorimetrically and the number of bacteria estimated
by classical plate counting.
Results: All strains were mecA positive and their methicillin MIC range
was 512−64mg/L. The presence of ica locus was demonstrated in 87%
of S. epidermidis and 40% of S. haemolyticus. As to BF formation all
ica-positive strains were BF strains. MICs and MBCs of glycopeptide
and tigecycline were summarized in Table 1 and in Table 2.
Conclusion: Tigecycline showed a good in vitro activity on CoNS-MR,
including glycopeptide-intermediate-resistant isolates. MBCs against BF
producing bacteria are similar to those determined against planktonic
bacteria. These previous results indicate tigecycline as a likely drug for
the therapy of BF-associated infections.
Table 1. In vitro activity of glycopeptides and tigecycline against
planktonic CoNS-MR
Strains MIC (mg/L)
Vancomycin Teicoplanin Tigecycline
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
S. epidermidis 2 16 2 4 0.06 1
S. haemolyticus 4 8 2 128 0.06 0.5
S. hominis 2 4 4 8 0.06 0.25
Table 2. MBCs of tigecycline against planktonic and BF-CoNS-MR
Strains MBC (mg/L)
Non-BF CoNS MR BF CoNS-MR
MBC50 MBC90 MBC50 MBC90
S. epidermidis 2 16 4 16
S. haemolyticus 0.5 8 1 8
S. hominis 1 4 2 8
Streptococci and pneumococci
P941 Antimicrobial susceptibility of Gram-positive non-urinary
isolates to fosfomycin
M. Falagas, S. Maraki, D. Karageorgopoulos °, A. Kastoris,
A. Kapaskelis, G. Samonis (Athens, Heraklion, GR)
Objective: We aimed to evaluate the antimicrobial activity of
fosfomycin against Gram-positive non-urinary isolates collected at the
microbiological laboratory of the University Hospital of Heraklion,
Crete, Greece, in 2008.
Methods: We included in our study all Gram-positive clinical isolates
originating from sites other than the urinary tract that were collected
over a 1-year period (January to December 2008) at the microbiological
laboratory of the 700-bed, University Hospital of Heraklion, Heraklion,
Crete, Greece.
Results: Susceptibility testing was performed with the disk diffusion
method for a total of 1846 isolates; 1275 (69.1%) were susceptible
to fosfomycin. Speciﬁcally, 416/419 (99.3%) Staphylococcus aureus
isolates [including 129/130 methicillin resistant Staphylococcus aureus
(MRSA) isolates], and 745/961 (77.5%) coagulase-negative staphylococ-
cal isolates were susceptible to fosfomycin. Among 42 Streptococcus
pneumoniae, 64 Streptococcus pyogenes, and 93 other streptococcal
isolates, 61.9%, 40.6%, and 48.4%, respectively, were susceptible.
Fosfomycin was inactive against the 166 enterococcal isolates tested.
Conclusions: This old antibiotic may deserve consideration for further
studies and use in clinical practice, especially for Staphylococcus aureus
(including MRSA) infections.
P942 Spectrum of activity of oritavancin and comparator agents
tested against subsets of vancomycin-resistant enterococci
from the United States and Europe
R. Mendes, S. Putnam, H. Sader, R. Jones ° (North Liberty, US)
Objectives: To evaluate the antimicrobial activities of oritavancin
(ORI) and comparators tested against subsets of vancomycin-resistant
enterococci (VRE) recovered from hospitalized patients in the United
States (USA) and Europe (EU) through the International ORI
Surveillance Program (2008–2009), which is part of the worldwide
SENTRY Antimicrobial Surveillance Program.
Methods: Enterococci (2,841) were consecutively collected from the
USA (28 sites) and EU (28 sites). Isolates were submitted to a monitoring
laboratory where identiﬁcations were conﬁrmed by standard algorithms
and Vitek 2. Isolates were tested for susceptibility (S) by reference CLSI
methods (M07-A8, 2009). Interpretive criteria were those from CLSI
(M100-S19, 2009). The VanA phenotype was characterized by non-S to
vancomycin (VAN) and teicoplanin (TEC), while the VanB phenotype
was non-S to VAN and S to TEC. The VanC phenotype was based on
species identiﬁcation (E. casseliﬂavus and E. gallinarum).
Results: Isolates were dominantly from bacteremia (61.5%), skin and
skin structure (14.2%) and urinary tract infections (12.5%). 24.8% of
strains were non-S to VAN, comprising 88.5% VanA, 6.7% VanB and
4.8% VanC phenotypes. 76.7% of VAN-non-S were from the USA.
E. faecium (EFM) represented 92.4% and 58.3% of strains with VanA
and VanB phenotypes, respectively. ORI was 4-fold more active against
VAN-S EFM (MIC50, 0.004mg/L) than VAN-S E. faecalis (EF;
MIC50, 0.015mg/L; see table). ORI activity against isolates displaying
a VanB phenotype was similar to that against VAN-S isolates from the
same species. ORI MIC90 values against VanA species were 16-fold
higher than their respective S strains. Ampicillin (MIC90, 2mg/L; 97.8%
S), daptomycin (DAP; MIC90, 1mg/L; 100.0% S) and linezolid (LZD;
MIC90, 2mg/L; 100.0% S) were also active against EF displaying a
VanA phenotype, while DAP (MIC90, 2mg/L; 99.7% S), LZD (MIC90,
2mg/L; 98.8% S) and quinupristin/dalfopristin (MIC90, 1mg/L; 95.2%
S) were active against EFM with a VanA phenotype.
Conclusions: ORI exhibited very potent in vitro activity against this
contemporary VRE collection from two regions. ORI MIC values were
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elevated when tested against isolates displaying a VanA phenotype
relative to VAN-S and VanB strains; however, all enterococci were
inhibited by ORI at only 1mg/L. In addition, ORI was at least 2- and
8-fold more active than the comparators when tested against EF and
EFM with a VanA phenotype, respectively.
Organism phenotype MIC (mg/L) Number (cumulative %) of isolates inhibited by oritavancin MIC (mg/L) of:
(no. Tested) 50% 90% 0.004 0.008 0.015 0.03 0.06 0.12 0.25 0.5
E. faecalis
VAN-Sa (1,709) 0.015 0.03 35 (2.0) 443 (28.0) 767 (72.8) 379 (95.0) 75 (99.4) 7 (99.8) 2 (99.9) 1 (100.0)
VanA (46) 0.25 0.5 1 (2.2) 0 (2.2) 1 (4.3) 1 (6.5) 2 (10.9) 5 (21.7) 17 (58.7) 17 (95.7)
VanB (20) 0.015 0.03 − 7 (35.0) 9 (80.0) 4 (100.0) − − − −
E. faecium
VAN-Sa (421) 0.004 0.008 222 (52.7) 190 (97.9) 8 (99.8) 1 (100.0) − − − −
VanA (583) 0.03 0.12 11 (1.9) 42 (9.1) 56 (18.7) 200 (53.0) 208 (88.7) 58 (98.6) 6 (99.7) 2 (100.0)
VanB (28) 0.008 0.008 13 (46.4) 14 (96.4) 0 (96.4) 1 (100.0) − − − −
VanC (34)b 0.008 0.015 4 (11.8) 25 (85.3) 4 (97.1) 1 (100.0) − − − −
aVAN-S = vancomycin-susceptible. b Includes E. casseliﬂavus (11 isolates) and E. gallinarum (23 isolates).
P943 In vitro activity of retapamulin and 16 other antimicrobial
agents against Streptococcus pyogenes clinical isolates
E. Tamayo °, M. Montes, V. Iriarte, J.M. Garcia-Arenzana,
E. Pe´rez-Trallero (San Sebastian, Tres Cantos, ES)
Retapamulin is a novel semi-synthetic antimicrobial agent approved for
topical treatment of impetigo and infected small lacerations, abrasions
or sutured wounds in humans. It selectively inhibits bacterial protein
synthesis through a novel mechanism of action. Streptococcus pyogenes
and Staphylococcus aureus are the main pathogens isolated from skin
infections.
Objectives: To evaluate in vitro activity of retapamulin and other
16 antibiotics used for skin and soft tissue infections, either of
topical (fusidic acid, mupirocin, neomycin, bacitracin) or systemic
(amoxicillin, erythromycin, cloxacillin, clindamycin, tetracycline) use
against Streptococcus pyogenes.
Methods: Four hundred Streptococcus pyogenes clinical isolates
obtained between January 2007 and December 2008 at Hospital Donostia
were tested by broth microdilution test (Sensititre, Trek Diagnostics
Systems, UK) performed and interpreted according to CLSI M100-S19
guidelines. A retapamulin breakpoint MIC of 0.25mg/mL was used
(CLSI has not interpretive standards for susceptibility).
Clinical isolates were obtained from skin lesions (n = 144) and other
body sites (n = 256). Samples of resistant isolates (R) were included:
Erythromycin-R (n = 187), clindamicin-R (n = 103), bacitracin-R (n = 45)
tetracycline-R (n = 99), and ﬂuoroquinolone-R (n = 59).
Results: All isolates were retapamulin susceptible with MICs ranging
from 0.015mg/mL to 0.12 mg/mL, being the MIC50 = 0.03mg/mL and
MIC90 = 0.06 mg/mL. Retapamulin had a higher intrinsic activity
than that obtained for all other tested topical antibiotics. The only
antimicrobial agents with an MIC90 0.12 mg/mL were the penicillins
and retapamulin. MIC results of all tested antimicrobial agents are
summarized in table1.
Conclusions: Retapamulin showed an excellent in vitro activity against
Streptococcus pyogenes isolates obtained from different body sites
including resistant and multiresistant isolates.
Table 1. MIC50 and MIC90 of retapamulin and other 16 antimicrobial
agents against 400 Streptococcus pyogenes isolates
MIC (mg/mL) skin isolates
(n = 144)
MIC (mg/mL) isolates from
other body sites (n = 256)
Total
(n = 400)
MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90 Range
Mupirocin <0.12 0.25 <0.12−1 <0.12 0.25 <0.12−1 <0.12 0.25 <0.12−1
Bacitracin 1 2 <0.25−>32 1 32 <0.25–>32 1 32 <0.25–>32
Fusidic acid 4 8 2−16 4 8 0.25−32 4 8 0.25−32
Neomycin 32 >64 <8–>64 32 >64 <8–>64 32 >64 <8–>64
Gentamicin 4 4 <1−32 4 4 <1–>32 4 4 <1–>32
Erythromycin <0.25 >32 <0.25–>32 8 >32 <0.25–>32 <0.25 >32 <0.25–>32
Josamycin base <0.5 >4 <0.5−>4 <0.5 >4 <0.5–>4 <0.5 >4 <0.5–>4
Clindamicin <0.25 >1 <0.25–>1 <0.25 >1 <0.25–>1 <0.25 >1 <0.25–>1
Lincomycin <0.5 >4 <0.5−>4 <0.5 >4 <0.5–>4 <0.5 >4 <0.5–>4
Norﬂoxacin <4 <4 <4–>32 <4 16 <4–>32 <4 16 <4–>32
Ciproﬂoxacin <1 <1 <1–32 <1 2 <1–>4 <1 2 <1−32
Tetracycline <2 >8 <2–>8 <2 >8 <2−>8 <2 >8 <2–>8
Tigecycline <0.5 <0.5 − <0.5 <0.5 − <0.5 <0.5 −
Penicillin <0.015 <0.015 <0.015–0.06 <0.015 <0.015 <0.015–0.03 <0.015 <0.015 <0.015–0.06
Amoxicillin <0.03 <0.03 <0.03–0.12 <0.03 <0.03 <0.03–0.06 <0.03 <0.03 <0.03–0.12
Cloxacillin 0.12 0.12 <0.12–>0.5 0.12 0.12 <0.06–>0.5 0.12 0.12 <0.06–>0.5
Retapamulin 0.03 0.06 0.015–0.12 0.03 0.06 0.015–0.12 0.03 0.06 0.015–0.12
P944 In vitro susceptibility of Streptococcus agalactiae: results of the
Tigecycline Evaluation Surveillance Trial (TEST), 2004–2008
D. Hoban °, M. Hackel, M. Renteria, R. Badal, S. Bouchillon,
B. Johnson, J. Johnson, S. Hawser, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Background: Streptococcus agalactiae (GBS) is a major cause of
neonatal and perinatal disease as well as a causative pathogen of
bacteremia and occasional skin and skin structure infections and urinary
tract infections. Although all GBS remain susceptible to penicillin,
resistance to erythromycin and clindamycin has been documented.
The Tigecycline Evaluation Surveillance Trial (TEST) examines the
susceptibility of pathogens isolated from patients in countries worldwide.
Methods: Clinically signiﬁcant GBS were obtained from the following
infection sites: blood, urine, respiratory, skin and skin structure, intra-
abdominal and gastrointestinal. MICs were determined for 6,428 isolates
of GBS isolated from a cumulative total of 1258 sites in 55 countries
during 2004–2008 using supplied broth microdilution panels. Results
were interpreted according to FDA / CLSI guidelines.
Results: The MIC50 and MIC90 (mg/L) for 6,428 GBS versus
comparative antimicrobial agents is shown in the table.
Conclusions: The MIC frequency distribution did not increase for any
studied antimicrobial over the 5 year study period. Global GBS isolated
from a variety of clinical specimens continued to demonstrate low
MIC50 and MIC90 including ampicillin.
Drug S. agalactiae − MIC50/MIC90 (mg/L)
2004 2005 2006 2007 2008
Ampicillin <0.06/0.12 0.12/0.12 0.12/0.12 0.12/0.12 <0.06/0.12
Ceftriaxone 0.06/0.12 0.06/0.12 0.06/0.12 0.06/0.12 0.06/0.12
Meropenem 0.12/0.12 0.12/0.12 0.12/0.12 0.12/0.12 0.12/0.12
Tigecycline 0.03/0.25 0.03/0.06 0.03/0.12 0.03/0.12 0.06/0.12
Vancomycin 0.5/0.5 0.5/0.5 0.5/0.5 0.5/0.5 0.5/0.5
N= 926 1036 1442 1858 1166
P945 Susceptibility of Streptococcus agalactiae strains to lactic
acid bacteria activity
M. Bodaszewska °, T. Gosiewski, M. Brzychczy-Wloch, P. Adamski,
M. Strus, P.B. Heczko (Cracow, PL)
Objectives: The vagina of healthy women is a balanced ecosystem
in which lactobacilli (Lactic Acid Bacteria; LAB) are predominant.
Streptococcus agalactiae (Group B streptococci; GBS) is one of
coexistent components of vaginal microﬂora. Antagonistic metabolites
of LAB protect against multiplication of pathogenic microorganisms as
well as GBS. Therefore, the aim of the study was the assessment of
sensibility of GBS strains (in relation to capsular polysaccharides of
GBS) to antagonistic activity of chosen species of LAB.
Materials and Methods: In the antagonism study 26 strains of GBS
isolated from the vagina of pregnant and nonpregnant women (n = 18)
and from newborns (n = 8) were tested. Characteristics of capsular
polysaccharides were tested using serological kit and multiplex PCR
method. Investigated GBS strains belonged to Ia, Ib, II, III or V
serotypes. The antagonistic properties of LAB were tested by 4 species
originating from the vagina of healthy women: L. plantarum (n = 3),
L. fermentum (n = 2), L. gasserii (n = 2) and L. rhamnosus (n = 2) and
1 standard strain. Antagonism between LAB and GBS was tested in
a mixture of ﬂuid 24 hrs cultures and the results were determined
quantitatively by serial dilutions in 3 time intervals (2 hrs, 4 hrs, 6
hrs).
Results:
1. Some strains of LAB have an ability to kill GBS already after 2 hrs.
2. Between isolates originating from women and newborns there were
no statistically signiﬁcant dependences in susceptibility of GBS
strains to LAB activity in general. However, statistically signiﬁcant
dependence was found in susceptibility of both groups of GBS strains
to L. plantarum (p = 0.019). GBS strains isolated from women were
more susceptible to LAB than GBS isolates from newborns.
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3. Statistically signiﬁcant dependence was conﬁrmed for sensitivity of
GBS serotypes to LAB effect (p = 0.0052). GBS strains with serotype
III were the least sensitive to LAB activity as opposed to serotype V
(p< 0.05).
4. LAB were insensitive to GBS activity. Their number did not change
during the study.
Conclusions: Sensitivities of GBS are not species attributes so they
change among strains and depend on GBS serotype. Probably the ability
of LAB species to rapidly kill GBS even after 2 hrs has resulted from a
mixture of 24 hrs ﬂuid cultures and activity of bacterial cells or bacterial
metabolites. More studies are needed to elucidate the antibacterial
property of L. plantarum and opportunity of its application as probiotic
preparation.
This study was partially supported by a grants from the Polish Ministry
of Research and Higher Education no. N N401 042337 and no. N N401
042938.
P946 Incidence and antibiotic sensitivity of Streptococcus agalactiae
isolated from the genital tract of sexually active individuals
E. Ostorha´zi °, B. Farkas, I. Bencze-Gyo¨ri, B. To´th, S. Ka´rpa´ti,
F. Rozgonyi (Budapest, HU)
Objectives: The aim of this study was to examine the frequency and
antibiotic susceptibility of Streptococcus agalactiae cultured from genital
discharges of sexually active individuals attended to our STD outpatient
service.
Methods: Sample was taken with universal swab into transport medium
then cultured on CROMagar and bood agar simultaneously in 5% CO2
thermostate at 35 Co for 24 h. S. agalactiae identiﬁcation was made with
conventional tests. Disc diffusion method was used for the determination
of antibiotic sensitivity. Only one isolate one patient was considered.
Results: Between May 2008 and October 2009 a total of 416
S. agalactiae strains was obtained from urethra (164), vagina (173),
glans-wound (97), ejaculate (14), urine (27) and anus (3). Resistance
to tetracycline (89%), erythromycin (51%) and clindamycin (52%)
proved to be extraordinary high. 45% of the strains was simultaneously
resistant to tetracycline-macrolide-lincosamide combination, therefore,
administering ex juvantibus any of them can select the cross-resistant
strains to all these three classes of antibiotics. 97−96% of the strains
were susceptible to all b-lactams and moxiﬂoxacin, however, penicillin-
resistant S. agalactiae appeared in Hungary in our patients, too.
Conclusions: Successful treatment of colonisation, carrying or manifest
infection caused by S. agalactiae needs not only cultivation but also
a prior antibiotic resistance testing since near half of the strains is
multidrug resistant. In case of mix infections with S. agalactiae and
Chlamydia or Ureaplasma, moxiﬂoxacin seems to be the drug of choice
since it is effective against all of them.
P947 In vitro anti-bacterial activity against Streptococcus
pneumoniae strains isolated from respiratory infections in
adults in France since 2002: annual analyses using new
EUCAST breakpoints
H. Drugeon °, A. Michaud-Nerard (Nantes, Beaucouze, FR)
Objective: The objective of this pneumococci resistance survey
is to assess the susceptibility to a range of antibiotics usually
prescribed/recommended of Streptococcus pneumoniae (SP) strains
isolated from adult respiratory tract infections in French hospital
microbiology laboratories (36−42).
Methods: During each campaign, participating laboratories had to
include 5 SP strains monthly from October to March. Minimal
inhibitory concentrations were determined in a central laboratory
(Drug R&D, Beaucouze´), by using a microdilution method against the
following antibiotics: penicillin (PEN), erythromycin (ERY), amoxicillin
(AMX), cefuroxime (CXM), telithromycin (TEL), pristinamycin (PRI)
et levoﬂoxacin (LVX). The rates of susceptible (S), intermediate
(I) and resistant (R) strains were calculated in accordance with
2009 EUCAST recommendations (with French Microbiology Society
−antiogram committee guidelines for PRI).
Results: 7074 strains have been studied. The PEN decreased susceptible
SP strains rates decreased from 2002–2003 (53.9%) to 2005–2006
(42.1%) and then stabilised. The high level of AMX resistance was
stable around 3%. Macrolides resistance was constantly decreasing from
54.2% to 35.5%. Resistance to LVX was currently less than <1%. In
2008–2009, TEL was active on 97.2% of strains and PRI on 99.9%
respectively.
S/R percents are shown in the Table.
Conclusion: macrolides resistance rate is decreasing signiﬁcantly
whereas the PEN diminished resistance is stable around 42% and the
diminished resistance to AMX 28%. LVX, PRI and TEL remain active
on SP.
Campaign n Susceptible/Resistant (%)
PEN AMX CFM ERY TEL LVX PRI
2002–2003 991 46.1/3.8 63.4/3.6 53.3/44.7 45.8/53.4 95.6/2.4 98.6/1.4 100/0
2003–2004 1003 49.5/6.7 67.3/3.0 58.7/39.9 48.1/51.8 94.9/2.6 99.0/1.0 100/0
2004–2005 1022 50.6/1.2 69.4/2.5 59.3/38.0 49.5/50.2 95.9/1.6 99.1/0.9 99.6/0.1
2005–2006 1027 57.9/7.2 72.8/4.5 65.9/32.0 57/42.7 95.3/2.6 99.1/0.9 99.9/0
2006–2007 1024 55.8/5.6 68.3/2.8 63.9/34.2 54.5/45.3 93.1/3.8 98.9/1.1 99.9/0
2007–2008 1025 58.6/5.4 72.8/2.5 65.2/32.9 57/42.3 94.2/3.9 99.5/0.5 99.8/0
2008–2009 979 57.7/4.2 74.5/3.1 67.0/31.5 64.5/35.1 97.2/1.5 99.6/0.4 99.9/0
Total 7074 53.8/4.9 69.8/3.2 61.9/36.1 53.7/45.9 95.2/2.6 99.1/0.9 99.9/0
P948 Surveillance of macrolide activity against Streptococcus
pneumoniae in a multi-country analysis − TEST 2007–2009
S. Bouchillon °, J. Johnson, R. Badal, S. Hawser, M. Hackel,
B. Johnson, D. Hoban, M. Renteria, M. Dowzicky (Schaumburg, US;
Epalinges, CH; Collegeville, US)
Objective: Macrolide susceptibility rates (%S) against Streptococcus
pneumoniae (Spn) have remained relatively stable in the past decade be-
tween 65−70%. However, macrolide %S varies widely from country-to-
country and region-to-region. The Tigecycline Evaluation Surveillance
Trial (T.E.S.T.) is an ongoing global surveillance designed to follow
trends in antimicrobial activity. This report evaluates macrolide activity
globally against S. pneumoniae during the years 2007 through 2009.
Methods: 2286 clinical isolates were collected from 424 cumulative
investigative sites in 48 countries. Clinical isolates were identiﬁed to
the species level at each participating site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
by the local laboratory using supplied broth microdilution panels and
interpreted according to CLSI and FDA (tigecycline) guidelines.
Results: Macrolide %S by country is presented in the graph.
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Conclusions: The lowest macrolide susceptibility rates were seen in four
Asian countries with %S ranging from 0% (Taiwan) to 35% (China).
The highest macrolide %S rates were seen in Europe but rates there still
ranged widely from 45% to 100%.
P949 Differences between adult and paediatric serotypes and
activity of ceftaroline for recent US isolates of Streptococcus
pneumoniae
M.R. Jacobs °, S. Bajaksouzian, A.R. Windau, C.E. Good, D. Biek,
I. Critchley, H. Sader, R. Jones (Cleveland, Oakland, North Liberty, US)
Objectives: The activity of ceftaroline, an investigational parenteral
cephalosporin, was studied against prevailing US adult and pediatric
serotypes of Streptococcus pneumoniae. Ceftaroline has broad-spectrum
activity against Gram-positive organisms, including methicillin-resistant
Staphylococcus aureus (MRSA), multidrug-resistant S. pneumoniae
(MDRSP), and common Gram-negative pathogens.
Methods: S. pneumoniae isolates were received in 2008 from 22
cities in 19 states throughout the US. Serotyping was performed by
capsular swelling with commercial antisera. Serotype 6C was identiﬁed
by PCR. MICs of ceftaroline, penicillin, amoxicillin, and ceftriaxone
were determined by CLSI broth microdilution method.
Results: A total of 891 isolates were tested. Isolates came from all body
sites, with distribution as follows: lower respiratory tract 58.9%, blood
15.6%, upper respiratory tract 8.4%, middle ear 7.4%, and other sites
9.7%. Serotype distribution by age for 859 strains with age data available
is shown in the Table.
Ceftaroline was the most active of the tested agents against S. pneu-
moniae, with MICs ranging from 0.008 to 0.5mg/L and MIC90s of
0.12mg/L for adult isolates and 0.25mg/L for pediatric isolates. MIC90s
were 2 and 4mg/L for penicillin, 4 and 8mg/L for amoxicillin, and 1
and 2mg/L for ceftriaxone, with pediatric isolates less susceptible than
adult isolates.
Conclusion: Pediatric and adult pneumococcal isolates differed widely
in serotype distribution, with serotype 19A providing one third of isolates
among children. Vaccine serotypes were uncommon in both age groups.
Pediatric isolates were less susceptible to penicillin, amoxicillin, and
ceftriaxone than were adult isolates. Ceftaroline was more active against
S. pneumoniae than any other tested agent.
Serotype (%) Adult isolates
(N = 574)
Pediatric isolates
(N = 285)
All isolates
(N = 859)
Vaccine* 5.9 7.0 6.3
19A 15.0 32.6 20.8
3 10.5 6.3 9.1
35B 7.5 5.6 6.9
7F 7.0 3.9 5.9
11A 5.7 4.6 5.4
6C 4.5 4.9 4.7
15A 4.9 3.2 4.3
22F 4.9 2.5 4.1
23A 3.8 3.9 3.8
23B 3.8 3.5 3.7
Other 26.5 22.1 25.0
*7-valent conjugate vaccine serotypes.
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P950 Impact of ciproﬂoxacin pre-exposure on emergence of
rifampin resistance mutations in Staphylococcus aureus
P. Vaudaux °, R.A. Villet, J.P. Didier, E. Huggler, D. Lew (Geneva, CH)
Objectives: The high prevalence of nosocomial methicillin-resistant
S. aureus (MRSA) isolates displaying widespread resistance to several
antibiotic classes is explained by the strong selective pressure of widely
used antimicrobial agents. In addition, DNA-damaging agents such
as ﬂuoroquinolones (FQ) might directly promote resistance-conferring
mutations by activating error-prone, bacterial DNA repair pathways.
This study evaluated the contribution of ciproﬂoxacin (CPX)-triggered,
DNA repair systems, in promoting rifampin (RIF) resistance-conferring
mutations in S. aureus.
Methods: FQ-susceptible and FQ-resistant, laboratory or clinical
S. aureus isolates were exposed to sub-inhibitory (ranging from 1/2
to 1/8 MIC) concentrations of CPX at different growth phases in
liquid cultures. Frequencies of RIF-resistant mutants in CPX-exposed
compared to CPX-unexposed organisms were determined by selective
plating on RIF (0.25mg/L)-supplemented agar. MICs of individual, RIF-
resistant mutants were determined by macrodilution, and correlated with
the resistance-conferring mutations identiﬁed by RNA polymerase B
subunit (rpoB) gene sequencing. Fitness costs of the different RIF-
resistant mutants were evaluated by competitive in vitro growth with
respective RIF-susceptible parents. CPX-triggered, key components of
DNA repair pathways were monitored by real-time RT-PCR.
Results: The frequency of RIF-resistant clones on CPX-free pre-cultures
of FQ-resistant and FQ-susceptible strains was ca. 10−7, but increased
dose-dependently by ca. 3−10 fold after exposure to sub-MICs of CPX.
In vitro ﬁtness costs of RIF-resistant mutants, as well as their increased
RIF MICs, were strongly inﬂuenced by the nature of each rpoB mutation.
rpoB sequencing in >200 RIF-resistant colonies revealed a wide diversity
of RIF resistance-conferring point mutations. In addition, some sub-
MICs of CPX triggered a high frequency of chromosomal insertions
or deletions in rpoB, which led to low-level RIF-resistant mutants. In
contrast, >10-fold lower frequencies of RIF-resistant mutants occurred
in a recA-null mutant grown in the presence or absence of CPX.
Conclusion: While exerting a moderate quantitative increase on rates
of RIF resistance, sub-MICs of CPX may also trigger substantial,
unanticipated qualitative changes in S. aureus genomic composition,
which may be due to the SOS error-prone response, and potentially
other, currently studied DNA repair systems.
P951 Differential expression of proteins in MRSA-15 after treat-
ment with manuka honey investigated by 2D electrophoresis
R. Jenkins °, R. Cooper, N. Burton (Cardiff, UK)
Objectives: To use 2-D electrophoresis coupled with MS/MS
MALDI-TOF to investigate changes in protein expression of meticillin
resistant Staphylococcus aureus 15 (MRSA-15) cells treated with
manuka honey.
Methods: EMRSA-15 (NCTC 13142) was cultivated at 37ºC for 4 hours
in TSB with and without 10% (w/v) manuka honey, and in TSB with 10%
(w/v) artiﬁcial honey (to determine if results seen were due to sugars).
Cells were harvested, treated in a bead beater and cell free extracts
containing 150 mg of protein were separated by 2D electrophoresis
using pH 3−10 IPG strips for isoelectric focussing followed by 4−12%
polyacrylamide gel electrophoresis in the second dimension. After
staining, images were recorded using a UVP AutoChemi gel doc system
and analysed using PDQuest software. Triplicate samples were analysed.
The spot showing highest differential expression (down regulation) was
then analysed by MALDI-TOF MS/MS.
Results: Spot patterns from honey treated cells were distinct from those
of untreated cells and cells treated with artiﬁcial honey. Compared to
untreated samples, 82% and 70% of proteins matched for artiﬁcial
honey and manuka honey, respectively. The protein which was most
highly down regulated after honey treatment compared to untreated and
artiﬁcial treatments was identiﬁed as universal stress protein A (uspA),
by combined PMF and MS/MS queries on the MASCOT database search
engine embedded into the Global Proteome Server explorer software on
the Swiss-Prot database. Six peptides were identiﬁed (E< 0.05).
Conclusion: Changes in protein expression in manuka honey treated
MRSA were not caused by sugars alone. The uspA protein confers
a general stress endurance activity on cells and its down regulation
could indicate a potential mode of for manuka honey. The differ-
ential expression of other proteins must be further investigated by
MALDI-TOF MS/MS.
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P952 Impact of daptomycin resistance on the susceptibility of
methicillin-resistant Staphylococcus aureus to gentamicin,
rifampicin and vancomycin
J.M. Entenza °, M. Giddey, J. Vouillamoz, P. Moreillon (Lausanne, CH)
Objectives: Several studies have shown that decreased daptomycin
(DAP) susceptibility in Staphylococcus aureus strains is correlated with
alterations in a few loci, including dlt (responsible for D-alanylation
of lipoteichoic acids), mprF (responsible for the addition of lysine
to phosphatidylglycerol in the plasma membrane), yycG (encoding a
sensor histidine kinase involved in both cell wall and cell membrane
metabolism) and mutations in rpoB/C subunits of the RNA polymerase,
identiﬁed in later stages of DAP resistance. Modiﬁcations in both dlt and
mprF of DAP-resistant (DAP-R) derivatives enhance the positive charge
of the cell envelope and could also affect the activity of positively-
charged molecules such as gentamicin (GEN). Likewise, mutations at
speciﬁc sites of rpoB are associated with rifampicin (RIF) resistance,
and thus DAP-R related mutations in this locus (and maybe rpoC) might
affect RIF susceptibility as well. Since GEN and RIF are maybe used
as partner drugs in combination therapy against methicillin-resistant
S. aureus (MRSA) infections, we determined whether the in vitro
development of DAP resistance in MRSA could have an impact on the
susceptibility of GEN and RIF. VAN, for which a decreased susceptibility
was previously observed in S. aureus with decreased DAP susceptibility,
was used as control.
Methods: Four MRSA clinical isolates were selected for DAP-resistance
by in vitro serial passage (for 7 days) on increasing concentrations of the
drug. The MIC of DAP was recorded after each passage, and the MICs
of VAN, GEN and RIF were recorded in DAP-R derivatives at the end
of the selection process.
Results: MICs at baseline and after in vitro serial DAP exposures are
presented in the Table. As previously shown, selection for DAP-R was
paralleled by an increase in VAN MIC, resulting in VAN-intermediate
S. aureus (VISA). Likewise, all four DAP-R MRSA derivatives displayed
consistent 2- to 4-fold increase in GEN MIC. In contrast, RIF MICs did
not change for two isolates, and increased only by 2-fold in the two other
strains.
Conclusions: Development of DAP-R in S. aureus is readily associated
with decreased susceptibility to VAN and GEN, but is less likely to affect
susceptibility to RIF.
MICs (mg/L) for DAP-susceptible/DAP-resistant MRSA
MRSA-1 MRSA-2 MRSA-3 MRSA-4
DAP 0.5/8 0.25/8 0.5/8 0.5/4
VAN 1/4 1/4 1/4 2/4
GEN 16/32 1/4 1/4 0.25/0.5
RIF 0.008/0.016 0.008/0.008 0.004/0.008 0.016/0.016
P953 Reversal of methicillin resistance in Staphylococcus aureus
by thioridzine: a universal phenomenon?
M. Poulsen °, J.K. Klitgaard, E.M. Lillebæk, M. Skov, B.H. Kallipolitis,
H.J. Kolmos (Odense, DK)
Objectives: Thioridazine, a phenothiazine agent, has been shown
to reverse oxacillin (methicillin) resistance in methicillin-resistant
Staphylococcus aureus (MRSA) in vitro. The molecular mechanism
underlying this effect appears to involve a reduced transcription of the
mecA gene, resulting in a reduced protein level of PBP2a. So far this
has been shown with only one clinical MRSA isolate. The aim of this
study was to determine if resistance reversal with thioridazine could
be reproduced in a broader selection of clinical isolates, and if the
molecular mechanism was the same in all isolates. To this end, we tested
the effect of thioridazine on all major epidemic clones of MRSA and
Staphylococcal cassette chromosome mec (SCCmec) types.
Methods: Growth of MRSA isolates was examined in liquid media in
the presence of the methicillin analogue oxacillin and the non-antibiotic
thioridazine alone and in combination. Furthermore, the transcription of
mecA was analyzed by Primer extension under the same conditions.
Results: We observed an increased susceptibility of MRSA towards
oxacillin in the presence of oxacillin and thioridazine compared to
bacteria grown with oxacillin or thioridazine alone. Transcription of
mecA was reduced with increasing concentrations of thioridazine in
the presence of oxacillin compared to bacteria grown with oxacillin or
thioridazine alone. However, in a few isolates mecA was transcribed
constitutively and did not display a reduced transcription of mecA with
increasing concentrations of thioridazine in the presence of oxacillin.
Thioridazine itself did not affect the growth of MRSA or the level of
mecA mRNA.
Conclusion: Results from the present study indicate that the reversal
effect of thioridazine on oxacillin resistance is universal for clinical
MRSA isolates of various epidemiological origins. Furthermore, the
data indicate that for most of the tested isolates, reversal of methicillin
resistance by thioridazine in MRSA may be explained by a reduced
transcription of the methicillin resistance gene, mecA. However, for a
few isolates, the reversal effect could not be explained by a reduction
in the level of mecA mRNA, indicating that the molecular mechanism
behind the reversal effect of thioridazine is far more complex than ﬁrst
anticipated.
P954 Site-speciﬁc mutation of Staphylococcus aureus VraS reveals
a crucial role for the VraR-VraS sensor in the emergence
of glycopeptide resistance
E. Galbusera, A. Renzoni, D. Andrey °, A. Monod, C. Barras,
P. Tortora, A. Polissi, W. Kelley (Milan, IT; Geneva, CH)
An initial response of Staphylococcus aureus to encounter with cell wall-
active antibiotics occurs by transmembrane signaling systems which
orchestrate changes in gene expression to promote survival. Histidine
kinase two-component sensor-response regulators such as VraRS
contribute to this response. In this study, we have focused on elucidating
molecular details of the VraS membrane sensor phosphotransfer
signal transduction. We have used in vitro autophosphorylation assay
with puriﬁed VraS[64–347] lacking its transmembrane anchor region
and tested site-speciﬁc kinase domain histidine mutants. We have
identiﬁed VraS H156 as the probable site of autophosphorylation. Using
phosphotransfer assay, we have shown 32P transfer in vitro from VraS
to puriﬁed VraR response regulator, but not to a mutant VraR (D55A)
lacking the phosphate acceptor aspartate. To examine the functional
consequences of the speciﬁc loss of VraS-VraR signaling, we site-
speciﬁcally engineered a S. aureus chromosomal mutation, vraS H156A.
Comparison of the mutant H156A strain and its isogenic vraS wild type
parent by northern blot and qRT-PCR following exposure to cell wall
active antibiotics revealed a pronounced reduction, but not complete
abrogation, of transcriptional induction of the vraRS operon promoter.
This result suggests that additional inducing signals, independent of
VraS-driven phosphotransfer, exist for this promoter. Genetic studies
show that the vraSH156 strain is severely impaired in its ability to
generate ﬁrst step reduced susceptibility teicoplanin and vancomycin
mutants. We also extended our analysis to derivatives of S. aureus strains
Newman and COL constructed by bacteriophage-mediated transduction
of the vraS H156A allele. Collectively, our results reveal important
details of the VraRS TCS signaling system and reinforce the prediction
that blockade of sensor kinase activity will have profound effects on the
emergence of cell wall active antibiotic resistance in this organism.
P955 Importance of efﬂux systems on the resistance to
ﬂuoroquinolones in Staphylococcus aureus
S.S. Costa °, C. Falca˜o, M. Viveiros, J. Melo-Cristino, L. Amaral,
I. Couto (Lisbon, PT)
Objectives: To study the role played by efﬂux pumps in the resistance
towards ﬂuoroquinolones in clinical isolates of Staphylococcus aureus.
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Methods: The efﬂux pump activity of 52 S. aureus clinical isolates
from a Portuguese Hospital showing ﬂuoroquinolone resistance was
evaluated by the Ethidium Bromide-Agar Cartwheel Method. All efﬂux-
positive and a group of efﬂux-negative isolates was selected for
further characterization by PFGE and minimum inhibitory concentration
determination to different efﬂux pumps substrates (ﬂuoroquinolones,
dyes and biocides), in the presence and absence of several efﬂux
pump inhibitors (EPIs − thioridazine, chlorpromazine, verapamil,
reserpine, carbonyl cyanide m-chlorophenylhydrazone). The presence
and expression of the genes coding for the most important S. aureus
efﬂux pumps (norA, norB, norC, mepA, mdeA, sepA, qacA/B, and smr)
were assessed by PCR and qRT-PCR, respectively. The variability of the
norA gene and its promoter region was studied by DNA sequencing.
Mutations that confer resistance to ﬂuoroquinolones were screened by
sequencing the quinolones-resistance determining regions (QRDR) of
grlA and gyrA genes.
Results: The application of these different approaches detected increased
efﬂux pump activity on 12 out of the 52 clinical isolates tested and
correlated this activity with increased resistance to ﬂuoroquinolones.
The inhibition of the active efﬂux systems did not result in reversion
of the resistance phenotype to susceptibility, yet it implied a signiﬁcant
decrease in the resistance levels to these antibiotics, regardless of the
type(s) of mutation(s) found in grlA and/or gyrA genes.
Among the efﬂux-positive isolates, over-expression of mepA, mdeA
and norB/norC was detected. Two norA alleles were found (norAI and
norAII), of which norAI was the prevalent one. However, no direct
correlation could be established between the type of norA allele and
the susceptibility proﬁle towards the different efﬂux pump substrates
tested.
Conclusions: The results obtained in this work underline the contribution
of efﬂux systems for the emergence of high-level resistance to
ﬂuoroquinolone and multidrug resistant S. aureus in hospitals and reveal
that pumps other than NorA are involved in this type of resistance.
P956 Interactions of oritavancin with Lipid II and interpeptide
bridge-containing Lipid II variants
T. Schneider °, A. Mu¨ller, A. Far, G. Moeck, H.G. Sahl (Bonn, DE;
St Laurent, CA)
Objectives: Oritavancin is a semi synthetic derivative of the glycopeptide
chloroeremomycin with activity against Gram-positive pathogens,
including vancomycin-resistant staphylococci and enterococci. Contrary
to vancomycin, binding of oritavancin (ORI) to the cell wall precursor
Lipid II appears to involve, in addition to the D-Ala-D-Ala terminus, the
interpeptide crossbridges, as seen by NMR. We studied the impact of
ORI and of its des-N-methylleucyl variant (des-ORI), which is unable to
bind to the D-Ala-D-Ala terminus, on staphylococcal interpeptide bridge
formation and Lipid II transglycosylation/transpeptidation.
Methods: The impact of ORI and des-ORI on pentaglycine interpeptide
bridge formation and on polymerisation of Lipid II and Gly1−5
containing Lipid II variants was studied in vitro using recombinant
FemXAB and PBP2 from S. aureus (Schneider et al., AAC 2009; 53:
1610). The glycopeptides were tested in molar ratios ranging from 0.25
to 4 with respect to radiolabelled Lipid II. Reaction products were
extracted and analysed by thin layer chromatography and subsequent
phosphoimaging. Binding constants of ORI to the different Lipid II
species were determined using liposomes doped with the Lipid II variants
and [14C]-labelled ORI.
Results: All Fem enzymes and PBP2 were inhibited by ORI in a dose-
dependent fashion. Similarly, des-ORI showed inhibitory activity in the
FemXAB-catalyzed synthesis of Lipid II-Gly1−5 (8% residual Lipid
II-Gly5 formation with ORI, as compared to 12% residual production
with des-ORI; antibiotic:Lipid II ratio of 2:1). Moreover, des-ORI was
inhibitory in the PBP2 transglycosylation/transpeptidation assays. ORI
caused cell wall precursor accumulation in VanA type enterococci
prompting additional studies with lipid II variants carrying a D-Ala-
D-Lac terminus and a pentaglycine-bridge attached.
Conclusions: The data verify the additional binding interactions between
ORI and Lipid II and provide further evidence that binding of Lipid
II involves both the D-Ala-D-Ala terminus and the pentaglycine
interpeptide bridge. Multiple interactions between ORI and cell wall
precursors, as demonstrated here, predict a reduced propensity for
target pathogens to develop mutational resistance to ORI.These studies
offer further experimental support to the observations that ORI inhibits
transglycosylation/transpeptidation and causes accumulation of cell wall
precursors even in VanA type vancomycin resistant organisms.
P957 A new SCCmec element in a Staphylococcus cohnii clinical
isolate might be an ancestral structure of type III SCCmec
Z. Zong °, Y. Gao, X. Lv (Chengdu, CN)
Objective: To characterize a “non-typeable” SCCmec in a Staphylococ-
cus cohnii clinical isolate.
Methods: The species identiﬁcation for methicillin-resistant S. cohnii
clinical isolate WC28 was performed by sequencing the 16s rDNA gene.
The detection of mecA gene and typing for SCCmec were carried out
using multiplex PCR (mPCR) as described previously (J Clin Microbiol
2005; 43: 5026−33.). Universal primers for amplifying ccrA and ccrB
genes were designed on the basis of the sequence alignment of all known
variants, which were retrieved from GenBank. A universal primer for left
side inverted repeat (IR-L) of SCCmec was deigned according to known
variants of SCCmec. The whole SCCmec was obtained by three long-
range PCR (Fermentas, Burlington, ON, Canada) amplifying regions
from mecA to orfX, from ccrA/B to mecA and from IR-L to ccrA/B
and sequencing. The sequence close to IR-L was identiﬁed using inverse
PCR and HindIII-restricted WC28 genomic DNA was self-ligated and
used as template.
Results: WC28 can grow on agar plates containing 4mg/L cefoxitin and
has a class A mecA complex (mecI-mecR1-mecA). However, SCCmec
of WC28 can not be typed by the mPCR method used, suggesting that
WC28 might harbor a new SCCmec element. The ccrA and ccrB genes
of WC28 were obtained using the newly-designed universal primers
and displayed the highest similarity (89%) with ccrASHP (GenBank
accession no. EU934095) of Staphylococcus haemolyticus and ccrB5
(AM904731) of Staphylococcus pseudintermedius, respectively. The
SCCmec of WC28 was fully characterized, ca. 35-kb in length, ﬂanked
by 8-bp perfect IR and generating 12-bp direct target repeat. Several new
ORFs including a putative AAA-ATPase-encoding gene were identiﬁed
in the J1 region (from IR-L to ccr). The J2 region (from ccr to mec) is
almost identical to the corresponding part of SCCmec III (AB037671)
and has a PsiTn554 transposon, while the J3 region (from mecA to orfX)
is the same as that in SCCmec type IV (AB063172) containing a single
copy of IS431.
Conclusions:WC28 has a new SCCmec element sharing similar features
with several known SCCmec including Type III and IV. As the structure
downstream of mecA in WC28 is also seen in a few different types
of SCCmec and type III SCCmec appears to be a hybrid of two
different SCC elements, the SCCmec of WC28 might be an ancestral
structure of the widespread type III SCCmec in the methicillin-resistant
Staphylococcus aureus.
P958 Endemy of methicillin-resistant Staphylococcus capitis in
French neonatal intensive care units
F. Laurent °, O. Raulin, D. Fournier, H. Salord, M. Bonﬁls, M. Bes,
C. Roure-Sobas, J. Grando, J. Picaud, F. Vandenesch, S. Tigaud (Lyon,
FR)
Coagulase negative staphylococci (CoNS) are frequently isolated from
blood culture in critically ill neonates. Staphylococcus capitis has not
been reported as the predominant species responsible for such infections.
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However, from January 2004 to June 2009 at the neonatal ward of the
Northern Hospital Group in Lyon, a total of 386 CoNS isolates were
detected in 478 positive blood cultures (81%), including 209 S. capitis in
136 neonates, i.e., 54% of all CoNS positive cultures. Almost all isolates
(99%) were resistant to methicillin and gentamicin. Seventeen of these
methicillin resistant S. capitis (MRSC), randomly chosen from blood of
neonates over the 2005 to 2009 period, were compared using pulsed-ﬁeld
gel electrophoresis (PFGE) with 33 S. capitis strains collected from 6
other French hopsitals: i) 22 MRSC isolated from blood of neonates
collected in six French hospitals; ii) 11 MRSC and 3 MSSC isolated
from adults and children (more than 2 years old).
Whereas all isolates from adults revealed unrelated PFGE proﬁles,
the PFGE proﬁles of the 39 MRSC from neonates clustered, showing
more than 80% of homology. Likewise, 15 MRSC isolates were
studied by analysing SCCmec: the eight isolates from neonates (from 6
different hospitals) revealed SCCmec type V whereas the seven MRSC
epidemiologically unrelated had different ones.
Our data highlight the fact that a single clone is circulating in different
neonatal wards in France. At our knowledge, it is the ﬁrst nationwide
endemic spread of MRSC. Investigations are underway to i) identify risk
factors associated to MRSC infections in neonates ii) identify the sources
and/or reservoir of this clone; iii) investigate the potential spread of this
clone in other European countries.
P959 Genetic relationship between methicillin-resistant and
methicillin-susceptible Staphylococcus pseudintermedius
isolates
J. Mikalsen, J. Slettemea˚s, H. Tharaldsen, M. Sunde ° (Oslo, NO)
Objectives: In 2008, 200 b-haemolysin-producing staphylococcal iso-
lates from canine infections were included in the Norwegian monitoring
programme for antimicrobial resistance in the veterinary sector (NORM-
VET). The isolates originated from clinical submissions from dogs in
ﬁve geographically distinct regions of Norway. This strain collection
was supplemented with methicillin resistant isolates (MRSP) strains
from the national diagnostic reference laboratory. Little is known about
spread of methicillin susceptible S. pseudintermedius (MSSP) in the
dog population, and knowledge about the phylogentic relation between
MSSP and MRSP isolates is sparse. To investigate this further we have
applied molecular typing to a selection of MSSP and MRSP strains for
comparison of resolution and identiﬁcation of successful lineages in the
Norwegian dog population.
Methods: Susceptibility was determined with a broth microdilu-
tion method (VetMIC™). Identiﬁcation of S. pseudintermedius was
performed by pta ampliﬁcation/MboI restriction, detection of mecA
was performed by PCR. Selected isolates were screened for reduced
susceptibility to disinfecting agents. Molecular typing was carried out
using Multi Locus Sequence Typing (MLST) and Pulsed Field Gel
Electrophoresis (PFGE).
Results: A large proportion (92%) of the isolates included in the
surveillance program was identiﬁed as S. pseudintermedius. Resistance
to oxacillin was not detected among these strains, having oxacillin
minimum inhibitory concentrations (MICs) of 0.125mg/L to 1mg/L.
The MRSP strains from the diagnostic laboratory had oxacillin MICs
from 1 to 32mg/L. None of the investigated isolates exhibited increased
tolerance to disinfecting agents.
Preliminary typing results indicate presence of at least two successful
MSSP clusters containing strains isolates from dogs in distinct
geographical areas. Moreover, our data indicates presence of related
strains, with and without the mecA gene, within the same linage.
Conclusion: The investigated MRSP strains exhibit overlapping oxacillin
MIC distribution to the wild type distribution, this represents a challenge
for identiﬁcation of true MRSP isolates based on phenotypical criteria.
New methodologies with different resolution indicate the existence
of some clusters representing possible successful lineages. However,
more cost efﬁcient typing methods are needed for implementation for
epidemiological surveillance and risk assessments.
P960 Correlation between superantigenic toxin gene proﬁles with
molecular types of 157 methicillin-resistant Staphylococcus
aureus isolates from Taiwan
W. Wang, J. Lu °, J. Sun (Miao-Li, Taichung, Taipei City, TW)
Background: Staphylococcus aureus, especially methicillin-resistant
S. aureus (MRSA), is a major cause of bacteraemia and sepsis. It also
produces various exotoxins that cause food poisoning and toxic shock
syndrome with high morbidity and mortality.
Objectives: The goals of this study were to delineate the superantigenic
toxin gene proﬁles and to correlate them with molecular types of clinical
MRSA isolates from Taiwan.
Methods: One hundred and ﬁfty-seven MRSA isolates from patients
with bacteraemia were obtained from the collection of Study Monitoring
Antimicrobial Resistance Trends (SMART). Eighteen superantigen toxin
genes were examined by multiplex PCR. MRSA isolates were typed
by PCR based on polymorphisms in accessory gene regulator (agr)
and staphylococcal cassette chromosome mecA (SCCmec). Correlations
between toxin gene proﬁles and molecular types were determined by
Fisher‘s exact test.
Results: Sixteen superantigenic toxin gene proﬁles were found in 157
non-duplicate MRSA isolates with the mecA gene. Of these, 95 (60.5%)
isolates possessed sea-selk-selq, 17 (10.8%) isolates had seb-selk-selq,
and 12 (7.6%) isolates contained selk-selq. Signiﬁcant associations were
found between sea-selk-selq and SCCmec III-agr I, seb-selk-selq and
SCCmec IV- and VT-agr I, and selk and SCCmec III-agr I (p< 0.001).
By comparing molecular types with each toxin gene, sea, selk, and selq
were found to be associated with SCCmec III and agr I, and seb, sec, seg,
sei, selm, seln, selo, selp, and tst1 were associated with SCCmec II, IV,
and agr II (p< 0.001). No isolates harbored see, seh, selj, or selr.
Conclusions: Limited superantigenic toxin gene proﬁles were identiﬁed
in MRSA isolates from Taiwan. Signiﬁcant associations between toxin
gene proﬁles and particular molecular types were noted.
Table 1. Association of superantigenic toxin gene proﬁles with molecular
types
Superantigenic toxin gene proﬁles SCCmec type agr type No. (%)
None VT I 3 (1.9)
selk-selq III I 12 (7.6)
sed-seg-sei-sell-selm-seln-selo-selp-tst1 II II 1 (0.6)
sec-seg-sell-selm-seln-selo IV I 1 (0.6)
sec-seg-sei-sell-selm-selo IV II 2 (1.3)
sec-seg-sei-sell-selm-selo-selp-tst1 II II 3 (1.9)
sec-seg-sei-sell-selm-selo-selp-tst1 II I 1 (0.6)
sec-seg-sei-sell-selm-seln-selo IV II 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-selp-tst1 II I 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-selp-tst1 II II 1 (0.6)
sec-seg-sei-sell-selm-seln-selo-selp-tst1 IV I 1 (0.6)
seb-selk-selq IV I 8 (5.1)
seb-selk-selq VT I 8 (5.1)
seb-selk-selq IV II 1 (0.6)
seb-selk-selp-selq IV I 6 (3.8)
seb-sei-selk-selq IV I 2 (1.3)
sea III I 7 (4.5)
sea-selk-selq III I 95 (60.5)
sea-selk-sell V I 1 (0.6)
sea-sec-seg-sei-sell-selm-selo-selp-tst1 IV II 1 (0.6)
sea-seb-selk-selq III I 1 (0.6)
Total 157 (100.0)
P961 Correlation between molecular types and in vitro susceptibil-
ity to vancomycin and daptomycin in 158 methicillin-resistant
Staphylococcus aureus blood isolates from Taiwan
W. Wang °, T. Chiueh, J. Lu (Miao-Li, Taipei, Taichung, TW)
Background: Staphylococcus aureus is a major cause of bacteraemia and
sepsis with an extremely high mortality. Methicillin-resistant S. aureus
(MRSA) has emerged since 1960s with a prevalence of 70−80%
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in Taiwan, but limited antibiotic regimens are available for MRSA
infections with occasional treatment failures.
Objectives: The purpose of this study was to correlate molecular types
with in vitro antibiotic susceptibility of MRSA isolates obtained from
patients with MRSA infections in Taiwan.
Methods: MRSA isolates from patients with bacteraemia were obtained
from the collection of Study Monitoring Antimicrobial Resistance
Trends (SMART). Minimal inhibitory concentrations (MICs) of isolates
to vancomycin (VA) and daptomycin (DPC) were determined by the
E-tests according to the manufacture‘s instructions. MRSA isolates
were also typed by speciﬁc PCR based on polymorphisms in accessory
gene regulator (agr) and staphylococcal cassette chromosome mecA
(SCCmec). Correlation between MICs and molecular types was
determined by Pearson’s and Mann–Whitney U (M-W-U) tests.
Results: A total of 158 non-duplicate MRSA isolates with mecA gene
were selected. Of these, 7 (4.4%) were SCCmec type II; 116 (73.4%)
type III, 23 (14.6%) type IV, 1 (0.6%) type V, and 11 (7.0%) type VT.
One hundred forty-eight isolates (93.7%) belonged to agr I, and the
other 10 belonged to agr II (6.3%). The mean MICs of the isolates for
VA and DPC were 1.67±0.34 ug/ml and 0.25±0.12 ug/ml, respectively.
Correlation factor (r) between MICs for VA and DPC was 0.47. MIC
for VA of SCCmec III isolates was higher than those of types IV and
VT isolates (p< 0.001). MICs for DPC of SCCmec II and III isolates
were higher than those of types IV and VT isolates (p< 0.001).
Conclusions: Two major clones of MRSA blood isolates with molecular
types of SCCmecIII-agrI and SCCmecIV-agrI were predominant in
Taiwan. The VA MICs of MRSA isolates correlated with those of DPC.
Higher VA and DPC MICs by E-test were seen in molecularly deﬁned
hospital-associated MRSA strains (SCCmec II and III) than those in
community-associated MRSA strains (SCCmec IV and VT).
Figure. Correlation between MICs to vancomycin (VA) and daptomycin
(DPC) in 158 MRSA blood isolates.
P962 Hyperproduction of norA by (methicillin-resistant) Staphy-
lococcus aureus is associated with its genetic background
P. Wolffs °, S. Croes, M. Luijten, R. Deurenberg, E. Stobberingh
(Maastricht, NL)
Objectives: NorA is a chromosomally encoded efﬂux pump of S. aureus,
which is known to be involved in the efﬂux of ﬂuoroquinolones, such
as norﬂoxacin, as well as ethidium bromide and disinfectants, such
as quaternary ammonium compounds. In literature, mutations in the
promoter of norA have been described to lead to overexpression of the
pump and consequently lead to increased resistance of S. aureus to the
different substrates. So far, no large studies have focused on determining
the prevalence of norA hyperproducing S. aureus, nor have looked at the
relationship between genetic background and norA hyperproduction. Our
study is aimed to provide answer to these questions.
Methods: A collection of S. aureus isolates (community- and hospital-
associated) was compiled to cover both methicillin resistant and
methicillin susceptible strains and a range of different clonal complexes
(CCs) as determined by multilocus sequence typing (MLST). Antibiotic
susceptibility proﬁles were determined by microbroth dilution. The norA
promoter was sequenced to determine the presence of mutations leading
to hyperproduction.
Results: In total 228 S. aureus strains were characterised and 71 of
these strains harboured mutations leading to overexpression of norA.
In strains resistant to ﬂuoroquinolones, a larger percentage (43%) of
hyperproducers was found as compared to sensitive strains (28%). For
other antibiotics no clear relations were found so far. For example, there
was no signiﬁcant difference between the percentage of hyperproducers
in methicillin resistant or susceptible strains. However, a very clear
relation was found with the genetic background the strains associated
with. CC30 (n = 25), CC45 (n = 26) and CC121 (n = 15) were found
to consist solely of hyperproducers where in other CCs, a maximum
of 7% of hyperproducers was found, with most CCs containing no
hyperproducers at all. In addition to the mutations found which are
known to lead to hyperproduction of norA, also other novel mutations
were found.
Conclusion: Hyperproduction of norA is correlated to certain clonal
complexes. Work is currently ongoing to determine the impact of novel
mutations on the expression of norA and correlated to that, on resistance
to different norA substrates.
P963 Characterization of lytic bacteriophages and co-treatment
with azithromycin to methicillin-resistant Staphylococcus
aureus
S. Kim °, M. Rahman, S.M. Kim, S.Y. Seol, D.T. Cho, J. Kim (Daegu, KR)
Objectives: Recently, lytic bacteriophages (phages) have come into
spotlight as an alternative therapeutic agent for the treatment of
infections caused by multi-drug resistant (MDR) bacteria. In this study,
we characterized newly isolated lytic phages able to kill methicillin-
resistant Staphylococcus aureus (MRSA) and determined the bactericidal
efﬁcacy of the phages alone or phage-azithromycin mixture for MRSA.
Methods: Phages were isolated from several nosocomial strains
of MRSA by induction with mitomycin C. The genomic DNA,
protein proﬁles, and morphologies of the phages were characterized
by restriction endonucleases digestion, SDS-PAGE, and transmission
electron microscope, respectively. Lytic activities of the phages against
MRSA were assessed by the plaque assay with 102 strains of MRSA
belong to four different clonal types (MLST 1, 5, 72 and 239).
Bactericidal efﬁcacy of the phage-azithromycin mixture for MRSA was
also assessed with bactericidal experiment.
Figure. Bactericidal efﬁcacy of the phage-azithromycin mixtures for
MRSA. MRSA planktonic cells (A) and bioﬁlm cells (B) were killed
by SAP26 alone (green) and SAP26–azithromycin mixtures (blue) in
dose-dependent manner. SAP26–azithromycin mixtures were 107 pfu +
1 ug/mg, 109 pfu + 2 ug/mg, and 1011 pfu + 4 ug/mg, from left to right
bar.
Results: Five lytic phages which showed a different susceptibility to 102
MRSA isolates were isolated. One phage was unique in band patterns
according to the results of restriction mapping and SDS-PAGE. The
others were indistinguishable in band patterns but their host ranges
were different. Among them, SAP26 phage showing the broadest MRSA
host range (101 lysed/102 hosts, 99%) was selected to characterize the
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morphologic and genotypic features. SAP26 was a kind of siphoviridae
having a double stranded DNA genome, an icosahedral head and a long
tail. SAP26 of 1011 pfu could kill approx. 70% of 1010 cfu planktonic
cells of MRSA and 45% of 1-day old bioﬁlm cells of MRSA for 24 hrs
comparing with untreated control. However, SAP26 of 1011 pfu-4 ug/ml
azithromycin mixture could kill approx. 97% of 1010 cfu planktonic
bacteria and 95% of 1-day old bioﬁlm bacteria for 24 hrs comparing
with untreated control. These bactericidal effects of SAP26 and the co-
treatment with azithromycin for MRSA showed dose-dependent manner,
respectively.
Conclusion: This study suggests that the mixture of SAP26 phage and
azithromycin would be a good therapeutic agent for the treatment of
MRSA infections and bioﬁlm-associated MRSA infection.
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P964 Evaluation of GeneXpert MRSA data: proposal to introduce
a ‘grey zone’ for interpretation of the results
P. Vandecandelaere °, R. Joseph, C. De Ridder (Ypres, BE)
Objective: In order to avoid reporting false positive and false negative
results by the GeneXpert Xpert MRSA real-time PCR assay (Cepheid)
we evaluated if implementation of grey zone interpretation criteria
based on SCC-Ct value and SCC-endpoint value, could improve the
performance characteristics of the test.
Methods: Screening swabs of nose and throat, perineum and wounds
were sampled with eSwab (Copan), specimens of the same patient were
pooled for analysis. The specimens were tested by Xpert MRSA assay
and by broth-enriched culture (Trypticase soy broth with 5% sodium
chloride) followed by plating onto a chromogenic medium (MRSA-
Select, BioRad). A grey zone interpretation was implemented for Xpert-
MRSA negative results with SCC-Ct value >0 and for Xpert-MRSA
positive results with SCC-endpoint <150 or SCC-Ct value >34.
Results: Among 659 specimens tested, 112 (17%) yielded a positive
MRSA culture.
When Xpert MRSA results are compared with broth-enriched chro-
mogenic medium culture as reference method, the sensitivity was 78.3%,
the speciﬁcity was 95.9%, the positive predictive value (PPV) was 84.2%
and the negative predictive value (NPV) was 94.1%.
Forty-two of the 659 specimens (6.5%) comply with the proposed grey
zone criteria.
Among the Xpert MRSA negative specimens 14 had a SCC-Ct value >0:
compared with broth-enriched chromogenic culture, 8 of these results
(57%) were false negative.
Among the Xpert MRSA positive specimens 28 had SCC-endpoint <150,
SCC-Ct value >34, or both: compared with broth-enriched chromogenic
culture, 14 of these results (50%) were false positive.
Excluding these ‘grey zone’ specimens, the Xpert MRSA assay has a
sensitivity of 81%, speciﬁcity of 98.6%, PPV of 93.3% and NPV of
95.5%.
Conclusions: By implementing a grey zone for negative Xpert MRSA
results with SCC-Ct value >0 and for positive Xpert MRSA results with
SCC-endpoint <150, SCC-Ct value >34, or both, we can improve PPV
of the Xpert MRSA assay from 84.2% to 93.3% and NPV from 94.1%
to 95.5%.
P965 Is there a need for a ‘grey zone’ for Xpert MRSA rapid
testing?
K. Van Vaerenbergh, A. Boel, R. Cartuyvels, G. Coppens, J. Frans,
A-M. Van den Abeele, H. De Beenhouwer ° for the BILULU Study Group
Objectives: Xpert MRSA (GX) testing was introduced in routine
screening for MRSA because of the high negative predictive value
(NPV). In this setting the potential beneﬁt of the use of an equivocal
interpretative category (grey zone) was evaluated in order to ameliorate
the reliability of a fast screening pathway.
Methods: Among ﬁve microbiology laboratories the MRSA screening
procedure was standardized for pooled samples. Indications for GX
screening were deﬁned as: previously being MRSA positive, recent
hospitalisation, resident in a chronic care facility and room mate of a
MRSA positive patient. The follow-up of patients in decolonisation was
done by culture on chromogenic media after non-selective enrichment.
GX gives a positive/negative result based on a cut-off Ct value of 36
cycli. Ct values of all negative GX tests were reanalyzed and any sample
with a Ct> 36 was cultured.
Results: During a ﬁrst extensive phase of evaluation all samples were
cultured and GX tested. This evaluation showed a high NPV (99.3%)
and an acceptable sensitivity (>95%) of GX in our patient populations,
permitting the use of GX to give fast and reliable exclusion of MRSA
positivity. Because of the rather low positive predictive value (80.3%),
positive results of GX needed to be conﬁrmed by culture. GX was
introduced in routine since January 2009. Until September 2009, 1536
samples were analysed with GX. For 1331 samples, GX was negative.
Culture was positive for 167 of the 205 positive GX samples, giving a
PPV of 81.5% for GX and a NPV of 99.3%, conﬁrming our ﬁrst results.
42 samples had a negative GX result with a Ct above 36. Of these 9
were positive with culture. Thus considering an equivocal interpretative
category 5% more positive samples were recovered.
Conclusion: A ‘fast-screening’ pathway based on Xpert MRSA gives
rapid and reliable exclusion of MRSA. However in our patient population
5% of the positive samples were GX negative but with a Ct above
36. In order to increase the sensitivity of the fast screening pathway,
introduction of an equivocal interpretative category − to be conﬁrmed
by culture − seems mandatory.
P966 Performance characteristics and utility of the cepheid
MRSA-Xpert for screening for MRSA from direct patient’s
samples at a tertiary care centre
S. Al Johani °, J. Akhter (Riyadh, SA)
Background: Methicillin-resistant Staphylococcus aureus is a well-
recognized pathogen responsible for nosocomial infections. More than
10% of bloodstream infections in hospitals are due to MRSA, which
associated with worse outcomes than those with methicillin-sensitive S
aureus. These encourage scientists to provide rapid screening tool for
high risk patients.
Objective: To evaluate the performance and utility of the Cepheid Xpert
MRSA test for rapid screening of high risk patients at a 1000 beds
tertiary care Hospital.
Materials and Methods: A total of 7394 high risk patients at King
Abdulaziz Medical City were sampled and screened for MRSA from
November 2008 − August 2009. Of those 324 were excluded by the
system, and from the remaining 7070 specimens there were 6630
negative specimens and 440 positive specimens. We evaluated the 440
positive specimens further to determine the number of true positives
and any false positives using two methods, ﬁrst by culture conﬁrmations
and second by graphic analysis of the real time PCR and melting curve
analysis on the screen.
Results: We ﬁnd that out of the 440 positive samples by GeneXpert
system, there were 235 (53.40%) culture conﬁrmed positive and 205
(46.59%) culture negative for MRSA, there were 3 samples reported
negative by PCR and turned to be culture positive. The sensitivity,
speciﬁcity, positive predictive value (PPV) and negative predictive value
(NPV) for the test as follow: 98.74%, 96.98%, 52.93% and 99.95%
respectively. We then report the results based on the real time PCR
graphic analysis, regardless to the reported result by the system. Then
out of the 440 positive samples, there were 282 tests compatible with
true positive and the rest looks negative. The statistical analysis with
the second method does not affect our sensitivity but it improves the
speciﬁcity and PPV to 99.31% and 83.33% respectively.
Conclusion: We conclude that the Xpert MRSA assay is a simple, rapid,
and accurate method for performing active surveillance for MRSA in a
variety of health care populations, a critical graphic analysis of the real
time PCR is essential to avoid overcalling MRSA cases.
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P967 Evaluation of the performance characteristics of
the new NucliSens® EasyQ MRSA for detection of
methicillin-resistant Staphylococcus aureus in nasal swabs
L. Cavalie´ °, O. Baron, M. Archambaud, R. Bauriaud, D. Clave´,
M.F. Prere, C. Jay, N. Fortin, S. Tierrie, C. Croguennec, S. Grosz,
V. Maisonniac, R. Cottarel, N. Marty (Toulouse, Grenoble, FR)
Objectives: To prevent and minimize the spread of MRSA in our
hospital, patient screening is performed on admission to intensive care
units and during prolong stays in the geriatric department according to
the “search and isolate” principle.
The aim of this study was to compare 3 screening techniques: the new
NucliSENS EasyQ® MRSA assay (NEQ), the BD GeneOhm MRSA
assay (BD) and culture on chromID® MRSA.
Methods: Sampling was conducted by swabbing patients with a 552C
dry ﬂocked swab (for NEQ) and a 141C non-ﬂocked swab (for culture
and BD) in the right and then in the left nostril of patients. A total of
340 samples were analyzed with the 3 methods. The BD technique is a
real time PCR technique detecting the SCCmec-orfX junction. NEQ is a
real-time NASBA DNA-based technique performed on the NucliSENS®
EasyQ platform and targeting both SSCmec cassette junction and mecA
gene.
Results: Using culture as the reference technique, results obtained for
NEQ showed a sensitivity of 93.55% (29/31), a speciﬁcity of 91.45%
(278/304), a negative predictive value (NPV) of 99.3% and a positive
predictive value (PPV) of 52.72%. For BD, results showed a sensitivity
of 96.77% (30/31), a speciﬁcity of 88.54% (255/288), a NPV of 99.6%
and a PPV of 47.6%. The number of invalid tests was 7/340, i.e. 2.06%,
for NEQ and 32/340 i.e. 9.41% for BD.
Conclusion: The low PPV, close to 50%, for both BD and NEQ, requires
a control with culture in case of positive result. The good NPV (>99%)
for these 2 techniques enables a negative result to be given for patients
screened as negative with a very low risk of error (less than 1%).
Screening of negative patients is therefore ensured by these 2 techniques
in about 3 hours, compared with culture which requires 48 hours. This
can reduce the duration of isolation on hospital wards and thereby
also decrease the extra costs. Finally, the low rate of invalids obtained
with NEQ is a main advantage that leads to time and cost savings.
According to the performance obtained, NucliSENS EasyQ MRSA is a
new assay adapted to an efﬁcient MRSA screening in a cost effective
way.
P968 Comparison of two rapid molecular methods: GeneOhm
MRSA and NucliSens EasyQ MRSA with the chromID
MRSA chromogenic medium for detection of methicillin-
resistant Staphylococcus aureus in 2,003 nasal swabs
V. Vernet-Garnier °, C. Jay, J. Madoux, S. Gicquel, N. Fortin, C. de
Champs, O. Bajolet (Reims, Grenoble, FR)
Objectives: Hospital acquired infections with Methicillin Resistant
Staphylococcus aureus (MRSA) pose a major problem threat to
hospitalized patients, increasing morbidity and mortality. Screening for
MRSA colonization in patients is a procedure carried out by the hospital
infection control to identify carriers at an early stage. We compared a
new NASBA method targeting both SCCmec cassette junction and mecA
gene (NucliSENS EasyQ® MRSA, bioMe´rieux − NEQ) and a PCR
method targeting the SCCmec junction only (BD GeneOhm MRSA −
BD), with a selective chromogenic MRSA agar (chromID® MRSA,
bioMe´rieux).
Methods: A prospective trial including a total of 2003 fresh nasal
specimens were collected from 1521 patients hospitalized in 12 units.
Testing required 2 swabs per patient: a dried ﬂocked swab (Copan 552C)
for NEQ and a non-ﬂocked swab for BD and chromID MRSA. In case of
suspected colonies on chromID MRSA, biochemical identiﬁcation and
methicillin resistance conﬁrmation were performed by using VITEK® 2
(bioMe´rieux) after subculture on blood agar. Frozen lysates were repeated
in case of invalid results with NEQ or BD.
Results: Both molecular methods presented high sensitivities (NEQ
92.9%, BD 92.8%) and speciﬁcities (NEQ 97.5%, BD 96.7%).
Agreement between NEQ and BD on chromID NEG samples is 96.4%.
Of 41 positive (POS) with BD and NEG with NEQ, 8 (19.5%) patients
were known to be colonized with MRSA according to patients’ follow-
up. Of 27 POS with NEQ and NEG with BD, 9 (33.3%) patients were
known to be colonized with MRSA. This suggests a higher rate of false
positives using BD compared to NEQ.
21 were found NEG by chromID MRSA but POS by NEQ and BD
showing that molecular biology is likely to be more sensitive than culture.
The percentage of invalid rate was 1.0% with NEQ and 3.5% with BD.
Conclusions: Both molecular assays are useful methods for providing
MRSA results within a very short period of time, compared to culture
(results between 48 and 72 h). Time to result was 3 hours maximum
from swabs to result dispatch using 44 tests per run for NEQ versus
14 tests for BD only. NEQ will give a MRSA positive result only if
both targets SCCmec cassette junction and mecA gene are detected,
reducing therefore the risk of false positive. This advantage combined
with the low rate of invalid results provide a better cost management and
an improved productivity. In conclusion, the new NASBA NEQ MRSA
assay demonstrates higher performance than BD.
P969 Nasal swabs alone are inadequate for optimum detection
of methicillin-resistant Staphylococcus aureus colonization
using the GeneOhm MRSA assay
K. Williams °, E. James (London, UK)
Objective: To determine the proportion of cases of MRSA colonisation
that are not identiﬁed if the perineum is not sampled when screening
patients using the GeneOhm MRSA assay.
Methods: Routine MRSA screening was performed using double-headed
swabs taken from nose and perineum sites. Swab heads from each site
were processed together in a single extraction step. An aliquot from
each of the nose/perineum extractions was then ampliﬁed by GeneOhm
MRSA reaction in a Smartcycler. Samples from newly identiﬁed MRSA
cases were cultured and the second head of each swab extracted and
processed individually by GeneOhm MRSA.
Results: Of 127 samples positive in combined nose and perineum
reactions, 20 (16%) were positive by PCR in the perineum site alone
when tested individually. Of 83 culture positive cases, 12 (14%) were not
detected by PCR of the nose sample when tested individually. Compared
to direct culture on chromogenic media the positive predictive values
of nose and combined nose/perineum methods were 67% and 65%
respectively.
Conclusion: Using nasal swabs alone when screening patients using
the IDI-MRSA will miss a signiﬁcant proportion of MRSA carriers.
Combining nose and perineum samples does not affect the positive
predictive value of the assay.
P970 The prevalence of the Panton-Valentine leukocidin-positive,
community-acquired methicillin-resistant Staphylococcus
aureus isolates in Queensland, Australia
M. Costello °, F. Huygens, R. Vohra (Brisbane, AU)
Objective: Community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) infections are emerging worldwide. The epidemiol-
ogy of MRSA has changed recently with new strains causing infections
in the community. In addition to novel methicillin resistance gene
cassettes, these harbor the Panton-Valentine leukocidin genes (PVL).
In Queensland, PVL-positive MRSA belonging to multilocus sequence
type (ST) 93 has spread and caused severe infections including deaths.
The aim of this project was to determine the prevalence of PVL positive
MRSA strains in the community by Real-Time PCR, and determine the
dominant genotype using Single Nucleotide Polymorphisms (SNPs).
Methods: 222 CA-MRSA isolates from specimens including swabs
collected from patients in the community in the period from May 2008
to May 2009 were analysed. Isolates were conﬁrmed as Staphylococcus
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aureus by phenotypic methods and conﬁrmed as CA-MRSA by the
antibiogram i.e. resistant to one or more non b-lactam antibitiocs. PCR
was performed for nuc and mecA genes, and conﬁrmed for the presence
of PVL gene by PCR. All isolates were then typed by SNP typing to
determine their genotype.
Results: Of the 222 CA-MRSA isolates, 207 (77%) of the isolates were
positive for the PVL gene. 16 different ST were detected, of which 88
(39%) of the 222 were found to be ST93, 20 (9%) were found to be ST30,
12 (5.2%) were ST22 and 8 (3.2%) were ST1. 100% of ST93 isolates
were PVL positive. The median age distribution of PVL positive ST93
isolates was 45 years with 49% in the age group between 0 and 29 years.
90% of ST93 isolates were from patients in Southeast Queensland.
Conclusions: 77% of CA-MRSA were found to be PVL positive. Of the
16 CA-MRSA clones that were characterized, ST93 and ST30 accounted
for half. In addition, PVL was detected in EMRSA-15 (ST22) isolates; a
hospital associated MRSA clone that is known to be highly transmissible
in the healthcare setting. An international PVL-positive CA-MRSA clone
USA300 MRSA (ST8) was also seen in this study. The presence of ST8
suggests that these strains have been introduced from the USA and even
though their numbers are small and widely dispersed in Queensland they
are of concern as local transmission may be occurring. This study has
shown that all ST93 strains from the community were positive for PVL.
The implications are that they are less likely to be treated appropriately
and more likely to cause severe infections leading to hospitalizations.
P971 Real-time PCR demonstrates the inhibitory activity of
probiotic soluble fractions on Staphylococcus aureus
quorum-sensing genes expression
A. Cotar, V. Lazar °, S. Dinu, C. Bleotu, D. Pelinescu, M.C. Chiﬁriuc
Balotescu (Bucharest, RO)
Objectives: The purpose of this study was to demonstrate by real-
time PCR the inhibitory activity of the soluble fraction of Lactobacillus
paracasei subsp. paracasei probiotic strain culture on the expression
level of quorum-sensing agr genes, involved in the regulation of
coordinated virulence factors expression in Staphylococcus (S.) aureus
strains.
Methods: The study was performed on 20 S. aureus strains isolated
from cardiovascular devices associated infections. PCR multiplex assay
of the hypervariable domain of the agr locus was used to identify the
accessory gene regulator (agr) speciﬁcity groups (I to IV) of the tested
strains. The S. aureus strains were previously grown in the presence of
subinhibitory concentrations of sterile supernatants of probiotic culture
and subsequently investigated for the expression of different phenotypic
features: growth curve, adherence to inert substrate (slime test), ability to
ferment mannitol and haemolysins production. Total RNA was extracted
from control as well as from bacterial cultures grown in the presence
of probiotic soluble fraction. Random hexamers primers were used for
cDNA synthesis. For the quantiﬁcation of agr gene expression there was
used real-time qRT-PCR with minor groove binder probes with a non-
ﬂuorescent quencher bound to the 3 end (Applied Biosystems). The 16S
rRNA reference gene was used for normalization of the results.
Results: The soluble fraction of Lactobacillus paracasei subsp.
paracasei probiotic strain culture inhibited the adherence to inert
substratum, the ability to ferment mannitol and the expression of
haemolysins in the tested strains. The S. aureus strains belonged to
agr I (6 strains) and agr III (14 strains) speciﬁcity groups. The results
qRT-PCR showed that the expression of agr I decreased with 42% and
that of agr III with 34% in the probiotic treated cultures comparatively
with control cultures expression.
Conclusion: The results of comparative quantiﬁcation of agr expression
in S. aureus strains grown in the presence of soluble fraction from
probiotic cultures showed an important inhibitory effect of the probiotic
soluble molecules on the agr expression. The inhibition of this important
regulatory mechanism of S. aureus virulence factors expression could
represent a possible new strategy for the attenuation of pathogenicity
and virulence in S. aureus strains isolated from cardiovascular devices
associated infections.
P972 Livestock-associated MRSA CC398 strains and human
epidemic MRSA strains are distinguished by a novel
single-nucleotide polymorphism in the Staphylococcus aureus
SCCmec-orfX junction
U. Reischl °, T. Holzmann, J. Frick, S. Ho¨rmansdorfer, K. Becker,
R. Ko¨ck, C. Tuschak, A. Sing (Regensburg, Oberschleißheim, Mu¨nster,
DE)
Objectives: Although classically considered as a nosocomial pathogen,
reports of methicillin resistant Staphylococcus aureus (MRSA) carriage
or infection in the community have become increasingly common
during the past decade. Recent studies in many European countries
demonstrated that especially swine, swine farmers or other persons
in contact with livestock are colonized with MRSA. Thus, livestock
animals may represent a new, separate reservoir for MRSA, which
are now termed livestock-associated MRSA (LA-MRSA). Molecular
characterization revealed that a distinct subgroup, the MRSA clonal
complex 398 (CC398), is predominant within this collective.
Methods: Different real-time PCR assays for direct detection of MRSA
in clinical specimens targeting staphylococcal cassette chromosome mec
(SCCmec) right extremity sequences and the S. aureus chromosomal
orfX gene (BD GeneOhm MRSA, Cepheid Xpert MRSA, and the
Roche LightCycler® MRSA Advanced test) were evaluated for their
performance to cover LA-MRSA strains of the most prevalent CC398
by testing a collection of 184 MRSA strains of human and animal origin
obtained from ﬁve European countries.
Results: With the exception of 6 MRSA strains harboring “uncommon”
SCCmec elements (IVa, n = 1; VII, n = 1; untypeable, n = 5), all LA-
MRSA strains tested were covered by the investigated PCR assays.
Sequencing of the region around the S. aureus SCCmec integration site
revealed a characteristic single-nucleotide polymorphisms (SNP) in the
SCCmec-orfX junction of MRSA CC398. Within a total assay time of 60
min plus 10 min for subsequent melting curve analysis, MRSA CC398
isolates of our study were clearly distinguished from human epidemic
MRSA strains by a characteristic SNP-induced shift in the Tm value
as observed in the Roche LightCycler® MRSA Advanced test. Melting
curve analysis data were not accessible with the other evaluated real-time
PCR assays.
Conclusions: Since MRSA carriage in livestock animals may give rise
to transmission and infection in humans, the development of rapid
molecular methods for screening and identiﬁcation of LA-MRSA CC398
will have important implications for surveillance, epidemiology and
infection control initiatives. Here, the novel SNP may serve as a suitable
CC398 marker for screening and diagnostic purposes. Studies to conﬁrm
the diagnostic accuracy of the presented SNP-based strain identiﬁcation
concept with a larger collection of clinical and animal-associated MRSA
strains are ongoing.
P973 Characterization of the microbiocoenosis of the human
anterior nares
D.H. Pieper, M.L. Wos-Oxley, I. Plumeier, S. Taudien, M. Platzer,
G. Peters, C. von Eiff, R. Vilchez-Vargas, K. Becker ° (Braunschweig,
Jena, Muenster, DE)
Objectives: Staphylococcus aureus colonizes the anterior nares of
about 20−30% of humans persistently and the other intermittently.
Nasal carriage by this opportunistic pathogen plays a crucial role as
a source of invasive infections. While differences in colonization by
S. aureus have been attributed to host factors, also microbial inter-species
interactions may also inﬂuence colonization. However, the composition
of the microbial ﬂora inhabiting the anterior nares is recorded only
in part because respective studies were traditionally performed using
culture-dependent methods. In this study, the bacterial diversity of the
anterior nares was analyzed by the means of both cultivation and culture-
independent tools.
Methods: The nasal microbial communities of 40 healthy volunteers
from two locations in Germany were studied using single strand chain
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polymorphism (SSCP) analysis of 16S rRNA gene fragments including
a subset of 20 volunteers comprising nasal S. aureus carriers (n = 10)
and non-carriers (n = 10) that was additionally applied for cultivation
purposes. Furthermore, specimens of six representative individuals were
analyzed by 454-pyrosequencing.
Results: The results of the cultivation approach were largely conﬁrmed
by the 16S rRNA gene ﬁngerprinting tools, however, the molecular
approach revealed much more phylotypes comprising a total of 30
bacterial phylotypes belonging to 4 bacterial phyla and 13 families
including putative novel taxa. Beside Propionibacterium acnes, the
most frequently occurring phylotypes across all volunteers were those
related to corynebacterial and staphylococcal species observed in
85−95% of volunteers followed by phylotypes related to species of the
genera Dolosigranulum, Finegoldia and Peptoniphilus (in 40−60% of
volunteers). While Finegoldia magna and Peptoniphilus spp. showed
a statistically signiﬁcant co-occurrence indicating a putative positive
(symbiotic) interaction, a substantially different distribution pattern was
found e.g. for Corynebacterium pseudodiphtheriticum and S. aureus
showing signiﬁcant avoidance to each other. A statistically signiﬁcant
converse association was also detected between S. aureus and F. magna.
Conclusion: In summary, applying the molecular approach, the core
nasal community was identiﬁed and indexed. Knowledge of the precise
composition of nasal ﬂora may contribute to develop strategies in order
to better control or eradicate S. aureus.
P974 False negative S. aureus test results in the Slidex Staph Plus
agglutination test is mainly caused by spa-type t001 and t001
related strains
F. Szabados °, J. Woloszyn, M. Kaase, S. Gatermann (Bochum, DE)
Objectives: The sensitivity of commercial agglutination kits for fast
identiﬁcation of S. aureus is well below 98%. In this study we reevaluated
the sensitivity of the Slidex Staph Plus (bioMe´rieux) agglutination kit
with three sets of molecular characterized S. aureus strains.
Methods: In this study 363 molecularly deﬁned clinical non-copy strains
of methillin-susceptible S. aureus (MSSA) and 240 molecularly deﬁned
clinical non-copy strains of methillin-resistant S. aureus (MRSA) were
included. Additionally, a collection of 104 molecularly deﬁned, pulsed
ﬁeld gel electrophoresis (PFGE) divergent MRSA strains were tested, to
compare the sensitivity of agglutination based identiﬁcation to matrix
assisted laser desorption / ionisation time of ﬂight mass spectrometry
(MALDI-TOF MS) based identiﬁcation using the Biotyper 2.0 database.
Results: The sensitivity of MALDI-TOF MS based S. aureus
identiﬁcation using the Biotyper 2.0 database was 100% (603 of 603).
Sensitivity of Slidex Staph Plus (bioMe´rieux) kit was higher in
methicillin-susceptible S. aureus (MSSA) strains (356 of 363 strains =
98%) than in methicillin-resistant S. aureus (MRSA) strains (227 of 240
strains = 94.5%, p = 0.0035). Two of seven MSSA agglutination negative
MSSA strains were spa-type t001(28.5%). Ten of thirteen agglutination
negative MRSA were spa-type t001(76.9%).
To rule out predominance of local MRSA-strains, the sensitivity was
additionally tested on 104 PFGE divergent MRSA-strains.
In the PFGE divergent MRSA collection, the sensitivity of the
Slidex Staph Plus (bioMe´rieux) agglutination kit was unexpected low
(70.1%). Interestingly, strains tested false negative by the Slidex Staph
Plus (bioMe´rieux) agglutination method in the PFGE divergent strain
collection were spa-type t001(24 of 32) and t001 related (7 of 32) strains.
To rule out a problem speciﬁc to the Slidex Staph Plus kit, the sensitivity
of two additional agglutination kits, the Pasteurex (Biorad; 82.7%) and
Staphytect Kit (Oxoid; 78.8) were tested in the PFGE divergent MRSA
strain collection (table 1).
Conclusion: The sensitivity of S. aureus identiﬁcation by MALDI-TOF
MS was superior (100%) to the sensitivity of the Slidex Staph Plus
(bioMe´rieux) agglutination test in MRSA. The MALDI-TOF MS based
identiﬁcation could be a substitution in agglutination test negative but
suspected S. aureus isolates, especially if the local prevalence of t001and
t001related strains is high.
Table 1
Strain Species PFGE-
group
sub-
group
spa-
type
Slidex
Staph
plus
Staphytect
Plus
Pastorex
Staph
Plus
1497 MRSA 01 2 001 neg neg p
2397 MRSA 02 1 001 neg neg neg
1352 MRSA 02 4 001 neg neg neg
2387 MRSA 02 7 001 neg neg neg
1583 MRSA 02 8 480 neg neg neg
2052 MRSA 02 9 480 neg w neg
1867 MRSA 02 001 neg w p
2615 MRSA 03 1 001 neg neg w
1874 MRSA 03 013 neg neg neg
0680 MRSA 05 001 neg neg w
2021 MRSA 06 001 neg neg p
2682 MRSA 07 10 001 neg neg w
2029 MRSA 07 11 001 neg w neg
1827 MRSA 07 3 001 neg w p
1655 MRSA 07 4 001 neg neg neg
2131 MRSA 07 6 001 neg p neg
1343 MRSA 07 7 001 neg neg neg
2610 MRSA 07 001 neg w p
2770 MRSA 09 001 neg neg w
2293 MRSA 10 001 w w w
1496 MRSA 11 1 001 neg w p
1565 MRSA 13 3 008 w neg neg
1651 MRSA 13 9 064 neg neg neg
1578 MRSA 14 3 109 neg neg w
1321 MRSA 22 2 001 neg neg neg
2239 MRSA 22 3 001 w w neg
0673 MRSA 29 480 neg w w
1518 MRSA 34 480 neg neg p
2450 MRSA 34 001 neg neg neg
2487 MRSA 35 13 032 neg neg neg
1452 MRSA 36 001 neg neg neg
0992 MRSA 43 5712 neg neg neg
1367 MRSA 45 001 neg w w
2351 MRSA 34 001 neg w w
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P975 Effect of sub-minimum inhibitory concentrations of
mupirocin on growth of high-level mupirocin-resistant
Staphylococcus aureus
E. Pe´rez Roth °, E. Armas Gonza´lez, J. Alcoba Florez, S. Kwong, N. Firth,
S. Me´ndez A´lvarez (La Laguna, Santa Cruz de Tenerife, ES; Sydney, AU)
Objectives: Mupirocin is used to control the prevalence of methicillin-
resistant Staphylococcus aureus. Conjugative plasmids harboring the
ileS2 gene play a key role in the dissemination of high-level mupirocin
resistance. Here we have investigated the effects of sub-minimum
inhibitory concentrations (sub-MICs) of mupirocin on growth kinetics
of S. aureus strains carrying different ileS2-encoding plasmids.
Methods: Wild-type S. aureus strains carrying ileS2-encoding plasmids
belonging to four different structural groups (i.e., S1 to S4) were
included. In addition, S. aureus NRS107 strain harboring pGO400, a
well known ileS2-carrying plasmid, was used. Transconjugants were
generated by ﬁlter mating experiments in order to compare the growth of
isogenic strains carrying the different plasmids. To analyze the inﬂuence
of mupirocin on growth rates of resistant cells, strains were cultured
at 37ºC either in the absence or presence of sub-lethal concentrations
of mupirocin and bacterial densities were monitored turbidimetrically
(OD600) at 30 min intervals for 3.5-h. Each data point was the mean of
at least three independent experiments.
Results: Growth experiments revealed that in the absence of mupirocin
there was no signiﬁcant difference between the growth rates of all
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wild-type and transconjugant strains. When mupirocin was added to
the medium the most common effect on growth was an incremental
lag compared with antibiotic free controls. This effect was observed
even at low concentrations of mupirocin. The curves highlighted a more
extended delay in the growth of strains carrying plasmids belonging to
the S3 and S4 groups, which include the sequenced pPR9 plasmid, in
comparison to the other strains. However, some strains showed no lag
whatsoever in comparison with the controls when grown in mupirocin.
We conﬁrmed the nucleotide identity of the ileS2 gene from each
plasmid, ruling out ileS2 mutations as the cause of the differences.
Conclusion: The results indicate that ileS2-carrying plasmids that
encode high-level mupirocin resistance differ signiﬁcantly in their
effectiveness at enabling growth of bacterial hosts in the presence of
sub-MIC levels of mupirocin. This suggests that some plasmids confer
a greater evolutionary advantage than others, which will likely have
ramiﬁcations for the ongoing development of resistance. The molecular
basis of the observed variation in mupirocin resistance phenotype is
under investigation.
P976 Characterization and comparative analysis of pPR9, a
staphylococcal conjugative plasmid encoding high-level
mupirocin resistance
E. Pe´rez Roth °, S. Kwong, J. Alcoba Florez, N. Firth, S. Me´ndez
A´lvarez (Santa Cruz de Tenerife, ES; Sydney, AU)
Objectives: High-level mupirocin resistance has been acquired by
different methicillin-resistant Staphylococcus aureus (MRSA) clones
due to the dissemination of plasmids bearing the ileS2 resistance
gene. To gain insights into the evolution of these medically important
plasmids and mupirocin resistance we have undertaken a comprehensive
comparison between the conjugative multiresistance plasmid pPR9 and
other characterized ileS2-carrying plasmids.
Methods: pPR9 was sequenced using a shotgun strategy and probable
genes were annotated. The predicted proteins were searched, using the
BLAST algorithm, against a nonredundant database at the National
Center for Biotechnology Information. Potential protein functional
domains were identiﬁed by searching against the NCBI conserved-
domain and Pfam databases. Comparative analyses were undertaken
with the other available completely sequenced ileS2-containing plasmids
pUSA03 and pV030−8, and the partially characterized plasmid pGO400.
Pairwise nucleotide comparisons were generated using JDotter and
GATA. Multiple sequence alignments were carried out with ClustalW.
Results: We have determined and analyzed the complete sequence
of pPR9, a 41.7-kb pSK41-like conjugative ileS2-carrying plasmid
recovered from a MRSA strain belonging to the ST36-SCCmecII
pandemic genotype. Unlike previously described pSK41-like plasmids,
the conjugative transfer region of pPR9 is not ﬂanked by copies
of IS257, and the plasmid was found to utilize a novel chimeric
replication initiation protein. Intriguingly, BLAST searches revealed
that the N-terminal 174 amino acids of pPR9 Rep share signiﬁcant
similarity to the N-terminal ends of phage proteins that are annotated
as putative replication proteins. Accessory regions encoding antibiotic
resistance also differed in pPR9, which also contains a second resistance
determinant in the form of a complete copy of a Tn552-like b-lactamase
transposon. Signiﬁcantly, comparative analysis revealed that the insertion
sites of the ileS2 gene in pPR9 and each of the three other plasmids
are distinct, suggesting that these plasmids have each arisen from
independent acquisition events associated with insertion sequence IS257.
In several cases, this element appears likely to inﬂuences the level of
transcription of the ileS2 gene.
Conclusion: Our ﬁndings highlight the continuing genetic ﬂexibility
of staphylococcal conjugative plasmids and the key role of IS257 in
mediating resistance gene capture.
P977 The resistance mechanism mediated by the cfr gene is
predominant in clinical isolates of Staphylococcus epidermidis
linezolid-resistant obtained in a Spanish hospital
E. Baos °, G. Morales, J. Picazo (Madrid, ES)
Objectives: To determine the presence of the cfr gene in S. epidermidis
linezolid-resistant isolates obtained from clinical specimens of patients
admitted to our hospital in one year.
Methods: We collected all S. epidermidis linezolid-resistant identiﬁed
in all type of biological specimens received during the period of one
year. Identiﬁcation and determination of antibiotic susceptibility were
performed using automated methods as Vitek 2 and Wider. Resistance
to linezolid was conﬁrmed using E-test. DNA of linezolid-resistant
strains was obtained by the triton-boiling method and the presence of
the cfr gene was determined by PCR and analyzed using agarose gel
electrophoresis.
Results: From April to December 2008 a total of 28 S. epidermidis
linezolid-resistant strains were isolated. 15 of them carried the cfr gene,
54% of all strains. 29.6% of the strains were obtained from blood
cultures, 37% from catheter (central and peripheral) and 33.4% from
other samples (aspirate, surgical wounds . . . ).
The hospital wards where S. epidermidis linezolid-resistant strains were
more frequently isolated were the ICU (66.6%) and traumatology and
nephrology (11.1%).
From January to May 2009 we isolated 15 S. epidermidis linezolid-
resistant strains, 12 of them carried the cfr gene, representing 80%.
26.3% of the strains were isolated from blood cultures, 36.8% from
catheters and 36, 9% from other samples.
Again, the hospital wards where S. epidermidis linezolid-resistant strains
were more frequently isolated were the ICU (52.6%) and traumatology
(21%).
In one year period 43 S. epidermidis linezolid-resistant isolates were
analyzed and we found that in 62.8% of them the resistance to linezolid
was mediated by the cfr gene.
Conclusions: In our hospital the predominant mechanism for linezolid-
resistance in S. epidermidis is the presence of cfr gene.
These data rise concern about the possibility of horizontal transmission
of this gene.
P978 Molecular characterization of linezolid-resistant
Staphylococcus epidermidis
I. Spiliopoulou °, A. Damani, S. Schoina, A. Liakopoulos, M. Marangos,
E. Malli, L. Leonidou, V. Maroulis, D. Velissaris, F. Fligou, K. Filos,
E.D. Anastassiou, E. Petinaki (Patras, Larissa, GR)
Objectives: To determine the molecular mechanism of resistance to
linezolid and set up the genetic relationship among Staphylococcus
epidermidis isolates in Greece.
Methods: A total of 22 linezolid-resistant S. epidermidis (MIC> 8mg/L)
isolated between February to August 2009 from blood and intravenous
catheter cultures of individual patients in two Greek University Hospitals
(from Patras and Larissa) were investigated. Bacterial DNA was ﬁrstly
tested for the presence of the most common resistance mechanisms, i.e.
the presence of G2576T mutation by PCR followed by NheI digestion
and the presence of cfr gene also by PCR. In addition, in order to detect
other than G2576T mutations, the region V of 23S rRNA gene was
sequenced and resulting data were analyzed by the use of CHROMAS.
Clonal relatedness of all isolates was investigated by MLST. For each
patient, demographic data (age, gender, source of specimen and antibiotic
therapy) were included.
Results: According to MIC values isolates were classiﬁed into two
categories: the ﬁrst included ten isolates with MIC ranges between 8 to
32mg/L, whereas, the second twelve with MICs greater than 256mg/L.
Among the ﬁrst group, three carried the C2534T mutation, while seven
isolates carried the G2576T one. All isolates with MICs greater than
256mg/L carried the recently reported T2504A mutation. MLST analysis
revealed the presence of two clones: clone ST22, including strains that
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carried both T2504A and C2534T mutations, and clone ST2, including
strains with G2576T mutation. The ST22 clone is closely related to ST2
with a difference of the tpiI allele. The majority of patients were treated
with linezolid prior to isolation of the speciﬁc strain.
Conclusion: Dissemination of common clones of linezolid-resistant
S. epidermidis among hospitals located in different areas of the country
emphasizes the need for strict control measures application, such as
isolation of infected patients, increased environmental cleaning, hand
hygiene and antibiotic policy.
P979 Emergence of linezolid-resistant Gram-positive clinical
isolates due to cfr-methylase gene production associated with
G2576T mutation in the 23S rRNA
E. Cercenado °, M. Marı´n, R. Insa, E. Bouza (Madrid, ES)
Objectives: To characterize a total of 46 linezolid-resistant (LNZ-R)
clinical isolates of grampositive cocci recovered in our laboratory from
January 2009 to October 2009.
Methods: MICs were determined by the broth microdilution method
using commercialized MicroScan panels (Siemens). CLSI guidelines
(2009) were followed for determination of breakpoints. LNZ-R isolates
were conﬁrmed by E-test. Detection of the G2576T mutation was
performed by PCR and sequenciation of the 23S rRNA gene. Presence
of the cfr-methylase gene was determined by PCR and sequencing as
previously described. S. aureus ATCC 29213 was used as linezolid-
susceptible control strain.
Results: The 46 LNZ-R clinical isolates recovered over the period of
study were S. epidermidis (39 isolates), methicillin-resistant S. aureus
(MRSA) (4 isolates), E. faecium (2) and E. faecalis (1) corresponding
to 40 patients. The origin of the isolates was IV catheter (14 isolates),
wound/abscess (14), blood (5), pleural ﬂuid (4), tracheal aspirates (4),
CSF (3), and peritoneal ﬂuid (2). The LNZ-MICs against the isolates
ranged from 8 to >256mg/L. The patients were hospitalized in 14
different wards, but 3 wards included 15 patients. Not all the patients
received linezolid previous to the isolation of the LNZ-R isolates. A total
of 20 isolates produced only the cfr gene (4 MRSA isolates from patients
isolated in different wards at different times, 1 E. faecalis, 1 E. faecium,
and 14 S. epidermidis); 19 had the G2576T mutation in addition to the
cfr gene, and 7 isolates (all S. epidermidis) presented only the G2576T
mutation.
Conclusions: To our knowledge this is the ﬁrst description in which
LNZ resistance in different species of grampositive clinical isolates is
due to the concomitant production of the cfr-methylase gene and the
G2576T mutation. We also describe for the ﬁrst time the cfr production
in clinical isolates of E. faecium and E. faecalis, and the spread of the
cfr gene among MRSA isolates from non-related patients.
P980 Nosocomial outbreak of methicillin and linezolid-resistant
Staphylococcus epidermidis associated with catheter-related
bloodstream infections in intensive care unit patients
C. Seral °, Y. Sa´enz, S. Algarate, E. Dura´n, P. Luque, C. Rubio-Calvo,
C. Torres, F.J. Castillo (Zaragoza, Logron˜o, ES)
Objective: To investigate the clonality of the strains and the mechanisms
of resistance to linezolid and other antibiotics in a nosocomial outbreak
of meticillin and linezolid-resistant S. epidermidis (MLzRSE) associated
with catheter-related bloodstream infection (CR-BSI) in an ICU.
Methods: From March 2008 to August 2009, 27 MLzRSE out
of 128 coagulase-negative staphylococci (21.09%) associated with
CR-BSI in the ICU of our hospital were recovered from blood
cultures (14) and catheter (13) of 21 patients. Thirteen patients
(61.90%) had received linezolid during the three months preceding
isolation of the MLzRSE. Susceptibility testing to 22 antibiotics was
performed by WIDER microdilution system. Linezolid, daptomycin
and tigecyclin MICs were determined by E-test and susceptibility to
MLS, aminoglycosides, chloramphenicol and tetracycline antibiotics by
disk diffusion. Detection and characterization of meticillin [mecA],
linezolid [23S rRNA mutations and cfr], aminoglycosides [ant(6)-
Ia, aac(6′)-Ie-aph(2′′)-Ia, aph(3′)-IIIa and ant(4′)] and chloramphenicol
[catA] resistance genes were studied by PCR and sequencing. Clonal
relationship was performed by PFGE using SmaI enzyme and by MLST
typing. The SCCmec type, the ica gene, IS256 and Tn4001 transposon
were also studied by PCR.
Results: Three closely related pulsotypes were identiﬁed among the 27
studied MLzRSE that belonged to the sequence type ST2 and harboured
the mecA gene and the SCCmec III type. Analysis inside the ampliﬁed
fragment of 23S rRNA region determined that the strains recovered from
patients 1 to 4 (pulsotype P1a) showed the nucleotide mutation G2474T
and carried the aac(6′)-Ie-aph(2′′)-Ia, ant(4′) and catA genes, whereas
the strains from patients 5 to 21 (pulsotype P1b and P1c) showed the
mutation G2603T in the 23S rRNA and carried the aac(6′)-Ie-aph(2′′)-Ia
gene. None strains ampliﬁed the cfr gene. The ampliﬁcation of the ica
gene and the IS256 were positive in all 27 MLzRSE strains.
Conclusions: The emergence of two new epidemic linezolid resistant
S. epidermidis strains, nearly coincident in time and genetically related,
with two different mutations in the 23S rRNA (G2474T and G2603T)
non-previously described before, are reported in this study as cause of a
nosocomial outbreak.
P981 Mupirocin resistance in methicillin-resistant Staphylococcus
aureus and mupirocin consumption over 10 years in a
tertiary hospital
A. Lee °, P. Franc¸ois, G. Renzi, M. Macedo, N. Vernaz, J. Schrenzel,
D. Pittet, S. Harbarth (Geneva, CH)
Objectives: Topical mupirocin is widely used to eradicate carriage
and prevent infection with methicillin-resistant Staphylococcus aureus
(MRSA). However, resistance to this antibiotic is emerging and may be
the result of selective pressure from mupirocin use. Low-level mupirocin
resistance (L-MuR) is associated with native tRNA synthetase mutations
while high-level resistance (H-MuR) is usually due to plasmid encoded
mupA (novel tRNA synthetase). This study aimed to determine the
prevalence and molecular mechanisms of mupirocin resistance in MRSA
blood culture isolates in our institution. We also aimed to correlate
mupirocin use and prevalence of resistance over time.
Methods: The ﬁrst 20 non-duplicate MRSA blood culture isolates per
year collected and stored at our institution between 1999 and 2008
were selected for the study. Non-viable and contaminated isolates were
excluded. The remaining isolates were screened for mupirocin resistance
using a 0.5 McFarland suspension on Mueller-Hinton agar with a 5
microgram disk. Resistant isolates had MIC determinations with Etests,
an allelic discrimination assay to detect the V588F point mutation and
MupA PCR. Mupirocin consumption data between 2000 and 2008 were
obtained.
Mupirocin resistance in MRSA blood cultures and mupirocin consump-
tion, 1999 to 2008.
Results: 200 MRSA isolates were retrieved. Of these, 9 were excluded
due to contamination and 3 were non-viable. The remaining 188 isolates
S266 20th ECCMID, Posters
were further evaluated. Resistance to mupirocin was found in 0 of 17
isolates in 1999, increased to 18 of 19 isolates (95%) in 2005 and then
decreased to 15 of 19 isolates (79%) in 2008 (Figure). The majority
of resistant isolates had L-MuR (89 of 103 isolates, 86%). The V588F
point mutation was found in all isolates with L-MuR. However, it was
also present in 12 of 14 (86%) isolates with H-MuR. The mupA gene
was found in all isolates with H-MuR. The trend in the consumption of
mupirocin paralleled the prevalence of resistance during this period, with
an increase from 96g to 194g between 2000 and 2005, then decrease to
137g in 2008 (r = 0.87, p = 0.002).
Conclusions: The prevalence of mupirocin resistance in our institution
is increasing and predominantly consists of L-MuR characterized by
the V588F mutation. This correlates with an increase in mupirocin use
over this period. The therapeutic implications of L-MuR remain to be
determined.
P982 Comparison of prevalence of antiseptic resistance genes in
Staphylococcus aureus and coagulase-negative staphylococci
from nurses and the general population in Hong Kong
M. Zhang, M. Boost °, M. O’Donoghue, E. Tong, K. Hiramatsu
(Kowloon, HK; Tokyo, JP)
Objective: Widespread use of antiseptic agents has led to the emergence
of Staphylococcus aureus and coagulase-negative staphylococci (CNS)
with decreased antiseptic susceptibility. This has been associated with
the presence of several genes including qacA/B and smr. This study
determined and compared the prevalence of antiseptic resistance genes
in S. aureus and CNS from nurses and the general population and
investigated risk factors for carriage by nurses of qacA/B or smr positive
S. aureus and CNS.
Methods: Nasal swabs were collected from 235 nurses and cultured for
the presence S. aureus and CNS. The nurses completed a questionnaire
providing demographics and data on antiseptic use, contact with MRSA
positive patients, and recent antibiotic therapy. 200 recent carriage
isolates of S. aureus and CNS from the general population were used
for comparison. PCR was used to detect mecA, qacA/B and smr genes.
Univariate and multivariate analysis were used to investigate associations
between presence of antiseptic resistance genes and potential risk factors.
Results: A signiﬁcant difference was noted in the prevalence from nurses
and the general public of both qacA/B and smr in CNS isolates and of
qacA/B in S. aureus (see table). Overall MRSA carriage was low (3%
nurses; 0.5% general public). There was a signiﬁcantly higher prevalence
of qacA/B in MRCNS strains than in MSCNS isolates (p< 0.001), but,
whilst the rate was higher in MRSA than MSSA, this did not reach
signiﬁcance.
Contact with MRSA patients increased risk of carriage of strains with
antiseptic resistance genes (OR 2.26; p = 0.031). Presence of mecA in an
isolate increased the risk of harbouring antiseptic resistance genes (OR
2.78; p< 0.001).
Table. Prevalence of antiseptic resistance genes in staphylococcal isolates
from nurses and the general population
Gene Nurses
(%)
General population
(%)
OR p
S. aureus qacA/B 52.8 11.3 8.8 <0.001
smr 5.4 5.6 na ns
CNS qacA/B 43.3 13.5 8.4 <0.001
smr 18.5 8.5 2.4 0.002
Conclusions: The increased prevalence of antiseptic resistance genes
in isolates from nurses indicates that the hospital environment exerts
selective pressure for carriage of these strains. The increased proportion
of antiseptic resistance gene positivity in mecA positive isolates suggests
co-selection of these genes, as does the increased risk of carriage of
antiseptic resistance gene positive strains by those in recent contact
with MRSA positive patients. Although qacA/B and smr do not confer
antiseptic resistance at concentrations used, they may pose an infection
control risk by persisting in areas with low level antiseptic residues. The
association between mecA and qacA/B/smr may contribute to survival
of MRSA in the hospital environment.
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P983 Signiﬁcant decrease in the prevalence of MRSA − another
inspiring tendency in Bulgaria
M. Petrov °, T. Velinov, V. Dimitrova, T. Kantardjiev (Soﬁa, BG)
Objectives: Investigation of the resistance levels and trends for MRSA
isolated in Bulgaria, from 2000 to 2008, as part of the Bulgarian
Surveillance Tracking Antimicrobial Resistance − BulSTAR.
Methods: BulSTAR monitors the isolation and antimicrobial suscepti-
bility of all clinically signiﬁcant microorganisms isolated from blood
cultures and other important sources in the participating microbiology
laboratories since 1997. One hundred and sixty-eight microbiology
laboratories from all regions of Bulgaria participated in the surveillance
in 2008. The number of investigated S. aureus strains varied between
10 000 and 22 000 per year. The participating laboratories identiﬁed all
microorganisms and performed susceptibility testing in accordance with
the Clinical Laboratory Standards Institute (CLSI, formerly NCCLS).
MRSA were conﬁrmed on Screen-agar or other relevant CLSI methods
like detection of PBP2′ or mecA gene. Each year an increasing
number of laboratories (n = 133 in 2008) have been using Laboratory
Information Systems (LIS) like WHONET or the local software National
Information System “Clinical Microbiology and Infections Surveillance”
for laboratory data management. According to the recommendations they
report only the ﬁrst isolate per patient for the year, though a part of the
participants lacking LIS are still reporting multiple isolates (n = 35 in
2008).
Results: Data from BulSTAR show an inspiring tendency. The
overall percentage of MRSA among Staphylococcus aureus isolates is
decreasing in Bulgaria from 13.9% in 2002 to 5.4% in 2008 (Figure 1).
This is mainly due to raised awareness on the problems with MRSA,
increased efforts on infection control and hand hygiene, rather then to
altered antibiotic policy in hospitals in the country.
Conclusions: The overall levels of MRSA in Bulgaria are decreasing
since 2002. The EARSS Annual Report 2007 indicated that seven
Member States report signiﬁcantly decreasing percentages of MRSA
among Staphylococcus aureus from bloodstream infections. This is
likely due to increased measures on infection control, hand hygiene
and antibiotic policy in hospitals in these countries as demonstrated by
national data from, e.g. Slovenia, France and UK. Further investigations
will determine that Bulgaria can be added to those seven countries (M.
Petrov and co-workers, unpublished data).
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P984 Hospital outbreak of methicillin-resistant Staphylococcus
aureus caused by a new, possibly hyperepidemic variant from
a previously sporadic strain
O. Clerc °, L. Senn, C. Bellini, I. Nahimana Tessemo, D.S. Blanc,
G. Zanetti (Lausanne, CH)
Objective: To describe an ongoing outbreak that tripled the annual de-
tection of methicillin-resistant Staphylococcus aureus (MRSA) carriage
in a tertiary care hospital.
Methods: Active surveillance of MRSA is performed since 20 years
in our hospital. Our protocol includes screening of patients transferred
from high-incidence health-care institutions or countries, roommates of
new MRSA cases, and wards where 2 patients acquired MRSA during
the same week. Contact precautions are used for known carriers. PFGE
was used for molecular typing until 2004, and was then replaced by
Double-Locus Sequence Typing (DLST).
Results: A median yearly incidence of 173 new carriers of MRSA was
observed from 2002 to 2007. Since September 2008, an increasing
number of new cases were observed, mainly as successive clusters
limited to distinct wards, reaching a total of 398 until October 2009.
The yearly incidence of new cases rose to 275 in 2008 and 613 in
2009. 60% of the cases were due to one strain: DLST 4−4, ST 228,
SCCmecI. The incidence of new cases due to the previously predominant
strains remained unchanged. The epidemic strain corresponded to a new
variant of a clone responsible for a previous outbreak in 2001, and
only sporadically isolated (mean of 20 cases/year) since then. A case–
control study documented a signiﬁcant association between acquisition
of the epidemic strain and a stay in intensive and intermediary care
units, a highest number of internal transfers, but did not identify a
point source of transmission. Infection control practices and antibiotic
policy had remained unchanged for several years. Compliance with hand-
hygiene as monitored yearly was on the rise. Screening of 313 healthcare
workers only found one carrier of the epidemic strain lately in the
outbreak. Additional infection control measures were enforced, including
screening at ICU admission and discharge with PCR-based rapid test,
routine screening for all patients leaving epidemic wards, introduction of
PCR-based rapid test for contact tracing, additional working forces for
environmental disinfection, and hospital-wide education of healthcare
workers. However, the outbreak was still ongoing after 5 months.
Conclusions: Factors linked to the dissemination of this new variant in
our institution remain undetermined. This unresolved outbreak suggests
that this new variant acquired hyperepidemic properties, which calls for
further investigations.
P985 Nosocomial infections by methicillin-resistant (MRSA) and
methicillin-sensitive Staphylococcus aureus: further exploring
the role of prior antibiotic usage as a predictor of MRSA
infection
I.G. Baraboutis °, E.P. Tsagalou, E. Mylona, V. Papastamopoulos,
M. Samarkos, C. Gogos, A. Skoutelis, S.B. Johnson (Athens, Patra,
GR; Chicago, US)
Objectives: Both total antimicrobial use as well as speciﬁc antimicrobial
classes have been implicated as risk factors for nosocomially-acquired
MRSA (NA-MRSA) infection. The aims of the study were: 1.to explore
predictors of a new NA-MRSA infection in comparison with a new
nosocomially-acquired MSSA (NA-MSSA) infection, 2.to thoroughly
assess recent antibiotic use (within the last 30 days of the positive culture
date) qualitatively and quantitatively.
Methods: The time-period for our study was from October 1997 through
September 2001. From the infection control records, we identiﬁed two
groups of inpatients, one with a new positive MRSA culture and one with
a new positive MSSA culture. We considered the infection acquired in-
hospital if (1) the culture was taken more than 48 hours after admission
and (2) if it was taken less than 48 hours but the patient had been
hospitalized within the last month. We only included patients with
adequate clinical and/or laboratory indications for active infection and
not just colonization. We recorded data pertinent to widely accepted risk
factors for Staphylococcus aureus colonization and infection considering
events up to 30 days before the positive culture date. We used the
electronic pharmacy records to obtain detailed data on intravenous
antibiotic use during the month before the culture date.
Results: We identiﬁed 127 patients with a new NA-MRSA infection
and 70 patients with a new NA-MSSA infection eligible for further
analysis. In univariate analysis, signiﬁcant differences were noted in
rates of hemodialysis, recent invasive procedures and major surgery,
intubation, indwelling urinary catheter placement, use of at least 3
antibiotics, use of penicillins, clindamycin, aminoglycosides, ﬂuoro-
quinolones (FQs), and quantitative use of total antibiotics, b-lactams,
penicillins, b-lactam/inhibitor combinations, FQs and aminoglycosides.
In multivariate analysis, no single factor stood out when including
only qualitative antibiotic use while total antibiotic use was the only
independent predictor of NA-MRSA infection when including only
quantitative data in the model. No siginiﬁcant differences in outcome
were noted.
Conclusion: From the analysis of these strictly deﬁned groups deriving
from a highly homogeneous population, we conclude that quantitative
antibiotic usage as a whole was the strongest predictor of NA-MRSA
infection, more than individual antibiotic usage or other traditional risk
factors for NA-MRSA infection.
P986 Effect of introduction of new antibiotic guidelines on
undetected methicillin-resistant Staphylococcus aureus
carrier rate on elderly care wards
F.M. Awadel-Kariem °, R.N. Manzoor, H. O’Connor, S. Khan
(Stevenage, UK)
MRSA is endemic in elderly care (EC) wards. This represents a hidden
threat which puts these patients at risk of serious systemic infection and
can be a source of infection to other hospitalised patients.
Objectives: To establish the impact of changing Antibiotic Guidelines
on the MRSA carrier rates on EC wards in a district general hospital.
Methods: The study was carried out in two phases. An audit was
conducted in 2007 prior to the introduction of antimicrobial guidelines
that restricted the use of cephalosporins (CEP) and ﬂuoroquinolones
(FQ). A follow-up audit was conducted in 2008 after the successful
implementation of the guidelines. In both audits, all patients in two
EC wards were screened for asymptomatic MRSA colonisation at
multiple sites including nose, throat and groin. Swabs were processed for
detection of MRSA using two protocols: a) 3M BacLite method; and b)
MRSA Chromogenic Agar method. Positive patients were then notiﬁed
to the infection control team and to the doctors looking after them to
start the eradication protocol.
Results: In the ﬁrst audit, 48 patients in 2 EC wards were screened.
Of these, 10 were found to be positive for MRSA in one or more sites.
Out of the 10 MRSA colonised patients 5 had conﬁrmed Clostridium
difﬁcile Associated Disease (CDAD). The new guidelines, restricting
the use of CEP and FQ, were then introduced. Several prescribing audits
conﬁrmed that changes in antibiotic prescribing habits had been effected.
In the follow-up audit, 51 patients were screened. Of these only 3 were
found to be positive for MRSA in 1 or more sites. In this audit, no
patients developed CDAD. There is a considerable shift in the MRSA
rates between 2007 and 2008 audits (20.8% and 5.9%; P = 0.028). A
similar shift is also seen in the CDAD rates (10.4% and 0.0%; P = 0.018).
Conclusion: The linkage of CDAD and MRSA colonisation rates
provides further evidence that they share similar risk factors (including
overuse of CEP and FQ). It is well-established that antibiotic stewardship
can inﬂuence the rates of CDAD and of MRSA bacteraemia and severe
disease. This study shows that it can also inﬂuence the rate of MRSA
colonisation on EC wards. As most health-care associated infections
(HCAI) are associated with misuse of antibiotics, it is not surprising
that this study also showed reduction in CDAD. Rates of other HCAI
(such as multi-resistant Gram-negative organisms) may also be reduced
at the same time.
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P987 Risk factors for MRSA carriage at admission to
rehabilitation centres
Y. Lerman, W. Naamana, J. Vidal Samso, J. Fierro Banzo, R. Formisano,
A. Salvia, A. Rossini, M.P. Balice, J. Salomon, C. Lawrence, J. Lasley,
J. Hart, M. Paul, E. Isakov, S. Lidji, M. Hochman, M. Kazma, A. Klein,
H. Mishali, Y. Carmeli ° on behalf of the MOSAR WP-5
Background: Identiﬁcation of MRSA carriers upon admission to
rehabilitation center may be important in order to install preventive
measures. We aimed to investigate the prevalence and predictors of
MRSA carriage in this setting.
Methods: A multicenter European study on prevention of spread of
resistance is conducted as part of MOSAR in 8 rehabilitation wards. A
prospective case–control study performed between Oct 08 and September
09. 742 patients to were screened for nasal carriage of MRSA on
admission to the study wards. Swabs were plated on BBLII CHROMagar
plates, and suspected colonies which were coagulase positive were
identiﬁed as MRSA. Demographic and clinical data were collected from
patient’s records. Risk factor univariate and multivariate analysis were
performed using SPSS software.
Results: 742 patients (age 72, 44.5% male) were screened, 64 (8.6%)
were found as MRSA carriers. Carriage varied between the centers
(7.4%-14.6%), MRSA positive cases where compared to MRSA negative
controls: cases were more frequently younger than 65 (38% vs. 26%),
female sex (74% vs. 58%), admitted after >2 weeks acute care hospital
stay (58% vs. 40%), admitted with an infection or colonization (30%
vs. 19%), admitted after staying in other long term care facility (30%
vs. 13%), had peripheral vascular disease (16% vs. 6%), and had been
treated with BL/BLI antibiotic (18% vs. 6%) or antibiotics classiﬁed as
other (32% vs. 15%( in the past month. Multivariate model identiﬁed
the following independent predictors for MRSA carriage; female sex
(p< 0.001); admitted after staying in other long term care facility
(p = 0.003), BL/BLI antibiotic treatment (p = 0.008); treatment with
antibiotics classiﬁed as “Other” (p = 0.017).
Conclusions: MRSA carriage on admission to rehabilitation center was
found commonly, but prevalence varied widely. Predictors identiﬁed in
this study are not speciﬁc enough to direct infection control measures.
Acknowledgement: supported by the European commission grant (FP6):
European Network for Mastering Hospital Antimicrobial Resistance and
its Spread into the Community (MOSAR; LSHPCT- 2007-037941).
P988 Prevalence and risk factors of methicillin-resistant
Staphylococcus aureus colonization among residents living
in long-term care facilities
J.A. Garcı´a-Garcı´a °, J. Santos-Morano, J.E. Corzo-Delgado,
M.L. Martı´n-Ponce, L.M. Martı´n-Rodrı´guez, S. Vergara-Lo´pez,
C. Castro, A. Mateos-Go´mez, E. Bayoll-Serradilla, F. Duarte-Sa´nchez,
E. Leo´n-Jime´nez, J. de la Cueva-Rubio, J.M. Go´mez-Mateos (Seville,
Osuna, ES)
Background: Methicillin-resistant Staphylococcus aureus (MRSA)
asymptomatic colonization predominantly affect individuals with co-
morbidity or other speciﬁc risk factors, such as prolonged hospital stay
and long-term care facilities. However, there is scarce information about
risk factors associated with MRSA colonization in these centers.
Objective: The objective of our study was to determine the prevalence
and factors associated with MRSA nasal colonization among subjects
living in long-term care facilities in southern Spain.
Patients and Methods: During the period from 31st March to 31st
October 2009, all subjects living in ten long-term care facilities of our
area were included in a cross-sectional study. Patients were screened
using nasal swabs. Residents were classiﬁed as nasal MRSA carriers,
methicillin-susceptible S. aureus carriers and non-carriers. The following
data were obtained for all residents: age, sex, time of living in residence,
number of residents, comorbidities (Charlson index), functional status
(Barthel index), previous antibiotic treatment in the last month, prior
MRSA isolation, presence of decubitus ulcers, use of invasive devices
and invasive procedures (surgery, endoscopies) in the last year. Data were
analyzed using SPSS version 15.
Results: Three hundred and seventy-two subjects were included. Male
sex were 136 (37%). The median (Q1-Q3) age of our population was
81 (75−86) years. The median (Q1-Q3) time of living in residence
was 20 (10−35) months. Barthel index lower than 40 occurred in 228
(62%). Thirty-one (8%) subjects were taken antibiotic treatment in the
last month. The prevalence of S. aureus and MRSA nasal colonization
was 24% and 12%, respectively. Signiﬁcant risk factors, identiﬁed by
multivariate analysis, were recent antibiotic use (p = 0.027), long time
of living in a long-term care facility (p = 0.019) and recent invasive
procedure (p = 0.014).
Conclusions: The prevalence of MRSA nasal colonization in the long
term care facilities of our area is high. In these centers, subjects under
recent antibiotic use, long time of living in the residence and recent
contact with hospitals are more susceptibility to be colonized.
P989 Cost analysis of rapid diagnostic testing of methicillin-
resistant Staphylococcus aureus in ICUs in a low endemic
setting
M.W. Wassenberg °, A. Troelstra, J. Kluytmans, M. Bonten on behalf
of the Dutch Rapid MRSA Diagnostics Study Group
Objectives: Pre-emptive isolation of high risk patients is a cornerstone
of the Dutch MRSA control strategy. However, most high risk patients
are not colonized and remain in isolation for 3 to 5 days awaiting
conventional culture results. We determined cost-efﬁcacy of adding rapid
diagnostic testing to the current MRSA control policy in intensive care
units (ICUs).
Methods: A prospective multi-center study was performed in 12
Dutch hospitals between 12/05 and 06/08. Patients at risk of MRSA
colonization and fulﬁlling the criteria for pre-emptive isolation according
to Dutch guidelines were eligible. In addition to the standard set of
conventional broth-enriched cultures, BD GeneOhmTM MRSA PCR
(‘IDI’) (BD Diagnostics) or the Xpert MRSA assay (‘GeneXpert’)
(Cepheid) was performed directly on patient material. Costs of IDI
and GeneXpert PCR were €56.22 and €69.62 per test, respectively.
Conventional culture results were used as reference to determine
sensitivity (Sens), speciﬁcity (Spec), and positive/negative predictive
values (PPV/NPV).
Results: 170 ICU patients (mean 52 years and 58% male) were enrolled.
89 (52%) using IDI and 81 (48%) using GeneXpert PCR, yielding 519
IDI PCRs and 288 GeneXpert PCRs (4.7 per patient including nose,
throat, perineum; with GeneXpert four or more sites were pooled).
MRSA prevalence was 2.9% and important risk categories were contact
screening related to MRSA positive patients 1.0% (1/97), hospitalization
abroad 2.0% (1/51) and contact with pigs 27.3% (3/11). Compared to the
reference Spec and NPV of IDI PCR (no MRSA positive patients) was
93.3% and 100%, and Sens, Spec, PPV and NPV of GeneXpert PCR
were 100%, 96.1%, 62.5% and 100%, respectively. In 105 (62%) patients
pre-emptive isolation was discontinued upon negative PCR results (study
protocol did not permit discontinuation of isolation in all hospitals).
Median time between start of isolation and discontinuation of isolation
in these patients (TOT) was 24.5 hours (27.6 and 22.1 hours for IDI
and GeneXpert PCR, respectively). Median time between start of pre-
emptive isolation and notiﬁcation of culture results was 91.9 hours.
Average screening costs per patient were €327.84 and €247.54 for IDI
and GeneXpert, respectively.
Conclusion: In a low endemicity setting, guiding of pre-emptive
isolation upon MRSA PCR on ICUs is safe and reduces pre-emptive
isolation time to 24.5 hours at the costs of €247.54 (GeneXpert PCR)
or €327.84 (IDI PCR) per patient screened.
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P990 Staphylococcus aureus reservoirs and transmission routes in
a neonatal intensive care unit: healthcare workers, mothers’
nipples and clinical folders
M. Aires-de-Sousa °, T. Conceic¸a˜o, M. Miragaia, E. Paulino,
R. Barroso, M.J. Brito, L. Sancho, T. Sardinha, H. Carreiro, G. de
Sousa, M.C. Machado, H. de Lencastre (Oeiras, Amadora, PT)
Objectives: Staphylococcus aureus is a major human pathogen
associated with a high mortality rate in neonatal intensive care units
(NICU). The aim of the present study was to identify reservoirs and
routes of transmission of S. aureus isolates responsible for infection in
the NICU of Hospital Fernando da Fonseca, a large (670 beds) tertiary
hospital located in the suburbs of Lisbon, Portugal.
Methods: Between July 2005 and December 2007, the presence of
S. aureus was evaluated in all infection episodes that occurred in the
NICU. Samples were recovered from the infected babies (hemoculture,
catheters, umbilical and intestinal exudates and urine), from nasal swabs
of the parents and health care workers (HCW) that had contact with
the babies, from the mothers’ nipples in case of breast feeding, and
from the environment of the NICU. All isolates were tested for the
presence of mecA and virulence determinants including the Panton-
Valentine leukocidin (PVL), staphylococcal leukotoxins LukM and
LukE/D, staphylococcal exfoliative toxins A, B and D, hemolysins g,
g-variant and b, staphylococcal enterotoxins A-E, G-J, L and P, and
the toxic shock syndrome toxin-1. Moreover, isolates were characterized
by pulsed-ﬁeld gel electrophoresis, spa typing, and multilocus sequence
typing.
Results: During the study period, 12 infection episodes occurred in this
NICU from which 54 S. aureus isolates were recovered. The molecular
characterization of the isolates revealed that the majority (70%, n = 38)
belonged to three main clones recovered during unrelated episodes:
PFGE type A, spa type t1228, ST5 (17 isolates); PFGE type B, spa
type t012, ST30 (12 isolates), and PFGE type C, spa type t922, ST1 (9
isolates). None of the isolates was resistant to methicillin nor carried
the PVL genes. However, leukotoxin LukE-LukD and hemolysin g-
variant were detected in all isolates other than clones B and J. The
transmission routes could be identiﬁed in three episodes and involved:
(i) one baby and three HCW; (ii) one baby and one HCW; (iii) a baby
and the mother’s nipples. Strains responsible for infection were detected
in unrelated episodes among different HCW and on a clinical folder.
Conclusions: Clonal types A, B and C are endemic in this unit. HCW,
clinical folders and the mothers’ nipples were identiﬁed as possible
reservoirs and vehicles of dissemination of S. aureus strains. Additional
infection control measures are warranted in this NICU.
P991 Bacteria, bacteria, everywhere: the role of gloves,
handwashing and environment in a microbiology laboratory
L. Ng, S. Tng, S.K. Ng, L.C. Eng, B.C. Ng, S. Chan, T.Y. Tan °
(Singapore, SG)
Objectives: This study was performed in a microbiology laboratory
to: (a) investigate the effect of glove usage on hand contamination (b)
document the effectiveness of hand hygiene (c) document the extent of
bacterial contamination on commonly used laboratory surfaces and (d)
differentiate contamination by commensal bacteria and potential bacterial
pathogens.
Methods: Bacterial culture was performed from the hands of 12
laboratory technologists prior to commencing work, after working with
bacterial cultures for 2.5 hours, and after standard handwashing. Staff
were divided into two groups: those who used gloves routinely during
work, and those who did not. Commonly touched surfaces in the
laboratory were also sampled by swabbing a deﬁned surface area.
Bacterial culture was performed semi-quantitatively on chromogenic agar
for presumptive identiﬁcation of methicillin-resistant Staphylococcus
aureus (MRSA), Salmonella spp., Enterobacteriaceae and Pseudomonas
aeruginosa. Total viable counts were performed on non-selective blood
agar plates. MRSA and P. aeruginosa were conﬁrmed by standard
laboratory methods.
Results: Technologists working without gloves had a signiﬁcantly
increased risk of hand contamination with MRSA (risk ratio 15.3), but
not with Enterobacteriaceae. P. aeruginosa or Salmonella spp. were not
isolated from any hand. Handwashing with chlorhexidine-based solutions
was effective at removing both pathogens and commensal skin bacteria.
Bacterial density was highest on tap handles, followed by telephone
handsets. Of potential pathogens, only MRSA was commonly detected
(highest density on telephone surfaces, followed by computer keyboards).
P. aeruginosa and Enterobacteriaceae were occasionally isolated from
environmental surfaces, but Salmonella spp. was not encountered.
MRSA was detected on 70% of laboratory surfaces sampled.
Conclusions: The use of gloves in microbiology laboratories is
protective against MRSA. MRSA is also the most common potential
pathogen isolated from laboratory surfaces.
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P992 Characterization of a high-level telithromycin-resistant
clinical isolate of Streptococcus pneumoniae collected from
the PROTEKT US surveillance study (years 1−6)
D. Knight °, J. Blackman Northwood, S. Brown, C. Couturier,
I. Morrissey (Fordham, UK; Portland, US; Paris, FR)
Background: PROTEKT US investigated the susceptibility of key
respiratory isolates collected from the USA between 2000 and 2006.
Of the 55729 Streptococcus pneumoniae (SP) from PROTEKT US
years 1−6 only 22 (0.04%) were telithromycin-resistant (TelR). Of these
isolates all except one (PU6080005) had a Tel MIC of 4 or 8mg/L.
PU6080005 had a Tel MIC of 256mg/L and in addition to macrolide
MIC values of 256mg/L the isolate was also resistant to tetracycline
but susceptible to b-lactams and ﬂuoroquinolones.
Methods: The presence of ermB was determined by PCR. Segments of
the L4 & L22 riboprotein genes, the ermB gene and the 4 copies of the
23S rRNA gene were sequenced using previously published methods.
Results: All TelR SP contained ermB with a stop codon at position
28 of their upstream control peptides. In addition, isolate PU6080005
possessed a novel U754A point mutation (E. coli numbering) at all four
alleles of domain II in the 23S rRNA. Riboprotein sequencing showed
wildtype L4 and L22 alleles.
Conclusion: We present the ﬁrst recording of a clinical strain of SP with
a Tel MIC of 256mg/L. The presence of ermB and the truncation of
its upstream control peptide confer low level resistance to telithromycin.
Riboprotein L4 and L22 were of wildtype in consequence we attribute
the very high Tel MIC to a U754A point mutation in domain II of the 23S
RNA at all four alleles never before reported in SP. Indeed it has been
demonstrated in E. coli, that the proximity of hairpin 35 (residues 738–
759) within domain II of 23S rRNA is close to the peptidyl transferase
centre and thus a constituent part of ribosomal function and macrolide
and ketolide binding afﬁnity. The mutation U754A indentiﬁed in E. coli
conferred low level TelR in addition to erythromycin resistance. We
propose that the U754A mutation at all four alleles can cause high level
TelR in SP, although this is extremely rare (1 in 55729).
P993 Prevalence of ﬁrst-step parC mutants with amino acid
alterations at resistance hot spots S79 and D83 among
Streptococcus pneumoniae isolates in Germany
B. Ko¨rber-Irrgang °, A. Ro¨hrig, M. Pletz, M. Kresken (Rheinbach,
Hanover, DE)
Objectives: Resistance (R) of S. pneumoniae (SPN) to ﬂuoroquinolones
(FQ) is mainly associated with mutations in the genes parC and gyrA
encoding for the ParC subunit of topoisomerase IV and the GyrA subunit
of DNA gyrase, respectively. Complete R to anti-pneumococcal FQs such
as levoﬂoxacin (LVX) requires alterations in both enzymes, while single
mutations (ﬁrst-step mutants) are often associated with susceptibility
S270 20th ECCMID, Posters
to LVX. However, a ﬁrst-step mutation increases the likelihood for the
acquisition of a second mutation resulting in complete R. Among ﬁrst-
step mutants, those with an alteration in ParC predominate. The aim of
this study was to evaluate the prevalence of isolates with a ﬁrst step
mutation at the resistance hot spots S79 or D83 in parC among SPN
recovered from outpatients with respiratory tract infections (RTIs).
Methods: 296 isolates consecutively collected in 29 laboratories
between Jan-Apr 2007 were studied. MICs of LVX, ciproﬂoxacin (CIP),
moxiﬂoxacin (MFX) and norﬂoxacin (NOR) were determined by the
broth microdilution method according the standard ISO 20776−1:2006.
EUCAST clinical breakpoints were applied to interpret MICs of LVX,
CIP and MFX. PCR-RFLP analyses were performed to screen the
isolates for mutations at amino acid positions S79 and D83 of parC.
Isolates harbouring mutations at the respective positions were further
analysed by sequencing.
Results: All isolates were susceptible to LVX and MFX, while 18/296
(6.1%) were R to CIP. The peak MIC of NOR was 8mg/L. Isolates
exhibiting NOR MICs of >8mg/L (n = 72) were included in the PCR-
RFLP analyses. RFLP screening indicated that 10/72 isolates harboured a
mutation in parC. In nine isolates only synonymous nucleotide exchanges
at D83 were found. MICs of NOR, CIP, LVX and MFX for these
isolates were 16−32, 2−4, 1−2 and 0.125–0.25mg/L, respectively. One
isolate, with MICs of 64, 4, 2 and 0.25mg/l for NOR, CIP, LVX and
MFX, respectively, had an amino acid exchange at position 79 (serine
to phenylalanine). This resulted in an overall prevalence of ﬁrst-step par
C mutants with exchanges at amino acid positions S79 or D83 of 0.3%
(1/296).
Conclusion: Based on our data, ﬁrst step par C mutants with alterations
at amino acid positions S79 and D83 are rare among SPN isolates
recovered from outpatients with RTIs in Germany. Regular screening
for such mutants, however, is important because they are precursors of
complete FQ-resistant isolates.
P994 Streptococcus pneumoniae invasive isolates of serotypes
19A and 24F after pneumococcal conjugate vaccine
implementation in Italy
M. Del Grosso °, G. Gherardi, R. Camilli, F. D’Ambrosio, M. Monaco,
G. Petrucci, G. Dicuonzo, A. Pantosti (Rome, IT)
Objectives: Introduction of the 7-valent pneumococcal conjugate
vaccine (PCV7) has caused a decrease of pneumococcal infections due
to vaccine serotypes and an increase of infections due to non-vaccine
serotypes. In Italy, in the periods 2001–2003 and 2006-June 2009 an
increased proportion of serotypes 19A (from 3.9 to 12.1%) and 24F
(from 0.23 to 3.2%) has been observed in Streptococcus pneumoniae
isolates from invasive diseases. Aim of this study was to characterize
isolates belonging to serotypes (st) 19A and 24F collected after PCV7
implementation in Italy.
Methods: All invasive S. pneumoniae st19A (79) and st24F isolates
(21), recovered from 2006 to June 2009, were studied. Antibiotic
susceptibilities were determined by Etest. Resistance genes erm(B),
mef(A), mef(E), tet(M), cat, were detected by PCR assay. To deﬁne
clonal groups, the isolates were examined by PFGE and representative
isolates by MLST.
Results: Of the 79 st19A S. pneumoniae isolates, 15 (18.9%) were
penicillin (PEN) non susceptible (PNSSP); 47 (59.5%) were resistant
to erythromycin (ERY), 44 (55.7%) to clindamycin (CLI), 44 (55.7%)
to tetracycline, 1 to chloramphenicol. By PFGE, the large majority
of the 64 PEN susceptible (PSSP) isolates clustered in PFGE type
44, corresponding to the clonal complex (CC) 199, which is related
to the clone Netherlands15B-37. 57.1% of CC199 isolates carried
erm(B) and tet(M). The majority of PNSSP isolates clustered in PFGE
type 2, corresponding to CC63, related to Sweden15A-25. The majority
of CC63 isolates carried erm(B) and tet(M). One PNSSP isolate
carrying erm(B), mef(E) and tet(M), with a unique PFGE proﬁle, was
found to correspond to CC271, related to the multidrug-resistant clone
Taiwan19F-14. Of the 21 st24F isolates, 10 (47.6%) were PNSSP, all
were ERY and CLI resistant and carried erm(B), 7 of which carried also
tet(M). They clustered in the PFGE type 3 corresponding to CC230,
related to the Denmark14−32 clone. Among the PSSP, fully susceptible
to the antibiotics tested, two different PFGE types were observed:
type 1, corresponding to CC156, related to Spain9V-3, and type 84
corresponding to CC72.
Conclusions: In Italy, the increase of st19A and st24F isolates was
mainly due to clonal spread. In both serotypes, PSSP and PNSSP isolates
are associated with different and speciﬁc clones, e.g. CC199 with st19A
PSSP isolates. Studies to deﬁne the resistance elements associated to
these clones are under way.
P995 Worldwide prevalence of macrolide resistance genotypes
among Streptococcus pneumoniae from 2004 to 2008
C. Lascols °, M. Hackel, A. Wierzbowski, D. Hoban, S. Bouchillon,
B. Johnson, J. Johnson, M. Dowzicky (Schaumburg, US; Winnipeg,
CA; Collegeville, US)
Background: S. pneumoniae is a key causative pathogen of community-
acquired respiratory tract infections. The clinical management of these
infections is complicated by the worldwide emergence and spread of
resistance to commonly used antibiotics. Resistance to macrolides in
S. pneumoniae is mediated by two major mechanisms: methylation of the
ribosomal macrolide target site, encoded by ermB or drug efﬂux, encoded
by mefA or mefE. Erm(B) typically confers high-level resistance to
macrolides, lincosamides and streptogramin B, whereas Mef(A) or (E)
confers low-level resistance to macrolides only. The aim of this study
was to determine the prevalence of such mechanisms of resistance in
various geographical regions.
Methods: A total of 648 macrolide-resistant (erythromycin MIC
1mg/L) S. pneumoniae clinical isolates collected through the
Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) from 2004 to
2008 were tested. Detection of genes conferring macrolide resistance
(ermB, mefE and mefA) was performed by multiplex PCR.
Results: Among these 648 isolates, 58.6% were isolated in North
America, 24.7% in Europe, 7.1% in Asia, 6.5% in Latin America, 1.5%
in Africa and 0.8% in Middle East and South Paciﬁc.
Of the 648 isolates studied, 35.2% were ermB-positive, 32.9% were
mefE-positive, 25% were positive for both ermB and mef and 4.5%
were mefA-positive. 2.5% of the isolates were negative for any of these
mechanisms. mefE was the most common gene identiﬁed in North
America (41.6%) while in Europe the most frequent was ermB (67.5%).
A high prevalence of ermB/mefE genes (25%) can be highlighted in
North America.
Conclusions: The worldwide distribution of pneumococcal macrolide
resistance is an important phenomenon because of the diversity of
prevalence by region. A rapid increase in isolates containing both ermB
and mefE has been noted in the last several years in the United States.
Region Macrolide resistance mechanism (number of strains)
ermB mefE mefA ermB+mefE Other Total
North America 84 158 3 126 9 380
Europe 108 17 16 13 6 160
Asia 20 13 − 13 − 46
Latin America 8 20 10 3 1 42
Africa 2 1 − 7 − 10
Middle East 3 2 − − − 5
South Paciﬁc 3 2 − − − 5
Total 228 213 29 162 16 648
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P996 Macrolide resistance mechanisms in serotypes of
Streptococcus pneumoniae
C. Lascols °, M. Hackel, K. Nichol, A. Wierzbowski, D. Hoban,
S. Bouchillon, J. Johnson, M. Dowzicky (Schaumburg, US; Winnipeg,
CA; Collegeville, US)
Background: Streptococcus pneumoniae is an important pathogen that
causes severe life-threatening illnesses in the elderly and children.
Increases in macrolide resistance in S. pneumoniae clinical isolates
have signiﬁcant clinical implications. The most common mechanisms
of macrolide resistance are methylation of the ribosomal target site
(encoded by the ermB gene) and drug efﬂux (encoded by the mefA
or the mefE gene). The aim of this study was to characterize these
mechanisms in various serotypes of S. pneumoniae in order to understand
the relationship between macrolide resistance and capsular serotypes.
Methods: 465 macrolide-resistant (erythromycin MIC 1mg/L) clinical
S. pneumoniae isolates, collected through the Tigecycline Evaluation and
Surveillance Trial (T.E.S.T.), were evaluated. Detection of genes involved
in macrolide resistance (ermB, mefA and mefE) and serotyping were
performed by multiplex-PCR.
Results: 54% of the isolates tested were from North America, 27%
from Europe with the remainder (19%) from other continents. Among
these 465 strains, the most prevalent pneumococcal macrolide resistance
genotypes were mefE/A (42%) and ermB (37%) followed by ermB+mefE
(18%) and then other mechanisms (3%). The most prevalent serogroup
was 19 (34%) and 6 (17%).
Among ermB+mefE-positive isolates, 84% were serogroup 19 while only
21% were serogroup 19 among ermB-positive isolates. Among mefE/A-
positive isolates, only 25% were serogroup 19 and the remaining were
other serotypes. High-level resistance (MLSB phenotype) was associated
with serogroup 19 while lower-level resistance (M phenotype) was
associated with other serotypes.
Conclusions: This study conﬁrms that certain capsular serotypes are
associated with macrolide resistance and conﬁrms also the predominance
of high-level macrolide resistance among serogroup 19. These ﬁndings
emphasize the need for continuous worldwide monitoring of macrolide-
resistance and serotypes among S. pneumoniae.
Serotype Macrolide resistance mechanism (number of strains)
ermB mefE/A ermB+mefE Other Total
19A/F 36 48 71 2 157
6A/B 32 46 1 1 80
Other 105 99 13 11 228
Total 173 193 85 14 465
P997 Genetic elements carrying either mef(E) or erm(B)+mef(E)
genes within pre-PCV-7 non-invasive Spanish Streptococcus
pneumoniae isolates belonging to PCV-7 serotypes
E. Gomez °, T.M. Coque, F. Baquero, R. Canton (Madrid, ES)
Objectives: After the introduction of the heptavalent conjugate vaccine
(PCV-7), serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F
and 23F) have decreased worldwide. In Spain, macrolide resistance
was maintained high after PCV7. To explain this, clonality and genetic
elements carrying mef(E) or erm(B)+mef(E) genes within pre-PCV-7
isolates belonging to these serotypes were studied.
Methods: 28 S. pneumoniae isolates belonging to serotypes 6B(n = 8),
9V(n = 3), 14(n = 10), 19F(n = 5) and 23F(n = 2) carrying mef (n = 11) or
erm(B)+mef(E) (cMLSB phenotype, n = 15 and iMLSB, n = 2) recovered
from 1999 to 2003 were studied. Population structure was analyzed by
MLST. Antibiotic susceptibility was determined by microdilution and
interpreted with EUCAST criteria. Genetic elements associated with
macrolide resistance were determined by screening of sequences related
to MEGA, MAS (Macrolide-Aminoglycoside-Streptothricin), Tn917
and Tn916 derivatives (intTn916, xisTn916, tnpATn917, tnpRTn917,
tetM, sat4, aphA-3) by multiplex PCR. Linkage among sequences was
established by overlapping PCR based on known platforms (Tn6003,
Tn6002, Tn3872) and sequencing.
Results: Isolates carrying mef genes were grouped in the Spain9V-3
clonal complex (n = 8) and 3 singleton clones (n = 3). Resistance rates
for penicillin, cefotaxime and tetracycline were 91% (10/11), 45% (5/11)
and 27% (3/11) respectively. All contained the MEGA element, except
one that harboured the mef(A) gene. intTn916, xisTn916, and tetM genes
were found in 3 isolates. No linkage between MEGA and Tn916 was
detected. Isolates containing erm(B)+mef(E) genes were grouped in 2
clonal complexes (n = 6) and 8 singleton clones (n = 11). Resistance rate
for penicillin was 88% (15/17), cefotaxime 41% (7/17) and tetracycline
88% (15/17). intTn916, xisTn916, and tetM genes as well as the MEGA
element were detected in 100% of the isolates. Sequencing of different
modules of Tn916 including an insertion of 13,000bp fragment in the
orf19-orf20 region (partial sequence compatible with a related MAS
element) indicates the presence of a Tn916 derivative similar to Tn6002-
Tn6003. They also contained MEGA not linked to Tn916.
Conclusions: The association of different transposable elements carrying
macrolide resistance genes and a polyclonal structure within pre-
PCV-7 non-invasive Spanish S. pneumoniae isolates belonging to PCV-7
serotypes might have contributed to the high macrolide resistance rates
in our country after the PCV-7 introduction.
P998 Molecular identiﬁcation of macrolide-resistant Streptococcus
pyogenes clones in central Greece
E. Tatsidou, E. Malli, A. Damani °, K. Pantelidi, E. Drougka,
I. Spiliopoulou, E. Petinaki (Larissa, Patra, GR)
Objectives: To investigate possible changes of the percentage and the
type of macrolide resistance among Streptococcus pyogenes in Central
Greece during a three year period.
Methods: A total of 495 S. pyogenes collected from clinical specimens
during 2006–2008 were tested for their resistance to macrolide by disk
diffusion method in combination with DD test. The ermA (TR), ermB
and mef genes were detected by PCR. In addition, all macrolide-resistant
isolates were characterized by multi-locus sequencing typing (MLST).
Results: The percentage of macrolide-resistant isolates was 24% and
remained stable during the studied period. Among the resistant strains,
17% expressed the M phenotype and 83% expressed the MLS(B)
phenotype. All strains of MLS(B) phenotype carried the ermA(TR)
gene, while the expression of M phenotype was correlated with the
presence of mef gene. Two major clones were identiﬁed among M
isolates, characterized as sequence types ST39 and ST28, whereas clones
ST39, ST63, ST550 and ST89 dominated among MLS(B) isolates.
Conclusions: Although the overall percentage of macrolide-resistant
S. pyogenes strains in Central Greece has increased since 2001 (19.5%),
an inversion in the dominant phenotypes has been identiﬁed, with an
increase in the MLS(B) phenotype combined with a decrease of the M
phenotype, that predominated until 2005 in our area. The presence of
ST39 and ST28 clones has been reported previously in other European
countries, suggesting a Europe-wide dissemination of few macrolide-
resistant lineages.
P999 Molecular epidemiology of macrolide- and telithromycin-
resistant group A Streptococcus and correlation with
antibiotic use in Belgium
L. Van Heirstraeten °, J. Vervoort, C. Lammens, S. Coenen, N. Hens,
M. De Falleur, H. Goossens, S. Malhotra-Kumar (Wilrijk, Brussels, BE)
Objectives: We assessed the evolution of macrolide-(MAC-R) and
telithromycin-resistant (TEL-R) Group A Streptococcus (GAS) during
2004–2008 and also examined the link between resistance and use of
macrolides, lincosamides, and streptogramins (MLS) in Belgium.
Methods: A total of 6673 conﬁrmed GAS isolates recovered from
tonsillopharyngitis patients in Belgium during 2004–2008 were pheno-
typed for macrolide resistance based on double disc diffusion and MICs
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to erythromycin, clindamycin, and telithromycin. MAC-R GAS were
classiﬁed into known phenotypes (constitutive, cMLS; inducible, iMLS;
and efﬂux, M). MAC-R genes (erm(A), erm(B), mef(A)) were detected
by PCR. Resistant GAS negative for MAC-R genes were analyzed
by sequencing L4, L22 and 23S rRNA genes. Emm typing was done
by PCR-sequencing. MLS use data for 2003–2008, collected by the
Belgian Institute of Health and Disability Insurance (WHO ATC DDD,
2009), was correlated to TEL-R GAS data for 2004–2008 utilizing linear
regression.
Results: Overall, 298 (4.5%) MAC-R and 87 (1.3%) TEL-R GAS (TEL
MIC 4mg/ml) were identiﬁed during 2004–2008 (Table). Prevalence
of MAC-R GAS decreased signiﬁcantly from 2004 to 2005 (c2 test;
P< 0.01) and remained steadily low for the next 3 years (P 0.29).
Prevalence of TEL-R GAS was low during all 5 years. cMLS phenotype
was identiﬁed in 159 (53.4%), M phenotype in 92 (30.9%) and iMLS
phenotype in 47 (15.8%) MAC-R GAS. Majority of the 298 MAC-R
isolates carried erm(B) (170, 57.1%), followed by mef(A) (96, 32.2%),
and erm(A) (30, 10.1%). Five (1.7%) MAC-R GAS did not show
presence of MAC-R genes; 2 harboured the A2059G mutation. TEL-R
GAS (TEL MICs 4−32 mg/ml) generally harboured erm(B) alone or with
mef(A). One TEL-R isolate each harboured mef(A) and a constitutively
expressed erm(A) gene. MAC-R GAS were distributed into 8 major emm
types (emm11, 26.2%; emm28, 19.5%; emm12, 15.8%; emm4, 9.7%;
emm77, 6.0%; emm1, 3.7%; emm75, 3.0%; emm89, 3.0%). TEL-R
GAS predominantly belonged to 3 emm types (emm11, 48.3%; emm28,
18.4%; emm12, 9.2%). MLS use declined from 2003 to 2004 and
remained at lower levels till 2008 (Table). Use of a million DDDs of
MLS in the preceding year was associated with a 0.82% (95%CI, 0.05–
1.59; P = 0.042) increase in TEL-R GAS.
Conclusions: Prevalence of MAC-R GAS decreased in Belgium during
2004–2008. TEL-R GAS were restricted to a few emm types. An overall
decline in MLS use seems to be a factor in sustaining low levels of
TEL-R GAS in Belgium.
Table. Yearly prevalence of macrolide- and telithromycin-resistant
Group A Streptococcus during 2004–2008 and consumption of
macrolides, lincosamides, and streptogramins (MLS) during 2003–2008
in Belgium
Year No. of GAS isolates Proportions of MAC-R phenotypes MLS (J01F) use*
Screened MAC-R
(%)
TEL-R
(%)
cMLS iMLS M
2003 − − − − − − 11.2
2004 1553 114 (7.3%) 38 (2.5%) 72 (63.2%) 4 (3.5%) 38 (33.3%) 8.8
2005 1439 64 (4.4%) 3 (0.2%) 33 (51.6%) 7 (10.9%) 24 (37.5%) 9.5
2006 1603 53 (3.3%) 22 (1.4%) 24 (45.3%) 14 (26.4%) 15 (28.3%) 9.4
2007 1175 35 (3.0%) 15 (1.3%) 21 (60.0%) 6 (17.1%) 8 (22.9%) 10.0
2008 903 32 (3.5%) 9 (1.0%) 9 (28.1%) 16 (50.0%) 7 (21.9%) 10.8
*MLS (J01F) use da a expressed in million DDDs.
P1000 Erythromycin-resistance decrease in group A streptococci
from acute pharyngitis attributable to change of emm
distribution over a 7-year period
S. Kim °, E. Koh, I. Bae, N.Y. Lee, H. Jung (Jinju, Seoul, Masan, KR)
Objectives: Group A Streptococci (GAS) are the major pathogens
associated with bacterial pharyngitis in children. With the increasing
resistance of GAS to macrolides in some countries (including Korea),
the erythromycin (EM) resistance rates and emm genotypes of GAS were
compared by study period.
Method: Throat cultures were taken from 499 patients with acute
pharyngitis (two years to 18 years old) at three pediatric clinics in
Jinju, Korea from September, 2008 to February, 2009. A total of 174
strains of GAS were isolated and antimicrobial susceptibility testing was
performed using the disk diffusion method. The phenotypes of macrolide
resistance were evaluated, and the frequency of ermB and mefA genes
was determined by PCR. The emm genotype was identiﬁed with PCR
and sequencing.
Results: The resistance rates of GAS to EM, clindamycin and
tetracycline were 4.6%, 2.9% and 2.3%, respectively. Constitutive
resistance with the ermB gene was 62.5%, whereas M phenotype with
the mefA gene was 37.5%. The emm4 was most frequent (28.2%) and
emm89 (20.1%) was next common.
Conclusion: The EM resistance rate of GAS isolated from acute
pharyngitis in 2009 was 4.6% which was dramatically decreased from
44.8% in 2002. The emm4 was most frequent (28.2%) and most of EM
resistant strains were emm28. A signiﬁcant decrease of emm12 strains
(3.4%) among total isolates also may have contributed to a rapid decrease
of EM resistance compared to 2002.
P1001 Assessment of macrolide and tetracycline resistance
phenotypes/genotypes among streptococci isolates from
bovine subclinical mastitis
M. Rato °, R. Bexiga, S.F. Nunes, L. Cavaco, C.L. Vilela, I. Santos-
Sanches (Caparica, Lisbon, PT; Cambridge, UK; Copenhagen, DK)
Objectives: To identify macrolide/tetracycline phenotypes and genotypes
among streptococcal species from bovine subclinical mastitis, valued in
therapeutic policies and to evaluate the routes of gene dissemination.
Methods: A total of 32 Streptococcus agalactiae (Group B Streptococ-
cus-GBS), 18 S. dysgalactiae subsp. dysgalactiae (Group C Streptococ-
cus-GCS) and 30 S. uberis, from 11 farms, were included in the study.
Resistance to penicillin-P, ampicillin-AMP, erythromycin-E, pirlimycin-
PRL, tetracycline-T, and the constitutive macrolide-lincosamide resis-
tance phenotype (cMLS) was evaluated by disk diffusion. Resistance
genes (mefA/ermA/ermB/linB/tetM/tetO/tetT/tetS/tetQ/tetK/tetW/tetL)
were PCR screened. Clonality was assessed by 80% similarity in
dendrograms (BioNumerics v. 4.0 software, Applied Maths) using SmaI-
pulsed ﬁeld gel electrophoresis (PFGE) patterns. Cfr9I digestion was
used in one SmaI-resistant GCS isolate. Presence of the composite
transposon Tn1207.3/phi10394.4 encoding a methyltransferase responsi-
ble for nontypeability using SmaI, was PCR tested in all GCS isolates.
This element is carried by the human pathogen S. pyogenes (Group A
Streptococcus-GAS).
Results: Co-resistance to macrolides-E and lincosamides-PRL (18−27%)
and T-resistance (60–100%) was observed in all species. Resistance
to PRL and susceptibility to E (LSA phenotype) was found in GCS
and S. uberis. Diverse genotypes were found: ermB/tetO/tetK in GBS;
ermB/tetO or linB/tetM in GCS; ermB/tetO or linB/tetS in S. uberis.
A total of three PFGE clusters comprised 72% of the GBS and four
PFGE clusters comprised 53% of the S. uberis and all were found
to be herd-speciﬁc. Among four PFGE clusters comprising 56% of
the GCS, three included strains from different farms. Ampliﬁcation of
Tn1207.3/phi10394.4 left junction showed an amplicon size different
from what’s described for GAS and no ampliﬁcation of the right junction
was observed.
Conclusions: Decreased susceptibility to P and AMP was noted
in all species, in contrast to other studies. Ampliﬁcation of
Tn1207.3/phi10394.4 left junction (despite variable size) in bovine GCS
suggests that this mobile element may be inserted in the comEC locus
as mapped for GAS. The linB gene, known to be carried by a large
conjugative plasmid was found in S. uberis and GCS indicating a possible
horizontal gene transfer event. The putative linkage of several erm/tet
genes in unique strains and clones suggests vertical and horizontal gene
dissemination.
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P1002 Molecular characterization of levoﬂoxacin resistance in
Streptococcus dysgalactiae ssp. equisimilis isolates from
Portugal
M.D. Pinho °, M. Ramirez, J. Melo-Cristino on behalf of the Portuguese
study group for streptococcal infections
Objectives: A very high proportion of S. dysgalactiae subsp. equisimilis
levoﬂoxacin resistant isolates (12.1%) was found among a collection of
b-haemolytic group C and G streptococci from Portugal (n = 315). To
gain further insights into the resistance mechanisms involved and the
clonal structure of the resistant population, we undertook molecular
characterization and evaluated the occurrence of recombination with
Streptococcus pyogenes (GAS) DNA.
Methods: Antimicrobial susceptibility testing was determined by
disk diffusion and MIC testing was done for all the levoﬂoxacin
nonsusceptible isolates. Pulsed-ﬁeld gel electrophoresis (PFGE) and
emm typing were used to characterize the population. Sequence analysis
of the quinolone-resistance determining region (QRDR) of gyrA and
parC was carried out in 56 S. dysgalactiae subsp. equisimilis isolates,
including representatives of the resistant, intermediate and susceptible
populations. Phylogenetic and recombination analysis were performed
with MEGA 4 and RDP3 software, respectively.
Results: A total of 38 isolates were resistant to levoﬂoxacin (MIC range,
6 to >32 ug/mL), and 4 expressed intermediate resistance (MIC range,
3 to 4 ug/mL). Among resistant isolates, 11 distinct emm types were
found distributed in 9 PFGE clusters that overlapped with the main
clusters detected in the population. The emm types stG166b (n = 12) and
stG6792 (n = 8) accounted for more than half of resistant isolates. Most
resistant isolates were found dispersed in the population but stG166b
was distributed in two main clusters, one comprising only levoﬂoxacin
resistant isolates and the other only susceptible ones. Mutations in
both gyrA and parC QRDR were necessary for high level resistance
to levoﬂoxacin while single mutations in each gene resulted in slightly
increased MICs. A much greater diversity was found among parC alleles
than among gyrA. Evidence for recombination with GAS was found in
some parC alleles of both resistant and susceptible isolates.
Conclusion: Levoﬂoxacin resistance had a polyclonal origin, with
resistance emerging among most susceptible clones. Our data supports
the existence of a common reservoir of genes conferring quinolone
resistance shared between S. dysgalactiae subsp. equisimilis and GAS.
The ocurrence of recombination with foreign DNA is not strictly
associated with resistance in S. dysgalactiae subsp. equisimilis.
P1003 Distribution of serotypes, antimicrobial resistance and
virulence-related genes among group B streptococci of
vaginal origin isolated in Romania
M. Straut °, S. Cretoiu, V. Ungureanu, A.M. Petrini, R. Georgescu,
L. Grigore, C.R. Usein (Bucuresti, RO)
Objectives: The ﬁrst regional surveillance of group B streptococci
(GBS) of vaginal origin isolated from healthy women has been organized
within a national research project. The aim of this prospective study is
to characterise GBS isolates using phenotypic and molecular methods.
Methods: Ninety-six GBS vaginal isolates were examined by phenotypic
and genotypic techniques. All isolates were characterized by latex
agglutination serotyping, susceptibility to antimicrobial agents and,
when appropriate, tetracycline resistance genes (tetM, tetO), tetM gene
association with conjugative elements of the Tn916 family, macrolide
resistance phenotypes and genes (ermA, ermB, mefA) were searched.
Molecular typing included capsular type assigning by multiplex PCR
assay and PCR screening for ﬁve major surface protein antigen genes.
Clonal relationships among epidemiologically unrelated isolates were
established by PFGE analysis of SmaI macrorestriction patterns.
Results: The isolates studied were fully susceptible to penicillin,
ampicillin, and cefuroxime, but the rate of tetracycline resistance was
high, accounting for 95% of them. tetM was the most prevalent gene.
tetO gene was detected in association with tetM in 7 resistant strains.
The int-Tn gene, encoding the integrase of Tn916, was found in 75%
of the strains harbouring tetM. Twenty percent of the strains studied
exhibited decreased susceptibility to macrolide and were positive for
ermB, constitutive MLS being the dominant phenotype. The isolates
belonged to every serotype from Ia, Ib to V and no non-typeable cases
were encountered. Serotypes III and II have been the most prevalent,
conﬁrming previous ﬁndings. The presence of one of the following
surface protein genes encoding A-C, Alp1, Rib, Alp2/3, and Alp4 protein
was documented in all the isolates tested. The association of serotypes
III and II with Rib protein encoding gene, and of serotype V with AC
was found.
Conclusion: Although testing for GBS carriage is mandatory during
pregnancy, the laboratory data regarding characteristics of GBS
circulating strains among Romanian women population is scarce. This
report is the ﬁrst molecular approach in characterisation of native GBS
isolates. Our results may provide useful additional information regarding
the reservoir of strains for a better understanding of the epidemiology
of GBS infections in Romania.
P1004 Diversity of CTn6000 among enterococci from different
ecological niches
C. Novais °, A. Freitas, F. Baquero, L. Peixe, A.P. Roberts, T.M. Coque
(Porto, PT; Madrid, ES; London, UK)
Objectives: Conjugative transposons (CTn) have contributed to the
spread of tetracycline resistance by encoding tetM (Tn916, Tn5397,
Tn5801) and less frequently, tetS (Tn6000, Tn916S). CTn6000 (formerly
EfcTn1) was initially identiﬁed in an Enterococcus casseliﬂavus strain
from a primate (J. Bacteriol 2006;188:4356) but it seems to be spread
among enterococcal species from different ecological niches (19th
ECCMID; P947). The presence and diversity of Tn6000 was analyzed
among tetracycline resistant enterococci from diverse origins.
Methods: Preliminary detection of CTn6000 was carried out by
screening for the presence of integrase (intCTn6000) and excision-
ase (xisCTn6000) genes among enterococci from animals (n = 164),
healthy/hospitalized human (n = 227) and environment (n = 126) (1996–
2008) by PCR and sequencing. Further analysis of CTn6000 backbone
was accomplished by long-PCR mapping based on the 33kb CTn6000
sequence (A.P. Roberts, unpublished). Amplicons were digested
(TaqI/AluI/EcoRI/DdeI) and representatives of different restriction
proﬁles were sequenced. Analysis of the chromosomal insertion site of
CTn6000 and mating assays were carried out as previously described.
Clonal relationship among strains was evaluated by PFGE and MLST.
Results: CTn6000 was found in 2% of human (n = 5/227) and
environmental (n = 3/126) isolates each. They include 5 E. faecalis (4
healthy humans faeces, ST55), 2 E. faecium (environmental farm sample
and human drinking water-ST32, CC22) and 1 Enterococcus spp (farm
waste lagoon). Two CTn6000 variants designated as types B and C
were identiﬁed. They differ from the original backbone (type A) by the
absence of a group II intron inserted in orf14 (CTn6000 type C) and the
presence of ISEfm2 in the intergenic region of orf13tetS (CTn6000-B).
All variants were inserted within the gene coding a L31 ribosomal
protein. Transfer of CTn6000 was only achieved for the CTn6000-A
carrying strain.
Conclusion: CTn6000 is a site-speciﬁc integrative element widely
disseminated among different enterococcal species from community
origin. The diversity of backbones identiﬁed in this highly modular
platform (CTn6000 contains sequences from mobile elements of
different Gram-positive bacteria) highlights the plasticity of CTns and
the interactions of bacteria from these ecological niches.
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Vancomycin-resistant enterococci (VRE)
P1005 Risk factors for the acquisition of VRE in a German
university hospital
A. Kola °, I. Hoffmann, D. Sohr, I. Chaberny, S. Suerbaum,
P. Gastmeier (Berlin, Hanover, DE)
Objective: To analyse an increase of vancomycin-resistant E. faecium
(VREfm) at Hanover Medical School (MHH), a 1 400 bed university
hospital with 40 000 admitted patients per year. The proportion of
VREfm rose from 1.2% in 2004 to 20.5% in 2006.
Methods: Genotyping of VREfm was performed by pulsed ﬁeld gel
elecrophoresis (PFGE): SmaI-restriction proﬁles yielding a similarity
of >80% using the Dice coefﬁcient (<4 different fragments) were
considered as clonally related. Typing results and conventional epidemi-
ology were applied for transmission analysis. For risk factor analysis, a
case–control study was carried out: Cases were inpatients with VREfm
acquisition from January 2005 through December 2006, controls patients
with vancomycin-susceptible E. faecium. Case and control patients were
matched 1:1 on date and site of isolation.
Results: PFGE was performed on 171 isolates of 166 patients
hospitalized on 30 wards and revealed 57 different genotypes (36 unique
and 21 in clusters of 2–31 isolates belonging to the same type). Sixty-
one patients (37%) with VREfm were in the general surgery unit and
38 patients (23%) in the haematological oncology unit. In these units,
30% of VREfm were due to patient-to-patient transmissions. Multivariate
logistic regression analysis of 142 cases and 142 controls identiﬁed the
presence of neutropenic days (OR 7.7, CI95 1.5–39.8, p< 0.05) and a
hospital admission within the previous 12 months (OR 5.3, CI95 2.5–
11.3, p< 0.05) as risk factors for acquisition of VREfm. Additional
independent risk factors were use of glycopeptides antibiotics (OR 3.7,
CI95 1.6–8.7, p< 0.05), mechanical ventilation (OR 3.4, CI95 1.1–10.1,
p< 0.05) and a history of additional multidrug-resistant organisms (OR
3.4, CI95 1.4–7.9, p< 0.05).
Conclusion: Risk factors like immunosupression, previous hospital-
ization and mechanical ventilation indicate that patients with severe
underlying diseases were mainly affected by VREfm. In these patients,
the use of glycopeptide antibiotics was a main risk factor for VREfm
acquisition. A substantial proportion of VREfm acquisition was due to
transmission.
P1006 Financial burden of nosocomial infections caused by
vancomycin-resistant Enterococcus
E. Ott °, L. Schwadtke, K. Graf, F. Schwab, F. Bange, I. Chaberny
(Hanover, Berlin, DE)
Background: Nosocomial infections due to vancomycin-resistant
Enterococcus (VRE) increased considerably during the last years. The
purpose of this study was to investigate the costs for nosocomial VRE-
infections inside the German DRG-System.
Methods: A case–control study was performed comparing patients with
nosocomial infections caused by VRE and by vancomycin-susceptible
Enterococcus (VSE) between January 2005 and December 2008. 47
nosocomial cases with VRE-infections were matched to 47 controls
with VSE-infections for admission and discharge in the same year,
the minimum length of stay corresponding to time at risk of the case,
Charlson comorbidity-Index ±1, stay on intensive care units (ICU) and
non-intensive-care units as well as for the type of infection, which were
deﬁned using the CDC criteria.
Results: The median overall costs for cases with nosocomial VRE-
infection were signiﬁcant higher than for control patients (€ 57,817 vs.
€ 38,334; p = 0.045). The median attributable costs for VRE-infections
were € 12,979 (p = 0.058). Furthermore, the multivariate analysis showed
that cost were driven by VRE-infection (multiplicative effect (ME) = 1.4;
p< 0.042), ventilation >500 h (ME= 3.3; p< 0.001), and stay on ICU
(ME= 2.4; p = 0.002). In contrast age over 60 years was a predictor for
decreased costs (ME= 0.7; p = 0.034).
Conclusion: This analysis revealed that nosocomial infections due to
VRE are associated with high costs for healthcare systems compared
with VSE-infections. Therefore hospital personal should implement
control measures to prevent the transmission of VRE.
P1007 Characterization of vancomycin-resistant Enterococcus
isolates recovered in a Spanish hospital, 2003–2008
M. Lopez °, E. Cercenado, E. Bouza, F. Ruiz-Larrea, Y. Sa´enz,
C. Torres (Logron˜o, Madrid, ES)
Objective: To study and characterize the resistance phenotype and
genotype, the mechanism of vancomycin resistance and the virulence
genes, in vancomycin-resistant enterococci (VRE) isolated in a Spanish
hospital.
Methods: Fifty VRE were recovered at the Gregorio Maran˜o´n Hospital,
Madrid, during a period of six years (2003–2008) from a total of 10,381
enterococci (0.48%). A species-speciﬁc PCR was used to identify these
isolates. Antimicrobial susceptibility to 11 antibiotics was determined
by disk diffusion and by broth microdilution methods. Vancomycin
resistance genotype was determined by PCR and sequencing of vanA,
vanB, vanC-1, vanC-2/3 and vanD genes. The presence of the resistance
erm(B), tet(M), tet(L), ant(6)-Ia, aac(6′)-aph(2′′), aph(3′)-IIIa, catA
and the virulence esp, hyl genes was determined by PCR. Tn5382
and Tn1546 structures were characterized in vanB and vanA isolates,
respectively.
Results: Twenty two of the VRE isolates were E. faecalis, 13 E. faecium,
13 E. gallinarum, 1 E. avium and 1 Enterococcus spp. The most prevalent
vancomycin genotype was vanB (46%), followed by vanA (28%) and
vanC1 (26%). No vanD gene was detected in our isolates. Almost
all VRE isolates showed a multiresistance phenotype and harboured
different resistance genes (number of isolates): erm(B) (45), tet(M) (37),
tet(L) (31), ant(6)-Ia (28), aac(6′)-aph(2′′) (21), aph(3′)-IIIa (41) y catA
(1). The analysis of the virulence genes esp and hyl showed the following
results (number of isolates): esp and hyl (20), esp (10), hyl (13), none
of these genes (7).
All of the vanB isolates presented the vanB operon included in the
Tn5382 and none of them contained IS150, ISEnfa110 or ISEnfa200
insertion sequences. In six vanB strains the linkage pbp5-Tn5382 was
evidenced. Study of the vanA operon, included in Tn1546, revealed 8
different structures, one of them identical to the prototype (GenBank
accession no. M97297), detected in two isolates, and the remaining
seven, showed different insertion sequences or deletions.
Conclusions: The incidence of VRE was low. Vancomycin-resistance
is more frequent among E. faecium, and the most prevalent genotype is
vanB2. vanA-containing enterococci showed a high variability in Tn1546
structure.
P1008 Diversity of hyl plasmids among international CC17
Enterococcus faecium strains, 1992–2009
A.R. Freitas °, A. Tedim-Pedrosa, C. Novais, L. Peixe, F. Baquero,
T.M. Coque (Porto, PT; Madrid, ES)
Objectives: To analyze the location and diversity of hyl genetic context
among epidemiological relevant Enterococcus faecium (Efm) strains
recovered from hospitalized patients of different countries over the last
two decades.
Methods: We analyzed 145 vancomycin-resistant (VREfm; 125 vanA,
20 vanB) isolates causing documented hospital outbreaks in 23 countries
(1986–2009) and 83 VSEfm [52 ampicillin-resistant (AREfm) and 31
ampicillin-susceptible ASEfm] bloodstream isolates from Spain (Madrid;
1995–2008). Clonality was established by PFGE and MLST. The
hylEfm gene was detected by PCR, sequencing and S1/I-CeuI PFGE
hybridization. Analysis of Hyl plasmids included determination of size
and the detection of relaxases (rel) and rep initiator proteins (rep) by
multiplex PCR typing schemes, designed to identify 100 different Gram-
positive plasmids, hybridization and sequencing.
Results: Hyl was identiﬁed among CC17-VREfm (28/145, 19%,
9STs) recovered from 15 countries (Spain, Portugal, The Netherlands,
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Germany, Poland, Hungary, Serbia, Italy, Greece, USA, Canada, Brazil,
Australia, Tunisia, South Arabia) of 5 continents (1992–2009) and among
CC17-AREfm isolates (17/52, 33%; 6 STs) from Spain (1997–2007).
None of the ASEfm (n = 31; most CC9 and CC22) analyzed contained
hyl. All sequenced hyl genes were identical to genes encoding putative
hyaluronidase proteins from different E. faecium genomes. Hyl was
consistently located on large plasmids ranging from 170 kb to 375 kb.
Although most of them did not contain any of the rep and rel sequences
analyzed, we identiﬁed relpEF1 (n = 15), relpAD1 (n = 2) or both (n = 3)
in some plasmids <300kb. Under antibiotic selection with vancomycin,
some relpEF1-Hyl+ plasmids (n = 4/15) were cotransferred with vanA
plasmids (3 plasmids of 50−60kb) or vanB-CTn (n = 1). van and hyl
genes were not identiﬁed in the same platform in any isolate.
Conclusions: Hyl is located on a diversity of large plasmids recovered
from isolates of different countries since early 90’s. The wide distribution
of these hyl-megaplasmids among VREfm and AREfm belonging to
CC17 might enhance adhesion and invasiveness abilities of CC17 as
suggested (Arias et al. AAC 2009; 53:4240) and thus, to have contributed
to the recent success of this lineage as leading nosocomial pathogen.
The possibility of cotransfer with plasmids encoding resistance to
vancomycin is of concern since it would further facilitate the success
of CC17 in hospitals.
P1009 Plasmid analysis of vancomycin-resistant enterococci
isolates from Portuguese poultry and healthy humans
A.R. Freitas °, C. Novais, A. Cunha, E. Silveira, L. Peixe, T.M. Coque
(Porto, PT; Madrid, ES)
Objectives: Despite growth promoter ban in Europe in 1997,
vancomycin-resistant enterococci (VRE) are still recovered from poultry
(P) and healthy humans (H) in Portugal. We analyzed the genetic
context of VRE strains to better understand the plasmid ecology and
the maintenance of community VRE in this country.
Methods: Fifty vanA enterococci from P carcasses (26 E. faecium
(Efm), 7 Enterococcus spp. (Es), 5 E. hirae (Eh), 4 E. durans (Ed);
1 E. faecalis (Efc); 9 commercial brands) and faecal samples of HV
(7 Efm) were studied. Clonality (PFGE, MLST), conjugation, antibiotic
susceptibility (CLSI) were performed by standard procedures. Plasmid
analysis included determination of size, content and location of vanA
(S1-PFGE, hybridization); comparison of RFLP patterns; and detection
of relaxases (rel), replication proteins (rep) and toxin-antitoxin systems
(speciﬁc PCR typing, sequencing).
Results: We identiﬁed 30 PFGE types: 25 among P (6 within Efm-
CC9 and 1 was Efc-ST16) and 5 among H (2 within Efm-CC17 and
1 singleton) multidrug resistant isolates, some persisting over years.
Eight Tn1546 types, mostly prototype A (30%), were located on large
plasmids (50–165kb). vanA was transferred to Efm GE-1 or 64/3
and Efc JH2−2 recipients (n = 24/50, 48%; 16Efm, 4Eh, 3Es, 1Ed),
frequently associated with resistance to erythromycin (46%) and/or
streptomycin (21%). Plasmids contained rel/rep sequences homologous
to pEF1 (60%/40%), theta replicating pB82/p200B (36%/50%), rolling-
circle-replicating pEFNP1 or pJS42/pRI1 (10%/14%), Inc18 (0%/6%),
pheromone-responsive pAD1 or pAM373 (34%/15%), pHTb/pMG1
(32%/14%) and mosaic as pVEF1/2 (0%/22%) or pRUM (6%/16%);
and the toxin-antitoxin omega-epsilon-zeta system (26%). vanA plasmids
often contained rel-pEF1 and rep-pEF1 although we did not identify any
rel in some cases. Rep-pRUM was conﬁned to plasmids from H. Three
vanA plasmids from P were identiﬁed among isolates of different species,
commercial brands and years i) type A, 60−80kb (4 Efm, 2 Eh clones,
3 brands, 1999–2000); ii) type B, 50kb (2 Efm clones; 2 brands; 2001)
and iii) type C, 75kb (Efm, Ed; 1999).
Conclusion: Besides clonal spread, different plasmid types seem to have
contributed to the maintenance and spread of VRE in the community
setting of our country. Further analyses are required to complete the
genetic backbone of vanA plasmids and their association with particular
Tn1546 types.
P1010 Vancomycin-resistant enterococci in Finland, 2006–2009
M. Karden-Lilja °, J. Vuopio-Varkila, S. Salmenlinna (Helsinki, FI)
Objectives: Vancomycin-resistant enterococci (VRE) are an emerging
cause of hospital-acquired infections. Especially one genetic lineage of
Enterococcus faecium, designated as clonal complex 17 (CC17) based on
multilocus sequence typing (MLST), ampicillin resistance and presence
of esp gene, has spread worldwide. In Finland, the ﬁrst VRE epidemics
were reported in the mid 1990s; since then eight epidemic strains have
been recognised. The aim of this study was to characterise the recent
Finnish VRE isolates by molecular means.
Methods: All VRE ﬁndings are reported to the National Infectious
Diseases Register and the corresponding isolates (1 per person) are sent
to National Institute for Health and Welfare for typing. All isolates from
2006–2009 were analysed by pulsed-ﬁeld gel electrophoresis (PFGE).
A strain was considered as epidemic when a PFGE proﬁle with <7
band differences was encountered from at least ﬁve persons. MLST was
performed to selected strains of E. faecium representing different PFGE
types from years 2006–2009 and to the Finnish epidemic VRE strains
from previous years. The presence of van genes was veriﬁed by PCR.
Results: In 2006–2009, VRE was isolated from 132 persons. The annual
number of strains varied between 58 in 2007 and 7 in 2009 and the
majority (117/132, 89%) came from two of the 21 health-care districts.
Thirteen isolates (10%) were from clinical infections, including three
from blood. E. faecium accounted for 90% (119/132) of the isolates and
92% of these carried vanB resistance gene (110/119).
In total, 49 PFGE types were encountered; two types, VRE IV and
VRE VII, accounted for 46% (61 isolates) and 15% (20 isolates) of the
isolates, respectively. A sporadic PFGE type was found from 44 (33%)
isolates.
Among 30 strains selected for MLST, 11 sequence types (ST) were
found. The STs of the two most prevalent epidemic strains were ST18
(VRE IV) and ST343 (VRE VII). Other STs among epidemic strains
were: ST16, ST17 and ST252. Of the 13 sporadic strains selected for
MLST, 8 had a different ST (ST275, ST78, ST412, ST192 and two new
STs) from STs of any of the epidemic strains.
Conclusions: VRE infections are rare in Finland. Most VRE strains are
vanB positive E. faecium and based on MLST, belong to CC17. Uneven
geographical distribution suggests differences in VRE diagnostic and/or
surveillance.
P1011 Epidemiology of vancomycin-resistant enterococci in an
Irish tertiary care hospital
C. Wrenn °, J. Kavanagh, N. O’Flaherty, L. Fenelon, K. Schaffer
(Dublin, IE)
Background: A signiﬁcant increase of infections with vancomycin
resistant enterococci (VRE) was noted among haematology, liver
transplant patients and general surgical patients of a large tertiary care
hospital in Ireland during 2006/7. Only patients on high risk ward
areas (haematology, liver transplantation and intensive care) had been
screened weekly for VRE carriage. Pulsed ﬁeld gel electrophoresis
(PFGE) identiﬁed two major outbreak strains circulating in the hospital
(EC4 and EC5). Objective: To investigate the VRE epidemiology in the
hospital in an attempt to contain VRE cross infections.
Methods: An environmental screen for VRE was performed in the high
risk ward areas and on the general surgical wards. In addition 115 faecal
specimen taken from the general in-patient population from all wards
and 100 specimens referred from the community were anonymously
investigated for VRE. Faecal specimens were cultured on chromID VRE.
After biochemical identiﬁcation and antibiotic susceptibility testing
clonal relationships were investigated by PFGE.
Results: The haematology and liver transplant unit are cleaned daily
with hypo-chlorite solution. From these wards only 1% of environmental
specimens were found to be positive. In contrast 19% of surfaces
screened in the surgical ward area which is not routinely cleaned with
hypo-chlorite solution yielded positive cultures for VRE. Screening of
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115 faeces samples from the general in-patient population revealed a
VRE prevalence rate of 38.3%. However VRE was found in 1 of 100
samples referred from the community. Pulsed ﬁeld gel electrophoresis
demonstrated that 66.7% of the isolates recovered from the in-patient
population belonged to the outbreak clusters EC4 and EC5.
Conclusion: VRE colonization is endemic in the endemic in the hospital.
Two dominant clonal strains are circulating in the hospital suggesting
that the main mode of transmission is nosocomial and environmental
screening suggests that contaminated surfaces are potential sources of
cross infection.
P1012 Expansion of CC2 Enterococcus faecalis lineage in a
Spanish tertiary hospital and its surrounding area
P. Ruiz-Garbajosa °, A. Tedim-Pedrosa, C. Rodrı´guez, R. Canto´n,
F. Baquero, T.M. Coque (Madrid, ES)
Background: The Enterococcus faecalis (Efc) population structure
comprises widespread clonal complexes (CC2, CC9 and CC87) over-
represented among hospitalized patients with heterogeneous distribution
in different countries. Vancomycin resistant Efc is mostly linked to CC2
lineage. The aim of this study is to assess the population structure of
Efc isolates in a geographic area with low occurrence of vancomycin
resistance.
Material and Methods: We analyzed 54 Efc isolates recovered
from hospitalized and community-based patients (one per patient)
during 2009. The collection included 20 invasive clinical isolates
(blood isolates); 20 non-invasive clinical isolates (13 urines and 9
wounds) and 14 faecal isolates. Population structure was analyzed
by MLST (www.mlst.net). Antibiotic susceptibility was determined by
microdilution (CLSI). Presence of asa1, cyl, esp, and gelE virulence
genes were tested by a multiplex PCR.
Results: Isolates were resistant to erythromycin (Er, 69%), levoﬂoxacin
(Lvx, 35%), minocicline (Mn, 42%) and high levels of resistance (HLR)
to streptomycin (HLR-Sm, 50%) and gentamicin (HLR-Gm, 38%). None
of the isolates were resistant to ampicillin, vancomycin, teicoplanin,
linezolid or daptomycin. The presence of gelE, asa1, esp and cylA
genes were detected in the 87%, 63%, 15% and 18% of the isolates,
respectively. MLST analysis revealed 27 STs, being ST6-CC2 (n = 16,
29%) and ST16 (n = 5, 9%) the most prevalent lineages. Remaining
Efc isolates (n = 33) were distributed in 25 STs (1 CC4, 1 CC9, 2
CC21, 1 CC25, 4 CC30, 2 CC55, 3 CC72) and 17 singletons (19).
ST6 comprises isolates from blood (50%), urine and wounds (38%) and
feces (12%) from patients at different hospital wards and community-
health care centers. Most of ST6 isolates contained gelE and asa1 (69%)
and a high percentage (81%) were resistant to Er, Mn, Lvx with HLR-
Gm and HLR-Sm. Only 3 isolates were cylA positive. ST16 isolates
were recovered from non-invasive sources and were HLR-Gm. Other
STs (25 STs/33 isolates) corresponded to isolates resistant to less than
two antibiotics (29/33; 88%). They contained either gelE alone (12/33;
36%) or in combination with asa1 (14/33; 42%).
Conclusions: We describe the predominance of the globally spread CC2
lineage among Efc isolates from our area, many of them causing serious
infections. Expansion of this lineage is of concern since it can serve
as substrate for vancomycin resistance as reported in other European
countries.
P1013 Prevalence of faecal carriage of vancomycin- and
ampicillin-resistant enterococci among healthy people in
Cantabria, Spain
P. Goicoechea °, M. Romo, J.I. Soto, J. Calvo, M.G. Gonzalez,
L. Martı´nez-Martı´nez, M.V. Francia (Santander, Noja, ES)
Objectives: During the last decade, the spread of vancomycin-resistant
(VRE) and ampicillin-resistant (ARE) enterococci has greatly increased
in our hospital. We aimed to determine the prevalence of VRE and
ARE faecal colonization among nonhospitalized individuals living in our
community. Antibiotic susceptibility, clonal relationship and the presence
of virulence determinants were speciﬁcally determined.
Methods: From March 2008 to August 2009, rectal swabs from 595
nonhospitalized subjects were inoculated onto azide bile-esculin agar
plates with ampicillin (16mg/L) or vancomycin (6mg/L) for 48 h.
Identiﬁcation and susceptibility testing were done with the Walk-Away
System and conﬁrmed by 16S DNA sequencing and E-test method,
respectively. Clonal relatedness was assayed by PFGE and MLST.
Speciﬁc virulence determinants were tested by PCR as previously
described.
Results: 5 strains were isolated from the vancomycin agar plates: 1
E. faecium, 1 E. gallinarum and 3 E. casseliﬂavus. 12 individuals
were ARE carriers (2%). All ARE isolates were E. faecium. The
percentages of resistance of the 13 E. faecium isolates recovered
were: ampicillin (92), ciproﬂoxacin (69), erythromycin (61), high-
level resistance streptomycin (84), high-level resistance gentamicin (0),
tetracycline (53), vancomycin (0), chloramphenicol (46), linezolid (0),
quinupristin/dalfopristin (53). Vancomycin MIC for the one E. faecium
isolate recovered after vancomycin selection was 6mg/L. The isolates
were classiﬁed into 6 PFGE types, highlighting the presence of two
clones containing 6 and 3 isolates, respectively. MLST analysis displayed
4 known sequence types (STs), ST117 (n = 6), ST264 (n = 3), ST265
(n = 1), ST5 (n = 1) and 2 new STs (n = 2). Only the CC17 isolates (n = 6)
were positive for esp acm and entA virulence genes.
Conclusions: ARE faecal carriage was 2% among healthy individuals in
our community. As many as 46% of the ARE isolates belonged to CC17
clonal complex suggesting a possible hospital acquisition of such strains.
Our results indicate absence of VRE colonization outside hospitals in
Cantabria in contrast to the ﬁndings in other European countries.
P1014 Prevalence of colonization with vancomycin-resistant and
ampicillin-resistant Enterococcus faecium in a university
hospital in northern Spain
M. Romo °, P. Goicoechea, J. Calvo, M. de la Cal, M. Gozalo, M. Alvarez,
M.C. Farin˜as, L. Martı´nez-Martı´nez, M.V. Francia (Santander, ES)
Objectives: CC17 Enterococcus faecium has increasingly been reported
as a nosocomial pathogen worldwide. We aimed to investigate
vancomycin-resistant (VRE) and ampicillin-resistant (ARE) E. faecium
intestinal colonization among inpatients at our hospital. Antibiotic
susceptibility, clonal relationship and the presence of virulence
determinants or mobile genetic elements were speciﬁcally determined.
Methods: From February to August 2009, 576 patients admitted
to several units at our hospital (and without hospital stays during
the previous year) were screened for VRE or ARE faecal carriage.
Rectal swabs (collected on admission and weekly until the patients’
discharge) were inoculated onto azide bile-esculin agar plates with
ampicillin (16mg/L) or vancomycin (6mg/L) for 48 h. Identiﬁcation
and susceptibility testing were done with the Walk-Away System and
conﬁrmed by 16S DNA sequencing and E-test method, respectively.
Clonal relatedness was assayed by PFGE and MLST. Speciﬁc virulence
determinants and plasmid content were tested by PCR as previously
described.
Results: On admission, 24 patients were colonized with ARE and
1 with VRE. 9 patients were ARE colonized after a hospital stay
>48 h. The percentages of resistance of the 34 E. faecium isolates
recovered were: ampicillin (97), ciproﬂoxacin (91), erythromycin (85),
high-level resistance streptomycin (82), high-level resistance gentamicin
(8), tetracycline (32), vancomycin (2), teicoplanin (2), chloramphenicol
(26), linezolid (0), quinupristin/dalfopristin (29). The isolates were
classiﬁed into 14 PFGE types, highlighting the presence of 1 major
clone containing 15 isolates. MLST analysis displayed 9 known sequence
types (STs), ST117, ST18, ST17, ST192, ST375, ST262, ST264, ST265,
ST123 and 2 new STs. Most of the isolates belonged to CC17 (76%).
The percentages of virulence genes were as follows: esp (55), hyl (17),
acm (44) and entA (88). Isolates encoded a variety of plasmid modules,
being pRE25, pEF1, pCIZ2, pAD1 and pEFNP1 the predominant ones.
Conclusions: 1 of every 25 patients was ARE colonized on admission
at our hospital. As CC17 represents a clonal complex usually associated
to hospital settings and rarely found in the community, CC17 carriage
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on admission might be associated with previous hospital stays. CC17
ARE intestinal persistence times might then be longer than 1year,
facilitating dissemination of these strains. VRE was nearly absent among
hospitalized patients at our hospital.
P1015 Phenotypic and genotypic traits of vancomycin-resistant
enterococci in a teaching hospital, Ankara, Turkey: the ﬁrst
vanB-positive Enterococcus faecium isolates
F.A. Coskun, I. Mumcuoglu, N. Balaban, Z.C. Karahan °, E. Us,
A. Tekeli, I. Baran, S. Kursun (Ankara, TR)
Objectives: Since the ﬁrst VRE isolation in our country in 1998, various
hospitals have been reporting increasing number of VRE isolations.
In this study, our objective was to determine genetic relationships
and resistance genotypes of VRE strains which were isolated from
surveillance cultures of patients mostly staying in ICUs and cultures
of various clinical specimens.
Methods: From January 2007 to March 2008 a total of 777 rectal swab
from 520 patients staying mostly in ICUs and some other clinics, 460
environmental specimens and 121 rectal swab specimens from hospital
staff were obtained. VITEK-2 system (bioMe´rieux, France) was used for
identiﬁcation and antimicrobial susceptibility test of enterococci. MICs
of vancomycin and teicoplanin were also analyzed by broth microdilution
method according to CLSI guidelines. PFGE was used to analyze clonal
relationships and PCR was used for determination of resistance genes.
Results: Forty-six VREs were isolated from 42 patients. VRE
colonization rate in our hospital was found 8.07%. No VRE was isolated
from environmental cultures and rectal swab specimens of hospital staff.
All isolates were identiﬁed as E. faecium. PFGE data of 8 VRE isolates
were undetermined so remaining 38 strains were included to study.
These strains were isolated from 33 rectal swab specimens and 5 clinical
materials. Strains were mostly isolated from ICUs and hematology clinics
as expected. As a result of broth microdilution method 30 strains were
found VanA phenotype, 8 strains were found Van B phenotype. vanA
resistance gene was determined by PCR in all 30 isolates that had VanA
phenotype. vanB resistance gene was determined in all 8 strains that
had VanB phenotype. Thirty-eight VRE strains formed 6 different band
models (A, B, C, D, E, and F) at PFGE. This band models contain 8, 10,
3, 5, 3, 3 isolates, respectively. All isolates with VanB type resistance
were in group A. Patients in this group were all hemodialysis patients
from different clinics.
Conclusion: This is the ﬁrst report of vanB resistance gene E. faecium
strains in our country. This emphasizes that VRE resistance diversity as
well as isolation rate is increasing. VRE isolation rates in our hospital
are gradually increasing since the ﬁrst isolation of VRE which is a great
concern. Effective surveillance studies should be done and source of
infection should be identiﬁed and expansion should be limited in order
to eliminate the spread of disease.
P1016 Polyclonal outbreak in a low-endemic area of CC17
genogroup vancomycin-resistant Enterococcus faecium
containing vanB2-Tn5382 and axe-txe plasmid addiction
system on pRUM-like transferable plasmid
E.K. Bjørkeng, G. Rasmussen, A. Sundsfjord, L. Sjo¨berg, K. Hegstad °,
B. So¨derquist (Tromsø, NO; O¨rebro, SE)
Objectives: To characterize an outbreak of vancomycin resistant
Enterococcus faecium (VREfm) with 17 isolates from 12 infected
and 3 colonized patients in a University hospital in Sweden between
2002–2004. All patients had underlying disorders and had received
antimicrobial therapy during the last 3 months.
Methods and Results: Pulsed ﬁeld gel electrophoresis (PFGE) revealed
that 14 isolates belonged to 3 different PFGE types and in addition
3 isolates had unique patterns. All isolates had multi locus sequence
types (ST17 (n = 5); ST18 (n = 3); ST125 (n = 7); ST262 (n = 1); ST460
(n = 1)) belonging to the successful hospital adapted CC17 genogroup
and harboured 3−5 virulence genes associated with CC17. The VREfm
isolates were shown to be susceptible to teicoplanin by Etest which
was in accordance with their vanB2 genotype. The ﬁrst isolate had a
unique PFGE type and Southern hybridizations of S1 nuclease digested
genomic DNA separated by PFGE suggested a chromosomally located
vanB2 integrated in a transferable genetic element (Tn5382), while the
other ﬁve PFGE types had Tn5382 located on a pRUM-like replicon
containing a plasmid addiction system (axe-txe). These resistance (R)-
plasmids supported intraspecies transfer by ﬁlter mating. In patient 6
both PFGE type III ST17 and later PFGE type I ST125 were isolated.
R-plasmid transfer in this patient seems to have resulted in a more
successful clone (PFGE type I ST125).
Conclusion: VanB-type VREfm can spread in a low-endemic area
through successful clones and plasmids with stability functions.
P1017 Bacteraemia caused by non-faecalis, non-faecium
Enterococcus sp. at a medical centre in Taiwan, 2000–2008
Y.T. Huang °, C.C. Lai, C. Wang, C.H. Liao, P.R. Hsueh (Taipei City, TW)
Objectives: Bactermia caused by non-faecalis and non-faecium En-
terococcus species are emerging. Nevertheless, the knowledge about
infections caused by these enterocci is limited.
Methods: We retrospectively review the computerized database of the
bacteriology laboratory from January 2000 through December 2008
at National Taiwan University Hospital to identify patients with non-
faecalis and non-faecium enteroccal bacteremia. Demographic data,
underlying diseases, clinical, microbiological, treatment and outcome
were collected. All the isolates were identiﬁed by the Rapid ID 32
STREP system (bioMe´rieux Vitek, Marcy l’Etoile, France), VITEK II
(bioMe´rieux Vitek) and conﬁrmed by sequencing 16S rRNA gene.
Isolates with discordant identiﬁcation results were further analyzed by
sequencing groESLgenes and spacer region.
Results: During the study period, 1887 patients had enterococcal
bacteremia and 182 (9.6%) of them were caused by non-faecalis and non-
faecium enterococcal. These included E. casseliﬂavus (n = 59, 3.1%),
E. gallinarum (n = 58, 3.0%), E. avium (n = 45, 2.4%), E. hirae (n = 9,
0.5%), E. rafﬁnosus (n = 9, 0.5%), E. durans (n = 2, 0.1%), E. cecorum
(n = 2, 0.1%), and E. canintestini (n = 1, 0.5%). Among the 182 patients,
74 (40.7%) had catheter-related bloodstream infection and 69 (37.9%)
presented with biliary tract infection. Ninety-nine (54.4%) episodes
of bacteremia acquired in the hospital and 106 (58.2%) episodes
were caused by polymicrobial pathogens. All cause mortality rate was
42.0% (76/181) and 51 (28.7%) deaths were considered to be related
to bacteremia. The attributed mortality was signiﬁcant higher among
patients with immunocompromised status, hospital acquired bacteremia,
prior hospitalization and ICU admission.
Conclusions: Non-faecalis and non-faecium Enterococcus species is not
rare in Taiwan. These unusual pathogens can cause protean manifesta-
tions which varied with the infecting Enterococcus species. The mortality
of bacteremia remains high, especially for immunocompromised patients
and patient with hospital-acquired infection.
P1018 Outcome of enterococcal bacteraemia in relation to start
of therapy
M. Pinholt °, N. Frimodt-Møller, J. Dahl Knudsen (Hvidovre,
Copenhagen, DK)
Objectives: To compare the mortality and the effect of delayed therapy
on mortality associated with Enterococcus faecalis and Enterococcus
faecium bacteraemia.
Methods:We performed a retrospective study of patients diagnosed with
enterococcal bacteraemia in the department of Clinical Microbiology
at Hvidovre University Hospital, serving ﬁve public hospitals (2200
somatic beds) in the Copenhagen City area (630,000 inhabitants). All
episodes of enterococcal bacteraemia from January 1, 2006 to July 31,
2009 were included. If a patient had more than one episode, only the ﬁrst
episode was included. Patients with cases of polymicrobial bacteraemia
were excluded. Data regarding the time to administration of appropriate
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therapy were obtained from medical records. Appropriate therapy was
for E. faecalis ampicillin, benzyl-penicillin, piperacillin, vancomycin or
linezolid, for E. faecium vancomycin or linezolid, if susceptible. Thirty-
day mortality was the main outcome measurement.
Results: A total of 322 patients with enterococcal bacteraemia were
recorded (E. faecalis, N = 209 and E. faecium, N = 113). Polymicrobial
cases were excluded (N= 117), why 205 patients were included in
the study (E. faecalis, N = 125 and E. faecium, N = 80). Two isolates
were vancomycin resistant. E. faecalis and E. faecium bacteraemia were
community-acquired in 68.8% and 22.5%, respectively. The E. faecalis
and E. faecium 30-day mortalities were 24.8% and 37.5%, respectively
(survival curves, log rank test, p = 0.04). For both species, start of
appropriate therapy more than 48 h after sampling was associated with
decreased cumulative survival rates and with no difference between the
two species. The average time to appropriate therapy was signiﬁcantly
shorter for E. faecalis (mean: 1.5 days, median 1) than for E. faecium
(mean 1.8 days, median 2), (p = 0.03).
Conclusions: Mortality after E. faecalis and E. faecium bacteraemia
increased signiﬁcantly with increasing delay of start of appropriate
antibiotic therapy. The 30-day mortality was higher for E. faecium as
compared to E. faecalis. The cumulative survival rates in relation to
start of therapy were not different. Delay of appropriate therapy was
more frequent for E. faecium compared to E. faecalis, which could be the
explanation for the higher 30-day mortality associated with E. faecium.
P1019 A sustained hospital outbreak of VRE bacteraemia due to
the emergence of Enterococcus faecium ST 203
P.D. Johnson °, S.A. Ballard, E.A. Grabsch, T.P. Stinear, T. Seeman,
H. Young, M.L. Grayson, B.P. Howden (Melbourne, AU)
Objectives: Improved infection control at our health service has
been associated with a progressive reduction in MRSA bacteraemia
but a paradoxical rise in vancomycin resistant Enterococcus faecium
bacteraemia. We hypothesised that a new hospital-adapted strain of
Enterococcus faecium (Efm) was responsible for this paradox.
Methods: We reviewed all patient episodes of Efm bacteraemia (both
vancomycin-sensitive [VSEfm] and vancomycin-resistant [VREfm]) over
an 11.5-year period (1998–2009). The ﬁrst available isolate from each
patient with conﬁrmed VSEfm or VREfm bacteraemia was typed
using multi-locus sequence typing (MLST). We also performed optical
mapping and whole genome sequencing on representative isolates from
the two most common sequence types (STs), one from early in the study
period (October 1998, AUS0004, ST 17) and the other more recent
(February 2009, AUS0085, ST 203).
Results: 85 isolates (51 VSEfm, 33 VREfm vanB genotype and 1
VREfm vanA genotype) obtained from patients with Efm bacteraemia
were typed by MLST. Seventeen different STs were identiﬁed. From
1998 to 2006, bacteraemia rates remained stable and the most common
blood culture isolate was Efm ST 17 (21/45 [47%]). Efm ST 203 was
not isolated. In late November 2005 Efm ST 203 was detected for
the ﬁrst time as VSEfm in a patient’s blood culture. The ﬁrst VREfm
ST 203 was isolated in a blood culture obtained in March 2007. Since
2007, coinciding with the emergence of VREfm ST 203, the rate of
VREfm bacteraemia has increased exponentially with ST 203 accounting
for 19/25 (76%) of VREfm blood culture isolates, while ST 17 only
accounted for 4/25 (16%) in the same period. During 2009, 10/14,
(71.4%) of all Efm bacteraemia isolates were ST 203. Although Efm
ST 203 is only a double locus variant of Efm ST 17, comparative
genomics revealed more than 500 kb of sequence difference between
AUS0004 (ST 17) and AUS0085 (ST 203), suggesting Efm ST 203 was
introduced recently from outside our hospital rather than developing
locally from an endemic ST 17 strain.
Conclusions: The initial detection of VSEfm ST 203 was followed
within 15 months by the emergence of VREfm vanB ST 203 that is now
causing a sustained outbreak of VRE bacteraemia. The dominance of
Efm ST 203, compared with other Efm-STs, suggests enhanced survival
and/or virulence under hospital conditions, but the determinants of this
adaptation/virulence are not yet known.
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P1020 Molecular characterization of Panton-Valentine leukocidin
positive methicillin-resistant Staphylococcus aureus isolates
in Serbia
I. Cirkovic °, M. Svabic Vlahovic, S. Stepanovic (Belgrade, RS)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is an
important cause of both nosocomial and community-acquired infections.
Severe MRSA infections, including necrotizing pneumonia, bacteraemia
and skin and soft tissue infections (SSTIs) have been associated with
the virulence factor Panton-Valentine leukocidin (PVL). The aim of
this study was to investigate the presence of PVL genes, clonality and
their susceptibility patterns in MRSA isolates collected from patients in
Serbia.
Methods: MRSA strains were collected from January to July 2007 in 30
clinical microbiology laboratory in Serbia. The identiﬁcation of MRSA
was conﬁrmed by detection of nuc gene and mecA gene by PCR. The
presence of genes encoding PVL was examined by PCR. The phenotypic
and genotypic characteristics of the strains were determined including
antibiotic susceptibility, SCCmec and agr types. Clonality of the MRSA
isolates was determined by pulsed ﬁeld gel electrophoresis (PFGE).
Results: During the six months period 162 MRSA isolates were
collected. Presence of PVL was demonstrated in 4 (2.5%) MRSA strains.
Three (75%) PVL positive MRSA strains had SCCmec V and agr
type 1, were susceptible to all non b-lactam antibiotics exept gentamicin,
kanamycin and tobramycin; and 2 of these strains were clonally related
according to PFGE analysis. The remaining PVL positive strain, had
SCCmec IV and agr type 3, were susceptible to all non-lactam antibiotics
exept kanamycin, tetracycline and intermediate resistant to fusidic acid;
and was not clonally related to any other strain.
Conclusion: PVL positive MRSA strains are an increasing problem due
to its involvement in SSTIs. In our country these isolates represent 2.5%
of MRSA strains. A half of these PVL positive MRSA isolates were
clonaly related.
P1021 High diversity of PVL-positive methicillin-resistant
Staphylococcus aureus in western Switzerland, 2005–2009
L. Senn °, P. Basset, C. Bellini, G. Zanetti, D.S. Blanc (Lausanne, CH)
Objective: To describe the molecular epidemiology of Panton Valentin
Leukocidin (PVL)-positive MRSA among newly diagnosed carriers in
an area of low MRSA prevalence over a ﬁve-year period (2005–2009).
Methods: All MRSA isolates (one per patient) recovered in the Vaud
canton of Switzerland were analyzed by the Double Locus Sequence
Typing (DLST) method (based on clfB and spa loci). The SCCmec type
of each isolate was determined with the ﬁrst two PCRs of the Kondo
scheme. PVL-encoding genes lukS-PV and lukF-PV were co-ampliﬁed
by PCR reactions.
Results: From January 2005 to October 2009, 2290 MRSA isolates (1
per patient) were analysed. Presence of PVL was detected in 115 (5%)
isolates with a mean number of cases of 23 per year (range 14 to 36).
Most isolates were recovered in patients with skin infections (70%) and
no outbreak was observed.
These isolates were grouped into 38 different DLST types. From DLST
and SCCmec type, it can be inferred that 42 cases (37%) belonged to
ST8-SCCmecIV, 31 cases (27%) to ST80-SCCmecIV (European CA-
MRSA clone), and 42 cases to others clones (e.g. ST5-SCCmecV,
ST152-SCCmecV, and ST30-SCCmecIV). Interestingly, only about half
of isolates of ST8-SCCmecIV showed the presence of the ACME region
that is speciﬁc to the USA300 clone. The other isolates belonged to the
Hospital Associated (HA) clone of Lyon and have acquired the PVL
genes.
Conclusion: The high diversity of DLST genotypes and the absence of
outbreak showed that local transmission of PVL-positive MRSA was not
frequent in our region.
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P1022 Widespread dissemination of the Panton-Valentine
leucocidin positive ST93-MRSA-IV clone in the Australian
community
G.W. Coombs °, J. Pearson, G. Nimmo, K. Christiansen on behalf
of the Australian Group for Antimicrobial Resistance
Objectives: To characterise and describe the epidemiology of Panton-
Valentine leucocidin (PVL) positive community-associated MRSA (CA-
MRSA) strains circulating in the Australian community.
Methods: In 2008, the 5th Biennial Community S aureus Surveillance
Programme was performed by the Australian Group for Antimicrobial
Resistance (AGAR). Up to 100 clinically signiﬁcant consecutively
isolated S aureus from 100 different outpatients were collected by 31
laboratories located throughout Australia. MRSA were referred to the
Western Australian Gram-positive Bacteria Typing and Research Unit
for typing. Isolates were characterised by pulsed-ﬁeld gel electrophoresis
(PFGE) and clonality determined by MLST/SCCmec typing. The
presence of PVL determinants was detected by PCR.
Results: 18% (553) of the 3,075 S aureus isolated were identiﬁed as
MRSA (this represents a signiﬁcant increase [<0.0001] when compared
to the 2000 AGAR survey). Molecular typing was performed on 98.9%
(547) of MRSA of which 62.2% (340) were identiﬁed as CA-MRSA
strains (20 MLST/SCCmec types from 22 PFGE pulostypes). Of these
64.7% (220) were PVL positive. ST93-MRSA-IV (colloquially known
as Queensland CA-MRSA) accounted for 67.7% (149) of the PVL-
positive CA-MRSA and 44.1% (150) of all CA-MRSA strains. Six
international PVL-positive CA-MRSA were identiﬁed (ST30-MRSA-
IV {Oceanic CA-MRSA} [46], ST8-MRSA-IV {USA300} [10], ST1-
MRSA-IV (USA400) [9], ST80-MRSA-IV {European CA-MRSA} [2]
and ST59-MRSA-VT {Taiwan CA-MRSA}[1]). The remaining three
PVL-positive CA-MRSA were identiﬁed as ST5-MRSA-IV, ST78-
MRSA-IV and ST88-MRSA-IV. A signiﬁcant difference (p< 0000.1)
in the age of PVL-positive CA-MRSA (mean 33y, median 30y) and
PVL-negative CA-MRSA infected patients (mean 53y, median 56y)
was identiﬁed. Although isolated in a range of specimens PVL-positive
CA-MRSA were predominantly associated with skin and soft tissue
infections (SSTI).
Conclusions: In earlier AGAR Community S aureus Surveillance
Programmes CA-MRSA infections in Australia were primarily caused
by PVL-negative strains. Due to the emergence and wide spread
dissemination of ST93-MRSA-IV and the introduction of several
international PVL-positive CA-MRSA strains a signiﬁcant increase
in the number of CA-MRSA infections occurring in the Australian
community has been identiﬁed. This increase has primarily been
associated with younger Australians with SSTI that often require
hospitalisation.
P1023 Molecular epidemiology and mechanisms of resistance of
Panton-Valentine leukocidin positive methicillin-resistant
Staphylococcus aureus strains
C. Pitart °, C. Lozano, E. Go´mez-Sanz, N. Cobos, J. Mensa, A. Soriano,
C. Torres, J. Vila, M.T. Jime´nez de Anta, F. Marco (Barcelona,
Logron˜o, ES)
Objectives: Panton-Valentine leukocidin positive methicillin-resistant
Staphylococcus aureus (PVL (+) MRSA) isolates have increasingly been
noted worldwide due to its involvement in severe infections. In our
institution these isolates represent 11.5% of all MRSA strains. In this
study, we investigated the molecular epidemiology of PVL (+) MRSA
isolates and their antibiotic (ATB) resistance mechanisms.
Methods: 33 PVL (+) MRSA strains were collected from patients (one
for patient) seen in our institution (October 07-May 09). All strains were
genotyped by pulsed ﬁeld gel electrophoresis (PFGE) after digestion with
SmaI. Only one isolate of each PFGE subtype and same susceptibility
pattern was further studied for molecular characterization. spa and
SCCmec typing, agr polymorphism and testing for ACME-arcA genes
was performed to 15 strains. MLST typing was done to isolates showing
different spa types and to two invasive strains. Isolates were screened
for the presence of resistance genes: erythromycin (ER) and clindamycin
(CL) (ermA, ermB, ermC and msrA), gentamicin (GE) and tobramicin
(TO) (aac(6′)-aph(2′′), ant(4′)), mupirocin (MU) (mupA) and tetracycline
(TE) (tetK, tetM, tetL). Mutations in grlA and gyrA were characterized
to study quinolone (FQ) resistance. NorA efﬂux mediated resistance
was also studied performing norﬂoxacin (NOR) MICs in presence of
reserpine.
Results: PVL positive MRSA strains belonged to four PFGE
types (20 isolates A, 11 B, 1 C and 1 D) and 9 subtypes. All
isolates were susceptible to cotrimoxazole, rifampin, vancomycin,
teicoplanin, daptomycin, fusidic acid and linezolid. Resistance to ATB
was as follows: ER 51% (msrA), ER and CL MLSB constitutive
phenotype 10% (msrA+ermC), TE 12% (tetK), GE and TO 6%
(one isolate aac(6′)-aph(2′′) and the other aac(6′)-aph(2′′)+ ant(4′)-Ia).
Two isolates showed high level resistance to mupirocin due to
plasmid mediated mupA. 21 isolates showed FQ resistance (63%).
Amino acid substitutions observed were: grlA Ser80Tyr (17), grlA
Ser80Phe (4) and gyrA Ser84Leu (21). One fold NOR MIC decrease
was seen in 20 isolates in presence of reserpine. The dominant
clone (ST8/SCCmecIVa/t008/agr1/ACME+/msrA+) represented 57%
of strains. Other clones observed were ST8/SCCmecIVa/t4816/agr1/
ACME+/msrA+(1); ST8/SCCmecIVc/t008/agr1 (11); ST146/SCCmecIV/
t002/agr2 (2) and ST72/SCCmecIV/t791/agr1 (1).
Conclusion: A major clone (57%) exhibited ST8, spa t008, agr1,
SCCmecIVa, presence of ACME and msrA. This clone related to
USA300 lineage included one isolate causing bloodstream infection and
meningitis.
P1024 Modulatory effects of antimicrobials on the expression of
Panton-Valentine leucocidin gene in community-acquired
methicillin-resistant Staphylococcus aureus
C.K. Wong, E.T. Leung, S.S. Chau, L. Zheng, K.F. To, M. Ip ° (Hong
Kong, HK)
Objective: Community-acquired methicillin-resistant Staphylococcus
aureus (CA-MRSA) infections have emerged as a major health concern
worldwide. The possession of panton-valentine leucocidin (PVL) in CA-
MRSA has been associated with recurrent soft tissue infections and
necrotizing pneumonia, amongst others. Studies showed that expression
of virulence genes by Staphylococcus aureus is under tight regulatory
control and depends on strain types and could be modulated by external
stimuli, including drugs such as antibiotics. This study investigates the
effects of commonly used antimicrobial agents at sub-inhibitory level on
PVL expression in CA-MRSA in vitro.
Methods: A representative strain of CA-MRSA of the Southwest Paciﬁc
clone, ST30 (spa t019), was used in the experiments. CA-MRSA was
cultured to late log phase in liquid medium. Sub-inhibitory concentration,
equivalent to 1/8th MIC of the respective antimicrobial (vancomycin,
linezolid, gentamicin and ciproﬂoxacin), was added to the broth culture
at early log phase (time point at OD600nm0.3). Aliquots of the broth pre-
and post antibiotics were collected at various time points (at OD600nm
0.6, 1.8, 2.1, 2.3) representing different phases of bacterial growth for
mRNA measurements. Total RNA was extracted and reverse transcribed
to cDNA for quantitative analysis of mRNA transcripts by RT-qPCR.
PVL expression levels were normalized against endogenous 16sRNA
levels and calculated as relative expression (ratio of copy numbers of
PVL against copy numbers of 16sRNA).
Results: PVL expression was up-regulated in vitro to different extent
by different classes of antimicrobials, as compared to the control group
(p< 0.05) (see ﬁgure). The effects are most marked with ﬂuoroquinolone,
ciproﬂoxacin.
Conclusions: Expression of staphylococcal virulence genes eg PVL
in CA-MRSA could be affected by the use of different classes of
antimicrobials. Regimens that minimize release of PVL and other
virulent toxins production may reduce severity of disease and improve
treatment outcome in CA-MRSA infections.
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Effect of antimicrobials on PVL expression.
P1025 Quantiﬁcation of PVL production by PVL-MRSA isolated
in England and Wales
E. Boakes °, A.M. Kearns, C. Badiou, C. Ratat, M. Leportier, G. Lina,
R. Hill, M.J. Ellington (London, UK; Lyon, FR)
Objectives: PVL production is often linked with some of the
most successful lineages of community-associated methicillin-resistant
Staphylococcus aureus (CA-MRSA). We sought to quantify PVL
production amongst dominant clones of PVL-MRSA in England and
Wales and to identify associations between the levels of PVL production,
the type of bacteriophage encoding the PVL genes and/or the genetic
lineage of the PVL-MRSA isolates tested.
Methods:We examined PVL production from 113 PVL-MRSA isolates,
representing USA300 (CC8); South West Paciﬁc clone (SWP) (CC30)
and the European clone (CC80). In addition we analysed PVL-MRSA
from CCs 1, 5, 22, 59, 88 and ST93. Culture supernatant from
standardised growth in CCY broth was taken in triplicate and PVL was
quantiﬁed using a solid-phase sandwich ELISA as described previously.
The PVL-phages were detected by PCR, as described previously.
Results: The UK PVL-MRSA tested produced 2.5–178.1 ng/ml of
PVL. Within MLST lineages, isolates harboured different PVL phages
and produced varying levels of PVL. CC8 isolates (n = 12) harboured
Sa2USA and produced relatively high levels of PVL (39.61–178.13
ng/ml, mean 89.75 ng/ml). In contrast some lineages produced low levels
of PVL ranging between 2.5–77.63ng/ml (mean = 33.72); these included
CC22 isolates (n = 47) which had 1 / 3 different PVL phages (108PVL,
PVL and icosahedral phage), CC5 isolates (n = 9) had 1 / 2 different
PVL phages (Sa2USA or unknown phage) and CC88 isolates (n = 5)
which all had an unknown elongated phage. All other lineages; CC1,
30, 59, 80 and 93 (with phages Sa2USA, Sa2MW, Sa2958-like phage
and unknown PVL phage/s) produced PVL concentrations between 6.27–
95.81ng/ml (mean = 47.94). Multiple examples of highly related isolates
that produced substantially different amounts of PVL were noted (CC8,
CC22, CC93).
Conclusion: Among PVL-MRSA found in the UK, the level of PVL
produced in vitro varied between lineages and also varied substantially
from isolate to isolate within the same lineage. There does not appear
to be a clear association between genetic lineage and the level of PVL
produced, nor is there any obvious association with the amount of PVL
produced and the type of PVL encoding phage. Notwithstanding the
variance observed amongst highly related isolates in this study suggests
mechanisms of modulation of production exist. Other factors effecting
PVL production, including host factors, warrant further investigation.
P1026 Unravelling Panton-Valentine leucocidin positive methicillin-
resistant Staphylococcus aureus transmission in North
Staffordshire, United Kingdom, using variable-number
tandem-repeat typing
K. Hardy °, P. Hawkey, C. McMurray, S. Shabir, A.M. Kearns,
J. Orendi (Birmingham, London, Stoke-on-Trent, UK)
Objectives: To understand the detailed molecular epidemiology of
PVL-positive community-associated MRSA (CA-MRSA) in North
Staffordshire, UK.
Methods: All MRSA isolates from an acute hospital and the
community (March 2006 to June 2009) that were either ciproﬂoxacin
sensitive/intermediate or clinical information suggested PVL-MRSA
were conﬁrmed by multiplex PCR. All conﬁrmed PVL-positive MRSA
isolates were epidemiologically typed using staphylococcal interspersed
repeat unit (SIRU) typing. Seven variable number tandem repeat loci
located around the genome were ampliﬁed and a 7 digit proﬁle
recorded. The household contacts of PVL-MRSA cases were screened
and epidemiological information regarding contacts recorded.
Results: A total of 63 patients were identiﬁed as being colonised
or infected with PVL-MRSA strains. Fifty four were designated as
community acquired, 7 hospital acquired and the origin of acquisition
could not be determined for two. Of 18 different SIRU proﬁles, four
were predominant. Of these four, three were closely related (1−2-2−2-
9−5-2, 1−2-1−2-9−5-2, 1−2-2−2-9−2-1) and belonged to the ST30-IV
CA-MRSA lineage, with the two most predominant proﬁles differing by
only one repeat. There were multiple PVL-MRSA cases in 14 households
and on all but one occasion, the SIRU proﬁles were indistinguishable
from other cases within the same household. Nine SIRU proﬁles were
associated with household or hospital transmission and nine SIRU
proﬁles with sporadic cases. Of the 24 index cases, 10 had no signiﬁcant
history of travel outside the UK in the previous two years.
Conclusions: Multiple PVL-MRSA clones are circulating within North
Staffordshire, with four strains predominating. SIRU demonstrates good
utility in being able to demonstrate cases of cross transmission within
and between households that have epidemiological links.
P1027 Panton-Valentine leukocidin production and association
with SCCmec types in MRSA in Turkey: is PVL still the
marker of SCCmec type IV?
Z. Gulay °, M. Bagsever, D. Gur, C. Kayacan, G. Soyletir (Izmir,
Ankara, Istanbul, TR)
Objectives: To investigate the association of Panton-Valentine Leuko-
cidin(PVL) and SCCmec type IV in MRSA isolates which were collected
from clinical samples between 2006–2009 in three different cities (Izmir,
Istanbul and Ankara) in Turkey.
Methods: A total of 203 MRSA isolates were taken into the study.
SCCmec typing and the presence of luk S-PV and luk F-PV genes were
studied by multiplex polimerase chain reaction (PCR).
Results: SCCmec type IV/IV E was detected in 6.3%, 9.6% and 14.6%
of MRSA isolated in Izmir, Ankara and Istanbul respectively. The
prevalence increased from 0.0% in 2006 to 4.8% in 2007 and to 23%
in 2008 and then decreased to 14% in 2009. Among 19 isolates bearing
a type IV SCCmec, only four strains were PVL positive. PVL positive
isolates were collected either in Ankara or Izmir in 2008. Nevertheless,
PVL genes was only detected in isolates carrying SCCmec type IV.
Conclusion: This study shows that in Turkey 79% of MRSA isolates
bearing a type IV/IVE SCCmec which is usually associated with
community acquired MRSA (CA-MRSA), do not carry the PVL gene.
This indicates that detecting PVL gene is not a reliable marker for
SCCmec type IV and CA-MRSA. Other interesting ﬁndings of this study
is the increase in the prevalence of MRSA/SCCmec type IV in Turkey
and the probable association of this SCCmec type with hospital acquired
MRSA(HA-MRSA).
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P1028 Variability of fusidic acid-resistant methicillin-sensitive
Staphylococcus aureus isolates in Casablanca, Morocco
M. Elazhari °, K. Zerouali, N. Dersi, R. Saile, M. Timinouni, M. Hassar
(Casablanca, MA)
Objectives: The aim of the present study is to determine the prevalence
of fusidic acid-resistant methicillin-susceptible Staphylococcus aureus
(FAR-MSSA) isolated from community infections, and to deﬁne whether
there are links between the antibiotic susceptibility of these strains, their
origin and accessory gene regulator (agr) groups, and to correlate them
with their toxic gene proﬁle.
Methods: Isolates were collected from clinical laboratories located in
Casablanca, from 1st January 2007 to 31st October 2008. They were
screened for susceptibility to fusidic acid by using a disc diffusion
method. MICs of fusidic acid for FAR-MSSA, their agr group, the
presence of toxins genes and pulsed-ﬁeld gel electrophoresis (PFGE)
patterns were investigated.
Results: Of 140 S. aureus isolates, 18 (12.9%) exhibited resistance to
fusidic acid. The “seh ” toxin gene was found in all 14 strains whose
harboured an agr group III, 9 of them were found with “sek” plus “seq”
toxin genes, witch 6 isolates, generally isolated from pus, and were
multidrug-resistant, shared an identical PFGE pattern, and possessed the
leukocidins (luk S-PV, luk F-PV) genes.
Conclusions: In conclusion, we found a close relationship between the
presence of the seh gene and the possession of agr group III in fusidic
acid-resistant methicillin-sensitive S. aureus (FAR-MSSA) strains. In
addition, our results indicate a relationship between 6 FAR-MSSA strains
belonging to the same pulsotype and harbouring agr group III with luk-
PV toxin genes.
P1029 Community-acquired methicillin-resistant Stapylococcus
aureus carrying the Panton-Valentine genes in invasive
infections in Algiers
N. Ramdani-Bouguessa °, K. Antri, H. Ziane, F. Djennane, M. Bes,
G. Lina, M. Tazir, J. Etienne (Algiers, DZ; Lyon, FR)
Objectives: Community acquired methicillin-resistant S. aureus
(C-MRSA) are spreading worldwide. They are responsible for lifethreat-
ning infections such as, necrotizing pneumonia and osteomyelitis.
Panton-Valentine leukocidin (PVL), a virulent factor, plays a role in
the pathophysiology of these infections. In Algeria, a high prevalence
of CA-MRSA-PVL+ has already been reported, however, the frequency
of C-MRSA-PVL+ in invasive infections is underestimated. The aim
of this study is to evaluate the frequency of invasive infections due to
CA-MRSA-PVL+.
Methods: A prospective study was conducted from january 2008
to october 2009. S. aureus was identiﬁed by coagulase and latex
agglutination. Antibiotic susceptibilities were determined by disk
diffusion according to CLSI recommendations. S. aureus identiﬁ-
cation was based on colony morphology, microscopic examination,
results of coagulase rabbit plasma and Staphyslide agglutination tests
(bioMe´rieux). The detection of mecA gene, PVL-genes (LukS-PV, lukF-
PV) and accessory gene regulator alleles (agr types 1 to 4) was
performed by multiplex PCR for 45 of the 51 invasive S. aureus
isolates.
Results: A total of 695 S. aureus strains has been collected, 356
(51%) were responsible for community-acquired infections. Of them,
57 were responsible for invasive infections: pneumonia (n = 26), bone
infections (n = 19), bacteraemia (n = 9), central nervous infection (n = 3),
endocarditis (n = 2) and peritonitis (n = 1). Thirty-two (56%) of these
infections were from children. C-MRSA infections were detected in 18
patients. PVL-genes were detected in 20 (44.4%) isolates: bone infec-
tions (n = 10), pneumonia (n = 7), bacteraemia (n = 1) and 2 endocarditis.
These isolates harboured the following proﬁles: agr3,mecA+,pvl+
(n = 13), agr3,mecA−,pvl+ (n = 4) and agr4,mecA−,pvl+ (n = 3). Three
patients died, all had C-MRSA-PVL+ infections, two pneumonia, one
bacteraemia and one endocarditis.
Conclusions: A high prevalence of C-MRSA-PVL+ severe infections is
observed, physician should reconsider the empiric antibiotic treatment
of these infections.
P1030 Community-associated methicillin-resistant Staphylococcus
aureus as the cause of healthcare-associated infection:
experience from an Indian tertiary hospital
B. Dhawan °, R. Gadepalli, C. Rao, V. Sreenivas, A. Kapil (New Delhi,
IN)
Objective: Community-associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) is an emerging threat worldwide. These strains
now cause serious infections in hospitalized patients. We conducted a
prospective study to evaluate the frequency of infections due to CA-
MRSA strains among hospitalized patients with HA-MRSA skin and
soft tissue infections (SSTIs). We also analysed the patients demographic
characteristics, clinical outcome and antimicrobial susceptibility patterns
associated with CA-MRSA infections acquired in the health care settings
compared with infection caused by HA-MRSA strains.
Methods: Fifty-six MRSA isolates obtained from patients admitted to
an Indian tertiary hospital from September 2008 through August 2009
with HA-MRSA SSTIs as per established deﬁnitions were included for
analysis in the study. Strains were tested for staphylococcal chromosomal
cassette mec (SCCmec) type I, II, III, IV & V and presence of Panton-
Valentine Leukocidin (PVL) genes by polymerase chain reaction (PCR)
methods. Susceptibility to ten antimicrobials was determined by the
disk diffusion method. Bacterial isolates were independently classiﬁed as
either CA-MRSA strains or healthcare-associated MRSA (HA-MRSA)
strains according to established molecular deﬁnition of CA-MRSA and
HA-MRSA.
Results: Twenty-ﬁve (44.6%) of the 56 MRSA isolates had a genetic
type characteristic of CA-MRSA strains; eighteen (32.1%) were SCCmec
type V and seven (12.5%) were SCCmec type IV. Ten of the 25 CA-
MRSA isolates (40%) carried PVL genes. The remaining 31 (56.4%)
isolates belongs to the SCCmec type I/III group. None of the isolates
were SCCmec type II. No differences were noted between the patients in
the SCCmec-I/II/III group and the patients in the SCCmec-IV/V group
with respect to the age; sex; medical service; underlying co-morbidities
or clinical outcome. Except for amikacin, whose susceptibility rates
were signiﬁcantly more for CA-MRSA strains, there was no statistical
difference in the susceptibility pattern of CA-MRSA and HA-MRSA
strains to ciproﬂoxacin, erythromycin, clindamycin, tetracycline, co-
trimoxazole and rifampicin. No resistance to vancomycin, teicoplanin
and linezolid was seen in both CA-MRSA and HA-MRSA strains.
Conclusion:MRSA strains with molecular characteristics of CA-MRSA
strains have emerged as an important cause of health-care-associated
SSTIs in our hospital. Further research is warranted to detect the impact
of CA-MRSA strains in Indian hospitals.
P1031 Changing proportions of clonal lineages of CA-MRSA in
Germany, 2006–2009
W. Witte °, C. Cuny, F. Layer (Wernigerode, DE)
Objective: To follow the proportion of clonal lineages of CA-MRSA in
samples of MRSA isolates from all Germany sent to a national reference
centre for molecular typing.
Methods: Typing my means of spa-typing, MLST, grouping of SCCmec
elements, AST by microbroth dilution assay, PCR demonstration genes
associated with virulence (luk-S, lukF, arcA, seh, etd) and resistance.
Results: Altogether the proportion of PVL-pos. MRSA of community
origin in the sample rose from 3.2% in 2005 to 6.2% in 2009. Within
this group the frequency of CA-MRSA ST8 decreased from 71% to
32% whereas that of CA-MRSA ST8 (“USA300”) increased from 12%
to 53%. The proportion of other clonal lineages such as ST1(IV),
ST5(V), ST22(IV), ST30(IV), ST152(V)did not exceed 5−10%. The
frequency of Livestock associated, PVL-neg. CC398(V) from severe
skin/soft tissue infections (SSTI) in humans exposed to livestock was
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11%.One PVL-pos. MRSA attributed to CC45(IV) was observed for
the ﬁrst time. About 4% of the isolates (attributed to ST1, ST5, ST8,
ST22, ST152) had acquired aminoglycoside resistance (aph2“aac6‘).
Furthermore tetracycline resistance emerged in a variety of clonal
lineages besides ST8..
Conclusion: The increasing proportion of CA-MRSAST8 and the
emergence of LA-MRSA CC398 as cause of SSTI need particular
attention in surveillance. Less broad resistance. Phenotypes are no longer
a characteristic of CA-MRSA.
P1032 Community-acquired methicillin-resistant Staphylococcus
aureus in the Tyrol (Austria) − a prevalence survey with
genetical characterization
M. Berktold °, D. Orth, K. Grif, M. Ma¨ser, R. Wu¨rzner (Innsbruck, AT)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) are
one of the most important human pathogens causing invasive infections
of the skin and soft tissue. Recently, certain strains among MRSA
developed which affected not only hospitalized patients, but also
healthy outpatients. These strains are called community-acquired MRSA
(caMRSA) and they typically possess the lukS-lukF gene, coding for
Panton-Valentine-Leukocidin.
The aim of this study was to investigate the occurrence and
characteristics of caMRSA at the University hospital Innsbruck, smaller
district hospitals and among patients of practitioners in the Tyrol
(Austria).
Methods: 220 MRSA strains, isolated from patients of the University
hospital Innsbruck (n = 174), district hospitals (n = 36) and practitioners
in the Tyrol (n = 10) from 2003 to 2007, were investigated for the
presence of lukS-lukF gene by PCR. For lukS-lukF-positive strains
antibiotic resistance testing was performed and the presence of SCCmec
element and accessory gene regulator (agr) was determined. Additionally
all lukS-lukF-positive isolates were typed by automatic ribotyping.
Results: Among 220 MRSA isolates 16 lukS-lukF-positive caMRSA
(7.3%) were identiﬁed: 10 from patients from the University hospital
Innsbruck (5.7%), 3 from district hospitals (8.3%) and 3 from outpatients
(30%). All caMRSA were resistant against the b-lactam antibiotics tested
as expected and susceptible to cotrimoxazol, rifampicin, fosfomycin and
vancomycin. Three strains showed resistance against fusidic acid. The
majority of the strains carried SCCmec IV (n = 12), one strain each
carried SCCmec I and SCCmec II. In two cases it was not possible
to identify the SCCmec element. Agr-gene-typing revealed a majority
of agr type 1 (n = 9), followed by agr type 3 (n = 4). One strain each
carried agr type 2 and 4, the agr type of one strain could not be
determined. Ribotpying revealed 8 different patterns, ribotpye 2 was the
most prevalent (n = 5).
Conclusion: CaMRSA are rather common in the outpatient community
in the Tyrol. Most caMRSA were similar in their genetic proﬁle
with SCCmec element IV and agr type 1 being the most prevalent.
Determination of caMRSA should always be considered in the
microbiological routine and especially practitioners should be alerted
to pay more attention to the threat of caMRSA.
P1033 Typing and characterization of antimicrobial resistance in
methicillin-resistant Staphylococcus aureus ST398 from pigs
including detection of clindamycin resistance mediated by
linA gene
C. Aspiroz, C. Lozano, F. Ruiz-Larrea, M. Zarazaga, C. Torres °
(Zaragoza, Logron˜o, ES)
Introduction and Objective: Methicillin resistant Staphylococcus
aureus (MRSA) isolates of sequence type ST398 have been identiﬁed
to colonize and cause infections in animals and humans, especially in
people in contact with pigs. The aim of this study was to characterize
the resistance phenotypes and genotypes of MRSA isolated from pigs of
a farm where one swine worker infected (skin lesion) and colonized by
MRSA ST398 was previously detected (Aspiroz et al. SEIMC, 2009).
Methods: Nasal swabs were collected from 12 pigs of the farm and
selective culture for MRSA recovery was performed on ORSAB agar
plates (OXOID) and one isolate per positive sample was characterized.
MRSA identiﬁcation was conﬁrmed by PCR of nuc and mecA
genes. Antimicrobial susceptibility was determined by VITEK-2 system
(bioMe´rieux) and by disc-diffusion method. MLST, SCCmec, agr and
spa-typing was performed by PCR and sequencing. The presence of
ermA, ermB, ermC, mrsA, linA, tet(K), tet(L), tet(M), tet(O), ant(4′),
aph(3′), aac(6′)-aph(2′) and dfrK genes as well as PVL (lukF/lukS) genes
were tested by PCR, and in some cases also by sequencing.
Results: MRSA ST398 were obtained from 11 of the 12 nasal swabs
(91.6%). All 11 MRSA isolates showed resistance to tetracycline
and were negative for PVL, and ten of them showed resistance
to cotrimoxazole. Seven isolates were typed as spa-t108, SCCmecV
and presented an unusual macrolide/lincosamides resistance phenotype:
resistance to clindamycin and susceptibility to erythromycin and
harboured linA in addition to tet(L), and dfrK genes. The four remaining
MRSA-ST398 isolates were typed as spa-t011 and SCCmecIVa, and
presented different resistance phenotypes, harbouring the following
genes (number of isolates): ermA (2), ermB (2), ermC (2), tet(L) (11),
tet(M) (5), dfrK (10), ant(4′) (4), aph(3′) (4), and aac(6′)-aph(2′) (3).
Conclusions:
1. A high rate of colonization by MRSA ST398 is detected in pigs,
being t011 and t108 the spa-types detected.
2. MRSA ST398 presents a wide diversity of antimicrobial resistance
phenotypes harbouring a high variety of resistance genes.
3. The unusual pattern of erythromycin susceptibility and clindamycin
resistance detected in 7 of 11 MRSA ST398 was mediated by linA,
being this gene the ﬁrst time found in a ST398 isolate.
4. Clindamycin resistance can compromise treatment of skin lesions
caused by MRSA ST398 of animal origin.
P1034 Methicillin-resistant and methicillin-susceptible Staphylo-
coccus aureus belonging to clonal lineage ST398: animal
and human prevalence, human clinical impact in France
F. Laurent °, E. Jouy, S. Granier, J. Vaucel, R. Ruimy, M. Bes,
J-P. Rasigade, B. Felix, A. Le Roux, C. Chauvin, J. Etienne, A. Brisabois
(Lyon, Ploufragan, Maisons Alfort, Saint Brieuc, Paris, FR)
Objective: The aim of this study was to evaluate the prevalence and
highlight the clinical impact of MRSA and MSSA belonging to clonal
lineage ST398 among pigs and human in France.
Methods and Results: To assess the prevalence of MRSA carriage
by French fattening pigs, we sampled 165 batches of 10 pigs by nasal
swabbing from January and September 2007 in 21 slaughterhouses.
Sampling was representative of national production. The prevalence
study demonstrated that 29.0% of batches and 13.3% of pigs were
MRSA carriers at slaughterhouse. ST398 was predominant (81%) and
was retrieved for 8 spa-types (t011, t034, t108, t588, t899, t1184, t1456,
t2370). ST398 MRSA isolates appear less prevalent but more diverse
than in other European countries.
To evaluate the prevalence of ST398 MRSA and MSSA in French
patients, we retrospectively screened all MRSA (n = 69) and MSSA
(n = 139) collected at St Brieuc Hospital (in an area with high density
of pig farming) from March to September 2009. No MRSA and only
4 MSSA belonged to clonal lineage ST398. These data indicate the
low prevalence of ST398 isolates in French patients that need to
be hospitalized, i.e, with severe infections without excluding possible
carriage and uncomplicated infections in the community.
Clinical impact of some ST398 isolates:
– a ﬁrst case of lethal necrotizing pneumonia due to a PVL+ ST398
MSSA strain in a healthy 14-year-old girl was reported in Orleans
(France). Clinical features and medical history were highly consistent
with those of previously published necrotizing pneumonia and ST398
S. aureus was isolated from various specimens.
– eight ST398 MSSA (7%) were identiﬁed among 114 MSSA isolates
collected during the French national survey on infective endocarditis
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(IE) conducted in 2008 while ST398 isolates are not classically
detected in nasal carriers.
– two related noscomial pulmonary infections were detected in a ICU
due to ST398 MSSA
Conclusion: The data collected indicate that the worldwide emerging
threat of livestock-associated ST398 S. aureus in France is so far limited
and especially focused on MSSA. The isolates are able to induce severe
infections and nosocomial dissemination. They illustrate the ability of
ST398 genetic background to acquire resistance and virulence factor
genes. Therefore, further studies are required to monitor i) the temporal
and geographical incidence in hospital and in the community; ii) the
potential genetic drift of ST398 in France and throughout Europe in the
future.
P1036 Staphylococcus aureus, methicillin-resistant S. aureus and
the mecA gene in a municipal wastewater treatment plant
S. Bo¨rjesson, S. Melin, A. Matussek, S. Lo¨fgren, P-E. Lindgren °
(Linko¨ping, Jo¨nko¨ping, Gothenburg, SE)
Objectives: Methicillin-resistant S. aureus (MRSA) and the mecA
(the gene encoding methicillin resistance) were recently detected and
quantiﬁed in wastewater. Knowledge is limited about their occurrence in
non-clinical environments, e.g. wastewater, and their role as a potential
human health hazard.
The project aims at
1. Investigating the occurrence of total S. aureus, MRSA and mecA
in a wastewater treatment plant (WWTP) and the effects on mecA
concentration, the prevalence of S. aureus and MRSA during the
process. Characterising the composition of the MRSA populations
and how the process affects it, in the WWTP.
Methods: The concentration of mecA and the occurrence of S. aureus
were determined by a recently developed real-time PCR assay. The
detection and quantiﬁcation of MRSA was carried out by real-time PCR
and cultivation by enrichment broth. MRSA were characterised by spa
typing, SCCmec typing and antibiograms.
Results: S. aureus and mecA could be detected over the year and during
the whole treatment process. No clear trend of the variation of the
mecA concentration could be noticed. However, a reduction in the mecA
concentration was found during the process.
MRSA could be detected by real-time PCR over a year, but mainly
in the inlet and early treatment steps. The results were conﬁrmed and
examined in more detail by selective cultivation of MRSA over a two-
month-period. Totally 189 MRSA colonies, belonging to 29 spa types,
were detected. 10 of these spa types were isolated for the ﬁrst time in
Sweden, including 6 novel spa types. 65% of the isolates were resistant
only to b-lactams, but 21% were resistant to more than two classes of
antibiotics (deﬁned as multi-resistant). 19 different spa types and 66%
of the isolates were cultivated from inlet, compared to 15 spa types from
the activated sludge step. All spa types carried either the SCCmec I or
IV. In activated sludge 40% of spa types were multi-resistant, bu only
21% in the inlet. Most spa types showed close genetic relationship to
clinical MRSA isolates, previously described in Sweden.
Conclusions:
1. S. aureus and mecA occur over the year and during the entire
treatment process, but the mecA concentration is reduced during the
treatment.
2. MRSA was for the ﬁrst time detected and isolated from municipal
wastewater, and showed a stable occurrence over time. However, the
WWTP process reduced the amount and diversity.
3. Wastewater isolates of MRSA might reﬂect the carriage in the
community.
P1037 Dynamic pattern and genotypic diversity of Staphylococcus
aureus nasal carriage in healthy kindergarten children
S. Blumental °, A. Vergison, S. Jourdain, A. Deplano, R. De Mendonc¸a,
S. Rottiers, E. Vandaele, P. Smeesters, M.J. Struelens, O. Denis
(Brussels, BE; Stockholm, SE)
Background: It is common wisdom that persistent carriage of S. aureus
is more frequent in young children than in adults.
Objectives: To assess temporal carriage pattern of S. aureus among
a healthy community of kindergarten children, with concomitant
description of genotype diversity, toxin-encoding gene and antibiotic
resistance proﬁles.
Materials and Methods: Children aged from 3 to 6 year attending 11
kindergartens in Belgium were followed over the school year. S. aureus
nasal carriage was assessed longitudinally by culture of sequential
nasopharyngeal aspirates collected during autumn, winter and spring.
S. aureus identiﬁcation was conﬁrmed by PCR for detection of 16S/ nuc/
mecA genes. Antimicrobial susceptibility was tested by disk diffusion
method. Toxin production proﬁle was determined by PCR for PVL/
TSST-1/ETa/b toxin genes. Typing was performed by spa sequencing
using Ridom StaphType 1.4 (Ridom GMbH).
Results: 898 samples were collected from 333 children, 286 (32%)
yielded S. aureus from 185 children (55%) being carriers at least once
over the school year. Among 271 children who underwent at least two
consecutive samplings, 90 had a single positive culture and 68 had two
or more. Based on consecutive genotype analysis, only 41/271 (15%)
were classiﬁed as persistent carriers and the remaining 117 (44%) as
intermittent carriers. Spa typing showed 89 types clustered into 13 spa
clonal complexes (CC) using the BURP algorithm. Fourteen strains
isolated from 11 (3%) children of ﬁve different schools were resistant
to methicillin. Seven (50%) MRSA strains belonged to the unusual spa
CC304 (corresponding to CC8 by MLST). MSSA isolates were more
diverse with 54% distributed into ﬁve spa CC. Rate of antimicrobials
resistance among MSSA strains reached 24% for erythromycin, 2% for
clindamycin, 8% for tetracycline and 1.5% for ciproﬂoxacin. TSST-1
gene was present in 70 S. aureus isolates (24%). In contrast, PVL gene
was carried only by four MSSA strains. Exfoliatin toxin genes were
detected in 10 (3.5%) MSSA strains of which 5 were related to the
impetigo clone CC121.
Conclusions: Although S. aureus nasal carriage was high among healthy
kindergarten children, persistent carriage seems to be less frequent than
previously reported. Prevalence of MRSA carriage was 3% but was not
associated with PVL. As expected, MSSA isolates were genotypically
diverse and included toxic shock and exfoliatin producing strains.
P1038 Diabetes is a risk factor for recurrent cellulitis
M. Karppelin °, T. Siljander, A. Aromaa, H. Huhtala, J. Kere,
J. Vuopio-Varkila, J. Syrja¨nen (Tampere, Helsinki, FI; Huddinge, SE)
Objectives: In previous case–control studies obesity, but not diabetes,
has been associated with acute and recurrent bacterial non-necrotizing
cellulitis. We evaluated the role of diabetes as a risk factor for recurrent
cellulitis in a retrospective case–control study.
Methods: A questionnaire and a consent form were sent to all
those who, according to National Health Insurance Institution, had in
year 2000 received reimbursement for benzathine penicillin, indicated
for prevention of cellulitis. Medical records were obtained from the
respective care providers to conﬁrm the diagnosis of cellulitis. Based
on the questionnaire the following variables were recorded: age, sex,
height, weight and diabetic status (all types). Body mass index (BMI)
was calculated as weight (kg) divided by square of height (m).
Control population consisted of 8005 Finnish subjects, aged 30 years
or over, participating in Health 2000 Health Examination Survey, a
national population based health survey, carried out in years 2000–
2001 by the former Finnish National Public Health Institute (KTL). This
survey consists of a randomly drawn, nationally representative sample
of the Finnish population. Data regarding the corresponding variables
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mentioned above were derived from the database. A logistic regression
analysis (method enter) was performed using STATA software.
Results: Of 960 subjects contacted, 487 (50%) returned a consent and
ﬁlled in a questionnaire. Recurrent cellulitis could be ascertained from
the medical records of 398 patients of which 235 (59%) were female.
The median age of the patients was 65 years (range 22−92). The mean
BMI was 31.5 and 32.5 for male and female patients, respectively, and
32.1 for the whole patient population, compared to 26.9 for controls. Of
the patients and controls 20.6% and 6.1% were diabetic, respectively.
The multivariate analysis of risk factors is presented in table.
Conclusion: In the present study, comprising large patient and control
populations, diabetes proved to be a risk factor for recurrent cellulitis,
independently of obesity and age. The incidence of bacterial cellulitis
has been suggested to be growing. Increasing prevalence of obesity and
adult type diabetes along with increasing longevity may contribute to
this.
Table. Multivariate analysis of risk factors for recurrent cellulitis in 398
patients and 8005 control subjects
Risk factor OR 95%CI
Sex 1.19 0.95–1.49
Age 1.05 1.04–1.06
Body mass index 1.17 1.14–1.19
Diabetes 1.69 1.26–2.27
P1039 Complex nature of locally invasive odontogenic infections
in patients requiring intensive care
L. Seppa¨nen °, A. Lauhio, C. Lindqvist, R. Rautemaa-Richardson
(Helsinki, FI)
Objectives: An increase in the number of locally invasive odontogenic
infections requiring hospital care has been recently observed in many
countries. Our aim was to analyse the microbiological ﬁndings of
odontogenic abscesses in relation to the clinical characteristics of the
patients and the need for intensive care.
Methods: Microbial ﬁndings and medical records of patients admitted
to the Helsinki University Central Hospital due to locally invasive odon-
togenic infection in 2004 were analysed retrospectively. Microbiological
reports were available from 69 patients and these patient cases were
included in the study.
Results: Twenty-eight (41%) patients were in need for intensive care.
Staphylococci, including Staphylococcus aureus, were a signiﬁcantly
more common ﬁnding in patients requiring intensive care compared to
those patients who did not (p< 0.0001 and p = 0.0484). Staphylococci
had been reported in 57% of the cases requiring intensive care in contrast
to 10% of cases who did not. In addition, microaerophilic streptococci
were more prevalent in patients requiring intensive care (p = 0.0152).
There was no difference in the isolation rate of anaerobes between
the two groups. Propionibacterium and Lactobacillus spp. were more
commonly reported in patients requiring intensive care (p = 0.0154 and
p = 0.0368). Many reported isolates demonstrated reduced susceptibility
to penicillin and macrolides. Resistance to clindamycin was more com-
mon than to doxycyclin. The clinical course of these infections was more
severe as reﬂected by signiﬁcantly more elevated inﬂammatory markers.
White blood cell count on admission (median 15.4 x 103/mL and 11.3
x 103/mL, p = 0.0038), and at maximum (median 16.2 x 103/mL and 11.
x 103/mL, p = 0.0002), as well as C-reactive protein level on admission
(median 161mg/L and 76mg/L, p = 0.0002) and at maximum (median
176mg/L and 85mg/L, p< 0.0001) were signiﬁcantly higher in patients
with the need for intensive care compared to patients without the need
for intensive care. Length of stay was 8.1 days for patients with intensive
care and 2.8 day in mean for patients without intensive care (p< 0.0001).
Conclusion: The microbial ﬁndings of this study suggest that
staphylococci may have a greater role in severe odontogenic infections
than generally appreciated. The possibility of their involvement should
be considered in the empiric antibiotic therapy of infections requiring
intensive care.
P1040 Evolution of methicillin-resistant Staphylococcus aureus
isolated at a community healthcare centre in Spain
C. Potel °, M. A´lvarez, L. Constenla, F. Lago, C. Varela (Vigo, ES)
Objective: To determine the distribution of Methicillin-Resistant Staphy-
lococcus aureus (MRSA) isolated from outpatients at a community
health care center serving a large population of 300.000 from the
Northwest of Spain.
Methods: In total 1.913 S. aureus were isolated between 2003 and 2007.
From these ones, 135 strains were MRSA.
The presence of mecA gene and pvl genes was identiﬁed in all MRSA
strains by PCR. The isolates were studied by analysis of restriction
fragment length polymorphism of the coagulase gene and digestion
with cfoI (RFLP) and pulsed-ﬁeld gel electrophoresis (PFGE). The
staphylococcal chromosome cassette (SCC)mec and the accessory gene
regulator (agr) types were determined by multiplex and duplex PCR
respectively. Representative strains were analyzed by spa typing and
multilocus sequence typing (MLST).
Results: The MRSA percentage ranged from 9% in 2003 to 12% in
2007. According to the RFLP patterns, the 135 MRSA isolates were
classiﬁed in seven clonal groups; 33.4% were identiﬁed as t018-ST36-
II-agr1 (British clone); 30% t002-ST5-IV-agr2 (New York/Japan clone);
25% t067-ST125-IV-agr2 or IVa-agr2; 4.5% t148-ST72-IVa-agr1; 4.5%
t037-ST239-II-agr3 (Brazilian clone); 1.5% t008-ST8-IV-agr1 (USA300
clone); 0.8% t002-ST5-IV-agr1 (Paediatric clone).
The pvl genes were detected in four isolates (3%); two strains belonged
to the USA300 clone (one was isolated in 2006 and the other in 2007),
one strain to the Paediatric clone, and another one to the ST125 clone.
Conclusion: In other surveillance studies, we described the local
epidemic lineages isolated in the hospital setting (1, 2). They were
typically health-care associated clones; ST36 (actually it is endemic
in our hospitals), ST5, ST125, and ST239 (it was endemic until
2002). In the present study these clones were isolated in outpatients,
therefore they were also circulating in the community setting. The clones
denominated as community-acquired MRSA were scarcely isolated,
only two USA300 isolates. We can state that the community setting
highlights the relationship between community and hospital MRSA
strains whichever might have been their acquisition, so we think that
it is useful to continue surveillance in this scenario.
Reference(s)
[1] Potel C, et al. Clin Microbiol Infect. 2007;13:728–730.
[2] C Potel, et al. Enferm Infecc Microbiol Clin. 2009; 27(1):58−64.
P1041 Community and healthcare associated methicillin-resistant
Staphylococcus aureus: observational study in a large
tertiary-care Italian hospital
A. Bartoloni °, E. Mantengoli, F. Bartalesi, A. Cavallo, D. Cecconi,
P. Pecile, E. Graglia, P. Nicoletti, G.M. Rossolini (Florence, Siena, IT)
Objective: To investigate the role of methicillin resistant Staphylococcus
aureus (MRSA) in community-associated (CA) infections in a large
tertiary-care university hospital in Italy, and to compare it with the role
of health-care associated MRSA (HCA-MRSA) infections in the same
setting.
Methods: MRSA isolated from patients within 48 hours of hospitaliza-
tion and without risk factors for HA-MRSA were deﬁned CA-MRSA.
HA-MRSA infections constituted the control group. A data questionnaire
was used to collect patients demographics, clinical history, HA- and CA-
MRSA risk factors.
Results: 30 patients were enrolled from April until September 2009:
6 infected by CA-MRSA and 24 by HA-MRSA. The mean ages
were, respectively, 64 (45−84 years) and 74 years (29–100 years).
All CA-MRSA were from skin and soft tissue infections (SSTI).
HA-MRSA were from SSTI (46%), sputum or BAL (42%), blood
(12%). 1 of 6 CA-MRSA infected patients had HIV as risk factor.
Most of HA-MRSA infected patients (23/24) had at least one risk
factor. Complications (septic shock, sepsis, pneumonia) were observed
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in none of the patients infected by CA-MRSA but in 9 of 24
(63%) of those infected by HA-MRSA [p = 0.02]. 5 death (21%)
were observed in the HA-MRSA infected patients and none in those
with CA-MRSA [p = 0.5]). The susceptibility rates for HA- and CA-
MRSA were, respectively: clindamycin 21% vs 50%; erythromycin
21% vs 33%; levoﬂoxacin 8% vs 0%; gentamicin 29% vs 67%;
tobramycin 17% vs 50%; rifampicin 87% and 100%; tetracycline 92%
vs 83%; trimethoprim sulfamethoxazole 96% vs 100%; all isolates
were susceptible to vancomycin, teicoplanin, linezolid and tigecycline.
Molecular analysis showed heterogeneity of SCCmec cassettes (type I
and IV in CA-MRSA and type I, II, and IV in HA-MRSA) and the
presence of PVL genes in only one CA-MRSA.
Conclusions: This is the ﬁrst report comparing molecular epidemiology,
clinical impact, treatment outcome and risk factors for HA- and CA-
MRSA infections in Italy. HA-MRSA infections had more complications
and seem to have a worse prognosis. CA-MRSA showed in general
an higher antibiotic susceptibility, even if we observed a remarkable
reduced susceptibility to aminoglycosides and a total resistance to
quinolones. HA-MRSA and CA-MRSA were found to share some
molecular features, as also recently reported.
P1042 Staphylococcus aureus carriage in healthy humans in Spain:
antibiotic resistance mechanisms, virulence traits and
genetic lineages
C. Lozano °, E. Go´mez-Sanz, F. Ruiz-Larrea, M. Zarazaga, C. Torres
(Logron˜o, ES)
Objective: To study the prevalence, resistance mechanisms, virulence
traits and genetic lineages of nasal S. aureus of healthy humans.
Methods: 135 nasal swabs were obtained from healthy people (aged
from 1 to 74) from April to October 2009 in La Rioja (Spain).
Samples were inoculated into BHI broth with 6.5% NaCl, incubated at
35ºC/24 h., and then seeded on ORSAB plates (OXOID) with 2mg/L of
oxacillin and Mannitol Salt Agar (BD) plates (for methicillin-resistant-
S. aureus (MRSA) and S. aureus recovery, respectively), and incubated
at 35ºC/36 h.. One isolate per positive sample was characterized.
Identiﬁcation was conﬁrmed by PCR of nuc gene. Proﬁle susceptibility
to 16 antibiotics was determined by disk diffusion method according
CLSI guidelines. Presence of mecA, ermA, ermB, ermC and msrA genes
was studied by PCR. Mutations in quinolone targets were determined by
sequence analysis of grlA and gyrA genes. spa and agr typing was im-
plemented on all the S. aureus strains. Presence of toxin genes lukF/lukS,
tsst1, eta, etb, hla, hlb, hld, hlg, and hlg-2 was investigated by PCR.
Results: 23 of 135 samples contained S. aureus (17%). A high diversity
of spa-types were identiﬁed (t002, t008, t012, t018, t021, t084, t190,
t209, t216, t270, t342, t571, t985, t1008, t1641), and four new spa-
types were detected. The most frequent spa-type was t002 (3 strains,
13%). Isolates presented agr-type I (30.5%), II (39.1%), III (26.1%) and
IV (4.3%). No MRSA were detected. Eight strains were resistant to
erythromycin and the following genes were detected (no strains): ermA
(5), ermB (1), ermC (1), and msrA (5). Two strains showed resistance
to ciproﬂoxacin; one of them presented Ser80Phe in GrlA and Ser84Leu
in GyrA amino acid changes, and Pro144Ser in GrlA and no mutation
in GyrA the other one. All strains were susceptible to other antibiotics
tested. The following toxin genes were detected (no strains): lukF/lukS
(0), tsst1 (9), eta (2), etb (0), hla (23), hlb (14), hld (23) hlg (14), and
hlg-2 (13).
Conclusions: A moderate prevalence of S. aureus nasal colonization, and
a high genetic diversity (19 different spa-types) have been detected in
healthy people in Spain. Four new spa-types were detected. No MRSA
was found. Different resistance and toxin genes were detected. 39%
of the strains were positive for tsst-1 gene and the majority of them
belonging to agr-typeIII.
P1043 Emergence and characterization of Panton-Valentine
leukocidin-positive community-acquired methicillin-
resistant Staphylococcus aureus infections in Canary
Islands, Spain, 2003–2008
A. Can˜as-Pedrosa °, I. Horcajada, F. Artiles, A. Vindel, B. Lafarga
(Las Palmas, Madrid, ES)
Objective: Community-associated methicillin-resistant Staphylococcus
aureus (CA-MRSA) has emerged rapidly in the United States and is
now emerging in Europe. In this study we assessed the prevalence,
microbiological characteristics, molecular epidemiology and outcomes
of Panton-Valentine leukocidin-positive (PVL-positive) CA-MRSA
infections in Gran Canaria over the last 6 years.
Methods: Patients with PVL-positive CA-MRSA infections between
January 2003 and December 2008, were eligible for inclusion in this
study. The PVL genes (lukS-PV and lukF-PV), mecA gene and arcA
region of ACME gene were detected by PCR. SCCmec types, SCCmec
IV subtypes and agr type were determined by using multiplex PCRs.
Strains were genotyped by pulse ﬁeld gel electrophoresis (PFGE) after
SmaI digested, spa typing and assigned to clonal complexes (CCs).
Results: A total of 560 new MRSA cases (1 per patient) were found
from 2003 to 2008. Of the MRSA cases, 2.7% (18) were PVL-positive
CA-MRSA. The female-to-male ratio was 0.29 and the mean age
was 20 years (range, 1−54). The proportions of PVL-positive CA-
MRSA cases were less than 2% from 2003 to 2006, 3.6% in 2007
and 15% in 2008. In total, 22% (4/18) of the patients were of non-
Spanish origin (Ecuador, Colombia and Filipinas). Skin and soft tissue
infections (SSTIs) were predominant (16 cases [88%]), followed by
invasive infections (arthritis and osteomyelitis) (2 cases [12%]). In 13
(82%) cases, SSTI was associated with an abscess. In total, 82% (13/16)
of the isolates genotyped were identiﬁed as spa-CC008-SCCmec IV, agr
I allele. Of these 13, three (23%) were found to be USA-300, ACME+,
SCCmec IVa, spa type t008, and 10 (70%) had a USA300-like PFGE
pulsotype, SCCmec IVc, spa type t008 (8) and t024 (2). Two isolates
(12%) were t019/ST30-SCCmec IVc, agr III allele (South Paciﬁc clone)
and one isolate (6%) was t311/ST5-SCCmec IVa, agr II allele (paediatric
clone).
Conclusions: Our results show an increase in the incidence of PVL-
positive CA-MRSA in 2008. PVL-positive CA-MRSA predominantly
caused SSTI in children, and abscesses were the most frequently
encountered indication. Well-known CA-MRSA strains, such as,
CC8:ST8-IV (USA300), CC30:ST30-IV (South Paciﬁc CA-MRSA) and
CC5:ST5-IV (paediatric clone) were found. However, CC80: ST80-IV
(European CA-MRSA) was not present. Clinical and microbiological
evidence suggests import and subsequent transmission as the most likely
sources of many of the new CA-MRSA cases.
P1044 Skin and soft tissue infections due to Staphylococcus
aureus producing Panton-Valentine leukocidin toxin in the
Nord-Pas-de-Calais region, northern France, 2004–2008
C. Gros, Y. Yazdanpanah, M. Roussel-Delvallez, A. Vachet,
E. Senneville, X. Lemaire ° (Tourcoing, Lille, Roubaix, FR)
Background: The aim of this study was to describe epidemiological
characteristics, clinical characteristics, and treatment of patients with
skin and soft tissue infections due to Staphylococcus aureus (S. aureus)
producing Panton-Valentine leukocidin (PVL) toxin in Nord-Pas-de-
Calais region, Northern France (4 millions of inhabitants).
Methods: All patients with S. aureus specimens producing PVL seen
in one of the 7 hospitals in the Nord-Pas-de-Calais region between
02/2004 and 04/2008 were ﬁrst identiﬁed. Epidemiological and clinical
characteristics for and antibiotics initiated in these patients were
extracted from their medical records or through telephonic interviews
using a standardized questionnaire.
Results: During the study period, S. aureus PVL was isolated in 64
cases from February 2004 to April 2008. 54 pts had skin and soft
tissue infections (35 abscesses), 3 had pneumonia, and 7 had only
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nasal carriage. Skin and soft tissue infections were abscesses with
inﬂammatory signs in 64.8% of the cases. Only 20% of these abscesses
were necrotic. Patients with skin and soft tissue infections were men in
63% and had a mean age of 24.7 years. Sixteen patients (29.6%) were
from the city of Roubaix (100,000 of habitants). The median number of
household members in a patient with S. aureus PVL was 4.5 (vs. 2.5
in Nord-Pas-de-Calais). 44.4% of patients had domestic animals. 70.3%
of patients had a methicillin resistant strain. An antibiotic therapy was
administered in 83.3% of patients and these antibiotics were considered
to be inadequate in 53.3% of the cases. Surgery was performed in 83.3%
of the patients. An exposition to antibiotic therapy in the previous 3
months was noted for 14 of the 38 patients with available data. A
methicillin resistant strain was isolated in 10 of these 14 patients.
Conclusion: A high number of household members and a previous recent
exposition to antibiotic therapy could lead to suspect a PVL in patients
with skin abscess. In these patients, efforts should be done to obtain skin
swab samples and cultures to adapt antibiotic use. Given the increasing
number of S. aureus PVL infections in the Nord-Pas-de-Calais region,
a prospective study should be initiated to better identify risk factors for
developing skin lesions related to PVL.
P1045 Prevalence and clinical signiﬁcance of infections caused by
toxin-producing Staphylococcus aureus isolates
T. Nhan, R. Leclercq, V. Cattoir ° (Caen, FR)
Objectives: Among virulence factors described in Staphylococcus
aureus, several are of major concern such as PVL, TSST-1/SEB/SEC
and ETA/ETB potentially implicated in complicated skin and skin
structure infections and necrotizing pneumonia, toxic shock syndrome
and staphylococcal scalded skin syndrome, respectively. The aim of this
study was to screen consecutive S. aureus clinical isolates (resistant or
not to methicillin) for the presence of six major toxin genes and to assess
the clinical signiﬁcance of these toxin-producing strains.
Methods: We screened all S. aureus clinical isolates recovered from
May to June 2009 from patients hospitalized at the university hospital
of Caen, France. Clinical data were obtained for each patient regarding
age, gender, predisposing conditions, site of isolation and clinical
presentation. PCR detection of pvl, tst, seb, sec, eta and etb genes was
performed using two multiplex real-time PCR assays. We compared
groups of patients presenting uncomplicated infections versus severe
infections (severe sepsis, toxic or septic shock) according to the presence
or not of toxin genes by using the Fischer’s test.
Results: During the two-month study period, 186 S. aureus strains
were isolated from 186 patients suffering from superﬁcial and invasive
infections (48.4% and 51.6%, respectively). Prevalence of nosocomial
infections was 53.2%. The mean age was 54 years (range 0−97 years),
sex ratio M/F was 1.6 and predisposing conditions were present in
94 patients (50.5%). At least one toxin gene was detected in 55
(29.6%) isolates as follows: pvl (n = 1), tst and sec (n = 5), seb (n = 19),
seb and sec (n = 1), sec (n = 28), eta (n = 1) and etb (n = 0). The
proportion of toxin-producing strains (40/151, 26.5%) in the group of
patients presenting uncomplicated infection and in that of patients with
severe infection (15/35, 42.9%) was not statistically different (P = 0.066)
although severity of infection tended to be associated with the presence
of a toxin gene.
Conclusion: This study contributed to estimate the prevalence of toxin
gene among consecutive clinical isolates of methicillin-susceptible and
-resistant S. aureus from France. Although the prevalence of toxin genes
is relatively high (about 30%), no statistically signiﬁcant relationship
between severity of infection and presence of toxin gene has been found.
P1046 Pathogenic mechanisms of methicillin-resistant
Staphylococcus aureus
A. Haggar °, A. Nguyen Hoang, M. Svensson, G. Arakere,
A. Norrby-Teglund (Stockholm, SE; Bangalor, IN)
Objective: Community-associated (CA)-MRSA has been reported in
association with highly aggressive infections, including necrotizing soft
tissue or lung infections as well as septic shock. Here we have studied
pathogenic responses elicited by MRSA isolates in human in vitro cell
and tissue model systems.
Methods: CA-MRSA isolates (n = 17) collected in Bangalore were
characterized with respect to agr type, superantigen gene proﬁle and
presence of the Panton-Valentine Leukocidin gene (PVL). Seven isolates
with matched agr type, but varying toxin proﬁles, were selected for
functional analyses and toxin-containing supernatants (SUPs) were
prepared from stationary phase cultures. These SUPs were tested for
ability to induce proliferation of peripheral blood mononuclear cells, and
for cytotoxic (epithelial damage, HMGB-1 release) and/or inﬂammatory
effects (IL8 expression) in a 3D organotypic lung tissue model. The
latter analyses were done by immunostaining and in situ image analyses
(ACIA) of SUP-exposed tissue.
Results: The proliferation assay showed that isolates clustered according
to their agr type. Type I and II strains induced signiﬁcantly stronger
proliferation than did agr type III and IV isolates (ANOVA, p = 0.02).
In fact, agr III and IV isolates induced a strong cytoxic response over a
broad concentration range. The cytotoxicity could not be related to PVL-
positivity, as the most cytoxic strain was PVL-negative. Western blot
analyses of SUPs revealed higher amounts of a-hemolysin in cytotoxic,
as compared to mitogenic, SUPs.
Two agr type II mitogenic isolates and three cytotoxic isolates (agr
III and IV) were further tested in the lung tissue model. SUPs were
added on the apical side of the epithelial layer in the tissue model and
after 24 h of exposure the tissue was analyzed for IL-8 and HMGB-1.
HMGB-1 was markedly increased in tissues exposed to the cytotoxic
SUPs (ACIA=38−40) whereas tissue exposed to mitogenic SUPs was
equal to control tissue (ACIA=19−23). IL-8 was upregulated in all tissues
exposed to the SUPs (ACIA=20−45) as compared to unstimulated control
tissue (ACIA=11).
Conclusion: Our ﬁndings reveal striking differences in mitogenic versus
cytotoxic functions of MRSA isolates of varying agr types. These
functional differences were also reﬂected in the responses elicited in the
human lung tissue model. Furthermore, the data implicates a-hemolysin,
rather than PVL, in these responses.
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P1047 Characteristics of longitudinal oropharyngeal asymptomatic
colonization and of multicolonizaton by different strains of
group A streptococci from Portugal
R. Pires °, C. Alves, F. Esteves, D. Rolo, J.M.F. Almeida, T. Ramos,
C. Gameiro, F. Andrade, A. Lopes, L. Romeiro, F. Vaz, A. Morais,
A. Brito-Avoˆ, J. Gonc¸alo-Marques, I. Santos-Sanches (Caparica,
Oeiras, Lisbon, PT)
Objective: To examine the long-term asymptomatic oropharyngeal
colonization status by Group A streptococci (GAS) and if co-colonization
of the oropharynx by multiple GAS strains occurs among asymptomatic
persons.
Methods: Between 2000 and 2004, 5,494 oropharyngeal samples were
taken during 12 sampling periods in October, February and May of
each year from 1,729 healthy individuals. Bacterial identiﬁcation was
carried out by standard methods. The total number of GAS isolates
was 626 (carriage rate 11.4%) out of which 243 (38.8%) were from
113 (6.5%) recurrent carriers − deﬁned as colonized by GAS more
than once during 2 to 12 sampling periods. These isolates were
considered as associated with long-term or longitudinal colonization.
All b-hemolytic colonies identiﬁed as GAS that were picked from each
of the primary plates containing the swabs of 23 participants, out of
865 (2.7%) persons sampled in one sampling period, were considered
as causing co-colonization or multicolonization of the same niche.
Isolates of both groups − 243 causing longitudinal colonization and
74 isolates causing multicolonizaton − were typed by pulsed-ﬁeld gel
electrophoresis (PFGE) for strain deﬁnition and by sequencing part of
the emm gene encoding the M surface protein (emm typing).
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Results: Of the 113 recurrent carriers, 111 were colonized in 2 or 3
sampling periods and 2 were colonized in 4 sampling periods. In the
majority of the recurrent carriers (n = 89, 78.8%), strain replacement was
observed. Examples that occurred frequently were emm12 (PFGE.AB)
replaced by emm1 (PFGE.X) or emm3 (PFGE.BG), and emm1
(PFGE.X) replaced by emm12 (PFGE.AP). The remaining 24 (21.2%)
persons were carriers of a same strain. Also, out of the 113 persons,
54 (47.8%) were carriers at least once of emm12 strains. Of the 23
participants of the multicolonization study, 6 (26.1%) were colonized by
multiple strains of different PFGE types and of a same emm type. An
example was one individual that carried 3 emm75 strains (PFGE.CY,
PFGE.FM and PFGE.FN types).
Conclusions: A replacement of GAS strains was frequently found
among recurrent carriers and co-colonization of the oropharynx by
multiple GAS strains was detected. emm12 isolates seem to be
successful colonizers as they were identiﬁed as widely disseminated
among epidemiological related and unrelated carriers and were persistent
overtime.
P1048 Unique and changing epidemiology of group A streptococcal
infection in western Australia
D. McLellan °, L. O’Reilly, A. Levy, T.J. Inglis, J.R. Dyer (Fremantle,
Perth, AU)
Objective: The aim of this study was to examine the clinical and
molecular epidemiology of group A streptococcal (GAS) disease over a
10-year period in Western Australia.
Methods: Isolates from patients with invasive GAS disease were
collected in two time periods, 2000−03 and 2006−09. These isolates were
subjected to emm typing and pulse ﬁeld gel electrophoresis (PFGE). For
comparison, 186 consecutive non-invasive isolates were also collected in
2007 and emm typed. Clinical information was collected from patients
identiﬁed in 2000−03.
Results: 61 patients with invasive GAS disease were identiﬁed in the
period 2000−03. 57% of cases were male and the mean age was 47.
Nineteen cases (31.1%) occurred in indigenous Australians. Necrotizing
fasciitis was evident in 6 patients (9.8%) and streptococcal toxic shock
syndrome (STSS) in 7 (11.5%). Seven (11.5%) deaths could be directly
attributed to GAS disease. In the 11 cases complicated by necrotizing
fasciitis and/or STSS there were 5 deaths (45.5%).
Of the 61 isolates, 27 different emm types were identiﬁed. Emm type 8
was the most common type, representing 6 of 61 isolates (9.8%). PFGE
analysis of the 61 isolates revealed a high concordance between emm
type and PFGE pattern. The 6 emm type 8 isolates were indistinguishable
based on their PFGE pattern.
For the period 2006−09, 51 patients with invasive GAS disease were
identiﬁed. Of the 51 isolates, 17 different emm types were identiﬁed.
The most common emm types were 1 (22%), 89 (18%), 28 (10%) and 12
(8%). Molecular analysis by PFGE of the emm type 1 isolates indicated
they were clonally related.
Of the 186 non-invasive isolates collected in 2007, 41 different emm
types were identiﬁed. The most common emm types were 4 (15.1%), 89
(10.2%), 49 (8.1%) and 87 (7%).
Conclusions: A remarkably heterogeneous population of emm types
have been identiﬁed causing both invasive and non-invasive infection
in Western Australia. This study also suggests that new emm types
are entering this population at regular intervals and are responsible
for severe disease. This epidemiology is different to what has been
reported in the Northern Hemisphere and eastern Australia and likely
reﬂects geographical isolation and other factors. This information
has implications for M protein-based GAS vaccines currently under
development.
P1049 Invasive group A streptococcal disease in Ireland, 2004–2008
J. Martin °, S. Murchan, D. O’Flanagan, F. Fitzpatrick (Dublin, IE)
Objectives: Diseases caused by Invasive Group A streptococcus (iGAS)
are a major clinical and public health challenge. There has been an
increase in prevalence of iGAS globally in recent decades. Many aspects
of their occurrence and characteristics remain poorly understood. The
aim of this study is to analyse the microbiological and epidemiological
characteristics of iGAS in Ireland over the ﬁve year period 2004–2008.
Methods: Enhanced surveillance data and laboratory results were
entered onto the national electronic reporting system. Data were entered
on patient demographics, risk factors for iGAS, clinical presentation
and outcomes associated with iGAS, in addition to source, timing
and clusters of disease. Collection of antimicrobial susceptibility data
commenced in 2008.
Results: Between Jan 1 2004 and Dec 31 2008, 270 cases of iGAS were
notiﬁed. Males and females were affected equally. Cases occurred in all
age groups but children up to 9 years and adults 55 year and over were
most common affected (median age, 42 years; range 0−94 years). iGAS
incidence increased from 2004 (0.9 per 100,000 population) to 2008 (1.6
per 100,000 in 2008). The most common risk factors associated with
iGAS were age over 65 years and skin/wound lesions. Thirteen cases
presented with streptococcal toxic shock syndrome (3 of whom died)
and 11 with necrotising fasciitis (4 of who died). Over the ﬁve year
period 21 people with iGAS died, eight of whom had iGAS identiﬁed
as the main cause of death (case fatality rate of 3%). Antimicrobial
susceptibility data was available on 38 of 68 isolates in 2008. All isolates
tested were susceptible to penicillin (n = 37), clindamycin (n = 5) and
vancomycin (n = 31). Resistance to erythromycin was reported in 3 of
30 (10%) isolates.
Conclusion: There appears to be an increase in iGAS infections over
time. This could be a genuine increase in the incidence of iGAS or could
represent better reporting of this disease, which only became notiﬁable
in Ireland as of 2004. The number of cases notiﬁed in Ireland still
remains low compared to other Northern European countries and the US.
Certain serotypes of GAS are known to be more virulent than others, e.g.
serotypes M1 and M3, but in the absence of a streptococcal reference
laboratory in this country, no serological typing data are available to
investigate such a link between Irish isolates and severity of disease.
P1050 Incidence and risk factors for chronic suppurative otitis
media in a birth cohort of children in Greenland
A. Koch °, P. Homøe, C. Pipper, T. Hjuler, M. Melbye (Copenhagen, DK)
Objectives: Inuits of the Arctic experience very high rates of chronic
suppurative otitis media (CSOM), yet world-wide very little is known
about the epidemiology of CSOM. The study aims were to determine
age-speciﬁc incidence, median age at debut, risk factors, and associated
population-attributable risks for CSOM in children in Greenland in order
to devise possible preventive measures.
Methods: A population-based cohort of 465 children aged 0−4 years
was followed closely for a two-year period 1996−98 in Sisimiut, the
second-biggest town of Greenland, and cases of CSOM and other
respiratory tract infections were registered based on medical history and
clinical examinations. Information on risk factors was obtained from
questionnaires, and risk factor analyses were carried out using Cox
regression models.
Results: The cumulative incidence rate of CSOM at 4 years of age
was 14%, and median age at debut was 336 days. Signiﬁcant risk
factors were being of Greenlandic descent, attending childcare centers,
having smokers in the household, having a mother who reported a
history of purulent ear discharge, and having a high burden of upper
respiratory tract infections. High population-attributable risks for CSOM
were associated with use of childcare centers (51%) and living with
smokers in the house (74%).
Conclusion: Greenlandic children have high rates of CSOM with debut
early in life, but the identiﬁed risk factors and the associated population-
attributable risks indicate that preventive measures regarding use of
childcare centers and passive smoking may reduce the frequency of
CSOM in this high risk population.
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P1051 Outcomes of hospitalized patients with bacteraemic and
non-bacteraemic community-acquired pneumonia caused
by Streptococcus pneumoniae with high rates of resistance
to b-lactam antibiotics
M.S. Hsu °, Y.T. Huang, P.R. Hsueh (Panchiao, Taipei City, TW)
Objectives: The impact of S. pneumoniae bacteraemia on the outcome of
pneumococcal pneumonia is not fully known, particularly in regions with
high rates of resistance to b-lactam antibiotics. This retrospective study
compared the outcome of hospitalized patients with bacteraemic and
nonbacteraemic pneumococcal community-acquired pneumonia (CAP)
treated at a medical center from 2000 to 2008.
Methods: Case of pneumococcal pneumonia was diagnosed by on a
positive blood culture for S. pneumoniae and positive S. pneumoniae
urinary antigen test from January 2000 to December 2008 were
identiﬁed from databases of the microbiology laboratory. Antimicrobial
susceptibility testing and MIC were according to guideline of CLSI.
Medical data were also collected.
Results: A total of 309 patients with pneumococcal pneumonia
(137 nonbacteraemic and 172 bacteraemic) were included. Patients
with bacteraemic pneumococcal pneumonia were older than those
with nonbacteraemic pneumococcal pneumonia (42.9±31.2 years vs.
21.9±31.1 years; P< 0.001) and were more likely to have underlying
medical diseases (61.6% vs. 34.3%; P< 0.001). The overall mortality
rates at 7, 14, and 30 days were signiﬁcantly higher in patients with
bacteraemic than nonbacteraemic pneumococcal pneumonia (10.5% vs.
2.2%; 14% vs. 3.6%; 17.4% vs. 5.1%; P< 0.01 for all comparisons). The
in-hospital mortality rate was higher in bacteraemic than nonbacteraemic
patients (22.1% vs. 5.8%; odds ratio [OR], 4.57, P< 0.001). The
difference of mortality rates between bacteraemic patients caused by
penicillin susceptible and non-susceptible pneumococcal isolates was not
signiﬁcant (26% vs. 20.7%, respectively, P = 0.57). Multivariate regres-
sion analysis showed that pneumococcal bacteraemia was correlated with
mortality (OR, 2.70; P = 0.003) and extrapulmonary involvement (OR,
5.0, P< 0.001).
Conclusions: Despite the decline in the incidence after pneumococcal
vaccination and the advances in antimicrobial agents, the presence of
pneumococcal bacteraemia increased the risk of mortality and extrapul-
monary involvement in patients with pneumococcal pneumonia. Further
study is needed to develop optimal antibiotic and vaccination strategy to
improve the outcome of bacteraemic pneumococcal pneumonia.
P1052 Pneumococcal infections as a sudden death cause: forensic
microbiological diagnosis
R. Abad Moralejo, M.A. Fernandez-Rodriguez ° (Madrid, Las Rozas,
Madrid, ES)
Objectives: Pneumococcal infection (PI) is a main cause of community-
acquired pneumonia (CAP) and meningitis in adults, sometimes leading
to a fatal outcome. The incidence of PI as responsible of sudden
unexpected death (SUD) has not been established to date. Since SUD
usually occurs outside of the hospital or soon after arrival in the
emergency department, in most occasions a microbiological analysis is
not performed at the hospital and a medico-legal autopsy is performed.
The aim of this study was to determine the incidence of PI as a cause
of SUD and to assess the utility of different techniques to detect this
pathogen in forensic postmortem samples.
Methods: Specimens were received from the different Forensic
Pathology Services all along Spain. We designed a ﬂexible protocol
including: (i) detection of capsular pneumococcal antigen by latex
agglutination and immunocromatography, (ii) bacteriological culture of
forensic samples, and (iii) detection of pneumococcal DNA by PCR
(ply, lytA and psa genes). Antigenic detection was always considered a
presumptive result. A positive result for a sample was deﬁned when a
pneumococcus had been isolated by culture and/or when a positive real
time PCR result was obtained from a sterile ﬂuid or tissue.
Results: We analyzed 377 SUD (255 in adults and 122 in infants)
(age range 19 days-90 years) and 1971 samples. In 46 SUD cases a
pneumococcus was detected, 36 in adults (age range 19−74) and 7 in
infants (4−16months) (16 females and 30 males). The cause of death
was directly attributed to pneumococcus in 44 of them according to
histopathology. Concomitant diseases were present at least in 32 of them.
One infant SUD had co-infection with the H1N1 virus. Other pathogens
were detected in 8 cases. In 38.3% of the positive cases the diagnosis
of PI was made by culture. In a 25.5% of the cases the diagnosis was
established by both culture and PCR. In a 36.2% only the PCR assay
permitted the detection of pneumococcus and, in 35.3% out of them, the
only specimen where a positive PCR result was obtained was a parafﬁn-
embedded tissue.
Conclusion: Pneumococcus is a pathogen involved in sudden death,
mainly due to meningitis (52.2%), CAP (28.3%) and Waterhouse-
Friederichen syndrome (15.2%). Attention should be paid when chronic
underlying diseases are present. A combined protocol including culture
and molecular techniques such a real time PCR is required to detect this
pathogen in forensic samples.
P1053 Surveillance of invasive pneumococcal disease in the Czech
Republic
J. Motlova, C. Benes, P. Kriz ° (Prague, CZ)
Objectives: Pneumococcal disease has been in the focus of interest
worldwide since the pneumococcal conjugate vaccine (PCV) became
available. The international organizations such as the World Health
Organisation, European Centre for Disease Control and Pneumococcal
Awareness Council of Experts motivate the countries to implement a
nationwide surveillance programme for invasive pneumococcal disease
(IPD) and to include PCV into the national immunization programme
(NIP) for infants. In the Czech Republic, PCV has been available since
2001 when the 7-valent vaccine (PCV-7) was registered, followed by the
10-valent vaccine (PCV-10) and 13-valent vaccine (PCV-13) in 2009.
PCV will be included into the Czech NIP for infants in 2010. The aim
of this project was to obtain information about the pre-vaccination IPD
incidence and serotype distribution.
Methods: A laboratory-based IPD surveillance programme was carried
out in 2000–2006 and a pilot enhanced IPD surveillance programme
followed in 2007. A nationwide IPD surveillance programme was
implemented in January 2008. An IPD case was deﬁned by the isolation
of S. pneumoniae from blood, cerebrospinal ﬂuid, or other normally
sterile sites. Each isolate was identiﬁed by standard methods and
S. pneumoniae isolates were serotyped by the Quellung reaction using
serotype-speciﬁc antisera.
Results: Based on the laboratory surveillance data, the IPD incidence
rates varied from 2.3 to 4.3 per 100 000 population between 2000 and
2006. Based on the enhanced surveillance data, the incidence rates were
2.9 in 2007 and 3.3 in 2008. The age-speciﬁc IPD incidence rate was the
highest in the <1 year-olds, reaching 15.7 per 100 000 according to the
laboratory-based surveillance data and 16.6 per 100 000 according to
the enhanced surveillance data. In the period 2000–2008, the coverage
by PCV-7 was 60% in the under-1-year-olds and 62% in the under-5-
year-olds, the coverage by PCV-10 was 71% in both age categories and
the coverage by PCV-13 was 79% and 82%, respectively.
Conclusions: The incidence of IPD in the Czech Republic is comparable
to the pre-vaccination data reported in other European countries. It is
recommended to include PCV in the routine vaccination scheme for
infants in the Czech Republic.
P1054 Invasive Streptococcus pneumoniae isolates before
introduction of PCV7 in Ankara, Turkey: antimicrobial
susceptibilities and serotype distribution
O¨. Ko¨seoglu Eser °, H. Uludag Altun, D. Gur, G. Hascelik (Ankara, TR)
Objectives: The present study evaluated the antimicrobial susceptibilities
and serotype distribution of invasive Streptococcus pneumoniae (SP)
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isolates identiﬁed from patients admitted to Hacettepe Hospitals before
the introduction of heptavalent pneumococcal conjugate vaccine (PCV-7)
in Turkey between 1996 and 2008.
Methods: Invasive SP clinical isolates were collected from children and
adults in Hacettepe Hospitals, Ankara. Susceptibilities of all isolates
were determined by CLSI broth microdilution testing for six antimi-
crobial agents; penicillin(PEN), ceftriaxone(CRO), levoﬂoxacin(LEV),
erythromycin(EM), clindamycin(CD) and vancomycin(VAN). Serotyping
was performed by Quellung reaction with speciﬁc antisera for SP.
Results: Of the 182 non-duplicated invasive pneumococcal isolates, 59
were isolated from children and 123 from adults. Of these, 32 were
cerebrospinal ﬂuid and 150 were blood isolates. Fifty seven (31.3%)
isolates showed reduced susceptibility to PEN (MICs >0.12 mg/ml).
Intermediate resistance (MIC 0.12−1 mg/ml) to PEN were found in
52(28.6%) penicillin-nonsusceptible isolates and high-level resistance
(MIC 2 mg/ml) in ﬁve (2.7%). Twenty three (12.6%) isolates revealed
resistance to EM (MICs 0.5 mg/ml), of these 11 were resistant to both
EM and CD. Nine (4.9%) of invasive SP isolates showed a multi-drug
resistance pattern. Antimicrobial susceptibilities of invasive SP isolates
are shown in Table 1. In the paediatric age group, 17 different serotypes
were recognized, while eight strains were nontypeable (NT). In the adult
group, 23 different serotypes were observed, with 7 NTs. The most
frequent serogroups in both age groups were 6, 3, 23, 9 and 5. The
potential coverage of 7- and 13-valent pneumococcal conjugate vaccine
were 44.1%, 66.1% in children and 39.8%, 71.5% in adults, respectively.
Conclusion: SP is the leading cause of morbidity and mortality
worldwide, especially in children presenting with meningitis and
bacteraemia. PVC-7 was licensed for use in Turkey in November, 2008.
As surveillance data before PCV-7 vaccination are insufﬁcient, this study
may provide an important baseline to assess the potential changes in the
epidemiology of IPD after PCV-7 introduction in Turkey. In addition,
widespread vaccination programme may contribute to decrease the high
penicillin and macrolide resistance patterns which are caused by the
selective pressure resulting from misuse of antibiotics against invasive
pneumococci.
Table 1. Antimicrobial susceptibilities of invasive pneumococcal isolates
MIC50 MIC90 Range Resistance
I, n (%) R, n (%)
Penicillin <0.06 1 <0.06−2 52 (28.6) 5 (2.7)
Ceftriaxone <0.25 0.5 <0.25−1 0 0
Levoﬂoxacin 1 1 <0.25–>8 0 2 (1.1)
Erythromycin <0.25 1 <0.25–>8 2 (1.1) 21 (11.5)
Clindamycin <0.25 <0.25 <0.25–>8 0 11 (6.0)
Vancomycin <0.25 <0.25 <0.25–<0.25 0 0
P1055 Phenotypical and genotypical differences of Streptococcus
pneumoniae carried by healthy children attending day care
centres in big cities versus small communities of Hungary
A. To´thpa´l °, S. Kardos, S.G. Amyes, K. Nagy, O. Dobay (Budapest,
HU; Edinburgh, UK)
Objectives: Streptococcus pneumoniae is a pathogen causing a wide
spectrum of severe diseases, which can be carried in the nasopharynx of
healthy individuals, especially children attending community centres. In
the present study, we have compared the carriage observed in day-care
centres of big cities versus small villages in Hungary.
Methods: Nasal swabs were collected from 187 children (age 3−6 years)
from 6 day-care centres (4 big cities and 2 small villages) in different
parts of Hungary. The pneumococci were selected from the normal
ﬂora, and their identity was conﬁrmed by optochin sensitivity and the
presence of the lytA gene. Serotyping was done by the combination of the
conventional method (antisera) and a PCR-based method. The antibiotic
sensitivity was determined by E-tests, and the genetic relatedness of the
strains was examined by PFGE.
Results: The pneumococcus carriage rate was 39.5% (n = 74). On one
occasion, we could detect the simultaneous carriage of 2 pneumococcal
strains. We could determine the serotype of 64 strains. The serotype
distribution showed that in the villages only 2 or 3 serotypes were
represented, while in the cities the diversity was much wider. The
serotypes in ranking order were: 14 (35.6%), 6 (24.1%, 6A> 6B), 19F
(9.2%), 15, 23F, 18C, 3, 19A, 13, 7. The strains were generally very
sensitive to antibiotics, except for macrolides. In the villages we detected
slightly lower penicillin MICs, but none of the strains were resistant (R)
to penicillin. The highest MICs (0.5−1mg/L) were detected in sero 14,
23F, 19F, and 18C (all part of the Prevenar vaccine). 18 strains showed
high-level R to erythromycin, these were of different serotypes, and 14
carried the ermB gene. We could identify the presence of very distinct
PFGE clones at the individual nurseries, e.g. different clones of serotype
14 strains from the different places.
Conclusions: There was no difference in the carriage rate between cities
and villages, and little in antibiotic sensitivity. The difference lay in the
serotype distribution. Based on our data and taking the relevant cross-
protections into account, Prevenar (serotypes 4, 6B, 9V, 14, 18C, 19F,
23F) would cover 77.0% of the total isolates, but 100% in the villages.
On the other hand, there was only one single strain, protection to which
is not provided by Pneumovax. We could clearly show the presence of
discrete clones within the nurseries, indicating the intensive exchange of
bacteria between children.
P1057 Prevalence of Streptococcus agalactiae in different age
groups presenting with vulvovaginitis
S. Baka °, A. Panopoulou, A. Lykas, I. Tsouma, I. Patikas, E. Kouskouni
(Athens, GR)
Objectives: Vaginal culture is one of the most difﬁcult cultures to be
evaluated in clinical microbiology practice. Streptococcus agalactiae
has been associated with serious infections and represents an important
cause of neonatal infection due to maternal-infant transmission. The
aim of the present study was to evaluate the prevalence of S. agalactiae
when isolated in the vaginal secretions of different groups of patients
presenting with vulvovaginitis.
Methods: A total of 2,130 vaginal cultures from different patients
presenting at the outpatient clinic for obstetrics and gynecology of our
hospital during January 2008 to October 2009 were studied. Cases were
divided into 4 groups: 245 samples from girls 2−14 years old, 1,294
samples from reproductive age (18−40 years old) non-pregnant women,
386 samples from pregnant women in their third trimester of pregnancy
and 205 postmenopausal women (50−65 years old). All women enrolled
presented with signs and symptoms of vulvovaginitis (vulvovaginal
irritation, itching and/or vaginal discharge) on physical examination.
Samples were inoculated onto blood agar, MacConkey, Mannitol Salt,
Sabouraud Dextrose agar, Gardnerella agar and Wilkins-Chalgren agar
as well as Thayer-Martin and chocolate agar followed by incubation in
aerobic, anaerobic or CO2 atmosphere at 37º C for 24 or 48 hours, as
appropriate. Wet mount and Gram stain preparations were examined to
investigate the presence of leukocytes and the type of microorganisms
present. The identiﬁcation of isolated strains and their susceptibility test
to antibiotics were carried out with the API System and the automated
system VITEK 2 (bioMe´rieux, Marcy l’Etoile, France).
Results: S. agalactiae was isolated from 6/245 (2.4%) of girls, in
88/1,294 (6.8%) of non-pregnant, reproductive age women, from 46/386
(11.9%) of pregnant women and 14/205 (6.8%) of postmenopausal
women.
Conclusion: Among the four groups studied, S. agalactiae was more
frequently isolated from women in late pregnancy. Although neonatal
group B streptococcal infection can and has been reduced by routine
screening and use of antibiotics, strict adherence to a culture-based
screening strategy is important to identify the mother-infant pairs at
risk of vertical transmission.
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P1058 Disease associations amongst bloodstream infections caused
by the new species included in the Streptococcus bovis
taxonomic group
A. Burillo, Y. Gil °, C. Flecha, M. Palomo, J. Go´mez-Garce´s (Madrid, ES)
Objectives: Modern taxonomy ascribes all clinical Streptococcus
bovis bacteria to a group that includes Streptococcus gallolyticus
subsp. gallolyticus (SGG), S. gallolyticus subsp. pasteurianus (SGP),
Streptococcus infantarius subsp. coli (SIC), and S. infantarius subsp.
infantarius (SII). We sought to identify possible disease associations
amongst bloodstream infections (BSI) caused by these species by
studying patient records.
Methods: Forty-four consecutive blood culture isolates initially desig-
nated S. bovis were further characterized using phenotypic methods (API
20 Strep®, bioMe´rieux). Patient records were examined.
Results: We identiﬁed 15 SGG, 24 SGP, 2 SIC and 3 SII isolates in
44 BSI episodes. Twenty-ﬁve (57%) of the 44 patients were men and
19 (43%) women. Median ages were 74 (IQR 65–81.5) years for the
men and similar for all taxa detected and 79 (IQR 68−87) years for the
women. The mean number of blood cultures positive for S. bovis was 2.2
(SD 1.2). Median follow-up was 7 months (IQR 1–23.5). Comorbidities
detected were: diabetes mellitus, 27%; intravenous drug addiction, 2%;
alcohol abuse, 17%; immunosuppression, 19%; chronic renal failure,
20.5%; chronic respiratory disease, 19%; cardiovascular disease, 56%;
urinary tract infection, 12%; solid organ neoplasm, 19%; hematological
malignancy, 7%; colon disease, 53% and hepato-biliary disease, 37%.
A colonoscopy was performed in 22 (50%) of the patients, and colon
disease was detected in 20 patients (adenomatous/vellous polyp in 10,
colonic carcinoma in 5 and other diseases in 5). Endocarditis was
recorded in a third of the patients.
Among the patients with SGG BSI, 64% and 36% presented colon
polyps or colon carcinoma, respectively; for SGP BSI, these ﬁgures
were 33% and 17%, respectively (p = 0.023). Hepato-biliary disease was
more common in patients with SGP BSI than SGG BSI (61% vs. 0%,
p< 0.001). Endocarditis was more frequent in patients with BSI caused
by SGG (67% vs. 9.5%, p = 0.001). Seven of the patients died during
the hospital stay in which S. bovis bacteremia occurred, but only in 2
cases was S. bovis bacteremia the single cause of death.
Conclusions: Our ﬁndings indicate that the association between S. bovis
bacteremia and endocarditis and/or colon carcinoma is highly dependent
on the causative species. SGG BSI is a surrogate for endocarditis and/or
colon disease, whereas SGP BSI is a surrogate for hepato-biliary disease.
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P1059 Local acquisition of methicillin-resistance in predominant
Staphylococcus aureus clones of western Switzerland
P. Basset, L. Senn, V. Vogel, G. Zanetti, D.S. Blanc ° (Lausanne, CH)
Objectives: Recent population genetic studies suggest that the Staphylo-
coccal Chromosome Cassettes mec (SCCmec) was acquired at a global
scale much more frequently than previously thought. We hypothesized
that such acquisitions can also be observed at a local level. In the present
study, we aimed at investigating the diversity of SCCmec in a local
MRSA population, where the dissemination of four MRSA clones has
been observed (JCM 2007, 45: 3729).
Methods: All the MRSA isolates (one per patient) recovered in the
Vaud canton of Switzerland from January 2005 to December 2008 were
analyzed in this study. We used the Double Locus Sequence Typing
(DLST) method, based on clfB and spa loci, and the e-BURST algorithm
to group the types with one allele in common (i.e. clone). To increase the
discriminatory power of the DLST method, a third polymorphic marker
(clfA) was further analyzed on a sub-sample of isolates. The SCCmec
type of each isolate was determined with the ﬁrst two PCRs of the Kondo
scheme.
Results: DLST analysis indicated that 1884/2036 isolates (92.5%)
belong to the four predominant clones. A majority of isolates in each
clone harboured an identical SCCmec type: 61/64 (95%) isolates to
DLST clone 1−1 SCCmec IV, 1282/1323 (97%) to clone 2−2 SCCmec
II, 237/288 (82%) to clone 3−3 SCCmec IV, and 192/209 (92%) to clone
4−4 SCCmec I.
Unexpectedly, different SCCmec types were present in a single
predominant DLST clone: SCCmec V plus one unusual type in 3 isolates
of clone 1−1; SCCmec I, IV, V, VI plus two unusual types in 41 isolates
of clone 2−2; SCCmec I, II, VI plus three unusual types in 51 isolates of
clone 3−3; and SCCmec II, IV, V plus one unusual type in 17 isolates of
clone 4−4. Interestingly, adding a third locus generally did not change
the classiﬁcation of incongruent SCCmec types, suggesting that these
SCCmec elements have been acquired locally during the dissemination
of the clones.
Conclusion: Although the SCCmec diversity within clones was
relatively low at a local level, a signiﬁcant proportion of isolates with
different SCCmec have been identiﬁed in the four major clones. This
suggests that the local acquisition of SCCmec elements is not a rare
event and illustrates the great capacity of S. aureus to quickly adapt to
its environment by acquiring new genetic elements.
P1060 Genetic ﬁngerprinting of MRSA from Abu Dhabi
S. Weber, R. Ehricht, P. Slickers, L. Abdel-Wareth, G. Donnelly, M. Pitout,
S. Monecke ° (Saarbruecken, Jena, DE; Abu Dhabi, AE; Dresden, DE)
Methicillin-resistant Staphylococcus aureus (MRSA) have become a
global problem. However, for many regions of the world only few, if
any, data on the actual distribution and abundance of various epidemic
or pandemic strains are available. This includes many countries of the
Middle East. In order to obtain such typing data, clinical isolates from
Sheik Khalifa Medical City, Abu Dhabi, have been characterised using
diagnostic DNA-microarrays.
Out of 62 MRSA isolates tested, two carried SCCmec elements of
type III. The most common SCCmec element was type IV which
was present in a total of 54 isolates. SCCmec elements of type V
were found in six isolates. SCCmec elements of types I and II were
not detected. Common resistance determinants included blaZ, ermC
and genes encoding aminoglycoside-modifying enzymes. Mupirocin
resistance was rare with mupR being detected in a single isolate. PVL
genes were present in as much as 26 isolates.
Based on array hybridisation proﬁles, eighteen strains could be
distinguished which belonged to eleven clonal complexes. The most
common clonal complex was CC22 (21 isolates), followed by CC8
(nine isolates, including USA300, ST72 and ST239 strains) and CC80
(seven isolates). Several unusual MRSA strains (such as ST6-MRSA-IV,
CC361-MRSA-V or ST573/772-MRSA-V) were also found.
Generally, a high diversity of different strains as well as a rather high
rate of PVL carriage were noted among isolates from Abu Dhabi. These
results warrant further investigations on the epidemiology of MRSA in
this region.
P1061 Characterization of S. aureus strains from two Turkish
hospitals
A. Alalem, M.D. Avsaroglu °, F. Bozoglu (Ankara, Van, TR)
Objectives: To characterize the S. aureus strains obtained from two
hospitals in Turkey during June-August 2007 according to their
antimicrobial susceptibilities, some genetic determinants and PVL-gene
content.
Methods: 305 samples were collected from Ankara and Hacettepe
hospitals. The strains were isolated from different clinical origin
samples on blood agar. Cultures were maintained on glass beads
by using Microbank at −70ºC. Conﬁrmation was done by Gram’s
staining, coagulase-, and catalase-tests followed by Phoenix Automated
Microbiology System (BD Diagnostic Systems) analyses. Antimicrobial
susceptibilities of the strains were investigated by disk diffusion method
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against 12 different antimicrobials, and only when oxacillin resistance
observed, the MIC value of oxacillin was detected by E-test by CLSI
standards for all. Genetic determinants were analyzed for randomly
selected 30 strains. The studies were carried out with the StaphPlex
system for 18 genetic determinants and monitored with the Liquichip200
Workstation.
Results: In this study out of 305 isolates, 95.7% was conﬁrmed as
S. aureus and 4.3% were CoNS. Except 30, all isolates were resistant
to one or more antimicrobials. All oxacillin resistant isolates displayed
the MIC value of at 256ug/ml There were 7 OXA resistant CoNS out
of 13 isolates. Among S. aureus isolates, 46% were MSSA and 54%
were MRSA. The VRSA was only 2% and there were no intermediate
susceptibility observed. The majority MRSA isolates were multi-resistant
to more than ﬁve classes of antibiotics (84.2%) and the resistant patterns
differed. The results of genetic investigations indicated that the mecA
gene was present in the majority of randomly selected 30 isolates;
the community acquired MRSA type (ccr-BIV) was present in three
and there was no case found to carry the hospital acquired MRSA
type (ccr-BI, -II, -III). Besides the methicillin resistance gene, only
tetracycline resistance determinants were obtained astetM and tetK. The
prevalence of PVL gene was low (only one isolate).
Conclusion: Although there was high prevalence of S. aureus among
tested clinical samples, there is no clonal spread of a speciﬁc isolate
according to phenotypical characterization. Multi-resistance of MRSA
isolates would be considered as a potential threat in Turkish hospitals
based on two hospitals results. Low incidence of VRSA isolates indicates
that vancomycin could be the drug for the treatment of S. aureus
infections in Turkey.
P1062 Clonal evolution and the changing molecular epidemiology
of methicillin-resistant Staphylococcus aureus in a Spanish
hospital
F. Menegotto, S. Gonza´lez Cabrero, A. Cubero, C. Garcı´a Loygorri,
A. Duen˜as, M.P. Gutie´rrez Rodrı´guez, A. Ordun˜a, M.A. Bratos °
(Valladolid, ES)
Introduction: The epidemiology of methicillin resistant Staphylococcus
aureus (MRSA) has undergone a series of changes over the years. The
predominant MRSA clones are constantly replaced by the new ones,
showing the dynamic genetics of this pathogen.
Objective: This study aims to assess the clonal evolution and the change
in the molecular epidemiology of the MRSA in a Spanish hospital.
Material and Methods: A total of 185 MRSA isolated were collected
from 2005 to 2008 from the Clinical University Hospital of Valladolid
(Spain) (800 beds). The most relevant genotypes characterized by PFGE
were selected for MLST analysis. The sequence type (STs) and their
alelic proﬁles were compared using the goeBURST algorithm, a globally
optimized implementation of the eBURST algorithm.
Results and Discussion: We have identiﬁed two main clones, ST228-
MRSA-I and ST125-MRSA-IV between the strains isolated in the year
2005. In that year, the ST228-MRSA-I clone was the most frequent
(68%), and the cassette SCCmec type I (71%) was the most prevalent.
In contrast, in the years 2007 and 2008, the cassette SCCmec type IV
was identiﬁed in the 83% of isolates. The ST125-MRSA-IV has been the
predominant clone (43%), followed by ST146-MRSA-IV (20%), ST8-
MRSA-IV (20%), ST228-MRSA-I (15%) and ST239-MRSA-III (2%),
underscoring the replacement of the ST228-MRSA-I clone by ST125-
MRSA-IV between 2005 and 2008. Using the algorithm goeBURST, all
the main clones joined two clonal complexes: CC5 and CC8. We have
been able to verify that the prevalent clone in 2005 (ST228-MRSA-I)
and the emerging clone (ST125-MRSA-IV) belong to the same clone
complex (CC5), since their alelic proﬁles are DLVs. The ST146-MRSA-
IV clone is also related with these clones, and all of these were derived
from epidemic MSSA lineages (ST5-MSSA) who acquired the cassette
SCCmec. The ST8-MRSA-IV and ST239-MRSA-III clones were only
identiﬁed in the year 2007. These clones are SLVs and belonging to the
CC8, which ancestor is the ST8-MSSA, also ancestor of the ﬁrst MRSA
strain isolated (ST250-MRSA-I).
Conclusions: The predominant ST228-MRSA-I clone in 2005 was
replaced by the ST-125-MRSA-IV clone in 2008. In this period an
increase in the prevalence of SSCmec type IV cassette was observed.
P1063 Molecular characterization of methicillin-resistant Staphylo-
coccus aureus isolates from Thailand by SCCmec type, vari-
able number of tandem repeats, and virulence determinants
C. Wilailuckana °, C. Tribuddharat, P. Tishyadhigama (Khon Kaen,
Bangkok, Nontaburi, TH)
Objective: To characterize genetic background of methicillin-resistant
Staphylococcus aureus (MRSA) isolates in Thailand by SCCmec
typing, variable number of tandem repeat typing (VNTR) typing, and
distribution of virulence genes.
Methods: A total of 106 MRSA isolates from 18 hospitals in Thailand
under an Antibiotic Resistance Surveillance Program, the National
Institute of Health, Ministry of Public Health, were characterized by
SCCmec typing, VNTR typing in spa gene and hypervariable region
downstream of mecA gene, and detection of virulence genes such as sak,
sea, seb, sec, sed, see, seg, sei, seh, lukSF-PV, and tst-1 by polymerase
chain reaction.
Results: Five SCCmec types were identiﬁed as type-III (41.5%), type-
IIIA (40.6%), type-III DCS (14.1%), type-II (1.9%), and type-I with
class C mec complex (1.9%), whereas spa and HVR typing could
distinguish MRSA into 5 and 12 groups, respectively. Eighty (75%),
and 61 (58%) isolates carried staphylokinase (sak) and staphylococcal
enterotoxin A (sea) gene, respectively. The major type of MRSA isolates
(20.8%) were type III SCCmec with estimated 15 direct repeat units
(DRUs) in HVR and 7 DRUs in spa gene, virulence genes of sea and
sak. In addition, high virulent leukocidin, lukSF-PV, was also detected
in three MRSA carrying type III, type III DCS and type II SCCmec.
Combination of all genetic markers could distinguish 106 MRSA isolates
into 35 groups.
Conclusion: Genetic diversity of MRSA in Thailand was demonstrated
by SCCmec, VNTR, and virulence determinants. The major clone might
be identiﬁed by these typing techniques. The genetic information may
be useful for development of appropriate typing methods for the tertiary
hospitals in our country.
P1064 Molecular epidemiology of methicillin-resistant and
methicillin-sensitive Staphylococcus aureus invasive isolates
in Russia
O. Dmitrenko °, N. Lavrova, I. Alexandrova, S. Ghilina, V. Karabak,
S. Rosanova, A. Gintsburg (Moscow, RU)
Objectives: During investigation conducted in 2002–2006 we discovered
circulation of several epidemic MRSA strains in hospitals in Russia. Two
of them REMRSA-1(spa-037, SCCmec type III) and REMRSA-2 (spa-
008, composite SCCmec: comlex mecB+, ccr1+, ccr2+) were discovered
in different parts of the country and REMRSA-3 (spa-030, SCCmecIII)
was identiﬁed only in one hospital of the Central Region. In the last
few years the MRSA proportion increased dramatically especially among
ICU patients. The increase incidents of invasive staphylococcal infections
were observed two. The aim of the present study was to identify the
MRSA genotypes currently circulating in the healthcare settings and
to compare genotype and superantigen proﬁles of invasive MRSA and
MSSA isolates.
Methods: 115 Staphylococcus aureus isolates were collected in 2005–
2009 in 9 hospitals of Central, Ural and North-West region of Russia
from blood (50), spinal ﬂuid (4), low respiratory tract (61). Antimicrobial
susceptibility was determined by standard methods. Genetic background
was investigated by coa and spa typing. Structural components of
SSCmec, sea, seb, sec, seh, seg, tst, pvl were tested by PCR additionally.
Results: 74 (64.3%) isolates were methicillin-resistant (MRSA). Among
30 MRSA recovered from blood and spinal ﬂuid 14 (46.6%) were
REMRSA-2 and 16 (53.4%) were REMRSA-3. Among 44 low
respiratory tract isolates 42 (95.4%) were REMRSA-3, and 2 (4.6%)
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were REMRSA-2. REMRSA-3 was detected in 8 of the 9 participating
hospitals. MRSA isolates recovered in different hospitals differed
by toxin genes proﬁles. 96.6% isolates carried sea. One isolate of
REMRSA-2 (6.3%) was sea+pvl+. Among REMRSA-3 17.2% isolates
carried sea,sec; 10.3% isolates carried sea,sec,tst. Isolates of REMRSA-1
were not discovered. In methicillin-sensitive S. aureus (MSSA) isolates
recovered from blood (24) and respiratory tract (9) spa-types 002, 015,
078, 156, 159, 164, 284, 359, 647, 737, 841, 3665 were discovered.
16.6% of MSSA isolates carried tst or pvl.
Conclusion: Progressive increase of the proportion of the MRSA isolates
in hospitals in Russia is a result of dissemination REMRSA-3 (spa-type
t030, SCCmec III). This strain was able to accumulate the toxin genes
successfully and replaced REMRSA-1 (spa t037, SCCmecIII). It became
the predominant strain as a causative agent of staphylococcal ventilator-
associated pneumonia. MSSA invasive isolates differed from MRSA by
genetic background and toxin genes proﬁles.
P1065 Trends in the occurrence of MRSA strains in Upper Austria
in a 4-year time period
K. Krziwanek °, S. Metz-Gercek, H. Mittermayer on behalf of the
MRSA Registry Upper Austria
Objectives: The project “MRSA-Registry Upper Austria” exists since
2006 and aims to systematically collect and analyse data of all human
MRSA-isolates which are detected in Upper Austria. All 9 Upper
Austrian laboratories and 22 Upper Austrian hospitals take part in this
project. In this study we investigated the trends in the occurrence of
MRSA types and subtypes in Upper Austria within a time period of 4
years.
Methods: From January 2006 until October 2009 we received all
consecutively collected primary clinical MRSA-isolates. All isolates
were cultured and investigated for the presence of mecA/femA as well
as for the PVL genes lukS-lukF via PCR. All isolates were typed using
PFGE, the bigger part of the isolates were additionally investigated by
spa-typing and MLST (multi locus sequence typing).
Results: We received 1,436 human primary MRSA isolates. The isolate
number was slightly decreasing over the years (2006 n = 461, 2007
n = 374, 2008 n = 385, Jan-Oct 2009 n = 216). 29 different MRSA types
were detected using PFGE as well as MLST. Both techniques showed
that the 4 most frequent strains comprised 83% of all isolates: ST8
34%, ST5 32%, ST22 11% and ST228 6%. Within these MRSA
types we recognised predominant PFGE-subtypes. Interestingly, these
PFGE- and MLST-types as well as the predominant subtypes remained
similar frequent throughout the 4 years. Investigating about 17% of all
isolates by spa typing, we detected 61 different spa-types. Also, the
main spa-types − t008, t190 (mostly CC8/ST8), t002, t003 (mostly
CC5/ST5), t001, t041 (mostly CC5/ST228) − remained the dominant
types throughout the described time period. The proportion of PVL-
positive isolates, especially those belonging to ST8, increased since
2007 (2006 8.0%, 2007 5.6%, 2008 6.2%, 2009 11.1%). Most of
the PVL-positive isolates belonged to ST8 (n = 21, 15 isolates thereof
were USA300), ST152 (n = 21), ST5 (n = 18), ST777 (n = 11) and ST88
(n = 10).
Conclusions: The MRSA population in Upper Austria is not as dynamic
as probably expected. No matter which typing method was used, the
predominant MRSA strains as well as subtypes remained to be the most
frequent ones throughout the last 4 years and were not replaced by minor
clones. The increase of PVL-positive isolates since 2007 is partly a
consequence of the occurrence of USA300 in Austria. Our data suggest
to continue MRSA surveillance with an additional focus on community
associated MRSA.
P1066 MRSA in north-eastern Scotland 2003–2007: evolving
strain distribution and resistance patterns
A. Hunt, B. Edwards °, K. Girvan, B. Cosgrove, G. Edwards, I. Gould
(Aberdeen, Glasgow, UK)
Objectives: This study explored strain distribution and resistance
patterns of MRSA over a 5 year period in North East Scotland (NES).
Methods: MRSA isolates used in this study were obtained from hospital
and GP specimens submitted to the Medical Microbiology Department,
Aberdeen Royal Inﬁrmary (ARI) during the period 2003–2007. During
this time, all new isolates were submitted to the Scottish MRSA
Reference Laboratory (SMRL), for typing by PFGE, extended antibiotic
resistance testing, and in ’07 for toxin gene testing.
Results: 7558 isolates were analysed. Over the ﬁve years, the number
of MRSA isolates sent to the SMRL increased from 985 isolates in ’03
to 1860 isolates in ’07. 85−90% of the isolates each year were of either
the two UK epidemic strains; E15 and E16. Unlike the rest of the UK,
in NES, E16 has previously been present at a higher rate in comparison
to E15. Over the course of ’03–’07 there has been a shift in the relative
rates of E15 and E16, with an increase in E15 from 51% of isolates in ’03
to 82% in ’07, and a corresponding decrease in the percentage of E16
isolates, bringing the pattern in line with the rest of the UK. An increase
in the community acquired (CA) strains SM106 (equivalent to ST5) and
SM153 (ST8 (US300)) has also been seen. In ’07 eta was detected in
25% of SM106 and lukF/lukS were detected in 95% of SM153.
During ’03–’07, the percentage of isolates resistant to trimethoprim and
fusidic acid increased from 7.8% and 4.4% in ’03 to 71.6% and 10.6%
in ’07 respectively. During the same time, the percentage resistance
to clindamycin, kanamycin, novobiocin and tobramycin (cl/ka/no/to)
decreased from around 43% to around 10%. The decrease in cl/ka/no/to
resistance seems to be linked to the decrease of E16. However, E16
composes a decreasing proportion of the isolates resistant to cl/ka/no/to
(from >90% in ’03 to 40% in ’07), showing that resistance to these
agents is increasing elsewhere. SM111 (ST45) appears to be the main
other strain in which this resistance pattern occurs. Although some of
these trends can be linked to changes in strain distribution, from 2003
ARI had a hospital policy of eradicating throat carriage of MRSA with
the oral agents trimethoprim and fusidic acid. This may have contributed
to resistance.
Conclusion: The incidence of MRSA continues to increase despite the
implementation of various control measures, especially CA strains. Strain
distribution and antibiotic resistance patterns are also evolving.
P1067 The changing epidemiology of MRSA in Scotland
J. Wilson °, A. Eastaway, G. Edwards, B. Cosgrove, C. Peter (Glasgow,
UK)
Objectives: Scotland has a mandatory reporting scheme whereby all ﬁrst
MRSA bacteraemia isolates are referred to the Scottish MRSA Reference
Laboratory for typing and antibiotic susceptibility testing. Bacteraemia
specimens are used as a proxy indicator of the level of MRSA infection
in Scottish hospitals. Little is known about the characteristics of non-
bacteraemia isolates at a national level. This study was designed to look
at MRSA isolated from all specimen types and will monitor trends in
strains, emerging antimicrobial resistance and toxin genes. The changing
epidemiology of MRSA is a matter of Public Health concern and this
study aims to provide epidemiological information on both hospital and
community associated strains for Scotland.
Methods: Scottish diagnostic laboratories were asked to send all “new”
MRSA isolates collected over a period of one week, 4 times a year to
the Scottish MRSA Reference Laboratory for typing and toxin testing.
A “new” isolate is deﬁned as: “one which the diagnostic laboratory has
no record of being isolated from that patient in the last twelve months”.
Epidemiological information was provided with each isolate. All isolates
were phenotypically typed using biotype and antibiogram. Genotyping
was performed using PCR-ribotyping and PFGE. Isolates were tested
for resistance to 22 antibiotics. Those with reduced susceptibility to
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mupirocin were further tested by PCR for the presence of the mupA
gene. Toxin testing was performed: toxic shock syndrome toxin-1 (tst),
two exfoliative toxins (eta and etb) and the PVL gene was tested for.
Sequenced based typing (spa typing) was performed on all isolates.
Surveillance period: Oct 2008–Mar 2009.
Results: Two hundred and seventy seven isolates were identiﬁed as
EMRSA-15, 54 were EMRSA-16 and 26 isolates were characterised
as “other”. A high proportion of the EMRSA-15 and EMRSA-16 were
resistant to ciproﬂoxacin, with slightly fewer resistant to erythromycin
as is typical for these clones. Eight isolates had the PVL gene and one
of these appears to be a true community associated MRSA strain. The
majority of isolates were spa type t032.
Conclusion: This “snapshot” programme has provided additional
information which has been used to augment the intelligence we already
have from our mandatory S. aureus bacteraemia reporting scheme. This
has provided us with a very clear picture of the epidemiology of S. aureus
in Scotland including information on community and hospital acquired
strains.
S. aureus susceptibility and GISA
P1068 Antimicrobial susceptibility pattern of Staphylococcus
aureus isolates collected in 2008 at a Detroit medical centre
H. Salimnia, C. Vidaillac °, K. Rossi, K. Kaye, M. Rybak (Detroit, US)
Background: With a rising rate of Staphylococcus aureus infections in
the health-care settings, prevalence and spread of methicillin-resistance
S. aureus (MRSA) is a major clinical concern. We performed a
surveillance of 5,533 S. aureus isolates collected at the DMC between
January and December 2008.
Methods: Minimum Inhibitory Concentration (MIC) values of van-
comycin (VAN), daptomycin (DAP), oxacillin (OXA), linezolid (LNZ),
clindamycin (CLI), trimethoprim-sulfamethoxazole (SXT) and tetracy-
cline (TCY) were determined by MicroScan PC29 panels for 2,309
clinical isolates of MSSA and 3,224 clinical strains of MRSA, defned
on the basis of OXA MIC. Typing of 13 VISA MRSA isolates identifed
by MicroScan and 1 hVISA conﬁrmed by modiﬁed population analysis
proﬁle was performed by Pulse Field Gel Electrophoresis. SCCmec type,
presence of the PVL gene and agr group were assessed by multiplex PCR
reactions.
Results: MIC50/MIC90 values and non-susceptibility (NS) rates
are reported in Table 1. No difference was observed between the
MIC distributions with regard to the specimen sources and the
susceptibility patterns of MSSA and MRSA collections (except for CLI).
Antimicrobial NS rates were less than 1% for all tested antibiotics, except
for CLI (5.5 and 27.4% for MSSA and MRSA isolates, respectively).
MIC50/MIC90 values of the 14 hVISA/VISA group of isolates were
4/8 and 2/2mg/L for VAN and DAP, respectively. USA 300 typing was
positive for 57% of the VISA isolates, and 50% were PVL positive. Of
interest, 67% of MRSA isolates exhibited a VAN MIC at 2mg/L.
Conclusion: Of interet, a high percentage of MRSA had a VAN MIC
at 2mg/L and more than 50% of VISA isolates were USA 300. This
surveillance of S. aureus isolates performed at Detroit Medical Center
demonstrated low NS rates for VAN, DAP, and SXT.
Table 1. In vitro activity and resistance frequency for 7 selected
antimicrobial agents against clinical MSSA and MRSA isolates
Agent MSSA (n = 2309) MRSA (n = 3224)
MIC50
(mg/L)
MIC90
(mg/L)
Resistance frequency
(% of isolates)
MIC50
(mg/L)
MIC90
(mg/L)
Resistance frequency
(% of isolates)
VAN 2 2 0.13 2 2 0.43
DAP 0.25 1 0.26 0.25 1 0.37
LNZ 2 4 0.04 2 4 0.03
SXT 0.25 0.25 0  0.25 0.25 0.37
CLI 025 0.25 5.50  0.25 >4 27.39
TCY 2 2 9.00 2 2 8.41
P1069 Increasing vancomycin and daptomycin minimum inhibitory
concentrations in methicillin-resistant Staphylococcus
aureus blood isolates from a Canadian inner-city hospital
T. Wong °, S. Champagne, M. Romney (Vancouver, CA)
Objectives: To describe vancomycin and daptomycin minimum in-
hibitory concentration (MIC) trends in methicillin-resistant Staphylococ-
cus aureus (MRSA) blood isolates at a Canadian tertiary care hospital
over a three year period, speciﬁcally to assess whether “MIC creep” is
present at this institution.
Methods: From July 2006 to June 2009, vancomycin and daptomycin
MICs were determined via Etest for 200 consecutive MRSA blood
isolates at St. Paul’s Hospital, a tertiary-care, inner-city hospital in
Vancouver, Canada. MIC determinations were read by a single observer
and categorised as susceptible, intermediate, or resistant according to
Clinical Laboratory Standards Institute (CLSI) breakpoints. Isolates were
tested according to manufacturer’s instructions. Only the ﬁrst isolate
for each patient was included. For statistical analysis, actual Etest MIC
values were used instead of using traditional 2-fold MIC values. MIC50,
MIC90, geometric mean, percentage susceptible and percentage above
baseline median MIC were calculated according to 12 month reporting
periods.
Results: Over the entire study period, all MRSA isolates were found to
be susceptible to both vancomycin (MIC50/MIC90: 1.00/1.50 ug/mL)
and daptomycin (MIC50/MIC90: 0.19/0.38 ug/mL). No vancomycin-
intermediate or resistant MRSA isolates were detected. No daptomycin
resistant isolates were detected. Geometric mean MIC for vancomycin
increased from 0.91 ug/mL to 1.17 ug/mL during the study period.
Geometric mean MIC for daptomycin also increased from 0.14 ug/mL
to 0.29 ug/mL. There was a statistically signiﬁcant increase in the
percentage of isolates that were above the median MIC for both
vancomycin (10.3% to 46.7%, p< 0.0001) and daptomycin (42.1% to
95.6%, p< 0.0001) compared to the MIC for the baseline study period.
Conclusions: Vancomycin and daptomycin MICs for MRSA increased
over a period of three years at this institution. Despite the increase in
MIC, all isolates remained under the CLSI susceptibility cutoff. Further
studies to determine the clinical impact of this phenomenon are currently
underway.
Proportion of MRSA isolates above baseline median MIC (n = 200)
Baseline MIC Isolates above baseline MIC (%)
(mg/mL) Period 11 Period 22 Period 33 P value
Vancomycin 1.000 10.3 39.6 46.7 <0.0001
Daptomycin 0.125 42.1 68.8 95.6 <0.0001
1Period 1 = June 2006 − July 2007; 2Period 2 = June 2007 − July 2008;
3Period 3 = June 2008 − July 2009.
P1070 Effect of vancomycin MIC creep in methicillin-resistant
Staphylococcus aureus bloodstream isolates from a single
centre between 1998 and 2009 on risk of complications
following catheter-related bloodstream infection
C.E. Miller °, R. Batra, A.K. Patel, N. Dawood, G. French,
J. Edgeworth (London, UK)
Objectives: A gradual increase in vancomycin (VAN) MIC of
susceptible methicillin-resistant Staphylococcus aureus (MRSA) isolates
over the past 5 years has been noted in some studies. Over the same
period VAN breakpoints have fallen (4 to 2mg/L) and concerns have
arisen that infections with isolates near the breakpoint (1−2mg/L)
may fail therapy. On a background of declining institutional MRSA
bloodstream infection rates, we assessed changes in VAN MICs of
MRSA bloodstream isolates and whether higher MICs were associated
with increased risk of deep-seated infection following MRSA catheter-
related bloodstream infection (CRBSI).
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Methods: VAN MIC (mg/L) of 886 clinically signiﬁcant single-patient
MRSA bloodstream isolates (Jan 1998–May 2009) were assessed by
Etest over 3 months. Clinical data were available for 2002–2009.
Complicated MRSA CRBSI was deﬁned as development of deep-
seated infection (endocarditis or osteomyelitis/septic arthritis) within 6
weeks. Individual serum VAN levels and hospital glycopeptide deﬁned
daily doses (DDDs) were obtained from computerised records. Hospital
guidelines advised VAN therapy for all MRSA CRBSIs. Non-parametric
and linear regression methods were used to assess trends/clinical
outcomes.
Results: MRSA bacteraemias decreased by >75% over the 10 year
period. All isolates had a VAN MIC2. The proportion of isolates
with VAN MIC1.5 increased from 5% (8/153) in 1998/1999 to 42%
(10/24) in 2008/2009 (p< 0.0001). The modal MIC increased from 0.5
in 1998/1999 to 1.5 in 2008/2009. Hospital glycopeptide DDDs doubled
over the same period (6380 to 14190, p = 0.0009). 234/425 episodes
(2002–2009) were CRBSIs. The occurrence of complicated CRBSIs
for isolates with MIC 1.5(4/60) vs MIC< 1.5 (4/174) approached
statistical signiﬁcance (p = 0.060). There was no difference in persistent
positive blood cultures at 3−7 or 8−42 days (p = 0.244 and p = 0.365)
between MIC groups. Serum VAN levels were available for 170 (73%)
CRBSIs; no difference in percentage of patients with a level <10mg/l
at any time 14 days between 1.5 vs <1.5 MIC groups was observed
(p = 0.551).
Conclusion: VAN MIC of MRSA bloodstream isolates has increased
over 10 years during which time MRSA BSI rates have decreased
and glycopeptide use has increased. MRSA CRBSIs with a VAN MIC
1.5 are associated with a trend towards increased risk of metastatic
complications.
P1071 Susceptibility and molecular characteristics of
Staphylococcus aureus isolates associated with glycopeptide
treatment failures
E. Mantengoli °, C. Tascini, E. Tagliaferri, A. Leonildi, F. Menichetti,
G.M. Rossolini (Siena, Pisa, IT)
Objective: Emergence of S. aureus with reduced susceptibility to
glycopeptides (VISA and hVISA) is known to be associated with
glycopeptide treatment failures.
Methods: All S. aureus isolates associated to teicoplanin treatment
failures or showing decreased teicoplanin susceptibility, isolated in
2008 in Pisa Cisanello Hospital (Italy) were studied. MICs of
vancomycin (VA), teicoplanin (TC), linezolid (LZ), daptomycin (DPT)
and tigecycline (TGC) were determined by CLSI broth and agar dilution
methods or Etest. Population analysis proﬁling (PAP), determination
of staphylococcal cassette chromosome mec (SCCmec) type, accessory
gene regulator (agr) group and presence of Panton-Valentine leukocidin
(PVL) were investigated. Genetic relatedness was analysed by pulsed-
ﬁeld gel electrophoresis (PFGE) and multilocus sequence typing
(MLST).
Results: PAP revealed a behavior typical of hVISA and VISA for 2
and 11 isolates, respectively, from diabetic foot infections (n = 3), SSTI
(n = 3), peritonitis (n = 2), osteomyelitis (n = 2), sepsis (n = 1), pneumonia
and pleural infection (n = 1). Ten isolates are methicillin resistant and
three are susceptible. Ten patients failed treatment with TC (mean daily
dose of 466±100mg/die for a median time of 42±36 days). Using
Etest isolates showed VA MIC of 2−4 mg/ml (median 3 mg/ml) and
TC MIC of 2−6 mg/ml (median 2 mg/ml). All isolates were susceptible
to LZ, 12 to TGC and only two to DPT. TC and VA were bactericidal
(MBC/MIC< 16) against only two isolates and DPT against 4. Molecular
typing of VISA and hVISA revealed: SCCmec cassette diversity [type I
(4), type II (1), type III (1), type IV (3) and untypable (4)]; 9 and 4
isolates belonged to agr group I and II, respectively; 3 isolates were
PVL-positive; all isolates were clonally unrelated excepted for two
PVL-positive isolates. MLST conﬁrmed clonal diversity. Infections were
successfully treated with oxacillin, linezolid or tigecycline.
Conclusion: Spreading of unrelated VISA and hVISA isolates were
observed in Pisa Cisanello Hospital in 2008. This phenomenon was
probably related to the use of teicoplanin for long time in this
setting. Daptomycin, as described, has a reduced activity and alternative
treatments should be considered.
P1072 Methicillin-resistant Staphylococcus aureus with
intermediate susceptibility to vancomycin: are strict
additional contact measures sufﬁcient?
I. Nahimana Tessemo °, C. Bellini, J.M. Entenza, G. Zanetti, D.S. Blanc
(Lausanne, CH)
Background: A hospitalised patient infected with MRSA was found to
harbour a VISA strain after 6 weeks of treatment with vancomycin.
Additional contact measures were reinforced according to CDCs
recommendations. We decide to evaluate if these applied control
measures were effective.
Objective: To evaluate the efﬁcacy of strict additional contact measures
to contain the dissemination of VISA from an infected patient.
Methods: All patients from the unit were screened weekly for MRSA
during a 6-week period, whereas health care workers (HCW) were
screened only once. Screening specimen included nose, throat, groin,
and clinical specimens for patients, and only nose and throat for
HCW. Broth enrichment and chromogenic agar (MRSA-select) were
used for MRSA detection. All MRSA isolates were tested on Van
screen plates, and growing colonies were tested for MIC of vancomycin.
MIC was performed using Etest. Population analysis was done for
VISA conﬁrmation. One strain per person was typed by Double Locus
Sequence Typing (based on clfB and spa sequencing).
Results: 66 patients hospitalized in the same service during the 6 weeks
and 55 HCW were screened for MRSA and VISA. MRSA was found in
16/66 (24%) patients and 1/55 (2%) HCW. 16/17 MRSA from patients
belonged to the same genotype that the VISA strain. The remaining
patient had a MRSA identical to the HCW isolate.
Among the 16 MRSA isolates sharing the same genotype than the VISA
strain, two showed Etests vancomycin MIC of only 4mg/L. MIC results
were conﬁrmed by the population analysis. They were not considered
as VISA, but as MRSA with increased vancomycin MICs. Both isolates
were obtained from two roommates.
Conclusion: Strict additional contact measures were found to be
effective to contain VISA dissemination. However, the identiﬁcation of
two isolates with increased vancomycin MIC (4mg/L) in two roommates
raised the question of the need to routinely test this susceptibility and of
adequate control measures for patients harbouring such isolates.
P1073 Methicillin-resistance and vancomycin heteroresistance in
Staphylococcus aureus in cystic ﬁbrosis patients
V. Caﬁso, T. Bertuccio, D. Spina, F. Campanile, D. Bongiorno,
M. Santagati, A. Sciacca, C. Sciuto, S. Stefani ° (Catania, IT)
Objectives: Methicilllin-resistant Staphylococcus aureus (MRSA) in-
fections are increasingly reported in cystic ﬁbrosis (CF) populations
worldwide. We sought to look at the epidemiology, the molecular
characterization and the antibiotic resistance of MRSA isolates in our
cohort of CF patients. All MRSA were collected prospectively at the
University Hospital of Catania (I) in a two-year study between mid 2005
and mid 2007 and underwent molecular, pathotype and susceptibility
characterizations.
Methods: We investigated the epidemiology, the molecular charac-
terization of the strains by MLST, SCCmec typing and PFGE, the
pathotype determination the virulence gene content including lukS/F-
PVL by Multiplex-PCR, the bioﬁlm production by spectrophotometric
assays and the antibiotic-resistance of LEV, TOB, VA, TEC, LNZ, DAP,
TYG by MIC according to the CLSI guidelines, and heteroresistance was
determined by macroEtest (AB-Biodisk SE) and conﬁrmed by population
analysis (PAP).
Results: Our study demonstrates persisting infections with both HA- and
CA-MRSA including PVL-positive strains in our CF population with
an overall prevalence of 7.8%. We demonstrated that in these patients,
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persistence was sustained by either identical clones that underwent subtle
changes in their toxin content or by different clones over time. The
isolation of MRSA in our CF population aged 7−24, was associated with
an increased severity of the disease even if, due to the small sample of
patients included and the paucity of data on the clinical outcome, these
results cannot be conclusive. Furthermore, 35.7% of strains were hVISA,
questioning the use of glycopeptides in the treatment of MRSA infections
also in these patients.
Conclusion: We report cases of persistent infections caused by HA-
and CA-MRSA including PVL-positive and hVISA isolates in our CF
population and their possible correlation with an increased severity of
the disease.
P1074 Increased rifampicin resistance among blood isolates of
methicillin-resistant Staphylococcus aureus among patients
who received current anti-tuberculosis treatment
M.S. Hsu °, Y.T. Huang, P.R. Hsueh (Panchiao, Taipei City, TW)
Objectives: The purpose of this study is to compare the rifampin
resistance rate of methicillin-resistant Staphylococcus aureus (MRSA)
recovered from patients with MRSA bacteremia that have or have not
been exposed to rifampicin-containing anti-tuberculosis (TB) treatment.
Methods: Patients with MRSA bacteremia were selected from a database
from year 2000 to 2008 in a 2000-bed tertiary hospital, and compared
with a TB database to identify patients with previously conﬁrmed
pulmonary tuberculosis. Patients matched with sex, age and time of
culture of the study group but without previously TB were selected in a
2:1 ratio as control group.
Table 1. MRSA bacteremia with or without previous anti-TB exposure
With previous
Anti-TB
exposure
(n = 49)
Without previous
Anti-TB exposure
(n = 90)
p
Age 69.6±15.5 70.8±14.5 0.641
Sex, Male (%) 36 (72.5) 65 (72.2) 0.875
Mortality % 59.2 41.1 0.041
Source of patients 0.948
Intensive care unit 16 (32.7) 27 (30.0)
Isolation ward 1 (2.0) 2 (2.2)
Ordinary ward 32 (65.3) 61 (67.8)
Appropriate Antibiotics 39/49 (79.6) 74/90 (82.2) 0.704
MIC50 for rifampin, median
(range)
128 (0.02–256) 0.015 (0.02–256) <0.001
Drug resistant
Rifampin 29/49 (59.2) 15/90 (16.7) <0.001
Clindamycin 41/49 (83.7) 82/89 (92.1) 0.126
Erythromycin 38/41 (92.7) 76/80 (95.0) 0.605
Gentamicin 33/41 (68.8) 66/89 (76.4) 0.331
Minocycline 37/48 (77.1) 74/90 (82.2) 0.469
Trimethoprim–sulfamethoxazole 17/26 (65.4) 37/44 (84.1) 0.072
Underlying disease
End stage renal disease 14/49 (28.6) 27/90 (30.0) 0.860
Diabetes 14/49 (28.6) 33/90 (36.7) 0.335
Liver cirrhosis 6/49 (12.2) 9/90 (10.0) 0.684
Steroid 7/49 (14.3) 5/90 (5.6) 0.113
Transplantation 1/49 (2.0) 3/90 (3.3) 1.000
HIV infection 1/49 (2.0) 0/90 (0) 0.353
Solid cancer 18/49 (36.7) 21/90 (23.3) 0.093
Hematological cancer 4/49 (8.2) 2/90 (2.2) 0.185
Site of Infection
Pneumonia 28/49 (57.1) 51/90 (56.7) 0.957
Catheter 19/49 (38.8) 23/90 (25.6) 0.105
Soft tissue 15/49 (30.9) 28/90 (31.1) 0.952
Urinary tract infection 5/49 (10.2) 12/90 (13.3) 0.591
Arthritis 2/49 (4.1) 0/90 (0) 0.123
Central nervous system 0/49 (0) 3/90 (3.3) 0.552
Intraabdominal infection 0/49 (0) 2/90 (2.2) 0.540
Pericardial 0/49 (0) 1/90 (1.1) 1.000
Primary 6/49 (12.2) 20/90 (22.2) 0.150
Results: The data of 139 patients with MRSA bacteremia (49 patients
with previous rifampin exposure and 90 patients without previous
rifampin exposure) were analyzed. The rifampin-resistant rate is
signiﬁcantly higher in patient with rifampin exposure (59.2% vs 16.7%,
p< 0.001). The MIC50 of rifampin against MRSA isolates from the
study group were also signiﬁcantly higher (128 vs 0.015, p< 0.001).
The mortality rate was signiﬁcantly higher in the study group (59.2% vs
41.1%, p = 0.041) (Table 1). Further analysis showed that MRSA isolated
from the patients with current usage of anti-TB were more likely to be
resistant to rifampin (83.3% vs 36%, p = 0.001) with higher MIC50 (256
vs 1, p = 0.002) and cause higher mortality rate than patients with remote
usage of anti-TB (79.2% vs 40%, p = 0.005) (Table 2). Multivariate
analysis showed that current anti-TB usage is the only risk factor for
rifampicin resistance (OR 7.457, 95%CI 1.581–35.167) and mortality
(OR 6.841, 95%CI 1.515–30.901) (Table 3).
Conclusions: Given the high rifampin resistant rate in patient with prior
anti-TB treatment, rifampin susceptibility test should be done before
considering combination treatment of rifampin in MRSA infection. The
higher mortality rate in patient with current rifampin usage in MRSA
bacteremia needs further investigation.
Table 2. MRSA bacteremia with current or remote Anti-TB exposure
Current Anti-
TB exposure
(n = 24)
Remote
Anti-TB
exposure
(n = 25)
p
Age 69.6±16.4 69.7±14.8 0.981
Sex Male (%) 14 (58.3) 22 (88.0) 0.875
Drug resistant
Rifampin 20/24 (83.3) 9/25 (36.0) 0.001
Clindamycin 20/24/ (83.3) 21/25/ (84.0) 0.950
Erythromycin 19/20/ (95.0) 19/21/ (90.5) 0.578
Gentamycin 17/23/ (73.9) 16/25/ (64.0) 0.459
Minocycline 19/23/ (82.6) 18/25/ (72.0) 0.382
Trimethoprim–sulfamethoxazole 11/14/ (78.6) 6/12/ (50.0) 0.127
MIC50 for Rifampin, median (range) 256 (0.02–256) 1 (0.02–256) 0.002
Appropriate Antibiotics 19/24 (79.2)0 20/25 (80.0) 1.000
Mortality % 79.2 40.0 0.005
Table 3. Risk factors for Rifampin resistant in patients with MRSA
bacteremia
p Odds ratio
Univariate
analysis
Logistic
regression
(95% Conﬁdence Interval)
Current Anti-TB usage 0.001 0.011 7.457 (1.581–35.167)
Steroid usage 0.018 0.628 1.873 (0.148–23.780)
Catheter-related infection 0.023 0.243 2.410 (0.551–10.543)
End Stage renal disease 0.045 0.555 1.666 (0.313–8.858)
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P1075 Performance of the new Vidas EBV assays versus
immunoﬂuorescence for the detection of EBV antibodies in
routine diagnostics
C. Koidl °, B. Schweighofer, S. Fett, M. Bozic, M. Hu¨bner, E. Marth
(Graz, AT)
Objective: To investigate the performance of the new bioMe´rieux
VIDAS® EBV VCA IgM, VCA/EA IgG and EBNA IgG assays on the
VIDAS® instrument (all bioMe´rieux SA, Marcy-l’Etoile, France) that
provide qualitative detection of EBV antibodies in a routine diagnostic
laboratory.
Methods: A total of 165 clinical serum samples were enrolled in this
study. All samples were tested with an IVD labelled immunoﬂuorescence
EBV assay referred to as standard method. In parallel all samples were
tested with the new VIDAS® EBV enzyme linked ﬂuorescent assays that
enable routine diagnosis of infectious mononucleosis and establishing
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of the stage of infection on the VIDAS® instrument. For all samples
with discordant results in interpretation of the EBV serological status,
the samples were retested with an IVD labelled recombinant EBV IgM
and IgG immunoblot assay. For the ﬁnding of ﬁnal interpretation (non
infected, primary infection and past infection) of serological status,
immunoﬂuorescence and immunoblot results were harmonized. All
assays were performed according to the manufacturer’s package inserts
in an International Standards Organization (ISO9001, 2000)-certiﬁed
routine clinical laboratory.
Results: With the standard method and optional immunoblot testing
29 EBV non infected, 52 EBV primary infections and 84 EBV past
infections were identiﬁed. With the new VIDAS EBV assays 29 EBV
non infected, 45 EBV primary infections and 84 EBV past infections
were identiﬁed. In 4 samples with primary infection the VCA IgM on
the VIDAS® instrument was found to be equivocal.
Conclusion: In conclusion, the new VIDAS® EBV assay includes all
features required for detection of EBV antibodies and interpretation
of serological results. It is important to check equivocal results with
testing of follow-up samples collected 1 to 2 weeks after ﬁrst blood
collection. The new Vidas® EBV assays proved to be suitable for the
routine diagnostic laboratory allowing a rapid and safe diagnosis of the
serological status.
P1076 Comparison of four commercial systems for the diagnosis
of Epstein–Barr virus primary infections
F. De Ory °, M.E. Guisasola, I.M. Garcı´a-Bermejo (Majadahonda,
Getafe, ES)
Objectives: To compare the performance characteristics of four
diagnostics systems to establish EBV seroproﬁles for the diagnosis of
EBV primary infections.
Material and Methods: A total of 125 samples from 125 infectious
mononucleosis cases were studied. The cases were classiﬁed as EBV
primary recent infection [presence of VCA-IgM and/or -IgG, in absence
of EBNA antibodies] (82), EBV past infection [presence of VCA-IgG
and EBNA antibodies, in absence of VCA-IgM] (26 cases), and not
infected [negative for the three markers] (17 cases). These samples were
used to compare the individual serological markers of each system, and
to establish the EBV seroproﬁles, as deﬁned. The following systems
were tested: Two ChemiLuminiscence ImmunoAssays (CLIA), (Liason,
Diasorin, Italy [CLIA-L] and Immulite 2000, Siemens, Germany [CLIA-
I]), Immunoﬁltration (IF) (All.Diag, France), and ELISA (Diasorin).
Speciﬁc IgM-VCA synthetic peptide p18 (in both CLIA and ELISA)
and against ZEBRA protein (in IF), speciﬁc IgG-VCA synthetic peptide
p18 (in CLIA-L, IF and ELISA) or against gp125 (CLIA-I), and
IgG-EBNA-1 synthetic peptide (IF, CLIA-L and ELISA) or against
a recombinant p72 (CLIA-I) were tested. As reference methods were
used indirect immunoﬂuorescence (IIF) for VCA-IgM and -IgG and
anticomplement immunoﬂuorescence for EBNA antibodies (Meridian
Bioscience, USA). To evaluate the crossreaction of EBV- and CMV-
IgM, 17 CMV-IgM positive, low avidity IgG additional samples were
assayed in all the EBV-IgM assays.
Results: In the IgM assays the sensitivity ranged from 74% (ELISA)
to 96.1% (CLIA-L), and the speciﬁcity from 93.8% (CLIA-L) to 100%
(IF). In VCA-IgG assays, the sensitivity varied from 86.9% (CLIA-L)
to 96.3% (CLIA-I), and the speciﬁcity from 94.4% (IF and CLIA-L) to
100% (CLIA-I). In EBNA assays, the sensitivity ranged from 81.3% (IF)
to 100% (CLIA-L), and the speciﬁcity from 32.3% (CLIA-L) to 91.4%
(IF). In relation to EBV proﬁles, IF showed sensitivity of 92.7% and
speciﬁcity of 90.7%. The corresponding ﬁgures for CLIA-L, CLIA-I
and ELISA were 91.5% and 93%; 89% and 97.7%; and 89.6% and
95.2%. When CMV cases were assayed positive EBV IgM result was
obtained in 9 (52.9%) (IIF), 13 (74.5%) (IF and CLIA-L), 7 (41.2%)
(CLIA-I), and 3 (17.6%) (ELISA).
Conclusion: Although there were limitations in some individual markers,
the systems evaluated seems to be useful for the diagnosis of EBV
infections by the establishment of EBV seroproﬁles.
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P1077 Evaluation of VCA IgM and ZEBRA IgM assays in
diagnosing acute status of EBV-infection
P. Singer °, F. Vlaspolder (Alkmaar, NL)
Objectives: For many years, the VCA IgM assay has been the most
widely used, yet limited, tool to diagnose the acute status of EBV-
infection. Recently, a ZEBRA IgM assay has been introduced as a
commercially available tool for this purpose as well. A widespread need
exists to come to a clear interpretation of the status of the patient using
EBV-serology. The focus of this research is therefore to deliver a valuable
contribution in the development of these conclusions.
Methods: To determine the performance of a VCA IgM assay (Siemens
Immulite 2000®) and a ZEBRA IgM assay (Clindia Benelux), we
made a selection from randomly selected sera (107 out of 629 sera)
for diagnosing EBV-infection in June and July 2009, based on their
serological screening results in Immulite 2000® EBNA-1 IgG, VCA
IgG and VCA IgM assays (see table).
Mostly proﬁles representing a clear result of a non-active status were
excluded.
The ﬁnal conclusions were based also on:
a. EBV-IgG (avidity) blot results using Mikrogen recomLine® EBV blot
b. Bloodsmear ﬁndings for 68 sera
c. Clinical diagnosis was traced in some cases
Results: The ﬁnal conclusions from this 107 sera were:
30 active infections
6 recent infections
48 past infections
23 cases a conclusion wasn’t possible
From this 107 sera, 85 sera were positive and 5 intermediate in the
VCA IgM assay and just 58 sera were positive and 18 intermediate in
the ZEBRA IgM assay.
The VCA IgM assay was positive or intermediate in 33 cases of active or
recent EBV infections, against 34 in the Zebra IgM assay. Sera showing
a positive result (46) in all of the 3 screening assays were the most
difﬁcult group to interpret. They revealed a percentage of 7.6 in the
whole sera population. The 3 sera in this group that had an active or
recent infection, were positive in both assays. In past infections the VCA
IgM was 43 times positive and 1 time intermediate. The ZEBRA IgM
assay however just 11 resp. 12 times.
Conclusion: The study revealed no signiﬁcant variance in sensitivity
between the VCA IgM and the ZEBRA IgM assay in active or recent
infections.
The VCA IgM assay, however delivered signiﬁcantly more positive and
intermediate results than the ZEBRA IgM assay in past infections, which
make interpretation difﬁcult. Based on these ﬁndings, it can be stated
that the ZEBRA IgM assay delivers a much higher positive predictive
value, resulting in more reliable conclusions.
EBNA IgG VCA IgG VCA IgM ZEBRA IgM results
intermediate negative positive Total
intermediate positive negative 1 1
intermediate positive positive 1 1
negative intermediate positive 1 1
negative positive intermediate 1 1 3 5
negative positive negative 5 6 5 16
negative positive positive 2 2 33 37
positive positive positive 10 22 14 46
Total 18 31 58 107
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P1078 Performance of the Access® CMV IgM assay
N. Groleau, B. Roussel, V. Potelle, M. Bullenger, J. Poropane,
C. Chandelier, R. Falcou-Briatte, F. Bouniort °, J. He, O. Flecheux
(Marnes-la-Coquette, FR; Nyon, CH; Chaska, US)
Objectives: An automated CMV IgM assay has been developed by
Beckman Coulter. The purpose of this study was to evaluate the
reproducibility, analytical speciﬁcity and the clinical sensitivity and
speciﬁcity of the Access® CMV IgM assay.
Methods: Reproducibility including intra-assay, inter-assay and inter-lot
precision were performed according to CLSI guidance EP5A using 2
negative, 2 low, a medium and a high positive sample for CMV IgM.
Clinical sensitivity was tested with 2 commercial seroconversion panels
and 222 samples from commercial panels, blood banks and hospitals
including pregnant women. Analytical speciﬁcity was validated with 369
samples from patients infected with other viruses or concerned with
abnormal autoimmune diseases. The clinical speciﬁcity was studied with
1729 samples from blood donors, hospitalized patients and pregnant
women. The studies were performed on the Beckman Coulter Access
system with the bioMe´rieux Vidas*CMV IgM used as the comparative
method.
Results: The average intra-assay, inter-assay and inter-lot CV’s were
4.9%, 7.2% and 5.0%, respectively. The Access CMV IgM assay detected
the seroconversion one sample earlier than Vidas for one panel and
simultaneously for the second panel. The clinical sensitivity was 96.0%
(213 / 222). Among the 369 samples tested for cross-reaction, 361
were found negative yielding an analytical speciﬁcity of 97.8%. The
clinical speciﬁcity for blood donors, hospitalized patients and pregnant
women was 97. 7% (428/438), 95.6% (770/805) and 96.5% (447/463),
respectively.
Conclusion: The Access CMV IgM assay demonstrated excellent
performance and can be performed on the family of Access immunoassay
systems (Access2, UniCel DxI 600/800) and including the integrated
platforms with closed tube sampling (clinical chemistry / immunochem-
istry).
* All trademarks are property of their owners.
P1079 Validation of the rapid ﬂuorescent focus inhibition test for
rabies antibodies performed on microplates
S. Stankov °, G. Stojadinovic (Novi Sad, RS)
Objective: Except one recent publication of the rapid ﬂuorescent focus
inhibition test for determination of potency of rabies immunoglobulin by
de Moura and colleagues in 2008, no articles which speciﬁcally address
validation of this test have so far been published. Therefore a thorough
examination of characteristics of the test was undertaken for the purpose
of establishing its utility for examination of sera from individuals that
have been vaccinated against rabies.
Methods: The performance of the test was assessed with regard to its
accuracy, speciﬁcity, analytical sensitivity (i.e. detection limit), intra-
assay precision, inter-assay precision and linearity.
Results: Rapid ﬂuorescent focus inhibition test for rabies antibodies
showed satisfactory accuracy, 100% speciﬁcity, intra-test variability of
14%, inter-test variability of 21%, and linearity in the range up to about
60 international units per milliliter.
Conclusions: Results of the test were meaningful from the standpoint of
adequate rabies prophylaxis, taking into account the minimal satisfactory
antibody level of 0.5 international units per milliliter of the serum
sample. In other words, this investigation showed that the test is suitable
for assessment of the satisfactory antibody level upon pre-exposure or
post-exposure rabies immunization.
P1080 Advantages of the state-of-the-art ELISA test at veriﬁcation
of an early HIV infection
I. Sharipova, N. Denisova, E. Baranova, M. Susekina, V. Puzyrev,
K. Sarkisyan, M. Vorob’eva, A. Obriadina, A. Burkov, T. Ulanova
° (Nizhny Novgorod, Moskow, RU)
Background: One of the problems of EIA diagnostic HIV infection
associated with the reliable conﬁrmation of the screening assays results.
The basic difﬁculties are connected with conﬁrmation screening result
at early stage of seroconversion because immune blot assays (WB) are
not intended for detection of presence p24 antigen − early serological a
marker of an HIV infection. The other problem is “indeterminate” WB
result. The aim of present study was to evaluate EIA test “DS–EIA–
HIV–Ab/Ag–spectrum” as a supplemental assay for conﬁrmation of the
HIV positive results at early stage of seroconversion.
Materials: The “DS–EIA–HIV–Ab/Ag–spectrum” is an in vitro
qualitative EIA for the detection of antibodies to individual proteins
of HIV 1 (including HIV 1 group 0), HIV 2 and HIV-1 p24 antigen
in human serum or plasma. Wells of microtiter plate are separately
coated by recombinant proteins comprising diagnostic relevant epitopes
of HIV 1 structural proteins gp41 and HIV-1 group 0 gp 41, gp120, p24,
p31 and gp36 of HIV 2 and mouse monoclonal antibodies to HIV 1
p24. Sensitivity of the test was evaluated by 16 commercial available
seroconversion panel (total n = 167) [ZeptoMetrix and BBI (USA)].
Results: EIA test “DS–EIA–HIV–Ab/Ag–spectrum” permits conﬁrma-
tion of earlier detection of HIV infection. This assay is able to conﬁrm
100 out of 167 seroconversion specimens as HIV positive. 28 of
them were positive for p24 antigen only. The delay of HIV infection
detection by EIA test “DS–EIA–HIV–Ab/Ag–spectrum” in comparison
with detection of HIV virus RNA is 1.2 days. WB can conﬁrm only 13
samples out of 167 as HIV positive and 54 samples as indeterminate.
The delay of HIV infection detection in comparison with detection of
HIV virus RNA is 18−19 days.
Conclusion: The received results demonstrated high diagnostic efﬁ-
ciency of new supplemental assay. Opportunity of detection p24 antigen
and high speciﬁcity allow to conﬁrm screening results from early stages
of HIV infection and reducing number indeterminate results received by
WB.
P1081 Comparison of the Avidity Index method with two
4th generation HIV assays
V. Regine, M. Raimondo, A. Rodella, C. Galli, N. Manca, L. Camoni,
M.C. Salfa, B. Suligoi ° (Rome, Brescia, IT)
Objective: To compare the performance of the Avidity Index (AI) in
indentifying recent HIV infections by using two 4th generation HIV
assays which detect HIV antigen and antibody.
Methods: 102 serum samples were collected from 29 HIV-positive
individuals for whom the date of seroconversion was estimated as
the midpoint between last negative and ﬁrst positive HIV antibody
test. Specimens positive for the Ag and specimens collected when the
individual was under ARV treatment were excluded from the analysis.
All samples were assayed for AI with both the AxSYM HIV Ag/Ab
Combo and the Architect HIV Ag/Ab Combo (Abbott).
The sensitivity and speciﬁcity of the two assays were evaluated using
for both a cut-off of 0.80 (AI 0.80 = recent infection, 6 months from
seroconversion; AI> 0.80 = long-standing infection, >6 months from
seroconversion). We calculated the correlation and the concordance rate
between the two assays; for the latter, a grey zone around the 0.80 cut-
off was included, thus classifying the specimens in three groups: recent
infection AI< 0.75, grey zone 0.75AI 0.84, long-standing infection
AI> 0.84.
Results: Based on estimated date of seroconversion, 68 specimens
(66.7%) were collected in the 6 months after seroconversion and 34
(33.3%) more than 6 months after seroconversion.
Sensitivity and speciﬁcity for recent infection were: for AxSYM HIV
Ag/Ab Combo 88.2% and 85.3% respectively, and for Architect HIV
S298 20th ECCMID, Posters
Ag/Ab Combo 89.7% and 76.5% respectively. The overall accuracy for
identifying or excluding recent infections was 87.2% for AxSYM and
85.3% for Architect. The regression coefﬁcient between the two assays
was 0.74 (95%CI 0.59–0.85).
Of the 102 serum samples, 84 gave concordant results with the two
assays, with an overall concordance rate of 82.4%. When excluding 20
specimens, classiﬁed in the grey zone, the concordance rate was 95.1%
(78/82) (Table 1).
Conclusions: The two assays showed a similar accuracy; Architect HIV
Ag/Ab Combo was slightly more sensitive but less speciﬁc. About 10%
of the specimens fell in the grey zone around the cut-off of 0.80: when
these specimens were excluded, the two assays showed a very good
concordance.
Table 1. Comparison of the AI results obtained with Architect HIV
Ag/Ab Combo and AxSYM HIV Ag/Ab Combo
Architect Combo AxSYM Combo
Recent inf. Grey zone Long-standing inf. Total
Recent inf. 54 4 3 61
Grey zone 5 2 5 12
Long-standing inf. 1 4 24 29
Total 60 10 32 102
Note: recent infection: AI< 0.75; grey zone: AI 0.75−0.84; long-standing
infection: AI> 0.84.
P1082 Study of sensitivity and speciﬁcity of ELISA test system
MONOLISA HCV Ag-Ab ULTRA
S. Mukomolov, E. Barantsevich °, A. Mukomolova, N. Barantsevich,
E. Schlyakhto (St. Petersburg, RU)
Testing the blood samples for hepatitis C antibodies (anti-HCV) is
a compulsory procedure for donor’s blood approbation. The third
generation of test systems based on EIA and chemiluminescent analysis
are currently used. It is known that anti-HCV are appearing in the blood
in hepatitis C infection later than hepatitis C virus RNA. There by it
is highly important to determine seroconversions and core viral antigen
early. Test-system, that allows to determine anti-HCV and HCVcore Ag
simultaneously, has recently appeared in the market.
Objectives: The present study was aimed to determine sensitivity and
speciﬁcity of ELISA test-system MONOLISA HCV Ag-Ab ULTRA.
Methods: 33 samples, that showed positive or uncertain result in donor
blood primary testing for anti-HCV, were tested repeatedly with:
– test systems MONOLISA HCV Ag-Ab ULTRA (Bio-Rad Laborato-
ries, France)
– test-systems Best anti-HCV (Vector-Best, Russia)
– test-systems for determination of hepatitis C RNA by PCR
(Interlabservice, Russia)
Results: After repeated testing of serum samples by test-system
MONOLISA HCV Ag-Ab ULTRA 14 samples were positive (42.4%).
In Best anti-HCV 11 samples showed to be positive (33.3%). 8 samples
showed concordance. 6 samples proved to be positive only by evaluation
with test, that determine both HCV core antigen and antibodies. That
could indicate that MONOLISA HCV Ag-Ab ULTRA test is more
sensitive. All 33 samples were tested by PCR for hepatitis C viral RNA
presence, it was conﬁrmed in 12 serums. In 6 samples, that were positive
only in MONOLISA HCV Ag-Ab ULTRA testing, hepatitis C RNA was
determined in 4 (67%).
Conclusion: In the selective sampling (only uncertain results for
hepatitis C virus samples) more than 10% (4 out of 33) were proved
to contain only viral antigen and were not determined by anti-HCV
testing. Early detection of hepatitis C infection before seroconversion
and anti-HCV appearance presents MONOLISA HCV Ag-Ab ULTRA
as an invaluable instrument for blood banks protection.
P1083 The highly sensitive enzyme immunoassay for HBsAg
detection as the alternative method to nucleic acid testing
N. Egorova, S. Igolkina, I. Pyrenkova, I. Sharipova, V. Puzyrev,
A. Obriadina, A. Burkov, T. Ulanova ° (Nizhniy Novgorod, RU;
Saronno, IT)
Background: Enhancement of sensitivity of the currently available EIA
assays is very important be-cause the early stage of HBV infection when
HBsAg level is below detection limit of the best available EIA kits
(0.05−0.1 IU/ml) is one of the main reasons of transfusion-associated
hepatitis A. The aim of the study was to evaluate the advantage of highly
sensitive assay DS-EIA-HBsAg-0.01 (0.01 IU/ml Second Interna-tional
Standard for HBsAg subtype adw2, genotype A, NIBSC code number:
00/588) for detection of HBsAg during seroconversion period.
Methods: The correlation between HBsAg and HBV DNA presence
in seronversion samples has been studied. Twenty eight commercial
panels PHM − 911, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934,
935A(M), 935B (Boston Biomedica Inc.) and HBV − 6271, 6273, 6275,
6277, 6278, 6279, 6281, 11001, 11002, 11003, 11006, 11008, 11011,
11012, 11017 (ZeptoMetrix Corp.) were used. The aggregate score was
calculated by summing the total number of reactive specimens in the all
panels detected by each test. The mean number of days delay in detection
of HBsAg and HBV DNA were also calculated.
Results: DS-EIA-HBsAg-0.01 assay detected 203 samples as HBsAg
positive out of 283 seroconversion samples. Only 181 seronversion
samples out of 283 were detected as HBV DNA positive.
The detection of HBsAg and HBV DNA ranged 0–133 days with the
means delay in detection of HBsAg of 21.85 days and detection of HBV
DNA of 24.48 days. DS-EIA-HBsAg-0.01 detected HBsAg in the speci-
mens of the PHM (926, 931, 933), HBV (6277, 6279, 11001, 11012,
11017) panels by one bleed earlier and in the specimens of the panels
PHM925, HBV11002, PHM932, HBV6275 by two, two, four and ﬁve
bleeds, accordingly, earlier than the initial detection of HBV DNA (100–
400 copies/ml) occurred.
With the use of the DS-EIA-HBsAg-0.01 for evaluation the specimens of
the PHM (927, 928, 929, 930, 934, 935A(M)), HBV (6271, 6273, 6281,
11003, 11006, 11008, 11011) panels, the moment of detection of HBsAg
coincided in the time of initial detection of HBV DNA. Hence using
more highly sensitive assay allows determining HBsAg simultaneously
to HBV DNA or even earlier.
Conclusion: Increasing sensitivity EIA for HBsAg detection up to a
level comparable to sensitivity of nucleic acid testing (NAT) allows to
consider it as the possible alternative to other methods which will raise
quality of screening of donor blood, will allow to reduce the risk of
posttransfusional hepatitis B infection.
P1084 The evaluation of the ELISA kit “EIA-anti-HCV” with new
recombinant antigens
G.B. Bochkova °, V. Puzyrev, A. Obriadina, A.N. Burkov, T. Ulanova
(Nizhniy Novgorod, RU)
Introduction: High heterogeneity is typical for hepatitis C virus. The
new generation enzyme immunoassay “EIA-ANTI-HCV” intended for
the detection of antibodies to viral hepatitis C in human serum or plasma
was developed. The recombinant antigens comprising only diagnostically
relevant regions of different variants of native HCV proteins were
specially selected.
Aim: The evaluation of the ELISA kit “EIA-anti-HCV”.
Objectives and Methods: The various sequences of recombinant
antigens comprising HCV Core, NS3, NS4, NS5 were adsorbed on
the microtiter plate. Diagnostic value of the assay was studied by
testing 1004 anti-HCV positive samples of patients with conﬁrmed
hepatitis C diagnosis, including 338 samples with determined genotype
1−6 (76 samples of genotype 1, 51 sample of genotype 2, 38 samples
of genotype 3, 25 samples of genotype 4, 5 samples of genotype 5,
8 samples of genotype 6); samples of 31 commercial seroconversion
panels (BBI Inc., ZeptoMetrix), samples of the “Anti-HCV Mixed Titer
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Performance Panel BBI PHV 206” (BBI Inc.) Sera samples of patients
with acute (n = 30) and chronic (n = 439) hepatitis C were studied for the
clinical efﬁciency assessment.
Diagnostic speciﬁcity was studied by testing samples of healthy donor
blood (n = 8107), clinical patients (n = 1225), pregnant women (n = 735),
patients with hepatitis B (n = 600).
Results: Out of 259 samples from 31 tested seroconversion panels the
kit “EIA-ANTI-HCV” detected 101 samples (40%) as positive. The kit
detected 23 positive results and indicated 2 negative results according to
data available from insert package of the panel “Anti-HCV Mixed Titer
Performance Panel BBI PHV 206”. It should be mentioned that the value
OD/Cut-off of the most of positive results were higher than the passport
date. The diagnostic sensitivity of the kit “EIA-ANTI-HCV” at testing
anti-HCV positive samples with clinical diagnosis of acute and chronic
hepatitis C was 100%. Sensitivity of the kit during testing the samples
with different genotypes was 100%.
The study showed high speciﬁcity of the kit “EIA-ANTI-HCV”.
Conclusion: The received results demonstrated high diagnostic efﬁ-
ciency of ELISA kit in the combination with high speciﬁcity.
P1085 Performance evaluation of the Access® HCV Ab Plus and
the Access HIV-1/2. New assays performed on the UniCel®
DxI 800 in a virology laboratory
C. Roussel, P. Zawadzki, E. Le Moal, N. Groleau, R. Falcou-Briatte °,
G. Duverlie (Amiens, Marnes-la-Coquette, FR)
Objective: Access HCV Ab Plus and Access HIV-1/2 New are in vitro
diagnostic assays for the qualitative detection of anti-HCV and anti-
HIV antibodies respectively in human serum or plasma. The aim of this
study was to evaluate the performance of these two assays in terms of
sensitivity, speciﬁcity and precision in our routine laboratory.
Methods: Access HCV Ab Plus and Access HIV-1/2 New assays
were evaluated on UniCel DxI 800 immunoassay system and compared
to Abbott AxSYM® anti-HCV and AxSYM® HIV 1/2 gO assays
respectively. For the performance studies, we used unselected serum
samples, positive samples, seroconversion panels and different quality
controls.
Results:
– Access HCV Ab Plus assay performance: On 500 unselected routine
serum samples, the global agreement between Access and AxSYM
was equal to 97.8% (96.1–98.9%). The clinical speciﬁcity for the
Access HCV Ab Plus assay was 99.0% (97.6–99.7%) versus 99.2%
(97.9–99.8%) for the AxSYM anti-HCV assay (2 equivocal samples
were excluded from the calculation). The clinical sensitivity was 100%
and the seroconversions were detected earlier with the Access HCV
Ab Plus assay.
– Access HIV-1/2 New assay performance: From unselected serum
samples tested on both Access and AxSYM assays, 6 were positive
and 540 negative. The agreement between Access and AxSYM assays
was 100%. The relative speciﬁcity was 100% and the seroconversion
sensitivity was equivalent.
Precision for both HCV and HIV assays was better on UniCel DxI 800
than on AxSYM.
Conclusion: Both Access HCV Ab Plus and Access HIV-1/2 New assays
showed good performance and good concordance with the AxSYM
assays.
The Access assays can be easily used on UniCel DxI 800 in a virology
laboratory with high volume of HCV and HIV screening tests.
P1086 Utility of rapid inﬂuenza antigen detection test for novel
inﬂuenza virus (H1N1)
J. Acosta °, J.R. Otero, L. Folgueira (Madrid, ES)
Objectives: RT-PCR is the method of choice for diagnosis of pandemic
H1N1 virus in respiratory samples; however such test cannot be readily
performed in primary health care settings. It makes necessary to establish
if currently commercially available rapid inﬂuenza diagnostic tests
(RIDTs) can detect novel inﬂuenza A (H1N1) virus. The aim of this
study was to compare the Directigen EZ Flu A+B® immunoassay
with the real-time polymerase chain reaction (RT-PCR) assay developed
by the Centers for Disease Control and Prevention (CDC) to detect
pandemic inﬂuenza A/H1N1 2009 virus.
Methods: 140 samples (54 nasal aspirates and 86 nasopharyngeal swabs)
collected from paediatric patients were submitted to the clinical virology
lab for rapid inﬂuenza viruses testing during June, July and August.
All tests were performed according to the manufacturer’s instructions.
Testing for pandemic inﬂuenza H1N1 2009 virus was performed using
the CDC developed RT-PCR assay.
Results: Of 140 specimens, 71 (50.7%) were positive and 69 (49.3%)
were negative by RT-PCR. Of the 71 specimens that tested positive by
RT-PCR, 50 tested positive by RIDT for a test sensitivity of 70.4% and
a positive predictive value of 100%. Of the 69 specimens that tested
negative by RT-PCR, 69 tested negative by RIDT for a test speciﬁcity of
100% and a negative predictive value of 76.6%. The overall agreement
between the two assays was 119/140 (85%).
Conclusions: RIDTs have lower sensitivity than RT-PCR or viral culture
in the detection of seasonal inﬂuenza viruses. Several reports have shown
that RIDTs have low sensitivity in detection pandemic inﬂuenza A/H1N1
2009 virus. In contrast, our data indicate that the sensitivity of BD
Directigen EZ Flu A+B® inﬂuenza antigen detection was comparable to
that of seasonal inﬂuenza previously reported for this assay, in samples
collected from paediatric population.
P1087 The usefulness of the direct immunoﬂuorescence assay for
inﬂuenza A (H1N1) virus
J.H. Lee °, H. Shim, J.H. Jo (Iksan, KR)
Objectives: The aim of this study is to evaluate the diagnostic accuracy
of direct immunoﬂuorescence assay(DFA) of the laboratory-conﬁrmed
cases of inﬂuenza A (H1N1).
Methods: From August 2009 to October 2009, of 2302 patients with
symptoms inﬂuenza-like illness, 1390 patients were performed DFA.
The specimens were obtained by the nasopharyngeal ﬂocked swabs and
DFA were conducted with D3 DFA Screening and the ID kit. (Diagnostic
Hybrid Inc., Athens, OH, USA) A positive result was indicated by the
presence of two or more intact cells exhibiting the speciﬁc ﬂuorescence
pattern. We evaluated the clinical usefulness of the DFA in detecting
inﬂuenza A(H1N1).
Results: The sensitivity of DFA were 62.9%. The sensitivity were
different in age groups, showing the highest(71.1%) in patients below age
of 10 years. When we stratiﬁed the results according to the patient’s body
temperature and the elapsed time from the onset of inﬂuenza like illness,
the sensitivities of DFA were higher in subjects with body temperature
above 38ºC (69.5% vs 54.6%), and in subjects who were done the
DFA within 48 hours after onset of the symptoms(60.2% vs 52.6%).
During the study period, the overall incidence of inﬂuenza A(H1N1)
was 39.3%(905/2302) by RT PCR method. The incidences of novel
inﬂuenza(based on the laboratory conﬁrmed cases) were increased
as follows; 10.7%(13/121) in August, 12.3%(77/624) in September,
30.1%(58/193) in the ﬁrst half of October, and 55.6%(758/1364) in
the second half of October. However, the DFA positive rates were not
inﬂuenced by the increase of the incidence.
Conclusion: DFA for inﬂuenza A (H1N1) virus had a positive rate
of 62.9%. DFA would be more useful to patients who have a body
temperature above 38ºC or young children below age of 10 years.
P1088 Quantitative HHV-6B antigenemia test for the monitoring
of transplant patients
R. Loginov, T. Karlsson, K. Ho¨ckerstedt, D. Ablashi, I. Lautenschlager °
(Helsinki, FI; Santa Barbara, US)
Objectives: Human herpesvirus-6 (HHV-6) infection, mostly caused by
the variant B, is common after solid organ transplantation, as previously
demonstrated by antigenemia test. Here we report a new modiﬁed method
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using a HHV-6B glycoprotein IgG-antibody, OHV-3, and attempt to
quantify the HHV-6 antigenemia after liver transplantation. Twenty-
four adult liver transplant recipients were frequently monitored by the
qualitative HHV-6 antigenemia test, which detects the HHV-6B virion
protein in peripheral blood mononuclear cells (PBMC).
Methods: HHV-6B antigens were now demonstrated using a glycopro-
tein OHV-3 IgG-antibody in the immunoperoxidase staining from the
same specimens and quantiﬁed as positive cells/10,000 PBMC. The
results were conﬁrmed and quantiﬁed by DNA-hybridization in situ using
biotinylated oligoprobe. Altogether 206 blood specimens were analyzed.
Results: During the ﬁrst six months, HHV-6 antigenemia was detected
in 17/24 (71%) recipients by using HHV-6B virion antibody. All, except
one patient with a faint positivity, demonstrated positive ﬁndings also
with the OHV-3 antibody. Altogether, 37% (77/206) of specimens were
positive with the virion antibody and 39% (78/201) by the OHV-3
antibody. The peak number of OHV-3 positive cells in the PBMC‘s
varied from 5 to 750/10,000 (mean 140/10,000).
Conclusions: The OHV-3 antibody was useful to quantify the HHV-
6B antigenemia. The ﬁndings of the HHV-6B quantitative antigenemia
using the OHV-3 antibody correlated well with the previous qualitative
HHV-6 antigenemia assay, and can be used as a quantitative method in
the monitoring of HHV-6 in transplant patients.
P1089 Comparison of nasopharyngeal aspirates and
nasopharyngeal ﬂocked swab specimens for the detection of
respiratory viruses by indirect immunoﬂuorescent method,
culture, and multiplex PCR
J.O. Kang °, H. Pai, H. Sung, N.Y. Lee, C.K. Lee, H. Kim, E.C. Kim,
K. Lee, C. Kang (Guri, Seoul, KR)
Objectives: Nasopharyngeal aspirates (NPA) have been considered the
gold standard for the respiratory virus samples, but the procedure is
uncomfortable for the patients and unpleasant for the medical staffs.
Copan Diagnostics Inc. (Brescia, Italy) recently marketed ﬂocked swab
kits and they have been reported to get respiratory specimens more
comfortably, and to improve the sensitivity of various diagnostic tests.
We compared the Copan nasopharyngeal ﬂocked swab (NPFS) kits with
the NPA, whether the kits could get better respiratory specimens or
increase sensitivity by the three most commonly employed diagnostic
methods for the detection of the respiratory viruses.
Methods: A total of 111 infants and young children were enrolled
who were admitted in Pediatric Department due to lower respiratory
tract infection in a university hospital. For NPFS, a ﬂocked swab was
introduced into the right nostril against the pharyngeal tonsil, and rotated
3 times. For NPA, the catheter was inserted into the left nostril to the
same depth, washed with saline, and aspirated out. All specimens were
sent to laboratory for the detection of the seven respiratory viruses
by indirect immunoﬂuorescent (IF) method (Chemicon, Temecula, CA,
USA), culture (R-Mix Too, Diagnostic Hybrids, USA, and multiplex
PCR (Seeplex® RV12 ACE Detection kit, Seegene, Korea).
Results: The percentage of inadequate specimens for indirect IF methods
due to lack of respiratory epithelial cells were 23.4% in NPA but 5.4%
in NPFS. Positive rates of respiratory viruses detected by indirect IF
method were 23.4% in NPA and 43.2% in NPFS (P< 0.05). By culture
with R-Mix cells, positive rates were 27.9% for NPA and 38.7% for
NPFS (P< 0.05). With multiplex PCR method, positive rates were 56.8%
for NPA and 71.2% for NPFS (P< 0.05). PNFS sampling method was
easier for the medical staff and more comfortable for the patients. The
specimen quality variation by different medical staffs was much less in
NPFS specimens.
Conclusion: The Copan NPFS was superior to NPA for sampling
respiratory epithelial cells for the indirect IF method, obtaining virus
for culture, or getting viral nucleic acids for multiplex PCR. It would be
possible to request seven respiratory viral tests in emergency room or
in outpatient clinic if PNFS were available. We conﬁrmed that sampling
method was very critical in detecting respiratory viral pathogens.
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P1090 Simplexa™ inﬂuenza A H1N1 (2009) assay for detection of
2009 pandemic inﬂuenza H1N1 with Microﬂuidic real-time
PCR system
M. Aye °, J. Chen, S. Dempsey, E. Eleazar, H. Mai, L. Nair, Y. Xie,
Y.P. Chen, M. Exner (Cypress, US)
Objective: In 2009, a new strain of Inﬂuenza A (H1N1) virus emerged
and rapidly spread into a global inﬂuenza pandemic. Because of its
unique sequence divergence by genetic shift, this virus was not readily
subtyped by pre-existing tests. In this study, we report development of a
real-time PCR-based Simplexa™ Inﬂuenza A H1N1 (2009) assay for
rapid detection and differentiation of pandemic inﬂuenza virus from
seasonal inﬂuenza A viruses.
Methods: Limit of detection studies and speciﬁcity studies were
performed to determine analytical performance characteristics of the
Simplexa™ Inﬂuenza A H1N1 (2009) assay. Clinical performance of
the was determined by testing blind panels of clinical specimens and
comparing results to those obtained using the CDC real-time RT-PCR
assay for Detection and Characterization of Swine inﬂuenza (version
2009).
Results: Limit of detection studies showed that the Simplexa™ assay
detected inﬂuenza A H1N1 (2009) and seasonal inﬂuenza H1 and H3
subtypes at less than 101 TCID50/mL. Sensitivity and speciﬁcity of the
Simplexa assay for inﬂuenza A H1N1 (2009) and, seasonal inﬂuenza
were 98.3% (59/60) and 99.1% (119/120), and 100% (118/118) and
96.8% (60/62), respectively, compared to CDC real-time RT-PCR assay.
Conclusions: The Simplexa assay (CE IVD) was demonstrated to
be a sensitive and speciﬁc method for detecting and discriminating
inﬂuenza A H1N1 (2009) from other seasonal inﬂuenza viruses. The
assay is compatible with automated and manual sample preparation
methods, and can produce the results in less than 90 min. Thus, Simplexa
assay provides a compact high throughput system for detection and
identiﬁcation of 2009 pandemic inﬂuenza H1N1 virus.
P1091 Development of recombinant adeno-associated virus vector
delivering short-hairpin RNAs to inhibit the replication of
inﬂuenza A viruses
G. Zhang °, M. Chen, B. Zheng (Hong Kong, HK)
Objectives: RNA interference is a powerful tool to inhibit viral infection.
Recombinant Adeno-associated virus (rAAV) vectors are promising and
widely used for gene delivery. This study is to select nucleocapsid protein
(NP) and matrix protein (M2) of inﬂuenza A virus as targets and to
develop rAAV vector to deliver antiviral short hairpin RNAs (shRNAs)
to combat inﬂuenza A.
Methods: rAAV plasmid (pAAV-H1-GFP) was constructed, which
contained H1 promoter and GFP marker gene. shRNAs targeting
M2(shM2) and NP(shNP) genes were inserted into the pAAV-H1-GFP.
rAAV-shM2 and rAAV-shNP were packaged using a modiﬁed AAV
Helper-Free system. The physical and biological titers of puriﬁed rAAV
were quantiﬁed by real time PCR and ﬂow cytometry and the shRNAs
expression were checked by real-time RT-PCR. rAAV and rAAV-shM2
and rAAV-shNP infected MDCK cells respectively. At 48 hours (h)
post-infection, MDCK cells were infected by H1N1 (MOI=1) and then
incubated at 37ºC for10 h. After aspirating medium, the MDCK cells
were washed with PBS and added fresh medium and then incubated at
37ºC for 1 h again to collect the supernatants to check the titers of H1N1
by plaque assay.
Results: The pAAV-H1-GFP was transfected into Hela, 293FT and
MDCK cells and rAAV pseudo-virus infected MDCK cells. At 24 h
post-transfection and 48 h post-infection, strong green ﬂourenscence can
be observed under ﬂuorensence microscope and at 48 h post-infection,
shRNA can be checked. The physical and biological titers of puriﬁed
rAAV are more than 1013 and 1010/ml respectively. The H1N1 virus titer
of the collected supernatant for rAAV and rAAV-shNP and rAAV-shM2 is
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2.9±104, 1.1±104 and 6.6±103 PFU/ml, respectively. Therefore, 62.1%
and 77.2% H1N1 virus were inhibited by rAAV-shNP and rAAV-shM2
respectively.
Conclusions: pAAV-H1-GFP which can express shRNAs and GFP has
been constructed and rAAV pseudo-virus with high titer and infectivity
has been packaged and puriﬁed successfully. rAAV-shM2 and rAAV-
shNP can infect MDCK cells and efﬁciently knock down M2 and NP
speciﬁc mRNA of H1N1 to inhibit the replication of the H1N1 in MDCK
cells. These preliminary results show that rAAV vector can be developed
to deliver antiviral-shRNAs to combat inﬂuenza A and encourage us
to further evaluate anti-H5N1 effects of rAAV-shM2 and rAAV-shNP
in vitro and in vivo.
P1092 In vitro selection and characterization of DNA aptamers
against H5N1 virus nucleoprotein
Y.P. Lin °, J.A. Tanner, B. Zheng (Hongkong, CN)
Objective: To develop DNA aptamers against H5N1 virus nucleoprotein
and study the ability to inhibit H5N1 viruses production.
Methods: Nucleoprotein of inﬂuenza A virus (A/vietnam1194/2004
(H5N1)) was cloned and expressed in E. coli. The single strand DNA
library is composed of 30 random nucleotides ﬂanked by constant
sequences for PCR ampliﬁcation. Magnetic beads-based approach was
used to screen DNA aptamers binding puriﬁed His-tagged nucleoprotein.
After 20 rounds of selection, the enriched pool was cloned and 40
colonies were sequenced. The structure of the G-quadruplex aptamers
was characterized by circular dichroism spectroscopy. MDCK cells
were transfected with representative aptamers by Lipofectamin 2000.
Four hours after transfection, cells were challenged with 100TCID50
inﬂuenza A virus (A/Vietnam/1194/2004(H5N1)). The viral titer was
determined by HA assay at 48 hours post-infection.
Results: The sequences from in vitro selection revealed fairly conserved
and could be classiﬁed into two groups, G-quadruplex and T-rich DNA
aptamers. G-quadruplex aptamers were found dominant in the population
and comﬁrmed by circular dichroism spectroscopy. Circular dichroism
spectroscopy gave ellipticity minima and maxima at 240 nm and 264
nm, indicating a parallel arrangement of the quadruplex strands. In the
early stage of post-transfection, DNA aptamers were mainly localized
in the nuclei where the replication and transcription of inﬂuenza virus
genome take place exclusively, which may facilitate successful antiviral
efﬁcacy. The T-rich aptamer had only mild effect on the inhibition of
H5N1 virus, whereas G-quadruplex forming aptamers exhibited potent
antiviral effect.
Conclusions: This study has demonstrated that nucleoprotein could be a
potential antiviral target for inﬂuenza H5N1 virus. Further investigation
will aim to elucidate the interaction between the G-quadruplex aptamer
and nucleoprotein, as well as the antiviral mechanism.
P1093 H1N1 inﬂuenza virus infection in north-Western Spain,
summer 2009
J. Fernandez, S. Perez, J. Torres, O. Touza, E. Martinez, I. Lopez °
(Vigo, ES)
Objective: To study the epidemiological characteristics of the In-
ﬂuenza A H1N1v infected patients during the Summer of 2009 in Galicia
(North West Spain).
Methods: From June to September 1466 samples (upper respiratory
tract) were received (MTV, 4ºC) in our laboratory from hospitals
throughout the Region. They were from the same number of patients
with ﬂu symptoms. RNA extraction was carried out using QIAamp Viral
Mini Kit (QIACube-Qiagen). The CDC rRT-PCR Flu Panel (Ag Path-ID
One-Step RT-PCR Kit) was used in order to detect the H1N1v virus.
Neuraminidase sequence analysis was performed in 20 positive cases
(BigDye 1.1 Applied Biosystems) to detect mutations causing resistance
to oseltamivir.
Results: 359 out of 1466 samples proved positive (24.5%). The
characteristics of the infected patients were: in-patients 79 out of 438
(18.0%); outpatients 177 out of 582 (30.4%, p< 0.0001), unknown
origin 103 out of 446 (23.1%). Gender: male 192 out of 797 (24.1%),
female 167 out of 669 (25%). Age: <5 yrs: 10 out of 98 (10.2%);
5−15yrs: 78 out of 136 (57.4%, p< 0.0001); 16−39yrs: 194 out of
608 (31.9%), 40−64yrs: 61 out of 397 (15.4%); >65yrs: 9 out of 207
(4.3%, p< 0.0001). The Crossing point (Cp) of the positive samples:
<20: 25; 20−24: 99; 25−29: 124; 30−34: 104; 35: 7. No neuraminidase
mutations were detected in the residues previously associated with
oseltamivir resistance (275, 295).
Conclusions: (1) The higher incidence of H1N1v infection was found
in outpatients and children between 5−15 yrs. (2) Patients more than 65
years old were the less affected. (3) Only a third of the positive samples
had a Cp< 25. (4) No oseltamivir resistance was detected.
P1094 Presence of several respiratory viruses in samples from
patients with suspected ﬂu A/H1N1 infection
A. A´lvarez-Buylla °, E. Culebras, C. Betriu, J. Picazo (Madrid, ES)
Objectives: Infections caused by the inﬂuenza virus have a signiﬁcant
repercussion on modern society and causes particular concern. Since
many of the signs and symptoms of respiratory virus infections are
similar, other respiratory virus pathogens can be overlooked when
focusing only on FluA. The aim of this study was to determine the
presence of different respiratory viruses in both positive and negative
pandemic inﬂuenza A samples.
Materials and Methods: A total of 60 respiratory specimens collected
from patients with inﬂuenza-like illness had been selected for the study
and previously tested by real time PCR. Specimens included 30 positive
and 30 negative for pandemic FluA (15+15 samples from June and 15+15
samples from October).
Samples were tested using commercial kit (CLART PneumoVir.
Genomica®) that employ a combination of two multiplex RT-PCR
followed by primer extension and microarray hybridization. This assay
can detect adenovirus; bocavirus, coronavirus; enterovirus (echovirus);
rhinoviruses (HRV); inﬂuenza viruses A (seasonal), B and C; human
metapneumoviruses (HMPV) A and B, human respiratory syncytial
viruses (HRSV) A and B; and parainﬂuenza viruses (PIV) of types 1, 2,
3 and 4.
Results: No other respiratory viruses were detected in pandemic
FluA positive samples from June, whereas six positive specimens
from October were identiﬁed as dual infections. These dual infections
included: one type 4 PIV, one HRV, one type 1 PIV, one RSV and
two seasonal FluA. In pandemic FluA negative samples 7 out of 15
specimens from June reveal the presence of another respiratory virus
(two samples with adenovirus, 2 samples coronavirus, one type 4 PIV,
one enterovirus and one FluC). Only three of the negative pandemic
FluA samples analyzed from October were positive in our study (HRV
the three specimens).
Conclusions: Different respiratory viruses are present in samples
obtained from patients with inﬂuenza-like illness. Detection of these
other respiratory viral etiologic agents can be difﬁcult in cases in which
the causal agent was not suspected and a speciﬁc test was not demanded
by the clinicians. The circulation of different respiratory viruses during
the same period of the year makes very complex to elucidate their
individual contributions to the global respiratory disease.
P1095 Interim report on pandemic H1N1 inﬂuenza virus infections
in Korea, August to October, 2009
S.H. Lee °, B.H. Park, H.Y. Kang, K.O. Lee, G.Y. Kim (Seoul, KR)
Objectives: In Early April 2009, the earliest conﬁrmed case of H1N1
inﬂuenza A virus was reported in Mexico. Currently, H1N1 is rapidly
transmitted from person to person worldwide. Rapid detection is essential
to instigate appropriate public health management and for disease
surveillance. We estimate the epidemiology and positive rates of novel
inﬂuenza H1N1 virus during the fall season in Korea.
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Methods: 52,899 nasopharyngeal samples in patients with inﬂuenza like
illness were collected over the country during mid August to October in
2009. H1N1 positive case was deﬁned by real time reverse transcription
PCR (rRT-PCR). H1N1 virus test using RNA was extracted using
RNA extraction kit (Zymo Research, CA, USA). For the detection of
inﬂuenza A and novel H1N1 virus, Genekam kit (Genekam, Duisburg,
Germany) were used according to the CDC protocols veriﬁed by WHO.
We analyzed the prevalence of virus according to age range, sex, regional
distribution, and time period.
Results: Of the 52,899 patient, H1N1 virus was detected in 29,554
samples (55.9%). The highest frequency was found in the 10−19 year-
olds’ group (M= 68.3% versus F = 64.8%) and followed by the 0−9 year-
olds’ group (M= 56.6% versus F = 54.7%). The positive rate of H1N1
virus decreased as age range increased in over the 30 years-olds’ group.
The mean positive rate was signiﬁcantly higher in men than in women
(M= 58.2% versus F = 53.2%). The prevalence of novel H1N1 virus was
high in some areas such as Gangwon, Daejeon, Chungcheong and Busan
among 13 provinces of Korea. The H1N1 positive rate increased over
time and showed signiﬁcantly a high peak at mid-September in 2009.
Conclusion: The positive rate of H1N1 virus is especially high in
adolescences and children groups in Korea. A peak in prevalence is found
at mid-September in 2009. Therefore, it is necessary to pay attention to
the younger patients with inﬂuenza like illness as well as the high risk
groups in epidemic season of H1N1 virus.
P1096 Predictive factors for mortality among in-hospital Mexican
patients infected with inﬂuenza A/H1N1
J.A. Mata-Marin °, I. Ascencio-Montiel, J.E. Gaytan-Martinez,
R. Arias-Flores, C. Martinez-Chacon (Mexico City, MX)
Objective: To determine predictive factors for mortality among in-
hospital Mexican patients infected with inﬂuenza A/H1N1.
Methods: We performed a case–control study of the factors associated
with unfavorable prognosis (mortality) among inpatients with docu-
mented inﬂuenza A/H1N1 infection. We enrolled patients seen from
April to October 2009 at the Hospital de Infectologia, La Raza National
Medical Center, in Mexico City. Cases were those patients who die
during the hospitalization and controls were those who were discharged
due to improvement. Patients were included if they had over 18 years old
and a positive inﬂuenza A/H1N1 RT-PCR test. Data collected included,
general attributes, medical history, presenting symptoms, records about
respiratory evolution, and routine laboratory tests.
We compared median differences using t test or Mann–Whitney U test
when data were skewed. Odds ratio and 95% conﬁdence interval were
calculated to assess the relationship between each predictive factor and
the risk of mortality. To adjust for the effects of potential confounders, we
used a logistic regression models. P-value was considering statistically
signiﬁcant if <0.05.
Results: We included 31 patients (11 cases and 20 controls), of the
patients enrolled 12 (38.7%) were male: 7 (63.6%) in cases group and
5 (25%) in controls group. The median (±SD) age of our subjects was
36.2±13.8 and 34.25±11.47 respectively (p = 0.685).
The risk factors associated to mortality were: male sex OR 5.25 (CI
95% 1.07–25.79), delayed in medical attention (>3 days) OR 6.41
(95%CI 1.18–34.61), delayed to start anti-ﬂu therapy (>3 days) OR
10.0 (95%CI 1.07–93.43), admission to the intensive care unit OR 9.9,
(95%CI 1.51–64.52), required mechanical ventilation OR 9.3 (CI 95%
1.43–61.14), presence of chronic diseases OR 10.86 (CI 95% 1.02–
114.57), and high creatinine levels (>1.0mg/dl) at admission to hospital
OR 11.2 (95%CI 1.05–120.32). After adjust for the effects of potential
confounders in a logistic regression model, we found only delayed in
medical attention aOR 22.68 (p = 0.02) and presence of chronic diseases
aOR 47.62 (p = 0.037) as predictors of mortality.
Conclusion: An early medical attention is necessary to decrease
mortality in patients with inﬂuenza A/H1N1. Presence of chronic
diseases increased the possibility of mortality in in-patients with
inﬂuenza A/H1N1 in Mexican population.
P1097 Epidemiologic characteristics of deaths associated with
2009 pandemic inﬂuenza A(H1N1) virus infection in Korea
H.S. Kim °, J.H. Kim, S.Y. Shin, Y.A. Kang, H.G. Lee, J.S. Kim, J.K. Lee
(Seoul, KR)
Objectives: To describe clinical and epidemiologic features of fatal cases
associated with 2009 inﬂuenza A(H1N1) infection in Korea.
Methods: Nationwide enhanced public health surveillance of Korea
residents who were died with laboratory evidence of pandemic 2009
inﬂuenza A(H1N1) infection reported to the Korea Centers for Disease
Control and Prevention between August 15 and November 05, 2009.
Results: During the study period there were 51 cases of death due to
pandemic 2009 inﬂuenza A(H1N1) infection reported in Korea. Among
the 51 cases, the median age was 55 years (range, 2 months-83 years);
27(52.9%) were male and 24(47.1%) were female. The median time
form symptom onset to diagnosis was 3days(range: 1−16days) and from
symptom onset to death was 6days. Antiviral drugs were administerd to
42patients(82.4%). 24patients(57.1%) of them start antiviral medication
before diagnosis and others start antiviral medications as soon as the
inﬂuenza conﬁrmed. 42 patients(82.4%) had risk factors for seasonal
inﬂuenza complications such as 1) age less than 59months were 4
patients, 2) age more than 65years were 22 patients(19 cases of these
had chronic medical conditions), 3) chronic medical conditions were 16
patients(malignant tumor, DM, chronic lung disease and chronic renal
disease).
46 patients (90.2%) of those had pulmonary complication like pneumo-
nia or acute respiratory distress syndrome. Evidence of coinfection was
found in specimens from 19.6%(10/51) patients, including 6 caused by
bacteria and 2 caused by funfus.
Conclusions: Fatal cases from 2009 inﬂuenza A(H1N1) in Korea
occurred in high-risk patients and was associated with viral pneumonia
and severe acute respiratory distress syndrome. Considering current
situation, we need to manage high-risk patients actively.
P1098 Dynamics of clinical symptoms in a case with pandemic
inﬂuenza A (H1N1)
C.S. Lee °, J.H. Lee (Jeonju, KR)
Background: The clinical spectrum of 2009 pandemic inﬂuenza A virus
infection is still being deﬁned, but both self-limited illness and severe
outcomes, including respiratory failure and death, have been observed.
Method: The 2009 H1N1 inﬂuenza was conﬁrmed by means of a
polymerase chain reaction assay (PCR). Upper respiratory symptoms
were deﬁned as rhinorrhea, sore throat, and nasal congestion. Lower
respiratory symptoms were deﬁned as cough, and dyspnea. Systemic
symptoms were deﬁned as subjective fever, headache, and myalgia.
Gastrointestinal symptoms were deﬁned as nausea, vomiting, and
diarrhea. The symptom score was average, and the range was from 0
to 3. All subjects were asked to complete a daily log at about the same
time every morning to document the severity of their inﬂuenza-related
symptoms on a 4-point scale sheet.
Result: During the evaluation period, 239 patients were diagnosed
with pandemic inﬂuenza A infection. Among them, 118 patients were
admitted to the hospital, and the other 121 were given oseltamivir and
sent home to rest. Among 118 patients, 85 patients (>9 years old), who
ﬁlled out the symptoms score completely, were analyzed for the study. Of
the 85 patients studied, 57 (67.1%) were male. The mean age, hospital
stay, and the interval from initial symptoms to oseltamivir administration
were 23.4±14.3 years, 5.7±1.5 days, and 2.3±1.4 days, respectively.
Among the clinical manifestations, fever (91.9%) and cough (91.9%)
were the most frequent, followed by sore throat (69.8%), rhinorrhea
(64.0%), headache (60.5%), nasal congestion (55.8%), myalgia (43.2%),
diarrhea (31.4%), nausea (24.4%), dyspnea (22.1%), and vomiting
(15.1%). The duration of cough was the longest, followed by myalgia,
and sore throat. Regarding the severity of symptoms, systemic symptoms
peaked the earliest (by day 2) and resolved faster than lower respiratory
symptoms (LRS), and upper respiratory symptoms (Fig 1). The LRS
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resolved slowly over many days. The gastrointestinal symptoms were
mild and short lived.
Conclusion: The pandemic H1N1 virus involve primarily lower
respiratory tract as in H5N1 virus. The risk groups with any chronic
lung disease should be advised to do their best to protect themselves
from this pandemic inﬂuenza virus.
Figure 1. The dynamics of clinical symptoms of the patients infected
with 2009 pandemic inﬂuenza (H1N1).
P1099 Investigation of the frequency of pandemic inﬂuenza A
2009 H1N1 virus and other respiratory viruses in patients
with acute respiratory tract infections
C. Cicek °, H. Pullukcu, E.U. Saz, G. Cok, B. Arda, F. Bacakoglu
(Izmir, TR)
Objectives: The aim of this study is to establish the frequency of
respiratory viruses (RSV, inﬂuenza viruses type A and B, parainﬂuenza
viruses type 1, 2, and 3, and adenovirus) and pandemic inﬂuenza A 2009
H1N1 virus in patients with acute respiratory tract infections in Izmir
since January 2009.
Methods: Nasopharyngeal swab specimens were collected from 480
[251 (52.3%) male, 229 (47.7%) female] patients with acute respiratory
tract infections between January 1st and November 17th 2009. The
age range of patients is between 6 days to 82 years (median: 15
years). Direct immunoﬂuorescent antibody (DFA) test and shell vial
cell culture method were performed when all the specimens arrived at
the laboratory. Cytocentrifuged specimens were stained with Respiratory
DFA Viral Screening & Identiﬁcation Kit (Light Diagnostics, Millipore,
USA) according to the manufacturer’s instructions. For the recovery
of respiratory viruses were used HEp-2 (RSV), A-549 (adenovirus),
Vero (parainﬂuenza viruses type 1, 2, and 3), and MDCK (inﬂuenza
viruses type A and B) cells line and shell vial cell culture method
were used. Coverslips were stained with a ﬂuorescein isothiocynate
labelled monoclonal antibody speciﬁc for each virus (Light Diagnostics,
Millipore, USA) according to the manufacturer’s instructions. Pandemic
inﬂuenza A 2009 H1N1 virus was detected by real time RT PCR assay
(Inﬂuenza A H1N1 primer and probe set, SuperScript™ III Platinum®
One-Step qRT-PCR System, Invitrogen, USA) by using ABI 7500
system.
Results: Of the 480 patients, 141 (29.4%) were positive for respiratory
viruses by using the combination of DFA and shell vial cell culture
method and ﬁve of these patients were infected by two different viruses
[18 (12.3%) RSV, 99 (67.8%) inﬂuenza type A, 5 (3.4%) inﬂuenza
type B, 9 (6.2%) parainﬂuenza viruses, and 15 (10.3%) adenovirus]. Of
99 inﬂuenza A viruses, 94 (94.9%) were typed as pandemic inﬂuenza A
2009 H1N1 virus.
Conclusion: Pandemic inﬂuenza A 2009 H1N1 virus was not very
common until the second week of November in Izmir. This may be
due to the temperate climatic conditions during this period (20–240C)
in Izmir. Two-thirds of pandemic inﬂuenza A 2009 H1N1 virus was
detected between November 9th and 17th due to cold weather. The
frequency of the other respiratory viruses decreased after September.
Except for inﬂuenza A virus, no other respiratory viruses have been
detected in patients since the ﬁrst of November.
P1100 Epidemiological and antiviral susceptibility data of
A(H1N1)v in northern Greece
A. Melidou, G. Gioula, M. Exindari, A. Papoutsi, D. Chatzidimitriou °,
E. Diza, N. Malissiovas (Thessaloniki, GR)
This study presents up-to-date information on the epidemiological
characteristics of inﬂuenza A(H1N1)v virus infections, as well as
antiviral susceptibility data, obtained from the northern part of Greece
until the 16th of November. 2149 pharyngeal swabs and/or washes were
examined at the National Inﬂuenza Centre for northern Greece. RNA
was extracted with the Qiagen Viral RNA mini kit and A(H1N1)v
infections were conﬁrmed using the CDC swine inﬂuenza real-time
RT-PCR kit following WHO recommendations. Results were reported
to HCIDC, WHO and ECDC. One step RT-PCR and sequencing of
the neuraminidase gene of 15 representative isolates was also done
in order to test the susceptibility of circulating strains to oseltamivir.
688 were conﬁrmed A(H1N1)v infections (32%). Conﬁrmed cases were
presented with ILI, with fever temperature ranging from 38ºC to 40.5ºC,
acute onset of symptoms, cough, catarrh, sore throat, fatigue, headache,
muscle pain and in some cases conjunctivitis, diarrhoea and/or vomitting.
There were 172 patients with pneumonia symptoms, of which 23 were
found positive for A(H1N1)v infection (13.4%). The mortality rate is
0.14, with a total of 3 deaths. There were also a small number of
asymptomatic infections, mostly detected during the summer period. The
age distribution showed a trend towards young adults. Sex distribution
showed similar infection rates at both sexes. During the ﬁrst wave of the
pandemic, until mid July, the majority (70%) of infected individuals were
travellers. Regarding the antiviral treatment, at the onset of the pandemic
all patients received oseltamivir (Tamiﬂu) after the conﬁrmation of
A(H1N1)v infection, but only 21% of the cases were treated from the
onset of symptoms. After widespread transmission within the country,
patients no longer received antiviral treatment unless necessary. 15
isolates were tested for antiviral resistance and they were all found
sensitive to oseltamivir. As already known, all isolates are resistant to
amantadine. A(H1N1)v infection rates in northern Greece showed an
initial peak during weeks 29−34 and the ongoing second peak initiated at
week 42 and is still growing. Epidemiology data of the ongoing pandemic
A(H1N1)v infections, as well the susceptibility of circulating strains to
antiviral drugs is considered essential at this point of the pandemic.
P1101 Evaluation of three commercial Rapid Antigen assays for
the detection of inﬂuenza An/H1N1
J. Perez °, E. Culebras, A. Alvarez-Buylla, C. Betriu, J. Picazo (Madrid,
ES)
Objectives: Pandemic inﬂuenza An/H1N1 emerged in mid-April 2009
leaving laboratories around the world scrambling to establish a diagnostic
test to detect this novel inﬂuenza virus. Reverse-transcriptase polymerase
chain reaction (RT-PCR) is considered the reference test for diagnosis of
inﬂuenza because of its high sensitivity and speciﬁcity as well as its rapid
turnaround time. However, RT-PCR is expensive and requires trained
expertise and batch testing, which delays reporting. Rapid inﬂuenza
antigen test might prove useful, because they have a fast turnaround time
(10−15 min) and require minimal training to perform. We evaluated three
rapid antigen detection test for their ability to detect inﬂuenza An/H1N1.
We calculated the sensitivity for each test.
Materials and Methods: We tested 3 different rapid inﬂuenza
antigen tests for pandemic infuenza An/H1N1 virus. We checked
BinaxNow® Inﬂuenza A&B (CV. Inverness Medical), Inﬂu A&B
Uni-Strip (IAB. Materlab) and QuickVue® Inﬂueza A+B test (QV.
Biomerieux). Twenty two nasopharyngeal specimens that were positive
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for pandemic inﬂuenza A virus by RT-PCR (Roche) were included. We
included samples with viral load between 1×102 and 1×108 copies/ml.
Only 5 samples were tested for the IAB test.
Results: Sensitivities of test were low to moderate: BinaxNow®
Inﬂuenza A&B (Inverness Medical) 3 of 22 specimens and QuickVue®
Inﬂueza A+B test (Biomerieux) 10 of 22 specimens. The detection limit
of both systems was 1×106 copies/ml and 1×104 copies/ml respectively.
IAB test was positive only in samples with >1times;106 copies/ml. All
samples with viral load below 9×103 copies/ml were negative with all
tests.
Conclusions:
1. QV test showed the highest sensitivity of the evaluated tests.
2. Positive results for rapid antigen tests correlates with higher viral
load.
3. Negative rapid inﬂuenza diagnostic test does not rule out infection
with novel inﬂuenza A (H1N1) virus.
4. Rapid inﬂuenza antigen tests can be used to avoid the RT-PCR assay
in samples positive for the rapid tests.
P1102 A comparative study between 2009 H1N1 inﬂuenza A
virus and seasonal inﬂuenza virus infections at a Bangkok
hospital, Thailand
E. Thiansukhon °, L. Paitoonpong, G. Suwanpimolkul, P. Bhattarakosol,
C. Suankratay for the Division of Infectious Diseases & Virology,
King Chulalongkorn Memorial Hospital, Bangkok
Objective: To compare the epidemiology and clinical features between
the patients with laboratory-conﬁrmed 2009 H1N1 inﬂuenza A and
seasonal inﬂuenza virus infections.
Methods: A retrospective study of laboratory-conﬁrmed 2009 H1N1
inﬂuenza A and seasonal inﬂuenza virus infected patients at King
Chulalongkorn Memorial hospital was carried out from June 3 to August
20, 2009. Reverse transcriptase polymerase chain reaction tests were used
to conﬁrmed diagnosis.
Results: There were 167 and 57 patients with 2009 H1N1 inﬂuenza A
and seasonal inﬂuenza infections. The 2009 H1N1 inﬂuenza A group
had less mean age (29.1+19.5 years) than the seasonal inﬂuenza virus
group (36.5+21.6 years) because there are less patients that are more
than 50 years old in 2009 H1N1 inﬂuenza A group. Of all 224 patients
with inﬂuenza infection, the most common symptom was fever (89.7%),
followed by cough (83.4%), rhinorhea (61.9%), sore throat (54.3%),
myalgia (45.3%), and dyspnea (22.9%). There was no signiﬁcant
difference in most clinical manifestations between the two groups except
a higher frequency of diarrhea in the 2009 H1N1 inﬂuenza A group than
the seasonal inﬂuenza virus group (16.3 vs 5.3%, p = 0.042). Pneumonia
was noted in 41 (24.7%) patients in the 2009 H1N1 inﬂuenza A group, in
comparison with 5 (8.8%) patients in the seasonal inﬂuenza virus group
(p = 0.013). The mortality rate was 1.8% in the 2009 H1N1 inﬂuenza A
group, but no patient in the seasonal inﬂuenza virus group died.
Clinical data of H1N1 2009 inﬂuenza A and seasonal inﬂuenza infections
in King Chulalongkorn Memorial Hospital
Total, n
(%)
H1N1 2009
(n = 167)
Seasonal
(n = 75)
P-value
Fever 200 (89.7) 147 (88.6) 53 (93) 0.453
Cough 186 (83.4) 144 (86.7) 42 (73.7) 0.037
Myalgia 101 (45.3) 72 (43.4) 29 (50.9) 0.357
Rhinorrhea 138 (61.9) 99 (59.6) 39 (68.4) 0.271
Sore throat 121 (54.3) 89 (53.6) 32 (56.1) 0.76
Dyspnea 51 (22.9) 42 (25.3) 9 (15.8) 0.2
Diarrhea 30 (13.5) 27 (16.3) 3 (5.3) 0.042
Vomit 29 (13) 26 (15.7) 3 (5.3) 0.065
Pneumonia 46 (20.6) 41 (24.7) 5 (8.8) 0.013
Dead 3 (1.3) 3 (1.8) 0 0.572
Conclusions: The patients with 2009 H1N1 inﬂuenza A infection are
younger than seasonal inﬂuenza virus infected patients. Diarrhea is only
symptom that is more common in 2009 H1N1 inﬂuenza A infected
patients. 2009 H1N1 inﬂuenza A infection seems to be more severe
because there are more pneumonia and death.
P1103 Multiplex assay for simultaneous typing of inﬂuenza A
viruses and subtyping into H1N1 and H3N2, including
novel 2009 swine origin inﬂuenza A H1N1 using a
microarray-based platform
A. Alema´n, O. Salazar °, M.L. Villahermosa, R. Cospedal
(Coslada-Madrid, ES)
Objectives: Recent outbreak of novel inﬂuenza A (H1N1) virus
(swine origin inﬂuenza virus [S-OIV]) makes necessary the design
of well-validated diagnostic tools for the rapid, sensitive and speciﬁc
identiﬁcation of the 2009 pandemic H1N1 inﬂuenza virus. We have
developed and validated a multiplex PCR assay followed for a
hybridization in a low-density microarray (CLART® FluAVir) for
simultaneously typing and subtyping of Inﬂuenza A viruses including
novel H1N1 swine origin inﬂuenza virus [S-OIV], human H1N1 and
H3N2 inﬂuenza A and generic Inﬂuenza A viruses.
Methods: The assay targets the genes NP (nucleoprotein) to type the
inﬂuenza A viruses and subtype human inﬂuenza A H1N1 and N3N2,
and the gene HA (haemagglutinin) to subtype and S-OIV H1N1. 446
clinical isolates were typed and subtyped using CLART® FluAVir assay.
Results: The assay achieved an analytical sensitivity of 10 to 102
copies of transcripts per reaction for each of the genes. The assay
correctly typed and subtyped 446 clinical isolates, including 228 S-OIV
H1N1, 15 A/H1N1 human, 60 A/H3N2 human, and 62 from other
viruses and 113 negative samples. Testing of the analytical speciﬁcities
revealed no-cross reactivity and demonstrated reproducibility of results.
Clinical tests showed 98.3 of sensitivity for Inﬂuenza A H3N2 and 100%
sensitivity and speciﬁcity for the rest of the types, including S-OIV
H1N1. Comparisons of the CLART® FluAVir results with multiple
validated in-house molecular assays, and CDC-validates FDA-approved
assay demonstrates a 100% positive agreement for all the viruses.
Conclusions: CLART® FluAVir is a rapid, sensitive, speciﬁc and
multiparametric assay for the typing and subtyping of inﬂuenza A
viruses, which allow to process up to 96 samples simultaneously in
a working day, being useful for de diagnosis and surveillance of 2009
pandemic (H1N1) inﬂuenza virus and necessary for clinical and public
health decisions.
P1104 Emergence of inﬂuenza A H1N1v oseltamivir-resistant
strain in a 2 year-old child with acute lymphatic leukaemia
G. Campanini, A. Piralla, F. Rovida, E. Percivalle, F. Locatelli,
F. Baldanti ° (Pavia, IT)
Our Center is part of a National network of 22 laboratoires monitoring
the evolution of the current inﬂuenza A pandemic sustained by the
H1N1v strain.
Methods: Emergence of oseltamivir resistance-associated mutations
was monitored in about 1/10 of untreated inﬂuenza A H1N1v strains
recovered at our center. In addition, all patients still positive after 10
days of antiviral treatment were analyzed for the emergence of drug-
resistant virus strains.
Results: Thus far, inﬂuenza A H1N1 neuraminidase gene was sequenced
in 35 untreated patients and oseltamivir- or zanamivir-associated
mutations were not detected. H1N1v neuraminidase gene was also
sequenced in virus strains from the nasal swab of 5 immunocompromised
patients undergoing oseltamivir administration and still positive after
more than 10 days of treatment. In 4 patients no drug-resistence
mutations were detected, while in a 2 years-old girl with acute lymphatic
leukemia the H274Y mutation was shown. Inﬂuenza A H1N1v was
detected by realtime RT-PCR in this patient on Oct. 27, 2009 in the
presence of a mild inﬂuenza like illness (ILI). Due the underlying
disease, the patient was administered oseltamivir (30mg Bid) starting
from Oct. 29, 2009 and presence of virus RNA was monitored every
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other day. On Nov. 14 the patient was still positive for inﬂuenza RNA
in nasal swab and the virus was sequenced showing the presence of a
resistant variant. Despite the emergence of a drug-resistant variant and
leading to failure of oseltamivir treatment, ILI is slowly improving in
this patient. This is the ﬁrst reported drug resistant inﬂuenza A H1N1v
strain in Italy since the beginning of the pandemic, while 43 resistant
strains have been reported worldwide.
Conclusions: (i) Emergence of drug resistant strains is a rare event in
this pandemic, (ii) monitoring of drug resistance is warranted in patients
undergoing prolonged antiviral administration.
P1105 Clinical and epidemiological characteristics of outpatients
with inﬂuenza-like illness during inﬂuenza A H1N1
pandemic in Buenos Aires, Argentina
C. Rodriguez, E. Cordova °, G. Oviedo, W. Cornistein, A. Noel,
L. Vazquez (Buenos Aires, AR)
Objectives: Describe the clinical and epidemiological characteristics of
a series of cases of inﬂuenza-like illness (ILI) attended at Infectious
Diseases Outpatient Department, ‘Cosme Argerich’ Acute General
Hospital, Buenos Aires, Argentina.
Methods: Descriptive and retrospective study of clinical and epidemi-
ological ﬁndings of patients with ILI attended at Infectious Diseases
Outpatient Department from 20/05/2009 to 31/07/2009 in the context
of inﬂuenza A H1N1 pandemic. ILI was deﬁned as documented fever
38ºC and cough or sore throat in the absence of another cause.
According to National Health Ministry recommendations no virological
diagnostic tests were performed to these patients.
Results: N=864. Male sex: 352 (41%). Median age (range): 34 years
(3 months-91 years). The age group of 20−29 years old was the most
affected by ILI: 210 cases (24%). Domicile: Buenos Aires city (75%).
The major incidence was seen between epidemiological week 26−28,
accounting for 63% of the cases.
Main clinical presentation: headache (98%), fever 38ºC (91%),
myalgia (86%), mild cough (63%). Median time between onset of
symptoms to medical assistance: 24 hours (range 0−17 days). History of
contact with a suspect case: 169/310 (55%). Previous immunization with
seasonal inﬂuenza vaccine 2009: 164/812 (20%). Among health care
workers with ILI this antecedent was only present in 44/91 (48%). Risk
factors for ILI: 199/836 (24%), corresponding to: asthma/COPD (11%),
diabetes (3%) and cardiopathy (3%). Chest X ray: interstitial inﬁltrate
(56%), interstitial-alveolar inﬁltrate (6%), alveolar inﬁltrate (3%), normal
(36%).
Treatment with oseltamivir: 783/816 (96%). Complications: 301/457
(66%), being more frequent: pulmonary compromise of probably viral
etiology, follow by acute sinusitis, acute otitis media and bacterial
pneumonia.
Conclusions: Different to what is commonly described for seasonal
inﬂuenza, young adults with no comorbidities were the age group more
frequently affected by ILI. The main complication observed during this
period was pulmonary compromise of probably viral etiology. A low
rate of vaccination for seasonal inﬂuenza was seen among health care
workers.
Outpatients with inﬂuenza-like illness during inﬂuenza A H1N1
pandemic attended at Infectious Diseases Outpatient Department ‘Cosme
Argerich’ Acute General Hospital, Buenos Aires, Argentina.
P1106 Antibodies to interferon-gamma in ultra-low doses: a new
option for pandemic inﬂuenza
S. Tarasov °, V. Zarubaev, J. Tafani, J. Dugina, S. Sergeeva, O. Epstein
(Moscow, St. Petersburg, RU; Maisons Alfort, FR)
Objectives: To assess antiviral activity of antibodies to interferon-
gamma in ultralow doses (ULDabIFNg) against inﬂuenza A/H1N1
viruses.
Methods: Antiviral activity of ULDabIFNg (Anaferon for children®)
was studied in experimental models of lethal infection of mice infected
by different inﬂuenza A/H1N1 virus strains. Studies were conducted in
Inﬂuenza Research Institute (Russia) and in APcis (France) in 2009.
In Inﬂuenza Research Institute 100 female outbred mice (16−18 g.,
20 mice/group) were infected intranasally with 10LD50 of inﬂuenza
virus A/California/07/2009swl. In APcis 60 female Balb/c mice (10−12
g., 20 mice/group) were infected intranasally with 3LD50 of inﬂuenza
virus A/NewCaledonia/20/99. In both studies ULDabIFNg given as
water solution were administered according to prophylactic/treatment
regimen (5 days before and 12 days after inoculation) via oral
gavage (0.2ml/mice 2 times/day). Besides ULDabIFNg were given
instead of drinking water. Control mice were given distilled water
according to the same schedule. In negative control group mice were
neither infected nor treated. In Inﬂuenza Research Institute efﬁcacy
of combination of ULDabIFNg with oseltamivir against monotherapy
with oseltamivir was also studied. Oseltamivir was administered
according to prophylactic/treatment regimen (25 hours and 1 hour
before and 3 days after inoculation) via oral gavage (0.2ml/mice
2 times/day at dose 20mg/kg/day) or (Apcis) from 1 hour to 5
days after inoculation (10mg/kg/day). Combination of ULDabIFNg
with oseltamivir was prepared by dissolving oseltamivir in water
solution of ULDabIFNg. Mortality rate and body weight change were
evaluated.
Results: In Inﬂuenza Research Institute ULDabIFNg signiﬁcantly
reduced mortality. In control group survival was 12.5%, in oseltamivir
group − 10%, in ULDabIFNg group − 50%, in oseltamivir+ULDabIFNg
group − 35%. In the second study (APcis) in the control group
inoculation caused deaths 60% of mice on day 7, treatment with
ULDabIFNg resulted in a later disease onset (on day 5 in ULDabIFNg
group mortality was 15% vs 40% in control group). In both studies mean
body weight of alive mice was constantly a positive function of time in
group treated with ULDabIFNg.
Conclusion: Antiviral activity of ULDabIFNg against two strains of
inﬂuenza A/H1N1 viruses including the pandemic one is comparable to
oseltamivir. Combination of ULDabIFNg with oseltamivir increases the
efﬁcacy of monotherapy with oseltamivir.
P1107 Inﬂuenza vaccination without compulsion for healthcare
workers
R. Givney ° on behalf of the Hunter New England Health V-Day Program
Immunisation of healthcare workers against inﬂuenza has been promoted
as a method of preventing disease in patients. Healthcare worker
immunisation rates against inﬂuenza are historically poor but recently
high rates of immunisation have been reported from mandatory
vaccination programs despite ethical concerns & the uncertainty about
their value in protecting patients.
We present data from a series of annual programs of voluntary staff
inﬂuenza seasonal inﬂuenza immunisation programs (2007−9) and from
the initial pandemic H1N1(2009) vaccination program in the Hunter New
England Area Health Service (16700 staff, 130000 square km) in New
South Wales in eastern Australia.
We demonstrate the effectiveness of voluntary program (>60%) when
there are committed immunisers, an effective communication strategy
about the beneﬁt to the workers, motivated leadership & funding to
provide vaccination services at the places where people are working at
the times they are working.
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2009 HNEH Healthcare Worker (HCW) seasonal inﬂuenza immunisation
by category [A, B or Unclassiﬁed (U)] and date of immunisation.
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P1108 Phylogenetic analysis of hepatitis E virus isolates originated
from Czech patients
P. Vasickova °, M. Slany, P. Chalupa, M. Holub, R. Svoboda, I. Pavlik
(Brno, Prague, CZ)
Objective: Hepatitis E virus (HEV) is the leading cause of hepatitis
non-A, non-B worldwide. Outbreaks of hepatitis E (HE) are associated
with faecal contamination of drinking water, while sporadic cases are
also linked with zoonotic potential of HEV. The virus is non-enveloped
and its genome contains linear positive-strand RNA. According to
phylogenetic analysis HEV isolates segregate into four genotypes.
Relative conservation of genotypes I and II corresponds with primary
circulation within humans, whilst diversity of genotypes III and IV is
related to zoonotic and foodborne origin. The objective of this study
was to perform phylogenetic analysis of HEV isolates from faeces of
HE patients and thus determine the origin of virus.
Figure 1. Part of the phylogenetic tree showing clustering of Czech
hepatitis E virus isolates within genotype III of genus Hepevirus.
Methods: Faeces from eight serologically conﬁrmed HE patients were
tested. RNA was extracted using QIAamp Viral RNA kit (Qiagen)
according to the manufacturer’s instructions. The detection of HEV RNA
was performed by nested RT-PCR targeting 287 bp long part of ORF 1.
The sequences were analysed by MEGA 3.1 software and compared with
the sequences in GenBank using the BLAST utility. Neighbor-joining
method was used for phylogenetic analysis.
Results: HEV RNA was detected in faeces of ﬁve patients. Comparison
of the obtained sequences with sequences in GenBank failed to ﬁnd
any 100% homologous HEV isolate. Sequence analyses showed that
these isolates share 82.2 to 100% nucleotide identities with each other.
Phylogenetic analysis revealed that all ﬁve Czech HEV isolates belong
to genotype III subgroups e, f and g (Fig. 1).
Conclusion: We detected HEV excretion in faeces of ﬁve patients from
a total number of eight serologically conﬁrmed HE cases. Phylogenetic
analysis suggests that Czech patients were infected in Europe. This
hypothesis is supported by patients anamnestic data: e.g. patient 108−09
reported visit of Sushi bar in Germany, which is in concordance to 93.8%
homology with German human isolate. 100% homology within isolates
CZhHEV113−09 and CZhHEV114−09 hints possible identical source of
infection. Due to the high genetic diversity of HEV isolates, phylogenetic
analysis even of such small part of its genome can help to determine
sources of HEV infection.
Acknowledgment: This work was supported by national Grants
No. MZE0002716202, OC08045 and international Cost Action 929
ENVIRONET.
P1109 Isolated anti-HBc proﬁle should be investigated in a country
of intermediate endemicity for hepatitis B
N. Hannachi °, O. Bahri, B. Boukatef, H. Triki, J. Boukadida (Sousse,
Tunis, TN)
Objectives: Isolated antibody to hepatitis B core antigen (anti-HBc) is a
common serologic ﬁnding in diagnostic settings. However, it is not clear
how this serological proﬁle should be interpreted and whether further
serological or molecular tests should be conducted routinely on these
samples. The aim of this study was to assess the frequency and clinical
signiﬁcance of anti-HBc alone in central Tunisia.
Methods: This study included 9294 subjects divided into two groups:
healthy group (857 blood donors and 2709 pregnant women) and a
group of hospitalized patients especially in hematology, pediatric and
infectious diseases services (5728 patients). HBs antigen (HBs Ag)
and anti-HBc were performed for all sera. Negative HBs Ag sera were
systematically tested for anti-HBs antibody (anti-HBs). Levels of anti-
HBs below 10mUI/ml were considered as negative. Isolated anti-HBc
sera were investigated for other hepatitis B markers (IgM anti-HBc,
HBe antigen and anti-HBe antibody), for hepatitis C (anti-HCV), for
hepatitis D (anti-HDV) and for human immunodeﬁciency virus infection
(anti-HIV). Presence of hepatitis B virus DNA (HBV DNA) was studied
by nested PCR.
Results: Prevalence of isolated anti HBc proﬁle was 4.7% (436 cases).
There was no statistical difference in this prevalence between healthy and
hospitalized subjects. However, the frequency of this proﬁle was higher
in patients with elevated transaminase levels (p< 0.0001). Analysis of
hepatitis B markers in isolated anti-HBc sera showed that a low reactivity
of anti-HBs (between 1 and 9.9mUI/ml) was present in 163 cases (37%).
In the remaining 273 isolated anti-HBc samples presence of anti-HBe,
anti-HCV, anti-HDV and anti-HIV was detected in 23.4%, 3.8%, 5% and
1% of cases, respectively. Acute hepatitis B was established in one case.
HBV DNA was detected in 4.1% of isolated anti-HBc tested samples.
Conclusion: In Tunisia, country of intermediate hepatitis B endemicity,
the ﬁnding of isolated anti HBc proﬁle is frequently indicative of past
infection. Nevertheless, acute or occult hepatitis B can occur and must
be researched especially in patients with abnormal liver function tests.
Coinfection with hepatitis C and D or HIV are not rare and should be
considered.
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P1110 Anti-HCV negative viral hepatitis C in HIV-infected
patients from AIDS centre, Prague
V. Aster °, J. Konig, L. Machala, H. Rozsypal, O. Shivairova,
M. Stankova (Prague, CZ)
Objectives: Negative anti-HCV test is rare in common population. In
contrast, in HIV infected persons with hepatitis C coinfection negative
anti-HCV test is more frequent, especially in intravenous drug abusers.
At the highest risk of seronegative HCV infection are HIV infected
intravenous drug abusers with transaminase elevation or low CD4+
count. The aim of the study was to determine patients at the highest
risk of seronegative HCV infection and to provide targeted HCV RNA
testing using PCR method.
Methods: 666 HIV infected patients were followed-up at AIDS-Center
Prague till August 2008. Data were collected through a retrospective
search through the patients’ clinical records. CD4+ count, transaminase
value, and anti-HCV testing were done at up to a maximum 8 week
interval. HCV RNA testing was started in HIV infected intravenous drug
abusers with aminotransferase elevations or in those with CD4+ levels
under 200/mcl.
Results: 49 (7.4%) of the 666 patients were intravenous drug abusers. In
14 of them transaminase elevation was observed; in 13, a CD4+ count of
under 200/mcl was observed. 16 patients out of these 17 (14+13) were
anti-HCV negative. To date to 7 of these anti-HCV negative patients
HCV RNA test has been provided. 6 patients were HCV RNA positive
and 1 patient HCV RNA negative.
Conclusion: Negative anti-HCV test in HIV/HCV coinfected patients,
more so in intravenous drug abusers with transaminase elevations or with
low CD4+ count, is more frequent than in patients with HCV infection
alone. HCV RNA testing in HIV infected patients should be performed
generally in anti-HCV positive patients, but also in selected anti-HCV
negative patients. The study is funded by the grant Nr/9288−3 from the
Internal Grant Agency of the Ministry of Health of the Czech Republic.
P1111 Hepatitis C virus genotyping and possible routes of
transmission in a Greek population
D. Kouniaki °, K. Tarassi, V. Kapsimali, T. Athanassiades, V. Kitsiou,
K. Gizori, C. Papasteriades (Athens, GR)
Hepatitis C virus (HCV) is classiﬁed into 6 genotypes (1 to 6) and more
than 70 subtypes (termed a, b, c, d, . . . ), according to the International
standardization of the Nomenclature. On the other hand, the distribution
of HCV genotypes is linked to geographical location and mode of
transmission.
Objectives: The aim of the present study was to deﬁne the distribution of
HCV genotypes/subtypes in a cohort of Greek patients and the possible
routes of transmission.
Subjects and Methods: in 258 serum samples (from 154 males and 104
females), HCV viral load was determined by Cobas Amplicor kits and
subsequent HCV genotyping was performed using the Versant (Lipa)
assay, detecting the 1a, 1b, 1a/1b, 2a/2c, 2b, 3a, 3b, 3c, 3k, 4a/4c/4d,
4c/4d, 4b, 4e, 4f, 4 h, 5a, 6a/6b subtypes.
Results: the frequencies of HCV genotypes/subtypes found in serum
samples tested have as follows: genotype 1: 40.7% (males 30.5%,
females 56.7%), genotype 2: 8.9% (males 6.5%, females 12.5%),
genotype 3: 38.3% (males 48%, females 24%), genotype 4: 12% (males
15.6%, females 6.7%) and particularly subtype 1a: 11.6% (males 9.1%,
females 15.4%), subtype 1b: 25.6% (males 17.5%, females 38.5%),
subtype 1a/1b: 1.5% (males 1.9%, females 0.9%), subtype 2b: 0.4%
(males 0%, females 0.9%), subtype 2a/2c: 8.5% (males 6.5%, females
11.5%), subtype 3a: 38.3% (males 48%, females 24%), subtype 4a/4c/4d:
0.7% (males 0.6%, females 0.9%), subtype 4c/4d: 2.3% (males 2.6%,
females 1.9%), subtype 4 h: 4.2% (males 6.5%, females 0.9%).
Conclusions: (1) The two major HCV genotypes among Greek patients
are 1 and 3 (particularly subtypes 1b and 3a), like in other populations in
Europe and North America. (2) The high frequency of subtype 3a (48%)
in males may be attributed to needle-sharing in intravenous drug users,
whereas iatrogenic procedures (blood-transfusions, operations etc) may
be responsible for the high incidence of subtype 1b (38.5%) among
females. (3) It is also pointed-out the relatively high frequency of
genotype 4 (12%) in Greek patients, which mainly characterizes patients
from Middle East and North Africa.
Besides epidemiological considerations, HCV genotyping in Greek
patients has also a clinical impact, as particular HCV genotypes are
associated with severity of liver disease and response to antiviral
therapy (e.g. subtype 1b is correlated with lower rates of response to
interferon-a).
P1113 Patients PCR status and hepatitis C avidity assay
S. Klimashevskaya °, T. Ulanova, A. Burkov, H. Fields, A. Obriadina
(Nizhny Novgorod, RU; Atlanta, US; Saronno, IT)
Objectives: Antibody Avidity is serological marker of primary infection
and avidity test is a reliable method to distinguish acute primary HCV
infections and chronic HCV infections for certain. But during this study
some limitations for the avidity assay were found.
Methods: 220 samples from 21 commercially available seroconversion
panels, 480 samples from anti-HCV and HCV RNA-positive blood
donors and samples from 21 anti-HCV positive, but HCV RNA negative
blood donors with resolved infection were tested. The detection of
antibody avidity was based on an indirect ELISA method using a
mixture of antigens, containing epitopes to core-1b, NS3−1a, 1b and NS4
(the artiﬁcial mosaic protein contains the HCV NS4 immunodominant
regions from 1, 2, 3, 5 genotypes).
Results: The mean AI value for seroconversion samples, obtained <65
days after the last anti-HCV negative result was 18.6% (95%CL, 3.5% to
33.7%). Samples from anti-HCV and HCV RNA positive patients with
chronic HCV infection showed the mean AI value of 100% (95%CL,
83.1% to 116.9%). Samples from patients with resolved infection showed
a mean AI of 54% (95%CL, 32.8% to 75%). The observed differences
were signiﬁcant (P< 0.001).
Patients with high PCR level had an AI increase during a shortest time
than patients with low PCR Level. The best correlation between AI value
and time after infection onset was observed from patients with PCR
status more than 1,000,000 copies: y = 0.83x + 1.5 against y = 0.3x + 31
for patients with PCR status 10,000–100,000 copies or p = 0.08x + 49 for
patients with PCR status <1,000 copies.
Conclusions: The AI may depends on patient PCR status. Persons with
low PCR level or PCR negative (resolved infection) may have the low AI
for a long time and the avidity assay is more reliable for PCR positive
specimens with high PCR level.
P1114 Switching of two genotypes of hepatitis A virus and clinical
relevance in the Republic of Korea over the past 10 years
Y.K. Yoon °, H.S. Sim, J.Y. Kim, D.W. Park, J.W. Sohn, J.E. Yeon,
J.H. Kim, M.J. Kim (Seoul, KR)
Objectives: As a result of declining seroprevalence of hepatitis A virus
(HAV) in the age of 10−20 years adolescents and young adults, an
outbreak of HAV infection with severe presentation among adults has
sustained in the Republic of Korea (ROK) since 2008. This study aimed
to investigate clinical features of HAV infection and the predominant
HAV genotypes in relation to inﬂuencing factors on disease severity
over the past ten years.
Methods: Study subjects included acute hepatitis patients with anti-HAV
IgM in 1997–2000 years (group 1, n = 49) and in 2009 year (group 2,
n = 66). Groups stratiﬁed by year, HAV genotype or disease severity (the
level of ALT) were compared for clinical features. To determine HAV
genotypes, nested RT-PCR targeting the VP1/2A and VP1 regions and
sequencing were carried out from serum or stool samples collected. The
VP1 region (~900 bp) was used for phylogenetic analysis.
Results: The patients in group 2 were older (21.7 ±6.0 vs 33.6
±6.7, p< 0.0001) and had a longer hospitalization (5.6 ±4.8 vs 18.8
±9.4, p< 0.0001), a higher level of ALT (915.8 ±2341.4 vs 3134.8
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±1817.5, p< 0.0001) and INR of prothrombin time (1.1 ±0.3 vs 1.3
±0.4, p = 0.003), and lower levels of platelets (219.1 ±81.4 vs 161.8
±68.0, p< 0.0001) and albumin (4.14±0.47 vs 3.60±0.40, p< 0.0001).
Genotyping of 82 HAV isolates revealed that the predominantly HAV
strains circulating during the period of 1997–2000 and year 2009
was genotype IA (96.4%) and genotype IIIA (92.6%) respectively. In
multivariate analyses, there was signiﬁcant differences between two
groups stratiﬁed by year in age [odds ratios= 1.47, 95% conﬁdence
interval= 1.08–2.00, p = 0.015] and genotype [OR= 134.46, CI= 10.31–
1752.78, p< 0.0001]. All 27 isolates in group 1 and 4 isolates in group 2
belonged to genotype IA showed high identities at the nucleotide level
with each other with homology 97–100% and 98–100% respectively.
Between group 1 and group 2, homology of genotype IA isolates was
97−99%. Comparison by HAV genotype (IA or IIIA) in multivariate
analyses presented no difference in clinical features. Comparison by
disease severity in multivariate analyses revealed the signiﬁcant factors
of patient’s age [OR= 57.50, CI= 14.12–234.22, p< 0.0001] and IIIA
genotype [OR= 22.49, CI= 6.74–75.08, p< 0.0001].
Conclusion: Our study indicates the changing molecular epidemiology
as well as host factors might be associated with severe clinical features
of HAV infection in the ROK.
P1115 Hepatitis C genotyping in haemodialysis patients and the
development of genotyping method based on Taqman probe
real-time PCR
H.A. Hamzah, M.I. Mustafa °, M.S. Abdul-M, A. Nasarudin, M.H. Bin
Hasmani (Kuantan, MY)
Objectives: This is a seroprevalence study of HCV genotypes amongst
infected haemodialysis patients in Pahang, Malaysia and the development
of genotyping method using real-time PCR.
Methods: Patients were screened using ELISA by detecting the anti-
HCV in the sera. HCV RNA was detected by RT-PCR technique
targeting 5′UTR region. All negative ﬁrst-round PCR products were
re-tested by nested PCR. The base sequence of the PCR products was
determined using the same primers as for the RT-PCR. By comparing the
obtained nucleotide sequence data with sequences of known genotypes
from the NCBI homepage, we deduced that our local isolates could
be assigned to genotypes 1, 3, 4 and 6. Based on the data, TaqMan®
probes were designed for the simultaneous identiﬁcation and quantitation
of these genotypes. A new batch of blood samples was recollected from
patients and one step real-time RT-PCR (Applied Biosystem) assay was
conducted for genotyping and viral load estimation.
Results: Out of 472 patients, 43 (26 males) were diagnosed positive
for anti-HCV by ELISA. Two seropositive patients were excluded as
they refused to give consent. Excluding another two patients who were
seroconverted to HCV negative, 66.6% (26/39) were of genotype 3,
23.1% (9/39) of genotype 1, 5.1% (2/39) of genotype 6, followed by
2.6% (1/39) of genotype 4 and one patient gave a discordant result with
the sequencing analysis.
Conclusion: Genotype 3 was the most prevalent genotype followed by
genotype 1, 6 and 4. TaqMan real-time PCR has the potential as a method
for rapid HCV genotyping.
P1116 Hepatitis D virus replication − clinical impact and viral
replicative interference with hepatitis B virus
G. Popescu, D. Otelea, C. Popescu °, M. Tinischi, S. Paraschiv,
E. Neaga, L. Gavriliu, M. Popa, E. Benea, A. Streinu-Cercel on behalf
of the HED-DM Group
A viral replicative interference between hepatitis B virus (HBV) and
hepatitis delta virus (HDV) with HDV dominance seems to exist; we
studied the extent of this interference. The clinical outcome of chronic
HBV hepatitis is worse with a dual HBV-HDV infection; we would to
evaluate if a replicative HDV infection is a supplemental risk factor for
these patients.
Methods: The study took place at Matei Bals Infectious Diseases
National Institute (Bucharest, Romania), between June 2006 and
December 2006. We included 223 chronic HBV infected patients
positive for anti-HDV assay. Controls consisted of 112 chronic HBV
monoinfected patients. The interactions between HDV and HBV were
studied by measuring HBV-DNA and HDV-RNA levels. Clinical data
were collected for both groups: ALT level, platelets count, prothrombin
level, and severe liver disease.
Results: From study group, 179 patients (80.27%) were viremic for at
least one virus, and 61 patients had dual HBV/HDV viremia (27.35%).
HBV viremia was reported in 64.57% patients in study group and in
81.11% patients in control group (p = 0.006); difference is conserved
for naı¨ve treatment patients from both groups: 67.33% versus 86.21%
(pYates=0.001). HBV-DNA signiﬁcant level (>104 copies/ml) was less
frequent in anti-HDV positive group: 18.39% versus 33.33% patients.
The detection rate of HDV RNA among anti-HDV-positive patients
was 42.60% versus only 2.68% in control group (p = 0.0001). HBV
replication was not different in the HDV viremic and non-viremic
patients from study group: 22.1% versus 24.2%. All analyzed clinical
parameters were more altered in anti-HDV positive group; clinical
parameters were more altered for HDV viremic versus HDV non-
viremic patients: elevated ALT values: 58.95% versus 28.91% (OR
3.40; p = 0.00001), thrombocytopenia (OR 2.22; p = 0.003), decreased
prothrombin index (OR 2.01; p = 0.03), but not for end-stage liver
disease: 18.95% versus 10.93% (OR 1.90; p = 0.09).
Conclusion: HDV is acting as a “dominant” virus in HBV-HDV dual
infection; HBV replication is less frequent and at lower levels as in
HBV monoinfected patients. Clinical parameters are worse in anti-HDV
patients, and worst in those who are HDV viremic. Less than half anti-
HDV positive patients are HDV viremic, raising the question of optimal
treatment for those with only HBV replicative infection.
P1117 Epidemiology of hepatitis D virus infection in Bucharest
area (HED-DM study)
G. Popescu, C. Popescu °, M. Ivan, L. Gavriliu, D. Antonica, A. Paise,
G. Ducu, M. Popa, E. Benea, A. Streinu-Cercel on behalf of the
HED-DM Group
Several studies indicated a decreasing trend in the hepatitis D virus
(HDV) prevalence in different regions. However, in the past twelve years
no studies were conducted to evaluate if there is a similar epidemiological
change in the Bucharest area.
Objective: This study was undertaken to obtain regional epidemiological
data on hepatitis delta virus (HDV) in symptomatic or asymptomatic
patients infected with hepatitis B virus (HBV).
Methods:We conducted a cross-sectional study at “Matei Bals” National
Institute of Infectious Diseases (Bucharest, Romania), between June
2006 and November 2006. A total of 1094 patients with HBsAg
positivity were evaluated for HDV antibodies with SmarTest Diagnostics
(Orgenics Ltd, USA). We explored the association between anti-HDV
positivity and several epidemiological and clinical parameters; HDV
genotypes were evaluated in PCR positive patients.
Results: Anti-HDV was positive in 223 of 1094 patients − 20.38%,
CI95% (18.10%; 22.87%), signiﬁcantly lower than 30.09% in a previous
study, p< 10−7. A signiﬁcant association between the age over 40 years
and anti-HDV positivity was found RR = 1.58 (1.19; 2.09), p = 0.0009.
Gender, HBeAg positivity, liver disease stage and HIV or HCV co-
infection were not signiﬁcantly associated with anti-HDV presence
(p> 0.05). Delta antigen was present in only one patient with anti-HDV
antibodies (0.45%). Dual HDV and HBV infection was associated more
frequently with elevated ALAT (p = 0.0004), with thrombocytopenia (RR
= 8.46, p< 10−7) and with end-stage liver disease RR=6.05 (4.52; 10.42),
p< 10−7. All the 26 HDV srains belonged to genotype I.
Conclusion: The results suggest that delta infection remains common in
our patients, but a transition towards a decreasing prevalence is possible
in Bucharest area. We found a signiﬁcant relationship between the age
of the patients (possible longer HBV infected status) and anti-HDV
positivity; delta antigen can not be considered as a marker of HDV
replication.
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P1118 Prevailing HCV genotypes and subtypes among
HIV-infected patients in Georgia
M. Karchava °, L. Sharvadze, L. Gatserelia, N. Badridze, T. Tsertsvadze
(Tbilisi, GE)
Introduction: Recent analysis of ART program data in Georgia showed
that end-stage liver disease is leading cause of death among HIV/HCV
co infected patients on ART after initiation of ART program in 2005.
Therefore, treatment of hepatitis C among HIV infected individuals
is essential for sustaining success of ART in Georgia and to improve
survival rates of HIV infected patients. HCV treatment response rate and
sustained viral suppression after antiviral treatment largely depends on
the HCV genotypes along with the inﬂuence of HIV co-infection itself.
The objective of this retrospective study was to study the prevailing
genotypes and subtypes of HCV virus in a cohort of HIV infected
patients in order to obtain the preliminary data.
Material and Methods: We analyzed 1490 HIV infected patients co
infected with HCV virus. Among them 59% were HCV coinfected.
Measurement of HCV RNA viral load was done by COBAS TaqMan
HCV-2.0 Test and HCV genotyping by reverse hybridization line probe
assay using VERSANT HCV Genotype kit 2.0 respectively.
Results: Detectable HCV RNA was found among 680 patients (91.%).
Less than 10 Iu/ml was found among among 67 (9%). This numbers
indicate low rate of self clearance of the virus among HIV persons.
Greater HCV RNA levels were associated with a greater chance to
be infected with HCV genotypes 1. Most prevalent genotypes were
genotype 1 accounting for 41.6%, followed by genotype 3 (34.7%) and
2 (17.6%), inter genotype recombinants were found among 5.8%.
Conclusion: Study demonstrated high prevalence of HCV infection
among HIV-infected patients and reveals 1 as predominant genotype. The
differences of prevailing HCV genotypes among general population and
HIV co infected group was probably attributed to the different methods
for sample selection used. Another option can be possible inﬂuence of
diverse transmission networks among HIV infected group. The high
number of intergenotype recombinants might be results of continues
parenteral exposure to different HCV genotypes during drug injection
paraphernalia. Study highlights and strengthens the need for careful
follow-up of HCV/HIV co infected patients, effective management and
therapies against HCV in order to reduce liver related death rates in
patients on ART.
P1119 Hepatitis D in Switzerland: a silent epidemic
I. Rossi, D. Genne´ ° (La Chaux-de-Fonds, CH)
Objectives: The seroprevalence of co-infection with the hepatitis B
virus (HBV) and the hepatitis D virus (HDV) is well known in many
European countries, starting from 6.8% in Germany to more than 27%
in some Turkish areas. To better describe this infection in Switzerland,
and to characterize affected people, a questionnaire was sent to all Swiss
gastroenterologists, hepatologists and infectologists.
Methods: 369 physicians received a questionnaire concerning their
HBV- and HDV-infected patients.
Results: A cohort of 101 HDV-positive patients followed by 78
specialists were analyzed. The physicians were in charge of 1699
patients with HBV (HBsAg-positive), giving a 5.9% prevalence of HDV
infection in HBV-positive patients. A predominance of males (75%)
from Switzerland (39%), and African origin (21%) was recorded. Co-
infection with HBV was reported at 16% and superinfection for 3% of
them; the relationship of time between the two infections was unknown
for 73% of the patients. Most were contaminated by intravenous drug
use (62%), followed by vertical transmission (15%), sexual contact
(13%), or transfusion (2%). The majority (74%) had a very low (<103
UI/ml) HBV viral load and 75% were HBeAg-negative. 76% of those
who had a liver biopsy had an advanced disease ( F2, 77%), and
only 21% had received a standard therapy (interferon or pegylated
interferon a). Meanwhile, 10% had healed spontaneously (anti-HBs-
positive).
Conclusion:With a prevalence of 5.9% of hepatitis D in HBsAg-positive
patients, Switzerland seems less affected than most other European
countries; it is, however, possible that this infection is underdiagnosed.
Intravenous drug use is the main risk factor. Associated advanced liver
disease is also very common.
P1120 Epidemiological analysis of potential risk factors
contributing to infection of HBV, HCV and HIV among the
population in Tripoli Area, Libya
A. Shabash °, M. Habas, A. Fara, M. Daw (Tripoli, LY)
Hepatitis B, Hepatitis C and Human Immune Deﬁciency viruses are a
major cause of concern among health institution with great social and
economic impacts on each country. Their epidemiology and associated
factors varied geographically. Tripoli is the largest populated city in
Libya.
The objectives of this study were to: (1) determine the prevalence of
HBV.HCV and HIV among Tripoli population. (2) Study the potential
risk factors associated with the infections of these viruses. (3) Study
social clustering of these viruses among the infected individuals.
(4) Alarm the public health authorities about the risky population
categories.
Methods: A total of 878 persons screened to be positive of one or more
of the Viruses(HBV, HCV, & HIV) using ELISA test were studied. Their
age varies from 14 to 72 years. The risk factors including, IV drug abuse,
blood transfusion, surgical and dentistry involvement etc were analyzed.
The social back ground and the social clustering were studied and the
data were analyzed using Microsoft word excel 2007.
Results: Of the total individuals studied, 654 (74.4%) were HBV
positive, 204 (23.2%) HCV positive, and 47 (5.3%) HIV positive.
13 (1.4%) persons were seropositive for both HIV and HCV antibodies,
eight (0.9%) persons were seropositive for both HBV and HCV, while
only three (0.3%) persons were seropositive for HBV, HCV and HIV.
726 (82%) males were infected with one of the viruses, though its only
152 (17%) females were infected. Male to female ratio were (6.8:1) for
HIV infected individuals followed by HCV (4.6:1) and then HBV (2.4:1).
The age peak of the infected individuals with HBV were range between
18−29 years, and with HCV were range between 33−40 years, HIV
ranged between 20−36 years with highest peak were 20 years. The most
infected areas were in a form of clusters. The potential risk factors were
surgical intervention, dentist visit, blood transfusion, and drug abuse
respectively.
Conclusion: HBV, HCV, and HIV infections were a major problem
among Tripoli population with young people were more borne to be
infected, this were associated with certain clustering among the society.
This however is an alarming problem to the Libyan society and hence
then speciﬁc programs have to be implemented to tackle the problem.
P1121 Six-year study of hepatitis A, B and C infection prevalence
in a Greek major hospital
V. Karabassi °, M. Pouyiouka, K. Achilleos-Geladaris, C. Petrocheilou,
A. Kiriakaki, M. Toutouza (Athens, GR)
Objectives: The purpose of this study was to perform a serological
analysis of Hepatitis A, B and C virus (HAV, HBV and HCV) infection
prevalence in the patients of a Greek major hospital within a six-year
period.
Methods: During the six last years 1/7/2003–30/6/2009, sera from 31580
patients (26180 in-patients and 5400 out-patients), were tested for the
detection of HAV, HBV and HCV markers. There were 4 groups of
patients, Group A: 10130 patients (7490 in-patients, 2640 out-patients)
who were controlled for HBV surface antigen (HBsAg), Group B: 21450
patients (18690 in-patients and 2760 out-patients) who were controlled
for the HBV markers: HBsAg, HBeAg, antiHBe, antiHBcore, antiHBs,
Group C: 22320 patients (19200 in-patients, 3120 out-patients) who
were controlled at the same time for HCV-antibodies and Group D:
3220 patients (2460 in-patients, 760 out-patients) who were controlled
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for HAV- antibodies (total and IgM). All tests were performed during
2003–2004 by MEIA methodology (AXSYM − Abbott) and during
2005–2009 by immunoluminometric assay method (ARCHITECT −
Abbott).
Results: In Group A of the 7490 in-patients and 2640 out-patients
were found to be positive for HBsAg 150 (2%) and 82 (3.1%)
respectively. In Group B of the 18690 in-patients and 2760 out-patients
were respectively: 8728 (46.7%), 1220 (44.2%) seronegative for HBV
markers, 1214 (6.5%), 345 (12.5%) positive for HBsAg, 2952 (15.8%),
174 (6.3%) positive for antiHBs due to HBV vaccination, 5794 (31%),
1020 (37%) negative for HBsAg and positive for the rest HBV markers.
In Group C of the 19200 in-patients and 3120 out-patients, HCV-
antibodies positive was found in 442 (2.3%) and 188 (6%) respectively.
2% of them were at the same time positive for HBsAg. In Group D of
the 2460 in-patients and 760 out-patients, HAV- antibodies total positive
was found in 1304 (53%) and 388 (51%) and HAV- antibodies IgM
positive was found in 50 (2%) and 10 (1.3%) respectively.
Conclusions: This study showed that there is a signiﬁcant prevalence
of HAV, HBV and HCV infection in the patients of our hospital
(53%, 37.5%, 2.3% for in-patients, 51%, 49.5%, 6% for out-patients
respectively). The effort for the prevention must be continual and the
control measures with the systematic Hepatitis A and Hepatitis B
vaccination should be strictly enforced.
P1122 HBV infection in immigrant population in Barcelona,
Spain. Immune tolerant phase and description of an
atypical serological pattern
E. Dopico, E. Grenzner, J. Ros, L. Guerrero °, E. Castro, L. Herna´ndez,
T. Vinuesa (Barcelona, ES)
Introduction: In low-prevalence areas, like Spain, HBV infection is
acquired mainly among young adults by sexual or parenteral transmission
and people with high replicative viral activity present hepatic injury.
In some world regions, like Eastern Asia, the most common transmission
occurs in the perinatal or early childhood period. On those cases, the
immune tolerant phase characterized by absence of hepatic damage can
span of more than 20 years.
Objective: The aim of the present study was to describe the cases of
chronic hepatitis B in patients showing a high replicative activity and a
normal hepatic function.
Methods: We included in the study 37 patients with chronic HBV
infection and HBeAg reactivity, detected from January 2008 to October
2009, in the Clinical Laboratory of l’Hospitalet-Cornella` of the Public
Health System that attends around 750000 inhabitants.
HBeAg and anti HBc were analyzed by chemiluminescent immunoassay
(Vitros® Johnson & Johnson), and HBV-DNA was quantiﬁed by Abbott
RealTime HBV DNA Assay®. The immune tolerant phase was deﬁned
by HBeAg presence, viral DNA >106 UI/mL and normal serum ALT
levels.
Results: Of the 37 patients, there were 15 men and 22 women, 7 of
them were pregnant.
Fifteen (40.5%) had normal ALT levels and 6 of them were in the
immune tolerant phase as they had viral loads >106 copies/ml.
The origin of those 15 patients was: 9 Eastern Asia, 3 Eastern Europe,
2 Northern Africa and 1 Western Africa. The immune tolerant patients
came in 6 cases from Eastern Asia and one from Western Africa. In
ﬁve of the 37 patients, anti HBc was negative and their viral loads were
>106 UI/mL.
Conclusions: In our environment is not uncommon to ﬁnd patients
infected by HBV with a high replicative activity and normal hepatic
function. They come from high-prevalence areas, mostly Eastern Asia.
Some of them are in the immune tolerant phase. The infections detected
in pregnant women were coming from the screening procedure. A widely
used diagnostic algorithm for screening hepatitis B virus infection is
based in anti HBc detection. We have to consider the atypical serological
pattern of anti HBc absence and high levels of viral DNA in serum,
especially in patients from Eastern Asia. Those patients have a high risk
of sexual and perinatal transmission.
P1123 Forecast modelling for prediction of hepatitis B and
hepatitis C seropositivity among Libyan population
A. Shabash °, M. Habas, A. Alhajrasi, A. Furarah, A. Bouzedi, M. Daw
(Tripoli, LY)
Blood born hepatitis (HBV, HCV) is a major health problem particularly
among developing countries. Hence then speciﬁc strategies have to be
implemented to overcome such problem. In Libya national strategies has
been developed to overcome such problem.
Objectives of this study were to: 1) determine the prevalence of
hepatitis B and C seropositivity among healthy Libyan population; 2)
implement a new model for short and long term forecasting of HBV
and HCV seropositivity; 3) outline the major steps to reduce the risk of
such viruses.
Methods: Data of hepatitis B surface antigen and HCV antibody
screening for 100,8214 person were reviewed between 2003–2008 at
three main laboratories in Tripoli Libya using ELISA test. The data
subjected to forecasting function of excel 2007 to predict the number of
seropositive patient after 2, 5 and 10 years.
Results: Of the total patients studied: 19878 (1.97%) were HBV positive,
and 17087 (1.77%) were HCV positive during the study period. The
prevalence of HBV seropositivity were decreased during the study period
from 3.5% on 2003 to 1.8% on 2008, while HCV prevalence decreased
from 2.6% on 2003 to 1.5% on 2005 though it was 1.8% on 2006, and
1.7% during the last two years. The prevalence of HBV were more than
that of HCV throughout the study. Using the forecasting function test of
excel the predicted number of HBV seropositive person after two, ﬁve
and ten years in comparison to 2008 (2010:2008, 2013:2008, 2018:2008)
the ratio were 1.5:1, 2:1, 2.5:1, while the expected HCV positive person
ratio were 1.5:1, 2:1, 2.8:1.
Conclusion: Our study reveal that, HBV and HCV infection was
an alarming problem among Libyan. Further evaluation is needed to
determine possible new strategies to control the spread of infection,
forecast model was valuable in highlighting such problem. In addition
assessment of effectiveness and continuity of the previous preventive
measures like vaccination and education programs is mandatory.
P1124 Seroepidemiological analysis of hepatitis C genotypes among
Libyan population and its association with risk factors
H. Elasifer °, B. Elagy, M. Eltaghdy, M. Daw (Tripoli, LY)
Introduction: Hepatitis C virus is major public health problem and it is
one of the most important causes of chronic liver disease. It has high rate
of spontaneous mutation which lead to a marked degree of heterogeneity
with a high molecular diversity world wide.
Objectives: To determine (1) epidemiology of HCV genotypes among
different Libyan patients, (2) its association with the risk factors involved
among the patient studied.
Methods: 479 patients with hepatitis C virus were studied. They were
recruited from the Department of Infectious Diseases at Tripoli Medical
Centre, from January 2003 to October 2008. The data collected was
designed to extract information from patients. The patients were positive
for HCV antibody. HCV genotyping was performed. The data were
analyzed using SPSS version 11.5 to identify the distribution of different
genotypes and its association with gender, age, and risk factors.
Results: 479 patients were studied. Their ages ranged from 16 to
84 years. Genotypes 5 and 6 were not detected in any patient. The
prevalence of genotypes were (G1) 32.6%, G2; (15%), G3; (16.7%) and
G4; (35.7%), according to subtypes 28% were unclassiﬁed G4, 14.6%
were G1b and some patients infected with more than one subtype (2.3%
G4c/d, 1% G2a/c), according to gender in male G4 the commonest
while in female G4 is the commonest the relationship between HCV
genotype and gender was signiﬁcant (P value=0.00). All genotypes were
common in patients less than 44 years except genotype 2 (G1 were
71.8%, G2 were 31.9%, G3 were 88.8%, G4 70.2% their age less
than 44 years). Genotype1 and genotype 4 were common in patients
with history of dental procedures, history of surgery was common in
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patients with G4 and G1, blood transfusion history was common in
patients with G4, IVDA history was common in patients with G1 and
G3, according to subtypes G1b was commonest in blood transfusion
and surgical procedure. The relationship was insigniﬁcant (P = 0.180).
The relationship between HCV risk factor for infection and gender was
signiﬁcant ‘P = 0.000’.
Conclusion: the epidemiology of HCV among Libyan patients was
variable and all genotypes were detected except genotypes 5 and 6,
further more speciﬁc genotypes were associated with certain risk factors,
hence then HCV genotypes could be used to monitor and follow HCV
infection in Libya.
P1125 Prevalence of hepatitis C virus among patients attending
a hospital in Sirte, Libya
S. Abddulsalam Bagar °, B. Abdallah, F. Neferro (Sirte, LY)
Background: Hepatitis C virus is a major global health care problem.
The WHO estimates that up to 3% of the world’s population has been
infected with the virus, equating to more than 170 million carriers of
HCV worldwide.
Objective: The present study was aimed to estimate the prevalence
of hepatitis C virus in this area and compare that with other regions
worldwide and other regions in Libya.
Patients and Methods: A retrospective study included 17419 patient’s
serum attended the medical center at Ibn Sina Hospital in Sirt region
during the years 2007 and 2008 for the presence of anti HCV antibodies
among them by ELISA method.
Results: Out of 17419 patients, 640 cases were HCV positive (3.67%).
Among then 482 males (75.31%) and 158 females (24.69%). The
majority of the positive cases belong to the age group 31−40 years.
Conclusions: The percentage of the HCV positive result study was
3.67% and that correlate with the results in other regions of the world.
Another study should be carried out and the necessary measures to be
taken to know the carriers and the infected individuals.
P1126 Prevalence of hepatitis B surface antigen among patients
attending a hospital in Sirte, Libya
S. Abddulsalam Bagar °, B. Abdallah (Sirte, LY)
Background: Hepatitis B virus (HBV) infection is a global health
problem, with an estimated 400 million being chronic carriers of the
virus that equating up to 5−10% of the world’s population, most of them
in south of the desert in Africa and in Far East countries.
Objective: The present study was aimed to estimate the prevalence of
hepatitis B virus in the Sirt region and compare that with other regions
in Libya, and also with other regions in the world.
Patients and Methods: A retrospective study included 17419 patient’s
sera attended the medical centre at Ibn Sina Hospital in Sirt region during
the years 2007 and 2008 for the detection of the presence of HBs antigen
by ELISA method.
Results: Out of 17419 patients, 1325 cases were HBV positive (7.66%).
Among them 925 males (69.25%) and 410 females (30.71%). The
majority of the positive individuals belong to the age group 31−40 years.
Conclusions: The percentage of the HBV positive in the present study
was (7.66%) and that correlate with other results in other regions of the
world which carried out in the same measures as in the present study.
P1127 High frequency of SEN virus viraemia in patients with
hepatitis B virus and hepatitis C virus infection in Iran
A. Karimi-Rastehkenari °, M. Bouzari (Isfahan, IR)
Objectives: After nomination of two viruses of HGV/GBV-C and TT
virus as possible causes of inaugurating hepatitis with unknown etiology,
there has been a continuing search for detection of additional hepatitis
viruses. On July 20, 1999, SEN virus (SENV) was discovered in the
serum of a human immunodeﬁciency virus type 1 (HIV-1)-infected
patient possessing hepatitis with unknown etiology in Italy, and was
named on the basis of initials of the patient. SEN virus is a blood-borne,
circular single-stranded DNA virus. Among nine genotypes of SENV
(A to I), SENV-D and SENV-H genotypes have strong association with
non-A-E hepatitis.
Methods: Nested-PCR was used for detection of partial ORF1 of
the SENV-D and SENV-H genotypes in 120, 50 and 50 sera from
healthy blood donors and patients with hepatitis B virus and hepatitis C
virus infection, respectively in Guilan Province, North of Iran. Also,
to explicate a possible role of SEN virus associated with HBV and
HCV on progression the liver inﬂammation, alanine and aspartate
aminotransferases were measured.
Results: SENV was identiﬁed in 109 out of 120 healthy blood donors
(90.8%), in 47 out of 50 patients with HBV infection (94%) and in 48
out of 50 patients with HCV infection (96%). Frequency of SENV-D
and co-infection (both SENV-D and SENV-H) viraemia was signiﬁcantly
higher among patients with hepatitis B and C infection than healthy blood
donors (P< 0.05). Frequency of SENV-H viraemia was signiﬁcantly
higher than SENV-D among healthy individuals. Alanine and aspartate
aminotransferases levels were signiﬁcantly correlated with HBV and
HCV viraemia but no with SENV viraemia. High genomic homology
observed between our sequences and some of the TT virus isolates.
Conclusion: The high rate of co-infection shows that different genotypes
of the virus have no negative effects on each other. The high frequency
of SENV infection in patients with hepatitis B virus and hepatitis C
virus indicate that there is the common route of blood transfusion
among these viruses. High frequency of SENV infection in healthy blood
donors indicates that other routes rather than blood transfusion also are
important. High genomic homology observed between our sequences and
some of the TT virus isolates may be the outlook to the evolutionary
history of SENV in relation to TT virus. SEN virus with high frequency
in patients with hepatitis B and C infection and healthy individuals is
capable of infecting all age groups that can be nominated as an endemic
virus in Guilan Province, North of Iran.
P1128 Prevalence of hepatitis E (HEV) infection in pregnant
women and clinical features associated to the detection of
antibodies to HEV in Spain
G. Gabilondo Alvarez °, B. Romero, M. Rodriguez, O. Martin,
M. Mateos (Madrid, ES)
Objective: hepatitis E virus (HEV) is the main cause of acute viral
hepatitis in developing countries. Acute infection by HEV generally
causes mild and self-limited hepatitis but it can also produce fulminant
hepatic failure in pregnant women and is associated with very high
mortality particularly in the third trimester of pregnancy.
The goal of this study was to investigate the seroprevalence of HEV
infection in pregnant women and the clinical features related to the
detection of antibodies to HEV in blood.
Methods: 769 pregnant women attended in the Obstetric Department for
routine screening were included in this study. 181 patients were studied
in 2007 and 588 in 2009. The range of age was 14 to 45 years (media:
30.6 years). None of the patients presented clinical symptoms associated
with hepatitis when the blood sample was withdrawn. ALT/AST levels
and clinical symptoms were assessed in all patients with positive results.
IgG anti-HEV antibodies were detected in serum by a commercial
immunoenzymatic method and all positive samples were further studied
for the presence of IgM anti-HEV antibodies (HEV Ab and HEV IgM,
Dia.Pro Diagnostic Bioprobes, Milan, Italia).
A result was considered positive when the sample’s optical density/cut
off optical density was superior to 2. Positive results by the
immunoenzymatic method were conﬁrmed by Western Blot analysis
(RecomBlot HEV IgG/IgM, Mikrogen, Martinsried, Germany).
Results: IgG anti-HEV antibodies were found in 2.1% (5/181) in the
2007 group, and 4.08% (24/588) in the 2009 group, and the overall
prevalence was 3.7% (29/769).
IgM anti-HEV antibodies were detected in 0.52% (4/769) suggesting
acute or recent infection. None of them presented clinical symptoms
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related to acute viral hepatitis. ALT and AST had normal values in all
the patients who presented IgG and IgM anti-HEV in serum.
Conclusions: asymptomatic HEV infection may be detected in
pregnant women in non-endemic countries. Seroprevalence of IgG HEV
antibodies was 3.7% and it has not increased in our country in these
recent years in spite of the increase in immigration and travels to endemic
areas.
P1129 Outcomes of infants born from chronic hepatitis B virus
infected mothers
M. Hasanjani Roushan °, M. Soleimani Amiri, M. Baiany, M. Javanian,
M. Sadeghi (Babol, IR)
Objectives: Infants born from chronic hepatitis B virus infected mothers
are predisposed for developing of HBV infection. The purpose of this
study was to assess the outcomes of infants born from chronic HBV
infected mothers.
Methods: From April 2004 to September 2009, infants born from
chronic HBV infected mothers were received Hepatitis B Immune
Globulin 0.5 cc and the ﬁrst dose of hepatitis B vaccine at birth. The
second and third doses of HBV vaccine were administered at 1 and six
months of age. Hepatitis B surface antigen (HBsAg) and anti-HBs were
performed at 12 months of age. Those who had anti-HBs titers <10
mIU/ml received the second series of HBV vaccine.
Results: Thirty-four and 201 infants born from chronic HBeAg or anti-
HBe+ mothers, respectively. HBsAg was detected in 6 (17.6%) cases
born from HBeAg positive mothers and in 3 (1.5%) cases born from
anti-HBe+ mothers (p = 0.0001). Anti-HBs >10 mIU/ml was developed
in 204 (86.8%) cases. The mean anti-HBs levels in infants born from
HBeAg+ mothers was 284.23±257.2 and for infants born from anti
HBe+ mothers was 367.2±322.8 mIU/ml (p = 0.213). Twenty-two (9.4%)
cases were not responder and among them 11 cases responded to the
second series of HBV vaccine.
Conclusion: The results of this study show that infants of HBeAg
positive mothers have higher risk of developing of HBV infection due
to higher viral load. Reduction of the viral load in this group of mothers
is recommended.
P1130 Pregnancy and chronic hepatitis B infection: a 3-year
evaluation
B. Kurtaran °, H.S. Aksu, A. Candevir, A.S. Inal, S. Komur, Y. Tasova
(Adana, TR)
Objectives:Vertical transmission of HBV is an important risk factor for
chronic infection in newborns. Pregnant women with positive hepatitis B
surface antigen should be screened in the early period of pregnancy.
Babies who born to mothers with hepatitis B infection should be
immunized after delivery as soon as possible, especially in 24 hours. This
study evaluates the risk factors, epidemiology, the progression of disease
and the assessment of antiviral treatment for chronic HBV infection
during pregnancy.
Methods: Pregnant patients with chronic hepatitis B infection followed
in the Department of Infectious Diseases in the Medical School of
C¸ukurova University. The study comprised between January 2007 and
March 2009.
Results: Totally 46 pregnant patients were followed with a mean age of
29±6 (number of the patients were 19;19; 8 according to years). Median
age of pregnancy was 16 weeks at the time of ﬁrst visit (minimum
4, maximum 36 weeks). Chronic hepatitis B infection diagnosis was
made in 54.4% of the patients before and 45.6% patients during the
pregnancy. Eighty three percent of the patients were HBe Ag negative.
Family history was positive in 48% of patients and no additional risk
factors were found. Delta hepatitis co/super infection was not detected.
Median ALT and HBV DNA values in ﬁrst visit were 22.5 u/L (8–
508 u/L) and 857 iu/ml (0−11×107 iu/ml) respectively. Patients of 39%
were treated. Patients with or higher than 2000 iu/mL HBV DNA level
were treated with lamivudine in the last trimester of their pregnancy.
Seven patients had a signiﬁcant increase in liver disease activity after
pregnancy, deﬁned as a three times increase in alanine aminotransferase
(ALT) within 6 months after delivery. These seven patients (of those
under treatment) used lamivudine during last trimester of their pregnancy.
Three patients continued lamivudine for six months after delivery. All
newborns vaccinated and applied HBV vaccine and HBIG. Only 30%
of those patients and their babies could follow after delivery.
Conclusion: Chronic hepatitis B diagnosed in second trimester of
majority pregnant women in spite of family history. Small percent of
mothers came to follow up after delivery. This means need more attention
and education for family practice.
P1131 Hepatitis B serological proﬁle and HBsAg(+) prevalence
among women inpatients of an obstetrics-gynaecological
unit in Greece
A. Papadimitriou, D. Theocharidou °, V. Koulourida, E. Siskou,
E. Martziou, S. Charalampidou, E. Sidiropoulos (Thessaloniki, GR)
Objectives: Vertical transmission from mother to infant is a very
important factor for HBV infection transmission. In Greece, HBsAg(+)
prevalence is 2%. Also, it must be evaluated women’s immigration from
countries with endemic HBV infection. The purpose of this study is to
evaluate the serological proﬁle of Greek and foreigner women admitted
to the obstetrics-gynecological unit of a Greek general hospital.
Methods: 2124 women, admitted to the Obstetrics-Gynecological
Unit of Papageorgiou General Hospital during 1/9/2008–31/8/2009,
underwent a screening serological testing process, which included
HBsAg, AntiHBs, AntiHBc, and further tests such as AntiHBcIgM,
HBeAg, AntiHBe, whether required (ABBOTT® kits applied on the
ARCHITECT® analyzer). SPSS 16.0 was used for data statistical
analysis.
Results: The 388 (18.3%) foreigner’s and 1736 (81.7%) Greek’s
serological proﬁle is shown in the table included. 1277 (60.1%) had
negative serological proﬁle and no sign of either past or present infection,
or vaccination. 495 (23.3%) were found with antiHBs >10IU/ml. Among
43 (2%) patients with HBsAg(+), who had a median age of 34 years,
27 were Greeks and 16 foreigners and none had signs of acute HBV
infection [AntiHBcIgM(−)]. 34 women (Group A) suffered from chronic
HBV infection. 1 patient (Group B) was a HBsAg carrier with no
signs of HBV replication. Among 8 women (Group C) we observed
the presence of both HBsAg and low titles of AntiHBs. Although, the
possibility of blood or plasma transfusion before serological testing could
not be eliminated, we couldn’t ignore the possibility of co-infection with
another HBV serotype. As far as, 27 (63.8%) of 43 HBsAg(+) were
women of reproductive age (range 17−44), their HBeAg(−)/AntiHBe(+)
status showed low risk of vertical transmission during a present or future
pregnancy.
Conclusion: Overall HBsAg(+) prevalence reported here is 2%. It is
signiﬁcantly higher (p = 0.002 <0.05, OR: 2.722, 95%CI: 1.452–5.104)
among foreign patients (4.1%) than among Greeks (1.6%). Immunization
rate (antiHBs >10IU/ml) reported here is 23.3%, signiﬁcantly higher
(p< 0.05 OR: 4.366 95%CI: 2.964–6.432) among Greeks (26.8%) than
among foreigners (7.7%). Our study shows that immigration can change
the epidemiology of HBV in our country, and the necessity of an
intensive vaccination program.
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P1132 Current vaccination coverage against hepatitis B in
pregnant women in Greece: far from the ideal target
I. Elefsiniotis, H. Brokalaki °, I. Glynou, I. Zorou, E. Vezali,
E. Apostolopoulou, H. Kada, G. Saroglou (Athens, GR)
Objectives: Vertical transmission of Hepatitis B virus (HBV) infection
occurs usually in perinatal period and is responsible for the majority of
the disease burden in endemic areas, so screening of pregnant women
for HBV serological markers is mandatory. Data concerning the current
serological status as well as the vaccination coverage against HBV in
women at reproductive age in Greece are limited.
Methods: Between September 2008 and September 2009 a total of
1826 pregnant women (mean age 29.9 years) who gave birth at
the Departments of Obstetrics and Gynaecology of ‘Elena Venizelou’
Hospital of Athens were prospectively evaluated for serological markers
of HBV infection.
All women in the study population were screened during delivery process
for HBsAg, anti-HBc and anti-HBs, whereas HBeAg and anti-HBe were
evaluated only in those who tested positive for HBsAg.
Results: More than half of the study population was originally from
Greece (56%), 30.9% was from Albania and 13.1% from Eastern
European countries. Overall, 3.83% (70/1826) of pregnant women were
HBsAg(+) and the vast majority of them (50/70, 71.42%) were Albanian.
Two of 70 (2.85%) HBsAg(+) women were HBeAg(+) whereas the
vast majority of them (97.15%) were HBeAg(−). About half (48.6%,
274/564) of the Albanian women exhibited anti-HBc seropositivity
followed by Eastern European women (21.3%, 51/239) whereas only 6%
(61/1023) of Greek women presented serological markers of previous
HBV exposure. Moreover, serological markers of past HBV infection
with spontaneous recovery [antiHBc(+) and antiHBs(+)] were observed
in 13.8% (252/1826) of the whole study population whereas only 19.76%
(361/1826) exhibited vaccination-induced protection [characterised by
the presence of isolated antiHBs(+)]. Importantly, vaccination-induced
protection rates were signiﬁcantly higher in Greek women [89.6%
of antiHBs(+) Greek women were isolated antiHBs(+)] compared
to Albanian [ 16.2% of antiHBs(+) Albanian women were isolated
antiHBs(+)] and Eastern European women [30% of antiHBs(+)
Eastern European women were isolated antiHBs(+)] (p< 0.001, in all
comparisons).
Conclusions: Current vaccination-induced protection rates against HBV
are very low among pregnant women in Greece, so surveillance and
immunisation programmes targeted at pregnant women are necessary in
order to avoid vertical transmission of the infection.
Acknowledgements: The study was partially supported by the Hellenic
Foundation of Gastroenterology.
P1133 Prevalence of serum HBV markers among pregnant women
in a secondary care hospital, Greece
I. Passalidou °, P. Karapavlidou (Kastoria, GR)
Infection with hepatitis B virus is a special problem for pregnant women.
Not only does a pregnant woman face the risks of hepatitis herself, she
also can pass the virus to her baby. Hepatitis B virus (HBV) has a
high rate of vertical transmission, causing fetal and neonatal hepatitis.
Additionally, mother-to-child transmission of HBV infection predisposes
to carriage, liver cirrhosis, and hepatocellular carcinoma in young adults.
Testing for the HBV is generally a standard, routine test performed in
all pregnant women at or before their ﬁrst antenatal visit, (usually before
12 to 14 weeks of pregnancy).
Objectives: To evaluate the seroprevalence of hepatitis B surface antigen
(HBsAg) in a group of pregnant women and to examine the presence of
hepatitis B e antigen (HBeAg), antibody to hepatitis B e antigen (anti-
HBe) as well as anti-HBs, anti-HBc-IgG, anti-HBc-IgM antibodies.
Methods: During a period of 3 years, a total of 974 pregnant women
were included in the study. Blood was collected during the ﬁrst trimester
of pregnancy. All samples were analyzed for HBsAg, HBeAg, anti-
HBs, anti-HBc-IgG, anti-HBc-IgM and anti-HBe. Blood analyses were
performed in the Roche Elecsys 2010 immunoenzymic analyzer.
Results: The majority of the study population were from Greece
(87.58%) whereas 121 (12.42%) of them were from Albania. Overall, 19
of 974 females (1.9%) were HBsAg(+). The seroprevalence of HBsAg
among Greek women was 1.63% (14/853) and among Albanian were
4.13% (5/121). All of HBsAg(+) women were HBeAg(−)/anti-HBe(+).
Also, among Greek women: 290 (34%) have been vaccinated,
139 (16.30%) were anti-HBs(+)/anti-HBc-IgG(+)/IgM(−)/anti-HBe(+),
and 410 (16.30%) were serum negative.
Among Albanian women: 1 (0.83%) has been vaccinated, 31 (25.62%)
were anti-HBs(+)/anti-HBc-IgG(+)/IgM(−)/anti-HBe(+), and 63 (52.07%)
were serum negative.
Conclusions: Our results suggest that: (1) The overall seroprevalence
rate of HBsAg is 1.95% among pregnant women in Greece. (2) The per-
centage of serum negative Greek women is relatively low but is higher
enough among Albanian, suggesting possibly that the vast majority of
the Albanian females have not been vaccinated.
P1135 Prevalence of viral hepatitis among inmates of Bulgarian
prisons
G. Popov °, K. Plochev, K. Ramshev, Z. Ramsheva (Soﬁa, BG)
Objective: To determine the prevalence of viral hepatitis and examine
risk factors for this infection among inmates of Bulgarian prisons.
Methods: This study was carried out in four Bulgarian prisons (for
men and women) and a juvenile correctional facility. Anonymous cross-
sectional data were collected for prisoners who agreed to participate
in the study and who were interviewed using a standard questionnaire
including demographic, imprisonment history and viral hepatitis related
risk behaviors items. Thereafter, the blood drawn from the participants
was tested for anti-HAV, anti-HBc, anti-HCV and anti-HDV antibodies
and HBsAg and HBeAg by ELISA tests.
Results: A total number of 498 inmates participated in our study. Three
hundred and sixty seven (74%) were men and one hundred thirty one
(26%) were women. The overall rate of antibody positivity for anti-
HAV was 368 (74%), anti-HBc − 292 (59%), anti-HCV − 123 (25%)
and anti-HDV − 46 (9%). The presence of huge number of prisoners
with viral hepatitis B and C are due to use of i.v. drugs, unprotected
sexual contacts, tattoo and other manipulations with skin and mucosa
lesions.
Conclusion: The seroprevalence of viral hepatitis among prisoners in
comparison with the general population in Bulgaria is very high. Our
results indicate the importance of policies to prevent transmission of viral
hepatitis during and following incarceration. We recommend providing
of free of charge condoms, needles and syringes as well as possibility
of voluntary testing for HBV, HCV and HIV.
P1136 Anti-HAV seroprevalence in Turkish military personnel and
its relation to demographic properties
H.C. Gul °, I.Y. Avci, O¨. Coskun, R. Ogur, Y.H. Basaran, C¸. Gu¨ney,
B. Besirbellioglu, C.H. Acikel, C.P. Eyigu¨n, A. Pahsa (Ankara, TR)
Aim: Turkey is a middle endemic area in terms of Hepatitis A Virus
(HAV) infection. Previous studies in Turkey showed that most residents
had been infected with HAV by the second decade of life. In this study
we aimed to detect the anti-HAV seroprevalence rate in Turkish military
personnel and its relation with demographic properties.
Material and Methods: Randomly selected 1049 military personnel
were enrolled in the study. All were male and their average age was
24.97±6.48 (Range: 20 to 50) years. A written questionnaire about his
demographic properties and an informed consent was obtained from
each subject. Statistical analysis was performed with SSPS 10.0 software
(SSPS, Inc, Chicago, III). Differences were considered signiﬁcant when
P< 0.05 for the two tails.
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Results: Anti-HAV-IgG test yielded positive result in 889 (84.7%)
subjects. The result was positive for 89.9% of the subjects older than 31
years old and 83.3% of the younger than 31 years old (P> 0.05).
Of these 1049 subjects, 67.2% were married. Of the anti-HAV-IgG
positive subjects, 91.6% were married whereas 81.8% of the anti-HAV-
IgG negative subjects were married (P< 0.01). Being a villager was
observed as a risk factor for HAV infection and HAV endemicity in
Marmara and Karadeniz regions was signiﬁcantly lower than that in the
other regions. The educational level of the subjects and also their parents
have seen affect Anti-HAV seropositivity. As the educational level of the
subjects and their parents increased, the Anti-HAV IgG seropositivity
decreased (P< 0.01).
Conclusion: The results of our study reveal that HAV exposure may
increase due to risk factors such as socioeconomic and infrastructural
problems, personal hygiene, sources of water and food. Improvement in
these factors will lead to fewer exposures to HAV.
P1137 High-risk of hepatitis B and C infection in Tunisian
multi-transfused patients
N. Hannachi °, L. Boughammoura, N. Ladhari, A. Khlif, S. Soussi,
H. Skouri, J. Boukadida (Sousse, TN)
Objective: Transfusion-transmitted infections continue to be a major
challenge for blood transfusion organizations across the world. Risk
depends on the epidemiology of infections in each country. We aimed to
evaluate the rate of seropositivity to hepatitis B and C infections among
adults and children receiving multiple transfusions in central Tunisia
compared with healthy controls.
Methods: This study includes 107 multitransfused patients (59 adults
and 48 children) and 317 controls (257 blood donors and 60 healthy
children). Blood was collected over a period of 3 months (December
2008 to February 2009) and serum samples were screened for HBs
antigen (HBs Ag) and anti hepatitis C antibody (anti-HCV) by the
enzyme linked immunosorbent assay (ELISA) method. The c2 test was
used for comparisons and a p value less than 0.05 was considered as
signiﬁcant.
Results: Mean age of multitransfused adults was 34.8 years old and
31.3 years old for blood donors. Mean age of children was 7.3
years old for multitransfused group and 7.9 years old for healthy
group. The prevalence of HBs Ag was higher in polytransfused group
(8.4%) than control group (3.1%) (p = 0.03). Prevalence of anti-HCV
was 9.5% in the multitransfused patients and 0.4% in controls, the
difference between the two groups was signiﬁcant (p< 0.0001). Age-
stratiﬁed analysis showed that risk of Hepatitis B or C was signiﬁcantly
higher in adults (older than 15 years). Risk of hepatitis C was less
important after the date of instauration of systemic HCV serological
screening in Tunisian transfusion centers. Signiﬁcant high frequency of
hepatitis B infection was found in patients transfused after 1973 (date
of instauration of systemic HBs Ag screening in Tunisian transfusion
centers).
Conclusion: Tunisian multitransfused adult patients must be considered
at high risk of hepatitis C infection even if hepatitis C endemicity is low.
Hepatitis B infection still occurs in multitransfused Tunisian patients in
spite of systemic HBs Ag screening. Deferring all reactive anti-HBc
antibody units of blood strategy is not defendable in country of important
prevalence of hepatitis B. Therefore, implementation of hepatitis B virus
DNA screening in transfusion centers should be considered especially
for multitransfused patients.
P1138 Seroepidemiology of hepatitis C in cases with history of
intravenous drug use in Isfahan province, Iran
B. Ataei, P. Adibi, M. Yaran °, N. Kassaian, Z. Nokhodian, M. Meshkati,
R. Fadaei Nobari (Isfahan, IR)
Objectives: Hepatitis C virus (HCV) which is prevalent among estimated
3% of the world population continues to be a major disease burden on
the world.
Several studies have documented that injecting drug use is a primary
mode of transmission for HCV. But, there is limited information of HCV
detection among intravenous drug users (IVDU) in Iran and in Isfahan
there is not any documentation about it. Hence, the present study was
conducted to understand the status of HCV infection among IVDUs in
Isfahan province, Iran.
Methods: In a cross sectional study, during November 2008-March 2009,
the cases with history of intravenous drug using in Isfahan, Iran from
drug treatment centers, prisons and community, came into study. HCV-
Ab was tested by ELISA, Diapro kit (Italy) and conﬁrmed by RIBA
test.
Results: There were 3284 cases (3251 male and 33 women): 1006 in
prisons, 531 in drop in centers (DIC) and 1747 in community. The totally
prevalence of HCV was 38% which was 40% in prisons, 47% in DICs
and 34% from community announcement.
Conclusion: It is important that high prevalence of HCV infection be
taken into consideration. Comprehensive harm reduction programs and
routine testing are needed for IVDUs in Iran in order to best control
further transmission of this infection.
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P1139 The relation between the cytokine levels and
histopathological activity and ﬁbrosis in chronic hepatitis B
and chronic hepatitis C infections
A. Tigli, F.Z. Akcam °, O. Kaya, M. Ciris (Isparta, TR)
Objectives: We ivestigated that possible correlation between the levels
of TNF-a, IL-18, IL-10, TGF-b, and INF-g and the Histological Activity
Index (HAI) and ﬁbrosis levels in patients with Chronic hepatitis
B and C.
Methods: Fifty patients were included in the study. Serum samples
were obtained and liver needle biopsy were performed on the same
day. Cyctokine levels were investigated by ELISA. Histopathological
examinations were carried out by the same pathologist.
Results: There was a statistically signiﬁcant positive mid-level
correlation between TNF-a with HAI and ﬁbrosis (p = 0.004 r = 0.401,
p = 0.003 r = 0.407). No signiﬁcant correlation was found between HAI
and ﬁbrosis with IFN-g, IL-10, IL-18, ve TGF-b.
Conclusion: HBV and HCV infections have elaborated pathogenetic
mechanisms. The cytokin activity has important impacts on clinical
severity and progression. The results obtained in this study shows that
further investigations on possible effects of cytokins on hepatocellular
damage and ﬁbrosis should be done. Thus, new immunotherapeutic
approaches in viral hepatitis may be arranged if this issue is further
studied.
P1140 Association of candidate susceptible loci with chronic
hepatitis B virus infection in a Chinese population
D. Chen °, B. Zheng (Hong Kong, CN)
Objectives: A number of genetic loci have been proposed to be
associated with persistent hepatitis B virus (HBV) infection. In this study,
we aimed to evaluate the association and interaction of susceptible genes
with HBV persistence in Chinese population.
Methods: Seventeen polymorphisms in 9 candidate genes were studied
in 361 Chinese chronic hepatitis B patients (CHP group) and 304
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spontaneously recovered individuals (SRI). Distribution frequencies of
polymorphisms associated with disease were analyzed in healthy Chinese
and Caucasian populations. Gene-gene interactions were tested by the
multifactor dimensionality reduction (MDR) method.
Results: The TNF −308 G/G genotype and G allele, IL-10RB codon
47 A allele, and MCP-1 −2518 G/G genotype and G allele were more
frequent in patients than controls (P< 0.01, after multiple corrections
Pc< 0.05), while TNF −308 A/G genotype and IL-10 −592 A/A
genotype were signiﬁcantly higher in the SRI group than in the CHP
group (Pc< 0.05). The distribution frequency of risk allele MCP-1 −2518
G and CTLA4 6230 G were much higher in Chinese than Caucasian
groups (P< 0.001). An interaction between CCR5 −2459, TNFA −863,
IL-10RB codon 47 and MCP-1 −2518 was detected by MDR (P = 0.001).
Conclusion: Our results suggest that genetic determinants may affect the
outcome of HBV infection in both independent and synergic manners.
P1141 Establishment of a non-transgenic mouse model for chronic
hepatitis B virus infection
L. Yang °, B. Zheng (Hong Kong, HK)
Objectives: Chronic hepatitis B virus (HBV) infection is a severe
worldwide public health problem. Although HBV transgenic mice have
been developed to mimic the immune tolerant state of chronic HBV
infection, lack of a non-transgenic mouse model make it difﬁcult, to
address what happen in the early phase of infection and how the outcome
of viral infection (to be eliminated or persistent) is determined. This
study aimed to develop a chronic HBV infection mouse model using a
humanized mouse strain with HLA-transgenic H-2 knockout background
(MHC-TgKO mouse).
Methods: 20 ug of pAAV/HBV1.2, a plasmid encoding 1.2-fold of HBV
genome, was delivered into mouse tail rein by hydrodynamic injection.
HBsAg, HBeAg and HBV DNA were monitored in one-week intervals
during a period of over 6 months. Early immune responses to HBV
antigens were also determined.
Results: The results showed that, over 60% of injected MHC-TgKO mice
persistently produced HBsAg and HBV DNA for over 6 months, which
met the criteria of chronic HBV infection in humans. HBV replicative
intermediates and transcripts were exclusively detected in the liver carrier
mice, but not in other organs. Similar to that in human, injected female
mice had lower HBsAg persistent rate, HBsAg concentration and HBV
DNA levels than the male. A signiﬁcant lower immune response to
HBcAg was detected in MHC-TgKO mice than that in C57BL/6 by
ELISPOT assay, which may explain the high persistent rate in MHC-
TgKO mice.
Conclusion: This study has established a mouse model for chronic HBV
infection, and further investigations are on going to characterize the
virological and immunological properties in carrier mice.
P1142 SLC29A1 −706G>C predict haemoglobin decrease in pa-
tients with hepatitis C treated with interferon and ribavirin
A. D’Avolio, M. Siccardi, A. Ciancio, L. Baietto °, M. Simiele,
S. Patanella, D. Aguilar Marucco, G. Cariti, A. Calcagno, M. Sciandra,
A. Smedile, F.G. De Rosa, S. Bonora, M. Rizzetto, G. Di Perri (Turin, IT)
Objective: Ribavirin (RBV) and pegylated interferon are the standard
of treatment in chornic hepatitis C. RBV plasma exposure correlates
with the achievement of sustained virological response and hematological
toxicity. The role of the equilibrative nucleoside transporter 1 (ENT1),
encoded by SLC29A1 gene, in the absorption, transport, metabolism
and erythrocyte disposition of RBV has been recently reported. The
objective of our investigation was to illustrate whether SNP −706G>C
in this gene has an effect on the hematological toxicity and its possible
role as a predictor of haemoglobin decrease.
Methods: Patients were recruited in Amedeo di Savoia Hospital and
Molinette Hospital in Turin, Italy. Sampling was performed after
written informed consent was obtained in accordance with local
ethics committee indications. Patients receiving RBV (1000mg/die)
and pegylated interferon therapy were included in this study. Main
inclusion criteria were: no concomitant interacting drugs, no renal
function impairment, self-reported adherence >95%. Genotyping was
conducted by real time PCR based allelic discrimination using standard
methodology. Statistical analysis was conducted by SPSS software.
Results: 34 patients were included in the study meeting the inclusion
criteria. No associations between patient demographics with ENT1
polymorphism were found. After 2 and 3 months of treatment with RBV
the median haemoglobin decrease, expressed as g/dL, in patients with the
mutant allele (GC or CC, n = 8) for SNP −706G>C was higher compared
to patients with wild-type genotype (GG, n = 26); after 2 months: −4.00
(−4.57 to −2.90) Vs. −2.45 (−3.22 to −1.60), p = 0.017; and after 3
months: −3.90 (−4.82 to −2.95) Vs. −2.7 (−3.50 to −1.66), p = 0.031; In
multivariate linear regressions analyses the presence of the mutant allele
was the only independent predictor of higher decrease of haemoglobin
after 2 (b = −1.13, 95%CI −2.04 to −0.23, p = 0.016) and 3 months
(b = −1.05, 95%CI −2.00 to −0.10, p = 0.032).
Conclusions: The mutant allele C correlates with an higher decrease
of haemoglobin after 2 and 3 months of treatment. This result suggests
that hENT1–706G>C may have an important inﬂuence on RBV-induced
anemia. Further studies are required to conﬁrm this association and
to clarify its clinical value in predicting RBV-associated hematological
toxicity.
hENT1 and Hb after 2 months of ribavirin treatment.
P1143 Factors related to the effectiveness of the chronic hepatitis C
virus infection therapy in patients with or without HIV
infection
A. Puerta Garcı´a °, A. Salinas Botra´n, E. Martı´nez Alfaro, J. Blanch
Sancho, F. Mateos Rodrı´guez (Albacete, ES)
Objective: To describe factors related to the effectiveness of the
hepatitis C treatment in coinfected and monoinfected patients.
Methods: Descriptive, retrospective study of 101 patients with chronic
hepatitis C with and without HIV infection treated with interferon
and ribavirin (guideline A) or with pegylated interferon and ribavirin
(guideline B) in our hospital during 9 years.
Results: 37 patients presented HIV co-infection and 64 were monoin-
fected. Within the group of patients with HIV infection: 7 patients
presented sustained virologic response (SVR) (18.9%), 1 out of 6 with
guideline A (16%) and 6 out of 31 patients treated with guideline B
(19%). 3 patients responded during the ﬁrst month and among them
there was SVR in 100%, 1patient responded during the third month and
got SVR as well, 4 responded during the sixth month and none of them
got SVR and 4 patients responded during the ninth month and 1 got SVR
(p = 0.03). Among the patients who got undetectable viral load during the
treatment, patients with SVR had an average of weeks for the treatment
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with undetectable viral load of the HCV of 30.6 whereas there were 18.3
weeks in patients without SVR (p 0.03). Regarding genotypes, from 26
patients with genotype 1, 11.5% presented SVR, from 6 patients with
genotype 3, 50% presented SVR and from 5 patients with genotype 4,
25% presented SVR (p = 0.14).
Within the group of monoinfected patients, 41 patients presented
SVR (64%). Patients treated with guideline A responded 5/15 (33%)
and patients treated with guideline B responded 36/49 (73%), with
statistically signiﬁcant differences (p = 0.026). From 19 patients that
responded in the ﬁrst month 17 presented SVR, from 21 patients that
responded in the third month, 18 presented SVR. In patients who got
undetectable viral load during the treatment, patients with SVR had an
average of weeks for the treatment with undetectable viral load of the
HCV of 32.7 whereas there were 19.1 weeks in patients without SVR
(p 0.03). Regarding genotypes, 22 out of 40 patients with genotype 1
(55%) presented SVR, 18 out of 22 patients with genotype 3 (81%) and
1 out of 2 with genotype 4 (50%).
Conclusions: In patients with chronic hepatitis C virus infection with or
without HIV coinfection the longer with undetectable viral load during
the treatment is related to SVR in a signiﬁcant way, therefore, it could
be possible to individualize treatment according to the viral response to
make SVR better.
P1144 The inﬂuence of HCV genotypes and other predicting
factors in virological response in patients treated with
INFa or PEG INFa 2a in combination with ribavirin
H. Elasifer °, B. Elagy, M. Eltaghdy, A. Draah, M. Daw (Tripoli, LY)
Introduction: Recombinant interferon a or pegylated interferon alone
or in combination with ribavirin are known treatment of hepatitis C virus
infection, HCV genotypes commonly used to outline such treatment.
Objectives: were (1) to determine the efﬁcacy of two different regimens
of therapies, (2) to asses the impact of virus genotype, gender, ALT level
and viral load on such treatments.
Methods: 479 of chronic HCV infected patients registered at Tripoli
Medical Centre were followed from January 2003 to October 2008. The
information were reviewed the data were collected. These include age,
gender, risk factors, ALT level, viral load at diagnosis, viral genotype,
the regimen of therapy ‘INF a or pegylated INF a 2a in combination
with ribavirin’, ETR, SVR. Only 229 were given therapy. The statistical
analyzed by using SPSS version 11.5.
Results: 86 patients were given INF in based therapy and 54% of them
had End Treatment Response (ETR) and 28% had Sustained Virological
Response (SVR). 143 patients were given PEG INF a 2a in based
therapy, 69% had ETR and 36% had SVR. The relationship between
ETR, SVR and gender was signiﬁcant in patients who were given INF
based therapy (ETR ‘P = 0.009’, SVR ‘P = 0.016’), and was insigniﬁcant
in patients who were given PEG INF based therapy. The relationship
between ETR, SVR and age, ALT at diagnosis, basal viral load, was
insigniﬁcant in both regimens. The ETR in patients who were given INF
based therapy was G1 33.3%, G2 69.2%, G3 52.4% and G4 64.3%, and
SVR were G1 16.7%, G2 30.8, G3 23.8% and G4 39.3%. ETR in patients
who were given Peg INF based therapy was G1 66.1%, G2 82.4%, G3
68.8% and G4 66.7% responded and SVR was G1 32.1%, G2 35.3%,
in G3 43.7% and G4 37%. The relationship between the genotype and
ETR to INF a regimen was statistically signiﬁcant (P = 0.037) and was
insigniﬁcant in PEG INF regimes (P = 0.345). The relationship between
the genotypes and SVR to INF a regimen was insigniﬁcant (P = 0.271),
in PEG INF the relation was insigniﬁcant (P value=0.792).
Conclusion: HCV genotypes was found to be important in predicting
ETR in patients who were given INF a based therapy. The gender
was also important in predicting ETR and SVR in patients who were
given INF a based therapy. Gender and genotype were not signiﬁcant in
patients who were given PEG INF based therapy. Moreover, the patient’s
age, basal viral load and basal ALT were found insigniﬁcant.
P1145 Prevalence of HBV Lamivudine-resistance mutations in a
cohort of Iranian HBV-infected patients with and without
HIV co-infection
M.R. Aghasadeghi °, A. Farahani Far, G. Bahramali, S.M. Sadat,
A. Memarnejadian, S.D. Siadat, M. Mohraz, M. Foroughi, F. Javadi,
F. Roohvand, R. Vahabpour, M.S. Pouriayevali (Tehran, IR)
Objectives: Individuals co-infected with human immunodeﬁciency virus
1 (HIV-1) and hepatitis B virus (HBV) often receive treatment with an
antiretroviral regimen including lamivudine (LAM) that is a nucleoside
analogue and inhibits HIV/HBV reverse transcriptase (RT). However,
its efﬁcacy is limited by the development of LAM-resistant strains
within the YMDD motif of the HBV polymerase gene. Prevalence of
mutations between HBV/HIV co-infected (HIVpos) and HBV mono-
infected (HIVneg) individuals on LAM therapy have not been extensively
documented in the Middle-East. The aim of this study was to determine
the prevalence of HBV LAM-resistance mutations in Iranian HBV
infected patients with and without HIV infection.
Methods: Fifty eight chronic hepatitis B patients including 30 HBV
mono-infected and 28 HIV/HBV co-infected patients were studied, while
receiving LAM as a part of antiretroviral therapy. The YMDD motif was
PCR-ampliﬁed and directly sequenced in HBV isolations. HBeAg, HBV
genotype and polymerase gene mutations were additionally assessed.
Results: The average LAM exposure was 24.35 ±21.91 and 25.3 ±13.94
months in HIVpos and HIVneg groups, respectively. All the patients
were infected with HBV genotype-D and the study revealed a signiﬁcant
correlation between the HBV/HIV co-infection and both HBV subtypes
of ayw3 and ayw4 (P< 0.001). Seventeen out of 28 HIVpos patients and
19 out of 30 HIVneg infected ones were shown to be HBeAg negative.
No association was observed between the type of infection and HBeAg
status (P> 0.05). M204V, M204I and L180M mutations were observed in
2 (6.66%), 7 (23.33%) and 5 (16.66%) HIVneg patients, respectively. The
dual mutations (M204V/I+L180M) were detected in 5 (16.66%) HIVneg
patients. Interestingly, LAM-resistance mutations were not detected in
HBV/HIV co-infected individuals.
Conclusion: In accordance to previous studies in Iran, HBV-D was the
only detected genotype in both HIVpos and HIVneg patients. This study
suggested that individuals With HBV infection that carry ayw4 and ayw3
subtypes are more likely to be infected with HIV. Moreover, in contrast to
several European investigations, reporting the LAM-resistance mutations
in mono- and co-infections, our study for the ﬁrst time in Iran indicated
these mutations just in HBV mono-infected patients. However, further
studies to clarify the role of HIV in HBV LAM-resistance mutations are
needed.
P1146 High rate of non-response and relapse associated with
peginterferon-alfa monotherapy for the treatment of acute
hepatitis C in HIV-infected patients
J.E. Arends °, S. van Assen, A.J. Wensing, C. Stek, T. Mudrikova, D. van
Baarle, H.G. Sprenger, A. Hoepelman (Utrecht, Groningen, NL)
Background: The incidence of acute hepatitis C virus infection (HCV)
in patients infected with human immunodeﬁciency virus (HIV) is rising.
Because of low patient numbers and a wide variety of inclusion criteria
between studies, the optimal treatment regimen is under debate. We
advocated peginterferon-alfa monotherapy (pegIFN-a) for acute HCV
in HIV-coinfected patients (Arends-JE et al. AIDS 2008; 22(11):1381–
138).
Methods: In HIV-infected patients acute HCV was diagnosed by anti-
HCV serology and quantitative PCR (HCV-RNA), in combination with
clinical signs or elevated alanine aminotransferase (ALAT), and a
negative serology within 1 year prior to diagnosis. All patients started
treatment with peginterferon alfa-2a (180 mgr /weekly) and continued if
a rapid viral response at week 4 (RVR, i.e. HCV-RNA <50 IU/ml) was
reached. If no RVR was reached, weight based ribavirin was added based
on the physician’s preference. Early viral response (EVR) was deﬁned
as >2 log10 decrease or undetectable HCV-RNA at week 12 of therapy.
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Results: Until July 2009 a total of 23 HIV-patients were diagnosed
in both centers (UMCU and UMCG) with acute HCV-infection (17
genotype 1 and 6 genotype 4) of whom 19 started peginterferon alfa-
2a monotherapy. A RVR was reached by 7 patients (37%) while 10
patients (53%) achieved an EVR. 2 patients reached an EVR with
addition of ribavirin from week 4 onwards. Nine patients (47%) were
non-responders with a less than 2log10 drop in HCV-RNA at week
12 with 1 patient receiving additional ribavirin from week 4 onwards.
All non-responders discontinued treatment at week 12 of therapy. With
respect to time between seroconversion and start of therapy, baseline
HCV-RNA viral load, maximum ALAT reached, baseline CD4 count and
HIV-RNA viral load, no statistical differences were observed between
responders (RVR and EVR) and non-responders. Interestingly, 5 out of
7 patients achieving a RVR also completed their 24-weeks of therapy.
Unexpectedly, 3 patients in this group experienced a relapse of their
HCV-infection. This relapse was conﬁrmed by sequence analysis of the
NS5B-region comparing the baseline quasi-species pool with the relapse
strains.
Conclusion: Peginterferon-alfa monotherapy resulted in a high per-
centage of non-responders. Furthermore, relapse of HCV-infection in
patients achieving a RVR, was common after completion of treatment.
Combination with ribavirin seems to be essential in HIV-infected patients
with acute HCV infection.
P1147 Correlates and prognostic value of hepatitis C virus core
antigen serum levels during chronic infection and treatment
E. Durante-Mangoni, L. Vallefuoco, E. Perna, D. Iossa, R. Andini,
C. Caianiello, E. Ragone, R. Utili, G. Portella ° (Naples, IT)
Objectives: The current assessment of chronic hepatitis C patients
includes determination of aminotransferases, viral load and HCV
genotype. Recently, a novel assay has been developed that allows
quantiﬁcation of HCV core antigen (HCVcoAg) with a sensitivity
of 3 fmol/L. In this study, we analysed HCVcoAg levels in a
cohort of chronic hepatitis C patients to assess their correlation with
clinical and virological parameters and their changes during antiviral
treatment.
Methods: We studied 26 chronic hepatitis C patients treated with
standard doses of pegylated interferon a and ribavirin. Baseline data
incuded quantitative HCV-RNA, HCV genotype, ALT, GGT as well as
histology parameters including necroinﬂammation, ﬁbrosis and steatosis.
HCV-RNA and HCVcoAg levels were also measured in samples obtained
2, 14 and 28 days after antiviral treatment start.
Results: HCVcoAg baseline levels showed a good correlation with
HCV-RNA (r = 0.26) and ALT (r = 0.32) levels and with liver necroin-
ﬂammatory activity (r = 0.24) but not ﬁbrosis or steatosis. Genotype 3
patients showed signiﬁcantly lower baseline levels of HCVcoAg than
both genotype 1 and 2 patients (1024 vs 8062 and 5538, respectively;
p< 0.05). Pre-treatment HCVcoAg levels did not show any predictive
value for ﬁnal treatment outcome. However, the early decline of
HCVcoAg from baseline to day 2 of treatment was signiﬁcantly greater
in patients who subsequently reached a sustained virological response
compared to those nonresponders or relapsers to treatment.
Conclusion: Our data suggest that the evaluation of HCVcoAg serum
levels may provide relevant data in the baseline clinical evaluation of
patients with chronic hepatitis C. In addition, early changes of HCVcoAg
serum levels during treatment mirror those observed with HCV-RNA
measurement. Further studies are underway to determine whether a
cheaper and faster assay such as HCVcoAg measurement may replace
HCV-RNA in the early assessment of virological response to peg-
interferon/ribavirin regimens.
P1148 A tertiary care facility experience on pegylated IFN efﬁcacy
in chronic hepatitis B patients
Y. Kurtoglu Gu¨l, C. Bulut, S. Kinikli, Z. Koc¸ak Tufan, C. Ataman
Hatipoglu, F.S. Erdinc, A.P. Demiroz ° (Ankara, TR)
Introduction: Pegylated interferons (Peg-IFN) have been used for the
treatment of chronic hepatitis B (CHB). The main properties of these
drugs with certain therapy durations and no resistance improvement
made them even more preferable. In this study we aimed to evaluate
the efﬁcacy of Peg-IFNs in our CHB patients.
Methods: This prospective study was conducted in our clinic between
2006 and 2008. The CHB patients admitted and treated with Peg-IFN
are included.
Results: Totally 40 patients (17 female, 23 male) were included. Mean
age was 37 (min 16, max 65). 13 of total were HBeAg(+), 24 were Anti-
HBeAg(+) while two were both HBeAg(+) and AntiHbe(+) and one was
negative for both.
HBeAg (+) patients: They treated for 24 weeks. Virological response rate
was 10%, biochemical response rate was 40%, sustained response rate
was 10% and primary nonresponse rate was 60% at the end of treatment.
Mean alanine aminotransferase (ALT) levels at the beginning and end
of treatment were 93.2±52.4 and 73.8±59.7 respectively (p = 0.413).
Mean decrease in the HBV DNA level during this perios was 2.4 log10
(p< 0.05). HBeAg seroconversion was seen in two (20%) patients.
HBsAg seroconversion was not seen in any patients.
HBeAg(−) patients: They were treated for 48 weeks. Virological and
biochemical response rates at the end of treatment were 76% and 67%
respectively. Mean ALT levels at the beginning and end of treatment
were 116.7±92.4 and 41.5±27.3 respectively (p = 0.003). Mean decrease
in the HBV DNA level during this period was 4.3 log10 (p = 0.000).
Sustained response rate was 14%. HBsAg seroconversion was seen only
in one patient.
Conclusion: Peg-IFN therapy was found to be more effective in
HBeAg(−) patients than HBeAg(+) ones. The treatment duration of
HbeAg(+) patiens are still not clear and prolonging the treatment time
to one year like the negative ones could be detected as well in further
studies.
P1149 Evolution of hepatitis B virus mutation during
nucleoside/tide analogues long-term therapy in chronic
hepatitis B patients
E. Arrese, M. Basaras, S. Blanco, P. Ruiz, R. Cisterna ° (Vitoia-Gasteiz,
Bilbao, ES)
Objective: The aim of the present study was to evaluate the therapy
with nucleos(t)ide analogues (adefovir dipivoxil (ADV), lamivudine
(LAM), entecavir (ETV)) in chronic hepatitis B virus (HBV) infected
patients with frequent measurements of DNA levels, to characterize HBV
genotypes, and to determine the emergence of nucleos(t)ide analogues
mutants before and during the two years of therapy by direct sequencing.
Patients and Methods: A total of twenty patients with chronic HBV
infection were treated with nucleos(t)ide analogues for at least two years.
We studied nucleos(t)ide analogue-naı¨ve patients as well as patients
previously treated with another nucleos(t)ide analogue. A virologic
breakthrough was deﬁned as an increase in serum HBV DNA level
and resistance to therapy was deﬁned as the emergence of resistance
mutations by direct sequencing of the polymerase gene, which was
looked for in all HBV DNA positive serum samples.
Results: Viral genotype was determined showing the presence of
genotype D (55%) in eleven patients, genotype A (40%) in eight
patients and genotype C (5%) in one patient. In the viral response
to long-term treatment, three patients developed LAM resistance
mutations (rtM204V/I+rtL180M; M204I; M204I+rtQ215S), one patient
developed ETV resistance (rtM204V+rtL180M+rtT184A+rtS202G),
one patient developed ADV resistance mutations (rtA181V+rtQ215S)
and another patient developed ADV+LAM resistant mutations
(rtL180M+rtA181V+rtN236T). In another two patients, the viral load did
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not respond sufﬁciently to therapy but they did no developed nucleotide
changes in the polymerase gene associated with viral resistance. On the
other hand, in twelve patients the viral load was undetectable after two
years of treatment.
Conclusions:
1. Frequent assessment of quantitative serum HBV DNA remains the
best approach to early detection of resistance.
2. Direct sequence analysis is an essential tool to detect mutations
and to optimize therapeutic management of HBV chronic infection
in clinical practice in order to choose the appropriate nucleos(t)ide
analogues.
P1150 Pregnancy outcome in women with chronic hepatitis B
virus infection − the value of serum HBsAg quantiﬁcation
I. Elefsiniotis, I. Glynou, I. Zorou, E. Vezali, H. Kada, G. Saroglou °
(Athens, GR)
Objectives: Preterm birth is the leading cause of perinatal morbidity and
mortality. The impact of maternal chronic HBV infection on pregnancy
outcome has been retrospectively evaluated in some studies mainly from
South-Eastern Asia but their results are controversial. The aim of this
study was to prospectively evaluate the spontaneous preterm birth (SPB)
rates in association with chronic HBV infection in a multinational
population of pregnant women (n = 1826) without several known risk
factors for preterm delivery. Moreover we examined the role of serum
HBsAg as well as serum HBV-DNA levels during perinatal period in
respect to SPB, in a subgroup (n = 44) of chronic HBV infected women
of our study population.
Methods: All women were screened for HBsAg, anti-HBc and anti-
HBs, whereas HBeAg and anti-HBe were evaluated only in those who
tested positive for HBsAg. Serum HBV-DNA was determined by using
the Cobas TaqMan HBV Test. HBsAg quantiﬁcation was done using the
Abbott ARCHITECT HBsAg assay.
Results: More than half of the study population was originally from
Greece (56%), 30.9% was from Albania and 13.1% from Eastern
European countries.
Overall, 3.83% (70/1826) of pregnant women were HBsAg(+) and the
vast majority of them (71.42%) were Albanian. Among Albanian women
the prevalence of HBsAg was 8.9% followed by 3.3% among women
from Eastern European countries. Thirty-three women (1.83%) presented
SPB (Greek women 1.5%, Albanian women 1.6%, Eastern European
women 3.8%, p = 0.051). A strong relationship between SPB and HBsAg
status was observed [7.25% (5/64) of HBsAg(+) mothers presented
SBP compared to 1.62% (28/1703) of HBsAg(−) ones (p = 0.007)]. The
relative risk of preterm delivery in HBsAg(+) mothers was 4.5 times
higher than in HBsAg(−) mothers.
SPB was not related either to the presence or absence of viremia
(p = 0.576) or to the level of viremia (p = 0.761), among HBsAg(+)
women. A trend for relationship between SPB and the HBsAg levels
[2520.87 IU/ml for HBsAg(+) women who had SBP vs 2120.51 IU/ml
for HBsAg(+) women without SPB, p = 0.079] was observed.
Conclusions: HBsAg(+) pregnant women exhibit a higher risk for
spontaneous preterm delivery compared to HBsAg(−) women, especially
those with relatively higher HBsAg levels during perinatal period.
Acknowledgements: The study was partially supported by the Hellenic
Foundation of Gastroenterology.
P1151 HBV-DNA presence in cord blood does not reduce the
efﬁcacy of the immunoprophylaxis schedule in neonates of
HBeAg-negative chronic HBV-infected women
I. Elefsiniotis, M. Papadakis, G. Vlachos, E. Vezali, C. Mihas,
G. Saroglou °, A. Antsaklis (Athens, GR)
Background/Aim: Intrauterine/transplacental transmission of HBV in-
fection is observed in a signiﬁcant proportion of pregnancies, resulting
in passive-active immunoprophylaxis failure. In our study we evaluated
the efﬁcacy of the currently used passive-active immunoprophylaxis
schedule in neonates of HBeAg-negative chronic HBV infected pregnant
women, in respect to maternal laboratory data during perinatal period as
well as to the presence or absence of HBV-DNA in cord blood samples.
Methods: 76 chronic HBV infected pregnant women were clinically,
haematologically, serologically and virologically evaluated during
perinatal period. Cord blood was obtained at the time of delivery and the
samples were evaluated for the presence of HBV-DNA (Cobas Amplicor
HBV Test).
Results: HBV-DNA was detectable in 13 (17.8%) cord blood samples
evaluated. Cord blood HBV-DNA positivity was signiﬁcantly correlated
with maternal viral load during perinatal period (p = 0.002). Chronic
HBV infected pregnant women with serum HBV-DNA levels higher
than 10.000 copies/ml during perinatal period exhibited 5.8 times higher
risk of HBV-DNA presence in their cord blood compared to women
with serum HBV-DNA lower than 10.000 copies/ml (50% vs 8.6%
respectively, p = 0.003). Median cord blood HBV-DNA levels were
signiﬁcantly lower than median maternal serum HBV-DNA levels (316
copies/ml vs 2.667 copies/ml respectively, p< 0.001). None of 44 infants
evaluated exhibit immunoprophylaxis failure.
Conclusions: The presence of HBV-DNA in cord blood does not
reduce the efﬁcacy of the currently used immunoprophylaxis schedule
in neonates of HBeAg-negative chronic HBV infected women.
P1152 Factors associated with severe liver ﬁbrosis in HIV/HCV
co-infected patients, ANRS CO13 HEPAVIH cohort
M.A. Loko °, F. Bani-Sadr, P. Carrieri, M. Winnock, K. Lacombe,
D. Neau, P. Morlat, P. Sogni, F. Dabis, D. Salmon on behalf of the
ANRS CO 13 HEPAVIH
Background: HCV-induced liver disease is a leading cause of death
among HIV/HCV coinfected patients. Liver stiffness measurement is
known to be well correlated to liver ﬁbrosis.
Aim: To assess factors associated with liver ﬁbrosis in HIV–HCV co-
infected patients.
Methods: The study focused on 671 HIV/HCV-coinfected patients
enrolled in the ANRS CO13 HEPAVIH cohort since January 2006 and
for whom successful results of liver stiffness measurements evaluated
by elastometry were available. The study outcome was severe liver
ﬁbrosis, deﬁned as a liver stiffness >9.5kPa. Logistic regression models
were used to identify correlates of severe liver ﬁbrosis among patients’
characteristics (input variables). Patients with anti-HCV treatment at
the time of liver stiffness measurements, as well as those with end-
stage liver disease were not included. Variables with P-values <0.10
in univariate analysis were included in multivariate models, carried out
using a backwards stepwise procedure.
Results: Among the 671 evaluated patients, 67% patients were male,
with a mean age of 45 (SD: 6.1) years. 67% were IVDU. The mean CD4
cell count was 506±295 /mm3 at the time of liver stiffness measurement,
186 (27.7%) presented a severe liver ﬁbrosis. In multivariate analyses,
factors associated with severe liver ﬁbrosis were male gender (OR:
2.4, [CI: 1.4−4.1], p = 0.002), receiving opioid substitution treatments
(methadone or buprenorphine), both proxies of longer history of HCV
infection (OR: 2.3, [CI:1.3−4.0], p = 0.004), presence of lipodystrophy
(OR: 2.0, [CI:1.2−3.3], p = 0.005), increased HOMA-insulin resistance
(OR: 1.1, [CI:1.0−1.2], p = 0.002) and a long duration under ART (OR:
1.1, [CI:1.0−1.1], p = 0.03).
Conclusion: Our study shows that a long exposure to ART and the
presence of metabolic disorders are associated with a more severe
liver ﬁbrosis in HIV–HCV co-infected patients. This ﬁnding may have
implications for the management of HIV–HCV co-infected individuals.
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P1153 Peripheral blood and intrahepatic natural killer cells in
chronic hepatitis C: relation to disease activity and hepatic
ﬁbrosis
H. El Aggan °, F.S. Mohamed, N.M. El Deeb, M.M. El Sawy,
M.S. Shater (Alexandria, EG)
Objectives: Cellular immune responses are thought to play a key role
in the pathogenesis of hepatitis C virus (HCV)-related liver damage.
Recently, increasing attention has been drawn towards components of the
innate immune system to HCV, including natural killer (NK) cells. The
present work was designed to study peripheral blood and intrahepatic NK
cells in patients with chronic hepatitis C in relation to disease activity
and severity of hepatic ﬁbrosis.
Methods: Fifteen patients with untreated CHC and 12 healthy subjects
were included in the current study. The NK and NKT cells in fresh
whole blood samples were identiﬁed using two-color ﬂow cytometry as
CD3-CD56+ and CD3+CD56+ cells respectively and the results were
expressed as percentages of the total lymphocyte count. Liver biopsies
were taken from all patients and the specimens were evaluated as
regards the histological activity grade and ﬁbrosis stage according to
METAVIR scoring system and for the presence and grade of steatosis.
Immunohistochemical staining was done using antibodies against CD56
and smooth muscle actin (SMA) for detection of intrahepatic NK
cells and activated hepatic stellate cells (HSCs) respectively. A semi-
quantitative method was used to score the intensity of immunostaining.
Results: The percentages of CD3-CD56+ NK cells and CD3+CD56+
NKT cells in peripheral blood showed signiﬁcant decreases in patients
with CHC compared with healthy subjects (P< 0.01) and was positively
correlated with the intensity of intrahepatic NK cells (P = 0.001). The
CD56+ NK cell inﬁltrate was found to be absent or minimal in about
70% of the liver biopsies of patients with CHC. Patients presented with
chronic fatigue showed signiﬁcantly lower percentages of circulating
NK and NKT cells and intensity of intrahepatic NK cells than patients
who were asymptomatic (P< 0.05). The percentages of peripheral blood
NK cells and NKT cells and the intensity of intrahepatic NK cells
showed signiﬁcant inverse correlations with serum HCV RNA levels,
steatosis grade, METAVIR ﬁbrosis stage and intensity of activated HSCs
(P< 0.05).
Conclusions: The deﬁciency of peripheral blood and intrahepatic
NK cells in patients with CHC may provide a mechanism for
immunosuppression resulting in viral persistence, disease chronicity and
progression of hepatic ﬁbrosis.
P1154 Recombinant mammalian cell derived hepatitis C virus-like
particles induce neutralizing antibody responses to
hepatitis C virus
D.F. Johnson °, R. Chin, L. Earnest-Silveira, H. Zentgraf, T. Bock,
B. Chua, D.C. Jackson, J. Torresi (Melbourne, AU; Heidelberg,
Tuebingen, DE)
Objective: Clearance of Hepatitis C virus (HCV) requires a strong and
broadly cross-reactive CD4+, CD8+ T cell and neutralising antibody
(Ab) responses. Virus like particles (VLPs) resemble mature parent virus
inducing protective humoral and cellular immune responses against HCV
and provide a viable prophylactic vaccine candidate.
Methods: Recombinant adenoviruses expressing HCVcore-E1-E2 were
used to infect Huh7 (hepatoma) cells and produce HCV VLPs. These
were isolated from cell lysates and puriﬁed by Iodixanol density gradient
ultracentrifugation. E1 and E2 glycoproteins of the correct size in
HCV VLPs were conﬁrmed by Western immunoblot. HCV VLPs were
analysed by testing for maturation of Dendritic cells (DC) and mice
were immunised with HCV VLPs alone and with alum and Freunds
adjuvants. The mice were assessed for (1) humoral responses against
both VLPs and a recombinant E2 protein of HCV, (2) production of
mouse antibody secreting cells (memory B cells) in splenocytes using B
cell Elispot assays and (3) neutralizing Ab in a Huh 7 cell entry assay. A
second group of mice were immunised with VLPs and 2 novel adjuvants.
Results:We have produced, puriﬁed and conﬁrmed the presence of HCV
VLPs of genotype 1a by western immunoblot, electron microscopy (EM)
and immunogold EM. HCV VLPs efﬁciently stimulate the maturation of
dendritic cells to level that are comparable to lipopolysaccharide (LPS).
Mice immunised induced strong humoral responses to E2 and VLPs and
mouse anti-HCV VLP serum neutralized VLP entry into Huh7 cells. B
cell elispot assays, using mouse splenocytes, demonstrated production of
mouse antibody secreting cells / memory B cells. Mice immunised with
VLPs and 2 novel adjuvants demonstrated a greater humoral response
and increased levels of mouse antibody secreting cells compared with
mice immunised with HCV VLPs alone or in Alum.
Conclusion: Mammalian cell derived HCV VLPs exhibit similar
morphological, biophysical and immunological properties as putative
HCV virions and are a viable vaccine strategy for HCV. HCV VLPs
of genotypes 1b, 3a and 4 are currently being produced. Studies of CD8
responses and methods to improve VLP immunogenicity and alternative
adjuvanting are ongoing.
P1155 Mutations in the S gene region of hepatitis B virus in
high-risk patients with occult HBV infection
A. Ramezani °, M. Mohraz, R. Hamkar, A. Aghakhani, S. Souﬁan,
A. Eslamifar, M. Banifazl (Tehran, Arak, IR)
Objective: Occult hepatitis B virus (HBV) infection is characterized by
presence of HBV infection with undetectable hepatitis B surface antigen
(HBsAg). Surface gene mutants (S mutants) have been reported in a
variety of patient groups, with variable rates of occurrence. Due to the
apparent increase in prevalence of S mutants and limited data regarding
these mutations in patients with occult HBV infections; we aimed to
determine the surface gene mutations of HBV among high risk patients
with occult HBV infection.
Patients and Methods: In this study, 395 patients including 289 patients
on chronic hemodialysis (HD) and 106 HIV infected subjects were
enrolled. The presence of HBV-DNA was determined in plasma samples
of patients with isolated anti-HBc (HBsAg negative, anti-HBs negative
and anti-HBc positive) by real-time PCR. In HBV-DNA positive patients,
surface gene region was ampliﬁed by nested PCR and surface gene
mutations were analyzed after direct sequencing.
Results: HBV-DNA was detectable in 12 out of 40 patients (30%,
95%CI, 15.8%-44.2%) who had isolated anti-HBc. Of these 12 patients,
9 of them were HD patients and 3 of them were HIV infected subjects.
Plasma HBV-DNA load was less than 50 IU/ml in all of these patients.
In 8 patients (5 HD and 3 HIV infected patients) the amount of DNA
was enough for analysis. In these patients, genotype and surface gene
mutations were analyzed after direct sequencing. Phylogenetic analysis
revealed that all of the HBV isolates were clustered in the Genotype D.
Insertion of a T residue at position 60 and a G residue at position 89
were detected in 2 isolates. Premature stop codons were created in 2
other isolates via replacing of T by A at position 44 and G by T at
position 28. The TTA to TAA stop mutation led to a premature stop
codon at position Leu15 and the GGA to TGA led to a premature stop
codon at position Gly10 in the S gene. Serine to asparagine substitution
at residue 207 (S207N), due to a G to A transition at nucleotide position
620 was found in the other 4 sequences.
Conclusion: HBV genotype D was the only detectable genotype
in Iranian patients with occult HBV infection. No “a” determinant
mutations were detected in our isolates. This study suggested that the
“a” region mutations did not play a major role in HBsAg detection and
other mutations may be responsible for the existence of occult HBV
infection and failure to detect HBsAg by routine laboratory tests.
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Community-acquired gastroenteritis
P1156 Outbreak of Listeria monocytogenes caused by beef meat
from a meals-on-wheel’s delivery, Denmark, 2009
B. Smith ° (Copenhagen, DK)
Objectives: To describe the ﬁrst outbreak of listeriosis in Denmark since
1986, this occurred in May 2009. Furthermore to describe the value of
rapid molecular typing of isolates in identifying cases being part of the
outbreak as a prerequisite for subsequent epidemiological investigation
and identiﬁcation of a possible single source of infection.
Methods: Two primary diagnostic laboratories each isolated L. mono-
cytogenes from the blood or cere-brospinal ﬂuid of three patients within
a few days. The isolated bacteria were referred to the national reference
laboratory and typed by MLVA and PFGE together with other isolates
from the last month. Patients identiﬁed from MLVA typing or their close
relatives were interviewed by telephone or in their homes about eating
habits and food delivery.
Results: The typing of the isolates showed that eight patients had
identical MLVA patterns distinguish-able from other isolates from Danish
patients. The patients were all adults; the median age was 78 years (range
44−94 years). All patients had predisposing risk factors. All patients
developed septicaemia and one patient presented with meningitis. Two
of the patients died. All patients except one had had ready-made food
delivered from the same catering company. From the records of the
catering company it was found that each of the seven patients had
individual diets, and the only meal they had in common was sliced
beef served with different sauces and vegetables, prepared three weeks
prior to onset of disease. Five samples obtained from remains of the
meat were sent for bacteriological examination without positive culture
of L. monocytogenes in any of them.
Conclusion: This outbreak incurred substantial health costs and caused
considerable public concern be-cause recipients of meals-on-wheels
constitute a large group of people with impaired health who are espe-
cially susceptible to Listeria infection. The meal was intended for heating
in the homes before consumption this didn’t happened. Food that may
be mistaken for ready-to-eat food should be free of L. monocytogenes.
P1157 Viral gastrointestinal infections in a paediatric hospital
E. Nika, T. Guajardo, K. Papavasileiou, A. Makri, I. Mammas,
E. Papavasileiou, A. Voyatzi ° (Athens, GR)
Objectives:To investigate the burden of etiological agents of childhood
viral gastroenteritis (V.G.E) with regard to age and to estimate the
prevalence and seasonal distribution of Rotavirus (R.v), Adenovirus
(A.v), Norovirus (N.v) and Astrovirus (As.v).
Material and Methods: During a two year period (2008–2009) a
total of 1352 faeces samples were examined for enteric viruses. The
study population were children <5 years which visited the outpatient
clinics with symptoms of acute gastroenteritis for medical advice or
hospitalized. Clinical features and possible transmission mode of patients
was recorded. R.v group A, A.v and N.v genogroups I and II were
screened by rapid chromatographic immunoassays, while As.v was tested
using enzyme immunoassay.
Results: V.G.E was diagnosed in 394 cases (an overall rate 29%).
Dehydration. diarrhoea, vomiting and fever were the predominant clinical
manifestations. The prevalence for R.v, A.v, N.v, and As.v were 16%,
7%, 5% and 1% respectively. Co-infections were found in 32 cases (8%)
and were associated with R.v group A and A.v. N.v was identiﬁed as
single leading cause of the illness in prematurity cases. V.G.E occurred
in 53% boys versus 47% girls. In a high rate of V.G.E (90.5%) suffered
children aged less than 3 years while 47.6% belonged in the age group of
6−24 months. Two nosocomial outbreaks of R.v occurred in born preterm
neonates. A seasonal ﬂuctuation of the R.v disease was observed with
the highest rate of the illness (68%) documented between Winter and
early Spring, while N.v infections peaked in Winter (78%). In contract
A.v infections occurred all year-round.
Conclusions: R.v remain still the main causative viral agent for the
majority of V.G.E cases in the paediatric population in Greece. Most
serious symptoms were presented in hospitalized children with R.v
infections compare to others viral agents. Our data showed the need
to develope a critical management for V.G.E in order to avoid the spread
of viruses (especially for R.v and N.v) in paediatric population.
P1158 Typhoid fever in Jordan
T.M. Al-Sanouri, B. Paglietti °, A. Haddadin, M. Murgia, D. Bacciu,
M. Youssef, S. Rubino (Amman, JO; Sassari, IT; Lyon, FR)
Background: Enteric fever caused by Salmonella enterica serovar Typhi
has not been adequately explored in Jordan.
Methodology: In this study we investigated antibiotic resistance patterns
and resistance determinants coupled with ﬁngerprint methods of forty-
eight isolates of S. Typhi obtained from 113 patients with suspected
enteric fever admitted at six governmental hospitals in different
directorates in Jordan. Twenty-four isolates were from an outbreak of
typhoid fever that occurred between October 2004 and January 2005,
and another twenty-four were from sporadic cases from 2005.
Results: All isolates of S. Typhi were resistant to streptomycin. A
multidrug resistant (MDR) pattern of ampicillin, chloramphenicol, co-
trimoxazole with tetracycline and streptomycin (R-type ACCoTS) was
found in 58% of the epidemic strains causing the outbreak and in 98% of
the strains from sporadic cases. MDR isolates harbored a single IncHI1
plasmid containing a class 1 integron (dfrA7). Plasmid conjugation
studies demonstrated a genetic transfer of resistance (ACCoT). S.
Typhi isolates were all sensitive to ﬂuoroquinolones and cefotaxime,
the alternative drugs recommended for treatment of typhoid fever. The
genomic analysis using PFGE showed: a) the outbreak was caused by
an introduced circulating clone with/without an MDR plasmid, and b)
isolates from the sporadic cases from 2005 are the same MDR clone
that persisted and spread in the country.
Conclusion: The emergence of MDR S. Typhi strains is a major
important public health issue in Jordan. This study should guide selection
of effective antibiotic therapy for the treatment of typhoid and monitoring
of the spread of MDR of S. Typhi.
P1159 Playground sand as an environmental source of a localized
community salmonella outbreak
M. Staff °, J. Musto, G. Hogg (Sydney, Melbourne, AU)
Objectives: To identify the source of a protracted Salmonella Paratyphi
B biovar Java (S. Java) outbreak localized to a single local government
area within metropolitan Sydney, Australia.
Methods: From 2007 to 2009 S. Java cases notiﬁed under public health
legislation to the Northern Sydney Central Coast Area Health Service
were interviewed to collect clinical information and to identify likely
sources of infection. Human isolates were classiﬁed by phage typing
and Multi-locus Variable number tandem repeat Analysis (MLVA).
Environmental samples were collected from various sources and isolates
classiﬁed using both phage typing and MLVA. Contaminated sand from
one playground was tested second monthly to assess environmental
persistence of the bacterium. An age-matched case control study was
conducted for outbreak cases identiﬁed in the ﬁrst half of 2008 to test
the hypothesis that close contact with playground sand was the source
of outbreak.
Results: A total of 69 cases of S. Java were notiﬁed among residents
in a single local government area (population 57,000) between 2007
and 2009 with 41% aged less than 2yrs. Most cases had signiﬁcant
gastrointestinal symptoms (including bloody diarrhoea) lasting a median
of 7 days. Of the 65 human isolates for which phage typing was available
72% were reported as Dundee with remainder typed as reacts does not
conform (RDNC). MLVA typing identiﬁed a speciﬁc outbreak strain with
no variation at the ﬁrst and ﬁfth loci and only minor variation at the
second locus. Case interviews implicated playground sand as a possible
source and subsequent environmental testing isolated S. Java with the
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outbreak MLVA pattern from 5 of 13 playgrounds tested. Second monthly
testing of sand from one playground left undisturbed and closed to public
access demonstrated that the organism could survive for at least 6 months
in sand. The case control study conﬁrmed playground sand exposure as
the source of the outbreak with cases being signiﬁcantly more likely to
have played with sand in known contaminated playgrounds (odds ratio
3.7, 95% ci 1.1 to 12.1).
Conclusion: This research demonstrates that S. Java can survive in
sand for a prolonged period and lead to a sustained community
outbreak of human disease. The use of sand in playgrounds can pose a
microbiological hazard especially to young children.
P1160 Two consecutive outbreaks of gastroenteritis due to
infections with Salmonella Typhimurium DT193 in the
Austrian Armed Forces, 2009
J. Pichler °, R. Fretz, P. Much, C. Kornschober, G. Mayr, A. Leodolter,
F. Allerberger (Vienna, Graz, Ried im Innkreis, AT)
In 2008, the Austrian National Reference Centre for Salmonella, AGES,
reported 21 isolates of Salmonella Typhimurium deﬁnite type 193 (ST
DT193) in humans. In June 2009, 99 isolates, and in September 2009,
28 isolates from members of two military caserns in the province of
Upper Austria were diagnosed with ST DT193. Consequently, AGES
was assigned to investigate the outbreaks. The objective was to determine
the magnitude of the outbreak and to identify the chain of transmission.
Methods: A descriptive-epidemiological investigation, a cohort study
of the ﬁrst outbreak, and a broad microbiological investigation were
carried out. An outbreak case was deﬁned as a person who (i) fell ill
with diarrhoea between May 25 and June 7, respectively between Aug
31 and Oct 2, (ii) was on military duty in the relevant time period, or
(iii) had a microbiologically conﬁrmed infection with ST DT193.
Results: The attack rates were 27% in the 1st outbreak (122/450 persons
from camp A), respectively 31% in the 2nd outbreak (61/200 members
of a battalion during a ﬁeld exercise, formed by persons of camps A+B).
A continuous common-source outbreak was assumed in the 1st outbreak,
based on the ﬁndings of descriptive and analytical epidemiology. Being
on military duty between May 25−31 (RR 9.3; p< 0.001) and consuming
several different meals in the dining hall of casern A (RRs 2.0–9.09;
p< 0.017) in the same time period were associated with illness. However,
the further conducted microbiological investigations (such as eggs from
the local egg producer) were all Salmonella-negative; and the vehicle
of infection was not identiﬁed. The most probable link between the two
outbreaks were the use of mobile cooking units and heating boxes from
camp A, which underwent inadequate cleaning and thermal disinfection
due to a failure of the steamer used. Furthermore, the washing facility
in camp A was in a very poor hygienic condition and a consequent
resoiling of cooking utensils from the ﬂoor was very likely.
Conclusion: In spite of extensive investigations in a clearly closed
setting, the vehicle of infection was not identiﬁed. However, failure in
the cleaning procedure of cooking utensils and poor kitchen hygiene in
the camp A may account for the 2nd outbreak.
P1161 Phenotypic and molecular characterization of a shigellosis
outbreak in Antofagasta, Chile, during the year 2008
J. Silva °, J. Gaona, N. Herrera, C. Chambel, B. Alcaide, K. Guerrero,
D. Gonzalez, N. Valenzuela, A. Marcoleta, R. del Campo on behalf
of the CIBERESP
Objectives: Shigellosis is a major cause of diarrhea with a high
morbidity and mortality, especially in the developing countries, being
Shigella ﬂexneri the more frequent specie detected in South America.
During the year 2008, we observed a dramatically increase in the Shigella
sonnei incidence from patients attended in different Health Centers of
Antofagasta (North of Chile). The aim of this work was to analyze the
phenotypic and molecular characteristics of these strains.
Methods: We recovered prospectively (January-June 2008) information
about identiﬁcation, serology and antibiotic susceptibility of 265 Shigella
isolates obtained in three different Health Centers: a Public Hospital, a
Private Clinic, and a Primary Health Center. Biochemical and serological
tests were applied for specie identiﬁcation, which was conﬁrmed by
speciﬁc PCR ampliﬁcations. Antimicrobial susceptibility to ampicillin
(AM), ceftriaxone (CTR), ciproﬂoxacin (CIP), cloramphenicol (CH),
cotrimoxazole (SXT), and nitrofurantoin (NF) was determined by the
agar dilution method. Plasmid presence was analyzed in all strains and
their genetic diversity was explored by PFGE.
Results: Specie identiﬁcation of the isolates corresponded to S. sonnei
(79%), S. ﬂexneri (13%), S. boydii (3%), S. dysenteriae (2%) and
Shigella spp (3%). About 50% of the diarrhea process in children with
10 years was caused by S. sonnei, and we focused our study in forty
randomized isolates (23 from children and 17 from adults) of this specie.
Most of patients were living in the same geographic zone; the north
area of Antofagasta, supporting that contaminated water was the most
probably the cause of the disease. High resistance to ampicillin (94%),
chloramphenicol (89%) and cotrimoxazole (89%) was detected in these
strains, being the 84% of the strains co-resistant to the three antibiotics.
A particular plasmid was observed in almost all forty isolated. Genetic
PFGE studies revealed that 95% of S. sonnei isolates grouped in the
same clone.
Conclusion: We detected a Sighella sonnei outbreak in our region,
affecting different patients from different Health Centers, being
contaminated water the most probable route of transmission.
P1162 Non-pathogenic Vibrio environmental strains carrying
virulence, ﬁtness and antibiotic resistance genes
M. Gennari °, V. Ghidini, M. Taﬁ, M. Lleo` (Verona, IT)
Objective: Vibrios are important members of the autochthonous ﬂora
of aquatic environments and include non pathogenic and pathogenic
species. Although it has been usually report that environmental bacteria
lack virulence and antibiotic resistance genes generally found in clinical
strains, recent studies indicate that acquisition of such genes might have
place in the aquatic environment. A collection of non-pathogenic vibrios
has been screened for genes generally found in pathogenic species.
Methods: Vibrio strains were isolated from water, plankton and sediment
samples obtained in the northern Adriatic Sea. The DNA extracted from
114 environmental isolates was subjected to PCR to screen a battery
of virulence, ﬁtness and antibiotic resistance genes usually found in
V. cholerae and V. parahaemolyticus. Two of the genes, yopP and trh,
are considered virulence determinants in V. parahaemolyticus while the
nanH gene from V. cholerae encodes a neuraminidase. ﬂrA is a gene
involved in the regulation of V. cholerae ﬂagella synthesis and response to
environmental changes. V. cholerae vpsR is involved in bioﬁlm formation
and environmental persistence, while V. cholerae luxA gene is involved
in bioluminescent expression. int15′cs is a gene included in a cassette
of antibiotic resistance determinants in V. cholerae.
Results: 40 marine strains resulted positive to PCR using primers
selected on the described genes: 11 strains carried the gene nanH and 3
the yopP gene while no strains carried the trh gene. 13, 6 and 7 strains
presented respectively the expected amplicons for ﬂrA, vpsR and luxA
while 7 strains carried int15′cs, a sequence from an integron involved
in antibiotic resistance. Further analysis of the strains resulting positive
to the presence of the gene nanH, which in V. cholerae is located in the
pathogenicity island VPI-2, showed that 5 out of 9 strains carried this
mobile genetic element.
Conclusions: The data obtained provide further support to the fact that
gene exchange occurs in the aquatic environment between pathogenic
and non pathogenic bacterial species and that in this exchanging may be
included large genetic elements such as integrons and entire or fragments
of pathogenicity islands. For this reason, environmental vibrios strains
could constitute a marine reservoir of virulence and antibiotic resistance
genes and might represent a risk for human health.
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P1163 Role of toxR on survival strategies of Vibrio cholerae O1
El Tor
S. Valeru, H. Abd °, G. Sandstro¨m (Solna, SE)
Objectives: Vibrio cholerae, the causative agent of diarrhoeal disease
cholera, utilises different survival strategies in aquatic environments. The
bacterium can survive as free-living or in association with zooplankton
and under starvation it can build bioﬁlm and rugose colonies. V. cholerae
expresses cholera toxin and toxin-coregulated pilus as the main virulence
factors, which are co-regulated by a transcriptional regulator toxR.
Aim of the current study was to investigate role of toxR gene on survival
of V. cholerae O1 El Tor under starvation or in association with the free-
living amoeba Acanthamoeba castellanii.
Methods: Starvation survival test, rugose switching test, bioﬁlm
analysis, analysis of protein expression, analysis of toxR expression and
bacteria-amoeba association assay.
Results: The results showed that toxR mutant can shift to rugose
colony morphology in response to nutrient starvation characterised by
wrinkled colony morphology, which shows increased bioﬁlm formation
and enhanced survival under speciﬁc conditions such different media
and different temperatures. The toxR mutant strain shows high frequency
of rugose switching at stationary phase when compared with wild-type
V. cholerae strains. Immunoblot analysis showed that expression of Omp
T was increased in rugose strains and Omp U seemed to be reduced.
The association assay of the bacteria with amoebae showed that presence
of A. castellanii enhanced growth and survival of V. cholerae wild-
type and toxR mutant to 100 fold at day 10. In comparison, growth
of bacteria decreased 10000 fold from day 4 in absence of the amoebae.
Despite A. castellanii grew well in absence of wild-type and toxR mutant
bacterial strains, presence of the each bacterial strain did not inhibit
growth of the amoebae.
Conclusions: The variation in expression of outer membrane proteins
seem to play an important role in V. cholerae O1 El Tor (strain 1552)
rugose and smooth switching. Rugose to smooth switching mechanism in
V. cholerae may be toxR dependent, and the toxR gene is also important
for the survival of V. cholerae in starvation conditions. A. castellanii
enhanced growth of both wild-type and toxR mutant V. cholerae strains
indicating that toxR has no affect on the interaction of V. cholerae
with A. castellanii and that the bacteria are adapted to survive with
the amoebae possibly in the aquatic environments.
P1164 A Campylobacter jejuni outbreak investigation in Crete,
Greece: indications for waterborne spread
I. Karagiannis, T. Sideroglou °, K. Gkolﬁnopoulou, E.N. Velonakis,
E. Scoulica, T. Panagiotopoulos, K. Mellou, S. Bonovas (Athens,
Heraklion, GR)
Objectives: To present the results of the investigation of a C. jejuni
outbreak, which took place around Chania, a town in Crete, Greece, in
late May to early June 2009.
Methods: Two analytical studies were conducted in parallel: a case–
control and a case-crossover study. Fifty cases were included in the two
studies and 124 controls, with respiratory track symptoms, frequency
matched for age, were recruited in the case–control study. The case
deﬁnition was the same for both studies. The questionnaires were
completed via telephone interviews with the children’s parents in July
2009. STATA v11.0 was used for data analysis. Stool cultures, PFGE
and MLST sub-typing in human samples and PFGE in chicken samples
were conducted. Water quality tests were run in the outbreak area.
Results: Thirty-seven cases and 79 controls responded. The median
age of cases and controls was 2 years. Sex distribution did not differ
between cases and controls. The most commonly reported symptoms
were diarrhoea (100%), fever (58.3%) and bloody stool (58.3%). In
the univariate analysis consumption of tap water from the town’s
supply system was protective against Campylobacteriosis (OR: 0.23,
95% C.I: 0.06–0.77). In the stratiﬁed analysis by tap water supplier,
consumption of tap water at home could be computed for rural areas
only (ORMH=3.26, 95% C.I: 0.98–10.82). For these areas statistically
signiﬁcant factors were: consumption of bottled water (OR: 0.15, 95%
C.I: 0.04–0.54), use of a tap water ﬁlter (OR: 0.00, 95% C.I: 0.00–
0.53), use of dishwashers for children’s utensils (OR: 0.16, 95% C.I:
0.03–0.75), consumption of concentrated milk (OR: 2.68, 95% C.I:
0.98–7.37) and consumption of milk types that need to be diluted with
water (OR: 3.05, 95% C.I: 0.99–10.49). In the multivariable analysis,
the town water supplier (OR: 0.17, 95% C.I.: 0.05–0.57) and drinking
tap water (OR: 4.39, 95% C.I: 1.30–14.8) were statistically signiﬁcant.
Case-crossover design revealed no risk factors. The strains from patients’
samples were identical but different from that of the chicken sample. No
Campylobacter was found in any water sample.
Conclusions: Although there are indications that tap water quality was
poor during and exactly before the outbreak, no Campylobacter was
found in any of the environmental samples. However, there is strong
epidemiological proof that tap water was the vehicle of the outbreak.
P1165 An outbreak of Campylobacter jejuni gastroenteritis at
an Australian boarding school: consistency between ﬂa-A
typing and multi-locus sequence typing
C.R. Moffatt, A.S. Cameron, L. Mickan, R. Givney ° (Canberra,
Adelaide, Newcastle, AU)
Campylobacter jejuni causes an estimated 2 million cases of gastroenteri-
tis each year in the United States more than either Shigella or Salmonella
infections. In Australia during 2007, there were approximately 17,000
cases notiﬁed, giving a national incidence rate of 120.2 per 100,000
population.
Despite the frequency and potential severity of Campylobacter
infections, point source outbreaks are rarely reported.
One reason for this is the lack of a standardised Campylobacter jejuni
sub-typing method to distinguish clusters of related cases from the
background of sporadic cases/
In this study an outbreak of Campylobacter jejuni gastroenteritis
occurring at a boarding school was investigated using a retrospective
cohort study and environmental health investigation. Molecular typing
of human and environmental isolates using Restriction Fragment Length
Polymorphism (RFLP) ﬂaA typing and multi-locus sequence typing
(MLST) was undertaken.
Thirty-ﬁve cases of gastroenteritis were reported among 58 persons
exposed, with 14 conﬁrmed as being C. jejuni infections. Attendance
at one evening meal was statistically associated with illness (Ratio of
proportions of 3.094, (95%CI, 1.206–11.11, p< 0.0085). There was no
statistically signiﬁcant association between any single food provided at
the implicated evening meal and illness, suggesting a potential cause of
the outbreak was a cross-contamination event.
Among human isolates two distinct RFLP ﬂa-A subtypes were
found. Results from subsequent MLST data were consistent with the
ﬂa-A typing results, indicating that RFLP ﬂa-A may be a potential
candidate method for Campylobacter jejuni sub-typing for public health
epidemiology.
Figure. UPGAM dendrogram of the ﬂaA RFLP patterns of C. jejuni
isolates from human and environmental sources.
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P1166 Helicobacter pylori infection: association with blood group,
demographics and life style in a Pakistani population
A.K. Khuwaja, F. Wahab, A. Valliani °, B. Ahmed (Karachi, PK)
Background: It is well known that blood group antigens are related
to the development of peptic ulcer and gastric carcinoma. H. pylori
infection is one of the most widespread infection in the world. Its
intensiﬁcation in the individual populations is strongly related to
economic conditions. Developing countries (Asia, Africa, Central and
South America, Eastern Europe) are at high risk, due to people living
in poor socioeconomic conditions. This study sought to determine the
relationship between H. pylori and ABO blood groups, age, gender,
smoking and life style.
Methods: Cross-sectional prospective study was conducted at endoscopy
suit in Public Sector Hospitals of Karachi from Sep 2008 to Nov 2008.
All the symptomatic patients coming for upper GIT endoscopy were
included in this study.
Results: Biopsy for histopathology was taken from 558 patients out
of them 222 (39.8%) were males with age range 18−65 years. Age
group of 21−40 years was found to be related with H. pylori infection.
Out of 558 patients 216 (38.7%) were turned out H. pylori positive
with a signiﬁcant male preponderance (p 0.05). Distribution of ABO
blood groups in H. Pylori group was A= 66/216 (30.5%), B = 12/216
(5.5%), AB= 6/216 (2.7%) and O= 132/216 (61.1%) which is statistically
signiﬁcant (p 0.05). Rh factor was also related to H. pylori infection
(p = 0.514). H. pylori could not be related with smoking (p = 0.075).
Excessive tea consumption was related to H. pylori infection.
Conclusion: This study demonstrates that H. pylori infection can be
related to ABO blood group, age, gender and even lifestyle. People of
blood group O are more prone to develop infection related gastritis,
ulcers, and even perforations, so they should be cautious against
transmission of it. Although there was no correlation found with smoking
in this study, other studies have shown otherwise. We suggest that there is
a need for making aware people to promote healthy life style, especially
after knowing their own health condition and demography.
H. pylori infection association with ABO blood group (n = 558).
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P1167 A foodborne norovirus outbreak in a healthcare facility,
Austria, 2009
H.W. Kuo °, M. Hell, S. Kasper, I. Lederer, F. Allerberger, D. Schmid
(Vienna, Salzburg, AT)
Objectives: A foodborne norovirus outbreak occurred in a health care
facility in Austria, from March 15 to March 27, including a total of
167 cases. Six out of ten cases tested were positive for norovirus. With
a maximum of 91 cases on March 17, the pattern of the outbreak spread
indicated foodborne origin, followed by a person-to-person spread. The
kitchen was disinfected on March 17, and it can be assumed that 114
resident-cases with disease onset from March 16 to March 18 were
suspected to be foodborne. A case-cohort study was performed among
the residents of the affected premises to test the hypotheses that exposure
to speciﬁc food items served on March 14, 15 and 16 was associated
with increased risk of norovirus infection.
Methods: Out of the cohort-at-risk, including 510 residents who were
exposed to food at least on one of the three risky days (March 14, 15
and 16), 274 persons were randomly selected regardless of the disease
status for the reference-group. The study subjects were interviewed
by self-administered questionnaire or face-to-face interviews on their
exposure to food items served on the risky days. Out of the 388 study
subjects, 350 responded to the questionnaire (response rate: 90%) and
therefore remained for the case-cohort analyses.
Results: The analyses revealed that consumption of a particular cold
cut (sausage) served on March 15 (OR= 3.98, 95%CI: 1.18−14,
p = 0.0166), a soup served with sliced bread (OR= 1.88, 95%CI: 1.11–
3.18, p = 0.0176), a meat dish with rice and salad (OR= 2.03, 95%CI:
1.16–3.55, p = 0.0112), and a rolled pancake ﬁlled with spinach served
on March 16 (OR= 1.72, 95%CI: 1.03–2.88, p = 0.037) were associated
with increased risk of a norovirus infection (Table 1).
Conclusion: Each of these epidemiologically identiﬁed risk-associated
food items could have been easily contaminated with norovirus during
preparation. Out of the 26 kitchen staff-members tested, 11 were positive
for norovirus. Out of these, 5 kitchen staff members − who stated
to have been asymptomatic − were on duty during the weekend prior
to the outbreak. Repeated training of food handlers working in health
care facilities in hand hygiene and environmental disinfection, and the
implementation of the concept of hazard analysis and critical control
points are indispensable to prevent foodborne norovirus outbreaks in
health care facilities.
Table 1. Food items associated with increased risk of norovirus infection,
odds ratio (OR) and 95% conﬁdence interval (95%CI)
Food items Univariable analyses
OR 95%CI p
March 15 breakfast
Particular cold cut (sausage) 3.98 1.18−14 0.0166
March 16 lunch
Soup served with sliced bread 1.88 1.11–3.18 0.0176
Meat dish with rice and salad 2.03 1.16–3.55 0.0112
March 16 dinner
Rolled pancake ﬁlled with spinach 1.72 1.03–2.88 0.037
P1168 High mortality following norovirus enteritis in hospitalized
elderly patients
L. Gustavsson °, L.M. Andersson, M. Lindh, J. Westin (Gothenburg, SE)
Objectives: Norovirus (NoV), particularly genogroup II (GII), is the
leading cause of epidemic gastroenteritis in high-income countries. NoV
may contribute to excess mortality in the elderly and chronically ill.
The objective of this study was to retrospectively describe the all-cause
mortality following NoV infection in hospitalised patients.
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Methods: All hospitalised adult patients with a stool sample positive
for NoV GII by PCR treated at Sahlgrenska University Hospital,
Gothenburg, Sweden, from August 2008 through June 2009, were
included. Patient ﬁles were reviewed and subjects characterised by
age, sex and concurrent medical conditions (immune suppression,
renal failure, diabetes, heart failure, malignancy, systemic inﬂammatory
disease or other signiﬁcant chronic illness). Deaths up to 90 days
following the time of positive sampling were noted. In-hospital as well
as 30- and 90-day mortality was calculated. c2 test was used to compare
proportions. A p-value <0.05 was considered signiﬁcant.
Results: 606 patients were initially included in the study. There were no
deaths among patients less than 60 years old during the study period and
these were not included in further analysis. The remaining 539 patients
were aged 60 to 101 years, with 58% females. Sixty-two percent were
diagnosed with at least one underlying condition. Total mortality rates in-
hospital, within 30 and 90 days were 5.9%, 8.5% and 16.7%, respectively.
Mortality rates increased with increasing age (see table). Total mortality
rates were higher in patients with underlying conditions listed above, as
compared to patients without these conditions (all ages combined: 10.5%
vs. 5.3% at 30 days, p< 0.05; 21.6% vs. 8.7% at 90 days, p< 0.001).
However, when looking at the age group >90 years isolated (n = 106),
this difference was not seen.
Conclusion: We found considerable all-cause mortality, in chronically
ill as well as in otherwise healthy elderly patients, within the 90 days
following a NoV infection, suggesting that NoV may cause excess
mortality in these patients.
Age (y) Patients (n) 30-day mortality (%) 90-day mortality (%)
60−69 63 1.6 11.1
70−79 108 5.6 13.1
80−89 262 9.2 16.8
90+ 106 14.2 23.6
P1169 Hospital-based phylogenetic analysis of noroviruses isolated
from children with acute gastroenteritis in Iran
Z. Fazeli Bavandpour, A. Moradi, N. Baghaie, S.A. Nadji ° (Tehran, IR)
Objectives: Noroviruses are the most important cause of acute
gastroenteritis worldwide. Phylogenetic analysis revealed that the
noroviruses could be divided into ﬁve genogroups (GI, GII, GIII, GIV
and GV). The genogroups are further classiﬁed according to amino acid
sequences from the capsid gene. The aim of the study was to determine
the prevalence and analysis of norovirus phylogeny in children with acute
gastroenteritis admitted to NRITLD, Iran.
Methods: A total of 47 fecal samples were collected from children
up to 17 years of age, with acute gastroenteritis from 2006 to 2008
in Masih Daneshvari hospital in Tehran, Iran. For screening, nested
PCR were performed to amplify sequences of the RNA polymerase
region. The positive samples were re-ampliﬁed by using the region D
primer sets (genogroup speciﬁc for GI and GII). 8 positive samples were
subjected to sequencing for VP1 (D region) gene region. Phylogenetic
and molecular evolutionary analyses were conducted using MEGA
version 3.1.
Results: The mean age of the study subjects was 30.26±28.61 (SD)
months (range 3–120). The gender ratio (male: female) was 1.47. The
Norovirus was detected in 21.3% of the subjects. Statistical differences
were not observed in gender, age group and seasonal distribution
of noroviruses. All isolates were identiﬁed as genogroup GII. The
phylogenetic analysis revealed that 7 samples belong to genotype GII.4
and only 1 sample belongs to genotype GII.3 (Figure 1). There were 95–
100% sequence identity at the amino acid level and 89.5–99.5% identity
at nucleotide level among GII.4 isolates.
Conclusions: Our results show that noroviruses, after rotaviruses,
are indeed a major cause of acute gastroenteritis in children and
genogroup GII, mainly GII.4 genotype, is the most common type.
P1170 Aetiology of diarrhoea in patients at a university hospital
in Sarajevo, Bosnia and Herzegovina
A. Dedeic-Ljubovic °, M. Hukic, I. Salimovic-Besic, D. Bekic, M. Babic,
S. Arapcic, S. Ramadani (Sarajevo, BA)
Objectives: A prospective study was carried out to investigate the
commonest etiologic agents of diarrhea for all ages from hospitalized
patients.
Methods: Stool samples from 890 patients (adults and pediatric) with
diarrhea admitted to the clinical center university of Sarajevo, Bosnia
and Herzegovina from May 01 to October 31, 2009 were collected
and processed for viral, bacteral, parasitic and yeast examination using
standard methods.
Results: Overall, in 51% (458/890) of patients a potential pathogen
is identiﬁed. A viral cause was found in 26% (233/890), bacterial
in 17% (151/890), parasitic in 6.8% (24/890) and yeast in 5.6%
(50/890) of cases. The occurrence of enteropathogens identiﬁed
was as follows: rotavirus (151/458) 33%, Salmonella (122/458)
26.6%, with Salmonella enteritidis as the most common, astrovirus
(54/458) 11.8%, diarrhoeagenic Escherichia coli (20/458) 4.3%, with
enteropathogenic E. coli (EPEC) 044:K74, and enterohaemorrhagic
E. coli (EHEC) O103:K- as the most common; Entamoeba histolytica
(15/458) 3.2%, adenoviruses (9/458) 2%, Giardia lamblia (7/458) 1.5%,
Campylobacter spp., Clostridium difﬁcile toxin A+B and Shigella sonnei
(3/458) 0.65%. No Yersinia enterocolitica was isolated. 9.4% of patients
had mixed infection with two viral agent. Mixed viral and bacterial
infection occured in 4% of patients. Most diarrheal episodes of viral and
diarrhoeagenic E. coli etiology occured during the ﬁrst three years of life.
10% (50/458) of patients with primarily non-gastrointestinal infection
had elevated Candida counts in the stool. The majority of these patients
were on antibiotic treatment. The most common species were Candida
albicans and Candida glabrata. Salmonella and Shigella isolates were
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tested for their susceptibility to common antimicrobial agents and most
of the isolates were sensitive to all tested antimicrobials.
Conclusion: This study demonstrated that rotavirus and Salmonella
were signiﬁcant enteropathogens. This study also, conﬁrms that
diarrhoeagenic E. coli is important causal agent of diarrheal diseases
in pediatric patients in Bosnia and Herzegovina. Our results also suggest
that antibiotics make an important contribution to the incidence of the
elevated Candida counts in the stool from patients with diarrhea.
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P1171 Brain damage in foetuses congenitally infected by
cytomegalovirus
L. Gabrielli °, M.P. Bonasoni, S. Lega, D. Santini, F. Baccolini,
G. Piccirilli, A. Chiereghin, E. Petrisli, B. Guerra, G. Gardini,
M.P. Landini, T. Lazzarotto (Bologna, Reggio-Emilia, IT)
Objectives: Cytomegalovirus (CMV) is the major infectious cause of
congenital abnormalities in the central nervous system due to intrauterine
infection in humans, with an average incidence of approximately 1.0%
live births. The aim of this study was to understand the histopathogenesis
of cerebral damage in 27 foetuses with congenital CMV infection
documented at 20−21 weeks gestation by invasive prenatal diagnosis
(amniotic ﬂuid CMV culture and PCR positive with a viral load
>105 GE/ml). All pregnancies were electively terminated at 22 weeks
gestation.
Methods: Foetal sections were studied with haematoxylin and eosin
staining and immunohistochemistry for CMV early antigen (ppUL44)
and leukocyte common antigen CD45. Inﬂammatory inﬁltrate in the
brain was characterized by immunohistochemistry for CD68PGM1,
CD20, CD3, CD4, CD8 and granzyme B.
Results: All of the foetuses had a disseminated CMV infection.
Inﬂammatory inﬁltrate was almost always present in CMV-infected
foetal organs and the severity of the inﬂammatory response was
correlated with the organ damage. Six out of 15 CMV-positive brains
showed mild inﬂammatory response without necrosis and only mild
telencephalic leukencephalopathy. Four CMV-positive brains showed
a moderate CD45-positive inﬂammatory response associated with
focal microglial nodules and telencephalic leukencephalopathy. The
inﬂammatory response in the remaining ﬁve CMV-positive brains
was severe and associated with diffuse cerebral damage such as
cortical necrosis, polymicrogyria and periventricular leukomalacia.
Characterization of inﬂammatory inﬁltration revealed the presence of
activated CD8 T lymphocytes around cytomegalic cells often associated
with apoptotic bodies. Diffuse chronic villitis with necrosis was found
in all of the placentas of foetuses with severe brain damage.
Conclusion: Brain damage seems to be the results of a combined
effect of viral infection and inﬂammatory inﬁltration with activated CD8
T-lymphocytes. The hypoxia due to severe placentitis may be a further
way in which CMV could damage the foetal brain.
P1172 Cytomegalovirus infection in neonatal intensive care units
A. Senok °, S. Al-Khawaja, A. Ismaeel, G. Botta (Sharjah, AE;
Manama, BH; Udine, IT)
Background: Human cytomegalovirus (HCMV) infections are among
the most prevalent viral infections worldwide with rates of congenital
infections varying in different populations. This study was to determine
the prevalence of congenital and perinatal HCMV infections among
newborns in two major neonatal intensive care units (NICU) in
Bahrain.
Methods: Preterm and term babies admitted to the NICU during the
study period (February-June 2006) as well as their mothers were included
in the study. During the ﬁrst six weeks of life, urine and saliva was
obtained from the babies weekly and serial breast milk samples were
obtained from the mothers. Maternal serum HCMV IgG was measured.
Virus isolation and detection was by shell vial culture and nested PCR.
HCMV infection was diagnosed in infants with virus excretion detected
by both methods on at least two occasions or in two different specimen
types.
Results: A total of 100 newborns (84 preterm; 16 term) and their
mothers were included in the study. Maternal HCMV IgG-seropositivity
was 100%. Congenital HCMV infection was conﬁrmed in 3 newborns
(preterm 2/84; 1.9%; term 1/16; 6.3%). HCMV DNA was detected in
the breast milk samples obtained during the ﬁrst 10days postpartum
from mothers whose babies had congenital HCMV. Among breast milk
samples collected 4−6weeks post-partum 22.5% were HCMV DNA
positive. It was determined that ﬁve pre-term babies acquired perinatal
infections via HCMV positive breast milk at 4−6weeks postpartum.
There were no signiﬁcant difference in the detection of HCMV using
shell vial culture versus nested PCR method.
Conclusion: Our ﬁndings suggest that neonatal ICU care should include
neonatal HCMV screening to detect the infection during early postnatal
period. Shell vial culture and PCR ampliﬁcation represent rapid and
sensitive methods can be used for diagnosis of suspected congenital
HCMV infections.
P1173 Prevention of cytomegalovirus disease in transplant
recipients. Evaluation of real-time PCR CMV, clinic
correlation and cutoff determination of pre-emptive therapy
C. Martı´n-Gandul °, E. Cordero, M. Sa´nchez, V. Cabello, J. Fijo,
C. Bernal, E. Lage, F. De la Cruz, M. Aguilar, M.J. Rodriguez,
E. Garcı´a for the Spanish Network for Research in Infectious Disease
Objectives: Preemtive therapy guided by threshold viral replication
allows optimizing cytomegalovirus (CMV) infection therapy. There is
not a standarised and validated cut off point to guide preemptive CMV
therapy in organ transplant patients. The aims of this sudy are: 1. To
study the correlationship between CMV viral load and the spectrum of
CMV infection in transplant recipients. 2. To set up a cutoff point of
CMV viral load to start preemtive therapy.
Methods: A prospective cohort study was performed from october 2008
to june 2009. Every trasplant recipients with viral replication detected by
PCR CMV were included. SPSS V15.0 was used for descriptive analysis
and G-Stat 2.0 for analysis by ROC (Receiver Operating Characteristics)
curves of sensitivity and speciﬁcity in the full spectrum of cutoff points
in the over range of observed results.
Results: One hundred and twenty patients were included: 104 solid
organ transplant recipients (28 liver, 63 renal, 1 liver-renal, 11 heart)
and 16 allogeneic hematopoietic stem cell transplant recipients. Median
age was 53 years (range 9−73), 64.7% were male and 16.6% were at high
risk for CMV infection. There were 7 episodes (5.83%) of CMV organ
disease (four gastritis, one colitis, one duodenitis, one pneumonitis and
retinitis), 6 episodes (5%) of viral syndrome and 107 episodes (89.17%)
of asyntomatic infection. Fifty-two patients (43.3%) received preemptive
therapy. The median CMV copies at the start of therapy was 4325 copies
/ml, interquartile range (1662.50 to 9265). After assessing the different
cutoff points by ROC curves, 2130 copies/ml was deﬁned as the best
cutoff point for early therapy initiation, with speciﬁcity 94.67%, sensitivy
84.62%, negative predective value 99.37% and positive predictive value
9.09%. The area under the curve (AUC) ROC of 87.9% represents a
high accuracy in the diagnostic test.
Conclusions: 1. Real time PCR CMV is an effective predictive dignostic
test to guide preemptive therapy. 2. 2130 copies /ml is deﬁned as the best
cutoff point for starting preemptive therapy. 3. A cutoff point higher than
5000 and 10000 copies/ml as suggested in the literature is not acceptable
in our experience because there were lower levels of CMV replication
in a signiﬁcant proportion of patients with CMV organ disease. 4. New
studies are needed to validate this cutoff point in a external cohort.
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P1174 Diagnosis and screening for congenital CMV infection
in pregnant women in Cuba as prognostic markers of
congenital cytomegalovirus in newborns
C. Correa, V. Kouri, D. Verdasquera, P.A. Martinez °, A. Alvarez,
Y. Aleman, L. Perez, J. Viera, R. Gonzalez, E. Perez, I. Moro,
M. Navarro, P. Melin (Havana, CU; Lie`ge, BE)
Objective: Human cytomegalovirus (HCMV) has established itself as
the most signiﬁcant cause of congenital infection in the developed
world, leading to mental and developmental retardation. The objective
of this research was to identify pregnant women and newborns at risk
of developing congenital infection due to HCMV.
Methods: A diagnostic algorithm utilizing Immunoglobulin G (IgG),
IgM, and, IgG avidity was used to prospectively screen serum from 1131
pregnant women enrolled from three municipalities from Havana City,
Cuba during 2007–2008. Qualitative nested PCR and quantitative Real
Time-based PCR testing of DNA from urine and saliva were performed
on women detected with active infection and their newborn. The
identiﬁcation of different clinical, demographical and epidemiological
factors was associated with the virological results, aiming to identify
prognostic markers of congenital infection.
Results: The majority of women were seropositive to HCMV (92.7%),
with 2.38% (27 women), having active infection (IgM positive or IgG
seroconversion). Primary infection was detected in 20 pregnant women
(1.77%) while 7 patients (0.62%) had active non primary infection.
HCMV DNA was found to be positive in 9 of the 27 pregnant
women. CMV congenital infection was diagnosed in 12 (1.06%) of
the 26 children born from mothers with active infection, for a vertical
transmission rate of 46.2%. Two newborns were symptomatic at birth and
two showed sequels during the follow up until 6 month age. It was found
that mothers with primary or non-primary active infection had signiﬁcant
risk, RR: 1.11 and RR: 1.16, respectively, to have congenital infected
children, furthermore, women with active infection showed signiﬁcant
risk (RR: 1.35) to have congenitally infected children.
Conclusions: It constitutes the ﬁrst study of diagnosis and screening
for congenital HCMV infection in pregnant women and their newborn
in Cuba, demonstrating high prevalence rates, although there is an
important group of women at risk to acquire infection during pregnancy
and produce congenital infection on their offspring. Prenatal diagnosis,
and early identiﬁcation and follow up of congenital CMV infected infants
are important for the conﬁrmation and/or deﬁnition of the medical
conduct with the positive infant, trying to avoid or reducing some
possible sequels.
P1175 Prenatal diagnosis of congenital cytomegalovirus infection
and outcome in 598 pregnant women undergoing a primary
cytomegalovirus infection
T. Lazzarotto °, L. Gabrielli, F. Baccolini, B. Guerra, C. Puccetti,
M. Lanari, A. Chiereghin, E. Petrisli, G. Piccirilli, M.P. Landini
(Bologna, IT)
Objectives: PCR detection of cytomegalovirus (CMV) in amniotic ﬂuid
(AF) will differentiate uninfected from infected fetuses in mothers with
primary CMV infection. Ultrasound has the advantage of not being
invasive and will disclose any structural and/or growth abnormalities
caused by CMV infection, but its sensitivity is poor.
Methods: This study describes a cohort of 598 pregnancies at risk of
CMV transmission in utero of which 598 were tested by AF sampling
followed by Real Time assay (target region: UL123) (Q-CMV Real Time,
Nanogen Advanced Diagnostics, Italy). PCR results were reported as
number of DNA copies per mL of AF.
603 AF samples were collected at 20−21 weeks gestation and at least
6−8 weeks after the onset of maternal CMV infection. Outcome was
fully documented in 545 newborns and 59 fetuses.
Results: Fewer than 500 copies were detected in 497 AF samples.
No congenital CMV infection was identiﬁed in 468 cases, while 29
newborns were infected without symptoms at birth or during subsequent
monitoring. 59 infected fetuses and 48 newborns were found in 106 AF
samples with >500 copies.
A total of 77 newborns were CMV infected, 20 were symptomatic and
57 asymptomatic. Among symptomatic and asymptomatic newborns,
the mean viral load was signiﬁcantly higher in symptomatic newborns
(P = 0.023) (mean values 2.1×106 vs 8.7×104).
The 59 infected fetuses were classiﬁed as having histological damage
in the brain and in 2 or more organs (group 1) or having histological
damage only in 2 or more organs (group 2).
When qPCR disclosed more than 106 copies/mL of AF, 60.7% of fetuses
had disseminated infection and brain damage (group 1) against 39.3% of
fetuses with disseminated infection alone (group 2). When viral load in
AF was between 105 and 106 copies only 40% of fetuses were classiﬁed
in group 1 that includes certain cases of more severe infection.
Conclusion: Negative PCR in AF at 20−21 weeks gestation and at least
6−8 weeks after maternal infection excludes congenital CMV infection.
Positive PCR in AF at 20−21 weeks gestation and at least 6−8 weeks
after maternal infection identiﬁes CMV infected fetuses.
Low viral loads (<500 copies/mL) in the AF, sampled at the appropriate
times, may be a good indicator for ruling out fetal damage. High viral
loads may be associated with symptomatic or asymptomatic congenital
infections, but the highest values tend to indicate more severe infection.
P1176 Multicentre evaluation of the CMV IgM assay on the family
of Access® immunoassay systems
L. Grangeot-Keros, C. Vauloup-Fellous, N. Gaidot, M. Rawlins,
N. Groleau, J. Ritchie, C. Darte, F. Bouniort °, M. Olson (Clamart, FR;
Salt Lake City, US; Marnes-la-Coquette, FR; Atlanta, US; Marseille,
FR; Nyon, CH; Chaska, US)
Objectives: The human cytomegalovirus (CMV) is a member of the
Herpesviridae family. CMV is transmitted person-to-person via close
non-sexual contact, sexual activity, breastfeeding, blood transfusions,
and organ transplantation. CMV infection is a serious concern for
women of child-bearing age because it is a leading cause of hearing and
vision loss, as well as mental retardation among congenitally-infected
children. Detection of CMV-IgM antibodies is only the ﬁrst step in the
differential diagnosis and conﬁrmation of active CMV infection. The
Access® CMV IgM assay is a two-step enyzyme immunoassay using
paramagnetic particles coated with inactivated CMV antigen, alkaline
phosphatase-conjugated sheep polyclonal anti-human IgM antibody and
chemiluminescent signal detection.
Methods: Access CMV IgM assay reproducibility was evaluated at three
centers using a panel of eight samples with varying degrees of reactivity
and two quality control materials (negative and positive). Five replicates
of each sample were analyzed each day for seven days to obtain at
least ﬁve days of valid data. Concordance (percent agreement) with
the bioMe´rieux VIDAS* and the DiaSorin Liaison* CMV IgM assays
was evaluated at one site. De-identiﬁed residual non-selected samples
from adult males, as well as adult pregnant and non-pregnant females
(n = 1,485) who had CMV IgM serology testing ordered were analyzed
using Access2 Immunoassay Systems.
Results: At the cut-off (1.0 S/CO), within site total %CV ranged
from 4.9% to 8.8%. The initial overall agreement (excluding equivocal
samples) of the Access CMV IgM assay with the VIDAS CMV IgM
assay was 99% (95%CI, 98% to 99%). The initial overall agreement
(excluding equivocal samples) of the Access CMV IgM assay with the
Liaison CMV IgM assay was 98% (95%CI, 97% to 99%).
Conclusion: The Access CMV IgM assay provides excellent concor-
dance with the comparison methods. The assay can aid in the diagnosis
of CMV infection and may be used to assess the serological status of
pregnant women with the advantage of a rapid, automated random-access
immunoassay system.
*All trademarks are property of their respective owners.
† Pending submission to and clearance by the United States FDA, not
yet available for diagnostic use in the U.S.
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P1177 Measurement of CMV speciﬁc IgG avidity by
Architect2000SR
D. Malotova °, J. Trbusek (Sternberk, Prague, CZ)
Objectives: Human cytomegalovirus (HCMV) is a member of the
Betaherpesviridae subfamily. HCMV is the common cause of intrauterine
infections and congenital abnormities. CMV also represents a serious
threat to immunodeﬁcient or immunosuppressed patients. Measurement
of CMV speciﬁc IgG avidity has proven to be a powerful tool for
distinguishing primary from non primary CMV infection.
The aim of our pilot study was to evaluate the new diagnostic test and
get into everyday praxis.
Methods:40 patients with positive IgG antibodies were examined for IgG
avidity. The samples were measured by instrument Architect 2000SR
from company Abbott Laboratories. The Architect CMV IgG Avidity
assay is a modiﬁed chemiluminescent microparticle immunoassay for
determination in serum or plasma and is called Architect AVIcomp assay
technology.
Results: From our group had 5 low IgG avidity and 35 high IgG avidity.
We compared it with diagnoses and clinical symptoms. After this pilot
study we have started this test to make in routine praxis.
Conclusion: Presence of high avidity IgG excludes the possibility that
infection occurred within the previous 4 months. Low IgG avidity is
a reliable indicator of infection within the previous 6 to 8 months.
Architect 2000SR is only one fully automated instrument for CMV
avidity testing.
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P1178 Epidemiology of high-risk human papillomavirus infections
and associated cervical lesions in women over 30 years of
age in St. Petersburg, Russia
E. Zolotoverkhaya °, E. Shipitsyna, D. Kuevda, O. Shipulina,
I. Kostyuchek, A. Savicheva (St. Petersburg, Moscow, RU)
Objectives: The study aimed to determine the prevalence of high-risk
human papillomavirus (HR HPV) types and associated cervical diseases
in Russian women over 30 years of age, as well as to identify socio-
demographic, behavioral and clinical predictors of HR HPV infection,
with a view to consider implementation of HPV-based strategies in
cervical cancer prevention in Russia.
Methods: Consecutive women aged 30 to 65 years (n = 823), not
pregnant and with no history of treatment for high-grade cervical
intraepithelial neoplasia (CIN), receiving routine gynaecological care
in the outpatient department of the D.O. Ott Research Institute of
Obstetrics and Gynaecology, St. Petersburg, Russia from June 2008 to
April 2009 were enrolled. Cervical swabs were evaluated for cytological
abnormalities and HR HPV types using Hybrid Capture 2 (HC2)
assay with subsequent genotyping of HC2 positive samples with real-
time PCR. Women with cytological abnormalities higher than atypical
squamous cells of undetermined signiﬁcance (ASCUS) and those who
were positive for HR HPV were referred to colposcopy and biopsy
conﬁrmation.
Results: Infection with HR HPV was present in 108 (13%) women.
Cytological abnormalities were found in 81 (9.8%) patients, including
59 (7.2%) women with ASCUS, 21 (2.5%) with low-grade squamous
intraepithelial lesions (LSIL), and one (0.1%) with high-grade SIL. In
one patient with normal cytology and positive HR HPV test biopsy
showed high-grade CIN and in one patient with LSIL and positive HR
HPV test biopsy showed invasive cancer. Of the 59 patients with ASCUS,
48 (81.4%) were HR HPV negative. The prevalence of HR HPV infection
was highest (18.6%) among women aged 30−34 years and lowest (7.8%)
among those aged 55 years or older. HPV DNA was less likely to be
found in women who have been pregnant more than once and those
who have been given live birth at least once. The only highly signiﬁcant
predictor of HR HPV infection was having symptoms of a urogenital
infection. The most common HPV types were HPV 16 (31%), HPV 31
(21%), HPV 52 (13%), and HPV 33 (11%).
Conclusion: The present study emphasizes the importance of implemen-
tation of new cervical screening protocols in Russia that would include
testing for HR HPV. Moreover, this study provides data on baseline
distribution of different HPV types before the introduction of vaccination
against HR HPV.
The work was supported by Award RUB1–4026-ST-08 of the U.S.
Civilian Research & Development Foundation.
P1179 Prevalence of human papillomavirus in anal samples of
homosexual men
G. Gabilondo Alvarez °, B. Romero, T. Hellin, J. Chacon, I. Sanz,
M. Mateos (Madrid, ES)
Objective: Persistent infection of human papillomavirus (HPV) is related
to a higher risk of developing anal intraepithelial lesions and anal cancer.
The aim of this study was to determine the prevalence of high
risk genotypes of HPV (HR-HPV) and its association with human
immunodeﬁciency virus.
Methods: 54 anal samples from 51 homosexual men were included in
this study. The range of age was 20−65 years (media 38.5 years) and
23 of them were from HIV positive. All patients were attended in the
Sexual Transmitted Diseases (STD) Unit of the Ramon y Cajal Hospital
from June to November 2009. Anal samples were collected with cervical
brushes (Cervix-Brush ®) and stored in PreservCyt ® medium. An anal
cytology using the Bethesda classiﬁcation and HPV genotyping (Linear
Array®, Roche Diagnostics, Mannheim, Germany) were performed in
all samples.
Results: Cytological results were obtained from 45 of the 54 samples.
In the remaining 9, cytological results could not be evaluated due to an
insufﬁcient cellularity. The cytology result was normal in 31.5% (17/54),
ASCUS in 7.4% (4/54), LSIL in 31.5% (17/54), HSIL in 7.4% (4/54)
and ISIL in 5.5% (3/54). HPV was not detected in 16.6% (9/54), being 5
normal, 1 LSIL and 3 not valuable. HPV-51 and HPV-73 were the most
frequent genotypes found (22.2%, 12/54); HPV-31 was found in 18.5%
(10/54) and genotypes 16 and 18 were found in only 12.9% and 9.2%
respectively. Mixed co-infections were seen in 64.8% (35/54), ranging
from 1 to 9 different HR genotypes in the same sample. The overall
prevalence of HR-HPV was 74% (40/54); 78.3% (18/23) in the samples
from HIV+ patients, and 70.9% (22/31) in the negative ones.
Conclusions: The results suggest that HR-HPV 51 and 73 are the most
prevalent in anal samples of homosexual men in our series. Genotypes
16 and 18 were not so frequently found as expected. This data must
be considered for vaccine administration. Mixed co-infections were
frequently observed. We could not ﬁnd any differences in prevalence
of HR-HPV genotypes between HIV positive and negative patients. The
follow up of these patients is very important to prevent anal cancer.
P1180 Relation between E6/E7 transcripts expression and clinical
and viro-immunolgical parameters in HIV/HPV co-infected
women
G. Orlando °, M. Fasolo, E. Casolati, M.R. Gismondo, C. Antonacci,
F. Mazza, S. Rimoldi, E. Omodeo Zorini, R. Beretta, P. Pileri,
F. Pagano, A. Agarossi, N. Zanchetta on behalf of the GISPAP
(Gruppo Interdisciplinare per lo Studio delle Patologie Associate
al Papillomavirus)
Introduction: HIV infected women have a higher oncogenic risk when
infected from HPV. Cancer screening and follow up with conventional
cytology or HPV typing need to be revisited due to the high prevalence
of mild conditions, the high sensitivity of DNA assays and the different
pattern of regression/progression in immunocompromized if compared
to immunocompetent people. Factors involved in progression to pre-
invasive and invasive lesions are virus and host dependant but, once the
HPV genome has integrated in host cell, an over-expression of the HPV
E6 and E7 genes can be detected.
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Here we want to evaluate the correlation between HPV E6 and E7
expression with clinical and immuno-virological parameters to verify
clinical performance of this test in the triage of HIV infected women.
Methods: HIV/HPV co-infected women included in the GISPAP cohort
(L Sacco University Hospital, Milan − Italy) have been included in
this analysis. Pts have been evaluated with cytology, HPV genotyping,
HPV E6/E7 mRNA analysis, colposcopy and biopsy of suspected
lesions; CDC stage of HIV infection, HIV RNA, CD4 and antiretroviral
treatments were collected from clinical records of the patients.
Results: Among 150 HIV/HPV co-infected women included in this
analysis, 209 high and low risk HPV genotypes were identiﬁed, HPV-
52, 16 and 66 being the most represented. Pap smears were neg for
cytological lesions in 81 patients, ASC in 3 pts, LSIL in 48 pts and
HSIL in 12 pts, unavailable in 6 pts. Colposcopic evaluation in 61 pts
revealed 21 abnormal patterns. Biopsies performed in 18 pts revealed 3
CIN-1, 5 CIN-2, 2 CIN-3 and 8 were neg for intraepithelial lesions.
E6/E7 test was positive in 68 (45.33%) of the cases. In a univariate
logistic regression model, HR genotypes, LSIL or HSIL, ANTZ1−2,
CD4 <200 and multi-experienced for antiretroviral treatment patients,
are strongly related to HPV E6/E7 mRNA expression (tab 1).
Discussion: E6/E7 mRNA expression is highly predictive of HPV related
lesions in HIV infected women. However, in severely immunosuppressed
patients and antiretroviral multiexperienced patients the odds ratio of a
positive result for mRNA transcripts is 8 and 4 timer higher respectively,
thus suggesting an important role of host interaction in promoting HPV
integrated onchogenic evolution.
Table 1. Clinical and immuno-virological parameters and odds ratio of
HPV E6/E7 positive results
Variable E6/E7 mRNA
(Npos/N neg)
Fisher’s
exact test
OR 95%CI
CDC stage (78 pts)
A 6/9 1
B 17/20 0.76 1.27 0.38 to 4.31
C 16/10 0.21 2.40 0.65 to 8.81
CD4 (138 pts)
>500 14/28 1
200–500 37/44 0.2471 1.682 0.7736 to 3.656
<200 12/3 0.0025 8.000 1.936 to 33.06
HIV RNA (138 pts)
<50 44/58
50–500 7/4 0.2186 2.307 0.6351 to 8.378
>500 12/13 0.4810 1.896 0.4412 to 8.147
TARV (141 pts)
No 6/8 1
Yes 59/68 1.0000 1.157 0.3795 to 3.527
ARV regimen experienced (81 pts)
0 6/8 1
1−2 10/6 0.4642 2.222 0.5136 to 9.616
3−5 6/10 1.0000 0.8000 0.1849 to 3.462
>5 22/6 0.0362 4.889 1.216 to 19.66
HPV genotypes (204 genotypes)
LR 30/41 1
HR 81/54 0.0186 2.050 1.144 to 3.674
Cytology (144 pts)
NEG/inadequate 25/56 1
ASC 1/2 1.0000 1.120 0.09695 to 12.94
LSIL 31/17 0.0002 4.085 1.917 to 8.704
HSIL 9/3 0.0074 6.720 1.675 to 26.96
Colposcopy (61 pts)
NTZ 11/29 1
ANTZ1 10/4 0.0091 6.591 1.706 to 25.47
ANTZ2 7/0 0.0005 38.48 2.027 to 730.3
Biopsy (18 pts)
Neg 4/4 1
CIN 1−2−3 8/0 0.0769 17.00 0.7373 to 392.0
Other STI* (81 pts)
Yes 38/36 1
No 2/5 0.4321 0.3789 0.06906 to 2.079
*STI: 1 HSV, 4 candida, 2 bacterial vaginosis. Boldface type indicates statistically signiﬁcant results.
P1181 E6/E7 expression in the triage of HIV-HPV co-infected
patients
G. Orlando °, R. Beretta, A. Agarossi, S. Rimoldi, C. Antonacci,
F. Mazza, N. Zanchetta, F. Pagano, M. Fasolo, P. Pileri, E. Omodeo
Zorini, E. Casolati, M.R. Gismondo on behalf of the GISPAP
(Gruppo Interdisciplinare per lo Studio delle Patologie Associate
al Papillomavirus)
Objective: Anal and cervical HPV related infections occur frequently
in HIV infected pts and progression to invasive lesions depends both on
HPV types and on host immune response. HPV E6/E7 genes are over-
expressed in high-grade lesions and cancers as a consequence of HPV
integrated cycle. Detection of E6/E7 mRNA could be a speciﬁc marker
for high-grade disease and cancer.
We want to evaluate the rate of HPV E6/E7 mRNA expression according
to cytology, CD4 cells and HIV-RNA in anal and cervical samples in HIV
positive persons to deﬁne the potential effectiveness of this molecular
approach in the primary screening of such pts.
Methods: E6/E7 mRNA expression was assessed by APTIMA® HPV
assay (Gen-Probe Inc, San Diego, CA, USA) in 235 (85 anal and 150
cervical) samples of HIV pos Males and Females included in the GISPAP
cohort − L Sacco Univ Hosp (Milan-Italy). Cervical and anal cytology
was evaluated according to Bethesda system 2001. HIV related immuno-
virological data were collected from clinical records.
Results: Diagnoses on cytology were: 85 neg, 5 inadequate, 3 ASC, 109
LSIL, 27 HSIL.
Proportion of E6/E7 expression was 81.48%, 73.39% and 30.95% in
HSIL, LSIL, and neg respectively (c2 test p< 0.0001). Decreasing rates
of mRNA expression in HSIL, LSIL and neg samples were conﬁrmed
when analysed according to site of infection (anal or cervical), HIV RNA
and CD4 levels. Severely immunosuppressed pts (CD4 <200/microL)
expressed E6/E7 in higher proportions when compared to pts with higher
CD4 levels with 75% of E6/E7 expression also in neg samples.
High sensitivity/NPV and low speciﬁcity/PPV in identifying HSIL was
assessed for any different group analysed (tab 1).
Conclusion: The molecular approach for HPV screening is aimed to
reduce over-treatment of low-grade and, often, transient abnormalities by
increasing speciﬁcity and PPV. Expression of E6/E7 mRNA is generally
strongly associated with the severity of histological diagnosis while
negative results, when 14 HPV genotypes are targeted, could have a
high NPV.
In HIV infected pts we found a very low speciﬁcity and PPV of E6/E7
mRNA test in identifying HSIL lesions thus preventing its use as primary
screening test to reduce the second level assessment need. The meaning
of E6/E7 expression in LSIL or neg samples, could be the sign that the
shift toward the integrated cycle has already begun and, added to other
screening tools, could identify pts with the highest risk of progressive
disease.
Table 1. Sensitivity, speciﬁcity, positive and negative predictive values
of HPV-mRNA detection in predicting HSIL
p Sensitivity
(95%CI)
Speciﬁcity
(95%CI)
Positive predictive
value (95%CI)
Negative predictive
value (95%CI)
Likelihood
ratio
All the patients 0.0031 0.81 (0.62–0.94) 0.50 (0.43–0.58) 0.20 (0.13–0.29) 0.94 (0.88–0.98) 1.64
Anal samples 0.72 0.87 (0.59–0.98) 0.22 (0.12–0.34) 0.21 (0.11–0.33) 0.87 (0.62–0.98) 1.11
Cervical samples 0.0655 0.75 (0.43–0.94) 0.57 (0.48–0.65) 0.14 (0.065–0.25) 0.96 (0.89–0.99) 1.73
Patients with
CD4 <200/mL 1.0000 1.00 (0.16–1.00) 0.13 (0.02–0.40) 0.13 (0.02–0.40) 1.00 (0.16–1.00) 1.15
CD4 200–500/mL 0.0371 0.85 (0.54–0.98) 0.47 (0.37–0.58) 0.18 (0.09–0.30) 0.96 (0.85–0.99) 1.606
CD4 > 500/mL 0.0385 0.89 (0.52–0.99) 0.49 (0.37–0.61) 0.17 (0.08–0.31) 0.97 (0.86–0.99) 1.73
Patients with
HIV viral load <50 copies/mL 0.0127 0.87 (0.59–0.98) 0.48 (0.39–0.57) 0.16 (0.09–0.26) 0.97 (0.89–0.99) 1.66
HIV viral load 50–500 copies/mL 0.5286 1.00 (0.29–1.00) 0.31 (0.09–0.61) 0.25 (0.05–0.57) 1.00 (0.4–1.00) 1.44
HIV viral load >500 copies/mL 0.3783 0.83 (0.36–0.99) 0.44 (0.28–0.60) 0.18 (0.06–0.37) 0.95 (0.74–0.99) 1.49
Boldface type indicates statistically signiﬁcant results. Likelihood ratio deﬁned as sensitivity/(1.0 − speciﬁcity).
P1182 Detection and typing of human papillomaviruses in
malignant, dysplastic, non-dysplastic and normal oral
epithelium by nested polymerase chain reaction
E. Blioumi, D. Chatzidimitriou °, C. Pazartzi, T. Katopodi,
G. Tzimagiorgis, A. Melidou, E. Emmanouil-Nikoloussi, A. Markopoulos,
N. Lazaridis, Z. Skouras, E. Diza, D. Antoniades (Thessaloniki, GR)
Introduction: Studies on human papillomaviruses (HPV) participation
in initiation and progression of oral neoplasia have generated conﬂicting
results. Speciﬁcally, HPV infection in oral carcinomas ranges from 0%-
100% and in the normal oral cavity from 0−60%.
Aim: This study aims at the detection of the HPV DNA in
oral carcinomas, dysplastic leukoplakias, non dysplastic leukoplakias,
ﬁbromas and normal mucosa by nested polymerase chain reaction
(nested-PCR) and the correlation of HPV presence with other factors
obtained from the patient’s records, such as histologic diagnosis, gender,
age, anatomic location, smoking and alcohol drinking.
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Material and Methods: 258 formalin-ﬁxed parafﬁn-embedded tissues
(63 carcinomas, 57 leukoplakias with dysplasia, 53 leukoplakia without
dysplasia, 50 ﬁbromas and 35 normal tissues) were deparafﬁnised, After
DNA extraction, a nPCR was performed using primers targeting the HPV
L1 gene; in the ﬁrst step MY09/11 and in the second step GP5+/GP6+.
Positive PCR products were sequenced for further HPV typing.
Results: HPV was detected in 22.2% of carcinomas, 31.5% of
dyspalsias, 35.8% of non-dysplastic leukoplakias, 40% of ﬁbromas and
40% of normal mucosas. HPV 16 was detected in 90% of positive
samples. Statistical analysis with X2 and pearson correlation test shows
signiﬁcant negative correlation between HPV prevalence and age. No
signiﬁcant correlation was detected between HPV prevalence and gender,
histological diagnosis, histological grading, location, smoking or alcohol
drinking.
Conclusions: HPV was detected in all study groups, though in normal
tissues more often than dysplastic or malignant. This fact does not
exclude nor conﬁrm the participation of HPV with the early stages of
oral carcinogenesis.
P1183 Immunohistochemical expression of Ki67, C-erbB-2 in
inﬁltrating duct carcinoma of the breast. Does C-erbB-2
cooperate with human papillomavirus in breast carcinoma
pathogenesis?
R. Harfoush °, N. Kamel (Alexandria, EG)
Objectives: Breast cancer encompasses a heterogeneous group of
neoplasms. Recently, studies have been suggesting that some types
of viruses might be involved in the pathogenesis of breast cancer
especially the human papilloma virus (HPV). Several factors can
predict the biological behavior and clinical outcome of breast cancer:
proliferation index, over expression of oncoprotein C-erb B2, tumor
size and grade of malignancy. Our aim was to investigate the presence
of low/intermediate/high risk types of HPV (DNA and/or antigen) in
association with the immunohistochemical expression of C-erbB2, and
Ki-67 as prognostic markers and to correlate the intensity of expression
with tumor size, grade and lymph node status.
Material and Methods: The present study included 20 retrospective
cases of inﬁltrating duct carcinoma of the breast. All samples were
analyzed for the presence of HPV DNA of 32 HPV types using
HPV LCD-Array Kit (HPV type 3.5), subjected to H&E staining
and immunohistochemical staining using HER2/neu, ki67 and HPV
antibodies.
Results:The gene sequences speciﬁc for HPV types were not detected.
Positive immunohistochemical expression of HER2/neu (3+) was
detected in 7 cases (35%), 6 cases (30%) were equivocal (2+), and
7 cases (35%) were considered negative (1+, 0). Positive immunohis-
tochemical expression of Ki 67 was detected in 15 out of 20 studied
cases (75%). A statistical signiﬁcant relation was detected between
immunohistochemical expression of HER2/neu (2+, 3+) on one hand.
and increasing age (P = 0.0012), increasing size of tumor (P = 0.041), and
high grade (P = 0.02) on the other hand. A statistical signiﬁcant relation
was detected between moderate to strong Ki-67 immunohistochemical
expression on one hand and increasing age (P = 0.012), and increasing
grade (P = 0.01) on the other hand. A statistically signiﬁcant relation
was detected between positive and equivocal immunohistochemical
expression of HER2/neu and increasing positivity of Ki 67 (P = 0.026).
Conclusion: Our analysis was not able to support a role of HPV
infection in breast cancer. It was therefore not possible to establish a
correlation between the oncogene expression of c-erbB-2 and the HPV-
DNA types. However, HER2 status might be incorporated into a clinical
decision along with other prognostic factors, regarding whether to give
any adjuvant systemic therapy. The usage of ki67 immunohistochemical
stain as a prognostic marker is not recommended.
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P1184 The HIV-1 protease L10I minor mutation decreases
replication capacity and confers resistance to saquinavir
F. Flor-Parra, A. Perez-Pulido, J. Pachon, P. Perez-Romero ° (Seville, ES)
Objectives: The objective of this study was to characterize the HIV
protease minor mutations of low prevalence, L10I and L10V, the highly
prevalent minor mutations, M36I and L63P, and the major mutations
D30N and I84V and their impact on viral ﬁtness, cytophatic effect and
resistance to protease inhibitors.
Methods: We studied the prevalence of the protease mutations L10I,
D30N, M36I, L63P and I84V, in treatment-naı¨ve patients and patients
receiving ART. To study their effect on RC, cell-killing and resistance
to PIs the mutations were introduced by directed mutagenesis into the
provirus pNL4.3ren. A structure prediction of the protease carrying the
L10I mutation was determined by molecular modeling.
Results: The prevalence of the major mutations D30N and I84V was low
in naı¨ve patients with 0% and 0.6% respectively, and it was signiﬁcantly
higher in treated patients with prevalences of 2.6% to 5.8%, respectively.
The prevalence of the minor mutations M36I and L63P in naı¨ve patients
was signiﬁcantly higher compared to major mutations, 28.1% and 48%
respectively and decreased in treated patients to 16.7% and 43.9%,
respectively. Interestingly, the prevalence of the minor mutation L10I
had a pattern similar to that found for major mutations, with a low
prevalence in naı¨ve patients and a signiﬁcantly higher in treated patients,
4.9% and 12.9% respectively. Furthermore, viruses carrying the major
mutations D30N or I84V or the minor mutation L10I showed a 90%
decrease in RC, while viruses carrying the minor mutations M36I or
L63P had RC similar to wild type (wt) virus. Cells infected with the
virus carrying the L10I mutation showed 50% less cytophatic effect
than wt virus infected cells at 4 days post-infection. In addition, the
L10I mutation confered complete resistance to saquinavir and partial
resistance to lopinavir. Molecular modeling of the protease carrying the
L10I mutation suggests that L10I affects the conformation of Leu23, a
critical residue in the substrate binding site.
Conclusions: The L10I mutation impairs RC and confers resistance
to saquinavir and lopinavir, similarly to other major mutations. These
effects may be related with changes in the binding site of the protease,
since the L10I mutation appear to affect the conformation of Leu23.
P1185 Genotyping analysis of the protease and reverse transcrip-
tase of newly diagnostic (naı¨ve) HIV-1 non-B patients
E. Papadimitriou °, A. Papoutsi, L. Skoura, B. Haidich, S. Metallidis,
P. Kollaras, P. Nikolaides, N. Malissiovas (Thessaloniki, GR)
Objective: The aim of this study was the identiﬁcation of treatment-
related mutations in non-B strains which might be relevant for resistance
to current antiretrovirals.
Methods: 215 naı¨ve subjects, reported to the National AIDS Reference
Laboratory of Northern Greece between 2000–2008, were included in the
study. The naı¨ve non-B patients had never been exposed to antiretroviral
drugs. Genotyping resistance testing was performed at the time of
diagnosis with a sequence-based assay (TruGene Genotyping Kit −
Siemens). 235 sequences from naı¨ve subjects infected with subtype B
HIV-1 virus were used as controls for comparison with those from naı¨ve
non-B individuals.
Results: The distribution of subtypes among the 215 non-B patients was
as follows: 151 A (70.23%), 34 CRF01/AE (15.81%), 12 other CRFs
(02/AE, 02/B, 04) (5.58%), 9 G (4.18%) and 9 C (4.18%).
34 of 215 patients harboured a virus with at least one mutation associated
with a phenotypic resistance. 5/215 with mutations to protease inhibitors,
especially D30N, M46IL and N88D. 7/215 with mutations associated
with resistance to nucleoside reverse-transcriptase inhibitors(NRTIs)
especially M184V and K219QE. 22/215 with mutations to non-
nucleoside reverse-transcriptase inhibitors (NNRTIs), especially K103N,
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Y181C and V179D. Most of the mutations were revealed from sequences
from subtype A.
Conclusion: Our results suggest that NNRTI-resistance mutations were
more prevalent than either NRTI mutations or PI mutations, underlying
the importance of genotyping resistance testing in HIV-1 non-B patients
before starting treatment.
P1186 Analysis of the mutations associated to integrase inhibitor
resistance in subtype B and non-B human immunodeﬁciency
virus type 1
O. Turriziani °, C. Montagna, F. Falasca, G. Russo, M. Bucci,
F. Graziano, P. Maida, K. Monteleone, L. Antonelli, G. Antonelli
(Rome, IT)
Objective: The integrase inhibitors (e.g. Raltegravir) are a new class of
antiretroviral drugs that have recently become available for the treatment
of HIV patients. The emergence of mutations that confer resistance to
the integrase inhibitors has been observed and characterized but viral
polymorphisms at the integrase gene caused by immune selection and/or
associated with non-subtype B is not completely understood. Here we
plan to study the genotypic resistance pattern associated to integrase
inhibitor resistance in plasma-HIV RNA derived from B and non B
HIV-1 infected individuals.
Methods: Thirty integrase inhibitors naı¨ve HIV-1 infected patients were
studied. Twenty non-B HIV-1 samples were collected from patients
from Cameroon and 10 subtype-B HIV-1 samples derived from Italian
patients. RNA was extracted from 140 mL of plasma using a QIAmp
Viral RNA kit (Qiagen, Milan, Italy) following the manufacturer’s
instructions. Sequencing was undertaken using CLIP, a DNA sequencing
technique for direct sequencing of small quantities of ampliﬁed template
(Open Kit-TruGene HIV-1, Siemens Healthcare Diagnostics).
Results: Among the 20 non B strains the subtype, the distribution was
as follows: 10 subtypes CRF02_AG, 3 subtypes CRF02_AE, 3 subtypes
D, 1 subtype CRF11_cpx, 1 subtype F2 and 2 subtypes G. No major
mutations associated with resistance to integrase inhibitor were detected
in HIV-1 subtype B samples. On the contrary major mutations were
found in non-B subtype samples. Speciﬁcally, 25% of samples showed
Y143 H/R/C mutation (4 CRF02_AG and 2 CRF02_AE) and at the same
position the Y143S polymorphism was detected in all non-B strain except
in subtype F and G. Interestingly in 1 sample belong to subtype G the
Q148H pathway (Q148H+E138A+G140S) was found. Other mutations
detected at the resistance sites were E92D and E157G/K. E92D was
found in 10% of subtype B samples and in 5% of non-B strains (1
CRF11_cpx). E157G/K was detected in 10% of B subtype and in 10%
of non-B subtype (1CRF01_AE and 1 CRF02_AG).
Conclusions: These ﬁndings indicate that integrase inhibitor resistance
mutations can be detected in non-B subtype patients in the absence of
drug exposure. This underlies the need for studies to further evaluate the
role of integrase inhibitors mutations in the management of HAART in
HIV patients.
P1187 Genotypic and phenotypic resistance to reverse
transcriptase inhibitors among 102 Cambodian children
with AIDS treated with HAART
I. Beldjebel °, V. Krcmery, J. Benca, M. Utesena, V. Noskova,
J. Sokolova, J. Chomroun, A. Shahum, L. Rabarova, P. Slavikova
(Phnom Penh, KH; Bratislava, Trnava, SK)
Objectives: The aim o this study is to describe few failures on 1st
line highly active antiretroviral therapy (HAART) in children treated
since 2003 in Phnom Penh, St. Maximillian Kolbe Tropical Pediatric
Clinic and asses the efﬁcacy of second line treatment among the ﬁrst
line failures.
Methods: We analyzed 102 children infected by HIV in age 4–16
years in our orphanages in Phnom Penh, Cambodia in 2003–2009 on
genotypic resistance as cause of 1st line failure and for adherence to
HAART, virologic, clinical and immunologic response to HAART. CD4
cells were investigated once per 3 months and viral load in 6 months
interval. Genotypic/phenotypic resistance tests were performed in case
of clinical or immunological failure by National Pediatric Hospital
laboratory afﬁliated to Institute Pasteur Cambodge, Phnom Penh.
Results: Mortality on AIDS and AIDS related opportunistic infections
in our group of 102 children was less than 3%, only tree children
died in 2003–2009. Two died even before the onset of therapy, one
at the beginning of HAART. The rest 98 children were treated with
HAART from 18 to 72 months: 7 of 99 (7%) failed between 15 to
36 months. As a failure we considered, when CD4 count decreased (2
measurements within 6 months) and viral load (VL) showed increasing
tendency (>1000 copies/ml). Only VL increase (without immunologic
correlate 1 child) or only CD4 decrease (discordant failure 2 children)
was not considered as indicator for replacement of the 1st line. Most of
the children failed on stavudine (d4T) + lamivudine (3TC) + nevirapine
(NVP), which was replaced by abacavir (ABC) or didanosine (DD1)
or zidovudine (ZDV) or tenofovir (TDF) with protease inhibitors (PI) −
lopinavir/ritonavir (LOP/RIT) or efavirenz. Commonest mutations of the
reverse transcriptase among NRTI’s were M184V (5 children), V75M (3
children), and T215Y, among NNRTI commonest mutations were K103N
(2 childeren) and K101E (2 children). Those who failed on 1st line were
treated by TDF, ABC or ZDV and DDI. DDI was still left in the NRTI
backbone with TDF or ZDV or ABC plus PI was added.
Conclusion: Prevalence of deaths (3%) and virological/immunological
failures (7%) among our group of children in Cambodia within 6 years of
follow up were low. Probably high proportion of those receiving efavirenz
(90%) versus nevirapin (8%) due to concomitant anti-TB therapy for
tuberculosis may explain our 7% failures rate (after 6 years follow up).
P1188 Characterization of vpr gene of HIV-1 subtype A variant
prevailing in Russia
I. Lapovok °, E. Kazennova, V. Laga, M. Bobkova (Moscow, RU)
Objectives: The HIV-1 viral protein R (Vpr) has a great number of
activities associated with reverse transcription, nuclear import of pre-
integration complex, cell cycle progression, regulation of apoptosis, HIV
5′-LTR transactivation. It makes Vpr an attractive target for antiretroviral
therapy.
There are numerous reported mutations in vpr gene associated with
secondary structure changes and altered protein functions. For example,
Vpr carrying W54R has high mutation rate in reverse transcription
process that may reduce the viral reproduction. Mutations E25K, I63K,
Q65E and L67S impair host cell nuclear localization and accumulation
of Vpr. Mutations L64P/A/R dramatically enhance Vpr pro-apoptotic
potential. Mutation I61A has the contrary effect.
The aim of work was to study vpr gene of HIV-1 subtype A variant
prevailing in Russia for the presence of possible peculiarities in Vpr
structure and activity.
Methods: 45 samples of peripheral blood mononuclear cells from HIV-
infected individuals have been studied. The analysis of gag and env
genes proved the belonging of all the specimens to HIV-1 A subtype.
The sequence analysis of vpr gene derived from all the specimens was
carried out followed by the comparison to sequences and consensuses of
other group M HIV-1 subtypes. All sequences have then been used for
the phylogenetic analysis.
Results: All sequences of vpr gene studied in this work clustered with
the HIV-1 subtype A isolates from Russia and Ukraine. We revealed no
mutations in vpr gene previously found to be associated with changes of
Vpr activities. Additionally, we showed the high rate of polymorphism
of C-terminal region of Vpr protein, for example in position 89.
Conclusion: The results of phylogenetic analysis conﬁrmed the
statement about the link between HIV pandemic in Russia and Ukraine.
HIV-1 Vpr protein of the variant prevailing in Russia has no mutations
potentially inﬂuencing the functions of this protein.
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P1189 Trends of transmitted antiretroviral resistance among
patients newly diagnosed with HIV infection in Taiwan
Y. Tseng °, C.L. Lu, C.C. Hung, M. Chen, S. Hsieh, W.H. Sheng,
S.Y. Chang (Taipei, TW)
Objectives: We aimed to determine the prevalence and trends of
antiretroviral drug resistance among newly diagnosed HIV-1-infected
patients who were antiretroviral-naive from 1999 to 2009.
Methods: Blood samples collected from 934 HIV-1-infected patients
were subjected to genotypic assays using nested reverse transcription-
PCR ampliﬁcation of a 1.2-kb fragment encompassing the protease gene
and the ﬁrst 240 amino acids of the RT gene. Drug resistance mutations
were identiﬁed in accordance with the drug-resistance mutation list of
the International AIDS Society-USA Consensus Guidelines. Prevalence
of antiretroviral resistance was compared among three study periods:
period 1, 1999 to 2003 (n = 424); period 2, 2004 to 2006 (n = 362); and
period 3, 2007–2009 (n = 208).
Results: Of 934 patients with a median age of 32 years, 65.5% of the
patients were men who have sex with men (MSM), while heterosexuals
and injecting drug users accounted for 15.8% and 11.9%, respectively.
The median CD4 was 240 cells per cubic millimeter and plasma HIV
RNA load was 5.02 log10 copies per milliliter. 77.2% of the isolates
were subtype B and 9.6% CRF07_BC. From period 1 to period 3,
the median CD4 count of the enrolled patients and the proportions of
patients who were MSM and infected with subtype B were increasing
signiﬁcantly. The prevalence of HIV-1 isolates that harbored one or
more primary mutations associated with antiretroviral resistance to either
reverse-transcriptase inhibitors or protease inhibitors was 6.6%, 12.7%,
and 10.1% in periods 1, 2 and 3, respectively. In periods 1, 2, and 3, the
prevalence of resistance to protease inhibitors was 1.2%, 4.4%, and 2.0%,
respectively, while that to non-nucleoside reverse-transcriptase inhibitors
was 2.8%, 5.5%, and 4.7%, respectively; and to nucleoside reverse-
transcriptase inhibitors, 4.5%, 6.1%, 4.1%, respectively. Prevalence of
isolates with multi-drug resistance (resistance to 2 classes or greater)
decreased from 1.7% in period 1 and 2.5% in period 2 to 0.7% in period
3.
Conclusions: Our ﬁndings suggest that the overall prevalence of
antiretroviral resistance to any of the three classes of antiretroviral
agents did not continue to increase in Taiwan over the past 10 years
and the trends of resistance varied with each class of antiretroviral
agents. Compared with period 2, prevalence of isolates with multi-drug
resistance was decreasing in period 3.
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P1190 Antiretroviral treatment and expression of the mRNA levels
for Pgp, MRP1, MRP4 and MRP5 in HIV antiretroviral
naı¨ve patients. Follow-up at 48 weeks
F. Falasca °, F. Graziano, L. Antonelli, P. Maida, C. Montagna,
B. Rizzo, L. Chiavozzo, V. Renda, G. Antonelli, O. Turriziani (Rome, IT)
Aim: The ATP-binding cassette genes represent the largest family of
transmembrane proteins [including multidrug resistant proteins (MRPs)
and P-glycoprotein (Pgp)] able to drive the transport of various molecules
across cell membranes. Several studies have demonstrated that most of
the above transporter are also able to transport antiretrovirals. The aim
of this study was to evaluate whether the antiretroviral treatment might
affect the mRNA expression of Pgp and some MRPs.
Material and Methods: Blood samples were collected from 13 HIV-
positive patients treatment naı¨ve. After the beginning of the treatment,
samples were collected at 12, 24, 36 and 48 weeks. Eight patients
were treated with Kaletra and Truvada (group I) and ﬁve patients with
Efavirenz and NRTIs (truvada or combivir) (Gropu II). Expression of
mRNA of the Pgp, MRP1, MRP4, and MRP5 was evaluated by real-
time-PCR using the TaqMan technology (ABI Prism 7000; Applied
Biosystems).
Results: MDR1 and MRP4 expression was not affected by treatment
with PI and NRTI. In fact, at all time analyzed the mRNA levels of
these transporters did not signiﬁcantly differed from the mRNA levels
detected before the beginning of treatment. As far as MRP1 and MRP5
are concerned, a modest, but not signiﬁcant, reduction in the mRNA
expression levels was observed after beginning of treatment. In patients
belonging to the group II basically the same results were obtained.
Looking at the individual trend of the mRNA expression of the above
transporters in each patient it can be seen that the expression levels of
these transporters seems to change during follow up but it is independent
of type and time of treatment. The expression of the mRNA levels of
these transporters appears to increase in some patients and decrease in
other individuals suggesting that a high interindividual variability in the
modulation of these mRNA does exist.
Conclusions: Antiretroviral treatment does not signiﬁcantly affect the
expression levels of mRNA of transported analyzed. However an
interindividual variability in the expression of these mRNA has been
documented during the follow up and further studies are needed to
evaluate whether the over-expression of these mRNA may affect the
success of therapy.
P1191 Clinical experience in Serbia concerning the effect of
antiretroviral therapy on immunological and virological
outcome in AIDS patents with terminal immunodeﬁciency
I. Pesic Pavlovic, J. Nikolic °, D. Salemovic, J. Ranin, S. Zerjav,
D. Jevtovic (Belgrade, RS)
Purpose of this study was to evaluate efﬁcacy of antiretroviral therapy
(ART) through examination of immunological and virological outcome
in patients with terminal immunodeﬁciency (CD4 <50/mm3). This
retrospective study included subpopulation of ART-naive 171 patients
(29.3% of total population of 582 HIV positive patients) with terminal
immunodeﬁciency, initiated with ART during 1997–2007 at the Clinic
for Infectious and tropical Diseases, Belgrade. Optimal success of ART
was deﬁned as an undetectable HIV RNA (HIV RNA <50 copies/ml
(1.7 log10)), and elevation of CD4 >400/mm3. Therapeutic failure was
deﬁned as HIV RNA >2 log10, despite of possible immunological
recovery. Third possible outcome was dissociation of immunological
and virological response (achievement of optimal suppression of viral
replication without immunological recovery).
Study group included 171 patients (36.8% female, 63.2% male), 36±9
years old, (67.8% were older than 40 years), treated for the duration
3.6±2.1 years (range 1−10 years). Optimal therapeutic outcome was
achieved in 23.2%, dissociative response in 50.4%, and therapeutic
failure was noted in 26.4% (p< 0.05). The outcome was signiﬁcantly
affected by choice of therapeutic protocol, including combinations of all
three classes of medications (p< 0.01).
This analysis suggests that ART can be provided successfully within the
limited choice of medications and when genotype resistance testing is
unavailable.
P1192 ICU mortality, in-hospital mortality as well as long-term
follow-up outcomes are signiﬁcantly improved in
HIV-infected patients admitted to ICU in the HAART era
C.M. Wind, S.F. van Lelyveld °, T. Mudrikova, H.J. van Leeuwen,
D.W. de Lange, A. Hoepelman (Utrecht, NL)
Objectives: Mortality data of patients infected with human immunodeﬁ-
ciency virus (HIV) admitted to an intensive care unit (ICU) in the highly
active antiretroviral therapy (HAART) era are inconsistent and often a
debate arises about the necessity for ICU care of HIV infected patients.
We investigated whether mortality after admission to ICU has changed
since the introduction of HAART.
Methods: In this retrospective cohort study, auto-intoxications and
post surgery patients were excluded (n = 36). Patient characteristics,
laboratory parameters, information of HIV infection and ICU admission
data were collected from medical records. We compared patients
admitted in the pre-HAART era (’91–’96) to those admitted in the
HAART era (’96–’08). The latter group was divided into two cohorts
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(early HAART ’96–’03 and late HAART ’03–’08). Primary outcomes
were in-ICU, in-hospital, 1-year and 5-year all cause mortality.
Results: 127 ICU admissions of 116 HIV infected patients were
included: 47 ICU admissions before and 80 after the introduction of
HAART (’96–’03; 42 and ’03–’08; 38). In the HAART era 36% used
HAART at admission, median CD4+ count was not different (83 versus
60 pre-HAART) and 20% had an undetectable viral load. Baseline
characteristics (pre-HAART vs. HAART) did not show statistically
signiﬁcant differences, except for mechanical ventilation (57 vs. 85%)
and ICU admission indication (neurologic 2 vs. 16%; hemodynamic 30
vs. 8%). Primary outcomes showed a signiﬁcant decrease of in-ICU (47
vs. 31%), in-hospital (60 vs. 45%) and 1-year (74 vs. 50%) mortality.
Moreover, 5-year mortality signiﬁcantly improved in the early HAART,
compared to the pre-HAART era (62 vs. 91%).
Conclusion: This study shows a statistically signiﬁcant reduction in
mortality of HIV infected patients admitted to ICU in the HAART era.
Therefore, there is no reason for excluding HIV infected patients from
ICU care.
P1193 Risk factors of atherosclerotic plaque measured by carotid
Doppler ultrasonography in HIV-infected Koreans receiving
antiretroviral treatment
J. Baek °, S. Han, B. Chin, H.K. Choi, S.Y. Shin, Y. Chae, S. Jin, Y.K. Kim,
C.O. Kim, J.Y. Choi, Y.G. Song, H.C. Lee, J. Kim (Seoul, Wonju, KR)
Objective: Antiretroviral therapy (ART) in HIV infection produces a
spectrum of metabolic complications, including dyslipidemia, insulin
resistance, lipodystrophy. It has been reported that ART is independently
associated with the increase in the rate of myocardial infarction. We
examined the risk factors for the existence of plaque in carotid artery,
which are predisposing conditions of cardiovascular disease, in HIV-
infected Koreans receiving ART.
Methods: Total 137 HIV-infected Koreans who have been treated with
ART during more than 6 months were examined the carotid intima media
thickness (IMT) and plaque existence by carotid doppler ultrasonography
from August 2007 to March 2008 at Severance Hospital, a 2,000-bed
tertiary care university hospital and referral center in Seoul, Korea.
Anthropometric parameters were examined by bioelectrical impedance
analysis and physical examination. The mean of the bilateral maximal
common carotid artery (CCA) IMT was used as the carotid IMT values in
our analyses, because it has been shown to have the strongest association
with cardiovascular risk factors. The atherosclerotic plaques were deﬁned
as localized echo structures protruding from the vessel lumen. Only
lesions for which the thickness was >1mm at either the right or left
CCA were considered as carotid plaques.
Results: Total duration of ART in total participants was 26.9 months.
Carotid plaque was observed in 33 (24.1%) patients. Carotid IMT values
in total patients had signiﬁcantly positive correlations with waist-to-hip
ratio (r = 0.190, p = 0.027), body mass index (r = 0.235, p = 0.006), total
cholesterol (r = 0.201, p = 0.019), LDL cholesterol (r = 0.269, p = 0.005),
total exposed duration of zidovudine (r = 0.247, p = 0.017) after the
adjusting for age. In multivariate logistic regression model, age and
history of hypertension were signiﬁcantly associated with the existence
of plaque (OR 1.09, 95%CI 1.02–1.17, p = 0.018, and OR 10.75, 95%CI
2.06–56.14, respectively). The total duration of HAART or total exposed
duration of each antiretroviral drug did not show any association with
the existence of plaque.
Conclusion: The increased carotid IMT and plaque existence in HIV-
infected Koreans receiving ART were associated with the traditional
risk factors of atherosclerosis known in non-HIV-infected individuals.
The carotid IMT and plaque measurement should be regularly examined
especially in the HIV-infected patients receiving ART with older age to
prevent cardiovascular disease.
P1194 Long-term safety and efﬁcacy of nevirapine-based HAART
C. Hidalgo, B. Alvarez, F. Be´cares, R. Garcı´a Delgado, M. Ferna´ndez
Guerrero, M. Go´rgolas ° (Madrid, ES)
Objectives: To evaluate the safety and efﬁcacy of long term NVP based
HAART in HIV infected patients.
Methods: Retrospective study of 107 HIV infected patients who started
NVP based HAART during 1998, 1999 or 2000, either as a ﬁrst line
therapy or as a simpliﬁcation strategy.
Results: 107p with a mean age of 34.8 years, (81% men and
19% women), 82.2% and 18.8% acquired the infection by sexual
and parenteral route respectively. The reasons to start NVP were:
(a) simpliﬁcation with undetectable viral load from PI based regimen
81p (75.7%), (b) previous PI failing regimen 13p (12.1%) and (c) naı¨ve
13p (12.1%).
Overall, the mean time on NVP based HAART was 63m, median 48m
(range 9–132m). 43p (40.1%) were still on NVP with undetectable
viral load after 104 m (range 12–130m) of follow up. 64p (59.9%)
discontinued NVP due to the following reasons: 1) Structured treatment
discontinuation 27p (25%); 2) Virologic failure 14p (13%); 3) Toxicity
11p (10.2%); 4) Change in treatment strategy 6p (5.6%); 5) Other reasons
6p (5.6%). From baseline to end of follow up the mean increment
of CD4 was 139±241 cells, the mean decrement in triglycerides was
48±178mg/dL, and the mean total cholesterol did not change.
Conclusion: Nevirapine based HAART is a long term (more than
8 years) safe and effective therapy for HIV infected patients. Virologic
failures ocurred in 13% of cases and drug related toxicity in 10.2%.
P1195 Experience of antiretroviral adverse effects in a Malawian
clinic
D. Morrison, C. McGoldrick °, L. Munthali (Aberdeen, UK; Ekwendeni,
MW)
Objectives: A high HIV prevalence exists in Malawi, the world’s third
poorest country, and only a fraction of those needing antiretrovirals
(ARV) receive them. For those who are treated, 1st line therapy consists
of stavudine (d4T), lamivudine (3TC) and nevirapine (NVP). As there
is a perceived risk of adverse effects (e.g. peripheral neuropathy) with
this older-fashioned regimen, our objective was to assess morbidity from
such effects, as well as to assess adherence in one Malawian antiretroviral
clinic.
Methods: An observational study was conducted retrospectively in
November 2008 at Ekwendeni Hospital, Malawi. Using a proforma, data
was collected from ARV clinic notes for individuals with HIV infection,
whose ﬁrst clinic attendance was between January 1st and June 30th
2006. Individuals whose care was subsequently transferred to another
facility were excluded.
Results: 160 individuals were identiﬁed and included (mean age 35.95
years, male to female ratio 0.62:1). 75.6% (121/160) had been taking
their most recent regimen in excess of 730 days. d4T, 3TC and NVP
was the last prescribed regimen in 97.5% (156/160). 1.875% (3/160)
had changed from this to zidovudine (ZDV), 3TC and NVP because of
peripheral neuropathy, and 0.625% (1/160) had changed to ZDV, 3TC
and efavirenz (EFV) for unrecorded reasons. Adverse effects of 1st line
regimens were reported in 30.6% (49/160); 34.7% (17/49) of whom
developed skin rash and 65.3% (32/49) of whom developed peripheral
neuropathy. 95.6% (153/160) continued to work or attend school. Pill
counting showed 90–100% adherence in 64.4% (103/160).
Conclusion: Most individuals were able to continue on ﬁrst line
antiretroviral regimens without change, and to continue to attend school
or work, despite almost one-third experiencing adverse effects (skin rash
or peripheral neuropathy). However, adherence was lower than expected
and this may have resulted from their experience of such adverse drug
side-effects.
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P1196 Differences between healthy volunteers and HIV-infected
patients in the activities of CYP3A, CYP2D6 and
P-glycoprotein
A. Jetter, G. Fa¨tkenheuer, D. Frank, T. Klaassen, A. Lazar,
A. Seeringer, O. Doroshyenko, J. Kirchheiner, W. Hein, E. Scho¨mig,
U. Fuhr, C. Wyen ° (Zurich, CH; Koeln, Ulm, DE)
Introduction: In inﬂammation and infection, cytochrome P450 en-
zyme activities are down-regulated. However, information on possible
discrepancies in activities of cytochrome P450 enzymes and drug-
transporters between HIV-infected patients and healthy people is scanty.
We compared the activities of CYP3A, CYP2D6 and P-glycoprotein
between 12 healthy Caucasians and 30 therapy-naı¨ve HIV-infected
patients using midazolam, dextromethorphan and digoxin.
Material and Methods: A “phenotyping cocktail” consisting of 1.5mg
midazolam (intestinal and hepatic CYP3A), 30mg dextromethorphan
(CYP2D6), and 0.5mg digoxin (P-glycoprotein) administered orally, and
of 1.0mg midazolam intravenously four hours later (hepatic CYP3A
activity), was administered to 30 therapy-naı¨ve HIV-infected patients and
to 12 healthy male controls. Plasma samples were analysed using im-
munoassays for digoxin and LC-MS/MS for all other analytes. Pharma-
cokinetics were calculated noncompartimentally. A parallel-group aver-
age bioequivalence approach was chosen for the comparison between pa-
tients and volunteers. The studies were endorsed by the Ethics Committee
of the University of Cologne, Germany, and conducted in accordance
with the laws of Germany. Written informed consent of each participant.
Results: Overall CYP3A activity (apparent oral midazolam clearance)
was 0.490-fold lower in patients than in healthy volunteers (90%
conﬁdence interval CI, 0.377–0.638). The CYP2D6 activity (plasma ratio
AUCdextromethorphan / AUCdextrorphan) was essentially unchanged
(point estimate 1.289, 90% CI 0.778–2.136). P-glycoprotein activity was
lower in patients (digoxin Cmax point estimate 1.304, 90% CI 1.034–
1.644). Additionally, activity changes after a single dose of ritonavir-
boosted lopinavir in healthy Caucasians were not useful to predict
changes in patients during chronic therapy.
Conclusion: The activities of CYP3A and P-glycoprotein were lower
in HIV-infected patients than in healthy volunteers, but, besides overall
CYP3A activity (roughly 50% lower overall CYP3A activity), differences
were small. The variability within the groups was much higher than
the discrepancy between them It may be prudent to use lower doses of
CYP3A substrates with narrow therapeutic indices in this population.
Single-dose inhibition studies in healthy volunteers are not useful to
accurately predict the interaction potential in HIV infected patients under
chronic therapy.
P1197 Comparative evaluation of two commercial viral load assays
for monitoring human immunodeﬁciency virus type 1 RNA
in plasma: automated NucliSens EasyMAG/EasyQ v.1.2 vs.
High Pure/Cobas Taqman HIV-1
A. Papoutsi °, A. Karava, P. Kollaras, P. Nikolaides, N. Malissiovas
(Thessaloniki, Athens, GR)
Objective: Quantiﬁcation of HIV viral load is used to evaluate response
to antiretroviral therapy and its monitoring. The aim of this study was
to evaluate the NucliSens EasyMAG/EasyQ HIV v1.2 (bioMe´rieux)
in terms of relevance in determination of viral load, reproducibility,
linearity and dynamic range of detection in comparison to the High Pure
Viral RNA kit/COBAS Taqman (Roche Diagnostics) used routinely in
the Northern Greece AIDS Reference lab for the last three years.
Methods: 251 plasma samples were collected randomly from 224
patients attending the HIV Treatment Center at First Pathology Clinic
of the AHEPA University Hospital of Thessaloniki. Fifty four of these
samples were consecutive follow up specimens from 27 individuals. The
majority of the patients included in this study were under antiretroviral
therapy. All viral load values reported according to the limits set by each
assay and the viral detection protocols applied by the manufacturer’s
instructions.
Results: The two techniques showed overall agreement 95.2% (239/251).
The relevance coefﬁcient of samples found positive with both techniques
was found to be r = 0.91 while the reproducibility of both methods was
excellent r = 0.96. No signiﬁcant differences were shown in the dynamic
range of detection for both NucliSens EasyMAG/EasyQ and COBAS
Taqman (2−7 logs). In samples from 27 patients with consecutive follow
up specimens, the mean log difference estimated for each patient with
the two techniques in their consecutive samples was found to be 0.15.
Conclusions: The NucliSens system requested less handling time than
COBAS Taqman (3.6 h vs. 6.1 h for 48 samples). Both quantitative
techniques are found to be equally reliable to be used for accurate
determination of HIV-1 viral load. So, it depends on the discrete
consideration of each laboratory to determine which one should be used,
in terms of clinician and patient convenience, workload and personnel
availability as well as ﬁnancial resources.
P1198 The ﬁrst knowledge, attitude, behaviour and practices
surveillance on HIV/AIDS amongst troops of Indian armed
forces stationed in Jaipur, India
M. Singh, A. Guleri ° (Jaipur, IN; Blackpool, UK)
Background: 2.31 million people are estimated to be living with HIV
in India. While HIV/AIDS is an important medical problem, it has a
considerable socio-economic impact. Indian Armed Forces[IAF] have
a successful containment programme. This ﬁrst knowledge, attitude,
behaviour and practices [KABP] surveillance was undertaken in Sept–
Oct 2008 amongst troops of IAF stationed in the pink city (Jaipur, India).
The objective was to inform strategic planning & consolidation of the
revised local containment programme.
Method: 250 soldiers [randomly selected] responded to the KABP
questionnaire. The entire procedure was explained in native language,
conﬁdentiality assured and verbal consent obtained. The questionnaire
included various aspects of basic knowledge, myths/misconceptions, per-
ception about high-risk behaviour, attitude towards HIV positive patients,
knowledge regarding condom usage, knowledge about HIV/AIDS related
services, etc.
Results: There were 250 male respondents (between 21−55yrs of
age; 82.8% married). The mode of awareness was media (TV/radio/
newspapers) 43.5%; Awareness sessions 17.1% & peer education
sessions 16.9%. Regarding risk of transmission during sex − 17% were
unaware of transmission risk associated with unprotected sex; 27% were
unaware and 10% disagreed potential risk of transmission associated
with unprotected sex with asymptomatic HIV carrier. Regarding condom
usage and safer sex, 57% agree to condom reducing risk during sex
with wife while 43% married women should use condoms with their
husbands; 87% agree to need for single persons to use it with their
partners; 12% disagreed with reduction in transmission risk by correct
and consistent use of condoms. Between 12.8% and 18.4% respondents
were unwilling to co-exist with a HIV positive person (at work, dine
with, domestic help, share house/family member, send child to school
with).
Conclusions: The results of this KABP surveillance were extremely
useful in informing the strategic planning of the local HIV/AIDS
containment programme. We believe that there is no room for
complacency despite commendable programme run by the IAF. Action
plan for stepping up efforts towards environment building and investing
in human resource through aggressive IEC campaigns and training
programs for peer educators. The results reveal negative bias and
lack of empathy for co-existence with HIV positive persons. Human
resource development, enhanced engagement, awareness campaign,
greater transparency and mentoring for more trained peereducators were
included.
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P1199 Designing and biological evaluation of single-cycle replicable
HIV-1 system as a potential vaccine strategy
S.M. Sadat °, R. Zabihollahi, R. Vahabpour, K. Azadmanesh, F. Javadi,
S.D. Siadat, A. Memarnejadian, K. Parivar, H. Khanahmad Shahreza,
R. Arabi Mianroodi, S. Hekmat, M.R. Aghasadeghi (Tehran, Isfahan, IR)
Objectives: Infection with human immunodeﬁciency virus (HIV) is a
spreading world health problem, so a vaccine is desperately needed
to control the AIDS pandemic. Inactive HIV particles may represent
suitable vaccine candidates as they have all the immunogenic structural
and surface antigens in their native forms. Accordingly, several
preclinical studies have already shown that inactive and attenuated HIV
virions can elicit protective humoral and cellular immune responses.
Herein, we designed and constructed a novel HIV-1 virion, capable
of replicating in a single cycle that provides a more immunogenicity,
while prevents any pathologic effects and further evaluated its biological
properties.
Methods: The pmzNL4−3 plasmid, containing the complete HIV
genome of NL4−3 strain with a 2-kb MlsI-digested fragment deletion
in reverse transcriptase (RT) and integrase (IN) genes was constructed,
conﬁrmed by sequencing reactions and transfected into HEK 293T
cell line. By further co-transfection of psPAX2 and pMD2.G plasmids,
which encoded HIV Gag-pro-pol and vesicular stomatitis virus surface
glycoprotein, into the same pmzNL4−3-harboring cells, pseudotyped
virions were produced, evaluated by electron microscopy and quantiﬁed
using P24 end-point ELISA assay. Infectivity of mzNL4−3 virions and
their efﬁciency towards the syncytium formation was evaluated on HIV-
sensitive MT-2 cells.
Results: Despite the occurrence of a designed long deletion within the
RT and IN genes the production of HIV virions was indicated by the
level of P24 protein in culture supernatant of transfected cells and was
further conﬁrmed by electron microscopy. Formation of syncytia in MT-2
cells also evidenced for the functionality of the surface glycoproteins in
produced pseudotyped virions. Interestingly, infectivity analysis veriﬁed
that the second generation virions were completely non-replicative.
Conclusion: While the introduced single cycle replicable (SCR) HIV
system completely maintained the antigenic structures of HIV-1, by
its one cycle replicating properties represented a good implication as a
potential vaccine candidate and this guarantees the further investigations
towards the assessment of its immunogenicity, which are currently under
process. Also, replacement of the deleted fragment in pmzNL4−3 with
various immunostimulatory sequences may present another interesting
approach towards the improvement of its application in HIV vaccine
researches.
P1200 Frequency of CCR5 delta 32 polymorphism and its relation
to disease progression in Iranian HIV-1 positive individuals
B. Moradmand Badie °, H. Najmabadi, G. Esmaeeli Djavid,
P. Kheirandish, F. Payvar, M. Akhlaghkhah, S. Jam, M. Rasoolinejad
(Tehran, IR)
Objectives: The (CC) b-chemokine receptor 5(CCR5) is an important
co-receptor for entry of human immunodeﬁciency virus type 1 (HIV-1)
to CD4+ T cells. Homozygosity or heterozygosity for 32-nucleotide
deletion (delta 32) within CCR5 gene may inﬂuence HIV acquisition and
progression in HIV-1 exposed or positive individuals respectively. In this
study, frequency of heterozygosity for CCR5 mutation in Iranian HIV
positive population was determined and its relation with their disease
progression was evaluated.
Methods: A total of 194 HIV positives patients from a referral health
care center of HIV/AIDS in Tehran, were enrolled in this study in 2008.
The CCR5 delta32 in peripheral blood mononuclear cells was detected
by the polymerase chain reaction (PCR) and gel electrophoresis. The
disease progression was determined based on changes in CD4 cell counts
or clinical presentation of recruited patients.
Results: Eight (4.1%) of all 194 enrolled patients were heterozygous
for (CCR5 delta 32) deletion 32 genotype (wt/del 32). We found no
homozygosity for the mutated (del 32/del 32). One hundred three
patients (42.9%) were in AIDS that through of them, 3 patients were
heterozygote. Although frequency of rapid progression to AIDS was less
in heterozygous individuals (37.5%) than in wild type patients (53.2%),
this difference was not statistically signiﬁcant (p = 0.4).
Conclusion: It seems that prevalence of CCR5 mutation in HIV-1
infected individuals is varying in Iranian normal population and it could
be related to extensive ethnicity variation. Studies on larger population
based on ethnicity may help to clarify the role of this mutation in
progression pattern in Iran.
P1201 Correlation between HIV viral load, increased ﬁbrogenesis
and HCV genotypes among HIV positive patients in Georgia
M. Karchava °, L. Sharvadze, E. Dolmazashvili, A. Abutidze,
L. Gatserelia, N. Dvali, L. Dzigua, T. Tsertsvadze (Tbilisi, GE)
Background: The progression of hepatitis C virus (HCV)-related liver
disease is accelerated in patients infected with HIV. The aim of this study
was to evaluate risk factors for the development of ﬁbrosis in co-infected
patients at baseline visit.
Methods: In a prospective analysis of 249 HCV co-infected patients,
associations between liver ﬁbrosis score, and liver enzime levels, HCV
viral loads, HIV viral loads, HCV genotypes, CD4 counts were assessed.
All analises were done on patients at baseine visit before ART initiation.
Measurement of HIV and HCV RNA viral load was done by COBAS
TaqMan 48 analiser. HCV genotyping was done by reverse hybridization
line probe assay using VERSANT HCV Genotype kit 2.0 respectively.
Transient elastography was performed by Fibroscan (Echosens, Paris,
France). The median value of 10 successful acquisitions, expressed in
kilopascal (kpa) with a success rate of at least 60% is used for liver
stiffness measurement for BMI< 28 and 35% for the liver stiffness
measurement in case of BMI> 28. LS< 5.5 kPa was considered as
ﬁbrosis stage F0-F1 by Metavir, 5.5−8.0 kPa − ﬁbrosis stage F2, 8.0–
10.0 kPa − ﬁbrosis stage F2−F3, 10.0–12.5 kPa − ﬁbrosis stage F3, 12.5–
14 kPa − ﬁbrosis stage F3−F4 and LS> 14.0 kPa − ﬁbrosis stage F4 by
Metavir.
Results: Statistical analysis demonstrated a signiﬁcant correlation
between both ALT and AST levels and HIV viral loads with at least mild
ﬁbrosis. Higher number of HIV viral load, length of HIV infection was
assosiated with the high number of LS. Study revealed no correlations
between CD4 cell counts, HCV viral loads or different HCV genotypes
with ﬁbrosis.
Conclusion: Our study revealed coreletion of HIV viral loads ALT and
AST levels with liver ﬁbrosis. These ﬁndings suggest a direct role for
HIV in development of liver ﬁbrosis as well as high liver enzime levels in
HCV co-infected individual. This ﬁndings support the need to maintain
low HIV viral loads and along the need for initation of HCV treatment
in order to minimize HCV disease progression among HIV infected
patients.
P1202 Prevalence and correlates of co-infection with human
immunodeﬁciency virus and hepatitis C virus in male
injection-drug users in Iran
S. Seyed Alinaghi °, P. Kheirandish, G. Esmaeili Djavid, H. Shirzad,
N. Karami, M. Hosseini, M. Jahani, S. Azimi, F. Payvarmehr,
M. Mohraz, W. McFarland (Tehran, IR; San Francisco, US)
Objective: Aim of the study was to evaluate the HIV and hepatitis C
virus (HCV) coinfection and associated risk behaviours among Injection
Drug Users (IDU) in Detention, Tehran, Iran.
Methods: A cross-sectional survey included 499 male IDU arrested by
police during a predetermined police sweep in Tehran (February, 2006).
At the temporary detention centre, they were screened using a urine
test and a physical examination for injection marks. Those who were
identiﬁed as injectors were sent to the rehabilitation centre for 3 months.
A questionnaire was ﬁlled out for each individual by interview. Blood
specimens were collected for HIV and HCV testing.
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The variables associated with HIV/ HCV coinfection at a signiﬁcance
level of p< 0.10 were considered in multivariate analysis.
Results: Of the 417 participants, 100 (24.0%) had HIV/ HCV coinfection
(95%CI 19.9–28.4). Factors independently associated with HIV / HCV
coinfection included history of using opioid in jail, and age (P< 0.05).
There were not any association between other demographic characteris-
tics (marital status, birthplace, residence and education), type and years
of drug abuse, age of ﬁrst injection, years of injection, sharing needles
inside and outside of jail, injection in jail, history of tattooing, any sexual
behaviour, and history of sexually transmitted diseases (STDs) with HIV
/ HCV coinfection (P> 0.05).
Conclusions: This study supports that incarceration is contributing to
the increased spread of HIV/HCV coinfection. So, there is urgent need
for effective harm reduction programs, particularly among incarcerated
IDU.
P1203 HIV and viral hepatitis (HBV and HCV) among four
vulnerable groups in Lebanon
S. Ramia °, Z. Mahfoud, R. Aﬁﬁ, J. Dejong, K. Kreidieh, S. Shamra,
K. Kassak for the HIV/AIDS Group
Objectives: AIDS-related policies and programs in the Middle East
and North Africa (MENA) region are highly constrained by the lack of
accurate information about the full scale of the HIV epidemic. Recently
we conducted an integrated bio-behavioral surveillance study among four
major vulnerable groups in Lebanon, namely prisoners, men who have
sex with men (MSM), female sex workers (FSWs) and injecting drug
users (IDUs). One of our aims in this study was to provide an estimate
of HIV prevalence as well as an estimate of HBV and HCV prevalence
and their co-infection with HIV in these populations. Furthermore, the
distribution of HCV genotypes was conducted among the anti-HCV
positive IDUs and the immune status of HBV infection was evaluated
among MSM and FSWs.
Methods: Two types of sampling methods were utilized: simple random
sampling for recruiting the prisoners in Roumyeh Prison and respondent
driven sampling to target MSM, FSWs and IDUs. Blood samples were
collected as dried blood spots and then eluted to be tested for HIV, HBV
and HCV by ELISA. Anti-HCV positive IDUs’ samples were subjected
to RNA extraction followed by qualitative detection and genotyping.
Results: A total of 580 prisoners, 101 MSM, 103 FSWs and 106
IDUs participated in study. Prisoners showed a signiﬁcantly higher
seroprevalence of HBV (1.7%) and HCV (3.4%) than reported in the
general population. Only 1 prisoner (0.17%) was conﬁrmed as anti-HIV-
positive. Among the MSM, only 1 (0.99%) was HBsAg carrier and 1
(0.99%) was conﬁrmed anti-HIV positive. No HCV cases were detected
in this population and only 10% of the MSM were immune to HBV.
Regarding FSWs, none were infected with HIV, HBV or HCV and 30%
were immune to HBV. Among IDUs, 56 (52.8%) were anti-HCV-positive
with Genotype 3 the predominant one (57.1%) followed by genotype 1
(21%). 3 (2.8%) IDUs were HBsAg carriers and 1 (0.9%) was conﬁrmed
as anti-HIV-positive. None of the 3 HIV-positive patients was co-infected
with HBV or HCV.
Conclusion: Although HIV does not seem to be a major problem among
the four high-risk groups studied in Lebanon however, HBV and HCV
seem to pose a serious health concern. Our results highlight the urgent
need to raise awareness among prisoners, MSM, FSWs and IDUs and
their health care providers of the availability and beneﬁts of HBV
vaccination in Lebanon. In addition, and due to the absence of vaccines
against HCV and HIV, education programs aiming at behavioral changes
should be intensiﬁed.
P1204 High diversity of HHV-8 molecular subtypes in AIDS-KS
Cuban individuals and its relation with HHV-8 load:
evidence of subtype B expansion
P. Martı´nez °, V. Kouri, Y. Aleman, O. Blanco, V. Capo´, M.E. Rodrı´guez,
M. Dovigny, L. Cardella´, A. Gala, N. Jime´nez, C. Luzardo, C. Correa,
L. Pe´rez, A. Alvarez, U. Hengge (Havana, Dusseldorf, CU)
Objectives: With the aim of investigate the distribution of KSHV
genotypes and its association with diseases pathogenesis, 30 Cuban
AIDS-KS patients diagnosed between 2005 and 2007 were studied.
Methods: Samples of plasma, saliva, peripheral blood mononuclear cells
(PBMC) and affected tissue were obtained for KSHV quantiﬁcation.
KSHV genotyping was performed by the nucleotide sequencing of the
variable ORFK1 gene from tissue samples. Amino acid sequences of
this gene were used to construct a neighbour-joining phylogenetic tree.
The median KSHV viral load (copies/100ng DNA) were 39, 151, 830603
and 143 in plasma, saliva, tissue and PBMC, respectively; being the viral
load from affected tissue and saliva signiﬁcantly higher in comparison
to the other samples.
Results: Phylogenetic characterization of Cuban specimens showed a
wide variety of subtypes [(A: n = 6 (20%), ﬁve being A5 (16.7%); C:
n = 6 (20%); B: n = 10 (33.3%); and subtype E: n = 3 (10%)], showing an
increasing tendency in the incidence of African genotypes (B and A5)
among the new AIDS-KS cases in comparison with previous reported
Cuban KSHV sequences. Interestingly, detection of type B KSHV strains
was associated with higher viral load in tissue and saliva samples
(p< 0.01).
Conclusion: The present result suggests that KSHV subtype B might
have evolve to more efﬁcient transmission over other subtypes among
Cuban AIDS-KS patients, replacing KSHV A subtype that used to be
more frequent before 2006.
P1205 HIV testing in tuberculosis patients in the United Kingdom
M.M. Raza, R. Mukherjee, M. Bhattacharya °, D. Mital (Milton Keynes,
UK)
Objectives: Universal HIV testing is recommended for those diagnosed
with tuberculosis (TB) under the UK National Guidelines for HIV testing
2008. Offering and uptake of such testing is an auditable standard which
is reviewed annually by the Chest/Infectious Diseases team. The audit
was done to ascertain the practice of universal HIV testing in this setting
and to identify measures to improve things if necessary.
Methods: This audit was done in a UK district general hospital and
included all cases of TB notiﬁed for the year 2008. The pathology IT
system was used to identify which cases had an HIV test. Case notes
were then reviewed to establish if the test was offered in cases where a
result was not available and if the test was done as part of diagnostic
work up or routinely after the diagnosis of TB.
Results: 40 cases were notiﬁed and included in the audit. 6 cases were
children and among the adults 2 were never seen by the hospital services
as one was diagnosed post-mortem and one had returned overseas at the
time of diagnosis and 3 were treated in a private clinic and 1 in another
specialist centre. As a result only 28 adult cases were seen in our hospital
clinics and the analysis was limited to them. HIV testing was done and
result documented in 16/28 cases (57.1%). HIV testing result or offer
was documented in 20/28 cases (71.4%). In 50% of cases where HIV
testing was done this was part of their diagnostic work up whereas in
only 25% this was routine testing. Routine HIV testing was offered in
only 8/28 (28.6%) of cases and uptake of routine testing was 62.5%.
Conclusions: HIV testing in adult patients seen in our hospital for TB
is good (71.4% tested or offered) but the offer of routine HIV testing
subsequent to the diagnosis of TB is poor (28.6%) although it’s upatke
is satisfactory (62.5%). To improve the offering and uptake of universal
testing in TB patients (target 100%) we plan to introduce a proforma
for all new TB diagnoses which will include offer of HIV testing and a
patient information leaﬂet to explain HIV testing in this setting.
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P1206 Human immune deﬁciency virus infection in patients
diagnosed at age 50 years or later
F. Almasi ° (Courbevoie, FR)
Objectives: Age related immune deﬁciency is a well known entity.
Having considered this fact, immune deﬁciency due to HIV infection
may be more severe in older patients.
Methods: A retrospective observational study in registered HIV infected
patients in order to review epidemiologic, clinical, laboratory data and
response to treatment in patients diagnosed at age of 50 or older.
Results: Among 1680 registered HIV infected patient there are 91 HIV
infected patients who found their HIV positive situation at age of 50−74,
aged 50−84 years. There are 22 women (24%) and 69 men (76%). HIV
transmission risk factor Is homosexual-bisexual contact in 44% of cases,
heterosexual contact in 44%, blood and blood product transfusion in 2%
and unknown risk factor in 10% respectively.
49 patients (54%) were asymptomatic (stage A of CDC), 16 patients
(17.5%) symptomatic non-C(Stage B) and 26 patients (27.5%)present
AIDS diﬁning condition(stage C). CD4 count before treatment ranged
between 4 and 754, as a mean 226 cells/ml. 35 patients (38.5%) present
low CD4 count (less than 200) and 15 patients (16.5%) with CD4 less
than 100 cells /ml.
79 patients (87%) are treated and 12 patients (13%) untreated including
1 patient with indication of treatment.
After treatment CD4 count ranged between 10 and 1511, as a mean 511.
CD4 count before and after antiretroviral treatment was increased (285).
After treatment there were 14 patients with viral load more than 500
copies /ml including 8 untreated patients. It means 6 patients (7.6%)
under treatment in virologic failure. There are 9 patients (11%) with
detectable viral load but less than 500 copies/ml.
Conclusion: 76% of diagnosed patients at age of 50 or later are
men. Male-female ratio is 3/1. Homosexual-bisexual contact is still an
important risk factor in patients diagnosed at age 50 or more.
Age related immune deﬁciency in patients older than 50 is an important
factor. Mean CD4 count was 226 in spite of 54% asymptomatic patients
(stage A). It means that this group of patients is more immune deﬁcient.
After antiretroviral treatment there is pretty increase in CD4 count, it
means a nice immunologic response.
Virologic response after treatment is as well as young even better may
be because of better observance.
P1207 Patients with newly-diagnosed HIV in 2004 versus 2008: no
apparent difference in progression
A. Brown °, C. Nı´ Bhuachalla, C. de Gascun, R. Hagan, C. Bergin
(Dublin, IE)
Objectives: Trends have recently been observed suggesting more rapid
progression in newly-diagnosed HIV-positive patients. This data is
limited by an inability to speciﬁcally identify time of infection. Our HIV-
positive cohort displays heterogenous acquisition risk and signiﬁcant
immigration from countries of high prevalence, and is ideal to study
changing epidemiology.
Methods: A retrospective cohort study was undertaken comparing
newly diagnosed HIV patients attending in the ﬁrst half of 2004
with those in 2008. Baseline demographics, laboratory and virological
parameters were gathered. Progression was followed for the ﬁrst year
after diagnosis. Patients with known seroconversion were of particular
interest − including those who were certain of time of infection, who
recalled signiﬁcant seroconversion illness and/or a negative test within
the preceding 6 months. Others with previous negative tests outside this
window were not designated as known seroconverters. Rapid progressors
(RPs) were deﬁned as those with documented seroconversion window
<2 years prior to presentation, who progressed to CD4 350 cells/mm3
within ﬁrst year of follow-up. Results were analysed using Fisher’s exact,
c2, student t tests and two-tailed p values with GraphPad InStat.
Results: Of the 200 charts reviewed 96 met inclusion criteria. Forty-two
from 2004 and 54 from 2008 were analysed. Baseline characteristics are
summarized in Table 1. CD4 350 cellls/mm3 at ﬁrst presentation in
2004 and 2008 respectively was seen in 20 (48%) and 31 (57%) p = 0.42.
CD4 count 350 by end of year 1 was 25 (60%) vs 35 (65%) p = 0.67.
Mean change in CD4% from diagnosis to end of year 1 or pre-ART was
−2.9% (SD5.1) vs +7.2% (SD 11.0) p< 0.0001 (95%CI −13.7718 to
−6.4882). AIDS-deﬁning illness in ﬁrst year was seen in 6 (14%) vs 7
(13%) p = 1.0. Of those with CD4 350 cells/mm3 at ﬁrst presentation,
18 (82%) vs 18 (78%) maintained CD4 350 cells/mm3 at end of year 1
untreated. Of those with known seroconversion window <2 years, rapid
progression was seen in 3/7 in 2004 and 9/20 in 2008 (p = 1.0).
Conclusions: In a diverse group of HIV patients, there was no difference
in progression to CD4 <350 cells/mm3 in the ﬁrst year of attendance
between 2004 and 2008 cohorts. Deﬁnite knowledge of time of infection
eliminates the bias of late presentation in assessing true progression.
Further large-scale prospective studies should focus on progression from
seroconversion and minimising late presentation.
Baseline characteristics 2004 2008
Age (yrs)
Mean 32.2 34.5
SD 7.41 12.7
% male 64 62.9
Country of origin (%)
Sub-Saharan Africa 38 41
Europe 62 52
Other 0 7
Acquisition (%)
Heterosexual 45 57
IVDA 36 6
MSM 19 26
Other 0 5
Subtype
A 5 6
B 45 46
CRFs 2 15
Other/Unknown 48 33
CD4 at diagnosis (cells/mm3)
Mean 402 425
SD 291 433
Known seroconversion (%) 19 43
Coinfections (%) 62 61
P1208 Uninfected children born to HIV-infected mothers: no
evidence of impaired immune function at 15 months of age
L. Kolte °, V. Rosenfeldt, L. Vang, D. Jeppesen, I. Karlsson, L. Ryder,
K. Skogstrand, S. Nielsen (Hvidovre, Copenhagen, DK)
Objectives: With the increasing number worldwide of uninfected
children born to HIV-infected mothers, any health problem that they may
have, even of minor character, may be an enormous health challenge
especially in developing countries. HIV-exposed uninfected (HIV-EU)
infants present haematological and immunological abnormalities at birth
including low CD4 counts and reduced thymic output, and it remains to
be clariﬁed if these abnormalities persist beyond infancy.
Methods: Twenty HIV-EU children at 15 months of age and 10 age
and sex matched controls were enrolled. Total and naive CD4 and CD8
counts, immune activation and regulatory T-cells (Tregs) were measured
by ﬂow cytometry. Thymic output estimated as CD4+ cells containing
T-cell receptor excision circles (TRECs) was determined by PCR.
Cytokines (interleukin (IL)-1b, IL-2, IL-4, IL-6, IL-8, IL-10, interferon-
gamma, transforming growth factor-b) were analyzed using Luminex
Technology, and Haemophilus Inﬂuenzae Type B (Hib) vaccination
responses were measured by ELISA.
Results: CD4 and CD8 counts did not differ between HIV-EU and con-
trol children, neither did thymic output estimated as CD4+ cells express-
ing naive (CD45RA+CD62L+CD27+, P = 0.31) or recent thymic naive
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(CD45RA+CD27+CD31+, P = 0.13) phenotype, or CD4+ cells contain-
ing TREC’s (P = 0.47). HIV-EU children and controls had similar levels
of activated cells (CD4+CD38+HLA-DR+, P = 0.87; CD8+CD38+HLA-
DR+, P = 0.22), Tregs (CD4+CD25+CD127lowFOXP3+, P = 0.53)
and naive Tregs (CD4+CD25+CD127lowFOXP3+CD45RA+CD27+,
P = 0.65). Finally, comparable levels of Hib protective antibodies in the
two groups were found (P = 0.43).
Conclusion: The study indicates that immune deﬁcits in HIV-EU
children are not long-term, and compared to children born to HIV-
negative mothers HIV-EU children have neither quantitative nor
qualitative immunological abnormalities at 15 months of age.
P1209 Prevalence of hyperphosphaturia and of proximal renal
tubular dysfunction and their associated factors in
HIV-infected patients, ANRS CO3 Aquitaine Cohort, 2009
F.A. Dauchy °, S. Lawson-Ayayi, C. Rigothier, F. Bonnet, G. Miremont-
Salame´, S. Delveaux, N. Mehsen, C. Greib, F. Dabis, M. Dupon for
the Groupe d’Etude Clinique du SIDA en Aquitaine (GECSA)
Objectives: Tubular dysfunction is of particular concern in the course
of HIV infection, as it may subsequently induce bone abnormalities.
The objectives of this study were to assess the prevalence of
hyperphosphaturia (HP) and of proximal renal tubular dysfunction
(PRTD) and to investigate their potential determinants in an open and
unselected cohort.
Methods: Consecutively enrolled HIV-infected subjects were prospec-
tively evaluated for PRTD. HP of tubular origin was deﬁned as a
ratio of maximum rate of renal tubular reabsorption of phosphate to
glomerular ﬁltration rate (TmP/GFR) 0.77mmol/L. PRTD (Fanconi
syndrome) was deﬁned as the presence of HP with hypophosphatemia
0.80mmol/L or at least 2 out of 4 of the following criteria: non-
diabetic glucosuria, renal acidosis, b2-microglobulinuria, or low serum
uric acid with a fractional excretion of uric acid >10%. Multivariable
analyses were conducted using two separate models relating to clinical
and biological patients’ characteristics and all antiretroviral treatment
exposure.
Results: 349 patients (268 males) were included in this survey. Median
age was 47 years (Interquartile Range [IQR]: 42−54), median CD4 count
472/mm3 (IQR: 342–638), 89% were treated with 3 antiretroviral drugs
and 81% had HIV-RNA <40 copies/mL.
HP was present in 52 patients (prevalence: 14.9%; 95% conﬁdence
interval [CI]: 11.1–19.5). In the ﬁnal model, male gender (OR= 11.1,
p = 0.001), age 55 (OR= 2.54, p = 0.047), lower estimated GFR
calculated with MDRD equation (OR= 7.96, p< 0.001), tenofovir
[TDF] (OR= 1.15, p = 0.046), zidovudine [ZDV] (OR= 1.07, p = 0.119)
and nelﬁnavir/r [NFV/r] (OR= 1.21, p = 0.013) exposure remained
independently associated with HP.
PRTD was diagnosed in 30 patients (prevalence: 8.6%; 95%CI: 5.8–
12.3%). Using the same analytical approach, male gender (OR= 4.3,
p = 0.035), MDRD (OR= 4.64, p = 0.009), ZDV (OR= 1.11, p = 0.069),
lamivudine (OR= 0.85, p = 0.023), lopinavir/r [LPV/r] (OR= 1.23,
p = 0.027) and atazanavir/r [ATZ/r] (OR= 1.28, p = 0.027) exposure
remained associated with the detection of PRTD. Longer exposure to
TDF was not retained (OR= 1.15, p = 0.116).
Conclusion: PRTD was a prevalent abnormality in this French
unselected cohort. Our patients were broadly exposed to TDF (64.8%
in the sample). The combined used of TDF, LPV/r, ATZ/r or NFV/r
increased the risk of tubular dysfunction. Further studies are needed to
assess the impact of the chronic exposure of TDF alone or combined
with protease inhibitors on the kidney function.
P1210 Findings from ﬁbre optic bronchoscopy in HIV-positive
patients in eastern London
P. Papineni °, Y. Ahmed, S. Limb, H. Noble, T. O’Shaughnessy,
G. Packe, G. Thomas (London, UK)
Objectives: Respiratory disease is a common complication of HIV
infection. Deﬁnitive diagnosis can be elusive with non-invasive testing.
We aimed to characterise the diagnoses made in HIV positive patients
following ﬁbre optic bronchoscopy (FOB) and assess the hypothesis that
FOB remains useful in the diagnosis of respiratory disease in HIV.
Methods: A retrospective observational analysis of FOB in HIV positive
patients at Newham University Hospital in East London between March
2005 and August 2008.
Results: 63 FOBs were performed on 58 HIV positive patients. There
were 64 diagnoses of which FOB supported or proved 26 (41%). The
most common diagnosis (30%) was Pneumocystis jirovecii pneumonia
(PJP) with 19 cases of which 12 were proven, all on bronchial washing
cytology. Of these 12 patients, 25% had CD4 counts >200×106/L. The
second most common diagnosis (27%) was tuberculosis with 17 cases
of which 15 were primarily pulmonary in focus. Culture of bronchial
washings was positive in 10 of these cases. Of the 15 cases of pulmonary
tuberculosis, 13 were sputum smear negative. Of these, 3 (23%) were
afforded early diagnosis by FOB with positive microscopy whilst 8
(62%) were culture positive, conﬁrming the diagnosis and providing
sensitivities. The rate of FOB proven PJP appears to have decreased
over time whilst that of pulmonary tuberculosis appears to have grown.
Average CD4 counts did not change consistently over this period.
Other diagnoses made at FOB include Cryptococcal pneumonitis,
pulmonary strongyloidiasis, interstial lung disease and lymphoma. Other
organisms isolated at FOB include Staphylococcus aureus (11%),
Haemophilus inﬂuenza, Pseudomonas spp. and Coliforms (each 5%)
and Aspergillus spp. (3%). The signiﬁcance of these organisms in the
patient’s illness was uncertain. Candida albicans was isolated following
18% of FOBs, nearly 3 times the rate found in our HIV negative patients.
No signiﬁcant association was found between organism isolated and CD4
count (student’s t test), perhaps due to limitations in sample size.
Conclusions: PJP and pulmonary tuberculosis are the most common
diagnoses following FOB in our HIV+ patients. FOB is useful in the
diagnosis of PJP and smear negative TB in HIV.
P1211 Is procalcitonin a useful biomarker of severe bacterial
infections in HIV-1-infected patients?
T. Mikula °, M. Dabrowska, J. Cianciara, A. Wiercinska-Drapalo
(Warsaw, PL)
Objectives: The role of procalcitonin (PCT) in immunocompromised
individuals is still investigated. The aim of our study was to evaluate the
usefulness of PCT in diagnosis of severe bacterial infections in HIV-1-
infected patients and its correlation with C-reactive protein (CRP), white
blood cells count (WBC), CD4 cell count, and plasma HIV-1 viral load.
Methods: A cross-sectional study was performed in 92 HIV-1(+)
subjects and 37 HIV-1(−) individuals (9 males and 28 females,
mean age 39.7 years). HIV(+) patients were divided into two groups:
group 1(n = 40, 33 males and 7 females, mean age 35.4 years, CDC
A/B, without cART) and group 2 (n = 52, 45 males and 7 females,
mean age 37.9 years, CDC C, on cART). Clinical symptoms of bacterial
infection, Systemic Inﬂammatory Response Syndrome (SIRS) or sepsis
lasting no longer than 3 days before the hospitalization were the main
inclusion criteria. WBC, PCT and CRP were analyzed in the ﬁrst
12 hours of hospitalization. Blood and urine bacterial culture were
performed. PCT serum concentration were evaluated with quantitative
immunoluminometric method (LUMITEST PCT kit, BRAHMS AG,
Berlin, Germany). Plasma HIV-1 RNA was calculated using the
Amplicor system. All statistical methods (median, standard deviation
and Pearsons correlation ratio) were performed in Statistica 8.0.
Results: Positive blood and/or urine bacterial culture were observed in
14 (27%) and 8 (21%) HIV(+) subjects, respectively. Moreover, ﬁfty
seven(62%) HIV(+) individuals had SIRS/sepsis conﬁrmation. Twenty
seven(47.3%) of them had normal PCT concentration (8 subjects in
group 1 and 19 subjects in group 2). No PCT elevation was observed
in control group. PCT sensitivity and speciﬁcity were estimated in all
studied groups. The lowest PCT sensitivity (48%) was estimated in
group 2; however, its speciﬁcity was still higher than CRP. In both
HIV(+) groups positive predictive values were low (46.4 and 64.0,
respectively) and negative predictive values rather high (91.0 and 93.0,
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respectively). No correlation between PCT level and WBC count, CD4
cell count and plasma HIV-1 viral load was observed.
Conclusion: Serum PCT concentrations in HIV-1-infected patients,
especially with AIDS, are mostly normal even during severe bacterial
infection. Therefore, the inﬂuence of immune deﬁcits in assessment
of PCT results should be always considered in the early diagnosis of
SIRS/sepsis in immunocompromised subjects.
P1212 New Advia Centaur® HIV Ag/Ab combo, 4th generation
screening assay, shows high level of speciﬁcity in a mixed
population of a routine diagnostic laboratory
D. Burki °, S. Pﬁster (Basel, CH)
In HIV-screening fourth generation assays detecting both HIV-1/2
antibodies and HIV-1 p24-antigen are the recommended standard. While
sensitivity is crucial in any HIV screening assay, it should not be
maximized at the cost of speciﬁcity as false-reactive reports result in
anxiety in the patient as well as additional costs for secondary testing.
With the aim of establishing speciﬁcity of the new Siemens ADVIA
Centaur® HIV Ag/Ab combo (CHIV) forth generation HIV-screening
assay (Siemens Healthcare Diagnostics, Tarrytown, USA) in a mixed
population of both in- and outpatients in screening situations or in the
investigation of a clinical suspicion of HIV infection, 1738 unselected
serum samples of a large diagnostic laboratory were compared with
the current routine method ABBOTT Architect HIV Ag/Ab combo
(ABBOTT Diagnostic Division, Wiesbaden, Germany).
Six reactive samples were conﬁrmed by immunoblot and viremia. 1732
samples were considered HIV-negative. Of these, one was reactive in
both assays, one in Architect only, and two in ADVIA Centaur® only.
Speciﬁcities at the cut-off of 1.00 S/CO were 99.71% for ADVIA
Centaur and 99.77% for Architect. When applying an extended grey
zone from 0.60 to 1.00 S/CO speciﬁcities were 98.79% for ADVIA
Centaur and 99.77% for Architect. Median S/CO was 0.05 (= limit of
detection) for ADVIA Centaur® and 0.16 for Architect.
Sensitivity of the new HIV screening assay was not addressed as it can
only be determined in very large populations or, more conveniently, using
seroconversion panels. Still, all six conﬁrmed samples were correctly
identiﬁed by ADVIA Centaur®.
Speciﬁcity, conversely, is best assessed using real populations including
individuals with clinical suspicion of HIV-infection as well as individuals
in mere screening situations. At the cut-off of 1.00, speciﬁcities of
the two assays were comparable. A low median of S/CO values in
ADVIA Centaur® suggested better discriminatory power than Architect.
However, a trailing of values in the high-negative range may signiﬁcantly
impair speciﬁcity if an extended grey zone is applied in the ADVIA
Centaur®
We conclude that in a mixed population the new Siemens ADVIA
Centaur® CHIV forth generation assay proved highly speciﬁc and may
therefore be introduced into routine testing.
P1213 Human immunodeﬁciency virus-1 F1 subtype is associated
with late presentation in newly diagnosed Romanian patients
D. Florea °, S. Paraschiv, M. Fratila, D. Otelea (Bucharest, RO)
Objective: Late presenters at the time of the HIV-1 diagnostic are
frequent in Romania. The purpose of the present study was to ﬁnd out if
these late presentations are correlated with particular virological and/or
epidemiological features.
Methods: Newly diagnosed patients from several representative HIV
Romanian centres were clinically, epidemiologically and virologically
evaluated. Late presentation was deﬁned as AIDS-related conditions
and/ or <200 CD4/mm3. The isolated HIV-1 strains were sequenced
using with the commercial Viroseq™ HIV-1 Genotyping System. For
subtyping purposes the nucleotide sequences (entire protease gene and
two thirds of the RT gene) were analysed with the publicly available
algorithm REGA HIV-1&2 Automated subtyping tool version 2.0. In
order to do phylogenetic analysis we used for aligning ClustalW software
as implemented in BioEdit and Mega 4 software for tree building.
Results: We analysed 250 patients diagnosed between 2007–2009. More
than half of them (54%) were late presenters: 35% had AIDS-related
conditions and 45% had CD4 counts <200 cells/mm3. Most of the
late presenters were infected with the F1 HIV subtype whereas the
asymptomatic patients were infected with more diverse subtypes (F, C,
B, A, G, CRFs). A signiﬁcant number of AIDS cases at the time of
diagnoses were in patients aged 15 to 22 years of age. Late presentation
was correlated to lack of acknowledged risk behaviour.
Conclusions: HIV-1 F1 subtype is associated with later presentation in
newly diagnosed Romanian patients. Our data suggest that these ﬁndings
are related to the epidemiological distribution of subtypes at the time of
infection rather than host related factors.
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P1214 Herpes simplex encephalitis in a national prospective
encephalitis cohort, France, 2007
A. Mailles, P. Morand, H. Peigue-Lafeuille, J.P. Stahl ° (Saint-Maurice,
Grenoble, Clermont-Ferrand, FR)
Objectives: The prognosis of herpes simplex encephalitis (HSE)
has been dramatically improved by the generalisation of acyclovir.
However, despite international recommendations, the exact regimen is
still discussed, as are the criteria for discontinuing the treatment. We
present the clinical features of HSE patients included in the French
encephalitis study in 2007 and the management of acyclovir prescription
in encephalitis case-patients with or without HSE diagnosis.
Methods: HSE case-patients were patients aged 28 days or older,
hospitalised in mainland France in 2007 with an acute onset of illness,
and at least one abnormality of the CSF (4 white blood cells/mm3
or 40mg/dl protein), and fever 38ºC and decreased consciousness
or seizures or altered mental status or focal neurological signs, and a
positive HSV PCR on CSF. Clinical, biological and management details
were collected using standardized questionnaires.
Results: Among 253 encephalitis patients, 55 had HSE, 76 had another
aetiological diagnosis, and 122 had no aetiological diagnosis identiﬁed.
The age of HSE patients ranged from 1 month to 85 years (median
58), and 31 (56%) were men. Upon admission, 48 (87%) had memory
loss, 15 (27%) had focal neurological signs and 14 (25%) had speech
disorders. All received acyclovir, 9 (16%) of them for 2 weeks and 41
(75%) for 3 weeks. Their case-fatality ratio was 5.5%, and 48 (87%) still
had remaining neurological signs on discharge, mainly speech disorders
or memory impairment. Among non-HSE patients, acyclovir was started
in 175 (88%) and discontinued after a median length of 8 days (range 1
to 25 days).
Conclusion: Our study showed a lower fatality ratio in HSE patients
compared with other studies. Among HSE patients, acyclovir was not
systematically prescribed following international recommendations. The
duration of acyclovir treatment in non HSE patients is considered with
regards to other aetiologies identiﬁed and the timeline of diagnosis.
We concluded that the dissemination of international recommendations
regarding the management of HSE should be reinforced in France.
P1215 Impact of varicella zoster virus exposure on frequency and
age of onset of herpes zoster in France: Mona study
J. Gaillat °, V. Gajdos, O. Launay, D. Malvy, S. Pinchinat, T. Derrough,
C. Sana, E. Caulin, B. Soubeyrand (Annecy, FR)
Context: Repeated contact with children suffering from varicella might
play a signiﬁcant role in maintaining immunity against varicella zoster
virus (VZV) and reduce the risk of herpes zoster in adulthood.
Objectives: The principal objective was to evaluate the frequency of
herpes zoster in a population with little or no exposure to children
(monks/nuns) compared to that in the general population. The reported
age of onset of herpes zoster in these two populations was a secondary
objective.
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Method: A national, comparative, observational, multicentre, epidemio-
logical study in an “exposed/non-exposed” design conducted by means of
self-administered questionnaires. The non-exposed population consisted
of monks and nuns in 40 isolated monasteries, excluding postulants or
novices and those without a command of French. Monks and nuns who
regularly came into contact with groups of children under 10 years of age
were excluded from the principal analysis population. The sample of the
general population was constituted from a pre-established ﬁle, based on
the quota method, which was representative of the French population
in terms of age group, sex, socio-occupational groups and regions.
Individuals who failed to return their questionnaire were contacted by
telephone. Those without a command of French and/or living in an
institution were excluded.
Results: The principal analysis population comprised 920 monks/nuns
(41.5% nuns) and 1,533 individuals (51.9% women) from the general
population. The reported frequency of herpes zoster was 16.2% in the
monks/nuns and 15.1% in the general population (p adjusted for sex
and age = 0.27). Herpes zoster had been conﬁrmed by a healthcare
professional in 92% of cases in both populations. The mean reported
age of onset of herpes zoster was 54.8 and 48.6 years, respectively
(p = 0.06). Women exhibited herpes zoster signiﬁcantly more often than
men in both populations [21% of nuns and 13% of monks (p = 0.002) −
18% of women and 12% of men (p = 0.002)].
Conclusion: In this study no difference in reported frequency and age
of onset of herpes zoster was demonstrated in these two populations
with a very different exposure to children. These results suggest that, if
exposure to the varicella virus does have a protective effect against the
onset of herpes zoster in adults, the effect is necessarily weak.
P1216 Aetiology and cerebrospinal ﬂuid ﬁndings in aseptic
meningitis
I. Vanaga, A. Broduza °, B. Rozentale (Riga, LV)
Objectives: Assessment of the etiology and cerebrospinal ﬂuid (CSF)
ﬁndings in patients with aseptic meningitis (AM) and correlation
between etiology, papilledema, cerebral trauma and CSF ﬁndings.
Methods: 222 medical records of patients with AM, treated at the
Infectology Center of Latvia during 2001 to 2008, were analyzed.
Patients with HIV, tuberculous and tick-borne encephalitis virus
meningitis were excluded. The etiology was conﬁrmed if a microbe or
microbe-speciﬁc nucleic acid was detected in the CSF or speciﬁc IgM
antibodies were detected in the blood. We analyzed CSF pleocytosis,
neutrophils/lymphocytes (Neu/Ly) ratio, and protein level.
Results: 222 cases of AM were reviewed. The patients ranged in age
from 15 to 82. The male/female ratio was 135/87. Etiology was deﬁned
in 33%. The most common causative agents were enteroviruses − 44,
herpesviruses − 17, B. burgdorferi − 6, mumps viruses − 5.
The patients with mumps meningitis had highest total pleocytosis in CSF
(774.2±598.0 cells/mm3), but the lowest was in meningitis caused by
B. burgdorferi (214.8±201.9 cells/mm3). 14% of all AM cases had Neu
predominance. Ly count was higher in cases of mumps (754.6±592.1
cells/mm3) and herpesviruses (632.1±406.1 cells/mm3) than enterovirus
(339.8±416.2 cells/mm3) meningitis, respectively, p = 0.049, p = 0.012.
In 27% cases of enterovirus meningitis Neu predominance was observed.
The highest CSF protein concentration were in patients with B. burgdor-
feri caused meningitis (1.13±1.26 g/l), but the lowest were in patients
with mumps meningitis (0.57±006 g/l). In cases with herpesviruses
meningitis CSF protein level (0.95±0.39 g/l) was higher than enterovirus
meningitis (0.63±0.43 g/l), respectively, p = 0.005.
The greatest part of B. burgdorferi caused meningitis patients had
papilledema. None patients with mumps meningitis had papilledema.
Papilledema and anamnestic head trauma didn’t affected CSF pleocyto-
sis, Neu/Ly ratio, and protein level.
Conclusion: 67% of AM the etiology remains undeﬁned. The leading
cause was enterovirus. The highest pleocytosis in CSF had patients
with mumps meningitis. AM patients CSF was not characterised only
as lymphocytar, in some cases, especially enterovirus meningitis, Neu
predominate. B. burgdorferi meningitis CSF protein level was highest.
Papilledema was more often in AM caused by B. burgdorferi.
P1217 Clinical presentations of echovirus 6 and 9 infections
among neonates, younger and older children in Taiwan
H. Lee °, Y.C. Huang, C.J. Chen, C. Chiu, C. Wu, T.Y. Lin (Taoyuan, TW)
Objectives: Echovirus 6 and 9, the predominant types of non-polio
enterovirus infections, have not been comprehensively evaluated. To
delineate the clinical features associated with echovirus 6 or 9 infections,
clinical presentations of infected neonates, younger (1 month-old and <3
year-old) and older children (3 year-old) were compared.
Methods: Culture-proven echovirus 6 or 9 infections were identiﬁed by
immunoﬂuorescent staining with virus-speciﬁc monoclonal antibody in
199 children in a teaching hospital from 2000 to 2008. The medical
records of all cases were reviewed and analyzed according to their ages.
Clinical manifestations, laboratory ﬁndings, treatments, and outcomes
were collected from data of 174 inpatients without any other concomitant
or secondary bacterial or virus infection.
Results: The mean age was 4.7 years (range, 4 days to 15 years)
and more than a half of patients (61.8%) were male. The disease
spectrums were similar for echovirus 6 (n = 100) and 9 (n = 74)
infections, with aseptic meningitis (49.0% and 51.3%) being the most
common syndrome, followed by meningismus (17.0 and 14.9%), upper
respiratory tract infection (7.0% and 6.8%), pneumonia (5.0% and
8.0%), and herpangina (5.0% and 4.1%) (Table 1). Aseptic meningitis
and meningismus, were common (70%) in neonates or older children,
but relatively uncommon (40%) in younger children (p< 0.001). The
laboratory values were of no signiﬁcant difference except for a
higher proportion of serum aspartate aminotransferase level >40U/L in
echovirus 6 infections (27.0% vs. 1.4%, p< 0.001). Fever, headache and
vomiting were “triad” found in almost all children older than 3-year-
old with echovirus meningitis (all >90%), and mannitol or glycerol
with antipyretic was beneﬁcial for these patients. Longer duration of
fever and more frequency of high temperature (>39ºC) were signiﬁcantly
found in echovirus 9 than in echovirus 6 infections (both p< 0.001). Six
(3.4%) children were severe, including fatal, rescued by extra-corporeal
membrane oxygenation (ECMO) or with long-term sequel with initial
presentations of seizure with blood sugar >150mg/dL, liver function
impairment, brain infarction or herniation and diagnosis of myocarditis.
Conclusion: Aseptic meningitis was the most common manifestation
of echovirus 6 and 9 infections in children requiring hospitalization.
Fatal outcome or long term sequel in survivors was rare but may be
encountered in children with speciﬁc presentations.
Table 1. Diagnosis of 174 children with echovirus 6 (n = 100) or
9 (n = 74) infections among three age distributions in Chang Gung
Memorial Hospital, 2000–2008
Age <1 month 1 month − 3 years >3 years All
Serotype 6 9 6 9 6 9 6 9
Number (%) 10 (10.0) 5 (6.8) 30 (30.0) 18 (24.3) 60 (60.0) 51 (68.9) 100 74
Aseptic meningitis 6 (60.0) 4 (80.0) 9 (30.0) 3 (16.7) 34 (56.7) 31 (60.8) 49 (49.0) 38 (51.3)
Meningismus 1 (10.0) 1 (20.0) 3 (10.0) 0 (0) 13 (21.7) 10 (19.6) 17 (17.0) 11 (14.9)
Upper respiratory infection 0 (0) 0 (0) 4 (13.3) 3 (16.7) 4 (6.7) 3 (5.9) 7 (7.0) 5 (6.8)
Non-speciﬁc febrile illness 2 (20.0) 0 (0) 5 (16.7) 0 (0) 2 (3.3) 2 (3.9) 9 (9.0) 2 (2.7)
Pneumonia 0 (0) 0 (0) 2 (6.7) 3 (16.7) 3 (5.0) 3 (5.9) 5 (5.0) 6 (8.1)
Herpangina 0 (0) 0 (0) 3 (10.0) 2 (11.1) 2 (3.3) 1 (2.0) 5 (5.0) 3 (4.1)
Exanthema 0 (0) 0 (0) 0 (0) 5 (27.8) 0 (0) 1 (2.0) 0 (0) 6 (8.1)
Hand–foot–mouth disease 0 (0) 0 (0) 1 (3.3) 2 (11.1) 0 (0) 0 (0) 1 (1.0) 2 (2.7)
Encephalitis 0 (0) 0 (0) 2 (6.7) 0 (0) 0 (0) 0 (0) 2 (2.0) 0 (0)
Myocarditis 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7) 0 (0) 1 (1.0) 0 (0)
Polio-like syndrome 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.7) 0 (0) 1 (1.0) 0 (0)
Acute gastroenteritis 0 (0) 0 (0) 1 (3.3) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
Hepatic necrosis with coagulopathy 1 (10.0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (1.0) 0 (0)
P1218 Longitudinal study of BK virus infection in adult allogeneic
haematopoietic stem cell transplant
J. Corneille, N. Dhe´din, C. Deback, M. Uzunov, S. Nguyen, J. Vernant,
H. Agut, D. Boutolleau ° (Paris, FR)
Objectives: In haematopoietic stem cell transplant (HSCT) recipients,
BK virus (BKV) infection is associated with haemorrhagic cystitis (HC)
occurring after engraftment. Nevertheless, no virological marker of late-
onset HC has been clearly identiﬁed. The aim of this longitudinal study
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was to determine the incidence and the risk factors of BKV infection
in HSCT recipients, to analyse the association of BKV load in whole
blood with HC, and to evaluate whether systematic follow-up of BKV
infection is warranted.
Methods: BKV load was measured retrospectively using a real-time
PCR assay in whole blood specimens from 61 consecutive allogeneic
HSCT recipients (38 men, 23 women, median age: 45 years) collected
at 0, 1, 2, 3, 6, 9, and 12 months post-transplantation.
Results: Fifteen patients (25%) developed BKV viraemia at a median
of 2 months (1−3) after transplantation. Acute leukaemia as underlying
disease was identiﬁed as a risk factor for BKV infection (P = 0.03). BKV
infection was associated with acute graft-versus-host disease (P = 0.003)
and haematuria (P< 0.001). The maximum BKV load was higher in
patients with haematuria than in those without haematuria (median,
1685 vs. 160 copies/mL; P = 0.05). The occurrence of haematuria was
statistically associated with a concomitant BKV load >500 copies/mL
(P = 0.04) and with BKV detection in at least two consecutive blood
specimens (P = 0.04). Lymphocyte recovery in patients with haematuria
was delayed compared to those without haematuria. Ten patients (16%)
experienced both BKV and cytomegalovirus (CMV) infections after
transplantation. In all cases, CMV infection appeared either before (n = 5)
or concomitantly (n = 5) with BKV infection. Overall, the frequency
of BKV detection was statistically higher in CMV-positive samples
than in CMV-negative samples (22% vs. 5%; P< 0.001). No adenovirus
infection was evidenced in patients with haematuria.
Conclusion: BKV viraemia is highly associated with the occurrence of
HC in HSCT recipients. Prolonged BKV viraemia and BKV load over
500 copies/mL of whole blood were identiﬁed as predictive markers for
the development HC. The analysis of BKV load kinetics and lymphocyte
recovery after transplantation underlines the potential role of cellular
immunity in the pathogenesis of HC. Our results suggest a possible role
of CMV in the process of BKV infection. The monitoring of BKV load
appears useful to identify HSCT recipients at risk for developing post-
engraftment HC.
P1219 Inﬂuenza and other respiratory viruses among febrile
children with and without respiratory symptoms in Tanzania
V. D’Acremont, P. Cherpillod, M. Kilowoko, E. Kyungu, S. Philipina,
W. Sangu, J. Kahama-Maro, P. Kibatala, L. Alamo, C. Lengeler,
B. Genton °, L. Kaiser (Basel, Geneva, CH; Dar es Salaam, Ifakara,
TZ; Lausanne, CH)
Objectives: Viral respiratory tract infections are the most frequent
cause of febrile illnesses in infants and young children in industrialized
countries but few studies have been conducted in Africa, especially
in outpatients. To assess the contribution of viral infections to febrile
episodes in children attending an outpatient clinic, we investigated the
prevalence of common respiratory viruses among children with and
without respiratory symptom/sign(s) in a rural and urban setting in
Tanzania.
Methods: All consenting children aged 2 months to 10 years with
temperature >38ºC were recruited between Apr-Dec 2008. Medical
history and clinical examination were done and nasal/throat swabs
taken for viral real-time PCR. Ct values were used to provide semi
quantitative viral loads. X-ray was performed when IMCI criteria for
clinical pneumonia were met. Other investigations were also undertaken
to ﬁnd a precise etiology of the fever episode with a probability level
based on a pre-deﬁned algorithm.
Results: 1005 children were recruited. 643 (64%) had at least one
respiratory symptom/sign (RSS): 507 children had an acute respiratory
infection (ARI) as primary diagnosis (high probability) (63% URTI, 20%
clinical pneumonia with normal Xray, 8% bronchiolitis, 6% pneumonia
conﬁrmed by X-ray, 3% pneumonia with no Xray done) and 136 children
had ARI as secondary diagnosis. 362 children had no RSS. Based on
preliminary viral analysis and excluding picornaviruses, the proportion
of children infected with at least one respiratory virus was 40% for
children with ARI as primary diagnosis, 21% for children with ARI as
secondary diagnosis and 15% for children without RSS. The proportion
of children with picornavirus was the same in the 3 groups (36%, 35%
and 33% respectively). The proportion of children with double infection
was 15%, 5% and 6% respectively.
The proportion of children with presumably high viral titers (Ct< 25)
were similar between the 3 groups, except for inﬂuenza A where more
children with ARI as primary diagnosis than ARI as secondary diagnosis
had high titres (see graph).
Conclusion: In these African children with febrile illnesses the
prevalence of inﬂuenza A and B and of other respiratory viruses was
higher than expected, especially in children without any respiratory
symptom or sign. This latter observation suggests that these viruses may
cause fever episodes without obvious respiratory manifestations.
Graph. Proportion of febrile children infected with each respiratory virus
stratiﬁed by the absence/presence of ARI and/or RSS. Left column: ARI
as primary diagnosis; Middle column: ARI as secondary diagnosis; Right
column: no RSS.
P1220 Virological diagnosis of respiratory virus infection in
patients attending an emergency department during the
inﬂuenza season
A. Pierangeli, C. Scagnolari, S. Trombetti, M. Gentile, B. Rizzo,
M.T. Spina, A. Iudicello, G. Bertazzoni, G. Antonelli ° (Rome, IT)
Objectives: The aim was to investigate the burden of inﬂuenza and
inﬂuenza-like respiratory illness in a hospital emergency department
(ED) during the seasonal inﬂuenza months.
Methods: Consecutive patients attending an ED during February and
March were enrolled within the framework of a respiratory infection
surveillance project; 103 nasopharyngeal washes were tested for several
common respiratory viruses using PCR-based methods.
Results: Inﬂuenza A viruses were detected in 25/103 samples (24%)
whereas a rapid inﬂuenza test was positive in only 1/31 samples
tested. Rhinovirus was detected in 15% of recruited patients, respiratory
syncytial virus in only one, and inﬂuenza B was not detected. Only
16% of inﬂuenza A infections matched the inﬂuenza-like illness
case deﬁnition at ED admission, whereas 19% of rhinovirus-infected
individuals would have been diagnosed as having inﬂuenza-like illnesses.
Conclusion: Data suggest that triage of inﬂuenza cases based on
syndromic occurrence of inﬂuenza would be insufﬁcient and unsuitable
for containing inﬂuenza virus spread during pandemic alerts, and
could also lead to unnecessary isolation of patients infected with other
respiratory viruses. The application of broader criteria at triage followed
by timely molecular tests for the most common respiratory viruses could
be effective in preventing transmission of new respiratory agents and in
appropriate case management.
New antibacterials − clinical trials and experience S341
P1221 Inﬂuenza like illness syndromes in an acute care geriatric
unit in Edouard Herriot Hospital, Lyon, France during 5
seasons
C. Re´gis, V. Escuret, B. Barret, C. Luxemburger, S. Pires-Cronenberger,
C. Gorain, L. Pollissard, F. Morﬁn, F. Najioullah, B. Comte, B. Lina,
P. Vanhems ° (Lyon, FR)
Objective: A prospective study was performed during 5 inﬂuenza
seasons (from November 2004 to April 2009) to report Inﬂuenza like
illness syndromes (ILI) in a geriatric unit of a French university hospital
and to describe cases of nosocomial inﬂuenza.
Method: Hospitalized patients (P) and healthcare workers (HCW) of an
acute care geriatric unit of 18 beds with ILI syndrome were included
in the study. An ILI syndrome was deﬁned as fever >37.8ºC or cough
or sore throat. Clinical diagnosis was conﬁrmed by inﬂuenza detection
using ELISA, viral culture and RT-PCR techniques performed on nasal
samples. Medical data were collected. A nosocomial case was deﬁned
as a case occurring after at least 72 hours after hospitalization for P
[Salgado; 2002] or exposure to an infected colleague or patient for HCW.
Results: During these 5 seasons, 135 P and 34 HCW were included.
Among the ILI, 27 P (20%) and 2 HCW (5.9%) presented a conﬁrmed
inﬂuenza. Attack rate (AR) for 100 hospitalizations were calculated for
the ﬁrst 3 months of each year, we observed a median AR of 7.1%
(min: 2.1; max: 24.7) for ILI and an AR of 1.1% (min: 0; max: 6.5) was
observed for conﬁrmed inﬂuenza.
Among patients, 95 (70%) presented the ILI before their hospitalization.
According to the deﬁnition, 20 cases (15%) were nosocomial. No
signiﬁcant difference was observed for symptoms (cough and sore throat)
between nococomial and community-acquired cases. 20 patients (15%)
presented their ILI 24 to 48 hours after hospitalization; 9 of them were
not hospitalized for a respiratory syndrome and 4 of them had a contact
with an ILI case.
Among HCW, 24 (71%) ILI cases were nosocomial and 1 HCW
presented nosocomial conﬁrmed inﬂuenza. Nosocomial cases were
observed from 28 potential transmission from P to HCW (n = 20) and
from HCW to HCW (n = 8).
Conclusion: Despite the absence of virologicaly conﬁrmed transmission
of nosocomial cases from HCW to patient, many nosocomial cases
of ILI were observed. These ﬁndings highlight the importance of the
preventive measures completed by vaccination in this unit where high
risk of contagiousness and high risk patients are present.
P1222 Kaposi’s sarcoma-associated herpesvirus selectively
establishes latency and activates a subset of tonsillar B-cells
L.M. Hassman °, T.J. Ellison, D.H. Kedes (Charlottesville, US)
To date, the identity of the subset(s) of B cells susceptible to KSHV
infection has only been indirectly inferred from histological data
(Chagas, et al., 2006) in which KSHV infection was observed in tonsillar
regions with a high proportion of IgM+ B cells. Evidence supporting
salivary transmission of KSHV, along with data showing that KSHV
infected B cells in Multicentric Castleman’s Disease (MCD) are also
IgM+, are consistent with the hypothesis that KSHV may preferentially
infect IgM+ tonsillar B cells in vivo.
Objectives: To establish which B cell subset(s) are susceptible to KSHV
and to determine the effects of KSHV infection on tonsillar B cells.
Methods: We exposed cultures of puriﬁed tonsillar B cells to KSHV
and analyzed the cells by multispectral imaging ﬂuorescence cytometry
(MIFC) as well as traditional ﬂow cytometry and quantitative PCR
(qPCR).
Results: Despite variation in susceptibility to latent infection (LANA
expression) among individual donor tonsils, LANA+ B cells were almost
exclusively IgM+ and expressed the lambda light chain. To assess
whether this selectivity was due to differences in the level of viral
entry or initiation of gene expression within the IgM+lambda population,
we infected pre-sorted tonsillar B cell subsets and then measured
intracellular viral genome copies and RNA expression by qPCR 24 h
later. Despite differences in LANA expression, or the establishment of
latent infection, approximately equivalent numbers of viral genomes as
well as equivalent levels of initial viral transcripts were evident in all
subsets. Latently infected B cells also displayed an activated phenotype
(CD5 and high level surface immunoglobulin) and preliminary data
suggest that infected B cells may show enhanced survival in vitro.
Conclusions: While multiple subsets of human tonsillar B cells were
permissive to the initiation of KSHV infection, evidenced by viral
entry and initial gene transcription, only IgM+lambda B cells displayed
evidence of latent infection. Notably, the selectivity of KSHV in our
ex vivo system corresponds to the phenotype of B cells found in MCD
lesions, suggesting the possibility that IgM+lambda tonsillar B cells
infected after exposure to salivary KSHV may serve as the cells of origin
for this disease. Furthermore, KSHV infection activated B cells and we
hypothesize that this activation may provide a survival advantage.
P1223 Non-productive JC virus infection as a premise for cell
transformation in colourectal malignancies
I. Tsekov °, D. Stoyanova, D. Dardanov, K. Kacarov, G. Kirov,
Z. Kalvatchev (Soﬁa, BG)
Objectives: Since the identiﬁcation of the oncogenic JC virus
(Polyomaviridae, Polyomavirus hominis 2) in samples from colorectal
malignancies, the role of this infection has been a subject to controversial
reports and further studies are needed. Our aim was to investigate a group
of patients with colorectal cancers (CRC) in order to determine a possible
role of JC virus for the development of the tumors. Furthermore, the
functional state of the infection was evaluated in terms of productivity.
Methods: Biopsy materials from colorectal cancers or polyps, paired
with matched normal, adjacent mucosa were collected from surgical
resection specimens. A total of 35 fresh pairs were investigated.
Following standard DNA extraction procedures, real time PCR assays
were used for detection and characterization of JC genomic sequences.
The ampliﬁed fragments were targeted: at the region encoding the viral
regulatory protein termed large T antigen (LT); and the non-coding
control region (NCCR). Melting curve analysis followed the cycling
reactions in order that a characteristic proﬁle of the amplicon was
generated.
Results: Speciﬁc JC sequences from the LT genomic regions were found
and characterized in 7 out of 18 polyps, and in 3 out of 17 cancer
specimens. Additionally, 5 adjacent tissues were determined to harbor
viral sequences. Only one specimen from a polyp was found positive
for the NCCR target. All positive samples had a very low viral load in
the range of 10–1000 starting copies. The results suggested either clonal
integration of LT fragments or NCCR changes altering a productive
course of the infection. Furthermore, the melting curve analysis depicted
the melting temperature (Tm) proﬁle of the ampliﬁed fragments. Seven
more samples from tumors or polyps that were considered negative, had
a similar pattern. This might be a result from changes in the targeted
sequences, but further investigation is needed for clariﬁcation.
Conclusion: The results support a possible ethio-pathogenetic associa-
tion of JC virus with colorectal malignancies. A non-productive course
of the infection in colorectal cells is suggested as a premise for malignant
transformation.
New antibacterials − clinical trials and
experience
P1224 Efﬁcacy of novel formulation of josamycin for 7 and 10
days in paediatric patients with acute tonsillopharyngitis:
results of multicentre study in Russia
V. Krechikov °, E. Bodyaeva, K. Shpynev, E. Danilova, S. Rachina,
M. Galaktionova, S. Kozlov (Smolensk, Krasnoyarsk, RU)
Objectives: To compare efﬁcacy of 7- and 10-day courses of novel
formulation of josamycin in children with acute tonsillopharyngitis (AT).
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Methods: In this multicenter (4 sites) open-label study of josamycin
(50mg/kg/day in two doses) children aged 5 to 16 years with AT were
randomized in two groups to receive either 7- or 10-day course of
antibiotic. Novel tablet formulation (1000mg) which can be either taken
as a tablet or dissolved in water was used in the study. One of the
inclusion criteria was assessment equal to 4−5 points on clinical score
based on symptoms and signs of AT developed by Centor and modiﬁed
by McIsaac, conﬁrming high probability of streptococcal infection
(>50%) and necessity of antibiotic prescription. Throat cultures were
collected at the entry visit (V1, Day 1), at the end of treatment visit
(V4, Day 11 for both groups) and at the follow-up visit (V5, Day 25).
Clinical signs and symptoms were assessed at every visit. Information
about episodes of AT and related antibacterial therapy in last three years
was also collected.
Results: By the moment of data-cut a total of 117 children (5−16
years, mean 11.5 years) were enrolled in the study and randomized in
two groups: 57 received josamycin for 7 days and 60 − for 10 days.
Demographic characteristics and severity of disease was comparable in
both groups. Twenty two patients (18.8%) received antibiotics in previous
three years. Clinical efﬁcacy at V4 was 94.9% in 7-day group and
96.1% in 10-day group, at V5–93.1% and 95.1% respectively. Forty
seven isolates of group A streptococci (GAS) were isolated at the entry
visit: 25 (in 43.9% of patients) in 7-day group and 22 (in 36.7% of
patients) in 10-days group. Bacteriological efﬁcacy at the end of therapy
(V4) was comparable in both groups (97.4% − 7-day vs 95.2% − 10-
day). The similar situation was observed at the follow-up visit: pathogen
was eradicated in 95.2% and 91.5% of cases, respectively. Frequency
of adverse events was low and comparable in both groups, the most
frequent AE was nausea.
Conclusion: Novel formulation of josamycin showed high clinical and
bacteriological efﬁcacy for both 7- and 10-day regimens for treatment
of AT in children.
P1225 A phase 2, randomized, double-blind, double-dummy study
of IV sulopenem with switch to oral sulopenem etzadroxil
compared to ceftriaxone with switch to amoxicillin/
clavulanate in subjects with community-acquired
pneumonia requiring hospitalization
K. Soma, A.M. Silvia, A. Hazra, S. Puttagunta, K. Durham, D. Kirby °
(New London, Groton, US)
Objectives: Assess efﬁcacy of 7−10 days (d) treatment for 3 regimens:
single dose IV sulopenem (S) 600mg with switch to oral sulopenem
etzadroxil (SE) 1,000mg BID (S-SIV); 2 d minimum IV S 600mg
BID with switch to SE 1,000mg BID (S-MIV); and 2 d minimum IV
ceftriaxone 2 gm QD with switch to amoxicillin/clavulanate suspension
(800mg/10mL) BID (COMP).
Methods: Adult subjects were enrolled if presenting in Pneumonia
Severity Index (PSI) risk class III-IV and with 3 symptoms/signs of
pneumonia. IV treatment could continue >2 days if needed and oral
switch was allowed after: a minimum 2 d on IV treatment (active or
placebo); improved cough and dyspnoea; afebrile or improved fever;
improved WBC. The primary endpoint was the proportion of clinically
evaluable (CE) subjects cured at the test of cure (TOC) visit, 7−14 days
after end of treatment. Safety was assessed in the intent to treat group.
Results: Although a greater number of subjects was initially planned, 33
subjects were enrolled: 10, 11, and 12, respectively, for S-SIV, S-MIV,
and COMP. Baseline demographic characteristics were similar. Ten, 8,
and 8 subjects, respectively, met CE criteria. PSI risk class in the CE
population for S-SIV, S-MIV, and COMP was III for 9, 5, and 6 subjects,
and IV for 1, 3, and 2 subjects, respectively. Twenty-three subjects
completed and 10 discontinued, with median treatment duration of 8.5,
10.0, and 8.0 d for S-SIV, S-MIV, and COMP, respectively. Subjects not
assessed due to early discontinuation were considered failures. Results
of the primary efﬁcacy analysis are presented in the table. Cure rates for
the CE population at TOC were 90%, 88%, and 63%, for S-SIV, S-MIV,
and COMP, respectively.
Adverse drug reactions (ARs) occurred in 4/10 (40%), 3/11 (27%), and
4/12 (25%) subjects for S-SIV, S-MIV, and COMP, respectively, with
gastrointestinal (GI) ARs reported in 2 (20%), 2 (18%), and 3 (25%)
subjects, respectively. Four subjects (1 S-SIV, 3 COMP) discontinued for
adverse events (AEs), one of which was an AR (COMP). Four subjects
(2 S-MIV, 2 COMP) reported serious AEs, one of which was an AR
(COMP). No deaths were reported.
Conclusions: These efﬁcacy results were not statistically signiﬁcant due
to the small numbers enrolled; however, both S/SE regimens appeared to
be comparable to COMP. ARs were comparable in all groups, including
GI ARs. S/SE regimens should be investigated further for subjects with
moderate to severe community acquired pneumonia.
Clinical response at TOC, CE population
S-SIV,
n (%)
S-MIV,
n (%)
COMP,
n (%)
S-SIV–
COMP (%)
S-MIV–
COMP (%)
Cure 9 (90.0) 7 (87.5) 5 (62.5)
80%CI (66.3, 99.0) (59.4, 98.7) (34.5, 85.3)
Difference 27.5% 25.0%
80% CI (−4.0, 55.3) (−13.1, 57.9)
P1226 Effect of ceftobiprole on the normal human intestinal
microﬂora
G. Panagiotidis, T. Ba¨ckstro¨m, C. Asker-Hagelberg, M. Rashid,
A. Weintraub, C.E. Nord ° (Stockholm, SE)
Objectives: Administration of antimicrobial agents to patients can cause
modiﬁcations of the normal microﬂora. Consequent reduction in the
colonization resistance leading to overgrowth of new or already present
microorganisms has been described. Increased resistance in many Gram-
positive bacteria has driven the need to develop new antibacterial agents
with activity against these pathogens including methicillin resistant
Staphylococcus aureus (MRSA). Ceftobiprole is a new broad spectrum
pyrrolidinone cephem active against S. aureus (MRSA and MSSA),
vancomycin-resistant Enterococcus faecalis and Gram-negative bacteria
such as Enterobacteriaceae and Pseudomonas spp. The purpose of
the present study was to investigate the effect of administration of
ceftobiprole on the normal intestinal microﬂora of healthy subjects.
Methods: Twelve healthy subjects (6 males and 6 females) 20−41
years of age received ceftobiprole 500mg by intravenous infusion q8 h
during 7 days. Plasma and faeces were collected on days 1, 4, 7,
10, 14 and 21 for determination of concentration by biological and
chemical methods. For analysis of the microﬂora, the faecal specimens
were cultured on non-selective and selective media. Different colony
types were counted, isolated in pure culture, and identiﬁed to genus
level. All new colonizing aerobic and anaerobic bacteria were tested for
susceptibility to ceftobiprole.
Results: The plasma concentrations of ceftobiprole were as follows: On
day 1, 14.7–23.6mg/l; on day 4, 15.9–24.5mg/l; and on day 7, 15.9–
23.9mg/l. No ceftobiprole was detected in plasma on days 10, 14 and 21.
No measurable concentrations were found in faeces on days 1, 4, 7, 10,
14 and 21. There were minor changes in the numbers of enterobacteria,
enterococci and Candida albicans, and there were moderate changes on
numbers of biﬁdobacteria, lactobacilli, clostridia and bacteroides during
the same period. No Clostridium difﬁcile strains or toxins were found.
No new colonizing aerobic and anaerobic bacteria with ceftobiprole
minimum inhibitory concentrations of >4mg/l were found.
Conclusion: Ceftobiprole had no signiﬁcant ecological impact on the
human intestinal microﬂora of healthy volunteers.
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P1227 Complicated skin and soft tissue infections treated with
daptomycin in the European Cubicin® Outcomes Registry
and experience (EU-CORE)
A. Cogo °, Z. Dailiana, P. Gargalianos-Kakolyris, T. Quast, V. Prisco,
A. Segado, C. Iacoboni, P. Dohmen, M. Heep, H.J. Thurston, R.L. Chaves
(Vicenza, IT; Larissa, Athens, GR; Bad Oeynhausen, DE; Mercato
San Severino, IT; Madrid, ES; Cefalu`, IT; Berlin, DE; Basel, CH)
Objectives: Daptomycin (DAP), a cyclic lipopeptide antibiotic, was
approved in Europe in January 2006 for the treatment of complicated
skin and soft tissue infections (cSSTIs) caused by a variety of Gram-
positive organisms. The aim of this retrospective, non-interventional
records review was to evaluate clinical outcomes of patients (pts) with
cSSTI receiving DAP therapy in Europe.
Methods: Clinically evaluable pts with a diagnosis of cSSTI who
were treated with at least 1 dose of DAP were included. Patient
demographic data, infection types, bacterial isolates, DAP dosing, and
clinical outcomes (cure, improved, failure, or non-evaluable) at end of
DAP treatment were collected and assessed by the investigators.
Results: A total of 1454 pts were included in the registry from Sept
2008 to Aug 2009. 484 pts (male 66%; age 65 years 53.3%) were
diagnosed with cSSTI with the following frequencies: wound 97 (20%),
major abscess 40 (8%), diabetic ulcer (excluding diabetic foot) 24 (5%),
diabetic foot 97 (20%), ulcer 53 (11%); surgical site infection (15%
superﬁcial, 14% deep incisional, 7% organ/space). 63% of inpatients
received concomitant antibiotics, most commonly carbapenems (20%)
and ﬂuoroquinolones (18%). For 320 pts (66%), primary pathogens have
been reported. Staphylococcus aureus (167/320) was the most frequent
species with MRSA (n = 104) as predominant subset. The most frequent
initial dose of DAP was 4mg/kg (44%), 43% of pts received 6mg/kg.
The overall clinical success rate was 84% (cure or improved). Failure
was reported in 8% of pts and the rate of non-evaluable pts was also
8%. Clinical success rates for cSSTI subtypes were: wound 81%, major
abscess 88%, diabetic ulcer (excluding diabetic foot) 92%, diabetic foot
85%, ulcer 85% and surgical site infection 88%, respectively. Adverse
events (AEs) regardless of the study drug relationship which led to
study drug discontinuation were reported in 2.9% of pts. Serious AEs,
regardless of relationship, were reported in 3.5% of pts.
Conclusions: Daptomycin was effective and well tolerated for the
treatment of cSSTI with high clinical success rate, in good agreement
with results from registration trials. DAP is a useful therapeutic option
for cSSTI caused by Gram-positive pathogens.
P1228 Daptomycin in the treatment of bacteraemia: clinical
experience in Europe
A. Galloway °, B. Galva´n-Guijo, A. Gonzalez-Ruiz, A. Rodrı´guez,
B. Almirante, T. Lejko-Zupanc, V.J. Gonza´lez-Ramallo, I. Lampreabe
Gaztelu, M. Heep, H.J. Thurston, R.L. Chaves (Newcastle upon Tyne,
UK; Madrid, ES; Kent, UK; Tarragona, Barcelona, ES; Ljubljana,
SI; Bizcaia, ES; Basel, CH)
Objective: Daptomycin (DAP) is approved in Europe for the treatment
of Staphylococcus aureus bacteraemia at a dose of 6mg/kg once daily.
Limited data are available for the treatment of bacteraemia in clinical
practice. The aim of this registry was to describe the clinical experience
with DAP for the treatment of bacteraemia.
Methods: The European Cubicin® Outcomes Registry and Experience
(EU-CORE) is a retrospective analysis of patients’ clinical outcomes
with DAP therapy. Only those patients (pts) with bacteraemia who were
treated with at least one dose of DAP were evaluated. Outcomes were
assessed by the investigator (cured, improved, failure, non-evaluable) at
the end of DAP therapy.
Results: Of the total of 1454 pts in the EU-CORE registry from Sept
2008 to Aug 2009 bacteraemia was diagnosed in 308 pts (21%), of which
53% were catheter related. Patients with bacteraemia were identiﬁed with
the following demographics: male 71%; age 65 years 47%. In total
39% of pts (120/308) received DAP in an ICU. Concomitant antibiotics
were received by 72% of inpatients, most commonly with carbapenems
(29%) and penicillins (22%). For 259 pts (84%) primary pathogens have
been reported. Coagulase-negative Staphylococci (109/259) ranked ﬁrst.
S. aureus (97/259) was the second most frequent species, with MRSA
(n = 45) a signiﬁcant subset. Enterococcus spp. were seen in 23 cases.
Most frequently used initial dose of DAP was 6mg/kg (75%).
The overall clinical success rate with DAP therapy was 74% (cure
or improved). Outcomes of the primary infection for catheter related
bacteraemia were: clinical success 76%, failure 11%, and non-evaluable
13%. For non-catheter related bacteraemia: clinical success 72%, failure
14% and non-evaluable 14%. Adverse events (AEs) regardless of the
study drug relationship which led to study drug discontinuation were
reported in 4% of pts. Serious AEs, regardless of relationship, were
reported in 12% of pts.
Conclusion: DAP was effective and well tolerated for the treatment
of Gram-positive catheter related bacteraemia and non-catheter related
bacteraemia.
P1229 Efﬁcacy and safety of high-dose daptomycin in
Staphylococcus aureus infections
M. Bassetti °, E. Nicco, E. Delﬁno, C. Fanciulli, C. Viscoli (Genoa, IT)
Objectives: Daptomycin is a cyclic lipopeptide antibiotic approved for
the treatment of complicated skin and soft-tissue infection (4mg/kg)
and Staphylococcus aureus bloodstream infection including right-sided
endocarditis (6mg/kg). On the basis of the drug’s pharmacokinetic
proﬁle and concentration-dependent killing, higher doses may be
beneﬁcial in treating severe infections. There are limited safety data
for high-dose and long-term daptomycin treatment. We describe our
efﬁcacy and safety experience with clinical use of daptomycin at doses
of 8mg/kg for Staphylococcus aureus infections.
Methods: A retrospective chart review for all patients treated with
daptomycin at San Martino University hospital, Genoa, Italy from
January 2008 through September 2009 was performed. Patients were
included in the study group if they received daptomycin at doses
of 8mg/kg for Staphylococcus aureus infections. Clinical data were
collected from their medical records (demographic conditions, clinical
diagnosis, microbiologic isolate identiﬁcation, antibiotic susceptibility,
treatment indication, dose, duration and adverse events). Clinical and
bacteriological outcomes were based on clinical assessment at baseline,
end of treatment and follow-up. Safety was deﬁned as adverse events
(graded 1−4) documented in the medical record.
Characteristics N= 21 %
Male gender 14 67
Age (years) 63
Mean duration of hospitalisation (median, range) 35.2 days (21, 6−148)
Co-morbid conditions
Diabetes mellitus 3 14
Peripheral vascular disease 3 14
Immunocompromised 2 9.5
Neutropenia 1 4.7
Type of S. aureus infections
Uncomplicated bloodstream infection 8 38
Complicated bloodstream infection 3 14
Skin and soft tissue infections 4 19.5
Left-side endocarditis 2 9.5
Right-side endocarditis 2 9.5
Osteomyelitis 2 9.5
Pathogens
MRSA 19 90
MSSA 2 10
Vancomycin MIC ’s
0.5 5 24
1 11 52
2 5 24
Results: Twenty-one patients met the inclusion criteria. See Table 1 for
clinical patient characteristics. Patients received a mean dose of 8mg/kg
(range, 7−9mg/kg), for a median duration of 28 days of treatment (range,
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10–162 days). The overall clinical and microbiological success rate at
end of treatment was 95% (20/21 treated patients). No recurrences in
the follow-up period (mean 75 days, range 30–180) were reported. Of
21 patients, 3 experienced grade 1 adverse events, and 1 experienced
grade 3 CPK level elevation, with complete resolution after treatment
discontinuation.
Conclusion: Our experience suggests that daptomycin was effective and
well tolerated at a mean dose of 8mg/kg for a median duration of 28 days
for S. aureus infections. Determining the optimal dosing regimen for
an antibiotic requires simultaneously maximising efﬁcacy, minimising
toxicity and minimising the selection of resistant organisms. Further
study of high-dose daptomycin in larger cohorts are warranted.
P1230 First description of successful treatment of multiresistant
typhoid fever with tigecycline
P. Pongratz °, H. Laferl, J. Leitner, C. Wenisch (Vienna, AT)
In typhoid fever, resistance to chloramphenicol, ampicillin and
trimethoprim–sulfamethoxazole, extended spectrum cephalosporins and
chinolones is widely spread and resistance to azithromycin and
carbapenems has emerged Herein we describe 4 patients with travel
(Pakistan) associated typhoid fever treated with tigecycline 1×150mg
for 14−21 days. All patients had at least one of the following risk factors,
indicating a severe case: persistent vomiting, severe diarrhoea, abdominal
distension requiring admission.
The demographic and clinical characteristics of these 4 patients with
enteric fever are shown in table 1.
In multiresistant S. typhi infection tigecycline 1×150mg iv daily could
be an save and effective therapeutic option.
P1231 Experience with tigecycline in the treatment of multidrug-
resistant pathogens at a university medical centre in Beirut
T. Baban, M. Yasmin, Z. Kanafani, A. El Zakhem °, S. Kanj (Beirut, LB)
Objectives: The rise in infections due to multidrug-resistant organisms
coupled with the decrease in the development of new antibiotics
has created a challenge to clinicians caring for critically-ill patients.
Tigecycline is a newly introduced broad-spectrum antibiotic. Analyzing
the use of tigecycline would help better evaluate and understand the
value of tigecycline alone or in combination with other antimicrobials
in treating various infections.
Methods: The aim of this study is to evaluate clinical characteristics
and outcomes of patients who have received at least one dose of
tigecycline for various infections between December 2006 and July 2009.
A retrospective review of the patients’ medical records was performed.
Information was collected regarding basic demographics, infection type
and location, concomitant antibiotic therapy, as well as microbiologic
and clinical outcomes.
Results: A total of 116 patients were included in the analysis. The
most common types of infection were ventilator-associated pneumonia
(28.4%), hospital-acquired pneumonia (26.7%), abdominal infections
(23.3%), skin infections (15.5%), and bloodstream infections (6%).
53.4% of infections were acquired in the intensive care unit. Tigecycline
was used for directed therapy in 44% of cases and empirically in 56%
of cases. In 58.6% of cases, concomitant antibiotics were required. The
most commonly isolated resistant organisms in this patient population
were imipenem resistant Acinetobacter spp. (27.4%), followed by
organisms producing extended-spectrum b-lactometers (5.3%). Other
outcomes of interest included sepsis (29.3%), superimposed infection
(19%), and recurrent infection (5.2%). Adverse events that were observed
with tigecycline treatment included elevated creatinine (6%), elevated
transaminases (2.6%), rash (1.7%), C. difﬁcile colitis (5.2%), and
nausea and vomiting (2.6%). The overall mortality rate was 44.8%,
whereas clinical and microbiological cure rates were 29.3% and 16.4%,
respectively.
Conclusion: Patients who received tigecycline had low clinical cure
rates and a high overall mortality. This might be explained by the fact
that tigecycline was mostly used as salvage therapy rather than a ﬁrst-
line agent. A large proportion of patients were critically ill with a high
expected mortality rate due to serious underlying conditions. In addition,
the majority of patients had infections with an MDR organism where the
available options for therapy were seriously limited.
P1232 Use of daptomycin in complicated cases of endocarditis: ex-
perience in a tertiary referral centre in the United Kingdom
I. Das °, T. Saluja (Birmingham, UK)
Background: Infective endocarditis (IE) is a serious form of infection
necessitating speciﬁc antibiotic therapy for a prolonged period with
or without surgery. Medical management can be a challenge because
of pre-existing/new development of organ dysfunction, lack of clinical
response or presence of allergic reaction to the speciﬁc antimicrobial
agents. Presence of resistance in the causative organism to the commonly
recommended antibiotics can also be a major issue as options on the
recommended antibiotic therapy for IE are limited.
Aim and Objectives: An observational study assessing the usefulness
of daptomycin, in the treatment of IE cases which are unresponsive
or intolerant to the recommended ﬁrst line agents. Cases for which the
recommended ﬁrst line agents could not be administered due to presence
of resistance in the causative organisms were also included in the study.
Method: From 1 October 08 to 30 September 09, all cases of IE were
followed up prospectively by the Microbiologists during regular ward
visits. IE cases were noted following positive blood culture reports and
consultation by the Cardiac unit.
Results: Eight of 89 cases of endocarditis were treated with daptomycin.
Median age was 65 yrs (range 25−76 yrs), 50% were male. Native
and prosthetic valves were affected in equal proportions (4 in each
group). Mitral valves were affected in 3 and aortic valve in 5 cases. The
causative organisms were known for all of the cases: Staphylococcus
aureus (2), Coagulase negative staphylococci (2), Enterococcus spp (2),
and viridians streptococci (2). Daptomycin was used as the second line
therapy for all of the cases. The reason for change from the ﬁrst line
antibiotic therapy was: therapeutic failure (4), high level aminoglycoside
resistance in Enterococcus (1), renal insufﬁciency (3), toxicity or allergic
reaction with the ﬁrst line regimen (3).
Prescribed daily doses daptomycin was 6mg/kg (in presence of normal
renal function) and an additional agent was used in 7 of 8 cases. Median
duration of daptomycin therapy was 4−6 weeks with a range of 4−32
weeks. No untoward effect was observed in any of the cases. All of the
cases were successfully treated with no further complications and have
been discharged home.
Conclusion: Daptomycin is well tolerated and is an effective agent in the
treatment of IE especially in cases of therapeutic failure or intolerance
to the ﬁrst line of agents.
P1233 Clinical experience with daptomycin from a regional
Lancashire cardiac centre in northwest England
A. Kumar °, M. Przybylo, S. Summers, A. Guleri (Blackpool, UK)
Background: Lancashire cardiac centre is a tertiary centre located in
Blackpool Victoria Hospital(BVH), a large district hospital in northwest
England. Two years of clinical experience of daptomycin usage is
presented here.
Methods: Outcomes of daptomycin usage were evaluated through
retrospective data collection. Patients’ age, sex, diagnosis, culture results,
treatment outcomes and adverse events were recorded along with the
response to the treatment. The treatment outcomes were categorized
as success (deﬁned as sum of cured and improved), failed and non-
evaluable.
Results: Between Dec 2007 and Nov 2009, daptomycin was used in 40
evaluable patients. Daptomycin was used as second-line therapy or as
concomitant antibiotic therapy for a range of serious infections. All the
patients received treatment in the hospital. The average age of patients
was 61.5 years and 87.5% were males.
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Majority (60%) of the cohort were treated for cardiac infections (50%
endocarditis, 5% pacemaker related infections and 5% aortic root
abscess following cardiac surgery). Of the patients treated for infective
endocarditis, 75% had left sided endocarditis of which 27% were
infection of prosthetic valves. Daptomycin was used as monotherapy
as well as in combination with rifampicin or fusidic acid.
Other indications of daptomycin usage were, soft tissue infections
(22.5%), bacteraemia (7.5%), osteomyelitis (2.5%), pyelonephritis
(2.5%), others(5%).
Conﬁrmed infections with positive cultures were available in 67.5% of
patients. Staphylococcus aureus was the most common isolated pathogen
with only one case of MRSA. The dose of daptomycin ranged between
3.6 to 6.5mg/kg. The most frequently used dose of daptomycin was
6mg/kg (50% of patients).
Serious adverse events were reported in 5 patients (12.5%) and 2 patients
(5%) discontinued the study drug due to side-effects. Details of use in
patients with continuous veno-venous haemoﬁltration and creatine kinase
monitoring to be presented.
The success rate with Daptomycin therapy was 65% (cured 25%,
improved 40%), 10% patients failed to show any improvement while
outcomes were non-evaluable in 25% of the patients.
Conclusions: Daptomycin was well tolerated in our cohort with overall
success rate of 65% in treating a range of serious infections. It was
predominantly used for cardiac patients and/or bacteraemia. Its been
included in the local endocarditis management pathway. 32.5% use has
been in empiric setting. Details to be presented.
Table 1. Infection types and outcomes
Infection type Patients, n (%)
Cured Improved Failed Non-evaluable
All 10 (25) 16 (40) 4 (10) 10 (25)
Endocarditis 8 (80) 5 (31) 1 (25) 6 (60)
Pacemaker infection 0 (0) 1 (6.25) 0 (0) 1 (10)
Aortic root abscess 1 (10) 1 (6.25) 0 (0) 0 (0)
Soft tissue infections 1 (10) 7 (44) 0 (0) 1 (10)
Bacteraemia 0 (0) 0 (0) 2 (50) 1 (10)
Osteomyelitis 0 (0) 1 (6.25) 0 (0) 0 (0)
Pyelonephritis 0 (0) 0 (0) 1 (25) 0 (0)
Others 0 (0) 1 (6.25) 0 (0) 1 (10)
P1234 Lack of serotonin syndrome among Veteran Affairs patients
receiving linezolid
L. Tristani, N. Patel °, B. Woo, A. Dihmess, H. VanDeWall, H. Li,
R. Smith, T. Lodise (Albany, US)
Objectives: Linezolid is a weak monoamine oxidase inhibitor and has
the potential to cause SS, especially when administered with other
serotonergic agents (SA). Limited data are available on the incidence
of SS among patients receiving L. The objective of this study was to
assess the incidence of serotonin syndrome among patients receiving L.
Methods: A retrospective, observational cohort study was conducted
among all hospitalized patients who received L for 48 h between
1/2005 and 8/2008 at the New York VA Health Care Network (VISN 2).
Demographics, co-morbid conditions, laboratory values, microbiology,
treatment data, concurrent SA, and clinical outcomes were collected from
the patients’ medical records. Patients that received L were evaluated
for clinical symptoms of SS using the Sternbach and Hunter Serotonin
Toxicity criteria. For SS and concomitant SA, pts were followed 35 d
prior to start of L to 14 d after discontinuation of L.
Results: During the study period, 298 pts received L therapy and were
included in the analysis. The median (IQR) duration of L therapy was
10 (6–16) days. The most common pathogens were Staphylococcus spp
(45.0%) and Enterococcus spp (34.9%). Of the 298 pts, 287 (96.6%)
were male with a mean (SD) age of 69.2 (12.3) years. The median
number of comorbidities was 2 (IQR 1−4), and the mean (SD) APACHE-
II score was 12.7 (6.5). Concomitant SA were used in 160 (53.7%)
patients. The mean (SD) number of concomitant SA was 1.4 (0.6). Of
the 160 pts receiving concurrent SA, 57 (35.6%) received an SSRI and
74 (46.3%) received fentanyl. None of the 298 VA patients met either
the Sternbach or the Hunter Serotonin Toxicity criteria for SS.
Conclusion: In this VA population with high concomitant use of
serotonergic agents, no cases of SS were observed while receiving L
therapy.
P1235 Safety and effectiveness of daptomycin in patients with
renal insufﬁciency not requiring renal replacement therapy
A. Gonzalez-Ruiz °, K.C. Lamp, M.Y. Lin, R.L. Chaves (Kent, UK;
Lexington, US; Basel, CH)
Objectives: Daptomycin (DAP) is approved in the US and EU and
other regions for the treatment of skin and soft tissue infections (SSTI),
right-sided infective endocarditis (IE) and bacteraemia (BAC). However,
the current approvals differ to some extent regarding pts with reduced
renal function. There is still limited published experience with DAP in
the treatment of patients with renal insufﬁciency. The objective of this
analysis was to describe DAP use in pts with renal insufﬁciency.
Methods: US-CORE (USA) and EU-CORE (Europe and Argentina)
are both retrospective multicenter observational registries. Pts enrolled
from Jan 2007 to Dec 2007 in US-CORE and from Jan 2006 to Sep
2008 in EU-CORE were included. All pts with SSTI, IE or BAC and an
initial estimated creatinine clearance (CrCl) were grouped into those with
values <30, 30−<50, and 50ml/min. Pts receiving renal replacement
therapy were excluded. Safety assessment: all adverse events noted
from the ﬁrst dose of DAP up to 30 days after the last dose of DAP
were collected. Investigators assessed outcome (cure, improved, failure,
nonevaluable) at the end of DAP therapy. Success was deﬁned as cure
or improved.
Results: A total of 1181 pts were identiﬁed; CrCl <30, n = 85 (7%);
CrCl 30−<50, n = 195 (17%); CrCl 50, n = 901 (76%). There were
factors (for example, ICU, outpatient, concomitant antibiotics) that were
different within the infection and renal groups that may have inﬂuenced
the rates of possibly-related AE and success; the overall results are shown
in the table.
Conclusion: In this group of pts, renal function was not associated with
increased rates of adverse events possibly related to DAP. Additionally,
no impact on the efﬁcacy of DAP was observed. Future studies should
control for differences in pt characteristics.
N (%) CrCl (ml/min)
<30 30−<50 >50
SSTI (n = 627) (n = 35) (n = 84) (n = 508)
Possibly-related AE 1 (3) 3 (4) 29 (6)
SSTI Success 27 (77) 71 (84) 434 (85)
SSTI Failure 2 (6) 2 (2) 26 (5)
SSTI Non-evaluable 6 (17) 11 (13) 48 (9)
BAC (n = 395) (n = 35) (n = 74) (n = 286)
Possibly-related AE 1 (3) 5 (7) 24 (8)
BAC Success 28 (80) 58 (78) 208 (73)
BAC Failure 2 (6) 6 (8) 33 (12)
BAC Non-evaluable 5 (14) 10 (14) 45 (16)
IE (n = 159) (n = 15) (n = 37) (n = 107)
Possibly-related AE 0 4 (11) 6 (6)
IE Success 11 (73) 26 (70) 88 (82)
IE Failure 1 (7) 5 (14) 5 (5)
IE Non-evaluable 3 (20) 6 (16) 14 (13)
P> 0.05 for possibly related AE or success by renal group within
infection types.
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P1236 Spectrum of activity of ceftaroline/NXL104 and b-lactam
comparator agents tested against methicillin-resistant
Staphylococcus aureus carrying different SCCmec types and
Gram-negative bacilli with well-characterized resistance
mechanisms
D. Farrell °, R. Mendes, G. Williams, I. Critchley, R. Jones, H. Sader
(North Liberty, Oakland, US)
Objective: To determine the spectrum of activity and potency of ceftaro-
line combined with a ﬁxed 4mg/L concentration of NXL104 (CPT104)
and comparator antimicrobial agents tested against selected molecularly
characterized MRSA carrying different SCCmec types and well-
characterized Gram-negative strains harbouring different b-lactamase
(BL)-encoding genes. Ceftaroline is a novel parenteral broad-spectrum
cephalosporin with activity against Gram-positive (including MRSA
and MDRSP) and -negative organisms, Ceftaroline has limited activity
against extended-spectrum b-lactamase (ESBL)- and AmpC-producing
strains. NXL104 is a novel non-b-lactam BL inhibitor that inhibits
Ambler class A, C, and D enzymes (eg, ESBL, KPC, and AmpC).
Methods: Susceptibility testing for all antimicrobials was performed
by CLSI broth microdilution method (M07-A8, 2009) on a total of
250 strains categorized as follows: MRSA (100 MRSA subcategorized
by SCCmec type [types I-IV and type IV subtypes]); E-ESBL (50
Enterobacteriaceae [ENT] with ESBLs); E-AMPC (49 ENT with Amp-C
enzymes [28 chromosomal, 21 plasmidic]); E-CARB (31 ENT with
carbapenemases [25 KPC, 5 OXA-48, 1 SME]); ACB (10 Acinetobacter
baumannii [3 wild-type, 7 OXA-23, -24, and -58]); and PSA (10
Pseudomonas aeruginosa [2 wild-type, others include AmpC, MexX,
OMP, and metallo-BL producers]).
Results: All MRSA strains were inhibited at 2/4mg/L of CPT104
and ceftaroline MIC was not affected by addition of NXL104. CPT104
was also very active against a wide variety of ENT with ESBL,
chromosomal/plasmidic AmpC, and carbapenemases (highest MIC,
4mg/L). Ceftaroline without NXL104 was not active against the vast
majority of these selected ENT. Although CPT104 demonstrated activity
against wild-type ACB and PSA, activity was low against BL-producing
strains. Ceftazidime and piperacillin/tazobactam (P/T) were inactive
against all six organism categories. Imipenem was active against E-ESBL
and E-AMPC but had very limited or no activity against other categories.
Conclusions: CPT104 was very active against all MRSA regardless of
SCCmec type or subtype and all ENT regardless of BL type, but had
limited intrinsic activity against ACB and PSA expressing a variety of
BLs. CPT104 had a wider spectrum of activity against these resistant
Gram-positive and -negative categories than the four comparators.
CPT104 represents a potential therapeutic option for empiric therapy
in settings where MRSA and BL-positive ENT predominate.
Antimicrobial MIC50/MIC90 (mg/L)
MRSA E-ESBL E-AMPC E-CARB ACB PSA
Ceftaroline 1/2 >64/>64 32/>64 >64/>64 >64/>64 >64/>64
CPT104a 1/2 0.06/0.25 0.12/0.5 0.5/2 16/>32 16/>32
Ceftazidime >16/>16 >16/>16 >16/>16 >16/>16 16/>16 >16/>16
P/T 64/>64 32/>64 32/>64 >64/>64 >64/>64 64/>64
Imipenem >8/>8 0.12/0.5 0.5/1 8/>8 >8/>8 8/>8
aConcentrations reported in the table for CPT104 refer to the concentration of
ceftaroline.
P1237 In vitro and in vivo activity of novel non-quinolone agents
targeting DNA gyrase and topoisomerase IV
M. Mitton-Fry °, L. Brennan, S. Brickner, J. Casavant, D. Fisher,
D. Girard, J. Hamel, J. Hardink, T. Hoang, M. Huband, S. McCurdy,
M. Plotkin, G. Stone, R. Zaniewski, C. Zook (Groton, US)
Objectives: DNA gyrase and topoisomerase IV are proven targets of
high value for antibacterial therapy. We sought to develop a novel series
of non-quinolone agents which would inhibit these targets and thus prove
useful in the treatment of infections caused by Gram-positive organisms,
especially methicillin-resistant Staphylococcus aureus (MRSA).
Methods: Novel analogs were synthesized and assessed using a number
of different techniques. Inhibitory activity against both DNA gyrase
and topoisomerase IV from S. aureus was assessed in vitro. MIC90
studies using isolates of both S. aureus and Streptococcus pyogenes were
also conducted. Analogs with appropriate in vitro potency and suitable
pharmacokinetic properties were subsequently evaluated in both murine
systemic and thigh infections caused by S. aureus. Finally, spontaneous
resistance studies were also conducted in S. aureus. Target mutations
and the resulting elevations in MICs for these mutants were evaluated.
Results: A novel series of analogs was prepared with excellent inhibition
of DNA gyrase (typical IC50 = 1 uM) and a range of inhibition of
the secondary target, topoisomerase IV (IC50 = 5−32 uM for selected
analogs). MIC90 values as low as 0.125 ug/mL against S. aureus and
0.25 ug/mL against S. pyogenes were obtained. The compounds displayed
promising in vivo activity, with PD50 values of ca. 10mg/kg in a murine
septicemia model. Doses required for achieving stasis in the murine thigh
infection model were also favorable (ca. 100mg/kg). Mutant S. aureus
isolates selected under drug pressure typically expressed one of two key
mutations in gyrA, either D83N or M121K. Improved MICs against
these mutant organisms correlated well with superior inhibition of the
secondary target, topoisomerase IV.
Conclusions:We have discovered a novel series of agents targeting DNA
gyrase and topoisomerase IV. These compounds have been shown to
display excellent activity both in vitro and in vivo against key causative
pathogens for serious Gram-positive infections.
P1238 Activity of the investigational ﬂuoroquinolone, ﬁnaﬂoxacin
and seven other antimicrobial agents against 114 obligately
anaerobic bacteria
R. Schaumann °, G.H. Genzel, W. Stubbings, C.S. Stingu,
H. Labischinski, A.C. Rodloff (Leipzig, Berlin, DE)
Objectives: Finaﬂoxacin (FIN) is a novel ﬂuoroquinolone antimicrobial
belonging to a 8-cyano subclass and exhibits enhanced activity at slightly
acidic pH. FIN is active against a wide range of Gram-positive and Gram-
negative aerobes and anaerobes. With the present study, the activity
of FIN was tested against 114 recently strains of obligately anaerobic
bacteria including reference strains and compared with various other
antimicrobials including investigations under acidic conditions.
Methods: The activity of FIN against 73 strains of the Bacteroides frag-
ilis group, 10 other obligately Gram-negative rods and 31 Clostridium
difﬁcile strains was tested and compared with the activity of moxiﬂoxacin
(MOX), levoﬂoxacin (LEV), ciproﬂoxacin (CIP), clindamycin (CLI),
imipenem (IMP), piperacillin/tazobactam (PIT) and metronidazole
(MET). MICs were determined employing the microdilution technique
in Wilkens-Chalgren broth supplemented with vitamin K1 and haemin.
Furthermore, the MICs of FIN against 11 selected B. fragilis strains, the
10 other Gram-negative rods and 10 selected C. difﬁcile strains were
tested under acidic conditions.
Results: The MIC50 and MIC90 values (mg/ml) of the 114 strains tested
are listed in the Table.
Antimicrobial
agent
B. fragilis group
(n = 73)
Other obligately
Gram-negative rods (n = 10)
C. difﬁcile
(n = 31)
MIC50 MIC90 MIC50 MIC90 MIC50 MIC90
FIN 0.5 2 0.06 0.25 4 16
MOX 1 2 0.5 1 8 32
LEV 2 8 0.5 2 32 >64
CIP 8 16 1 16 16 64
CLI 1 8 0.03 64 8 64
IMP 0.25 0.5 0.03 0.06 2 4
PIT 0.5 4 0.06 0.06 0.5 2
MET 0.5 1 0.25 1 0.125 1
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Under acidic conditions FIN has an increased activity against the selected
obligately anaerobes compared to the activity at a neutral pH (data not
shown).
Conclusions: FIN has promising activity against several pathogenic
species of the B. fragilis group and other Gram-negative rods and is
slightly more active than MOX against the obligately anaerobic bacteria
tested here. Under acidic conditions FIN is more active against obligately
anaerobes compared to the activity under neutral conditions.
P1239 Assessment of oritavancin serum protein binding across
species
F. Arhin °, A. Belley, I. Sarmiento, G.A. McKay, T. Parr Jr., G. Moeck
(Ville Saint Laurent, CA)
Objective: Estimates of serum protein binding are essential to translate
drug exposure from nonclinical studies to humans during assessments
of toxicology, pharmacokinetics, and pharmacodynamics. Oritavancin is
a late-stage investigational lipoglycopeptide under study for treatment
of serious Gram-positive infections. Nonspeciﬁc binding of oritavancin
to plastic, glass, and ﬁltration/dialysis membrane surfaces confounds
traditional biophysical methods to assess protein binding. We estimated
binding of oritavancin to human, mouse, rat and beagle dog serum
from serum-induced increases in minimal inhibitory concentrations
(MICs) using arithmetic drug dilutions under conditions that minimize
nonspeciﬁc binding to labware surfaces.
Methods: Serum ultraﬁltrate from each species was prepared using
Centricon Plus-50 ultraﬁlters, whose molecular weight cutoff (50 kDa)
excludes serum albumin. Oritavancin, ceftriaxone and daptomycin MICs
against Staphylococcus aureus ATCC 29213 were determined by broth
microdilution using arithmetic drug dilutions in 95% serum and 95%
serum ultraﬁltrate (supplemented with 5% cation-adjusted Mueller-
Hinton broth) in parallel to assess the impact of serum albumin on
their antimicrobial activity. Serum protein binding for each drug was
calculated as follows: % bound = (1 − [MIC in serum ultraﬁltrate/
MIC in serum])× 100%.
Results: Increases in arithmetic oritavancin MIC in serum vs. serum
ultraﬁltrate, by species, were similar across species (range, 5.5- to 7.8-
fold). Such shifts yielded mean values of oritavancin serum binding
that were similar for the four species tested (range, 81.9% to 87.1%).
Daptomycin binding to serum protein was more variable across species,
ranging from 65.6% to 82.9%. Ceftriaxone was highly bound to human
serum (92.6%) but substantially less bound to serum from mouse, rat,
and beagle dog (range, 20.9% to 37.5%).
Conclusions: The broth microdilution-based method described here
allowed for estimation of oritavancin serum protein binding with
minimal drug losses to labware vessels. This method would likely
be suitable for other drugs exhibiting nonspeciﬁc binding to labware
surfaces. Oritavancin binding to serum was consistent across the species
tested, with serum protein binding values reported here approximating
those reported previously for human serum. These values will support
translation of oritavancin exposure from nonclinical studies to humans.
Agent Human serum Mouse serum Rat serum Beagle serum
fold MIC
increase*
%
bound
fold MIC
increase*
%
bound
fold MIC
increase*
%
bound
fold MIC
increase*
%
bound
Oritavancin 5.5 81.9 6.8 85.3 5.7 82.4 7.8 87.1
Ceftriaxone 13.5 92.6 1.6 37.5 1.5 34.0 1.3 20.9
Daptomycin 5.8 82.9 4.2 76.0 2.9 65.6 3.9 74.5
*The fold MIC increase is the ratio of the mean arithmetic MIC in 95% serum to the mean arithmetic MIC in
95% serum ultraﬁltrate.
P1240 Efﬁcacy of BAL30072, alone and combined with
meropenem, against VIM-producing enterobacteria in a
murine thigh infection model
V. Miriagou °, C. Papagiannitsis, S. Kotsakis, A. Zioga, E. Siatravani,
A. Loli, E. Tzelepi, L. Tzouvelekis, M. Donzelli, J. Spickermann,
M. Page (Athens, GR; Basel, CH)
Objectives: BAL30072 is a siderophore sulfactam active in vitro against
Gram-negative bacteria. The in vivo efﬁcacy of BAL30072 alone and
combined with meropenem, against Klebsiella pneumoniae (K.pn.) and
Escherichia coli (E.co.) strains producing VIM-1 metallo-b-lactamase
was evaluated in a murine thigh infection model.
Methods: 3 K.pn. producing VIM-1 [V-KP], 3 K.pn. producing VIM-
1+SHV-5 [V+S-KP]), 1 E.co. producing VIM-1+CMY-2 [V+C-EC]
and 2 sensitive isolates were used. MIC and MBC of BAL30072
(BAL), meropenem (MEM) and a 1:1 combination (BAL:MEM) were
determined by broth microdilution with inocula of 5×105 and 107
CFU/mL. Neutropenic female CD-1 mice were infected with 106
bacteria. BAL (30 and 60mg/kg), BAL:MEM (30:30 and 60:60mg/kg)
or saline were administered i.p. every 2 h for 24 h. Mice were sacriﬁced
at 0, 6 and 24 h and log10 [CFU/thigh] was determined. Pharmacokinetic
parameters were determined in blood samples taken at intervals after i.p.
injection of a single dose of BAL (30 or 60mg/kg).
Results: BAL was active in vitro against V-KP (MIC0.06, MBC0.06)
and V+C-EC (MIC0.5, MBC0.5) isolates, whereas the V+S-
KP isolates were highly resistant to this compound (MIC16–256,
MBC32–1024). All K.pn. isolates (MIC16–128, MBC16–128) and
the V+C-EC isolate (MIC8, MBC8) were resistant to meropenem.
Reduction of the MICs 16 fold were observed when BAL:MEM was
tested.
The Cmax values were 16.8 and 39.3mg/L for BAL30 and BAL60
dosing schemes, respectively. Peaks were observed at 10min after i.p.
injection, followed by a fast elimination (half-time of 12min). AUC were
determined as 8.5 and 21.6mg.h/L.
In the in vivo experiments, the mean log10 [CFU/thigh] reductions
at 24 h for BAL30/BAL60 regimes were 0.93/1.6 for V-KP, 0/0 for
V+S-KP and 1.03/2.76 for V+C-EC infected animals. BAL:MEM
combinations exhibited higher efﬁcacies resulting in substantial log10
[CFU/thigh] reductions at 24 h (means, respectively for the 30:30mg/kg
and 60:60mg/kg regimes, of 4.1/4.2 for V-KP, 3.8/4.6 for V+S-KP and
6.7/7.8 for V+C-EC infected animals).
Conclusion: BAL was effective against enterobacterial isolates produc-
ing VIM-1 metallo-b-lactamase, but not SHV-5, in the murine thigh
infection model. Co-administration with MEM enhanced the activity
against all isolates, even those producing multiple enzymes which were
resistant to BAL or MEM alone. Further in vivo studies are required to
fully assess the therapeutic potential of BAL30072 and this combination.
P1241 The role of iron transport in the activity of the siderophore
sulfactam BAL30072 against Pseudomonas aeruginosa
M. Page °, C. Mu¨ller, B. Hofer, E. Desarbre, J. Dreier, F. Vidal (Basel,
CH)
Objective: BAL30072 (BAL) is a novel monocyclic b-lactam that is ac-
tive against many aerobic Gram-negative bacteria, including multidrug-
resistant P. aeruginosa (MDR-PA). BAL30072 has a siderophore side
chain that could enhance its activity, especially against strains with
restricted inﬂux due to porin mutations. The role of iron and of
siderophore receptors in the activity of BAL30072 has been studied in
MDR-PA.
Methods: 35 clinical MDR-PA isolates, with a variety of resistance
mechanisms, were investigated. MICs of BAL and comparators were
determined by broth microdilution using cation-adjusted Mu¨ller-Hinton
broth (MH) and Iso-Sensitest broth (IS)as provided by the manufacturer
or supplemented with either 16mg/L 2,2′ bipyridyl (BPL, to induce
siderophore systems) or with 0.01 mM ammonium ferric citrate (AFC, to
repress siderophore systems). Production of the siderophore pyoverdine
was determined spectrophotometrically. Mutants were selected by serial
passage in the presence of increasing concentrations of BAL30072 in IS
broth. PCR primers speciﬁc for the major siderophore receptors (fpvA,
fpvB, fptA, pfeA, pirA) were designed using the published sequences.
Expression levels of the receptors were determined by quantitative
RT-PCR.
Results: The BAL MICs for individual strains differed between MH
and IS by 0−3 doubling dilution steps. Production of pyoverdine by
individual strains differed between MH and IS 2−9 fold. There was little
correlation between pyoverdine production and BAL MIC. Adding BPL
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increased pyoverdine levels in most cultures (up to 10-fold increase)
and adding AFC stopped its production in all cases. There was again
no correlation between pyoverdine levels and BAL MIC. Individual
strains showed increased MIC in the induced state while others had the
expected decreased MIC, compared to the repressed state. There was no
correlation between BAL MIC and the presence, or expression level, of
any one of the major siderophore receptors. None of the mutants selected
for resistance to BAL had a phenotype characteristic of a tonB defect or
deﬁciency in iron-transport.
Conclusions: BAL does not require any one of the major siderophore
receptors for its activity against MDR-PA, nor does it appear to depend
on TonB-mediated uptake. It is possible that BAL is a weak substrate
for several systems and can therefore exploit any one of these that
is available. This contrasts with the behaviour of earlier siderophore
b-lactams.
P1242 The antibacterial activity of MUT056399, a speciﬁc FabI
inhibitor against staphylococci
S. Escaich °, C. Soulama, F. Moreau, V. Gerusz, V. Vongsouthi (Paris,
Romainville, FR)
Background: MUT056399 was designed and optimized as a speciﬁc
inhibitor of S. aureus FabI enzyme. Its spectrum of activity was
investigated against a panel of 658 bacterial strains and fungi.
Methods: Strains used were methicillin-susceptible and non susceptible
S. aureus (MSSA and MRSA), VISA and Linezolid-resistant isolates.
Standard procedures were used for the MIC and time-kill experiments.
Linezolid and Vancomycin were used as comparators.
Results: MUT056399 was highly active against 129 S. aureus isolates
including MSSA, MRSA and CA-MRSA (MIC50/90:0.03/0.12mg/ml).
MUT056399 was also very potent against coagulase negative staphylo-
cocci (165 isolates Methicillin susceptible or resistant) with MIC50/90
=0.06/2mg/ml. MUT056399 had no activity against enterococci and
streptococci. A. baumannii was susceptible, some isolates showed high
MICs.
In Gram negative bacteria H. inﬂuenzae and Neisseria spp. were
very susceptible to MUT056399 (MIC90 = 0.03 and 0.25mg/ml). The
Enterobacteriaceae showed variable susceptibilities with high activity on
E. coli and P. mirabilis (MIC50 = 0.5−1); C. freundii; M. morganii &
S. marcescens being non-susceptible. P. aeruginosa was not inhibited
by MUT056399. The intracellular pathogens C. pneumoniae was
susceptible to MUT056399, but the atypical pathogen M. pneumoniae
and M. fortuitum were not inhibited by MUT056399. L. pneumophila
was susceptible with MIC90 = 0.5. Finally, MUT056399 was inactive
against anaerobes and yeasts.
MUT056399 demonstrated an in vitro bacteriostatic activity at 4 times
the MIC against MSSA, MRSA, Linezolid resistant, and VISA (mean
reduction of 2 log10 cfu/ml at 24 hours). Spontaneous resistance
frequency was low in 6 strains of S. aureus (2.5−7×10−9 at 4×MIC).
In vitro resistant clones were isolated, and point mutations in the active
site of the Fab I enzyme were linked to MUT056399 resistance.
Conclusions: The novel FabI inhibitor MUT056399 has a speciﬁc
spectrum of activity for bacteria which are strictly dependant on the
FabI enzyme for fatty acid synthesis. It is very potent against S. aureus,
a range of resistant isolates and coagulase negative staphylococci. These
properties support MUT056399 as a very promising new chemical entity
to treat speciﬁcally the staphylococcal infections.
P1243 Action of novel copper compounds on the viability of
Helicobacter pylori
F. Perna, T. Hall, S. Hickok, V. Gant, D. Vaira, J. Holton ° (Bologna,
IT; London, UK)
Objectives: Owing to the increasing prevalence of antibiotic resistance
in H. pylori and the falling eradication rate, novel antimicrobial agents
are being actively sought. One novel biocide is a series of highly
reductive copper complexes that have broad antimicrobial activity. These
compounds have no effect upon eukaryotic cell viability until an excess
of 100ppm. Copper is also recognized as angiogenic and may have
healing effects on ulcers. Therefore we have investigated the action of
two of these compounds on the viability of Helicobacter pylori.
Methods: Cag A positive (NCTC11637); CagA negative (NCTC 12908
and ACTC J99) and 53 clinical isolates were tested. For 5 of the
isolates a kill curve was performed with an inoculum of 107−8 cfu/ml
in sterile water at differing concentrations (0.5, 1.0, 5.0, and 12ppm) of
two copper compounds CuAL42 and CuPC33 for 15, 30, 60 and 120
minutes. At each time point samples were withdrawn, decimal diluted
into 1/4 strength Ringers lactate, plated and incubated. Subsequently all
the isolates were tested at the same inoculum against 12 ppm for 60
and 120 mins. The plates were incubated for 5 days at 370 C in an
atmosphere generated by CampyGen (Oxoid UK).
Results: CUAL42 was more active than CUPC33. At 5ppm the viable
count was reduced by 5−6 logs at 2hrs whilst for CUAL42 at 1 hour and 2
hours respectively 20 and 40 isolates were completely killed compared to
CUPC33, where 16 and 34 isolates were killed at 1 and 2 hours exposure.
Neither Cag A status nor antibiotic sensitivity bore any relationship to
the efﬁcacy of the copper compounds.
Conclusions: These novel copper compounds deserve further study in
relation to eradication of Helicobacter pylori
P1244 Global screening of therapeutic bacteriophage preparations
against clinical isolates of Pseudomonas aeruginosa
S. Morales, G. Mearns, A. Smithyman ° (Sydney, AU)
The ongoing rise in antibiotic resistance has prompted renewed interest in
bacteriophage (phage) therapy as an alternative or complimentary means
of treating bacterial infection. Phage therapy refers to the targeted use of
lytic phages to destroy pathogenic bacteria. By their nature phages are
generally highly speciﬁc, with a spectrum of reactivity from the genus
to sub-isolate level.
This gives phage therapy a major advantage over antibiotics as normal
bacterial ﬂora are unaffected by treatment. However such speciﬁcity can
also be a disadvantage in that a phage preparation developed in one
country against the dominant isolates of a particular bacterial pathogen
may prove too speciﬁc to that region and thus ineffective in a different
geographical location.
Objectives: To investigate the reactivity of therapeutic bacteriophages
developed in Australia against clinical strains of P. aeruginosa in four
geographical locations, namely Australia, the United Kingdom, United
States and Central America.
Methods: Lytic phages were isolated from environmental sources and
screened against a representative panels of 100 P. aeruginosa clinical
isolates collected in Australia. Combinations of these phages were then
tested for their speciﬁc and broad activity against 550 isolates in four
separate geographical regions.
Results: Therapeutic phages showed a very broad host range infecting
over 85% of the P. aeruginosa isolates tested.
Conclusion: Lytic phages with broad speciﬁcity for P. aeruginosa were
combined into phage cocktails and tested in vitro against a wide range of
clinical targets from four geographical areas. The phage cocktails reacted
with over 85% against the isolates tested, with only minor variations
between the geographical areas screened. This study showed that the
speciﬁcity of bacteriophages can be addressed during the development
of therapeutic products to ensure a wide coverage of the targeted bacteria
around the world.
P1245 In vitro cytotoxicity testing of bacteriophages against
Acinetobacter spp.
A.E. Henein °, G.W. Hanlon (Brighton, UK)
Objectives: Acinetobacter spp. have emerged as a major clinical chal-
lenge, due to multiple and pan-drug resistance, particularly in high-risk
patients, including those with severe burns. Bacteriophages have shown
promise in applications as systemic and topical antibacterials, as well as
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FDA-approved food decontaminants. No previous comprehensive studies
have been published investigating cytotoxicity and cell proliferation of
puriﬁed phage suspensions on (human) dermal cells in vitro.
Methods and Results: A 3T3 mouse ﬁbroblast cell line, human
dermal ﬁbroblasts (HDF) and keratinocytes (HDK) with 3T3 feeder
layers were exposed to dilutions of puriﬁed phage. The cytotoxic
impact and effect on cell proliferation were measured using a range
of assays. No statistically signiﬁcant difference could be detected
between controls and phage with the Trypan blue method (3T3 cells
only). 3T3 cell Hoechst Propidium Iodide stain experiments remained
inconclusive; There was no statistically signiﬁcant difference between
concentrated phage samples and controls at any time points. After 72
hour incubation, controls gave rise to signiﬁcantly higher cell counts
than dilute phage preparations (p< 0.001). Lactate dehydrogenase (LDH)
and MTS tetrazolium compound reduction results showed no evidence
of statistically signiﬁcant cytotoxic effect of phage on 3T3 cells, HDF
or HDK. Some data suggested phage may have a beneﬁcial effect on
cell survival of HDK (p< 0.001) and proliferation of HDF (p< 0.001)
and 3T3 cells (p< 0.05) compared to controls. Colony formation assays
utilising a V79 hamster cell line were used to indicate the cytotoxicity of
puriﬁed phage in different diluents. There was no statistically signiﬁcant
difference in terms of colony numbers or colony size (where measured)
between phage samples and controls.
Conclusion: Bacteriophages lytic against Acinetobacter spp. had no
cytotoxic effects on a range of cultured skin cells but may even
exert a positive effect on cell proliferation. With the FDA having
granted GRAS status to Listeria bacteriophages in food decontamination,
the next logical step would be to consider concentrated phage
suspensions as wound decontaminants and antibacterials in multiple-
resistant Acinetobacter spp. infections, particularly in burns patients.
P1246 Antibacterial activity of supercritical Usnea barbata
extract against staphylococci, streptococci and enterococci
originated from animals
D. Misic °, J. Ivanovic, I. Zizovic (Belgrade, RS)
Objectives: Studies of antimicrobial activity of extracts obtained by the
process of supercritical ﬂuid extraction (SFE) are mainly performed on
foodborne pathogens because of potential use of supercritical extracts
as food additives. Due to the lack of new antibiotics on the market,
studies of antibacterial activities of supercritical extracts on pathogenic
bacteria are more present nowadays, with the objective to treat humans
and animals in cases of infections. It is well known that plant extracts
obtained by different technologycal processes have good antimicrobial
activity, but mostly, they contain traces of organic solvents so they are
unsuitable for pharmaceutical and nutritional use. Plant extracts obtained
by SFE do not contain any solvents.
Methods: In this investigation, lichen Usnea barbata was used for the
SFE. Supercritical extraction with CO2 as a slovent was performed in
the Autoclave Engineers Screening System at pressure of 30 MPa and
temperature of 60ºC. For the determination of MIC values of supercritical
usnea extract, broth microdillution method (CLSI, 2008) was used, and
the extract was previously dissolved in 1−2 propanediol. For comparison
of the results, erythromycin was included too. The investigation has
been performed on 14 Staphylococcus, Streptococcus, and Enterococcus
strains of animal origin including VRE, MRSA and ATCC strains.
Results: Determined MIC values of the supercritical usnea extract
for all strains ranged from 1.25 to 80 mcg/mL and MIC values
of erythromycin ranged from 0.06 to >32 mcg/mL. The strongest
antibacterial activity with MIC value of 1.25 mcg/mL usnea extract
showed on two S. intermedius strains isolated from dogs’ skin swabs. The
weakest antibacterial activity with MIC value of 80 mcg/mL supercritical
extract showed on S. aureus ATCC 11632 and on 1 MRSA strain isolated
from dog’s wound swab. Investigated supercritical extract showed good
antibacterial activity against streptococci and enterococci including VRE
with obtained MIC values of 10 to 40 mcg/mL. One methicillin-resistant
S. haemolyticus strain isolated from ear swab of cat and 1 S. uberis strain
originated in guinea pig were resistant to erythromycin with MIC value
>32 mcg/mL but MIC values of supercritical extract for these two strains
were signiﬁcantly lower, 10 to 20 mcg/mL.
Conclusion: According to obtained low MIC values, investigated
supercritical usnea extract showed very strong antibacterial activity
against investigated bacteria.
P1247 The potential of a naturally-produced inhibitory substance
(E226), which is produced by Staphylococcus epidermidis
strain E226 and shows activity against epidemic MRSA-15
M. Al-Mahrous °, J. Tagg, M. Upton (Manchester, UK; Dunedin, NZ)
Objectives: In recent years, there has been much focus on a promising
class of bacteriocins known as lantibiotics. The most prominent
representative of lantibiotics, nisin, has already a long history of use
in the protection of foodstuffs. Lantibiotics have also been considered
for application in humans; however, they have not yet been used in the
setting of chemotherapy on the same scale as traditional antibiotics.
We here investigate the cationic peptide antibiotic (E226) as a future
opportunity for treating staphylococcal infections.
Methods:
1. Investigation of S. epidermidis strain E226 was performed using
simultaneous and deferred-antagonism against MRSA
2. Puriﬁcation and/or concentration of free inhibitors in broth super-
natants was carried out using ammonium sulphate precipitation, Sep-
Pak® cartridge, Speed-Vac®, Cation-exchange; then C18 reverse-
phase chromatography.
3. MALDI TOF/TOF was used for mass analysis
4. Electron microscopy was used for ultra-structure diagnosis of a range
of MRSA indicators
5. Biological activities were tested using spot-on-loan assay
Results: The biological activity of E226 is heat-stable and displaying
speciﬁcity for the closely-related S. aureus.
The high ammonium sulphate saturation (80%) needed for pre-
cipitating E226 suggests its small mass. The cationic-exchange
chromatography (pH 5.2) and the late elution from C18 column suggest
the cationic nature of E226. MALDI TOF/TOF showed 3 species and
sized the mass in a window between 2000 and 2800Da (Figure 1). This
suggests further puriﬁcation using high resolution HPLC to eliminate, if
any, unrelated species.
The Electron microscopy diagnosis reveals a clear damage in the cell
wall.
Figure 1. [A] Isolation of the active fraction using HPLC; [B] Detection
of peptide species of E226 using mass spectrometry. Resulting amino
acids were detected on a time-of-ﬂight (TOF) mass spectrometer with
matrix-assisted-laser-desorption ionization (MALDI).
Conclusions:
1. The biological activity of the highly-puriﬁed extract of the heat-stable
small mass inhibitory agent E226, which shows speciﬁc inhibitory
activity against Epidemic MRSA-15 and strains of MSSA, suggests
its nature as a bacteriocin, possibly of Class-I.
2. The cationic-exchange separation and late elution of E226 from C18
reverse-phase column suggest that it is a hydrophobic in nature.
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3. Based on the electron microscopy diagnosis, E226 shows obvious
damage to the protective cell wall of the sensitive indicators. This
postulates the binding of the hydrophobic E226 to the negatively-
charged lipid-II in the cell-membrane resulting in its lysis.
4. E226 could have potential as topical therapeutic agents for treating
highly drug-resistant staphylococcal infections.
P1248 Lethal photosensitization of Enterococcus using Fotolon®,
a chlorine e6 derivative
E. Dworniczek, M. Trendel, M. Wawrzynska, A. Seniuk, W. Strek,
B. Kowalska-Krochmal ° (Wroclaw, PL)
Objective: The growing resistance of enterococci to conventional antimi-
crobial agents necessitates the development of alternative approaches to
treating infections. Photodynamic inactivation (PDI) may be effective
therapeutic option in which the non-toxic photosensitizers (PS) in
combination with activating light, generate cytotoxic species. This
investigations aimed to determine PDI efﬁciency using Fotolon® against
Enterococcus strains.
Methods: PDI employed Fotolon®, (Belmedpreparaty, Belarus) and 662
nm diode laser light, against 9 clinical strains (4 E. faecalis, 4 E. faecium,
1 E. casseliﬂavus), and 1 reference strain (E. faecalis ATCC 29212).
The antibacterial spectrum of the photosensitizer was evaluated by zone
of inhibiting testing. The minimal inhibitory concentration of PS was
determined using the broth dilution method. For evaluation of phototoxic
properties of Fotolon strains were incubated with different concentrations
of the medication and exposed to ﬂuencies of 662 nm laser light (5, 10,
20, 40 J/cm2). The viability of bacteria was assessed by a colony forming
assay. Visualization of the bacterial structure pre- and post photodynamic
inactivation was performed in transmission electron microscope (SEM).
Results: All strains of Enterococcus were susceptible to killing by PDI.
The bactericidal effect depended on the concentration of Fotolon and
light dose. Fotolon in concentration of 40 mg/mL activated by laser
light 40 J/cm2 was the most effective and reduced >50% of bacterial
populations tested. However, for some strains the best results in reduction
of viable cells were obtained for lower concentration of Fotolon. The
laser light alone did not affect the bacteria signiﬁcantly. Maximal
light dose (40 J/cm2) reduced <5% of enterococcal populations.
Fotolon and light inﬂuenced the morphology of bacterial colonies.
Different size colonies were observed after treatment with activated
photosensitizer. SEM analysis revealed destructive changes in the cell
structure. E. faecalis and E. faecium showed internal, electron lucent
areas, not seen in control cells, which may indicate chromosomal
alteration and condensation of DNA.
Conclusion: Photodynamic inactivation may be a useful approach in the
treatment of enterococcal infections. These results showed that PDI with
Fotolon acts lethally on different species of Enterococcus. However, the
effectiveness of inactivation was dependent on the particular strain.
P1249 Ototoxic potential of ACHN-490 compared to gentamicin
and amikacin in the guinea pig
C.F. Kostrub, D.F. Dolan, R.A. Altschuler, T.J. Baird, R.L. Tapp,
J.A. Boggs, J.B. Bruss ° (San Francisco, Ann Arbor, Mattawan, US)
Objectives: ACHN-490 is a “neoglycoside”, a next-generation aminogly-
coside (AG), currently being advanced through clinical development by
Achaogen, Inc. ACHN-490 shows broad-spectrum bactericidal activity
in vitro, and its potency is unaffected by most types of AG-modifying
enzymes that confer resistance to AGs. In the present studies, the ototoxic
potential of ACHN-490 relative to the AG comparators gentamicin and
amikacin was investigated over 28 days in guinea pigs. The relative
ototoxicity of shorter duration gentamicin treatment (1, 3, or 5 days)
was also studied.
Methods: In the guinea pig model, compounds were administered
once-daily for 14 days, and both structural and functional evaluations
for ototoxicity were employed. Auditory function was quantiﬁed by
comparing pre-dose and terminal auditory brainstem response (ABR)
values at each of 3 stimulus frequencies (4, 10, and 20 kHz). In addition,
cochleas were removed and examined histologically for evidence of hair
cell damage. Short-term dosing was investigated by dosing separate
cohorts of animals for 1, 3, or 5 days, and assessing ABRs both 1
day after the last dose for each cohort and again 28 days after the initial
dose for all cohorts.
Results: Gentamicin at 80 or 100mg/kg/day for 14 days produced
substantial hearing loss. Amikacin, with less antibacterial potency but
roughly an equivalent therapeutic index in comparison to gentamicin, was
associated with profound hearing loss at a therapeutically comparable
dose of 300mg/kg/day. In both cases, histological analyses showed
cochlear hair cell loss consistent with the functional ABR shift.
By contrast, ACHN-490 demonstrated no signiﬁcant effects on ABR
thresholds up to a dose of 80mg/kg/day, with no hair cell loss, as
determined by cytocochleogram analyses. Gentamicin administration
(80mg/kg/day) for 1, 3, or 5 days did not result in signiﬁcant functional
ABR shift or histopathological evidence of ototoxicity.
Conclusions: The absence of ototoxicity observed for ACHN-490 in
this 28-day guinea pig model suggests a lower ototoxic potential for
ACHN-490 compared to gentamicin. The absence of hearing loss with
shorter courses of gentamicin may support the hypothesis that the risk
of AG-induced ototoxicity could be mitigated by avoiding extended
treatment regimens. Taken together, these studies provide rationale for
the continued clinical investigation of ACHN-490 in high-dose, short-
course antimicrobial therapy.
P1250 Imidazolines as non-classical bioisosteres of N-acyl
homoserine lactones and Quorum sensing inhibitors
A. Bucio-Cano, M. Montenegro-Sustaita, E. Curiel-Quesada °,
A. Reyes-Arellano, G. Aparicio-Ozores (Mexico City, MX)
Objectives: Synthesis of six non classical N-acyl homoserin lactone
bioisosters and evaluation of their inhibitory effects on quorum sensing
in Chromobacterium violaceum and Serratia marcescens.
Methods and Results: Imidazolyl ethers were synthesized by alkylation
of 4-hydroxibenzadehyde followed by cyclization with ethylenediamine.
Imidazolyl amides were synthesized by reaction of 4-amino benzonitrile
with organic acids followed by cyclization with ethylenediamine.
Products were characterized by NMR and EM. Structures of synthesized
bioisosters are shown in Figure 1.
Figure 1. 3a: R = O–CH2–(CH2)4–CH3; 3b: R = O−CH2–(CH2)7–CH3;
3c: R = NH−CO–CH2–(CH2)3–CH3; 3d: NH−CO–CH2–(CH2)6–CH3.
In order to study their effect on QS, test bioisoster was added to
bacterial cultures at ﬁnal 100 pM to 1 mM concentrations and cultures
were incubated for 15 h. Growth was monitored at OD720 while
violacein production was measured at 577nm. For prodigiosin synthesis,
S. marcescens was incubated for 48 h and pigment was recorded at
540 nm.
Molecular epidemiology of ESBL S351
Figure 1 shows speciﬁc violacein production in the presence of four of
the bioisosters assayed.
Molecular epidemiology of ESBL
P1251 Emergence of ESBL-producing Klebsiella pneumoniae in
Danish hospitals: this is in part explained by spread of one
CTX-M-15 clone in Zealand
C.H. Lester °, S.S. Olsen, M. Arpi, K. Fuursted, D.S. Hansen,
O. Heltberg, A. Holm, T. Højbjerg, K. Truberg Jensen, H. Krogh
Johansen, U. Stenz Justesen, M. Kemp, J. Dahl Knudsen, B. Røder,
N. Frimodt-Møller, A.M. Hammerum (Copenhagen, Herlev, Aarhus,
Hillerød, Næstved, Odense, Aalborg, Esbjerg, Vejle, Hvidovre, Slagelse,
DK)
Objectives: The spread of resistance to third-generation cephalosporins
in Klebsiella pneumoniae is a continuing cause of public health concern.
Before 2007 the occurrence of third-generation cephalosporin resistance
was low among K. pneumoniae isolated from bloodstream infections
in Danish patients. However, the rate of resistance has increased from
4.4% in 2006 to 10.8% in 2008 (EARSS). The aim of the present study
was to investigate the spread of third-generation cephalosporin resistant
K. pneumoniae in Danish hospitals and to do a molecular characterisation
of the collected isolates.
Methods: All Danish Departments of Clinical Microbiology were asked
to send third-generation cephalosporin resistant K. pneumoniae isolated
from blood in 2008 to Statens Serum Institut, Denmark. ESBL and/or
AmpC phenotypes were tested using the NeoSensitabs double disk
method (Rosco Diagnostica, Ta˚strup, Denmark). Based on the obtained
phenotypes, PCR ampliﬁcation and sequencing was performed with
primers speciﬁc to identify blaTEM, blaCTX_M, blaOXA, blaSHV and
ampC b-lactamase genes. All ESBL and ampC positive isolates were
PFGE typed. The PFGE patterns were compared using Bionumerics 6.01
(Applied Maths, Sint-Martens-Latem, Belgium).
Results: In total, 80 isolates were received: 77 isolates were ESBL
positive, 2 isolates were ampC positive and 1 isolate was both ampC
and ESBL positive. Among the ESBL positive isolates 47% (n = 37)
belonged to the same PFGE cluster and had the genetic proﬁle: CTX-
M-15, SHV-28. The isolates in this cluster originated from eight hospitals
all located in Zealand. Another cluster included nine isolates (12%) with
the genetic proﬁle CTX-M-15, SHV-1. The isolates in this cluster were
all from hospitals in Copenhagen. The three ampC positive isolates were
positive for the DHA-1 gene and PFGE showed that they were possibly
related (>85% similarity). Among the 78 ESBL positive isolates, CTX-
M-15 was detected in 64 isolates (82%); CTX-M-14 was detected in ﬁve
isolates.
Conclusion: Emergence of third-generation cephalosporin resistance
among K. pneumoniae in Denmark is mostly due to ESBL-producing
isolates; 82% of the isolates contain CTX-M-15. Many of the isolates
were clonally related (47%); these isolates were recovered from one
region of the country (Zealand) indicating clonal spread within the
hospitals in this region.
P1252 Molecular epidemiology and genetic background of
extended-spectrum b-lactamase producing Escherichia coli
isolated from human clinical samples in Hungary, 2006–2007
I. Damjanova °, A´. To´th, T. Mag, S. To´th, G. Hajbel-Ve´kony, J. Pa´szti,
M. Fu¨zi (Budapest, HU)
Objectives: There is limited information on dissemination of ESBL-
producing E. coli in Hungary, thus study was conducted for character-
izing representative collection of isolates from human clinical samples.
Materials and Methods: During 2006–2007 113 ESBL-producing
E. coli clinical isolates were submitted to the National Center for
Epidemiology for further investigation. Of these 45 isolates from 21
centres were selected for molecular typing and genetic characterization.
Antibiotic susceptibility testing by agar dilution and serotyping were
performed by standard methods. PCRs and sequencing of ESBL-genes
(blaCTX-M, blaSHV, blaTEM), PCR for ST131 strains, PFGE and
phylogenetic group (PG) determination were done.
Results: The majority of strains carried resistance to more than two
drugs. Several b-lactamases were detected (SHV-2, -5, -12, TEM-1,
CTX-M-1) with CTX-M-15 being the most common. Only 9 strains
belonged to comensal PGs A and B1, 36 strains proved to be members
of B2 and D PGs. 46% of strains (21/45) from 12 centres belonged to
the international O25-ST131/B2 clone, while 9 isolates from 7 centers
shared O15 serotype. Serotypes O8 and O9 were presented by two-two,
and serotypes O1, O142 and O162 by one isolate each. 22 different PFGE
proﬁles were distinguised, with 18 O25-ST131/B2 strains representing
EC003 cluster, and 8 O15/D strains representing two closely related
clusters (EC026 and EC027).
Conclusion: This is the ﬁrst comprehensive study on molecular
epidemiology of ESBL-producing E. coli clinical isolates in Hungary.
The ciproﬂoxacin-resistant CTX-M-15-producing O25-ST131/B2 and
O15/D strains proved to be widespread among Hungarian healthcare
facilities.
P1253 Local epidemiology of ESBL and AmpC producing
Enterobacteriaeceae seen in urine samples in Glasgow
P.M. Lansdell, J. Boyes, N. Khanna, A. Hamouda, A.M. Younes,
S.G. Amyes ° (Glasgow, Edinburgh, UK)
Aims:
1. Deﬁne the prevalence of AmpC/ESBL (extended spectrum b-lactam-
ases) producing organisms in our urinary isolates.
2. Compare the distribution of isolates for age, location and organism
type.
3. Identify common genotypes from community and hospital isolates.
Methods: Isolates were taken over a 12-week period from community
and hospital urine samples received at our laboratory. The isolates
underwent identiﬁcation and antibiotic sensitivity testing as deﬁned
by the Health Protection Agency. Isolates resistant to amoxicillin
and cephalexin had this conﬁrmed by the Vitek2® system. Isolates
sensitive to amoxicillin or cephalexin, or if they could not be
identiﬁed by Vitek2®, were discarded. The ﬁnal set then had their
antibiograms conﬁrmed using CLSI and Vitek2® methodologies.
Phenotypic resistance mechanisms were identiﬁed using Vitek2®, HPA
and MAST ID ESBL/AmpC methods. Of these ESBL and AmpC
producing organisms a selection of underwent PCR genotyping.
Results: 9139 samples were processed of which 347 potential
ESBL/AmpC producing isolates from 256 patients were identiﬁed. Of
these isolates 219 were identiﬁed as E. coli, 56 as Klebsiella species,
30 Enterobacter species, 17 Serratia marcesans, 14 Citrobacter species,
8 Morganella morganii and 3 Proteus species. Amongst our E. coli
54.8% were phenotypically ESBLs, 16.9% were phenotypically AmpC
producers and 3.2% showed duel mechanisms of resistance. We saw 116
isolates from the community and 231 isolates from inpatient locations.
The predominant inpatient location was general medical wards. 53.3%
of isolates were from the over 75 age group. A set of CTX-M ESBLs
were genotyped; 90% were conﬁrmed as CTX-M producers but only
60% were identiﬁed as being CTX-M-15, the commonest CTX-M type
in the UK.
Organism Number
(%)
ESBL
(%)
AmpC
(%)
Duel
(%)
Neg
(%)
E. coli 219 (63.1) 120 (54.8) 37 (16.9) 7 (3.2) 55 (25.1)
Klebsiella species 56 (16.1) 49 (87.4) 3 (5.4) 1 (1.8) 3 (5.4)
Enterobacter species 30 (8.6) 0 19 (63.3) 9 (30) 2 (6.7)
S. marcescens 17 (4.9) 2 (11.8) 14 (82.4) 0 1 (5.8)
Citrobacter species 14 (4) 2 (14.3) 10 (71.4) 2 (14.3) 0
M. morganii 8 (2.3) 0 7 (87.5) 1 (12.5) 0
Proteus species 3 (0.9) 1 (33.3) 2 (66.7) 0 0
Total 347 174 (50.1) 92 (26.5) 20 (5.8) 61 (17.6)
Conclusions: Our study shows almost 14% of our Enterobacteriaeceae
are potential AmpC/ESBL producers, with over 80% conﬁrmed
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phenotypically as producing either ESBL or AmpC or both. These
organisms are seen most often in the over 75 age group and on
general medical wards. In addition genotyping suggests common
enzyme types in community and hospital isolates, raising concerns over
treatment options for patients, with only parenteral antibiotics being
available. In conclusion we feel current data on community and hospital
prevalence, age distribution, resistance mechanism and organism type of
ESBL/AmpC producers is lacking. We hope to raise awareness of these
organisms and the impact they have on patient care.
P1254 Shifts in extended-spectrum b-lactamase types with
increasing prevalence of Escherichia coli producing
extended-spectrum b-lactamase in western Sweden
L. Helldal °, N. Karami, S. Skovbjerg, K. Floren, C. Unosson,
C. Welinder-Olsson, E. Moore, C. Ahren (Gothenburg, SE)
Objectives: Contrary to other multidrug-resistant pathogens, the
prevalence of bacteria producing extended-spectrum b-lactamase (ESBL)
is increasing rapidly in Sweden. In Europe, ESBL of CTX-M-, TEM-,
OXA- and SHV-types are generally associated with E. coli infections,
CTX-M being the most predominant. We have investigated how the
prevalence of these types has changed during the last ﬁve years in the
low endemic setting of western Sweden.
Methods: Yearly resistance in urinary (approximately 10,000 iso-
lates/year) and blood (approximately 250 isolates/year) E. coli during
2004–2008 were determined. Cephalosporin-resistant isolates were
screened for ESBL, using a double-disk assay with clavulanic acid as
the inhibitory agent. All ESBL-E. coli isolated in the region during
the periods Sept 2003-April 2005 (n = 46) and April 2008-March 2009
(n = 256) were typed by multiplex-PCR, detecting CTX-M, TEM, OXA
and SHV. CTX-M-positive isolates were sub-typed by real time Q-PCR
for CTX-M-1, CTX-M-2 and CTXM-9 groups.
Results: During 2004–2008, ESBL-producing E. coli strains increased
from 0.3−1.5% in urinary and 0−1.4% in blood isolates. Resistance to
quinolones and trimethoprim was observed in 60−80% of strains, as
compared to less than 8% in non-ESBL-producing E. coli. The majority
of the ESBL-E. coli strains possessed the CTX-M gene-type, increasing
from 78% (36/46) in 2003–2005 to 93% (238/256) in 2008–2009.
Between these time-periods, a marked shift occurred in the distribution
of CTX-M types, in that strains with the CTX-M-9 group decreased from
42% (15/36) of isolates to 21% (51/238, p = 0.01) and, simultaneously,
strains with the CTX-M-1 group increased from 58% (21/36) to 78%
(185/238, p = 0.02). Furthermore, strains of CTX-M-type exhibiting also
TEM- and/or OXA increased to comprise 86% of cases, as compared to
75% previously. Similar trends were seen for community and hospital
detected isolates and with no differences associated with age in affected
patients.
Conclusion: A steady increase in multidrug-resistant ESBL-E. coli,
possessing the genes for multiple ESBL-types, was observed in western
Sweden, contrary to the patterns of other multidrug-resistant bacteria. As
ESBL has increased during the ﬁve-year study period, we detected a shift
in the prevalence of ESBL-types, currently dominated by the CTX-M-1
group. These observations suggest that a novel ESBL-producing E. coli
clone may have emerged in the area, which will be further investigated
and presented.
P1255 Continuous spread of E. coli producing extended-spectrum
b-lactamases CTX-M-3 and CTX-M-15 in Bulgaria from
2002 to 2009
R. Markovska °, I. Schneider, E. Keuleyan, M. Sredkova, D. Ivanova,
B. Markova, T. Kostyanev, I. Mitov, A. Bauernfeind (Soﬁa, BG;
Munich, DE; Pleven, BG)
Objectives: Previous investigations have shown that CTX-M-type
extended-spectrum b-lactamases (ESBLs) became the most widespread
enzymes in Bulgaria since 2002, particularly in E. coli. The aim of this
work was to characterize the epidemiology of CTX-M-producing E. coli
in seven clinical centres from three towns in Bulgaria.
Methods: Antibiotic susceptibility was determined by the disc diffusion
method (CLSI, 2005). The ESBL-production was conﬁrmed by the CLSI
double disc ESBL conﬁrmatory method. Conjugation was performed on
solid medium. Isoelectric focusing, followed by bioassay, ESBL-group
speciﬁc PCR as well as sequencing of ESBL genes for representative
isolates were carried out. Epidemiological analysis was performed
by RAPD with ERIC-1A and ERIC-2 primers and PstI plasmid
ﬁngerprinting.
Results: During a survey on ESBLs in Bulgaria from 2002 to 2009,
196 ESBL-producing E. coli from seven centres in three different
towns were detected. The most widespread enzymes were those of
the CTX-M-type (86%). CTX-M producing E. coli could be divided
into two main groups: 11 isolates (6%) from four centres harboured
an enzyme with a pI of 8.6 which was identiﬁed as CTX-M-3. All
other isolates (185; 94%; from seven centres) showed b-lactamases
with a pI of 8.8 corresponding to CTX-M-15. 18 strains additionally
produced a b-lactamases with a pI of 8.2 (SHV-12), while two E. coli
co-produced TEM-139. Epidemiological analysis by RAPD revealed a
broader diversity of RAPD-types among CTX-M-3 producing E. coli.
In contrast, the CTX-M-3 encoding plasmids showed only one dominant
type. Among 128 CTX-M-15 producers investigated, 95 isolates (74%)
from four centres showed an identical ERIC type. The remaining
isolates clustered in 14 ERIC types consisting of one to six members.
However, plasmid ﬁngerprinting showed a broader variety among CTX-
M-15 encoding plasmids than blaCTX-M-3 harbouring plasmids. The
dominant type of CTX-M-15 producing E. coli showed high resistance
rates: Augmentin (88%), Cefoxitin (3%), Cefepime (89%), Tobramycin
(95%), Gentamicin (85%), Ciproﬂoxacin (100%), Tetracycline (95%),
Cotrimoxazole (48%), and Chloramphenicol (46%).
Conclusions: Our data demonstrate the dissemination of a multiple
resistant CTX-M-15 producing E. coli clone in four centres in two towns
in Bulgaria over eight years (2002 to 2009) and underline the necessity of
more stringent measures to prevent further persistence and dissemination
of resistant clones.
P1256 Molecular epidemiology of Gram-negative bacteria resistant
to newer generation b-lactams in a rehabilitation centre
R. Izdebski °, A. Baraniak, M. Herda, J. Fiett, A. Rossini, M.P. Balice,
A. Salvia, S. Malhotra-Kumar, C. Lammens, H. Goossens, Y. Carmeli,
M. Gniadkowski (Warsaw, PL; Rome, IT; Antwerp, BE; Tel-Aviv, IL)
Objectives: To characterize Gram-negative strains resistant to newer
generation b-lactams colonizing patients of a rehabilitation centre.
Methods: The Hospital Santa Lucia in Rome, Italy, is an institution
specialized in functional recovery. Its two wards admitting patients with
orthopedic, neurological and spinal disorders (106 beds) participate in
the EU Project MOSAR. All patients are being screened for colonization
with ESBL-producing enterobacteria at admission, then every two weeks,
and at discharge. The material was collected in 02–03.2009 by plating
rectal swabs on the Brilliance ESBL agar (Oxoid). Pure cultures were
identiﬁed by API32 tests (bioMe´rieux) and checked for resistance to
newer b-lactams by the ESBL double-disk test (with and w/o cloxacillin),
and by carbapenem disks. Typing was performed by PFGE and MLST
(E. coli and K. pneumoniae). b-Lactamases were proﬁled by isoelectric
focusing and identiﬁed by PCR and sequencing.
Results: From 169 specimens, 208 enterobacterial or non-fermenting
(n = 58) isolates were cultured, of which 134 isolates from 48 patients
with relevant acquired resistance mechanisms were retained. Among 85
non-duplicates there were 39 P. mirabilis isolates, including one wide-
spread PFGE type (21 isolates, 17 patients) with the CMY-16 AmpC
b-lactamase. Other P. mirabilis isolates were of 11 types and produced
TEM-92 or TEM-72 ESBLs. 24 E. coli isolates were classiﬁed into 18
PFGE types showing no signiﬁcant clonal spread; however, 11 types
(14 isolates) belonged to the international sequence type ST131. Other
STs represented clonal complexes CC10, CC69 and CC405. The ESBL
CTX-M-15 prevailed in E. coli (14 PFGE types), followed by other
CTX-Ms and SHV-5. The ST131 isolates had CTX-M-15, CTX-M-1 or
SHV-5. Clonal spread played also a little role among K. pneumoniae
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with 12 isolates split into 7 PFGE types and STs. Only 4 patients had
a single clone, ST101 with CTX-M-15, and this enzyme dominated
in K. pneumoniae even more than in E. coli (5 PFGE types/STs). A
single P. aeruginosa isolate produced MBL. More than 20 patients were
colonized by several organisms, and in the majority of patients the
colonization with a single strain persisted over the study period.
Conclusions: This is one of the ﬁrst complex studies on resistance
epidemiology in a specialized rehabilitation centre. It showed a
remarkable variety of colonizing organisms with diverse b-lactamases
and of epidemiologic phenomena in this type of environments.
P1257 pMLST typing of IncI1 plasmids in E. coli and S. enterica
isolates derived from animals and humans
C.M. Dierikx °, A. van Essen-Zandbergen, K. Veldman, D.J. Mevius
(Lelystad, NL)
Objective: A study on ESBL-producing E. coli and S. enterica isolates
derived from Dutch poultry revealed that incI1 plasmids were the
predominant replicon types associated with ESBL in both E. coli and
S. enterica isolates. These incI1-plasmids carried the b-lactamase genes:
CTX-M-1, TEM-1, TEM-20 and TEM-52. Also in human isolates incI1
has been associated with b-lactamase-genes (a.o. CTX-M-1, CMY-2,
CTX-M-14, CTX-M-15). In the Netherlands CTX-M-1 has also been
found on incI1 plasmids in enterobacteria derived from clinical infections
in humans indicating a potential relation with an animal reservoir. The
objective of this study was to determine the population structure of incI1
plasmids from different backgrounds and to compare subtypes of ESBL-
carrying incI1 plasmids in E. coli and S. enterica of animal and human
sources.
Methods: A collection of incI1 plasmids derived from animal or human
E. coli or Salmonella isolates were typed by plasmid Multi Locus
Sequence Typing (pMLST) as described in Garcia-Fernandez et al., 2008.
These incI1 plasmids harboured CTX-M-1 (N= 19), TEM-52 (N= 6),
TEM-20 (n = 4), TEM-1 (N= 8), intI1 (N = 6) and unknown resistance
genes (N= 5).
Results: The population structure of incI1 was diverse with 10 different
pMLST sequence types detected. Three major clusters were found:
Clonal Complex 7 (CC-7) (N = 16), ST-3 (N= 11) and ST-10 (N= 6)
for IncI1 plasmids harbouring ESBLs. CC-7 included ST-7 and ST-30
(single allele difference in the ardA-gene). All CC7 plasmids carried
CTX-M-1, and all ST-10 plasmids carried TEM-52. These two plasmid
clusters were present in both E. coli and S. enterica isolates from
Dutch poultry. ST-3 plasmids associated with CTX-M-1 or TEM-20 were
present in E. coli and S. enterica isolates. New ST’s 24–30 associated
with various genes were uploaded in the pMLST database.
Conclusion: pMLST typing of IncI1 plasmids is a valuable tool to
understand the contribution of IncI1 plasmids in the transmission of
b-lactamase genes. The results of this study illustrate that ESBL-genes
are linked to speciﬁc IncI1-sequence types. Dissemination of sequence
types occurs between bacterial species within the same host, but also
between hosts. This knowledge can be used to study the attribution of
the animal reservoir of b-lactamase genes to infections in humans.
P1258 Emergence and clonal spread of multidrug-resistant
Klebsiella pneumoniae of sequence type 14 in a Spanish
tertiary hospital, 2007–2009
M. Cubero, C. Ardanuy, L. Calatayud, F. Tubau, J. Ayats,
M.A. Domı´nguez, C. Pen˜a, R. Martı´n, J. Lin˜ares ° (L’Hospitalet de
Llobregat, ES)
Objectives: To analyze the genotypes and the resistance mechanisms in
a multidrug-resistant K. pneumoniae outbreak in our hospital.
Methods: Antimicrobial susceptibility was tested by microdilution
and disk diffusion method. The b-lactamase family was screened
by PCR. Sequencing of PCR products was performed in selected
isolates. Integrons were analyzed by the Levesque method. The
molecular characterization of isolates was performed by pulsed ﬁeld
gel electrophoresis (PFGE, XbaI) and by Multi Locus Sequence Typing
(MLST). The quinolone-resistant determinant regions (QRDRs) of gyrA
and parC were sequenced.
Results: From August 2007 until June 2009, 107 multidrug resistant
K. pneumoniae isolates were detected from clinical samples of
44 patients, 73% of them admitted to the ICU. The source of
isolates was: urine (n = 28), blood (n = 20), bronchial aspirate (n = 20),
catheter (n = 13), abdominal samples (n = 12), wound swabs (n = 6),
bronchoalveolar lavage (n = 5) and other (n = 3). The strains were
resistant to amoxicillin/clavulanic acid, piperacillin/tazobactam, to-
bramycin, amikacin and ciproﬂoxacin and had diminished susceptibility
to cefepime (MICs range 1−4mg/ml). This multidrug-resistant pattern
was transferred by conjugation to E. coli J53−2. A common PFGE
pattern was observed in all K. pneumoniae isolates related to ST14 (1−6-
1−1-1−1-1) by MLST. K. pneumoniae isolates and their transconjugants
had the blaOXA gene, conﬁrmed as blaOXA-1 after sequencing. The
blaOXA-1 gene was located in the variable region of a class I integron
which also contains the aac(6′)Ib-cr gene. The sequencing of the QRDRs
revealed a S83F change in GyrA and no changes in ParC.
Conclusion: The increase in multidrug-resistant K. pneumoniae isolates
in our hospital was associated to the clonal spread of an epidemic strain
belonging to ST14 and harboring blaOXA-1 and aac(6′)Ib-cr genes in
a class I integron. Control measures and continuous surveillance are
needed in order to prevent the spread of these epidemic strains.
P1259 Comparison of ESBL genes from extended-spectrum
b-lactamase carrying Escherichia coli from sewage sludge
and human urinary tract infection
G. Zarfel °, G. Feierl, H. Galler, D. Haas, E. Leitner, F. Mascher,
A. Melkes, J. Posch, I. Winter, L. Masoud, A.J. Grisold, E. Marth,
F.F. Reinthaler (Graz, AT)
Objectives: Extended-spectrum-b-lactamase carrying Enterobacteri-
aceae are a growing problem in hospital and community. Beside human
reservoir, ESBL carrying Enterobacteriaceae can also be found in the
environment. Different groups of b-lactamase genes are the genetic
basis of the ESBL mediated resistance. In this study, ESBL carrying
Escherichia coli from sewage sludge and human urinary tract infection
were investigated for their phenotypes and the occurence of six different
ESBL gene groups.
Methods: A sample of 20 ESBL E. coli from sewage sludge collected
from ﬁve different sewage treatment plants in the area of Styria between
January and September 009 and a sample of 20 ESBL E. coli strains from
urinary tract infections, isolated at the Medical University Graz (Austria)
in the same time period, were analysed. Strains were screened for 6
ESBL gene groups (CTX-M, TEM, SHV, OXA, VEB, GES) by PCR,
and genes detected were subsequently sequenced. Further, strains were
phenotypically characterized by the Phene-Plate™ System (DiaTeam,
Austria) using PhP-RF microtiter plates 03 R PHP EC E. coli.
Results: In ESBL E. coli from sewage sludge CTX-M 1 was the most
common ESBL gene and was present in nine of the 20 strains. CTX-M
15 was identiﬁed in six and CTX-M 3 in two strains. A total 17 (85%)
sewage sludge strains contained a CTX-M gene. Further, one ESBL
E. coli from sewage sludge harboured a SHV-15 gene, whereas two
isolates had no positive PCR product for any of the tested ESBL gene
groups. All 20 ESBL E. coli from urinary tract infection harboured a
CTX-M gene; CTX-M 15 was detected in 15 strains and CTX-M 1
in ﬁve strains. 40% of all strains (16 strains from both sources) were
carrying, in addition to CTX-M, the non ESBL b-lactamase TEM-1.
Phenotyping of the strains resulted in four different phenotypical clusters
(PHPtype clusters) with correlation coefﬁcients higher than 0.95. 25
single strains could not be assigned to any of the clusters. Cluster one was
formed by seven strains from urinary tract infection. The other clusters
contained strains from both sources. The phenotypic data correlated
with the PCR results, as within a cluster, all strains harboured the same
CTX-M gene.
Conclusions: CTX-M genes were the dominant ESBL group in the
analyzed samples. All ESBL gene variants present in human urinary
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tract infection were also present in sewage sludge. Consistently, strains
from both sources were assigned together into the same phenotypical
clusters.
P1260 Paediatric faecal colonization with extended-spectrum
b-lactamase producing Enterobacteriaceae in northern
Portugal
D. Gonc¸alves °, H. Rodrigues, H. Ferreira (Porto, PT)
Objectives: Our previous work, in faecal colonization in the community,
alerted us for the ﬁnding of extended-spectrum b-lactamase (ESBL)
producers in particular niches, as nursing homes. In some Portuguese
social solidarity institutions, we can ﬁnd a day care centre (DCC)
adjacent to a nursing home facility. In that way, the aim of our study was
the detection and characterization of ESBL producing Enterobacteriaceae
in the faecal ﬂora of children attending DCC, in Northern Portugal.
Methods: Faecal samples of children from few months to 6 years
old, attending two DCC, from the North of Portugal, were collected
from April to July 2009. Samples were suspended in BHI. Isolates
were selected in MacConkey agar with ceftazidime (2mg/L), cefotaxime
(2mg/L), and aztreonam (2mg/L). Lactose fermenters were randomly
selected and susceptibility to antimicrobial agents was determined by
agar diffusion methods. Screening of ESBL producers was performed
by the double disk synergy test and conﬁrmed according to the CLSI.
Identiﬁcation of the selected strains was achieved by API 20 E.
b-lactamases were characterized by isoelectric focusing. Conjugation
assays were performed with Escherichia coli HB101.
Results: Of 105 faecal samples of children attending two day care
centres in the North of Portugal we screened 32 ESBL producing
Enterobacteriaceae isolates: 18 Escherichia coli, 2 Citrobacter freundii,
3 Enterobacter cloacae, 1 Enterobacter aerogenes, 2 Enterobacter
sakazaki, 2 Klebsiella ornithinolytica, 2 Hafnia alvei, 1 Pantoea spp.
and 1 Klebsiella oxytoca, predominantly showing an ESBL of pI> 8
alone or in association with b-lactamases of pIs 5.4, 7.4 and 7.8. Other
ESBLs of pI approximately 8 and 7.6, were also present in some isolates.
ESBL gene was successfully transferred coding a b-lactamase of pI> 8
and 5.4 plus approximately 8.
Conclusion: Our results showed that young children are colonized with
ESBL producing Enterobacteriaceae. Isoelectric points of predominant
b-lactamases, alert for the hypothesis of one successful track of
community dispersion of a putative CTX-M-15, in this young population,
in different combination with other b-lactamases, as in the CTX-M-15
producing ST131 Escherichia coli epidemic clone. The hypothesis of
spread from the neighbour nursing homes to the young population needs
to be assessed by strain relationship determination. This reality might
create a cycle of dispersal of ESBL producers, to the healthy community.
b-lactam activity against Enterobacteriaceae
P1261 Comparative in vitro activity of cefditoren and other
antimicrobials against Enterobacteriaceae causing
community-acquired uncomplicated urinary tract infections
in women: a Spanish nationwide multicentre study
O. Cuevas, E. Cercenado °, M. Gimeno, M. Marin, P. Coronel,
E. Bouza for the Spanish Urinary Tract Infection Study Group (SUTIS)
Objectives: Cefditoren is a third generation orally administered
cephalosporin with a broad spectrum of activity against Gram-positive
and Gram-negative bacterial species. After an oral 400-mg single dose,
the mean concentrations in urine are 186.5mg/L at 2−4 h, and 12.7mg/L
at 8−12 h, and is a potential drug to be used in the treatment of urinary
tract infection (UTI). We performed a multicenter nationwide study
in Spain in order to determine the in vitro activity of cefditoren and
other comparative agents against Enterobacteriaceae causing community-
acquired uncomplicated UTI in women.
Methods: From June 2008 to March 2009, 89 institutions participated in
the study. A total of 2152 Enterobacteriaceae were collected and sent to a
reference laboratory where identiﬁcation and antimicrobial susceptibility
testing was performed against 20 antimicrobials using and automated
microdilution method (MicroScan). Cefditoren MIC’s were determined
by the broth microdilution method (CLSI guidelines) using the same
inoculum.
Results: Microorganisms isolated were E. coli (81.8%), Klebsiella
pneumoniae (7.9%), Proteus mirabilis (5.2%), and others (5.1%).
A total of 51 isolates (2.4%) were extended-spectrum b-lactamase
(ESBL) producers, 3 (0.1%) produced plasmidic AmpC enzymes,
and 64 (2.9%) chromosomal AmpC. The MIC50/MIC90 (mg/L)
of cefditoren against all isolates was 0.12/0.5. Cefditoren inhibited
96.5% of isolates at 1mg/L, and was uniformly active against all
isolates with the exception of strains producing ESBLs or AmpC
enzymes. The MIC50/MIC90 of other antimicrobials were: ampicillin
(AMP) >16/>16; amoxicillin/clavulanic (A/C) 8/4/16/8; cefuroxime
(FUR) 4/8; cefotaxime (CTX) 1/1; ciproﬂoxacin (CIP) 0.12/>2;
cotrimoxazole (SXT) 2/38/>4/76; and fosfomycin (FOS) 16/16.
The respective percentages of resistance were: 61%, 17.2%, 5.5%, 2.3%,
20.2%, 27.4%, and 4.8%.
Conclusions: The activity of cefditoren against Enterobacteriaceae
producing community-acquired uncomplicated UTI in women was
superior to that of AMP, A/C, FUR, CIP, SXT, and similar to that of
FOS.
P1262 Susceptibility of Gram-negative pathogens isolated from
intra-abdominal infections in Europe in 2008–2009 − The
SMART Study
R. Badal °, S. Bouchillon, D. Hoban, A. Johnson, M. Hackel
(Schaumburg, US)
Objectives: The Study for Monitoring Antimicrobial Resistance Trends
(SMART) program has been monitoring activity of ertapenem (Etp),
amikacin (Ak), cefepime (Cpe), cefoxitin (Cfx), ceftazidime (Caz),
ceftriaxone (Cax), ciproﬂoxacin (Cp), imipenem (Imp), levoﬂoxacin
(Lvx), ampicillin-sulbactam (AS), and piperacillin/tazobactam (PT) vs.
Gram-negative bacteria from intra-abdominal infections (IAI) since
2002. This report summarizes susceptibility levels for key IAI pathogens
in Europe during 2008–2009.
Methods: 31 labs in Europe each collected up to 100 consecutive Gram-
negative bacteria/year from IAI in 2008–2009. MICs were determined
by broth microdilution, and interpreted using EUCAST guidelines if
available. Susceptibility rates were determined for species with 10
isolates.
Results: 3209 isolates were collected; however, only those with N10
(3130, 97.5% of the total) were included in this analysis. The remaining
79 isolates represented 35 species. The table below shows % susceptible
for each drug; values 90% are shaded.
Conclusions: E. coli (~50% of all IAI pathogens) was 90% susceptible
vs. only 3 drugs: Imp, Etp, and Ak. K. pneumoniae (~11% of all IAI
pathogens) was 90% susceptible vs. only 2 drugs (Imp and Etp), and
just 1 other (Ak) was >80%. No drug achieved even 80% susceptible
vs. P. aeruginosa. Until deﬁnitive identiﬁcation and susceptibility testing
results are known, options for effective empirical therapy of IAI
in Europe have diminished to include very few (e.g., carbapenems,
amikacin) of the agents evaluated in this study.
Organism N Imp Etp Ak Cpe PT Cax Cfx Caz Lvx Cp AS
Escherichia coli 1563 100 99 92 87 87 85 85 85 76 75 44
Klebsiella pneumoniae 359 92 90 87 75 71 73 74 73 76 71 53
Pseudomonas aeruginosa 280 70 na 76 75 77 na na 79 70 72 na
Enterobacter cloacae 211 99 85 96 77 67 56 56 58 91 87 22
Klebsiella oxytoca 136 99 100 100 94 89 91 94 99 99 96 71
Proteus mirabilis 131 83 100 97 100 99 82 61 63 88 81 1
Acinetobacter baumannii 93 47 na 54 na na na na na 16 16 na
Citrobacter freundii 79 100 100 97 87 78 69 69 68 99 97 50
Morganella morganii 72 83 100 97 100 99 82 61 63 88 81 1
Enterobacter aerogenes 56 93 88 96 84 61 52 54 48 93 93 25
Proteus vulgaris 37 89 100 97 92 97 51 78 84 97 97 54
Serratia marcescens 31 97 97 94 94 84 77 87 97 97 77 19
Stenotrophomonas maltophilia 29 10 7 14 10 10 10 10 38 86 14 na
Citrobacter koseri 21 100 100 100 95 100 95 95 95 95 95 90
Hafnia alvei 21 100 85 95 76 43 33 43 24 100 100 10
Citrobacter braakii 11 100 100 100 91 82 64 64 64 100 100 64
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P1263 Comparison of antimicrobial susceptibility of Gram-negative
pathogens from ICU vs. non-ICU − SMART, 2008–2009
R. Badal °, S. Bouchillon, D. Hoban, A. Johnson, M. Hackel
(Schaumburg, US)
Objectives: Pathogens recovered from intensive care units (ICUs) tend to
be more resistant than those from non-ICUs. The Study for Monitoring
Antimicrobial Resistance Trends (SMART) program monitors the
activity of ertapenem (Etp), amikacin (Ak), cefepime, cefoxitin,
ceftazidime (Caz), cefotaxime (Cft), ceftriaxone (Cax), ciproﬂoxacin,
imipenem, levoﬂoxacin (Lvx), and piperacillin–tazobactam (PT) against
Gram-negative bacteria (GNB) from intra-abdominal infections (IAI)
globally. This report compares susceptibility levels for key IAI pathogens
isolated from patients in ICUs vs. non-ICUs in 2008–2009.
Methods: 118 labs in 36 countries each collected up to 100 consecutive
GNB per year from IAI in 2008–2009. MICs were determined by broth
microdilution, and interpreted using CLSI guidelines. Susceptibility rates
(%S) for isolates from ICU and non-ICU patients were determined for
species with 10 isolates in both locations. Differences were evaluated
for signiﬁcance using Fisher’s Exact Test.
Results: 14 species (A. baumannii, C. freundii, E. aerogenes, E. cloacae,
Enterobacter spp., E. coli, K. oxytoca, K. pneumoniae, M. morganii,
P. mirabilis, P. vulgaris, P. aeruginosa, S. marcescens, and S. maltophilia)
had 10 isolates in both ICU and non-ICU locations. Of 168
organism/drug pairings, 15 could not be evaluated due to absence of
CLSI S/I/R breakpoints; 10 were identical between ICU and non-ICU;
in 30 cases the ICU %S was higher (none signiﬁcant, P> 0.05); and
in 113 cases the non-ICU %S was higher (40 signiﬁcant, P< 0.05).
Species with the highest number of signiﬁcant differences were E. coli,
K. pneumoniae, P. mirabilis, and E. cloacae (9, 8, 8, and 6 drugs,
respectively). Drugs with the highest number of signiﬁcant differences
were PT (6), Caz (5), Cax (5), Cft (4), and Lvx (4). Etp was the only
study drug to maintain 89% susceptibility in ICU and non-ICU vs. all
species for which it is indicated.
Conclusions: These data suggest that IAI pathogens from ICU are often
more resistant to commonly-used drugs, but some species did not show
signiﬁcant differences. Etp and Ak showed the least number of signiﬁcant
differences between ICU and non-ICU. Etp had good in vitro activity vs.
ICU and non-ICU isolates.
P1264 In vitro activity of tigecycline against multi-resistant
Klebsiella pneumoniae isolates
A. Tsatsagias °, O. Vasilaki, S. Spyroglou, E. Protonotariou,
S. Mpalodimos, K. Karozis, S. Metallidis, F. Tsiapara, F. Frantzidou,
E. Diza (Thessaloniki, GR)
Objectives: Tigecycline (TGC), the ﬁrst glycylcycline antibacterial
agent, has been shown to be highly effective against a wide range of
bacteria including multi-resistant Gram negative and positive pathogens.
The purpose of our study was to evaluate the in vitro activity of
tigecycline against multiresistant K. pneumoniae clinical isolates that
phenotypically produce KPC.
Methods: From 11/11/08 to 12/11/09 we collected 37 non-duplicate
multiresistant Klebsiella pneumoniae isolates recovered from blood,
bronchoalveolar secretions, urine, trauma, pus and central venus catheter.
The samples were isolated from patients hospitalized in ICU, surgical
and internal departments of AHEPA University Hospital in Greece.
Bacterial identiﬁcation and initial antimicrobial susceptibility testing
were performed by the VITEK 2-automated system (bioMe´rieux,
France). All the isolates had reduced susceptibility or resistance to
carbapenems. The isolates were phenotypically identiﬁed as possible
KPC producers based on the positive synergy test using boronic acid
and meropenem. The prescence of KPC genes was selectively performed
using PCR in 10 isolates and all were positive for the blaKPC. MICs
of tigecycline were determined by Etest following the manufacturer’s
instructions (AB Biodisk, Solna). All isolates with MIC< 2mg/ml were
considered as susceptible according to FDA proposed breakpoints.
Results: All 37 K. pneumoniae isolates were resistant to almost
all classes of antibiotics (including cephalosporines, carbapenems,
ﬂuoroquinolones, co-trimoxazole, aminoglycosides (except gentamicin).
The only active agents were colistin and gentamicin. In vitro
susceptibility testing with E-test showed that MICs for tigecycline ranged
from 0.38 to 3 mg/ml and MIC50 and MIC90 values were 0.75 mg/ml
and 3 mg/ml, respectively. Tigecycline was active against to most of
the examined isolates (32/37). Five isolates (13.5%) were classidied as
intermediate to tigecycline (MIC of 3 mg/ml). Overall, TGC resistance
rates were 10.8% for K. pneumoniae isolates recovered from both ICU
and non-ICU patients.
Conclusions: According to the current breakpoints established by FDA,
tigecycline was active against most of the K. pneumoniae isolates
tested inhibiting >90% in concentrations <2mg/ml. Nevertheless, it is
of concern that higher MICs have begun to emerge in our hospital that
might limit our therapeutic options in future.
P1265 Potent activity of ceftazidime/NXL104 tested against
Enterobacteriaceae isolates carrying multiple b-lactamase
enzymes
M. Castanheira, P. Rhomberg, R. Jones, D. Farrell ° (North Liberty, US)
Objectives: Treatment of infections caused by pathogens carrying
multiple b-lactamases (BLs) can be challenging due to the association
of b-lactam-resistance mechanisms with other genetic determinants
encoding resistance to non-b-lactam compounds. NXL104 is a broad
spectrum BL-inhibitor and, combined with ceftazidime (CAZ), is
undergoing clinical trials to treat hospital infections caused by Gram-
negative pathogens, including those with multidrug resistance. The
objective of this study was to assess the activity of CAZ/NXL104 against
a panel of Enterobacteriaceae (ENT) carrying multiple BL enzymes.
Methods: CAZ activity combined with NXL104 at ﬁxed 4mg/L was
evaluated by CLSI broth microdilution methods against 80 ENT strains
(9 species) producing 2 to 4 BLs. BLs included: narrow-spectrum (3
SHV-, 2 OXA-types, TEM-1), ESBLs (4 SHV-, 4 CTX-M-, 2 OXY-
variants, OXA-1/30), serine-carbapenemases (3 KPC-, 2 SME-types,
NMC-A) and metallo-BLs (VIM-1, VIM-2) all identiﬁed by PCR and
sequencing. ENT hyperproducing chromosomal AmpC were also tested.
Results: Strains producing 2 (59), 3 (19) and 4 (2) BLs were evaluated.
66 of 80 (82.5%) strains showed CAZ/NXL104 MIC results at 2mg/L.
Inhibitory effect was observed despite the number of BLs (Table). Only
5 KPC-producers (1 C. freundii and 4 E. cloacae) and 5 SHV-12 (all
E. cloacae) showed CAZ/NXL104 MIC results at 4mg/L, but MIC
reductions were 16- to 128-fold compared to CAZ alone. 2 KPC- and
2 VIM-producers (all Enterobacter spp.) had MICs at 8mg/L for
CAZ/NXL104, though inhibitory effect (16- and 32-fold decrease) was
noted for the KPC-producers. The great majority (85%) of ENT had
MICs lowered 4- to 512-fold by NXL104. Four isolates showing no
inhibitory effect carried MBL enzymes; one isolate had low/susceptible
CAZ MIC value (2mg/L).
Organisms MIC (mg/L) MIC reduction
(no. tested) 2 4 8 16 32 with NXL104
2 b-lactamases (59)
CAZ 12 2 1 3 41
CAZ/NXL104 45 10 1 1 2 Nonea to >512-fold
3 b-lactamases (19)
CAZ 1 3 1 3 11
CAZ/NXL104 19 − − − − 4- to 512-fold
4 b-lactamases (2)
CAZ − − − − 2
CAZ/NXL104 2 − − − − 128- to 256-fold
aFour isolates showing no inhibitory effect carried MBL enzymes; one
isolate had low/susceptible CAZ MIC value (2mg/L).
Conclusions: The addition of NXL104 to CAZ resulted in a 4- to
512-fold decrease in MIC for most isolates having multiple BLs.
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CAZ/NXL104 MIC values were within the CLSI CAZ susceptibility
range for the vast majority of ENT tested (>95% of strains), regardless
of the number of BLs present or CAZ MIC. These data demonstrate that
CAZ/NXL104 could be a signiﬁcant therapeutic option for treatment of
contemporary, most challenging BL-producing ENT species.
P1266 In vitro activity of ceﬁxime combined with clavulanate
vs. enterobacterial urinary isolates producing
extended-spectrum b-lactamases
P. Khanna °, D. Wareham (London, UK)
Objectives: Treatment of UTI due to Enterobacteriaceae producing
ESBLs is problematic. Conventional oral b-lactams and inhibitor
combinations are inactive and many strains also exhibit co-resistance to
quinolones, trimethoprim and nitrofurantoin. Ceﬁxime combined with
clavulanate is a potential oral treatment option. We therefore assessed
its in vitro activity against a contemporary collection of ESBL producing
urinary isolates.
Methods: Strains were isolated and identiﬁed from routine urine samples
using CHROMagar orientation and the Microscan Walkaway system.
Cefpodoxime resistant isolates were screened for ESBL production using
commercial cefpodoxime / clavulanate combined discs and TEM, SHV
and CTX-M genes were ampliﬁed by PCR. Susceptibility to ceﬁxime in
combination with clavulanate was determined by disc diffusion using 5
ug ceﬁxime discs supplemented with 1.25, 2.5 and 4 ug of clavulanate.
The MIC of ceﬁxime with and without clavulanate was determined by
Etest for 32 of the ESBL producers using isosensitest agar supplemented
with clavulanate at 4mg/L.
Results: 85 cefpodoxime resistant isolates were recovered over a 4
month period. All were resistant to amoxicillin, cefalexin and ceﬁxime.
76.5% were also resistant to trimethoprim, 84.7% to ciproﬂoxacin and
16.5% to nitrofurantion. TEM, CTX-M and SHV genes were found in
100, 82.4 and 15.2% respectively. The mean zones of inhibition for
ceﬁxime discs supplemented with clavulanate at 1.25, 2.5 and 4 ug were
19.1mm, 20.6mm and 21.8mm respectively. Using BSAC zone diameter
interpretative breakpoints these concentrations restored susceptibility
to ceﬁxime in 41.2, 62.4 and 74.1% of isolates if breakpoints for
systemic infection were used (sensitive >20mm) and in 81.2, 89.4 and
94.1% isolates if urinary cephalosporins breakpoints were used (sensitive
>16mm). MICs in combination with clavaulante were all <1mg/L in
the 32 isolates tested by Etest, with an MIC50 of 0.38 and an MIC90 of
0.75mg/L.
Conclusions: Due to the increasing involvement of ESBL producing
bacteria in uncomplicated UTI, there is a rising need for effective oral
treatments in mild cases. We found clavulanate restored the activity
of ceﬁxime against enterobacteria producing TEM, SHV and CTX-M
ESBLs in up to 94% of isolates tested. There are anecdotal reports
of the efﬁcacy of this combination in the treatment of lower urinary
tract infection but to our knowledge a clinical trial has not yet been
undertaken.
P1267 Antimicrobial resistance of extended-spectrum b-lactamase
producing Escherichia coli and Klebsiella pneumoniae
strains from north-eastern Romania
C. Tuchilus °, L.S. Iancu, B. Copacianu, A. Poiata, A. Badescu,
A. Ambarus, C. Lapuste, D. Buiuc (Iassy, RO)
Family Enterobacteriaceae have developed resistance to third- and
fourth-generation cephalosporins via production of extended-spectrum
b-lactamases (ESBL). The antimicrobial resistance patterns of ESBL-
producing organisms and their prevalence may vary between geographic
areas.
Objectives: to evaluate the in vitro antimicrobial resistance and the
prevalence Escherichia coli and Klebsiella pneumoniae producing
ESBL, isolated from hospital and community in 2009, January-October
period.
Materials and Methods: We selected 112 strains (from which, 84
strains were identiﬁed as E. coli and 28 as K. pneumoniae) among
611 enterobacteria strains, by using disk diffusion method as initial
screening for ESBL, according to Clinical and Laboratory Standard
Institute (CLSI) guidelines. For selected strains, the ESBL phenotypic
conﬁrmation was performed with double disk test and the replacement
disk method. The minimum inhibitory concentrations (MICs) for
next antimicrobial agents tested: ceftazidime, cefotaxime, ceftriaxone,
cefepime, cefpirome, imipenem, meropenem, ertapenem, moxiﬂoxacin,
gatiﬂoxacin, levoﬂoxacin, oﬂoxacin were performed by agar dilution
method. Resistance rates were reported using the CLSI breakpoints
for the fully susceptible category; moderately susceptible isolates were
classiﬁed as resistant. K. pneumoniae ATCC 700603 and E. coli ATCC
25922 were used for quality control.
Results: All 112 tested strains (18.3%) were phenotypically conﬁrmed
as ESBL producer, when two phenotypic conﬁrmatory tests were used.
Resistance rates for ceftazidime, cefotaxime, ceftriaxone and aztreonam
among tested strains were very high: 84.5%, 100%, 100% and 96.4% for
E. coli and 98.8%, 98.8%, 97.6% and 89.2% for K. pneumoniae, with the
MIC90 values >256mg/l for either antimicrobial tested agent. The MICs
for fourth generation cephalosporins ranges from 4mg/l to 512mg/l.
The MICs for tested quinolones were >2mg/l for 89.2% strains. Using
breakpoint for susceptibility, all isolates were sensitive to ertapenem,
imipenem and meropenem.
Conclusions: Results of this study have shown that ESBL producing
E. coli and K. pneumoniae strains circulating in Romania are associated
with multidrug resistance. In this study, carbapenems demonstrated the
highest degree of activity and are the treatment of choice for ESBL
producers.
P1268 In vitro interactions of colistin in combination with
meropenem or ertapenem or piperacillin/tazobactam against
metallo-b-lactamase-producing Klebsiella pneumoniae
clinical isolates
M. Souli °, P.D. Rekatsina, I. Galani, Z. Chryssouli, H. Giamarellou
(Athens, GR)
Objectives: The dissemination of metallo-b-lactamases (MBLs) in
Enterobacteriaceae represents an emerging therapeutic challenge. These
enzymes hydrolyse carbapenems although the MICs could be at the
susceptible level. Treatment options against these strains are scarce and
combination regimens are often used although the potential advantage of
these combinations has not yet been studied. Our aim was to determine
the interactions of colistin (COL) in combination with meropenem
(MER) or ertapenem (ERT) or piperacillin/tazobactam (PIP/TAZ) against
clinical isolates of VIM-producing K. pneumoniae (K. p.).
Methods: MICs were determined with standard methodology, according
to CLSI. MBL-production was screened for using the imipenem-EDTA
disc synergy test and conﬁrmed by PCR with speciﬁc primers for
blaVIM followed by RFLP analysis with SacI. Clonal relatedness
among studied isolates was investigated using REP-PCR with speciﬁc
primers. Interactions were investigated with time-kill methodology with
an inoculum of 5×105 CFU/ml. Tubes containing each antibiotic alone
and in combination at 1×MIC or 4×MIC for susceptible strains as well
as at a concentration representing the steady state of each antibiotic
(MER or ERT 10mg/L, COL 5mg/L, PIP/TAZ 35/7mg/L) for non-
susceptible strains were subcultured at 0, 3, 5 and 24 hours for colony
counts.
Results: Thirty-three clonally distinct strains of K.p. were studied. All
exhibited a positive synergy test and carried a blaVIM-1-type gene. The
combination of COL-ERT showed synergy for 5 of 14 (35.7%) COL-S
isolates and for 3 of 18 (16.7%) COL-R isolates. One of 14 (7.1%)
COL-S and 2 of 18 (11.1%) COL-R isolates showed antagonism with
ERT. The combination of COL-MER exhibited synergy for 3 of 10 (30%)
COL-S isolates and for 3 of 18 (16.7%) COL-R isolates. Antagonism
with MER was observed against 2 of 10 (20%) COL-S and 1 of 18
(5.6%) COL-R isolates. The combination COL-PIP/TAZ was synergistic
against 5 of 12 (41.7%) COL-S and 1 of 17 (5.9%) COL-R isolates.
Antagonism was observed against 4 of 12 (33.3%) COL-S isolates. All
other isolates showed indifference.
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Conclusion: The combinations of COL with either ERT, MER or
PIP/TAZ although often used in clinical practice, result in strain-speciﬁc
interactions. Indifference was most commonly observed in our study.
P1269 Susceptibility of Gram-negative pathogens to ceftobiprole,
ceftazidime and cefepime isolated from centres in Austria,
Germany and Switzerland
H. Seifert, S. Gatermann, W. Pﬁster, C. Poehlmann, S. Huhulescu,
K. Muehlemann, J. Laeuffer, S. Decker-Burgard, M. Cassettari °,
I. Morrissey (Cologne, Bochum, Jena, Dresden, DE; Vienna, AT;
Berne, Baar, CH; Neuss, DE; Fordham, UK)
Objectives: Ceftobiprole (BPR) is a novel cephalosporin with bacteri-
cidal activity against both Gram-negative and Gram-positive bacteria.
Here we report the comparative activity of BPR, ceftazidime (CAZ)
and cefepime (CFP) against Gram-negative pathogens (GNP) isolated
from hospitalized patients with serious infections collected by 18 centres
across Austria, Germany and Switzerland.
Methods: 691 GNPs (including 200 Escherichia coli [EC], 172
Pseudomonas aeruginosa [PA], 127 Klebsiella pneumoniae [KP], 143
Enterobacter spp. [ES] and 49 Haemophilus inﬂuenzae [HI]) were
collected from May to Oct 2008 from hospitalized patients with
complicated skin and soft tissue infection (cSSTI), blood stream
infections or nosocomial pneumonia including ventilator associated
pneumonia (VAP). MICs were determined at each centre using Etest
methodology.
Results: Against all GNPs included in the study, the three tested agents
had an MIC90 of 4mg/L and both BPR and CFP had an MIC50 of
0.06mg/L compared with 0.25mg/L CAZ. Enterobacteriaceae and HI
were highly susceptible to all three cephalosporins with MIC90 of BPR,
CAZ and CFP of 0.12/2/0.25mg/L and 0.12/0.12/0.25mg/L respectively.
Against ES, BPR and CFP had an MIC90 of 1 and 2mg/L compared with
64mg/L for CAZ. BPR, CAZ and CFP were comparable in activity to
PA with an MIC50 of 2mg/L and MIC90 of 16/8/8mg/L respectively.
BPR was at least 2-fold more active than CFP and CAZ against 33.4%
and 73.7% of GNPs respectively and CFP was at least 2-fold more active
than BPR and CAZ against 20.7% and 71.3% of GNPs respectively. BPR
had identical MIC values to CFP and CAZ against 45.9% and 13.7% of
GNPs respectively. CFP and CAZ had the same MIC values for 17.4%
of GNPs.
Conclusion: Ceftobiprole was comparable to ceftazidime against
Pseudomonas aeruginosa but generally more active against other GNPs
and was comparable to or more active than cefepime against GNPs
collected from centres in Austria, Germany and Switzerland in this study.
P1270 Antimicrobial activity of ceftaroline combined with NXL104
tested against a collection of organisms expressing multiple
b-lactamases
H. Sader °, G. Williams, G. Moet, M. Castanheira, I. Critchley,
R. Jones (North Liberty, Oakland, US)
Objective: To evaluate the activity of ceftaroline combined with
NXL104 (ﬁxed 4mg/L; CPT104) against Enterobacteriaceae (ENT)
with various types of b-lactamases (BL), with most strains carrying
multiple BLs. Ceftaroline is a novel, parenteral cephalosporin with
broad-spectrum activity against Gram-positive (including MRSA and
MDRSP) and -negative organisms. Ceftaroline has limited activity
against extended-spectrum b-lactamase (ESBL)- and AmpC-producing
strains. NXL104 is a novel non-b-lactam BL inhibitor that inhibits
Ambler class A, C, and D enzymes (eg, ESBL, KPC, and AmpC).
Methods: CPT104 and comparators were tested for susceptibility (S) by
CLSI broth microdilution methods against 148 clinical strains of ENT
producing KPC + AmpC (26 strains), ESBL + AmpC (27), KPC + ESBL
(7), multiple ESBLs (38 strains), SME or NMC-A carbapenemases (7),
KPC (12), CTX-M (8), plasmidic AmpC (15), and metallo-BL (MBL;
8). Isolates were collected from 1999–2008 from global surveillance
programs.
Results: CPT104 exhibited potent inhibitory effects against all BL types
except MBLs. All isolates were inhibited at CPT104 MIC 4mg/L
except the MBL-producing strains (Table). CPT104 was highly active
against ENT producing KPC (MIC90, 0.5mg/L), KPC + AmpC (MIC90,
2mg/L), and KPC + ESBL (MIC100, 1mg/L). CPT104 was more
active than meropenem (MIC90, >8mg/L) against these 3 groups.
ENT-producing CTX-M (highest CPT104 MIC, 0.5mg/L) and those
producing more than one ESBL type (including CTX-M, SHV, TEM,
OXA and OXY; MIC90, 1mg/L) were also very S to CPT104. The
highest CPT104 MIC observed among plasmidic AmpC was 0.5mg/L.
All strains producing SME or NMC-A were also inhibited at 0.5mg/L
of CPT104. CPT104 (MIC, >32mg/L) and all b-lactam compounds
tested showed limited activity against MBL-producing ENT.
Conclusions: Results of this study clearly demonstrated that NXL104,
when combined with ceftaroline, effectively lowers ceftaroline MIC for
ENT that produce the most clinically signiﬁcant BLs, except MBLs.
CPT104 was highly active against ENT that produce KPC, various ESBL
types, and AmpC (chromosomally derepressed or plasmid mediated),
as well as those producing more than one of these BL types (Table).
CPT104 represents a promising therapeutic option for treatment of
infections caused by multidrug-resistant ENT.
BL type (no. tested) Cumulative % inhibited at CPT104 MIC (mg/L):
0.06 0.12 0.25 0.5 1 2 4 >4
KPC + AmpC (26) 3.8 3.8 8.6 30.8 73.1 96.2 100.0 −
ESBL + AmpC (27) 0.0 14.8 37.0 55.6 74.0 96.3 100.0 −
KPC + ESBL (7) 0.0 0.0 14.3 57.1 100.0 − − −
Multiple ESBLs (38) 2.6 60.5 86.8 89.5 97.4 100.0 − −
SME/NMC-A (7) 0.0 14.3 42.9 100.0 − − − −
KPC (12) 0.0 0.0 16.7 91.7 100.0 − − −
CTX-M (8) 12.5 75.0 87.5 100.0 − − − −
Plasmidic AmpC (15) 13.3 60.0 86.7 100.0 − − − −
MBL (8) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0
P1271 Antibiotic resistance of Escherichia coli isolated from
community-acquired urinary infections
A. Topan °, D. Tatulescu, V. Zanc, A. Almas, M. Flonta, A. Slavcovici
(Cluj-Napoca, RO)
Objectives: Intensive use of ﬂuoroquinolones in the treatment of urinary
infections has led to the spread of resistant microorganisms. The aim of
our study is to determine the antimicrobial resistance of uropathogenic
Escherichia coli strains isolated from patients admitted in our hospital.
Methods: We retrospectively reviewed medical records of 86 patients
aged 18 years or older, with urinary symptoms and cultured documented
urinary tract infection (UTI) admitted to our hospital between 1st of
January − 31st December 2008. Data abstract from each medical record
included demographic aspects; the causative organism; the current use
of antibiotics within 3 months; hospitalization within the prior year,
previous UTI episodes, complicated or uncomplicated UTI.Hospital stay
within prior month; indwelling urinary catheters and residence in long-
term care facility were criteria of exclusion. The antibiotic sensitivity was
determined by standard disc-diffusion method according to the NCCLS
and CLSI standards. Categorical variables were compared using Fisher
exact test. Signiﬁcance was set at p< 0.05.
Results: Among the 86 positive cultures 57 (66.27%) were from female
and 29 (33.72%) were from males. Median age of the patients was 61
(range 19−86). The most frequent agent as expected, was Escherichia
coli 66.27% (n = 57), followed by Klebsiella pneumoniae 10.46% (n = 9).
E. Coli presented a resistance rate to ampicillin of 66.66%, to TMP-
SMX of 50.87% and to ciproﬂoxacin and norﬂoxacin to 26.33%. E. coli
was sensitive to nitrofurantoin in 76.78% cases. E. coli resistant to
ﬂuroquinolone was signiﬁcantly related to: age greater than 65 years
(p = 0.048); current use of antibiotics within 3 months (p = 0.0078); prior
hospitalization (p = 0.007). There was no statistical signiﬁcance when we
evaluated E. coli ﬂuroquinolone resistant and sex (p = 0.051); previous
episodes of UTIs (p = 0.24) or complicated UTIs (p = 0.13).
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Conclusions: Resistance of E. coli to ﬂuroquinolones in almost one
third of cases shows that the broad use of these drugs needs to be
revised. Current use of antibiotics within 3 months, prior hospitalization
within 1 year and age over 65 years is a limitation to the use of
ﬂuoroquinolones as ﬁrst choice for empirical therapy in community-
acquired UTIs. Nitrofurantoin should be encouraged to use, especially
for treatment of non-severe community acquired UTIs.
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P1272 Outburst emergence of blaKPC-3-Tn4401a in Madrid
(Spain) is associated with a pKPN3/4-like plasmid carried
by a newly epidemic ST384-Klebsiella pneumoniae clone
T. Curiao °, M.I. Morosini, P. Ruiz-Garbajosa, F. Baquero, T.M. Coque,
R. Canto´n (Madrid, ES)
Objectives: KPC-2 and KPC-3 carbapenemase-producing Klebsiella
pneumoniae isolates have been increasingly reported in different conti-
nents since ﬁrst detection in USA in 1996. They have recently emerged in
South European countries. We analyzed the ﬁrst K. pneumoniae isolates
expressing a KPC enzyme detected in our hospital.
Methods: Five K. pneumoniae isolates from 4 patients (Sep-Oct, 2009)
hospitalized in different areas [internal medicine (n = 2), oncology
(n = 1) and paediatrics (n = 1)] showing decreased susceptibility to
carbapenems and a positive modiﬁed Hodge test were screened for
the presence of carbapenemase encoding genes (PCR, sequencing,
hybridization). Clonal relationship was established by PFGE (XbaI and
SpeI) and MLST. Plasmid content, plasmid size determination (S1
nuclease), incompatibility group (PCR, hybridization and sequencing),
and comparison of RFLP patterns (XhoI, HIndIII) were determined. The
genetic environment of blaKPC was characterized by long PCR mapping
based on known Tn4401 sequence, RFLP of amplicons and sequencing.
Results: Isolates were recovered from urine (n = 2), pharyngeal aspirate,
wound and faeces (n = 1 each). They showed imipenem and meropenem
MIC 8mg/L and were susceptible to aminoglycosides and quinolones
(both nalidixic acid and ciproﬂoxacin). All isolates showed related
PFGE patterns and belonged to a newly characterized ST348 clone
not previously detected among multi-resistant K. pneumoniae isolates
from our institution. The blaKPC-3, blaOKP-5 and blaTEM-1 genes
were detected in all isolates. They carried two plasmids, one of 70−90
kb (carrying blaKPC-3 and blaTEM-1) and a megaplasmid ranging
from 180 to 320 kb. KPC-plasmids showed similar RFLP patterns and
sequences highly homologous (97% identity) to pKPN3/pKPN4 from
K. pneumoniae (GenBank CP000648, CP000649). The blaKPC-3 gene
was located on a 10kb-Tn4401 containing a 100 pb-deletion between istB
and blaKPC (isoform a, which has been mostly linked to blaKPC-2) in
all isolates.
Conclusions: The emergence of a Tn4401-blaKPC-3 associated with a
pKPN3/4-like plasmid and a newly deﬁned ST384-K. pneumoniae clone
was detected. Although KPC-3 has been scarcely reported in Europe
when compared with USA, its location in both a widespread transposon
and plasmid might fuel its future dissemination.
P1273 Characteristics and outcomes of intensive care unit
patients with carbapenem-resistant Klebsiella pneumoniae
bacteraemia
K. Vardakas, D. Matthaiou °, E. Antupa, E. Pappas, G. Kechagioglou,
A. Koteli, E. Antoniadou (Thessaloniki, GR)
Background: Carbapenems are frequently used to treat infections due to
extended-spectrum b-lactamase-producing Klebsiella pneumoniae. Thus,
the emergence of infections due to carbapenem-resistant K. pneumoniae
(CRKp) is a major public health concern.
Objective: To study the characteristics and outcomes of intensive
care unit patients with carbapenem resistant K. pneumoniae (CRKp)
bacteremia.
Methods: A retrospective cohort of patients requiring ICU treatment.
The study was conducted in an 8-bed ICU between January 2006 and
September 2009.
Results: During the study period 56 patients were diagnosed with CRKp
bacteremia. The mean age of patients was 65.8±14.3 years. Thirty-
two (57%) were males. The mean APACHE II score was 18.1±7.0.
The median duration of hospital stay till bacteremia was 14.5 days.
Twenty-nine patients (52%) had bacteremia of unknown origin, 17
(30%) had bacteremia secondary to other infections, and 10 (18%) had
catheter-related bacteremia. Thirty-seven (66%) and 22 (39%) patients
had previous and concurrent infections, respectively. Forty two (75%)
patients died. The univariate analysis showed that APACHE II score
(p = 0.01), cardiovascular disease (p = 0.03), red blood cell transfusion
(p = 0.02), shock (p = 0.01) and acidosis (p = 0.04) immediately after the
isolation of CRKp were the factors associated with death. None of these
variables was an independent predictor of outcome in the multivariate
analysis. Correct empirical treatment (p = 0.02) and successful outcome
of the infection (p< 0.001) were the factors associated with survival.
Conclusions: Bacteremia due to CRKp in the ICU is associated with
high mortality. Empirical treatment should include coverage against
CRKp in ICUs with high prevalence of the infection.
P1274 Multiclonal dissemination of KPC-2-producing Klebsiella
pneumoniae strains in a Greek hospital
A. Poulou °, E. Voulgari, F. Markou, S. Pournaras, G. Vrioni,
C. Katsiampeki, M. Lapatsi, A. Tsakris (Serres, Athens, Larissa, GR)
Objectives: Class A KPC carbapenemases represent a new threat for
the antimicrobial treatment of K. pneumoniae infections. The increase
of KPC-producing K. pneumoniae isolates in different hospital settings
has been associated with the dissemination of a single clonal type.
This genotype conforms to a hyperepidemic clonal type, which has
been spread in different countries, including the USA, Israel and
Greece. We document the multiclonal dissemination of KPC-producing
K. pneumoniae in a Greek health care facility.
Methods: During the study period (January 2008-September 2009)
63 K. pneumoniae isolates that exhibited reduced susceptibility to
carbapenems (MIC >1mg/L), were recovered from separate patients
in our facility. Meropenem discs with and without boronic acid and
EDTA were used for phenotypic detection of KPC and MBL genes,
respectively and the modiﬁed CLSI ESBL conﬁrmatory test was used
for the detection of ESBLs among KPC producers. The production of
KPC, VIM and ESBL enzymes was genotypically conﬁrmed by PCR
and sequencing assays. PFGE was performed to test the clonality of the
isolates.
Results: The phenotypic assays showed that 20 isolates contained KPCs
and 16 of them ESBLs. Molecular testing revealed that all 20 isolates
carried blaKPC-2. Additionally, 7 isolates carried both blaKPC-2 and
blaVIM-1 genes; two of them carried also ESBL genes. ESBL-positive
isolates carried SHV-12 (n = 16), SHV-5 (n = 1) and CTX-M-15 (n = 1).
PFGE revealed 5 clonal types among KPC producers; the major clonal
type was detected in 15 isolates and contained two subtypes. The
next more frequent type contained 7 isolates with two subtypes, while
the remaining types contained from 3 to 1 isolate. The KPC-positive
isolates were scattered among patients hospitalized in 8 hospital wards.
The major clonal type was responsible for an outbreak among ICU
patients. Medical history of the majority of the patients revealed previous
hospitalization in different Greek hospitals.
Conclusions: In difference with the situation described in other
geographic regions, in our hospital several distinct clonal types of
K. pneumoniae have incorporated KPC genes. The transfer of patients
between hospitals seems to contribute to the dissemination of clonally
unrelated KPC-producing K. pneumoniae strains. Early laboratory
detection and enforcement of infection control measures are needed to
prevent the dissemination of KPC-producing clonal strains in our hospital
environment.
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P1275 Molecular characterization of blaKPC-containing plasmids
from the four different clones of Klebsiella pneumoniae
isolated in Greece
I. Galani °, M. Souli, F. Panayea, Z. Chryssouli, H. Giamarellou
(Athens, GR)
Objectives: The aim of our study was the molecular characterization
of KPC-producing K. pneumoniae isolates reported from our hospital
during the 2008 outbreak.
Methods: One representative isolate of each of the four clones and one
subclone (Kp 1−5) identiﬁed in the outbreak reported in our hospital
were further examined. The presence of b-lactamases in these strains
was detected by IEF and conﬁrmed by PCR and sequencing. MICs were
determined by Etest. Conjugation experiments were carried out by a ﬁlter
method using a rifampin resistant Escherichia coli K12 laboratory strain
as a recipient. Transformation experiments were carried out with E. coli
DH5a laboratory strain. Molecular typing was performed by pulse-ﬁeld
gel electrophoresis of SpeI-restricted genomic DNA. Plasmid analysis
was carried out by PFGE of S1 nuclease-digested total DNA as well as
RFLP analysis. Aminoglycoside modifying enzymes were determined by
a phenotypic method.
Results: The Kp1 belonged to clone A which was the predominant
clone of the outbreak. The other four K. pneumoniae isolates (Kp2-
Kp5) belonged to clones B1, B2, C and D. blaKPC-2 and blaTEM-
1-like were identiﬁed in all isolates. Kp1 (clone A) and Kp5 (clone
D) harboured also blaSHV-12 and blaSHV-11 while Kp3 (clone B2)
and Kp4 (clone C) blaCTX-M-15 and blaSHV-11 or blaLEN-19. Kp2
(clone B1) coded also SHV-11. S1 nuclease method showed that all
isolates harboured at least two plasmids. Conjugation experiments were
repeatedly unsuccessful while transformation was successful for all
cases. Plasmid RFLP analysis showed that Kp1 and Kp5 had the same
plasmid coding for KPC-2 and TEM-1-like, conferring resistance only to
b-lactams and inhibitor combinations. Kp3 and Kp4 harboured the same
plasmid coding for KPC-2, CTX-M-15, TEM-1-like and aminoglycoside
modifying enzymes (AAC(3)-V), conferring resistance to b-lactams,
inhibitor combinations and aminoglycosides. Kp2 harboured a plasmid
conferring resistance to b-lactams and inhibitor combinations (coding
for KPC-2 and TEM-1-like) which had a different RFLP pattern than
the previous plasmids.
Conclusions: KPC-producing Kp is an emerging threat in Greek
hospitals. We documented a complex epidemiology of strains causing
an outbreak in our hospital.
P1276 Emergence in Rome of an ertapenem-resistant Klebsiella
pneumoniae clone ST37, carrying a novel OmpK36 porin
variant
A. Garcı´a-Ferna´ndez, A. Giordano, C. Venditti, V. Miriagou,
C. Papagiannitsis, M. Venditti, C. Mancini, A. Carattoli ° (Rome, IT;
Athens, GR)
Objectives: In Klebsiella pneumoniae carbapenem resistance has been
associated with the Extended-Spectrum b-Lactamase (ESBL) production
and the loss of the major non-speciﬁc porins. Ertapenem resistant
(ETP-R) K. pneumoniae clone ST37 caused a small outbreak in a
hospital in Rome in 2008. This strain carried ESBLs and expressed a
novel OmpK36 variant, showing an insertion of two codons in one of the
most conserved site of the protein, the so called Loop 3. The objective of
the study was to determine the diffusion of this clone within the hospital.
Methods: 60 multidrug resistant K. pneumoniae strains (one per
patient) were collected in 2008–2009. 42/60 strains showed ETP-R.
Representative strains from this collection were tested by PFGE, MLST,
plasmid typing, b-lactamase identiﬁcation, SDS-PAGE and analysis of
the ompK36 gene. A speciﬁc PCR-based test was devised for a rapid
screening of the ompK36V variant gene.
Results: All the ETP-R strains were ESBLs positive and exhibited
ETP-MIC 8mg/L. 32/42 showed, IPM-MIC 1.0 and MEM-MIC
=1.0mg/L, 9 exhibited IPM-MIC 1.0mg/L and MEM-MIC 16mg/L
and one strain was resistant to the three carbapenems. In the latter the
loss of the OmpK36 by an early termination of translation was detected.
A PCR-based test positively ampliﬁed the ompK36V variant in strains
showing the ETP-MIC8.0, IPM-MIC1.0mg/L and MEM-MIC =1.0
phenotype. These strains belonged to ST37 and were recovered
from patients in different wards, suggesting a wide circulation of
the K. pneumoniae clone within the hospital. ompK36V was not
ampliﬁed from strains showing MEM-MICs higher than the clonal
strains, suggesting a different carbapenem resistance mechanism in these
strains. All carbapenem susceptible strains tested were negative for the
ompK36V.
Conclusion: This is the ﬁrst report of a natural variant of the OmpK36
protein associated to the ETP-R in a K. pneumoniae clone disseminating
within the hospital. The OmpK36 represents the main pathway for
the penetration of ertapenem into the bacterial periplasmic space. In
particular, the ertapenem has a net negative charge and two carboxylic
groups are able to form hydrogen bonds with the basic residues of the
channel. Amino acids mutations in the transmembrane b-strand loop
3 (L3) that constitutes the channel eyelet of enterobacterial porins are
affecting the channel properties, reducing the uptake of carbapenems and
cephalosporins.
P1277 Carbapenem-resistant K. pneumoniae: epidemiology and
molecular analysis of a 6-year period (2004–2009)
H. Moraitou °, M. Makarona, A. Mavrommati, I. Galani, N. Souﬂa,
P. Tsarpali, A. Georgousi, C. Anthoulaki, V. Spyropoulos, S. Kanavaki
(Athens, GR)
Objectives: Carbapenem resistance in K. pneumoniae (CRKP) strains
is emerging worldwide. The aim of this study was to retrospectively
analyze the epidemiology and mechanisms of resistance of CRKP, in
our Hospital throughout 2004–2009.
Materials and Methods: All CRKP isolates were collected since 2003,
when the ﬁrst resistant strain occurred in our hospital. From January
2004 to June 2009, 209 single patient/ CRKP strains were isolated both
from ICU and non-ICU patients. Susceptibility testing was performed
by Kirby Bauer, E-test and Vitek2 automated system, according to
CLSI guidelines. All strains were further tested for the production
of various b-lactamases, both phenotypically (VIM EDTA test, E-test
imipenem, Hodge test, boronic acid/imipenem disc test) and by PCR for
the detection of blaVIM and blaKPC gene. Rep-PCR was performed to
investigate the clonal spread of isolates.
Results: The overall emergence of CRKP strains throughout the study
period was 16.4% (187/1140 K. pneumoniae). In 2004, 18 CRKP were
isolated out of 199 K. pneumoniae strains (9.0%). The following years
(2005−08) the rate was 10.1%, 8.8%, 10.4%, 25.6% respectively, and up
to 26.7% in the ﬁrst semester of 2009. All CRKP isolates throughout
2004 to 2007 harbored the blaVIM gene (100%), while blaKPC emerged
up to 23.3% (17/73) in 2008 and 73.7% (14/17) in 2009. Rep-PCR
proved the clonal spread of resistant strains. The most of the strains
originated from ICU patients (57.7%), although the rate decreased from
88.8% in 2004, to 45.2% in 2008 and 47.0% in the ﬁrst semester of
2009.
Conclusions: There is an increasing rate of CRKP prevalence in our
Hospital since 2004, when the ﬁrst metallo-b lactamase producers
emerged. It is of interest, that in 2004−07, when only blaVIM harbouring
strains were detected, the rate of CRKP remained rather stable. When
KPCs emerged in 2008, they dominated and were rapidly disseminated
in several units, making KPC production the commonest mechanism of
carbapenemase resistance in the Hospital the last years. The infection
control committee should be alerted in any case and measures should be
taken to avoid further dissemination. The microbiology laboratory could
contribute to this purpose, by including phenotypic investigation of all
multidrug resistant Enterobacteriaceae in routine practice.
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P1278 The ongoing challenge of acquired carbapenemases:
simultaneous production of VIM-1 and KPC-2 in Klebsiella
pneumoniae
V. Miriagou °, A. Zioga, E. Douzinas, M. Tsakiri, E. Tzelepi,
L. Tzouvelekis, N. Legakis (Athens, GR)
Objectives: VIM-1 and KPC-2 b-lactamases have been established
among Enterobacteriaceae in Greek hospitals. We report here on the
characteristics of 17 K. pneumoniae isolates of which ﬁve produced
VIM-1, eight KPC-2 and the remaining four were positive for both
carbapenemases.
Methods: Seventeen Klebsiella pneumoniae isolates exhibiting
imipenem MICs >0.5mg/L were derived from clinical material in
Evgenidion hospital in Athens during March-August 2009. Carbapen-
emase activities were examined by conventional synergy techniques and
biochemical methods (isoelectric focusing and photometric assays using
imipenem as an indicator substrate). Entire blaVIM and blaKPC genes
were ampliﬁed by PCR and sequenced. Isolates were typed by PFGE
following digestion of genomic material with XbaI. Medical records of
the respective patients were followed throughout the study period.
Results: PCR and biochemical assays documented that 13 isolates
produced either KPC-2 (n = 8; group 1) or VIM-1 (n = 5, group 2)
exhibiting the characteristic phenotypic traits conferred by the respective
b-lactamases. The remaining four isolates (group 3) exhibited a
resistance phenotype reminiscent of KPC production, yet they were
positive for both KPC-2 and VIM-1. All group 3 isolates, while positive
by the EDTA-based inhibition tests, appeared negative in the synergy
tests combining carbapenems with boronates. This can be probably
attributed to a masking effect of the VIM-1 b-lactamase. It could be
hypothesized that the contribution of the latter enzyme in carbapenem
resistance was more important than that of KPC-2. Nevertheless, total
carbapenemase activities and carbapenem MICs did not signiﬁcantly
differ between the three groups.
PFGE typing classiﬁed the studied isolates into two distinct clusters, A
(including group 1) and B (including both groups 2 and 3). Each cluster
comprised isolates with highly similar macrorestriction patterns strongly
suggesting common origins. It is therefore proposed that group 3 isolates
evolved from an endemic VIM-1-producing strain through blaKPC-2
acquisition likely facilitated by a plasmid.
Conclusion: There have been indications in Athens hospitals for a partial
“substitution” of KPC-for-VIM-producing enterobacteria. Nevertheless,
this study documents establishment of at least one K. pneumoniae strain
expressing both carbapenemases. Diffusion of such strains may be of
serious consequences.
P1279 Interspecies spread of KPC carbapenemase in a single
patient
I. Galani °, M. Souli, F. Panayea, Z. Chryssouli, H. Giamarellou
(Athens, GR)
Objectives:We described an ICU patient who was sequentially colonized
by two species of carbapenem-resistant Enterobacteriaceae, which
produced KPC-2 b-lactamase and were further characterized.
Methods: A K. pneumoniae (Kp) and an E. aerogenes (Ea) carbapem-
resistant isolates as well as a susceptible Ea isolated from the same
patient were included in the study. The presence of b-lactamases in these
strains was detected by IEF and conﬁrmed by PCR and sequencing. MICs
were determined by Phoenix automated system. Conjugation experiments
were carried out by a ﬁlter method using a rifampin resistant Escherichia
coli K12 laboratory strain as a recipient. Transformation experiments
were carried out with E. coli DH5a laboratory strain. Molecular typing
was performed by PFGE of SpeI-restricted genomic DNA. Plasmid
analysis was carried out by PFGE of S1 nuclease-digested total DNA as
well as RFLP analysis.
Results: The patient was admitted for pneumonia in Attikon University
hospital ICU at 26 September 2008 and was colonized on day 10 by
a KPC-positive Kp which was thought to be acquired by horizontal
transmission. She developed bacteremia by this strain 17 days after
her ﬁrst colonization. Ea KPC-positive-strain was ﬁrst isolated three
months after the patients ICU admission, while earlier the patient was
colonized by a susceptible Ea strain. The ﬁrst Kp isolated from faeces
and the Kp isolated from blood were identical and belonged to clone A
which was the predominant clone of the outbreak that was reported in
our hospital during 2008. These isolates were resistant to b-lactams,
inhibitor combinations, amikacin and cotrimoxazole, with imipenem
(IMP) MIC 8mg/L. Ea KPC producing strain belonged to the same
clone as the sensitive strain. It was resistant to b-lactams, inhibitor
combinations, amikacin and colistin, with IMP MIC >8mg/L. The Kp
isolates harboured blaKPC-2, blaSHV-12, blaSHV-11 and blaTEM-1-
like while the Ea harboured blaKPC-2, and blaTEM-1-like. S1 nuclease
method showed that these isolates harboured three and two plasmids,
respectively. Conjugation experiments were repeatedly unsuccessful
while transformation was successful for both cases. Plasmid RFLP
analysis showed that Kp and Ea had the same plasmid coding for KPC-2
and TEM-1-like, conferring resistance only to b-lactams and inhibitor
combinations (IMP MIC 2mg/L).
Conclusions: We documented the spread of a plasmid harbouring
blaKPC-2 from a Kp to an Ea isolate colonizing the same patient.
P1280 Metallo-b-lactamases among Enterobacteriaceae from
routine samples in an Italian tertiary care hospital and
long-term care facilities during 2009
R. Aschbacher °, L. Pagani, G. Spoladore, P. Innocenti, L. Moroder,
R. Meyer, E. Pagani, D. Livermore, C. Larcher (Bolzano, IT; London,
UK)
Objectives: Metallo-b-lactamase (MBLs) producing Enterobacteriaceae
have been isolated since 2005 in a 850-bed tertiary care hospital
and associated long-term care facilities, serving an area of 200,000
inhabitants, in Bolzano, Italy. All routine isolates in 2009 were screened
for MBLs and case details were reviewed for source patients.
Methods: Basic screening of Enterobacteriaceae with the Vitek 2
automatic system using cards that included an ESBL-conﬁrmation test.
Carbapenemase and MBL activity were sought with Hodge-cloverleaf
and EDTA-synergy tests, respectively; VIM- genes were sought by PCR.
Clinical data were collected retrospectively.
Results: The prevalence of MBL producing Enterobacteriaceae from in-
and out-patient samples during the ﬁrst 9 months in 2009 was 0.67%
(28/4200), almost exactly the same as in 2008 (0.65%; 36/5,500). All
the producer strains from both years had VIM enzymes. Prevalence
rates in 2009 varied from 0.4% (13/3,000) for E. coli, 0.8% (1/126) for
E. cloacae, 1.6% (6/372) for K. pneumoniae, 2.2% (1/46) for C. freundii,
2.3% (1/44) for E. aerogenes, 2.3% (3/129) for K. oxytoca up to 3.1%
(2/64) for M. morganii, together with 1/1 for C. amalonaticus. These 28
MBL-producers were from 26 patients (one patient had MBL-positive
E. coli, K. pneumoniae and K. oxytoca) in 8 hospital departments
(14 isolates), 4 long-term care facilities (7 isolates) or outpatients (7
isolates); risk factors in the latter group remain unspeciﬁed. Seventeen
were from urine samples (8 E. coli, 4 K. pneumoniae, 2 M. morganii, 1
E. cloacae, 1 E. aerogenes and 1 C. amalonaticus); two were from blood
(1 K. pneumoniae and 1 C. freundii), 7 were from respiratory specimens
(4 E. coli, 2 K. pneumoniae and 3 K. oxytoca); the remaining 2 were from
peritoneal ﬂuid (E. coli) and an ulcer (K. pneumoniae). Altogether 88
MBL-producing Enterobacteriaceae belonging to 10 species have been
isolated since 2005.
Conclusion: Isolation of VIM MBL-producing Enterobacteriaceae from
eight hospital departments and four long-term care facilities or nursing
homes conﬁrms the endemic persistance of this mode of resistance and
its encoding elements in the Bolzano health care district.
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P1281 Dissemination of a clone KPC-3-producing Klebsiella
pneumoniae in hospitals, Bogota, Colombia
S.Y. Saavedra, C.A. Alvarez, S.I. Cuervo, N. Olarte, J.A. Escobar,
A.L. Leal, J.S. Castillo London˜o ° (Bogota´, CO)
Objective: Typing molecular from isolates carbapenem-resistant Kleb-
siella pneumonia and to detected microbiological and molecular
ocurrence from carbapenemases.
Methods: Fifty-eight isolates carbapenem-resistant K. pneumoniae
recovered from patients in six hospitals of Bogota were collected
from 2008 to 2009. The identiﬁcation and the susceptibility testing
were performed with automated system; imipenem, meropenem and
ertapenem susceptibilities were determined by disk diffusion and the
carbapenemases production was conﬁrmed with the modiﬁed Hodge test.
The detection of genes encoding metallo and KPC-type carbapenemases
was performed by PCR using speciﬁc primers for blaIMP, blaVIM
and blaKPC genes. Ampliﬁcation products were analyzed by restriction
disgestion of the amplicom with the enzymes BstNI and RsaI
and conﬁrmed by sequentiation. The characterisation molecular by
assessment the relatedness of the isolates was realised by ERIC-PCR, the
cluster analysis was realised with Fingerprinting II software (Bio-Rad).
Results: All Isolates were resistant to ertapenem, ceftriaxone, cef-
tazidime, cefotaxime, eleven isolates were susceptible to imipenem and
seven to meropenem. All isolates were phenotypically identiﬁed as
possible carbapenemases producers and the presence of blaKPC gene
was conﬁrmed by PCR. Sequencing and restriction test conﬁrmed the
presence of KPC-3 in all isolates. Typing results showed presence of a
clone predominant conformed by ﬁfty-seven isolates from ﬁve hospitals
and a ﬁngerprint unique genomic.
Conclusions: Our results indicate the ocurrence of a clone KPC-3
producing K. pneumoniae in ﬁve hospitals from Bogota. This is the
ﬁrst report of dissemination of KPC-3 in hospitals from Colombia.
P1282 First two isolates of metallo-b-lactamase-producing Serratia
marcescens in the Czech Republic
E. Chudackova °, M. Fridrichova´, E. Bebrova, P. Urbaskova,
H. Zemlickova, J. Hraba´k (Plzen, Prague, CZ)
Objectives: Resistance to carbapenems in Enterobacteriaceae is me-
diated by the production of various carbapenemases and/or by the
decreasing permeability of the outer cell membrane together with
a hyperproduction of extended spectrum or AmpC b-lactamases. In
the Czech Republic, Gram-negative bacteria with acquired metallo-
b-lactamases (MBLs) are sporadic, with the ﬁrst isolates of IMP-7
producing strains of Pseudomonas aeruginosa identiﬁed in 2008. The
ﬁrst two strains of Serratia marcescens resistant to carbapenems were
sent to the National Reference Laboratory for Antibiotics at the end of
2008.
Methods: Production of b-lactamases was analyzed by the modiﬁed
double disk synergy test. Carbapenemase activity was detected by
imipenem hydrolysis assay. b-lactamases were visualized by isoelectric
focusing followed by bioassay. Genes of b-lactamases were ampliﬁed and
sequenced. The b-lactamase gene environments were determined as well
as a replicon typing of plasmids was performed. Strains were compared
by PFGE.
Results: The strains were isolated in different hospitals in the central
region of the Czech Republic. Both strains were highly resistant
to antibiotics; produced VIM-1 carbapenemase carried out on class
1 integron and intrinsic AmpC b-lactamase. The strains represented
different PFGE proﬁles. One isolate also produced b-lactamases with
pIs of 5.9 and 7.9 that were identiﬁed as TEM-6 (extended-spectrum
b-lactamase) and DHA-1 respectively. blaDHA-1 was carried out on
the complex class 1 integron with a different genetic organization than
observed in Klebsiella pneumoniae strains endemic in some Czech
hospitals. b-lactamases were localized on the plasmids with FIB, L/M
and A/C replicons.
Conclusions: This is the ﬁrst observation of MBL producing enterobac-
teria in the Czech Republic. To our knowledge, this is also the ﬁrst
identiﬁcation of an inducible DHA-1 AmpC in S. marcescens.
This work was ﬁnanced by a research project grant NS9717–4/2008.
P1283 First outbreak of carbapenemase-producing Klebsiella
pneumoniae in a tuberculosis care facility in the Netherlands
N. Meessen °, J. Wiersinga, K. van der Zwaluw, R. van Altena
(Groningen, Bilthoven, NL)
Background: Carbapenems are drugs of choice for serious infections
caused by ESBL producers. Klebsiella pneumoniae carbapenemase
(KPC) is a b-lactamase which confers resistance to all b-lactam
antibiotics, including carbapenems. Clonal expansion of KPC producing
K. pneumoniae (KPC-Kp) is emerging in Europe. KPC producing strains
are particularly alarming due to the multidrug resistance which is carried
on plasmids.
Methods: Identiﬁcation and susceptibility testing of isolates were
performed with Vitek2 and Etest. Carbapenemase and other b-lactamase
genes were identiﬁed by PCR. PFGE was used for epidemiological
comparisons. Medical records of patients that harboured KPC producers
were retrospectively reviewed to ascertain factors that may have
inﬂuenced the acquisition and persistence of the organism.
Results: After admission to the university hospital, a multidrug-resistant
Kp was isolated from a wound of a leukaemic patient. The patient
was isolated and no intrahospital transmission was observed. However,
screening of all patients in the 20-bed extramural TB-care facility
where the patient initially stayed, revealed another 6 patients with
carbapenem-resistant Kp. Cohort isolation was applied and hygiene
measures intensiﬁed. Due to poor compliance the KPC-Kp could spread
further. In total 13 other patients proved to be colonized with KPC2-Kp,
Environmental cultures also yielded KPC-Kp, despite extra cleaning.
Isolates expressed high-level resistance to all non-carbapenem b-lactam
antibiotics, aminoglycosides (exept for gentamycin), cotrimoxazol,
aztreonam, and quinolones. MICs of imipenem and meropenem ranged
from 1.5 to 32 microg/ml. MIC90 values for colistine and tigecycline
were 1 microg/ml and 0.75 microg/ml, respectively.
Prior to acquisition, almost all patients were on TB medication, in
some cases including moxiﬂoxacine and amikacin. Most patients were
asylum-seeker and originated from non-Europe countries. Some of the
African patients travelled to The Netherlands via Greece where KPC-Kp
is highly-endemic.
Conclusions: Social and cultural aspects of behaviour contributed to the
poor hygiene-compliance of the patients involved in this ﬁrst outbreak
of KPC-Kp described in The Netherlands. Since treatment options for
infections with KPC-producers are extremely limited, spread should be
avoided. Strict infection control measurements are effective. To achieve
more awareness, local and national surveillance is needed.
P1284 The ﬁrst carbapenemase-producing Klebsiella pneumoniae
strains in the Netherlands are associated with international
travel
J.W. Cohen Stuart, G. Voets, D. Versteeg, J. Scharringa, M. Tersmette,
E. Roelofsen, A.C. Fluit, M. Leverstein-van Hall ° (Utrecht,
Nieuwegein, Groningen, NL)
Objectives: Carbapenems are often used as a last resort for treating
serious infections caused by multidrug-resistant Gram-negatives (MDR-
GN). Carbapenemase-producing Enterobacteriaceae are emerging world-
wide, but, until now, none have been reported in The Netherlands. In this
study, we determined whether the elevated carbapenem MICs of three
K. pneumoniae isolates (KPN) isolated in 3 different Dutch hospitals
were due to carbapenemase production. Isolate KPN-1 en KPN-2 were
isolated from 2 patients that had recently returned from a holiday trip in
India. During their trip they had not visited any medical care facility but
had taken unspeciﬁed tablets against enteritis. The KPN-3 was from a
patient transferred from a Greek hospital to which he had been admitted
during his holiday.
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Methods: MICs were determined using broth micro-dilution (MBD),
VITEK and Etests (bioMe´rieux, Paris, France). For phenotypic
conﬁrmation a modiﬁed Hodge test, imipenem-EDTA and imipenem-
boronic acid (BA) synergy tests were performed. Genotypic conﬁrmation
was done by PCR and sequencing.
Results: Table 2 shows the results of the susceptibility tests for
3 carbapenems and the conﬁrmation tests. KPN-1 and 2 were
only susceptible to colistin, tigecycline and chloramphenicol. KPN-1
contained a New-Delhi metallo-carbapenemase gene (NDM-1), a CTX-
M-1 group ESBL gene, and two AmpC genes (CMY-6, DHA-1) while
in KPN-2 only NDM-1was detected. These ﬁndings are in line with
previous reports on NDM-1 positive isolates obtained from patients with
prior medical treatment in India.
KPN-3 was only susceptible to gentamicin, tobramycin, amikacin,
colistin, and tigecycline. In this strain a KPC-2 gene and a SHV-12
ESBL gene were identiﬁed, consistent with the hyperepidemic clone
described in Greek hospitals.
Conclusion: The ﬁrst carbapenemase-producing KPN in The Nether-
lands were travel-associated. Patients undergoing medical treatment in
countries with high prevalence of MDR-GN have an increased risk
of acquiring these micro-organisms. In low endemic countries, the in-
hospital spread of MDR-GN may be prevented by identifying those
patients treated in high risk countries, and to screen them at admission.
However, when travelers may also acquire acquire carbapenemase
producing isolates without medical treatment, this control strategy
may fail, resulting in an uncontrollable introduction and spread of
carbapenemases in low endemic countries such as The Netherlands.
Meropenem Imipenem Ertapenem
Hodge
test
Imi-
EDTA
Imi-BA MBD Etest Vitek MBD Etest Vitek MBD Etest
KPN-1 +/− + − >32 >32 4 2 >32 8 1 >32
KPN-2 + + − >32 >32 nd 8 >32 nd >8 >32
KPN-3 + − + >32 >32 >16 8 >32 8 >8 >32
P1285 Molecular characterization of VIM-producing Klebsiella
pneumoniae from Scandinavia
Ø. Samuelsen °, M. Toleman, V. Hasseltvedt, K. Fuursted,
T.M. Leegaard, T. Walsh, A. Sundsfjord, C.G. Giske (Tromsø, NO;
Cardiff, UK; Lillehammer, NO; Aarhus, DK; Oslo, NO; Stockholm, SE)
Objectives: The emergence and dissemination of MBL-producing
Klebsiella pneumoniae has become a public health problem in certain
countries. The aim of this project was to characterise MBL-producing
K. pneumoniae isolates identiﬁed in Scandinavia.
Materials and Methods: The study included eight MBL-producing
isolates of K. pneumoniae identiﬁed in Scandinavia (Norway, Sweden
and Denmark) year 2005−08. The isolates were characterised with
respect to resistance proﬁle (Etest), clonal relatedness (multi-locus
sequence typing) and by PCR assays for the presence of MBLs, ESBLs,
plasmid-mediated quinolone resistance (qnr), 16S rRNA methylases and
for plasmid-replicons. Plasmid transfer was assessed by conjugation
and transformation experiments. Epidemiological data were collected
retrospectively.
Results: Epidemiological data revealed that 7/8 isolates were associated
with recent hospitalization outside Scandinavia (Greece, n = 6 and
Turkey n = 1). All eight isolates harboured blaVIM and expressed
a multi-drug resistant phenotype. MLST analysis showed that four
isolates belonged to ST147 while the other isolates belonged to ST36,
ST272, ST273 and ST383. All isolates supported in vitro transfer
of blaVIM consistent with plasmid localisation. PCR-replicon typing
of transconjugants/transformants (TC/TF) suggested that blaVIM was
associated with IncN (n = 3) and A/C (n = 1) replicons. Four TC/TF
were negative for the eighteen tested replicons. ESBL-genes were found
in six isolates; CTX-M-3 (n = 1), CTX-M gr. 1 (n = 1), SHV-5 (n = 2),
and SHV-12 (n = 2). The 16S rRNA methylase armA and the plasmid-
mediated quinolone resistance gene qnrS was identiﬁed in one and two
isolates, respectively. Co-transfer of blaVIM, blaCTX-M-3, armA, and
qnrS was observed.
Conclusion: Emergence of MBL-producing K. pneumoniae in Scandi-
navia is still related to strain import. Characterisation of the isolates
shows that blaVIM is co-localised on plasmids along with other major
resistance determinants resulting in multi-drug resistant isolates.
P1286 Infections caused by KPC-2-producing K. pneumoniae: the
impact of antimicrobial treatment on patients’ outcome
O. Zarkotou, G. Chrysos °, S. Pournaras, E. Voulgari, T. Pittaras,
D. Voutsinas, A. Prekates, K. Digalaki, A. Tsakris (Athens, Larissa, GR)
Objectives: KPC-producing K. pneumoniae (KPC-KP) infections pose
a new therapeutic challenge. The results of a cohort study regarding
antimicrobial treatment of KPC-KP infections and patients’ outcome are
presented.
Methods: All patients identiﬁed as infected by genotypically-conﬁrmed
KPC-KP between May 2008 and September 2009, were evaluated.
Clinical and laboratory records were reviewed.
Results: 63 patients (37 males; median age, 72 years) were infected
by KPC-2-producing KP. The mean time of hospital stay prior to
isolation was 19.8 days, the majority of patients had >2 comorbidities
(38/63), were mechanically ventilated at isolation (35/63) and had
prior hospitalizations (42/63). Bloodstream infections were prevalent
(38/63) followed by urinary tract (11/63), skin and soft tissue (7/63),
hospital-acquired pneumonia (5/63), intra-abdominal (1/63) and CNS
infections (1/63). The overall mortality was 46% and infection mortality
was 28.6%. Appropriate antimicrobial treatment (deﬁned by in vitro
activity and treatment duration >3 days) was received by 40 patients;
among those, infection mortality (IM) was 15% and microbiological
response was observed in 23/25 patients having cultures available. IM
was signiﬁcantly higher (52.2%; p = 0.002) among patients who did
not receive appropriate treatment. The most commonly used treatment
regimen was tigecycline (22/40), either as monotherapy (10/40, IM
10%), or in combination with: colistin (6/40, IM 16.7%), gentamicin
(4/40, IM 0%), meropenem (1/40, IM 0%), and colistin plus meropenem
(1/40). Colistin was administered as monotherapy to 5/40 patients (IM
20%), while 5/40 and 2/40 patients received colistin in combination
with gentamicin (IM 20%) and meropenem (IM 50%) respectively. No
signiﬁcant differences regarding IM were detected when administration
of one active antimicrobial (IM 17.6%) was compared with combination
schemes (IM 13%, p = 0.67).
Conclusion: KPC-KP has emerged as a common cause of infections
associated with high infection mortality, among severely ill patients in
our region. Appropriate antimicrobial treatment contributes signiﬁcantly
to a favorable patient’s outcome.
P1287 Outbreak of multiresistant Klebsiella pneumoniae producing
DHA-cephamycinase and resistant to carbapenems due to
porin loss in an intensive care unit
M. Lorenzo °, M.R. Go´mez-Gil, Y. Moatassim, E. Salvarelli, B. Galvan,
A. Gutie´rrez, J. Mingorance (La Paz, ES)
Objective: Description of an outbreak of K. pneumoniae producing DHA
cephamycinase associated with an OXA extended spectrum b-lactamase
(ESBL) and resistance to carbapenems due to loss of porins in the burn
intensive care unit of Hospital Universitario La Paz (Madrid) between
April 2008 and June 2009.
Materials and Methods: We studied 26 isolates of K. pneumoniae
isolated from 21 patients of the burn intensive care unit of HU La Paz
(Madrid, Spain) between April 2008 and June 2009 with resistance to
cefotaxime, cefoxitin and cefepime. The isolates were obtained from
blood (13), urine (7), burns (2), bronchoalveolar lavage ﬂuids (2),
catheter (1) and tracheal ﬂuid (1). The identiﬁcation and antibiotic
susceptibility assays were done by MIC/ID Wider® (Soria Melguizo) or
Vitek ® (Biomerieux) using CLSI breakpoints. ESBLs were conﬁrmed
in all isolates with CMI> 1 microg/mL to cefepime using E-test® with
cefepime and cefepime with clavulanic acid. Hodge’s test was done to
rule out carbapenemases. Speciﬁc PCR reactions were done to detect
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the genes coding for b-lactamases of the SHV, OXA, TEM, CTX-M
groups and the plasmidic AmpC families (MOX, CIT, DHA, ACC, EBC,
FOX). Clonality was assessed by Rep-PCR using the DiversiLab system.
The presence of porins was analyzed by SDS-PAGE analysis of outer
membrane preparations.
Results: All the isolates were resistant to cephalosporines and
cephamycin and to b-lactams with b-lactamase inhibitors. Among the 26
isolates, 24 had an OXA ESBL gene, and 23 of these had a DHA-1 gene.
These 23 isolates were clonally related. Ten isolates had intermediate
susceptibility or were resistant to carbapenems according to CLSI’s
criteria. Loss of the porins OmpK 35 and 36 was observed in all ten.
Hodge’s test was negative in all the cases, as were KPC-speciﬁc PCR
assays. All the isolates had resistance to quinolones, aminoglycosides
and trimethopim-sulfamethoxazole.
Conclusions: We describe the ﬁrst outbreak in Spain of K. pneumoniae
producing OXA ESBL and DHA cephamycinase with resistance
to all the b-lactams, including combinations with b-lactamase in-
hibitors, quinolones, gentamycin and tobramycin and trimethopim-
sulfamethoxazole. Development of resistance to carbapenems by loss
of OmpK35/36 porins was observed during the outbreak.
P1288 Imipenem-resistant K. pneumoniae and E. coli in 49
German ICUs, 2005–2008
E. Meyer °, F. Schwab, B. Schroeren-Boersch, P. Gastmeier (Berlin,
Freiburg, DE)
Objectives: To analyse imipenem resistance (imiR) in K. pneumoniae
and E. coli in German intensive care units (ICUs) participating in the
SARI (Surveillance of Antimicrobial Use and Antimicrobial Resistance
in Intensive Care Units) and to look for temporal changes.
Methods: Prospective unit and laboratory based surveillance in
49 German ICUs from 2005–2008. The data were speciﬁed as
imipenem resistant by the clinical laboratory using interpretive criteria
recommended by CLSI or DIN. The proportion of non-duplicate resistant
isolates (RP) and resistance densities (RD; i.e. the number of resistant
isolates of a species per 1000 patient days) were calculated. Resistance
data were tested by incidence density test.
Results: 49 ICUs reported data on 3128 K. pneumoniae and 8100
E. coli isolates tested to imipenem. In 2008, the pooled mean of imiR
K. pneumoniae was 1.1% corresponding to 7 resistant isolates and was
0.1% (n = 2) of imiR E. coli. Two of the 7 isolates were tested and
identiﬁed as KPC-producing bacteria by molecular conﬁrmation tests.
From 2005–2007, the burden of resistance i.e. imiR K. pneumoniae per
1000 pd signiﬁcantly increased from 0.011 to 0.047 in 2008 (p = 0.009).
RD of imiR E. coli was 0.019 in 2005 and 0.013 in 2008.
Conclusion: There was a signiﬁcant increase imiR K. pneumoniae in
2008 compared to the previous years indicating that KPC producing
K. pneumoniae have arrived in German ICUs.
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P1289 Impact of a hypoxic environment on the efﬁcacy of
antimicrobials to intracellular pathogens
K. Shima, J. Gieffers, W. Solbach, J. Rupp ° (Lubeck, DE)
Objectives: Chlamydiae are obligate intracellular pathogens that cause
infections of the respiratory tract, the urogenital tract and the eyes.
Currently available antimicrobials are effective in treating acute
infections with C. pneumoniae (Cpn) or C. trachomatis (Ctr), but fail to
eradicate persistent chlamydial infections in diseased organs. We found
out recently that a microenvironment of low oxygen, that can be found
even under physiological conditions in the urogenital tract and the lung,
strongly induces chlamydial growth and progeny. The aim of this study
was to investigate the activity of different antimicrobials on intracelllular
chlamydial growth under hypoxic conditions.
Methods:We determined the MIC of doxycyclin, rifampin, erythromicin
and moxiﬂoxacin on chlamydial growth in HEp-2 cells under normoxic
and hypoxic (2% O2) conditions. Uptake kinetics of C14-labeled
moxiﬂoxacin were monitored to assess changes in the intracellular
accumulation under hypoxia. To analyze differences in the antimicrobial
efﬁcacy to different chlamydial developmental stages time-kill curves
were performed.
Results: Culture in hypoxia strongly enhanced chlamydial growth
and progeny to a more than 3-fold increase compared to normoxic
conditions. Nevertheless, MIC for doxycyclin, rifampin, erythromicin
and moxiﬂoxacin on Cpn and Ctr did not differ between normoxia
and hypoxia. Using C14-labeled moxiﬂoxacin we could prove that
intracellular uptake and accumulation was not affected by a low oxygen
environment, showing high intracellular concentrations of the drug
within 5 min after stimulation. Interestingly, drug-dependent differences
to kill Ctr in the early phase of the developmental cycle (2 to 8 h
p.i.) were observed between normoxia and hypoxia. Thus, reduction in
chlamydial growth was less effective in doxycyline (2 mg/mL) treated
cells when cultured under hypoxia than in normoxia. No differences
were observed in cells treated with rifampin (8 mg/mL).
Conclusion: Low oxygen concentrations have a strong impact on the
transcriptional activity and metabolism of host cells that have to be
considered in testing antimicrobial efﬁcacy to intracellular pathogens.
We suggest to perform time-kill curves instead of standard MIC testing
to calculate efﬁcacy of antimicrobials under low oxygen concentrations.
Further studies will show whether reduced antibiotic efﬁcacy under
hypoxia contributes to the emergence of persistent chlamydial infections
in humans.
P1290 Antimicrobial effects of different wound dressings: an
in vitro study
S. Baka °, E. Kouskouni, D. Rizos, S. Demeridou, Y. Skalkidis,
V. Arapoglou (Athens, GR)
Objectives: Wound dressings have been developed for several decades
to keep the wound clean by absorbing the exudate, thus contributing to
the healing process. They help in the treatment of moderately to highly
exuding leg ulcers mostly when healing is delayed due to the bacteria
present. This study aimed to compare the effect of ﬁve commercially
available wound dressings, in vitro, on the survival and proliferation of
ﬁve different microorganisms frequently isolated from leg ulcers in our
hospital.
Methods: Two protocols were used to test ﬁrst, the ability of each
dressing to inhibit bacterial growth on an already inoculated surface and
second, to resist bacterial colonization after impregnation with the same
concentration of each of the microorganisms tested. The antimicrobial
activity of Contreet / Biatain Ag (a silver-containing foam dressing) and
Biatain − Ibu (a foam dressing containing ibuprofen) was compared to
Biatain (a plain foam dressing) (all foam dressings from Coloplast A/S,
Humlebaek, Denmark) serving as control, while two gauze dressings
(both from Dermagenics Europe BV, Kaatsheuvel, The Netherlands),
MelMax® [impregnated with a mixture of metalloproteinase-regulating
Poly Hydrated Ionogens (PHI-5) and buckwheat honey] and PHI − 5®
(DerMax®) (containing zinc and rubidium ions) were compared to sterile
gauze used in the operation rooms which served as a general control
and as speciﬁc control for the 2 types of gauze dressings. Based on
the prevalence in our hospital, ﬁve microorganisms were used to test
the ability of the wound dressing to resist infection in both protocols:
Staphylococcus epidermidis, ATCC 35984, S. aureus, ATCC 29213,
Clinical isolate of methicillin-resistant S. aureus (MRSA), Escherichia
coli, ATCC 35218, Pseudomonas aeruginosa, ATCC 27853.
Results: In both protocols Contreet/Biatain Ag foam dressing dis-
played antibacterial activity against Escherichia coli and Pseudomonas
aeruginosa for 9 days, Staphylococcus epidermidis for 10 and 7 days,
respectively, Staphylococcus aureus growth was inhibited for 10 and
6 days, respectively, while MRSA for 11 and 10 days, respectively.
Two other dressings, MelMax® and PHI-5® inhibited MRSA and
S. epidermidis growth, respectively, for 4 days.
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Conclusion: Contreet/Biatain Ag foam dressing displayed a broader
antibacterial activity in both protocols performed, suggesting that it can
be left in place for a longer period of time.
P1291 In vitro activity of tigecycline against Brucella sp. isolated
from 1997 to 2009
S. Al Johani °, Z. Memish (Riyadh, SA)
Background: Brucellosis is an endemic zoonotic infectious disease
in Saudi Arabia. To date, there is no optimum antibiotic therapy for
brucellosis due to relatively high rates of relapse and treatment failure.
The use of new antibiotics, such as tigecycline, may hold future promise.
Objective: The aim of this study was to investigate in vitro activity
of tigecycline (TIG) against Brucella spp isolated at Microbiology
Laboratory, King AbdulAziz Medical City over the last 12 years.
Material and Methods: A total of 471 Brucella strains, isolated from
blood and sterile body ﬂuid and saved at −80 degrees from January 1,
1997 to November 2009, was sub cultured twice then tested against
TIG using E-test (AB Biodisk, Sweden ®), and the minimal inhibitory
concentration (MIC) was measured, along with MIC50 and MIC90.
Results: A total of 471 Brucella strain sub cultured, out of the 471, there
were 8 isolates excluded because it fail to grow. Of the remaining 463
isolates were tested against TIG using E-test, the MIC were determined
for each isolates. MIC range (0.064–0.125 mg/ml), MIC50 (0.064 mg/ml)
and MIC90 (0.094 mg/ml). Out of 464 isolates, there were 286 isolates
(61.77%) has an MIC below 0.125 mg/ml, and the rest 176 (38.01%) has
an MIC between (0.250–1.50 mg/ml).
Of the 287 presumed susceptible strains, there were 136 isolates
(47.39%) where their MIC below (0.064 mg/ml) and 151 (52.61%) has
MIC between (0.064–0.125 mg/ml).
Conclusion: The results of this in vitro study suggest that tigecycline has
a promising future to be used as a therapeutic alternative for brucellosis.
These observations need to be supported with clinical trials. This is the
ﬁrst study to analyze a large number of brucella isolates at our region.
P1292 Antibiotics effect on S. aureus adhesion to human ﬁbronectin
O. Dumitrescu °, A. Moulay, A. Tristan, M. Bes, F. Vandenesch,
J. Etienne, G. Lina (Lyon, FR)
Background: Staphylococcus aureus is a human pathogen responsible
of a large variety of severe infections. Its pathogenicity is strongly
related to the production of many virulence factors. Among these,
ﬁbronectin binding molecules (FnBPA and FnBPB) are involved in the
invasion and the intracellular passage of S. aureus, causing persistent
infections non-responding to usual antibiotic treatment. Fibronectin
binding molecules are major determinants of the pathogenesis of
staphylococcal endocarditis and osteoarthritis. Unsuccessful outcome in
these infections may be linked to the impaired diffusion of antibiotics
at the infection site. In this work, we explored the effect of main anti-
staphylococcal antibiotics, at subinhibitory concentrations, on S. aureus
adhesion to human ﬁbronectin.
Methods: We assayed for the adhesion to ﬁbronectin of six different
S. aureus strains by using a microplate adhesion test. Prior to
the adhesion assay, the strains have been cultured in presence of
subinhibitory concentrations of antibiotics (1/4 of the MIC). The
antibiotics tested were: oxacillin, gentamicin, vancomycin, rifampicin,
linezolid and moxiﬂoxacin. By using relative quantitative RT-PCR, we
also explored the effect of the antibiotics mentioned on the transcription
of fnbA and fnbB genes coding for FnBPA and FnBPB.
Results: The results showed that the antibiotics differently modulate
S. aureus adhesion to human ﬁbronectin. Oxacilline, moxiﬂoxacin and
linezolid treatment led to the acquisition of a hyperadhesive phenotype
consistent with the increased FnBPA and FnBPB mRNA levels after
oxacilline, moxiﬂoxacin and linezolid treatment. On the contrary, all the
strains treated with rifampicin showed signiﬁcantly decreased adhesion
to ﬁbronectin, while gentamicin and vancomycin had little impact on
S. aureus adhesion to ﬁbronectin.
Conclusion: Our results, showing an inhibitory effect of rifampicin on
S. aureus adhesion to human ﬁbronectin, support the use of rifampicin,
in association with other anti-staphylococcal agents, for the treatment of
severe S. aureus infections. Additionally, our observations may provide
explanation for the poor outcome of staphylococcal infections in case of
impaired antibiotics diffusion.
P1293 Gram-negative anaerobe susceptibility rates in six European
countries, 2007–2009
S. Bouchillon °, M. Renteria, M. Hackel, B. Johnson, M. Dowzicky
(Schaumburg, Collegeville, US)
Background: The Tigecycline European Surveillance Trial (TEST)
monitors susceptibility of European aerobic and anaerobic bacteria to
tigecycline (Tig), cefoxitin (Cfx), clindamycin (Cd), meropenem (Mer),
metronidazole (Met), and piperacillin–tazobactam (P/T). This report
summarizes susceptibility of Gram-negative anaerobes in 6 countries
to these drugs.
Methods: Anaerobic isolates collected by 43 cumulative labs in 6
countries from 2007–2009 were sent to a central lab in the United
States for agar dilution susceptibility testing, following CLSI guidelines.
Results were interpreted by EUCAST breakpoints and guidelines; FDA
breakpoints were used for tigecycline where none are deﬁned by
EUCAST.
Results: % Susceptible of each organism group in each country is
summarized in the table below.
Conclusions: The most active drugs were tigecycline, meropenem,
metronidazole, and piperacillin–tazobactam, each inhibiting >90% of
all Gram-negative anaerobes at their respective breakpoints. Cefoxitin
and clindamycin showed wide ranges in susceptibilities between
countries and organism groups. Hungary demonstrated statistically lower
susceptibility rates to cefoxitin and clindamycin against Gram-negative
anaerobes than other countries in this study.
Organism Demographics N Tig Cfx Cd Mer Met P/T
Bacteroides spp. Belgium 86 97.7 80.2 74.4 95.4 98.8 91.9
Czech Republic 100 98.0 86.0 71.0 96.0 100.0 92.0
France 316 96.5 81.7 70.3 97.5 100.0 91.5
Germany 504 96.0 85.5 77.6 96.8 99.0 91.1
Hungary 404 96.3 73.3 73.5 97.5 99.8 87.6
United Kingdom 10 100.0 100.0 90.0 100.0 100.0 100.0
Prevotella spp. Belgium 45 95.6 100.0 71.1 100.0 97.8 100.0
Czech Republic 41 100.0 97.6 85.4 100.0 100.0 100.0
France 93 98.9 98.9 79.6 98.9 98.9 98.9
Germany 250 99.6 97.6 85.6 100.0 96.4 98.0
Hungary 111 97.3 78.4 58.6 99.1 99.1 91.0
United Kingdom 3 100.0 100.0 100.0 100.0 100.0 100.0
Total 1,963 97.1 84.6 75.3 97.8 99.0 92.2
P1294 Three-year susceptibility analysis of Gram-positive
anaerobes in Europe − TEST, 2007–2009
R. Badal °, S. Bouchillon, M. Hackel, B. Johnson, D. Hoban, S. Hawser,
M. Dowzicky (Schaumburg, US; Epalinges, CH; Collegeville, US)
Objectives: Tigecycline has a broad spectrum of activity that includes
anaerobic bacteria. The Tigecycline European Surveillance Trial (TEST)
has been monitoring susceptibility of anaerobes in Europe since 2007.
This report compares the most recent data from 2009 to susceptibility
levels observed in 2007 and 2008 of Gram-positive anaerobes in Europe.
Methods: 1643 Gram-positive anaerobic pathogens (518 in 2007, 586
in 2008, 539 in 2009) were collected and identiﬁed from 44 sites in
7 countries in Europe, and sent to a central laboratory in the USA
where MICs of tigecycline and ﬁve comparators were determined using
CLSI agar dilution. Tigecycline MICs were interpreted using US FDA
breakpoints, while EUCAST guidelines were used for all other drugs.
Results: Overall % susceptibility for Gram-positive anaerobes is shown
in the table.
Conclusions: Tigecycline retained excellent in vitro activity against
Gram-positive anaerobic bacteria isolated from European hospitals
in 2009, inhibiting nearly 100% of all isolates. Metronidazole and
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meropenem were nearly as active as tigecycline, while clindamycin and
penicillin inhibited less than 80% of Gram-positive isolates in 2009.
Susceptibility of Gram-positive anaerobes in Europe, 2007–2009.
P1295 Streptococcal bacteriocin-like inhibitory activity against
potential upper respiratory tract pathogens
M. Santagati, M. Scillato, V. Metoldo, R. Burtone, F. Patane`, S. Stefani °
(Catania, IT)
Objectives: The use of bacteria as a probiotic is in continuous
development thanks to capacity to maintain or restore a host’s natural
microbiota by interference and inhibition with other microrganisms. This
is due to the production of antimicrobial peptides such as bacteriocins. In
the oral cavity, a-haemolytic streptococci such as S. salivarius, S. mitis,
S. mutans, S. sanguis are the major producers of bacteriocin which are
able to reduce the frequency of colonization of the main pathogens
involved in upper respiratory tract infections. Bacteriae-therapy may
offer a valid alternative in the prevention or treatment of bacterial
infections. In our study, we analyzed 15 a-haemolytic streptococci from
nasal and pharyngeal swabs of children to: i) evaluate the bacteriocin-like
inhibitory activity against potential pathogens; ii) determine bacteriocin
products and iii) to assay the capacity of adhesion on Hep-2 cell lines.
Methods: Thirty-one children were enrolled in this study (2−12 years).
All samples were plated onto Mitis Salivarius agar at 37ºC in 5% CO2.
All strains were identiﬁed by API Strep and sequencing of 16S rDNA
and SodA gene. The bacteriocin production was evaluated by deferred
antagonism test and the structural genes were investigated by PCR and
sequencing. The adherence assays based on Benga L. et al. 2004.
Results: Among 81 a-haemolytic streptococci isolated from 31 samples,
only 15 were bacteriocin producers. We found that three S. mitis and
seven S. salivarius were active against S. pneumoniae, two strains −
S. sanguis and S. mitis − against M. catharralis and two S. mitis showed
a broad inhibitory activity against S. pyogenes, S. pneumoniae, S. aureus
and S. salivarius and carried salivaricin B. Only one S. mitis with
S. pyogenes inhibitory activity, contained the salA gene. The preliminary
results of S. salivarius tests adhesion on Hep-2 cell lines demonstrated
its excellent adhesion capacity.
Conclusion: This study focused on the streptococcal inhibitory activity
demonstrating the capability of commensal ﬂora of upper airways to
interference and/or inhibit the growth of potential pathogens associated
with their ability to produce bacteriocis. It is interesting to note that two
S. mitis carrying salB act with a broad spectrum of activity.
P1296 Frequency and antibiotic susceptibility of Ureaplasma
urealyticum isolated from the genital tract of sexually active
individuals
E. Ostorha´zi °, B. Farkas, I. Bencze-Gyo¨ri, J. Gordos, K. Po´nyai,
S. Ka´rpa´ti, F. Rozgonyi (Budapest, HU)
Objectives: The aim of this study was to examine the incidence and
antibiotic sensitivity of Ureaplasma urealyticum strains cultured from
urethra and vagina of sexually active individuals attended to our STD
outpatient service.
Methods: Samples were taken from the urethra and cervix with universal
swab (Biolab®) into Urea-Myco DUO kit (Bio-Rad®) and incubated
in ambient air for 48 h at 37 Co. The determination of antibiotic
sensitivity was performed in U9 broth using SIR Mycoplasma kit (Bio-
Rad) under the same conditions. Only one isolate per patient was taken
into consideration.
Results: Between May 2008 and October 2009 a total of 169 strains
were obtained from urethra (38) and cervix (131). Most strains were
sensitive to tetracycline (95%), doxycycline (97%), pristinamycin (96%),
azithromycin (95%), josamycin (95%) and oﬂoxacin (93) but not to
erythromycin (13%) and clindamycin (22%). 75% of the strains were
resistant simultaneously to erythromycin-clindamycin combination also,
suggesting that ex juvantibus administration any of them may select
cross-resistant strains for both antibiotics.
Conclusions: Not only cultivation but also prior antibiotic sensitivity
testing is needed for successful treatment of subclinical or manifest
U. urealyticum infection since none of the analyzed strains was fully
susceptible to all examined antimicrobials. In case of U. urealyticum
infections or Chlamydia trachomatis and U. urealyticum coinfections,
azithromycin is the drug of choice since it is effective against both agents.
However, clarithromycin is also recommended since it inhibits bioﬁlm
formation of U. urealyticum.
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P1297 Extended nosocomial outbreak with multidrug-resistant
Acinetobacter baumannii in a French university hospital
C. Landelle °, P. Lesprit, P. Legrand, F. Cizeau, S. Soing-Altrach,
C. Brun-Buisson, E. Girou (Cre´teil, FR)
Objective: Describe the course and measures taken to control an
outbreak with multidrug-resistant Acinetobacter baumannii (MRAB) in
a university hospital.
Methods: During the epidemic period, all intensive care units (ICUs)
patients (pts) were screened weekly in rectal and throat swabs. The
identity of isolates was conﬁrmed by pulsed-ﬁeld electrophoresis.
Results: Between 01/08 and 06/09, the same strain of MRAB (sensitive
only to colistin) was identiﬁed in screening specimens for 28 pts and
in clinical samples for 58 pts; 36 pts also had co-colonization with
Klebsiella pneumoniae producing extended-spectrum b-lactamase. After
the admission of a pt with toxic epidermal necrolysis (TEN) and
MRAB carriage from Tahiti, 15 cross transmissions (CT) occurred in
2 ICUs between 01 and 04/08. Adherence to standard precautions was
reinforced; contact precautions, auditing health-care workers (HCW)
practices and environmental screening were implemented; rooms were
cleaned with hydrogen peroxide mist disinfection after pt discharge
or death, until the outbreak stopped. Admission of a second TEN pt
with the same MRAB strain from the same Tahitian hospital led to 69
secondary cases in 4 ICUs and 3 wards during 4 periods between 06/08
and 05/09 (table). Previous measures were resumed. Because MRAB
was detected in air, surfaces and from sink traps and pts’ washing
basins in one ICU, a weekly cleansing protocol with sodium hypochlorite
solution for all sinks was initiated. Use of sink water for nasogastric
tube rinsing or oral medication administration was forbidden. Care and
cleaning procedures were revised or implemented. Chlorhexidine skin
decontamination was initiated. ICU A, where most cases occurred was
closed to new admissions and moved to another ICU four times (table). In
05/09, all MRAB pts in wards or discharged from ICU A were cohorted
to an isolation unit, and cared for by trained and dedicated HCW. The
outbreak of MRAB then stopped. Most likely modes of transmission
were CT from colonized or infected pts via the hands of HCW, poor
cleaning of equipment, splashing of contaminated water from sink traps,
and reintroduction in the ICU of MRAB from pts previously colonized
or personnel.
Conclusions: MRAB outbreaks are notoriously difﬁcult to control. This
extended outbreak involving several ICUs was controlled only after
implementation of an extensive control program and eventual cohorting
of all carriers of MRAB in a dedicated area with a dedicated staff.
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Number of MRAB cross transmissions after transfer of Tahitian patient
with MRAB carriage
ICU A ICU B ICU C ICU D ICU E Medical
ward
Surgical
ward A
Surgical
ward B
Admission of a patient with MRAB carriage
Period 1: 01/08–06/09 10 5
Outbreak stopped − Admission of a second patient with MRAB carriage
Period 2: 06–09/08 12 1 1
Admissions in ICU A were stopped and the activity was moved in ICU D while ICU A
was cleaned
Period 3: 10–11/08 11 2
Admissions in ICU A were stopped and the activity was moved in ICU D while ICU A
was cleaned
Period 4: 12/08–02/09 12 7 1
Admissions in ICU A were stopped and the activity was moved in a new ICU E
Period 5: 03–05/09 − 3 4 11 2 1 1
Admissions in ICU E were stopped until discharge of all MRAB carriers − all MRAB
patients of wards or discharged from ICU E were cohorted into a isolation unit, with
dedicated HCW
P1298 Emergence of OXA-carbapenemase- and ArmA-producing
Acinetobacter baumannii isolates of European clonal
lineages I and II in Norway
N. Karah °, B. Haldorsen, N.O. Hermansen, Y. Tveten, E. Ragnhildstveit,
D.H. Skutlaberg, S. Tofteland, A. Sundsfjord, Ø. Samuelsen (Tromsø,
Oslo, Tønsberg, Fredrikstad, Bergen, Kristiansand, NO)
Objectives: Acinetobacter baumannii has emerged as an important
cause of hospital-acquired infections due to its remarkable propensity to
acquire resistance determinants and environmental resilience. The aim
of this project was to characterise carbapenem-resistant A. baumannii
isolates identiﬁed in Norway.
Materials and Methods: The study included 10 carbapenem-resistant
isolates of A. baumannii submitted to the Reference Centre for
Detection of Antimicrobial Resistance. The isolates were collected
between 2004−09 from various clinical specimens in six different
laboratories. Susceptibility testing was performed by Etest. PCR assays
were performed for detection of OXA-carbapenemase genes, 16S rRNA
methylase genes, ISAba1, ISAba3, intI1 and for determination of
epidemic clonal lineages. Determination of the full-length sequences of
blaOXA-51-like genes and the occurrence of mutations in the quinolone
resistance determining regions (QRDRs) was done by sequencing.
Results: All ten isolates expressed multidrug resistance (MDR), but were
consistently susceptible to colistin. Epidemiological data showed that all
isolates were associated with hospitalization abroad; Greece, Thailand
(n = 2), China, India (n = 3), Cyprus, Italy and Pakistan. Carbapenem
resistance was explained by the presence of OXA-carbapenemases;
blaOXA-23-like (n = 8), blaOXA-58-like (n = 1) and blaOXA-24-like
(n = 1). ISAba1 was detected upstream of blaOXA-23-like genes in
all isolates and downstream in ﬁve isolates. ISAba3 was detected
downstream of the blaOXA-58-like gene. The 16S rRNA methylase gene
armA was detected in the three isolates with high level aminoglycoside
resistance to all tested aminoglycosides. All ten isolates were resistant to
ciproﬂoxacin due to mutations in the QRDR region (Leu83Ser in GyrA
and Leu80Ser in ParC). The intI1 gene was detected in 6/10 isolates.
Seven isolates contained the blaOXA-66 variant and were all of European
clone II. The remaining three isolates contained the blaOXA-69 variant
with one of them belonging to European clone I.
Conclusion: MDR A. baumannii isolates belonging to European clones
I and II have emerged in Norway, all associated with hospitalization
abroad. Resistance mechanisms included OXA-carbapenemases, 16S
rRNA methylases and mutations in the QRDRs. Three isolates of
European clone II co-produced blaOXA-23-like and armA.
P1299 Molecular characterization of carbapenem-resistant
Acinetobacter baumannii clinical isolates from Portugal by
Multilocus sequence typing
N. Mendonc¸a, A. Duarte, G.J. da Silva ° (Coimbra, Lisbon, PT)
Acinetobacter baumannii is an emergent nosocomial pathogen often
resistant to multiple antibiotics. The emergence of carbapenem resistant
strains has been increasingly reported worldwide.
Objective: The goal of the study was to genotype carbapenem resistant
A. baumannii (CRAb) isolates recovered from different Portuguese
hospitals. Methods. Representative isolates were selected from the
collection recovered since 1998 until 2007 from hospitals of different
geographic regions. Antimicrobial susceptibility was determined by disk
diffusion method for b-lactams, quinolones (QNL) and aminoglycosides
(AG). MICs for b-lactams were determined by E-test. Molecular typing
was performed by random ampliﬁed polymorphic DNA (RAPD) and
in representative strains by multilocus sequencing typing (MLST) to
conﬁrm the genotype and allow a global comparison of results with
others ST types described worldwide.
Results: According to antimicrobial susceptibilities were formed three
groups: R1, isolates resistant to all b-lactams but susceptible to QNL
and a AG (only 3 collected in 1998/99); R2, those resistant to all
antibiotics except tobramycin and/or amikacin and colistin (1999–2007);
R3, isolates resistant to all antibiotics except AG and colistin (2004–
2007). For all isolates the MICs for imipenem and ceftazidime were
>32mg/L and >256mg/L, respectively. RAPD ﬁngerprinting showed
two distinct patterns: A (group R1) and B (groups R2 and R3).
The isolates included in groups R2 and R3 were not identical but
were genetically related. A new MSLT proﬁle deposed as ST55 at
Acinetobacter MLST website correspond to isolates of group R1. This
strain produced the IMP-5 metalo-b-lactamase. Analysis of website data
showed that it was only related with one strain, sharing the gdh-B, rec-A
and rpoD genes. Groups R2 and R3 belong to MSLT proﬁle ST33, and
isolates from both groups produced an OXA-40 carbapenemase. The
results showed that isolates with ST33 proﬁle are endemic in Portugal
for years and, according website data, worldwide.
Conclusion: The study showed that not all CRAb have capacity of
dissemination. However, the need for surveillance of CRAb strains and
the knowledge of well identiﬁed clones with deﬁned characteristics is
crucial to track potential epidemic strains and to improve infection
control measures. We describe for the ﬁrst time a new MLST proﬁle
corresponding to the IMP-5 producer strain apparently with no epidemic
potential.
P1300 Multifocal spreading of an OXA-23-producing Acinetobacter
baumannii clone in different Italian clinical settings
L. Pagani °, R. Migliavacca, G. Fugazza, E. Nucleo, M. Spalla,
M.M. D’Andrea, T. Giani, R. Daturi, M. Balzaretti, M. Tinelli,
D. Marchetti, G.M. Rossolini (Pavia, Siena, Milan, Lodi, Bologna, IT)
Objectives: A. baumannii is an oppotunistic pathogen responsible of
nosocomial infections in intensive-care-units (ICUs) and in patients
exposed to elevated risk factors. Infections caused by multidrug-resistant
(MDR) strains of A. baumannii are difﬁcult to treat, and reports of
carbapenem resistance (CR) have accumulated worldwide. In our country
CR in A. baumannii has been mainly attributed to acquisition of blaOXA-
58 determinant, even though nowadays class D carbapenemase OXA-23
is an emerging problem. Objective of this study was to evaluate the
spread of OXA-23 producing A. baumannii in different italian settings
and to investigate clonal relationship of such isolates.
Methods: 43 non-replicate carbapenem resistant A. baumannii, negative
by PCR for blaOXA-24/58 genes, were collected from different wards
of 5 Acute Care Hospitals and 1 Long Term Care and Rehabilitation
Facility between August 2008-September 2009. Isolates were identiﬁed
and tested for antimicrobial susceptibility using the GNI card (Vitek
System, bioMe´rieux) and panels NMIC/ID4 (Phoenix System, BD),
respectively. Molecular identiﬁcation of the species level was performed
by PCR ampliﬁcation of blaOXA-51-like allele. Analytical isoelectric
focusing (IEF) of crude extracts was performed. The nature and presence
of blaOXA-23 and blaOXA-51-like determinants were investigated by
PCR and sequencing. Genotyping was performed by PFGE analysis and
the assignment of sequence type group was performed by multiplex-
PCR.
Results: IEF for all the 43 A. baumannii showed the presence of enzymes
with pI 9.0 and 6.7, the latter consistent with the expression of the OXA-
23 enzyme. PCR, followed by direct amplicon sequencing conﬁrmed the
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presence of blaOXA-23 gene in all isolates. PFGE analysis showed that
all the isolates were clonally related (>75% similarity); multiplex-PCR
showed that isolates belonged to the sequence type Group 1, related to
European clone II. Interestingly, the number of isolates from different
settings varied signiﬁcantly (ranging from 1 to 35) on the basis of
infection control measures adopted.
Conclusions: Results showed an intra- and inter-hospital spread in
different italian settings of an OXA-23 producing clone of A. baumannii
and emphasize the ability of such pathogen to become epidemic/endemic
acquiring resistance genes in the hospital environment if the diffusion is
not promptly limited.
P1301 Clonal diversity of OXA-23 producing Acinetobacter
baumannii isolates from Rio de Janeiro, Brazil
F. Grosso, S. Quinteira °, A. Ramos, A. Assef, K. Carvalho, M. Asensi,
L. Peixe (Porto, Vila Nova de Famalica˜o, PT; Rio de Janeiro, BR)
Objectives: Multidrug-resistant (MDR) Acinetobacter baumannii (Ab)
are a leading cause of nosocomial infections in Brazilian hospitals, being
OXA-23 producers disseminated in several hospitals.
The aim of this study was to assess the diversity of OXA-23-producing
Ab isolates disseminated throughout hospitals in Rio de Janeiro (2006–
2007) and to analyse blaOXA-23 carrying genetic structure.
Methods: From a collection of 96 OXA-23 producing Ab recovered in 8
hospitals (January 2006 to September 2007) from Rio de Janeiro, Brazil,
isolates representative of different pulsotypes (n = 5) were selected for
further characterization. Susceptibility tests and identiﬁcation by rDNA
sequencing were performed. Pulsotypes were determined by PFGE with
ApaI. The genomic location of the bla OXA-23 gene was determined by
I-CeuI technique and with PCR using speciﬁc primers for the composite
transposon Tn2006. MLST scheme was conducted according to the Ab
MLST database (http://pubmlst.org/abaumannii/). The blaOXA-51 type
was identiﬁed by PCR and sequencing.
Results: Ab isolates were resistant to several b-lactams, presenting
variable susceptibility to amikacin (clones A and E were susceptible),
kanamycin and sulfamethoxazole/trimethoprim (clone E was suscepti-
ble). In all isolates, the blaOXA-23 gene was inserted in Tn2006 and
located on the chromosome. The 5 pulsotypes clustered in 4 different STs
that presented 4 new allelic combinations and 2 new gpi alleles. These
new allelic proﬁles were related to other STs found in Latin America, but
not related with ST22, already described in several European countries
and Korea which is also associated to OXA-23 producers. Genotype A
(69% of the OXA-23 producing isolates), the most prevalent and found
in seven hospitals, was assigned in the same ST of clone D (1%)
both presenting blaOXA-66. Genotypes B (25%) C (4%) and E (1%)
presented blaOXA-132, blaOXA-95 and blaOXA-69, respectively.
Conclusions: This is the ﬁrst study describing the population structure
of MDR OXA-23-producing Ab clones in Brazil. Our ﬁndings indicate
an ongoing spread of blaOXA-23 associate to new and diverse ST of
A. baumannii in hospitals of Rio de Janeiro. The identiﬁcation of the
blaOXA-66 as the predominant lineage conﬁrms its ability to disseminate
and establish in the hospital setting.
P1302 Analysis of carbapenem resistance genes in Acinetobacter
baumannii isolates from Kuwait hospitals
N. Al-Sweih °, M. Al-Hubail, V.O. Rotimi (Kuwait, KW)
Objectives: This study was designed to investigate the molecular
epidemiology and genetic basis of the carbapenem resistance in clinical
isolates of Acinetobacter baumannii obtained from all government
hospitals in Kuwait.
Methods: A total of 250 clinical isolates were collected from 8 hospitals.
Their susceptibility to 18 antibiotics was determined by E test method.
Carbapenems resistant isolates were screened for phenotypic MBL
production by disk approximation test (DAT) and MBL E test. Genetic
characterization of the resistant mechanisms was performed by PCR.
Their clonal relatedness was assessed by PFGE.
Results: All the isolates were multidrug resistant. Of the 250 isolates,
93 (37.2%) were resistant to carbapenems. The prevalence of MBL-
producing isolates was 74.2% and 57% by DAT and MBL Etest,
respectively. Sixty-ﬁve (69.9%) of the carbapenem-resistant isolates were
positive for one or more resistance genes; 37 were positive for blaIMP-1,
17 blaVIM-1, 43 blaVIM2, 24 blaSPM-1, 32 blaOXA-23, 1 blaOXA-24.
PFGE demonstrated widespread clones of similar strains in different
hospitals and a cluster of 3 clones found only in one particular hospital.
Conclusion: Resistance clinical isolates to carbapenem has reached
unacceptable levels in Kuwait and MBLs, as well as oxacilinases, are
highly prevalent among A. baumannii in our hospitals.
Acknowledgment: This work was supported by a Kuwait University
Research Grant no. YM 01/08 which is gratefully acknowledged.
P1303 Genetic relatedness of Acinetobacter baumannii strains
isolated from patients in a university hospital in Bialystok,
Poland
P. Wieczorek °, P. Sacha, E. Tryniszewska (Bialystok, PL)
Objectives: Acinetobacter baumannii is an opportunistic pathogen that
gives rise to nosocomial infections and outbreaks, in particular, in the
intensive care unit. The increasing resistance to antibiotics leads to
appearing of multi-drug resistant strains. Examining the genetic diversity
of randomly chosen A. baumannii strains isolated in University Hospital
in Bialystok and the examination of sensitivity to antibiotics were a
purposes of the study.
Analysis of genetic relatedness of Acinetobacter baumannii strains.
ICU, intensive care unit; SCH, surgery of the chest; RU, rescue
unit; VS, vascular surgery; IC, invasive cardiology; H, haematology;
G, gastroenterology; S, surgery; N, neurology.
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Methods: There were examined 51 strains of A. baumannii that were
biochemically identiﬁcated by using VITEK2 apparatus according to
the procedure of the producer. The identiﬁcation to the species was
conﬁrmed genetically on the basis of the presence of carbapenemase
blaOXA-51-like genes with the PCR technique.
Susceptibility to antibiotics was performed by using broth microdilution
method. MIC value was determined and interpreted according to criteria
proposed by Clinical and Laboratory Standards Institute for the following
antibiotics: ampicillin/sulbactam, piperacillin, piperacillin/tazobactam,
ceftazidime, cefotaxime, cefepime, imipenem, meropenem, tetracycline,
gentamicin, netilmicin, amikacin, ciproﬂoxacin.
The genetic relatedness of A. baumannii strains was examined by using
pulsed-ﬁeld gel electrophoresis (PFGE) with ApaI as the restriction
enzyme. Cluster analysis was performed by the unweighted pair group
method with mathematical averaging (UPGMA) and DNA relatedness
was calculated by using the band-based Dice coefﬁcient.
Results: Analysis of genetic diversity revealed nine different clones of
which three clones C, D and G were dominated. The degree of the
genetic similarity of strains was determined at 89% value. Majority of
A. baumannii strains were isolated from patients treated in the intensive
care unit.
Clone C was more resistant to the majority of antibiotics than two
remaining clones. Strains belonging to the clone D and G were
susceptible in the 100% to cefepime, meropenem, and piperacillin/
tazobactam, meropenem, respectively. Three clones were resistant to
piperacillin and ciproﬂoxacin.
Conclusion: Three clones of A. baumannii dominates in University
Hospital in Bialystok, especially in intensive care unit, amongst which
clone C demonstrates the multi-drug resistance phenotype, including
resistance to carbapenems. All strains of the dominating clones were
resistant to piperacillin and ciproﬂoxacin, and combination of ampicillin
with sulbactam showed as the most active antibiotic.
P1304 Nosocomial spread of multidrug-resistant Acinetobacter
baumannii: collateral damage from the war on terror
A. Troelstra °, M. JagtZwetsloot, H. Blok, T.E. Hopmans, M. Bonten
(Utrecht, NL)
Background: Pre-emptive isolation and screening for multi-drug
resistant bacteria in patients with increased risks for carriage is standard
care in Dutch hospitals. This policy has been extremely successful in
controlling nosocomial spread of MRSA and VRE. Repatriated soldiers
from Afghanistan are considered at risk for carriage of multi-drug
resistant Acinetobacter spp (MDR-AB), which can cause nosocomial
outbreaks, colonisation and infections.
Our hospital (Dutch Central Military Hospital (CMH) as part of the
UMC Utrecht) provides health services for all Dutch military patients.
Outbreaks: In april 2008, a wounded soldier repatriated form Uruzghan
was admitted to our ICU and immediately (pre-emptively) treated in
isolation. Screening- and clinical cultures on admission revealed MDR-
AB (but not MRSA) in sputum and blood. The patient underwent several
surgical procedures on several days. Subsequently, 3 patients that had
received surgery in the same operation room (OR) as well as 2 patients
treated in the same ICU acquired colonization with the same MDR-AB
isolate (documented with DNA-ﬁngerprinting) as the index-patient.
In august 2008, another wounded soldier was repatriated from Uruzghan
and admitted to ICU. Again the patient was treated in isolation
immediately, but in this case subsequent acquisition of MDR-AB was
documented in 13 patients; 1 patient in the emergency room, 5 in ICU,
6 on a general ward and 1 patient in the revalidation department.
During both outbreaks, several interventions were implemented to
control the situation. Screening of all contact-patients was performed,
resulting in at least 2670 cultures taken from 178 patients for both
outbreaks. Pre-empitve isolation was implemented until at least three
sets of cultures taken from throat or sputum, axilla, wounds, groin
and perineum revealed negative. Furthermore extended cleaning and
disinfection procedures were performed on a daily basis.
Conclusion: Despite pre-emptive isolation and adherence to recommen-
dations of our guidelines, MDR-AB introduced by 2 patients caused
nosocomial spread to 18 patients. These outbreaks illustrate that a
strategy, proven effective for controlling MRSA, can fail in controlling
transmission of MDR-AB.
P1305 Acinetobacter baumannii infections in intensive care units
patients: predictors of risk factors of multidrug resistance
A. Acar °, O. Oncul, M. Ozyurt, S. Budak, L. Gorenek, T. Haznedaroglu
(Istanbul, TR)
Objective: This study was designed to evaluate the incidence, epidemi-
ologic and clinical features and outcome of patients of Acinetobacter
related nosocomial infections in our intensive carte units, and to identify
predictors of multi drug resistance (MDR) for Acinetobacter baumannii.
Methods: Prospective study of all patients with nosocomial A. bau-
mannii infections in ICU from January 1, 2007 to December 31,
2008. MDR in A. baumannii was deﬁned as resistance to at least
three classes antibiotics (antipseudomonal penicillins, antipseudomonal
cephalosporins, antipseudomonal ﬂouroquinolones, aminogllycosides,
or trimethoprim-sulfamethoxazole) but susceptibility to carbapenems,
and non-MDR was deﬁned as suspectibility to carbapenems and
other alternative antipseudomonal antimicrobial agents (eg, penicilins,
cephalosporins, ﬂuoroquinolones, or aminoglycoside).
Results: Among the 147 ICU patients, 197 A. baumannii infections were
developed. Their mean age was 57.04±25.8 years. Infections site were:
bloodstream 40.6%, respiratory tract 28.4%, and burn wounds 14.5%.
Congestive heart failure (40.3%), cerebrovascular illness and diabetes
mellitus (24%) were the most common underlying disease. Mortality was
56.7%. Of 197 episodes of Acinetobacter infections, 168 (85.3%) caused
by MDR strains were identiﬁed. The most effective antibacterial agents
for A. baumannii were netilmicin (61.4%), doxycycline (60.8%) and
tobramycin (59.6%) respectively. Congestive cardiac failure (p = 0.03),
chronic obstructive lung disease (p = 0.02), diabetes mellitus (p = 0.04),
previous antibiotic usage in last three months (p = 0.04), steroid usage
(p = 0.03), dopamine usage (p< 0.001), and previous emergence of
E. coli infections (p = 0.03) were risk factors for multi drug resistance
in univariate analysis. Multivariate analysis showed that steroid usage
(p = 0.91; odds ratio [OR], 4.7; 95% conﬁdence interval [CI], 1.4–16.4)
and previous emergence of E. coli infections (p = 0.004; OR, 6.4; 95%CI,
1.8–21.2) as independent predictors of MDR.
Conclusion: A. baumannii infections in ICU patients are associated high
mortality and MDR. Avoidance of unnecessary antibiotics and steroid
is high priority and speciﬁc attention should be paid to patients with
infections Gram-negative enteric pathogens especially E. coli.
P1306 Multidrug-resistant Acinetobacter baumannii in an intensive
care unit: the never ending ﬁght
E. Carretto °, D. Barbarini, L. Carnevale, A. Amatu, A. Grosini,
G. Iotti, P. Marone (Pavia, IT)
Objective: Acinetobacter baumannii is an important cause of nosoco-
mial infections in many hospitals, most often in critically ill patients
admitted to intensive care units (ICUs). After the ﬁrst isolation (April
2008) of a multi-drug resistant (MDR) A. baumannii strain (susceptible
only to ampicillin-sulbactam and colistin) in an ICU of our Institution,
we performed an active surveillance study up to July 2009. The results of
the molecular typing of the strains collected and the molecular analysis
of the mechanisms of carbapenems resistance are showed.
Methods: all the Acinetobacter strains showing a MDR phenotype were
further characterized as belonging to the genomospecies 2/13 using
the criteria of Gerner-Smidt et al. (JCM, 1991:277). We collected a
single isolate for each patient, irrespective of the site of isolation.
Susceptibility testing using the standardized disk-diffusion method
(CLSI criteria) and E-test were performed. The molecular typing was
performed using the rep-PCR Diversilab Microbial Typing System
(bioMe´rie´ux, France). In the experiments the EU-AFLP type strains were
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included as control (Dijkshoorn et al., 1996:1519). The mechanisms of
carbapenems resistance were investigated initially using a phenotypic
screening to detect metallo-b-lactamases (MBL). The MBL-negative
strains were subsequently investigated using a multiplex PCR to detect
genes encoding the OXA carbapenemases prevalent in Acinetobacter
species, using the PCR protocol described in Woodford et al.(Int. J.
Antimicrob. Agents 2006:351).
Results: 41 different MDR Acinetobacter strains belonging to genomo-
species 2/13 were collected. The microorganism was recognized to be
endemic, with 2−3 patients per month colonized or infected. During
the study period we documented two large outbreaks (June 2008, 6
patients and March 2009, 11 patients involved). The rep-PCR allowed
us to demonstrate two major clones. The ﬁrst one comprised different
isolates collected in the ﬁrst 6 months of the study; this clone was then
replaced by another one, strictly related to the EU clone II (from July
2008 to July 2009). None of our isolates was MBL positive; the wide
majority of our strains carried the OXA51/OXA58 carbapenemases.
Conclusions: our study conﬁrms the wide circulation of the A. bauman-
nii EU clone II, that replaced another lineage not linked to other EU
clones. As expected, the OXA51/OXA58 proﬁle was most commonly
involved in the high-level resistance to carbapenems of our strains.
P1307 Genospecies identiﬁcation of Acinetobacter baumannii
complex bacteraemia in critical patients
Y.C. Chuang °, W.H. Sheng, S.C. Chang (YunLin, Taipei City, TW)
Objectives: Acinetobacter baumannii (A. baumannii) is an emerging
nosocomial pathogen. Due to rapid increase in the drug resistance of
A. baumannii, the choices of antimicrobial agents were limited. However,
it is difﬁcult to differentiate A. baumannii (DNA group or genospecies
2), from genospecies 3 and 13TU by classic methods. We aimed to
investigate the differences of characteristics, clinical presentations and
outcomes between different genospecies within A. baumannii complex
by genospecies identiﬁcation.
Methods: 62 adult patients with A. baumannii complex bacteremia
at the intensive care units of a teaching hospital in northern Taiwan
between April 2008 and February 2009 were prospectively enrolled.
A. baumannii complex was identiﬁed by classic methods and veriﬁed by
the Phoneix system. 16S-23S rRNA intergenic-spacer sequences were
used for genospecies identiﬁcation.
Results: Among 62 patients of A. baumannii complex bacteremia, 43
(69.4%) had genospecies 2 bacteremia, 11 had genospecies 13TU, 2 had
genospecies 3 and 6 had others. Genospecies 2 had signiﬁcant higher
MIC of Ciproﬂoxacin (MIC50 32 vs. 0.25), Amikacin (MIC50 >128
vs. 4), Imipenem (MIC50 16 vs. 0.5), Sulbactam(MIC50 16 vs. 1), and
Tigecycline (MIC50 2 vs. 0.25) (P< 0.001, respectively). Genospecies 2
had less primary bacteremia (20.9% vs. 47.4%, P = 0.03). Genospecies
2 also caused more severe sepsis than the others (P = 0.03) (Pittsburgh
bacteremia score: median 5, interquartile range (IQR) 4−7; median 4,
IQR 2−5, respectively). Patients with genospecies 2 bacteremia were
associated with a higher rate of mortality (81.4% vs. 52.6%, P = 0.02).
Genospecies 2 bacteremia was the independent predictive factor (odds
ratio 3.9, 95%CI: 1.11–13.62) for mortality after adjusting sex, age,
severity of underlying disease, and empiric antibiotics use.
Conclusion: In patients with A. baumannii complex bacteremia,
genospecies 2 was associated with higher resistance and mortality.
Genospecies identiﬁcation might be important in those high risk groups.
P1308 Carbapenem and multidrug-resistant Acinetobacter
baumannii colonization/infection: epidemiology and factors
associated to infection
A. Herna´ndez-Torres, E. Garcı´a-Va´zquez °, G. Yagu¨e,
A. Ferna´ndez-Rufete, E. Moral-Escudero, J. Go´mez, M. Canteras,
H. Albendı´n-Iglesias, J.A. Herrero, J. Ruiz (Murcia, ES)
Objective: To study an outbreak of nosocomial colonisation/infection
due to multidrug and carbapenem resistant A. baumannii (ABMDR-C).
Patients and Methods: Prospective study of patients with ABMDR-C
colonisation/infection (January 2007-June 2008). Epidemiological and
clinical variables and predictors of infection versus colonization were
analysed.
Results: 24 out of 101 cases were considered colonisations and
77 infections (27 bacteraemia); global mortality (colonisations and
infections) was 42% (4 colonisations and 38 infections − 18
bacteraemia). All together incidence was 3.2/1000 admissions/day;
29% had been previously admitted and 79% had received previous
antibiotic treatment (29% carbapenem; 34% piperacillin–tazobactam;
12.5% boths); 78% had an underlying condition; 81% were UCI
patients; 90% had gone through invasive procedures; 65% had another
microorganism isolated. In multivariate analysis, infection predictor
factors were isolation of ABMDR-C in respiratory samples (OR 5.406;
95%CI 1.419–20.599); male patients (OR 8.842; 95%CI 1.988–39.325);
previous hospitalization (OR 9.720; 95%CI 1.383–68.291) and initial
clinical severity (OR 30.897; 95%CI 5.533–172.543).
Conclusions: Our cohort of patients with ABMDR-C colonisa-
tion/infection is characterised by its underlying comorbidity, the high
rate of previous invasive procedures, previous hospitalisation and
previous broad-spectrum b-lactam treatments (especially carbapenem);
initial severity and respiratory samples with ABMDR-C isolates were
predictors of infection versus colonisation.
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P1309 Cross-transmission of Klebsiella pneumoniae in intensive
care units: interhospital and intrahospital spread
A. Agodi, M. Barchitta °, G. Valenti, R. Marzagalli, M.A. Romeo,
L. Giaquinta, C. Santangelo, G. Castiglione, A. Tsakris (Catania,
IT; Athens, GR)
Objectives: In order to identify, assess and apply relevant evidence
for better health care decision-making, our study was conducted to
evaluate whether HCAIs due to “Klebsiella pneumoniae” in intensive
care units (ICUs) originate mainly from patients’ endogenous ﬂora
or from exogenous sources, by determining: i) the occurrence of
“K. pneumoniae” carriage; ii) the ICU-acquired “K. pneumoniae”
infection and colonization rates, by site; iii) the impact of cross-
transmission using molecular typing data.
Methods: The study design integrated the patient-based and the
laboratory-based surveillance approaches at the ICUs of two Italian
Hospitals. Standard deﬁnitions of carriage and colonization were used.
Infections were in accordance with the protocol of the Italian Nosocomial
Infections Surveillance in Intensive Care Units (SPIN-UTI). Molecular
typing of “K. pneumoniae” isolates was performed by macrorestriction
analysis of the XbaI-digested genomic DNA. A cross-transmission
episode was assumed when two patients had indistinguishable isolates.
Results: During a seven-months period, from October 2008 to April
2009, a total of 171 patients were enrolled in the study and a total
of 107 isolates were collected from 51 patients. In particular, carriage
was associated to 15.5% of isolates; colonization to 24.1%, infection to
23.1%, and colonization/infection accounted for the remaining 37.3%
of isolates. Bloodstream infections were the most encountered (56%).
Cumulative incidences of “K. pneumoniae”-sustained colonization and
infections were respectively 15.2 per 100 patients and 14.6 per 100
patients. PFGE analysis of “K. pneumoniae” isolates led to the
identiﬁcation of a total of 27 unrelated pulse-types. Particularly, 4
clones were associated to cross-transmission and the remaining 23
were single patterns associated with sporadic strains. Two major
clones were identiﬁed involving 38.3% and 22.4% of isolates, showing
respectively interhospital as well as intrahospital spread. The impact
of “K. pneumoniae” cross-transmission was estimated to be at least
56.5%, thus deﬁning the exogenous preventable proportion of all cross-
transmission episodes.
Conclusion: Our data underline the impact of “K. pneumoniae” in
the ICU settings and highlight the need of appropriate epidemiologic
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investigations to trace sources and transmission routes in order to provide
evidences to address screening at admission and other control policies.
P1310 Epidemiology and clinical features of extended-spectrum
b-lactamase-producing Klebsiella pneumoniae in neonates
and adults in Spain: a multicentre study (GEIH BLEE 2006)
J. Rodrı´guez-Ban˜o °, C. Ruiz de Alegrı´a, M. Cano, M. Dı´az, J. Calvo,
J. Herna´ndez-Bello, A. Pascual, L. Martı´nez-Martı´nez on behalf of
GEIH and REIPI
Objectives: To analyse the epidemiology and clinical features of
extended-spectrum b-lactamase producing Klebsiella pneumoniae (ES-
BLKP) in the era of CTX-M predominance.
Methods: A multicenter cohort study including all cases of ESBLKP
colonization/infection in 33 Spanish hospitals in February-March 2006
was performed. Epidemiological and clinical data were prospectively
collected. ESBLs were characterized by PCR and sequencing. Clonality
was studied by REP-PCR and PFGE.
Results: ESBLKP was isolated from 162 different patients from 33
hospitals. Twenty-six were neonates; clusters of related isolates were
found in 5 of 7 neonatal units with cases. Among neonates, the most
frequent ESBL was CTX-M-15 (19 patients); 18 (69%) had a urinary
catheter, 16 (62%) an umbilical catheter, 17 (65%) were intubated, and
15 (58%) had previously received antibiotics. Twenty-three neonates
(88%) had an infection, and 8 were bacteraemic (35% of those with
infection). Appropriate empirical therapy was administered to 14 (61%
of patients with infection). Three patients died (crude mortality, 12%).
There were 3 other paediatric patients, but data were available only for
one. Finally, ESBLKP was isolated from 133 adult patients. Clusters of
clonally related isolates were found in 16 of the 22 centers with >1 adult
case. The most frequent ESBLs in adults were CTX-M-15 (47 isolates),
SHV-12 (29), and CTX-M-14 (18). Clinical data were available from
102 adults (85/85 [100%] and 17/45 [38%] patients with nosocomial
and non-nosocomial ESBLKP, respectively). Among the 85 nosocomial
ESBLKP, the predisposing features of patients with clustered isolates
(55) and sporadic isolates (30) were compared. Those with sporadic
isolates more frequently had chronic pulmonary disease (39% vs 7%,
p = 0.01) and recent antibiotic use (90% vs 53%, p = 0.001). Seventy
patients had an infection (82%); of these, 7 (23%) were bacteraemic, 53
(76%) received appropriate empirical therapy, and 13 (19%) died. Among
the 17 patients with non-nosocomial ESBLKP with available data, 12
patients had an infection (9 urinary tract, 2 pneumonia, 1 cellulitis), and
1 died.
Conclusion: Infections caused by ESBLKP mainly affected neonates
and predisposed adults; bacteraemia was frequent. CTX-M enzymes,
particularly CTX-M-15, were the most prevalent ESBLs. Clonally-
related clusters of cases were apparent in most hospitals. Patients with
sporadic isolates had more predisposing factors that those with epidemic
isolates.
P1311 Relevance of mucosal surveillance cultures in predicting
Gram-negative sepsis in neonatal intensive care units
U¨. Parm °, E. Sepp, T. Metsvaht, M. Ilmoja, K. Pruunsild, L. Maipuu,
M. Pauskar, I. Lutsar (Tartu, Tallinn, EE)
Objective: To examine the spectrum and time course of bowel and
nasopharyngeal (NP) colonisation with Gram-negative (GN) bacteriae
and to deﬁne the value of surveillance cultures (SC) in predicting late
onset sepsis (LOS) in neonates admitted to neonatal intensive care units
(NICU) due to suspected or conﬁrmed early onset sepsis (EOS).
Methods: From August 2006 until December 2007 NP and rectal swabs
were collected on admission and thereafter twice weekly in all newborns
admitted within the ﬁrst 72 h of life with suspected or conﬁrmed EOS.
Blood cultures were obtained on admission and further as clinically
indicated. The genetic relatedness between mucosal and bacteraemic
strains of K. pneumoniae, E. cloacae and A. baumannii was deﬁned
by pulsed ﬁeld gel electrophoresis (PFGE).
Results: A total of 278 patients (144 with BW <1500g) were recruited;
171 became colonised with GN bacteria. About half of the rectal
(693/1250) and NP (558/1153) samples contained GN microorganisms.
Among 877 sterile body ﬂuid samples 31 (5.6%) were positive for
GN organisms. The number of different species per patient ranged
between 1 to 8 (mean 1.53; SD 0.11). The most common colonisers
were E. cloacae (27.3% of patients), K. pneumoniae (18.3%), and
Acinetobacter spp (16.9%). Culture proven GN LOS was diagnosed in 32
cases. Altogether 2108 invasive and mucosal culture pairs were analysed.
The overall sensitivity, speciﬁcity, positive and negative predictive values
were 27%, 66%, 4% and 94%, respectively. At all time points the
sensitivity values for Enterobacteriaceae were greater than those for
nonfermentative organisms (66% vs 22% on Day 2−5 prior LOS, 36%
vs 14% on Day 7−10 and 50% vs 16% on Day 11−14). Compared with
non-colonised patients those with prior colonisation of K. pneumoniae
(p = 0.011), K. oxytoca (p = 0.003), E. coli (p = 0.004), Stenotrophomonas
spp (p = 0.032), and Pseudomonas spp (p = 0.005) were more likely
to have a LOS whereas no association was found for A. baumannii,
Serratia spp. and E. cloacae. In the PFGE analysis the invasive and
mucosal strains were identical and had similar antibiotic susceptibility
pattern.
Conclusion: Routine mucosal cultures to all GN organisms are
inefﬁcient in predicting LOS in NICU. However, if targeted for
speciﬁc organisms (e.g Klebsiella spp., E. coli, Stenotraphomonas and
Pseudomonas) identiﬁcation of a microbe in mucosal surfaces may offer
the opportunity of implementation of infection control measures and
timely initiation of appropriate antibiotic therapy.
P1312 Trends in multidrug resistance among Escherichia coli and
klebsiellae in Germany, 1995–2007
M. Kresken °, D. Hafner on behalf of the Antimicrobial Resistance
Working Party
Objectives: Escherichia coli (ECO) and klebsiellae are among the
most common pathogens causing infections in in- and outpatients.
Antimicrobial agents such as 3rd generation cephalosporins (3GC),
carbapenems (carba) and ﬂuoroquinolones (FQ) are essential drugs
to treat serious illness. Treatment outcome, however, has increasingly
been threatened by the emergence and dissemination of resistant (R)
strains (multi-drug R [MDR] strains in particular). The objective of this
study was to document changes in the R patterns of ECO, Klebsiella
pneumoniae (KPN) and Klebsiella oxytoca (KOX) in Germany between
1995 and 2007.
Methods: Susceptibility data of clinical isolates collected in 21, 20,
21, 22 and 21 laboratories that participated in ﬁve surveillance studies
conducted by the Paul-Ehrlich-Society in 1995, 1998, 2001, 2004 and
2007, respectively, were analysed. MICs of antimicrobial agents were
determined by the broth microdilution procedure according to the
standard DIN ISO and interpreted by EUCAST criteria. The CLSI MIC
method using ceftazidime (CAZ)±clavulanic acid (CLA) and cefotaxime
(CTX)±CLA was employed as screening test for ESBL-producing
isolates. MDR was deﬁned as antimicrobial R to more than two of the
following four drug classes: 3-cef, carba, FQ, aminoglycosides.
Results: A total of 3,964 isolates primarily recovered from urine (33%),
wounds (20%), respiratory specimens (19%), and blood (11%) were
tested. Tere were 890 (24%) ICU isolates and 3,074 (76%) non-ICU
isolates. Single R to ciproﬂoxacin (CIP) in ECO, KPN, and KOX
increased from 6% (26/449), 4% (9/224) and 2% (2/83), respectively,
in 1995 to 28% (115/418), 13% (25/190) and 17% (17/101) in 2007. R
to CTX in all three species rose from 1−4% in 1995 to 11−15% in 2007.
Concurrently, an increase in the percentage of strains showing the ESBL
phenotype was observed, while R to carba (ertapenem [ERT], imipenem
[IMP], meropenem [MEM]) remained uncommonly. MDR rates for each
of the species and study years are shown in the table. Of the 36 MDR
isolates recovered in 2007, none were susceptible (S) to CTX and CIP,
8% to gentamicin and 39% to piperacillin–tazobactam. In contrast, carba
were active against MDR isolates, except one KOX (MICs of ERT, IMP,
MEM 16−64mg/l).
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Conclusions: Single R to CIP and CTX, representing FQ and 3GC,
respectively, as well as MDR in ECO and klebsiellae increased between
1995 and 2007. In contrast, activity of carba did not change over the last
10−15 years.
Phenotype 1995 1998 2001 2005 2007
ECO R to >1 drug class 3.8% 4.2% 6.6% 10.8% 15.6%
MDR 0% 0.2% 1.2% 3.4% 5.3%
KPN R to >1 drug class 1.8% 3.7% 5.8% 5.2% 10.5%
MDR 0% 0% 2.6% 1.6% 6.3%
KOX R to >1 drug class 1.2% 7.7% 0.9% 10.9% 8.9%
MDR 0% 0% 0% 0.8% 2.0%
P1313 Transmission rate of ESBL-producing Enterobacteriaceae
within the hospital and in households
B.Y. Betsch °, S. Droz, K. Bo¨gli-Stuber, K. Mu¨hlemann (Berne, CH)
Objective:We studied the transmission rate of E. coli and Klebsiella spp.
with extended-spectrum b-lactamase (ESBL) production from index
patients with ESBL carriage to hospital room mates and household
members.
Methods: Patients with ESBL carriage newly detected during diagnostic
work-up were recruited prospectively during the time period May 7
2008 to September 30 2009. Hospital contacts were deﬁned as room-
mates for 48 hours. Screening was performed weekly for the duration
of contact between index patient and roommate and continued for 1
week after separation from the index patient and included a screening at
hospital discharge. Screening included always a fecal sample; additional
samples were examined if the following risk factors were given:
intubation/tracheostoma, skin lesions, catheters draining urin or body
ﬂuids. Fecal samples were collected from household contacts in a
3-monthly interval. Stool samples were analyzed with 3 different ESBL
selective culture media: ChromID ESBL agar (Biome´rieux) and ESBL
agar (AES), a bi-plate with 2 selective media (MacConkey agar plus
Ceftazidim and Drigalski agar plus Cefotaxim).
Results: 111 index patients, 67 inpatients (60.3%) and 44 outpatients
(39.7%) were analyzed. Fecal carriage was more frequent in inpatients
(76.1%) than in outpatients (52.3%) (p = 0.039). The proportion of ESBL
E. coli was higher among outpatients (86.4%) than among inpatients
(58.0%) (p = 0.003). ESBL carriage was detected in 27 of 64 (42.2%)
of household (32 of 103 members) and in 20 of 153 (13.1%) hospital
contact patients (p = 0.00001). Fecal ESBL carriage in index patients
was slightly higher in households with transmission (76.9%) than among
households with no transmission detected (62.2%) (p = 0.33). The index
patient isolates were CTX-M-producers in 81.9% and SHV-producers in
13.3%. The percentages for the contact patients resp. household contacts
were 76.5% and 17.6% resp. 93.1% and 3.4%. ESBL-speciﬁc TEM-
production was detected in overall 2%.
Conclusions: Inhospital patient-to-patient transmission rates of ESBL
producing E. coli and Klebsiella spp. are lower than transmission rates
within households. The higher rate of positive household contacts might
be explained by the closer and longer duration of contact compared to
the hospital setting.
P1314 Investigation of gastrointestinal carriage of multi-resistant
Gram-negative bacilli in a population served by a district
general hospital
L. Jenkinson °, J. Smullen, N. Weightman, K.G. Kerr (Harrogate, UK)
Objectives: The purpose of this study was to determine the incidence
of faecal carriage of extended-spectrum b-lactamase (ESBL) producing
Enterobacteriaceae in hospital and community patients served by a small
district hospital in the north of England and to investigate whether a
change in incidence had occurred over a four year period.
Methods: One thousand and seventy six samples were screened at
Harrogate District Hospital during May-August 2004 and from March-
June 2009 (973 samples).
During both periods all faecal samples submitted to the laboratory for
routine microbiological investigations were anonymised and screened for
the presence of ESBL, AmpC and K1 enzyme production by inoculation
onto modiﬁed CLED agar containing 6mg/L vancomycin and 8mg/L
cefalexin. Colonies from this medium were assessed for cefpodoxime
resistance (10 mcg disc) and resistant isolates were examined further
using the double disc method in accordance with BSAC guidelines. In
addition, all cefpodoxime-resistant isolates were identiﬁed to species
level using the API system (Biomerieux, France).
Results: Of 1076 samples screened in 2005, 16 (1.48%), 52 (4.8%) and 7
(0.7%) were identiﬁed as ESBL, AmpC and K1 producers, respectively.
Of in-patient samples 1.25% were positive for ESBL compared with
1.55% community samples.
In 2009, 973 samples were screened and 70 (7.2%), 100 (10.28%) and
1 (0.51%) yielded ESBL, AmpC and K1 producers, respectively. ESBL
producers were identiﬁed in 6.67% of inpatients compared with 7.42%
of specimens from the community.
Conclusion: We found a signiﬁcant increase (p< 0.05; c2 test) in faecal
carriage of multi-resistant Gram-negative bacilli (MRGNB) between
2004 and 2009 for both inpatient and non-inpatient groups with overall
increases in AmpC and ESBL carriage of 5.48% and 5.7%, respectively.
Over the same time periods bloodstream infections associated with
MRGNB in our hospital increased from 8 to 23. We conclude that faecal
carriage of MRGNB in our small semi-rural population is increasing in
line with reports from centres which serve large urban communities.
Given that colonisation likely precedes clinically overt infection these
ﬁndings have important public health implications.
P1315 Population structure of multidrug-resistant non-typhoidal
Salmonella enterica isolates from Portugal
P. Antunes °, J. Moura˜o, A.R. Freitas, L. Peixe (Porto, PT)
Objectives: Salmonellosis is one of the most common foodborne
infections in Europe and multidrug-resistant (MDR) Salmonella is
emerging worldwide with increasing involvement of particular clones.
Our aim was to analyze the population structure of MDR nontyphoidal
Salmonella enterica isolates in order to assess the relationship between
antibiotic resistance genetic elements and MLST genotypes.
Methods: We selected 40 Salmonella isolates from a large Portuguese
collection (2002–2008), representative of MDR clones from human
infections (n = 21), food (n = 14), environment (n = 1) and piggeries
(n = 4). Clonal relatedness was established by PFGE and MLST
(http://mlst.ucc.ie/mlst). Analysis of antibiotic resistance genetic ele-
ments included characterization of plasmid and integron backbones
(PCR, sequencing), transferability and genomic location (I-CeuI/S1
nuclease hybridization).
Results: The isolates studied (13 serotypes) corresponded to 24 PFGE
types and 16 different sequence types (STs) including a new combination
of known alleles. Most S. Typhimurium (n = 16/18; 4 PFGE types)
belonged to the worldwide spread ST19 (n = 14) and to its SLV, ST313
(n = 1). They included the 3 most widespread clones in Portugal (DT104,
OXA-30/CMY-2 and sul3) carrying different integron types and Inc
plasmids (FIIA, A/C, I1, N). The globally disseminated ST11 was
identiﬁed in all but one of the S. Enteritidis isolates (n = 4; 2 PFGE-
types), including one carrying qnrS and belonging to a major clone.
Isolates belonging to the emerging S. Rissen clone (n = 5) were assigned
to the singleton ST469 or to its SLV, a new ST, only previously
reported in European isolates of the same serotype. The remaining MDR
isolates of different serotypes were identiﬁed as ST15, ST27, ST32,
ST40, ST82, ST334 and the singletons ST48, ST64, ST102, ST306
and ST358. Mostly, a ST represented a single serotype. Distribution
of different plasmids (IncFIIA, IncP, IncI1, IncN) and integron types
was observed among different clonal lineage. Particular integrons and
plasmids (IncA/C, IncHI1) were conﬁned to speciﬁc STs.
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Conclusions: This is the ﬁrst study describing the population structure of
Salmonella in Portugal. Our results conﬁrm the prevalence of particular
clusters enclosing major MDR clones that cause human infections. The
selection and worldwide spread of particular STs might be inﬂuenced by
the acquisition and horizontal transfer of speciﬁc resistance genes and
genetic elements.
P1316 Extended-spectrum b-lactamase producing
Enterobacteriaceae in retail meat
I.T.M.A. Overdevest °, J. Kluytmans (Tilburg, Breda, NL)
Objectives: Worldwide there is a rapid increase of resistance in
Enterobacteriaceae causing infections in humans, especially of ESBL.
Potential sources for ESBL in humans are food-products like meat. The
aim of this study is to determine the prevalence of ESBL-producing
Enterobacteriaceae in meat used for consumption.
Methods: A prospective observational study was performed between
17th august and 30th October, 2009. In this period parts of raw, non-
spiced meat which was bought for consumption were collected. The meat
was inoculated into a TSB broth which was incubated at 37ºC for at least
16 hours. Subsequently part of the initial broth was transferred to another
TSB broth which contained vancomycin and cefotaxim. After at least
16 hours of incubation 10ml of the broth was inoculated on a selective
chromogenic agar (Biomerieux ESBL ChromID) and incubated again for
at least 16 hours. Determination was done by Vitek2; and conﬁrmation
of the presence of ESBL was done by e-test.
Results: A total of 249 meat samples were included in this study (mean
weight: 11.9 g). From 45.9% of the samples ESBL were recovered
(95%CI: 39.5%-52.2%). The animal sources of the meat were in 92
(37.0%) chicken; 75 (30.1%) beef; 53 (21.9%) pork and 29 (11.6%)
were from other animals. ESBL was most frequently recovered from
chicken (88.0%, 95%CI: 79.6%-93.9%). Beef and pork had statistically
signiﬁcant lower recovery rates, 18.7% and 18.9% respectively. 83.9%
of the meat included in the survey was not produced biologically. Non-
biological produced meat had a higher rate of ESBL-carriage than
biological produces meat (48.8% vs. 33.3%), but this was not statistical
signiﬁcant.
Conclusion: Almost half of the meat in retail stores contained ESBL
producing bacteria. However, chicken contained signiﬁcantly more often
ESBL than pork or beef. This is a potential source of the current
pandemic of ESBL and further investigations are warranted to elucidate
the role of antimicrobial use in food production animals.
P1317 Epidemiology of multi-resistant Gram-negative bacteria
isolated from 65 years and older residents of a nursing
home in France
S. Thibaut °, J. Caillon, N. Foucher, F. Ollivier, M.L. Meas,
G. Grandjean, F. Ballereau on behalf of Medqual Network
Background: The aim of this survey was to study the epidemiology of
Multi-Resistant Bacteria (MRB) in French nursing home. The network
MedQual has conducted this survey and has compared risk factors
leading to an infection with MRB among elderly patients 65 old and
more, living either at home or in nursing homes.
Methods: This prospective epidemiological survey has been carried out
since January 1st 2009 with a network of 169 laboratories in ﬁve regions
of western France: Pays de la Loire, Bretagne, Centre, Basse-Normandie
and Poitou-Charentes. MedQual collected MRB antibiograms (MRSA
and 3rd-generation cephalosporins (3GC)-resistant Enterobacteria) and
socio-demographic patients’ characteristics. 3 kinds of housing were
considered: home (G1), nursing home without (G2) or with (G3) medical
care.
Results: 875 patients MRB have been included, of which 539 (61.6%)
were 3GC-resistant Enterobacteria: 381 in G1 (69.5%), 129 in G2
(47.8%), 29 in G3 (50.9%).
Within the last 12 months, 51.6% have experienced hospitalization (G1:
49.1%; G2: 55.0%; G3: 68.9%) and 70.5% have received an antibiotic
treatment (G1: 70.6%; G2: 71.3%; G3: 65.5%). 94.9% of the 3GC-
resistant Enterobacteria were isolated in urine and 70.3% were E. coli
strain (G1: 73.9%; G2: 74.7%; G3: 68.9%). 58.8% of E. coli producing
a ESBL enzyme (G1: 55.9%; G2: 67.4%; G3: 60.0%). Among the ESBL
E. coli, 61.8% were resistant to ciproﬂoxacin, 55.6% to sulfamides. No
difference was observed among the 3 kinds of housing for the resistance
to these antibiotics. Only 4% of ESBL E. coli were resistant to furans.
Conclusion: MRB (MRSA and 3GC resistant Enterobacteria) distribu-
tion was signiﬁcantly different between people living at home and living
in nursing home (without or with medical care). Same risk factors were
observed (in different proportions) among the 3 groups. Enterobacteria
distribution was similar between the 3 kinds of housing, and the ration
of ESBL E. coli didn’t changed signiﬁcantly according to the 3 groups
of elderly patients. A better knowledge of the epidemiological behaviour
of these MRB will contribute to better-adapted antibiotic strategies.
P1318 Predictor factors of ESBL versus non-ESBL E. coli
bacteraemia at a university hospital, 2006–2007
A. Garcı´a-Herna´ndez, E. Garcı´a-Va´zquez °, J. Go´mez,
A. Herna´ndez-Torres, A. Ferna´ndez-Rufete, E. Moral-Escudero, J. Ruiz,
J.A. Herrero, M. Cantero (Murcia, ES)
Objectives: Incidence of ESBL E. coli bacteraemia (ESBLB) has
progressively increased; the aim of this study was to evaluate predictor
factors of ESB in a cohort of patients with E. coli bacteraemia (EB).
Patients and Methods: Observational and comparative study of a
cohort of non-paediatric patients with EB admitted at a university
afﬁliated hospital. Data collection from clinical records has been done
according to a standard protocol. We analysed epidemiological, clinical,
microbiological and laboratory data from January 2006 through May
2007. Patients with EB were identiﬁed by review of results of blood
cultures from the hospital microbiology laboratory. E. coli isolation,
identiﬁcation and sensitivity test (VITEK-2; Biomerieux, France) were
performed by standard criteria.
Results: 153 patients with EB were studied; prevalence of ESBLB
was 22% (n = 34). Mean age was 59 years (range 14−94); in bivariate
analysis, risk factors associated with ESBLB were: acquisition of the
infection in Surgical Wards, nosocomial-acquired EB, previous antibiotic
treatment, previous surgery, previous invasive techniques, structural
renal diseases, comorbidity score of Charlson >3, severity of illness
at onset according to Winston criteria “critical” or “poor” and shock
on presentation. In the multivariate analysis, risk factors associated with
ESBLB were previous antibiotic treatment (OR 2.6; 95%CI 1.1−6.2)
and severity Winston score I-II (OR 9.8, 95%CI 3.4–28.3). In the
multivariate analysis, risk factors associated with ESBLB were previous
antibiotic treatment (OR 9.8, 95%CI 3.4–28.3) and severity Winston
score I-II (OR 2.6; 95%CI 1.1−6.2).
Conclusions: Previous antibiotic treatment and severity Winston score
I-II are the factors associated in our study to ESBL versus non-ESBL
E. coli bacteraemia.
P1319 Bloodstream infections due to Escherichia coli and
Klebsiella spp. producing extended-spectrum b-lactamase:
factors inﬂuencing adequacy and mortality
G. Peralta °, L. Anibarro, M. Lamelo, M. Velasco, A. Delgado-Iribarren,
J.P. Horcajada, M. Montero, M.C. Farin˜as, J. Alonso, M. Roiz,
J.A. Capdevila for the SEMI-BLEE Study Group
Objectives: Bloodstream infections due to E. coli and Klebsiella
producing extended-spectrum b-lactamase (ESBL) are increasing. The
precise role of factors inﬂuencing adequacy of empirical antibiotic
treatment and outcome are controversial.
Methods: Retrospective study of cases Escherichia coli and Klebsiella
spp ESBL bacteremia from 2003 to 2008, in 18 Hospitals of Spain.
Cases were identiﬁed from Microbiology laboratory databases. Empirical
antimicrobial therapy was judged to be either adequate or inadequate on
the basis of the in vitro susceptibility of an isolated organism, and/or the
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initiation of antibiotic treatment within 24 h of blood culture extraction.
ESBL production was screened by the double disc synergy method as a
complementary test for automated systems.
Results: In the period of study 372 cases of bacteremia (85% E. coli)
with a mortality of 24.3% were identiﬁed. The origin of bacteremia
were mostly urinary (50.7%), biliary (10.8%), and of unknown origin
(10%). Of them 144 (38.8%) cases were nosocomial and 127 (34.4%)
health related. Empirical antibiotic treatment was adequate in 45% of
cases. In a logistic regression analysis the only clinical factor associated
with the adequacy of empirical antibiotic therapy was the abdominal
origin (ORa: 3.19; 95%CI: 1.26–8.11). Factors associated with mortality
in the whole cohort were severe sepsis or shock (ORa: 8.84, 95%CI:
4.76–16.41), Charlson index score >2 (ORa: 2.92; 95%CI: 1.51–5.64),
nosocomial acquisition (ORa: 2.26; 95%CI: 1.19–4.28) and adequate
empirical treatment (ORa: 0.35; 95%CI: 0.21–0.94).
Conclusions:Mortality of E. coli and Klebsiella spp. ESBL bloodstream
infections is high. Adequacy of empirical antibiotic treatment is an
independent risk factor for mortality in these patients.
P1320 Impact of empiric cefepime therapy on mortality
among patients with bloodstream infections due to
extended-spectrum b-lactamase-producing pathogens
T. Chopra °, J. Zhao, R. Tansek, D. Hatahet, J. Hothi, K. Chaudhry,
H. Rahbar, T. Chen, T. Truong, V. Rodriguez, L. Bernabela,
A. Bhargava, D. Marchaim, G. Alangaden, K. Kaye (Detroit, US)
Objective: To study the impact of empiric cefepime for the treatment of
blood stream infections (BSIs) due to extended spectrum b-lactamase-
producing pathogens (ESBLs).
Methods: A cohort study was conducted at DMC from 1/05 to 12/07 in
5 hospitals. Retrospective chart review was conducted on patients with
ESBL-producing Klebsiella pneumoniae and Escherichia coli (ESBLs).
Patient variables collected included demographics, comorbid conditions,
empiric treatment and in-hospital mortality. Empiric antibiotics were
deﬁned as antibiotics initiated during the time spanning from 2 days
prior to culture to 3 days after culture. Logistic regression was used to
create a prediction model for in-hospital mortality.
Results: 145 ESBL BSIs were identiﬁed; 83% were K. pneumoniae
and 16.5% were E. coli. 35.2% of the BSI were catheter-related.
The mean age of the patients was 66 years, 51% were female and
79.3% were African-American. The in-hospital mortality rate was 35%
(n = 51). Cefepime was utilized as an empiric antibiotic in 68 patients
(46.9%) and carbapenems in 40 (27.6%) patients. In logistic regression,
predictors of in-hospital mortality included: admission to intensive
care unit (OR= 2.14, 95%CI 0.96–4.76), central line present prior to
positive culture (OR= 2.13, 95%CI 0.70–6.45), presence of a rapidly
fatal condition at the time of admission (OR= 5.71, 95%CI 2.36–
13.8) and prior hospitalization (OR= 1.75, 95%CI 0.76–4.02). Type
of empiric antibiotic was not associated with mortality. In multivariate
analysis, receipt of cefepime alone (n = 42) was associated with increased
mortality, although this association did not reach statistical signiﬁcance
(OR= 1.58, 95%CI 0.67–3.70). There was a trend between empiric
carbapenem therapy and decreased mortality (OR= 0.59, 95% 0.24–
1.45). These associations remained unchanged after controlling for
hospital and anatomic source of infection. A sub-analysis was performed
on 42 patients who were treated with empiric cefepime alone, comparing
survival and MIC to cefepime. No association was found between
cefepime MIC and mortality in this sub-group.
MIC Cefepime (mg/ml) In-hospital mortality [deaths/total (%)]
2 4/12 (33.3%)
4 1/4 (25%)
8 1/2 (50%)
16 10/24 (42%)
Conclusion: Empiric use of cefepime alone for BSI due to ESBLs was
associated with a trend towards increased mortality. We were not able
to demonstrate an association between MIC to cefepime and mortality,
but were underpowered to do so. Additional study of the efﬁcacy of
cefepime therapy in treating ESBLs should be conducted.
P1321 Pseudo outbreak of Pseudomonas mendocina in stem
cell-cultures
S. Tschudin, C. Arber, A. Tichelli, D. Nogarth, M. Dangel, R. Frei,
A.F. Widmer ° (Basel, CH)
Objectives: P. mendocina was ﬁrst isolated in the 1970s from soil and
water samples collected in the province of Mendoza, Argentina [1].
The ﬁrst clinical case report was reported in 1992 with P. mendocina
endocarditis, followed by two further case-reports of infections due to
this organism. However, the association with human infections is largely
unknown. We report a cluster of P. mendocina in diagnostic stem cell-
cultures of the haematology unit.
Methods: We initiated an outbreak-investigation after the detection of
Gram-negative bacteria by routine-microscopy of 21 diagnostic stem
cell-cultures.
Identiﬁcation of the Gram-negative bacteria was performed by conven-
tional culture and additional conﬁrmation by sequencing of 16s rDNA.
Pulsed-ﬁeld gel electrophoresis (PFGE) was performed to reveal the
identity of the strains. For source-investigation environmental cultures
of the involved surfaces in the affected laboratory, as well as water
samples and the unopened fresh reagents used for the preparation of the
diagnostic stem cell-cultures were examined.
Results: Culture and identiﬁcation of the Gram-negative bacteria of
three contaminated stem cell-cultures revealed P. mendocina. The
environmental cultures and the water samples were negative for this
pathogen. Culture of one of the reagents used however also revealed
P. mendocina. PFGE revealed that the strains isolated were identical
(Figure). Further outbreak investigation of the manufacturer conﬁrmed
contamination of their product. The computerized database of the clinical
microbiology unit revealed that this pathogen has never been isolated
before at our hospital in the last decade.
Conclusions: This is the ﬁrst report of an outbreak caused by
P. mendocina. We conclude that this environmental pathogen has the
potential to cause contamination of reagents used in clinical settings.
Our report demonstrates that commercial sterile product may be a
source of outbreaks. During the entire outbreak no clinical isolate with
P. mendocina was identiﬁed, nor was there evidence for an unusual
increase of other Pseudomonas infections.
Reference(s)
[1] Palleroni, N. J., M. Doudoroff, and R. Y. Stainer. Taxonomy of the
aerobic Pseudomonas: the properties of the Pseudomonas stutzeri
group. J. Gen. Microbiol. 1970; 60:215–231.
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P1322 Molecular epidemiology and characterization of extensive
drug-resistant Pseudomonas aeruginosa outbreak in a
haematology unit
T.T. Tan °, T.H. Koh, B.H. Tan (Singapore, SG)
Objectives: Infections caused by extensive-drug-resistant Pseudomonas
aeruginosa (XDR PAE) pose a serious problem in immunocompromised
hosts. Metallo-b-lactamase (MBL) producing strains are now commonly
seen around the world. We recently showed that clones of MBL-
producing P. aeruginosa have not become established in our center.
However, over a 24-mth period, XDR PAE was repeatedly isolated among
our hematology patients. We describe the molecular epidemiology and
characterization of these P. aeruginosa isolates as well as the measures
taken to contain this outbreak.
Methods: All archived P. aeruginosa isolates kept during the study
period were retrieved for analysis. These included antimicrobial
susceptibility proﬁle, pulsed-ﬁeld gel electrophoresis (PFGE) and multi-
locus sequence typing (MLST). The resistance mechanisms were
elucidated by outermembrane analysis for porin expression and a real-
time reverse transcription-PCR for the expression of various efﬂux
pumps, b-lactamases as well as porins.
Results: The PFGE revealed a predominant clone that resurfaced many
times over the course of the study. This clone was characterized by
resistance to penicillins, cephalosporins, carbapenems, aminoglycosides
and ﬂuoroquinolones. It remained susceptible only to colistin.
It was a non-MBL producing clone. Outermembrane analysis did not
reveal the loss of any porins. The over expression of the MexXY-OprM
efﬂux system appeared to be the predominant resistant mechanism.
Furthermore, environmental survey found the presence of such XDR
PAE clones in the drains of sinks in 2 rooms. Clinical isolates from
previous occupants of the rooms with identical PFGE pattern suggested
the sinks to possible contamination sites that help to propagate the
outbreak. Strict contact and isolation protocols for known colonized
patients were instituted. A change of sinks and drains that proved difﬁcult
to clean ﬁnally resulted in the termination of this outbreak. There was no
further isolation of this clone of XDR PAE in the following 6 months.
Conclusion: This study illustrates the ability of non-MBL producing
XDR PAE to persist in the environment and argues for the need to track
the epidemiology MDR organisms to identify clonal outbreaks.
P1323 Risk factors for acquisition of multidrug-resistant
Pseudomonas aeruginosa in patients with haematological
malignancies
Y.X. Liew, W. Lee, T.T. Tan, J.L. Ng, A.L. Kwa ° (Singapore, SG)
Objective: Multi-drug-resistant Pseudomonas aeruginosa (MDRPa) has
been associated with increased mortality. Thus, the identiﬁcation of risk
factors for the acquisition of MDRPa will help to identify hospitalized
patients who are at increased risk for harbouring MDRPa & implement
interventions that can limit its spread & to identify potential causative
factors leading to antimicrobial resistance.
Methods: A matched case (n = 28) − control (n = 61), study involving
recruitment of patients from Singapore General Hospital (SGH), was
conducted to examine the risk factors for MDRPa acquisition in
Haematology ward retrospectively. Univariate & multivariate analysis
(conditional logistic regression) via STATA MP10 were used. Pulsed-
Field Gel Electrophoresis (PFGE) was also performed to ascertain the
clonality of MDRPa strains.
Results: Forty-six males & 43 females, aged 46.57 (SD 1.50)
were recruited from Dec 06 to Dec 08. Signiﬁcant risk factors
were length of hospitalization (Odds ratio [OR] = 1.06; Conﬁdence
interval [CI] = 1.02–1.10; P = 0.003), APACHE II score (OR= 1.31;
CI = 1.08–1.58; P = 0.007), presence of central venous catheters
(OR= 5.30; CI = 1.47–19.04; P = 0.010) & foley catheters (OR= 6.38;
CI = 1.69–24.07; P = 0.006), antibiotic use before MDRPa isolation,
namely aminoglycosides (OR= 5.03; CI = 1.79–14.10; P = 0.021),
ﬂuoroquinolones (OR= 4.60; CI = 1.29–16.90; P = 0.019), carbapenems
(OR= 10.06; CI = 2.93–34.56, P = 0.001), vancomycin (OR= 6.15; CI =
2.00–18.90; P = 0.002) & metronidazole (OR= 8.13; CI = 1.72–38.42;
P = 0.008) & prior high-dosed cytarabine used (OR= 5.13; CI = 1.24–
31.34; P = 0.026). The risk of dying from a MDRPa infection is 41 times
higher (P = 0.001; CI = 0.03–0.172) than from no Gram-negative bacteria
infection. PFGE of the MDRPa revealed that half of all isolates were
clonally related, where MexXY multi-drug efﬂux system overproduction
may be the predominant mechanism of resistance.
Conclusion: We reported for the ﬁrst time, the use of high
dosed cytarabine was associated with acquisition of MDRPa. Prior
aminoglycoside exposure may have induced the expression of MexXY
multi-drug efﬂux system that renders cross-resistance to carbapenem &
ﬂuoroquinolones. Other signiﬁcant risk factors include central venous &
foley catheters, APACHE II score & length of hospitalization. Patients
with these risk factors can be identiﬁed early for active surveillance &
treated with appropriate antibiotics therapy empirically, if needed.
P1324 Genetic ﬁngerprints of phenotypic different Pseudomonas
aeruginosa strains from cystic ﬁbrosis patients with
DiversiLab® rep-PCR analysis
J. Posch °, L. Masoud, G. Thalhammer, G. Zarfel, G. Feierl, E. Leitner,
A.J. Grisold, U. Wagner-Eibel, D. Haas, E. Marth (Graz, AT)
Objectives: P. aeruginosa is highly prevalent in cystic ﬁbrosis (CF)
patients, causing chronic airway infection. This study was conceived
to investigate various aspects of colonization in order to answer the
following questions:
1. Is one patient colonized by one speciﬁc genotype?
2. Are phenotypic different strains of one patient also genotypic
dissimilar?
3. Are there epidemic strains colonizing two or more patients?
4. Are the results of rep-PCR comparable to pulsed-ﬁeld gel elec-
trophoresis (PFGE-Spe I)?
Methods: From July to October 2009 a total of 46 P. aeruginosa
consecutive strains were collected from the sputum of 17 CF patients.
Routine methods for identiﬁcation and susceptibility testing were
employed. Extraction of DNA, rep-PCR and generation of genetic
ﬁngerprints were done following the manufacturer’s instructions. To
determine the strain relatedness the DiversiLab® software was used. The
strains were considered as “linked” with similarities >95% respectively a
maximum of two peak changes. To evaluate the rep-PCR data 25 strains
were also analyzed by PFGE-Spe I.
Results: In most cases patients were colonized by P. aeruginosa strains
with only one speciﬁc genotype. A total of 30 strains from 12 patients
showed at least one phenotypic difference concerning resistance pattern
or morphology (mucus, colour). Nevertheless the major part of these
strains was related to four main genotypic patterns. In regard to question
three, we found that there are epidemic strains colonizing two up to six
different patients. In comparison to PFGE the rep-PCR provided similar
results in most cases. Four strains showed differences with a maximum
of four band changes.
Conclusion: We conclude that there is an evidence for the presence
of epidemic P. aeruginosa strains in CF patients. As a consequence of
our ﬁndings further investigations will focus on sources and possible
transmission routes to avoid cross-contamination. We are convinced of
the superiority of the DiversiLab® system, because it provides results
comparable to PFGE. Rapidity, easy handling and user friendly analysis
are major advantages.
P1325 blaCTX-M-15 genetically linked to qnrB1 on conjugative
plasmids from Klebsiella pneumoniae
Z. Zong, S.R. Partridge °, J. Iredell (Chengdu, CN; Sydney, AU)
Objective: blaCTX-M-15 appears to be the dominant extended-spectrum
b-lactamase gene worldwide, including in Sydney. The qnrB1 quinolone
resistance gene was ﬁrst identiﬁed on a plasmid from K. pneumoniae
that also carried blaCTX-M-15. These two important antibiotic resistance
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genes have since been detected together in bacterial strains from different
locations. Here, the multi-resistance regions (MRR) of conjugative
plasmids carrying both genes were characterised to identify any direct
link between them.
Methods: Two different K. pneumoniae clinical strains carrying blaCTX-
M-15 and qnrB1, isolated at Westmead Hospital, Sydney in 2006, were
mated with a rifampicin-resistant derivative of DH5a. Transconjugants
identiﬁed as carrying both genes by PCR were analysed by S1 nuclease
pulse-ﬁeld gel electrophoresis and the plasmids subjected to PCR-based
replicon typing and HpaI restriction digestion. A combination of PCR
mapping with reference to known MRR (including that of pC15−1a,
carrying blaCTX-M-15), inverse PCR and limited DNA sequencing was
used to characterise MRR.
Results: Transconjugants from each strain contained a single plasmid
carrying both blaCTX-M-15 and qnrB1. These plasmids, pJIE127 (~130
kb) and pJIE146 (~145 kb), appeared closely related and their replicons
could not be typed. The large (>45 kb) MRR of pJIE146 consists of
a region almost identical to the pC15−1a MRR (including blaTEM-
1b, aac(3)-II, aac(6′)-Ib-cr, blaOXA-30, tetA(A), IS26, ISEcp1, Tn2,
Tn1721 and Tn5403) ﬂanked by other common MRR components and
additional resistance genes (qnrB1, dfrA14, sul2, strB). The pJIE127
MRR contained all of these components in a different conﬁguration plus
additional copies of IS26.
Conclusions: qnrB1 is linked to blaCTX-M-15 within a single large
MRR on each plasmid. The pJIE127 MRR could have arisen from the
pJIE146 MRR by homologous recombination, illustrating the importance
of this mechanism in the evolution of MRR. Mapping the pJIE127
and pJIE46 MRR on the basis of known MRR structures was feasible
because of the mosaic nature of these regions, which appear to be
composed of components from a limited set arranged in different ways.
The relationship of these MRR to the MRR of pC15−1a, from Canada,
demonstrates how large structures carrying multiple resistance genes may
spread between geographic locations. The pJIE127 and pJIE146 MRR
may provide the basis for examining other strains/plasmids carrying both
blaCTX-M-15 and qnrB1.
P1326 First report of the plasmid-mediated quinolone-resistant
gene qnrB5/19 on a 40 kb IncR plasmid in Escherichia coli,
isolated from veal calves
J. Hordijk °, J. Wagenaar, A. van Essen-Zandbergen, A.B. Bosman,
D.J. Mevius (Utrecht, Lelystad, NL)
Objective: The presence of plasmid mediated quinolone resistance
(PMQR) is increasingly reported world wide. The majority of PMQR
genes described are qnr genes, associated with various bacterial species
on both chromosomal dna and plasmids. The qnr-B5/19 genes were
detected previously on IncN, IncL/M, ColE1 plasmids in Klebsiella
spp, Escherichia spp, Salmonella enterica. The aim of this study
was to characterize a recently detected qnrB5/19-gene and its genetic
environment on a 40 kb IncR plasmid in E. coli, isolated from veal
calves in the Netherlands.
Methods: Plasmids were isolated from a qnr positive E. coli and
transferred to DH10B(TM) cells by electroporation. Transformants were
selected on MacConkey agar with 0.03mg/L ciproﬂoxacin. Plasmids
from the donor strain and the transformant DH10B(TM) cells were
isolated and analyzed by Southern hybridization to locate the qnr-gene.
PCR and sequencing was performed to detect mutations in the QRDR
region of the gyrA/B and parC/E-genes and on the qnr ﬂanking regions
by primer walking. Incompatibility groups were determined by PCR-
based replicon typing with additional PCR protocols for ColE, IncR and
IncU. Furthermore, MIC values and the presence of resistance genes
other than qnr were compared between the donor and recipient strain by
broth microdilution and Identibac array analysis, respectively.
Results: No mutations were found in the gyrA/B and parC/E genes
in the donor strain. The qnrB-gene was determined to be qnrB5/19. A
ﬁnal designation of the qnr-subtype is performed currently. The plasmid
harbouring this gene was IncR, which is based on the detection of the
repB gene in the donor and its transformant with 100% homology to
that of the of reference plasmid pK245.
MIC-values and array analysis suggested that next to qnrB5/19, sul1,
dfr12 and a class 1 integron are located on the same plasmid. Moreover,
both donor and recipient show kanamycin and tetracycline-resistance
(MICs > 128 and 64mg/L, respectively).
The determination of the genetic environment of the qnr-gene in relation
to the other resistance genes is in progress.
Conclusions: To our knowledge, this is the ﬁrst report of a qnrB5/19
in E. coli of animal origin in the Netherlands and the ﬁrst report of this
gene on IncR.
P1327 High prevalence of qnr genes in Escherichia coli from
healthy animals in Nigeria
D. Fortini, K. Fashae, A. Garcı´a-Ferna´ndez, L. Villa, A. Carattoli °
(Rome, IT; Ibadan, NG)
Objectives: The animal reservoir of plasmid-mediated quinolone
resistance (PMQR) is still controversial and little information is available
on the prevalence of these resistance determinants in developing
countries. The aim of this study was to identify and characterize PMQR
in a collection of Escherichia coli isolated from healthy chickens and
pigs at slaughter, collected in November-December 2006 at Ibadan,
Nigeria.
Methods: Faecal samples from 100 chickens and 100 pigs were plated on
Eosin-methylene blue agar containing 100ug/mL ampicillin, recovering
96 E. coli from chickens and 66 from pigs. Strains were tested for
antimicrobial susceptibility by disk diffusion assay. Breakpoints for
ciproﬂoxacin (CIP) were determined by Etest (AB Biodisk, Solna
Sweden). PMQR genes were screened by PCR and DNA sequencing.
Clonal relatedness of the isolates was determined by ERIC-PCR.
Plasmids were analysed for PMQR positive strains by conjugation
or transformation, PCR-based replicon typing and restriction fragment
length polymorphism (RFLP).
Results: 82 strains from chickens and 10 from pigs were resistant
to nalidixid acid, 69 and 2, respectively, showed resistance to CIP
(MIC> 4.0 mg/ml), 13 and 5, respectively showed reduced susceptibility
to CIP (MICs 0.125−0.5mg/ml). Only one strain showed resistance to
ceftazidime and cefotaxime. The ERIC-PCR showed that the isolates
were distributed among 17 clonal groups. PMQR genes were detected
in 18 strains (18/92, 19.6%) and 11 of them were in the group showing
reduced susceptibility to CIP. 12 strains carried qnrS1, 3 qnrB19, 1
qnrB10 and 3 qepA; one strain carried both qepA and qnrB10. None of
isolates carried qnrA, qnrC, qnrD and aac(6′)-1b-cr genes. qnrS1 was
located on IncX, IncN, and IncI1 plasmids, qnrB19 was located on a
small ColE-like plasmid and qepA was located on IncHI2. The strain
showing CAZ and CTX resistance carried qnrS1 and the CTX-M-15
extended spectrum b-lactamase, but located on different plasmids.
Conclusion: To our best knowledge, this is the ﬁrst study on the
prevalence of qnr genes in bacteria from animal sources from Africa. Our
ﬁndings suggest that food animals could represent an important reservoir
of these resistance genes. Previous studies reported high prevalence of
qnr genes in clinical isolates from humans in the Ivory Coast and Algeria,
suggesting that the spread of these resistance determinants in Africa
could be particularly relevant.
P1328 Analysis of plasmid-mediated quinolone resistance
determinants among ESBL-producing Enterobacteriaceae
in Belgium
H. Rodriguez-Villalobos °, R. de Mendonc¸a, P. Bogaerts,
A. Cardentey-Reyes, I. Montesinos, C. Cardona, A. Deplano,
M.J. Struelens, Y. Glupczynski (Brussels, BE; Stockholm, SE)
Objectives: Plasmid-mediated quinolone resistance determinants are
widespread among ESBL-producing organisms enhancing selection and
transmission of multiresistance. qnr genes have not yet been reported
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in clinical isolates from Belgium. We evaluated the prevalence of Qnr
determinants in ESBL-producing isolates.
Methods: 117 ESBL-producing clinical isolates recovered from January
2000 to December 2007 at Erasme University Hospital (Brussels) with
MIC of ceftazimime >8mg/L and MIC of ciproﬂoxacin >0.25mg/L
were studied. Isolates included E. coli (n = 43), K. pneumoniae
(n = 42), E. cloacae (n = 17), E. aerogenes (n = 9), S. marcescens
(n = 2), P. mirabilis (n = 2) and Providencia spp.(n = 2). The presence
of ESBL was conﬁrmed by double combination disk test. ESBLs were
characterized by PCR-sequencing assay. Qnr genes were analysed by
multiplex PCR targeting blaqnrA, blaqnrB, blaqnrS and sequencing. The
genetic environment of qnr genes was analysed by PCR mapping and
sequencing. Clonality was assessed by PFGE. Conjugation assay was
performed with E. coli J53 azide resistant as recipient strain.
Results: qnr genes were found in 37 isolates (32%). Only 1 CTX-M-15-
producing E. coli isolate harboured qnrS1 (2%). Seventeen E. cloacae
harboured qnrA1 (100%). These strains co-produced CTX-M-9 and
SHV-12 (n = 15) or CTX-M-9 alone (n = 2). qnrA gene was present into
a complex class 1 integron being ﬂanked upstream by Orf 513 (ISCR1)
and downstream by qacEdelta1 genetic elements (qac/sul 3′ end). No
transconjugants were obtained neither from E. coli nor E. cloacae. 19/42
(45%) CTX-M-15 producing K. pneumoniae showed qnr genes (17 qnrS1
and 2 qnrB). These strains belong to a major epidemic clone in ICU.
The analysis of transconjugants showed that blaqnrS1 was transferred
with or without blaCTX-M-15, suggesting the location of qnr genes in
different plasmids. blaqnrB was co-transferred with blaCTX-M-15. No
qnr were found in the other species. Susceptibility to quinolones varied
according to qnr type and host species.
Conclusion: This is the ﬁrst description of qnr genes in ESBL-producing
Enterobacteriaceae clinical isolates in Belgium. Our ﬁndings show a high
prevalence of qnr genes among epidemic ESBL-producing E. cloacae
and K. pneumoniae. They underline the need for caution in using
quinolones for treatment of ESBL producers. Further study will examine
the spread of qnr genes in other Belgian hospitals.
P1329 Identiﬁcation of different CMY-2-producing strains of
Proteus mirabilis in a Czech hospital
J. Hrabak °, V. Jindrak, E. Chudackova, T. Bergerova, D. Cervena,
P. Urbaskova (Plzen, Prague, CZ)
Objectives: Acquired AmpC-type b-lactamases, especially DHA-1
producing strains of Klebsiella pneumoniae and Serratia marcescens, are
endemic in some Czech hospitals. blaDHA-1 gene, mobilized by ISCR1
insertion sequence, has been localized as a part of class 1 integron in
these strains. However, CMY type AmpC had only been described in
veterinary isolates in this country. First two AmpC-producing isolates of
Proteus mirabilis were sent to the Department of Microbiology of the
Faculty of Medicine in Plzen for further analysis in spring of 2009.
Methods: Strains were identiﬁed by a standard microbiological method
using ENTEROtest 12 (Pliva Lachema Diagnostika, Brno, Czech
Republic). AmpC detection was performed by a modiﬁed double-disk
synergy test on the plates with and without cloxacillin (128mg/l).
MICs to 24 antibiotics were determined as proposed by EUCAST.
b-lactamase content was analyzed by isoelectric focusing followed by
visualization with 0.5mM nitroceﬁn. Multiplex PCR was performed
for preliminary identiﬁcation of acquired AmpC-like genes. Entire
gene was subsequently ampliﬁed and sequenced. Presence of ISEcp1
insertion sequence was determined by speciﬁc primers. Strains were
compared by pulse-ﬁeld gel electrophoresis after the digestion with XbaI
endonuclease.
Results: The isolates showed different MIC and PFGE patterns.
According to EUCAST criteria, both strains were intermediate sus-
ceptible to third generation cephalosporins and remained susceptible to
aminoglycosides, ﬂuoroquinolones and trimethoprime. In both isolates,
CMY-2 AmpC-type b-lactamase was identiﬁed. Conjugative transfer of
the blaCMY-2 gene was not successful as well as the presence of ISEcp1
element was not identiﬁed.
Conclusions: This is the ﬁrst report of CMY type AmpC b-lactamase
identiﬁed in clinical isolates as well as the ﬁrst observation of acquired
AmpC in P. mirabilis in the Czech Republic. Mobilization of blaCMY-2
by ISEcp1 seems to be common in other European countries, but this
element was not found in described isolates that may indicate a different
type of mobilization. Sequence analysis of blaCMY-2 gene environment
is ongoing.
This work was ﬁnanced by research project grants NS9717–4/2008,
MSMT 2E08003 and MSM0021620819.
P1330 Occurrence of acquired AmpC b-lactamases and clonal
relationship among Proteus mirabilis at a university hospital
complex in Santiago de Compostela, Spain, 2006–2009
M. Trevin˜o °, L. Martı´nez-Lamas, A. Garcı´a-Zabarte, C. Garcı´a-Riestra,
D. Pen˜alver, B.J. Regueiro (Santiago de Compostela, ES)
Objectives: Proteus mirabilis is one of the most b-lactam-susceptible
enterobacteria because it does not express AmpC cephalosporinase.
Because of the increasing clinical relevance of this bacteria usually
associated with complicated urinary tract infections an bacteriemia is
of great importance to know the prevalence of multidrug-resistance by
acquired AmpC b-lactamases and their epidemiology.
Methods: Isolates were obtained from routine cultures at the University
Hospital Complex of Santiago de Compostela from 2007 to July 31th
2009. Only one isolate per patient was considered for analysis. Identi-
ﬁcation to the species level was achieved with Vitek 2 (bioMe´rieux).
Antimicrobial susceptibility testing was assayed by Vitek 2. The isolates
selected for this study were those showing intermediate or total resistance
to amoxicillin–clavulanic, cefotaxime or ceftazidime according to CLSI
breakpoints. AmpC screening were performed by double-disk synergy
test with ceftazidime (30 mcg), cefotaxime (30 mcg) and cefoxitin (30
mcg) against cloxacillin (500 mcg) and boronic acid (300 mcg).
Molecular typing of the isolates was performed by automated rep-PCR
using DiversiLab system (bioMe´rieux).
Results: Among the 2,217 isolates of P. mirabilis recovered, 35 were
acquired AmpC b-lactamase producers (1.58%). This isolates were
recovered from urine, blood, surgical wound, catheter tip, tracheal
aspirate and skin ulcer. Forty percent of samples were from ambulatory
patients. Resistance of the AmpC-producers to non-b-lactam antibiotic
was not very high except for quinolones. Isolates showed resistance to
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nalidixic acid (81%), ciproﬂoxacin (51%), trimethprim-sulfamethoxazole
(19%), gentamicin (11%), tobramycin (5%). No resistance was seen
against amikacin.
Fingerprinting analysis of the last 21 isolates recovered showed high
genetic diversity. Hospital source strains tended to be arranged in clusters
different from community source strains.
Conclusion: Knowledge about the prevalence and diffusion of this
emergent resistance may be helpful to establish preventive measures that
will curb their spread.
P1331 Effect of different environmental parameters upon the
expression of certain virulence factors and resistance
features in Escherichia coli aquatic strains
E. Panus °, N. Rosoiu, C. Bleotu, L. Dascalu, L. Ditu, M.C. Chiﬁriuc
Balotescu, V. Lazar, C. Iordache, C. Larion, O. Dracea, M. Bucur
(Constantza, Bucharest, RO)
Purpose: To investigate the expression of 8 virulence factors (VF) and
bacterial resistance features of 20 E. coli aquatic strains isolated from
Black Sea incubated at different temperatures and in variable culture
media.
Material and Methods: The expression of cell-associated (i.e. adhesion
to HeLa cells) and soluble VF (i.e. lecithinase, lipase, gelatinase,
caseinase, amylase, aesculin hydrolysis, DN-ase) as well as the resistance
to different bivalent metals (Cu, Co, Mn, Zn, Ni) were investigated at
different incubation temperature, salinity and glucose concentration; pH
in aerobic and respectively, anaerobic conditions.
Results: The tested strains have grown at 22ºC, 37ºC, 44ºC, irrespective
to the salinity, pH and glucose concentration, in aerobic and anaerobic
incubation conditions. The VF were better expressed at 37ºC, especially
adherence ability, siderophores, amylase and caseinase production. At
0% NaCl only amylase and siderophores production was expressed. At
2% and 3% NaCl the amylase was better expressed. The best expression
of siderophores and caseinase was at 6% NaCl. Thereafter, the expression
of VF started to decrease till 10%. The adherence to HeLa cells was
decreased by higher salinities. The tested strains proved high resistance
to a broad range of pH from 4 to 9.6. The amylase and caseinase were
better expressed at pH 9.6 and siderophores at pH 7. The higher glucose
concentrations (3%) inhibited the expression of amylase and caseinase.
The incubation conditions exhibited no signiﬁcant differences on the
VF expression. The metals resistance patterns varied with the tested
parameter and the bivalent metal. The temperature growth induced an
increase in susceptibility of the tested strains to Zn, Mn, Cu and Ni. The
high salinity induced to occurrence of susceptibility to all tested metals.
The higher glucose concentration of 3% and the alkaline pH induced
higher rates of susceptibility to Mn, Zn and Ni.
Conclusion: Our results demonstrate the high adaptation ability of
enterobacterial strains of water origin to different environmental stress
conditions and the possibility of virulence potential expression even
in limiting environmental conditions, demonstrating the role of these
environmental parameters in the selection of resistance genes in the
aquatic strains.
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P1332 A rapid aetiologic diagnosis using a multiplex RT-PCR
panel can reduce antibiotic prescription rate in respiratory
tract infections − a randomized prospective study
R. Brittain-Long °, J. Westin, S. Olofsson, M. Lindh, L.M. Andersson
(Gothenburg, SE)
Objective: Etiologic diagnosis in acute respiratory infections (ARTI’s)
is difﬁcult yet crucial for the decision to use antibiotics or not.
Recently, multiplex real time PCR methods, that detect several common
respiratory viruses, with high sensitivity allowing a rapid result, have
been introduced. The objective of the study was to evaluate if the use of
such a method in community-acquired ARTI would have an impact on
the antibiotic prescription rate.
Methods and Study design: In an open randomized prospective study,
nasopharyngeal and throat swabs were collected from adult patients,
seeking primary health care with symptoms of respiratory tract infection
during 3 consecutive winter seasons (Oct-Apr 2006–2009). Patients
were randomized to receive either a quick result (the following day)
or a delayed result (after 10 days ±2), which was given at a follow
up consultation offered for all patients. Any treatment options were
left at the discretion of the physician. The real-time multiplex PCR
targeted the following 15 respiratory agents; parainﬂuensavirus 1−3
(PIV), inﬂuensavirus A (IfA) and B (IfB), human metapneumovirus
(MPV), respiratory syncytial virus (RSV), rhinovirus (RV), enterovirus
(EV), adenovirus (AdV), human coronaviruses 229E, OC43 and NL63,
M. pneumoniae and C. pneumoniae.
Results: 426 patients were included in the study, of whom 206 (48%)
were positive for one or more agents at initial visit. 13 patients
(6.3%) had double infections. Inﬂuenza A virus was most commonly
found (28%), followed by rhinovirus (22%) and coronaviruses (15%).
Antibiotics were prescribed in 10.8% (n = 46) of the cases at initial visit.
In the group randomized to a quick PCR result, 15 patients (7.2%)
received antibiotic treatment, compared to 31 patients (14.2%) in the
delayed result group (p< 0.02, c2 test).
Conclusion: The use of a multiplex real time PCR panel for etiologic
diagnosis of viral ARTI’s may be a useful tool in reducing overuse of
antibiotics in an outpatient setting.
P1333 Factors associated with outcome and length of parenteral
therapy in outpatient parenteral antibiotic therapy-treated
patients with skin and soft tissue infections
R.A. Seaton °, E. Bell, V. Bezlyak, C.J. Weir (Glasgow, UK)
Objectives: The Glasgow outpatient parenteral antibiotic therapy (OPAT)
service provides treatment for patients with skin and soft tissue infections
(SSTIs) referred either via emergency departments, general practitioners
or inpatient specialties. Factors associated with treatment failure or
prolonged OPAT in SSTI were explored.
Methods: Treatment failure (readmission or switch to another parenteral
agent following progression or adverse event) and duration of parenteral
therapy were assessed at time of completion of therapy and recorded on
a prospectively maintained data base (2001–2008). Baseline variables
potentially inﬂuencing outcomes were identiﬁed from the database and
explored via univariate and multivariate analysis. Logistic regression was
used for factors related to outcome and linear regression analysis for
factors associated with increase in (log-transformed) duration of OPAT.
Results: 963 patients were identiﬁed. 41.1% were male, median age 48
yrs. 4.9% were MRSA, 7.4% penicillin allergy, 8.8% diabetic, 3.1%
vascular disease and 5.1% immune-compromised. 870 (90.3%) had
cellulitis, 29 (3.0%) bursitis, 26 (2.7%) wound infection and 8 (0.8%)
infected ulcer. 62.7% were referred from the community. 56.8% were
managed through a nurse-led protocol (patient group direction). 811
(84.2%) received ceftriaxone and 144 (15%) teicoplanin as ﬁrst-line
treatment. Median duration of therapy was 3 days (inter-quartile range
2−5). There was a signiﬁcant trend towards reduced duration of OPAT
over time (c2 test for linear trend, p< 0.0001). 87.1% were treatment
successes. In the multivariate models; treatment failure was associated
with female gender, diabetes mellitus and teicoplanin therapy (table);
prolongation of OPAT therapy was associated with increasing age,
MRSA infection, vascular disease, teicoplanin therapy and a diagnosis
other than cellulitis or infected ulcer. Reduced duration of therapy was
observed in patients referred from the community and in those managed
through patient group direction.
Conclusions: In patients with SSTI managed through OPAT we
identiﬁed several factors independently associated with treatment failure
or with prolongation of OPAT. Teicoplanin was the only factor associated
with both prolongation of therapy and treatment failure. There may be
other factors of importance that were not recorded in the study.
S378 20th ECCMID, Posters
Table. Factors with signiﬁcant association with treatment failure or
duration of OPAT
Lower
95%CI
Upper
95%CI
p
Parameter associated with treatment failure OR*
Female 1.646 1.096 2.473 0.0163
Diabetes 2.023 1.116 3.668 0.0202
Teicoplanin 1.872 1.051 3.334 0.033
Parameter associated with duration of OPAT Effect size**
Age (per additional 10 years) 1.030 1.007 1.053 0.0097
MRSA 1.468 1.170 1.843 0.0010
Vascular disease 1.288 1.011 1.641 0.0409
Teicoplanin 1.320 1.160 1.502 <0.0001
Other diagnosis (not cellulitis) 1.248 1.001 1.558 0.0494
Managed via PGD 0.708 0.652 0.770 <0.0001
Community referral 0.910 0.839 0.986 0.0211
*Multivariate logistic regression.
**Multivariate linear regression of log(OPAT duration); e.g. Effect size of 1.32 equates to a 32% increase in duration
of OPAT compared to those without this risk factor.
P1334 Clinical and economic impact of pharmacy therapeutic
substitution from piperacillin–tazobactam to cefepime and
metronidazole
R.M. Chambers °, S. Davis, E. Szandzik, M. Zervos (Detroit, US)
Objectives: Therapeutic substitution (TS) is a strategy often employed
by hospitals to maintain a closed formulary when agents with the
same efﬁcacy exist within a therapeutic class. To our knowledge, TS
has not been previously applied between differing antibiotic classes. In
February 2009, our institution implemented a pharmacist-driven criteria-
based TS from piperacillin–tazobactam (PT) to cefepime with or without
metronidazole (C/M). We sought to: 1. Compare clinical outcomes
before and after implementation; 2. Evaluate the impact on pharmacy
expenditures.
Methods: Quasi-experimental comparison of 50 patients who received
PT prior to policy implementation and 47 patients who underwent
TS to cefepime +/− metronidazole. Data collected: demographics,
microbiology, antibiotic treatment, clinical and microbiologic success,
length of stay, in-hospital mortality, Clostridium difﬁcile rates, and cost
of PT or C/M. Hospital wide antibacterial use was evaluated in the 4
months pre and post TS as deﬁned daily doses per 1000 patient days
(DDDs). Outcome analysis: c2 test to compare categorical variables and
Student’s t-test or Mann Whitney-U to compare continous variables.
Economic analysis: Data log transformed and compared via Student’s
t-test.
Results: Infection types and outcomes were similar between groups
(table 1). Median cost of therapy (US): $62.40 TS versus $330.72
PT (p< 0.0001). Hospitalwide cefepime use increased from 111 to 180
DDDs while PT use decreased from 80 to 16 DDDs. Total antibacterial
use also decreased from 945 to 881 DDDs.
Conclusions: A pharmacist-driven TS from PT to C/M resulted in
similar clinical outcomes before and after implementation of a hospital-
wide policy. The TS policy was associated with reduction in antibacterial
cost per patient and hospital wide antibacterial use.
Table 1
Variable PT, n = 50
(%)
TS, n = 47
(%)
p-value
Site NS
BSI 3 (6) 4 (9)
Urine 5 (10) 7 (15)
Respiratory 25 (50) 12 (26)
Skin 12 (24) 16 (34)
Intra-abdominal 6 (12) 9 (19)
Other 7 (14) 6 (13)
Conﬁrmed Gram-negative infection 16 (32) 21 (45) 0.199
Appropriate initial dose 43 (86) 43 (92) 0.392
Clinical success 42 (84) 38 (81) 0.684
Microbiologic eradication 13/17 (77) 17/25 (68) 0.551
Mortality 5 (10) 6 (12.8) 0.668
C. difﬁcile 6 (12) 4 (8.5) 0.572
P1335 Impact of National Hospital Evaluation Programme on
surgical antibiotic prophylaxis in Korea
E.S. Kim °, Y.G. Kwak, S.W. Park, C.S. Moon, C.S. Lee, B.N. Kim
(Goyang, Busan, Seoul, Jeonju, KR)
Objectives: Inappropriate antibiotic use in surgical prophylaxis is
related to the development of surgical site infections (SSIs) and
antibiotic resistance and an increase in cost. The quality assessment
in surgical antimicrobial prophylaxis has been implemented as a part
of national hospital evaluation program (NHEP) since 2007 in Korea.
We investigated the use of prophylactic antibiotics in surgery before and
after the assessment.
Methods: We retrospectively reviewed medical records of patients who
underwent three types of operations (arthroplasty, gastrectomy, and
hysterectomy), which were included for the assessment of NHEP, and
two other types of operations (craniotomy and spine surgery), which
were not, in six university-afﬁliated hospitals from 2006 to 2008. Data
for the use of prophylactic antibiotics (regimen, timing, and duration)
and SSI rates in each type of operations underwent from August to
October in each year were collected for comparison.
Results: Among 2,207 operations, 1,949 were enrolled; 356 arthroplas-
ties, 273 gastrectomies, 615 hysterectomies, 168 craniotomies, and 537
spine surgeries. There were no signiﬁcant changes in gender distribution,
mean ages, and National Nosocomial Infections Surveillance system
(NNIS) risk index scores in each type of operations during the study
period. The quality of surgical prophylaxis was signiﬁcantly improved
whether the operations were included for the assessment of NHEP or
not. The changes of SSI rates were not signiﬁcant (Table).
Conclusion: Implementation of the assessment of surgical antimicrobial
prophylaxis as a part of NHEP resulted in dramatic improvement in
the use of prophylactic antibiotics in major surgery in Korea. Further
prospective studies are needed to investigate its effects on SSI rates and
antibiotic cost.
Group Quality indicators 2006 2007 2008 P Value
Arthroplasty Adequate timing (%) 12.3 94.4 99.1 <0.001*
Adequate selection (%) 0.9 27.2 51.7 <0.001*
Duration (days) 21.6±9.6 10.3±7.2 8.5±5.5 <0.001*
SSI rates (%) 3.6 3.3 1.8 0.445
Gastrectomy Adequate timing (%) 33.7 97.7 97.6 <0.001*
Adequate selection (%) 0 71.9 48.2 <0.001*
Duration (days) 11.6±7.9 6.7±3.1 8.8±5.3 <0.001*
SSI rates (%) 6.1 4.5 6.0 0.942
Hysterectomy Adequate timing (%) 33.1 96.6 97.4 <0.001*
Adequate selection (%) 23.7 83.9 92.3 <0.001*
Duration (days) 12.8±2.8 6.9±4.8 7.0±4.8 <0.001*
SSI rates (%) 3.4 2.4 2.1 0.401
Craniotomy Adequate timing (%) 25.5 52.8 50.9 0.01*
Adequate selection (%) 0 15.1 23.3 <0.001*
Duration (days) 14.3±10.6 12.0±7.0 10.4±7.4 0.055
SSI rates (%) 5.8 0 1.8 0.198
Spine surgery Adequate timing (%) 13.1 73.0 79.9 <0.001*
Adequate selection (%) 0 2.6 5.9 0.001*
Duration (days) 17.3±7.6 13.3±8.6 14.3±9.6 <0.001*
SSI rates (%) 4.5 5.3 2.5 0.289
P1336 Antibiotic consumption in 30 French nursing homes: a
point prevalence study from the European Surveillance of
Antimicrobial Consumption nursing home subproject
G. Gavazzi °, P. GIbert, L. Fontaine, R. Stroobants, E. Hendrickx,
A. Muller, V. Vankerckhoven, H. Goossens, B. Jans on behalf of the
European Surveillance of Antimicrobial Consumption (ESAC) Project
Group
Objectives: Elderly individuals and particularly elderly living in Nursing
home (NH) exhibit speciﬁc features for infections including diagnostic
difﬁculties, increased multidrug resistant bacteria and high antibiotic
(AB) use. Optimizing the use of ABs in the nursing home population is
therefore an important priority of quality of care. However, considering
AB consumption, no data are available in Europe. The objectives of the
European Surveillance of Antimicrobial Consumption Nursing Home
(ESAC-NH) subproject are to study AB use and prescriptions among
European residents living in high skilled NH. The results presented here
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are from the 30 French Nursing homes participating to the ESAC-NH
sub-project.
Methods: In accordance with the methodology of the ESAC-NH
subproject, a ﬁrst point prevalence survey (PPS) was carried out in
30 NH in France within a one-month-period (one day in April 2009).
Inclusion criteria for residents were to be resident in the NH (>24
hours) and to receive systemic AB(s) at the time of the PPS. Data were
obtained from nursing notes, medication administration records and staff
related to antimicrobial prescribing, facility and resident characteristics
(e.g. prevalence of urinary and vascular catheter, wound, disorientation,
bedridden). Indication, type and dosage for AB and, microorganisms
were reported. Data were entered into customised web-based software
and analysed descriptively.
Results: ABs were administered to 112 (4.8%) of 2318 eligible
elderly residents. Characteristics of the residents were as follows:
presence of urinary catheter (1.4%), vascular catheter (<0.01%), urinary
incontinence (56.1%), disorientation (55.9%), wound (13.6%), bedridden
(35.4%). Respiratory (RTI) and Urinary tract infections (UTI) were the
most frequent infections (60.3% and 25.8%, respectively). Microbial
identiﬁcation was only present in 1.5% of RTI, and in 65.5% of UTI.
The most frequent ABs were b-lactams for RTI (>70%, oral route 82%);
quinolones(34.5%), cotrimoxazole (20.7%), and nitrofuranes (10.4%)
were the most frequent ABs for UTI (intravenous route <10%).
Conclusion: Surprisingly in France, antibiotic use in the NH population
was moderate. Although the PPS was organised during the Spring, which
may explain the low rate of antibiotic use, the low prevalence of urinary
catheter may have decreased the rate of AB use for UTI. This study
indicates also that, to optimize antibiotic use in NH, guidelines should
mainly focus on UTI and RTI.
Economic impact of infectious diseases and
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P1337 MRSA complicated skin and skin structure infections in
Glasgow; evaluation of hospital management and potential
for earlier discharge
R.A. Seaton °, J. Coia, R. Masterton, N. Reid, S. Cooper, B. Jones
(Glasgow, Ayr, London, UK)
Objectives: In the UK, MRSA skin and skin structure infections (cSSTI)
are usually treated in hospital with glycopeptides. Opportunities for
earlier hospital discharge include switch to an effective oral agent or
outpatient parenteral antibiotic therapy (OPAT).
Methods: A retrospective review of MRSA SSTIs admitted to six acute
hospitals in Glasgow was undertaken (September 2007 to December
2008) to identify patient treatment pathways and the potential for earlier
discharge. Patients were identiﬁed through ICD-10 clinical coding and
cross matched with patients known to have has a positive MRSA isolate.
Results: 605 (9.6%) patients had cSSTI and were MRSA positive.
Of 476 case notes reviewed, 173 were conﬁrmed with MRSA
cSSTI. Median age was 68 years (54% female). cSSTI were surgical
site (44.5%), cellulitis (23.7%), infected ulcer (18.5%) and abscess
(5.8%). 61% were community-associated (isolate 48 hours following
admission). In 20.2% MRSA therapy was empiric, in 68.8% it followed
a positive culture. 144 (83%) were managed entirely as inpatients,
19 (11%) had oral therapy post discharge and 10 (5.8%) received
OPAT (following admission in one). 110 (63.6%) were treated with
intravenous (IV) +/− oral therapy, 33 (19.1%) IV then oral switch, 8
(4.6%) oral therapy only and 22 (12.7%) did not receive anti-MRSA
therapy. Vancomycin was the most commonly prescribed IV agent
(68.8%) and linezolid the most commonly prescribed oral agent (9.2%).
Median duration of stay following a positive MRSA result was 15 days
(1–217 days) and 4352 days in total. 37 (34%) of those who received
IV therapy in hospital were potentially suitable for earlier discharge
(oral therapy or OPAT) as they received >72 hours IV therapy and
were discharged within 72 hours of discontinuing therapy. 28 (16.2%)
of patients died during their admission (cause not determined) and 15
(8.7%) were readmitted with cSSTI within 30 days of discharge.
Conclusions: MRSA infection is implicated in about 10% of cSSTI in
Glasgow hospitals, the majority are community-associated, re-admission
rate is 8.7% and mortality 16.2%. There is variability in management
with approximately one third of patients who remain in hospital
receiving IV therapy, potentially suitable for earlier hospital discharge
either through IV to oral switch or OPAT. Earlier discharge should be
considered in MRSA infected patients with SSTI in view of the potential
economic, infection control and social beneﬁts.
P1338 Outcomes and costs of previous vancomycin exposure
in patients with complicated bacteraemia and infective
endocarditis due to MRSA
J. Brown °, K. Brown, A. Forrest, W. Wisniewski, R. Betts, F. Doloresco
(Buffalo, Rochester, US)
Objectives: MRSA is the primary cause of complicated bacteraemia
(CB) and infective endocarditis (IE) in patients (pts). Standard treatment
for these infections is vancomycin (V). Studies have questioned the
costs/outcomes of V as compared to other therapies, yet to our knowledge
no study has investigated the timing and degree of previous V on
outcomes and associated hospital costs for pts with CB or IE due to
MRSA.
Methods: We performed a retrospective review of pts treated for
conﬁrmed MRSA CB and IE from 7/1/06 to 6/31/08. Pts with
CB or deﬁnite or possible IE as deﬁned by the Modiﬁed Duke
Criteria were included. CB was deﬁned using standard accepted
deﬁnitions. Data collection included clinical, microbiological, acuity,
treatments, outcomes and hospital costs for pts exclusively treated at
our institution. Failure was deﬁned as clinical failure, microbiological
failure, death or discontinuation of effective anti-MRSA therapy
due to adverse events. Success and failure were evaluated using
standard deﬁnitions. Hospital costs included: antibiotic costs, IV
admixture/administration costs, antimicrobials for treatment failures,
therapeutic drug monitoring, medications/procedures associated with the
diagnosis/management of adverse drug events with possible/probable
association and CB/IE associated length of hospitalization. Classiﬁcation
and regression tree analysis (CART) was used to identify prior V
associated with failure. Students T test, Mann–Whitney test and Fishers
Exact tests were used for univariate analysis and logistic regression
was used for multivariate modeling. MICs were determined using
E test.
Results: A total of 32 CB and 18 IE pts were included in the analysis.
Overall, 34/50 had successful outcomes. The average total hospital costs
for those with successful outcomes was $23,597 as compared to $37,505
for those experiencing failure (p = 0.03). Upon univariate analysis pts
with any V in the prior 3 years (13/34 vs. 12/16, p = 0.03) and V MIC
2 (7/34 vs. 9/16, p = 0.02) were associated with failure. The CART
derived partition point for prior V was 18.75 grams or 14 days of V
within the prior 3 years. In the ﬁnal regression model only pts receiving
14 days of V (p = 0.002) or 18.75 grams (p = 0.002) in the prior 3
years were predictors of failure.
Conclusions: In our model of pts with MRSA CB or IE, predictors of
failure included, pts receiving 14 days of V or 18.75 grams in the
prior 3 years. Further analyses are warranted to explore/conﬁrm these
ﬁndings.
P1339 Prior vancomycin exposure and its impact on MRSA-
complicated bacteraemia and infective endocarditis-related
mortality
J. Brown °, K. Brown, A. Forrest, W. Wisniewski, R. Betts, F. Doloresco
(Buffalo, Rochester, US)
Objectives: MRSA is a major cause of CB and IE. V traditionally has
been the antibiotic of choice in these pts. Several analyses of CB/IE pts
have found prior V an independent risk factor for poor outcomes and
increasing V MICs. This exploratory study, quantitatively investigated
the effects of prior V on MRSA CB and IE attributable mortality (AM).
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Methods: We performed a retrospective review of pts treated for
conﬁrmed MRSA CB and IE from 7/1/06 to 6/31/08. Pts with CB or
deﬁnite or possible infective endocarditis (IE) as deﬁned by the Modiﬁed
Duke Criteria were included. CB was deﬁned using standard accepted
deﬁnitions. Based on sample size calculations at = 0.05, 25 subjects with
and without (50 total) prior V within the past 3 years were randomly
selected. Data collection included clinical, microbiological, acuity and
treatment information for pts exclusively treated at our institution.
Classiﬁcation and regression tree analysis (CART) was used to identify
the amount of prior V exposure associated with an increased AM.
Students T test, Mann–Whitney test and Fishers Exact tests were used
for univariate analysis and logistic regression was used for multivariate
modeling. MICs were determined using E test. AM was deﬁned as deaths
where CB or IE was documented as the main cause or where CB or IE
was mentioned as the main diagnosis.
Results: A total of 32 CB and 18 IE pts were included in the analysis.
The overall AM rate was 16% (8/50). Pts with any V in the prior 3 years
(6/8 vs. 19/42, p = 0.25) and pts with IE (4/8 vs. 14/42, p = 0.436) were
not associated with AM. The CART derived partition point for prior V
was 45 grams or 31 days of V within the prior 3 years. Upon univariate
analysis variables associated with AM included: APACHE II (12 vs. 10,
p = 0.04), V MIC 2 (6/8 vs. 10/42, p = 0.009), 45 grams of V (5/8 vs.
2/42, p = 0.0001) or 31 days (5/8 vs. 2/42, p = 0.0001) of V within the
prior 3 years were. In the ﬁnal regression model APACHE II (p = 0.04),
pts receiving 31 days of V (p = 0.002) or 45 grams (p = 0.002) in the
prior 3 years were predictors of AM.
Conclusions: In our model of pts with MRSA CB or IE, predictors of
AM included higher APACHE II, pts receiving 31 days of V or 45
grams in the prior 3 years. Further analyses are warranted to explore
and conﬁrm these interesting ﬁndings.
P1340 Cost and outcome implications of the newly developed
high-dose vancomycin consensus guidelines
R. Kullar °, S. Davis, K. Kaye, T. Taylor, M. Rybak (Detroit, US)
Objectives: Recent 2009 consensus guidelines on the therapeutic
monitoring of vancomycin (VAN) has recommended using larger dosages
of VAN for patients with complicated infections in order to achieve
trough serum concentrations of 15−20mg/L. We evaluated the costs and
outcomes of patients with methicillin-resistant Staphylococcus aureus
bacteraemia (MRSAB) before and after implementation in March 2007
of a policy to target high trough concentrations in complicated infections.
Methods: A quasi-experimental study conducted from 2005–2009 at
Detroit Medical Centre. Consecutive adult patients treated with VAN for
72 hours for conﬁrmed MRSAB in two study phases: Pre (2005 −
March 2007) and Post (March 2007–2009) policy implementation. We
evaluated patient characteristics, clinical outcomes and variable direct
costs, in U.S. dollars, in both phases. Costs were adjusted for inﬂation
and non-parametric tests were used for skewed data.
Results: 214 eligible patients were identiﬁed (107 pre-implementation;
107 post-implementation). Baseline characteristics in patients were
similar amongst pre- and post-implementation (Table 1). Median length
of stay (LOS) was higher in patients pre- vs. post-implementation
(18 days vs. 15 days, P = 0.22), although this was not statistically
signiﬁcant. Total variable hospital costs were higher in the pre-period
compared to the post-period ($5,638.10 vs. $4,205.46, P = 0.017).
However, VAN monitoring costs were signiﬁcantly higher in patients
post-policy implementation (Table 1). Likewise, the median VAN dose
was statistically higher in patients during the post-period (2000mg
vs. 1450mg, P = 0.006), which was associated with higher VAN drug
cost ($166.40 vs. $116.48, P = 0.007). Rates of nephrotoxicity were
numerically higher in patients following the policy implementation
(18.7% vs. 16.8%, P = 0.60). Patients during the pre-period had
signiﬁcantly higher rates of VAN failure (57% vs. 44.9%, P = 0.048).
Conclusion: Implementation of a VAN dosing policy to achieve troughs
of 15−20mg/L resulted in improved clinical success and reduced LOS
and hospital cost in a cohort of MRSAB. Treatment post implementation
was associated with increased VAN drug and monitoring costs.
Table 1
Pre (n = 107)
Median (range) or
n (%)
Post (n = 107)
Median (range) or
n (%)
P-value
Patients’ Characteristics
Age (years) 52 (27−89) 53 (20−94) 0.81
Apache II score 8 (0−22) 7 (0−26) 0.22
Weight (kg) 70.2 (35.4–178.0) 71.8 (36.1–186.0) 0.52
Creatinine clearance (ml/min) 68.2 (6.2–189.4) 64.8 (6.1–212.0) 0.41
Renal failure during hospitalization 35 (32.7%) 41 (38.3%) 0.39
Hemodialysis 15 (14.0%) 11 (10.3%) 0.39
Concomitant sites of infection 0.62
IV catheter 19 (17.8%) 24 (22.4%)
Skin/wound 21 (19.6%) 13 (12.1%)
Endocarditis 25 (23.4%) 19 (17.8%)
Osteomyelitis 11 (10.3%) 11 (10.3%)
Cost and Resource Utilization Data
Total hospital variable cost ($) 5,638 (261−11,826) 4,205 (500−95,016) 0.017
VAN drug cost ($) 116 (8–648) 166 (12–1984) 0.007
Number of trough levels drawn 3 (0−14) 4 (0−27) 0.005
Cost of trough levels ($) 30.60 (0–142) 40 (0–275) 0.005
Monitoring labour cost (consult) ($) 56.56 (0–189) 68 (0–347) 0.006
P1341 The cost of a ﬁctional b-lactam allergy
M. Ibeto °, M. Przybylo, I. Maitland, M. Qulaghassi, R. Kato, A. Guleri
(Blackpool, UK)
Background: The British National Formulary [BNF]-standard UK drug
manual, reports allergic reaction to penicillins occur in 1−10% of
exposed individuals. It is an acceptable observation amongst clinicians
that a large number of patients are labeled allergic to penicillin. Penicillin
and other b-lactam allergies are conventional. Properly identifying
patients who are erroneously labeled b-lactam allergic will lead to
improved utilization of antibiotics while avoiding the use of less efﬁcient/
more expensive alternatives.
Method: Cost identiﬁcation of a ‘penicillin allergy’ was made by
comparing the price of the alternative vs ﬁrst line b-lactam antibiotic
course for each patient prescribed over a month period at a general
practice centre in Northwest England. Data was collected from the
electronic medical record database. The history of each allergic reaction
to penicillin was reviewed. The alternative antibiotics used were
compared to their b-lactam equivalents. The price of each antibiotic
course were obtained and compared from the BNF.
Results: Within one month, antibiotics were prescribed to 196 patients.
8% (16/196) of patients were labeled ‘penicillin allergic’. 100% (16/16)
had no detailed history of the allergic reaction to penicillin. The overall
cost of all the non-b-lactam antibiotics used considering the penicillin
allergy was £59.32. The cost of the ﬁrst line b-lactam equivalents was
£24.48. Non-b-lactam second line alternative antibiotics are two and a
half times more expensive than their b-lactam equivalents.
Discussion: Although penicillin is still the most commonly reported
allergy, less than 20% of all patients that believe that they have a
penicillin allergy are truly allergic to penicillin. Penicillin allergy is
an overused/ over prescribed diagnosis. Patients often report typical
side-effects of b-lactams as a true allergy. This notion undermines the
efforts to curb emerging resistance and has a big economic impact when
considering how many people consider themselves b-lactam allergic.
Investigations into true b-lactam allergies must be considered for future
antibiotic consolidation and management. Clinical details of patients to
be presented.
Community-acquired respiratory tract
infections
P1342 Sensitivity of both PCR and serology for diagnosis of
Mycoplasma pneumoniae and Chlamydophila pneumoniae
in a primary care setting
K. Loens °, A. Vanderstraeten, C. Lammens, D. Ursi, S. Dettlaff,
T. Verheij, P. Little, H. Goossens, M. Ieven and the GRACE study team
Objectives: Serology and PCR are widely used for diagnosis of atypical
bacteria such as M. pneumoniae (MP) and C. pneumoniae (CP) in
respiratory tract infections. The aim of this study was to investigate the
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role of these organisms in patients presenting with lower respiratory tract
infections (LRTI) in 11 primary care networks (PCNs) in 8 European
countries using sensitive real-time PCRs and serology.
Methods: From October 2007 through May 2008, a total of 861 adult
patients with LRTI in the community were enrolled during the ﬁrst
winter period in a prospective study in 11 PCNs in 8 European countries.
Among other samples, nasopharyngeal ﬂocked swabs (COPAN), sputa
if productive cough, and paired sera were collected and sent to the local
laboratory to be frozen. Specimens were transported regularly to the
central lab in Antwerp for in-house real-time PCR for MP, and CP
detection. IgG serology was performed using Mycoplasma pneumonia-
IgG-ELISA and Chlamydia pneumonia-IgG-ELISA plus kits (Medac
GmbH, Wedel, Germany) for the detection of a IgG seroconversion or
signiﬁcant rise in anti MP/CP IgG in paired sera collected 3−4 weeks
apart according to the instructions of the manufacturer. 43 and 59 paired
sera were tested for the presence of MP and CP IgM, respectively.
Results: The results of the IgG serological study indicated that MP and
CP were the causative agent in 1.6% (11/689) and 2.2% (15/690) of the
studied adult patients with CA-LRTI. 7/43 patients were found positive
for speciﬁc-IgM.
Only 1/8 patients showing a MP IgG seroconversion, tested positive
for IgM. For the 4 MP positive patients identiﬁed by a signiﬁcant rise
in IgG, 2 tested IgM positive. Only 5 patients tested positive for the
presence of CP IgM: 1 patient with a IgG seroconversion, 2 patients
with a signiﬁcant rise in IgG. For the other 2 patients, no signiﬁcant
change in IgG titer was observed.
In 0/689 and 3/689 (0.4%) nasopharyngeal ﬂocked swabs MP and CP
were detected by PCR, respectively. Three patients were found to be MP
positive when PCR was applied to sputum. All PCR positive patients
were also found positive by IgG serology.
Conclusion: Although nasopharyngeal sampling with ﬂocked swabs is
well tolerated and suitable to be used in an outpatient setting the rate
of positive results for MP was higher when PCR applied to sputum or
when examining paired sera for a signiﬁcant rise/seroconversion in anti
MP/CP IgG. IgM antibodies are of limited value in early diagnosis.
P1343 Is there a role for CRP or PCT as inﬂammatory parameters
in the management of outpatients with community-acquired
lower respiratory tract infections?
K. Loens, C. Lammens, A. Vanderstraeten, F. Coenjaerts, E. Claas,
A. Van Loon, T. Verheij, P. Little, H. Goossens, M. Ieven ° on behalf
of the GRACE study team
Objectives: CRP and/or PCT measurement is often used for the
management of patients with a Community-acquired Lower Respiratory
Tract Infection (CA-LRTI). This study investigated the correlation
between 2 CRP methods and between CRP and PCT as inﬂammatory
markers for the management of adult outpatients presenting with a CA-
LRTI in the GRACE network.
Materials and Methods: From 10/2007 to 05/2008, a total of 847
adult patients with CA-LRTI were enrolled during the ﬁrst winter
period in a prospective study in 11 primary care networks (PCNs) in
8 European countries. Among other samples, nasopharyngeal ﬂocked
swabs (COPAN), sputa and sera were collected and sent to the local lab
to be frozen. Specimens were transported regularly to the central lab in
Antwerp for in-house real-time PCR for detection of atypical bacteria
and respiratory viruses. Sputa were cultured for bacterial etiology at
the local labs. Nasopharyngeal ﬂocked swabs were cultured for the
presence of S. pneumoniae and Haemophilus spp at the central lab.
CRP was measured by a lab-based test and a POCT (Orion), PCT
was measured by the Kryptor (Brahms GmbH). Interpretation of PCT
values was done according to Christ-Crain (Lancet 2004): <0.1mg/L:
absence of bacterial infection; 0.1–0.25mg/L: bacterial infection unlikely;
0.25−0.5mg/L: possible and >0.5mg/L suggestive for a bacterial infection.
Results: For 430 patients of 6 PCNs, CRP, PCT, PCR and culture results
are available.
A bacterial or viral etiology was found in 29.8% and 49.0% of patients,
respectively: 13.3% of these were mixed infections. The concordance
between the lab-based CRP and POCT CRP test varied between
98.9%, 97.8% and 90.6% for concentrations <20mg/L, 20−50mg/L and
>50mg/L respectively. Elevated CRP values of >20mg/L were found in
125/430 (29.1%) of patients. PCT values of >0.25mg/L were found in
only 10/430 (2.3%) of patients. CRP was >50mg/L in 49/417 (11.8%)
patients with PCT values <0.25mg/L. According to the PCT criteria
used 97.0% of all infections belong to the groups “absence of bacterial
infection” or “bacterial infection unlikely”. For 96.1% of patients from
whom bacteria were isolated, PCT values were not indicative for a
bacterial infection.
Conclusions: Correlation between POCT CRP and lab based CRP is
excellent. The measurement of PCT in primary care is of limited help
for the GP to distinguish bacterial from viral infections. CRP seems
more sensitive as inﬂammatory parameter than PCT in outpatients with
CA-LRTI.
P1344 Epidemiology, clinical features, and outcomes of community-
acquired pneumonia in patients with liver cirrhosis
D. Viasus, C. Garcia-Vidal °, J. Castellote, J. Adamuz, R. Verdaguer,
F. Gudiol, J. Carratala` (Barcelona, ES)
Objective: Although liver cirrhosis is associated with an increased
susceptibility to infection, little information is available regarding
community-acquired pneumonia (CAP) in this setting. We aimed to
ascertain epidemiology, clinical features, and outcomes of CAP in
patients with liver cirrhosis. The prognostic value of several speciﬁc-
disease scores was also analyzed.
Methods: Observational analysis of a prospective cohort of nonseverely
immunosuppressed hospitalized adults with CAP (1995–2008). Liver
cirrhosis was diagnosed by histology or by clinical, laboratory and
imaging criteria.
Results: We documented 3421 CAP episodes, of which 90 cases
occurred in patients with liver cirrhosis. The median value of model
for end-stage liver disease (MELD) was 14 (range 6−36). According
to the Child-Pugh (CP) score, 56% of patients were grade B and 21%
grade C. Patients with liver cirrhosis were younger (61.4 vs 66.3 years;
p = 0.001), more often male (80% vs 68%; p = 0.021), current smokers
(41% vs 26%; p = 0.002) and heavy alcohol drinkers (35% vs 17%;
p< 0.001) than the remaining patients. They had more frequently altered
mental status at admission (33% vs 13%; p< 0.001), shock (13% vs 6%;
p = 0.011), and were more commonly classiﬁed into high-risk pneumonia
severity index (PSI) classes (group IV-V) (74% vs 57%; p = 0.002).
Streptococcus pneumoniae (46% vs 33%; p = 0.009) and Pseudomonas
aeruginosa (4.4% vs 0.9%: p = 0.001) were more frequently documented
in patients with liver cirrhosis. Bacteraemia was also more common
among these patients (21% vs 13%; p = 0.023). Speciﬁc-disease scores
were comparable in predicting severe disease (30-day mortality and/or
ICU admission); area under the ROC curve were 0.83 (MELD), 0.75
(CURB-65), 0.74 (CP), and 0.70 (PSI). Early (<48 h) (5.6% vs 2.1%;
p< 0.048) and 30-day mortality rates (14.4% vs 7.4%; p< 0.024) were
higher in patients with liver cirrhosis.
Conclusions: CAP is associated with a poor outcome in patients with
liver cirrhosis. Speciﬁc-disease scores, especially MELD, may help
identify patients at high risk of adverse outcomes. Strategies aimed to
improve the management of CAP in liver cirrhosis patients are needed.
P1345 Causes and risk factors of poor outcome in patients with
non-severe community-acquired pneumonia
M. Falguera °, M. Velasco, O. Sacrista´n, I. Chica, P. Cabezas,
A. Ruiz-Gonza´lez, J.M. Porcel (Lleida, ES)
Objectives: To recognize causes and risk factors associated with poor
outcome (mortality, long hospital stay and readmission) among patients
with non-severe community-acquired pneumonia.
Methods: From a database of patients with community-acquired
pneumonia, prospectively collected in a 10-year period, we selected those
patients with non-severe disease according to the Pneumonia Severity
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Index (PSI) (classes I to III). Mortality, long hospital stay (10 days
or more) and readmission in 30 days were selected as poor outcome
indicators. Causes were evaluated from clinical records and risk factors
were determined by means of univariate and multivariate analyses.
Results: Eight of 706 (1%) patients died, directly related to pneumonia;
risk factors associated with mortality in multivariate analyses were:
oxygen saturation <88%, arterial systolic blood pressure <90mmHg
and plasmatic sodium level <133 mEq/L. Mortality rates were 0%, 2%,
10% and 100% for patients with 0, 1, 2, or 3 risk factors, respectively.
A long hospital stay was recorded in 155 (22%) patients, directly
attributable to pneumonia in 81, exacerbation of underlying diseases
in 55, appearance of new events in 13, and others in 6; multivariate
analyses selected the following predictive factors: presence of underlying
diseases, pleural effusion, empyema, hematocrit level <32%, arterial
systolic blood pressure <90mmHg and arterial pO2 <60mmHg. Finally,
52 (7%) patients were readmited in 30 days after discharge due to
exacerbation of underlying diseases in 25, appearance of new events
in 13 and pneumonia related causes in 14; risk factors determined by
multivariate analyses were: presence of neoplasm, hematocrit level <30%
and arterial pCO2 level >45mm Hg.
Conclusions: In patients with non-severe community-acquired pneumo-
nia, poor outcome seems predictable. Mortality is related to pneumonia;
a long hospital stay can derive from pneumonia or from exacerbation
of underlying diseases; and readmissions are frequently due to non-
pneumonia related causes. Presence of risk factors can help to decide
hospital admission.
P1346 SMART-COP in severe pneumonia − is it as smart as it
seems?
J. Seddon °, R. Vancheeswaran, D. Mack (London, Herts, UK)
Objectives: Pneumonia severity is notoriously difﬁcult to estimate with
no single factor accurately predicting mortality or need for invasive
ventilation. Composite scoring tools are vital to inform clinical decision-
making and to predict risk of death. We audited management of
pneumococcal pneumonia and compared the new SMART-COP tool with
the traditionally used CURB-65 tool.
Method: We performed a retrospective case note review of all patients
admitted to Barnet and Chase Farm Hospitals with pneumonia who had
blood cultures positive for streptococcus pneumoniae between October
2008 and April 2009. We audited the use of CURB-65 by the admitting
doctor and compared it with the SMART-COP score to determine the
accuracy of each in predicting death and IRVS.
Results: We analysed data for 28 of the 32 patients with positive
pneumococcal blood cultures. Due to small numbers, we pooled severity
scores into high (3) and low (<3) groups. Graph 1 shows patient
numbers in each category. In addition, we found that 50% (3/6) of those
that died had not received IRVS. CURB-65 score was documented in
only 32% of patients. Antibiotic protocol compliance was only 50%
when patients were CURB-65 scored appropriately.
Conclusion: Estimating pneumonia severity by means of a scoring tool
has always been a dilemma between accuracy and simplicity of use.
On opposite ends of this spectrum lie the precise, but time-consuming
Pneumonia Severity Index (PSI) and the straightforward CURB-65. As
CURB-65 is universally accessible it forms the backbone of treatment
guidelines published by both the American and British Thoracic
Societies. SMART-COP is appealing in forging a middle ground. We
have shown that mortality and need for IRVS increases with higher
CURB-65 and SMART-COP scores and that in our septicaemic patients
with pneumonia there was no beneﬁt in using a more complicated
scoring tool. Moreover, we found poor use of CURB-65 with the score
documented in only 32% of patients. Given that severity scoring guides
antibiotic prescription, that only 50% of patients received antibiotics
compliant with BTS guidelines was not a surprise. Clearly, if patients
are not scored for severity, appropriate management becomes an even
greater challenge. As has been shown in a number of studies, there are
signiﬁcant barriers to using even simple scoring tools. The lack of clear
beneﬁt, compounded by a more time-consuming and less memorable
tool will limit widespread use of SMART-COP as a scoring system.
P1347 Invasive pneumococcal disease in a Spanish university
hospital from 2007 to 2009: epidemiology and serotypes
I. Rebollo °, J. Esperalba, M.P. Mendaza, R.M. Daza, P. Costa,
A. Ma´rquez, D. Da´maso (Majadahonda, ES)
Objectives: A 3-year invasive pneumococcal disease (IPD) enhanced
surveillance project in the “Hospital Puerta de Hierro de Majadahonda”
(HPHM) between February 2007 and November 2009. It aims to describe
the incidence of IPD and the clinical and epidemiological characteristics
of cases in HPHM.
Methods: IPD cases were deﬁned by isolation of S. pneumoniae from
a normally sterile site. Data recorded for each isolate were age, gender,
diagnosis and isolate type. Diagnosis was classiﬁed as bacteraemia,
meningitis, pneumonia or empyema. S. pneumoniae cases were serotyped
in a reference laboratory, using the Quellung reaction with serotype-
speciﬁc antiserum and latex agglutination test (Pneumolatex). The
HPHM is a 613-bed hospital and covers a population of approximately
5 hundred thousand people. The incidence of IPD was assessed using
estimates of population from the Ofﬁce for Local Statistics. Isolates from
children <5 years were collected since October 2008.
Table 1. Summary of IPD isolates 2007–2009
All <5 years* 5−64
years
>65 years
Number of isolates 95 8 52 35
Number of males (%group) 55 6 (75%) 32 (62%) 17 (49%)
IPD incidence (per 100,000 persons) 6.2
[4.3−8.6]
23
[10.2−46.3]
5.9
[3.5−9.4]
36.3
[18.9−63.52]
Number of different serotypes identiﬁed 28 5 22 22
Rank serotype (number of isolates, more than 2)
1 1 (18) 1 (2) 1 (15) 3 (8)
2 3 (13) 5 (2) 3 (4) 5 (3)
3 5 (8) 24F (2) 8 (4) 4 (2)
4 4 (5) − 4 (3) 11A (2)
5 8 (5) − 5 (3) 18C (2)
6 19A (5) 11A (2) 19A (2)
7 11A (4) 14 (2) −
8 18C (4) 18C (2) −
9 14 (3) 19A (2) −
10 24F (3) 22F (2)
Total isolates represented by top ten serotypes 71% 82% 75% 54%
PPV23 coverage 79 (83%) 9 (82%) 45 (87%) 28 (84%)
PCV7 coverage 15 (16%) 0 8 (15%) 7 (20%)
*Data from October 2008 to November 2009.
PPV23 serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and
33F. PCV7 serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F.
Results: A total of 95 strains were isolated between February 2007
and November 2009. 55 were men (58%). The overall IPD incidence
in the HPHM population was 6.2 cases per 100,000 per annum [95%
conﬁdence interval (CI) 4.3−8.6]. The incidence in children under ﬁve
was 23 [95%CI 10.2–46.3]. The incidence of serotypes included in
the vaccine PPV23 (83%) was 5.1 [3.4−7.3]. A seasonal pattern of
disease was observed. Twenty-eight serotypes were isolated in total, ﬁve
different serotypes were found in the under ﬁves (8 isolates), twenty-two
in the over 65 age group (35 isolates) and twenty-two in the 5−65 age
group (52 isolates). Most common serotypes in the general population
were 1 (18 isolates), 3 (13 isolates), 5 (8 isolates), 4 (5 isolates),
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8 (5 isolates), 19A (5 isolates), 11A (4 isolates) and 18C (4 isolates),
compromising 62% of the total isolate collection. See Table 1. The
diagnosis was known in 71% of patients. Of these, the most frequent
being pneumonia 76%, followed by bacteraemia 11%, meningitis 7%,
empyema 3% and other 3%.
Conclusions: The incidence of IPD varied with age, with the highest
rates being among young children and the elderly, and is also coherent
with data reported by other regions and developed countries. The
proportion of cases by serotypes included in the PCV7 was lower than
that observed in studies conducted by Madrid in prior years, primarily
in children. Continuous surveillance of IPD is fundamental in order to
assess the evolution of the overall incidence and serotypes.
P1348 Community-acquired pneumonia and pleural effusion.
A comparative study between complicated and
uncomplicated parapneumonic effusion
M. Falguera °, J. Carratala`, I. Chica, C. Garcı´a-Vidal, S. Bielsa,
J. Dorca, F. Gudiol, J.M. Porcel (Lleida, Barcelona, ES)
Objective: To determine the incidence, etiology and outcome of
community-acquired pneumonia with parapneumonic effusion and to
recognize predicitive factors for complicated ﬂuid.
Methods: We analyzed databases from 2 university hospitals in
Catalonia (Spain) that enrolled consecutive patients with community-
acquired pneumonia for a 12-year period and selected subjects who
had radiological evidence of pleural ﬂuid. Complicated parapneumonic
effusion was deﬁned as empyema (presence of pus) or pleural ﬂuid
meeting one or more of the following criteria: pH< 7.20, glucose level
<40mg/dl or positive culture. Remaining cases were considered as
having an uncomplicated effusion. Univariate and multivariate analyses
were employed to compare patients with complicated and uncomplicated
ﬂuid.
Results: A total of 882 of 4715 (19%) patients with community-acquired
pneumonia had radiologial evidence of pleural ﬂuid, 261 (30%) of them
met criteria for complicated parapneumonic effusion. In multivariate
analyses, the development of complicated effusion was associated with
4 clinical factors: age <60 years (p = 0.018), alcoholism >60 g/day
(p = 0.002), pleuritic pain (p = 0.003), and tachycardia >100 beats/minut
(p = 0.003). Rates of complicated parapneumonic effusion were 12%,
21%, 32%, 50% and 63% in presence of 0, 1, 2, 3 or 4 risk factors,
respectively. Patients with complicated effusion also showed substantial
differences in percentages of causal agents with a greater incidence of
conventional bacterial microorganisms, particularly non-pneumococcal
Gram-positive cocci. Moreover, these patients had a signiﬁcantly longer
hospital stay, although the mortality was not increased.
Conclusions: In patients with community-acquired pneumonia and
radiological evidence of pleural ﬂuid (19% of cases), age <60
years, alcoholism, pleuritic pain and tachycardia increased the risk of
complicated parapneumonic effusion (30% of cases). These patients also
showed a greater incidence of infection caused by Gram-positive cocci
and had a longer hospital stay, although the mortality was not increased.
Community-treated paediatric infections
P1349 Mono and mixed gastrointestinal paediatric infection:
epidemiological and clinical features
S.G. Rimoldi °, F. Stefani, C. Pagani, I. Di Bartolo, A. Lombardi,
N. Zanchetta, D. Dilillo, F. Ruggeri, M.R. Gismondo (Milan, IT)
Objective: Concerning the gastroenteritis surveillance in Italy the
existing data about the viral agents are poorly known. This study was
designed to assess the prevalence of viral agents among pediatric children
admitted with acute gastroenteritis to L. Sacco University Hospital
(Milan, Italy).
Methods: An eighteen months study (2008–2009) involving 118
patients, aged on average 30 months, was carried out. Stool specimens
were tested for bacteria while Rotavirus was detected by enzymatic
immunoassay card (Meridian).
Samples, stored at −80ºC until use, were processed for Norovirus (NoV),
Bocavirus (HBoV), Adenovirus and Enterovirus by Real time PCR kit
(Argene); Astrovirus with a multiplex PCR assay (Seegene).
Demographic and clinical data were collected in accordance with 20
point Ruska Vesikari Scoring System. Clinical information was obtained
from the virology request forms and from case sheets. According to
that, the severity of the gastroenteric disease was scored: minor (1−8),
moderate (9−14) and serious (>15).
Results: 93 out of 118 children have shown diagnosis of gastroenteritis
due to an infective cause (4 bacteria, 3 parasites, 86 viruses), 25 cases
were without a cause. In the 75 mono-infection enteric viruses were:
35.6% for HRVes, 13.6% for NoVs, 11.0%for HBoV and 3.4% for
Adenoviruses. Among the dual infection (11 cases) HRV/NoV were
present in 4 cases (3.4%), HBoV/NoV in 1 case (0.8%), HBoV/HRV
in 6 cases (5.1%). In a single case, a mixed infection supported by
NoV/C. difﬁcile was detected.
A moderate score of clinical severity(RVS)for HRV (1.5), Nov (2.15),
HBoV (2.36)and Adenovirus (2.05) were reported. Moreover in mixed-
infections synergic effects are likely to occur: NoV/HBoV infection
showed the higher RVS (3) followed by HBoV/HRV (2.33) and
NoV/HRV (2.00).
Conclusion: An high prevalence of HRV (53.9%) was detected following
by NoV (22.5%), HBoVs (15.7%), Adenoviruses (4.5%). A severe score
of seriousness was reached with HBoV in mixed infection with Nov and
HRV. due to the synergic action of more pathogens that increases the
clinical severity of illness or the different timing of viruses excretion
and incubation.
P1350 Changes in infectious disease mortality in children,
1969–2004
M. Lantto, M. Renko °, M. Uhari (Oulu, FI)
Objectives: The aim was to evaluate the changes in infectious disease
mortality in children in Finland from 1969 to 2004. Our main interest
was in mortality of previously healthy children. We especially wanted to
ﬁnd out whether the infection mortality could be further reduced by the
means of existent vaccines not included in current national vaccination
programme.
Methods: We analysed infectious disease mortality data obtained from
the ofﬁcial cause of death statistics in Finland for 1969–2004. Annual
mortality rates were calculated in proportion to those at risk of dying.
Infection mortality rates were conducted for neonatal group and children
aged one month to 15 years.
Results: Mortality due to infectious diseases reduced by 89% in
childhood group, from 0.12‰ in 1969 to 0.013‰ in 2004. In neonatal
group relative decline was 69%, from 0.50‰ in 1969 to 0.16‰ in 2004.
Pneumonia, CNS infections and septicaemia were the most common
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fatal infections in childhood. Decline in mortality occurred evenly in all
these groups, as well in all age groups in childhood.
Conclusions: Mortality from infectious diseases has decreased signiﬁ-
cantly during last decades in Finland. By the means of existent vaccines
mortality could be still further reduced.
P1351 Characterization of Haemophilus inﬂuenzae strains isolated
in Portuguese children with acute otitis media in the
pre-vaccination period with PCV10-HiD
M. Bajanca-Lavado °, C. Betencourt on behalf of ARSIP
Objective: Non capsulated Haemophilus inﬂuenzae (HiNC) along with
Streptococcus pneumoniae (Spn) are the most common cause of bacterial
acute otitis media (AOM) in children. A vaccine with 10 Spn serotypes,
each one conjugated to a recombinant non-lipidated form of protein D
as carrier protein, a conserved cell surface protein of Hi, already showed
to induce protection against non-capsulated (NC) Hi strains. Our aim is
to characterize the serotype and to determine antibiotic susceptibility in
192 Hi strains isolated in children, with an otitis diagnose, to emphasise
the importance of immunization against this disease.
Methods: From January 2001 to June 2009 we characterized 192 Hi
strains isolated in 9 collaborating Hospital Laboratories, in Portugal.
b-lactamase production was determined by a nitroceﬁn assay. Serotyping
was performed by PCR, using primers speciﬁc to each capsule type (a
to f). Minimum inhibitory concentrations (MIC; mg/L) were determined
for 13 antibiotics by a micro dilution assay, according to CLSI.
Results: Serotype determination characterized all 192 Hi strains
as NC (100%). b-lactamase production was detected in 8.3% of
the strains. Thirteen b-lactamase negative strains (7.4%) had MIC
values to ampicillin1mg/L, being considered ampicillin resistance-
non-b-lactamase producers (BLNAR). High levels of resistance were
obtained with cefaclor (32.3%) and SXT (22%).
Conclusions: Our results of 100% NC strains isolated from otitis are in
accordance with the literature that refers HiNC as one of the principal
causes of AOM episodes. This infection is one of the most common
cause of antibiotic prescription, as well as one of the principal reasons
to visit the paediatrician, which represents high economic costs. Several
trials have indicated that the vaccine PCV10-HiD provide protection
against HiNC disease, causing a decrease in more than 30% of the cases.
In relation to resistance, we are worried about BLNAR strains, since
this kind of strains are not detected in routine laboratory techniques.
Molecular methods, that determine speciﬁc mutations in the resistance
gene, are necessary to their characterization. The burden of the disease
and the excessive antibiotic consumption justiﬁes immune prophylaxis,
preferentially by active immunization. The vaccine, reducing AOM
episodes, also reduces antibiotic consumption, as well as resistance,
which can be translated in clinical and public health impact.
P1352 Correlation between malnutrition and parasitic infection
among children from rural areas in Constanta County,
Romania
C.M. Mihai °, R. Stoicescu, G. Taralunga, G. Lilios (Constanta, RO)
Background: Malnutrition and intestinal parasitic infections are
common public health problems of children from rural areas of Constanta
County, Romania.
Objective: To establish the correlations between malnutrition and
parasitosis in child from rural areas, Constanta County.
Methods: We examined these correlations in a cross-sectional program
in Prodiagnostic Laboratory, Constanta, Romania. 339 children from 24
rural communities were screened for intestinal parasites. Examinations
of stool specimens were done using fresh preparate and sedimentation
and ﬂotation techniques (ZnSO4 ﬂotation). Children were assessed for
the presence of malnutrition. Anthropometric measurements consisted
of height and weight determination The body mass index (BMI) was
determined by dividing the weight in kilogram by the squared value of
the height in meters. Nutritional status was determined as weight-for-age
(WFA), weight-for-height (WFH), and height-for-age (HFA). There were
159 girls and 180 boys, aged 6 months to 12 years.
Results: The relationship between the prevalence and the nutritional
status of the children showed that 28.9% of examined children were
infected with one parasite and 4.1% were infected with two or three
parasites. Out of total number of the infected children, according to their
BMI, 23.5% were malnourished and there was a signiﬁcant difference
(P< 0.05) of malnutrition between infected and non infected children.
The prevalence of malnutrition was 19.2% (WFA), 10.1% (WFH), and
27.4% (HFA). Parasitosis were more prevalent in children less than 6
years of age with low HFA and WFA. In older children low WFA was
more closely associated with parasitic infections. Ascaris and Toxocara
were more prevalent in malnourished children.
Conclusions: Malnutrition associated with intestinal helminth infections
is an important contributory factor for children’s diseases from rural
areas in our county. Therefore, it is recommended that the local health
representatives should establish a guideline for regular examination,
diagnosis and treatment for intestinal parasitic infections and associated
malnutrition among children from rural areas.
P1353 Vulvovaginitis in pre-pubertal and pubertal girls
S. Baka °, I. Patikas, A. Panopoulou, A. Lykas, A. Spathi, I. Tsouma,
E. Kouskouni (Athens, GR)
Objectives: Vulvovaginitis is the most common gynecological problem
in prepubertal and pubertal girls. Nevertheless, the interpretation of the
results of vaginal cultures performed in children is often difﬁcult since
clinical data and possible risk factors must be taken into consideration.
This study aimed to evaluate the vaginal microﬂora in a group of
prepubertal (PP) and pubertal (P) girls with vulvovaginitis.
Methods: A total of 245 girls aged 2 to 17 years, presenting at
the outpatient clinic for pediatric and adolescent gynecology of our
hospital during January 2008 to October 2009 with signs and symptoms
of vulvovaginitis (vaginal redness and discharge and/or itching) were
included. Cases were divided into 2 groups: 101 PP (age 2−11 years)
and 144 P (age 12−17 years). Vaginal secretions were collected using
a sterile newborn suction catheter carefully inserted into the vagina.
Samples were inoculated onto blood agar, MacConkey, Mannitol Salt,
Sabouraud Dextrose agar, Gardnerella agar and Wilkins-Chalgren agar
as well as Thayer-Martin and chocolate agar followed by incubation in
aerobic, anaerobic or CO2 atmosphere at 37º C for 24 or 48 hours, as
appropriate. Wet mount and Gram stain preparations were examined to
investigate the presence of leukocytes and the type of bacteria present.
In order to rule out the presence of Enterobius vermicularis a Graham
test was performed in all cases. The identiﬁcation of isolated strains
and their susceptibility test to antibiotics were carried out with the API
System and the automated system VITEK 2 (bioMe´rieux, Marcy l’Etoile,
France).
Results: Bacterial pathogens were isolated from 60/101 (59.4%) of
PP girls and 99/144 (68.8%) of P girls. Interestingly, leukocytes were
observed only in samples where pathogens were retrieved. Isolated
bacteria in the PP and P groups included 12/101 (11.9%) and
72/144 (50.0%) anaerobes, 27/101 (26.7%) and 9/144 (6.3%) Gram-
positive cocci, 21/101 (20.8%) and 10/144 (6.9%) Gram-negative rods,
respectively. Candida species were isolated in 8/144 (5.6%) only in the
P group. Finally, in 41/101 (40.6%) in PP group and 45/144 (31.2%) in
P group no pathogen was isolated.
Conclusion: In the PP girls predominantly Gram-positive cocci and
Gram-negative rods were isolated while in the P girls, anaerobes.
Candida species were found only in the P group. The presence
of leukocytes in vaginal samples increases the likelihood of ﬁnding
pathogens which require speciﬁc treatment.
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P1354 Pneumococcal carriage in the Warao Amerindians from
Venezuela: high colonization rates and frequent serotype
sharing among mothers and children
M.C. Sisco °, I.A. Rivera-Olivero, M. Rodrı´guez, B. Del Nogal,
P. Hermans, J. De Waard (Caracas, VE; Nijmegen, NL)
Objectives: To obtain insight in the dynamics of pneumococcal
transmission in the Warao people and to determine the role of the mother
in the transmission of the pathogen we investigated pneumococcal
colonization and serotype distribution among Warao children and their
mothers in 157 families.
Methods: From July 2007 through August 2008, nasopharyngeal
samples were obtained from 157 families, including 336 children
between 2 months and 10 years old and 152 mothers. The mean
number of children per family was 2.14. S. pneumoniae was isolated
and identiﬁed according to standard microbiological procedures.
Pneumococci were serotyped by multiplex PCR for the serotypes present
in the 23 polysaccharide vaccine with exception of serotype 2.
Results: The overall pneumococcal nasopharyngeal carriage rate was
59.6% (n = 291) with 236 children (70.2%) and 55 mothers (36.2%)
colonized. The most important capsular serotypes/serogroups found were
6 (25.3%), 19A (12.3%) and 23F (10.9%); 32.2% (n = 118) of the isolates
were not typeable with the PCR method. We further observed that
among children <2 years of age the carriage rate was 74.6%, among
children between 3−5 years of age 75.2% and between 6 and 10 years
of age 59.2%. In 42 (26.8%) families, only one individual was colonized
representing 3 mothers and 39 children. In 91 families at least two
members were colonized, and 48 families were colonized with the same
serotype. In 28 of these 48 families, the serotype was shared between
the siblings, and in 22 families the serotype was shared by the mother
and at least one of the children.
Conclusion: This study shows high pneumococcal carriage rates in the
Warao mothers (36.2%) and in their children (70.2%). Of the 55 mothers
colonized with pneumococcus 22 mothers (40%) shared the serotype
with their children, indication transmission between mother and child
or vice versa. To determine the relationship between strains shared by
mother and child molecular epidemiological studies are under way to
determine the genotypes of the shared strains of these 22 families.
Interestingly, 33 mothers were colonized with serotypes not found in
their children, indicating a possible role of the mother bringing new
serotypes into the family.
P1355 Macrolide and multidrug resistance in Campylobacter
strains from acute gastroenteritis in childhood. Is there an
emergency? A 5-year retrospective review
E. Staikou, A. Makri, K. Papavasileiou, F. Vagia °, E. Papavasileiou,
A. Voyatzi (Athens, GR)
Objectives: 1. To investigate the prevalence of Campylobacter spp
(Cspp) in our paediatric hospital during a ﬁve year period (2005–
2009). 2. To compare the in vitro activities of novel and established
antimicrobials as well as the emergence of macrolide and multidrug
resistance.
Material and Methods: Out of 5200 feces specimen were
tested for common enteropathogens (Cspp 44.8%, Salmonella 47.5%.
Shigella 1.03%, E. coli EPEC 3.5%, Y. enterocolitica 2%, A. hy-
drophila 0.9% and Cl.difﬁcile 0.27%). Identiﬁcation and suscepti-
bility patterns were performed according to CLSI guidelines. MIC
values were determined by E-test and the examined agents were
as follows: Erythromycin/EM, Nalidixic acid/NA, Ampicillin/AM,
Amoxicillin–clavulanic/AMC, Tetracycline/TE, Ciproﬂoxacin/CIP, Gen-
tamicin/GM, Chloramphenicol/CL, Levoﬂoxacin/LE, Azithromycin/AZ,
Roxithromycin/RO, Clarithromycin/CH. C. jejuni ATCC 33560 served
as the control strain.
Results: Cspp were detected in 6.7% (348/5200) of the samples; 97.7%
were identiﬁed as C. jejuni (C.j) and 2.3% as C. coli. Two strains of C.j
were characterized as doylei subspecies. More than half of Cspp (52%)
derived from paediatric clinics while 48% from outpatients ones. Males
predominated over females (ratio 2:1). Isolates showed a signiﬁcant
resistance to NA 52%, CIP 48.9%, TE 33% followed by AM 12.35%,
EM 4.31% and AMC 1%.All strains were susceptible to gentamicin.
Only 7% of Cspp resistant to EM were susceptiple to CIP and LE. As
a whole, 65.52% of Cspp strains presented resistance while multidrug
resistance (2 classes of agents) was found in 49%. The predominant
resistance patterns (RP) in Cspp were determined as CIP/NA(RP) (52%),
TE/CIP/NA(RP) (14.9%), E/CIP/NA(RP) (0.57%), TE/CIP/NA/AM(RP)
(5.46%) and CIP/TE/AM/NA/E(RP) (1.43%) respectively. The ex-
amined Cspp strains showed the following MIC50/90 (mg/l):
EM:0.5/2(mg/l), AZ:0.047/0.25(mg/l), CH:0.50/3(mg/l), RO:1/3(mg/l),
AMC:0.75/1.5(mg/l), AM:4/48(mg/l), CIP:32/>32(mg/l), LE:8/32(mg/l),
TE:16/256(mg/l), CL:2/4(mg/l), NA:256/256(mg/l). Remarkably, a grad-
ual decrease in EM resistance was observed during the study period
(2005:8.2%, 2009:3.0%).
Conclusions: 1. Cspp remain a leading cause of bacterial diarrhoea.
2. Among macrolides AZ was found to be the most active, followed
by EM. Our data do not support emerging macrolide resistance.
3. Nevertheless, multidrug resistance poses a public health problem and
global antimicrobial susceptibility surveillance is urgent.
P1356 Randomized trial of cranberry juice for the prevention of
recurrences of urinary tract infections in children
J. Salo °, T. Kontiokari, M. Helminen, M. Korppi, T. Nieminen,
T. Pokka, M. Uhari (Oulu, Tampere, Kuopio, Helsinki, FI)
Objectives: Urinary tract infection (UTI) has a great tendency to recur
after the initial episode, and there is a great need for methods to prevent
UTIs. Previously we have shown, that regular drinking of cranberry juice
reduces the recurrence of UTIs in adult women. The objective of the
study was to evaluate, whether cranberry juice is effective in preventing
UTI recurrences in children who have had at least one episode of acute
UTI.
Methods: Between 2001–2008 a double-blind randomized controlled
trial was performed in seven pediatric departments. Altogether 263
children referred to pediatric departments because of UTI were
randomized to receive either cranberry juice (n = 129) or placebo
(n = 134) for six months. The patients were followed for 12 months,
and all their recurrences of UTIs were recorded.
Results: Twenty (16%) patients in the cranberry group and 28 (22%)
patients in the placebo group had at least one recurrence of UTI during
the 12 months follow up (difference between the proportions 6%, 95%
conﬁdence interval 16% to 4%, P = 0.21). There were altogether 27
episodes of UTI during the follow up in the patients in the cranberry
group and 47 in the patients in the placebo group. The cumulative inci-
dence rate of the recurrences did not differ between the groups (Fig. 1).
Figure 1. Time to the ﬁrst UTI recurrence during 12 months follow up
in patients receiving cranberry juice or placebo juice. The difference
between the groups was not signiﬁcant (P = 0.32).
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Conclusion: Cranberry juice did not reduce clinically signiﬁcantly
the recurrence of UTI in children who had had at least one acute
symptomatic UTI.
P1357 Norovirus outbreak in a hotel associated to a children’s club
A. Domenech-Sanchez °, C.I. Berrocal (Palma de Mallorca, ES)
Objective: To determine the aetiological agent responsible for a
gastroenteritis outbreak in a hotel located in northern Majorca.
Methods: We deﬁned a case as any guest or employee of the
hotel with acute onset of at least two of the following symptoms:
diarrhoea, vomiting, abdominal clumps, or fever (>37ºC). Environmental
samples, including food, drinking water, ice cubes and pool water
were analyzed for bacterial pathogens. Stool samples were analyzed
for intestinal pathogens, including members of Salmonella, Shigella,
Yersinia, Cryptosporidium and norovirus. In children samples rotavirus
and adenovirus were also analyzed.
Results: First case was described on June 18th. Ten of 685 guests were
affected: 5 adults, 4 children and 1 baby (attack rates were 1.06%, 2.4%
and 2.0%, respectively). Four of 90 employees were also affected (attack
rate 4.4%). When only the entertainment team was analyzed, attack rate
increased up to 66.7%, rising a 100% when working directly in the
children club of the hotel. The most frequent symptoms were vomiting
(93%), diarrhoea (50%), abdominal pain (29%) and fever (7%). The
duration of symptoms ranged from 1 to 4 days. Two children and 1
woman were hospitalized for hydration support, with good outcome.
Four stool samples from 4 patients were taken during the acute phase
of the gastroenteritis for culture. Genotype 2 norovirus was detected
in 2 of the 4 samples, 1 from an adult and 1 from a child, by the
ELISA test. All other pathogens tested negative. As for the environmental
samples, microbiological levels were acceptable in all cases, ruling out
their role as a source of infection. Once detected the problem related
to gastroenteritis cases a speciﬁc control plan was rapidly implemented.
Enhanced hand hygiene practices were established, and cleaning and
disinfection of frequently contacted surfaces (doorknobs, phone keys . . . )
with alcohol 70% were carried out. Common areas, especially toilets,
were also frequently treated with bleach. Special care was taken at the
children club and patients’ rooms. Last case was detected on June 24th.
Conclusions: Genotype 2 norovirus was the responsible for the
gastroenteritis outbreak. Immediate implementation of appropriate
measures allowed a rapid control of the outbreak.
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P1358 Infective endocarditis should be treated in experienced
centres
N. Ferna´ndez-Hidalgo °, B. Almirante, P. Tornos, M.T. Gonza´lez-Alujas,
A.M. Planes, A. Pahissa (Barcelona, ES)
Objectives: The aims of this study were: 1) to compare the
characteristics of adult patients with left-sided infective endocarditis (IE)
diagnosed and treated in a tertiary care hospital with those of patients
referred from other centres because of the same diagnosis or suspicion;
and 2) to establish the accuracy of diagnosis and treatment in referred
patients and their inﬂuence in outcome.
Methods: A prospective, observational cohort study was conducted at
Vall d’Hebron Hospital, Barcelona, Spain, a 1000-bed teaching hospital
with all the medical and surgical services and a referral centre for cardiac
surgery.
Results: Between January 2000 and September 2009, 337 episodes of
left-sided IE in 334 patients were treated in our hospital. Of them, 114
(34%) were transferred from 35 hospitals. As compared with patients
diagnosed in our hospital, transferred patients acquired IE less often
in relation with health care system (16.7% vs 38.1%, p< 0.0005);
were in better health before onset (Charlson index 1.44±1.65 vs
2.36±2.27, p< 0.0005); experienced more complications (94.7% vs
78.9%, p< 0.0005), including heart failure (68.4% vs 39%, p< 0.0005),
myocardial abscess (38.6% vs 18.8%, p< 0.0005), and acute renal failure
(69.3% vs 22.1%, p< 0.0005), underwent more surgeries (69.3% vs
22.1%, p< 0.0005) with a lower EuroSCORE (8.9±3.3 vs 10.6±3.7,
p< 0.0005); and experienced a non-statistically different rate of in-
hospital mortality (22.8% vs 31.4%, p=NS). Focused on the subgroup of
114 referred patients, only 52 (45.6%) initially received an antimicrobial
regime included in the American, European or Spanish guidelines. In
the remaining patients, the median days of incorrect treatment was 5
(IQR 3−10, range 1−42). Mortality was greater in patients without an
appropriate antimicrobial regime than in the other group (32.3% vs
11.5%, OR 3.65, 95%CI 1.34–9.96, p = 0.009). Moreover, in 42 out
of 114 patients (36.8%), an echocardiogram performed in our centre
demonstrated a complication no diagnosed at origin. Although not
statistically signiﬁcant, this group of patients experienced greater in-
hospital mortality than the other group (28% vs 18.8%, p = 0.24).
Conclusions: IE is a rare and severe condition that should be treated
in experienced centres by multidisciplinary teams. Mistakes in the
initial diagnosis and antimicrobial treatment are associated with greater
mortality.
P1359 Risk factors for precocious mechanical ventilation in
pneumococcal meningitis: a 12-year experience
P. Pagliano °, V. Attanasio, M. Rossi, F. Fraganza, G. Esposito,
M. Conte, F. Faella (Naples, IT)
Despite continuing improving in the ﬁeld of intensive cares and
infectious diseases therapy, pneumococcal meningitis still represents
a life-threatening disease. Aim of our study was to evaluate the
characteristics of patients with pneumococcal meningitis receiving
precocious mechanical ventilation in respect to those with less severe
disease presentation.
Materials and Methods: In a prospective study we enrolled adult
patients with pneumococcal meningitis admitted in our department
during a 12-year period. Epidemiological, clinical and laboratory ﬁndings
at admission were investigated. Statistical analysis was performed by
two-tailed c2 test, by Fisher exact test, and by Mann–Whitney U-test.
Data are expressed as median and Interquartile range(IQR).
Results: One-hundred-eighty-four cases of pneumococcal meningitis
were enrolled [median age 58 years (IQR 39−66), males 55%]. Eighty-
ﬁve (46%) patients received mechanical ventilation within 48 hours from
admission (Group A), among the remaining 99 patients (Group B) only
2 had to receive mechanical ventilation during the course of disease.
Condition leading to immunodepression were present in 40 (47%)
group A patients and 25 (25%) group B patients (p< 0.01; RR= 1.86;
95%CI 1.24−2.8). No signiﬁcant difference was observed in respect to
the incidence of cases with sinus or middle ear infection and in respect to
the time between ﬁrst symptoms evidence and admission to the hospital.
Penicillin susceptible strains of Streptococcus pneumoniae were cultured
in 28% of Group A patients and 17% of Group B patients. Laboratory
ﬁndings are reported in the table. Mortality rate was 48% for group A
and 2% for group B patients.
Discussion: Immunodepressed patients with pneumococcal meningitis
are at high risk for precocious respiratory insufﬁciency. Factors
commonly associated to higher meningitis mortality, such as low CSF
glucose, high CSF protein and low WBC counts are present more
frequently in cases with rapidly progressive disease needing precocious
mechanical ventilation. These evidences suggest a close relationship
between some delay in the setting of precocious immune response and
patients presentation and outcome.
Table 1. Laboratory ﬁndings in respect to the necessity of mechanical
ventilation*
CSF cells
(×103/mL)
CSF glucose
(mg/dl)
CSF protein
(mg/dl)
WBC
(×103/mL)
Platelets
(×103/mL)
Group A 1.8 (0.6−7.8) 7 (2−17) 643 (360–950) 17.4 (12−26) 151 (121–239)
Group B 3.5 (0.8−9) 12 (5−31) 498 (314–685) 21.3 (16−28) 229 (165–299)
P 0.13 0.045 0.018 0.008 0.07
* Data are expressed as median (IQR).
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P1360 Bacterial meningitis due to pericraneal ﬁstula in adults:
thirty years of experience
M. Bodro °, C. Cabellos, R. Verdaguer, L. Lopez, F. Gudiol, J. Acebes,
P. Fernandez Viladrich (Barcelona, ES)
Objective: To know the etiology, clinical characteristics and outcome of
bacterial meningitis due to pericranial ﬁstula.
Methods: In our hospital all cases of bacterial meningitis are routinelly
recorded in a 120 variables protocol. Pericranial ﬁstula was diagnosed
when pts referred patent rhino or otoliquorrhachia, when a bone defect
was present in a CT scan or MRI, when isotopic cisternography revealed
a CSF leak or with a history of neurosurgery trough nose or otologic
surgery or cranial trauma. CSF and blood cultures were performed
by standard methods. Early post surgical ﬁstula was deﬁned as that
presenting in the ﬁrst 20 days after surgery and late ﬁstula as cases
presenting later. Traumatic cases were classiﬁed in <1 yr, 1−10 yrs and
>10 yrs according with the time of traumatic event.
Results: Between 1977 and 2008, 1256 episodes of bacterial meningitis
in adults have been treated in our hospital. Among them 141 episodes
in 129 pts were due to pericranial ﬁstula. Pericranial ﬁstula related
episodes were present in 94 men (66%) and 47 women (34%). Mean
age was 46.3 (16−93). Fistula was due to previous surgery in 60
episodes (42%), 31 (51%) due to early ﬁstula and 29 (49%) to late
ﬁstula. Previous trauma was present in 67 (47%), 1 yr before in
31 (46.2%), 1 to 10 yrs in 20 (29.8%) and >10 yrs in 16 (24%). 38
episodes were recurrent meningitis. 2 pts presented 3 episodes. Etiology
was S. pneumoniae in 63 (44%), H. inﬂuenzae in 17 (12%), other
streptococcal in 11 (8%), Neisseria spp. in 2 (2%), anaerobical in 1 and
unknown in 45 (32%). On admission fever was present in 115 (81%),
headache in 113 (80%), nausea/vomiting in 86 (61%), GCS< 8 in
30 (21%), seizures in 19 (13%). Blood cultures were positive in 57 (40%)
and CSF culture in 80 (56%). Sequelae were present in 7 (5%). Overall
mortality was 8 (5.6%) (4 due to early neurological causes, 1 due to late
neurological causes and 3 due to not related causes). Reparative surgery
was performed in 52 pts. Among pneumococcal meningitis episodes a
comparison was made in mortality among episodes due to ﬁstula or
other focus. Mortality was signiﬁcantly lower in ﬁstula related episodes
5/63 (8%) than in other pneumococcal episodes 56/200 (28%), p< 0.05.
Conclusion: Bacterial meningitis related to pericranial ﬁstula is still due
mainly to S. pneumoniae and H. inﬂuenzae. Trauma or neurosurgery may
be a remote fact. Prognosis is good with a very low mortality and special
efforts should be done to repair the ﬁstula to avoid further episodes.
P1361 Epidemiological changes in community-acquired bacterial
meningitis: 20 years of follow-up
A. Madurga °, I. Sanfeliu, I. Pons, M. Lloret, P. Ferreros, M. Espasa,
S. Capilla, D. Fontanals (Sabadell, ES)
Objectives: The aim of this study is to know the aetiology and the
epidemiological changes of community acquired bacterial meningitis
in our centre over the past 20 years. To review the incidence of
microorganisms included in the vaccination calendar and its variation
in this period of time.
Methods: We reviewed 283 community acquired meningitis cases
between 1990 and 2009. Hospital Parc Taulı´ has an adult as well as a
paediatric reference area that varies from 380300 inhabitants in 1990 to
414080 inhabitants in 2009. Serotypes and serogroups of microorganisms
were studied by The National Reference Centre of Microbiology in
Majadahonda (Spain).
Results: The aetiology was: N. meningitidis 113 cases (39.9%),
S. pneumoniae 74 (26.1%), C. neoformans 17 (6%), L. monocytogenes
16 (5.7%), H. inﬂuenzae 16 (5.7%), S. agalactiae 14 (4.9%), other
microorganisms 33 (11.9%). Concerning H. inﬂuenzae serotype b, all
cases were children <5 years old, of which 62.5% were male patients. It
showed an incidence rate of 8.6/105 inhabitants in 1994 that decreased
successively since the introduction of the conjugated vaccine until its
complete eradication. There were three cases of H. inﬂuenzae among
adult patients non b serotype. As to N. meningitidis, it was present over
the whole age spectrum and it was the leading cause of meningitis in
young adults. It was slightly more common among women, 51.3%, and
the incidence rate decreased from 6.2/105 before the vaccination period,
to 0.5/105 in 2009. B serogroup was the most prevalent until 1997,
>50% of the cases. During 1998 and 1999 C serogroup was present in
50% of the cases. After the introduction of the conjugated vaccine in
2000, serogroup C decreased until its complete disappearance. Finally,
S. pneumoniae was more prevalent among adult patients of which 54.7%
were men. Regarding children, 75% of them were younger than 5 years.
The incidence rate showed a similar pattern, from 1.3/105 to 1.1/105.
Serotypes 19A, 7F and 24 appeared after the vaccine introduction. Since
2002, 3 children had meningitis, which serotypes were 33, 7F and 14.
Conclusions: After the introduction of conjugated vaccines, we
observed an important decrease of meningitis due to H. inﬂuenzae and
N. meningitidis. Nevertheless, meningitis due to S. pneumoniae remained
stable in time, with variations between serotypes depending on the period
of time.
P1362 Clinical features and prognosis of Escherichia coli vertebral
osteomyelitis. A descriptive study of 28 cases
M.E. Jime´nez-Mejı´as, J.D. Ruı´z-Mesa, E. Garcı´a-Cabrera °, A. Plata,
J. Valencia, M. Delgado, J. Ma´rquez-Rivas, J.D. Colmenero-Castillo
(Seville, Ma´laga, ES)
Objectives: To study the epidemiologic, clinical and diagnostic features,
treatment and prognosis of vertebral osteomyelitis (VO) caused by
Escherichia coli.
Patients and Methods: Multicentric, prospective, and descriptive study
of 534 patients diagnosed of VO between January 1983 and October
2009. Inclusion criteria: 1) spinal inﬂammatory pain, or fever and spinal
pain on physical examination; 2) compatible imaging ﬁndings with VO;
and 3) aetologic diagnosis.
Results: Sixty-nine patients (13%) were diagnosed of VO caused by
gramnegative bacili (GNB). E. coli was the responsible agent in 33
cases (48% of VO by GNB, and 6.2% of total VO). Five patients with
polymicrobial isolates were excluded. Seventeen (61%) were females.
Mean age: 63.9 (50% >65 years old). Ten (36%) patients had underlying
diseases (5 diabetes, 3 inmunosuppression, 2 liver cirrhosis, 2 others).
Primary infection foci was recorded in 23 (82%) cases: 17 genitourinary
tract, 3 digestive, and 4 others. Previous bacteremia in 13 (46.4%).
The vertebral levels involved were: 6 thoracic (21%), 2 dorso-lumbar,
15 lumbar (54%) and 5 (18%) lumbo-sacral. The mean duration of
symptoms prior to diagnosis was 51.4 days (r:7–185). Clinical features:
back pain 28 cases (100%), inﬂammatory pain 25 (89%), fever 24 (86%),
constitutional symptoms 20 (71%), neurological deﬁcits 19 (68%),
sciatic pain 16 (57%). All cases had raised ESR, 85% high levels of
C-reactive protein, and 50% elevated leucocyte count. Blood cultures
were positive in 50%, vertebral biopsies in 10 of 12 cases (83%), adjacent
infectious foci cultures in 75% (6 of 8)and urine cultures in 54% (12
of 22). Sixteen patients (73%) presented paravertebral masses, 12 (43%)
epidural abscesses, and ﬁve (18%) psoas abscesses. All patients were
treated with antimicrobial agents (mean:64 days, r:30–144 d.) and 11
(39%) required surgical treatment. Two patients (7%) showed therapeutic
failures (one medical and one surgical failure). Twelve cases (42.8%)
presented severe functional sequelae: 11 pain and one paraplegia. One
patient died, but the death was not related with VO.
Conclusions: 1) E. coli is the microorganism more frequent isolated in
VO by GNB. 2) Genitourinary tract infections and previous bacteremia
by E. coli are the principal predisposing factors. 3) Blood, adjacent
infectious foci and vertebral biopsy cultures showed high diagnostic
yields. 4) Paravertebral masses and epidural abscesses and severe
functional sequelae are frequents.
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P1363 Clinical and microbiological features of pyogenic liver
abscess. A multicentre study from Spain
F. Mateos Rodrı´guez °, I. Terrancle, G. Peralta, L. Fuentes,
J. Pe´rez-Arellano, P. Geijo, F. Marcos, M. Garcı´a, J. Blanch Sancho,
E. Martı´nez Alfaro for the Infectious Diseases Group of the Spanish
Society for Internal Medicine (SEMI)
Objectives: The aim of the present study was to examine our experience
over pyogenic liver abscess (PLA).
Methods: Multicenter and retrospective review of the PLA diagnosed in
six Spain’s Hospitals during seven years were studied. Statistical analysis
was performed with the SPSS software package.
Results: A total of 175 patients with PLA were managed. PLA was
more common in males (61%). The median age was 65 (range 27−91).
Concomitant medical problems included diabetes mellitus in 33 patients,
neoplasm in 7 and transplantation in 2 (1 kidney and 1 liver). Most
patients presented with non-speciﬁc clinical and biochemical features.
Pre-admission, patients were symptomatic for a median 16 days, with
the most common symptoms and signs being fever (85%) and abdominal
pain/tenderness (70%). A raised ESR (median 81, range 2–159) was
the most common laboratory found in about 86%. Ultrasonography was
not as sensitive as computed tomographic scans in detecting abscesses.
Single lesions were found in 119 patients, multiple lesions in 56.
PLA occurring more frequently in the right hepatic lobe (70%). The
microorganism responsible was identiﬁed in 126 (71%) of the cases, with
enterobacteria being the greatest number isolated. 52% of the positive
abscess cultures were polymicrobial. Escherichia coli was the most com-
mon etiological agent detected in cultures of blood and abscess aspirates.
E. coli was cultured from the blood in 24 patients and 31 on abscess
aspirate cultures. Abscesses were classiﬁed by the presumed route of
hepatic invasion: (a) biliary tree (65, 37%), (b) portal vein (18, 9.5%),
(c) hepatic artery (18, 9.5%), (d) direct extension from contiguous focus
of infection (16, 8.6%) and (e) cryptogenic (58, 33%). All patients were
treated with intravenous antibiotics. The most commonly used antibiotic
combination was a cephalosporin 3d G with metronidazole. 112 (63%)
had both antibiotics and radiologically guided percutaneous catheter
drainage. All these patients had abscesses with diameters measuring 2
or more cm. Only 24 (14%) need surgery; 16 because another illness
who required surgery, 5 because of deterioration despite antibiotics and
drainage and 3 because of failure of percutaneous drainage.
Conclusion: PLA require a high index of suspiction for early diagnosis.
Imaging techniques provide the main support in both the diagnosis
and treatment. When appropiate theraphy in the form of antibiotics in
combination with percutaneous drainage is administered, morbility and
mortality are low.
P1364 Prevalence of invasive meningococcal subtypes in Bilbao
after immunization
M.J. Unzaga, C. Ezpeleta, J.A. Alava, I. Gerediaga, M. Sanchez,
R. Cisterna ° (Bilbao, ES)
Objectives: In 1990 an increasing number of serogroup C meningo-
coccal strains were observed in Basque Country. These strains were
characterized as C:2b: P1.2,5. As results a mass immunization campaign
was conducted in 1997. The aim of our study was to determine
the serotypes of invasive meningococcal disease nowadays, years after
establishing vaccination.
Methods: The strains isolated from blood a cerebrospinal ﬂuid in our
hospital in 2008 and 2009 were sent to the Spanish Reference Laboratory
for serotyping with monoclonal antibodies.
Results: The results of 18 meningococcal strains were analyzed. One
strain was C serogroup C:2a:P1.5 and 17 strains were B serogroup.
Completely serosubtypable were 10 strains: [seven: B:1:P1.14, one:
B 4:P1.2,5 one B:2a:P1.5, one B:15:P1.15], Partially serosubtypable
were ﬁve strains: [three, B 1:NT, and one respectively B:4:NT, and
B:NT:P1.14] and B non-serosubtypable two strains. The outcome of
invasive disease was not death whatever the serogroup involved.
The most prevalent strain B:1:P1.14 was not involved in complex
diseases in either case. The C serogroup was isolated from a male 39
y-old and B:2a: P1.5 from another male 33 y-old. The disease was severe
in both cases with complications as pericardial and pleural ﬂuid, internal
malleolus abscess in C serogroup strain and arthritis in B serogroup
strain. The only strain B: 15: P1.15 was involved in the development of
a more severe disease with multiple organ failure. The two strains caused
by B non-serosubtypable also developed complications such as arthritis
and leg edema. The patients were an adult and a child respectively.
No strain was resistant to penicillin, while 11 of them showed
intermediate sensitivity: 4 strains B:1:P1.14, the three strains B 1:NT,
the two strains B non serosubtypable, B:15:P1.15 and the B 4:P1.2,5
strain. All of isolates were susceptible to cefotaxime, rifampin and
ciproﬂoxacin.
Conclusions: The most prevalent meningococcal subtypes in our
hospital is B:1:P1.14. The disease is not severe. The isolation of
B:2a:P1.5 and C:2a:P1.5 strains from sporadic cases coincide with
meningococcal C vaccination as in other regions and suggest that strong
immunological pressure might be selecting these types of strains that
evade the immune response produced by the vaccine. These strains
behave more aggressive than other serotypes.
P1365 Factors inﬂuencing the length of hospitalization of elderly
patients with cellulitis
D. Kofteridis, A. Valachis, D. Dimopoulou °, M. Christofaki, S. Maraki,
L. Sifaki, G. Samonis (Heraklion, GR)
Objectives: Cellulitis in the elderly can be a serious disease with
prolonged hospitalization and considerable cost. The aim of the study
was to determine factors signiﬁcantly associated with the length of
hospitalization of elderly patients with cellulitis.
Patients and Methods: All records of patients aged >65 years,
admitted to the department of Medicine of the University Hospital of
Heraklion, Greece, diagnosed with cellulitis from January 2002 through
July 2009 were retrospectively reviewed. Diagnosis was deﬁned using
established criteria. Patients with more than one episodes of cellulitis
were considered to have recurrent disease. Patients were classiﬁed into
2 groups according to the length of hospital stay: those discharged in
<11 days and those hospitalized for >11 days.
Results: A total of 107 episodes of cellulitis occurring in 102 patients
have been evaluated. Fifty seven (56%) were women. Median age was 77
years (range: 65–102). The most common comorbidities were diabetes
mellitus (45 patients; 44%), heart failure (29; 28%), chronic obstructive
pulmonary disease (17; 17%), renal failure (12; 12%), obesity (9; 9%)
and cancer (8; 8%). Portals of entry were known in 47 episodes (44%),
with trauma being the most frequent (18 episodes; 38%), followed by
chronic ulcer in (9; 19%). The predominant local predisposing factors
were venous insufﬁciency (16; 15%), and presence of oedema (15; 14%).
The most commonly infected site was the lower extremities (96 episodes;
90%), followed by the trunk (6; 6%), the face (4; 3%), and the upper
extremities (1; 1%). Blood cultures were positive in 8 episodes (7.5%).
The causative organisms were Streptococcus viridans in 2, Streptococcus
group G in 2, Streptococcus group A in 1, Staphylococcus epidermidis
in 2, and Staphylococcus saprophyticus in 1. The median length of
hospitalization was 6 days, with a range from 2 to 60 days. Eighty-
six patients (80.4%) were hospitalized for <11 days and 21 (19.6%) for
more. Outcome was favourable in all cases. Logistic regression analysis
showed that venous insufﬁciency (P = 0.002) and duration of symptoms
for >3 days prior to admission (P = 0.043) were independently related to
prolonged hospitalization.
Conclusions: The present study showed that venous insufﬁciency and
duration of symptoms for >3 days prior to admission are independently
associated with prolonged hospitalization in elderly patients with
cellulitis.
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P1366 Infectious bursitis: short-course adjuvant antibiotic therapy
is not a risk factor for recurrence in adult hospitalized
patients
A. Huttner °, I. Uc¸kay, D. Lew (Geneva, CH)
Objectives: No evidence-based recommendations exist for the manage-
ment of infectious bursitis. We examined epidemiology and risk factors
for recurrence of septic bursitis. Speciﬁcally, we compared outcome
in patients receiving bursectomy plus short-course adjuvant antibiotic
therapy (7 days) to that of patients receiving bursectomy plus longer-
course antibiotic therapy (>7 days).
Methods: Retrospective study of adult patients with infectious olecranon
and patellar bursitis requiring hospitalization at Geneva University
Hospital from January 1996 to March 2009.
Results:We identiﬁed 343 episodes of infectious bursitis (237 olecranon,
106 patellar). Staphylococcus aureus predominated among the 256 cases
with an identiﬁable pathogen (85%). 312 cases (91%) were treated
surgically, 142 (46%) with bursectomy and closure in one-stage, 146
in two-stage. All received antibiotics for a median duration of 13 days
with a median intravenous component of 3 days. Cure was achieved
in 293 (85%) episodes. Total duration of antibiotic therapy (OR 0.9,
0.8−1.1) showed no association with cure. In multivariate analysis, only
immunosuppression was linked to recurrence (odds ratio 5.6, 95%CI
1.9–18.4). Eight to 14 days (OR 0.6, 0.1−2.9) or >14 days of antibiotic
treatment (OR 0.9, 0.1–10.7) were equivalent in outcome to only 7
days, while the duration of intravenous therapy also had no bearing on
recurrence outcome (OR 1.1, 1.0−1.3).
Conclusions: In severe infectious bursitis requiring hospitalization,
adjuvant antibiotic therapy may be limited to seven days in non-
immunosuppressed patients.
P1367 Disease spectrum and diagnostic usefulness of needle
aspiration biopsy in cervical lymphadenopathy
Y.J. Kim °, K.W. Hong, S.I. Kim, S.H. Wie, Y.R. Kim, M.W. Kang (Seoul,
KR)
Objective: To evaluate the disease spectrum in patients with cervical
lymphadenopathy and diagnostic utility of ﬁne needle aspiration
biopsy (FNAB) in various benign, tuberculosis (TB) and malignant
lymphadenopathy.
Methods: From January 2003 up to December 2008, we reviewed
retrospectively medical records of 447 adult patients with cervical
lymphadenopathy in Seoul St. Mary’s Hospital of Korea. When histologic
diagnosis through FNAB was relevant to the histologic ﬁndings via
excision biopsy and clinical course, it was regarded as “accurate”.
Results: Three hundred ﬁve (82 male, 223 female) patients were
performed FNAB among a total of 447 patients with cervical
lymphadenopathy. The mean age was 36.7±14.5 years. Among the 305
FNABs, adequate material was obtained in 289 cases (96.4%). The
histologic diagnoses were non-speciﬁc lymphadenitis in 161 (55.7%)
patients, TB in 63 (21.8%) patients, Kikuchi’s disease in 29 patients
(10%) and malignancy in 11 cases (3.8%). It was accurate at 98% of non-
speciﬁc lymphadenitis and Kikuchi’s disease, 63% of TB lymphadenitis,
and 90% of malignancy. Previous TB evidence (past history of TB or old
TB scar on chest X-ray) was the signiﬁcant predictors as an inaccurate
diagnosis of FNAB in patients with TB lymphadenopathy (p = 0.001).
There were no FNAB-related complications.
Conclusion: The disease spectrum of patients with cervical lym-
phadenopathy in Korean patients showed somewhat different from that
of European, African, and American patients. Tuberculosis is still
important cause of cervical lymphadeopathy in Korea. FNAB is a
useful procedure for diagnosis of cervical lymphadenopathy. However
in patients with previous TB evidence, diagnostic usefulness of FNAB
has to be reassessed and early excisional procedure was considered to
perform.
P1368 Fine needle aspiration biopsy in the diagnosis of lym-
phadenopathy in children in a hospital, Kampala, Uganda
S. Samuel °, L. Robert, N. Betty (Masaka, Kampala, Rakai, UG)
Objectives: To evaluate the efﬁcacy of ﬁne needle aspiration biopsy
(FNAB) in diagnosis of lymphadenopathy in children and determining
the common causes of lymphadenopathy in children.
Methodology: A comparative cross sectional study was done with 94
children 12 years and bellow. FNAB and excision biopsy were done
on one lymph mode from each patient and the histopathological and
cytopathological specimen were examined by pathologists, sensitivity,
speciﬁcity, PPV and NPV were calculated as well as the inter-rater
agreement by the Kappa co-efﬁcient.
Results: A high proportion of children were diagnosed with lym-
phadenopathic kaposi’s sarcoma (14.6%), though majority revealed non-
speciﬁc lymphadenitis (60%). Tuberculosis was also an important cause
of lymphadenopathy (15.7%). Sensitivities were low (0 to 34.1%), but
speciﬁcities were high (85.3 to 97.7%). The highest values being for
diagnosis e.g “non-speciﬁc lymphadenitis”. Similarly PPV was low (0–
94.9%), where as NPV was high (86.0–97.6%). The kappa co-efﬁcient
was signiﬁcant only for “non-speciﬁc lymphadenitis”.
Conclusion: Kaposi’s sarcoma is proving to be an increasingly important
cause of lymphademopathy in children. FNAB proved to be only useful
in diagnosing non-speciﬁc lymphadenitis.
P1369 RIFLE classiﬁcation as predictive factor of 7-day mortality
in severe sepsis patients
D.W. Park °, B.C. Chun, J.W. Sohn, H.J. Cheong, J.Y. Choi, H.J. Choi,
Y.H. Choi, H.Y. Kim, J.S. Eom, S.I. Kim, Y.G. Song, K.R. Peck,
Y.S. Kim, J.M. Kim, M.J. Kim (Ansan, Seoul, Suwon, Wonju, KR)
Objectives: Severe sepsis and septic shock, often complicated by acute
kidney injury (AKI), are the most common causes of mortality in
intensive care units (ICU). RIFLE, a newly developed international
consensus classiﬁcation for AKI, deﬁnes three grades of severity − risk
(class R), injury (class I) and failure (class F). This study investigates the
outcomes of patients with severe sepsis and elucidates the association
between prognosis and RIFLE classiﬁcation.
Methods:We performed retrospective analysis of prospectively collected
data from the Korean Sepsis Registry System (KSRS). Community
acquired severe sepsis patients were registered in KSRS from May 2005
to December 2008 by 12 teaching hospitals in Korea. Demographic,
clinical, laboratory data were recorded for analysis as predictors of
mortality and infectious characteristics of severe sepsis patients.
Results: A total of 1192 severe sepsis patients were enrolled in
KSRS. 7-day mortality rate was 12.4% (147/1183). Acute kidney
injury occurred in 62.5% (736/1178), with maximum RIFLE class R,
class I and class F in 18.8%, 20.1% and 23.6%, respectively. 7-day
mortality was signiﬁcantly associated with male, underlying cancer,
primary bloodstream infection, number of organ failure, Charlson‘s
score, Acute Physiologic and Chronic Health Evaluation II (APACHE
II) score, sequential organ failure assessment (SOFA) score and RIFLE
classiﬁcation (p< 0.05). The severity of RIFLE classiﬁcation correlated
with number of organ failure, Charlson‘s score, APACHE II score,
SOFA score, and 7-day mortality. The area under receiver-operator
characteristic curve (AUROC) analysis veriﬁed SOFA score, APACHE
II score and RIFLE classiﬁcation had signiﬁcant discriminatory power
in comparison of prognostic scoring systems, with AUROC of 0.75, 0.73
and 0.61, respectively.
Conclusion: RIFLE classiﬁcation was signiﬁcantly associated with 7-day
mortality but it is less useful than other scores.
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P1370 Spectrum of pathogens causing acute rhinosinusitis in
young adults and their antimicrobial susceptibility in
prospective study using invasive technique
R. Kozlov °, I. Otvagin, A. Kolosov (Smolensk, RU)
Objectives: Majority of published reports on etiology of acute
rhinosinusitis use culture of nasal lavage samples and/or biopsy
specimens of anterior ethmoidal mucosa. Historically, sinus aspirate was
considered to be a ‘gold standard’ for microbiological diagnosis, though
currently it is rarely used in many countries. The aim of our study was
to determine the spectrum of pathogens causing rhinosinusitis and their
susceptibility to the most commonly used antimicrobials.
Materials and Methods: Sinus aspirates were obtained from 112
patients with acute rhinosinusitis aged 19.4 + 1.4 years and transported
within 2 hours to the single microbiological laboratory. Cultures
were performed both in aerobic with increased CO2 concentration
and anaerobic conditions, Susceptibility was determined used broth
microdilution technique. Interpretation was performed using CLSI
criteria (2009) were used for determination of susceptibility.
Results: Positive cultures were obtained in 62 (55.4%) of cases. Single
pathogen was isolated in 90.3% of cases. The most common bacteria
was H. inﬂuenzae (51.6%), followed by S. pneumoniae (21.0%) and
S. pyogenes (11.3%). Susceptibility of H. inﬂuenzae to amoxicillin,
amoxicillin/clavulanate and levoﬂoxacin was 94%, 100% and 100%,
respectively. S. pneumoniae was susceptible to penicillin, erythromycin
and levoﬂoxacin in 92%, 100% and 100% of cases.
Conclusion: In our study, H. inﬂuenzae was found to be the most
prevalent pathogen, followed by S. pneumoniae and S. pyogenes with no
M. catarrhalis isolated. In general, all predominant pathogens retain high
percentage of susceptibility to the most commonly used antimicrobials
in acute rhinosinusitis.
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P1371 The goat connection − a retrospective cohort study
investigating the link between an identiﬁed veterinary
source of Q fever and subsequent outbreak in humans
V.H. Hackert °, H.L. ter Waarbeek, N.H. Dukers-Muijrers, R. Boesten,
E. Leclercq, C.J. Hoebe (Geleen, NL)
Once a sporadic disease, Q fever has turned into an epidemic in the
Netherlands since 2007, possibly linked to intensive dairy goat farming.
Lack of ﬁrm evidence to support this assumption has impeded effective
control measures. We are ﬁrst to investigate a veterinary point source
of Q fever in relation to subsequent human cases, in a region hitherto
virtually Q-fever free, presenting the ﬁrst out of several studies to deliver
evidence for a causal link and assess routes of primary and secondary
transmission and geographical spread of Q fever.
We received veterinary notiﬁcation of a dairy-goat farm outbreak in
March 2009. Based on contact tracing, we performed a retrospective
cohort study. Primary cases were farm contacts seropositive for phase II
IgM to C. burnetii. Secondary cases were household members of primary
cases unexposed to the affected farm and seropositive with self-reported
symptoms of Q fever. All contacts had a questionnaire on risk factors and
transmission. We calculated attack rates (AR) and associations between
outcome and risk determinants. Cases with no link to the farm, living in
its wider surroundings, were notiﬁed to us by physicians in subsequent
months.
Preliminary data show an AR of 100% in farm workers (25/25; 3
proved immune; response 68%(28/36)). AR in farm visitors, including
two infected public health ofﬁcials who had visited the farm on one
short occasion, was 67% (20/30; response 94% (32/34)). High AR are
congruent with high concentration of Coxiella found in environmental
farm samples at 1 km. Primary contacts had mild symptoms, not
requiring hospital admission. 8 of 17 secondary contacts were positive.
An additional 206 cases were notiﬁed from neighbourhoods up to 12
km from the farm in the months following. Mean age in this group was
signiﬁcantly higher (49 years) compared to farm contacts (31 years),
and so were admission rates and symptom severity. Most cases in this
group occurred in the 3 months following veterinary notiﬁcation, when
removal of manure from the affected premises was banned.
Contact tracing and active case ﬁnding in farm workers and visitors at
the moment of a veterinary outbreak of Q fever yielded an unexpectedly
high attack rate. Even short-term visits seem to carry high risk of
infection. Secondary transmission through contaminated fomites was
frequent. Aerogenic spread seems the primary route of transmission in
cases with no link to the farm. Disease seems more severe in non-farm
cases.
P1372 The role of Clostridium difﬁcile culture in colo-rectal surgery
S.N. Reddy °, G. Fewster, B.J. Mander, R.G. Wilson, I.R. Poxton
(Edinburgh, UK)
Objectives: Clostridium difﬁcile Infection (CDI) has become a growing
concern world-wide with an increased reported incidence among patients
admitted to surgery. Our aim was to review prospectively the number
of colorectal surgical in-patients who had a delayed diagnosis or were
undiagnosed using current testing practices from December 2007 to
January 2009 inclusive.
Methods: All faecal samples, submitted to Lothian University Hospitals
Division, were processed in a single enteric laboratory following national
guidelines − all hospital diarrhoeal in-patient samples from those aged
1year and above were tested for C. difﬁcile toxins A and B by enzyme
immunoassay(EIA). The faecal samples submitted to the laboratory from
colorectal surgical symptomatic in-patients were reclaimed for toxigenic
culture (culture on selective media and EIA).
Results: 632 samples, from 483 patients (median age 71 years, ranging
from 18–100 years) were reclaimed for toxigenic culture. Of these 105
samples (16.6%) were found by the laboratory to be positive by EIA.
Following toxigenic culture a further 72 samples (11.4%) were identiﬁed
as positive. 38 patients, who were symptomatic at the time of testing,
were therefore not identiﬁed with CDI during their admission. The
diagnosis of a further 17 patients was delayed by a median period of
6 days (range 1−19 days) prior to C. difﬁcile toxin detection, from
the time of their ﬁrst negative sample being assessed to the ultimate
positive sample, with a median of 3 (range 2−5) samples sent prior to
detection. These patients were found to be toxigenic culture positive on
their ﬁrst sample. 32% of the patients whose diagnosis was delayed or
not conﬁrmed had undergone major colorectal surgery. Seven samples
found to be toxin positive by the lab were culture negative.
Conclusion: CDI diagnosis or recognition at present may be delayed,
as with current national guidelines CDI detection is based solely upon
C. difﬁcile toxins A+B EIA. Current resources cannot support toxigenic
culture for all suspected faecal samples, however this therefore has
implications in regards to delayed treatment, further patient management
and infection control procedures. This cohort of patients is at high-risk
for CDI and a provision should be available for toxigenic culture if a
high index of clinical suspicion persists via multidisciplinary discussions
between the clinical team and microbiology, whilst taking into account
toxin positive-culture negative samples.
P1373 Staphylococcus simulans as an authentic pathogenic agent
of osteoarticular infections
M. Mallet, X. Lemaire °, C. Loiez, H. Melliez, Y. Yazdanpanah,
E. Senneville (Tourcoing, Lille, FR)
Objectives: To evaluate the role of Staphylococcus simulans (Ss) in
osteoarticular infections (OAIs) and determine their main characteristics.
Methods: A search in the database of the microbiology laboratory
of Lille’s regional university hospital and Tourcoing’s hospital was
performed. Only results from blood, bone, orthopedic devices cultures
were taken in account for hospitalized patients between January 2004
and January 2009. We considered cases in which Ss was the only
bacteria isolated in all of the patient’s biological samples with clinical and
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biological signs of infection. For patients with complete medical records,
we recorded their age, sex, and if they lived in a rural environment,
the localization of the infection, the presence of orthopedic devices,
antibiotic susceptibility, the antibiotic therapy and ﬁnally the clinical
outcome.
Results: 7 cases of OAIs due to Ss were recorded, with 6 cases related
to orthopedic devices infections. The median age was 48 years old and
3 patients lived in rural areas. All strains were susceptible to methicillin.
Orthopedic device infections were localized in each case on the lower
limbs and occurred less than one year after the initial procedure in 4
cases (3 and 20 years afterwards for the other cases). In 4 cases the initial
pathology was traumatic (with an initially open wound for one patient
in whom the infection occurred 3 years after). In 5 out of 6 patients,
Ss was isolated in per operative samples exclusively, and in one patient
only blood cultures were positive. For the last patient who was a farmer,
Ss was isolated in blood cultures. This patient had a spondylodiscitis,
and chronic foot ulcers due to gout disease were suspected to be the
origin of the infection. All patients were healed after a mean follow-up
of 12±3 months. Orthopedic devices were removes in 5 of the 6 patients
concerned. The combination of rifampicin plus levoﬂoxacin was used in
5 patients for duration of 3 months.
Conclusion: The present data suggests that even though Ss remains
rarely observed in clinical pathology, its role in OAIs, especially in case
of infected orthopedic device, is not exceptional. In our group of patient,
almost half had a contact with a rural environment. As for the antibiotic
treatment, the combination of rifampicin and levoﬂoxacin seems to be
an effective strategy, regarding our clinical results.
P1374 Surprising change in diagnosis and treatment of focal liver
lesion
L. van Dommelen °, J.H. Stoot, V.C. Cappendijk, M.A. Abdul Hamid,
F.F. Stelma, L.M. Kortbeek, A.M. Oude Lashof (Maastricht, Bilthoven,
NL)
Case report: A 55-year-old female, with a history of multiple myxoid
liposarcomas, presented at our hospital with cervical pain. Metastases in
the cervical spinal column were suspected. MRI showed no abnormalities
of the spinal column and FDG-PET-scan was negative. However,
the diagnostic abdominal CT-scan showed seven hypodens lesions in
the liver, suspect for metastases, not present 6 months earlier. Her
liver enzymes were normal. After two chemotherapy cycles, partial
hepatectomy was performed, leaving four lesions in situ.
Pathologic examination of the liver revealed three circumscribed nodules
with central necrosis, a peripheral wall of histiocytes and containing
foreign material, resembling Echinococcus structures. Echinococcus
granulosis serology was borderline positive and therefore isolated DNA
from unpreserved resected liver material was used for a nucleic acid
ampliﬁcation test and found positive for E. multilocularis (Em) using
two targets (CO1 and NADH) and sequencing. Genotyping is in progress.
After this diagnosis, our patient started with albendazole 400mg twice
daily.
Patient’s travel history was only signiﬁcant for three short holidays to
Switzerland, Italy and Austria in 2006 and 2007. She was not extensively
exposed to forest environment, did not consume forest fruits, had no
contact with animals, did not work in the garden and bought her fruits
and vegetables in regular supermarkets.
Discussion: This case displays two remarkable ﬁndings. Firstly, the PET-
scan-negative, multiple, circumscript, hypodens lesions in the liver seen
at regular CT in our patient are not classical for Em and represents a
highly unlikely diagnosis in our region. Taking in account our patient’s
history, it is therefore reasonable to suspect metastases.
Secondly, our patient’s history did not reveal behaviour associated with
acquiring Em (like hunting and gardening) and only undertook short
holidays to known endemic areas. Em however, is also prevalent in Dutch
foxes and surveillance data have shown that Em is increasing its range
by 2.7 kilometres per year in Northern direction. Considering duration
of exposition, domestically acquired Em therefore seems most likely.
Conclusions: This patient probably represents the ﬁrst case of
Echinococcus multilocularis acquired in The Netherlands. Future
research has to reveal whether Em is an emerging pathogen in Western
Europe or whether we are facing isolated cases.
P1375 Emerging Clostridium difﬁcile infections in neonatal piglets
in the Netherlands
E.C. Keessen °, L. Lipman, L.A. van Leengoed, D. Bakker, E.J. Kuijper
(Utrecht, Leiden, NL)
Objectives: Clostridium difﬁcile infections (CDI) are emerging as a
cause of neonatal diarrhoea in piglets. Isolates of piglet C. difﬁcile type
078, which is considered the predominant ribotype in pigs, have a close
genetic relatedness with human isolates of type 078. In humans with
CD C. difﬁcile type 078 is currently the third most common strain in the
Netherlands and Europe. There are no surveillance on the prevalence
of C. difﬁcile in pigs in the Netherlands. The aim of this study was
to investigate the presence and distribution of various C. difﬁcile PCR
ribotypes in piglets on farms with persistent problems with neonatal
diarrhoea.
Methods: At eighteen pig breeding farms with persistent problems with
neonatal diarrhoea, samples were taken from piglets from one to seven
days old from at least three different litters. In total, 98 faecal samples
were collected from piglets with diarrhoea and 87 faecal samples from
piglets without diarrhoea.
All samples were cultured on C. difﬁcile agar (bioMe´rieux) with
ethanol shock pre-treatment and anaerobic incubated for 48 hours at
37ºC. Typical C. difﬁcile colonies were inoculated on Schaedler agar
(bioMe´rieux) and anaerobic incubated for 48 hours at 37ºC. Suspected
colonies of C. difﬁcile were transported to the Leiden University Medical
Centre where additional identiﬁcation tests and PCR ribotyping were
performed The Pearson Chisquare test was used to asses the association
between C. difﬁcile isolation and presence of diarrhoea.
Results: C. difﬁcile was isolated from 63 out of 98 samples of piglets
with diarrhoea and from 31 of 87 samples of piglets without diarrhoea,
leading to an odds ratio for diarrhoea when C. difﬁcile is present of
3.3 (95% conﬁdence interval: 1.8−5.9). Statistical analysis of the data
showed a signiﬁcant association of presence of C. difﬁcile and diarrhoea
(P = 0.0001). C. difﬁcile was encountered at all farms investigated. At
16 farms all isolates belonged to type 078 whereas at 2 farms only type
045 was found. All isolates of type 078 and 045 contained genes for
toxin A, toxin B and the binary toxins.
Conclusion: Of 18 pig farms with persistent problems of neonatal
diarrhoea, C. difﬁcile PCR ribotype 078 was present in 16 farms and
type 045 was found in 2 farms. The results of this study indicate the
importance of CDI in diarrhoeal piglets and emphasizes the need for
further research to the association of C. difﬁcile emerging disease in
humans and piglets.
P1376 The use of a geographic information system to identify
a goat dairy farm as the most likely source of an urban
Q fever outbreak
B. Schimmer °, T. Veenstra, R. ter Schegget, M. Wegdam-Blans,
L. Zu¨chner, A. de Bruin, P.M. Schneeberger, P. Vellema, W. van der
Hoek (Bilthoven, Eindhoven, Helmond, The Hague, ’s Hertogenbosch,
Deventer, NL)
Objectives: A Q fever outbreak occurred in an urban area in the south
of the Netherlands in May 2008. Distribution of cases in time and place
suggested a common source. We studied the spatial links between the
residence locations of human cases and nearby small ruminant farms,
of which one dairy goat farm had experienced abortions due to Q fever
since mid April 2008. A generic geographic information system (GIS)
was used to develop a method for source detection in the still evolving
major epidemic of Q fever in the Netherlands.
Methods: All notiﬁed Q fever cases in the area were interviewed.
Postal codes of cases and of small ruminant farms (size >40 animals)
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located within 5 kilometres from the centre of the cluster area were geo-
referenced as point locations in a GIS-model. For each farm, attack rates
and relative risks were calculated for 5 concentric rings of 1 kilometre
each, using the 5−10 kilometres zone as reference, to study the presence
of a distance-response effect. These data were linked to the results of
veterinary investigations.
Results: Persons living within 2 kilometres of an affected dairy goat
farm (>400 animals) had a much higher risk for Q-fever than those living
more than 5 kilometres away (Relative risk 31.1 [95%CI 16.4–59.1]).
However, comparable attack rates and relative risks were found around
two nearby sheep farms (around 50 animals each) that had experienced
no clinical Q fever problems.
Conclusion: The study supported the assumption that a dairy goat farm
was the source of the outbreak. GIS-based attack rate analysis is a
promising tool for source detection in outbreaks of human Q fever.
P1377 Infection with Clostridium difﬁcile in patients with
ulcerative colitis
I. Chudzicka-Strugala °, A. Szkaradkiewicz, R. Marciniak, P. Majewski,
B. Zwozdziak, T.M. Karpinski (Poznan˜, PL)
Objectives: Numerical and qualitative disturbances in intestinal mi-
croﬂora are known to be associated with emergence of Clostridium
difﬁcile in the alimentary tract. Pathogenicity of the important
enteropathogen is determined by two protein toxins: enterotoxin A
(encoded by tcdA) and cytotoxin B (encoded by tcdB), which mediate
diarrhoea and colitis (C. difﬁcile-associated disease − CDAD). Taking
the above into account present study aimed at analysis of manifestation
of Clostridium difﬁcile infection in active ulcerative colitis.
Methods: The investigated group included 20 patients (10 men and
10 women, age range 21−65 years) with active ulcerative colitis (UC),
hospitalized at the Department of General, Gastroenterological and
Endocrinological Surgery, University of Medical Sciences in Poznan˜,
Poland. The diagnosis was based on clinical, radiological, endoscopic
and histological criteria. The standard surgical treatment was applied
in all the patients. Due to the signs/symptoms of acute abdomen,
three of the above mentioned patients were urgently subjected to
colectomy. The diagnostic material included intra-operative sections
of large intestines. DNA of Clostridium difﬁcile was isolated from
the intestinal samples using QIAamp DNA Mini Kits (Qiagen). For
ampliﬁcation of tcdB, hyplex ClosTox PCR Module was applied (BAG
Healthcare). PCR product was detected using hybridization with the
Multiplex-PCR-ELISA-System kits (hyplex ClosTox; BAG Healthcare)
and the absorbance was read out at 450nm (Reader 250, bioMe´rieux).
Values >0.3 were evaluated as positive.
Results: In 4 patients presence of tcdB C. difﬁcile was detected in
intestinal samples and, in parallel, histological examination demonstrated
a vast inﬂammatory inﬁltrate which included muscularis layer. In the
remaining 16 patients no tcdB C. difﬁcile could be detected in intestinal
samples and histologically the inﬂammatory inﬁltrate was restricted to
mucosa of the large intestine.
Conclusion: The obtained results indicate that development of active
ulcerative colitis may be accompanied by infection with C. difﬁcile.
Therefore, cases of UC should be monitored for presence of toxin-
forming strains of C. difﬁcile as well as novel diagnostic/therapeutic
strategies should be worked out for the morbid unit.
P1378 MLVA patterns and antibiotic resistance of emerging
Clostridium difﬁcile PCR ribotype 078; an indication for
zoonotic transmission?
M. Hensgens °, E.C. Keessen, D. Bakker, L. Lipman, E.J. Kuijper
(Leiden, Utrecht, NL)
Objectives: In both veterinary and human medicine, Clostridium difﬁcile
infections (CDI) are emerging. The hypervirulent C. difﬁcile strain 027
was identiﬁed as the major cause of nosocomially acquired outbreaks
in humans. Type 078, however, is the most commonly detected strain
in pigs. As type 078 is currently also the third most common strain
in humans in the Netherlands, a common source for both human and
animal CDI is suspected. Genetical relatedness and overlapping antibiotic
susceptibility patterns of human and animal strains may indicate a high
degree of similarity, and prompted us to study this for type 078 infections
in the Netherlands.
Methods: Fifty human C. difﬁcile type 078 isolates were selected at
random from all samples submitted to the Dutch national reference labo-
ratory between June 2006 and May 2009. FromMay 2009 ﬁfty C. difﬁcile
type 078 isolates were collected from piglets with neonatal diarrhoea.
To diminish selection bias due to one predominant epidemic strain, a
maximum of two isolates per farm were included. In total, antibiotic
susceptibility patterns of 100 isolates with PCR ribotype 078 were deter-
mined using the E-test method. A suspension of C. difﬁcile was cultured
on non selective blood agar plates in an anaerobic environment at 37ºC.
Minimal inhibitory concentrations (MICs) for tetracycline, amoxicillin,
co-trimoxazol, erythromycin, clindamycin, moxiﬂoxacin, cefuroxim,
imipemen and ciproﬂoxacin were determined after an incubation of 48
hours. For each antibiotic analysed, MICs were compared between the
two groups. Genetic resemblance of type 078 isolates was determined
by using multi-locus variable-number tandem repeat analysis (MLVA).
Results: As results are expected towards the end of December 2009, no
preliminary results can be presented in this abstract.
Conclusion: Previous studies found similar antibiotic susceptibilities in
type 078 from pigs and humans, however, very limited numbers of strains
were investigated. This study will give an systematic, broad, view on
antibiotic susceptibility patterns in CDI due to type 078. Furthermore,
the degree of resemblance will provide insight in the (possible) common
source of human and porcine CDI.
P1379 Epidemiological survey of hantavirus pulmonary syndrome
in the north-eastern region of Rio Grande do Sul, Brazil
L. Michelim °, J. Fracasso, P. Garrido, V. Buffon, A. Rocha, E. Kieling
(Caxias do Sul, BR)
Objectives: Hantavirus pulmonary syndrome (HPS), commonly referred
to as hantavirus disease, is a febrile illness characterized by bilateral
interstitial pulmonary inﬁltrates and respiratory compromise usually re-
quiring supplemental oxygen and clinically resembling acute respiratory
disease syndrome (ARDS). Humans can contract the disease when they
come into contact with infected rodents or their urine and droppings. The
aim of this study is to show an epidemiological survey of cases of HPS
from 2002 to 2008 in the northeast region of Rio Grande do Sul − Brazil.
Methods: Retrospective review of all notiﬁed and conﬁrmed cases of
hantavirus pulmonary syndrome in the northeast region of Rio Grande
do Sul/Brazil between January 2002 and December 2008. Cases were
identiﬁed through the Local Health Epidemiology Service surveillance
database and were supplemented by chart review.
Results: A total of 74 cases were identiﬁed during the study period of
which 32 (43.3%) patients laboratory conﬁrmed viral disease, 42 (56.7%)
had clinical and epidemiological criteria, and 13 (17.5%) progressed
to death. Incidence varied substantially by sex and race: 49 (66.2%)
cases were male and 25 (33.8%) women; 53 (71.6%) were caucasian,
12 (16.2%) brown, 8 (10.8%) black and 1 (1.4%) yellow. The mean age
of conﬁrmed case patients is 27 years (range: 16 to 63 years). Potential
occupational exposures have included grain farmers and agricultural,
mill, construction workers. Many of these individuals had concurrent
peridomestic exposures.
Conclusions: Based on these data, we can conclude that the hantavirus
is an emerging disease of epidemiological importance in our region,
requiring preventive measures to alert the population, control of rodents
in rural areas and a higher degree of suspicion by physicians.
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P1380 Colonization or infection? A case report of Nocardia
isolation in a patient with cystic ﬁbrosis
E. Fiscarelli °, G. Ricciotti, C. Concato, L. Coltella, V. Lucidi, F. Callea
(Rome, IT)
Objectives: Nocardia spp. are Gram-positive, aerobic saprophytic
bacteria with worldwide distribution. Infection by Nocardia spp. is
relatively uncommon and usually manifests as primary pulmonary
disease, acquired through inhalation of dust particles. Pulmonary
diseases that compromise local airway defences, including chronic
obstructive airway disease, bronchiectasis, pulmonary ﬁbrosis, asthma,
emphysema, and alveolar proteinosis are risk factors for developing
nocardiosis. Surprisingly, the isolation of Nocardia spp. from the
respiratory tract of cystic ﬁbrosis (CF) patients is a very unusual ﬁnding.
We describe clinical and microbiological features of our CF patient
who presented Nocardia in her respiratory secretions with the aim of
evaluating the clinical impact.
Methods: A 34 year old CF Caucasian woman was admitted to
our Hospital with severe cough, increased sputum production and
left thoracic pleuritic pain. WBC (11.7×109/L) and CRP (40.6mg/L)
were elevated. Chest CT showed nodular opacities in the left lower
lobe and dense consolidation in the right one in addition to diffuse
bronchiectasis. A sputum specimen was smear-and culture-positive for
organism resembling Nocardia spp. Staphylococcus aureus was also
isolated.
Results: The organism isolated from sputum was identiﬁed as Nocardia
asteroides/cyriacigeorgica by 16S rDNA gene sequencing; a full
gene sequencing of 16S rDNA was necessary to obtain an univocal
identiﬁcation. Antimicrobial susceptibility testing was performed by
E-test against amikacin (2 mcg/mL), ceftazidime (256 mcg/mL),
ceftriaxone (0.5 mcg/mL), meropenem (4 mcg/mL), imipenem (2
mcg/mL), tobramycin (0.75 mcg/mL) and TMP/SMX (0.12 mcg/mL).
The patient received amikacin and meropenem i.v. for a 4 week period;
such treatment resulted in improvement of the clinical picture. Repeated
sputum cultures performed in the following months (the last one 1 month
ago) were again smear-and culture-positive for the same microorganism.
No speciﬁc antinocardial therapy was started, due to the absence of
broncho-pulmonary symptoms.
Conclusion: Colonization or infection? In the case described, we cannot
attribute a speciﬁc pathogenetic role to a single microbial species. The
presence of Nocardia from the respiratory tract of the CF patient does
not necessarily imply the disease. We could suppose that Staphylococcus
aureus was the cause of the symptoms and that it responded to the
antimicrobial therapy.
P1381 Detection of a KPC-2 carbapenemase producing Serratia
marcescens isolate in a pleural ﬂuid sample: a case report
M. Kimouli, I. Petraki, I. Daniil, E. Voulgari, N. Rekliti,
D. Petropoulou °, A. Tsakris (Athens, GR)
Objectives: KPC carbapenemases are among the most common
b-lactamases mediating carbapenem resistance in Enterobacteriaceae.
They have been widely spread among Klebsiella pneumoniae isolates in
United States, South America, Israel and Greece. This is the ﬁrst report
of a KPC-2 carbapenemase producing Serratia marcescens in Europe.
Methods: A 62-year man was admitted to the cardiothoracic ward
due to a signiﬁcant right side pleural effusion. Over a two month
period prior to his admittance he reported fatigue, fever and weight
loss. A pleural needle biopsy was preformed and ﬂuid was collected
for cytological analysis and cultures. MICs of the clinical relevant
isolate were determined by E-test. Phenotypic assays for carbapenemase
production included the modiﬁed Hodge test, the combined EDTA test
and the boronic acid potentiation disk tests. PCR and sequencing assays
were used to identify b-lactamases (blaKPC, blaVIM, blaSME, blaSHV,
blaCTX-M, blaTEM genes).
Results: On physical examination, the patient was afebrile, had a
pulse of 75/min, blood oxygen saturation 95% and presented reduced
right side respiratory sounds. Cytological examination of the turbid
pleural ﬂuid revealed the presence of numerous inﬂammatory cells,
mainly lymphocytes. No malignant cells where detected. CBC showed
a WBC count of 10,180/ml and a PLT count of 586,000/ml. Blood
chemistry showed ALT 118 IU/L, ALP 484 IU/L, gGT 331 IU/L and
CRP 121.2mg/L. A Chest CT scan revealed the presence of a unilateral
encysted hydropneumothorax and a notable increase in width of the
pleura. Sputum samples were negative for acid-fast bacilli. A pleural
ﬂuid sample was processed with standard bacteriological methods and
the BacTAlert 3D. Cultures yielded a Gram-negative rod, which was
identiﬁed as S. marcescens by Vitek 2 automated system and API
20E. The isolate exhibited imipenem MIC 16mg/L, meropenem MIC
8mg/L and ertapenem MIC 8mg/L and was phenotypically positive
for KPC production. PCR assays and DNA sequencing identiﬁed the
presence of blaKPC-2 and blaTEM-1 genes.
Conclusion: KPC-producing organisms have emerged as serious
problem worldwide. Apart from K. pneumoniae isolates, which typically
harbour blaKPC genes, other genera of Enterobacteriaceae have also
sporadically detected as KPC producers. Effective measures for their
early identiﬁcation and control should be adopted in order to prevent
their potential dissemination.
P1382 Seroprevalence of leptospirosis in Mazandaran Province,
Iran using indirect immunoﬂuorescence assay, 2006–2007
S.P. Ziapour °, B. Esfandiari, M. Assmar, M. Alipour Espeh-Kolaie,
M.R. Youseﬁ, H. Shokri, G. Amirbozorgi, B. Amini Navai,
Z. Farzaneh-Nejad (Amol, Tehran, Babol, IR)
Objectives: Leptospirosis is a worldwide zoonotic infection with a much
greater in tropical and temperate regions and has now been identiﬁed
as one of the emerging infectious diseases. Because of leptospirosis is
signiﬁcantly high in temperate regions, rice ﬁeld workers and livestock
animals; it will be necessary to evaluate condition of leptospirosis in
Mazandaran province, Iran.
Methods: In this survey, 127 serum samples of suspected human were
collected in different parts of Mazandaran province from November 2006
to July 2007. Serums were tested by Indirect Immunoﬂurescence Assay
(IFA) in Pasteur Institute of Iran, Amol Research Center, Department Of
Parasitology.
Results: The results showed that prevalence of Leptospirosis disease in
Mazandaran province is 25.98% using IFA methods. In this survey, 33
samples were positive which 84.85% of them were belonged to male
and 15.15% to female. Rice ﬁeld workers showed the most frequent
occurrence of infection and showed signiﬁcant variance with other
occupations (P< 0.01). Among 107 samples that were collected from
males and 20 from females, 26.16% and 25% samples were positive,
respectively. There was no signiﬁcant variance between genus and
leptospirosis (P> 0.05). Living place (urban or rural) and contact with
animals did show no signiﬁcant variance with leptospirosis. The most
positive cases were found in age range of 40−50 years.
Conclusion: Because in Mazandaran Province, men and women work
together at rice ﬁeld, also urban peoples still relate to agriculture, it
is acceptable that genus and living place have not signiﬁcant variance
with prevalence of leptospirosis. In order to as certain that the effect of
contact with animals has no signiﬁcant variance with the prevalence of
leptospirosis, it needs more investigations, direct sampling from animals
or their urine and comparison of them to the results of this study. The
IFA test is a potentially valuable tool for the diagnosis of leptospirosis.
P1383 Continue active transmission foci of VEEV activity in
coastal areas of Chiapas, Mexico
F.J. Ramirez Aguilar, S. Va´zquez Corzo, R. Navarro Lopez, G. Leal,
A. Travassos Da Rosa, S. Weaver, J.G. Estrada Franco ° for the
International Group of Emerging Infectious Diseases
Venezuelan equine encephalitis (VEE) is considered an emerging
arboviral disease and a human health threat throughout the Americas.
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The objective was to demonstrate through serosurveys the widespread
presence of VEE in humans and dogs in coastal areas of the Mexican
Paciﬁc in the State of Chiapas and the identiﬁcation of a putative hotspot
of VEEV.
Methods: A cross-sectional study was conducted in 2008 and 2009 in a
southern coastal village of the State of Chiapas, Mexico. Fasting venous
blood samples (humans and dogs) were collected without anticoagulant
to obtain serum. Oral informed consent was obtained from all individuals
taking part in the study. All procedures were approved by the institutional
review boards at the Chiapas State University and at the University of
Texas Medical Branch. The serum samples from 142 individuals and 40
dogs (<6 months old) were analyzed using HI and PRNT assays.
Results: Human seroprevalence was 82% (116/142). Gender analysis
showed 64% (91/142) males and 36% (51/142) females with VEEV
antibodies. Odds ratio risk analysis using the stata program did not
show any statistically signiﬁcant association with several independent
variables at the 95%CI including occupation, age, and clinical status
of the sampled population. By occupation the highest percentage
in a seropositive group were housewifes with 45% (n = 142, 74
positives), followed by students with 31% seropositives 44 seropositives
(n = 142, 44 positives), agricultural workers with 18% (n = 26/142)
and an undetermined group of 8 individuals that did not report any
information about occupational status. By age most notably was the
higher percentage of seropositive individuals in the group older than
60 years as seropositive (N= 26, 23 seropositives, 88% seropositivity).
These rates suggest endemic transmission since VEEV PRNT values
are known to last >25 years. Our dog seroprevalence was 37.5% 15/40
with high titers (7 dogs) HI and PRNT above 1:620 suggesting recent
infections. Our entomological studies and other vertebrate data reinforces
our observations.
Conclusion: The results of our studies suggest a continuous active
transmission foci of VEEV in coastal Chiapas. Sampling of the dog
population suggests recent VEEV activity and even transmission within
the household premises. We further discuss the complications arising
from co-infections of other arboviral diseases circulating simultaneously
in the same area (e.g. dengue and West Nile viruses) and the need to
clearly conduct differential diagnosis in order to identify the disease
burden of VEE and to distinguish this pathology from others.
P1384 Mosquito-borne diseases in Slovakia
N. Jalili °, V. Krcmery, E. Kalavsky, F. Ondriska, P. Baba´l (Bratislava, SK)
Objectives: Malaria was endemic in Slovakia up to 1959. After the
elimination of malaria, the study of mosquitoes in Slovakia once again
gained new impetus following the demonstration of their role as vectors
of arboviruses in Central Europe. Bardosˇ & Danielova´ (1959) isolated an
entirely new mosquito-borne arbovirus called Tahyna and later another
arbovirus, Calovo was also discovered. West Nile virus was isolated from
mosquitoes in 1974 and there is evidence for the activity of another
mosquito-borne virus, Sindbis, isolated from birds, sentinel animals and
frogs. Diroﬁlariosis of dogs, the causative agent of which is transmitted
by mosquitoes, represents a serious problem for dogs and cats especially
in several tropical and subtropical countries including Southern Europe.
In connection to the global warming, recently this disease has been
penetrated into Central Europe, Slovakia included.
Methods: Malaria was diagnosed in all suspected cases by microscopic
examination of tick and thin blood smears, stained by Giemsa. Cases
of cutaneous diroﬁlariasis were diagnosed clinically, histologically and
determination of parasite genom by PCR.
Results: Since the eradication of malaria in the former Czechoslovakia,
150 malaria cases were reported into Slovakia, of which 50 cases
imported by foreigners. From the identiﬁed species 45% of all malaria
cases were due to Plasmodium falciparum; 40% due to P. vivax; 10%
due to P. malariae and P. ovale species; the rest 4% were cased due
to mixed infections, mainly by P. falciparum and P. vivax and 1% by
Plasmodium sp. Diroﬁlariosis of dogs, the causative agent of which is
transmitted by mosquitoes, has been spread to Slovakia recently. Two
conﬁrmed human cases are reported as well.
Conclusion: Although the number of imported malaria into Slovakia
is not as high as in western European countries, but the possibility
of its resurgence in the country still remains. Recently, due to global
warming a new mosquito born disease became endemic. With respect to
the fact, that mosquitoes are vectors not only of human malaria causative
agents, but transmitting many other arboviruses and for this reasons their
permanent monitoring, especially of their breeding places, is of constant
importance even because of ever changing areas of pathogens transmitted
by mosquitoes.
Acknowledgment: This paper was supported by project No 2007/35-UK-
20 Ministry of Health of the Slovak Republic.
P1385 Detection of Leptospira by PCR and comparison of different
methods for early diagnosis of leptospirosis
P. Chandrasiri °, P. Wahala, R. Ramesh, K. Kulathunge (Colombo, LK)
Leptospirosis is a zoonotic disease of worldwide distribution. The
infection is caused by Leptospira interrogens. The disease is maintained
in nature by chronic renal infection of carrier animals which excrete
bacteria in urine. Leptospirosis is endemic in Sri Lanka. The incidence
is rising dramatically over the last few years & the number of deaths
due to leptospirosis was 204 in 2008.
Objectives: To introduce a PCR technique for the early diagnosis of
Leptospirosis. To compare the PCR results with existing methods such
as culture & serology.
Methodology: Two teaching hospitals in Western province were selected
for the study. Blood was taken from the patients suspected of having
Leptospirosis as a part of the normal investigation process. The blood
was collected for PCR, culture & serology prior to antibiotic therapy.
The blood was inoculated into EMJH media at the bedside & incubated
at room temperature. The genus speciﬁc microagglutination test (MAT)
was performed using Leptospira Patoc strain. ELISA test was performed
to detect IgM antibodies. PCR was done using G1/G2 primers.
Results: A total of 59 samples were tested. Up to 05 cells could be
detected in the 50ul of PCR reaction mixture. Of the 59 samples 08
were posive by PCR test whereas only 06 were positive for culture.
Seven samples gave diagnostic cut off titre of 1/800 with the MAT test &
17 gave positive by ELISA test. Out of the 08 PCR positive specimens
only 1 gave positive with the MAT test whereas out of the 07 MAT
positives only 01 was posive for PCR. Out of 08 PCR positives only 02
were positive for IgM whereas out of 17 ELISA positives only 2 were
positive with PCR.
Conclusion: IgM Elisa is the most sensitive method to diagnose
Leptospirosis in the early stage of the disease. MAT test is useful if
the patient is presented later to the hospital. Speciﬁcity of the PCR
method is 92.2% when compared to the gold standard culture method,
PCR is more sensitive and rapid method than culture for the deﬁnitive
diagnosis of Leptospirosis & is a valuable & reliable test to diagnose
Leptospirosis in the initial stage of the disease.
P1386 Detection of human bocavirus in adenotonsillar tissue
specimens by polymerase chain reaction
B. Gultekin °, M. Eyigor, H. Eyigor, N. Aydin (Aydin, TR)
Purpose: The human bocavirus (HBoV) is a recently identiﬁed
parvovirus detected in respiratory secretions of children who had an
infection of the lower respiratory tract. Several studies have identiﬁed
HBoV in respiratory specimens from children with acute respiratory
disease, but the full spectrum of clinical disease and the epidemiology
of HBoV infection remain unclear. In this study, our objective was to
detect whether adenoid and/or tonsillar tissue of patients diagnosed with
chronic adenotonsilitis was a reservoir for HBoV.
Methods: This study was performed with 47 patients with the
diagnosis of chronic tonsillitis and adenoid hypertrophy. The criteria
for tonsillectomy was to have ﬁve or more tonsillitis attacks in a year,
while the criteria for adenoidectomy was the 2/3 blockage of choana
on endoscopy which causes obstruction symptoms. After the surgery
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DNA extraction was performed with NucleoSpin Tissue (Macherey-
Nagel, Germany) extraction kit from adenoid or tonsil tissues. Human
bocavirus was searched by polymerase chain reaction (PCR). The
primers were 188F (5′-GACCTCTGTAAGTACTATTAC-3′) and 542R
(5′-CTCTGTGTTGACTGAATACAG-3′). The expected product size
was 354 bp. All PCR products were sequenced to conﬁrm that they
were speciﬁc for HBoV.
Results: Eight (17%) patients underwent adenotonsillectomy, 12 (25.5%)
patients underwent tonsillectomy, and 27 (57.5%) patients underwent
adenoidectomy. Fifty-ﬁve (35 adenoid, 20 tonsil) tissue samples from 47
patients were included in the study. The average age of the patients varied
from 4 to 42 (8±7.050). Bocavirus was detected in ﬁve (9%) specimens
(one of them was tonsil and the others were adenoid specimens) from
ﬁve children.
Conclusions: These ﬁndings indicate that the palatine tonsils can be
colonized by HBoV. Further studies are needed to clarify the possible
role of HBoV in upper aerodigestive tract diseases such adenotonsillitis.
P1387 Low prevalence of Clostridium difﬁcile in retail meat in the
Netherlands
J.T. Zwartkruis-Nahuis °, C. Harmanus, E.J. Kuijper, E. de Boer
(Zutphen, Leiden, NL)
Objectives: Recent reports indicate that a large proportion of
community-acquired Clostridium difﬁcile infections (CDI)are not linked
to recent antibiotic therapy, older age, signiﬁcant comorbidity or previous
hospitalization. The signiﬁcance of contaminated food as source of
C. difﬁcile is unknown. Since data from US and Canada indicate that
C. difﬁcile contamination of food frequently occurs, we performed a
surveillance study to the prevalence of C. difﬁcile in meat.
Methods: A total of 500 samples of raw beef, pork, calf, lamb and
chicken were collected from the retail trade in the period October 2008
to March 2009. The detection and isolation method used was based
on the method described by Rodriguez-Palacios et al. (2007), using 5
g of meat added to 20ml of selective C. difﬁcile broth incubated for
10−15 days at 37ºC, under anaerobic conditions and shaking conditions.
From the enriched broth, 2ml was used for an alcohol shock treatment
and streaked onto selective C. difﬁcile moxolactam norﬂoxacin agar.
Presumptive identiﬁcation of suspect colonies was done by testing
for agglutination using the C. difﬁcile test kit (Oxoid DR1107A).
Further identiﬁcation was done by testing for the presence of tpi (topo
isomerase), tcdA (toxin A) and tcdB (toxin B) genes using real-time
PCR and by PCR ribotyping.
Results: The detection limit of the method applied for minced meat
was in the range of 2 CFU per 5 g. In total, 500 raw meat samples
were included which derived from beef (145), pork (63), calf (19), lamb
(16), and chicken (257). Of 500 samples, only 8 (1.6%) were positive
for the presence of C. difﬁcile: 1 from lamb (6.3%) and 7 from chicken
(2.7%). C. difﬁcile from lamb was positive for TcdA, TcdB, binary toxin
genes and belonged to PCR ribotype 060. Three isolates of chicken were
negative for the presence of toxin genes and belonged to 3 different
PCR ribotypes (071 and unknown types). The remaining four isolates
belonged to PCR ribotype 003 (n = 2), 001 and 087; all contained TcdA
and TcB, whereas binary toxin genes were absent.
Conclusion: In The Netherlands, retail meat is contaminated with
C. difﬁcile in a very low percentage. The strains which have been found
in meat, are different from the types currently found in patients with
hospital acquired CDI of community-acquired CDI.
P1388 Immune reconstitution syndrome associated with hip septic
arthritis after successful treatment of visceral leishmaniasis:
analysis of the immunomodulatory environment
F. Robert-Gangneux °, Y. Poinsignon, V. Ciubotaru, C. Guiguen,
J-P. Gangneux (Rennes, Vannes, FR)
Objectives: Immune reconstitution syndrome (IRS) is well recognized
during two main situations: AIDS and solid organ transplantation (SOT).
After the advent of potent highly active antiretroviral therapy during
AIDS or after reduction or withdrawal of iatrogenic immunosuppressive
agents in SOT patients, concomitant infections were reported. Here, we
observed that visceral leishmaniasis (VL) can also be an underlying
condition for IRS and investigated the immunological environment
during one episode.
Methods: A 75-year old patient living in Brittany, France, presented
with febrile hepatosplenomegaly and pancytopenia. The only noteworthy
background consisted in a right total hip arthroplasty for coxarthrosis 3
years before. However, the patient reported a pain of the right hip since
his return of the South of France. The diagnosis of VL was established
with a Giemsa stained bone marrow aspiration and a positive culture of
promastigotes identiﬁed as L. infantum. After treatment with liposomal
amphotericin B at a dose regimen of 3mg/kg at days 1, 2, 3, 4, 5 and 10,
the patient presented with septic shock in relation to an infection with
Staphylococcus aureus of the right total hip arthroplasty. The echography
revealed a 4×8 cm abcess of the cup. The treatment combined surgery
(one-stage revision of the acetabular cup without femoral stem changing)
and adapted antibiotherapy. A deﬁnitive cure of both VL and septic
arthritis was assessed after a long term follow up of the patient, without
relapse or sequela. In parallel, we performed blood dosages of IL-10
and IL-12 (by ELISA) and of soluble HLA-G, a type I MHC antigen
previoulsly described as a powerful immunomodulator agent.
Results: The analysis of this case suggests that the septic hip infection
was silent during the period of neutropenia in the active phase of VL.
Dosages of cytokines showed that the patient had high serum levels of
IL-10 and very low levels of IL-12 at the time of diagnosis, pointing
to an inhibition of the Th1 immune pathway. Furthermore, particularly
high levels of sHLA-G were detected, suggesting an immunomodulatory
environment. The clinical expression was only observed after recovery
of a normal count of polymorphonuclear neutrophils, and at a time point
when the cytokinic balance was reversed, with a restoration of high IL-12
and low IL-10 levels.
Conclusion:We report for the ﬁrst time an IRS-like syndrome following
a successful VL treatment revealing a deep bacterial infection.
P1389 Importance of therapy compliance in patients with
trichinellosis from Timis County, Romania
I. Marincu °, L. Negrutiu, I. Iacobiciu, A. Neghina, R. Neghina
(Timisoara, RO)
Objectives: Numerous studies conducted on groups of patients with
acute or chronic diseases highlight the role of therapy compliance in the
evolution and prognosis of these diseases. Our study aimed to emphasize
the importance of therapy compliance in a group of patients diagnosed
with trichinellosis.
Methods: The authors have retroactively processed and analyzed data
from the medical charts of 72 patients originating from an urban
outbreak of trichinellosis broke out in 2006 in Timis County. Diagnosis
was based on epidemiological aspects (the onset of infection following
consumption of infected pork with Trichinella spiralis.), clinical features
(fever, headache, chills, nausea, diarrhoea, facial/eyelid oedema, myalgia,
urticaria) and laboratory tests (erythrocyte sedimentation rate, ﬁbrinogen,
anti-Trichinella IgM antibodies, leucocyte counts, eosinophil counts,
serum protein electrophoresis, serum calcium, kalemia). Data of the
epidemiological survey were collected from the Institute of Public
Health. The statistical processing was done using Epi Info 3 software.
Results: All patients belonged to the gipsy ethnic minority with a
low level of education and medical knowledge. Of the 72 subjects, 57
(79.2%) presented to the Hospital of Infectious Diseases in Timisoara
for a medical evaluation, and 15 patients (20.8%) didn’t present
although they were advised by the doctors who have performed
the epidemiological investigation of the outbreak. Ten patients were
hospitalized with a moderately-severe clinical course of disease, and
22 individuals refused the admission to hospital. Although physicians
prescribed ambulatory treatment for 40 patients (55.6%), only 8
followed the therapeutic cure with albendazole and the rest refused
to purchase the drugs. None of the patients presented for the clinical
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and laboratory post therapy re-evaluation. Patients were not informed
about the danger of pork consumption from uncontrolled or unauthorized
sources. Only 4 patients owned medical insurance and were following
intermittent medical therapy for chronic disorders (ischemic heart
disease, hypertension, chronic hepatitis).
Conclusions: Low therapy compliance associated with lack of alimen-
tary and personal hygienic rules require implementation of speciﬁc
projects. These must promote information and medical education in
the gipsy community in order to prevent further trichinellosis or other
infectious diseases outbreaks.
P1390 Acanthamoeba keratitis: clinical presentation, diagnosis,
treatment and outcome
K. Tzanetou, D. Miltsakakis, K. Ziva °, E. Tsianou, S. Strigari, E. Petrou,
E. Marda, A. Goula, G. Ganteris, E. Malamou-Lada (Athens, GR)
Acanthamoeba keratitis is a sight-threatening infection of the cornea
caused by the ubiquitous free-living Acanthamoeba spp. The main risk
factor for acquisition of this serious parasitic infection is the use of soft
contact lenses.
Purpose: To review the clinical presentation, diagnosis, treatment, and
outcome of patients with Acanthamoeba keratitis during a ﬁve year
period.
Patients and Methods: All the patients, contact lens wearers, who
presented with symptoms and signs of keratitis during the study period
(from January, 2005 to October, 2009), underwent corneal scraping.
The scrapings from the infected cornea were inoculated on 1.5% non-
nutrient agar plates overlaid with E. coli, sheep blood agar, chocolate
and sabouraud dextrose agar for isolation of Acanthamoeba, bacteria and
fungi.
Results: Culture-proven Acanthamoeba keratitis was diagnosed in
25 patients. Seventeen of the 25 (68%) patients presented with
symptoms and signs of early stage of the disease (pain, photophobia,
epithelial and subepithelial opacities, dendritiform epithelial lesions, and
radial keratoneuritis). Fourteen (82%) and six (35%) of early cases
presented with pseudodendritic epitheliopathy (dendritiform epithelial
lesions can mimic herpes simplex keratitis) and radial keratoneuritis
(a nearly pathognomonic sign) respectively. Eight of the 25 (32%)
patients presented with signs of late stage of the disease (annular and
disciform stromal inﬁltration). The patients received topical treatment
with polyhexamethylene biguanide (PHMB) 0.02% and hexamidine
(desomedine or ophtamedine) 0.1% in combination or neosporine
combined with desomedine or ophtamedine (duration of treatment was
6 to 12 months). The outcome of the early cases was clinical resolution
and cure, while the advanced cases underwent therapeutic penetrating
keratoplasty (one case complicated by scleritis, corneal ulceration and
cataract).
Conclusions: The clinical presentation of Acanthamoeba keratitis may
be pathognomonic (radial keratoneuritis), characteristic (ring-shaped
stromal inﬁltrate) or non-speciﬁc. The early diagnosis and treatment with
combined antiacanthamoeba agents are critical for a good outcome and
vision maintenance.
P1391 An outbreak of Plasmodium vivax malaria in Lakonia,
southern Greece, August-October 2009
P. Andriopoulos, A. Oikonomopoulou, K. Rigaki °, N. Kaplanis,
D. Rebelou, G. Assimakopoulos (Sparta, Athens, GR)
Objectives: Malaria is considered to be eradicated in Europe. Only
sporadic cases from travellers in endemic areas are occasionally reported.
A cluster of Vivax malaria infected patients from Lakonia Greece is
presented.
Methods: 8 patients were hospitalized from August to October
2009 in Sparta General Hospital with plasmodium vivax malaria.
Epidemiological data, clinical symptoms, diagnosis and treatment are
described.
Results: Two patients, 24 and 28 years old, immigrants from Pakistan
and Afghanistan accordingly were admitted because of fever, jaundice
and abdominal pain. The latter was treated for malaria with a 3-day
regiment of chloroquine a year ago. Two weeks later and during a
period of two months, six more patients, natives of Lakonia and living
in different regions of the state from the ﬁrst two, were admitted with
similar symptoms. Blood smear tests were positive for all patients for
plasmodium vivax which was veriﬁed with PCR testing. Sensitivity tests
showed that all the strains were chloroquine-sensitive. All patients had
irregular fever patterns, haemolytic anemia, thrombocytopenia, transient
neutropenia, splenomegaly and elevated liver function tests. They were
treated with combined regiment of chloroquine followed by primaquine
and completed the treatment uneventfully.
Conclusion: A re-emergence of malaria may become a growing concern
since populations migrate from Asia to Europe in poor sanitary
conditions causing occasional local transmission. Surveillance and
prevention are crucial in order to prevent further epidemics.
P1392 Risk factors for prolonged fever in patients with scrub
typhus
Y.S. Kim °, S. Park (Daejeon, KR)
Objectives: Scrub typhus is an important rickettsial infection whose
incidence has been rapidly increasing in Korea since 2004. With the
increasing incidence of the disease, patients with delayed defervescence
have become more common. We intended to compare the proportion of
patients with prolonged fever in 2002 to those of 2008 and determine
the risk factors.
Methods: We retrospectively analyzed data on the patients conﬁrmed
with scrub typhus by indirect immunoﬂuorescence assay who were
hospitalized in Chungnam National University Hospital. We used
multiple logistic regression to determine risk factors for prolonged fever.
Results: The proportion of patients with fever 48 h increased from
14.9% (7 of 47 in 2002) to 41.3% (50 of 121 in 2008). Hypoxemia
(OR, 3.58; 95%CI, 1.13–11.35) was more common in patients with
prolonged fever. The choice of doxycycline or azithromycin for the
treatment regimen did not affect the time to defervescence.
Conclusion: The proportion of patients with delayed response to
antibiotic treatment has been increasing in Korea and hypoxemia was a
risk factor. Disease severity may play a more important role in affecting
the response to treatment than the choice of antibiotics.
P1393 Diversity and coexistence of Borrelia spp., Anaplasma
phagocytophilum, Rickettsia spp. and Babesia spp. in Ixodes
ricinus ticks in Middle Germany
A. Hildebrandt °, K. Pauliks, A. Kra¨mer, S. Sachse, E. Straube (Jena, DE)
Objectives: So far, there are only few data about infection rates of
Anaplasma spp., Rickettsia spp., Babesia spp. and their distribution in
animal reservoirs in Germany and many other parts of Europe available.
Possible coinfections with Borrelia spp. are of great importance since in
case of human disease difﬁculties of diagnosis and treatment can occur.
The aim of our study was to investigate the circulation and cocirculation
of different tick-borne pathogens in a region of Middle Germany.
Methods: In 2006 and 2007 about 1000 Ixodes (I.) ricinus ticks were
collected from a small recreational forest area in Middle Germany
(Thuringia). Single ticks were investigated by PCR and RFLP or
sequencing for Borrelia spp. (ospA gene), Anaplasma spp. (16S rRNA
gene), Rickettsia spp. (gltA gene) and Babesia spp. (18S rRNA gene).
Results: Overall 27.0% (270/1000) of ticks were infected with
Borrelia spp., 5.4% (54/1000) with Anaplasma phagocytophilum, 14.7%
(147/1000) with Rickettsia spp. and in 5.0% (50/1000) of the ticks
Babesia spp. speciﬁc DNA was present. B. garinii (133/270) was
detected most frequently, followed by B. burgdorferi (70/270), B. afzelii
(42/270), B. valaisiana subgroup I (28/270), not typable Borrelia spp.
(5/270), B. spielmanii (3/270), B. valaisiana subgroup II (2/270) and
B. lusitaniae (1/270). In 1.4% of investigated ticks several Borrelia
species were found. At least two different Rickettsia spp. were identiﬁed:
Rickettsia helvetica and Rickettsia monacensis. All Babesia spp. positive
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amplicons were sequenced to distinguish between Babesia microti and
Babesia divergens. In 7.0% (70/1000) of ticks two different pathogens
were detected, 1.1% (11/1000) of ticks harboured more than 2 pathogens.
Single, but also mixed infections occurred signiﬁcantly more frequent in
adult ticks compared to nymphs.
Conclusion: Systematic large-scale surveys of the coexistence of several
tick associated pathogens are lacking. Our study is one of the limited
numbers of smaller studies that have attempted to identify the prevalence
of pathogens in individual ticks which is an important prerequisite for
improved local risk assessment. Clinically, tick-borne mixed infections
proceed often more severely than the corresponding diseases caused by a
single pathogen. This implies the necessity of a comprehensive approach
to the diagnosis, treatment and prophylaxis of these infections.
Table 1. Single and mixed infections of Borrelia spp., Anaplasma
phagocytophilum, Rickettsia spp. and Babesia spp. in Ixodes ricinus ticks
from a recreational forest area of Middle Germany (Thuringia)
Nymphs
2006/2007
(%)
Females
2006/2007
(%)
Males
2006/2007
(%)
Total (%)
Number collected 430 293 277 1000
Single infections
Borr 86 (20.0) 84 (28.7) 100 (36.1) 270 (27.0)
Ana 20 (4.7) 14 (4.8) 20 (7.2) 54 (5.4)
Rick 40 (9.3) 63 (21.5) 44 (15.9) 147 (14.7)
Bab 8 (1.9) 29 (9.9) 13 (4.7) 50 (5.0)
Total 154 (35.8) 190 (64.8) 177 (63.9) 521 (52.1)
Mixed infections
Borr/Ana 4 (0.9) 4 (1.4) 4 (1.4) 12 (1.2)
Borr/Rick 4 (0.9) 15 (5.1) 11 (4.0) 30 (3.0)
Borr/Bab 0 5 (1.7) 5 (1.8) 10 (1.0)
Ana/Rick 1 (0.2) 1 (0.3) 3 (1.1) 5 (0.5)
Ana/Bab 0 1 (0.3) 0 1 (0.1)
Rick/Bab 3 (0.7) 7 (2.4) 2 (0.7) 12 (1.2)
Borr/Ana/Rick 1 (0.2) 1 (0.3) 2 (0.7) 4 (0.4)
Borr/Rick/Bab 0 2 (0.7) 4 (1.4) 6 (0.6)
Borr/Ana/Bab 0 0 0 0
Ana/Rick/Bab 0 1 (0.3) 0 1 (0.1)
Borr/Ana/Rick/Bab 0 0 0 0
Total 13 (3.0) 37 (12.6) 31 (11.2) 81 (8.1)
Borr – Borrelia spp.; Ana – Anaplasma phagocytophilum; Rick –
Rickettsia species; Bab – Babesia spp.
P1394 Clinical course and microbiology of diphtheria in Latvia
R. Paberza °, I. Vingre, M. Suvalova, F. Arsa, J. Storozenko, V. Kuse
(Riga, LV)
In recent years Latvia still remains the only country in the EU with
regulary registered diphtheria cases. Sporadic cases continue to occur,
but morbidity has decreased from 2006–2009.
Objectives and Methods: Using retrospective analysis of case − records
summarize results of microbiology and imunological examinations,
peculiarities of the course and outcomes of diphtheria in 56 patients
treated in Infectology Center of Latvia (ICL) during period from 2006
till november 2009. The throat swabs for toxigenic corynebacteria were
examined according to our standart protocols and the WHO guidelines.
The level of antitoxic IgG antibodies were detected by ELISA.
Results: In period from 2006 till november 2009 at ICL were
hospitalized 56 diphtheria patients: in 2006–24 patients, in 2007–12,
in 2008–14 and in 2009–6 patients. Early hospitalisation before 5 days
were in 34 cases. Only 13 patients were vaccinated according schemes,
partially vaccinated and unvaccinated − 43. Toxigenic C. diphtheriae
var. gravis were isolated in 54 cases, var.mitis − 1 case. The protective
level of antitoxic IgG antibodies were insufﬁcient in 35 cases. Course
of diphtheria were mild in 26 cases, moderate − 7 cases, severe in 22
cases. 7 patients died. Severity criteria were: stridor, oedema of neck,
skin petechia, circulatory collapse, acute renal insufﬁciency, myocarditis,
motor paralysis. All patients with severe and those who died had not
sufﬁcient antitoxic IgG antibodies level. Because of severe course and
clinical indications 12 patients were mehanically ventilated. From them
9 patients had pneumonia. In 3 cases from bronchial lavage and blood
Klebsiella pneumoniae and multiresistant Acinetobacter baumannii was
obtained.
Conclusions: Most of all diphtheria cases were idetected to unvacci-
nated, socially deprived adults. Pneumonia to mechanically ventilated
patients was caused by gramnegative multiresistant microﬂora and
treatment include broad spectrum antimicrobial. To provide further
decrease of diphtheria level it is necessary to continue vaccination of
adults.
P1395 The emergence of the major European clones of
carbapenem-resistant Acinetobacter baumannii in Kuwait
A. Al-Hasan °, A. Hamouda, S.G. Amyes (Edinburgh, UK)
Objectives: Acinetobacter baumannii is an increasingly important
nosocomial pathogen because of its ease of transmission and ability
to become multidrug resistant. It has become a particular problem in
Kuwaiti hospitals and this study aimed to examine the genotypic changes
in the organism as it spread through one hospital.
Methods: A total of 88 Acinetobacter baumannii samples were collected
from the Mubarak Al-Kabeer Hospital, over a three year period, 2006–
2008, and they were identiﬁed phenotypically, by Vitek-2 systems, and
then genotypically, by PCR ampliﬁcation of blaOXA-51-like gene. The
resistance to the carbapenems, Imipenem and Meropenem, was identiﬁed
by use of the Minimal Inhibitory Concentration (MIC) test. Pulsed Field
Gel Electrophoresis (PFGE) was used to type the strains and classify
them into clonal groups. With this information, a dendogram showing
the resistance proﬁle and clonal relationship of all the isolates was
constructed. Gene Sequencing was used to identify the blaOXA-51-like
gene types of each of the isolates.
Results: All 88 isolates were identiﬁed as Acinetobacter baumannii
by Vitek-2 system and were shown to carry a blaOXA-51-like gene.
Resistance to Imipenem was found in 30% of the isolates, whereas
resistance to Meropenem was found in 24% of the isolates. Overall
carbapenem resistance was observed in 32% of the total isolates, with
a slight increase in resistance of isolated over the 3 years of collection.
In all, there were 10 different blaOXA-51-like genes identiﬁed. The
sequences of these genes suggested there was some degree of real-
time evolution of the blaOXA-51-like genes during the study period.
There were four main clonal clusters. There were three main European
clones (blaOXA-66, blaOXA-69, and blaOXA-71) plus a new clone-with
blaOXA-51-like genes with sequences clustered around the blaOXA-98
gene.
Conclusion: This study has shown four major clones were found in
the hospital during the study period, three closely associated with those
found in Europe and elsewhere and one new clone, containing a blaOXA-
98-like gene that appears to be more prevalent in this part of Asia.
P1396 Seroprevalence and genetic characterization of Dobrava and
Saaremaa hantaviruses among rodents (Apodemus agrarius,
A. ﬂavicollis) in Hungary and Northern Croatia
V. Ne´meth °, M. Madai, B. Be´rczi, A. Mara´czi, G. Horva´th, M. Oldal,
T. Kova´cs, F. Jakab (Pe´cs, HU)
Background: Dobrava and Saaremaa hantaviruses belongs to the
genus Hantavirus, family Bunyaviridae and carried by yellow necked
(Apodemus ﬂavicollis) and striped ﬁeld (Apodemus agrarius) mice.
Dobrava hantavirus causes severe hemorrhagic fever with renal
syndrome (HFRS) in many European countries, while Saaremma virus
seems to causes milder form of HFRS.
Objectives: The goals of this study were (i) to determine the
seroprevalence of Dobrava and Saaremaa hantaviruses in A. ﬂavicollis
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and A. agrarius, rodents, (ii) to genetically characterize those viruses
detected by RT-PCR.
Methods: The rodents were trapped in seven different locations of the
Transdanubian region of Hungary and Northern Croatia, during the
summer and autumn seasons of 2005–2007. The rodents were dissected
and lung tissues were used for hantavirus detection. The viral RNA was
extracted from lung suspensions with TRIzol reagent according to the
manufacturer’s recommendation. Hantaviruses were detected by SYBR
Green-based real-time PCR, using newly designed virus speciﬁc primers.
Positive samples were selected for sequence and phylogenetic analysis.
Representative Dobrava strain was selected for protein expression.
Truncated nucleocapsid protein (rNP50) was expressed in BL21 E. coli
cells using pET28a expression system. Recombinant protein contained
6×His tag; therefore it was puriﬁed using Ni-NTA column. The presence
of IgG antibodies in the collected rodents were determined by ELISA
reaction.
Results: During the study period a total of 130 Apodemus sp. (67
A. agrarius, 63 A. ﬂavicollis) were tested for the presence of hantaviruses.
Out of the 130 Apodemus rodents 10 (3 A. agrarius and 7 A. ﬂavicollis)
were infected with hantavirus. Based on the molecular sequence and
phylogenetic analysis − as we expected − at least two hantavirus types,
Dobrava and Saaremaa virus circulate parallel in the examined region.
The seroprevalence of these hantaviruses were 15% in the collected
rodents.
Conclusion: In this study we reported the occurrence and genetic
characteristic of Dobrava and Saaremaa hantaviruses circulate in
Hungary as well as in the northern part of Croatia. Based on the clinical
experience and our new molecular and serologic data from this region we
concluded that extended molecular and serological investigations might
be important in the future.
P1397 Some data of leptospirosis in Albania
E. Puca °, A. Ndreu, A. Pilaca, K. Shkurti, E. Puca, M. Josiﬁ (Tirana, AL)
Objective: To give same data of leptospirosis in Albania during
January 2002–October 2009.
Methods: We study cases with leptospirosis during January 2002–
October 2009 in our clinic UHC “Mother Teresa” which is the only
tertiary center in Albania. All cases were conﬁrmed serologically with
ELISA (enzyme-linked immunoassay) positive for IgM antibodies.
Results: This study investigated retrospectively 38 consecutive patients
with serologically conﬁrmed leptospirosis admitted to our hospital during
the period January 2002–October 2009. They were 89.4% males (34)
and 10.6% females (4). Mean age at the time of diagnoses were 42.5
years old with 15.3±DS range 17−73. Distribution according to the
season was: spring 15.8% (6 cases); summer 31.6% (12 cases); autumn
34.2%( 13 cases); winter 18.4% (7 cases). Distribution according to
the years were: 2002 2 cases; 2003 7 cases, 2004 1 case, 2005 2
cases, 2006 4 cases, 2007 2 cases, 2008 4 cases and 2009 14 cases.
The time from the ﬁrst symptoms until they presented to hospital were
7.5 days. Sign and symptoms were: myalgia 89.4%, temperature with
average 38.8ºC in 86.8% of cases; fatigue 84.2%, headache 78.9%,
jaundice in 68.4%, vomiting and abdominal pain 57.8%, respiratory signs
in 44.7%, renal insufﬁciency in 23.9% of cases and 13.8% diagnosed
during 2009. Laboratory results included: hyperleukocytosis in 55.2%
of cases, thrombocytopenia in 28.9%, Average level of bilirubinaemia
4.82mg/dl range and hyperbilirubinaemia were present in 73.7% of
cases with average level 7.48mg/dl, hepatic abnormalities(86.8%): AST
(aspartate aminotrasferase) were elevated in 78.9% of cases with average
level 467.6UI/dl range 40–4000, ALT(alanine aminotransferase) were
elevated in 82.4% of cases with average level 591.3UI/dl range 40–6000
and renal abnormalities: elevated serum creatinine 36.8%, proteinuria in
73.6% of cases, haematuria in 31.5% of cases, leukocyturia in 42.1% of
cases. 38 (100%) patients received antibiotics. Mortality was 0%.
Conclusions: There was a predominance of the males in ratio 8.5:1.
The disease was more frequent during summer-autumn. The study
conﬁrmed the variable clinical and biological symptoms of leptospirosis,
and indicated that hepatic and renal abnormalities are common feature
of leptospirosis.
P1398 The efﬁcacy of ribavirin treatment in Crimean-Congo
haemorrhagic fever in Turkey
G. Tuncer Ertem, F. Temocin, C. Ataman Hatipoglu, M. Sonmezer,
B. Oral, N. Tulek ° (Ankara, TR)
Objectives: Bunyaviridae family are known as generally sensitive to
ribavirin. It was shown that ribavirin is effective against Crimean-
Congo Haemorrhagic Fever (CCHF) in vitro and the positive effect of
ribavirin was reported in some studies. However there are no randomized
controlled clinical trials, ribavirin use in treatment of CCHF is suggested
by World Health Organization. The aim of the study is to analyze the
effect of ribavirin use on clinical course of the disease.
Methods: All patients with CCHF hospitalized at our clinic between
2007 and 2009 in Ankara Training and Research Hospital were evaluated
retrospectively. All of the cases were conﬁrmed at National Reference
Laboratory by presence of IgM positivity by ELISA or positive RT-PCR
tests. The patients were grouped on the basis of ribavirin use or not.
Patients who did not use ribavirin served as control group. Then the
patients who treated with ribavirin grouped according to receiving within
3 days of the onset of symptoms (Group 1) or later (Group 2). The levels
of laboratory ﬁndings at the beginning, 5th day and end of treatment were
compared for evaluation of the efﬁcacy of ribavirin.
Results: Eighty-nine patients (48 female and 41 male) were included
in our study. The mean of age the patients was 48 years (range:
16−80 years). Two patients were died (2.2%). Fourty-six (51.7%) of
patients received oral ribavirin, 43 (48.3%) of not received. Died
patients had entered to the hospital later (3 days) but both of them
received ribavirin. One of them died on next day of admission, other
died four days later. The mean of platelet values was signiﬁcantly
higher in ribavirin receiving group on 5th day of treatment (p = 0.04).
The mean of activated partial thromboplastin time (APTT) values
on 5th day and prothrombin time (PT) values on 10th day were
lower in ribavirin group (respectively p = 0.04, p = 0.004). Aspartate
aminotransferase (AST), lactate dehydrogenase (LDH) levels, platelet
and APTT values rapidly normalized in ribavirin receiving group
compared with nonreceiving group (respectively p = 0.009, p = 0.018,
p = 0.000, p = 0.015). There were no statistically difference for mean
of leukocyte, alanine aminotransferase (ALT), AST, LDH and creatine
kinase (CK) levels in group 1 and 2. PLT values rapidly normalized in
group 1 (p = 0.033), but for other parameters no difference was found.
Conclusion: We found a useful effect of ribavirin treatment especially
on platelet, APTT, AST and LDH levels.
P1399 Public health importance of Crimean-Congo haemorrhagic
fever in Iran as an emerging infectious disease
S. Chinikar °, S.M. Ghiasi, M. Moradi, M. Bouloy, R. Flick,
H. Feldmann (Tehran, IR; Paris, FR; Lowa, Bethesda, US)
Background and Aims: Crimean-Congo Hemorrhagic Fever (CCHF)
is a tick-born viral disease with high mortality rate which caused by
CCHF virus, belongs to Nairovirus genus and Bunyaviridae family, and
is transmitted to humans by infected tick bite, handling of infected blood
or tissues or nosocomially. The disease contains four distinct phases
including incubation, prehemorrhagic, hemorrhagic, and convalescence.
In 1999 after re-emergence of CCHF in Iran, it was considered as a
major public health problem and now most provinces of Iran became
endemic. The CCHF is diagnosed by molecular and serological assays.
Methods: As national reference laboratory, human probable sera are
collected from different parts of Iran. All sera were analyzed for CCHF
detection by sandwich-IgM and sandwich-IgG speciﬁc ELISA and gel-
based and real-time RT-PCR.
Results: As our data showed that the disease has infected 23 out of 30
provinces of Iran and has been continuously seen in some provinces such
as Sistan and Baluchistan, Isfahan, Khorasan in the last 10 years, while
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it was sporadically seen in some provinces such as Yazd in some years.
Also, the epidemiological data implied that symptoms’ severity and
mortality of the CCHF differs in different provinces. By a phylogenetic
survey, it was cleared that the majority of genome isolates from different
part of Iran have close relationship to Matin (Pakistan) strain.
Conclusions: By respecting a major public health problem, CCHF is
in the most important rank of viral hemorrhagic fevers in Iran. As
the most infected province, Sistan and Baluchistan has faced to the
disease annually, because it neighbors to Pakistan and Afghanistan with
a large border where the CCHF is endemic. Moreover, the phylogenetic
studies conﬁrmed the origin of the CCHFV from Pakistan, but more
pathogenesis and phylogenetic studies need to investigate in order to
determine why the severity and mortality rate are different in different
years and different provinces, it may perhaps be due to different strains
or with different genotypes and or different pathogenicity.
P1400 Identiﬁcation of virulent L. monocytogenes strains isolated
from wastewater
L. Ballesteros, Y. Moreno °, P. Santiago, G. Cuesta, M.A. Ferru´s
(Valencia, ES)
Objectives: Listeria monocytogenes is the causal agent of a severe food-
borne disease. It is also responsible for the highest hospitalisation rates
(around 90%) amongst known food-borne pathogens L. monocytogenes
is widely distributed and due to its capacity to resist adverse conditions it
can survive in different environments as soil, animal and human faeces,
superﬁcial waters, sewage sludge and even chlorinated water.
Presence of L. monocytogenes in wastewater could represent a high
health risk since a possible route of human infection could be the
consumption of fresh vegetables irrigated with these contaminated
treated waters.
The aim of this study was to determine the prevalence of L. monocyto-
genes virulent serotypes in wastewaters from a domestic and industrial
treatment plant from Valencia, Spain to determine the possible infection
risk through reutilization of these waters.
Methods: A total of 80 wastewater samples were analyzed. An amount
of 100ml was ﬁltered through 0.45 mm membrane ﬁlters and membranes
were incubated in modiﬁed Fraser selective broth and subsequently were
platted on Aloa and Palcam agar. All colonies suspected to be Listeria
were subcultured on blood agar plates to check the haemolytic activity.
Oxidase, catalase and Gram-stained tests were also applied. Presumtive
L. monocytogenes strains isolated were characterized by serology with
Listeria antisera set (Denken Seiken. Co, Ltd., Tokio, Japan) according
to manufacturers’ instructions, biochemical proﬁles with API Listeria
identiﬁcation system (Biomerieux, Mercy L’Etoile, France), multiplex
PCR and virulence characteristics determining the presence of lmo2821
gene were performed.
Results: Most of the 57 biochemicaly comﬁrmed L. monocytogenes
isolates belonged to 4b and 1/2b serotypes, the main recovered from
human listeriosis infection. A high percentage of L. monocytogenes
isolated showed the presence of the region gene that encodes the
fragment of the internalin protein lmo 2821 (a virulence gene).
Conclusions: This study show the high presence of virulent serotypes
of L. monocytogenes in wastewater. Use of treated waters to irrigated
crops could be an important route of the pathogen transmission due to
the ingestion of uncooked contaminated vegetables, therefore a efﬁcient
treatment and control of these waters is a priority to prevent Listeria
infection.
P1401 Interesting insights into the co-circulation of pathogens
in Ixodes ricinus ticks from rodents, birds and in questing
stages in Middle Germany
A. Hildebrandt °, J. Fritzsch, J. Franke, S. Sachse, E. Straube (Jena, DE)
Objectives: Babesia spp., Anaplasma phagocytophilum and Rick-
ettsia spp. are potentially emerging tick-borne pathogens, whereas many
issues about their ecology, e.g. reservoir host speciﬁcity, are still unclear.
The aim of our study was to get an interesting insight into the circulation
and co-circulation of different tick-borne pathogens in small mammals
and birds as potential reservoirs, but also in questing ticks from the same
area of investigation in Middle Germany.
Methods: From May until October 2007 a total of 658 Ixodes ricinus
ticks were collected from rodents (273), birds (189) and questing stages
(196) in Reifenstein in Norththuringia/Germany. They were investigated
for Babesia spp. (18S rRNA gene), Anaplasma spp. (16S rRNA gene)
and Rickettsia spp. (gltA gene) by PCR, RFLP and sequencing.
Results: Overall 13.1% (86/658) of the investigated ticks were infected
with at least one pathogen. Babesia spp. speciﬁc DNA was detected
in 9.7% (64/658) of ticks, 1.4% (9/658) were infected with Anaplasma
phagocytophilum and 2.6% (17/658) harboured rickettsiae. Babesia spp.
positive amplicons were sequenced to distinguish between Babesia
divergens (33/64) and Babesia microti (29/64). Two amplicons were only
characterized as Babesia spp. (2/64). At least two different Rickettsia spp.
were detected: Rickettsia helvetica (7/17) and Rickettsia monacensis
(2/17). The distribution among the different hosts showed the highest
infection rate with Babesia spp. in birds (13.2%, 25/189), whereas
in rodents (6.6%, 18/273) and questing ticks (10.7%, 21/196) lower
infection rates were found. Rodents and birds were identiﬁed as reservoir
or at least important co-vectors for the three pathogens, but in each
host different tick developmental stages seem to be more susceptible for
infections. Coinfections with two different pathogens occurred in 0.6%
(4/658) of the ticks, only in subadult stages (Babesia spp./Anaplasma
spp.: 2/658; Babesia spp./Rickettsia spp.: 2/658).
Conclusion: In Germany there are only few studies reporting about
the prevalence of several tick-borne pathogens and their reservoirs. Our
investigations contribute to the prevalence of Babesia spp., Anaplasma
spp. and Rickettsia spp. in Ixodes ricinus ticks of small mammals,
birds and questing ticks of the same investigation area in Middle
Germany. Further systematic studies are necessary to detect interactions
in transmission cycles and assess the risk for human diseases.
Coexistence of different pathogens in Ixodes ricinus ticks from rodents,
birds and questing stages in the same investigation area of Middle
Germany
No. of ticks collected No. (%) of positive specimens
Babesia spp. Anaplasma spp. Rickettsia spp. Total
larvae nymphs adults larvae nymphs adults larvae nymphs adults larvae nymphs adults
Rodents* 258 13 2 14/64 [1]
(21.9)
4/64 (6.3) 0 3/9 [1]
(33.3)
0 0 5/17
(29.4)
0 0 26/273
(9.5)
Birds** 62 127 0 12/64 [1]
(18.8)
13/64 [1]
(20.3)
0 2/9 [1]
(22.2)
4/9
(44.4)
0 0 4/17 [1]
(23.5)
0 35/189
(18.5)
Questing ticks 0 162 34 0 20/64 [1]
(31.3)
1/64
(1.6)
0 0 0 0 7/17 [1]
(41.2)
1/17
(5.9)
29/196
(14.8)
Total 320 302 36 26/64
(40.6)
37/64
(57.8)
1/64
(1.6)
5/9
(55.6)
4/9
(44.4)
0 5/17
(29.4)
11/17
(64.7)
1/17
(5.9)
90/658
(13.7)
No., number; [ ], number of coinfections.
*Yellow-necked mouse (Apodemus ﬂavicollis), bank vole (Myodes glareolus).
**Blackbird (Turdus merula), European robin (Erithacus rubecula), marsh warbler (Acrocephalus palustris), Dunnock (Prunella modularis),
Eurasian bullﬁnch (Pyrrhula pyrrhula).
P1402 Crimean-Congo haemorrhagic fever virus, south-eastern
Bulgaria: a case report and review
N. Kalvatchev °, I. Christova (Soﬁa, BG)
Objectives: During the last decade Crimean-Congo hemorrhagic fever
(CCHF) emerged or re-emerged in about 30 countries around the world
including Bulgaria, Albania, former Yugoslavia, Ukraine, Russia, Turkey,
and recently, in Greece. Our country is endemic region of CCHF and
sporadic cases are observed every year. Rapid and accurate diagnostic
algorithm in suspected patients is essential for a proper treatment of
infection, favorable outcome and prevention of its spread.
Methods: A man residing in southeastern city of Bulgaria, Sliven,
received a tick bite. Blood samples from the patient were drawn and
transported to the laboratory. Molecular techniques like polymerase
chain reaction (PCR) and its modiﬁcations real-time RT-PCR and nested
RT-PCR were recently introduced and now used for diagnostics of CCHF.
Results: The present case report of this viral hemorrhagic fever was
conﬁrmed by the mentioned above molecular methods. New borne mice
were infected with patient’ blood and Crimean-Congo hemorrhagic
fever virus (CCHFV) was isolated and determined by Complement
S400 20th ECCMID, Posters
Fixation Assay (CFA). A sequence of the partial gene is performed and
phylogenetic tree is designed.
Conclusion: We report here, the combined use of real-time RT-PCR,
nested RT-PCR and CFA for detection of CCHFV in this patient. With
this study we revealed and compared genetic heterogeneity of the virus
in Southeastern Bulgaria and other close endemic area.
P1403 Recent emergence of tularaemia in the region of Burgundy
(France): usefulness of real-time PCR for diagnosis of
atypical presentations
S. Mahy °, N. Roch, M. Duong, M. Grappin, M. Maurin (Dijon,
Grenoble, FR)
Background: Tularemia is a zoonotic disease caused by a Gram-negative
bacterium, Francisella tularensis. A recent increase in cases of tularemia
has been observed in France: in 2008, 105 cases were reported that is
twice more than in 2007. Two endemic areas are known in France: the
west and east (Alsace) areas. In the region of Burgundy, no cases were
reported in 2007 whereas 8 cases were notiﬁed in 2008.
Objectives and Methods: To describe the clinical presentations of ﬁve
cases of tularemia observed in the Department of Infectious diseases,
CHU Dijon from 2008 to 2009 and to show the contribution of real-
time PCR technology for early and accurate diagnosis of tularemia.
Results: Table 1: Clinical and biological characteristics of 5 patients
with tularemia.
Discussion: The clinical presentations of tularemia are polymorphous
and vary according to the routes of entry of bacteria (Table 1). As
compared to serology, real-time PCR detection of F. tularensis DNA
allows a more accurate diagnosis of tularemia, including in the early
steps of the disease. It can be performed on various tissue samples such
as skin or lymph node biopsies, conjunctival discharge or sputum.
Conclusion: Tularemia is an emerging infectious disease in the region
of Burgundy, possibly by spreading from the tularemia-endemic Alsace
region. Clinicians should be aware of the polymorphous clinical
presentations of the disease. Real-time PCR detection of F. tularensis
now supplants standard bacteriology, and allows earlier diagnosis than
serology. It provides an accurate diagnosis and allows determination of
the F. tularensis subspecies involved, which should be considered in the
context of bioterrorism threat.
Table 1. Clinical and biological characteristics of 5 patients with
tularemia
Age Suspected
route of entry
Clinical form Serology 1
(titre)
Serology 2
(titre)
PCR Therapy
1 36 Inhalation Pneumonia 1/1280 1/640 + (lymph node) Moxiﬂoxacin
2 42 Contact with
deadwood
Oculoglandular
infection
<1/20 1/1280 + (lymph node) Doxycyclin
3 38 Contact with
cold meat
Acute
lymphadenitis
1/320 Not done + (lymph node) Doxycyclin
4 48 Tick bites Acute fever <1/20 1/1280 + (skin) Levoﬂoxacin
5 40 Tick bites Chronic
lymphadenitis
1/320 1/320 + (lymph node) Ciproﬂoxacin
P1404 Vibrio-associated gastroenteritis in Italy, 2006–2008
D. Ottaviani °, F. Leoni, E. Rocchegiani, C. Canonico, S. Potenziani,
S. Santarelli, L. Masini, L. D’annibale, A. Carraturo (Ancona, Perugia,
Latina, IT)
Objectives: Vibrio infections have been rarely reported in Italy in the
past decades. For this reason, these microorganisms are not included in
the Microbiological Surveillance System for Infectious Gastroenteritis.
Results from 2006, described here show a different picture.
Methods: From January 2006 to December 2008, a passive surveillance
study for Vibrio diseases was conducted at two Hospitals of Central
Italy. A total of 100 stool specimens from hospitalized patients with
acute diarrhoea, was examined. Samples were collected on the patients’
admission to the hospital, before antibiotic treatment. Phenotypic and
genotypic characterization of the isolates was performed by standardized
procedures while susceptibility to antibiotics (amoxicillin–clavulanic
acid, ampicillin, cephalotin, cephalexin, cephoperazone, ciproﬂoxacin,
colistin, gentamicin, kanamycin, oxolinic acid, tetracycline, trimetho-
prim/sulphamethoxazole) was tested according to CLSI guidelines.
Results: Of 100 stool samples 2% were positive for V. cholerae non
O1, non O139 and 3% for V. parahaemolyticus, in absence of other
enteric pathogens. Their molecular, serological and antibiogram proﬁles
are summarized in Table.
Conclusions: We report the isolation of V. parahaemolyticus O3:K6
pandemic clone in two sporadic cases occurred in Italy in two different
years and the ﬁrst case of a gastroenteritis with V. parahaemolyticus
O1:KUT serotype in Europe. The recurrent report of Vibrio-associated
gastroenteritis, with mussels as the most probable source of infection,
emphasizes the need to include Vibrio spp in the epidemiological
surveillance of gastrointestinal diseases and re-examine control programs
for shellﬁsh-harvesting areas in Italy.
Table 1. Results of serotyping, molecular and antibiogram patterns of
Vibrios isolated from stools, Italy, 2006–2008
PCR*
Isolates Serotype Origin Source of
infection
ctxA tcpA stn/sto hylA tdh trh ToxRS Antimicrobial
resistance†
V. cholerae O176 Diarrhoeal patient
Central Italy 2006
prawn − − − + n.p. n.p. n.p. AMP; AMOX-CA
V. cholerae O37 Diarrhoeal patient
Central Italy 2006
mussels − − − + n.p. n.p. n.p. AMP
V. parahaemolyticus O3:K6 Diarrhoeal patient
Central Italy 2007
mussels n.p. n.p. n.p. n.p. + − + AMP; AMOX-CA;
CEP; CEPH
V. parahaemolyticus O3:K6 Diarrhoeal patient
Central Italy 2008
mussels n.p. n.p. n.p. n.p. + − + AMP; AMOX-CA;
CEP; CEPH
V. parahaemolyticus O1:KUT Diarrhoeal patient
Central Italy 2008
mussels n.p. n.p. n.p. n.p. − + − AMP; AMOX-CA;
CEP; CEPH; COL
*ctxA, cholera-toxin gene; tcpA, toxin-coregulated pilus gene; stn/sto, heat stable enterotoxin gene; hylA, El Tor-like haemolysin gene;
tdh, thermostable direct haemolysin gene; trh, TDH-related haemolysin gene; toxRS, pandemic marker of V. parahaemolyticus.
n.p., not performed; †AMP, ampicillin; AMOX-CA, amoxicillin–clavulanic acid; CEP, cephalotin; CEPH, cephalexin; COL, colistin.
P1405 A case of Crimean-Congo haemorrhagic fever with
acalculous cholecystitis and intra-abdominal abscess
R. Caylan °, I. Hasanoglu, D. Yapar, M.A. Tasyaran (Ankara, TR)
Crimean Congo Haemorrhagic Fever (CCHF) is a fatal systemic viral
infection and it is an important health problem in Turkey. Since it leads to
diffuse endothelial damage, many complications can be seen during the
course of the disease. We report here an atypical presentation of CCHF
with acute acalculous cholecystitis (AAC) and intraabdominal abscess
(IAA).
Case presentation: A 29-year old previously healthy female applied to a
regional health-care facility with complaints of fever, headache, myalgia
and fatigue. Despite no tick-bite history, her doctor recommended
hospitalization based on elevated liver enzymes, leukopenia and
thrombocytopenia with a prediagnosis of CCHF and referred to our
hospital because of severe trombocytopenia.
Upon admission her body temperature was 39.7ºC and had a platelet
count of 12000 K/mcL, aspartate aminotransferase (AST) 160 U/L,
alanine aminotransferase (ALT) 68 U/mL and lactate dehydrogenase
(LDH) 596 U/L. Her CCHF diagnosis was conﬁrmed by RT-PCR. She
had severe epistaxis and was treated with fresh frozen plasma, platelet
transfusions and nasal packing. Meanwhile, she developed somnolence
and had right hypocondrial and epigastric pain. Her liver enzymes
elevated suddenly (AST 4045 U/L, ALT 1223 U/mL). Ultrasonography
showed that her gallbladder wall thickness was 16mm and there was
no gallstone, so she was diagnosed as having CCHF with AAC. Her
oral intake was ceased immediately and ciproﬂoxacin was initiated.
Twenty days after admission, the patient’s fever was still high despite
antibiotheraphy. The abdominal tomography (CT) showed multiple IAA.
Her clinical status improved with antibiotheraphy and percutaneous
drainage. A control CT showed considerable reduction in the dimensions
of the abcesses.
Since endothelial damage is a main contributor in the pathogenesis of
CCHF, it can be seen in many different clinical manifestations and
complications. Although it is known as a rare complication of viral
haemorrhagic fevers, AAC hasn’t been reported in the course of CCHF.
Our case was also complicated with IAA which hasn’t been reported as
a complication of CCHF as well. It is difﬁcult to explain IAA in this
case while many aspects of the CCHF pathogenesis remain unclear. This
may have been caused by bacterial translocation during the development
Current emerging infections in Europe S401
of multiple haemorrhage sites seen in cases with aggressive courses. In
conclusion, CCHF is a systemic viral infection which can be seen with
many complications such as AAC and IAA.
P1406 Sandﬂy surveillance within an emerging epidemic focus of
cutaneous leishmaniasis in southern Iran
M.R. Yaghoobi-Ershadi °, M. Hakimiparizi, A.A. Akhavan (Tehran, IR)
Objectives: To determine the species richness and relative abundance of
sandﬂies, their distribution, monthly prevalence, number of generations
and leishmanial infection of sandﬂies in the study area.
Methods: The study was carried out from April to October of 2006
in Bahraman rural district of Kerman Province, south of Iran. Sandﬂies
were collected biweekly from indoors and outdoors ﬁxed places in the
selected villages, using 30 sticky paper traps from the beginning to the
end of the active season and they were mounted and identiﬁed. Some
blood fed and gravid female sandﬂies of rodent burrows and indoors
were dissected and examined microscopically for natural promastigote
infection of leishmania parasite during August to September. The
physiological age of each female was also determined by the presence
or absence of granules in the accessory glands. All dissected sandﬂies
were mounted and identiﬁed.
Results: In total, 2439 specimens comprising 8 species (3 Phlebotomus
and 5 Segentomyia) were identiﬁed. The most common sandﬂy is
P. papatasi and represents 87.1% of sandﬂies from indoors and 57.2%
from outdoors. The activity of the species extended from April to end
October. There are two peaks in the density curve of this species, one
in June and the second in August. Natural promastigote infection was
found in P. papatasi and it was calculated to be 12.7%. Examining the
accessory glands of the female sandﬂies from rodent burrows showed
that 85.45% of P. papatasi were parous and the rest were nuliparous and
unknown.
Conclusions: Phlebotomus papatasi is considered as a probable vector
among gerbils and to humans with a high percentage of promastigote
infection in this new focus of cutaneous leishmaniasis. The Bahraman
area which until recently was unknown as an endemic area seems now
to represent a focus of zoonotic cutaneous leishmaniasis transmission in
Iran.
P1407 Investigation for yellow fever virus exposure in humans
from central/south-eastern Anatolia
K. Ergunay, M. Saygan, S. Aydogan °, N. Litzba, M. Niedrig, N. Ozer,
S. Bulut, D. Us (Ankara, TR; Berlin, DE)
Objectives: Yellow fever is a viral hemorrhagic fever with high
mortality that is transmitted by mosquitoes. The disease is present
now in Africa and Central/South America, although historically, large
outbreaks occurred in Europe and North America. Mosquitoes capable
of transmitting yellow fever exist in regions where the disease does not
presently occur. Data available on possible Yellow Fever virus (YFV)
activity in Turkey is limited to a single study where total YFV antibodies
were found in 9.7% in a survey of 1074 sera from Aegean region of
Turkey but none could be conﬁrmed. The aim of this study, partially
supported by Hacettepe University Research Fund and Turkish Red
Crescent Society, was to investigate YFV exposure in persons from
Central and Southeast Anatolia. This is the ﬁrst study to investigate
YFV exposure in these regions.
Methods: A total of 1523 sera, that comprise 1454 sera from blood
donors at 4 major branches (Ankara, Konya, Eskis¸ehir and Zonguldak)
of Turkish Red Crescent Middle Anatolia Regional Blood Center, along
with 69 sera obtained from adults attending to outpatient clinics of State
Medical Centers of Sanliurfa and Siverek (southeastern Turkey) for other
laboratory analyses were included after informed consent. All individuals
were asked to ﬁll out a survey to reveal risk factors for vector-borne viral
infections and persons with a history of Yellow Fever vaccination were
excluded. All sera were previously evaluated with commercial ELISA
assays for other ﬂaviviruses (Anti-Dengue virus, Anti-TBE virus and
Anti-West Nile virus ELISA, EUROIMMUN, Germany) and found to
be negative. Evaluation for the presence of YFV IgG was performed by
a commercial IgG indirect immunoﬂuorescence test (IIFT) (Anti-Yellow
Fever virus IgG IIFT, EUROIMMUN, Germany). All positive samples
were retested twice and further evaluated by YFV plaque reduction
neutralization assay to conﬁrm antibody speciﬁcity.
Results: A total of 10 sera (10/1523, 0.65%) were positive in initial
evaluation and repeat testing by the YFV IgG IIFT. All were negative in
the plaque reduction neutralization assay.
Conclusions: No conﬁrmed exposure to YFV could be demonstrated in
this study. In order to rule out the presence of YFV activity in Anatolia,
detailed vector surveillence data should be collected and thoroughly
evaluted to identify mosquito species that may act as potential vectors.
P1408 Comparison of Clostridium difﬁcile genotypes isolated from
patients, environment and animals
V. Zidaric °, S. Janezic, M. Ocepek, B. Kotnik Kevorkijan, N. Oresic,
J. Rebersek Gorisek, M. Rupnik (Maribor, Ljubljana, SI)
Objectives: Clostridium difﬁcile is important human pathogen of health
care-associated infections. Recent studies from North America have
indicated large overlap between genotypes isolated from pigs and
cattle with human isolates. Reports from the Netherland showed that
strains of emerging ribotype 078 isolated from humans and pigs are
indistingushable. The objective of this study was to compare genotypes
present in humans in our region with animal and environmental strains
isolated in the same geographic region in same time interval.
Methods: Strains were collected from January 2008 to June 2009. The
majority of strains was isolated from humans and originated from the
routine diagnostic laboratory. Animal strains were isolated from animal
fecal samples collected at small and large farms (pig, poultry, and cattle
farms) or from pets. Environmental samples included rivers and soil.
Strains were identiﬁed as C. difﬁcile accoding to cultural morphology and
presence of sequences speciﬁc for toxigenic or nontoxigenic strains. All
strains were PCR ribotyped and patterns were compared by Bionumerics
software.
Results: Altogether, 327 strains were isolated from: patients in different
health care settings (n = 116), different animal species (n = 48) and from
environment (soil and water) (n = 163); 261 strains were toxinogenic and
67 nontoxinogenic. They were distributed into 58 PCR ribotypes.
Human strains were included into 42 PCR ribotypes, 5 of them were
also found in animals and 19 in environmental samples.
Three PCR ribotypes were found only in animals and 13 only in
environmental samples.
Three most prevalent PCR ribotypes were 014, 002, INT010 accounting
for 22.3%, 12.0% and 10.1% strains, respectively. All of them were
present in different hosts and environments.
Conclusion: Diversity of C. difﬁcile genotypes in different hosts and
environments is considerable, but almost 50% of all strains belonged to
only three PCR ribotypes, all of them present in humans, most animal
species and rivers.
P1409 Microbiological and clinical features of Clostridium difﬁcile
infection cases visiting emergency room in a tertiary care
hospital
B. Shin °, S. Mun, E. Kuak (Seoul, KR)
Objectives: Clostidium difﬁcile is one of the most important pathogens
responsible for nosocomial diarrhea. Recently, community acquired
C. difﬁcile infection (CA-CDI) have been reported worldwide. We have
experienced C. difﬁcile positive cases among patients visiting emergency
room in a tertiary hospital. The purpose of this study is to provide the
basic features of the microbiological and clinical features of them to
differentiate CA-CDI from hospital acquired CDI.
Methods: We performed 201 cases of toxin A/B EIA test, C. difﬁ-
cile culture and enteric pathogen (Salmonella/Shigella) culture from
patients visiting ER from Feb, 2006 to Nov 2009. We ampliﬁed
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toxin A and B genes in culture positive cases to differentiate toxin
positive(tcdA+tcdB+), variant(tcdA−tcdB+) and negative(tcdA−tcdB−)
strains. PCR-ribotyping was performed. Laboratory ﬁndings (albumin,
creatinine, WBC), underlying diseases and histories about antibiotic
usages were evaluated.
Results: C. difﬁcile were isolated in 29 cases (14.4%). No Salmonella
or Shigella spp. were isolated. Their mean age was 54 years (19−92) and
no statistical difference was observed between male and female. Toxin
gene PCR assay revealed that the proportion of positive, variant and
negative strains were 76%, 17% and 7%, respectively. PCR ribotyping
revealed diverse patterns among C. difﬁcile strains except variant
strains. Among the culture positive cases, 19 cases (65.5%) had no
histories of antibiotics, but10 cases (34.5%) had the history of antibiotic
usage and cephalosporin was the main antibiotic taken (80%). Mean
value of albumin, creatinine and WBC of CDI cases were 3.42 g/dL,
1.16mg/dL and 1,1240/uL, respectively. The main underlying diseases
were malignancy, pneumonia and gastroenteritises.
Conclusion: Compared with HA-CDI cases, CDI cases visiting ER were
relatively younger patients. Some of the CDI cases with antibiotic history
were associated with cephalosporin more than quinolone. Toxin variant
strain was also important strain among CDI cases visiting ER and diverse
PCR ribotyping patterns were observed.
P1410 Detection and characterization of kobuviruses (in family Pi-
cornaviridae) in human and in new host species in Hungary
G. Reuter °, A´. Boldizsa´r, A´. Boros, P. Pankovics (Pe´cs, HU)
Objectives: Picornaviruses (family Picornaviridae) are small, non-
enveloped viruses with single-stranded, positive-sense genomic RNA
which is divided into eight genera. Kobuvirus genus consists of 2
ofﬁcially recognised species, Aichi virus and Bovine kobuvirus. Aichi
virus has been isolated in stool sample from human with gastroenteritis
in Japan, in 1990. Bovine kobuvirus (strain U-1) has been detected in
clinically healthy cattle in Japan, in 2003. Up to 80−95% of the human
population at the age of 30−40 years has antibodies against Aichi virus.
Methods: Fecal samples collected from human (N= 65), cattle (N = 32),
domestic pig (N= 60+60) and sheep (N= 8) were tested for kobuvirus
by RT-PCR in Hungary. For detection and characterization of viral
genome, newly designed screening, typing primers, “genome-walking”
and sequencing methods were used.
Results: Aichi virus was found in 1 (1.5%) of the stool samples
from children under age of 10 years with diarrhea with unknown
origin. Bovine kobuvirus was detected in two cattle (6.25%) at the
ﬁrst time outside Asia. Serendipitously, new kobuvirus species were
found from fecal samples collected from domestic pigs in Hungary.
Porcine kobuvirus (S-1-HUN, EU787450) was found in healthy pigs
and complete nucleotide (8,210nt), amino acid (2,488aa) sequences and
genetic organization were determined. The 5′ untranslated region (UTR)
forms an unique hepacivirus/pestivirus-like type IV IRES element. Two
copies of 90 nucleotides long tandem repeat was detected in 2B and
a unique sequence in 3′UTR. The genetic identity on coding region
between Aichi, U-1 and S-1-HUN viruses are between 35% (L-protein)
and 74% (3D region). By 21 months follow up study, high incidence
(65% and 53%) and endemic circulation of porcine kobuvirus were
found at the tested farm (in vivo evolution rate for VP1 is 6.75×10−3
substitutions/nucleotide/year). Porcine kobuvirus was also present in pig
sera samples (32/60; 26.6%) indicating kobuvirus viraemia at the ﬁrst
time. Kobuvirus sequences related to bovine kobuvirus strains were also
found in newborn sheep (N= 5, 62.5%).
Conclusion: Kobuviruses were identiﬁed in 4 host species including
human. Our knowledge’s (about diversity, pathogenesis, geographical
distribution, transmission, epidemiology, virus organization etc.) are
not complete related to enterically transmitted viruses especially
kobuviruses.
Infections in the immunocompromised host
and transplant patients
P1411 Epidemiology and outcome of Gram-positive bloodstream
infection in solid organ transplant recipients
M. Ferna´ndez-Ruiz °, L. Linares, C. Cervera, M. Almela, M. Tuset,
F. Cofa´n, M.J. Ricart, M. Navasa, A. Escorsell, E. Roig, A. Moreno
(Barcelona, ES)
Aim: Bloodstream infection (BSI) is one of the most frequent
complication in solid-organ transplantation (SOT) recipients. Our aim is
to estimate the incidence, outcomes and risk factors for Gram-positive
BSI in this population.
Methods: Prospective cohort study in the period between July,
2003 and December, 2007, including patients receiving renal, liver,
heart and simultaneous double-organ transplantation. Demographics,
underlying conditions, immunosuppressive schemes, and post-transplant
complications were prospective collected. BSI was deﬁned as signiﬁcant
according to the CDC criteria. BSI-related mortality was deﬁned as a
death occurring within the ﬁrst 30 days. Multivariate logistic regression
analysis was performed to identify variables associated with Gram-
positive BSI after SOT.
Results: A total of 1,049 SOT were performed in the study period (528
kidney, 318 liver, 83 heart, and 120 double transplant). We diagnosed
186 recipients (17.7%) with at least one episode of Gram-positive
infection. There were 72 episodes of Gram-positive BSI in 64 patients
(6.1% of global cohort). The cumulative incidence according to the
type of SOT was: kidney (2.6%), liver (12.5%), heart (2.4%) and
double transplant (6.6%) (p< 0.001). The most frequent source of BSI
was catheter-related (40.3%). Thirty-nine percent of episodes occurred
during the ﬁrst month after transplantation. Isolated species were:
methicillin-resistant coagulase-negative staphylococci (CoNS) (27.8%),
Enterococcus faecalis (23.6%), methicillin-susceptible CoNS (16.7%),
methicillin-susceptible Staphylococcus aureus (12.5%), Enterococcus
faecium (8.3%), methicillin-resistant S. aureus (MRSA) (1.2%), and
others (9.9%). Vancomycin (29% of episodes) and teicoplanin (22%)
ﬁgured as the most common ﬁrst-line treatments. Multivariate analysis
revealed as independent risk factors for Gram-positive BSI: liver
transplantation (OR 3.74, CI 95% 2.18–6.39) and re-operation (OR 2.79,
CI 95% 1.65−4.3). Twenty-three of 64 patients with Gram-positive BSI
(35.9%) deceased, including 9 cases with related mortality.
Conclusion: The incidence of Gram-positive BSI after SOT was high,
speciﬁcally in liver transplant recipients. Type of transplant and re-
operation revealed as independent risk factors for the occurrence of such
complication. Our results provide preliminary evidence of the decreasing
prevalence of MRSA as a cause of BSI in SOT recipients, and the
emergence of Enterococcus in this group of patients.
P1412 First isolation of catalase-negative Staphylococcus aureus
from cerebrospinal ﬂuid: case report and review
M.R. Vicente °, E. Escribano, J. Lozano, M. Garcia-Sa´nchez,
M.D. Crespo (Albacete, ES)
Objectives: Isolation of catalase-negative Staphylococcus aureus
(CNSA) from cases of human infection has occasionally been reported.
We report a case of endocarditis and meningitis in which methicillin-
resistant CNSA was isolated from cerebrospinal ﬂuid (CSF), blood and,
probably, from the prosthetic aortic valve.
Methods: Case report and review of the English and Spanish medical
literature.
Results: On 7 September 2009, a 67-year-old woman was admitted
to our hospital for fever, chills, vomiting, rigor and confusion. She
had underwent mitral and aortic valves replacement two months
before. For suspected central nervous system infection a lumbar
puncture was performed. CSF showed 92 leucocites/mm3 (74%
PMN), proteins 0.85 g/L and glucose 98mg/dL. She was started on
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vancomycin and meropenem therapy. On hospital day 3, she began with
signs of heart failure. Transesophageal echocardiogram (TEE) showed
multiple vegetations on mitral valve, periprosthetic abscess and severe
periprosthetic mitral regurgitation. At this time, methicillin-resistant
S. aureus (MRSA) was isolated from blood and CSF cultures, so
treatment was changed to vancomycin, gentamicin and rifampin. She
underwent aortic and mitral prosthetic valves replacement. An external
laboratory reported us the isolation of MRSA from the prosthetic aortic
valve. She presented multiorganic failure with renal insufﬁciency and
vancomycin was changed to linezolid. After six weeks with antibiotics,
a new TEE showed new vegetations and periprosthetic mitral valve
regurgitation, so new cardiac surgery was performed. S. aureus isolated
from blood and CSF was repeatedly catalase negative. Reference
laboratory reported that both strains belonged to the same mixed phage
group. We have found other 25 documented cases of CNSA human
infection or colonization. Most cases came from Europe (13/26). Patients
were predominantly male (15/25), with a mean age of 53 years (range,
1−80) and frecuently had underlying conditions. Six out of 16 reported
autcomes were fatal. The most frecuent culture sources were blood
(12/25) and wound or soft tissue samples (10/25). Seven out of 20 strains
were methicillin-resistant.
Conclusion: This is the ﬁrst report of CNSA meningitis and the ﬁrst
report of methicillin-resistant CNSA human infection in Spain. Reports
of infections caused by CNSA and caracterization of such strains must
be encouraged to clarify the role of catalase in the pathogenicity of
Staphylococcus sp.
P1413 Infectious endocarditis in patients with cirrhosis of the
liver: unique causative agents and dreadful prognosis
M. Ferna´ndez Guerrero °, M. Go´rgolas (Madrid, ES)
Objectives: Infectious Endocarditis (IE) is, more than in the past, an
infection of the chronically ill, fragile patient. We hypothesized that
patients with cirrhosis of the liver (CL) may be at increased risk
of developing IE in the community and the hospital settings, valve
replacement is denied even when indicated and prognosis is gloomy.
Methods: Retrospective review of consecutive cases of IE in patients
with CL during a period of 10-years in a single institution. Only cases
of deﬁnite IE according to the modiﬁed Duke’s criteria in patients with
clinical or pathogical criteria for CL were included. Patients with chronic
hepatitis were excluded. A control group composed by 2 patients without
CL − the immediate preceding and the immediate following a case
patient − was chosen for comparison.
Results: LC was found in 27 out of 286 cases of IE (9.4%). Alcoholism
and hepatitis B and C virus were the main causes of CL. Patients with CL
were younger than controls (58.6 vs 67.3 y). Differences on predisposing
valve disorders or location of IE were not observed. Non-viridans
streptococci (OR 4.9; CI95% 1.4–16.6; p< 0.05) and b-hemolytic
streptococci (OR 12; CI95% 1.3–109; p< 0.05) were causative agents of
IE more frequently in patients with CL than in controls. IE was hospital-
acquired in 37% of patients with CL and in 12.9% of controls (OR 3.9;
CI95% 1.3−12; p< 0.05). Venous catheters, Foley catheters, parenteral
nutrition, colonoscopy, liver biopsy and Sengstaken-Blakemore baloon
were the sources of nosocomial IE in patients with CL. Surgery was
indicated in 16 cases (59.2%) with CL and in 23 of controls (42.5%);
remarkably, while surgery was undertaken in 19 (82.6%) of controls, it
was performed in only 4 (25%) of patients with CL (OR 0.07; CI95%:
0.01–0.33; p< 0.05). Mortality of patients with CL was signiﬁcantly
higher than in controls (48% vs 20%; OR 3.6; CI95%:1.3−9.9; p< 0.05).
Conclusions: Cirrhosis of the liver is nowadays a common underlying
condition in patients with IE. Patients with CL have a serious hazard
of acquiring IE during admission to hospital for invasive diagnostic or
therapeutic procedures. “Virulent” microorganisms such as b-hemolytic
streptococci and S aureus are the most frequent causative agents of IE
in patients with CL. Sugery, even when indicated, is denied or refused
and mortality is exceedingly high.
P1414 Incidence, aetiology and chronology of urinary tract
infections after renal transplantation
A. Martı´n-Pen˜a °, E. Cordero, M.E. Garcı´a-Prado, V. Cabello,
G. Bernal, M.J. Rodrı´guez-Herna´ndez for the Spanish Network for
Research in Infectious Disease (REIPI)
Objectives: Urinary tract infection (UTI) after renal transplantation
remains a source of morbidity and graft faliure. The aim of this study
was to evaluate the incidence, etiology and chronology of UTI in renal
transplant recipients during the ﬁrst year postransplantation.
Method: Retrospective and observational study of a cohort of adult
recipients that consecutively received a renal transplant enrolled from
January to December of 2008.
Results: During the study period, 89 patients (66.3% men) were
included, with a median age of 52 (range: 17, 53) years and a
median follow up of 262.5 (range: 65, 453) days. A total of 152
UTI were recorded in 61 patients of whom 124 (81.6%) were lower
UTI and 28 (18.4%) pyelonephritis. Fourteen pyelonephritis (50%) were
bacteremic. The global incidence of UTI was 70% (81.6% lower ITU,
18.4% pyelonephritis). Among patients with UTI, median number of
episodes/patients was 1.7. The main etiology of UTI was Escherichia coli
(91, 54.8%) being in nine cases extended blactamase (ESBL) producers,
followed by Enterococcus faecalis (22, 13.3%) and Klebsiella pneumonia
(14, 9.6%). Etiology was polymicrobial in 14 cases. Lower UTI was
caused in ﬁve episodes by Candida glabrata. ESBL producer E. coli,
was more frequent in pyelonephritis 21.4% (3/14) than in lower UTI
4.8% (6/124), RR 4.4 CI95% 1.2–15.8, P = 0.05. Median time to UTI
appearance after transplantation was 52 days (range: 1–436). Most of the
UTI occurred during the ﬁrst month post-transplantation (62, 40.8%)
being lower UTI the most frequent clinical presentation (54, 87.1%).
Between second to sixth month post transplantation, 72 UTI were
diagnosed, 25% of them were pyelonephritis. After six months, 11.1%
(2/18) of episodes were pyelonephritis. Most of UTI (95, 62.5%) had
a good prognosis and 36.8% were recurrent infections. Seven patients
(7.8%) death during the study period but only in one case (0.6%) death
was considered infection related, a complicated pyelonephritis caused by
ESBL producer E. coli.
Conclusions: Urinary tract infections are a common syndrome after
renal trasplantation. Escherichia coli is the most common etiology of
these infections with a high rate of ESBL producer strains mainly in
pyelonephritis. Despite their frequency, urinary tract infections have a
good prognosis.
P1415 A two-centre retrospective study on the microbiology of
bisphosphonate associated osteonecrosis of the jaws
M. Jackson °, J. Sna¨ll, R. McFadzean, A. Smith,
R. Rautemaa-Richardson (Glasgow, UK; Helsinki, FI)
Objective: Bisphosphonate associated osteonecrosis (BON) of the jaws
is a side effect of bisphosphonate therapy, which is commonly used in
the management of osteoporosis, multiple myeloma and bone metastasis.
The bisphosphonates act by inhibiting bone resorption resulting in an
interference with the normal process of bone turnover. This creates the
potential for aseptic necrosis of bone which may subsequently become
infected. The mandible in particular appears at heightened risk for
BON. There is very little information in the literature concerning the
microbiology of infected BON of the jaws. The aim of this study was
to determine the microbiology of specimens from BON lesions of the
jaws.
Method: A review of cases with a clinical history of BON was
determined by a data-base search over the period 2005–2007 (Helsinki)
and by hand searching laboratory records over the period 2006–
2009 (Glasgow), submitted to the respective regional diagnostic oral
microbiology laboratories.
Results: In Helsinki (He), 18 cases of BON of the jaws were identiﬁed.
Of these, specimens had been submitted for microbiological analyses
in 11 cases. In Glasgow (Gl) 14 specimens had been analysed. All
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specimens demonstrated mixed growth comprising Actinomyces spp.
(8/11 specimens He, 2/14 Gl), S. anginosus group (2/11 He, 5/14
Gl), anaerobic cocci (4/11 He, 3/14 Gl) and anaerobic Gram negatives
such as Prevotella and Fusobacterium spp (8/11 He, 1/14 Gl) in
addition to Viridans group streptococci (10/11 He, 8/14 Gl). Many
isolates demonstrated reduced susceptibility to penicillin and macrolides.
Resistance to clindamycin was more common than to doxycyclin.
Conclusions: Our results from this small cohort of patients with infected
BON of the jaws demonstrates that Actinomyces spp, Streptococcus spp.
and Gram negative anaerobes are the predominant ﬁndings, many with
reduced antimicrobial susceptibility. Clinicians should be encouraged
to submit appropriate samples to aid in the management of this
condition. This data should be considered when proposing guidelines
for prophylaxis and therapy of infected BON of the jaws. It appears
that the choice and duration of empiric antimicrobial therapy should be
directed towards Actinomyces spp. Laboratory protocols should include
prolonged culture for these slowly growing facultative and anaerobic
pathogens.
P1416 Prostethic-joint infections in cancer patients
D. Nisichenko, N. Dmitrieva, I. Petukhova °, Z. Grigoryevskaya,
I. Shilnikova, E. Sokolova (Moscow, RU)
Infections associated with prosthetic joints lead to signiﬁcant morbidity,
increase of ﬁnancial costs and worsening of the quality of life.
Aim: to evaluate the postoperative rate of prosthetic joint infections (PJI)
in cancer patients (pts) with various malignant tumors of bones.
Materials and Methods: 385 pts with primary or metastatic tumors
of hip, tibia or shoulder after surgical bone resection and prosthesis
implantation were included in the analysis. The time of onset symptoms
due to infections was registered. Identiﬁcation and susceptibility testing
of microorganisms isolated from synovial ﬂuid in cases of postoperative
PJI was performed with VITEK-2 (bioMe´rieux, France).
Results: PJI were registered in 55/385 (14%) of pts. The rate of PJI var-
ied due to tumor localization: 6% − after tumor resection with shoulder
joint endoprosthesis, 16% − after resection with hip joint endoprosthesis,
8% and 20% (p< 0.05 compared to shoulder joint) after resection and
knee joint endoprosthesis depending on the tumor localization in hip
bone, and 15% after total prosthesis of the hip. Early infections (<3
month) were revealed in 27/55 (49%) of pts, delayed infections (from
3 month till 2 years) in 9/55 (16%) of pts and late infections (>2
years) in 19/55 (35%) of pts. Early and late infections were registered
signiﬁcantly more often (p< 0.001 and p< 0.05). Conservative treatment
including antimicrobials was successful in 40% of patients. 5-year
survival rate of prosthesis ranged between 26% (total hip prosthesis)
and 74% (shoulder prosthesis). The main pathogens were Staphylococcus
aureus and coagulase-negative staphylococci − 42−55% depending on
prosthesis localization. Enterococcus faecalis, Pseudomonas aeruginosa,
Acinetobacter baumannii, anaerobes (Fusobacterium nucleatum and
Peptostreptococcus magnum) were rarely isolated.
Conclusion: PJI were registered more often in early and late periods
after operation. Infection rate was maximal after resection with knee
endoprosthesis. Staphylococcus spp. were the main cause of PJI in
malignant bone tumors pts.
P1417 Mycobacterium tuberculosis in kidney transplant recipients:
a single centre 19-year experience in Korea
S.I. Kim °, K.W. Hong, Y.J. Kim, S.H. Wie, Y.R. Kim, M.W. Kang (Seoul,
KR)
Objectives: Transplant recipients are highly susceptible to various
opportunistic infections. Epidemiologic data showed thatMycobacterium
tuberculosis (MTB) is not common in western countries; however Korea
has been one of endemic area for MTB. Special considerations are
needed to prevent and to treat the MTB in transplant recipients. To
make proper strategy, we reviewed medical records to ﬁnd the incidence,
manifestations and outcomes of MTB infection in renal transplant
recipients of our center.
Methods: We retrospectively reviewed the medical records of 1,325
patients who had renal transplantation since January 1990 to September
2009.
Results: MTB was diagnosed in 5.05% (67/1,325) of renal transplant
recipients. Mean age was 51 year-old, and 67.1% (45/67) were men.
Diabetes was seen in 34.3% (23/67) of patients, 40.2% (27/67) had
episode of rejection before MTB manifestation, and 13.4% (9/67)
had positive results for cytomegalovirus reactivation during MTB
manifestation. Regarding past history, 25.3% (17/67) had previous
history of MTB. Among them only 2 patients had received isoniazid
prophylaxis before transplantation.
Pulmonary involvement [55.2% (37/67)] was more common than
extrapulmonary involvement [44.7% (30/67)]. Disseminated MTB was
14.9% (10/67). The mean time between transplant and MTB was 43.5
months. Twenty-ﬁve patients (37.3%) were diagnosed with MTB within
the ﬁrst year after transplantation.
Mean duration of treatment was 12.4-month. Anti-TB therapy related
renal toxicities were found in 26.8% (18/67) and hepatotoxicities were
found in 5.9% (4/67). Drug interactions that need to modify the
immunosuppressive agents were found in 43.2% (29/67).
Treatment success rate was 68.6% (46/67). Six patients (8.9%) died;
among them one case was MTB related mortality. Nine patients (13.4%)
experienced recurrence of MTB after cessation of anti-TB treatment and
one patient experienced aggravation of MTB during treatment. Graft loss
occurred 43.2% (29/67) of patients after MTB.
Conclusion: Our center showed 5.05% incidence of post-renal transplant
MTB, which is much higher than general population (0.07%) and
Western countries. MTB infection in renal transplant recipients showed
lower rate of treatment success and was related with high rate of graft
rejection. Considering that Korea is endemic area for MTB, patients
with previous history of MTB, more aggressive preventive strategies are
needed to reduce the risk of MTB reactivation and graft loss.
P1418 Prophylaxis vs. pre-emptive therapy for cytomegalovirus
disease in (D+/R−) liver transplant recipients
N. Ferna`ndez-Sabe´ °, L. Llado´, M. Bodro, J. Niubo´, J. Castellote,
E. Ramos, J. Fabregat, J. Carratala` (Hospitalet, ES)
Objective: Cytomegalovirus (CMV)-seronegative recipients (R−) of
CMV-seropositive donors (D+) have the highest risk of CMV disease.
The most appropriate strategy to prevent CMV disease in this population
is a matter of active debate. We aimed to compare prophylaxis and
preemptive therapy for the prevention of CMV disease in D+/R− liver
recipients.
Methods: Analysis of a prospective cohort of liver recipients (1992–
2009). D+/R− patients were identiﬁed from the liver transplant program
database.
Prophylaxis
n = 35
Preemptive
therapy
n = 39
p-value
Viremia (%) 3 (9) 15 (38) 0.003
Mean days after Tx 98 42 0.041
Viral syndrome (%) 2 (6) 6 (15) 0.267
Mean days after Tx 113 30 0.301
CMV disease (%) 3 (9) 13 (33) 0.010
Type of CMV disease
Hepatitis 0 7
Digestive disease 3 4
Pneumonitis 0 2
Mean days after Tx 104 45 0.143
Late-onset CMV disease
(>90 days after Tx)
2 0 0.220
Allograft rejection (%) 6 (17) 6 (15) 0.838
Other opportunistic infections (%) 1 (3) 4 (10) 0.361
One-year case fatality rate 2 (6) 5 (13) 0.435
Infections in the immunocompromised host and transplant patients S405
Results: Among 878 consecutive liver recipients, 80 (9%) were
D+/R−. Six patients died within 30 days of transplantation (Tx) and
were excluded. Of the remaining D+/R− patients, 35 (47%) received
prophylaxis and 39 (53%) followed a preemptive strategy, based on
CMV antigenemia surveillance. Fifty-four (73%) were men; mean age
49 yrs (15−68). Mean follow-up was 86 months (8–214). Baseline char-
acteristics and initial immunosuppressive regimens were similar in the
two groups. Either ganciclovir or valganciclovir were the antiviral drugs
initially used in both strategy groups. The table details the main results.
Conclusions: In D+/R− liver patients, CMV disease signiﬁcantly
occurred more frequently among patients following preemptive therapy,
whereas late onset CMV disease was more common in patients receiving
prophylaxis. No signiﬁcant differences in allograft rejection, other
opportunistic infections and mortality were observed.
P1419 Herpesviridae viral infections following chemotherapy
in patients with lymphoma: incidence, risk factors, and
prevention
J.Y. Park °, H. Kwon, H.S. Lee (Busan, Daegu, KR)
Objectives: Herpesviridae viral infection(HVI) can cause serious
complications such as dissemination and bacterial superinfection in
lymphoma patients undergoing chemotherapy. But there was no
consensus on the dose and the duration of antiviral prophylaxis during
chemotherapy in lymphoma patients. We retrospectively analyzed the
incidence and the risk factors for HVI.
Methods: 266 patients who newly diagnosed and received an
chemotherapy without prophylaxis of acyclovir between June 1996 and
August 2009 were enrolled retrospectively at a teaching hospital in
Korea. HVI was conﬁrmed based on clinical diagnosis, serologic test
or pathologic diagnosis. The characteristics of the patients were as
follows: the median age was 54 years (range 15−83) with a female-
to-male ratio of 150:116. The included lymphomas were diffuse large B
cell lymphoma (n = 151), Hodgkin’s disease (n = 16), T cell lymphoma
(n = 43) and other lymphoma (n = 56). The results were analyzed using
a c2 test and independent samples T test. For the multivariate analysis,
we used logistic regression test.
Results: Forty three patients (16.2%) developed HVI at a median of
5.43 months (range 0.43–51.33) after initial chemotherapy. In univariate
analyses, risk factors for HVI were gender (p = 0.002, 10% in male
vs 24.1% in female), cumulative dose of prednisone (p< 0.001, 4.0%
in less than 4000mg vs 31.6% in more than 4000mg), duration of
chemotherapy (p = 0.009, 11.8% in less than 6 months vs 24.0% in
more than 6 months), presence of relapse (p = 0.007, 24.7% in relapse
vs 11.9% in non-relapse), salvage chemotherapy (p = 0.009, 11.8% in no
salvage chemotherapy vs 24.0% in salvage chemotherapy), and presence
of neutropenic fever (p = 0.019, 26.9% in neutropenic fever vs 13.6%
in no neutropenic fever). In multivariate analysis, the results conﬁrmed
2 variables as independent predictive factors for the female (p< 0.001,
hazard ratio (HR): 4.915, 95% conﬁdence interval (CI) 2.200–10.981)
and cumulative dose of prednisone (p< 0.001, HR: 14.269, 95%CI
5.241–38.848). There was no different mortality and survival rate
between HVI and non-HVI group.
Conclusion: Female and high dose prednisone was seemed to be high
risk for HVI in lymphoma patients undergoing chemotherapy without
acyclovir prophylaxis. Antiviral prophylaxis for HVI may be needed in
higher risk lymphoma patients undergoing chemotherapy.
P1420 Cytomegalovirus infection after liver transplantation −
incidence and beneﬁt of ganciclovir prophylaxis
P. Schnitzler °, K. Weigand, J. Schmidt, F. Chahoud, D. Gotthardt,
P. Schemmer, W. Stremmel, P. Sauer (Heidelberg, DE)
Objectives: Cytomegalovirus (CMV) infection represents a complication
after liver transplantation. Depending on CMV status of donor and
recipient and individual risk proﬁle antiviral prophylaxis is recommended
in clinical practice guidelines.
Methods: Altogether 211 liver transplant recipients were retrospectively
analyzed for CMV infection after transplantation, inﬂuence of donor and
recipient CMV status and effect of antiviral prophylaxis. Underlying liver
disease and immunosuppressive protocol was correlated to incidence
of CMV infection. The mean follow-up time after transplantation was
24.5±13.5 month. Patients were divided in four groups according
to CMV donor/recipient (D/R) proﬁle: group A (D−/R−), Group B
(D−/R+), Group C (D+/R+), Group D (D+/R−).
Results: The donor/recipient proﬁle distributed as follows: Group A, 28
patients (pts), group B, 64 pts, group C, 79 pts and group D, 40 pts. CMV
infection was observed in 17.9%, 29.7%, 24.1% and 22.5%, respectively
and was not signiﬁcantly different in groups A, B, C and D. In group A
with a low risk proﬁle a CMV infection occurred in 5 pts (17.9%),
despite an antiviral prophylaxis in 4 pts. In contrast, in group D with a
presumed high risk proﬁle only in 9 of 40 pts (22.5%) CMV infection
was observed in spite of prophylaxis in most patients. Most frequent
infection rates were found in group B and C (R+ groups), with 29.7%
and 24.1%, respectively. Underlying liver disease or immunosuppressive
protocol had no inﬂuence on CMV infection.
Conclusion: Independently from donor/recipient CMV status, approx-
imately one fourth of patients will acquire CMV infection after liver
transplantation. Surprisingly, antiviral prophylaxis seems not sufﬁcient
to reduce this proportion of patients, neither in the high risk, nor in the
low risk situation.
P1421 HHV-6-DNAemia after liver transplantation monitored by
two quantitative real-time PCR methods
T. Karlsson, R. Loginov, K. Ho¨ckerstedt, I. Lautenschlager ° (Helsinki,
FI)
Objectives: HHV-6 is a ubiquitous virus with a high seroprevalence
(>95%). Like other herpesviruses HHV-6 can reactivate under
immunosuppression. In liver transplantation, most HHV-6 reactivations
are asymptomatic, but also symptoms and graft dysfunction have been
described. The aim of the study was to compare two quantitative HHV-6
PCR tests and correlate with HHV-6 antigenemia in liver transplant
patients.
Methods: Thirty adult liver allograft recipients were frequently
monitored for HHV-6 during the ﬁrst 6 months after transplantation.
HHV-6 reactivations were diagnosed by the antigenemia test in PBMC
using indirect immunoperoxidase staining and monoclonal antibodies
against HHV-6. Altogether, 170 whole blood specimens (mean 5
samples/patient) were analyzed. HHV-6-DNA was tested by using
automated sample preparation system MagNa Pure LC and quantitative
Taqman-based “in-house” real-time PCR and commercial quantitative
Argene CMV, HHV6, 7, 8 R-geneTM kit. Argene’s test ampliﬁes a
sequence of viral U57 gene and the “in-house” assay ampliﬁes a
sequence of viral U67 gene, detecting both HHV-6A and HHV-6B
variants.
Results: HHV-6-antigenemia was recorded in 17/30 (56%) patients and
HHV-6 DNAemia in 13/30 (43%). HHV-6-DNAemia usually occurred
during the ﬁrst weeks after transplantation. The viral loads by the “in-
house” Taqman test varied between 520−19 700 copies/ml (median
1310) and by Argene’s test 250−24 070 copies/ml (median 440). The
correlation of viral loads between two quantitative tests was good
(R = 0.93).
Conclusions: HHV-6 reactivations were common after liver transplan-
tation. The results of the both PCR methods correlated mostly with
HHV-6 antigenemia, and the correlations between the two quantitative
PCR assays was good.
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P1422 Incidence of invasive fungal infection in adult liver
transplant recipients in the intensive care unit: a prospective
validation of a risk stratiﬁcation scheme
A. del Palacio °, M.S. Cue´tara, M.E. Alvarez, A. Alhambra, M. Catala´n,
J.C. Montejo, J. Ponto´n (Madrid, Legane´s Madrid, Lejona-Vizcaya, ES)
Objective: Hellinger et al (Liver Transpl 2005; 11:656) proposed a
risk group stratiﬁcation of invasive fungal disease (IFD) in adult liver
transplant recipients (LTR). Our aim was to prospectively validate this
proposal in LTR requiring mechanical ventilation in the intensive care
unit (ICU) and the relationship between the incidence of IFD (per patient)
and risk group.
Methods: Patients were stratiﬁed into 3 groups: (1) High risk LTR were
patients on haemodialysis at the time of transplantation or with delay of
hospital discharge beyond day 7 after transplantation due to allograft
or renal insufﬁciency; (2) Intermediate risk − retransplantation or
transplantation due to fulminant hepatic failure; (3) Low risk − absence
of conditions in groups 1 and 2. Conventional diagnostic methods,
biomarkers (Galactomannan, (1−3)-B-D-glucan), tissue biopsies and
necropsies, with the assessment of risk factors, signs, symptoms and
radiologic imaging were used for the diagnosis of IFD as deﬁned by De
Pauw et al (Clin Infect Dis 2008; 46: 1813).
Results: 43 adult LTR requiring ICU admission were prospectively
studied. Evidence of IFD was documented in 8 patients (6 proven and 2
probable cases). The incidence of IFD in the high risk group was 29.6%
(8/27) whilst the incidence of the intermediate and low risk groups was
nil. The mortality in the IFD group was 62% (5/8) and in the nonIFD
group was 42.85% (15/35). The rate of necropsies was 45% (9/20).
Conclusions: Our current data showed that the risk stratiﬁcation scheme
described and proposed by Hellinger et al is a valid method for
identifying in the clinical setting those LTR patients at highest risk of
developing IFD. In conclusion, readily identiﬁable patient characteristics
can be used to stratify LTR for risk of developing IFD. Prospective
studies with antifungal targeted prophylaxis given to high risk LTR may
provide if this approach could lead to cost-effective prevention of IFD.
Acknowledgments: This investigation was supported by grants Fondo
de Investigacion Sanitaria, Instituto de Salud Carlos III, Proyecto
Investigacion PI 070134 (to MSC), PI 070107 (to A d P) and PI 070376
(to JP), grant IT-26407 of Departamento de Educacion, Universidades e
Investigacion del Gobierno Vasco (to JP) and Saiotek from Departamento
de Industria, Comercio y Turismo del Gobierno Vasco (to JP) and an
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P1423 Relevance, occurrence and signiﬁcance of positive
Aspergillus cultures: a prospective study in adult liver
transplant recipients in an intensive care unit
M.S. Cue´tara, M.E. Alvarez, A. Alhambra, M. Catala´n, J.C. Montejo,
J. Ponto´n, A. del Palacio ° (Madrid, Vizcaya, ES)
Objective:Most Aspergillus culture isolates from respiratory samples do
not represent invasive aspergillosis (IA). Our aim was to prospectively
assess the signiﬁcance of positive Aspergillus cultures of respiratory
samples and their relationship with IA in a cohort of high risk liver
transplant recipients (LTR) requiring mechanical ventilation in the
intensive care unit (ICU).
Methods: Patients were stratiﬁed into 3 risk groups (high, intermediate
and low) as proposed by Hellinger et al (Liver Transpl 2005: 11: 656).
Conventional diagnostic methods, biomarkers (Galactomannan, (1→ 3)-
B-D-glucan), tissue biopsies and necropsies, with the assessment of
risk factors, signs, symptoms and radiologic imaging were used for the
diagnosis of Invasive Fungal Disease (IFD) as deﬁned by De Pauw et al
(Clin Infect Dis 2008; 46: 1813).
Results: 43 adult LTR requiring ICU admission were prospectively
studied. Evidence of IFD was documented in 8 patients (2 proven IA and
2 probable IA cases, as shown in the table). 14/43 (32.6%) patients had
positive Aspergillus cultures: 3/14 (21.4%) were IA and 11/14 (78.6%)
were colonizations (p = 0.0572). The respiratory samples were obtained
one day after hospital admission for transplantation in 63.6% (7/11)
patients. The overall Aspergillus colonization rate was 25.5% (11/43).
Conclusions: The mortality in the IFD group was 62% (5/8) and in the
nonIFD group was 42.85% (15/35). The rate of necropsies was 45%
(9/20). An early study of Kusne et al (J Infect Dis 1992; 166:1379),
maintains that the isolation of Aspergillus has a high predictive value
of IA in LTR, however in our study, the isolation of Aspergillus was
not signiﬁcant possibly due to its small size. It would appear that other
factors are needed for the development of IA. The high rate of respiratory
Aspergillus colonization one day after hospital admission suggests that
fungal colonization of the lungs is present before entry in the hospital
(Lass-Flo¨rl C et al Br J Haematol 1999; 104: 745).
Acknowledgments: This investigation was supported by grants Fondo
de Investigacio´n Sanitaria, Instituto de Salud Carlos III, Proyecto
Investigacion PI 070134 (to MSC), PI 070107 (to A d P) and PI 070376
(to JP), grant IT-26407 of Departamento de Educacio´n, Universidades e
Investigacio´n del Gobierno Vasco (to JP) and Saiotek from Departamento
de Industria, Comercio y Turismo del Gobierno Vasco (to JP) and an
Educational grant from Pﬁzer (to A d P) and Gilead Spain (to A d P).
Table 1. Risk stratiﬁcation in 43 LTR: signiﬁcance of positive
Aspergillus cultures in respiratory samples and relationship with invasive
aspergillosis
Non IFD patients IFD patients
Risk group High Intermediate Low High (n = 8)
(n = 19) (n = 3) (n = 13) Non IA1
(n = 4)
IA
(n = 4)
Patients with positive Aspergillus cultures, n (%) 5 (26.3) 1 (33.3) 5 (19.2) 0 (0) 3 (75)
A. fumigatus 1 1 2 0 0
A. niger 2 0 1 0 0
A. terreus 0 0 2 0 0
A. ﬂavus 1 0 0 0 1
A. versicolor 0 0 0 0 2
A. fumigatus and Rhizopus microsporus 1 0 0 0 0
Dead patients with
positive Aspergillus cultures 4 1 1 0 3
negative Aspergillus cultures 7 1 1 2 0
Patients with necropsy and
positive Aspergillus cultures 2 1 0 0 3
negative Aspergillus cultures 2 0 0 1 0
1Non IA: non invasive aspergillosis (1 proven invasive candidiasis; 2 proven zygomycoses; 1 mixed proven invasive
candidiasis and zygomycosis).
P1424 Two cases of atypical Guillain–Barre´ syndrome associated
with Chlamydia pneumoniae infection
M. Pape °, S. Prodromidou, C. Kanonidou, K. Chatzikosta-Mandraveli,
S. Dionysopoulou, M. Paschalidou, E. Diza (Thessaloniki, GR)
Objective: Guillain–Barre´ syndrome (GBS) is a disorder in which the
body’s immune system attacks part of the peripheral nervous system.
Guillain–Barre´ has been associated with viral or bacterial infection.
We present two cases of atypical GBS associated with Chlamydia
pneumoniae (CP) infection.
Methods: Case-1: A 45 year old female was admitted for acute weakness
in the left arm that presented 2 weeks ago. The neurological examination
revealed mild sensory disturbances in the left arm, absent reﬂexes
and weakness. Case-2: A 22 year old female experienced mild left
arm weakness 4 weeks before admission. The neurological examination
revealed only left arm weakness, diminished reﬂexes and superﬁcial
hypoesthesia. Antecedent respiratory illness occurred before onset of
neurological manifestations in both patients. Paired blood samples (time
of admission-two weeks later) and Cerebrospinal ﬂuid (CSF) were
examined for DNA detection of CMV, EBV, HSV, VZV using Real-
time PCR. Sera and CSF were also tested for the presence of antibodies
against CMV, EBV, HSV, VZV Mycoplasma pneumoniae, Chlamydia
pneumoniae, Coxiella burneti, Bartonella henselae/quintana, using the
indirect immunoﬂuorescent antibody (IFA) test and the enzyme-linked
immunosorbent (ELISA) assay. CSF cytochemical examination and
electrophoresis and computer tomographic scan were also conducted.
No surgery or vaccination was reported.
Results: No viral genome was detected and there was no serological
evidence of acute infection with CMV, EBV, HSV, VZV, Mycoplasma
pneumoniae, Bartonella henselae/quintana and Coxiella burnetii in
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blood and CSF specimens. CSF cytochemistry and electrophoresis
were normal and computer tomographic scan showed no apparent
abnormalities. Concerning CP the detection of IgM antibodies and
seroconversion in paired blood samples strongly supported acute
infection. They received doxicycline for 14 days. On follow up clinical
improvement was noted in both patients.
Conclusions: Our cases suggest that CP should be added to the
differential list of agents associated with the GBS syndrome.
P1425 Monoclonal subtyping of clinical and environmental-related
Legionella strains in epidemiological investigations of
legionellosis cases
L. Franzin °, N. Bonfrate, V. Demarie (Turin, IT)
Objective: Positive culture is the only method that allows the comparison
of patient and environmental Legionella strains necessary to conﬁrm
or exclude a given environmental reservoir as the source of infection.
Subtyping of Legionella pneumophila serogroup 1 strains by using
monoclonal antibodies (MAb) is useful method in epidemiological
investigations. The aim of the study is MAb subtyping of clinical
and related environmental strains in epidemiological studies of culture
positive legionellosis cases.
Methods: Culture was performed from 545 respiratory samples (sputum,
bronchoalveolar ﬂuid, bronchoaspirate, pulmonary biopsy) of patients
with pneumonia. Aliquots of untreated, heat treated and acid-washed
suspensions were plated on BCYE, BMPA and MWY. The strains
of Legionella isolated were serologically typed. MAb subtyping of
L. pneumophila 1 isolates was performed by immunoﬂuorescence assay
(Dresden panel). Culture of Legionella was performed from water of
related environmental sites by quantitative methods. L. pneumophila 1
environmental strains (54) were typed by MAb and also by molecular
techniques (PFGE, RAPD and SBT).
Results: Legionella culture was positive from respiratory samples of
48 patients. L. pneumophila 1 strains were isolated from samples of
45 patients. Clinical strains and related environmental strains were
available in 9 epidemiological investigations. In all these studies, the
strains isolated from the patient showed the same MAb subtype as
the related environmental strains isolated from water. Five cases of
legionellosis were acquired in different hospitals: four cases were
caused by Pontiac group (2 Philadelphia and 2 Knoxville) strains
and one by non-Pontiac group (OLDA) strains. Pontiac group strains
were isolated in all the community acquired legionellosis cases. MAb
subtype of clinical and related water strains isolated from two patients
home was Philadelphia. Clinical and related environmental strains were
France/Allentown subtype in the another case.
Conclusions: In these epidemiological investigations Pontiac group
isolates (virulent MAb3/1 positive strains) were prevalent (8 out of 9).
MAb subtyping is not speciﬁc enough to distinguish between closely
related strains, but it very useful as ﬁrst method to screen the isolates
before molecular typing. MAb subtyping plays an important role in
typing L. pneumophila 1 strains in source tracking and, when used with
molecular techniques, can increase typing speciﬁcity.
P1426 Serotype-speciﬁc analysis of bacteraemic pneumococcal
pneumonia in adults
Z. Blechova, O. Dzupova, M. Trojanek °, T. Bergerova, A. Gabrielova,
H. Zemlickova, J. Motlova, G. Krakorova, V. Maresova (Prague, Pilsen,
CZ)
Objectives: The objectives of this study were to describe the
clinical course, laboratory features, risk factors and microbiological
characteristics of adult cases of bacteraemic pneumococcal pneumonia
(BPP), comparing patients hospitalized in two university hospitals.
Methods: Retrospective descriptive clinical study included adult patients
(age over 18 years) with BPP hospitalized at Bulovka University Hospital
and Pilsen University Hospital during 2000–2008. Clinical data were
obtained from hospital records and microbiological characteristics of the
isolates were determined at National Institute of Public Health in Prague.
Results: During the study period S. pneumoniae was isolated from blood
in 135 patients hospitalized with community-acquired pneumonia (CAP).
Age median was 57 years with male to female ratio 81:54. The most
frequently identiﬁed risk factors were: smoking in 57 cases, chronic lung
disease (40), chronic heart disease (34), diabetes mellitus in 24 cases.
Disease severity was assessed using PORT/PSI with total score medians
93.5 (Bulovka UH) and 115.5 (UH in Pilsen). Parapneumonic effusion
was observed in 58 patients and atelectasis in 24. Septic shock developed
in 26 patients and the disease had lethal outcome in 21 patients (15.6%)
with the highest case fatality ratio (27.3%) in the age cohort over 65
years. The most frequently isolated serotypes of S. pneumoniae were:
4 (22 cases), followed by 1 (18×), 3 (17×) and 8 (16×). Potential
vaccine coverage with 23-valent polysaccharide vaccine was 91.6% and
71.7% with 13-valent conjugated vaccine. All isolates were susceptible
to blactam antibiotics (MIC’s of penicillin 0.06mg/l) and resistance to
other tested antibiotics was very rare.
Conclusion: Bacteraemic pneumococcal pneumonia is a serious disease
with risk of complications and unfavourable outcome particularly in
the elderly. The clinical and epidemiological characteristics of BPP are
inﬂuenced by pneumococcal serotype. Study results imply to recommend
the vaccination of the risk groups. The empirical antibiotic therapy
in CAP should effectively cover S. pneumoniae. Susceptibility of the
isolated strains to blactams enables to recommend the use of penicillin
in empirical treatment of pneumococcal infections in the Czech Republic.
Supported by a research grant A/CZ0046/2/0007 from Iceland,
Liechtenstein and Norway through the EEA ﬁnancial mechanism and
by a research grant IGA-MZCR-9643−4.
Clinical characteristics of CAP cases caused by four most frequent
serotypes
Serotype 4 1 3 8
Number of cases 22 18 17 16
Age (mean) 53.0 48.9 60.9 49.3
PORT/PSI (median) 106 68 132 71
P1427 Risk factors for microbiological contamination in allografts
V. Mirabet °, M.D. Ocete, P. Solves, L. Villamayor, M. Calabuig,
L. Larrea, N. Tormo, R. Roig, C. Gimeno (Valencia, ES)
Objectives: Human cell and tissue banking involves several activities:
donation, processing, storage, delivery, transplantation. Surgical proce-
dures in the operation theatre and manipulation in the bank are the main
factors related to microbiological contamination.
Methods: We have analyzed the results of microbiological cultures
related to 8354 tissue pieces: 6613 musculoskeletal tissues, 533 heart
valves, 1146 skin units (318 cm2 each) and 62 vascular segments. We
have considered the following variables: type of source (multiorgan
donor, live donor), donor blood culture, number of pieces collected,
sampling time (surgical procurement, processing, storage, delivery) and
type of sample (tissue fragment, swabbing, liquid solution). In addition,
we have assayed the efﬁcacy of the disinfection protocol established
in our laboratory with the use of an antibiotic solution (tobramycin,
cotrimoxazole, vancomycin and amphotericin B, all of them 50mg/ml in
Hanks’ balanced salt solution).
Results: Samples at tissue collection are the most frequently contami-
nated. The bigger tissues and those requiring longer surgical procedures
show higher contamination rates. Skin has especial consideration,
because the presence of some microorganisms can be considered as
normal. The use of a disinfection protocol reduces signiﬁcantly the
presence of microorganisms. The main species isolated correspond to
air environmental microorganisms.
Conclusions: Algorithms for approval or rejection of tissues as allografts
must be based in a quality assurance system, providing safe and
clinically efﬁcient products. Then, the process for taking decision
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requires microbiological monitoring of all activities related to tissue
banking and qualiﬁed personnel to analyze results.
Healthcare-associated infections:
epidemiology and risk factors
P1428 National nosocomial infections surveillance network in
intensive care units, France, 2004–2008
A. Savey °, F. Nguyen, A. Lepape, F. L’Heriteau, P. Jarno, S. Boussat,
A.G. Venier, B. Coignard on behalf of the REA-RAISIN working group
Objectives: Within a nosocomial infections (NI) surveillance network,
to assess and compare rates over time and amongst intensive care units
(ICU), providing an evidence-based approach for improving infection
control practices.
Methods: Since 2004, the national REA-RAISIN network conducts
6 months a year a patient-based NI surveillance in ICU. On a
voluntary basis, participating ICUs collect data for each patient staying
more than 2 days in the unit. Focusing on device-related infections,
surveillance provides the units with incidence rates concerning
ventilator-associated pneumonia (PNE), urinary tract infection (UTI)
associated with indwelling urinary catheter (UC), central venous catheter
(CVC) colonisation with or without catheter-associated bacteraemia
(COL/CRB) and blood stream infection (BSI). Feedback of incidence
data used rates per 1000 device-utilisation days, and standardised
incidence ratio (SIR) for PNE.
Results: In 2008, 174 ICU included 25,225 patients. Patient character-
istics were: mean age 61.0 yrs, sex-ratio 1.6, type of admission (medical
67%, emergency surgery 18%, scheduled surgery 15%), trauma 10%,
impaired immunity 14%, patient origin (community 52%, acute care
41%, LTCF 4%, other ICU 3%), antibiotic treatment at admission 53%,
mean SAPS II 41.9, mean length of stay 11.4 days. Device exposure was
high: intubation 64%, CVC 61% and UC 85%, with device utilisation
ratio being 58.9, 61.9 and 79.0 respectively.
Among 25,225 patients, 13.6% had at least one infection. Overall
incidence rates were: 14.50 PNE/1000 intubation-days, 5.63 COL/1000
CVC-days (including 1.93 CRB), 3.46 BAC/1000 hosp.-days and 5.30
UTI/1000 UC-days. Unit distributions and SIR were used to compare
units’ performance.
From 2004 to 2008, changes in patient characteristics mainly concerned
patient severity at admission (SAPSII from 39.4 to 41.9, antibiotic
treatment +9.4% and impaired immunity +8.2%) and device exposure
(intubation +9.0%, CVC +9.5%, UC +4.0%). Incidence rates decreased
for UTI 36.3%, PNE − 10.8% and COL − 4.3%, but increased for BSI
+4.5% and CRB +29.6%.
Conclusion: These data from a large sample of French hospitals
represent a national reference to better document infectious risk in ICU.
Feedback provides the participants with relevant information to improve
care practices. Even if catheter-related infections are not frequent in ICU,
their increase suggests that prevention efforts should focus on central
venous catheter insertion and monitoring.
P1429 Epidemiology of nosocomial urinary tract infections in 165
French intensive care units
M. Giard °, F. Nguyen, M. Leone, A. Lepape, B. Coignard, A. Savey
on behalf of the REA-RAISIN working group
Objectives: Urinary tract infections (UTI) are the most frequent
nosocomial infections (NI) (30%) and the second after nosocomial
pneumonia in Intensive Care Units (ICU). As they appear not very severe
compared with other NI in ICU, they may not be considered as a priority
in infection control. In the literature, UTI have been correlated to crude
mortality ratio, but they are not considered as an independent risk factor
for ICU and hospital mortality. The present epidemiological study aimed
at determining the risk factors (RFs) and prognosis of UTI in ICU.
Methods: Data were collected from the national NI surveillance network
(REA-RAISIN), covering 165 French ICU in 2007. A total of 22,927
patients hospitalised in ICU for at least two days were included. Both
cumulative incidence of UTI per 100 admissions or 100 catheterised
patients and incidence rate per 1000 urinary catheter (UC) days were
assessed. Two multivariate logistic regression analyses were performed
to identify the RFs for UTI and to determine if UTI is an independent
RF for mortality. Confounders tested were: 1) age, gender, severity score
(SAPS II), immunodeﬁciency, UC (percentage of exposure and duration),
intubation, central venous catheter, diagnostic category, antibiotics at
admission, ICU length of stay and patient origin for both analyses, and
2) additionally, nosocomial pneumonia and nosocomial bacteraemia for
mortality RFs analysis. Results are expressed as percentages, medians
and adjusted odds ratio (95% conﬁdence interval).
Results: The UTI cumulative incidence was 5.7/100 admissions. The
incidence rate was 6.5/1000 UC days. A total of 83.8% of the
patients had a UC, 6.8% of whom developed a UTI. The duration
of catheterisation was 6 [4−13] days. The most frequently isolated
pathogens were Escherichia coli (30.5%), Pseudomonas aeruginosa
(15.9%) and Candida sp. (14.8%). A bacteraemia followed UTI in 18.1%
of UTI patients. Compared with patients without UTI, the UTI patients
had longer lengths of stay in ICU (27 vs 6 days, p< 0.001) and higher
crude mortality rate (23.5% vs 17.7%, p< 0.001). Independent RFs for
UTI and mortality are described in the Table.
Conclusion: Prolonged duration (>5 days) of UC exposure increases
UTI occurrence. Surprisingly, UTI are associated with a reduced risk
of mortality. This may be due to the impact of antibiotic use in these
patients. Nevertheless, the inconvenience for patients and the potential
excess of cost should encourage speciﬁc preventive measures.
Table: Risk factors for urinary tract infection (UTI) and mortality
(multivariate analysis)
aORa 95% CIb
UTI risk factors
Urinary catheter duration (days)
0 1
1 3.38 0.78–14.67
2 0.93 0.32–2.71
3 0.73 0.37–1.43
4 1.69 0.95–2.98
5 2.68 1.55–4.63
6 3.81 2.21–6.56
7 9.22 5.95–14.28
Female gender 1.94 1.71–2.21
Central venous catheter (CVC) 1.37 1.13–1.67
Intensive care unit (ICU) length of stay (1-day increment) 1.05 1.05–1.06
Antibiotics at admission 0.57 0.50–0.65
Mortality risk factors
UTI 0.72
Male gender 1.12 1.03–1.22
CVC 2.04 1.81–2.29
Nosocomial pneumonia 1.17 1.04–1.32
Nosocomial bacteraemia 1.90 1.61–2.24
Antibiotics at admission 1.14 1.05–1.25
Patient origin
Community 1
Long term care 1.11 0.93–1.34
Acute care 1.15 1.05–1.25
Other ICU 1.32 1.08–1.63
SAPS IIc
[0−10[ 1
[10−20[ 0.28 0.11–0.70
[20−30[ 0.76 0.35–1.70
[30−40[ 1.31 0.59–2.91
[40−50[ 2.23 1.01–4.94
[50−60[ 3.89 1.76–8.62
[60−70[ 5.52 2.49–12.26
[70 and over[ 7.49 3.38–16.60
aAdjusted odds ratio, b95% conﬁdence interval, cSimpliﬁed Acute Physiology
Score II.
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P1430 French multicentre survey of hospital mortality related
to nosocomial infections: assessment of attributable and
preventable part of deaths
A. Decoster °, M.F. Demory, B. Grandbastien, V. Leclercq for the
Regional Network “Nosocomial infection and mortality conference”
Objectives: The aim of this study was 1: to evaluate the number of deaths
associated with NI, 2: their relative contribution and 3: the preventable
trait of NI and death through a mortality conference.
Methods: The study was performed in 14 French hospitals on 13,537
consecutive deaths (january 2007-december 2008). Patients with a Mac
cabe score of 2 (short-term mortality) or who died within 2 days
after admission were excluded. Medical records of the 2,355 eligible
patients were reviewed for cause of death, NI and disease severity. The
contribution of NI to death was assessed by an expert comity including
hospital physicians and nurses in charge of the patient. Attributable and
preventable trait of NI and of death were respectively assessed according
to a 6-category scale and a 4-category scale of probability.
Results: Most of the 2,355 eligible patients came from medical wards
(51%) or ICU (37%), and 23% (n = 552) presented at least one
nosocomial infection: pneumonia (n = 280, 51%), bacteremia (n = 117,
21%), urinary tract infection (n = 55, 10%), surgical site infection (n = 33,
6%), GI tract infection (n = 33, 6%), skin infection (n = 9, 1.6%),
catheter related infection (n = 8, 1.4%), bone infection (n = 7, 1.3%) and
other infections (n = 7, 1.3%). Enterobacteriaceae (28%), Staphylococcus
aureus (18%) and Pseudomonas aeruginosa (16%) were the most
frequently identiﬁed microorganisms. The part of multidrug resistant
bacteria was 57% for S. aureus (MRSA) and 16% for enterobacteria
(ESBL). Mortality was attributable to NI for 182 patients (34% of NI)
and estimated as preventable in 61 cases (11%). Death was considered
as preventable in 35 cases (6%). Among them, 10 were attributable to a
preventable NI in patients in which death was totally unexpected (1.8%).
Conclusion: Based on a consensual and thorough review of each
patient’s clinical story, this study conﬁrms that NI is a leading cause
of death and that a large part is preventable. If the same scale was used
on a national level, the number of deaths attributable to NI in France
would reach 3,500 (CI95%: 2,605−4,036), of which 1,300 NI (CI95%:
357−2,196) and 800 deaths (CI95%: 51−1,481) could be considered as
preventable. To improve healthcare quality, mortality conferences are
needed to identify circumstances that might be associated with severe
NI contributing to death, and target as speciﬁcally as possible preventive
measures. All healthcare workers must be associated to these mortality
conferences.
P1431 Healthcare-associated infection surveillance in nursing
homes in the Netherlands
N.A. Brunner, M-J. Veldman-Ariesen, A. Haenen, H. van de Sande,
B.H. Benthem ° (Bilthoven, Leiden, NL)
Objective: To determine risk factors of healthcare associated infections
in nursing home residents.
Methods: Twenty-three nursing homes were recruited to participate in
SNIV, the national sentinel surveillance network for infectious diseases in
nursing homes, since 2009. Inﬂuenza like illness (ILI), gastro-enteritis
(GE), and probable pneumonia (PP) cases from every nursing home
were registered on a weekly basis. Infections were registered by nursing
home physicians using standardized clinical deﬁnitions. Results were
calculated over a 44 week period. From a baseline questionnaire, nursing
home characteristics were derived, e.g. number of residents, living
conditions, and inﬂuenza vaccination rate of residents and healthcare
workers (HCWs). Poisson regression analysis was used to determine
risk factors for the occurrence of ILI, GE, and PP.
Results: In total, 3643 nursing home residents were included. The
average weekly incidence rate for GE and PP were in the same range;
3.8/1,000 cases per week and 3.7/1,000 cases per week. The average
weekly incidence rate for ILI was much lower at a level of 1.9/1,000
cases per week. Table 1 shows odds ratios and conﬁdence intervals
of every signiﬁcant determinant per infection. Nursing homes where
residents share a toilet had a 2.6 higher risk of GE cases. Furthermore,
nursing homes in which GE outbreaks occurred previously, GE incidence
turned out to be higher in the current year (p< 0.0001). Nursing homes
that didn’t have single rooms only, had a 2.64 higher PP incidence
(p< 0.0001). Furthermore, incidence was 42% higher when HCWs
worked on multiple departments (p = 0.0001). Inﬂuenza vaccination
degree of HCWs is a protecting determinant for ILI in residents,
especially in the larger nursing homes and in nursing homes where
HCWs are working on multiple departments.
Conclusion: Infections in nursing homes could be predicted by nursing
home characteristics quite well, despite a relatively small sample size.
Nevertheless, to achieve a real indication of incidence rates, infection
rates should be registered for the whole year, taking seasonality of some
infectious diseases into account.
Table 1. Determinants of gastro-enteritis, probable pneumonia, and
inﬂuenza-like illness with odds ratios and 95% conﬁdence intervals
OR 95% CI
Gastro-enteritis
– sharing of toilet 2.62 1.80–3.80
– Previous GE outbreak in 2008 4.14 2.82–6.07
Probable pneumonia
– Sharing of rooms 2.64 1.83–3.82
– Interdepartmental labour 1.42 1.19–1.70
Inﬂuenza-like illness
– Number of residents >158 1.41 0.98–2.03
– Interdepartmental labour 1.54 1.16–2.05
– Inﬂuenza vaccination degree of HCWs <16.3% 3.27 2.33–4.58
P1432 Incidence of and risk factors for nosocomial infection in
a medical ward
E. Calbo °, M. Riera, C. Nicolas, O. Monistrol, R. Font, N. Freixas,
J. Garau (Terrassa, ES)
Objective: Prospective surveillance of nosocomial infection (NI)
requires exhaustive resources and solid data are scarce. The aim of our
study was to describe the incidence and risk factors for NI during a hand
hygiene (HH) multimodal campaign in medical wards.
Methods: The study was conducted in all the medical wards of a
500-beds acute care University Hospital. All inpatients with >24 h of
hospitalization were included. The surveillance was carried out in two
10 weeks periods, pre and post intervention. A multimodal campaign
to improve HH compliance was conducted between the two periods.
Data on potential intrinsic factors (demographics, co morbidities and
functional status measured by Charlson and Barthel scores) and extrinsic
risk factors (LOS, urinary and venous catheter days) for NI were
collected. NI were prospectively identiﬁed by clinical ﬁndings and
conﬁrmed by laboratory and/or clinical data or physician diagnosis. NI
were diagnosed and classiﬁed according to the standard deﬁnitions of
the CDC 2008.
Results: 1963 patients were included. NI was diagnosed in 108
(5.5%)patients. Density of incidence was 6.8 NI/1000 admission days.
Most frequently NIs identiﬁed were pneumonia 43 (39.7%), 15 of
those attributed to aspiration (13.8%), and urinary tract infection 42
(38.8%). Patients with NI were more frequently female (59.6% vs.
40.4%, p = 0.001), were older (76 vs. 71 y-o, p = 0.007) and had a lower
Barthel score (36 vs. 63, p = 0.001) as compared to non infected patients.
Patients with NI had a longer LOS (18.6 vs. 8.1 days, p< 0.001), a higher
use of venous catheters (11.7 vs. 4.8 mean days, p< 0.001) and urinary
catheters (9.5 vs. 5.6 mean days, p< 0.001). No differences were found
between both surveillance periods in the presence of intrinsic or extrinsic
risk factors, or in the global NI rates. Independent risk factors for NI
were female gender (OR 2.1, CI95% 1.3−3.5, p = 0.003); Barthel score
(OR= 2, CI95%1.1−3.6, p = 0.01), LOS (OR= 1.1, CI95%=1.08−1.1;
p< 0.001) and urinary catheter (OR= 1.1, CI95%1.05−1.1, p< 0.001).
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Conclusions: In our hospital, the overall incidence of NI in medical
wards was lower than expected according to the previous prevalence
rates reported. This is important in order to accurately calculate sample
size in studies designed to measure the impact of an intervention on the
incidence of NI. Aspiration pneumonia was identiﬁed as an emerging
problem in acute care hospitals, likely due to the increasing age of
inpatients.
P1433 Hospital-associated infections in children − a prospective
international multicentre post-discharge follow-up study
S. Kinnula, M. Bu¨ttcher, T. Tapiainen °, M. Renko, K. Vepsa¨la¨inen,
R. Lantto, U. Heininger, M. Uhari (Oulu, FI; Basel, CH; Joensuu, FI)
Objectives: Viruses, especially gastrointestinal and respiratory viruses,
spread easily in paediatric wards causing hospital-associated infections
(HAIs). Marked differences have been reported in HAI frequencies
between different paediatric wards and hospitals. Reasons behind these
differences are not well known. The study was done to evaluate the rate
of viral HAIs and their risk factors in different paediatric settings in two
hospitals in Finland (Oulu, Joensuu) and in one hospital in Switzerland
(Basel).
Methods: One infectious diseases ward and three general paediatric
wards were included in the survey. Data were collected prospectively
for two years including a one-week follow-up after discharge with
questionnaires. Post-discharge follow-up was done using a standardized
questionnaire, where parents were asked for when the child was fully
recovered, and if the child got symptoms of a new infection since hospital
discharge and if so when the new symptoms had appeared. Altogether
5110 patients were hospitalized (mean age 3.7 years, standard deviation
(SD) 4.2, mean time in hospital 4.0 days SD 6.9).
Results: Total HAI frequency was 13.5%. In hospital 3.7% of patients
HAI, most often gastroenteritis. Of HAI, only 13% manifested during
hospitalization whereas the great majority, 87%, became symptomatic
within 72 hours after discharge. We found marked differences in HAI
frequencies between the wards, the HAI frequency was the lowest in the
general paediatric ward for older children in Basel and the highest in
the general paediatric ward in Joensuu (Figure). The highest HAI rate
was in a general paediatric ward where shared rooms were common. The
lowest HAI rate was in a general paediatric ward where patients older
than one year of age were hospitalized, mainly in single rooms. In logistic
regression analysis shared room, young age, longer hospitalization time
and antibiotic treatment were associated with the increased occurrence
of HAI.
Conclusion: We suggest that single room bedding is effective in
prevention of HAIs, especially preventing the spread of respiratory
viruses. It also seems that treating patients with infectious diseases in
their own unit is advantageous compared to a general ward.
P1434 Characteristics of polyphasic nosocomial outbreaks −
a systematic review
S. Thon, R.P. Vonberg ° (Hannover, DE)
Objectives: During the investigation of an outbreak, infection control
efforts aim for terminating this incident at its most early stage. Some
epidemic curves of nosocomial outbreaks show additional peaks of
infection despite the introduction or enforcement of appropriate infection
control measures. This systematic review shows the characteristics of
such polyphasic nosocomial outbreaks.
Methods: A search of the medical literature was performed using the
following sources: a) Worldwide Outbreak Database (www.outbreak-
database.com), b) PubMed, and c) hand search of reference lists of
relevant articles. Search terms applied were “Nosocomial”, “Outbreak”,
“Epidemic”, and “Polyphasic”. Data got collected on setting (place,
time, duration, ward, kind of unit), type of infection (number of
cases, pathogen, type of infection), epidemiological features (source,
mode of transmission, typing), and infection control measures. Findings
from polyphasic outbreaks were then compared to 2.089 monophasic
nosocomial outbreaks as ﬁled in the Outbreak Database.
Results: 124 polyphasic nosocomial outbreaks got included, thereof
58 outbreaks in which intensive care units were involved. Surgical
departments were more often affected by polyphasic outbreaks (33.9%
vs. 21.9%; p< 0.01), and hepatitis B virus was determined as the
predominanat causative agent (9.7% vs. 3.2%; p< 0.01). The following
types of infection were more frequently observed in polyphasic
outbreaks: blood stream infection (p< 0.05), respiratory tract infection
(p< 0.01), wound infection (p< 0.01), urinary tract infection (p< 0.01),
skin and soft tissue infection (p< 0.05), and meningitis (p< 0.05). The
distribution of infection control measures is shown in FIGURE 1.
These measures (except for change of equipment, protective clothing,
and vaccination) were signiﬁcantly more often applied in polyphasic
outbreaks. There were 245 sources identiﬁed in 124 polyphasic outbreaks
compared to only 2.169 sources in the 2.089 monophasic events.
Conclusion: The greater number of infections and infection control
measures is most probably a consequence of the prolonged outbreak.
Most likely the existence of an undiscovered additional source or the
formation of such a secondary source during the ﬁrst phase of the
outbreak (rather than not identifying its primary source) was responsible
for further outbreaks phases. Infection control staff should be aware
of the possibility of a secondary source whenever investigating a
nosocomial outbreak.
P1435 Five-year retrospective epidemiological survey of anaerobic
bacteraemia in a university hospital
E. Urba´n °, G. Terhes, A. La´za´r, E. Nagy (Szeged, HU)
Objective: Bacteraemia due to anaerobic organisms occurs in 0.5−12%
of blood cultures worldwide, however recent studies from EU and the
US presented inconsistent data regarding the prevalence of anaerobic
bacteraemias. We examined the occurrence of bacteraemias due to
anaerobic bacteria during a 5-year period, in order to determine its
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prevalence and evaluate the importance of anaerobic blood cultures in a
university hospital in Szeged, Hungary.
Methods: Two bottles were routinely collected for blood culture: an
aerobic bottle enabling preferential growth of aerobic microorganisms,
and an anaerobic bottle enabling preferential growth of strict anaerobic
bacteria. All blood culture bottles were placed in a BacTec system and
monitored in accordance with the manufacturer’s instructions. Clinical
data was retrieved from patients’ medical records.
Results: A total of 43,992 blood cultures were submitted to the
laboratory in this period. From those, 305 (0.69%) anaerobic isolates
were detected from blood cultures. The number of positive anaerobic
blood culture results per 1,000 blood cultures performed decreased
from 8.74 to 5.36 between 2005 and 2009. The P. acnes accounted for
57.7% of isolates (mainly contaminant), followed by Clostridium spp.
(12.8%), B. fragilis group spp. (8.9%) and anaerobic Gram-positive
cocci (5.9%) and Fusobacterium spp. (3%). During this period, the
proportion of isolated anaerobic organisms compared to the number
of all organisms isolated from blood cultures declined from 6.3% to
4.0%. Similar to the decrease in the number of anaerobic isolates, the
number of patients with anaerobic bacteremia decreased from 69 patients
to 44 patients. The most common risk factors were gastrointestinal
surgery and active haematological malignancies with chemotherapy.
The lower gastrointestinal tract and the oropharynx were the two most
frequent presumed or proven sources for relevant bacteraemia. Fatal
outcome correlated with the severity of underlying diseases and the
immunosuppressed status of the patients rather than with the causative
pathogen or the effectiveness of antimicrobial therapy.
Conclusions: In this report we retrospectively analyzed the low
proportion of anaerobes out of total blood cultures and the distribution
of different anaerobic bacteria isolated from positive anaerobic blood
cultures in order to characterize their involvement in anaerobic blood
cultures during a 5-year period.
P1436 Risk factors associated with inadequate initial empirical
antibiotic therapy for nosocomial Pseudomonas aeruginosa
bacteraemia in non-haematologic patients
H.H. Chang °, S. Jung, S.W. Kim, K.H. Park, J.M. Lee, N. Kim (Daegu,
Gwangju, KR)
Background: There is a few report about risk factors associated
with inadequate initial empirical antibiotic therapy in non-hematologic
inpatients with nosocomial Pseudomonas aeruginosa bacteremia.
Methods: The medical records of adult patients (age >18 years) with
Pseudomonas aeruginosa bacteremia in two tertiary teaching hospitals
from January 2004 to June 2008 were evaluated. Among total 280 cases
of Pseudomonas bacteremia occurred during study period, 88 cases of
community acquired bacteremia and 69 cases that occurred in patients
who had hematologic diseases or neutropenic fever were excluded.
Demographic, clinical, laboratory and treatment data were collected,
and statistical analysis was performed using SPSS® ver.17.0 program.
Inadequate empirical antibiotic therapy was deﬁned as no antibiotic or
starting non-susceptible antibiotics within 48 hours after initial positive
blood culture.
Results: 123 episodes of nosocomial Pseudomonas aeruginosa bac-
teremia were evaluated. The most common source of bacteremia
was intra-abdominal infections(55, 44.7%), followed by pneumonia(24,
19.8%), urinary tract infections(23, 19.0%) and catheter-related blood-
stream infection(17, 13.8%). 60 cases(48.8%) received appropriate initial
empirical antibiotic therapy. In univariate analysis, the statistically
signiﬁcant risk factor for inadequate initial empirical antibiotic therapy
was bacteremia occurred in general ward[odds ratio 1.786(95%
C.I.1.041–3.063), p = 0.015], bacteremia originating from urinary tract
infection [odds ratio 1.777 (95% C.I.0.933–3.384), p = 0.041], but
catheter-related bacteremia was a major factor against inadequate initial
empirical antibiotic therapy [odds ratio 0.527 (95% C.I. 0.387–0.718),
p = 0.003]. In multivariate analysis, catheter-related bacteremia was a
major factor against inadequate initial empirical antibiotic therapy[odds
ratio 0.246 (95% C.I. 0.062–0.985), p = 0.047]. There was no signiﬁcant
difference in clinical course and outcomes between patients receiving
inadequate and adequate antibiotic therapy.
Conclusions: Over a half of the patients with nosocomial Pseudomonas
aeruginosa bacteremia received inadequate initial empirical antibiotic
therapy. Bacteremia originating from urinary tract infections and
occurring in general ward need more physician’s attention about the
probability of Pseudomonas aeruginosa bacteremia.
P1437 The resistible rise and fall of a burns and ICU-related
hospital outbreak of multi-resistant Acinetobacter baumannii
T. Gottlieb °, R. Bradbury, E. Cheong (Sydney, AU)
Objectives: A report of a 9 year period of surveillance and management
of Acinetobacter baumannii (MRAB) and its ultimate effective control.
Results: Concord Hospital provides the major state-wide Burns service
for the state of NSW (Australia). In 2000, the ﬁrst strains of carbapenem
resistant OXA-23 producing Acinetobacter baumannii (MRAB) were
identiﬁed in two Burns Unit patients. This resulted in a clonal outbreak
affecting both Intensive Care and Burns unit patients. MRAB became
endemic with peaks of prevalence related to difﬁculties in cleaning,
crowding and infection control management. These related to events
such as a change to a temporary intensive care unit, severe bushﬁres,
mattress contamination and the Bali bombing in 2002. The latter event
was due to polyclonal MRAB strains, but after a few months there was
a reversion to the original MRAB clone. In the 12 months period from
June-July 2000−01 there were 54 patients who became colonised with
MRAB, a median of 13 days after admission. At its peak in 2001, 35%
of burns inpatients became colonised by MRAB. Between 2000–2006,
there were 59 bacteraemias with a 7 day mortality of 15% and 30 day
mortality of 34%. Of clinical specimens collected in 2000–2006, 16%
were from blood cultures, mostly related to iv cannula sepsis.
An intensiﬁed environmental screening and unit cleaning service was
instituted in early 2005, and will be described. Since improvement in
infection control management there has been a dramatic reduction in
incidence of MRAB at Concord Hospital. In 2008 3 patients were
colonised (an incidence of 3% of Burns patients), in 2009 no MRAB
isolates have been identiﬁed on cultures to date. The rate of MRAB has
fallen from 35% of all Burns patients colonised yearly in 2001 to 0% in
2009.
Conclusions: Hospital MRAB rates are reversible. Attention to
scrupulous environmental cleaning and identiﬁcation of patient and
inanimate reservoirs are crucial for effective control but require
considerable administrative and staff support.
P1438 Ranking the pathogens: a competing-risks model on
the effect of ICU-acquired bacteraemia with different
pathogens on ICU mortality
M.J. de Regt °, A.M. de Smet, R. Willems, M. Bonten (Utrecht, NL)
Objectives: In studies quantifying the effect of bacteremia on ICU-
mortality, ICU discharge is a competing endpoint: after discharge
patients can no longer die in ICU. Logistic regression addresses this
issue, but cannot deal with the time-dependent nature of bacteremia,
which might lead to time-dependent bias. Survival models can
address time-dependency, but cannot account for competing endpoints.
Competing risks models can incorporate competing endpoints and time-
dependent covariates. We used this methodology to quantify prognosis
of ICU-acquired (ICU-acq) bacteremia on ICU mortality and ICU
discharge.
Methods: Data on ICU-acq bacteremias were collected in a large
multi-center study in the Netherlands (NEJM 2009;360:20). ICU-acq
bacteremia was deﬁned as a positive blood culture >48 h after ICU-
admission; patients with an ICU stay of <3 days were excluded.
Only the ﬁrst event of ICU-acq bacteremia was taken into account.
Polymicrobial bacteremia was deﬁned as isolation of >1 microorganism
<48 h. Coagulase-negative staphylococci, Micrococcus spp, Bacillus
spp, diphteroids and propionibacteria were considered contaminants.
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Data were analysed using a competing risks model based on Cox
proportional hazards models. Patients with an ICU stay >40 days were
administratively censored.
Results: Of 5939 included patients, 5456 were eligible for analysis,
of which 266 (5%) were censored at day 40. 769 patients had ICU-
acq bacteremia (353 with a contaminant). The highest daily hazard
ratio (HR) for mortality after ICU-acq bacteremia was obtained for
non-fermenters (HR: 3.14, 95%CI 1.94–5.02) (table 1). In addition,
the daily risk for discharge decreased (HR: 0.63, 95%CI 0.39–0.99),
further enhancing the cumulative risk for dying in ICU. Similar
prognostic effects were found for ICU-acq bacteremia with Candida spp,
enterococci, Enterobacteriaceae and polymicrobial infection. ICU-acq
bacteremia with streptococci or S. aureus was not signiﬁcantly associated
with changed mortality or discharge rates. Although bacteremia with
contaminants did not increase mortality rate (HR:1.12, 95%CI 0.87–
1.45), patients had an increased cumulative risk of dying in the ICU due
to a prolonged ICU stay (HR: 0.79, 95%CI 0.69–0.91).
Conclusion: The prognosis of ICU-acq bacteremia differs markedly
between pathogens and imposes, for some pathogens, a directly increased
risk of dying per day as well as an indirect risk of dying in ICU because
of a reduced daily probability of ICU-discharge.
Table 1
Group n HR 95% CI p-value HR
discharge
95% CI p-value Onset, median
(IQR)
Non-fermenters 47 3.12 1.94–5.02 <0.001 0.63 0.39–0.99 0.05 12 (13.5)
Candida spp./yeasts 28 2.74 1.55–4.87 <0.001 0.55 0.31–0.96 0.04 6.5 (5.25)
Polymicrobial 42 2.69 1.69–4.27 <0.001 0.45 0.27–0.74 0.001 11.5 (13)
Enterococci 114 2.31 1.68–3.16 <0.001 0.52 0.39–0.69 <0.001 12 (11)
Enterobacteriaceae 130 2.13 1.55–2.91 <0.001 0.49 0.38–0.66 <0.001 11.5 (14)
Streptococci 18 1.63 0.61–4.35 0.33 0.91 0.50–1.64 0.75 5 (7.5)
Contaminants 353 1.12 0.87–1.45 0.38 0.79 0.69–0.91 <0.001 9 (9)
S. aureus 37 0.94 0.42–2.11 0.88 0.71 0.47–1.09 0.12 7 (9)
n = number of patients; HR= hazard ratio; IOR= interquartile range.
P1439 Polymicrobial bacteraemias in ICU patients. Impact on
outcome
S. Sancho, R. Zaragoza °, J. Camarena, A. Artero, R. Gonza´lez,
J. Nogueira (Valencia, ES)
Introduction: The aims of this study were to know the epidemiological
and clinical features of polymicrobial bacteremias in UCI patients and
to know their impact on mortality.
Methods: From January 2000 to Juny 2009 all clinically signiﬁcant
bacteremias in a teaching hospital were collected. Clinical and
microbiological characteristics were recorded. Polymicrobial bacteremia
was deﬁned when two or more microorganisms were isolated in the same
blood culture. Multivariate analysis was used to determine the differences
between polymicrobial and monomicrobial bacteremias and to analyse
the factors associated to related mortality to infection, using the SPSS
package (13.0).
Results: Among 293 ICU-bacteremias, 45 (15.3%) were polymicrobial.
The mean age of patients was 61.9 SD 14 years. Bacteremia was
hospital-acquired in 93.3% of these cases. 26.7% developed septic
shock and 57.8% severe sepsis. The main sources of bacteremia were:
respiratory (31.1%), catheter (17.7%) and abdominal foci (13.3%). The
microorganisms most frequently isolated were: Acinetobacter baumannii
(35.5%), Enterococcus spp (24.4%) and Pseudomonas aeruginosa
(22.2%). Empirical antimicrobial treatment was inadequate in 28.9%
of these cases. The global mortality rate was 53.3% and the related
mortality 22.2%. The isolation of Enterococcus spp. in blood culture
was the only factor associated with polymicrobial bacteremias (p = 0.037;
OR= 7.06; 95%CI: 1.12–44.51). The factors associated with related
mortality were: S. aureus (p = 0.004; OR= 10.06; 95%CI: 2.07–48.94),
the presence of septic shock (p = 0.0001; OR= 9.80; 95%CI: 3.01–
31.89), the APACHE II during bacteremia (p = 0.0001; OR= 1.21;
95%CI: 1.11–1.31), and inadequate empirical antimicrobial treatment
(p = 0.018; OR= 4.24; 95%CI: 1.28–14.11) but not polymicrobial
bacteremias.
Conclusions: Polymicrobial bacteremias had a high prevalence in
the ICU, were hospital-acquired, and their main sources of infection
were repiratory and abdominal. Enterococcus spp were the unique
microorganism associated with polymicrobial bacteremias. Although the
rate of inadequate empirical antimicrobial treatment was high, mortality
rates were not higher in polymicrobial bacteremias than in the group
with monomicrobial bacteremias.
P1440 Incidence and microbiology of intensive care unit acquired
infections in the region of Crete in Greece
C. Tsioutis, E.I. Kritsotakis °, K. Chaniotaki, M. Roumbelaki,
D. Babalis, A. Gikas on behalf of the Cretan Coordination Center
for Nosocomial Infection Control
Objectives: To determine the incidence of intensive care unit (ICU)
acquired infections and to specify the microbiological and antibiotic
resistance proﬁles of infecting organisms in the region of Crete in
Greece.
Methods: An active surveillance protocol was introduced in the ICUs
of ﬁve major public hospitals in the region. All patients who presented
an infection at least 48 hours after ICU-admission were surveyed until
discharge. Infections were deﬁned according to the Centers for Disease
and Prevention criteria. Infecting pathogens and antibiotic-susceptibility
test results were obtained from each hospital’s laboratory reports. Multi-
drug resistant isolates were deﬁned as those resistant to two or more
classes of antibiotics.
Results: During February to December 2007, 1249 patients who were
hospitalized in the ICUs for a mean length of stay of 7.5 days acquired
307 infections for an overall incidence rate of 32.8 infections per 1000
patient-days. Three infection sites represented 92.8% of all infections;
lungs (43%), bloodstream (42.3%), and urinary tract (7.5%). Eighty-
ﬁve percent of the recorded ICU-acquired infections were culture
positive, 34% of which were polymicrobial. Of the 370 bacterial strains
isolated, 55.7% were Gram-negative microorganisms, 34.8% Gram-
positive microorganisms, 9.2% fungi, and 0.3% were anaerobes. Most
frequently isolated pathogens included Acinetobacter spp (24.6% of
all isolates), coagulase-negative Staphylococcus (17.6%), Pseudomonas
aeruginosa (11.9%), Staphylococcus aureus (9.7%), Klebsiella spp
(9.5%), Candida spp (8.9%), and Enterococcus spp (5.9%). The
distribution of pathogens by site of infection is shown in the Figure.
Overall, 81% of Acinetobacter spp, 25% of P. aeruginosa, and 53%
of Enterobacteriaceae isolates were multi-drug resistant. Thirty-three
percent of the S. aureus isolates were methicillin resistant, and 28.6%
of Enterococcus isolates were vancomycin resistant.
Conclusion: ICU-acquired infections constitute a major problem in the
region, complicated by the high rates of multi-drug resistant pathogens.
Study results emphasize the need for comprehensive infection control
programs to reduce the burden of nosocomial infections in the ICUs of
the region.
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P1441 High frequency of non-fermenters among respiratory
isolates from hospital-acquired pneumonia and ventilator-
associated pneumonia in Asian countries: an ANSORP study
J.H. Song ° (the Asian Network for Surveillance of Resistant Pathogens
(ANSORP)
Objectives: Pathogen distribution of hospital-acquired pneumonia
(HAP) and ventilator-associated pneumonia (VAP) is important to select
appropriate empirical antimicrobial therapy. Although it might vary by
country, few data have been available in Asian countries.
Methods: The Asian Network for Surveillance of Resistant Pathogens
(ANSORP) performed a prospective surveillance study of respiratory
isolates from HAP and VAP in adult patients from 75 hospitals in 10
Asian countries from 2008 to 2009. The bacterial isolates were classiﬁed
into deﬁnite, probable and possible pathogens according to the type of
specimens.
Results: A total of 2,640 cases of HAP or VAP were enrolled
and 1,508 cases of HAP and 898 of VAP were evaluated. Cultures
of respiratory specimens were positive in 69.4% of cases. In HAP,
Staphylococcus aureus (15.8%) and Pseudomonas aeruginosa (15.5%)
were the most frequent isolates followed by Acinetobacter spp. (12.7%),
and Klebsiella pneumoniae (11.0%). In VAP, Acinetobacter spp. was the
most frequently isolated (35.4%) followed by P. aeruginosa (26.0%),
K. pneumoniae (17.0%) and S. aureus (12.9%). Among deﬁnite
pathogens of HAP or VAP, S. aureus was most frequent (22.1%) followed
by Acinetobacter spp. (13.2%), P. aeruginosa (13.2%), K. pneumoniae
(11.8%), and E. coli (11.8%). P. aeruginosa and Stenotrophomonas
maltophilia were more frequent in late-onset HAP than in early-onset
HAP, while Acinetobacter and P. aeruginosa were more frequent in late-
onset VAP than in early-onset VAP. The distribution of the bacterial
isolates differed by country: S. aureus (Korea); Acinetobacter (China,
Thailand, and Malaysia); P. aeruginosa (Hong Kong and Taiwan) and
K. pneumoniae (Philippines, Indonesia, and Singapore) were the most
common respiratory isolates.
Conclusion: Acinetobacter, P. aeruginosa, S. aureus, and K. pneumoniae
were the most frequent respiratory isolates from adults with HAP or
VAP in Asian countries. Acinetobacter and P. aeruginosa were frequent
pathogens in Asian countries, especially in cases of late-onset VAP.
P1442 High burden of S. aureus bloodstream infections in
European hospitals, irrespective of methicillin susceptibility
M. de Kraker °, M. Wolkewitz, H. Grundmann on behalf of the
BURDEN Study Group
Objective: Determine the excess mortality and the excess length of
stay attributable to methicillin resistant S. aureus (MRSA) blood stream
infections (BSI) in Europe using a novel approach.
Methods: BSI caused by MRSA affect patients that are older, more ill
and have a longer hospital stay than BSI caused by methicillin susceptible
S. aureus (MSSA), making direct comparisons difﬁcult. In this study a
parallel matched cohort design was used, where patients with a S. aureus
BSI (exposed) were compared to patients without such a BSI (controls).
Two parallel cohorts were constructed, comparing either MRSA or
MSSA exposure. Matching was based on duration of admission prior
to enrolment. Thirteen hospitals from as many countries participated in
this study from July 2007 to July 2008. Hospital patients were routinely
sampled and all patients above 18 years with a S. aureus BSI were
included as exposed patients. Modern statistical methods were used for
comparing mortality and length of stay within the two parallel cohorts:
multivariate Cox’s regression for competing events and a multivariate
generalized linear model with gamma distribution.
Results: In total 2489 patients could be included into the study: 248
patients had a BSI caused by MRSA, 618 patients had MSSA BSI and
1623 were controls. Hospital mortality for MRSA patients was 36%
compared to 9% for the controls. For MSSA patients 22% died and 7%
of the controls died in the hospital. Cox’s regression for competing events
showed that MRSA patients died more often than the controls (hazard
ratio (HR) 3.5, conﬁdence interval (CI) 2.4−5.2). MRSA patients also
stayed longer in hospital. The overall difference in length of stay was 9.2
days (interquartile range (IQR) 5.2–13.5). The impact of a MSSA BSI
on in-hospital mortality was comparable to the HR found in the MRSA
cohort (HR 3.1, CI 2.3−4.2). MSSA patients stayed 8.6 days longer in
hospital than the controls (IQR 6.8–10.4). When combining the data of
the two parallel cohorts, the HR for in-hospital mortality was 1.1 times
larger (CI 0.7−1.8) for MRSA versus MSSA, the excess length of stay
was 0.6 days (IQR −3.7−5.3).
Conclusions: The burden of S. aureus blood stream infections in the
hospital is high, for MRSA as well as MSSA. Infection prevention should
be aimed at decreasing the number of S. aureus blood stream infections,
irrespective of methicillin susceptibility.
P1443 Catheter-related bloodstream infections among VINCat
hospitals: the impact outside the ICU
F. Bella °, N. Freixas, B. Almirante, M. Pujol, E. Limo´n, J. Valle´s,
F. Barcenilla, L. Matas, F. Gudiol on behalf of the VINCat Committee
Background: Catheter-related bloodstream infections (CR-BSI) con-
tinue to be a cause of high morbidity and mortality rates despite they
are the most preventable health-care associated infections. Surveillance
of CR-BSI is useful for quality improvement, however, while there is a
huge amount of information based on Intensive Care Units (ICU), only
few data concerning non-ICU patients are available.
Objective: to determine the comparative frequency of CR-BSI in ICU
and non-ICU patients admitted to VINCat hospitals during 2008.
Methods: VINCat is a nosocomial infection surveillance program in
Catalonia, (6.5 million population), in Spain. Beginning 2007, 39
hospitals perform laboratory based prospective standardized surveillance
for CR-BSI using CDC deﬁnitions. Rates of central venous catheter
(CVC) BSI and short and midline peripheral venous catheter (PVC)
BSI were expressed by 1.000 patient-days according to area of
hospitalization.
Results: From January to December 2008, 608 episodes of CVC-
BSI (0.20 ep/1.000 patient-days) and 117 episodes of PVC-BSI (0.04
ep/1.000 patient-days) were recorded. Among patients with CVC-BSI,
232 episodes were acquired in the ICU, 199 in medical wards and 177
in surgical wards. While the crude number of CR-BSI were higher
in non-ICU areas, adjusted rates for ICU patients were: 1.9 ep/1.000
patient-days, for medical patients: 0.12/ep/1.000 patient-days and for
surgical patients: 0.14/ep/1.000 patient-days. Among patients with PVC-
BSI, 18 episodes (0.15 ep/1.000 patient-days) were observed in ICU
patients, 30 (0.02 ep/1.000 patient-days) in surgical patients and 69
(0.05 ep/1.000 patient-days) in medical patients. Among patients with
CVC-BSI, coagulase-negative staphylococci (CNS) were the causative
microorganisms in 50% of cases, followed by Staphylococcus aureus
(14%) and Pseudomonas aeruginosa (7%). In contrast, patients with
PVC-BSI had more frequently S. aureus (53%) followed by CNS (30%).
Conclusions: The VINCat surveillance program has allowed us to
determine that CR-BSI among non-ICU patients remains largely
underestimated and are frequently caused by S. aureus. Targeted
interventions in speciﬁc areas are needed to reduce this serious
complication.
P1444 The clinical outcome of intravascular cathetertip
colonization with Gram-negative micro-organisms in
patients without preceding bacteraemia
A. van Eck van der Sluijs, J.J. Oosterheert °, M. Ekkelenkamp,
A. Hoepelman, E. Peters (Utrecht, NL)
Introduction: Although Gram-negative micro-organisms are frequently
associated with catheter-related bloodstream infections, the prognostic
value and clinical implication of a positive cathetertip culture with Gram-
negative micro-organisms remains unclear. The aim of this study was to
determine the outcomes of patients with intravascular catheters colonized
with these micro-organisms, without preceding positive blood cultures,
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and to identify the risk factors for the development of subsequent
bacteremia.
Methods: All patients with positive intravascular cathetertip cultures
with Gram-negative micro-organisms between 2005 and 2009 were
retrospectively studied at the University Medical Center Utrecht, the
Netherlands. Sixty-seven patients with a positive blood culture in a
period of 48 hours before catheter removal were excluded. Possible risk
factors for Gram-negative bacteremia were recorded. The main outcome
measure was bacteremia with Gram-negative micro-organisms. Other
endpoints were duration of hospital admission, in-hospital mortality,
secondary complications of Gram-negative bacteremia and duration of
intensive care admission.
Results: Two-hundred-and-thirteen catheter tips from 181 patients were
colonized with Gram-negative micro-organisms. Forty (19%) developed
subsequent Gram-negative bacteremia. Multivariate analysis showed that
arterial catheters were associated with the development of subsequent
Gram-negative bacteremia (odds ratio (OR)=5.17, 95% conﬁdence
interval (95%CI): 1.24–21.60) and jugular catheters were a protective
factor (OR= 0.21, 95%CI: 0.046–0.98). Mortality was signiﬁcantly
higher in the group with subsequent Gram-negative bacteremia (35%
versus 20%, OR= 2.12, 95%CI: 1.00–4.49).
Conclusion: Intravascular cathetertip colonization with Gram-negative
micro-organisms can predict a subsequent Gram-negative bacteremia.
A bacteremia is more likely in patients with an arterial catheter and
the patients with a Gram-negative bacteremia seemed to have a higher
mortality. This may have clinical implications for the management
of intravascular catheter tips colonized with Gram-negative micro-
organisms in patients without preceding bacteremia.
P1445 Central venous catheter and catheter-related bloodstream
infections surveillance: an innovative use of 20th century
technology for 21st century solutions
M. Przybylo °, L. Moorhouse, S. Staff, S. Hamid, A. Guleri (Blackpool,
UK)
Objectives: Catheter-related blood stream infections(CR-BSI) account
for a third of all post-48 h BSI. A comprehensive HCAI containment
programme(CHCP) was initiated in 2008 in Blackpool Victoria Hospital.
The trust is investing in a cutting edge electronic patient record system
(EPR) to modernize patient record system, enhance clinical quality
and patient safety but the e-referral, e-prescribing, e-surveillance will
be rolled out in 2nd phase of the project. Currently data capture on
all central venous catheters (CVC) inserted, monitoring and CR-BSI
was quite challenging with staff limited infection control team (ICT)
working on other HCAI reducing initiatives. We present an innovative
use of current and limited IT system in addressing a challenge −
surveillance/audit of CVC bundles & CRBSI.
Methods: An innovative use of existing IT technology to create
a facility from intranet page for e-registration of CVC data was
discussed with hospital webpage planning department. The switchover
to ‘CVC e-register’ began in May09. Hospital computers are password
protected. A hyperlink for CVC e-register on trust intranet page, opens
a simple input form. Medical profession inserting a CVC is required to
enter basic essential data and submit it to ICT managed database. The
head nurse of critical care & wards submit a daily tally of number of
patients with CVCs. This database is used to obtain daily patient list,
central collation of data from follow up of patients outside critical care,
line care data, outcomes & CRBSI.
The database is cross referenced against positive blood cultures. This
system alerts the microbiologist who can then clinically advice clinical
team of the patient.
Results: Since May 2009 − 493 central venous procedures were
recording using the CVC e-register. 31% (151) CVCs, 12% (59)
Hickman lines, 56% (276) others and <1% femoral and Picc lines.
Ward followup surveillance of CVCs reveals 33% in medical, 9% in
surgical & 59% in critical care unit. Compliance has increased with
time and feedback to clinical teams (11−91%). Details to be presented.
Discussion: 42% of CVCs inserted on critical care are managed on
wards with limited expertise of CVC line care. Feeding back of results
and raised awareness of the CHCP has increased compliance for using
CVC e-register. Phase 2 of this project would be integration with the
EPR in about 12-months. This innovative use of existing technology has
been successful in gathering data on CRBSI and CVC use/care.
P1446 Catheter-related bacteraemia and infective endocarditis
caused by Kocuria species
C.Y. Liu °, C.C. Lai, C.H. Liao, P.R. Hsueh (Taipei City, TW)
Objective: Kocuria species is a member of the Micrococcus family,
most are normal ﬂora of human skin and mucosa. Misidentiﬁcation
of coagulase-negative staphylococcus is not uncommon, which requires
genomic sequencing for precise identiﬁcation. We reported ﬁve patients
with Kocuria spp. Bacteremia from a university hospital from 2006 to
2009.
Methods: We retrospectively review the clinical features of patients
with Kocuria spp. bacteremia from January 2006 through June 2009 at
National Taiwan University Hospital. The identiﬁcation of Kocuria spp.
was conﬁrmed by 16S rRNA gene analysis. Demographic data,
underlying diseases, clinical, microbiological, treatment and outcome
were collected.
Results: A total of 21 blood isolates from ﬁve patients were identiﬁed
as Kocuria spp. by conventional biochemical methods during the study
period. Twenty isolates of K. kristinae were conﬁrmed by 16S rRNA.
One isolate initially identiﬁed as K. varians was ﬁnally conﬁrmed to be
K. marina. The clinical courses of four patients indicated that signiﬁcant
infections were caused by K. kristinae, while the other patient probably
reﬂected contamination. Various underlying conditions, including gastric
cancer, short bowel syndrome and Port-A catheter for total parental
nutrition were found. One patient had clinically diagnosed infective
endocarditis. All infections were successfully treated with antibiotic
therapy and removal of catheters without infection-related mortality.
Conclusions: Kocuria species is an emerging cause of infection in
immunocompromised patients. The clinical manifestations are protean,
and include catheter related infection and infective endocarditis.
Accurate identiﬁcation with molecular methods is imperative for the
diagnosis of these unusual pathogens.
P1447 Microbiological investigation in patient care with invasive
devices
D. Platace ° (Riga, LV)
Objective: In modern day medicine the invasive devices continue to be
essential for the management of critically ill patients. Approximately
50% of health care-associated infections (HAIs) happen due to the
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combined effect of the patient’s ﬂora and invasive devices. The risk for
HAI is 11% to 38% with colonization by methicillin-resistant S. aureus,
25% with colonization by vancomycin-resistant enterococcus, and as
high as 38% with colonization by Candida.
Methods: By means of microbiological investigation the contamination
level of the ICUs and surgical units was determined: a) using a Count-
Tact applicator and a culture medium specially selected for this method
(n = 100), b) using the swab method (n = 90), c) using the urinary and
peripheral venous catheters sedimentation method (n = 30), d) using air
microbiological contamination test method with “Sas Super Iso 100”
(n = 199). The samples taken with the aim of identifying bacterial species
present were put on selective culture mediums. Interpretation of the
Count-Tact method results was performed according to the risk level
present and the colony forming unit (CFU) count on a 25 cm2 surface.
Results: The amount of microorganisms on the nurses’ hands exceeded
acceptable level sixteen-fold, and medium to high levels of bio-
contamination were discovered on patient’s changed bed sheets as well
as in nurses’ hair and their workwear. Mucor fungi were detected in
78.5% (44/56) cases on nurses’ workwear. Aspergillus, Penicillium,
Mucor fungi were identiﬁed in all air samples. In 21.4% (3/14) of
cases Staphylococcus aureus was discovered in the sterile zone of
the peripheral venous catheter 72 hours and 96 hours after catheter’s
insertion. Both 72 hours and 7 days after the insertion of a urinary
catheter 100% (16/16) of the cases revealed the presence of at
least one and in some cases several of the following pathogens:
Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, b
haemolytic Streptococcus and fungi, such as Candida albicans and
Candida tropicalis.
Conclusions: The medium to high levels of microbiological contamina-
tion and urinary catheters’ colonization with pathogens were determined
in patients care with invasive devices. Although microbiological
contamination does not necessarily lead to infection, it is nevertheless
an indication that infection control measures can be improved.
This study has been supported by the project of Europen Social Fond
(ESF).
P1448 Infections in patients undergoing craniotomy: ﬁrst attempt
to identify risk factors associated with post-craniotomy
meningitis in Greece
I. Kourbeti °, G. Bertsias, D. Karabetsos, C. Neophytou, M. Filippou,
A. Ioannou, A. Vakis (Chalkida, Heraklion, GR)
Objectives: Nosocomial meningitis is usually seen in neurosurgical
patients after craniotomy and leads to prolonged length of hospital
stay (LOS), surgical revisions, neurological impairment or death. We
conducted a retrospective cohort study to determine the incidence,
bacteriology and risk factors for post-craniotomy meningitis (PCM)
in Greece and describe the infection rates in patients undergoing
craniotomies.
Methods: Patients >18 years old, having non-stereotactic craniotomies
between 1/1999 and 12/2005 in University of Crete Medical Center were
eligible. Surgical Site infections (SSI) and other infections were deﬁned
using NNIS criteria. Data were analyzed with SPSS.
Results: 619 surgeries for 479 patients (64.6% male) were analyzed.
The median age was 48. Most craniotomies were performed for trauma
(41%). The median delay to surgery was 2 days. The median length
of stay was 13 days. There were 38 cases of PCM (6.1%). The median
interval to the diagnostic lumbar puncture was 13 days.5 patients had >1
episode. 74% of the episodes were culture conﬁrmed. Univariate analysis
revealed that meningitis was associated with concomitant infection
outside the surgical ﬁeld (p< 0.001), presence of another SSI (p< 0.001),
low pre-op GCS (p = 0.016, emergency procedure (p = 0.005), ICP
placement (p = 0.009) and duration of ICP monitoring (p = 0.004),
presence of any drain and duration of drain placement (p< 0.001),
presence of a ventricular and lumbar drains (p< 0.001), CSF leak
(p< 0.001), revision surgery (p = 0.017), admission to ICU (p = 0.007),
prolonged ICU stay (p< 0.001), length of stay from admission to
surgery (p = 0.012) and use of dural substitute (p = 0.003). Multivariate
analysis indicated that emergency procedure, concomitant infection,
malignancy and drain presence, especially of lumbar and ventricular
drains were independently associated with the risk of meningitis. The
overall mortality in the cohort was 13.4% but it was 31.6% in patients
who developed meningitis (OR 3.3). Ventilator associated pneumonia
(VAP) was the most common infection outside the surgical ﬁeld (13.1%).
SSI other than meningitis/ventriculitis developed in 9%. 26% of the
patients developed at least one infection.
Conclusion: A signiﬁcant percentage of patients undergoing craniotomy
developed at least one infection with VAP being the most prevalent. SSI
were second. Continuing device-related perioperative communication of
the CSF and the environment, concomitant infections and emergency
surgery were independent risks factor for PCM development.
P1449 The inﬂuence of nutritional status on the emergence and
evolution of nosocomial infections
M. Gamaletsou °, K.A. Poulia, D. Karageorgou, M. Yannakoulia,
N. Sipsas (Athens, GR)
Objectives: The aim of the present study was to record the incidence of
the emergence of the malnutrition in a sample of elderly patients and to
look into a possible association of malnutrition with the emergence of
nosocomial infections.
Methods: Patients over 60 years old admitted to a tertiary medical center
of Athens from January until September 2009 were included in the study.
On admission, anthropometric measurements and nutritional status was
evaluated by the Subjective Global Assessment questionnaire (SGA).
During hospitalization, nutritional status, nutritional interventions,
laboratory results and applied treatment were recorded, while patients
were observed for nosocomial infections development.
Results: 248 patients aged 75.22±8.459 years were included. According
to statistical analysis of data, 54% of patients had mild to severe
nutritional status on admission day. Poor nutritional status correlated
with low albumin levels and increased weight loss in the recent past. The
emergence of nosocomial infections was associated with the nutritional
status of the patients, since 39.5% of those who had poor nutritional
status developed a nosocomial infection, whereas only 11.8% of those
with good nutritional status developed a nosocomial infection (p = 0.016).
The emergence of nosocomial infections was associated with a greater
weight loss in the recent past (p = 0.022), a longer hospitalization
duration (p< 0.001) and a higher mortality rate (p< 0.001).
Conclusion: The results of this prospective clinical study underscore the
necessity of nutritional status assessment on admission day and timely
nutritional intervention, when indicated, in order to decrease the risk of
nosocomial infections.
Surgical site infections
P1450 Are antibiotic impregnated cement spacers safe in the
treatment of two-stage orthopaedic revision surgery?
M.L. Sorlı´ °, R. Torres, L. Puig, A. Gonzalez, A. Alier, M. Montero,
J. Villar, H. Knobel, J.P. Horcajada (Barcelona, ES)
Background: In two-stage orthopedic revision surgery, the use of
antibiotic-impregnated cement spacer is a common procedure. We
hypothesized that culturing of samples obtained from the cement spacers
would improve the microbiological diagnosis of subclinical prosthetic
joint infections.
Methods: Prospective cohort study. Patients undergoing a second-stage
orthopedic revision surgery from January 2007 to July 2008 were
prospectively included. Before second-stage surgery patients received 6
weeks of guided antimicrobial therapy and had an antibiotic free period
of 3.2 weeks (4.1 SD). Periprosthetic tissue (PT) specimens (5) were
collected for culture. Removed spacers were sonicated during 5 min.
(40Hz). Both PT and sonicate-ﬂuid (SF), were inoculated in aerobic
agar (Chocolate Polyvitex), anaerobic agar (Schaedler + 5% blood) and
in thioglycolat for 7 days. Cut-off positive culture was deﬁned as growing
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of >5 CFU on either plate. Subclinical prosthetic joint infection (SPJI)
was deﬁned as having at least one positive culture. All patients with SPJI
diagnosis were treated with guided antibiotic therapy. Microorganisms
isolated were assessed and compared with those isolated in the ﬁrst-stage
surgery. Clinical status was evaluated after a median follow-up of 44
weeks. Clinical failure was deﬁned when purulence in the synovial ﬂuid
or implant site, sinus tract and/or clinical signs of acute inﬂammation
were present.
Results: 55 patients were included (37 knee, 17 hip, 1 shoulder). 3
patients dropped from follow up. 10 (19.2%) SPJI were detected. Clinical
failure was found in 17 (32.7%) patients. 70% of these were patients
previously diagnosed of SPJI (7 out of 10), and 23.8% were patients
with negative cultures (10 out of 42). pf -0.009.
Conclusions: (1) Positive cultures of sonicated spacers or PTs (SPJI)
were found in 19.2% of patients undergoing a second-stage orthopedic
revision surgery. (2) SPJI is associated with a poor clinical outcome.
(3) Periprosthetic tissue cultures and sonication should be done in order
to rule out SPJI.
P1451 Reducing surgical site infection rates in orthopaedic implant
surgery: results of a 6-year infection control programme
R. Finkelstein °, O. Eluk, T. Mashiach, D. Levin, B. Peskin,
G. Nirenberg, S. Karkabi, M. Soudry (Haifa, IL)
Background: To report the results of an infection control program
on surgical site infections (SSIs) complicating total hip and total knee
replacement.
Methods: Prospective cohort study of patients undergoing total hip and
total knee replacement. Interventions included prospective surveillance,
chlorhexidine 4% showers, depilation before surgery, administration
of preoperative antibiotic prophylaxis in the operating room and
comprehensive postdischarge follow-up. Infections were evaluated using
CDC’s deﬁnitions. Logistic regression models were ﬁtted to assess
infection rates over time, adjusting for factors known to affect SSI
rates (NNIS risk index category, type of operation, sex, age, emergency
operation, administration of preoperative antibiotic prophylaxis, length
of stay in hospital before surgery).
Results: 1720 consecutive procedures were evaluated from April 1, 2002
to May 31, 2008. Rates of organ/space infections remained low, but
unchanged over the study period (mean 1.09%). The overall rate of
infections, the rates of superﬁcial (SUP) and deep incisional SSIs during
the ﬁrst two years were 7.90%, 5.78%, and 0.96%, respectively and
they decreased to 1.96%, 1.06%, and 0.0, respectively by the end of the
study (p< 0.001, <0.001, and 0.03, respectively). The rate of SSIs due
to S. aureus decreased from 1.54% to 0.30% (p = 0.02). The adjusted
odds ratios for these infections at the end of the study as compared to
March 31, 2004, were as follow: total number of infections 0.23 (95%
conﬁdence interval [CI-95], 012–0.44), SUP 0.17 (CI-95, 0.07–0.39) and
SSI due S. aureus 0.14 (CI-95, 0.03–0.64).
Conclusions: We observed signiﬁcant reductions in infection rates in
most types of infections, particularly in the overall rate of SSIs and
infections due to S. aureus. These differences remained signiﬁcant when
adjusted for potential confounding variables.
P1452 The effect of hospital volume on surgical site infection rates
following orthopaedic procedures: what seems to be the
most appropriate threshold?
D. Weitzel-Kage °, D. Sohr, M. Behnke, P. Gastmeier (Berlin, DE)
Background: Surgical site infections (SSI) belong to the most common
nosocomial infections. The association between the operation volume
and the risk of SSI is an importend issue. We wanted to investigate
if high volume hospitals have lower surgical site infection (SSI) rates
following orthopaedic operations.
Objectives:We used 3 orthopaedic procedures to analyse the association
between the annual volume of operations and the incidence of SSI.
Method: The German national nosocomial infection surveillance system
(KISS) is focussing on surveillance of 29 selected indicator procedures.
KISS is using the deﬁnitions of the Centers for Disease Control and
Prevention and the method of the National Health Safety Network for
recording SSI. We analysed the data for 3 orthopaedic procedures types
performed between January 2001 and June 2006: 35.579 hip prosthesis
procedures, 29.237 knee prosthesis procedures and 16.642 arthroscopic
operations were included. Two limits were considered: 50 and 100
procedures per year.
Results: Higher SSI rates in low volume hospitals were found for all
3 three procedure types considering the limit of an annual number of
50 operations per year with signiﬁcant differences for hip and knee
prosthesis. (Table).
Using the limit of >100 operations per year the SSI rates were even
lower in the group of high volume hospitals (Knee prosthesis SSI rate
0.91%, Hip prosthesis SSI rate 0.94%).
Conclusion: The annual volume of operations has a signiﬁcant impact
on SSI rates following orthopaedic procedures. The hospitals should
perform at least 50 operations annually, but more than 100 operations
per year is even better.
Type of operation SSI rate in hospitals
with an annual number
of procedures
Odds ratio p value
50 OPs >50 OPs
Hip prosthesis 1.73% 1.06% 1.65 0.017
Knee prosthesis 1.91% 1.00% 1.93 0.016
Arthroscopic operations 0.33% 0.27% 1.24 0.561
P1453 Clinical features and prognosis of prosthetic joint infection:
a multicentre cohort in Andalusia, Spain
M.D. del Toro, I. Nieto, F. Guerrero, J. Palomino, E. Nun˜o,
J.E. Corzo-Delgado, A. del Arco, J.M. Lomas, C. Natera, A. Ruı´z,
P. Rico, A. Romero, J. Delgado, J. Rodrı´guez-Ban˜o °, M.A. Muniain
and the Prosthetic Joint Infection Group of SAEI
Objective: To describe the more relevant clinical characteristics and
prognosis of prosthetic joint infection (PJI) in 12 Andalusian hospitals.
Method: Prospective observational study of the cohort of PJI recruited
from 1/10/06 to 1/10/09 in the participating hospitals using stantard
criteria, with a follow-up of at least 12 months after the end
of antimicrobial treatment. Infectious diseases physicians provided
recommendations bases in a previously launched consensus management
guideline.
Results: 273 patients were included: 108 (39.5%) hips (46 hemiarthro-
plasty), 143 (52.5%) knees and 22 (8%) elbow/ankle implants; 172
(64%) were women; median age was 72 years (range: 32−95); 63%
(171) had comorbidities. 33% had peroperatory risk factors for infection
(surgical site infeccio´n [SSI] 28, surgical hematoma/bleed 37), and
24% risk factors after the implantation. Types of infection according
to Tsukayama’s classiﬁcation: 89 (32%) acute postsurgical (API), 133
(48%) chronic potsurgical (CPI), 37 (13%) acute haematogenous (AHI),
and 14 (5%) culture positive in prosthesis exchange without previous
infection data. Aetiology: S. aureus 76 (29%) (15 were methicillin-
resistant), coagulase-negative staphylococci 73 (27%), Gram-negative
bacilli 36 (13%), Streptococcus 27 (10%), polymicrobial 22 (8%),
others 11 (4%), unknown 28 (10%). Initial treatment planned was
surgical debridement with prosthesis retention in 114 (42%), prosthesis
removal in 103 (38%), arthrodesis/resection arthroplasty in 34 (12%)
and supressive antibiotic therapy in 22 (8%). After 12 months of follow-
up, 48.5% were considered cured; 20.5% failure of inicial treatment;
19% were still using antibiotic; 3.6% died; and 8.4% were lost. The
prosthesis was mantanied in 45%, exchanged in 35%, and resection
arthoplasty was performed in 20% (1 patient was amputated). At the
end of therapy, 28% walked without help, 54% needed 1−2 crutches,
and 18% could not walk. On univariate analysis, factors associated with
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failure of inicial treatment were: for API, to have an infection caused by
a multi-drug resistant organism; for CPI, prosthetis retention and delay
of surgical treatment; and for AHI, diabetes mellitus and infection due
to MRSA.
Conclusion: Overall, unselected cases of PJI are associated with a high
morbidity and high frequency of functional disability 12 months after
the completion of therapy. PJI due to multidrug-resistant organisms are
associated with treatment failure.
P1454 Improving the quality of prophylactic antibiotics in total
knee arthroplasty
K.S. Chan ° (Yung-Kang, TW)
Objectives: Infection of a total knee arthroplasty (TKA) remains a
devastating complication associated with this procedure. It leads to
prolonged hospital stay, readmissions to the hospital, increased morbidity
and mortality, and excesses the healthcare cost. Prophylactic antibiotics
have proven to be effective in reducing the incidence of infection after
TKA. However, inappropriate use of antimicrobial prophylaxis could
cause prolonged duration and use of broad-spectrum antibiotics, increase
the incidence rate of resistant microorganism. The objectives of this study
were to reduce the quantity of prophylactic antibiotics and improve the
quality of surgical prophylaxis.
Methods: This was an intervention study in a 1311-bed tertiary
hospital. The intervention program was initiated from October, 2008.
All patients underwent TKA during the study period were collected.
Intervention programs included education regarding current evidence-
based guidelines, development of local guidelines, and implementation of
reminders to facilitate adherence to the local guidelines. Antibiotic with
5 doses or more (Cefazolin 1 dose before and 3 doses after the procedure
were suggested by the guideline) is deﬁned as prolonged prophylaxis.
The quality of prophylaxis was audited before and after the intervention
during a six-month period. Outcome parameters were dosage and costs
of antibiotic use, length of hospital stay, unplanned hospital readmission.
Results: There were 140 procedures before the intervention and 126
during the intervention period. A signiﬁcant improvement in the
adherence to the local guidelines was noted between the pre-intervention
and intervention periods. Prolonged prophylaxis was observed in1.6%
instead of 90.75% in the pre-intervention period. The costs of antibiotics
reduced by 44.8% per procedure (P< 0.001). The length of hospital stay
of pre-intervention period was signiﬁcantly longer than the intervention
period (7.7±1.9 days VS 7.2±2.1 days, p = 0.023). No patient was re-
admitted to the hospital during the study period.
Conclusions: The intervention led to improved quality of surgical
prophylaxis and to reduced antibiotic use. In addition, it shortened
the hospital stays and reduced the costs without impairment of patient
outcome.
P1455 No correlation between skin microbial counts after
preoperative skin disinfection and surgical site infections
S. Tschudin, D. Egli-Gany, M. Dangel, D. Oertli, W. Weber, R. Frei,
A.F. Widmer ° (Basel, CH)
Objectives: Preoperative skin disinfection as outlined by WHO is
standard practice for the prevention of surgical site infections (SSI),
yet few studies examined the association between skin microbial ﬂora
after disinfection and the development of a SSI. No study examining an
association between skin microbial counts and a subsequent infection
has so far been completed in a large sample compromised of a variety
of surgical patients.
Therefore we examined the correlation between total colony forming
unit counts of skin ﬂora after preoperative skin disinfection at surgical
incision site and the development of a subsequent SSI in patients from
different surgical specialties.
Methods: Prospective observational study in which 1014 skin cultures
immediately were taken from patients after preoperative skin disinfec-
tion, before incision. Disinfection of the surgical site was performed
according to the study protocol, using standardized procedure under
supervision of a study nurse or the attending surgeons. Skin swabs
were incubated for 48 hours and colony forming units (cfu) were
enumerated and identiﬁed by means of standard laboratory identiﬁcation
methods. The ﬁnding of more than 10 cfu was regarded as signiﬁcant
colonization. The diagnosis of SSI was based on surveillance, full chart
review and postdischarge surveillance (30 days after surgery) using the
Centers for Disease Control/National Nosocomial Infection Surveillance
(CDC/NNIS) deﬁnitions.
Results: 1014 skin cultures from surgical sites were taken from a total
of 1005 patients, mainly receiving orthopedic or cardiac surgery. 36
(3.6%) cultures revealed signiﬁcant colonization of the preoperative site
after skin disinfection. Coagulase-negative staphylococcus was the most
common organism detected (83.3%), followed by S. aureus (8,3). 41
SSIs were detected accounting for a surgical site infection rate of 4.0%.
Most SSIs occurred in cardiac surgery (34.2%). Signiﬁcant cfu counts
after skin disinfection were not correlated with SSI (Table).
Conclusion: This large study was not able to establish a correlation
between residual colonization and SSI, indicating that a standardized
three step disinfection is sufﬁcient to prepare the surgical site.
Residual cfu after disinfection Rate of SSI
<10 3, 8%
10 0, 2%
P1456 Timing of antibiotic prophylaxis inﬂuences the incidence
of surgical site infection rates after colon surgery
P. Rafeiner °, U. Beutner, J. Celeiro, K. Di Salvo, G. Rettenmund,
J. Lange, M. Zu¨nd, M. Schlegel (St. Gallen, CH)
Objectives: Surgical site infection (SSI) is a common adverse event
after colon surgery leading to high morbidity and mortality. Published
SSI rates for colon surgery (COLO SSI rate) range between 5 and 30%.
In 2008 we performed a surveillance study to determine the SSI rate for
colon surgery and to identify risk factors for SSI.
Methods: The study was performed at a tertiary care centre during 2008.
Data from all patients with a colon surgery according to the National
Nosocomial Infections Surveillance System (NNIS) COLO deﬁnition
were entered prospectively into a database. The Centers of Disease
Control (CDC) guidelines for diagnosis of SSI were followed. Follow-up
lasted for 30 days. Discharged patients were contacted by phone 30 days
after surgery.
Results: 227 cases have been surveyed. Age (median) was 66.4 years.
The SSI rate for colon surgery was 20.7% (95%CI: 15.9–26.4%). There
were found 49% superﬁcial infections, 10.6% deep and 40.4% organ /
space infections.
Out of 207 cases 98 cases (43%) got the antibiotic prophylaxis
with correct timing (30−60min pre-op). SSI rate after properly timed
antibiotic prophylaxis was 12.2% (CI 95%: 7.1–20.2%). Otherwise, the
rate was signiﬁcantly increased: 60−90min pre-op: 30.8% (CI 95%:
16.5−50%), 90–120min pre-op 28.6% (CI 95%: 11.7–54.6%), <30min
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pre-op: 17.5% (CI 95%: 9.8–29.4%). Higher body surface was linked
to a higher infection rate (body surface <1.7 m2: 11.6% (95%CI: 6–
21.2%), 1.7 m2: 24.7% (95%CI: 18.6−32%), p = 0.03).
Conclusions: Our SSI rate for COLO is higher than reported by
NNIS (5.4%), but similar to published rates obtained under study
conditions. Since data contribution to NNIS is voluntary, a selection
bias or qualitative differences cannot be excluded. We identiﬁed incorrect
timing of antibiotic prophylaxis as the key risk factor for surgical site
infections. Efforts must be done for optimizing the processes to obtain
an appropriate timing of pre-op antibiotic prophylaxis. Check lists (as
the ‘Surgical Safety Checklist’, proposed by WHO) might contribute to
achieve this aim.
P1457 Surveillance and epidemiology of surgical site infections
after cardiothoracic surgery in the Netherlands, 2002–2007
J. Mannie¨n, J.C. Wille, J.J. Kloek, B.H. van Benthem ° (Bilthoven,
Amsterdam, NL)
Objective: Surgical site infections (SSI) after cardiothoracic surgery sub-
stantially increase the risk for illness, mortality and costs. Surveillance
of SSIs might assist in the prevention of these infections. This study
describes the Dutch surveillance methods and results of data collected
between 2002 and 2007.
Methods: Three cardiothoracic procedures were included: coronary
arterial bypass grafts (CABG), valve surgery, and a combination of
CABG with concomitant valve surgery. The SSIs were divided into
sternal and harvest site SSIs. Postdischarge surveillance of SSIs was
mandatory for sternal wounds and elective for harvest site wounds,
with a follow-up period of 42 postoperative days. Multivariate logistic
regression was used for risk factor analysis of CABG, with adjustment
for random variation among hospitals.
Results: Eight of the sixteen Dutch cardiothoracic centers participated
and collected data on 4066 procedures and 183 SSIs, revealing a SSI rate
of 2.4% for sternal wounds and 3.2% for harvest sites. Sixty-one percent
of all SSIs were recorded after discharge. For sternal SSI after CABG, the
signiﬁcant risk factors were rethoracotomy, diabetes, preoperative length
of stay, and obesity; for harvest site SSI the most relevant risk factor
was a long time on the extra-corporal circulation (Table 1). Adjusted
SSI rates regarding CABG varied between hospitals from 0.0% to 9.7%.
A culture result was available for 46 of the 53 (87%) deep sternal SSIs
and for 26 of the 44 (59%) superﬁcial SSIs. Fifty-eight percent (49 of
84) of the isolated micro-organisms were identiﬁed as Staphylococci (37
Staphylococcus aureus). For 41 of the 86 (48%) harvest site SSIs, a
culture result was recorded. Thirty-one percent (19 of 61) of the isolated
micro-organisms were identiﬁed as Staphylococci (15 Staphylococcus
aureus).
Conclusions: Large differences were found in SSI rates between Dutch
hospitals, which indicate room for improvement. The follow-up of
patients after hospital discharge avoids underestimation of SSI rates.
P1458 Surgical site infections after orthopaedic surgery in Cyprus:
incidence, risk factors, microbiology and impact
E.I. Kritsotakis °, I. Dimitriadis, D. Bagatzouni, M. Alexandrou,
V. Zinieri, C. Tsioutis, A. Gikas (Heraklion, GR; Larnaca, Nicosia,
Limassol, Pafos, CY)
Objectives: To determine the incidence of surgical site infections (SSI)
after common orthopaedic surgery procedures in Cyprus, compare
observed rates with international data, and specify main epidemiologic
features including risk factors, predominant pathogens and resistance
patterns, use of antibiotic prophylaxis, and impact of SSI on patient
outcome.
Methods: The US National Nosocomial Infections Surveillance (NNIS)
system protocols were employed to prospectively collect data for patients
who underwent orthopaedic surgery during an 11-month period in the 4
public hospitals of Cyprus. Procedures surveyed included open reduction
of fracture (FX), knee prosthesis (KPRO), and hip prosthesis (HPRO).
Comparisons of procedure-speciﬁc SSI rates with international data were
performed by means of standardized infection ratios after stratiﬁcation by
the NNIS risk index. Risk factors for SSI were evaluated by multivariate
logistic regression.
Results: A total of 44 SSIs were detected in 1403 operations (3.1 per
100 operations), of which 27% were detected post-discharge. Among
the recorded SSI, 61% were superﬁcial, 23% were deep and 16%
were organ-space infections. Most frequently isolated pathogens were:
Staphylococcus aureus (29.4%; of which 60% methicillin-resistant),
Pseudomonas aeruginosa (17.6%; none resistant to ciproﬂoxacin,
ceftazidime or imipenem), Enterococcus spp. (11.8%; none resistant to
vancomycin), and coagulase negative staphylococci (11.8%). Antibiotic
prophylaxis was administrated for 98% of the procedures classiﬁed as
clean and for 92% of clean-contaminated procedures, for a median
duration of 2 days. Procedure speciﬁc SSI rates and risk-adjusted
comparisons with international data are presented in the Table. SSI
rates were signiﬁcantly higher for KPRO and HPRO compared with US
data, and for KPRO compared with Spanish data. Among 12 potential
risk factors examined, signiﬁcantly and independently associated with
increased risk for SSI were: Charlson comorbidity index 4 (odds ratio
[OR]=3.1, p = 0.040), and wound class not clean (OR= 5.6, p< 0.001).
The mean postoperative hospital stay was signiﬁcantly longer for patients
with SSI than those without SSI (20.1 vs 10.1 days, p< 0.001). SSI was
not associated with mortality.
Conclusion: This study demonstrated the feasibility of implementing a
standardized surveillance protocol of SSI in Cypriot public hospitals
and generated data useful for designing targeted infection control
interventions.
Procedure-speciﬁc SSI rates in Cyprus and risk-adjusted comparisons
with international data
NNIS Operative Category Study results Risk-adjusted comparisons with:
No. of SSI/ SSI rate US rates [l] Spanish rates [2] UK rates [3]
procedures (%) SIR p SIR p SIR p
Knee prosthesis 14/288 4.9 4.5 <0.001 2.5 0.002 1.2 0.270
Open reduction of fracture 24/832 2.9 2.2 <0.001 0.9 0.408 0.8 0.240
Hip prosthesis 6/283 2.1 1.6 0.194 0.5 0.057 1.1 0.495
NNIS, National Nosocomial Infection Surveillance system; SSI, surgical site infection, SIR, standardized infection
ratio. [1] Am J Infect Control 2004;32:470−85. [2] Am J Infect Control 2006;34:134−41. [3] UK Health Protection
Agency 2006.
P1459 Surgical site infection after open heart surgery
C. Ezpeleta °, E. Gomez, M.J. Unzaga, I. Atucha, J.A. Alava, A. Arias,
R. Cisterna (Bilbao, ES)
Objective: To know the rates of NI (Nosocomial Infection) and surgical
site infections (SSI) in patients operated on open heart surgery in our
hospital and to compare with those of HELICS (Hospital in Europe Link
for Infection Control trough surveillance).
Patients and Methods: The 2422 patients (pt) operated on open-heart
surgery in our hospital from Jan 2000 to Oct 2009 were included.
Preoperative protocol regarding infection control includes: shower with
4% clorhexidine soap the night before surgery and repeated the day
of surgery. Hair clipping just before surgery. Antibiotic prophylaxis:
Cefuroxime 1.5 gr. IV 5 minutes before surgery. A second dose is
administrated intraoperatively if the length of surgery is >6 hours or
hemodilution >15ml/kg or blood loss >1.5 l. All the pt are prospectively
studied since the day they are operated until the end of the episode by
the infection control team during admission and continued 1 year after
discharge. Variables under surveillance are age, sex, underlying illnesses,
predisposing conditions, ASA, NNIS risk index, antibiotic prophylaxis,
nosocomial infections, microorganisms, length of hospital stay, treatment
and outcome. CDC deﬁnitions of nosocomial infection are used.
Results: 1630 men, mean age 66.6 y. Nosocomial infections: 487 pt
acquired 708 NI, 127 of them were surgical site infections (SSI),
Respiratory 231, Urinary tract 187, local catheter site 62, bacteremia 64:
primary 24, secondary 30, and catheter related 10. Cumulated incidence
of pt with NI 20.11%. SSI: 32 incisional superﬁcial, 39 deep incisional
and 56 organ space. NNIS score 0: 156 pt, 1.9% SSI; Score 1: 1510 pt,
4.2% SSI; Score 2: 724 pt, 6.4% SSI, Score 3: 30 pt, 26.7% SSI.
Antibiotic prophylaxis was administered in 99.5% of the cases. The
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dosage, time, drug and duration of the prophylaxis were appropriated
(99.9%, 99.5%, 99.8% and 95.2% respectively). Microorganisms in SSI:
coagulase negative Staphylococci (CNS) 45, P. aeruginosa 12, S. aureus
18 (6 SAMR). Cumulated incidence of SSI 5.24%.
Conclusions: Comparing our data of SSI (5.24%) with the latest
HELICS-SSI report 2004 (1043 cases) our results are lower than the
total results (10%). Gram positive cocci are the most common isolated
in SSIs in our hospital, similarly in the HELICS report Gram-positive
cocci are recovered in 68.4% of cases. In our case series CNS are the
most frequent recovered from SSI and in the HELICS report S. aureus
predominates with 31.6% of isolates.
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P1460 Molecular characterization and antimicrobial phenotypes
in clinical isolates of Clostridium difﬁcile in a tertiary care
hospital, Mallorca
C. De´niz °, E. Riera, J.L. Pe´rez, A. Oliver, A. Mena (Palma, ES)
Objectives: There have been some changes in the epidemiology of the
Clostridium difﬁcile infection, mainly represented by the rapid spread
of epidemic strains, including hypervirulent strain known as ribotype
027. In order to know the epidemiology of our hospital environment we
performed molecular characterization and antimicrobial phenotypes of
toxigenic C. difﬁcile clinical isolates collected from August 2007 to Au-
gust 2009, at the major public hospital of the island of Mallorca, Spain.
Methods: A total of 70 clinical isolates of C. difﬁcile obtained from
different patients with diarrhoea during 2 years were studied. Rapid
ELISA detection of toxins A and B (Wampole®, Inverness medical),
directly from the stools or from the culture, were performed for all
the isolates. Molecular toxigenic proﬁle of the strains was studied by
PCR ampliﬁcation of the tcdA (toxin A), tcdB (toxin B) and cdtA,
cdtB (binary toxin) regions. Typing and clonal relation was studied by
PCR ribotyping through ampliﬁcation of the 16S-23S rRNA. C. difﬁcile
ribotypes 001, 078 and 027 were used as controls. Isolates with PCR
ribotypes patterns different from those control strains were classiﬁed
by letters. Finally, antimicrobial susceptibility patterns to metronidazole
(MTR), vancomycin (VAN), clindamycin (CLIN), erythromycin (ERY)
and moxiﬂoxacin (MXF) were studied by determining the MIC using
the Etest method.
Results: 96% of the isolates were toxigenic by PCR and 3 isolates were
false positives ELISA results. All toxigenic isolates produced toxins A
and B and 27% of the isolates also produced binary toxin. We found
30 different PCR ribotype patterns. The most prevalent ribotypes were
A ribotype (A+B+, 21%), 078 ribotype (A+B+bin+, 19%), B ribotype
(A+B+, 13%) and 001 ribotype (A+B+, 9%). All strains were susceptible
to MTR and VAN, but resistance to CLIN, ERY and MXF was found in
61%, 23% and 23%, respectively. We also observed almost 100% CLIN
resistance and 50% ERY resistance in ribotypes 078 and 001 and 50%
MOXI resistance in ribotype 001.
Conclusion: The ﬁrst epidemiological study of C. difﬁcile in our hospital
shows the presence of heterogeneous ribotyping population with binary
toxin-producing strains, mainly represented by the hypervirulent ribotype
078. We found no clear association between antimicrobial proﬁles and
ribotyping. Finally, there is no evidence of occurrence of clusters in our
hospital or presence of the 027 epidemic ribotype and A-B+ strains.
P1461 Ribotyping and further subtyping of isolates from
Clostridium difﬁcile infection in a UK teaching hospital is
effective in analysing transmission and assessing impact of
enhanced measures to control spread
G. Jones °, J.K. Sutton, S. Green (Southampton, UK)
Objective: Standard infection control measures to reduce the incidence
of C. difﬁcile infection, (CDI) operate in our hospital. We assessed the
impact of these measures on the distribution of C. difﬁcile ribotypes over
an 8 month period in 2009.
Methods: Ribotyping was performed on C. difﬁcile isolates obtained
from culture of toxin A+B enzyme immunoassay (EIA) positive faeces
conﬁrmed by polymerase chain reaction. Multi-locus variable number of
tandem repeats analysis (MLVA) was performed on selected isolates of
ribotype 027 during a period of increased incidence of CDI. Movements
of patients with indistinguishable ribotypes and MLVA subtypes were
tracked to determine transmission networks.
Results: 170 cases of CDI were identiﬁed and 166 C. difﬁcile isolates
were ribotyped. 65 (39%) were ribotype 027 and 21 (13%) were ribotype
106. 47 strains representing 9 other ribotypes were identiﬁed and 33
strains were of sporadic unidentifed ribotypes. MLVA identiﬁed 13
distinct subtypes from 49 027 isolates. Two dominant 027 subtypes
comprising 16 and 14 isolates respectively, identiﬁed transmission
between patients within wards A and B. MLVA also clearly demonstrated
that a patient transfer from ward A to ward B introduced the ﬁrst subtype
to ward B to create a cluster of cases comprising both dominant 027 sub-
types. A smaller ribotype 106 cluster was identiﬁed on another ward. Ri-
botyping and MLVA data combined with analysis of patient movements
were used to track transmission between patients and wards. Enhanced
control measures including introduction of adenosine triphosphate
bioluminescence monitoring to improve cleaning reduced CDI from 95
cases in the ﬁrst 3 months of the study to 36 in the ﬁnal 3 months (61%
reduction). Strikingly, the proportion of 027 cases fell from 51/95 (54%)
in months 1−3 to 1/36 (3%) in months 5−8. In the ﬁnal 3 months of the
study, no single ribotype accounted for more than 6 of the 36 isolates.
Conclusions: Routine ribotyping and selective MLVA were effective
in characterizing outbreaks and improving control of CDI. Enhanced
measures to control spread of CDI were effective and resulted in
the virtual elimination of 027 strains by the end of the study
period. Overall the observations were compatible with a signiﬁcant
reduction in nosocomial transmission and highlight the need for other
ongoing measures to reduce CDI including continued effective antibiotic
stewardship.
Number of C. difﬁcile ribotypes identiﬁed per month
Month of study Total
1 2 3 4 5 6 7 8
O27 ribotype (n) 8 24 19 9 3 1 0 0 65
All ribotypes (n) 22 40 29 23 15 12 11 13 166
P1462 Detection of hypervirulent strains PCR-ribotype 027 and 078
causing severe Clostridium difﬁcile infection in northern Italy
A. Tuscano °, R. Baldan, P. Cavallerio, C. Parlato, L. Fossati, M. Moro,
R. Serra, D. Cirillo (Milan, Turin, IT)
Objectives: Clostridium difﬁcile (Cd) is recognized as the main cause of
hospital acquired antibiotic-associated diarrhoea worldwide. Its virulence
is attributed to the production of toxins A and B. From 2003 increasing
incidence, severity and mortality of Cd infection (CDI) were reported
and related to the emergence and spread of highly virulent strains, such
as PCR-ribotype 027 and 078. These hypervirulent strains produce the
binary toxin (CDT) and harbour mutations/deletions in the tcdC gene,
encoding for an inactive negative regulator of toxins A/B production.
In order to investigate the presence and spread of hypervirulent strains
and to characterize the main Cd clones, we examined at the molecular
level all the toxigenic Cd strains isolated in 2 large Italian nosocomial
settings, the San Raffaele (hSR) and the San Giovanni Battista hospitals
(SGBh).
Methods: We characterized by PCR-ribotyping, detection of tcdA, tcdB,
cdtA/cdtB genes and sequencing of the tcdC gene 129 SGBh Cd strains
and 157 hSR Cd strains. All strains were investigated for the presence of
ermB gene, responsible for the macrolide-lincosamide-streptogramin B
resistance phenotype, and selected strains were tested for susceptibility
to ciproﬂoxacin, moxiﬂoxacin, metronidazole and vancomycin.
Results: 9 cases (8 at the SGBh (6.2% of the SGBh isolates) and 1 at the
hSR) of severe CDI were caused by ribotype-027: strains were resistant to
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moxiﬂoxacin and susceptible to vancomycin and metronidazole; 55.5%
harboured the ermB gene. 28 cases were caused by ribotype-078 (21 at
the hSR, where it represents the second most commonly isolated ribotype
(14%), 7 (5.4%) at the SGBh): 70.5% of these strains were resistant
to moxiﬂoxacin and all susceptible to vancomycin and metronidazole;
60.7% harboured the ermB gene. In both hospitals we identiﬁed also
ribotype 018 as the main clone, accounting for half of the isolates, and
ribotype 001.
Conclusion: The main clone detected in both hospitals was the ribotype
018, but we report here that the hypervirulent strains 027 and 078
are present in Northern Italy. Ribotype 078 represents the second most
frequently identiﬁed ribotype at the hSR, while ribotype 027 accounts for
6.2% of the SGBh Cd isolates. We noticed that the antibiotic resistance
pattern of ribotypes 027 and 078 is changing toward the development of
high-level resistance to antibiotics.
P1463 Molecular epidemiology and antimicrobial resistance of
Clostridium difﬁcile isolates in Taiwan
Y.C. Lin °, Y.T. Huang, N.Y. Lee, C.H. Liao, W. Ko, P.R. Hsueh (Taipei
City, TW)
Objectives: Clostridium difﬁcile associated diarrhea is a global health
problem and a highly virulent strain (ribotype 027) has disseminated
throughout North America and European countries. Data regarding
the molecular epidemiology and antimicrobial resistance of C. difﬁcile
isolates in Taiwan remained limited.
Methods: Eighty-six isolates of C. difﬁcile obtained from patients treated
at National Taiwan University Hospital (NTUH) and 25 from National
Chen-Kung University Hospital (NCKUH) from August 2007 and June
2009 were analyzed. Molecular typing using a repetitive-element PCR
typing (DiversiLab® kits for C. difﬁcile) and antimicrobial susceptibility
testing to 15 antimicrobial agents were performed. Another 14 isolates
identiﬁed during 2001 and 2004 were also included for analysis. Isolates
with a correlation of 95% determined by DiversiLab® software version
3.4 were considered to be within the same clone.
Results: Among these isolates, 12 clones were identiﬁed with a major
clone (Clone A) covering 47.4% (N= 55) of isolates. Furthermore, clone
A was distinct from North American pulsotype1 (NAP1, corresponding
to ribotype 027), NAP7 and NAP8 (ribotype 078). Isolates of this clone
were distributed equally among both centers and could be traced back to
2001. Clone C (N= 14) isolates, appeared since 2001, were only detected
at NTUH and appeared to be similar to NAP7. No metronidazole- or
vancomycin-resistant isolates were identiﬁed. Decreased susceptibility
for moxiﬂoxacin (MIC8mg/dL) were found in 18 isolates among
different clones (9 isolates in clone A, 2 in clone B, 3 in clone C, 2
in clone E and 1 in clone F) and these isolates also exhibited decreased
susceptibility to gemiﬂoxacin and nemonoxacin. Partial sequence of
gyrA and gyrB genes for the 19 quinolone resistance isolates revealed
the substitution Thr82 to Ile (13 isolates), Asp81 to Asn (1 isolate),
Asp71 to Gly (1 isolate) in GyrA, Asp426 to Val (1 isolate) in GyrB.
Three isolates have substitution in both GyrA and GyrB: 2 with Thr82
to Ile in GyrA plus Ser 416 to Ile in GyrB and 1 with Thr82 to Ile in
GyrA plus Asp426 to Val in GyrB.
Conclusions: Dissemination of ﬂuoroquinolone-resistant clones of
C. difﬁcile occurred in Taiwan. Although no NAP1 (ribotype 027)
isolates were detected in the current surveillance from Taiwan, further
monitoring is mandated.
P1464 Mortality and attributable mortality of C. difﬁcile infection
in critical ill patients
J. Leitner °, D. Schmid, H.W. Kuo, F. Allerberger, P. Tesik, V. Michl,
C. Wenisch (Vienna, AT)
Objectives: A prospective hospital-based cohort study was performed
between November 2008 and August 2009 to measure the attributable
mortality of C. difﬁcile infection (CDI) in patients with CDI compared
with non-diarrhoea patients admitted at the intensive care unit (ICU)
with equal comorbidity score.
Methods: 90 CDI patients and 180 ICU non diarrhea patients were
included. Death risk ratio and attributable risk of death (i.e. excess
mortality) were used to measure the relative and absolute effect of
CDI on the risk of pre-discharge mortality within the two comorbidity-
severity categories low and moderate-severe comorbidity using the
Charlson Comorbidity score. Death risk ratio was calculated by death
risk in the CDI-group (exposed group) / death risk in the ICU-
group (unexposed group) and the attributable risk of death (attributable
mortality) was calculated death riske − death risku. The attributable
risk percent, AR% (mortality fraction) was calculated by AR%=
(death riske − death risku) / death riske X 100. Death risks were
compared by using c2 test or the Fisher’s exact test. The survival time
between the CDI-patient-group and ICU-patient group within the two
comorbidity-severity categories was analysed by using Kaplan–Meier
survival analysis. For the CDI-patient group day zero corresponded to the
date of disease onset, and for the IC-patient group day zero corresponded
to the day of ICU admission. Study subjects with a follow up period of
at least 30 days were included in this survival analysis. A total of 141
ICU-patients and all the 90 CDI patients remained for this analysis.
Results: Table 1 shows the risk of death in low compared to moderate &
severe comorbidity in CDI and ICU non diarrhea patients.
Within 30 days CDI patients with low comorbitiy showed higher survival
rate than the ICU patient-group (p< 0.001). No signiﬁcant difference was
observed between survival rates of the CDI patients and ICU patients in
the moderate/severe comorbidity category.
Conclusion: C. difﬁcile infection does neither result in increased
mortality in patients with low nor with moderate/severe Charlson
comorbidity score.
Table 1. Effect of CDI on the mortality risk; CDI-patient group compared
with the ICU-patient group by comorbidity severity categories low and
moderate/severe
Comorbidity severity Risk of death in: RR (95% CI) Excess mortality Mortality fraction
CDI-patient-
group
ICU-patient-
group
Sub-cohort I:
Low comorbidity
4.2% (2/48) 39.8% (53/133) 0.1 (0.03–0.41) n.a. n.a.
Sub-cohort II:
moderate & severe
comorbidity
28.6% (12/42) 21.3% (10/47) 1.34 (0.65–2.78) 7.3% 25.5%
P1465 Community-associated Clostridium difﬁcile infection in
Denmark: clinical features and molecular characterization
L.M. Søes °, M. Kemp, S. Persson, K.E. Olsen (Copenhagen, DK)
Objective: The aim of this study is to clarify clinical features and risk
factors in Clostridium difﬁcile infections and to determine toxin gene
proﬁles of isolates found in faecal specimens from patients attending
their general practitioner on suspicion of gastroenteritis.
Methods: Stool samples submitted from general practitioners from
eastern parts of Zealand on suspicion of gastroenteritis are analysed
for bacterial, viral and parasitic gastrointestinal pathogens including
C. difﬁcile. The C. difﬁcile isolates are analysed by PCR for detection
of the toxin genes tcdA, tcdB and cdtA/cdtB. A case–control study
is being conducted to reveal clinical features of disease, including
severity of disease, prior use of antibiotics and co-morbidity and to
investigate possible risk factors in terms of acquisition of disease,
including exposure to animals and young children.
Results: Currently 60 patients have been enrolled and diagnosed with
C. difﬁcile by stool culture. Age ranges from 14 weeks to 93 years,
with half of the patients being less than 24 month of age. Even when
excluding these, mean age is 54 years. Preliminary data of toxin gene
proﬁle analysis are shown in Table 1. Concomitant bacteria are found in
two in 21 stool samples in the group of patients less than 24 months of
age with toxigenic strains. These two are attaching-and-effacing E. coli.
According to present data duration of diarrhoea is approximately one
month for patients more than 24 months of age and half a month for
patients less than 24 months of age. Mean stool frequency is seven and
C. difﬁcile infection S421
ten times a day for the two age groups, respectively. Weight loss during
illness is reported by approximately seventy percent of the patients.
Conclusion: Preliminary data indicates average age in the group of the
patients more than 2 years of age to be as low as 54 years. In the
group of patients being younger than 24 months of age, approximately
two thirds of the strains harbour genes encoding Toxin A and B. No
concomitant bacterial pathogens of known importance are found in this
group, suggesting C. difﬁcile could be of importance for developing
disease. Furthermore it may reﬂect the possibility of young children
being a reservoir for C. difﬁcile. For the patients already enrolled into
the study current data indicates marked symptomatology with longlasting
diarrhoea with high stool frequency often followed by loss of weight.
Table 1. Distribution of toxin proﬁles
Toxin proﬁle Patients
<24 months
of age
(N= 33)
Patients
>24 months
of age
(N= 27)
Toxin A, Toxin B, Binary toxin CDT1 1 9
Toxin A and Toxin B2 21 16
Non-toxigenic 11 2
1Strains PCR-positive for the toxin genes tcdA, tcdB and cdtA/cdtB
encoding Toxin A, Toxin B and the binary toxin CDT. 2Strains PCR-
positive for the toxin genes tcdA and tcdB encoding Toxin A and Toxin B.
P1466 Impact of Clostridium difﬁcile infection on resource
utilization and clinical outcomes in hospitalized patients
M.F. Emons °, B.H. Nathanson, H.T. Yu, T. Haidar, E. Alemao,
D. Gardiner, R.K. Spoeri (Beverly Hills, Longmeadow, Collegeville, US)
Objective: To evaluate the impact of Clostridium difﬁcile infection (CDI)
on resource utilisation and in-hospital mortality in patients with hospital-
onset healthcare facility-associated (HO-HCFA) CDI.
Methods: This retrospective analysis utilised data from April 1, 2005 to
December 31, 2008 within Cerner’s Health Facts® database. Qualifying
cases included adults with an inpatient encounter with a primary or
secondary diagnosis of pseudomembranous colitis (ICD-9-CM code:
008.45) AND a positive C. difﬁcile toxin test AND the ﬁrst positive
C. difﬁcile test (index event) was ordered more than 72 hours after
admission. Non-CDI controls were hospitalised for at least 72 hours
with no diagnosis of pseudomembranous colitis AND no C. difﬁcile
culture or toxin assays during the study period. Primary outcomes
were in-hospital mortality, hospital length-of-stay (LOS) and 90-day
all-cause readmission. A propensity-score-matched sample and a non-
parse regression model with the propensity score itself and all other
covariates (eg, patient demographics, clinical markers of severity of
illness, treatments of interest [ie, antibiotics, proton pump inhibitors,
H2 antagonists, and non-steroidal anti-inﬂammatory drugs]) were both
used to assess the effect of HO-HCFA CDI on outcomes.
Results: A 5:1 Greedy algorithm matched 1,312 cases to 1,312 controls.
Patients with HO-HCFA CDI had signiﬁcantly longer unadjusted hospital
LOS than non-CDI patients (mean [SD]: 22.0 [19.0] versus 6.6 [5.8]
days, P< 0.001). After matching, the LOS among survivors with HO-
HCFA CDI was 10.8 days (95%CI, 9.7–12.0) longer than the non-CDI
control group and LOS after the CDI event was equivalent to the entire
LOS in the control group. No signiﬁcant differences in mortality were
found between matched HO-HCFA CDI and non-CDI groups (odds
ratio = 0.89; 95%CI, 0.69–1.15) though the matched mortality rate of
HO-HCFA CDI patients was high (8.7%). Thirty-three percent of all
matched survivors required readmission within 90 days. The relative
risk for readmission was signiﬁcantly higher for HO-HCFA patients:
1.56 (95%CI, 1.38–1.76).
Conclusions: HO-HCFA CDI is a growing public health concern and
is associated with signiﬁcantly longer hospitalisations and higher risk
of hospital readmission within 90 days. To reduce the higher resource
utilisation among these patients, a better understanding is needed of risk
factors and potential preventative measures.
P1467 Rapid and effective routine typing of Clostridium difﬁcile
isolates in a hospital setting using the repetitive sequence-
based polymerase chain reaction DiversiLab® system
I. Khan °, V. Garcia Arias, J. Laughlin (Slough, UK)
Objectives: Clostridium difﬁcile (C. difﬁcile) infection (CDI) is the
leading cause of nosocomial diarrhoea. Rapid and reproducible typing
methods are essential for tracking and monitoring CDI. Our aim
was to characterise the epidemiology and understand the underlying
picture of CDI within our 500-bed hospital using the DiversiLab®
repetitive sequence-based polymerase chain reaction (rep-PCR) system
(bioMe´rieux) and integrate our ﬁndings within infection control practice.
Methods: CDI cases were detected by routine hospital surveillance using
the VIDAS® C. difﬁcile Toxin A & B assay (bioMe´rieux). Isolates were
cultured and DNA was extracted, and ampliﬁed using the DiversiLab
Clostridium Fingerprinting kit. PCR products were separated using
microﬂuidics chips and analysed using the web-based software provided
with the system.
Results: From April 2009 to July 2009 a total of 43 C. difﬁcile
toxin positive stool samples from 38 patients were detected. Forty-
one isolates were available for typing. Eight isolates (19.5%) from six
different patients showed >93.5% similarity in their ﬁngerprint proﬁles,
suggesting the existence of a predominant cluster. The isolates had >95%
similarity to the C. difﬁcile NAP1 strain in the DiversiLab database
and all were conﬁrmed to be ribotype 027 by the reference laboratory.
Infection control investigations showed the six patients had been in the
same ward at some point and enhanced surveillance and infection control
precautions were implemented. Seven more clusters of two or more
isolates with >90% similarity in their ﬁngerprint patterns were observed
with no epidemiological links and no similar strains found in the library
database. A further ﬁve isolates (12.2%) showed a low discrimination
ﬁngerprint pattern with two bands common to NAP2, 4 and 6 strains.
The remaining 10 isolates showed unique rep-PCR ﬁngerprints. One
patient had two recurrences of CDI with the same NAP1/027 strain and
another had a second episode of CDI with a different ﬁngerprint strain.
Conclusions: Routine in-house typing of C. difﬁcile using the
DiversiLab rep-PCR system enabled us to gain an understanding of the
epidemiology of CDI within our hospital setting. The system offered us
rapid, accurate and reproducible results to support the infection control
team in routine C. difﬁcile surveillance and CDI outbreak investigations.
P1468 Clostridium difﬁcile resistant to ﬂuoroquinolones in Italy:
emergence of PCR-ribotype 018
P. Spigaglia °, F. Barbanti, P. Mastrantonio (Rome, IT)
Objectives: To investigate the susceptibility of Italian Clostridium
difﬁcile isolates to ﬂuoroquinolones over time.
Methods: 147 toxigenic C. difﬁcile isolates collected by the Istituto
Superiore di Sanita, from 1985 to 2008, were investigated for
susceptibility to ﬂuoroquinolones and for a possible association between
ﬂuoroquinolone and MLSB-resistance. All strains were typed by PCR-
ribotyping and analysed for susceptibility to moxiﬂoxacin (MX),
levoﬂoxacin (LE), gatiﬂoxacin (GA), ciproﬂoxacin (CI), erythromycin
(EM) and clindamycin (CM) by the E-test method. All resistant strains
were characterized for substitutions in GyrA and GyrB by real-time PCR
and for the presence of an ermB gene by PCR assay.
Results: For convenience we divided the strains in two groups: the ﬁrst
group included 70 isolates from 1985 to 2001, the second group 77
isolates from 2002 to 2008. In total 50 isolates (34%) were found
resistant to ﬂuoroquinolones, with MICs between 8 and 32mg/L for
MX and GA, 24 and 32mg/L for CI and 32mg/L for LE. 10%
(7/70) belonged to the ﬁrst group, whereas 56% (43/77) to the second
group. All strains had the substitution Thr82 to Ile in GyrA, except
one isolate in the ﬁrst group and one isolate in the second group that
showed the substitution Asp426 to Asn in GyrB. 98% (49/50) of the
C. difﬁcile isolates resistant to ﬂuoroquinolones were also resistant to EM
and/or CM. Among the resistant strains isolated from 1985 to 2001, 57%
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(4/6) had an erm(B) gene compared to 9% (4/43) among those isolated
from 2002 to 2008. C. difﬁcile strains resistant to ﬂuoroquinolones and
isolated from 1985 to 2001 belonged to type 001 (two strains), 126
(two strains) and 012, 020, 078 (one strain for each type). Fifty six
percent (24/43) of the ﬂuoroquinolone resistant strains isolated between
2002 and 2008 belonged to type 126, 40% (17/43) to type 018 and
2% (1/43) to type 020 and 001, respectively. Interestingly, all isolates
resistant to ﬂuoroquinolones isolated in 2007 and 2008 belonged to PCR-
ribotype 018, that also represents the predominant PCR-ribotype in Italy
at present.
Conclusions: The results indicate an increase of ﬂuoroquinolone-
resistance among Italian clinical isolates, recently associated to the
spread of a clone PCR-ribotype 018.
P1469 A Clostridium difﬁcile 027 epidemic in a hospital in Vienna,
Austria, 2008–2009
S. Kasper °, E.E. Kanitz, A. Indra, T. Watkins-Riedel, H. Masoud,
S. Eberl, S. Huhulescu, F. Allerberger, D. Schmid (Vienna, AT)
Objectives: From January to August 2009, 174 cases of C. difﬁcile
infections (CDI), including 38 cases of infection with C. difﬁcile ribotype
027(027CDI) occurred in a Viennese hospital (HX). Previously, in 2008,
11 cases of 027CDI were identiﬁed in Austria. The objective was to
describe the 027 CDI outbreak by time, place, person and to ascertain
antibiotic exposure prior to diarrhoea onset, the frequency of recurrent
CDI and the 30-day mortality.
Methods: Surveillance case deﬁnitions were given by the Study Group
for Clostridium difﬁcile (ESGCD). An outbreak case was deﬁned as
a patient with 027CDI, who became ill between December 2008 and
August 2009 in HX or who was epidemiologically linked to HX. The
epidemiological link was deﬁned as stay at HX within 4 weeks prior to
027CDI occurrence or as contact to a 027CDI case of HX. A recurrent
CDI was deﬁned as the occurrence of a second episode of CDI within
60 days after the ﬁrst episode. PCR ribotyping of C. difﬁcile isolates was
performed by the National Reference Laboratory for C. difﬁcile, AGES.
Medical charts of the 027 cases of HX were reviewed for recurrent
episodes, antibiotic exposure prior to diarrhoea onset and outcome.
Results: A total of 38 027CDI outbreak cases occurred in HX and
another 12 cases of 027 CDI in further 5 Viennese hospitals were
epidemiologically linked to the 027CDI outbreak Twenty-four of 38 cases
were male (60%), the median age was 80 years (range: 31−98 years). The
proportion of recurrence was 15.8% (6/38) and the 30-day mortality was
34.2% (13/38). Medical records were available for 27 (66%) outbreak
cases. All these received antibiotics prior to diarrhoea onset (b-lactam
antibiotics: 55.6%, ﬂuoroquinolones: 59.3%). ESGCD control measures
were implemented in the third week of July.
Conclusion: Non-compliance to evidence based control measures as
recommended by ESGCD resulted in a rapid spread of a high virulent
CD strain, which caused a very high patient mortality. Following the
measure implementation, the hospital-based CD surveillance indicated a
decreasing trend of all CDI cases in HX within the past three months.
The ﬁndings of the outbreak investigation underline the importance of
ribotyping in elucidating links between separate hospital clusters.
P1470 CDI in England in 2008−09 versus 2007−08 as determined
by The Clostridium difﬁcile Ribotyping Network for
England and N. Ireland (CDRN, formerly the CDRNE)
M. Wilcox °, W. Fawley, M. Shemko, D. Fairley, A. Birtles, E. Bolton,
S. Green, K. Hardy, P. Hawkey, P. Hawtin, J. Magee, B. Patel,
A. Sails, N. Shetty, M. Wren for the C. difﬁcile Ribotyping Network
for England & N. Ireland CDRN), Regional Microbiology Network,
Health Protection Agency
Objectives: To describe the key epidemiological ﬁndings concerning
CDI in England in 2008−09 versus 2007−08 as determined by The
Clostridium difﬁcile Ribotyping Network for England and N. Ireland
(CDRN, formerly the CDRNE).
Methods: CDRN expanded in 2009 to 8 regional laboratories in
England and N. Ireland. CDRN provides ribotyping and enhanced DNA
ﬁngerprinting to identify cross-infection, reduce transmission, optimise
management of outbreaks and determine the epidemiology of C. difﬁcile.
Results: In 2008/09 CDRN processed 4,682 faecal samples from 190
healthcare facilities (~100% increase over 2007/08); hence, about 1
out of every 8 or 9 C. difﬁcile cases in England were examined by
CDRN. Marked changes in ribotype prevalence in 2008/09 occurred,
with a striking 19% decrease (from 55% to 36%) in CD 027, and
‘compensatory’ increases in other less common types. The prevalence
of ribotypes 106 (13%) and 001 (8%) remained similar. There were
clear regional differences in ribotype prevalence e.g. CD 027 was the
commonest in each region except the North East (CD 001, 20.0% vs
CD 027, 12.6%; p< 0.001). There have been shifting regional ribotype
prevalences since CDRN(E) was introduced, most clearly demonstrated
for 027. There was a signiﬁcant association between all cause mortality
and CD 027 (OR= 1.9; p< 0.001).
Notably, there was an increase from 9.6% to 12.5% in the proportion of
(toxin positive) faecal samples that are C. difﬁcile culture-negative. This
may reﬂect more false positive samples, as CDRN examines samples that
have tested locally as ‘toxin positive’. Susceptibility testing of over 1000
C. difﬁcile isolates has shown more evidence of emergence of reduced
susceptibility to metronidazole with some institutional clustering.
Conclusions: Since CDRN was introduced in early 2007 there has been
a marked decrease in incidence of CDI in England. During the same time
frame recorded deaths due to CDI have decreased. These changes likely
reﬂect successful control of ribotype 027. We believe that provision of
timely ribotyping data by CDRN to hospitals has helped to control and
reduce the prevalence of ribotype 027. Access to timely typing data is
important for infection control teams to identify and control transmission
of C. difﬁcile.
P1471 Epidemiology of Clostridium difﬁcile during norovirus
outbreaks
C. Holmes °, K. Hardy, S. Gossain, S. Manzoor, P. Hawkey (Leicester,
Birmingham, UK)
Objective: There have been reports noting an increase in the incidence
of Clostridium difﬁcile infection (CDI) during norovirus outbreaks.
Hypotheses proposed for this increase include increased transmission
of C. difﬁcile due to norovirus diarrhoea, norovirus causing increased
severity of CDI, or increased submission of diarrhoeal samples. The
aim of this study was to document the incidence of CDI during hospital
norovirus outbreaks.
Methods: The study was performed between December 2008 and April
2009 in 3 linked hospitals with 1,800 beds. All loose stools from patients
on wards with conﬁrmed norovirus outbreaks were examined using an
RT-PCR norovirus assay. In addition all samples were examined for C
difﬁcile using an in-house and the BD GeneOhm PCR assay as well
as the TechLab EIA toxin test. All C. difﬁcile positive samples were
cultured for that bacterium and PCR ribotyped.
C. difﬁcile
Patient Outbreak Norovirus
status
BD Gene
Ohm PCR
In-house
PCR
EIA Culture
(Ribotype)
A 3 + + + + + (001)
B 3 + + Inhib − + (062)
C 5 + + + − Insuf
D 14 − + + − + (020)
E 15 + + + − + (001)
F 16 + + + + + (174)
G 16 + + − − −
Inhib: inhibitory PCR; Insuf: insufﬁcient specimen for culture.
Results: One hundred and seven patient samples were included in the
study from 21 norovirus outbreaks of which 70 (65%) were norovirus
positive. Seven patients were positive for C. difﬁcile by at least one of the
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methods used; all but one of these patients were positive for norovirus
(See table). Two instances of more than one C. difﬁcile positive patient in
the same norovirus outbreak were detected. In one of these, the patients
had different C. difﬁcile ribotypes, and in the other, one of the results
may represent a false-positive PCR as culture was negative.
Conclusions: Only a small number (6) of patients with norovirus also
had C. difﬁcile in their stool, and no evidence of transmission of
C. difﬁcile during a norovirus outbreak was found, suggesting only a
weak linkage between the two infectious agents. If EIA alone had been
used to diagnose CDI only 2 of the 7 cases would have been detected.
This demonstrates the low sensitivity of EIA compared to PCR for the
detection of C. difﬁcile.
P1472 Does linezolid protect against Clostridium difﬁcile infection
in major heart surgery patients?
M. Valerio °, M. Pedromingo, P. Mun˜oz, M. Marin, L. Alcala´, E. Bouza
(Madrid, ES)
Objectives: Clostridium difﬁcile infection (CDI) is one of the main
causes of diarrhea associated to antimicrobial therapy. Antibiotics with
good “in vitro” activity against C. difﬁcile, other than metronidazole or
vancomycin, could be protective of CDI. One of these drugs is linezolid.
We tried to assess the potentially protective role of linezolid in the
development of CDI in patients receiving linezolid therapy for Ventilator
Associated Pneumonia (VAP).
Methods: During a four year period, we retrospectively analyzed a
cohort of patients who developed VAP after major heart surgery (MHS)
in our institution. Patients were divided in those who developed CDI in
the postoperative period and those who did not. We analyzed the charts
in order to determine variables associated to the development of CDI
including the role of antimicrobial therapy. We collected data involving
pre-surgical, intraoperative and post-surgical variables. Treatment with
Daily Deﬁned Doses (DDD’s) of linezolid and other antimicrobials were
carefully registered. Univariate and multivariate analysis were performed.
All statistical tests were two-tailed.
Results: Overall, 1844 patients had MHS. 105 cases had VAP, of which
complete clinical data were available in 91 cases. CDI occurred in 22
(24.2%) patients. When comparing VAP cases with and without CDI,
EUROSCORE and overall antibiotics prescribed were not signiﬁcantly
different. Patients with chronic renal failure were more prone to develop
CDI than patients without it (32% vs. 13%; p = 0.04) and patients with
CDI had received more doses of linezolid than dose without CDI (DDD’s
12.4±9.7 vs 6.7±4.0; p = 0.007). A multivariate analysis conﬁrmed that
receiving more DDD’s of linezolid protects against developing CDI (HR
0.908, p = 0.04, CI 95% 0.83–0.99).
Conclusion: Our study shows that VAP patients treated with more
DDD’s of linezolid therapy may have a lower occurrence of CDI. Our
work has some limitations; it is retrospective, has a limited number of
cases and addresses a very particular population but it is the ﬁrst to
suggest on clinical bases the potential impact of linezolid in protecting
against CDI.
P1473 Real-time monitoring and ﬁne tuning of joint (PCT −
acute hospital) Clostridium difﬁcile infections containment
programme: common root cause analysis of CDI in the
community and hospital − the missing link
R. Kato °, I. Maitland, M. Ibeto, M. Qulaghassi, A. Guleri (Blackpool,
UK)
Introduction: A dynamic passage exists for patients with healthcare
associated infections between community and acute hospital. Clostridium
difﬁcile infections (CDI) is associated with signiﬁcant morbidity,
mortality, associated cost, compromise in clinical quality and patient
safety. Reduction in CDI in community & hospitals is of high priority for
Department of Health (DH). The joint (PCT-hospital) infection control
teams (ICT) identiﬁed the need to develop a root cause analysis (RCA)
tool that could be used in community and the hospital. We present a
feasibility study of developing and using such a common CDI RCA tool
(pre48 h and post48 h). The results of RCA were used to inform the joint
CDI containment programme and ﬁne tune action plans to address new
challenges.
Method: In the setting of St Mary’s Medical Practice and Blackpool,
Victoria Hospital, data was collected, analysed and fed back to
clinical/nursing teams on 20 CDI RCAs (10 each pre48 h & post48 h).
Results: Data from 20 RCAs (10 each pre48 h & post48 h) revealed
that virtually all the patients were elderly (>70 years). The single most
common association with CDI was non-compliance with (primary care /
hospital) antibiotic formulary with prolonged, inappropriate and repeated
antibiotic courses. 1.5% were on proton pump inhibitors. 5−15% patients
were on laxatives or antimotility agents; 15% has recurrent episodes
in last 12-months; Hand hygiene compliance was variable. There were
lapses in infection control protocols in care homes / rehab hospital.
There was a delay in collection of sample in 30%; 25% each were in
patients and care home residents; 15% rehab patients.
Conclusion: Management of healthcare-associated infections incl. CDI
should be addressed as a continuum rather than a hypothetical divide
between community-acquired and hospital-acquired. The importance
of the applying the root cause analysis in both the hospital and the
community is to attempt to eliminate the risk factors, as opposed to
merely addressing the resulting problems. In so doing, we are able to
identify areas for change, develop any recommendations and to look for
new solutions. Nursing staff at care homes would beneﬁt from training
on management & monitoring patients with CDI. Primary care trusts
should direct their local GP practices to put in place assurance systems
which demonstrate how they are complying with good infection control
practice through rigorous clinical audit and root cause analysis.
P1474 C. difﬁcile strain dependency of sporocidal acitivity of
disinfectants
M. Martin, I. Winterfeld, P. Goroncy-Bermes, F. Mattner ° (Lubeck,
Hamburg, DE)
Background: C. difﬁcile infections (CDI) are recognized as the major
causes of nosocomial gastroenteritis with an increasing morbidity and
mortality. A considerable part of CDI is acquired by transmission through
hand-hand contacts or by indirect contact to surfaces. Sporocidal activity
of disinfectants is crucial for prevention of nosocomial transmission.
Objective: To compare sporocidal activity of different disinfectants
using spores of different genotypical and epidemiological characterized
C. difﬁcile strains.
Methods: B. subtilis ATCC 6633, one C. difﬁcile strain isolated form
only one patient, one endemic strain, ribotyp 027, 126, and 078 (1.5
to 5 106 CFU per ml) were used to test glutaraldehyde (2%), peracetic
acid (PAA) (0.05%), sodium hypochlorite (500 ppm), perform® (2%) and
gigasept PAA concentrate ® (1 and 2%) for sporocidal activity according
to DIN EN 13704. A reduction factor (Rf) of 3 or more was regarded
as effective.
Results: Rf for glutaraldehyde (30 min) were 0.89 for B. subtilis and >4
for all C. difﬁcile strains. Rf for PAA (15 min) were 0.17 for B. subtilis
and between 0.1 and 3.94 for C. difﬁcile strains. Sodium hypochlorite
was effective after 15 min for B. subtilis and 5 min for all C. difﬁcile
strains. Perform was effective after >120 min for B. subtilis and between
60 and 180 min for C. difﬁcile. Gigasept PAA concentrate® 2% (1%)
was effective after 5 (5) min for B. subtilis and between 5 (15) and 15
(30) min for different C. difﬁcile strains. The unique C. difﬁcile strain
and ribotyp 027 and 078 were less susceptible against most disinfectants
compared to other C. difﬁcile strains and B. subtilis ATCC 6633 used as
surrogate for sporocidal activity.
Conclusion: In comparison to B. subtilis, C. difﬁcile strains were less
susceptible against PAA and gigasept PAA concentrate and more against
sodium hypochlorite. Susceptibilities against disinfectants seem to be
strain dependent. Our results question the usefulness of surrogate testing
for the determination of sporocidal activity of different disinfectants.
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P1475 Characterization of multi-resistant Clostridium difﬁcile
clinical strains isolated in Europe
P. Mastrantonio °, F. Barbanti, P. Spigaglia on behalf of the ESGCD
and the EACCAD
Objectives: To investigate the multi-resistant Clostridium difﬁcile
clinical isolates collected in 14 different European countries during
ESGCD Prospective Study performed in 2005.
Methods: 316 toxigenic strains were analysed for resistance to
erythromycin (EM), clindamycin (CM), moxiﬂoxacin (MX), tetracycline
(TC), chloramphenicol (CL), rifampin (RIF) metronidazole (MZ) and
vancomycin (VA) by the E-test method. Isolates resistant to MX were
also analysed for their susceptibility to gatiﬂoxacin (GA), levoﬂoxacin
(LE) and ciproﬂoxacin (CI). Multi-resistance was deﬁned as resistance
to at least 3 classes of antibiotics. The mechanisms of resistance were
investigated by PCR and/or nucleotide sequencing. All strains were
previously typed by PCR-ribotyping.
Results: 148 strains were resistant to at least one class of antibiotic and
82 of these strains (55%) resulted multi-resistant (M-R). M-R strains
belonged to 24 different PCR-ribotypes and 5 of them, 001, 012, 017,
048 and 168, included the majority (91%) of the isolates. All strains
were resistant to EM and CM. In particular, 39 strains (48%) were also
resistant to MX and RIF, 24 (30%) to MX, 6 (7%) to TC, 6 (7%) to
TC, MX, CL and RIF, 5 (6%) to MX, CL and RIF, 1 (1%) to TC and
MX, 1 (1%) to TC, MX, RIF. All strains resistant to MX were also
resistant to GA, LE and CI. As far as the mechanisms of resistance
are concerned, 76 isolates (93%) were ermB-positive. The remaining
strains were also negative for other important erm classes, for mutations
in the 23SrRNA, L4 and L22 genes, and for the presence of efﬂux
pumps. Among the ermB-positive strains, different genetic organizations
of the ErmB determinant were observed. Only 3 strains resistant to MX
showed a substitution in position 426 of GyrB, whereas the others had
the substitution Thr82 to Ile in GyrA. All strains resistant to RIF had
two substitutions, His502 to Asn and Arg505 to Lys in RpoB, except for
two isolates showing the substitution Arg505 to Lys. All strains resistant
to TC were tetM-positive and carried a Tn5397. Four isolates showed
the co-presence of a tetM and a tetW gene. Finally, all strains resistant
to CL had a catD gene.
Conclusions: The results indicate an increased tendency of C. difﬁcile
clinical isolates to acquire resistance to different classes of antibiotics
and underline the importance of a constant monitoring of antibiotic
susceptibility in this bacterium.
P1476 Community-onset Clostridium difﬁcile infection in eastern
London
J. Rangaiah °, M. Wilks, M. Millar (London, UK)
Objectives: Clostridium difﬁcile infection (CDI) is increasingly being
recognised as a problem in community in Europe and North America.
We undertook this study to determine the clinical and epidemiological
aspects of community-onset CDI (CO-CDI) in the East London
community to which Microbiology Laboratory, Barts and The London
NHS Trust provides diagnostic services to.
Methods: The data on faeces samples processed in microbiology
laboratory between May 2007 and April 2008 and the patient details
were obtained by searching the laboratory computer database. Patients
with positive CDT result on admission and in community were identiﬁed
based on patient location at the time of specimen collection. Details on
clinical presentation, risk factors, clinical management and outcome of
the CDT positive patients were obtained from the case notes and GPs.
Results: Of the 4036 specimens sent by GPs only 93 (2.30%) were
requested for CDT as compared to 6281 of 15,084 (41.64%) by hospital
doctors. Twelve of the 93 (12.90%) GP samples and 782 of the 6281
(12.45%) hospital samples tested positive. The 93 GP requests came from
35 of the 823 (4.25%) GP surgeries and a single GP practice accounted
for 27.95% of all GP requests. Twelve patients tested by GP and another
twelve presenting to A&E were tested positive resulting in a total 24
patients fulﬁlling the deﬁnition of CO-CDI. Previous hospitalisation
(n = 20) and exposure to antibiotics (n = 22) were the most signiﬁcant
risk factors followed by exposure to proton pump inhibitors (n = 10) and
previous CDI (n = 5). Four patients presenting to A&E with worsening
diarrhoea had visited a GP surgery in the last week, where CDI was not
considered as a possible diagnosis. In 3 patients death was attributable
to CDI.
Conclusions: This study supports the view that there is considerable
under-diagnosis of CDI in the community as evidenced by a wide
variation in the testing practice for CDI among GPs. While the question
of what are the other risk factors for community associated CDI remains
to be investigated further, it is very important to have a robust mechanism
for early diagnosis and adequate management of patients with known risk
factors of CDI becoming symptomatic in community. It may be more
cost-effective to manage these patients in the community and may also
reduce the risk of further spread of infection in the hospital.
P1477 Risk factors for endemic Clostridium difﬁcile infections in
an academic hospital in the Netherlands
M. Hensgens °, A. Goorhuis, C. van Kinschot, M.J. Crobach,
E.J. Kuijper (Leiden, NL)
Objectives: Clostridium difﬁcile infection (CDI) is the most important
cause of nosocomial diarrhoea. Risk factor analyses have almost
exclusively been performed in outbreak situations, using retrospective
data. We performed a prospective analysis of risk factors for CDI in an
endemic setting.
Methods: In a prospective case–control study from July 2006 through
May 2009, we compared demographic and clinical data of all consecutive
CDI patients (n = 93) to the data of patients without diarrhoea (n = 76)
and of patients with non-CDI diarrhoea (n = 63).
Antibiotic usage in the three months prior to CDI was assessed using
Deﬁned Daily Doses, to take into account both dosing and duration of
the antibiotic therapy.
Results: The incidence of CDI in the LUMC was 2 per 10 000 in-patient
days. In total 24 different PCR ribotypes were found, among which types
014 (16%), 078 (13%) and 015 (8%) were the most frequent. Independent
risk factors for CDI were previous admission, recent endoscopy and
the use of 2nd and 3rd generation cephalosporins. Previous endoscopy
and previous use of 3rd generation cephalosporins, vancomycin and
gentamicin were associated with diarrhoea in general. The use of ﬂuoro-
quinolones and proton pump inhibitors was not associated with endemic
CDI. During the study period, 38 outpatients were diagnosed with CDI.
Compared to CDI case patients, they were younger (mean age 49 vs 56)
and more often had community-associated CDI (52% vs 4%). Interest-
ingly, second generation cephalosporins (15%) and immunosuppressive
agents were frequently (63%) used by outpatients with CDI. Mortality
rates after 60 days were 7.5% CDI in-patients and 5.3% for outpatients,
compared to a low mortality rate in both control groups (1.6% and 0%).
Conclusion: Some previously described risk factors for CDI were found
to be risk factors for diarrhoea in general. Furthermore, the use of
ﬂuoroquinolones and proton pump inhibitors did not inﬂuence the risk of
CDI in this endemic setting. Outpatients with CDI represented a distinct
group of patients, associated with a relatively high 60-day mortality rate.
P1478 Factors associated with Clostridium difﬁcile infection in a
cohort of patients
C. Micallef °, V. Siva, L.D. Liebowitz (King’s Lynn, UK)
Introduction: In England, the Department of Health set speciﬁc targets
to reduce hospital-acquired infections including Clostridium difﬁcile
infection (CDI). Known predisposing factors for developing CDI include:
age 65 years, previous antibiotic therapy and proton pump inhibitors
(PPIs).
Objectives:
– To establish whether a relationship exists between incidence of CDI
and co-amoxiclav in a cohort of patients admitted to a CDI Isolation
Unit with laboratory and clinically conﬁrmed CDI.
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– To identify additional key predisposing factors for developing CDI.
Methodology: The Queen Elizabeth Hospital (QEH) is a district
general hospital in Norfolk, England, with ca. 500 beds, providing a
service to 280,000 people. In March 2008, a ten-bedded isolation unit
for CDI was inaugurated. Only patients with a laboratory-conﬁrmed
Clostridium difﬁcile toxin A and B positive stool tested are admitted
to the unit. All consecutive patients were reviewed retrospectively.
The following parameters were recorded: age, sex, antibiotic history,
PPIs, co-morbidities, positive Meticillin-resistant Staphylococcus aureus
(MRSA) colonisation/infection status, renal dysfunction, white cell
count, C-reactive protein (CRP) and albumin on diagnosis.
Results: Preliminary results revealed that 55.3% of patients who
developed CDI were given co-amoxiclav prior to the infection. Females
accounted for 68.4% of cases and 78.9% of patients were 65 years
of age. In addition: 68.4% of patients also had cardiovascular disease.
PPIs were prescribed in 42.1% of cases. Previous/concomitant MRSA
was found in 18.4% of patients. Renal dysfunction was present in 42.1%
of patients. Albumin levels were low in 89.5% of cases with 32.3% of
these, having levels <20g/l. A CRP of >5mg/l was found in 97.3%
of cases and 60.5% had WCC> 10×109/l, with 56.5% of these having
levels >15×109/l. The study is on-going and we will be presenting the
ﬁnal data, with statistical analysis at ECCMID 2010.
Conclusions: At the QEH, after decreasing the use of cephalosporins
and quinolones, co-amoxiclav is the antibiotic most frequently associated
with CDI. Most CDI patients also suffer from cardiovascular diseases.
The majority of patients had a low albumin level and increased CRP.
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P1479 Inhaled colistin for the treatment of tracheobronchitis and
pneumonia in critically ill children without cystic ﬁbrosis
M. Falagas, G. Sideri, I. Korbila, E. Vouloumanou °, J. Papadatos,
D. Kafetzis (Athens, GR)
Objective: The role of inhaled colistin in the treatment of chronic
Pseudomonas aeruginosa infection in patients with cystic ﬁbrosis has
already been evaluated. Yet, data regarding the role of inhaled colistin
in critically ill pediatric patients without cystic ﬁbrosis are scarce.
Methods:We present a small case series of critically ill children without
cystic ﬁbrosis who received inhaled colistin (colistimethate sodium)
treatment.
Results: Three children (1 female), admitted to the intensive care
unit (ICU) of a tertiary-care pediatric hospital in Athens, Greece,
during 2004–2009, were identiﬁed to have received inhaled colistin as
monotherapy for tracheobronchitis (2 children), and as adjunctive therapy
for necrotizing pneumonia (1 child). Colistin susceptible Acinetobacter
baumannii and Pseudomonas aeruginosa were isolated from the cases’
bronchial secretions specimens. All 3 children received inhaled colistin
in a dosage of 75mg diluted in 3ml of normal saline twice daily
(1.875.000 IU of colistin daily), for a duration of 25, 32, and 15 days
respectively. The infections improved in all 3 cases. Also, a gradual
reduction, and ﬁnally total elimination of the microbial load in bronchial
secretions was observed during inhaled colistin treatment in the reported
cases. All 3 cases were discharged from the ICU. No bronchoconstriction
or any other type of toxicity of colistin was observed.
Conclusions: Inhaled colistin was effective and safe for the treatment
of 2 children with tracheobronchitis, and 1 child with necrotizing
pneumonia. Further studies are needed to clarify further the role of
inhaled colistin in pediatric critically ill patients without cystic ﬁbrosis.
P1480 Differences in intestinal colonization of term and pre-term
born neonates hospitalized at a neonatal intensive care unit
T. Gschliesser °, V. Strenger, A.J. Grisold, G. Feierl, L. Masoud,
B. Resch, W. Mu¨ller, B. Urlesberger (Graz, AT)
Objectives: Whereas human gut is sterile at delivery, bacterial
colonisation occurs within the ﬁrst days/weeks thereafter. Intestinal ﬂora
is a possible source of late onset sepsis in neonates. The aim of the study
was to describe intestinal colonisation with enterobacteria in neonatal
intensive care unit (NICU) patients.
Methods: We included newborns hospitalised at the NICU Graz from
June 2006 to May 2009. Stool samples were routinely taken at the NICU
twice a week. All children received a prophylaxis to prevent necrotising
enterocolitis with Lactobacillus rhamnosus, Gentamicin or Colistin and
Nystatin. We retrospectively analysed the spectrum of enterobacteria
for different groups of patients and performed statistical analysis by
means of SPSS for Windows (Mann–Whitney U test, Fisher’s exact test).
Bacterial species that were found in less than 10 patients were excluded
from statistical analysis.
Results: 808 patients (437 boys, 371 girls, 611 <36 weeks of gestation)
were analysed. 232 had a birth weight <1.500g (very low birth
weight − VLBW). The median age (in days) at ﬁrst colonisation with
enterobacteria was: term borns 6 (1−72), preterm borns 13 (1–109),
VLBW 20 (1–109). Preterm and term borns were colonised with 1−8
species (median 1) and 1−5 (median 1), respectively. We found 29
different enterobacteria species and included 12 in statistical analyses.
Further results see table 1.
Conclusion: Analysing the 12 most commonly detected enterobacteria
species, VLBW were colonised signiﬁcantly later. This may occur
because of different feeding regimens in VLBW.
Table 1. The 12 most commonly detected species; number and age at
ﬁrst colonization
Number colonised Age (days) at colonisation, median (range)
Species All
(n = 808)
<1,500 g
(n = 232)
1,500 g
(n = 576)
p-value <1,500 g 1,500 g p-value
Citrobacter amalonaticus 11 4 7 n.s. 62 (29−91) 26 (9−36) 0.023
Citrobacter freundii 53 23 30 n.s. 48 (12–202) 14.5 (1−38) <0.001
Enterobacter cloacae 243 100 143 0.007 26.5 (5–112) 13 (1−72) <0.001
Escherichia coli 301 69 232 n.s. 27 (1–202) 9 (1−63) <0.001
Klebsiella oxytoca 277 104 173 n.s. 30 (5–202) 12 (1−73) <0.001
ESBL pos. 10 3 7 n.s. 93 (67–102) 11 (5−32) 0.017
Klebsiella pneumoniae 203 77 126 n.s. 24 (2–121) 11 (1−78) <0.001
ESBL pos. 34 17 17 n.s. 38 (9−71) 18 (3−36) <0.001
Morganella morganii 74 34 40 n.s. 18 (2−58) 11.5 (1−52) 0.008
Pantoea species 10 3 7 n.s. 31 (25–328) 7 (2−18) 0.016
Proteus mirabilis 24 4 20 n.s. 16 (1−78) 11 (2−26) n.s.
Serratia marcescens 47 22 25 n.s. 29 (5−91) 9 (2−26) <0.001
P1481 Evaluation of Streptococcus agalactiae positive newborn cases
E. Hajdu´ °, T. Szabo´, Z. Reiger, P. Ga´l (Szeged, HU)
Objectives: Streptococcus agalactiae (Group B Streptococcus − GBS)
emerged as the leading infectious cause of neonatal morbidity and
mortality. These bacteria can colonise the vagina of women without
any infectious symptom. Infants can become infected with GBS during
passage through the birth canal, although the majority of infants who
are exposed to GBS during labour become colonized on skin or mucous
membranes but remain asymptomatic. Our objective was to evaluate the
GBS positivity among newborns.
Methods: The nasopharynx and stomach ﬂuid surveillance samples of
newborns admitted to the Neonatal Intensive Care Unit during 2007
and 2008 were cultured. We also used latex agglutination test (Pastorex
Meningitis StreptoB, BioRad, Hercules, California US) for the detection
of GBS antigen in urine and cerebrospinal ﬂuid of newborns. Inﬂamma-
tory parameters (C reactive protein, white blood cells and thrombocyte
count) were used to conﬁrm the presence of GBS infection. The vaginal
samples of the GBS positive newborns’ mothers were also analysed. The
vaginal ﬂuids of the pregnant women were cultured between the 35 and
37 gestational week according to CDC recommendations.
Results: Newborns in whom both the antigen test and the surveillance
culture were positive for GBS all showed infectious signs (9 cases).
Newborns with positive GBS latex urine samples only, had symptoms
of infection in 44% (28 out of 63 cases), while those with only
positive GBS surveillance cultures had clinical signs of infection in
38%. Vaginal culturing was performed in 51% of the affected women
with 24% positivity rate (41/10). All GBS positive mothers received
antibiotic prophylaxis during delivery. In the other 24 cases antibiotic
was administered after the risk assessment for GBS infection.
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Conclusion: The indication of antibiotic prophylaxis − for avoiding
development of GBS caused infection in newborns − is based on risk-
assessment or positive culturing. Among GBS positive newborns mothers
had GBS positive vaginal culturing in low number, probably because of
the improper sampling. Latex agglutination is a rapid test for detecting
GBS but in itself it is not diagnostic.
2007 2008 All
Number of positive GBS latex urine samples of newborns 26 37 63
Number of positive GBS culture of newborns 12 6 18
Number of cultured vaginal samples of mothers/GBS positive samples of mothers 16/7 25/3 41/10
Number of cases received antibiotic prophylaxis during delivery 13 21 34
Number of newborns with infectious symptoms 20 23 43
P1482 Bloodstream infections due to Gram-negative bacilli in a
neonatal intensive care unit: a 6-year study
M. Papadimitriou, A. Alexaki, D. Kyriakou, N. Paleologou, K. Kallergi,
J. Kapetanakis, E. Lebessi ° (Athens, GR)
Objectives: Bloodstream infection (BSI) due to Gram-negative bacilli
(GNB) is a frequent complication in neonatal intensive care units
(NICUs). Moreover, multidrug resistant organisms are on the increase
and pose a formidable clinical challenge. The aim of the present study
was to assess the BSI due to GNB in a 30-bed, university-afﬁliated, level
III-IV NICU at a large pediatric hospital in Athens.
Methods: The charts of all neonates with culture-proven BSI due to
GNB admitted to our NICU over six years (Jan 2003Dec 2008) were
reviewed, in order to estimate epidemiological and clinical features,
bacteriologic pattern and antimicrobial susceptibility.
Results: A total of 2815 neonates (58.5% males) were admitted
during the study period. Among those, 57 episodes of BSI involving
59 GNB were diagnosed in 55 neonates (63.6% males, 50.9%
preterms). Associated pathology in the above group included congenital
anomalies (44.6%), necrotizing enterocolitis (21.4%), while meningitis
was diagnosed in 10%. Mortality rate was 18.2% (10/55), while overall
mortality in the NICU was 3.7% (104/2815). Average hospitalization
in the NICU before infection was 39.4 days (0 to 322 d), and the
mean NICU length of stay was 70.4 days (7 to 338 d). Thirty
two cases were NICU-acquired. The incidence of NICU-acquired BSI
due to GNB was 11.3/1000 admissions. No outbreaks or epidemics
were observed. GNB accounted for 19.6% of organisms isolated from
blood cultures. Twelve bacterial species were identiﬁed: Escherichia
coli 42% (25), Klebsiella pneumoniae 23% (14), Enterobacter cloacae
12% (7), Enterobacter aerogenes 5% (3), Klebsiella oxytoca (2),
Acinetobacter baumannii (2), Serratia marcescens (1), Proteus mirabilis
(1), Salmonella non typhi (1), Pantoea agglomerans (1), Pseudomonas
aeruginosa (1) and Chryseomonas luteola (1). Production of extended-
spectrum b-lactamases (ESBLs) was detected in Klebsiella spp (63%),
E. coli (16%) and Enterobacter spp (10%). Overproduction of AmpC
b-lactamases was recognized in 20% of Enterobacter spp. Susceptibility
to carbapenems was found to be 100%, to ciproﬂoxacin 98% and to
aminoglycosides 85−90%.
Conclusion: Neonatal septicemia due to GNB is a major cause of
morbidity and mortality. There was appreciable resistance to commonly
used antimicrobials. Understanding the local epidemiology of neonatal
BSI can lead to more appropriate initial antibiotic therapy and may
contribute to improvement of infection control practices.
P1483 Congenital and neonatal cytomegalovirus infection in
pre-term neonates
E.M. Gonzalez Barbera °, B. Acosta Boga, M. Cernada Badia,
A.W. Rosingh, J. Cordoba Cortijo, M. Gobernado (Valencia, ES)
Objectives: To study the incidence of congenital or neonatal cyto-
megalovirus (CMV) infection children hospitalized in the Neonatology
unit of a tertiary care hospital during the period January 2006–
October 2009.
Methods: A prospective observational study was carried out in the
Neonatology unit including neonates with a birth weight 1.500 g. or
signs/symptoms compatible with CMV infection.
Congenital (CMV positive result in the two ﬁrst weeks of life)
and neonatal CMV infection were identiﬁed through urine shell-vial
culture [MRC5 cell line (Vircell™), CMV monoclonal antibody stain
(Chemicon™)] and/or plasma CMV viral load [artus CMV LC PCR
Kit (Qiagen)]. We studied 1591 urine samples by shell-vial culture and
178 plasma samples by CMV viral load from 894 neonates. The same
techniques were used for follow-up study (and in some cases we also
carried out a CMV maternal study). We also collected data about blood
transfusions in these patients.
Results: Fifty-three (5.93%) neonates were diagnosed with cy-
tomegalovirus infection. Fourteen of them (26.41%) were considered
congenital, in seven infants (13.20%) we couldn’t distinguish between
congenital or perinatal infection and thirty-two children (60.38%) were
considered perinatal infection. Of them, in 16 cases the breast milk
was studied for CMV presence (shell-vial/viral load) ﬁnding ten positive
results.
All children except two with perinatal infection received blood products
(one with shell-vial positive result of breast milk).
Conclusion: In our study neonatal CMV infection is frequent in preterm
infants. The role of breast feeding is important in perinatal transmission
(10 positive results/16 studied cases), but most of them (30/32) had been
exposed to other transmission routes, such as the use of blood products.
CMV urine shell-vial culture is a good and non invasive test for
screening, but not for follow-up patients. CMV plasma viral load could
be the best choice for following up on these patients.
P1484 Virulence factors and antibiotic resistance in uropathogenic
Klebsiella pneumoniae isolates from paediatric units at a
Portuguese hospital
S. Arriaga Cerqueira °, P. Machado, J. Marto, A. Silva, L. Lito, J. Melo
Cristino, A. Duarte (Lisbon, PT)
Objectives: The aim of this study was to verify the relationship of
Klebsiella pneumoniae isolates, as well as investigate their extended-
spectrum b-lactamases (ESBLs) and virulence factors.
Methods: This study included thirty-nine Klebsiella pneumoniae isolates
identiﬁed from urine culture collected from eight paediatric patients
at Santa Maria Hospital, Lisbon, throughout 2008. Antibiograms
were determined by disk diffusion method on Mueller-Hinton agar
plates. Molecular typing was performed by M13-Polymerase Chain
Reaction (PCR) ﬁngerprinting and in representative strains by Multilocus
Sequence Typing (MLST) to conﬁrm the genotype. Genetic environment
of blaCTX-M-type and virulence factors (iucC, magA, rmpA, khe, ﬁmH,
mrkD, capsular gene k2) were screened by PCR and the products were
sequenced.
Results: M13-PCR ﬁngerprinting identiﬁed two predominant clones
among the isolates, which we designated M1 and M2. MLST conﬁrmed
this result, showing different sequence types (STs): M1 proﬁle matched
ST15 and ST326, which differed only in tonB allele sequence
(98.1% of similarity); M2 corresponded to ST20. 40% of M1 isolates
showed antibiotic resistance proﬁle R1 (resistance to cefotaxime, CTX,
ceftazidime, CAZ, gentamicin, GM, and ciproﬂoxacin, CIP) and 60%
showed proﬁle R2 (resistance to CTX, GM and CIP). 14.3% of M2
isolates exhibited proﬁle R1, 71.4% was proﬁle R3 (resistance to CTX,
CAZ and GM) and 14.3% was proﬁle R4 (resistance to CTX and CAZ).
All the isolates of both M13-PCR ﬁngerprinting proﬁles were imipenem-
susceptible. We could also detect the gene for CTX-M-15 in 43.6% of
all the isolates included in the study. None of the clones showed iucC,
magA, rmpA or capsular gene k2, but they were positive for khe (50%
in M1 isolates; 85.7% in M2), ﬁmH (100% in M1; 92.9% in M2) and
mrkD (80% in M1; 100% in M2).
Conclusion: The isolates included in this study have a high incidence
of ﬁmH and mrkD, which reinforces the fact that they are uropathogenic
and might explain their persistence in some patients for periods as long
as four months.
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P1485 Antimicrobial resistance trends in b-haemolytic streptococci
from throat infections in a paediatric hospital in Greece
K. Giannakopoulou, G. Antonaki, N. Paleologou, A. Kallimani,
A. Margoni, S. Christopoulos, E. Lebessi ° (Athens, GR)
Objectives: To evaluate the antimicrobial susceptibilities and
macrolide − resistance phenotypes of large-colony-forming b-haemolytic
streptococci (BHS) isolated from throat infections at a pediatric
population in the area of Athens.
Methods: All BHS isolated from 7710 pharyngeal specimens obtained
from patients referred to “P. & A. Kyriakou” Children’s Hospital over
a ﬁve-year period (Jan 2004 through Dec 2008) were reviewed using
the laboratory archives. Streptococcus agalactiae isolates were not
included. Susceptibility testing to penicillin, erythromycin, clindamycin,
tetracycline, chloramphenicol, cefotaxime, rifampin and vancomycin was
performed by disk diffusion test according to the CLSI guidelines.
Macrolide resistance phenotypes were determined for strains isolated
during 2006 to 2008, by double-disk diffusion test using erythromycin
and clindamycin.
Results: During the study period a total of 1908 BHS were isolated.
Of these, Streptococcus pyogenes was accounted for 95.2% (1817/1908)
and Streptococcus dysgalactiae subsp. equisimilis (Lanceﬁeld group C,
G) for 4.8% (91/1908). Among S. pyogenes isolates, resistance to
erythromycin was found in 19% (annual resistance rates from 2004 to
2008: 13.1%, 15.8%, 21%, 19.8%, 26%), resistance to chloramphenicol
and tetracyline was found in 0.4% and 7.9%, respectively. Sixty
seven percent of tetracycline resistant strains were also resistant to
erythromycin. Among S. dysgalactiae subsp. equisimilis isolates, higher
resistance rates to erythromycin, chloramphenicol and tetracycline were
found to be 23.1%, 1.1%, and 37.3%, respectively. The macrolide-
resistance phenotype distribution (2006 through 2008) was as follows:
M; 44.4%, 55.5%, 32.4%, MLSBi; 33.3%, 22.2%, 44.5%, MLSBc;
22.2%, 22.2%, 22.9%. The prevalent phenotype of MLSB resistance
in S. pyogenes isolates have been changed from the M to the MLSBi.
Resistance to antimicrobial agents other than macrolides, clindamycin,
tetracycline, and chloramphenicol was not found.
Conclusions: There was a progressive increase of resistance to
macrolides and a relative decrease in the M phenotype. This reduces the
effectiveness of macrolides and clindamycin as an alternative treatment.
Continual monitoring of antimicrobial resistance among large-colony-
forming BHS is very important for the option of the empiric therapy.
P1486 Susceptibility rates, emm-types and endotoxin genes among
Streptococcus pyogenes isolated from invasive paediatric
infections
A. Makri, A. Stathi, J. Papaparaskevas, T. Guajardo, L. Zachariadou,
A. Pangali, A. Voyatzi °, A. Tsakris (Athens, GR)
Objectives: The epidemiological investigation of Streptococcus pyo-
genes (Group A Streptococcus − GAS) strains isolated from invasive
infections in a pediatric Greek hospital.
Materials and Methods: During a two year period (2007–2008), all
invasive GAS isolates together with clinical and demographic data were
collected prospectively. Antibiotic susceptibility was investigated using a
gradient strip method (E-test, bioMe´rieux). Resistance phenotypes were
assigned by the double disk approximation test, using erythromycin (E)
and clindamycin (CL) disks. M-typing was performed with emm-gene
sequencing. PCR was used for detection of speA/B/C endotoxin genes.
Results: Invasive GAS strains were collected from 50 patients.
Specimens comprised deep soft tissue (54%), middle ear aspirates after
myringodectomy (22%), blood (8%), BAL and pleural ﬂuid (12%), and
joint aspirates (2%). Emm-types 1, 77, 6, and 12 (14, 12, 10 and 8%,
respectively) dominated (44% of all infections), whereas less frequent
types were emm-type 5, 91, 28 and 11 (all with a rate of 6%). All
emm-type 1 isolates were fully susceptible to all antibiotics tested.
Overall E and CL resistance rates were 22% and 12% respectively.
The Constitutive (CR-MLSB) and the Inducible Resistant (IR-MLSB)
phenotypes were detected in 12% and 10% of all isolates, respectively,
whereas the M-phenotype was detected in 2%. The speA toxin gene
was detected mostly amongemm-type 1 isolates, whereas the speC was
more common in several emm-types such as 6, 77, 12, 91 and 5. The
IR-MLSB phenotype was related with emm-type 77, in contrast with
CR phenotype which was associated with several other emm-types (11,
28, 77, and 12). There was a correlation between speciﬁc emm-types
and clinical presentations. More speciﬁcally, emm-type 1 isolates were
associated with sepsis and Streptococcal Toxic Shock Syndrome (STSS)
cases.
Conclusions: Emm-type 1 susceptible isolates prevailed among invasive
GAS pediatric isolates, were associated with speA toxin gene, and were
detected mostly in cases of sepsis and STSS. The CR-MLSB phenotype
was the main resistance phenotype, was detected in speciﬁc emm-type
strains and was associated with the SpeC toxin gene. In contrast, the
IR-MLSB phenotype was associated detected mostly among emm-type
77 strains.
P1487 Paediatric Chagas’ disease in a non-endemic area
A.C. Aguilar °, T. Juncosa, A. Gene´, V. Fumado´ (Barcelona, ES)
Objectives: Until the middle of the 20th century Chagas’ disease was
conﬁned to the rural area in Central and South America, but after
industrialization country people moved to the cities taking with them
culture and diseases, among others Chagas’ disease.
Nowadays, the increase of migration from this countries to non-endemic
areas such as USA and Europe has introduced among our paediatric
population some patients infected by T. cruzi, either in their original
country or in ours trough vertical transmission from their mothers.
The aim of this study was to describe the cases of children with Chagas’
disease admitted in our Imported Pathology Unit during the last six years
(2003–2008).
Methods: All patients coming from endemic areas, and newborns
from Chagas’ disease seropositive pregnant women were studied by
two ELISA tests (Bioelisa Chagas BiokitR with recombinant antigens
and in-house ELISA with complete antigens). Patients with available
sample were also screened by nested PCR (TCZ3/Z4). In the seroreactive
patients younger than one year old the ELISA test were done again
up to 12 month old, in order to demonstrate vertical transmition if
antibodies persist. Conﬁrmed cases received Benznidazol as a treatment
(8−10mg/Kg/day, during 60 days). Both PCR and speciﬁc antibodies
must be negative in order to demonstrate the effectiveness of treatment.
Results: Screening was performed in 202 patients from one day to 14
years old (157 were immigrants and 45 were born in Spain). Forty three
of them (30 younger than one year old) were seroreactive in both ELISA
tests (21.2%). We performed forty PCR tests, which were positive in ten
cases. In 18 patients Chagas’ disease were diagnosed. In seven of them,
who were born in our country, vertical transmission was demonstrated.
All 18 patients were treated. In ﬁve cases the speciﬁc antibodies become
negative and demonstrated the healing. Follow up is in course in eleven
of the seroreactive patients. Two patients didn’t continue attending our
hospital.
Conclusion: Taking into account the possible severity of Chagas’
disease, the effectiveness of the treatment in the ﬁrst years of live
and the incidence in paediatric immigrate population from Central and
South America found in our study, we suggest the systematical serologic
screening in this population.
P1488 Antimicrobial resistance of pathogens in hospitalized
children with urinary tract infection in Greece
S. Konstantopoulou °, I. Daniil, I. Petraki, E. Nikolarou, E. Balampani,
P. Ntoska, D. Papageorgiou, A. Charalampidou, D. Petropoulou
(Athens, GR)
Objectives: The manifestation of urinary tract infection (UTI) in
children tends to be nonspeciﬁc, so the culture of urine collected
appropriately is the method of choice for the diagnosis and management
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of UTI, especially in infants and young children. Moreover, UTIs are
among the most common infections with an increasing resistance to
antimicrobials worldwide. The aim of this study was to indentify the
causative pathogens in children hospitalized for community acquired
febrile UTI in a tertiary hospital in Greece and to investigate their
resistance to common antibiotics.
Methods: During three-years period (2007–2009), we studied a total
of 117 urine culture specimens from children (65% female and 35%
male, aged 0.08 to 13 years) hospitalized with symptoms and signs of
UTI. Transurethral catheterization or bladder tap was the urine collection
method in children <2 years old, while clean voided midstream urine
specimens collected from older children. The urine specimens were
examined by Gram stain and culture in appropriate media (blood agar and
McConkey agar) for detection of uropathogens. Any isolated pathogen
(after 24−48 hours incubation) was identiﬁed using BBL™ Enterotube™
II (BD Diagnostic Systems, Germany), Api System and Vitek 2 Compact
(Biomerieux, France). Disk diffusion agar method was used according
to the current CLSI guidelines for the antibiotic susceptibility test of
isolated uropathogens.
Results: The most frequent UTI pathogens detected in children enrolled
in the study were: E. coli (73.4%), Klebsiella spp. (8.9%), P. mirabilis
(8.1%), E. faecalis (3.2%) and Pseudomonas spp. (1.6%). Antimicrobial
resistance of E. coli isolates to commonly used antibiotics was:
ampicillin 67%, trimethoprim-sulfamethoxazole (TMP-SMX) 27.3%,
cefuroxime 11% and gentamicin 7.7%. Resistance to ampicillin, TMP-
SMX, cefuroxime and gentamicin was noted for 67%, 31.5%, 12.1%
and 8.1% of the total uropathogens, respectively.
Conclusion: Escherichia coli was the most prevalent pathogen in
children hospitalized with UTI. Several of the ﬁrst-line agents for
empirical treatment of childhood UTI seem to have become ineffective,
mainly ampicillin and TMP-SMX. Staining and culture examination of
urine samples and antibiotic susceptibility test of detected uropathogens,
along with the clinical information available at diagnosis, can help in
treatment selection.
P1489 Bacterial ﬂora in infected ingrown toenails in a paediatric
population
A. Margoni, G. Schinas, K. Giannakopoulou, M. Matsas, G.L. Morassi,
V. Soranoglou, N. Nikolaides, E. Lebessi ° (Athens, GR)
Objectives: Ingrown toenails (IGTNs) is a common problem in pediatric
population, especially adolescents. Conservative and surgical methods
are available for treatment, but antibiotics necessity still remains
controversial. The aim of this study was to deﬁne the bacteriological
spectrum and the antimicrobial susceptibility patterns in healthy children
with infected IGNTs, referred for care at “P. & A. Kyriakou” Children’s
Hospital.
Methods: Infected IGTNs treated at the outpatient clinic and the
department of orthopedics from Jan 1, 2007 to Oct 31, 2009 were
reviewed retrospectively, using the laboratory archives and patients
charts. Antimicrobial susceptibility was tested by disk diffusion method
according to CLSI criteria.
Results: Totally, 157 specimens from an equal number of children
(56% boys), with a mean age 11.7±SD2.48 years, were recorded.
Cefaclor or amoxicillin/clavulanate, were given in all cases as empiric
therapy. The majority of infections were mixed with two to ﬁve
organisms (76%). The most frequently isolated bacteria in mixed
cases were Staphylococcus aureus (79%) and anaerobes (53%),
followed by Pseudomonas aeruginosa (11%), Enterobacteriaceae (14%),
Streptococcus pyogenes (9%), Acinetobacter baumannii (7%), Eikenella
corrodens (6%), Stenotrophomonas maltophilia (5%), Streptococcus
agalactiae (5%), Streptococcus anginosus group (3%), Haemophilus
parainﬂuenza (3%), Haemophilus inﬂuenza (2%), Candida spp (2%).
In monomicrobial cases (24%), S. aureus was also the most common
(89%), followed by S. pyogenes (8%). Of all S. aureus isolates, 79%
were found resistant to penicillin and 6% to methicillin (MRSA).
All but one MRSA strains had the same resistant phenotype peni-
cillin/oxacillin/fusidic acid/kanamycin/tetracycline, which commonly
characterizes the community-acquired strains (CA-MRSA). Among
S. aureus isolates the resistance to macrolides was 13.2% (17/128) [M-
phenotype; 5, MLSBi (inducible resistance); 5, and MLSBc (constitutive
resistance); 7]. Of S. pyogenes isolates, 14.2% (2/14) were resistant to
macrolides. All other bacteria were wild strains.
Conclusions: A wide range of bacterial ﬂora was observed in infected
IGTNs, with the predominance of S. aureus. It is of note, that
bacteria with intrinsic resistance, such as P. aeruginosa, S. maltophilia,
A. baumannii, were isolated in signiﬁcant frequencies. The identiﬁcation
and susceptibility testing of pathogens is useful, as pre-operative
empirical treatment could be ineffective.
P1490 Enteroviruses linked to type 1 diabetes onset in young
children
C.M. Mihai °, R. Stoicescu, I. Durbala (Constanta, RO)
Background: A rapid rise of T1DM (type 1 diabetes mellitus) among the
youngest age group (1−9 years of age) is particularly marked for regions
in Central and Eastern Europe. Despite a strong genetic component
to the susceptibility of T1DM, this marked increase in incidence in
different populations within a short period of time cannot be explained
by increased transmission of T1DM susceptibility genes.
Objectives: To assess the link between the recent onset in T1D and
the exposure to environmental triggers-Enteroviruses (EV) historically
considered the prime suspects, in children with human leukocyte antigen
(HLA)-conferred susceptibility or protection to T1DM at the onset, using
direct detection of the EV genome by Reverse transcription polymerase
chain reaction (RT-PCR) in peripheral blood.
Methods: Serum samples were collected from children with newly
diagnosed type 1 diabetes (n = 21), aged 1−9 years; islet autoantibody-
positive (n = 16) and -negative (n = 5) ﬁrst-degree relatives of type 1
diabetic patients (n = 40); and control subjects (n = 64).
Results: 7 children newly diagnosed with T1DM tested positive for
enterovirus (33.3%). Newly diagnosed T1DM children (7/21, 33.3%)
and islet autoantibody-positive ﬁrst-degree relatives (4/40, 10%) tested
positive more than their corresponding matched controls (2/64, 3.1%),
95% conﬁdence interval; OR 15.7, P< 0.001 and OR 21.4, P< 0.01,
respectively). 2 children with low genetic risc, carring the HLA
DQB1*0602 tested positive for enterovirus RT-PCR. All 7 children
tested positive for enterovirus presented with severe diabetic ketoacidosis
(pH< 7.1), 1 was negative for islet autoantibodies.
Conclusions: The presence of enteroviral infection appeared to be
associated with severe diabetic ketoacidosis at onset, high circulating
islet cell antibodies (ICA) titres. In patients with T1DM, who are at low
genetic risk, enteroviruses could contribute to diabetes onset.
P1491 Prevalence and clinical features of respiratory syncytial
virus and human metapneumovirus lower respiratory
disease among children in Greece
F. Vagia °, A. Makri, H. Iliadou, I. Mammas, T. Guajardo, E. Nika,
N. Myriokefalitakis, A. Voyatzi (Athens, GR)
The clinical symptoms of human Metapneumovirus (hMPV) resemble
those of respiratory syncyntial virus (RSV) and inﬂuenza A/B (Flu A/B).
The symptoms range from inﬂuenza like illnesses to severe respiratory
tract infections as bronchiolitis and pneumonitis. A rapid diagnosis of
these respiratory viral agents should be valuable for appropriate patient
management and infections control measures. Objectives: of the present
study were: 1) to identify and compare the incidence by age group of
infections due to RSV, hMPV and ﬂu A/B in infancy and early childhood,
2) to analyze clinical features and seasonality of the RSV, hMPV ﬂu A/B
during a two year period (2008–2009).
Material and Methods: A total of 606 children (male/female 2:1) below
5 years old (<2 y = 305), (2−5 y = 301) were hospitalized for lower
respiratory tract illness (LRTi). Nasopharyngeal aspirates were tested
for RSV, hMPV, ﬂuA/B antigen using rapid and accurate immunoassays
(Meridian Bioscience USA-Biotrin International Ltd, Ireland Quidel
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Corporation, USA respectively). The patients clinical data were recorded.
Disease severity was determined by the length of hospitalization and
increased O2 requirement.
Results: RSV was detected in 28.5%, hMPV in 10.4% FluA 5%
and FluB 3% in respiratory samples. Fourteen co-infections were also
observed caused by hMPV+RSV (12) and RSV+FluA (2). Similar
clinical symptoms (retractions, wheezing, crackles) for RSV and hMPV
were found in 75%. No children required admission in intensive care
unit. Oxygen requirement for RSV pneumonia was found 65% while for
hMPV was decreased 30%. The remaining infants had uncomplicated
clinical bronchiolitis and required a short hospital stay (<5 days). The
mean age for hMPV was below 4 months and for RSV was 7 months
while Flu A/B was detected as single infection in a group age among
children for 2 to 5 years old. The signiﬁcant RSV and hMPV incidence
peak occurred during colder months while the occurrence of inﬂuenza
followed seasonal patterns that become more expanded during the year.
Conclusions: (1) RSV (28.5%) remains the most frequent virus among
neonates <2y. (2) The most prevalent diagnosis in children with positive
sample for hMPV was bronchiolitis. (3) Our data conﬁrm that rapid
clinical diagnostic assays will be necessary to distinguish hMPV from
RSV infection. (4) The burden of disease due to RSV, hMPV suggest
that a vaccine should have signiﬁcant health and socioeconomic beneﬁts.
P1492 Seasonality of Mycoplasma pneumoniae, Chlamydia
pneumoniae, respiratory syncytial virus and adenovirus
paediatric respiratory tract infections in northern Greece −
a 2-year study
S. Prodromidou °, C. Kanonidou, M. Pape, V. Anagnostou,
K. Mandraveli-Chatzikosta, S. Dionysopoulou, E. Diza (Thessaloniki,
GR)
Objective: Mycoplasma pneumoniae (MP), Chlamydia pneumoniae
(CP), Respiratory syncytial virus (RSV), and Adenovirus (AV) are
among the pathogens of respiratory tract infections in childhood. The aim
of this retrospective study was to investigate the seasonal distribution of
these infections in a paediatric population in northern Greece and their
association with local temperature conditions.
Methods: The study population consisted of 572 patients (2 months-6
year old) admitted to AHEPA University Hospital of Thessaloniki with
symptoms of respiratory tract infection from 11/07 until 10/09. The
presence of speciﬁc antibodies (IgG, IgM, IgA) was quantitatively
determined by ELISA (RIDASCREEN, r-biofarm) in paired serum
samples from each patient: for MP in 462, CP 356, RSV 72 and AV
409. x2 test and x2 goodness of ﬁt test were performed.
Seasonality of M. pneumoniae, RSV, Adenovirus, and C. pneumoniae
respiratory tract infections in children.
Results: 136 (30%) of 461 paired samples tested for the above pathogens
in winter were positive. AV was the most common pathogen (44%).
From 405 cases in spring, 94 (24%) were positive and MP infection
was the most frequent (35%). 76 (27%) of 278 samples were positive
in summer and the number of MP infections was the highest (54%). In
autumn 55 (35%) of 158 samples were positive and AV infection was
diagnosed in 50% of cases. MP exhibited a peak of activity in summer
(38%), although no signiﬁcant difference was found between the 2 years
of study and different seasons as well. A spring peak of RSV positive
cases (54%) was observed. The prevalence of RSV infections was lower
in summer (41%) and autumn (41%). A signiﬁcant reduction of positive
cases occurred from autumn to winter (6%) (p< 0.05). AV infections
reached a peak in autumn (50%). A signiﬁcant raise was observed from
summer to autumn (p< 0.01) and a signiﬁcant reduction from winter to
spring (p< 0.001). Statistical difference among the years of study was
also observed (p< 0.01). CP was detected all year round. A signiﬁcant
increase of positive cases was found during the second year (p< 0.05).
The mean monthly local temperature value did not vary signiﬁcantly
between the 2 years.
Conclusion: The occurrence of respiratory tract infections in children
was almost the same all year round. Each pathogen demonstrated distinct
seasonal patterns. The peak of MP infections was observed in summer,
of RSV in spring and AV in autumn. Studies on seasonality are valuable
for optimizing medical management.
Antimicrobial stewardship, antibiotic policies
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P1493 Implementing antimicrobial stewardship and control of
antibiotic prescription to decrease MRSA in the intensive
care unit
L. Pagani °, R. Aschbacher, N. Vernaz, M. Falciani, P. Mian, B. Moser,
P. Zanon (Bolzano, IT; Geneva, CH)
Objectives: to evaluate the impact of an Antimicrobial Management
Team (AMT) on appropriateness of antimicrobial prescription and
control of MRSA prevalence in the Intensive Care Unit (ICU) of a
tertiary hospital.
Methods: after reviewing clinical, microbiological and pharmaceutical
data of 2002 as historical comparison, a two-phase intervention by
the AMT was implemented in our 18-bed general ICU. From January
2003 to March 2004, a regular on-site educational activity was carried
out by infectious disease consultant, aimed at deﬁning optimized
antimicrobial therapy according to local epidemiology of MRSA and
clinical pharmacology parameters. From April 2004 to December 2007,
direct control or restriction on antimicrobial prescription by the AMT
was added to, and mainly concerned broad-spectrum and last-generation
drugs.
Results: the percentage of MRSA isolates recovered in ICU decreased
progressively and signiﬁcantly from 38% (95%CI, 29−47%) in 2002 to
15.6% (95%CI, 6−20%) in 2007 (−5.1% per year; r = −0.99; P = 0.001),
which corresponds to a likewise signiﬁcant decrease in resistance rates:
9.3 MRSA isolates per 1,000 patient-days in 2002 to 3.3 MRSA
isolates per 1,000 patient-days in 2007 (−1.3 MRSA isolates per 1,000
patient-days; r = − 0.97; P = 0.001). Variations in consumption of some
antimicrobials, expressed in deﬁned daily doses (DDD) per 100 patient-
days, were assessed through time-series analysis and are shown in the
table.
Conclusion: the interventional antibiotic policy carried out by the AMT
has signiﬁcantly decreased the prevalence of MRSA in this setting.
These ﬁndings demonstrate that antimicrobial stewardship may help
improve patient safety, while decreasing both antimicrobial resistance
and aggregate economical costs.
Antimicrobials January 2002 to December 2002 January 2003 to December 2007 Trend
Average monthly use
(min-max)
% of J01 use Average monthly use
(min-max)
% of J01 use
Total antibiotic use 618 (398–810) 100% 513 (110–829) 100% stable
Oxacillin NA 0% 58 (0–200) 11% stable
Ampicillin/sulbactam 327 (224–525) 53% 157 (50–368) 31% downward*
Cefuroxime 10 (0−30) 2% 6 (0−37) 1% downward*
III gen. Cephalosporins 80 (25–130) 13% 46 (0–140) 9% downward*
Fluoroquinolones 126 (56–182) 20% 126 (8–274) 25% stable
Vancomycin 35 (8−75) 6% 19 (0−73) 4% downward*
Linezolid NA 0% 22 (0−65) 4% upward*
*Statistically signiﬁcant at p-value <5%.
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P1494 Antibiotic stewardship programmes: national
recommendations, public release of structure and process
indicator and practical implementation in south-western
French hospitals, 2005–2008
C. Dumartin °, A.M. Rogues, M. Pefau, B. Amadeo, A.G. Venier,
P. Parneix, C. Maurain (Bordeaux, FR)
Objectives: According to the national strategy launched in 2001 to
improve antibiotic (AB) use, French hospitals are required to implement
AB stewardship programmes (ABS). The Ministry of Health (MoH)
issued recommendations regarding AB monitoring, organisation for
prudent use (2006), and enforced mandatory reporting of a structure and
process indicator (SPI) reﬂecting ABS, intented for public disclosure
(2007). We performed yearly surveys to describe the development of
hospital ABS in Southwestern France and to assess the compliance with
national requirements.
Methods: Annual retrospective surveys were conducted in a convenience
sample of 84 hospitals (22% of hospital beds in the region): 24
secondary/tertiary public hospitals, 31 acute care private hospitals,
14 rehabilitation centres, 8 local and 7 psychiatric hospitals. ABS
was assessed by questions on structure and organisation; resources,
guidelines, surveillance and evaluation. We described each measure, the
SPI and their evolution for each hospital from 2005 to 2008.
Results: Improvements were seen in the content of ABS for each
type of hospitals. SPI values were higher for private hospitals and
rehabilitation centres than in others. In 2008, at least 98% of hospitals
had implemented formularies, antibiotic committees, AB prophylaxis
guidelines, and monitored AB use. AB advisors were appointed in
85% of hospitals in 2008 compared to 50% in 2005. Areas covered
by ofﬁcial texts and included in SPI sharply improved from 2006:
treatment guidelines (2006), computerised tools for AB management
(2006), AB monitoring (2007), evaluation (2007). Little progress was
made regarding time dedicated by pharmacist to AB management and
restricted dispensation of AB using stop-orders.
Conclusion: Ofﬁcial texts and the public disclosure of a SPI have
increased professionals and hospital managers’ commitment to develop
ABS, and resulted in improvements in most hospitals. However, even in
hospitals involved in voluntary surveys, some measures still need to be
reinforced, e.g. computerized tools for AB management, evaluation. It
also appears crucial to consider practical implementation of regulatory
required measures, as it will impact on their effectiveness: time spent by
professionals, type of restrictive dispensation system, real use of evalu-
ation and surveillance data, adaptation to hospital resources and needs.
P1495 Surveillance of antibiotic consumption in 861 French
hospitals: lessons from a nationwide network, 2008
C. Dumartin °, F. L’Heriteau, M. Pefau, P. Angora, X. Bertrand,
S. Boussat, P. Jarno, L. Lacave, F. Nguyen, K. Saby, A. Savey,
S. Alfandari, B. Coignard, B. Schlemmer, S. Touratier, A. Carbonne,
A.M. Rogues (Bordeaux, Paris, Rennes, Nancy, Lyon, Tourcoing,
Saint-Maurice, FR)
Objectives: To improve antibiotic (AB) use, French hospitals are re-
quired to implement AB stewardship programmes including surveillance
of AB consumption. A survey was performed by the regional centres
for healthcare associated infections prevention and control, under the
auspices of the French RAISIN-network, to describe AB consumption
at hospital and ward level and provide tools for benchmarking.
Methods: Antibacterials for systemic use (J01 class of the WHO
Anatomical Therapeutic Chemical classiﬁcation (ATC)-Deﬁned daily
doses (DDD) system, 2008) were surveyed. Rifampin and oral imidazole
derivatives were also included to better assess total AB exposure. AB
consumption for inpatients, expressed in number of DDD per 1,000
patient-days (PD), and number of PD in 2008 were retrospectively
collected by 861 voluntary hospitals: 35 teaching hospitals, 503 non-
teaching hospitals, 11 cancer centres, 157 rehabilitation centres, 72
local hospitals, 83 long-term care (LTC) and psychiatric hospitals. They
accounted for 42% of French hospitals beds and for about 58 million PD.
Results: AB use (pooled mean) was 370 DDD/1,000 PD. The most
frequently used antibiotics were: amoxicillin–clavulanic acid (32% of
total number of DDD), amoxicillin (17%) and oﬂoxacin (5.5%). Median
consumption ranged from 56 DDD/1,000 PD in LTC and psychiatric
hospitals to 610 in teaching hospitals, with wide variations among
hospitals belonging to the same group. Median consumption differed
according to hospital clinical wards: 59 in psychiatric wards, 71 in LTC
wards, 199 in rehabilitation, 316 in gynaecology, 332 in paediatrics, 570
in surgery and medicine, 1,465 in intensive care units. Among similar
wards, variations were seen in both AB volume and distribution.
Conclusion: AB use in French acute care hospitals did not seem higher
than that reported in other European countries, when expressed in
DDD/1,000 PD. This multicentre survey provided detailed information
on AB use in a large sample of hospitals and wards. Its ﬁndings
underscore 1) the relevance of data collection at ward level to foster
consumption analysis and target AB use practice audits; 2) the usefulness
of a nation-wide surveillance network, allowing relevant comparisons
and benchmarking through sharing of experiences. Data from this
network, together with information from practices audits, will enable
to monitor trends in AB use in hospitals and to assess the impact of AB
stewardship programmes.
P1496 The European Surveillance of Antimicrobial Consumption:
point prevalence survey of antimicrobial prescriptions in
116 Belgian nursing homes
B. Jans °, K. Latour, E. Broex, R. Stroobants, A. Muller,
V. Vankerckhoven, H. Goossens on behalf of the European Surveillance of
Antimicrobial Consumption (ESAC) Nursing Homes Sub-project Group
Objectives: While rational antibiotic (AB) prescribing is an important
measure to control the emergence of AB resistance, particularly in frail
nursing home (NH) populations, European (EU) prevalence data on
AB-use in NH are scarce. In April 2009, the European Surveillance
of Antimicrobial Consumption (ESAC) NH sub-project, funded by the
European Centre for Disease Prevention and Control, carried out a ﬁrst
point prevalence survey (PPS) in order to measure and describe AB
prescriptions among residents living in European NH. We present the
results for Belgian NH.
Methods: The PPS was carried out in April 2009. Inclusion criteria for
residents were to be present in the NH for at least 24 hours and to receive
systemic antibiotic(s) on the day of the PPS. Data were obtained from
nursing notes, medication administration records and staff in relation to
antimicrobial prescribing, characteristics, risk factors and determinants
at NH- and at resident level.
Results: Data were available for 116 Belgian NH (11% of all Belgian
NH). The mean number of beds by NH was 108 (25–324 beds). Among
12.085 eligible NH residents, 690 (median 5.1%, 0–16.3%) received an
AB on the PPS-day. Residents with AB had a mean age of 84.3 years
(35–109). In 7 NHs no residents received AB. In the total NH-population
2.2% (0–14.5%) had an urinary catheter, and of these, 21% received an
AB. Wounds were present in 10.3% of the NH population (0−35%) and
AB were prescribed in 13% of them. Vascular catheters were uncommon
(0.13%). Among residents treated with an AB, 23% had a recent hospital
stay (last 3 months). AB were administered orally in 94%, parenteral in
4% and nasally (decolonisation MRSA) in 2%. 46% of all treatments
concerned the urinary tract (prophylactic: 43%) and 35% the respiratory
tract (empirical: 92%). 55% of all prescribed regimens was an empirical
treatment (RTI: 56%, UTI: 21%), 23% was prophylactic (UTI: 86%, RTI:
7%) and 20% was for a documented infection (UTI: 72%, GTI: 8%). The
most frequently prescribed molecule was amoxicillin + enzyme inhibitor
(17%) followed by nitrofurantoine (13%). Ciproﬂoxacin represented 8%
of all treatments.
Conclusion: The Belgian NH AB-prevalence was only 5.1%. Notwith-
standing the low urinary catheter use, AB-use in this group was
important. This high proportion of AB-use for urinary tract and
especially the high use of uroprophylaxis was surprising and needs to
be explored.
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P1497 Infection control resources in European nursing homes
and their relation to antibiotic use: data of the European
Surveillance of Antimicrobial Consumption (ESAC)
Nursing Home subproject
K. Latour °, E. Broex, A. Muller, N. Drapier, V. Vankerckhoven,
R. Stroobants, H. Goossens, B. Jans on behalf of the European
Surveillance of Antimicrobial Consumption (ESAC) Nursing Home
subproject group
Objectives: The aim was to explore infection control (IC) resources in
European nursing homes (NHs) and their relation to antibiotic (AB) use.
Methods: Within the framework of the European Surveillance of
Antimicrobial Consumption (ESAC) NH subproject, NHs in European
countries were asked to complete a standardised questionnaire on IC and
AB policy.
Results: Across 16 countries 270 NHs returned the questionnaire. An
IC practitioner was present in 25.3% of the NHs which responded to this
question (n = 261). More public institutions had an IC expert appointed
in comparison to private NHs (71.2% vs. 28.8%; p = 0.0035). Out of 66
NHs, 54% had a nurse as IC practitioner, 1.5% a physician and 43.9%
both a nurse as well as a physician.
An IC committee was responsible for IC policies in 31.6% of the NHs
(n = 253), while 56.4% of the NHs (n = 266) reported to have an ofﬁcial
link with a hospital IC team.
The difference in prevalence of AB use was not signiﬁcant between NHs
with or without an IC practitioner (median 6.6% vs. 5.3%; p = 0.12) or
IC committee (median 7.1% vs. 5.7%; p = 0.34). However, institutions
ofﬁcially collaborating with a hospital IC team showed a signiﬁcant
higher rate of AB prescriptions compared to those without a hospital
link (median AB prevalence 6.7% vs. 5.1%; p = 0.0062).
In relation to AB use two important tasks of the IC practitioner were
documented for 61 NHs. Formulation of recommendations on and advice
for good AB use, including the development of an AB policy, was part of
job responsibilities of 41.9% of the IC practitioners. Feedback to the GPs
on AB consumption was given by 24.2% of the experts. However, NHs
where the IC practitioners exercised these tasks showed no signiﬁcant
differences compared to NHs where IC experts did not do these tasks
(p = 0.48 and p = 0.96, respectively).
Conclusion: A potential explanation for the higher median rate of AB
use for NHs with an IC practitioner, an IC committee and especially
with a link with a hospital IC team could be that these NHs experience
a higher occurrence of infections, which justiﬁes their need for internal
or external IC expertise. However, further research on AB use and
healthcare associated infections is needed to support this hypothesis.
P1498 Impacts on antimicrobial consumption in a community
hospital by antibiotic stewardship and establishment of an
effective informative system − a 30-month survey
W. Wang °, J. Lu, H.L. Chen (Miao-Li, Taichung, TW)
Introduction: Optimal antibiotic therapy has great impacts on patient
prognosis and selection of resistant microorganisms in community
and hospital settings. Data concerning antibiotic use in healthcare
systems provide valuable information in designing antibiotic prescription
program. We intended to illustrate trends of antibiotic use before and
after implementation of several infection control maneuvers and an
informative system for monitoring and control of antibiotic prescription
in a community hospital.
Materials and Methods: Three stages were selected as following:
stage I (from January 1st to December 31th, 2007-no infectious disease
specialist nor protocol for rational antibiotic use available); stage II (from
January 1st to August 31th, 2008 an infectious disease specialist on board
with implementation of protocols and education for rational antibiotic
use); stage III (from September 1st, 2008 to June 30th, 2009 establishing
an information system to monitor and examine speciﬁc antibiotic
prescriptions in the hospital). Data concerning amounts of antibiotic
usage were searched from Pharmacology Database and were expressed
as deﬁned daily dose (DDD) per 1,000 in-patient hospitalization day
according to WHO criteria. The differences and correlations of total
and several categories of antibiotics between stages were determined by
Manny-Whitney U test and Pearson’s correlation test, respectively.
Results: The average of total antibiotic consumption in study period
was 2,891 (2,100 in oral and 791 in parenteral antibiotics) DDD/1,000
patient-day. Cephalosporins (37%) and penicillins (20%) were two
leading categories of antibiotic consumption. Decrease in total antibiotic
use correlated signiﬁcantly with decrease in oral antibiotic use in
study period (r = 0.99). Trends in penicillins and cephalosporins showed
moderately negative correlations with that of quinolones (r = −0.43 and
−0.35, respectively). Oral antibiotic consumption in stage I was found
to decrease signiﬁcantly while comparing to that in stage III (p = 0.03).
Amounts of antibiotics use showed decrease in most antibiotic categories
during study period except quinolones (p< 0.05).
Conclusion: The trends of total and oral antibiotic consumptions
showed decreased tendency and were signiﬁcantly correlated with
implementation of maneuvers and effective informative system. The
impact of change in antibiotic consumption on antibiotic resistance
patterns needs further studies to clarify.
P1499 Comparison of antibiotic usage across hospitals in the
north-central London sector using a standardized approach
P. Panesar °, P. Coen, A. Lim, K. Patel, E. James (London, UK)
Objectives: We set to explore the feasibility of using a standard data
collection method to benchmark antibiotic consumption in terms of
deﬁned daily doses (DDDs) per 1000 occupied bed days, with the
intention to compare it against hospital acquired infections such as
Clostridium difﬁcile. Antibiotic dispensing records, which are readily
available from pharmacy stock control databases, were used to generate
this information.
Methods: Antibiotic dispensing records were extracted for the period
April 2006 to March 2009 from three North Central London (NCL)
hospitals, which provide secondary and tertiary care to over 1000
residents. We focused on a subset of systemic antibiotics that
have a higher propensity to cause Clostridium difﬁcile infection,
such as cephalosporins, clindamycin, quinolones and aminopenicillins.
Dispensing records included antibiotic packs issued for hospitalised
patients only, either as ward stock or dispensed to individual
patients. Although antibiotic dispensing records were extracted from
three different pharmacy stock management systems, these were
all processed using the same methodology. The usage data were
initially converted to DDDs by means of a standard conversion
table and subsequently converted to rates per 1000 occupied
bed days.
Results: We were able to produce usage data for all the antibiotics that
were targeted. The results indicate variability in the use of antibiotics
across the hospitals. An example of quinolone usage from the hospitals
in the NCL sector is shown below.
Conclusion: We were able to present standardised antibiotic usage data
in spite of it coming from different pharmacy systems. The method
used facilitates benchmarking among different hospitals and has potential
for identifying interventions to improve antibiotic use and to study its
association with resistance in microorganisms. Not all current pharmacy
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systems in the UK are designed for easy translation of records into
standard usage data. We managed to develop working processes to
generate compatible antibiotic usage data from the various existing
pharmacy systems, which laid the groundwork for future epidemiological
and surveillance studies.
P1500 A National Point Prevalence survey of antimicrobial
prescribing for surgical prophylaxis
M.L. Heginbothom ° (Cardiff, UK)
Objectives: An All-Wales Point Prevalence Survey (PPS) of antibacterial
usage in secondary care was supported and carried out by pharmacists
in twenty three hospitals across Wales during November/December
2008 to mark the ﬁrst European Antibiotic Awareness Day. The
data presented concentrates speciﬁcally on antimicrobial prescribing
for surgical prophylaxis. The objective was to examine antimicrobial
prescribing and duration of surgical prophylaxis.
Methods: Patients from 226 wards in 23 hospitals across Wales were
included in the PPS. The number of patients surveyed on each ward, and
the number prescribed antimicrobials at or before 8:00 am on the day
of the PPS was recorded. Note: Not all hospitals surveyed all patients,
and there was a bias towards surveying patients from medical wards.
The auditors were asked to record the antimicrobial prescribed, site of
infection, and duration of surgical prophylaxis based on the number of
doses prescribed: Single dose; one day; >one day.
Results: Of the 4888 patients surveyed 1503 were prescribed
systemic antimicrobial/s (31%); 206 patients were prescribed systemic
antimicrobials for surgical prophylaxis (4.2%). Antimicrobial prescribing
varied between hospitals dependant largely on specialties, with 22
different antimicrobials being prescribed. Cefuroxime was the most
commonly prescribed antimicrobial (35.2% of total antimicrobials),
which is of concern with regard to the association with Clostridium
difﬁcle infection. 85.2% of the antimicrobials prescribed for surgical
prophylaxis were for IV administration. The proportion of patients
receiving surgical prophylaxis for >one day ranged from 0–100% with
an All-Wales average of 48.2%. Prophylaxis prior to urinary tract surgery
or bone & joint surgery was less likely to be prescribed for more than
one day than for the other sites.
Conclusions: The Scottish Intercollegiate Guidelines Network guide-
lines for antibiotic prophylaxis in surgery state that ‘a single standard
therapeutic dose of antibiotic is sufﬁcient for prophylaxis under most
circumstances’. Clearly, in some instances prescribing falls outside of the
guidelines. It is hoped that short period audits with stakeholder feedback
will reduce the number of patients receiving unnecessarily prolonged
prophylaxis, and steer prescribers away from cephalosporin use. The PPS
is being repeated in November 2009, and comparisons will be presented
highlighting differences between the 2008 & 2009 PPS results.
P1501 Computerized surveillance of antibiotic usage and
resistance: monitoring the impact of interventions
D. Lye °, T.M. Ng, C.B. Teng, L.M. Ling, I.J. Hsieh, S.C. Yeak, H.Y. Tai,
Y.S. Leo, B.S. Ang (Singapore, SG)
Objectives: With high rates of multidrug-resistant (MDR) bacteria, we
aimed to monitor antibiotic usage and resistance rapidly, at hospital and
unit level, and in response to any intervention.
Methods:We built a computer programme downloading daily data on all
positive cultures from Microbiology since January 2006, and antibiotic
dispensing from Pharmacy since January 2007. Infection control (IC)
and antimicrobial stewardship programme (ASP) interventions included:
active MRSA surveillance and decolonisation from October 2006,
enhanced with chlorhexidine wipes from November 2008 in medical
Intensive Care Unit (ICU); hospital-wide MDR Gram-negative bacteria
(GNB) isolation and hand hygiene campaign from January 2009;
ertapenem to treat ESBL GNB from late 2007; an empiric antibiotic
guideline from March 2009; and prospective review and feedback on all
carbapenem orders from April 2009.
Results: Rise in amoxycillin–clavulanate and cefepime from March
2009 coincided with empiric guideline. Rise in ertapenem coincided
with fall in imipenem from October 2007. Meropenem use fell from
27DDD/1000 bed-days in May 2008 to 17DDD/1000 bed-days in April
2009 and 10 in August 2009. Ceftriaxone fell from 141DDD/1000
bed-days in January 2007 to 93DDD/1000 bed-days in August 2009.
Piperacillin–tazobactam rose from 40DDD/1000 bed-days in February
2008 to 54DDD/1000 bed-days in June 2009. Usage of vancomycin,
ceftazidime and ﬂuoroquinolones remained stably high. Incidence of
MRSA fell from 3.1/1000 bed-days in January 2006 to 1.9/1000 bed-days
in August 2009. MDR Acinetobacter baumannii (MDR AB) fell from
1.4/1000 bed-days in February 2006 to 0.16/1000 bed-days in February
2008, but rose to 1.8/1000 bed-days in August 2009; this rise was
most marked in surgical and medical ICUs. ESBL Escherichia coli and
Klebsiella, and carbapenem-resistant Pseudomonas aeruginosa remained
stable. Active MRSA surveillance in medical ICU failed to reduce
MRSA incidence but chlorhexidine wipes did. MDR GNB isolation was
limited by lack of isolation rooms. Hand hygiene compliance did not
correlate with MRSA or MDR AB incidence.
Conclusions: Computerised surveillance facilitates monitoring of impact
of IC and ASP interventions. It highlighted high usage of ﬂuoro-
quinolones and piperacillin–tazobactam, and a worsening problem of
MDR AB. Prospective review and feedback on piperacillin–tazobactam,
and a study on MDR AB are planned.
P1502 The rate of potentionally inappropriate antibiotic use in
respiratory tract infections
M. Matuz, R. Benko, E. Hajdu °, G. Soos (Szeged, HU)
Objectives: To estimate the necessity of antibacterial therapy prescribed
for respiratory tract infections.
Methods: The aggregated regional-level reimbursement data on systemic
antibiotic prescriptions were purchased from the National Health Fund
Administration. The study period was between 2007 January and June.
All prescriptions claimed in the pharmacies of the region (n = 445
pharmacies) during this half year were included in the analysis.
Antibiotic use was evaluated by means of the ATC/DDD methodology
(version 2008). The indications of antibiotic therapies were determined
according to the registered ICD (International Classiﬁcation of Diseases
version 10) codes. With the help of an infectologist consultant we
classiﬁed indications (based on registered ICD-10 codes) into three
categories: a) antibiotic therapy is probably required and useful b)
antibiotic treatment is probably needless 3) undeterminable due to the
inadequate nomenclature of the ICD code.
Results: Antibiotic therapy was judged to be probably required and
useful in 33.3%, probably needless in 60.3% and undeterminable in
6.4%.
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Table: Necessity of antibacterial use in different respiratory diseases
according to the indicated ICD-10 codes
DDD per 1000
inhabitant-days
Cum
%
Probably required and useful S= 4.7 DDD per 1000 inhabitant-days (100%)
J0390 Acute tonsillitis 1.7 36.9
J0200 Acute streptococcal pharyngitis 0.7 51.6
J0100 Acute sinusitis 0.5 61.8
J0300 Acute streptococcal tonsillitis 0.4 70.7
J2000 Acute bronchitis (Mycoplasma pneumoniae) 0.3 76.3
J1890 Pneumonia 0.2 81.4
J1800 Bronchopneumonia 0.2 86.1
J0190 Acute sinusitis 0.2 89.5
J40H0 Bronchitis, unspeciﬁed 0.1 91.6
Probably needless S= 8.5 DDD per 1000 inhabitant-days (100%)
J0290 Acute pharyngitis 3.5 41.0
J2090 Acute bronchitis 2.8 73.8
J0690 Upper respiratory tract infection 1.0 85.4
J00H0 Common ﬂu 0.5 91.2
Undeterminable S= 0.9 DDD per 1000 inhabitant-days (100%)
J0410 Acute tracheitis 0.3 39.1
J0400 Acute laryngitis 0.2 64.7
J0420 Acute laryngotracheitis 0.2 86.1
J0600 Acute laryngopharyngitis 0.1 96.4
Conclusion: According to our estimation antibiotic therapies were
prescribed for mainly viral diseases in high number. However this
methodology gives upper estimation of antibiotic overuse (due to lack
of clinical signs and knowledge on concomitant chronic diseases) the
results are disappointing and alarming.
P1503 Modelling treatment strategies to contain resistance in
hospital wards
P.K. Schulz zur Wiesch °, R.D. Kouyos, S. Bonhoeffer (Zurich, CH)
Nosocomial infections with drug-resistant bacteria are often associated
with a worse prognosis and higher costs than those caused by their
susceptible counterparts. Several strategies that coordinate the use of
antibiotics in a population have been proposed to delay and minimize
the rise of resistance, among them “cycling” (sequential use of different
drugs), “mixing” (simultaneous use of different drugs in different
patients), or population-wide combination therapy. Theoretical studies
predict that combination therapy should in most cases be superior to
the other strategies and that mixing should be generally preferable to
cycling. The clinical evidence, however, does neither generally support
combination therapy in nosocomial infections nor show a pronounced
disadvantage for cycling. Thus, we currently do not have an understand-
ing for the discrepant ﬁndings between theoretical and empirical studies.
We developed a stochastic epidemiological model that describes a
hospital ward, which is characterized by a small population size, a high
population turnover and by the presence of both direct and environmental
transmission. It considers four main compartments, in which the hosts
are either protected by a microﬂora, susceptible, colonized or infected.
Two different empirical therapies are available, and we monitor resistance
to either or both of these antibiotics, which may arise via mutations or
horizontal gene transfer. Both the total prevalence and the total amount
of patients receiving inappropriate therapy are used as endpoints.
Compared to direct transmission, the dynamics differed profoundly
when transmission occurred via environmental contamination, since the
environmental reservoir impedes extinction and acts as a “memory”.
Cycling was sometimes beneﬁcial, when the population size and
prevalence of resistance allowed for an extinction of strains resistant
to the previous antibiotic. The relative success of the three strategies
was greatly inﬂuenced by the prevalences among the incoming patients,
the costs and the rates at which resistance was acquired for each of the
three resistant genotypes. Furthermore, short-term and long-term success
were not always correlated.
This study shows that the success of treatment strategies in containing
resistance may depend on inherent differences in the biology of the
speciﬁc diseases.
P1504 Pharmacist interventions on antibiotic dosage performed
trough a computer-assisted management programme with
real-time alerts
J. Ferna´ndez-Morato´, S. Grau °, D. Conde-Este´vez, M. Marin-Casino,
J. Mateu-de Antonio, O. Ferra´ndez, E. Salas (Barcelona, ES)
Objectives: Inadequate antibiotic dosage (ID) may produce an increase
in antimicrobial resistance, treatment failures and adverse effects.
Computer-assisted management programs for antibiotic prescription
linked to Computer Physician Order Entry-System (CMP-CPOE) have
shown good results in antibiotic therapy optimization. The aim of this
study was to assess a CMP-CPOE utility in pharmacist interventions
on antimicrobial dosage adjustment (IADA), to compare clinical and
antibiotic therapy features between patients with an IADA versus those
with other interventions on antimicrobial therapy (OAI) and to identify
predictive factors of ID.
Methods: Retrospective study in a 450-bed university hospital including
all patients with antimicrobial interventions (AI) performed through
a CMP-CPOE during 3 months (June-August 2008). This CMP-
CPOE ran with real time alerts appearing on the computer screen.
Pharmacists wrote AI in the computerized medical history. Data
collected: demographics, SAPS-II at admission, type of admission,
medical ward, lenght of hospital stay, crude mortality, creatinine
clearence MDRD (CrCl), type of antibiotic, site of infection and
empirical or directed antibiotic therapy. ID was considered when dose
was not adjusted to patient characteristics or infectious foci.
Results: Total antibiotic prescriptions: 3599. Total AI: 175 (4.9% related
of total antibiotic prescriptions). Patients with IADA: 89. IADA: 96
(54.9%)(1.1/patient): ID related to CrCl 55 (57.3%), infradosiﬁcation 24
(25%), overdosiﬁcation 12 (12.5%) and inadequate schedule 5 (5.2%).
The clinical and antibiotic therapy features’ differences observed
according to IADA or OAI (univariate analysis) and the predective
factors of ID (logistic regression) are presented in Table.
Conclusions: 1) More than half of AI were related to inadequate dosage.
The real time CrCl reduction warnings allow to perform IADA focused
in patients with severe renal impairment. Pharmacist intervention
acceptance was remarkable in IADA, especially those related to
overdosiﬁcation, while in OAI was limited. The CMP-CPOE showed
as a useful tool to optimize antimicrobial dosage. 2) Patients with IADA
present higher severity of illness at admission and have more respiratory
tract infections and empirical therapy with amoxicillin/clavulanate
and levoﬂoxacin. In multivariate analysis, patients with empirical
antimicrobial therapy and severe renal impairment were associated
independently with ID.
IADA OAI p OR (95%CI; p)
SAPS-II at admission 31.8 28.6 0.046
95%CI 29.8–33.8 26–31.2
Crude mortality 15 (15.6%) 5 (6.3%) 0.054 –
CrCl <30ml/min/1.73m2 50 (52.1%) 16 (20.3%) <0.001 4.5 (1.9−10.8; 0.001)
Nephrology admission 13 (13.5%) 4 (5.1%) 0.059 –
Amoxicillin/Clavulanate 20 (20.8%) 8 (10.1%) 0.055 –
Levoﬂoxacin 9 (9.4%) 1 (1.3%) 0.024 –
Respiratory tract infection 36 (37.5%) 15 (19%) 0.007 –
Empirical antimicrobial therapy 61 (63.5%) 29 (29.1%) <0.001 3.8 (1.8−8; <0.001)
Acceptance 24−48 h post IADA* 70 (72.9%) 42 (53.2%) 0.007 –
*All IADA related to overdosiﬁcation were accepted: 12 (10.7%) vs 0 (0%) (p = 0.005).
P1505 Prevalence study on antibiotic consumption in Latvian
general practitioners
U. Dumpis °, E. Tirans, M. Akermanis, S. Veide (Riga, LV)
Introduction: The largest proportion of antibiotics is used in ambulatory
care. Despite general consumption data are calculated, they don’t provide
information on indications for use and demographics of the patients.
This information is essential to analyze resistance selection pressure.
Easy and cheap methodology was designed to benchmark ambulatory
antibiotic use.
Methods: GPs where asked to record data on each patient that received
antibiotics during one week in November, 2008. The questionnaire was
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handed out on registration for the annual conference. Explanation on the
methodology was given during the presentation in conference and written
instructions. Questionnaire contained information of an antibiotic, dose
and dosing interval, indication for use and general demographic data.
Participation was voluntary and did not contain ﬁnancial incentives.
Results: Two hundred forty eight questionnaires out of 600 (41%) where
returned by post to the investigators. During one week one GP made
mean 113 consultations and antibiotic was prescribed in mean 7 patients
(0−33). Children younger than 10 years received most the prescriptions
(24.8%). Patients older than 60 years accounted for 13% of the treated.
All together, 1763 antibiotics were prescribed during the study period.
Most of the patients received monotherapy, only 22 (1.3%) patients where
prescribed two antibiotics. Most commonly prescribed antibiotic was
amoxicillin (34% of prescribed), amoxicillin/clavulanate (19%) and clar-
ithromycin (8%). Most commonly treated infections where pharingitis
(29.1%), acute bronchitis (24.7%) and rhinosinusitis (9.9%). Pneumonia
was mostly treated with amoxicillin/clavulanate(25%) amoxycillin (16%)
and clarithromycin (19%). Uncomplicated urinary tract infection was
mostly treated with oral furagine (27.5%), ciproﬂoxacin (22%) and
norﬂoxacin (19%).
Conclusions: Methodology employed was cheap and easy to use and
provided information on antibiotic use pattern in general practice.
Despite rather low return rate and possible bias, we consider
obtained information extremely important. Future interventions to reduce
ambulatory antibiotic prescriptions should be focused on treatment of
acute pharyngitis and bronchitis in children. Another point of signiﬁcant
concern was the high use of ﬂuoroquinolones for uncomplicated urinary
tract infection.
P1506 Attitude of healthcare professionals on antibiotic use in
Lithuanian general and nursing hospitals − qualitative study
A. Jurkeviciene °, A. Berzanskyte, R. Valinteliene, J. Miciuleviciene,
A. Ambrozaitis (Vilnius, LT)
Objectives: Survey in Lithuania showed huge variation of antibiotic
consumption (11.5–79.5 DDD/100-bed days in general and 0–26.6
DDD/100-bed days in nursing hospitals) and their structure between
hospitals in 2007. The main aim of following qualitative study was to
enlighten health care professionals’ attitude to antibiotic use.
Methods: Discussions with focus groups were organized inviting
different staff. Questions about guidelines, antibiotic prescribing
control, consumption surveillance, collaboration with microbiology
laboratories, impact of pharmaceutical companies, needs of knowledge
and teaching were discussed. Content analysis was applied working up
the conversation material in several steps: multiple listening/reading
of discussions; search of semantically close answers and keywords;
summarising by forming categories, subcategories; interpretation.
Results: Focus group discussions showed that due to antibiotics obtained
by patients antibiotic consumption in general hospitals should be higher
than the one found in quantitative study in 2007. Representatives from
nursing hospitals conﬁrmed low antibiotic use. The general hospitals
most often have guidelines approved by hospital chief, but seldom control
on antibiotic prescribing. Guidelines for antibiotic use are available
in larger nursing hospitals. Sometimes they are established locally as
procedures, algorithms. Almost all participants expressed wish to have
national guidelines. Antibiotic prescribing is generally based on doctor’s
decision, most often empirically in both types of hospitals. However in
regional or smaller hospitals the staff prefers not to change any routine.
According to physicians afﬁrmation pharmaceutical companies don’t
inﬂuence antibiotic choice and prescribing. That is even more evident
in nursing hospitals, as because of low consumption pharmaceutical
companies are not interested in advertising, presenting antibiotics there.
The need of knowledge and teaching on antibiotic subject was expressed
in general hospitals and not prioritized in nursing hospitals, where other
topics were considered to be more relevant.
Conclusions: The study revealed the absence of strict national policy
on antibiotic use in Lithuanian hospitals in general. Lack of stewardship
was enlightened as the main problem to work on.
P1507 The impact of educational campaign on public attitudes
towards antibiotics
N. Radosevic °, B. Popovic, G. Palcevski, V. Vlahovic-Palcevski (Rijeka,
HR)
Objective: Education of patients on inappropriate use and importance
of compliance with instructions on taking antibiotics is an important
strategy for improvement of antimicrobial use and containing emergence
of resistance. The objective of this study was to assess the impact of
a public campaign about rational use of antibiotics by perceiving the
alterations in patients’ attitudes towards antibiotics reviewed prior and
following the campaign.
Methods: The public campaign about the rational antibiotic use and
treatment of mild upper respiratory tract infections was conducted among
the population in Primorsko-Goranska county during February 2009
through local daily newspapers, radio and TV spots and programmes,
booklets and handouts for patients, posters and organised lectures.
Before the campaign anonymous questionnaires were dispensed to
patients in primary care, who visited pharmacies and general practition-
ers. The questions concerned patients’ knowledge on antibiotics, their
expectations from physicians regarding prescribing an antibiotic and their
awareness of the risks associated with the over consumption and misuse
of antibiotics.
After the end of the campaign, another questionnaire was presented to
the patients in the primary care. They were asked the same questions as
they were before the campaign, with additional questions on the impact
of the campaign.
Results: A total of 461 qustionnaires were ﬁlled in before the
campaign, and 345 patients completed the questionnaire after the
campaign. A signiﬁcant difference was noted in responses concerning
the appropriateness of taking antibiotics for typical viral symptoms (sore
throat, fever, cold, ﬂue) (Fig. 1.). About 2/3 of the respondents (62%)
were informed about the campaign, mostly through TV spots (56%)
and posters (43%). The majority remembered the inappropriateness of
selfmedication (85%) and ineffectivenes of antibiotic treatment for viral
infections (50%) as the main messages of the campaign.
Conclusion: A short term effect of educational campaign about the
rational antibiotic use was a considerable impact on public knowledge
on appropriate antibiotic usage. A long term effect and our future
goal is continuous patient education as an important measure in
decreasing unnecessary antibiotic prescribing and even decreasing
bacterial resistance.
Figure 1. Attitudes towards appropriateness of taking antibiotics for
typical viral symptoms.
P1508 Patients’ perception about rational use of antibiotics
E. Keuleyan °, R. Benchev, P. Yovchevski, N. Smilov, M. Valentinova,
S. Tete, T. Anakieva (Soﬁa, BG)
Objectives: On the occasion of 18 November 2009 − the day of
antibiotics, an inquiry was performed at the Medical Institute − Ministry
of the Interior, aimed to know the current patients’ perception about
antibiotic usage.
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Methods: A questionnaire of 11 questions with multiple choice answers
was developed by a multi-disciplinary equip and was distributed on 10
and 11 November 2009 among in-patients and out-patients of our 350-
bed national multi-proﬁle hospital. The inquiry was anonymous. Correct
answers were announced on 18 November 2009.
Results: Ninety four forms were returned out of 149 distributed (63%).
Probably, because of coincidence with grippe epidemics, 71% of patients
(Ps) responded that antibiotics (AB) were created both against bacterial
and viral infections. Majority (84%) considered AB indispensable to treat
severe infections, e.g. pneumonia, peritonitis, but only 40% mentioned
AB important in severe pandemics, e.g. plague, anthrax. Only 2%
considered AB should be used in common cold and uncomplicated
diarrhea. Top answers to the question: “What are the most frequent
reasons for failure of AB therapy, were: “the duration of treatment
was not respected” (60%) and “microorganisms are not susceptible”
(53%). Replies to the question “Why AB should be prescribed only
upon special considerations” showed that Ps are informed about AB
resistance (83% responded, because the overuse of AB is followed by
development of AB resistance, and 27% were aware about emergence of
pan-resistant bacteria). Almost all (96%) responded that one should not
take AB without prescription. Patients’ perception about possibilities
doctors to limit AB resistance was revealed as follow: “to prescribe
the most appropriate AB in most appropriate regimen” − 64% and
“to prescribe AB on speciﬁc occasions and after antibiogramme” − 62%.
As to the control of infections, majority of Ps acknowledged the role
of hand washing (78%), but only 36% considered the importance of
vaccines.
Conclusions: This investigation revealed that majority of patients was
aware about antibiotic resistance and was against the self-medication. At
the same time it showed area for further education, e.g. accent on the
importance of prophylaxis of infections through immunizations.
P1509 What do pharmacists recommend for men with acute
urethritis symptoms: 2009 vs. 2003–2004
S. Korolev, I. Andreeva, S. Kozlov, A. Fokin °, E. Shal, D. Iliin,
A. Muraviov, P. Bortulev (Tula, Smolensk, RU)
Objectives: In Russian Federation antibiotics are not ofﬁcially included
on the list of OTC medications, which was approved by the Ministry
of Health. Nevertheless people can freely purchase antimicrobials
from drug stores. We aimed our study to compare pharmacists’
recommendations for men with acute urethritis symptoms in 2003–2004
vs. 2009.
Methods: Young male doctors (25−30 years old) − “simulated
patients” − were trained to present complaints of acute urethritis to drug
store personnel. In 2004 in 4 Russian cities (Moscow, Smolensk, Kaluga,
Kaliningrad) and in 2009 in 5 cities (Moscow, Smolensk, Kaluga,
Kalinigrad, Tula) pharmacists were asked for recommendation according
to standard questionnaire.
Results: In 2004 and 2009 360 and 409 pharmacists were questioned,
respectively (139/117 − in Moscow, 78/83 − in Smolensk, 72/64 −
in Kaluga, 71/73 − in Kalinigrad, respectively, and 72 − in Tula in
2009 only). 208/168 (57.8%/41.1%) of pharmacists recommended to buy
medications, 74/103 (20.6%/25.2%) advised to visit a doctor, 76/138
(21.1%/33.7%) recommended both in 2004 and 2009, respectively.
In 273/291 cases (96.1%/95.1% from pharmacists who recommended
treatment) drug store personnel advised antimicrobials in 2004 and 2009,
respectively: nitroxoline (23.6%), norﬂoxacin (14.8%), nitrofurantoin
(12.4%), ciproﬂoxacin (8.1%), pipemidic acid (7.4%), co-trimoxazole
(4.3%), fosfomycin (3.8%) in 2004 and norﬂoxacin (24.3%), nitroxoline
(13.0%), fosfomycin (12.4%), pipemidic acid (11.0%), ciproﬂoxacin
(8.2%), furazidine (7.8%), nitrofurantoin (5.8%), amoxicillin/clavulanic
acid (4.0%), azithromycin (2.0%) in 2009. Duration of recommended
treatment course was 6.0±1.5 and 5.6±3.0 days in 2004 and 2009,
respectively. In 16.5%/17.6% of cases in 2004 and 2009, respectively,
drug store personnel recommended non-antimicrobials (the most
commonly herbal remedies).
Conclusions:
1. Pharmacists are responsible for substantial number of OTC prescrip-
tions of antimicrobials.
2. In general pharmacists’ behavior has not changed over 5 year’s period
and antimicrobials remain the most frequently prescribed medications
for acute urethritis in men.
3. Special programs should still be developed for drug store personnel
to discontinue sales of antimicrobials without prescription.
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P1510 Quantifying use of alcohol handrub and soap by
non-healthcare workers in hand hygiene intervention studies
J. Savage, C. Fuller, S. Besser, S.P. Stone ° (London, UK)
Objectives: The volumes of alcohol hand rub & soap procured by
wards provide a proxy measure of hand hygiene compliance. This may
be distorted by use of alcohol handrub (AHR) at ward entrances &
bedside use of AHR/soap by patients & visitors. In England & Wales,
the national cleanyourhands campaign promoted use of bedside AHR by
healthcare workers (HCW). An unintended consequence of the campaign
was that many hospitals had AHR at ward entrances & encouraged staff,
patients & visitors to use it. An evaluation of the campaign 2004−8
showed procurement of soap & AHR had tripled but it is not clear
how much of the increase was due to non-HCW use of consumables at
ward entrances & the bedside. Such use has not been studied previously.
The objectives of this study were to estimate the proportion of ward
procurement of AHR and soap attributable to use of AHR at ward
entrances, and to use of soap & AHR by non-HCWs at the bedside.
Methods: Proportion of AHR & soap used by visitors/patients inside
the ward: Thirty six hours of direct observation of bedside hand hygiene
behaviours by HCWs, patients and visitors were performed during
weekday ward visiting hours (13.00–20.00hrs) on 27 acute medical wards
and ITUs in 9 English trusts.
Proportion of AHR used at ward entrances: Each bag/bottle of AHR was
collected from ward entrance dispensers for four consecutive days on 10
wards in 4 hospitals. Mean daily volume used was compared with mean
daily ward procurement for the previous 12 months.
Results: At the bedside, only 6 (3.95%) out of 152 observed uses of
AHR and 6 (4.35%) of 138 uses of soap were by visitors. No patient
used soap or AHR. Mean daily use of AHR at ward entrances was 21.4%
(range 7.8–32.8%) of mean daily procurement.
Conclusions: In this multicentre study, 96% of all bedside soap/AHR
use appeared to be by HCWs. Although the proportion of AHR used
at ward entrances varies widely, much of its use occurs outside visiting
hours, so it seems reasonable to assume at least half of such use is
by HCWs. This implies that at least 85% of ward AHR procurement
represents use by HCWs. The rise in consumables reported during the
cleanyourhands campaign is largely attributable to their use by HCWs,
rather than visitors & patients. We suggest that hand hygiene intervention
studies using consumables as a proxy measure should assess & adjust
for such use.
P1511 Assessment of blinding of hand hygiene observers in
randomized controlled trials of hand hygiene interventions
C. Fuller, J. Savage, S. Besser, S.P. Stone °, E. Fragaszy, J. McAteer,
S. Michie, B.D. Cookson, J. Gardiner (London, UK)
Objectives: Trials evaluating interventions to improve healthcare
workers’ hand hygiene compliance use directly observed compliance
as a primary outcome measure. Observers should be blinded to the
intervention, that is, have no knowledge of the allocation of wards or
units to the intervention, and the effectiveness of blinding assessed, to
prevent systematic bias with compliance over-estimated in intervention
wards and underestimated in non-intervention wards. This issue has not
been addressed in the literature.
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The study aimed to design a method of assessing blinding, use it
to determine the effectiveness of blinding in a current randomised
controlled trial, and thus inform future hand hygiene trial methodology.
Methods: A method of assessing blinding was designed and used to
assess blinding in a current randomised controlled trial, the Feedback
Intervention Trial (NRR website N0256159318). The study hand hygiene
observer, trained another researcher, blinded to the intervention, in use
of a robustly standardised, valid, reliable and sensitive measure of
hand hygiene compliance, the Hand Hygiene Observation Tool (HHOT)
(www.idrn.org/nosec.php). 1030 simultaneous observations were carried
out over 20 hours, on 7 intervention and 6 non-intervention wards in
the trial. Between observer differences were compared for both types of
ward using Cohen’s kappa (individual hand hygiene behaviours) and the
Mann–Whitney U (overall compliance).
Results: Raw agreement between observers for individual hand hygiene
behaviours was excellent in both intervention wards (91.5%, kappa =
0.886 [CI 95% 0.792–0.98]) and non-intervention wards (92.4%, kappa
= 0.894 [CI 95% 0.845–0.987]). There was no statistically signiﬁcant
difference between observers for overall compliance.
Conclusions: This study describes a robust and pragmatic method for
assessing the adequacy of blinding in hand hygiene intervention trials.
It demonstrates that blinding of the study hand hygiene observer to
ward allocation was effective in a current trial, and that assessments
of hand hygiene compliance were not biased. All hand hygiene studies
should blind observers to the intervention and assess the effectiveness
of blinding.
P1512 Do widespread shortcomings in hygienic cleaning limit
the impact of other healthcare interventions to prevent
pathogen transmision?
P. Carling ° for the Healthcare Environmental Hygiene Study
Group Hospitals
Objective: Despite improved hand hygiene compliance and the use of
active surveillance cultures to optimize isolation practice, there is limited
evidence that these interventions have led to widespread or sustained
decreases in the overall burden of hospital associated infections. In
view of the documented increased risk of acquisition of MRSA, VRE,
C. difﬁcile and A. baumannii from prior room occupants and recent
studies prospectively demonstrating decreased transmission of MRSA,
VRE and A. baumannii as a result of improved hygienic cleaning in the
context of our previous ﬁnding of suboptimal discharge cleaning in 36
acute care hospitals, a broader evaluation of thoroughness of hygienic
cleaning was undertaken by the Environmental Hygiene Study Group
hospitals.
Methods: A novel ﬂuorescent targeting system was covertly used to
objectively evaluate if the thoroughness of disinfection cleaning (TDC)
of standardized sets of high risk objects was being performed in a manner
consistent with previously established guidelines in a range of healthcare
settings.
Results: Terminal TDC in the ﬁrst 36 acute care hospitals studied (48%)
was similar to that found in 50 hospitals participating in the Iowa MRSA
Reduction Project (62%), 14 other test hospitals (42%), 16 hospitals’
operating rooms (32%) and 7 hospitals’ neonatal intensive care units
(36%) (Figure). Daily TDC in ICU isolation rooms in 7 hospitals (31%),
in 4 ambulatory chemotherapy suites (26%), in 4 dialysis units (28%)
and in 4 long-term care facilities (34%) was also suboptimal (Figure).
Overall the mean TDC was 47.9 (Range 3−88; 95%CI 44.8–50.9).
Conclusion: The evaluation of hygienic cleaning of >62,500 high touch
surfaces in 103 different institutions and 142 study sites conﬁrmed the
existence of similar opportunities to improve such cleaning in all venues.
While it will remain for future studies to further quantify the favorable
impact of more thorough hygienic cleaning in many of these settings,
the realization of substantial improvement in cleaning using a structured
objective process improvement program in 36 hospitals (ICHE 2008; 29:
1035−41) suggests that such interventions have signiﬁcant potential for
improving hygienic practice in many settings.
P1513 Hand hygiene in paediatric and neonatological intensive
care unit patients: determination of daily indications and
indication- and profession-speciﬁc analysis of the compliance
S. Scheithauer °, J. Oude-Aost, T. Schwanz, K. Heimann, H. Haefner,
B. Waitschies, T. Orlikowsky, S. Lemmen (Aachen, DE)
Objectives: Hand hygiene (HH) is considered to be the single
most effective tool to prevent healthcare-associated infections (HAIs).
Intensive Care Units (ICUs), especially those caring for neonates
represent a centre for HAIs with great impact on morbidity and
mortality. Although there have been several reports on compliance rates
(CRs), data on daily hand hygiene indications (HHI) and CRs for
pediatric/neonatological ICUs (P/NICUs) are still lacking.
Methods: Therefore we conducted a prospective observational study
to determine HHIs for and CR with HH according to the WHO
deﬁnition in P/NICU-patients. The observation was carried out patient-
directed by one observer only over 192 hours. Observation periods were
distributed equally over the day (0:00−24:00). Analysis was performed
P/NICU-, indication-, profession-, and shift-speciﬁcally. Observed CRs
were correlated with disinfectant usage (DU), data were obtained from
the spending records.
Results: HHI were signiﬁcantly higher for PICU (316/24 h) than NICU
(194/24 h) patients (p = 0.004). Observed CR resulted in 56% (PICU)
and 61% (NICU) being signiﬁcantly higher in nurses (61 and 66%) than
in physicians (29 and 52%; p< 0.001). CRs were signiﬁcantly higher
before patient contact and aseptic task than after contact with patients and
their surroundings (p = 0.009). Shift-speciﬁc CR was signiﬁcantly highest
during night shift (64%; p = 0.05). Glove usage instead of disinfection
before patient contact /aseptic task was more common in PICU-(39%)
than in NICU-patients (20%). Worrisomly, compared to direct observed
results calculation by DU reveiled a 3-fold lower CR (20%).
Table 1: Hand hygiene characteristics for representative pediatric (PICU)
and neonatological (NICU) ICU-patient-days (24 h)
Hand hygiene
indications
Hand hygiene
activities
Compliance rate
(%)
PICU NICU PICU NICU PICU NICU
Early shift 109 78 58 40 54 51
Late shift 104 69 59 41 56 60
Night shift 103 47 59 37 57 79
Indication 1 72 54 36 42 50 78
Indication 2 64 24 48 16 75 67
Indication 3 46 23 22 11 48 49
Indication 4 64 56 38 35 59 62
Indication 5 79 37 39 16 49 44
Nurses (ICU-associated) 260 145 149 96 57 66
Physicians (ICU-associated) 35 14 10 7 29 52
Others 24 35 10 15 41 41
Sum 316 194 176 118 56 61
Legend: Indication 1: before patient contact; Indication 2: before aseptic task;
Indication 3: after contact with body ﬂuids; Indication 4: after patient contact;
Indication 5: after contact with the patients’ surroundings.
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Conclusion: This study provides the ﬁrst data on daily HH in
N/PICU-patients including comparison of observed and calculated CR.
Fortunately, direct observation reveiled high CRs especially in nurses
and in situations of greatest impact. Unfortunately, inﬂuence of direct
observation seems to be high. Thus, these data allow focusing future
efforts in hand hygiene to reduce HAIs and improve patients’ safety.
P1514 Hand hygiene promotion worldwide: strategies and achieve-
ments of the WHO First Global Patient Safety Challenge
B. Allegranzi °, C. Kilpatrick, W. Graafmans, S. Bagheri Nejad,
M. Chraı¨ti, E. Mathai, H. Richet, D. Pittet (Geneva, CH)
Objective: The WHO First Global Patient Safety Challenge (GPSC),
launched in October 2005, aims at reducing healthcare-associated
infections (HAI) worldwide, in particular by promoting hand hygiene
(HH) and infection control (IC) best practices at the point of care. We
evaluated the strategies and achievements of the First GPSC related to
this objective.
Methods: The following components were assessed: 1) development
and testing of guidelines and accompanying implementation strategies
and technical tools; 2) evaluation of test results; 3) ﬁnalization and
dissemination of implementation strategies and tools. Main indicators of
success were HH compliance measured by a validated direct observation
tool and the number of healthcare settings implementing HH promotion
worldwide.
Results: The advanced draft of the WHO Guidelines on HH and the
WHO multimodal HH improvement strategy and tools were developed
with the contribution of more than 100 international experts and were
tested in 2007–2008 in 8 pilot sites and in over 250 health-care
settings worldwide. Main results from pilot sites were: a signiﬁcant
(p< 0.01) increase in the weighted mean of HH compliance from
34.0% at baseline to 55.7% after a three-month intervention period in
7/8 sites; preferred recourse to alcohol-based handrub for HH in all
sites with local production of a WHO formulation at low cost in 6/8
sites and national scale-up in 4/6 sites; and improvement in healthcare
workers’ perception and knowledge about the importance of HAI and
HH. Following evaluation of lessons learned, the ﬁnal Guidelines and
Implementation Toolkit were issued in May 2009. To catalyze their
dissemination and to support long-term HH improvement worldwide,
a new initiative, “Save Lives: Clean Your Hands”, was launched on 5
May 2009. As of 5 November 2009, 5801 hospitals from 125 countries
have registered to be part of this initiative using the WHO Guidelines
and tools for HH promotion.
Conclusions: The feasibility and reliability of the WHO Guidelines and
tools and their impact on HH procedures were demonstrated through
testing in settings with different cultures and resource availability. The
First GPSC has generated an unprecedented global momentum and
mobilized thousands of healthcare settings to achieve HH improvement.
By making IC a priority in healthcare everywhere, with HH as its solid
and essential basis, the First GPSC efforts have the potential to save
millions of lives and engender major cost savings.
P1515 Hand-hygiene champion junior doctor picks up the
gauntlet: a randomized prospective study of 2,500 minutes
of hand hygiene audit conducted by 17 junior doctors in
a large district hospital of northwest England
M. Przybylo °, M. Qulaghassi, A. Guleri (Blackpool, UK)
Objectives: “Scientists estimate that people are not washing their hands
often or well enough & may transmit up to 80% of all infections by their
hands. Hand washing may be the single most important act to help stop
the spread of infection and stay healthy (CDC)”. Several Dept health
high proﬁle hand hygiene(HH) campaigns have made HH compliance
results a standard item of trust board, divisional, hospital infection
control meetings, trust induction day, etc. HH audits are conventionally
conducted monthly by infection control/link nurse. We present an
innovative project by a junior doctor(JD). The aim was to collect
prospective, unbiased, sizeable data on HH compliance. Raise awareness
and engage JDs in the hospital hand hygiene programme (HHP).
Methods: Data from 2500 minutes (125× 20-min observational (HHA))
performed by randomly selected 17-JDs across 18-wards. Standard
HHA tool (as used by nurses for monthly HHA) used. Consultant
microbiologist explained the method of conducting the audit. The
observer could choose any 1−3-clinical areas and conduct 4× 20-min
observational HHA at different times/different days (to eliminate ‘bad-
day’ effect) in each area. ‘Fly-on-the-wall’ [un-noticed] technique was
used during observations (to eliminate observation related change in
behaviour). Deﬁnitions: Opportunity (O) for HH − touching patient
or immediate surrounding (bed frame, med equipment, curtains,
notes/trolley on bedside, etc). Hand hygiene (H) with alcohol gel or
washing-soap & water. HH compliance = (total H÷ total O)× 100.
Overall and grade (staff nurse, jr nurses, jr docs, consultants,
registrar/staff grade, pharmacist, dietician/domestics, etc).
Results: From 2500 mins (125 observations) data: Clinical areas −
surgical (64 obs), medical (38), ITU (23 obs). Overall compliance was
37% (667/1787). Consultants 58% (O= 55), sr doctors 55% (O= 157),
JDs 44% (O= 271), staff nurses 30% (O= 507), etc. Compliance was
highest in intensive care 58% (O= 334), Surgical wards 35% (O= 860)
and medical wards 30% (O= 582).
Conclusion: Poor hand hygiene compliance can potentially undermine
hospital HCAI progam. This study has revealed detailed picture of hand
hygiene compliance. The project has engaged and raised awareness about
HH in junior doctors. The HHA will be repeated after 6-months to
compare the change. It is stipulated that announced HH observations may
potentially change HH behavious and single 20-min observation/month
in each ward may fail to provide a complete picture.
P1516 Increase of alcoholic handrub consumption in 1261 German
non-ICU units within one year
N. Mo¨nch °, M. Behnke, P. Gastmeier, C. Reichardt, C. Geffers (Berlin,
DE)
Objective: Hand hygiene is the essential method to prevent hospital ac-
quired infections. HAND-KISS, a module of the German Krankenhaus-
Infektions-Surveillance-System (KISS), established a new module for the
systematic surveillance of alcohol-based hand rub consumption (AHC)
in 2007. It is mandatory for all hospitals participating in the national
hand hygiene campaign “AKTION Saubere Ha¨nde”, which was started
in January 2008 and is supported by the German ministry for health, to
feed their AHC data into the HAND-KISS module.
We compared the consumption data for the years 2007 and 2008 of those
hospitals, participating in HAND-KISS and the national hand hygiene
campaign since 2008.
Methods: The following data are provided annually per unit: AHC,
the number of annual patient days per unit and the unit characteristics.
HAND-KISS calculates the consumption in ml per patient day (PD) for
individual units and provides reference data stratiﬁed according to the
specialty of the unit.
We examined the data of those units providing consecutive data for
the years 2007 and 2008. Differences of consumption were tested by a
Wilcoxon rank sum test for signiﬁcance.
Results: 181 hospitals provided consumption data of 2041 non-ICUs
in 2007, and 330 hospitals of 3328 non-ICUs in 2008. 1261 non-ICUs
out of 134 hospitals provided data for both years. The median overall
consumption rate for 2007 is 14.6ml/PD (interquartile range (IQR) 10.6–
20.8ml/PD) and 16.9ml/PD (IQR 12.2–23.8ml/PD) in 2008. There was
a signiﬁcant increase between 2007 and 2008 in all types of units (table).
The maximum increase of consumption is found in medical and medical-
surgical units representing an increase of 14%.
Conclusion: The consumption of AHC in participating units is
increasing. Since it is a mandatory measurement, all hospitals
participating in the national hand hygiene campaign are also providing
data to HAND-KISS. Among other interventions (e.g. lectures, increase
availability of alcohol-based hand rub, reminders, national hand hygiene
days, yearly meeting of campaigning hospitals, system change), the
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annual measurement of unit based AHC and feed back of data to staff
is one of the key elements of the campaign. Moreover, the placement of
local consumption data in comparison to national reference consumption
data provides a benchmarking system. This is the basis for ongoing
discussions about hand hygiene and sustained sensibility for this topic
in health care workers.
Table 1. AHC in ml/PD per unit type in 2007 compared to 2008
Type of unit No. AHC (ml/PD) p-value
of Median Difference 2008−2007
units 2007 2008 (ml) (%)
Surgical 276 15 16.8 2 13 <0.05
Medical 359 15.1 17.8 2.1 14 <0.05
Medical–surgical 110 14.4 17.2 2 14 <0.05
Other 439 12.8 14.4 1.6 13 <0.05
Paediatric 77 30.6 36 3 10 <0.05
All 1261 14.6 16.9 1.9 13 <0.05
P1517 Performance of and knowledge about hand hygiene in
medical students
S. Scheithauer °, T. Schwanz, H. Haefner, M. Weishoff-Houben,
S. Lemmen (Aachen, DE)
Objectives: Hand hygiene (HH) is considered to be the single most
effective tool to prevent healthcare-associated infections (HAIs). Despite
several recommendations available, compliance especially in physicians
remains low. In order to evaluate knowledge about hand hygiene and
their performance of hand hygiene in medical students, we conducted an
observational study at the University Hospital / RWTH Aachen, Germany
in 2009.
Methods: Performance of hand disinfection was evaluated in ﬁrst
(N = 28), third (N = 193), and ﬁfth (N= 45) year medical students
by using a black box. Several groups were compared: before and
after instructions concerning HH, with and without information about
measurement of results. Knowledge about HH was assessed using a
standardized questionnaire.
Table 1: Performance of hand disinfection in medical students
First year Third year Fifth year
Before
teaching
(N= 14)
(%)
After
teaching
(N= 14)
(%)
Before teaching,
no information
about result
control (N = 63)
(%)
Before teaching,
with information
about result
control (N = 64)
(%)
After
teaching
(N= 66)
(%)
No teaching,
no information
about result
control
(N = 45) (%)
Disinfection gap 12 (86) 10 (71) 58 (92) 45 (70) 12 (18) 33 (73)
1 gap 2 (14) 6 (43) 8 (13) 6 (9) 9 (14) 17 (38)
2−3 gaps 3 (21) 2 (14) 21 (33) 19 (30) 3 (5) 12 (27)
>3 gaps 7 (50) 2 (14) 29 (46) 20 (31) 0 (0) 4 (9)
Right hand gaps only 2 (14) 1 (7) 8 (13) 3 (5) 8 (12) 4 (9)
Left hand gaps only 0 (0) 4 (29) 4 (6) 3 (5) 1 (1) 3 (7)
Right and left hand gaps 10 (71) 5 (36) 46 (73) 39 (60) 3 (5) 26 (58)
Localization of the gap:
Back of the hand 5 (36) 1 (7) 13 (21) 18 (28) 0 (0) 3 (7)
Palm of the hand 4 (29) 1 (7) 6 (10) 3 (5) 0 (0) 8 (18)
Thumb 3 (21) 2 (14) 33 (52) 14 (22) 8 (12) 4 (9)
Foreﬁnger 6 (43) 5 (36) 14 (22) 9 (14) 0 (0) 3 (7)
Middle ﬁnger 5 (36) 2 (14) 8 (13) 7 (11) 0 (0) 1 (2)
Ring ﬁnger 3 (21) 1 (7) 12 (19) 10 (16) 0 (0) 0 (0)
Little ﬁnger 4 (29) 0 (0) 5 (8) 7 (11) 0 (0) 5 (11)
Fingertips 0 (0) 0 (0) 3 (5) 1 (2) 0 (0) 2 (4)
Finger nails 5 (36) 2 (14) 33 (52) 22 (34) 0 (0) 16 (36)
Knuckles 0 (0) 0 (0) 8 (13) 0 (0) 0 (0) 2 (4)
Interstitial ﬁnger sides 5 (36) 3 (21) 2 (3) 0 (0) 0 (0) 5 (11)
Wrist 2 (14) 0 (0) 22 (35) 16 (25) 2 (3) 9 (20)
Rings 3 (21) 1 (7) 2 (3) 2 (3) 0 (0) 0 (0)
Results: Disinfectant gaps were observed signiﬁcantly more often in
beginners (22/28; 79%) than in third year students (115/193; 60%; OR:
2.5 (1.0−6.4); p = 0.04). In third year students disinfectant gaps were
seen signiﬁcantly more often without information about result control
(58/63; 92%) than with information about result control (45/64; 70%;
OR: 5.0 (1.7–14.1); p = 0.001) and than after giving instructions on HH
(12/66; 18%; OR: 52.2 (17.2–158.0); p< 0.001). Without instructions
and without information about result control third year students (58/63;
92%) showed signiﬁcantly more disinfectant gaps than last year students
(33/45; 73%; OR: 4.2 (1.4–13.0); p = 0.007). More than 3 disinfection
gaps were documented more often in ﬁrst than in ﬁfth year students
(9/28 (32%) versus 4/45 (9%); OR: 4.9 (1.3–17.8)). Gaps on both hands
were seen more often before teaching (46/63 and 39/64 vs. 3/66; OR:
34.0 (10–120) and OR: 56.8 (15.7–205.4)). Detailed results were shown
in Table 1. All students knew about the importance of hand hygiene, no
association to the level of education was observed.
Conclusion: Performance of hand hygiene was inﬂuenced by informa-
tion about result control, and raised by teaching. Best performance was
documented immediately after teaching, a training effect during studies
could be documented. Thus we suggest implementing training on hand
hygiene on a regular basis to improve quality of care in order to prevent
HAIs.
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P1518 Evaluation of asymptomatic transmission and impact of
control measures in contacts of a patient with Marburg
haemorrhagic fever in 2008 in the Netherlands
A. Timen °, M.P. Koopmans, L. Isken, S. Dittrich, P. Willemse,
F. van den Berkmortel, P. Emmerich, D. Croonen-van Oudheusden,
H.P. Daemen, M.E. Hulscher, A.E. Brouwer, J.T. van Dissel (Bilthoven,
Helmond, Nijmegen, NL; Hamburg, DE; Leiden, NL)
Objectives: In July 2008 an import case of Marburg hemorrhagic fever
(MHF) was diagnosed in the Netherlands. We studied asymptomatic
transmission among contacts with exposure and evaluated the impact of
(restrictive) control measures.
Methods: Retrospective cohort study involving 130 contacts in the
hospital and household setting. Blood samples were collected from
December 2008 through February 2009, 5−7 months after possible
exposure and were tested for the presence of MARV antibodies using an
immunoﬂuorescent antibody (IFA) assay. A questionnaire was designed
addressing understanding of the rationale for the control measures, clarity
of instructions, reported compliance with the measures and perceived
impact (based on the Impact of Event Scale/IES). Data were analyzed
using SPSS v.15. Results were stratiﬁed by risk (high risk meaning
unprotected exposure, low risk meaning exposure after institution of
strict hygienic measures). Differences in means were assessed by
Student’s t test. Logistic and linear regression methods were used to
model variables associated with IES and risk level, respectively. Overall
scales were composed for impact, compliance and clarity of instructions.
Results: Of the 130 contacts, 85 (65%; 50 high-risk, 35 low-risk)
provided a blood sample and 78 (60%) completed the questionnaire.
All sera tested were negative for IgG and IgM antibodies to MARV.
Compliance with measuring temperature twice a day was seen in 81%,
and for daily temperature reporting in 60%. 14% Felt restricted in the
social contacts during the temperature monitoring, 58% was afraid to
develop MHF, 40% was afraid to infect family or other people, 45%
of the contacts were afraid that a colleague might be infected, 33%
experienced stress and 20% cancelled a planned holiday abroad. The
contacts with low-risk experienced more difﬁculties with measuring and
reporting fever (p< 0.001) and with the prohibition to leave the country
(p< 0.001). Contacts with high-risk had signiﬁcantly higher scores on
the impact scales (p< 0.001), both during as after the monitoring period.
Conclusions: The serosurvey conﬁrms that no secondary transmission
took place between the patient and any contact who provided a blood
sample. Being a contact of a patient with MHF is a stressful event and
restrictive control measures have a signiﬁcant impact on the daily life
of the contacts. Outbreak control teams in charge of the follow up of
contacts need to be aware of the potential impact of the measures.
P1519 Evaluation of silver-based disinfectant designed for use on
non-porous hard surfaces in healthcare facilities
R. Rennie °, L. Turnbull, B. Bennett (Edmonton, CA)
Objectives: Materials that have incorporated silver have achieved wide
acceptance in advanced wound dressings to reduce the development
Infection control S439
of infections. In this study we have examined a silver-based liquid
disinfectant that would be utilized on non-porous surfaces to reduce
organism loads and prevent the transmission of resistant bacterial species.
Methods: SILVAsan™ (Exciton Inc. and Ostrem Chemical, Edmonton,
AB) was provided by the company in three proprietary formulations;
SIL-0, SIL-1 and SIL-2. Each disinfectant contained a different
concentration of silver diluted 1:16. Two strains of bacteria were tested;
S. aureus ATCC 33591 (MRSA) and P. aeruginosa ATCC 27853. The
samples were tested using American Organization of Analytical Chemists
(AOAC) Ofﬁcial Method 955.15 Use-dilution Method. Sterile carriers
were placed into inoculated broth and then removed and dried. The dried
carriers were then incubated with the disinfectant for 1, 5 and 10 min
at room temp. Samples were neutralized and then incubated for 48 hr at
350C and examined for growth.
Results: The sterility and viable controls each performed as expected.
For these tests secondary neutralization was required and was conﬁrmed
with 5 replicates for each micro-organism. The carrier colony count for
the S. aureus strain was 4.3×106 CFU/ml. The count for P. aeruginosa
was 3.6×106 CFU/ml. The SIL-0 formulation failed at 10 minutes; 3 of
60 samples were positive for both S. aureus and P. aeruginosa. SIL-1
failed for the S. aureus strain. 20 of 60 tests were positive after 1 min,
and 1 of 60 tests was positive after 5 min. P. aeruginosa was therefore
not tested. The SIL-2 formulation passed the AOAC test parameters. For
both species, none of 60 tests was positive after a 1 min. exposure. As a
quality control check these same results were conﬁrmed after 5 and 10
min. exposure.
Conclusion: Disinfectants containing silver in the correct form and
concentration are effective at rapidly inhibiting the growth of relatively
high concentrations of bacterial pathogens. The results presented show
that a disinfectant such as SILVAsan™ can be used on inanimate surfaces
to effectively prevent the spread of both MRSA and P. aeruginosa,
common isolates in intensive and chronic care units, and burn units.
The formulations presented have very low concentrations of silver (25
ppm), are present in a silver citrate complex form, and do not present
any environmental, worker or patient health issues.
P1520 Survey on the use of multidose vials and ﬁngerstick blood
sampling devices in emergency departments compared with
intensive care units in Korea
Y.G. Kwak °, S.O. Lee, T.H. Kim, E.J. Choo, M. Jeon, J.B. Jun, K. Kim,
J. Jeong, Y.S. Kim, J.W. Chung, M.S. Lee (Goyang, Seoul, Asan, Ulsan,
Jecheon, KR)
Objective: Parenteral medications are commonly dispensed in multidose
formulations that might be used for prolonged periods for one or
more patients, and ﬁngerstick blood sampling devices are widely used
for capillary-blood sampling for glucose monitoring in patients with
diabetes mellitus. This study investigated the status of use of multidose
vials (MDVs) and ﬁngerstick blood sampling devices in emergency
departments (EDs) in comparison with intensive care units (ICUs).
Methods: The study population was 389 nurses working at either
ICUs or EDs in 6 university-afﬁliated hospitals in Korea, with routine
patient contact through clinical care. A questionnaire on the use of 4
MDVs, such as heparin, insulin, lidocaine, and normal saline as well
as ﬁngerstick devices was administered to each of these nurses between
December 2007 and February 2008. Questionnaire items involving the
use of infection control practices were derived from previous reports.
Results: Surveys were completed by 338 (86.9%) of 389 nurses,
including 159 (86.4%) of 184 ED nurses and 179 (87.3%) of 205 ICU
nurses. When comparing the use of MDVs between EDs and ICUs,
signiﬁcant difference existed only in preparing heparin lock solution.
When using heparin lock solution, 70.4% of the ED and 63.7% of the
ICU nurses stated they always made heparin lock solution each time
(P = 0.005). On the contrary, 21.3% of ED and 33.5% of ICU nurses
reported that they batched the heparin solution in syringes for multiple
heparin locks (P = 0.019). There were no other signiﬁcant differences in
using the 4 MDV medications between EDs and ICUs. For the ﬁngerstick
device, the rate of using separate ﬁngerstick devices for each patient
(71.7% vs 54.3%, P = 0.001) and cleaning the devices between patients
(36.5% vs 26.0%, P = 0.038) were higher in ED, and the rate of hand
hygiene was lower in EDs, both before (43.7% vs 74.3%) and after
(64.6% vs 91.6%) using the device (P< 0.001, respectively).
Conclusions: Findings from this investigation underscore the need for
education, training, adherence to standard precautions, and speciﬁc
infection-control recommendations targeting MDVs and diabetes-care
procedures in both EDs and ICUs. Strategies for improving compliance
with fundamental methods of infection control, especially hand hygiene
in EDs and the use of heparin lock solution in ICUs, need to be explored.
P1521 Control of multidrug-resistant Acinetobacter baumannii
epidemic nosocomial outbreaks
M. Galie`, E. Pistella, L. Emili, C. Santini ° (Rome, IT)
Objectives: Epidemic outbreaks due to multidrug resistant microrgan-
isms signiﬁcantly increase the amount of hospital-acquired infections
and the related morbidity and mortality. The results of standard
infection control interventions are often disappointing and new, more
complex strategies are probably needed. Clusters of infection due
to multidrug resistant Acinetobacter baumannii (MRAB) have been
frequently described in Rome. We report our experience of controlling
two MRAB outbreaks occurred in our hospital.
Methods: Since 2002 in our tertiary care hospital is active a program
for nosocomial infection control, mainly aimed to increase the hand-
washing compliance. Since 2004, weekly microbiologic surveillance of
long term (>1 week) ICU patients is performed and colonized patients
are isolated.
Results: From June 2008 to March 2009 we observed two outbreaks
of MRAB infections. Both clusters originated from patients admitted in
ICU from other hospitals. The ﬁrst cluster lasted 80 days and involved
17 patients, 11 before and 6 after the adoption of the follow speciﬁc
precautions: contact cohort isolation of infected-colonized patients in a
restrict area with speciﬁcally dedicated nurses, hand washing priority
and use of disposable gloves and gowns before and between patient
contact for health care personnel and for all visitors. No MRAB was
detected in the following 3 months. On December 2008 a second
outbreak involved 16 patients (4 early and12 late) in 6 distinct wards
of 3 departments (ICU, Surgery and Internal Medicine). The infection
control program was further implemented and extended to all the wards,
with the following precautions: environmental disinfection and routine
surveillance cultures from environmental sources and patients, daily ward
round of the infection control nurse, surveillance cultures from patients
coming from other hospitals at the admission. Protocol violations (mainly
in hand washing compliance and availability of dedicated nurses) were
registered and reported to the Infection Control Committee. Overall 33
patients were involved (18 late, despite the adoption of implemented
precautions);14 died for infection (mortality: 42.4%).
Conclusions: MRAB can enter in hospital by patients admitted from
other hospitals and rapidly spreads across the wards representing a
marker of the level of compliance with routine isolation precautions.
An aggressive infection control strategy decrease the diffusion rate and
ultimately allow the eradication.
P1522 Point-of-use water ﬁlters reduce contamination by
opportunistic Gram-negative bacteria present in the water
distribution system of a haematology ward
C.L. Wright °, L. Newton, K.G. Kerr, A.M. Snelling (Bradford,
Harrogate, UK)
Objectives: Studies have identiﬁed hospital water supplies as a source
of outbreaks of Gram-negative infection, yet little attention has been
paid to hospital water as a reservoir of the opportunistic pathogens
Pseudomonas spp. and Stenotrophomonas maltophilia in non-outbreak
settings. We investigated the longitudinal prevalence of these species,
as well as overall microbiological quality of water, in water outlets of
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a haematology ward before and after the introduction of point-of-use
(POU) water ﬁlters.
Methods: Over 13 months, bi-weekly 100ml water samples from
39 outlets, including kitchen taps, hand-wash stations and 3 outlets
per patient room (2 sinks and shower) were obtained and ﬁltrates
incubated on R2A agar for 48 h before sub-culture for identiﬁcation of
Pseudomonas spp. and S. maltophilia. In Phase 1, water was not ﬁltered.
In Phase 2, all outlets had POU devices (Pall Aquasafe 14-day ﬁlters).
Incidences of bacteraemia were recorded in both phases.
Results: Phase 1 (06/08–01/09): 786 samples were collected of which
99% yielded bacterial growth, which was too numerous to count (TNTC)
in 90%. Presumptive Pseudomonas spp. and S. maltophilia were isolated
from 16% and 10% of samples, respectively; often in association with
speciﬁc outlets. Phase 2 (01/09–07/09): there was a signiﬁcant and
immediate reduction in the frequency and density of isolation. Of
690 samples, only 136 (20%) yielded any bacterial growth with a
mean of just 8.2 CFU per growth-positive ﬁlter. Pseudomonas spp
and S. maltophilia were isolated from one (0.14%) and 10 (1.4%)
ﬁltered samples, respectively. Of 11 Gram-negative bacteraemias in
Phase 1, 3 were associated with P. aeruginosa. In Phase 2, 9 Gram-
negative bacteraemias occurred, with only one episode caused by
P. aeruginosa.
Conclusions: The water supply on the ward represented a persistent
source of Pseudomonas spp and S. maltophilia. Although a reduction in
P. aeruginosa bacteraemias was observed with POU ﬁltration, the overall
numbers were small. Nevertheless, ﬁltration was associated with a drastic
reduction in both the frequency and numbers of these species isolated
from every outlet. Accordingly this study has been extended with further
ﬁltration/no-ﬁltration phases and will use molecular typing to compare
P. aeruginosa and S. maltophilia isolates from water with those from
clinical specimens, to further examine the role of water ﬁltration as a
technique to prevent infection of immunocompromised patients.
P1523 Air ﬂow modellization by computational ﬂuid dynamics for
optimizing control for airborne microbial contamination in
an intensive care room for severely burned patients
C. Beaucheˆne, N. Laudinet, F. Choukri, J. Rousset, J. Larbre,
V. Bergeron, M. Chaouat, M. Benbunan, M. Mimoun, J. Lajonche`re,
F. Derouin ° (Chatou, Montigny, Paris, Lyon, FR)
Objective: Controlling airborne contamination is of major importance
in burn units because of the high susceptibility of burned patients to
infections. In this study, Computational Fluid Dynamics (CFD) modeling
was used to optimize the design of an intensive care room for severely
burned patients.
Methods: The study was carried out in 4 steps: 1) patient room design,
2) CFD simulations to model air ﬂows throughout the patient room,
adjacent anterooms and the corridor, 3) construction of a prototype room
that simulates the hospital environment 4) validation experiments.
The free access computational program Code_Saturne® program was
used to mesh the rooms, the medical staff and the equipment into
330 000 cells and to simulate airﬂows and diffusion of microbial
contaminants originating from different sources. Experiments with inert
aerosol particles followed by time resolved particle counting were
conducted in the prototype room for testing the CFD observations.
Results: CFD studies allowed testing several scenarii simulating the
consequences of introduced contaminations. When the surgical zone was
artiﬁcially contaminated, most particles dispersed toward the peripheral
part of the room and were rapidly cleared, but part of them was trained
by convection currents to the upper part of the room. This resulted in
delayed particulate clearance times and justiﬁed the increase of upper
exhaust grilles ﬂow rates. Simulating health care workers’ trafﬁc between
rooms revealed that opening the door between rooms that are at different
temperatures resulted in turbulent air exchanges between the rooms.
This phenomenon bypassed the pressure differences between the rooms.
Experiment conducted in a full-scale pilot room validated CFD ﬁndings
with respect to levels of conﬁnement, protection of the patient’s zone,
decontamination kinetics and particle transfer at door opening.
Conclusion: CFD analysis was an effective tool for the design of
intensive care rooms for burn patients. The combination of a 15 Pa
positive pressure, high air exchange rates with an efﬁcient ﬁltration (or
inactivation) were efﬁcient in preventing entry and spread of microbial
contaminants in the room. The major protective role of negatively
pressured anterooms was also conﬁrmed, although opening between
rooms that are at different temperature could bypass this protection.
Spiking experiments realized in a prototype room conﬁrmed these
ﬁndings, thereby validating the CFD prediction.
P1524 Effect of disinfection and drying on bioﬁlm formation by
bacteria and yeasts isolated from contaminated endoscopes
J. Kovaleva °, J.E. Degener, H.C. van der Mei (Groningen, NL)
Objective: Bioﬁlm formation within endoscope channels can result
in failure of the endoscope reprocessing and is an important factor
in the pathogenesis of endoscopy-related infections. The ability for
bioﬁlm formation and the effects of the peracetic acid disinfectant
and drying procedure on Candida albicans, Candida parapsilosis,
Pseudomonas aeruginosa and Stenotrophomonas maltophilia, isolated
from contaminated ﬂexible endoscopes, in single- and dual-species
bioﬁlms were studied.
Methods: The bioﬁlms were prepared in sterile tissue culture polystyrene
96-well microtiter plates. After 72 h incubation, single- and dual-species
bioﬁlms were treated for 10 min with the disinfectant at concentrations
conform the minimal bactericidal concentration (MBC) of the strains
tested and at 1% concentration, recommended for disinfection of ﬂexible
endoscopes by the company. In order to mimic the bioﬁlm formation and
to establish a possible regrowth of bioﬁlms inside the endoscope channels
after reprocessing, we developed the in vitro bioﬁlm model which
underwent the different steps of the disinfection and drying procedures
applied for reprocessing of ﬂexible endoscopes. The viability of the
bioﬁlm was quantiﬁed by using the tetrazolium salt (MTT) reduction
assay and by counting colony-forming yeasts and bacteria of the 10-fold
serial bioﬁlm dilutions on agar plates.
Results: A low MTT formazan signal was demonstrated in all single-
and dual-species bioﬁlms directly after 10 min treatment with the MBC
and 1% disinfectant. A total inhibition of microbial growth in all bioﬁlms
on agar plates occurred after treatment with 1% disinfectant. MBC
caused a marked inhibition of microbial growth of all bioﬁlms but not
a 100% bactericidal and fungicidal efﬁcacy. Regrowth of all bioﬁlms
occurred following 48 h incubation with trypticase soy broth directly
after treatment with the MBC and 1% disinfectant if the drying procedure
was skipped. No microbial growth and a low formazan signal was found
in all bioﬁlms after the disinfection procedure followed by drying for 1,
3 and 5 days.
Conclusion: Routine cleaning procedures do not remove bioﬁlm
reliably from endoscope channels. This study demonstrated the high
efﬁcacy of the drying procedure after the disinfection step against
yeasts and bacteria in all single- and dual-species bioﬁlms. Failure
of decontamination endoscopes can be explained by an invalid drying
procedure.
P1525 Infection control at a tertiary care centre: success depends
on available head count
T. Bregenzer °, C. Mohr, E. Bucheli, R. Laffer, M. Buehlmann (Aarau,
Langenthal, CH)
Background: Infection control (IC) teams frequently are understaffed.
Up to four 100%-jobs per 500 patient beds are recommended for IC.
Costs for IC teams can be calculated easily, whereas savings due to a
reduction in the nosocomial infection (NI) rate are difﬁcult to calculate.
Therefore, it is difﬁcult to quantify the returns of IC programs. Hand
hygiene (HH), preferably with 70% alcohol hand rub, is probably the
most effective measure to reduce NI. Repetitive HH instructions are
necessary to maintain high HH compliance rates but are personnel-
intensive and time-consuming.
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Methods: NI prevalence was recorded in our hospital in 1999, 2002–
2004, and 2006–2009 according to the Swiss Nosocomial Infection
Prevalence study protocol. All healthcare workers (HCW) were trained
in HH and repeated instructions were performed in 2005, 2007 and
annually thereafter (indications and procedure according to EN 1500).
HH compliance was measured according to the protocol of the Swiss
Hand Hygiene Campaign in 2005 and 2007–2009, and was reported to
HCW and hospital administration annually. Statistical analysis was done
by c2-test.
Results: During the pre-intervention period the median NI rate was
11.74%. Additional IC staff was recruited in 2005. The ﬁrst HH
instruction in 2005 reduced the NI rate by approximately 40%.
After temporary cessation of the HH instruction due to manpower
shortage in the IC team, the NI rate rose to previous levels. After
regular HH instruction was re-established, NI rates declined again and
stayed continuously below 8% (correlation coefﬁcient −0.83 (CI 95%
−0.29, −0.97), p = 0.0117).
Conclusion: NI rates at our institution correlate with HH compliance
and head count of the IC team. This intervention is only feasible with at
least 1.5 full time IC-staff member per 500 beds. To maintain a low rate
of NI, continuous HH promotion with repeated instructions is necessary.
Intervention Pre-intervention Established
period 1999 2002 2003 2004 2005 2006 2007 2008 2009
IC-staff/500 beds 0.89 0.95 0.92 0.93 1.39 0.46 1.86 1.74 2.19
HH training for all HCW ND ND ND ND + ND + ND +
HH promotion campaign ND ND ND ND + ND + + +
HH compliance (%) ND ND ND ND 59 79 ND 58 74
NI rate* 12.9 10.7 10.5 12.8 ND 6.8 12.1 7.2 7.9*
*Chi-square for trend: 4.356, p = 0.0369, ND: not done.
P1526 Policies for healthcare workers safety in European facilities
designed to deal with HIDs: EuroNHID data from a survey
of 44 isolation facilities in 14 European countries
G. Thomson, B. Bannister, H. Brodt, P. Brouqui, F.M. Fusco °,
R. Gottschalk, H.C. Maltezou, S. Schilling, V. Puro, G. Ippolito for
the European Network for Highly Infectious Diseases Group
Objective: Highly Infectious Diseases (HIDs, e.g. Viral Haemorrhagic
Fevers and SARS) are life-threatening, human-to-human transmissible
diseases that may cause Public Health emergencies, requiring special
procedures for their containment. To review health-care workers (HCWs)
safety policies, the European Network for Highly Infectious Diseases
project conducted, through a speciﬁcally developed checklist, a survey
in the facilities designed to deal with HIDs. Data from 44 facilities in
14 European Countries are described.
Methods: The checklist, including 7 items and 27 questions, was
developed through a “networking strategy”: a project partner with
speciﬁc expertise sent drafts for comments and amendments. Final
agreement had been reached during a meeting involving all partners.
Facilities to be surveyed were selected by national authorities, and are
those planned for giving care to patients affected by HIDs. In site surveys
were conducted from March to November 2009.
Results: Speciﬁc services for HCWs safety (e.g. occupational health
service, risk manager, infection control team) are operating on 24
hours-basis in almost all surveyed facilities, and general protocols
for the management of the main type of incidents are available, too.
Special insurance and special compensation for HCWs working with
HID patients are planned in 2 facilities only. Psychological aspects in
HCWs safety were explored: assessment of HCWs fears and concerns
about HID, such as assessment of safety climate and safety culture,
were performed in about 50% of surveyed facilities. HCWs working
with HIDs are not selected on the basis of a pshycological attitude.
A pshycological support for HCWs is available in 85% of facilities.
The availability of speciﬁc medical procedures on HCWs safety,
that include the monitoring of health status, policies for vaccination
and chemoprophylaxis, and post-exposure evaluation and management,
differs among participating countries, but generally these aspects are
appropriately considered and addressed. Only 25% of facilities have
special training requirements to be completed before working with HID
patients, and about 75% have speciﬁc programs of continuous education,
that include also infection control issues.
Conclusion: According to these data, administrative and medical aspects
are generally well addressed. Speciﬁc training programs should be
implemented, while the psychological aspects in HCWs safety are still
poorly attended.
P1527 Surveillance of nosocomial bloodstream infections and pneu-
monia in patients with haematopoetic cell transplantation
(ONKO-KISS data) − do patient numbers matter?
M. Dettenkofer °, R. Babikir, D. Luft, P. Gastmeier, W. Kern,
A.F. Widmer, H. Bertz and the ONKO-KISS Study Group
Objectives: For surveillance of nosocomial bloodstream infections
(BSI) and pneumonia during neutropenia in adult patients undergoing
hematopoetic cell transplantation (HCT), an ongoing multicenter
surveillance project was initiated by the German National Reference
Centre for Surveillance of Nosocomial Infections in 2000 (ONKO-
KISS). Differences between centers with regard to the number of patients
treated are analysed.
Methods: Nosocomial infections are identiﬁed using CDC deﬁnitions
for laboratory-conﬁrmed BSI and modiﬁed criteria for pneumonia in
neutropenic patients [for detailed information see: CID 2005; 40: 926, or
in German language: http://www.nrz-hygiene.de/surveillance/onko.htm].
In addition infection rates were compared between 15 continuously
participating centers (2004–2008) divided in two subgroups with either
>300 patients treated/5 years (subgroup a) or <300 patients treated/5
years (subgroup b).
Results: Over the 60-month period from July 2004 up to June
2009 23 centers participated. Altogether 5,853 patients with 86,340
neutropenic days were investigated. Of these, 3,391 (58%) had undergone
allogeneic and 2,462 (42%) autologous HCT. The mean length of
neutropenia was 14.8 days (9.0 d after autologous and 18.9 d after
allogeneic transplantation). In total, 904 bloodstream infections and
490 cases of pneumonia were identiﬁed. Incidence densities for
allogeneic transplantation were 8.7 BSI/1,000 neutropenic days (ND)
and for pneumonia 5.9/1,000 NDs (for autologous transplantation:
15.5/5.1). Following allogeneic transplantation, 16.6 BSI/100 patients
and 11.1 cases of pneumonia/100 pts. occurred whereas following
autologous transplantation 13.9 cases of BSI/100 pts. and 4.6 cases of
pneumonia/100 pts. were observed. The main pathogens associated with
BSI were coagulase-negative staphylococci (42.3%). For results of the
subgroup analysis see Table.
Conclusion: The ongoing ONKO-KISS project adds to the improvement
of quality of care in HCT-patients by providing sound reference data on
the occurrence of BSI and pneumonia during neutropenia. Comparison
of centers with regard to the numbers of patients treated revealed a
higher BSI rate in centers with smaller patient numbers. The difference
was notably high in patients undergoing autologous transplantation.
Results within subgroups
a) 7 centers transplanting
>300 patients/5 years
Range 45–267
b) 8 centers transplanting
<300 patients/5 years
Range 341–778
Type of transplantation Allogeneic Autologous Allogeneic Autologous
Patients 2,297 1,147 621 724
Neutropenic days 4,343 10,978 13,183 6,375
Mean length of neutropenia (days) 18.9 9.6 21.2 8.8
BSI incidence density 8.3 12.9 9.2 17.9
Pneumonia incidence density 5.8 5.2 5.7 5.5
BSI cases per 100 patients 15.7 12.4 19.5 15.7
Pneumonia cases per 100 patients 11.0 5.0 12.1 4.8
Incidence densities per 1,000 neutropenic days, BSI: Bloodstream infection.
P1528 Effect of different antimicrobial agents on the antibacterial
activity of soap formulations and their acceptability by
healthcare staff
O. Lozhkina °, E. Vorobyeva, A. Savinov (St. Petersburg, RU)
Objectives: The aim of the present work was to examine how different
antimicrobial agents added to the same soap base effect the antibacterial
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properties of soap formulations and their acceptance by personnel of
healthcare facilities.
Methods: We have prepared six antimicrobial soap compositions
having the same base (anionic surfactants and emollients) and
different commercially available antimicrobial agents: (1) triclosan,
(2) methylisothiazolinone and methylisothiazoline, (3) imidazolidinyl
urea and parabens, (4) diazolidinyl urea and parabens, (5) phenoxy-
ethanol and parabens, (6) methylisothiazolinone, methylisothiazoline,
phenoxyethanol and parabens, which were introduced into the base soap
at concentrations recommended by their producers. The antimicrobial
activity of the soaps was evaluated using a volunteer method according
to the European Standard EN 1500 and in vitro tube dilution method.
Afterwards, we studied the acceptance of the formulations with a
bacterial reduction factor 3 log10 by 98 healthcare workers in 5
hospitals in St. Petersburg, examining such factors as skin irritating and
dryness, smell and washing off quickness.
Results: The in vitro study has shown that the compositions 1, 4 and
6 produced higher log10 reduction in colony forming units of tested
organisms Escherichia coli and Staphylococcus aureus (3.5–5.58) than
did samples 2, 3 and 5 (0.29−4.4). The formulations 1, 4, and 6
demonstrated better antimicrobial activity in respect to Gram-positive
than Gram-negative bacteria. In the test using volunteer method, the
results seemed to be the same. The formulations 1, 4 and 6 showed better
reduction factor in colony forming units (3.2−3.4) than the compositions
2, 3 and 5 (2.4−2.7). The investigations of the acceptance of the
formulations 1, 4 and 6 by healthcare facilities personnel revealed that
the samples 1 and 6 caused moderate skin irritation and dryness at
frequent use, the composition 6 was also poorly accepted because of
the speciﬁc smell, and only the formulation 4 met compliance with the
requirements of the staff.
Conclusions: The antibacterial soaps 1, 4 and 6 provided a greater
bacterial reduction than the plain soap, but only the soap 4 was well
accepted by healthcare workers. So, when choosing antimicrobial agents
for soap, producers should pay a particular attention not only to their
biocidal activity but also to skin irritation effect because it is a key factor
that inﬂuences acceptance and ultimate usage.
P1529 Fungal spores in the air of a hospital environment: seasonal
variability of baseline data
E. Bucheli °, M. Reichmuth, M. Oberle, C. Ottiger, R. Laffer,
H. Fankhauser (Aarau, Lucerne, Langenthal, CH)
Background: The soil of plants is a source of mould fungus spores
(MFS). Cases have been described in which human pulmonary mould
infections in neutropenic patients had their source in plant soil. There
are only few studies comparing air MFS count of an environment with
and without plants. Therefore, when it was decided to install plants in
the staircase of the building of our medical department (including a 4
bed protective haematologic isolation unit) we started measuring MFS
concentration in the air during one year before the installation. It is our
intention to compare air MFS count in a hospital environment with and
without plants. Baseline data will be presented from the pre-installation
era.
Methods: During 12 months (September 2008 − August 2009, pre-
installation era), fungal spore count in the air was measured twice
weekly at 6 standardized locations by sampling 0.5 m3 air (MBV
mas100 Microbiological air sampler) directly over a selective culture
medium (sabouraud-agar). Air temperature and humidity were recorded
in addition. The plates were incubated for pathogenic (thermo-tolerant)
moulds at 35ºC for 2 days and at 28ºC for 4 days. Growing
moulds were microscopically identiﬁed to genus level (Aspergillus,
Mucor/Rhizopus, Cladosporium, Penicillium, Alternaria, Fusarium,
Trichoderma, Scopulariopsis, Paecilomyces, Chrysonilia sitophila).
Results: Between December and May (relative humidity (RH) of 44.8%,
SD±5.1) the mean concentration of MFS at 28ºC was 11.7/m3 (SD±2.1),
during the remaining months (RH of 56.8%, SD±6.1), it was 101.7/m3
(SD±61.9). The MFS concentration on plates incubated at 35ºC did not
show seasonal ﬂuctuation (mean 3.3/m3, SD±1.2). A peak, mainly of
the concentration of Aspergillus spores, up to 110/m3, was documented
when Christmas trees were removed in early January 2009.
Conclusions: Baseline count of pathogenic MFS is low and evenly
distributed within the building. MFS count on culture plates correlates
with humidity and shows seasonal variability. Dust dispersing activities
may dramatically rise the concentration of MFS. These baseline data
will be compared with results from the second interval (post-installation
era) after the installation of the plants in one year.
P1530 Effect of relative humidity on the survival of airborne
opportunistic Gram-negative pathogens
P.J. Airey °, C.B. Beggs, K.G. Kerr, A.M. Snelling (Bradford, Harrogate,
UK)
Objectives: There is increasing evidence that the hospital environment
plays a major role in nosocomial infections. Bacteria can be disseminated
to both patients and surfaces via the air, but it is not clear how
readily different opportunistic pathogens persist in an airborne state. We
investigated the ability of 4 such Gram negative species to survive in air
under conditions typical of a ward environment, and looked at the effect
of changing relative humidity (RH) as a potential control measure.
Methods: Representative isolates of Acinetobacter baumannii, Steno-
trophomonas maltophilia, Burkholderia cepacia and Pseudomonas
aeruginosa were nebulised (in water) into a 72m3 aerobiological
chamber, in which temperature, relative humidity (RH) and ventilation
rate was controlled. Air was sampled at 10−15 min intervals using a
6-stage Anderson sampler, and surviving bacteria recorded as cfu/m3 of
room air. Firstly survival rates under ambient (50% RH, 23ºC) conditions
were determined in a series of decay-curve experiments. Then, under
steady-state conditions, the effects of RH under two ramping humidity
proﬁles were investigated. Bacteria were nebulised into the chamber
for 240 min with RH held at 30% (LOW) for the ﬁrst 80 min, 50%
(AMBIENT) for the central third (80–160 min) and 70% (HIGH) for the
ﬁnal 80 minute phase (160–240 min). In repeat experiments the humidity
proﬁle was reversed (i.e. HIGH-AMBIENT-LOW for consecutive 80min
periods).
Results: Bacteria were nebulised into the chamber to a concentration of
~104 cfu/m3. There was an immediate 3-log decrease in counts observed
with each species on the decay curves. However, viable cells were still
recovered from the air after 90mins, for all species except P. aeruginosa.
In the steady-state experiments (bacterial numbers maintained at an input
of ~104 cfu/m3) the number of cfus recovered was 1−2 log higher at 70%
RH than 50% RH. Few, or in most cases no, cfu/m3 were recovered in the
dry, 30% RH phases for three of the species. In contrast, larger numbers
of B. cepacia were always recovered (~100 cfu/m3) at low RH.
Conclusion: Low levels of three of these Gram negative nosocomial
pathogens can survive in an airborne state for at least 90 min, which
would facilitate their dissemination around a ward space. These results
suggest that, by reducing the RH, even for a short period, such
dissemination could be limited, thereby helping to reduce cross-infection
of patients and contamination of surfaces.
P1531 Presence of pathogens on doctors’ neckties
B. McGovern °, E. Doyle, S.F. FitzGerald, L. Fenelon (Dublin, IE)
Objectives: To assess whether potential pathogens − Staphylocococcus
aureus, vancomycin-resistant enterococci (VRE) and Gram-negative
bacilli (GNB) − were present on the neckties of the male doctor
population at an Irish tertiary care hospital.
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Methods: Each participant completed an anonymous questionnaire
detailing their grade, speciality, frequency of laundering their tie and
their preference for wearing a tie at work. The front portion of the
necktie was sampled using a Columbia blood agar contact plate which
was then incubated in air at 37ºC. Bacterial growth was quantiﬁed and
organisms identiﬁed after 48 hours.
Results: 95 doctors participated. 55% of ties belonged to doctors
working in the medical specialities, 32% in surgical specialities and
the remainder in other specialities e.g. radiology. 61% of the total male
NCHD population working in the hospital at the time were sampled.
50% of ties sampled cultured >50 colony-forming units (cfu) of bacteria
and 18% cultured >100cfu. Skin commensals such as coagulase-negative
staphylococci, micrococcus and diptheroids were found on all ties
sampled. In addition, Staphylococcus aureus was isolated from 10 ties
(12%); 8 of which were resistant to methicillin (8.5% of ties were
MRSA-colonized). GNB were isolated from 12% of ties. VRE was not
isolated. Potential pathogens were present in low numbers, 2−10cfu per
plate.
55% of participants had never laundered their tie. 80% stated that they
would have no objection to abandoning the tie as part of their work
attire. Doctors who stated they would prefer to wear a tie at work were
not signiﬁcantly more likely to have laundered their tie (x2=0.618, dF=1,
p = 0.4097). The magnitude of growth did not correlate with laundering
of ties. There was no correlation between the presence of pathogens and
the laundering of ties (x2=2.244, dF=1, p = 0.1341). No grade of staff
was more likely to have laundered their tie.
Conclusion: 1 in 5 neckties worn by doctors were colonized with
potential pathogens. Almost 1 in 10 ties sampled were found to be
colonized with MRSA (8.4%). 4 out of 5 doctors would be happy not
to wear a tie to work. The presence of skin ﬂora on all ties sampled
suggests that they are being handled regularly. This implies that neckties
worn by doctors may act as a potential reservoir of organisms which
could be harmful to patients if transmitted.
P1532 Implementing peripheral vascular catheter care bundle in
a tertiary referral hospital in Dublin, Ireland
M.R. Finan °, A. Fetalento, J. Walsh, V. Caffrey, A. Morris, E. Smyth,
F. Fitzpatrick (Dublin, IE)
Background: The 2006 hospital infection society survey of health care
associated infection found that two thirds of patients in this hospital had
a peripheral vascular catheter (PVC) in situ.
An increased incidence of PVC-related Staphylococcus aureus bacter-
aemia was noted in this institution since 2006. Compliance with hospital
policy for documentation of PVC is poor. In August 2009, the national
PVC care bundle was implemented in two medical and one surgical ward.
The aim was to improve PVC documentation, increase staff awareness
and reduce PVC-associated infections.
Methods: Initial introduction and educational sessions on the PVC
bundle were carried out with ward nursing staff. Compliance with
the care bundle was assessed initially on a daily basis for two weeks
and weekly thereafter for ten weeks. The following were assessed;
were PVC’s in situ still required, was there evidence of extravasation
or inﬂammation, maintenance of dressing, the duration of insertion,
and whether hand hygiene was performed with all PVC procedures.
Immediate feedback was given to staff in regards to non-compliance
and advice on the appropriate action.
Results: A mean of 60 patients were assessed and 18−35 peripheral
lines reviewed each time PVC care bundle compliance was audited in
the 3 wards. Compliance was 86% on the medical wards (range 55–
100%) and 72% on the surgical ward (range 50–100%). The target of
100% compliance was reached on 10 occasions and 3 occasions on the
medical and surgical wards respectively. The failure to comply occurred
with PVCs remaining in situ, when not clinically indicated, duration
of use in excess of 72 hours and poor maintenance of PVC dressings.
There were no PVC-related S. aureus infections during the study period,
in contrast to 3 episodes in the previous six months of this year.
Conclusion: PVC care bundle is basic best practice to prevent
PVC-related infections. Major non-compliances have been identiﬁed.
Ownership by ward staff and immediate feedback and education to staff
is essential for success. This is reﬂected in compliance reaching 100%
on both wards when PVCs were audited and feedback given daily, rather
than weekly. While the study period was short, it is encouraging that no
PVC-related bacteraemia occurred by comparison with the period prior
to care bundle introduction. We hope to implement the PVC care bundles
in all wards with the ward staff taking ownership of auditing compliance
in order to maintain optimal care.
P1533 Shedding of enterococci and environment contamination in
patients with diarrhoea
M. Ro¨ttig, E-M. Zeitlberger, R. Bliem, C. Sebesta, O. Janata ° (Vienna,
AT)
Objectives: Vancomycin-resistant Enterococci (VRE) are emerging
pathogens especially in hospitalized patients. Consumption of glycopep-
tides and transmission from patient to patient are the major risk factors
for the acquisition of these pathogens. Enterococci (EC) are part of
the human gastrointestinal ﬂora; they are shed with the stool and can
contaminate the patient bedside environment. Aim of our study was to
determine whether patients with nosocomial diarrhea shed EC or not
and what are the risk factors for dissemination.
Methods: In 2009 we quantiﬁed the EC-load in the bedside environment
of 81 patients using sedimentation-plates (2 plates per patients’ bed-
surroundings) with selective media. After 2 hours exposure time the
plates were incubated at 37ºC for 5 days. Colonies were counted and
deﬁned as colony forming units (cfu). Patient data collected included
patient mobility, duration of hospitalization and the presence or absence
of diarrhea. Diarrhoea was deﬁned as nosocomial if symptoms started
later then 72 hours after admission.
Results: Sedimentation-plates of 46 patients with diarrhea and 35
controls without diarrhoea were investigated. Patients with diarrhea
spread EC more often and to a larger degree than the controls. Given
that a baseline level of EC contamination is to be expected, we deﬁned
a threshold level of 2 cfu for the control. We observed at least 2 cfu per
plate in 21 surroundings of 46 patients with diarrhoea (46%) but only in 7
of 35 patients without (20%). In addressing the issue of patient mobility,
we observed EC with 57% of the bedridden non-mobile patients with
diarrhea, and 27% of the patients with diarrhea were mobile and could
use the restroom (toilet), whereas partially mobile patients indicated a
value 43%.Regarding the control-group EC grew on 36% of the plates
positioned around bedridden patients and only in 17% around mobile
patients. It must be pointed out that 4 of 7 EC-positive patients without
diarrhoea were located next to EC-positive Patients with diarrhea.
Conclusion: Using sedimentation-plates positioned around the beds of
patients with or without diarrhea we found that the spread of EC into
the immediate bedside environment was markedly higher in patients with
diarrhea, especially if they were bedridden, mobility being a signiﬁcant
factor. Furthermore, the environmental contamination around patients
without diarrhea was clearly higher in rooms also occupied by patients
with diarrhea.
P1534 Nursing home-associated infections in France: Delphi
consensus guidelines for prevention
G. Gavazzi °, K. Chami, R. Derbal, B. De Wazie`res, B. Lejeune,
F. Piette, J. Hajjar, M. Rothan-Tondeur for the Observatoire du Risque
Infectieux en Geriatrie Association (ORIG)
Objectives: Because the prevalence of nursing home associated Infection
(NHAI) is high in France (14.5%) and because infection control
measures for hospital can not be applied in nursing home (NH),
we elaborated a survey aiming to establish consensus guidelines for
prevention of NHAI for elderly living in French NH.
Methods: A nationwide survey using a two-round modiﬁed Delphi
procedure (Rand Corporation) has been performed by the “Observatoire
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du Risque Infectieux en Ge´riatrie”. An investigative group of 5
specialists in the ﬁeld of infectious disease, geriatrics and infection
control conducted a comprehensive literature search and review based
on English or French published practice guidelines, systematic review
and articles (or abstracts when articles were not available) on the topic
of infection prevention in Long-term care Facilities, nursing homes or
hospitals. The literature search has been fulﬁlled by 4 research analysts.
The literature search has been examined by 25 specialists who compiled
a preliminary list of guidelines. Using a modiﬁed Delphi survey
online instrument developed by INSERM UMR-S 707 “Epidemiology,
Information Systems, Modelling” and modiﬁed by the Geriatric Infection
Risk Monitoring Organization (ORIG), 80 experts of all relevant medical
specialities in the ﬁeld of prevention and infection control or geriatrics
and randomly selected medical coordinator in nursing homes, rated
their agreement with each of these 301 guidelines using a 9-point
scale (1=strongly disagree to 9=strongly agree). Recommendation-
speciﬁc median were estimated. The consensus was deﬁned if the
recommendation was rated by at least 90% of the experts and if the
median score was greater than 7.
Results: The response rate was 93% for the ﬁrst round, and 99%
for the second round. The expert panel reached consensus on 264
recommendations and 37 recommendations were rejected. The different
relevant topics were organisational procedures (outbreak, surveillance),
basic hygiene measures, antibiotic policies, general measures linked to
patient (vaccination) and multiltidrug resistant pathogens. The difference
between ﬁrst and second round emphasizes the issue of implementation
in NH.
Conclusions: The guidelines for NHAI prevention in French Nursing
Homes will be published nationwide. A cluster-randomized controlled
trial has been launched with the purpose of evaluating the effectiveness
of an infection prevention program, using these consensus guidelines.
MRSA control
P1535 Integrated MRSA management − a novel approach
combining in-house and outpatient MRSA decolonization
A. Stroh, B. Jahn ° (Wiesbaden, DE)
Objectives: Eradication of methicilline resistant Staphylococcus aureus
(MRSA) represents a key element to abolish the risk of subsequent
MRSA infection. Therefore, decolonization to eradicate MRSA is
recommended. In many patients, length of stay (LOS) is to short to
successfully eradicate MRSA in the hospital setting. To optimize and
economize the MRSA decolonization related input, the concept of an
Integrated MRSA Management (IMM) was developed. IMM adapts
the principles of in house decolonization schemes to the outpatient
setting and MRSA decolonization is continued immediately after hospital
discharge.
Material and Methods: All elements of MRSA decolonization
including treatment of nose, throat, skin, hair and wounds were adapted
to be performed by a specially trained nursing team or by the patient
himself. Within 72 h after discharge and according to the patient’s
situation and colonization state, requirements regarding nursing and
decolonization, cleaning and disinfection of patient surroundings as well
as domestic services were evaluated. An IMM decolonization plan was
set up and decolonization, based on mupirocine for topical antibiotic
treatment of the anterior nares and polyhexanide as antiseptic compound
for body washings, mucosa and wound care was performed, concomitant
with the supporting procedures. The colonization state was assessed
by microbiological controls. Communication and all activities were
documented by pda.
Results: Within IMM in 73% of patients without skin alteration MRSA
eradication was successful according to german national guide lines,
compared to 34% success rate in patients bearing this risk factor (e.g.
wounds, entry sites). Overall MRSA eradication success was 47%.
Conclusion: The concept of IMM allows complete MRSA decoloniza-
tion even with short LOS. In perspective, IMM will minimize patients’
risk of MRSA infection and decrease the MRSA load for hospitals as
former MRSA patients can be readmitted as MRSA negative. The needs
of caMRSA carriers in the outpatient setting can also be addressed within
IMM.
P1536 MRSA screening in cardiac intensive care − the Achilles’
heel: a clinical audit and survey of outcomes at Lancashire
cardiac centre
S. Summers, M. Przybylo °, M. Purohit, A. Guleri (Blackpool, UK)
Objectives: MRSA PCR screening of patients on admission to cardiac
intensive care and then weekly thereafter (by culture) for long stay
patients was introduced in Apr08 at Lancashire cardiac centre (LCC),
Blackpool Victoria Hospital (BVH). Rapid detection of MRSA carriage
permits timely decisions on optimal treatment, isolationbio-burden
reduction, reducing the potential for cross transmissionself infections and
cost containment. All patients for elective cardiac surgery get screened
for MRSA in preassessment clinic (PAC). This clinical audit was
performed following a case of PAC MRSA screen negative, postoperative
(POp) MRSA PCR positive developing post-op MRSA infection. The
results of this audit were used to inform the HAI containment programme
for LCC.
Methods: Case notes data extraction & root cause analysis on cardiac
patients identiﬁed as MRSA screen (PAC) culture negative and MRSA
PCR (POp) positive [MCNPP] between April 08 − 09 from pathology
data system. Review of literature on antibiotic prophylaxis (cardiac
surgery) & MRSA and trust MRSA policy & antibiotic formulary.
Results: Between April 08−09, 15 MCNPP patients age 56−84yrs were
identiﬁed. 80% (12/15) were males; length of stay 5−29 d. Cardiac
surgeries included coronary artery bypass graft (CABG) 60% (9/15);
CABG & aortic valve replacement (AVR) 20% (3/15); 7% (1/15)
each CABG revision, AVR and decortication. 20% (3/15) were PAC
screened negative >12 weeks pre-op while 80% (12/15) 3-weeks
preop. All MCNPP patients received topical bio-burden reducing regime
(TBRR) within 24-hrs of MRSA PCR result. The cardiac surgeons
vary in choice & duration of antibiotic prophylaxis (cefuroxime ±
glycopeptides). Hence 47% (7/15) managed to receive glycopeptides at
induction. 73% (11/15) had no documented healthcare contacts between
PAC screen and operation, while remaining included occupational
(nurse), angiograms, cataract operation & day case. POp infections
included pneumonia (13.3%); wound infection (6.7%) and none (80%).
Discussion: BVH won HCAI innovation technology award 2009 (78%
reduction in MRSA using PCR for emergency admissions). In this
audit MRSAPCR picked up 100% carriage & TBRR was offered
on same postop day. 20% POp infections were seen in this cluster.
The recommendations from this clinical audit included 3-week validity
of PAC MRSA negative screen; considering a MSSA/MRSA PCR
preop screening; introduction of consistent evidence based antibiotic
prophylaxis policy; Details to be presented.
P1537 MRSA PCR screening: is it still a cost-effective option
during times of ﬁnancial turbulence in NHS hospitals?
A. Guleri, B. Lunt, J. Carter Lyndsay °, N. Harper, R. Palmer, A. Jones
(Blackpool, Malton, UK)
Background: Rapid and accurate identiﬁcation of meticillin-resistant
Staphylococcus aureus (MRSA) in hospital admissions is essential for
timely decisions on optimal treatment, isolation/bio-burden reduction,
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reducing the potential for cross transmission/self acquisition of
healthcare-associated infections (HCAI) and cost containment. The NHS
is expected to face a £15bn budget shortfall due to effects of recession.
Here we present the cost effectiveness of the second year of a rapid
MRSA screening programme which was implemented at Blackpool
Victoria Hospital and the economic advantages of continuing the service
despite a 15% cut in overall budget.
Methods: The clinico-economic re-evaluation included various aspects
including cost analyses (total cost of the service [equipment, con-
sumables, salaries), estimated savings from reduction in total MRSA
infections including bacteraemia, savings from collateral beneﬁts of the
associated MRSA programme). Clinical implications, patient and staff
feedback were also collected.
Results: In the ﬁrst year (08−09) a 78% reduction (9 bacteraemia against
40 in 07−08) was recorded, 45% (4/9) of which were HCAIs. In the
second year (09−10) 5 bacteraemias were recorded between Apr − Nov
09, of which 20% (1/5) were post-48hrs (Fig 1). The cost of service over
18 mths was approx £591,332. Estimated savings from the overall 30%
reduction in all MRSA infections over the previous 18 mths ranged from
£806,000 (using £2,000/infection including bacteraemia) to £2,014,597
(using £4,999/infection including bacteraemia) models. A 51% reduction
in glycopeptide unit-days and spend was also recorded from £251,168
(06−07) to £124,060 (08−09). A total of 31,867 tests were performed
and 96% of patients could be re-assured of their negative MRSA status
within an average 5hr turn-around-time.
Conclusions: Rapidly available MRSA results are routinely used to
complement clinical decision making and optimise treatment in our
hospital. The cost effectiveness of a HCAI programme is proportional to
its success. The key to success in this model was the teamwork between
CEO, ICT & clinical teams (med & nursing)in the hospital. The body
of evidence which supports the efﬁcacy of rapid screening is growing.
A sound business case and return on investment for the use of rapid
diagnostic methods in our hospital can be made. These technologies also
enhance clinical quality, improve patient safety and reduce the overall
cost of MRSA infections.
P1538 Natural history of MRSA colonization − a 4-year experience
from southern Sweden
A.K. Larsson °, E. Gustafsson, H. Ringberg, E. Melander (Helsingborg,
Malmo¨, SE)
Objective: The natural history of MRSA colonization is not well
studied and the duration of colonization varies among existing studies.
Most studies deals with healthcare associated MRSA and carriage after
hospitalization. In Ska˚ne County, southern Sweden, all known MRSA
cases have been followed up the same way since 2003 enabling a good
base for studying the natural history of MRSA colonization.
Methods: All notiﬁed MRSA cases in Ska˚ne County are followed with
cultures from the nares, throat, perineum and possible skin lesions
as long as they are colonized and at least for a year with at least
ﬁve consecutive negative cultures. They are examined for risk factors.
Contact tracing among household contacts and possible health care
contacts is performed.
Results: 442 of the 578 notiﬁed MRSA cases during 2003–2006
were correctly followed up and included. 91% cleared their MRSA
colonization during the followup-time. The median duration of MRSA
colonization was 4.6 months. Having household contacts with MRSA,
young age, colonization with spa-type t002 or colonization in more
than 2 locations was signiﬁcantly associated with a longer duration of
colonization. Receiving treatment for a clinical infection (as compared
to asymptomatic carriage) and spa-type t355 was signiﬁcantly associated
with shorter duration of colonization.
Conclusions: The study of our MRSA cohort, a mix of healthcare- and
community associated MRSA cases, indicates that MRSA coloniazation
can be cleared in less than 6 months and that MRSA cases can be
deﬁned as “MRSA negative” with a thorough follow-up with consecutive
negative cultures, no MRSA among house hold contacts and absence of
risk factors. This may have implications for the future handling of MRSA
cases in our country.
P1539 MRSA admission screening − much ado about nothing?
A. Witteck °, G. Rettenmund, M. Schlegel (St. Gallen, CH)
Objectives: In 2007, the number of patients with newly detected MRSA
doubled at the cantonal hospital St. Gallen (MRSA rate 2.5% in isolates).
In order to early diagnose MRSA and prevent its spreading within
the hospital, new guidelines for screening/preemptive isolation were
implemented. Aim of this surveillance was to evaluate these guidelines
and to compare MRSA patients detected by admission screening with
those diagnosed by clinically indicated cultures during hospitalization.
Methods: The surveillance was performed from 04/2008 to 03/2009 in
patients admitted to the tertiary-care hospital St. Gallen and 10 afﬁliated
public hospitals in Eastern Switzerland. All MRSA admission screenings
in accordance with the guidelines and all MRSA newly detected by
clinical sample were included. The screening guidelines considered
epidemiological factors (stay in a foreign hospital, a Swiss hospital
with known high MRSA prevalence or a chronic care facility during
the past six months) and personal risk factors (wound, tracheostoma,
urinary catheter and IVDU).
The MRSA admission screening consisted of nasal, throat and
axillary/inguinal swabs as well as wound swabs, urine in the case
of urinary catheter and respiratory secretion provided the patient was
intubated or a tracheostoma present.
Results: During the one-year observation period, 161 patients were
screened for MRSA (111 in St. Gallen, 50 in the afﬁliated hospitals).
Only 6/161 (3.7%) MRSA were detected by screening (number needed
to screen: 27). During the same time period 21 patients were diagnosed
by clinically indicated samples. Patient characteristics are shown in the
table.
MRSA screening MRSA detection
Negative
(n = 155)
Positive
(n = 6)
by clinical sample
(n = 21)
Age (mean, 95%-CI) 61.3±2.9 60.8±13.3 56.1±8.6
Sex, % female 43.2 (67/155) 33.3 (2/6) 57.1 (12/21)
Personal RF %
Skin leason 39.2 (47/120) 83.3 (5/6)$ 80.9 (17/21)
Tracheostoma 10.5 (13/124) 0 (0/6) 5.3 (1/19)
Urine catheter 32.2 (38/118) 33.3 (2/6) 21.1 (4/19)
PEG 4.8 (6/124) 0 (0/6) 0 (0/19)
IVDU 3.9 (5/127) 0 (0/6) 0 (0/18)
Immunosuppression 1.7 (2/118) 16.7 (1/6)§ 11.1 (2/18)
Dialysis 9.5 (12/126) 0 (0/6) 5.0 (1/20)
Diabetes 13.6 (16/118) 0 (0/6) 26.3 (5/19)
Epidemiological RF %
Foreign hospital 65.8 (75/114) 83.3 (5/6) 0 (0/18)*
CH high prevalence hospital 9.5 (11/116) 0 (0/6) 0 (0/18)
Chronic care facility 20.7 (25/121) 16.7 (1/6) 9.5 (2/21)
CI: Conﬁdence Interval, RF: Risk factor, PEG: Percutaneous endoscopic
gastrostomy, IVDU: Intravenous drug use, CH: Switzerland.
*<0.001, Screening vs clinical pos. $p = 0.08, §p = 0.13, Screening neg vs pos.
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All MRSA-positive patients would have been detected either by
nasopharyngeal or wound swabs (except by one with only positive urine).
In the patients with positive MRSA screen, all swabs of axilla/inguina
were negative.
Conclusions: In our setting with low MRSA-prevalence, the majority
(77.8%) of patients with newly detected MRSA was diagnosed by
clinically indicated samples. Several well-accepted risk factors seem
not to be relevant (tracheostoma, IVDU, dialysis). Wounds and
immunosuppression tend to be more frequent in positive versus negative
screened patients. Screening of axilla/inguina did not increase the
sensitivity of the screening (no positive results).
However, due to small numbers (probably because of not performed, but
indicated screenings) results must be considered with caution and may
differ in other settings.
P1540 Effect of search-and-destroy policy on Staphylococcus aureus
bacteraemia and overall methicillin-resistant S. aureus
rates: experience from neurosurgery clinic of a tertiary-care
educational university hospital with endemic MRSA
O. Sipahi °, B. Arda, A. Bayram, S. Aydemir, T. Turhan, F. Cilli,
H. Sipahi, S. Ulusoy (Izmir, TR)
Objectives: S. aureus is one of the most important etiologic agents in
nosocomial infections. Search&destroy policy is effective for preventing
S. aureus infections in settings with low MRSA rates. The aim of this
study was to evaluate the effect of search&destroy policy on S. aureus
bacteremia, meningitis and overall MRSA rates in neurosurgery clinic
of a developing world tertiary-care educational university hospital where
MRSA is endemic.
Method: This study was performed at a tertiary care general teaching
hospital with an active neurosurgery ward with 78 beds, 16 of which
are in intensive care unit. After 1 July 2008, patients admitting to
neurosurgery intensive care unit of our setting were sampled for
nasal S. aureus carriage. Bacteriologic culture and identiﬁcation of
S. aureus from any sample was performed with conventional methods.
Antibacterial susceptibility testing was performed with disk-diffusion
test according to CLSI criteria. Cases who had nasal S. aureus carriage
were treated with nasal bacitracin ointment (three times a day, for three
days, control culture performed on day 5−6). Cases with MRSA carriage
were put under contact isolation. Resistance patterns of the samples, total
number of patients and patient days in the overall neurosurgery clinic
(including both ICU beds and normal beds) were retrieved from hospital
records database. The preintervention period was considered as January
2007–2008 June and post intervention period was considered as July
2008-October 2009.
Results: Overall S. aureus bacteremia rate decreased signiﬁcantly
(20/3651 cases and 0.41/1000 patient days vs 6/2959 and 0.2/1000
patient days, p = 0.02). Overall S. aureus meningitis rate did not change
signiﬁcantly (4/3651 vs 8/2959, p< 0.05). MRSA rate in any clinical
sample (only one sample from each case) did not change signiﬁcantly
(55/99 versus 38/61 p> 0.05).
Conclusion: Despite the fact that the search&destroy policy was
performed in only ICU cases, overall bacteremia rate decreased
signiﬁcantly. However overall MRSA rate did not change. Our ﬁndings
suggest that this strategy may be beneﬁcial in resource-limited countries
where bacteremia is a signiﬁcant problem.
P1541 Regional surveillance of MRSA and benchmarking in the
EUREGIO MRSA net-project
A. Jurke °, R. Ko¨ck, I. Daniels-Haardt, A.W. Friedrich (Mu¨nster, DE)
Objectives: MRSA is a major cause of Healthcare-associated infections
(HCAI). Since MRSA can be disseminated between hospitals serving
one regional patient catchment area, successful prevention and control
of MRSA-HCAI requires concerted efforts. Therefore, regional bench-
marking of hospital MRSA surveillance data might open up opportunities
to reduce infection rates.
Methods: 35 hospitals (92% of all hospitals) covering 10.851 patient
beds and comprising 343.000 admissions in 2008 in the German
part of the EUREGIO Twente/Mu¨nsterland have established a network
for combating MRSA infections. In 2007 they have agreed upon a
synchronized strategy for screening of risk patients at admission and are
reporting MRSA data. In 2007 and 2008 the following indicators were
assessed: rate of nasal swabs/100 patients admitted, MRSA incidence,
nosocomial MRSA incidence density, nosocomial MRSA-cases/1,000
MRSA days and the number of MRSA blood cultures. Wilcoxon signed-
rank test was used.
Results: In average, the rate of screening cultures/100 patients in
the 35 hospitals was 22.2% in 2008 (Q(25)=8.2%, Median 17.0%,
Q(75)=39.2%. There was a signiﬁcant (p< 0.05) increase of this rate
from 2007 to 2008. Alltogether 88,464 patient were screened in 2008.
The MRSA incidence in 2008 was in average 1.47 MRSA cases per
100 admissions (Q(25)=0.68, Median = 1.03, Q(75)=1.40), which also
increased signiﬁcantly (p< 0.05) since 2007. The number of MRSA-
positive blood cultures (MRSAB) decreased from 2007 (2.8 per 100,000
patient days) to 2008 (1.32 per 100,000 patient days).
The mean nosocomial MRSA incidence density in 2008 was 0.19 noso-
comial MRSA-cases per 1,000 patient days (Q(25) = 0.02, Median = 0.16,
Q(75) = 0.24) and remained stable from 2007 to 2008. In 2008, there
were an average of 8.6 nosocomial MRSA-cases per 1,000 MRSA-
days (Q(25) = 4.3, Median = 8.7, Q(75) = 12.4) with a slight decrease
(p> 0.05) compared to 2007.
Conclusion: Successful adherence to the synchronized regional screen-
ing strategy was measurable by continued increased performance of
screening in hospitals. The enhanced screening of risk patients resulted
in a considerably higher MRSA-incidence, since an increased number
of carriers were detected at admission. Nevertheless, the number of
MRSAB decreased in the study period. All surveillance data is given
as feedback to the regional hospitals and health authorities. This should
encourage regional benchmarking and improve prevention and control
of MRSA HCAI in the long run.
P1542 Is it worthwhile to control methicillin-resistant
Staphylococcus aureus in a highly endemic country?
A 9-year experience in a Portuguese hospital
M.L. Gonc¸alves °, A. Costa, J. Narciso, L. Afonso, C. Hipolito, O. Neto,
A.B. Correia, F. Fernandes, A. Canudo, A. Santos Costa, P. Pedro,
C. Gasparinho, F. Ferreira, R. Mato, I. Sanches, H. de Lencastre
(Lisbon, Oeiras, Caparica, PT; New York, US)
Objective: To evaluate the impact of a prolonged comprehensive
control program for methicillin-resistant Staphylococcus aureus (MRSA)
infection and colonization, in a Hospital located in a country with a very
high MRSA prevalence.
Methods: Hospital SAMS is a 121-bed acute-care private hospital in
Lisbon, Portugal, serving a population of 122,000 that also uses other
healthcare institutions. MRSA has been endemic in SAMS since at least
1997, representing almost 50% of all S. aureus isolates. Medical and
surgical wards and medical-surgical intensive care unit (ICU) were the
most affected. After a baseline study period (1997–1999), an infection
control program was launched in 2000 in these units. It included
screening cultures (universal screening in ICU and screening of high-
risk patients in the selected wards), use of contact-droplets precautions,
appropriate hand hygiene and decolonization of colonized patients.
The program was available for evaluation during three time periods:
Period 1 (2000–2003) − full implementation of the program; Period 2
(2004–2005) − adherence to the program was progressively discontinued;
Period 3 (2006-June 09) − reimplementation of the full-program plus
screening of high-risk patients at hospital admission. An analysis
comparing the incidence rate of hospital-acquired MRSA infections per
1,000 patient-days in the different intervention periods was carried out.
Results: Patients infected or colonized with MRSA have been admitted
to the Hospital since the beginning of the program. Of the 2,327 patients
screened at admission in ICU (2000-Jun2009) 2.8% were colonized. In
Period 3 from the 833 high-risk patients screened at Hospital admission
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14.4% were colonized. The majority came from nursing homes or other
Hospitals. The baseline rate of hospital-acquired MRSA infections in
ICU was 4.56 infections per 1,000 patient-days and decreased to 0.83
(P = 0.02) and to 0 (P< 0.001) in periods 1 and 3 respectively. The global
baseline rate of hospital-acquired MRSA infections in the three units was
0.57 and decreased to 0.15 in periods 1 and 3 (P< 0.001). In contrast,
there was an increase of hospital-acquired MRSA infections in all units
during Period 2.
Conclusions: A comprehensive program to control MRSA infection and
colonization can be successful even in a highly endemic area and can
be sustained for a prolonged period. Motivation, education and feedback
are some of the most important tools for the sustainability of such a
control policy.
P1543 Resistance proportion, incidence density and the number
of isolation days − where lies the real burden of MRSA?
K. Kaier, R. Babikir, M. Dettenkofer, U. Frank, M. Kist, C. Schneider,
A. Conrad ° (Freiburg, DE)
Objectives: Knowledge of the burden of methicillin-resistant Staphy-
lococcus aureus (MRSA) at hospital level is important for infection
control. The aim was to compare how the monthly MRSA proportion
and incidences of MRSA differ (magnitude, trends). In addition, MRSA-
related isolation days were assessed describing the monthly burden of
isolating patients with MRSA.
Methods: Data were collected retrospectively (01/2003–12/2008) at
University Medical Center Freiburg, Germany, a 1,600-bed tertiary
care hospital. The MRSA proportion was deﬁned as the number
of non-duplicate MRSA positive strains relative to all non-duplicate
S. aureus isolates, excluding screening results. MRSA incidences were
determined (MRSA-cases/1000 patient days (pd)) and were grouped in
colonisations, infections, hospital acquired cases (MRSA detected >48 h
after admission) and patients admitted with MRSA. Additionally, the
length patients were isolated was assessed and incidences of isolation
days/1000 pd were calculated.
Results: The MRSA proportion did not follow any trend (p = 0.1)
showing a mean proportion of 0.09. A slight increase (p< 0.001) in
the incidence of all MRSA cases was identiﬁed (mean: 0.5/1000 pd). In
detail, a decreasing (p = 0.0012) incidence of hospital acquired MRSA
(mean: 0.15/1000 pd) faces an increasing (p< 0.001) incidence of
patients admitted with MRSA (mean: 0.35/1000 pd). The incidence
of MRSA-related isolation days for hospital acquired MRSA (mean:
2.54/1000 pd) decreased (p = 0.034) whereas the incidence of isolation
days related to patients admitted with MRSA (mean: 4.1/1000 pd)
increased (p< 0.001). The average length patients with hospital acquired
MRSA-infections were isolated (mean: 23.1 days) was longer than
the length of isolation of patients with hospital acquired MRSA-
colonisations (mean: 17.0 days). Similarly, the average length of isolation
for patients admitted with MRSA-infections (mean: 17.5 days) was
longer than that of patients colonized with MRSA at admission (mean:
11.6 days).
Conclusion: Both the MRSA incidences based on isolation events and
based on isolation days show comparable dynamics with decreasing
trends for hospital acquired MRSA and increasing trends regarding
patients admitted with MRSA. Furthermore, the average length of
isolation is longer for hospital acquired MRSA rather than for patients
admitted with MRSA and, within these two groups, longer for patients
infected with MRSA rather than patients colonized with MRSA.
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P1544 Patients included in randomized controlled trials do not
represent those seen in clinical practice
M. Falagas, E. Vouloumanou, C. Sgouros °, S. Athanasiou, G. Peppas,
I. Siempos (Athens, GR)
Objective: Clinicians rely on ﬁndings of randomized controlled trials
(RCTs) to formulate clinical decisions regarding individual patients. To
examine whether patients included in RCTs are representative of those
encountered in real life clinical situations.
Methods: PubMed was searched for RCTs referring to the ﬁeld of
infectious diseases. Data regarding the exclusion criteria of the identiﬁed
RCTs were extracted and critically evaluated.
Results: Thirty trials (seventeen referring to respiratory tract, ﬁve to skin
and soft tissue, four to intra-abdominal, two to gynecologic, and two to
bloodstream infections) were included in our study. All retrieved RCTs
reported extensive exclusion criteria. After comparing in a qualitative
manner (based on our clinical experience) the eligible patient population
in the identiﬁed RCTs with the respective population that would be
encountered in general practice, we noted that the abovementioned
patient populations differ considerably.
Conclusions: RCTs in the ﬁeld of infectious diseases use extensive
and stringent exclusion criteria; a fact that may lead to considerable
difference between the patient populations of RCTs and those viewed in
clinical practice. The application of the ﬁndings of RCTs to the care of
individual patients should be performed cautiously.
P1545 Aerosolized in combination with intravenous colistin vs.
intravenous colistin in the treatment of ventilator-associated
pneumonia: a matched case–control study
D. Kofteridis, A. Valachis, C. Alexopoulou, S. Maraki, D. Dimopoulou °,
F. Economidou, E. Mavrogeni, M. Christofaki, L. Sifaki,
D. Georgopoulos, G. Samonis (Heraklion, GR)
Objectives: The incidence of ventilator-associated pneumonia (VAP)
caused by multidrug-resistant (MDR) strains is increasing. Intravenous
(IV) or aerosolized (AS) plus IV colistin have been recently used to
treat these life threatening infections. However, little is known for the
beneﬁcial role of AS colistin in VAP patients. The purpose of this study
was to compare the efﬁcacy and safety of AS plus IV colistin vs only
IV colistin in patients with Gram-negative MDR VAP.
Methods: A retrospective, matched case–control study was performed
at the Intensive Care Unit of the University Hospital of Heraklion,
Greece, from January 2005 through December 2008. Forty-three patients
suffering of VAP diagnosed by standard criteria, caused by Gram-
negative MDR as documented by positive cultures of bronchial secretions
or bronchoalveolar lavage ﬂuid, received AS plus IV colistin and were
matched based on age, and APACHE II score to 43 control patients who
had received only IV colistin. Patients who received at least 6 doses of
AS or >3 days of IV therapy were eligible for evaluation.
Results: Demographic characteristics, clinical status, and Gram-negative
isolated pathogens were similar between the two treatment groups.
A. baumannii (66 cases; 77%) was the most common pathogen, followed
by K. pneumoniae (12; 14%) and P. aeruginosa (8; 9.3%). One patient
in the IV group had concurrent A. baumannii bacteremia, while in the
AS plus IV group 2 had A. baumannii and 1 K. pneumoniae bacteremia.
No colistin resistant strain was isolated from patients of either group.
No signiﬁcant differences between the two groups were observed
regarding eradication of pathogens (P = 0.679) clinical cure (P = 0.10)
and mortality (P = 0.289). Eight patients (19%) in each treatment group
developed reversible renal dysfunction. No AS colistin adverse events
were recorded.
Conclusion: Addition of AS to IV colistin did not provide additional
therapeutic beneﬁt to patients with Gram-negative MDR VAP.
P1546 Activity of doripenem in patients with baseline bacteraemia
in 6 pooled phase III pivotal studies
O. Umeh, K. Kaniga, M. Lee, N. Ketter, A. Quintana °, R. Redman
(Raritan, US)
Objectives: Doripenem (DOR) 500mg given every 8 hours as a 1-hour
infusion was studied and is approved in the US & Europe (EU) for
complicated intra-abdominal infections (cIAI) and complicated urinary
tract infections in adults, and in the EU as a 1 or 4-hour infusion for
nosocomial pneumonia (NP) including ventilator-associated pneumonia
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(VAP). DOR is active in vitro against most bacteria commonly isolated
from bacteremic patients (pts). To date, outcomes in the subgroup of
DOR-treated pts with concurrent bacteremia and either cIAI, cUTI or
NP has not been reported. Here we report the clinical and microbiological
(micro) outcomes in a subgroup of pts with bacteremia at baseline (BL)
from 6 pooled DOR clinical studies.
Methods: Micro outcomes for all micro evaluable (ME) subjects with
BL bacteremia in DOR studies 05–10 were obtained. The ME analysis
set excluded pts who received concomitant non study antibiotics. Micro
eradication was either deﬁned as the presence of 1 post-BL negative
blood culture or presumed if a patient had no post-BL blood culture but
recovered from the index infection. The overall response to treatment in
bacteremic and non bacteremic pts was compared.
Results: The table below summarizes the ﬁndings.
Overall, DOR was effective in clearing baseline bacteremia. The
response to treatment in DOR-treated pts with bacteremia was similar
to pts without bacteremia. In contrast, in the comparator arm, there
was a trend towards lower clinical cure rates in bacteremic versus non-
bacteremic pts; however this comparison is limited by the small sample
size.
Conclusion: DOR is a good therapeutic option for subjects with cIAI,
cUTI or NP who have concomitant bacteremia at diagnosis.
Table: Summary of clinical cure at TOC and clearance of baseline blood
pathogen in ME patients
Doripenem Comparator Diffa
N n % N n % (%) 95% CI
Clearance of blood pathogen(s)
Overall 80 76 95.0 77 71 92.2 2.8 (−6.1; 11.7)
cUTI 47 47 100.0 23 23 100.0 0.0
cIAI 14 13 92.9 23 22 95.7 −2.8 (−24.4; 18.8)
NP (non-VAP) 3 3 100.0 11 9 81.8 18.2 (−25.8; 62.2)
VAP 16 13 81.3 20 17 85.0 −3.7 (−34.1; 26.6)
Had both clinical cure at TOC and clearance of blood pathogen for subjects
with bacteremia at baseline
Overall 80 68 85.0 77 57 74.0 11.0 (−2.8; 24.8)
cUTI 47 44 93.6 23 23 100.0 −6.4 (−16.6; 3.8)
cIAI 14 12 85.7 23 17 73.9 11.8 (−19.6; 43.2)
NP (non-VAP) 3 3 100.0 11 7 63.6 36.4 (−13.3; 86.0)
VAP 16 9 56.3 20 10 50.0 6.3 (−32.1; 44.6)
Clinical cure rates at TOC for subjects without bacteremia
Overall 984 858 87.2 706 584 82.7 4.5 (0.9; 8.1)
cUTI 474 449 94.7 231 206 89.2 5.5 (0.7; 10.4)
cIAI 311 263 84.6 285 242 84.9 −0.3 (−6.5; 5.8)
NP (non-VAP) 68 57 83.8 66 58 87.9 −4.1 (−17.3; 9.2)
VAP 131 89 67.9 124 78 62.9 5.0 (−7.4; 17.5)
aDoripenem minus Comparator.
P1547 Efﬁcacy of tigecycline versus ampicillin–sulbactam or
amoxicillin–clavulanate to treat complicated skin and skin
structure infections − study 900
P. McGovern °, D. Rill, E. Zito, T. Babinchak on behalf of the 900
study group
Background: Tigecycline (TGC) has demonstrated clinical efﬁcacy
and safety versus vancomycin plus aztreonam in previous complicated
skin and skin structure infection (cSSSI) trials. The current study was
a global, multicenter, open label, randomized, comparative study of
tigecycline (TGC) versus ampicillin-sulbactam (AS) or amoxicillin–
clavulanate (AC) for the treatment of hospitalized subjects with cSSSI
conducted in 19 countries.
Methods: Subjects meeting the deﬁnition of cSSSI (i.e. infections
involving deeper soft tissue, or requiring signiﬁcant surgical intervention,
or a signiﬁcant underlying disease state such as deep or extensive
cellulitis, infected ulcers, major abscess, burns, or infected bites) were
randomized to receive TGC 100mg loading dose followed by 50mg q 12
hours or AS 1.5−3 gms q 6 hours or AC 1.2 gms q 6−8 hours for 4 to 14
days. The protocol allowed the addition of vancomycin 1 gm q 12 hours
to the AS or AC-treated subjects if infection with methicillin-resistant
Staphylococcus aureus (MRSA) was suspected or conﬁrmed. Subjects
were not allowed to switch to oral therapy. The primary efﬁcacy endpoint
was the clinical response in the clinically evaluable (CE) population at
the test of cure (TOC) assessment which occurred 8−50 days after the
last dose of test article.
Results: For the CE population, clinical cure rates were 77.5%
(162/209) for TGC versus 77.6% (152/196) for AS or AC (95%CI
−8.7, 8.6; p 0.001 for non-inferiority). Microbiologic efﬁcacy in the
ME population was similar between the two treatment arms with 79.2%
(95/120) of TGC treated organisms and 76.8% (76/99) of AS or AC
treated organisms considered eradicated at the TOC. Clinical cure rates
in the ME population for subjects with MRSA infection were 69.4%
(25/36) in TGC treated subjects and 75.0% (18/24) in AS or AC treated
subjects who received concomitant vancomycin. The most frequently
reported adverse events were nausea (43.7% in TGC; 17.1% in AS or
AC) and vomiting (23.9% in TGC; 5.7% in AS or AC).
Conclusion: Tigecycline monotherapy was found to be non-inferior to
AS or AC with or without vancomycin in subjects with complicated skin
and skin structure infections.
P1548 Efﬁcacy of tigecycline versus ceftriaxone and metronidazole
for complicated intra-abdominal infections − analysis of
pooled clinical trial data
P. McGovern °, H. Leister, E. Zito, H. Tucker, D. Mansﬁeld,
T. Babinchak (Collegeville, US)
Objectives: Tigecycline (TGC) has demonstrated clinical efﬁcacy
and safety versus imipenem-cilastatin and ceftriaxone (CTX) plus
metronidazole (MET) in previous phase III and phase IV clinical trials.
The current analysis is a pooled analysis of 2 phase IV multicenter, open-
label, randomized, comparative studies of TGC versus CTX/MET for
the treatment of hospitalized subjects with complicated intra-abdominal
infection conducted in 23 countries world-wide.
Methods: 946 subjects with complicated intra-abdominal infection were
randomized to receive TGC 100mg loading dose followed by 50mg q
12 hours or CTX 2 grams once daily, plus MET 1 gram to 2 grams
daily, for a minimum of 4 days and not more than 14 days. Subjects
were stratiﬁed at randomization based on APACHE II scores 10 or
>10. Subjects were not allowed to receive oral therapy. The primary
efﬁcacy endpoint was the clinical response in the clinically evaluable
(CE) population at the test of cure (TOC) assessment which occurred
8−44 days after the last dose of test article.
Results: For the CE population, clinical cure rates were 76.2%
(295/387) for TGC versus 76.9% (289/376) for CTX/MET (95%CI
−6.8, 5.3; p< 0.001 for non-inferiority). Clinical response for subjects
with APACHE II scores 10 were 69.2% (54/78) for TGC versus 70.7%
(53/75) for CTX/MET. Microbiologic efﬁcacy in the ME population
was similar between the two treatment arms with 74.7% (192/257)
of TGC-treated subjects and 75.1% (184/245) of CTX/MET-treated
subjects considered eradicated at the TOC. One CTX/MET subject with
a Bacteroides thetaiotamicron isolate developed decreased susceptibility
to metronidazole while on therapy. Nausea (30.1% TGC, 25.1%
CTX/MET), vomiting (20.5% TGC, 15.7% CTX/MET), and diarrhoea
(14.7% TGC, 12.7% CTX/MET) were the most frequently reported
adverse events. Overall discontinuation rates due to adverse events were
similar in each treatment arm, 8.3% TGC and 5.6% CTX/MET.
Conclusion: This pooled analysis demonstrates that tigecycline
monotherapy was efﬁcacious and well-tolerated when compared to a
combination regimen of CTX/MET in subjects with complicated intra-
abdominal infection.
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P1549 Efﬁcacy and safety of moxiﬂoxacin vs. ertapenem in
complicated intra-abdominal infections: results of the
PROMISE study
J. De Waele °, J. Tellado, J. Alder, P. Reimnitz, M. Jensen, B. Hampel,
P. Arvis (Ghent, BE; Madrid, ES; Montville, US; Wuppertal,
Leverkusen, Berlin, DE; Loos, FR)
Introduction: Source control and initiation of optimal antimicrobial
therapy are the cornerstones of the management of complicated intra-
abdominal infections (cIAIs). Moxiﬂoxacin (MXF) is an important
treatment option for cIAI as it has proven clinical efﬁcacy, and activity
against the vast majority of causative organisms. The current study was
carried out to compare the efﬁcacy and safety of MXF and ertapenem
(ERTA) in the treatment of patients with cIAI.
Methods: PROMISE was a prospective, randomised, double-dummy,
double-blind, multinational trial in patients with cIAIs. Patients were
treated for 5−14 days with MXF, 400mg IV qd, or ERTA, 1 g IV qd.
The primary efﬁcacy variable was clinical response 21−28 days after the
end of therapy. Non-inferiority of MXF was demonstrated if the lower
limit of the 95% conﬁdence interval (CI) was above −10%.
Results: Of 804 patients randomised (two-thirds from European
countries), 798 were valid for the ITT/safety analyses (MXF 408, ERTA
390). Demographics and baseline characteristics were similar in both
treatment arms. In the PP population (MXF 352, ERTA 347), the
mean (±SD) APACHE II score was 6.8 (±4.4). The mean (±SD)
POSSUM (35.1[±7.6]) and Mannheim Peritonitis Index (19.0[±7.2])
scores demonstrate that patients with severe peritonitis were included.
The most common cIAI diagnosis was diffuse, secondary peritonitis
(MXF 181, ERTA 185). For the primary efﬁcacy variable, MXF was
non-inferior to ERTA (Table). This included good efﬁcacy in the more
seriously ill patients (APACHE II >10: MXF 55/66, 83.3%; ERTA 53/62,
85.5%; 95%CI −14.8, 10.5), patients with diffuse, secondary peritonitis
(MXF 162/181, 89.5%; ERTA 174/185, 94.1%; 95%CI −9.2, 1.9), and
patients with non-appendicitis (MXF 160/180, 88.9%; ERTA 157/171,
91.8%; 95%CI −8.8, 3.5). Good bacteriological efﬁcacy was also seen
overall (Table) and in patients with polymicrobial infections (MBV
population: MXF 212/250, 84.8%; ERTA 205/231, 88.7%). Similar
numbers of patients in both arms experienced drug-related treatment-
emergent adverse events (ITT/safety population: MXF 77/408, 18.9%;
ERTA 74/390, 19.0%).
Conclusions: MXF, the only ﬂuoroquinolone currently marketed for
monotherapy of cIAI, was as effective and well tolerated as ERTA. This
included good efﬁcacy in the most severely ill patients.
Table 1. Clinical and bacteriological response in the different patient
populations of the PROMISE study
Populations MXF, n/N (%) ERTA, n/N (%) 95% CI
Clinical response
PP 315/352 (89.5) 324/347 (93.4) −7.9, 0.4
MBV 265/297 (89.2) 254/276 (92.0) −7.6, 1.9
ITT 334/408 (81.9) 339/390 (86.9) −9.9, 0.0
ITT with organisms 280/340 (82.4) 263/308 (85.4) −8.8, 2.2
Bacteriological response
MBV 257/297 (86.5) 249/276 (90.2) −9.0, 1.5
ITT with organisms 271/340 (79.7) 258/308 (83.8) −10.0, 1.5
PP: per protocol, MBV: microbiologically valid, ITT: intent-to-treat.
P1550 Efﬁcacy of IV/PO moxiﬂoxacin and IV piperacillin/
tazobactam followed by PO amoxicillin–clavulanate in the
treatment of diabetic foot infections: results of the RELIEF
study
N. Schaper °, M. Dryden, P. Kujath, D. Nathwani, P. Arvis, P. Reimnitz,
J. Alder, B. Hampel, I. Gyssens (Maastricht, NL; Winchester, UK;
Luebeck, DE; Dundee, UK; Loos, FR; Wuppertal, DE; Montville,
US; Berlin, DE; Nijmegen, NL)
Objectives: Diabetic foot infections (DFIs) cause substantial morbidity
and are a leading cause of lower-extremity amputations. As DFIs are
usually polymicrobial, broad-spectrum antibiotics − as well as proper
wound care − play an important role. Due to their broad spectrum
of activity and pharmacodynamic properties, ﬂuoroquinolones, such
as moxiﬂoxacin (MXF), have several potential advantages over other
antimicrobial classes. The RELIEF study was conducted to provide
further data on the efﬁcacy of MXF in speciﬁc complicated skin and
skin structure diagnoses. Data on DFIs are presented.
Methods: This was a double-dummy, double-blind, randomised, con-
trolled, multinational trial. Patients with a DFI requiring antimicrobials
were stratiﬁed according to infection severity and the requirement for
surgery, and received either IV/PO MXF 400mg qd or IV piperacillin/
tazobactam 4.0/0.5g tds followed by PO amoxicillin/clavulanate
875/125mg bd (PIP/TAZ-AMC), for 7−21 days. The DFI diagnosis was
based on predetermined criteria, documented by repeated photographs
and conﬁrmed by an independent data review committee (DRC).
The primary efﬁcacy variable was clinical response 14−28 days after
completion of therapy (test-of-cure, TOC) as determined by the DRC.
Table 1. Clinical and bacteriological success rates at TOC
MXF n/N (%) PIP/TAZ-
AMC n/N
(%)
P-value‡
Clinical cure
PP 84/110 (76.4) 75/96 (78.1) 0.65
MBV 69/92 (75.0) 64/85 (75.3) 0.70
ITT 86/123 (69.9) 76/110 (69.1) 0.98
ITT with organisms 71/102 (69.6) 65/96 (67.7) 0.93
Bacteriological success§
MBV 66/92 (71.7) 61/85 (71.8) –
ITT with organisms 69/102 (67.6) 62/96 (64.5)
Bacteriological success by key organism (MBV population)§
Staphylococcus aureus –
Methicillin-susceptible 43/53 (81.1) 39/57 (68.4)
Methicillin-resistant 8/11 (72.7) 10/12 (83.3)
Streptococcus pyogenes 3/3 (100) 2/2 (100) –
Enterococcus faecalis 19/30 (63.3) 20/29 (69.0) –
Escherichia coli –
ESBL-producing 1/1 (100) 1/1 (100)
Non ESBL-producing 6/8 (75.0) 8/11 (72.7)
Bacteroides fragilis 3/3 (100) 3/4 (75.0) –
‡Cochran–Mantel–Haenszel test. §n/N = number of patients experiencing
eradication or presumed eradication/number of patients with pathogen
isolated. ITT: intent-to-treat; PP: per-protocol; MBV: microbiologically
valid.
Results: A total of 206 patients were valid for the PP analysis
(MXF=110, PIP/TAZ-AMC=96). There were fewer men in the MXF vs
the PIP/TAZ-AMC arm (55.5% vs 71.9%; P = 0.02) and mean HbA1c
levels were higher in the MXF vs the PIP/TAZ-AMC arm (9.7% vs 9.0%;
P = 0.04). Most patients had moderate-to-severe DFIs with a PEDIS
score of 3 (MXF 87/107, 81.3%; PIP/TAZ-AMC 81/94, 86.2%). In the
MBV population, polymicrobial infections were common (MXF: 56/92,
60.9%; PIP/TAZ-AMC: 53/85, 62.3%); the most frequently isolated
organism overall was S. aureus (MXF 64/92, 69.6%; PIP/TAZ-AMC
69/85, 81.2%). MRSA was isolated from relatively few patients overall
(23/206; 11.1%). Initial surgeries were carried out on 150 patients (MXF
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78/110, 70.9%; PIP/TAZ 72/96, 75.0%). A total of 23/110 (20.9%)
MXF- and 24/96 (25.0%) PIP/TAZ-AMC-treated patients had additional
surgeries after the start of therapy. MXF and PIP/TAZ-AMC had similar
efﬁcacy with respect to clinical cure at TOC (Table). Bacteriological
success rates were also comparable (Table).
Conclusion: In this large randomised trial IV/PO MXF had similar
efﬁcacy to IV PIP/TAZ-AMC in the subset of patients with DFI. MXF
can be considered a valuable option for the treatment of DFI.
P1551 Efﬁcacy and safety of daptomycin versus vancomycin or
teicoplanin for the treatment of complicated skin and soft
tissue infections: a multicentre, randomized, assessor-blind
trial
H. Gollnick °, G. Fierlbeck, R.A. Seaton, H.J. Thurston, R.L. Chaves
(Magdeburg, Tubingen, DE; Glasgow, UK; Basel, CH)
Objectives: Daptomycin (DAP) is effective in treatment of complicated
skin and soft tissue infections (cSSTI) caused by non-resistant and
multidrug-resistant Gram-positive bacteria. Only limited comparative
data is available regarding cSSTI treatment in elderly. Furthermore, no
comparative data for DAP vs. teicoplanin in cSSTI has been published
to date. The primary objective of this study was to compare DAP
vs. vancomycin or teicoplanin (comparator) at test of cure visit (TOC,
Day 7−14) for Clinical Success (CS, complete resolution of signs and
symptoms or improvement requiring no additional therapy).
Methods: This phase IIIb, comparative, assessor-blinded study included
adult patients with cSSTI who were randomised (1:1) and stratiﬁed
by age (65 yrs) and by presence of systemic inﬂammatory response
syndrome. Intravenous therapy with study drugs was to be given for at
least 4 days before oral therapy switch, if needed (total therapy duration
of 5−14 days).
Results: Of 189 patients exposed to treatment, 97 were in the DAP
group and 92 in the comparator group (vancomycin 46; teicoplanin 46
patients). Treatment exposure was similar in the two groups, and 1/3
of patients were elderly. Descriptive efﬁcacy was comparable in DAP
and the comparator group (Table). Discontinuation for adverse events
(AEs) or death occurred more frequently in the comparator group (n = 9,
9.8%) than in the DAP group (n = 3, 3.1%). CPK increase was more
often reported as an AE in the comparator group vs. DAP (5 vs. 1);
1 patient discontinued the study in comparator group due to this AE.
55 (56.7%) patients in the DAP group and 51 (55.4%) patients in the
comparator group reported AEs. The majority of AEs were mild or
moderate in intensity. 33 patients experienced serious adverse events
(SAE), 17 (17.5%) in the DAP group and 16 (17.4%) in the comparator
group. Discontinuations due to SAE were few in both arms (3.1% and
2.2%).
Conclusions: DAP appeared to be at least as effective with a trend to
superior efﬁcacy relative to vancomycin or teicoplanin, especially in the
elderly and in the microbiologically evaluable populations. The safety of
all study drugs was similar and good.
Daptomycin Pooled
comparator
Vancomycin Teicoplanin 95% CI
Primary efﬁcacy criterion at TOC: Clinical success in clinically evaluable population
Number of patients 58 47 22 25
Clinical success 53 (91.4) 41 (87.2) 19 (86.4) 22 (88.0) −10.0–13.5
age <65 years 37 (92.5) 28 (93.3) 16 (94.1) 12 (92.3) −12.4–11.7
age 65 years 16 (88.9) 13 (76.5) 3 (60.0) 10 (83.3) −22.4–45.1
Clinical success in ITT population
Number of patients 97 92 46 46
Clinical success 65 (67.0) 58 (63.0) 31 (67.4) 27 (58.7) −9.2–17.6
age <65 years 45 (72.6) 41 (67.2) 26 (72.2) 15 (60.0) −11.4–20.7
age 65 years 20 (57.1) 17 (54.8) 5 (50.0) 12 (57.1) −21.4–26.2
Microbiological success in microbiologically evaluable population
Number of patients 57 43 – – –
Microbiological success 56 (98.2) 39 (90.7) – – −20.8–32.0
age <65 years 38 (97.4) 26 (96.3) – – −30.2–36.8
age 65 years 18 (100.0) 13 (81.3) – – NA
All values expressed as n (%) unless otherwise speciﬁed.
P1552 Daptomycin in the treatment of osteomyelitis caused by
MRSA. A comparative observational study
T. Ascione °, M.D. Iannece, P. Rosario, M. Conte, S. Quaranta,
R. Pempinello (Naples, IT)
New antibiotics have recently been shown to be effective in cases
of serious infections sustained by Meticillin-resistant Staphylococcus
aureus (MRSA) strains. Objectives: to compare the efﬁcacy of
Teicoplanin in respect to Linezolid and Daptomycin in patients with
chronic osteomyelitis sustained by MRSA.
Materials and Methods: In an observational study we included all cases
of osteomyelitis sustained by MRSA treated with Teicoplanin, Linezolid
or Daptomycin during the last 3 years in our division. Epidemiological,
laboratory and microbiological ﬁndings were considered. Patients were
evaluated for clinical efﬁcacy, safety and tolerability. Cure was deﬁned by
the clinical and radiologic evidences, coupled with a negative Magnetic
Resonance Imaging study or by the absence of captation by scintigraphic
examination with leukocytes labelled in vitro with 111In, as was assessed
3 months after the end of treatment.
Results: Fifty-three patients with post-traumatic chronic osteomyelits
(median age 58 [range 19−70], 66% males) were included. Fracture
ﬁxators were present in 10 (19%) cases. Median (range) time from
diagnosis of chronic osteomyelitis to our observation was 9 months
(range 3−12). Ineffective antimicrobial treatment before our observation
was reported in 32 patients. We treated 29 patients with Teicoplanin,
13 with Linezolid and 11 with Daptomycin. Median (range) length
of antibiotic treatment was 16 (12−24) weeks for cases treated with
Teicoplanin, 12 (8−12) weeks for cases treated with Linezolid, and 11
(6−12) weeks for cases treated with Daptomycin. Cure rates (intention
to treat evaluation) were 83%, 77% and 91%, respectively, for cases
receiving Teicoplanin, Linezolid and Daptomycin. Antibiotic treatment
was discontinued in 3 patients receiving Linezolid because of side effects
(2 cases had optic neuritis, 1 had moderate anemia). Three patients who
failed after Teicoplanin treatment had MIC to Teicoplanin between 1 and
2 microg/ml.
Conclusion: Teicoplanin is largely employed in the daily practice for
patients with osteomyelitis. However, it needs to be administered for a
longer period and it is not always effective because of the emergence
of glycopeptides tolerant MRSA. Many concerns arise in suggesting the
long term administration of Linezolid because of side effects on the
nervous and haemopoietic systems. Daptomycin whose administration
was safe and effective represents an effective choice for all cases with
osteomyelitis sustained by MRSA.
P1553 Predictors of clinical failure in patients with complicated
skin and skin structure infections caused by methicillin-
resistant Staphylococcus aureus by diabetes mellitus status:
results from 3 randomized controlled trials of linezolid and
vancomycin
B. Lipsky, A. Reisman, D. Ruzzi, D. Huang ° (Seattle, New York, US)
Objective: Complicated skin and skin structure infections (cSSSI)
caused by methicillin-resistant Staphylococcus aureus (MRSA) are
common and often difﬁcult to treat. The rate of treatment failure appears
to be higher for diabetic compared with nondiabetic patients. Knowing
which demographic or clinical factors, especially in diabetics, may be
associated with clinical failure of treatment of patients with MRSA
cSSSI could help improve outcomes.
Methods: Using data from 3 prospective, open-label, randomised phase
3b/4 clinical trials comparing the efﬁcacy of linezolid (LZD) and
vancomycin (VAN) for treating cSSSI, we conducted a post hoc analysis
of factors associated with outcome. In the analysis cohort, we included
only patients who received at least 1 dose of study medication and
had culture-conﬁrmed MRSA infection. We deﬁned clinical failure as
persistence or progression of clinical signs and symptoms of infection
after receiving at least 2 days of treatment. Using a multivariate logistic
regression model, we examined baseline demographic and clinical
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variables to identify signiﬁcant independent predictors of clinical failure
at end of study (EOS, 6 to 28 d after last dose of study drug) for diabetics
and nondiabetics. We selected predictors by c2-df, stepwise selection by
Akaike Information Criterion, and validated the model with the Hosmer-
Lemeshow goodness of ﬁt test. Because of the exploratory nature of the
analysis, we included variables signiﬁcant at 0.10 in the model.
Results: Among 1038 patients (LZD 539, VAN 544) eligible for
inclusion in these analyses, 845 (81%) had observations present for
all variables included in the model, including 287 (34%) diabetics and
558 (66%) nondiabetics. By stepwise multivariate regression analysis,
we found 4 variables signiﬁcantly associated with clinical failure in
the diabetic population, and 3 associated with clinical failure in the
nondiabetic population (see below).
Conclusions: Factors signiﬁcantly independently associated with a
higher likelihood of clinical failure of treatment of cSSSI (other than
randomisation to 1 particular study) among diabetics were the presence
of a polymicrobial infection, or peripheral vascular disease, or decreased
weight; and among nondiabetics, they were treatment with VAN, or the
presence of a polymicrobial infection. The presence of these factors,
especially in diabetics, should alert physicians to patients possibly at
higher risk of poor outcomes.
Table 1. Predictors of clinical failure at EOS
Population Predictor of clinical failure at EOS Odds Ratioa 95% CI
Diabetic Presence of a polymicrobial infectionb 3.10 1.52, 6.33
Randomised in the Itani studyc 3.03 1.74, 6.25
Presence of PVD 1.81 1.03, 3.17
Decreased weight 1.01 1.00, 1.02
Nondiabetic Treatment with VAN 2.22 1.34, 3.66
Presence of a polymicrobial infectionb 2.04 1.16, 3.62
Randomised in the Itani studyc 1.68 0.96, 2.95
aOdds ratios greater than 1.0 indicate excess failure.
bPolymicrobial infection was deﬁned as culture-conﬁrmed MRSA + any other
pathogen. cThe Itani study excluded patients with a primary baseline diagnosis of
cellulitis. CI, conﬁdence interval; PVD, peripheral vascular disease.
P1554 Safety proﬁle of oral torezolid phosphate 200, 300, or
400mg once daily in an acute complicated skin and skin
structure infection, phase 2 study
C. De Anda °, P. Bien, P. Prokocimer (San Diego, US)
Objective: Torezolid is the active moiety of the prodrug torezolid
phosphate (TP), an oxazolidinone with 4- to 16-fold greater activity than
linezolid against Gram-positive species including methicillin-resistant
Staphylococcus aureus (MRSA). Our objective is to report the TP safety
proﬁle in patients with complicated skin and skin structure infections
(cSSSI) enrolled in the Phase 2 dose-ranging study.
Methods: Patients diagnosed with cSSSI were randomized to receive
200, 300, or 400mg oral TP once-daily (QD) for 5 to 7 days. Treatment
emergent adverse events (TEAE) were assessed from ﬁrst dose through
the late follow-up (LFU) visit. Safety laboratory tests including a
chemistry panel and complete blood count (CBC) with differential were
to be obtained from patients at screening/day 1, day 3, day 5, end of
therapy (EOT), and test of cure (TOC) visits.
Results: There were 188 patients that received at least one dose of
study drug, of which 69% experienced at least one TEAE. TEAEs were
overwhelmingly mild (72%) to moderate (25%). The most common study
drug-related TEAEs (>5%) reported were nausea, diarrhoea, vomiting,
and headache. No patients discontinued study drug due to an adverse
event. Five patients reported a serious adverse event (SAE) during the
study, only one of which was reported as related. Five patients had a
substantially abnormal value (deﬁned using standard regulatory criteria)
in ALT, 3 in AST, 1 in alkaline phosphatase, and 1 in serum creatinine.
Of the 8 patients with substantially abnormal ALT or AST, none had
elevated levels of both, 3 were Hepatitis C positive (3 were negative and
2 were not tested), and 5 have an admitted history of IV drug or alcohol
abuse. No patients had substantially abnormal values in platelet count,
absolute neutrophil count, or hemoglobin levels.
Conclusion: TP proved to be well tolerated in all dosage levels with
no signiﬁcant difference in TEAE occurrences between the doses over
a 5−7 day period of administration. These data support the usage of
200mg QD for further development into the treatment of severe cSSSI.
P1555 Linezolid use in the treatment of vancomycin-resistant
Enterococcus in paediatric patients
J. Deville, J. Goldfarb, S. Kaplan, O. Equils, D. Huang °, J. Ang,
J. Salazar (Los Angeles, Cleveland, Houston, New York, Detroit,
Hartford, US)
Objective: Vancomycin-resistant Enterococcus (VRE) is a difﬁcult to
treat pathogen in hospitalised paediatric patients. Our objective was to
assess the efﬁcacy and safety of linezolid (LZD) for treatment of VRE
infections in paediatric patients.
Methods: Hospitalised children with VRE infection were enrolled in
a multicentre, open-label, noncomparator study from 2002–2004, as an
extension to the parent study of LZD vs vancomycin for treatment of
resistant Gram-positive infections in children. Patients less than 11 y
received LZD 10mg/kg (up to 600mg) every 8 h; all others received
LZD 600mg every 12 h. Intravenous (IV) treatment was required for
the ﬁrst 3 d, and then oral LZD could be used, at the discretion of the
investigator. The primary efﬁcacy measures were the patients’ clinical
outcomes at test of cure (TOC; 12−28 d after treatment completion).
Safety measures included reported adverse events (AE).
Results: Thirteen seriously ill children aged 4 m to 17 y (mean±SD:
7 y±6.4 y) were enrolled. Primary baseline infections were vascular
associated bacteraemia (n = 4), bacteraemia of unknown source (n = 3),
urinary tract infection (n = 3), skin and skin structure infection (SSI,
n = 1), pyelonephritis (n = 1) and intra-abdominal abscess (n = 1). In
69% (9/13) of the patients, vancomycin-resistant (VR) E. faecium
was isolated, 1 had VR E. faecalis, 1 had vancomycin-intermediate
(VI) E. faecium and VI E. gallinarum, 2 had vancomycin-susceptible
E. faecium, 1 also had E. gallinarum; however, no susceptibility testing
was performed on the latter because of insufﬁcient culture sample. Mean
treatment duration of LZD was 17.1±7.2 d. At the TOC, the clinical cure
rate was 8/12 (66.7%) for the intent-to-treat population (1 was withdrawn
from the study per protocol exclusionary criteria) and 5/7 (71.4%) for the
microbiologically evaluable group (culture-conﬁrmed VRE infections).
Three patients had drug-related AE (diarrhoea, anaemia, decreased
cyclosporine level). One patient discontinued LZD due to AE (abdominal
distention and pain, diarrhoea, and anaemia). Two patients died during
the study but neither death was related to LZD (end-stage liver disease
and end-stage renal disease waiting for a heart transplant). Changes
in haematology and chemistry parameters were consistent with the
underlying disease states and were largely transient.
Conclusion: LZD was effective and well tolerated in treating severely
ill children with VRE infections.
P1556 Oral torezolid phosphate in the treatment of severe
complicated skin and skin structure infections in a phase 2
dose-ranging study
C. De Anda °, P. Bien, P. Prokocimer (San Diego, US)
Objective: Torezolid (T) is the active moiety of the prodrug torezolid
phosphate (TP), a second generation oxazolidinone with 4- to 16-
fold greater activity than linezolid against Gram-positive species. The
objective of this analysis was to review the clinical and microbiological
outcome rates of the more severe cases of complicated skin and skin
structure infections (cSSSI) including large abscesses, cellulitis and
wound infections with oral TP once daily (QD), 200mg, 300mg, or
400mg at the end of therapy (EOT) and test of cure (TOC) visits in
the modiﬁed intent-to-treat (MITT) and the clinically evaluable (CE)
patient populations. In line with latest regulatory recommendations,
severe cSSSI was deﬁned as having systemic signs or symptoms of
infection (>38ºC oral temperature, >10,000/mm3 white blood cells, or
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>10% bands) or lymphatic involvement adjacent to the primary lesion,
and a lesion measurement of at least 10 cm or greater at baseline.
Methods: Patients were randomized to receive 200, 300, or 400mg oral
TP QD for 5 to 7 days. Patients were evaluated for clinical response by
the investigator at EOT and TOC. Microbiological samples were to be
obtained from the cSSSI site at baseline and then any follow-up visits if
medically indicated.
Results: A total of 80 of the 188 patients that received study drug met
the criteria for severe cSSSI as deﬁned above. Of these 80 patients, 85%
had systemic signs of infection and 15% had lymphatic involvement
in the absence of systemic signs of infection. Lesion sizes ranged from
10 cm to 46 cm. The clinical cure rates at EOT and TOC were as follows:
A total of 59 patients of this sub-group had S. aureus as the baseline
pathogen (15% MSSA, 85% MRSA). The microbiologic outcome was
100% eradication for all pathogens.
Conclusion: TP demonstrated high clinical cure rates and high
microbiological eradication in all dosage levels tested in patients with
severe cSSSI. These data support the selection of 200mg QD for further
development towards the treatment of severe cSSSI.
200mg 300mg 400mg
MITT population
EOT 24/26 (92%) 25/25 (100%) 27/29 (93%)
TOC 23/26 (88%) 25/25 (100%) 26/29 (90%)
CE population
EOT 23/24 (96%) 24/24 (100%) 27/28 (96%)
TOC 22/23 (96%) 23/23 (100%) 25/26 (96%)
P1557 Vancomycin for the treatment of patients with Gram-positive
infections: a meta-analysis of randomized controlled trials
K. Vardakas °, M. Mavros, N. Roussos, M. Falagas (Athens, GR)
Objective: To clarify whether the use of vancomycin could be associated
with improved outcomes in comparison with other approved or in
phase III trials investigational antibiotics for the treatment of infections
caused by Gram-positive cocci.
Methods: Data from randomized controlled trials were pooled using the
methodology of meta-analysis.
Results: Fifty trials comparing vancomycin with linezolid, dapto-
mycin, quinupristin-dalfopristin, tigecycline, ceftaroline, ceftobiprole,
telavancin, teicoplanin and dalbavancin were included in the meta-
analysis. In the ITT population vancomycin was equally effective to
comparator antibiotics [1.08 (0.98–1.19)]. In the clinically evaluable
populations, comparators were more effective than vancomycin when all
infections [1.16 (1.4–1.36)] and skin and soft tissue infections [SSTIs,
1.18 (1.00–1.38)] were studied. No differences were noted when patients
with febrile neutropenia [1.07 (0.82–1.39)], pneumonia [1.08 (0.82–
1.43)], and bacteremia [1.10 (0.79–1.53)] were studied. Comparators
were more effective in open label trials [1.28 (1.08–1.50)], but not in
double-blind trials [1.06 (0.90–1.25)]. Total adverse effects attributed
to studied antibiotics were more common in comparators [1.12 (1.01–
1.24)], but fewer patients were withdrawn from trials in the comparator
arm [0.78 (0.63–0.98)]. Mortality was not different between vancomycin
and comparator antibiotics when all trials were included in the analysis
[OR 1.08 (95%CI 0.93–1.25)]. In double blind trials, vancomycin was
not associated with lower mortality [0.83 (0.65–1.05)], but in open label
trials comparators were associated with higher mortality [1.28 (1.05–
1.55)].
Conclusion: Based mainly on data from open label trials, vancomycin is
an effective treatment choice for patients with Gram positive infections
other than SSTIs.
P1558 Treatment with ciproﬂoxacin for 7 or 14 days in women
with acute pyelonephritis. A randomized, double-blind,
placebo-controlled multicentre trial with parallel groups
T. Sandberg °, G. Kahlmeter, N. Kuylenstierna, A. Lannerga˚rd, G. Otto,
B. Settergren, G. Skoog, G. Stridh (Go¨teborg, Va¨xjo¨, Falun, Uppsala,
Lund, Kristianstad, Solna, SE)
Objectives: To compare the bacteriological and clinical efﬁcacy and
safety of 7 and 14 days treatment with ciproﬂoxacin in women with
community-acquired acute pyelonephritis.
Methods: 251 non-pregnant women, 18 years of age or older, with a
presumptive diagnosis of acute pyelonephritis were randomly assigned
to treatment with ciproﬂoxacin 500mg twice daily for 7 or 14 days. The
study was double blind and placebo-controlled during the second week
of treatment. To be included in the per protocol analysis, patients must
have demonstrated a positive urine culture with a strain susceptible to
ciproﬂoxacin. The main endpoint was the bacteriological and clinical
outcome 10 to 14 days after completion of treatment with active
drug. Long-term outcome was assessed 5 to 8 weeks post-treatment.
Recruitment of study patients took place at 21 departments of infectious
diseases in Sweden.
Results: A total of 156 patients with a median age of 43 years
(range 18−86) could be evaluated according to the protocol. Escherichia
coli was the predominant pathogen (92%). 42 (27%) patients had
positive blood cultures. Short-term cure rate for patients treated with
ciproﬂoxacin for 7 days (n = 73) and 14 days (n = 83) was 97.3%
and 96.4% (p = 0.004; one-sided non-inferiority test), respectively.
Cumulative efﬁcacy at long-term follow-up was 93.2% and 92.9%
(p = 0.015; one-sided non-inferiority test), respectively. Both regimens
were well tolerated.
Conclusion: Treatment of acute pyelonephritis in women with
ciproﬂoxacin for 7 days was not inferior to a 14 day-course.
Animal models − antimicrobials
P1559 In vivo assessment of activity of calcium-deﬁcient
apatite linezolid drug delivery system versus systemic
administration of linezolid in a rabbit osteomyelitis
experimental model due to MRSA
A. Gaudin °, G. Amador, H. Gautier, V. Le Mabecque, A.F. Miegeville,
G. Potel, J.M. Bouler, P. Weiss, J. Caillon, C. Jacqueline (Nantes, FR)
Background: Linezolid is considered as an alternative to vancomycin
for severe osseous infections. Calcium-deﬁcient apatites (CDA) can be
associated with therapeutic agents such as linezolid to form drug-delivery
systems. The aim of this work was to evaluate the in vivo activity
of linezolid adsorbed onto CDA microparticles in addition to standard
treatments.
Methods: Femoral trepanation of rabbits was performed, followed by
injection of 109 CFU MRSA (linezolid MIC = 2 mg/mL) suspension
into the knee cavity. A surgical debridement of the infected tissues was
performed 3 days later and animals were randomly assigned to: V(iv)
(vancomycin constant IV infusion to reach a 20×MIC serum steady-
state concentration), L(iv) (10mg/kg/12 h IV infusion), CDA (osseous
gap ﬁlled with 100mg CDA), L(CDA) (100mg CDA with linezolid
10 mg/mg) and L(CDA)+ L(iv) (100mg CDA with linezolid 10 mg/mg
ﬁlling in addition to 10mg/kg/12 h IV infusion). Surviving bacteria were
counted in joint ﬂuid (JF), bone marrow (BM) and bone (BO) at days 3
and 7 (4-day treatment).
Results: See graphic.
Conclusions: (1) V(iv) was ineffective against MRSA after a 4-day
treatment. (2) CDA alone showed no in vivo antibacterial activity.
(3) CDA as linezolid drug delivery (L(CDA)) system demonstrated
signiﬁcant in vivo activity in BM and BO, in this model, as compared
to vancomycin. (4) L(CDA) + L(iv) treatment did not exhibit a greater
efﬁcacy in the three compartments than L(CDA) alone.
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Treatment n Mean±SD delta log10 CFU/g of tissue
(day 7 − day 3)
JF BM BO
V(iv) 5 −0.03±0.93 −0.73±1.84 −0.61±0.76
L(iv) 5 −0.77±1.32 −2.69±2.00* −2.25±1.63*
CDA 5 −0.49±0.32 0.56±0.31 0.22±0.25
L(CDA) 5 −0.80±1.11 −2.56±1.48* −1.18±0.86**
L(CDA) + L(iv) 5 −1.21±0.30 −3.51±0.43* −1.85±0.95**
n: number of animals; *P < 0.05 vs V(iv) and CDA; **P < 0.05 vs CDA.
Student–Newman–Keuls test after ANOVA.
P1560 Comparative efﬁcacy of moxiﬂoxacin and the inﬂuence of
therapy withdrawal in a murine uterus infection caused by
Bacteroides fragilis
M. Glenschek-Sieberth °, K. Merfort, S. Obertegger, R. Endermann
(Wuppertal, DE)
Objectives: Female reproductive organs are often affected by severe
complications following complicated intra-abdominal infections (cIAIs).
Such complications, including uterine tube infections, can result in
infertility. The efﬁcacy of moxiﬂoxacin (MXF), piperacillin/tazobactam
(PIP/TAZ), ertapenem (ERTA) or metronidazole (MET) plus ceftriaxone
(CRO) or ciproﬂoxacin (CIP) was assessed in a murine model of chronic
uterus infection caused by Bacteroides fragilis.
Methods: C57BL/6JOla mice were treated with b-estradiol. After 4
days, the left uterine tube was infected with a suspension of B. fragilis
O6688 (3×108 colony forming units [CFU] per mouse). To evaluate
therapeutic efﬁcacy, mice were treated b.d. IV for 4 days starting at day
21 post-infection (p.i.) with MXF 100mg/kg, PIP/TAZ 400mg/kg, ERTA
25mg/kg, or MET 100mg/kg plus CRO 30mg/kg or CIP 90mg/kg.
These doses simulate the pharmacokinetic/pharmacodynamic drivers of
the human IV doses. CFUs in the uterine tubes were determined after
hysterectomy. Therapeutic efﬁcacy was assessed as the reduction in CFUs
in the uterine tube homogenates on day 25 p.i. To evaluate the inﬂuence
of therapy withdrawal on efﬁcacy, CFUs in uterine tube homogenates
were also assessed on day 30 p.i.
Results: CFU reductions in the uterine tubes on days 25 and 30 p.i. are
shown in the table. In the murine chronic uterus infection model:
• MXF monotherapy had signiﬁcantly higher efﬁcacy than PIP/TAZ or
ERTA and comparable activity to combination therapy with MET/CRO
or MET/CIP in terms of CFU reduction one day after end of therapy.
• Six days after the cessation of treatment, the mean B. fragilis count
reached the level of the untreated control animals for all treatment
regimens except MXF and MET/CIP.
• MXF also displayed the highest CFU reductions on day 1 and day 6
after the withdrawal of therapy.
• MXF was the only regimen that reduced B. fragilis CFUs to below the
detection limit in some animals at six days after the end of treatment.
Conclusions: A four-day treatment duration was probably too short to
effectively eliminate B. fragilis from site of infection. Nonetheless, MXF
was the only treatment option that eradicated B. fragilis to below the
detection limit in some animals at six days after the end of treatment.
MXF monotherapy seems to be a valuable treatment option for infections
caused by B. fragilis.
Comparison of CFU reduction in uterine tubes on days 25 and 30 post-
infection
Day 25 post-infection (1 day after therapy withdrawal) Day 30 post-infection (6 days after therapy withdrawal)
Treatment Median Dlog10
CFU reduction
compared
to untreated
control (n = 30)
P-value† (active
treatment
vs untreated
control)
P-value†
(MXF vs
comparator)
Treatment Median
Dlog10CFU
reduction
compared
to untreated
control (n = 23)
P-value† (active
treatment
vs untreated
control)
P-value†
(MXF vs
comparator)
MXF (n = 33) −4.78 <0.0001 – MXF (n = 22) −2.40 0.0031 –
PIP/TAZ (n = 20) −1.25 0.0004 <0.0001 PIP/TAZ (n = 10) −0.36 0.3573 0.0770
ERTA (n = 15) −1.62 0.237 0.0003 ERTA (n = 10) +0.40 0.6808 0.0047
MET/CRO (n = 10) −4.19 0.0001 0.2684 MET/CRO (n = 10) +0.23 0.5969 0.0078
MET/CIP (n = 10) −4.69 0.0001 0.4292 MET/CIP (n = 10) −2.21 0.0031 0.8869
†Mann–Whitney test.
P1561 Efﬁcacy of garenoxacin, a des-F (6) quinolone, in
an experimental skin infection model caused by
methicillin-resistant Staphylococcus aureus in diabetic mice
Y. Fukuda °, M. Takahata, K. Hashimoto-Hasegawa, Y. Ito, Y. Sugiura,
K. Kizawa, I. Nozawa, J. Mitsuyama (Toyama, JP)
Objectives: Garenoxacin (GRN), a des-F (6) quinolone, exhibits potent
antibacterial activity against S. aureus, including MRSA, which causes
severe skin infection, especially in diabetic patients. The efﬁcacy of GRN
in experimental skin infection models with MRSA in diabetic mice was
evaluated and compared to levoﬂoxacin (LVX) and moxiﬂoxacin (MXF).
Methods: Male C57BLKS/J Iar-+Leprdb/+Leprdb mice were used
as skin infection models caused by MRSA in diabetic mice. Under
anesthesia, mice were infected by placing a 5 uL droplet containing ca.
105 CFU of MRSA F-3410 (MIC: GRN 0.0313mg/L, LVX 0.25mg/L,
MXF 0.0625mg/L) on the thigh skin, from which hair had been shaved.
At 2 h after infection, 5mg/kg of each quinolone was administered
orally once. The viable cells counts in skin were measured at 24 h
after infection. At the same time, histopathological observation was
performed. Drug concentrations in the serum and thigh skin of mice
infected with MRSA F-3410 were also measured by HPLC with a single
oral dose of 20mg/kg, and pharmacokinetic evaluations were performed
by non-compartment analysis.
Results: The viable cell count in the skin (Log10 CFU/skin)
of the GRN-treated group (3.41±0.51) was signiﬁcantly less than
LVX- (6.18±0.39*), MXF- (4.44±0.31*) and non-treated (6.34±0.40*)
groups, (N = 10, Mean±S.D„ *p< 0.001 vs. GRN). In the non-treated
group, 24 h after infection, inﬁltration of inﬂammatory cells surrounding
bacterial colonies reached subcutaneous adipose tissue. After GRN
treatment, although cell debris derived from inﬂammatory cells persisted
on the skin surface, the inﬂammatory reaction was very slight compared
to non-treated mice. The AUC0−24 of GRN in serum and thigh skin at
20mg/kg was 12.7 and 7.51 ug-h/mL or g (N= 3, Mean), and the AUC0–
24/MIC ratios were 405 and 240, respectively, which were greater than
LVX and MXF. The greater AUC/MIC ratios of GRN in both serum and
skin reﬂected its favorable therapeutic effect.
Conclusions: GRN is considered a valuable quinolone in the treatment
of skin infections caused by S. aureus, including MRSA in diabetes.
P1562 Evaluation of oritavancin efﬁcacy and pharmacokinetic
proﬁle in the hamster model of Clostridium difﬁcile infection
I. Fadhil, H. Deng °, O. Rozborskaya, J. Gagne´, O. Be´langer,
V. Ostiguy, I. Be´dard, C. Cadieux, M. Malouin, S. Fournier, A. Rafai
Far, T. Parr Jr., D. Lehoux (St. Laurent, CA)
Objectives: Oritavancin (ORI) is a novel lipoglycopeptide which
demonstrates activity against Clostridium difﬁcile (CD) and prevents
spore outgrowth. It is under preclinical evaluation for the treatment
of infections caused by CD. We report here, the pharmacokinetic (PK)
proﬁle of ORI and its efﬁcacy in a hamster model of Clostridium difﬁcile
infection (CDI).
Methods: CDI was established in Golden Syrian hamsters with a
subcutaneous dose of clindamycin at 100mg/kg one day before infection
followed by oral gavage with 105 colony-forming units (CFU) of spores
of CD ATCC 43255 on Day 0. On Day 1 post-infection (PI), either
ORI at 10, 50 or 100mg/kg/day (in hydroxypropyl b-cyclodextrin),
vancomycin (VA) (in phosphate buffered saline) at 50mg/kg/day (n = 10
hamsters/group) or ORI in PEG400 at 100mg/kg/day (n = 5/group) were
administered orally (PO) once daily for 5 days. Animals were observed
daily for clinical signs during 20 days. The hamsters were also dosed
intravenously (IV) at 10, 25 and 50mg/kg of ORI or PO at 10, 50 and
100mg/kg. Blood samples and cecal contents were harvested at 8 time
points ranging from 15 min to 120 h (n = 3/time point), and ORI levels
were determined by liquid chromatography/mass spectrometry.
Results: ORI at 10, 50 and 100mg/kg prolonged survival by 9, 13
and 17 days over untreated controls, respectively. On Day 12 PI, ORI
at 100mg/kg exhibited superior efﬁcacy to VA with 100% survival for
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animals treated with ORI compared to 0% survival with VA. In PEG400,
ORI yielded 100% survival at Day 20. After PO administration, the
maximal concentration (Cmax) in plasma was 0.12mg/L at 2 h. The
Cmax in cecal matter was between 196 mcg/g and 1922 mcg/g after
PO administration, and below 1 mcg/g for all doses by 72 h. After
IV administration, the concentration in plasma was between 59 and
279mg/L at 15 min and decreased to 0.13–0.52mg/L at 48 h.
Conclusion: Oritavancin is maintained at high levels in the hamster
cecum, where the CD infection is. As such, ORI displayed efﬁcacy in
the hamster model of CDI, preventing CDI relapse longer than VA, and
preventing relapse when it was formulated in PEG400.
P1563 Comparison of the efﬁcacies of silver-containing dressing
materials for treating a full-thickness rodent wound infected
by methicillin-resistant Staphylococcus aureus
J. Chae °, J.H. Lee, D.G. Kim, S.H. Hong, W.M. Lee, M. Ki (Seoul,
Daejeon, KR)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) may
cause infections during wound dressing. We aimed to compare the
antibacterial activities and wound-healing effects of commercially
available silver-coated or silver-impregnated wound dressings on MRSA-
infected wounds.
Methods: Full-thickness skin defects were made on the back of
rats (N = 108) and were infected with MRSA. The rats were divided
into the following 6 groups according to the dressing used for the
wounds: nanocrystalline silver (Acticoat®, silver carboxymethylcellulose
(Aquacel® Ag), silver sulfadiazine (Medifoam silver®, silver sulfadi-
azine (Polymen silver®, silver sulfadiazine (Ilvadon®, and povidone
iodide (Betadine). We analyzed the wound sizes, histological ﬁndings,
and bacterial colony counts for the groups. We also inoculated the silver
materials on Mueller-Hinton agar plates containing MRSA and compared
the inhibition zones in the agar plates.
Results: The order of the rate of wound-size decrease was Acticoat® >
Aquacel® Ag > Polymen silver® > Medifoam silver® > Ilvadon® >
Betadine. The histological ﬁndings revealed that the Acticoat showed
more reepithelialization and granulation tissue formation and less
inﬂammatory cell inﬁltration than the other materials. The order of the
time required for wound healing was Acticoat® > Aquacel® Ag >
Polymen silver® > Ilvadon® > Medifoam silver® > Betadine. The
bacterial colony counts reduced in all the groups, except in the Medifoam
silver® group. The order of the size of the inhibition zone was
Acticoat® > Aquacel® Ag > Ilvadon® > Polymen silver® > Betadine >
Medifoam silver®.
Conclusion: Silver-coated or silver-impregnated wound dressings can
be used for treating MRSA-infected wounds. Considering its superior
efﬁcacy in comparison to the efﬁcacies of other silver-coated or silver-
impregnated wound dressings, Acticoat should be preferentially used for
the treatment of MRSA-infected skin wounds.
P1564 Efﬁcacy of ceftazidime/NXL104 combination in murine
septicaemia caused by extended-spectrum b-lactamases and
AmpC-producing Enterobacteriaceae sp.
P. Levasseur °, A.M. Girard, L. Lavallade, C. Miossec, D. Shlaes,
M. Black, J. Pace, K. Coleman (Romainville, FR; Connecticut, US;
Philadelphia, US)
Objective: NXL104 is a novel b-lactamase inhibitor that has been shown
in vitro to inhibit both class A and class C enzymes. It is in phase 2
of clinical development in combination with ceftazidime (CAZ). In
this study, the efﬁcacy of CAZ/NXL104 was evaluated against CAZ-
resistant (CAZ-R) Enterobacteriaceae bearing extended spectrum and
AmpC b-lactamases in a murine septicaemia model.
Methods: MICs were determined with NXL104 at 4 microgram/mL
ﬁxed concentration and variable concentrations of CAZ. Septicaemia:
Groups of mice (n = 10 to 20) were intraperitoneally infected with one of
12 CAZ-R strains (MICs 32−>128 microgram/mL) expressing multiple
b-lactamases including CTX-M, SHV, TEM, and AmpC: ﬁve strains
of Klebsiella pneumoniae; three strains of Escherichia coli; two strains
each of Enterobacter cloacae and Citrobacter freundii. Sub-cutaneous
treatments were given one- and four-hours post-infection. CAZ/NXL104
was administered at 4/1 weight ratio; reference treatments were CAZ
alone, cefotaxime (CTX) and piperacillin/tazobactam (PTZ). The 50%
effective dose (ED50) was calculated by the Probit method.
Results: MICs of CAZ/NXL104 for the 12 CAZ-R strains were
0.125−1 microgram/mL. In vivo, CAZ/NXL104 was signiﬁcantly more
effective compared to CAZ, CTX, or PTZ against all strains (p< 0.05).
ED50 ranges of CAZ/NXL104 were 2−27mg/kg for these strains
compared to >60mg/kg, >90mg/kg, and >90mg/kg respectively for
CAZ, CTX, and PTZ.
Conclusion: The potent in vitro activity of NXL104 when combined
with CAZ, against CAZ-R Enterobacteriaceae bearing class A ESBLs
and class C b-lactamases, translates into good parenteral efﬁcacy in the
mouse septicaemia model.
P1565 In vivo synergism between cefditoren and speciﬁc antibodies
against a penicillin-resistant serotype 6B Streptococcus
pneumoniae in a mice sepsis model
F. Caﬁni, M.J. Gimenez °, J. Yuste, D. Sevillano, L. Aguilar, L. Alou,
M. Torrico, N. Gonzalez, J. Prieto, P. Coronel (Madrid, ES)
Objective: To explore the in vivo effect of the presence of speciﬁc
antibodies on the efﬁcacy of cefditoren (CDN) treatment of sepsis caused
by a serotype 6B S. pneumoniae isolate non-susceptible to b-lactams
(penicillin and cefotaxime MIC of 2mg/l, amoxicillin MIC of 4mg/l).
Methods: CDNMIC for the infecting strain was 1mg/l. Eight to 12 week
old female BALB/c mice weighing 19−22 g were used. Hyperimmune
serum (HS) was obtained from mice weekly inoculated with whole cell
heat-inactivated inoculum for 5 weeks. All experiments were performed
in groups of 5 animals inoculated with 2×107 cfu by intraperitoneal
(i.p.) route. Animals were observed and deaths recorded for 7 days. The
highest double dilution (1/2, 1/4, 1/6) of HS producing 0% survival
(when single administered 1 h before inoculation of the infecting strain)
and the highest CDN dose (6.25, 12.5, 25 and 50mg/kg; three times daily
for 48 h initiating subcutaneous treatment 1 h after inoculation) showing
0% survival of infected animals were determined in separate dose-
ranging studies versus placebo. The HS dilution and CDN dose showing
0% survival of infected animals in separate experiments were combined
to explore synergism: animals received an i.p. single administration of
the HS dilution 1 h prior to inoculation, and CDN treatment (three times
daily for 48 h) was initiated 1 h after inoculation.
In addition, for pharmacodynamic purposes, serum concentrations of
CDN were measured in non-inoculated mice at 15 min, 30 min, 1 h, 2 h,
4 h, 6 h and 8 h after a single dose administration of the minimal dose
obtaining 100% survival in experiments with antibiotic administration
alone. Two animals per timepoint were used. The percentage of the
dosing interval that concentrations exceeded the MIC (T>MIC) was
determined.
Results: The table shows %survival over time.
Experimental arm % Survival
24 h 48 h Day 7
Control (placebo) 40 0 0
HS 1/2 dilution 80 40 40
HS 1/4 dilution 60 20 0
CDN 50 100 100 100
CDN 25 40 40 40
CDN 12.5 60 0 0
CDN 12.5 + HS 1/4 100 100 100
CDN 50mg/kg provided a T>MIC of 33.4% of the dosing interval (8 h).
Conclusions: CDN showed 100% efﬁcacy at doses of 50mg/kg, with
T>MIC of 33.4%. In the presence of antibodies, sub-therapeutic doses
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of CDN produced 100% survival in mice infected by a b-lactam non-
susceptible serotype 6B strain, due to the synergistic action of CDN
12.5mg/kg (0% survival alone) and HS 1/4 dilution (0% survival alone).
P1566 Synergistic antimicrobial efﬁcacy of furanone C30
and tobramycin against Pseudomonas aeruginosa in an
intraperitoneal foreign-body infection mouse model
L. Christensen °, M. van Gennip, M. Alhede, N. Kumar, S. Kjelleberg,
N. Høiby, T. Bjarnsholt, M. Givskov (Copenhagen, DK; Sydney, AU)
Objective: Pseudomonas aeruginosa bioﬁlms are frequently linked
to infections on foreign-body implants, which can cause serious
complications. P. aeruginosa uses quorum sensing (QS) to regulate its
virulence, and the bioﬁlm mode of growth contributes to P. aeruginosa’s
tolerance towards the immune system and numerous antibiotics.
Previously, we have shown that in vitro wild-type (WT) P. aeruginosa
bioﬁlms treated with either the QS inhibitor (QSI) furanone C30 or
tobramycin alone had little effect on the eradication, but treatment with
both C30 and tobramycin showed a synergistic effect and killed the
bioﬁlm. This synergistic effect was also tested in an in vivo bioﬁlm
model.
Methods: The pharmacokinetics of 30mg/kg body weight (BW)
tobramycin was estimated in non-infected BALB/c mice and the
calculated half-life (t1/2) was 0.37 hours. We used a modiﬁed version of
the in vivo foreign-body infection model introduced in 2007 and inserted
silicone tube implants (id 4mm, od 6mm) instead of square implants
in the mice. The implants were colonized with WT P. aeruginosa and
inserted in the peritoneal cavity of BALB/c mice. Treatments consisted of
i.p. injection of: (a) C30 (1mg/kg BW, dissolved in 2.6% ethanol) every
8-hour, (b) 2.6% ethanol every 8 hour, (c) 30mg/kg BW tobramycin,
and (d) 0.9% NaCl. Treatment with C30 and tobramycin was initiated
1-hour and 24-hours post-insertion, respectively. After insertion the mice
were divided into four groups: Gr. 1 (combination treatment) injection
(a and c) (n = 11); Gr. 2 (C30 group) injection (a and d) (n = 8); Gr. 3
(tobramycin group) injection (b and c) (n = 10); Gr. 4 (placebo) injection
(b and d) (n = 9). Implants were removed 48-hours post-insertion and the
CFUs per implant were determined.
Results: Combination treatment of WT P. aeruginosa (Gr. 1) resulted in
a signiﬁcant clearing of the implants as compared to both the placebo
and the single treatments groups (Gr. 2, Gr. 3) (p = 0.0002, p = 0.0003
and p = 0.001, respectively). A signiﬁcant difference in clearing was also
observed between the placebo group and the single treatment groups
(p = 0.006 and p = 0.0003). We also found a signiﬁcant difference in
clearing between the two single treatment groups (p = 0.01).
Conclusion: The present results showed that a synergistic antimicrobial
efﬁcacy can be achieved when treating with a combination of furanone
C30 and tobramycin, resulting in an increased clearance of P. aeruginosa
during a foreign-body infection in mice.
P1567 Effect of qnrA, qnrB and qnrS on the in vivo activity of
ﬂuoroquinolones
J. Domı´nguez-Herrera °, C. Velasco, F. Docobo-Pe´rez,
J.M. Rodrı´guez-Martı´nez, R. Lo´pez-Rojas, A. Briales, C. Pichardo,
P. Dı´az-de-Alba, J. Pacho´n, A. Pascual (Seville, ES)
Objectives: Since the introduction of the ﬂuoroquinolones, resistance of
the Enterobacteriaceae to these agents has become common. The main
mechanism of quinolone resistance is the accumulation of mutations
in the Type II Topoisomerases. However, plasmid-mediated quinolone
resistance, mainly qnr genes, contributes to reduced susceptibility to
those agents allowing the emerging of high level resistant mutants
in vitro. The aim of the study was to investigate the in vivo implication
of qnrA, qnrB or qnrS, using transformed strains of Escherichia coli, in
order to clarify the clinical implication of these genes in the treatment
of infections with ﬂuoroquinolones.
Methods: The bacteria strain E. coli ATCC 25922 was transformed with
the pBK-CMV plasmid alone or the same plasmid with the qnrA, qnrB
or qnrS genes. Pharmacokinetic studies were performed after a single
intraperitoneal dose of ciproﬂoxacin (CPX) (20mg/Kg) or levoﬂoxacin
(LVX) (25mg/Kg), in female immunocompetent mice C57BL/6. Using
an agar diffusion bioassay the pharmacokinetic parameters, area under
curve (AUC) and serum peak concentration (Cmax) were determined.
To evaluate the efﬁcacy of different treatments, we used an experimental
pneumonia model in female immunocompetent mice C57BL/6 during
72 hours. The animals were included in three different therapeutic
groups (n = 15): control (without treatment), CPX (40mg/Kg·day) or
LVX (50mg/Kg·day), for the four strains. After this, viable bacteria in
lungs (log10 CFU/g of lung), mortality (%) and qualitative blood culture
(%) were measured. Results were statistically analyzed with the ANOVA
(with post-hoc test of Tukey and Dunnett) or c2 tests.
Results: Pharmacokinetic parameters: CPX (AUC 8.21 ug·h/mL y Cmax
13.22 ug/mL) and LVX (AUC 5.39 ug·h/mL and Cmax 8.71 ug/mL).
Pharmacodynamic parameters (PD) (AUC/MIC 0−24 h) for each strain
are shown in the attached table.
The results in the pneumonia model are shown in the table.
Conclusions: The presence of the qnrA, qnrB or qnrS genes, in E. coli
strains reduces the therapeutic efﬁcacy of ciproﬂoxacin and levoﬂoxacin
in an experimental pneumonia model in mice.
E. coli strain Group MIC
(mg/L)
PD parameter
(AUC/MIC 0−24 h)
Log10 CFU/
g of lung
(mean±sd)
Mortality
(%)
Positive blood
culture (%)
ATCC 25922 (pBK-CMV) Control – – 9.37±0.48 100 100
CPX 0.002 8210 1.87
a ±2.07 53.33a 0a
LVX 0.004 2695.21 1.67a±2.50 28.57a 0a
ATCC 25922 (pBK-Qnr A) Control – – 9.40±0.25 100 92.86
CPX 0.125 131.36 5.71ab±0.86 53.33a 26.67a
LVX 0.5 21.56 5.71ac±0.75 71.43a 21.40a
ATCC 25922 (pBK-Qnr B) Control – – 8.84±0.75 100 100
CPX 0.125 131.36 4.95ab±1.71 57.14a 35.71ab
LVX 0.125 86.25 4.54ac±1.49 50a 28.57ac
ATCC 25922 (pBK-Qnr S) Control – – 8.36±1.26 93.33 93.33
CPX 0.125 131.36 5.38ab±1.75 42.86a 28.57ab
LVX 0.5 21.56 4.99ac±1.63 35.71a 21.43a
Statistical signiﬁcance (p 0.05): avs. internal control group; bvs. E. coli ATCC 25922 (pBK-CMV) CPX treatment;
cvs. E. coli ATCC 25922 (pBK-CMV) LVX treatment.
P1568 A single 1200mg human equivalent dose of oritavancin is
highly efﬁcacious in the neutropenic mouse thigh infection
model
D. Lehoux °, K. Laquerre, V. Ostiguy, I. Fadhil, M. Malouin,
C. Cadieux, N. Goyette, S. Fournier, I. Sarmiento, F. Arhin, G. Moeck,
T. Parr Jr. (St. Laurent, CA)
Objectives: Oritavancin (ORI) is a lipoglycopeptide active against Gram-
positive bacteria including streptococci, staphylococci, enterococci,
and clostridia irrespective of their vancomycin- or oxacillin-resistance
phenotype. Previous animal studies and a Phase 2 clinical study
demonstrated that single and infrequent doses of ORI are efﬁcacious
dosing regimens. In this study, we compared the efﬁcacy of several ORI
human equivalent (HEQ) doses including a single dose in a neutropenic
murine thigh infection model using 14 Staphylococcus aureus (SA)
clinical isolates.
Methods: Thigh infection was established in neutropenic female
CD-1 mice (19−21g; n = 3/group). Mice were made neutropenic by
intraperitoneal injection of cyclophosphamide 4 days (150mg/kg) and 1
day (100mg/kg) before the infection. Each inoculum consisted of one of
14 clinical isolates (3 methicillin-susceptible SA [MSSA], 11 methicillin-
resistant SA [MRSA]; ORI MICs 0.015 to 2mg/L). The mice were
infected with the inoculum containing 105 colony forming units (CFU)
into each thigh. Efﬁcacy of ORI doses simulating human exposure (i.e.
24 h AUC-matched) of 100, 200, or 400mg daily x 3 days, or a single
1200mg HEQ dose was evaluated. Both thighs were harvested and CFU
were counted after 72 h treatment. Mean Log CFU/thigh changes from
baseline were calculated, and correlation between the efﬁcacy and MIC
of tested strains was evaluated.
Results: ORI efﬁcacy was HEQ dose-dependent. Treatment with 100,
200, or 400mg daily x 3 days, or a single 1200mg HEQ dose generated
1.5, −0.1, −1.6, and −2.7 log CFU/thigh changes from baseline against
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MSSA, and 0.8, −0.9, −2.8, −2.8 Log CFU/thigh changes from baseline
against MRSA, respectively. Bacterial load reduction was signiﬁcantly
greater (p0.05) for the single 1200mg dose compared to the 200mg
daily dose for both MRSA and MSSA. The log CFU reduction observed
with the 200mg daily dose x 3 remained similar for all tested strains
independent of their MIC, as it did with the single 1200mg HEQ dose.
Conclusion: Front loading of ORI exposure was the most effective
dosing regimen in this model. The more rapid and profound bacterial
killing that was achieved by the 1200mg HEQ dose of ORI is consistent
with its concentration-dependent bactericidal activity in vitro. The
apparent lack of impact of ORI MIC on in vivo efﬁcacy, for the strains
evaluated here, suggests that the test strains fall within the wild-type
ORI susceptibility distribution.
P1569 Ceftaroline is superior to cefepime against a Klebsiella
pneumoniae strain an experimental rabbit meningitis model
P. Cottagnoud °, A. Stucki, F. Accosta, U. Eggerman, D. Biek,
M. Cottagnoud (Berne, CH; Oakland, US)
Objectives: In the present study we tested ceftaroline versus cefepime
as monotherapy against a Klebsiella pneumoniae strain in the rabbit
meningitis model and determined the penetration of ceftaroline
into inﬂamed meninges and uniﬂamed meninges. Ceftaroline is a
novel, parenteral, broad-spectrum cephalosporin exhibiting bactericidal
activity against Gram-positive organisms, including methicillin-resistant
Staphylococcus aureus (MRSA), as well as common Gram-negative
pathogens.
Methods: We used the rabbit meningitis model as described by Dacey
and Sande. The Klebsiella pneumoniae strain has been kindly provided
by Dr. S. Droz, Inst. Inf. Dis., Bern. The MICs (mg/L) were the
following: cefepime: 0.25mg/L, ceftaroline: 1mg/L. Meningitis was
induced by intracisternal inoculation of 106 CFU. Treatments were
administered 8 h after inoculation and evaluations were performed over
a period of 8 h. Ceftaroline (40mg/kg) was injected at h 0 and 4 in
order to mimic kinetics in humans. Cefepime (100mg/kg) was injected
at hour 0 and 4, as a standard dose previously used in this model and
corresponding to high doses in humans. CSF samples were repeatedly
collected during therapy in order to determine killing rates. Results of
the bactericidal activity are expressed in delta log10 CFU/ml·h and delta
log10 CFU/ml over 8 h. Penetration of ceftaroline into inﬂamed meninges
was measured by comparison of CSF AUC/serum AUC (Area Under
the Curve). Killing rates of the different regimens are presented in the
following table.
Results: Penetration of ceftaroline into inﬂamed meninges: 15.1%±9.7,
and into uninﬂamed: 3.17%±1.3.
Conclusions: 1. Ceftaroline was superior to cefepime against Klebsiella
pneumoniae in this experimental rabbit meningitis model. The pene-
tration of ceftaroline into inﬂamed meninges was 15% and 3% into
uninﬂamed meninges.
Groups (N) Inoculum
(log10 CFU/ml)
Killing rates/h
(delta log10 CFU/ml·h)
Killing rates/8 h
(delta log10 CFU/ml·8 h)
Controls (10) 6.13±0.24 +0.12±0.02 +1.0.8±0.22
Cefepime (10) 5.82±0.88 −0.48±0.09 −3.54±0.94
Ceftaroline (10) 6.18±0.70 −0.70±0.17* −5.61±1.08**
*P< 0.01, ceftaroline versus cefepime; **P< 0.01, ceftaroline versus cefepime.
P1570 Protective effect of xylitol and lactobacilli against
Clostridium difﬁcile infection in hamster model
P. Naaber, K. Truusalu °, I. Smidt, S. Ko˜ljalg, E. Sepp, P. Hu¨tt,
R. Ma¨ndar, J. Stsepetova, M. Mikelsaar (Stavanger, NO; Tartu, EE)
Objectives: To optimize Clostridium difﬁcile infection model in
hamsters and to evaluate the protective effect of lactobacilli, xylitol and
their combinations.
Methods: To ﬁnd an optimal C. difﬁcile infection model, the hamsters
were treated with ceftriaxone (n = 10) or ampicillin (n = 20) prior
inoculation with C. difﬁcile VPI 10463. Intestinal lactobacilli, C. difﬁcile
and total anaerobes were counted in the intestine of dead or sacriﬁced (on
Day 5 after challenge with C. difﬁcile) animals. To evaluate protective
effect hamsters were treated with lactobacilli (L. rhamnosus GG, n = 5;
mixture of lactobacilli − L. paracasei B472 and L. rhamnosus B11,
n = 5), xylitol (n = 6) and their combination (n = 12 and n = 5) before and
after ampicillin and after C. difﬁcile administration.
Results: (1) Ceftriaxone (60mg/kg) and C. difﬁcile spores (105) did not
induce infection in hamster model. (2) The optimal model was achieved
applying ampicillin 30mg/kg and 10−30 C. difﬁcile spores. The lethal
infection was registered during 1−3 days with high C. difﬁcile counts
in small intestine (6−8.3 log CFU/g). (3) Lactobacillus GG or mixture
of lactobacilli (108 CFU/ml) administered a day before and daily after
challenge with C. difﬁcile did not prevent lethal C. difﬁcile infection. (4)
Xylitol (1ml 20% solution) alone or in combinations with lactobacilli
(1010 CFU/ml) administered daily starting 5 days before C. difﬁcile
challenge signiﬁcantly delayed lethal infection (median of survival days
4−5 vs 1, p0.001). Xylitol in combination with applied lactobacilli
signiﬁcantly increased survival of animals on Day 5 after challenge with
C. difﬁcile: xylitol 2/6, p = 0.1; xylitol + GG 7/12, p = 0.005; xylitol
+ mixture of lactobacilli 3/5, p = 0.02 vs control 0/10. At the same
time, lactobacilli in combination with xylitol enhanced signiﬁcantly
5-Day survival when compared to xylitol mono-treatment (OR 0.1 [CI
95%; 0.010–0.975]). All survived animals were C. difﬁcile and its toxin
negative. No differences in lactobacilli, anaerobes and C difﬁcile counts
were found in different settings.
Conclusion: In our hamster model prophylactic administration of xylitol
delayed lethal infection and reduced mortality. Co-administration of
xylitol with lactobacilli had synergistic effect. The protective effect may
be due to the inhibition of C. difﬁcile adhesion by xylitol and modulation
of intestinal microﬂora by xylitol and lactobacilli.
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P1571 Non-invasive imaging technologies to monitor bacterial skin
infection in rodent models
S. Kimber, C. DeBank, R. Garland, N. Williams ° (Bristol, UK)
Objective: Staphylococcus aureus is the most prevalent bacterial
pathogen isolated from skin and soft tissue infection in human
patients. Increasing methicillin-resistance necessitates the identiﬁcation
of alternative treatments. Testing potential treatments requires the use
of predictive models of infection and these should generate high quality
data, while at the same time considering the 3Rs. The aim of our studies
is to assess the beneﬁts of non-invasive luminescent and thermographic
in vivo imaging techniques in monitoring bacterial skin infection.
Methods: BALB/c mice were anaesthetised and subjected to tape-
stripping to disrupt the epidermis. Stationary growth phase S. aureus
(either a luciferase expressing strain or a wild type) were inoculated
onto the area. At 2 or 4 hours post-infection, separate groups of mice
were treated with vehicle or topical antimicrobial treatment. Mice were
observed regularly for symptoms of clinical disease throughout the
timecourse of infection, and the luminescence imaging used to monitor
the extent and spread of bacterial growth. In addition, thermal imaging
was used to measure the local temperature at the wound site as a marker
of inﬂammatory changes. At termination, the wound area was excised,
homogenised and plated out to assess bacterial numbers.
Results: The optimal dose of bacteria leading to clinical infection was
identiﬁed. At these doses, cutaneous lesions were established without
systemic clinical signs of infection over the timecourse. Positive control
treatment was effective in reducing bacterial counts. Thermal imaging
allowed a comparison of skin spot temperature with core temperature
(using rectal thermometer/transponders). This was compared between
infected, non-treated animals; infected, treated animals and uninfected
(shaved only) animals. Bioluminescent strains allowed the quantiﬁcation
of infection, as superﬁcial infections are not associated with the loss of
signal which can occur in deep tissue infections.
Conclusions: Non-invasive imaging can allow additional real-time
information to be obtained from cutaneous infection models. The data
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obtained correlates closely to recovered bacterial numbers, but has the
advantage of allowing kinetic measurements to be made on many fewer
animals. Thermal imaging may also prove useful (provided controls are
employed to clarify whether temperature changes simply reﬂect core
temperatures, responses to shaving, or the extent of bacteria infection).
P1572 Pharmacological modiﬁcation of iron homeostasis by nifedip-
ine affects the course of Salmonella Typhimurium infection
S. Mair °, M. Nairz, T. Muehlbacher, A. Schroll, T. Sonnweber,
G. Weiss (Innsbruck, AT)
Objective: Iron overload aggravates the clinical course of infections by
negatively affecting cell mediated immune mechanisms of macrophages
and T helper cell type 1 effector pathways. Recently, we have shown
that the calcium antagonist nifedipine enhances DMT1 mediated iron
transport in vitro and causes subsequent depletion from liver and the
circulation in iron overloaded mice. Herein, we thus investigated whether
nifedipine may impact on the clinical course of an invasive infection.
Methods: Mice were fed with a control diet or iron enriched diet for
three weeks, infected intraperitoneally with Salmonella Typhimurium and
treated with solvent control or nifedipine for three consecutive days. 24
hours later mice were sacriﬁced, the bacterial loads were quantiﬁed in
the liver and the spleen, and the expression of iron and innate immunity
genes were determined by means of RT-PCR and Western blot analysis.
Results: Nifedipine treated mice, independently of dietary iron overload,
showed an improved survival and presented with reduced numbers
of Salmonella in the liver and the spleen as compared to solvent
injected animals. Even though these effects were more pronounced in
the iron diet fed group. This was paralleled by reduced iron content
and decreased ferritin expression in the liver in the nifedipine treated
group. Interestingly, we did not observe differences in the expression of
a panel of pro- and anti-inﬂammatory cytokines according to nifedipine
treatment.
Conclusion: Although, detrimental effects of nifedipine could have been
anticipated in this sepsis model, our data provide evidence that nifedipine
has a beneﬁcial effect and may be a promising adjunct therapy by
mobilizing iron and decreasing the availability of this essential nutrient
for bacteria.
P1573 Gene expression studies on the effect of dexamethasone in
infant rats with pneumococcal meningitis
C. Blaser °, M. Wittwer, S.L. Leib (Berne, CH)
Objectives: An intensive inﬂammatory reaction of the host contributes
to the pathophysiology of bacterial meningitis (BM). In consequence,
the anti-inﬂammatory dexamethasone (DXM) has been advocated as
adjuvant therapy to antibiotics. Recent meta-analyses have demonstrated
that adjunctive DXM is beneﬁcial in the treatment of adults with BM
but showed no beneﬁcial effect in neonates and children. In an unbiased
approach, differential gene expression by dexamethasone was assessed
in infant rats with pneumococcal meningitis.
Methods: Eleven days old rats were infected intracisternally with 10 mL
saline containing Streptococcus pneumoniae (serogroup 3, 6.18 log10
cfu/ml; n = 8) or sham-infected with sterile saline (n = 6). All animals
were treated with ceftriaxone (100mg/kg body weight s.c.). Animals
of both groups were then randomized to either receive placebo (0.85%
sterile saline s.c., q8 h, n = 4 for meningitis and n = 3 for controls) or
an equal volume of saline containing DXM (0.7mg/kg body weight
s.c., q8 h, n = 4 for meningitis and n = 3 for controls). The animals
were sacriﬁced at 72 h after infection and the hippocampus and cortex
were dissected. Total RNA was isolated and processed for analysis of
gene expression based on Rat Exon 1.0 ST Microarrays of Affymetrix
and quantitative real-time PCR. Based on the results of a previous
microarray study in experimental pneumococcal meningitis, 47 genes
such as neuronal markers, components of neurogenetic pathways (wnt,
TGF), microglial markers, on and off signals for chemotaxis were
selected for real-time PCR analysis.
Results: A signiﬁcant correlation between the results of microarray
analysis and quantitative PCR was observed (r = 0.842, p< 0.0001).
In ongoing analysis of the microarray and PCR results, Aif1, Cxcl10
and P2ry6 were found to be up-regulated by the infection and down-
regulated under DXM treatment. In contrast, P2ry12 was not regulated by
the infection but was down-regulated in infected DXM-treated animals
below the level found in sham-infected, saline-treated animals.
Conclusions: Aif1, Cxcl10, P2ry6 and P2ry12 are associated with
microglial activation and/or induction of chemotaxis. In summary,
infection with S. pneumoniae and the subsequent inﬂammatory reaction
activates microglia and chemotaxis. The anti-inﬂammatory DXM can
reduce these processes.
P1574 The impact of Panton-Valentine leukocidin on the
patogenicity of Staphylococcus aureus USA300 in rabbit
skin infection model
U. Lipinska, O. Dumitrescu °, C. Badiou, A. Tristan, Y. Benito,
F. Vandenesch, J. Etienne, K. Hermans, G. Lina (Ghent, BE; Lyon, FR)
Background: S. aureus encoding Panton Valentine leukocidin (PVL)
have been epidemiologically linked to primary skin and soft tissue
infection in humans. This link, as well as the detection of PVL in
human samples, suggests that PVL plays a role in the pathophysiology
of primary skin and soft tissue infections. Conﬂicting data were obtained
in experimental studies using mice, a species poorly sensitive to PVL.
However, to date, the role of PVL in skin infection has not been
investigated using rabbits, a species highly sensitive to PVL.
Methods: USA300 PVL positive, its isogenic deltaPVL and USA300
deltaPVL PVL-complemented strains were cultured until mid-
exponential growth phase and washed with sterile PBS. The bacteria
were resuspended in PBS and approximately 108 cfu in 50 microliters
was immediately used for intradermal injection into the rabbits (11
animals per group). The size of the lesions and the area of dermonecrosis
were recorded on a daily basis, until day 21. On day 21, the animals were
euthanized and skin lesions were sampled for bacteriology and sera were
investigated for the presence of antibodies against PVL.
Results: The surface of the skin lesions due to PVL positive strains
(USA300 and USA300 deltaPVL PVL-complemented) were signiﬁcantly
higher compared to those induced by the PVL negative strain, from
day 1 to 7 for the USA300 wild strain and from days 1 to 3 for the
USA300 deltaPVL PVL-complemented strain. Dermonecrosis records
yielded similar results, but signiﬁcant difference was observed only the
ﬁrst day. Only rabbits challenged with PVL positive strains developed
antibodies against PVL, attesting for the in vivo PVL production by the
PVL positive strains. The median anti-PVL antibody titer increased 8.6-
fold after inoculation of USA300 strain and 20.7-fold after inoculation
of the USA300 deltaPVL PVL-complemented strain.
Conclusions: Rabbit model of skin abscess showed that PVL has an
impact at the early phase of the constitution of S. aureus USA300 skin
infection.
P1575 The choice of murine infection model and the immune
status of the mice has an impact on the pharmacodynamics
of dicloxacillin against Staphylococcus aureus infection
A. Sandberg-Shaal, C. Vingsbo Lundberg °, N. Frimodt-Møller
(Copenhagen, DK)
Objectives:Murine infection models are useful tools in pharmacokinetic
(PK) and pharmacodynamic (PD) studies of antibiotics. In this study we
compared the peritonitis model to the thigh infection model and the
impact of immunosuppression on the sensitivity of the infection models
in determining PD parameters for dicloxacillin.
Methods: NMRI mice were immunosuppressed with cyclophosphamide
at day 4 and 1 before inoculation. Immunosuppressed mice or
immunocompetent mice were then inoculated with S. aureus (clinical
isolate E19977) either intraperitoneally or intramuscularly. At one hour
post infection, mice were treated subcutaneously with a single dose of
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dicloxacillin ranging from 0.1 to 400mg/kg (n = 3 for each treatment
group). The bacterial loads in the peritoneum or the thigh were
determined at 4 hours post treatment.
Results: The log10 CFU level at start of treatment, the total increase
of log10 CFU levels (Emax) and the half max effective dose (ED50)
for the four infection models, immunocompetent peritonitis model
(IC peritonitis), immunosuppressed peritonitis model (IS peritonitis),
immunocompetent thigh model (IC thigh) and immunosuppressed thigh
model (IS thigh) is shown in table 1. The ED50 for dicloxacillin
was in the IC peritonitis model 6.7mg/kg, in the IS peritonitis model
10.6mg/kg, in the IC thigh model 20.6mg/kg and the IS thigh model
28.2mg/kg.
Conclusions: The murine peritonitis model resulted in a lower ED50
value for dicloxacillin than the thigh model regardless of immune
status of the mice, indicating that the peritonitis model is more
sensitive to antibiotic treatment of S. aureus infections. Further,
the immunocompetent variants resulted in lower ED50 values than
the corresponding immunosuppressed model, indicating that an intact
immune system contributes to the effect of the antibiotic. Thus, the
choice of infection model will have an impact in the PKPD results,
and this may especially be of importance when extrapolating PKPD
parameters to human infection.
Table 1. PD parameters for dicloxacillin in four infection models
CFU at start Emax (log10) ED50 (mg/kg)
IC peritonitis 5.75 2.43 6.75±1.55
IS peritonitis 5.30 3.63 10.59±1.32
IC thigh 6.74 1.94 20.62±1.35
IS thigh 6.79 2.91 28.24±1.63
P1576 Eradication of E. coli associated with inﬂammatory bowel
disease in a mouse model using ciproﬂoxacin and the
probiotic strain E. coli Nissle
A.M. Petersen, S. Schjørring °, S.C. Gerstrøm, K. Krogfelt
(Copenhagen, DK)
Objectives: Speciﬁc E. coli of the phylogenetic group B2 has been
linked to active Inﬂammatory Bowel Disease (IBD). In some studies
antibiotics have shown some, although shortlived, effect in the treatment
of IBD, and it has been demonstrated that E. coli Nissle has prophylactic
abilities comparable to 5-ASA in IBD. Our objective was to test treatment
of IBD associated E. coli combining Ciproﬂoxacin with E. coli Nissle
in a mouse model.
Methods: Two B2 E. coli strains from IBD patients and one E. coli
isolate from a healthy person were investigated. Colonisation was
achieved in streptomycin treated mice for 5 days with all tested E. coli
strains, and subsequently 3 different treatment setups were tested,
either treatment with inoculation for 3 days with E. coli Nissle alone,
treatment with 3 days of Ciproﬂoxacin alone or treatment with 3 days of
Ciproﬂoxacin followed by 3 or 9 days of treatment with E. coli Nissle.
Results: After colonisation of the mouse intestine with the tested strains
introduction of E. coli Nissle did not result in eradication of neither
IBD associated E. coli nor the E. coli from a healthy control, however
co-colonisation was obtained. Treatment with Ciproﬂoxacin for three
days alone resulted in effective eradication of tested E. coli, without any
detection of tested E. coli for the following nine days. Combination of
Ciproﬂoxacin for 3 days followed by E. coli Nissle for 3 days resulted
in a lack of colonisation with E. coli Nissle, however introduction of
E. coli Nissle every day for the rest of the study made it possible
to achieve an increase in colonisation with E. coli Nissle again. In
one set of experiments the tested IBD strain were surprisingly able
to recolonise after Ciproﬂoxacin treatment when E. coli Nissle were
introduced, however at a level 3 logs under E. coli Nissle.
Conclusion:, In the mouse model E. coli Nissle can not be used alone
as treatment of IBD associated E. coli, however 3 days of Ciproﬂoxacin
are efﬁcient in eradicating these strains. After Ciproﬂoxacin treatment
colonisation with E. coli Nissle is not possible with only 3 days
of inoculation. Furthermore, the introduction of E. coli Nissle may
support recolonisation with IBD associated E. coli after a treatment with
ciproﬂoxacin.
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P1577 Tolerance to prolonged treatment with linezolid
E. Martinez Alfaro °, M. Garcı´a Sanchez, J. Blanch Sancho, F. Mateos
Rodriguez (Albacete, ES)
Background: The goal of this study was to asses de tolerance to
prolonged treatment with linezolid, describe the adverse reactions and
consequences.
Methods: We reviewed retrospectively all patients attended at the
infectious disease unit between July 2002 until December 2008, who
received linezolid for more than one month.
Results: We included 30 patients. Fifty percent were women. The mean
age of patients was 58.5 years (range 16−85). The mean duration
of the treatment was 6.4 months (range 1.5−23 months). The main
indication for prolonged treatment with linezolid was prosthetic joint
infection in 11 of the 30 patients (36.36%) caused for both multidrug
resistant microorganism or either patients with allergic reactions to other
antibiotic, sixteen percent of patients had chronic ostheomielytis. Other
indications were diabetic foot infections, vascular devices infections,
multidrug tuberculosis and chronic ostheoarthritis. Twenty patients did
not present adverse reactions (66%), ﬁve patients presented severe
anaemia, three patients polyneuropathy (10%), 3 patients dizziness,
headache and insomnia (10%) and just one patient (3%) deafness.
Linezolid was stopped for the adverse reactions in ten patients (33%).
The patient with deafness and two patients with polyneuropathy were
recovered at 6 months. Just one patient have severe polyneurophaty,
after two years without treatment with linezolid.
Conclusions: Linezolid had adverse reactions when it was used for a
long time, so, it is important monitoring their effects. Almost all adverse
reaction disappear when the treatment is stopped. Polyneuropathy can
produce severe consequences and disablement for a long time.
P1578 Lack of an effect of linezolid on QTc interval prolongation
B. Damle °, R. LaBadie, C. Cuozzo, C. Alvey, C. Chong, H. Choo,
D. Kirby (New York, New London, US; Singapore, SG)
Objective: To demonstrate the lack of an effect of single intravenous
(IV) infusion doses of linezolid (600 and 1200mg), relative to placebo,
on the QTc interval.
Methods: This was a randomized, 4-way crossover, double-blind (for
linezolid/placebo; open label for moxiﬂoxacin) study in 40 healthy
subjects. Treatments included 1-h IV infusion of linezolid 600 and
1200mg, placebo, and oral moxiﬂoxacin 400mg (positive control), each
separated by a washout of 96 h. Pharmacokinetic (PK) samples and
triplicate 12-lead ECG were collected as follows: predose [−1 and −0.5 h
for ECG, and 0 h for ECG and PK], and 30 min, and at 1 (end of
infusion), 2, 4, 8, 12 and 24 h after dosing. PK were determined by
noncompartmental analyses. Time-matched, placebo-subtracted change
in QT intervals with Fridericia’s (QTcF) correction were determined for
linezolid and moxiﬂoxacin using a repeated measure mixed effect model
with appropriate terms for the given design and baseline as a covariate.
Results: The ﬁgure provides time-matched adjusted differences of QTcF
for each treatment compared to placebo values as obtained from the
statistical model. For both linezolid doses, the upper bound of the 90%
CI at every time point postdose was below 10 msec, thus satisfying the
criteria for a negative thorough QT/QTc study. Using the same repeated-
measures model, at population Tmax for moxiﬂoxacin (between 2 and
4 h) the 2-sided 90% CI when comparing moxiﬂoxacin to placebo was
greater than 5 msec indicating that the study was sensitive to assess
QTc prolongation. An increase in linezolid dose from 600 to 1200mg
resulted in an increase in mean Cmax and AUCinf values of 104%
and 134%, respectively. Mean clearance of linezolid was 13.7% lower
Clinical and experimental studies S459
for the 1200mg compared with the 600mg dose. Median Tmax values
and mean Vss values were comparable across doses but mean half-life
slightly increased with dose. A total of 29 treatment-emergent adverse
events (AEs) were reported by 24 subjects. The most common AE was
nausea occurring in 4 subjects receiving 1200mg linezolid. Other AEs
were headache and dysmenorrhoea, reported by 2 subjects each.
Conclusions: Therapeutic and supratherapeutic doses of linezolid did not
have a clinically relevant effect on QT/QTc interval. Linezolid exposure
increased in a more than dose proportional manner from 600 to 1200mg
dose. Single doses of linezolid up to 1200mg were well tolerated.
P1579 Safety, tolerability and pharmacokinetics of intravaginal
pentamycin
B. Frey Tirri, J. Bitzer, B. Geudelin, J. Drewe, C. Winnips ° (Basel, CH)
Objectives: Pentamycin is a polyene macrolide with a wide spectrum of
antimicrobial activity. The 3-mg dose strength of intravaginal pentamycin
is already registered in Switzerland for the treatment of vaginal candidi-
asis, trichomoniasis and mixed infections. The currently approved treat-
ment regimen is 3 to 6mg daily for 5−10 days. A higher-dosed vaginal
tablet of pentamycin (10-mg dose strength) is being developed for global
registration and the objective of this study was to evaluate the safety,
tolerability and pharmacokinetics of doses of intravaginal pentamycin
up to 10 times the new daily therapeutic dose in healthy volunteers.
Methods: This study was a double-blind, randomised (3:1), vehicle-
controlled, escalating-dose study in 19 healthy women (age range: 21−36
years), who applied daily either one of 5 doses of intravaginal pentamycin
(3, 10, 30, 60 or 100mg) or the corresponding dose of pentamycin
vehicle alone for 6 days. Safety and tolerability were assessed by physical
examination, complete gynaecological examination, monitoring of vital
signs and electrocardiogram, recording of adverse events, and laboratory
tests. Plasma concentrations of pentamycin were measured pre-dose and
then at 30 minutes, 1, 2, 4, 6, 12 and 24 hours post-dose on days 1 and 6
and pre-dose on days 2−5. The lower limit of quantiﬁcation of the assay
(high-performance liquid chromatography and mass spectrometry) was
5 ng/ml.
Results: There were no major differences in the occurrence of adverse
events across the dose groups and between the subjects treated with
the active compound (n = 15) and the vehicle-treated subjects (n = 5).
The most frequently reported adverse events were mild or moderate
vaginal discharge and mild symptoms of vaginal irritation, which
also occurred in women who applied the vehicle. The gynaecological
examination performed after treatment completion did not reveal
any abnormality. Blood pressure, electrocardiographic recordings and
laboratory parameters did not show signiﬁcant changes attributable to
the type of treatment or to the dose of active ingredient applied during
the study. The plasma levels of pentamycin were below the limit of
quantiﬁcation in all samples.
Conclusion: The intravaginal administration of pentamycin at a dose as
high as 100mg daily for up to 6 days does not increase the occurrence
of adverse reactions versus vehicle alone, and is not associated with
systemic absorption of the active ingredient through the vagina.
P1580 Antimicrobial effect of doxycycline on control of glycaemia
in diabetic patients with moderate periodontitis after
phase 1 periodontal treatment
M. Zangeneh, N. Zangeneh °, M. Naseh, J. Poursamimi, S. Golbon
(Tehran, Qazvin, IR)
Background: There are contradictory results of different studies about
the effect of periodontal treatment on metabolic control of diabetes. Due
to the importance of management of these patients, the purpose of this
study was to examine the effect of periodontal treatment (scaling and
root planning [SRP]) with doxycycline on glycemic control of type 2
diabetic patients.
Material and Methods: In this double blind randomized controlled
clinical trial, 40 patients with type 2 diabetes mellitus who had moderate
periodontitis were treated with SRP+ placebo (SRP; N= 20) or with SRP
+ doxycycline (SRP+Doxy; N= 20), 100mg/day, for 21 days. Periodontal
parameters including bleeding on probing (BOP), clinical attachment loss
(CAL), plaque index (PI), probing depth (PD) and also metabolic pa-
rameter (HbA1c) were recorded at baseline and 3 month after treatment.
Results: After 3 month, all periodontal parameters and HbA1c showed
signiﬁcant improvement in each group. (p< 0.001) The reduction of
all periodontal parameters and HbA1c was not signiﬁcant between
two groups in this study (pBOP= 0.799), (pCAL=0.667), (pPI=0.253),
(pPD=0.989), (pHbA1c = 0.301).
Conclusion: Periodontal treatment with the adjunctive systemic doxy-
cycline therapy may inﬂuence the systemic conditions of patients with
type 2 diabetes mellitus, but no statistical difference was observed
between control and treatment groups. Therefore, conﬁrmmatory studies
with a larger sample and controlled diabetic patients is necessary.
Research supported by the Islamic Azad University, Tehran Medical
Branch, Tehran, Iran.
P1581 Adult native septic arthritis: 10 years in review in order
to establish local guidelines on empiric antibiotic therapy
O. Clerc °, L. Senn, G. Prod’hom, G. Greub, G. Zanetti (Lausanne, CH)
Objective: Antibiotic stewardship includes development of practice
guidelines incorporating local microbiology and resistance patterns. In
case of septic arthritis (SA), addition of vancomycin to the empiric
therapy and broad-spectrum antibiotherapy in some clinical settings
are subjects of discussion. Our objective was to review the local
epidemiology of native septic arthritis in adults, in order to establish
local guidelines for empiric therapy.
Methods: Retrospective study based on positive synovial ﬂuid cultures
and hospital discharge diagnoses of SA obtained from 1999 to 2008
in patients 16 years. Medical records were reviewed to assess the
diagnosis and complete relevant clinical information.
Results: During this ten-year period, we identiﬁed 233 SA on native
joints in 231 patients. 107 episodes (46%) were obtained through positive
synovial ﬂuid cultures, and 126 episodes (54%) through the discharge
diagnosis. 147 SA (63%) were large joint infections (LJI). 35 SA (15%)
occurred in intravenous drug users. Preexisting arthropathy was present
in 51% of cases. 42% of patients with small joint infection (SJI) were di-
abetic, vs. 23% with LJI (p = 0.003). When available, synovial ﬂuid direct
examination was positive in 35% of cases. Etiologic agents are reported
in the table. Five of the 11 MRSA SA (45%) occurred in known carriers.
SJI were more frequently polymicrobial (24% vs. 1%, p< 0.001).
For LJI, an empiric treatment with amoxicillin/clavulanate (A/C) would
have been appropriate in 85% of cases. MRSA (8 cases) and tuberculous
(7 cases) arthritis would have been the most frequently untreated
pathogens. Addition of vancomycin to A/C in MRSA carriers would
rise the adequacy to 87%. In contrast, A/C would cover only 75% of
SJI (82% if restricted to non-diabetic patients). MRSA (3 cases) and
P. aeruginosa (9 cases, 7 monomicrobial) would be the main untreated
pathogens. An anti-pseudomonal penicillin would have been appropriate
in 94% of cases of SJI (P = 0.002 vs. A/C, p = 0.19 if diabetic patients
not included).
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Conclusions: Treatment with A/C seems adequate for empiric coverage
of LJI in our setting. Broad-spectrum antibiotherapy was signiﬁcantly
superior for SJI in diabetic patients, due to different causative bacteria.
In an area of low MRSA incidence, our results do not justify a systematic
empiric therapy for MRSA, which should be considered in a known
carrier.
Etiologic agent Large joints
No. of cases (%)
N= 147
Small joints
No. of cases (%)
N= 86
Polymicrobial 2 (1.4%) 21 (24.4%)
Staphylococcus aureus
–MSSA 78 (53%) 26 (30.2%)
–MRSA 8 (5.4%) 3 (3.5%)
Streptococcus spp. 20 (13.6%) 13 (15.1%)
P. aeruginosa 4 (2.7%) 7 (8.1%)
Other Gram-negative 14 (9.5%) 6 (7%)
Coagulase-negative staphylococci 3 (2%) 3 (3.5%)
Others 13 (8.8%) 2 (2.3%)
Unknown 5 (3.4%) 5 (5.8%)
P1582 Short parenteral antibiotic treatment for native septic
arthritis
L. Tovmirzaeva, J. Garbino, A. Moldovan, F. Jaques, I. Uc¸kay °
(Geneva, CH)
Objectives: The ideal duration of antibiotic treatment in the therapy of
septic native joint arthritis is unknown. To assess the epidemiology of
septic arthritis at Geneva University Hospitals. To assess risk factors for
recurrence with emphasis on surgical and medical treatment parameters.
Methods: Case–control study.
Results: A total of 169 episodes in 157 patients (median age 63 years,
65 females) were retrieved. The infected joints were: knee (n = 51),
hip (n = 21), shoulder (n = 32), ankle (n = 9), sterno-clavicular (n = 2),
elbow (n = 2), sacroiliac (n = 1), and interdigital (n = 43). In 21 episodes
(21/169, 12%), arthritis recurred after the end of antibiotic treatment.
In multivariate analysis, lack of surgical intervention (odds ratio 11.3,
95% conﬁdence interval 2.7–46.2), Gram-negative infection (OR 5.9,
1.4–25.3), and immunosuppression (OR 5.3, 1.3−22) were signiﬁcantly
associated with recurrence, while open arthrotomy vs. arthroscopic
drainage (OR 0.5, 0.2−1.8), total duration of antibiotic therapy (OR 1.0,
1.0−1.0), or duration of intravenous antibiotic therapy (OR 1.0, 1.0−1.0)
were not. Seven days of intravenous therapy had the same effect than
8 to 15 days (OR 0.4, 0.1−1.7) or <21 days of intravenous treatment
(OR 1.1, 0.4−3.1). 2 weeks of total antibiotic treatment had the same
outcome as a therapy of 2 to 4 weeks (OR 0.4, 0.1−2.3) or >4 weeks
(OR 0.4, 0.1−1.6).
Conclusions: Among modiﬁable parameters, at least one surgical
intervention is of utmost importance in the treatment of septic native
joint arthritis. The modalities of concomitant antibiotic therapy are
secondary. Selected antibiotics might be administered orally after few
days of parenteral regimen for a total duration of two weeks.
P1583 Initial empirical antimicrobial therapy and clinical outcome
of hospital-acquired pneumonia and ventilator-associated
pneumonia in Asian countries: an ANSORP study
D. Chung °, J.H. Song for the Asian Network for Surveillance of
Resistant Pathogens (ANSORP)
Objectives: We evaluated the empirical antimicrobial therapy and the
clinical outcome of hospital-acquired pneumonia (HAP) and ventilator-
associated pneumonia (VAP) among adults in Asian countries.
Methods: A total of 1,508 cases of HAP and 898 of VAP collected from
a prospective surveillance study performed by the Asian Network for
Surveillance of Resistant Pathogens (ANSORP) in 10 Asian countries
from 2008 to 2009 were analyzed. Clinical outcome was assessed by
crude mortality, pneumonia-related mortality at 30 days, and the length
of hospital stay.
Results: Late-onset pneumonia accounted for 83.1% of HAP and 73.7%
of VAP. Acinetobacter spp., Pseudomonas aeruginosa, Staphylococcus
aureus, Klebsiella pneumoniae were the most frequent respiratory
isolates. Among culture-positive cases of HAP and VAP, polymicrobial
infection accounted for 23.3% and 31.2%, respectively. Initial empirical
antimicrobials included penicillins (48.0%), cephalosporins (41.9%), ﬂu-
oroquinolones (27.7%), carbapenems (22.5%) and glycopeptides (12.1%)
in HAP, whereas cephalosporins (47.6%), penicillins (44.5%), carbapen-
ems (35.7%), ﬂuoroquinolones (19.0%) and glycopeptides (15.2%) in
VAP. Due to the emergence of Acinetobacter spp. in many countries,
colistin was initially used in 3.0% of HAP and 14.3% of VAP cases.
Initial empirical antimicrobial regimen was concordant in 73.7% of HAP
and 67.6% of VAP. Crude mortality at 30-day was 34.9% (14.3–57.4%)
in HAP and 44.8% (11.1–66.7%) in VAP. Pneumonia-related mortality at
30-day was 22.8% for HAP and 30.2% for VAP. Pneumonia-related mor-
tality in those receiving concordant empirical therapy was lower than in
those receiving discordant therapy (17.6% vs. 23.9% in HAP, P = 0.045;
26.6% vs. 37.1% in VAP, P = 0.014). The length of hospital stay in HAP
and VAP was 30.5 days (SD 36.0) and 28.5 days (SD 34.4) respectively.
Conclusion: Anti-pseudomonal b-lactams and glycopeptides were
frequently used as initial empirical antimicrobial regimens for HAP and
VAP in Asian countries. Colistin was also frequently used for treatment
of VAP for the treatment of Acinetobacter pneumonia. Antimicrobial
resistance in major pathogens negatively affected the clinical outcome
of HAP and VAP.
P1584 Clinical efﬁcacy of oral vancomycin compared to oral
and to intravenous metronidazole in Clostridium difﬁcile
infection, 2009
J. Leitner °, D. Schmid, H.W. Kuo, F. Allerberger, V. Michl, P. Tesik,
C. Wenisch (Vienna, AT)
Objectives: Recent reports showed frequent treatment failure of
metronidazole for the treatment of Clostridium difﬁcile infection (CDI).
Therefore we wanted to compare the efﬁcacy of oral vancomycin with
oral and intravenous metronidazole in inpatients with CDI.
Methods: The source population comprised CDI patients of a Viennese
hospital fulﬁlling the case deﬁnition given by ESCD with the need
of antimicrobial therapy. Study subjects were included consecutively
according to their hospital admission between November 2008 and
August 2009. Exclusion criterion was the lack of 30-day follow-
up. The treatment regimes oral metronidazole (group I), intravenous
metronidazole (group II) and oral vancomycin (group III) were compared
with regards to duration of diarrhoea following the start of antibiotic
therapy, treatment failure of the ﬁrst chosen antibiotic therapy regime
(deﬁned by change to an alternative antibiotic regime), frequency of
recurrent CDI (i.e. deﬁned by recurrent episode following 2 weeks
previous episode) and 30-day mortality. For univariable analyses c2 test,
c2 test for contingency tables or Fisher’s exact test and the t-test were
used. The Charlson Index was used for co-morbidity scoring.
Univariable analyses
Outcome Therapy regime
Metronidazole p.o.
N = 47
c2 -test p Metronidazole i.v.
N = 11
c2 -test p Vancomycin
N= 5
n (%) RR (95%CI) n (%) RR (95%CI) n (%) RR (95%CI)
No response to ﬁrst choice
antibiotic(s)
8 (17%) 0.43 (0.12−1.48) 0.24 1 (9.1% ) 0.23 (0.03−1.96) 0.21 2 (40%) 1
Recurrent episode of diarrhoea
(2 weeks since the onset of
the previous episode)
2 (4.3%) n.c. 1 1 (9.1%) n.c. 1 0 1
30-day mortality 3 (6.4%) n.c. 1 4 (36.4%) n.c. 0.24 0 1
Metronidazole p.o.
N = 44
t-test p Metronidazole i.v.
N = 11
t-test p Vancomycin
N= 5
Mean Range Mean Range Mean Range
Duration of diarrhoea (days) 14 1−82 0.86 8.4 3−24 0.12 13.4 7−21
Results: After the exclusion of 25 patients due to missing follow up
data, a total of 63 study subjects remained for analyses. The patient
characteristics of the three therapy groups did not reveal relevant
imbalances in age, sex or comorbidities. There were no signiﬁcant
differences regarding therapy response, recurrences, and duration of
diarrhoea between the treatment regimes (Table 1). In contrast, 30-
day mortality was signiﬁcantly higher in patients on intravenous
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metronidazole compared to the two oral treatment regimens (p = 0.01
using c2 test for contingency tables).
Conclusion: Intravenous metronidazol was associated with a poor
outcome in C. difﬁcile infection compared to oral vancomycin and oral
metronidazole.
P1585 Phagocytic activity and production of reactive oxygen
species in J774 mouse macrophages exposed to increasing
concentrations of oritavancin: comparison with vancomycin
and azithromycin
S. Lemaire °, P. de Galard, P.M. Tulkens, M.P. Mingeot-Leclercq, F. Van
Bambeke (Brussels, BE)
Objectives: Oritavancin (ORI) is a lipoglycopeptide that accumulates to
high levels in macrophages (up to 300-fold) and localizes in lysosomes.
Although ORI shows extensive activity against intraphagocytic forms of
S. aureus (Barcia-Macay et al, AAC, 2006), concerns have been raised
about the possibility for the drug to also impair critical macrophage
functions. Our aim was to assess the effect of ORI in vitro on
phagocytosis of infectious organisms and production of reactive oxygen
species (ROS) in macrophages at clinically-relevant conc. Azithromycin
(AZI, accumulating to high levels in lysosomes) and van (VAN, low
cellular accumulation) were used as comparators.
Methods: J774 mouse macrophages were incubated for 3 h with
increasing concentrations of ORI (0−50mg/L; Cmax in patients:
25mg/L) or VAN or AZI (0–100mg/L) and then used to measure
(i) the phagocytosis of serum-opsonized P. aeruginosa PAO1 (CFU
counting [MIC of ORI >32mg/L]) and ﬂuorescent red latex beads [2
mm diameter] (ﬂuorimetry; subcellular localization assessed by confocal
microscopy in comparison with the lysosomal tracer lysotracker green),
and (ii) production of ROS by monitoring the cell permeant indicator
5-(and-6)-chloromethyl-2′,7′-dichlorodihydroﬂuorescein diacetate acetyl
ester in the presence of 0.5% H2O2.
Results: As shown in the table, exposure of J774 macrophages to ORI
(i) did not signiﬁcantly inhibit their ability to engulf P. aeruginosa
over the whole range of conc., or phagocytize latex beads (for conc.
<25mg/L; these localized in lysosomes as in control cells [no change
in latex beads engulfment seen for cells incubated with VAN or AZI
up to 100mg/L]); (ii) did not impair the production of ROS (for conc.
<40mg/L).
Conclusions: At extracellular conc. up to its human Cmax, ORI did not
affect two critical functions of macrophages related to the handling and
killing of infectious organism in vitro. Differences in conc. needed to
affect phagocytosis of latex beads and P. aeruginosa cells may be related
to opsonization of bacteria (receptor-mediated phagocytosis). Together
with our previous observation that ORI at Cmax is bactericidal against
S. aureus phagocytized by macrophages, the data presented here suggest
that no untoward effect is to be expected from extensive accumulation of
ORI in macrophages in a context of intracellular infection and handling
of particulate matters, as long as its concentration in serum remains in
this range or lower.
Parameter studied Values at increasing oritavancin extracellular concentrations
0mg/L 1mg/L 10mg/L 25mg/L 40mg/L 50mg/L
P. aeruginosa phagocytosisa 100±0.1 99.9±0.1 99.9±0.1 99.9±0.1 nd 99.9±0.1
Latex beads phagocytosisb 100±7.6 125.3±8.4 106.5±7.1 40.6±17.9 nd 45.3±19.4
ROS productionc 117±5.3 120.7±8.5 118.2±4.1 118.1±1.5d 146.8±1.8 nd
apercentage of control (106 CFU/mg cell prot.); bpercentage of control (106 beads/mg cell prot.); cﬂuorescent
signal at 25 min (in % of value measured at time 0 min); d tested at 20mg/L; nd: not determined.
P1586 The modulatory effect of rifampicin and gentamicin on
expression of virulence factors in Escherichia coli O157: H7
E.A. Rahal °, A. Kanbar, G.M. Matar (Beirut, LB)
Objectives: Escherichia coli O157: H7 is the agent of food poisoning
outbreaks that may result in diarrhea, hemorrhagic colitis and the
potentially fatal hemolytic uremic syndrome. The pathogenic process of
E. coli O157: H7 mainly relies on intimin, a bacterial outer membrane
attachment protein, and the production of two cytotoxins: shiga-like toxin
(SLT) I and II. Our goal was to assess the effects of antibiotic exposure
on the expression and production of toxins in this bacterium.
Methods: We assessed the in vitro effects of rifampicin and gentamicin
on the expression of intimin, SLTI and SLT II in E. coli O157: H7 strains
obtained from outbreaks in the United States. Toxin gene expression
at the RNA level was assessed by reverse transcription polymerase
chain reaction (RT-PCR); toxin protein levels were semiquantitatively
examined by reverse passive latex agglutination (RPLA).
Results: Minimal inhibitory concentrations (MIC) of these antibiotics
were capable of inhibiting detection of transcription of the genes
encoding these virulence factors. Moreover, MIC concentrations also
resulted in decreasing toxin release from bacteria by more than 10
fold. On the other hand, minimal bactericidal concentrations (MBC) of
these antibiotics were incapable of decreasing expression and subsequent
release of these toxins. Expression and release of toxins was inhibited
when bacteria were exposed to the MIC concentration of either
rifampicin or gentamicin and then incubated in an MBC concentration
of the same antibiotic.
Conclusions: These data have implications on treatment of E. coli O157:
H7 and indicate that inhibition of toxin synthesis and release prior to
administration of a bactericidal dose of an antimicrobial agent might be
more appropriate. Such a regimen would circumvent toxin release and
hence prevent potentially fatal sequelae.
P1587 Protective effect of daptomycin and rifampicin on osteoblast-
like cells bearing intracellular Staphylococcus aureus
J-P. Rasigade °, S. Trouillet, T. Ferry, F. Vandenesch, S. Tigaud,
J. Etienne, F. Laurent (Lyon, FR)
Objective: Staphylococcus aureus is the most frequent pathogen in
osteomyelitis. It can be internalized by and survive inside osteoblasts,
thus evading from the host immune response and most antibiotics.
Intracellular persistence of S. aureus has been proposed as an explanation
for the recurrent nature of osteomyelitis. Among the antibiotics used in
treating bone infections, daptomycin and rifampicin are effective against
intracellular pathogens including S. aureus. We aimed at investigating the
yet unknown inﬂuence of these antibiotics on the survival of osteoblasts
bearing intracellular S. aureus.
Methods: Osteoblast-like MG-63 cells were infected with ATCC 9144
S. aureus reference strain for 2 hours. Cultures were then incubated
for 2 hours with 100mg/l gentamicin, alone or in combination with
daptomycin (6mg/l or 60mg/l) or rifampicin (5mg/l or 10mg/l).
Gentamicin has no intracellular bactericidal activity and was solely used
to eliminate the remaining extracellular S. aureus. Cultures incubated
with gentamicin alone served as control. After 2 h, cultures were washed
and incubated in 1% penicillin-streptomycin medium to avoid survival
of bacteria released by cell lysis. After 18 h, cell viability was assessed
using trypan blue exclusion and the remaining intracellular S. aureus
were quantiﬁed by plating Triton X100 cell lysates on agar.
Results: The effects of daptomycin and rifampicin on the survival
of S. aureus-infected MG-63 cells were expressed as the mean fold
increase in cell viability after 18 h, as compared with that of cultures
incubated with gentamicin alone. Results were ranked as follows:
10mg/l rifampicin (2.68-fold, p< 0.02), 60mg/l daptomycin (2.51-fold,
p< 0.02), 6mg/l daptomycin (2.25-fold, p< 0.02) and 5mg/l rifampicin
(1.64-fold, non-signiﬁcant). Plate counting of the remaining viable
intracellular S. aureus after 18 h showed no signiﬁcant difference between
wells initially incubated with gentamicin, daptomycin and rifampicin
(mean 104 S. aureus CFU/well).
Conclusions: Daptomycin and high concentration rifampicin signiﬁ-
cantly improved survival of S. aureus-infected osteoblast-like cells in
culture. The maintained effect of daptomycin at low concentration is of
interest in clinical practice. Further studies are ongoing to determine
if sustained incubation of S. aureus-infected cells with daptomycin or
rifampicin eventually leads to the complete elimination of intracellular
bacteria.
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P1588 Effect of multidrug-resistant gene polymorphisms on
daptomycin concentrations: preliminary results
L. Baietto °, A. D’Avolio, F.G. De Rosa, M. Dominici, S. Garazzino,
M. Siccardi, G. Di Perri (Turin, IT)
Objectives: Daptomycin (DAPT) is a new antibiotic with acitivity
against Gram-positive bacteria and approved for complicated skin and
skin structure infections (cSSSI) and right-side infective endocarditis due
to S. aureus. DAPT is a substrate of P-glycoprotein (MDR1), an efﬂux
transporter involved in the removal of metabolites and xenobiotics from
cells into urine, bile, and the intestinal lumen. Because renal excretion
is the primary route of elimination of DAPT and dosage reduction
is mandatory when the Clcr is <30ml/min, we aimed to evaluate
the effect of MDR1 C3435T, C1236T and G2677T single nucleotide
polymorphisms (SNPs) on DAPT pharmacokinetic (PK) parameters in
patients with cSSSI.
Methods: The study involved 12 patients with normal renal function
treated with DAPT (4mg/kg, OD) administered by a 30 min IV infusion.
Blood samples were collected at 0, 0.5, 1.5, 5, 9, 24 hour post dose
at steady state. Plasma DAPT concentrations were determined by an
HPLC-MS method. DAPT PK parameters (AUC0−24, Cmax, Ctrough,
t1/2, V, Cl) were determined using a non-compartmental method. Patients
were genotyped for C3435T, C1236T and G2677T SNPs using RT-PCR.
Statistical analysis was performed using the Mann Whitney test.
Results: Medians [IQR] of AUC0−24, Cmax, Ctrough, t1/2, V and
CL were, respectively, 634.2 [599.1–1058.2] mg*h/ml, 72.0 [31.7–
93.5] mg/ml, 7.6 [3.2–12.5] mg/ml, 7.8 [2.8−6.7] h, 0.083 [0.060–
2.38] L/kg and 6.4 [4.1–12.8] ml/h/kg. Patients homozygous for MDR1
3435T (N= 3) had Ctrough and t1/2 signiﬁcantly higher (p = 0.018
and p = 0.036). Patients with MDR1 2677T (N=:8) had lower Ctrough
(p = 0.048) and t1/2, (not statistically signiﬁcant). No correlation was
observed for C1236T SNP. Consistent with the results of genotyping
analyses, patients were divided into two groups: a) 3435TT/2677GG
and 3435TT/2677GT (N= 3); b) 3435CT/2677TT, 3435CC/2677TT and
3435CT/2677GT (n = 9). We observed that the ﬁrst group of patients
had a statistically signiﬁcant higher Ctrough and t1/2 compared with the
second group (p = 0.018 and p = 0.036).
Conclusion: PK parameters obtained were similar to available data in
healthy volunteers. We observed a relationship between DAPT Ctrough
and t1/2 and the SNPs C3435T and G2677T probably due to different
renal excretion of DAPT. Further studies are needed to conﬁrm these
data and to understand their clinical signiﬁcance, especially for dosage
adjustment in renal diseases, DAPT-related muscular toxicity and clinical
outcome.
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P1589 Pharmacokinetics of azithromycin in serum after
administration of extended-release and immediate-release
formulations in paediatric patients with acute otitis media
A. Fang °, P. Liu, R. LaBadie, P. Crownover, A. Arguedas (New York,
New London, US; San Jose, CR)
Objectives: A 30mg/kg single dose of AZ-IR has been used in
paediatrics to treat AOM. AZ-ER formulation provides higher dose in
one administration and has been used in adults. To provide exposure
bridging between the two formulations, this study was to determine
whether a 60mg/kg single dose of ER provides similar or greater AZ
systemic exposure compared to the 30mg/kg IR in paediatric patients
with AOM, by demonstrating that the lower boundary of the 90%
conﬁdence interval (CI) of the primary endpoint (ER/IR ratio of area
under the curve over 72 hours AUC72) and the secondary endpoint
(point-to-point concentration ratios) are 80% and 70% respectively.
Methods: This was a randomized open-label single-centre study. Thirty-
eight AOM patients (6 months to 6 years old) received a single dose of
AZ-ER 60mg/kg or AZ-IR 30mg/kg (n = 19 per group). Serum samples
were collected at 1, 2, 3, 4, 8, 24, 48 and 72 hours after dosing. AZ
levels were analyzed by validated HPLC/MS/MS method. PK analysis
was done by non-compartmental method. Log transformed PK data were
analyzed by one-way analysis of variance.
PK endpoint Adjusted geometric mean
AZ-ER
N=18
AZ-IR
N= 18
ER/IR Ratio of
adjusted means
(%)
90% conﬁdence interval
for ratio (%)
Parameter
AUC72 (ng·h/mL) 9848 6234 157.98 (98.87, 252.44)
Cmax (ng/mL) 611.5 667.3 91.63 (56.21, 149.38)
Tmax (h)* 3 (2−8) 2 (1−4) N/A N/A
Concentration (ng/mL)
C1 100.0 152.8 65.44 (23.56, 181.77)
C2 293.1 579.7 50.57 (25.24, 101.30)
C3 382.0 381.7 100.07 (57.91, 172.92)
C4 441.8 267.9 164.93 (103.78, 262.12)
C8 244.8 140.3 174.41 (110.07, 276.36)
C24 142.4 82.3 173.01 (111.45, 268.55)
C48 94.8 50.1 189.35 (129.76, 276.30)
C72 56.0 30.6 183.14 (124.61, 269.14)
AUC72: area under the curve over 72 hours; Cmax: the maximum concentration; Tmax: the time to reach Cmax;
N/A: not applicable; *: median (range).
Results: Thirty-six Hispanic patients completed the study (61% male).
Summary statistics of the PK parameters and concentrations at each time
point are shown in the table.
• Primary Comparison of PK parameters: The ratio of the adjusted
mean AUC72 (ER/IR) was 157.98% with the lower boundary
of the 90%CI >80%.
• Secondary Comparisons of concentrations: The lower boundaries of
the 90% CIs of ER/IR AZ concentration ratios for the ﬁrst 3 hours
were <70%, which was expected for ER formulation since it was
designed to slow down the absorption (delayed Tmax and lower Cmax)
to improve the tolerability. AZ ER concentrations at all remaining time
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points after 3 hours were higher than those from IR with the lower
boundary of the 90%CI >70%.
• Safety: No serious adverse events or clinically signiﬁcant safety labs
other than from AOM were observed.
Conclusions: AZ-ER 60mg/kg single dose provides similar or greater
systemic exposure in paediatrics compared with the AZ-IR 30mg/kg
single dose. Both ER and IR were well tolerated.
P1590 Pulmonary pharmacokinetics of the prodrug colistin
methanesulphonate and formed colistin following
pulmonary administration of the prodrug in rats
S. Ws Yapa °, J. Li, R. Nation, C.J. Porter, M.P. McIntosh (Melbourne,
AU)
Objectives: Colistin methanesulphonate (CMS), an inactive prodrug of
colistin, is being used increasingly by inhalation to treat respiratory
infections caused by multidrug-resistant Gram-negative bacteria such
as Pseudomonas aeruginosa, Klebsiella pneumoniae and Acinetobacter
baumannii. However, very limited pulmonary pharmacokinetic (PK)
information on CMS and generated colistin is available. The objective
was to determine the pulmonary PK of CMS and generated colistin
following pulmonary instillation of CMS to rats.
Methods: The study was conducted in conscious, male Sprague-Dawley
rats (n = 3 per time point). For pulmonary administration (15mg/kg), rats
received an intratracheal instillation of 100 mL CMS solution. Following
blood sample collection, rats were sacriﬁced at pre-determined time
points up to 12 hr. The lungs were lavaged with phosphate buffered saline
(4ºC). CMS and colistin concentrations in lavage ﬂuid were quantiﬁed
by validated HPLC assays. Urea concentrations in lavage ﬂuid and
plasma were determined using a commercially available assay kit to
allow determination of the volume of epithelial lining ﬂuid (ELF).
Results: The ELF volumes were 82±14 mL. Initial CMS concentrations
in ELF were in the vicinity of 20,000mg/L and declined with a half life
(t1/2) of 1.8 hr to approximately 100mg/L at 12 hr (Figure 1). Colistin
concentrations of 59±5mg/L were evident in ELF 5 min post dose with
a maximum concentration of 803±322mg/L achieved at 4 hr declining
to 262mg/L at 12 hr. The t1/2 in the terminal phase for colistin was 4.8
hr. The area under the ELF concentration versus time curve (0−12 hr) for
CMS and colistin was 33,056mg·hr/L and 5,608mg·hr/L, respectively.
Conclusion: To the best of our knowledge, this is the ﬁrst study to
report the time-course of CMS and generated colistin in ELF after
pulmonary administration of CMS in rats. Extended exposure to CMS
and, importantly, colistin in ELF was achieved. This may be beneﬁcial
given that the minimum inhibitory concentrations for colistin against
susceptible Gram-negative pathogens are 2mg/L. This study provides
important information on the pulmonary PK of CMS and formed colistin
after pulmonary administration of the prodrug.
Figure 1. Time course of the concentration of CMS and colistin in ELF.
P1591 Rationale for the therapeutic dose selection of oral torezolid
phosphate in complicated skin infections
P. Bien °, K. Bartizal, A. Louie, G. Drusano, P. Prokocimer (San Diego,
Albany, US)
Objectives: Dose selection for use in pivotal Phase 3 trials is a
critical milestone in any drug development program. In the torezolid
phosphate (TP) program, the objective of selecting an optimal Phase 3
therapeutic dose was based on PK/PD modeling, Phase 1 safety/PK,
and Phase 2 dose-ranging trial results in complicated skin and skin
structure infections (cSSSI). TP is 4−16 fold more potent in vitro and
4−8 fold more potent in vivo than linezolid, the only currently marketed
oxazolidinone antibiotic.
Methods: Nonclinical PK/PD mouse thigh models of infection identiﬁed
the dose and schedule of TP linked with optimal antimicrobial effect.
Target attainment analyses were performed by MIC. The population PK
analysis (3 stage Hierarchical Bayesian approach) was used to perform
a 10,000 subject simulation for AUC from the Phase 2 clinical study
(n = 188) results where oral doses of 200, 300, or 400mg torezolid
phosphate once-daily for 5 to 7 days were administered to patients with
cSSSI.
Results: AUC/MIC was found to be the PK/PD parameter best correlated
with efﬁcacy. Once-daily dosing provided the same efﬁcacy as equally
divided doses. Single-dose 72-hour studies in mouse thigh models
of MRSA infection demonstrate the pivotal role of granulocytes in
amplifying torezolid antibacterial effect. This granulocyte-mediated am-
pliﬁcation of torezolid bacterial killing is of a magnitude unprecedented
for antibacterials. The overall expectation analysis showed that on Day
1, 98.5% of the population achieved stasis; on Day 3 this was 99.8%,
where 89.3% of the population achieved maximal cell kill. Population
PK analysis and PD simulations demonstrated that 165mg of torezolid
(equivalent to a 200mg TP dose), is expected to provide maximal
bacterial killing in cSSSI in human. Results from the Phase 2 cSSSI
clinical trial (mean duration of treatment 6.4 dosing days) showed that
TP was equally safe, well tolerated, and efﬁcacious at all three dose
levels tested, with an overall clinical cure rate of 95.7%.
Conclusion: Both the PK/PD investigation and the Phase 2 study results
point towards the selection of a 200mg QD dose of TP for the Phase 3
pivotal studies in cSSSI.
P1592 Microbiological efﬁcacy of torezolid phosphate in patients
with complicated skin and skin structure infections
P. Bien °, C. De Anda, P. Prokocimer (San Diego, US)
Objective: Torezolid (T) is the active moiety of the prodrug torezolid
phosphate (TP), an oxazolidinone with 4- to 16-fold greater activity than
linezolid against Gram-positive species including methicillin-resistant
and linezolid-resistant Staphylococcus aureus (MRSA). The objective of
this analysis was to evaluate the microbiological efﬁcacy of TP in patients
with complicated skin and skin structure infections (cSSSI) enrolled in
the oral Phase 2 dose-ranging study.
Methods: Patients diagnosed with cSSSI were randomized to receive
200, 300, or 400mg oral TP once-daily (QD) for 5 to 7 days.
Microbiological samples were to be obtained from the cSSSI site at
baseline and then any follow-up visits if medically indicated.
Results: There were 188 patients that received at least one dose of study
drug, of which 82% had a skin pathogen isolated at baseline. Of the
154 patients with a baseline pathogen isolated, S. aureus was the most
common pathogen isolated (90%) of which 19% were MSSA and 81%
were MRSA. The MIC range for MRSA was 0.12−0.5 mg/mL with a
MIC90 of 0.25 mg/mL. The microbiological eradication at Test of Cure
(TOC) in the Microbiological Evaluable (ME) patient population was
97.7% for all pathogens, 97.9% for MRSA, and 95.7% for MSSA for
all dosage groups.
Clinical Response rates at TOC in the ME patient population are
presented in the table.
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Conclusion: TP demonstrated high microbiological efﬁcacy in all dosage
levels tested in patients with severe cSSSI, consistent with the clinical
success rates reported at all doses investigated in this study. These data
support the selection of 200mg QD for further development for the
treatment of severe cSSSI.
200mg 300mg 400mg
Cure Failure Cure Failure Cure Failure
Aerobic Gram-positive organisms 43
(100%)
0
(0.0%)
41
(93.2%)
3
(6.8%)
44
(95.7%)
2
(4.3%)
Staphylococcus aureus 39
(100%)
0
(0.0%)
33
(91.7%)
3
(8.3%)
43
(97.7%)
1
(2.3%)
MRSA 32
(100%)
0
(0.0%)
25
(92.6%)
2
(7.4%)
36
(97.3%)
1
(2.9%)
MSSA 7
(100%)
0
(0.0%)
8
(88.9%)
1
(11.1%)
7
(100%)
0
(0.0%)
P1593 Bioavailability and pharmacokinetics of torezolid phosphate
after intravenous administration in healthy subjects
K.A. Mun˜oz, P. Bien, C. Bethune, R. Wright, P. Prokocimer ° (San
Diego, Madison, US)
Objectives: Torezolid phosphate (TP) is a novel oxazolidinone phosphate
prodrug antibiotic that is rapidly converted to the microbiologically
active molecule torezolid. Torezolid is active against Gram-positive
bacteria, including linezolid- and methicillin-resistant Staphylococcus
aureus and vancomycin-resistant enterococci. To further characterize
intravenous TP, a randomized, double-blind, placebo-controlled, single-
dose escalation, bio-availability, safety, tolerability, and pharmacokinetic
study was performed in healthy subjects. Doses were escalated from 100
to 200 to 400mg/day. Absolute bioavailability was assessed following a
single 200mg dose of TP in tablet and infusion formulations.
Methods: Three cohorts of 12 subjects each (9 active and 3 placebo)
received a single dose of placebo or 100, 200, or 400mg intravenous TP
in one of three possible regimens: 1) in 500mL of saline infused over 2
hours, 2) in 250mL of saline infused over 2 hours or, 3) in 250mL of
saline infused over 1 hour. For the absolute bioavailability determination,
a cohort of 8 subjects received the following treatments in a cross-over
design: a single 1-hour infusion of 200mg TP in 250mL saline and, 2)
a single dose of one 200mg TP tablet administered with 240mL water.
Results: After single dose administration, preliminary estimates
indicated mean Cmax and AUC0−inf values for torezolid increased in
a linear and proportional manner to TP dose levels ranging from 100 to
400mg (1.16 to 4.98 mg/mL and 16.34 to 56.96 mg·hr/mL, respectively).
Torezolid systemic clearance (CL) and volume of distribution (Vss) were
not affected by dose levels. The prodrug was only detected above the
limit of quantitation (5 ng/mL) during the infusion, and for a maximum
of 4 hours after infusion. The absolute bioavailability of torezolid from
the TP tablet was approximately 100%.
Conclusions: The absolute bioavailability of torezolid from TP tablets
was approximately 100%, demonstrating TP is rapidly and completely
converted to the active moiety and absorbed. Single dose escalation
from 100 to 400mg TP by intravenous administration resulted in dose
proportional exposure and linear pharmacokinetics for torezolid.
P1594 Improved pharmacokinetics of the novel oxazolidinone
antibiotic torezolid phosphate compared to linezolid in
healthy subjects
K.A. Mun˜oz, C. Bethune, J. Bohn, R. Wright, P. Bien, P. Prokocimer °
(San Diego, Madison, US)
Objectives: To compare the pharmacokinetics and safety of the
therapeutic dose of torezolid phosphate (TP) and the prescribed dose
of linezolid after multiple dosing in healthy adults.
Methods: A multiple-dose study was performed to determine the
pharmacokinetics of the prodrug TP and its active moiety, torezolid,
compared to linezolid in healthy adults. Each cohort of 10 subjects (8
active and 2 placebo) received oral doses of 200mg TP once a day or
twice daily oral doses of 600mg linezolid for 21 days.
Results: Following oral administration of TP capsules at 200mg
QD for 21 days, the pharmacokinetics of torezolid appeared to be
generally independent of duration of dosing. Steady-state concentrations
of torezolid were achieved after 3 days administration of TP and there
was no evidence of accumulation. The torezolid oral clearance (CL/F)
values ranged from 6.63 to 7.48 L/hr on Days 1 and 21. Mean apparent
volume of distribution (Vz/F) values for torezolid were independent
of duration of dosing, as well. Torezolid was eliminated with terminal
mean half-life (t1/2) values ranging from 11.1 to 14.7 hours. In contrast,
linezolid mean Cmax and AUC values increased after multiple dosing
as a function of the duration of dosing, with the highest values observed
on Day 21. Linezolid mean CL/F values decreased approximately 34%
from Day 1 to Day 21, with values on Day 1 of 8.73 L/hr and decreasing
to 5.76 L/hr on Day 21. The mean t1/2 values for linezolid increased
from 3.8 to 5.8 hours for Days 1 and 21, respectively. Mean linezolid
Vz/F values were comparable on Days 1 and 21 with observed values of
42.9 and 46.1 L, respectively. Multiple doses of 200mg QD TP and 600
BID linezolid through 21 days were well-tolerated with similar numbers
of adverse events and treatment-related adverse events reported in each
cohort. There were no serious adverse events reported in either cohort.
Conclusions: After multiple dosing with TP or linezolid for 21 days,
linezolid exposure increased and was nonlinear with respect to time
while torezolid exhibited consistent exposure without accumulation.
Both drugs were safe and well-tolerated.
P1595 In vitro pharmacodynamic assessment of efﬁcacy and
resistance potential for a novel non-quinolone DNA
gyrase/topoisomerase inhibitor
M. Kuhn °, D. Hanna, J. Hardink, J. Hamel, M. Maloney,
M. Mitton-Fry, D. Girard (Groton, US)
Objectives: The clinical need for new antimicrobials to combat
hospital and community acquired Gram-positive infections caused by
methicillin-resistant Staphylococcus aureus (MRSA) remains important.
The objective of this work was to assess the clinical durability of
novel (non-quinolone) lead compounds targeting DNA gyrase and
topoisomerase IV utilizing in vitro static and in vitro dynamic (IVDM)
and in vivo pharmacology models. The efﬁcacy of the lead compound
and its relationship to resistance emergence was tested by simulating
projected human dosing parameters in the in vitro models. The in vitro
results were compared with the in vivo infection model data.
Methods: Static concentration time kills (SCTK) were performed
following CLSI guidelines against FQR MRSA 01A1095. A previously
described in vitro PKPD hollow ﬁber model was employed to simulate
human PK parameters in a multi-day q24 h dosing regimen at inoculum
of 106 and 109. Single dose rat systemic and thigh infection models
were used to test mutant suppression.
Results: SCTK exhibited >3-log kill at 4X MIC. AUC/MIC 50 and
above completely eradicated 106 burden of 01A1095 in the hollow ﬁber.
AUC/MIC 50 resulted in a 1-log kill at 24 h at 109 in the hollow ﬁber,
but was unable to suppress the emergence of gyrA (D83N) mutant sub-
population upon additional dosing. To examine suppression of ﬁrst step
mutant in vivo, rats were challenged with 1:5 log ratio of gyrA (D83N)
mutant to sensitive parent 01A1095. In both in vivo models, bacterial
burden was reduced after single dose. Animals were rarely cleared of
infection by the lead agents with cultures at 24 h showing all gyrA
(D83N) mutant at high doses of 200mg/kg, 100mg/kg and 50mg/kg.
Conclusions: SCTK, IVDM and in vivo efﬁcacy models reveal a potent
bactericidal agent targeting FQR MRSA. Multi-day q24 h dosing in the
hollow ﬁber showed the predicted human efﬁcacious dose exhibited >2-
log decrease in CFU. Inoculum studies simulating relevant infection
burden in the in the hollow ﬁber showed pre-existing sub-populations,
in particular gyrA (D83N), was able to persist at AUC/MIC ratio of 50
and conﬁrmed in the in vivo setting. Chemical attributes to increase the
TI or topoisomerase activity, as well as looking at combination therapy
would greatly enhance the clinical durability of this novel series against
serious Gram-positive infections.
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P1596 Penetration of moxiﬂoxacin and levoﬂoxacin into human
cerebrospinal ﬂuid and brain tissue
A. Tsona, S. Metallidis °, P. Selviaridis, P. Kollaras, N. Foroglou,
P. Nikolaides (Thessaloniki, GR)
Objectives: The aim of the present study was to determine the penetra-
tion of moxiﬂoxacin and levoﬂoxacin into cerebrospinal ﬂuid(CSF) and
brain tissue of humans.
Methods: A total of 38 patients undergoing hydrocephalus drainage
or brain tumor excision were evaluated. 20 patients received a single
intravenous dose of 400mg moxiﬂoxacin and 18 patients received a
single intravenous dose of 500mg levoﬂoxacin. Samples of blood, CSF
and brain(brain-adjacent tumour tissue) were collected during surgery 2 h
after drug administration. Moxiﬂoxacin and levoﬂoxacin concentrations
in serum, CSF and brain homogenate were analysed by means of a
validated HPLC method.
Results: Mean concentrations of moxiﬂoxacin in serum and CSF,
respectively, were 3.67 mg/ml and 0.90 mg/ml. Mean concentrations of
moxiﬂoxacin in serum and brain, respectively, were 4.94 mg/ml and 9.90
mg/gr. Penetration index was 23% in cerebrospinal ﬂuid and 216% in
brain samples. Mean concentrations of levoﬂoxacin in serum and CSF,
respectively, were 3.49 mg/ml and 1.45 mg/ml. Mean concentrations of
levoﬂoxacin in serum and brain, respectively, were 3.53 mg/ml and 1.8
mg/gr. Penetration index was 37% in cerebrospinal ﬂuid and 55% in brain
samples.
Conclusions: Concentrations of moxiﬂoxacin in CSF were lower than
those in serum, in contrast to brain tissue concentrations that exceeded
serum concentrations. Concentrations of moxiﬂoxacin in brain were ten
fold higher from concentrations in CSF. Concentrations of levoﬂoxacin
in CSF and brain were lower than those in serum.
Concentrations of levoﬂoxacin in brain were higher from concentrations
in CSF. Levoﬂoxacin achieved better penetration in CSF and moxi-
ﬂoxacin in brain. These ﬁndings suggest that valuable informations
on brain tissue penetration can be obtained only from brain material.
Data from CSF penetration cannot be extrapolated to the brain
since the blood: CSF barrier differs from the blood:brain barrier.
Both moxiﬂoxacin and levoﬂoxacin are effective for the treatment of
meningitis, postneurosurgical meningitis and brain abscesses caused
by H. inﬂuenzae, N. meningitidis, S. pneumoniae, staphylococcus,
streptococcus, Enterobacteriaceae, anaerobes because they achieve
concentrations higher than the MIC90 in serum, CSF and brain tissue.
P1597 Monte Carlo simulations in support of NXL103 dose
selection
M. Felices, V. Gualano, A. Tarral, C. Sable, H. Merdjan ° (Evry,
Romainville, FR; Plymouth Meeting, US)
Objectives: NXL103 is a novel oral streptogramin, a combination
of linopristin (PI) and ﬂopristin (PII) with activity against S. aureus
(SA), including methicillin-resistant (MR) strains, S. pneumoniae
(SP), including multidrug resistant strains, H. inﬂuenzae, and atypical
pathogens. The study objective was to predict the probability of target
attainment (PTA) for various combinations of dose regimen and MIC
values, by using Monte Carlo (MC) simulations.
Methods: In murine models of thigh and lung infections, NXL103
efﬁcacy demonstrated to be best correlated with the AUC24/MIC ratios
of 14 and 32 for SA and SP, respectively. The MIC90 values for a
contemporary population of SA and SP isolates were 0.25 and 0.5
microg/ml, respectively. As a result, the selected MIC values were 0.25,
0.5 and 1 microg/ml. The simulated dose regimens were 300, 500, 600 or
1000mg BID, and 250, 500 or 600mg TID. PI and PII were in a 5:7 dose
ratio in the above NXL103 doses. Given the beneﬁcial food-effect on
NXL103 bioavailability, it was assumed that either all doses were given
with food, or either one, or two, or three daily doses (TID only) were
given fasted. For each dosing condition, 10,000 replicates of PI and
PII AUCs were simulated from validated population pharmacokinetic
models. The steady state AUC24 of NXL103 was derived, together with
its distribution. Ultimately, the PTA was calculated as the proportion of
the AUC24/MIC distribution above a given target. All calculations were
done with SAS.
Results: The PTA is tabulated for the various dose regimens given in
fed conditions and for both target AUC24/MIC values. Efﬁcacious daily
doses should not be changed if a maximum of one dose per day is taken
fasted. These results speciﬁcally apply to the current tablet formulation
of oral NXL103 containing PI and PII in a 5:7 dose ratio (ca 42:58).
Conclusion: A 500mg BID dose regimen should be efﬁcacious against
SA with MIC values of 0.25 and 0.50 microg/ml, including CA-MRSA
and HA-MRSA strains. Higher doses may be required to treat infections
caused by SP strains.
Target AUC24/MIC= 14 Target AUC24/MIC= 32
Dose regimen MIC= 0.25 MIC= 0.5 MIC= 1 MIC= 0.25 MIC= 0.5 MIC= 1
300mg BID 0.93 0.53 0.11 0.43 0.07 0.00
250mg TID 0.98 0.69 0.20 0.59 0.13 0.01
500mg BID 1.00 0.89 0.40 0.82 0.31 0.04
600mg BID 1.00 0.95 0.56 0.91 0.44 0.07
500mg TID 1.00 0.98 0.72 0.96 0.61 0.14
600mg TID 1.00 0.99 0.84 0.99 0.76 0.24
1000mg BID 1.00 1.00 0.91 0.99 0.85 0.34
P1598 Pharmacokinetics and tolerability of NXL104 in normal sub-
jects and patients with varying degrees of renal insufﬁciency
H. Merdjan °, A. Tarral, W. Haazen, E. Evene, M. Robertson, C. Sable
(Romainville, FR; Antwerp, BE; Paris, FR; Fordham, UK; Plymouth
Meeting, US)
Objectives: NXL104 is a broad spectrum class A and C b-lactamase
inhibitor currently developed by Novexel in combination with cef-
tazidime (CAZ) for the treatment of serious infections due to resistant
Gram-negative pathogens. Most of NXL104 elimination occurs by renal
excretion of unchanged drug in urine, making NXL104 potentially
sensitive to changes in renal function. The objectives were to investigate
the pharmacokinetics (PK) and tolerability of a single 100mg dose of
NXL104 (30-min intravenous infusion) in normal subjects and in patients
with varying degrees of renal impairment.
Methods: This was an open-label study conducted in 6 healthy male
subjects (creatinine clearance CrCL >80mL/min), and in patients of
either sex (n = 6 per group) with mild (CrCL 50 to 79mL/min), moderate
(CrCL 30 to 49mL/min), or severe renal impairment (CrCL <30mL/min
non anuric), and in anuric patients requiring hemodialysis (HD). Anuric
patients participated in 2 randomised sessions 7 to 14 days apart: within
and between 4-hour HD sessions. Blood samples for PK were collected
for up to 44 h after the infusion start. During HD, arterial and venous
blood was collected every 30 min for the determination of HD clearance
(CL). Whenever possible, urine fractions were collected for measuring
NXL104 renal CL. NXL104 was analysed in plasma and urine by
using validated LC-MS/MS methods. PK interpretation was by non-
compartmental analysis. Tolerability was assessed by physical and safety
laboratory examinations, ECG, vital signs and adverse events (AEs)
recording.
Results: Four mild episodes of possibly related AEs (general discomfort,
stomach pain, ructus, transient symptoms of hypoglycaemia in an insulin-
dependent patient) were recorded in 3 anuric patients. NXL104 total
CL was found to decrease as a function of CrCL: 14.6±1.2 L/h in
normal subjects, 5.8±1.6 L/h in mild renal impairment, 3.8±0.6 L/h in
moderate impairment, 2.2±0.9 L/h in severe impairment, and 1.0±0.8
L/h in anuric patients. Based on published data quantitatively similar
changes are seen in CAZ CL. NXL104 HD CL was 9.3±0.1 L/h resulting
in 54% of the dose being removed by a 4-hour HD session.
Conclusion: NXL104 was well tolerated in renally impaired patients.
CrCL was a major determinant of NXL104 PK. The ﬁndings suggested
that CAZ and NXL104 doses should be adjusted to the same proportions
in renally impaired patients. NXL104 should preferably be administered
after the end of an HD session.
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P1599 Combined population pharmacokinetic analysis of four
phase 1 studies with NXL104
M. Felices, V. Gualano, A. Tarral, C. Sable, H. Merdjan ° (Evry,
Romainville, FR; Plymouth Meeting, US)
Objectives: NXL104 is a broad spectrum class A and C b-lactamase
inhibitor currently developed by Novexel in combination with cef-
tazidime for the treatment of serious infections due to resistant Gram-
negative pathogens. This analysis was conducted to characterise the
pharmacokinetics (PK) of NXL104 in healthy subjects and renally
impaired patients, and to identify the covariates that inﬂuence its PK
parameters.
Methods: A population (Pop) PK analysis was performed by combining
the data from 4 Phase 1 studies totalling 136 healthy subjects and 24
patients with varying degrees of renal impairment. The dataset included
some diversity with regard to age, sex, unit doses, dosing duration,
concomitant medications and creatinine clearance (CrCL). Two basic
models were built: one based on plasma concentrations only, the other
one incorporating both plasma and urine concentrations of NXL104.
A distinction was made a priori between primary and exploratory
covariates. Data were analysed using the NONMEM software.
Results: Based on plasma data only, the structural PK model was
a two-compartment model parameterised in terms of total (CL) and
intercompartment (Q) clearances, central (V1) and peripheral (V2)
volumes of distribution. The typical values for non-renal clearance, Q,
V1 and V2 were 0.456 L/h, 6.27 L/h, 13.8 L and 7.20 L, respectively.
The between-subject variability on CL, Q and V1 was 20%, 30%,
and 31%, respectively. The residual error model was mixed, with
proportional and constant terms of 26% and 0.2 ng/mL, respectively.
The most signiﬁcant primary covariate was CrCL (+9.65 L/h on CL
per 100mL/min increment of CrCL). In addition, a signiﬁcant age-
effect was found on CL (+0.21 L/h per 10-yr increment) and was
of low enough magnitude not to warrant any dose adjustment as a
function of age in adults. No primary covariate was found to inﬂuence
V1 or V2. The effects of unit dose and treatment duration were not
signiﬁcant, suggesting that NXL104 PK is directly dose proportional and
time-invariant. The model based on joint plasma and urine data led to
essentially similar results. Validation tests demonstrated the descriptive
performance of these Pop PK models.
Conclusion: This Pop PK analysis done with Phase I data allows the use
of a sparse sampling approach for estimation of individual PK parameters
in further studies. It demonstrated the strong relationship between CrCL
and NXL104 CL.
P1600 Rationale of combined antibiotic therapy derived from
in vitro PK/PD studies: role of treatment duration simulated
in a dynamic model
S. Zinner, M. Smirnova °, E. Strukova, Y. Portnoy, A. Firsov
(Cambridge, US; Moscow, RU)
Objective: Duration of simulated treatments with antibiotics may be
critical in searching for optimal antibiotic combinations. To study the
possible impact of this factor on the delineation of the pattern of
interaction between linezolid (LZD) and doxycycline (DOX), the effects
of LZD+DOX on Staphylococcus aureus were examined at different
times after the start of treatment at varying antibiotic exposures.
Methods: S. aureus ATCC 43300 (MIC of LZD 2mg/L, MIC of DOX
0.25mg/L) was exposed to twice-daily LZD (ratios of 24-hour area
under the curve (AUC) to the MIC 25, 50 and 150 h), once-daily
DOX (AUC/MICs 50, 100 and 270 h) or their combinations (LZD/DOX
25 h/50 h, 50 h/100 h and 150 h/270 h) for 5 days. Mono-exponential
concentration-time proﬁles of LZD and DOX given alone and in
combination were simulated with half-lives of 6 and 15 h, respectively.
The central compartment of the model was multiply sampled to count
surviving organisms on antibiotic-free media. The antimicrobial effects
were expressed by areas between the bacterial concentration − time
curves with and without antibiotic (ABBCs) calculated from time zero
to 1, 2, 3, 4 and 5 days after the start of treatment.
Results: Regardless of the observation period, the effects of LZD+DOX
at the minimal and intermediate AUC/MIC ratios were greater than those
of LZD and DOX given alone at the respective AUC/MICs throughout
the entire time courses of the ABBC. At the maximal AUC/MIC
ratios that approach clinically achievable values, the advantages of the
combination over monotherapy with LZD were seen only on the 4th day,
when the ABBC with LZD+DOX was 30% greater than the ABBC of
LZD. A more pronounced (43%) increase in the antimicrobial effect of
LZD by DOX was observed at the end of treatment.
Conclusions: These data suggest that (1) combined treatment with
LZD+DOX is more beneﬁcial at relatively small AUC/MIC ratios, and
(2) synergistic interactions between LZD and DOX were revealed only
in long-term simulations.
P1601 Bacterial resistance studies in an in vitro dynamic model:
use of antibiotic-susceptible organisms supplemented with
their resistant mutants
A. Firsov °, M. Smirnova, E. Strukova, Y. Portnoy, S. Zinner (Moscow,
RU; Cambridge, US)
Objective: Bacterial resistance studies using in vitro dynamic models
are highly dependent on the starting inoculum (SI) that might or might
not contain spontaneous resistant mutants (RM)s. To standardize the
initial experimental conditions, SI can be reconstructed using antibiotic-
susceptible bacteria supplemented with its RM. This method was
examined with linezolid-exposed Staphylococcus aureus.
Methods: To obtain RMs, a clinical isolate of S. aureus (MIC
of linezolid 2mg/L) was serially passaged in Mueller-Hinton broth
containing successively increasing concentrations of linezolid (from 1
to 512mg/L). To optimize the relative content of the parent strain and
its RM in the SI, the mutant prevention concentrations (MPCs) were
determined with and without RMs. Using an optimized inoculum (parent
strain/RM), ﬁve-day treatments with twice daily linezolid were simulated
at concentrations either between the MIC and MPC or above the MPC for
most of the dosing interval. Selection of RMs was detected by population
analysis and susceptibility testing (culture MICs).
Results: RMs were enriched starting with the 5th-6th passage, with
continued loss in susceptibility up to the 15th passage. RMs obtained
after the 8th (RM8) and 15th (RM15) passages had MICs of 8 and
128mg/L, respectively, and these MICs were stable after 15 passages
on antibiotic-free plates. The presence of RM15 (2 and 4 log CFU/ml
added to 10 log CFU/ml of the parent strain) dramatically increased the
MPC. Unlike RM15, the MPCs determined with and without 2 log (but
not 4 log) CFU/ml of RM8 were similar (14mg/L). At a SI of 8 log
CFU/ml (parent strain) plus 2 log CFU/ml (RM8) exposed to linezolid
concentrations between the MIC and MPC but not at concentrations
above the MPC, RMs were enriched over the 5 days. This enrichment
was accompanied by the concomitant loss in susceptibility.
Conclusions: Data obtained with the reconstructed SI support the mutant
selection window hypothesis. This method provides a standardization of
resistance studies using in vitro models. However, the relative amounts
of susceptible and resistant subpopulations are critical for the prediction
of anti-mutant dosing regimens.
P1602 Mouse thigh MRSA infection model data and mathematical
modelling to determine telavancin dosing for complicated
skin and skin structure infection trials
T. Lodise, N. Patel, S. Hegde, S. Barriere °, J. Shaw, G. Drusano
(Albany, San Francisco, US)
Objectives: Telavancin is a lipoglycopeptide approved in the US and
Canada for complicated skin and skin structure infection (cSSSI) due
to Gram-positive bacteria, including MRSA. The objectives were to (1)
identify the pharmacodynamic (PD) target using a mouse thigh infection
model against MRSA and (2) conduct population (pop) PK modeling
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and Monte Carlo simulation (MCS) to determine an optimal telavancin
dose for cSSSI trials. Speciﬁcally, the goal was to identify a dosing
regimen that had >90% probability of achieving the desired PD target
derived from the mouse thigh infection model for organisms with MICs
<2mg/L. An MIC value of 2mg/L was selected for the probability of
target attainment (PTA) analysis because it is 4-fold higher than the
telavancin MIC90 for MRSA.
Methods: The neutropenic mouse thigh infection model was used to
identify the PD linked variable for telavancin. Mouse thigh infection
studies were performed for a single MRSA strain (ATCC 33591; MIC =
1mg/L). A number of dosing regimens (10−16 mice per dosing cohort)
were evaluated. An inhibitory sigmoid-Emax model was ﬁt to the data
using ADAPT II and PK parameters were identiﬁed using BigNPAG.
Total drug exposure target associated with a −1 log10 (CFU/gm) drop
from stasis served as the PD target for the MCS analysis. Telavancin
plasma concentration-time proﬁles from 73 volunteers were modeled
using a 2-compartment model with zero-order infusion & 1st order
elimination & transfer. Model parameters were identiﬁed in a pop PK
analysis (NPAG). MCS (ADAPT II) of 9999 subjects was used to identify
a telavancin dose that provided a >90% probability of achieving the PD
target for MICs 2mg/L.
Results: The PD target associated with −1 log10 (CFU/gm) drop from
stasis in the mouse thigh infection model was a total AUC/MIC ratio
of 219 (ﬁgure). In the pop PK analysis, mean (SD) values for volume,
clearance, K12 and K21 were: 4.79 (2.46) L, 0.99 (0.28) L/hr, 1.51 (0.74)
hr-1, and 1.14 (0.52) hr-1 respectively. In the PTA analysis, telavancin
doses of 750mg IV Q24H provided a >90% probability of achieving a
total AUC/MIC of 219 for organisms with MIC values 2mg/L (ﬁgure).
Conclusions: Based on the animal data and mathematical modeling, the
telavancin dose selected for cSSSI trials was 10mg/kg/day (~750mg
daily for normal weight subjects). This regimen had a >95% probability
of achieving an AUC/MIC ratio of 219 for organisms with MICs less
than or equal to 2mg/L.
P1603 Aerosol therapy with colistin: a biopharmaceutical concern
as illustrated in rats
S. Marchand, D. Thi Viet Phuong, P. Gobin, J. Olivier, O. Mimoz,
W. Couet ° (Poitiers, FR)
Objective: The aim of this study was to investigate the pharmacokinetics
of colistin methanesulphonate (CMS) and colistin following CMS
nebulisation in rats.
Methods: Male rats (280–320g) received (i) a CMS dose of 15mg·kg−1
either as an intravenous (IV) bolus (n = 6) or (ii) by nebulisation using
a MicroSprayer IA-1B® system (Penn Century Inc, Philadelphia, US)
(n = 6), or (iii) colistin subcutaneously (SC) at a dose of 1.5mg·kg−1.
Multiple blood samples were drawn from a catheter implanted the day
before through anaesthesia in a femoral artery, for up to 300min. CMS
and colistin plasma concentrations were determined by a new validated
LC-MS/MS assay. Pharmacokinetics parameters were estimated using a
non-compartmental analysis.
Results:Mean±SD concentrations of CMS and or colistin are illustrated
below (TABLE).
Colistin clearance was estimated to 8.5±1.0mL/min/kg after SC
administration, assuming complete bioavailability and allowing to
estimate that the fraction of CMS converted to colistin after CMS
IV administration was only equal to 13% on average. It could then
be estimated that after CMS nebulisation 69% of the dose reached
directly the systemic circulation and that 30% was converted within
the lung before being absorbed. Therefore colistin area under curve
was higher after CMS nebulisation (486±170 mg·mL/min) than after IV
administration of CMS at the same dose (160±20 mg·mL/min), meaning
that colsitin exposure was 3 folds greater after nebulisation than IV
administration of CMS.
Conclusion: Because colistin is nebulised as a prodrug (CMS),
conversion to the active moiety within the lung is necessary to provide
efﬁcacy. Yet because systemic conversion of CMS into colistin is limited
to 13% on average, and because colistin formed within lungs (30% of the
dose) is eventually totally absorbed, colistin systemic exposure is greater
after nebulisation and therefore toxicity may also be greater. Although
this observation should not be directly extrapolated to humans, this issue
deserves consideration.
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P1604 Impact of area-under-the-inhibitory-curve on clinical and
microbiologic outcomes in ﬂuconazole treated candidaemia
B. Footer °, S. Monte, L. Podkulski, G. Prescott, C. Rotstein, J. Brown,
J. Paladino, J. Schentag (Buffalo, US; Toronto, CA)
Objectives: The goal of this case series was to identify an AUIC break-
point for ﬂuconazole that links pharmacokinetics and pharmacodynamics
with microbiologic and clinical outcomes as well as time to organism
eradication in adults with candidemia.
Methods: This study was a retrospective, case series of adult patients
(>18 years)with an index Candida bloodstream infection and sufﬁcient
demographic, laboratory and microbiologic data to calculate serial
AUICs and determine clinical and microbiologic outcome. Patients had
to have received at least three days of ﬂuconazole. Because failures and
successes were enrolled, time to eradication for both groups in relation
to PK/PD parameters could be examined. Clinical and pharmacokinetic
information was used to determine the optimal AUIC breakpoints (25,
50, 75, 100, 250, and 400) that were predictive of microbiologic and
clinical outcomes, as well as more rapid fungal eradication.
Results: For all Candida species, the AUIC 100 breakpoint was
descriptively and statistically superior to breakpoints <100 for micro-
biologic and clinical outcomes as an AUIC >100 versus those <100
demonstrated greater microbiologic eradication (72% vs. 56%; p = 0.122)
and clinical success (61% vs. 39%; p = 0.067). Similar to all species,
the AUIC 100 breakpoint was descriptively and statistically superior
to other breakpoints <100 for both outcomes in non-albicans species.
The AUIC >100 breakpoint was signiﬁcantly associated with greater
microbiologic eradication (78% vs. 44%, p = 0.035) and clinical success
(81% vs. 28%, p = 0.05). Higher AUICs did not provide additional
microbiologic or clinical beneﬁt for both the all Candida and non-
albicans species. In terms of time to eradication, an AUIC >100 tended
to be associated with a more rapid time to eradication versus those <100
in the all Candida species group (p = 0.095). For non-albicans species a
statistically signiﬁcant more rapid time to eradication in those patients
with an AUIC >100 was achieved (p = 0.004).
Conclusion: An AUIC >100 appears predictive of greater microbiologic
eradication, positive clinical outcomes, and time to eradiation for
all known Candida species. A statistical relationship existed for
microbiologic eradication and time to eradication in non-albicans species
at the AUIC >100 breakpoint. Further research is needed to correlate
these ﬁndings with venous access catheter removal to assess that effect
on microbiologic, clinical, and time to eradication outcomes.
P1605 The effect of posaconazole on the pharmacokinetics of
midazolam and simvastatin in healthy volunteers
G. Krishna °, L. Ma, P. Prasad, A. Moton, M. Martinho, G. Weiner,
E. O’Mara (Kenilworth, Miami Gardens, US)
Objectives: To determine the effect of posaconazole (POS) on the
pharmacokinetics (PK) of simvastatin (SMV) and characterize the
CYP3A4 inhibitory potential of POS for a range of doses with
concomitant administration with midazolam (MDZ).
Methods: This was a randomized, ﬁxed-sequence, parallel-group, single-
site, open-label study. Healthy male and female subjects (n = 35) received
POS 50mg, 100mg, or 200mg once daily (QD) for 13 days. In all
groups, subjects received POS plus 1 dose of MDZ 2mg on day 8 and
POS plus 1 dose of SMV 40mg on day 11. Subjects also received 1 dose
of MDZ 2mg alone on day −9 and SMV 40mg alone on day −6. Blood
samples for assessment of MDZ, SMV and SMV acid were collected
at predetermined time points. Log-transformed PK parameters for POS,
MDZ, SMV and SMV acid were analysed separately for each treatment
group using ANOVA model to extract the effect due to treatment and
subject.
Results: Coadministration of multiple oral administrations of POS
signiﬁcantly increased MDZ, SMV and SMV acid exposure (Table).
MDZ Cmax increased by 2.0-, 2.4- and 2.7-fold and AUC by 3.1-, 4.0-
and 5.7-fold, respectively, after POS 50mg, 100mg and 200mg QD,
compared with MDZ alone. MDZ median Tmax ranged from 0.5 to 1 h.
MDZ terminal phase half-life (t1/2) signiﬁcantly increased from 4.1 h
with SMV alone to 6.8, 8.7 and 10.7 h, respectively, after POS 50mg,
100mg or 200mg QD. The variability (%CV) for MDZ Cmax and AUC
ranged from 18% to 46%. SMV Cmax increased by 7.4-, 9.4- and 11.4-
fold and AUC by 5.7-, 10.3- and 10.6-fold, respectively, after POS 50mg,
100mg and 200mg QD, compared with SMV alone. SMV median Tmax
ranged from 1 to 2 h; t1/2 was slightly lower with coadministered POS
than with SMV alone. SMV %CV for Cmax and AUC ranged from 42%
to 89%.
SMV acid Cmax increased by 5.5-, 9.2- and 9.5-fold and AUC by 5.4-,
7.3- and 8.5-fold, respectively, after POS 50mg, 100mg and 200mg QD,
compared with SMV alone. SMV acid median Tmax ranged from 3 to
4 h; t1/2 was slightly lower with coadministered POS than with SMV
alone. SMV acid %CV for Cmax and AUC ranged from 46% to 67%.
POS 50mg, 100mg and 200mg was safe and well tolerated when
coadministered with MDZ and SMV.
Conclusions: Coadministration with POS increased plasma concentra-
tion of MDZ, SMV and SMV acid, which is consistent with inhibition of
CYP3A4-mediated metabolism of MDZ, SMV and SMV acid by POS.
Analyte Treatment comparison POS dose Ratio estimate
(mg) (%) 90% CI
MDZ MDZ + POS vs MDZ 50 305 257–362
100 399 306–519
200 570 482–674
SMV SMV + POS vs SMV 50 565 443–722
100 1031 840–1267
200 1060 863–1302
SMV acid SMV + POS vs SMV 50 535 418–684
100 734 582–925
200 848 704–1023
Gram-negative infections: clinical and
PK/PD studies
P1606 What is the impact of a rapid-diagnostic test (E-test) in the
treatment of patients with Gram-negative bacteraemia?
E. Moral-Escudero, E. Garcı´a-Va´zquez °, A. Ferna´ndez-Rufete,
A. Herna´ndez-Torres, J. Ruiz, G. Yagu¨e, H. Albendı´n-Iglesias,
J.A. Herrero, J. Go´mez (Murcia, ES)
Objectives: To evaluate inﬂuence of a rapid-diagnostic test (RT)
in antibiotic (AB) therapeutic decisions in non-paediatric patients
with Gram negative bacteraemia (GNB. Patients and Methods: A RT
(validated in 5 hours)consisting in direct antibiogram (Mueller-Hinton
agar) was done in blood isolates of GNB. AB used in the E-test were
ciproﬂoxacin, cefotaxime, cefepim, cefepim-clavulanic, and imipenem.
GNB were also identiﬁed and sensitivity test performed by standard
criteria (McFarland). RT information was provided at the physician
in a 24 hour-working routine (<24 hours after blood cultures were
obtained). Data collection has been done according to a standard
protocol (epidemiological, clinical, microbiological and laboratory data).
Information about empirical treatment was registered (T1) as well as
the AB administered once the information of RT was provided (T2)
and on the ideal AB the Infectious Diseases consultant would have
prescribed (considering not only sensitivity results but also clinical
characteristics, localization of infection and minimum “ecological”
impact) (T3). Decision about T2 was always taken by the physician
in charge or the physician on duty. The economic cost of 72 hours
(mean “won time” by RT compared to standard sensitivity test) of T1,
T2 and T3 was calculated according to the price of AB provided by our
Pharmacy Department; RT cost was 14€.
Results: RT was performed in 99 patients; one blood culture yield 2
different GNB; 4 patients died before RT results were available (excluded
for the analysis); 5 patients died due to non-infectious complications
and 9 died with septic shock (mortality 18.2%). Microbiological isolates
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were: E. coli (60%; 19.3% ESBL), K. pneumoniae (10.5%; 2% ESBL),
P. aeruginosa (10.5%) and other enterobacteria 13.7%. Main AB
used in T1 were quinolones (14%), 3rd generation cephalosporins
(16%), carbapenems (15%) and piperacillin–tazobactam (28.3%). T1 was
considered adequate in 26.3% and T2 in 60%. Economical cost of 72
hours of T1, T2 and T3 per patient was 70.6€, 69.9€ and 44.2€; the
economical cost of T3 including 14€ of the RT is 58.2€.
Conclusions: In an era of increasing MDR-GNB, RT provides early
and useful information about AB treatment options; this data should
be interpreted by an Infectious Diseases specialised physician to make
information economically and “ecologically” proﬁtable. New diagnostic
techniques are not cost-effective if they are not properly interpreted.
P1607 Colistin plus rifampin or other antibiotics in 90 patients
with serious MDR Ps. aeruginosa or A. baumannii infection
S. Fondelli °, C. Tascini, P. Malacarne, F. Giunta, B. Viagi, F. Forfori,
P. Lambelet, F. Fallani, A. Novelli, E. Tagliaferri, A. Leonildi,
F. Menichetti (Pisa, Viareggio, Florence, IT)
Background: Best Colistin (C) combination therapy for infections due
to MDR non fermenter Gram-negative bacilli has not been established
as well as the best dose-schedule (tid vs. od).
Methods:We reviewed patients (pts) treated with C at Pisa Hospital from
2001 to 2009 analyzing clinical and microbiological outcome, adverse
events and dose schedule.
C was administered as 3 M tid or 9 M od. Agents used in combination
were Rifampin (R) (600mg/day) or other antibiotics (OA) (mostly
carbapenem).
Cure was deﬁned as resolution of signs of infection (SI); improvement as
reduction of SI; and failure as death or increasing of SI. Microbiological
eradication was considered only when culture control resulted negative;
microbiological failure was deﬁned a persistence of the causative
pathogen. Renal and neurological toxicity was studied. Serum calcium
concentration was recorded in all pts and correlated with clinical
outcome.
Results: In the study period 90 pts (males 67, females 23, mean
age 57.6) with 98 infections caused by MDR/PDR Gram-negative
rods (P. aeruginosa 58%; A. baumannii 35%) were treated with C in
combination. Infections were represented by: VAP 36%, SSTI 27%,
Sepsis 15%, Pneumonia 12%, Osteomyelitis 5%, other infections 5%.
C was administered intravenously for 26±12 days (D). The overall
clinical response was obtained in 69% of patients (38% C, 31% I) and
microbiological eradication was obtained in 55% of cases. Clinical and
microbiological response in pts treated with C+R or C+OA are shown
in the table. C od (9M) was administered in 11 pts for a mean period of
17 days without adverse events or emergence of resistant strains. Mean
Cmax±SD was 79±39mg/L. All pts with favourable clinical outcome
had serum calcium concentration >8.6mg/dL. Renal toxicity was noted
in 3% of pts.
Conclusions: C+R or C+OA seems to have similar clinical efﬁcacy
but C+R seems to be most effective in sepsis and in microbiological
eradication in VAP. Colistin od provide Cmax concentration well
above the breakpoint for MDR Gram-negative rods. Serum calcium
concentration seems to inﬂuence the clinical outcome.
Table 1. Clinical and microbiological response in pts treated with C+R
or C+OA
C+R C+OA
CR MR CR MR
Overall 32/45 (71%) 27/45 (60%) 35/53 (66%) 26/53 (50%)
VAP (35) 7/13 (54%) 9/13 (69%) 16/22 (73%) 8/22 (36%)
Sepsis (15) 5/5 (100%) 4/5 (80%) 3/10 (30%) 5/10 (50%)
SSTI (26) 10/16 (63%) 9/16 (57%) 9/10 (90%) 8/10 (80%)
P1608 Targeting multidrug-resistant Pseudomonas aeruginosa:
pharmacodynamics of the combination of colistin and
ciproﬂoxacin
J. Li, A. Poudyal, H. Yu, R. Owen, J.B. Bulitta, A. Forrest, B. Tsuji,
R. Nation ° (Melbourne, AU; Albany, Buffalo, US)
Objective: Multidrug-resistant (MDR) Pseudomonas aeruginosa (Pa) is
presenting a global medical challenge due to lack of new antibiotics.
Rational combinations (combos) must be considered to minimize
development of resistance particularly to colistin (COL), a last-line
therapy. This study evaluated the pharmacodynamics (PD) of COL
and ciproﬂoxacin (CIP), both alone and in combo, using a rational
approach.
Methods: MICs of COL and CIP were measured with microbroth
dilution. Against 12 strains (3 COL susceptible (COLS), 6 heteroresistant
(COLHR) & 3 resistant (COLR)), checkerboard synergy panel studies
were conducted with COL/CIP and viable counting was performed at
24 h to enhance detection of synergy for translation to static time-kill
(STK) studies. COL/CIP were evaluated in STK studies against 1 COLS,
4 COLHR and 1 COLR strains with an inoculum of ~106 CFU/mL: 8
concentrations for COL alone & CIP alone, and 9 combos of COL/CIP
(low, mid & high for each) up to 64×MIC for S and HR strains or
16mg/L for R strains. Viable counting was done up to 48 h and COL
population analysis proﬁles (PAPs) were examined at 48 h.
Results: MICs of COL and CIP were 0.5 to >128mg/L and <0.125
to 32mg/L, respectively. COL/CIP fractional inhibitory concentrations
were >0.5 for most strains. However, COL 2mg/L/CIP 2mg/L (clinically
achievable for COL and CIP) inhibited visible growth of all 12 strains;
for the strain resistant to both COL and CIP, viable counting revealed
COL 2mg/L/CIP 2mg/L achieved substantial killing (to 2.45 log
CFU/mL at 24 h). In STK, COL alone showed rapid initial killing
(up to ~6 log) against all strains except COLR Pa. Good killing was
also observed with CIP alone against CIPS strains. For COL or CIP
alone, substantial regrowth occurred at 48 h for some strains even at
64×MIC. Generally the COL/CIP combos with mid and high COL
showed synergistic killing (up to ~6 to 7 log kill within 4 h or at 48 h)
against most strains. PAPs showed emergence of resistance in 3 COLHR
strains with low COL alone and in only 1 COLHR strain with the low
COL/low CIP combo.
Conclusions: A COL/CIP combo is increasingly being used against
MDR Pa, in particular in cystic ﬁbrosis clinics. This study highlights
the importance of optimizing the absolute and relative concentrations of
COL and CIP.
P1609 A semi-mechanistic pharmacokinetic–pharmacodynamic
model with adaptation development for in vitro activity of
ciproﬂoxacin against Pseudomonas aeruginosa
N. Gre´goire °, S. Raherison, C. Grignon, E. Comets, M. Marliat,
M.C. Ploy, W. Couet (Poitiers, Limoges, Paris, FR)
Objective: To implement pharmacokinetic–pharmacodynamic (PK-PD)
model to describe over time the effects of ciproﬂoxacin (CIP) against
P. aeruginosa in vitro.
Methods: Time-kill curves were generated over 24 h with an inoculum
of 5×106 CFU/mL at concentrations from 0.5 to 16×MIC. P. aeruginosa
susceptibility to CIP was assessed before and after 24 h exposure
to CIP: (i) modiﬁcations of the DNA gyrase and topoisomerase IV
enzymes caused by mutations in Quinolone Resistance Determining
Region of gyrA and parC subunit genes, were investigated using PCR,
(ii) CIP efﬂux pumps activation was tested by addition of Phenyl
Arginine b-naphthylamide, a known inhibitor of Mex multidrug efﬂux
system implicated in ﬂuoroquinolones active efﬂux in P. aeruginosa.
A previously described PK-PD model (1), in which the concentration
necessary to achieve 50% maximal kill rate (EC50) increased as a
function of antibiotic concentration and time, to account for bacteria
adaptation, was ﬁtted to the time-kill data. A population approach was
used with Nonmem® software.
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Results: At intermediate CIP concentrations, microbial regrowth was
observed after initial killing. Sub-inhibitory CIP concentrations (
MIC) favoured the emergence of mutants with increased but moderate
resistance to CIP (MIC 8 fold increase), only by over-expression of Mex
efﬂux pumps. The selected PK-PD model with adaptation adequately
described the microbial response to CIP in the range of concentrations
investigated.
Conclusion: Susceptibility of P. aeruginosa to CIP may rapidly decline
after multidrug efﬂux pump activation. This phenomenon was adequately
described by a PK-PD model with adaptation. Resistance development
over longer period of time should now be investigated using dynamic
approaches (hollow-ﬁber model) to mimic multiple dosing treatments.
Reference(s)
[1] V.H. Tam et al., J. Antimicrob. Chemother. 55: 699–706 (2005)
P1610 Pharmacokinetic/pharmacodynamic analysis using Monte
Carlo simulation to evaluate cumulative fraction of
response of doripenem against Pseudomonas aeruginosa
and Enterobacteriaceae
A. Canut °, A. Isla, M.A. Solinı´s, A. Labora, A. Rodrı´guez-Gasco´n
(Vitoria, ES)
Objective: Carbapenems are widely used therapies for serious infections
involving Pseudomonas aeruginosa and multidrug-resistant Enterobac-
teriaceae. The main objective of this study is to calculate the probability
of attaining targeted pharmacodynamic exposure for two intermittent
infusion rates of doripenem against P. aeruginosa and ESBL phenotype
Enterobacteriaceae or Enterobacteriaceae with stably depressed AmpC
production.
Methods: Susceptibility data to doripenem of clinical P. aeruginosa
isolates; ESBL phenotype E. coli, K, pneumoniae, K, oxyotca and
P. mirabilis; and E. cloacae, E. aerogenes, C. freundii, S. marcescens
and M. morganii with stably depressed AmpC production were obtained
from recently published data (Castanheira et al, 2009, Mendes et
al, 2009). Four dosing regimens consisting on 500mg every 8 h or
1000mg every 12 h with short (1 h) or prolonged (4 h) duration of
infusion were evaluated. Percentage of the dosing interval duration
for which concentrations of the antibiotic were above the MIC of the
pathogen (T>MIC) was used as the pharmacodynamic parameter to
predict doripenem efﬁcacy (target of 40% of the dose interval). For each
infusion rate 20,000 patients were simulated based upon a log-normal
distribution of volume of distribution and elimination half-life. Mean
pharmacokinetic parameters and their distribution were extrapolated
from published studies. Cumulative fraction of response (CFR) for
the requisite pharmacodynamic target was calculated considering the
distribution of MICs for each of the species under the current study.
Results: Against P. aeruginosa, at least 1000mg every 12 h, administered
as a short infusion were necessary to obtain a CFR90%, obtaining
lower success rates with the 500mg dosage regimens, principally due to
the high frequency of strains with MIC 4mg/L. Calculated CFRs were
higher than 90% against all Enterobacteriaceae with all perfusion rates
(the MIC90 values were <1 for all species).
Conclusion: Taking into account the latest published susceptibility
patterns, the probability of success against P. aeruginosa is only higher
than 90% when 1000mg are administered every 12 h. In contrast,
doripenem 500mg administered as 1 h perfusion is enough to achieve
a high likelihood of obtaining the pharmacodynamic target against
multidrug-resistant Enterobacteriaceae isolates.
P1611 Rational design of colistin and ciproﬂoxacin combination
regimens against Pseudomonas aeruginosa using
mechanism-based models
J.B. Bulitta °, A. Forrest, A. Poudyal, H. Yu, R. Owen, J. Li, B. Tsuji,
R. Nation (Albany, Buffalo, US; Melbourne, AU)
Objectives: The present lack of efﬁcacious treatment options against
severe infections by multidrug-resistant (MDR) Pseudomonas aerugi-
nosa (Pa) causes a global healthcare problem. Our aim was to develop a
rational approach to optimize combination regimens with colistin (COL)
and ciproﬂoxacin (CIP) against Pa using mechanism-based models
(MBM).
Methods: Population pharmacodynamic (PD) modelling using the
MC-PEM algorithm in S-ADAPT (V1.56) was applied to evaluate
killing of the predominant subpopulation by COL & CIP alone or in
combination. We modelled quantitative viable counts and turbidity data
from checkerboard synergy panel studies at 24 h for 12 Pa strains (see
abstract number 2063). Time-kill (TK) data (inoculum: 106 CFU/mL; 8
samples over 48 h per proﬁle) on one COL-susceptible (COLS), one
COL-heteroresistant (COLHR) and one COL-resistant (COLR) strain
with 8 concentrations of COL or CIP alone and 9 concentrations of
COL/CIP in combination were modelled in NONMEM VI. MBM with
up to 6 subpopulations were developed and ﬁtted to all data of one
strain simultaneously. These MBM assessed the degree and potential
mechanisms of interaction.
Results: MBM of the synergy panel data indicated additive killing by
CIP & COL for 10 strains, synergy for one COLS strain, and antagonism
for one COLS strain. MBM of TK data yielded unbiased and reasonably
precise population predictions (slopes: 0.99 to 1.00, r2: 0.79 to 0.96).
Killing was described by a Hill-function for CIP and by a 2nd-order
function for COL. For the mechanism of synergy, COL effectively
reduced the EC50 of CIP to 10−13% of that in the absence of COL for
the CIPR subpopulation against the COLS and COLR strain. A reduction
of CIP-EC50 to 35% was achieved against the CIPS subpopulation of
the COLR strain. No reduction was seen for the CIPS and CIPintermediate
subpopulation of the COLS strain. A half-maximal reduction of CIP-
EC50 was achieved by 0.88mg/L COL. Killing of the COLHR strain by
COL and CIP was additive.
Conclusions:MBM of the synergy panel data correctly predicted largely
additive effects of COL & CIP against the predominant susceptible
subpopulation. For 2 of 3 strains, the time-kill modelling identiﬁed
a reduction of the CIP-EC50 at low COL concentrations against the
CIPR population as the most likely mechanism of synergy. This may be
explained by COL increasing intracellular concentrations of CIP.
P1612 Carbapenem-resistant Acinetobacter baumannii pneumonia:
meropenem–rifampicin combination versus colistin
J.Y. Song °, W. Choi, J. Heo, J. Noh, D.W. Park, J.W. Sohn, W.J. Kim,
M.J. Kim, H.J. Cheong (Seoul, KR)
Background: Carbapenem-resistant Acinetobacter baumannii has be-
come a major nosocomial pathogen during the past years, and pneumonia
is the most serious nosocomial infection with limited therapeutic options.
Methods: A retrospective study was performed on 51 adult patients
with carbapenem-resistant A. baumannii pneumonia admitted to three
Korea University Hospitals from September 2006 through August
2009. Clinical and microbiological outcomes of meropenem-rifampicin
treatment were compared with those of colistin treatment.
Results: Out of 51 patients with carbapenem-resistant A. baumannii
pneumonia, 22 were treated with meropenem-rifampicin and 29 with
colistin. No signiﬁcant difference was found between two groups regard-
ing the baseline characteristics (demographic ﬁndings, co-morbidities,
severity of illness, etc) and laboratory ﬁndings. Meropenem-rifampicin
showed better clinical cure rates (77.3% versus 20.7%, p< 0.01)
and lower 30-day mortality rates (13.6% versus 65.5%, p< 0.01);
mean intervals from antibiotic start to death were 15.0±3.4 days and
15.9±8.1days respectively (p = 0.86). Microbiological eradication rates
were 68.2% for the meropenem-rifampicin group and 20.6% for the
colistin group (p< 0.01).
Conclusion: Meropenem-rifampicin was better effective than colistin
in treating carbapenem-resistant A. baumannii pneumonia. Considering
poor microbiological eradication rates, new antimicrobial agents and
combinations need to be investigated.
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P1613 Clinico-epidemiologic and molecular characteristics of
extended-spectrum b-lactamase-producing Escherichia coli,
Klebsiella spp. and Enterobacter spp. causing infections at
ﬁve Indian hospitals, 2007–2009
D. Mathai °, A. Kapil, K. Radhakrishnan, S. Parija, D. Mendiratta,
K. Prasad, J. Hepsibah, K. Mayank, A. Manoharan on behalf of the
ICMR-ESBL Study Group
Objective: The association with community acquisition (CA), nosoco-
mial (NO) occurrence, clinical risk factor and treatment outcome of
blood stream (BSI), Respiratory tract (RTI), urinary tract (UTI) and
Skin and soft tissue including surgical site (SSTI) infections caused by
ESBL producing Gram-negative bacilli (GNB) that are endemic in Indian
hospitals remains poorly characterized.
Methods: We determined ESBL prevalence, clinical risk factor and
treatment outcome among 1849 [Escherichia coli (EC) (n = 984),
Klebsiella spp., (KS) (710) and EC (155)] isolates that were
consecutively collected at ﬁve tertiary care hospital laboratories causing:
636 UTI; 522 BSI; 348 RTI and 343 SSTI. During May 2007 to
September 2009 (28 month) these isolates were forwarded to BMPLIII
for susceptibility testing against 13 antimicrobials (ﬁve classes) by disk
diffusion and Etest methods and using CLSI interpretive criteria. Multi-
drug resistant (MDR), if resistant 2 classes. PCR testing for blaTEM,
blaSHV, and blaCTX-M was done on 416 blood isolates Infection was
clinically deﬁned as CA when acquired as outpatient with no records of
hospitalization up to 1 year and patients did not have any features of
health care associated (HA) or NO (seen >72 hours after admissions).
Outcome (death within 14 days was evaluated.
Results: Overall, ESBL prevalence ranged 67.2% to 90.4%. NO and
CA rates were 43.6% and 21.9% respectively. Prior hospitalization and
male were signiﬁcant risk factor for ESBL, with 163 post surgical
SSTIs. Among ESBLs, resistance to levoﬂoxacin was 83.4%, Pipercillin/
tazobactum 61.5%, amikacin 50% and carbapenems and tigecycline
13.5%. Overall, MDR among ESBLs was 37% and in CA isolates 7.4%.
CTX-M genotype was(67.1%)Overall 7.4% patients died; 79.0% with
ESBL. Intial choice of antimicrobials was inappropriate in 75.7%.
Conclusion: ESBL and MDR isolates continues to be high in Indian
hospitals and their emergence in the community is alarming. There is a
six fold greater mortality. Surgical SSTI should be largely preventable via
good infection control practice Carbapenem and tigecycline resistance
mechanism is to be elucidated. CTX-M seems to be the predominant
genotype. Measures to limit further escalation into community and limit
spread inter and intra in hospitals are urgently needed.
P1614 Antibiotic resistance in Escherichia coli infection in the
Valencian community, Spain
J.M. Sahuquillo-Arce °, M. Selva-San Adria´n, J. Beltra´n-Heras,
E. Gonza´lez-Barbera´, M. Gobernado (Valencia, ES)
Objective: To analyze the distribution of Escherichia coli resistance
to cefuroxime (CFX), ceftriaxone (CTO), ciproﬂoxacin (CIP) and co-
trimazol (STX), according to sex and age in a period time of 33 months
in the Valencian Community, a Spanish region with a population of
almost ﬁve million people.
Methods: Retrospective analysis of data compiled by the Valencian
Community Microbiological Watch Network (RedMIVA) referring to
E. coli infections from January 2007 to August 2009. This network
registers information from 22 hospitals. All isolates where identiﬁed
according to standard procedures and the regarding information is
transmitted daily via the internet to the Public Health Centre server,
where it is automatically treated and recorded.
Data was analyzed by means of the Deviation Information Criteria
method (DIC) and logistic regression (LR).
Results: The number of isolates studied was above 100,000 in all four
antimicrobials. Data from the three years was added together for each
antibiotic since it displayed similar patterns and trends. Men had higher
levels of resistance and exhibited an abrupt increase at the age of puberty,
while resistance development in women seemed inhibited until the pre-
menopause age. Statistical analysis proved that resistance in women and
men presented with different patterns. Data is shown in table 1.
Conclusions: This work exposes the distribution of resistance to four
antimicrobials with a widespread use. Surprisingly, men and women
exhibited different patterns in the acquisition of resistance. Thus, age
and sex materialize as crucial factors to be taken into account when the
time comes to establish antibiotic use guides.
Whether these results are repeated in different regions is still to be
conﬁrmed; but, the idea of a hormonal inﬂuence is very appealing.
Table 1. Percentages of antibiotic resistance in women and men
Resistance (%) by age group Total n
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CIP
Men 5.6 7.1 14.2 34.9 28.0 32.1 37.1 29.3 34.1 32.0 36.0 40.7 43.4 46.6 52.8 55.8 59.4 66.8 36828
Women 8.3 9.5 13.1 12.0 12.5 13.2 14.2 16.0 19.5 24.1 25.2 31.8 34.5 38.7 41.6 44.3 46.7 49.1 90655
CTO
Men 5.2 4.4 6.8 10.5 8.9 10.3 9.5 8.1 10.8 11.5 13.2 13.5 14.7 13.3 16.2 16.2 17.1 15.4 30510
Women 5.0 3.6 3.8 3.8 3.3 3.7 3.1 5.0 5.6 6.4 7.8 7.9 9.8 11.3 11.1 11.9 11.9 12.7 72951
CFX
Men 7.2 5.2 9.4 17.7 14.7 11.8 14.1 12.1 15.7 16.1 16.8 18.4 19.6 18.1 20.5 21.6 22.5 23.7 41580
Women 6.7 5.8 6.0 5.3 4.9 4.8 4.6 6.7 7.0 9.0 10.3 10.6 12.5 14.3 14.7 15.8 15.5 17.0 96893
STX
Men 26.4 27.9 35.8 36.9 33.6 36.0 40.4 35.7 39.1 40.5 38.7 42.1 41.9 38.6 41.7 43.1 41.2 44.0 30666
Women 29.1 30.3 32.5 25.7 26.9 25.3 25.3 27.0 28.5 30.4 31.7 35.4 35.7 39.1 38.5 39.0 39.2 38.0 77563
P1615 Antimicrobial resistance surveillance in Germany: ﬁrst
results for E. coli, K. pneumoniae and P. mirabilis from
urine samples in ambulatory care, 2008–2009
I. Noll °, B. Schweickert, G. Krause, T. Eckmanns (Berlin, DE)
Objectives: In 2008, Germany expanded the scope of its national
antimicrobial resistance surveillance system to the sector of ambulatory
care. This presentation gives a ﬁrst insight into resistance in the most
frequent Gram-negative pathogens isolated from urine samples from
outpatients in 2008/2009. Data will be stratiﬁed by age groups and
selected geographical regions.
Methods: The dataset is taken from the German Antimicrobial
Resistance Surveillance (ARS) System. Analysis is based on non-
duplicate isolates of E. coli, K. pneumoniae and P. mirabilis from
urine samples in four laboratories with continuous data collection
from January 2008 to October 2009. Species identiﬁcation and
antimicrobial susceptibility testing is performed by VITEK 2, results
are evaluated according to CLSI guidelines. Proportions of susceptible
isolates were calculated for the following antibiotics: ampicillin (AMP),
ampicillin/sulbactam (AMS), piperacillin (PIP), piperacillin/tazobactam
(PIT), cefotaxime (CTX), ciproﬂoxacin (CIP), co-trimoxazole (SXT).
Results: The most frequent Gram-negative pathogens isolated from a
total of 87.873 urine samples were E. coli (n = 49,179; 47.2% out of
104,248 isolates), P. mirabilis (n = 5,065; 4.9%) and K. pneumoniae
(n = 4,393; 4.2%). Results of susceptibility testing are displayed as
percentages of susceptible isolates of all non-duplicate isolates tested
in table 1. In E. coli overall proportions of susceptibility for the most
frequently used antimicrobials in urinary tract infections as AMP, AMS,
SXT and CIP vary from 54.6% (AMP) to 84.2% (CIP), in P. mirabilis
the corresponding range spans from 64% (SXT) to 92.3% (AMS) and
in K. pneumoniae proportions for selected antibiotics are all above
80%. Stratiﬁcation by age groups shows signiﬁcant lower levels of
susceptibility for patients older than 60 for AMP, PIP, CIP and SXT
in E. coli as well as in P. mirabilis. Regional differences with similar
patterns are observed for CIP, SXT and PIP across species. Signiﬁcant
changes in resistance between 2008 and 2009 did not occur.
Conclusions: These ﬁrst large-scale data from ambulatory care indicate
that non-susceptibility of E. coli and to a lesser degree of P. mirabilis
from urines to ﬁrst-line antibiotics is highly prevalent, that it is even
higher in patients older than 60 and that there are some regional
variations. Interpretation of the data should consider that in ambulatory
care settings specimens are mainly taken from pre-treated patients.
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Table 1. Susceptibility of E. coli, P. mirabilis, K. pneumoniae from urine
samples of outpatients in Germany 2008/09
Pathogen Stratiﬁcationa Susceptibilityb n
AMP AMS PIP PIT CTX CIP SXT
E. coli Total 54.6 69.2 57.2 87.3 97.0 84.2 70.8 41,449
by agegroup
15 57.7 72.9 59.6 90.1 98.2 96.6 75.3 4,391
16−59 58.2 71.1 60.3 88.7 97.6 89.3 74.6 15,555
60 51.4 67.2 54.5 85.7 96.3 78.1 67.1 21,503
by region
BE –c –c 60.1 88.3 97.0 88.8 73.8 8,944
BW –c 70.1 60.9 86.2 94.9 83.8 74.3 3,677
NW 53.7 68.4 54.4 87.2 97.9 82.6 67.9 17,667
SH 56.6 71.5 57.7 88.2 96.9 84.6 70.4 6,519
P. mirabilis Total 68.2 92.3 71.4 96.1 99.0 87.9 64.0 4,577
by agegroup
15 79.7 93.9 79.1 96.8 99.4 96.1 74.6 727
16−59 72.8 93.6 74.4 96.7 99.3 90.9 65.2 1,150
60 63.5 91.4 68.0 95.6 98.8 84.4 60.6 2,700
by region
BE –c –c 77.1 97.9 99.7 93.5 70.4 1,059
BW –c 92.7 73.1 96.6 99.1 89.0 68.6 328
NW 66.8 90.7 67.0 94.6 98.7 81.7 57.9 1,844
SH 71.2 95.0 71.7 96.9 98.8 93.5 63.2 804
K. pneumoniae Total R* 82.8 R* 89.1 96.2 92.4 86.4 3,975
by agegroup
15 R* 82.5 R* 90.6 99.4 97.7 89.8 177
16−59 R* 83.7 R* 89.2 97.2 94.6 86.7 1,245
60 R* 82.3 R* 88.9 95.5 90.9 86.1 2,553
by region
BE R* – R* 91.9 96.8 96.4 90.4 788
BW R* 82.7 R* 89.1 95.7 91.0 84.8 376
NW R* 83.6 R* 88.0 96.1 90.4 86.2 1,680
SH R* 80.2 R* 88.5 95.7 95.0 80.9 575
aBE, Berlin; BW, Baden-Wuerttemberg; NW, North Rhine-Westfalia; SH, Schleswig-Holstein.
bPercentages of susceptible isolates from non-duplicate isolates tested (n) against AMP, ampicillin; AMS, ampicillin/
sulbactam; PIP, piperacillin; PIT, piperacillin/tazobactam; CTX, cefotaxime; CIP, ciproﬂoxacin; SXT, co-trimoxazole.
cNot tested.
*Intrinsic resistance.
P1616 Imported raw chicken meat as a potential reservoir for
ESBL-producing Escherichia coli in the United Kingdom
H. Dhanji °, N.M. Murphy, S. Durmus, S. Lee, J. Iverns, R. Hope,
N. Woodford, D. Livermore (London, UK)
Objective: Clinical E. coli isolates with group 1 CTX-M ESBLs have
become frequent in the UK since 2003. Most have CTX-M-15 or (less
often) CTX-M-3 enzyme encoded by IncFII or IncI1 plasmids and many
of these isolates belong to the international O25b:H4 ST131 lineage
(phylogenetic group B2). It was postulated that the spread of this clone
might be facilitated either (i) by human-to-human contact, along with
travel, or (ii) via a food source disseminated by the global market.
To investigate the latter possibility we examined the antibiotic proﬁles,
phylogenetic grouping, ESBL genes and plasmid types of 141 oxyimino-
cephalosporin-resistant E. coli isolated from raw chicken meat imported
into the UK from South America.
Methods: MICs were determined by the BSAC agar dilution method.
Multiplex PCR was used to seek antibiotic resistance genes and to assign
isolates to phylogenetic groups. CTX-M ESBL-encoding plasmids were
transferred by conjugation to E. coli K12 J53−2 (rifR). Plasmids were
extracted and rep typed by PCR. A real-time PCR assay was used to
identify ST131 isolates.
Results: Among the 141 isolates, 44 had CTX-M group 2 enzymes, 38
had CTX-M group 8 and 59 had CMY-type AmpC; none had group 1
CTX-M ESBLs. No isolates with CTX-M group 8 ESBLs belonged
to phylogenetic group B2, however 5/44 (11%) CTX-M group 2-
positive isolates and 2/59 (3%) CMY-positive isolates belonged to this
extraintestinal virulent group; none of the isolates belonged to the
O25b:H4 ST131 clone. Phylogenetic group D was dominant among
CTX-M ESBL-producing isolates and group B1 was dominant among
isolates producing CMY-type AmpC. In contrast with most clinical
E. coli with CTX-M ESBLs, all isolates with CTX-M group 8, 39/44
(89%) with CTX-M group 2 and 54/59 (92%) with CMY enzymes
were susceptible to ciproﬂoxacin. CTX-M group 2 genes were found
on IncFIB plasmids and CTX-M group 8 genes on IncI1 plasmids.
Conclusion: Imported raw poultry from South America is a reservoir
for E. coli with CTX-M group 2 and 8 ESBLs, which are extremely rare
in UK clinical isolates, and for those with CMY-type AmpC enzymes.
However, it is not a reservoir for the clinically dominant group 1 CTX-M
ESBLs nor for the E. coli O25b:H4 ST131 lineage.
P1617 Prevalence of ESBL-producing Escherichia coli and
Klebsiella pneumoniae rapidly increasing in Denmark
D.S. Hansen °, H. Schumacher, K. Schønning, F. Hansen, M. Stegger,
F.B. Hertz, N. Frimodt-Møller for the DANRES working group
Objectives: Escherichia (EC) and Klebsiella pneumoniae (KPN)
producing ESBL have been on the increase in Northern Europe during
the last years. Our aim was to conduct a national prevalence study of
nosocomial and community acquired ESBL-producing EC, KPN and
Proteus mirabilis (PM) isolates from blood and urine.
Methods: During September-October 2007, 13 of 15 laboratories
(covering 95% of the country) screened all EC, KPN, and PM isolates
from blood and urine for ESBL-production. Conﬁrmatory ESBL-test
positive isolates were sent to a central laboratory for further susceptibility
testing and for ESBL genotyping by PCR and sequencing. Phylogenetic
grouping of the EC isolates was done using PCR.
Results: 18.259 patients were blood cultured and 47.504 patients had
urine cultures taken. Among blood or urine cultures positive with EC
(N= 12.382), KPN (N= 1.751) or PM (N= 541), 257 (2.1%), 93 (5.3%)
and one (0.2%) isolate(s), respectively, were reported ESBL positive. The
prevalence of ESBL-producing EC from nosocomial and community
acquired urine samples were 2.3% and 1.5%, for KPN 6.6% and
5.0%, respectively. Among 280 isolates with ESBL phenotype CTX-M
enzymes dominated among the 205 EC (92%), 74 KPN (89%) and one
PM isolate(s). CTX-M-15 was the most prevalent among EC (60%) and
KPN (76%) isolates. The distribution of the 205 EC isolates among
phylogroup A, -B1, -B2 (78% were CTX-M15), D, and NT, were 41
(20%), 31 (15%), 54 (26%), 65 (32%), and 14 (7%) isolates, respectively.
Extended susceptibility testing showed susceptibility towards meropenem
(100%), fosfomycin (98%), and cefoxitin (91%).
Conclusion: The ESBL is now quite prevalent in Denmark, mainly due
to CTX-M-15. This development challenges the empiric sepsis treatment
with cephalosporin monotherapy.
P1618 Carbapenem resistance in extended-spectrum b-lactamase
producing Klebsiella spp. and Escherichia coli blood isolates
O. Koseoglu Eser °, H. Uludag Altun, B. Sener, G. Hasc¸elik (Ankara, TR)
Objectives: Carbapenem resistance in Enterobacteriaeceae is usually
associated with treatment failure in life-threatening infections. This study
was conducted to test the in vitro effect of imipenem (IMP), meropenem
(MER) and ertapenem (ERT) on Klebsiella spp. and Escherichia coli
blood isolates and to evaluate the underlying carbapenem resistance
mechanism.
Methods: A total of 210 non-duplicated K. pneumoniae (n = 47),
K. oxytoca (n = 10) and E. coli (n = 153) isolates which were all ESBL
positive with BD Phoenix system, were tested for IMP, MER and
ERT susceptibility by microdilution test. All carbapenem non-susceptible
isolates were then screened for metallo b-lactamase (MBL) with IMP-
EDTA E-test, for AmpC b-lactamase with cefoxitin-boronic acid (BA)
and for ESBL with CTX/clavulanate (CLA) and CAZ/CLA and also with
a modiﬁcation using CLA together with BA. KPC-type carbapenamases
were screened with the modiﬁed Hodge test and combination disk
method with MER/MER-BA and ERT/ERT-BA.
Results: The resistance rates of IMP, MER and ERT were 5.7%, 1.9%
and 2.4%, respectively. All the isolates susceptible to IMP and MER,
were also susceptible to ERT, except one. Twenty-three isolates were non-
susceptible to any of the carbapenems. Seven of these yielded negative
ESBL result with CTX/CLA and CAZ/CLA, however, six of them were
found ESBL positive with the addition of BA to CTX/CLA. Three
isolates which were found to be KPC producers with one of the screening
tests, were all ERT resistant K. pneumoniae. AmpC activity was present
in three isolates of which two were also KPC producers. Only one isolate,
resistant to all carbapenems, showed phenotypic MBL production and
was also a producer of KPC and AmpC.
Conclusion: Laboratories should consider testing for ertapenem
susceptibility since it is one of the indicators of KPC activity. However,
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alternative mechanism of carbapenem resistance may be a combination
of ESBL or AmpC with porin loss. Therefore more reliable ESBL
conﬁrmatory tests such as use of CLA together with BA seems to be
mandatory to detect ESBL co-presence with AmpC. Carbapenem non-
susceptible ESBL isolates may pose a new problem in the future due to
limited treatment choices and hospital infection control.
P1619 Plasmid mediated antimicrobial resistance. Characterizing
extended-spectrum b-lactamases in E. coli isolated from
cattle
C.J. Boinett, N. Coldham °, M.F. Anjum, M. Kirchner, A. Carattoli,
M.J. Woodward (Surrey, UK; Rome, IT)
Objectives: The aim of this study was to characterize plasmids
harbouring CTX-M genes and other antimicrobial resistance markers,
with respect to their relative plasticity and ease of dissemination.
Methods: Bovine Escherichia coli isolates (n = 52) found to posses the
CTX-M gene, which encodes for a b-lactamase conferring resistance
to extended spectrum b-lactams were examined. Resistance phenotypes
were determined using the disk diffusion assay. Isolates were also
subjected to analysis by pulse ﬁeld gel electrophoresis, plasmid proﬁling,
miniaturized DNA microarray analysis and PCR based replicon typing.
Results: All 52 isolates were found to be resistant to cefotaxime (CTX),
however when analysed by PFGE, their macro-restriction proﬁles varied
considerably with similarities between 25–100%. Analysis of the plasmid
content showed that all 52 isolates harboured multiple large plasmids
(50–100kb). DNA microarray analysis was used to identify genes that
confer antimicrobial resistance. All the isolates were found to encode
either CTX-M group 1 (CTX-M-1, -15 and -32) or CTX-M group 9
(CTX-M-14 and -14b) variants, with 3 isolates encoding both CTX-
M-14 and -15 genes and the majority encoding multiple antimicrobial
resistance genes. Plasmid transfer rates were determined for 26 / 52
strains by in vitro conjugation studies. The isolates for conjugation were
selected on the basis of distinct plasmid proﬁles and also considering
their antimicrobial resistance proﬁles. Twelve of these isolates were
able to transfer plasmids conferring cefotaxime resistance to recipient
E. coli K12 strains with frequency of transfer rates between 3.75×10−3
and 3.69×10−7. The majority of the isolates harboured multi-replicon
plasmids, with 39 / 52 having an IncF variant.
Conclusion: These data conﬁrm the highly variable nature of the CTX-M
ESBL E. coli strains found on different farms although these were found
to carry only limited CTX-M types. Interestingly 20 isolates encoded the
CTX-M-15 gene, the most prevalent b-lactamase worldwide. FIA, FIB,
FII replicons in E. coli have been linked with the dissemination of CTX-
M-15 genes and therefore the success of plasmids harbouring this gene.
It is proposed that complex methods of gene acquisition may have given
rise to these CTX-M encoding strains and that the plasmids are likely
to be promiscuous.
P1620 In vitro activity of doripenem, a new carbapenem, against
recent Gram-negative clinical isolates from Belgium
C. Lammens, Y. Glupczynski, J. Van Eldere, U. Thomson, H. De
Beenhouwer, E. De Laere, P. De Mol, A. Dediste, D. Govaerts,
H. Jansens, S. Lauwers, K. Magerman, E. Nulens, M.J. Struelens,
M. Van De Vyvere, G. Verschraegen, H. Goossens ° (Wilrijk, Yvoir,
Leuven, Aalst, Roeselare, Liege, Brussels, Montigny-le-Tilleul, Edegem,
Hasselt, Bruges, Antwerp, Ghent, BE; Stockholm, SE)
Objective: The objectives were to document the susceptibility of Gram-
negative clinical isolates to doripenem and competitor antimicrobial
antibacterials in Belgium, and to document the prevalence of resistant
phenotypes and genotypes.
Method: Non-duplicate, consecutive Gram-negative aerobic species
isolates were collected from patients admitted in ICU and hospitalized
for minimum of 48 hours and potentially associated with deep seated
infection in which a deep specimen was collected, during a survey
carried out in 14 Belgian hospitals, in 2008–2009. MICs were determined
by microbroth dilution method according to CLSI guidelines. Testing
included doripenem (DOR), meropenem (MER), imipenem (IMI),
as well as ceftazidime, cefepime, piperacillin–tazobactam, amikacin,
ciproﬂoxacin, levoﬂoxacin and tigecycline. ESBLs and MBLs were
detected and characterized phenotypically and genotypically.
Results: MICs obtained are listed in the table.
Resistance rates of Enterobacteriaceae and Pseudomonas spp to DOR,
MER and IMI were 1.0/14.4, 1.3/31.5 and 4.4/42.5%, respectively.
ESBLs were detected by double combination discs in 55/571 (9.6%)
Enterobactericaceae (range of ESBL by centre: 2.1–23.8%), mainly
of the CTX-M-group. Four plasmidic ampC cephalosporinases were
detected in 3 E. coli and 1 K. pneumoniae strains. MBLs were detected
by PCR-sequencing in 5/174 (2.9%) P. aeruginosa and class D OXA-
carbapenemases 3/21 (14.3%) A. baumannii.
Conclusion: The in vitro activity of doripenem was comparable to that of
meropenem and superior to that of imipenem against Enterobacteriaceae.
Doripenem was the most active carbapenem tested against Pseudomonas
spp, regardless of b-lactam resistance. Overall carbapenems retained
excellent activity against Enterobacteriaceae including all ESBL-and
AmpC-producing isolates. However, the emergence of MBLs and oxa-
carbapenemases in Pseudomonas spp. and in Acinetobacter spp. in
several Belgian ICUs is a matter of concern and warrants close
epidemiologic surveillance.
Doripenem Meropenem Imipenem
Organism n Range MIC50 MIC90 Range MIC50 MIC90 Range MIC50 MIC90
Acinetobacter spp. 21 0.06−32 2 32 0.06−32 2 32 0.06−32 4 32
Citrobacter spp. 20 0.03–0.25 0.125 0.25 0.03–0.25 0.06 0.125 0.125−16 0.25 8
E. coli 178 0.03−0.5 0.06 0.125 0.015−1 0.06 0.125 0.125−32 0.25 1
Enterobacter spp. 143 0.015−32 0.25 1 0.03−32 0.125 1 0.015−32 1 4
Haemophilus spp. 29 0.015−1 0.25 0.5 0.015−0.5 0.25 0.5 0.125−4 2 4
Klebsiella spp. 145 0.015−8 0.125 0.25 0.015−32 0.06 0.125 0.015−32 0.5 2
Morganella spp. 31 0.015−4 1 2 0.015−1 0.25 1 0.5−16 2 8
Proteus spp. 43 0.125−8 1 2 0.06−2 0.25 1 0.25−32 4 16
Pseudomonas spp. 181 0.06−32 2 16 0.25−32 4 32 1−32 8 32
Serratia spp. 51 0.015−32 0.25 1 0.03−32 0.125 1 0.125−32 1 8
Stenotrophomonas spp. 56 0.5−32 32 32 0.5−32 32 32 2−32 32 32
Other
Enterobacteriaceae 11 0.015−16 0.06 0.125 0.015−32 0.06 0.25 0.015−0.5 0.25 0.5
Non-Enterobacteriaceae 13 0.25−32 16 32 0.25−16 4 16 0.5−16 4 16
P1621 Intestinal colonization by carbapenemase-producing
enterobacteria among patients in an intensive care unit
L.N. Andrade °, J.C. Ferreira, M.A. Evaristo, F. Bellissimo-Rodrigues,
A. Basile-Filho, R. Martinez, A.L. Darini (Ribeira˜o Preto, BR)
Objective: The aim of this study was to investigate the intestinal
colonization by carbapenemase-producing enterobacteria among patients
in the intensive care unit (ICU) at the University Hospital of the Faculty
of Medicine of Ribeirao Preto-University of Sao Paulo (HCFMRP-
USP) at Ribeirao Preto, Brazil after an outbreak of KPC-2-producing
Klebsiella pneumoniae.
Methods: Ninety-four patients admitted at the ICU from June to
September of 2009 were submitted to a selective culture of rectal swab
specimens collected on admission and at discharge or death. However,
only 135 rectal swab specimens were collected, 71 on admission and
64 at discharge from the hospital or death. Carbapenemase-producing
bacteria were selected in MacConkey medium with imipenem (8
mcg/mL) or ceftazidime (32 mcg/mL). Identiﬁcation and antimicrobial
susceptibility proﬁle of the isolates were performed using the Vitek® 2
System (bioMe´rieux). The Modifed Hodge test was used to detect
carbapenemase production. PCR and sequencing was performed to
investigate carbapenemases-encoding genes.
Results: Sixty-ﬁve bacterial species (48.1%) were isolated out of the
135 rectal swabs specimens evaluated. Among these, 46.1% (30/65)
were identiﬁed as enterobacteria: 66.6% (20/30) K. pneumoniae, 13.3%
(4/30) Enterobacter cloacae, 6.6% (2/30) Citrobacter freundii, 3.3%
(1/30) Enterobacter aerogenes, 3.3% (1/30) Pantoea sp., 3.3% (1/30)
Escherichia coli and 3.3% (1/30) Citrobacter youngae. All enterobacteria
showed a multiresistance proﬁle. The Modifed Hodge test was positive
for 43.3% (13/20) K. pneumoniae, indicating carbapenemase production
and negative to other enterobacteria. PCR ampliﬁcation and sequencing
identiﬁed blaKPC-2 gene in the 13 K. pneumoniae detected as
carbapenemase producers but no carbapenemase-enconding gene was
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detected in the other 17 enterobacteria. Thus, other resistance genes
may be responsible for the multiresistance proﬁle in the last ones.
Conclusion: After control of the KPC-2-producing K. pneumoniae out-
break, isolation of these bacteria in infections was not frequent. However,
this investigation showed that KPC-2-producing K. pneumoniae and
other multiresistant bacteria are present in intestinal colonization of
patients at the ICU and can be source of infections and dissemination
of resistance genes.
P1622 Emergence of Escherichia coli isolates producing
metallo-b-lactamase VIM-1 in Italy
M.M. D’Andrea °, T. Giani, C. Venturelli, E. Giacobazzi, F. Arena,
G.M. Rossolini (Siena, Modena, IT)
Background: The increasing rate of resistance to oxyimino-
cephalosporins and ﬂuoroquinolones in clinical isolates of Enterobacte-
riaceae prevents the use of these drugs. Given this fact carbapenems are
increasingly used in therapy to eradicate infections due to such strains.
The appearance of carbapenem resistant isolates of Enterebacteriaceae
is worrisome because of the limited therapeutic options that remain for
the treatment of infections caused by such strains. In this work we report
the appearance and persistence of VIM-positive Escherichia coli strains
in an Italian hospital.
Methods: 5 bacterial carbapenem resistant isolates of E. coli were
collected during November 2008 − October 2009 from the Modena
University Hospital. Identiﬁcation at the species level and antimicrobial
susceptibility tests were performed using the Vitek automated system.
MIC for carbapenems were conﬁrmed using Etest and interpreted
according to the criteria of CLSI. Genotyping was performed by RAPD
and PFGE. b-lactamases content was investigated by PCR using primers
speciﬁc to blaVIM and blaIMP alleles. Presence of class I integrons
was assessed by PCR using primers speciﬁc to Int1 integrase gene and
the 3′CS sequences. Ampliﬁcation products were sequenced on double
strand using ampliﬁcation primers.
Results: Analyzed isolates were susceptible only to aminoglicoside,
gentamicin and tigecycline. Etest analysis showed a lowering of the
MIC values in the presence of EDTA, suggesting the production of a
metalllo-b-lactamase. PCR analysis were positive for the blaVIM allele
and negative when performed using primers for the blaIMP alleles.
Genotyping techniques showed that at least two isolates, obtained from
the same ward, were related to each other. PCR investigations showed
that the blaVIM-1 allele was part of a class I integron. Sequencing
demonstrated that all isolates carried the blaVIM-1 allele.
Conclusions: This study demonstrate the appearance and persistence
of VIM-producing clones of E. coli. Such isolates were detected from
samples obtained from 2 different wards, suggesting the persistence
of such strains in the hospital. Resistance to carbapenems in strains
of Enterobacteriaceae is quite uncommon in Italy, and this particular
phenotype has mainly to be related to alteration of outer membrane
permeability.
P1623 Prevalence of multi-resistant micro-organisms in the
ambulatory setting in a Swiss region
A. Kronenberg °, S. Ko¨nig, S. Droz, K. Mu¨hlemann (Berne, CH)
Objectives: To determine the prevalence of Methicillin-resistance in
Staphylococcus aureus (MRSA) causing skin infections and extended-
spectrum b-lactamase (ESBL) producing Enterobacteriaceae in urinary
tract infections in the ambulatory setting in the canton of Berne,
Switzerland. Resistance rates were compared with resistance rates of
the passive Swiss surveillance system ANRESIS (www.anresis.ch).
Methods: From September 2008 to February 2009 all primary care
physicians residing in the canton of Berne (n = 1284) were asked to
collect skin swabs or urine samples from consecutive patients with
newly diagnosed purulent skin infection or urinary tract infection (UTI).
For analysis samples were categorized as “routine” (if the physician
indicated that this diagnostic procedure would have been performed
also outside the study) and solicited samples (if samples were taken
for study purpose only). All samples were analyzed at the Institute
for Infectious Diseases, University of Berne, following local laboratory
standards. Basic demographic data were collected for all patients, in case
of multiresistance detailed data on risk factors were collected in addition.
Results: A total of 1018 urine samples were collected, 68% of which
were culture positive. 87% were monobacterial infections. E. coli was the
most prevalent microorganism isolated (71%), followed by enterococci
(17.3%), Klebsiella spp. (5.3%), S. saprophyticus (4.1%) and Proteus
mirabilis (3.7%). Susceptibility rates in solicited samples were higher
than in routine samples for all antibiotics tested with the exception
of fosfomycin (Table 1). Antibiotic use during three months before
sampling was a signiﬁcant risk factor for antibiotic resistance for all
antibiotics tested except fosfomycin (p< 0.01). 5 (1%) ESBL producing
E. coli were conﬁrmed, 4 of the 5 patients had known risk factors, but
none had a history of ESBL infection or carriage.
A total of 213 wound swabs were analyzed, of which 138 (65%) were
culture positive. The prevalence of MRSA was 2.1% (2 of 94 S. aureus
isolates).
Conclusion: Resistance prevalence among E. coli causing UTI in the
ambulatory setting are higher among patients with complicated UTI than
those with uncomplicated UTI. Therefore, passive resistance surveillance
based on routine microbiological data do not reﬂect resistance rates in all
patient groups. The prevalence of community-associated multi-resistance
(MRSA and ESBL) is still rare in this region.
Table 1. Susceptibility rates (%) and n tested of E. coli in solicited and
routine samples
Antibiotic solicited routine p-value
Amoxicillin–clavulanic acid (amc) 82.7 (231) 69.8 (232) <0.01
Ampicillin (amp) 66.2 (231) 54.7 (232) 0.02
Cefuroxime axetil (cxa) 77.9 (231) 69.8 (232) 0.06
Fosfomycin (fos) 100 (31) 100 (31) –
Nitrofurantoin (nfu) 97.5 (40) 87.5 (48) 0.12
Norﬂoxacin (nor) 93.5 (231) 82.3 (232) <0.01
Trimethoprim–sulfamethoxazole (sxt) 79.2 (231) 73.3 (232) 0.16
Multiresistance* 8.2 (231) 15.9 (232) 0.02
*Deﬁned as resistance to at least 3 out of amc, cxa, nor or sxt.
P1624 Molecular and phenotypic characterization of
enteroaggregative Escherichia coli clinical isolates and their
antibiotic resistance pattern
M.Y. Alikhani °, M.M. Aslani, A. Zavari, A.R. Zamani (Hamadan,
Tehran, IR)
Objective(s): Enteroaggregative Escherichia coli (EAEC) is an emerging
category of diarrheagenic E. coli. EAEC can induce growth impairment
and malnutrition in children, even in children without diarrhea. The aim
of the present study was to investigate the frequency of EAEC in children
with diarrhea and their antibiotic resistance patterns.
Methods: Stool specimens from 140 children under 12 years of age
with acute diarrhea were collected. The specimens were cultured for
E. coli using standard methods, and then screened for EAEC using a PCR
and HeLa cell adherence. PCR to detect gene of the EAEC-associated
plasmid pCVD432 were performed. Adherence of EAEC was examined
by a method described by Scaletsky et al. Antimicrobial susceptibility
testing was performed using the Bauer-Kirby method according to
protocols of CLSI. The reference strains, E. coli 17-2, E. coli K12 and
E. coli ATCC 25922 were included as a quality control in all assays.
Results: 15 (10.8%) EAEC were detected in 700 E. coli colonies
tested with pCVD432 PCR. Of the EAEC isolates 13 (86.7%) showed
AA pattern. In overall, 73.3% of the EAEC isolates were resistant to
at least one of 14 antimicrobials tested. The isolates were resistant
to ampicillin (100%), erythromycin (100%), Cephalothin (78.6%), co-
trimoxazole (71.4%), tetracycline (64.2) and Nalidixic acid (57.1%),
cefexim (50%), amoxiclav (50%), ceftriaxone and cefotaxime (42.8%).
Considerable numbers of isolates were also reduced susceptible to
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ciproﬂoxacin (42.8%) and norﬂoxacin (7.1%). Multidrug resistance to
antibiotics was observed in 8 cases (53.3%) and the major resistance
proﬁle was ampicillin − erythromycin − Cephalothin.
Conclusions: EAEC is a diarrheal pathogen of emerging importance.
The pCVD432 PCR showed good correlation with the HeLa cell
adhesion assay, as 86.7% of pCVD432 positive isolates were conﬁrmed
as EAEC. However, compared to the assay for AA adherence the PCR
has been found to be simple and speciﬁc in epidemiological studies. This
study showed that EAEC isolates were highly resistance to tetracycline,
co-trimoxazole and ampicillin, which are commonly used antibiotics in
our area. It has been explained that the increased antibiotic resistance
was due to a readiness for transfer of antibiotic resistance via conjugation
probably encoded by the pCVD plasmid. Guidelines for appropriate use
of antibiotics in developing countries need updating.
P1625 Activity of colistin against Klebsiella pneumoniae from 2007
to 2009, including isolates resistant to carbapenems
S. Hawser °, S. Bouchillon, D. Hoban, M. Dowzicky (Epalinges, CH;
Schaumburg, Collegeville, US)
Background: Due to signiﬁcant resistance to currently available thera-
pies, successful treatment of infections due to Klebsiella pneumoniae
is becoming limited. Moreover, a recent increase in the numbers of
carbapenem-resistant isolates has been documented. The emergence
of drug-resistant isolates has led in more recent years to the re-
introduction of “salvage” therapies such as colistin (polymyxin E). This
study investigated the activity of colistin against clinical isolates of
K. pneumoniae originating from multiple infection sources that were
collected during 2007–2009.
Methods: All isolates were collected during the T.E.S.T surveillance
program (Tigecycline Evaluation and Surveillance Trial) and included
infection sources such as blood or other normally sterile ﬂuids,
pneumonia, and non-catheter related urinary tract specimens. MICs were
performed according to CLSI guidelines and interpreted using EUCAST
breakpoints. A total of 280 clinical isolates were tested for their suscep-
tibilities to colistin and additional comparator antimicrobial agents.
Results: See table.
Conclusions: These data show that colistin exhibited good in vitro
activity against the majority of isolates, including carbapenem-resistant
isolates. Only 8 isolates (2.9%) were resistant to colistin, though there
was no apparent relationship between colistin resistance and resistance
to other antimicrobials.
Antimicrobial Mode MIC50 MIC90 %S MIN MAX
Ceftazidime =0.5 =0.5 16 86.1 =0.5 >16
Colistin 0.25 0.25 0.5 97.1 =0.12 >4
Ertapenem =0.03 =0.03 =0.03 96.8 =0.03 >32
Gentamicin =0.25 =0.25 1 90.7 =0.25 >8
Imipenem 0.25 0.25 0.5 98.9 =0.03 4
Levoﬂoxacin =0.25 =0.25 4 86.4 =0.25 >4
Piperacillin/Tazobactam 4 4 >64 78.9 =0.5 >64
Tigecycline =0.5 =0.5 1 93.6 =0.5 >2
%S, percent susceptible using EUC AST breakpoints
P1626 Global surveillance update of Enterobacteriaceae from the
TEST programme, 2004–2009
B. Johnson °, S. Bouchillon, J. Johnson, D. Hoban, R. Badal,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Cross-resistance to several classes of antimicrobials is of-
ten seen in nosocomial pathogens. The T.E.S.T. program determined the
in vitro activity of tigecycline and comparators against strains of Enter-
obacteriaceae cross-resistant to one or more of the following antimicro-
bials: amoxicillin–clavulanic acid, piperacillin–tazobactam, levoﬂoxacin,
ceftriaxone, cefepime, ampicillin, amikacin, minocycline, ceftazidime,
meropenem and imipenem. The isolates were collected from 1,334
cumulative investigational sties in 58 countries throughout 2004–2009.
Methods: A total of 67,130 clinical Enterobacteriaceae were identiﬁed
to the species level at each site and conﬁrmed by the central
laboratory. Minimum Inhibitory Concentrations (MICs) were determined
by the local laboratory using broth microdilution panels. Antimicrobial
resistance was interpreted according to CLSI or FDA (tigecycline)
breakpoints, where available.
Results: 5,401/41,112 (13.1%) E. coli and Klebsiella spp were
ESBL producers. Of the Enterobacteriaceae, 17.2% were resistance
to levoﬂoxacin, 12.1% to minocycline, 2.1% to amikacin, 0.2% to
imipenem, 1.4% to meropenem and 0.6% to tigecycline. Of the
26,018 Enterobacter spp. and S. marcescens collected, 1,778 (6.8%)
presented resistance to ceftriaxone and ceftazidime but susceptible
to cefepime suggestive of AmpC phenotype. Only 1,992 (3.0%)
Enterobacteriaceae showed any degree of non-susceptibility against
tigecycline. Tigecycline also showed excellent inhibitory activity
against members of Enterobacteriaceae that were resistant to amikacin,
levoﬂoxacin, minocycline and meropenem inhibiting 92%, 94%, 82%
and 88% of isolates, respectively.
Conclusion: The presented data suggest that tigecycline is little affected
by cross-resistance and may be an effective therapeutic option against
nosocomial or community pathogens regardless to the resistance patterns.
P1627 CROMagar KPC evaluation for detection of
carbapenemase-producing Enterobacteriaceae
F. Panayea °, I. Galani, P. Adamou, M. Souli, A. Antoniadou,
H. Giamarellou (Athens, GR)
Objectives: Our aim was to compare CROMagar KPC with MacConkey
agar with imipenem 1mg/mL for the detection of KPC and VIM
producing Enterobacteriaceae strains from surveillance cultures.
Methods: 135 rectal swabs from 120 patients (78 ICU and 42 pathology/
surgery wards) were tested. Swabs were plated on both MacConkey agar
No3 + imipenem 1mg/mL (MC) and CROMagar KPC (Hy labs)(CR) and
were incubated at 35ºC, O2 for 48 h. Identiﬁcation and antimicrobial
susceptibility testing of all different colonies from MC and all different
blue colonies from CR was performed by Phoenix (BD). Strains
were screened for KPC and VIM by merop-merop+boronic acid and
merop-EDTA, ceftaz-EDTA disc respectively and conﬁrmed by PCR
methodology. Isolation of Enterobacteriaceae on CR was also tested with
known VIM + and KPC+ strains.
Results: Carbapenem resistant strains recovered from MC were:
Kl. pneumoniae 44 (36 KPC+, 8 VIM+), Ps. aeruginosa 20,
Pr. mirabilis 4, E. cloacae 1 (KPC+), E. aerogenes 1 (KPC+)
and A. baumannii 21. CR recovered 54 carbapenemase producing
Kl. pneumoniae strains (41 KPC+, 13 VIM+), isolated the ﬁrst
day of incubation. KPC+ strains were 100% non-susceptible to
imipenem (MIC8) and 95.3% to meropenem (8) and VIM+ strains
were 93.3% non-susceptible to imipenem and 46.7% to meropenem.
Enterobacter spp. strains were not isolated, most probably due to the
resemblance of their colonies to the coexisting Kl. pneumoniae strains.
Ps. aeruginosa and A. baumannii strains exhibited white colonies.
Pr. mirabilis strains were not recovered. Collectively, Kl. pneumoniae
isolated strains were 43 KPC+ (34 both plates, 7 only CR, 2 only MC)
and 15 VIM+ (6 both plates, 7 only CR, 2 only MC). Sensitivity of
MC and CR for Kl. pneumoniae KPC+ strains was 83.7 and 95.3 and
for VIM+ strains 53.3 and 86.6 respectively. All false (−) results on
CR were due to the coexistence of VIM+ and KPC+ Kl. pneumoniae
strains in the sample (same colonies). On the contrary, in 10 out of 14
false (−) results on MC there was no growth of lac(+) colonies, although
strains’ imipenem MIC was within non-susceptible range. MC and CR
detected carbapenemase producing Kl. pneumoniaestrains with an overall
sensitivity 81.5, 100 and speciﬁcity 100, 100 respectively.
Conclusion: CR detects with high sensitivity and speciﬁcity within
24 h either KPC or VIM producing Enterobacteriaceae strains in
surveillance cultures, allowing immediate implementation of infection
control measures to avoid spread of resistant clones.
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P1628 Activity of colistin against Enterobacteriaceae from 2007
to 2009, including drug-resistant isolates
S. Hawser °, S. Bouchillon, D. Hoban, M. Dowzicky (Epalinges, CH;
Schaumburg, Collegeville, US)
Background: Due to signiﬁcant resistance to currently available
therapies, successful treatment of infections due to Enterobacteriaceae
is becoming limited. Moreover, a recent increase in the numbers of
carbapenem-resistant isolates has been documented. The emergence
of drug-resistant isolates has led in more recent years to the re-
introduction of old “salvage” therapies such as colistin (polymyxin E).
This study investigated the activity of colistin against clinical isolates of
Enterobacteriaceae originating from multiple infection sources that were
collected during 2007–2009.
Methods: All isolates were collected during the T.E.S.T surveillance
program (Tigecycline Evaluation and Surveillance Trial) and included
infection sources such as blood or other normally sterile ﬂuids, pneu-
monia and non-catheter related urinary tract specimens. Colistin MICs
were performed on a selection of clinical isolates and tested according
to CLSI guidelines and interpreted using EUCAST breakpoints. A total
of 1,360 clinical isolates were tested for their susceptibilities to colistin
and comparator antimicrobial agents.
Results: See table.
Conclusions: These data show that colistin exhibited good in vitro
activity against the majority of isolates, many of which were resistant
to other antimicrobials. Overall, the percent susceptibilities for colistin
ranged from 85.3% (E. cloacae) to 98.8% (E. coli).
Organism (n) MIC50 MIC90 MIC Range %S*
Enterobacter aerogenes (292) 0.5 1 0.25−>4 95.2
Enterobacter cloacae (258) 0.5 >4 =0.12−>4 85.3
Escherichia coli (254) 0.5 0.5 =0.12−>4 98.8
Klebsiella oxytoca (276) 0.25 0.5 =0.12−>4 97.5
Klebsiella pneumoniae (280) 0.25 0.5 =0.12−>4 97.1
*%S, percent of isolates susceptible using EUCAST breakpoints.
P1629 Ineffectiveness of carbapenems against Klebsiella
pneumoniae clinical isolates and increasing resistance to
colistin. A 4-year study from a Greek university hospital
I. Neonakis °, S. Maraki, H. Messaritakis, S. Baritaki, A. Georgiladakis,
D. Spandidos (Heraklion, GR)
Objective: Klebsiella pneumoniae has emerged as one of the most
problematic pathogens as treatment has largely been limited to only a few
antimicrobials. Usually, carbapenems are the molecules used and in cases
of non-suscepribility to these, colistin is the antibiotic that routinely is
administered. The aim of the present study was to determine the rates and
trends of non-susceptibility to cabapenems and colistin in our Hospital.
Methods: A total of 959 K. pneumoniae strains from different patients
isolated in our hospital over the last four years (2005–2008) were
analyzed. The numbers of isolates per year were: 2005, 143; 2006,
194; 2007, 293; 2008, 329. Identiﬁcation and susceptibility testing were
performed using the Vitek II system (Biomerieux, France). Isolates with
either intermediate or full resistance to an antibiotic were characterized
as non-susceptible to this agent. The statistical signiﬁcance of the
differences in non-susceptibility observed among the years for each
antimicrobial was determined by the Pearson Chi-Square test [Asymp.
Sig. (2-tailed)]. Probability (P) was set signiﬁcant at the level of 0.05.
Statistical analysis was performed using the SPSS 11.5 software (SPSS,
Chicago, IL).
Results: The non-susceptibility rates found for each year (2005, 2006,
2007 and 2008) were: A) Imipenem (IMP): 14.0%, 25.8%, 28.7% and
49.5%; B) Meropenem (MER): 9.2%, 27.3%, 32.8% and 51.7% and
C) Colistin (COL): 1.4%, 4.1%, 9.6% and 18.5%. The increase of
non-susceptibility was statistically signiﬁcant (P< 0.0001) for all three
antimicrobials. The overall non-susceptibility rates found over the four-
year period were: IMP: 33.1%, MER: 36.5% and COL: 10.3%. Among
the IMP-non-susceptible isolates almost one out of four (23.8%) was
also non-susceptible to COL.
Conclusion: The results of the present study indicate that the
effectiveness of carbapenems has been dramatically compromised over
the last years and the increase of non-susceptibility to COL is rapid
and steep. Unless effective policies will be designed and implemented,
carbapenems and COL will no more be therapeutic options against
K. pneumoniae isolates within the next few years.
P1630 Fluoroquinolone resistance of Pseudomonas aeruginosa
isolates causing nosocomial infection is correlated with
levoﬂoxacin but not ciproﬂoxacin use
H. Liu °, Y.J. Lee, Y.C. Lin, K. Sun, C.L. Chun, P.R. Hsueh (Taipei
City, TW)
Objective: This study investigated the correlation between ﬂuo-
roquinolone (ciproﬂoxacin or levoﬂoxacin) use and the rates of
ﬂuoroquinolone-resistance in Pseudomonas aeruginosa isolates from
patients with nosocomial infection at a teaching hospital in Taiwan.
Methods: Antibiotic utilization data were extracted on a monthly basis
from the inpatient pharmacy computer system records from January 2003
through December 2008. Fluoroquinolone use was expressed as deﬁned
daily dose per 1,000 patient-days (DDDs/1,000PDs) and correlated with
the rates of ﬂuoroquinolone-resistant P. aeruginosa every six months.
Regression analysis was performed to explore the relationship between
ciproﬂoxacin and levoﬂoxacin use (both parenteral and oral forms) and
the resistance of P. aeruginosa isolates.
Results: During the study period, the susceptibility of P. aeruginosa to
ﬂuoroquinolones decreased after increasing use of ﬂuoroquinolones, and
increased after decreasing use of levoﬂoxacin. Parenteral levoﬂoxacin use
was signiﬁcantly positively correlated with resistance of P. aeruginosa
to ciproﬂoxacin (P = 0.015) and ﬂuoroquinolones (either ciproﬂoxacin
or levoﬂoxacin, P = 0.014). Use of both parenteral and oral forms of
levoﬂoxacin were also signiﬁcantly positively correlated with resistance
of P. aeruginosa isolates to ciproﬂoxacin (P = 0.029), levoﬂoxacin
(P = 0.031), and ﬂuoroquinolones (P = 0.010). The total amount of
ciproﬂoxacin (oral and parenteral) and parenteral ciproﬂoxacin use
were negatively correlated with resistance of P. aeruginosa isolates
to ﬂuoroquinolones. However, the amounts of oral ciproﬂoxacin and
oral levoﬂoxacin were each positively correlated with resistance of
P. aeruginosa to ﬂuoroquinolones.
Conclusions: Levoﬂoxacin use was associated with increased resistance
of P. aeruginosa to ﬂuoroquinolones, whereas ciproﬂoxacin use did not
have a signiﬁcant impact on ﬂuoroquinolone resistance rates.
P1631 Antimicrobial susceptibility among Pseudomonas aeruginosa
isolates from a central hospital in the centre of Portugal:
a 6-year surveillance
S. Pereira °, L. Albuquerque, H. Oliveira, R. Leita˜o, O. Cardoso
(Coimbra, PT)
Objectives: Pseudomonas aeruginosa (PA) is an important nosocomial
pathogen causing a wide spectrum of infections and leading to substantial
morbidity and mortality. In order to apply optimal therapeutic guidelines
physicians must be aware of recent resistance surveillance, and
epidemiological data. The main objective was to determine antimicrobial
susceptibility of PA isolates in order to assist the guidelines for empirical
regimens and infection control measures.
Methods: From April 2003 to April 2009, 2210 PA isolates were
collected in Centro Hospitalar de Coimbra. Nosocomial isolates
(N = 1411) and ambulatory ones (N= 799) were obtained from sputum
(40.2%), urine (23.7%), exudates (13.8%), blood (5.1%) and other
sources (12.2%). They were identiﬁed with API32GN (bioMe´rieux)
and MicroScan WalkAway (Dadebehring) and susceptibility patterns
were determined with these panels. Susceptibilities to Piperacillin (PIP),
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Piperacillin plus Tazobactam (TZP), Aztreonam (AZT), Ceftazidime
(CAZ), Imipenem (IP), Meropenem (MP), Amikacin (AMK), Gentam-
icin (GN), and Ciproﬂoxacin (CIP) were guideline by CLSI.
Results: Overall, AMK was the best agent (87.1%), followed by TZP
(86.5%), MP (83.6%), PIP (83.4%), CAZ (80.0%), AZT (76.4%), IP
(75.3%), GN (70.4%) and CIP (63.1%). Nosocomial isolates responded
to AMK (83.4%), TZP (81.1%), PIP (76.8%), MP (75.3%), CAZ
(72.5%), AZT (67.5%), IP (64.8%), GN (64.0%), and CIP (56.0%).
Ambulatory isolates presented susceptibility superior to 90%, except for
GN (81.6%) and CIP (75.7%). During these years the susceptibilities to
most important b lactams (IP, MP and CAZ) had diminished; activity
of IP decreased 10.5%, MP 8.0%, CAZ 7.3%, and among nosocomial
isolates the decrease was greater: IP 15.4%, MP 13.0% and CAZ 10.3%.
TZP fortunately sustained the activity along time.
Conclusion: Appropriate empirical treatments based on knowledge of
particular resistance patterns are important determinants of the success of
therapeutics, therefore studies of surveillance can be helpful in ﬁghting
the development and spread of resistance.
P1632 Multidrug-resistant Klebsiella pneumoniae isolates in a
tertiary hospital
S. Tsiplakou, V. Papaioannou, A. Stylianakis, D. Paraskevopoulou,
F. Zoubouloglou, P. Petraki, P. Papanikolaou, A. Koutsoukou ° (Athens,
GR)
Objectives: Multidrug resistant (MDR) Klebsiella pneumoniae isolates
are increasingly encountered as nosocomial pathogens. The aim of the
present study was to deﬁne the resistance proﬁle of MDR K. pneumoniae
for a period of three years in a tertiary hospital.
Methods: From November 2006 to October 2009 a total of 1215
K. pneumoniae isolates, one per patient, were collected from patients
hospitalized in ICUs (441 isolates) and non-ICU wards (774 isolates)
of our hospital. Identiﬁcation and susceptibility testing were performed
using the Vitek 2 system (Biomerieux) according to CLSI guidelines.
The antimicrobials tested were aztreonam (AZT), amoxicillin–clavulanic
acid (AMC), cefepime (FEP), cefoxitin (FOX), ceftazidime (CAZ),
ceftriaxone (CRO), imipenem (IMP), meropenem (MER), piperacillin–
tazobactam (TZP), amikacin (AN), gentamicin (GM), netilmicin (NET),
ciproﬂoxacin (CIP), colistin (CS), and tetracycline (TE). Additionally
E-test strips (AB Biodisk) were used to determine susceptibility to IMP,
MER and CS. Susceptibility to tigecycline (TG) was determined the
last year of the study. Isolates with MIC values for imipenem and/or
meropenem >1mg/L were screened for metallo-b-lactamase (MBL)
production by E-test MBL strips.
Results: A total of 805 isolates (66.2%) were multidrug resistant 387
(87.7%) isolates were collected from ICU patients and 418 (54%) from
non-ICU patients. Among MDR isolates high resistance levels were
observed for b-lactams, reaching up to 91% for CAZ, 92% for FEP,
95% for FOX and TZP, 93% for AZT, AMC and CRO, 82% for IMP
and 78% for MER. Resistance rates to aminoglycosides varied from 23%
for GM, to 52% for AN and to 88% for NET. Resistance rates were as
high as 89% for CIP, 33% for TE and 16% for CS. Seventy ﬁve isolates
were found to be resistant to TG. According to E-test MBL results 68%
of the carbapenem non-susceptible isolates were MBL producers.
Conclusions: The majority of Klebsiella pneumoniae isolates from ICUs
and more than half the isolates from non-ICU wards are multidrug
resistant. Commonly used antimicrobials such as lactams, carbapenems
included, quinolones and aminoglycosides cannot be used in empiric
treatment as resistance rates are high. Susceptibility to colistin at
84% shows that it remains active for MDR K. pneumoniae isolates.
Tigecycline may also be used for the management of infections due to
MDR isolates although emergence of resistance is already documented.
P1633 Emergence of KPC-producing Klebsiella pneumoniae
isolates in a Greek hospital
E. Vagiakou °, G. Ganteris, A. Kyratsa, M. Orfanidou, E. Marda,
P. Giakkoupi, A. Vatopoulos, E. Malamou-Lada (Athens, GR)
Objectives: To evaluate the frequency and phenotype resistance of Kleb-
siella pneumoniae carbapenemase producing (KPC-producing) strains
isolated from clinical samples, during one year period (October 2008–
October 2009), in the General Hospital of Athens “G. Gennimatas”.
Methods: During one year period a total of 412 Klebsiella pneumoniae
strains were isolated from an equal number of patients. Susceptibility
tests were performed by Kirby-Bauer method, MICs determination by
automated system (Vitek 2-Biomerieux) and E-test method (AB Biodisk,
Solna, Sweden), according CLSI standards. Preliminary phenotypic
detection of KPC enzymes was based on the combination of a bioassay
test − Hodge (cloverleaf) test − and the CD synergy test (CD test with
meropenem and boronic acid). The presence of the bla-KPC gene was
conﬁrmed by PCR and molecular typing was performed by pulsed ﬁeld
gel electrophoresis (PFGE).
Results: Eighty-one from a total of 412 Klebsiella pneumoniae strains
were KPC-producers (81/412, 19.7%) and isolated from cultures of
blood (n: 24), bronchial secretions (n: 11), urine (n: 2), wounds (n: 10),
catheter tips (n: 15), cerebrospinal ﬂuid (n: 1), peritoneal ﬂuid (n: 1),
nasal (n: 2) and enteric colonisation (n: 15). The distribution of isolates
was as follows: ICU (38), Haematology unit (20), Surgical units (15),
Neurology (6), Neurosurgery (1), Nephrology (1). Hodge test was
positive for production of carbapenemases and CD test was positive for
KPC production. All strains had reduced susceptibility to carbapenems
(MIC range: 2−16mg/L) and were sensitive to gentamicin. Eleven were
resistant to tetracycline (11/81, 13.6%), 10 to tigecycline (10/81, 12.5%)
and 8 to colistin (8/81, 10%). Most of the isolates belonged to PFGE
type-1.
Conclusions:
1. KPC producers are rapidly disseminating in several units of our
hospital environment.
2. Phenotypic detection of carbapenemase-producing K. pneumoniae
isolates is critical for limiting the spread of the multi-resistant strains.
3. All K. pneumoniae strains with reduced susceptibility to carbapenems
should be monitored for KPC enzymes by simple screening methods
conﬁrmed by molecular assays.
4. Most of the K. pneumoniae strains of our hospital belonged to PFGE
type-1.
P1634 Increasing occurrence of CMY-producing Proteus mirabilis
causing bloodstream infections
G. Brigante, M.M. D’Andrea, C. Pianetta, T. Giani, C. Comi,
S. Bracco, N. Corbo, G.M. Rossolini, F. Luzzaro ° (Lecco, Siena, IT)
Objectives: Plasmid-mediated AmpC b-lactamases (CBLs) have been
increasingly reported over the last few years. However, prevalence and
distribution of CBLs among enterobacteria are still largely unknown.
The aim of this study was to evaluate the CBL production in blood
culture isolates in comparison with the production of extended-spectrum
b-lactamases (ESBLs).
Methods: Enterobacteria obtained from blood cultures performed at
the Manzoni Hospital (Lecco, Italy) during a 5-year period (2004
to 2008) were included in the study. Identiﬁcation and antimicrobial
susceptibility testing were carried out using the VITEK2 automated
system (bioMe´rieux, Marcy l’Etoile, France). ESBL and/or CBL
production were assessed according to CLSI criteria (when available)
and conﬁrmed by PCR and gene sequencing.
Results: Overall, 45 ESBL-positive isolates were detected, including Es-
cherichia coli (n = 29), Proteus mirabilis (n = 5), Klebsiella pneumoniae
(n = 5), Enterobacter cloacae (n = 2), Enterobacter aerogenes (n = 2) and
Serratia marcescens (n = 2). No signiﬁcant differences were observed
over the years (2004, n = 5; 2005, n = 10; 2006, n = 11; 2007, n = 11;
2008, n = 8). On the contrary, CBL production was detected solely in
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Proteus mirabilis isolates (n = 6), starting from February 2007 from a
neurosurgical patient. The remaining 5 isolates were collected from
February to August 2008 from patients admitted to different wards
(nephrology, n = 1; infectious diseases, n = 2; and intensive care unit,
n = 2). All CBL-producing isolates were positive for blaCMY genes
(blaCMY-2, n = 1, and blaCMY-16, n = 5). Carbapenems and amikacin
were consistently active against both ESBL- and CBL-positive isolates.
With respect to CBL-producing isolates, bacteremia was associated
with urinary tract infection in 5/6 cases. Partial or complete response
was obtained in the above patients treated with meropenem (n = 4) or
cefepime (n = 1). The remaining patient died for causes non attributable
to infection (therapy was not assessable).
Conclusions: Proteus mirabilis isolates producing CBLs have emerged
among enterobacteria causing bloodstream infections in our hospital.
Together with ESBL-producing enterobacteria, they represent a new
challenge for physicians and microbiologists. Carbapenems and amikacin
show potent in vitro activity against both ESBL- and CBL-positive
isolates thus representing a valid therapeutic option for treating infections
caused by these MDR pathogens.
P1635 Multidrug-resistant Pseudomonas aeruginosa: associated
epidemiological trends and clinical risk factors
R. Ngo °, M. Kanatani (Los Angeles, US)
Objective:The purpose of this study was to determine the incidence
of multidrug-resistant Pseudomonas aeruginosa (MDRPA) at the
Ronald Reagan University of California, Los Angeles Medical Centre
(RRUCLAMC) and identify contributing clinical risk factors. Antibiotic
resistance patterns, antibiotic utilization trends, and outcomes associated
with MDRPA were also evaluated.
Methods: Between August 2004 and December 2008, all patients
with positive Pseudomonas aeruginosa (PA) blood cultures and their
associated antibiotic susceptibilities were retrospectively identiﬁed. PA
strains resistant to >3 classes of anti-pseudomonal antibiotics (b-lactams,
ﬂuoroquinolones, carbapenems, and/or aminoglycosides) were classiﬁed
as MDRPA. Clinical characteristics, such as underlying disease states,
medications received during hospitalization, and patient outcome data
were also analyzed.
Results: Over the study period, 187 PA blood isolates were iden-
tiﬁed, of which 53 were MDRPA. Patients who received transplant
immunosuppressants, corticosteroids, or total parenteral nutrition (TPN)
were two times more likely to develop MDRPA bacteremia than those
who did not receive these medications. The cumulative percentages of
PA (and MDRPA) isolates resistant to each of the antibiotic classes
were as follows: 16.6% aminoglycosides (96.8% MDRPA), 32.6%
b-lactams (75.4% MDRPA), 37.4% carbapenems (68.5% MDRPA), 45%
ﬂuoroquinolones (38.1% MDRPA). Carbapenem utilization increased by
50%, and PA resistance to carbapenems increased by over 40%. During
the speciﬁed time frame, the incidence of MDRPA decreased by 25%.
Patient outcome data illustrated that 25% of patients with non-MDRPA
expired, while 51% of patients with MDRPA expired.
Conclusions: Over a 3-year period, almost 30% of all PA blood isolates
identiﬁed were MDRPA. Patients receiving immunosuppressants and
TPN were two times more likely to develop MDRPA. Cumulative
resistance of PA isolates was highest with ﬂuoroquinolones and lowest
with aminoglycosides, indicating the low susceptibility of PA to
ﬂuoroquinolones and high susceptibility to aminoglycosides. Increased
utilization of carbapenems may be associated with increased resistance
towards this anti-pseudomonal antibiotic class and the decreased
incidence of MDRPA. Thus, a ﬁne balance exists between the judicious
use of anti-pseudomonal antibiotics to avoid resistance and appropriate
therapy, making the treatment of MDRPA challenging.
P1636 Imipenem and ciproﬂoxacin consumption are risk factors
for selection of resistant Pseudomonas aeruginosa: results
of a multicentre observational study in French hospitals
K. Miliani, F. L’Heriteau, L. Lacave, A. Carbonne °, P. Astagneau
(Paris, FR)
Objective: To determine whether high consumption of speciﬁc antibi-
otics (ABs) could be independent risk factors for high incidence rates
of key resistant P. aeruginosa: Ceftazidime-, Imipenem-, Ciproﬂoxacin-,
or, Amikacin-resistant.
Methods: Data collected were collected from the antimicrobial
surveillance network in Northern France and the public reporting system
of infection control indicators. The collected data were related to
hospital characteristics (hospital size, type, proportion of long-term care
beds), annual AB consumption expressed in deﬁned daily doses per
1000 patient-days (PD), annual incidence rates of key P. aeruginosa
pathogens expressed in number of non-susceptible isolates/1000 PD
and quality indicators of nosocomial infection control including hydro-
alcoholic hand-rub products consumption. The study sample were the
volunteer healthcare facilities participating in the Network for the 2007
period, which have performed AB susceptibility test in more than 10
non-duplicate P. aeruginosa isolates during the year. Univariate and
multivariate logistic regression analyses were carried out to determine
risk factors of being HCF with at least one key resistant P. aeruginosa
pathogens with incidence rate >75th percentile (p75).
Results: Of 102 HCF participating in the survey, 84 had tested >10
isolates. Among those, 11 were public teaching hospitals, 39 public
non-teaching, and 34 private. Overall, 51.3% were HCFs <300 beds and
67.9% had a proportion of long-term care beds 25%. In the univariate
analysis, total and speciﬁc ABs (except imidazoles) consumption higher
than p75 were associated with at least one P. aeruginosa key resistance
rates >p75 (P< 0.1). In the multivariate analysis, after adjustment for
hospital type and proportion of long-term care beds, high P. aeruginosa
resistance rates were related to highly imipenem and ciproﬂoxacin
consumption (adjusted OR [95%CI]: 14.6 [2.8–77.2] and 5.6 [1.3–
23.2], P< 0.05 respectively). In contrast, P. aeruginosa resistance was not
signiﬁcantly related to alcohol-based hand-rub consumption (P = 0.20).
Conclusion: These ﬁndings suggest that imipenem and ciproﬂoxacin
could play a major role in a high incidence of resistant P. aeruginosa,
independently of cross-transmission.
P1637 Longitudinal analysis of the activity proﬁle of tigecycline
and comparators against important Gram-negative
pathogens in Europe, 2000–2009
M.K. Torres, N.P. Brown, C.M. Pillar, C. Thornsberry °, D.F. Sahm,
M. Dowzicky (Chantilly, Collegeville, US)
Objective: TIG, a broad spectrum glycylcycline, is utilized in the
hospital where infections can be difﬁcult to treat due to antibiotic
resistance (R) because of its potency against prevalent R pathogens.
In this setting, R among Gram-negatives (GN) is of concern and it is
important to understand both the changes in R patterns among common
agents and the potential emergence of R to recently approved agents.
This study analyzes the activity (ACT) proﬁle of TIG and comparator
agents against Enterobacteriaceae (EN) and Acinetobacter spp. (AC) in
Europe (EU) for the past 10 years, a period spanning TIG’s approval for
use in Europe in 2006.
Methods: A total of 2,379 EN (E. coli, K. pneumoniae, Citrobacter spp.,
Enterobacter spp. and S. marcescens) and 322 AC isolated between
2000–2009 were collected from 12 countries across EU. Isolates (ISO)
were centrally tested by broth microdilution (CLSI M7) against TIG and
comparator agents. TIG was analyzed according to relevant R phenotypes
including MDR status (concurrent R to 3 different classes of agents).
EUCAST breakpoints (BPs) were used to interpret TIG MICs and CLSI
(M100-S19) BPs for all other agents, where applicable.
Results: The ACT proﬁle of TIG against EN was consistent from year
to year, with MIC50s of 0.25 or 0.5mg/L and MIC90s of 0.5 or 1mg/L.
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TIG R among EN remained <1%. R to ceftriaxone (7.6% in ’05; 14.2%
in ’09) and MDR (9.4% in ’05; 14.3% in ’09) ﬂuctuated over time
for EN. In contrast to other agents, TIG and imipenem ACT was not
notably affected against cephalosporin R and MDR populations of EN.
Against AC, TIG was the most potent agent with a consistent MIC50
of 0.25 or 0.5mg/L and an MIC90 of 1 or 2mg/L. Among AC, MDR
rates increased from 15% to 52% over the evaluated period. In contrast
to other agents where little ACT was observed against MDR ISO, TIG
maintained MIC50s of 0.5−2mg/L and MIC90s of 1−4mg/L, though
MIC distributions showed a slight elevation in TIG MICs against MDR
ISO relative to non-MDR ISO.
Conclusions: Over the period spanning early development and three
years beyond the approval of TIG for use in EU, TIG has maintained
a consistent ACT proﬁle against targeted GN pathogens from across
EU. In contrast to the majority of agents evaluated, the potency of
TIG is maintained over this period against R subpopulations, including
MDR ISO. Continued surveillance is warranted to monitor for changes
in patterns of R and for any changes in TIG ACT as usage increases.
P1638 Susceptibility of Gram-negative pathogens to colistin and
comparators in Germany, 2007
M. Kresken °, D. Hafner on behalf of the Antimicrobial Resistance
Working Party
Objectives: The emergence of healthcare associated infections caused by
multidrug-resistant Gram-negative bacteria (MDR GN) has become an
increasing problem over the past 20 years. Colistin (COL), a “forgotten”
antibiotic, has attracted attention, because of its activity against MDR
GN. It is, however, not active against Proteeae and Serratia spp.
The objective of this study was to evaluate the susceptibilities of
clinical isolates of Enterobacter cloacae (ECL), Escherichia coli (ECO),
Klebsiella pneumoniae (KPN), Klebsiella oxytoca (KOX), Pseudomonas
aeruginosa (PAE) and Acinetobacter baumannii group (ABA) to COL
and comparators.
Methods: A total of 1,529 isolates were prospectively collected
from 21 microbiology laboratories across Germany, which participated
in the surveillance study conducted by the Paul-Ehrlich-Society in
November 2007. MICs of COL, ciproﬂoxacin (CIP), ceftazidime (CAZ),
gentamicin (GEN) and meropenem (MEM) were determined by the broth
microdilution procedure according to the standard DIN ISO. MICs were
interpreted by EUCAST criteria, if available. Breakpoints of COL were
2mg/L (susceptible) and >2mg/L (resistant). The CLSI MIC method
using CAZ±clavulanic acid (CLA) and cefotaxime±CLA was employed
as screening test for ESBL-producing isolates.
Results: Isolates were primarily recovered from wounds (26%),
respiratory specimens (26%) urine (20%) and blood (9%). There were
460 ICU isolates and 1,069 non-ICU isolates. Of the ECO, KPN and
KOX isolates, 11.5%, 10.5% and 15.8% showed an ESBL-phenotype.
MIC-50 and MIC-90 values (mg/L) are displayed in the table. Of the
ECO isolates, 100% were susceptible (S) to COL and MEM, while 72%
were S to CIP and 87% to GEN. Of the ECL isolates, 91% and 9% were
S and resistant to COL, respectively. Susceptibilities of ECL to CAZ,
CIP, GEN and MEM were 52%, 89%, 88%, and >99%, respectively.
Among KPN and KOX isolates, susceptibilities to COL and MEM were
98–100%, while susceptibilities to CIP and GEN were 82−85% and
94−96%, respectively. COL was the most active drug against ABA and
PAE, with susceptibility rates of 100% for either species. For ABA,
susceptibilities of comparators varied from 78% (CIP) to 95% (MEM).
Susceptibility rates of PAE for comparative agents were as follows: GEN
(91%) followed by CAZ (87%), MEM (85%) and CIP (75%).
ECO ECL KPN KOX ABA PAE
n 418 191 190 101 113 516
COL 0.25/0.25 0.25/2 0.25/0.5 0.25/0.25 0.25/0.5 0.5/1
CAZ 0.25/2 1/64 0.25/4 0.25/1 4/32 2/16
CIP 0.06/16 0.06/1 0.06/4 0.06/4 0.25/16 0.25/4
GEN 1/32 0.5/4 0.5/1 0.5/1 1/16 2/4
MEM 0.25/0.25 0.25/0.25 0.25/0.25 0.25/0.25 0.25/1 0.5/8
Conclusions: Overall, susceptibility to COL seems to be high among
GN pathogens in Germany. COL may be considered as an important
treatment option.
P1639 Distribution of SGI1 among clinical multidrug-resistant
strains of Salmonella enterica serotype Typhimurium from
Southern Italy, 2006–2008
M. Legretto, R. Monno °, A. Pupillo, D. De Vito, G. Rizzo, C. Pazzani
(Bari, IT)
Objectives: The objective of this study was to investigate and
characterize the prevalence of Salmonella Genomic Island (SGI)
among clinical multidrug-resistant (MDR) strains of Salmonella enterica
subspecies enterica serovar Typhimurium isolated from Apulia (Southern
Italy) in 2006–2008. The genetic basis of antimicrobial resistance and
clonal relatedness was also assessed in this study.
Methods: Antimicrobial susceptibility was determined by the disc
diffusion method. Detection of SGI, class 1 integrons and antimicrobial
resistance genes was performed by PCR. Primers complementary
to tdhF-int and SO44-yidY were employed to amplify the left and
right junction of SGI, respectively. Class 1 integrons, gene cassettes,
sulfamethoxazole, chloramphenicol and tetracycline resistance genes
were detected by primers complementary to intl1, 5′ and 3′ conserved
regions, sul1, ﬂoR and tetG, respectively. Genomic relatedness was
established by random ampliﬁed polymorphic DNA patterns.
Results: A total of 255 S. Typhimurium strains from clinical cases were
investigated. Eight-eight strains were multidrug-resistant (exhibiting
resistance to three o more antimicrobials). A major pattern of resistance
to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole and
tetracycline was detected in 56 isolates which accounted for 64% of
all multidrug-resistant strains. The presence of SGI was detected in 86%
of strains which exhibited the major resistance pattern. None of the
other multidrug-resistant strains, except for one isolate, was found PCR
positive for SGI. The isolates PCR positive for SGI were further analysed
for the presence of class 1 integrons, sul1, ﬂoR and tetG resistance genes.
The resistance pattern to ampicillin, chloramphenicol, streptomycin,
sulfamethoxazole and tetracycline was encoded by the blaPSE-1, ﬂoR,
aadA1, sul1 and tetG genes, respectively; which were organized in a gene
array indistinguishable to that found in SGI1. All isolates PCR positive
for detection of SGI were clustered into a unique ampliﬁed DNA pattern.
Conclusion: This study has highlighted the widespread of SGI among S.
Typhimurium clinical strains isolated from Southern Italy in three years
of study. The presence of SGI was detected in 21% of all isolates and
accounted for the most prevalent identiﬁed multidrug resistance pattern.
Additionally, all strains PCR positive for SGI were clonally related and
characterized by a unique RAPD cluster type.
P1640 Surveillance of antimicrobial resistance of human
non-typhoid Salmonellae in Bulgaria
G. Asseva °, P. Petrov, T. Kantardjiev (Soﬁa, BG)
Objectives: (1) To study the etiology of human salmonelloses in
Bulgaria, (2) to perform screening for resistance to antibiotics and to
establish characteristic groups for each serotype typical for the country,
(3) to study with genetic methods resistant isolates.
Methods: Conventional microbiological methods for identiﬁcation and
serotyping of salmonellae. Resistance to 16 antimicrobial agents was
studied with Bauer-Kirby disc diffusion method. Screening for ESBLs
was performed using the double-disc synergy method. Plasmid analysis,
PCR, sequencing, PFGE were applied for investigation of resistant
isolates.
Results: For the period 1999–2006 2626 Salmonella enterica isolates
belonging to non-typhoid serotypes have been studied with conventional
microbiological and genetic methods. Three hundred twenty nine
Salmonella isolates were resistant to antimicrobial agents. For the
three leading serotypes in Bulgaria: S. Enteritidis, S. Typhimurium,
S. Corvallis a statistically signiﬁcant increase of resistance to all
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antimicrobial groups was proved. The most frequent mechanisms of
resistance were as follows: S. Enteritidis − to quinolones (65.8% of
isolates), S. Typhimurium − to ampicillin, carbenicillin, tetracycline,
chloramphenicol (48% of isolates), S. Corvallis − to cefotaxime, ampi-
cillin, carbenicillin, ceftazidime, cefuroxime, cephalothin, gentamicin,
chloramphenicol (18.9% of isolates). Extended-spectrum b-lactamases
(ESBLs) of several types: CTX-M, TEM, SHV were proved to be the
main mechanism of resistance in clinical S. Corvallis isolates and were
found in clinical isolates of S. Enteritidis, S. Typhimurium, S. Isangi,
S. Brandenburg, S. Virchow as well.
Conclusions:
1. Clinical Salmonella isolates from nontyphoid serotypes, distrtibuted
in Bulgaria demonstrated a deﬁnitive increase in resistance to all
groups of anitibiotics.
2. Different mechanisms of resistance were proved for the leading
serotypes causing human salmonelloses in Bulgaria
3. ESBLs from several types: TX-M, TEM, SHV were discovered to
be the main mechanism of resistance in S. Corvallis; these enzymes
were found in clinical isolates of S. Enteritidis, S. Typhimurium, S.
Isangi, S. Brandenburg, S. Virchow.
4. The genetic method PFGE and cluster anaslysis demonstrated
distribution of 4 clones of S. Corvallis (3 of them clustering resistant
isolates) 2 clones of S. Brandenburg (1 of them clustering resistant
isolates).
P1641 Salmonella enterica bloodstream infections in eastern
London: trends in antimicrobial resistance
J. Rangaiah °, S. Reddy, A. Sefton (London, UK)
Objectives: Invasive Salmonella infections are severe and can be life
threatening. Antimicrobial susceptibility patterns are constantly changing
in clinically important serotypes. Microbiology department, Barts and
The London NHS Trust provides diagnostic services to an ethnically
diverse community in East London including a large immigrant
population from Indian Subcontinent. We undertook this retrospective
surveillance study to determine relative proportions of serotypes and
recent trends in antimicrobial resistance in SALMONELLA ENTERICA
bacteremia isolates in this setting.
Methods: All SALMONELLA ENTERICA serotypes isolated from
blood cultures between 2005 and 2008 were included in the study.
Duplicate isolates from the same patient excluded. Antibiotic suscep-
tibility testing was performed according to national standard methods.
Ciproﬂoxacin and ceftriaxone MIC were determined using E-test on
relevant isolates. All isolates were sent to the national reference
laboratory for conﬁrmation of identiﬁcation and phage typing.
Results: One hundred thirty-three SALMONELLA ENTERICA in-
cluding serotypes S. TYPHI (n = 66), S. PARATYPHI A (n = 32), S.
PARATYPHI B (n = 1), S. ENTERITIDIS (n = 16), S. TYHPIMURIUM
(n = 5) and others (n = 13). Incidence of overall infections and by S.
TYPHI, S. PARATYPHI A and S. ENTERITIDIS peaked in 2006 (47,
20, 17 and 7 respectively) and a clear trend in their fall through 2007 till
2008 was observed (26, 14, 5 and 2 respectively). E1 was the commonest
phage type (n = 20) followed by E9 (n = 9). Multidrug resistance was
observed in 38.4% of S. TYPHI. Reduced ciproﬂoxacin susceptibility
(MIC 0.125−1mg/l) was noted in 77.6% (38/49) of S. TYPHI and
84% (21/25) of S. PARATYPHI A isolates. This increased by 9.6% from
2006 (72.2%) to 2008 (81.8%) for S. TYPHI. In all but 1 S. TYPHI and
3 S. PARATYPHI A isolates reduced ciproﬂoxacin susceptibility was
associated with resistance to Nalidixic acid. All isolates were sensitive
to 3rd generation cephalosporins and ceftriaxone MIC was <1mg/l in
all tested (n = 79).
Conclusions: Though Enteric fever is less common in the developed
world, it is a signiﬁcant problem (74.4% of all salmonella bacteremia
in this study) in communities who have a higher risk of exposure.
Therefore, it is important to determine on a regular basis, the incidence
of these infections and antimicrobial susceptibility patterns which would
in turn help in devising preventive strategies and empirical antimicrobial
guidelines.
P1642 Molecular characterization of Shigella sonnei biotype G
strains harbouring class 2 integrons isolated from faecal
samples in Mexico City
F. Tuz-Dzib °, L. Reyes-Gonzalez, P. Lopez-Rivas, G. Ruiz-Palacios
(Mexico City, MX)
Objective: To characterize the presence of Shigella sonnei biotype g
strains, multiresistant and carrying a typical class 2 integron (gMR-Int2)
isolated from fecal specimens in a tertiary hospital in Mexico City, 1999
to 2007.
Methods: A total of 53 S. sonnei strains isolated from 8,607 fecal
samples during 1999 January to December 2007 in Mexico City were
evaluated. All isolates were tested for resistance to a panel of 22
antimicrobial agents by microdilution method according to the CLSI
guidelines. Also, biotyping was carried out by fermentation proﬁle to
rhamnose, xilose and ONPG and detection of class 1 and 2 integrons
was investigated by PCR using primers for integrases and conserved
region of integrons. Molecular typing was performed by pulsed-
ﬁeld gel electrophoresis (PFGE), enterobacterial repetitive intergenetic
consensus-sequenced based PCR and plasmid proﬁle.
Results: S. sonnei isolates were resistant to: trime-sulphamethoxazole
(66%), spectinomycin (86.7%), tetracycline (71.7%) streptomycin (85%).
No isolates were resistant to quinolones and spectrum-extended
cephalosporins. Class 1 integrons were detected in 2 isolates only.
From 2003 to 2007, 97% (38/39) were classiﬁed as biotype g with the
presence of typical class 2 integron (2.2 Kb) and a resistance phenotype
to streptromycin-trimethoprim, while only 2 (14%) sporadic cases of
S. sonnei gMR-Int2 during 1999 to 2002 (p< 0.001) were identiﬁed.
Plasmid analysis resulted in 7 different plasmid proﬁles with two a
ﬁve DNA bands. Based on PFGE analysis, all the more recent Shigella
isolates showed closely related pulsotypes.
Conclusions: Our data showed that S. sonnei gMR-Int2 strains are
emerging in Mexico since 2003. Molecular typing, indeed, suggest the
spread of S. sonnei gMR-Int2 in our country, could be attributed to a
few clones. These ﬁndings support the evidence seen in many countries
to consider S. sonnei gMR-Int2 isolates as a pandemic strain.
P1643 Antimicrobial resistance in faecal Escherichia coli isolated
from calves
V. Kmet °, D. Bujnakova, S. Novak, M. Kmetova (Kosice, Zvolen, SK)
Objectives: Commensal animal Escherichia coli may act as reservoir
of antibiotic resistance genes (blactamase and quinolone) and virulence
factors (verotoxins) for human population. Animal Escherichia coli
ﬂuoroquinolone resistance is increasing (Slovak Antimicrobial Resis-
tance Veterinary Database, http://www2.saske.sk/atbres/). The aim of
study was to characterize antibiotic resistance of faecal Escherichia coli,
resistance mechanisms and verotoxin production.
Methods: During 2009 year a 123 faecal Escherichia coli isolates from
calves from various regions in Slovakia were isolated and analyzed. For
phenotypic antibiotic resistance determination, CLSI (2008) criteria were
used. Verotoxin genes (vt1 and vt2), ESBL CTX-M, plasmid quinolone
resistance (qnrA, B, S), integron 1, replicon typing of plasmids and
phylogenetic analysis were determined by PCR.
Results: The most frequently occurences were resistance to tetracycline
(86%), streptomycin (78%) and ampicillin (79%). Among tested
Escherichia coli isolates also high resistance rates to neomycin
(50%), chloramphenicol (59%) and ﬂorfenicol (30%), cotrimoxazole
(49%) and spectinomycine (21%) could be recorded. Resistance to
ampicillin+sulbactam (10.6%), ceftiofur (1.6%), gentamicin (14%) were
lower. The high level of ﬂuoroquinolone MICs (CIP 4mg/L and ENR
16mg/L) reached 42%, however plasmid quionolone resistance was
not detected. Majority of strains contained vt1 or vt2 genes, integron 1
and plasmid replicon types B/O, FIC, FIB or F1B. Strains belonged to
pathogen phylogenetic group B2 a D and commensal group A and B1
also. Only one strain with ESBL CTX-M1 was detected in Escherichia
coli from one farm.
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Conclusions:
1. The high level of ﬂuoroquinolone MICs in Escherichia coli was
recorded and food animals could be a reservoir of quinolone
resistance for human population.
2. ESBL CTX-M1 was detected in Escherichia coli only from one farm.
3. Majority of faecal Escherichia coli strains were verotoxigenic and
belonged to pathogen and commensal phylogenetic groups.
P1644 Low prevalence of plasmid-mediated quinolone resistance
determinants from farm animal faeces in a cattle-rearing
area of France
F. Garnier °, D. Chainier, O. Barraud, F. Denis, M.C. Ploy (Limoges, FR)
Objectives: We conducted a retrospective study to determine the
prevalence of plasmid-mediated quinolone resistance determinants
(PMDR), qnr-like, aac(6′)-Ib-cr and qepA genes from farm animal faeces
after enrichment infusion of the samples.
Method: We screened 258 stool samples from bovines (n = 131), pigs
(n = 45), poultry (n = 42) and ovines (n = 40). Two hundred milligrams of
stool were enriched by an overnight culture in a 5 milliliters Brain Heart
Infusion (BHI) broth, at 37ºC without agitation. One milliliter and a half
of the BHI broth was then centrifuged and DNA was extracted from
pellets by using the QIAamp DNA Minikit (Qiagen®). The qnrA, qnrB,
qnrS, aac(6′)-Ib-cr and qepA genes were then screened by simplex PCR-
based techniques. Ampliﬁcation products obtained were sequenced and
analyzed with the GenBank of the ncbi website (www.ncbi.nlm.nih.gov).
Results: Out of 258 farm animal faeces, only 5 samples contained a qnrB
gene (1.3%) and 1 a qnrS gene (0.38%). The qnrB-like genes detected
were 1 qnrB2 gene from a poultry, 3 qnrB6 genes from one bovine and
two poultry and 1 qnrB17 from a bovine. The qnrS1 gene was detected
from a poultry. The qnrA-like, aac(6′)-Ib-cr and qepA genes were not
found.
Conclusion: To our knowledge, this is the ﬁrst time that screening of
PMDR was realized directly from faeces after an enrichment step. Our
results showed a low prevalence of PMDR in farm animal faeces in a
cattle-rearing area of France.
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P1645 Activity of tigecycline against levoﬂoxacin-resistant
pathogens from 2008
S. Hawser °, B. Johnson, S. Bouchillon, R. Badal, M. Dowzicky
(Epalinges, CH; Schaumburg, Collegeville, US)
Background: Levoﬂoxacin (LVX) is indicated for use in multiple
therapeutic indications including urinary tract infections, skin and
skin structure infections, pneumonia, sinusitis, pyelonephritis amnongst
others. Resistance to this agent has risen since its introduction in
clinical use and cross-resistance with other antibacterial classes has
been reported. This report documents the activity of tigecycline and
other antimicrobial agents against a range of LVX-resistant organisms
isolated worldwide during 2008 as part of the Tigecycline Evaluation
Surveillance Trial (T.E.S.T.) study.
Methods: MICs were performed and interpreted according to CLSI and
EUCAST / FDA guidelines where appropriate. A total of 32,468 clinical
isolates were collected in this study of which 8,060 isolates (24.8%)
exhibited resistance to LVX.
Results: The majority of LVX-resistant isolates were from Europe
(48.6%), Latin America (24.5%) and North America (15.4%). The
susceptibility of the most commonly detected LVX-resistant organisms
for which tigecycline is indicated for use are shown in the table.
Conclusions: Taken together, this substantial body of data shows that
LVX resistance is common though resistance to tigecycline was very
low. There was no relationship between LVX-resistance and resistance to
tigecycline. Tigecycline continues to exhibit excellent activity, including
against isolates that are resistant to the widely used antibiotic LVX.
Organism (n) MIC90 %S %I %R
Gram-positives
Staphylococcus aureus MRSA (1101) 0.5 99.9 0 0.1
Staphylococcus aureus MSSA (118) 0.25 100 0 0
Enterococcus faecalis (612) 0.25 99 0 1
Enterococcus faecium (606) 0.25 100 0 0
Gram-negatives
Enterobacter aerogenes (129) 2 92.2 7.8 0
Enterobacter cloacae (434) 4 83 13 4
Escherichia coli ESBL+ (621) 1 99.7 0.24 0.06
Escherichia coli ESBL− (1063) 1 99.6 0.4 0
Klebsiella oxytoca ESBL+ (16) 4 87.5 6.2 6.3
Klebsiella oxytoca ESBL− (42) 4 88.1 11.9 0
Klebsiella pneumoniae ESBL+ (520) 4 89.6 8.1 2.3
Klebsiella pneumoniae ESBL− (327 ) 2 90.2 8 1.8
P1646 Antimicrobial activity of tigecycline and comparator agents
tested against clinical bacterial strains from the Asia-Paciﬁc
region, 2008–2009
J.M. Bell, H. Sader °, D. Farrell, R. Jones, J. Turnidge (North Adelaide,
AU; North Liberty, US)
Background: To assess the activity of tigecycline and comparator
agents against strains collected in various countries in the Asia-Paciﬁc
(APAC) region. Tigecycline is the ﬁrst glycylcycline approved for
clinical use and has demonstrated activity against key Gram-positive and
-negative bacterial pathogens worldwide, including multidrug-resistant
(MDR) Acinetobacter spp., ESBL-producing Enterobacteriaceae (ENT),
methicillin-resistant S. aureus (MRSA), and vancomycin-resistant
enterococci (VRE); pathogens frequently isolated in the APAC region.
Methods: As part of the SENTRY Antimicrobial Surveillance Program,
35 institutions from 8 nations contributed 9,804 strains as follows (no.
of medical centres/strains): Australia (7/2,494), China (CH; 17/4,098),
Hong Kong China (1/395), South Korea (KOR; 3/960), New Zealand
(NZ; 3/634), Singapore (SIN; 1/433), Taiwan (TW; 2/590) and Thailand
(1/200). All isolates were forwarded to a central laboratory (USA or
Australia) where they were tested against tigecycline and comparators by
CLSI broth microdilution methods. CLSI and EUCAST interpretations
were applied for comparison agents. Tigecycline breakpoints published
by the USA-FDA were applied for indicated species.
Table 1
Organism (no. tested) Cumulative % inhibited at tigecycline MIC (mg/L)
of:
0.06 0.12 0.25 0.5 1 2 4
S. aureus (3,142) 2.0 29.7 92.1 99.5 100.0 – –
CoNS (214) 4.7 31.3 86.9 99.1 100.0 – –
Enterococcus spp. (1,129) 11.6 51.1 97.9 99.8 100.0 – –
b-haemolytic strep. (362) 93.4 98.6 100.0 – – – –
Viridans group strep. (96) 90.6 96.9 99.0 100.0 – – –
S. pneumoniae (907) 84.2 93.7 100.0 – – – –
E. coli (1,056) 1.6 29.7 91.1 99.1 99.8 100.0 –
Klebsiella spp. (714) 0.0 1.7 32.1 80.5 95.9 98.3 99.9
Enterobacter spp. (405) 0.0 0.5 21.7 85.2 94.3 97.8 99.0
Acinetobacter spp. (533) 4.7 19.7 32.5 49.2 89.7 99.1 100.0
P. aeruginosa (731) 0.0 0.0 0.3 0.6 1.1 4.2 22.2
Results: MRSA rate was 43.4% overall, ranging from 8.7% in NZ
to 70.1% in SIN and 77.3% in KOR. 83.6% of coagulase-negative
staphylococci were resistant to oxacillin. VRE rates (10.1% overall)
were highest in TW (47.4%) and KOR (32.6%). Prevalences of ESBL
phenotype among E. coli/Klebsiella spp. were 35.4/33.7% overall,
highest in TW (41.9/54.2%) and CH (62.0/42.6%). Imipenem (IMI)
resistance (R) among Acinetobacter spp. was 49.5% overall, highest
in KOR (78.7%) and SIN (87.5%). Tigecycline was very active
against the most frequently isolated organisms, except P. aeruginosa
(Table). >99% of staphylococci and enterococci were inhibited at
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0.5mg/L of tigecycline. Among ENT (including ESBL-producing
strains) and Acinetobacter spp. (including IMI-R strains) 97.8–100.0%
were inhibited at 2mg/L of tigecycline.
Conclusion: Almost 10,000 clinical strains from the APAC region
were tested and tigecycline was very active against the organisms most
frequently recovered from the hospitals evaluated, except P. aeruginosa.
Tigecycline spectrum included MRSA, VRE, ENT with ESBL phenotype
and IMI-R Acinetobacter spp. Tigecycline appears to be a valuable
option for the treatment of infections caused by MDR organisms
frequently isolated in the APAC region.
P1647 Multicentre evaluation of tigecycline activity in Europe:
report from the SENTRY Antimicrobial Surveillance
Programme, 2009
D. Farrell °, D. Biedenbach, R. Jones, H. Sader (North Liberty, US)
Objectives: To assess the contemporary potency and spectrum of
tigecycline and comparator antimicrobials against recent (2009) Gram-
positive (GP) and -negative (GN) pathogens from Europe. Tigecycline,
the ﬁrst glycylcycline, presents a therapy option for emerging multidrug-
resistant (MDR) GP and GN pathogens and is approved by the European
Medicines Agency (EMEA) for the treatment of complicated skin and
skin structure (cSSSI) as well as intra-abdominal infections (IAI).
Methods: A total of 4,284 GP and GN clinically-signiﬁcant non-
duplicate isolates from multiple types of infections were collected
from 13 European (EU) countries and Israel that participated in the
tigecycline surveillance program during 2009. Susceptibility (S) testing
was performed by a central monitoring laboratory (JMI Laboratories)
against a large panel of antimicrobials using CLSI methods (M07-A8,
2009). Identiﬁcations were conﬁrmed and interpretive/screening criteria
were also by CLSI guidelines (M100-S19, 2009). All quality control
tests were within published ranges.
Results: Tigecycline inhibited all S. aureus isolates at 0.5mg/L
(MIC90 at 0.25mg/L) and coagulase-negative staphylococci (CoNS) at
1mg/L (MIC90 at 0.5mg/L) regardless of S to oxacillin. Tigecycline
also had potent activity against all enterococci (MIC90, 0.25mg/L),
including vancomycin-resistant (VRE) strains, and b-haemolytic strepto-
cocci (BHS; MIC90, 0.06mg/L). The MIC90 for Enterobacteriaceae was
0.25, 1, and 1mg/L for E. coli, Klebsiella spp. and Enterobacter spp.,
respectively. Tigecycline was active against Acinetobacter spp. (MIC90,
2mg/L), but less potent against isolates of P. aeruginosa (MIC50/90,
4/>4mg/L). Tigecycline activity is summarized in the Table against nine
organism groups.
Conclusions: In 2009, tigecycline continued to demonstrate broad
antimicrobial activity against common pathogens associated with
cSSSI and IAI occurring in the EU. Tigecycline was active against
antimicrobial-resistant as well as MDR strains including MRSA, VRE,
and Enterobacteriaceae (including ESBLs). Based on the potency and
spectrum shown here, tigecycline has a role in empiric therapy for
treating cSSSI and IAI bacterial pathogens in these EU nations.
Tigecycline exhibited spectrum/potency generally exceeding currently
available agents against sampled isolates from the EU.
Table 1. Activity of tigecycline tested against 4,284 isolates of Gram-
positive and -negative pathogens from European medical centers (2009)
Organism (no. tested) Cumulative % inhibited at MIC (mg/L)
0.03 0.06 0.12 0.25 0.5 1 2 4
S. aureus (1,403) 0.0 9.6 41.7 97.6 100.0 – – –
CoNS (462) 1.3 12.8 34.4 89.2 99.6 100.0 – –
Enterococcus spp. (614) 1.5 19.4 48.9 96.4 100.00 – – –
BHS (214) 55.6 95.3 99.1 100.0 – – – –
E. coli (795) 0.0 9.8 49.9 94.2 99.9 100.0 – –
Klebsiella spp. (297) 0.0 0.0 4.0 57.9 87.9 94.6 100.0 –
Enterobacter spp. (147) 0.0 0.0 0.0 39.5 86.4 92.5 96.6 100.0
P. aeruginosa (287) 0.0 0.4 0.4 0.7 0.7 3.1 11.2 100.0
Acinetobacter spp. (65) 0.0 1.5 18.5 36.9 53.9 75.4 96.9 100.0
P1648 Results of the Finnish national resistance surveillance FiRe
network from 1996 to 2008
M. Bergman °, A. Nissinen, P. Huovinen, A. Hakanen and the Finnish
Study Group for Antimicrobial Resistance (FiRe network)
Objectives: Nationwide laboratory networks are essential when mon-
itoring trends in antimicrobial susceptibility in different bacteria.
Susceptibility testing standards and data collecting systems are in a key
role when producing reliable and uniform data. In this study, we present
the structure and operating model and main results of the Finnish Study
Group for Antimicrobial Resistance (FiRe).
Methods: FiRe is a coalition of the Finnish clinical microbiology
laboratories and the bacteriology units of the National Institute for
Health and Welfare (THL). FiRe was founded in 1992 and one of its
primary goals was to standardise the antimicrobial susceptibility testing
methodology in the country. In 1996, the CLSI (NCCLS) standard
method was accepted as the basis for the standard methodology to be
recommended in Finland. However, from the beginning of 2011, FiRe
will adapt its susceptibility testing to the EUCAST standard. Since 2006,
resistance data has been collected into a centralized database using
WHONET program in the data processing. WHONET is a Windows-
based database software developed for the management of antimicrobial
susceptibility test results.
Results: The resistance of Escherichia coli (N >750,000) has changed
during the last years from 23.7% to 16.6% to trimethoprim, from 3.5%
to 5.1% to ﬂuoroquinolones and from 3.2% to 1.0% to nitrofurantoin.
The resistance of Streptococcus pneumoniae (N >50,000) has increased
during the same period from 1.4% to 3.1% to penicillins, from 5.3% to
24.6% to macrolides and from 3.3% to 11.5% to clindamycin. In 2008,
susceptibility data from the whole of Finland was obtained electronically
for the ﬁrst time. The database was able to automatically produce a report
for different bacteria (Finres). In 2008, the number of tested isolates was
402 727 including 2 860 334 susceptibility test results. The data collected
covered 18 clinically most important bacterial species.
Conclusions: According to our experience, resistance surveillance
beneﬁts of a centralised organization with a uniform nationwide
susceptibility testing standard. This kind of structure enables efﬁcient
and timely national resistance surveillance.
P1649 Resistance patterns of selected respiratory tract pathogens
in Poland (continuation of the Alexander Project)
I. Wasko °, A. Skoczynska, A. Kuch, A. Golebiewska, M. Forys,
W. Hryniewicz (Warsaw, PL)
Objective: To obtain the antimicrobial susceptibility data on major
pathogens responsible for community acquired respiratory tract infec-
tions (RTI) in Poland, 2007–2009.
Methods: From January 2007 until September 2009, 1041 isolates were
collected: 424 S. pneumoniae, 345 H. inﬂuenzae, and 272 S. pyogenes.
The ﬁrst two species were isolated from patients with community
acquired lower RTIs. S. pyogenes was isolated from patients with
pharyngitis/tonsilitis. The isolates were identiﬁed to the species level
by standard procedures and MICs were determined by the broth
microdilution method and interpreted according to the CLSI guidelines.
Results: Among S. pneumoniae isolates 26.7% had penicillin MICs
>0.06mg/l whereas 9.7% of them had MIC >2mg/l. The proportion of
isolates with MIC >2mg/l has increased from 3.9% (only intermediate-
resistant) in the ﬁrst year to 12.0% and 15.9% in the second and third
year of the study, respectively. The susceptibility of S. pneumoniae was
as follow: amoxicillin (94.3%), cefaclor (72.0%), cefprozil (76.5%), 3rd
generation cephalosporins (90.3%), macrolides (68.9%), ciproﬂoxacin
(91.0%), levoﬂoxacin (99.0%), clindamycin (75.2%), tetracyclines
(70.8%), trimethoprim/sulfamethoxazole (49.3%), rifampicin (99.8%)
and telithromycin (98.7%).
Among H. inﬂuenzae isolates 4.4% were resistant to ampicillin, via
production of b-lactamases and 13.4% had changes in PBP3 being
low-BLNAR. All H. inﬂuenzae isolates were susceptible in vitro to
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amoxicillin/clavulanic acid, 3rd generation cephalosporins, azithromycin,
ﬂuoroquinolones and chloramphenicol (except one isolate), whereas
93.9%, 97.7%, 99.4% and 72.8% were susceptible to cefaclor, cefprozil,
tetracyclines and trimethoprim/sulfamethoxazole, respectively.
A signiﬁcant number of S. pyogenes isolates was non-susceptible to
tetracycline (22.8%) and erythromycin (14.7%). Among isolates resistant
to erythromycin half represented cMLSB and the other half iMLSB
phenotype.
Conclusions: The percentage of pneumococci with higher penicillin G
MICs have been increasing during the study including highly resistant
isolates, what may eliminate this drug from empirical RTIs therapy
caused by this pathogen. A trend of quickly growing percentage of
S. pyogenes isolates resistant to erythromycin and tetracycline was
observed.
P1650 Trends of resistance in Helicobacter pylori isolates in
Austria, 2004–2008
E. Ju¨lg, G. Zarfel, M. Ho¨nigl, G. Feierl, E. Leitner, L. Masoud,
U. Wagner-Eibel, E. Marth, A.J. Grisold ° (Graz, AT)
Objectives: Incidence of Helicobacter pylori infection has increased
worldwide, with H. pylori being the primary cause of peptic ulcer disease
and an etiologic agent in the development of gastric cancer. Eradication
of H. pylori infection requires a proton pump inhibitor (PPI) and a
combination of two or more antibiotics depending on the antibiotic-
susceptibility of isolates. As the infection is primarily treated with a
standard therapeutic regimen, it is important to know the local antibiotic-
susceptibility patterns. Aim of this study was to analyze the susceptibility
trends of H. pylori strains isolated from gastric biopsies.
Methods: In this retrospective study 546 H. pylori strains, isolated from
2004–2008 at the Institute of Hygiene, Medical University of Graz,
Austria, were investigated. The isolates were characterised by standard
laboratory methods. Susceptibility testing was performed by minimum
inhibitory concentration (MIC) determination by the E-test method (AB
biodisk, Solna Sweden) for amoxicillin, clarithormycin, metronidazole,
tetracycline and ciproﬂoxacin according to the recommendations of
CLSI.
Results: From 2004–2008 a total of 546 H. pylori isolates were
investigated (2004: 64; 2005: 94; 2006: 132; 2007: 109; 2008: 147).
All isolates, except one in 2006 were susceptible to amoxicillin,
and all except one in 2008 susceptible to tetracycline, respectively.
For ciproﬂoxacin resistance rates (%/year) were 5.4 /2004; 8.0/2005;
15.0/2006; 15.8/2007; 13.3/ 2008, for clarithromycin: 53.6/2004;
66.6/2005; 65.4/2006; 66.4/ 2007; and 68.8/2008 and for metronidazole:
35.7/2004; 53.3%/ 2005; 35.5/ 2006; 48.4/ 2007, and 50.4/2008,
respectively.
Conclusion: In this retrospective study of H. pylori isolates 99.8%
susceptibility was found for amoxicillin and tetracycline. For clar-
ithromycin resistance rates were found to be constantly high at 65.4% to
68.8%. Varying resistance rates were found for metronidazole, ranging
from 35.5% (2006) to 53.9% (2005), whereas rates of resistance for
ciproﬂoxacin were at a low but increasing rate from 5.4% in 2004
to 13.3% in 2008. These data underline once more the usefulness of
individual testing and local surveillance in H. pylori.
P1651 Primary Helicobacter pylori resistance to antimicrobial
agents in southern Poland
E. Karczewska °, I. Wojtas, E. Sito, A. Budak (Cracow, PL)
Objectives: Common consumption of antibiotics and chemioterapeutics
contributed to the development of resistance among Helicobacter pylori
clinical strains that is the main factor compromising the efﬁcacy of
eradication therapy. Therefore, the aim of this study was to determine
the current state of amoxicillin, metronidazole and clarithromycin
primary resistance prevalence in H. pylori clinical isolates obtained from
symptomatic adult patients over a period of one year (from January 2008
to February 2009). According to the appearance of alternative regimens
including newer ﬂuoroquinolones, the susceptibility to levoﬂoxacin was
also assessed.
Methods: Fifty eight H. pylori strains isolated from gastric biopsies of
patients who underwent upper gastrointestinal endoscopy at gastrological
clinic in Krakow were examined. Only patients with no previous
H. pylori eradication attempt were enrolled in the study. Minimal
inhibitory concentration (MIC) values of amoxicillin, metronidazole,
clarithromycin and levoﬂoxacin were determined by Etest method.
Resistance breakpoints to amoxicillin, metronidazole, clarithromycin and
levoﬂoxacin were deﬁned as MIC values: >1 mg/ml, >4mg/ml, 1 mg/ml
and >1 mg/ml respectively.
Results: All strains were susceptible to amoxicillin which showed
the highest in vitro activity (MIC = 0.016 mg/ml). Resistance to
metronidazole was 55%, to clarithromycin 26% and 19% of isolates were
simultaneously resistant to clarithromycin and metronidazole. High level
of resistance to metronidazole (MIC >256 mg/ml) was observed in the
majority of resistant strains. Resistance to levoﬂoxacin was detected in
7% of H. pylori strains. Two of ﬁfty eight H. pylori strains (3%) were
multi-resistant (to clarithromycin, metronidazole and levoﬂoxacin).
Conclusion: Our results revealed high rates of H. pylori primary
resistance to metronidazole, clarithromycin and to both: clarithromycin
and metronidazole in adults patients in the southern part of Poland.
It was shown that nitroimidazole resistance is less clinically relevant
than clarithromycin resistance. Therefore clarithromycin should not
be recommended for empirical eradication therapy. To avoid the
increasing clarithromycin resistance and treatment failure, pretreatment
susceptibility testing should be performed routinely. Amoxicillin is still
very effective against H. pylori strains. Low rate of H. pylori resistance
to levoﬂoxacin allows to reserve this ﬂuoroquinolone to rescue treatment.
P1652 Antimicrobial susceptibilities of Propionibacterium acnes
isolated from patients with acne lesions
M. Hui °, L.H. Fu, Z.H. Liu, L.Y. Lam, M. Eastel, N.M. Luk, A.K. Chan,
K.K. Lo, C.Y. Chan (Shatin, Hong Kong, HK)
Objectives: Prolonged antibiotic use is sometimes required for patient
with acne. In the absence of routine anaerobic susceptibility testing, the
choice of antibiotics is often empirical. Therefore we aimed to determine
the Propionibacterium acnes susceptibility proﬁles from patients with
acne lesions.
Methods: Patients presented to the dermatology clinic with acne lesions
were recruited. Skin swabs were taken from the lesions and transported in
Amies medium. These were then cultured anaerobically on horse blood
agar supplemented with vitamin K for 14 days at 37ºC. Identities of the
organisms were conﬁrmed by Gram’s staining, biochemical reactions
and short chain fatty acid production. MIC testing was performed
with agar dilution method according to the CLSI M11-A7. Ampicillin,
doxycycline, minocycline, erythromycin, clarithromycin, tetracycline and
clindamycin were tested. Interpretive criteria for ampicillin, tetracycline
and clindamycin were adopted from CLSI. Descriptive data was recorded
for other antibiotics.
Results: A total of 57 isolates were collected. All of them were
susceptible to ampicillin. Tetracycline and clindamycin susceptibilities
were 53 (93.0%) 46 (80.7%) respectively. MIC50 and MIC90 for
doxycyline were 0.25mg/L and 2mg/L respectively; while that of
minocycline were 0.12mg/L and 1mg/L respectively. Erythromycin and
clarithromycin MICs frequency distribution showed bimodal distribution.
For erythromycin, a cluster of 46 isolates had MIC of 0.06mg/L, while
the remaining 11 isolates had MIC of 128mg/L. These two clusters of
isolates exhibited the same bimodal distribution with clarithromycin (at
<0.03mg/L and 125mg/L).
Conclusion: Antibiotic resistance against ampicillin, tetracycline were
uncommon. However, clindamycin resistance appeared to be emerging.
Cross resistance with erythromycin and clarithromycin was observed,
suggesting a common resistant mechanism. Minocycline and doxycy-
cline MICs were still low when compared with previously reported data.
Overall, antibiotic resistance in Propionibacterium acnes appears to be
emerging and requires continue surveillance.
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P1653 Increasing resistance of Bacteroides fragilis and related
species to carbapenems: a US survey, 2006–2008
D.R. Snydman °, N.V. Jacobus, L. McDermott, R. Ruthazer, Y. Golan,
D.W. Hecht, E.J. Goldstein, L. Harrell, S. Jenkins, D. Newton,
J.E. Rosenblatt (Boston, Chicago, Culver City, Durham, New York,
Ann Arbor, Rochester, US)
Objectives: Since recognition of transferable clindamycin and tetra-
cycline resistance in Bacteroides in 1980, we have coordinated a US
national survey on the susceptibility of B. fragilis to assess trends in
resistance and to provide guidance on susceptibility, since these species
are not routinely tested in clinical laboratories.
Methods: Agar dilution MICs were determined for 1314 isolates from
2006–2008 for B. fragilis and related species from 7 geographically
diverse centers in the US. Antibiotics included 4 carbapenems, 2
b-lactam/b-lactamase inhibitors, 1 quinolone, 1 glycylcycline, clin-
damycin, metronidazole, and chloramphenicol. Isolate identity was
conﬁrmed by API 20ATM.
Results: Analysis of resistance trends from 2006–2008 for Bacteroides
fragilis showed an increase in resistance to the carbapenems, with
resistance rates rising from 1%, 2% and 1.5% in 2006 for imipenem,
meropenem and doripenem rose to 2.7%, 5.4%, and 5.4% in 2008.
Ertapenem resistance rose from 2% in 2006 to 4.5% in 2008. Cefoxitin
resistance rose from 3.5% to 9.4%. Clindamycin resistance remained
unchanged with rates of 29.5%. Moxiﬂoxacin resistance rose from
29.8% to 34.8% in 2008. Tigecycline resistance was 3% in 2006
compared to 5.3% in 2008. For the b-lactamase inhibitors, piperacillin–
tazobactam resistance rose from 1% to 2.7%, while ampicillin-sulbactam
remained unchanged (3.5%). For non fragilis species such as B. ovatus,
B. thetaiotaomicron, and B. vulgatus moxiﬂoxacin resistance rose from
approximately 35% to over 60% in 2008. Clindamycin resistance was
over 40%. Chloramphicol remained 100% active, however, isolates
from geographically diverse areas had MIC’s to chloramphenicol of 16
mcg/ml. No metronidazole resistance was observed in 2008 although 4
isolates had MIC of 8 mcg/ml.
Conclusion: In 2008 resistance of B. fragilis to the carbapenems
increased dramatically. However, even with the rise in resistance. the
rates are still low and represent only a handful of isolates from
geographically diverse areas. The blactamase inhibitors also remain
active. Clindamycin and moxiﬂoxacin resistance is very high, and these
agents can not be regarded as useful as monotherapy for seriously
ill patients with intraabdominal mixed infections. Metronidazole and
chroramphenicol resistance, although not detected, shows a shift to a
few strains with higher MIC’s. Whether these trends will continue will
be assessed in future surveillance studies.
P1654 Identiﬁcation and sensitivity testing of Bacteroides species
from blood cultures
A. Smith °, A. Berry, A. Lennon, A. Tyers, M. Jackson, M. Riggio
(Glasgow, UK)
Objective: Routine identiﬁcation and sensitivity testing of anaerobes in
routine diagnostic microbiology is usually undertaken using phenotypic
testing with a limited range of antimicrobial agents. Inadequate identiﬁ-
cation and sensitivity testing compromises surveillance of antimicrobial
susceptibility patterns and empiric choice of antibiotics. The aim of
this study was to pilot the surveillance of antimicrobial resistance in
Bacteroides species from blood cultures using molecular identiﬁcation
(16S rRNA gene sequencing) and antimicrobial susceptibility testing
using E-test methodology.
Method: Blood cultures collected at Glasgow Royal Inﬁrmary over a
4-year period (n = 73,862) were reviewed for the number of anaerobes
identiﬁed over this study period. We identiﬁed 151 strict anaerobes
from these records and selected 28 consecutive isolates provisionally
identiﬁed as Gram negative anaerobic rods for further study. Isolates
were retrieved from frozen cultures and sub-cultured for purity. Isolates
were subsequently identiﬁed by PCR and sequencing of the 16S rRNA
gene and compared to phenotypic methods of Mast ring, Rapid Ana II
and Rapid32A.
Results: 16S rRNA gene sequencing identiﬁed isolates as Bacteroides
fragilis (n = 16), 4 Bacteroides thetaiotaomicron (n = 4), Bacteroides
ovatus (n = 2), B. vulgatus (n = 2), Parabacteroides distasonis (n = 1) and
uncultured bacterial clones (n = 3). Concordance between genotypic and
phenotypic identiﬁcation was 50% for the Mast ID and Rapid Ana
II systems and 66% for the Rapid 32A system. The antimicrobial
susceptibility of the B. fragilis isolates comprised MIC50 = 16ug/ml;,
MIC90 32 for penicillin; MIC50 = 0.125, MIC90 = 0.5 for augmentin;
MIC50 = 0.75, MIC90 = 2.0 for erythromycin; MIC50 = 0.19, MIC90 = 4
for clindamycin and MIC50 = 4, MIC90 = 12 for tetracycline.
Discussion: Use of 16sRNA sequencing of Gram negative anaerobes
from blood cultures has proved useful in accurate identiﬁcation of
isolates to species level, although 3 isolates were identiﬁed as previously
uncultured clones. Antimicrobial susceptibility testing suggests that
augmentin has a useful spectrum of activity against B. fragilis isolates.
Phenotypic assays have a limited role in accurate species identiﬁcation
and should not be used in surveillance schemes for antimicrobial
resistance in anaerobes. Molecular sequencing techniques provide an
accurate method for identiﬁcation and should be considered as the gold
standard for identiﬁcation of septicaemic isolates.
P1655 Prevalence of multidrug-resistant bacteria and Clostridium
difﬁcile in Dutch hospitals, 2007–2009
T.I. van der Kooi °, J. Mannie¨n, J.C. Wille, B.H. van Benthem
(Bilthoven, Utrecht, NL)
Objectives: To assess the prevalence of presence of colonization
or infection of meticillin resistant Staphylococcus aureus (MRSA),
extended spectrum b-lactamase producing bacteria (ESBL), vancomycin
resistant enterococci (VRE) and Clostridium difﬁcile in Dutch hospitals
and possible trends therein.
Methods: Since 2007 the PREZIES network for the surveillance
of nosocomial infections (NI) in the Netherlands organizes biannual
national prevalence surveys. Data on the presence of multidrug resistant
(MDR) bacteria and C. difﬁcile were collected from admission through
the survey day. All inpatients of one year and older, that have been
admitted before the survey day were included, with the exception of
patients in psychiatry and (haemo)dialysis. The surveillance took place
on several days in March and/or October, but patients of one ward had
to be included on the same day.
Results: In total, 37,601 patients of 50 hospitals were included from
March 2007 through March 2009. 53% of all Dutch hopsitals participated
and 76% of them participated more than once. The average prevalence
of NI was 6.6% and the proportion of patients with NI 5.8%. Table 1
shows the prevalence of the MDR micro-organisms and C. difﬁcile over
time.
Table 1. Percentage of patients (and range between hospitals) positive
for multidrug resistant organisms and Clostridium difﬁcile per survey
March 2007 October 2007 March 2008 October 2008 March 2009
Number of patients 8,424 3,497 9,449 5,760 10,471
Number of hospitals 30 12 29 21 37
MRSA 0.2 (0.0−1.2) 0.2 (0.0−0.6) 0.2 (0.0−12) 0.1 (0.0−13) 0.3 (0.0−3.8)
ESBL 0.5 (0.0−2.2) 0.4 (0.0−1.5) 0.6 (0.0−3.2) 0.6 (0.0−1.7) 1.0 (0.0−3.0)
VRE 0.04 (0.0−0.6) 0.03 (0.0−0.3) 0.03 (0.0−0.3) 0.02 (0.0−0.8) 0.2 (0.0−1.7)
Proportion of hospitals
with VRE
6.7 8.3 10.3 4.8 16.2
C. difﬁcile 0.5 (0.0−1.9) 0.3 (0.0−0.8) 0.6 (0.0−4.7) 0.1 (0.0−1.3) 0.3 (0.0−0.9)
The prevalence of MRSA and C. difﬁcile remained constant. The
prevalence of ESBL showed a signiﬁcant increase (Spearman’s rank
correlation coefﬁcient 0.02, p< 0.0001) over time. In the seven hospitals
that participated in all ﬁve surveys, the increase was signiﬁcant too (0.2,
0.3, 0.4, 0.4 and 0.8 respectively). The high prevalence of patients with
VRE in March 2009 could partly be contributed to an outbreak in one
hospital. However, when only the number of hospitals with VRE was
considered the increase was signiﬁcant too.
In the Netherlands, routine screening of MRSA occurs in patients that
havebeen admitted to foreign hospitals, in calf and pig farmers and
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their family members, and in contacts of MRSA patients. Therefore, the
proportion cannot be interpreted as the prevalence of MRSA infection.
For VRE only contact screening, in speciﬁc wards, is recommended. For
the other organisms there are no screening recommendations.
Conclusion: The prevalence of C. difﬁcile infection and MRSA
colonization or infection did not increase during 5 successive surveys.
The prevalence of ESBL and VRE increased signiﬁcantly over the last
2 years. This increase might be partly explained by increased awareness
for ESBL and VRE in the last year.
P1656 Heteroresistance to imipenem observed for clinical
Clostridium difﬁcile isolates using E-test susceptibility testing
T. Nore´n °, I. Alriksson, J. Andersson, M. Unemo (O¨rebro, SE)
Objective: Carbapenems are frequently used in critically ill hospital
patients who are at high risk of Clostridium difﬁcile infection (CDI).
The resistance rate in C. difﬁcile, measured by minimal inhibitory
concentration (MIC), is generally found low by standard agar dilution
(imipenem 4−8, meropenem 1−4 and ertapenem 4−8mg/L), thus
presumably a low risk of inciting CDI. In contrast, using the Etest
(Biodisk AB, Solna, Sweden), a high level of imipenem resistance (97%
of 606 isolates, MIC> 32mg/L) was observed in 1993–2008 required
further evaluation.
Method: The Etest was performed on 21 toxigenic C. difﬁcile isolates
recovered consecutively during January 2008 belonging to 11 different
PCR-ribotypes. Recommended IsoSensitest agar media.was used for four
different concentrations of C. difﬁcile inoculum (McFarland 0.5, 1, 2 and
4). The MIC was read at the intersection on the antimicrobial gradient
strip after 48 h anaerobic incubation at 37ºC. Imipenem, ertapenem
and meropenem were tested. Brucella and Mu¨eller-Hinton agar were
compared and ﬁnally agar dilution was performed according to CLSI
to conﬁrm our result. Susceptible controls C. difﬁcile (ATCC 9689),
Bacteroides fragilis (ATCC 25285) and C. perfringens (ATCC13124)
were included.
Results: Out of the samples investigated 14/21 had initially MICs of
>32mg/L by Etest. Double zones were read on 10 of these 14 (>32
and 2−4mg/L). Microcolonies sub-cultured from the resistant zone gave
similar results of double zones. Diluted concentrations of the inoculum
(McFarland 4 to 0.5) still read±one step of MIC on the E-test strip.
Mu¨eller-Hinton or Brucella agar did not alter the MIC interpretation.
Agar dilution in Brucella agar, however, lowered MICs of all but one
isolate to expected levels of 1−4mg/L. Two isolates were ertapenem
resistant using the Etest while all were susceptible to meropenem
according to CLSI guidelines.
Conclusion: Etest results from testing C. difﬁcile against imipenem may
show incorrect high MICs or may result the selection of a heteroresistant
subpopulation within the inhibition zone of the E-strip. Accordingly
caution should be made evaluating Etest results for imipenem when
testing C. difﬁcile and possibly if encountering unexpected imipenem
Etest related resistance in other pathogens.
P1657 Prevalence and antimicrobial susceptibility of mycoplasmas
isolated from male urethral exudates in a Spanish hospital
A. Beteta °, L. Vega, S. Martı´nez, L. Go´mez-Chaco´n, M. Gil (Talavera
de la Reina, ES)
Objectives: Mycoplasma hominis and Ureaplasma urealyticum can
cause various pathologies such as urethritis, prostatitis, epididymitis,
urethral syndrome and urolithiasis. The aim of this study was to describe
the antibiotic susceptibility proﬁle of M. hominis and U. urealyticum
isolated from male urethral exudates in patients with urethritis, from
2000–2009 at the Ntra. Sra. del Prado Hospital in Toledo.
Methods: The samples obtained from urethral exudates from men
with symptoms of urethritis were collected by standard procedures
from January 2000 to October 2009. Detection, quantiﬁcation and
antimicrobial susceptibility testing of U. urealyticum and M. hominis
were performed by Mycoplasma IST2 test (bioMe´rieux SA).
Results: A total of 736 patients were recruited, and 383 (52%)
samples were considered of microbiological value and informed to the
clinician. Ureaplasma urealyticum was isolated in 11.5% patients, and
Mycoplasma hominis in 2.6% of them.
For Ureaplasma urealyticum isolates the susceptibility rate was 10.2%
for ciproﬂoxacin and 30.8% for oﬂoxacin. The susceptibility rates for
azithromycin, clarithromycin and erithromycin were 89%, 83% and
87.2% respectively. For josamycin and pristinamycin were 97% and
93.1%. For both doxycycline and tetracycline were 100%.
For Mycoplasma hominis isolates, the susceptibility rates for
ciproﬂoxacin and oﬂoxacin were 66.7% and 62.5% respectively.
All the isolates were resistant to azithromycin, clarithromycin and
erithromycin. For josamycin, pristinamycin, doxycycline and tetracycline
the susceptibility rate was 100%.
Conclusions: Fluoroquinolones resistance was very high among
U. urealyticum and M. hominis isolates. Macrolides resitance was low
in U. urealyticum, while M. hominis was resistant to all of them.
Both U. urealyticum andM. hominis indicated high rates of susceptibility
to doxycycline and tetracycline, so they may be used in empirical
treatment of Mycoplasmas genital infections.
P1658 Prevalence rate and antimicrobial susceptibilities of
Ureaplasma urealyticum and Mycoplasma hominis in
pregnant women residing in Jinju, Korea
I. Bae °, E. Koh, S. Kim, N.Y. Lee, H. Jung (Jinju, Seoul, Masan, KR)
Objectives: Ureaplasma urealyticum and Mycoplasma hominis are
associated with an increased risk of developing pregnancy complications,
such as a preterm birth and premature rupture of membranes. The
distribution of antimicrobial susceptibility of genital mycoplasmas has
changed over time and geographic area. The purpose of this study
was to determine the isolation rates and antimicrobial susceptibilities
of U. urealyticum and M. hominis in pregnant women who reside in
Jinju, Korea.
Methods: Vaginal swabs were obtained from 258 pregnant women from
the years 2004 and 2008. The swabs were tested for the presence
of U. urealyticum and M. hominis at Gyeongsang National University
Hospital. The identiﬁcation and antimicrobial susceptibilities were deter-
mined with commercially available kits, Mycoplasma IST2 (bioMe´rieux,
Marcy-l’Etoile, France) and evaluated according to the CLSI.
Results: U. urealyticum and M. hominis were detected in 114 of 258
specimens (44.2%). U. urealyticum was detected in 105 specimens
(38.6%) and M. hominis was detected only in two specimens (1.8%).
Seven specimens (6.7%) were positive both for U. urealyticum
and M. hominis. Susceptibility of U. urealyticum to azithromycin,
erythromycin, and clarithromycin were 75.2%, 82.9% and 88.6%,
respectively, while almost all of the isolates were susceptible to
josamycin (99.0%) and pristinamycin (100%). Susceptibility of oﬂoxacin
and ciproﬂoxacin were shown to be 56.2% and 15.2%.
Conclusion: The isolation rates of genital mycoplasma in pregnant
women were 44.2% in Jinju; most of the mycoplasmas were identiﬁed as
U. urealyticum. U. urealyticum were highly resistant to quinolones, but
susceptible to josamycin and doxycyline. Characteristically, susceptibility
to azithromycin (the empirical treatment for pregnant women in our
region), was not as high as expected. Therefore, empirical treatment with-
out the isolation of genital mycoplasma will fail in many cases. In vitro
determination of the antimicrobial susceptibility of the genital mycoplas-
mas in each clinical case is required to avoid therapeutic failures.
P1659 Prevalence of micro-organisms responsible for ventilator-
associated bacterial pneumonia among patients in intensive
care unit of a hospital in Madrid. Comparison with a
multicentre study
M.C. Martı´nez °, B. Buendı´a, M.J. Moreno, S. Agudo, M. Lo´pez-Brea
(Madrid, ES)
Objective: To study the most prevalent microorganisms isolated in
patients with mechanical ventilation of ICUs in Hospital Universitario
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de la Princesa during a period of six month and compare it with a
multicentric epidemiological study (ENVIN-UCI: Estudio Nacional de
Vigilancia de Infeccio´n Nosocomial en Servicios de Medicina Intensiva)
realized in more than one hundred ICUs from hundreds of Spanish
hospitals in the years 2006, 2007 and 2008.
Methods:149 purulent tracheobronquial secretion removed by bron-
choaspirate from patients with ventilator-assiated pneumonia (VAP) − in
accordance with the criterias of ventilator-associated pneumonia − were
processed by quantitative culture techniques in blood agar and chocolate
agar and incubated at 37ºC in O2 and CO2 atmosphere respectively
until 48hs. Gram stain was realized to begin an empirical antibiotic
therapy. Identiﬁcation of microorganism was performed by MicroScan
of Siemens and antibiotic susceptibility by microdilution.
Results: From 365 patients admitted in ICU from March to August
of Hospital Universitario de la Princesa, we had 149 isolated from
60 patients with ventilator-associated pneumonia. The most prevalent
microorganisms in ICU of Hospital Universitario de la Princesa,
compared with the multicentric epidemiological study, are listed in the
table.
The most prevalent microorganism isolated in bronchoaspirate has been
MSSA, with a percentage similar to the multicentric study, followed
by Pseudomonas aeruginosa. We can probe Pseudomonas aeruginosa
has a signiﬁcant reduction in his prevalence, compared to multicentric
study, and this percentage is slightly lower than MSSA. Furthermore,
the rest of the microorganisms isolated are so different from the total
epidemiological study.
Conclusion:The primary organisms responsible for VAP include
Pseudomonas aeruginosa, Staphylococcus aureus and Enterobacteri-
aceae. However, precentage of aetiologies differs considerably between
intensive care units.
We have proved Acinetobacter baumannii is lower in our hospital than
in the rest of Spanish hospital included in ENVIN-UCI, where this
microorganism is one of the most prevalent Gram-negative rod isolated.
In our hospital Acinetobacter baumannii has suffered a considerable
reduction in its prevalence in the last years. The signiﬁcant morbidity and
mortality associated with VAP require early konwledge of the prevalence
of the microrganisms responsible of it in our ICUs to select appropriate
empirical therapy.
Microorganism H.U.de la Princesa’s ENVIN-UCI
UCI 2006 2007 2008
MSSA 12.75% 11.81% 12.50% 11.27%
Pseudomonas aeruginosa 12.08% 16.90% 17.55% 18.63%
Stenotrophomonas maltophilia 8.05% 2.34% 4.21% 4.98%
MRSA 7.38% 7.42% 4.09% 3.58%
Haemophilus inﬂuenzae 7.38% 5.91% 5.17% 6.28%
Enterobacter aerogenes 6.71% 1.37% 1.44% 1.63%
Escherichia coli 6.04% 6.73% 7.21% 7.58%
Streptococcus pneumoniae 4.03% 2.34% 2.64% 2.23%
Acinetobacter baumannii 2.68% 12.77% 11.78% 8.99%
P1660 High rates of multidrug resistance in major bacterial
isolates from adult patients with hospital-acquired
pneumonia and ventilator-associated pneumonia in Asian
countries: an ANSORP study
J.H. Song ° for the Asian Network for Surveillance of Resistant
Pathogens (ANSORP)
Objectives: Antimicrobial resistance which has prominently emerged
in major respiratory pathogens in many parts of the world can lead
to inappropriate empirical antimicrobial treatment in patients with
pneumonia. Acinetobacter spp., Pseudomonas aeruginosa, Klebsiella
pneumoniae and Staphylococcus aureus were the most common
respiratory isolates from HAP or VAP cases in Asian countries.
Methods: The Asian Network for Surveillance of Resistant Pathogens
(ANSORP) performed a prospective surveillance study of hospital-
acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP)
in 10 Asian countries from 2008 to 2009. Among respiratory isolates,
Acinetobacter spp. (330 isolates), Pseudomonas aeruginosa (335),
Klebsiella pneumoniae (225), and Staphylococcus aureus (215) were
tested for antimicrobial susceptibility according to CLSI guidelines.
Results: Acinetobacter spp. showed a very high resistance rate to
imipenem which was 70.0% (MIC90 >64mg/L), especially in Malaysia,
Thailand, and China. Resistance rates to ceftazidime, ciproﬂoxacin,
ampicillin/sulbactam, and piperacillin/tazobactam were 77.9%, 82.1%,
76.4%, and 77.9%, respectively. Resistance rate to colistin was 0.6%.
Resistance rates of P. aeruginosa to ceftazidime, cefepime, piperacillin–
tazobactam, imipenem, and ciproﬂoxacin were 31.9%, 24.8%, 33.7%,
26.3%, and 26.0%, respectively. None was resistant to colistin.
Resistance rate of P. aeruginosa to imipenem was the highest in China
(64.1%). MIC90 of imipenem and doripenem for P. aeruginosa were
32mg/L and 8mg/L, respectively. Among K. pneumoniae isolates, 36.0%
were resistant to cefotaxime, 29.3% to ciproﬂoxacin, and 2.2% to
imipenem. MIC90 of doripenem for K. pneumoniae was 0.12mg/L.
In Asian countries, S. aureus isolates showed high resistance rates
to methicillin (77.2%), ciproﬂoxacin (73.0%), clindamycin (56.7%),
erythromycin (71.6%), and tetracycline (64.2%). MIC90 of doripenem
for S. aureus was 2mg/L.
Conclusion: Major respiratory isolates from HAP or VAP in Asian
countries showed very high resistance rates to major antimicrobial
agents. Particularly, Acinetobacter spp. and P. aeruginosa showed high
resistance rates to imipenem in Asian countries, which could limit the
therapeutic options in the clinical practice.
Antimicrobial resistance in Gram-positive
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P1661 Characterization of Staphylococcus aureus clinical isolates
from skin and soft tissue infections collected between 2006
and 2009 in Poland
D. Zabicka °, A. Kozinska, K. Bojarska, W. Hryniewicz (Warsaw, PL)
Objectives: The study was performed to evaluate the antibiotic
susceptibility of Staphylococcus aureus skin and soft tissue isolates, both
methicillin sensitive (MSSA) and methicillin resistant (MRSA), collected
in hospitals from various locations in Poland between 2006 and 2009 and
to characterize on molecular level the MRSA isolates from this group.
Methods: Study was performed on a group of 340 S. aureus clinical
isolates from skin and soft tissue infections in hospitalized patients from
various locations in Poland. Minimal inhibitory concentration (MIC) for
daptomycin, tigecycline and linezolid was done by using Etest method,
MIC of oxacillin, vancomycin, teicoplanin, gentamicin, rifampicin,
trimethoprim-sulfametoxazole, tetracycline, doxycycline and fusidic acid
was done by using broth microdilution method. Susceptibility to
erythromycin and clindamycin and evaluation of MLSB resistance
mechanism was done by disc diffusion method. Methicillin resistance
was detected by cefoxitin disc diffusion test and the presence of mecA
gene was conﬁrmed by PCR. All MRSA strains were characterized by
SCCmec typing and detection of eta, etb, tst and lukPV toxins genes by
PCR based methods.
Results: Among the examined strains 87 (25%) were methicillin
resistant. The presence of ﬁve SCCmec types was detected, with
type IV or V in 44 isolates. lukPV gene was detected only in
the isolates of SCCmec type IV (n = 2) or V (n = 14). None of the
examined MRSA isolates contained eta or etb genes, two isolates
contained tst gene. All examined S. aureus strains were susceptible
to daptomycin with MIC50 = 0.25mg/L and MIC90 = 0.5mg/L. There
was no signiﬁcant difference of daptomycin MIC values observed
between methicillin MSSA and MRSA. All examined isolates were also
susceptible to linezolid and tygecycline. Approximately 50% of MRSA
were susceptible to most of the examined antibiotics. However, 39%
of MRSA were resistant to gentmicin, 39% to tetracycline and 29.2%
to doxycycline. Most of the MRSA (69.1%) strains were resistant to
erythromycin and clindamicin in MLSB mechanism. In the group of
MRSA 4 isolates (2.3%) had vancomycin MIC mg/L.
Conclusion:The study enabled to evaluate the baseline susceptibility
to daptomycin of S. aureus strains isolated from skin and soft
tissue infections in Poland between 2006 and 2009 on the level of
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MIC50 = 0.25mg/L and MIC90 = 0.5mg/L. High prevalence of strains
with SCCmec type IV and V was observed in analysed population of
clinical isolates.
P1662 Antimicrobial drug susceptibility and mecA ﬁnding in
clinical isolates of Staphylococcus spp. from canine pyoderma
M.C. Emanuele °, R. Bosco, C. Piraino, M. La Giglia, M. Bivona,
M. Vitale (Palermo, IT)
Objectives: The susceptibility to selected antimicrobial agents of
Staphylococcus spp isolates from dogs affected by recurrent canine
pyoderma was tested. The methicillin resistance was also investigated
by conventional and molecular methods, since companion animals can
act as reservoirs for MRSA/MRSI spreading for human infections.
Methods: 15 strains of Staphylococcus (3 S. aureus and 12 S. in-
termedius) were tested for their antimicrobial susceptibility by disk
diffusion test (DDT) against the following agents: ampicillin (AMP),
amoxicillin+clavulanate (AMC), cefotaxime (CTX), clindamycin (CL),
enroﬂoxacin (ENR), eritromycin (E), penicillin (P), tetracycline (TE),
vancomycin (VA). Oxacillin (OX) susceptibility was tested by DDT and
by microdilution test, according to NCCLS guidelines. The strains were
also analyzed for the presence of mecA gene by PCR on DNA extracted
from the isolates.
The reference S. aureus strains: ATCC29213 and ATCC43300 were
included as controls.
Results: All strains showed resistance to at least three of the
antimicrobials tested whereas are susceptible to cefotaxime, enroﬂoxacin
and vancomycin. Frequently the strains exhibited associations and the
resistance phenotypes are showed in the table. 5 of them showed
eritromycin resistance, in 2 strains together with clindamycin. The
mecA gene was found in 3 multiresistant S. intermedius strains
and 1 S. aureus, showing heterogeneous characteristics, phenotipically
susceptible or with low levels of MIC. Because of the heterogeneous
expression of methicillin resistance in Staphylococcus, the ﬁnding of
mecA phenotipically susceptible strains suggests a repressed mec A
expression.
Conclusion: The ﬁnding of antibiotic resistance in all the isolates is
likely to be due to the selective pressure exerted by previous and repeated
antimicrobial treatment since the dogs were affected from recurrent
pyoderma. Multiresistant S. intermedius mecA-positive from dog have
been reported in Europe and their ﬁnding implies the risk of the carriage
to human.
Monitoring of antibiotic resistance in animals can elucidate the possible
contribution of pet to the spread of staphylococcus methicillin resistant
in the community and surveillance activity worldwide contributes to
acquire updated epidemiological data.
N Strains Resistance phenotype OX 35ºC MIC OX 35ºC MecA
1 S. aureus AMP-AMC-P S 0.5 NEG
2 S. aureus AMP-AMC-P-TE R 4 POS
3 S. intermedius AMP-AMC-P-E-TE S 2 POS
4 S. intermedius AMP-AMC-P-E-TE S <0.5 NEG
5 S. intermedius AMP-AMC-P I <0.5 NEG
6 S. intermedius AMP-AMC-P S <0.5 NEG
7 S. intermedius AMP-AMC-P-E-TE S <0.5 NEG
8 S. intermedius AMP-AMC-P S <0.5 NEG
9 S. intermedius AMP-AMC-P I 0.5 POS
10 S. aureus AMP-AMC-P-TE S 2 NEG
11 S. intermedius AMP-AMC-P S <0.5 POS
12 S .intermedius AMP-AMC-P S <0.5 NEG
13 S. intermedius AMP-AMC-P S <0.5 NEG
14 S. intermedius AMP-AMC-P-E-CL-TE S 0.5 NEG
15 S. intermedius AMP-AMC-P-E-CL-TE S 0.5 NEG
P1663 Detection of reduced glycopeptide susceptibility and
heterogeneous resistance among Staphylococcus epidermidis
isolated from blood cultures of neonates using the E-test
macromethod and the glycopeptide resistance detection
method
K. Svensson, B. So¨derquist ° (O¨rebro, SE)
Objectives: Coagulase-negative staphylococci (CoNS) are today the
most common ﬁnding in blood cultures obtained from neonates.
Since the prevalence of methicillin resistance as well as multi drug
resistance is high among CoNS, vancomycin is one of few remaining
therapeutic alternatives. During the 1990s staphylococci with decreased
susceptibility to vancomycin has been recognized. However, these
bacteria often constitute a limited fraction of the bacterial population
(i.e. a heterogeneous bacterial population). In addition, slowly increasing
minimum inhibitory concentration (MIC) values (MIC creep) for
glycopeptides among S. aureus has been reported. The aim of this
study was to investigate if the MIC values of S. epidermidis isolated
from patients with neonatal bacteraemia have changed (MIC creep)
regarding glycopeptide resistance during the three last decades. In
addition, the presence of heterogeneous glycopeptide resistance (HGR)
was investigated.
Material and Methods: All isolates (n = 341) of CoNS isolated from
blood cultures obtained from neonates (<28 days of age) from 1984 to
2008 that have been stored at −70ºC were screened by TMB and ﬁnally
determined to species level by API32STAPH or by sequencing the rpoB
gene. Antibiotic susceptibility test of S. epidermidis isolates (n = 236)
was performed by Etest (bioMe´rieux, Sweden) by the standard method
(Mu¨ller-Hinton agar, 0.5 McFarland) as well as by the macromethod
(Brain heart infusion agar, 2.0 McFarland) and the newly developed
glycopeptides resistance determination (GRD)-test (bioMe´rieux).
Results: All isolates were susceptible to vancomycin (VA) but 20 isolates
showed decreased susceptibility to teicoplanin (TP). The mean values
for the MIC (mg/ml) for VA for the three decades were 1.67, 1.71,
and 1.76, respectively, and for TP 3.78, 5.01, and 4.33, respectively. The
percentage of isolates with MIC 3 1.5 for VA increased from 85% during
the 1980s to 94% during the ﬁrst decade of the 21st century and for TP
with MIC 3 2 the percentage were 63% and 83%, respectively. HGR was
shown among 45 isolates using the macromethod and among 128 by the
GRD method.
Conclusion: AMIC creep regarding glycopeptides among S. epidermidis
isolated from blood cultures from neonates is present during the three
last decades in Sweden. In addition, HGR among S. epidermidis was
found. However, discordance between the two methods used was found,
but the GRD test has not been evaluated for CoNS previously, only for
S. aureus.
P1664 Identiﬁcation of the ﬁrst clinical glycopeptide-intermediate
Staphylococcus aureus in Switzerland
A. Bizzini °, M. Oriol, O. Sakwinska, P. Moreillon, J. Bille, J.M. Entenza
(Lausanne, CH)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) are a
leading cause of morbidity and mortality. Invasive MRSA infections
frequently require the use of glycopeptides-based regimens, vancomycin
(VAN) or teicoplanin (TEC) being the drugs of choice. MRSA with a
reduced susceptibility to glycopeptides (GISA) have been associated with
treatment failures and detected in various countries. Here we describe
the development of the ﬁrst clinical GISA isolated in Switzerland, in a
patient on a ventricular assist device chronically colonized by MRSA.
Methods: MRSA were isolated from the patient at various timepoints
during the hospital stay. Antibiotic susceptibility testing was performed
by E-test according to the CLSI recommendations. The presence of
resistant subpopulations was determined by population analysis proﬁle
(PAP) using S. aureus ATCC 29213, Mu3 and Mu50 as VAN-suceptible,
hetero-GISA and GISA controls, respectively. Molecular typing was
done by ampliﬁed fragment length polymorphism analysis (AFLP).
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Results: 4 representative MRSA isolates were isolated in november 2008
(MRSA 1), march 2009 (MRSA 2), april 2009 (MRSA 3) and june 2009
(MRSA 4). VAN and TEC MICs (in mg/L) were, respectively, MRSA
1: 2 and 3, MRSA 2: 2 and 2, MRSA 3: 4 and 12, MRSA 4: 8 and 16.
PAP for the tested strains are represented in Figure 1. All strains were
genetically related as determined by AFLP.
Conclusions: Because of persistent colonisation of the ventricular
assist device by MRSA, and serial exposure to various antibiotic
treatments (including VAN for MRSA bacteremia episodes) the original
glycopeptide-susceptible MRSA gradually evolved towards a hetero-
GISA then a GISA phenotype. Relatively to other countries, MRSA
prevalence is relatively low in Switzerland (ca. 10%) and GISA strains
have not been detected thus far. Our results therefore represent the
identiﬁcation of the ﬁrst clinical glycopeptide-intermediate S. aureus
in Switzerland. Ongoing work with the VAN-susceptible, hetero-GISA
and GISA organisms aims at deﬁning the genetic evolution of the tested
strains.
Figure 1. PAP of the tested strains.
P1665 The evaluation of VISA and VRSA in MRSA strains isolated
from patients hospitalized at intensive care units in Turkey
H. Irmak, S. Cesur °, H. Simsek, N. Coplu, H. Kilic, U. Arslan,
G. Bayramoglu, B. Ozhak Baysan, Z. Gulay, S. Hosoglu, M. Berktas,
S. Gencer, A. Pekcan Demiroz, B. Esen, N. Karabiber, F. Aydin,
A. Nevzat Yalcin (Ankara, Konya, Trabzon, Antalya, Izmir, Diyarbakir,
Van, Istanbul, TR)
Aim: The aim of this study is to determine whether VISA and
VRSA strains are present among MRSA strains isolated from patients
hospitalised at intensive care units in 8 cities in 7 geographical regions
representative of Turkey and to establish the MIC values of isolated
strains for vancomycin, teicoplanin, linezolid, tigecycline, quinupristin-
dalfopristin and daptomycin.
Material and Methods: 260 MRSA strains from 8 cities (Ankara,
Konya, Antalya, istanbul, Izmir, Diyarbakir, Van and Trabzon) which
are representative of 7 geographical regions of Turkey. Wheteher VISA
and VRSA are present on MRSA was investigated using vancomycine
screening agar method and E-test methods.
The sensitivity of MRSA strains to vancomycin, teicoplanin, linezolid,
tigecycline, quinupristin/dalfopristin and daptomycin was determined
using E-test method. In statistical evaluation, Kruskal–Wallis test was
used. p< 0.05 was considered statistically signiﬁcant.
Results: VRSA and VISA was detected in none of overall 260 strains.
All MRSA strains were 100% sensitive to vancomycin, teicoplanin
and linezoide, 99.6% (259/260) was sensitive to daptomycin, 96.9%
(252/260) to tigecycline and 95% (246/259) to quinupristin-dalfopristin.
The MIC values of MRSA strains for vancomycin, teicoplanin, linezolid,
tigecycline, quinupristin-dalfopristin and daptomycin were signiﬁcantly
different betweeen different cities (p< 0.05).
Conclusion: In the present study, no VRSA and VISA strains were
detected in the MRSA strains isolated form intensive care units.
The establishment of 3% (8/260) resistance to tigecycline, 0.4%
(1/260) resistance to daptomycin and 5% (13/259) resistance to
quinupristin/dalfopristin.was striking.
It is our opinion that screening of antibiotic surveillance data in our
country at certeain intervals will be beneﬁcal in preventing the spread
of these strains and determining the correct antibiotic treatment.
P1666 Staphylococci resistance in specialized hospitals
V. Goik, N. Kozlova, E. Barantsevich °, N. Barantsevich, E. Schlyakhto
(St. Petersburg, RU)
Objectives: The aim of the present study was to determine the resistance
to widely used antibiotics of airborn staphylococci from hospitals of
different specialization in St. Petersburg.
Methods: Serial dilution method with the use of Muller-Hinton agar
was used to determine the sensitivity of 473 Staphylococci strains
(169 S. aureus strains − SA and 304 coagulase negative Staphylococci
strains − CNS) isolated from the air of six St-Petersburg hospitals to
seven antibiotics.
Results: The antibiotic resistant strains ratio of Staphylococci in the air
was the highest in the burn trauma hospital − 100%. All SA and 78.3%
of CNS strains were polyresistant and 92.3% of SA and 64.9% of CNS
were meticillin resistant.
In haematologic hospital resistant strains ratio equaled 76.4%, with
85.7% among SA and 73.2% in CNS. Polyresistant strains of SA equaled
71.4%, in CNS-14.6%. The ratio of meticillin resistant strains was
47.3%.
In the operation room of the cardiosurgical hospital 62.6% of
Staphylococci were resistant to antibiotics. Meticillin resistant strains
equaled 23.4% and 14.3% in SA and CNS respectively. The ratio of
polyresistant strains was 23.3% in SA and 9.5% in CNS.
In the air of general surgery operation room the number of resistant
strains in CNS was higher (85.7%) that in S. aureus (66.7%). The
absence of polyresistant and meticillin resistant SA strains and presence
of 19.0% meticillin resistant CNS was detected there.
In the operation room of traumatological hospital resistant strains of
Staphylococci equaled 83.1% with the absence of the polyresistant
strains. Only 1.7% meticillin resistant strains were discovered in this
hospital and all of them were CNS.
In the delivery room 84.0% of resistant strains were revealed, but the
polyresistant and meticillin resistant strains were found only among the
CNS (2.6%). In general surgical and traumatological hospitals and the
delivery hospital, strains resistant to 1 or 2 antimicrobial agents prevailed
among resistant Staphylococcus spp.
Conclusions:
1. The presence of polyresistant and meticillin resistant strains of
Staphylococcus spp. in the air of hospitals depended upon the type
of the hospital.
2. The ratio of these strains was higher in the hospitals with
immunosupressed, severily ill patients and widely used antibiotic
agents (burn, haemathological, cardiosurgical hospitals), than in
traumatological, general surgical and delivery hospitals, where the
selective factors were lacking.
P1667 Resistance of airborne hospital Staphylococcus strains in
St. Petersburg
V. Goik, N. Kozlova, E. Barantsevich °, N. Barantsevich, E. Schlyakhto
(St. Petersburg, RU)
Objectives: The present study was aimed to determine the sensitivity of
Staphylococci, isolated from the air of 6 St-Petersburg hospitals, to the
antimicrobial agents.
Methods: Airborn Staphylococcus strains from 6 St-Petersburg hospitals
(burn trauma, haematological, cardiosurgical, traumatological, general
surgical and birth centers) were obtained by aspiration method with
4-cascade impactor BP 50/100/200. Serial dilution method with the
use of Muller-Hinton agar was used to determine the sensitivity of
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473 Staphylococcus strains (169 S. aureus − SA and 304 coagulase
negative Staphylococcus − CNS) to 7 antibiotics: Penicillin (Pn),
Oxacillin (Ox), Gentamicin (Gm), Erythromycin (Er), Tetracycline (Tc),
Rifampicin (Rf), Vancomycin (Van). Oxacillin was used to determine
meticillin resistant strains of S. aureus (MRSA) and coagulase negative
Staphylococci (MRCNS).
Results: The study revealed, that 76.0% of Staphylococcus strains were
resistant to one or more antibiotics, the ratio of resistant strains among
SA and CNS was comparable: 74.6% and 78.0% respectively. About a
half of the strains appeared to be resistant to Pn (49.5%) and Er (44.0%),
less than 1/3 − to Ox (26.2%), Tc (26.0%) and Gm (24.4%) and only
1.1% showed resistance to Rf. All strains were sensitive to Vancomycin.
The ratio of SA strains, resistant to Pn, Ox, Gm, Tc, versus all the
isolated ones (64.7%, 37.3%, 32.5%, 33.1%) was almost twice exceeding
the same ratio in CNS (39.5%, 20.0%, 19.7%, 22.0%). On the contrary,
the number of strains, resistant to Er, among CNS exceeded the one of
SA: 52.3% and 30.0% respectively. The number of strains resistant to Rf
in SA and CNS was almost the same: (1.2% and 1.0%). 33 spectrums of
antibiotic resistance were discovered in Staphylococci, with polyresistant
strains (resistant to 4 and more antibiotics) comprising more than 1/4 of
the number of the strains (29.9%). SA showed 36.0% of polyresistant
strains and CNS − 23.3%.
Conclusions:
1. The majority of airborn Staphylococcus spp., obtained from the
hospital environment in St. Petersburg, demonstrated resistance to
antibiotics.
2. Polyresistant Staphylococcus strains comprised 29.9% of the airborn
Staphylococci in hospitals of St. Petersburg.
3. The resistance to most antibiotics tested in S. aureus strains exceeded
the one in coagulase negative Staphylococci.
P1668 Daptomycin activity and spectrum when tested against
contemporary (2009) Gram-positive strains collected in
European medical centres
S. Putnam, R. Jones, G. Moet, H. Sader ° (North Liberty, US)
Objectives: To evaluate the in vitro activity and spectrum of daptomycin
(DAP) tested against clinical isolates collected in European (EU)
hospitals. Gram-positive antimicrobial resistance (R) continues to pose
healthcare concerns worldwide. DAP is a cyclic lipopeptide approved
in the United States (2003) and EU countries (2006) for the treatment
of complicated skin and skin structure infections (cSSSI) and S. aureus
(SA)-associated bacteremia (BSI) and right-sided endocarditis.
Methods: 2,775 consecutive strains were collected in 2009 from 24
medical centers located in EU countries (Belgium [BE], France [FR],
Germany [GE], Ireland [IR], Italy [IT], Spain [SP], Sweden [SD],
Switzerland [SL], Turkey [TU], and UK) and Israel [IS]. The collection
included: SA (1,398; 22.7% oxacillin-resistant [MRSA]); coagulase-
negative staphylococci ([CoNS] 454; 82.8% oxacillin-resistant); Ente-
rococcus spp. ([ESP] 613, 15.0% vancomycin [VAN]-R); b-haemolytic
(BHS; 212) and viridans group streptococci (VGS; 98). Organisms
were isolated mainly from BSI (48.6%) and cSSSI (23.3%). The
strains were susceptibility tested against DAP and comparators by CLSI
broth microdilution methods in cation-adjusted Mueller-Hinton broth
supplemented to 50mg/L of calcium for DAP tests.
Results: DAP was very active against SA and CoNS (100.0% susceptible
[S]; MIC50/90, 0.5/0.5mg/L for both). MRSA rates ranged from a
low of 0.0% (SD) to a high of 48.1% (IR); seven countries had an
MRSA rate >25.0%. DAP was highly active against MRSA (MIC50/90,
0.5/0.5mg/L) as was linezolid (MIC50/90, 2/2mg/L; 100% S) and
vancomycin (MIC50/90, 1/1mg/L, 100% S). All ESP were S to DAP
(MIC50/90, 1/2mg/L) and linezolid (MIC50/90, 2/2mg/L). Tigecycline
and ampicillin were active against 97.2 and 62.2% of ESP, respectively.
The overall prevalence of vancomycin-resistant (VR) ESP was low at
15.0%, ranging from 0.0% (BE, IS, SP, SD and SL) to 35.9% (IR)
and 51.0% (TU). VAN-R did not adversely inﬂuence DAP activity
against ESP and all VAN-R E. faecalis (MIC50, 1mg/L; 7 strains)
and E. faecium (MIC50/90, 2/2mg/L; 86 strains) were S to DAP. DAP
was also active against BHS (MIC90, 0.25mg/L) and VGS (MIC90,
0.5mg/L).
Conclusions: DAP showed signiﬁcant, sustained potency against recent
(2009) clinical Gram-positive organisms isolated in EU medical centers.
All organisms presented here were DAP-S based on CLSI and EUCAST
breakpoints.
Organism (no. tested) Cumulative % inhibited at daptomycin MIC (mg/L) of: %S
0.12 0.25 0.5 1 2 4 CLSI EUCAST
S. aureus (1,398) 1.3 56.4 99.2 100.0 100.0 100.0
OXA-S (1,080) 1.4 59.0 99.4 100.0 100.0 100.0
OXA-R (318) 0.9 47.5 98.7 100.0 100.0 100.0
CoNS (454) 9.3 52.9 95.4 100.0 100.0 100.0
Enterococcus spp. (613) 0.2 1.6 11.9 58.1 91.4 100.0 100.0 –
BHS (212) 67.0 98.1 100.0 100.0 100.0
VGS (98) 24.5 54.1 91.8 100 100.0 –
P1669 Molecular characterization of clinical isolates of
vancomycin- and teicoplanin-resistant Enterococcus faecium
and Enterococcus faecalis from any hospitals located in the
Picardie region, France
M. Biendo °, C. Adjide, S. Castelain, M. Belmekki, F. Rousseau,
M. Slama, O. Ganry, F. Eb (Amiens, FR)
Objectives:The aim of the present study was to use pulsed-ﬁeld gel
electrophoresis (PFGE) to characterise glycopeptide resistant E. faecium
(GREfm) and glycopeptide resistant E. faecalis (GREfs) isolates from
clinical samples. The van genotypes of the GRE isolates and the
virulence factor genes, gel E, hyl, asa1, esp and cyl A were detected
by multiplex PCR, hybridisation and sequenced.
Methods and Results: A total of 138 GRE recovered from 127 patients
were collected between April 2004 and January 2009 from ﬁve Picardie
area hospitals (France). The patients were 67 (52.7%) men and 60
(47.3%) women. The distribution of patients according to the positive
samples for GRE showed that, 94 patients had one rectal swab each
positive, and 1 patient presented 3 positive rectal swabs; 24 patients had
one positive clinical sample each, and 8 patients had 11 positive clinical
samples + 6 rectal swabs. The molecular identiﬁcation showed that, 131
enterococci isolates belonged to the species E. faecium (94.9%) and 7
(5.1%) isolates to the species E. faecalis. All these GRE isolates had
only the van A gene. Multiplex PCR showed that, the genotype efm
A+ hyl+ esp+ and the genotype efm A+ hyl+ were found in 89, 67.9%
and 42, 32.1% of the 131 clinical strains GREfmA respectively, where
there were: rectal swabs, 76.4% (100/131) and clinical samples, 23.6%
(31/131) of whom: deep pus, urine, blood, bile, sputum, catheter, and
urethral swab. The efs A gene is frequently associated with gel E or/and
asa1 genes while the efmA gene is frequently associated with hyl or/and
esp. The cyl A gene was not detected in this study (Table 1). PFGE
revealed seven different pulsotypes, designated A to G. Pulsotype A
included 131 GREfm A genetically indistinguishable. The pulsotypes
B, C, D, E, F and G included each one GREfs A isolate, which were
considered as unrelated.
Conclusion: Our results show high GRE fecal carriage rate, Efm A
being the mainly encountered GRE. An emerging Efm A clone has been
identiﬁed during hospital Picardie area outbreaks. In contrast, only 7 Efs
A have been isolated in our institutions. Molecular analysis showed the
intra-hospital spread of gel E-, asa1-, hyl-, esp-positive GRE clones.
Isolate type Phenotype Susceptibility data (MIC – mg/mL) PFGE Virulence factor
van Penicillin Ampicillin Vancomycin Teicoplanin type genes
E. faecalis GRE n= 7 A 3 1.5 >256 32 B gel E+ asa1+
A 3 1.5 >256 32 C gel E+ asa1+
A 3 0.50 >256 32 D gel E+
A 3 0.75 >256 32 E gel E+
A 1.5 1.5 >256 >256 F gel E+
A 2 1.5 >256 32 G asa1+
A 4 1 >256 32 G gel E+ asa1+
E. faecium GRE n= 131 42 (32%) A 96−>256 48−>256 >256 32−>256 A hyl+
89 (67%) A 96−>256 48−>256 >256 32−>256 A hyl+ esp+
asa1 = aggregation substance; gel E = gelatinase; cylA = cytolysin; esp = enterococcal surface protein; hyl = hyaluronidase.
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P1670 First report of conﬁrmed cases of vancomycin-resistant
enterococcal infection in Thailand
A. Leelaporn °, S. Pattanachaiwit, S. Limsrivanichakorn, T. Yungyuen,
T. Wensanthia (Bangkok, TH)
Objective: A conﬁrmed case of infection caused by vancomycin-
resistant enterococci (VRE) had never been reported in Thailand.
Therefore, the aim of this study was to identify vanA-VRE, and vanB-
VRE from various specimens collected from patients at Siriraj Hospital,
Mahidol University, Bangkok, Thailand.
Methods: All enterococci isolated from clinical specimens sent to
the Diagnostic Bacteriology Laboratory, Department of Microbiology,
Faculty of Medicine Siriraj Hospital, between January 2004 and October
2009, were screened for VRE by vancomycin (Vm) disk diffusion and/or
Vm agar screen methods. Suspected VRE isolates were conﬁrmed as
VRE by multiplex polymerase chain reaction technique targeting vanA,
vanB, vanC1, vanC2, Enterococcus faecalis and E. faecium speciﬁc
sequences. Species identiﬁcation of enterococci was also performed by
biochemical method and automated Vitek 2 system. Susceptibility to
other antimicrobial agents was determined by disk diffusion method.
Results: Approximately 10,200 enterococcal isolates were detected in
various clinical specimens studied. Among those isolates, 16 VRE were
identiﬁed from urine (13 isolates), pus (2 isolates) and blood (1 isolate).
All VRE isolates were E. faecium. The majority of them (12/16 isolates,
75%) were vanA VRE whereas the remaining isolates were vanB VRE.
All VRE isolates were still susceptible to linezolid.
Conclusion: A total of 12 isolates of vanA-VRE and 4 isolates of vanB-
VRE have been identiﬁed from clinical specimens in Siriraj Hospital
since the ﬁrst isolate was detected in 2004. All VRE isolates were
E. faecium. This is the ﬁrst report of genetically conﬁrmed clinical VRE
isolates in Thailand.
P1671 Antimicrobial susceptibility of daptomycin and comparator
agents tested against bloodstream isolates of Staphylococcus
aureus: analysis of a 5-year trend in European medical
centres (2005–2009)
D. Biedenbach, R. Jones, H. Sader ° (North Liberty, US)
Objectives: To evaluate daptomycin activity against S. aureus collected
from patients with bloodstream infections (BSI) in European (EU)
hospitals. Daptomycin is a natural lipopeptide derived from Streptomyces
roseosporus that is rapidly bactericidal against Gram-positive pathogens.
Daptomycin is approved by the European Medicine Agency (EMEA) for
treating complicated skin and skin structure infections and S. aureus-
associated bacteremia and right-sided endocarditis, including those
caused by methicillin-resistant S. aureus (MRSA).
Methods: S. aureus BSI isolates (4,886) were consecutively collected
from 29 sites in 13 EU countries. Susceptibility (S) was determined by
the CLSI broth microdilution method. Cation-adjusted Mueller-Hinton
broth was used for testing all agents and was supplemented to 50mg/L
of calcium for testing daptomycin as recommended by the CLSI and
EUCAST.
Results: Between 2005 and 2009, the MRSA rate declined nearly 9% in
EU, with an overall rate of 27.4% during the ﬁve year period. The lowest
MRSA rate was observed in Sweden (two sites, 1.1%) and the highest
rate was in Greece (two sites, 53.8%). Resistance (R) to erythromycin
and clindamycin also declined from 33.6 and 18.1% in 2005 to 26.4 and
10.1% in 2009, respectively. The highest MIC value for daptomycin was
1mg/L (100.0% S using CLSI and EUCAST breakpoints) with MIC50
and MIC90 values of 0.25 and 0.5mg/L, respectively. Vancomycin
(MIC50/90, 1/1mg/L; 100.0% S) and linezolid (MIC50/90, 1/2mg/L;
>99.9% S) were two- to four-fold less active than daptomycin. Only one
linezolid-R was observed and quinupristin/dalfopristin-R isolates were
only observed in France. Daptomycin potency was very uniform among
the countries evaluated and daptomycin MIC distributions did not vary
signiﬁcantly overtime (Table).
Conclusions: Daptomycin showed consistent potency against an
extensive collection of clinical isolates of S. aureus, including MRSA,
from numerous EU medical centres over the last ﬁve years. All isolates
were S to daptomycin, which was more potent compared to vancomycin
and linezolid and has excellent activity against S. aureus isolates with
co-R to other antimicrobial classes.
Year Organism (no.) Cumulative % inhibited at daptomycin
MIC (mg/L) of:
0.06 0.12 0.25 0.5 1
2005 MSSA (701) 0.0 3.7 80.0 99.7 100.0
MRSA (323) 0.0 1.9 59.1 99.1 100.0
2006 MSSA (826) 0.0 7.1 92.3 99.8 100.0
MRSA (284) 0.4 2.8 73.6 99.7 100.0
2007 MSSA (823) 0.0 5.0 89.3 99.8 100.0
MRSA (321) 0.3 3.7 77.9 98.8 100.0
2008 MSSA (814) 0.1 2.7 66.7 99.6 100.0
MRSA (298) 0.0 2.7 48.3 98.3 100.0
2009 MSSA (384) 0.0 1.0 58.3 100.0 –
MRSA (112) 0.0 2.7 50.0 97.3 100.0
P1672 Eight-year (2002–2009) summary of the Zyvox Annual
Appraisal of Potency and Spectrum Programme in
European countries
R. Jones °, J. Ross, M. Stilwell, R. Mendes (North Liberty, US)
Objectives: To document the rates of susceptibility (S) for the
oxazolidinone, linezolid (LZD), when tested against a longitudinal
resistance (R) surveillance sample of European (EU) medical center
isolates (ZAAPS; 2002–2009). Samples from 12−24 sites annually in 11
countries were monitored by a central laboratory design using reference
methods (CLSI) and regional interpretations (EUCAST).
Methods: A total of 13,966 Gram-positive pathogens were tested
from 6 pathogen groups: S. aureus (SA; 6,096), coagulase-negative
staphylococci (CoNS; 2,073), enterococci (2,055), S. pneumoniae
(2,267), b-haemolytic (BHS; 947) and viridans gr. (VGS; 528)
streptococci. CLSI (M07-A8, 2009) methods and interpretations (M100-
S19, 2009) were used, supplemented by EUCAST (2009) breakpoints. At
least 15 comparator agents were tested. LZD-R strains (MIC, 8mg/L)
were conﬁrmed by a second method (disk, Etest) and then by molecular
tests to determine R-mechanisms (cfr, target mutations) and clonality by
PFGE and/or automated riboprints for perceived clusters.
Results: LZD generally remained without documented R from 2002–
2005, but beginning in 2006 LZD-R strains emerged at very low rates
1.1% among SA (G2576T mutant in Ireland, 2006), CoNS (usually
S. epidermidis; France and Italy, 2006–2008) and enterococci (E. faecium
in Germany [2006, 2008, 2009], E. faecalis in Sweden and UK [2008]),
each strain having a target mutation. A mobile cfr was detected in an Ital-
ian CoNS strain (2008), and clonal spread was noted for LZD-R strains
at that site (PFGE results). Overall the LZD-S rates were >99.9, 99.7
and 99.8% for SA, CoNS and enterococci, respectively. All LZD MIC90
results ranged from 1 to 2mg/L. All streptococci were LZD-S (2mg/L),
but penicillin-R was 26.7% in pneumococci and ﬂuoroquinolone-R
was >1% in BHS and VGS. Other resistances noted were: MRSA
and MRCoNS ranging from 20.0–30.1% and 37.5–83.8%, respectively,
without trends toward greater R. VRE rates increased from 6.9% (2002)
to 16.9% (2009), with 79.3% having VanA phenotype in 2009.
Organism (no. of strains) Cumulative % inhibited at ceftaroline MIC (mg/L) of:
0.06 0.12 0.25 0.5 1 2 4
MSSA
Europe (2895) 0.9 5.9 88.3 99.9 100.0 – –
USA (2169) 0.7 4.5 88.4 99.9 100.0 – –
MRSA
Europe (1004) 0.0 0.0 2.2 31.6 83.9 99.5 100.0a
USA (2674) 0.0 0.1 1.1 34.3 94.7 100.0 −
aOnly 5 strains (Greece and Italy).
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Conclusions: ZAAPS surveillance for LZD-S rates conﬁrmed high
levels (99.7% S) for staphylococci and enterococci from 2002–2009
and without R among streptococci. No trends toward LZD MIC creep
or escalating R rates were detected in this multi-year post-marketing
surveillance program for the EU (see Table).
P1673 Report of linezolid resistance from the Zyvox® Annual
Appraisal of Potency and Spectrum Programme (Europe,
Latin America, Asia-Paciﬁc)
J. Ross, R. Jones °, H. Sader, U. Uchino, F. Ikeda, Y. Fukui,
I. Kobayashi (North Liberty, US; Tokyo, Kochi, JP)
Objectives: To monitor the in vitro activity and to detect resistance (R)
to linezolid (LZD) in various geographic areas of the world, excluding
the United States (USA), the Zyvox® Annual Appraisal of Potency
and Spectrum Program (ZAAPS) surveillance program was established
in 2002. LZD, the ﬁrst oxazolidinone agent clinically applied, is an
important therapeutic option for infections caused by antimicrobial-R
Gram-positive (GP) pathogens. Although rare, LZD-R has been observed
particularly in enterococci (ENT) and recently among coagulase-negative
staphylococci (CoNS). Resistance rates remain extremely low for
indicated S. aureus (SA) and streptococci.
Methods: 5,367 isolates were collected from 64 sites in 21 countries
in 2009. Isolates were received from the following organism groups
(n): SA (2,767), CoNS (802), ENT (668), Streptococcus pneumoniae
(SPN; 597), viridians group streptococci (VGS; 207) and b-haemolytic
streptococci (BHS; 326). At least 200 isolates from each country (expect
China [n = 800] and the United Kingdom [n = 400]) were requested to
be sent to a reference laboratory. CLSI broth microdilution susceptibility
testing was performed using TREK Diagnostic (Cleveland, OH, USA)
panels. LZD-R isolates were conﬁrmed with Etest (bioMe´rieux, North
Carolina, USA) and disk diffusion. PCR and sequencing were performed
to detect mutations in 23S rRNA, L3, L4, and L22 proteins, and acquired
gene (cfr).
Results: Overall LZD-susceptibility (S) in the ZAAPS study was
>99.9% with only 3 LZD-R ENT isolates identiﬁed. Non-susceptible
(NS) staphylococci strains were not detected in ZAAPS 2009 compared
to the 2008 program where 3 NS CoNS strains were found. MRSA
rates varied from 0.0% (Sweden) to 82.0% (Korea) with an overall
rate of 35.6%. Vancomycin-R ENT rates ranged from 0.0% (Japan,
Belgium, Mexico, Spain, Sweden) to 50.0% (Taiwan). Three ENT
isolates were LZD-R (0.45%; see table). SPN had overall penicillin and
erythromycin R rates of 33.4% (MIC, 2mg/L) and 55.9%, respectively.
All streptococci had LZD MIC values of 2mg/L.
Conclusions: LZD-R was considered very low (<1%) among contem-
porary pathogens from indicated organism groups in this worldwide
surveillance study. As LZD use continues to evolve, the need for
close monitoring of the in vitro activity of LZD versus Gram-positive
pathogens and for the emergence of R is apparent.
Table 1. Linezolid-R isolates found in the 2009 ZAAPS Program
Species City/Country LZD MIC
(mg/L)
R- mechanisma
(23S mutation)
E. faecium Frankfurt/Germany >8 G2576T
E. faecium Frankfurt/Germany 8 G2576T
E. faecalis Shenzhen/China 8 Not found
aAll isolates were screened for cfr and were negative.
P1674 A longitudinal perspective of tigecycline activity in
the EU against Staphylococcus aureus, Enterococcus
faecalis, and Streptococcus spp. including resistant and
multidrug-resistant phenotypes
D. Draghi, C.M. Pillar, M. Dowzicky, D.F. Sahm ° (Chantilly,
Collegeville, US)
Background: Due to the prevalence of methicillin resistant S. aureus
(MRSA), penicillin resistant S. pneumoniae (PRSP), and erythromycin
resistant S. pyogenes (SPY), agents used to treat Gram-positive (GP)
infections should maintain activity against these resistant subpopulations.
Tigecycline (TIG) is primarily intended for treatment of infections
encountered in healthcare settings where resistance (R) is a continuous
threat. It is important to understand current activity and trends in R to
utilized agents, in particular those recently approved for use. This study
reports the activity proﬁle of TIG over 10 years spanning its development
and approval for use against target GP organisms in Europe (EU).
Methods: TIG activity was proﬁled from 2000 until 2009 against a
collection of 2195 S. aureus (SA), 88 vancomycin-susceptible E. faecalis
(VSEf), 611 S. pneumoniae (SP), and 493 S. pyogenes (SPY) collected
from 12 countries in EU. Isolates were tested by broth microdilution
against TIG and comparators utilizing CLSI guidelines (M7-A9).
EUCAST breakpoints (BPs) were applied to TIG results. CLSI (M100-
S19) BPs were used to interpret all comparators (where applicable).
Results: Against SA, TIG maintained consistent activity from year to
year with MIC50s of 0.06–0.12mg/L and MIC90s of 0.12–0.25mg/L,
and >99% susceptibility. The TIG activity proﬁle was not altered
against MRSA or MDR subpopulations. SA also remained >99%
susceptible to linezolid, vancomycin and daptomycin in contrast to
other evaluated agents (e.g. clindamycin [CLI], erythromycin [ERY],
levoﬂoxacin). Similar to SA, TIG had a potent and consistent activity
proﬁle against both SP (MIC50s 0.015–0.03mg/L and MIC90s 0.015–
0.06mg/L; 100%S) and SPY (MIC50s 0.015–0.03mg/L and MIC90s
0.03–0.06mg/L; 100%S) including PRSP and macrolide R SPY
subpopulations. Excluding CLI and ERY, there was little observed R
to the evaluated agents among the tested streptococci. TIG also was
potent year to year against VSEf, with MIC50s 0.06–0.25mg/L and
MIC90s 0.12−0.5mg/L. No TIG R was detected among VSEf across
the evaluated period.
Conclusions: Over the years studied, TIG has maintained potent in vitro
activity overall against target GP cocci with >99% susceptibility rate,
including R and MDR isolates. Notable trends in decreased activity
for TIG were not observed despite increased use since approval in
2006; however, continued surveillance is warranted as the threat of R
development is ongoing.
P1675 Limited variety of genetic lineages drive the increase of
multidrug resistance among non-invasive pneumococci in
southern Finland
L. Siira, J. Jalava °, P. Tissari, M. Vaara, T. Kaijalainen, A. Virolainen
(Helsinki, Turku, Oulu, FI)
Objectives: The proportion of multidrug resistant Streptococcus
pneumoniae isolates has increased in the Southern Finnish Helsinki
and Uusimaa districts from 1.6% (15 of 959 isolates) in 2007 to 3.6%
(34 of 949 isolates) in 2008. Multidrug resistance was deﬁned as non-
susceptibility to penicillin, erythromycin, clindamycin, trimethoprim/
sulfamethoxazole, and doxicycline. The aim of this study was to combine
our antimicrobial susceptibility results with sero- and genotyping to ﬁnd
out whether the increase in multidrug resistance is clonal.
Methods: Twelve non-invasive multidrug resistant isolates collected in
year 2008 were selected for further characterization in this study. Antimi-
crobial susceptibility was tested by the agar plate dilution method at 5%
CO2. Serotyping was performed with latex agglutination for the neutral
serogroups/types 7 and 14, followed by counterimmunoelectrophoresis
with pneumococcal antisera. The capsular reaction test Quellung was
used for conﬁrmation where needed. Genotyping was carried out by
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multilocus sequence typing and the resulting sequence types (STs) were
assigned to genetic lineages.
Results: The serotype distribution of the isolates was limited to ﬁve
serotypes, 19F (n = 5), 19A (n = 3), 6B (n = 2), 23F (n = 1), and 14 (n = 1),
while nine different STs and four genetic clonal complexes (CCs) were
represented in the material. The CCs were CC271 (n = 8), CC90 (n = 2),
CC81 (n = 1), and CC156 (n = 1). CC271 claimed all serotype 19F and
19A isolates.
Conclusion: The proportional increase of multidrug resistance among
pneumococci seems to have a clonal component, which is indicated
by the limited variety of genetic lineages, dominated by CC271.
Furthermore, the CC271 isolates expressed both serotypes 19F and 19A.
Similarly, on the serotype level, serogroup 19 is overrepresented and the
serotype distribution of our subset of multidrug resistant isolates differs
both from that of the invasive pneumococci collected in Helsinki and
Uusimaa districts in year 2008 and the national serotype distribution
of invasive resistant pneumococci. CC271 has previously been noted
to include drug resistant serogroup 19 isolates, such as the international
Taiwan19F-ST236 strain, and some members of this CC display capsular
switching within serogroup 19.
P1676 Trends in antimicrobial resistance in Canadian strains of
S. pneumoniae, 1993 to 2009
K. Green °, A. McGeer, A. Plevneshi, S. Pong-Porter, K. Hassan,
W. Rudnick, D. Low on behalf the Canadian Bacterial Surveillance
Network
Background: The Canadian Bacterial Surveillance Network (CBSN) has
been monitoring resistance trends in Canadian isolates of S. pneumoniae
(SP) since 1993.
Methods: CBSN is a collaborative network of microbiology laboratories
from across Canada that submit bacterial isolates to a central laboratory
for broth microdilution antimicrobial susceptibility testing performed
according to CLSI standards.
Results: Of the 32, 868 SPN isolates submitted and tested between
1993 and November of 2009, 36% were from blood/CSF (blood: 35%;
CSF: 1%), 33% from sputum, 31% from other sites. The trends in
antimicrobial susceptibility are expressed below as percentage resistant.
Preliminary results from 2009 suggest increasing resistance in all
classes of antibiotics except ﬂuoroquinolones. From 2008 to 2009,
erythromycin resistance and tetracycline resistance increased from 21.2%
to. 25.3% (p = 0.02) and from 9.8% to. 12.7% (p = 0.03), respectively.
Resistance to clindamycin increased from 8.5% in 2008 to 11.3% in 2009
(p = 0.02). Penicillin resistance increased from 6.5% in 2008 to 8.8% in
2009 (p = 0.04). Ceftriaxone resistance (meningeal breakpoint MIC 2)
increased from 3.3% in 2008 to 5.4% in 2009 (p = 0.01). Amoxicillin
resistance continued to increase: to 3.5% in 2009 from 2.1% in 2008
and 1.6% in 2007 (p = 0.04). In contrast, resistance to ciproﬂoxacin and
levoﬂoxacin did not change signiﬁcantly from 2008 to 2009 (2.2% vs.
2.3% and 1.5% vs. 1.6% respectively; however, between 2008 and 2009,
moxiﬂoxacin resistance decreased slightly (0.7 vs. 0.5 (p NS)).
Conclusion: In 2009, antimicrobial resistance increased to peni-
cillin, amoxicillin, ceftriaxone, erythromycin, trimethoprim/sulfa and
tetracycline. Resistance to ciproﬂoxacin and levoﬂoxacin remained
stable/increased slightly; resistance to moxiﬂoxacin did not change.
Moxiﬂoxacin remains the most active agent against pneumococci in
Canada.
Resistance (%)
1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Pen NS 5.7 8.1 8.8 11.9 13.6 15.0 13.4 12.3 14.4 15.2 14.9 14.8 15.3 15.3 17.2 16.6 22.0
Pen R 0.9 1.3 2.2 4.1 6.6 5.7 5.9 5.9 6.8 6.6 6.2 5.4 4.8 6.3 4.6 6.5 8.8
Amox R 0.0 0.0 0.0 0.0 0.1 0.1 0.2 0.1 0.5 0.6 1.1 1.1 1.1 1.4 1.6 2.1 3.5
Eryth R 1.9 3.4 3.2 4.8 6.8 10.5 9.8 11.2 12.8 14.2 15.9 18.0 19.1 19.4 22.5 21.2 25.3
Clinda R 0.0 1.7 1.3 2.4 3.6 5.1 4.4 5.5 5.8 6.5 7.4 8.1 8.2 8.6 9.7 8.5 11.3
T/S R 3.8 4.7 9.7 12.7 14.6 12.3 12.0 11.3 12.0 13.2 13.3 13.5 12.2 11.8 12.0 11.3 14.1
Tet R 1.4 2.3 3.4 2.5 6.4 9.1 7.1 5.5 9.1 9.6 9.7 10.9 10.4 11.2 13.1 9.8 12.7
Ceftrx R (M)* 0.0 0.2 0.1 0.7 1.3 2.5 1.5 2.0 2.4 1.5 1.8 2.5 1.9 3.7 2.9 3.3 5.4
Ceftrx R (NM)** 0.0 0.0 0.0 0.2 0.1 0.1 0.3 0.1 0.1 0.2 0.2 0.1 0.2 0.2 0.3 0.2 0.9
Cipro R¶ 0.5 0.8 0.7 0.8 1.8 1.8 1.6 1.4 2.1 2.7 1.8 2.0 2.4 2.7 2.0 2.2 2.3
Levo R 0.0 0.4 0.1 0.2 0.5 0.3 0.4 0.9 1.2 1.9 1.2 1.5 1.5 1.7 1.2 1.5 1.6
Moxi R NT NT 0.0 0.0 0.3 0.2 0.2 0.4 0.4 0.3 0.4 0.6 0.7 0.9 0.7 0.7 0.5
*M=meningeal breakpoint; **NM=non-meningeal breakpoint; ¶ breakpoint used for reduced susceptibility 4mg/mL; NT= not tested.
P1677 Antibacterial resistance among Streptococcus pneumoniae,
Haemophilus inﬂuenzae and Moraxella catarrhalis from
Kuwait and 5 centres in Turkey: results from the Survey
of Antibiotic Resistance (SOAR), 2007–2009
D. Gur, A. Tunger, S. Aydemir, G. Soyletir, G. Altinkanat, G. Bayramoglu,
F. Aydin, C. Kayacan, Z. Aktas, E. Mokaddas, A. Acar, D. O’Brien °
(Ankara, Izmir, Istanbul, Trabzon, TR; Kuwait City, KW; London, UK)
Objectives: Antibiotic resistance among community-acquired respi-
ratory tract pathogens such as Streptococcus pneumoniae (SP) and
Haemophilus inﬂuenzae (HI) is a worldwide problem. Moraxella
catarrhalis (MC) remains one of the three leading causes of acute
otitis media (AOM) in children. SP, HI and MC data from the SOAR
programme are reported.
Methods: MICs for various antimicrobials were determined using Etest;
disk susceptibility testing was performed according to CLSI guidelines.
Susceptibility was assessed using CLSI interpretive criteria.
Results: 524 SP, 418 HI and 67 MC strains were collected from ﬁve
centres in Turkey. Overall, 47.2% (247/524) of SP were penicillin-
susceptible and 52.8% (277/524) were penicillin-nonsusceptible (PNSP)
based on CLSI 2009 oral penicillin breakpoints. Based on CLSI
2009 IV penicillin breakpoints, 99.2% (520/524) were susceptible to
penicillin. PNSP prevalence was highest (64.8%; 59/91) in Istanbul
but lowest (42.7%;35/82) in Trabzon in Turkey. Overall, susceptibility
to amoxicillin/clavulanate (XL), cefuroxime (XM), and clarithromycin
(CH) was 97.7% (512/524), 64.7% (339/524), and 61.9% (324/524),
respectively. The level of non-susceptibility to oﬂoxacin (OF) was 11.1%
(58/524). A total of 418 HI isolates were collected of which 2.6%
(11/418) produced b-lactamase (BL). Overall, 9 isolates (2.2%) were
ampicillin resistant but BL negative (BLNAR). Overall, susceptibility
to XL, XM and OF was 100% (418/418), 97.1% (406/418) and 99.8%
(417/418), respectively. All MC strains were b-lactamase positive but
amoxicillin/clavulanate susceptible. Also, 97 SP strains were collected in
Kuwait. The prevalence of PNSP was 60.8% (59/97) and erythromycin-
nonsusceptible S. pneumoniae (ENSP) was 42.3% (41/97) in Kuwait.
The level of susceptibility to XL, XM, and OF was 100% (97/97), 63.9%
(62/97), and 96.9% (94/97), respectively.
Conclusion: XL and XM retained good in vitro activity against SP
and HI strains. Among SP strains, the prevalence of quinolone non-
susceptibility such as OF is increasing.
P1678 Antibacterial resistance among Streptococcus pneumoniae
from 4 centres in Thailand: results from the Survey of
Antibiotic Resistance (SOAR), 2007–2009
B. Khantawa, V. Baosount, B. Warachit, C. Yodsawat, K. Malatham,
P. Santanirand, W. Reechaipichitkul, A. Lulitanond, P. Chaimance,
S. Sawatwipachai, D. O’Brien ° (Chiangmai, Hat Yai, Ramathibodi,
Khon Kaen, Bangkok, TH; London, UK)
Objectives: Streptococcus pneumoniae is the main bacterial pathogens
implicated in community-acquired respiratory tract infections (CARTIs),
which occur frequently and account for signiﬁcant morbidity and
mortality. The emergence of drug resistance in these organisms has
complicated empirical treatment of such infections. It is therefore
imperative to know the susceptibility pattern of CARTI pathogens when
selecting an antimicrobial agent for empirical therapy.
Methods: The study was split into three phases. Phase 1: disk
diffusion to determine susceptibilities to key therapeutic drugs
(oxacillin, erythromycin, clindamycin, co-trimoxazole. tetracycline,
chloramphenicol, oﬂoxacin) Phase 2: Strains that were non-susceptible
to oxacillin and/or erythromycin were tested against other antibiotics
(penicillin, amoxicillin/clavulanate, cefprozil, ceftriaxone, azithromycin,
clarithromycin, levoﬂoxacin) by using Etest. Phase 3: Erythromycin-
clindamycin double-disk test was used to determine the resistance
phenotypes of erythromycin-resistant S. pneumoniae isolates. Prior to
the start of each phase of the survey, a quality control four-day run-
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in period test was performed. Susceptibility was assessed using CLSI
interpretive criteria.
Results: In total 281 (Phase 1), 159 (Phase 2) and 97 (Phase 3)
S. pneumoniae strains were tested from four centres in Thailand. 49.8%
(140/281) of SP were penicillin-susceptible and 50.2% (141/281) were
penicillin-nonsusceptible based on oxacillin resistance (Phase 1) and
CLSI 2009 oral penicillin breakpoints (Phase 2). Overall, resistance
to erythromycin was 34.6% (97/281). Among erythromycin and/or
penicillin resistant strains, the level of susceptibility to amoxi-
cillin/clavulanate and azithromycin/clarithromycin was 98.7% (157/159)
and 25.8% (41/159) respectively. Among 97 erythromycin resistant
strains, 57.7% (56/97) were MLSB types and 42.3% (41/97) were M
types.
Conclusion: Amoxicillin/clavulanate retained excellent in vitro activity
against S. pneumoniae strains. Among S. pneumonaie isolates, the
prevalence of macrolide resistance was high.
P1679 Oral b-lactam activity against recent (November 2008–
June 2009) penicillin non-susceptible serotype 19A
Streptococcus pneumoniae isolates in Spain
A. Fenoll, L. Aguilar °, M.J. Gimenez, M.D. Vicioso, O. Robledo,
J.J. Granizo, P. Coronel (Madrid, ES)
Objective: To explore susceptibility to oral b-lactams vs. cefotaxime
of penicillin (PEN) non-susceptible serotype 19A isolates since in Spain
this serotype has signiﬁcantly increased in last years after introduction of
the 7-valent pneumococcal conjugate vaccine, with signiﬁcant reduction
in PEN susceptibility.
Methods: 268 successive PEN non-susceptible (MIC 0.12mg/l)
serotype 19A isolates received from November 2008 to June 2009 in the
Spanish Reference Pneumococcal Laboratory were tested. Susceptibility
was determined by agar dilution following CLSI, using Mueller-Hinton
agar supplemented with 5% sheep blood, incubating under 5% CO2
atmosphere. CLSI breakpoints (oral for PEN and cefuroxime; non-
meningitis for amoxicillin and cefotaxime) were used.
Results:MIC50, MIC90 (mg/l), range and percentage (%) of susceptible
(S), intermediate (I) and resistant (R) isolates are shown in the table.
Conclusions: Cefditoren exhibited the highest intrinsic activity in terms
of MIC50 and MIC90, with values four times lower than those of
cefotaxime. Non-susceptibility (intermediate + resistant) rates to oral
b-lactams with current CLSI breakpoints were high, ranging from 33.2%
for amoxicillin to 98.9% for cefaclor.
MIC50 MIC90 Range %S %I %R
PEN 1 2 0.12−8 − 75.0 25.0
Amoxicillin 1 8 0.06−32 66.8 8.6 24.6
Cefaclor 32 32 1−32 1.1 1.1 97.8
Cefuroxime 4 8 0.12−32 25.4 17.9 56.7
Cefpodoxime 2 4 0.06−16 25.4 10.1 64.6
Cefdinir 4 8 0.06−16 24.6 1.5 73.9
Cefditoren 0.25 0.5 0.03−2 * * *
Cefotaxime 1 2 0.06−8 85.1 11.9 3.0
*No CLSI breakpoints available.
P1680 Molecular epidemiological surveillance of Streptococcus
pneumoniae: 1998–2009 in Monterrey, Mexico
R.M. Hinojosa-Robles °, H. Martinez-Rodriguez, M.E. Velazquez-Meza,
L.G. Rivera-Morales, I.M. Rivera-Morales, G.M. Gonzalez-Gonzalez,
J. Ramos-Jimenez, F. Rositas-Noriega, M. De la Cruz-Valdez,
R. Tijerina-Menchaca (Monterrey, MX)
Objectives: To Identify resistance patterns of Streptococcus pneumoniae,
determine the serotypes prevalence, to identify the presence of drug
resistant clones and estimed the coverage of the 7-valent pneumococcal
conjugate vaccine and the PPV-23 polysaccharide vaccine in patients
with pneumococcal infections.
Methods: Strains were identiﬁed by standard methods, serotyped
by the Quellung reaction, and the molecular analysis was done by
PFGE. Antimicrobial susceptibility testing was performed by the broth
microdilution technique and the E-test method and interpreted according
to CLSI guidelines.
Results: A total of 466 pneumococcal clinical isolates were recovered
from 1998 to 2009 from paediatric and adult patiens with invasive
diseases;29%, pneumonia;37%, and no-invasive diseases;34%.The most
frequent capsular types were: 19F, 23F, 6B, 6A, 14, 19A, 9V, 4, 35B,
3, 11, and 18C accounting for 83% of the isolates. Resistance to
penicillin was observed in 77% of meningeal isolates and 37% in non-
meningeal isolates. Resistance to cefotaxime was 49% to meningeal
isolates and 33% to non-meningeal isolates. Resistance to macrolide
was 46%, imipenem 31%. Resistance to chloramphenicol, tetracycline,
trimethoprim/sulphamethoxazole was 14%, 45% 72% respectively.
Levoﬂoxacine, linezolid and quinupristin/dalfopristin were active against
99.8% and vancomycin 100% of the isolates tested. Molecular analysis
showed the presence of 5 international resistance clones: Spain 23F-1,
Cleveland 23F-2, Tennessee 23F-4, Taiwan 19F-14 y Spain 9V-3. The
coverage to 7-valent vaccine was 70% and for the PPV-23 was 68%. The
Mortality observed in this study was 10%.
Conclusions: Is important to determine the antimicrobial with 99–
100% activity in order to select the most appropriated treatment for
our patients. The clonal relationship between mexican strains and
the international clones indicates its imminent spread to northeastern
Mexico. The vaccination coverage is within expected ranges for the
mexican population. These results encourage us to continue this
surveillance system.
P1681 Changing patterns of antibiotic resistance and serotype
distribution in group B streptococcus isolated in a maternity
hospital in Kuwait
S. Boswihi, N. Al-Sweih, E. Udo ° (Kuwait, KW)
Objectives: Group B streptococcus (GBS) is a common cause of
infections in neonates and pregnant women. Although still susceptible
to penicillin, there are reports of reduced susceptibility to penicillin in
some GBS isolates. In this study GBS isolates obtained from patients
at the Maternity hospital in Kuwait were studied for their serotypes and
susceptibility to antibiotics, and the results were compared to those of a
previous study conducted in 2001.
Methods: A total of 154 GBS isolates were collected from 1 July to
31 October 2007 from HVS, urine, blood and miscellaneous sources.
All isolates were serotyped using latex agglutination test. Antibiotic
susceptibility testing was performed by the disk diffusion method. MIC
for penicillin, erythromycin and clindamycin was performed by E-test
or agar dilution methods.
Results: Most of the isolates belonged to serotype V (38.3%), serotype
III (19.5%), serotype Ia (10.4%), serotype II (10.4%). Seventeen isolates
(11.0%) were nontypeable. Eighteen (11.68%) and 10 (6.5%) isolates
were resistant to erythromycin (MIC: >1mg/L) and clindamycin (MIC:
>2mg/L), respectively. They were susceptible to penicillin. However
MIC determination showed that 31.2% of them had elevated penicillin
MIC values of 0.064mg/L and 13.6% had MIC of - 0.094mg/L. Eight
isolates (5.2%) expressed reduced susceptibility to penicillin (MIC:
0.125–0.19mg/Ll).
Conclusion: The result showed that serotype V detected in 38.3% of the
isolates became the dominant serotype in 2007 whereas serotype III was
the dominant serotype in 2001. The proportion of GBS isolates resistant
to erythromycin and clindamycin increased from 0.7% and 1.7% in 2001
to 11.6% and 6.5% in 2007. There was a signiﬁcant shift in the number
of isolates expressing penicillin MIC of 0.064mg/L from 4.4% in 2001
to 44.8% in 2007. Furthermore, whereas none of the 2001 isolates had
MIC 0.125–0.19mg/L, this was detected in 5.2% of the 2007 isolates.
The result demonstrated a trend towards increasing antibiotic resistance
in GBS isolates in a Kuwait hospital.
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P1682 Antimicrobial susceptibility proﬁles in Streptococcus
agalactiae invasive and colonizing strains from Greece: a
6-year study
S. Vourli °, A. Tarpatzi, K. Tsiveriotis, M. Bompola, N. Bournas,
G. Salamalekis, L. Zerva (Athens, GR)
Objectives: Streptococcus agalactiae (Group B Streptococcus, GBS)
is an important pathogen during the perinatal period, but it is also
responsible for various invasive infections, most frequently skin and
soft tissue infections, in non-pregnant adults. Most GBS strains are
susceptible to penicillin, but resistance to erythromycin and clindamycin
seems to be increasing. Few data on antimicrobial resistance of strains
isolated in Greece are available. We present antimicrobial susceptibility
proﬁles of GBS isolates from a 730-bed tertiary hospital of Athens.
Material: We studied 189 GBS isolates collected in the Clinical
Microbiology Laboratory of our hospital from 2004 to 2009. Ninety-
three of these were consecutively isolated from routine clinical specimens
(urine, vaginal swabs, blood, synovial ﬂuid and pus), and the remaining
96 from the colonisation screening of pregnant women (performed from
2008 to 2009).
Identiﬁcation and antimicrobial susceptibility testing were carried out
by the Phoenix ™100 automated system. Medical ﬁles of GBS-positive
patients were retrieved from the hospital records and all information
concerning the clinical signiﬁcance of the isolates was collected.
Results: Overall, antimicrobial susceptibility results were available for
145 out of 189 GBS isolates. No penicillin, ampicillin, cefazolin or
vancomycin resistance was observed in any of the examined strains.
Twenty-eight strains (19.3%) were found to be erythromycin resistant.
Only 9 out of the 93 clinical isolates (2 isolated from blood, 1 from
synovial ﬂuid and 6 from pus) were considered as invasive, after review
of the medical records, and they were susceptible to all antibiotics tested.
Conclusions: Taking into account the size of our hospital, the rate
of GBS invasive infections in non-pregnant adults appears to be low,
according to our ﬁndings. A high percentage of erythromycin resistant
was noticed, which is consistent with results coming from studies in
other countries. Notably, invasive isolates were more susceptible than
non-invasive ones.
P1683 Impact of new CLSI S. pneumoniae penicillin susceptibility
testing breakpoints on reported resistance changes over time
R.M. Mera °, L.A. Miller, H.A. Madsen, D.F. Sahm (Durham, Upper
Providence, Hendon, US)
Objectives: To describe and contrast the differences over time in
S. pneumoniae penicillin susceptibility rates when applying either the old
or the new CLSI (Clinical & Laboratory Standards Institute) penicillin
breakpoints using a large surveillance database.
Methods: The analysis comprised a total of 93,661 US isolates from
the TSN Network® surveillance database (Euroﬁns Medinet) during the
period 1996 to 2008. Under the former CLSI criteria, S. pneumoniae
penicillin resistance was deﬁned as MICs 2 mg/ml irrespective of
clinical syndrome. The new CLSI guidelines are identical for oral
penicillin use and non-meningitis sources, with a resistant breakpoint
of 2 mg/ml. For non-meningitis and parenteral penicillin, the revised
resistant breakpoint is 8 mg/ml; while for meningitis, the revised
resistant breakpoint is 0.12 mg/ml.
Results: Penicillin resistance, when deﬁned using the old CLSI
breakpoint of MICs 2 mg/ml, had a very distinctive pattern over time,
with an initial rise that starts in 1996, a peak in 2000, decline until
2005 and rebound through 2008 (15.6%, 23.2%, 15.2% and 17.0%,
respectively). Using the new CLSI criteria and applying a resistance
breakpoint of 8 mg/ml to blood and sputum isolates, the average
resistance levels were 1.9% and 2.6%, without any appreciable changes
over time. Using the new meningitis criteria of 0.12 mg/ml, resistance
prevalence was 34.8% in 2008, while it was 12.3% using the old criteria
of 2 mg/ml. Evaluating MIC levels separately, the percent of non-
meningitis isolates with MICs of 1 mg/ml had a continuous decline from
14.3% in 1996 to a low of 6.3% in 2008, while the percent of isolates
with MICs of 2 mg/ml showed a rise from 12.2% in 1996 to a peak of
16.1% in 2001 and a decline to 8.3% in 2008. The percent of isolates
with MICs of 4 and 8 mg/ml show no signiﬁcant changes from their
average levels of 5.3% and 1.4% respectively.
Conclusion: The rise, fall and subsequent rebound of penicillin
resistance in the US presumably inﬂuenced by the introduction of the
conjugate pneumococcal vaccine is not observed when the new8 mg/ml
resistance breakpoint is applied. In the post-vaccine period, isolates with
MICs of 1 and 2 mg/ml decline while those with MICs of 0.12 to 0.5
increase, which may signal the loss of resistant vaccine serotypes and
the acquisition of resistance by non-vaccine serotypes.
P1684 Analysis of quinolone-resistant Streptococcus pneumoniae
collected from PROTEKT studies between 2000 and 2007
J. Blackman Northwood, C. Couturier, S. Brown, I. Morrissey °
(Fordham, UK; Paris, FR; Portland, US)
Objective: The genetic & geographical relationship between quinolone-
resistant (QR) S. pneumoniae (SP) collected as part of PROTEKT
Global & PROTEKT US was determined.
Methods: SP were collected from PROTEKT Global (47 countries
worldwide; N = 41,693) & PROTEKT US (49 states; N = 55,729).
MICs were determined using CLSI guidelines. Quinolone resistance
determining regions (QRDR) within gyrA, gyrB, parC & parE were
sequenced & multi locus sequence typing determined for QRSP by
previously published methods.
Results: QR rates for both studies remained stable ~1% each year
(Table). However, Italy had a steadily increasing rate of QR. Hong Kong
had a very high QR rate while Massachusetts (MA), Colorado (CO),
New Jersey (NJ) & New York (NY) had higher than the US average
(0.9% [SD0.6]) QR rates.
Globally, QRSP were from a wide range of sequence types (ST) &
clonal complexes (CC). QRSP from Hong Kong were mainly ST81
(58/71), which was found in numerous locations worldwide. ST66 was
the dominant clone in Italy (58/81), most collected from a single centre.
There were 3 dominant CC in the US: CC81 (67/527), CC271 (37/527) &
CC439 (34/527). QRSP were represented by >23 CC & were evenly
distributed across the US except for CC81 which peaked in NY &
CC439 which peaked in MA. QR was due to typical QRDR mutations
as previously reported.
Conclusion: QR in Hong Kong was due to the dominance of CC81,
as previously reported. QR in Italy was due to the emerging resistant
clone ST66, although this could be a localized outbreak as most came
from 1 centre in Catania over a short period of time. QRSP in the US
was due to the presence of numerous clones including CC81 & CC439.
The presence of CC271 in QRSP is also important as this clone is
often associated with resistance to macrolides, penicillin, tetracycline &
cotrimoxazole.
This study shows QR remained very low during both studies & was
caused by multiple CC in most countries.
Table 1. Total number of isolates collected (N) & %QR by Year [NT;
not tested]
Region 2000−01 01−02 02−03 03−04 04−05 05−06 06−07 Average
Hong Kong N 70 58 74 70 62 73 93 71
%QR 14.3 15.5 10.8 11.4 17.7 17.9 12.9 14.2
Italy N 119 284 267 285 228 192 590 281
%QR 0.0 0.7 1.5 3.9 4.4 5.2 7.5 4.1
MA N 353 268 246 205 137 106 NT 219
%QR 4.8 1.9 1.2 2.4 2.2 0.0 NT 2.5
CO N 65 239 265 108 226 167 NT 178
%QR 4.6 4.2 2.6 0.9 0.9 0.6 NT 2.2
NJ N 191 193 160 35 81 NT NT 132
%QR 1.0 3.1 1.9 2.9 0.0 NT NT 1.8
NY N 542 529 597 493 626 548 NT 556
%QR 1.7 1.1 3.0 1.6 1.4 1.3 NT 1.7
Global average N 3435 4256 6320 6739 7083 6395 7465 5956
%QR 1.4 1.1 0.9 1.0 1.0 1.4 1.4 1.1
US Average N 10,103 10,012 10,886 8494 9487 6747 NT 9288
%QR 0.9 1.2 0.8 1.1 0.9 0.8 NT 0.9
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P1685 Trends in antimicrobial resistance in invasive isolates of
Streptococcus pneumoniae in Turkey, 2003–2008
D. Gu¨lmez °, D. Gu¨r, G. Hasc¸elik on behalf of EARSS-Turkish Study
Group
Objectives: Antimicrobial susceptibility test results of blood and
cerebrospinal ﬂuid (CSF) isolates of S. pneumoniae collected between
2003–2008 from 16 centers in Turkey were evaluated.
Methods: Antimicrobial susceptibility tests were performed in individual
laboratories following CLSI guidelines (2009) according to the European
Antimicrobial Resistance Surveillance System (EARSS). In vitro
susceptibilities were interpreted for penicillin, erythromycin, tetracycline
and ﬂuoroquinolones.
Results: A total number of 683 isolates were evaluated. Of these,
547 were blood, and 136 were CSF isolates. In CSF isolates, overall
resistance to penicillin was 26.5%; which has increased from 7.7%
in 2003 to 57.1% in 2008. In the blood isolates, the results for
penicillin interpreted according to the oral and parenteral breakpoints,
erythromycin, tetracycline and ﬂuoroquinolones are shown in the Table.
Conclusions: The level of resistance to penicillin in CSF isolates is
high in Turkish isolates and has increased over the years. In the blood
isolates, the rate of resistance to erythromycin has increased gradually
and has not shown a steady increase in tetracycline and ﬂuoroquinolones.
These results should be taken into account in the empirical therapy of
meningitis and other invasive infections due to S. pneumoniae.
Table 1. In vitro resistance rates to antimicrobial agents in blood isolates
of S. pneumoniae (2003–2008)
I +R (%)
Penicillin
oral
Penicillin
parenteral
Erythromycin Tetracycline Fluoroquinolones
2003 14.3 1.1 7.5 25.0 0
2004 23.0 0 8.9 9.7 1.8
2005 21.6 0 8.4 6.7 2.4
2006 20.7 2.4 14.9 10.8 0
2007 22.7 4.5 14.3 20.9 2.3
2008 31.6 2.6 23.7 10.5 12.0
Total 22.1 1.6 12.5 14.0 2.2
I: Intermediate, R: Resistant.
P1686 Susceptibility to respiratory ﬂuoroquinolones in
Streptococcus pneumoniae in Toronto, Canada
K. Green, D. Low, A. McGeer ° on behalf of the Toronto Invasive
Bacterial Diseases Network
Background: FQ resistance (FQR) emerged in S. pneumoniae (SPN)
shortly after the introduction of ciproﬂoxacin. FQR increased from 1995
to 2002, and by 2002 was clinically signiﬁcant in the elderly, and those
with recent exposure to FQ and healthcare institutions. We examine
trends in FQR in SPN in at-risk populations in Toronto since 2002.
Methods: Since 1995, TIBDN has collected all SPN isolated from sterile
sites in residents of Toronto/Peel (pop 4M); from 2002, respiratory
tract isolates were collected and the population area expanded. Broth
microdilution susceptibility testing to CLSI standards is performed on
all isolates. Pop’n FQ use is obtained from IMS Health. Demographic
and medical data were collected from patients.
Results: From 1995–2008, FQ use increased from 67.3–97.3
scripts/1000pop/yr; Levo use from 0 to 12.3 scripts/1000pop/yr, and
Moxi use from 0 to 17.7 scripts/1000pop/year. 8645/9796 (88%) of
SPN isolates were available for testing. After 2002, FQR decreased
signiﬁcantly for isolates in all subgroups (see Table), with the exception
of isolates from respiratory specimens in patients currently receiving FQ.
In 2008/9, ﬂuoroquinolone resistance appeared to increased marginally,
but the differences are not statistically signiﬁcant. In 2009, moxiﬂoxacin
resistance rates were less than 2% in all patients except those patients
failing ﬂuoroquinolone therapy, and residents of nursing homes.
Conclusion: Despite increased use of respiratory ﬂuoroquinolones,
ﬂuoroquinolone resistance in pneumococcal isolates is not increasing.
Only nursing home patients, and patients failing treatment with
ﬂuoroquinolones at presentation are at risk of ﬂuoroquinolone resistance.
Lev R Mox R Lev R Mox R Lev R Mox R Lev R Mox R
Invasive disease 2000−2 (N= 857) 2003−5 (N= 943) 2006−7 (N= 775) 2008−9 (N= 746)
All adults 1.8% 0.50% 1.3% 0.33% 0.30% 0 1.1% 0.32%
Adults >65 y 3.2% 1.0% 1.2% 0.41% 0.27% 0 1.4% 0.72%
Hospital-acquired 7.4% 0 3.9% 0 0 0 0 0
Nursing home acquired 8.6% 2.5% 2.5% 0 2.1% 0 7.9% 2.6%
Failing FQ therapy 21% 7.1% 27% 9.1% 0 0 9.1% 9.1%
FQ prior 3 months 4.8% 1.6% 1.9% 0.93% 1.5% 0 1.9% 1.9%
Respiratory isolates 2002 (N= 352) 2003−5 (N= 1317) 2006−7 (N= 935) 2008−9 (N= 868)
All adults 5.7% 1.2% 3.4% 1.6% 2.7% 1.4% 3.0% 1.5%
Adults >65 y 8.6% 1.7% 4.0% 1.8% 3.9% 2.6% 9.6% 2.3%
Hospital-acquired 8.7% 4.4% 0.8% 0.4% 3.2% 2.1% 1.9% 0
Nursing home acquired 9.1% 0 11% 7.1% 3.9% 0 18% 9.1%
Current FQ therapy 60% 20% 25% 9.4% 38% 25% 50% 50%
FQ prior 3 months 15.4% 0 7.4% 3.7% 3.8% 1.9% 6.1% 1.5%
P1687 Current proﬁle of respiratory tract infection agents against
Streptococcus pneumoniae and Haemophilus inﬂuenzae in
Europe: impact of patient population
D. Draghi, N.P. Brown, C.M. Pillar °, C. Thornsberry, D.F. Sahm
(Chantilly, US)
Objective: The impact of comorbidities, including patient age, on
patterns of resistance among respiratory pathogens is an important
consideration for the empiric therapy of respiratory tract infections (RTI).
This study reports the current susceptibility (S) proﬁle in Europe (EU) of
agents commonly used to treat RTI infections caused by S. pneumoniae
(SP) or H. inﬂuenzae (HI), including isolates with multi-drug resistance
(MDR), and also evaluates the overall impact of patient age on resistance
patterns.
Methods: From 2006–2009, the GLOBAL surveillance program
collected 1790 SP and 1715 HI isolates from 6 countries across EU.
All isolates were centrally tested by broth microdilution in accordance
with CLSI (M7-A8). Current CLSI (M100-S19) and FDA breakpoints
(BP) were applied as appropriate. MDR was deﬁned as resistant (R) to
2 of the following: penicillin (PEN), cefuroxime (CFX), azithromycin
(AZI), trimethoprim-sulfamethoxazole (SXT), and tetracycline (TET).
Patient age was deﬁned by years; pediatric 17 (PED); adult 18−64
(ADT); elderly 65 (ELD).
Results: Against SP overall, S among common RTI agents ranged
from 98.3% (levoﬂoxacin [LVX]) and 96.4% (AMC) down to 68%
(clarithromycin [CLA]/AZI). PEN-R and MDR rates among SP varied
by patient age (PED/ADT/ELD): %PEN-R (11.6/11.1 /9.2); %MDR
(35.2/28.2/25.0). % susceptible to TET, macrolides/ketolides, and CFX
also varied by age (PED/ADT/ELD): TET (68.7/75.7/79.9); AZI
(60.1/67.7/71.3); CLA (60.1/67.2/71.0); CFX (78.5/83.7/84.5). LVX
MIC90s remained at 1mg/L and S exceeded 98% against SP, regardless
of age or R phenotypes. Though rare, LVX-R was generally restricted to
MDR isolates where it was most common among the ELD (4.2%) and
ADT (2.5%). Among HI, ampicillin R varied from 11.2% for PED to
13.8% for ELD. For HI regardless of age, S rates were >99% for LVX,
CIP, AZI, AMC, CFX and 77−78% for CLA and SXT.
Conclusions: Among SP, decreased S to CLA, CFX, and TET and
increased PEN-R and MDR was observed among the PED population.
Regardless of patient age, SP remained susceptible to LVX (>98%S)
and AMC (>95%S). The evaluated ﬂuoroquinolones (FQ; LVX/CIP),
macrolide (AZI), and b-lactams (CFX, AMC) were potent against HI
(>99%S) regardless of age. Variation in the S of SP to b-lactams and
macrolides among subpopulations and the consistent activity of FQ
across these populations are important factors to consider when choosing
an empiric agent for the treatment of respiratory infections.
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Intestinal microbiota and detection of
enteropathogens
P1688 Molecular diagnostics of gastroenteritis in clinical samples:
a multicentre, quality control study in the Netherlands
T.A. Schuurs °, H. Nguyen, A.J. Stellingwerff, A.M. Kooistra-Smid,
G.T. Noordhoek (Leeuwarden, Groningen, NL)
Objectives: Molecular diagnostics on samples from patients with gas-
troenteritis is a new development in medical microbiology laboratories.
However, at this moment there are no proﬁciency panels available
to evaluate the performance of these laboratories for detection of
gastroenteritis in clinical samples. Therefore, as an initiative of the
gastroenteritis study-group in The Netherlands, in August 2009 a quality
control panel was organised.
Methods: The panel consisted of 11 duplicated and randomized faeces
samples (total 22). The samples contained, in varying loads, none, one or
several of the following bacteria and/or parasites: Salmonella enterica,
Campylobacter jejuni, Giardia lamblia and/or Cryptosporidium parvum.
The performances of the laboratories were anonymously evaluated in
combination with a questionnaire on the molecular methods used.
Results: Of twenty laboratories participating, 9 tested both for bacteria
and parasites, 3 bacteria only and 8 parasites only. Four out of 12
labs, reporting bacterial targets, submitted results corresponding with
the expected outcome. For the parasite targets this was 9 out of 17
labs. Two false-positives were submitted by 2 different labs. However,
incorrect results were mainly false-negatives and were on samples
with low target-loads. Average delta Ct-values of high-positive samples
were signiﬁcantly higher for labs that missed low-positives. In general,
no differences existed between laboratories with correct and incorrect
results, regarding pre-treatment, DNA extraction and real-time PCR
methods used. However, laboratories with false-negatives added higher
percentage of the sample to the extraction procedure than those with
correct results (33% vs. 18%; p = 0.065). Furthermore, laboratories that
missed G. lamblia, pre-treated samples by heating (80–100ºC) in lysis
buffer whereas ﬂawless laboratories pre-treated by vigorously shaking in
lysis buffer.
Conclusion: Labs performed better for parasitic than for bacterial
targets. Decreased sensitivity was reﬂected by false-negative results
on weak-positive samples and by increased Ct-values on samples with
higher loads, correctly reported by those laboratories. Large differences
in applied methods suggest that the underlying factor(s) explaining
decreased sensitivity are probably lab-speciﬁc. In order to improve
sensitivity we recommend to optimize the amount of faeces added to the
extraction procedure and to avoid excessive heating during pre-treatment.
P1689 Development and clinical evaluation of a multiplex real-time
PCR for the detection of bacterial gastroenteritis
J.H. van de Bovenkamp °, C.M. van Herk, I.O. Op den Buijs, A. van
den Brule, H.T. Tjhie (Veldhoven, NL)
Objectives: A multiplex real-time PCR was developed to detect
simultaneously Salmonella spp., Shigella spp., Yersinia enterocolitica
and Campylobacter spp. (SSYC) and was internally controlled with
phocid herpesvirus (PhHv). A new screening strategy was chosen for
the detection of gastroenteritis causing pathogens. Except for the internal
control, labelled with Vic, all different probes used in the multiplex real-
time PCR were labelled with FAM.
Methods: This multiplex PCR was evaluated in a six week summer
period in which most positive samples were expected. In parallel with
PCR also culture, as “the gold” standard, was tested. Faeces was cultured
on speciﬁc plates for Campylobacter, Yersinia and Salmonella. In
addition, a selinite broth was used for Salmonella. DNA was extracted the
next day with the easyMag from a mixture of overnight cultured selinite
broth and faecal suspension and subsequently used for the multiplex
PCR. Multiplex positive samples were directly retested in a single real-
time PCR for Salmonella and Campylobacter. Shigella and Yersinia were
tested the next day if the single real-time PCR was negative.
Results: From the 507 consecutive samples, 63 (12.4%) were positive
for both culture and PCR; 423 both negative; 3 (0.6%) were culture
positive and PCR negative; and 18 (3.6%) culture negative and PCR
positive. All 18 PCR positives and culture negative samples could be
conﬁrmed as positive in separate PCR’s.
Of the 81 PCR positive samples 53 were positive for Campylobacter spp.,
9 were positive for Salmonella spp., 9 for Shigella spp., 8 for Yersinia,
and two combined Campylobacter and Shigella, and one was positive
for both Campylobacter and Yersinia infections.
Conclusions: This multiplex real-time PCR strategy can be used as a
screening method for bacterial faecal pathogens which could reduce the
workload for culture. Furthermore, this approach enables the inclusion
of other pathogens such as Shiga toxin producing E. coli (STEC) or
separately labelled viral and parasite infections.
P1690 IS-pro: high-throughput molecular ﬁngerprinting of the
intestinal microbiota
A.E. Budding °, M.E. Grasman, A.A. van Bodegraven, P. Savelkoul
(Amsterdam, NL)
Introduction: The composition of the human intestinal microbiota is
currently receiving much attention. While large scale sequencing efforts
are effectively being employed in its characterization, the complex and
expensive nature of these techniques restricts implementation to a small
number of highly specialized laboratories. We have developed a proﬁling
technique, IS-pro, for high-throughput analysis of the human intestinal
microbiota. This technique combines species identiﬁcation by 16S-23S
interspace length with phylum identiﬁcation by colour labelling and
provides an instant overview of the Bacteroidetes/Firmicutes composition
of samples. We validated it in silico, in vitro and in vivo, for colonic
mucosal biopsies.
Methods: The potential of IS-pro was evaluated in-silico with a database
containing sequences of 342 bacterial species. In vitro validation was
performed with monocultures and mixes of cultured bacteria. Finally,
we performed in vivo validation with 100 colonic mucosal biopsies of
20 healthy individuals obtained from 5 locations throughout the colon:
Caecum, hepatic ﬂexure, splenic ﬂexure, sigmoid and rectum. Bands that
were commonly found in multiple individuals were sequenced.
Results: In silico evaluation showed that IS-pro can theoretically
discriminate >50,000 bacterial species. In vitro testing showed lower
detection limit to be 10 bacteria/ml. No interactions were found between
species within or between different phyla. In vivo validation on duplicate
samples showed excellent reproducibility of IS-pro. A high level of
correlation of mucosal samples throughout the colon was identiﬁed
by IS-pro, corresponding well with current knowledge and further
underlining the reproducibility of the technique. All sequenced bands
could be traced back to gut microbes. Phylum coloring was correct for
all identiﬁed species.
Conclusion: IS-pro has a very high discriminatory potential, and is
well suited for analysis of the complex microbiota of the human gut.
The test is not inﬂuenced by interactions between different bacteria
in complex mixtures and is highly reproducible on clinical samples.
Because of its simplicity, IS-pro can be performed in general clinical
microbiological laboratories. As such it can make analysis of the human
intestinal microbiota broadly accessible to clinical practitioners. The
high-throughput nature of the test makes analysis of large numbers of
samples feasible and as such it can play a critical role in research efforts.
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P1691 Impact of antenatal antibiotic or corticosteroid treatment
on the implantation of the neonatal intestinal microbiota
E. Montassier °, N. Molinari, P. Loisel, C. Gras-Leguen, D. Darmaun,
C. Rouge´, J.C. Roze´, G. Potel, M.F. de La Cochetie`re (Nantes,
Toulouse, Montpellier, FR)
Objective: At birth, the gastrointestinal tract is essential germ free.
Initial colonisation occurs during birth and shortly afterwards until
a dense, complex microbiota develops. Intestinal microbiota has a
profound effect on the development of the gastrointestinal tract and in
the maintenance of the integrity of the mucosal surface. Establishment of
normal microbiota is important for physiologic, nutritional, and immune
development. Perturbations of the intestinal ecosystem, especially during
early development, may have consequences that extend well beyond the
neonatal period. Study of the implantation of the intestinal microbiota in
newborn is thus of utmost signiﬁcance. Our work stands in this context.
The aim is to study the impact of antenatal antibiotic or corticosteroid
treatment on the implantation of the neonatal intestinal microbiota.
Methods: Criteria for enrolment were gestational age <32 weeks, birth
weight <1500 grams, postnatal age no greater than 2 weeks and absence
of any disease other than those linked to prematurity. Faecal samples
were collected weekly from birth up to 11 weeks. After DNA isolation,
V6 to V8 region of the 16S rRNA gene ampliﬁcation, samples were
analysed using a ﬁngerprinting method (Temporal Temperature Gradient
Gel Electrophoresis). Each dominant microbiota was converted into
electrophoretic distances, digitized and further analyzed. A bivariable
model was used to study correlations between antenatal treatment and
neonatal microbiota.
Results: 47 neonates born to 34 women were included. 242 faecal
samples were analyzed. Results are summarized in Table 1: signiﬁcant
correlations have been found between (1) corticosteroid treatment
and the implantation of phylum Firmicutes − family Lachnospiraceae,
and phylum Proteobacteria − family Enterobacteriaceae; (2) antibiotic
treatment and the implantation of phylum Firmicutes − family
Clostridiaceae, phylum Firmicutes − family Staphylococcaceae, Phylum
Actinobacteria − family Biﬁdobacteriaceae. No link has been found when
the treatment was given during labour or delivery.
Conclusion: To our knowledge it is the ﬁrst time that correlations
are highlighted between antenatal treatment and speciﬁc intestinal
microbiota implantation. Although this pilot study stands at a very early
stage in the impact of antenatal treatment analysis, it suggests microbiota
modulation possibilities.
Antenatal Neonatal microbiota
treatment Multivariate analysis Phylogenetic signature
electro-
phoretic
distances
OR p-value phylum class order family
Corticosteroids
(28 mothers)
110 39.42
[2.915−533.373]
0.0057 Firmicutes Clostridia Clostridiales Lachnospiraceae
211 22.41
[2.124−236.445]
0.0097 Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae
Antibiotics
(18 mothers)
43 18.33
[1.918−175.174]
0.0116 Firmicutes Clostridia Bacillales Staphylococcaceae
97 0.048
[0.0005−0.482]
0.0099 Firmicutes Clostridia Clostridiales Clostridiaceae
322 39.30
[1.693−900.072]
0.0221 Actinobacteria Actinobacteria Biﬁdobacteriales Biﬁdobacteriaceae
P1692 Increased risk of gastric cancer associated with combined
effect of Helicobacter pylori virulence determinants
M. Douraghi °, Y. Talebkhan, H. Zeraati, M. Eshagh Hosseini,
M. Mohagheghi, M. Mohammadi (Tehran, IR)
Objectives: Persistent colonization and maintenance of H. pylori in
harsh conditions of stomach are attributed to a series of virulence
determinants. Two potent polymorphic secretory toxins; vacA and cagA
and the functionally active adhesin babA2 are identiﬁed as the more
ubiquitous virulence markers in disease associated strains. This study
was undertaken to determine whether H. pylori virulence markers as
screening determinants affect the risk of gastric cancer independently or
cooperatively.
Methods: Collectively, 212 H. pylori infected patients including 48
gastric cancer (GC) and 164 non gastric cancer patients were assessed
for Hp vacA polymorphic alleles, cagA polymorphism and functional
babA2 using PCR.
Results: Our study revealed that each gene individually or cooperatively,
were signiﬁcantly associated with GC (Table 1). The OR for GC risk
was further increased signiﬁcantly with the number of studied genes. As
indicated in Table 1, the s1 or i1 allele individually affect the GC risk up
to more than 8-fold which was higher than that of concurrent carriage
of s1i1m1/babA2+/ABCC CagA. However, the proportion of those who
actually have disease (PPV) of the latter as triple-positive genotypes is
higher than any other studied genes singly or synergistically.
Conclusion: This analysis thus reveals that speciﬁc virulence gene
clusters are associated with an increasing risk of GC. Therefore, the
current study provides evidence of cooperative activity of H. pylori
virulence genes in the development of gastric malignancy. We propose
the exploration of the screening power of multiple H. pylori virulence
determinants for improved population screening for the risk of GC
development in high prevalent geographic regions. These efforts
should focus on joint screening powers of host–pathogen-environment
susceptibility factors.
Table 1. Association of H. pylori genotype(s) with gastric cancer
Genotype (Positive vs. others) Cases,
n (%)
Controls,
n (%)
P value OR 95% CI PPV NPV
s1 46 (95.8) 119 (72.6) 0.004 8.697 2.027–37.326 27.8 95.7
i1 42 (87.5) 75 (45.7) 0.001 8.307 3.347–20.614 35.8 93.6
m1 29 (60.4) 42 (25.6) 0.001 4.434 2.254–8.720 40.8 86.5
babA2 41 (85.4) 104 (63.4) 0.006 3.379 1.427–8.003 28.2 89.5
ABCC CagA 20 (41.7) 36 (22) 0.007 2.540 1.283–5.026 35.7 82
s1i1m1 29 (60.4) 39 (23.8) 0.001 4.892 2.47–9.667 42.6 86.8
s1i1m1/ABCC CagA 13 (27.1) 11 (6.7) 0.001 5.1 2.137–12.492 54.1 81.3
s1i1m1/babA2+ 27 (56.3) 29 (17.7) 0.001 5.985 2.980–12.019 48.2 86.5
s1i1m1/babA2+/ABCC CagA 13 (27.1) 9 (5.5) 0.001 6.397 2.535–16.143 59 81.5
OR, odds ratio; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value.
Molecular typing: streptococci and
staphylococci
P1693 PBPs and MurM variations in invasive b-lactam-resistant
19A Streptococcus pneumoniae ST320, ST81 and ST276
clones from Spain, 1997–2007
R. del Campo °, C. Ardanuy, D. Rolo, E. De la Pedrosa, R. Canto´n,
A. Fenoll, F. Baquero, J. Lin˜ares on behalf of the CIBERESP
Background: Since PCV-7 was introduced in 2002 in Spain, a
signiﬁcant increase in invasive infections caused by 19A S. pneumoniae
was observed. Sequential alterations in PBP sequences are the classical
mechanism to acquire penicillin resistance, whereas murM mutations
are required for high penicillin and cefotaxime resistance. The aim of
this study was to analyze the PBPs and murM genetic variants in a
19A S. pneumoniae collection recovered before and after of the PCV
introduction (1997–2007).
Material and Methods: Forty-two invasive 19 A S. pneumoniae isolates
with both penicillin and cefotaxime resistance were collected at the
Spanish Reference Laboratory for Pneumococci. Population structure
was evaluated by PFGE-SmaI and MLST. Internal fragments of the
PBP1a, PBP2b, PBP2x and MurM encoding genes were ampliﬁed and
sequenced.
Results: The proportion of serotype 19A among penicillin resistant
strains progressively increased from 2% in 1997 to 12.1% in 2007.
This increase was especially noticeable in the 2005–2007 period.
Resistance rates were as follows: tetracycline, 100%; co-trimoxazole,
88%; erythromycin, 74%; clindamycin, 74% and chloramphenicol, 38%;
amoxicillin, 33% resistant and 10% intermediate resistant (IR) (MIC
range 0.5−8). Eight different PFGE patterns were observed, and three
major clonal groups were identiﬁed by MLST: ST81-Spain23F (17
isolates); ST320-Taiwan19F (16 isolates); and ST276-Denmark14 (9
isolates). Identical DNA and protein sequences were detected in all
isolates for the murM gene. Two different DNA/protein alleles were
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observed in the pbp1a sequences, one of them related to the ST320
isolates. Four different alleles were found for the pbp2b gene, clustering
two of them to ST320 isolates, another one only in ST81 isolates, and
the last one present in ST81 and ST276 isolates. For the pbp2x gene two
different DNA sequences were obtained, corresponding one of them to
the ST320 isolates, but PBP2x aminoacid sequences were identical in
all isolates.
Conclusion: In recent years, incidence of 19A invasive multirresistant
S. pneumoniae isolates is increasing in Spain, mainly due to the spread
of the clones ST81-Spain23F, ST276-Denmark14 and ST320-Taiwan19F.
PBP1a, PBP2x, and MurM proteins are almost identical in ST81 and
ST276, suggesting association between 19A capsular transformation and
modiﬁed PBPs. In ST320 isolates, speciﬁc alleles were found for PBP1a
and PBP2x, indicating a possible 19F/19A cps recombination event.
P1694 Genotypic analysis of invasive resistant Streptococcus
pneumoniae by semi-automated repetitive-element PCR
F. Pardo °, M.L. Pe´rez del Molino, L. Martı´nez-Lamas, M. Herna´ndez,
B.J. Regueiro (Santiago de Compostela, ES)
Objective: To determine by using rep-PCR (DiversiLab System) the
degree of clonal diversity among invasive resistant S. pneumoniae
isolates, related with results obtained by serotyping.
Methods: We analized all invasive resistant strains of S. pneumoniae
(2004–2007). Serotyping was carried out by the quellung reaction with
speciﬁc antisera. Minimal inhibitory concentration (MIC) was obtained
by the agar microdilution method. Clonality dispersion was obtained by
rep-PCR. In the phylogenetic analysis, were considered indistinguishable
isolates or those with the same genotype had a similarity index (SI) of
97% and no obvious band differences. Isolates were characterized as
being similar or subtypes if they had 97% similarity and one band
different.
Results: The 97 resistant strains, classiﬁed into eleven different serotypes
(48.5% included in 7-valent pneumococcal conjugate vaccine). The
strains could be grouped in 55 genotypes, belonged to 14 clusters, 9
of these overlapping between serogroup and genotype and 4 grouped
strains of different serogroups. The strains belonging to serotype 19A,
all erythromycin-resistant, were genetically similar, 83.3% had a SI
above 93%. Only 18.2% of 11 isolates of serotype 19F can be clustered
(SI> 97%). In the serogroup 14 a 90.9% had a SI below 92%. About 75%
strains belonging to serotype 15A (all resistant to penicillin, tetracycline
and erythromycin) had a SI> 95.
Conclusion: There is clear greater clonal diversity among vaccine
serotypes. The rep-PCR, have proven to have a greater discriminatory
power in the phenomena of genetic exchange than serogroup. Our data
indicate a need for continued monitoring of invasive pneumococcci,
to detect changes in emergence of serogroups and to determine the
effects of the vaccine its genetic struture. The Diversilab System has
the potential to increase the speed of analysis and to obtain compared
results.
P1695 The presence of pilus and clade types among invasive
pneumococci recovered in the Czech Republic
H. Zemlickova °, V. Jakubu, M. Fridrichova, M. Trojanek, M. Musilek,
J. Motlova (Prague, CZ)
Objectives: Streptococcus pneumoniae is a major cause of meningitis
and pneumonia. Although at least 91 serotypes have been identiﬁed,
only a limited number of them are more frequently detected in disease.
The effective spread of the given serotypes represented by a few clones
has not been fully elucidated yet and several virulence factors have
been suggested to inﬂuence the success of particular clones. One of the
identiﬁed virulence factors is adhesive pilus that can be organized into
3 clade variants. The aim of the study was to determine the prevalence
of the pilus and clade type among the pilus positive isolates from a
collection of invasive strains of serotypes 4, 6B, 9V, 14, and 19F.
Methods: A total of 256 invasive isolates of serotypes 4 (65), 6B (34),
14(57), 9V (48), and 19F (52) recovered from 1996 to 2003 were studied.
Serotyping was performed by the Quellung reaction and all isolates
were analyzed by MLST. MICs of antibiotics were determined by the
broth microdilution method. The presence of pilus was detected by PCR
targeting the sortase B, C, and D genes which are structural parts of the
pilus. Conﬁrmation of pilus absence was done by ampliﬁcation of the
entire pilus islet. For the pilus positive strains, the clade type (I, II, and
III) was determined using PCR.
Results: The pilus was found in all serotypes, although the proportion
of pilus positive isolates varied between serotypes from 1.7% in serotype
14 to 77% in serotype 9V. Out of 88 pilus positive isolates, 26.1% were
penicillin non-susceptible. The STs were homogenous for the presence of
the pilus and clade type. The pilus was found in all isolates of serotypes
9V, 6B, and 4 representing Spain9V-3, Poland6B-20, and Sweden4−38
clones, respectively. Of the piliated isolates, 67% were classiﬁed into
clade type I, 19.3% into clade type II, and 13.6% into clade type III.
Clade I was found in serotypes 4, 14, 9V, and 19F; clade II in serotype
6B; and clade III in serotypes 4 and 6B. The prevalence of serotype 4
among the invasive isolates increased from 1.7% in 1996 to 11.1% in
2003 and an upward trend from 3.3% in 1996 to 5.3% in 2003 was also
observed in serotype 9V.
Conclusions: The expresion of the pilus could constitute a selective
advantage in competition with other serotypes and could contribute to
the increase of serotype 4 among the invasive pneumococcal isolates.
Supported by grant IGA 9643−4 (CZ) and grant A/CZ0046/2/0007 from
Iceland, Liechtenstein and Norway (EEA).
P1696 Association of group A streptococcal emm types with
virulence traits and macrolide resistance
G. Blandino °, S. Puglisi, M. Minutolo, R. Musumeci, A. Speciale
(Catania, Monza, IT)
Objectives: Aim of this study was to determine M (emm) subtypes of
Streptococcus pyogenes strains isolated from asymptomatic carriers and
children with pharyngitis, and to investigate the correlation between emm
types, the presence of ﬁbronectin binding protein genes, and phenotypes
of antibiotic resistance.
Methods: We detected and characterized emm subtypes in 59 strains
of S. pyogenes isolated in Sicily (Italy) from asymptomatic carriers
(29) and children with pharyngitis (30) previously characterized for
the presence of prtF1 and pfbpI genes and erythromycin resistance
phenotypes (Musumeci et al., Clin. Infect. Dis. 2003; 37:173–179).
emm gene speciﬁc PCR and emm sequence typing were performed
as described by Beall et al. (J. Med. Microbiol. 1998; 47:893–898).
In addition, to conﬁrm the relationship between emm pattern type and
SOF (serum opacity factor), sof gene was detected and sequenced basing
upon PCR and sequence analysis of a variable length 450–650-base PCR
fragment.
Results: The most frequent emm subtypes detected in isolates from
pharyngitis were: emm1.0 (30.0%), emm89.0 (23.3%), emm2.0 (13.3%)
and emm28.0 (10.0%). One new emm12 subtype (emm12.40) was
detected. In isolates from asymptomatic carriers (enrolled from different
classes of many primary schools) the most frequent emm subtypes
were: emm12.0 (51.7%) and emm94.0 (10.3%); while there were no
emm1.0 strains. The most signiﬁcant differences between the two groups
concerned the presence of the two more common emm subtypes, 1.0
(P = 0.001) and 12.0 (P< 0.001). The prtF1 and prtF2 genes were
simultaneously present in 14 of 16 (87.5%) emm12.0 and 8 of 9 (88.9%)
emm89.0 isolates. Correlation with phenotypes of resistance showed that
9 of 11 (81.0%) M phenotype strains belonged to emm12.0 subtype and
all 3 iMLS-A phenotype strains to emm89.0.
Conclusion: This study suggests that S. pyogenes emm12 and emm89
isolates, mainly positive for prtF1 and prtF2 genes, are more virulent than
the others, and that emm12 isolates may have a role in the asymptomatic
carrier status.
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P1697 Distribution of PFGE types of group B streptococci
originating from Polish pregnant women in relation to
capsular polysaccharides and surface protein genes
M. Brzychczy-Wloch °, T. Gosiewski, M. Bodaszewska, W. Pabian,
D. Ochonska, P.B. Heczko (Cracow, PL)
Objectives: Capsular serotyping, based on capsular polysaccharides
(CPS), is the classic method for typing Streptococcus agalactiae.
Group B streptocopcci (GBS) can also be classiﬁed on the basis of
surface protein antigens. Genotyping methods, like pulsed ﬁeld gel
electrophoresis (PFGE) are used to characterize and distinguish speciﬁc
clones among GBS isolates. The study tried to ﬁnd out the correlation
between PFGE pulsotypes and serotypes or surface protein genes in GBS
isolates.
Methods: Research was carried out from August 2007 till July
2009. 1176 women in the 3rd trimester of pregnancy from Southern
Poland region underwent GBS colonization screening according to CDC
recommendations. A multiplex PCR method was used to determine
the genes coding particular capsular polysaccharides (CPS) and to
detect the surface protein genes bca, rib, e, alp 2, alp 3 and alp4.
Isolates were genotyped by pulsed ﬁeld gel electrophoresis (PFGE) after
macrorestriction with SmaI enzymes. The PFGE banding patterns were
analyzed with the Jaccard coefﬁcient and UPGMA by using Molecular
Analyst (Applied Maths) software. Into detailed genetic analysis we
chose to include 100 S. agalactiae isolates originating from vaginal and
rectal carriage, representing serotypes: Ia (n = 25), Ib (n = 7), II (n = 14),
III (n = 29), IV (n = 7) and V (n = 18).
Results: The PFGE method showed high genetic diversity between
S. agalactiae strains originating from pregnant women. In 100 strains
a total of 63 restriction proﬁles were identiﬁed using PFGE. At an 80
per cent similarity level, 56 different PFGE patterns were established.
We showed the exact correlation between strains belonging to speciﬁc
pulsotypes and serotypes. Within each serotype, PFGE patterns differed
considerably, the largest degree of heterogeneity was observed among
type Ib, II and III strains. Serotype Ia, IV and especially V were more
homogeneous. Strains with identical macrorestriction proﬁles belonged
to the same CPS type, but varied with regard to serosubtypes, based on
surface protein genes.
Conclusion: For studies of epidemiology and pathogenesis of GBS, it is
important to identify as many phenotypic or molecular markers as pos-
sible to increase the discriminatory power of typing systems. Serotypes
distribution of Streptococcus agalactiae varies with geographical region,
ethnic origin and the virulence of clinical isolates. This is the ﬁrst study
dealing with the molecular characterization of GBS isolates in Poland.
P1698 Molecular typing of Streptococcus agalactiae by multiple
locus variable-number of tandem-repeat analysis
E. Haguenoer, G. Baty, C. Pourcel, M.F. Lartigue, A.S. Domelier,
A. Rosenau, R. Quentin, L. Mereghetti, P. Lanotte ° (Tours, Orsay, FR)
Background: Multilocus Sequence Typing (MLST) is presently the
reference method for genotyping Streptococcus agalactiae strains,
the leading infectious cause of morbidity in newborns which also
causes substantial diseases in immunocompromised children and adults.
Multiple Locus Variable Number of Tandem repeats (VNTR) Analysis
(MLVA), a PCR method based on the study of tandem repeats
polymorphism, could represent an alternative to type bacterial strains.
Objectives: The purpose of this study was to describe a MLVA scheme
for the genotyping of S. agalactiae and to compare its performances
with those of MLST.
Methods: A collection of 186 strains isolated from human and cattle
was studied. Among the 152 human strains, 71 were from vaginal
carriage, 59 were from cerebral-spinal ﬂuid, 17 were from endocarditis
(bacteremia) and 5 were from gastric ﬂuid of newborns. The 35 bovine
strains were linked to clinical evidence of mastitis. Seven VNTR loci
were selected for their polymorphism and used to genotype the bacterial
population. The MLVA proﬁle is composed of a string of allele numbers,
corresponding to the number of repeats at each VNTR Locus. The rela-
tionships between the strains were evaluated with the UPGMA algorithm
by comparison of allelic proﬁles. The results were compared to those
obtained by MLST based on the analysis of seven housekeeping genes.
Results: The results showed a good concordance between the two
techniques and demonstrated the higher discriminatory power of MLVA
as compared to MLST. One hundred and twelve genotypes were
discriminated with the panel of 7 VNTR loci (diversity index: 0.96
versus 0.88 for MLST). The analysis with the UPGMA algorithm showed
a clonal distribution of the population similar to the one obtained by
MLST, except for the strains of clonal complex CC23 divided into two
groups according to the serotype and for the strains of clonal complex
CC17 divided into two groups according to the human or bovine origin.
Conclusion: The MLVA scheme proposed here is a rapid, cheap and
easy to perform genotyping method with exchangeable results between
laboratories, applicable to epidemiologic surveillance of S. agalactiae
and to outbreak situations.
P1699 Phenotypic and molecular characterization of Streptococcus
pyogenes isolated from scarlet fever patients
C. Silva-Costa °, M. Ramirez, J. Melo-Cristino (Lisbon, PT)
Objectives: Streptococcus pyogenes (GAS) is a human pathogen
responsible for a number of disease presentations, including scarlet
fever. The aims of this study were the phenotypic and molecular
characterization of 101 GAS isolated from cases of scarlet fever collected
in 2002–2008 in a teaching hospital in Lisbon.
Methods: Antimicrobial susceptibility testing and macrolide resistance
phenotype were determined by disk diffusion and macrolide resistance
genotypes were determined by PCR. The exotoxin proﬁle was
determined by PCR for the detection of genes speA, speB, speC,
speF, speH, and ssa. A combination of T typing, emm typing, pulsed-
ﬁeld gel electrophoresis (PFGE) was used to deﬁne clones. Bacitracin
susceptibility was determined for all the isolates by disk diffusion.
Results: during the seven years of the study, the overall rate of
erythromycin resistance was 9.9% (n = 10) and all the macrolide resistant
isolates presented the M-phenotype carrying the mef(A) gene. All the
101 isolates included in this study were typeable by PFGE and seven
major clones accounted for 81% of the isolates. With minor exceptions,
each clone was associated with a T type, emm type and an exotoxin
proﬁle. All the isolates carried the chromosomal speB and speF genes,
whereas the phage-encoded speA, speC, speF, and ssa were variable. The
genes speA and speC, often associated with scarlet fever, were present
together in 7.9% (n = 8), and alone in 28.7% (n = 29) and 54.5% (n = 55)
of the isolates, respectively.
Conclusion: There was a large diversity among GAS strains isolated
from scarlet fever paients, although seven clones accounted for the
majority of the isolates. Only 8.9% of the isolates lacked the two scarlet
fever associated toxins SpeA and SpeC, although only a fraction carried
both.
P1700 Molecular typing of methicillin-resistant Staphylococcus
aureus in animal origin foods
Z. Salehipour, M.M. Soltan Dallal, S. Eshraghi, T. Zahraei Salehi,
A. Rahimi Forushani, T.P. Abedi Mohtasab °, J. Fallah Mehrabadi
(Tehran, IR)
Objective: Methicillin-resistant staphylococcus aureus (MRSA) strains
are common pathogens in serious infections and nosocomial outbreaks.
These strains might be transmitted to humans via consumption of
animal origin foods. Aim of this study is prevalence and molecular
characterization of these strains in different foods.
Methods: 913 food samples of animal origin were collected from July
2006 to November 2007 and cultured on Baird Parker agar. All suspected
colonies were characterized by biochemical tests. presence of mecA
gene was conﬁrmed by PCR method. MRSA isolates were evaluated by
the disk diffusion method for different antimicrobial agents along with
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minimum inhibitory concentration (MIC) determination of oxacillin.
Presence of tst gene in MRSA isolates was assessed via PCR and reverse
passive latex agglutination test and followed by biotyping and spa typing.
Results: Among 93 S. aureus isolates, ﬁve (5.37%) harbored the mecA
gene. 60% of the ﬁve MRSA isolates were resistant to tetracycline,
while 40% were resistant to Ceftriaxone. Four out of ﬁve MRSA isolates
(80%) produced SEs and TSST1. Three MRSA isolates belonged to
human biotype, whereas the remaining two isolates belonged to non-
host-speciﬁc (NHS) biotype. Ampliﬁcation of spa gene showed three
different fragments. Applying HindIII and HaeII, 4 and 3 distinct RFLP
patterns were yielded, respectively.
Discussion: In present study, prevalence of MRSA strains in foods is
worrying relatively. Bacterial strain typing for MRSA can be considered
a tool of importance to investigate suspected outbreaks together with
their control and surveillance, and PCR-RFLP is a reliable method for
typing.
P1701 Probing Staphylococcus aureus diversity through a novel
ﬂuorescent ampliﬁed fragment length polymorphism assay
D. Desai °, M.J. Ellington, C. Arnold, M. Desai (London, UK)
Objectives: FAFLP is a robust, high-resolution, PCR-based methodology
used for the analysis of genetic diversity within bacterial genomes,
without prior knowledge of genome sequence. It combines the
principle of restriction fragment length polymorphism with selective
PCR ampliﬁcation of subsets of fragments generated by restriction
endonucleases. Here we sought to evaluate and establish a novel
ﬂuorescent ampliﬁed fragment length polymorphism (FAFLP) assay
to assess the genetic diversity within Staphylococcus aureus including
major methicillin resistant clones.
Methods: A total of 53 S. aureus isolates, from 11 major multilocus
sequence types, including 15 isolates of the Epidemic MRSA-15 clone
were used for comparative analysis using FAFLP. Genomic DNA
was restricted using the endonuclease combination Csp6I and BglII.
A combination of four one-base selective ﬂuorescently-labelled BglII
primers (selective base +A, T, G & C) with a non-selective Csp6I primer
(+0) were evaluated for the development of a multiplex assay. FAFLP
products were analysed using the ABI 3730 sequencer and GeneMapper
software (v.4.0) for data analysis. Clusters from the generated
proﬁles were compared with staphylococcal cassette chromosome mec
(SCCmec) and multilocus sequence typing (MLST) data.
Results: FAFLP generated 240 to 290 ampliﬁed fragments ranging in
size from 60–600bp: these fragments constituted an FAFLP proﬁle.
Thirty-ﬁve unique proﬁles were exhibited amongst the 53 isolates. The
multiplex assay differentiated EMRSA-15 (ST22) from EMRSA-1, 3 and
16 (ST36) isolates as well as isolates that were ST30 and ST5. Genetic
heterogeneity within the EMRSA-15’s was also revealed. Comparison of
FAFLP data with SCCmec data showed that FAFLP data differentiated
isolates harbouring type I and II as well as IV; it also discriminated
between isolates harbouring different sub-types of SCCmecIV.
Conclusions: The established multiplex FAFLP assay increased the
discriminatory power by approximately four-fold compared to a
singleplex, as the number of data points spanning the genome increased.
This approach provides a cost-effective and high-throughput method
applicable to outbreak analysis through to global epidemiological
studies and has the potential for use in hospital infection control. The
identiﬁcation of differential fragments between different lineages of
MRSA will be incorporated into a PCR-based diagnostic assay.
P1702 Development of an automated method for high-throughput
multilocus sequence typing of Staphylococcus aureus
T.M. Pryce °, G.W. Coombs, L. Lim, F. O’Brien, L.K. Smith (Perth, AU)
Objectives: To develop and implement automated and high-throughput
DNA extraction and PCR ampliﬁcation methods for multilocus sequence
typing (MLST) of Staphylococcus aureus using existing laboratory
automation.
Methods: A protocol using the MagNA Pure robotic instrument was
developed for all pre-PCR steps. These steps include genomic DNA
extraction from S. aureus and pipetting prepared DNA templates into
the separate master mixes representing the seven MLST housekeeping
genes (alleles). Following DNA extraction, PCR ampliﬁcation of all
seven alleles was performed using BIORAD MyCycler. Subsequent PCR
products were puriﬁed with a magnetic bead system (Ampure) using the
Perkin Elmer EP3 robotic instrument. Sequencing reactions (forward and
reverse) and sequencing clean-up steps were performed using the Perkin
Elmer Multi-Probe II and the Perkin Elmer EP3 instruments respectively.
All sequencing reactions were analysed by capillary electrophoresis
using the ABI 3730XL Genetic Analyser. Twenty control strains of
S. aureus of known sequence type were used as controls to develop
the automated test method.
Results: The MagNA Pure robotic instrument produced consistent DNA
quality and high yield from S. aureus that was suitable for PCR. The
mean DNA concentration was 17.8 ng/mL (SD 2.5 ng/mL). The OD
260/280 ratio was 1.805 (SD 0.04). The PCR sensitivity for six of the
seven housekeeping gene alleles was approximately 5 pg/ul. A 10-fold
decrease in PCR sensitivity was observed for the tpi housekeeping allele
(approximately 50 pg/uL) and therefore the primer concentration for
this allele was increased to ensure adequate and comparable sequencing
signal strengths to the other six housekeeping gene alleles. The PCR
ampliﬁcation produced consistent PCR product ampliﬁcation. Sequence
analysis of S. aureus GPBTU ST22 control from 35 consecutive MLST
runs demonstrated high reproducibility and high sequence quality.
Conclusions: The assay was highly reproducible and produced consistent
and expected results for all controls tested. The method has minimal
pipetting steps and is less labour-intensive than other manual molecular
methods and has improved sequence quality and streamlined workﬂow.
This automated method has now been used for more than 300 clinical iso-
lates identifying 56 S. aureus sequence types. The method is well-suited
to reference laboratories performing high-throughput S. aureus MLST.
P1703 Comparison of two multi-locus variable-number tandem
repeat analysis methods for genotyping highly clonal
methicillin-resistant Staphylococcus aureus in Scotland
A. Holmes °, W. Hannant, K. Girvan, G. Edwards, K. Templeton
(Edinburgh, Glasgow, UK)
Objectives: The aim of this study was to investigate the usefulness of two
different multi-locus variable number tandem repeat analysis (MLVA)
methods for subtyping the major Scottish and UK lineages of methicillin-
resistant Staphylococcus aureus (MRSA), EMRSA-15 (ST22) and
EMRSA-16 (ST36), which account for 70% and 20% of isolates referred
to the Scottish MRSA Reference Laboratory respectively.
Method: A gel-based MLVA method, MLVA-gel (Sabat et al. JCM
41:1801–1804, 2003), based on seven loci, was compared to an
automated capillary electrophoresis-based method, MLVA-frag (Schouls
et al. PLoS ONE 4(4):e5082, 2009), based on eight loci; the methods
shared two common loci, sspa and spa. A total of 60 MRSA strains that
had previously been analysed by pulsed-ﬁeld gel electrophoresis (PFGE;
21 EMRSA-15, 16 EMRSA-16, and 23 MRSA strains with diverse
PFGE patterns) were investigated. In addition, 30 EMRSA-15 strains
with identical PFGE patterns (PF15 h) from two geographically linked
but epidemiologically distinct outbreaks and several sporadic cases were
analysed.
Results: All isolates were typeable by both MLVA methods. The MLVA-
gel method was more discriminatory resolving 16 EMRSA-15 and 10
EMRSA-16 types, compared with 10 EMRSA-15 and 4 EMRSA-16
types using the MLVA-frag method; both methods were equally able to
distinguish between the 23 diverse PFGE types. Analysis of the PF15 h
outbreak and sporadic isolates revealed the MLVA-gel and MLVA-frag
methods were able to resolve them into 7 and 6 subtypes, respectively.
Importantly, both assays were able to conﬁrm that the two geographically
related outbreaks were not genetically linked.
Conclusion: The MLVA-gel method was better able to distinguish
closely-related variants of EMRSA-15 and EMRSA-16, most likely
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a reﬂection of the faster molecular clock of some of the loci used.
Importantly, both methods were able to subtype strains indistinguishable
by PFGE, suggesting these assays would be useful epidemiological tools
for identifying and tracking speciﬁc subtypes of highly clonal MRSA
lineages in Scotland.
P1704 Genetic homogeneity within the methicillin-resistant
Staphylococcus aureus lineage ST398
T. Bosch °, X.W. Huijsdens, M.E. Heck, A.J. de Neeling, H. Grundmann,
L.M. Schouls (Bilthoven, NL)
Objective: In 2003, the ﬁrst isolates of livestock-associated methicillin
resistant Staphylococcus aureus (LA-MRSA) belonging to sequence type
(ST) 398 were reported. Since then, the LA-MRSA ST398 lineage has
frequently been isolated in the Netherlands and other countries. In 2008,
37% of all MRSA isolates analyzed in the Dutch national surveillance
program belonged to this lineage. In this study, the genetic diversity of
ST398 lineage isolates was investigated using three molecular typing
tools.
Methods: All MRSA (n = 5510) submitted from January 2008 till
October 2009 for the national surveillance were characterized using
staphylococcal protein A (spa) typing and multiple-locus variable
number of tandem repeat analysis (MLVA). Many of the isolates
belonged to the MLVA complex (MC) 398, representing the ST398
lineage. Pulsed-ﬁeld gel electrophoresis (PFGE) using restriction enzyme
Cfr9I was performed on a random selection (n = 93) of the MC398
isolates.
Results: Spa-typing of 2257 MC398 isolates revealed 48 different spa-
types. Spa-types t011 (n = 1315) and t108 (n = 578) were predominant,
accounting for 84% of all isolates. MLVA-typing yielded 42 different
MLVA types (MTs) with MT398 (n = 1267) and MT572 (n = 559) as the
predominant MTs which made up 81% of all MC398 isolates. PFGE
typing of 93 MC398 isolates resulted in 48 distinct patterns which could
be sub-divided in 11 PFGE clusters (clusters A-K, cut off value 80%).
However, isolates from cluster A (n = 16) and E (n = 49) accounted for
>70% of all 93 isolates. No match was found when comparing the
PFGE proﬁles of the MC398 isolates with the national MRSA PFGE
database containing proﬁles from over 4000 isolates. The Simpson
diversity indices for spa, MLVA and PFGE were 59.3%, 62.0%, and
95.5%, respectively.
Conclusions: MC398 isolates in the Netherlands represent a genotypic
homogeneous group comprising two genogroups that make up more than
80% of all isolates. PFGE using restriction enzyme Cfr9I enabled us to
further differentiate MC398 and yielded proﬁles that were distinct from
those of all other MRSA. However, the division into 2 predominant
groups was retained. The results indicate that LA-MRSA MC398 is
a distinct clonal MRSA lineage. Whole genome sequencing will be
required to elucidate the origin and evolution of these isolates.
P1705 SCCmec type VII (former VT) found in Danish
ST8-t024-PVLneg CA-MRSA
K. Boye °, S. Pulis, L. Hansen, S. Sørensen, H. Westh (Hvidovre,
Copenhagen, DK)
Objective: In Copenhagen, Denmark, the second-most common
SCCmec cassette found in MRSA is type V based on a multiplex
PCR targeting ccrC and the IS431 next to the truncated mecR that
is characteristic of type V (Boye et al, 2007). One of the type V
cassettes from a MRSA-ST8 was sequenced as part of a full-genome
sequencing project. Comparison with GenBank sequences revealed that
the cassette was most homologue to the SCCmec type VII (former VT)
found in MRSA-ST59 from Taiwan (Takano et al, 2008). The cassette
was annotated and described.
Methods: The MRSA-isolate M253 was recovered in 2005 from a 90-
year old woman living in a nursing home in Copenhagen. The isolate was
characterized by PCR for mecA, spa, PVL, AMCE and by spa-typing
and SCCmec typing. Whole genome sequencing was performed on a
GS FLX (454 Life Sciences, a Roche company, CT, USA). Reads were
aligned and assembled using the Newbler assembler software provided
with the GS FLX instrument. The contigs were compared to GenBank
sequences using BLAST and the detailed alignment optimized by visual
inspection.
Results: The SCCmec cassette of M253 was 41,500 bp in length and
carried two ccrC-genes, ccrC2 and ccrC8, as has been described in
SCCmec type VII from Taiwan (Higuchi et al, 2008). It contained
the IS431 next to the truncated mecR as SCCmec type V does. The
Taiwan SCCmec VII contained a Sau-like IS not found in the Danish
cassette. While the Taiwan MRSA was isolated from children, belonged
to sequence type ST59 and carried the PVL-genes, the Danish type
VII came from an old woman, belonged to ST8 and was PVL-negative.
SCCmec VII is misclassiﬁed as SSCmec V in our multiplex PCR (Boye
et al, 2007).
Discussion: CC8-MRSA t024 is very common in Denmark especially in
nursing homes. It is, however, an interesting question where the SCCmec
VII originated. All other MRSA found in the patients nursing home have
been t024 SCCmec IVa. This patient has been screened yearly since 2005
and later isolates have been t024 SCCmec IVa. Both MRSA are ST8-
t024-PVLneg. Based on the full genome sequence the two isolates are
unrelated and the patient must have had two different MRSAs.
Boye et al (2007): Clin Microbiol Infect 13: 725–727. Takano et al
(2008): Antimicrob Agents Chemother 52: 837–845.
P1706 Laboratory identiﬁcation of healthcare-associated and
community-associated MRSA strains using SCCmec Evigene
J. Lamson, B. Raaby, J. Villadsen, D. Houg, A. Rasmussen °, H. Stender
(Roskilde, Kogens Lyngby, Vedbaek, DK; Woburn, US)
Objective: Healthcare-associated methicillin-resistant Staphylococcus
aureus (HA-MRSA) and community-associated-MRSA (CA-MRSA)
have traditionally been identiﬁed by the onset of the infection but today
HA-MRSA strains are emerging outside health-care settings and CA-
MRSA strains are emerging within hospitals. HA-MRSA strains are
linked to increased resistance to a wide range of antibiotics, including
higher vancomycin MIC, whereas CA-MRSA strains remains susceptible
to non-b-lactams but linked with invasive necrotizing infections. There
is therefore a need for diagnostic tools to differentiate HA-MRSA and
CA-MRSA strains to ensure optimal patient therapy and management.
In this study we used SCCmec EVIGENE, a signal-ampliﬁed, sandwich
hybridization format, with probe sets for each of the ﬁve SCCmec
(staphylococcal cassette chromosome mec) types for the laboratory
identiﬁcation of HA-MRSA strains by the presence of SCCmec types
I, II or III and identiﬁcation of CA-MRSA strains by the presence of
SCCmec types IV or V.
Methods: The ﬁve SCCmec type speciﬁc probe sets used in the
EVIGENE assay were veriﬁed on PCR SCCmec typed strains (Oliviera
and de Lencastre, 2002) determined by Statens Serum Institut and a
SCCmec type V strain provided by Ito et al. The SCCmec EVIGENE
was tested on 175 clinical MRSA isolates obtained from Europe (152),
Middle East (2), North America (8) and South America (13) for
the presence of each of the ﬁve SCCmec types. In addition, mecA
EVIGENE® was performed to conﬁrm the presence of the mecA gene.
Results: All (175/175) were mecA positive. 50.9% (89/175) were
identiﬁed as HA-MRSA strains by the presence of SCCmec type I (40),
II (27) or III (22) and 44.0% (77/175) were identiﬁed as CA-MRSA
strains by the presence of SCCmec type IV (61) or V (16). 5.1% (9/175)
were unidentiﬁed due to detection of multiple SCCmec types (9).
Conclusions: Unequivocal identiﬁcation as HA-MRSA or CA-MRSA
was obtained for 94.9% of the MRSA strains. SCCmec EVIGENE with
probe sets for each of the ﬁve SCCmec types therefore offers laboratory
identiﬁcation to supplement the clinical diagnosis of HA-MRSA and
CA-MRSA infections.
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P1707 In vivo evolution of a single ST247-MRSA-I clone recovered
over 13 years from a cystic ﬁbrosis patient: variation in the
spa-type and immunogenicity
R. del Campo °, V. Go´mez-Pin˜a, M. Pe´rez-Va´zquez, A. Vindel,
A. Ferna´ndez-Olmos, M. Garcı´a-Castillo, A. Garcı´a-Sa´nchez, L. Ma´iz,
R. Canto´n, E. Lo´pez-Collazo, A. Lamas (Madrid, ES)
Objective: Methicillin-resistant Staphylococcus aureus (MRSA) is a
signiﬁcant cause of chronic pulmonary infection in Cystic Fibrosis (CF)
patients. The aim of this study was to analyze the in vivo evolution of
MRSA in a single CF-patient, analyzing the microbiological aspects as
well as the inmunogenicity particularities.
Material and Methods: MRSA isolates were obtained from single
CF-patient during 13 years (1996–2009). Antibiotics susceptibility was
performed by agar dilution method and PFGE-Sma I was applied to
analyze genetic relatedness among the isolates. SCCmec, spa, pvl, and
MLST typing methods were carried out by speciﬁc PCR reactions.
Immunogenicity ability was determined in parallel in a CF-MRSA isolate
and in the HARMONY ST245-MRSA reference strain with different
settings: planktonic or bioﬁlm growth, and presence of subinhibitory
ciproﬂoxacin concentrations. Sonic crude extract of both strains were
added to human monocytes, incubating for 3, and 6 hours. TREM-1,
TNF-a, IL-6, IL-12 and IL-10 expression levels were analyzed by real-
time quantitative PCR.
Results: A total of 30 ST247-MRSA-I isolates with related PFGE
patterns were ﬁnally selected. Most of them presented a multirresistant
phenotype including aminoglycosides, quinolones, and macrolides.
During the ﬁrst eight years, t051 spa type was the predominant one,
whereas six different spa types were detected (t051, t052, t303, t2849,
t2482 and t5125) along the time, ﬁve of them belonging to the same spa-
clonal complex (spa-CC051). In the last isolates we identify mainly the
spa type t303. All isolates were negative for pvl gene. A particular mode
of growth was identiﬁed only able to growth around tetracycline and
erythromycin disks. When human circulating monocytes were exposed
in vitro to the different strains and settings, the inﬂammatory response
was lower in the CF-MRSA isolate comparing with the HARMONY
strain, and also in the bioﬁlm formation comparing with the planktonic
one. However, the presence of ciproﬂoxacin exerted no effect on the
inﬂammatory response.
Conclusion: A single ST247-SCCmecI-MRSA clone was detected
during 13 years in the sputum of a CF-patient, presenting six different
spa-types and a singular mode of growth. The bacterial adaptations in
these patients may shift the response of the monocytes from the classical
response to an alternative or attenuated response. This could be reﬂected
in the altered immune response is observed in these patients.
P1708 Comparison of the DiversiLab system with spa typing and
pulsed-ﬁeld gel electrophoresis for the characterization of
methicillin-resistant Staphylococcus aureus isolates
D. Goldenberger, E. Schultheiss, A.F. Widmer, R. Frei ° (Basel, CH)
Objectives: Evaluation of the performance of the DiversiLab system
(DL), a commercially available repetitive sequence-based PCR, com-
pared to pulsed-ﬁeld gel electrophoresis (PFGE) and spa typing. Typing
methods were applied to a well-deﬁned set of methicillin-resistant
Staphylococcus aureus (MRSA) isolates from the University Hospital
Basel evaluating discriminatory power and feasibility in a diagnostic
routine setting.
Methods: By use of the DL system, we analyzed a total of 109
MRSA isolates which had been previously characterized by PFGE,
spa typing, and spa clonal complex analysis. To get signiﬁcant results,
only non-repetitive isolates differing by at least one band in the PFGE
pattern were selected. The DL method was performed according to the
manufacturer’s guidelines including DNA extraction, PCR ampliﬁcation
and capillary electrophoresis using micro-ﬂuidic chips. The deﬁnition
for DL clustering comprised >95% similarity or a ﬁngerprint pattern
with one band difference. The results of DL, PFGE, spa typing and
spa clonal complex analysis were compared and analyzed using the DL
on-line software tool as well as the GelCompar software.
Results: DL typing separated the 109 MRSA isolates in 12 distinct
clusters and 6 singleton patterns. The 5 largest DL clusters represented 91
(83%) strains. spa typing differentiated the collection into 49 spa types.
Clustering analysis into spa clonal complexes resulted in 3 clusters: spa-
CC 067/548 including spa types t001, t002, t041, t067, t548 (n = 29);
spa-CC 008 including t008, t024, t051, t064, t121, t400 (n = 28); and
spa-CC 012 including t012, t018, t030, t037, t074 (n = 9). spa-CC 008
and spa-CC012 share 2 DL clusters, while spa-CC 067/548 strains
mainly clustered in 2 distinct DL patterns. DL typing grouped the strains
similarly as spa typing and spa clonal complex analysis, but PFGE had
the highest resolution.
Conclusion: The DL method is rapid and easy to perform in contrast to
spa typing and PFGE. However, the DNA extraction step is rather labor-
intensive and might be replaced by a shorter, preferentially automated
technique. DL typing shows good correlation with spa typing and
spa clonal clustering, while PFGE remains the most discriminatory
technique.
P1709 The impact of strain typing method on assessing the
relationship of paired nares and wound isolates of
methicillin-resistant Staphylococcus aureus
J. Clarridge °, A. Harrington, M. Roberts, K. Maquelin (Seattle, US;
Rotterdam, NL)
Objectives: Although the anterior nares is the site of choice for
the Veterans Administration methicillin-resistant Staphylococcus aureus
(MRSA) surveillance program, a close correlation between nares
colonization and wound infections has not been established. The purpose
of this study is two-fold: to determine the relatedness of paired wound
and nares specimens from 40 patients by four different methods of strain
typing and to compare the methods.
Methods: MRSA from wounds and nares were identiﬁed by routine
methods. Specimens categorized as wound included abscess aspirates,
joint ﬂuids, pleural ﬂuids and superﬁcial and deep wound swabs. Nares
isolates were paired with wound isolates if the nares isolate was obtained
within 48 hours of the wound isolate. Eighty strains from 40 patients
were studied. Isolates were typed by rep-PCR using the DiversiLab
System (DL) (bioMe´rieux, Durham, NC), pulsed-ﬁeld gel electrophoresis
and the SpectraCell Raman typing (SCR) system (River Diagnostics).
Additionally an antibiotic proﬁle on each strain was obtained, thus four
major measures were available for strain typing.
Results: PFGE analysis divided the 80 isolates into 5, SCR into 12
groups and DL into 9 different groups. Overall by combining the
four measures the 80 strains could be divided into 19 unique groups.
Comparing only the pairs of wound and nasal MRSA strains, 27 (67.5%)
were grouped together by all the methods used, indicating that the
isolates from both sites were the same. Four (10%) pairs of strains
differed by all methods and represent different strains at the two different
sites. The remaining 9 pairs (23%) differed by only one method: the
outliers were: SCR, 7; DL, 1; antibiotic proﬁle, 1.
Conclusions: In this study the four typing methods agreed about
the pairing for 77.5% of the MRSA isolate pairs: 67.5% were
indistinguishable and 10% differed. The remaining 22.5% of the pairs
were indistinguishable with 3 of 4 typing methods. However, a problem
in establishing an exact or causal linkage between the stains from
individual patients and not just an epidemiological association is that
by PFGE and DL about 70% of strains fall into only 2 large groups. It
is hoped that a more discriminatory method such as SCR if robust might
ﬁll such a role.
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P1710 Comparison of high-resolution melting curves analysis of
the short-sequence repeat region of the protein A, spa
sequencing and pulsed-ﬁeld gel electrophoresis for the
investigation of an outbreak due to MRSA
J.I. Stuart °, R.C. Reyes, A. Stuart, M. McGavin, P. Ainsworth,
M.A. John, Z. Hussain (London/ON, CA)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is a
leading cause of nosocomial infection world-wide. In an outbreak
situation, rapid identiﬁcation and typing is an important epidemiological
tool in determining clonal relatedness. Several molecular techniques are
available for differentiating S. aureus but no method is superior under all
conditions. Pulse ﬁeld gel electrophoresis (PFGE) has been widely used
and is the gold standard. More recently sequencing of the polymorphic X
or short sequence repeat region of the protein a gene (spa) has been used
as an alternative to current techniques. We here describe the comparison
of spa sequencing, PFGE and a method using high resolution melting
curve analysis (HRM) of the polymorphic X region in the investigation
of an outbreak due to MRSA.
Methods: Nineteen outbreak-related MRSA strains were typed by spa
sequencing, PFGE and HRM. The DNA sequences of the spa repeat
region in both directions were imported as ABI ﬁles and analyzed
by automated spa typing (tools.egenomics.com), using Kreiswirth
nomenclature. PFGE was performed using standard techniques. MRSA
types (CMRSA) were deﬁned using Canadian MRSA PFGE typing
guidelines. Amplicons of the spa region X were analyzed by HRM
utilizing a difference graph format. S. aureus ATTC 43300 was included
with each for standardization of curves.
Results: Strains from seventeen patients were identical by all three
methods, corresponding to spa type 2 and CMRSA 2 PFGE type. One
strain was closely related to the 17 strains by spa typing. It was spa-type
407. The only difference is the 6th cassette, which is G1 in spa-type 407
and D1 in spa-type 2. The D1 and G1 repeats differ by 2 nucleotides.
PGFE and HRM failed to differentiate this strain from outbreak strains.
One strains classiﬁed as CMRSA 9 and Spa-type 1 was unrelated to
other strains, and was also deemed as unrelated by HRM analysis.
Conclusions: There was an excellent correlation clustering of strains by
HRM compared to PFGE. The spa sequencing was most discriminatory,
because it identiﬁed a strain, which was different though closely
related to outbreak-causing strains. PFGE and HRM failed to discern
this difference. HRM potentially represents a quick and inexpensive
screening tool to rule out similarity of strains.
P1711 New typing assay based on PCR ampliﬁcation of IS257-ileS2
junctions for tracking high-level mupirocin resistance
dissemination in staphylococci
E. Pe´rez Roth °, J. Alcoba Florez, B. Rivero Pe´rez, S. Me´ndez A´lvarez
(Santa Cruz de Tenerife, ES)
Objectives: Transfer of ileS2-carrying plasmids plays a critical role in
the dispersion of mupirocin resistance. Here we have investigated the
presence, location, and orientation of insertion sequence IS257 ﬂanking
the ileS2 gene and we have evaluated the utility of PCR ampliﬁcation
of IS257-ileS2 junctions for tracking high-level mupirocin resistance.
Methods: Forty-eight MRSA clinical isolates each carrying one of
nine well characterized ileS2-carrying plasmids encoding high-level
mupirocin resistance belonging to four structural groups was included.
Speciﬁc primers were designed and used for the ampliﬁcation of the
upstream and downstream IS257-ileS2 junctions. IS257-ileS2 junctions
conﬁrmation was carried out by Southern blotting and hybridization with
two probes speciﬁc for the ileS2 and an IS257 internal probe. Filter
mating and curing experiments, as well as hybridization with speciﬁc
DNA probes were performed to investigate the antibiotic resistance gene
content of the plasmids.
Results: Using the same ampliﬁcation conditions four single PCRs
were performed for each S. aureus clinical isolate harbouring an ileS2-
encoding plasmid to detect the existence and orientation of IS257
copies ﬂanking the ileS2 gene. In all nine plasmids the ileS2 gene
was found to be ﬂanked by IS257 copies. Considering upstream and
downstream regions, plasmids belonging to different groups have distinc
IS257-ileS2 organizations. Isolates carrying plasmids of the same group
showed an identical organization of the IS257-ileS2 spacers and thus
the same ampliﬁcation patterns. As in the case of pGO400, pUSA03,
and pV030−8 ileS2-encoding plasmids, S1 and S2 plasmids showed
directly repeated copies of IS257 but upstream ampliﬁcation patterns
differed in size. S3 group plasmids have inverted copies of IS257,
while in S4 plasmids, both IS257 copies were in opposite orientation
to ileS2. Interestingly, IS257-ileS2 ampliﬁcation patterns correlate with
the ileS2-hybiridizaton polymorphs. However, the antibiotic resistance
gene content vary for plasmids of the same group.
Conclusion: Our study highlights the value of IS257-ileS2 junctions
heterogeneity for distinguishing ileS2-carrying plasmids through PCR
ampliﬁcation. This novel assay offers a rapid, simple, and feasible
method for typing ileS2-carrying plasmids, and hopefully it could serve
as a useful tool for clinicians and epidemiologists in their efforts to
prevent and control high-level mupirocin resistance.
P1712 Molecular characterization of sporadically-occurring
nosocomial methicillin-resistant Staphylococcus aureus
isolates from Ireland
P. Kinnevey °, A. Shore, A. Rossney, D. Coleman (Dublin, IE)
Objective: Ireland has a high prevalence of MRSA and the predominant
strains from Irish hospitals since the 1970s have been well characterised.
However, there are no published data on sporadically-occurring
MRSA isolates from Ireland. This study aimed to undertake detailed
molecular characterisation of representatives of such sporadically-
occurring MRSA.
Methods: Forty-seven MRSA isolates recovered from patients in
Irish hospitals between 2000 and 2006 with unfamiliar antibiogram-
resistogram or pulsed-ﬁeld gel electrophoresis typing patterns underwent
spa and SCCmec typing. Representatives of each spa and SCCmec type
combination underwent multilocus-sequence typing (MLST).
Results: The 47 MRSA isolates yielded 21 spa types; the most prevalent
of which were t032 (10/47, 21%), t190 (5/47, 11%), t242 (5/47, 11%)
and t008 (4/47, 9%). Thirty-one isolates (66%) harboured SCCmec II,
III or IV, or previously described subtypes, while 26% (12/47) yielded
additional SCCmec amplimers indicative of novel SCCmec I, II, IV and
V subtypes. Four isolates (9%) harboured potentially novel SCCmec
elements and failed to yield ccr and/or mec amplimers. The 33 spa and
SCCmec type combinations identiﬁed belonged to 22 sequence types
(STs), with ST8 predominating (8/33, 24%). Four STs were represented
by more than one spa type: (a) ST8; t190, t064, t1209 and t008 (b)
ST22; t032, t022 and t2951 (c) ST36; t012 and t018 (d) ST5; t109
and t242. Conversely, six spa types were represented by more than one
ST; in three instances the STs belonged to the same clonal complex
(CC) (a) t008; CC8 (ST8, ST983, ST985 and ST1337), (b) t242; CC5
(ST5 and ST1435), (c) t127; CC1 (ST1115 and ST1336) but in three
instances the STs belonged to different CCs (a) t002; CC6 (ST979) and
CC5 (ST930 and ST100) (b) t032; CC616 (ST984) and CC22 (ST22)
(c) t018; CC30 (ST36) and CC731 (ST982). spa, SCCmec and MLST
typing yielded 36 type combinations, belonging to 12 CCs, among the
47 isolates, with CC8 predominating (28%; 13/47), followed by CC22
(11/47, 23%), CC5 (10/47, 21%), CC1 (3/47, 6%), CC30 (2/47, 4%) and
CC45 (2/47, 4%). Six CCs (CC731, CC6, CC862, CC779, CC361 and
CC616) were represented by single isolates.
Conclusions: This study revealed extensive genetic diversity among
Irish ‘sporadic’ nosocomial MRSA. The considerable variability within
SCCmec of these isolates further highlights the diversity of SCCmec and
represents a signiﬁcant gene pool for recombination events with other
SCCmec elements.
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P1713 Raman spectroscopy to determine endogenous or exogenous
Staphylococcus aureus surgical-site infection of dermatology
patients
R. te Witt °, E. Hopman, K. Munte, D. Willemse-Erix, G. Puppels,
K. Maquelin, W. van Leeuwen, A. van Belkum (Rotterdam, NL)
Background: Surgical site infections (SSI) are one of the most
common hospital-acquired infections, frequently caused by endogenous
Staphylococcus aureus. At the department of Dermatology a study has
been performed, to investigate whether nasal and wound screening for
S. aureus during dermatological surgery could predict SSI.
Methods: A prospective pilot study was conducted involving 106
patients with 133 lesions between March 1 2009 and July 10 2009.
Intra-operative and postoperative, culture swabs were taken from
dermatological surgery wounds. Moreover, nasal swabs of patients and
staff were examined to determine the carrier state for S. aureus. Bacterial
isolates were characterized in triplicate using Raman spectroscopy to
discriminate endogenous from exogenous infection.
Results: Sixteen percent of the patients were persistent carrier of
S. aureus. A SSI occurred in 14% of the persistent carriers, compared
to 3.5% in the non-persistent carriers, which was not statistically
signiﬁcant (p = 0.09). All SSI’s of the persistent carriers were shown
to be endogenous infections, i.e. strain type from nose matched that of
the lesion. For the non-persistent carriers, all infections were proven to
be exogenous. The isolate obtained from 1 patient matched that found
in a colonized staff member.
Discussion: Nasal carriers of S. aureus may have an elevated risk
for developing SSI in a dermatologic setting. However, due to a low
incidence rate of infections in dermatologic surgery, peri-operative
screening for S. aureus carriage might not be useful. Raman spectroscopy
proved to be a rapid and reproducible typing technique to discriminate
endogenous from exogenous infection.
P1714 Characteristics of Panton-Valentine leukocidin positive
Staphylococcus aureus strains isolated from abscessing
pneumonias in the Czech Republic
I. Machova °, J. Kahankova, M. Fridrichova, L. Kuntova´, M. Dvora´kova´,
J. Doskar, H. Zemlickova, R. Pantucek, P. Petras (Prague, Brno, CZ)
Objectives: Description of phenotypic and genotypic characteristics of
Panton − Valentine leukocidin (PVL) positive strains isolated from eight
abscessing pneumonias in the Czech Republic between December 2007
and May 2009. Short case reports are described too. Five of them were
lethal.
Methods: Carriage of the lukS-PV and lukF-PV genes for PVL, and
mecA gene was tested by a multiplex PCR assay. The phenotypic
and genotypic methods were used for detection of superantigens
(enterotoxin A − J, TSST-1, and exfoliatins A and B), and antibiotic
resistance to 12 antibiotics by microdilution method. The PVL positive
MRSA strains were characterized by PFGE, spa typing, SCCmec typing,
arcA gene detection, and agr typing.
Results: Four PVL positive strains from the collection of 8 strains were
MRSA. Those strains were characterized by molecular methods and
correlated with the known European MRSA types. Three isolates were
classiﬁed into SCCmec type IV, which is ordinarily found in community
acquired methicillin resistant S. aureus strains (CA-MRSA). One strain
was composite type IV + V. The last 4 strains were MSSA.
Conclusions: Abscessing pneumonias in Czech Republic are caused by
CA-MRSA and by methicillin sensitive S. aureus producing PVL. Early
detection of PVL production is very important for treating patients. All
three survived patients have been treated by linezolid.
Acknowledgements: Supported by grants Grant Agency of Czech
Republic (310/09/0459), Internal Grant Agency, Ministry of Health (CZ),
IGA 9642−4, and MSM0021622415 from the Ministry of Education,
Youth and Sports of the Czech Republic.
Molecular typing: other bacteria
P1715 Ages-Webribo − a new deterministic identiﬁcation algorithm
for the characterization of Clostridium difﬁcile isolates by
capillary gel electrophoresis-based PCR-ribotyping
A. Indra °, M. Blaschitz, M. Schneewe, S. Huhulescu, S. Kernbichler,
A. Fiedler, F. Allerberger (Vienna, AT)
Objectives: Clostridium difﬁcile is a frequently identiﬁed cause of
hospital-acquired infections. Identiﬁcation of newly emerging hypervir-
ulent C. difﬁcile strains − like 027, 078 and 053 is mostly done by
PCR-ribotyping. Although ribotyping is widely used the method lacks an
interlaboratory interchangeable format. In order to overcome capillary-
sequencer-dependent result variations of different types of sequencing
machines a newly developed deterministic identiﬁcation algorithm −
AGES-WEBRIBO (webribo.ages.at) − was applied for capillary gel
electrophoresis based Clostridium difﬁcile-PCR ribotyping.
Methods: 2600 isolates collected between the years 2006 to 2009 at
Austrian healthcare facilities were primarily analysed with an Applied
Biosystems (ABI) 310 Genetic analyzer yielding 303 different PCR-
ribotypes. 65 of the 303 ribotypes were randomly chosen and retested
with on an ABI 3130 Genetic Analyzer. Quality control of data gained
was done using the AGES-WEBRIBO internet platform.
Results: There was no increase in discrimatory power using different
sequencer machines, although there was better narrow double-peak
resolution with the ABI-3130 system. Three (4.5%) of the 65 on the
ABI-3130 sequencer examined samples showed no correct identiﬁcation
after analysing the data with AGES-WEBRIBO.
Conclusion: 95.5% correct identiﬁcations of C. difﬁcile ribotypes were
achieved between different ABI-Sequencer models with the newly
developed deterministic-data-analysis approach (AGES-WEBRIBO).
This result clearly shows that every user is able to determine even rare
PCR-ribotypes without a respective reference strain at hand. Further
tests will show the ability of AGES-WEBRIBO (webribo.ages.at) to
correctly identify data gained with capilliary sequencer models from
other suppliers than ABI. We consider the updated version of AGES-
WEBRIBO in combination with capillary gel electrophoresis based PCR
ribotyping to be a universal tool for inter-laboratory comparability of
C. difﬁcile ribotyping.
P1716 Epidemiological study of Clostridium difﬁcile isolates in
a French university hospital, during a 4 year-period from
2006 to 2009
I. Poilane °, C. Rousseau, P. Cruaud, A. Collignon (Bondy, FR)
Objectives: Recently, the epidemiology of Clostridium difﬁcile infec-
tions have changed with the emergence of a hypervirulent strain PCR-
ribotype 027. After Canada and the North of Europe, an outbreak due to
this strain was described in France in 2006. The aim of this study was
to perform a phenotypic and molecular characterization of C. difﬁcile
strains in order to follow the epidemiology of C. difﬁcile infections from
2006 to 2009 in Jean Verdier-Rene´ Muret hospitals.
Methods: From 2006 to 2009, 95 strains isolated from symptomatic
patients were studied. For the diagnostic of C. difﬁcile infections, a two
step algorithm was performed: toxin A and B were detected on stools
with an immunoenzymatic method (ICTAB, Meridian) and a toxigenic
culture was performed with detection of toxins A and B on colonies
with the same immunoenzymatic method. The agar diffusion method
was performed for screening antibiotic resistance to metronidazole,
vancomycin, erythromycin and moxiﬂoxacin. The E-test was performed
for determination of metronidazole and vancomycin MICs.
For molecular characterization, PCR-ribotyping was performed accord-
ing to Bidet et al. In addition, binary toxin genes cdtA and cdtB were
detected by PCR.
Results: From 2006 to 2009, all the isolates studied were susceptible
to vancomycin and metronidazole with no signiﬁcant increase of MICs.
The susceptibility to erythromycin and moxiﬂoxacin increases from 2007
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to 2009 respectively 14% to 100% for erythromycin and 28.5% to 100%
for moxiﬂoxacin. In 2007, 8% of the isolates were positive for cdtA
and cdtB genes and 11.7% in 2008. PCR-ribotype JV18 was the most
prevalent PCR-ribotype in 2007 and 2008 but disappeared in 2009.
This PCR-ribotype corresponds to the PCR-ribotype 001 according to
Stubbs et al. The isolates displaying this PCR-ribotype were resistant to
erythromycin and moxiﬂoxacin and were principally isolated in the same
ward, suggesting a cross infection.
Conclusion: This study showed that the susceptibility to metronidazole
and vancomycin remained stable on a 4 years period. Different clones of
C. difﬁcile circulated with emergence of an epidemic strain resistant to
erythromycin and moxiﬂoxacin displaying the PCR ribotype 001. This
isolate emerged in the gastroenterology unit where ﬂuoroquinolones are
frequently used demonstrating the role of antibiotic selection pressure.
During the period of the study, no isolate with a PCR-ribotype 027 was
detected.
P1717 Comparison of PCR ribotyping and an optimized random
ampliﬁcation of polymorphic DNA protocols for genotyping
of Clostridium difﬁcile produces proﬁles similar in
discriminatory power and reproducibility
L.M. Green °, T. Worthington, A.C. Hilton, P.A. Lambert (Birmingham,
UK)
Objectives: To determine if a newly optimised random ampliﬁcation
of polymorphic DNA (RAPD) PCR protocol provides comparable
discriminatory power and reproducibility to PCR ribotyping for
genotyping isolates of Clostridium difﬁcile.
Methods: An optimised RAPD PCR protocol was used to type a panel
of eleven known control PCR ribotypes incuding epidemic UK strains.
DNA preparations of all eleven isolates were prepared at different times
in order to determine the reproducibility of the method. PCR ribotyping
was also performed on isolates in order to obtain ampliﬁcation proﬁles
for the known ribotypes.
RAPD PCR was performed using two 10 base pair primers in
independent reactions performed in 25ml reaction volumes. The
ampliﬁcation cycles were as follows: 5 cycles of 4.5 minutes at 94ºC,
30 seconds at 94ºC, 2 minutes at 20ºC and 1 minute at 72ºC; this
was followed by 30 cycles of 5 seconds at 94ºC, 30 seconds at 36ºC
and 1 minute at 72ºC. Following ampliﬁcation, PCR products were size
separated on a 2% agarose gel in 1 x TAE buffer (40mM Tris-HCl, 1mM
EDTA, 0.1% (v/v) glacial acetic acid, pH 8). Following electrophoresis,
amplicons were detected by Ethidium Bromide staining and viewed
under UV light. PCR Ribotyping was performed as previously described
by Stubbs et al., (1999) with modiﬁcations. Following characterisation,
Gelcompar II (Applied Maths, Belgium) was used to analyse the
discriminatory capacity of both methods and also determine the
reproducibility of proﬁles produced by this RAPD protocol.
Results: Eleven distinct proﬁles were produced from the eleven
ribotypes investigated; both for PCR ribotyping technique and RAPD
protocols. PCR ribotyping produced proﬁles that were grouped into
four distinct clones at a 70% similarity level when analysed by
Gelcompar; similar results were produced in the RAPD reactions. RAPD
ampliﬁcation proﬁles for each ribotype were reproducible when repeated
in independent reactions at different times; these proﬁles displayed 100%
similarity when analysed with Gelcompar.
Conclusion: The RAPD protocol described here produces ampliﬁcation
proﬁles that are equivalent in reproducibility and discriminatory power
to the widely used PCR ribotyping. RAPD is considerably quicker than
PCR ribotyping protocols and proﬁles produced uncomplicated and easy
to compare and analyse. RAPD genotyping of C. difﬁcile as described
in this study may provide a rapid, clinically relevant, easily adopted
characterisation method for local epidemiological mapping of C. difﬁcile.
P1718 Genotypic characterization of Clostridium difﬁcile strains
isolated from patients with C. difﬁcile infection in a tertiary
hospital in Spain
M. Marin °, A. Martin, L. Alcala, R. Insa, E. Cercenado,
M. Sanchez-Somolinos, E. Bouza (Madrid, ES)
Objectives: Clostridium difﬁcile (CD) is the main aetiological agent of
antibiotic-associated diarrhoea and a common nosocomial pathogen. In
recent years, epidemic strains belonging to the 027 and 078 ribotypes
have emerged (both binary toxin+). Genotypic characterization of
isolates is essential for recognition of these strains and complements
epidemiological investigations. Data on the genotypic characteristics of
CD strains circulating in Spain are scarce. We genotyped CD strains
circulating in our hospital and isolated from patients with CD infection
(CDI) during the year 2007.
Methods: Only strains from patients with a new episode of CDI at
least 60 days after a previous episode were considered for study. Strains
were cultured and identiﬁed by conventional microbiological methods.
DNA was obtained from pure cultures using Chelex resin (Instagene
matrix, BioRad). The tcdA gene (toxin A), tcdB gene (toxin B), and
binary-toxin genes cdtA and cdtB were detected by multiplex PCR
(Persson, 2008). Isolates were characterized by PCR-ribotyping (Stubbs,
1999). Phylogenetic analysis of ribotyping proﬁles was conducted
using Bionumerics software 5.0. tcdC gene PCR and sequencing were
performed only for clustered strains as previously described (Rupnik,
1998 and Spigaglia, 2002).
Results: Seven hundred and ﬁfty-six CD strains were isolated during
2007. Non-toxigenic CD isolates (96 strains) and those belonging to the
same episode (212 strains) were excluded from the study. Overall, 448
CD strains from 435 patients with CD-associated diarrhoea were studied.
Two toxigenic proﬁles were detected: tox A+B+bin− (386 isolates,
86.2%, 45 ribotypes) and tox A+B+bin+ (62 strains, 13.8%; 7 ribotypes).
CD strains were clustered in 22 different ribotypes (418 strains, 93.3%)
and 30 ribotypes were non-shared. The most frequent ribotypes were
001 (222 strains, 49.5%) and 014 (75 strains, 16.7%). Ribotype 078 was
the third most frequent (48 strains, 10.7%). Only 6 isolates (2 patients)
belonged to ribotype 027. Analysis of the tcdC gene revealed deletions
of 18 bp to 54 bp in 62 strains. All but 2 strains were tox A+B+bin+.
Conclusions: Most of our toxigenic CD isolates were distributed in two
ribotypes. Ribotype 078, which is a frequent cause of diarrhoea in our
patients, accounted for 10% of toxigenic CD isolated at our institution
during 2007. Epidemic strains of ribotype 027 were detected in only 2
patients. All the bin+ CD isolates had deletions in the tcdC gene.
P1719 Molecular toxin genotyping of Clostridium perfringens
animal isolates by multiplex PCR
M.C. Ossiprandi °, L. Zerbini (Parma, IT)
Objectives: Clostridium perfringens is common in the environment
and in the intestinal tracts of humans and domestic and wild animals.
This microorganism is perhaps one of the most widespread pathogenic
bacteria and it is undeniably the most important cause of clostridial
disease in animals. The species is classiﬁed into ﬁve types (A to E),
based on the possession of one or more of four major toxin genes (a,
b, e, and i). However, C. perfringens can produce up to 15 toxins in
various combinations, including lethal toxins such as perfringolysin O,
enterotoxin, and b2 toxin. In this study we evaluated the molecular toxin
gene proﬁle of C. perfringens animal strains using a multiplex PCR.
Methods: Seventy-eight C. perfringens strains were isolated from
biological samples of different animal origin (32 rabbits, 20 calves, 14
dogs, 10 pigs, and 2 broilers). All animals (except for 8 healthy dogs)
had presented gastrointestinal tract disease.
Presumptive identiﬁcation of C. perfringens was made based on
colony morphology (circular-to stellate and smooth), the presence
of a distinctive double zone of haemolysis and by Gram staining
(Gram-positive short, plump rods with blunt ends, “box cars”). The
species identiﬁcation was conﬁrmed through the Rapid ID32A assay
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(bioMe´rieux). All C. perfringens isolates were multiplex PCR-screened
for the detection of alfa, b, b2, e, i and enterotoxin (CPA, CPB, CPB2,
ETX, IAP, and CPE) toxin-encoding genes, as previously described by
Baums et al. (2004).
Results: Seventy-two C. perfringens isolates (72/78: 92.3%) were type A
(CPA gene-positive). Seventeen type A strains (17/72: 23.6%) also
possessed the CPB2 toxin-encoding gene. Three strains (3.85%) were
type C (CPA and CPB genes-positive) and all possessed CPB2 gene.
Finally, 3 isolates (3.85%) were type D (CPA and ETX genes-positive): 2
also possessed CPB2 gene, and 1 CPE gene. Of all the 78 C. perfringens
isolates, 22 (28.2%) were PCR positive for CPB2 gene.
Conclusion: The results of this study highlight that the majority of our
C. perfringens isolates were type A and a relatively high percentage of
strains carried the CPB2 gene, that varies with the genotype, but that
was detected especially in type A in our tested samples.
We can conclude that multiplex PCR may provide a useful and reliable
tool for C. perfringens genotyping in routine veterinary diagnostics.
P1720 Genomic identiﬁcation of pathogenic and non-pathogenic
Leptospires by multilocus variable-number tandem-repeat
analysis
P. Khaki °, M. Abdollahpour Alittapeh, S. Moradi Bidhendi,
M. Esmaelizad, K. Tadayon (Karaj, IR)
Background: Leptospirosis is an emerging zoonotic diseases which
caused by pathogenic Leptospires. Detection and identiﬁcation of
Leptospires has conventionally been performed by cultural and
serological methods. These methods are tedious, time consuming, and
potentially biohazardous. Recently several PCR based techniques such
as VNTR have been demonstrated to provide useful tools in detection
and identiﬁcation of leptospiral serovars but most these techniques have
drawbacks. VNTR can also provide information relating to both the
evolutionary and functional areas of bacterial diversity.
Objective: The present study was carried out to set up of VNTR tech-
nique for the genotyping of pathogenic and nonpathogenic Leptospiral
serovars.
Methods: The pathogenic and non-pathogenic reference serovars of
Leptospira spp. were obtained from the Microbial Culture Collection at
the National Reference Laboratory for Leptospira at the Microbiology
Department of Razi Vaccine & Serum Research Institute, karaj, Iran.
Leptospiral strains were subcultured into the liquid EMJH medium and
incubated at 28 for 7 days.
Genomic DNA of Leptospiral serovars were extracted using the phenol-
chloroform method. PCR was performed with the three selected VNTR
loci (VNTR4, 10, 36). The ampliﬁed products were analyzed by agarose
gel electrophoresis. The sizes of the ampliﬁed products were estimated
by comparison with a 100-bp ladder.
Result: All loci successfully ampliﬁed in all pathogenic leptospiral
serovars with the primers. Although VNTR-4 was unable to discriminate
between Grippotyphosa and Hardjo, Icterohemoragaea and Pomona,
this locus was thoroughly differentiated between pathogenic and non-
pathogenic. VNTR-10 had an appropriate discrimination to differentiate
among these strains but was unable to differentiate between pomana
and semaranga. VNTR-36 successfully ampliﬁed in all of the strains.
Although This locus aptly separated serovar pomona from other strains,
but could not separated Grippotyphosa and semaranga.
Conclusion: The sizes of the ampliﬁed products displayed a wide range
of polymorphisms, suggesting variation tandem-repeat copy numbers
in the VNTR loci. The combination of the VNTR-4, VNTR-10, and
VNTR-36 loci was useful for typing L. interrogans. Although VNTR-4
was poorly discriminatory, was the only marker for separation between
pathogenic and non-pathogenic. The VNTR method provides rapid
typing as well as a highly discriminant assay to identify L. interrogans
serovars.
P1721 Molecular epidemiology of Brucella melitensis strains
isolates from human by MLVA-16 (Multiple locus VNTR
analysis-16) in Spain
S. Gonza´lez-Cabrero, F. Menegotto, A. Cubero, M.P. Gutie´rrez
Rodrı´guez, A. Duen˜as, C. Garcia Loygorri, M.A. Bratos, A. Ordun˜a °
(Valladolid, ES)
Introduction: Brucellosis remains the commonest anthropozoonosis
worldwide and it was a very important health problem in Spain during
the past century. Even now the brucellosis still persists in some regions of
Spain with a human incidence higher as 3/100.000, where B. melitensis
causes more than 99% of the human cases. In these areas, molecular
epidemiology could be a very useful tool to know the origin and
evolution of Brucella epidemic.
Objective: The aim of this study is to know the genetic variability of
172 Brucella melitensis strains isolates from humans from 1975 till 2008
and its importance in the evolution of the epidemic outbreaks.
Material and Methods: The genomic proﬁle of 172 strains of
Brucella melitensis was determined by Multiple Locus VNTR Analysis-
16 (MLVA-16). The repeated regions with a variable number of 8
minisatellite markers (more preserved), or 8 microsatellite markers (with
more discriminative power) were ampliﬁed by following the protocol
previously by Al-Dahouk et al. The analysis of gels was performed by
InfoQuestFP software (BioRad).
Every Brucella isolates was identiﬁed using biochemistry tests, speciﬁc
antiserum anti-A or anti-M and a multiplex-PCR.
Results: The 48.2% of studied strains belonged to B. melitensis biovar
1, 46% to B. melitensis biovar 2 and the 5.8% to B. melitensis biovar 3.
Using the microsatellite MLVA analysis we found 8 different genotypes,
and the locus bruce11 was the most homogeneous. Using the complete
MLVA-16 analysis (mini and microsatellite), the 172 human isolates
clustered in 140 different genotypes, and the locus bruce04 was the
most heterogeneous.
The 172 Brucella strains corresponding to the period 1976–2008 are
clustered in 8 different genotypes by the microsatellite analysis, and
two of these (genotypes 42 and 60) were the most prevalent with a
homology of 50% among them. The genotype 42 is represented by
B. melitensis biovar 2 and the genotype 60 is represented by B. melitensis
biovar 1. We may conclude that during this period appeared two major
epidemic outbreaks, one of them caused by genotype 42 and the second
by genotype 60. On the other hand, the genotypes 36 and 55 were
represented by a single strain, and we consider that both cases were
sporadic. In the present work we discuss the geographical distribution
of the Brucella genotypes and the evolution of the Brucella epidemic in
Spain during 1976–2008.
P1722 Dissemination of limited imipenem-resistant Acinetobacter
baumannii clones in Asian countries
K.S. Ko °, H.W. Kim, J.Y. Choi, J.H. Song on behalf of ANSORP
Objectives: Current ANSORP (Asian Network for Surviellance of
Resistant Pathogens) study on hospital-acquired pneumonia (HAP)
shows that Acinetobacter spp. is the most frequently isolated pathogens
in Asian countries. Moreover, it is quite problematic due to high
imipenem resistance rate (69.9%) of Acinetobacter spp. isolates in the
ANSORP study. We investigated the genetic relatedness of imipenem-
resistant A. baumannii isolates, which caused HAP in adult patients in
8 Asian countries from 2008 to 2009.
Methods: Species identiﬁcation was performed for 189 Acinetobac-
ter spp. isolates by rpoB gene sequence analysis. Genetic relatedness
among 123 imipenem-resistant A. baumannii isolates was investigated
by method of multilocus sequence typing (MLST). Genes encoding OXA
carbapenemases and the other antibiotic resistance genes such as blaPER,
blaIMP, and blaVIM were detected by PCR.
Results: As a result of species identiﬁcation using rpoB gene sequences,
A. baumannii was the most common species (85.4%), followed by
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Acinetobacter genomospecies 13TU (6.9%). All but one imipenem-
resistant isolates belonged to A. baumannii. MLST showed that CC
(clonal complex) 22, which includes six sequence types (STs), was the
most prevailing (59.0%) and disseminates in several Asian countries
such as Korea, Malaysia, Hong Kong, India, Taiwan, and Thailand.
The second most common was CC43 (18.0%), which was found in two
Asian countries such as India and Malaysia. Most of imipenem-resistant
A. baumannii isolates belonging to CC22 contained both oxacillinase
genes such as blaOXA-23-like and blaOXA-51-like genes and blaPER-1.
Conclusion: Only a few closely related clones of imipenem-resistant
A. baumannii disseminate in Asian countries. Especially, more detailed
investigation on CC22, a clone distributing worldwide, is required.
P1723 Multilocus variable-number tandem-repeat analysis of
Salmonella enterica subsp. enterica serovar Typhimurium
in the Netherlands
M.E. Heck °, M. van Luit, K. van der Zwaluw (Bilthoven, NL)
Objective: Salmonella enterica subsp. enterica serovar Typhimurium
(STm) is a pathogen frequently responsible for outbreaks of gastoenteri-
tis. To elucidate outbreaks an epidemiological subdivision of this serovar
is indispensable. Phage-typing and pulsed ﬁeld gel electrophoresis
(PFGE) are among the methods most frequently applied. Both have
been used successfully but have the disadvantage that reading the typing
results can be subjective and difﬁcult to standardize. Reliable typing
results are critical to both detecting and determining the source of an out-
break. Multilocus Variable-Number Tandem-Repeats Analysis (MLVA)
is a PCR method based on the ampliﬁcation and fragment analysis of
ﬁve repeat loci. Advantages of MLVA are: it is fast, easy to perform, less
labour intensive and yield unambiguous typing data. In this publication
we want to demonstrate that MLVA is an alternative to type STm.
Methods: For this study we typed 2800 S.Tm isolates which were sent
to our lab for serotyping from, 1st Jan. 2006 up to 1st Oct. 2009. All
strains were characterised by phage typing and MLVA typing. To test
technical skills our lab participated in a MLVA ring trial. MLVA data
were stored in a Bionumerics data base. Simpson’s diversity indices (DI)
were calculated to determine the discriminatory power of both methods.
An overall comparison was made between the two typing methods.
Results: All isolates were typeble with MLVA whereas phage typing
was unable to type 6% of the strains and yielded 15% atypical strains.
The DI’s of MLVA- and phage typing were 0.87 and 0.98 respectively.
We found that dubious phage types, which account for a substantial
portion of the strains, could be sub-divided by MLVA and MLVA
consequently provided a signiﬁcant understanding of these phage types.
The concordance between the methods was good in known outbreaks
but as anticipated did not establish a 100% match. MLVA revealed that
some outbreaks have not been detected in the past.
Conclusions: MLVA turned out to have a discriminatory power that
surpasses phage typing and yields clearly deﬁned data that can be stored
and exchanged easily. MLVA can sub-divide ‘dubious and meaningless’
phagetypes signiﬁcantly.
Because MLVA is fast, easy to perform and less labour intensive we
strongly believe that MLVA typing is an alternative and consequently
a step forward in typing Salmonella enterica subsp. enterica serovar
Typhimurium.
A future target is to establish international accessible data base.
P1724 Typing of plasmids of multi-resistant E. coli producing or
not extended-spectrum b-lactamases using two different
assays: replicon typing and relaxase detection
B. Ruiz del Castillo °, A. Alvarado Garcı´a, M. Garcilla´n-Barcia, F. de
la Cruz, L. Martı´nez-Martı´nez (Santander, ES)
Background: Classiﬁcation of epidemiologically-relevant plasmids is
currently based in the detection of plasmid replication and partition
regions, leading to their grouping in incompatibility (Inc) groups.
Plasmids conferring antibiotic-resistance are mainly transmissible. They
have been recently classiﬁed in six MOB families according to the
evolutionary relationships or their relaxase, a key protein in the transfer
process. Here we have accomplished the identiﬁcation of plasmids in a
multiresistant E. coli collection from clinical isolates. Two classiﬁcation
approaches have been used: the classical PCR-based replicon typing and
MOB identiﬁcation. Results allowed us to compare the efﬁciency and
speciﬁcity of both methods and to depict the nature of the plasmids
involved in the multiresistant phenotype of the isolates.
Methods and Results: Transconjugants (Tc) were obtained from 19/20
ESBL and 13/20 non-ESBL isolates. Plasmid DNA from donor and
Tc were extracted and characterized by replicon typing and MOB
identiﬁcation using a set of degenerate primers speciﬁc for each relaxase
family. In the multiresistant, non-ESBL collection, the most prevalent
group was IncF (12/13), followed by IncI1 (7/13). Members of the groups
IncB/O (3/13), K (1/13), A/C (3/13), and Pa (1/13) were also present.
Relaxase detection conﬁrmed these results: MOBF12 (12/13), MOBP12
(8/12), MOBH12 (3/12), MOBP11 (1/13). Cryptic mobilizable MOBQ
plasmids without Inc group assigned and IncX plasmids, both missed
by the replicon typing method, were also found by MOB ampliﬁcation.
In the ESBL collection, MOBP12 plasmids were the most abundant,
being present in all isolates. They cluster members of IncI1 (7/19),
IncK (14/19) and IncB/O (12/19) groups. MOBF12 plasmids were the
second most prevalent (17/19), while 18/19 were found to belong to
the F group (FIA, FIB, Frep) by replicon-typing. Also MOBP11 (IncPa
plasmids), MOBQ and MOBC12 (both omitted in the replicon typing)
were observed in 2/19, 3/19 and 3/19 isolates, respectively.
Conclusions: Our collection contains transmissible plasmids of different
incompatibility groups. MOB detection and replicon typing are
complementary methods for classifying plasmids in clinical isolates of
E. coli. The ﬁrst one is especially useful for classifying plasmids that
harbour multiple replicons and those without Inc group assigned. The
use of combined methods provides higher accuracy and more information
about the plasmid backbone.
P1725 Serotypes, virulence genes, and PFGE patterns of shiga
toxin-producing Escherichia coli isolated from Peruvian
children
C. Contreras °, J. Ruiz, F. Rivera, Y. Sa´enz, N. Zavaleta, C. Lanata,
R. Maves, C. Torres, T. Cleary, T. Ochoa (Lima, PE; Barcelona, ES;
Logron˜o, ES; Houston, US)
Objectives: The objectives of this study were to determine the
distribution of virulence genes in Shiga toxin-producing Escherichia coli
(STEC) strains and investigated the genetic relationships of these strains
from humans by pulsed-ﬁeld gel electrophoresis (PFGE).
Methods: We analyzed 18 STEC strains isolated from stool samples
of children with and without diarrhoea from four previous cohort
studies in Peruvian children. All studies were in the community setting,
485 children (0−36m) were followed in 1987 in Huaraz-Ancash; 313
(6−18m) in 2004 in Villa El Salvador-Lima; 1025 (0−12m) in 2007
in Chorrillos-Lima and 1250 (0−24m) in 2008 in Lima-north. The
strains were analysed by PCR to identify the presence of stx1, stx2,
eae, ehxA, and chuA genes and the genetic diversity study was carried
out by PFGE. The serotypes were determined using polyvalent and/or
monovalent antibodies.
Results: We have 18 STEC strains (1/485 strain-Huaraz, 4/313 strains-
Villa El Salvador, 10/1025 strains-Chorrillos and 3/1250 strains-Lima-
north). Among the isolated STEC strains, stx1 was the most common
toxin-gene than stx2 (16/18 89% vs. 2/18 11%), and eae was present in
14/18 (78%). All eae genes were present only in stx1 STEC samples.
The other virulence genes, chuA was found 75% (6/8) in DS, 43%(3/7)
in controls and 33%(1/3) in ND; and exhA in 63%(5/8), 57%(4/7)
and 100%(3/3) respectively. 60%(9/15) of the strains has a typeable
serotype, the most frequent is O26:H11 (40%), others serotypes found
were O1:H7, O125:H21, O6:H- y O-:H2. PFGE revealed 17 distinct
restriction patterns, based on a difference of a single band as a basis
for discrimination between isolates. In the dendrogram produced by
the UPGMA algorithm, the isolates were clustered in 9 groups (I−IX;
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1−5 strains/group) of 85% similarity according to the Dice similarity
index. Isolates of the O26:H11, stx1, eae were grouped together in
the dendrogram. No relation between the ehxA, chuA genes and
characteristics as date of isolated and locality of isolated were found
with the distribution in the different PFGE clusters.
Conclusion: The majority of the STEC strains in the community setting
were stx1+ and eae+. The absence of haemolytic uremic syndrome may
relate to the low frequency of stx2+ strains. The distribution of virulence
genes exhA and chuA among diarrhea and control is similar. The STEC
strains isolated in different decade share a genetic relationship indicating
that the same clones are circulating in Peruvian population in the last 20
years.
P1726 The Diversilab system versus pulsed-ﬁeld gel
electrophoresis: characterization of extended-spectrum
b-lactamase producing Klebsiella pneumoniae
A. Brolund °, S. Haeggman, P.J. Edquist, L. Gezelius,
B. Olsson-Liljequist, K. Tegmark Wisell, C.G. Giske (Stockholm, SE)
Objectives: Nosocomial and community associated spread of ESBL-
producing Klebsiella pneumoniae is of great concern. Fast and reliable
epidemiological typing methods for rapid identiﬁcation of outbreaks
and epidemic strains are of value. For these purposes pulsed-ﬁeld gel
electrophoresis (PFGE) is considered the gold standard method. The
main limitations of PFGE are that it is time-consuming and requires
rigorous standardization and experienced personnel in order to achieve
reproducible results. Hence, faster, simpler and more easily standardized
tools are needed. The DiversiLab system (DL) has been proposed for
these purposes. We here, to our knowledge, show the ﬁrst systematic
comparison of DL and PFGE on K. pneumoniae.
Methods: We compared DL to PFGE on a national collection of 48
K. pneumoniae producing extended spectrum b-lactamases, as deﬁned by
clavulanic acid-reversible resistance to oxyiminocephalosporins collected
in 26 clinical laboratories in Sweden during February − April 2007.
Different cut offs for the Dice coefﬁcients were evaluated for PFGE; 90,
85 and 80%. The cut-off for DL was set at 97% identity in addition
to electropherogram overlay analysis, where no peak differences were
accepted for isolates to be considered identical.
Results: Simpson’s index of diversity was higher for DL (88.6%)
than for PFGE (85.6 and 83.9% for Dice 90/85 and 80, respectively).
The directional information about the partition relations by Wallace
coefﬁcients demonstrated that the probability of two strains being
classiﬁed as the same type by PFGE having the same DL type was
79.6% (95%CI: 57.6–100) to 70.3% (95%CI: 46.9–94.8) (Dice 90/85
and 80). Conversely the probability was 100% regardless of cut-off. Only
four of 48 isolates had discordant results with the two methods.
Conclusion: Although the number of isolates investigated in this study
was relatively low and the results therefore should be interpreted with
some caution, DL and PFGE showed a high degree of concordance.
However, if one considers PFGE the gold standard method for
probable close epidemiological relatedness in outbreak investigations
the apparent higher discriminatory power of DL could represent a
challenge for laboratories using this method for primary screening of
clonal relatedness.
P1727 Phenotypic and genotypic characterization of Haemophilus
inﬂuenzae strains isolated from children with cystic ﬁbrosis
R. Cardines, M. Giufre`, E. Fiscarelli, M. Accogli, M. Cerquetti °
(Rome, IT)
Objectives: Patients suffering for the cystic ﬁbrosis (CF) disease
are prone to recurrent respiratory infections caused by a variety of
bacterial pathogens including Haemophilus inﬂuenzae, Staphylococcus
aureus, Pseudomonas aeruginosa and Burkholderia cepacia complex.
H. inﬂuenzae commonly infects the respiratory tract of CF patients early
in childhood. The objective of the study was to characterise H. inﬂuenzae
isolates from CF patients included in a 5-year follow-up study (2004–
2009).
Methods: Fifty-eight H. inﬂuenzae strains were recovered from the
respiratory secretions of 45 CF patients attending the CF center of the
“Bambino Gesu`” paediatric hospital in Rome. Eleven of the 45 patients
contributed two or more H. inﬂuenzae isolates over time. The median age
of the patients was 5 years (range 0.25−27 years). The capsular serotype
was identiﬁed by PCR. MICs were determined by E-test. Production of
b-lactamase was detected by the ceﬁnase disk test. Genetic relatedness
among isolates was assessed by PFGE. The presence of the hia and
hmw adhesin encoding genes was detected by PCR and colony blotting
techniques, respectively.
Results: Of the 58 strains, 52 (89.7%) were nonencapsulated or
nontypeable (NTHi), 4 type e and 2 type a. The rate of b-lactamase
producers was 13.8%; 3 strains showed the b-lactamase negative
ampicillin-resistant phenotype. Heterogeneous resistance to imipenem
was identiﬁed in 11 strains (18.9%). No strains were found resistant
to cephalosporins and amoxicillin–clavulanic acid. Resistance to
azithromycin and chloramphenenicol was 13.8% and 5.2%, respectively.
No increase in antibiotic resistance was observed in strains serially
isolated from the same patient. By PFGE, the 52 NTHi isolates yielded
47 different proﬁles but 11 minor clusters were identiﬁed, each including
from 2 to 6 strains. Of 11 patients with sequential isolates, 4 harboured
strains exhibiting identical PFGE proﬁles, while 7 patients possessed
strains without close genetic relationships. Some NTHi isolates from
different patients shared related genotypes, but 16 isolates were totally
unrelated to each other. A minority of the NTHi isolates harboured the
hia and hmw genes, the former being the most frequent (16/58, 27.6%).
Conclusions: Resistance to imipenem in H. inﬂuenzae has emerged in
Italy. Persistence of an identical clone was observed in 36% of patients.
No apparent association between antimicrobial resistance and persistence
was found.
P1728 Multilocus sequence analysis of Stenotrophomonas spp. and
delineation of S. maltophilia
Z. Vasileuskaya-Schulz °, S. Kaiser, D. Jonas (Freiburg, DE)
Objectives: During the last years, the genus Stenotrophomonas has been
the focus of applied microbiology and biotechnology. Nevertheless, the
genetic and phenotypic heterogeneity within the genus complicates the
choice of representative strains for investigation, e.g. for comparative
genomics of clinical versus environmental isolates. MLST of 70 S. mal-
tophilia strains previously revealed genogroups with DNA-similarities
below 95%, which exclusively comprised strains of environmental origin.
To unravel the uneven distribution of environmental isolates within the
MLST genogroups and to reveal genetic relationships within the genus
we extended multilocus sequence typing to analysis of a further 21
S. maltophilia-isolates of environmental origin, Stenotrophomonas spp.
and related genera.
Methods: In this research, 12 Stenotrophomonas maltophilia strains,
S. rhizophila, S. terrae, S. humi, S. nitritireducens, S. acidaminiphila,
S. chelatiphaga, S. koreensis, Stenotrophomonas sp. (DSM2408),
Pseudomonas beteli and Pseudoxanthomonas dokdonensis were charac-
terized by multilocus sequence analysis (MLSA) of seven housekeeping
genes (atpD, gapA, guaA, mutM, ppsA and recA). The data from
previous multilocus sequence typing of 70 Stenotrophomonas spp. were
integrated into a larger MLSA.
Results: Our recent data demonstrate that the seven-gene MLSA
provides good discrimination of all the investigated species on the intra-
and interspecies levels. Based on this, some isolates, previously described
as S. maltophilia, need to be re-examined and presumably reclassiﬁed as
S. rhizophila. Moreover, the data provide further genetic evidence that
P. beteli belongs to the genus Stenotrophomonas and Px. dokdonensis,
described initially as Stenotrophomonas dokdonensis is a representative
strain of a different genus only distantly related to stenotrophomonads.
Conclusions: Multilocus sequence analysis is a practical and robust
approach for distinguishing Stenotrophomonas spp. at both the genus
and species levels. This approach provides a reliable means for selection
of isolates for comparative genomic investigations.
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P1729 The prevalence of magA-positive Klebsiella pneumoniae
strain in a Japanese medical centre
Y. Kohayagawa °, A. Nakashima, H. Fukushima (Izumo, Matsue, JP)
Objectives: Klebsiella pneumoniae is a Gram-negative pathogen that
causes many infectious diseases, especially urinary tract infections and
pneumonia. Primary pyogenic liver abscess caused by K. pneumoniae,
sometimes complicated by endophthalmitis or central nervous system
infection, has recently become an emerging disease in the world. MagA
(mucoviscosity-associated gene A)-positive K. pneumoniae has been
reported to be extremely virulent. We evaluated the prevalence of magA-
positive K. pneumoniae strains collected in a 679-bed medical centre in
Japan.
Methods: Culture, identiﬁcation, and susceptibility testing of isolates
were performed according to standard microbiological methods. We col-
lected clinical K. pneumoniae strains from outpatients and hospitalized
patients. Isolates were obtained by culture from all types of samples
(blood, pus, bile, urine, sputum, etc.). K. pneumoniae strains were
collected for 1 year (2008 to 2009) and stored at −30ºC before use. We
performed bacterial capsular polysaccharide synthesis (cps) genotyping
by polymerase chain reaction to detect magA. The medical records of
all patients from whom we collected magA strains were scrutinized
meticulously.
Results: Sixty-two strains of K. pneumoniae from 61 patients were
collected. Of the 62 strains, 10 strains were magA positive. We judged
that 6 strains from 5 patients (4 patients with pyogenic liver abscess
and 1 patient with meningitis) were causal microbes. One patient of
pyogenic liver abscess died and the meningitis patient experienced higher
brain dysfunction. The other 4 strains were only colonization. Tests for
the strains isolated from our patients indicated good susceptibility to
antimicrobial drugs.
Conclusion: We found the prevalence of magA-positive K. pneumoniae
at 16% was not rare. While magA-positive K. pneumoniae is extremely
virulent, the existence of patients with colonization means there is
the possibility of immunotherapy, i.e. vaccine or monoclonal antibody.
MagA-positive K. pneumoniae is an important microbe which causes
pyogenic liver abscess and/or central nervous system infection. Despite
advances in intensive care medicine, pyogenic liver abscess and central
nervous system infection are still catastrophic illnesses. Many cases of
magA-positive K. pneumoniae infection have been reported in Taiwan,
but few cases have been reported in the rest of Asia, North America or
Europe. Further epidemiological investigation of this virulent organism
is needed.
P1730 Clonal diversity of high-level gentamicin-resistant Entero-
coccus faecalis isolated from clinical samples in Tehran, Iran
M. Saiﬁ °, M.R. Pourshaﬁe, M.M. Soltan Dallal, M. Talebi (Tehran, IR)
Objectives: Following the worldwide increased of high-level gentamicin
resistace (HLGR); we report the clonal relatedness of HLGR Enterococ-
cus faecalis HLGR-EF) from clinical samples in Tehran, Iran.
Methods: From September 2006 to 2007, 266 enterococcal isolates were
collected from medical centers in Tehran. All strains were identiﬁed to
species level by conventional and PCR methods. CLSI recommendations
were used for antimicrobial susceptibility and gentamicin MICs of
HLGR-EF isolates. Analysis of gentamicin resistant genes was done
by PCR method. Filter mating experiment was used for conjugation test
among HLGR-EF isolates. Boichemical ﬁngerprint typing (PhP typing)
was applied for primary typing of enterococcal population. Analysis
of the SmaI restriction digest of genomic DNA by pulsed ﬁeld gel
electrophoresis was performed for genotyping of the HLGR-EF isolates.
Results: A total of 190 (71.5%) of the isolates were identiﬁed as
Enterococcus faecalis (E. faecalis) and 58(30.5%) of them were HLGR-
EF (MIC1024 mg/ml). All HLGR-EF isolates contained aac(6′)-Ie-
aph(2”)-Ia gene. Among 10 mating experiments, only one transconjugant
were obtained with the high frequency of 6×10−9 for aac(6′)-Ie-aph(2′′)-
Ia gene.
PhP typing of HLGR-EF isolates included one dominating cluster, 10
smaller clusters and 14 unique patterns. PFGE resulted in 36 different
patterns among the 58 isolates. Only 12% (7 isolates from different
medical centers) of the HLGR-EF isolates belonged to one PFGE cluster.
The other common types consisted of 45% (26 isolates) were limited only
to 1−3 medical centers and the rest (43%) were single types.
Conclusion: PFGE showed more discriminatory power than PhP typing.
High diversity observed indicating that the isolates belonged to several
clonal groups which could be mostly endogenous origin. However one
dominating cluster which observed among studied E. faecalis population,
revealed the clonal dissemination among the HLGR-EF isolates from
different medical centers. We detected a strong association between
HLGR phenotype and the aac(6′)-Ie-aph(2”)-Ia gene. This ﬁnding can be
explained by horizontal transmission of this gentamicin resistance gene.
P1731 Genotypic analysis of Helicobacter pylori strains circulating
in St. Petersburg, Russia at present
R. Ferman, A. Zhebrun, Y. Alyapkina, A. Svarval ° (St. Petersburg,
Moscow, RU)
A strain-speciﬁc H. pylori gene, cagA, has been recognized as a marker
for strains that confer increased risk for peptic ulcer disease and gastric
cancer. VacA of H. pylori is a highmolecular weight multimeric pore-
forming protein that causes massive vacuolation in epithelial cell lines.
As with cagA, no close homologs of vacA exist in other Helicobacter
species or in other bacteria, which suggests its importance in the speciﬁc
relationship of H. pylori with the human stomach. However, unlike cagA,
vacA is conserved among all H. pylori strains, although signiﬁcant poly-
morphism exists. vacA alleles possess one of two types of signal region,
s1 or s2, and one of two mid-regions, m1 or m2, occurring in all possible
combinations. H. pylori strains with different forms of vacA exhibit var-
ied phenotypes and have particular associations with gastro-duodenal dis-
eases. vacA s2 strains are rarely isolated from patients with peptic ulcers
or gastric adenocarcinoma. s1/m2 forms of VacA bind to and vacuolate
a narrower range of cells than s1/m1 forms and induce less damage.
vacA s1/m1 strains are most closely associated with gastric carcinoma.
In our study we analysed peculiarity of H. pylori strains that are
circulating in Sainkt-Petersburg at present by means of PCR method.
Materials and Methods: We have studied 30 H. pylori strains isolated
from patients with chronic gastritis, gastroduodenitis, ulcer disease and
gastric cancer. The patients were aged from 13 to 65. The presence of
16SrRNA, CagA, vacA was determined. Genotyping of H. pylori vacA
was carry out for 14 strains.
Results: All studied strains of H. pylori revealed 16SrRNA. Estimated
that 76.67% of them were cagA-positive. By genotyping vacA it was
found out that s1m1 genotype was prevailing (in 57.14% of strains).
It was associating with cagA gene in 87.5% cases. The s1m2 vacA
genotype was estimated in 21.43% of strains and the s2m2 vacA
genotype in 14.29% of strains. There was also one strain of H. pylori
separated from the patient with ulcer disease that possessed the genotype
cagA+/s1m1m2. The strain isolated from the patient with gastric cancer
possessed the genotype cagA+/s2m2 vacA of H. pylori.
Conclusions: The fulﬁlled analysis showed that in Saint-Petersburg area
H. pylori strains with cagA+/s1m1vacA genotype are prevailing. It is
known that such strains are associated with more serious pathology
therefore dynamic observation of patients with such strains is necessary.
P1732 Molecular-epidemiological diversity of V. cholerae strains
isolated in Siberian and the far eastern regions of the
Russian Federation
A. Kozhevnikova, S. Balakhonov, E. Kulikalova, L. Urbanovich,
N. Breneva, M. Afanas’ev ° (Irkutsk, RU)
Objectives: Cholera is a severe gastrointestinal disease that due to Gram-
negative bacterium Vibrio cholerae. Threat of infection’s carries from
Africa and South-Eastern Asia demand to effective molecular-typing
based surveillance measures. The purpose of this study was to evaluate
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molecular-epidemiological diversity of V. cholerae strains isolated in
Siberian and the Far Eastern regions of Russia.
Methods: V. cholerae strains (n = 32) have been selected during
epidemiological monitoring of Siberia and Far East from 1994 to
2005. Sample set include toxigenic strains (n = 14) from patient and
environmental samples, isolated during outbreaks and sporadic cases of
cholera in 1994, 1997 and 1999 years and non-toxigenic strains (n = 18)
from environment. Strains’ isolation and identiﬁcation was performed
according to WHO protocols. Detection of virulence’s determinants
(ctxAB, tcpA, toxR, attrS, zot, rstC, nanH, ompU), fragments of
pandemic islands (VSP-I and VSP-II) and determinants of environmental
persistence (hapA1, mshQ and A, mbaA1 and A2, vpsR) was performed
by previously described PCR systems. Standard procedure of VNTR
typing, that based on ampliﬁcation of ﬁve loci − VcA, VcB, VcC, VcD
and VcG, was carried out as described previously.
Results: Twenty nine strains (90.6%) belonged to the O1 serotype,
all were identify as El-Tor biovar. Three strains belonged to the O
139 serotype. Main virulence’s determinants (ctxAB and tcpA) were
detected in 14 (14/32; 43.8%) strains and 11 (11/14; 78.6%) of them
had fragments of VSP-I and VSP-II. Signiﬁcant association between
presence of environmental persistence’s and virulence’s determinants did
not observe. Nineteen different VNTR proﬁles were identiﬁed, including
13 (68.4%) unique and 19 strains grouped into six clusters (from 2 to
6 strains in each). Seven main VNTR genotypes formed large subgroup
that included strains isolated from patients and environmental samples
during cholera outbreaks. Among strains belonged to these VNTR-
genotypes we observed complete set of virulence’s determinants and
fragments of pandemic islands.
Conclusion: Seven VNTR-genotypes, which associated with worsening
of cholera’s situation in Siberia and Far East, were revealed. VNTR
typing demonstrates sufﬁcient discrimination power and, in combination
with virulence’s and pathogen’s determinants PCR detection, may be
useful for V. cholerae typing in Siberian and Far Eastern regions of
Russia.
P1733 Characterization of Shigella sonnei isolated from
hospitalized children in Tehran, Iran
R. Ranjbar °, M.R. Pourshaﬁe, M.M. Soltan Dallal, M. Izadi, N. Jonaidi
(Tehran, IR)
Objective: Shigellosis is one of the main causes of morbidity in children
with diarrhea in Iran. The present study was conducted to examine
the prevalence of Shigella spp., antibiotic susceptibility and the genetic
characterization of S. sonnei strains recovered from hospitalized children
(<12 years old) with acute diarrhea in Tehran, Iran in 2003.
Methods: Fecal specimens and rectal swab collected from patients were
cultured and identiﬁed as Shigella by the conventional methods. The
isolates of S. sonnei, as predominant species, were further examined.
Antimicrobial susceptibility, plasmid proﬁling, and ribotyping were used
to study the relatedness between the S. sonnei isolates.
Results: Out of 3050 patients with acute diarrhea, 302 cases were
diagnosed as having shigellosis on the basis of clinical presentations
and laboratory ﬁndings. S. sonnei as the predominant Shigella spp.
(58.9%) was further studied. Majority of S. sonnei isolates (94%) were
resistant to co-trimoaxozle. On the other hand, they were relatively or
completely sensitive to 15 commonly used antibiotics. The extracted
plasmids showed 12 different proﬁles with two closely related patterns
constituting 70% of the total isolates. Ribotyping using PvuII, HindIII
or SalI restriction enzymes generated a single pattern for all S. sonnei
isolates.
Conclusion: The results showed that S. sonnei has replaced S. ﬂexneri
as the predominant serogroup in children with less than 12 years of
age in the hospitals in Tehran. Single ribotype dominance was also
supported by the data that 70% of the isolates harbored closely related
plasmid patterns. The results further conﬁrm that continuous monitoring
is needed for over a prolonged period in Tehran to detect the changes
in the serotype distribution and the antimicrobial resistance pattern of
Shigella.
P1734 Genotypic and phenotypic proﬁles of Streptococcus mutans
in children with and without dental caries
F. Gamboa °, M. Chaves, C. Valdivieso (Bogota, CO)
Objective: Streptococcus mutans, an acidogenic and aciduric microor-
ganism that colonizes the oral cavity is recognized as the main causal
agent of dental caries. Epidemiological studies have shown a strong
correlation between the number of S. mutans in the oral cavity and
prevalence and incidence of caries. At present different genotypic and
phenotypic methods are known to determine the proﬁles of settling and
epidemiological distribution of S. mutans. The aim of this study was
to investigate the proﬁles of S. mutans isolated from children with
and without dental caries by using the AP-PCR (arbitrarily primed
polymerase chain reaction) and api-Zym methods.
Methods: In the AP-PCR method, random DNA segments of the target
bacterium are ampliﬁed with single primers of arbitrary sequence. The
api-Zym system (bioMe´rieux, Marcy-le´toile, France) is a phenotypic
micro-method that allows simultaneous detection of 19 enzymatic
activities from bacterial inoculum. A transversal observational study was
conducted, which ﬁnally included 120 3- to 5-year-old children (75 with
and 45 without dental caries), who attended a preschool institution in
Bogota (Colombia).
Results: S. mutans was isolated in 15 of the 45 children without-dental
caries (33.3%) and in 31 of the 75 children with caries (41.33%). In
the 15 healthy patients with S. mutans, 24 strains were isolated, while
in the 31 caries patients 45 strains were isolated. With api-Zym system
were detected 36 different biotypes, 22 for the caries group and 15 of the
healthy group. The biotype XX was present in the two groups. With AP-
PCR method identiﬁed 27 different ﬁngerprinting proﬁles; both groups
of patients shared four of these genomic proﬁling.
Conclusion: The information shows a great diversity in S. mutans
genotypes and phenotypes in the studied population.
P1735 Neoscytalidium spp. superﬁcial infections in Madrid
R.B. Mohedano °, M.S. Cue´tara, A. Aguilar, S. Vazquez, S. Rey-Cao,
M. Gallego, I. Wilhelmi (Madrid, ES)
Objective: Neoscytalidium dimidiatum (N. dimidiatum) (synamorph
Nattrassia mangiferae, formerly known as Hendersonula toruloidea) is
a dematiaceous plant pathogen that can cause endemic (geographical
restricted to tropical and subtropical areas) superﬁcial skin and nail
infections, clinically indistinguible from Trichophyton (rubrum and
interdigitale). In temperate zones, infections have been noted in
immigrants from endemic areas. In areas with important immigration
such as most European countries, misdiagnosis of this infection is
possible if cycloheximide is not withdrawn from the usual culture
medium. The objective of this work was to show the epidemiology of
N. dimidiatum species in a temperate European capital (Madrid).
Methods: Retrospective study (from 2003 to 2009). After a dermato-
logical suspicion, scrapings from nails and skin (soles, palms, toe and
ﬁnger webs) and in one case a subcutaneous nodule were planted on
Sabouraud agar slants and dishes supplemented with cloramphenicol
and cycloheximide and in media without cycloheximide. Media were
incubated at 25ºC for up to 30 days. Samples were examined after
treatment with treatment with potassium hydroxide. Neoscytalidium
species were identiﬁed according to usual macroscopic and microscopic.
Results: Neoscytalidium spp. superﬁcial infections were diagnosed in
8 immigrants from endemic areas; a subcutaneous infection (plantar
granuloma) was diagnosed in a Spanish patient with no history of travels,
but who had close contact (at work) with immigrants.
The table shows the infected sites, species responsible of the infection
and geographical origin. In our population direct examination showed
sinuous and irregular hyphae in bright ﬁeld illumination.
No dermatophytes were either visualized or cultured. The response to
treatment (oral/topical) was unsatisfactory.
Conclusions: In Spain Neoscytalidium spp. is a uncommon agent
of dermatomycoses, and misdiagnosis could explain that although
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immigration is high, this species is only occasionally identiﬁed. This
is the ﬁrst autochtonous N. dimidiatum infection in Madrid probably due
to close contact of the patient with immigrants with clinical infection
due to this agent. Another important and widely documented issue is the
very poor response to treatment. In European areas such as London and
Paris these infections show an ascending incidence linked to expertise
of clinical mycologists and clinical suspicion of dermatologists.
Age/Sex Origin Soles Toe-webs Toenails/
Fingernails
Subcutaneous
nodule
TTO
43/M Spain + − −/− + yes
65/F Guinea + + +/− − yes
24/F Colombia − − +/+ − yes
37/F Cameroon + + +/− − yes
40/F Brazil + + +/− − yes
39/F Guinea − − +/− − no
54/F Rep. Dom − − +/− − no
35/F Guinea − + +/− − yes
31/F Cameroon − − +/− − no
Sex: M=male; F = female; TTO: topical and oral treatment.
P1736 Identiﬁcation of clinical isolates using the RiboPrinter®
system
C. Be´got °, F. Wegerhoff (Meyrin, CH; Indianapolis, US)
Objectives: To assess the use of the RiboPrinter® Microbial Char-
acterization System to identify bacterial strains isolated from clinical
specimens.
Methods: The RiboPrinter® is an automated ribotyping system based
on genomic restriction fragment length polymorphism (RFLP) analysis,
and it generates patterns based on the portion of DNA that encodes
for ribosomal RNA. These patterns are used to characterize a bacterial
sample, and identify the bacterium by comparing it with static composite
identiﬁcation patterns in the DuPont, or Custom ID Libraries. A total of
1870 strains (Gram-negative and Gram-positive) isolated from sputum,
urine, skin and skin structure infections were tested.
Results: About 67% of strains were automatically identiﬁed with the
RiboPrinter® system with “matches” above the similarity threshold (SI
0.85). A further 7% were identiﬁed after manual assignment from a
list of nearest neighbors generated by the system (SI< 0.85), whereas
26% of strains were not identiﬁed by the system. Of the automatic
and manual identiﬁcations, the most frequent organisms included
64 different genus and species, such as Pseudomonas aeruginosa,
Stenotrophomonas maltophilia, Escherichia coli, Klebsiella pneumoniae,
Serratia marcescens and Enterococcus faecalis.
The strains not identiﬁed by the RiboPrinter® system were identiﬁed
using phenotypic methods such as GNI (Vitek®), API strips and
additional biochemicals tests. These included particular strains of
Sphingomonas paucimobilis, Providencia rettgeri, Proteus vulgaris,
Citrobacter freundii and Enterobacter species. RiboPrint patterns from
bacterial identiﬁcations that were obtained with a high conﬁdence
level by phenotypic systems were added to the Custom ID Library.
The RiboPrinter® system will therefore have an increased chance of
recognizing these patterns and identifying the strains in future testing of
patient isolates.
Conclusion: The RiboPrinter® offers a dynamic system for accurate
automated identiﬁcation of clinical isolates by simultaneous use of the
manufacturer’s ID library (6950 bacterial species, 40496 patterns) as well
as the custom ID library, thereby increasing the chances for deﬁnitive
bacterial identiﬁcation.
Bacterial identiﬁcation following a molecular
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P1737 Usefulness of polymerase chain reaction and DNA
sequencing in routine diagnostics of bacterial infections
K.H. Jensen °, R. Dargis, J.J. Christensen, M. Kemp (Copenhagen, DK)
Objectives: Sequencing of 16S rRNA genes (rDNA) has been widely
used for taxonomic classiﬁcation of bacteria and has proven to be a useful
tool in clinical laboratories for bacterial identiﬁcation as well. Since
2003 the Clinical Microbiology Laboratory at Statens Serum Institut
has offered this analysis as a routine diagnostic procedure on culture
negative samples. After six years and more than 2600 analyses we felt
it important to evaluate the usefulness of PCR and DNA sequencing
as a routine diagnostic tool. The bacteria identiﬁed and type of sample
material examined may indicate in which type of infections the method
may be of particular value.
Methods: The records of 16S rDNA analyses from June 2003 to October
2009 were used to obtain information about the type of sample material,
number of samples in which bacterial DNA were found and what bacteria
that were identiﬁed.
Results: In a six year period from June 2003 to October 2009, 2628
clinical samples have been submitted for detection and identiﬁcation of
bacterial DNA. In 695 of the samples, bacterial DNA was detected and
PCR products for sequencing were obtained (Table 1). The bacterial
species or clinical relevant genus/group was identiﬁed in 556 of the
sequenced samples. 421 (76%) and 135 (24%) bacteria were identiﬁed
at species and genus level, respectively. In 103 (74%) of the 139
cases where no identiﬁcation could be obtained, the sample was judged
as multibacterial by viewing the chromatogram. The main group of
bacteria encountered was facultative anaerobic and aerobic strains and
the majority of these were Gram-positive strains. The most frequently
encountered bacteria in this group were Streptococcus pneumoniae,
Staphylococcus epidermidis, Streptococcus dysgalactiae, Streptococcus
intermedius, Streptococcus pyogenes and Staphylococcus aureus. Of the
anaerobic strains found, more than half were Propionibacterium acnes
and other Propionibacterium species.
Conclusion: The ﬁnding of bacterial DNA in one fourth of culture
negative samples demonstrates that PCR and sequence-based detection
and identiﬁcation of bacteria are good supplements to conventional
diagnostics.
Table 1: Results of PCR and 16S rRNA sequencing of samples submitted
for analysis during a 6-year period
No. of
samples
Bacterial DNA found
(% total samples)
Strain identiﬁeda
(% sequenced PCR products)
2003 33 17 (52) 9 (53)
2004 99 25 (25) 24 (96)
2005 201 58 (29) 39 (67)
2006 305 151 (50) 96 (64)
2007 441 112 (25) 88 (79)
2008 694 126 (18) 117 (93)
2009 855 206 (24) 183 (89)
Total 2628 695 (26) 556 (80)
aIdentiﬁcation obtained at either genus or species level.
P1738 Bacterial detection with a microﬂuidic reactor for
polymerase chain reaction
J.R. Peham °, H. Steiner, W. Grienauer, R. Heer, M.J. Vellekoop,
C. Noehammer, H. Wiesinger-Mayr (Seibersdorf, Vienna, AT)
Objectives: A novel microﬂuidic reactor, applicable for infectious dis-
ease diagnostics was developed. To enable rapid and sensitive bacterial
detection in a continuous operation mode, genomic DNA ampliﬁcation
of the 16S rRNA gene was realized by polymerase chain reaction (PCR)
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in a ﬂow-through and miniaturised device. A detailed comparison of this
microﬂuidic approach to conventional PCR methods is presented.
Methods: DNA was extracted from pure bacterial cultures by thermal
lysis and puriﬁed. PCR reagents were added and the complete mix was
directly injected into the new device. The cyclic ﬂow PCR device was
designed with 40 turns of polytetraﬂuoroethylene (PTFE) tubing (400
micrometer inner diameter), representing 40 PCR cycles, coiled around
a prismatic heating device, operated by Peltier elements. The aqueous 10
microliter PCR mix is driven by a silicone oil of low viscosity through
three equidistant temperature zones (95º C, 55º C, 72º C) per turn. Flow
rates of 137 nl/s, 274 nl/s and 548 nl/s have been applied to achieve 60,
30 and 15 s retention time per temperature zone respectively.
Results: Target PCR amplicons of 153bp, 418 bp and 720 bp have
successfully been ampliﬁed with the developed device. The standard
laboratory processing time of 3 h could be decreased to 30 min with the
microﬂuidic reactor without loosing PCR efﬁciency. Using the current
design, this will allow analysis of 60 samples per hour in continuous
operation.
Conclusion: It has been shown that the presented system can rapidly
amplify the 16S rRNA gene and thereby allows a fast detection of
bacteria, which is crucial for clinical microbiology. The performance can
be increased with smaller sample volumes and parallel tubing, leading
to a high-throughput device. Integrating an optical ﬂuorescence detector
for dsDNA measurement would evolve this device into a micro total
analysis system for infectious diseases.
P1739 Comparison of four real-time PCRs for Listeria
monocytogenes
D.L. Hess °, P. Savelkoul, E. De Boer, A. Heuvelink, L. Spanjaard,
C.W. Ang (Amsterdam, Zutphen, NL)
Objectives: Real-time PCR is a widely used method for detection of
microbial nucleic acid sequences. In the past years, several real-time
PCR’s have been developed for the detection of Listeria monocytogenes.
The aim of this study was to assess the sensitivity of four real-time
PCR’s for L. monocytogenes strains from food and human origin.
Methods: We selected two primer-probe combinations from literature,
based on the number of investigated strains, sensitivity, speciﬁcity and
Genbank nucleotide BLAST results. The primer-probe combinations are
published by Rodrı´guez-La´zaro et al. and Oravcova´ et al., targeting the
hly gene and actA gene, respectively. These primer-probe combinations
were compared with a primer-probe set used by the Food and Consumer
Product Safety Authority (VWA, unpublished), targeting the iap gene,
and a primer-probe set developed by Huijsdens et al., targeting the hly
gene. All PCR’s used FAM-labelled probes. 168 human clinical isolates
from the Netherlands Reference Laboratory for Bacterial Meningitis
(RBM), 111 food isolates from the Food and Consumer Product Safety
Authority (VWA), 3 complete genome sequenced strains (ATCC BAA-
679 (=EGDe), F2365, HCC23) and L. monocytogenes type strain ATCC
15313 were used to determine the sensitivity of the four real-time
PCR’s. Speciﬁcity was assessed using a total of 40 non-L. monocytogenes
strains, including all other Listeria species.
Results: The Huijsdens PCR detected 76 out of a total of 182
L. monocytogenes isolates (41.8%). These results were in line with
nucleotide BLAST results. The complete set of isolates was analyzed
with the remaining three PCRs. The Rodrı´guez PCR detected 277 out
of 279 (99.3%) of all isolates, the VWA PCR and Oravcova´ PCR
both accurately identiﬁed 278 out of 279 (99.6%) of all isolates.
The undetected isolates originated from four different human clinical
cases, all phenotypically as well as AFLP and PFGE typed as
L. monocytogenes. Preliminary results suggest that detection limits of
the PCRs are comparable to previously published results (<100 CFU/ml
in the VWA PCR). Speciﬁcity of all PCRs is 100%.
Conclusion: The Huijsdens PCR identiﬁes less than half of all isolates
tested, whereas the other real-time PCRs identify almost all isolates
accurately. The considerable variation in sensitivity of real-time PCRs
should be taken into account when selecting real-time L. monocytogenes
PCR for diagnostic use.
P1740 Multiplex PCR to differentiate between Acinetobacter
calcoaceticus and Acinetobacter genomic species 3
P.G. Higgins °, M. Lehmann, H. Seifert (Cologne, DE)
Objectives: Acinetobacter calcoaceticus is a non-pathogenic environ-
mental organism that can colonise hospitalised patients. In contrast,
the closely related Acinetobacter genomic species 3 (GS3) is a known
nosocomial pathogen. In routine diagnostics both these organisms, in
addition to A. baumannii and Acinetobacter genomic species 13TU
(GS13TU), are grouped together as the Acinetobacter calcoaceticus-
baumannii complex (Acb complex). We have previously established a
gyrB multiplex PCR to differentiate between A. baumannii and GS13TU
(Higgins PG et al. (2007) Clin. Microbiol. Infect.; 13: 1199–201). The
aim of this study was to develop a simple and rapid PCR-based method
to differentiate between Acinetobacter calcoaceticus and GS3 that could
be used alongside the established multiplex PCR to differentiate within
the Acb complex.
Methods: The gyrB genes from 20 non-identical A. calcoaceticus and
21 GS3 were ampliﬁed by PCR, sequenced and aligned. Species-speciﬁc
annealing sites were identiﬁed. Primers were designed to work under the
same cycling conditions as the established multiplex PCR and to amplify
products that are easily distinguishable from each other. Primers were
tested against 24 A. calcoaceticus, 22 A. baumannii, 37 GS3 and 29
GS13TU.
Results: All A. calcoaceticus tested ampliﬁed a 428bp PCR product.
GS3 isolates ampliﬁed a PCR product of 182bp. Addition of gyrB
primers speciﬁc for A. baumannii and GS13TU unambiguously
correctly identiﬁed each of the 4 species. No PCR products were
ampliﬁed when tested against other species of the Acinetobacter
genus (haemolyticus, junii, johnsonnii, lwofﬁi, berezinae, guillouiae,
radioresistens, beijerinckii, venetianus, ursingii, schindleri, and genomic
species 6, 9, 14 and 15TU).
Conclusions: This multiplex PCR can be used to identify and
differentiate between A. calcoaceticus and GS3. Addition of the primers
from the previously established multiplex PCR now allows for the rapid
identiﬁcation of the various species belonging to the Acb complex.
P1741 Isolation of Ralstonia insidiosa from cystic ﬁbrosis patients
in a Turkish university hospital
O. Dogan, O¨. Ko¨seoglu Eser °, P. Vandamme, B. Sener (Ankara, TR;
Gent, BE)
Objectives: The identiﬁcation of non-fermentative Gram-negative bacilli
(NFGNB) isolated from the sputum of cystic ﬁbrosis (CF) patients is
still a challenge for microbiology laboratories. Although the clinical
importance of such bacteria is debated, they are increasingly recovered
in CF patients. The aim of this study was to evaluate phenotypic
and genotypic identiﬁcation and clinical impact of a series of non-
fermentative isolates from CF patients.
Methods: A series of 13 NFGNB were recovered from CF patients
during September-November 2008 period. All these oxidase positive
isolates were either identiﬁed as Ralstonia pickettii or Burkholderia
cepacia by BD Phoenix automated system. The isolates were then
examined by 16S rRNA gene sequencing for identiﬁcation. Antibiotic
susceptibilities were tested by disk diffusion and the genetic relatedness
of them were evaluated by arbitrarily primed-PCR (AP-PCR).
Results: Gene sequencing revealed that 11 of the isolates were
Ralstonia insidiosa, one was Pandoraea pulmonicola and one was
Stenotrophomonas maltophilia. All the R. insidiosa isolates except one
and the S. maltophilia strain had the similar antibiotic susceptibility pat-
tern as imipenem, amikacin, tobramycin, colistin resistant; ceftazidime,
cefepime, meropenem, levoﬂoxacin and ciproﬂoxacin susceptible. The
patients had neither serious clinical symptoms nor acute exacerbation
ﬁndings. R. insidiosa had never been recovered again during their
ongoing controls. None of the patients were socially related. AP-PCR
analysis of R. insidiosa isolates revealed four different genotypes. Seven
isolates were observed to be genetically related, while two other isolates
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revealed another identical pattern. The remaining was genotypically
unique.
Conclusion: Automated bacterial identiﬁcation systems do not fulﬁll the
demand of adequate identiﬁcation of NFGNB in CF isolates and should
be replaced by molecular methods. Although R. insidiosa isolation was
regarded as an intermittent colonisation according to these ﬁndings, its
clinical impact on CF pathogenesis is not yet clear. Since these bacteria
are mostly of environmental origin, these results emphasized the need
for more cautious infection control measures for CF clinics.
P1742 Polymorphism of pertussis toxin gene in circulating
Bordetella pertussis strains in Serbia
G. Dakic °, T. Pljesa, T. Kallonen, A. Elomaa, M. Svabic-Vlahovic,
Q. He (Belgrade, RS; Turku, FI)
Objectives: Despite the routine use of pertussis vaccines, pertussis
remains an important cause of disease among young infants, adolescents
and adults. Pertussis toxin (Ptx) is one of the major virulence factors
of Bordetella pertussis and is included in all of the acellular pertussis
vaccines. Ptx consists of ﬁve subunits (S1-S5, or PtxA-E). The S1
subunit (PtxA) contains the catalytically active site and has been
shown to be immunodominant. So far four ptxA alleles (ptxA1-ptxA4)
have been reported. In many countries, the allele ptxA2 and/or ptxA3
are present in most vaccine strains and predominated in the isolates
circulating in pre-vaccine era. However, the “vaccine type” strains were
gradually replaced by “non-vaccine” type” ptxA1 after the vaccination
was introduced. Today, almost all of circulating strains have been ptxA1.
However, little is known of polymorphism of ptxA gene in B. pertussis
isolates in Serbia where whole cell vaccine has been in use since 1957.
The aim of this study was to analyze and compare ptxA genotypes in
the Serbian isolates collected since 1953.
Methods: The analysis included genotyping of ptxA by sequencing and
LightCycler PCR. A total of 70 clinical isolates together with four
vaccine strains were tested. The vaccine strains 2047/57 and 1772/57
were isolated in 1957, and the strains 23/81 and 8/84 were isolated in
1981 and 1984. Current composition of the Serbian vaccine contains the
four strains and has been used since 1985. The clinical isolates were
from 1953 to 1956 (n = 10), from 1957 to 1984 (n = 43) and from 1985
to 2000 (n = 17).
Results: The vaccine strains 2047/57 and 1772/57 represented ptxA2
genotypes, whereas the vaccine strains 23/81 and 8/84 harbored ptxA1
genotypes. Shift from ptxA2 to ptxA1 has been observed in isolates
since the late of 1960s. During the period of 1980–1984, all isolates
represented ptxA1 genotype. Reappearance of the isolates containing
ptxA2 was noticed after the two strains harboring ptxA1 were added
into the vaccine in 1985. From 1985 to 2000 35% of isolates tested
were ptxA2.
Conclusions: The Serbian vaccine strains showed difference in ptxA.
The frequency of modern B. pertussis isolates with ptxA2 was high in
Serbia compared to that found in most of countries with long vaccination
history.
P1743 Detection of anaerobic bacteria within 15 minutes
P.J. Winklehner °, C. Mittermayr, F. Winner (Freistadt, AT)
Objectives: A fast and easy detection system for bacteria is the goal
of this project. The use of a DNA-microarray enables reliable and
simultaneous detection and differentiation of many microorganisms.
The short timeframe requires a PCR-free method. Ease of use is
guaranteed by a microﬂuidic lateral ﬂow device. Proof of principle will
be demonstrated by the detection of anaerobic bacteria that are difﬁcult
to culture.
Methods: A disposable single use polymer microﬂuidic chip has been
developed. The chip has the same dimensions as a standard microscope
slide. It comprises an inlet which can accept solutions from pipets or
dropper bottles, a reaction channel and a ﬂuid reservoir that controls the
ﬂow in the channel. The ﬂow is driven by capillary forces without the
need for external control mechanisms or pumps. The combination of this
microﬂuidic chip with colorimetric detection and visual readout allows
the analysis of biological samples without any expensive laboratory
equipment.
The platform was applied to a 16S rRNA based analysis procedure.
Differentiation was done by a DNA-microarray which was printed
into the reaction channel. All reaction steps were conducted at room
temperature.
Results: Identiﬁcation of bacteria by their 16s rRNA is accomplished
within 15 minutes. Analysis is done by dropping lysed bacteria and
three solutions for washing and colour reaction onto the platform using
disposable pipets and dropper bottles. The limit of detection was 5×104–
1×105 bacteria/analysis-volume (=20ml).
Conclusions: The advantages of this system are low cost mass
production by mold injection technology, the possibility for chair-side
analysis of infectious diseases and the elimination of complex liquid
handling systems or other laboratory equipment. The advantages of
microﬂuidic in the context of microarray analysis are the handling of
minute volumes and the reduction of dilutions in order to improve
the limit of detection. The marriage of microarray and microﬂuidics
promises the advent of a powerful platform for bioanalytical applications,
like the diagnosis of diseases, establishing genetic predispositions or high
through put screening for drug discovery.
P1744 Evaluation of polymerase chain reaction as rapid diagnostic
tool compared to culture in respiratory tract infections
A. Makri, G. Tzanakaki, S. Kalimeratzi, H. Iliadou, A. Xiroyianni,
J. Kremastinou, A. Voyatzi ° (Athens, GR)
Introduction: In spite of the availability of effective antimicrobial
therapy both otitis media with effusion (OME) and chronic obstructive
pulmonary disease (COPD) are still important infections for children,
leading to serious health problems.
Objectives: To investigate the diagnostic value of polymerase chain
reaction (PCR) for the detection of bacterial DNA in MEE and broncho-
alveolar lavage (BAL) specimens and to compare the conventional
culture methods accepted as the “gold standard” to the modecular
techniques.
Material and Methods: A total of 102 samples collected from
hospitalized children (30 BAL and 72 middle ear effusion − MEE)
were analyzed. Multiplex PCR protocol was applied for the detection
of Haemophilus inﬂuenzae, Pseudomonas aeruginosa, Staphylococcus
aureus, Streptococcus pneumoniae and Streptococcus spp including
Streptococcus pyogenes (GAS). Two stepdown multiplex-PCR assays
were used for the simultaneous detection of nine main serotypes of
S. pneumoniae directly in clinical samples.
Results: The frequency of the tested bacteria by the conventional
cultures methods was H. inﬂuenzae 42.1%, St. aureus 21.5%, Gas
14%, Ps. aeruginosa 10.7% and S. pneumoniae 8.8%. The sensitivity
of PCR assay compared to cultures was 92% for H. inﬂuenzae,
S. pneumoniae and GAS while the method indicated 100% total
speciﬁcity. In comparison to the cultures PCR assay was more sensitive
for S. pneumoniae (20.55 vs 8.85) and GAS (23% vs 14%). The most
prevalent serotypes of S. pneumoniae were 19F, 6, 14, 19A, 3 and a high
proportion were of not typable (not included in the 7-valent conjugate
vaccine).
Conclusions: PCR method could be considered as a rapid, reliable and
feasible method for the detection of the most common fastidious bacteria
that lead to OME and COPD.
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P1745 Comparison of cell cultures and three conventional
PCR for detecting Chlamydophila pneumoniae in adults
pharyngotonsillitis
C. Bonaccorso °, B. Bisignano, R. Timpanaro, A. Stivala, A. Garozzo,
G. Tempera (Catania, IT)
Objectives: Chamydophila pneumoniae is a common cause of acute
respiratory tract infections although it is considered like a non
conventional pathogen for pharyngotonsillitis. The incidence among
children has been well documented whereas there is a lack of
epidemiological data about the spreading of this intracellular pathogens
in adults. The aim of the study was to investigate the frequency of
C. pneumoniae detection in clinical samples of adult patients with
pharyngotonsillitis through the use of different methods.
Methods: This study investigated 94 throat swabs collected from patients
with clinical diagnosis of acute pharyngotonsillitis. After three serial
passages in cell cultures the presence of chlamydial inclusions was
evaluated by immunoﬂuorescence test (IFA) using FITC-conjugated
anti-C. pneumoniae MAb. The obtained data were compared with a
conventional PCR targeting the 16S rRNA gene and two nested PCRs,
targeting the 16S rRNA gene and the ompA gene respectively.
Results: The presence of chlamydial inclusion in cell cultures was
observed in 11/94 samples (11.70%) by IFA. C. pneumoniae DNA was
detected in 12/94 (12.76%) specimens by the 16S rRNA gene nested
PCR, 4/94 (4.26%) by ompA gene nested PCR and in 2/94 (2.13%) by
16S rRNA single step PCR.
Conclusion: Our results indicate that there is a diffusion of C. pneumo-
niae in acute pharingotonsillitis in adults. Isolation of C. pneumoniae by
cell cultures is essential to document the viability of the pathogen even if
it is complicated and time-consuming; therefore tests that target pathogen
DNA, such as PCR, have become widely used. Our data show poor
agreement between the three applied DNA-ampliﬁcation methods; in
fact, 16S rRNA gene nested PCR conﬁrmed all positive results obtained
by IFA, while the other two PCR assays had a lower sensitivity.
P1746 Use of ESwab for the detection of Mycoplasma hominis and
Ureaplasma urealyticum from genital specimens
S. Castriciano °, D. Piccoli, C. Mazzi, R. Sforza, M. Valbusa, A. Fenzi,
S. Gaino, M. Caputo (Brescia, Bussolengo, IT)
Objectives: Mycoplasma hominis (Mh) and Ureaplasma urealyticum
(Uu) are common inhabitants of the urogenital tract of women. ESwab
(Copan Italia), a Liquid Based Microbiology device, for collection
and transportation of clinical specimens, preserves microorganisms at
room temperature. This study validates the use of the ESwab kit for
the collection and storage of clinical specimens for the detection of
M. hominis and U. urealyticum with the MYCOFAST Evolution 3 test.
Methods: ATCC strains of Mh and Uu and clinical specimens were used
for this study. Mock specimens were prepared by adding 100 ul of Mh
and Uu culture to Rayon swabs and to the ﬂocked swabs of the Eswab kit.
The rayon swabs were added to the UMMt broth, while the ﬂocked swabs
were added to the1ml Amies medium tubes, then different volumes were
added to the UMMt broth. Genital specimens (102) for the diagnosis of
genital infections, collected with the ﬂocked swab and transported in the
Amies medium, were tested with the MYCOFAST Evolution 3 (Elitech,
distributed by DID in Italy). Clinical specimens were tested the same
day of collection and after 24 hours storage at room temperature (RT)
following the method for liquid specimen. Each specimen was vortexed
and 300 microliters were inoculated into an UMMt broth vial as per the
kit manufacturer procedure. Vials and trays were incubated at 37ºC and
read after 48 hours incubation.
Results: In the mock specimens, 300 ul of the ESwab specimens gave
the same results as the Rayon swabs after 36 to 48 hours incubation.
In the 102 genital specimens 32(31.37%) were positive, 6 Mh and 26
Uu and 70 negative for the same day testing while 34(33.33%) were
positive, 9 Mh and 25 Uu and 68 negative when tested after 24 hours at
room temperature. There was 100% antibiotic resistance correlation in 6
Mh and 15 Uu at both testing times. The resistance of the other positive
was variable with both inoculation times.
Conclusions: ESwab didn’t interfere with the performance of the
MYCOFAST Evolution 3 for the detection of Mh, Uu, and antibiotic
resistance with mock and clinical specimens. Genital specimens,
collected with the ESwab kits, can be stored for 24 hours at RT when
unable to same day test and can be tested for other STDs from the same
specimen.
P1747 Usefulness of galactomannan testing in broncoalveolar
lavage ﬂuid for diagnosis of invasive aspergillosis in HSCT
recipients
E. Furfaro, M. Mikulska °, A. Raiola, F. Gualandi, M. Van Lint,
A. Dominietto, V. Del Bono, F. Miletich, A. Bacigalupo, C. Viscoli
(Genoa, IT)
Introduction: The diagnosis of invasive aspergillosis (IA) remains
difﬁcult and non invasive diagnostic tests are of increasing interest in
clinical settings. In particular the galactomannan assay (GM) has been
widely studied in serum, while fewer studies have focused on GM in
bronchoalveolar lavage (BAL).
We investigated the role of GM in BAL ﬂuid as a tool for diagnosis of
IA in HSCT recipients.
Methods: Recipients of allogeneic HSCT between January 2007 and
October 2009 were included in this study. Data from CT scans and GM
testing, both in serum and BAL, were evaluated. GM positivity was
deﬁned as 0.5 in a single sample of BAL and IN two consecutive
serum samples. Patients were classiﬁed as proven, probable, possible
and no IA according to 2008 EORTC/MSG criteria.
Results: A total of 61 patients had GM testing performed both in
serum and BAL because of clinical signs compatible with invasive
fungal infection (IFI) (table 1). Of them, 19 (31%) had typical signs
on CT scan that fulﬁlled the clinical criteria for possible IA according
to EORTC/MSG (dense, well-circumscribed lesions, air-crescent sign or
cavity). In 6 of them (32%) serum GM was positive, thus upgrading these
cases to probable disease. BAL GM was positive in all but one patients
with positive serum (5/6) and in additional 5 patients with negative serum
GM. Therefore the proportion of patients with possible IA upgraded to
probable disease increased from 6/19 (32%) with serum GM positive to
11/19 (58%) with either BAL or serum GM positive. The median GM
value in 10 patients with probable IA and positive GM was 1.5 (range
0.52−4.8) and 7 (70%) patients had GM> 1.0. Using GM cut-off for
BAL of 1.0, 9 patients could be upgraded to probable IA (32%> 47%).
Among 42 patients with no typical pulmonary inﬁltrates, 9 had positive
serum GM and negative BAL GM, 6 had negative serum GM and
positive BAL GM, and 27 had both serum and BAL GM negative.
Median BAL GM value was 1.9 (range; 0.7−3.7) and in 5 BAL GM
was >1.0 (83%).
Conclusion: Our results suggest that BAL GM is useful to upgrade
diagnosis of IA from possible to probable (25% increase).
Increasing the cut-off of BAL GM from 0.5 to 1 allows for fewer patients
to be upgraded to probable IA.
Many high risk patients with clinical signs of IFI have pulmonary lesions
that cannot be classiﬁed as typical according to 2008 EORTC criteria
and positive GM results are extremely difﬁcult to interpret in this setting.
Table 1. Number of patients with galactomannan testing results from
BAL and serum, divided into those with and without typical CT lesions
according to 2008 EORTC/MSG
Patients with typical lesion on CT
(19)
Patients with no typical lesions on CT
(42)
BAL+ BAL− BAL+ BAL−
Serum+ Serum− Serum+ Serum− Serum+ Serum− Serum+ Serum−
5 5 1 8 0 6 9 27
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P1748 Study of Trichomonas vaginalis polymorphism in conditions
of in vitro infection
A. Ivanov °, N. Razdolskaya, O. Gavrilova, A. Krivoruchko,
D. Zaslavsky, I. Timochin (St. Petersburg, RU)
Objectives: Human urogenital parasite Trichomonas vaginalis is
considered as poorly cultivated organism, appropriate models of infection
are absent. Trichomonas can exist in clinical samples in different
morphological forms: pearlike motile, amoeboid, and round immotile.
Standard microscopic methods of diagnosis are reliable only for pearlike
form.
Methods: Clinical isolates were cultivated on MDCK, L-41, and HEP-2
cell lines. Monolayer (106 cell/ml) were inoculated by pearlike forms in
concentrations 102–108 cell/ml. Morphology of parasite was investigated
by direct observations and May-Grunvald-Gimsa staining.
Results: Culture L-41 appeared the most suitable. Monolayer was
destroyed within 24 h, when infection dose was 104–106 cell/ml, and
within 1 h, when it was 108 cell/ml. Differences between T. vaginalis
strains were not signiﬁcant. Morphological changes were induced
immediately after contact with monolayer, within 1 hour all pearlike
forms were transformed into amoeboid. In course of transformation cells
increased in size, free ﬂagella lost motility, ﬁlose pseudopodium were
formed, acsostyle reduced, vacuoles appeared in cytoplasm. Staining
revealed that 25% of cells was with 2 and more nuclei. In pearlike forms
population part of dividing cells consisted only 6%, and multinuclear
cells never were detected. Multinuclear cells revealed correspondent
kit of free ﬂagella and inner ﬂagella roots. Amoeboid cells can be
considered as stage of proliferation with postponed cytokines. After
6 h pseudo plasmodium of amoeboid forms was detected on place of
already destroyed monolayer, and round immotile cells appeared in
suspension. Round forms were similar with amoeboid ones: immotile
free ﬂagella, reduction of aksostyle, vacuoles in cytoplasm, big variety in
size, signiﬁcant percentage of dividing cells. That round forms appeared
when amoeboid cells have been lost contact with monolayer. After full
destruction of monolayer amoeboid cells were transformed in typical
pearlike motile.
Conclusion: Round form of T. vaginalis basing on normal morphological
structure, ability to reproduce, to induce destruction of monolayer may
be considered as virulent, but not degenerative form. Appearance of
round forms in clinical samples is a singe of active infection.
P1749 PCR-based diagnosis of human diroﬁlariosis achieved on
samples embedded in parafﬁn
S. Gabrielli °, S. Tasic, M. Magi, G. Cancrini (Rome, IT; Nis, RS;
Pisa, IT)
Objectives: Aim of this paper is to report the successful application of
molecular diagnostics to identify ﬁlarial DNA extracted from 5 parafﬁn-
embedded nodules.
Methods: Surgically removed nodules were been processed for
histological analysis. Then, the haematoxylin-eosin coloured sections and
part of the worms embedded in the parafﬁn blocks were submitted to
DNA extraction, following a by us modiﬁed DNA isolation protocol,
and to PCR assays using primers previously designed.
Results:Morphological features of the sections of the worms, in optimal
state of preservation, were indicative of the presence D. repens; PCR
assays performed on the parafﬁn blocks had a successful application
and conﬁrmed the identiﬁcations.
Conclusions: For many years the diagnosis of human diroﬁlariosis has
been achieved by the histological examination of surgically removed
nodules, and the identiﬁcation of the worms was based on the features
of the cuticle of adult specimens. However, identiﬁcation was impossible
when the cuticle was altered by regressive phenomena or in the case of
infection by larval stages, and it risked of turning out unreliable in areas
where many ﬁlarial species are present in animal population. Therefore,
molecular diagnostics then developed have to be considered the gold
method for the undisputable diagnosis of zoonotic ﬁlariae in humans. The
employment of this technique and of different DNA extraction protocols
on histological sections, to date hampered by the effect of the formalin
on the DNA quality, could permit the re-examination of archival formal-
ﬁxed cases, and the evaluation of the real importance of each zoonotic
ﬁlarial species in human infections.
P1750 Evaluation of Liaison toxoplasma IgG and IgM: comparison
with Vidia and Architect assays
S. Roisin °, C. Liesnard, M-L. Delforge (Brussels, BE)
Objective: Comparison of three automated diagnostic systems, Liaison
(Diasorin), Vidia (bioMe´rieux) and Architect (Abbott) for the determi-
nation of Toxoplasma gondii-speciﬁc immunoglobulin G and M.
Methods: According to Vidia results, 172 serums were classiﬁed
in 6 groups: negative, past toxoplasmosis, doubtful immunity, IgM
persistence, seroconversions, recently acquired toxoplasmosis, potential
cross-reactions. Toxoplasma IgG and IgM were tested by two automated
methods: Liaison and Vidia. Immunoﬂuorescent assay (IFA) was used as
a reference technique in case of discordant results. In a second time, 61
of these sera were tested by a third automated method, Architect. IgG
avidity index was determined by Liaison and Architect on 31 sera.
Results: IgG: of 152 specimens tested for IgG, a total of 44 samples were
classiﬁed as non reactive by Vidia, including 43 specimens that were
concordantly non reactive on both Vidia and Liaison and one discordant
specimen categorized as true non-reactive by IFA. The relative speciﬁcity
was 97.7% for the Liaison assay.
Of these 152 specimens, 95 were classiﬁed as reactive by Vidia. 92
were concordantly reactive on both Vidia and Liaison. Three samples
were discordant, IFA classiﬁed 2 samples as non reactive and one as
doubtful. The relative sensitivity for Liaison assay was 100%.
Of the 13 samples classiﬁed as doubtful by Vidia, 8 were negative, 3
positive and 2 doubtful with Liaison.
IgM: for the117 non reactive sera, using a cut-off of 10 AU/mL, the
agreement between the two methods was 100%.
Of 13 sera from 5 seroconvertions and 18 sera of recently acquired
toxoplasmosis, 2 were negative on Liaison. IFA was positive for these 2
samples.
Of the 17 sera with persistent IgM on Vidia, 14 samples were discordant
if the cut-off of 10 AU/mL was used. All these discrepant samples were
negative by IFA.
Of the 20 potentially cross-reacting samples, all were negative by both
methods.
Of the 61 sera tested with Architect, the agreement between this assay
and Liaison was 100% for IgG. Concerning IgM, Architect showed more
positive results in the persistent IgM group.
31 samples were tested for IgG avidity index on Architect and Liaison.
Three were discordant. For these 3, the results of Liaison were more
concordant with the clinical history.
Conclusions: The fully automated Liaison Toxo IgG and IgM assay
provided sensitive and speciﬁc measurements and showed a good
agreement with Vidia and Architect assays.
P1751 Evaluation of the Architect Toxo IgG, IgM and IgG avidity
assays
G. Maine °, A. Francisco, R. Stricker, R. Stricker (Abbott Park, US;
Cham, Geneva, CH)
Objective: Evaluate the performance of the ARCHITECT Toxo IgG,
IgM, and IgG avidity assays in samples from women with documented
seroconversion for toxoplasmosis during gestation and in samples from
the Toxoplasma Serology Laboratory in Palo Alto, CA.
Methods: Archived patient samples (n = 200) selected from pregnant
women (n = 47) with documented recent seroconversion for toxoplasmo-
sis were tested and the results compared to the Abbott AxSYM Toxo IgG
and IgM assays. Archived patient samples (n = 400) from the Toxoplasma
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Serology Laboratory were tested and the results compared to the Sabin-
Feldman Dye test, the differential agglutination test (AC/HS), and the
Vidas Toxo IgG avidity assay.
Results: In samples from pregnant women undergoing seroconversion
for toxoplasmosis the ARCHITECT and AxSYM Toxo IgG and IgM
assays detected the same ﬁrst bleed as Toxo IgG and IgM positive or
equivocal in 42/47 and 45/47 patients, respectively. In the remaining
patients either the ARCHITECT or AxSYM assay detected the patient as
positive for Toxo IgG or IgM one bleed earlier. Detection of Toxoplasma-
speciﬁc IgM before IgG occurred in 5/47 patients (11%). The clinical
sensitivity of the ARCHITECT Toxo IgG avidity assay using a cutoff
of 4 months post-seronegative bleed was (111/112) = 99.1% (95%CI =
95.1–100%). In samples from the Toxoplasma Serology Laboratory the
agreement between the ARCHITECT Toxo IgG test and the Toxo IgG
+ IgM tests with the Dye test was (383/392) = 97.7% (95%CI= 95.7–
98.9%) and (389/392) = 99.2% (95%CI = 97.8–99.8%), respectively.
Agreement between the ARCHITECT and Vidas IgG avidity assays was
(229/234) = 97.9% (95%CI = 95.1–99.3%). The agreement between the
ARCHITECT and Vidas Toxo IgG avidity assays with the AC/HS test
was (231/241) = 95.9% (95%CI = 92.5–98.0%) and (247/258) = 95.7%
(95%CI = 92.5–97.9%), respectively.
Conclusion: The performance of the three fully automated Abbott
ARCHITECT Toxo immunoassays was equivalent to the reference assays
and easier for a laboratory to perform than the Dye test and AC/HS assay.
P1752 Association of plasma levels of serum amyloid in kidney
transplant patients with cytomegalovirus infection
C. Steininger °, W. Ho¨pler, H. Kerschner, T. Popow-Kraupp, M. Kundi,
J. Kletzmayr, S. Schmaldienst, W. Graninger (Vienna, AT)
Objectives: Cost-effective pre-emptive therapy of cytomegalovirus
(CMV) infection in solid-organ transplantation requires frequent
screening of patients for active CMV infection with the use of
inexpensive rapid diagnostic assays. Serum amyloid A (SAA) is an
acute phase protein that was used successfully to identify in paediatric
patients acute respiratory virus infections or in HIV-infected patients
CMV infections. We evaluated the usefulness of measurement of SAA
and high-sensitivity C-reactive protein (hs-CRP) levels in plasma for the
identiﬁcation of kidney transplant patients with CMV infection.
Methods: Plasma samples (n = 132) were collected from 23 CMV-
seronegative patients who either received an organ from a CMV-
seropositive (D+/R−, n = 16) or a CMV-seronegative donor (D−/R−,
n = 7). All samples were screened for the presence of CMV-DNA and
increased levels of SAA or hs-CRP.
Results: Primary CMV infection was diagnosed in 16 (100%) of the
D+/R− patients and in one (14%) of the D−/R− patients. CMV-DNA
was detected in 70 of the 132 (53%) samples and increased SAA levels
were detected in 96% of CMV-DNA-positive samples. Levels of SAA
correlated well with those of hs-CRP (P = 0.001). However, levels of
SAA were increased in almost all available samples (125/132, 95%)
and overall, increased levels of SAA were not associated with presence
of CMV-DNA (P = 0.430). Some samples negative for CMV-DNA but
positive for SAA were collected concomitantly with manifestations of
other acute inﬂammatory disorders including acute kidney rejection
(n = 7), or respiratory, gastrointestinal, or urinary tract infections (n = 8).
P1753 High throughput sequencing and proteomics to identify
immunogenic proteins of a new pathogen: the dirty genome
approach
G. Greub °, C. Kebbi, C. Bertelli, F. Collyn, B. Riederer, C. Yersin,
A. Croxatto, D. Raoult (Lausanne, CH; Marseille, FR)
Objectives: With the availability of new generation sequencing
technologies, bacterial genome projects have undergone a major
boost. Still, chromosome completion needs a costly time-consuming
gap closure. However, incomplete genome data may be sufﬁciently
informative to derive the pursued information. For emerging pathogens
such as Parachlamydia, lack of release of genome data during gap closure
is medically counterproductive. We thus investigated the feasibility of a
dirty genome approach, i.e. the use of unﬁnished genome sequences to
develop an ELISA.
Methods: Genomic DNA of Parachlamydia acanthamoebae was
sequenced using 454 (GS20) and Solexa technologies. Sequences were
assembled using Edena and Newbler. Then, an ORFing was performed
with Glimmer. In parallel, two-dimensional immunoblots of bacterial
proteins were performed with sera of humans and rabbits positive
for Parachlamydia. Spots corresponding to immunogenic proteins were
selected by computer-assisted matching of the Coomassie blue-stained
gel and immunoblots, and further analyzed by mass spectrometry.
The identiﬁed immunogenic proteins were then expressed and used to
elaborate ﬁrst steps of an ELISA.
Results: Solexa technology produced 1’655’941 short reads of 36bp,
which could be assembled in 8’616 contigs. The latter were assembled
with the 566’453 GS20 reads in 95 contigs covering more than 97% of
the genome.
The protein database derived from the genome sequences enabled to
identify 18 different immunogenic proteins. Some of them, such as
chaperonin GroEL (Hsp60) and DnaK (Hsp70) were already known to be
antigenic. Five proteins represented good candidates for the development
of an ELISA since exhibiting signiﬁcant reactivity to sera taken from
humans infected by Parachlamydia and from immunized rabbits but
no cross-reactivity to sera from humans infected with C. pneumoniae,
C. psittaci and negative controls. The potential of two of these ﬁve
proteins to develop a diagnostic tool was suggested by preliminary
ELISA tests.
Conclusions: This work constitutes the proof of principle for a dirty
genome approach, i.e. the use of unﬁnished genome sequences of
pathogenic bacteria, coupled with proteomics to rapidly identify new
immunogenic proteins useful to develop speciﬁc diagnostic tests such
as ELISA, immunohistochemistry and direct antigen detection. These
diagnostic tools will allow further evaluations of the pathogenic potential
of this Chlamydia-related obligate intracellular bacterium.
P1754 Diagnostic signiﬁcance of a-defensins (HNP 1−3) in
recognition of chronic periodontitis in adults
A.K. Szkaradkiewicz, T.M. Karpinski °, J. Hofman (Poznan˜, PL)
Objectives: Chronic periodontitis represents a complex, multicausal
pathology, in which anaerobs of oral cavity microﬂora (most frequently
P. gingivalis, T. forsythia and T. denticola) play a principal role. However,
laboratory diagnosis of periodontitis is difﬁcult since it is based on
detection of the above mentioned periodontopathogens using, mostly,
molecular methods. Salivary antimicrobial peptides and, in particular,
a-defensins (HNP 1−3), seem to play a very important role in the local
immune reaction. Considering the above, the studies aimed at analysis
of diagnostic suitability of HNP 1−3 detection in full saliva and in sera
of patients with chronic periodontitis.
Methods: The studies were conducted on 50 adults persons. Clinical
criteria allowed to distinguish two research groups. Group 1 included
25 patients, 35 to 49 years of age, with chronic periodontitis, in 14 of
whom moderate (group 1A) and in the remaining 11 severe periodontitis
(group 1B) was diagnosed. Group 2 included 25 individuals, 20 to
42 years of age, with healthy parodontium (the control group). The
investigated material involved supernatants of centrifuged full saliva
and sera. Levels of HNP 1−3 defensins were estimated using Elisa test
(Hycult Biotechnology). In statistical analysis the non-parametric Mann–
Whitney test was used (p< 0.05).
Results: Levels of HNP 1−3 in saliva supernatants in the patients with
moderate or severe chronic periodontitis (groups 1A and 1B) amounted
to, respectively, 628±378 pg/ml and 784±640 pg/ml while in the control
group (group 2) the level was 246±148 pg/ml. The levels obtained in
either group 1A or 1B were signiﬁcantly different than those in group 2
(control group). In turn, sera of patients with moderate (group 1A) and
severe chronic periodontitis (group 1B) contained mean concentrations
(±SD) of HNP 1−3 defensins of 89±64 pg/ml and 91±41 pg/ml,
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respectively. The results did not signiﬁcantly differ from those in sera of
the control group (109±60 pg/ml).
Conclusion: In the course of chronic periodontitis, independently of its
advancement, saliva contains elevated levels of a-defensins (HNP 1−3),
which seems to reﬂect local immune response. Therefore, elevated level
of HNP 1−3 in saliva may represent a novel diagnostic marker of chronic
periodontitis in adults.
P1755 Evaluation of diagnostic cut-off values of immunoglobulin G
antibodies against pertussis toxin
S.C. de Greeff, D.W. Notermans, B. Elvers, H.E. de Melker, P. Teunis,
J.F. Schellekens ° (Bilthoven, Groningen, NL)
Objectives: Measuring IgG antibodies against pertussis toxin (IgG-PT)
with ELISA can be used to diagnose pertussis infection; however, cut-
off points have not unanimously been determined. We applied binary
mixture models to interprete IgG-PT antibodies in diagnostics samples
obtained from patients with suspected pertussis using single serum
samples and the increase in paired sera, to determine optimal cut-offs.
Methods: IgG-PT levels were used from clinical diagnostic samples
between 1st October, 2003 and 31st December, 2007 and assayed with
an in-house IgG-PT ELISA that was calibrated with the international
FDA lot 3 IgG-PT reference serum. The validity of cut-off levels in a
single serum sample was assessed by selecting patients sampled within
100 days after onset of symptoms (n = 11655). Increase in antibody titre
was studied in patients with two serum samples where the second sample
was taken within 10−28 days after the ﬁrst sample (n = 2205).
Children eligible for the acellular booster vaccination at four years of
age or vaccination with an acellular in infancy were excluded, to avoid
potential interference of a vaccine induced IgG-PT rise.
Binary distribution mixtures were ﬁtted to the age stratiﬁed data, using
the two ﬁtted components to calculate ROC curves and determine
optimum cut-off levels for positives in single samples and increase
(seroconversion) in paired samples.
Results: Given the distributions of antibody levels, an IgG-PT titre of
79 U/ml yielded the highest sensitivity (96.5%) and speciﬁcity (94.4%)
as diagnostic cut-off level. Mixtures ﬁtted to separate age categories
produced similar results: for the age-groups 1−9, 10−19, 20−39, 40−59
and >60 years a cut-off for IgG-PT titre of 66 U/ml, 92 U/ml, 81 U/ml,
78 U/ml and 107 U/ml respectively yielded the highest sensitivity (97.2,
95.3, 97.2, 96.8, 97.3%) and speciﬁcity (95.8, 91.5, 96.1, 96.0, 95.9%).
In addition, a 3.4 fold increase in IgG-PT titre in paired serum samples
yielded a high diagnostic sensitivity (99.4%) and speciﬁcity (99.7%) for
all ages.
Conclusion: We show that diagnostic samples for pertussis can be
classiﬁed into two subpopulations: a highly reactive population (persons
with infection) and a baseline population (persons without infection);
from these bimodal distributions, cut-offs for absolute values and
dynamics of IgG-PT can be derived that are associated with very high
diagnostic sensitivity and speciﬁcity.
P1756 Cerebrospinal ﬂuid D-lactate concentration in patients with
bacterial and viral meningitis
S. Ziankova °, V. Semenov, I. Veramei (Vitebsk, BY)
Goal: The aim of our study was to investigate the possibility
of cerebrospinal ﬂuid D-lactate concentration usage for differential
diagnosis of bacterial and viral meningitis.
Methods: D-lactate concentration has been deﬁned in 40 patients with
bacterial meningitis. Control group has been composed of 69 patients
with viral meningitis, 21 patients with acute respiratory tract infections
and meningism symptom and 14 patients with noninfectious origin of
CNS lesions. Etiology of meningitis was estimated by bacteriological
method of examination, LAT and PCR. CSF D-lactate concentration
was determined by the spectrophotometric technique in the beginning of
disease and later.
Results: CSF D-lactate concentration in patients with bacterial
meningitis was signiﬁcantly higher than in control group (p< 0.00001).
CSF D-lactate concentration median in patients with bacterial meningitis
in the beginning of the disease was 10.5mg/l (7.24–13.18mg/l); in
patients with viral meningitis − 1.58mg/l (0.31–3.88mg/l). Differential
diagnostic level of CSF D-lactate is 6.265mg/l (corresponding sensitivity
83.33% and speciﬁcity 93.48%, area under the ROC curve = 0.932;
standard error = 0.042; 95%CI = 0.868–0.971; P = 0.0001). In
addition, CSF D-lactate concentration of 8.62mg/l corresponds to 100%
speciﬁcity. We didn’t reveal signiﬁcant differences in CSF D-lactate
concentration in patients with bacterial meningitis of a various aetiology
(p = 0.83), but CSF D-lactate concentration in patients with the malignant
disease course (focal neurologic symptoms and etc.) was signiﬁcantly
higher than in patients without concomitant encephalitis (p = 0.036).
CSF D-lactate concentration have been reduced for the treatment of
acute bacterial meningitis to a 1.28–4.20 times within 2−4 days provided
effective antibacterial therapy and raised in 4.62–9.22 times at negative
dynamics.
Conclusions: Thus, CSF D-lactate concentration more than 6.265mg/l
may be used as additional criterion of bacterial meningitis diagnostics.
A growth of CSF D-lactate concentration for the process of treatment
can be an indicator of inefﬁcacy of antibacterial therapy.
P1757 Antibodies to Bordetella pertussis antigens measured in saliva
M. Riffelmann °, M. Littmann, C. Hu¨lße, C. Wirsing von Koenig
(Krefeld, Rostock, DE)
Objectives: IgG-anti-pertussis toxin (PT) antibodies used in pertussis
serology are usually measured in serum samples. Measuring antibodies
in saliva samples could offer an alternative.
Methods: 206 adolescent and adult patients with longer lasting coughs
were recruited by 19 sentinel physicians (10 general practitioners, 9
paediatricians) in the Rostock (Germany) region between January 2008
and April 2009. Clinical symptoms were recorded. From every patient,
a nasopharyngeal swab, a serum sample and a saliva sample was
taken. Saliva samples were collected in a standardized manner by a
commercially available device (OraSure®). Bordetella-DNA (B. pertussis
and B. parapertussis) was detected by real-time PCR in nasopharyngeal
swabs. The levels of serum IgG and IgA, and the levels of saliva IgG and
IgA were measured by rate nephelometry. IgG- and IgA-antibodies to PT
and ﬁlamentous hemagglutinin (FHA) were quantiﬁed by a standardized
ELISA in serum and saliva samples. In serum samples, IgG-anti-PT
levels of 100 IU/ml were regarded as indicative of recent contact, and
IgG-anti-PT levels of 40 IU/ml were interpretede as not indicative of
a recent contact.
Results: In a total of 45 patients (18%) a recent contact to Bordetella was
substantiated either by serum antibodies alone or also by PCR (n = 12).
PCR was more often positive in adolescent patients. Antibodies in saliva
could be measured by the standardized ELISA procedure used for serum
samples. The antibodies measured in saliva correlated well with the
serum concentration, when the total IgG / IgA content of the saliva
samples was taken into account. Similar to serum, IgG anti-PT was
found to be more often indicative of recent contact than IgA-anti-PT.
Conclusions: Measuring IgG-and IgA-anti-PT antibodies in saliva
samples taken with a standardized device and correlated to the total
IgG/IgA content of the saliva could offer an alternative to measuring
anti-pertussis antibodies in serum samples.
P1758 Peripheral blood RNA gene expression proﬁling in the
patients with community-acquired bacterial meningitis
M. Lill °, S. Ko˜ks, U. Soomets, L.C. Schalkwyk, C. Fernandes, I. Lutsar,
P. Taba (Tartu, EE; London, UK)
Objectives: We aimed to describe the genetic pathways activated
during the community acquired bacterial meningitis (BM) and healthy
controls by using genome-wide RNA expression proﬁling combined with
functional annotation of transcritpional changes.
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Study was performed in 21 patients with BM and their data were
compared with eighteen age and sex matched healthy controls.
Methods: We included 21 patients (median age 56.1 years) with
culture proven BM hospitalised between the 1st of January and 31st of
December 2008. The control group consisted of 18 age and sex matched
subjects (median age 55.3 years). The blood samples were collected via
venepuncture on admission. The RNA was extracted from whole blood,
a and b globin mRNA was depleted and gene expression proﬁling was
performed with GeneChip Human Gene 1.0 ST Arrays (Affymetrix,
Santa Clara, USA) enabling the analysis of 28,869 genes.
To verify the genechip results, we chose ten genes (CD177, IL1R2,
IL18R1, IL18RAP, OLFM4, TLR5, CPA3, FCER1A, IL5RA, IL7R)
from the gene expression proﬁling data and performed further analyse
with real-time (RT) PCR. Quantitative RT-PCR successfully veriﬁed
previously found differences. Gene expression proﬁle data was analysed
by Bayesian modelling. To deﬁne changed genetic networks functional
annotation of enriched gene sets was used.
Results: BM was mainly caused by Streptococcus pneumonia (14)
followed by Neisseria meningitidis (2) and Streptococcus agalactiae (2).
Comparing the controls with the patients, we identiﬁed the signiﬁcant
changes at p values of <0.05 in 8569 genes, after False Discovery Rate
(FDR) correction total of 5500 genes remained signiﬁcant at p value of
<0.01. Functional annotation and network analysis indicated that most
of the genes were related to activation of inﬂammatory processes. Next
common of the upregulated genes were responsible for allergic reactions
and anaphylaxia. Those changes were seen in our study both among the
adults and the children.
Conclusion: This study demonstrates a strong functional evidence of
the activated immune response. This may indicate that the protective
reactions caused by severe and active infection are even too strong.
P1759 Saccharose-stabilized intravenous immune globulin as a
cause of false-positive Aspergillus galactomannan assay in
patients
M.E. Bougnoux °, H. Coignard, A. Alanio, F. Lanternier, C. Charlier,
F. Suarez, E. Catherinot, P. Frange, M. Debre´, R. Clement, M. Ben
Soltana, M. Lecuit, P. Bourget, O. Lortholary (Paris, FR)
Objective: The detection of galactomannan (galactofuran) antigen
(GMA) in serum by the Platelia® Aspergillus kit is extensively used
for diagnosis of invasive aspergillosis (IA). However, the GMA assay
yields a number of false positive results due to cross reactivity. Cross
reactivity has already been described with some antibiotics or parenteral
nutrition preparations. We observed a recent increase in the frequency of
positive tests in patients receiving intravenous immune globulin (IVIG),
with no evidence of IA at the time of sampling or during follow up.
In this study, we prospectively investigated whether IVIG administration
could induce false positive GMA test in 15 patients.
Methods: The sera from 9 adult patients who received saccharose-
containing IVIG products (Sa-IVIG) and of 6 pts who received maltose-
containing IVIG products (Ma-IVIG) were assayed for the presence of
GMA. We also tested for GM (i) batches of IVIG solutions given to each
of these patients, (ii) samples of 5 other commercially available IVIG
(4 non-sugar- and 1 glucose-containing products), and (iii) each sugar
alone at the concentration used to stabilize the IVIG preparations.
Results: GM was detected in sera from 6/9 patients treated by Sa-IVIG
(index: 0.7−2), while all sera from patients receiving Ma-IVIG were
negative. All Sa-IVIG batches tested yielded positive results (index: 2−7)
while the other IGIV solutions were all negative. All saccharose solutions
were positive (index: 2−3) while glucose and maltose solutions were
negative.
Conclusions: These results demonstrated a strong cross reactivity
between the Platelia® kit and Sa-IVIG. These false positive results
could be due, in part, to a cross reactivity with saccharose which has
a biochemical structure closely related to that of galactofuran which is
detected by the assay. Clinicians should be aware of this problem which
might lead to inappropriate suspicion of IA.
P1760 Evaluating the validity for using serum neopterin and
chitotriosidase levels in follow-up brucellosis patients
O¨. Coskun °, S. O¨ter, H. Yaman, S. Kilic¸, C.P. Eyigu¨n (Ankara, TR)
Due to its high morbidity rates, the systemic inﬂammatory disease
Brucellosis is still an important health problem, particularly in
Mediterranean regions. One third of the patients are characterized
with musculoskeletal involvement. Principally in chronic cases, there
are difﬁculties in follow-up the success of the treatment. Radiological
imaging methods are used in musculoskeletal Brucellosis in addition to
standard serological tests. Two macrophage products, namely neopterin
(NPT) and chitotriosidase (ChT), are used as novel markers in order to
reﬂect the status of inﬂammatory diseases. In this study, we aimed to
test the validity of these markers in follow-up of Brucellosis patients. A
total of 40 Brucellosis cases were included in the study and 27 healthy
individuals were used as controls. Twenty of the Brucellosis patients
presented involvement of the sacroiliac joint. A 6-week treatment of
doxycycline combined with rifampicin or streptomycin was used to treat
Brucellosis. Clinical observations and serological outcome was used to
decide whether treatment was successful or not. All of the 20 Brucellosis
patients without musculoskeletal involvement healed with the ﬁrst cure of
treatment, but all of the Brucella-sacroiliitis patients had to be retreated.
In addition to routine testing, serum NPT and ChT levels were evaluated
after each treatment. The results presented a clear fall in both NPT
and ChT levels in parallel to the serological data of the patients. In
conclusion, NPT as well as ChT seem to be useful markers in the follow-
up of Brucellosis patients and for evaluating the success of therapy.
P1761 Evaluation of cerebrospinal ﬂuid viscosity as a novel
diagnostic measure for acute meningitis
F. Yetkin °, U. Kayabas, Y. Ersoy, Y. Bayindir, S. Altunisik Toplu, I. Tek
(Malatya, Ankara, TR)
Objectives:In this study we aimed to evaluate the role of CSF viscosity
as complemantary measure for diagnosis of meningitis in suspected
patients.
Methods: Forty one consecutive patients who undergone lumbar
puncture to rule out meningitis were included in the study. The cases
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were further categorized into two subgroups: (i) the bacterial meningitis
group, whose CSF culture yielded one or more known causative bacteria;
and (ii) the aseptic meningitis group, comprising those with negative
CSF and blood cultures and recovery without more than 4 days of
antibiotic treatment. In the remaining 14 patients diagnosis of meningitis
was ruled out. A blood or CSF sample was also placed into a tube
containing ethylenediaminetetra-acetic acid (EDTA) anticoagulant for
viscosity analysis. Measurements of CSF and plasma viscosity were
performed using Brook-ﬁeld DV-II viscometer (Brookﬁeld, Stoughton,
MA, USA).
Results: Among the 41 patients included in the study, 27 patients
were diagnosed as meningitis. Of whom 13 patients were aseptic
meningitis, 14 patients were bacterial meningitis. Causative agents in
bacterial meningitis were found to be Streptococcus pneumoniae in 10
(71%) patients, Neisseria meningitidis in 2 (14%) patients, Streptococcus
pyogenes in 1 (7%) patients and Acinetobacter spp in 1 (7%) patient.
Meningitis was ruled out in 14 patients. CSF protein and CSF viscosity
were signiﬁcantly higher in patients with meningitis compared to non
meningitis(Table 1). ROC analysis revealed that CSF viscosity was
highly sensitive (100%) and speciﬁc (93%) measure for the diagnosis of
meningitis in the study population and was comparable to those of CSF
protein. Although speciﬁcity of plasma viscosity is comparable with CSF
protein and viscosity, sensitivity of plasma viscosity was signiﬁcantly
lower than those of CSF protein and viscosity. Additionally patients
with meningitis were also divided into two subgroups as having bacterial
and aseptic meningitis. CSF viscosity also signiﬁcantly differed between
bacterial and aseptic meningitis.
Conclusion: Although the sensitivity and speciﬁcity of the CSF viscosity
is comparable to those of CSF protein, CSF viscosity which is a simple
and easy method can be used as an adjunctive measure for the diagnosis
of meningitis. With the support of further and larger clinical studies CSF
viscosity may have a role in the discrimination of bacterial versus aseptic
meningitis.
Table 1. Baseline characteristics of patients and cerebrospinal ﬂuid
analysis of patients
Patients
without
meningitis
Patients with
meningitis
P value
Age (year) 49±19 42±15 0.19
Gender (female) 54% 32% 0.19
White blood cell/mm3 9520±4431 14190±7352 0.058
Erythrocyte sedimentation rate (mm/h) 27±27 55±34 0.006
C-reactive protein (mg/dL) 29±32 120±102 0.005
Plasma viscosity (mpa·s) 1.23±0.06 1.33±0.10 0.002
Cerebrospinal ﬂuid
Protein (mg/dL) 33.3±10 218±177 <0.001
Glucose (mg/dL) 86±37 50±40 0.001
CSF viscosity (mpa·s) 0.72±0.018 0.84±0.08 <0.001
CSF: Cerebrospinal Fluid.
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P1762 Changing traditional diagnostic medical bacteriology into
a lean-automated workﬂow
M. van Straten, J.J. de Vries, F. Keuren, B.M. Diederen °, G. Mulder,
D. Veenendaal (Haarlem, Drachten, NL)
Objective: Most medical microbiological Laboratories (MML) perform
bacteriology in which technicians process specimens from start to ﬁnish.
Some MML improve the work process by lean methodology;efﬁciency
with less costs and labor, conserving high quality. Due to a
high difference of specimens and procedures, lean methodology in
medical bacteriology is more difﬁcult to implement compared to
industrial bacteriology. For this raison we implemented lean-automated
bacteriology, supported with a management efﬁciency tool.
Methods: In September 2008 an automated transportation, inoculation
and reading system for bacteriological cultures was implemented in
the Public Health laboratory in Haarlem, The Netherlands. This MML
services a 550,000 community with 3 teaching hospitals, nursing homes
and general practitioners. Per day 500–600 specimens are processed.
Culture media are digitally recorded, the digitalized pictures are scored
on a computer screen and signiﬁcant colonies are selected by a software
tool for determination and sensitivity testing. The work ﬂow changed
from traditional single person to a multi-person multistep controllable
workﬂow. Using lean methodology a scoring tool was developed for
efﬁciency measurement.
Results: Analysis of the traditional workﬂow showed 4 primary decision
and 25 different handling steps. Implementing the automated sample
transportation, inoculation and viewing system the number of handling
steps reduced to 17 (34% decrease). By spreading decision and handling
steps over the day the overall bacteriology laboratory productivity index
(i.e. the number of specimens per technicians) increased 25%. Additional
overtime by technicians decreased with 33% from 592 in 2007 tot
396 hours in 2009 on a yearly basis. Implementation of automation
and changes according lean methodology, further improved the mean
variation time of sample throughput.
Conclusions: Implementing automated medical diagnostic bacteriology
substantially changes the bacteriological workﬂow from a difﬁcult
to control traditional single work spot to a multistep controllable
workﬂow. A business management software tool is needed to analyze
the effectiveness of sample processing including variables as the
number of different specimens, culture media, decision and handling
steps. Implementing automated bacteriology and changing the workﬂow
according to lean methodology will lead to a controlled continuous
improvement of the medical bacteriological workﬂow.
P1763 Validation of the MicroScan WalkAway-96 for identiﬁcation
of Enterobacteriaceae and detection of b-lactam resistance
mechanisms
P. Bogaerts °, L. Patteet, M. Ieven, Y. Glupczynski (Yvoir, Antwerp, BE)
Objectives: Detection of extended-spectrum b-lactamases (ESBL)
is a challenging task for diagnostic laboratories. We aimed to
evaluate the performance of the MicroScan WalkAway-96 (MScan)
instrument (Siemens) for identiﬁcation and detection of ESBL-producing
Enterobacteriaceae (EB) (ESBLE).
Methods: A collection of 180 EB (145 ESBL-, 32 non-ESBL- and 3
carbapenemases-producing isolates) fully identiﬁed in the scope of a
national Belgian survey in 2008 was used. All isolates were identiﬁed
by VITEK2 and API20E. Their ESBL status was conﬁrmed by double
disk test according to CLSI guidelines. For AmpC producers, boronic
acid was used in combination disc synergy tests to conﬁrm the ESBL
status. Resistance genes were identiﬁed by PCR-sequencing targeting
ESBL, carbapenemases, plasmidic and chromosomal AmpC coding
genes. Identiﬁcation and susceptibility testing on MScan were performed
with Negative BP Combo 40 panel with integrated ESBL conﬁrmation
according to the manufacturer’s recommendations. The screening of
ESBL-producing microorganisms was based on rules contained within
the LabPro Expert System adapted to the current international guidelines.
Results: Of 180 isolates (76 E. coli, 36 K. pneumoniae, 36 E. aerogenes,
16 E. cloacae, 7 K. oxytoca, 4 C. freundii and 5 others) 177 (98%) were
correctly identiﬁed by MScan.
Regarding the detection of the resistance phenotypes, overall agreement
between MScan and reference methods was 81.7%. Among 145 ESBLE,
124 (86%) were detected as ESBL-producers but 4 needed additional
testing. Seventeen of 21 (81%) isolates not correctly identiﬁed as ESBLs
were AmpC producing strains. Among the 32 non ESBL strains, 23
(72%) were correctly assigned as non ESBL isolates including 14
AmpC producers: these required additional testing according to the
“possible ESBL” additional remarks by MScan. Nine out of the 32
(28%) non ESBL isolates, (including 5 AmpC producing E. coli, 2 K1
K. oxytoca, 2 OXA-30 E. coli) were however misidentiﬁed as ESBLE.
For carbapenemases, the 2 MBL and KPC-producing isolates were
referred as possible KPC carbapenemase while the OXA-48 expressing
isolate was not detected.
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Conclusion: Species identiﬁcation of Enterobacteriaceae by MScan is
excellent. Concerning ESBL detection, the system seems more adapted
to non-AmpC expressing strains. Differentiation between AmpC and
ESBL producing strains remains challenging especially among AmpC
producing strains which are often misidentiﬁed as ESBLEs.
P1764 Comparative evaluation for automated plate streaking on
stool samples using Previ Isola®
S. Zimmermann °, M. Trampe (Heidelberg, DE)
Objectives: We performed this study on automated plate streaking of
stool samples using the PREVI Isola® to evaluate the system in terms
of sensitivity, quality of the results and time saving compared to the
manual method used in our laboratory before.
Methods: A total of 2811 stool samples were analysed within six
months. 1358 faecal specimen were plated manually in 3 month (May-
July 2009) and 1453 specimen were inoculated by an automated plate
streaker (August-October 2009).
For manual streaking the stool was directly plated using a loop, for
automated streaking 1g of faeces was diluted in 1.5ml saline solution
(0.45%). The instrument selects the media to inoculate, applies a radical
inoculum onto the agar plate and performs a circular streaking (345º)
with a disposable applicator. The time measurement for manual and
automated performance was recorded for all steps of the procedure.
The suitability of the automated streaking was judged by the technicians
as higher, equivalent or lower to the manual streaking (56 samples).
A sensitivity test was performed by serial dilutions of the main
gastrointestinal pathogens (Salmonella, Shigella, Campylobacter and
Yersinia) in stool inoculated with both methods.
Over a 3 month period the number of detected bacterial pathogens were
analysed in retrospect.
Results: The PREVI Isola® allowed a faster processing of the faeces
than the manual method. The suitability of the automated streaking was
rated as higher in 48% and as equivalent in 48% of the samples, only 4%
of the plates were ranked as lower quality. Serial dilutions of Salmonella,
Shigella, Yersinia and Campylobacter strains in inhibitor free stool of
healthy adults resulted in an at least comparable plating efﬁciency of the
automated stool inoculation. Within 1358 stool samples plated manually
12 Salmonella species were detected (0.9%) and 3 Campylobacter strains
(0.2%) between May and July 2009. In 1453 faecal samples processed on
the PREVI Isola® (August–October 2009) 24 Salmonella species (1.7%)
and 6 Campylobacter species (0.4%) were found; additionally 2 Shigella
strains, one Plesiomonas shigelloides and one Listeria monocytogenes
were isolated.
Conclusion: The PREVI Isola® system seems to produce a higher
suitability in streaking of faecal samples. The time saving procedure has
a comparable sensitivity for the detection of gastrointestinal bacterial
pathogens. A higher detection rate in a retrospective analysis has to be
conﬁrmed in further evaluations.
P1765 A new automated test on the Vidas instrument to detect
Escherichia coli O157 in human stool without enrichment
F. Heskia °, P. Mariani-Kurkdjian, S. Martin, J.F. Rey, S. Ait-Ifrane,
B. Inc¸aurgarat (Marcy l’Etoile, Paris, FR)
Objectives: VIDAS E coli O157 Clinic is an automated ELISA test
based on Phage Technology for the qualitative detection of the O157
serogroup (including H7 serotype) directly from human stool. The
performance obtained with the VIDAS E coli O157 kit using human
stool, without enrichment was evaluated.
Methods: Antibody-based assays can exhibit cross-reactions and non-
speciﬁc binding resulting in false-positive results. To improve assay
speciﬁcity, we used bacteriophage recognition elements on the solid
phase (VIDAS SPR) responsible for bacterial capture during the ELISA:
These recognition elements utilized by bacteriophages to speciﬁcally
bind to their bacterial hosts are extremely speciﬁc as they are essential
for phage propagation and survival. To process samples, stools were
simply diluted in buffered peptone water. No enrichment was performed.
Detection limit and precision studies were performed on artiﬁcially
spiked human stools. An interference study was performed with 18 of the
more common bacteria strains responsible for diarrhoea, including other
STEC serogroups (O26, O103, O111, O145). Sensitivity and speciﬁcity
studies were performed on 149 natural samples routinely collected from
E. coli National Reference Center in Robert Debre´ Hospital, Paris,
France.
Results: VIDAS E coli O157 displayed a very good detection limit on
human stools, i.e 4.5×103 CFU/mL. The precision study was performed
according to the CLSI document EP5-A2. The total % CV observed was
11.3% for a sample around the cut-off. No interference was observed
with bacteria responsible for diarrhoea tested nor with other STEC
serogroups. 149 naturally positive and negative human stool samples
were tested with the VIDAS E coli O157 assay. Their clinical status
for E coli O157 was established following the Robert Debre´ laboratory
algorithm. The VIDAS E coli O157 assay showed a sensitivity of 96.97%
and a speciﬁcity of 97.41% in comparison to this status.
Conclusion: VIDAS E coli O157 Clinic has several advantages in
comparison with classical detection of E coli O157 on SMAC culture.
These advantages are processing simplicity (sample dilution, VIDAS
reagents and instrument ease of use), quickness (results obtained in 1.5
hour from sample processing to ﬁnal result), test sensitivity compared
to culture, and ease of interpretation (automated result).
The VIDAS E coli O157 Clinic shows good sensitivity with a rapid time
to result.
P1766 The yield of pathogens and isolated colonies by automated
streaking using the InoqulA®
P.D. Sturm °, P.J. Cuppen, C.J. Siebes, S. Kuipers (Nijmegen, NL)
Objective: Automated streaking by the InoqulA (Kiestra) was evaluated
for the yield of (potential) pathogens and isolated colonies.
Methods: Specimens received in the laboratory for routine diagnostics
were investigated by standard culture methods with manual streaking
(MS). Subsequently, suspensions were prepared from swabs and purulent
parts of sputum, in 1ml saline and 0.5ml sputolysin, respectively. For
automated streaking (AS), 25 microlitre of the suspensions and 10
microlitre of urine was used. Identical culture procedures were followed
with respect to culture media, and incubation. Enumeration of growth
on urine culture after AS was done by using the extent of growth of
isolated colonies on 1/4, 1/2, 3/4, and 4/4 of the agar surface.
Results: In total, 67 swabs, 36 sputum, and 83 urine specimens were
evaluated using 283 culture media. Using MS and AS, 171 and 172
potential pathogens were detected, of which 137 and 135 were present
as isolated colonies, respectively (Table 1). Of the 11 swab cultures
with S. aureus, 3 of 22 media showed no growth by AS while 1, 3,
and 9 colonies were present by MS. Streptococci and Pseudomonas
were detected in all cases by both methods. Other Gram negative rods
(GNR) were cultured from 22 swabs on 42 media: 8 media showed
growth of 1 additional GNR morphology by AS. By MS, 4 and 1 media
showed additional growth of 1 and 2 morphologies, respectively. Sputum
was cultured on 79 media. H. inﬂuenzae, S. pneumoniae, Moraxella
catarrhalis, and S. aureus were detected on 15 media from 10 sputa
by both methods. GNR were detected on 9 media from 5 sputa. With
MS, 10 morphologies were detected and 11 with AS. Enumeration of
growth from urine after AS correlated well with MS. Of the 51 specimens
reported as negative by routine culture, 38 showed no growth with AS,
and 12 showed scanty growth of single colonies only on 1/4 of the
surface, and 1 on 1/2 of the surface. 32 specimens were reported positive
of which 2 contained 104–105 cfu/ml after MS, with growth on 2/4 and
4/4 of the surface after AS, and 30 contained >105 cfu/ml with growth
after AS on 2/4 in 2 specimens and on 4/4 in 28. In the 32 positive
urine specimens, 46 uropathogen morphologies were detected by both
methods, and 1 addidtional GNR was detected by AS. With both MS
and AS a similar number of pathogens were present as isolated colonies.
Conclusion: AS resulted in similar detection of pathogens as with
routine MS. Isolated colonies were obtained equally by both methods.
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Pathogens detected Isolated colonies
MS AS MS AS
Swabs, n = 67; 121 media
S. aureus 22 19 19 18
Streptococci 7 7 7 7
Pseudomonas 9 9 9 9
GNR 62 64 40 37
Sputum, n = 36; 79 media
S. pneumoniae 2 2 2 2
H. inﬂuenzae 5 5 5 4
M. catarrhalis 3 3 3 3
S. aureus 5 5 4 3
GNR 10 11 7 7
Urine, n = 13; 83 media
uropathogens 46 47 41 45
Total 171 172 137 135
P1767 Setting a new improved standard for quantization of
bacterial growth using the InoqulA
C. Visser °, H. Knol, B. de Wever (Amsterdam, NL)
Objectives: In routine bacteriological diagnostics semi-quantitative
cultures are used. The quantization of urine cultures is even more
exact since a standard volume is used for inoculation. Recently
several automated inoculation systems have been introduced in routine
diagnostics. One of these systems is the InoqulA (KIESTRA Lab
Automation, the Netherlands). This system differs from the other
systems and manual inoculation in using a magnetic bead instead of an
inoculating loop or similar device. To determine the quantity of bacterial
growth when using this novel inoculation system a new standard had to
be set to be able to interpret the amount of growth.
Methods: An 8-fold dilution series of an Escherichia coli strain was
prepared. 10 microliter of each dilution was inoculated on Orientation
agars (Becton Dickinson) and incubated over night at 37ºC O2. Per
dilution 4 plates were inoculated; 3 with different patterns on the InoqulA
and 1 manually.
Results: See table 1.
Conclusion: A clear difference in amount of growth corresponding to
the inoculated numbers of bacteria could be observed. This difference
was more distinct on the plates which were inoculated automatically
with the InoqulA than on the manually inoculated plates. Quantization
is very well possible when using this novel inoculation system. Because
the system allows a wide variety of inoculation patterns this standard
has to bet set for each different pattern.
Concentration
in cfu/ml
Escherichia coli
Absolute
number of
bacteria/agar
Result
7×108 7×106 Single colonies on last 1/3 of the agar
(depending on the pattern). First 2/3
of the agar shows conﬂuent growth
7×107 7×105 Idem
7×106 7×104 Single colonies on second half of
the agar. First half shows conﬂuent
growth
7×105 7×103 Single colonies up to 2/3 of the agar
7×104 7×102 Single colonies on ﬁrst half of the
agar
7×103 7×101 Single colonies up to max. 1/3 of the
agar
7×108 7×100 Only growth on site of inoculation
7×108 7×10−1 No/scant growth on site of inoculation
P1768 In vitro comparison of two blood culture systems for the
detection of polymicrobial sepsis
V. O¨zenci °, S. Muhammed, L. Klingspor (Stockholm, SE)
Objectives: To compare the performance of Bactec aerobic (AE),
anaerobic (AN) and mycosis and Bact/ALERT aerobic (FA) and
anaerobic (FN) blood culture vials in detection of polymicrobial sepsis
caused by yeasts and bacteria.
Methods: A total of 6 reference and 28 clinical isolates of Escherichia
coli, Staphylococcus aureus, Candida albicans and Candida glabrata
were included in the study. Different polymicrobial models of C. albicans
+ S. aureus, C. albicans + E. coli, C. glabrata + S. aureus, C. glabrata +
E. coli, C. albicans + C. glabrata were prepared. Each combination was
inoculated in ﬁve different blood culture vials. Then the two systems
were compared for culture positivity and time to detection (TDT).
Results: Twenty-four mixed cultures with a yeast and a bacteria were
prepared and tested in 120 blood culture vials. Mycosis vials from Bactec
could detect yeasts in all 24 cultures (100%). The aerobic vials from
both Bactec and BacT/Alert could detect both yeasts and bacteria in
22/24 cultures (91.66%). In two mixed cultures Bactec AE vials could
detect only yeasts whereas BacT/Alert FA vials could detect only yeasts
in one and only bacteria in the other mixed culture. Bactec AN vials
could detect both microorganisms in 19/24 (79.16%) and only bacteria
in 5/24 (20.83%) mixed cultures. The BacT/Alert FN vials could detect
both microorganisms in only 7/24 (29.16%) and only bacteria in 14/24
(58.33%). Seven polymicrobial sepsis models with one C. albicans and
one C. glabrata isolates were also tested. Mycosis vials could detect
both yeasts in 7/7 (100%) mixed cultures. The aerobic vials from
Bactec and BacT/Alert could detect both yeasts in 3/7 and 2/7 mixed
cultures, respectively. The Bactec AN vials could detect both yeasts in
6/7 mixed cultures whereas BacT/Alert FN vials could not detect any
yeast growth in 7 mixed cultures tested. The mean + STdev fo¨r TDT
were signiﬁcantly shorter in mycosis vials (17.8+1.6 h) compared to all
other vials (29.03+4.36 h) in the study.
Conclusion: The present study shows that Bactec and BacT/ALERT
have different characteristics in detection of polymicrobial sepsis with
yeasts and bacteria. Only Bactec mycosis vials could detect growth of
all yeasts in polymicrobial sepsis models tested. The aerobic vials from
Bactec and Bact/Alert performed similarly whereas the BacT/Alert FN
vials signiﬁcantly inferior in detection of yeasts compared to Bactec AN
vials.
P1769 Molecular versus conventional methods and Vitek2 NH
card for identiﬁcation of fastidious Gram-negative rods in
the clinical microbiology laboratory
R. Zbinden °, A. Zbinden, J. Scho¨nenberger, G.V. Bloemberg,
E.C. Bo¨ttger (Zurich, CH)
Objectives: The use of 16S rRNA gene sequence analysis in the clinical
laboratory as a means of identifying fastidious Gram-negative rods
(GNR) was evaluated.
Methods: A total of 130 isolates, subdivided into two groups, were
analyzed by comparing biochemical identiﬁcation with that of 16S
rRNA gene sequencing; (i) a control group of 84 well-identiﬁed clinical
isolates, analyzed retrospectively, and (ii) a study group of 46 clinical
isolates, collected and analyzed prospectively.
Results: Conventional identiﬁcation correctly identiﬁed 55 of the 130
isolates (42%) to species level, in particular Aggregatibacter aphrophilus,
Cardiobacterium hominis, Eikenella corrodens, Pasteurella multocida,
and 22 isolates (17%) correctly to genus level, notably Capnocytophaga
sp.; 53 of the isolates (41%) were not identiﬁed or misidentiﬁed.
Additional analysis of a subgroup of 81 of the 130 isolates by the
colorimetric VITEK 2 NH card (Bio-Me´rieux, Marcy-l’Etoile, France)
revealed that this system supports the identiﬁcation of fastidious GNR
similar to that of conventional biochemical reactions (39.5% correct
identiﬁcation to species or genus level; 36% incorrect assignment to
species or genus level; 24.5% no identiﬁcation). In comparison, 16S
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rRNA gene sequencing correctly identiﬁed 117 (90%) of the isolates
to species level; of the remaining 13 isolates 12 (9%) were correctly
identiﬁed to genus level and 1 (1%) to family level.
Conclusion: The 16S rRNA sequencing is an effective means for
identiﬁcation of fastidious GNR in the clinical microbiology laboratory,
which are difﬁcult to identify by conventional methods.
P1770 Rapid identiﬁcation and antimicrobial susceptibility testing
of bacterial strains from positive blood cultures with
combination system Bactec/SST/Phoenix®
B. Kowalska-Krochmal °, I. Dolna, A. Szkarlat, E. Wrzyszcz, S. Balicka
(Wroclaw, Cracow, PL)
Objectives: Rapid microbial diagnostic may accelerate intoduction of
accurate antibacterial treatment. The aim of our study was estimation
of agreement direct diagnosis of positive blood culture bottles in to
Phoenix® automated system (BD) with standard methods.
Methods: 64 monobacterial positive Bactec® (BD) blood cultures bottles
(n = 64) were estimated. Positive culture − 8.5ml was aspirated to
vacutainer tube − SST (BD) and centrifugated in a swinging bucket rotor
at 2,000g for10 min. After centrifugation supernatant was discarded,
bacterial pellet over the gel was resuspensed and inoculated in Phoenix®
ID broth to obtain 0.5MC Farland. According to Gram staining,
adequate the Phoenix® ID/AST panels were choosen and performed with
agreement of manufacturer’s instruction. Results of direct identiﬁcation
and direct susceptibility tests were compared to the standard methods
(Phoenix, disk diffusion method and E-test®) with used pure overnight
bacterial cultures on the plates. Discrepaciens in the identiﬁcation were
resolved by API® or ID Crystal®.
Results: Among 64 blood cultures 44 were Gram-negative rods and
20 Gram-positive cocci. In 3 cases of Gram-negative rods, both
direct and standard identiﬁcation, was impossible. Direct identiﬁcation
was correct in 87% − 53/61 (among Gram-negative rods − 90%
and Gram-positive cocci − 70%). For Gram-negative rods: in direct
and standard AST Phoenix® were shown total agreement results for
amikacin, cefepime, ceftazidime, imipienem and meropenem, 2 major
errors one for gentamicin and one for piperacillin/tazobactam,; in
direct method vs disk diffusion test was observed total agreement
only for imipenem and meropenem, 1 very major error − cefepime
and 5 major errors (gentamicin − 1, cefepime − 1, ceftazidime − 1,
piperacillin/tazobactam − 2); in direct method vs E-test respectively
total agreement − ceftazidime, imipenem, meropenem; 1 very major
error − cefepime. For Gram-positive cocci: direct method was in total
agreement with standards methods for vancomycin and teicoplanin;
1 very major error was conﬁrmed for oxacillin.
Conclusions: (1) Direct identiﬁcation and susceptibility test performed
with used combination system (Bactec/ SST/Phoenix® test) was shown
as accurate method for Gram-negative rods. (2) Direct method seems
to be not acceptable in identiﬁcation of Gram-positive cocci especially
Staphylococcus species.
P1771 Comparative evaluation of a new commercial method
Vitek 2 vs. CLSI M38-A2 reference method for susceptibility
testing of antifungal agents against ﬁlamentous fungi
S. Vega, M.T. Gonzalez, A. Romero, A. Martos, C. Castro, A. Gonzalez,
E. Martin-Mazuelos ° (Salamanca, Seville, ES)
Objectives: The incidence of invasive and opportunistic fungal infec-
tions has increased signiﬁcantly over the past two decades. Emerging
fungal pathogens include species of Aspergillus and other ﬁlamentous
fungi as Fusarium spp and Scedosporium spp. The variable susceptibility
to established antifungal agents has created a need for in vitro test to
determine the susceptibility of clinical isolates of ﬁlamentous fungi. Our
objective was to compare the automated commercial system VITEK2
(bioMe´rieux, SA) was compared to CLSI broth microdilution method
(M38-A2) for determining the in vitro susceptibility to amphotericin B,
ﬂucytosine, voriconazole and ﬂuconazole against ﬁlamentous fungi.
Methods: A total of 57 clinical isolates were evaluated: 14 A. fumigatus,
14 A. terreus, 12 A. ﬂavus, 11 Scedosporium spp and 6 Fusarium spp.
Quality control was ensured by testing the strains: Candida krusei ATCC
6258 and Candida parapsilosis ATCC 22019. A ﬂavus ATCC 204304
and A. fumigatus ATCC 204305 were used as reference strains in each set
of experiments. The AST-YS01 VITEK 2 system was realized according
to manufacturer instructions. Broth microdilution test was performed
in accordance with CLSI guidelines (document M38-A2) and read at
48 hours of incubation. The results obtained were expressed as MIC90
(mg/L) and essential agreement within±2 dilutions.
Results: The MIC90 results obtained by the VITEK 2 system for all
species and antifungal agents tested were two or three dilutions higher
than those obtained by BMD, with the exception of ﬂuconazole.
The overall agreement between both methods against Aspergillus spp
was 67% for amphotericin B, 60% for ﬂucytosine, 57% for voriconazole
and 53% for ﬂuconazole. For Fusarium spp, the best agreement was
obtained with ﬂucytosine and voriconazole (86%), and the worst results
were obtained with amphotericin B (57%) and ﬂuconazole (29%).
Scedosporium spp showed the best agreement with ﬂucytosine (83%) and
voriconazole and ﬂuconazole (70%) but lower concordance was obtained
with amphotericin B.
Conclusions:
1. The VITEK 2 system reliably detected ﬂuconazole resistance, as all
strains tested showed MIC90 64mg/L.
2. Good concordance was obtained with Fusarium spp and ﬂucytosine
and voriconazole, Aspergillus spp and amphotericin B and Scedospo-
rium spp with ﬂucytosine.
3. More studies with resistant strains are necessary to comprobe
the ability of VITEK 2 system to detect antifungal resistance in
ﬁlamentous fungi.
P1772 A comparative study to determine the recovery rate of
micro-organisms of bloodstream infections: two versus
three blood culture specimens
T. Shanthachol °, G. Suwanpimolkul, C. Suankratay (Bangkok, TH)
Background: There has been the development of automated and
continuous-monitoring blood culture system which is more sensitive for
the detection of microorganisms. Whether two or three blood cultures
obtained during a 24-hour period using this automated system achieving
a higher recovery rate of microorganism remains to be determined. Our
study was aimed to compare the recovery rate of microorganism of
blood-stream infections using two and three blood culture specimens.
Methods: A prospectively investigator-blinded study was conducted in
patients who needed to have blood cultures in Medicine wards and
intensive care units as well as emergency room of King Chulalongkorn
Memorial Hospital, Bangkok, Thailand between September 2008 and
January 2009. Three blood culture specimens were obtained from each
patient during a 24-hour period. Each specimen was inoculated into
an aerobic bottle of blood culture broth (Trek Diagnostic Systems,
Cleveland, OH, USA), and then was incubated at 37OC for 7 days.
Results: Of 210 patients, there were 48 (22.85%) unimicrobial episodes
with 3 blood cultures obtained during a 24-hour period. There were 30
(14.28%) and 18 (8.5%) episodes of true pathogen and contaminant,
respectively. Nineteen (63.3%), 21 (70%), and 30 (100%) were detected
with the ﬁrst one, two, and three blood culture specimens, respectively
(P< 0.05 between the recovery rate of the ﬁrst two and three blood
culture specimens). There were 21 (43.75%) and 30 (62.5%) episodes
of true pathogen detected with the ﬁrst two and three blood culture
specimens, respectively. There were 33 (68.75%) and 15 (31.25%)
isolates of Gram-positive and Gram-negative bacteria. Among 33 Gram-
positive bacteria, Streptococcus pneumoniae was the most common
isolate (5, 15.2%), followed by coagulase-negative Staphylococcus
(4, 12.1%) and Enterococcus faecalis (3, 9.1%). Among 15 Gram-
negative bacteria, Escherichia coli was the most common isolate (5,
33.3%), followed by Pseudomonas aeruginosa (4, 26.7%) and Klebsiella
pneumoniae (3, 20%).
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Conclusions: To the best of our knowledge, our study is the ﬁrst in
Asia to determine the recovery rate of microorganisms of blood-stream
infections using the automated blood culture system. Three blood culture
specimens are required to achieve the recovery rate of more than 99%.
MALDI-TOF
P1773 Detection of highly pathogenic bacteria by MALDI-TOF MS
M. Blaschitz °, L. Meidlinger, U. Sagel, G. Wewalka, F. Allerberger,
A. Indra (Vienna, AT)
Objectives: Highly pathogenic bacteria both acquired by natural
infection or after deliberate dissemination cause severe diseases in
humans, thus their fast identiﬁcation is of paramount importance. Matrix-
Assisted Laser Desorption Ionisation Time-of-Flight Mass Spectrometry
(MALDI TOF MS) represents a rapid tool for the species speciﬁc
identiﬁcation of microorganisms due to ribosomal protein proﬁles by
mass spectrometry.
Methods: Bacillus anthracis, Yersinia pestis, Francisella tularensis,
Brucella spp., Burkholderia mallei and B. pseudomallei were cultivated
under Biosafety Level (BSL) 3 conditions. Colonies were picked,
inactivated and subsequently tested for survival. Ribosomal proteins
were extracted from killed cells and measured by the microﬂex™ LT
MALDI-TOF system. Data were analysed using the Bruker Daltonics
Maldi Biotyper 2.0 and Flex Analysis 3.0 software and the reference
library 3.0.
Results: The reference library 3.0 had the following entries available:
Bacillus: 109 species, Yersinia: 11 species, Francisella: 0, Brucella:
0, Burkholderia: 25 species. Of 14 samples measured, all except
for the Francisella- and Brucella samples were correctly identiﬁed
at the genus level by the microﬂex™ LT system. B. anthracis was
identiﬁed as probable B. cereus, Y. pestis was identiﬁed as probable
Y. pseudotuberculosis and B. mallei and pseudomallei were both
identiﬁed as probable B. thailandensis species.
Conclusion: For an accurate identiﬁcation of highly pathogenic bacteria
by MALDI TOF the MALDI Biotyper Security Library would have been
an optimal choice as it comprises reference mass spectra of respective
bacteria. However, the present study demonstrates that highly pathogenic
bacteria are deﬁnitely not identiﬁed as any other not highly pathogenic
microorganism by the microﬂex™ LT MALDI-TOF system. Since
sample cultivation is required prior to a MALDI TOF measurement,
prompt DNA isolation from sample material and subsequent real-time
PCR currently represent the fastest and most reliable methods for the
identiﬁcation of highly pathogenic bacteria.
P1774 Development and evaluation of automated sample prepa-
ration for bacterial identiﬁcation with MALDI-TOF MS
C. Lang °, O. Dubuis, E.H. Viollier (Basel, CH)
Objectives: Matrix-Assisted Laser Desorption Ionisation-Time of Flight
Mass Spectrometry (MALDI-TOF MS) allows for identiﬁcation of
bacteria and yeasts within minutes. The weakness of the systems for
high throughput is the manual inoculation of the samples on 3mm spots
on the target plates. We aimed at developing a protocol for automated
sample application on the target with a pipetting workstation and to
compare it to the manual approach that was already used in our routine
microbiology laboratory.
Methods: For automated sample preparation bacterial isolates were
suspended in distilled H20 to obtain turbidity at McFarland standards
between 2 and 4. A Freedom EVO Clinical liquid handling and robotics
platform (Tecan, Ma¨nnedorf, CH) was adapted to apply the samples
and the matrix onto the MALDI-TOF target plate. For the conventional
method bacterial isolates were directly smeared onto the target plate and
matrix was distributed by manual pipetting. Identiﬁcation was performed
with a Microﬂex LT MALDI-TOF System / Biotyper 2.0 SR1 software
(Bruker Daltonics, D-Bremen). Automated pipetting processes as well
as parameters such as sample and matrix volume and drying times were
optimised in collaboration with Tecan.
Results: By comparing the identiﬁcation score of manual and automated
sample preparation, we found that in 43% of the tested bacteria
isolates (n = 127) automated sample preparation resulted in superior
identiﬁcation. Particularly identiﬁcation of Enterobacteriaceae and other
Gram-negative rods rendered higher yields with this method. On the
other hand, in 19% of the isolates identiﬁcation by manual sample
preparation lead to better results. Mainly Streptococci were easier to
identify by manual sample preparation.
Conclusion: For high sample throughput automated liquid sample
preparation is suited for MALDI-TOF MS. The quality of the
identiﬁcation results is comparable to that of the traditional manual
method used in our laboratory. The main advantages are standardisation,
improved traceability and reduced hands on time. Due to the long
drying time (approximately 25 min) of the bacterial suspension there
is no signiﬁcant reduction in sample preparation time. Furthermore, this
method is less ﬂexible than the manual approach and not applicable
if conventional and extraction (for yeasts and fastidious bacteria)
preparation methods are routinely coapplied. This issue could be resolved
if the extraction procedure were applied to all samples.
Quality of results manual versus automated sample preparation
No. of Better score Identiﬁcation only
isolates manual automated manual automated
Enterobacteriaceae 64 4 42 2 6
Gram-negative rods (other than Enterobacteriaceae) 17 1 7 1 2
Staphylococci 23 7 2 1 0
Streptococci 12 9 0 7 0
Other bacteria (anaerobes, Gram-positive rods, Neisseria) 11 3 3 2 2
Total 127 24 54 13 10
P1775 MALDI Biotyper, experience in routine clinical bacteriology
in a university hospital
E. Bessede °, M. Angla-Gre´, Y. Delagarde, S. Sep Hieng, A. Menard,
F. Megraud (Bordeaux, FR)
Matrix-assisted laser desorption ionization time-of-ﬂight (MALDI-TOF)
appears to have the potential to replace conventional techniques in
a routine bacteriology laboratory. Its performance still needs to be
evaluated on a large scale. Our aim was to compare MALDI-Biotyper
identiﬁcation of bacteria to the conventional phenotypic identiﬁcation in
a large University Hospital Bacteriology laboratory.
Methods: A prospective study was carried out from April to May 2009.
Bacterial isolates from clinical samples were identiﬁed by conventional
phenotypic bacteriological methods (Phoenix, Beckton Dickinson & Api
strips, bioMe´rieux) and in parallel with a mass spectrometer (Ultraﬂex
III TOF/TOF, Bruker Daltonics, Germany). In case of discrepancy
between these results at the genus level, a 16S rRNA and /or rpoB
gene sequencing was performed.
Results: Of the 1,013 bacteria tested, 98% were correctly identiﬁed at
the genus level by the MALDI Biotyper vs. 97% with the conventional
methods.
The majority of bacteria could be identiﬁed without the step of extraction
and gave a score >2. It was even possible to correctly identify bacteria
with a score slightly lower that 2 when there was matching with the
same species proﬁle several times.
The limits of MALDI Biotyper concerned some Acinetobacter species
(4 times), rare species not yet in the data basis (6 times) and at this stage
the subspeciation for Salmonella enterica.
Conclusion: The MALDI Biotyper allowed an accurate identiﬁcation
of bacteria, much quicker than conventional phenotypic methods. The
integration of this identiﬁcation method with the antimicrobial testing
remains the challenge for the future.
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P1776 Two-year experience with MALDI-TOF MS in a routine
microbiology department of a laboratory in Germany
C. Boogen, M. Kostrzewa, U. Weller ° (Cologne, Bremen, DE)
Objectives: Introduction of MALDI-TOF mass spectrometry is changing
the general workﬂow in a clinical microbiology laboratory, with the
expectation of increased speed and accuracy of microbiological results,
thereby enabling improved therapy. We report about our experiences
during two years after introduction of the MALDI Biotyper (MBT)
system in our routine laboratory.
Methods: As a ﬁrst and fundamental change, after validation of the
MBT system, we cancelled all biochemical identiﬁcations except for
mycoplasma which are not yet in the MBT database. Basic tests such,
as oxidase, catalase and Staphyloccous coagulase were disposed as not
needed prior to mass spectrometry. Coagulation tests for subtyping of
Shigella, Salmonella, Yersinia, Haemophilus inﬂuenzae, pneumococci
and meningococci were continued. As ﬁrst step to identiﬁcation always
MALDI-TOF proﬁling is used. We also stopped to rely on colour change
of chromogenic media, as this is generally only due to one biochemichal
reaction and known as not always reliable.
Results: Introduction of MALDI-TOF MS for microbial identiﬁcation
signiﬁcantly reduced the usage of consumables in our laboratory.
The extensive reference database gives far better results especially
for rare microbes, where the biochemical approaches are limited. For
instance, Helicobacter pullorum now readily can be distinguished from
Campylobacter sp..
Workload has been considerably reduced for Salmonella. The Kligler
test prior to sero-subtyping is only needed after an isolate has been
identiﬁed as Salmonella sp. by the MBT. This frequently eliminates the
need for subculture. Identiﬁcation of anaerobic bacteria is speeded up
for several days, since from appearance of colonies on the agar plate
the bacterium now readily can be identiﬁed. Success rate here is at
95%, a 50% increase over our previous biochemichal methods. Yeasts
are quickly and reliably identiﬁed by the MBT after extracting the cells
prior to mass spectrometry with a success rate of >95%.
Conclusion: Introduction of MALDI-TOF mass spectrometry for
identiﬁcation of microorganisms has led to considerable positive changes
to our lab since introduced. Not only that it considerably changed
our workﬂow, it also shorted our turn around time, signiﬁcantly, and
improved quality of results. In addition, workload has been reduced and
consumption of consumables, too.
P1777 Rapid identiﬁcation using MALDI-TOF MS for routine
bacterial identiﬁcation
S. Bocher, R. Abdul-Redha ° (Copenhagen, DK)
Objectives: Matrix-assisted laser desorption ionization time-of-ﬂight
mass spectrometry (MALDI-TOF-MS) is increasingly used as a rapid
method for identiﬁcation of bacteria in the clinical microbiology
laboratories. The objective of the present study was to evaluate bacterial
identiﬁcation using MALDI-TOF-MS, Bruker, Germany testing both
bacterial isolates and positive blood culture specimens.
Materials and Methods: 90 bacterial isolates from positive routine
blood cultures and 97 positive blood culture specimens were used in the
evaluation.
Methods: All bacterial isolates and bacteria/fungi from blood cultures
were tested by routine laboratory identiﬁcation methods, prior to testing
in by MALDI-TOF MS. Bacterial/fungal isolates: Matrix preparation
was performed as recommended by the manufacturer (Bruker Daltonics,
www.bdal.com). A small portion of a freshly grown colony was smeared
onto the MALDI steel target, whereafter 1mL matrix was added and
MALDI-TOF mass spectra were generated using Bruker microﬂex LT
instrument. Positive blood culture specimens: 4mL blood culture was
transferred to gel containing vacuette tube and centrifuged at 2500 rpm
for 10 min, hereby separating blood cells and bacteria. Following discard
of supernatant, the sediment was washed in 1mL deionised water. After
further centrifugation proteins were extracted from the bacterial cells
using formic acid /acetonitrile. 1 mL of the extract was spotted onto
the MALDI steel target and MALDI-TOF mass spectra were generated.
Bacteria were identiﬁed using the Maldi Biotyper 2.0 software, taking
into consideration the score, number of identical identiﬁcations, distance
to next best taxon match, next best taxon match and the automatic
evaluation of the obtained identiﬁcation.
Results: Considering culture and phenotypic characterization the gold
standard, 34 genera and 77 different species were represented among 90
isolates and 97 blood culture specimens. Concordant results, different
genus and inconclusive identiﬁcations are given in the table. CoNS and
streptococci accounted for 31 of 55 inconclusive identiﬁcations.
Discussion and Conclusion: This study showed a high concordance be-
tween routine bacterial identiﬁcation and identiﬁcation by MALDI-TOF,
especially the species frequently causing bacteraemia. The speed and
price seems promising for future routine examination of as well bacterial
isolates as clinical specimens, ensuring fast and correct treatment of
patients.
Table 1: MALDI-TOF-MS results from blood specimens and isolates
Genera No. of strains/positive blood culture specimens
examined / genus (species) level
Isolates Positive blood culture specimens
Bacteroides 3/3 (2)
Candida 1/1 (1)
Citrobacter 4/4 (3)
Enterobacter 1/1 (1)
Enterococcus 4/4 (3) 4/4 (3)
Escherichia 5/5 (5) 5/3 (3)
Haemophilus 2/2 (2) 1/1
Klebsiella 4/4 (4)
Moraxella 5/5 (5)
Proteus 2/2 (2)
Pseudomonas 3/3 (3) 5/5 (5)
Salmonella 1/1 1/1 (1)
Staphylococcus 9/9 (9) 11/11 (11)
Streptococcus 15/15 (9) 15/13 (2)
Other genera 32/17 (11) 5/5 (5)
Total nr./genus (species) 91/76 (60) 73/67 (54)
aIn brackets: no. of identical identiﬁcation(s) using MALDI-TOF-MS and
phenotype characterization, respectively, on genus/species level.
P1778 Performance of MALDI-TOF MS for the identiﬁcation of
routine and difﬁcult to identify bacterial strains isolated in
a clinical microbiology laboratory
A. Bizzini °, K. Jaton-Ogay, C. Durussel, J. Bille, G. Greub,
G. Prod’hom (Lausanne, CH)
Objectives: The Matrix-Assisted Laser Desorption/Ionization Time-of-
Flight Mass Spectrometry (MALDI-TOF) has recently been introduced
in diagnostic microbiology laboratories for the identiﬁcation of isolates
from clinical samples. In this study, we prospectively compared
MALDI-TOF to conventional phenotypic identiﬁcation on routine
isolates, and retrospectively assessed the ability of MALDI-TOF to
replace 16S rRNA sequencing on isolates which were difﬁcult to identify
by conventional methods.
Methods: A) Routine isolates: for a 4 week period, all bacteria and
yeast isolates retrieved from clinical samples and identiﬁed in our
laboratory at the species level using conventional methods (Vitek2
or API systems, bioMe´rieux, France) were tested in parallel using
MALDI-TOF (Microﬂex LT instrument with the BioTyper automation
2.0 software, Bruker Daltonics, Germany). Colonies were analyzed
by MALDI-TOF either by direct deposition on the target plate or
after a formic acid:acetonitrile extraction step if no valid result was
initially obtained. B) Difﬁcult to identify isolates: 500 bacterial samples
representing >100 different species which had been sent for 16S rRNA
sequencing were selected from a culture collection.
Results: A) Among 1371 isolates identiﬁed by conventional methods,
1278 (93.2%) were putatively identiﬁed at the species level by
MALDI-TOF, 61 (4.4%) at the genus level, and no reliable identiﬁcation
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was obtained in 32 (2.3%). Among the 1278 isolates identiﬁed at
the species level by MALDI-TOF, 63 (4.9%) discordant results were
initially identiﬁed. Most discordant results (42/63) were due to systematic
database-related taxonomical differences, 14 were explained by poor
discrimination of MALDI-TOF spectra obtained and 7 were due to errors
in the initial conventional identiﬁcation. An extraction step was required
to obtain a valid MALDI-TOF identiﬁcation for 25.6% of the 1278 valid
isolates. B) Out of 500 samples which had been previously impossible
to identify by conventional phenotypic method, ca. 60% were accurately
identiﬁed at the species level by MALDI-TOF MS.
Conclusions: MALDI-TOF MS is a fast and reliable technique, which
has the potential to replace conventional phenotypic identiﬁcation
for most bacterial strains routinely isolated in clinical microbiology
laboratories.
P1779 Reassessment of conventional identiﬁcation of clinical
non-fermenting isolates excluding Pseudomonas aeruginosa
and Stenotrophomonas maltophilia from cystic ﬁbrosis
patients using the MALDI-TOF system
A. Fernandez-Olmos °, M. Garcı´a-Castillo, M.I. Morosini, A. Lamas,
L. Ma´iz, R. Canto´n on behalf of the CIBERESP
Different bacterial species recovered from respiratory samples of cystic
ﬁbrosis (CF) patients display distinct degrees of pathogenicity thus
requiring different clinical management. Correct identiﬁcation of these
bacteria by conventional microbiology methods is often limited due to
low biochemical reactivity. Recently, Matrix-Assisted Laser Desorption
Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS) that
produces speciﬁc mass spectral ﬁngerprints for different organisms has
been introduced in clinical microbiology laboratories.
Objective: We reassessed historical routine identiﬁcation results
obtained by WIDER (Fco. Soria Melguizo, Spain) and by API 20 NE
(bioMe´rieux, France) systems using MALDI-TOF (MALDI BioTyper
2.0, Bruker Daltonik, Germany).
Methods: 194 isolates identiﬁed by conventional methods (65 Achro-
mobacter spp., 56 Burkholderia spp., 16 Acinetobacter spp., 10 non-
aeruginosa Pseudomonas, 8 Chryseobacterium spp., 7 Bordetella spp.,
4 Ralstonia spp., 3 Ochrobactrum anthropi, and 25 other non-fermenting
Gram-negative bacilli) recovered from routine sputum cultures from
CF patients (1994–2009) and stored at −80ºC were re-identiﬁed using
MALDI-TOF (direct colony material). Discrepancies were resolved with
molecular techniques (PCR of 16S rDNA or other speciﬁc genes and
sequencing).
Results: 83% of isolates displayed identical identiﬁcation at genus level
when using conventional and MALDI-TOF methods although this ﬁgure
was only of 57% at species level. Lack of identiﬁcation (6.1% of isolates)
with MALDI-TOF was ascribed to insufﬁcient database entries and
was resolved by the molecular approach. Moreover, pathogens such as
A. xylosoxidans (4) and B. cepacia complex (6) that were misclassiﬁed
by routine methods were identiﬁed by MALDI-TOF, being also able to
differentiate members of the B. cepacia complex. Additionally, other
bacteria such as Burkholderia gladioli (7) and Pandoraea spp. (6) that
have never been previously identiﬁed by conventional methods in our
laboratory were correctly identiﬁed by MALDI-TOF.
Conclusions: MALDI-TOF is a quite versatile tool that improves rapid
identiﬁcation of bacteria including non-fermenting isolates that usually
have limited biochemical reactivity and different morphotypes that lead
to misidentiﬁcation by classical phenotypic means. However, despite
its accuracy, MALDI-TOF database needs to be enlarged mainly with
infrequent or even rare species recovered from CF patients.
P1780 The experience of a 2-year application of MALDI Biotyper
technique in a routine setting
A. Borovskaya, E. Ilina, S. Sidorenko, A. Kruglov, D. Mudrak,
T. Savinova, T. Maier, M. Kostrzewa, V. Govorun ° (Moscow, RU;
Bremen, DE)
Objectives: The burden falls to clinical microbiology laboratories
to provide accurate and rapid identiﬁcation of the pathogens. Many
laboratories rely upon automated microbial identiﬁcation system.
Though, there are some examples in the literature of the misidentiﬁcation
by commercial systems because of unusual strains which may lack
key phenotypic characters required for their reliable identiﬁcation. We
demonstrated the prolonged using of MALDI Biotyper technique as a
rapid, accurate and cheap method for bacterial species identiﬁcation in
routine practice.
Methods: Species identiﬁcation in the course of two years of routine
bacteriological practice for the broad clinical specimen was done in
parallel by both traditional microbiological methods and by MALDI
Biotyper technique (Bruker Daltonics, Germany). In addition, 16S rRNA
gene sequencing for discordant results was performed.
Results:Wide clinical specimens of 820 patients were investigated. 2780
bacterial colonies from 2003 plates (785 primaries, 549 selective plates
and 669 plates for susceptibility testing) were tested by MALDI Biotyper
technique. The Biotyper ID did succeed for 2764 (99.4%) colonies, in
16 cases (0.6%) the measuring procedure failed because no mass spectra
could be acquired. The efﬁcacy of identiﬁcation was slightly different in
different groups (table), and in 126 (4.5%) cases there was no reliable
identiﬁcation (log score <1.7).
For 98 from 110 cases of discordance the correctness of MALDI
Biotyper ID was conﬁrmed by 16S rRNA gene sequencing.
Conclusion: The MALDI Biotyper technique demonstrates as suitable
for accurate species identiﬁcation of quantum amount of species
prevalence in routine clinical setting with the diagnostic sensitivity
99.4%.
Table. Distribution of MALDI BiotyperTM ID in microbial groups
Group of microorganisms Log score 2
species ID
1.7Log score 2
genus ID
Non-fermenting bacteria 152 54
Coryneform bacteria 73 45
Anaerobic microorganism 2 3
Enterobacteriaceae 623 132
Genus Staphylococcus 585 102
Genus Streptococcus 249 127
Genus Enterococcus 203 27
Other Gram-positive bacteria 59 49
Other Gram-negative bacteria 76 28
Total 2061 (74%) 576 (21%)
P1781 Bacterial identiﬁcation by Axima Saramis SirWeb
MALDI-TOF MS: application in a clinical routine
laboratory
O. Dauwalder °, H. Meugnier, A.M. Freydiere, N. Baida, Y. Benito,
M. Badoz, M. Chomarat, S. Boisset, P. Girardo, M.E. Reverdy,
J. Etienne, G. Lina, F. Vandenesch (Bron, FR)
Objectives: Evaluation of a bacterial identiﬁcation (BI) by AXIMA
SARAMIS SIRWEB-MALDITOF mass spectrometry (MS) in real
clinical setting in comparison with a conventional identiﬁcation by
biochemical test systems (CI) and molecular methods (MM) in case
of discrepancy.
Materials and Methods: 323 strains prospectively isolated in the labora-
tory requiring a bacterial identiﬁcation were included in the study. These
strains provided from blood culture (16%), urine sample (29%), sputum
(20%) or cutaneous samples (12%), others (23%) and were isolated on
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various media (blood agar, chromogenic media) after 24 to 72 hours of
incubation. Strains were identiﬁed simultaneously by biochemical panels
(BP) using Phoenix (Becton Dickinson) or API systems (bioMe´rieux)
and by SM AXIMA (Shimadzu) coupled with the SARAMIS spectral
database (Anagnostec) and the SIRWEB-MALDITOF software (I2A)
using a-cyano-4-hydroxy-cinnamique matrix. We did a single test for
with each method. In case of non-identiﬁcation by MS, strains were
retested with or without formic acid extraction. Discrepancies were
resolved by 16S rDNA-sequencing (MM) [PCR/sequencing, le BIBI
(www.pbil.univ-lyon1.fr/bibi)].
Results: Of the 323 strains tested, 305 (94.4%) yielded a concordant
BI to the species level between MS and CI. For 87.6% of these strains,
the BI was obtained within one minute. A second test was required for
23.5% of strains. For 4 strains (1.2%), the MS provided no BI even
after formic acid extraction. For 14 strains (4.3%) a discrepant BI was
obtained between MS and CI requiring MM methods. Out of these 14
strains, 6 were identiﬁed correctly by the MS either to the genus or to
the species level while 5 were identiﬁed by the CI to the genus or to
the species. For the 3 last strains, the BI obtained with CI and MS were
different from that obtained by MM.
Conclusion: MALDI-TOF MS method performed equally well with the
CI for bacterial identiﬁcation in our clinical routine laboratory with the
advantage to be a low cost and fast method.
P1782 Comparing conventional identiﬁcation of bacteria to
identiﬁcation with MALDI-TOF in a routine clinical setting
Y. Han, D. Radjenovic, U. Nydegger, M. Wydler, L. Risch, M. Risch °
(Pjongjang, KP; Liebefeld, CH)
Background: Matrix-assisted laser desorption/ionization time-of-ﬂight
mass spectrometry (MALDI TOF) bacterial identiﬁcation is in the
process of completing, if not replacing bacterial identiﬁcation by
morphological and biochemical techniques (conventional identiﬁcation,
CI).
Methods: In order to assess comparability of the results obtained with
MALDI-TOF to CI, we have analysed 204 clinical samples with the
following origins: 66 samples were urine specimens, 17 positive blood
cultures, 27 genital specimens, 27 wound swabs, 23 fecal specimens
and the remainder were 6 sputum and various other samples taken
under precaution to avoid commensal contamination. MALDI-TOF was
performed with a Bruker microﬂex system, whereas CI comprised the
VITEK II and API system, both bioMe´rieux.
Results: Of the 204 isolates identiﬁed, 72 were Gram-positive and
130 were Gram-negative strains and 2 were yeasts (candida). In
27 samples (13.2%), a disparity of the species and/or genus name
could be seen. The disparity appeared with 16 Gram-negative (12.3%)
and with 11 Gram-positive germs (15.3%; n.s.). In the latter 6
samples showed the same disagreement with Streptococcus pneumoniae
(MALDI) and Streptococcus mitis/oralis (CI) constellation. Among
Gram-negative samples, most instances exhibited a difference on
the species level only, e.g. Enterobacter cloacae versus Enterbacter
kobei. According to genus- and species-differences, we classiﬁed the
disparities into two disparity levels (1+ and 2+ differences). Twenty-
two differences were 1+. In 5 instances, the differences related
to genus disparities: Enterobacter/Raoultella, Streptococcus/Gemella,
Pseudomonas/Burkholderia, Microbacter/Sphingomonas and Candida/
Cryptococcus. The most pertinent difference was Microbacterium
arborescens (MALDI TOF) and Sphingomonas paucimobilis (CI).
Conclusion: We conclude, that there is a good comparability between
MALDI TOF analysis and conventional identiﬁcation procedures
(86.8%). Differences are mainly due to disparities at the species level.
With respect to clinical decision making, our observations direct special
attention to streptococcal species.
P1783 Automated detection of mixed cultures of micro-organisms
using MALDI-TOF MS
T. Wenzel, S. Klepel, T. Maier, S. Stumpf, B. Wegemann, M. Kostrzewa °
(Bremen, Leipzig, DE)
Objectives: MALDI-TOF mass spectrometry ﬁngerprint analysis for
identiﬁcation of microorganisms recently has emerged as a powerful
tool in clinical microbiology diagnostics. Starting with a single colony
characteristic proﬁle spectra are acquired for an unknown microbe and
identiﬁcation is performed by bioinformatic comparison with a dedicated
database. One current drawback of the technology is that in the case of
mixed cultures, e.g. in case of contaminations, generally only one of the
microorganisms is detected in automated analyses. Sometimes even any
identiﬁcation is hampered by the mix of proﬁles in the mass spectra. On
the other hand, careful evaluation of the mass spectra derived from two or
even three different bacteria in a mixture can be unravelled after inspec-
tion by eye, frequently. We present a bioinformatic approach to check
automatically spectra for the probable existence of such contaminations.
Methods: Mixtures of different bacterial cultures were prepared in
different ratios. Further, several blood cultures spiked with different
bacteria were prepared. The blood cultures were incubated for several
hours at 35 deg C. Next, they were harvested under standard conditions,
puriﬁed and prepared for MALDI-TOF MS analysis according to a
protocol developed in our lab. Bacteria were analysed after extraction
using a microﬂex benchtop mass spectrometer according to standard pro-
cedures. Resulting spectra were automatically analysed using the MALDI
Biotyper 2.0 software package and, in parallel, with a novel algorithm
which is calculating the possibility of a mixed-culture spectrum.
Results: Several two compound-mixed cultures, from artiﬁcial mixtures
as well as from spiked blood cultures were unambiguously recognised as
mixed-cultures using the novel algorithm. For some mixes, in particular
from blood culture experiments, only one species was detected or the
analysis failed at all. No false mixture alarm appeared from blood
cultures, also no wrong identiﬁcation was observed. Two compound
mixed cultures spiking experiments using other body ﬂuids (e.g. human
urine) are under current investigation.
Conclusion: The principle applicability of automated mixed culture
identiﬁcation, even for positively ﬂagged blood cultures, could be
demonstrated. The novel algorithm enables a rapid spectra check of
real-life samples for probable existence of mixed cultures. Potential of
further improvement of sensitivity of the method and algorithm is being
investigated.
P1784 Rapid and accurate identiﬁcation of clinical Campylobacter
jejuni and Campylobacter coli isolates with MALDI-TOF MS
E. Leitner °, M. Keimel, G. Feierl, A.J. Grisold, L. Masoud, J. Posch,
U. Wagner-Eibel, G. Zarfel, E. Marth (Graz, AT)
Objectives: Within the genus Campylobacter, C. jejuni and C. coli
are the main causes of campylobacter enteritis in humans. In routine
diagnostic laboratories the differentiation of Campylobacter spp. is
still a challenge due to their poor biochemical activity. Basically, the
hippurate hydrolysis test and indoxyl acetate hydrolysis test are employed
for differentiation. The objective of this study was to show the easy,
rapid and accurate identiﬁcation of Campylobacter spp out of clinical
samples with the Matrix Laser Desorption/Ionisation − Time of Flight
(MALDI-TOF)-based method. Furthermore we wanted to verify the
uncommon high portion of 12.5% (56 out of 447) of C. coli in 2005.
Methods: At least 54 identiﬁed C. coli isolates; 54 C. jejuni isolates
and one C. fetus isolate collected from the routine diagnostic laboratory
in 2005 were re-cultured on blood and modiﬁed charcoal cefoperazone
desoxycholat agar plates. Additionally, six different Campylobacter spp.
reference strains were tested. MALDI-TOF target plates were inoculated
by applying a small amount of a single colony directly on the target plate
in a thin smear. The microbioal ﬁlm was overlaid with 1ml of matrix
solution and air dried. Mass-spectra were collected with MALDI-TOF
spectrometer (Bruker Daltonics) and for analysis the MALDI Biotyper
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software was employed. For discordant results the hippurate hydrolysis
and the indoxyl acetate hydrolysis test were repeated. Additionally,
polymerase chain reaction (PCR) was used for veriﬁcation.
Results: The results showed that the MALDI-TOF MS was correct in
100% of the identiﬁcations, including all reference strains and the 109
test strains. Results were independently from the used agar plate types.
In 2005, two C. jejuni isolates were misidentiﬁed with the traditional
methods. These MALDI-TOF results were proven with PCR.
Conclusion: High speciﬁcity and fast performance make the
MALDI-TOF method a progress for identiﬁcation of Campylobacter spp.
strains. We were able to identify two hippurate negative C. jejuni strains
which represent a minority. Furthermore, we conﬁrmed the high portion
of C. coli isolates at our laboratory in 2005.
P1785 The performance of MALDI-TOF MS in the identiﬁcation
of Enterobacteriaceae and Pseudomonas aeruginosa clinical
isolates
G.H. Genzel, R. Schaumann °, N. Knoop, W. Schellenberger,
A.C. Rodloff, K. Eschrich (Leipzig, DE)
Objectives: We investigated the ability of matrix-assisted laser desorp-
tion/ionization time-of-ﬂight mass spectrometry (MALDI-TOF MS) to
identify Enterobacteriaceae and Pseudomonas aeruginosa as compared
to the identiﬁcation with biochemical reactions. Moreover, we attempted
to separate out strains with Extendend Spectrum b-Lactamase (ESBL)
and Metallo b-Lactamase (MBL) production.
Methods: To create a reference mass spectra database, 20 strains of
Escherichia coli, including 11 ESBL-positive strains, 20 Klebsiella
pneumoniae including 12 ESBL-positive strains and 40 P. aeruginosa
strains including 15 MBL-positive strains were analyzed. The strains
were identiﬁed previously by biochemical reactions. MICs were
determined by broth microdilution test. ESBL and MBL were detected
with appropriate Etest. Subsequently, all strains were analyzed by
MALDI-TOF-MS. Peak lists derived from the mass spectra were
analyzed by different methods of multivariate statistical analysis. For
this classiﬁcation, support vector machine algorithms turned out to be
most powerful. In an alternative approach, for the Identiﬁcation of ESBL-
positive and MBL-positive strains the whole mass spectra were analyzed
instead of peak lists.
Results: A reliable reference spectra database was established with 20
E. coli, 20 K. pneumoniae, and 40 P. aeruginosa strains, respectively.
ESBL-producing E. coli and K. pneumoniae strains and MBL-producing
P. aeruginosa could not be identiﬁed unequivocally.
Conclusion: MALDI-TOF-MS has an excellent ability to identify
rapidly E. coli, K. pneumoniae and P. aeruginosa. It can therefore serve
as a valuable tool for laboratory diagnosis of these pathogens. On the
other hand, ESBL and MBL-producing strains could not be distinguished
unequivocally.
P1786 New genotypic and phenotypic analyses of clinically-relevant
Gram-negative, non-fermenting bacteria: MALDI-TOF MS
as a rapid, high-resolution method for identifying and
typing micro-organisms
L.A. Svensson °, M. Gomila, S.A. Mihaylova, M. Erhard, E. Moore
(Go¨teborg, SE; Palma, ES; Pleven, BG; Potsdam, DE)
Objectives: Identiﬁcation of Gram-negative, non-fermenting bacilli,
using phenotypic characterization is problematic. Many of the species of
this group are frequent nosocomial infectious agents and are ubiquitous
in the environment. The aims of this study were to assess the resolving
capacities of “house-keeping” gene sequences, including 16S rRNA,
atpD, gyrB, recA, rpoB and rpoD, and to compare a multi-locus sequence
analysis (MLSA) with matrix-assisted laser desorption time-of-ﬂight
(MALDI-TOF) mass spectrometry analyses for identifying and typing
strains of Achromobacter, Bordetella, Burkholderia, Pseudomonas, and
Stenotrophomonas species.
Methods: Genotypic analyses. Type strains of the focus genera
and species-complexes, other well-characterised reference strains and
selected clinically-relevant strains representing a range of phenotypic
and genotypic similarities were included in this study. Partial genes,
16S rRNA, atpD, recA, gyrB and rpoD recA were ampliﬁed by PCR
and sequenced. DNA-DNA hybridisation analyses were carried out on
selected strains for conﬁrmation of species designations.
MALDI-TOF analysis. Bacterial biomass were prepared from cultures on
agar medium and analysed by MALDI-TOF MS, in the positive mode,
using the SARAMIS software for analysis [1].
Results: MLSA, using the respective house keeping genes were able to
differentiate and identify the most closely related species of the analysed
taxa and cluster analyses showed similarities of branching order between
species that correlated well between different genes. However, different
genes were not equally effective in differentiating species of the different
genera.
The MALDI-TOF analyses were effective in differentiating the most
closely related species of the respective genera. Good correlation was
observed between the results of MALDI-TOF MS and MLSA data.
Conclusion: In most cases, clinically-relevant isolates and strains
of Gram negative, non-fermenting bacilli exhibited good agreement
between the methods of this study. In some cases, strains previously
deﬁned as given species were observed to be genotypically more similar
to other species, as well as some strains with highly aberrant phenotypes
were almost genotypically identical to the type strain. MALDI-TOF
identiﬁcation was very well correlated to the MLSA results, and is a
much less expensive and effectively able to reduce identiﬁcation times
by 24−48 hours.
Reference(s)
[1] Vanlaere E et al. J. Microbiol. Meth. 75: 279–286 (2008).
P1787 Preliminary identiﬁcation of Salmonella serovar Enteritidis
by MALDI-TOF MS
U. Sagel °, C. Kornschober, A. Indra, M. Blaschitz, B. Springer,
F. Allerberger (Vienna, AT)
Objectives: Human infections by Salmonella enterica subsp. enterica
serovar Enteritidis (S. Enteritidis) are often due to the consumption of
contaminated eggs or egg-products. Preliminary identiﬁcation of this
serovar may provide public health ofﬁcers with a rapid indication of the
source of infection. As many routine laboratories send their Salmonella
isolates to reference laboratories for serotyping, deﬁnitive reports about
the serovar may be delayed. We studied the applicability of matrix-
assisted laser desorption ionisation time-of-ﬂight mass spectrometry
(MALDI TOF MS) as a tool for rapid identiﬁcation of S. Enteritidis.
Methods: From the most common serovars identiﬁed by the Austrian
Reference Centre for Salmonella we tested 51 isolates (S. Enteritidis:
10, S. Typhimurium: 10, S. Infantis: 10, S. Hadar: 10, S. Saintpaul: 6,
S. Agona: 5) using the mass spectrometer microﬂex™ LT MALDI-TOF
(Bruker Daltonics, Bremen, Germany). Isolates were prepared for testing
both by using a speciﬁc extraction method and by using the more
convenient smear method. Using the MALDI Biotyper 2.0 software we
analysed the mass spectra for peak differences between serovars and
exported the peak list to STATA 10.1 (STATA Corp, College Station,
TX, USA) for further statistical analysis. All m/z-values were rounded
to±5, m/z-values of <600 were set as 600.
Results: All 51 isolates were correctly identiﬁed as Salmonella spp.
using the MALDI Biotyper Automation Wizard with both preparation
methods. S. Enteriditis often revealed peaks at about m/z 3020 and 6040
while other serovars often showed peaks at m/z 3005 and 6010. Thereof
we derived the index = intensity at m/z 3020/intensity at m/z 3005 +
intensity at m/z 6040/intensity at m/z 6010 Index values >2.0 point at
S. Enteritidis, values 2.0 point to other serovars. Setting the threshold
to 2.5, sensitivity and speciﬁcity were 90% (9/10) and 100% (41/41)
if isolates were prepared according to the extraction method, and 70%
(7/10) and 100% (41/41) for the smear method, respectively.
Conclusion: Preliminary testing for S. Enteritidis using MALDI TOF
MS appears to be feasible for routine laboratories. Our diagnostical
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approach needs to be evaluated using more reference strains before
application on a regular basis.
P1788 Rapid identiﬁcation of coagulase negative staphylococci by
MALDI-TOF MS in a clinical lab
P. Rosseel °, I. Wybo, K. Vandoorslaer, E. Roebben, I. Van
Cauwenbergh, A. De Bel, S. Lauwers (Brussels, BE)
Objective: Coagulase negative Staphylococci (CNS) are important
pathogens especially in device-related bloodstream infections. Correct
identiﬁcation is important but neither the standard biochemical
identiﬁcation nor commercial identiﬁcation systems are able to correctly
differentiate CNS at the species level. We evaluated a MALDI-TOF Mass
Spectrometry (MALDI-TOF MS) system for the identiﬁcation of a set
of selected clinical strains and reference strains.
Methods: Strains: 69 clinical isolates (26 recent blood isolates, 14 stock
strains with atypical biochemical tests, 30 biochemically good typiﬁed
stock strains already used in an earlier interlaboraty evaluation) and 4
reference strains, representing 10 different species. The included species
were Staphylococcus capitis, S. cohnii, S. epidermidis, S. haemolyticus,
S. hominis, S. lugdunensis, S. saprophyticus, S. schleiferi, S. warneri and
S. saccharolyticus. MALDI-TOF-MS was performed by using the direct
smear method on the Microﬂex LT® (Bruker®, Germany).
The resulting mass spectra were automatically analyzed by the Biotyper
2.0 Software® and Bruker library® 3.0.1.0. Thresholds for species and
genus identiﬁcation were respectively a score value of 2.0 and 1.7.
All discrepant results were reanalysed by standard biochemical tests,
a second MALDI-TOF-MS analysis and/or 16S rRNA sequencing for
deﬁnitive species assignment.
Results: 78% of the selected strains could be identiﬁed up to species
level by MALDI-TOF MS compared to 53% with biochemical testing
only. Correct genus identiﬁcation was reached for 96% of the strains.
Almost all included strains of S. capitis, S. epidermidis, S. hominis,
S. warneri, S. haemolyticus and S. saprophyticus were correctly identiﬁed
up to species level. If we take into account the prevalence of these
species during the last 7 years (total number of CNS isolates: 8561),
MALDI-TOF MS can identify 91% of our CNS isolates up to species
level.
Conclusions: MALDI-TOF MS is a very fast and accurate identiﬁcation
method for CNS that can lead to a signiﬁcant improvement in speed and
accuracy of CNS identiﬁcations in a routine lab.
P1789 Identiﬁcation of Campylobacter isolates by MALDI-TOF MS
I. Wybo °, A. De Bel, K. Vandoorslaer, J. Breynaert, P. Rosseel,
D. Pie´rard, S. Lauwers (Brussels, BE)
Objectives: C. jejuni en C. coli are the most frequent causes of
bacterial enteritis and represent 86.2% of Campylobacter isolates in
our laboratory. Several other Campylobacter species are occasionally
associated with diarrhoea or bacteraemia in patients with immune
deﬁciency. MALDI-TOF MS is a new tool for fast and reliable
identiﬁcation of bacteria in the routine microbiology setting. In this
study, we evaluated the performance of MALDI-TOF MS in species
identiﬁcation of Campylobacter isolates.
Methods: Fifty-seven well characterised isolates comprising 12 species
were included. For MALDI-TOF MS sample preparation small amounts
of intact cells were directly applied onto the target plate and covered by
alfa-cyano-4-hydroxycinnamic acid matrix. Identiﬁcation was performed
with Microﬂex LT mass spectrometer in combination with the MALDI-
Biotyper 2.0 software and Reference Library 3.0.1.0 (Bruker Daltonik
GmbH, Bremen, Germany). Results were compared to conventional
phenotypic tests and whole-cell fatty acid analysis with the Microbial
identiﬁcation System (MIS-Microbial ID, Newark, Del). The MALDI
Biotyper output is a log(score) in the range 0−3.0. Thresholds for species
and genus identiﬁcation were respectively a log(score) of 2.0 and 1.7.
Results: Overall 32/57 (56.1%) of isolates were identiﬁed at species
level: C. jejuni (6/6), C. coli (8/8), C. fetus (4/4), C. hyointestinalis
(3/3), C. gracilis (1/1) C. lari (5/6), C. jejuni doyli (3/5), C. upsaliensis
(1/4) and C. curvus (1/8). When the MALDI-TOF results for these 32
isolates were compared with our routine identiﬁcation, no discrepant
results were found. Additionally, 11 isolates (19.2%) were identiﬁed to
genus level: 6 C. curvus, 2 C. jejuni doyli and 3 C. upsaliensis isolates.
Fourteen isolates were not identiﬁed including 1 C. lari, 1 C. curvus,
6 C. consisus, 4 C. mucosalis, 1 C. rectus and 1 C. sputorum (1). The
latter 4 species are not included in the database.
Conclusion: In our study no Campylobacter isolates were misidentiﬁed
by MALDI-TOF MS. Although some isolates belonging to less
common species could not be identiﬁed, our results suggest that
MALDI-TOF MS is an accurate and rapid method for routine
identiﬁcation of Campylobacter isolates. Extension of the Reference
Library will improve the performance of the system.
P1790 Use of MALDI-TOF MS for species identiﬁcation of
Bacteroides and parabacteroides clinical isolates
I. Wybo °, A. De Bel, I. Van Cauwenbergh, K. Vandoorslaer, P. Rosseel,
D. Pie´rard, S. Lauwers (Brussels, BE)
Objectives: B. fragilis and related species may cause severe infections
of different origin. Phenotypic identiﬁcation methods require long
incubation and it is not always possible to distinguish between closely
related species.
The aim of this study was to evaluate the use and value of
MALDI-TOF MS in the rapid species identiﬁcation of Bacteroides and
Parabacteroides clinical isolates.
Methods: Two reference strains and sixty-four clinical isolates were
selected from previous studies. Twenty different species were included.
Routine species identiﬁcation was obtained by classical biochemical
tests. For MALDI-TOF MS one colony was smeared directly on the
target plate and overlaid by alfa-cyano-4-hydroxycinnamic acid matrix.
Identiﬁcation was performed with Microﬂex LT mass spectrometer in
combination with the MALDI-Biotyper 2.0 software and Reference Li-
brary 3.0.1.0 (Bruker Daltonik GmbH, Bremen, Germany). The MALDI
Biotyper output is a log(score) in the range 0−3.0. Thresholds for species
and genus identiﬁcation were respectively a log(score)of 2.0 and 1.7.
Results: Overall 43/66 (65%) isolates were identiﬁed at species level.
MALDI results were identical to routine species ID for 34 isolates. Nine
isolates were originally misidentiﬁed: repeating of phenotypic testing
(n = 6) or 16S rRNA gene sequencing (n = 3) conﬁrmed MALDI ID. All
B. fragilis (n = 6), B. thetaiotaomicron (n = 9) and P. distasomis (n = 6)
included were identiﬁed at species level. These species represent more
than 60% of Bacteroides and Parabacteroides isolates in our laboratory.
Ten (15.2%) isolates were only identiﬁed to genus level. Eight strains
(12.1%) were not identiﬁed (not included in the database or included with
<3 reference spectra). In 5 strains (7.6%) no distinction was possible
between closely related species (B. nordii/salyersiae and B. vulgatus/
B. dorei).
Conclusion: MALDI-TOF MS is a fast and more accurate method for
species identiﬁcation compared to routine biochemical identiﬁcation. We
estimate that 75% of Bacteroides and Parabacteroides isolates wil be
identiﬁed to species level by MALDI-TOF in our laboratory. Further
extension of the database will be needed to improve the performance of
this methodology.
P1791 Rapid identiﬁcation of bacteria from positive blood culture
bottles by MALDI-TOF MS ﬁngerprinting
M. Christner °, H. Rohde, M. Wolters, I. Sobottka, K. Wegscheider,
M. Aepfelbacher (Hamburg, DE)
Objective: To establish and evaluate a method for rapid identiﬁcation
of bacteria from positive blood culture bottles using MALDI-TOF mass
spectrometry.
Methods: Bacteria were isolated from positive BACTEC blood culture
bottles by differential centrifugation and prepared for mass spectrometry
ﬁngerprinting by formic acid extraction. Spectrum acquisition and
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identiﬁcation was performed with a microﬂex LT mass spectrometer and
the MALDI Biotyper 2.0 software from Bruker. Reference identiﬁcation
was established from agar subcultures using well-proven biochemical
and molecular typing methods.
Results: During the study period a total of 304 positive aerobic and
anaerobic blood culture bottles from our clinical microbiology laboratory
were investigated. Samples that grew yeast (8) or showed no sign of
microbial growth by conventional processing (3) were excluded from
further analysis. Isolates from the remaining study samples constituted a
representative collection of bloodstream pathogens. Results from direct
mass spectrometry ﬁngerprinting matched reference identiﬁcation for
262 of 277 monobacterial and 13 of 16 polymicrobial samples. A
second isolate was correctly recognized in 4 of 16 mixed cultures
(Gram stain: 2 of 16). The method worked equally well for aerobic and
anaerobic culture bottles and was only slightly inﬂuenced by culture age.
Misidentiﬁcations mostly resulted from insufﬁcient bacterial numbers
after sample preparation and were almost exclusively limited to Gram-
positive isolates. Incorrect direct identiﬁcation results could be reliably
rejected by identiﬁcation score cut-offs or tests for the bacterial origin
of matched signals.
Conclusions: Combined with an efﬁcient procedure for the preparation
of bacteria from positive culture bottles, mass spectrometry ﬁngerprint-
ing is a reliable tool for the rapid identiﬁcation of bloodstream pathogens.
Compared to conventional identiﬁcation from solid media subcultures,
time to result is reduced by at least one workday. Providing species-level
identiﬁcation not later than one day after laboratory entry for 80% of our
samples, the approach could facilitate targeted treatment optimizations
within the critical phase of septic illness.
P1792 High-speed blood culture diagnostic with MALDI-TOF MS
C. Litﬁn °, A. Sohns, A. Koch (Karlsruhe, DE)
Objectives: Rapid identiﬁcation of bacteria from blood cultures is essen-
tial for an early appropriate therapy in patients with bacteremia. Usually,
time consuming subcultivation is needed prior to identiﬁcation based
on biochemical reactions. Matrix-Assisted Laser Desorption/Ionisation
Time-Of-Flight Mass Spectrometry (MALDI-TOF MS) is an approved
method for rapid identiﬁcation of microorganisms [1]. We evaluated a
sample preparation method to obtain identiﬁcation within 4 hours after
detection of bacterial growth directly from blood culture bottles.
Methods: From 646 positive blood cultures (BacT/ALERT®,
bioMe´rieux), containing Gram-positive (N= 364) or Gram-negative
(N= 282) bacteria, an aliquot is enriched in brain-heart-infusion. 1ml
of the supernatant is spinned down and the pellet is resuspended in
70% ethanol before the next centrifugation step. The resulting pellet is
then treated with formic acid and soniﬁcated. For the last centrifugation
step acetonitrile is added. 1 ml of this supernatant is applied on
the MALDI-TOF target and HCCA (a-Cyano-4-hydroxycinnamic acid)
matrix is added to perform MALDI-TOF MS with a Microﬂex LT
(Bruker Daltonics). Results are compared to those obtained on basis
of biochemical and agglutination reactions (MicroScan® WalkAway®,
Siemens and API® strips, bioMe´rieux).
Results: 273 Gram-positive and 270 Gram-negative bacteria provide a
result within 4 hours after detection of bacterial growth. 90.8% of the
Gram-positives and 98.5% of the Gram-negatives are identiﬁed correctly
on species level. The positive predictive value is 100% for all tested
coagulase negative staphylococci, Staphylococcus aureus, enterococci,
group A and B streptococci and nearly all Gram-negative rods. Other
streptococci are identiﬁed correctly on genus level, but cannot be
distinguished reliably and require additional identiﬁcation steps.
Conclusion: The described method provides fast same day identiﬁcation
of bacteria directly from positive blood cultures. This identiﬁcation
procedure allows earlier species speciﬁc treatment, resulting in a better
patient outcome and cost savings because of early deescalation therapy.
Reference(s)
[1] Fenselau, C., Demirev, PA. Characterization of Intact Microorgan-
isms by MALDI Mass Spectrometry. Mass Spec Reviews, 2001, 20:
157–171.
P1793 Use of tubes equipped of separating gels for MALDI-TOF
assisted bacterial identiﬁcation in blood cultures
G. Pre´vost °, W. Moussaoui, B. Jaulhac, A. Hoffmann, B. Ludes,
M. Kostrzevra, P. Riegel (Strasbourg, Bremen, FR)
Introduction: Matrix-Assisted Laser Desorption/Ionization − Time Of
Flight or MALDI-TOF now represents an attractive challenge for
bacterial identiﬁcation [1, 2], because of the technological and medical
interests to provide rapid and cost-effective bacterial identiﬁcation. The
application to blood cultures would constitute an advantage for care of
patients and sometimes for therapy.
Materials and Methods: Positive blood cultures were harvested over
three months at the Strasbourg University Hospital. Were positive,
samples of 1.5mL of the medium was transferred into tubes containing
1mL of separating gel. After centrifugation, bacteria present at the
gel surface were suspended and recovered, before to be pelleted again
and further treated for whole proteins extraction. Mass spectra of
most abundant proteins were established onto a BiFlexII − Compass
1.2, Bruker Daltonics, Bremen, GE) as recommanded [1, 2]. Bacterial
identiﬁcations were then obtained by using BioTyper 1.2 software
(Bruker Daltonics).
Results: By including 24 negative controls, 526 samples were
considered. Eleven of these samples contained yeast, in 29 cases where
genus were only obtained while 555 bacteria could be identiﬁed. Thus,
compared to the routine, including 21 polymicrobial samples leading
to 50 bacteria, MALDI identiﬁcation was effective for 499 bacteria
(89.72%) distributed in 378 with good scores (1.9−3.0), and 72 with
middle-ranged scores. For other good identiﬁcations, at least the ﬁrst
three identiﬁcation proposals were identical. Concerning polymicrobial
samples, MALDI-assisted identiﬁcation allowed 22 bacteria to be
characterized, according to presence of species ratio. All together,
a better identiﬁcation of Gram-negative bacteria (95% vs 86%) was
obtained versus Gram-positive bacteria.
Conclusion: MALDI-TOF-assisted bacterial identiﬁcation can be
applied to blood cultures, and may bring species diagnosis in >90%
of the samples, before bacterial culture on agar media. This results can
increase the analytical information given to physicians.
Reference(s)
[1] Sauer S, Freiwald A, Maier T, Kube M, Reinhardt R, Kostrzewa
M, Geider K. (2008) Classiﬁcation and identiﬁcation of bacteria by
mass spectrometry and computational analysis. PLoS One 3:e2843.
[2] Mellmann A, et al. (2009) High inter-laboratory reproducibility
of MALDI-TOF mass spectrmetry-based species identiﬁcation of
nonfermenting bacteria. J Clin Micorbiol, 47: 3732−4.
P1794 Urinary tract pathogens direct identiﬁcation from urine
samples by MALDI-TOF MS
L. Ferreira, F. Sa´nchez Juanes, M. Gonza´lez A´vila, D. Cembrero
Fucin˜os, A. Herrero Herna´ndez, J.M. Gonza´lez-Buitrago Arriero,
J.L. Mun˜oz Bellido ° (Salamanca, ES)
Objectives: MALDI-TOF mass spectrometry (MS) has been suggested
as a fast and reliable method for bacterial identiﬁcation from culture.
Direct analysis of clinical samples may increase the usefulness of this
method, since can shorten the time for microorganism identiﬁcation.
We compared conventional methods for UTI diagnosis and urinary tract
pathogens identiﬁcation (automated screening and plate culture) and a
fast method based on conventional screening plus MALDI-TOF MS.
Methods: 260 urine samples from outpatients and inpatients with
symptoms of UTI, reported as positive by an automated screening
device based on ﬂow cytometry (UF-1000i) were processed. Positives
samples were studied by culture and conventional identiﬁcation, and by
MALDI-TOF MS.
Results: The screening device reported as positive 20 samples that were
negative in culture. All these cases were also negative in MALDI-TOF.
Five samples positive in the screening were reported as contaminated
in the culture. In these samples, MALDI-TOF reported a non reliable
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identiﬁcation in 2 cases, but reported microorganism identiﬁcation in 3
cases. 235 samples reported as positive by the screening device, led to
signiﬁcant bacterial growth in culture. 220 of them (93.6%) had bacterial
counts (BC) >100,000 CFU/mL, 7 (3.0%) had BC between 50.000 and
100.000 CFU/mL, and 8 (3.4%) had BC <50,000 CFU/mL. In whole,
MALDI-TOF MS identiﬁed correctly the microorganism involved in the
UTI, directly from the urine sample, in 91.8% of cases at the species
level, and at 92.7% at the genus level. Failures were observed in only
6.9% of samples. The most frequent microorganism isolated was E. coli
(173 isolates). MALDI-TOF ME identiﬁed the microorganism in 163
cases (94.2%) (97.6%. when BC was >100,000 CFU/mL).
Conclusion: MALDI-TOF MS gives a realiable identiﬁcation of
UTI pathogens, previously to culture, in >90% of positive samples.
MALDI-TOF performance is optimal when there is a high BCs and
Gram negatives are involved.
P1795 MALDI-TOF ICMS: capability, potentiality and limits in
the fast identiﬁcation of Trichophyton rubrum from clinical
cases occurrence in Portuguese health centres
L. Pereira, N. Dias °, C. Santos, N. Lima (Braga, Gandra, PT)
Objective: Trichophyton rubrum is presently the most common
worldwide pathogen causing dermatophytoses such as tinea corporis,
tinea capitis, tinea pedis, and onychomycosis [1]. The main aim
of the present work was assess MALDI-TOF ICMS as a fast and
reliable technique in the identiﬁcation of T. rubrum from clinical
cases occurrence in the Portuguese health centres, and evaluates the
potentialities and limits of this new microbial identiﬁcation technique
on the taxonomy of these infectious dermatophytes.
Methods: Fungi were grown for 10 days in solid medium (SDA,
Sabouraud Dextrose Agar) and then the mycelia were direct transferred
from the SDA plate to the MALDI stainless steel template and mixed
with 1ml MALDI matrix solution (75mg/ml 2,5-dihydroxybenzoic acid
in ethanol/water/acetonitrile [1:1:1] with 0.03% triﬂuoroacetic acid).
The sample mixtures were air dried at room temperature. The analyses
were performed in our laboratory on an Axima LNR system (Kratos
Analytical, Shimadzu, Manchester, UK) equipped with a nitrogen laser
(337 nm). The mass range from m/z = 2,000 to 20,000Da was recorded.
Escherichia coli strain DH5a with known mass values of ribosomal
proteins was used for external calibration. The fungi classiﬁcation was
performed on the SARAMIS software (AnagnosTec mbH, Potsdam-
Golm, Germany). Molecular biology was used when appropriated
with PCR based-technology. The presence of a 203-bp PCR product
conﬁrmed T. rubrum identiﬁcation.
Results: All strains were accurately and consistently identiﬁed as
T. rubrum by MALDI-TOF ICMS combined to SARAMIS database
analysis. Spectral mass analysis proven to be a rapid method since
the analysis took only a few minutes to perform with the beneﬁt of
any laborious sample preparation procedures or any expensive chemical
reagent was needed.
Conclusions: The fungal spectral analysis by MALDI-TOF ICMS was
as good as molecular biology in order to identify T. rubrum but much
faster and cheaper.
Reference(s)
[1] Degreef, H. (2008) Clinical Forms of Dermatophytosis (Ringworm
Infection) Mycopathologia 166: 257–265.
P1796 A MALDI-TOF assay for the rapid identiﬁcation of
Aspergillus and Candida sp. in clinical samples
L. Putignani °, L. Mancinelli, F. Del Chierico, M. Onori, L. Coltella,
P. Bernaschi, E. Fiscarelli, M. Argentieri, L. Pansani, S. Ranno,
B. Lucignano, L. Dimiziani, C. Russo, D. Menichella (Rome, Macerata,
IT)
Objectives: Invasive mould infections are becoming worldwide in-
creasing, resulting in signiﬁcant morbidity and mortality especially in
paediatric populations, immunocompromised and transplanted patients.
Particularly the phyla Ascomycota, and Basidiomycota are involved in
severe infections in children. The Ascomycota includes yeasts of the
genera Saccharomyces, Pichia, and Candida and many ﬁlamentous fungi
of the genera Aspergillus, Penicillium and Fusarium. The Basidiomycota
Cryptococcus neoformans is an emerging opportunistic human pathogen.
Identiﬁcation of the increasing diversity of fungal pathogens by
conventional methods (biochemical methods for yeast and phenotypic
methods for mould) is often difﬁcult, time-consuming and frequently,
for unusual fungi, inconclusive.
In our study, we exploited the MALDI-ToF MS (Matrix-assisted laser
description ionization-time of ﬂight-mass spectrometry) Biotyper to
for rapid and speciﬁc identiﬁcation of fungal species from clinical
specimens.
Methods: 270 yeast and 80 mould fungi strains were collected from
diversiﬁed clinical samples in our microbiology unit and grown on
Sabouraud solid medium. Protein proﬁles were provided by using
MALDI-ToF MS Biotyper for both clinical and reference strains, the
latest purchased from the Centraalbureau voor Schimmelcultures (CBS)
culture collection. Generated spectra were acquired and processed to
produce appropriate species identiﬁcation.
The results were compared to conventional biochemical and phenotyping
identiﬁcations in order to produce concordance data. When appropriate,
MALDI-TOF-based results were compared to sequencing-based identi-
ﬁcation analysis (D2 LSU 28S rDNA).
Results: MALDI-Tof MS provided the correct yeast identiﬁcation with
a sensitivity of 95% and speciﬁcity of 94% compared to conventional
methods. For mould identiﬁcation the MALDI-ToF MS provided a 80%
of sensitivity, due to the absence of appropriate reference species in
the database. The MALDI-ToF-MS identiﬁcations provided 100% of
concordance with the 28S rDNA D2-LSU-based sequencing analysis for
all the analysed isolates.
Conclusions: This study provides a fast and reliable method, based on
MALDI-ToF MS detection, for the identiﬁcation of fungal species in
clinical samples. This procedure might overcome current diagnostic tests
and may represent a new frontier for the rapid and speciﬁc management
of fungal infections in paediatric patients.
P1797 Identiﬁcation of clinical fungi by MALDI-TOF MS: how
to deal with growth-dependent variability in peak patterns
M. Erhard, U. Hipler, F. Seyfarth, Y. Gra¨ser, M. Welker ° (Potsdam,
Jena, Berlin, DE)
The identiﬁcation of microorganisms by MALDI-TOF MS is about to
replace biochemical identiﬁcation procedures for routine diagnostics.
While the mass spectral identiﬁcation of most bacteria is straightforward,
the identiﬁcation of fungi with whole cell MALDI-TOF MS is more
challenging for several reasons. Most importantly, the peak pattern
of an individual isolate can change dramatically in dependence of
incubation time and medium composition. Especially the transition from
non-sporulating to sporulating mycelium generally results in marked
differences in mass ﬁngerprints.
One option to overcome this difﬁculty is to strictly standardize the
cultivation conditions of reference and sample isolates. This can,
however, be rather impractical due to differences in growth behaviour,
particular medium demands, and handling requirements of individual
isolates. Another strategy is to obtain reference data from well
characterized isolates for different growth conditions. The latter strategy
is followed for the Spectral Archive and Microbial Identiﬁcation System
(SARAMIS) by the acquisition of whole cell mass spectra of reference
isolates grown on a variety of solid media and at different incubation
times. Generally, reference isolates are incubated on three different media
and mycelium samples are taken after three different incubation times.
By this 3 x 3 approach the variability of mass ﬁngerprints of individual
isolates is largely captured and the mass spectra are deposited in the
reference database. When multiple isolates of a species are contained in
the database, the corresponding data were used to compute SuperSpectra
for fully automated identiﬁcation.
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SARAMIS allows the rapid, automated identiﬁcation of most clinically
relevant fungi by direct on-target smear preparation of fresh mycelium
taken from agar plates. Examples will be presented for the identiﬁcation
of dermatophytes, yeasts, Aspergillus sp., and Fusarium sp.
P1798 Comparison of 4 different commercial identiﬁcation
methods and antibiotic susceptibility testing on clinical
relevant coryneform bacteria
I. Geerts °, A. Smismans, R. Cartuyvels, H. De Beenhouwer, J. Verhaegen,
E. Verhoye, J. Frans (Bonheiden, Hasselt, Aalst, Leuven, BE)
Objectives: Identiﬁcation of coryneforms is hampered by poorly
discriminative biochemical reactions. The aim of this study is to compare
4 commercially available identiﬁcation methods with 16S rRNA gene
sequencing as gold standard. In vitro susceptibility was assessed by both
MIC determinations (CLSI, M45-P) and disk diffusion for 9 clinically
relevant antibiotics.
Methods: A total of 53 clinical isolates of Corynebacterium spp. and
related genera (22 different species) from clinically signiﬁcant infections
was collected in two Belgian hospitals from november 2008 to may 2009.
The strains were tested with API® Coryne strip (bioMe´rieux), BBL
Crystal™ GP system (BD), Vitek 2 ANC card (bioMe´rieux) and
MALDI-TOF (Bruker). Genotyping was performed by sequencing of
the 16S ribosomal region.
Antimicrobial susceptibility was performed on Mueller-Hinton agar
supplemented with 5% horse blood with both disk diffusion (Rosco
Diagnostica) and MIC determination (E-test, bioMe´rieux). The plates
were inoculated with a 0.5McFarland suspension and incubated in
5% CO2 at 36ºC for 24−48 h.
Results: Forty-six strains were successfully sequenced. The remaining 7
strains were not retained for the evaluation of the identiﬁcation methods.
MALDI-TOF accurately identiﬁed 43 out of the 46 strains (93.5%) to
the genus and 38 strains (82.6%) to the species level. API® Coryne,
BBL Crystal™ GP system and Vitek 2 ANC card were able to identify
respectively 37 (80.4%), 29 (63%), 36 (78.3%) strains to the genus and
18 (39%), 3 (6.5%), 20 (43.5%) strains to the species level.
All isolates (n = 53) were sensitive to vancomycin, linezolid and
doxycycline. Sixty-eight % appeared resistant to clindamycin and
erythromycin, 62.3% to ciproﬂoxacin, 47.2% to levoﬂoxacin, 32%
to trimetoprim-sulphamethoxazole (TMP-SXT) and 15% to penicillin.
Comparison between disk diffusion and MIC determination revealed 15
minor, 6 major and 7 very major errors. The very major errors were
related to erythromycin (n = 2), ciproﬂoxacin (n = 1), levoﬂoxacin (n = 3)
and TMP-SXT (n = 1).
Conclusions: Coryneform bacteria can be reliable identiﬁed by the
MALDI-TOF. API® Coryne, BBL Crystal™ GP system and Vitek 2
ANC yielded erroneous results in 20−30% of the isolates. Antibiotic
susceptibility testing is inaccurate by disk diffusion method and should
rely on MIC determinations.
Table 1: Correctly identiﬁed coryneforms by the different identiﬁcation
methods
Strain (No.) MALDI-TOF API Coryne strip BBL Crystal GP Vitek 2 ANC
C. amycolatum (11) 11 6 0 10
C. glocuronolyticum (5) 4 5 0 0
C. urealyticum (3) 3 3 0 3
C. ulcerans (2) 2 1 1 1
C. propinquum (2) 2 0 1 0
C. aurimucosum (2) 1 0 0 0
C. xerosis (2) 0 0 0 0
C. coyleae (2) 2 0 0 0
Other (17) 13 3 1 6
P1799 Rapid species identiﬁcation and differentiation of
Arcobacter, Helicobacter and Campylobacter by
MALDI-TOF MS analysis and its clinical application
M. Alispahic °, K. Hummel, D. Jandreski-Cvetkovic, K. No¨bauer,
E. Razzazi-Fazeli, M. Hess, C. Hess (Vienna, AT)
Objectives: Identiﬁcation and differentiation of species belonging to
the Arcobacter, Helicobacter and Campylobacter genera has become
increasingly important, since many of them are recognised as human
and/or animal pathogens. Matrix-assisted laser desorption/ionization
time-of-ﬂight mass spectrometry (MALDI-TOF MS) was shown to be
a rapid and sensitive method for charcterisation of microorganisms. In
this study, we established a reference database of selected Arcobacter,
Helicobacter and Campylobacter species. The second objective was to
use the reference database to identify 144 clinical isolates and compare
the results to molecular method. The third objective was to evaluate the
reproducibility using different growth media and age of bacteria, which
are relevant in a diagnostic lab.
Methods: Besides the species with signiﬁcance as food-borne
pathogens − Arcobacter butzleri, Helicobacter pullorum, Campylobacter
jejuni and Campylobacter coli − several other members of these genera
were included in the reference library, grown on Columbia agar. In
parallel to MALDI Biotyper 1.1 software package (Bruker Daltonik)
identiﬁcation, all strains were analysed by PCR-RFLP.
Results: Strains that made up for the reference database library yielded
reproducible and unique mass spectra proﬁles, which were compared
with the Bruker Biotyper database, version 2. It was found that correct
identiﬁcation could be obtained even if the bacteria are stored at
room temperature or at +4ºC up to 9 days until being tested. In
addition, bacteria were correctly identiﬁed when grown on Campylosel-
agar, however not when grown on modiﬁed charcoal cefoperazone
deoxycholate agar. All ﬁeld isolates gave sufﬁcient spectra for species
identiﬁcation. In total, MALDI-TOF MS identiﬁed all 144 clinical
isolates at species level.
Conclusion: Altogether, these data show that MALDI-TOF MS
ﬁngerprinting is a fast and reliable method for the identiﬁcation
of Arcobacter and Helicobacter species and their distinction from
phenotypically similar Campylobacter species with applications in
clinical diagnostics. As a result, considering the speed with which
reliable identiﬁcation can be obtained, this technique is well suited for
large-scale research and diagnostic analyses.
Molecular tools to diagnose meningitis,
sepsis, respiratory tract and bone and joint
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P1800 Molecular diagnosis of meningococcal meningitis; factors
inﬂuencing genomic Neisseria meningitidis bacterial load
within cerebrospinal ﬂuid
T. Darton °, M. Guiver, S. Naylor, D. Jack, E. Kaczmarski, R. Borrow,
R. Read (Shefﬁeld, Manchester, UK)
Objective: Polymerase chain reaction (PCR) detection of Neisseria
meningitidis (Nm) in patients with presumed meningococcal disease has
greatly increased diagnostic yield and allows accurate quantiﬁcation of
bacterial genome copies within invasive sites. We sought to identify
factors associated with a positive Nm PCR within the cerebrospinal
ﬂuid (CSF) of patients with meningococcal disease and the factors that
inﬂuence the detectable copy number.
Methods: Nm DNA quantiﬁcation by Taqman PCR was conducted on
CSF samples from patients presenting with meningococcal meningitis
to hospitals throughout England and Wales during the period 1999–
2004, and correlated using multivariate regression to patient, clinical and
microbiological variables. Bacterial load (BL) data are log transformed.
Results: The National Reference Laboratory received 383 CSF samples
over 5-years from patients with subsequently conﬁrmed meningococcal
disease. Of the samples submitted 132 (35%) were Nm PCR positive.
Individuals with a positive CSF PCR were at no greater risk of death
compared with those with a negative PCR (3.8% vs. 2.4%, p=NS), but
those who had a CSF sample sent were at signiﬁcantly less risk of death
when compared to all individuals presenting with MD (n = 1486) (2.9%
vs. 10.6%; p< 0.0001, chi-square).
The median time from admission to hospital until sample receipt by the
laboratory was <24 hours (range 0−25 days). Time delay had no effect on
likelihood of PCR positivity or on BL measured. Factors associated with
a positive PCR by multivariate regression included serogroup B infection
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(B = 1.71, p< 0.0001), older age (B = 0.022, p = 0.002) and antibiotic
receipt prior to hospital admission (B = 1.205, p = 0.043).
The median CSF BL was 5.97 copies/ml (IQR, 4.99–7.26). The
respective plasma BL for this population was 3.40 (IQR, 2.70–5.63). The
CSF BL was signiﬁcantly greater in individuals with serogroup B than
with serogroup C infection (median BL 6.01 vs. 5.09; p = 0.02, Mann–
Whitney). There was no correlation between the CSF and plasma BL
in individuals with serogroup B infection (p=NS, Pearson’s correlation).
In serogroup C infection there was a tendency towards a direct positive
correlation (r = 0.241; p = 0.074, Pearson’s correlation).
Conclusions: These data suggest that in meningococcal meningitis, there
is strain to strain variation in penetration of or replication within CSF,
and that translocation of bacteria from blood to CSF does not follow a
concentration gradient.
P1801 Severe Mycoplasma pneumoniae respiratory tract infections
in children, suspected on clinical ground, are conﬁrmed by
laboratory tests
A. Marangoni °, F. Delucca, R. Bergamaschi, D. Zama, F. Specchia,
S. Accardo, A. Moroni, R. Cevenini (Bologna, IT)
Objectives: About 15%-20% of cases of community-acquired pneumo-
nias are estimated to be due to Mycoplasma pneumoniae, whereas 1%
to 5% of M. pneumoniae pneumonias may require hospitalization for
respiratory distress. In these cases, a speciﬁc diagnosis is essential for
the choose of the antimicrobial treatment since b-lactam antibiotics, often
delivered to young outpatients with pneumonias, are ineffective against
M. pneumoniae.
In this study, children hospitalized for suspected pneumonia not-
responder to the treatment with b-lactam antibiotics, were studied
in order to etiologically diagnose M. pneumoniae infection, both by
polymerase chain reaction (PCR) and serology.
Methods: Study group. From January 2009 to October 2009 two
paired samples (a nasopharingeal aspirate specimen and a serum
specimen) were taken on hospital admission from children hospitalized
for suspected pneumonia diagnosed on clinical ground and conﬁrmed
by radiology. Specimens were obtained from a total of 61 children
(aged between 1−14, mean age 5.5) hospitalized at S. Orsola Hospital,
Bologna, Italy, during the study period.
Molecular diagnosis of M. pneumoniae infection. Automated DNA
extraction was performed by using Nuclisens® easyMag system,
bioMe´rieux. Real Time PCR was performed by using MYCOPLASMA
pn. Q - PCR Alert AmpliMIX, Nanogen Advanced Diagnostics. System
standardization was carried out on Applied Biosystems ABI PRISMTM
7300 instrument. M. pneumoniae serology. We used Mycoplasma
pneumoniae IgG e IgM Novagnost™, Siemens Healthcare Diagnostics,
for the serological diagnosis of M. pneumoniae.
Results: M. pneumoniae was detected by PCR in aspirate specimens of
11 of 61 (18%) patients with pneumonia. All the PCR-positive patients
but one had also IgM positive results on serum samples.
In 10/61 aspirate specimens the ﬁrst result of the ampliﬁcation reaction
was undetermined for the DNA of the human b-globin gene.
Conclusion: The concordance of M. pneumoniae PCR and IgM
serology in 10 out of 11 (90.9%) young patients hospitalized with
pneumonia, conﬁrmed that the timing of pathological samples collection
for laboratory investigations in M. pneumoniae pneumonias is crucial for
optimizing the results. In addition, the rapid acquisition of the laboratory
results allowed the clinicians to modify the antimicrobial therapy without
delay, by replacing b-lactam antibiotics with macrolides.
P1802 Relevance of PCR-based pathogen detection assay in
critically ill patients
S. Sachse °, F. Bloos, A. Kortgen, K.H. Schmidt, M. Lehmann,
M. Bauer, K. Reinhart, E. Straube (Jena, DE)
Objectives: Traditional culture based methods for detection of sepsis
pathogens take too long to guide empiric antimicrobial therapy in sepsis.
Furthermore, blood cultures often yield negative results despite presence
of sepsis. PCR based methods may help to overcome this problem
since these methods accelerate pathogen identiﬁcation. We report the
performance of PCR based pathogen detection compared to blood culture
in ICU patients with suspected infection.
Methods: Patients treated on an interdisciplinary ICU were included
into this observational study if a blood culture (BC) was drawn on
discretion of the treating physician. Blood cultures and EDTA-blood
were taken by sterile venous puncture. The EDTA-blood was processed
with a PCR-based assay (VYOO(R), SIRS-Lab GmbH, Jena), which
detects a panel of 34 bacterial and 6 fungal pathogens as well as ﬁve
antibiotic resistances. Data are given as median and interquartile range.
Results: 64 patients were included into this study. Median age was 68.0
(55.5; 74.0) years. 92 pairs of BCs and PCRs have been investigated.
7 (8%) BCs and 29 (32%) PCRs were positive. 42.1% patients had at
least one positive PCR and 12.3% patients had at least one positive BC.
At study inclusion, 5% of the BCs and 35% of the PCRs were positive.
3 out of 9 pathogens detected in the BC were also reported by the PCR.
However, 4 BCs were contaminated with S. epidermidis which was not
detected by the corresponding PCR. Fungi were detected in 10 PCR
specimens compared to 1 Candida spp. detection in BC. 50% of the
patients with positive PCR amplicon for fungi died. Likewise, 50% of
patients (2 out of 4) with more than one positive PCR result died, as well.
None of the differences in mortality rates reached statistical signiﬁcance.
Conclusions: The PCR based assay resulted in considerably higher
amount of positive results than the blood culture in this group of high risk
patients. Furthermore, the data suggest that PCR can detect a high risk
group of patients with positive results for fungi. The fact that repetitive
positive PCR results were associated with a high mortality rate further
suggests the clinical relevance of microbial DNAemia.
P1803 Development and the evaluation of a real-time PCR assay
for molecular diagnosis of polymicrobial sepsis
A. Fouad, A. Kalkanci °, A. Seyer, M. Dizbay, O. Tunccan, K. Hizel,
K. Caglar, S. Kustimur (Ankara, TR)
Objectives: The current microbiological diagnosis of sepsis is based
on blood culture. However, blood culture systems suffer from several
limitations such as lack of rapidity and, in cases such as fungal infections
and polymicrobial infections, low sensitivity. In the present report, a
real-time PCR assay using a LightCycler instrument, is described for
the detection of bacterial and fungal DNA in simulated and clinical
samples. The detection of Aspergillus fumigatus, Candida albicans,
Staphylococcus aureus and Escherichia coli were aimed.
Methods: During the proces we have evaluated a range of different
primers and probes, targeting different gene regions and including a
variety of amplicon detection methods. As a result of this proces, a
single-reaction TaqMan PCR assay targets selected in the ITS regions
of Candida and Aspergillus and 16S rRNA gene region of bacteria
were selected. Bacterial primers were F-CAACGCGAAGAACCTTACC,
and R-ACGTCATCCCCACCTTCC, Gram-positive probe was FAM-
ACGACAACCATGCACCACCTG-TAMRA, Gram-negative probe was
FAM-ACGACAGCCATGCAGCACCT-TAMRA, Aspergillus primers
were F-CTGTCCGAGCGTCATTG, ITS-TCCTCCGCTTATTGATAT,
probe was FAM-AGCCGACACCCAACTTTATTT-TAMRA, Candida
primers F-CCTGTTTGAGCGTCRTTT, ITS-TCCTCCGCTTATTGATAT,
probe CATTGCTTGCGGCGGTA. Bacterial and fungal ampliﬁcation
was performed using the 50 cycles of 15 s at 95 C and 60 s at 60
C for target ampliﬁcation. DNA derived from A. fumigatus, C. albicans,
S. aureus and E. coli as positive control samples.
Results: The analytical sensitivity using pure cultures and EDTA-
anticoagulated blood samples spiked with each microorganism cell
suspensions was shown to be at least 1 CFU per PCR, corresponding to 5
to 10 CFU/ml blood. To assess the clinical applicability, blood samples
of sepsis cases were retrospectively tested and real-time PCR results
were compared with results from culture, histology, or a galactomannan
enzyme-linked immunosorbent assay (ELISA) results. Sepsis cases were
diagnosed correctly. Spiked blood samples had a 100 percent rate of
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positive testing for all four types of microorganism (10/10 replicates) at
each time point.
Conclusions: Our data suggest that the PCR assays may be appropriate
for use in clinical laboratories as simple and rapid screening tests and
might become an important tool in the early diagnosis of sepsis in the
future.
P1804 Rapid same-day identiﬁcation of 69% of bacteria and yeast
from positive blood culture bottles using ﬁve PNA FISH™
ﬂuorescence in situ hybridization probes
D.S. Hansen °, L. Leerbeck, H. Kofod, B. Bruun (Hillerød, DK)
Objectives: Early diagnosis of bloodstream infections is essential for
rational antibiotic therapy and minimizing morbidity and mortality.
Routine identiﬁcation must await subculture and are thus unavailable on a
same day basis, subjecting patients to broad spectrum empiric antibiotic
therapy until identiﬁcation. Fluorescence in situ hybridization (FISH)
testing provides results within 1.5 h. The purpose of this study was to
evaluate a ﬁve PNA FISH probe approach with regard to feasibility and
coverage of the spectrum of positive blood cultures.
Methods: The assay is performed directly on smears from positive blood
culture bottles (BCB) with ﬂuorescence labeled peptide nucleic acid
(PNA) probes targeting rRNA of the micro organisms. During 8 weeks
in August − October 2009 all positive blood cultures detected daytime
Monday to Friday were included. Each BactAlert blood culture set (BCS)
consisted of two BCB. On all positive BCB wet mount and Gram stain
microscopy were done. Based on this data ﬂuorescence microscopy of
blood smears stained with the relevant set(s) of PNA FISH™ (AdvanDx)
probes were done as follows:
– Gram negative rods − E. coli/P. aeruginosa and EK (E. coli-
K. pneumoniae)/P. aeruginosa
– Gram positive cocci (GPC) in clusters − S. aureus/CNS
– GPC in pairs and chains − E. faecalis/other enterococci (OE)
– yeast − C. albicans/C. glabrata.
If more than one BCB from a patient were positive, but had same sample
date and Gram microscopy, only one PNA FISH microscopy was done.
Conventional identiﬁcation was performed in parallel.
Results: In the study period 2,631 BCS from 1,026 patients were
cultured. Of these, 298 BCS from 169 patients were positive. PNA
FISH was done on 135 (45%) of the BCS and on 116 (69%) of the
patients. PNA FISH resulted in identiﬁcation in 93 (69%) BCS tested;
80 (69%) of patients tested. Also a negative PNA FISH result has
diagnostic implication, e.g. GPC in pairs and a negative E. faecalis/other
enterococci PNA FISH doubles the propability for pneumococci.
All PNA FISH results were correct except for a non-hemolytic
streptococcus which was falsely judged positive in the OE assay (orange,
not red colour).
Conclusion: PNA FISH using ﬁve probe sets is a rapid and accurate
method for identiﬁcation of micro organisms directly from positive BCB
and provides important information for appropriate antibiotic therapy.
The method is reliable, easy to perform, and saves time for technologists,
clinical microbiologists and clinicians.
P1805 Use of a commercially available multiplex real-time PCR
assay (SeptiFast) to detect bacterial and fungal pathogens
in septic patients
J. So´ki, E. Szabo´, E. Hajdu´, A. La´za´r, E. Nagy ° (Szeged, HU)
Objectives: The aim of this study was to evaluate the usefulness of
the SeptiFast PCR system for rapid diagnosis of 21 pathogens in septic
patients with or without antibiotic therapy and compare the results with
blood culture tests.
Methods: Blood samples were taken from patients displaying symptoms
of sepsis for blood culture (Bactec, Becton-Dickinson) and EDTA-blood
sample was collected for the multiplex real-time PCR (SeptiFast, Roche)
tests. Patients were from different ICUs and the haematology department
of our University Hospital.
Results: 162 parallel samples were tested: blood culture sets (1 aerobic
and 1 anaerobic bottle) were cultured and SeptiFast PCR tests were
preformed. The two diagnostic methods were compared in two groups
of patients: (1) patients laying in ICUs with several types of disease
background other than haematological disorders and (2) patients with
haematological malignancies with fever. While in the case of the
ﬁrst group of patients (n = 36) the results were concordant with some
superiority of the SeptiFast system (11 both positive with concordance
in the pathogens, 1 only blood culture positive 4 only PCR positive
and 21 both negative). Out of the four cases where SeptiFast tests were
positive and the blood cultures were negative in two patients Aspergillus
fumigatus was detected by SeptiFast and in two other patients, already
receiving antibiotics, E. coli and Enterobacter cloaceae/aerogenes were
detected. In the case of haematology patients (n = 126) the two types of
tests gave somewhat divergent results (10 both positive with concordance
in the pathogens, 17 only blood culture positive, 14 only PCR positive
and 85 both negative). Among the only blood culture positive samples
(altogether 19 isolates) 2 patients were found positive with pathogens
(Clostridium sp, Pseudomonas putida), which are not included into the
SeptiFast kit, and 12 different coagulase-negative staphylococci were
considered as contaminants. In all cases where the SeptiFast was positive
and the blood cultures were negative antibiotic therapy was already
introduced before taking samples.
Conclusion: The SeptiFast system cannot as yet replace blood cultures
in the initial diagnostics of septic patients with or without haematological
disorders, but may provide helpful information in episodes with
persistent fever during antibiotic therapy and detect fungal infections
difﬁcult to prove by blood culture method.
P1806 Evaluation of molecular detection of bloodstream pathogens
in 144 patients arriving in the emergency room with clinical
signs of sepsis
M. Avolio °, P. Diamante, S. Zamparo, M.L. Modolo, S. Grosso,
P. Zigante, N. Tosoni, R. De Rosa, P. Stano, A. Camporese (Pordenone,
IT)
Objectives: In this study we wished to compare traditional Blood
Culture (BC) with multiplex Real-time PCR, LightCycler SeptiFast Test
M Grade (Roche Molecular System), in 144 patients with suspected
bloodstream infections arriving at emergency room (ER) in order to
know the agreement degree about those two methods applied in this
category of patients.
Methods: 144 adult patients admitted to ER of our hospital with at
least two criteria of the systemic inﬂammatory response syndrome were
included in the study. During a febrile episode a single venipuncture
was used to draw samples for 2 x 3 bottles of Bact/Alert (bioMe´rieux,
Marcy l’Etoile, France). Immediately after the blood was drawn for the
BC (8−10mL/bottle), a 1.5mL of whole blood was collected in sterile
EDTA-KE tubes (Sarstedt, Nu¨mbrecht, Germany) for the molecular
method.
Results: SeptiFast results were compared with the results obtained with
all culture bottles taken on different time points during a 24-h period
and arrived simultaneously in our laboratory, showing a sensitivity of
92.5%, a speciﬁcity of 91% with a PPV and NPV of 78.7% and
97.1% rescpectively (values obtained by excluding CoNS and DNA not
detectable by SeptiFast).
A median of 36 hours was necessary to obtain Gram staining and at least
72 hours, calculated from the arrival of the sample to the laboratory, for
ﬁnal bacterial species identiﬁcation of pathogens using blood culture
and biochemical identiﬁcation. A median time of 15 hours (range 6−30
hours) was sufﬁcient to obtain a molecular analytical result.
Conclusion: Several studies have underlined the limitations of both
molecular and BC methods in diagnosis of BSI (Westh et al. Clin
Microbiol Infect 15(6), 2009; Bouza et al. Clin Infect Dis 39, 2004). Our
study conﬁrms that SeptiFast is limited by its test menu, the speciﬁcity
of its primers and probes, and the genetic variability of the target site,
but on the other hand, an inadequate sample volume, antimicrobial
therapy before drawn or the number of repeated blood draws affected
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the sensitivity of BC. On the basis of our results, either in terms of
concordance of results, either in terms of TAT, despite its limitations,
SeptiFast could be useful as an adjunct to traditional culture methods to
facilitate detection of BSI (Andrade et al. Shock 30(1), 2008), especially
in cases where BC is negative, but BSI is strongly suggested. For these
clinical conditions we wish to further investigate the use of SeptiFast.
P1807 Real-time PCR seems to be not superior to blood cultures
during the treatment course of infective endocarditis in
anticipating valves sterilization
P. Fanourgiakis °, E. Kraniotaki, E. Platsouka, E. Perivolioti,
M. Katsimpoulas, E. Gikas, A. Tsarbopoulos, A. Skoutelis, O. Paniara
(Athens, GR)
Objectives: To ﬁnd out whether real-time PCR in blood could be a
sensitive tool during the antibiotic treatment of infective endocarditis that
could monitor the bacterial load in blood and probably in vegetations.
If this hypothesis proved to be true, it should have serious implications
in the management of IE with regard to duration of treatment, earlier
recognition of complications or treatment failures and perhaps to animal
models of IE.
Methods: We conducted our study during our experiments regarding
the efﬁcacy of daptomycin in rabbit enterococcal endocarditis. After
left catheterization (day 0) 108 CFUs of a clinical strain Enterococcus
faecium were inoculated on day 2. On day 4 daptomycin was initiated
(days 4−8) and on day 9, animals were sacriﬁced, vegetations excised and
quantitatively cultivated. Before inoculation, before treatment initiation
and before sacriﬁce, blood samples were drawn for routine culture and
PCR. Hemoglobin was removed, and DNA was extracted using the High
Pure PCR Template Preparation Kit (Roche). The extract was eluted
in 100 ml of elution buffer. LightCycler Enterococcus Kit MGRADE
(Roche) was employed. 5 ml of the extracted DNA were used in a total of
20 ml reaction mixture. A standard curve of E. faecium DNA consisting
of seven 10-fold dilutions of a stock solution of 108 CFU (107 CFU
equivalents/PCR) was included in each run for automatic calculation of
the bacterial DNA load. Analytical sensitivity was determined to be less
than 10 CFU equivalents/PCR. No false positive results were observed.
Results: All blood cultures on day 4 were positive whilst on days 2 and
9 were sterile. None excised vegetation was sterile. Mean bacterial load
on vegetations (mean log10 numbers per gram±SD) was 5.75±0.89.
Results of real-time PCR were positive during proved bacteremia but
negative when BCs had turned sterile No correlation seems to exist
between bacterial DNA load (BDL) on day four and ﬁnal bacterial load
on vegetations.
Conclusions: Our results propose that real-time PCR is not sensitive
enough in the case of animal enterococcal endocarditis to detect
bacteremia when blood cultures turned negative. Thus its utility in
predicting valves sterilization is improbable.
Table 1: Results of real-time PCR on day 4 and of quantitative cultures
of excised vegetations
Rabbits Blood-PCR day 4
Log10 copies/reaction
Vegetations
Log10 CFU/g
1 4.511 6.47
2 3.382 6.51
3 5.014 6.44
4 2.548 5.8
5 1.604 4.05
6 2.959 6.25
7 4.707 5.87
8 1.988 5.95
9 4.504 5.97
10 3.817 4.23
Mean±SD 3.503±1.2 5.75±0.89
P1808 Usefulness of a microarray method for the diagnosis of
bone and joint infections directly on clinical samples: a new
application of Prove-it™ sepsis
E. Allais °, S. Boisset, A.M. Freydie`re, T. Ferry, S. Lustig, J. Etienne,
S. Tigaud, F. Vandenesch, F. Laurent (Bron, Lyon, FR)
Objectives: We evaluate the performance of Prove-it™ Sepsis assay
(PISA) (Mobidiag®) for rapid detection and identiﬁcation of bacteria
directly from bone and joint infections (BJIs) clinical samples, compared
to conventional culture and universal 16S PCR. This microarray assay,
targeted gyrB, parE and mecA genes, was initially developed to identify
bacterial species (n> 50) in positive blood cultures in less than 3 hours.
Methods/Results: We selected 114 clinical BJI samples, for which
microbiological diagnosis had been previously established either by
culture (C+) or by PCR16S-sequencing (C−/PCR16S+). All these
positive samples were chosen within the spectrum of bacteria included
on the array. Sixteen negative clinical samples (C−/PCR16S−) were also
included.
• C−/PCR16S− (n = 16): 15 samples were negative; 1 sample was
positive with S. epidermidis which has been conﬁrmed by the tuf
gene ampliﬁcation and sequencing
• C+/PCR16S+ (n = 32): 23 samples (71.9%) were positive with
concordant identiﬁcation, 3 samples were positive and concordant
but revealed the presence of a second species; 6 samples remained
negative
• C+/PCR16S− (n = 20): 5 samples (25%) were positive and concordant;
15 samples remained negative as PCR16S
• C−/PCR16S+ (n = 62): 36 samples (58%) were positive and concor-
dant, 4 samples were positive with a mix of 2 to 4 species; 22 samples
remained negative.
A new generation of PISA (StripArray) including speciﬁc probes for
Kingella kingae and Propionibacterium acnes was also tested on culture-
negative synovial ﬂuids from children (n = 159):
• C−/PCRKingella+ (n = 45): 35 were positive for K. kingae (77.8%).
Ten samples remained negative, but seven revealed positive-Kingella
probes in insufﬁcient number to meet the strict positive identiﬁcation
criteria, deserving complementary studies.
• C−/PCR16S− (n = 114): 110 samples were negative and 4 samples
were found positive (K. kingae, P. acnes, S. aureus, S. pneumoniae).
Conclusions: The preliminary results of this rapid and cost-effective
method are promising. Its advantages include: no sequencing step,
detection of a large panel of bacterial species with a single multiplex PCR
assay, detection of polymicrobial BJIs, detection of mecA. Currently,
the new version of PISA is further evaluated with prospective BJI
clinical samples as well as optimization of DNA extraction/ampliﬁcation
protocols is underway to improve the sensitivity of the test. The new
version of PISA could eventually replace conventional 16S PCR for the
diagnosis of BJIs.
P1809 Detection of uncultured organisms in paediatric bone and
joint infections by a Multiplex real-time PCR panel
N. Ahmad °, P. Marsh, A. Monk, A. Pallett, K. Saeed, N.M.P. Clarke,
S.N. Faust (Southampton, UK)
Objectives: The clinical features of osteoarticular infection (OAI) can
vary considerably in children of different ages. Treatment is often started
and continued empirically due to the low sensitivity of conventional
blood and tissue culture in these patients. Better and more rapid
microbiological diagnostic techniques are required to ensure more
accurate therapy in order to reduce morbidity and overall (patient and
ﬁnancial) costs of treatment.
In a review of microbiology data at Southampton University Hospitals
NHS Trust (SUHT), a deﬁned pathogen was identiﬁed in only 8% of
the 1200 samples received for culture and microscopy. Therefore our
objectives were to develop a sensitive, speciﬁc and rapid multiplex PCR
protocol for the detection of uncultured pathogens in paediatric OAI,
and to investigate the level of infections left undetected by culture-based
detection.
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Method: A new real-time PCR diagnostic protocol was developed to
identify the presence of the most common organisms known to cause
bone and joint infections including the emergent paediatric pathogen
Kingella kingae (identiﬁed from both the literature and basic local
alignment search tool (BLAST) in samples taken from children with
OAI at SUHT. A real-time PCR panel comprising of two triplexes was
developed using three different reporter dyes (one for each target).
DNA extractions were carried out using an automated system, MagNA
pure LC by Roche® using the MagNA Pure LC DNA isolation kit III
(bacteria and fungi) Roche®..Real-time PCR was carried out using a
Rotor-gene 6000 (Corbett).
Results: 95 paediatric bone and joint samples from SUHT were assayed
from 56 patients (age range 270 days to 192 months) by PCR. Pathogenic
bacteria were detected in 22 out of 56 patients where culture-based
detection failed (including 6 K. Kingae, 7 Staphylococcus aureus and
3 Streptococcus pneumoniae) and 6/56 where culture conﬁrmed the
diagnosis.
Conclusions: We have developed a new, rapid (same day) method for
detection of uncultured pathogens direct from paediatric bone and joint
samples. Important OAI pathogens detected by PCR were missed by
culture-based detection. Work is ongoing to establish the clinical value
and cost-effectiveness of widespread introduction of this technique into
routine clinical practice.
P1810 Comparative evaluation of four serological methods and a
quantitative real-time PCR assay in asymptomatic subjects
with a previous history of brucellosis
M.J. Castan˜o Aroca °, E. Navarro, M. Andicoberry, S. Lorente,
J. Solera (Albacete, ES)
Objectives: Brucella spp. antibodies, despite falling to low levels, can
remain measurable after recovery from acute brucellosis. This makes
it difﬁcult to distinguish between cured patients, chronic brucellosis
patients and those healthy individuals living in areas in which brucellosis
is endemic. This is the basis for the controversy in the deﬁnition of the
chronicity of the disease. The presence of Brucella spp. DNA in clinical
samples in this setting remains unknown.
The aim of the present study was to evaluate both serological tests
and a quantitative real time PCR (QPCR) assay for the presence of
Brucella melitensis DNA in a cohort of asymptomatic subjects with a
well-documented history of brucellosis.
Methods: Twenty asymptomatic subjects that had been diagnosed with
brucellosis between three and 12 years prior to the study were included.
Subjects were followed ranging between three to 34 months (mean 15
months). Between three and 6 blood and serum samples (172 samples in
total) were screened by QPCR, classical serological tests (Rose Bengal,
standard agglutination test (SAT) and Coombs test) and the commercial
Brucellacapt® test. The methodology used for detecting B. melitensis
DNA have been previously described by our group(a).
Results: All subjects had negative Rose Bengal test results. The SAT
test showed antibody titres in three (15%) subjects (range, 1/20–1/80).
The Coombs test showed antibody titres in four (20%) subjects (range,
1/160–1/640). The Brucellacapt® showed antibody titres in 10 (50%)
subjects (range, 1/40–1/160). Seropositive samples by SAT or Coombs
test were also positive by Brucellacapt®.
Brucella melitensis DNA was found in ﬁve (25%) subjects with a mean
bacterial DNA load of 218 copies/ml in blood samples. All of them had
seropositive samples by the Brucellacapt® (range, 1/40–1/160). However,
only ﬁve (33.3%) out of the remaining 15 subjects with negative QPCR
samples had seropositive samples by Brucellacapt® (range, 1/40–1/80)
(p = 0.03; two tails Fisher test).
Conclusion: The individuals harbouring B. melitensis DNA in their
blood are more likely to show a seropositive sample than the remaining
participants. These ﬁndings suggest that the presence of bacterial DNA
at low levels derived from latent bacteria are capable of producing a
week immune response in the host.
Reference(s)
(a) Castano MJ et al, J Clin Microbiol 2009 Jul 1; 47(7):2084−9.
P1811 Quantitative real-time PCR may be the only diagnostic tool
for chronic brucellosis patients
E. Navarro °, M.J. Castan˜o Aroca, E. Pescador, M.D. Mun˜oz, J. Solera
(Albacete, ES)
Objective: A minority of chronic brucellosis patients shows low or
negative antibody titres (1) that make diagnosis difﬁcult. In the present
study we evaluated the usefulness of a quantitative real time PCR
(QrtPCR) assay in the diagnosis of this group of patients.
Methods: Seventeen symptomatic patients with a well-documented
history of brucellosis that had been diagnosed between 3 and 34 years
previously were followed for more than one year. At the entry of the
study, six (16%) patients were seronegative by all the three conventional
serological methods. Three of them had a focal complication (one
multiphocal motor neuropathy of upper limbs, one brucellar orchitis and
one spondylitis). The remaining three had unspeciﬁc symptoms such as
asthenia, arthralgias and/or myalgias. From these patients we analyzed a
total of 167 samples including 83 blood samples, 83 serum samples and
one sample of synovial ﬂuid. Samples were screened by QrtPCR for the
presence of Brucella melitensis DNA and conventional serological tests
(Bengal Rose (BR), standard agglutination test (SAT) and Coombs test).
Collected samples were analyzed randomly in a single blinded way. The
methodology used for detecting and quantifying the bacterial DNA have
been previously described by our group (2).
Results: Samples from the six patients were seronegative by the three
conventional serological methods (BR, SAT and Coombs test). Regarding
the QrtPCR assay, B. melitensis DNA was found in the six patients,
quantifying 98±221 copies/ml (n = 7), 642±1106 copies/ml (n = 13)
and 149 copies/ml (n = 1) in blood, serum and synovial ﬂuid samples,
respectively.
Conclusion: QrtPCR may be the only method for diagnosis of chronic
brucellosis patients when conventional serological tests show negative
results.
Reference(s)
[1] Imboden JBl. Arch Intern Med. 1959;103:406−14.
[2] Navarro E. Clin Infect Dis 2006;42:1266−73.
P1812 Preliminary evaluation of a rapid oligochromatographic as-
say for the detection of Bordetella sp. in respiratory samples
J.A. Carrillo Avila, I. Pedrosa Corral, M. Pe´rez Ruiz, J. Mendoza
Montero °, A. Rojas Gonza´lez, D. Gonza´lez Ferna´ndez, J.M. Navarro
Marı´ (Santa Fe, Granada, ES)
Objectives: To evaluate a rapid and simple new commercial assay,
SpeedOligo® Bordetella (Vircell). The assay is based on a multiplex
PCR coupled to the visualization of PCR products by means of a
dipstick device and is intended for the detection of Bordetella species in
respiratory samples. Results are available in less than one hour.
Methods: DNAs from 57 respiratory samples (nasopharyngeal exudates
or aspirates) previously tested for the presence of Bordetella pertussis at
Hospital Universitario Virgen de las Nieves (Granada) were used for
the evaluation. DNA was extracted using the automated bioMe´rieux
NucliSENS® easyMAG® platform (bioMe´rieux). The reference method
was an “in house” real-time PCR that ampliﬁed a 179-bp fragment of
the IS481 element of B. pertussis. SpeedOligo® Bordetella ampliﬁes
two speciﬁc Bordetella genes: a 114-bp fragment of the IS481 element
present in B. pertussis, B. holmesii and B. bronchiseptica, and a 119-
bp fragment of the ptxA promoter gene of B. pertussis. The human
b-globin gene was used as internal control. Following ampliﬁcation, the
procedure was completed by oligochromatography. Hybridization of PCR
products was carried out on a dipstick using probe pairs (for Bordetella
and internal control detection), one conjugated with colloidal gold and
the other immobilized onto nitrocellulose. The results were interpreted
by visual reading of 3 lines: two for Bordetella gene fragments (IS481
and ptxA) and the third one corresponding to the internal control.
Results: The reference method yielded 26 positive results for
B. pertussis. SpeedOligo® Bordetella was positive in 25 of these. B
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pertussis was conﬁrmed in 22 samples. Reaction with only the IS481
element test line was observed for the remaining 3 samples, indicating
the presence of either B. pertussis, B. holmesii or B. bronchiseptica. No
false positive or invalid results were observed. A 96.1% sensitivity and
100% speciﬁcity was calculated for the new assay.
Conclusion: SpeedOligo® Bordetella is a rapid, sensitive and speciﬁc
assay for the detection of Bordetella infection. The ampliﬁcation of two
different Bordetella gene targets may increase sensitivity and speciﬁcity
of the assay.
P1813 Evaluation of the Septifast molecular test applied to
bronchoalveolar lavage samples for the microbiological
documentation of severe pneumonia in the intensive care unit
J. Tankovic °, J-L. Baudel, R. Dahoumane, A. Galbois, H. Ait-Oufella,
J. Lemant, E. Maury, J.C. Petit, B. Guidet, G. Offenstadt (Paris, FR)
Objectives: An important determinant of outcome in severe community-
acquired or nosocomial pneumonia is prompt and appropriate initiation
of antimicrobial chemotherapy. To achieve that, rapid and accurate
microbiological documentation is of critical importance. We compared
the results obtained by microscopic examination and quantitative culture
of bronchoalveolar lavage (BAL) samples with those obtained with the
rapid molecular test Septifast (SF) applied on those same samples.
Methods: Microscopic examination and culture were performed
according to standard protocols. The SF test has been designed for
the rapid detection (6 hours) in a 1.5-ml blood sample of the 25
bacteria and fungi representing 90% of the cases of bacteremia. In our
study, the protocol for blood was used without modiﬁcation. Positive
results for streptococci, enterococci, CNS and Candida spp. were not
taken into account, because these microorganismes were considered as
commensals. We determined the sensitivities (SE), speciﬁcities (SP),
positive and negative predictive values (PPV and NPV) of the three
techniques.
Results: 34 consecutive patients with suspicion of infectious pneumonia
(19 men, mean age 64±15, immunosuppression 50%, IGS II: 43.5
±18.3, septic shock 29%, mechanical ventilation 41%) were included
between April 10 and July 29 2009. One week after the realization of
BAL, all the patient ﬁles were reevaluated and the diagnosis of infectious
pneumonia was conﬁrmed only for 23 of the 34 patients included
(community-acquired: 10; nosocomial: 13). The diagnostic accuracies of
the three techniques are shown below. The sensitivity of SF for patients
with ongoing antimicrobial treatment was signiﬁcantly greater than those
from the conventional techniques.
Conclusion: For patients with severe pneumonia, analysis of BAL sam-
ples with the Septifast® molecular test permits a fastest microbiological
documentation than culture and is more sensitive than culture, at least for
patients with ongoing antimicrobial treatment at the time of realization
of BAL.
Gram stain Culture Septifast p
All infected patients (n = 23)
SE 0.35 0.48 0.74 NS
SP 0.73 0.82 0.55 NS
PPV 0.73 0.85 0.77 NS
NPV 0.35 0.43 0.5 NS
Infected patients with ongoing antimicrobial treatment (n = 15)
SE 0.14 0.29 0.79 0.02
SP 0.67 0.78 0.67 NS
PPV 0.4 0.67 0.79 NS
NPV 0.33 0.41 0.67 NS
P1814 Comparison of DNA extraction and real-time PCR methods
for the detection of Coxiella burnetii
J.J. Tilburg °, E.J. van Hannen, M. Hermans, A. Horrevorts,
W.J. Melchers, M.H. Nabuurs-Franssen, A.M. Pettersson, J.W. Rossen,
M.C. de Vries, C. Klaassen (Nijmegen, Nieuwegein, ’s-Hertogenbosch,
Amsterdam, Tilburg, Bilthoven, NL)
Objectives: In the Netherlands there is an unprecedented and ongoing
Q fever outbreak with thousands of affected individuals. Routinely
diagnosis of Q fever using serological methods are of limited use in the
acute phase of the disease and therefore are not sufﬁcient for accurate
diagnosis. Real-time PCR however, can be useful in establishing an early
diagnosis of acute and chronic Q fever.
Methods: We compared 7 different DNA extraction and real-time PCR
methods implemented by 7 medical diagnostic laboratories. Three-fold
serial dilutions of DNA extracted from the Nine Mile strain (RS 493)
were send to all laboratories to compare the sensitivity of the different
real-time PCR methods. In addition, positive clinical serum samples with
relative high and low DNA loads were used.
Results: A minimum difference in sensitivity was observed between
the real-time PCR methods using three-fold serial dilutions of DNA
extracted from the Nine Mile strain (RSA 493). More differences were
obtained between several combinations of DNA extraction and real-time
PCR methods using actual clinical positive serum samples. Differences
in sensitivity of the real-time PCR could partially be explained in the
design of the primers and probes. Although the results of the real-time
PCR method obtained by 2 out of 7 laboratories yielded the highest
percentage overall of positives, the combination of DNA extraction
method and real-time PCR of each laboratory individually however,
resulted in comparable number of positives for 6 out of 7 laboratories.
Conclusion: This study show that the DNA extraction and real-time PCR
method implemented by 6 out of 7 medical diagnostic laboratories can
be used for a reliable screening of Q fever suspected patients and can
substantially contribute to the early diagnosis of acute Q fever during
the ongoing Q fever outbreak in the Netherlands.
P1815 Broad-range survey of tick-borne pathogens from southern
Germany
M. Eshoo °, O. Nolte, C. Crowder, H. Matthews, F. Li, R. Sampath,
D. Ecker (Carlsbad, US; Konstanz, DE)
Objectives: Early treatment for tick-borne human infections such as
Lyme Borreliosis, Babesiosis and Anaplasmosis is critical for a positive
prognosis. We developed and validated an Ibis T5000 assay (Ibis
Biosciences, Inc., Carlsbad, CA) that can detect and identify a wide range
of tick-borne pathogens from ticks and clinical samples / specimens.
Methods: A multi-locus assay was used that employs 8 broad-range
PCR reactions with primers targeting all known tick-borne bacterial and
protozoan pathogen families. Electrospray ionization mass spectrometry
of the PCR amplicons was used to determine their base composition.
These base composition signatures were subsequently used to identify
the organisms found in the samples. The assay was developed using ﬁeld
collected ticks and a wide range of clinical sample types and has been
shown to be sensitive to the stochastic limits of PCR.
Results: Extracts from 178 ﬁeld collected ticks and ticks removed from
patients from Southern Germany were screened using the Ibis broad-
range tick-borne pathogen detection assay. 39 of the specimens tested
positive for one or more Borrelia species (B. afzelii, B. burgdorferi
s.s., B. garinii, B. lusitaniae, B.spp. LB-2001, B. valaisiana and
B. spielmanii). In addition 4 specimens were positive for Anaplasma
phagocytophilum and 8 (4.5%) were positive for Babesia microti
including 3 Babesia/Borrelia co-infected ticks.
Conclusions: We demonstrate broad-range detection of tick-borne
pathogens in a single assay using ticks from Southern Germany. The
Ibis assay detected a diverse range of Borrelia species and surprising
high frequency of Babesia microti. The Ibis T5000 system and the next
generation PLEXID systems can be completed within ﬁve hours from
specimen processing to result reporting, provides rapid and accurate
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detection and identiﬁcation of a broad range of pathogens causing tick-
borne human infections.
P1816 Improving performance of bacterial identiﬁcation DNA
arrays by ROC analysis guided probe design
H. Peter °, T.T. Bachmann (Edinburgh, UK)
For the development of DNA microarrays for bacterial species detection
it is crucial to design oligonucleotide probes with a high degree of
speciﬁcity and sensitivity. However, even if probes were very speciﬁc
in silico, their experimental performance on the array is often less
optimal, thus reducing sensitivity and speciﬁcity of the system. The
deﬁnition of an experimentally guided probe assessment and threshold
deﬁnition should therefore improve the array characteristics in terms
of limit of detection and detection speciﬁcity. In this study we used
ROC-Analysis (Receiver Operating Characteristic) for genotyping DNA
microarrays to optimise and streamline probe validation, resulting in
advanced sensitivity and speciﬁcity.
We present a ROC based approach on the example of the development
of a DNA microarray for the detection of toxic cyanobacteria (170
speciﬁc probes). The study is based on 120 reference hybridizations of
30 reference strains. For data analysis we developed a mathematical MS
Excel based tool, which automatically carries out ROC-Analyses for all
probes. The tool is designed to speciﬁcally suit the needs of genotyping
arrays. For every probe the mathematical sensitivity and speciﬁcity was
calculated for a wide range of cut-offs and processed into one graph, to
receive the ROC-curve. The area under the curve (AUC) was used as
a quality measure to either keep or abandon an individual probe. Only
the best probes with an AUC value >0.9 should be used for an optimal
array platform. In addition, individual cut-offs were calculated for each
probe, to increase the sensitivity, maintaining maximum speciﬁcity. The
sensitivity could be adjusted by modifying the probes’ individual cut-off
and the associated, accepted false positive rate. In the presented example,
we set a false positive rate of 2%. To conﬁrm the approach, a test set
of 50 additional hybridizations with target DNA from reference strains
was successfully performed.
In conclusion and after further examples on other genotyping DNA
array modules we consider the ROC approach on probe validation as
a highly useful and versatile tool to achieve signiﬁcantly improved assay
performance which is in particular required for successful translation
into diagnostic applications.
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P1817 Molecular diagnosis of septicaemia: SeptiFast vs. blood
culture
M. Kotnik °, C. Luger, A. Huber-Wechselberger, S. Stumvoll,
A. Bocksrucker, B. Sammer, S. Metz-Gercek, P. Apfalter,
H. Mittermayer (Linz, AT)
Objective: Rapid diagnosis of bacteraemia is of prime importance in
the management of febrile patients. The SeptiFast (SF) blood assay
detects 19 bacterial and 6 fungal pathogens in blood samples by nucleic
acid ampliﬁcation. Molecular biology methods provide faster results than
conventional culture methods, hence SF allows a rapid diagnosis of septic
episodes. We evaluated SF in comparison to blood culture in patients
with suspected septicaemia.
Methods: Blood samples for SF were processed according to the
manufacturer’s speciﬁcation. In short whole blood sample undergoes
mechanical lysis with ceramic beads. In further puriﬁcation steps DNA
is extracted. PCR is carried out in three parallel real time reactions. The
amplicons are detected by ﬂuorescence emission. Blood cultures were
processed according to the SOP‘s of the respective laboratories. Over
a period of two and a half years we tested 440 patients and compared
SeptiFast (SF) results to BC.
Results: For 384 out of 440 samples complete data were available. 82
(21.4%) of samples were positive in BC, 122 (31.8%) in SF. Of 122
detected pathogens by SF, 65 were isolated from BC. Differing results
between the two methods were obtained in 45 instances, BC was only
positive in 8 (9 pathogens) and SF in 36 cases, respectively. In BC
only the following pathogens were detected: S. epidermidis; b-haemolytic
Streptococci (1); S. aureus (2); E. coli (1);E. coli and C. albicans (1);
C. albicans (1); C. glabrata (1); C. parapsilosis (1); and BC-negative
and SF-positive samples: S. epidermidis; b-haemolytic Streptococci (3);
S. pneumoniae; S. spp. (6); S. aureus (3); E. faecalis (1); E. faecium (1);
E. coli (6); K. pneumoniae/oxytoca (5); P. aeruginosa (5); C. albicans
(4); C. tropicalis (1); A. fumigatus (1).
Conclusions: SF detected considerably more microorganisms than BC.
The most striking differences were observed in S. pneumoniae, E. coli,
Klebsiella, P. aeruginosa and C. albicans. In nine cases, however, BC
yielded pathogens, which were not recovered by SF. In our study SF has
been proven as a valuable tool for rapid diagnosis of septicaemia with a
higher recovery rate than BC.
P1818 Biochemical and molecular characterization of Escherichia
albertii isolated from clinical samples
L. Nimri °, N. Strockbine, C. Tarr, E. Sowers (Irbid, JO; Atlanta, US)
Objectives: Escherichia albertii sp. nov. is a newly recognized species
whose initial members were isolated from Bangladeshi children with
diarrhea. Identiﬁcation of these organisms is problematic for clinical
laboratories due to limited phenotypic and genotypic data upon which
to base diagnostic algorithms. The study aimed at the characterization
of additional isolates is needed to deﬁne the boundaries of phenotypic
and genotypic variation for developing reliable identiﬁcation methods to
support studies to address their role in disease, and epidemiology.
Methods: Selected coliform isolates from the CDC reference collection
were screened by PCR for allelic variation in two housekeeping genes
(lysP and mdh) speciﬁc for E. albertii. Twenty strains were identiﬁed
as members of the E. albertii lineage and characterized phenotypically
with a set of 45 traditional biochemical tests and panels of E. coli
and Shigella typing antisera. Isolates were also tested by PCR for 14
virulence markers [eae, cdtB, phoE, stx1, stx2, stx2f, ehx, bfpA, ipaH,
LT, ST, phoE, EAgg and EAF].
Results: Findings from biochemical tests revealed that all E. albertii
strains are non-motile, methyl red positive and Voges-Proskauer negative.
All produced acid from the fermentation of D-glucose (with gas),
D-mannitol, D-mannose and failed to ferment lactose, sucrose, dulcitol,
L-rhamnose, and melibiose within 48 hr at 35 C. Variable reactions
(11%-89% positivity) were noted for the following tests: indole, lysine
decarboxylase, ornithine decarboxylase, D-sorbitol, maltose, trehalose,
glycerol, mucate, acetate and b-galactosidase. Most isolates were rough
or failed to agglutinate with E. coli and Shigella antisera. Agglutination
of 4 strains was observed with E. coli antisera against the following O
antigens: O63 (2), O101 (1) and O180 (1). All isolates were positive
for the eae gene, 17/20 (85%) were positive for the cdtB gene, 2/20
(10%) were positive for ehx, 18/20 (90%) were positive for phoE, and
1/20 (5%) was positive for stx2f. None were positive for the remaining
virulence markers.
Conclusion: These ﬁndings illustrate the variability extent within
this lineage and highlight the importance of including information
on E. albertii strains within commercial databases to improve the
identiﬁcation of these bacteria.
P1819 Extended-spectrum b-lactamases and their detection
applying on-chip PCR
I. Barisic °, S. Schoenthaler, C. Noehammer, H. Wiesinger-Mayr
(Seibersdorf, AT)
Objectives: The gold standard for pathogen identiﬁcation and charac-
terization in clinical routine are cultivation-based methods. However,
these methods are laborious and generally last from blood withdrawal
to antibiotic resistance determination two to three days, sometimes even
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weeks. Hence we develop a DNA-based high throughput method that
can characterize pathogens from blood within a few hours.
Methods: First steps included the download of all available extended
spectrum b-lactamase (ESBL) DNA sequences from NCBI and the
construction of a database with the sequence management tool ARB.
Phylogenetic trees of the ESBL genes using the Neighbour-Joining
method were calculated and primers targeting DNA encoding those
enzymes were designed. The primers were covalently attached to a solid
support by printing them onto a speciﬁcally modiﬁed glass slide using a
microarrayer. A PCR mix was then applied onto the slide surface and the
slide was put into a thermo cycler. The main difference to conventional
PCR is the covalent attachment of the two primers to the microarray
surface. In an additional reaction Cy3 labelled CTPs were incorporated
into the ampliﬁed and attached DNA and signals were analyzed using a
microarray scanner.
Results: Phylogenetic analyses based on amino acid alignment revealed
two distantly related groups of ESBLs. The OXA b-lactamases form a
very diverse group showing low homology to other known ESBLs. The
second group includes the remaining ESBLs like TEM, SHV, CTX-M,
TLA, PER, etc. but is still less diverse then the OXA group.
DNA ampliﬁcation with on-chip PCR could be achieved. Preliminary
results indicate adequate sensitivity which has been evaluated by real
time PCR. Speciﬁcity will be validated by DNA sequencing.
Conclusion: An important precondition in medical diagnostics is a low
number of working steps thus single tube reactions like multiplex-PCRs
are preferred. Since multiplex PCRs are however well-known to cause
various difﬁculties, our method of choice to detect the high number of
different b-lactamases is based on on-chip PCR circumventing the primer
dimer formation in complex primer mixtures.
P1820 MALDI-TOF MS analysis and molecular typing by pulsed-
ﬁeld gel electrophoresis of environmental Vibrio isolates
R. Eddabra °, R. Mimouni, O. Meunier, L. Moussaoui, G. Prevost,
J.M. Scheftel (Strasbourg, FR; Agadir, MA)
Objectives: Pulsed ﬁeld gel electrophoresis (PFGE) is widely used as
an epidemiological tool for the typing and identiﬁcation of bacterial
strains. In contrast, Matrix-Assisted Laser Desorption Ionisation/Time-
of-Flight Mass Spectrometry (MALDI-TOF MS) offers a new and
promising approach to rapid identiﬁcation and differentiation of
bacterial strains. This study compares a novel Matrix Assisted Laser
Desorption/Ionisation–Time of Flight (MALDI-TOF)-based method to
PFGE patterns for Vibrio differentiation.
Methods: 30 Vibrio environmental isolates (14 V. cholerae non-O1, 10
V. alginolyticus, 5 V. ﬂuvialis and one strain of V. metschnikovii) identiﬁed
by Vitek 2 system (bioMe´rieux). Differentiation of Vibrio isolates
was done using PFGE of NotI-digested genomic DNA. Computer-
assisted analysis of the PFGE banding patterns was performed using
Fingerprinting IITM software (Bio-Rad Laboratories). In addition
MALDI-TOF-MS was performed. Small amounts of intact cells of a
single colony were directly applied onto the target plate, mixed with
matrix solution and air dried. Mass spectra were acquired using Ultraﬂex
II MALDI-TOF mass spectrometer (Bruker Daltonics, Germany) and
analyzed by BioTyper™ 1.1 software.
Results: Out of the 30 strains of Vibrio examined in this study, 6 isolates
could not be typed by PFGE and consistently appeared as a smear on the
gel. In general, high genetic biodiversity among the isolates was found
regardless to the isolation source. The results of MALDI TOF analysis
show that the spectral proﬁle, consisting of about 20 to 25 prominent
peptide peaks masses ranging between 2 and 12 kDa, have indeed
taxonomic signiﬁcance and appears to be a rapid and inexpensive method
to taxonomically cluster environmental isolates. The main spectra of
Vibrio isolates have been included in the BioTyper library.
Conclusion: This study proves that the MALDI BioTyper system is an
easy to use and highly suitable tool for the Vibrio species differentiation.
MALDI-TOF MS could cluster the isolates from each species into the
same pattern, whereas PFGE had lower discriminatory ability between
species.
P1821 Prognostic value of chromogranin A at admission in
critically ill patients
M.H. Metz-Boutigue °, F. Schneider, T. Lavaux, D. Zhang, J.E. Herbrecht,
C. Bach, H. Chung, P. Garnero, D. Aunis (Strasbourg, FR)
Objectives: Critically ill patients are usually admitted with clinical and
biochemical signs of systemic inﬂammation as a consequence of their
disease. A recent study was conducted to evaluate the signiﬁcance of
Chromogranin A (CGA), a stress marker released by chromafﬁn cells
and neutrophils, for prognosis of critically ill patients with systemic
inﬂammatory response syndrome (SIRS) or sepsis [Zhang D and al., Clin
Chem, 2009]. This study is now completed by a comparative proteomic
analysis of the CGA-derived peptides present in serum from patients and
healthy controls.
Methods: We measured in 53 patients and 14 healthy controls the serum
concentration of CGA, procalcitonin and C-reactive protein. We also
assessed the Simpliﬁed Acute Physiological Score (SAPS) in the patients.
The proteomic analysis of the CGA-derived peptides present in serum
was performed by using reverse phase HPLC and Western blot.
Results: Serum CGA concentrations were signiﬁcantly increased in
SIRS patients when compared to healthy controls, with a median
value of 115 mg/L. When infection was associated with SIRS, patients
had the highest increase in CGA with a median value of 138.5
mg/L. CGA concentrations positively correlated with inﬂammation
markers (procalcitonin, C-reactive protein) and the Simpliﬁed Acute
Physiological Score (SAPS II). Receiver Operating Characteristic (ROC)
analysis showed that CGA is equivalent to SAPS as an indicator for 28-
days mortality. We reported also the comparative expression of complete
CGA and its natural derived fragments in serum of critically ill patients
and healthy controls. These data are related to the processing machinery
acting during sepsis.
Conclusion: Patients with CGA concentration superior to 71 mg/L have
a signiﬁcantly shorter survival. A Cox model conﬁrmed that CGA and
SAPS were independent predictors of outcome.
P1822 Presence of infectious agents in plasma samples from
patients with atherosclerotic disease
R. Musumeci °, B. Sibra, A. Giuliano, A. Cialdella, A. Careddu,
G. Parati, C. Cocuzza (Monza, IT)
Background: During the last decades, numerous clinical and epidemi-
ologic studies have explored the possible direct or indirect role of
infectious agents in the pathogenesis of atherosclerosis. The infectious
agents that have in recent years gained considerable interest as having
a potential role in atherosclerosis include: Chlamydophila pneumoniae,
Mycoplasma pneumoniae, Cytomegalovirus, HHV-6, HHV-7, and more
recently, periodontal pathogens (Porphyromonas gingivalis, Prevotella
intermedia, Tannerella forsythia, Fusobacterium nucleatum). In previous
studies, the high prevalence of infection by some of these pathogens
in the human population has represented a major drawback in demon-
strating an association between microbial agents and atherosclerosis by
means of serological methods. More recently newer diagnostic assays,
such as quantitative Real-Time PCR, have been developed for the direct
detection of infectious agents from atherosclerotic plaques; however few
studies have applied these methods to analyse the presence of a wide
panel of pathogens in plasma of atherosclerotic patients.
Objective: To evaluate the presence of b-herpesviruses (CMV, HHV-6
and HHV-7), periodontal and atypical bacteria in patients with
atherosclerosis as compared to patients with only risk factors for the
disease.
Methods: Detection by qRT-PCR assays of microbial DNA in plasma
samples in patients with previous cardiovascular events (CE, n = 32),
demonstrated atherosclerotic carotid artery disease but no events
(ACaAD, n = 37), with only risk factors but no evidence of disease (RF,
n = 33) and healthy subjects (HS, n = 20).
Results: The prevalence of microbial pathogens as demonstrated by
DNA detection in patients plasma is shown in the ﬁgure.
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The median value (mean±SD) of the total pathogen DNA load/ml
was found to be 26 (32±24) in HS, 999 (5173±11706) in RF, 843
(2617±5244) in ACaAD and 2258 (52154±179205) in CE.
Conclusions: Both patients with only risk factors and with known
cardiovascular disease showed a relatively high prevalence of microbial
pathogen DNA present in plasma samples. However the total microbial
DNA load or “pathogen burden” was found to be markedly higher in
patients with previous documented cardiovascular events.
Prevalence of microbial pathogens in patients’ plasma samples.
P1823 Improvement of Legionella pneumophila early diagnostics
in severe community-acquired pneumonia patients admitted
to an intensive care unit
N. Poblet-Mas °, M. DelaTorre, J.M. Calvera, J. Garcia-Gil (Girona, ES)
Objectives: Due to its difﬁcult diagnostic, Legionella pneumophila
(LP) incidence might be underrated. An early diagnostic is crucial to
apply an appropriate antibiotic therapy. The main goal of this work
was to assess the accuracy of a newly developed real time quantitative
PCR method (RTi-PCR) speciﬁc for all known serogroups of LP as
a routine analysis. Our secondary aim was to evaluate the aetiology
of severe community-acquired pneumonia (sCAP) and the incidence of
polymicrobial infections.
Methods: During a 24-month period, 345 specimens (blood, bron-
choalveolar lavage and urine) from 135 patients (95 affected of sCAP
and 40 controls) admitted in the intensive care unit (ICU) of a
hospital in Girona (Spain) with sCAP were included prospectively.
Etiological agents were analysed by culturing, enzimoimmunoassay
(EIA) techniques and RTi-PCR for LP, using the ﬁs gene as target. An
internal ampliﬁcation control (IAC) was included in each PCR reaction
to minimise contamination and to reduce the chance of false negative
results.
Results: Among the 95 sCAP affected patients included in this study,
LP was identiﬁed by RTi-PCR in 41cases (33 LP-positives in BAL, 25 in
urine and 23 in serum samples), whereas 17/95 cases were LP-positive
by EIA and 27/95 by culture. LP-positives by RTi-PCR were correlated
with EIA and culture (P< 0.001).
Streptococcus pneumoniae (SP) was present in 33/95 patients, S. aureus,
H. inﬂuenzae, E. coli, and Pseudomonas aeruginosa in 5/95, 4/95, 4/95,
2/95 of the patients, respectively. No bacterial aetiology was found in
27% of sCAP patients.
In a 22.1% of the LP infected patients, antibiotic therapy was initiated
before specimens were obtained. In a 45% of these patients the
antibiotics were changed after diagnosing. Polymicrobial infections
accounted for 32% of the cases with sCAP. Signiﬁcant differences
between sCAP and control patients (P< 0.05) in mortality rate, shock
and ICU length of stay were only observed when the infection was
polymicrobial.
Conclusions: The RTi-PCR method for is more accurate than culture
or EIA, and allows a rapid diagnostic of LP infections. It is especially
important in patients in whom antibiotic therapy has been initiated. We
propose its use as a complementarily routine analysis in hospitals.
LP and SP are the leading causes of all sCAP cases admitted in the ICU,
and polymicrobial infections are important since they present a worse
prognosis and a more aggressive clinical evolution.
P1824 Optimizing the workﬂow in a diagnostic laboratory by
combining an internally controlled parasitical real-time
PCR with an internally controlled enteric real-time PCR
for simultaneous detection of both parasitic and bacterial
pathogens in faecal samples
E. van Zanten °, S. Hofs, A.M. Kooistra-Smid (Groningen, NL)
Objectives: Routine enteric diagnostics on fecal samples in our
laboratory consists of two real-time PCR assays targeting 4 bacterial
enteric pathogens and Giardia lamblia. When speciﬁc parasitic diagnosis,
other than G. lamblia, is requested, microscopy is used. The Triple
Faeces Test (TFT) is employed for the detection of cysts and Chlorazol-
Black staining for the detection of trophozoites. Microscopy is time
consuming and relies heavily on well trained personnel. Moreover, results
obtained abundantly yield information on non-pathogenic parasites.
This study describes a real-time PCR assay targeting Cryptosporidium,
Entamoeba histolytica and Dientamoeba fragilis to complement our
existing multiplex PCR assays, reducing hands on time and creating
a single work ﬂow for both bacterial and parasitic diagnosis.
Methods: A total of 533 faecal samples were analyzed. For 228
samples, speciﬁcally requested for parasitic diagnostics, both microscopy
and parasitic real-time PCR was performed and for 305 samples, for
which only routine diagnostics was requested, additional parasitic real-
time PCR was performed. Microscopy consisted of a TFT test which
was assessed by two lab technicians for the presence of cysts and
trophozoites. Chlorazol black staining was performed by the technicians
on samples ﬂagged suspicious for trophozoites. DNA extraction for TFT
samples was performed on the unpreserved faeces. After easyMag DNA
extraction real-time PCR was performed using the ABI7500 system.
Results: Parasitical microscopy on the 228 samples yielded: 12
D. fragilis, 33 Blastocystis hominis, 8 Endolimax nana, 5 Entamoeba
coli, 1 Entamoeba hartmanni and 1 Iodamoeba bu¨tschlii. Real time PCR
on these samples resulted in: 45 D. fragilis and 2 Crytosporidia. The
305 samples additionally screened with PCR yielded 37 D. fragilis and
2 Cryptosporidium positive samples.
Conclusion: The incorporation of D. fragilis, E. histolytica and
Cryptosporidium in our enteric real-time PCR assays improves detection
rates of pathogenic parasites, other than G. lamblia, from 5% to 16%.
Moreover, incorporating a parasitic real-time PCR in the enteric PCR
workﬂow resulted in detecting a considerable number of pathogenic
parasites in samples originally not suspected of parasitic infection.
Furthermore, a patient is no longer asked to collect faeces over a three
days period, alleviating patient effort and speeding up time to result.
P1825 Vocma, Variation-tolerant Capture Multiplex analysis − a
new multiplex method for detecting virus, bacteria and fungi
C. O¨hrmalm °, R. Eriksson, M. Jobs, B. Herrmann, A˚. Melhus,
J. Blomberg (Uppsala, SE)
Objectives: We have developed a new multiplex method for simulta-
neous detection of nucleic acid from virus, bacteria and fungi, called
VOCMA, Variation-tolerant Capture Multiplex Analysis. Today the
panels of VOCMA Gastroenterits and VOCMA Sepsis are 7-plex and
22-plex resp.
The method is variation tolerant i.e. it can detect nucleic acid from
viruses like calici virus (winter vomiting disease) or inﬂuenza virus,
which are highly disposed to genomic variation with the aim of avoiding
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the immune defense of the host. The variation tolerance is also allowing
VOCMA to cover whole groups of similar genes like e.g antibiotic
resistant genes as ctxm group I and ctxm group IV.
Methods: VOCMA is based on well established steps as nucleic
acid extraction, followed by ampliﬁcation and labelling of the target
sequences of the pathogen. Target speciﬁc probes are attached to the
different xMAP microspheres and a mixture of beads, consisting of
the panel of interest, are allowed to hybridize to the sample. With a
Luminex® 200 ﬂow cytometer the ampliﬁed and labeled nucleic acid of
the target genes are identiﬁed and quantiﬁed.
Result: The VOCMA method is a highly multiplex (e.g. 22-plex
VOCMA sepsis) and provides tolerance to variation in the nucleic
acid sequence. Even though it is variation tolerant the VOCMA is
still highly speciﬁc for the intended target. The method, which is
being further optimized, has shown an analytical sensitivity of 10–
10000 targets/reaction for both the VOCMA Gastroenterits and VOCMA
Sepsis.
Conclusion: VOCMA is a multiplex and speciﬁc method for detection of
nucleic acid of different microorganism. By utilizing xMAP technology
and Luminex® 200 the composition of the multiplex panels can easily
be changed, combined and expanded, which creates a large ﬂexibility
of the assay. A third panel which contains virus, bacteria and fungi
causing respiratory infectious diseases is also under development. A
multiplex method like VOCMA both saves time, reduces the cost per
microbe analysed, as well as the consumption of sample, and increases
the possibility of discovering co-infections.
P1826 Improved accuracy of DNA quantitation using a chemistry
model-based method for estimating nucleic acid quantities
in PCR ampliﬁed samples
B. Archer, M. Dobbs, R. Hazelo, M. Exner ° (Cypress, US)
Objectives: Quantitative interpretation of a PCR result requires a
mathematical algorithm or method to determine the amount of template
in a sample. The method most commonly used depends on a speciﬁed
threshold and a calibration plot of the fractional cycle at threshold
crossing vs. the logarithm of the DNA amount in the sample. We
have developed a new method based upon physical models in which
parameters represent attributes of the PCR chemistry. This study sought
to examine the potential of this method for determining concentrations of
CMV, BKV, and EBV viruses in clinical specimens, and to compare the
results with those obtained using threshold based methods. In addition,
the ability of the chemistry method to assess the efﬁciency of individual
PCR reactions was evaluated.
Methods: Analytical studies were performed to evaluate linearity,
reproducibility, and accuracy of the chemistry based method in
comparison with a threshold based method. For these studies, the
3M integrated cycler was used to run serial dilutions of viral DNA
standards for each target being tested, and observed quantity values
were compared to expected quantity values. In addition, suboptimal PCR
reactions (containing inhibitory substances) were analyzed, and accuracy
of quantitation in these specimens was monitored.
Results: The chemistry model-based method was found to be both
accurate and precise over a very wide dynamic range of template
concentrations, with a linear range beyond what was observed for the
threshold based model. The chemistry method also was able to provide
a more accurate quantiﬁcation of DNA in samples for which PCR
conditions were not optimal and replication efﬁciency was reduced.
Conclusions: By eliminating the assumptions required by threshold
methods of quantitation and automatically accounting for replication
efﬁciency in each reaction, the chemistry model-based algorithm
provides more accurate quantity determinations from clinical specimens.
Using this method will improve performance of diagnostic tests. The
estimation of parameters that represent attributes of the chemistry and
an estimate of efﬁciency for each reaction based on these parameters
will be helpful in new test development.
Molecular diagnostics for sepsis
P1827 Novel quantitative point-of-care molecular diagnostic system
M. Schamesberger, B. Hierschla¨ger, C. del Rio, C. Wechselberger,
M. Sonnleitner ° (Freistadt, AT)
Introduction: Molecular diagnostics at the Point-Of-Care (POC) is
mostly carried out using simple strip tests. Unfortunately, such tests only
give yes/no answers and often have to be reconﬁrmed by quantitative tests
in the lab, which are still time-consuming and have to be performed
by expert operators using complex systems. This typical process ﬂow
in medical diagnostics often causes signiﬁcant delay in appropriate
medication and facilitates the spread of infectious diseases.
To solve this problem we developed a quantitative POC molecular
diagnostics system that is able to simultaneously quantify more than
8 different target bacteria down to concentrations of ~104 cfu/ml within
15 minutes, without the need for an expert operator.
Objectives: We addressed following POC platform requirements,
– minimum need for operator intervention in the different steps of the
assay
– a simple and reliable but still sensitive detection methodology
– a device that ﬁts typical Point of Care settings like physician ofﬁces
Methods: We developed a microﬂuidic test cartridge which uses
transparent surface coated substrates onto which different capture oligo-
nucleotides are deposited. The substrates are then laminated to a
proprietary microﬂuidic channel system.
During the assay procedure, DNA/RNA is extracted and labeled. The
remaining assay-steps like hybridization of target molecules, washing,
and the ﬁnal chemiluminescence (CL) reaction are controlled via
capillary forces in the microﬂuidic channel system. CL-signals from
different locations on the chip are detected in a compact readout device.
Results and Conclusion: We developed a generic platform for rapid
multi-parameter quantitative molecular diagnostics at the POC.
The platform combines a disposable microﬂuidic test cartridge with
a compact device for CL based optical detection. While the use of
capillary-ﬂow based microﬂuidics avoids the need for complex micro-
pumping schemes, CL enables sensitive and robust detection in a very
compact optical architecture.
Our system is able to simultaneously quantify more than 8 different
target bacteria down to concentrations of ~104 cfu/ml within 15 minutes,
without the need for an expert operator.
The modular architecture of the platform allows easy adaptation to any
type of diagnostic test.
P1828 Dissection of polybacterial clinical samples using group
speciﬁc broad range primers and DNA sequencing followed
by RipSeq analysis
Ø. Kommedal ° (Bergen, NO)
Objectives: Detection and identiﬁcation of bacteria directly from clinical
samples by broad range PCR targeting the 16S rRNA gene and DNA
sequencing (Direct 16S sequencing) is a valuable tool in clinical
microbiology. RipSeq (iSentio, Norway) is a web based application
for the analysis of mixed DNA chromatograms that enables the use
of this approach on typical polybacterial specimens such as abscesses
and empyema. However, the use of a single universal ﬁrst PCR reaction
limits the potential of the method because all bacteria in a sample will
be competing for the same reagents, leaving those present at the lowest
concentrations at risk for remaining undetected. Also, the RipSeq algo-
rithm has only been validated for chromatograms containing up to three
different species. The aim of this study was to reduce the impact of these
factors by replacing the universal PCR with three separate group speciﬁc
broad range PCRs. The group speciﬁc broad range primer pairs (A, B
and C) all ampliﬁed 500 bp of the 16S rRNA gene and were designed to
match approximately one third of the human bacterial pathogens each.
Methods: Twenty polybacterial clinical samples were included and
investigated using group speciﬁc real-time SYBR-green PCRs followed
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by DNA sequencing. A positive PCR was deﬁned if ﬂuorescence
threshold value (Ct) was reached 3 cycles before the negative
control. All samples had previously been analyzed using culture based
identiﬁcation and standard direct 16S sequencing with a single universal
primer pair followed by RipSeq analysis.
Results: The results for the group speciﬁc direct 16S sequencing are
given in Table 1. In nine samples no additional species were found
when compared to standard direct 16S sequencing. In the remaining 11
samples a total of 23 additional bacteria were found ranging from 1 to
4 species per sample. Only 27 out of the 74 bacteria identiﬁed by group
speciﬁc direct sequencing grew by culture. Ninety percent of the samples
were affected by antibiotics administrated prior to specimen collection.
Conclusion: Group speciﬁc direct 16S sequencing and RipSeq analysis
identiﬁed a high number of pathogens undetected by culture and
standard direct 16S sequencing. The method allows for sequence based
identiﬁcation of up to nine species in a sample and can be established
in any laboratory with experience in standard direct 16S sequencing.
Table 1. Detailed results for group speciﬁc ampliﬁcation and DNA
sequencing
Sample type Primer pair A Primer pair B Primer pair C
1 Abscess brain* G. morbillorum
S. intermedius
– F. nucleatum
2 Abscess brain* S. intermedius – F. nucleatum
3 Abscess brain P. micra
S. intermedius
A. aphrophilus
H. parainﬂuenzae
F. nucleatum
4 Abscess brain A. meyeri
S. intermedius
C. gracilis F. nucleatum
P. pleuritidis
5 Abscess brain A. meyeri
P. micra
C. gracilis
Eikenella sp.
N. elongata
F. nucleatum
6 Abscess liver E. faecium E. coli
K. pneumoniae
L. rhamnosus
S. haemolyticus
7 Abscess liver G. morbillorum
S. parasanguinis
S. pyogenes
H. parainﬂuenzae P. melaninogenica
8 Abscess liver* E. coli C. perfringens
9 Abscess pancreas* E. faecium – B. fragilis
10 Abscess pancreas A. meyeri C. concisus P. melaninogenica
S. epidermidis
11 Abscess para-aortic* C. tuberculostearicum – S. haemolyticus
12 Abscess subcutaneous* E. faecium
F. magna
– –
13 Bile* – E. coli F. nucleatum
14 Pacemaker pouch* P. acnes – S. epidermidis
15 Empyema P. micra
S. anginosus
– P. nigrescens
P. stomatis
16 Empyema* S. intermedius C. gracilis Fusobacterium sp.
17 Empyema P. micra
S. constellatus
S. mutans
C. gracilis F. nucleatum
18 Empyema S. constellatus
P. micra
C. gracilis
H. parainﬂuenzae
F. nucleatum
P. melaninogenica
19 Empyema P. micra
S. intermedius
C. gracilis
Eikenella sp.
P. pleuritidis
20 Empyema D. invisus
P. micra
– P. nigrescens
* Samples with identical results for standard direct sequencing and group speciﬁc direct sequencing.
P1829 A multicentre study of bacteraemia using a new commercial
universal 16S rDNA PCR test
S.G. Sakka, M. Lustig ° (Cologne, Bremen, DE)
Bloodstream infection is a life-threatening condition with a high
mortality rate, especially in intensive care and neutropenic patients.
Standard diagnostics is based on blood culturing (BC). However,
limitations of BC include relatively low sensitivities and a long time-
to-result for the identiﬁcation of the pathogen, generally over two days
and more. On the grounds of data from a multicentre study using a
universal 16S rRNA gene PCR assay, SepsiTest™, molecular diagnosis is
discussed as a rapid and sensitive tool for the detection and identiﬁcation
of pathogens supportive of BC.
Objectives: A new commercial PCR test, SepsiTest™, for direct
detection of bacteria in whole blood was compared to BC in terms of
sensitivity, speciﬁcity, predictive values and time to positivity (TTP) of
bacterial infections of the blood stream of critically ill patients.
Methods: The test, SepsiTest™ (Molzym, Bremen), comprises the
extraction and 16S rRNA gene PCR detection of bacterial DNA in
whole blood samples. Bacteria in positive samples were identiﬁed by
sequence analysis of the amplicon. In a prospective multicentre study 342
blood samples from 187 patients with systemic inﬂammatory response
syndrome (SIRS), sepsis, or neutropenic fever were included.
Results: Compared to BC, the diagnostic sensitivity and speciﬁcity
of PCR/sequencing was 87.0% and 85.8%, respectively. The positivity
rate of PCR/sequencing (25.7%) was higher than BC (15.8%). Of 31
PCR/sequencing-positive, BC-negative patients, most of whom received
antibiotics, the PCR results of 25 were judged as true or possible to
bacteraemia. Using a routine testing workﬂow, time to positivity of the
PCR-test was on average decreased by 40 hours for anaerobe/fastidious
infections and by 54 hours for yeast infections.
Conclusions: The PCR approach enables the detection and identiﬁcation
of bacteraemia in blood samples within a few hours. Despite the
indispensability of BC diagnostics, the rapid detection of bacteria by
SepsiTest™ appears to be a valuable tool, allowing earlier pathogen-
adapted antimicrobial therapy in critically ill patients.
P1830 Value of multiplex-PCR (SeptiFast) for the diagnosis of
bacterial and fungal pathogens in newborns and children
with suspected sepsis
P. Bernaschi °, S. Ranno, B. Lucignano, B. Pizzorno, O. Liesenfeld,
D. Menichella (Rome, Monza, IT; Pleasanton, US)
Objectives: Sepsis continues to be a major health problem in neonates
and children. Early diagnosis and provision of appropriate antimicrobial
therapy strongly correlates with positive outcomes of sepsis. Multiplex
PCR has the potential to rapidly identify blood stream infections and ﬁll
this diagnostic gap in sepsis patients.
Methods: Between May 2007 and May 2009, multiplex PCR with the
ability to detect 25 different bacterial and fungal pathogens (SeptiFAST)
was compared to standard blood culture in 1673 paired blood samples
obtained from 803 neonates and children with suspected sepsis in a large
Italian pediatric hospital.
Results: SeptiFAST identiﬁed an additional 97 microorganisms and 90
blood samples that blood culture failed to detect. Coagulase-negative
staphylococci (CNS) (29.6%), Pseudomonas aeruginosa (16.5%), and
Staphylococcus aureus (11.6%) were the most frequent pathogens
detected by SeptiFAST. Blood culture detected 27 additional microorgan-
isms in 24 SeptiFAST-negative blood samples; 8 of these 27 pathogens
were not included in the SeptiFAST menu, 8 additional pathogens
were CNS. Contaminants were detected signiﬁcantly more frequent in
blood culture than in SeptiFAST (n = 97 vs. 26, respectively). Excluding
contaminants, sensitivity and speciﬁcity of SeptiFAST compared to blood
culture were 85.0 and 93.5%.
Conclusion: Real-time multiplex PCR served as a highly valuable
adjunct to conventional blood culture in neonates and children, adding
diagnostic yield, decreasing the number of contaminants, and shortening
the time to pathogen identiﬁcation.
P1831 Evaluation of a commercial multiplex PCR (SeptiFast)
in the aetiological diagnosis of community-acquired
bloodstream infections
P. Josefson °, K. Stra˚lin, A. Ohlin, T. Ennefors, B. Dragsten,
L. Andersson, H. Fredlund, P. Mo¨lling, P. Olce´n (O¨rebro, SE)
Objectives: The SeptiFast test is a commercial PCR test which detects 25
bacterial and fungal pathogens in whole blood samples within 6 hours.
We aimed to evaluate the SeptiFast test on consecutive adult patients
subjected to blood culturing during one full year at an infectious diseases
clinic, predominantly on hospital admission.
Methods: In a prospective study we included for evaluation the ﬁrst
blood culture (BC)/PCR set (two BC bottles and one PCR tube)
providing a positive culture and/or PCR result if any positive result
was noted. The PCR results were compared with the results of BC and
other microbiological data. In addition, positive PCR results without
microbiological support were related to the clinical presentation.
Results: Among 1092 included patients BC was positive in 138 patients
and PCR was positive in 107 patients. The positive PCR results
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were supported by BC in the same BC/PCR set in 50 cases, by
other cultures in another 10 cases, and by the clinical presentation in
additionally 9 cases. No patient with positive BC was PCR positive
for another pathogen. Compared with BC, PCR showed speciﬁcities
and neg predictive values of >97% for all detectable pathogens. The
following sensitivities and positive predictive values (PPV) were noted:
Staphylococcus aureus, 67% and 43%; Streptococcus species, 43% and
77%; Streptococcus pneumoniae, 12% and 67%; Escherichia coli, 53%
and 56%; and Klebsiella species 43% and 23%. If other cultures and
clinical presentation were included in the reference standard, the PPV
for detection of these bacteria rose to 57%, 92%, 100%, 75% and 62%,
respectively.
Conclusion: The SeptiFast test showed high speciﬁcities for detection
of community-acquired blood stream infections. However, the low
sensitivities and suboptimal PPV of the test are essential shortcomings
that prohibit a routine use of the test in its present form.
Interferon-gamma release assays
P1832 Evaluation of Quantiferon-gold (tuberculin skin test) for the
identiﬁcation of latent tuberculosis infection in would-be
transplant recipient patients referring to an Iranian
transplant clinic from September 2007 to December 2008
Z. Ahmadinejad °, M. Razaghi, A. Jafarian (Tehran, IR)
Introduction and Objective: Two billion people carry the Tuberculosis
(TB) bacteria. The rate of tuberculosis in solid organ transplant recipients
has been estimated to be 50-fold higher than in the general population.
Diagnosis & treatment of Latent Tuberculosis Infection (LTBI) are the
most important strategies to control TB in transplant candidate patients.
In this study we aimed to compare Tuberculin Skin Test (TST) with
QuantiFERON-TB Gold In-Tube (QFT) in the detection of LTBI in those
patients.
Patients and Methods: Patients at the transplant clinic at the Imam
Khomeini Hospital, Tehran, Iran between 2008 and 2009 were eligible for
inclusion in the study if they were on the waiting list of transplantation.
Patients were screened for LTBI with both QFT & TST. Concordance
between test results & variables associated with test discordance were
assessed.
Results: A total of 61 patients were enrolled in the study. In 10 patients
the TST was not read. So, complete results were available for 51
patients. Average age was 40.2±13.2 years. Thirty patients (58.8%)
were male. Four patients (7.8%) had positive TST & 7 patients (13.7%)
had positive QFT. Two patients (5.9%) had indeterminate QFT. Overall
agreement between tests was 82.4% (k = 0.091, p = 0.495). Discordant
test results were seen in 3 TST positive/QFT negative patients & in 6
TST negative/QFT positive patients.
Conclusion: Overall agreement between test results was high, but its
percentage was not signiﬁcant based on p-value (p> 0.05) & k value
(k< 0.4) represented poor agreement. Thus, neither of the two tests is
recommended to the patients on waiting list as a more preferable test
to detect LTBI. The decision to select QFT or TST will depend on the
purpose of testing & resource availability.
P1833 Increasing the yield of interferon-gamma release assay for
M. tuberculosis
S. Chandrasekharan °, F. DeVilliers (Greenock, UK)
The Interferon-gamma Release Assay (IGRA) is a useful aid to diagnose
infection with M tuberculosis (MTB). In our institution the IGRA is
performed once weekly using the T-spot®.TB test, a commercial assay
by Oxford Immunotec. This in vitro test has an acclaimed speciﬁcity of
95% towards MTB and is not inﬂuenced by previous BCG administration
or by infection with common non-tubercle bacilli. There are no patient
exclusions (e.g. age, HIV) from the test. The test was introduced in 2006,
but suffered a failure rate of 37.3% during that year.
Objectives:
1. To identify the reasons for early failures.
2. To evaluate the impact of guidelines on failure rates and cost per test.
Methods: A retrospective audit of all IGRA tests performed between
2006 and April 2009. All IGRA requests are routinely recorded and
resulted in the laboratory information system (LIS); for failed tests, the
reasons are recorded and reported. The LIS was mined for the annual
total number of tests performed, total number of valid results obtained,
total number of failures and reasons for failures. The impact of speciﬁc
sampling guidelines (issued in 2007) was evaluated.
Results: 484 samples were processed for the IGRA by the T-spot®.TB
test; 71 tests failed. The annual failure rates are shown in table1.
During 2006, 84% of failures were due to insufﬁcient viable cells for
testing. Introduction of sampling guidelines reduced this to 18% by 2008,
paralleled by an overall decrease in failures. The relative contribution of
laboratory processes to failure increased from 4% in 2006, to 25% in
2007, and to 55% by 2008.
Conclusion: There has been a marked improvement in the number
of reportable IGRA after introduction of speciﬁc sampling guidelines.
Adherence to an 8ml minimum specimen volume, or 16ml in the elderly/
immunocompromised maximised the likelihood of extracting adequate
effector T-cells. This intervention had the greatest positive impact. As
specimen volume and quality improved, the contribution of laboratory
techniques towards failures increased. The IGRA test became most cost-
effective during 2008. This audit highlighted that laboratory procedure
has now become the most important reason for failure. Finally, the audit
sounds a warning that the specimen quality issues might be recurring at
present (2009).
2006 2007 2008 2009 (Jan–April)
Failed tests 25 28 11 7
Total tests 67 173 172 72
Failure rate 37% 16% 6% 10%
P1834 Comparison of QuantiFERON® TB Gold with tuberculin
skin test for the diagnosis of tuberculosis infection in risk
groups
E. Perez-Escolano °, J. Gutierrez-Rodriguez, E.M. Menor, J.C. Alados,
M.I. Lo´pez, S. De Tena, M.D. Lo´pez-Prieto (Jerez de la Frontera, ES)
Objective: To evaluate the agreement of the QuantiFERON® TB Gold
In Tube test (QFT) and the tuberculin skin test (TST) for the diagnosis
of tuberculosis infection (TBI) in risk groups (RG), and to establish the
utility of QFT as a tool for the indication of TBI treatment.
Methods: We studied 409 immunocompetent persons who came for
screening of tuberculosis infection; average age was 41 years (SD: 14.8),
79% were men and 263 (65.4%) had been vaccinated with BCG. All
were screened with chest X-ray, TST, QFT (Cellestis, Australia) and
risk factors were registered in a questionnaire. TST was performed
by Mantoux method and a positive test was deﬁned as an induration
5mm in non-vaccinated and 15mm in vaccinated people. QTF
was made according to the manufacturer speciﬁcations. We considered
as vaccinated persons those presenting with a suggestive scar. CDC
recommendations were followed for the interpretation of the QFT and the
treatment of the TBI. Agreement between TST and QFT was assessed
by the Cohen kappa coefﬁcient.
Results: Agreement between the TST and the QFT was 78.7%
(Kappa 0.51, CI (0.36–0.65)) among non-vaccinated population. In the
vaccinated group, agreement was smaller (69.6%, Kappa 0.38, CI (0.27–
0.49). QTF(−)/TST(+) was the most frequently detected discordant result
for the non-vaccinated group. Whereas, for vaccinated people, rate of
QTF(+)/TST(−) results and QTF(−)/TST(+) results were similar. TST
was positive in 107/136 non-vaccinated people, from these 26 were
negative for QTF. In the vaccinated group, 120/263 were TST positive,
from these 46 were negative for QTF. The indication of TBI treatment
made by TST and risk situation was modiﬁed in 42% of cases according
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to QFT test. We prescribed treatment of TBI by QFT in 25% of the
patients that did not have indication according to the TST.
Conclusions: Agreement between TST and QFT was low in vaccinated
people, even thought TST was considered positive for 15mm. Whereas,
in non-vaccinated people the agreement was moderate. The use of QFT
allows for a better selection of infected individuals and to reduce the
number of unnecessary treatment of TBI.
P1835 Whole-blood interferon-gamma release assay for diagnosis
of tuberculous lymphadenitis
Y.K. Kim °, H.Y. Kim, Y. Uh, M. Cho, C.O. Kim (Wonju, KR)
Background: Tuberculous (TB) lymphadenitis is not uncommon
in Korea. The invasive procedure is needed for the diagnosis of
TB lymphadenitis and it is sometimes difﬁcult. We evaluated the
usefullness of whole-blood inferferon-g release assay (QuantiFERON-
TB Gold[QTF-G], Cellestis, Carnegie, Australia) for diagnosis of TB
lymphadenitis.
Materials and Methods: From July 2007 to August 2009, 67 patients
had lymph node biopsy and underwent the QTF-G assay concurrently in
Wonju Christial Hospital, Yonsei University Wonju College of Medicine.
Sixty-three patients were reviewed retrospectively with exclusion of 4
patients whose QTF-G results were indeterminate. Among them, 16
patients were pathologically conﬁrmed as TB lymphadenitis and 47
patients were diagnosed as other than TB lymphadenitis. The diagnostic
performances of the QFT-G assay were evaluated.
Results: Mean age was 35.2±15.9 year old and 18 (28.6%) patients
were male. The positive result of QFT-G assay was found in all 16
patients with TB lymphadenitis, but false positive result was found
in 6 patients without TB lymphadenitis. The sensitivity of QTF-G
was 100% (95%CI, 79.4–100) and the speciﬁcity was 87.2% (95%CI,
74.3–95.1). The positive predictive value was 72.7% (95%CI, 49.8–
89.3) and the negative predictive value was 100% (91.4–100). In
the patients with positive QTF-G results, the value of interferon-
gamma was much higher in the patient with TB lymphadenitis than
in the patients without TB lymphadenitis (45.53±55.54 IU/mL versus
1.20±1.05 IU/mL, p< 0.001).
Conclusion: The value of interferon-gamma must be considered for the
interpretation of QTF-G result. The QTF-G would be very helpful for
the diagnosis of TB lymphadenitis.
P1836 Interferon-gamma release assays for the diagnosis of latent
tuberculosis infection in patients with rheumatic diseases
M. Losi, M. Meacci, D. Ferrari, R. D’Amico, D. Giuggioli,
F. Luppi, B. Meccugni, C. Manzini, C. Ferri, P. Roversi, L. Richeldi,
F. Rumpianesi ° (Modena, IT)
Objectives: Treatment with tumor necrosis factor a (TNF-alfa)
antagonists or immunosuppressive drugs in patients with rheumatic
diseases is related to an increased risk of tuberculosis (TB), due
to reactivation of latent tuberculosis infection (LTBI). Treatment of
subjects latently infected with M. tuberculosis reduces the risk of
developing active TB. The tuberculin skin test (TST) performs sub-
optimally in immunocompromised individuals: the new interferon-
gamma release assays (IGRA) might improve LTBI diagnosis in this
vulnerable population.
Aim of the study was to evaluate in a prospective study the performances
of QuantiFERON-TB Gold In-Tube (QFT-IT) and T-SPOT.TB (TS.TB)
assays in patients with rheumatic diseases in an area with low prevalence
of TB.
Methods: Both IGRA and TST were simultaneously performed
in 39 patients (90% Italians, 74% females, mean age 53±14.6
years, 8% BCG vaccinated) affected by rheumatoid arthritis (44%),
psoriatic arthritis (26%), ankylosing spondylitis (10%), undifferentiated
spondyloarthropathy (5%) and other rheumatic disorders (15%). Twenty-
nine patients were on immunosuppressive treatment at the time of testing:
12 (41%) were treated with disease modifying anti-rheumatic drugs
(DMARDs), 10 (34%) with steroids and DMARDs and 7 (24%) with
steroids only. Most (87%) patients were screened before treatment with
TNF-alfa antagonists.
Results: TST was positive (with the 5mm cut-off) in 9, QFT-IT in
7 and TS.TB in 13 patients (TST vs QFT-IT p = 0.41, TST vs TS.TB
p = 0.10, QFT-IT vs TS.TB p = 0.0143). Overall agreement between QFT-
IT and TS.TB was substantial (88.5%, k = 0.71). Three of the 6 TST-
negative/IGRA-positive patients were on immunosuppressive treatment.
Indeterminate IGRA results due to low positive control values were more
frequent with QFT-IT (n = 4, 10%) than with TS.TB (0%, p = 0.045).
Conclusions: The results of this study indicate that among patients
with rheumatic diseases, TS.TB identiﬁes as infected more subjects,
as compared to QFT-IT. Furthermore, indeterminate results are more
frequent with QFT-IT than with TS.TB.
P1837 Role of the interferon-gamma assay in the diagnosis of
active tuberculosis
M. Losi, A. Fabio, M. Meacci, F. Luppi, R. D’Amico, C. Del
Giovane, P. Roversi, M. Apice, B. Meccugni, L.M. Fabbri, L. Richeldi,
F. Rumpianesi ° (Modena, IT)
Objectives: Diagnosis of pulmonary (pTB) and extra-pulmonary (eTB)
active tuberculosis might be difﬁcult when standard microbiological
methods are negative, in particular in extra-pulmonary cases. Data are
not completely consistent across different studies: the new interferon-
gamma release assays (IGRA) might improve the diagnosis of active
TB.
Methods: In a multicenter study, we retrospectively evaluated 87 patients
with culture-conﬁrmed active TB (77.0% pTB, 23.0% eTB) tested
with QuantiFERON-TB Gold In-Tube (QFT-IT) (Cellestis Ltd, Carnegie,
Australia). Most patients were male (62.1%), mean age was 40.7±19.0
years: 65 (74.7%) subjects were foreign-born. All QFT-IT assay were
performed before initiation of anti-TB treatment.
Results: Indeterminate QFT-IT were 11.9% in pTB and 5.0% in eTB: the
test was positive in 71.6% of pulmonary and 80.0% of extra-pulmonary
patients (p=ns). IFN-g levels were similar in the two groups (4.6 pTB vs
7.0 eTB UI/ml, p=ns). Interestingly, 14 patients (16.1%) had determinate
negative QFT-IT: 11 (78.5%) had pulmonary disease.
Conclusions: These preliminary data indicate that QFT-IT might be
a reliable tool in diagnosing active TB, both in pulmonary and extra-
pulmonary cases, in routine clinical practice.
P1838 Use of interferon-gamma release assay in the United
Kingdom: compliance with national guidance
C. Ijeh °, M.M. Raza, M. Bhattacharya, R. Mukherjee (Milton Keynes,
UK)
Objectives: The National Institute of Healthcare and Clinical Excellence
(NICE) in the United Kingdom (UK) has published its guidance on
tuberculosis (TB) in March 2006. This includes recommendations for
diagnosis of active and latent tuberculosis in various settings including
use of interferon-gamma release assay (IGRA). We undertook an audit
of the use of an IGRA (ELISpot) in our hospital since July 2006 to
establish if this was in compliance with NICE guidance.
Methods: This audit was done in a UK district general hospital. The
microbiology laboratory system was used to identify all patients who had
an ELISpot test requested between July 2006 and December 2008. Case
notes of these patients were then reviewed to establish the indication for
the test, whether a prior Mantoux test was performed and compliance
with NICE guidelines.
Results: 54 adult patients had the test done during the period of the study.
Approximately half (48%) of patients were between 16−35 years of age
with an equal sex distribution. 75% of the ELISpot tests were requested
by a member of Respiratory or Infectious Diseases team. In 29 patients
the test was done for diagnosis of suspected latent TB but of these only
13 requests were compliant with NICE guidance in this area. In the
other 16 cases the non-compliance was due to age being greater than
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35 (7), absence of prior Mantoux testing (3), both age and no Mantoux
(4) and in 2 cases the Mantoux reading was not high enough to justify
the ELIspot testing. In the remaining 25 patients the test was done for
suspected active TB in various presentations including lymphadenopathy,
pleural effusions, cavitating lung disease, discitis, persistent cough. As
NICE does not recommend IGRA as a routine test in the diagnosis of
active TB therefore compliance with NICE recommendations for use of
IGRA was seen in 13/54 cases (24%).
Conclusion: In our hospital use of IGRA for the diagnosis of TB is in
compliance with national guidance in only a minority of cases (24%).
There are clear recommendations for its use in the diagnosis of latent
tuberculosis but still its use in this area was outside the guidance in 16/29
cases of suspected latent TB. Use of IGRA is not recommended in the
diagnosis of active TB but may have a role in certain cases. Therefore
we recommend that use of the test is restricted by requiring requesting
or prior approval by a Respiratory/infectious Diseases Physician.
P1839 Performance evaluation of an in-house interferon-gamma
release assay in the diagnosis and follow-up of active
tuberculosis disease
L. Alagna °, C. Fortis, L. Galli, P. Scarpellini (Milan, IT)
Objectives: To evaluate the performance of the interferon-gamma release
assays (IGRA) for the diagnosis of the active tuberculosis disease (TD)
and to describe the changes of the IGRA during the follow-up.
Methods: 238 patients (pts)[M= 140, F = 90] have been tested with
the IGRA because suspected of active TD.187 out of 238 were tested
with the tubercoline skin test (TST). Pts were classiﬁed according to
the American Thoracic Society (ATS) classiﬁcation. The home-made
IGRA detects the number of speciﬁc g interferon producing T cells by
means of an enzyme-linked immunospot assay, using a restricted pool of
synthetic highly immunogenic peptides derived from ESAT-6 and CFP-
10 proteins. For the evaluation of the IGRA follow-up in pts with active
TD (15 pts), we considered this timeline: T0=mean of the IGRA values
up to one week after the start of the therapy, T1=second and third months
after the start of the therapy and T2=end of the therapy. The TST and the
clinical classiﬁcation were taken as reference when compared to IGRA.
McNemar test and k statistics were calculated. Linear regression was
applied.
Results: Among pts with active TD (ATS3) no agreement was
detected between the IGRA and TST (k = 0.0767, 95%CI [0.126–
0.280]); sensibility (SS)=84%, speciﬁcity (SP)=24%, Negative Predictive
Value (NPV)=50% and Positive Predictive Value (PPV)=61%. There
was a high number of pts with positive IGRA and negative TST
[23/30 (77%), p = 0.0013]. We analysed the performance of both tests
in relation to the clinical classiﬁcation (ATS3 vs non ATS3): TST,
SS=59%, SP=70%, PPV=55% and NPV=72% and no agreement was
found (k = 0.278, 95%CI [0.139–0.418]). IGRA, SS=82%, SP=62%,
PPV=54% and NPV=86%; agreement was fair (k = 0.4015 [0.293–
0.509]). During follow up, signiﬁcant decrease of IGRA quantitative
values was observed [median slope = −2.98 spot forming cells per
million lymphocytes per week, p = 0.0215 (SFCML)]. 13 out of 15 pts
show a decrease of values (median −4.23 SFCML, p = 0.021).
Conclusions: Our results show a different performance of TST and the
IGRA in pts with active TD. In particular, given the high SS, IGRA has
a better performance than TST. Regarding the follow up, the decline in
the IGRA values during the therapy is signiﬁcant; further studies can
help to evaluate if this decline could predict a favourable outcome.
P1840 Assessment of the use of the Quantiferon-TB gold in-tube
assay for the diagnosis of TB infection in Lothian, Scotland
A-L. Seagar °, C. Doig, C. McSparron, A. Hill, I. Laurenson
(Edinburgh, UK)
Objectives: The Quantiferon-TB Gold In-tube assay (QTBG; Cellestis)
detects IFN-g which is released from patients T-cells in response to
M. tuberculosis speciﬁc antigens. Unlike the TST, results are unaffected
by BCG vaccination and most atypical mycobacteria. We assessed
appropriateness of assay use from Lothian area patient data from
September 2007 to July 2009.
Methods: Scottish and NICE guidance recommends use of interferon-
gamma release assays following a positive or unreliable TST. We do
not recommend routine use in diagnosis of active TB infection (ATBI).
Clinical information sheets completed at the time of sampling were used
to assess whether the patient had ATBI or latent TB infection (LTBI).
ATBI was determined if TB symptoms were indicated (e.g. weight loss
and fever). LTBI was determined in patients with a positive TST result,
travel history or CXR changes. If ATBI or LTBI could not be determined
from the sheets then an “unknown” verdict was recorded.
Results: Samples were collected from 104 patients. Samples from 7
patients were unsuitable for QTBG testing. 18 (17.3%) QTBG positive,
68 (65.4%) negative and 11 (10.6%) indeterminate results were obtained.
10% of all specimens received were from patients 5 years of age. 76 of
97 patients (78.3%) tested by QTBG had clinical details recorded on the
data sheets. ATBI, LTBI or an “unknown” diagnosis was identiﬁed in 35
(36.1%), 46 (47.4%) and 23 (23.7%) of patients respectively. 10 (21.7%)
of LTBI cases produced a QTBG positive result and 4 (11.4%) of ATBI
cases produced a positive result. 14 of 83 (16.9%) of patients assessed
to be at high risk of TB produced a QTBG positive result. 54 (65.1%) of
these patients had a positive TST result (9 [16.7%] were QTBG positive).
31 patients had a TB contact (3 [9.7%] QTBG positive). 8 of 15 patients
who had an abnormal CXR and 12 of 14 patients with a history of travel
or living abroad were investigated for LTBI (3 [37.5%] and 4 [33.3%]
were QTBG positive respectively). 2 of 6 immunocompromised patients
produced QTBG indeterminate results.
Conclusions: 36.1% of QTBG tests were used in assessment of
ATBI generally considered inappropriate as false negatives are well
documented. In Lothian, QTBG is not currently being used to support
the diagnosis of LTBI for healthcare workers and new entrants. To allow
the correct interpretation, advice and audit sufﬁcient clinical information
is required with requests.
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TB contact 31 14 15 2 3 (9.7) 22 3 3 23 (2)
Travel/lived abroad 14 2 12 0 4 (28.6) 8 2 0 12 (3)
Abnormal CXR 15 7 8 0 4 (26.7) 9 1 1 8 (3)
TB symptoms only 3 3 0 0 2 (66.7) 1 0 0 2 (1)
Pre-BCG 5 0 5 0 1 (20.0) 4 0 0 1 (0)
Anti-TNF 3 0 3 0 0 2 1 0 3 (0)
Other 12 9 3 0 0 9 1 2 5 (0)
No clinical details 16 N/A N/A 16 4 (25.0) 10 1 1 9 (2)
No data sheet 5 N/A N/A 5 0 3 2 0 N/A
ALL 104 35 46 23 18 (17.3) 68 11 7 63 (11)
*One detail per patient; #Six overﬁlled tubes and one incubated incorrectly.
P1841 Diagnostic challenges of tuberculosis peritonitis in patients
with and without liver cirrhosis
C. Yang °, C.H. Liao, P.R. Hsueh (Taipei City, TW)
Objectives: Little was known of the diagnostic features of tuberculosis
(TB) peritonitis among patients with liver cirrhosis compared with those
without liver cirrhosis. We conducted a retrospective study in patients
with and without liver cirrhosis from over a period of 8 years to analyze
the clinical features for TB peritonitis.
Methods: The medical records of all patients with TB peritonitis who
were seen at National Taiwan University Hospital and Far Eastern
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Memorial Hospital from 2000 through 2008 were reviewed. The
diagnosis of TB peritonitis was based on culture of ascetic ﬂuid and/or
peritoneal biopsy specimens.
Results: During the study period, 73 patients (32 with liver cirrhosis and
41 without liver cirrhosis) had TB peritonitis. Acid-fast smears (AFS) of
ascites were negative in all patients. The patient with liver cirrhosis had
less co-existing pulmonary tuberculosis (9% vs 29.2%, p< 0.05) and less
ascites total protein level (2.19 g/dL ±1.0 vs 3.90g/dL ±1.7, p< 0.05).
Although the white cell differential count in ascites was lymphocyte-
predominant between the two study groups, almost one-third patients
with liver cirrhosis were treated as spontaneous bacterial peritonitis
(SBP) because of elevated absolute neutrophil count (250 cell/mm3)
in ascites. More than half patients with liver cirrhosis died before the
diagnosis of TB peritonitis was established (59.4% vs 19.5%, p< 0.05).
In addition, fewer patients with liver cirrhosis could complete the anti-TB
treatment than patients without liver cirrhosis (25% vs 60.9%, p< 0.05).
Conclusion: TB peritonitis had nonspeciﬁc and variable manifestations.
High mortality rate and difﬁculty in the treatment of TB peritonitis were
observed in patients with liver cirrhosis. It should be considered if the
treatment of SBP had poor clinical response.
P1842 Immunological diagnosis of tuberculous uveitis: ﬁrst
experiences
M. Peracchi °, L. Fallico, R. Manganelli, A. Sattin, G. Palu`, S. Tognon
(Padua, IT)
Objectives: To determine whether Quantiferon-TB Gold In Tube (QFT-
IT) is a useful alternative to TST in the immunological diagnosis of
tuberculous uveitis and whether it evolves in response to anti-tuberculous
therapy.
Methods: We identiﬁed 38 patients, seen at the Clinical of
Ophthalmology-University of Padua, Italy, with suspected TB uveitis
in a two years period (2006–2008). Their medical records, including
chest radiographs, and ocular visit were reviewed. All of them were
subjected to QFT-IT pre-therapy, while 8 patients were also screened
after treatment. TST was performed in 20 patients. Fifty percent of the
patients had been previously diagnosed with tuberculosis resolved after
antitubercular treatment (ATT).
Results: all patients resulted positive to QFT-IT before therapy and
correlated, when tested, with TST. No indeterminate results occurred. Six
patients were found to have culture positive TB pulmonary infections.
The QFT-IT mean positive value for the 19 patients with previous TB,
was 6.4 (0.39–37.53), while the mean positive value for patients never
diagnosed with TB before was 16.1 (0.59–46.83). Four patients refused
therapy, 28 assumed recommended ATT for at least 6 months and 6 are
actually under ATT. After treatment all patients but one had decrease of
recurrences. The value of QFT-IT decreased after therapy in ﬁve out of
eight patient tested so far.
Conclusion: these preliminary results suggest that positive Quantiferon-
TB Gold In Tube correlated with a positive TST, although QFT
performed better in terms of speciﬁcity and had a better compliance
by the patients. For this reason QFT-IT should be useful, instead of the
TST, to presume a TB uveitis and aid the decision to initiate ATT.
P1843 Clinical usefulness of Elispot assay for diagnosis of
tuberculosis in a Korean population
H. Kim °, C.H. Kim, M. Hur, M. Park, W. Song, H.J. Kang, K. Lee
(Seoul, KR)
Objectives: Tuberculosis-speciﬁc ELISPOT assay (T-SPOT.TB, Oxford
Immunotec, UK) is a test that detect interferon-gamma producing T-cells
after stimulating patient’s lymphocytes with two kinds of tuberculosis-
speciﬁc antigens (ESAT-6 and CFP-10). We evaluated clinical usefulness
of T-SPOT.TB test in Koreans whose incidence of tuberculosis is
intermediate and BCG vaccination has been mandatory at birth.
Methods: T-SPOT.TB test was performed in 79 patients and 64 healthy
volunteers and these patients and volunteers were classiﬁed into four
groups: group 1, patients with active tuberculosis (n = 30); group 2,
patients with not-active or treated tuberculosis (n = 27); group 3, patients
without tuberculosis (n = 24); group 4, healthy volunteers without
tuberculosis history (n = 62). Positive rates and average spot counts of
T-SPOT.TB test were obtained among these groups.
Results: Positive rates of group 1 (96.4%) and group 2 (92.3%) were
higher than those of group 3 (31.6%) and group 4 (27.4%) (P< 0.0001).
Sensitivity deduced from group 1 and speciﬁcity deduced from group 4
of T-SPOT.TB test was 96.4% and 72.6%, respectively. The average
spot counts of group 1 and group 2 were higher than those of group 3
and 4 (P< 0.001). There was a tendency of increasing positive rate with
increasing age. Overall agreement between T-SPOT.TB test and TST
(tuberculin skin test) was 63.8% (kappa=0.29).
Conclusions: T-SPOT.TB test seemed to be a very useful screening and
supplementary test for diagnosis of tuberculosis due to high sensitivity.
However, positive results of T-SPOT.TB should be cautiously interpreted
because of high positivity in treated tuberculosis patients and healthy
volunteers in Korea.
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P1844 Molecular and clinical characteristics of invasive group A,
C and G streptococcal disease in western Norway
B. Kittang °, S. Skrede, N. Langeland, H. Mylvaganam (Bergen, NO)
Objectives:
• Determine the incidence and clinical manifestations of invasive disease
caused by group A, C and G streptococci (GAS, GCS and GGS) in
western Norway during February 2006-March 2009.
• Identify possible correlation between clinical syndromes and virulence
gene proﬁles.
Methods: We included 110 patients with invasive disease caused by
GAS, GCS and GGS within an area in western Norway populated
by approximately 405 000 inhabitants. All the 107 available bacterial
isolates were emm typed and screened for the presence of 11 GAS
superantigen genes (SAg genes) and the gene encoding streptococcal
phospholipase A2 (SlaA). The 48 GCS/GGS isolates were also subjected
to PCR with primers targeting speGdys.
Results: Sixty invasive GAS (iGAS) infections were registered,
corresponding to a mean annual incidence rate of 5.0/100 000. Invasive
GCS/GGS (iGCS/GGS) accounted for the remaining 50 infections (mean
annual incidence rate of 4.1/100 000). The 30 day case-fatality rate
was 10% and 2% among patients with iGAS and iGCS/GGS disease,
respectively. Non-necrotic skin or soft tissue infections were the most
common clinical manifestations of both iGAS (27%) and iGCS/GGS
(60%) disease. Necrotising fasciitis (NF) was diagnosed in 14 patients
with iGAS infections (23%) and in one patient with iGCS/GGS infection.
Streptococcal toxic shock syndrome (STSS) developed in six patients
with iGAS disease and in one patient with iGCS/GGS disease. emm1,
emm3 and emm28 accounted for 32 (54%) of the GAS isolates. emm3
was associated with three cases of NF that all developed STSS, and
emm 1 was associated with three cases of NF and two cases of STSS
without NF. SAg gene proﬁles were conserved within most of the GAS
emm types, although ﬁve different proﬁles were obtained within isolates
of emm28. Nineteen GAS isolates possessed SlaA, including nine out
of 10 isolates of emm3, six out of 13 isolates of emm28 and all four
isolates of either emm9 or emm75. stG643 (n = 11) was the dominating
GCS/GGS emm type, and this type together with stC74a, stG10, stG485,
stG6 and stG652 accounted for 77% of the GCS/GGS isolates. speGdys
was detected in 35 out of 48 GCS/GGS isolates and was restricted to
certain emm types.
Conclusions:
• The incidence of both iGAS and iGCS/GGS disease was high in our
community;
• NF was an unusually frequent manifestation of iGAS disease;
• emm1 and emm3 were associated with severe clinical infections;
• emm28 isolates seemed to have different phage preferences.
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P1845 Quality management of Streptococcus pyogenes detection by
Gen-Probe in a regional hospital
R. Rennie °, T. Bennett, S. Juraville (Red Deer, CA)
Objectives: This study was designed to investigate reasons for large
numbers of indeterminate Streptococcus pyogenes detection(GASD)
results in a large community based hospital when tested by Gen-Probe
Group A Streptococcus Direct (Gen-Probe Inc., San Diego CA) that then
required culture as a gold standard to arbitrate the observations. Solutions
were implemented which modiﬁed the manufacturer’s recommendations
and reduced the number of these imprecise results.
Methods: The investigation was divided into two six month study
periods (A and B). Throat swabs were received in Copan 140CQ
transport medium and were processed in each period according to
the manufacturer. All samples were then processed using the Gen-
Probe GASD kit and were read on the Gen-Probe Leader 450. Results
were recorded as Negative (<4500 RLU). We have established an
indeterminate range of 4500–10000 In the ﬁrst study period, samples
were read 5 min. after incubation (manufacturer’s instructions − within
1 hr). In the second study period, samples were allowed to cool for
a deﬁned 15 min. before reading. Samples from each period that
were in the Indeterminate range were re-plated on anaerobic BAP and
examined after 24 hr incubation for b-haemolytic streptococci typical
of S. pyogenes. Suspect colonies were then grouped using antisera to
groups A, C, and G.
Results: In periods A and B there were 2558 and 1147 positive GASD
results respectively (i.e. >10,000 RLU) that were not further tested. For
samples in the indeterminate range, in period A there were 592 that
required repeats and culture, and of these 103 were culture positive.
In period B, there were 542 In the Indeterminate range, with 39 that
were culture positive. In period A, 345 samples were between 4500–
5000 RLU; this was reduced to 194 in period B. Positive cultures in the
modiﬁed grey zone were reduced from 17. 4 to 7.1%.
Conclusion: The manufacturer does not currently have a grey zone.
Results are considered positive at >4500 RLU. Increasing the positive
cut-off to >10,000 RLU and further investigation of our in-house
established grey zone results, the number of tests requiring repeated Gen-
Probe and culture was reduced by approx. 50%. Further, extending the
cooling period before reading resulted in more consistent observations
and reduced back-up cultures by greater than 50%. We conclude that
these modiﬁcations improve the accuracy of GASD results with better
turn-around, and lower cost for the laboratory.
P1846 New insight in Streptococcus agalactiae phylogeny provided
by multilocus sequence typing in comparison with
multilocus enzyme electrophoresis
L. Mereghetti °, G. He´ry-Arnaud, J.L. Jany, P. Lanotte, S. Gouriou,
N. van der Mee-Marquet, A. Rosenau, M.F. Lartigue, R. Quentin
(Tours, Brest, FR)
Objective: Multilocus enzyme electrophoresis (MLEE) was the ﬁrst
technique used to explore the genetic diversity of Streptococcus
agalactiae population, and it has remained a reference method for many
years. The aim of this study was to compare multilocus sequence typing
(MLST), a more recent typing method that has never been formally
evaluated for S. agalactiae species, to MLEE.
Methods: We compared MLST to MLEE by studying a collection of
113 S. agalactiae human strains well-characterized by MLEE. We ﬁrst
re-analyzed previous MLEE data using the Sequence Type Analysis
and Recombinational Test software. The phylogeny provided by the
MLST data was then analyzed with the allelic proﬁles and with the
nucleotide sequences of the seven MLST genes concatenated into
a single “supergene”. The maximum-likelihood (ML) analyzes were
conducted on the supergene obtained from the MLST data.
Results: The congruence between the two typing methods was 87.3%,
with a signiﬁcative statistical association (P< 2.2×10−16). The 58 MLEE
types, based on the analysis of 12 enzymes, resolved into seven new
clonal groups, while MLST was able to distinguish four main genetic
divisions (CC12, CC17, CC19 and CC23) and 42 sequence types based
on the analysis of nucleotidic sequences of seven housekeeping genes.
Discriminatory index was 0.939 for MLEE while it was 0.897 for MLST.
However, phylogenetic position of CC23 differs between methods. CC23
was conﬁrmed by ML analysis using the ModelTest software with the
MLST data. This is all the more interesting that CC23, unidentiﬁed
by MLEE, is marked by speciﬁc biological features: (i) CC23 strains
are the lonely that resist to bacteriophages from hyperinvasive CC17
strains, (ii) CC23 strains express greater variation in molecular weight
of putative “species-identifying” biomarker ions than strains of other
clonal complexes, and (iii) there is a discrepancy between CC23
strains low adherence to human ﬁbrinogen and the high prevalence
of fbsB gene within these strains. Conversely, ML shows a widely
distribution of strains that were supposed to cluster into CC19. This was
consistent with the high recombination rate observed between strains, as
assessed by determining the recombination pairwise homoplasy index
(P = 3.48×10−13).
Conclusion: Even though discriminatory power of MLEE is higher than
MLST, phylogenetic analysis based on MLST data brings considerable
information concerning the genetic structure of S. agalactiae population.
P1847 The diagnostic utility of lytA real-time PCR in sputum and
nasopharyngeal swabs for pneumococcal pneumonia and
colonization in HIV-infected adults
W. Albrich °, P.V. Adrian, N. van Niekerk, M. Wong, M. Khoosal,
P. Zhao, A. Deatly, M. Pride, M. Sidhu, K. Jansen, S.A. Madhi,
K.P. Klugman (Aarau, CH; Soweto, ZA; Pearl River, US; Atlanta, US)
Objective: Pneumococcal aetiology is underestimated in patients with
pneumonia as specimens are unavailable from lung tissue. We evaluated
the diagnostic accuracy of real-time PCR in HIV-infected South African
adults who either had X-ray conﬁrmed pneumonia with pneumococci
identiﬁed on at least one diagnostic specimen or were asymptomatic
outpatients serving as controls.
Methods: lytA real-time PCR was applied on sputum and nasopha-
ryngeal (NP) swabs of HIV-infected patients with X-ray conﬁrmed
pneumonia; and on NP swabs in HIV-infected asymptomatic controls.
Pneumonia was assumed pneumococcal if Streptococcus pneumoniae
was identiﬁed in blood culture, sputum culture or Gram stain or urinary
Binax® Now.
Results: In 91 pneumonia patients with evidence of pneumococcal
aetiology, sensitivity of lytA PCR in sputum was 92.3%, and 97.3%
in patients who had pneumococci identiﬁed by sputum culture. lytA
PCR from NP swabs was positive in 90 of 100 (90%) pneumonia
patients and in 79/83 (95.2%) of those with a positive NP swab
culture; in comparison, it was positive in 57 of 288 (19.8%; RR:
4.55, p< 0.001) asymptomatic controls, and in 23/29 (79.3%; RR: 1.20,
p = 0.02) of controls with a positive NP swab culture. Among those with
positive lytA PCR from NP swabs, log10 copies/ml were signiﬁcantly
higher in patients (mean: 6.86; 95%CI: 6.18, 6.52) than controls
(mean: 4.02; 95%CI: 3.59, 4.45; p< 0.001). There were signiﬁcant
correlations between log10 of quantitative NP colony counts achieved by
microbiological culture and of lytA PCR copies/ml (r: 0.7, p< 0.001).
The AUC-ROC of lytA PCR for pneumococcal aetiology in pneumonia
patients was 0.7 for both sputum and NP swab.
Conclusion: lytA real-time PCR from sputum and NP swab is
highly sensitive for detection of both pneumococcal colonization
and pneumonia in South African HIV-infected adults with a large
burden of pneumococcal disease. Higher copy numbers correlate with
clinical disease and higher bacterial loads as identiﬁed by standard
microbiological tests. Quantitative lytA real-time PCR on sputum or NP
swab may be a promising tool for diagnosis of pneumococcal pneumonia,
both for clinical diagnostic and epidemiologic purposes.
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P1848 Evaluation of real-time PCR in whole blood to detect
pneumococcal infection in children
J. Chantreuil, S. Cantagrel, Z. Maakaroun, G. Baty, L. Bret, A.L. Bastier,
F. Monceaux, E. Saliba, A. Goudeau, P. Lanotte ° (Tours, Orle´ans, FR)
Objective: Streptococcus pneumoniae is a major pathogen implicated
in invasive diseases in children such as pneumonia with or without
pleuritis, meningitis and bacteremia. Actually, the laboratory diagnosis
of invasive pneumococcal disease (IPD) relies on culture based-methods.
The interest of the rapid urine antigen is controversed in children.
The objective of this study was to determine the beneﬁt of speciﬁc
S. pneumoniae real-time PCR on serum samples suspect of IPD.
Methods: Children suspected of IPD between November 2008 and
May 2009 were enrolled. The pneumococcal diseases suspected were
classiﬁed in four clinical categories according to the probability of
S. pneumoniae with the clinical and biological data. Real-time PCR of
ply and/or lytA genes on sera were performed in a second time.
Results: We prospectively enrolled 76 children, aged from seventeen
days to twelve years. Five cases were considered as certain based on
pneumococcal positive blood cultures: four pleuro-pneumonia, and one
lobar pneumonia; 38 infections were likely (24 pleuro-pneumonia, ﬁve
pneumonia and nine isolated fever), 26 possible, and eight unlikely. The
secondary analysis with real-time PCR on serum samples identiﬁed 12
pneumococcal infections with a prevalence of 15.8%. The sensibility of
PCR was 60% in certain infections (2/5 with positive blood cultures)
but 75% in the pleuro-pneumonia versus 44.4% with the culture alone.
The global sensibility to detect IPD with the PCR method was 83.3%
(10/12) and the speciﬁcity 97%. Only one false positive was found with
the ampliﬁcation of the gene ply: the blood culture was positive with
group A Streptococcus.
Conclusion: Our study demonstrates the interest of real-time PCR
especially in infections with pleural affect. The beneﬁt can be discussed
in septic shock and meningitis. Moreover our study has shown the
greatest speciﬁcity of the ampliﬁcation of the lytA gene than ply gene.
P1849 A semi automated real-time duplex PCR assay for rapid
detection of Streptococcus pneumoniae directly from clinical
samples
M. Sidhu °, P. Zhao, A. Deatly, S. Huijts, M. Pride, K. Jansen (Pearl
River, US; Utrecht, NL)
Background: Accurate diagnosis of pneumococcal infections is critical
in assessing the effectiveness of pneumococcal-conjugate vaccination
on colonization in light of both serotype switching and replacement.
Sensitive, rapid, and reliable detection is essential for surveillance
of nasopharyngeal carriage. We developed and characterized a semi-
automated, real-time duplex PCR assay to detect S. pneumoniae (SPn)
directly from clinical samples.
Methods: Targeting the lytA and ply genes simultaneously, we tested
91 SPn serotypes in addition to 26 non-related bacterial strains. Assay
sensitivity was established by spiking different concentrations of SPn into
naı¨ve human blood. The method was then applied to DNAs extracted by
automation from 100 mL of 150 blood (chest X-ray conﬁrmed CAP),
22 pleural ﬂuid (PF), and 147 cerebrospinal ﬂuid (CSF) specimens.
In positive DNA, the Prevnar 13 vaccine serotypes were identiﬁed by
capsule speciﬁc real-time PCR.
Results: Detection limits for lytA and ply genes were reproducibly
established at 160 CFU/mL of blood. Only SPn strains were ampliﬁed
showing an assay speciﬁcity of 100%. Of the 150 blood samples, 13%
were detected by blood culture while 14% by PCR. Detection rates in
PF and CSF were 91% and 12%, respectively.
Conclusion: Our highly sensitive (1.6 CFU per reaction) and speciﬁc
PCR assay offers rapid detection of SPn in clinical specimens.
Substantially increased detection rates observed in PF swabs indicate
the usefulness of this assay on samples obtained from sites with higher
bacterial burden. Details of the method and a comparison between PCR
and blood culture method will be presented at the meeting.
P1850 Differentiation of Streptococcus pneumoniae from Strepto-
coccus mitis/Streptococcus oralis by recA-gene-based PCR
A. Zbinden °, N. Ko¨hler, G.V. Bloemberg (Zurich, CH)
Objectives: 16S rRNA gene analysis is the gold standard for molecular
identiﬁcation of bacteria. However, the discriminatory power of the 16S
rRNA-gene is too low to differentiate S. pneumoniae from S. mitis and
S. oralis. We propose the recA-gene as additional, more discriminatory
target for proper identiﬁcation to species level.
Methods: A recA-PCR was developed and investigated with a
preliminary number of strains. Type strains of S. pneumoniae, S. mitis
and S. oralis as well as 18 strains of S. pneumoniae identiﬁed
by conventional phenotypic methods including colony morphology,
susceptibility to optochin and bile solubility, were analysed. With a
speciﬁc set of recA-primers, a 313-bp fragment of the recA-gene
was ampliﬁed and sequenced. The recA-sequences were aligned for
the search of positions that distinguished those closely related species
(molecular signatures). 20 strains formerly identiﬁed as belonging to the
group S. pneumoniae/mitis/oralis by 16S rRNA-gene sequencing were
tested using the recA-PCR for species identiﬁcation.
Results: Partial recA-gene sequence similarity between the type strains
was 95.2% for S. pneumoniae and S. mitis, 91.4% for S. pneumoniae and
S. oralis and 91.7% for S. oralis and S. mitis. The recA-sequences of all
18 isolates phenotypically identiﬁed as S. pneumoniae showed >99.7%
sequence homology to recA-sequences of S. pneumoniae. Within the
ampliﬁed recA-fragment of the type strains and the 18 S. pneumoniae
isolates, we found 7 signature nucleotides speciﬁc for S. pneumoniae.
Those nucleotides were found in all the S. pneumoniae strains and
differed from those of the type strains of S. mitis and S. oralis in every
single position.
The recA-sequences of the 20 strains grouped to S. pneumoniae/
mitis/oralis revealed <95.9% sequence homology to recA-sequences
of S. pneumoniae. Additionally, differentiation from S. pneumoniae
according to the 7 speciﬁc nucleotide positions was determined for all
20 isolates, the identiﬁcation of which resulted in S. mitis or oralis.
Conclusion: Our investigations present a more discriminatory molecular
tool than the 16S rRNA-gene for proper identiﬁcation of pneumococci.
A recA-gene based PCR and analysis of 7 signature positions within the
ampliﬁed fragment allowed an accurate differentiation of S. pneumoniae
from S. mitis/S. oralis.
P1851 Rapid detection of vancomycin-resistant enterococci from
rectal swabs by the Cepheid Xpert vanA/vanB assay
N. Bourdon, R. Be´renger, A. Mouet, C. Lesteven, F. Borgey,
M. Fines-Guyon, R. Leclercq °, V. Cattoir (Caen, FR)
Objectives: The GeneXpert™ vanA/vanB real-time PCR assay
(Cepheid) is a fully automated process that allows detection from rectal
swabs of the major vancomycin resistance genes, vanA and vanB, in less
than 1 hour. The purpose of this study was to assess the accuracy of this
technique in comparison with vancomycin-resistant enterococci (VRE)
selective culture after broth enrichment, as a reference technique.
Methods: From April to July 2008, 804 rectal swab specimens were
obtained from 794 patients hospitalized at the university hospital of
Caen, France. Each swab was suspended in 1ml of sterile water
by vortexing. For culture, a 5-ml BHI broth containing 10mg/L
of aztreonam and 3mg/L of vancomycin was inoculated with 100
ml of the suspension. Broth cultures were incubated aerobically for
24 h, then subcultured onto chromogenic ChromID VRE™ agar plates
(bioMe´rieux) and incubated aerobically for 24, 48 and 72 h. Identiﬁcation
of enterococci and of vancomycin resistance genes was performed
by a multiplex PCR assay. For real-time PCR, the suspension was
discharged into a cartridge and automatically processed for extraction,
PCR and detection. The rest of the suspension was kept frozen at
−80ºC. For samples VRE(−) by culture but vanB(+) [possibly containing
resistant anaerobes], Schaedler broths containing aztreonam (10mg/L) or
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aztreonam (10mg/L) + vancomycin (3mg/L) were inoculated with 100
ml of the frozen suspension, incubated for 72 h and subcultured.
Results: Eleven samples (1.4%) yielded VRE by culture, including 8
E. faecium vanA(+) and 3 E. faecium vanB(+) whereas 793 remained
negative. Real-time PCR assay was positive for vanA and vanB in 12
(1.5%) and 115 (14.3%) samples, respectively. Eight of the vanA(+)
samples and 3 of vanB(+) samples were conﬁrmed as VRE by culture.
Sensitivity of the PCR technique was 100% for both vanA and vanB
genes whereas speciﬁcity was 85.4% and 86%, respectively. PPV was
8.7% and 2.6% for vanA and vanB genes, respectively, whereas NPV was
100% for both genes. Screening for Gram-positive anaerobes harbouring
the vanB gene was performed on 15 specimens. No vanB(+) anaerobic
bacteria was detected.
Conclusion: This is the ﬁrst report of the use of the Xpert™ vanA/vanB
kit for detecting VRE from rectal specimens. This rapid (<50 min)
technique showed a low prevalence (1.3%) of carriage of VRE among
patients in our facility. Due to its excellent NPV, this method may reduce
laboratory labour allowing to control only positive PCR results.
P1852 Xpert VanA/VanB for managing an outbreak of VRE
L. Cavalie´ °, D. Clave´, M.F. Pre`re, S. Malavaud, M. Metais, J.M. Conil,
N. Kamar, L. Lavayssiere, L. Rostaing, N. Marty (Toulouse, FR)
Objectives: From late October 2008 to April 2009 the University
Hospital of Toulouse was facing an outbreak of vancomycin resistan
E. faecium (VRE) type B. This led to the introduction of screening by
PCR using the new technology Xpert vanA-vanB (Cepheid).
Method: Following the detection of VRE in a patient in the nephrology
ICU department all admitted and contacts nephrology patients were
screened. Additional contact precautions were set up with three dedicated
cohort areas (carriers, contacts and incoming patients). The screening of
patients was performed by perianal swabbing and culturing on BEA
vancomycin agar or chromID VRE ™ (Biomerieux). The plates were
incubated 24−48 H and suspect colonies were identiﬁed by Vitek 2 and
antibiogram. Carriage of the van A or van B gene was conﬁrmed by
molecular biology (Genotype Enterococcus ®, Hain Lifescience).
After conﬁrmation of the outbreak, screening was performed using the
real-time PCR Xpert VanA/VanB assay (Cepheid) to speed up result
availability. Swabs were collected using double-headed swabs (Copan
139C). These were transported in liquid Stuart medium.
Results: We screened 1000 different patients (all techniques combined)
over 10 months, some patients were analysed several times. We found
31 E. faecium van B (outbreak), 2 E. faecium Van A and 1 E. faecalis
vanA.
182 samples were screened with both Xpert VanA/VanB and culture.
121 were negative in both, 19 positive in both, 38 positive with PCR and
negative with culture. One was culture positive but PCR negative. The
sensitivity for Xpert VanA/VanB was determined to be 95%; speciﬁcity
76.1%; PPV 33.3% and NPV 99.1%. These results led us to consider
negative all PCR negatives without the need for culture conﬁrmation.
PCR positives were conﬁrmed by culture using the second swab as
recommended by Cepheid.
Conclusions: The high NPV of Xpert VanA/VanB makes it very useful
for screening. In an outbreak situation, a negative result can be delivered
in less than an hour compared to up to 5 days for culture allowing
early release from isolation of patients on admission. The cost for the
analysis should be weighed against the reduced cost of unnecessary
isolation (rooms, equipment, personnel). A positive PCR result needs
to be conﬁrmed by culture and the patient kept in isolation until the
results are available.
P1853 Development of a high-throughput vanA and vanB
gene real-time PCR assay for the screening of
vancomycin-resistant enterococci from enrichment broth
and clinical isolates using the LightCycler 480 instrument
T.M. Pryce °, I.D. Kay, J.P. Morgan, G.W. Coombs (Perth, AU)
Objectives:
1. To increase the throughput of our existing 32-capillary LightCycler
1.0 (LC1) vanA and vanB gene assay to a 96-well capacity using the
LightCycler 480 (LC480) system.
2. Compare PCR sensitivity, cost and turnaround time for each assay.
3. Evaluate an internal control for the LC480.
Methods: Patient rectal swabs cultured in Enterococcosel broth
containing 6mg/L vancomycin (EV broths) which turned visually black
(n = 370) were screened for the presence of both vanA and vanB genes
using the LC1 and LC480. Twenty clinical isolates were also tested. DNA
standards from vanB Enterococcus faecalis and vanA E. faecium control
strains were used to determine the analytical sensitivity of each assay. EV
broths were extracted using the MagNAPure robotic instrument. Clinical
isolates were extracted by a heat-lysis method. Identical primer-probe
sequences and thermal cycling conditions were used for each assay,
however for the LC480 detection system the vanA ﬂuorophore was
modiﬁed from LC Red-705 to LC Red-610. To detect the presence of an
internal control, 5mL aliquots of an internal control construct (Bioline
Cat. No. AUS-99005) was added to 50 EV broths, then extracted and
tested in parallel in a modiﬁed LC480 assay containing speciﬁc internal
control primers and probes.
Results: From the 370 black EV broths, 25 (6.7%) and 42 (11.3%)
were vanB positive using the LC1 and LC480 assays respectively. All
LC1 positive broths were LC480 positive. All negative LC480 broths
were LC1 negative. All clinical isolates tested were concordant. The
analytical sensitivity for vanA and vanB was 5pg and 50pg respectively
for LC1 and 5pg for vanA and vanB for the LC480. The internal control
was ampliﬁed for all broths tested and no inhibition was observed. For
a routine run of 25 tests the material cost of the LC480 assay was
approximately 2AUD per test compared to 4AUD per test for the LC1.
Turnaround time was reduced for the LC480 depending on the number
of tests performed.
Conclusions: The LC480 demonstrated a 10-fold increase in the
analytical sensitivity for the detection of vanB in the E. faecalis DNA
standard. Detection of vanB in the cultured EV broths from rectal
swabs increased 4.6% using the LC480. Signiﬁcant cost savings were
achieved and turnaround times were reduced for the LC480. In addition,
incorporation of an internal control may be useful for monitoring test
performance and reduce reporting of false-negative results.
P1854 Direct PCR detection and identiﬁcation of oral streptococci
from carious dentin samples
C.S. Stingu °, J. Thiel, R. Schaumann, A.C. Rodloff (Leipzig, DE)
Objectives: Streptococcus mutans has been implicated as a major
etiological agent of dental caries. On the other hand there are recent
studies that indicated that also low pH non mutans oral streptococci
have the ability to produce dental caries. Previous research has identiﬁed
S. mutans in carious dentine. Little is know about the prevalence of the
other acidogenic streptococci. Our goal was to use molecular methods
to detect the most important species of oral streptococci (mutans and the
low pH non mutans streptococci) in the carious dentin.
Methods: 27 patients (mean age 41 years) with clinical proof of
dental caries were enrolled in this study. None of the carious lesions
had signs of pulpitis. All lesions were cavitated with exposure of
the dentin. Samples of the carious dentin were collected with a
sterilized STOMA excavator 4621.15 taking care not to allow the
excavator to touch the adjacent and cervical enamel to prevent sample
contamination. The dentin samples were then immersed in 1ml brain
heart infusion broth. The samples were vortexed for 30 s and stored
at −20ºC until analyzed. The samples were then brought to the room
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temperature and DNA was extracted using Dneasy Blood&Tissue for
Gram-positive bacteria from Qiagen GmbH, Germany according to
the manufacturer’s instructions and prolonging the incubation time
with proteinase K up to 2 hours. Genotypic identiﬁcations were
performed by species-speciﬁc PCRs for: S. mutans, Streptococcus oralis,
Streptococcus mitis, Streptococcus salivarius, Streptococcus sanguinis,
Streptococcus parasanguinis, Streptococcus gordonii, Streptococcus
anginosus, Streptococcus constellatus, Streptococcus intermedius.
Results: A number of 10 different species of oral streptococci were
identiﬁed with a mean of 3.6 strains per dentin sample. The most
prevalent species were S. gordonii, S. oralis and S. anginosus (present
in 77.8%, 62.96%, 48.14% of samples, respectively). S. mutans was
detected in 12 dentin samples (44.44%). Signiﬁcant numbers of
S. anginosus were only present in dentin samples were S. mutans was also
present. Signiﬁcant differences between male and females and between
smokers and non-smokers with respect to prevalence of oral streptococci
were not found.
Conclusions: The low pH non mutans streptococci S. gordonii, S. oralis
and S. anginosus dominate the carious dentine ﬂora. They outnumber
the mutans streptococci which were present in less of half of carious
dentin samples.
P1855 High-level ﬂuorescence labelling of Gram-positive pathogens
S. Aymanns, S. Mauerer, G. van Zandbergen, C. Wolz, B. Spellerberg °
(Ulm, Tubingen, DE)
Objectives: Fluorescence labelling of bacterial pathogens has a broad
range of interesting applications including the observation of living
bacteria within host cells. To facilitate ﬂuorescence labelling of
streptococci and related genera we wanted to improve green ﬂuorescent
protein (GFP) expression in these species.
Methods: We constructed a novel vector based on the E. coli
streptococcal shuttle plasmid pAT28 that can propagate in numerous
bacterial species from different genera. The plasmid harbours a
promoterless copy of the green ﬂuorescent variant gene egfp under the
control of the CAMP-factor gene promoter of Streptococcus agalactiae
and was designated pBSU101.
Results: Upon transfer of the plasmid into streptococci, the bacteria
show a distinct and easily detectable ﬂuorescence using a standard
ﬂuorescence microscope and quantiﬁcation by FACS-analysis demon-
strated values that were 10−50 times increased over the respective
controls. To assess the suitability of the construct for high efﬁciency
ﬂuorescence labelling in different Gram-positive pathogens, numerous
species were transformed. We successfully labelled Streptococcus
pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae subsp.
equisimilis, Enterococcus faecalis, Enterococcus faecium, Streptococcus
mutans, S. anginosus and Staphylococcus aureus strains utilizing the
EGFP reporter plasmid pBSU101. In all of these species the presence of
the cfb promoter construct resulted in high level EGFP expression that
could be further increased by growing the streptococcal and enterococcal
cultures under high oxygen conditions through continuous aeration.
Conclusion: The plasmid pBSU101 harbouring the egfp gene under the
control of the CAMP factor promoter of S. agalactiae results in high-
level ﬂuorescence in numerous streptococcal species and related genera.
It represents a versatile novel vector for in vitro and in vivo studies of
bacterial pathogenesis.
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P1856 Tick-borne infections in natural populations from Altai
mountains, Russia
A. Grishechkin °, O. Morozova, L. Karan, E. Isaeva, V. Zlobin (Moscow,
RU)
Objectives: Tick-borne encephalitis in Altay region, Russia for 2007–
2009 remains high (26 clinical cases per 100,000 men) and exceeds
the average disease level in 10 times. The aim of current study was
to analyze tick-borne viral and bacterial infection agent prevalence and
genetic diversity among ixodid ticks.
Methods: In 2007 404 ticks (mainly Ixodes persulcatus Schulze
with a few samples of Hyalomma concinna) have been collected
in Altai Mountain near to village Mangerok (85.7N, 51.8 E). Tick-
borne encephalitis virus (TBEV) was detected by ELISA, bioassay on
permissive PS cells, haemagglutionation test, RT-nested PCR or RT-
real time PCR. Borrelia, Ehrlichia, Anaplasma, Bartonella DNA were
detected using PCR with speciﬁc primers.
Results: ELISA allowed us to reveal TBEV in 68 from 404
samples (16.8±1.8%). Molecular typing with TaqMan subtype-speciﬁc
probes showed the absolute dominance of Siberian genetic subtype.
Borrelia-speciﬁc DNA was detected in 20.8%±1.8% samples, Ehrlichia
chaffeensis, Anaplasma phagocytophilum − in 5.2±2.0% and 1.5±1.2%
samples analyzed, respectively. Deﬁnition of virus loading by a method
Real-time RT-PCR has shown a range of threshold cycles Ct 21−33
that corresponds 10,000−1,000,000 genes-equivalents in individual tick.
The sequencing 790-bp fragments of gene E followed by phylogenetic
analysis using neighbor-joining and bootscanning was performed.
Nucleotide sequence data of the PCR products have conﬁrmed the
dominance of viruses Sibirian subtype in Altai mountains, however also
presence of viruses European subtype was revealed.
Conclusions: The TBEV infection rate among ixodid ticks in Altay
Mountain, Russia was high and despite the abundance of Siberian genetic
subtype was dangerous for non-immune tourists from non-endemic
regions. Beside the TBEV tick-borne bacterial pathogens can cause
serious infections among populations.
Figure 1. Phylogenetic tree, based on 790-bp fragment gene E sequences
of tickborne encephalitis virus (TBEV). Original names of TBEV are
presented. The tree was constructed by the neighbor-joining method.
P1857 Molecular epidemiology of norovirus outbreaks in
Edinburgh, Scotland
A. Holmes °, L. Garcia, F. Cameron, K. Cloy, J. Danial, J. Cepeda,
P. Simmonds, K. Templeton (Edinburgh, Basingstoke, UK)
Objectives: The aim of this study was to determine the genotypes
responsible for norovirus (NoV) outbreaks in Edinburgh and to study the
temporal occurrence of the genotypes to enable a better understanding
of the epidemiology of the outbreaks.
Methods: A total of 161 samples positive for NoV genogroup II
(GII) RNA by reverse transcription (RT) real-time PCR during routine
diagnostic testing were investigated. Samples were obtained from a
representative number of outbreaks (n = 66) of gastroenteritis that
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occurred between February 2008 and May 2009 in Edinburgh healthcare
facilities. Nested RT-PCR, targeting a 311bp region of the major capsid
gene, and sequencing was used to genotype the NoV strains.
Results: 118 of the 161 samples (73%) were successfully ampliﬁed and
sequenced. A total of 20 NoV strains belonging to six different genotypes
(GII.1, GII.2, GII.3, GII.4, GII.6 and GII.12) were detected. The
predominant genotype was GII.4, which included 13 variants separated
into three genoclusters, 2006a (n = 3), 2006b (n = 6) and GII.4/2007
(n = 4). The majority of outbreaks (65%) were caused by 2006b,
and two variants of 2006b, v1 (Hu/GII-4/Kumamoto2/2006/JP) and
v4 (Hu/GII.4/VIC4681/2007/AU). These variants circulated at different
times; initially 2006b was the predominant strain causing outbreaks
at multiple healthcare facilities, and continued to cause outbreaks
throughout the study period. 2006b v1 was prevalent during April and
May 2008, whilst 2006b v4 predominated from January 2009 until May
2009. Linking this data with the incidence of NoV during the study
period showed large increases in NoV activity to coincide with the
emergence of these 2006b variants.
Conclusion: In 2006, GII.4 2006a was the predominant genotype
detected in Scotland. This study reveals 2006b variants are now the
predominant circulating strains, in Edinburgh at least, with other types
circulating for shorter periods or sporadically. Importantly, increases in
norovirus activity coincided with the introduction of new NoV 2006b
variants, highlighting the need for an active surveillance system to allow
the rapid identiﬁcation of new, highly transmissible strains.
P1858 Spread and outbreaks of enterovirus types in Novosibirsk,
Russia
A. Demina °, V. Ternovoi, S. Netesov (Novosibirsk, RU)
Non-polio enteroviruses cause a wide variety of clinical diseases
frequently associated with the affection of central nervous system. They
are recognized now as the most common cause of viral meningitis.
Purpose of this study: Investigation of the clinical, epidemiological
features and etiology of enteroviral infections (in particular, one of its
wide-spread forms − aseptic meningitis (AM)) in Novosibirsk, Russia.
Materials and Methods: We have analyzed 951 case-records of adult
patients which were being treated in Novosibirsk Municipal Infectious
Diseases Clinical Hospital No. 1 because of the “aseptic meningitis”
diagnosis during the period 1993–2008. We also have analyzed 203
specimens of cerebro-spinal ﬂuid (CSF) and feces from the patients with
the same diagnosis in 2008–2009.
Results: There were 3 signiﬁcant outbreaks of AM: in 1993–74 patients,
1998–97 pat., 2004–194 pat. The morbidity among men was 5−10%
higher than among women. Among the patients high portion comprised
the persons younger 30 years. The majority of cases occurred during
July-October. The main possible sources of infection were: swimming
in water reservoirs (30%); contact with the patients with AM or acute
respiratory viral infection (12%); recreation in summer camps (6%);
usage of raw water (6%) or raw milk (2%). Aseptic meningitis was
acute infection, but the majority of cases were fast and mild infections.
Fever was noted at all patients; 83% − febrile fever; 15% had two- or
three-wave fever. 78% had headache; 60% had sickness and retching.
We observed the signiﬁcant number of speciﬁc symptoms which are
typical for the enteroviral infection: catarrhal inﬂammation − 40%;
rhinitis − 13%; exanthema − 9%; scleritis − 5%; diarrhea − 5%. The
analysis of CSF showed that three-digit cytosis predominated in all years.
The nature of pleocytosis was neutrophilic, mixed or lymphocytic in
the different years. Diagnosis was established on the basis of clinico-
epidemiological information and was conﬁrmed by PCR detection of
enterovirus RNA: in 70% − in the CSF, in 9% − in the blood and
in 21% − in both CSF and blood. In 2008–2009 we have analyzed
203 specimens of CSF and feces by the RT-PCR and we found the
following enteroviruses: ECHO30 − 4 samples; Enteroviruses90 − 6;
Coxsackie76 − 1.
Summary: The epidemic ascent of diseases occurs each 5−6 years.
Upshot of all aseptic meningitis was favorable. Mainly there were
isolated ECHO30 and enterovirus90 in Novosibirsk region.
P1859 Astrovirus in Italy, emergence of a novel 2c lineage
M.A. Platia, V. Rotolo, C. Colomba, A. Cascio °, V. Martella,
G.M. Giammanco, S. De Grazia (Palermo, Messina, Bari, IT)
Objectives: Human astroviruses (HAstVs) are enteric viruses associated
with gastroenteritis in young children in both developed and developing
countries. The pathogenic role of HAstVs is still disputed since they are
frequently found in mixed infection. In the present study we investigated
on the prevalence of HAstVs in Palermo, Italy, in 2002–2005. Genetic
diversity of HAstVs was determined by sequence analysis of ORF2
which allows to predict serotypes (1 to 8).
Methods: 708 faecal samples were obtained from children, less than ﬁve
years, hospitalised in Palermo from January 2002 to December 2005.
The samples were screened for the presence of HAstVs by EIA and
positive specimens were analysed by RT-PCR to obtain ORF2 amplicons
for genotyping through sequence and phylogenetic analysis. All stool
specimens were also tested for presence of rotaviruses and noroviruses
by RT-PCR.
Results: HAstVs were found in 28 (3.95%) patients. Mixed infections
were found in 50% of the HAstV-positive samples. Coinfections with
rotavirus were the most frequent. There were no signiﬁcant differences
in symptoms between patients with HAstV single infection and mixed
infections. Fourteen HAstVs were genotyped by sequence analysis and
HAstV types-1, -2, and -4 were detected. In particular, HAstVs-1 were
identiﬁed in 2003–2005, HAstV-2 and -4 circulated only in 2002. In
the phylogenetic tree, all Italian HAstVs-1 belonged to lineage 1d and
HAstVs-4 to lineage 4b. The two Italian HAstVs-2 segregated in a
well deﬁned genetic cluster that differed from the presently described
lineages and was designated 2c. Conserved nt polymorphisms allowing
to differentiate the novel 2c lineage were observed.
Conclusion: The data obtained in this study conﬁrm the role of HAstVs
as agents of acute gastroenteritis in children and indicate HAstV-1d as
the predominant type. This lineage, already circulating in Palermo in
1999, re-emerged in 2003 and continued to circulate until 2005. In 2002,
HAstV-2c ﬁrst appeared in Italy after occasional detection in other geo-
graphic areas. The emergence and re-emergence of different genotypes
and lineages of astrovirus may depend on population immunity pressure.
Nation-wide investigations concerted at an international level could be
useful to gather more information on the impact of HAstV on enteric
disease in children. Knowledge of the viral types circulating worldwide
is required to plan prevention and control strategies.
P1860 Molecular epidemiology of enterovirus types causing aseptic
meningitis in Greece, 2007–2009
S. Papadopoulou, N. Apostolopoulou, E.T. Piperaki °, V. Pitiriga,
N. Spanakis, A. Tsakris (Athens, GR)
Background: Enteroviruses is considered the most common cause of
viral meningitis. The detection and identiﬁcation of the enteroviruses
in such cases contributes to the proper use of antibiotics and to the
assessment of their epidemiological proﬁle. The aim of the present study
was to detect and identify by molecular methods the circulating types of
enteroviruses causing aseptic meningitis and encephalitis in Greece for
the period 2007–2009.
Methods: One hundred and ten CSF specimens from patients-both
children and adults-from 5 tetriary care hospitals in Athens with
diagnosed or suspected aseptic meningitis, were examined in order to
determine a possible enteroviral etiology.
RNA was extracted from CSF using the QuickGene-810 extraction
system. RT-PCR targeting the 5-UTR of viral genome was used for
detection of enteroviruses. RT-nested PCR targeting the VP1 gene,
followed by sequencing, was then performed in order to determine the
enterovirus serotype. The primers were supplied by Macrogen ltd and
the RT-PCR reactions were carried out using the QIAGEN One-step
RT-PCR kit.
Results: Fifty nine specimens (53.6%) were positive for the presence of
enterovirus and 26 (44%) of the positive specimens were successfully
typed. coxsackie B5 was determined as the predominant serotype
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(34.6%), followed by echovirus 30 (26.92%), echovirus 6, 9, 13 and
coxsackie virus B4 (7.7% each), coxsackie A9 and echovirus 11 (3.8%
each). Among the 59 patients 37 were male and 22 were female. The vast
majority were children up to15 years old (96%) and only 4% were adults
(>15 years). All, but one, patients who were found to be enterovirus
positive showed abnormal CSF proﬁle, with higher than normal white
cell blood count (>5/mm3) and/or elevated protein level (>45mg/dl) and
all presented the typical clinical symptoms of aseptic meningitis.
Conclusions: Eight co-circulating enterovirus serotypes causing aseptic
meningitis were identiﬁed. Coxsackie virus B5 was most frequently
isolated, followed by echovirus 30. The prevalence of coxsackie virus B5
as well as the presence of echoviruses 6, 13, 11, 30 was also previously
reported in Greece. However, echoviruses 15 and 4 that previously
reported to cause outbreaks in Greece were not isolated in this study.
P1861 Two prevalent Pseudomonas aeruginosa genotypes are
unique in Dutch patients with cystic ﬁbrosis and absent in
other patient populations
R. van Mansfeld °, M. Bonten, R. Willems (Utrecht, NL)
Objectives: We previously demonstrated, based on multi locus sequence
typing (MLST), the presence of prevalent clones of Pseudomonas
aeruginosa in Dutch cystic ﬁbrosis (CF) patients. Sequence types (STs)
ST406 and ST497 were found in 15% and 5% of the patients colonized
with P. aeruginosa, respectively. ST406 and ST497 were not genetically
linked to previously described international epidemic clones, which were
not found in this CF population. In the study we aimed to determine
whether ST406 and ST497 were unique for CF patients.
Methods: 205 P. aeruginosa respiratory isolates from intensive care
unit (ICU) patients, 100 P. aeruginosa respiratory isolates from CF
patients and 103 multiple resistant P. aeruginosa strains isolated in
our hospital between 2006 and 2008 were genotyped with Multiple
Locus Variable Number of Tandem Repeats Analysis (MLVA). The
prevalence of speciﬁc genotypes and genetic diversity, expressed as the
Simpsons index of diversity (ID) with 95% conﬁdence interval (CI), were
compared between the three clinical settings. Particularly, the prevalence
of ST406 and ST497 equivalent MLVA types (MT) in non-CF patients
was investigated.
Results: 272 MTs were identiﬁed in 408 isolates. The ID of all isolates
was 0.995 (CI 0.994–0.997), indicating a highly diverse population, and
IDs were not signiﬁcantly different between the three clinical settings.
Only 17 MTs were shared between the different clinical settings and in
all three settings more prevalent MTs were found. These were MT80
(5%) and MT265 (15%) in the hospital hygiene collection and MT155
(10%) in the ICU collection. However, these MTs were not unique to
one clinical setting, and also obtained from patients in other settings.
The CF related clones ST406 and ST497, represented by MT27 (21%)
and MT11 (7%) were unique to CF patients.
Conclusion: The population structure of P. aeruginosa obtained from
different clinical settings is highly diverse and characterized by many
unique and some more prevalent genotypes. The two prevalent genotypes
previously documented in the Dutch CF population, which are not
genetically linked to previously described epidemic clones, appeared
unique to the CF related P. aeruginosa population and were not found
in other clinical settings.
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P1862 Activity of different antibiotics against Borrelia burgdorferi
determined by bacterial heat production (microcalorimetry)
Y. Achermann °, M. Vogt, A. Trampuz (Zurich, Baar, Lausanne, CH)
Objectives: Antimicrobial susceptibility testing in Borrelia burgdorferi
sensu lato is not routinely performed due to laborious procedure
and lacking correlation with treatment outcome. The MIC and MBC
values determined by the colorimetric microdilution assay provide no
information on the antimicrobial activity over time. Therefore, we
evaluated the activity of 4 antibiotics by measurement of heat production
using an ultrasensitive real-time instrument (microcalorimeter, detection
limit 025 microwatt).
Methods: We used B. burgdorferi sensu stricto (strain 1408/94) isolated
from a patient with erythema migrans. Microcalorimetry (detection
limit 0.2 mW) was performed in duplicate by adding 0.1ml of culture
containing 106 CFU of B. burgdorferi in 3.9ml BSK-H medium
containing serial 2-fold dilutions of standard antibiotics (amoxicillin,
doxycycline, rifampin, levoﬂoxacin). Heat production was measured
at 37ºC under static conditions for up to 21 days. The minimal heat
inhibition concentration (MHIC) was deﬁned as the lowest antimicrobial
concentration inhibiting heat production within 14 days after heat was
detected in cultures without antibiotics.
Results: Heat of B. burgdorferi was detected in absence of antibiotics
after 2 to 8 days and reached a peak of 30 and 50 microwatt. The peak of
heat-ﬂow was proportionally delayed with increasing dose of amoxicillin,
whereas the peak was also decreased with doxycycline and levoﬂoxacin
(Figure). Growth of B. burgdorferi was not affected by rifampin up to
16 mg/ml. The MHIC (mg/ml) was 0.5 (amoxicillin), 1 (doxycycline),
8 (levoﬂoxacin) and >16 (rifampin). At amoxicillin concentrations >0.5
mg/ml, identical heat ﬂow curves were observed even after 14 days delay.
Conclusions: Doxycycline showed the highest activity against
B. burgdorferi by microcalorimetry, followed by amoxicillin and
levoﬂoxacin, whereas rifampin showed no antiborrelial activity. The
MHIC values correlate well with the reported MIC values (Hunfeld
et al., 2000). Microcalorimetry is a useful tool for rapid and real-time
assessment of growth characteristics of and antimicrobial activity against
B. burgdorferi and potentially other slow-growing microorganisms.
P1863 Chip-calorimetric evaluation of the efﬁcacy of antibiotics
and bacteriophages
J. Lerchner °, D. Mueller-Hagen, I. Klare, H. Roehr, A. Wolf,
F. Mertens, R. Mueller, W. Witte (Freiberg, Viersen, Wernigerode, DE)
Objectives: Rapid detection of the antibiotic resistance of bacterial
strains from clinical material would allow a faster intervention and
implementation of infection control treatments and an early selective
antibiotic therapy. In the clinical practice, however, conventional
antibiotic susceptibility tests often need 24 h until a result is obtained
and necessary actions can be taken.
The metabolic heat production of bacteria is an excellent possibility
to measure their physiological activity and could therefore be used for
a rapid discrimination of resistant and non-resistant bacterial strains.
Unfortunately, conventional calorimeters suffer from high sample need,
slow operation, and high costs which restrict their application in clinical
laboratories. The presented work demonstrates that a new type of
calorimeters developed on silicon-chip technology enables the detection
of antibiotic resistance on a minute time-scale.
Methods: In the present study, a prototype chip calorimeter was used
[1]. Crucial part of the calorimeter is a heat power transducer comprising
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a silicon thermopile chip, a heat sink, and a measurement chamber (see
Fig.). At least a volume of 100 ml of a bacterial suspension is necessary
to ﬁll the measurement chamber. A few minutes after sample injection,
a stable heat signal is available displaying the present metabolic activity
of the bacteria. The sensitivity of the calorimeter is 20 nW related to
the heat production of about 104 bacteria. For a clear discrimination
of antibiotic resistance and non-resistance by the presented micro-
calorimetric method, about 105 bacteria are required.
Results: The antibiotic or bacteriophage susceptibility of different strains
of Staphylococcus aureus and Escherichia coli was studied. For instance,
for S. aureus strains 1ml of tryptic soy broth with and without a
breakpoint concentration of cefoxitin, respectively, were inoculated with
100 ml of a suspension of a single fresh colony in 220 ml tryptic soy
broth in each case. After incubation of the samples at 37ºC for 90 min
the calorimetric measurements were performed.
Conclusions: The comparison of the heat production of cultures
incubated with bacteriophages and antibiotics to those without these
antibacterial preparations enabled a clear discrimination of resistant and
non-resistant strains already after totally 120 min.
Reference(s)
[1] J. Lerchner, A. Wolf et al., Thermochim Acta 447 (2008) 48−53.
P1864 Multiplex PCR for rapid detection of genes encoding
class A carbapenemases
S.G. Hong °, S.K. Hong, J.Y. Huh, M.S. Kang (Gyeonggi-do, Seoul, KR)
Objectives: Class A carbapenemases (CACs) include the SME,
IMI/NMC-A, SFC, KPC, and some type of GES families. The genes
for SME, IMI/NMC-A, SFC enzymes are all chromosomally located
except IMI-2 and the genes for KPC and GES enzymes are carried
on plasmid. KPC producers have induced severe treatment problems
in hospitals around New York and have also been reported in Europe,
South America and China. Therefore, the conﬁrmation of type of CACs
is important to ensure optimal therapy and to prevent their spread. This
study was to develop a multiplex PCR assay to detect and differentiate
CAC genes in a single reaction.
Methods: The strains comprised 11 CAC-producers (1 SME-producing
Serratia marcescens, 2 IMI/NMC-producing Enterobacter cloaceae, 2
KPC-producing Enterobacteriaceae and 6 GES-producing Klebsiella
pneumoniae), 8 metallo-b-lactamase (MBL) producers (2 IMP-producing
Pseudomonas aeruginosa, 3 VIM-producing P. aeruginosa, 1 IMP-
producing Acinetobacter baumannii, 1 SIM-producing A. baumannii
and 1 VIM-producing Alcaligenes feacalis), and 5 non-carbapenemase-
producing Enterobacteriaceae. Four primer pairs were designed to
amplify fragments of 4 CAC families (SME, IMI/NMC-A, KPC, and
GES). The PCR were done for the detection of CAC genes with above
strains.
Results: The multiplex PCR detected all the genes for 4 CAC families
that could be differentiated by the fragments size according to the gene
types. All non-CAC producers did not show PCR product bands.
Conclusion: This multiplex PCR appears to be a simple and useful
approach to detecting and distinguishing CAC genes in carbapenem
resistant strains that show negative results to the detecting test for MBL
producers. Therefore, this method should be helpful for characterization
of CACs and in controlling the spread of pathogens producing these
enzymes.
P1865 Detection of point mutations on 23S rRNA of Helicobacter
pylori and resistance to clarithromycin by PCR-RFLP in
Spain
S. Agudo °, T. Alarco´n, G. Pe´rez-Pe´rez, M. Lo´pez-Brea (Madrid, ES)
Objective: The identiﬁcation and characterization of clarithromycin
resistant Helicobacter pylori strains is a long and expensive process that
requires culture and isolation of H. pylori from gastric biopsies. The
purpose of the present study was to identify H. pylori strains resistant to
clarithromycin and determine the most common point mutation present
in the 23S rRNA gene using a PCR-RFLP technique.
Methods: Gastric biopsies were obtained by endoscopy from paediatric
patients with gastric symptoms. H. pylori was cultured according
to standard microbiological procedures and clarithromycin resistance
determined by E-test. DNA extraction was performed by NucliSens
platform with the NucliSens magnetic extraction reagents (bioMe´rieux)
according to manufacturers instructions. Clarithromycin resistant and
sensitive strains were determined by PCR and DNA sequencing for
mutations in 23S rRNA gene. Restriction fragment length polymorphism
was performed using BsaI enzyme to detect restriction sites that
correspond to the mutation.
Results: We found 42 out of 118 (35.6%) strains resistant to
clarithromycin by E-test. E-test results were conﬁrmed for the presence
of point mutation in 34 (88.1%) of these strains. There were 8 H. pylori
strains resistant to clarithormycin by E-test but without any point
mutation in the 23 rRNA gene. Mutation A2143G was found in 85.3%
of the strains. Restriction enzyme analyses with BsaI was able to detect
the presence of that mutation in 100% of the resistant cases.
Conclusion: PCR-RFLP is an usefull method to detect clarithromycin-
resistant H. pylori infection in countries with a high prevalence as Spain.
Only A2143G mutation could be detected with this assay, but it is the
most prevalent in Spain as well as in the other countries. It may be
useful to apply this methodology before choosing regimens of H. pylori
eradication.
P1866 Evaluation of the new WalkAway® plus automated
microbiology system for identiﬁcation and antimicrobial sus-
ceptibility testing of Gram-negative bacilli in routine practice
L. Armand-Lefe`vre °, C. Moreau, M. Perrot, A. Andremont,
C. Muller-Serieys (Paris, FR)
The WalkAway® plus (Siemens) is an automated system designed for
identiﬁcation (ID) and antimicrobial susceptibility testing (AST) of
clinically signiﬁcant human bacterial pathogens.
Objectives: We have evaluated performance of the new WalkAway®
plus instrument for ID and AST of clinical Enterobacteriaceae (Eb) and
non fermentative Gram-negative bacilli (Nfb) isolated in a bacteriology
laboratory.
Methods: The MicroScan® Neg Fermenteur Combo Type 47 and
Neg Non fermenteur Combo Type 48 panels were tested for Eb and
Nfb, respectively. ID results were compared to those of conventional
biochemical ID systems: API 20E (Eb) and API 20NE (Nfb)
(bioMe´rieux, La Balme les Grottes). AST category results (S, I, R) were
compared to those of the standard disk diffusion method after expertise
using SIR software (I2A), and according to CA-SFM guidelines.
Discrepant results were retested in duplicate. ID discrepancies were
resolved by 16S rRNA sequencing. AST discordant results (I or R instead
of S results and vice-versa), were resolved by MIC determination (E-test,
AB biodisk).
Results: A total of 331 Eb (144 E. coli, 58 Klebsiella spp, 45 Proteus
spp, 44 Enterobacter spp, 16 Citrobacter spp, 13 S. marcescens, 11
others) and 105 Nfb (84 P. aeruginosa, 8 A. baumannii, 4 S. maltophilia,
9 others), recovered from routine cultures, were tested. The percentages
of concordant ID at the species levels were 97.6% (323/331) and 96.2%
(101/105) for Eb and Nfb, respectively. The rate of categorical complete
agreement for AST of Eb ranged from 90.6 to 99.4% for b-lactams, from
95.5 to 97.3% for aminoglycosides, 98.8% for ﬂuoroquinolones and from
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97.7 to 99.1% for other antibiotics. The lowest value (90.6%) was for
the genus Proteus and aminoglycosides. Overexpression of penicillinases
in E. coli caused a low concordance rate (90.6%) for the combination
of amoxicillin and clavulanic acid, using the WalkAway® plus system.
Among 18 ESBLs producing isolates, 4 were not detected (all were from
the genus Enterobacter). Complete agreement for AST of P. aeruginosa
ranged from 95.2 to 100% for b-lactams, to 95.2% for aminoglycosides
and 98.8% for ciproﬂoxacin.
Conclusion: The new WalkAway® plus instrument is a reliable
microbiology automated system for ID and AST of Enterobacteriaceae
and non fermentative Gram-negative bacilli commonly isolated in a
clinical laboratory.
P1867 Correlation of ciproﬂoxacin and levoﬂoxacin sesitivity
interpretation in Gram-negative bacteria
B. Grabein, M. Hoeck, A. Toniolo, B. Wiedemann ° for the EPICENTER
Network
Objectives: For infections due to Gram negative pathogens,
Ciproﬂoxacin and Levoﬂoxacin are the most commonly used ﬂuo-
roquinolones. Both drugs have the same mechanism of action and
resistance. Their activities and pharmacokinetics are, however different.
Using data from theEPICENTER Network group, we analysed whether
it is possible to test only one of the above drugs and if results for the
other ca be deduced.
Methods: At present time four laboratories participate in the network
using the automated BD PHOENIX-systems measuring MICs. The BD
EPICENTER Data-Management-System is used for the evaluation of the
data in the laboratory and for the transfer of the data to the concentrator,
where the drug susceptibility data are interpreted using appropriate
breakpoints. Copy strains are excluded. Quality control assays are
routinely performed. Data of two German and one Italian laboratory have
been analyzed. Using EUCAST breakpoints MIC results were interpreted
for ciproﬂoxacin (S 0.5, R> 1) and levoﬂoxacin (S 1, R> 2) for
Enterobacteriaceae and P. aeruginosa.
Results: We analysed 54 137 strains: 35254 E. coli, 4319 E. cloacae,
7109 K. pneumoniae, 6175 P. mirabilis and 1280 P. aeruginosa strains.
Results for ciproﬂoxacin and levoﬂoxacin were virtually identical for
E. coli, E. cloacae, and K. pneumoniae (see table). Major errors
were below 1% for all Enterobacteriaceae. In the case of P. mirabilis
9.39% minor errors were detected. Including minor errors, an almost
perfect correlation was found between results for Enterobacteriaceae with
agreement in over 99% of cases. The results with P. aeruginosa were less
convincing: 3.15% major errors and 14.26% minor errors were detected.
Using modiﬁed breakpoints for Levoﬂoxacin (S 2, R> 4) correlation
levels were increased: perfect agreement in 92.25% of cases, 0.61 major
errors, and 6.48% minor errors.
Conclusion: The data show that, for the investigated enterobacterial
species either of the drugs can be tested; results can be deduced for
the missing one. Using common EUCAST breakpoins, this appears
not to be possible for P. aeruginosa. Shifting the breakpoints (S 2,
R> 4) signiﬁcantly improved the agreement of MIC interpretation. This
correlates with the wild type cut off values for Ciproﬂoxacin and
Levoﬂoxacin of 0.5 and 2mg/l, respectively.
Table 1. Correlation of ciproﬂoxacin and levoﬂoxacin sensitivity results
E. coli E. cloacae K. pneumoniae P. mirabilis P. aeruginosa
Identical 99.22% 98.80% 97.67% 90.53% 82.51%
Major error 0.06% 0.25% 0.34% 0.18% 3.51%
Minor error 0.23% 0.36% 1.38% 9.39% 14.26%
P1868 Comparison of the agar dilution and the disc diffusion
method in 242 Campylobacter spp. strains
M. Lehtopolku °, P. Huovinen, A. Siitonen, E. Eerola, P. Kotilainen,
A. Hakanen (Turku, Helsinki, FI)
Objectives: Several studies have been published comparing the disk
diffusion and agar dilution or broth dilution method in determining
susceptibilities in Campylobacter spp. In some of the previous studies
results have been in line between the disk diffusion and agar dilution
method, but there have also been results, where disk diffusion method
has not been reliable. The European Committee on Antimicrobial
Susceptibility Testing (EUCAST) is presently developing a disk diffusion
test for routine antimicrobial susceptibility testing. The aim of this study
was to compare the agar dilution method with disk diffusion method in
Campylobacter spp.
Methods: The in vitro activities of 10 antimicrobial agents against
242 Campylobacter spp. strains collected in Finland between 2003
and 2008 were analyzed by standard agar dilution method and disk
diffusion method according to CLSI; Muller-Hinton agar plates with
5% of sheep’s blood. In addition, a number of strains were tested
using the EUCAST disk diffusion test; MH-F plates containing Muller-
Hinton agar with 5% of deﬁbrinated horse’s blood and 20mg/l beeta-
nicotinamide adenine dinucleotide. These results were compared to
the CLSI method. The evaluated antimicrobials were erythromycin,
azithromycin, clarithromycin, spiramycin, telithromycin, clindamycin,
ciproﬂoxacin, nalidixid acid, tetracycline and tigecycline.
Results: According to our results, there was a notable variation in
the results between agar dilution and disk diffusion methods regarding
all antimicrobials tested. Of the 33 erythromycin-resistant strains
(MIC 16mg/l), 29 strains did not show any erythromycin inhibition
zone (<6mm) and 4 strains showed inhibition zones between 18–
42mm. In addition, among the 209 erythromycin-susceptible strains
(MIC< 16mg/l) tested, erythromycin inhibition zone varied between
10–55mm. In disk diffusion analyses, repeatability was good only in
approximately half of the strains, whereas in the rest of the strains
inhibition zones varied signiﬁcantly although tests were performed
according to the same instructions. The disk diffusion results by the
EUCAST MH-F plates were similar to those of the CLSI method.
Conclusions: It is a major concern that the disk diffusion method may
not be a reliable tool for susceptibility testing of Campylobacter spp.
Further studies are needed whether all susceptibilities of campylobacters
should be done using a MIC based method.
P1869 Efﬁcacy of disinfectants against Legionella pneumophila by
an inverse bioﬁlm assay
M.E. Portillo °, A. Aguinaga, C.A. Alonso, J. Leiva (Pamplona, ES)
Objectives: Legionella pneumophila persists in man-made aquatic
installations despite treatments. More information about disinfectants
could improve the effectiveness of treatments. This study tests the
susceptibility of both the planktonic and bioﬁlm bacteria against 3
disinfectants used in cooling tower treatments.
Methods: We determined the minimal inhibitory concentration (MIC),
minimal bactericidal concentration (MBC), bioﬁlm’s minimal inhibitory
concentration (BMIC) and bioﬁlm’s minimal bactericidal concentration
(BMBC) of sodium hypochlorite (SH), chloramite T trihydrate (CT)
and benzalkonium chloride (BC) against 6 L. pneumophila serogoup
1 isolates (5 native isolates and 1 type culture collection ATCC 33152).
The MIC and BMIC were determined by the conventional microdilution
method in a buffered yeast extract broth. The MBC and BMBC were
determined by a variant of the Calgary’s method. We determined these
values after 3 h and after 48 h of disinfectant exposure. Replicated assays
produced identical results for all strains.
Results: The distribution of MIC and MBC values was similar for each
disinfectant against all strains after 3 h and 48 h treatment. The MIC and
BMIC values were similar too. (Table 1).
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Conclusions: The method described for bioﬁlm formation and deter-
mination of bioﬁlm susceptibility for L. pneumophila is reproducible.
Efﬁcacy of disinfectants is similar against planktonic and bioﬁlm
bacteria. The more effective disinfectant tests is benzalkonioum chloride.
Disinfectants can be applied in shock and continuous treatments of water
systems. Our results demonstrate that 3 h treatments are as effective as
48 h treatments for these disinfectants.
Strains Disinfectants Treatment time 48 h Treatment time 3 h
MIC (ppm) BMIC (ppm) CBI/BMIC MIC (ppm) CIB (ppm) CBI/MIC
CUN1 CT 1024 1024 1 512 2048 4
SH 128 256 2 128 256 2
BC 2 4 2 2 4 2
CUN3 CT 1024 1024 1 512 512 1
SH 256 256 1 128 128 1
BC 2 2 1 2 2 1
CUN4 CT 1024 1024 1 512 512 1
SH 256 512 2 128 512 4
BC 1 1 1 2 2 1
CUN5 CT 1024 2048 2 512 1024 2
SH 256 512 2 128 256 2
BC 1 1 1 4 4 1
CUN6 CT 1024 2048 2 512 1024 2
SH 256 256 1 512 512 1
BC 1 1 1 2 2 1
ATCC 33152 CT 512 1024 2 64 1024 16
SH 128 512 4 32 1024 32
BC 1 4 4 2 8 4
P1870 In vitro susceptibility of Pseudomonas aeruginosa isolated
from cystic ﬁbrosis patients to aztreonam and tobramycin
in a bioﬁlm susceptibility test panel
R. Rennie °, L. Turnbull, C. Brosnikoff, N. Brown, B. Rawal, M. Olson
(Edmonton, CA)
Objectives: Both aztreonam(AZ) (conditional approval in Europe
and Canada as CAYSTON) and tobramycin(TO) (world-wide as
TOBI)are available as inhalation modules for treatment of P. aeruginosa
causing pulmonary infections in cystic ﬁbrosis(CF) patients. These
microorganisms often exist as a bioﬁlm and are difﬁcult to treat. We
have tested AZ and TO in a bioﬁlm susceptibility test (bioFILM PA™,
Innovotech, Inc, Edmonton, Alberta) against 149 strains of P. aeruginosa
isolated from CF patients to better understand their potential efﬁcacy for
treatment in CF patients.
Methods: Isolates were tested for inhibition of planktonic and sessile
(bioﬁlm) growth in the bioFILM PA™ module. Isolates were grown on
plastic pegs in a 96 well format by placing in an orbital shaker at 110
rpm to generate identical bioﬁlms on the pegs. The pegs were then placed
into trays containing Mueller-Hinton broth with antimicrobial agents at
varying concentrations, both alone and in combination. After overnight
incubation, the pins were washed, and placed in a recovery medium to
measure inhibition of the bioﬁlm cells. Isolates were categorized as (S),
(I) or (R) according to CLSI systemic breakpoints.
Results: 27 (18%) and 7 (5%) strains did not grow in the control wells
in the MIC and bioﬁlm state respectively. These were rough variants that
did not form bioﬁlms well. Of the 122 strains that formed bioﬁlms on
the bioFILM PA™ pegs, for AZ alone, 73% and 43% were susceptible
by MIC and bioﬁlm respectively. For TO, 63% and 34% were susceptible
respectively. The remainder were either I or R. When AZ and TO were
analysed combined in the same wells, 93% were susceptible by MIC
and 64% by bioﬁlm test. Two additional strains (1%) were I in the
combination by MIC and 14 strains (9%) were I by bioﬁm test. The
remainder of those that formed bioﬁlms were R.
Conclusion: The bioFILM PA™ data are of value in determining the
potential effectiveness of these inhaled antimicrobials on strains of
P. aeruginosa in a bioﬁlm state. These in vitro results suggest that there
are important differences in the effect of these agents on cells in a
bioﬁlm. There is greater resistance in the bioﬁlm to individual agents
thought to be effective for therapy of P. aeruginosa. Combinations of
these agents showed signiﬁcantly greater efﬁcacy in vitro. Such isolates
should be tested by a standardized method such as bioFILM PA™ to
understand the potential for effective therapy or treatment failure.
P1871 Direct application of E-test on positive blood cultures −
more than fast susceptibility testing only?
J.V. Bjørnholt °, T. Brastad, L. Kløvfjell, B.O. Johnsen, C.T. Andersen,
T.M. Leegaard (Oslo, NO)
Objective: To validate and implement direct Etest on positive blood
cultures in a routine laboratory.
Methods: Samples taken directly from consecutive Bactec blood culture
bottles ﬂagging positive and with Gram stain showing bacteria. They
were plated onto 140mm Mueller-Hinton plates with 5% sheep blood
and Etest MIC’s were determined for: 1) Gram-negative rods: cefotaxime,
meropenem, ciproﬂoxacin, co-trimoxazole, gentamicin and one optional
antibiotic. 2) Gram-positive cocci in clusters: vancomycin, gentamicin,
ampicillin, clindamycin with adjacent erythromycin disk for MLS-B,
cefoxitin, one optional antibiotic. In addition they were plated onto an
oxacillin screening plate. 3) Gram-positive cocci in chains: Penicillin
G (low), vancomycin, gentamicin (high), ampicillin, clindamycin with
adjacent Erythromycin disk for MLS-B and one optional antibiotic.
The plates were read as early as possible, after 3−8 hours dependent
on growth (Etest I), and reincubated for reading next work day (Etest
II). All isolates were identiﬁed and susceptibility testing was performed
according to routine methods (VITEK 2 or Etest depending on species
and additional methods if needed). Time to Etest I and discrepancies
between Etest I and II and routine susceptibility were recorded.
Results: 155 positive blood cultures were included, 120 analysed per
protocol. (19 mixed cultures and 16 not indicated when Etest was
read were excluded). 5 positive cultures did not show any growth on
resistance plates (3 anaerobic isolates, 1 Haemophilus inﬂuenzae, 1
Actinomyces spp.). Median time to Etest I 6 hours (range 3−24). There
were no major inconsistencies between Etest I and II or between Etest I
and routine susceptibility, except from difﬁculties in interpretation of co-
trimoxazole for Gram-negative rods and clindamycin for staphylococcus
and enterococcus species, see table 1.
Conclusion: Direct Etest on positive blood cultures gives rapid
and reliable results on antibiotic susceptibility although bacteriostatic
antibiotics should be interpreted carefully. Maybe even more important
than the fast susceptibility testing was the continuous monitoring of
growth which resulted in a much faster identiﬁcation of the isolates.
An automated ID or manual ID could be initiated at the same time as
the reading of Etest I, meaning that in many cases identiﬁcation and
susceptibility testing was on the clinicians desk 24 hours earlier than
previously.
Table 1. Proportion of major groups of isolates with inconsistencies
between Etest I and II, and affected antibiotics. Proportion of isolates
where Etest I could not be read due to insufﬁcient growth
Inconsistencies∗ No growth Drugs affected
Enterobacteriaceae 1/30 1/30 co-trimoxazole
Non-fermenters 2/10 1/10 co-trimoxazole
Staphylococcus aureus 3/16 2/16 clindamycin/ampicillin
Coagulase neg. staphylococci 10/29 5/29 clindamycin/ampicillin
Enterococcus species 1/10 3/10 clindamycin
Other Gram-positive cocci 2/9 0 clindamycin/penicillin G
Corynebacterium species NA 6/6 All
*deﬁned as 2 dilutions difference between readings.
P1872 Evaluation of different Mueller-Hinton agars for disc
diffusion susceptibility testing of tigecycline, doxycycline,
minocycline and tetracycline against multi-resistant bacteria
R. Cayoˆ °, J. Calvo, C. Ferna´ndez-Mazarrasa, L. Martı´nez-Martı´nez
(Sao Paulo, BR; Santander, ES)
Objectives:We evaluated the accuracies of different commercially avail-
able Mueller-Hinton agars (MH) for susceptibility testing of tigecycline
(TGC), doxycycline (DX), minocycline (MN) and tetracycline (TE)
against multiresistant bacteria by disc diffusion method (DD).
Methods: A total of 75 clinical isolates (one per patient, clonally
unrelated as assessed by REP-PCR and/or PFGE) were evaluated: 15
A. baumannii (Ab), 15 E. faecium (Ef), 15 ESBL(+) E. coli (Ec), 15
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ESBL(+) K. pneumoniae (Kp) and 15 Methicilin-Resistant S. aureus
(MRSA). Discs of 15 mg (TG) and 30 mg (DO, MN and TE) from
Oxoid® were used. Eleven different freshly prepared MH (<24 h old)
were evaluated according to CLSI, from the following manufacturers:
Difco®, Merck®, Oxoid®, BioRad®, Remel®, Pronadisa® and Sigma®.
Iso-Sensitest (Oxoid) was also tested. Results were compared to broth
microdilution according to CLSI, using fresh MH broth (<12 h old) from
Difco. CLSI and FDA breakpoints were used for tetracyclines and TG,
respectively.
Results: For MRSA, all MH presented an overall category agreement
(CA) of 93.3–100% compared with the reference method. High
correlation was also observed for: TE for Ef, Ec and Kp (except
Merck-MH I and Iso-Sensitest, minor errors-mE=13.3% for both); TGC
for Ef (except Merck-MH I, major errors-ME=15.4%) and Ec (except
Merck-MH I and Oxoid, mE=53.3% and 13.3%, respectively). Also,
the following combinations showed CA> 90%: (Ef/Oxoid), (Kp/Remel
and Pronadisa-MH II) and (Ab/Difco-MH I) for DX; (Ef/Remel),
(Kp/Pronadisa-MH II and Merck-MH according CLSI), (Ec/all MH
except Merck-MH I) for MN; (Kp/Difco-MH I and Iso-Sensitest) for
TGC; and (Ab/Remel) for TE. Most VME were detected in Ab, with rates
>20% when testing DX (Merck-MH according CLSI, Oxoid, Sigma-
MH I and Iso-Sensitest), MN (Difco-MH I, the both MH from Merck,
Sigma-MH I and Iso-Sensitest), TE (Difco-MH I) and TGC (Sigma-
MH I). ME were detected in the following combinations: (Ef/Merck-
MH I), (Kp/Merck-MH I, Remel, Bio-Rad and Pronadisa-MH I),
(Ab/Merck-MH I, Remel and Sigma-MH II) for TGC; (Ef/Difco-MH
I, Oxoid, Remel, Bio-Red, Pronadisa-MH I and Sigma-MH II) for DX;
(Ab/Sigma-MH II) for TE and MN.
Conclusions: Our results enlarge the observation of the effect of
differences in the MH agar formulations not only for TGC, but also for
tetracyclines susceptibility. Thus, until we have more conclusive results,
caution should be exerted when testing these antimicrobial agents against
clinical isolates.
P1873 A comparative study of antibiotic gradient devices for
meropenem, ceftriaxone and clindamycin against CLSI and
BSAC reference methods
S. Reed, D. Crabtree, E. Scopes ° (Basingstoke, UK)
Objectives: The aim of this study was to compare the performance
of meropenem, ceftriaxone and clindamycin M.I.C.Evaluator™ strips
(Oxoid) and Etest™ strips (bioMe´rieux) against the CLSI and BSAC
broth /agar dilution reference methods.
Methods: A range of clinically signiﬁcant organisms were tested,
including anaerobes, staphylococci, streptococci and Enterobacteriaceae.
These were grown overnight on Columbia Blood Agar and a 0.5 (1.0 for
anaerobes and some streptococci) McFarland suspension of each isolate
was used for both the GOLD standard agar/broth dilution and plate
inoculation. Both BSAC and CLSI reference methods were followed.
All inoculated plates were incubated in appropriate conditions for 24 h
or 48 h (anaerobes). Results were read and used to determine essential
agreement (EA).
Results: Meropenem, ceftriaxone and clindamycin M.I.C.Evaluator
strips achieved an EA of >90% across all groups of organisms when
compared with both CLSI and BSAC reference methods. However, with
the organisms groups and method tested, the Etest strips demonstrated
<90% essential agreement, with 33% of meropenem, 39% ceftriaxone
and 17% clindamycin falling below this ﬁgure. See Table 1.
Conclusion: Meropenem, ceftriaxone and clindamycin M.I.C.Evaluator
strips, both BSAC and CLSI methods achieved an essential agreement of
greater than 90%. Etest strips were not able to display the same level of
essential agreement with 30% of the results falling below 90% essential
agreement.
M.I.C.Evaluator strips performed consistently and signiﬁcantly better
than Etest strips for meropenem (p = 0.029), ceftriaxone (p = 0.002) and
clindamycin (p = 0.034).
Gradient diffusion devices are a rapid, easy and reliable alternative to the
reference methods for measuring organism susceptibility to meropenem,
ceftriaxone and clindamycin.
Table 1. Essential agreement (%) for each antibiotic tested
Meropenem Ceftriaxone Clindamycin
CLSI BSAC CLSI BSAC CLSI BSAC
Enterococci M.I.C.E. 96.97 100.00
Etest 90.91 100.00
Staphylococci M.I.C.E. 93.33 100.00 93.33 96.43 100 100
Etest 90.00 100.00 86.67 78.57 94.95 98.04
Streptococci M.I.C.E. 95.24 95.24 100.00 100.00 99.22 96.38
Etest 95.24 47.62 90.48 95.24 88.33 93.36
Pseudomonas M.I.C.E. 90.48 95.12 97.78 90.48
Etest 86.06 95.12 93.33 90.48
Acinetobacter M.I.C.E. 100.00 100.00 100.00 93.75
Etest 100.00 96.77 100.00 100.00
Haemophilus M.I.C.E. 90.00 90.00 100.00 94.74
Etest 80.00 85.00 83.33 79.00
Neisseria M.I.C.E. 92.31 100.00
Etest 92.31 100.00
Moraxella M.I.C.E. 100.00 100.00 100.00 90.00
Etest 100.00 90.00 80.00 100.00
Anaerobes M.I.C.E. 93.33 95.45 90.91 100.00 96.77 95.59
Etest 93.33 81.82 86.96 86.96 94.62 90.91
Enterobacteriaceae M.I.C.E. 97.51 97.50 94.26 94.53
Etest 90.76 84.57 80.09 86.85
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P1874 Antimicrobial activity of doripenem against clinical
bacterial pathogens from Europe, 2009
D. Farrell °, G. Moet, H. Sader, S. Putnam, R. Jones (North Liberty, US)
Objectives: To evaluate the in vitro antimicrobial activity of Doripenem
(DOR) against prevalent Gram-negative and -positive pathogens isolated
in Europe (EU) during 2009. DOR is an approved carbapenem in EU
for the treatment of nosocomial pneumonia (NP), including ventilator-
associated pneumonia (VAP), complicated intra-abdominal infections
(cIAI) and complicated urinary tract infections (cUTI).
Methods: A total of 5,481 consecutive, non-duplicate isolates from
a wide variety of infections were collected from 24 medical centers
located in Europe, Turkey, and Israel during 2009. Species identiﬁcation
was conﬁrmed by the central monitoring laboratory and all isolates
were susceptibility (S) tested using reference CLSI broth microdilution
methods (M7-A8, 2009) against DOR and comparator agents.
Organism (no. of strains) Cumulative % inhibited at doripenem MIC (mg/L):
0.06 0.12 0.25 0.5 1 2 4 8 >8
Enterobacteriaceae (1,480) 83 94 98 99 99 99 99 99 100
Acinetobacter spp. (65) – 3 14 26 42 58 66 74 100
P. aeruginosa (277) 4 20 34 56 68 75 86 93 100
S. aureus (1,398) 74 77 79 83 86 89 92 96 100
MRSA (318) 1 4 10 26 41 52 65 81 100
MSSA (1,080) 95 99 99 99 100 – – – –
CoNS (454) 23 30 37 45 58 70 76 84 100
MR-CoNS (376) 10 15 24 34 49 64 72 81 100
MS-CoNS (78) 85 100 – – – – – – –
Enterococcus faecalis (357) – – – – 1 31 89 99 100
beta-haemolytic strep. (212) 100 – – – – – – – –
S. pneumoniae (485) 81 82 86 97 99 100 – – –
Results: Doripenem was very active against Enterobacteriaceae,
inhibiting 99% of isolates at 0.5mg/L (MIC 90, 0.12mg/L). DOR
had good activity against P. aeruginosa (MIC50/90, 0.5/8mg/L) and
most Acinetobacter spp., inhibiting >70% of isolates at 8mg/L
(MIC50/90 = 2/>8mg/L). Against Gram-positive pathogens, DOR had
very high activity against methicillin-susceptible S. aureus (MSSA), MS-
coagulase-negative staphylococci (CoNS), b-haemolytic streptococci,
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and S. pneumoniae with MIC90 values of 0.06, 0.12, 0.06, and
0.5mg/L, respectively. DOR was less active against MRSA and MR-
CoNS with both having an MIC50 of 2mg/L, as well as E. faecalis
(MIC50, 4mg/L). DOR was not active against the vast majority of
E. faecium (MIC50, >8mg/L, range 0.25−>8mg/L).
Conclusions: DOR exhibited a wide spectrum of antimicrobial activity
against 5,481 contemporary EU pathogens and excellent activity against
most Gram-positive pathogens except for MRSA, MR-CoNS and
Enterococci. Against Gram-negative pathogens, DOR exhibited excellent
activity against Enterobacteriaceae and good activity against many
multidrug resistant P. aeruginosa and Acinetobacter spp. This data
supports the use of DOR as therapy for hospitalized patients, in whom
carbapenem therapy would be warranted to treat serious and typically
difﬁcult-to-treat infections, such as NP, cIAI, VAP, and cUTI in Europe,
Turkey and Israel.
P1875 Ceftobiprole activity when tested against clinical bacterial
pathogens from Europe, 2009
D. Farrell °, G. Moet, H. Sader, S. Putnam, R. Jones (North Liberty, US)
Objectives: To evaluate the in vitro antimicrobial activity of ceftobiprole
(BPR) against prevalent Gram-positive and -negative pathogens isolated
in Europe (EU) during 2009. BPR is an investigational drug seeking
regulatory approval in EU for the treatment of complicated skin and
skin structure (cSSSI) infections due to methicillin-resistant (MR)
staphylococci. Ceftobiprole was also evaluated in clinical trials for the
treatment of nosocomial pneumonia (NP), including ventilator-associated
pneumonia (VAP).
Methods: A total of 5,481 consecutive, non-duplicate isolates from a
wide variety of infections were collected from 24 medical centers located
in Europe (Belgium, France, Germany, Ireland, Italy, Spain, Sweden,
Switzerland, United Kingdom), Turkey, and Israel during 2009. Species
identiﬁcation was conﬁrmed by the central monitoring laboratory and
all isolates were susceptibility (S) tested using reference CLSI broth
microdilution methods (M7-A8, 2009) against BPR.
Results: Against Gram-positive pathogens, BPR had high activity
against methicillin-susceptible (MS) SA, MS-coagulase-negative staphy-
lococci (CoNS), b-haemolytic streptococci, and S. pneumoniae with
MIC90 values of 0.5, 0.25, 0.06, and 0.5mg/L, respectively. BPR
was active against MRSA and MR-CoNS with both having a MIC90 of
2mg/L with 99% of isolates inhibited at 2 and 4mg/L, respectively. BPR
was not active against the vast majority of E. faecium (MIC50, >8mg/L,
range 0.12−>8mg/L), but was active against E. faecalis (MIC50/90,
0.5/4mg/L). Against Gram-negative pathogens, BPR was active against
the majority of Enterobacteriaceae with >80% inhibited at 0.12mg/L
(MIC90, 4mg/l), but had limited activity against Acinetobacter spp.
(MIC90, >8mg/L) and P. aeruginosa (MIC90, >8mg/L).
Organism (no. of strains) Cumulative % inhibited at ceftobiprole MIC (mg/L):
0.06 0.12 0.25 0.5 1 2 4 8 >8
S. aureus (1,398) 1 1 31 79 94 99 100 – –
MRSA (318) – – – 11 74 99 100 – –
MSSA (1,080) 1 1 40 99 100 – – – –
CoNS (454) 3 11 23 40 76 94 99 99 100
MR-CONS (376) 2 4 8 27 71 93 99 99 100
MS-CoNS (78) 8 47 94 100 – – – – –
E. faecalis (357) 1 12 32 66 73 89 97 99 100
b-haemolytic strep. (212) 99 100 – – – – – – –
S. pneumoniae (485) 78 80 84 98 100 – – – –
Enterobacteriaceae (1,480) 78 83 85 87 88 88 90 90 100
Acinetobacter spp. (65) 2 5 14 19 28 31 35 35 100
P. aeruginosa (277) – – – 3 15 45 64 78 100
Conclusions: BPR exhibited a wide spectrum of antimicrobial activity
against 5,481 contemporary EU pathogens and excellent potency against
most Gram-positive pathogens including MRSA (MIC90, 2mg/L) and
MR-CoNS (MIC90, 2mg/L). Against Gram-negative pathogens, BPR
exhibited high potency against most Enterobacteriaceae, but was much
less active against P. aeruginosa and Acinetobacter spp. This data
showing the potent activity of BPR against a broad range of key cSSSI
and NP (including some VAP) pathogens and are consistent with a
potential role of BPR in targeted therapy for hospitalized patients with
these infections in Europe, Turkey and Israel.
P1876 In vitro activity of ceftaroline tested against leading
Gram-positive and -negative European bacterial pathogens
collected in 2009
M. Castanheira, R. Jones, H. Sader ° (North Liberty, US)
Objective: To evaluate the activity of ceftaroline (CPT) against prevalent
Gram-positive and -negative pathogens isolated in Europe during 2009.
CPT is a novel, parenteral, broad-spectrum cephalosporin exhibiting
bactericidal activity against methicillin-resistant S. aureus (MRSA) and
multidrug-resistant S. pneumoniae, as well as against common Gram-
negative pathogens.
Methods: A total of 4212 consecutive, nonduplicate isolates from
bloodstream, skin and skin structure, and respiratory tract infections were
collected from 24 medical centres in Europe, Turkey, and Israel during
2009. Species identiﬁcation was conﬁrmed by the central monitoring
laboratory and all isolates were tested for susceptibility (S) to CPT and
comparator agents using reference CLSI broth microdilution methods.
Results: CPT inhibited 99.9% of S. aureus strains (22.5% were MRSA)
at 2mg/L. Only one MRSA strain (0.1% of all S. aureus strains)
from Italy had CPT MIC of 4mg/L. CPT MIC90 of MRSA strains
was 1mg/L, at least 16-fold lower than both ceftriaxone (CRO) and
cefepime (FEP). CPT activity against coagulase-negative staphylococci
(CoNS; 83.3% methicillin resistant) was similar to that against S. aureus
(99.9% of S. aureus strains had MIC 2mg/L). CPT inhibited all
tested S. pneumoniae at 0.25mg/L. Against 19 (3.9%) penicillin-resistant
pneumococci (MIC 2mg/L), CPT MIC50 and MIC90 values were 4-
to 32-fold lower than values for all other b-lactams. All b-haemolytic
streptococci (BHS) and all but one viridans group streptococci (VGS)
were inhibited at 0.25 and 0.5mg/L, respectively. CPT MIC90 values
for BHS and VGS (0.03 and 0.06mg/L, respectively) were lower than
those of penicillin, CRO, and FEP against these streptococci groups. CPT
activity against Enterobacteriaceae (MIC50 0.12mg/L) was similar to
CRO and FEP (MIC50s 0.25 and 0.12mg/L, respectively). Extended-
spectrum b-lactamase (ESBL) phenotype was observed in 12.2% of
E. coli and 20.0% of Klebsiella spp., and all cephalosporins tested
showed limited activity against ESBL-producing strains. H. inﬂuenzae
strains were highly S to CPT (MIC90, 0.015mg/L).
Conclusions: CPT demonstrated enhanced activity against European
staphylococci, including MRSA, different streptococcal groups, and
H. inﬂuenzae. CPT also demonstrated activity against Enterobacteriaceae
that is similar to currently available broad-spectrum cephalosporins.
Organism (no. tested) Cumulative % at CPT MIC (mg/L) MIC (mg/L)
0.25 0.5 1 2 4 50% 90%
S. aureus (1200) 69.0 86.4 97.1 99.9 100.0 0.25 1
MRSA (270) 2.9 40.0 87.4 99.6 100.0 1 2
CoNS (432) 54.6 84.9 92.8 99.0 100.0 0.25 1
S. pneumoniaea (485) 100.0 – – – – 0.008 0.12
BHS (195) 100.0 – – – – 0.008 0.03
VGS (80) 97.5 98.7 98.7 98.7 98.7 0.03 0.06
E. faecalis (357) – 2.2 28.3 65.8 72.5 2 8
E. coli (788) 75.2 81.7 85.6 87.8 89.0 0.12 16
Klebsiella spp. (294) 69.7 75.1 78.6 80.3 81.3 0.12 >32
Enterobacter spp. (146) 52.7 60.3 63.7 68.5 69.9 0.25 >32
H. inﬂuenzae (235) 100.0 – – – – 0.008 0.015
aIncludes 19 (3.9%) penicillin-resistant strains (MIC 2mg/L).
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P1877 Activity of ceftaroline against recent (2009) and
multidrug-resistant Streptococcus pneumoniae isolates from
Europe and the United States
D. Farrell °, G. Moet, P. Rhomberg, H. Sader, R. Jones (North Liberty,
US)
Objective: To determine the activity of ceftaroline against recent (2009)
S. pneumoniae (SPN) and multidrug-resistant (MDR) SPN isolated in
Europe (EU) and the United States (USA). Antimicrobial resistance
in SPN and MDR-SPN are increasing globally and rapidly in some
countries, including the USA. Ceftaroline is a novel, parenteral, broad-
spectrum cephalosporin exhibiting bactericidal activity against Gram-
positive organisms including SPN and MDR-SPN and is currently in
late stage clinical development.
Methods: Susceptibility testing for ceftaroline and commonly used
antimicrobials was performed by CLSI broth microdilution methods on
a total of 987 isolates from the 2009 Ceftaroline Surveillance Program.
MDR-SPN status was determined by resistance to 2 or more classes of
antimicrobials.
Results: Ceftaroline MIC50, MIC90, and MIC range (all mg/L) against
all isolates and resistance phenotypes are listed in the Table. Ceftaroline
was very active against all isolates, with MIC50 and MIC90 of
0.008 and 0.12mg/L. MIC50 and MIC90 were slightly higher in
drug-resistant SPN and MDR-SPN than in non-MDR-SPN isolates.
The highest ceftaroline MIC found was 0.5mg/L. MIC90 was 1 log2
dilution higher in USA isolates than in EU isolates due to the higher
prevalence of MDR-SPN in the USA (21.5% vs. 14.2% in EU).
Ceftaroline was very active against isolates resistant to the commonly
used antimicrobials penicillin, ceftriaxone, erythromycin, levoﬂoxacin,
trimethoprim/sulphamethoxazole (T/S), and tetracycline.
Conclusions: Antimicrobial resistance in SP and MDR-SPN continues
to escalate each year, highlighting the need for new antimicrobials.
This study demonstrated the potent in vitro activity of ceftaroline
against recent (2009) SPN isolates, regardless of MDR status, resistance
phenotype, or geographic location (EU or USA). These data suggest that
ceftaroline may emerge as an important therapy for infections caused by
SPN resistant to b-lactams and other commonly used antimicrobials as
well as MDR strains.
n MIC50 MIC90 Range
All isolates 987 0.008 0.12 0.008−0.5
All Europe 485 0.008 0.12 0.008−0.5
All USA 502 0.015 0.25 0.008−0.5
MDRSP 177 0.12 0.25 0.008−0.5
Penicillin 4mg/L 109 0.25 0.25 0.06−0.5
Ceftriaxone 2mg/L 105 0.25 0.25 0.06−0.5
Erythromycin 2mg/L 344 0.12 0.25 0.008−0.5
Levoﬂoxacin 4mg/L 11 0.06 0.25 0.008–0.25
T/S 4mg/L 218 0.12 0.25 0.008−0.5
Tetracycline 8mg/L 242 0.12 0.25 0.008−0.5
P1878 Oritavancin activity against Gram-positive pathogens
isolated from United States and European medical centres,
2008–2009
R. Mendes, R. Jones °, H. Sader (North Liberty, US)
Objectives: To evaluate the antimicrobial susceptibility (S) of Gram-
positive (GP) organisms collected from United States (USA) and
European (EU) medical centres. The International Oritavancin (ORI)
Surveillance Program was initiated in 2008 as part of the SENTRY
Antimicrobial Surveillance Program to monitor the activity of ORI and
various comparators in the USA and EU. We report the results obtained
by this program during the 2008–2009 period.
Methods: GP isolates (11,853) were consecutively collected from 55
hospitals in the USA (61.0%) and 13 EU member states. Isolates were
submitted to a central laboratory where bacterial identiﬁcations were
conﬁrmed using standard algorithms and Vitek 2. Isolates were tested
for S against ORI and comparators by CLSI methods (M07-A8, 2009).
CLSI (M100-S19, 2009) and EUCAST (2009) interpretative criteria were
applied, when available.
Results: Infection sites included: blood (bacteremia; 43%), skin and
skin structure (26%) and lower respiratory tract (19%). ORI (MIC90,
0.06mg/L) was 8-fold more potent than daptomycin (DAP; MIC90,
0.5mg/L) and 16 to 32-fold more active than vancomycin (VAN;
MIC90, 1−2mg/L) or linezolid (LZD; MIC90, 1−2mg/L) against
staphylococci. Clindamycin (MIC90, >2mg/L; 54.0–81.3% S) and
levoﬂoxacin (LEV; MIC90, >4mg/L; 25.8–61.9% S) exhibited limited
activity against staphylococci. While tetracycline (90.0% S) and
trimethoprim/sulfamethoxazole (98.6% S) showed generally higher S
rates against S. aureus, sub-optimal activity was noted against coagulase-
negative staphylococci (51.9–86.4% S). ORI tested against E. faecalis
(0.03mg/L; 4.2% VAN resistant [R]) displayed an MIC90 value 2-fold
lower when compared to E. faecium (0.06mg/L; 60.5% VAN R). Among
the comparators, only DAP and LZD were active against all enterococci
(MIC90, 2mg/L; 99.3% S), whereas E. faecalis were also S to
ampicillin (MIC90, 2mg/L; 99.8% S). ORI (MIC90, 0.008mg/L)
was 128-fold more active than VAN (MIC90, 1mg/L), LZD (MIC90,
1mg/L), LEV (MIC90, 1mg/L) and ceftriaxone (MIC90, 1mg/L) against
S. pneumoniae. The activity of ORI (MIC90, 0.12mg/L) was comparable
to that of penicillin (MIC90, 0.06mg/L; 100.0% S) against b-haemolytic
streptococci.
Conclusions: Based on MIC90 values, ORI demonstrated potent in vitro
activity against this contemporary collection of GP pathogens. In
addition, the ORI activity was not adversely affected by resistance to
other currently-marketed antimicrobials agents.
MIC (mg/L)
Oritavancin Vancomycin Daptomycin Linezolid
Organism (No. tested) 90% 90% %Sa %Sb 90% %Sa %Sb 90% %Sa %Sb
S. aureus (6,731) 0.06 1 100.0 100.0 0.5 99.9 99.9 2 >99.9 >99.9
MRSA (3,020) 0.06 1 100.0 100.0 0.5 99.8 99.8 2 99.9 99.9
CoNS (1,082) 0.06 2 100.0 99.3 0.5 99.6 99.6 1 98.9 98.9
MRCoNS (792) 0.06 2 100.0 99.1 0.5 99.7 99.7 1 98.6 98.6
E. faecium (669) 0.06 >16 39.0 39.0 2 99.4 – 2 99.3 99.3
E. faecalis (1,178) 0.03 2 95.6 95.6 2 100.0 – 2 100.0 100.0
SPN (1,198) 0.008 1 100.0 100.0 – – – 1 100.0 100.0
BHS (526) 0.12 0.5 100.0 100.0 0.25 100.0 100.0 1 100.0 100.0
VGS (199) 0.03 0.5 100.0 100.0 0.5 99.5 99.5 1 100.0 100.0
aCLSI and bEUCAST interpretation criteria, if available.
MRSA=methicillin-resistant S. aureus; CoNS= coagulase-negative staphylococci; MRCoNS=methicillin-resistant
CoNS; SPN= S. pneumoniae; BHS= beta-haemolytic streptococci; VGS= viridans group streptococci; – = not
available.
P1879 Spectrum of activity of oritavancin and comparison
agents tested against contemporary Staphylococcus aureus
collected in European hospitals
R. Mendes, H. Sader, R. Jones ° (North Liberty, US)
Objectives: To assess the spectrum of activity and potency of oritavancin
(ORI) and comparators tested against S. aureus (SA) recovered
from hospitalized patients in Europe (EU) during the 2008–2009
International ORI Surveillance Program, as part of the SENTRY An-
timicrobial Surveillance Program. This analysis includes categorization
of methicillin-resistant SA (MRSA) based on antimicrobial resistance
(R) patterns.
Methods: 3,788 consecutive, non-duplicate SA were collected from
medical centers located in 13 EU countries. Isolates were submitted to
a central monitoring laboratory and species identiﬁcation performed by
Gram stain, biochemical tests and Vitek 2, when needed. Susceptibility
(S) testing was performed using CLSI methods (M07-A8, 2009).
Regional interpretive criteria (EUCAST, 2009) were applied, when
available. ORI activity was also evaluated according to R patterns.
MRSA displaying R phenotypes to at least four classes of drugs were
considered as multidrug-resistant (MDR).
Results: The majority of isolates were from bacteremia (39.9%) and
skin and skin structure infections (35.8%). The overall MRSA rate was
25.6% and highest in Greece (59.5%), followed by Poland (40.9%),
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Belgium (38.5%), Ireland (36.0%) and the United Kingdom (30.6%).
MRSA rates in other EU countries were <30.0%. Among MRSA, 30 R
patterns were noted and MDR strains comprised 39.3%. SA were very
S to vancomycin (VAN; 100.0%), daptomycin (DAP; 100.0%), linezolid
(LZD; 100.0%), teicoplanin (99.3%) and trimethoprim/sulfamethoxazole
(99.2%). Levoﬂoxacin, erythromycin and clindamycin (71.7–87.9% S)
showed suboptimal activity. ORI (MIC50/90, 0.03/0.06mg/L) was eight-
fold more potent than DAP (MIC50/90, 0.25/0.5mg/L) and 16 to 32-
fold more active than VAN (MIC50/90, 1/1mg/L) and LZD (MIC50/90,
2/2mg/L). ORI exhibited stable and potent activity (based on MIC50/90
results) against SA, regardless of MRSA categorization, sampling year,
country of origin and R patterns, including a MDR phenotype (see
Table).
Conclusions: ORI demonstrated consistent and potent in vitro activity
against this contemporary collection of EU SA strains. The ORI
MIC50/90 values did not vary when tested against SA from different
countries, sampling years or R phenotype. In addition, ORI was at
least eight-fold more potent than comparators. Continued longitudinal
surveillance of new and currently marketed agents against this important
clinical pathogen is a prudent practice to monitor for emergence of R.
Organisma (no. tested) MIC (mg/L) Number (cumulative %) inhibited at oritavancin MIC (mg/L) of:
50% 90% 0.015 0.03 0.06 0.12 0.25 0.5
S. aureus (3,788) 0.03 0.06 972 (25.7) 2019 (79.0) 704 (97.5) 86 (99.8) 6 (>99.9) 1 (100.0)
MSSA (2,816) 0.03 0.06 748 (26.6) 1493 (79.6) 511 (97.7) 59 (99.8) 5 (100.0) –
MRSA (972) 0.03 0.06 224 (23.1) 526 (77.2) 193 (97.0) 27 (99.8) 1 (99.9) 1 (100.0)
Resistance patternb
OX, LE, CL, ER (254) 0.03 0.06 54 (21.3) 131 (72.8) 59 (96.1) 9 (99.6) 0 (99.6) 1 (100.0)
OX, LE, ER (236) 0.03 0.06 54 (22.9) 135 (80.1) 44 (98.7) 3 (100.0) – –
OX, LE (201) 0.03 0.06 46 (22.9) 109 (77.1) 38 (96.0) 8 (100.0) – –
OX, LE, CL, ER, TC (81) 0.03 0.06 26 (32.1) 46 (88.9) 5 (95.1) 3 (98.8) 1 (100.0) –
OX (51) 0.03 0.06 12 (23.5) 25 (72.5) 13 (98.0) 1 (100.0) – –
MDR (382) 0.03 0.06 87 (22.8) 205 (76.4) 76 (96.3) 12 (99.5) 1 (99.7) 1 (100.0)
aMSSA=methicillin-susceptible SA; MRSA=methicillin-resistant SA.
bMost prevalent R patterns noted among MRSA. Intermediate and R results grouped as R. Criteria for susceptibility were those published
by EUCAST (2009). OX= oxacillin, ER= erythromycin, CL= clindamycin, LE = levoﬂoxacin and TC= tetracycline. MDR=R to at least four
classes of drugs. Non-S results for vancomycin, daptomycin or linezolid were not observed.
P1880 Antibiotic senstivity of urinary tract isolates from
outpatients in the Sirte region, Libya, 2005–2008
S. Abddulsalam Bagar °, B. Abdallah, M. Tayar (Sirte, LY)
Objectives: To document the incidence of resistance against commonly
used antimicrobials in uropathogens isolated from outpatients in Sirte,
Libya.
Methods: Six thousand nine hundred and thirty-one consecutive urine
samples were collected from patients with symptoms suggestive of
urinary tract infections at the New Central Polyclinic in Sirte, Libya
from 2005 to 2008. Samples were cultured on MacConkey Agar with
crystal violet and pure isolates with colony counts of 104 or above
were identiﬁed and tested for antimicrobial resistance by the Kirby-Bauer
method.
Results: One thousand six hundred and ninety-nine cultures were
positive. Escherichia coli was isolated from 1265 female and 301 male
patients, Klebsiella spp. was isolated from 81 female and 18 male
patients, Pseudomonas aeruginosa was isolated from 16 female and 9
male patients and Proteus spp. was isolated from 7 female and 2 male
patients. In E. coli, the highest resistance rates (20 to 70%) were seen
against Ampicillin, Co-trimoxazole, Doxycycline, Chloramphenicol,
and Nalidixic acid, with little difference across age and sex groups.
Resistance rates against 1st generation cephalosporins, Gentamicin and
Nitrofurantoin were 7–8% among infants but increased to around 20%
with age and there was little difference between the sexes. Resistance
against Amoxycillin–clavulanate and Amikacin was absent among
infants but rose with age to reach levels of 13% and 14% respectively
in men above the age of 50 years. Resistance to Ciproﬂoxacin was
absent among infants and increased with age up to 5%. Only 25% of
E. coli isolates were simultaneously sensitive to the older antimicrobials
(Ampicillin, Co-trimoxazole, Doxycycline, Chloramphenicol, Nalidixic
acid, 1st generation cephalosporins, Gentamicin and Nitrofurantoin) but
no isolate was simultaneously resistant to all of them.
Conclusion: Given the high rates of resistance to commonly used
antimicrobials such as Ampicillin, Co-trimoxazole, Doxycycline, Chlo-
ramphenicol, Nalidixic acid, and even 1st generation cephalosporins and
Gentamicin, one cannot recommend their use for severely ill patients
without a sensitivity test report. Among the orally active antimicrobials,
Nitrofurantoin remains a fair choice for lower urinary tract infections
in an outpatient setting without sensitivity testing. Ciproﬂoxacin showed
even lower resistance rates but its use should be restricted to preserve
the general utility of all ﬂuoroquinolones.
Point of care testing
P1881 Simple and rapid high-throughput test for high-sensitivity
antigen detection of swine inﬂuenza virus
J.O. Koskinen °, T. Vuorinen, A.E. Soini (Turku, FI)
Objective: Few options are available for prompt high-throughput
diagnostic testing in pandemic respiratory infection outbreaks. The use
of conventional rapid tests is limited by their testing capacity and
compromised sensitivity. The use of centralized testing is limited by
the total price of the testing, the long time-to-result, and by the capacity
of the specialized laboratories.
A novel methodology for rapid testing of pandemic inﬂuenza viruses is
based on separation-free ArcDia TPX assay technique and dried reagents.
Nasopharyngeal swab sample is combined with sample buffer, the tube
is vortexed, and 20 ml of the sample is dispensed into an assay well. The
well is sealed for incubation and automated kinetic measurement by the
ﬂuorometer. The test can be operated in batch-mode (up to 1000 tests a
day) or in random-access mode.
The objective of this study was to evaluate the performance of the new
test for the detection of inactivated standard strains of swine (H1N1) and
avian (H5N1) inﬂuenza A viruses.
Methods: The new test was compared to a commercial state-of-the-
art lateral ﬂow test and to a highly sensitive central laboratory antigen
detection test (time-resolved ﬂuorometry, TR-FIA) by analysis of sample
dilution series. It is well recognized that the TR-FIA technique is superior
in sensitivity to standard colorimetric ELISA. Hemagglutinin titre of the
swine inﬂuenza virus stock was 32.
Results: The new test returned positive all swine inﬂuenza virus samples
equal or stronger than the dilution 1:1620 (from the original stock) at
the 30 minute time point. At the 2 hours time point, all samples equal or
stronger than the dilution 1:14580 returned positive (Figure). The lateral
ﬂow test returned positive samples equal or stronger than the dilution
1:540, which still gave visible but very faint line. The TR-FIA test
returned positive all samples equal or stronger than the dilution 1:4860.
Conclusions: The analytical sensitivity of the new test for both viruses
was 10−20 times better compared to the lateral ﬂow test and 2−3
times better compared to the laboratory immunoassay test. The new
test can report strong and medium positive samples in 15−30 minutes.
Low positive and negative samples are reported in 2 hours. The new
methodology would be well suited for rapid screening of pandemic
respiratory infections, both in specialized virological laboratories and
in health-care units to enable prompt laboratory testing and high sample
through-put.
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P1882 Relative lymphopenia is not useful in selecting patients for
testing for inﬂuenza A virus H1N1
K.J. O’Connell °, S. Bergin, B. Hanahoe, C. Faherty, M. Cormican
(Galway, IE)
Objectives: A recent publication by Dr. Cunha and colleagues suggested
that relative lymphopenia appears to be a marker to identify those
patients likely to have H1N1 and thus to merit selection of patients
for RT-PCR testing. To determine if there is an evidence base for this
suggestion we retrospectively analysed complete blood count results on
all patients presenting to our emergency department who were tested
for Inﬂuenza A virus (H1N1) using real time reverse transcriptase
polymerase chain reaction (rtRT-PCR).
Methods: Between July 1st and 31st October 2009, 263 patients
presenting to our hospital emergency department were tested for
Inﬂuenza A virus by rtRT-PCR. Complete blood count results were
available for 205 patients (111/125 adults and 94/138 children).
Results: Patients ranged in age from less than one year to 88 years and
comprised 51% males and 49% females. Relative lymphopenia (21%)
was present in 27/33 adults who tested positive for H1N1 and in 60/78
adults who tested negative. (82% vs 78% respectively). In children,
relative lymphopenia was observed in 20/34 (59%) of those who tested
positive compared with 36/60 (60%) who tested negative.
Conclusions: Our data indicates that a recent suggestion that relative
lymphopenia can be used to prioritise patients for testing for H1N1
is not supported by evidence. Relative lymphopenia may be a non-
speciﬁc feature associated with acute viral respiratory tract infection
and should not be used in prioritizing patients for testing for inﬂuenza
virus infection.
P1883 Identiﬁcation and characterization of blood-derived
pathogens within a few hours enabled by DNA microarray
assay automation and integration
H. Wiesinger-Mayr °, S. Schoenthaler, J.R. Peham, I. Barisic,
C. Noehammer (Seibersdorf, AT)
Objectives: We present a rapid method for identiﬁcation and character-
ization of pathogens from different infectious diseases, by combining
PCR ampliﬁcation with microarray detection both integrated in one
analytical platform.
Methods: For identiﬁcation microbial DNA ampliﬁcation and labelling
is carried out using universal primers targeting 16S and ITS rRNA. The
microbial panel for oligonucleotide microarray detection, applying 20-
to 30mer probes, was extended for the identiﬁcation of 70 pathogens
relevant for different infectious diseases with pathogen occurrence
in blood. Antibiotic resistance patterns of Gram positive and Gram
negative species are determined by multiplex PCR and labelling prior
to chip hybridisation. Result readout is related to the method used in
identiﬁcation testing.
Results: As expected from sequence similarity of the 16S and ITS target
genes, members of the Enterobacteriaceae family are too conserved for
accurate species identiﬁcation based on single species speciﬁc DNA
probes. However, typical hybridisation patterns of each species could
be successfully employed for accurate discrimination. The combination
of rank normalisation and nearest-centroid method enabled a correct
determination of 100% of the bacteria at genus level and 98.7%
at species level. After thorough assay optimization (DNA isolation,
PCR ampliﬁcation, PCR target labelling) we succeeded to identify 10
E. coli cells per mL whole blood. Further probes for the detection of
fastidious and intracellular pathogens have been introduced. Validation
of microarray-based antibiotic resistance testing using clinical isolates
showed good agreements with conventional identiﬁcation methods.
For Gram positive species twelve different antibiotic resistance genes
are analysed using the conventional multiplex-PCR and microarray
hybridization setup. For the simultaneous detection of b-lactamases in
Gram negative species and identiﬁcation of different ESBL types an
on-chip PCR approach has been chosen.
Conclusion: Relying on our promising results from pathogen microar-
rays we currently develop a Lab-on-a-Chip (LOC) device aiming to
miniaturize and accelerate the diagnostic assay further. Thus different
approaches have been tested for efﬁcient DNA ampliﬁcation followed
by DNA labelling and detection. A software for automated pathogen
classiﬁcation including above mentioned statistical analysis has been
developed and successfully applied.
P1884 A simple blood culture bacterial pellet preparation for
accurate direct bacterial identiﬁcation and antibiotic
susceptibility testing with the Vitek 2 system
G. Prod’hom °, C. Durussel, J. Bille, G. Greub (Lausanne, CH)
Objectives: Blood cultures are the best approach to establish the
etiology of bloodstream infections. Rapid identiﬁcation and antimicrobial
susceptibility tests (AST) are pivotal to guide antibiotic treatment. This
may be accurately done using the Vitek 2 system inoculated with
subcultures. However, direct testing of bacterial pellets from positive
blood cultures do not provide consistent results. Thus, we developed a
speciﬁc procedure to prepare pellets from positive blood culture that
may be directly used to identify both Gram-positive and Gram-negative
bacteria with Vitek cards.
Methods: Pellets from positive blood culture vials (Bactec 9240) were
treated with ammonium chloride lysing solution and centrifuged. GN
and GP Vitek cards were used for the identiﬁcation of Gram-positive
cocci and Gram-negative rods, respectively. The AST-P586 and AST-
GN26 Vitek cards were used for AST of staphylococci and Gram-
negative rods, respectively. Identiﬁcation and AST were repeated using
subcultures (gold standard). Identiﬁcation was classiﬁed as correct, low-
level of discrimination, misidentiﬁcation, and non-identiﬁcation. For
AST, discordance results were classiﬁed as: very major error when the
result of direct method was susceptible and that of the reference method
was resistant; a major error was the opposite (resistant vs susceptible).
All other errors were minor errors.
Results: Among a total of 122 blood cultures, 90 (74%) gave correct
identiﬁcation by Vitek direct inoculation. Among 38 Gram-negative rods,
36 (95%) were correct and 2 (5%) gave low discrimination. Among 84
Gram-positive cocci, 54 (64%) gave a correct identiﬁcation. The number
of low discrimination, misidentiﬁcation and non-identiﬁcation were 6
(7.1%), 19 (22.6%)(12/19 S. intermedius), and 5 (5.9%), respectively.
AST results were analysed for 86 isolates with congruent identiﬁcation.
For 34 Gram-negative rods, the overall categorical agreement was
96.9%. The number of very major, major, minor was 1 (0.15%), 5
(0.7%), 15 (2.2%), respectively. 8/21 errors occurred with one isolate
(K. pneumoniae). For 52 staphylococci, the overall categorical agreement
was 97%. The number of very major, major, minor was 0 (0%), 2 (0.2%),
27 (2.7%), respectively.
Conclusion: Bacterial pellets from positive blood cultures prepared with
an ammonium chloride-driven hemolysis allow direct inoculation of
Vitek cards used for identiﬁcation and antimicrobial susceptibility testing
with relatively good accuracy.
P1885 Evaluation of the Legionella V-Test for detection of
Legionella pneumophila antigen in urine samples
J.P. Bruin, M.F. Peeters, E. Ijzerman, B.M. Diederen ° (Haarlem,
Tilburg, NL)
Introduction: We evaluated a new immunochromatographic assay
(Legionella V-TesT, Coris BioConcept, Gembloux, Belgium) for its
ability to detect Legionella pneumophila serogroup 1 antigen in urine.
Test devices were read at various time points to determine the optimum
incubation time in relation to performance. The results were compared
with those obtained by the BinaxNOW urinary antigen test (Binax, INC.,
Scarborough, USA).
Materials and Methods: The Legionella V-TesT was evaluated against
the BinaxNOW urinary antigen test using frozen urine samples. Urine
samples were collected by the Laboratory for Medical Microbiology and
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Immunology, St. Elisabeth Hospital, Tilburg and the Regional Laboratory
of Public Health, Haarlem, The Netherlands between 1999 and 2009 and
stored at −70ºC until processing was performed. A case of conﬁrmed
Legionella pneumonia was deﬁned according to the European Working
Group on Legionella Infections (EWGLI) criteria. Urine samples from
patients with respiratory tract infections other than Legionella infections
were tested in a similar manner to test the speciﬁcity of the assays.
Only one sample per patient was included. All Legionella positive and
negative urine samples were read at 15, 30, 45 and 60 minutes.
Results: A total of 189 samples were tested. Four samples yielded
nonvalid results in the Legionella V-TesT; these samples were not
included in the calculations. Sensitivity and speciﬁcity were estimated
as, respectively, 82% (97/118; 95% conﬁdence interval [CI], 74 to 88%)
and 99% (1/71; 95%CI, 91 to 100%) for the Legionella V-TesT test
and 84% (99/118; 95%CI, 76 to 90%) and 100% (0/71; 95%CI, 94 to
100%) for the BinaxNOW urinary antigen test after 15 min of incubation
(table 1). The sensitivities of the Legionella V-TesT and BinaxNOW tests
increased to 91% (108/118; 95%CI, 85 to 95%) and 91% (108/118;
95%CI, 85 to 95%), respectively, when the tests were examined after 60
min of incubation.
Conclusion: The Legionella V-TesT has a performance comparable to
that of the BinaxNOW test and could be a good alternative for the
detection of L. pneumophila antigen in urine from patients suspected of
having Legionnaires’ disease.
Table 1. Results of BinaxNOW and Legionella V-TesT after 15min and
1 h of incubation
Test and incubation time (min) % Sensitivity % Speciﬁcity
V-TesT
15 82 (97/118)# 99 (1/71)
60 91 (108/118) 99 (1/71)
BinaxNOW
15 84 (99/118) 100 (0/71)
60 91 (108/118) 99 (1/(71)
#The values in parentheses are the number of samples positive/total.
P1886 Alarmingly poor performance in Chlamydia trachomatis
point-of-care testing
L. van Dommelen °, F.H. van Tiel, S. Ouburg, E.E. Brouwers,
P.H. Terporten, P. Savelkoul, S.A. Morre´, C.A. Bruggeman, C.J. Hoebe
(Maastricht, Amsterdam, Geleen, NL)
Objectives: Infection by Chlamydia trachomatis (CT) is the most
prevalent sexually transmitted disease (STD) worldwide. The most
frequently used diagnostic test for CT is a nucleic acid ampliﬁcation
test (NAAT), which is highly sensitive and speciﬁc. To further shorten
time delay until diagnosis has been made, in order to prevent CT spread,
the use of point of care (POC) tests could be the way forward. Three
POC tests, Handilab-C, Biorapid CHLAMYDIA Ag test and QuickVue
Chlamydia test, were evaluated regarding diagnostic performance in
comparison with NAAT.
Methods: All women, above the age of 16 years old, consulting at an
STD clinic between September 2007 and April 2008, were asked to
participate. Women were asked to complete a short questionnaire and
to collect 6 self-taken vaginal swabs (SVS). SVS 2 was used for NAAT
and SVS 3 to 5 were randomized for the different POC tests. SVS
1 and 6 were used for determining quantitative CT load to validate
the use of successively SVS. All POC tests were performed without
knowledge of NAAT results. NAAT was used as the ‘gold standard’
for sensitivity. During the consultation, demographic data were collected
and, if indicated, samples were collected for other STD diagnostics. A
questionnaire was handed out to add more speciﬁc questions concerning
CT testing methods.
Results: 772 women were included. The median age of ﬁrst sexual
contact was 16 (range 6−36 years). The median lifetime number of sexual
partners was 9 and almost half of these contacts were considered as
unsafe sexual contact. During the last six months, the median number
of newly acquired sexual partners was 3. CT prevalence was 11% in
our population. Sensitivities of the Biorapid CHLAMYDIA Ag test,
QuickVue Chlamydia and Handilab-C test were 17%, 27% and 12%
respectively.
Conclusions: Our results show poorer laboratory performance of the
different POC tests than has previously been described and underline the
need for good quality assurance of POC tests, especially in view of the
Internet era. Although excellent guidelines on CT POC test evaluation
exist, these guidelines are regularly ignored, and thus tighter regulations
are urgently needed to prevent unrestrained marketing. In our opinion,
the CT POC tests evaluated in our study are not ready for widespread
use.
P1887 Evaluation of the Immunocard Stat!® Campy for detection
of Campylobacter: a routine laboratory perspective
A. Dediste °, P. Retore, L. Vlaes, O. Vandenberg (Brussels, BE)
Objectives: To evaluate the use of the new commercialised Immunochro-
matographic Rapid Test IMMUNOCARD STAT!® CAMPY (Meridian
BioScience, USA) allowing a 20 minutes qualitative detection of both
Campylobacter antigen directly in human stool specimens.
Methods: During four months, all stool samples specimens, from non-
hospitalized children and HIV-infected patients (adults and children)
submitted to our laboratory were evaluated with IMMUNOCARD
STAT!® CAMPY. Results were compared with those obtained by routine
culture methods using both a speciﬁc medium and a ﬁltration method
for the recovery of Campylobacter species.
Results: Of the 500 stool specimens cultured, 35 were found positive
for either C. jejuni or C. coli, giving an overall recovery rate of 7.0%.
24 samples were positive by both culture and Meridian Assay and
11 were positive by culture only, giving a sensitivity of 68.6%. In
addition, of 465 samples negative by culture, 7 were initially positive
by IMMUNOCARD STAT!® CAMPY. We found no cross-reaction with
other bacterial enteropathogens isolated in stool specimens. These results
conﬁrm thus a high speciﬁcity (98.5%) for both C. jejuni or C. coli. The
positive and negative predictive values found were 77.4% and 97.7%
respectively.
Conclusion: These data suggest that IMMUNOCARD STAT!® CAMPY
is a rapid and easy-to-use test for the detection of both C. jejuni and
C. coli in stool specimens. It could be used for patients for which early
antibiotic therapy is needed or for epidemiological studies.
P1888 Usefulness of procalcitonin for early diagnosis and
therapeutic monitoring of non-bacterial sepsis, bacterial
sepsis, and severe sepsis or septic shock compared with
other inﬂammatory markers
S.Y. Lee °, J. Lee, Y.J. Park, K. Han, S.H. Oh, S.P. Choi (Seoul, KR)
Objectives: Procalcitonin is useful to asscess the severity of bacterial
infection. In this study, we evaluated the diagnostic value of procalcitonin
in nonbacterial sepsis, bacterial sepsis, and severe sepsis or septic
shock, compared with C-reactive protein (CRP), erythrocyte sediment
rate (ESR), white blood cell (WBC), and neutrophil. The usefulness
of procalcitonin for antibiotic therapeutic guideline and monitoring was
also evaluated.
Methods: 146 Patients (50 clinical nonbacterial sepsis, 80 identiﬁed
(44) and clinical (36) bacterial sepsis and 16 severe sepsis or septic
shock) admitted to the emergency room of St. Mary’s hospital from
May 2009 to August 2009, were recruited into the study. Procalcitonin
(Elecsys® BRAHMS PCT), CRP, ESR, WBC, and neutrophil levels
were estimated prior to commencement on antibiotics. For 29 patients of
them, procalcitonin, interleukin (IL)-6 (Roche Diagnostics), CRP, WBC,
neutrophil, and absolute count/% of immature granulocytes (IGs) were
monitored at least three times on days 0, 0.5, 1, 2, 3, 4.
Results: Initial serum procalcitonin level was signiﬁcantly higher in
patients with bacterial sepsis (median 0.213 ng/mL) including severe
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sepsis and septic shock (median 7.120 ng/mL) than nonbacterial
sepsis (median 0.094 ng/mL) (respectively, P = 0.0405 and 0.0201). Of
other inﬂammatory markers, CRP, WBC and neutrophil count showed
signiﬁcant difference between nonbacterial sepsis and bacterial sepsis
and CRP also did between nonbacterial sepsis and severe sepsis or septic
shock (respectively, <0.05). The areas under the curve of procalcitonin
for differentiating bacterial infection and severe sepsis or septic shock
were 0.70 and 0.93 (sensitivity 64.2%, speciﬁcity 67.9%, optimum
cutoff 0.159 ng/mL and sensitivity 81.3%, speciﬁcity 86.3%, optimum
cutoff 0.921 ng/mL, respectively). It revealed the best performance for
differentiating severe sepsis or septic shock and was only comparable
to neutrophil count for diagnosing bacterial infection. The procalcitonin
was best inﬂammatory marker for antibiotic therapeutic monitoring and
should be monitored after 3 days from admitted day in this study.
Conclusion: Procalcitonin was the most useful marker for severity
asscessment of bacterial infection and antibiotic therapy may be applied
to patients when their prcocalcitonin concentration is higher than
0.159 ng/mL.In addition, serial procalcitonin measurement offered the
information about bacterial infection control.
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P1889 EpiSouth: a new voice in communicable disease
epidemiology in the Mediterranean and Balkans
F. Riccardo °, V. Alfonsi, M. Fabiani, M.G. Dente, S. Declich for the
EpiSouth Network
Objective: A country’s response to a major outbreak and its capacity
to limit the spread of disease across international borders are dependant
on the international exchange of information and expertise. Although
countries bordering the Mediterranean Sea share concerns in the ﬁeld of
communicable disease epidemiology (CDE), they spread across different
continents, 3 WHO regions, and are only partially covered by European
networks for infectious disease surveillance and control. Local political
tensions and conﬂicts further limit cooperation in the ﬁeld of public
health (PH). The EpiSouth project aims to create a solid information
sharing network among these countries.
Methods: The EpiSouth project started among 5 EU countries: Italy,
Spain, France, Greece and Bulgaria. Today it includes 26 countries
embracing Southern Europe, the Balkans, North Africa and the Middle-
East, and a roster of international organizations (EU, ECDC, and WHO)
(Figure 1). In the past three years, through its dedicated web-based
platform, this peer-to-peer network of epidemiologists studied several
aspects of CDE, including vaccine-preventable disease and emerging
zoonosis, developed a cross-border epidemic intelligence platform,
directories of PH institutions and veterinary/human PH ofﬁcers, and
established a CDE training programme. All the project outputs are freely
available on the web (www.episouth.org). EpiSouth produces two regular
bulletins and thematic notes on regionally relevant CD issues including
Inﬂuenza A H1N1.
Results: As of the 3rd of November 2009, recipients from 59 different
countries (Europe 64%, Balkans 20%, North Africa 4%, Middle East
7% and Other 5%) had subscribed to the EpiSouth Bulletin, with a 41%
increase in number since the ﬁrst issue, released in September 2007. 13%
of recipients come from countries not included in the EpiSouth region,
denoting a growing interest in the network also from other countries.
Access to the public website increased dramatically during the past three
years, with 15,664 different users counted in September 2009.
Conclusions: With its extended geographical reach, highly committed
participants and it’s accessibility, Episouth has become a leading voice
on the epidemiology of CD in the Balkans and Mediterranean Basin.
It created cohesion and concrete collaboration among 26 countries
with common PH problems and is now an internet resource providing
information to hundreds of users inside and outside the EpiSouth region.
P1890 Experiences with a new computer-based system
for automated monitoring and surveillance of
healthcare-acquired infections in intensive care
W. Koller °, A. Blacky, H. Mandl, K.P. Adlassnig (Vienna, AT)
Objectives: To compare infection alerts and healthcare-acquired
infection (HCAI) surveillance results generated by the computer-based
system MONI/Surveillance-ICU with the ones generated in parallel
by trained infection control staff. MONI/Surveillance-ICU is a new
release of an already established knowledge-based expert system used
for monitoring of HCAIs in the intensive care units at the Vienna General
Hospital.
Method: Direct comparison of surveillance results generated automati-
cally by MONI with the ones generated in parallel by trained surveillance
staff and attending clinical specialists who reviewed patient charts and
used other on-site information.
Results: In 50 admissions covering 382 patient days, both systems gave
identical results in 40 cases (33 without and 7 with infection). In 6
cases MONI detected HCAIs (2 LRT and 4 CVK-related) which had
been missed by the attending clinical specialists. In 4 admissions MONI
missed HCAIs (3 LRT and 1 CVK-related) which had been reported
by human experts. Though MONI in all those cases reported general
indicators for infection, speciﬁc information on the actual infection
site (e.g., radiology and/or microbiology lab reports indicative for LRT-
infection) had not been imported into the surveillance database of MONI
and was therefore not available for the automated inference process,
which on its own was impeccable. MONI made gradual emergence and
fading of HCAIs visible during a patient stay.
Conclusion: MONI/Surveillance-ICU proved to be reliable, quick and
even better than human observers in sensing and surveilling HCAI in
intensive care, provided all relevant information held in the ICU patient
data management system and microbiology lab IT was correctly matched
and imported into the MONI database. In our present setting, MONI
serves excellently its intended purpose of “infection radar” in intensive
care. For a fully-automated surveillance reporting system not all relevant
criteria are accessible yet and improvements are planned especially in
the IT interfaces to radiology and microbiology.
P1891 The potential of Twitter for early warning and outbreak
detection
P. Kostkova °, E. de Quincey, G. Jawaheer (London, UK)
Aims and Objectives: The use of user-generated content in Web 2.0
tools for predicting outbreaks has been seen as a great potential, however,
the recent swine ﬂu outbreak in April-May 2009 truly demonstrated
the potential of these media for early warning systems. Web 2.0 has
generated a great interest recently as a possible media for early warning
system for outbreak detection and epidemic intelligence (EI). Traditional
systems such as GPHIN, Medisys are well established and used by ECDC
and WHO on a daily bases, however, there has been recent interest in the
ability to estimate ﬂu activity via aggregating online search queries for
keywords relating to ﬂu and its symptoms by commercial companies like
Google. However, the search data remain proprietary and therefore not
useful for research. The increase in user generated content on the web
via social networking services such as Facebook and Twitter, however,
provides researchers with a highly accessible view into people’s online
and ofﬂine activity.
S562 20th ECCMID, Posters
Methods (Twitter use on swine ﬂue outbreak): Twitter, a microblogging
service that allows people to post and read other users’ 140 character
messages currently has over 15 million unique users per month. Twitter
allow third parties to search user messages using an open source API
and return the text along with information from the poster’s proﬁle, such
as their location, in a format that can be easily stored and analysed.
We searched and collected over 1 million tweets in the period from May
until August 2009 and carry on collecting them on a minute bases to
understand public concerns, keywords used and the proﬁle of users who
discuss these topics on the web.
Results: We found over 1 million tweets reporting ﬂu related illnesses
and symptoms via Twitter in this period. Most popular words in tweets
were these (frequency in brackets): ﬂu (138, 260), Swine (99, 179), Have
(13, 534), Cases (13, 300), H1N1 (9, 134), Has (8, 010) etc. The actual
sentence “I have swine ﬂu” appeared 2, 888 times and “I have ﬂu” 1,530
times. Further evaluation of the collected tweets, semantic relationship
of keywords, geolocation of posters is underway and will be presented
at the conference.
Conclusion: The potential of Web 2.0 system for early warning systems
and for better understanding public concerns about their health is
enormous, however, further research is required to reveal the underlying
principles and implement adequate integration with existing healthcare
services.
P1892 Can Web games teach children hygiene and antibiotic
resistance? Evaluation of the e-Bug junior games
D. Farrell, P. Kostkova °, J. Weinberg, D. Lecky, C. McNulty (London,
Gloucester, UK)
Introduction: e-Bug is a EC funded antibiotic and hygiene teaching
resource aiming to reinforces an awareness of microbes, hand and
respiratory hygiene and prudent antibiotics use among junior and senior
school children across Europe. e-Bug web games were developed for
2 age groups (junior and senior children) teaching the key learning
outcomes (LOs) of the e-Bug project and complementing physical packs
distributed to schools across Europe.
The e-Bug junior game: The junior platform games has a number of
“levels” teaching the given set of LOs. Player, shrunken inside human
body, interacts with good and bad cartoon microbes (Fig 1) as well as
antibiotics and viruses. Teaching the LOs is implemented through the
way the player interacts with microbes (e.g. turning milk into yogurt (Fig
3), ﬁnishing course of antibiotics (Fig 2). Children knowledge is tested
seamlessly before and after each level in a Game Show style similar to
the popular TV game “Do you want to be a Millionaire?”
Evaluation results: Evaluation was primarily conducted in the UK
and online demonstrating statistically signiﬁcant knowledge gain of the
learning outcomes. This was complemented by qualitative studies (focus
groups and observational studies). 29 pupils took part in the focus
groups (and fully completed the pre and post questionnaire) from three
schools. Before playing the game, only 4 pupils “agreed” that fungi
were microbes while after playing 18. Smaller improvements were seen
in other questions including: “We use microbes to make things like bread
and yogurt” (11 correct before, 23 correct after) and “Soap can be used
to wash away bad bugs” (20 before vs 24 after).
The main evaluation took place in the period of May − August 2009.
Each of the completed level was evaluated for statistical signiﬁcance of
knowledge change of the LOs. As many questions were correct before
and after the game, the statistically signiﬁcant improved responses were
measured (using McNemar’s test), for the following questions: “if you
cannot see a microbe it is not there”, “most coughs and colds get better
without medicine” and in particular “we use good microbes to make
things like bread and yogurt”. There was a trend towards improved
knowledge however in other questions did not reach statistic signiﬁcance.
Conclusion: The study demonstrated that computer games can teach
children about hygiene and antibiotics in an enjoyable way. Further study
is needed to evaluate an impact on behaviour change.
P1893 Bibliometric analysis of European publications in infectious
diseases and clinical microbiology areas
O. Sipahi °, H. Sipahi, M. Tasbakan, H. Pullukcu, B. Arda,
T. Yamazhan, S. Ulusoy (Izmir, TR)
Objectives: In this study it was aimed to make the bibliometric analysis
of 1996–2007 and 2007 European publications related to infectious
diseases and clinical microbiology areas.
Methods: Bibliomeric data related to 1996–2007 and 2007 were
retrieved from SCImago journal and country rank web site
(www.scimagojr.org). Data related to infectious diseases and clinical
microbiology were accessed by using the infectious diseases subcategory
and clinical microbiology subcategory of the database. Top 10 European
countries according to total publication number was also detailed with
data of citable publications (articles+reviews), total citations, citation per
paper and H index.
Table: Top ten European countries both in 1997–2007 and 2007 time
periods
Country Total
publications
Citable
publications
Total
citations
Citation
per paper
Hirsch (H)
index
Infectious diseases area (1997–2007)
United Kingdom 5,130 4,220 57,276 12.36 79
France 4,056 3,640 24,138 6.33 53
Germany 1,973 1,728 20,869 12.88 56
Netherlands 1,654 1,513 14,746 11.55 49
Italy 1,644 1,336 10,844 7 89 38
Spain 1,392 1,127 9,390 9.08 37
Switzerland 971 884 14,328 16.7 53
Belgium 903 814 8,864 11.89 41
Turkey 773 518 3,467 5.7 23
Sweden 504 478 5,699 13.12 33
Infectious diseases area (2007)
United Kingdom 565 440 1,441 2.55 79
France 410 363 679 1.66 53
Germany 245 200 498 2.03 56
Spain 235 173 448 1.91 37
Italy 220 177 430 1.95 38
Netherlands 181 163 400 2.21 49
Switzerland 122 106 391 3.2 53
Belgium 109 100 288 2.64 41
Turkey 94 59 140 1.49 23
Greece 76 55 201 2.64 24
Medical microbiology area (1997–2007)
Spain 3,634 2,877 15,224 4.31 43
Germany 2,811 2,624 29,711 11.35 60
Italy 2,428 2,241 10,945 4.99 40
United Kingdom 2,191 2,005 24,379 12.3 60
France 1,759 1,556 19,414 11.76 53
Russian Federation 1,356 1,347 2,657 2.08 21
Turkey 1,067 984 2,679 2.9 19
Netherlands 972 916 12,824 14.87 50
Sweden 897 859 9,291 10.63 39
Denmark 826 798 9,739 11.79 42
Medical microbiology area (2007)
Spain 273 198 492 1.8 43
Germany 268 247 953 3.56 60
United Kingdom 267 235 863 3.23 60
France 199 171 615 3.09 53
Italy 160 141 266 1.66 40
Netherlands 132 120 414 3.14 50
Turkey 116 107 74 0.64 19
Russian Federation 102 98 69 0.68 21
Sweden 90 76 155 1.72 39
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Results: When evaluated according to total number of publications,
United Kingdom, France and Germany are the top three countries in
the infectious diseases area both in 1997–2007 and 2007 periods. In the
medical microbiology area in 1997–2007 period top three countries are
Spain, Germany and Italy whereas in 2007 top three are Spain, Germany
and United Kingdom (See table). United Kingdom which is European
number one in infectous diseases, is globally the second after United
States in both 1997–2007 and 2007 periods. Spain which is the European
number one in medical microbiology, is the third in 1997–2007 period
(after United States and Japan) and the ﬁfth in 2007 (after United States,
China, Japan and Brazil) (data not shown).
Conclusion: Although at least some of the European countries are quite
competitive both in infectious diseases and medical microbiology areas,
further progress is needed.
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P1894 Response of Staphylococcus epidermidis bioﬁlms cells to the
effect of farnesol
B. Leite °, F. Gomes, P. Teixeira, C. Souza, E. Pizzolitto, R. Oliveira
(Braga, PT; Sa˜o Carlos, Araraquara, BR)
Objective: Staphylococcus epidermidis is a leading cause of medical-
device-related infections, especially in immunocompromised patients.
The treatment of these infections is further complicated by the emergence
of multiresistant strains. The ability of S. epidermidis to form bioﬁlms
on biotic and abiotic surfaces is believed to contribute signiﬁcantly to
the pathogenesis of these infections. Bioﬁlms are notoriously difﬁcult to
eradicate and are often resistant to systemic antibiotic therapy. Recently,
farnesol has been described as having antimicrobial properties, and
therefore a possible action on the prevention of S. epidermidis related
infections. In previous studies it was shown that 300 microM farnesol
was effective against S. epidermidis planktonic cells but having only a
slight effect on bioﬁlm cells. So, the goal of this study was to assess the
antimicrobial activity of higher farnesol concentrations (1 and 100 mM)
against bioﬁlm cells of S. epidermidis.
Methods: Two S. epidermidis strains bioﬁlm-producing (9142 and 1457)
were used in this study. Farnesol (0, 1 mM, 100 mM) was added to
24 h bioﬁlm cells. Bioﬁlm formation was assessed through crystal violet
(CV) staining that measure total biomass of bioﬁlm and cellular viability
through XTT and colony-forming units (CFU/ml).
Results: The results didn’t show a signiﬁcant effect of both farnesol
concentrations on bioﬁlm biomass and activity. In fact, bioﬁlm cell
reduction was less than 2 Log, similarly to most antibiotics (e.g.
tetracycline and vancomycin).
Conclusion: Although the reduction promoted by farnesol was less than
3 Log as requested for an antibiotic agent, its efﬁcacy is similar to
vancomycin. On account of that we are now testing the combined effect
of farnesol with agents that disrupt the bioﬁlm matrix.
P1895 The inﬂuence of oleanolic and ursolic acids on bioﬁlm
formation and hydrophobicity of bacteria
A. Kurek °, J. Ufnalewska, K.I. Wolska (Warsaw, PL)
Objectives: Frequent infections caused by Staphylococcus aureus,
S. epidermidis or Pseudomonas aeruginosa, are related to their ability to
form bioﬁlm. Chemotherapy of such infections is seldom fully effective,
due to high bioﬁlm resistance. Pentacyclic triterpenoids, including
oleanolic acid (OA) and ursolic acid (UA) can be considered as potential
antibioﬁlm agents. OA and UA are present at the signiﬁcant amount in
many plants of commercial and medical importance. Our previous results
showed that OA and UA inhibit growth and survival of several bacterial
species, mainly Gram-positive and also inﬂuence cell morphology,
autolysis, peptidoglycan turnover in planktonic cultures. The aim of this
study is to evaluate the ability of OA and UA to impair bioﬁlm formation
by pathogenic bacteria and their inﬂuence on cell surface hydrophobicity.
Materials and Methods: MICs of OA and UA for planktonic bacteria
were determined according to the standards of NCCLS. S. aureus
ATCC29213, S. epidermidis ATCC12228 P. aeruginosa ATCC10145
and E. coli ATCC23546 were used as planktonic cultures or 24-hour-
old bioﬁlm built in the wells of polistyren microplate in the presence
of the subinhibitory concentrations: 0.15, 0.25 and 0.5 MIC of OA
or UA. BIC and BEC (Bioﬁlm Inhibitory Concentration and Bioﬁlm
Eradicating Concentration) were estimated by the crystal violet staining
and spectrophotometric measurement and by the BacTiter Glo assay
which measures active metabolism of bacteria that survived in the
presence of OA or UA. Cell surface hydrophobicity of planktonic
bacteria in the presence of the OA or UA was estimated by SAT (Salt
Aggregation Test).
Results: It was demonstrated that OA and UA showed antibacterial
effect. Both compounds inhibit bioﬁlm formation by bacterial species
sudied. The decrease of bioﬁlm formation, especially by two Gram-
positive species, 8% and 20%, were observed in the presence of 0.25 and
0.5 MIC of OA/UA, respectively. The lowest concentration of ammonium
sulfate giving visible aggregation of bacteria, SAT value, was two-fold
and three-fold decreased in the presence of 0.5 MIC OA/UA, for Gram-
negative and Gram-positive bacteria, respectively.
Conclusion: Bioﬁlm formation could be inhibited by treatment with OA
and UA. Hydrophobicity of the bacterial cell surface are also changed
in the presence of the subinhibitory concentration of OA and UA.
This study was supported by Grant No N N302 027937 (MNiSW).
P1896 Bioﬁlm formation is important for Propionibacterium acnes
pathogenesis and antibiotic susceptibility
A. Holmberg °, R. Lood, M. Mo¨rgelin, P. Nordenfelt, B. So¨derquist,
E. Holst, B. Christensson, M. Rasmussen (Lund, O¨rebro, SE)
Objectives: Propionibacterium acnes is a common and probably
underestimated cause of delayed joint prosthesis infection. Bacterial
bioﬁlm formation is important for bacterial pathogenesis and antibiotic
tolerance in infections related to foreign material, and P. acnes forms
bioﬁlm both in vitro and in vivo. We hypothesed that invasive P. acnes
isolates form more bioﬁlm in vitro than non-invasive isolates. Moreover,
we aimed to study the three-dimensional structure of a P. acnes bioﬁlm.
We also wanted to compare antibiotic susceptibility between P. acnes in
planctonic and bioﬁlm growth phase.
Methods: Bioﬁlm formation in vitro on a plastic surface was analyzed
for 93 P. acnes isolates either from invasive infections related to foreign
material (n = 45) or from the skin of healthy controls (n = 48). The
sequence of recA was used for typing. The bioﬁlm was visualized by
scanning and transmission electron microscopy (SEM and TEM) and
by ﬂuorescence microscopy (FM). The three-dimensional structure was
studied using a wide-ﬁeld microscope equipped with a motorized stand
and deconvolution software. The antibiotic susceptibility was tested using
a modiﬁed Calgary Bioﬁlm Device.
Results: The majority of isolates from deep infections formed bioﬁlm
on the plastic surface, whereas the skin isolates were poor bioﬁlm
producers (p< 0.001 for a difference). The presence of human plasma
inhibited bioﬁlm formation. There were no differences in the distribution
of serotypes between the invasive and skin isolates. The bioﬁlm was
visualized by different modalities and the multilayered architecture of
the P. acnes bioﬁlm could clearly be demonstrated by FM. Moreover,
an extracellular material within the bioﬁlm was demonstrated by both
TEM and SEM. Bioﬁlm formation on beads of bone cement could
also be seen with SEM. For selected isolates we have determined the
minimal inhibitory concentration (MIC) and minimal bioﬁlm inhibitory
concentration (MBIC) for relevant antibiotics. The MIC values obtained
were as expected very low, but interestingly MBIC is for most antibiotics
much higher.
Conclusions: Our ﬁndings demonstrate for the ﬁrst time that P. acnes
can form a multilayered bioﬁlm and that bioﬁlm formation is important
for P. acnes virulence. Moreover, our data suggest that bioﬁlm formation
should be considered in the choice of antibiotic treatment for invasive
infections with this organism.
S564 20th ECCMID, Posters
P1897 Different bioﬁlm types contribute to resistance of
Staphylococcus epidermidis against uptake by macrophages
H. Rohde °, N. Schommer, M. Hentschke, K. Ruckdeschel,
M. Aepfelbacher (Hamburg, DE)
Objectives: Formation of adherent multi cellular aggregates is the
key mechanism involved in Staphylococcus epidermidis virulence in
device associated infections. Aside from polysaccharide intercellular
adhesin PIA, accumulation associated protein Aap and extracellular
matrix binding protein Embp act as intercellular adhesins, mediating
S. epidermidis bioﬁlm accumulation. The aim of this study was to
characterize structural features of PIA-, Aap-, and Embp-mediated
S. epidermidis bioﬁlms in more detail and to evaluate, by using well
characterized S. epidermidis strain pairs, their speciﬁc contribution to
bioﬁlm-related S. epidermidis immune escape.
Results: PIA-dependent bioﬁlms were characterized by densely packed
bacteria, embedded in a PIA containing extracellular matrix. In sharp
contrast, neither Aap- nor Embp-mediated bioﬁlms featured a signiﬁcant
extracellular matrix. Despite this marked difference, PIA-, Aap-, and
Embp-mediated bioﬁlms protected S. epidermidis with similar efﬁciency
against up-take by J774.A1 macrophages. The reduced phagocytic up-
take was likewise associated with a signiﬁcantly reduced NF-kappaB
and AP-1 activation and Il-1b production compared to macrophage
responses to bioﬁlm-negative S. epidermidis strains not expressing the
respective intercellular adhesins. Thus, interference of S. epidermidis
bioﬁlm formation with phagocytosis is due to over-all reduced phagocyte
activation. More-over, contact with bioﬁlm forming S. epidermidis also
induced a reduction in macrophage’s LPS responsiveness, suggesting
bioﬁlm-related induction of anti-inﬂammatory host cell events.
Conclusions: Our results not only demonstrate that independent
mechanisms of bioﬁlm formation are similar effective in protecting
S. epidermidis from phagocytic up-take, but point towards speciﬁc events
during S. epidermidis − macrophage interactions which interfere with
phagocyte activation. As these result in failure to take up and eradicate
S. epidermidis a detailed elucidation of the involved mechanisms could
open new directions for development of therapeutic strategies to combat
S. epidermidis infections.
P1898 Unpredictable effects of rifampicin as adjunctive agent
in elimination of rifampicin-suseptible and -resistant
Staphylococcus aureus grown in bioﬁlm
S. Croes, P.S. Beisser °, C. Neef, C.A. Bruggeman, E. Stobberingh
(Maastricht, NL)
The use of rifampicin as adjunct in bioﬁlm-associated infections is
based on (i) the ability of this antibiotic to penetrate in bioﬁlms
and (ii) a presumed activity against dormant bacteria. Yet, its efﬁcacy
remains poorly deﬁned and rifampicin-resistant strains frequently emerge
during therapy. Therefore, the efﬁcacy against rifampicin-susceptible
and isogenic rifampicin-resistant methicillin-susceptible Staphylococcus
aureus (MSSA) isolated was evaluated. Bioﬁlms were induced in MSSA
cultures with various genetic backgrounds. Oxacillin + rifampicin at
various concentrations, or oxacillin alone were subsequently added
and, after 24 hours, biomass and viable cell counts were determined.
Reduction in biomass and viable cell count upon rifampicin treatment
varied dramatically and was independent of clonal lineage. Surprisingly,
in some cases, biomass was dramatically increased upon treatment
with either rifampicin, oxacilin, or both. Overall, subinhibitory con-
centrations of added rifampicin were effective for bioﬁlm disruption in
approximately 20% of the rifampicin-susceptible isolates. Additionally,
rifampicin had no additional value in disruption of bioﬁlms of isogenic
rifampicin-resistant isolates. Although reductions in were observed in
some of these isolates, others exerted a signiﬁcant increase in viable
count. In conclusion, the effect of rifampicin in the reduction of bioﬁlm
is unpredictable and the use of rifampicin against bioﬁlm containing
rifampicin-resistant variants is unwarranted.
P1899 A model system for genetic analysis of bioﬁlm formation
during catheter-associated urinary tract infections
A. Reisner °, A. Wo¨ran, M. Holzer, K. Schilcher, E. Stabentheiner,
E.L. Zechner (Graz, AT)
Objectives: Catheter-associated urinary tract infections (CAUTI) are the
most frequent nosocomial infections in hospitals and other health care
facilities. Catheter insertion in the bladder creates a surface subject to
extensive bioﬁlm formation that in turn provides a niche for bacterial
growth with inherently increased antibiotic resistance. Despite extensive
research using simple bioﬁlm model systems, little is known about
the genetic determinants promoting colonization of catheter polymers.
We aimed to establish a dynamic model system that allows analysis
of molecular factors affecting catheter colonization under conditions
mimicking a catheter-associated urinary tract infection.
Methods: Wildtype strains of E. coli, Pseudomonas aeruginosa,
Staphylococcus aureus and Enterococcus faecalis as well as various
mutant derivatives that were previously shown to give attenuated bioﬁlm
formation in simple laboratory bioﬁlm models were inoculated in a
slightly modiﬁed model system for a catheterized bladder previously
used for studying catheter encrustation (Stickler, et al. (1999) Methods
Enzymol 310: 494–501). Models with an inserted all-silicone Foley-
catheters (Ch14) were incubated for 1 to 5 days using a constant artiﬁcial
urine ﬂow of 30ml/h. Several methods were tested to monitor bladder
and catheter colonization including harvest of bacteria followed by
determination of colony counts, confocal laser-scanning and electron
microscopy, and enzymatic assays revealing microbial activities on the
catheters.
Results: All strains formed bioﬁlms on the catheters. Using standardized
protocols, bladder and catheter colonization was monitored reproducible
over time. We found that the most suitable inoculation strategy to identify
mutants attenuated in bioﬁlm formation is to co-inoculate wild-type and
mutant strains in an initial ratio of 1:1. Decreased ﬁtness of mutant
strains is monitored by shift in the bladder and catheter-colonizing
population. The best representation of the bioﬁlm structure formed on
the catheter surface was obtained using electron microscopy. Not all
mutations that have been shown to give attenuated bioﬁlm formation
in simple laboratory bioﬁlm models were also attenuated for catheter
colonization in this model mimicking a catheter-associated urinary tract
infection.
Conclusion: The presented model system for a catheter-associated
urinary tract infection is suitable for application of molecular analysis
of catheter colonization.
P1900 Effect of xylitol and other carbon sources on Streptococcus
pneumoniae bioﬁlm formation and gene expression in vitro
P. Kurola, T. Tapiainen °, J. Sevander, T. Kaijalainen, M. Leinonen,
M. Uhari, A. Saukkoriipi (Oulu, FI)
Objectives: Xylitol inhibits the growth and adherence of Streptococcus
pneumoniae. In clinical trials, xylitol decreases the occurrence of acute
otitis media but does not affect nasopharyngeal carriage of pneumococci.
We hypothesized that xylitol inhibits bioﬁlm formation of S. pneumoniae
and measured pneumococcal bioﬁlm formation and gene expression
levels of the capsule gene cpsB and two other genes, autolysin encoding
gene lytA and competence gene comA in different growth media in vitro.
Methods: Twenty pneumococcal isolates were grown on polystyrene
plates for 18 hours in test media containing 0.5% xylitol, 0.5% glucose,
0.5% xylitol and 0.5% glucose, 0.5% fructose, 0.5% xylitol and 0.5%
fructose or BHI medium supplemented with 10% horse serum. The
polystyrene plates were made in duplicate; one set for RNA extraction
and another set for crystal violet staining.
Results: The means of the OD values were 0.04, 0.03, 0.16, 0.15, 0.12
and 0.13 for BHI, xylitol, glucose, glucose supplemented with xylitol,
fructose and fructose medium supplemented with xylitol, respectively
(Figure). The results differed signiﬁcantly between the test media
(P< 0.001). The OD values were signiﬁcantly lower in xylitol compared
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with BHI medium with a mean difference of −0.015 [95% conﬁdence
interval (CI) −0.028 to −0.002, P = 0.03]. Xylitol also decreased the
expression levels of the cpsB and lytA genes. When the medium
was supplemented with glucose or fructose, bioﬁlm formation was
enhanced and the inhibitory effect of xylitol on bioﬁlm formation was
not observed.
Conclusion: We found that xylitol inhibits the bioﬁlm formation of
S. pneumoniae whereas other extra carbon sources such as fructose and
glucose enhance bioﬁlm formation. The decrease in bioﬁlm formation
may further explain the efﬁcacy of xylitol in preventing acute otitis media
in previous clinical trials.
P1901 Visualization of in vivo bioﬁlm developing on silicone
implants and the interaction with the cellular response
M. van Gennip °, L. Christensen, K. Qvortrup, M. Alhede, P. Jensen,
N. Høiby, M. Givskov, T. Bjarnsholt (Copenhagen, DK)
Objective: Pseudomonas aeruginosa is associated with infections of
medical implants in humans, where they form bioﬁlms. The bioﬁlm
mode of growth contributes to the tolerance against treatment with
antibiotics as well as to the host response. Polymorphonuclear leukocytes
(PMNs), which are part of the innate immunity and some of the ﬁrst cell
types to be recruited to the site of infection, most often fail to eradicate
the bioﬁlm infection. P. aeruginosa produces rhamnolipids which causes
the PMNs to undergo a necrotic death. We have previously shown that a
P. aeruginosa mutant unable to produce rhamnolipids was cleared from
ﬂat implants inserted into the peritoneal cavity of mice. By modifying the
in vivo foreign-body infection model established by Christensen et al. in
2007 using 4mm silicone tubes (id 4mm, od 6mm) instead of ﬂat, square
implants, we followed the development of P. aeruginosa bioﬁlms as well
as the pathogen-host interaction by means of quantitative bacteriology
and scanning electron microscopy (SEM).
Methods: Wild-type (WT) P. aeruginosa (PAO1) and its corresponding
rhlA mutant were harvested by centrifugation from an overnight culture
and resuspended in 0.9% NaCl to an OD600nm of 0.1. The implant
tubes were colonized for 20-hours with shaking at 110 rpm and inserted
in the peritoneal cavity of BALB/c mice at day 0. Tubes removed
from euthanized mice were either prepared for SEM (ﬁxed in 2%
glutaraldehyde, post-ﬁxed in 1% OsO4, critical point dried using CO2
and sputter coated with gold according to standard procedures) or
evaluated for quantitative bacteriology (CFU per implant). Specimens
for SEM were investigated with a FEI XL Feg30 SEM microscope.
Results: Quantitative bacteriology showed that the mice were able to
clear the rhlA mutant by day 3, but the WT was still cultivated on day
7 post-insertion. The SEM pictures revealed that by day 1 a bioﬁlm had
formed, and subsequently a continuously increase in bacterial biomass.
As for the host response it was evident that by day 1 an abundant number
of PMNs had been attracted and seemed to enter the tubes from the tube
openings. Even more PMNs were seen on day 2, however, most of them
seemed to be damaged and embedded in the bioﬁlm matrix.
Conclusion: Quantitative bacteriology conﬁrmed our previous ﬁndings
that a rhlA mutant is cleared faster than the WT. The SEM visualization
conﬁrmed this ﬁnding and clearly emphasised the WT enabled
destruction of the PMNs.
P1902 Oritavancin activity against in vitro bioﬁlms derived from
clinical isolates of Staphylococcus aureus from a phase 2
study
A. Belley °, T. McClure, I. Sarmiento, T. Parr Jr., G. Moeck (St.
Laurent, CA)
Objective: Oritavancin (ORI) is an investigational lipoglycopeptide that
exhibits activity against in vitro bioﬁlms, a bacterial growth state that
exhibits remarkable tolerance to antimicrobial agents and consequently
poses a serious clinical challenge. We assessed ORI activity against
in vitro bioﬁlms derived from Staphylococcus aureus clinical isolates
and tested for relationships between its anti-bioﬁlm activity and both
clinical outcome and methicillin-susceptibility status of the isolates.
Methods: S. aureus isolates (n = 87; 37 MSSA, 50 MRSA) from the
clinically-evaluable population of patients enrolled in a Phase 2, multi-
center, double-blind, randomized study of ORI treatment of complicated
skin and skin-structure infections were used to form in vitro bioﬁlms.
All isolates were susceptible to vancomycin. Seventy-two hour bioﬁlms
were established in MBEC Physiology & Genetics plates (Innovotech,
Edmonton, Canada) at 37ºC with rotation (150 rpm) in tryptic soy
broth containing 1% glucose (with daily replacement of media). The
minimal bioﬁlm eradication concentration (MBEC), the concentration
of drug needed to sterilize the bioﬁlms after 24 hours of exposure, was
determined for ORI and vancomycin after a 72-hour recovery period
to detect surviving bacteria that tolerated exposure to the antibacterial
agents. MBEC distributions were analysed using Fisher’s exact test.
Results presented are modal MBECs from 4 independent experiments.
Results: Robust bioﬁlms were formed by all 87 clinical isolates of
S. aureus in MBEC plates after 72 hours incubation as evidenced by
recovery of adherent bacteria on the MBEC plate pegs (mean cell density
of 6.7±0.9 log cfu/peg). All bioﬁlms exhibited vancomycin MBECs
>128mg/l. In contrast, ORI retained activity against the bioﬁlms (MBEC
mode, 8mg/l; MBEC90, 32mg/l). The distribution of ORI MBECs for
isolates from the cure and failure outcome groups were not statistically
different (P = 0.34). However, ORI had signiﬁcantly lower MBEC values
for the MRSA bioﬁlms compared to the MSSA bioﬁlms (P = 0.03).
Conclusion: Against robust in vitro bioﬁlms of S. aureus for
which vancomycin was inactive, ORI demonstrated notable activity
at pharmacologically-relevant concentrations of drug. No association
between ORI MBEC and clinical outcome in the phase 2 study was
evident. This study revealed that bioﬁlms derived from clinical isolates
of MRSA were sterilized by ORI at least as readily as bioﬁlms of MSSA.
Oritavancin MBEC (mg/1) Number of isolates
Cure (%) Failure (%) MSSA (%) MRSA (%)
4 4 (9.3) 9 (20.5) 1 (2.7) 12 (24.0)
8 16 (37.2) 13 (29.5) 14 (37.8) 15 (30.0)
16 9 (20.9) 13 (29.5) 10 (27.0) 12 (24.0)
32 10 (23.3) 5 (11.4) 6 (16.2) 9 (18.0)
>32 4 (9.3) 4 (9.1) 6 (16.2) 2 (4.0)
Total 43 (100) 44 (100) 37 (100) 50 (100)
P1903 Effect of weak organic acids on bioﬁlms as observed by
scanning electronmicroscopy
Z. Nack °, J. Stenos, H. Dunstan, T. Roberts, S. Graves (Geelong,
Newcastle, AU)
Objective: Scanning electron microscopy (SEM) was used to monitor
the effect of selected weak organic acids (WOAs) (ascorbic. citric,
lactic and malic) and their combinations on bioﬁlm structure. Bioﬁlms
were formed by methicillin resistant Staphylococcus aureus, vancomycin
resistant Enterococcus faecium, multiresistant Acinetobacter baumannii
and extended spectrum b-lactamase positive Klebsiella pneumoniae.
Methods: A 200 ml bacterial suspension (grown in nutrient broth
overnight) was added to 10ml RPMI-1640 and supplemented with 1%
ethanol, 1% sodium chloride and 5% foetal calf serum. Using 24 well
microtiter plates, SEM aluminium stubs were immersed into 2ml of the
solution above and incubated for 72 hours in a 30ºC incubator.
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Following incubation the bacterial suspension was removed and the stubs
exposed to 70% ethanol for 30 minutes (positive control) and to 10%
WOAs (diluted in sterile distilled water) for 10, 15, 30 and 60 minutes.
Following the exposure the stubs were vacuum dried for1 hour and gold
coated for 120 seconds for SEM.
Results: Untreated bioﬁlms, formed by any of the multiresistant bacteria
showed normal bacterial structure with smooth cell morphology and
a well developed extracellular polymeric substances (EPS). Bioﬁlms
treated with 70% ethanol (15, 30 and 60 minutes) showed normal
EPS structure but bacterial morphologies were affected, including cell
deformity, cell collapse and leakage of cytoplasmic material as observed
by SEM. Bacterial bioﬁlms treated with selected WOAs and their
combination (longer than 15 minutes) showed dramatic changes in
their bioﬁlm structure. EPS was completely destroyed and in most
cases completely eliminated. Remaining bacterial cells showed major
deformity, due to the loss of their cytoplasm (‘ghost cells’).
Conclusion: Our ﬁnding in SEM showed a good correlation with
our earlier studies on bioﬁlms exposed to WOAs. Short-term WOAs
treatment of bioﬁlms (10 min or less) showed no signiﬁcant effect,
but treatments of 15 minutes or more displayed irreversible damaged
bacterial cells and EPS structures. This study strongly indicates that
WOAs are effective agents against not just planktonic bacteria but also
against bioﬁlm complexes.
P1904 Activity of daptomycin, vancomycin and moxiﬂoxacin alone
or in combination with clarithromycin or rifampicin in a
novel in vitro model of Staphylococcus aureus bioﬁlm
J. Parra-Ruiz °, C. Vidaillac, W. Rose, M. Rybak (Detroit, Madison, US)
Objectives: Bioﬁlm is a common virulence factor that protects
bacteria from host responses and antibacterial agents. The study
aims were to assess the in vitro activity of several antimicrobials
alone or in combination against 2 S. aureus isolates using a novel
pharmacokinetic/pharmacodynamic (PK/PD) model of bioﬁlm.
Methods: 1 methicillin-susceptible S. aureus (MSSA SH1000) and 1
methicillin-resistant S. aureus (MRSA NK315) were evaluated in a
CDC bioﬁlm reactor with polystyrene coupons (Biosurfaces Technology
Corp., MT, USA). A 36 h bioﬁlm conditioning phase was performed
prior to antimicrobials administration. Regimens simulated free peak
concentrations of daptomycin (DAP) 10mg/Kg/24 h, vancomycin (VAN)
1g/12 h, and moxiﬂoxacin (MOX) 400mg/24 h alone or in combination
with rifampicin (RIF) 600mg/24 h or clarithromycin (CLA) 250mg/12 h.
Media and coupon samples were aseptically removed at 0, 4, 8, 24, 48
and 72 h to assess for the presence of viable planktonic (P) and embedded
bioﬁlm (EB) cells. Cidal activity and synergy were deﬁned as 3 log10
decrease in the viable CFU/mL and 2 log10 reduction compared to the
most efﬁcient agent alone, respectively. Bioﬁlm recovered on coupons
was evaluated by scanning electron microscopy (SEM) at 0, 24 and 72 h.
Results: Starting planktonic and bioﬁlm inocula were about 7.4 and
8.8 log10CFU/mL for SH1000, and about 7.3 and 6.8 log10CFU/mL for
NK315, respectively. For SH1000, DAP and MOX were not cidal against
P or EB cells. DAP+CLA and MOX+CLA were both cidal against P and
EB cells at 24 h and 32 h, respectively. Only DAP+CLA was synergistic
and reduced bioﬁlm cells to the limit of detection at 72 h.
For NK315, DAP was bactericidal at 24 h against P cells but bacterial
regrowth, uncorrelated to the emergence of resistance was observed after
48 h. In contrast, sustained cidal activity was observed with VAN+RIF
from 32 h against P cells. Both regimens reduced bioﬁlm cells only
1.8−2 log10 CFU/mL. The synergistic combination of DAP+RIF was
cidal at 8 h against P and EB cells, and decreased the bacterial density to
the limit of detection at 72 h. SEM studies conﬁrmed changes observed
in bioﬁlm cells CFU/mL.
Conclusion: We developed a novel PK/PD model to assess the in vitro
activity of antimicrobials against bacterial bioﬁlm. DAP and MOX
combinations were the most effective regimens and represent promising
alternatives to treat persistent infections caused by staphylococci
embedded in bioﬁlm.
P1905 Investigation of daptomycin as a locking agent for line
colonization with Gram-positive organisms
F.M. Awadel-Kariem °, R.N. Manzoor, H.A. Jeraj, K. Farrington
(Stevenage, UK)
Background: Most line colonization, leading to bacteraemia and/or
line removal, is caused by Gram-positive organisms. Line removal can
have serious implication for patient management as patients may require
the continuous presence on intra-vascular access (e.g. for total parental
nutrition, haemodialysis and chemotherapy). Attempts to rescue precious
lines especially in patients running out of sites to place central venous
catheters have been an important part of line management. This is
achieved by “locking” an antibiotic (to which the organism is sensitive)
in the colonized lumen(s) of the central lines while the lumen is not
in use. Antibiotics used for this purpose include aminoglycosides and
glycopeptides. Daptomycin is a new and powerful anti-Gram-positive
antibiotic that can be effective against organisms that are resistant to the
other agents.
Objective: To assess the stability of daptomycin as a locking agent with
heparin and anti-Gram-negative agents, and to evaluate its ability to
sterilize simulated line infection with bioﬁlm forming reference strains.
Methods: Daptomycin was prepared as recommended by the man-
ufacturer and mixed with different anti-Gram-negative speciﬁc drugs
(gentamicin and amikacin) and heparin. Various concentrations were
assessed for stability. Once the ideal concentrations for all agents were
identiﬁed they were employed on an in vitro line infection model
against bioﬁlm-forming reference strain of MRSA, MSSA, MRSE and
VRE. Similar preparations, with Vancomycin, teicoplanin or linezolid
substituted for daptomycin, were used as controls. All experiments were
carried out in triplicates.
Results: The optimal concentration for daptomycin as a locking agent
was identiﬁed at 5mg/ml. The optimal concentration for heparin was
5000 U/ml, and for both gentamicin and amikacin was 5mg/ml. At these
concentrations the three agents could be combined in a stable locking
solution. When this solution was tested in the in vitro line infection model
sterility was achieved with all Gram-positive strains tested. However,
sterility was not achieved with the other agents against all the Gram-
positive reference strains.
Conclusions: This study conﬁrms that daptomycin can be combined with
different anti-Gram-negative agent and heparin in a stable manner that
makes it ideal for line locking. Our line infection model has demonstrated
that daptomycin is at least as effective as current anti-Gram-positive
agents as a locking agent.
P1906 Effectiveness of antimicrobial agents in the prevention of
bioﬁlm forming Staphylococcus epidermidis growth on the
surface of PMMA cement
S.K. Sandiford °, J. Tagg, P. Kay, M. Upton (Manchester, UK; Dunedin,
NZ; Wigan, UK)
Objective: Staphylococcus epidermidis is one of the major causative
agents of bioﬁlm infections associated with indwelling medical devices.
The ever increasing resistance of bioﬁlm forming isolates to conventional
antimicrobial therapy enforces the requirement for new therapies to
prevent initial adhesion of bacteria to biomaterial surfaces.
The aim of the current study was to assess the ability of antimicrobial
peptide gallidermin (2164 Da) and a novel inhibitor (NI01) to prevent
growth on polymethylmethacrylate (PMMA) bone cement.
Methods: Lantibiotic gallidermin (MIC 62.5mg/ml, MBC 125mg/ml)
with an inhibitory activity of >5120 AU/ml and NI01 (MIC 2.18mg/ml,
MBC 4.37mg/ml) with an inhibitory activity of 2560 AU/ml were
incorporated into PMMA bone cement. Columns of bone cement with
a diameter of 4mm and height of 7mm were attached to the lid of a
96 well microtitre plate. The cement columns were then incubated with
106 cfu/ml clinical bioﬁlm forming Staphylococcus epidermidis strain
156 for 1 hour. The columns were then rinsed in phosphate buffered
saline (PBS) and immersed in PBS containing 0.25% glucose, (NH4)2
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SO4 and 1% TSB. Growth of adhered bacteria was then monitored in
real time using a kinetic plate reader over 48 hours, producing a time
proliferation curve for each well.
Results: Gallidermin (125mg/ml) and NI01 (4.37mg/ml) incorporated
into columns of PMMA cement resulted in a signiﬁcant decrease in the
growth of clinical Staphylococcus epidermidis isolate 156 (p = 0.001).
Conclusion: Antimicrobial agents, gallidermin and NI01 were able to
inhibit growth of clinical bioﬁlm forming isolate 156. The ability of these
inhibitors to prevent cement colonization indicates their potential use to
prevent bacterial growth and therefore subsequent bioﬁlm formation.
P1907 Foodborne enterococci in oral bioﬁlm: an in vivo human
study
A. Al-Ahmad °, B. Spitzmu¨ller, J. Maier, A. Wittmer, M. Follo,
E. Hellwig, D. Jonas (Freiburg, DE)
Objectives: Persistence of microorganisms or reinfection are the main
reasons for failure of root canal therapy. Enterococci, particularly
Enterococcus faecalis, have frequently been isolated from root-ﬁlled
teeth associated with periradicular lesions. Up to now enterococci are
considered as transient and not belonging to the normal oral ﬂora. The
aim of this study was to examine the ability of food born enterococci to
integrate in mature dental oral bioﬁlm.
Methods: Six healthy volunteers with an age range of 25−26 wore dental
splints loaded with equal sized pieces of BSE-free bovine enamel. After
3 days, the volunteers consumed cheese which included E. faecalis,
Enterococcus faecium, Enterococcus avium and Enterococcus durans.
The supragingival bioﬁlm was analysed by culture technique. E. faecalis
was also analysed using ﬂuorescent in situ hybridisation (FISH).
Isolated members of the different enterococci found in cheese and
bioﬁlm were also conﬁrmed by 16S rRNA gene sequencing. All strains
were characterised genotypically by macrorestriction analysis using
the restriction endonuclease SmaI and pulsed-ﬁeld gel electrophoresis.
Molecular masses of all bacterial DNA ﬁngerprints were determined
using the control strain Staphylococcus aureus NCTC 8325. Similarities
were presented as dendrograms.
Results: E. faecalis, E. faecium, E. avium and E. durans were isolated
from the initial bioﬁlm after 2 h, as well as from the mature dental plaque
bioﬁlm which developed after 5 days. Similarities between E. faecalis,
E. faecium and E. avium isolated from cheese, as well as strains of these
species isolated from the initial bioﬁlm and from the 5 day-old bioﬁlm,
were revealed by macrorestriction analysis. E. faecium and E. avium
integrated into an already existing 3 day-old bioﬁlm. E. durans could
be isolated from both the initial and 5 day-old oral bioﬁlm, yet no
similarities to the E. durans strains isolated from cheese were detected.
E. faecalis was also detected in dental plaque bioﬁlm using ﬂuorescent
in situ hybridisation (FISH). Individual differences among the tested
volunteers were shown.
Conclusions: E. faecalis, E. avium and E. faecium could be resident
in the dental oral bioﬁlm and not only transient. Fermented food is
one source of these enterococci in the oral cavity. The genotypic
characterisation of enterococci strains is essential in order to study their
origins within the oral cavity.
P1908 Micro-morphological features for the characterization of
in vitro microbial bioﬁlm development on central venous
catheters
M. Lorenzato, F. Tessarolo °, I. Caola, F. Piccoli, G. Nollo, P. Caciagli
(Trento, IT)
Objectives: To deﬁne new microscopic features for characterizing the
in vitro development of bacterial bioﬁlm on the surface of central venous
catheters (CVCs) by scanning electron microscopy (SEM).
Methods: Three wild strains of S. epidermidis (strong, intermediate,
and weak bioﬁlm producer according to the Microtiter-plate test)
were selected from cultures of infected CVCs. Nine catheter segments
were obtained from four types of commercial CVCs: uncoated (STD),
benzalkonium chloride coated (BC), silver impregnated (S), and
chlorhexidine-silver sulfadiazine coated (CSS) devices. Segments were
longitudinally sectioned and glued to cover glasses to obtain thirty-
six testing samples (TS) exposing both lumenal and external catheter
surfaces as well as the glass area. Each TS was introduced in a
screw-cap tube with 3ml of bacterial suspension (0.5 McF in tryptone
soy broth + 1% glucose) and incubated in a oscillating waterbath at
37ºC. After 1, 3 or 7 days, TS were extracted, washed in HEPES,
ﬁxed in 2.5% glutaraldehyde in HEPES, dehydrated, dried, and gold
sputtered for SEM. For each TS, 16 representative ﬁelds were collected at
magniﬁcations from 50 to 4000 times. Collected images were reviewed to
score TS according to the presence (+) or not (−) of the following micro-
morphological features: (a) bioﬁlm demarcation line at the air–liquid
interface, (b) bacterial cells with viable morphology, (c) extracellular
matrix, (d) three-dimensional architectures (Figure 1). TS scores were
grouped according to catheter type, bacterial strain, incubation time and
surface of interest. Percentages of “+” scores were ﬁnally computed.
Results: Percentages of “+” scores according to catheter type were
62%, 52%, 21%, 11% for STD, BC, S, and CSS respectively.
Percentages according to bacterial strain were 38%, 35%, 37% for
strong, intermediate, and weak bioﬁlm producer. Percentages according
to incubation times were 26%, 40%, and 44% for 1, 3, and 7 days.
Percentages according to surface of interest were 21%, 45%, 44% for
lumenal, external and glass surface.
Conclusion: Four new morphological features for characterizing the
in vitro growth of microbial bioﬁlm on CVCs were deﬁned. These
features were able to evidence different bacterial colonization and bioﬁlm
accretions on antimicrobial CVCs and uncoated catheters.
The micromorphological features (b), (c) and (d) here presented could
also have potentialities in assessing microbial bioﬁlm on CVCs recovered
from patients.
Figure 1. Micro-morphological features for the characterization of
microbial ﬁlm. Representative images for the presence of: (a) bioﬁlm
demarcation line at the air–liquid interface; (b) bacterial cells with viable
morphology; (c) extracellular matrix; (d) three-dimensional architectures.
P1909 treC contributes to bioﬁlm formation and in vivo
colonization of Klebsiella pneumoniae strains causing
pyogenic liver abscess
M.C. Wu °, T.L. Lin, P.F. Hsieh, H.C. Yang, J.T. Wang (Taipei City, TW)
Objectives: Community-acquired pyogenic liver abscess (PLA) caused
by Klebsiella pneumoniae is an emerging infectious disease. The
formation of bioﬁlms is important for bacterial pathogenicity in many
tissue infections. Therefore, we sought to identify genes related to bioﬁlm
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formation in K. pneumoniae and to determine their association with
colonization in animals.
Methods: A microtiter plate assay was used to determine the levels of
bioﬁlm formed by K. pneumoniae clinical isolates and to screen bioﬁlm-
altered mutants from a transposon mutant library of a K. pneumoniae
PLA-associated strain. Deletion and complementation of the candidate
gene were performed to investigate its role in bioﬁlm formation by
K. pneumoniae. Slide culture was used to test the bioﬁlm-forming
ability of the isogenic mutants on glass surface. DNA microarray and
intragastrical infection in mice were used to compare gene expression
and the ability of colonization between the parental strain and the
bioﬁlm-deﬁcient mutant.
Results: In a polystyrene microtiter plate assay, higher levels of bioﬁlm
formation were demonstrated by K. pneumoniae strains associated
with PLA. Screening and genetic analysis of a transposon-insertion
library revealed a trehalose-6-phosphate hydrolase (treC) mutant that
produced decreased levels of bioﬁlm. Bioﬁlm formation was reduced
in reknock-out treC mutant and was restored to normal levels by
chromosomal complementation. Glass-slide culture conﬁrmed the role
of treC in bioﬁlm formation. Using a microarray analysis, differences in
a cluster of genes associated with glycerol transportation and metabolism
between the parental strains and treC mutant were found. In vitro and
in vivo competition revealed that the treC mutant was attenuated in
competiveness with regard to bioﬁlm formation and colonization during
infection.
Conclusions: treC contributes to the formation of bioﬁlm and in vivo
colonization by K. pneumoniae PLA strains in intragastrically infected
mice.
P1910 Conjugation-mediated protein translocation as a novel
strategy to combat bioﬁlm-associated infections
K. Schilcher °, A. Reisner, S. Lang, E.L. Zechner (Graz, AT)
Objectives: Bioﬁlm-associated infections pose a signiﬁcant challenge
in clinical settings because most antibiotics fail to kill cells protected
in a bioﬁlm. We aim to evaluate a novel strategy to combat bioﬁlm-
associated infections that is based on horizontal gene transfer (HGT)-
mediated delivery of toxic proteins to cells located in a bioﬁlm.
Methods: Translocation efﬁciencies of various Cre-TraI fusion proteins
from a conjugation-proﬁcient E. coli donor into suspended E. coli
recipient cells were quantiﬁed based on Cre recombinase activity that is
associated with acquisition of a permanent chloramphenicol resistance
phenotype in the recipient cells. Translocation of the Cre-TraI fusion
carrying the best translocation signal was further evaluated in an in vitro
model for a catheterized bladder (CAUTI model). Bactericidal effects
upon addition of a conjugation-proﬁcient E. coli strain expressing the
Cre-TraI-CcdB fusion protein to an established E. coli bioﬁlm were
monitored in different model systems using selective plating, electron
microscopy and a ﬂuorescein diacetate hydrolysis assay.
Results: Among the tested Cre-TraI fusions, the fusion carrying the
TraI region from aa993 to aa1756 was the shortest fusion that still gave
translocation levels comparable to the full length protein. In the CAUTI
model, Cre-TraI (993–1756) fusion protein was efﬁciently translocated
leading to detectable Cre activities in 17% (CAUTI Model) of the
transconjugant population. The ccdB gene encoding a potent inhibitor of
bacterial replication was inserted into the vector carrying this Cre-TraI
fusion to create a Cre-TraI-CcdB fusion protein. The functionality of the
Cre-TraI-CcdB fusion protein was conﬁrmed by lethal effects following
expression in E. coli hosts. Co-expression of antidote complemented the
phenotype. The fusion protein was used to detect bactericidal effects
upon translocation to sessile E. coli populations in different model
systems including an in vitro model for a catheterized bladder.
Conclusion: HGT-mediated delivery of toxic proteins may provide
a useful strategy to combat bioﬁlm-associated infections. Our initial
results prove that protein translocation to recipient cells is detectable at
signiﬁcant levels under conditions mirroring the situation of a catheter-
associated infection. Ongoing efforts aim to reveal the efﬁciency of toxin
translocation to combat bioﬁlm-associated infections.
P1911 Bioﬁlm formation by Acinetobacter spp. in the air–liquid
and solid–liquid interphases
S. Marti, J. Rodriguez-Ban˜o, P. Espinal, M. Catel-Ferreira, J. Vila,
H. Seifert °, T. Jouenne, E. De´ (Mont-Saint-Aignan, FR; Seville,
Barcelona, ES; Cologne, DE)
Objectives: Bioﬁlm formation by Acinetobacter baumannii could be
responsible for the high level resistance to desiccation and disinfection.
This bioﬁlm can be formed at the air–liquid (ALI) and solid–liquid (SLI)
interphases. The aim of this study was to determine the prevalence of
these types of bioﬁlm in different members of the genus Acinetobacter.
Methods: The study was performed on the clinically relevant members
of the A. baumannii-A. calcoaceticus(ABC) complex (A. baumannii,
Acinetobacter G3 and G13TU), together with other species less
important in the clinical environment (A. johnsonii, A. lwofﬁi and
A. radioresistens). The cultures were started at OD600=0.01 in MH broth
in polypropylene tubes for the ALI bioﬁlm and in 96-well-plates for the
SLI bioﬁlm. This study was performed by duplicate at 25ºC and 37ºC.
The results for the ALI bioﬁlm were determined by visual identiﬁcation
while the SLI bioﬁlm was stained with 0.5% crystal violet and solubilised
with 95% ethanol to be quantiﬁed at 550 nm.
Results: The results for the ALI bioﬁlm would represent the total bioﬁlm
formation because the crystal violet stains both structures. Bioﬁlm
formation was generally more important at 25ºC than at 37ºC which
suggests that this mechanism could be used to persist in the hospital
environment. The bioﬁlm formation by the members of the ABC-
complex was at least 4 times higher than the other species (80−91%
versus 5−24%). In addition, only the isolates belonging to this complex
were able to form ALI bioﬁlm; all the other genomic species analysed
showed a lack in the formation of this structure. Finally, within the ABC-
complex, there was no difference in the amount of SLI bioﬁlm produced;
however, the formation of ALI bioﬁlm was almost 4 times higher for
A. baumannii and Acinetobacter G13TU than for Acinetobacter G3
(34%, 27% & 9% respectively).
Conclusion: Our results suggest that the members of the ABC-complex
had a higher ability to form bioﬁlm than the other genomic species. This
feature could be related to the higher presence of these microorganisms
(mainly A. baumannii) in the hospital environment and therefore increase
the risk of infection. In addition, they were also able to form ALI bioﬁlm,
an ability that has not been observed yet in the other genomic species.
P1912 Combined effect of copper and silver versus
multidrug-resistant clones of Acinetobacter baumannii
N. Gordon °, J. Turton, D. Wareham (London, UK)
Objectives: Acinetobacter baumannii is a non fermentative Gram-
negative cocco-bacillus which has become an increasing problem as
a multi-drug resistant nosocomial pathogen, particularly in intensive
therapy units (ITU). Its ability to form bioﬁlms enables it to evade
routine cleaning and allows colonisation of abiotic surfaces, resulting in
numerous outbreaks. The dearth of effective antimicrobials means there
is an urgent need for the development of novel management strategies.
The antimicrobial effects of copper and silver have been known for
centuries and in recent years there has been increasing interest in their
use as topical agents, antimicrobial coatings and cleaning agents. In
this study we evaluated the synergistic effect of these elements on
A. baumannii and their effect on bioﬁlm formation, to investigate their
potential use against this formidable pathogen.
Methods: Seven MDR A. baumannii isolates belonging to the UK
South East, OXA-23−1, OXA-23−2, and Burn clones were identiﬁed by
examination of pulsed ﬁeld gel electrophoresis proﬁles. A. baumannii
ATCC 19606 was used as an antibiotic sensitive type strain. MICs to
copper and silver nitrate were determined by broth microtitre dilution
with synergy assessed in checkerboard assays interpreted using FICI
criteria. The effect of copper and silver on MDRAB bioﬁlm formation
at 1/4 MIC was investigated by crystal violet staining of 24 hr cultures
grown in polystyrene microtitre plates.
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Results: Versus all strains the MIC of Cu(NO)3 was 1024mg/L and the
MIC of Ag(NO)3 was 16mg/L. MICs were reduced when Cu(NO)3 and
Ag(NO)3 were used in combination with marked synergy (FICI 0.5)
observed versus 3 isolates. In the majority of strains, bioﬁlm formation
was unaffected or slightly increased following exposure to Ag(NO)3 or
Cu(NO)3 alone. However, when both agents were used in combination a
reduction was seen for all strains (range 7−64%), which was statistically
signiﬁcant in four.
Conclusion: The combination of Cu(NO)3 and Ag(NO)3 showed
marked synergy against MDR A. baumannii, and was associated with
reduction in bioﬁlm formation by some strains. The potential use of
this combination in cleaning materials, topical formulations and medical
device coatings warrants further evaluation.
P1913 Biological cost of antibiotic pressure in Pseudomonas
aeruginosa bioﬁlm phenotype
I. Machado °, H. Lopes, S. Lopes, D. Alves, M. Pereira (Braga, PT)
Objectives: P. aeruginosa (PA) has become recognized as an oppor-
tunistic pathogen of clinical relevance mainly when encased in bioﬁlms.
Bacteria facing adverse conditions (e.g. in the course of antibiotic
chemotherapy) can survive, multiply and form bioﬁlms as a defensive
tactic. This work aimed to evaluate the role of antibiotic pressure in
bioﬁlm phenotype and in the selection of persisters.
Methods: P. aeruginosa from collections (PAO, ATCC, CGCT) and
isolated from an endoscope (PAI) were used to form bioﬁlms in the
presence of several doses of rifampicin (RIF) and ciproﬂoxacin (CIP).
Bioﬁlm phenotype was evaluated by biomass (CV), respiratory activity
(XTT) and number of bioﬁlm-grown cells. MIC and MBC of RIF and
CIP against all bacterial strains were assessed.
Results: For all strains, RIF MIC was 32 mg/ml and MBC 64 mg/ml.
MIC and MBC of CIP were strain dependent, varying from, respectively,
0.1−0.4 mg/ml and 0.8−3 mg/ml. However, P. aeruginosa strains did not
loose the ability to form bioﬁlms even when facing extreme doses of
CIP and RIF. Bioﬁlm mass was only altered at MIC value, being noticed
a big reduction but not total inability of all strains to form bioﬁlms. PAI
and PAO were the strains more able to form bioﬁlms even at excessive
doses of RIF (64 mg/ml) and CIP (6 mg/ml). Concerning activity, bioﬁlms
developed by bacteria that survive in the presence of both antibiotics still
able to colonize surfaces, giving rise to metabolically active bioﬁlms also
at MBC and 2×MBC. PAI, ATCC and CGCT were the strains that give
rise to more active bioﬁlms in CIP and PAI, ATCC and CGCT in RIF.
Despite having a good reduction in activity and a reasonable reduction
in bioﬁlm mass, results are still worrisome as the number of viable
bioﬁlm-cells was very high. There was only a 2-log reduction at MIC
and a 3-log reduction at MBC for both antibiotics, being the ﬁnal cell
number around 1E4 CFU/cm2.
Conclusions: The presence of antibiotics during bioﬁlm formation
seems to enforce a selective pressure on bacteria members, eliminating
planktonic cells, slowing down bioﬁlm formation and interfering with
bioﬁlm phenotype. But cells that survived to antibiotic attack by surface
adhesion were the ones among the communities that were more resistant
to antimicrobials. These cells may give rise to phenotypically altered
bioﬁlms with increasing virulence factors and be the cause of persistent
bioﬁlm infections.
P1914 Virulence factors of Pseudomonas aeruginosa strains
isolated from catheterized patients
K. Olejnickova °, V. Hola, F. Ruzicka (Brno, CZ)
Objectives: Infections caused by Pseudomonas aeruginosa are serious
problem for patients with cystic ﬁbrosis, catheterized and immuno-
compromised persons. P. aeruginosa is opportunistic pathogen and
the imbalance between host’s immune system and virulence factors
of the bacterium plays important role in the origin of infection. We
focused on several virulence factors in P. aeruginosa-− the motility
(swimming and twitching), the bioﬁlm formation, production of air–
liquid (A−L) interface bioﬁlm and resistance to selected antibiotics.
Swimming motility allows the bacterium to move in water and low-
density environment. Moving on the solid surface, enabled by type IV
pili, is called twitching motility. Cells capable of forming bioﬁlm are
more resistant to antimicrobial agents and host’s immune system. They
are often observed in persistent infections.
Methods: We tested 119 strains of P. aeruginosa from patients of St.
Anne’s University Hospital with urinary or bloodstream catheterization.
The bioﬁlm formation was tested according to Stepanovic´ et al. (2007).
The A−L interface bioﬁlm was tested by growing the bioﬁlm in
polystyrene tubes and dividing submerged and A−L interface bioﬁlm.
The bioﬁlm formation was quantiﬁed by A590 nm. The swimming
motility was tested according to Rashid and Kornberg (2000); brieﬂy,
we inoculated bacteria with a toothpick and incubated plates for 24 h
at 37ºC. Twitching motility was tested by two different methods, which
were compared as for reproducibility of results. We used method of
Rashid and Kornberg (2000); we inoculated bacterial suspension and
incubated plates for 24 h at 37ºC; and method of Zolfaghar et al. (2003);
the bacteria were inoculated with a toothpick and incubated for 16 h
at 37ºC and subsequently 72 h at room temperature. All methods were
assessed by measuring the diameter of the turbid zone.
Results and Conclusion: Both types of motility, antibiotic resistance and
production of submerged and A-L interface bioﬁlm respectively differed
in particular strains. There is no signiﬁcant correlation between motility
and production of bioﬁlm but we proved correlation between both types
of motility (p< 0.05; correlation coefﬁcient 0.37 and 0.434 resp.). The
resistance proﬁles showed different patterns in several groups of tested
strains. Relationships between virulence factors of P. aeruginosa are
complex and they will be also subject of following studies.
This work was supported by the Grant IGA MZ CR 9678−4.
P1915 The biocidal activity of silver nanoparticles toward
Pseudomonas aeruginosa plankton and bioﬁlm
A. Kalicinska, J. Stefanska, K. Szczepanowicz, S. Tyski ° (Warsaw,
Cracow, PL)
Objectives: The knowledge about silver possessing some antimicrobial
activity has been commonly available for many years. Silver or silver
coated surfaces are unfavourable environment for microbial colonization
and growth. Recently, the rapid development of nanotechnology is
observed. It seems interesting to investigate the antimicrobial activity
of silver nanoparticles toward cells of clinical Pseudomonas aeruginosa
strains.
Methods: The silver nanoparticles were synthesized chemically. The
average size of nanoparticles as measured by dynamic light scattering
(DLS) and scanning electron microscopy (SEM) techniques was below
20 nm. The range of nanoparticles concentrations used in this study was
160−2.5 ug/ml.
Nineteen P. aeruginosa isolates (10 from sputum of cystic ﬁbrosis
patients and 9 from urine) were under investigation. The minimal
inhibitory concentration (MIC) and minimal bactericidal concentration
(MBC) values of nanoparticles were estimated using standardised
plankton cells suspensions of strains. Parallel, 26 h bioﬁlms of
analysed strains growing on polystyrene microplate surface were treated
with silver nanoparticles concentrations for a 6−48 h contact time.
Staining with 3-(4,5-dimethyl-2-thiazolyl)-2,5 diphenyl-2H-tetrazolium
bromide (MTT) and measuring the absorbance at A = 554 nm, were
applied to estimate the level of viable bacterial cells. The 50% of
absorbance reduction after silver nanoparticles treatment was calculated
as signiﬁcant level of antibacterial activity.
Results: Analyzing all strains and different silver nanoparticles
concentrations, the following values were calculated: MIC50=20
ug/ml, MIC90=80 ug/ml, MBC50=80 ug/ml, MBC90=160 ug/ml. The
MBC/MIC ratio in case of 4 strains was 8, in case of 9 strains was 4 and
in case of 2 strains the ratio value was 1. The MIC and MBC values for
sputum strains were generally lower then such values for urine isolates.
The 6 h contact time of bioﬁlm with silver nanoparticles was ineffective.
However, after 24 h, 30 h and 48 h contact times in case of about half
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of the strains regardless of isolation site, the bioﬁlm populations were
reduced at least in 50%. Silver nanoparticles concentration 160 ug/ml
proved to be less effective against bioﬁlm structure, than concentrations
range 20−80 ug/ml.
Conclusion: Analysed silver nanoparticles showed antibacterial activity
against tested P. aeruginosa clinical strains cells, both in plankton form
and in bioﬁlm structure.
P1916 Proteomic analysis of Helicobacter pylori ATCC 43504
bioﬁlms
P. Pattiyathanee, R. Vilaichone, N. Chaichanawongsaroj ° (Bangkok, TH)
The bioﬁlms formation by Helicobacter pylori plays an important role
not only for environmental survival but also for colonization in vivo.
However the underlying factors involving H. pylori bioﬁlms formation
have not been characterized. In the present study, a proteomic analysis
was performed in order to compare the difference in protein expression
proﬁles between bioﬁlms-grown cells and planktonic counterparts of
H. pylori. Three proteins involving in chemotaxis and motility (FlgE,
FliD, FlaA) exhibited higher level of expression in bioﬁlms stage.
Additional proteins were found only in the bioﬁlms but not in planktonic
cells included oxidative stress response (KatA, TrxB, TsaA, electron
transport proteins (PorB, HPSH_01160, FldA), elongation factors (EF-
TU, EF-P, Tig), heat shock proteins (Hsp60 and GrpE), proteins involved
in nitrogen (UreA and UreB) and carbohydrate (AcnB and GltA)
metabolism. Proteomic technologies could enhance the understanding
of precise mechanisms related to bioﬁlms formation in H. pylori which
facilitate treatment and prevention of H. pylori infection.
P1917 Simvastatin inhibits the bioﬁlm formation of Candida
albicans
M. Kadowaki °, Y. Eriguchi, Y. Uchida, Y. Nagasaki, Y. Harada,
K. Sumida, N. Shimono (Fukuoka, JP)
Objectives: Candida albicans forms bioﬁlms on indwelling devices and
it is difﬁcult to treat device related infections caused by C. albicans.
Because of difﬁculty to eradicate bioﬁlms from devices, it is desirable
to prevent making bioﬁlms. Statins inhibit HMG-CoA reductase and are
mainly used as the cholesterol lowering agents, however, they showed
some additional effects. As to infectious diseases, they are reported to
decrease the risk of pneumonia, to improve the survival of patients with
sepsis, and so on. In this study, we investigated the potential efﬁcacy of
simvastatin (SVS) on the prevention of bioﬁlms formed by C. albicans.
Methods: SVS was hydrolyzed in ethanolic sodium hydroxide at 60ºC
for 2 h and kept as active open acid form. Three clinical strains of
C. albicans isolated from blood culture were used throughout this study.
Susceptibility testing, the minimal inhibitory concentration (MIC) of
SVS were determined based on NCCLS M27A.
Bioﬁlms of C. albicans were grown on the discs in the 96 well
microplates at 37ºC under several concentrations of sub MIC of SVS
for different incubation times. Morphological features of bioﬁlms were
observed under the light microscope and the confocal scanning laser
microscope (CSLM) used with ConA. Dry weight of bioﬁlms was
also measured. The total RNA was extracted from bioﬁlms using
RNeasy mini kit. First strand cDNA was made from total RNA using
high capacity cDNA reverse transcription kit. Reverse transcription-
polymerase chain reaction (RT-PCR) of genes related to bioﬁlm
formation was investigated.
Results: The MIC of C. albicans strains used in this study against SVS
was 16 microg/ml. The formation of bioﬁlms formed by C. albicans (CA
bioﬁlms) was inhibited microscopically, even if it is incubated under the
sub MIC of SVS. The maximum thickness of CA bioﬁlms without SVS
was approximately 200 microm. The thickness of CA bioﬁlms under
1/4 MIC was reduced up to 30%. The dry weight of CA bioﬁlms was
also decreased dose dependently and showed 50% reduction compared
to control. The expression of bioﬁlm related genes, including adherence,
hyphal formation, was investigated by RT-PCR. The genes related to
hyphal formation were poorly expressed in CA bioﬁlms under SVS
exposure.
Conclusion: Our data suggested that simvastatin inhibited C. albicans
bioﬁlm formation in vitro. The administration of SVS will be expected
to prevent forming C. albicans bioﬁlms on indwelling devices.
P1918 Drug susceptibility and virulence factors in Candida glabrata
mutants deﬁcient in proteins involved in histone modiﬁcation
S. Borecka °, T. Schwarzmu¨ller, S. Novohradska, K. Kuchler, J. Subik
(Bratislava, SK; Vienna, AT)
Objectives: The aim of this study was to determine the sensitivity to
chemical, osmotic and oxidative stress of C. glabrata mutant strains
deﬁcient in histone deacetylases and histone methylases, and to assess
their factors of virulence.
Methods: Drug susceptibilities were determined by broth microdilution
method in 96-well plates according to the CLSI (formerly NCCLS)
M27-A3 standard guidelines and by zone inhibition assay. To test for
heat shock sensitivity, the strains were incubated at 55ºC and in minute
intervals plated out on glucose-rich medium. Cell surface hydrophobicity
was measured by the water-octane two-phase assay. Bioﬁlm formation
was quantiﬁed by staining with crystal violet dye and biochemically
using the XTT reduction assay. The quantitative real time PCR was
carried out with the Maxima SYBR Green qPCRMaster Mix (Fermentas,
Vilnius, Lithuania) using the LightCycler 480 Real-Time PCR System
(Roche Diagnostics, Mannheim, Germany).
Results: The lack of histone modiﬁers studied in this work only
moderately affected the drug susceptibility and stress responses in
C. glabrata mutant strains. However, the heat shock sensitivity of the
strains with disrupted RPD3 and PHO23 genes was increased. Moreover,
virulence factors assessed at both 30ºC and 37ºC were signiﬁcantly
altered in some studied strains. Extremely high bioﬁlm formation was
observed at 30ºC in strains deleted in the SIR2 and SIR3 genes. On the
other hand, lower bioﬁlm formation ability was coupled with deletion of
RPD3 and PHO23 genes. The altered bioﬁlm formation in mutant strains
was accompanied by changes in expression of the EPA genes encoding
major adhesins of C. glabrata.
Conclusion: We identiﬁed histone deacetylases (encoded by the RPD3,
PHO23, SIR2 and SIR3 genes) regulating the bioﬁlm formation in
C. glabrata. Histone deacetylases Rpd3p and Pho23p may be the targets
for novel drugs reducing bioﬁlm formation and enhancing the activity
of other antimycotics in combination therapy.
P1919 In vivo efﬁcacy of anidulafungin, with and without alcohol,
lock therapy against Candida albicans catheter-related
infection
L. Long, A. Cirino, A. Miller, M. Ghannoum ° (Cleveland, US)
Objectives: C. albicans (CA) is the most common fungal pathogen
associated with colonization and bioﬁlm formation on the surfaces of
indwelling medical devices, such as IV catheters. The discovery of
antifungals that are able to sterilize prosthetic devices infected with
CA bioﬁlms should reduce the morbidity and mortality associated with
nosocomial candidiasis. Antifungal lock therapy (AFLT) provides a
means for delivering high concentrations of drug to the resistant bioﬁlms
formed on catheter surfaces. In this study, we compared the anti-bioﬁlm
efﬁcacies of anidulafungin (AND), with (w) and without (w/o) alcohol,
in the treatment of CA in a rabbit catheter-associated bioﬁlm model.
Methods: Silicone catheters were surgically placed in New Zealand
White rabbits. In 4 experiments, implanted catheters were infected
with CA bioﬁlm. Daily ﬂushes with heparinized saline (hep/sal) were
performed for 3 days after which blood cultures were drawn to conﬁrm
the presence of CA and treatment began. Next, animals were randomized
into groups; AND 2mg w alcohol (n = 6), AND 2mg w/o alcohol
(n = 2), AND 1mg w alcohol (n = 6), AND 1mg w/o alcohol (n = 2),
and untreated control (UC) (n = 8). Treatment was locked in the catheter
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lumen for 8 h/day for 7 days. Animals were sacriﬁced, and catheters
removed for quantitative culture and scanning electron microscopy.
Results: Quantitative culture of catheters treated with AND 2mg w and
w/o alcohol, and 1mg w/o alcohol yielded zero colony forming units.
AND 1mg w alcohol and the UC yielded 0.21±0.32 and 1.85±1.68,
respectively. AND 2mg w alcohol demonstrated signiﬁcant efﬁcacy
compared to the UC (P = 0.036). There was a trend towards signiﬁcance
with all other AND treated groups. Additionally, there was no signiﬁcant
difference between AND treated groups w and w/o alcohol.
Conclusions: AND 2mg w alcohol showed signiﬁcant efﬁcacy when
compared to the UC. There was no signiﬁcant difference between AND
w alcohol, and w/o alcohol-treated groups. AFLT with AND 2mg w
and w/o alcohol were able to sterilize intravenous catheters infected
with CA bioﬁlms. These ﬁndings suggest that future studies examining
the ability of AND lock therapy to salvage catheters infected with CA
may be warranted.
P1920 Comparison of bioﬁlm production by Candida albicans
isolates from blood and oral cavity
E. Eraso °, I. Miranda-Zapico, G. Quindos, C. Marcos-Arias (Leioa, ES)
Candida albicans is a major cause of superﬁcial and invasive mycoses.
Bioﬁlm production is considered a major virulence factor in candidiasis
associated to catheters, prosthesis and dentures.
Objective: To compare bioﬁlm production by C. albicans isolates from
blood, oral mucosa and dentures.
Methods: One hundred and ﬁfty one oral (51 from denture and 50
from oral mucosa) and 46 blood C. albicans isolates were tested for
bioﬁlm production. Bioﬁlms were developed in a 100 well polystyrene
microtitre plate and incubating during 24 and 48 h at 37ºC. Bioﬁlm
production was calculated by a tetrazolium salt (2,3-bis(2-methoxy-
4-nitro-5-sulfo-phenyl)-2H-tetrazolium-5-carboxanilide, XTT) metabolic
test. C. albicans NCPF 3153 and the hypha-deﬁcient mutant C. albicans
Ca2 were used as reference strains.
Results: All the C. albicans isolates studied formed bioﬁlms but showed
important differences depending on their origin: 48% of oral mucosa
isolates and 35.3% of denture isolates were highly bioﬁlm producers at
24 h. 35.3% of oral mucosa isolates and 52% of denture isolates were
intermediate bioﬁlm producers. Conversely, only 2.2% of bloodstream
isolates were highly producer and 47.8% of the isolates were found
to be intermediate producers. Oral C. albicans isolates, both from the
denture and the oral mucosa, were found to be more producers of
bioﬁlm than bloodstream C. albicans isolates, being this difference
statistically signiﬁcant (p< 0.05). However, there was not signiﬁcant
difference (p = 0.18) when bioﬁlm production was compared between
denture oral mucosa isolates, being more producers those isolates from
denture and from the oral mucosa.
Conclusion: Bioﬁlm production in C. albicans is strongly related to the
clinical origin of the isolates: Oral isolates are richer bioﬁlm producers
than blood isolates.
Funding: Projects GIC07 123-IT-222−07 (Departamento de Educacion,
Universidades e Investigacion, Gobierno Vasco), S-PE08UN35 (Saiotek
2008, Departamento de Industria, Comercio y Turismo, Gobierno Vasco)
and PI061895/2006 (Fondo de Investigacion Sanitaria del Ministerio de
Sanidad y Consumo de Espan˜a).
P1921 Morphogene BolA: its role in bioﬁlm formation and
respiration of E. coli K-12 MG1655
M. Adnan °, M. Pereira, I. Machado, G. Morton, S. Hadi (Preston,
UK; Braga, PT)
Objectives: One important and clinically relevant example of E. coli
adaptation through systematized gene expression is their ability to grow
in bioﬁlms in different environmental conditions. Stress response genes
are induced whenever a cell needs to survive under adverse growth
conditions. One of the possible gene having an inﬂuence on this process
is morphogene BolA. Therefore, our work aims to understand the stress
tolerance response of E. coli in relation with BolA gene under different
environmental conditions.
Methods: RNA Extraction: Bacterial cells were harvested and resus-
pended into RNAprotect® Bacteria Reagent (Qiagen, UK) and RNA
was extracted using Qiagen RNeasy® kit. RNA quality was assessed by
agarose gel electrophoresis.
Real time RT-PCR: Real time RT-PCR was used to examine the
expression level of BolA gene in bioﬁlms and planktonic cells. Total
RNA was extracted, converted to cDNA that was processed using real
time PCR (ABI PRISM 7500, Applied Biosystems). Reactions were
performed in a 25 ml reaction volume. BolA speciﬁc primers were
developed in house for this purpose.
Metabolic activity-respiratory activity: The respiratory activity of the
several biological (bioﬁlm suspensions or suspended cultures) samples
was evaluated by measuring oxygen uptake rates in a biological oxygen
monitor (BOM) in short-term assays. The assays were performed in a
Yellow Springs Instrument BOM (Model 53).
Results: The expression level of BolA gene was found to be higher in
wild type strain in bioﬁlm mode when compared with planktonic phase.
This was quantiﬁed during both planktonic growth and in bioﬁlms by
real time RT-PCR during different stress conditions. This is the ﬁrst
study involving respirometric analysis which showed that BolA gene
might have a major role in respiration of E. coli in both bioﬁlm and
planktonic phases.
Conclusion: It has been shown that the growth rate of E. coli remained
the same without BolA gene in planktonic cells and also that BolA
mutant cannot grow as cell aggregates like wild type E. coli does
which suggests the contribution of BolA gene in bioﬁlm formation. A
comparison between wild type and BolA mutant strains also clearly
established the ability of BolA gene to respond and adapt to several
stress conditions. The involvement of BolA gene in E. coli respiration
was observed by checking its glucose metabolism and oxygen uptake
under various environmental stress conditions in both wild type and
mutant strains.
P1922 The effect of silver and gold nanoparticles on several
bacterial species
K.I. Wolska °, A. Kraczkiewicz-Dowjat, W. Klapczynska, A.M. Grudniak
(Warsaw, PL)
Objectives: Antibacterial activity of silver and gold ions has been well
proved. Recently there is a growing interest connected with silver and
gold colloidal nanoparticles (Ag NPs and Au NPs, respectively) which
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also show an antimicrobial activity. Until now the number of papers
on this subjects is very scarce. Ag NPs and Au NPs can attach to
bacterial membranes and penetrate inside cells. The aim of this study
was to evaluate the antimicrobial activity of Ag NPs and Au NPs
against nine bacterial species, including pathogens, by the MICs values
measurement and the estimation of nanoparticles effect on bacterial
growth and survival. The inﬂuence of Ag NPs on cell morphology and
bioﬁlm formation was also investigated.
Methods: Ag NPs and Au NPs were provided by Daunlop, Poland, their
diameter varied from 30 to 50 nm. MICs value were measured by two-
fold dilution method. The effect of 0.75MIC of Ag NPs and Au NPs on
bacterial growth was studied by measuring the absorbance at 600 nm of
exponentially growing cultures. The effect on cell survival was estimated
by counting of cfu, after plating appropriately diluted samples on solid
media. The inﬂuence of Ag NPs on cell morphology was examined
using scanning electron microscopy (LEO 1430VP, Carl Zeiss) at 2500
x magniﬁcation. To study bioﬁlm formation the classic method based on
the absorbance of crystal violet by cells adhered to the wells of microtitre
dishes was applied.
Results: MICs of Ag NPs of all bacterial cultures varied from 1 to 12.5
micrograms mL−1 and MICs of Au NPs, from 5 to 12.5 micrograms
mL−1. Both compounds inhibited bacterial growth and survival. Ag NPs
showed the stronger inhibition of bacterial growth and survival than Au
NPs, the inhibitory effect depended on the bacterial species tested. Ag
NPs affected bacterial morphology and impaired formation of bioﬁlms.
Conclusions: Ag NPs and Au NPs are the potent antibacterial
agents inhibiting bacterial growth and survival. Ag NPs inﬂuence cell
morphology and bioﬁlm formation.
Host defence and pathogenesis
P1923 The role of cathepsin X in the immune response to infection
with Helicobacter pylori
M. Skvarc °, A.N. Kopitar, S. Jeverica, B. Tepes, A. Ihan (Ljubljana,
Rogaska Slatina, SI)
Objectives: Cathepsin X has been shown to regulate immune response.
Its active role has been demonstrated previously in chronic inﬂammation
of gastric mucosa and tumorgenesis of gastric cancer. In this study we
demonstrate its role in presenting the antigens to immune cells and in
the immune response to H. pylori infection.
Methods: We used the monoclonal antibody against cathepsin X and
ﬂow cytometry to determine the level of cathepsin X in THP-1 cells
primed with H. pylori antigens isolated from subjects suffering from
gastritis, who either successfully eradicated the H. pylori (seven patients
158/189) or not (seven patients 108/152) after the antibiotic therapy. We
also compared the expression of cathepsin X on the THP-1 cells after
priming the cells with H. pylori antigens and polymixin B, that binds to
lipid A, in the same two groups of patients. We also measured the level
of IL-6 and, IL-12/23 using ﬂow cytometry. We used Mann–Whitney
test to analyze the data.
Results: The group Hp108/152 expressed statistically signiﬁcant less
cathepsin X on the THP-1 cells than the group Hp158/189. We
discovered that adding polymixin B to H. pylori antigens effects the
expression of cathepsin X. Expression was higher in the group 158/189
than in the group 108/152. The difference was statistically signiﬁcant.
The trend was the same as when we tested the expression of cathepsin
X with H. pylori antigens only. We measured the level of IL-6 and
IL-12/23 in the supernatant from the THP-1 cells. The level of IL-12/23
was higher when we used strains 158/189. The difference was statistically
signiﬁcant in comparison with the strains 108/152. LPS does not have
such a strong inﬂuence on the expression of cathepsin X and on the level
of cytokines as we speculated when we added polymixin B. We got the
opposite results as we expected.
Conclusion: In our previous study we compared the level of IFN-g and
discovered that strains 108/152 produced weaker immune response than
the strains 158/189.
In this study we have proven that different strains of Helicobacter pylori
have different cathepsin X proﬁls and that the level of cytokines is
different when we add H. pylori antigens, that were gathered from the two
group of patients. The patients 108/152 did not eradicate the H. pylori
because the antigens from these strains of H. pylori are less immunogenic
than the antigens from strains 158/189. Apparently cathepsin X plays a
vital role in this process.
P1924 Puriﬁcation and characterization of an anti-pneumococcal
capsular polysaccharide IgG antibody preparation
E. Lock, P. Worthington, L. Foyle, L. Garner, J. McGough, R. Barber,
P.D. Stubbs, F. Alcock, R. Hughes, G.L. Wallis, A.R. Parker °
(Birmingham, UK)
Objectives: Streptococcus pneumoniae is a major human pathogen
causing pneumonia, sepsis, meningitis and otitis media. The major
virulence factor of S. pneumoniae is the capsular polysaccharide (PS),
of which there are 90 different types each inducing their own serotype
speciﬁc antibodies. Since anti-PS antibodies are highly protective, efforts
have focused on using the PS as immunogens for the development
of pneumococcal vaccines. Standardisation of quantitative PS antibody
measurement is of utmost importance between different laboratories.
The objective of the study was to purify speciﬁc anti-PS IgG antibodies
against the 23-valent PNEUMOVAX™ vaccine (Merck and Co. Inc).
Methods: Pooled plasma from multiple donors (6 to 10) were
clotted. Three independent pools were prepared. Total IgG was
puriﬁed using ammonium sulphate precipitation and anion-exchange
chromatography. Following adsorption of contaminating non-speciﬁc PS,
pneumococcal capsular polysaccharide(PCP)-speciﬁc antibodies were
obtained by afﬁnity puriﬁcation using PNEUMOVAX™ covalently
linked to Sepharose. The puriﬁed PCP speciﬁc IgG was characterised
for purity, serotype composition, function, and then quantiﬁed.
Results: SDS-PAGE analysis suggested that the puriﬁed PCP speciﬁc
IgG was at least 95% pure. Functionally, the preparation contained
no contaminating Haemophilus inﬂuenzae type b, diphtheria toxoid or
tetanus toxoid or contaminating non-speciﬁc PS antibodies. The major
IgG subclasses in the preparation were IgG2 > IgG1 with negligible
levels of IgG3 and IgG4. Immunoglobulin classes IgA and IgM were
absent. Serotype analysis indicated that this preparation reacted with all
23 serotypes present in the PNEUMOVAX™ vaccine.
Conclusion: Determination of accurate antibody titre is essential for
serodiagnosis, epidemiological investigation and evaluation of vaccine
response. We show that it is possible to purify a sample containing 23
serotype speciﬁc antibodies produced in response to PNEUMOVAX™
vaccination which could be used to aid standardisation of different
technologies to measure antibodies to PCP.
P1925 CD36 is a phagocytic receptor for Streptococcus pneumoniae
and involved in bacterial clearance during pneumococcal
pneumonia in vivo
O. Sharif °, U. Matt, K. Stich, B. Doninger, S. Knapp (Vienna, AT)
Objective: CD36 is a class B scavenger receptor that is expressed on
several cell types including monocytes, macrophages and platelets and
exhibits pleiotropic functions including: adhesion to thrombospondin,
inhibition of angiogenesis, transport of long chain fatty acids and
clearance of apoptotic cells. Additionally, CD36 has been implicated
in the host immune response since it has been shown to act as a co-
receptor for Toll like receptor 2 (TLR2) and to play a role in malaria
and Staphylococcus aureus infection. However, its role in other Gram
positive bacterial infections is unclear. Here, using mice mutant in CD36
we sought to examine the role of CD36 in pneumococcal pneumonia, a
major cause of morbidity and mortality worldwide.
Methods: WT and CD36 mutant mice were intranasally inoculated with
Streptococcus pneumoniae. Survival, bacterial counts, neutrophil inﬂux
and chemokine/cytokine responses were evaluated in vivo in a time
dependent manner. In vitro, WT and CD36 mutant alveolar and bone
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marrow derived macrophages were utilized to study the response to
S. pneumoniae treatment.
Results: We show that early in infection although CD36 mutant mice
have an exaggerated inﬂammatory response, S. pneumoniae bacterial
loads are similar in CD36 mutant compared to wild type (WT) mice.
However, at later time points, although CD36-mutant mice exhibit
impaired bacterial clearance, they surprisingly do not show decreased
survival compared to their WT counterparts. In vitro studies utilizing
CD36 mutant primary cells conﬁrm enhanced early inﬂammation in
response to S. pneumoniae. Furthermore, phagocytosis assays show that
CD36 mutant alveolar macrophages exhibit impaired phagocytosis in
response to S. pneumoniae.
Conclusion: These data show that CD36 plays an indispensable role in
the lung in response to S. pneumoniae infection by virtue of its ability
to act as a phagocytic receptor, but suggest mortality is not different
because this defect is compensated for by enhanced inﬂammation.
P1926 Inhibition of macrophage ingested MDR M. tuberculosis
growth
J. Gvozdeva °, L. Kovalchuk, T. Smirnova, L. Gankovskaya,
L. Chernousova (Moscow, RU)
A natural cytokines complex (CNC) and antimicrobial peptides (AMP)
is a standardized complex of cytokines produced by pig’s activated
peripheral blood leukocytes, for which activity of interleukins 1, 2,
6, tumor necrosis factor, migration inhibitory factor, and transforming
growth factor have been determined. Besides low-polymeric fraction
cytokines, peptides similar to protegrin with direct antiviral and
antimicrobial effects were identiﬁed.
Aim:to study CNCplusAMP effect on growth of MDR M. tuberculosis
ingested by macrophages. We used an ex vivo model exposed to
CNCplusAMP on peritoneal macrophages of C57Bl/6 mice infected by
MDR M. tuberculosis. Macrophages were preliminarily incubated with
CNCplusAMP, 5:1, on 96-well plates using RPMI1640 medium with
5mM HEPES, 2mM L-glutamin, 5%FCS at 5%CO2. M. tuberculosis
growth was estimated on day 7 using quantitative PCR, real-
time (M. tuberculosis-M.bovis DNA test-system). M. tuberculosis
cytopathogenic effects on macrophages were estimated by LDH
release from injured macrophages into media according to the
“Promega” instruction. The studies demonstrated that on day 7
M. tuberculosis growth rate increased from 5.6±0.03 to 6.0±0.07
lgCFU. Macrophages inhibited mycobacteria growth (5.8±0.03 lgCFU).
Preliminary incubation of infected macrophages with CNCplusAMP in
the concentration of 5mkg/ml revealed the trend towards complementary
inhibition of mycobacteria growth (5.7±0.03 lgCFU). CNCplusAMP
in the concentrations of 1mkg/ml and 0.1mkg/ml did not produce
reliable inﬂuence on mycobacteria growth. CNCplusAMP inﬂuence
on infected macrophages represented a reliable decrease of cytotoxic
effect of M. tuberculosis on macrophages: speciﬁc macrophage lysis
reached 23.8±1.16%(p = 0.002) at 5mkg/ml of CNCplusAMP and
24.0±0.84%(p = 0.001) at 1mkg/ml CNCplusAMP as compared to
M. tuberculosis infected macrophage lysis (30.6±1.23%).
CNCplusAMP activated macrophages, which led to increased bacteri-
cidal effect of macrophages on MDR M. tuberculosis. The degree of
growth inhibition depended on CNCplusAMP doses; the maximal effect
was observed at the concentration of 5mkg/ml.
P1927 Coxiella burnetii antigen-stimulated dendritic cells mediate
protection against C. burnetii challenge in Balb/c mice
Y. Wei °, X. Wang, B. Wen (Beijing, CN)
Objectives: Coxiella burnetii, an obligate intracellular bacterium, is the
etiological agent of human Q fever. To investigate the role played by
dendritic cells (DCs) in protective immunity to the pathogen, C. burnetii
antigens were applied to stimulate DCs and their responses were
analyzed.
Methods: The immature DCs derived from bone marrow cells of Balb/c
mice were stimulated with C. burnetii whole cell antigens (phase I Ag
and phase II Ag) and recombinant protein antigens (rP)124, rP105, and
rP54, respectively, and expression of MHC-II and cytokines of antigen-
pulsed DCs were evaluated by ﬂow cytometry. The antigen-pulsed DCs
were transferred to Balb/c mice and the mice were challenged with
virulent C. burnetii organisms 24 h later. Coxiella loads in spleens of
mice were measured by quantitative polymerase chain reaction 6 days
postinfection.
Results: Compared with mice receiving rP54-pulsed DCs, mice
receiving DCs pulsed with phase II Ag, phase I Ag, rP124, or rP105
exhibited signiﬁcantly lower levels in coxiella loads of spleens, and
however there was no signiﬁcant difference between mice receiving rP54-
pulsed DCs and naı¨ve mice. After 24 h of coculturing with homologous
antigen-pulsed DCs, expression of CD69, IFN-g, and IL-17 on CD4 T
cells from mice receiving phase I Ag-, phase II Ag-, rP124-, or rP105-
pulsed DCs were signiﬁcantly higher than that of mice receiving rP54-
pulsed DCs. However, the percentage of CD4+ and IL-17 double-positive
cells in mice receiving DCs pulsed with phase I Ag, phase II Ag, rP124,
or rP105 were higher than that of mice receiving rP54-pulsed DCs. In
addition, higher level of IL-6 and IL-12 and low lever of IL-10 were
detected in supernatants of splenocytes from mice receiving DCs pulsed
with phase I Ag, phase II Ag, rP124, or rP105, and opponent results
were detected in that of mice receiving rP54-pulsed DCs after 24 h of
coculturing with homologous antigens.
Conclusion: The data suggest that a vigorous proinﬂammatory response
in DCs is associated with protective immunity against C. burnetii.
Besides whole cells phase II Ag and phase I Ag, surface protein antigens
rP124 and rP105 have the ability to activate DCs to mediate protection
against C. burnetii infection.
P1928 Increased serum concentration of high-mobility group Box-1
(HMGB-1) in tuberculous lymphadenitis: a pilot study
W.S. Choi °, Y.K. Youn, Y.M. Jo, J.Y. Kim, J.Y. Song, J.W. Sohn,
H.J. Cheong, W.J. Kim, M.J. Kim, D.W. Park (Seoul, KR)
Objectives: HMGB-1 is a DNA-binding protein that is passively
released by necrotic and damaged cells. Extracellular HMGB-1 is
considered as a necrotic marker. Tuberculous lymphadenitis is a chronic
granulomatous inﬂammation with caseation necrosis of the lymph
node. The necrotic feature of lymph node usually improves with
anti-tuberculous chemotherapy. Sometimes it is difﬁcult to assess the
treatment response of tuberculous lymphadenitis. This study is a pilot
study to determine the possibility of HMGB-1 as a biomarker for
assessing the treatment response of tuberculous lymphadenitis.
Methods: Serum HMGB-1 level was measured quantitatively using a kit
(HMGB1 ELISA Kit II, Shino-Test Corporation, Sagamihara-shi, Japan).
Sera samples were collected from 14 patients with conﬁrmed tuberculous
lymphadenitis before initiating anti-tuberculous chemotherapy and 10
persons (controls) with no evidence of M. tuberculosis infection.
Tuberculous lymphadenitis was conﬁrmed by pathology, culture or
polymerase chain reaction (PCR).
Results: The mean age of 14 patients was 41.86±11.92 years and 12
(85.7%) were female. The mean age of 10 controls was 37.80±8.07
years and 5 (50.0%) were female. There were no signiﬁcant differences
in age (P = 0.361) and sex (P = 0.085). Among 14 patients, 7 (50.0%)
were conﬁrmed by PCR, 6 (42.9%) by pathology and PCR, and 1 (7.1%)
by culture and PCR. Serum HMGB-1 level was signiﬁcantly (P = 0.002)
elevated in patients (10.94±2.69 ng/ml) before initiating anti-tuberculous
chemotherapy compared with controls (7.93±2.52 ng/ml).
Conclusion: The current study revealed that serum HMGB-1 level is
elevated signiﬁcantly in patient with tuberculous lymphadenitis before
initiating anti-tuberculous chemotherapy. The result suggested that
HMGB-1 could be a biomarker for treatment response. Further studies
will be followed to determine the serum HMGB-1 level in the middle
and in the end of the treatment.
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P1929 Role of leukotrienes in resistance and susceptibility to
infection by Histoplasma capsulatum
A. Secatto °, E. Soares, A. Medeiros, L. Faccioli (Ribeira˜o Preto,
Araraquara, BR)
Introduction and Objectives: Histoplasma capsulatum (H. capsulatum)
is a dimorphic pathogenic fungus that causes a wide spectrum of
diseases. Macrophages are an important phagocytic cells in host
defense against fungi. In order to enhance host defense, these resident
cells secrete chemotactic substances such as leukotrienes (LTs) and
cytokines that recruit effector cells to the focus of infection. LTs
are potent lipid mediators of inﬂammation and host defense, derived
from the 5-lipoxygenase (5-LO) pathway of arachidonic acid (AA)
metabolism. We have been shown that the absence of leukotrienes
in genetically modiﬁed mice (5-LO−/−) or by treating WT animals
with pharmacological inhibitor MK886, have increased susceptibility
to infection when they are infected with H. capsulatum. Recent
studies show that susceptibility or resistance of different strains to
certain infections, such as Leishmania amazonensis, is associated with
differential production of LTs. In the present study, we evaluated the
production of LTB4 by peritoneal macrophages (PM) from susceptible
and resistant mice after challenge with H. capsulatum and the effect of
LTs in phagocytosis by macrophages of both strains.
Methods and Results: Macrophages from C57BL/6 (susceptible) and
sv129 (resistant) mice were infected for 48 h at a ratio of 1:5 (H. cap-
sulatum:macrophage). Supernatants were collected and the production
of LTB4 was evaluated by ELISA. The phagocytosis was assessed
by ﬂuorescence using unopsonized or IgG-opsonized FITC-labeled
H. capsulatum and MK886, a LTs inhibitor, was added to the cells
previously to the infection. Interestingly, macrophages from resistant
mice produced higher levels of LTB4 upon H. capsulatum challenge
than did those from susceptible mice. As expected, PMs from sv129
phagocytosed 1.9 fold-increased IgG-opsonized-H. capsulatum than PMs
from C57BL/6. However, phagocytosis of IgG-opsonized-H. capsulatum
by PMs from C57BL/6 and sv129 are both dependent on endogenous
LTs, since when the LTs synthesis is pharmacologically inhibited, the
phagocytosis was decreased 10 and 20-fold respectively.
Conclusion: LTs are important mediators involved in the mechanisms of
host defense by participating in the patterns of resistance/susceptibility
to infection of H. capsulatum.
P1930 Identiﬁcation of new epitopes in the Trypanosoma cruzi
membrane antigen that are recognized by CD8+ T
lymphocytes from Chagas patients
A. Egui Machado °, C. Maran˜on, C. Thomas, M. Segovia, M. Lo´pez
Lo´pez (Granada, Murcia, ES)
Objectives: Trypanosoma cruzi is the aetiological agent of Chagas
disease or American trypanosomiasis, which affects 15 million people
in Central and South America, and thus represents an important health
problem. CD8+ T cell response has been widely reported as essential
for immune-protection against the T. cruzi infection. However, only few
CD8+ epitopes recognized by chagasic patients have been described,
remaining unknown the functionality of speciﬁc T cells for most of them.
Here we characterized human CD8+ epitopes selected from the deduced
amino acid sequence of the T. cruzi TcCA-2 gene (TcMe protein) using
models of experimental infection in transgenic C57BL/6-A2Kb mice and
mononuclear cells from chagasic patients.
Methods: Using SYFPEITHI software, we predicted peptides capable
of biding to the human Class I molecule HLA-A*0201 located in the
repeated amino-terminus of the TcMe protein. The binding capacity
of these peptides to HLA-A*0201 was quantiﬁed in T2 cells. We
have evaluated the processing and presentation of the peptides during
experimental infection throughout the IFN-g secretion test in splenocytes
of infected A2/Kb transgenic mice after in vitro stimulation with
each peptide. The recognition of epitopes during natural infection
was evaluated by measuring IFN-g and TNF-a secretion in circulating
mononuclear cells from chagasic patients and healthy individuals from
endemic areas. Finally, we determined the number of TcMe-speciﬁc
granzyme B-producing cells by an ELISPOT assay in both patients and
controls.
Results: We found ten peptides candidates for binding to HLA-A*0201,
located in the repeated sequence of the TcMe protein. Five of these
peptides showed to be successfully processed and presented in both
experimental and natural infection models, producing the expression
and secretion of TNF-a and IFN-g cytokines. We detected granzyme
B-producing cells for two of the referred epitopes.
Conclusions: Five new epitopes of the T. cruzi TcMe protein restricted
to HLA-A*0201 are efﬁciently processed, presented and recognized by
CD8+ T lymphocytes during the natural course of the Chagas disease.
Our results suggest that CD8+ T cells speciﬁc to these epitopes have
both cytotoxic and cytokine secretory capacity in patients with Chagas
disease.
P1932 The impact of single nucleotide polymorphisms of
the tumour necrosis factor gene for the advent of
ventilator-associated pneumonia
A. Kotsaki, A. Savva, F. Baziaka, P. Koutoukas, A. Spyridaki,
E.J. Giamarellos-Bourboulis ° (Athens, GR)
Objectives: Tumor necrosis factor (TNF)-a is a major pro-inﬂammatory
cytokine produced early during sepsis cascade. Several studies have
tried to elucidate the role of single nucleotide polymorphisms (SNPs)
within the promoter region of TNFa gene regarding predilection to
sepsis or sepsis severity. The results so far have been contradictory with
many of the discrepancies grounded to the limited number of patients
enrolled. We aimed to deﬁne the role of SNPs of the TNFa gene in the
development of ventilator-associated neumonia (VAP).
Methods: 214 consecutive patients were followed-up after intubation
and admission in three academic intensive care units; 169 developed
VAP. Time to development of VAP was estimated. Whole blood was
collected in EDTA-coated tubes from those who developed VAP. DNA
was extracted by Purigen Blood Core Kit C (Qiagen) standard technique.
TNF-a SNPs of the promoter region i.e. −376G/A, −238G/A and 308
G/A were estimated by RFLP and visualization of the digested PCR
products after UV photometry on 2.0% agarose gels.
Results: Regarding the −376 SNP 166 (98.2%) patients were carriers
of the GG wild-type haplotype and three patients (1.8%) were GA
heterozygotes. Regarding the −308 SNP 132 (78.1%) patients were
carriers of the GG wild-type haplotype, 35 patients (20.7%) were
GA heterozygotes and two patients (1.2%) were homozygotes for the
AA mutation. Regarding the −238 SNP 164 (97.0%) patients were
carriers of the GG wild-type haplotype and ﬁve patients (3.0%) were
GA heterozygotes. The allele frequency in the population was in
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Hardy-Weinberg equilibrium. Time to advent of VAP was signiﬁcantly
shortened among carriers of at least one SNP than among non-carriers
of any SNP (log-rank: 4.08, p: 0.043, Figure).
Conclusions: SNP of the TNFa gene promoter region are associated
with a predilection for earlier development of VAP after intubation.
P1933 Prospective analysis of salivary IgA responses in children
during the ﬁrst three months of life against pathogen of
oral cavity. Inﬂuence of prematurity in this response
R.D. Nogueira °, M.C.L. Borges, M.L.T. Sesso, V.P.L. Ferriani (Ribeirao
Preto, BR)
Objectives: The analysis of the mucosal immune system represents an
interesting way to understand the microbial colonization in early life,
particularly the response of SIgA (Secretory IgA) present in saliva
because it represents the ﬁrst line of defense. Previous study showed
in children with 6 months of age, a high complexity of SIgA response
to antigens of mutans streptococcal (MS), main pathogen of the dental
caries, but little is known about the ontogeny of the mucosal immune
system in the ﬁrst 3 months of life especially in preterm newborn
(below 37 weeks of gestation). For this reason, we compared the levels
and speciﬁcity of SIgA to MS and others species enrolled with initial
infection in fullterm (FT) and preterm (PT) early in life.
Methods: Stimulate saliva from 160 children, with 0 day of life (T0) and
after 3 months (T3), were enrolled in this study. Salivary IgA and IgM
levels were determined by ELISA. Subsets of 24 fullterm (FT) and 24
Preterm (PT) children showing similar salivary IgA levels were paired
and matched for gender, racial background, breastfeeding. SIgA antibody
reactivity to Streptococcus mutans (MS), Streptococcus sanguinis (SSA),
Streptococcus mitis (SMI) and Streptococcus gordonii (SGO) Ags was
determined in Western blot assays.
Results: Levels of SIgA were statistically different (Whitney test,
p< 0.05) between groups and in FT were 2.5 times higher than PT
children at T0, but not T3 (p> 0.06). Signiﬁcant diversity was observed
in IgA antibody response patterns to Ags. The number and intensity of
reactive bands was higher in FT than PT children for all antigens tested
only T0. In T3 SIgA response was similar in PT and FT. Some antigens
were more frequently detected in salivas, such as: 153KDa of SGO,
170KDa of SSA, 202KDa of SMI, 185 and 160KDa of SM. Responses
to 153KDa of SGO (glucosyltransferase activity) were unique among
those antigens that presented different in their pattern of recognition
between FT and PT at T0 (Chi-square:, p< 0.02).
Conclusions: The data indicate that salivary IgA responses to Ags can
occur in the ﬁrst day of life and children PT show a diminished response
to microorganisms tested that may reﬂect a lower concentration of IgA,
but with 3 months of age PT and FT have the same SIgA response.
CNPq 472928/2007−4, FAPESP 02/07156−1; 04/07425−8.
P1934 Benzodiazepines and cannabinoids lead to enhanced
susceptibility and severity of orthopoxvirus infection
H.P. Huemer °, C. Lassnig, D. Bernhard, S. Sturm, N. Nowotny,
E.U. Irschick, M. Kitchen, M. Pavlic (Innsbruck, Vienna, AT)
Introduction: Benzodiazepines are widely used as tranquilizers,
anticonvulsives and various other indications. The leaves and resin of
Cannabis sativa (Indian hemp) are known substances of abuse, but have
been also documented since 2000 years as herbal medicine in many
cultures. In certain countries, including Austria, its main psychoactive
compound THC (d9-tetrahydrocannabinol) is licensed as a medical drug
for stimulating appetite in kachectic patients and a means for pain
release. There is growing evidence that also other constituents of the
resin other than THC may have signiﬁcant drug effects which may be
usable in medicine.
Methods: Balb/c mice were treated with a single dose of diazepam
and/or cannabinoids one day before infection with vaccinia virus (VACV)
and cowpox virus (CPXV). Infected animals were monitored and weight
and disease index recorded. The anti-CPXV antibody response was
determined in an ELISA assay. The different substances were also
tested for their ability to interfere with the mitogen-mediated immune
stimulation of peripheral blood mononuclear cells (PBMC) as well
of human and murine spleen cells in proliferation assays using H3-
thymidine labeling. Additionally the late apoptosis of whole spleen cells
was tested by propidium iodide staining and FACS analysis.
Results: Diazepam as well as cannabis/THC led to earlier onset of
disease, prolonged duration of symptoms, higher weight loss and
overall disease index in mice infected with VACV. In CPXV infected
mice the typical poxviral skin lesions developed after administration
of diazepam only and also a signiﬁcant decrease in the anti-CPXV
speciﬁc antibody response was observed in the drug treated animals.
Cannabinoids, diazepam and to a certain extent also alprazolam inhibited
the proliferative response of human PBMC or human and murine spleen
cells in vitro but did not show noteworthy apoptotic effects. The cannabis
resin was fractionated also by HPLC and inhibitory fractions could be
also extracted from cigarette smoke extracts.
Conclusions: Together with our recent ﬁndings of a human case of
unusual severe CPXV infection in a young drug taker these data indicate
a certain risk of “soft drugs” for suszeptibility of orthopoxvirus infection.
As VACV is still used as an outdated life vaccine against smallpox
infection, these data provide a ﬁrst evidence of a risk of certain drugs
for more severe side effects and/or possible interference with the success
of vaccination.
P1935 Enhanced anti-inﬂuenza IgA production in airway mucosa
by clarithromycin and its restoration effects on mucosal
immunity in patients treated with oseltamivir
H. Kido °, S. Suzuki, K. Iwase (Tokushima, Nagoya, JP)
Objectives: The antiviral neuraminidase inhibitor oseltamivir (OSV)
suppresses inﬂuenza viral RNA replication and viral antigenic produc-
tion, resulting in a limited immune response against virus, particularly
airway IgA response. The macrolide clarithromycin (CAM) is used to
treat bacterial infections and has immunomodulatory activities. This
retrospective study investigated the immunomodulatory effects of CAM
in inﬂuenza patients who were treated with or without OSV.
Methods: The study recruited 40 children with acute inﬂuenza, and
grouped them according to the treatment received: ﬁve days treatment
with OSV (n = 14), CAM (n = 8), OSV+CAM (n = 12) and untreated
(n = 6). The Before and after treatment comparisons were made of the
level of secretory IgA (sIgA) against inﬂuenza A virus (H3N2) and
(H1N1), total sIgA, viral RNA copy numbers in nasopharyngeal aspirates
and disease symptoms.
Results: Infection induced anti-viral mucosal sIgA in the nasopharyngeal
aspirates of most patients of all treatment groups. Particularly prominent
increases in the levels were found in the CAM and OSV+CAM groups.
Low induction of anti-viral sIgA was observed in the OSV group, but the
addition of CAM to OSV augmented sIgA production and restored local
mucosal sIgA levels. The frequency of residual cough in the OSV+CAM
group was signiﬁcantly lower than in the other groups including the
group treated with OSV.
Conclusion: CAM boosted the nasopharyngeal mucosal immune
response in children presenting with inﬂuenza A, even in those treated
with OSV who had low production of mucosal anti-viral sIgA, and
alleviated the symptoms of inﬂuenza.
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P1936 Quantitative evaluation of Clostridium difﬁcile and intestinal
lactobacilli in patients with antibiotic associated diarrhoea
I. Smidt °, E. Sepp, M. Ra¨tsep, S. Ko˜ljalg, K. Lo˜ivukene, I.H. Lo¨hr,
O. Nata˚s, R. Ma¨ndar, P. Naaber (Tartu, EE; Stavanger, NO)
Objectives: (1) To evaluate the correlation between presence of
Clostridium difﬁcile (CD) toxins and CD population level in the intestine
we compared CD counts in direct toxin test positive and negative
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(C. difﬁcile infection) CDI patients. (2) To evaluate the role of lactobacilli
(LB) in colonization resistance against C. difﬁcile we compared the
counts and diversity of intestinal LB in CDI and non-CDI patients with
antibiotic associated diarrhoea (AAD).
Material and Methods: Faecal samples of AAD patients were collected
from Norway (n = 42) and Estonia (n = 36). Direct toxin A+B EIA test
was performed and quantitative cultures from serial dilutions were made
on LAB 160 agar for CD and on MRS and Rogosa agar for LB.
Results: From 43 faecal samples that were culture positive for toxigenic
CD strain (CDI cases), 28 were toxin positive and 15 negative by EIA
test. In CDI patients CD counts varied from 5 to 7.3 log CFU/g (median
6.3). Although CD counts were somewhat higher in toxin positive CDI
cases than in negative cases (medians 6.9 vs 6.0) the difference was
not statistically signiﬁcant. Comparing CDI and non-CDI AAD cases
no signiﬁcant differences were found in total counts of intestinal LB
(medians 2.7 and 2.9 log CFU/g), in their prevalence (60 vs 54%)
and numbers of different LB strains (medians 1 vs 1). Comparing
Estonian and Norwegian AAD patients we found more different LB
strains (medians 2 vs 0) and higher LB counts (medians 4.14 vs 0 log
CFU/g; p = 0.02) in Norwegian patients. Similar trends were present if
comparing CDI and non-CDI samples separately.
Conclusion: In our study positive direct toxin test did not predict higher
population level of CD in the intestinal tract of CDI patients. Correlation
between intestinal CD counts and severity of disease should be evaluated
in future studies. We did not ﬁnd any correlation between presence
of cultivable LB or their count in intestine and presence of CD as
cause of AAD. Thus our study does not support the role of LB in
maintenance of colonization resistance against CD. Higher counts of
intestinal LB in Norwegian AAD patients probably reﬂect common usage
of probiotics containing yogurts in the hospital and in the community
rather than differences in antibiotic treatment. Further studies are needed
to determine the causes of higher colonization of Norwegians with LB
and its possible effect on AAD and CDI incidences.
P1937 Resistance to colistin associated with mutations in pmrB
in Acinetobacter baumannii and its effect on virulence and
bacterial ﬁtness
R. Lo´pez-Rojas °, J. Domı´nguez-Herrera, M.J. McConnell,
F. Docobo-Pe´rez, Y. Smani, J. Pacho´n (Sevilla, ES)
Objectives: Acinetobacter baumannii has clinical relevance due to the
high number of nosocomial infections that it causes, and its ability
to develop resistance to all antimicrobials, including colistin (COL).
Recently, mutations in the regulatory system PmrAB were associated
with COL resistance in A. baumannii strains (Antimicrob Agents
Chemother. 2009; 53:3628−34). The aim of this study is to evaluate
the effect of COL resistance caused by mutations in the PmrAB system
on the virulence and ﬁtness of A. baumannii.
Methods: The strains used were A. baumannii ATCC 19606 (ATCC),
and its COL resistant mutant (RC64) obtained by selective pressure
(COL MIC=64 mg/mL). Virulence was assessed in a murine peritoneal
sepsis model by inoculating groups of 10 C57BL/6 mice with 8 log
CFU/mL and diminishing the inoculum by a factor of 10 until 0%
mortality was reached (mortality and time to death were measured). For
in vitro growth and competition index (CI) experiments, growth curves
in Mueller-Hinton broth were performed for both strains separately and
in combination, and bacterial concentrations at 2, 4, 8 and 24 h were
determined. For in vivo growth and CI experiments, groups of 12 mice
were infected with both strains separately, and with a 50% mixture of
both. In each group 3 animals were sacriﬁced at 2, 4, 8 and 24 h, and the
bacterial concentration in the spleen was determined. In addition, for the
in vivo CI, 9 animals were inoculated with the mixture and sacriﬁced at
24 h. In order to characterize pmrA and pmrB mutations, genomic DNA
from ATCC and RC64 strains was extracted, ampliﬁed with speciﬁc
primers, and sequenced.
Results: ATCC was more virulent than RC64 in terms of mortality
(see table) and time to death (20.0 h vs. 38.4 h respectively, p< 0.001,
T-student test). There were no in vitro growth differences between
strains, separately or when grown together, nor in CI (CI was 1.08).
During in vivo growth, ATCC reached a maximal concentration in the
spleen of 10 log CFU/g, whereas RC64 reached a maximal concentration
of 9 log CFU/g. Growing in competition, ATCC remained at 10 log
CFU/g, while RC64 decreased to 8 log CFU/g. The in vivo CI was 0.016.
There were no mutations in pmrA, whereas in pmrB two mutations were
identiﬁed: arg134cys and ala227val.
Conclusion: The acquisition of COL resistance in A. baumannii, related
to PmrB mutations (arg134cys and ala227val), leads to an in vivo ﬁtness
loss and a decrease in virulence.
Mortality 108.5 CFU/mL 107.5 CFU/mL 106.5 CFU/mL 105.5 CFU/mL
ATCC 19606 100% 80% 20% 0%
RC64 100% 0% 0% 0%
P1938 Antibiotic-associated haemorrhagic colitis caused by
Klebsiella oxytoca
D. Orth °, A. Naim, S. Ehrlenbach, K. Grif, R. Wu¨rzner (Innsbruck, AT)
Objectives: Klebsiella oxytoca has been isolated from stool samples
of patients with Clostridium difﬁcile-negative antibiotic-associated
hemorrhagic colitis. However, the pathogenic role of this organism has
not been fully elucidated yet.
The aim of our study was to investigate the presence of toxin producing
Klebsiella oxytoca in patients with antibiotic-associated hemorrhagic
colitis.
Methods: 2500 stools specimens from patients with the clinical diag-
nosis antibiotic-associated hemorrhagic colitis and 85 stool specimens
of a healthy control group were examined in the period from June to
November 2007 in the Tyrol (Austria).
The specimens were cultured on MacConkey agar and investigated
for the presence of K. oxytoca by standard microbial procedures.
The cytotoxic effect of K. oxytoca strains was tested on Hep-2
cells and Vero cells, the amount of cytotoxicity was determined by
Lactat-Dehydrogenase release. The Klebsiella strains were characterized
phenotypically by antibiotic susceptibility testing and were typed by
Pulsed-Field Gel-Electrophoresis. In addition, all stool samples were
investigated for Clostridium difﬁcile toxin by ELISA.
Results: 119 of 2500 stool specimens (4.8%) of patients with antibiotic-
associated hemorrhagic colitis yielded K. oxytoca. In the control group
only 2 of 85 specimens (2.4%) were positive for K. oxytoca. The rate of
cytotoxic strains among K. oxytoca was 46% in patients with antibiotic-
associated hemorrhagic colitis compared with none in the healthy control
group. In addition we could demonstrate that Vero cells are superior to
Hep-2 cells for investigating K. oxytoca strains for toxin production.
Eleven percent of the stool specimens were positive for Clostridium
difﬁcile toxin.
Conclusions: Our study demonstrates that beside Clostridium difﬁcile
cytotoxigenic K. oxytoca are a causative agent of antibiotic-associated
hemorrhagic colitis. Thus, cytotoxigenic K. oxytoca should be included
in routine microbiologic diagnostic of stool specimens. Furthermore
we recommend Vero cells for determination of the cytotoxic effect of
K. oxytoca strains.
P1939 Virulence factors and pathogenicity islands in
extended-spectrum b-lactamase-producing Escherichia coli
bloodstream isolates
C. Caneiras °, A. Narciso, M. Jose´ Salgado, L. Lito, J. Melo-Cristino,
A. Duarte (Lisbon, PT)
Objectives: The aim of this study was to evaluate the relationship
between phylogenetic groups, virulence determinants and ESBL
production in bloodstream E. coli isolates recovered at the Hospital de
Santa Maria in Lisboa.
Methods: This study included 45 E. coli clinical isolates, identiﬁed
from blood cultures of patients hospitalized between 2001 and 2007
at Hospital de Santa Maria. It was included representatives of the
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major endemic E. coli isolates producing CTX-M-15 enzyme (n = 39),
as well as others ESBL (n = 6). The isolates were classiﬁed according to
phylogenetic group and screened by PCR ampliﬁcation for gene markers
of eight pathogenicity islands (PAI) and nine virulence factors genes.
Results: Twenty seven E. coli isolates belonged to the virulent extra-
intestinal phylogenetic group B2, ten to group D, two to group B1
and six to group A. The genes associated with pathogenicity islands
were detected for ﬁve different PAIs: PAI IV536 (87%), PAI ICFT073
(51%), PAI IICFT073 (44%), PAI IJ96 (31%) and PAI II536 (16%).
Gene markers for PAI I536, IIj96 and PAI III536 were not detected. The
most frequent virulence genes were ﬁmH (91%), iucC (62%), and EcpA
(91%). The haemolysin hylCA was presented in one isolate (2%) while
no papC, sfa, afa and cnf were detected. 55% of the bloodstream isolates
showed the virulence pattern ﬁmH, ecpA and iucC genes, followed by
ﬁmH and ecpA genes (31%). Only one isolate (2%) presents four of
the nine virulence factors studied, namely ﬁmH, ecpA, iucC and hylCA.
The prevalence of the virulence factors detected was comparable among
all phylogenetic groups, isolates with endemic CTX-M15 enzyme, and
among those with non-CTX-M ESBLs.
Conclusions: The same virulence pattern has been observed in
pathogenic and commensal isolates what suggested that the combination
of virulence factors could not be predictive different pathotypes. The role
of virulence factors in the etiology of E. coli bacteremia remains unclear,
although ﬁmH and ecpA were signiﬁcantly more prevalent among the
endemic CTX-M15 isolates. Our results are generally in accordance with
recent reports and indicate a distribution of bloodstream infection isolates
in low virulent and highly resistant group, regardless the E. coli strain
background.
P1940 Correlation between azole resistance and virulence
attributes displayed by C. parapsilosis
A. Silva °, A. Silva-Dias, I. Miranda, C. Pina-Vaz, A.G. Rodrigues
(Porto, PT)
Objectives: C. parapsilosis is common yeast, particularly isolated
from invasive infections. There is a growing concern about the
rise of antifungal drug resistance, although short knowledge is yet
available regarding phenotypic characterization of drug-resistant fungal
strains. In order to study the correlation between drug resistance
and pathogenicity attributes, we induced resistance in one susceptible
C. parapsilosis clinical strain by sub-culturing it in the presence of
increasing concentrations of ﬂuconazole, voriconazole and posaconazole.
The set of strains obtained displayed variable degrees of resistance and
was characterized regarding their virulence attributes.
Methods: Growth Kinetic. Strains were incubated at 30ºC under
agitation for 48 h using an initial inoculum density of 0.1 in liquid
YPD medium; growth was assessed by measuring O.D. along time.
Adherence Assay. From a overnight culture, a PBS yeast suspension (106
blastoconidia/mL); a stock solution of 105 microspheres/mL in PBS was
prepared; equal volumes of both suspension were mixed; the percentage
of yeast cells attached to microspheres was assessed by ﬂow cytometry.
Bioﬁlm Formation. A initial 5 x 107 blastoconidia/mL suspension
was incubated at 37ºC in YPD medium in 12 wells polystyrene
plates; after 24 and 48 hours bioﬁlm mass was determined by crystal
violet method. Phenotypic Switching. Blastoconidia were plated onto
YPD and incubated at 30ºC for 96 h; the presence of distinct colony
phenotypes was scored and the frequency of switching was determined.
Pseudohyphal Development. Blastoconidia were incubated in RPMI
1640 medium with 10% fetal calf serum for 24 h at 37ºC; pseudohyphal
development was checked microscopically.
Results: Overall, speciﬁc growth rates and adherence ability displayed
by resistant strains were higher compared to the susceptible strain;
however, resistant strains were less capable to form bioﬁlm. phenotypic
switching and pseudohyphal formation occurred extensively among
resistant strains.
Conclusion: Our results demonstrate that in vitro induced resistance
to azoles alters growth rate, adherence, phenotypic switching and
pseudohyphal development of C. parapsilosis, considered important
attributes favouring invasive fungal infection.
P1941 Quinolones induce a decrease in kidney colonization of
uropathogenic Escherichia coli associated with a decrease
in P-ﬁmbria production
S. Soto °, N. Frimodt-Møller, J. Vila (Barcelona, ES; Copenhagen, DK)
Objective: Urinary tract infections (UTIs) develop in an ascending
manner beginning with peri-urethral colonisation, followed by that of
the urethra into the bladder causing cystitis, and in some cases, if left
untreated, ascension of the ureters into the kidneys establishing acute
pyelonephritis. In more than 80% of all cases of uncomplicated acute
pyelonephritis, the etiologic agent is uropathogenic Escherichia coli
(UPEC). The aim of this study was to determine the effect of the partial
loss of a PAI induced by quinolones in bladder and kidney colonisation.
Methods: The UPEC HC14366 strain and its non-haemolytical
derivative with partial loss of a PAI were selected. An ascendant urinary
tract infection animal model was used to evaluate the infectious capacity
of these two strains. Six mice were inoculated with these strains, and
urine samples from bladder and kidney were collected. RT-PCR was
used to determine the expression of the papA and lrp genes. The whole
genome of both strains was sequenced using the SOLID procedure.
Results: Both strains were inoculated in mice and the number of
bacteria found in the urine, bladder and kidney was determined. The
HC14366/PAI− strain presented the same capacity to colonise the bladder
as the wild-type strain but lost the capacity to colonise the kidney. The
number of CFU/ml or CFU/g of urine in both cases was 107 in urine
and 5×105 in bladder. On the other hand, the number of CFU/g found in
the kidney was 103 and 100 in the wild-type strain and in its derivative
PAI−, respectively. The expression of P-ﬁmbriae, related to this function,
in both strains was analysed by RT-PCR. Differences in gene expression
were found between and the wild-type strain and its derivative. The
expression of papA was lower in the non-haemolytical strain than in
the wild-type strain. The lrp gene was cloned and introduced into
HC14366/PAI−. It The lrp and papA genes were found decrease their
expression in the HC14366/PAI− strain. However, when this strain is
complemented with the lrp gene, the expression became normal.
Conclusion: The partial loss of a PAI induced by quinolones in UPEC
causes a decrease in kidney colonisation due to a reduction in pap gene
expression mediated by the Lrp protein.
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P1942 The role of IFN-g receptor in the control and clearance of
Legionella micdadei from its experimental murine host
I. Gobin °, T. Grubesic, D. Turkovic, D. Rebic, M. Susa, M. Doric
(Rijeka, HR; Ulm, DE)
Objectives: Legionella micdadei (Pittsburgh pneumonia agent) is
commonly identiﬁed as a cause of nosocomial infection. Illness due to
L. micdadei occurs in heart and kidney transplant patients, HIV-infected
patients and other immunocompromised patients. Since the infections
by L. micdadei occurs predominantly in immunocompromised hosts,
we examined the virulence of L. micdadei in immunodeﬁcient IFN-g
receptor knockout mice. We explored the kinetics of bacterial clearance
and patohistological changes in IFN-gR −/− and control C57Bl/6 mice.
Methods: Pathogen-free 61- to 10-weeks-old IFN-gR −/− and C57Bl/6
mice were infected by intratracheal inoculation with L. micdadei (clinical
isolate) using a dose of 107 CFU. We determined the mortality rate and
bacterial clearance from the lung, liver and spleen of infected mice at
different time points post infection. We also followed the patohistological
changes in these organs during 168 hours of infection.
Results: Our results showed a higher mortality rate of IFN-gR −/− mice
in comparison to control C57Bl/6 mice. After intratracheal inoculation
of 107 CFU of L. micdadei all IFN-gR −/− mice died within 12 days,
while control mice survived the infection. The numbers of L. micdadei
recovered from the lungs of IFN-gR −/− mice were signiﬁcantly
higher compared to the control C57Bl/6 mice. At day 7 post infection
L. micdadei was not detected in the spleens and livers of C57Bl/6 mice,
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whereas, IFN-gR −/− mice showed signs of systemic bacterial infection.
In comparison to C57Bl/6 mice, IFN-gR −/− showed signiﬁcantly higher
inﬁltration of inﬂammatory cells on the 3rd day of infection with
progression of disease on 7th day. IFN-gR −/− mice developed severe
bronchopneumonia with inﬁltration of interstitial tissue, while control
mice showed only mild peribronchial inﬂammatory cell inﬁltration. Nods
of inﬂammatory cells were present in the liver of IFN-gR −/− mice
from day 3 after infection in contrast to control mice which cleared the
bacteria.
Conclusion: In this study we demonstrate a critical role of IFN-gR in the
control and clearance of L. micdadei from mice. IFN-gR−/− mice failed
to control L. micdadei and eventually succumbed to an overwhelming
bacterial burden.
P1943 Characterization of the cerebrospinal ﬂuid inﬂammation in
patients with tick-borne encephalitis
D. Grandgirard °, H. Schudel, S. Bigler, S.L. Leib (Berne, CH)
Objective: Tick-borne encephalitis (TBE) is a potentially fatal
neurological infection. In most cases, patients recover spontaneously
within 2 weeks after onset of symptoms but TBE may cause long-term
neurological/neuropsychiatric sequelae in affected patients. Different
forms of brain damage including neuronal and glial destruction,
spongiform focal necrosis, inﬂammation and perivascular inﬁltration
have been documented in autopsy cases. Since the virus is rarely
detectable in the cerebrospinal ﬂuid (CSF) during the encephalitic stage
of disease the main pathogenic mechanism of brain destruction may be
the inﬂammatory host reaction. The aim of this study was to investigate
the pathogenesis of TBE by characterizing the pattern of inﬂammatory
mediators in the CSF of patients with TBE.
Methods: Ten patients with conﬁrmed TBE, hospitalized between
March-July 2008 in western Switzerland were enrolled in this study. CSF
samples were taken for diagnostic purpose on the day of hospitalization,
centrifuged and stored at −80ºC until analysis. CSF samples from
patients with unrelated indications for lumbar puncture served as controls
(n = 9). Inﬂammatory parameters in the CSF were determined with
commercially available microsphere-based assays. Statistical analyses
were performed using GraphPad Prism 5.01. Clinical data were collected
retrospectively in the documented patient’s history by chart review.
Results: Inﬂammatory parameters were signiﬁcantly increased in CSF
from patients with conﬁrmed TBE (n = 10) vs. controls (n = 9) including
white blood cells (p = 0.001); total protein (p = 0.01); MMP-9 (p = 0.001);
IFN-g (p = 0.0001); IL-6 (p = 0.04); IL-10 (p = 0.04); and IL-1RA
(p = 0.0001). There was a statistically signiﬁcant positive correla-
tion between deﬁned cytokines e.g. (IL-6/IL-10, r = 0.91, p = 0.002;
IFN-g/IL-1RA, r = 0.84, p = 0.02). Importantly, TGF-a was found to be
signiﬁcantly downregulated in TBE patients vs. controls (p = 0.006).
Conclusion: Our results support the notion that the inﬂammatory host
reaction is critically involved in the pathogenesis of TBE. In TBE, CSF
levels of pro-inﬂammatory mediators including IL-6, IFN-g and MMP-9
were signiﬁcantly increased which was accompanied by an increase in
levels of IL-10 and IL-1RA (regulatory proteins of the inﬂammation).
Deciphering the inﬂammatory host reaction to TBE within the brain
compartment will lead to a better understanding of its pathogenesis and
in consequence more efﬁcient therapies.
P1944 Concentration of sVCAM-1 and CXCL10, CXCL11,
CXCL12, CXCL13 chemokines in patients with tick-borne
encephalitis
A. Muszynska-Mazur, J. Zajkowska, S. Pancewicz, M. Kondrusik,
S. Grygorczuk, P. Czupryna, A. Moniuszko ° (Bialystok, PL)
Objective: The objective of a study was to measure concentration of
soluble form of adhesion molecule sVCAM-1 and chemokins: CXCL10,
CXCL11, CXCL12, CXCL13 in serum and cerebrospinal ﬂuid (csf)
in patients with TBE before and after treatment. We also analyzed
usefulness of measurement of concentration of these molecules in
diagnostic and monitoring of inﬂammatory process during TBE.
Methods: Samples of serum and csf were taken from 23 patients hospi-
talized in The Department of Infectious Diseases and Neuroinfections of
Medical University in Bialystok. Patients were divided into 2 groups:
i. patients with conﬁrmed TBE(by detection antibodies against TBE in
serum and csf)
ii. control group: patients with excluded TBE by csf evaluation.
In group I serum and csf were evaluated twice: at diagnostic evaluation
and after resolving symptoms with control tests. In group II serum and
csf − only once. Concentrations of analyzed molecules were measured
by ELISA kits (Bender MedSystem, R&D).
Results: We observed increased concentration of soluble form of
sVCAM-1, CXCL10, CXCL11, CXCL12, CXCL13 in serum and csf
in group of patients with TBE. Concentration of CXCL10, CXCL11,
CXCL12, CXCL13 in csf during convalescence decreased, but still was
higher in comparison with controls. Higher concentrations of CXCL10,
CXCL12, CXCL13 in csf than in serum were observed. Correlation
between pleocytosis and concentration of CXCL10 in csf was noticed.
Conclusions:
1. Increased concentration of soluble form of sVCAM-1, CXCL10,
CXCL11, CXCL12, CXCL13 in serum and csf, indicates partici-
pation this molecules in immunopathogenesis of TBE.
2. Decrease of concentration of CXCL10, CXCL11, CXCL12, CXCL13
in csf during convalescence proves delay in fading of inﬂammation,
despite clinical recovery.
3. Signiﬁcant increase of concentration of CXCL13 in csf in an acute
period of disease in comparison with controls may indicate usefulness
of this chemokine as a biomarker of inﬂammatory process in TBE.
4. Higher concentration of CXCL10, CXCL12, CXCL13 in csf than
in serum may be a proof of its local production in central nervous
system (CNS) or compartmentalization of inﬂammation process in
neurological phase of disease.
5. Correlation between pleocytosis and concentration of CXCL10 in csf
conﬁrms role of this chemokine as a chemoattractant for lymphocytes
in TBE.
6. Chemokines CXCL10, CXCL12, CXCL13 may be used as biomark-
ers of inﬂammatory process in CNS.
P1945 Caspase-3 activation induces cleavage of tau protein in
neurons infected with herpes simplex virus type 1
C. Otth °, R. Neira, R. Lerchundi, M. Villalba, K. Vio, M. Concha,
A. Zambrano (Valdivia, CL)
Objective: Herpes Simplex Virus Type 1 (HSV-1) is ubiquitous,
neurotropic, and the most common pathogenic causes of sporadic acute
encephalitis in humans. Herpes simplex encephalitis is associated with
a high mortality rate and signiﬁcant neurological, neuropsychological,
and neurobehavioral sequelae, which afﬂict patients for life. HSV-1
infects limbic system structures in the central nervous system, and
has been suggested as an environmental risk factor for Alzheimer’s
disease. In a previous study we demonstrated that HSV-1 triggers
hyperphosphorylation of tau epitopes serine 202/threonine 205 and
serine 396/serine 404 in neuronal cultures, resembling what occurs in
neurodegenerative diseases. Therefore, the aim of the present study
was to further evaluate at a cellular level other possible mechanisms
associated with neurodegeneration triggered by HSV-1 infection in
primary neuronal cultures, such as caspase-3 induced cleavage of tau.
Methods: Western blot and immunoﬂuorescence techniques were used
to study caspase-3 activation and tau protein processing in mice neuronal
primary cultures infected with HSV-1.
Results: It is shown that HSV-1 infection induced caspase-3 activation
and cleavage of tau protein at aspartic acid 421, generating an epitope
that is recognized by TauC3 antibody. In agreement with our previous
study on tau hyperphosphorylation, tau cleavage was also observed
during the ﬁrst 4 hours of infection, before neuronal death takes place.
Conclusions: Neuronal HSV-1 infection induces caspase-3 activation
triggering the cleavage of tau at its speciﬁc site. This tau processing
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has been previously demonstrated to increase the kinetics of tau
aggregation and has been observed in neurodegenerative pathologies.
Funding FONDECYT 11080067, DID-UACH.
P1946 Human metapneumovirus: interferon sensitivity and
production in airway epithelial cells
C. Scagnolari, C. Selvaggi °, T. Carbone, A. Solda`, L. Spano, P. Di
Marco, F. Maggi, E. Riva, A. Pierangeli, G. Antonelli (Rome, Pisa, IT)
Objectives: Actually very little is known about Human Metapneu-
movirus (hMPV) pathogenesis and the activation of innate immune
response triggered by infection.
The aim of this study was to investigated whether hMPV is sensitive to
the antiviral activity of interferon (IFN) b, leukocyte IFN a and several
IFN a subtypes. The sensitivity of hMPV was compared with that of the
vesicular stomatitis virus (VSV) which is known to be highly sensitive
to the action of all types of IFN. In addition we evaluated the transcript
expression of IFN a subtypes after hMPV infection.
Methods: Antiviral effect of IFNs against hMPV or VSV replication in
human laryngeal carcinoma Hep-2 cells were analysed by yield reduction
assay. The transcriptional induction of the IFN a subtypes in Hep-2
infected with hMPV or transfected with PolyIC were investigated by
real time reverse transcript-PCR.
Results: Results indicated that IFNs showed substantially different
capacities for inhibiting the hMPV yield in Hep-2 cells. In particular in
Hep-2 cells pre-treated with IFNs and infected with hMPV for 24 hours,
leukocyte IFN a were less potent than IFN b. Among IFN a subtypes
investigated, IFN5, IFN6, IFN8 and IFN10 were the most active while
IFN17 and IFN21 were the least potent. IFN1, IFN2b, IFN7, IFN14
had comparable intermediate activity. In addition results indicate that
the IC50 values of the different type I IFNs preparations against VSV
were signiﬁcantly lower compared to those against hMPV. Furthermore
we found that, over a timecourse of 48 hours of infection, lower levels
of IFN a subtypes were transcribed in Hep-2 cells infected with hMPV
in contrast with those induced by Poly IC.
Conclusion: This study provides evidence that hMPV are partially
resistant to the antiviral activity of IFN type I, although some IFN
a subtypes appear to be more active against hMPV than others.
Furthermore hMPV appears to be a weak inducers of IFN type I too.
The implications of these observations in terms of hMPV pathogenesis
is now under study.
P1947 Immune proﬁle in lymphoma patients with febrile
neutropenia secondary to high-dose chemotherapy with
autologous stem cell support
D. Torfoss °, A. Høiby, H. Holte, J. Bjerner, T. Bjøro, G. Gaudernack,
G. Kvalheim, T. Mollnes, S. Kvaløy (Oslo, NO)
Objective: To study the immune proﬁle during episodes of febrile
neutropenia.
Methods: During the clinical study “Tobramycin once versus three times
daily, given with penicillin G, to febrile neutropenic cancer patients in
Norway: a prospective, randomized, multicentre trial” (J. Antimicrob.
Chemother. 2007; 59: 711−7) blood samples were taken from lymphoma
patients undergoing high-dose chemotherapy with autologous stem cell
support when they developed febrile neutropenia and one to two days
later. The samples were tested for procalcitonin, a 17 cytokine proﬁle
and mannan-binding lectin (MBL).
Results: Sixty-one patients constituted a homologous population with
a mild and benign course of febrile deep neutropenia for more than
a week and then recovering as expected. Four patients had a positive
blood culture (Gram-positives only). There was a mild, but signiﬁcant,
increase in procalcitonin and the following cytokines: IL-1b, IL-4, IL-6,
IL-7, IL-8, G-CSF, GM-CSF, INF-g and TNF-a. There was a signiﬁcant
decrease in IL-5 whilst no change was observed in IL-2, IL-10, IL-12,
IL-13, IL-17, MCP-1 and MIP-1b. Six patients were MBL deﬁcient
(<100 ng/ml) and another six patients had decreased MBL values, all
without a signiﬁcant different clinical course.
Conclusions: The proﬁles of procalcitonin, 17 cytokines and MBL
suggest a mild proinﬂammatory response in lymphoma patients with
fever of unknown origin and a benign course of febrile neutropenia after
high-dose chemotherapy with autologous stem cell support.
P1948 sCD30: a novel prognostic factor for chronic brucellosis?
A. Raﬁei °, M. Hasanjani Roushan, Z. Hoseini-Khah (Sari, Babol, IR)
Background: It is suggested that CD26 and CD30 are surface molecules
expressed on activated Th1 and Th2 cells, respectively. The aim of the
present study was the determination of the levels of soluble (s) CD26 and
CD30 co-stimulatory molecules in sera of brucella-infected individuals.
The correlations of sCD26 and sCD30 levels with clinical presentation
of the disease were assessed.
Methods: The study included 90 brucellosis patients (56 acute disease
and 34 chronic form) and 70 healthy controls. The levels of sCD26 and
sCD30 were determined by a sandwich enzyme-linked immunosorbent
assay in sera of study population.
Results: The serum level of sCD26 and sCD30 were differed in patients
with brucellosis. Stratiﬁcation of patients according to disease status
showed signiﬁcant higher levels of sCD26 in the acute brucellosis
compared to chronic disease and controls (P< 0.0001). The highest
signiﬁcant levels of sCD30 were shown in patients with chronic
brucellosis (P< 0.0001).
Conclusion: These ﬁndings indicate that sCD30 is more relevant to
disease activity than sCD26 in patients with brucellosis. Therefore,
sCD30 is a prognostic valuable marker for chronic brucellosis.
P1949 NK cells activity and IL-10 in gastric carcinoma patients
with or without Helicobacter pylori infection
T.M. Karpinski °, A. Szkaradkiewicz, M. Borejsza-Wysocki, M. Drews,
P. Majewski (Poznan˜, PL)
Objectives: The study aimed at analysis of NK cell cytotoxic activity
and serum levels of IL-10 in patients with gastric carcinoma, as related
to presence of infection with H. pylori and tumour advancement.
Methods: The study was conducted on 42 adult patients with gastric
adenocarcinoma. Depending on parallel presence of H. pylori infection,
was distinguished group1 of 15 patients with presence of H. pylori
and group 2 of 27 patients without H. pylori infection. Histological
analysis of the gastric tumours disclosed 5 patients with stages I-II and
10 with stages III-IV in group 1 and 9 patients with stages I-II plus
18 with stages III-IV in group 2. The investigated material included
intra-operative samples of gastric carcinoma and peripheral blood of
the patients. Presence of H. pylori in the samples was conﬁrmed using
cultures and biochemical tests. Estimation of serum IL-10 levels was
conducted by ELISA, using Quantikine HS Human IL-10 Immunoassay
kit (R&D System). NK cells were isolated using EasySep Human NK
Cell Enrichment Kit (StemCell Technologies). Cytotoxic activity of NK
cells toward gastric adenocarcinoma cells AGS (ATCC CRL-1739) was
estimated using CytoTox 96 Non-Radioactive Cytotoxicity Assay kit
(Promega).
Results: In group 1 cytotoxic activity of NK cells averaged at
36.5±15.2% and it did not signiﬁcantly differ from that in the group 2.
In parallel, mean cytotoxic activity of NK cells in group 1 patients with
stages I-II amounted to 42.2±17.1%, and in those with stages III-IV
to 31.1±11.6%, while in group 2 it was 38.3±11.3% in patients with
stages I-II and 31.1±11.6% in patients with stages III-IV. Mean serum
levels of IL-10 were 4.27±3.44 pg/ml in group 1, averaging at 2.38±3.47
pg/ml in the subgroup with stages I-II and at 5.21±3.18 pg/ml in the
subgroup with stages III-IV. In group 2 mean levels of IL-10 amounted
to 4.05±2.81 pg/ml, averaging at 2.93±2.58 pg/ml in the subgroup with
stages I-II and at 4.61±2.82 pg/ml in the subgroup with stages III-IV.
The analysis demonstrated no relationship between presence of H. pylori
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infection in patients with gastric carcinoma on one hand and cytotoxic
activity of NK cells or serum IL-10 levels on the other.
Conclusion: The result indicated that development of gastric carcinoma
is linked to a signiﬁcantly decreased cytotoxicity of NK cells and
elevated serum levels of IL-10. However, the reduced cytotoxic activity
of NK cells and elevated levels of IL-10 do not depend directly on
H. pylori infection.
P1950 The viral TLR3 agonist poly(I:C) stimulates phagocytosis
and intracellular killing of Escherichia coli by microglial cells
N. Adam °, S. Ribes, S. Ebert, T. Regen, S. Bunkowski, U-K. Hanisch,
R. Nau (Gottingen, DE)
Objectives: Escherichia coli K1 meningitis is associated with a high
rate of mortality and long term sequelae despite antimicrobial therapy,
especially in pediatric patients. Microglial cells, the resident phagocytes
in the central nervous system, express Toll-like receptors (TLR) that
mediate the innate immune response upon recognition of invading
pathogens. Polyinosine–polycytidylic acid [poly(I:C)] is a TLR3 agonist
structurally similar to viral double-stranded RNA. Here, we show that
a viral TLR3 agonist can stimulate microglial cells and increase their
phagocytic activity and intracellular killing of E. coli K1, a pathogenic
encapsulated bacterial strain.
Methods: Primary cultures of murine microglia were exposed to
poly(I:C) at 0.1 or 10mg/l for 24 h. A control group of unstimulated cells
was included in all experiments. After stimulation, supernatants were
collected and stored at −80ºC until measurement of cyto-/chemokine
levels. Microglial cultures were co-incubated with live E. coli K1 for
phagocytosis and intracellular killing assays at a ratio of 100 bacteria
per cell. Phagocytosis was left to proceed for 30 and 90 min at 37ºC.
For phagocytosis inhibition studies, cytochalasin D (CD) was used at
10 microM. For intracellular killing assays, cells were incubated with
bacteria for 90 min. After bacterial exposure, microglial cultures were
washed and cultured in medium containing gentamicin (200mg/l). At
various time points, cells were washed and lysed with distilled water.
Viable intracellular bacteria were enumerated by quantitative plating
of serial 10-fold dilutions. ANOVA (followed by Bonferroni’s multiple
comparisons test) was performed to analyse differences between groups
(n 11); p< 0.05 was considered statistically signiﬁcant.
Results: The supernatants of unstimulated cells were devoid of
measurable amounts of cyto-/chemokines. Unstimulated microglia
ingested bacteria at a low rate. Poly(I:C) stimulated murine microglial
cultures in a dose-dependent manner to secrete TNF-a and CXCL1 and
increase their ability to phagocytose (p< 0.05 after 30 min, p< 0.01 after
90 min) and kill intracellular E. coli K1. CD blocked the bacterial uptake
by 90%.
Conclusions: Stimulation of microglia with a viral agonist of the TLR
system such as poly(I:C) could increase the resistance of the brain to
bacterial infections. This may be a promising approach to protect the
brain of septicemic patients from meningitis, cerebritis and brain abscess.
P1951 Yersinia V-antigen binds to recombinant CD14 and TLR2
D. Reithmeier-Rost, T. Pirch, R. Darveau, K. Jung, J. Heesemann,
A. Sing ° (Munich, DE; Seattle, US; Oberschleißheim, DE)
Objectives: The virulence antigen LcrV of Yersinia enterocolitica O:8
(LcrVO:8) induces IL-10 in macrophages via Toll-like receptor 2 (TLR2)
and CD14 thus causing TNF-a-suppression in mice.
Methods: In the present study, using ELISA and Biacore analysis it is
shown that this effect is triggered by direct binding of LcrV to both
TLR2 and CD14.
Results: The N-terminal, but not the C-terminal part of recombinant (r)
LcrVO:8 seems to be responsible for TLR2- as well as CD14-binding,
as rLcrVO:81–130 strongly binds to both a TLR2- or CD14-coated
sensor chip, whereas rLcrVO:868–334 does not show any interaction.
The afﬁnity to TLR2 and CD14 seems to be Y. enterocolitica serotype-
dependent, since rLcrVO:8 showed stronger afﬁnity to both innate
immune receptors when compared to rLcrVO:3. Moreover, the saturation
level for rLcrVO:8 was higher than for rLcrVO:3. rLcrVO:8K42Q
bearing a point mutation in the TLR2-active region showed rather strong
afﬁnity to TLR2. Derived from kinetic studies it could be demonstrated
that rLcrVO:8 binding is kinetic-controlled, whereas the interaction of
rLcrVK42Q with TLR2 and CD14 is more thermodynamically regulated.
rLcrVK42Q even blocks the TLR2 receptor as the dissociation constant
is very low. The mutagenesis of CD14 in single aa positions revealed the
region responsible for LcrV-binding. Especially aa positions 11 and 37
seem to be important for the interaction indicating that ionic binding is
involved. Furthermore, the active regions within CD14 for LPS-, BLP-
and LcrV-binding seem to overlap.
Conclusions: LcrV binds to recombinant CD14 and TLR2.
P1952 Screening of the immunoprotective protein from the clinical
strain of Mycobacterium tuberculosis
S. Suraiya °, R. Suppian, J. Ashraful Haq, A.R. Zaidah, M. Musa
(Kelantan, MY)
One third of the world’s populations have been exposed to Mycobac-
terium tuberculosis. Approximately 2 million people died each year from
the disease. Tuberculosis (TB) was predicted to be the largest single
infectious cause of death between 1990 and 2020. In Malaysia, BCG
vaccination is mandatory, given to all newborn and will be repeated at 12
years old if no BCG scar observed during routine school children medical
examination. The tuberculosis protection by BCG is questionable, but
thus far no new TB vaccine available in the market.
The objective of the study was to compare the immune reaction towards
the BCG strain as compared to circulating strain of M. tuberculosis.
Materials and Methods: The BCG strain and the clinical strain of
M tuberculosis were culture in the Middlebrooks supplemented with
OADC. The whole protein lysate from both were extracted and the
protein proﬁles were studied by the SDS-PAGE. The serum sample
were taken from BCG vaccinated, healthy and The western blotting for
detection of IgG were done from pool sera of BCG vaccinated healthy
person and pool sera of conﬁrmed TB patients.
Results: The whole protein lysate was successfully extracted from BCG
strain and the clinical strain of M. tuberculosis. There is higher level
of existing immune response against clinical strains of M tuberculosis
as compared to immune reaction towards the BCG strains. There is also
presence of a speciﬁc band around 90KD that only present in the healthy
subject but not in the TB patients.
Conclusion: There is a potential protein present in the circulating
clinical strain that might have an immunoprotective component. This
speciﬁc band attracts special interest in the development of DNA based
tuberculosis vaccine in the near future.
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P1953 Spread of Panton-Valentine leukocidin positive S. aureus
among patients of a children’s clinical university hospital,
Riga, Latvia
L. Cupane °, N. Pugacova, I. Selga, A. Balode, D. Gardovska,
E. Miklasevics (Riga, LV)
Objectives: Althought S. aureus is considered to be an opportunistic
pathogen certain clones are more prone to cause invasive disease due to
the presence of virulence factors like Panton-Valentine leicocidin (PVL).
PVL producing strains can cause severe skin infections and necrotizing
pneumonia in previously healthy children and young adults. Aim of this
investigation was to detect spread of invasive S. aureus among paediatric
patients at hospital and presence of PVL.
Methods: Antibacterial susceptibility was determined according to CLSI
standards (M2-A9, M100-S16). The luk-PV gene was detected by PCR.
Chromatograms of the spa sequences were analysed by Ridom StaphType
software (Ridom GmbH).
Results: Investigation of 370 invasive S. aureus (21 blood isolate,
349 − from pus) from patients, who were admitted to Children Clinical
University Hospital in Riga from November, 2006 to November, 2008
revealed that 241 (65%) isolates carried genes for PVL synthesis. 8
of them were identiﬁed as MRSA. Investigation of clonal relationship
among the luk-PV positive S. aureus showed that majority of the
typed strains belongs to the spa type t435, or closely related types.
Retrospective analysis of patients medical histories from November
2006 throught March 2007 showed, that majority of patients were
hospitalised in surgery department − 64%, others in therapeutical proﬁle
departments − 27%. Patients were hospitalised mainly with purulent skin
and soft tissues infections like furunculosis, absceses, limfadenitis and
mastitis.
Conclusions: the obtained data provides evidence for wide spread of
PVL producing spa type-t435 staphylococci in community.
P1954 The prevalence of Panton-Valentine leukocidin toxin
in Staphylococcus aureus from a Birmingham teaching
hospital during three distinct time periods, 2002–2009
K. Hardy °, S. Shabir, C. McMurray, M. Oliver, P. Hawkey
(Birmingham, UK)
Objectives: To investigate the prevalence and epidemiology of panton-
valentine leukocidin (PVL)toxin carrying Staphylococcus aureus over a
seven year time period.
Methods: Three S. aureus collections from distinct time periods from
Birmingham, UK were examined for the presence of PVL toxin using
PCR. Collection 1: 115 MRSA and 110 MSSA isolates from nasal
screening samples from intensive care unit patients (Feb 2002 to Feb
2004). Collection 2: 793 MRSA isolates from nasal screening samples
from surgical patients (Nov 2005 to May 2007). Collection 3: 412
MRSA and 410 MSSA strains from a mixture of clinical and screening
samples (Dec 2008 to Apr 2009). All isolates were non-duplicate patient
isolates. All PVL− S. aureus isolates were epidemiologically typed using
staphylococcal interspersed repeat unit (SIRU) typing looking at seven
variable number tandem repeats located around the genome, with a
subset being analysed using MLST.
Results: Forty four (2.4%) of the 1831 S. aureus isolates screened were
positive for PVL. The overall prevalence of PVL in MRSA isolates was
1.1% (14/1320), decreasing from 2.6% in the ﬁrst collection to 0.9% and
1.0% respectively in collections 2 and 3. Six of the PVL-MRSA isolates
were highly related (<2 loci different) by SIRU typing and were all
ST22. Four of these isolates belonged to collection two. The prevalence
of PVL within the MSSA isolates was 5.6% (29/520), increasing from
2.7% in collection 1 to 6.6% in collection 3. Ten of the isolates were
closely related (<2 loci different), all belonged to ST22 and were all
from collection 3. In addition four isolates were closely clustered (<1
loci different) and all were ST30, the second most predominant type. All
of these isolates were from collection 3.
Conclusions: This study demonstrates that the prevalence of PVL
amongst MRSA isolates has not increased over the last seven years, with
the highest prevalence being observed amongst ITU screening samples
from 2002−04. The prevalence of PVL amongst MSSA isolates showed
an increase between the ITU screening samples and the clinical samples
in the third collection, but this may have been due to the samples
being from infected patients rather than screening for carriage. The
most predominant MLST type (ST22) was the same for both MRSA
and MSSA isolates and is the same as the most common UK hospital
MRSA strain.
P1955 Determination of Staphylococcus aureus and presence
of staphylococcal enterotoxin A by molecular and
microbiological methods in meatball meals cooked by
two-bedded treatment institutions
F. Uyar, C. Mirza, E. Ruh °, B. Sener, A. Alp, Y. Beyhan (Ankara, TR)
Objective: This study was planned and carried out for rapid deter-
mination of Staphylococcus aureus and Staphylococcal Enterotoxin A
presence in meatball meals cooked in two different bedded treatment
institutions (institution A and institution B) by using molecular and
classical microbiological methods. Two genes, nucA and entA, were
targeted in terms of S. aureus and Staphylococcal Enterotoxin A,
respectively.
Methods: In this study, a total of 60 samples (30 samples from each
institution) were included and the ability of real-time PCR technology
for detection of nucA and entA genes was examined. FRET and TaqMan
probes were designed for nucA and entA, respectively. Additionally,
samples from meatball meals were also inoculated into sheep blood
agars and S. aureus speciﬁc barid-parker media for further identiﬁcation
of S. aureus.
Results: By using real-time PCR, nucA and entA positive strains were
detected in 23.1% and 16.5% of the samples from institution A and
institution B, respectively. By the classical microbiological methods,
S. aureus and S. aureus Enterotoxin A positive strains were detected
in 16.5% and 6.6% of the samples collected from institution A and
institution B, respectively. The results from molecular procedure were
compared with those obtained from classical procedure and no statistical
difference was reported (p> 0.05).
Conclusion: Our study shows that real-time PCR technology can
succesfully be performed for rapid demonstration of S. aureus and
enterotoxin A producing S. aureus strains in the food samples from
food poisoning cases.
Our study also underlines the importance of the hygenic rules and
sustainable training of personnel which should be ensured to prevent
food poisoning cases in institutional food service systems.
P1956 Enterotoxins production, biotyping and genetic
ﬁngerprinting in Staphylococcus aureus isolated from milk
and dairy products
A. Cataleta, E. Crisetti, L. Latorre, C. Nardella, S. Tola, G. La
Salandra ° (Foggia, Sassari, IT)
Objectives: Staphylococcus aureus is an important food-borne pathogen
because of its ability to synthesize one or more staphylococcal
enterotoxins (SEs). The present study aims to characterize 209
enterotoxigenic strains of S. aureus isolated from milk and dairy products
during 2008–2009, in order to determine the ecological origin of the
strains by biotyping and to obtain genetic ﬁngerprinting, using pulsed
ﬁeld gel electrophoresis (PFGE).
Methods: Genomic DNA was extracted from overnight culture of
S. aureus by boiling. The detection of the genes encoding for 12
SEs (SEA, SEB, SEC, SED, SEE, SEG, SEH, SEI, SEJ, SEM, SEN,
SEO) was carried out using three multiplex PCR assays. All the 209
enterotoxigenic strains were biotyped by detection of some properties of
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the strain tested and genotyped by PFGE after SmaI restriction treatment.
PFGE banding patterns were identiﬁed by computer analyses (Applied
Maths). Dendrograms were created using the unweighted pair group
method using geometric averages (UPGMA) and Dice’s coefﬁcient.
Results: The results obtained indicate a prevalence of classical SEs
encoding genes (sea, seb, sec, sed and see), and the high incidence
of the “new” SEs encoding genes. Most of the isolated strains carried,
alone or in association, the sed gene (42%), followed by sea (35.4%),
sej (29.6%), ecg cluster: seg, sei, sem, sen, seo (26.8%), sec (23.2%),
seh (5.7%), seb (3.8%) and see (1.9%). Of the 209 analyzed strains,
52.6% belonged to the Non-Host-Speciﬁc ecovar followed by the ovine
(15.8%), human (13.9%), poultry-like (4.3%) and bovine (1.4%) ecovars.
Same strains (12%) were not included in studied ecovars. All the strains
were typable by PFGE and showed a great genetic heterogeneity both
among the bovine and the ovine food isolates.
Conclusion: The results of this study remark the presence of
enterotoxigenic strains of S. aureus in milk and dairy products. To
correctly evaluate the foodborne risk linked to the consumption of foods
contaminated with S. aureus it is crucial to monitor them to characterize
the isolates and to gain information about their potential ability to
synthesize SEs and their traceability; accordingly here we have applied a
molecular approach for typing the 209 S. aureus strains. Further studies
are required to better elucidate the relationship between the pulsotype
and the presence of particular type of SEs.
This work was supported by IZS PB 006/08 RC.
P1957 Pneumococcal clones and the role of pili in invasive disease
in Iceland, 1995–2008
K. Kristinsson °, H. Erlendsdottir, M. Hjalmarsdottir, T. Gunnarsdottir,
H. Jensdottir, H.D. Johannsdottir, G. Haraldsson (Reykjavik, IS)
Objectives: The pneumococcal capsule is recognised as one of the most
important virulence factor for invasive disease. Apparently, virulence
may vary between certain clones belonging to the same capsular type.
The importance of other virulence factors is not as clear. Pili have
recently been recognised as potentially important virulence factors. Our
aim was to analyse the pneumococcal clones causing invasive disease in
Iceland, especially with regard to the presence of pili.
Methods: Invasive pneumococcal disease has been recorded for the
whole Icelandic population since 1975. Since 1995 most of the invasive
pneumococcal isolates (blood and CSF) have been collected and stored
at −80ºC. We subcultured all viable isolates for serotyping and molecular
typing using PFGE, after DNA restriction with the SmaI enzyme.
MLST typing was performed on representative isolates of the most
prevalent PFGE clones. The presence of pili was veriﬁed using the
slightly modiﬁed PCR method of Paterson and Mitchell (2006) and the
separation of the pili into clades was determined using the PCR method
of Moschioni et al (2008).
Results: Of the 498 pneumococci isolated from invasive infections, 459
were from blood and 39 from CSF. 121 were from children <7 years old,
13 from 7−17 year old, 174 from 18−64 year old and 190 from >64 year
old. Of the 491 that were serotyped, the most frequent types were 7F/7
(86), 14 (60), 4 (41), 9V (35), 6B (32), 23F (31), and 19F (19). PFGE
typing has been performed on 460 (92%) isolates. The number of clones
within serotypes varies signiﬁcantly. For serotype 7F, all isolates belong
to only two clones (ST191 and ST218). The prevalence of the most
common clones varies between years, with a decline in the number of
ST90 (type 6B) and ST218 (type 7F). Pilus genes could not be detected
in the two most prevalent clones (ST191 and ST218). Of the 7 most
common clones, pilus genes were detected only in ST162 (type 9V),
ST205 (type 4) and ST90 (type 6B), the ﬁrst two of clade I and the last
of clade II.
Conclusion: The clonal diversity within serotypes varies between
serotypes. Clonal incidence can change with time, which may not be
reﬂected in serotype incidence. The presence of the pilus genes in only
3 of the 7 most common invasive clones, indicates that it is not important
for invasiveness.
P1958 Temporal variations among invasive pneumococcal disease
serotypes in children and adults and pneumococcal vaccine
coverages in Germany from 1992 to 2008
M. Imo¨hl °, R. Reinert, M. van der Linden (Aachen, DE; Paris, FR)
Objectives: This study was performed to evaluate the serotype distri-
bution of S. pneumoniae among isolates with invasive pneumococcal
disease (IPD) that were sent to the German National Reference Center for
Streptococci (NRCS) between 1992 and 2008, analyse temporal trends
and, supplementary, calculate the vaccine coverages for the 7-valent, 10-
valent and 13-valent (in development) pneumococcal conjugate vaccines.
Methods: A population and laboratory based surveillance study of
invasive pneumococcal disease was conducted in Germany. Cases from
January 1, 1992 to December 31, 2008 were included in this study.
Results: A total of 12,137 isolates from invasive pneumococcal disease
was collected between January 1, 1992 and December 31, 2008. Data
on serotypes were available for 9,394 isolates. The leading serotypes
were serotypes 14 (16.5%), 3 (8.0%), 7F (7.6%), 1 (7.3%) and 23F
(6.0%). Concerning the epidemic serotypes 1−3 and 5, a slight increase
was noticed during the last years, reaching levels around 20% among
children and adults in 2008. Variations in serotype distribution over the
years are partly extensive, especially concerning serotype 14 (min 7.4%,
max 33.5%). Serotype 14 is considerably more frequent among children
(22.5%), than among adults (13.7%). Serotype 1 and serotype 7F have
been increasing clearly over the last approximately 10 years, both among
children and among adults. Serotype 3 is far more common among adults
(10.2%) than among children (3.3%). The increase observed during the
last years seems to be slightly higher among adults than among children.
Concerning serotype 19A no clear change in frequency can be observed
during the period under study. Variations in serotype distribution also
affect theoretical vaccine coverages. The overall serotype coverage for
the 7-valent conjugate vaccine was 45.4% during 1992–2008. For the 10-
valent vaccine and the 13-valent vaccine (in development) the coverages
were 60.9% and 76.6%, respectively.
Conclusions: Temporal changes in the incidence of different serotypes
have been reported from different countries. However, in particular
against the background of the general recommendation of pneumococcal
conjugate vaccination for children <2 years in Germany at end of July
2006, ongoing nationwide surveillance is necessary to observe further
developments of pneumococcal serotype distribution in Germany.
P1959 Allelic variation in internalin genes of Listeria monocytogenes
isolated from humans, small rodents and mollusks
E. Zaytseva °, S. Ermolaeva, G. Somov (Vladivostok, Moscow, RU)
L. monocytogenes is facultative intracellular pathogen, which causes an
invasive disease with such severe symptoms as septicemia, meningitis,
meningoencephalitis and stillbirths in human and animals. The surface
and secreted proteins of the internalin family play a main role in
L. monocytogenes invasion into eukaryotic cells. The structure of
internalins includes LRR- (for leucine-rich repeat) domains. Among both
eukaryotes and prokaryotes the LRR domains are involved in speciﬁc
protein-protein interactions.
The purpose of this study is to analyze distribution of various internalin
gene alleles among L. monocytogenes isolated from different sources
and regions.
Methods: 50 and 17 L. monocytogenes isolates obtained in Far East
and in European parts of Russia, respectively, were investigated. Four
internalin genes − inlA, inlB, inlC, inlE, and the housekeeping gene prs,
were partly sequenced. The study included three host speciﬁc groups of
invasive isolates obtained from tissues of aborted fetuses (n = 19), small
rodents (n = 13), marine organisms (n = 13). Control groups included
isolates obtained from food (n = 22).
All isolates were divided into 32 sequence types (STs) according to
results of sequencing. Geographic and host speciﬁc allelic variations
in L. monocytogenes genes encoding invasion factors of the internalin
family were revealed. The region speciﬁcity of STs to suggests the
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polyclonal distribution of L. monocytogenes strains in geographically
distant regions. Some STs were isolated from particular hosts with high
frequency although they were not host speciﬁc. There were ST1, ST6
and ST9 among isolates from aborted fetuses, ST1 among rodent isolates
and ST17 among marine organism isolates.
The analysis of allelic variations in individual genes revealed a
statistically relevant host speciﬁc prevalence of particular alleles for
the following genes: inlA and inlC among aborted fetus isolates, inlB
among rodent isolates, inlA, inlC, inlE among marine isolates. Alleles of
all tested genes were distributed uniformly in control group. Alleles of
the prs gene were distributed uniformly in all groups. Obtained results
conﬁrm with the knowledge on role of internalins in host speciﬁcity of
L. monocytogenes.
P1960 Helicobacter pylori cagA subtyping and its role in
identiﬁcation of mixed infections
Z. Karimi °, M. Douraghi, Y. Talebkhan, S. Saberi, M. Bababeik,
M. Mohammadi (Tehran, IR)
Objectives: Cytotoxin-associated gene A product (CagA) is one of the
most important virulence markers in pathogenesis of Helicobacter pylori
(Hp) strains. Different investigations show that 60% of Western and
approximately all of the East Asian H. pylori strains are cagA positive.
Variation in the type and number of EPIYA-motif in the 3’ end of
CagA has provided this protein with varying degrees of risk in cagA+
strains of different geographical regions. The Hp cagA subtype status
and the presence of multiple infections among Iranian GI patients were
investigated in this study.
Methods: Totally, 202 H. pylori infected patients including 38 GC,
34 PUD, 130 NUD were enrolled in this study. cagA diversity was
determined in 585 Hp isolates from at least two biopsy specimens from
different locations of the stomach. PCR ampliﬁcation was performed
using primers cag2/cag4. SPSS package was used for data analysis.
Results: Based on multiple biopsy sampling, 54 percent of the examined
patients suffered from multiple infections (harboring more than one cagA
subtypes) while this percentage had been diminished to 12.8% when just
one antral biopsy specimen was obtained. Of these 202 patients, 585
isolates were recovered which produced 711 Hp strains of which 659
(92.7%) were cagA-positive distributed in the following nine different
categories: 400bp (1.2%), 450bp (4.7%), 500bp (2.7%), 550bp (56.3%),
600bp (2.3%), 650bp (28.5%), 750bp (3.8%), 800bp (0.2%), 850bp
(0.3%).
Conclusion: According to this investigation, approximately half of
Iranian dyspeptic patients were infected with more than one cagA
subtype Hp strains which thereby identiﬁes cagA typing as an accessible
marker for detection of mixed infections. Furthermore, these ﬁndings
indicated that obtaining more than one biopsy sample from each patient
and assessing multiple strains from one location are critical for accurate
identiﬁcation of the infecting cagA subtypes.
P1961 Helicobacter pylori vacA and cagA gen: changes over a
period of 15 years in Spain
S. Agudo °, T. Alarco´n, P. Urruzuno, G. Pe´rez-Pe´rez, M. Lo´pez-Brea
(Madrid, ES)
Introduction: The presence of cytotoxin-associated gene A (cagA) and
expression of vacuolating cytotoxin activity encoded by vacuolating
cytotoxin gene A (vacA) are considered the two major virulent markers
of H. pylori. VacA and CagA of H. pylori strains showed genetic
variability. The aim of this study was to determine the prevalence of
CagA and VacA genotypes among H. pylori isolated in Madrid, Spain
over two periods: 1994 and 2008.
Methods: We obtained 64 biopsies from symptomatic gastric patients
from four different regions (Madrid, Aviles, Almeria and Ibiza) of
Spain in 1995 and 90 biopsies from patients with gastric symptoms
from Madrid, Spain in 2008. Standard microbiological procedures
were used for H. pylori culture. DNA extraction was carried out
with phenol/chloroform/isoamil alcohol (25:24:1) in 1994 and by the
NucliSens easyMAG platform with the NucliSens magnetic extraction
reagents (bioMe´rieux) in 2008. VacA genotypes (s, m) were determined
by PCR and agarose gel. CagA status was determined by PCR and those
CagA negative, we conﬁrmed the absence of the pathogenicity island by
“empty-site” PCR. The identiﬁcation of the number and type of CagA
EPIYA motifs was based on sequencing analyses.
Results: The results of VacA are showed in the table 1. Around 27%
biopsies were cagA gene positive in strains from Madrid 1994 and 2008.
69% were cagA gene positive in strains from the rest of regions in 1994.
We conﬁrmed the lack of pathogenicity island in the rest of strains
that were CagA negative. CagA with three EPIYA motifs (ABC) was
observed in 53% and 68% of CagA positive strains in Madrid 1994 and
2008, respectively.
Conclusions: In Madrid, Spain most of H. pylori isolates are VacA
s2/m2 and CagA negative in both periods of time, different to the rest of
the regions in 1994. The prevalence of CagA proteins with three EPIYA
motifs (ABC) was the most frequently found.
n s1m1/m2 s2m2 s2m1
n % n % n %
Madrid 22 5 22.7 16 72.7 1 4.5
Almeria 20 14 70.0 5 25 1 4.5
Aviles 6 2 33.3 3 50 1 16.7
Ibiza1 16 10 62.5 2 12.5 2 12.5
Madrid 20082 90 23 25.6 64 71.1 2 2.2
12 strains showed mixed signals; 21 strain showed mixed signals.
P1962 Distribution of putative iron-utilization genes in European
clinical strains of Acinetobacter baumannii
L.C. Antunes °, F. Imperi, K.J. Towner, P. Visca (Rome, IT; Nottingham,
UK)
Objective: Iron is an essential nutrient for bacteria and, as such,
bacterial iron uptake mechanisms are important factors for pathogenesis.
A gene cluster in Acinetobacter baumannii is known to be responsible
for synthesis of the siderophore acinetobactin. Genomic analysis
of sequenced A. baumannii strains enabled us to identify further
gene clusters putatively involved in biosynthesis/transport of other
siderophores, haem utilisation and ferrous iron uptake. The aim of this
study was to investigate the distribution of these genes in a collection of
42 representative A. baumannii strains from 17 European countries.
Methods: PCR primers were designed to screen for 16 of the putative
iron-utilisation genes identiﬁed from the genotypic sequence analysis.
These primers were used in standard PCRs to screen a diverse collection
of 42 European clinical A. baumannii strains of known sequence
groups. In addition, the reference strain ATCC 19606 and the sequenced
and annotated strains ACICU, AYE, ATCC 17978 and SDF were
also investigated. The distribution of iron-utilisation genes among the
different strains and sequence groups was analysed.
Results: Two putative siderophore gene clusters, including that coding
for acinetobactin, were conserved among the clinical isolates of
A. baumannii, while a third cluster was present in less than 5% of strains.
Furthermore, a putative haem utilisation gene cluster was conserved
in all strains, while a second haem utilisation cluster was found in
approximately 50% of strains. Lastly, the Feo cluster, putatively coding
for genes involved in the uptake of ferrous iron, was conserved in all
strains. Notably, no apparent correlation was found between the sequence
group (lineage) of the strains and the presence/absence of speciﬁc iron-
utilisation genes.
Conclusions: The apparent universal distribution of the acinetobactin
gene cluster, an additional and previously undescribed siderophore
cluster, the Feo cluster for the uptake of ferrous iron, and one of two
haem uptake clusters, indicates their potential importance for the survival
and/or virulence of A. baumannii in the clinical setting. It remains to
be determined if a second haem uptake cluster, present in approximately
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50% of strains, and/or a third siderophore cluster, present in less than
5% of strains, further enhance the survival and/or virulence properties
of speciﬁc A. baumannii strains.
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P1963 Impact of genes upstream of the RD1 region on
virulence of Mycobacterium tuberculosis and ESAT-6
secretion/modiﬁcation
D. Bottai, L. Majlessi, R. Simeone, W. Frigui, C. Laurent, P. Lenormand,
M. Huerre, C. Leclerc, S. Cole, R. Brosch ° (Paris, FR; Lausanne, CH)
The pathogenesis of Mycobacterium tuberculosis largely depends on the
secretion of key virulence factors, such as ESAT-6 (EsxA) and CFP-
10 (EsxB) via the ESX-1/T7SS system. Several genes located in the
region of difference 1 (RD1) have been shown to play a role in this
process, but little is known about the genes situated further upstream
of RD1. Thus, in an attempt to elucidate the role of genes rv3865 and
rv3866, in the secretion of ESAT-6 and virulence of M. tuberculosis, we
constructed rv3865/66 and large scale RD1 knock-out M. tuberculosis
strains and tested these mutants in various in vitro and in vivo systems.
This analysis showed that inactivation of either of the two genes
has a strong attenuating effect on the virulence of M. tuberculosis.
However, unlike their orthologs in the faster growing model organisms
Mycobacterium smegmatis and Mycobacterium marinum, rv3865 and
rv3866 of M. tuberculosis do not impact on the secretion and T cell
recognition of ESAT-6, but rather contribute to the pathogenicity via an
as yet unknown mechanism. These ﬁndings indicate that in spite of many
similarities, speciﬁc differences of the ESX-1/T7SS system exist between
M. tuberculosis and other less virulent mycobacteria that may reﬂect the
different adaptation processes undergone by each these species.
Funding: EC contract HEALTH-F3–2007–201762.
P1964 Intracellular penetration capacity of Mycobacterium
tuberculosis drug-resistant isolates using a murine
macrophage model
E. Rey °, G. Tudo´, S. Borrell, F. Alcaide, G. Codina, P. Coll, N. Martı´n,
V. Mick, M. Montemayor, M. Salvado´, E. Vicente, J. Gonza´lez
(Barcelona, ES; London, UK)
Objectives: To determine the penetration capacity into macrophages
of Mycobacterium tuberculosis isolates resistant to different drugs
compared with susceptible clinical isolates.
Methods: Isolates: Seventeen susceptible isolates were collected from
tuberculosis (TB) patients of the Hospital Clinic of Barcelona. Forty-two
isolates resistant to isoniazid (H) and/or rifampicin (R) were selected
from an isolate collection of TB patients attended in ﬁve university
hospitals of the Barcelona area according to their molecular mechanism
associated with resistance. Of these, 5 isolates showed mutation in the
katG gene, 11 mutation in the inhA gene, 5 mutation in the rpoB gene,
11 mutations in the katG gene and rpoB and 10 were wild-type at these
positions. Mutations in the katG gene were at position 315.
Measurement of M. tuberculosis penetration in macrophages: Murine
macrophages from the cell line J774.2 were used as an in vitro infection
model. The cell monolayer was infected with M. tuberculosis isolates in
duplicate using a 1:1 MOI. After 3 hours of incubation, the monolayers
were washed to remove extracellular bacteria. The monolayers were then
lysed. Cellular lysates and inoculum were plated on Middlebrook 7H11
plates and incubated at 37ºC, being read at the end of 3 and 4 weeks.
Penetration (%) was calculated as: total CFU cellular lysates / total CFU
inoculum.
Results: Lower penetration percentages were observed in resistant
isolates inside the macrophages compared with susceptible isolates
(p< 0.05). H-resistant isolates with mutation in the katG gene and
multidrug-resistant (MDR) isolates with mutation in the rpoB and
katG genes had a lower penetration percentage than isolates with
other mutations or susceptible isolates (p< 0.05). Resistant isolates with
mutations in the inhA or rpoB genes or resistant without detected
mutations had a similar behaviour to that of susceptible isolates. No
signiﬁcant difference was found between isolates with mutation in the
katG gene and isolates with mutations in the katG and rpoB genes.
Conclusions: H-monoresistant and MDR isolates of M. tuberculosis
with mutation at codon 315 in the katG gene have a lower penetration
capacity inside murine macrophages, which could be associated with
lower virulence. The lack of a signiﬁcant difference between isolates
with a katG mutation and with katG and rpoB mutations suggests the
absence of an accumulative effect.
P1965 The transcriptome of extraintestinal pathogenic Escherichia
coli in response to human serum
N. Cooke °, S. Smith, T. Rogers (Dublin, IE)
Objectives: Escherichia coli infections of the bloodstream often
originate from the urinary tract, and are associated with high morbidity,
mortality and economic cost. The emergence of multidrug resistant
strains highlights the need for alternative antimicrobial strategies. The
ability to survive in serum is a key attribute in the pathogenesis of
uropathogenic E. coli (UPEC) related sepsis. It is unknown how UPEC
responds to assault by serum at a gene transcription level. The aim of
this study is to characterise the transcriptome of E. coli when exposed
to human serum.
Methods: The bactericidal activity of serum collected from healthy
donors was veriﬁed. Next, RNA from virulent UPEC strain CFT073,
exposed to normal human serum (NHS) and heat-inactivated NHS (HIS),
was extracted. RNA was labelled and hybridised to a CFT073 expression
microarray. Transcriptional proﬁles in NHS and HIS were compared.
qRT-PCR was employed to validate expression results against an
endogenous control. Highly upregulated genes of interest were assessed
for a direct role in serum resistance by knockout mutational studies.
Results: Expression microarray analyses revealed 97 and 58 genes
were respectively upregulated and downregulated by 3-fold in CFT073
exposed to NHS. Many genes with the highest expression fold
differences clustered within functional operons. Among the highly
upregulated genes there was a bias towards carbohydrate metabolism
systems (fructose, maltose, trehalose) and also, pyruvate formate lyase
and colanic acid biosynthesis. Downregulated genes included those for
OmpF, fatty acid transport and, ascorbate and galactosamine metabolism.
Results from the microarray were veriﬁed by qRT-PCR. Knockout
mutational studies revealed that the viability of CFT073 mutants lacking
gmd (colanic acid biosynthesis), malE (maltose metabolism), yjbE
(exopolysaccharide production) or ybiW (pyruvate formate lyase) in
NHS were signiﬁcantly decreased in comparison to the wild-type
(P = 0.0001, 0.0001, 0.0022 and 0.0025, respectively).
Conclusions:We have identiﬁed four genes, gmd, malE, yjbE and ybiW,
to have a direct and signiﬁcant role in the ability of CFT073 to resist
the lytic action of NHS. These genes may represent novel virulence-
speciﬁc therapeutic targets as alternatives to antimicrobial therapy of
E. coli sepsis.
P1966 Escherichia coli clinical isolates causing febrile urinary
tract infection. In vivo acquisition of a pathogenicity island
S. Soto °, P. Ulleryt, S. Zu´n˜iga, J. Vila (Barcelona, ES; Boras, SE;
Valencia, ES)
Objectives: Uropathogenic Escherichia coli (UPEC) strains are the most
frequent cause of urinary tract infections (UTIs). The persistence of the
same E. coli strain in the urinary tract may be the cause of recurrent
prostatitis. We analysed E. coli clinical isolates causing febrile UTI in
men, collected previously and posterior to treatment with ciproﬂoxacin.
The aim of this study was to determine if UTI recurrence is associated
with relapse or re-infection and evaluate the possible effect of virulence
factors of the isolates causing these infections.
Methods: A total of 30 E. coli isolates were collected from 15 patients
showing febrile UTI in the Shalgrenska University Hospital, Sweden.
The ﬁrst isolate from each patient was collected before antimicrobial
treatment with ciproﬂoxacin and the second after this treatment. The
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isolates were analysed by PFGE, REP-PCR and MLST in order to
determine the epidemiological relationship. Phylogenetic group and
virulence factors were analysed by PCR using gene speciﬁc-primers.
The whole genome of the 14A and 14F isolates was sequenced using
the SOLID procedure.
Results: The two isolates were completely similar and were considered
as relapse in only ﬁve patients (33.3%), while the ﬁrst isolates collected
from the other 10 patients (66.6%) were different fromthose collected
after treatment, considering these cases as re-infections. On comparing
the isolates causing relapse from each patient the virulence proﬁle was
similar in all cases, except one. However, in the case of isolates 14A and
14F, the ﬁrst (14A) lacked hly, cnf1, hra and P-ﬁmbriae with respect to
the second (14F), all these factors belonging to a pathogenicity island.
The isolates 14A and 14F were analysed by MLST to prove their
similarity. The results obtained conﬁrm that they are the same strain.
Using SOLID sequencing the 14F isolate presented 92 genes which were
not presented by the 14A isolate. Among these genes the pefC ﬁmbria,
the perC transcriptional regulator, the operon TetR, the CCT cytotoxin
and the heat-resistant agglutinin 1 were found.
Conclusion: The results obtained show that horizontal transfer of
virulence factors contained in pathogenicity islands had taken place.
This fact allows the bacteria to become more virulent and, therefore, to
cause a greater damage or colonise new niches.
P1967 Role of EspFu/Tccp in the establishment of the attaching
and effacing lesion caused by atypical enteropathogenic
Escherichia coli displaying different interactions with
epithelial cells in vitro
S. Rocha, C. Abe, S. Bando, V. Sperandio, W. Elias ° (Sao Paulo, BR;
Dallas, US)
Enteropathogenic Escherichia coli (EPEC) has been classiﬁed as typical
and atypical (aEPEC), based on the presence or absence of the EAF
plasmid, respectively. EPEC cause the attaching-effacing (A/E) lesion
on the intestinal mucosa, which is triggered by proteins encoded by
the pathogenicity island named LEE. However, some aEPEC strains are
unable to cause A/E in vitro, despite the presence of LEE.
Objective: Structural and functional analysis of the LEE region of A/E-
negative aEPEC strains.
Methods: Four aEPEC strains were studied: O55:H7 (displaying
the localized-like adherence pattern/LAL), O55:H7 (displaying the
diffuse adherence pattern/DA), O125ac:H6 (displaying the aggregative
adherence/AA) and O88:HNM (nonadherent/NA). Adherence and
capacity to cause A/E (FAS assay) were investigated in HeLa, HEp-2,
Caco, T84 and HT29 cells, and Tir phosphorylation in HEp-2 cells. The
espFu/tccp gene was searched by PCR. Transcription of LEE operons
was measured by real time PCR (qRT-PCR). Expression of intimin,
Tir, EspA, EspB and EspD was detected by immunoblotting. A EspFu-
expressing plasmid (pKC471) was used to transform the A/E-negative
aEPEC strains.
Results: The adherence patterns observed in HEp-2 and HeLa cells were
maintained in all cell lines of intestinal origin. The capacity to cause A/E,
to phosphorylate Tir and the presence of espFu/tccP was detected only in
the LAL-expressing strain. Transcriptional proﬁles of LEE as measured
by qRT-PCR were analysed in comparison to the atypical EPEC strain
BA320 (LAL/FAS+). LEE 1−5 transcription levels were decreased in the
AA, DA and NA strains in both culture conditions (DMEM and HeLa
cells), except for LEE 4 (espA) which showed higher transcription level
in the DA strain in DMEM. All four aEPEC strains studied expressed
intimin, Tir, EspA, EspB and EspD. The DA and NA strains harbouring
espFu/tccp were able to cause A/E in HeLa and Hep-2 cells. The presence
of espFu/tccp was not efﬁcient to induce the A/E lesion in vitro by the
AA strain.
Conclusions: Despite the incapacity to cause A/E, the transcription and
expression of LEE 1−5 demonstrated that LEE is functional in these
strains. The incapacity to cause A/E in vitro by the DA and NA aEPEC
strains is due to the absence of espFu/tccp. The complete mechanism
involved in the establishment of A/E by the AA aEPEC of serotype
O125ac:H6 remains unknown.
P1968 The anti-aggregation protein dispersin is not involved in
the establishment of the diffuse and non-characteristic
adherence patterns of Escherichia coli on HEp-2 cells
L. Bevilacqua, F. Vasconcellos, W. Elias ° (Sao Paulo, BR)
The anti-aggregation protein dispersin is a 10.2-kDa protein encoded
by the aap gene. This protein is an important virulence factor of
enteroaggregative Escherichia coli (EAEC) and was demonstrated to be
immunogenic in studies with human volunteers. Mutants in the aap gene
express a very intense autoagglutination, indicating that dispersin acts re-
covering the surface of the bacterium, diminishing the autoaggregation
and allowing the bacteria to disperse along the intestinal tract. Recent
ﬁndings of our group demonstrated that the aap gene is not exclusive of
EAEC, since it was also detected in diffusely adherent E. coli (DAEC)
and non-pathogenic E. coli displaying a non-characteristic adherence
pattern to HEp-2 cells.
Objective: Determine the role of dispersin in the establishment of
the diffuse and non-characteristic patterns of adherence to HEp-2 cells
expressed by E. coli strains that harbour the aap gene.
Methods: Three aap-positive E. coli strains isolated from children with
diarrhea were selected. These strains display the aggregative adherence
(AA) pattern (strain 268), the diffuse adherence (DA) pattern (strain 84)
and a non-characteristic (NC) pattern (strain 901) on HEp-2 cells. The
aap genes of these strains were mutagenized using the suicide vector
pJP5603. An internal fragment of aap was ampliﬁed by PCR using the
EAEC prototype strain 042 as template and cloned in the suicide vector.
Conjugation of E. coli DH5a lambda-pir harbouring this construct
and the wild type strains led to the aap knockout by homologous
recombination. The effect of aap inactivation on the adherence ability of
the wild type strains was evaluated on HEp-2 cells (3- and 6-h assays).
Results: The correct inactivation of aap in the transconjugates obtained
was conﬁrmed by PCR and Southern-blot analysis. The mutants selected
were named 268::pLB2, 84::pLB2 and 901/Nal::pLB2. These mutants
were tested in HEp-2 cells adherence assays with incubation periods of
3 and 6 h. The results demonstrate that the mutation in aap abolished the
AA pattern of the 268::pLB2 mutant, which did not occur in the other
two mutants expressing DA (84::pLB2) and NC (901/Nal::pLB2).
Conclusions: the product of the aap gene (dispersin) is involved in the
establishment of the AA phenotype, but not in the DA and NC, which
are mediated by uncharacterised adhesins.
P1969 Evaluation of frequency of secreted proteins (EspA,
EspB, EspD and EspC) and actin polymerization in
enteropathogenic E. coli isolated in Peru
C. Contreras °, V. Bustamante, T. Ochoa, C. Lanata, T. Cleary,
J. Puente (Lima, PE; Cuernavaca, MX; Houston, US)
Objective: The aims of this study is to describe the diversity and
relationship between protein secretion of E. coli secreted proteins (EspA,
EspB, EspD and EspC) and the ability of adherent strains to cause
A/E lesions was evaluated by the FAS (Fluorescent actin stain) test,
in enteropathogenic Escherichia coli (EPEC) isolated in the population.
Methods: Protein secretion (EspA, EspB, EspD and EspC) was analysed
in 57 (42 from diarrhea cases and 15 from controls) representative
isolates of 120 EPEC strains isolated from children with and without
diarrhea under 1 years of age living in Lima, Peru´. FAS test was evaluated
in 69 (46 from diarrhea cases and 23 from controls) representative
strains. Only isolated from episodes with infections due to a single
pathogen were evaluated in all cases. The characterisation among
typical EPEC (tEPEC) and atypical EPEC (aEPEC) were determined
by presence of bfpA gene evaluated by PCR.
Results: EspB/D was the most frequently protein recovery in both
groups diarrhea 55%(23/42) and control 27%(4/15); same similarity was
observed in tEPEC 7/10 (70%) and aEPEC 20/47 (43%). The protein
EspA was more frequently found in diarrhoea episodes than controls
(21/42, 50% vs 0/15, 0%; P< 0.05). The frequency of EspA among
tEPEC y aEPEC was similar. The EspC protein have similar frequency
among diarrhea cases 15/42 (36%) and controls 3/15 (20%). The strains
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that secreted all proteins were related whit diarrhoea cases compared with
controls (17/42, 19% vs 0/15, 0%; p< 0.05). In all strains analyzed for
FAS test we observed a statistical relationship among tEPEC and actin
polymerization (p< 0.05); whereas the frequency of actin polymerization
is similar between diarrhoea cases and controls (8/46, 17% and 2/23 9%,
respectively). The high percentage of strains do not polymerized actin
(38/46, 83% in diarrhea cases and 21/23, 91%).
Conclusions: Our ﬁnding indicates that few EPEC strains secreted all
proteins evaluated in this study. EspA is an important marker for virulent
EPEC in human isolates. The small frequency of actin polymerization
among the isolates is due to the small frequency of tEPEC in our
population.
P1970 Relation between 20-kDa polysaccharide and polysaccharide
intercellular adhesin of Staphylococcus epidermidis
A. Spiliopoulou °, F. Kolonitsiou, M.I. Krevvata, N.K. Karamanos,
G. Dimitracopoulos, L.G. Harris, T.S. Wilkinson, A.P. Davies, D. Mack,
E.D. Anastassiou (Patras, GR; Swansea, UK)
Objectives: Extracellular polysaccharide molecules from S. epidermidis
have proved notoriously difﬁcult to characterise as numerous original
descriptions of unique molecules have ultimately been conﬁrmed to be
closely related or identical to Polysaccharide Intercellular Adhesin (PIA).
In the present work (ESCMID09 Fellowship) we have investigated the
relation of 20-kDa PS and PIA.
Methods: 75 CoNS strains isolated from blood cultures and central
venous catheter tips in the Clinical Laboratory of the General University
Hospital of Patras, Greece, were identiﬁed at the species level and
screened for bioﬁlm formation, icaADBC presence, and 20-kDa PS
expression. Nine different S. epidermidis reference strains were also used
in the present study. Parallel screening of reference and selected clinical
strains for 20-kDa PS and PIA using speciﬁc anti-20-kDa PS and anti-
PIA rabbit antisera was performed. Susceptibility of both antigens to
certain chemicals and enzymes was examined by treatment of bacterial
suspensions with sodium meta-periodate, proteinase K and speciﬁc
N-acetylglucosaminidase, Dispersin B (DspB). Antigen detection was
accomplished by immunoﬂuorescence microscopy and ELISA.
Results: Among the clinical isolates, 20 strains were found to be
ica+bioﬁlm+20kDaPS+, 10 ica−bioﬁlm−20kDaPS−, 6 ica+bioﬁlm−
20kDaPS+, 6 ica−bioﬁlm−20kDaPS+, 5 ica+bioﬁlm−20kDaPS− and 5
strains ica+bioﬁlm+20kDaPS−. All other CoNS were ica−20kDaPS−.
All PIA positive reference strains (1457, 8400, and 9142) were 20-kDa
PS positive, whereas, a PIA negative strain (1585) was also 20-kDa
PS negative. Expression of 20-kDa PS does not seem to be related to
icaADBC activity or bioﬁlm formation as isogenic icaA::Tn917 PIA-
negative mutants (1457-M10 and 8400-M10) were still 20-kDa PS
positive. 20-kDa PS is resistant to treatment with proteinase K, sodium
meta-periodate and DspB, whereas, PIA is resistant to proteinase K
but sensitive to sodium meta-periodate treatment and DspB. Fractions
of Q-Sepharose containing the PIA-antigenic peak were devoid of 20-
kDa PS. Finally, the two molecules have distinct antigenic properties, as
shown by cross absorption experiments.
Conclusions: 20-kDa PS is a main antigenic determinant of S. epi-
dermidis. Our data show that 20-kDa PS is distinct from PIA. It is
therefore of great importance to elucidate its biologic properties and
role in pathogenesis of biomaterial-associated infections by constructing
isogenic mutant(s) devoid of 20-kDa PS.
P1971 Nasal carriage of Staphylococcus aureus: a histological
approach
N.J. ten Broeke-Smits, J.A. Kummer, A.C. Fluit, E. Boel ° (Utrecht, NL)
Objectives: Nasal carriage of Staphylococcus aureus is an endemic risk
factor for blood-borne and surgical site infections. Around 20% of the
human population is persistent carrier of one type of strain and an
additional 60% is intermittent carrier of varying strains. Decolonization
with topical antibiotics like mupirocin, is rather effective, however
relapses are common within months. Nasal colonization is thought to
occur in the vestibulum nasi. It has been hypothesized that intermittent
carriers could be mucosal carriers, while persistent carriers could use
a niche for S. aureus cells. However, the exact niche for S. aureus to
reside in the nose is currently not known. To determine this niche, we
performed a study in which sections of different parts of the nose were
stained with antibodies against staphylococcal protein A (SpA).
Methods: Study objects were human bodies donated for scientiﬁc
purposes. After nasal swabs for culture of S. aureus were taken, noses
were removed anatomically, vertically dissected, formalin ﬁxated and
embedded in parafﬁn. We used 9 out of 37 culture-positive noses and 8
culture-negative noses for staining. To stain for S. aureus, sections were
incubated with anti-SpA (1mg/ml), followed by Powervision Goat anti-
Mouse/Rabbit/Rat IgG and stained with 3′,3′-Diaminobenzidine (DAB).
Sections were counterstained with haematoxylin and visually inspected
with light microscopy.
Results: S. aureus was detected in the region of the vestibulum nasi
in 8 of the 9 culture-positive noses. The majority of the bacteria were
found within the corniﬁed layer of the stratiﬁed squamous epithelium
and in the associated keratin and mucous debris within the vestibulum.
Interestingly, in some cases the bacteria were also detected in the outer
portion of the hair follicle shafts. No bacteria were detected in the
ciliated mucosa covering the major part of the nose or its associated
serous glands. Negatively cultured noses did not show stained bacteria
indicating that the primary antibody was speciﬁc for S. aureus.
Conclusion: This study revealed the presence of S. aureus in the
corniﬁed layer and associated debris as well as in hair follicles in the
nasal cavity. This shows that colonization of the nose is indeed restricted
to the vestibulum nasi.
P1972 Correlation of bioﬁlm formation with agr polymorphism
and quantiﬁcation of RNAIII in Staphylococcus aureus
E. Bae °, M.Y. Lee, M.N. Kim, S.H. Lee (Seoul, KR)
Objective: The purpose of this study is to measure the effect of activity
and polymorphism of accessory gene regulator (agr) on production of
bioﬁlm in Staphylococcus aureus.
Methods: From November 2003 to April 2004, blood culture isolates
of S. aureus were collected by one per one patient. Minimum inhibitory
concentration of vancomycin was determined by Clinical and Laboratory
Standards Institute broth dilution method. agr polymorphism and the
presence of ica were determined by PCR. Relative quantity of RNAIII
transcript was measured by real time reverse transcription PCR compared
to those of 16s rRNA. Delta cycles of threshold (delta CT) were
calculated from CT of 16s rRNA minus CT of RNAIII. Under the
conditions of tryptic soy broth(TSB) or TSB plus 4% ethanol (TSBE) or
3% NaCl (TSBN) or vancomycin of one fourth of MIC (TSBV), bioﬁlm
mass produced on polystyrene microtiter plate was stained by crystal
violet and OD490 of bioﬁlm substracted from OD490 of blank were
averaged from triplicate assays of each isolates.
Results: Total of 46 isolates included 21 methicillin-susceptible
S. aureus (MSSA) comprising 7 agr1, 4 agr2, 8 agr3, and 2 agr4 and 25
methicillin-resistant resistant S. aureus (MRSA) comprising 11 agr1, 12
agr2, and 2 agr3. All of them except one were ica-positive. There was
no signiﬁcant difference found in bioﬁlm production according to agr
polymorphism or conditions of bioﬁlm assay, but OD490 of MSSA agr1
were signiﬁcantly higher than those of other groups of MSSA; 1.97±1.44
vs 0.27±0.08 (P< 0.001) in TSBN and 0.89±0.71 vs 0.33±0.15 in
TSBV (P< 0.05). MRSA showed higher mean OD490 than MSSA;
0.59±0.43 vs 0.37±0.24 (P< 0.05) in TSB and 0.79±0.65 vs 0.45±0.27
in TSBE (P< 0.05). Mean delta CT were 4.57±2.24 for MSSA and
7.7±3.45 for MSSA (P< 0.05). 10 isolates including 8 MRSA of agr2
and 2 MSSA agr3 showed delta Ct over 10 and higher OD490 than the
others; 0.67±0.35 vs 0.44±0.36 in TSB (P< 0.05) and 0.99±0.65 vs
0.54±0.46 in TSBE (P< 0.05).
Conclusion: Difference of bioﬁlm production was not prominent
according to agr polymorphism but certain conditions such as salt or
vancomycin enhanced the difference. MRSA of agr2 were predominant
in agr-defective strains. MRSA and agr-defective strains were correlated
with higher production of bioﬁlm.
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P1974 Interconnection in phosphoregulation pathways underlines
the complexity of Staphylococcus aureus virulence
M.E. Cluzel °, J.P. Didier, M. Becchi, I. Zanella-Cleon, V. Molle,
A.J. Cozzone, B. Duclos (Lyon, FR)
Objectives: Reversible phosphorylation of prokaryotic proteins on
serine, threonine and tyrosine residues has become a growing ﬁeld
of interest, since it is involved in several virulence pathways. The
Stk1/Stp couple, including a serine/threonine kinase and its associated
phosphatase, is one of the main actors of the phosphoproteome of Staphy-
lococcus aureus. Besides this kinase/phosphatase couple, two-component
systems (TCS) are speciﬁc prokaryotic systems that involve phosphore-
lay between both sensor and response elements. Response elements are
DNA-binding proteins, leading to the modulation of virulence through
genetic regulation. Thus, TCS and Stk1/Stp are implicated at different
levels of Staphylococcus aureus pathogenesis, with distinct phosphore-
lays. We have focused on these two parallel systems to point out an
interconnection that implicates a further degree of virulence regulation.
Methods: We have speciﬁcally analyzed the autolysis regulatory locus
response element (ArlR) and the staphylococcal accessory element
response element (SaeR) proteins. These proteins contain conserved
serine and threonine amino acids in their primary structures, as shown
by interspecies alignment. We used radioactive ATP labeling, analysis
of speciﬁc phosphoamino acids, mass spectrometry and site-directed
mutagenesis to evidence the interconnection between these two systems
and to identify the phosphorylated positions.
Results: Radioactive experiments have pointed out that both response
elements ArlR and SaeR are substrates for Stk1. Phosphorylated amino
acids are phosphothreonine for SaeR and both phosphoserine and
phosphothreonine for ArlR. Two distinct phosphorylation sites have
been identiﬁed in the N-terminal and C-terminal regions. Considering
that the loop formed to link DNA is located in the C-terminal
region, phosphorylation may modify the DNA-binding process and thus
contribute to the regulation of bacterial virulence.
Conclusion: As response elements ArlR and SaeR have been
identiﬁed as substrates for the serine/threonine kinase Stk1, the two-
component systems and the Stk1/Stp system are therefore shown
to be interconnected, suggesting that new antibiotic drugs against
Staphylococcus aureus could be elaborated to inhibit this interrelation.
P1975 Comparison of expression of virulence genes among invasive
and colonizing methicillin-resistant Staphylococcus aureus
clinical isolates
A. Abu Othman, E. O’Neill, H. Humphreys, D. Hughes ° (Dublin, IE)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) can
mediate infection by the expression of a wide array of virulence factors,
encoded by various virulence genes to facilitate invasion and tissue
damage. Some virulence markers have been reported to be associated
more with invasive MRSA isolates than with colonising isolates. We
compared the expression of virulence genes among 20 colonising and
20 invasive (bloodstream) isolates of MRSA.
Methods: The invasive and colonizing (e.g. nasal carriage) isolates
were collected in Beaumont Hospital, Dublin, Ireland between 2001–
2006. We determined the expression levels of the virulence genes hlg,
cna, sea and the accessory gene regulator agr, in isolates grown in the
presence of human serum (to mimic the in vivo environment) using
reverse transcriptase real-time PCR (RT-PCR).
Results: There was considerable variation in the expression of virulence
genes among both groups of isolates. Transcription of hlg was up-
regulated greater than 2 fold in 60% of invasive isolates compared to
35% of colonizing isolates (P value = 0.0193), cna transcription was up-
regulated in 63% of invasive isolates compared to 100% of colonizing
isolates (P value = 0.0110). Sea transcription was down-regulated in
100% of invasive isolates and 85% of colonizing isolates (P value =
0.0074). Transcription of RNAIII, the effecter gene of the agr regulation
system was up-regulated greater than 2 fold in 40% of invasive isolates
and 25% of colonizing isolates but this was not statistically signiﬁcant.
The transcription of RNAIII was not accompanied by a reduction in
transcription of cna or increased transcription of hlg and sea.
Conclusions: The pattern of expression of speciﬁc virulence associated
genes in invasive versus colonising isolates differs, which may contribute
to the pathogenicity of MRSA. However, some virulence genes are pref-
erentially up-regulated in colonizing isolates suggesting that colonising
isolates have the capacity to promote host damage in certain settings.
Therefore bacterial virulence is only one factor in invasive infection and
other factors, e.g. the host immune response also contribute to infection.
P1976 Processing of antimicrobial peptides derived from
chromogranin A by Staphylococcus aureus virulence factors
M.H. Metz-Boutigue °, P. Shooshtarizadeh, J.F. Chich, C. Corazzol,
S. Lefe`vre, B. Gue´rold, F. Delalande, F. Jehl, G. Pre´vost, Y. Haı¨kel,
D. Aunis (Strasbourg, FR)
Objectives: Recent studies have shown that S. aureus strains produce
virulence factors that are proteolytic enzymes able to interact with
tissue components and the host defence mechanisms. The antimicrobial
peptides play a crucial role in innate immunity and avoidance
mechanisms deployed by S. aureus may include proteolytic degradation.
The present study is conducted to evaluate the effects of several S. aureus
virulence factors against the antimicrobial chromogranin A (CGA)-
derived peptides.
Methods: By using a combination of RP-HPLC, Edman sequencing
and Maldi-Tof mass spectrometry, we analyzed the processing of
Chromofungin (CGA57−66), Catestatin (CGA344–364) and Cateslytin
(CGA344–358), three potent antimicrobial CGA-derived peptides, after
incubation in presence of two S. aureus supernatants, (S1, a MRSA
strain and S2 a strain without resistance against tested antibiotics). A
similar experimental strategy was applied to determine the effects of the
endoprotease Glu-C of S. aureus on the degradation of CGA-derived
peptides released by chromafﬁn cells during stress. The structure of
the new generated peptides was related with the antimicrobial activities
against bacteria, fungi, yeasts and Plasmodium.
Results: After incubation with S. aureus S1 or S2 for 18 h, we observed
the degradation of Catestatin and we determined the sequence of new
generated fragments. The degradation proﬁle was different with both
strains and for the strain S2 aureolysin might be involved in the
proteolytic process. In contrast, Cateslytin and Chromofungin remained
mostly intact after incubation with either strain. Furthermore, when the
material released by chromafﬁn cells was treated by the Glu-C protease
from S. aureus, we observed the degradation of numerous antibacterial
peptides to generate new antifungal peptides.
Conclusion: We evidence that S. aureus subverts innate immunity to
degrade highly conserved antibacterial peptides and to produce new
antifungal peptides.
P1977 Genetic organization of pathogenicity island XII of group B
streptococci
E. Kuleshevich °, A.N. Suvorov (St. Petersburg, RU)
Objectives: Group B streptococci (GBS) are the major cause of neonatal
meningitis, sepsis, and pneumonia leading to newborn mortality. At
the beginning of XXI-st century sequencing of the genomes of several
GBS strains have been carried out. It allowed to discover a number of
previously unknown surface protein genes including SspB1(A. Suvorov,
2006). The gene encoding for this protein is localized on the GBS
pathogenicity islands (PAI). PAI are mobile genetic elements which
might be apprehended by GBS due to horizontal gene transfer and can
differ signiﬁcantly between the epidemic strains. The aim of the work
was to analyze the organization of PAI XII which usually carries SspB1.
Methods: Three collections of GBS strains have been studied: 16 from
Russia, 12 from USA and 9 from Czech Republic. All the strains have
been serotyped using capsular speciﬁc antibodies and speciﬁc set of PCR
primers (C. Poyart, 2007). Localization of the genes on PAI 1 XII have
been studied by the following methods: PCR and DNA hybridization.
Results: Genetic organization of pathogenicity island XII GBS
containing sspB1 gene have been studied. Following genes have been
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chosen for the investigation: sspB1 (gbs1356), putative zeta toxin
(gbs1343), putative Zn-ﬁnger protein (gbs 1348), putative helicase
(gbs1352), putative transposon Tn5252 (gbs1360), type IV secretory
pathway protein (gbs1364). G+C content of the genes under study
differs from typical GBS G+C content by 4−7%. Gene encoding for
the putative protease (gbs1376) located on the verge of the island and
present in all GBS strains was used as positive control. Three collections
of clinical GBS strains was analyzed. None of the genes belonging to the
pathogenicity island under study were found in strain collections from
USA or Chech Republick. Island had been found in eight strains from
Russian collection. These strains belonged to different serotypes which
excludes clonality. Composition of the genes on PAI XII was different
between the strains.
Conclusion: Pathogenicity island XII have been found only in eight
from sixteen strains of Russian collection but haven’t been found in
other strain collections. Results obtained allows speculating that virulent
GBS strains containing pathogenicity island XII might have speciﬁc
geographical distribution.
P1978 Evidence for capsular switching in Streptococcus agalactiae
E.R. Martins °, J. Melo-Cristino, M. Ramirez (Lisbon, PT)
Objectives: The polysaccharide capsule is a major antigenic factor
in Streptococcus agalactiae (GBS). Previous observations suggest that
exchange of capsular loci is likely to occur rather frequently in GBS,
even though GBS is not known to be naturally transformable. The aim
of this study was to evaluate the concordance between serotype and
the clusters deﬁned by pulsed-ﬁeld gel electrophoresis (PFGE) and to
further characterize any putative transformants to establish unequivocally
that capsular switching occurs in GBS.
Methods: We analyzed a large collection of GBS isolates (n = 463) by
serotyping and PFGE in order to evaluate the genetic heterogeneity
within bacterial clones and to investigate how often they express different
capsular types. Each putative transformant (n = 9) was compared to
other isolates in the same PFGE cluster by analysis of multiple genes
spread across the GBS genome, including multilocus sequence typing
(MLST), and surface protein and pili gene proﬁling. The capsular locus
was also characterized in these isolates by restriction fragment length
polymorphism (RFLP), sequencing and southern blot hybridization.
Results: We show that capsular switching by horizontal gene transfer
is not as frequent as previously suggested. Serotyping errors may be
the main reason behind the overestimation of capsule switching, since
phenotypic techniques are prone to errors of interpretation. The identiﬁed
capsular switching events involved the acquisition of the entire capsular
locus and were not restricted to the serotype-speciﬁc central genes, the
previously suggested main mechanism underlying capsular switching.
Since we found no evidence of recombination inside the capsular locus
we surmise that the recombination breakpoints are located outside this
region and most probably outside the cps operon.
Conclusions: Our data, while questioning the frequency of capsular
switching, provide clear and unambiguous evidence for in vivo capsular
transformation in S. agalactiae which may be of critical importance in
planning future vaccination strategies against this pathogen.
P1979 Adhesion mechanism of Streptococcus anginosus to mucosal
epithelial cells
Y. Kodama °, M. Sasaki, Y. Shimoyama, S. Tajika, S. Kimura (Morioka,
JP)
Objective: Although Streptococcus anginosus is a part of the normal
ﬂora found in human dental plaque, recent studies indicate that
S. anginosus infection in oral mucosa can be associated with oral
squamous cell carcinoma. The organism possesses a number of
pathogenic properties, however, adhesive mechanism that mediate the
initial process of S. anginosus infection to oral mucosal epithelial
cells remained to be elucidated. In this study, the adhesive abilities of
S. anginosus to mucosal epithelial cells of a human larynx carcinoma
cell line (HEp-2 cells) and a gingival epithelial cell line (GE1 cells) as
well as the immobilized ﬁbronectin were investigated.
Methods: S. anginosus ATCC 10713 and clinical isolates were used.
The adhesive ability of S. anginosus was assessed by binding of bacteria
to the cultured epithelial cells, and the immobilized extracellular matrix
proteins. The ﬁbronectin expression of HEp-2 cells was analyzed by
Western blotting and RT-PCR assay.
Results: S. anginosus can adhere to both mucosal epithelial cells as other
oral streptococci do. The adhesive ability could be ascribable to mainly
its ﬁbronectin-mediated adherence to the mucosal epithelial cells. It was
also indicated that the adhesive ability to HEp-2 cells of the S. anginosus
isolates from oral cancer tissues was signiﬁcantly higher than that of the
isolates from the plaque sample of healthy subjects. The cell-surface
expression of ﬁbronectin in HEp-2 cells was augmented by the bacterial
adhesion itself and the autocrine activation of TGF-b1 induced by the
bacterial adhesion. Furthermore, the addition of exogenous ﬁbronectin
(10 nM) enhanced the S. anginosus adherence to HEp-2 cells. The
pretreatments with ﬁbronectin of the bacterial cells as well as HEp-2
cells enhanced the S. anginosus adherence, and the enhancements were
abrogated by the addition of anti-ﬁbronectin antibodies, suggesting the
coexistence of a direct adhesion of S. anginosus to the ﬁbronectin
of HEp-2 cell surfaces and another ﬁbronectin-mediated adhesion
mechanism involving a ﬁbronectin bridge between the S. anginosus
ﬁbronectin-binding molecule(s) and the integrins of HEp-2 cells.
Conclusion: The present ﬁndings suggest that S. anginosus could adhere
to mucosal epithelial cells via multiple adhesion mechanisms, and the
adhesive ability to ﬁbronectin could be involved in the pathogenicity of
S. anginosus, leading to the onset of oral squamous cell carcinoma.
P1980 Isolation of two genetic loci involved in anti-phagocytosis
and pathogenesis in K. pneumoniae through a Dictyostelium
model
Y.J. Pan °, T.L. Lin, J.T. Wang (Taipei City, TW)
Objectives: Dictyostelium has been used for study the interaction of
phagocyte-bacteria because it displays highly similarity to mammalian
macrophage. Thus we determined to investigate virulence factors of anti-
phagocytosis related genes in a clinical strain of Klebsiella pneumoniae
causing pyogenic liver abscess which is highly resistant to phagocytosis
using a Dictyostelium model.
Methods: Plaque assay was used for screening the mutants susceptible
to Dictyostelium phagocytosis. The transposon-disrupted genes were
further identiﬁed in these selected mutants. Unmark deletion mutant and
complementation constructs were generated and conﬁrmed with plaque
assay. Bacteria carrying a plasmid encoding green ﬂuorescence protein
(GFP) incubated with Dictyostelium or human neutrophils were observed
using confocal microscopy and the numbers of phagocytosed bacteria
were also determined. Five week-old female BALB/cByl mice were in-
traperitoneally inoculated with 103 CFU bacteria. Four to eight mice were
infected in each group and monitored for 30 days. Survival of different
groups of mice were compared and analyzed with Kaplan–Meier method.
Results: Thirty of 2500 mutants were permissive for Dictyostelium
growth. Among the 30 mutants, capsular genes and two non-capsular
genes were identiﬁed. One is encoding a subunit of protease (clpX)
and the other is encoding a lipopolysaccharide transporter (wzm).
The two genes were conﬁrmed by generating their deletion and
complementation strains. The results showed that clpX− mutant and
wzm− mutant became more susceptible to Dictyostelium phagocytosis,
and the complementation strains restored the ability of anti-phagocytosis.
Moreover, we have proved that the two mutants not only became
more easily to be phagocytosed by Dictyostelium but also by human
neutrophils. Also, the mutants were attenuated in virulence in a
mouse model, implicating they play important roles in pathogenesis of
K. pneumoniae.
Conclusion: We have isolated 2 genes, clpX and wzm, which
are involved in anti-phagocytosis and also in vivo virulence of
K. pneumoniae using a Dictyostelium model.
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P1981 Development of neonatal sepsis is not dependent on the
presence of magA, k2A, rmpA and kfu genes in Klebsiella
pneumoniae
K. Huik °, U¨. Parm, K. Denks, M. Pauskar, R. Avi, T. Metsvaht,
M. Ilmoja, I. Lutsar (Tartu, Tallinn, EE)
Background: K. pneumoniae is one of the leading causes of infections
in neonatal intensive care units (NICU). In adults its pathogenicity has
been associated with virulence genes like magA, k2A, rmpA and kfu.
Their role in neonatal infections is less well known.
Objectives: To determine the population dynamics of K. pneumoniae in
two NICUs in Estonia and evaluate the presence of the above mentioned
virulence genes among invasive and colonising strains.
Methods: From Aug 2006 to Dec 2007 rectal and nasopharyngeal (NP)
surveillance cultures were collected from all neonates admitted with sus-
pected or conﬁrmed early onset sepsis. Blood cultures were obtained as
clinically indicated. Isolates were typed using ampliﬁed fragment length
polymorphism (AFLP) PCR analysis. In parallel, 5 mucosal and 5 inva-
sive isolates in 5 pts with invasive disease were typed using pulse ﬁeld gel
electrophoresis (PFGE). Hypermucoviscosity test was deﬁned as positive
string test. The magA (speciﬁc to K1 capsule serotype), k2A (speciﬁc
to K2 capsule serotype), rmpA (regulator of mucoid phenotype) and kfu
(an iron uptake system) were detected by PCR using speciﬁc primers.
Results: A total of 47/278 pts had mucosal carriage of K. pneumoniae
and 6 had BSI including 38 colonised pts in unit A (5 with BSI) and 9 in
unit B (1 with BSI). Altogether, 88 rectal, 55 NP, and 5 BSI isolates were
analysed. The ALFP analysis identiﬁed 6 different clonal groups 2 of
which predominated in unit A (type A in 26 pts over 7mo and, type K in 6
pts over 2mo), while in unit B all colonising K. pneumoniae strains were
different. 5/6 BSI were caused by type A; the invasive and colonising
strains had similar genotype in PFGE analysis. Hypermucoviscosity
strains were detected only among mucosal isolates; in 16/30 isolates
in pts with and in 0/118 without BSI (P< 0.001). No magA and rmpA
genes were detected. The k2A and kfu genes were rare and present in
7/143 and 4/143 mucosal isolates, respectively but only in pts without
BSI. A concordance between AFLP type and presence of k2A and kfu
genes was identiﬁed − type B was related to k2A and type P to kfu.
Conclusions: AFLP method is an alternative in evaluating the
spread of K. pneumoniae in NICU and allows to identify potential
cross-colonisation clusters. Although none of the tested virulence
genes was associated with BSI, the testing of colonising strains for
hypermucoviscosity appeared to be a simple method identifying patients
at risk for BSI.
P1982 Evidence of the inhibitory activity of the Lactobacillus
paracasei probiotic strain soluble fraction on the expression
of Pseudomonas aeruginosa quorum-sensing genes
quantiﬁed by real-time qRT-PCR
M.C. Chiﬁriuc Balotescu °, A. Cotar, C. Bleotu, S. Dinu, D. Pelinescu,
V. Lazar (Bucharest, RO)
Objectives: The purpose of this study was to demonstrate by real-
time PCR the inhibitory activity of the Lactobacillus paracasei subsp.
paracasei probiotic culture ﬁltrate on Pseudomonas (Ps.) aeruginosa
quorum-sensing expression.
Methods: The study was performed on 30 Ps. aeruginosa strains
isolated from different clinical specimens. The characterization of
quorum-sensing systems (las and rhl) of Ps. aeruginosa analysed strains
was performed by PCR using speciﬁc primers for detection of genes
lasI, lasR, rhlI and rhlR. The Ps. aeruginosa strains were grown
in the presence of subinhibitory concentrations of sterile supernatant
of probiotic culture, that exhibited inhibitory effects on growth and
adherence to the inert substrate. Total RNA was extracted from standard
bacterial cultures, and from bacterial cultures grown in the presence
of probiotic culture supernatants. Random hexamers primers were used
for cDNA synthesis. The quantiﬁcation of lasI, lasR, rhlI and rhlR
genes expression in Ps. aeruginosa cultures grown in the presence of
probiotic cultures ﬁltrates versus controls was performed by real-time
qRT-PCR with SYBR Green I ﬂuorescent dye using the instrument
Mx3005 (Stratagene). In addition, the expression of each target gene
(lasI, lasR, rhlI and rhlR) in the control versus experimental sample was
normalized using the 16S rRNA reference gene.
Results: The results of PCR assays showed that all Ps. aeruginosa strains
possess all quorum sensing tested genes. Also, the results of the real time
qRT-PCR showed that in all Ps. aeruginosa strains grown in the presence
of probiotic culture ﬁltrate, the level of expression is reduced compara-
tively with the control cultures. The expression level of lasI and rhlI gene
in experimental samples was reduced with 35.6% comparatively with
the control samples. The expression level of lasR and rhlR gene in the
experimental samples was reduced with 41.6% and respectively 41.5%.
Conclusion: The comparative quantiﬁcation of quorum sensing genes
expression in Ps. aeruginosa strains grown in the presence of probiotic
culture ﬁltrate proved the inhibitory effect of soluble molecules
accumulated in the supernatant on the quorum sensing genes expression
level. These results prove that the inhibition of virulence factors
regulation mechanisms by soluble molecules secreted by probiotics could
represent an interesting way of attenuation of pathogenicity and virulence
in Ps. aeruginosa nosocomial strains.
P1983 Pseudomonas ﬂuorescens can increase the permeability of
Caco2/TC7 and modify the actin cytoskeleton
A. Madi °, P. Svinareff, N. Orange, M.G. Feuilloley, N. Connil (Evreux,
FR)
Context: Pseudomonas ﬂuorescens has been proposed as a normal
low-level resident of the intestine (Wei et al, 2002). However, its I2
speciﬁc antigen has been shown highly prevalent in the serum of patients
suffering from crohn’s disease (Arnott et al, 2004) suggesting a putative
role of this bacterium in the initiation of the pathology.
Objectives: As we have recently demonstrated that P. ﬂuorescens MF37
is able to bind and exert cytotoxic effects on undifferentiated Caco-2/TC7
cells (Madi et al, 2008), the aim of the present work was to investigate the
interaction of P. ﬂuorescens MF37 with fully differentiated Caco-2/TC7
monolayers.
Methods: Caco-2/TC7 cells were seeded onto inserts and cultivated in
Dulbecco’s modiﬁed Eagle’s medium containing 10% fetal calf serum
at 37ºC in 5% CO2 during 21 days. The differentiated cells were
infected with P. ﬂuorescens MF37 at a multiplicity of infection (MOI)
of 100. Bacterial cytotoxicity was evaluated using the CytoTox 96
assay kit (Promega). Transepithelial resistance (TER) was estimated
using a Millicell-ERS apparatus and the paracellular permeability was
quantiﬁed by ﬂuorimetry using 4 kDa FITC-Dextran beads. The F-actin
cytoskeleton was visualized with Alexa ﬂuor® 488 phalloidin.
Results and Conclusions: No cytotoxicity was observed after 24 h-
infection of the differentiated Caco-2/TC7 cells with P. ﬂuorescens
MF37. However, a slight decrease of TER was obtained correlated
with an increase of paracellular permeability. This increase of
permeability was associated with a profound reorganization of the
F-actin cytoskeleton. Further studies will help to understand the signaling
pathways involved in these mechanisms and might partially explain the
implication of P. ﬂuorescens in the etiology of crohn’s disease.
Reference(s)
[1] Arnott et al (2004) Am. J. Gastroenterol. 99: 2376–2384.
[2] Madi et al (2008) 15th International Congress on In Vitro Toxicology,
25−28 Sept, Stockholm, Sweden
[3] Wei et al (2002) Infect. Immun. 70: 6567–6575
P1984 Acinetobacter baumannii and other genomic species:
characteristics of adhesion and bioﬁlm
E.H. Takagi, J.C. Campos, C.R. Taddei, M.B. Martinez ° (Sa˜o Paulo, BR)
Bacterial species of Acinetobacter calcoaceticus-A. baumannii complex
are nosocomial pathogens of increasing importance, but the mechanisms
involved in their virulence are largely unknown. This study investigated
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the potential of different species of this complex to produce bioﬁlm on
abiotic surface and adhere to eukaryotic cells: Hep-2, NCI-H292 and
MRC-5. A modiﬁed PCR-based method was created and used to distin-
guish between Acinetobacter baumannii and Acinetobacter genomic sp.
13TU and 3TU. This genomic identiﬁcation method exploits differences
in gyrB gene and 16S-23S rRNA gene spacer region sequences. Thirty
non-clonal isolates from intensive unit care patients, 18 were identiﬁed
as A. baumannii, eight as A. 13TU and four A. as 3TU. During this study,
3 clinical strains of A. 3TU, 3 of A. 13TU and 3 of A. baumannii, were
examined for bioﬁlm formation and adherence assays. Bioﬁlm formation
was evaluated by quantitative method through microtitre plate assay by
means the crystal-violet staining method. Adherence of clinical isolates
to eukaryotic cells was examined by light microscopy. The strains under
this study displayed high variability in bioﬁlm formation among isolates
from the same species. None isolate adhere to Hep-2 cells. On NCI-
H292 cells it was possible to observe differences, such as A. baumannii
presents dispersed adherence, while A. 13TU shows some cluster cells
adherence and A.3TU did not adhere. However, dispersed adherence
was observed by A. baumannii, A. 3TU and A. 13TU with variability in
number of bacterial cells adhered on MRC-5 cells. This study describes a
PCR-based method that allows the identiﬁcation of major clinical species
from Acinetobacter calcoaceticus-Acinetobacter baumannii complex.
Differences on assays performed on NCI-H292 cells could be a possible
explanation for a minor isolation frequency of A. 3TU and A. 13TU.
P1985 Environmental Stenotrophomonas maltophilia strain is less
virulent than clinical strain from cystic ﬁbrosis patient
A. Pompilio, V. Crocetta, S. Pomponio, A. Bragonzi, V. Hola`,
E. Fiscarelli, R. Piccolomini, G. Di Bonaventura ° (Chieti, Milan,
IT; Brno, CZ; Rome, IT)
Objective: S. maltophilia is considered an emergent pathogen in cystic
ﬁbrosis (CF). Since S. maltophilia is widespread in the environment, it is
important to determine the potential virulence of environmental strains
for CF patients. For the ﬁrst time, in this study two S. maltophilia strains
of environmental and clinical origin were compared for their virulence
in a mouse model of airway infection.
Methods: DBA/2 strain mice (n = 10/group) were exposed once to an
aerosol with PBS only (control) or PBS containing S. maltophilia Sm111
CF strain or C39 environmental (waste water) strain. At day 1 and 3
post-exposure mice were sacriﬁced, and the lungs were observed in situ
for macroscopic damage, then homogenized for quantitative bacteriology
and cytokine (IL-6, IFN-g, TNF-a, MIP-2) measurements. In each group,
two mice were randomly selected for histology. To evaluate dissemination
of infection, spleens were homogenized and cultured.
Results: Clinical strain was able to persist longer than environmental one
in the lungs of infected mice (day 1: 4.1±2.8×106 vs 10.9±11.1×103
CFU/g; day 3: 2.5±3.2×104 vs 1.8±3.5×103 CFU/g, respectively;
P< 0.01). Dissemination of infection was signiﬁcantly more frequent
in mice exposed to clinical strain (day 1: 90 vs 10%, day 3: 40 vs 0%,
respectively; P< 0.01). Exposure of DBA/2 lungs to environmental strain
caused a mortality rate comparable to that observed with clinical strain
(10 vs 20%, respectively). Macroscopic lung examination did not reveal
signiﬁcant differences in lung damage although lung histopathology
showed a signiﬁcantly higher polymorphonuclear inﬁltrate in the
alveolar septa of mice infected with Sm111 strain (60 vs 20% of
visualized lumens, respectively; P< 0.05). At day 1, cytokine levels
were signiﬁcantly higher in lungs infected with clinical strain than
environmental one (TNF-a: 498.8±92.4 vs 187.0±56.2 pg/lungs; IFN-g:
198.4±44.6 vs 19.03±22.9 pg/lungs; IL-6: 977.2±297.6 vs 457.5±590.0
pg/lungs; MIP-2: 2703.4±157.3 vs 2124.6±279.8 pg/lungs, respectively;
P< 0.01). At day 3, cytokine levels were comparable in both groups.
Conclusion: Our results showed that S. maltophilia environmental strain
is potentially virulent although less than the corresponding CF strain,
thus suggesting that environment could be a potential reservoir for the
acquisition of infection by CF patients.
This work was supported by the Italian CF Research Foundation; grant
FFC7/2007.
P1986 Transfer of a putative hyaluronidase hylEfm and
distribution of its putative pathogenicity island in different
Enterococcus faecium isolates
J. Laverde Gomez °, C. Fleige, W. van Schaik, G. Werner (Wernigerode,
DE; Utrecht, NL)
Objectives: The increasingly important nosocomial pathogen Enterococ-
cus faecium possesses a putative hyaluronidase gene, hylEfm, which has
been a supposed pathogenicity factor coded on a pathogenicity island
(PAI)-like structure of ca. 20 Kb (Rice, L. et al 2003). Distribution of
this putative virulence factor varies among clinical strains of E. faecium.
We aimed to investigate the structure and distribution of the putative
pathogenicity factor hylEfm and its putative PAI among various clinical
isolates and resolve the composition and structure of the hylEfm-plasmid.
Methods: We re-annotated the supposed PAI-like element by comparing
available genomic contigs of E. faecium strains DO and U0317 (Willems,
R. and van Schaik, W. personal communication) using DS Gene 1.5
software. Presence of this structure was investigated by long template
PCR, regular PCR and sequencing in 40 E. faecium isolates of different
clonal types and complexes. We identiﬁed the genomic localization of
hylEfm in our set of strains by Sma-I and S1-nuclease macrorestriction of
genomic DNA resolved by PFGE and analyzed by southern hybridization
(Roche®). Transfer of hylEfm among E. faecium was tested by in vitro
ﬁlter mating. Sequencing of 2 selected plasmids was done using 454
technology.
Results: The hylEfm putative PAI is a 17.824 bp element similar but not
identical to the structure previously described. This cluster is conserved
in 40 hylEfm positive strains with slight differences downstream hylEfm.
The island was exclusively located on large plasmids (150 to 350
kb). hylEfm-plasmids were horizontally transferred using in vitro ﬁlter-
mating. Sequencing of selected plasmids resolved conjugation and
plasmid related determinants, additional to sugar uptake and metabolic
genes, heavy metal resistance, several antibiotic resistance clusters and
additional pathogenicity factors such as surface-exposed pili genes on
the same plasmid with the putative hylEfm PAI.
Conclusions: The putative hylEfm PAI structure is highly conserved and
located on transferable plasmids of different sizes. hylEfm conjugative
plasmid bears additional putative pathogenicity factors and antibiotic
resistance genes. These ﬁndings suggest horizontal gene transfer of
virulence factors and antibiotic resistance gene clusters by a single
genetic event (conjugation) which might be triggered by heavy antibiotic
use common in health care units where E. faecium is increasingly
prevalent.
P1987 A new Helicobacter pylori vacuolating cytotoxin
determinant, the intermediate region
S. Agudo °, T. Alarco´n, G. Pe´rez-Pe´rez, J. Martı´nez, M. Lo´pez-Brea
(Madrid, ES)
Introduction: VacA, the vacuolating cytotoxin encoded by the vacA
gene is a highly polymorphic. It has two regions: signal (s) and middle
(m) that are well characterized markers of virulence. Functionally, s1/m1
strains cause more extensive vacuolation and clinically, are associated
with gastric atrophy. Recently, a new polymorphic region of vacA
designated intermediate (i) region, was described as a major determinant
of vacA toxicity. The aim of this study was to determine the prevalence
VacA genotypes and determine the association with VacA intermediate
among H. pylori isolated in Madrid, Spain.
Methods: We obtained 118 biopsies from patients with gastric
symptoms, from June 2008 to January 2009. Standard microbiological
procedures were used for H. pylori culture. DNA extraction was
carried out by the NucliSens easyMAG platform with the NucliSens
magnetic extraction reagents (bioMe´rieux). VacA genotypes (s, m) were
determined by PCR and agarose gel. VacA i genotype were determined
by PCR and DNA sequencing in all s1m2 and in 10 random s2m2 and
s1m1 strains. The criteria used for determining i-type (either i1 or i2)
were based on the amino acid sequences.
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Results: The results of VacA are showed in the table 1. Two i-region
types were identiﬁed, i1 and i2. S1/m1 and s2/m2 strains were exclusively
i1 and i2, respectively. 15 out of 16 (93.7%) s1m2 strains were i1.
Conclusions: The s2m2 was the most frequent vacA mosaicism,
observed in 63% of our patients. This study shows the strong association
between vacA i1 genotype and s1 allele of vacA gene. Further studies
are needed in other to know if vacA i-region is an important marker of
H. pylori toxicity.
Total
n %
s1m1 22 19.3
s1m2 16 14.1
s2m1 4 3.5
s2m2 72 63.2
Mixed strains 4 3.4
m1m2s1 2
m1m2s2 2
P1988 Demonstration of the role of heat shock proteins in Vibrio
parahaemolyticus pathogenesis by in vitro and in vivo
approach
G. Pircalabioru °, M.C. Chiﬁriuc Balotescu, B. Gilea, V. Lazar,
L. Dascalu, G. Enache, M. Hirt, A. Dragodan, M. Chivu, C. Bleotu
(Bucharest, RO)
Objective: Different cellular fractions of V. parahaemolyticus haemolytic
and non-haemolytic strains grown under sub-lethal heat and osmotic
stress were analyzed in order to evaluate the survival proﬁles, the
morphological changes, the levels of heat shock proteins (hsp) and their
immunogenicity using in vivo experimental models.
Methods: Different cellular fractions (supernatants concentrated by
ultraﬁltration, periplasmic and cellular lysates) were obtained from
bacterial cultures submitted to different stress conditions and further used
for: i) the assessment of total protein (Bradford) and hsp concentration
(Western blot, using monoclonal antibodies against hsp 10, 60 and
70 kDa); ii) in vivo immunization of holoxenic mice by repeated i.p.
injection, once a week during 10 weeks. After immunization, the hsp
antibodies were assessed by ELISA and the mice were challenged with
wild V. parahaemolyticus strains.
Results: Our studies conﬁrmed the expression of different hsp, i.e.
GroES (10kDa), GroEL (60kDa) and DnaK (70kDa). GroEL exhibited
the highest expression after heat, osmotic and combined stress and
GroES the lowest, being expressed only after heat stress. The haemolytic
strain constitutively over-expressed high levels of GroEL, while the non-
virulent V. parahaemolyticus strain exhibited GroEL in direct relation
with the heat shock. No cross-protective effect was observed between
different stress factors. The heat shocked cells exhibited a more intensive
hemolytic activity on blood agar, proving the role of the heat-stress
proteins in the increase of pathogenic potential. The osmotic stress
induced important changes in cell morphology, with the occurrence
of fusiform, spiraled forms with low afﬁnity for the Gram staining.
The immunized batches exhibited good survival rates after challenge
with the virulent V. parahaemolyticus strain. The supernatant of heat
stressed bacterial cultures induced the early occurrence of anti-hsp
antibodies (after 4 immunizations), while after 8 immunizations, the
anti-hsp antibodies were present in the majority of the tested batches,
the most immunogenic fraction proving to be the heat-stressed culture
supernatants.
Conclusion: The hsps accumulated in the supernatants and total
cellular extracts exhibited a protective role against the infection with
V. parahaemolyticus virulent strains, the good survival rates being
correlated with high titers of anti-hsp antibiodies.
P1989 Locations of proteases in cellular fractions and association
with vesicles in Porphyromonas gingivalis
S. Oishi, M. Miyashita, A. Kiso, Y. Kikuchi, O. Ueda, K. Hirai,
Y. Shibata, S. Fujimura ° (Shiojiri, JP)
Objective: Arginine gingipain (RGP) and lysine gingipain (KGP) are
major proteases of P. gingivalis and are important in the pathogenesis of
periodontitis. These proteases are found in the culture supernatant, in the
envelope and within the cytoplasm. Two types of proteases were found
to exist in the culture supernatant, free from any cellular components
and vesicle-bound forms. Since vesicles of Gram-negative bacteria may
contribute to the transportation of their virulence factors to the host cells,
we undertook to investigate the interaction of proteases and vesicles.
Methods: P. gingivalis ATCC 33277, W83 and 381 were cultured
anaerobically and the envelope and crude extract of the cells were
prepared by a combination of ultrasonication of cells and centrifugation.
Vesicles were collected from the culture supernatants by ammonium
sulfate precipitation (40% saturation) and centrifugation. Solubilization
of the vesicles and the envelope was carried out using a detergent.
Protease and peptidase activities were determined using p-nitroanilide
derivatives of amino acids and peptides.
Results: Locations of RGP in the cellular fractions in the crude extract,
envelope, vesicles and culture supernatants were 48%, 16%, 17% and
31%, respectively, while the corresponding values of KGP were 47%,
10%, 7% and 36%, respectively, indicating that distribution rates of both
proteases in the cellular fractions are similar. Although the molecular
masses of RGP and KGP in the culture supernatant had previously been
determined as 43 kDa and 46 kDa, respectively, their molecular masses
of RGP and KGP solubilized from the vesicles were estimated to be
over 1,500 kDa, since they eluted in the void volume of the column
of Sephacryl S-300. Interestingly, the conversion to the macromolecular
size could not observed in other enzymes tested such as mono-, di- and
tripeptidyl peptidases as well as alkaline phosphatase. Therefore, this
conversion may be restricted to the proteases. When vesicle and culture
supernatants containing free RGP and KGP were mixed and incubated,
neither RGP nor KGP seemed to bind to vesicles. Both RGP and KGP
bound to the vesicles were found to be more stable than the unbound
forms in the heat treatment at 60 C.
Conclusion: The cellular locations of proteases of P. gingivalis in the
culture supernatant, crude extract, vesicle and envelope were determined
and molecules of the proteases bound to the vesicle were conﬁrmed to
increase the molecular size.
P1990 Rifampin protects human lung epithelial cells against resis-
tant Acinetobacter baumannii clinical isolates pathogenesis
Y. Smani °, J. Domı´nguez-Herrera, R. Lo´pez-Rojas, M.J. McConnell,
F. Docobo-Pe´rez, J. Pacho´n (Seville, ES)
Objectives: In recent years, it has become apparent that rifampin, in
addition to having antimicrobial activity, can act on eukaryotic cells
modulating the production of host mediators. The aim of this study is to
evaluate the cytoprotective effect of rifampin on resistant Acinetobacter
baumannii clinical isolates that induce cell death in human lung epithelial
cells.
Methods: Three A. baumannii strains: ATCC 19606 (susceptible to
rifampin), 1327 and 113−16 (both resistant to rifampin) were used.
Standard inoculum 5×105 cfu/mL was used for time-kill studies. Cellular
viability and apoptosis were assessed using the 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT), Live/Dead and DAPI after
addition of ATCC 19606, 1327 or 113−16 (108 cfu/mL) for 24 h in
presence or absence of different concentrations of rifampin (0.5×,
1× and 2× MIC of each strain). Host mediators associated with
A. baumannii pathogenesis like superoxide anion and cytokine (TNF-a
and IL-6) were measured. Moreover, bacterial count was performed to
evaluate the efﬁcacity of rifampin in A549 cells culture medium in
presence of these strains.
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Results: At standard inoculum, time-kill curves showed that rifampin
was bactericidal (a 3 log reduction in cfu/mL) at 2× MIC against 1327
and 113−16 and at 4×MIC against ATCC 19606 at 24 h. The assessment
of A549 cells survival by the MTT assay and Live/Dead showed that
rifampin reduced the cell death induced by ATCC 19606, 1327 and
113−16. Nuclear staining of A549 cells with DAPI showed that rifampin
reduced the apoptosis induced by these strains. Moreover, we determined
that the cytoprotective effect of rifampin was associated with the decrease
of superoxide anion, TNF-a and IL-6 concentrations induced by these
strains in A549 cells. Surprisingly, the bacterial count performed in A549
cells culture medium pretreated with rifampin showed that rifampin at
0.5×, 1× and 2× MIC of both resistant strains (1327 and 113−16) does
not reduce signiﬁcantly the bacterial concentrations for 24 h.
Conclusion: These data demonstrate for the ﬁrst time that rifampin is
able to attenuate the pathogenesis of resistant A. baumannii clinical
isolates without being relevantly bactericidal. Indeed, cytoprotective
effect of rifampin was observed on the decrease of dead cells induced
by A. baumannii by reducing oxidative stress and pro-inﬂammatory
cytokines release.
Pathogenesis − case reports
P1991 Condyloma acuminatum caused by HPV13: a case report
E. Blioumi, D. Chatzidimitriou °, E. Gavriilaki, H. Kalekou,
A. Markopoulos, E. Nikoloussi-Emmanouil, E. Diza, D. Antoniades
(Thessaloniki, GR)
Introduction: Condylomata acuminata are benign proliferative lesions
of the stratiﬁed squamous epithelium of the genitalia, the perianal region,
mouth and larynx, induced by human papillomavirus (HPV). HPV types
usually detected are: 2, 6, 11, 16, 18, 31, 33, 51, 53, 54. Herein we
present a case of an oral condyloma accuminatum HPV13, consisting
in the ﬁrst description of HPV13 as an etiological factor of condyloma
acuminatum.
Material and Methods: We describe an 18-year-old female patient with
multiple non-tender oral lesions, reporting condylomas of the perianal
region, anorexia and depression in her medical history.
Clinical examination revealed multiple, non-tender, wide-based exo-
phytic nodules, with a normal colour and a size of 0.2−0.8 cm, found on
the labial mucosa, the buccal mucosa, the lateral surface of the tongue
and on either side of the lingual frenum.
The lesions were surgically excised. Sections of parafﬁn-embedded
tissue were stained by hematoxylin-eosin stain for histopathological
examination. DNA extracted from the parafﬁn-embedded tissue was
ampliﬁed by polymerase chain reaction (PCR) in standard protocols.
Nested PCR, using primers (MY09/MY11 and GP5+/GP6+) targeting
the L1 gene, and sequencing were conducted.
Results: From clinical and histopathological examination condylomata
acuminata were diagnosed. HPV infection was conﬁrmed by nested PCR.
Sequencing revealed HPV type 13.
Conclusions: It should be emphasized that to our knowledge, oral
condyloma acuminatum induced by HPV13 has never been reported.
P1992 Orientia tsutsugamushi meningitis or meningoencephalitis
D.M. Kim °, N. Yun (Gwang-Joo, KR)
Background: Orientia tsutsugamushi spreads via the bloodstream and
lymphatics. It induces vasculitis leading to symptoms of systemic organ
invasion including meningitis and meningoencephalitis, which are life-
threatening manifestations.
Methods: We conducted a prospective case–control study of scrub
typhus patients who were admitted to Chosun University Hospital
between 2004 and 2008 to investigate the clinical and laboratory features
of patients with scrub typhus meningitis or meningoencephalitis, and the
therapeutic outcomes, and to determine the predictor factors. Cases were
22 patients with scrub typhus meningitis or meningoencephalitis, and
controls were 303 patients without meningitis or meningoencephalitis.
Results: Multivariate analysis demonstrated that the presence or absence
of pneumonitis was associated with the occurrence of scrub typhus
meningitis and meningoencephalitis (OR, 8.9; P< 0.001; CI, 2.9–27.2).
Although appropriate antimicrobials such as doxycycline agents were
administered at an early stage, mengititis or meningoencephalitis still
occurred.
Conclusions: Physicians should be aware that meningitis or meningoen-
cephalitis may develop during appropriate drug therapy such as doxycy-
cline. Close observation and great care are essential for patients with risk
factors associated with meningitis or meningoencephalitis, particularly
pneumonitis. Increasing the dosage of doxycycline, or administering
antimicrobial agents such as rifampin with good penetration to the central
nervous system, might be considered in such cases.
P1993 Case of endocarditis due to Bacillus cereus
O. Barraud, N. Hidri, P. Manea, K. Ly, F. Garnier °, F. Denis,
M.C. Ploy (Limoges, FR)
Objectives: Bacillus cereus is an ubiquitous telluric bacteria mainly
responsible for food borne infections due to toxins production. Isolation
of the bacteria is of particular concern in immunocompromised patient,
but can also be related to rare clinical infections (endophtalmitis, fasci-
itis, meningitis, peritonitis . . . ) in non-immunocompromised patients. We
describe here a case of endocarditis due to Bacillus cereus.
Methods: Eighteen blood cultures were sampled from a 65 years-old
patient presenting a 25mm per 10mm vegetation contiguous to the
right ventricular pacemaker sensor. Bottles were incubated into the
BacT/ALERT® system (bioMe´rieux®). After pacemaker withdrawal,
two electrodes were cultivated into thioglycolate broth for 48 hours.
Bacteria were identiﬁed using molecular biology targeting 16S RNA-
encoding DNA and rpoB gene. Susceptibility testing was performed
using Mueller-Hinton agar according to the recommendations of the
French Society for Microbiology.
Results: Concerning blood cultures, two aerobic and one anaerobic
bottles derived from three different samples were detected positive. Gram
staining detected presence of long Gram positive rods and culture grew
two different morphotypes with different antibiograms. Both electrodes
yielded Gram positive rods with three different macroscopic aspects. For
all morphotypes obtained, sequencing of the 16S RNA-encoding DNA
was unable to discriminate the species among Bacillus genus, contrary
to the sequencing of rpoB gene which lead to the precise identiﬁcation
of Bacillus cereus sensu stricto.
Conclusion: Endocarditis due to Bacillus cereus has been exceptionally
previously reported in the literature. This study underlines the
contribution of molecular biology in bacterial species identiﬁcation,
notably the interest of using rpoB gene to discriminate the Bacillus
species among the genus.
Staphylococcal bacteraemia
P1994 Molecular variability of methicillin-resistant Staphylococcus
aureus strains isolated from blood in the Czech Republic,
2000–2005
M. Fridrichova °, H. Zemlickova, K. Tyllova, V. Jakubu, P. Urbaskova
(Prague, CZ)
Objectives: Methicillin-resistant Staphylococcus aureus (MRSA) is
usually viewed as a major nosocomial pathogen that is associated with
hospitals and healthcare facilities. It is also known as a cause of
community acquired infections. Prevalence of MRSA infections is still
increasing in most of countries but there are also places where decreasing
trend of these infections is seen. Prevalence of MRSA infections in the
Czech republic increased from 4.3% in 2000 to 12.9% in 2005. The aim
of the study was to describe clonality of MRSA blood isolates collected
in years 2000–2005.
Methods: Thirty three national microbiology laboratories participating
in the European Antimicrobial Resistance Surveillance System (EARSS)
Staphylococcal bacteraemia S593
submitted to the National Institute of Public Health MRSA isolates
collected from individual patients in each hospital from 2000 to
2005. S. aureus strains were identiﬁed by conventional methods. All
MRSA isolates (n = 144) were conﬁrmed by the MRSA Screen latex
agglutination test and PCR detection of the mecA gene. Antimicrobial
susceptibility testing was based on the method recommended by the
Clinical and Laboratory Standards Institute (CLSI). Clonality of MRSA
isolates were characterized by SCCmec typing and spa typing.
Results: Spa typing revealed 20 different spa types and 4 SCCmec types.
Ten spa types were identiﬁed in at least 2 isolates The most prevalent spa
types were as follows: t003 (n = 52) with SCCmec type II, t030 (n = 45)
with SCCmec type III, and t002 (n = 11) SCCmec type II. Since the ﬁrst
isolation in 2000, spa type t003 has gradually replaced spa type t030 that
was highly prevalent in the Czech Republic until 2003. The proportion
of spa type t003 increased from 0% in 2000 to 80% in 2005 while that
of spa type t030 decreased from 60% to 8.6%.
Conclusion: A signiﬁcant shift in the prevalence of spa types was
observed. Spa type t030 with SCCmec type III (Brazilian clone) has
been replaced by spa type t003 (Rhine Hesse clone) with SCCmec type
II.
This work was supported by a research grant from the Internal Grant
Agency, Ministry of Health (CZ), IGA 9642−4.
P1995 Invasive methicillin-resistant Staphylococcus aureus in a Ro-
manian university hospital − do we have the entire picture?
E. Szekely °, L. Lorinczi, D.V. Bilca, A. Foldes (Taˆrgu Mures, RO)
Objectives: Many surveillance studies are based on the evaluation of
the frequency of MRSA (methicillin-resistant S. aureus) deﬁned as
percentage of methicillin resistant strains from the total number of
invasive S. aureus isolates. Results might be inﬂuenced by local sampling
habits, as collection of blood samples mainly in severe cases already
on antibiotic treatment may lead to overestimation of resistance. On the
other hand, expression of frequency as incidence rate seems to be a more
precise approach although the results still might be inﬂuenced in case
of low sampling rate, which leads to underestimation of the incidence.
We intended to estimate the local epidemiology of invasive MRSA in a
Romanian university hospital with 1200 beds.
Methods: We evaluated the frequency of blood culture MRSA isolates
during a 4 year period (2005–2008) expressed both as percentage of total
S. aureus isolates and as incidence rate. Sampling rate and the percentage
of blood samples collected after initiation of antibiotic therapy were also
assessed.
Results: The percentages of methicillin-resistance were as follows: 73%
in 2005, 71% in 2006, 70 in 2007, 56% in 2008 (p = 0.22). Incidence
rates varied annually between 5, 5, 7 and 6/100000 bed-days (p = 0.37) in
the same period. Blood culture sampling rates increased annually during
the study period from 2 to 4.2/1000 bed-days (p< 0.05). Samples were
collected from patients on antibiotic therapy in case of 79% of blood
culture sets.
Conclusions: The very high percentage of MRSA did not correlate
with the relative low incidence rates found. This discrepancy could have
resulted from selective sampling and low sampling rates and suggests
that neither methods of assessing frequency are reﬂecting reality. This
was the ﬁrst study from Romania which analyzed comprehensive
epidemiological data regarding MRSA in a large university hospital.
P1996 Incidence and mortality of Staphylococcus aureus
bacteraemia in Iceland
H. Asgeirsson °, O. Gudlaugsson, K. Kristinsson, S. Heiddal,
M. Kristjansson (Reykjavik, Akureyri, IS)
Objectives: To determine the incidence, source and mortality of
Staphylococcus aureus bacteraemia in Iceland.
Methods: Cases of S. aureus bacteraemia occurring between January 1
1995 and December 31 2008 were identiﬁed by clinical microbiological
laboratories performing blood cultures in Iceland. Patients 18 years or
older with a positive blood culture for S. aureus were included. Recurrent
episodes were classiﬁed as re-infections if they occurred more than 90
days apart or if the isolates had a different antibiotic susceptibility proﬁle.
If recurrences took place within 90 days they were considered a relapse
of the original bacteraemia. From December 1 2003 to November 30
2008 clinical data regarding source was collected from patients’ charts
(307 out of 308 available, 99.7%). National population statistics and
dates of death were retrieved from the National Registry.
Results: 692 individuals from 18 institutions had 721 distinct episodes
of S. aureus bacteraemia. Mean age at diagnosis was 62.6 years (range 18
to 99) and male to female ratio was 1.43, extending throughout the study
period. During 1995 to 2008 age speciﬁc incidence of bacteraemia rose
from 22.7 to 28.9 per 105 per year (p = 0.016, trend across years) and
30 day case fatality rate decreased from 27.9% to 8.7% (p = 0.001, trend
across years). Susceptibility to penicillin increased from 14.3% to 20.7%
(p = 0.13, trend across years), with no correlation between penicillin
sensitivity and case fatality (p = 0.8). Four cases of methicillin resistant
S. aureus bacteraemia were identiﬁed (0.6%), all of whom lived. Among
308 episodes in 2003 to 2008, 125 (40.5%) were hospital acquired, 82
(26.6%) health care associated and 101 (32.8%) community acquired.
There was no difference in case fatality between groups (p = 0.36).
The most common sources of bacteraemia were intravascular catheters
(20.2%) and skin infections (13.4%) whereas the focus was unknown
in 23.5%. The 30 day case fatality was highest among those with
pneumonia (29.6%) and unknown source (22.2%), and lowest for those
with skin (2.4%) and intravascular catheter related (8.1%) infections
(p = 0.04).
Conclusion: During 1995 to 2008 a signiﬁcant increase in the incidence
of S. aureus bacteraemia in Iceland and a signiﬁcant reduction in 30
day case fatality were noted. The reason for this change is not clear.
The source of bacteraemia could be identiﬁed in majority of cases and
different foci were associated with a difference in mortality.
P1997 MSSA bloodstream infection (BSI), MRSA’s evil twin! A
review of the epidemiology, risk factors and outcomes
among hospitalized patients with Staphylococcus aureus
(MSSA & MRSA) bacteraemia
M. Przybylo, J. Chang, M. Lau °, M. Qulaghassi, A. Khan, A. Guleri
(Blackpool, UK)
Objective: Staphylococcus aureus (meticillin sensitive − MSSA &
meticillin resistant − MRSA) blood stream infections(BSI) are associated
with morbidity, mortality and associated costs. While MRSA-BSI has
received signiﬁcant attention of the media, department of health, NHS
and infection control teams (ICT), rates of MSSA BSI have remained
unabated. This study is aimed to determine the epidemiology, risk
factors, mortality and morbidity for MSSA & MRSA BSI in a large
district hospital and inform the new trust MSSA/MRSA containment
programme (MMCP).
Method: Cases with SA-BSI were identiﬁed from pathology database.
Data was extracted at case note review on patients with BSI with
MSSA & MRSA between Nov07 − Aug09. Parameters investigated
included indication for blood culture, demographics, apache scores,
outcome, timing & appropriateness of antibiotic treatment, length of
hospital stay, intensive care admissions and mortality.
Results: Data on 68 cases of SA-BSI (52 MSSA & 16 MRSA) are
presented here. Average age was 61years (MSSA) & 72years(MRSA)
respectively with a comparable male/female ratio (3:2). 66% (MSSA)
and 56%(MRSA) patients recovered to be discharged from hospital.
Average length of stay was 23.2d (MSSA) and 26.3d (MRSA).
Average Apache II score at the time of blood cultures were 13
(MSSA) & 16(MRSA). Intensive care admissions were 18% (MSSA)
and 19%(MRSA) respectively. 20%(MSSA) & 56%(MRSA) had a ‘Do
not attempt resuscitation’ order at the stage of their illness. Mortality was
recorded in 34%(MSSA) and 44%(MRSA) SA-BSIs. 71%(MSSA) and
80% (MRSA) had pre-48 h BSIs. 84% (MSSA) and 54%(MRSA) had
optimal antibiotics initiated before results of blood cultures were known.
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100% of MSSA & MRSA − BSI were initiated on optimal antibiotics
after Microbiology consultations.
Discussion: The study revealed signiﬁcant morbidity, increased length of
stay and mortality associated with SA-BSIs. A signiﬁcant (71%MSSA &
80% MRSA) SA-BSI were pre-48 h. SA bacteraemia is associated with
increased length of stay putting a ﬁnancial burden on the health services.
The ﬁndings of this study have been used to inform the new trust
MSSA/MRSA containment programme. Details to be presented.
P1998 Risk factors and attributable mortality in patients with
nosocomial methicillin-resistant Staphylococcus aureus
bacteraemia
Y.Y. Chen °, L.C. McDonald, F-D. Wang, C.S. Chen, I.H. Chen (Taipei
City, TW; Atlanta, US)
Objectives: Staphylococcus aureus bacteremia in patients is an in-
creasingly prevalent problem. Particularly, methicillin-resistant S. aureus
(MRSA) is one of the most serious healthcare issues currently
inﬂuencing morbidity, length of hospitalization, healthcare costs, and
mortality. This study was to examine the clinical signiﬁcance of MRSA
and methicillin-susceptible S. aureus (MSSA) bacteremia.
Methods: The retrospective cohort study was conducted in a 2,900-
bed tertiary refer medical center. All patients admitted to the hospital
who had developed nosocomial infections (NIs) from 1999 to 2008 were
eligible. The diagnosis of NI was based upon criteria established by the
Centers for Disease Control and Prevention. The Cox regression analyses
were used to estimate the risk factors of MRSA and prognostic factors
of mortality.
Results: A total of 1,230 patients were diagnosed with nosocomial
S. aureus bacteremia. The proportion rate of MRSA was 78%. The
dependent variable for Cox regression was length of ICU stay prior to
the onset of the ﬁrst infection, after controlling potential risk factors
for MRSA bacteremia, used of mechanical ventilator (Relative Risk
[RR], 1.19; 95% conﬁdence interval [CI] 1.02–1.39) and insertion of
central venous catheter (CVC) (RR, 1.42; 95%CI 1.03–1.94), were
independent risk factors (p< 0.05) for MRSA. The difference between
the crude mortality rates of MRSA bacteremia (42.4%) and MSSA
bacteremia (24.1%) was 18.3% with statistical signiﬁcance (P< 0.001).
The dependent variable for Cox regression was length of ICU stay
from after the onset of the ﬁrst infection to mortality, after potential
prognostic factors of mortality were adjusted, MRSA bacteremia (RR
1.46, 95%CI 1.07–1.99), age (RR 1.01, 95%CI 1.01–1.02), used of
mechanical ventilator (RR 1.05, 95%CI 1.02–1.09), and insertion of
CVC (RR 1.32, 95%CI 1.07–1.632) were independent factors (p< 0.05).
Conclusion: We found MRSA bacteremia to have a higher attributable
mortality than MSSA bacteremia. In addition, invasive devices were
the important risk factors and prognostic factors after adjusting for
covariates. This study emphasizes the importance of continuous efforts
in prevention of device-associated infections.
P1999 The clinical feature and mortality of community-associated
methicillin-resistance Staphylococcus aureus: comparison
with healthcare-associated methicillin-resistant and
methicillin-susceptible S. aureus bacteraemia
S. Kang °, S.M. Choi, H. Jang, K.H. Park, S. Jung (Gwangju, KR)
Objective: No conclusive data is available about the difference in
mortality between in patients with community-associated methicillin-
resistant Staphylococcus aureus(CA-MRSA) bacteraemia and Health-
care associated methicillin-resistant Staphylococcus aureus(HA-MRSA)
bacteremia. In this study, we compared the outcome of CA-MRSA
bacteraemia with that of HA-MRSA bacteraemia and that of methicillin-
susceptible Staphylococcus aureus(MSSA) bacteraemia.
Methods: 556 adult patients with S. aureus bacteremia were analysed,
who were admitted to Chonnam National University Hospital and
Hwasun Chonnam National University Hospital in Korea from January
2005 to December 2008. The CA-MRSA was deﬁned as S. aureus
carring SCCmec type IV or IVa by multiplex PCR.
Results: Of the 556 S. aureus bacteraemia, 205(36.9%) were by
MSSA, 290(52.2%) by HA-MRSA, and 61(11.0%) by CA-MRSA.
Among 351 MRSA isolates, 240(68.4%) carried SCCmec type II,
49(14.0%) SCCmec typeIII, 22 (6.3%) SCCmec type IV, and 39(11.1%)
SCCmec type IVa. Of the 61 patients with CA-MRSA bacteraemia,
56(91.8%) had risk factor for healthcare exposure, and 52(85.2%)
were caused by clindamycin susceptible isolates. Only one CA-MRSA
isolate carried Panton-Valentine leukocidin gene(PVL+), and no HA-
MRSA isolate carried PVL. The 30-day mortality in patients with CA-
MRSA bacteraemia was signiﬁcantly higher than that in patients with
MSSA bacteraemia(34% vs 21%, P = 0.007), but was not different with
that in patients with HA-MRSA bacteraemia (34% vs 31%P= 0.649).
In multivariate analysis using Cox-porportional hazard model, the
independent risk factors for 30-day mortality were higher APACHEII
score and cancer. After adjustment of these factors, the 30-day mortality
in patients with CA-MRSA bacteraemia was not signiﬁcantly higher than
that in patients with MSSA bacteraemia(hazard ratio 1.17; 95%CI 0.67–
2.04; P = 0.585) or that in patients with HA-MRSA bacteraemia(hazard
ratio 0.85; 95%CI 0.52–1.37; P = 0.846).
Conclusions: The 30-day mortality in patients with CA-MRSA
bacteremia was comparable with 30-day mortality in patients with HA-
MRSA bacteremia, but was signiﬁcantly higher than 30-day mortality
in patients with MSSA bacteremia. However, after adjustment of other
factors, mortality in patient with CA-MRSA bacteraemia without PVL
gene was not different with mortalities in patients with MSSA bacteremia
and in patients with HA-MRSA bacteremia.
P2000 Insights in Staphylococcus aureus strains from bacteraemia
and infective endocarditis in Italy
F. Campanile, D. Bongiorno, S. Borbone, A. Goglio, A. Raglio, F. Suter,
M. Venditti, C. Mancini, C. Venturelli, F. Rumpianesi, S. Stefani °
(Catania, Bergamo, Rome, Modena, IT)
Objectives: Staphylococcus aureus bacteraemia (SAB) is a serious
infection both in hospital and the community, possibly leading to
infective endocarditis (IE), with a high risk of mortality despite
aggressive therapy. The glycopeptides use has been recently challenged
by various forms of low-level resistance. This study evaluated the
distribution of MSSA and MRSA isolates from bacteraemia (B)
and infective endocarditis (IE) in Italian hospitals, their antibiotic
susceptibility features − focusing on the emergence of hVISA strains −
and their genotypic relationships.
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Methods: 106 S. aureus strains from patients with bacteraemia (58)
or infective endocarditis (48), were collected from 3 Italian hospitals
between 2004 and 2008. MICs for anti-Gram + drugs were determined
according to CLSI guidelines; vancomycin heteroresistance was tested
by macro Etest, and conﬁrmed by PAP; PFGE and SCCmec (the latter
only for MRSA) analyses were also performed.
Results: From 106 S. aureus strains, 30 were MRSA (13 MRSA-B
and 17 MRSA-IE) and 76 MSSA (45 MSSA-B and 31 MSSA-IE). The
hVISA phenotype was particularly diffused among MRSA strains, both
from B (4/13) and IE (7/17), but an increase was shown also among
MSSA (7 MSSA-B and 6 MSSA-IE). 3 PVL positive strains were
detected only among MSSA. All S. aureus strains showed similar but
not genetically related PFGE proﬁles. There was a major diffusion of
SCCmec IV (subtypes a, c and g), related to a spread of CA-MRSA, both
in IE and B patients (47 to 61%); HA-MRSA strains were associated
to SCCmec types I/IA in 3 MRSA-B and 8 MRSA-IE strains. There
was a correlation among hVISA strains and SCCmec types I/IA (7/11).
Concerning antibiotic resistance, almost all the HA-MRSA/hVISA were
MDR strains; a low rate of resistance was observed among MSSA, with
only one showing the hVISA phenotype.
Conclusion: In this study we analysed the circulation of S. aureus strains
cause of bacteraemia and infective endocarditis in Italy, their antibiotic
and genotypic features, showing the emergence of hVISA phenotype
among MSSA and MRSA strains, and the major spread of CA-MRSA.
P2001 Clinical characteristics of Staphylococcus lugdunensis
bacteraemia
S. Choi °, E.H. Song, E.J. Lee, J.B. Jun, J.W. Chung, J.M. Kang,
M.S. Lee, S. Choi (Seoul, Gangneung, Ulsan, Pohang, KR)
Objectives: The clinical signiﬁcance of S. lugdunensis bacteremia
has been largely unknown, mainly understood from the fatal cases
of infective endocarditis. To evaluate the frequency and severity of
S. lugdunensis bacteremia, we retrospectively reviewed all the cases with
S. lugdunensis bacteremia from 7 tertiary care hospitals in Korea.
Methods: Identiﬁcation of clinical isolates was performed using
MicroScan Gram-positive combo panels (Dade Behring, CA, US) or
Vitek 2 card for Gram-positive cocci (bioMe´rieux, Marcy l’Etoile,
France). Antimicrobial susceptibilities were determined by the same
automated systems using standard criteria prescribed by the Clinical
Laboratory Standards Institute.
Results: There were 61 patients with S. lugdunensis bacteremia. The
isolation rates of S. lugdunensis were ranged from 0.3% to 1.2% and
from 0.9% to 3.4% among all blood isolates and CNS blood isolates,
respectively. Of the 61 patients, 17 had signiﬁcant S. lugdunensis
bacteremia. Majority (82.4%) had underlying diseases, which were
mostly nonfatal underlying diseases according to the criteria of McCabe
and Jackson (70.6%). Resistance rates to antimicrobials were as follows;
penicillin (87.5%), oxacillin (31.2%), gentamicin (12.5%), erythromycin
(13.3%), tetracycline (6.3%), ciproﬂoxacin (6.3%), clindamycin (12.5%)
and fusidic acid (9.1%). Multidrug resistant isolates had hospital-
associated bacteremia with long hospital stay before bacteremia. The
probable sources of bacteremia were unknown source (41.2%), catheter
(29.4%) and skin/soft tissue (29.4%). All Patients with catheter-related
bacteremia had healthcare associated infection. Infective endocarditis
was observed in 4 patients with community-associated infection except
one. Severe sepsis (17.6%) and septic shock (5.9%) were rarely observed.
Inappropriate antimicrobial therapy was not observed in fatal cases.
Bacteremia-related death was not observed.
Conclusion: Signiﬁcant S. lugdunensis bacteremia occurred rarely in
the clinical practice. Signiﬁcant bacteremia developed with mild clinical
presentation frequently in patients with nonfatal underlying diseases.
Whereas catheter-related bacteremia was frequent in hospital-associated
infection, infective endocarditis was frequent in community-associated
one. Bacteremia caused by multidrug resistant organisms was found more
frequently than that of previous studies, especially in patients with longer
hospital stay before bacteremia.
P2002 Delayed removal of catheter deteriorates clinical outcome
in patients with catheter-related bloodstream infection due
to coagulase-negative staphylococcus
M. Kamimura °, Y. Yoshino, K. Tatsuno, T. Kitazawa, Y. Ota (Tokyo, JP)
Objectives: Coagulase-negative staphylococcus (CNS) is commonly a
cause of catheter-related bloodstream infection (CRBSI). Catheters are
frequently retained CNS CRBSI. The aim of the study is to evaluate
whether the timing of catheter removal inﬂuence on outcomes in case of
CNS CRBSI.
Methods: From April 2003 to December 2006, all the patients with CNS
bacteraemia at the University of Tokyo Hospital were enrolled. Clinical
data were retrospectively collected from medical records; age, gender,
clinical background, and acute physiology and chronic health evaluation
(APACHE) II score, the timing of initiation of appropriate antimicrobial
treatment and catheter removal. The endpoints were 7-day mortality and
clinical improvement.
Results: 153 cases were enrolled in the study period. Seven-day
mortality and the ratio of clinical improvement were 3.9%, 69%,
respectively. For 7-day mortality, high score of APACHE II (>18),
older age (>60 years old) and delay of appropriate anitimicrobial
treatment (>48 hours after onset) were identiﬁed as risk factors, by
univariate analysis, although high score of APACHE II was the only
negative prognostic factor by multivariate analysis (odds ratio (OR)
14.26; p = 0.011). For clinical improvement, high score of APACHE
II (OR 0.116; p = 0.005) and delay of catheter removal (OR 0.404;
p = 0.014) were identiﬁed as negative prognostic factors by multivariate
analysis.
Conclusions: In addition to the severity of the illness, the delayed
removal of catheter deteriorated clinical response in patients with CNS
CRBSI.
P2003 Cotrimoxazole versus vancomycin for the treatment of
methicillin-resistant Staphylococcus aureus bacteraemia −
a retrospective cohort study
E. Goldberg °, M. Paul, Z. Samra, O. Talker, M. Raskin, R. Chazzan,
L. Leibovici, J. Bishara (Petah Tikva, IL)
Objectives: To evaluate the efﬁcacy and safety of cotrimoxazole versus
that of vancomycin in adults with methicillin-resistant Staphylococcus
aureus (MRSA) bacteremia.
Methods: We identiﬁed 1006 clinically signiﬁcant consecutive episodes
of Staphylococcus aureus bacteremia between 1999 and 2009. Demo-
graphic, bacteriologic and clinical data, including the presumptive focus
of infection and outcomes were retrieved retrospectively. We identiﬁed 38
patients with MRSA bacteremia treated with cotrimoxazole as the main
therapeutic agent, deﬁned as at least one week of continuous treatment
with cotrimoxazole alone or with another drug other than vancomycin,
daptomycin, linezolid or quinupristin/dalfopristin. We matched them with
76 patients treated with vancomycin as the main agent. The groups
were matched for age, sex, functional status, endovascular source of
infection, appropriateness of empirical antibiotic therapy, presence of a
foreign body, sepsis severity and Charlson score. The outcomes collected
were 30 day mortality, persistent bacteremia, relapse and adverse events.
Persistent bacteremia was deﬁned as positive blood culture (BC) >14
days after the ﬁrst positive BC. Relapse was deﬁned as recurrence of the
same phenotype >30 days after the ﬁrst positive BC within 12 months.
Results: The baseline characteristics of patients in the two groups are
presented in the table. Overall, the groups were well matched with no
signiﬁcant differences in the baseline characteristics. Thirty day mortality
was not signiﬁcantly different between the groups [cotrimoxazole 13/38
(34.2%), vancomycin 31/76 (40.8%); p = 0.49]. There was only one case
of relapse in the cotrimoxazole group (2.6%) compared with 9 cases
in the vancomycin group (11.8%). Incidence of relapse or persistent
bacteremia was lower in the cotrimoxazole group (3/38, 7.9%) than in
the vancomycin group (13/76, 17.1%), although the difference was not
statistically signiﬁcant (p = 0.182). There was no signiﬁcant difference
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between the groups in renal failure as a complication [cotrimoxazole
11/38 (28.9%); vancomycin 21/76 (27.6%)].
Conclusions: Within the limitations of a small retrospective study,
cotrimoxazole had a safety and efﬁcacy proﬁle similar to vancomycin
and may offer an attractive additional therapeutic option for MRSA
bacteremia. A prospective, randomized controlled trial is warranted.
Table 1: patient characteristics
Variable Cotrimoxazole
group (n = 38),
N (%)
Vancomycin
group (n = 76),
N (%)
Age 74.7±15.9* 75.8±13.7*
Female gender 26 (68.4) 51 (67.1)
Bedridden patients 17 (44.7) 34 (44.7)
Diabetes 15 (39.5) 34 (44.7)
McCabe score:
None 11 (28.9) 18 (23.7)
Ultimately fatal disease 20 (52.6) 40 (52.6)
Proximally fatal disease 5 (13.2) 12 (15.8)
Charlson score 3.53±2.46* 3.21±2.29*
Hospital acquired infection 20 (52.6) 43 (56.6)
Endovascular source of infection 9 (23.7) 18 (23.7)
Skin and soft tissue source of infection 7 (18.4) 19 (25)
Presence of central venous catheter 4 (10.5) 13 (17.1)
Appropriate empirical treatment 12 (31.6) 26 (34.2)
Septic shock 10 (26.3) 27 (35.5)
*Mean±standard deviation.
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P2004 Continuing changing proﬁle of infective endocarditis −
results of a repeat one-year population-based survey in
France, 2008
B. Hoen °, M. Ce´lard, F. Alla, V. Le Moing, T. Doco-Lecompte,
M. Revest, C. Strady, E. Cambau, A. Bouvet, C. Selton-Suty, X. Duval
for the AEPEI Study Group on infective endocarditis
Objectives: Important changes in the characteristics and management of
infective endocarditis (IE) were observed over the past decades. For the
third time we conducted a one-year, population-based prospective survey
to describe the changes in epidemiological, clinical, and microbiological
characteristics, surgical management, and outcome of IE, as compared
to the results of the 2 similar surveys we had conducted in France in
1991 and 1999.
Methods: We collected data of all adult patients hospitalized for IE in
2008 in the regions that participated in the previous 2 studies and in
2 additional regions, accounting for a total of 20 million inhabitants,
i.e. 32% of the whole French population. Cases were notiﬁed by
the patient’s attending clinicians, echocardiographists, surgeons, and/or
microbiologists. For each patient, a case report form was ﬁlled out by
a specially trained research nurse. A validation committee reviewed all
forms. Of the 983 cases notiﬁed, 487 cases fulﬁlled the inclusion criteria,
were Duke-Li deﬁnite and were analysed. Standardised annual incidence
rates (SAIR) were calculated and compared between the 3 surveys.
Results: Sex ratio was 3M/1F. Patients’ mean age was 62.4 years.
50.7% of patients had no known valve disease and 22.6% had a
prosthetic valve. The distribution of causative microorganisms was
as follows: Staphylococcus aureus 26.9%, oral streptococci 18.5%,
group D streptococci 12.5%, enterococci 10.5%, coagulase-negative
staph 10.1%, pyogenic streptococci 4.7%, other streptococci 1.8%, and
other pathogens 8.0%. More than one and no microorganism was
identiﬁed in 1.6% and 5.3% of the cases respectively. Blood cultures
were negative in 8.4% of the cases. Valve surgery was performed in
48.3% of the patients during the initial hospital stay. Overall in-hospital
lethality rate was 21%. Overall SAIR of IE in 1991, 1999, and 2008
were 35.0, 33.4, and 32.4, per 100.000 inhabitants respectively. Speciﬁc
incidence rates increased for IE in patients with no known valve diseases
and IE due to S. aureus, decreased for group D streptococcal IE, and
remained stable for oral streptococcal IE.
Conclusion: Incidence of IE appears stable in France. This repeat
population-based survey conﬁrmed the increasing proportion and
incidence rate of S. aureus IE as well as the increasing incidence of
IE in patients with no known valve disease. Conversely, the incidence
of group D streptococcal IE sharply decreased.
P2005 Rising incidence and persistently high mortality of
bacteraemia: a 15-year population-based study in Denmark
M. Søgaard °, M. Nørgaard, L. Mortensen, H.C. Schønheyder (Aalborg,
DK)
Objective: Bacteraemia incidence has increased during the last decades,
but population-based data are sparse. We have examined temporal trends
of community-acquired, health care-related, and nosocomial bacteraemia
within a deﬁned population.
Methods: We conducted a population-based cohort study to examine
changes in incidence and 30-day mortality associated with community-
acquired, health care-related, and nosocomial bacteraemia in North
Jutland County, Denmark between 1992 and 2006. All patients with
a ﬁrst-time bacteraemia diagnosis were identiﬁed in regional databases
and followed for all-cause mortality through the Danish Civil Registry
System. We determined age- and gender-standardised incidence rates
and adjusted mortality rates associated with origin of bacteraemia and
calendar period.
Results: We identiﬁed 12,535 patients with a ﬁrst-time bacteraemia
episode; 5,941 (47.4%) were community-acquired, 4,619 (36.9%)
nosocomial, and 1,975 (15.8%) health care-related. Between 1992 and
2006, the overall incidence increased from 116 to 181 per 100,000
person-years, corresponding to an age and sex adjusted incidence rate
ratio of 1.56 (95%CI 1.34–1.80). Age- and sex standardized incidence
rates of community-acquired and nosocomial bacteraemia peaked at
92.1/100,000 and 77.2/100,000 in 2004 and 2002, respectively, whereas
the incidence of health care-related bacteraemia increased steadily from
2.9/100,000 in 1992 to 39.8/100,000 in 2006 (Figure 1).
The overall 30-day mortality was 16.4% in patients with community-
acquired bacteraemia, 22.2% in patients with health care-related
bacteraemia, and 28.2% in patients with nosocomial bacteraemia. During
the 15-year study period, the 30-day mortality decreased among patients
with community-acquired bacteremia (19.0% in 1992–1996; 15.1% in
1997–2001, and 15.4% in 2002–2006), but was virtually unchanged in
patients with health care-related (23.4%, 22.1%, and 22.0%, respectively)
and nosocomial bacteraemia (27.9%, 29.1%, and 27.7%, respectively).
Because of the increasing incidence, the total number of deaths per
5-year period increased from 757 in 1992–1996, to 920 in 1997–2001,
and 1036 in 2002–2006.
Conclusion: The incidence of bacteraemia, regardless of origin,
increased considerably in Denmark during the last 15 years. The 30-
day mortality only improved for community-acquired bacteremia, which
is of clinical and public health concern.
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P2006 Transoesophageal echocardiography in Staphylococcus
aureus bacteraemia − when is it dispensable?
A. Kaasch °, S. Rieg, H. Birkholz, S. Neumann, G. Peppinghaus,
G. Peyerl-Hoffmann, W. Kern, H. Seifert (Cologne, Freiburg, DE)
Objectives: Infective endocarditis (IE) is a severe complication in
patients with Staphylococcus aureus bacteraemia (SAB). Therefore,
it has been suggested that transoesophageal echocardiography (TEE)
should be performed in every patient with SAB. In some clinical
scenarios however, IE is unlikely to occur. We sought to develop and
validate criteria for the indication of transoesophageal echocardiography
(TEE) in patients with SAB.
Methods: Data from 570 consecutive patients with SAB was assessed.
All patients were enrolled in the prospective INSTINCT study from
January 2006 to June 2009 at the Cologne and Freiburg University
hospitals. Patients with and without IE were analyzed for predisposing
factors, clinical features, diagnostic procedures, and outcome. The
diagnosis of IE was based on the Duke criteria and patients were followed
closely for the development of IE during a 3 months follow-up period.
Guided by clinical judgement, criteria for performing TEE were deﬁned
as: community-acquired SAB, prosthetic heart valve, vascular implant,
hemodialysis, injection drug use, documented or possible (no follow
up blood cultures taken in due time) prolonged bacteraemia (>3 days),
vertebral and non-vertebral osteomyelitis. The suitability of the criteria
set was assessed retrospectively.
Results: In 9.5% (54) of patients with SAB, a diagnosis of IE was made
during hospitalization. Further 3 patients (0.5%) developed IE during the
follow-up period. The aortic (45%) and mitral valves (38%) were most
commonly affected; 19% of cases were prosthetic valve infections.
Of all patients with SAB, 460 (81%) fulﬁlled one or more criteria for
echocardiography, mainly possible or documented prolonged bacteraemia
(57%), community acquisition (46%), occurrence of a vascular implant
(16%) and hemodialysis (9%). All patients with a ﬁnal diagnosis
of S. aureus IE fulﬁlled at least one criterion for performing TEE
(sensitivity: 100%). Among patients not fulﬁlling any of the criteria for
performing TEE, none developed IE during hospitalization and follow-
up (negative predictive value: 100%). The positive predictive value of
TEE increased from 10% to 14.6% when using the criteria set.
Conclusion: A simple criteria set for patients with S. aureus
bacteraemia was developed that allows to safely reduce the number of
echocardiographic evaluations for infective endocarditis by about 20%.
P2007 Linezolid in infective endocarditis − it seems to work
T.K. Lauridsen °, L.E. Bruun, R.V. Rasmussen, C. Moser,
H.K. Johansen, M. Arpi, C. Hassager, N.E. Bruun (Copenhagen, DK)
Background: The increasing number of resistant bacterial strains
in infective endocarditis (IE) emphasizes the need for a constant
development of new antimicrobials. Linezolid is a new antibiotic with
effect on Gram-positive cocci. Only few casuistic reports describe its
utilization in treatment of IE.
The objective of this study is to report our experience with linezolid
from a large contemporary cohort of IE patients.
Methods: In a prospective cohort study data from 521 consecutive
patients were collected at two tertiary University Hospitals in
Copenhagen, Denmark. Only patients with culture negative IE or IE
due to Gram-positive micro organisms were included in the study. Main
endpoints were in-hospital and post-discharge mortality in IE patients
receiving linezolid for a part of their treatment period vs. non-linezolid
treatment.
Results: 521 patients were enrolled in the study, 39 patients received
linezolid treatment, and 482 received non-linezolid treatment. Reasons
for changing to linezolid were allergic reactions (N= 10), nephrotoxicity
(N = 2) and inadequate response to given treatment (N = 17). There
were no signiﬁcant differences in age, gender or co-morbidity such
as diabetes, kidney dysfunction, heart failure, cardiac surgery or
neurological diseases. There were no differences in the infected valve
location or complications to IE such as pseudoaneurysms or intracardiac
abscesses. Median duration of linezolid treatment was 18 days (range
2−69 days). No differences in in-hospital mortality (10% vs. 14%, NS)
or post-discharge mortality at 12 months follow-up (26% vs. 27%, NS)
linezolid vs. no linezolid, respectively were observed. Only few side
effects of linezolid were noted. During linezolid therapy >28 days, 4 of
9 patients developed drug related anemia, requiring blood transfusions.
Conclusion: No difference was found between in-hospital and post-
discharge mortality in IE patients receiving linezolid for a part of their
treatment period vs. patients with conventional treatment. Despite our
results, controlled studies are warranted before linezolid more generally
can be recommended for treatment in IE.
P2008 Effect of management interventions on short- and long-term
mortality in patients with cardiovascular implantable
electronic device infections
K. Le °, M. Sohail, P. Friedman, D. Uslan, S. Cha, D. Hayes, W. Wilson,
J. Steckelberg, L. Baddour (Rochester, Los Angeles, US)
Objective: To evaluate the impact of management interventions on
in-hospital and overall mortality among patients with cardiovascular
implantable electronic device (CIED) infections.
Background: CIED infections are associated with mortality during both
index hospitalization and overall mortality over long-term follow-up. The
speciﬁc impact of management interventions has been poorly deﬁned.
Methods: We retrospectively reviewed all cases of CIED infection
seen at Mayo Clinic Rochester between 1991 and 2008. Mortality was
considered from time of presentation to time of death during the index
hospitalization, and to time of death during the subsequent follow-up
period. The impact of management interventions were identiﬁed using
Cox proportional hazard regression.
Results: Of the 418 patients who presented with CIED infection, 30
(7.1%) died during the median of 13 days of hospitalization, and 140
(33.5%) died during the median of 0.95 years of subsequent follow-up.
Of the 396 patient who underwent device removal, 39 (9.8%) of them
developed extraction complications, and seven (1.7%) of them died. In
a multivariable analysis that included adjusting for signiﬁcant clinical
predictors of mortality, device extraction complications were associated
with elevated in-hospital mortality (HR 9.86 [3.01, 32.34]). Despite the
risk of complications related to extraction, our data suggest that overall,
patients beneﬁted from device removal. Antibiotic therapy without device
removal was associated with increased in-hospital mortality (HR 7.69
[2.88, 20.56]), and over-all mortality (HR 2.18 [1.05, 4.48]) when
compared to combined management with antibiotic therapy plus device
removal. Additionally, the timing of device removal had an impact on
in-hospital mortality. Compared to device removal at initial hospital
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presentation, device removal after failure of antibiotic therapy was
associated with increased in-hospital mortality (HR 3.22 [1.09, 9.50]).
Conclusions: Our ﬁndings indicate that although device removal can
result in complications that are associated with increased in-hospital
mortality, these complications are rare. Therefore, timely initiation of
antibiotic therapy and complete device removal early on are crucial for
increasing in-hospital survival.
P2009 Endocarditis: effects of routine implementation of
echocardiography in the work-up of high-risk patients with
Gram-positive bacteraemia
F.J. Vos °, C.P. Bleeker-Rovers, P.D. Sturm, W.J. Oyen, B.J. Kullberg
(Nijmegen, NL)
Objectives: Although the advice from the literature is clear, routine
echocardiography is only performed in a minority of patients with
S. aureus bacteraemia. The aim of the study was to evaluate if routine
performance of echocardiography in a high risk patient group with
Gram-positive bacteraemia leads to an increased percentage of diagnosed
endocarditis and to a better outcome when compared to clinically driven
requests for echocardiography.
Methods: In this prospective case control study, a regime of “obligatory”
echocardiography within two weeks after admission in the study group
was compared to a perfectly matched historical control group in the
same hospital in whom echocardiography was performed at the discretion
of the attending physician.115 patients with Gram-positive bacteraemia
and at least one risk factor for the presence of metastatic infection
were prospectively included between 2005 and 2008 and compared to a
matched historical control group of 230 patients treated between 2001
and 2004. Endocarditis was diagnosed according to the Duke criteria.
Results: Echocardiography was performed signiﬁcantly more often
in the study group (81.7% vs. 27.4%, p< 0.001). The yield of
echocardiography was 23% in the study group and 30% in the control
group (p = 0.7). In the absence of a heart murmur, 70% of patients
did have an echocardiogram in the study group against 21% in the
control group (p< 0.001). Endocarditis was diagnosed signiﬁcantly more
often among study patients, 22/115 (19.1%) vs. 17/230 (7.4%) in
the control group (p = 0.002). In the control group, endocarditis was
ﬁrst detected by autopsy in an additional two patients. No differences
in adherence to AHA guidelines concerning choice and duration of
antibiotic treatment were found between both groups in patients with
deﬁnite endocarditis. Overall mortality was 19% in the total number of
study patients compared to 32% in control patients (p = 0.007). In the
subgroup of endocarditis patients, overall mortality was 23% in study
patients and 63% in control patients (p = 0.012).
Conclusion: Correctly diagnosing endocarditis in a larger proportion of
patients was associated with a signiﬁcant decrease of mortality rates,
probably because endocarditis was recognised only in an advanced stage
in all historical controls who were therefore not treated adequately.
Therefore, echocardiography should be performed in all patients with
Gram positive bacteraemia and at least one risk factor for complicated
infection.
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P2010 Protective effect of DNA vaccine cocktail including plasmids
encoding Toxoplasma gondii major surface antigen 1 and
complete Rhoptry2 against lethal toxoplasmosis in BALB/c
mice
K. Hosseinian Khosroshahy °, F. Gaffarifar, S. D’Souza, Z. Shariﬁ,
A. Dalimi Asl (Tehran, IR; Brussels, BE)
Objectives: Toxoplasma gondii is an obligate intracellular protozoa that
causes toxoplasmosis in human and animal. In recent years, signiﬁcant
progress has been made in the identiﬁcation of vaccine candidates which
can induce a protective response.
Like other unicellular organisms Toxoplasma gondii is composed of
various immunogenic antigens. Excreted/Secreted antigens and surface
antigens maybe the best forms of antigens for stimulation of the cell
mediated immune response and hence they appear to be good candidates
for vaccine against toxoplasmosis.
In this study we used complete Rhoptry proteoin2 (ROP2) and major
surface antigen 1 (SAG1) genes of Toxoplasma gondii as DNA vaccine
cocktail.
Methods: Genomic DNA extracted by phenol-chloroform method and
ampliﬁed by PCR method. The PCR products cloned in to pTZ57R/T
plasmid and then conﬁrmed by sequencing.
Result of sequencing indicate a 1686 bp fragment of ROP2 gene of
Toxoplasma gondii was cloned into pTZ57R/T plasmid. The results of
BLAST in NCBI showed that this gene has 99% and 98% homology
with RH strain Gene Bank Accession Numbers. Z36906.1 and S
54994.1 respectively. Then this gene subcloned into pc DNA3 and after
transfection of Eukaryotic cell (CHO) with this recombinant plasmid
(pc-ROP2), expression of this gene was conﬁrmed by SDS-PAGE and
western blot.
Afterwards, we investigated the efﬁcacy of pc SAG1 + pc ROP2 (DNA
cocktail) with or without adjuvant Alum in female inbred BALB/c mice
against toxoplasmosis. Mice were intramuscularly immunized three times
at 3 week interval.
Results: DNA cocktail immunization induced a protection against a
lethal challenge with the highly virulent Toxoplasma gondii RH strain,
whereas control groups were not protective.
Anti-T. gondii IgG values (OD) increased markedly in the case groups,
which were signiﬁcantly higher than those of control groups (P< 0.05).
The results of cytokine (IFN-g, IL-4) assay show that mice immunized
with pc SAG1 + pc ROP2 elicited stronger Th1-type cellular immune
responses than those immunized with empty plasmid, or phosphate buffer
salin (high level of IFN-g and low level of IL-4).
Conclusion: Our study indicates that the DNA vaccine cocktail (pc
ROP2 + pc SAG1) is more powerful and efﬁcient than single vaccines,
and the co-delivery of Alum not enhanced the potency of DNA vaccine.
These results support further investigations to achieve a multi-gene
anti-T. gondii DNA vaccine.
P2011 Immnunization of dogs with a recombinant cysteine
proteinase from Leishmania chagasi in an endemic region
(Teresina-PI, Brazil) of visceral leishmaniasis
P.H.C. Pinheiro °, S. Katz, J.H.L. Ferreira, C.L. Barbie´ri (Teresina,
Sa˜o Paulo, Picos, BR)
A recombinant protein, rLdccys1, produced by expression of the gene
encoding a 30 kDa cysteine proteinase from Leishmania (Leishmania)
chagasi, was used for immunization of dogs and evaluation of its possible
protective role against L. (L.) chagasi infection in an endemic region of
visceral leishmaniasis (VL), Teresina, Piauı´ State, Brazil.
Cellular immune responses induced by the recombinant antigen
were evaluated after immunization of dogs with rLdccys1 plus
Propionibacterium acnes. Peripheral blood mononuclear cells isolated
from rLdccys1-immunized dogs showed signiﬁcant stimulation indexes
after in vitro incubation with either rLdccy1 or L. (L.) chagasi amastigote
extracts. Cytokine dosages in the supernatants from lymphocyte cultures
showed signiﬁcant levels of IFN-g, whereas IL-10 was not detected.
Whereas 3 from 4 dogs immunized with rLdccys1 plus P. acnes
and challenged by intraperitoneal injection of 1×104 L. (L.) chagasi
amastigotes survived ten weeks after challenge, control dogs which
received either PBS or P. acnes died after four and six weeks,
respectively. The load of L. (L.) chagasi amastigotes in spleen, liver,
and bone marrow from rLdccys1-immunized dogs was signiﬁcantly
reduced in comparison to that of non immunized controls. A signiﬁcant
concentration of IFN-g and basal levels of IL-10 were detected in sera
from dogs immunized with rLdccys1.
All dogs immunized with rLdccys1 plus P. acnes and challenged by
the bite of L. (L.) chagas infected Lutzomyia longipalpis survived until
sixteen weeks after challenge, whereas control dogs injected with PBS
or P. acnes died after seven and nine weeks, respectively. Control dogs
showed a signiﬁcant number of L. (L.) chagasi amastigotes in liver and
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spleen, but no parasites were found in rLdccys1-immunized dogs. During
immunization with rLdccys1 there was an increase of serum levels of
IFN-g in the immunized dogs that peaked one week after challenge.
In contrast, a very low concentration of IL-10 was detected in these
animals.
Overall, these ﬁndings indicate that L. (L.) chagasi recombinant cysteine
proteinase is potentially useful for immunoprophylaxis of canine VL. We
believe that results obtained open perspectives for immunization of dogs
in the ﬁeld and evaluation of the impact on the disease incidence.
P2012 Antibody dynamics after tick-borne encephalitis and
Measles–Mumps–Rubella vaccination in children post early
thymectomy
M. Zlamy °, C. Goeggele, J. Scho¨nlaub, R. Wu¨rzner, H. Holzmann,
L. Zimmerhackl, M. Prelog (Innsbruck, AT)
Objectives: In a previously published prospective controlled cohort
study, thymectomized children, who had thymectomy in early childhood
due to open heart surgery, completed a three-dose immunization
regimen in order to analyze the clinical impact of immunological
alterations in thymectomized patients after exposure to a new antigen
(tick-borne encephalitis virus (TBEV) vaccine). In the previous study,
thymectomized children showed signiﬁcantly lower TBEV IgG antibody
levels after the second vaccination when compared to healthy age-
matched controls, but a normal response after the third vaccination.
Methods: The present study was aimed to analyze the TBEV-speciﬁc
IgG antibody response 3 years after the third TBE vaccination in 22
thymectomized patients compared to 37 non-thymectomized healthy
controls from the previously published cohort, to identify patients
with waning antibody titers. Additionally, the serum samples were
tested for measles, mumps and rubella IgG antibody concentrations
after immunization with live-virus-attenuated vaccine administered post
thymectomy. The TBEV-, measles- and rubella-speciﬁc IgG antibody
avidity was analyzed by an adapted ELISA.
Results: Although there was a great inter-individual variety in the TBEV-
speciﬁc IgG concentrations, thymectomized patients showed equal levels
compared to healthy controls. The humoral immune response to measles,
mumps and rubella was normal in thymectomized patients. There was no
difference in avidity maturation of TBEV-, measles- and rubella-speciﬁc
IgG antibodies between patients and healthy controls.
Conclusions: Despite a delayed primary humoral immune response to
new vaccine antigens, thymectomized patients are able to produce and
maintain an appropriate memory immune response to TBEV and live-
virus-attenuated vaccines administered post thymectomy. The follow-
up data underline the hypothesis of a normal memory function but
a diminished primary humoral immune response to new antigens in
thymectomized patients, which may also have an impact in later life
with increased risk of morbidity or mortality due to infectious diseases
with new pathogens.
P2013 Distribution of pertussis antibodies among Iranian children
of different age groups
A. Eslamifar, A. Aghakhani, M. Banifazl °, A. Khadem-Sadegh,
A. Ramezani (Tehran, IR)
Objective: Pertussis is a highly communicable, vaccine-preventable res-
piratory disease characterized by paroxysmal cough often accompanied
by inspiratory whoop and posttussive emesis. Although the largest
number of reported cases is among young infants, the most dramatic
increase in pertussis incidence has been reported among adolescents and
young adults. In this study we determined the distribution of antibody
levels against pertussis antibodies among children of different age groups
in Tehran, Iran.
Methods: Plasma samples of 833 children (459 male and 374 female)
between ages of 6−20 years were tested for the presence of pertussis
toxin (PT), ﬁlamentous hemagglutinin (FHA) and different lipopolysac-
charides (LPS) IgG antibodies by Enzyme-linked immunosorbent assay
(ELISA). All cases vaccinated ﬁve times with DTP vaccine. The
pertussis antibodies >24 U/ml was considered positive. The children
were separated to three age groups: Group 1 (6.0–10.9 years; n = 361),
Group 2 (11.0–15.9 years; n = 284) and Group 3 (16.0–20.9 years;
n = 188).
Results: The overall prevalence of pertussis antibodies was 45.5%
(95%CI: %42.1-%48.9). The mean antibody titer was 43.3±47.8 U/ml.
Pertussis antibodies prevalence rates according to age groups were
as follows: Group 1; 39.1%, Group 2; 45.8% and Group 3; 57.4%.
Pertussis antibodies positivity in terms of age groups was signiﬁcantly
different from each other (P< 0.001) and signiﬁcant elevation in
pertussis antibodies rates was observed with increasing age. For all age
groups, there was no statistically signiﬁcant difference between genders
regarding to pertussis antibodies positivity.
Conclusion: Our study showed that Bordetella pertussis infection is
widespread and on the rise in Iranian adolescents and young adults.
Booster vaccination of this age group with acellular pertussis vaccines
appears to be the most logical approach to disease prevention in
adolescents and control the circulation of the organism.
P2014 Cross-reactivity evaluation of Neisseria meningitidis
serogroups A and B outer membrane vesicles as a method
to induce cross-immunity against both serogroups
A. Sharifat Salmani °, S.D. Siadat, M.R. Aghasadeghi, K. Parivar,
S.M. Sadat, S. Amini, M. Razavi (Tehran, IR)
Objective: Outer membrane vesicle (OMV) of Neisseria meningitidis
is an immunogenic structure and would promote speciﬁc and long-
lasting serologic responses against the organism. All the serogroups of
N. meningitidis poses this outer membrane structure which is released
from the cell surface during growth of the organism.
Method: OMV of N. meningitidis serogroups A and B puriﬁed through
Classen method. Serogroup B OMV injected intramuscularly to animal
model (rabbit). Booster doses injected 2 and 4 weeks after the ﬁrst
immunization. Serum samples of immunized animals collected two
weeks after any injection. Two different ELISA kits designed with
serogroup A and B OMV as the solid phase antigen to assay total IgG
titer against Serogroup A and B OMV. Optimized concentration of OMV
determined by checkerboard and coated. The probable cross-reactivity
between these two antigens was evaluated by measurement of anti-
serogroup A OMV IgG in the animals immunized by the serogroup B
OMV.
Results: OMV of N. meningitidis serogroup B elicited high titer of
speciﬁc antibody. The produced antibody against serogroup B OMV was
highly cross-reactive with serogroup A OMV. The elicited titer against
Serogroup A OMV was close to the titer of anti-serogroup B OMV.
Conclusion: OMV of N. meningitidis serogroup B has efﬁciently
promoted the synthesis of anti-OMV IgM and IgG.Sera of immunized
animals with serogroup B OMV reacted with serogroup A OMV and
high titers of anti-serogroup A OMV detected in the sera of serogroup B
OMV-immunized animals. The detected titer of anti-serogroup A OMV
in the sera of animals immunized against serogroup B OMV reveals
the cross-reactivity between OMV of A and B serogroups. Since OMV
consists of different outer membrane proteins, anti-OMV antibodies may
be protective against Meningococci. The protective antigen of available
vaccine for Meningococcal meningitis is a capsular polysaccharide.
Immune responses against polysaccharides mostly lacks memory, isotype
switching and afﬁnity maturation of antibodies that may leads to weak
opsinization of the microorganism and increase of microorganism chance
to survive. Opsonophagocytic activity of anti-OMV antibodies would be
studied to determine the cytolytic activity of these antibodies and the
probability of the OMV application as the protective antigen in a new
meningococcal meningitis candidate vaccine to overcome drawbacks
of the available vaccine and induce cross-immunity against both of
serogroups A and B.
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P2015 Recombinant group B streptococcal peptides as protection
against broad range of pathogens
A.N. Suvorov °, G.F. Leontieva, M. Grudinin, M. Stukova, A. Shaldzhyan,
E. Romanko, K. Grabovskaya, L. Meringova, I. Koroleva, N. Duplik,
A. Korjueva, T. Gupalova, A. Totolian, O. Kiselev (St.Petersburg, RU)
Objectives: Group B streptococcus (GBS) is known as the major
cause of newborn mortality and morbidity in the elderly. This pathogen
together with other Gram positive bacteria can follow and complicate the
viral infections. Several research groups are working on GBS vaccine
employing various polysaccharides or peptides. In our previous studies
we have selected several surface localized GBS proteins as the antigens
for complex GBS vaccine. Some of the peptides under study share
immunogenic domains with the proteins from other bacterial species.
The goal of the present study was to evaluate the possibility to construct
a vaccine protecting not only against GBS, but group A streptococcus
(GAS), pneumococcus and inﬂuenza A virus.
Materials and Methods: Recombinant streptococcal peptides based on
ScaAB, SspB1, ScpB, Clp and Bac immunogenic regions were expressed
in pQE cloning system and afﬁnity puriﬁed. Equimolar quantity of
recombinant HA protein was added to the set of bacterial antigens
for viral protection. Immunogenicity in mice model was evaluated by
ELISA. Protection in vitro was done by opsonophagocytosis. In vivo
protection was accomplished on either previously immunized mice or
after adding the protective IgG together with the microbes. Viral load in
the lungs was determined by a TCID50 assay on Vero cells.
Results: Bacterial surface polypeptides under study provided protection
against the challenge with the most of GBS and GAS strains in all
models tested. In addition ScaAB and SspB1 antibodies were able to
opsonize the pneumococci. The mixture of peptides performed better
range of protection compared to the single antigens. Introduction the
inﬂuenza virus antigen in the vaccine composition decreased the viral
load without the loss of protectivity against bacterial infection.
Conclusion: Recombinant polypeptide vaccine has a potential for
protection not only against the bacterial but viral-bacterial infections.
P2016 The humoral immune response of infants to potential
vaccine candidates of Moraxella catarrhalis
S.J. Verhaegh °, C.P. de Vogel, K. Riesbeck, T.F. Murphy,
E.R. Lafontaine, H.A. Moll, A. van Belkum, J.P. Hays (Rotterdam,
NL; Malmo, SE; Buffalo, Athens, US)
Objective: M. catarrhalis is a frequently found nasopharyngeal
commensal of young children that has the capacity to also cause upper
respiratory tract infections. M. catarrhalis outer membrane proteins
(OMPs) play a signiﬁcant role in the colonization and infection process,
with several potential OMP vaccine candidates having been described.
However, relatively little is known about the development of the humoral
immune response to M. catarrhalis OMP vaccine candidates within the
ﬁrst few years of life.
Methods: Nine different potential M. catarrhalis vaccine candidates
from laboratories in the USA and Europe were included: OMPs
Hag385−863, McaP51−333, MhaC, MID764−913, MID962−1200, orf238,
orf296, UspA1557−704 and UspA2165−318. Serum samples were collected
from cord blood and venepuncture at 6, 14 and 24 months of age from
a cohort of Dutch infants participating in the Rotterdam Generation R
Study. Antigen-speciﬁc IgG, IgA and IgM levels against the respective
M. catarrhalis OMPs were measured using the Luminex bead based ﬂow
cytometry technique, and a timeline of antibody responses was obtained.
Results: Antigen-speciﬁc IgG, IgA and IgM levels showed extensive
inter-individual variability over time. The level of antigen-speciﬁc IgG
in cord blood was signiﬁcantly higher for Hag, MID764, MID962, UspA1
and UspA2 than at 6 months of age (P< 0.001). However, IgG levels
against MID764, MID962, UspA1 and UspA2 rose signiﬁcantly between
6 months to 2 years of age. IgG levels to M. catarrhalis OMPs Hag,
McaP, MhaC, orf238 and orf296 remained relatively low and did not
signiﬁcantly increase over the 6 month to 2 year time period. IgA and
IgM levels to all 9 OMPs were relatively low throughout the study period.
However, IgA levels to the OMPs Hag, MID764, MID962, UspA1 and
UspA2, and IgM levels to MhaC, MID764, MID962, UspA1 and UspA2
increased signiﬁcantly (P< 0.05) over the 6 month to 2 year time period.
Conclusions: This is the most intensive study of the infant immune
response to potential vaccine candidates of M. catarrhalis performed
to date. Infants develop a range of IgG, IgA and IgM responses to
potential M. catarrhalis vaccine candidate proteins in a time dependent
manner, though IgG responses predominate. Antibody responses to the
major OMPs MID/Hag, and UspA1 and UspA2 were most signiﬁcant.
Further studies are required in order to determine whether these immune
responses correlate with protection from re-colonization and infection.
P2017 Implications of universal childhood pneumococcal
vaccination on invasive pneumococcal disease in HIV
population − a review of current infecting serotypes
C. Rock °, T. Coulter, K. Rock, N. Conlon, C. Dowling, J. Jackson,
C. Feighery, C. Bergin (Dublin, IE)
Objectives: Invasive pneumococcal disease (IPD) is associated with high
morbidity and mortality. HIV is a well described risk factor with annual
incidence of up to 1% in the AIDS population. Vaccination with 23-
valent pneumococcal polysaccharide (23 PPV) is recommended, with 5
yearly booster. Childhood vaccination schedule in Ireland includes CPV7
since 2008. We review IP isolates in adult patients (HIV positive and
negative) for serotypes, risk factors prior to introduction of universal
childhood CPV 7 and examine potential beneﬁt of prime boost strategy.
Methods: Laboratory surveillance and medical records were reviewed
for sex, age, HIV status, comorbidities of all IP isolates from 2006 to
2008, IP serotype from March 2007.
Results: There were 98 IP isolates, 96 (98%) blood culture and 2 (2%)
PCR on cerebrospinal ﬂuid. 30 were HIV positive, 68 HIV negative.
HIV positive: 21 (70%) male, average age 38, risk factors for HIV;
25 (83%) IVDU, 4 (13%) African HIV negative; 34 (50%) male, average
age 61. IVDU (83%) and malignancy (28%) were strong risk factor
for IPD in HIV positive and negative respectively. IP serotype was
known for 20/31 (64.5%) HIV positive, 27/67 (40.2%) negative. HIV
positive vs negative: 15 (75%) vs 26 (96.3%) in PPV23, 5 (25%) vs
21 (80.7%) in both vaccines, 5 (25%) vs 5 (18.5%) in neither vaccine,
10 (50%) vs 5 (18.5%) in PPV23 but not CPV7. These differences
in vaccine coverage are important when considering prime boosting
strategy. There was no difference in antibiotic sensitivity of isolate per
HIV status. 83% were fully sensitive, 13% intermediate sensitivity to
penicillin. Only 7 (21%) HIV had PPV23 prior to IPD, 3 had serotype
covered in PPV23, all IVDU with low CD4 count, none required ICU
admission.
Conclusion: CPV7 should not replace PPV23 in adult HIV population
but prime boosting approach may confer greater immunity. IPD in HIV
population as a surrogate marker for lack of access to healthcare in
IVDU population. Targeted strategies are required to engage this cohort
in vaccination services.
P2018 Changing epidemiology of Streptococcus pneumoniae
in Morocco, 2006–2008 − implications for national
immunization programme
N. El Mdaghri °, H. Belabbes, J. Najib, K. Zerouali, M. Benbachir
(Casablanca, MA)
Objectives: To assist decision makers in determining the best choice
of pneumococcal conjugate vaccines (PCV) to be introduced soon in
national program immunization in Morocco.
Methods: Susceptibility testing and serotyping were performed on
Streptococcus pneumoniae (Sp) isolates recovered from invasive diseases
in children 5 years or less hospitalized in the children university hospital
in Casablanca (Morocco) in 2006–2008 and compared with surveillance
data from earlier periods.
Results: From 1998–2001 to 2006–2008, the overall prevalence of
penicillin non-susceptible pneumococcal isolates increased from 15.3%
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(12% with intermediate resistance) to 24.4% (15.7% with intermediate
resistance). This increase was particularly of concern among paediatric
isolates (21.4% to 43.3% versus 13% to 15% among adult isolates).
The prevalence of non susceptible isolates to other antibiotics were
for amoxicillin (2.7%), ceftriaxone (0.7%), erythromycin (14.3%),
chloramphenicol (8%) and tetracycline (30.5%). Seventeen serotypes
were recognized among the 83 isolates recovered from invasive diseases
in children 5 years in 2006–2008. Predominant serotypes were 19F
(14.5%), 23F (13.25%), 14 (12%), 6B (10.8%), 5 (10.8%), 19A (9.6%)
and 1 (8.4%). Pneumococcal isolates with higher rates of penicillin non-
susceptibility were serotypes 14 (100%), 6B (89%), 19A (75%), 23F
(54.5%) and 19F (41.7%). Serotypes included in the PCV-7, PCV-10
and PCV-13 accounted for 54%, 76% and 88% respectively but the
potential coverage of these vaccines regarding penicillin non-susceptible
isolates would be 71.4%, 76.2% and 90.5% respectively. The serotype
distribution ﬂuctuated signiﬁcantly with time, showing an increase of
PCV-7 and PCV-7 related serotypes among children invasive isolates,
from 28% in 1998–2001 to 65% in 2005–2008.
Conclusions: This study documents the increase of penicillin-non-
susceptibility among Sp isolates causing invasive diseases in paediatric
population in Morocco and the ﬂuctuation of serotype distribution over
the time before conjugate vaccine introduction. These changes stress the
need for continuous and country wide laboratory surveillance to guide
treatment recommendations and conjugate vaccine formula choice.
P2019 Serotype coverage of present and future pneumococcal
vaccines
A.W. Rosingh °, E. Canton, G.F. Fagundez, F. Gonzalez, M. Gobernado
on behalf of the MIVA Network
Background: Infection with Streptococcus pneumoniae can cause
invasive pneumococcal disease (IPD). IPD is a cause of high mortality
and morbidity worldwide. The currently available vaccine includes 7
serotypes (PCV7) and the two future vaccines include 10 (PCV10)
and 13 (PCV13) serotypes. To make decisions about including a
pneumococcal vaccine, a description of the serotype distribution of
S. pneumoniae is essential.
Objective: The aim of this study is:
1. To describe the serotype distribution of isolates of S. pneumoniae
from IPD in the Comunidad Valenciana (5.1 million inhabitants)
during the year 2007, in the whole population and in infants (<15
years of age).
2. To determine the serotype coverage of present and future vaccines.
Materials and Methods: A total of 362 strains of S. pneumoniae causing
IPD in the Comunidad Valenciana, were collected from 22 participating
hospitals during 2007. 72 Of these isolates were from infants. Serotyping
was performed by serum slide agglutination (Denka-Seiken, Tokyo,
Japan), and if necessary by the Quellung reaction. The Quellung reaction
was also used as gold standard.
Results: The serotypes of S. pneumoniae found in order of prevalence
in the whole population were: 19A (10.8%), 1 (10.8%), 14 (10.2%), 8
(8.6%), 7 (7.7%), 3 (6.9%), 4 (4.4%), 7F (3.6%), 6A(3.9%), 22 (2.8%),
11 (2.5%). The rest of the serotypes were less than 2.5%. The serotypes
of S. pneumoniae found in order of prevalence in infants were: 7 (26%),
1 (25%), 14 (15%), 19A (12%), 18 (5%), 8 (3%), 6 (3%), 4 (2%), 16
(2%), 19F (2%), 22 (2%), 23A (2%), 23F (2%), and 24 (2%).
The serotype coverage of the pneumococcal vaccine in the whole
population is 22.8% by the PCV7, 41.3% by the PCV10, and 62.9%
by the PCV13.
The serotype coverage of the pneumococcal vaccine in infants is 29%
by PCV7, 80% by PCV10 and 95% by PCV13.
Conclusions:
• The three most prevalent serotypes in the whole population, with
percentages >10%, causing IPD in the Comunidad Valenciana during
the year 2007 are 19A, 1 and 14.
• The four most prevalent serotypes in infants, with percentages >10%,
causing IPD in the Comunidad Valenciana during the year 2007 are
7, 1, 14 and 19A
• Taking into account the high serotype coverage (80% by PCV10
and 95% by PCV13) of the two future vaccines, it might be
recommended to include the future PCV10 or PCV13 vaccine in
childhood immunization programs.
P2020 Immunization with the 7-valent pneumococcal conjugate
vaccine in children leads to herd immunity among adults
in Germany
M. van der Linden °, R. Reinert, M. Imo¨hl (Aachen, DE; Paris, FR)
Objectives: Streptococcus pneumoniae remains a leading cause of
pneumonia, sepsis and meningitis and disproportionately affects young
children and the elderly. In July 2006, vaccination with pneumococcal
conjugate vaccine was generally recommended by the German Health
authorities for all children up to the age of 24 months. In fact, the
vaccination program started in January 2007 in all federal states, with
the exception of Saxony where vaccination of children started 9 months
earlier. In this study, we present the indirect effects of routine vaccination
of young children with PCV7 on the rates of IPD in the adult population
(herd immunity effect).
Methods: The National Reference Center for Streptococci has monitored
the epidemiology of invasive pneumococcal disease (IPD) in adults
in Germany since 1992. Cases of IPD in adults are reported by
a laboratory-based surveillance system, including 265 laboratories
throughout Germany. For three federal states (since 2001 in North
Rhine-Westphalia, since 2006 in Saxony and Bavaria) a population-based
surveillance has been conducted. In January 2007, a nationwide web-
based surveillance system was introduced. The present analyses include
IPD cases documented between 2002 and 2009. Species conﬁrmation
was done by optochin testing and bile solubility testing. All isolates
were serotyped using the Neufeld Quellung reaction.
Results: The number of reported IPD cases considerably increased with
enhanced surveillance from 421 in the pneumococcal season 2003–
2004 to 1964 in 2008–2009. From 2002 to 2006, the percentage of
vaccine (PCV7) type IPD in adults in Germany varied between 42.9%
and 48.5%. In 2007–2008, this percentage dropped to 33.4%, in 2008–
2009 to 25.2%, and in Saxony even to 14%. While reporting of IPD is
not mandatory in Germany and therefore calculation of incidences is not
possible, this reduction of the percentage of IPD cases caused by vaccine
serotypes indicates an indirect vaccination effect. Of particular interest,
the13-valent vaccine (PCV13, in development) reveals a coverage of
68.0% based on the most recent (2008–2009) German data on IPD in
adults.
Conclusions: While the burden of disease due to IPD is substantial
in Germany, the strong reduction of IPD in children after introduction
of the routine childhood immunisation with PCV7 was followed by a
considerable reduction in the percentage of IPD cases in adults caused
by the PCV7 serotypes.
P2021 Determination of serotypes distribution among Streptococcus
pneumoniae in North America by multiplex PCR
C. Lascols °, M. Hackel, K. Nichol, D. Hoban, S. Bouchillon,
B. Johnson, J. Johnson, M. Dowzicky (Schaumburg, US; Winnipeg,
CA; Collegeville, US)
Background: Streptococcus pneumoniae is a major causative agent
of infections among young children and the aged. The pneumococcal
capsule is a major virulence factor in S. pneumoniae. To optimize
the development of future conjugate vaccines and to evaluate their
efﬁcacy, it is essential to monitor the changes in the sero-epidemiology
of S. pneumoniae. Accurate serotype determination of S. pneumoniae is
critical as vaccine development presently relies on serotype prevalence
data.
Methods: 184 S. pneumoniae clinical isolates collected through the
Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) were tested.
Based on published serotype distribution, we devised a simple PCR-
based assay of four sequential multiplex reactions to reliably deduce
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speciﬁc pneumococcal serotypes for a large number of isolates. PCR
results were conﬁrmed by the conventional Quellung reaction.
Results: The most common serotype was 19A (16.8%) followed by
serogroup 6B/A (9.2%), serotypes 22F (7.6%) and 3 (5.4%).
• The ﬁrst PCR reaction allowed determining the serotype for 46% of
the isolates.
• Overall, this multiplex typing scheme identiﬁed the serotype of 92%
of the isolates with 100% correlation with the Quellung reaction.
8% of isolates were non-typeable by PCR.
• 33 various serotypes were identiﬁed (see table).
Serotypes (%) identiﬁed
19A: 16.8% 4, 33F and 35B: 2.7%
22F: 7.6% 15C, 17F, 23F and 9V: 2.2%
3 and 6B: 5.4% 10A, 15B and 16F: 1.6%
7F: 4.4% 1, 8, 31, 33A and 38: 1.1%
11A, 6A and 19F: 3.8% 7A, 9A, 15A, 18B, 20, 34 and 35F: 0.6%
14, 12F and 18C: 3.3% Non typeable: 8.2%
Conclusions: This study conﬁrms the high prevalence of serotype 19A
in the United States and conﬁrms the accuracy and utility of multiplex-
PCR for serotyping, which could be of valuable use in microbiology
laboratories to monitor sero-epidemiological changes. Additionally, this
method appears to be a fast and cost-effective way to analyze large
numbers of isolates.
P2022 Surveillance of invasive pneumococcal disease in adults in
Asturias, Spain
A. Rueda °, R. Rico, L. Garrido, P. Capo´n, R. Carballo, I.S. Folgueras,
F. Pe´rez, A. Fleites (Oviedo, ES)
Objectives: The 7-valent conjugate pneumococcal vaccine (PCV7) was
introduced in Asturias, in 2001, with an individualized immunization use.
We evaluated the impact of PCV7 on trends in invasive peumococcal
disease (IPD) in adult patients, serotype distribution and penicillin
resistance.
Methods: Population-based surveillance. We have studied consecutively
all invasive isolates of Streptococcus pneumoniae at the Hospital Central
(Oviedo, Asturias), serving a adult population of 281849–299669, during
2001–2008. Demographic data were obtained from ofﬁcial statistics.
98% of strains were serotyped at the National Center Ref. (Madrid).
Penicillin susceptibility was determined by microdilution method and
oxacillin disk (CLSI). A Chi-square test was used.
Results: A total of 297 cases were identiﬁed: 69.7% pneumonia, 12.5%
meningitis, 11.4% sepsis, 4.4% empyema, 2.0% others. The average
rates of incidence (cases per 100000/year) were compared in 2001−04
vs. 2005−08. Overall IPD incidence increased from 11.8 (135 cases,
range 9.5–13.2) to 13.7 (162 cases, range 9.3–16.9). Age-speciﬁc trends
in IPD incidence were: among adults 65 yrs. (142 episodes) 25.3
vs. 28.3 and among adults 15−64 yrs. (155 episodes) 7.7 vs. 9.5. The
annual incidence of bacteremic pneumonia increased from 8.6 to 9.2
and data for meningitis were 1.7 vs. 1.4. A total of 32 serotypes/groups
were identiﬁed. Between 2001−04 and 2005−08 the proportion of PCV7
serotypes decreased from 44.4% to 25.8% (p = 0.001) corresponding
with a signiﬁcant decrease (p = 0.004) in the prevalence of serotype
6B (8.3% to 1.3%) and a decrease (not signiﬁcant) of serotypes
4, 14, 18C, 23F. Vaccine-related and nonvaccine serotypes increased
from 55.6% to 74.2% corresponding with a signiﬁcant increase in the
prevalence of serotypes 6A (0.7% to 6.3%, p = 0.013) and 7F (3.8% to
11.3%, p = 0.017) and not signiﬁcant increase in 19A, 22, 23A. During
2005−08, 73.0% of the detected serotypes were included in the 23-
valent vaccine. In this comparative period, similar frequency of penicillin
non-susceptible S. pneumoniae isolates was observed: 33.3% vs. 30.9%
(p = 0.650) and so was a non signiﬁcant decrease in penicillin-resistant
strains 14.1% vs. 7.4% (p = 0.074).
Conclusion: Our results show a slight increase in the incidence of IPD in
adults. Changes in the distribution of prevalent serotypes were found. The
penicillin non-susceptible rates remain unchanged. Surveillance should
be continued.
P2023 Serotype distribution of Streptococcus pneumoniae isolated
from patients with invasive pneumococcal disease in 2008
A.W. Rosingh °, E. Canton, G.F. Fagundez, F. Gonzalez, M. Gobernado
on behalf of the MIVA Network
Objective: To describe the serotype distribution of S. pneumoniae
associated with invasive pneumococcal disease in patients in the Valencia
Community (5.1 million inhabitants), Spain, during the year 2008, after
introduction of the 7 valent pneumococcal conjugate vaccine (PCV7).
Methods: We serotyped S. pneumoniae, isolated from blood, spinal
ﬂuid (CSF) and sterile liquid cultures collected during the year 2008 in
patients who were diagnosed with invasive pneumococcal disease in any
of the 22 participating hospitals. Serotyping was performed by antiserum
agglutination (Denka Seiken, Tokyo Japan). If necessary, more detailed
serotyping was done by the Quellung reaction (Staten Serum Institute).
Results: 335 Isolates of S. pneumoniae from 335 patients (blood
cultures, CSF and sterile body ﬂuids) were serotyped. The serotypes
in order of frequency were: 7F (17.6%), 19A (14.9%), 1 (13.1%), 3
(10.4%), 14 (6.3%), 22 (3.9%), 19F (3.3%), 11 (3%), 8A (2.7%). These
serotypes represent a total of 77.2% of the total number of isolates that
were serotyped. The other serotypes counted for percentages of less than
2.5%.
Conclusions: Of the serotypes isolated in this study, only 14.4% are
included in the PCV7-vaccine. Continued surveillance is needed to guide
development of future formulations of conjugate vaccines and to monitor
the effects of continued vaccine use.
P2024 Invasive Streptococcus pneumoniae serotypes associated
with adult and paediatric isolates from the United States
M. Hackel °, C. Lascols, D. Hoban, S. Bouchillon, J. Johnson,
M. Dowzicky (Schaumburg, Collegeville, US)
Background: Streptococcus pneumoniae (SPN) is a major cause of
invasive diseases and upper respiratory tract infections. Introduction
of the pneumococcal conjugate 7-valent vaccine (PV7) into the US
childhood vaccine schedule in 2000 has signiﬁcantly reduced invasive
pneumococcal disease in children and adults, with concurrent reduction
in the seven vaccine serotypes. Consistent monitoring of possible
replacement serotypes is essential to determine possible antibiotic
resistance patterns as certain serotypes are more closely associated with
antibiotic resistance, as well as to determine targets for future vaccines.
In this study we evaluate the serotypes of invasive SPN isolates from
pediatric and adult patients from 2004.
Methods: The capsular serotypes of 275 invasive SPN isolates collected
in the US through the Tigecycline Evaluation Surveillance Trial were
determined using sequential multiplex PCR and conﬁrmed using the
Quellung reaction. Invasive isolates were deﬁned as those from normally
sterile sites, such as blood, CSF and other body ﬂuids.
Results: Results are presented in the table.
Conclusions: While PV7 serotypes have declined since 2000, in 2004
approximately 20% of the invasive isolates from this study were from the
seven vaccine types (4, 6B, 9V, 14, 18C, 19F, 23F). Pediatric and adult
patients were equally likely to carry PV7 serotypes. Serotype 19A was
the most common serotype in both groups, which is cause for concern
as this serotype is often non-susceptible to penicillin and erythromycin.
Continued monitoring of post-vaccine serotype trends is on-going and
will be vital to the management of pneumococcal disease.
Total PV7 serotypes, Non-PV7 serotypes, N (%)
N N (%) 19A 6A 3 22F 15 7 Others
Pediatric 46 9 (20) 13 (28) 3 (7) 2 (4) 3 (7) 0 (0) 4 (9) 12 (26)
Adult 230 50 (22) 38 (17) 9 (4) 15 (7) 13 (6) 10 (4) 10 (4) 85 (37)
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P2025 Variable serological response to PPV in HIV-positive
patients − a need to review pneumococcal boost-prime
strategies?
A. Brown °, C. Rock, C. Nı´ Bhuachalla, T. Coulter, C. Dowling,
C. Bergin (Dublin, IE)
Objectives: International guidelines recommend 23-polyvalent polysac-
charide pneumococcal vaccination (PPV) for HIV-positive patients with
CD4 >200 cells/mm3. Historical data shows suboptimal response to
vaccination in HIV-positive patients when measured by pneumococcal-
speciﬁc IgG and vaccine serotype-speciﬁc IgG2. There is little data to
support the efﬁcacy of vaccination in consistently producing serological
response, or to assess the role of conjugate vaccine in adults.
Methods: In a cross-sectional study, 82 random blood samples were
taken from HIV-positive outpatients. The samples were assessed for
pneumococcal IgG and IgG2. IgG2 levels >69 microgram/L are
considered good serological evidence of response in the absence
of baseline titres with which to compare post-vaccination response.
Demographic, vaccination and laboratory data was recorded. Results
were analysed using Fisher’s exact test and two-tailed p values with
GraphPad InStat.
Results: Four patients were excluded who had no prior history of
pneumococcal vaccination, and two due to incomplete data. The
remaining 76 patients (M= 47, F = 29) were aged between 21 and 71
years (mean= 39.1yrs, SD 9.86) at the time of ﬁrst vaccination. Twenty-
six patients (34%) received booster. Sixty-one patients (80%) were
taking ART at the time of sampling. Thirteen patients (17.1%) had
a vaccine serotype-speciﬁc IgG2 titre 69 microg/L at the time of
random sampling. Achieving an IgG2 titre 69 microgram/L was not
associated with any of the measured variables − age <35 yrs vs >35 yrs
at vaccination (p = 0.54); male vs female sex (p = 0.54); CD4 count <200
cells/mm3 vs 200 cells/mm3 at ﬁrst vaccination (p = 0.58); CD4 count
<350 cells/mm3 vs >350 cells/mm3 at ﬁrst vaccination (p = 1.00); CD4
count <350 cells/mm3 vs >350 cells/mm3 at time of sampling (p = 0.34);
ART at sampling time vs no ART (p = 1.00); single vs boosted doses
(p = 0.19); <234 weeks (4.5 years) since vaccination vs >234 weeks
(p = 0.37).
Conclusions: In the HAART era only a minority of patients show
adequate levels of vaccine serotype-speciﬁc IgG2 regardless of time since
vaccination or booster dosing. Although immunoglobulin measurements
are a surrogate marker of immunity, there is no reliable predictor of
whether a HIV-positive patient will mount adequate serological response
to PPV. Further studies are needed to assess the nature of response
to PPV, alternative conjugate prime-boosting strategies, and the cost-
effectiveness of mass vaccination programmes.
P2026 Rabies vaccine: A comparative study on adverse events
of four 0.1ml intradermal booster doses on day 0 with
conventional booster vaccination
T. Tantawichien °, M. Benjawongkulchai, T. Tantawichien (Bangkok, TH)
Booster vaccination of previously immunized persons with potentially
exposure to rabies is two doses of cell-culture vaccine (CCV)
intramuscularly (IM) or intradermally (ID) on days 0 and 3 as WHO
recommendation. We previously demonstrated that four 0.1-mL ID
booster doses administered on day 0 induced signiﬁcantly higher titers
of neutralizing antibody (Nab) than did conventional booster doses to
previously vaccinated subjects. Since 1998, our institute’s guideline has
recommended use of either (1) the four 0.1-mL ID booster doses given
on day 0, or (2) the conventional two 0.1-mL ID booster doses given on
days 0 and 3 for previously vaccinated individuals. During the past 10
years, a total of 5,116 previously vaccinated patients who had exposed
to rabies (65% had severe exposure as WHO category III) were given
four 0.1-mL ID booster doses of CCV on day 0. None of all patients had
any severe adverse reactions and there were no reported rabies deaths.
We therefore carried out a prospective study on comparing the 4-site
ID booster regimen in terms of safety and tolerance with conventional
2-site ID booster regimen.
Methods: Our patients who received ID booster vaccination were re-
cruited after providing informed consent approved by ethical committee.
The safety endpoints assessed the frequency and severity of solicited
local, systemic symptoms and serious adverse events collected at 30
minute post-vaccination, and during the 7-day period following booster
vaccination.
Results: Three hundred patients (251 patients received 4-site ID booster
regimen; gr. A and 49 patients received 2-site ID booster regimen; gr. B)
were recruited. Ninety patients (87 patients in gr. A and 3 patients
in gr. B) who received tetanus toxoids simultaneously were excluded.
Among 164 patients in gr. A (mean age 43.0 years) and 46 patients
in gr. B (mean age 44.6 years), there were no reports of serious side
effects other than minor symptoms. Local pain was more frequent in
gr. A (20.1%) than gr. B (6.5%), however, the incidence of itchiness,
erythema at site of injection and local lymphadenopathy were similar
in both groups. The incidence of mild generalized symptoms such as
fever (9.1%), headache (10.9%), dizziness (11.6%), nausea (6.7%) were
more often with the gr. A than gr. B (2.2%, 2.2%, 6.5% and 2%).
Conclusion: The four 0.1mL-site ID booster regimen has been proven
to be highly immunogenic and more convenience but has a few
disadvantages, such as local pain and mild adverse events.
P2027 Long-term protection provided by hepatitis B vaccine and
need for booster dose: a meta-analysis
J. Poorolajal ° (Hamadan, IR)
The duration of protection provided by hepatitis B vaccine is still
unknown but can be estimated through long-term follow-up studies.
Electronic databases and conference databases to December 2008 were
searched. Reference lists of articles were screened and the studies authors
and manufacturers were contacted for additional unpublished references.
Randomized clinical trials and prospective cohort studies addressing the
long-term protective effect of hepatitis B vaccine were included in this
meta-analysis. We assessed 42 separate cohorts involving overall 11,090
subjects; 34 cohorts involving 9356 subjects were included in the ﬁnal
meta-analysis.
Results indicate that the overall cumulative incidence of HBV
breakthrough infection 5−20 years post-primary vaccination was 0.007
[95%CI: 0.005 to 0.010] with a variation among studies from 0 to 0.094.
Available data do not allow us to exclude an increased risk for infection
with time since vaccination.
We conclude that the protection provided by three or four doses of
monovalent HB vaccine persists for at least two decades in the great
majority of immunocompetent individuals. Additional studies are needed
for assessing vaccine efﬁcacy for longer periods of time and the need of
booster doses in different subgroups of population.
P2028 Cellular immune activation and regulatory mechanisms
after inﬂuenza vaccination
S. Wang °, H. Lei, C.C. Liu (Tainan City, TW)
Background and Purpose: Inﬂuenza virus infections can cause primary
inﬂuenza viral pneumonia; exacerbate underlying medical conditions.
Inﬂuenza vaccination is the most effective method for preventing
inﬂuenza virus infection and its potentially severe complications. Two
broad categories of regulatory T cells (Tregs) have been described,
CD4+CD25+ Treg subset and transcription factor forkhead box P3
(Foxp3). We conduct this study 1) to explore the role of regulatory
T cells and effector T cells immunological mechanisms after receiving
inﬂuenza vaccination; 2) to characterize the expression of regulatory T
cells and antibodies production after inﬂuenza vaccination.
Material and Method: Healthy volunteers (n = 35) at the time of
blood collection donated whole blood via venous puncture before
inﬂuenza vaccination and two weeks after the immunization in each
year. Peripheral blood mononuclear cells (PBMCs) were isolated from
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EDTA whole blood by Ficoll separation. Following activation, ﬁxation
and permeabilization was performed using either the ﬁx/perm buffer
recommended by eBiosciences for detection of Foxp3 (PCH101).
Results: The mean white blood cell counts and mean absolute
lymphocyte counts were similar before and after vaccination. The
ratio of expression frequency of CD4+CD25+Foxp3+/isotype and
CD127 increased signiﬁcantly after vaccination, in comparison with
that of before vaccination (p< 0.05). The expression frequency of
CD3 also enhanced after vaccination. There was no difference of
immunophenotypes expression frequency on PBMCs of CD4+, CD8+,
and CD20+, before and after vaccination.
Conclusions: Use of the CD4+CD25+Foxp3+ and CD127 phenotype
to discriminate Tregs may permit better understanding of the role of
Treg cells in vaccination. Natural Treg cell participate in the immune
response of inﬂuenza vaccination. The altered expression of natural Treg
cell may be used as a surrogate measurement of regulatory function and
may inﬂuence the efﬁcacy of protective immunity.
P2029 Biological and immunological characteristics of a new
lipopolysaccharide-based conjugate vaccine for brucellosis
S.D. Siadat °, M.R. Aghasadeghi, M. Mohammadi, M. Kheirandish,
D. Norouzian, J. Izadi Mobarakeh, M. Razavi, M. Zangeneh,
S.M. Sadat, A. Sharifat Salmani, A. Moshiri (Tehran, IR)
Objective: The development of an efﬁcacious vaccine for brucellosis
has been a challenge for scientists for many years. At present, there
is no licensed vaccine against human brucellosis. To overcome this
problem, currently, antigenic determinants of Brucella cell wall such
as Lipopolysaccharide (LPS) are considered as potential candidates to
develop subunit vaccines. Since naturally occurring strains lacking LPS
show reduced survival, LPS is considered to be a major virulence factor.
Also, the LPS of B. abortus is considered one of the most important
antigens from the point of view of the primary targets of the innate
immunity.
Methods: We have undertaken detoxiﬁed of Brucella abortus S99 LPS
by basic hydrolysis and resultant amine groups were used for their
conjugation to Neisseria meningitidis serogroup B outer membrane
vesicle as carrier protein using carbodiimide and adipic acid-mediated
coupling and linking respectively. Groups of ten Balb/c mice were
injected intramuscularly with 5 mg of dLPS alone, combine or conjugated
on 0, 14 and 28 days. Sera were taken before and 14 days after each
injection. The anti-LPS IgM and IgG were measured in serum.
Results: The molar ratio (dLPS/OMV) of the resulting conjugate was
45:1. The dLPS-OMV conjugates was the most immunogenic compound
that stimulated following the ﬁrst injection an increase in IgG titre of
about 9.50, 5.80 and 4.53 fold higher than that produced against LPS,
LPS in non covalent complex to OMV (LPS+OMV) and LPS with
complete Freund’s adjuvants, respectively. The highest anti-LPS IgG titer
was detected two weeks after the third injection (the day 42) of dLPS–
MV conjugates.
Conclusion: Our previous studies demonstrated that LPS+OMV was
immunogenic in mice and elicited high level of anti-LPS IgG titers. In
this study, conjugation of LPS to OMV was designed and the antigenicity
of this conjugated was evaluated by ELISA. The conjugated elicited
higher titers of IgG than LPS+OMV, that showed a 120- to 165-fold
rise of anti-LPS IgG in mice. These results indicate that the conjugated
LPS obtained by us, can be used as a brucellosis vaccine after further
investigation.
P2030 How long after the last vaccine dose can pertussis serology
not be used?
M. Riffelmann °, M. Littmann, C. Wirsing von Koenig, C. Hu¨lße
(Krefeld, Rostock, DE)
Objectives: IgG-anti-pertussis toxin (PT) antibodies used in pertussis
serology can be induced either by vaccination with acellular vaccines
or by infection with Bordetella pertussis. As a consequence, diagnostic
serology cannot be correctly interpreted for some time after vaccination.
However, it is unclear, how long this interference lasts in clinical practice.
Methods: 206 adolescent and adult patients with longer lasting coughs
were recruited by 19 sentinel physicians (10 general practitioners,
9 paediatricians) in the Rostock (Germany) region between January
2008 and April 2009. Clinical symptoms and vaccination history were
recorded. Bordetella-DNA (B. pertussis and B. parapertussis) was
detected by real-time PCR in nasopharnygeal swabs. IgG- and IgA-
antibodies to PT and ﬁlamentous hemagglutinin (FHA) were quantiﬁed
by a standardized ELISA. IgG-anti-PT levels of 100 IU/ml were
regarded as indicative of recent contact, and IgG-anti-PT levels of
40 IU/ml were interpretede as not indicative of a recent contact. IgG-
anti-PT levels between 40 IU/ml and 100 IU/ml were complemented by
measuring IgA-anti-PT and IgG/IgA-anti-FHA.
Results: In a total of 45 patients (18%) a recent contact to Bordetella
was substantiated either by serology alone or by PCR (n = 12). PCR was
more often positive in adolescent patients. The share of patients with
pertussis in the study population was similar to other rates observed in
previous studies. ROC-curve analysis substantiated that a cut-off of IgG-
anti-PT between 30 and 40 IU/ml was sufﬁciently sensitive and speciﬁc.
A survival time analysis comparing the time to the last vaccine dose
between the pertussis group and the non-pertussis group showed that the
Kaplan–Meier plots were similar one year after the last vaccine dose.
Conclusions: Our results indicate that diagnostic pertussis serology is
difﬁcult to interpret for one year after vaccination with acellular pertussis
vaccines.
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P2032 Evaluation of GeneXpert MTB/RIF assay on pulmonary and
extra-pulmonary samples in a high-throughput laboratory
S. Naidoo ° (Johannesburg, ZA)
Objectives: In South Africa, tuberculosis (TB) and HIV co-infection is
wide spread and these patients are more prone to have smear-negative
TB or extra-pulmonary TB. Most nucleic acid ampliﬁcation methods
have poor sensitivities with smear-negative samples and culture results
from these samples can take weeks, leading to higher mortality rates and
further spread of multi-drug resistant TB. The GeneXpert MTB/RIF test
integrates and automates sample processing and simultaneous detection
of Mycobacterium tuberculosis complex and rifampicin resistance, using
real-time PCR, within single-use disposable cartridges. The time to
result is less than 2 hours and it requires minimal training. We have
assessed the performance and feasibility of the Xpert MTB/RIF assay for
rapid identiﬁcation of MTB complex and rifampicin resistance, in both
pulmonary (smear negative and smear positive) and extra-pulmonary
samples in a routine diagnostic high-throughput TB laboratory in South
Africa over a period of two months.
Methods: The results of 1140 sputum samples were compared with
validated conventional methods including smear microscopy, liquid
culture (MGIT) and culture identiﬁcation (Accuprobe). In addition, the
GeneXpert results from 361 extra-pulmonary samples including bone
marrow, cerebrospinal ﬂuid, lymph nodes and urine samples were also
compared with conventional testing.
Results: Xpert MTB/RIF results showed great sensitivity (99.8%) and
speciﬁcity (94.1%) compared to conventional testing in pulmonary
samples, resulting in a PPV of 97.6% and NPV of 99.4%. Results
also correlated very well with conventional drug susceptibility testing,
with sensitivity of 99.4% and speciﬁcity of 98.8% (PPV 95.2% and
NPV 99.8%). We also showed that TB can be successfully identiﬁed in
various types of extra-pulmonary samples with the Xpert MTB/RIF test
(sensitivity 93.5%, speciﬁcity 99%, PPV 98.7% and NPV 94.6%).
Conclusions: The Xpert MTB/RIF assay has proved to be a user-
friendly system with remarkably high sensitivity and speciﬁcity, in
both pulmonary and extra-pulmonary samples, in a high-throughput
laboratory in South Africa. The routine implementation of the test
has signiﬁcantly alleviated the workload of the laboratory and lead
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to much quicker result reporting and earlier treatment of patients than
conventional TB testing.
Pulmonary samples
Culture positive Culture negative
MTB detected 800 20
MTB not detected 2 318
Sensitivity = 99.8% PPV = 97.6%
Speciﬁcity = 94.1% NPV = 99.4%
RIF Resistant RIF Sensitive
RIF Resistant 157 8
RIF Sensitive 1 635
Sensitivity = 99.4% PPV = 95.2%
Speciﬁcity = 98.8% NPV = 99.8
Extra-pulmonary samples
Culture positive Culture negative
MTB detected 157 2
MTB not detected 11 191
Sensitivity = 93.5% PPV = 98.7%
Speciﬁcity = 98.7% NPV = 94.6
P2033 Molecular typing of clinical isolates of Mycobacterium
tuberculosis complex obtained in Bogota´ (Colombia) based
on Spoligotyping and MIRU-VNTRs
I. Cerezo, Y.J. Jime´nez, J. Herna´ndez, T. Zozio, N. Rastogi,
M.I. Murcia ° (Bogota´, CO; Guadeloupe, FR)
Objectives: The present study focused on molecular typing of
M. tuberculosis strains isolated from TB patients diagnosed in Bogota´-
Colombia between 1995 to 2006. Our primary aim was to have a ﬁrst
insight on the population structure of tubercle bacilli in Bogota´.
Methods: we studied 154 clinical isolates collected from different
hospitals in Bogota´. The strains were genotyped using spoligotyping
and mycobacterial interspersed repetitive units-variable number of
tandem repeats MIRU-VNTRs (classical 12 loci format) in order to
determine the percentage of unique and clustered isolates. Spoligotypes
in binary format and 12-digit MIRU patterns were entered in the
SITVIT2 proprietary database of the Pasteur Institute of Guadeloupe to
assign major phylogenetic clades and sub-lineages for M. tuberculosis
isolates. In this database, SIT (Spoligotype International Type) designates
spoligotyping shared by 2 or more patient isolates, whereas MIT (MIRU
International Type) designates 12-locus MIRU patterns shared by 2
or more patient isolates, as opposed to “orphan” patterns designating
patterns reported for a single isolate. The discriminatory power of the
methods used was calculated using the Hunter Gaston Discriminatory
Index (HGDI).
Results: Using Spoligotyping as ﬁrst molecular marker and MIRU-
VNTRs as second marker we obtained 100 single patterns and 54
grouped strains into 15 clusters. The lineages found in our sample
were in the following order: Latin American & Mediterranean (LAM)
49.25%; Harlem, 25.97%; ill-deﬁned T, 12.33%; S family 1.3%; X
lineage, 1.3%; Beijing, 0.65%, and unknown, 7.14%. The MIRU-VNTRs
patterns corresponded to 51 MITs for 111 strains and 43 orphan patterns.
The most frequent patterns were MIT190 (n = 12), MIT45 (n = 10), and
MIT25 (n = 9). The HGDI of both methodologies gave a value of 0.983.
In our setting, the HGDI of a ﬁve loci subset (MIRU- 26, 40, 10, 31,
23) contributed most to the discriminatory power of the 12-loci format
used.
Conclusions: M. tuberculosis lineage distribution showed that more
than 3/4 of strains in Bogota´ are commonly found in Latin-America,
Caribbean, and Europe. This observation reﬂects the common post-
Columbus history of Colombia and its Latin-American neighbors as
well as the strains brought by 20th century immigrants from Europe.
We also show the usefulness of MIRU-VNTRs to detect polyclonal
infections, and high stability across time allowing us the detection of
chronic infections and endogenous reactivations.
P2034 Analysis of an additional 9-loci MIRU-VNTR conﬁrms a
large single clone of Mycobacterium tuberculosis in the West
Midlands, United Kingdom
A. Gibson °, J. Evans, S. Gardiner, G. Smith, P. Hawkey (Birmingham,
UK)
Objective: The Mercian strain of Mycobacterium tuberculosis is the
single most prevalent strain of tuberculosis in the West Midlands, UK. It
was ﬁrst identiﬁed in 2003 after the start of routine DNA ﬁngerprinting
and accounted for 171/1899 (9.0%) of all clustered cases between
2004–2008. Archive data suggests Mercian M. tuberculosis has been
circulating for at least 14 years, however it appears to be geographically
restricted as only 6 isolates have been identiﬁed outside the West
Midlands. Routine 15-loci Mycobacterial Interspersed Repetitive Unit-
Variable Number tandem Repeat (MIRU-VNTR) typing identiﬁed a
common proﬁle unique to Mercian strains. The aim of this study was to
determine if the addition of the optimal 9-loci (P Supply et al, 2006. J
Clin Microbiol 44:4498–510) to the 15-loci MIRU-VNTR typing panel
would sub-divide this highly prevalent clade.
Methods: A total of 182/198 (91.9%) Mercian isolates identiﬁed
between 2003–2008 were studied. In addition, isolates (n = 19) identiﬁed
as the Mercian strain through previous epidemiological investigations
from 1996–2002 were analysed. All isolates (n = 201) had previously
undergone 15-loci MIRU-VNTR typing and were further typed for the
additional 9 loci using a WAVE® System.
Results: A large single clone remained after the addition of 9-loci
to the MIRU-VNTR typing panel. The most common Mercian strain
type (type A) accounted for 170/201 (84.6%) isolates. The remaining
31 isolates were single locus variants (2 clusters of 23 and 5 isolates
respectively [type B and C] and 2 unique isolates [type D and E]) along
with a double locus variant (1 isolate, type F). Only 3 out of 9 loci
were variable. Analysis according to year of isolation showed the most
prevalent MIRU-VNTR type (type A or “True Mercian”), was present in
isolates from all study years. In 2000 the ﬁrst variant type was identiﬁed
(type B), followed by type C in 2002, type D in 2005 and types E and F
in 2006, suggesting that the Mercian strain is evolving slowly over time.
Conclusion: The addition of 9-loci conﬁrmed the presence of a highly
prevalent conserved clone (True Mercian) containing 170 isolates. To
the best of our knowledge this is the largest single M. tuberculosis clone
to date, based on the optimal 24-loci MIRU-VNTR typing method. True
Mercian may have unique genetic properties that enable it to outcompete
other more widely encountered strains in the UK.
P2035 Molecular genetic analysis of multidrug-resistant
Mycobacterium tuberculosis in Bulgaria
V. Valcheva °, I. Mokrousov, G. Slavchev, N. Rastogi, N. Markova
(Soﬁa, BG; St.Petersburg, RU; Abymes, FR)
Objectives: Multidrug-resistant tuberculosis (MDR-TB) in Bulgaria has
reached alarming proportions (WHO estimation: 10.7% of new TB
cases), much higher than in the EU neighbours. Here, we studied the
population structure and drug resistance patterns of Mycobacterium
tuberculosis strains in Bulgaria.
Methods: A total of 133 M. tuberculosis clinical isolates from different
regions across Bulgaria were analyzed by spoligo-, 24-MIRU-VNTR,
IS6110-RFLP typing and rpoB, katG, inhA, embB drug resistance
mutations analysis.
Results: The spoligotype-based population structure of M. tuberculosis
in Bulgaria was sufﬁciently heterogeneous. The Beijing genotype strains
were not found. Novel 15/24-loci MIRU-VNTR format achieved the
highest discrimination. Three types of the rpoB mutations were found in
20 of 27 RIF-resistant isolates; rpoB S531L was the most frequent (17
strains). Eleven of 23 INH-resistant isolates had katG S315T mutation.
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A mutation in embB306 was found in 7 of 11 EMB-resistant isolates.
A monoresistance was found in 15 of 37 drug-resistant isolates.
Conclusion: M. tuberculosis population in Bulgaria is dominated by
several global and Balkan speciﬁc spoligotypes. rpoB and embB306
mutations may serve for rapid genotypic detection of the majority of RIF
and EMB-resistant strains in Bulgaria; the results on INH resistance are
complex and further investigation of more genes is needed. Transmission
of MDR-TB in Bulgaria is not inﬂuenced by the global spread of the
Beijing genotype which apparently has not yet reached this country.
A local circulation of the particular area-speciﬁc clones appears to
be an important factor to take into consideration in the molecular
epidemiological studies of tuberculosis in Bulgaria.
This work was supported by grant DMU 02/01.
P2036 Fast detection of frequent multidrug resistance conferring
mutations in Mycobacterium tuberculosis isolates using a
duplex high-resolution melting curve assay
A. Pietzka °, A. Sto¨ger, F. Allerberger, W. Ruppitsch (Vienna, AT)
Objective: Rapid diagnosis of multidrug-resistant (MDR) tuberculosis
has substantial impact on progression and spreading of the disease. A
widely used surrogate marker for MDR-TB testing is resistance against
rifampicin, which is caused by diverse mutations in the RNA polymerase
b-subunit gene (rpoB). The aim of this study was a general improvement
in multidrug-resistance testing ofMycobacterium tuberculosis isolates by
optimisation and simpliﬁcation of PCR based methods. As a model we
used a duplex high-resolution melting (HRM) curve analysis approach
to scan for the most frequent mutations in cluster I and outside cluster
I of the rpoB.
Methods: Thirty-four MDR-TB and nineteen fully susceptibleMycobac-
terium tuberculosis strains were used to develop a duplex HRM PCR
assay to screen simultaneously for the V176F mutation and cluster I
codon 456 mutations of the rpoB on a LightCycler480 instrument using
LightCycler 480 software 1.5 (Roche Diagnostics, Penzberg, Germany).
For analysis melting curves were normalised, temperature-shifted, and a
difference plot was generated (Figure 1).
Results: Parallel gene scanning of two distinct regions within the
rpoB allowed the correct identiﬁcation of 34 MDR-TB isolates and
all 19 non-MDR-TB isolates in a single closed-tube assay format.
HRM curve analysis generated four distinct and highly reproducible
curve proﬁles each speciﬁc for the respective SNP. Thus, non MDR-TB
isolates were easily distinguishable from MDR-TB isolates independent
of the kind of mutation. In addition the method allowed a differentiation
between MDR-TB isolates due to the speciﬁc SNP conferring rifampicin
resistance (Figure 1).
Conclusions: The developed duplex high resolution melting assay
represents a diagnostic improvement in terms of speed, simplicity,
accuracy and cost-effectiveness. Moreover, since the entire ampliﬁcation
product is scanned for sequence variations any mutation can be detected
by HRM due to melting curve proﬁles that will be unrelated to the
non-MDR-TB melting curve proﬁle used as a standard.
P2037 Multiple mutations in the katG encoding catalase proxidase
in isoniazid-resistant Mycobacterium tuberculosis isolates
correlate with high level of resistance in patients with active
pulmonary tuberculosis in Iran
Z. Bostanabad °, M. Rahimi, P. Adimi, M. Shekarabei, H. Hosseinaei
(Parand, Tehran, IR)
The aim of this study was to investigate the signiﬁcance of multiple-
mutations in the katG gene, predominant nucleotide changes and its
correlation with high level of resistance to isoniazid in Mycobacterium
tuberculosis isolates that were randomly collected from sputa of 42
patients with primary and secondary active pulmonary tuberculosis
from different geographic regions of Iran. Drug susceptibility testing
was determined using the CDC standard conventional proportional
method. DNA extraction, katG gene ampliﬁcation and DNA sequencing
analysis were performed. Thirty four (80%) isolates were found to have
multiple-mutations (composed of 2−5 mutations) in the katG gene.
Increased number of predominant mutations and nucleotide changes
were demonstrated in codons 315 (AGC_ACC), 316 (GGC_AGC),
309 (GGT_GTT) with a higher frequency among patients bearing
secondary tuberculosis infection with elevated levels of resistance to
isoniazid (MIC mg/ml − 5−10). Furthermore it was demonstrated
that the combination of mutations with their predominant nucleotide
changes were also observed in codons 315, 316 and 309 indicating
higher frequencies of mutations among patients with secondary infection
respectively. In this study 62% (n = 21) of multi-mutated isolates found to
have combination of mutations with predominant nucleotide changes in
codons 315 (AGC_ACC), 316 (GGC_GTT), 309 (GGT_GGT) and also
demonstrated to be more frequent in isolates of patients with secondary
infections, bearing higher level of resistance to isoniazid (5−10 mg/ml).
P2038 Rapid identiﬁcation of Beijing Mycobacterium tuberculosis
strains by high-resolution melting analysis
Y. Navarro °, M. Alonso, F. Barletta, M. Martinez Lirola, E. Gotuzzo,
E. Bouza, D. Garcı´a de Viedma (Madrid, ES; Lima, PE; Almeria, ES)
Background and Objective: Genotypic analysis of Mycobacterium
tuberculosis (MTB) has enabled us to deﬁne several lineages. Among
these, the Beijing family is considered highly virulent and transmissible,
has been associated with resistance in certain settings and involved in
severe outbreaks, making it one of the most closely monitored lineages.
Therefore, rapid identiﬁcation of cases infected by Beijing MTB strains
could be relevant at a clinical and epidemiological level. Our aim in this
study was to develop and evaluate a new rapid procedure to identify
Beijing MTB isolates using high-resolution melting (HRM) analysis.
Methods: We designed a real-time polymerase chain reaction followed
by HRM analysis based on the identiﬁcation of the single-nucleotide
polymorphism A191C in the Rv2629 gene, which is a marker for the
Beijing lineage. We analysed thirty-two MTB strains (18 representatives
of the Beijing genotype and 14 representatives of the non-Beijing
genotype, according to their spoligotypes) and 44 smear-positive clinical
respiratory samples. Finally, 84 MTB strains were selected from a
prospective cohort of 145 isolates from 5 areas in Peru between
December 2008 and March 2009.
Results: HRM analysis efﬁciently differentiated Beijing and non-Beijing
strains from the 32 reference strains. HRM was able to assign a
Beijing/non-Beijing genotype in 100% of respiratory specimens with a
high bacterial load and in 73.1% of those with a low/intermediate load.
An indirect analysis based on the identiﬁcation of heteroduplexes when
Beijing and non-Beijing DNA were combined in the reaction succeeded
in assigning a genotype in 50% of the cases where the direct HRM
analysis had failed. Our HRM design identiﬁed 10.7% of the Peruvian
strains as belonging to the Beijing genotype; this proportion reached
20% in the North Lima area.
Conclusion: Our HRM-based method is a rapid, reliable, and sensitive
method for the efﬁcient identiﬁcation of cases infected by high-risk
Beijing MTB strains. A Beijing/non-Beijing genotype was succesfully
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assigned in 100% of the MTB isolates and in 90.9% of the respiratory
specimens assayed. Its application to a Peruvian sample of MTB isolates
revealed high representativity of Beijing strains, especially in the Lima
area.
Y. Navarro was receiving a grant for International Cooperation of
the “Fundacio´n para la Investigacio´n Biome´dica del Hospital Gregorio
Maran˜o´n”.
This study was partially funded by the FIS (FIS060882; FIS061467;
FIS06/90490; 06/90357; PS09/02205).
P2039 Oligonucleotide array-based identiﬁcation of Mycobacterium
tuberculosis complex and non-tuberculous mycobacteria
Y. Jenh, R. Jou, P. Lu, Y. Yang, W. Huang, H.M. Chen, T. Chang °
(Tainan, Taipei City, Kaohsiung, TW)
Mycobacterial infections have been a serious health problem worldwide.
Conventional methods for the identiﬁcation of Mycobacterium are
time-consuming and identiﬁcation can be difﬁcult for closely related
nontuberculous mycobacteria (NTM). Rapid differentiation of NTM
from Mycobacterium tuberculosis complex (MTBC) is of clinical
importance since antimicrobial agents used to treat infections caused
by NTM are different from those caused by MTBC. In addition,
accurate identiﬁcation of members in MTBC may have epidemiological
value. The aim of this study was to develop an oligonucleotide array
to rapidly differentiate NTM from MTBC, to differentiate members
in MTBC, and to identify 19 clinically important species of NTM.
Speciﬁc oligonucleotide probes (18 to 25-mers), immobilized on nylon
membrane, were designed from the 16S-23S rRNA gene intergenic
spacer (ITS) region and gyrase B gene (gyrB). The method consisted
of PCR ampliﬁcation of the ITS regions using mycobacteria universal
primers, followed by hybridization of the digoxigenin-labeled PCR
products to oligonucleotide probes on the array. Three probes were
found to useful for differentiating NTM from MTBC, and a combination
of multiple probes could effectively differentiate members in MTBC.
Moreover, probes were successfully designed to identify 19 species
of NTM. The current method provides a rapid and accurate tool to
differentiate NTM from MTBC, to identify different species in MTBC,
and to identify clinically important species of NTM. The identiﬁcation
procedures can be ﬁnished within 24 h, starting from isolated colonies.
P2040 Molecular epidemiology of Mycobacterium tuberculosis in
an Italian north-eastern area
L. Fallico °, M. Peracchi, R. Manganelli, G. Palu` (Padua, IT)
Objectives: The control of tuberculosis (TB) requires methods for rapid
detection and tracing sources of infection, so that further transmission
can be arrested. Objective of this study was that to characterize the
molecular epidemiology of M. tuberculosis in an area of northwester
Italy surrounding Padua.
Methods: M. tuberculosis strains isolated in the Laboratory of
Microbiology and Virology of the Hospital of Padua during three years
(1 January 2006/ 31 December 2008) from patients with pulmonary
and extra pulmonary TB, were genotyped by spoligotyping. The study
population (383 isolates) included 101 strains collected during 2006, 139
during 2007, and 143 during 2008. Spoligotypes were analyzed using the
International Spoligotype Database (SpolDB4) available at the following
link: http://www.pasteur-guadeloupe.fr/tb/bd_myco.html.
Results: The 3-year survey showed that 108 isolates were grouped
in two major spoligotypes (ST1378, belonging to the CAS family, 57
isolates; ST1, belonging to the Beijing family, 17 isolates) and 8 minor
spoligotypes distributed among the CAS, Bovis, U, EAI families.
Of the remaining isolates, 15 were present as orphan (only one reported
worldwide) while 275 were not present in the database. Among these,
110 isolates clustered in 9 major spoligotypes; including 5 (3 clusters), 6
(2 clusters), 8, 21, 25, and 29 isolates respectively; 65 isolates clustered
in 27 minor spoligotypes. Finally, 100 isolates were orphan.
Conclusions: Our results demonstrate a characteristic epidemiological
pattern of M. tuberculosis, represented by two well known major
spoligotypes (ST1378 and ST1) and 9 major spoligotypes not yet
reported in the SpolDB4 database. The identiﬁcation of large clusters of
isolates belonging to still unreported spoligotypes suggests the possibility
of local outbreaks with ongoing transmission. At the best of our
knowledge, this is the ﬁrst report showing the presence of isolates
belonging to the Beijing family in northern Italy.
P2041 Routine non-tuberculous mycobacteria detection and
molecular identiﬁcation, Athens, Greece, 2005–2009
S. Nikolaou, D. Papaventsis °, S. Karabela, P. Ioannidis, A. Sainti,
E. Konstantinidou, I. Marinou, S. Kanavaki (Athens, GR)
Objective: Infections caused by non-tuberculous mycobacteria (NTM)
are diagnosed with increasing frequency. The purpose of this study was
to present NTM isolations during a 5-year period, in Athens, Greece.
Methods: From Jan 2005 to Oct 2009, 85540 clinical specimens were
tested. Microscopy was performed by the Ziehl–Neelsen stain, culture
in both Lo¨wenstein-Jensen (LJ) and in the automated BACTECTM
MGIT 960 (Becton Dickinson, USA). Identiﬁcation at the species level
was done by the Genotype Mycobacterium CM/AS (Hain Lifesciences,
Germany). Susceptibilities to ﬁrst and second-line anti-tuberculous
drugs were determined with the classical proportion method on LJ
(Biomerieux, France and Lioﬁlchem, Italy) and the MGIT 960. Tests
were performed with the following critical concentrations based on
methods recommended by the CLSI for M. tuberculosis (MTB) and
slow-growing mycobacteria: isoniazid (0.2 ug/ml for LJ), rifambicin (40
ug/ml for LJ), ethambutol (2 ug/ml for LJ), streptomycin (5 ug/ml for
LJ), clarithromycin (4, 16, 64 ug/ml for MGIT), and oﬂoxacin (2 ug/ml
for MGIT).
Results: 2540/85540 (2.9%, range 2.7−3.0%) acid-fast bacteria were
isolated. 2215/2540 (87%, range 85−90%) acid-fast isolates were
identiﬁed as MTB, while 325/2540 (12.8%, range 10−15%) were NTM.
277/325 (85%) were successfully identiﬁed on species level. In total:
70 isolates (25%) were M. avium, 53 (16%) M. fortuitum, 35 (11%)
M. intracellulare, 26 (8%) M. chelonae, 23 (7%) M. gordonae, 19
(6%) M. peregrinum, 11 (3%) M. abscessus and 11 (3%) M. kansasii,
9 (2.5%) M. xenopi, 6 (2%) M. malmoense, 6 (2%) M. lentiﬂavum,
and 6 (2%) M. celatum. Only 2 isolates (0.5%) were identiﬁed as
M. marinum. Susceptibility testing revealed the following resistance
rates to clarithromycin and oﬂoxacin: M. avium 20% and 80%,
M. intracellulare 16% and 100%, M. fortuitum 70% and 66%,
M. chelonae 20% and 80%, respectively. M. kansasii was 67% resistant
to isoniazid and 22% to rifampicin. All M. gordonae isolates were found
susceptible to quinolones.
Conclusions: During the study period, NTM detection rate remained
constant. The NTM:MTB detection rate was estimated at 1:7 to 1:10.
Identiﬁcation to species level has been substantially improved by
molecular techniques. M. avium complex (MAC) was the most frequent
species. Interpretation of the results of susceptibility testing remains
controversial, and determination of NTM clinical signiﬁcance relies upon
good collaboration between clinicians and microbiologists.
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P2042 BacTec MGIT 960 system evaluation for susceptibility
testing of Mycobacterium tuberculosis against second-line
anti-tuberculosis drugs
S. Nikolaou, D. Papaventsis °, S. Karabela, E. Konstantinidou,
I. Marinou, A. Sainti, S. Kanavaki (Athens, GR)
Objective: The purpose of this study was to evaluate the BACTECTM
MGIT 960 system (Becton Dickinson, USA) for drug susceptibility test-
ing (DST) of multi-drug resistant (MDR) Mycobacterium tuberculosis
(MTB) clinical isolates to second-line anti-tuberculous drugs.
Methods: The accuracy of the MGIT 960 system was compared to
susceptibility testing by the proportion method in Lo¨wenstein-Jensen
(LJ) slants (Biomerieux, France and Lioﬁlchem, Italy). Forty seven
MDR MTB clinical strains isolated from previously untreated patients
were included (1 isolate/patient). For MGIT 960, testing concentrations
used were: Oﬂoxacin (OFL) 2 mg/ml, Rifabutin (RIF) 0.5 mg/ml,
Ethionamide (ETH) 5 ug/ml, Capreomycin (CM) 2.5 mg/ml. For LJ,
drug concentrations were: OFL 5 and 10 mg/ml, RIF 30 and 50 mg/ml,
ETH 20 and 30 mg/ml, and CM 20 and 40 mg/ml. Discordant results
were repeated by both methods. The ability to detect true resistance
(sensitivity), the ability to detect true susceptibility (speciﬁcity) for
MGIT 960, and agreement between the 2 methods were calculated. The
chi-square test was used to compare agreement ratios at a signiﬁcance
level of 95% cases.
Results: The prevalence of resistance to second-line anti-tuberculous
drugs of the 47 MDR MTB strains based on the LJ method was:
OFL 8.51–12.57%, RIF 12.77–27.66%, ETH 36.17–42.55%, CM 8.51–
17.02%. The MGIT 960 system showed sensitivities ranging from 50
to 100%, and speciﬁcities from 79.41 to 90.70%, for OFL, RIF, ETH
and CM, respectively. Overall agreement between MGIT 960 and the
LJ method was 80.61%. The two methods had 87.23% (k = 0.554,
MODERATE), 82.98% (k = 0.628, GOOD), 80.85% (k = 0.601, GOOD)
and 82.98% (k = 0.397, FAIR) agreement at +1 log2 dilutions for MICs of
OFL, RIF, ETH and CM, accordingly. At +2 log2 dilutions, agreement
remained the same for OFL, decreased for RIF and ETH (to 72.34%
(p< 0.05) and 78.72% (p> 0.05), respectively), and increased to 91.49%
(p< 0.05) for CM. The median time for obtaining susceptibility results
was 7.29 days (range 4.11–11.22 days).
Conclusions: This study shows that nowadays, the BACTECTM MGIT
960 system is useful for rapid and reliable drug susceptibility testing of
MDR MTB clinical isolates against second line anti-tuberculous drugs.
However, further standardization is needed in order to optimise the
clinical relevance of the results obtained.
P2043 Evaluation of the GenoType MTBDRPlus assay for the
diagnosis of tuberculosis and rapid detection of rifampin
and isoniazid resistance in clinical specimens
C. Cavusog˘lu °, D. Gursel, H. Bozkurt (Izmir, TR)
Objectives: Mycobacterium tuberculosis remains one of the most
signiﬁcant causes of death from an infectious agent. Several molecular
methods have been developed in recent years for the diagnosis of
tuberculosis and rapid detection of drug resistance in clinical specimes.
The Genotype MTBDR plus assay (Hain Lifescience GmbH, Nehren,
Germany) is a novel kit-based method for the detection of the most
common mutations in the M. tuberculosis rpoB, katG, and inhA genes.
The aim of this study was to determine the performance of the Genotype
MTBDRplus assay for diagnosis of tuberculosis and rapid detection of
rifampin and isoniazid resistance in smear-positive clinical specimens.
Methods: A total of 90 clinical specimens of 57 patients were included
in the study. The Genotype MTBDRplus assay was used according to the
instructions of the manufacturer. The results obtained by the Genotype
MTBDRplus assay were then compared with the results obtained by
culture and phenotypic drug susceptibility testing (DST).
Results: A total of 90 clinical specimens which 82 smear-positive and
8 smear negative were included in the study. Overall 80 interpretable
results were obtained for 90 specimens (88.9%) with readability rates
signiﬁcantly higher in clincal samples graded 4+, 3+, and 2+ compared
to 1+ (Table 1). Among the 80 interpretable clinical specimens obtained
from 47 patients, 71 clinical specimes obtained from 43 patients were
pansuspcetible, 5 clinical samples obtained from 2 patients had INHr and
RIFs pattern, 2 clinical samples obtained from 1 patient had INHr and
RIFr pattern, and 2 clinical samples obtained from 1 patient had INHs
and RIFr pattern. The overall rate of concardence between the results of
the MTBDRplus assay and those of the DST for the assessment of RIF
resistance was 97.3%. The overall rate of concordance between two tests
for assessment of INH susceptibility was 98.6%.
Conclusion: In conclusion, the test has a short turnaround time and
simultaneously provides the RIF and INH susceptibility pattern in 1
working day. Although the MTBDRplus assay could be a useful tool for
rapid identiﬁcation of RIF- and INH-resistant M. tuberculosis in smear
positive clinical samples, the test results must always be conﬁrmed by
drug susceptibility testing.
Table 1. MTBDRplus assay results according to the auramine-rhodamine
microscopy staining for the culture positive 90 clinical samples
MTBDRplus Number (%) of specimens
Test result* Smear 4+ Smear 3+ Smear 2+ Smear 1+ Smear-
negative
Total
MTBDRplus + 18 (85.7) 19 (100) 22 (88) 12 (70.6) 6 (75) 7 (85.6)
MTBDRplus ± 0 (0) 0 (0) 1 (4) 2 (11.8) 0 (0) 3 (3.3)
MTBDRplus − 3 (14.3) − 2 (8) 3 (17.6) 2 (25) 10 (11.1)
Total 21 19 25 17 8 90
*MTBDRplus + interpretable and concordant test results with DST; MTBDRplus ± interpretable and discordant
test results with culture and DST; MTBDRplus − invalid test results.
P2044 Detection of rifampin resistance mutations inMycobacterium
tuberculosis by TaqMan probes
V. Slizen °, L. Surkova, L. Titov, O. Zalutskaya, S. Zaker (Minsk, BY)
Steady tendency of increase in tuberculosis incidence is complicated by
alarming spread of multidrug resistant strains. Most of rifampin-resistant
strains of M. tuberculosis possess genetic alterations within an 81-bp
fragment of the rpoB gene that encodes the b-subunit of DNA dependent
RNA. Many different allelic variations have been detected within this
locus, and speciﬁc rpoB genotypes are known to be associated with
high-level rifampin resistance. Identiﬁcation of the importance of rpoB
and katG in antituberculosis drug resistance has led to the application
of a variety of rapid methods to detect mutations in these genes. The
aim of this study was to evaluate method for rapid detection of the
major mutations causing rifampicin resistance of M. tuberculosis using
real-time ampliﬁcation and TaqMan probes.
Methods: Forty four clinical isolates of multi drug resistant M. tuber-
culosis were studied and their mutation proﬁles in 81-bp region of rpoB
gene were characterized. For this purpose 411-bp PCR-products of rpoB
gene of M. tuberculosis were sequenced. Real-time PCR with TaqMan
probes was used to detect mutations in codons 516, 526, 531 of rpoB
gene.
Results: It was found as much as twenty types of mutations locating
in codons 507, 508, 510, 512, 516, 520, 521, 523, 525, 526, 531 with
the prevalence of mutations in triplets 510, 526, 523, 531 comprising
78.9% of all mutations. According to our sequencing data mutations
in codons 510, 526, 523, 531 encountered in 47.7, 45.5, 38.6, 29.5%
of isolates correspondingly. Mutations in codons 516, 526, 531 were
detected TaqMan technology in 9.1, 38.6, 27.2% isolates correspondingly
hence the sensitivity of the TaqMan assay was 89%, speciﬁcity 95%.
Conclusion: MDR M. tuberculosis belongs to “mutator” strains having
the universal mechanisms for generating whole-genome mutations; such
method as real-time PCR with TaqMan probes for SNPs detection in
the most frequently mutated codons allow to determine whether the
strain “mutator” or not. Selective pressure of anti-TB drugs induces
accumulation of resistance associated mutation and expansion of such
clones.
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P2045 Mutations in rpoB gene in rifampin-resistantMycobacterium
tuberculosis isolates identiﬁed in the West-Bohemian region
of the Czech Republic
J. Amlerova °, T. Bergerova, D. Cervena, J. Hrabak (Plzen, CZ)
Objectives: Laboratory of Mycobacteriology of the Department of
Microbiology of the Faculty of Medicine in Plzen serves the whole
West-Bohemian Region of the Czech Republic with ca 567 500 citizens
and two centers specialized in tuberculosis treatment. In the last years,
many new factories employed thousands foreign workers (usually from
the Far East) have been opened in this region. Therefore, there is a
permanent migration of the people in some cities. Interestingly, despite
these social-geographical characteristics, the rifampin resistance in the
Mycobacterium tuberculosis isolates seems to be low. The aim of this
study was to determine the resistance mechanisms in the rifampin
resistance isolates.
Methods: Since the February of 2004, the isolates of rifampin-
resistant M. turberculosis have been stored. Resistance to rifampin was
determined by a proportion method. A 305-bp region covering the 81-bp
rifampin resistance determining region of the gene of b-subunit DNA-
dependent RNA polymerase (rpoB) was ampliﬁed and sequenced.
Results: During the study period, 344 M. tuberculosis isolates were
identiﬁed. Ten isolates were found to be resistant to rifampin (2.91%).
Sequencing analysis of the rifampin resistance region revealed the single
mutation in codon 531 (Ser − Leu) in all resistant isolates.
Conclusions: Our data indicate that the resistance to rifampin in the
isolates collected in the industrial area of the Czech Republic is low.
The resistance mechanism was identiﬁed as a mutation in codon 531
responsible for the cross-resistance to rifamycin derivatives (rifampin,
rifapentine, rifabutin, and rifalazil). The typing based on insertion
sequence IS6110 analysis and restriction fragment length polymorphism
(RFLP) is ongoing.
This work was ﬁnanced by a research project grant MSM0021620819.
P2046 Assessment of GenoType MTBDRplus assay performance
compared to culture using respiratory and non-respiratory
samples in Scotland
A-L. Seagar °, A. Rayner, P. Claxton, I. Laurenson (Edinburgh, UK)
Objectives: The GenoType MTBDRplus (MTBDR+) assay (HAIN
Lifescience) was evaluated for rapid, direct detection of Mycobacterium
tuberculosis complex (MTBC) and simultaneous resistance to rifampicin
(RIF) and isoniazid (INH) in specimens using line-probe technology. The
MTBC detection and drug susceptibility results were compared to those
obtained by culture and Bactec MGIT 960.
Methods: 322 specimens (266 respiratory and 56 non-respiratory)
that were AFB-positive (n = 293) or had high suspicion of TB were
examined from June 2006 to November 2009. MTBDR+ testing was
performed once weekly as part of the routine reference laboratory
service. Additionally 96 MTBC cultures were extracted for INH and
RIF resistance testing only and the results compared to phenotypic
susceptibility results.
Results: The MTBDR+ assay was positive for MTBC in 182 specimens.
Compared to culture the sensitivity, speciﬁcity, positive and negative
predictive values for the MTBDR+ assay were 84.9%, 85.4%, 89.6%
and 79.3% respectively. 11 of 29 MTBC-culture positive specimens
not detected by MTBDR+ contained large numbers of AFB on
microscopy. 19 of 154 (12.3%) MTBC culture-positive respiratory
specimens produced negative MTBDR+ results. 10 MTBC culture-
negative respiratory specimens and 4 non-respiratory specimens that
gave positive results using the MTBDR+ assay were from known TB
patients. No specimens contained PCR inhibitors. Assay sensitivity for
MTBC detection was 87.7% for 266 respiratory specimens and 73.7%
for 56 non-respiratory samples.
163 of the 170 (95.9%) specimens with interpretable resistance results
and found to contain MTBC were sensitive to both RIF and INH. INH
mono-resistance was detected in 6 specimens and both RIF- and INH-
resistance was detected in a single specimen. The MTBDR+ resistance
results were conﬁrmed in all 122 cases where Bactec MGIT 960 results
were available. For the 96 culture extracts, 98.9% of MTBDR+ RIF
and 86.7% of INH resistance results concurred with the phenotypic
susceptibility results.
Conclusions: The MTBDR+ assay is appropriate for weekly batching
of small specimen numbers. Assay sensitivity was 87.7% for respiratory
specimens but reduced for non-respiratory specimens. 19 MTBC cases
‘missed’ using MTBDR+ require further investigation. Overall, the direct
RIF resistance results correlated well with BACTEC MGIT 960 but some
INH resistant strains may be missed.
MTBDRplus result Culture result
MTBC NEG MOTT Total
MTBC-POS 163 19 0 182
MTBC-NEG 29 39 72 140
Total 192 58 72 322
P2047 Evaluation of XpertMTB/RIF assay and ampliﬁed
Mycobacterium tuberculosis direct test in direct detection
of pulmonary M. tuberculosis complex
J.S. Lin °, C. Lin, R. Hsiao, L. Shih (Changhua, TW)
Objective: Nucleic acid ampliﬁcation test on respiratory samples
for rapid detection of Mycobacterium tuberculosis complex (MTBC)
aids to the early diagnosis of pulmonary tuberculosis. Recently, the
XpertMTB/RIF (XMTB; Cepheid, SunnyVale, CA) has been introduced
as a semi-quantitative nested real-time polymerase chain reaction in vitro
diagnostic test for rapid identiﬁcation of MTBC and rifampicin resistance
on pulmonary samples. The aim of this study is to compare the detection
sensitivity of pulmonary MTBC using MTB assay and the Ampliﬁed
Mycobacterium tuberculosis Direct test (MTD; Gen-Probe, Sandiego,
CA) against mycobacterial culture.
Methods: Clinical respiratory specimens submitted for MTD test were
enrolled. Only samples with a smear positive (one to two plus) for acid-
fast bacilli (AFB) were eligible for further testing. After MTD testing
and inoculation onto culture media, the rest of samples were kept frozen
at −70ºC until XMTB testing. Both MTD and XMTB assays were tested
once on each sample respectively. The mycobacterial culture used both
liquid and solid media and was regarded as a gold standard in this study.
Results: A total of 38 unrelated respiratory samples were recruited
for comparison. Of them, 27 were culture-positive and 11 were
culture-negative. When compared with mycobacterial culture, both
MTD and XMTB assays had the same detection sensitivity of
MTBC, i.e., 92.6% (25/27). The concordance rate between MTD and
MTB assays was 84.2%, i.e., six discrepant samples consisting of
MTD−/XMTB+/culture+ (n = 2), MTD+/XMTB−/culture+ (n = 2) and
MTD+/XMTB−/culture− (n = 2), respectively.
Conclusions: This preliminary study suggests that XMTB test is
comparable with MTD in terms of MTBC detection on AFB-positive
respiratory samples and aid to the early diagnosis of pulmonary
tuberculosis.
P2048 Diagnosing pulmonary tuberculosis in a low prevalence
setting − the Xpert MTB/RIF test
T. Bodmer °, A. Stro¨hle (Berne, Niederwangen, CH)
Objectives: Rapid detection of Mycobacterium tuberculosis (MTB) in
respiratory specimens is the key to breaking the chain of transmission
and initiating drug therapy. The novel Xpert MTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) simultaneously detects both MTB and rifampin
(RIF) resistance in sputum. We evaluated the assay’s ability to detect
MTB not only in sputa, but in all types of respiratory specimens.
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Methods: Beginning on the 7th September 2009 500 ml aliquots of
decontaminated sediments were tested, following clinical request, using
the Xpert MTB/RIF assay according to the manufacturer’s instructions.
All respiratory specimens were decontaminated (NALC); sediments were
examined by ﬂuorescence microscopy and cultured (35ºC/8 weeks)
on liquid and solid media. Mycobacteria were identiﬁed via partial
sequencing of the 16S rRNA gene and the GenoType® MTBC assay
(Hain Lifescience, Germany). Drug susceptibilities were assessed by the
Bactec MGIT 960 method (BD Diagnostics, Switzerland).
Results: To date, 231 specimens from 149 patients (mean, 1.58
specimens per patient) have been tested, sputum (n = 83); bronchial
secretions (n = 70); and broncho-alveolar lavage (n = 78). No sample
inhibition was observed. Four (1.7%) tests had to be repeated once due
to ERROR ﬂags. MTB was isolated from 6 (2.6%) specimens. Of these,
5 (2.2%) were positive by the Xpert MTB/RIF test (sensitivity, 83.3%;
C.I. 95%, 43.6–96.9). Four (1.7%) specimens yielded non-tuberculous
mycobacteria; none of these were positive by the Xpert test (speciﬁcity,
100%; C.I. 95%, 98.3–100). The NPV was 99.5% (C.I. 95%, 97.5–
99.9%); the PPV was 100% (C.I. 95%, 56.5–100). The assay was ﬂexible,
robust and readily integrated into the laboratory workﬂow taking 2 hours
to perform.
Conclusions: The Xpert MTB/RIF provides rapid and speciﬁc detection
of MTB in all types of NALC-decontaminated respiratory specimens.
The sensitivity of the assay was good. Further testing will allow a more
robust assessment of its potential to rule out transmissible TB on the
basis of a single test result. The assay’s role in the diagnosis of extra-
pulmonary TB should be assessed.
P2049 Comparison of polymerase chain reaction and Ziehl–Neelsen
staining with histopathologic ﬁnding in formalin-ﬁxed,
parafﬁn-embedded tissue specimens for diagnosis of
tuberculosis
S. Khazaei °, B. Izadi, J. Zandieh, A. Alwandimanesh, S. Vaziri
(Kermanshah, IR)
Objective: Even in the 21th century, Tuberculosis to be a problem
infecting about 1/3 of the world population. Rapid correct diagnosis is
necessary for Therapy. The aim of this study is to compare PCR to detect
Mycobacterial DNA on formalin-ﬁxed, parafﬁng-embedded tissues with
Ziehl–Neelsen Staining and Histopathologic Finding.
Methods: Parafﬁn blocks of the submitted specimens of the patients
clinically suspicious for tuberculosis or containing granuloma were
selected. Ziehl–Neelsen Staining & TB-PCR (IS6110 element) was
carried on. The results of tests were compared by using McNemar chi-
square test. Statistical signiﬁcance was accepted when the P value was
less than 0.05.
Results: 45 specimens were included in the study, 35 had granulomas
(19with caseous necrosis). Acid-fast bacilli were identiﬁed in 17
(37.8%). TB-PCR was positive in 16 (84%) with caseating granulomas,
11 (68.8%) with non-caseating granulomas & 6 (60%) without
granulomas. (P value = 0.59) (Table 1).
Comparison of three tests (PCR, Histopathology & Ziehl–Neelsen
staining)
Histopathology Ziehl–Neelsen staining PCR Sum, n (%)
Negative, n (%) Positive, n (%)
Without granulomas Negative 4 (40%) 4 (40%) 8 (80%)
Positive 0 (0%) 2 (20%) 2 (20%)
Sum 4 (40%) 6 (60%) 10 (100%)
Caseating granulomas Negative 3 (15.8%) 9 (47.4%) 12 (63.2%)
Positive 0 (0%) 7 (36.8%) 7 (36.8%)
Sum 3 (15.8%) 16 (84.2%) 19 (100%)
Non-caseating granulomas Negative 5 (31.1%) 4 (25%) 9 (56.3%)
Positive 0 (0%) 7 (43.8%) 7 (43.8%)
Sum 3 (31.3%) 11 (68.8%) 16 (100%)
Conclusions: TB-PCR on parafﬁn-embedded tissue is a potentially
useful approach for early, rapid and sensitive test for diagnosis of
tuberculosis. It is especially useful when granuloma is seen in tissue
section, while acid-fast stain is negative. There is on signiﬁcant
difference between PCR and histopathology ﬁnding. (P value = 0.59)
where PCR is not available, histopathology ﬁnding can be used for
detecting and conforming tuberculosis.
P2050 Clues to enhanced virulence in Mycobacterium tuberculosis:
mapping of IS6110 in Lisbon strains
J. Perdiga˜o °, C. Pinto, J. Moniz-Pereira, I. Portugal (Lisbon, PT)
Objectives: Tuberculosis (TB) is responsible for about 2 million
deaths worldwide. National TB control programs have to cope
with the enhanced virulence of some Mycobacterium tuberculosis
(M. tuberculosis) strains. It is the case in Lisbon Health region, where
a speciﬁc strain family, designated Lisboa family, is responsible for the
high number of multidrug and extensively drug resistant TB (MDR-
TB and XDR-TB, respectively) cases. Given the high prevalence of
such strains one may ask what genomic factors may be triggering such
high virulence and/or transmission. Genetic expression plasticity may
be conferred by the differential location of several genomic mobile
elements, of which the most notorious is insertion sequence IS6110.
This study intends to map these insertion sequences in a Lisboa family
strain to possibly infer on its phenotypic consequences.
Methods: The genomic position of IS6110 in a representative Lisboa
family strain, previously characterized by 24 loci Mycobacterial
Interspersed Repetitive Unit − Variable Number of Tandem Repeats
(MIRU-VNTR), was analyzed through Ligation-Mediated PCR and
Heminested Inverse PCR with restriction endonucleases and speciﬁc
primers directed at IS6110. Ampliﬁed fragments were characterized by
DNA sequencing analysis.
Results: In this study, using the above methodology, we were able to
map the location of six IS6110. The insertion sites were mapped to
positions 483580, 932202, 1998809, 2456838, 3480373 and 4183430
relative to M. tuberculosis H37Rv genome. Three of these insertion
sites were located at intergenic sites, while the others were inserted
in Rv0403c (mmpS1), Rv3113 and Rv3732 open reading frames. The
latter encode a hypothetical protein with unknown function, a possible
phosphatase and a membrane protein. On the other hand, two of the
intergenic IS6110 may inﬂuence the expression of the upstream genes.
Conclusion: We have identiﬁed the location of six IS6110 in the
genome of a Lisboa family strain, of which 5 may inﬂuence the strain’s
metabolism. The identiﬁcation of more insertion sites will allow a
better characterization of the inﬂuence of these mobile elements in the
metabolism and adaptation of these strains. Further search for other
insertion sites is ongoing.
P2051 Rapid simultaneous detection of Mycobacterium tuberculosis
and Beijing/W genotype directly from clinical respiratory
specimens
E.T. Leung °, M. Ip, N. Lee, L. Zheng, E.W. Chan, R.C. Chan (Hong
Kong, HK)
Objective: Fighting tuberculosis is a challenge and a major public
health concern worldwide. Recent clinical and epidemiological studies
have highlighted the virulence of Mycobacterium tuberculosis (MTB)
Beijing/W strains. Beijing/W strains have evolved unique properties,
including the abilities to acquire drug resistance more frequently, to
disseminate more efﬁciently, and to evade the protective effect of BCG
vaccination. This study aims to develop a rapid, sensitive, reliable and
high throughput protocol which has the potential for routine clinical
identiﬁcation of MTB, with simultaneous differentiation of Beijing/W
strain type, by using an optimized DNA extraction method and multi-
probe multiplex quantitative PCR.
Methods: Three different sizes/materials of beads (200um glass beads,
900£gm glass beads and 0.1mm zirconia beads) for mycobacterial cell
lysis and four different DNA puriﬁcation methods (Chelex-100 resin,
QIAgen DNA mini kit, QIAgen viral DNA/RNA kit, and Invitrogen
MyOne SILANE magnetic particles with in-house formulated buffers)
were compared for their sensitivities in capturing minute quantities
of MTB DNA from clinical specimens. New primers and Taqman
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probes were designed for simultaneous ampliﬁcation of MTB IS6110
gene, MTB RD105 (Beijing/W identiﬁcation), and human B-globin
gene (internal positive control). Speciﬁcities of primers and probes were
tested. Quantitative PCR conditions and component concentrations were
optimized.
Results: The combination of using 200um glass beads and Invitrogen
magnetic particles with in-house formulated buffers gave the highest
sensitivity. The primers and probes had no ampliﬁcation with
DNA extracts from non-TB clinical specimens and non-tuberculosis
mycobacterium isolates. The detection limit of this protocol is 10 copies
of IS6110, which corresponds to approximately one H37Rv bacillus.
Addition of RD105 and B-globin primers has no interference on the
sensitivity and speciﬁcity. The turnaround time for detection of MTB
from specimen is approx. 7 hours.
Conclusions: The protocol developed provides a rapid, sensitive and
reliable reference to physicians while waiting for the traditional culture
results. The method is more affordable in comparison with any TB
diagnosis kits currently in the market. This protocol has the potential
to be widely adopted in clinical laboratories worldwide.
P2052 Rapid detection of ciproﬂoxacin resistance in Mycobacterium
tuberculosis clinical isolates by two colorimetric assays
E. Ruh °, H.Y. O¨cal, P. Yurdakul, Z. Saribas, A. Alp (Ankara, TR)
Objective: New diagnostics including rapid drug susceptibility tests are
attractive for tuberculosis research. Colorimetric assays have previously
been used for rifampin and isoniazid susceptibility testings. In this
study, we searched the efﬁciency of two colorimetric assays using
tetrazolium violet (TV) and resazurin (RES), in terms of rapid detection
of ciproﬂoxacin resistance in M. tuberculosis clinical isolates.
Methods: Thirty isolates were included in this study. Fifteen isolates
were tested for TV assay, and 15 were tested for RES assay. The tests
were performed in four sets (day 5, 7, 10 and 12) in order to optimize
the incubation period. For each isolate, an inoculum of 2 McFarland
turbidity was prepared in Middlebrook 7H9 media. One mililiter from
these suspensions was transferred into new sterile tubes. Then, 1ml from
4 micrograms/ml ciproﬂoxacin stock solution was added into these tubes
in order to achieve a ﬁnal breakpoint value of 2 micrograms/ml and 1
McFarland of inoculum. In the ﬁrst assay, 100 microliters of TV were
added into the control and the drug containing tubes. After incubation
for 4 hours, 50 microliters of 0.1 N HCL were added into the tubes.
These mixtures were re-incubated for one hour and any change in colour
into purple was recorded as bacterial growth. In the second assay, 100
microliters of RES were added into the control and the drug containing
tubes. After an overnight incubation, any change in colour into pink
was recorded as bacterial growth. The results were compared with those
obtained from agar proportion method.
Results: For both of the two assays, no change in colour occured on
day 5. Regarding the bacterial growth, changes in colours in the control
tubes were detected on day 7. However, three of the isolates tested for
TV and 5 of those tested for RES showed only a little change in colour.
These isolates successfully changed the colour of the test media on day
10 and 12. The changes in the colour of drug containing media were
recorded as resistance to ciproﬂoxacin and these results matched with
those obtained from agar proportion method.
Conclusion: In this study, we showed that, the 7th day of incubation
gives important information on bacterial growth and resistance, but in
some cases, this should be supported by a further 10th or 12th day
incubation. Our results suggest that TV and RES assays can be used
for rapid detection of bacterial growth and ciproﬂoxacin resistance in
tuberculosis.
P2053 Isolation of non-tuberculous mycobacterium in patients
with suspected pulmonary tuberculosis in Korea
S.H. Lee °, K.H. Song, M.H. Kim, L.S. Park, K.H. Choi (Seoul, KR)
Objectives: In recent, prevalence of pulmonary nontuberculous my-
cobacterium (NTM) infection has been increased in Korea. The aim of
this study was to assess the prevalence of NTM infection and each type
of the NTM species in patients with suspected pulmonary tuberculosis
in Korea in which was a high prevalence area for mycobacterium
tuberculosis (MTB).
Methods: 44,789 specimens were cultured on Lowentein-Jensen media
between January 2007 and Jun 2009. Positive cultures were analyzed
using acid fast bacilli (AFB) stain and conventional or real-time PCR
methods with Cobas Taqman 48 (Roche Diagnosticsm, Mannheim,
Germany) in order to differentiate pulmonary NTM from MTB. Each
strain of the NTM species was identiﬁed by the Line probe assay
(LPA) (GenoType Mycobacterium CM/AS kit, Hain-Lifescience GmbH,
Nehren, Germany). We evaluated the prevalence of pulmonary NTM
disease in all specimens and its incidence rates were compared according
to each year, sex and age range. Each strain was analyzed for the NTM
species identiﬁed from the sputum specimens in 2009.
Results: 4,890 of 44,789 (10.9%) specimens were positive for culture.
The NTM species were isolated in 561 (11.5%). Rates of NTM positive
cultures were 10.7% (184/1723) in 2007, 13.1% (251/1911) in 2008, and
10.0% (126/1256) in half of 2009. Frequency of NTM disease increased
signiﬁcantly in old age and male groups: highest in the 70−79 year old,
66.0% in male versus 44.0% in female. The strains of the NTM species
were as follows: M. intracellulare (n = 30, 31.9%), M. avium (n = 13,
13.8%), M. abscessus (n = 12, 12.8%), M. gordonae and M. peregrinum
(n = 10, 10.6%), M. fortuitum (n = 7, 7.4%), M. kansasii (n = 6, 6.4%),
M. chelonae (n = 5, 5.3%), and M. szulgai (n = 1, 1.1%).
Conclusion: Culture positive rate is about 10% in patients with suspected
pulmonary tuberculosis and the NTM species are isolated above 10% of
positive cultures. Therefore, it may be important to differentiate MTB
from NTM for proper treatment and management. The LPA is very
precise and convenient method for NTM identiﬁcation.
P2054 Analysis of prevalent Mycobacterium tuberculosis strains in
the United Kingdom: detection, distribution and expansion
of MIRU-VNTR proﬁles containing high numbers of isolates
J. Evans °, S. Gardiner, G. Smith, P. Hawkey (Birmingham, UK)
Objectives: Universal DNA ﬁngerprinting of M. tuberculosis strains has
been utilised previously in population-based transmission studies and
outbreak detection. This 4 year study describes the distribution and
expansion of large clusters deﬁned by MIRU-VNTR (Mycobacterial
Interspersed Repetitive Units containing Variable Number Tandem
Repeats) typing with the aim of identifying expanding clusters of
M. tuberculosis earlier and directing public health control efforts and
resources.
Methods: All M. tuberculosis isolates (n = 4,207) referred to the Health
Protection Agency Midlands Regional Centre for Mycobacteriology from
2004−07 were typed by MIRU-VNTR using the 3 ETR and 12 MIRU
loci on a WAVE(R) System. BioNumerics v5.1 was used to analyse the
distribution and expansion of MIRU-VNTR clusters.
Results: Within the 4,207 isolates, 439 clustered MIRU-VNTR proﬁles
containing 2,575 isolates were identiﬁed. Proﬁles containing paired
isolates accounted for 196/439 (45%) of all clusters and 392/4,207 (9%)
of all isolates. There were 127 (29%) clusters containing 5 isolates
which contained 1,779 (43%) isolates. Clusters containing 2−17 isolates
accounted for 415/439 (95%) of all clustered proﬁles and 1,1544/4,207
(37%) isolates with the largest 5% of all clusters containing 24 MIRU-
VNTR proﬁles which varied from 19–126 isolates in size and contained
1,027/4,207 (24%) of all isolates. In clusters that reached 5 isolates
within 2 years, the ﬁrst two strains were identiﬁed within an average
of 4.04 months (95%CI: 3.11–4.97) of each other whereas the ﬁrst
two strains in clusters that did not reach 5 isolates within 2 years were
identiﬁed within 12.12 months (95%CI: 10.94–13.29) of each other.
Conclusion: M. tuberculosis MIRU-VNTR proﬁles normally occur in
small-medium sized clusters with few proﬁles exhibiting rapid expansion
rates to reach very high numbers of isolates. These expanding clusters
more often have a second isolate appear more rapidly (4 versus 12
months), thus potentially allowing early identiﬁcation and control.
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P2055 Deletion and single nucleotide polymorphism typing of
Mycobacterium tuberculosis Lisbon family strains in Portugal
J. Perdiga˜o °, C. Silva, I. Portugal (Lisbon, PT)
Objectives: Multidrug and extensive drug resistant tuberculosis poses
a very serious threat for public health. Lisbon Health Region has one
of the world’s most serious situation regarding this problem. Such, is
the result of a continued circulation of an endemic and predominant
strains of a particular genetic family − Lisboa family. Little is known
regarding the phylogeny, relative virulence and genetic background of
these strains. The loss or deletion of speciﬁc genomic regions constitutes
the most important way by which Mycobacterium tuberculosis diverges
and adapts. Several deletions, named Regions of Difference (RD), have
already been described and associated with phyllogeographic lineages.
Alternatively, single nucleotide polymorphism (SNP) analysis allows
a more precise positioning in the global Mycobacterium tuberculosis
phylogeny. The characterization of Lisboa family in this manner may
elucidate its origin and perhaps be helpful in explaining its high
prevalence.
Methods: Three representative clinical isolates of different genetic
clusters of Mycobacterium tuberculosis (M. tuberculosis) strains
circulating in Lisbon Health Region were screened for the presence of 16
distinct RDs. Deletion detection was performed by PCR carried out using
primers ﬂanking each RD. Conﬁrmation was performed by sequencing
analysis. SNP analysis was performed through the analysis of 9 SNP
regions, ampliﬁed by PCR and characterized by sequencing analysis.
Results: All three isolates were found to possess four of the tested
deletions: TbD1, pks15/1, RD174 and RDRIO. It was not possible to
discriminate between the strains using this deletion typing approach.
However, it was possible to infer on the phylogeography of these strains.
The presence of TbD1 and pks15/1 deletion positions the strains in the
modern and Euro-American lineage, respectively. On the other hand,
RD174 suggests that the analyzed strains are related to the West-African
sub-lineage.
SNP analysis revealed that all strains under analysis belong to SNP
Cluster Group (SCG) 5.
Conclusion: The present study points toward the fact that Lisboa
strains and others circulating in Lisbon belong to modern lineages of
M. tuberculosis, speciﬁcally a widespread lineage very prevalent in West
African countries. Also, the position of Lisbon-circulating strains in the
global SNP phylogenetic tree became established. This study therefore
reveals more on Lisboa family’s origin and genomic distinctiveness.
P2056 Evidences for scanty spread of Mycobacterium tuberculosis
Beijing genotype in the Balkan Peninsula
S. Panaiotov °, E. Bachiiska, V. Levterova, N. Brankova, S. Tafaj,
V. Katalinic-Jankovic, M. Zolnir-Dovic, R. Durmaz, T. Kantardjiev
(Soﬁa, BG; Tirana, AL; Zagreb, HR; Golnik, SI; Malatya, TR)
Objectives: To search evidences for spread of Mycobacterium tubercu-
losis Beijing genotype in the Balkan Peninsula.
Methods: Spoligo- and MIRU-VNTR typing was applied for typing
of M. tuberculosis Beijing genotype in strains collected across the
Balkan Peninsula. Personal research data, spoligo- and MIRU-VNTR
data available in SpolDB4 database and publications were the sources
for data collection of M. tuberculosis genotypes in the Balkan Peninsula.
Results: Strains collected from Albania (100), Bulgaria (329), Croatia
(2200) and Slovenia (1250) were typed by spoligotyping and MIRU-
VNTR. M. tuberculosis Beijing genotype was not identiﬁed, except for
four strains isolated from three Albanian patients, one Russian immigrant
in Croatia and one Chinese woman working in Slovenia. Published data
for Greece do not give evidences for existence of Beijing genotype in
the country. No Beijing genotype strains are found in Bulgaria, Romania
and Serbia. Beijing genotype was found in Istanbul, Turkey where 4069
strains were typed. The prevalence rate was 1.13% and these strains
were carried over from countries of the former Soviet Union. On Asian
Turkey, the Beijing genotype is similar to that obtained from Istanbul.
Conclusions: Our supposition that Beijing genotype was recently
introduced in the Balkan peninsula (Albania, Croatia, Slovenia) is
supported by the facts that in the Balkan countries Beijing genotype
is not or rarely detected and most often is carried over from recent
migrations. In the near past (1960s-80s) China and Albania had tight
political, commercial and cultural relations. Albanian isolates with
Beijing genotype have intrafamilial transmission between brothers-in-
law. They both lived in a city where a steel factory was built by
Chinese specialists. There are no evidences for spread of Mycobacterium
tuberculosis Beijing genotype in Bulgaria, Greece, Croatia (with one
immigrant exception), Romania, Serbia and Slovenia (one Chinese
immigrant). There are no data for Macedonia.
Natural resistance of the local population to Beijing genotype could be
supposed. Environmental and cultural factors preventing adaptation of
the Beijing genotype to the population could be supposed too. Although
our results do not provide direct evidence for resistance of the Balkan
populations to M. tuberculosis Beijing genotype, it does suggest that
associations between host and parasite populations are sufﬁciently stable
for such resistance/adaptation to evolve.
P2057 Analysis of the role of genes ethA, ethR, ndh, mshA, inhA
and the inhA-promoter in resistance to ethionamide, a
second-line antituberculosis drug
F. Brossier °, N. Veziris, V. Jarlier, W. Sougakoff (Paris, FR)
Objectives: Ethionamide (ETH) is a prodrug which is activated by an
enzyme (EthA) and targets the InhA protein involved in biosynthesis
of the mycobacterial cell wall. Resistance to ETH has been previously
reported to be linked to mutations in genes ethA and its transcriptional
regulator ethR, as well as in inhA and its promoter inhA-pro. More
recently, two additional genes have been suggested to be involved in
resistance to ETH: ndh encoding a NADH dehydrogenase and mshA
encoding an enzyme involved in the biosynthesis of mycothiols. Our
goal was to investigate the presence of mutations in these genes in a set
of clinical isolates showing different levels of resistance to ETH.
Methods: 87 M. tuberculosis clinical strains collected in 2003–2004
at the National Reference Center for Mycobacteria were included, 47
ETH-resistant (ETH-R), 24 ETH-susceptible (ETH-S) and 16 showing an
intermediate level of resistance to ETH (ETH-I). The drug susceptibility
testing was performed on Lowenstein-Jensen medium with the standard
proportions method. The genes ethA, ethR, inhA, inhA-pro, ndh and
mshA were sequenced.
Results: Of the 47 ETH-R strains, 23 were mutated in ethA and/or ethR,
and 29 in inhA and/or inhA-pro (14 in both). The 9/47 strains without
mutation in these genes were shown to have no mutation in ndh and
mshA. Regarding the ETH-I strains, 7/16 were mutated in ethA, while
wild-type ndh and mshA genes were found in 9/9 and 8/9, respectively,
of the ETH-I isolates showing no mutation in ethA/ethR, one strain
having a N111S mutation in mshA. Finally, of the 24 ETH-S strains, 23
had no mutation in ethA-ethR and inhA/inhA-pro, one displaying a rare
mutation (−47 g→ c) in inhA-pro.
Conclusions: These results strongly suggest that ndh and mshA are not
implicated in resistance to ETH in clinical strains of Mycobacterium
tuberculosis. In 81% of the ETH-R M. tuberculosis clinical isolates
analyzed in the present study, resistance to ETH resulted from the
combination of mutations (1) in ethA-ethR and inhA-pro and (2) in inhA
and inhA-pro. In the ETH-I strains, the intermediate level of resistance
to ETH was mainly associated with mutations in ethA (7/16) which
were all different from those found in the ETH-R isolates. For 17/63
ETH-R or ETH-I strains, the mechanism of resistance to ETH remained
unknown as no mutation was found in ethA, ethR, inhA-pro, inhA, ndh
and mshA, highlighting the complexity of the mechanisms of resistance
to ETH in M. tuberculosis.
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P2058 Clinical usefulness of rpoB gene mutation analysis in
tuberculous lymphadenitis
K.T. Kwon °, D.Y. Song, J.Y. Park, J.H. Kim, R.S. Yeol (Daegu, KR)
Background: Tuberculous lymphadenitis (TL) is the most common
extra-pulmonary tuberculosis and frequently shows paradoxical response
(PR) during the treatment. Differential diagnosis between PR and
treatment failure is not easy without drug susceptibility test (DST). But,
it is rarely performed and delayed due to low culture yield and long
process. RpoB gene mutation analysis is rapid detection method for
rifampin resistance but has not yet been evaluated in TL. To evaluate
clinical usefulness of rpoB gene mutatinon analysis in TL, we performed
direct sequencing for rpoB gene with ﬁne-needle aspirates (FNAs) from
lymph node (LN).
Materials and Methods: A total of 24 cases which revealed positive
results upon the polymerase chain reaction (PCR) for M. tuberculosis
in FNAs from LN were included. With these cases, direct sequencing
for rpoB gene was performed. Also, clinical and microbiologic data
were reviewed retrospectively and investigated with rpoB gene mutation
results.
Results: A total of 18 evaluable rpoB gene sequences were obtained.
Six evaluable rifampin susceptibility data (1 resistance, 5 susceptibilities)
were compatible with mutation analysis. Two (11%) of 18 cases showed
rpoB gene mutation. One case with D516Y mutation showed rifampin
resistance in DST. The other case with S522A mutation needs 2nd
line treatment and percutaneous drainage for tuberculous psoas abscess.
Among 16 cases without mutation, 15 cases (93.75%) were cured with
1st line anti-tuberculous drug and 9 cases (56.2%) showed PR. Among
them, 4 cases (44.4%) were treated with steroid, 2 cases (22.2%) were
treated with surgical drainage.
Conclusions: It can be rapid and effective to detect rifampin resistance
and to manage the clinical course of TL by using rpoB gene mutation
analysis with FNAs from LN.
P2059 Comparison of the BacTec MGIT 320 to the BacTec MGIT
960 for the growth, detection and susceptibility testing of
Mycobacterium tuberculosis
P. Beaty °, E. Carrese, M. Warns (Sparks, US)
Objective: Critically compare the BACTEC MGIT 320 to the BACTEC
MGIT 960. The MGIT 320 is a new lower capacity instrument for the
growth and detection of M. tuberculosis and antimicrobial susceptibility
testing using the BACTEC MGIT reagents.
Method: Growth and detection was evaluated in a paired study that
included three strains of M. tuberculosis. The study design included
both instrument position and microbial detection limit as variables. Three
dilutions (highest dilution approximately 0 to 10 CFU) per strain were
tested. There were 16 replicates per dilution distributed throughout the
MGIT 320 or MGIT 960 drawer. A total of 144 paired cultures were ana-
lyzed for recovery and time to detection (Wilcoxon Parametric Analysis).
Susceptibility testing was compared using one strain in a MGIT SIRE
susceptibility test and two strains in a PZA comparison test. A total of 48
AST sets were distributed evenly in the MGIT 320 or MGIT 960 drawer.
Results: There was no difference in total recovery with a McNemar
Pvalue = 1. The recovery rate for the MGIT 320 and the MGIT 960
was 93.7 and 93.0%, respectively. All recovery failures were with the
highest dilution (0 to 10 CFU). The mean TTD in the MGIT 320 and
the MGIT 960 was 355 and 365 hours, respectively. The median time to
detection difference was 10 hours (N = 131 paired cultures) earlier in the
MGIT 320. The percent agreement for all SIRE tests was 99.6%. The
difference was a borderline streptomycin determination (43 versus 38%
of streptomycin tests determined resistant, 320 and 960 respectively).
There was a mean difference in time to result of the SIRE sets of 7 hours
(earlier in the MGIT 320). There was 100% agreement and no time in
protocol differences for the 32 PZA tests between the two systems. There
were no observable differences in growth characteristics based on total
Growth Unit (GU) accumulation in the test sets.
Conclusion: The data demonstrate that the MGIT 320 and the MGIT
960 systems are functionally equivalent for growth, detection and
antimicrobial susceptibility testing of M. tuberculosis.
P2060 Comparison of INNO-LiPA Rif. TB, genotype MTBDRplus,
PCR-RFLP and DNA sequencing for detecting
multidrug-resistant Mycobacterium tuberculosis isolates
M.A. Mokaddas °, N. Al Mutairi, S. Ahmed (Dasma, KW)
Objective: Rapid identiﬁcation of multidrug-resistant (resistant at least
to rifampicin, RMP and isoniazid, INH) strains of Mycobacterium
tuberculosis (MDR-TB) is crucial for early institution of appropriate
therapy and to limit further transmission. The performance of two line
probe assays (INNO-LiPA Rif. TB and Genotype (g) MTBDRplus),
PCR-restriction fragment length polymorphism (PCR-RFLP) and DNA
sequencing was compared for rapid detection of RMP and INH resistance
conferring mutations in hot-spot region of rpoB (HSR-rpoB), katG
codon 315 (katG315) and inhA regulatory region (inhA-RR) in MDR-TB
strains.
Methods: Eighty-two phenotypically documented MDR-TB and 43
pansusceptible M. tuberculosis strains isolated from 99 patients in
Kuwait during 2001–2008 were analyzed. Mutations in HSR-rpoB and
katG315 and/or inhA-RR were detected by INNO-LiPA, gMTBDRplus,
PCR-RFLP and DNA sequencing of regions of interest ofM. tuberculosis
genome. Strain relatedness was determined by PCR-based ﬁngerprinting
methods and genetic group analysis.
Results: All 43 pansusceptible strains contained wild-type sequences in
HSR-rpoB, katG315 and inhA-RR. The RMP resistance was detected in
94% (77/82) and 95% (78/82) of MDR-TB strains by INNO-LiPA and
gMTBDRplus assay, respectively. Two isolates with insertion514TTC
were detected as RMP susceptible by INNO-LiPA, 1 isolate with L533P
mutation was detected as RMP susceptible by gMTBDRplus while 3
isolates were detected as RMP susceptible by both the assays. Two of
the latter 3 isolates contained a novel I572F mutation that is outside
the HSR-rpoB. Rate of concordance of INNO-LiPA and gMTBDRplus
assays for RMP resistance detection with HSR-rpoB sequencing was
96% (120/125) and 97% (121/125), respectively. INH-resistance was
detected in 72% (59/82), 72% (59/82), 27% (22/82) and 93% (76/82) of
MDR-TB strains by katG315 PCR-RFLP, katG315 sequencing, inhA-RR
sequencing and gMTBDRplus assay, respectively. Majority of MDR-TB
isolates in Kuwait were genotypically distinct strains.
Conclusions: The gMTBDRplus assay alone while three other tests
combined (INNO-LiPA or HSR-rpoB sequencing, katG315 PCR-RFLP
or katG315 sequencing and inhA-RR sequencing) were required to
accurately detect MDR status of ~87% (71/82) of MDR-TB strains. The
high cost of gMTBDRplus assay is the main limitation of this test for
rapid detection of majority of MDR M. tuberculosis strains for proper
management of the disease when MDR-TB is suspected.
P2061 Cluster association of gyrA mutations in extensively
drug-resistant tuberculosis isolates from Lisbon, Portugal
J. Perdiga˜o, R. Macedo, L. Brum, I. Portugal ° (Lisboa, PT)
Objectives: Previous reports have shown that a high rate of extensively
drug-resistant (XDR) tuberculosis (TB) exists in Lisbon Health Region.
One of the factors contributing to this high rate is the high prevalence
of speciﬁc clusters. Moreover, Portugal has the highest rate of
ﬂuoroquinolone prescription rate in the European Union. Such, high
usage may be selecting Mycobacterium tuberculosis strains resistant
to ﬂuoroquinolones in infected patients. In this study we intend to
characterize which mutations are conferring ﬂuoroquinolone resistance
in Lisbon Health region and eventually correlate them with speciﬁc
clusters.
Methods: We have analyzed 26 ﬂuoroquinolone-resistant M. tubercu-
losis strains, all of which XDR-TB, isolated in Lisbon Health Region
during the year of 2005. An internal fragment of gyrA gene of each
isolate was ampliﬁed by PCR and characterized by sequencing analysis.
S614 20th ECCMID, Posters
All strains were also genotyped by 12 loci Mycobacterial Interspersed
Repetitive Unit − Variable Number of Tandem Repeats (MIRU-VNTR).
Results:We have found three different missense mutations in gyrA gene:
S91P, D94A and D94G. The most common mutation was S91P, which
was present in 11 isolates. One isolate did not have any mutation. The
26 isolates were divided by two MIRU-VNTR clusters: Lisboa3 and Q1.
Both have been previously associated with XDR-TB. Mutations S91P
and D94G were associated with Lisboa3 cluster, while mutation D94A
was associated with Q1.
Conclusion:We veriﬁed that an association exists between the mutations
conferring ﬂuoroquinolone resistance and genotype. Such mutations may
be helpful in determining a clinical isolate’s genotype and possible
association with XDR-TB. We also verify that given the high clonality
of the analyzed isolates, active XDR-TB transmission is taking place.
P2062 Mycobacterium tuberculosis Beijing family strains: analysis
of molecular typing and of the epidemiological and clinical
factors associated with an emerging lineage in the urban
setting of Milan, 1996–2007
F. Zanini °, M. Carugati, C. Schiroli, A. Lombardi, E. Mazzola,
L. Codecasa, A. Gori, F. Franzetti (Milan, Monza, IT)
Objectives: Among the most prevalent Mycobacterium tuberculosis
strains, the Beijing genotype raises major concern because of its global
spreading, hyper-virulence and association with multiple drug resistance
(MDR). The aim of the study was to evaluate the role of Beijing
family in the urban setting of Milan from 1996 to 2007 and to identify
epidemiological and clinical factors associated with this genotype strain.
Methods: 2401 culture positive tuberculosis (TB) cases diagnosed in
Milan and surrounding area were included. Epidemiological, microbi-
ological and clinical data were assessed. The genotypic proﬁle of the
clinical isolates was obtained by spoligotyping method. Mycobacterial
interspersed repetitive unit (MIRU) typing was executed on Beijing
isolates to assign MIRU type (MT). The c2 test and a multivariate logistic
regression model were used to identify predictors signiﬁcantly associated
with Beijing strains.
Table 1. Multivariate logistic analysis of epidemiological and clinical
factors associated with Beijing related tuberculosis
Epidemiological and clinical features AOR§ (95% CI)#
Gender
Female 1*
Male 1.4 (0.77–2.54)
Age group
40 yr 1*
40 yr 1.24 (0.59–2.58)
Geographic area of patient’s born
Italy 1*
China 118.0 (43.7–321.0)
Asia (without China) 6.25 (2.11–18.6)
Eastern Europe 4.97 (1.66–14.9)
Southern America 3.45 (1.31–9.09)
Africa 1.48 (0.41–5.31)
Site of tuberculosis
Pulmonary 1*
Extra-pulmonary 0.40 (0.05–3.21)
Lymph nodes 1.62 (0.64–4.13)
Disseminated 1.03 (0.43–2.49)
Drug susceptibility of clinical isolates
Susceptible 1*
Other resistance 0.83 (0.36–1.89)
MDR 4.07 (1.81–9.15)
HIV co-infection
Absent 1*
Present 2.31 (0.92–5.76)
§Adjusted odds ratio (AOR), #Conﬁdence interval (CI), *Reference
category.
Results: Beijing family accounted for 67 isolates (2.8% of the total).
From 1996 to 2007 its prevalence raised from 1.8% to 3.2% (p=.104).
At the univariate analysis, the Beijing group displayed a lower average
age at the diagnosis (p< 0.0001) and a higher proportion of foreign
patients (p< 0.0001) and MDR cases (p = 0.009). The multivariate
logistic analysis (Table 1) conﬁrmed that foreign origin increased
signiﬁcantly the risk of having a Beijing related TB [AOR= 6.0
(95%CI:2.5–13.4)]: the highest values were observed among Chinese
[AOR= 118.0 (95%CI:43.7–321.0)] and Eastern European patients
[AOR= 4.9 (95%CI:1.7–14.9)]. MDR [AOR=4.1 (95%CI:1.8−9.1)]
and HIV infection were also independently associated with Beijing
genotype but the latter without a signiﬁcant statistical difference
[AOR= 2.3 (95%CI:0.9−5.7)]. Sixty-six isolates were grouped in 28
MIRU types. The predominant MT resulted the founder strains MT11
and MT33, always present during study period and including isolates
belonging to a wide range of nationality. One type not previously
identiﬁed (called S10) was detected exclusively in four Italian patients.
Conclusion: Beijing family was an emerging lineage in metropolitan
area of Milan and it displayed to be predominant in young foreign people,
causing preferentially lymph-nodal and disseminated TB. Foreign born
origin and MDR pattern were signiﬁcantly associated to Beijing related
TB. The Beijing MIRU types founders conﬁrmed to be overriding and
related to geographical origin of patients.
P2063 Comparison of rapid drug susceptibility tests for
Mycobacterium tuberculosis clinical isolates
M. Aranzamendi Zaldumbide °, C. Fernandez Mazarrasa,
L. Martı´nez-Martı´nez, J. Agu¨ero Balbin (Santander, ES)
Objectives: Drug resistant tuberculosis is a growing concern worldwide.
Clinical microbiology laboratories should provide reliable results
on susceptibility testing to assess effective treatment schemes and
appropriate intervention measures to control the disease. In the present
study, the efﬁciency of Etest and genotypic detection of isoniazid (INH)
and rifampin (RAMP) resistance was evaluated by comparing results to
those of the multiple proportion method as a reference.
Methods: 100 Mycobacterium tuberculosis strains were selected from
a stock collection of clinical isolates (January 2000–July 2009). CMI
was determined by Etest in 50 strains known to be INH-R (n = 42) or
INH+RAMP (n = 8) and in 50 susceptible strains. The genome regions
associated with INH-R (including the codon 315 of the katG gene and
the fabG1(mabA)-inhA regulatory region) and RAMP-R (81-bp hot spot
region of the rpoB gene called RRDR) were ampliﬁed in all the strains
by PCR and the DNA sequences were studied.
Multiple proportion method
INH RAMP
Etest VME rate 38% 0%
ME rate 0% 1.08%
mE rate 19% 1%
CA rate 81% 99%
Genotypic detection VME rate 42% 0%
ME rate 0% 0%
mE rate 21% 0%
CA rate 79% 100%
Results: Very Major Error (VME) rates for INH susceptibility testing
were 38% for Etest and 42% in genotypic detection with Category
Agreement (CA) rates of 81% and 79%. In contrast, CA rates for Etest
and genotypic detection were 99% and 100% respectively, for RAMP.
Mayor Error(ME) rate for RAMP using Etest was 1.08%. Overall a
signiﬁcant number of isolates harbouring the mutation S315T in the katG
and the total of multiresistant isolates showed high-level resistance (INH
>256mg/L, RAMP >32mg/L). The results are summarized in Table 1.
Conclusions: Our results demonstrated a low sensitivity of these
methods to detect INH-R strains, and points to the need of ﬁnding out
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new phenotypic methods and other mutant regions. On the other side,
conﬁrm the feasibility of implementing both methods as fast and accurate
alternatives for assessment of RAMP-R, which in turn is a marker for
multiresistance.
P2064 Characterization of puriﬁed recombinant ESAT6, CFP10
and ESAT6/CFP10 fusion protein of Mycobacterium
tuberculosis C for detection of human tuberculosis in Iran
M. Hemmati °, Z. Mostafavi-pour, A. Seghatoleslam, M. Rasti,
S. Ebadat (Shiraz, IR)
Mycobacterium tuberculosis (M.tb) is major cause of human tuberculosis
(TB) which kills millions of people annually. The two secretory proteins
of M.tb that recently have been focused on, are Early secretory antigenic
target 6 (ESAT6) and Culture ﬁltrate protein 10 (CFP10). These proteins
are potent T-cell antigens recognized by over 70% of tuberculosis
patients. In addition the two proteins are dominant g interferon (IFN-g)-
induced antigens which has led to their proposed usage as diagnostic
reagents for Human tuberculosis via ELISPOT (Enzyme Linked Immuno
Spot) assay. To see whether each one of these proteins or the combination
can detect M.tb from nontuberculosis mycobacteria with high speciﬁcity
in biological ﬂuids, we produced the proteins from M.tb C strain that was
provided by Razi Institute. esat6, cfp10 and esat6/cfp10 fusion gene were
ampliﬁed by Polymerase Chain Reaction (PCR). Cloning of the genes
into pGEX4T1 plasmid was performed. Recombinant plasmids were
sequenced to conﬁrm the insertion. E. coli strain BL21 was transformed
with the recombinant plasmid. The expressed proteins were puriﬁed
by afﬁnity chromatography with Glutathione agarose beads in order
to produce GST-tagged proteins, and then analyzed by SDS-PAGE and
western blotting. Purity and antigenicity of the proteins were conﬁrmed
by western blotting. In this study ESAT6, CFP10 and ESAT6/CFP10
fusion protein obtained successfully. In order to compare the proteins
alone or their combination in detection of TB, we performed ELISPOT
assay by separation of tuberculosis patient WBC and analyzed effect of
the proteins ESAT6, CFP10 and ESAT6/CFP10 in production of IFN-g in
comparison with PPD. Results indicated high sensitivity and speciﬁcity
of these proteins in comparison with PPD in detection of tuberculosis.
P2065 A comparison of two specimen preparation methodologies
and their effect on the outcome of standard diagnostic
protocols used for mycobacteria detection
G. Skenders °, L. Broka, I. Prokopovica (Riga, LV)
Objectives: Sputum and other respiratory specimens are the primary
means to diagnose pulmonary tuberculosis and other mycobacteria
infection. In order to be useful for diagnostic protocols, these specimens
must be liqueﬁed and decontaminated, but the failure to control
pH inherent in conventional protocols for specimen preparation can
signiﬁcantly reduce the number of viable mycobacteria in the patient
sample and negatively affect analytical protocols. In this study we
attempted to examine the effect of two separate specimen preparation
methods on the outcome of common diagnostic procedures for AFB
infection.
Methods: Pulmonary samples submitted for diagnosis were split evenly
and subjected to two separate specimen processing methodologies; the
conventional methodology using NALC, 3% NaOH and M/15 Phosphate
Buffer, and a new methodology offered by the NAC-PAC™ EA3
[Alpha Tec Systems Inc., Vancouver, WA]. Once prepared for diagnosis
each sample was initially screened via Auramine O / Rhodamine B
staining, and, if positive, organism concentration was graded based on
the WHO/IUATLD evaluation scale. All samples were cultured using
Lowenstein-Jensen medium at 36ºCelsius for 8 weeks. Culture positive
specimens were graded based upon the number of colony forming units
present.
Results: Of the 113 samples submitted for diagnostics 22 were positive
for AFB by either microscopy or culture. Of these positive samples all
22 were detected using the Alpha Tec methodology and 20 were detected
using conventional specimen preparation methodology. The two samples
undetected using conventional methodologies were smear negative but
culture positive using the Alpha Tec methodology. One sample that was
smear negative but culture positive using the conventional methodology
was smear positive using the Alpha Tec methodology. Four smear
negative culture positive samples showed non-correlating growth, three
samples using the Alpha Tec methodology showed a greater number of
AFB colonies, one sample using the conventional methodology showed
a greater number of colonies.
Conclusion: The Alpha Tec NAC-PAC™ EA3 AFB Specimen Process-
ing reagent system identiﬁed positive smears and cultures otherwise
missed by the conventional NALC/NaOH/M/15 Buffer methodology.
Aggregated results
Smear−/Culture− Smear+ Smear−/Culture+
ATS 91 14 8 (3 with increased CFU,
2 undetected using NaOH/PBS)
NaOH/NALC 93 13 7 (1 with increased CFU)
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P2066 Tuberculosis in immigrants: clinical ﬁndings and epidemio-
logical trends in the last decade in an area of northern Italy
P. Brugnaro °, E. Morelli, F. Eseme, M. Fiscon, F. Cavinato, F. Ebo,
S. Grandesso, U. Fedeli, C. Ziprani, E. Raise (Venice, Castelfranco
Veneto, IT)
Objectives: The immigration wave occurred in Italy in the last decade
is dramatically acting on the epidemiology of tuberculosis (TB) in our
region. The aim of our study was to compare the prominent disease
features between Italian and immigrant patients with TB who came to
our attention in the last ten years.
Methods: From January 2000 through May 2009 all consecutive patients
with diagnosis of TB admitted to our hospital were included in this
study. Immigrants patients were compared with native residents in
relation to the following data: demographics, comorbidities, clinical and
radiological ﬁndings of TB disease, drug resistance.
Results: Among the 188 consecutive patients with TB diagnosis Italians
were 92 (49%) and immigrants were 96 (51%). The frequency of foreign-
born patients was signiﬁcantly higher in the period 2005–2009 (71.9%)
than in the period 2000–2004 (28.1%; p< 0.001). Among immigrants
the median time from arrival in the host country to TB diagnosis
was 36 months (range 1–336). Italians patients had a greater mean
age (64.3 versus 30.0 years; p< 0.001) and a higher frequency of
concomitant chronic illnesses (35.9% versus 6.3%; p< 0.001), whereas
foreigners were more commonly affected by social risk factors such as
low-income and homelessness (25% vs 2.2%; p< 0.001). Immigrants
patients had a higher frequency of sputum positive pulmonary TB on
direct microscopy (65.6% vs 42.4%; p = 0.001) and radiological signs
of lung cavities (52.9% versus 29.3%; p = 0.007). The detection of
lung cavities on chest-X-ray was strictly associated with smear-positive
pulmonary TB (p< 0.001). Drug resistance was detected in 30 out of
109 Mycobacterium tuberculosis isolates (27.5%): multidrug-resistant
M. tuberculosis isolates were 3.7%. The distribution of resistances did
not show difference between local and immigrant patients (30.8% in
immigrants versus 22.7% in local patients for any resistance; p = 0.356).
Conclusions: During the last decade the prevalence of foreign-born
patients with tuberculosis surpassed the native patients. Immigrant are
represented by otherwise healthy younger people, with a recent arrival
from countries with high incidence of TB. They develop more commonly
smear-positive pulmonary TB with cavitary lung lesions compared to
the local patients. Updated surveillance and preventive strategies of
screening, diagnosis and treatment of TB are mandatory in the ever-
changing scenario of immigration in our country.
S616 20th ECCMID, Posters
P2067 Epidemiological investigation of a tuberculosis cluster
including an untraceable infant case in the Tyrol, Austria,
2006–2009
R. Fretz °, W.M. Prodinger, P. Much, A. Indra, M. Prem, W. Volkan,
J. Schwanninger, A. Luckner-Hornischer, F. Allerberger (Vienna,
Innsbruck, Kitzbu¨hel, Kufstein, AT)
The incidence of tuberculosis (TB) disease in Austria has steadily
declined from 1480 TB cases in 1997 (18.6/100 000) to 890 TB cases
in 2008 (10.7/100 000). A cluster of isolates from 9 TB cases was
identiﬁed with identical spoligotype (International Type − SIT276) and
indistinguishable 25 loci MIRU-VNTR and IS6110-RFLP genotypes. All
TB cases (including a 6m old infant) were diagnosed in the Tyrol in the
years 2006−09.
Methods: To enlighten the chains of TB transmission, a 3-stage
strategy was applied: The databases of the NRCT and of DHMM
were searched from 2002 onwards (year of implementation of general
spoligotyping at NRCT) about information on further TB cases with
identical spoligotype; the already conducted TB contact investigations,
the TB notiﬁcation reports and hospital discharge letters were reviewed,
and a network analysis among the identiﬁed contacts of TB cases was
carried out. A 2nd round of personal interviews with the Tyrolean
TB cases was performed to obtain in-depth information around an
individual’s exposure to infection prior to diagnosis.
Results: In total, 15 TB-cases with spoligotype SIT276 were identiﬁed
from 5 Austrian provinces: Carinthia (n = 1), Styria (n = 2), Upper Austria
(n = 2), Vorarlberg (n = 1), and the Tyrol (n = 9). Of these, the 9 isolates
from the Tyrol had an identical VNTR and/or RFLP genotype. All Non-
Tyrolean TB cases were diagnosed earlier than the Tyrolean TB cases.
Besides the local and temporal clustering of the Tyrolean TB cases, the
age structure differed between Non-Tyrolean and Tyrolean TB cases:
the median age was 68y (range: 53−78y), respectively 21y (range: 6m–
59y). The epidemiological investigations revealed a probable chain of
transmission from a female consultant to her male colleague, and from
him to his girl-friend. Furthermore, possible transmission chains from the
index case (a waitress with cavitary TB) to the female consultant and to 2
further TB cases were established. However, no apparent epidemiological
links to the infant TB case and to the 2 remaining cases were found.
Conclusion: The investigation underlines the role of genotyping to be
able to clarify growing TB clusters and links to rare cases, e.g. in infants.
This infant TB case’s untraceable link to an emerging cluster nevertheless
appears as probable, and illustrates the low risk in industrial countries
for contracting TB from non-family sources at infant age.
P2068 Extrapulmonary tuberculosis in intermediate-TB endemic
area
Y.J. Kim °, S.I. Kim, Y.R. Kim, K.W. Hong, M.W. Kang (Seoul, KR)
Background: Tuberculosis (TB) in Korea is still common, and
remains as important cause of mortality. The characteristics of
extrapulmonary TB vary from country to country. This study is to
evaluate the epidemiology and clinical outcome of extrapulmonary TB
in intermediate-TB endemic area.
Methods: From January 2004 and December 2007, we reviewed
retrospectively inpatient medical records of the patients who had been
with extrapulmonary tuberuculosis(TB).
Results: Among 140,661 inpatients, 168 patients (0.1%; 57 male, 111
female) were diagnosed as extrapulmonary TB, including cervical lymph
nodes (131/168, 77.9%), intestine and/or peritoneal (13/168, 7.7%),
genitourinary (7/168, 4%), pleural (6/168, 3.6%), meningeal (4/168,
2.4%), bone (2/168, 1.2%), psoas abscess (2/168, 1.2%), laryngeal
(1/168, 0.6%), and disseminated TB (2/168, 1.2%) cases. The mean age
was 39 years, and 36.3% of cases were <30 years of age. Previous
tuberculosis history was seen in 44 cases (26.2%) of patients, HIV
infection in 5 cases (2.9%). In 143 (85%) patients, the diagnosis was
established on histopathologic methods, in 10 cases on microbiologic
methods, and in 6 cases on PCR method. In 10 cases who conﬁrmed
by microbiologic methods, one patient was MDR TB case. TB-related
mortality showed in one case with HIV-infected patient, who diagnosed
with disseminated TB. Five patients (2.9%) experienced recurrence of
extrapulmonary TB after the cessation of anti-TB treatment.
Conclusion: Cervical lymph nodes were the most common site of
extrapulmonary TB. This study shows a different epidemiologic pattern
in that the majority of extrapulmonary TB patients are female with young
age. Further study is needed to identify the cause the higher incidence
of extrapulmonary TB infection in younger females.
P2069 Tuberculous meningitis in adults − a 6-year survey
E. Miftode °, G. Juganariu, D. Leca, A. Vata, O. Dorneanu, D. Teodor,
A. Teodor, C. Manciuc, C. Dorobat (Iasi, RO)
Objective: To assess the present epidemiology, clinical presentation and
outcome of adult patients with tuberculous meningitis (TBM) (except
HIV-patients).
Method: We conducted a retrospective study that included all adult
patients diagnosed with tuberculous meningitis in an Infectious Diseases
Hospital.
Results: In the past 6 years 84 patients with TBM were hospitalized in
the Hospital of Infectious Diseases Iasi. The patients age ranged from
16 years to 73 years (mean, 31 years). The neurological state at the
time of admission was: coma in 22 patients (26%), other consciousness
abnormalities (dizziness, changing in personality) in 18 patients (20%),
and cranial nerve palsies in 6 cases (7%). A history of contact with
tuberculosis was detected in 12% of adults and prior tuberculosis was
mentioned in 19% of them. In 23 cases (27%) a pulmonary location of
tuberculosis was revealed. Pulmonary lesions had a miliary pattern in 13
cases (15.5%), ﬁbro-cavitary − in 8 cases (9.5%), and pleural effusion
in 2 cases (2.3%). Tuberculin skin test elicited a positive reaction only
in 21% of patients. The CSF smear for acid-fast bacilli was positive in
7 patients (9%). A positive culture result M. tuberculosis was available
only in 13 patients (15.5%). The rate of quantiferon test positivity in the
blood was 69% (29 cases). The level of albumin in CSF was very high
(>3g/l) in 30 patients (35.7%) (much more frequently in adults than in
children − p = 0.048) and glucose level, markedly low (<0.3 g/l) in 29
cases (34.5%) − with no differences between adults and children.
Sixteen patients (19%) developed neurological complications during
the hospitalization: hydrocephalus (4 cases), cranial nerves paralysis (4
cases), hemiplegia/monoplegia (3 cases), tuberculomas (5 cases), and 8
patients died (9.5%).
Conclusions: We observed a high rate of complications in our study,
due to the late presentation of patients to the hospital. The low rate
of mycobacterium documentation requires other methods of diagnosis
such as the DNA/RNA polymerase chain reaction which has become
the method of choice for early diagnosis. Several specimens and large
volumes of CSF ﬂuid are important for obtaining higher cultures and
smear positivity rates.
P2070 Tuberculous meningitis: evaluation and review of 32 cases
U. Demirpek °, U. Dizer (Istanbul, Ankara, TR)
Objectives: Tuberculous meningitis(TBM) is the most devastating form
of meningitis and prompt accurate diagnosis remains the key to its
treatment. Conventional microbiology has limited utility and nucleic
acid-based methods have not been widely accepted for many reasons.
Therefore, evaluation of common clinical and laboratory features of the
TBM patients could be contribute to its fast diagnosis, consequently
treatment.
Methods: Over a six-year period (1999–2005), clinical and laboratory
data of the 32 patients admitted to 1000-bed hospital were reviewed
retrospectively.
Results: Male to female ratio was 27:5. The mean age of the patients
was 21.7 years; ranged 20−36 years. The criteria evaluated were
BCG vaccination previously, tuberculous contact, initial symptoms,
CSF (cerebrospinal ﬂuid) analysis, culture for M. tuberculosis, TB
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PCR(polymerase chain reaction), chest X-ray, MRI of the head. Ten(10)
of the patients have had BCG vaccination beforehand. Five(5) of the
patients have had TB contacts. The symptom present on admission were
fever in 20 patients (62.5%). All of the patients had CSF leucocytes
ranged 40–1480 cells/mm3. Only one patient was diagnosed by acid-
fast stain from CSF.Protein quantity ranged between 60–760mg/ml
CSF.M. tuberculosis had been cultured 13 patients (41%). PCR analysis
of CSF forM. tuberculosis were positive for all of the cases (100%). Five
of the patients (16%) had abnormalities of the chest X-ray.21 patients
(66%) had abnormalities found on MRI.Hydrocephalus found in eight
of the patients on MRI (25%). Just four of the patients had tuberculomas
on MRI.
Conclusion: TB is a signiﬁcant health issue in terms of outcome and
sequela. TB meningitis is difﬁcult to diagnose due to the nonspeciﬁc
clinical presentation of patients; the initial differential diagnosis includes
many other diseases. Early diagnosis and laboratory conﬁrmation is
important to manage the treatment. Positive cultures, ranging 15−75
per cent, have lower rates to conﬁrm diagnosis. Molecular methods and
neuroimaging could be used for fast and accurate diagnosis.
P2071 Extra-pulmonary tuberculosis: epidemiology and risk
factors
J.F. Garcı´a-Rodrı´guez °, H. A´lvarez-Dı´az, M.V. Lorenzo-Garcı´a,
E. Solla-Babio, A.I. Marin˜o-Callejo, P. Sesma-Sa´nchez (Ferrol, ES)
Objective: To describe the epidemiology and risk factors associated with
Extra-pulmonary tuberculosis (EPTB).
Method: The new tuberculosis (TB) cases diagnosed from 1991
to 2008 in a sanitary area with 218000 caucasian population were
classiﬁed as either EPTB or pulmonary tuberculosis (PTB). EPTB
encompassed pleural, lymphatic, genitourinary, bone and/or joint,
skin, meningeal, peritoneal, gastrointestinal and unclassiﬁed cases. We
excluded patients with concurrent EPTB-PTB and disseminated TB
(miliary). Of all diagnosed cases, 1.233 (63.9%) were prospectively
followed in a monographic unit of TB. A standardized protocol was
developed for each patient, including demographic characteristics, drug
susceptibility test results, and risk factors, considering: female gender,
age, BCG vaccination, history of contact with TB patients, gastrectomy,
smoking, alcoholism, diabetes mellitus, chronic renal failure (CRF),
neoplasia, use of immunosuppressive drugs/steroids, albumin and human
immunodeﬁciency virus (HIV) status. Variables were compared between
EPTB and PTB groups.
Results: Among 1,929 cases diagnosed, 1,037 (53.8%) were PTB
and 649 (33.6%) were EPTB, including pleural 281, lymphatic 184,
genitourinary 44, bone and/or joint 36, skin 31, meningeal 28, peritoneal
18, and other 27 cases. A reduction in the number of cases of EPTB
appears to be slower than that showed in cases of PTB: 283 EPTB and
505 PTB cases in the 1991–1996 period versus 136 and 178 respectively
in the 2003–2008 period. An increase of EPTB has taken place from
35.9% of the cases of TB in the 1991–1996 period to 43.4% in the
last six years, p = 0.02. Compared with PTB, EPTB was associated with
female gender (56.4% vs 33.7%), age average (43.3±22.5 vs 35.7±17.3
years old), BCG vaccination (10.5% vs 20%), contact with TB patients
(24.4% vs 36.4%), gastrectomy (0.4% vs 1.7%), smoking (23.5% vs
52.5%), alcoholism (5.3% vs 20.6%), and CRF (1.8% vs 0.3%), p< 0.05.
Multivariate logistic regression analysis showed that being female (OR
1.78; 95%IC: 1.35–2.34), age (OR 1.02; 95%IC: 1.01–1.03), alcoholism
(OR 0.37; 95%IC: 0.23−0.6), smoking (OR 0.43; 95%IC: 0.32–0.57)
and BCG vaccination (OR 0.63; 95%IC: 0.43–0.93) were associated
with EPTB.
Conclusions: The proportion of EPTB has increased. Risk factors to
EPTB differ from those of PTB. The proportional increase in EPTB
could be explained by older population and increase of female gender,
and by a decline of smoking and alcohol use habits.
P2072 Long-term efﬁcacy of 6-month therapy with isoniazid and
rifampin for pleural tuberculosis
J.F. Garcı´a-Rodrı´guez °, H. A´lvarez-Dı´az, E. Solla-Babio,
S. Sa´nchez-Trigo, A.I. Marin˜o-Callejo, P. Sesma-Sa´nchez (Ferrol, ES)
Introduction: Incidence of tuberculosis (TB) is high in our city and
primary drug resistance is <4%. Objective: To investigate the long-term
efﬁcacy of a 6-month treatment regimen of isoniazid and rifampicin
(6HR) for pleural TB in the HIV-negative population.
Methods: HIV-negative patients with pleural TB attended in our
hospital from 1991 to 2008 entered a 6HR treatment protocol and
were prospectively followed in our TB Unit for 10.6±4.3 years (1–
18.1 years). The diagnosis of pleural TB was based on pleural ﬂuid
analysis and cultures and/or pleural biopsy pathology or cultures. Patients
with empyema and those with associated pulmonary inﬁltrates were not
included. Pleural effusions were deemed slight if they affected less
than one ﬁfth of the hemithorax, moderate if they affected between
one ﬁfth and one third and extensive if they affected more than one
third. Treatment regimen consisted of H 5mg/Kg and R 10mg/Kg
daily for 6 months. In patients with extensive effusion that caused
dyspnea, therapeutic thoracocentesis and respiratory physiotherapy were
performed. Demographic and clinical variables (including pleural ﬂuid
analysis, BCG, tuberculin skin testing, chest x-ray, acid-fast bacillus
smears, Lowenstein culture, assessment of treatment tolerance and illness
evolution) were collected in each case. Chest x-ray was performed at
the end of the treatment. Then, patients were followed by telephone
interview.
Results: 93 patients followed: 51 men and 42 women, mean age
32.3±15.9 years old (14−79). The diagnosis was conﬁrmed by culture
or histological examination in 51.6% of cases; in 22.6% of patients the
pleural effusion was exudative with lymphocytosis and ADA> 45UI/l;
in 25.8% of the patients the diagnosis was based on a compatible clinical
picture and successful treatment. Pleural effusions were: slight 32.3%,
moderate 28% and extensive 39.8%. Susceptibility tests were performed
in 24 cases: all M. tuberculosis were susceptible to ﬁrst-line agents. All
patients completed treatment, 14 (15%) developed drug side effects and
3 (3.2%) toxic hepatitis. In 2 cases it was precise to modify the treatment
and to prolong its duration (1 due to H-hepatitis and 1 due to R-fever).
An overall success was achieved in all patients; 15% developed residual
pleural thickening and none of them required surgery.
Conclusion: 6HR should be adequate for pleural tuberculosis in HIV-
negative population if the incidence of primary drug resistance is <4%.
P2073 Clinical features and outcomes of genito-urinary tract
infection caused by non-tuberculous mycobacteria at a
university hospital in Taiwan, 1996–2008
C. Yang °, C.Y. Liu, C.H. Liao, P.R. Hsueh (Taipei City, TW)
Background: Genitourinary infections caused by nontuberculous
mycobacteria (NTM) are rarely reported.
Methods: The medical records of all patients with GU NTM infections
treated at National Taiwan University Hospital from 1996 to 2008 were
retrospectively reviewed.
Results: Fifteen patients were identiﬁed, of whom 10 (67%) were
male. More than two-thirds of patients had underlying diseases, and
the most common one was chronic renal disease. Only one patient had
acquired immunodeﬁciency syndrome. Acid-fast smears (AFS) of urine
were negative in all patients. Eleven of the 15 isolates were stored
and available for further conﬁrmed by sequencing of their 16S rRNA
gene. Mycobacterium avium complex (MAC) was the most common
etiology of genitourinary NTM infections and was isolated in ﬁve
(33%) patients. Rapidly growing mycobacteria (RGM) were isolated
in four (27%) patients: two each for Mycobacterium abscessus and
Mycobacterium fortuitum. Of 12 patients receiving anti-NTM treatment,
only four received adequate prescribed regimens, and none died of
NTM infections. Another two patients died of refractory urosepsis
before urinary NTM infections were diagnosed. Comparisons of clinical
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characteristics between these 15 patients and 43 patients with GU
tuberculosis reported previously were also analyzed. Patients with GU
NTM infection were more likely to report constitutional symptoms, seek
medical help within one month after onset of symptoms, and develop
leukocytosis. However, patients with GU tuberculosis were more like to
have ureteral strictures and abnormal chest radiographs associated with
active ore inactive tuberculosis.
Conclusion: Although rare, GU NTM infections were signiﬁcantly and
potentially life-threatening, and should be considered in the differential
diagnosis of genitourinary infections, especially those unresponsive to
conventional antibiotic treatment.
P2074 Intracranial tuberculomas: report of 24 cases
F. Bouattour, B. Hammami °, D. Lahiani, I. Maaloul, C. Marrekchi,
K. Ben Mahfoudh, M. Ben Jemaa (Sfax, TN)
Central nervous system involvement in the form of TBC meningo-
encephalitis is found in approximately one in ﬁve of patients with extra
pulmonary tuberculosis.
Among the patients with tuberculosis only 1% develop intracranial
tuberculomas.
The aim of this study is to characterize the clinical and radiological
manifestations of brain tuberculoma.
Methods: This was a retrospective case survey of 24 patients admitted
to infectious disease department over a 17-year period (1993–2009).
Criteria used for the diagnosis of a tuberculoma were suggestive ﬁndings
on a CT scan or MRI, supported by clinical and biological investigations
and conﬁrmed by the culture of CSF.
Results: We identiﬁed 7 men and 17 women affected by intracranial
tuberculomas, without documented immunodepression. The mean age of
this group was 28 years (14−60years). The main neurological symptoms
and signs were meningeal irritation in 15 patients, focal neurological
signs in 14 and alteration of consciousness in 11.
Mycobacterium tuberculosis was isolated in cerebrospinal ﬂuid of 4
patients. Tuberculomas were solitary in 5 cases and multiple in 19
cases, with miliary aspects in 5 cases. They are particularly found in
supratentorial compartment. Associated hydrocephalus was detected in 8
patients, infarction in 4 and meningitis in 20. Anti tuberculosis treatment
was given to all patients associated with corticosteroid therapy for 17
patients. Paradoxical development or enlargement of tuberculomas was
reported in 7 cases. With anti tuberculous chemotherapy for at least 12
months, the course was favorable without sequelae in only 11 patients.
Permanent neurological sequelae were found in 4 patients.
Conclusions: The clinical presentation of intra cranial tuberculoma was
polymorphous. MRI is useful for diagnosis and for follow-up during
treatment. CNS tuberculosis continues to be a condition which carries
signiﬁcant morbidity and mortality.
P2075 Mycobacterium bovis infections in a tertiary-care centre in
Mexico: a case–control study
R. Franco °, M. Bobadilla, A. Ponce de Leo´n, A. Galindo, A. Martinez,
B. Chavez, L. Rodriguez, A. Hernandez, C. Lee, J. Sifuentes (Mexico
City, MX)
Objective: To determine the clinical and epidemiological characteristics
of M. bovis (MB) disease in comparison with M. tuberculosis (MTB)
disease in patients treated in a tertiary-care centre in Mexico.
Methods: We included all MB clinical isolates recovered from patients
seen at this centre from 01/2000 to 12/2007. We randomly selected as
controls two cases of MTB disease per each MB case. Demographics,
clinical manifestations, treatment and outcome were collected. All
isolates were properly identiﬁed by conventional biochemical tests,
conﬁrmed and grouped by RFLP and spoligotyping. Antimicrobial
susceptibility testing was done by the radiometric method. For
comparison we used X2 or Fisher‘s exact test accordingly, and a p value
<0.05 was considered signiﬁcant.
Results: From a total of 226 MTB complex isolates recovered during
the study period, 52 were MB (23%) and 174 MTB (77%); 40% of MB
isolates were recovered in the last two years. Spoligotyping revealed
different MB lineages (BOV, 2; BOV-1, 1; BOV-2, 19; BOV-3, 8; no
lineage, 14; not done 1). Only 45 MB were recovered for further analysis;
these patients were compared with a group of 90 MTB cases. Patients
with MB were younger, and showed a trend towards having chronic liver
disease. MB disease caused more gastrointestinal symptoms and MTB
more respiratory symptoms. Localized disease was seen in 24 (53.3%)
and in 62 (68.9%) patients, (p = 0.07); pulmonary involvement in 10
(22%) and 34 (37.8%); extra-pulmonary disease in 35 (77.8%) and 56
(62.2%), respectively (p = 0.06). The frequency of HIV/AIDS was the
same in both groups. We were able to follow-up 36 (89%) MB cases and
79 (88%) MTB cases; no difference in the intensive phase of treatment
was noted, however MB patients received longer treatment with more
than two drugs during the maintenance phase. The cure rate was high in
both groups 87.5% and 95.7%, respectively, and the rate of relapse was
low. Pansusceptibility was seen in 75% of MB and 90% MTB (p = 0.026)
isolates; 11% of the MB isolates were resistant to streptomycin and 9%
to isoniazid, without differences between groups.
Conclusion: MB disease seems to be a re-emergent problem in Mexico,
although the burden of disease remains unknown. Surprinsingly, we
found a higher resistance rate among MB isolates, although the cure
rate was very high in both groups.
P2076 Tuberculosis meningoencephalitis with severe neurologic
sequelae in an immigrant family’s child
K. Kart Yasar °, F. Pehlivanoglu, G. Sengoz, E.R. Ince, S. Sandikci
(Istanbul, TR)
Objective: Tuberculous meningitis (TBM) is the most devastating
manifestation of tuberculosis. It is a challenge for clinicians because of
the difﬁculty in making an early diagnosis and the severe consequences
of delayed treatment. The aim of this report is to point out relation
between migration and tuberculosis based on a 14-year old child of an
immigrant family with tuberculous meningoencephalitis.
Case: A 14-year old child of an immigrant family was applied
to our clinic with the complaints of fever, headache and vomiting
lasted for 10 days. The emergent cranial CT scan showed no
pathological ﬁndings thereby lumbar puncture was performed to examine
cerebrospinal ﬂuid (CSF). The ﬁndings were: CSF cell count: 57/mm3
leucocyte (60% lymphocyte), 18/mm3 erythrocyte and glucose: 13mg/dl
(simultaneous blood glucose 109), protein 243mg/dl. Laboratory tests:
WBC 12300/mm3, haemoglobin 11.7 g/dl, CRP 12mg/dl and Anti HIV
antibody negative.
On the same day sudden loss of conscience, bradycardia, hypotension
developed and the patient transferred to the intensive care unit (ICU)
ceftriaxone and acyclovir therapy was started. The patient’s mother
had a tuberculosis history and general condition of the patient didn’t
ameliorate, for these reasons antituberculous therapy was started on the
second day and vital ﬁndings were improved on seventh day. The patient
was transferred to the ward from ICU. The patient was evaluated as stage
III and cranial MRI showed multipl tuberculoma, basal meningitis and
minimal hidrocephalus, thorax CT showed miliary pattern. CSF PCR
for tuberculosis (GeneXpert MTB-RIF, Cepheid®, USA) was positive,
Mycobacterium tuberculosis was isolated from CSF and Quantiferon TB
gold test (Cellestis®, Australia) was positive. During the hospitalization
period convulsion, hearing loss, aphasia, motor deﬁcits developed and
the patient was discharged from the hospital on the 24th day with mild
sequelae (aphasia, minimal motor deﬁcits and hearing loss). Follow
examinations has been continuing.
Conclusion: Migration, crowded living conditions and positive family
history contribute the severe course of tuberculosis as TBM and miliary
TB forms. Tuberculosis control may prevent these severe manifestations
of the disease.
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P2077 Childhood tuberculosis in a large city: incidence evolution
and factors associated to unsuccessful treatment completion
during a 21-year period
J.L. Nelson °, A. Moreno, A. Orcau, N. Altet, A. Martinez-Roig,
J. Cayla, M. Casals, J.P. Millet, F. Moraga and the Childhood
Tuberculosis Working Group of Barcelona
Objectives: To date, few studies have been published on childhood
tuberculosis (TB). Furthermore, the global burden cannot be accurately
assessed due to lack of epidemiological data and consistently-used
deﬁnitions across different regions. The objective of our study was to
examine the TB incidence evolution and factors associated with an
unsuccessful TB treatment outcome of children in Barcelona, Spain
during a 21-year period.
Methods: The study utilized an observational longitudinal design and
included TB cases less than 15 years of age, residing in Barcelona, who
started treatment between 1987 and 2007, and were registered in the
TB control program. Number of cases and incidence were calculated
for the total study population, according to Barcelona consensus data,
and stratiﬁed by year of treatment initiation, sex, and age. A logistic
regression analysis was performed to analyze the factors associated
with unsuccessful treatment completion (deﬁned as treatment outcome
other than cured), calculating odds ratio (OR) and corresponding 95%
conﬁdence interval (CI).
Results: One thousand children were included in the study: 512 (51.2%)
were male, 922 (92.2%) were Spanish, and 466 (46.6%) were under 5
years of age. Regarding treatment outcome, 925 (92.5%) cases were
considered cured, 2 (0.2) died due to TB, 4 (0.4%) died due to other
causes, 31 (3.1%) transferred out of Barcelona, and 37 (3.7%) were
lost to follow-up. Incidence dropped from 48.1 cases per 100,000
children in 1987 to 10.6 cases per 100,000 children in 2007 (p< 0.001),
with an annual decline of 3.7% (Figure 1). Factors associated with
an unsuccessful treatment included age under 5 years (OR= 1.8; CI
1.0−3.3), residence in the inner-city district (OR= 1.8; CI:1.2−3.1), and
an unknown radiology result (OR= 7.5; CI:2.6−24).
Conclusions: Childhood TB incidence declined during the study period,
probably due to increasing development of the TB control program
created in 1987. Children under 5 years generally contributed more cases
and represented a higher incidence whereas small differences existed by
sex. The proportion of successfully treated patients in our study was high
and transfer-out cases had an important presence within unsuccessful
treatment outcomes. According to the multivariate analysis results, we
found that evaluating successful treatment by comparing cured and all
non-cured cases is not conclusive in a setting with a high percentage of
cured and transfer-out cases.
Incidence of childhood tuberculosis per 100,000 children by year (
n = 1000). Barcelona, 1987–2007.
P2078 Description of tuberculosis cases involving both respiratory
and extra-respiratory sites and genotypic characterization
of their isolates
Y. Navarro °, M. Herranz, M. Ruiz Serrano, M. Martinez Lirola,
E. Bouza, D. Garcı´a de Viedma (Madrid, Almeria, ES)
Background and Objectives: The application of molecular tools has
revealed that infection by Mycobacterium tuberculosis (MTB) could be
more complex than initially assumed. We analysed tuberculosis cases
in which MTB was isolated from both respiratory and extrarespiratory
specimens. Our aims were to describe these cases, determine their
proportion to the total number of TB cases, and apply systematic
molecular analysis to identify cases with clonally complex infections
(mixed infections, coexistence of clonal variants, compartmentalized
infections) as a ﬁrst step in the in-depth characterization of these strains.
Methods: We analyzed the TB databases of two hospitals between
January 2003 and October 2009. Patients were distributed in 3 groups
according to the number (1 to 3) of extrarespiratory specimens from
different tissues yielding MTB in addition to the respiratory sample.
Genotyping of the MTB isolates from the selected cases was performed
by MIRU-VNTR.
Results: In 97 out of 1733 isolates (5.6%), MTB was isolated from at
least 1 extrarespiratory specimen in addition to the respiratory sample.
The extrarrespiratory specimens most frequently yielding MTB were
urine (40 cases), blood (31), pleural ﬂuid (17), stool (8), and CSF (7). In
most cases (70, 72%), MTB was isolated from only one extrarespiratory
specimen in addition to the respiratory sample (Group 1). Additionally, in
27 cases (28%), MTB was isolated in 2 or more different extrarespiratory
specimens: Group 2, 16 cases; and Group 3, 11 cases. Preliminary
genotyping results from 21 representatives (10, 6, and 5 cases form
Groups 1, 2, and 3, respectively) showed identical VNTR-MIRU-types
for all the the isolates in 16 cases and genotypic differences in the isolates
from the remaining 5 cases (in 1, 3, 4, 6, and 16 loci).
Conclusion: The isolation of MTB from both respiratory and
extrarespiratory specimens was not anecdotal. In certain cases, the
extrarespiratory infection involved several different tissues. Preliminary
genotyping data allowed us to identify cases infected with isolates
showing genotypic differences (mostly subtle) at the respiratory and
extrarespiratory sites. Further genotyping could help us determine more
precisely the degree of bacterial clonal complexity in these patients.
Y. Navarro was receiving a grant for International Cooperation of
the “Fundacio´n para la investigacio´n biome´dica del Hospital Gregorio
Maran˜o´n”.
This study was partially funded by the FIS (FIS060882; FIS061467;
FIS06/90490; 06/90357; PS09/02205).
P2079 Clinical features and outcomes of disseminated infection
caused by non-tuberculous mycobacteria
K. Kao °, C. Chou, P.R. Hsueh, H.Y. Chen, C.Y. Chen, C. Huang
(Taipei City, Douliu, TW)
Objectives: This study investigated the clinical characteristics and
prognostic factors of patients with disseminated non-tuberculous
mycobacteria (NTM) infection in Taiwan.
Methods: This retrospective study included patients who fulﬁlled the
criteria for disseminated NTM infection at a medical center in Taiwan
from January 2004 to December 2008. Data on etiology, clinical
characteristics, laboratory ﬁndings, and outcome were collected from
medical records.
Results: Disseminated NTM infection was diagnosed in 40 patients
during the study period. The mean age was 46 years (range 22−79),
and male gender was predominant (80%). More than half of the patients
(n = 22, 55%) had HIV infection and fever was the most common initial
presentation (n = 21, 52.5%). There were 13 episodes of co-infection
with other bacterial pathogens in 11 patients (30%). Anemia, elevated
alkaline phosphatase, aspartate aminotransferase, lactate dehydrogenase,
and C-reactive protein were commonly noted in disseminated NTM
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infection. The most common site of NTM isolation from culture was
blood (62.5%) followed by respiratory tract (52.5%). M. avium complex
was the most common isolated species (70%). The overall mortality
rate due to disseminated NTM infection was 30%. Univariate survival
analysis showed signiﬁcantly higher mortality rates in female patients,
patients without anti-NTM treatment, and patients co-infected with other
bacterial pathogens. Multivariate analysis showed that lack of anti-NTM
treatment was the only prognostic factor for poor outcome (p = 0.001).
Conclusions: Maintaining a high level of suspicion and starting
appropriate anti-NTM treatment promptly after diagnosis are crucial to
improve outcome of patients with disseminated NTM infection.
P2080 Epidemiological monitoring of pulmonary tuberculosis in a
correctional facility population, Athens, Greece, 2005–2009
S. Karabela, D. Papaventsis °, S. Georgoulas, S. Nikolaou, P. Ioannidis,
E. Konstantinidou, A. Sainti, I. Marinou, S. Kanavaki (Athens, GR)
Objective: Correctional facilities are extremely high-risk environments
for tuberculosis (TB) infection (co-infection with HIV is common), due
to overcrowding, poor nutrition, limited access to health care, unsafe
drug injecting practices and unprotected sex. However, limited data are
available concerning the TB epidemiology in prisons. The purpose of
the present study was to investigate the rate of TB in a large prison, in
Athens, Greece.
Methods: Korydallos Prison Complex, Athens, is the main correctional
facility in Greece, housing maximum security men and women. The
majority of the nowadays 2.002 detainees are foreigners (1287, 64%),
and 715 (36%) are Greeks. Between January 2005 and October 2009, a
case-ﬁnding through self-referral survey was carried out in Korydallos
Prison Complex Hospital. Prisoners who had symptoms suggestive of
pulmonary TB were included in the study (cough of at least 1 week
duration or fever or haemoptysis), underwent chest radiography, were
offered HIV testing, and three “spot specimens” of sputum were tested
for TB by both conventional and modern molecular methods. The sputum
specimens were processed at the National Reference Laboratory for
Mycobacteria, Athens.
Results: In total, sputum samples from 190 prisoners were tested (most
were men <40 years old). Twenty (10.5%) had pulmonary TB: 6 were
taking anti-tuberculous treatment (5 from Africa and 1 from Greece)
and 14 were undiagnosed at the start of the study; 11 (5.8%) were
sputum-smear positive and 9 (4.7%) were sputum-smear negative. The
prevalence of active pulmonary TB in the prison’s population determined
by the number of persons with active TB divided by the total number
of prisoners was approximately 250 per 100,000, which is 15.6 times
higher than the general population (OR= 15.66, 95%CI: 9.44 to 25.96).
Total resistance rates of TB isolates were: 30% for isoniazid, 25% for
both rifampicin and ethamboutol, 15% for pyrazinamide, and 25% for
streptomycin. 3/20 (15%) of TB isolates were multidrug-resistant strains
(MDR), and 2/20 (10%) were extensively drug-resistant strains (XDR).
Conclusions: Pulmonary TB in Korydallos Prison Complex was 15.6
times more common than in the general population in Greece. This ratio
was slightly above the mean ratio in prisoners compared to civilians in
Europe. Moreover, MDR/XDR TB was prevalent in the study population.
Improving living conditions in correctional facilities and adhering to TB
control programmes are urgently required.
P2081 Extrapulmonary tuberculosis as an aetiological factor of in-
creasing importance in patients with fever of unknown origin
G. Stevanovic °, M. Pelemis, M. Pavlovic, L. Lavadinovic, B. Milosevic,
S. Stojakovic, J. Nikolic, N. Mitrovic (Belgrade, RS)
Objectives: The aims of this study were to determine prevalence of
extrapulmonary tuberculosis in patient with fever of unknown origin
(FOU) who was HIV negative, to show prevalence of, and types of
extrapulmonary tuberculosis (TB) and to determine trends of prevalence
among patients with FOU.
Methods and Results: During period 1994–2009, 2842 with FUO were
evaluated and treated in the Clinic for infectious and tropical diseases,
Belgrade. Extrapulmonary TB were diagnosed in 134 (4.7%) patients.
Genitourinary TB in 73 patients (renal − 60, orhiepididymitis − 4,
salpingo-oophoritis − 9); TB lymphadenitis in 13; meningitis in 15;
TB pericarditis in 8, spondylodiscitis in 6, liver TB in 4 and in one
patient small intestine TB. In 14 patients we did not conﬁrm tuberculosis
and after pulmonary TB was excluded, they were treated empirically
with antituberculous drags, and had a good response. As a diagnostic
methods we used: PPD skin test, cerebrospinal ﬂuid (CSF), sputum and
urine cultivation, computed tomography, echocardiography, intravenous
pyelography, patohistological examination of lymph nodes, intestine and
liver, and gynecological laparoscopy. For urine and CSF specimens
PCR test was used after year 2001. The sensitivity of conformation
test were: CSF culture 100% (PCR 100%), urine culture 45% (PCR
68%), for histopathology lymph nodes 78%, small intestine 100% (single
patient) and liver 85%. As a diagnostic criteria, clinical course of
the illness, radiological examination, laparoscopy and other endoscopic
examinations and response to empiric therapy, were also used. Incidence
of extrapulmonary TB was in slight increasing after year 2001. Isoniazid,
rifampin, pyrazinamide, ethambutol and streptomycin were used for
treatment. Multi drug resistant TB were conﬁrmed in 4 patients and in
7 patients (drug sensitive TB) had relapses of the illness after treatment.
Conclusions: Extrapulmonary TB is increasing cause factor in patients
with FOU and should be always considered during evaluations of this
patients.
P2082 Incidence of thromboembolic events in hospitalized
tuberculosis patients and its risk factors
M. Marjani °, P. Baghaei Shiva, P. Tabarsi, D. Mansouri, M. Masjedi
(Tehran, IR)
Background: Pulmonary tuberculosis may be associated with a
hypercoagulable state but there are few studies about incidence of deep
vein thrombosis (DVT) and pulmonary thrombo-embolism (PTE) in
tuberculosis patients. This study was performed to determine risk factors
and incidence of DVT and PTE in admitted tuberculosis patients.
Methods: In a cross sectional study we calculated incidence of diagnosed
thromboembolic events in all pulmonary and extra pulmonary new cases
of tuberculosis patients admitted in our center since August 2007 to
August 2009. Prophylactic strategies for prevention of DVT and PTE
have been performed for high risk patients.
We randomly selected 100 tuberculosis patients without thromboembolic
complications as control group and compared risk factors between case
and control groups.
Table 1. Comparison of risk factors between case and control groups
Case group,
N (%)
Control group,
N (%)
OR 95% CI P-value
Male gender 21 (78) 48 (48) 3.79 1.411–10.189 0.006*
Age (yrs), mean 64 50.4
50 yrs 15 (56) 49 (49) 1.301 0.554–3.057 0.545
Active smoker 10 (37) 24 (24) 1.863 0.853–4.609 0.175
Opium 12 (44) 22 (22) 2.83 1.16–6.93 0.019*
IDUs 4 (15) 12 (12) 1.275 0.376–4.325 0.696
Diabetes mellitus 3 (11) 12 (12) 0.917 0.239–3.512 0.899
HIV 2 (7) 8 (8) 0.920 0.184–4.609 0.919
HTN 8 (30) 13 (13) 2.8 1.24–7.74 0.039*
Total 27 100
Abbreviations: OR = Odds ratio, CI = Conﬁdence interval, * = Signiﬁcant, IDU =
Intravenous drug user, HIV = Human immunodeﬁciency virus, HTN = Hyper-
tension.
Results: The incidence of established thromboembolic complications
was 27 of 1011 admitted tuberculosis patients (2.7%; 95% conﬁdence
interval: 1.8 to 3.9%). It was 1.8% for DVT and 1.0% for PTE.
Thromboembolic events and DVT were more common in men than
women, 3.8% versus 1.4% (p-value= 0.019) and 3.1% versus 0.4%, (p-
value= 0.001) respectively.
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Also, in this study 100 tuberculosis patients without thromboembolic
complications were entered randomly as the control group and risk
factors between case and control groups were compared. Hypertension
was more common among patients with thromboembolic events: 30%
versus 13% (p-value= 0.039). Also opium addiction was more common
among cases with TEE than control group: 44% versus 22% (p-
value=0.019).
Other than sex, history of HTN and opium addiction there was not any
relation among thrombo-embolic events and other risk factors such as
smoking, diabetes mellitus or Rifampin dose between case and control
groups.
Conclusion: It must be considered that this study was performed in a
tertiary hospital and this may cause selection bias because many of our
cases were complicated but it was enough to evoke special attention
to thrombo-embolic events in admitted (and probably non-admitted)
tuberculosis patients. Patients should be educated about its symptoms
and clinicians should consider prevention, diagnosis and management of
these events as soon as possible.
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P2083 Combining C6 ELISA and IgM immunoblot for the
detection of antibodies in early Lyme infection
T. Herremans °, A. Hofhuis, D.W. Notermans, N. Nozari, C. Nijhuis,
L.M. Kortbeek, J. van der Giessen (Bilthoven, NL)
Objectives: Lyme borreliosis is a zoonotic disease transmitted by ticks
and caused by the spirochetes of the Borrelia burgdorferi sensu lato
group. Diagnosis depends on clinical suspicion, the recognition of
characteristic symptoms, and serology. Although frequently applied,
serodiagnosis is not indicated in Erythema migrans (EM) patients
because clinical signs are speciﬁc and serology is usually negative during
this phase of Lyme disease. We used a population of EM patients
to evaluate which assay or combination of assays provides the best
algorithm for identifying early Lyme infections.
Methods:We analyzed 274 EM patients serologically at the start of their
symptoms and approximately 12 weeks thereafter. Sera were tested in a
commercially available C6 ELISA, an in-house inhibition ELISA based
on the ﬂagella antigen, and by an in house IgM and IgG immunoblot. In
addition, sera from 307 tick bite patients taken directly after they were
seen by their GP and from the general population of the Netherlands
(n = 836) were also investigated to determine background levels.
Results: With 34.3% positive EM patients, the C6 ELISA was the most
sensitive assay, followed by the IgM immunoblot (19.7%), the inhibition
ELISA (10.9%) and the IgG immunoblot (6.9%). An algorithm using
both a C6 ELISA and/or a IgM immunoblot positive results gave the
highest sensitivity (41.2%). Examination of follow-up serum samples
gave similar results in seroprevalence. In tick bite patients, the C6 ELISA
showed the highest seroprevalence (11.4%) followed by IgG (7.2%), IgM
(5.2%) and the inhibition ELISA (4.6%). Low C6 ELISA results could
usually not be conﬁrmed by immunoblot. In the general population, we
identiﬁed 4.7% C6 positive persons. Increasing the cut-off level to a
Lyme Index of 1.70 (the average + 3 x Standard Deviation) improved
the speciﬁcity of the C6 ELISA from 95.3% to 97.8%, with a sensitivity
loss in EM from 34.3% to 26.6%.
Conclusion: Serology in EM is insensitive, and the antibiotic treatment
probably prevented further antibody development, making follow-up
serology of limited clinical value. For these reasons, the serological
investigation of EM patients should not be recommended. C6 ELISA
values between 1.1 and 1.7 should be interpreted with caution in the
absence of other conﬁrmative serology. However, a combination of the
C6 ELISA and the IgM immunoblot proved to be the most sensitive
combination for detecting antibodies in early Lyme infections.
P2084 Comparison of eight ELISAs and ﬁve immunoblots
for detection of anti-Borrelia antibodies reveals large
differences between test strategies
C.W. Ang °, D.W. Notermans, M. Hommes, A.M. Simoons-Smit,
M. Herremans (Amsterdam, Bilthoven, NL)
Objectives: (1) To compare a wide range of methods (ELISA,
immunoblot, whole cell, recombinant) for detecting anti-Borrelia
antibodies (2) To investigate the inﬂuence of the choice of assay on
the result in a two-tier testing algoritm.
Methods: 92 serum samples from clinically well deﬁned patients were
tested in eight ELISA systems. Samples were tested in four assays based
on whole cell antigens (Enzygnost, Moran, VIDAS, Virion/Serion), two
assays with whole cell antigens supplemented with VlsE (Euroimmun,
Virotech) and two assays using recombinant proteins (Immunetics,
Mikrogen). A subset of samples was tested in ﬁve immunoblots. One
whole cell blot (home-made), one whole cell blot supplemented with
VlsE (Virablot) and three recombinant blots (Euroimmun, Mikrogen,
Virotech).
Results: The number of positive ELISA results in the group of patients
suspected for Borrelia ranged from 34% (Moran) to 61% (Virotech),
depending on the ELISA assay used. The speciﬁcity of the ELISA’s
differed widely. The percentage of positives in samples from syphilis
patients and patients with recent M pneumoniae infection ranged from
0% (Immunetics) to 38% (Virotech). Reactivity in healthy controls was
low to absent in all assays.
Comparison of the immunoblots yielded large differences in inter-test
agreement and showed at best a moderate agreement between tests.
Kappa-values for IgM ranged from 0.02 (Virablot vs Euroimmun) to
0.50 (home-made vs Mikrogen). Agreement on the presence of IgG
anti-Borrelia was better with kappa-values between 0.37 (home-made vs
Euroimmun) and 0.81 (home-made vs Mikrogen). There was only very
limited agreement on the presence of speciﬁc immunoreactive bands.
Even between recombinant blots there was substantial disagreement.
Some immunoblots gave positive results in samples that had been tested
negative by all ELISAs.
The percentage of positive blots, following a positive ELISA result
depended heavily on the choice of ELISA-immunoblot combination and
ranged from 60–100%. In only 76% of the samples all 40 ELISA-
immunoblot combinations yielded the same result (either positive or
negative).
Conclusion: ELISA’s and immunoblots for detecting anti-Borrelia
antibodies have widely divergent sensitivity and speciﬁcity. Immunoblots
for detecting IgM show only very limited agreement. The choice
of ELISA-immunoblot combination severely inﬂuences the number of
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positive results making exchange of test-results between laboratories with
different methodologies hazardous.
P2085 Spectrum of clinical forms and seasonal distribution of
Lyme borreliosis in children
P. Mikola´sˇek °, L. Homola, L. Krbkova´, J. Pavelka, D. Bartosˇova´ (Brno,
CZ)
Objectives: The aim of the study was to identify clinical forms and the
course of Lyme borreliosis (LB) with in relation to the season, gender
and age of children during the period. of 28 months.
Methods: 453 children were examined for dermatoborreliosis in out
patient clinic or they were admitted for neurologic and joint involvement
of LB from May 2007 to September 2009. Children with early localized
borreliosis were diagnosed clinically. Children with disseminated disease
fullﬁlled EUCALB criteria.
Results: 453 children (55% boys / 45% girls) with LB represent
4.1% of all reported cases during the same period in the Czech
Republic, this predomination is opposite to adults in Europe. Cutaneous
manifestations were clinically characterized by erythema migrans (EM),
erythema migrans multiple (EMM), and borrelial lymphocytoma (BL),
all together 76.5%. A prevalence of dermatoborreliosis was detected
in the age group seven months to eight years in contrast to Lyme
arthritis, which was extremely rare. After the ten years of age skin and
joint manifestations were diagnosed equally. Neurologic manifestations
(n = 61) were the second largest group 13.5%. The joint involvement
(n = 45) was diagnosed in 9.9% of children. There were only four cases of
LB in patients of age under one year (EM twice, EMM twice). During 3
following years, the most children 21.4% developed their clinical features
in July. In cases with BL two seasonal peaks were seen, from June to
August (38%) and from October to December (38%).
Conclusion: 252 children (55.6%) have clinical symptomes of EM.
95 children (21%) suffered from LB disseminated cutaneous stage. 31
children (6.8%) were seen with borrelial lymphocytoma, which is typical
for children age.
No suspected diagnoses of acrodermatitis chronica athrophicans was
proven during the evaluated period. 16 children have to be admitted for
prolonged course of Lyme arthritis, whereas 29 were treated orally. The
outcome of neuroborreliosis in all children was excellent. Coinfection
with tick-borne encephalitis was conﬁrmed in two children.
P2086 Evaluation of two automated tests on the Vidas instrument
to detect anti-Lyme disease antibodies IgG and IgM in
human serum, plasma and CSF
G. Bouchard, O. Peter °, A. Bonnet-Pierroz, R. Vonlanthen, P. Cosin,
N. Ammour, A.M. Brevet, P. Broquedis, N. Dehainault, C. Perret,
B. Incaurgarat (Marcy l’Etoile, FR; Sion, CH)
Objectives: VIDAS Lyme IgG and VIDAS Lyme IgM are two automated
ELISA tests for the qualitative detection of IgG or IgM antibodies against
Borrelia burgdorferi sensu lato (B. afzelii, garnii, sensu stricto) in human
serum or plasma. VIDAS Lyme IgG can also detect IgG in cerebrospinal
ﬂuid. Analytical and clinical performance were assessed.
Methods: Speciﬁc recombinant proteins are used on the ELISA solid
phase to recognize and capture serum antibodies. The precision study
was performed according to the CLSI document EP5-A2 with a sample
around the cut-off. Cross reactivities with Spirocheatae bacteria, EBV,
SLE, HSV, CMV and non-speciﬁc antibodies RF, ANA, HAMA were
evaluated.
Results: The total precision % CV observed was <10% for a sample
around the cut-off. Cross-reactions observed with Spirocheatae bacteria
(Treponema, Leptospira) and EBV were <4% with VIDAS Lyme IgG
test, and <12% with VIDAS Lyme IgM. No signiﬁcant cross reactivity
was observed for FR, ANA, HAMA, SLE, HSV, and CMV.
About 300 human serum samples were evaluated with the VIDAS
Lyme IgG and Lyme IgM assays. All sera were from patients with
well-established clinical status of early Lyme borreliosis (LB) or early
disseminated and late LB. The VIDAS Lyme IgG assay showed a
sensitivity of 60% and the VIDAS Lyme IgM assay showed a sensitivity
of 72% in early LB (N= 60). When both assays were combined, the
sensitivity reached 82% on a selection of sera, including seroconversions.
In late LB, 79 out of 81 serum samples were found positive with
VIDAS Lyme IgG (2 seronegative Lyme arthritis). Preliminary assays
for IgG detection in CSF were performed on 12 samples with intrathecal
antibody production (IAP) and 16 without IAP, gave expected results.
Speciﬁcity for both IgG and IgM assays was assessed using sera from
patients with EBV, HAV, syphilis, as well as autoimmune disease,
(N = 130). Sera from 6 patients were IgG positive (4.5%) and 20 were
IgM positive (15.3%).
Conclusion: The VIDAS Lyme IgG assay, without equivocal status
results, showed good sensitivity and speciﬁcity and a rapid time to result
(27′). The preliminary testing on CSF, performed in the same manner
as serum samples, appears promising. The VIDAS Lyme IgM assay,
with equivocal status results, showed good sensitivity and moderated
speciﬁcity. Using speciﬁc recombinant proteins, the VIDAS Lyme IgG
and IgM assays provide good detection of IgG and IgM allowing precise
and accurate assessment of disease status.
P2087 Recommendations for diagnosis and treatment of Lyme
borreliosis: a comparison of guidelines and consensus
papers from specialist societies and expert groups in
Europe and North America
S. O’Connell ° on behalf of the European Union Concerted Action
on Lyme Borreliosis (EUCALB)
Objective and Background: The European Union Concerted Action on
Lyme Borreliosis (EUCALB) initiative promotes Lyme borreliosis (LB)
research and evidence-based clinical practice through multi-disciplinary
collaborations and a highly-regarded, frequently updated website. Its
clinical case deﬁnitions for LB were published in 1997 and an updated
version is to be published. EUCALB’s current programme includes a
review of diagnosis and treatment recommendations in Europe, and the
evidence on which they are based.
The Infectious Diseases Society of America published updated
guidelines for LB in 2006. There has since been considerable public
dispute internationally regarding LB diagnostic criteria and treatment
duration, particularly for patients with persistent symptoms following
standard treatment. Some patient support groups and a minority of
physicians in North America and Europe are very active in promoting
nonspeciﬁc diagnostic criteria and prolonged or multiple repeated
antibiotic courses. There is signiﬁcant evidence that some patients have
been seriously harmed by these practices, prompting this EUCALB
review.
Method: EUCALB participants collated diagnostic and treatment
guidelines prepared independently by European specialist societies and
expert groups. Guidelines, including those from the Czech Republic,
Denmark, Finland, France, Germany, the Netherlands, Norway, Poland,
Slovenia, Sweden and Switzerland were evaluated and compared with
respect to diagnostic criteria and treatment recommendations (antibiotic
agents, dosages and durations) for erythema migrans, neuroborreliosis,
Lyme arthritis and persisting symptoms. They were also compared to
those of the IDSA and the American Academy of Neurology.
Results: Recommendations and evidence bases of all of the guidelines
will be tabulated to permit easy detailed comparison. There are great
similarities in diagnostic criteria and antibiotic choice, with some minor
differences in dosing and treatment duration, mainly depending on
clinical indication. Doxycycline and amoxicillin are the most frequently
recommended oral antibiotics; ceftriaxone is the most commonly
recommended parenteral agent. The most common treatment durations
range from 10−30 days. Notably, none of these guidelines recommends
very prolonged treatment courses for patients with persisting symptoms.
Conclusion: There is overall very good concordance between these
independently developed, evidence-based European and American
guidelines.
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P2088 Preferential reactivity towards Borrelia afzelii in the sera of
patients with Lyme borreliosis from the north-east of Poland
S. Grygorczuk °, O. Pe´ter, J. Zajkowska, M. Kondrusik, A. Moniuszko,
S. Pancewicz (Bialystok, PL; Sion, CH)
Objective: Several Borrelia burgdorferi sensu lato (B. burgdorferi
s.l.) genospecies act as causative agents of Lyme borreliosis (LB) in
Europe, with apparent differences in their prevalence between countries.
Clinical form of a disseminated LB correlates with a genospecies,
so the natural course of the disease may vary in different areas.
Neuroborreliosis (NB) is more often associated with Borrelia garinii,
chronic cutaneous lesion (acrodermatitis chronica atrophicans, ACA)
with Borrelia afzelii and Lyme arthritis (LA) with Borrelia burgdorferi
sensu stricto (B. burgdorferi ss). In the north-east of Poland late
Lyme borreliosis presents as NB or ACA. Osteoarticular symptoms are
frequent, but usually mild and unspeciﬁc, while typical Lyme arthritis is
rare. Different genospecies could possibly co-exist in the area, but their
prevalence has not been studied so far.
Methods: From the Podlaskie province (north-eastern Poland), a group
of 22 patients was selected with a positive serology and symptoms
compatible with disseminated Lyme borreliosis lasting for >6 weeks
(>6 months in 21), including 7 patients with NB, 10 with osteoarticular
symptoms (Lyme arthritis, LA), 3 with ACA and 2 with mixed symptoms
(LA + NB and LA + ACA). Of patients classiﬁed as LA, 3 had mild
arthritis while the others presented with chronic arthralgia and myalgia.
Serum samples were serotyped with a previously validated immunoblot
assay, able to detect preferential reactivity towards one of the four
B. burgdorferi s.l. genospecies (B. afzelii, B. burgdorferi ss, B. garinii,
B. valaisiana) in patients with long-lasting active infection.
Results: The preferential reactivity towards B. afzelii was found in
19 patients irrespective of the clinical form of LB. The reactivity
towards B. garinii prevailed in a single patient with LA. No patient
had preferential reactivity towards B. burgdorferi ss or B. valaisiana. In
2 patients with NB no preferential reactivity could be determined.
Conclusions: B. afzelii seems to be a main aetiological agent of
disseminated Lyme borreliosis in the north-east of Poland. In this area
it is responsible for all clinical forms of late Lyme borreliosis, including
neuroborreliosis and osteoarticular symptoms. The unspeciﬁc clinical
course of the osteoarticular LB in the study area may be related to the
lack or scarcity of B. burgdorferi sensu stricto.
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P2089 A twelve-month retrospective audit of reactive Toxoplasma
gondii serology in pregnant women in Ireland
K. Burns °, V. McDonnell, D. Murphy, S. Collum, R. Twohig, J. Connell,
W. Hall (Dublin, IE)
Objectives: Primary maternal infection with Toxoplasma gondii may
result in transplacental transmission of infection to the fetus. Prompt and
accurate recognition of primary maternal toxoplasma infection enables
initiation of effective anti-toxoplasma chemotherapy. Interpretation of
Toxoplasma serology results can prove challenging. Patients may have
detectable IgM levels to T. gondii which persist for months to years
following primary infection and false positive IgM results are not
uncommon. Referral to a reference laboratory for further conﬁrmation
of reactive T. gondii serology is recommended in pregnant women. This
audit was carried out to determine the indication for performing T. gondii
serology on women of childbearing age and to determine the frequency
and signiﬁcance of reactive serology results.
Methods: The results and clinical information of 2,497 samples tested
for antibodies to T. gondii, received from females aged fourteen to ﬁfty
years of age from January 1st to December 31st 2007 were reviewed.
Results: Of 540 women of childbearing age with reactive T. gondii
serology, 234 (43%) were pregnant or had been recently pregnant at
the time of testing. Routine antenatal screening and investigation of
intrauterine death were the testing indications for 82% of reactive
T. gondii specimens.
There was no serological evidence of recent T. gondii infection in 218
(93%) of pregnant women with reactive T. gondii serology. Twelve
pregnant women had a ﬁrst positive IgM to T. gondii. High IgG avidity
results were recorded in nine of ten IgM positive specimens, indicating
that the T. gondii infection was not acquired in the preceding three
months.
One sample had low IgG avidity, conﬁrmed at the Toxoplasma Reference
Unit (TRU) suggestive of a recently acquired T. gondii infection. The
indication for performing T. gondii serology in that case was presence
of fetal ventriculomegaly on ultrasound examination.
Conclusions: It was possible to conﬁrm recent acquisition of primary
T. gondii infection in only one of 234 pregnant women with reactive
serology for T. gondii in 2007. The results of this audit suggest that
testing for T. gondii as part of routine antenatal screening in the absence
of a clinical indication should be reconsidered owing to the implications
of detection of a positive IgM result for a pregnant woman.
Routine testing for T. gondii in the investigation of intrauterine death
should also be reevaluated owing to the low yield of positive results.
P2090 Testing for toxoplasmic immunity − are we prepared?
C. Costache, L.M. Junie °, Z. Coroiu on behalf of the ESGP
The onset of screening programs for toxoplasmic infection in women of
fertile age was preceded by studies for the appreciation of contamination
level in the area in all countries unrolling this type of follow-up. Lobby
among women of fertile age for performing this analysis is carried out
in our country by doctors as there is no national program for this.
Methods: Prospective epidemiologic (questionnaire) and serologic study
over 280 mothers selected from obstetrics departments, during 2006–
2009, (15.896 births). Inclusion criterion was birth of a child with
abnormalities clinically possible to be of toxoplasmic origin.
Results: Ig G positive serology in mothers was higher in 21−30 years
old interval (34.3%). Relation between positive/negative serology and
living area showed statistic signiﬁcant association (p< 0.05) between
positive serology for T. gondii and rural area. The abortion and still
birth rate were 32% in this group. Of all 280 mothers which ﬁlled
the questionnaire, 77.14%, CI=[66.7%-87.3%] of them express their
availability to participate in future testing within a national free screening
program, while 22.85%, CI=[12.9%-33.4%] of them do not want to
participate, 20%, CI=[11.38%-31.27%] of them being within 18−25
years of age interval. Only 12.85%, IC = [6.1%-23.3%] of mothers have
had a test for T. gondii infection while 87.14%, IC= [76.7%-93.9%] of
them were never checked for this infection. Conﬁrmation of congenital
toxoplasmosis diagnostic in 8.6% of neonates was due to Ig. A testing
while speciﬁc antitoxoplasmic Ig.M was negative.
Conclusions:
1. There is statistic signiﬁcant association between rural area and
contamination with T. gondii during fertile age.
2. A small number of women were followed for the appreciation of
antitoxoplasmic immunity, a statistically larger percentage did not
undergo this procedure ever, even if they had given birth to children
with congenital abnormalities or have had pregnancy loss (abortion)
in antecedent.
3. A quarter of mothers do not want to be tested, a ﬁfth of this group
being very young females (18−25 years of age).
4. Ig.A testing in serologic screening for congenital toxoplasmosis of
neonates is important due to Ig.M negative serology.
Percentage of women according to their attitude to future testing.
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P2091 Type II Toxoplasma gondii strains from human congenital
toxoplasmosis: differential phenotypic characteristics in vitro
M.P. Brenier-Pinchart, R.L. Bertini, D. Maubon, H. Pelloux °
(Grenoble, FR)
Objective: More than 80% of human congenital toxoplasmosis (CT)
is attributable to Toxoplasma strains belonging to type II lineage in
France, while three main lineages have been described in Europe.
Our original hypothesis is that type II strains can present speciﬁc
phenotypic characteristics that differ from one isolate to another which
could partially explain the varying degrees of severity observed during
toxoplasmosis. The objective was to study the in vitro phenotype of type
II strains isolated from different clinical forms of CT.
Methods: Four T. gondii strains of type II from the French Biological
Toxoplasma Resource Centre (BRC Toxoplasma) originated from
different forms of CT and two laboratory reference strains were
investigated. Three key steps of the parasite life cycle were compared
in human ﬁbroblast model (HFF): i) cell invasion was determined by
microscopy 1 h after infection, ii) Toxoplasma replication by measuring
3H-uracil uptake 24 h after infection and iii) cyst formation was evaluated
by the number of cysts counted after immunoﬂuorescence staining using
the cyst-speciﬁc BSR4 antibody 7 days after infection (±IFN-g).
Results: In vitro, the invasion rate was signiﬁcantly higher for one
strain isolated from symptomatic CT (retinochoroiditis) than for the
reference type II strain (PRU) and for the three other strains. The
parasite multiplication level was not signiﬁcantly different among the
four strains compared to this same reference strain. Interestingly, the
capacity to form cysts was not equivalent among these strains: the two
strains responsible for asymptomatic infection formed signiﬁcantly fewer
cysts than the two strains isolated from symptomatic toxoplasmosis (table
1). The susceptibility of the four strains to IFN-g did not differ.
Conclusions: The virulence of the three main clonal lineages of T. gondii
has been described in the mouse model but a close relationship between
the genetic structure and the human clinical expression has not yet been
demonstrated. In this study, we show for the ﬁrst time that the phenotypic
patterns of type II strains differ in a human in vitro model: strains that
have led to an asymptomatic infection form fewer cysts than type II
strains isolated from symptomatic infection. This result underlines the
interest to identify the genetic and/or epigenetic variations responsible for
these phenotypic differences and the predictive markers of symptomatic
and serious congenital infections.
Table I. Characteristics of the type II T. gondii strains
Strain Genotype Date of
maternal
infectiona
Clinical form of congenital
toxoplasmosis (CT)
Number of cysts
(Standard Error)
BRC TgH20018A II 36 WA Symptomatic CT, retinochoroiditis 25±12.6
BRC TgH20002A II 34 WA Symptomatic CT, encephalitis,
retinochoroiditis, medical abortion
26.6±18.7
BRC TgH38034A II 36 WA Asymptomatic CT 7.4±1.1∗
BRC TgH20017A II 36 WA Asymptomatic CT 16±10.3∗
PRU strain II / Laboratory reference strain 27±12.5
RH strain I / Laboratory reference strain /
aWeeks of amenorrhoea (WA); *p< 0.05 from type II PRU based on analysis of variance (ANOVA).
P2092 Congenital toxoplasmosis in France in 2007: ﬁrst results
from a national surveillance system
I. Villena, C. Delmas, T. Ancelle, H. Pelloux ° on behalf of the National
Reference Centre on Toxoplasmosis
Objectives: Toxoplasmosis is generally asymptomatic when infection
is acquired in immunocompetent humans. However, transplacental
transmission of Toxoplasma gondii may lead to severe congenital
infection. The national prevention programme for congenital toxoplas-
mosis in France has been in place since 1978; however no reliable
data was available regarding the annual number of cases or the
severity of infection. In 2006, French National Institute of Public
Health Surveillance and the National Reference Centre (NRC) for
Toxoplasmosis recommended a laboratory-based surveillance system, in
order to estimate the perinatal burden of this infection and follow the
impact of the national prevention programme. A surveillance system
(“Toxosurv” network with laboratories carrying out the diagnosis) was
implemented in 2007.
Methods: A case of congenital toxoplasmosis was deﬁned as a foetus, a
newborn or a child less than one year in whom was detected the presence
of at least one of the following elements: T. gondii in body tissues or
ﬂuids, synthesis of speciﬁc IgM or IgA antibodies, synthesis of speciﬁc
IgG antibodies within the ﬁrst 12 months of life, persistently positive
IgG until one year of age. Cases diagnosed between the 1st January and
the 31st December 2007 in France were declared to the NRC among the
process of notiﬁcation described in 2008.
Results: During 2007, 31 laboratories declared at least one congenital
case to the surveillance system with a total of 272 cases notiﬁed. Eleven
terminations of pregnancy were reported. Among live born infants, 206
were asymptomatic and 28 were symptomatic. Since 818 700 births
occurred in 2007, the overall prevalence of congenital toxoplasmosis
observed was 3.3 per 10 000 births, the rate of symptomatic congenital
toxoplasmosis could be estimated at 0.34 cases per 10000 births.
Conclusion: The surveillance system for congenital toxoplasmosis cases
based on the “Toxosurv” network appears to be effective and provides
for the ﬁrst time reliable French data on congenital toxoplasmosis.
This surveillance needs to continue to appreciate the overall prevalence
of congenital toxoplasmosis. The toxoplasmosis seroprevalence among
women of childbearing age is regularly estimated in France through
National Perinatal Surveys based on cross-sectional surveys of birth on
a national level during a week. With these two indicators it will be
possible to perform economical analyses for the development of different
strategies of screening.
P2093 Decreased seroprevalence and age-speciﬁc risk factors for
toxoplasmosis in the Netherlands between 1995–1996 and
2006–2007
L.M. Kortbeek °, A. Hofhuis, C. Nijhuis, Y. van Duynhoven, L. Mollema,
F. van der Klis, W. van Pelt (Bilthoven, NL)
Objective: To estimate the toxoplasmosis seroprevalence and determine
risk factors for toxoplasmosis in the Netherlands.
Methods: Sera from a nation wide serum bank of the general population
of the Netherlands were tested with an in house Toxoplasma IgG ELISA,
using the same methods as in a previous study performed in 1995/1996
(ref Kortbeek 2004). Additionally, participants returned questionnaires
including questions on food habits and contacts with young cats.
Results: Sera and data of 5541 participants were available for analysis.
The overall seroprevalence showed a marked decrease to 26.0%, as
compared to 40.5% in 1995/1996. Among women of reproductive age,
the seroprevalence decreased from 35.2% in 1995/1996 to 18.5% in
2006/2007. In participants aged 20 and older, Toxoplasma seropositivity
was associated with living in the Northwest, living in urban areas, low
educational level, consumption of raw pork, keeping a cat, and not having
professional contact with clients or patients. For younger participants,
risk factors were keeping sheep or cattle, consumption of raw unwashed
vegetables and putting sand in the mouth.
Conclusion: The seroprevalence of toxoplasmosis decreased in the
Netherlands. The majority of pregnant women is susceptible to
primary infection with Toxoplasma gondii and therefore of congenital
toxoplasmosis. There is a regional difference in seroprevalence in adults
that cannot be explained. Consumption of raw or undercooked pork meat
is a risk factor as is contact with cats, but not with young cats.
Reference(s)
[1] Kortbeek LM, De Melker HE, Veldhuijzen IK, Conyn-Van Spaen-
donck MA. Population-based Toxoplasma seroprevalence study in
The Netherlands. Epidemiol Infect. 2004; 132(5): 839−45.
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P2094 In vitro effects of ivermectin and sulphadiazine on
Toxoplasma gondii
M. Bilgin, T. Yildirim, M. Hokelek ° (Samsun, Amasya, TR)
Objectives: Toxoplasmosis is an infection disease caused by the
obligate intracellular parasite Toxoplasma gondii occur worldwide.
Currently, the most effective treatment for both congenital and acquired
toxoplasmosis is the combination of pyrimethamine-sulphadiazine. The
aim of this study was to investigate in vitro activities of ivermectin and
sulphadiazine, against T. gondii RH strain on Hep-2 epithelial cells.
Methods: In this study, Hep-2 cells in tissue culture plates were infected
with the tachyzoites isolated from peritoneal ﬂuid of mice infected
with T. gondii. Subsequently, ivermectin and sulphadiazine were added
and their inhibitory activities were assessed after 24, 48 and 72 hours
incubations using inverted microscopy and ELISA. The toxicities of
drugs for Hep-2 cells were also determined with NRUD assay.
Results: Ivermectin was found to have signiﬁcant inhibitory activity
against tachyzoites after 48 h of incubation at the concentration of
5 and 2.5 microgram/ml (P< 0.01) and higher concentrations. The
50% inhibitory concentrations (IC50) of ivermectin and sulphadiazine
were found 0.27 microgram/ml and 7.3 microgram/ml after 48 h of
exposure, respectively. None of the concentrations tested for each drugs
demonstrated toxicity to Hep-2 cells after 72 h of incubation.
Conclusion: Our results indicated that ivermectin signiﬁcantly inhibited
replication of the tachyzoites of T. gondii RH strain. Further studies are
needed to combination of ivermectin with other drugs and animal model
for toxoplasmosis treatment.
Sexually-transmitted and other
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P2095 Intraprostatic Trichomonas vaginalis might be implicated
in the inﬂammatory pathogenesis of benign prostatic
hyperplasia
D. Mitteregger °, S. Aberle, A. Makristathis, J. Walochnik, W. Brozek,
M. Marberger, G. Kramer (Vienna, AT)
Objectives: Benign prostatic hyperplasia (BPH) is a progressive disease
originating as small nodular proliferations as early as the fourth
decade. Forty percent of men in their 70s have developed nodules
of large mass producing obstructive symptoms which may progress
to acute urinary retention requiring prostatic surgery. Chronic tissue
inﬂammation, invariably present in BPH tissue, has been causally
linked to prostate growth and disease progression. The etiology of
chronic inﬂammation is, despite suggestions of autoimmunity, currently
unknown. In search of a possible infectious etiology, we investigated the
presence of microorganisms in BPH tissue.
Methods: Transurethrally resected samples from 86 patients (mean age
69±8.3 years) were investigated for Trichomonas vaginalis by PCR
and culture. Proportions of the samples were simultaneously examined
for bacteria by culture and broad-spectrum PCR, for fungi by culture,
broad-spectrum and multiplex PCR, and for viruses by organism-speciﬁc
PCR assays. To exclude urinary infection, urine from all patients was
investigated for bacteria and fungi by culture. Type and density of
leukocytic tissue inﬁltration was assessed by immunohistochemistry
of cryo-sectioned BPH tissue. Several clinical parameters and the
characteristics of the inﬁltrate were compared with microbiological
results.
Results: Trichomonas vaginalis was detected by PCR in 29/86 (33.7%)
tissue samples. Various bacteria were found in 8/55 (14.6%) tissue
samples, while fungi were not detected (0/55). Parvovirus B19 and
BK virus were identiﬁed in 1/17 tissue samples, respectively, and JC
virus in 2/17. Trichomonas vaginalis in BPH tissue correlated with the
presence of a chronic B-lymphocytic inﬁltrate (p< 0.01) and elevated
blood monocyte counts (p< 0.01).
Conclusions: The bacterial detections in BPH tissue may represent
true infections but it remains difﬁcult to interpret these ﬁndings since
different species were involved. The presence of the identiﬁed viral
species does not seem to be relevant compared with their general
seroprevalence. However, the unexpectedly high detection rate of
Trichomonas vaginalis in BPH tissue correlating with local and systemic
signs of inﬂammation suggests an implication of that organism in the
pathogenesis of BPH. The high prevalence of Trichomonas vaginalis in
this elderly study population might point towards a yet unrecognized
chronic course of male trichomoniasis.
Authors S. Aberle, A. Makristathis and J. Walochnik contributed equally.
P2096 Congenital syphilis surveillance
A. Marangoni °, A. Moroni, E. Tridapalli, M.G. Capretti, G. Faldella,
S. Accardo, R. Cevenini (Bologna, IT)
Objectives: Congenital syphilis (CS) is mainly a consequence of the
lack of antenatal care and control of sexually transmitted infections. The
bedrock of the prevention of CS is syphilis diagnosis by serological
screening during pregnancy. Current Italian guidelines suggest that all
the pregnant women should be tested in the ﬁrst trimester. Due to the
frequently absence of speciﬁc signs of infection at birth, Laboratory tests
are often the only method for a correct CS diagnosis.
The aim of this study was to evaluate the usefulness of T. pallidum
IgM Western Blot (WB) and Polymerase Chain Reaction (PCR) on
cerebrospinal ﬂuid (CSF) as an aid in the diagnosis of CS during
a prospective surveillance study carried out at St. Orsola Hospital in
Bologna, Italy, from January 2008 through March 2009.
Methods: All pregnant women during pregnancy and at delivery were
screened for syphilis by ARCHITECT® Syphilis TP, Abbott. Positive
samples were further analysed by TPHA and RPR tests, Radim. An
in-house Western Blot (WB) was also performed.
Infants born to syphilis seropositive mothers were enrolled in a
prospective follow up. At birth, tests were performed (including IgM
WB). Infants with positive RPR tests at birth born to mothers not
adequately treated received also a long bone radiograph as well
as a complete CSF analysis, including VDRL (Siemens Healthcare
Diagnostics) and PCR testing.
All seroreactive infants received careful follow up examinations and
serological testing at 0, 3, 6, 9, 12 months or until the tests became
negative.
Results: In this study, positive syphilis serology was noted in 21 pregnant
women delivering in our hospital. Four women had never been adequately
treated, and two out these four women gave birth to infected newborns.
Both the infants had positive IgM WB results on serum samples and
also positive PCR and VDRL results on CSF specimens. One baby
had characteristic long bone lesions at X-ray examination and bullous
eruptions on palms and soles.
Conclusions: These observations conﬁrmed that antenatal syphilis
screening facilitates treatment during pregnancy and offsets vertical
transmission; moreover, the use of IgMWB and careful CSF examination
allowed the identiﬁcation and treatment of high risk newborns.
P2097 Large proportion of patients with positive darkﬁeld
microscopy samples also have positive syphilis serology
E. Muldoon °, S. Squance, M. Kelleher, G. Courtney, F. Lyons,
C. Bergin, F. Mulcahy, B. Crowley (Dublin, IE)
Background: The diagnosis of primary syphilis can be problematic.
Darkﬁeld microscopy requires expertise both in obtaining the specimen
for analysis and in making the diagnosis. Sensitivity of darkﬁeld
microscopy approaches 80%, however it may not be available in all
centres, necessitating the reliance on other methods of diagnosis. There
has been a recent increase in syphilis diagnoses in our centre.
Methods: All patients who had a specimen taken for darkﬁeld
microscopy from 2007 to March 2009 were identiﬁed. Data was collected
on the site the specimen was obtained from, the result of the examination
by darkﬁeld microscopy and the results of syphilis serology taken on the
same day and any subsequent samples sent for syphilis serology. All
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statistical data was performed using SPSS 17.0 commercially available
software.
Results: 66 samples were collected for darkﬁeld microscopy from
patients with clinically suspected primary syphilis. 4 were either
incorrectly labelled or unsuitable for analysis and were excluded. Of
the remaining 62 samples, 58 (93.5%) were taken from men and the
mean age of patients was 36.5 year (range 19−63, median 35.5 years).
14 (22.6%) samples were positive. Of the 14 patients that had a positive
darkﬁeld sample, 12 (85.7%) also had a positive EIA on the same day,
all of whom had a positive rapid plasma reagin (RPR) titre. All 12 of
these patients had a positive syphilis immunoglobulin M (IgM). Of the
2 patients with negative syphilis serology, 1 patient had a positive RPR
and IgM 4 weeks after initial presentation and the other patient remained
seronegative.
Conclusion: This series demonstrates high degree of correlation between
a positive darkﬁeld microscopy examination and syphilis serology. This
is in contrast to previous reports that syphilis serology may several weeks
to months to become positive after appearance of a primary chancre.
This may give solace to physicians who do not have readily available
darkﬁeld microscopy facilities and who rely in part on syphilis serology
in the diagnosis of primary syphilis.
P2098 Community-acquired Staphylococcus saprophyticus urinary
tract infections
C. Marne, N. Baez, A. Borque, M. Arias, A. Servera, M.J. Revillo °
(Zaragoza, ES)
Objectives: Staphylococcus saprophyticus is a coagulase-negative
species with urinary tract pathogenic role, causing cistitis mainly in
female patients. It has been associated with rectal, vaginal and urethral
colonization, hormonal changes during menstruation, sexual activity,
use of spermicides and Candida infection. Main virulence factors are
extracellular slime production, adherence to urothelial cells and urease
production. The aim of the study is the update of microbiological and
epidemiological characteristics of Staphylococcus saprophyticus urinary
tract infections.
Methods: Over an eleven year-period (1998–2008), a total of 333524
urine specimens from both hospitalized and outpatients from an area
of circa 400000 inhabitants, were cultured by standard methods.
Identiﬁcation and antimicrobial susceptibility were performed by
authomated microdilution system.
Results: In our study 255962 (76.7%) urocultures were negative or
contaminated and 77562 (23.3%) were positive for bacteria or yeasts.
S. saprophyticus was isolated from 368 (0.5%) positive urocultures
corresponding to 356 patients. Represent 16.4% of all our coagulase-
negative staphylococci urine isolates. Sex distribution was 92.4% women
(range 8−88 years) and 7.6% men (range 10−89 years). In both sexes
11 patients were under 15 years.
Only one patient had recurrent infection by this species with two
episodes.
Autumn was the seasonal period with more cases.
Percentages of susceptibility to antibiotics used for uncomplicated
urinary infection treatment in outpatients was: clotrimazole 99%,
ciproﬂoxacin 95%, nitrofurantoin 99%, fosfomycin 38%, cefuroxime
64% and amoxicillin–clavulanic acid 56%.
Conclusions:
1. S. saprophyticus was isolated almost exclusively from female patients
and half of them were under 30 years.
2. A small percentage were men and and most over 50 years.
3. Infection by this species is exceptional in pedriatric patients.
4. Frequently S. saprophyticus clumping factor card test results cannot
be interpreted due to aglutination with both positive and negative
reagents.
5. Infections can be considered community-acquired.
6. blactams and fosfomycin should not be used empirically.
7. Quinolones and clotrimazole showed good activity.
8. Due to the high effectiveness of nitrofurantoin against both
S. saprophyticus and E. coli, it must be considered in empirical
treatment for uncomplicated urinary tract infections in young women.
P2099 Current state of diagnostics and management of bacterial
sexually transmitted diseases in Russia: results of
multicentre study
Y.A. Belkova, O.Y. Aleksandrova, B.V. Berezhanskiy, E.N. Bochanova,
V.V. Chebotarev, I.L. Chechula, E.P. Cigankova, A. Dekhnich,
V.V. Evstaﬁev, A.V. Grinev, E.V. Eliseeva, E.A. Ortenberg, A. Savicheva,
S.V. Sekhin, I.A. Toropova, R. Kozlov ° (Smolensk, Ekaterinburg,
Moscow, Krasnoyarsk, Stavropol, Krasnodar, Vladivostok, Tyumen,
St. Petersburg, Yakutsk, RU)
Objectives: To reveal the main problems in current practice of
management of bacterial sexually transmitted diseases (STDs) in Russia.
Methods: A multicenter retrospective study was conducted in 10 cities
of Russia. Clinical records of patients treated for bacterial STDs during
one year period were collected.
Results: The data on 1250 patients (61% male, 39% female, mean
age 28.8±9.2) with early syphilis (n = 341), uncomplicated gonococcal
(n = 309), chlamydial (n = 310), mycoplasmic (n = 137) and ureaplasmic
(n = 153) infection were analysed. We discovered wide use of outdated
low informative methods in diagnostics of STDs which can result in
considerable underestimation of its prevalence. Thus the main methods
to diagnose syphilis were microprecipitation (81.5%) and complement
ﬁxation tests (13.3%). Furthermore in 81% of patients syphilis was
diagnosed by microprecipitation alone and in 12.9% by combination
of these tests. The most common method to diagnose gonococcal
infection was methylene blue stain and/or Gram’s stain microscopy
(82.5%). For 80.7% of patients it was the only test performed.
Culture was done in 18.7% of patients with susceptibility testing only
in 2.3% of cases. Polimerase chain reaction and culture test were
used to diagnose infections caused by intracellular pathogens only
in 37.1% and 14.8% of cases, whereas low informative microscopy,
direct immunoﬂuorescence test and ELISA were used unjustiﬁably often
(21.5%, 13.4% and 13.3%). The most common treatment problems
were administration of inappropriate antibacterial agents and higher then
necessary course doses of antibiotics. Thus in about 30% of patients
gonorrhea was treated by inappropriate agents such as tetracyclines
(7.2%), aminoglycosides (6.6%), ﬂuoroquinolones (5.7%), macrolids
(5.4%) and penicillins (4.2%). Although the majority of syphilis cases
were treated by penicillins, 26.9% of patients received ceftriaxone.
Chlamydial, mycoplasmic and ureaplasmic infections were treated by
macrolids (56.3%), tetracyclines (28.6%) and ﬂuoroquinolones (15.1%),
but not all agents were chosen appropriately. Administered therapy went
in conﬂict with national guidelines in 28.2% of patients, international
guidelines − in 24.2%. Among correctly chosen agents only 24% and
11%, respectively, were used in recommended course doses (higher
dose − 69.1% and 83.7%, lower − 6.9% and 5.3%).
Conclusion: The current practice of STDs diagnostics and management
in Russia is in need of revision and correction.
P2100 Chlamydia trachomatis proctitis in Italian men who have
sex with men: report from an STD unit
R. Beretta, M. Fasolo, F. Mazza, A. Lombardi, G. Orlando ° (Milan, IT)
Objective: the burden of sexually transmitted infection (STIs) is
increasing all around the world; increasing rates of Syphilis, Gonorrhea,
sexually transmitted HAV, HSV and Chlamydia trachomatis infections
including proctitis (CTP) are observed in high risk patients in our unit.
Here we describe a CTP epidemic among men who have sex with men
(MSM) attending the STD unit of L Sacco University Hospital and the
correlation with other STIs.
Methods: patients attending the STD unit between Oct 07 and Feb
09 with proctitis were included in this analysis. The diagnosis of
CTP was achieved through a real time PCR (Chlamydia Tr Q PCR
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Alert − Nanogen) on anal swabs. All included pts underwent anoscopy,
anal swab for bacteria, HSV nucleic acid ampliﬁcation (HSV2 Q-PCR
Alert AmpliMix), TPPA and RPR for syphilis, HIV test and anal HPV
genotyping on liquid based cytology (InnoLipa).
Results: 13 pts aged 36.5y (range 26−45) with symptomatic proc-
titis/proctocolitis and tenesmus, rectal pain, bleeding, discharge and
ulceration or anal ﬁssure on ano/colonscopy, have been observed during
a 17 months period. Mean time to CTP diagnosis was 23 days (IQR
15−43 days); in 3 pts the diagnostic delay (3−6 months) was due to
a misdiagnosis of Crohn’s disease on histology. HIV co-infection was
observed in 12 pts (92.3%) most of whom (75%) off-HAART; primary
syphilis in 4 pts (33.3%), anal Mycoplasma hominis in 1 patient (8.33%).
Anal HPV infections (10/10 pts tested) were due to High Risk genotypes
(HPV-HR). Multiple HPV infections (from 3 to 6 genotypes) in 5 cases
(55.5%) were assessed in 9/10 pts. HPV-52 (55.5%), HPV-51 (44.4%),
HPV-16, HPV-35 and HPV-66 (33.3% each) were the most frequently
observed genotypes. Anal cytology, performed in 8 pts, showed anal
LSIL in 7 patients and HSIL in 1 patient. Histology on anoscopic guided
biopsies showed AIN-1 in 3 pts and AIN-2 in 1 patient. In 91.67% of the
cases multiple infections (2 pathogens) have been diagnosed in these
pts (infections/pt 3.25) (Fig 1).
Anal CT was treated with doxycycline 100mg BID for 7 days
or azitromycine 1 g/d for 3 days with clinical and microbiological
resolution.
Conclusions: among patients attending an STD Unit, MSM are at very
high risk of sexually transmitted infections. The high rate of multiple
infections reported in this work suggest the need for a complete STI
evaluation and for speciﬁc counseling programs after a diagnosis of an
STI in very high risk persons.
Figure 1. Patients with Chlamydia trachomatis proctitis and co-infection
with other STIs.
P2101 Prevalence and antibiotic susceptibility of Ureaplasma
urealyticum and Mycoplasma hominis in women with
vulvovaginitis
S. Baka °, I. Tsouma, A. Lykas, A. Panopoulou, I. Patikas, E. Logothetis,
E. Kouskouni (Athens, GR)
Objectives: Ureaplasma urealyticum (Uu) and Mycoplasma hominis
(Mh) are members of a unique group of microorganisms that are
commonly found in the vaginal ﬂora and have been associated with
a plethora of clinical manifestations on the genital system of women.
We aimed to study the prevalence and the susceptibility to antibiotics of
Uu and Mh isolated from the vaginal secretions in a group of women
with vulvovaginitis.
Methods: Vaginal samples from 1902 symptomatic women of repro-
ductive age presenting with signs and symptoms of vulvovaginitis to the
Outpatient Clinic of Aretaieion University Hospital from February 2007
to October 2009 were studied. For the isolation and susceptibility testing
of both mycoplasmas the commercial kitMycoplasma IST2 (bioMe´rieux,
France) was used. After inoculation onto the respective nutrient medium,
the samples were incubated at 36−37ºC for 48 h in aerobic conditions.
Results: Out of the 1902 samples Uu was isolated in 497 (26.1%)
samples while Mh in 42 (2.2%), always in association with Uu.
Only concentrations of >104 CFU/ml at 48 h were included as
positive samples in the study. As for the susceptibility testing to
antibiotics, doxycycline and tetracycline displayed the lowest percentages
of resistance (0.6% and 1.2%, respectively) as well as intermediate
susceptibility (0.2% and 1.4%, respectively) in the isolates studied.
Among the macrolides, the same percentages for azithromycin,
clarithromycin and erythromycin were 9.6, 11.0 and 12.4, respectively
(resistant) and 6.9, 1.8 and 4.4, respectively (intermediate susceptible). In
contrast, the genital mycoplasmas tested showed decreased susceptibility
to quinolones. Speciﬁcally, 33.4% and 6.9% of the mycoplasmas
were resistant to ciproﬂoxacin and oﬂoxacin, respectively, while the
intermediate susceptibility was 50.1 and 43.0%, respectively.
Conclusions: The isolates studied were highly resistant to quinolones,
probably due to the increased use in the last years. It is imperative to
stop the empirical treatment of genital mycoplasmas and to relay the
therapeutic approach on the results of the in vitro susceptibility testing
since nowadays, with the aid of commercially available systems, it is
just a simple laboratory procedure.
P2102 Molecular and serological evidence of the role of Chlamydia
trachomatis in miscarriage
D. Baud, G. Goy, K. Jaton-Ogay, M. Osterheld, S. Blumer, N. Borel,
A. Pospischil, F. Damnon, Y. Vial, G. Greub ° (Lausanne, Zurich, CH)
Objectives: Mostly asymptomatic, untreated Chlamydia trachomatis
infections are responsible for a large proportion of salpingitis, pelvic
inﬂammatory disease, ectopic pregnancy and infertility in women.
During pregnancy, C. trachomatis is a recognised agent of preterm labour
and premature rupture of membranes. However, its role on miscarriage
is unclear. We thus analysed patients with or without miscarriage for the
presence of C. trachomatis.
Methods: Three-hundred heighty six women were prospectively enrolled
at the Obstetrical ward of the University Hospital of Lausanne,
Switzerland. The “miscarriage” group (n = 125) included women
diagnosed with an acute episode of miscarriage. The “control” group
(n = 261) included women with an uneventful pregnancy and without
any previous history of miscarriage, stillbirth or preterm labour. All
sera were tested for IgG and IgA antibodies against C. trachomatis with
the Ridascreen Chlamydia IgG/IgA kit (R-biopharm) according to the
manufacturer’s instructions. Presence of C. trachomatis DNA in vaginal
swabs was investigated by real-time PCR targeting the cryptic plasmid, as
described previously (Jaton et al., 2006). Placenta were also investigated
by histology, and remain to be tested by PCR and immunohistochemistry.
Results: Anti-C. trachomatis IgG prevalence was higher in women from
the miscarriage group (15.2%) than the controls (7.3%, p = 0.018). This
association between miscarriage and anti-C. trachomatis IgG remained
signiﬁcant, even after adjustment for age, origin, education and number
of sexual partner (odds ratio 2.3, 95% conﬁdence interval 1.1−5.1).
Cervico-vginal C. trachomatis DNA was more often detected in patients
from the miscarriage group (n = 5, 4%) than from the control group
(n = 2, 0.7%, p = 0.026). All placentas were analysed for the presence of
inﬂammation. In the chorion, presence of deciduitis was present in 39.5%
and 26.2% of patients with and without C. trachomatis IgG positive
serology (p = 0.081).
Conclusion: In conclusion, our study showed the association between
miscarriage and evidence of C. trachomatis infection. C. trachomatis
screening should thus be proposed to all women experiencing a
miscarriage, and pre-conceptional screening could be considered to
potentially reduce the prevalence of this adverse pregnancy outcome.
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P2103 Re-emergence of infectious syphilis among homosexual men
and HIV co-infection in Spain, 2003–2008
X. Camino °, M. von Wichmann, H. Azkune, M. Goenaga, J. Iribarren,
F. Rodriguez-Arrondo, M. Bustinduy, J. Arrizabalaga (San Sebastian, ES)
Background: An increase in syphilis infections since the mid 1990s has
been documented, especially in homosexual men, in different European
and North-American cities.
Methods:Retrospectively reviewed all cases of early syphilis diagnosed
in a monograph consultation sexually transmitted diseases (STD)
between 2003 and 2008. We describe the characteristics of newly
diagnosed cases of syphilis.
Results: In that time period, a total of 76 early syphilis: 18 in 2003–
2005, 12 in 2006, 22 in 2007 and 24 in 2008. 26 (34.2%) of them
agreed with the diagnosis of HIV infection. 70 patients were men and
6 women. The mean age was 36.5 years. About 75% of diagnoses were
in homosexual patients and 25% of patients were immigrants. Only 5%
of patients were engaged in prostitution. The diagnosis was clinical in
34 patients and all had a score of RPR and FTA-abs/TPHA (+) with
quantitative VDRL (+). Predictive factors of HIV coinfection were age
>30 years (p: 0.004) and having a HIV positive partner (P: 0.042).
Conclusion: It is seen in the last two years a signiﬁcant increase in
cases of early syphilis, especially in homosexual patients. An important
group of them are simultaneously diagnosed early syphilis and HIV. This
problem should emphasize prevention campaigns and highlights the need
for consultation monograph of STIs.
Brucellosis, Q-fever, tetanus, rickettsiosis
P2104 Sero-epidemiology of Q fever in the Netherlands,
2006–2007, preceding a series of large outbreaks
D.W. Notermans °, B. Schimmer, M.G. Harms, J.H. Reimerink,
J. Bakker, P.M. Schneeberger, L. Mollema, P. Teunis, W. van Pelt,
Y. van Duynhoven (Bilthoven, Den Bosch, NL)
Objectives: The Netherlands were confronted with a series of large
outbreaks of Q fever starting in 2007 and increasing in size with over
2200 reported cases in 2009. Before 2007, Q fever was a rare disease
in the country, with on average 17 notiﬁed cases annually. Q fever is
asymptomatic in the majority of infected persons and might have been
missed in symptomatic patients as well before national awareness was
aroused by the outbreaks. Seroprevalence of Q fever and risk factors for
sero-positivity were investigated in samples taken prior to the outbreaks.
Methods: Serum and a questionnaire were obtained from a repre-
sentative sample of the Dutch population as part of the ‘PIENTER2
project’, a population-based study primarily focussed on evaluation of
the national vaccination programme, performed in 2006 and early 2007.
IgG phase 2 antibodies were measured with an ELISA (Serion). To
increase sensitivity, borderline results were considered positive. A subset
of ELISA-negative samples was also tested in IFA (Focus Diagnostics).
Information on age, ethnic origin and urbanization degree was available
for the total study population. Associations of seropositivity with
patient characteristics were studied with logistic regression analysis.
Seroprevalence was weighted by age and degree of urbanization.
Results: ELISA results were available for 5654 individuals. IgG phase 2
antibodies were detected in 85 samples, of which 47 had borderline
levels. In the IFA-tested subset of 504 ELISA-negative samples, 6 (1.2%)
had low-level IgG phase 2 titres ranging from 1:32 to 1:128.
Overall weighted seroprevalence based on ELISA results was 1.5%
(95%CI 1.2%-1.8%). Seropositivity increased with age from 0.4%
(95%CI 0.1−0.7%) in the 0−14 years age group to 2.3% (95%CI
1.4−3.1%) in the 60−79 years age group. Univariately, contact with farm
animals and being a Turkish or Moroccan immigrant (1st generation)
seem signiﬁcant risk factors. No signiﬁcant association was observed
for gender, region and degree of urbanisation.
Conclusion: Seroprevalence of Q fever in The Netherlands was very
low prior to recent outbreaks. The rate given should be considered
a maximum estimate as borderline results were considered positive.
Although municipalities included in the study sample were not at
the epicentre of the Q fever outbreak, surrounding municipalities did
not show a higher seroprevalence, supporting the hypothesis that the
Netherlands is confronted with a new emerging Q-fever problem since
2007.
P2105 Decreased health status of Q fever patients one year after
the ﬁrst Dutch outbreak: a case–control study
G.J. Limonard °, M.H. Nabuurs-Franssen, J.B. Peters, A. Horrevorts,
G. Weers-Pothoff, R. Besselink, J.H. Vercoulen, R. Dekhuijzen, C. Groot
(Nijmegen, ’s-Hertogenbosch, Herpen, Oss, NL)
Objectives: Q fever is a zoonosis caused by the obligate intracellular
bacterium Coxiella burnetii. The two long term complications after
primary infection are chronic Q fever in about 1% of patients, and a
chronic fatigue syndrome in 10 to 20%. However, the existence of a
protracted decreased health status after Q fever remains controversial.
The aim of the present study was to determine the health status of the
patients of the Q fever outbreak in the Netherlands in 2007, one year
after primary infection.
Methods: Health status of the patients from the 2007 Dutch Q fever
outbreak was compared to age-, sex- and geographically matched, and
Q fever seronegative controls. Health status of both patients and controls
was assessed with the Nijmegen Clinical Screening Instrument (NCSI).
Results: A total of 54 Q fever patients from the 2007 Herpen outbreak
provided thirty-four age and sex-matched controls from the same
neighbourhood. Eleven controls had positive Q fever serology and were
excluded. There were no differences in gender (61% vs 42% male), age
(53 vs 53 yrs) and comorbidity (41% vs 39%), all p> 0.05 between
patients and controls. Results on the subdomains of the NCSI are
provided in Figure 1. Overall quality of life was decreased in both
patients and controls, 59% vs. 39% (ns) respectively. However, Q fever
patients had abnormal fatigue scores (eg increased) compared to controls
(74% vs 48%, p< 0.05). Furthermore, clinically signiﬁcant fatigue levels
were present in 52% of patients vs. 26% in controls, p< 0.05. In
addition to the primary data analysis, we compared NCSI scores of
the seropositive controls who were excluded (n = 11) to the scores of
seronegative control subjects (n = 23). The NCSI scores of seropositive-
and seronegative controls were not statistically different in all 8 measured
sub-domains of health status (p> 0.05 for all sub-domains).
Conclusion: These data strongly support a sustained decrease in health
status in Q fever patients in the Netherlands, one year after primary
infection. With more than 3000 new Q fever patients in the last 2 years
in the setting of the ongoing Dutch Q fever epidemic, these are the
ﬁrst clinical data indicating a major long-term burden of the disease in
the years to come. Clinical expression of Q fever infection seems to
be necessary for the subsequent development of a long-term decreased
health status.
Figure 1. Percentages of clinically relevant scores for each sub-domain
of the NCSI for the patient and control group. *p< 0.05.
P2106 Evaluation of immune response in brucellosis
N. Aktug Demir, O. Ural °, U. Arslan, D. Findik (Konya, TR)
Objectives: Although all brucellosis patients are treated by the same
therapy protocol, while the greater part of patients get over the illness,
some become chronically ill and some have rare relapses. The reason for
this clinical variation is unknown. Cytokines are important mediators and
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there are some investigations into this subject. In the present study we
aimed to determine the alterations in cytokine levels during brucellosis
and their effects on the diagnosis of relapses.
Methods: Forty-two patients with brucellosis and 43 healhy controls
were evaluated in the study. Acute brucellosis was diagnosed according
to the results of STA tests and positive blood cultures besides clinical
symptoms. Serum samples were collected from the patients on the 1st
and 45th days of illness The patients were followed for one year and
had controls at three month intervals. If they had relapses serum samples
were taken at the time of the ralapse and after the second therapy. If there
were no relapses the serum samples were taken at the end of the ﬁrst
year. The cytokine levels (TNF-a, IFN-g, IL-2, IL-4, IL-6, IL-8, IL-10,
sIL-2R) of the samples were measured by the ELISA method according
to the manufacturer’s instructions.
Results: The mean serum levels of TNF-a, IFN-g, IL-2, IL-8, sIL-2R
were observed to be signiﬁcantly higher but the mean IL-4 levels
signiﬁcantly lower in acute brucellosis patients compared to the control
group. No signiﬁcant differences were found between the two groups
in terms of IL-6 and IL-10 mean levels. Also there were no signiﬁcant
differences among serum samples taken on the 1st day, on the 45th
day and on the 1st year of the illness in terms of TNF-a, IFN-g, IL-2,
IL-4, IL-6, IL-8, IL-10, sIL-2R mean levels. Relapses were observed
in 7 patients during the one year follow up. According to statistical
analysis the 1st day IL-2 and IL-6 mean levels were higher in patients
with relapses than patients without relapses (p = 0.027) but mean levels
of sIL-2R were lower. Mean levels of IL-6 on the 45th day increased in
patients with relapses.
Conclusion: Our results revealed that 1st day and 45th day IL-6 values
are useful tools to detect relapses and also can show the prognoses of the
illness. Another important thing is that, on the ﬁrst day if IL-2 and IL-6
levels are high and sIL-2R is low clinicians need to be careful about
relapses.
P2107 Brucellosis: a Tunisian experience
L. Ammari °, H. Ben Hamza, H. Tiouiri Benaissa, M. Zribi, B. Kilani,
C. Fendri, T. Ben Chaabane (Tunis, TN)
Brucellosis is a chronic granulomatous infection caused by intracellular
bacteria. It is an endemic disease in Mediterranean countries and Tunisia.
Brucellosis shows the involvement of many systems and it seems to be
responsible for the high incidence of relapse. The aim of this study is
to analyze the clinical, laboratory ﬁndings and therapeutic features in
patients with brucellosis.
Patient and Methods: We conducted a retrospective study of patients
who developed brucellosis between January 1986 and December 2008
and admitted in the department of infectious diseases of Rabta Hospital
in Tunis. The diagnosis was based on clinical ﬁndings compatible with
brucellosis, serological tests positive, and/or isolation of Brucella species
from blood, or other tissues.
Results: 117 cases were included. The mean age was 38 years (13−72
years) and sex ratio was 2.34. An occupational history relevant for
Brucella exposure was present in 58% of the cases and consumed
contaminated animal product was noted in 79% of cases. The mean
diagnostic delay was 37 days, much longer in focal brucellosis. Acute
brucellosis was predominant, in 66% of cases. The focal brucellosis
complications were seen in 31.5%: osteoarticular involvement (73%),
nervous system central (21.6%), infective endocarditis (1.7%). Chronic
brucellos occurs in 2.5% of cases. Clinical manifestations include non-
speciﬁc symptoms such as fever (100%), sweats (92%), arthralgia and
lower back pain (71%). All the patient had serological titre 1/160.
Overall, 37% of blood culture were positive. 98.5% of the patients were
cured by antibiotherapy included Doxycycline and rifampicin. Relapse
in follow-up period was observed in 2 patients.
Conclusion: Brucellosis is an infection with multiple presentations. Its
early diagnosis was mandatory to avoid severe complications.
P2108 Assessment of prognosis of tetanus and its related factors
among Albanian adults
A. Pilaca °, A. Ndreu, Z. Delia (Tirana, AL)
Objective: To assess the associated factors with prognosis of tetanus
among the adult population of Albania.
Methods: All reported cases of tetanus (N= 64) hospitalized in the
regional hospitals of Tirana (the Albanian capital), Shkodra (main district
in north Albania) and Korca (one of the main districts in Southeast
Albania) for the period 1984–2004. Four patients were excluded from
the analysis due to missing information on prognosis. Data on prognosis-
related factors included age, sex, incubation period, onset period, as well
as location and type of wounds. Multivariable-adjusted binary logistic
regression was used to asses the independent association of prognosis
(survival vs. death) with covariates.
Results: The overall case-fatality rate was 38.6%. It was higher among
older individuals (P< 0.01), and in those with a shorter incubation period
(<11 days; P< 0.01) and with infected wounds (P = 0.03). There was
no association, however, with location of wounds. Upon simultaneous
adjustment for all covariates, age (>50 years vs. <50 years) and a shorter
incubation period (<11 days vs. 11−20 days) were positively related to
case-fatality (OR= 3.4, 95%CI=1.23–5.13 and OR= 2.41, 95%CI=1.19–
4.37, respectively), whereas the association with infected wounds was not
statistically signiﬁcant any further (P = 0.13).
Conclusions: Age, incubation period and type of wound are important
factors related to prognosis of tetanus in Albanian adults. Health
care practitioners should actively seek information on prognostic
characteristics of patients with tetanus in order to institute effective and
prompt treatment of this disease.
P2109 Prevalence of Rickettsia helvetica in Ixodes ricinus ticks
from a recreational forest in Denmark
B. Kantsø °, C. Svendsen, P. Jensen, J. Vennestrøm, K. Krogfelt
(Copenhagen, DK)
Objective: To study the prevalence of Rickettsia in speciﬁc habitats in
a Danish recreational forest.
Methods: 704 ticks of the species Ixodes ricinus collected in 3 different
habitats were screened for Rickettsia DNA by a genus species-speciﬁc
real-time PCR.
Results: 4.7% (31/662) of the nymphs were positive for rickettsial
DNA, The infection rate was highest in May as compared to July,
August and October. Ecotone (forest clearing) had elevated prevalence
as compared to spruce or beech forests. Sequencing revealed only DNA
from Rickettsia helvetica
Conclusions: The ﬁndings in this study substantiate the previous
ﬁndings of R. helvetica in I. ricinus ticks from Denmark, a low-
prevalence country of rickettsiosis. Furthermore, it emphasizes that
rickettsiosis is a diagnosis to be considered along with that of borreliosis.
P2110 Targets for clinical diagnosis of Coxiella burnetii and
vaccine development identiﬁed by proteomics techniques
G. Flores-Ramirez °, R. Toman, L. Skultety (Bratislava, SK)
Objectives: Coxiella burnetti is an intracellular Gram negative bacterium
that causes Q fever in humans. Human infections are mainly acquired
via the respiratory route by inhalation of aerosols produced by infected
farm animals. The aim of the study is to identify candidate proteins for
diagnosing of C. burnetii using an immunoproteomic approach.
Methods: Whole cell extracts from C. burnetii phase II cells were
separated by two-dimensional electrophoresis (2-DE) and probed against
hyperimmune rabbit serum and sera of three patients with various form
of infection. Reactive proteins were matched to a 2-DE gel prepared in
parallel, trypsin digested and analyzed by liquid chromatography tandem
mass spectrometry (LC-ESI-MS/MS). To identify the respective proteins,
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the peptides were matched against databases. Bioinformatics tools were
applied to predict the possible functions of these proteins.
Results:More than twenty protein spots were identiﬁed that reacted with
the sera from patients infected with C. burnetii. Speciﬁc antigens have
been detected. The immunoreactive proteins belong to the groups of
chaperones/heat shock proteins, ribosomal proteins, metabolic enzymes,
transport proteins and hypothetical proteins.
Conclusions: Here we present our ﬁrst immunoproteomics study
of the C. burnetii proteins that may allow us to identify possible
candidates molecules for serodiagnosis of the infectious agent and
vaccine development against Q fever.
Imported infections: tropical and travel
medicine
P2111 Leishmania mixed infection in great gerbil population of
a hyperendemic focus of zoonotic cutaneous leishmaniasis
in Iran
A.A. Akhavan °, A. Khamesipour, M.R. Yaghoobi-Ershadi,
H. Mirhendi, M.H. Alimohammadian, Y. Rassi, N. Shareghi, R. Jafari,
M.H. Arandian, H. Abdoli, M. Ghanei, N. Jalali-Zand (Tehran, IR)
Objectives: Zoonotic cutaneous leishmaniasis, a neglected tropical
disease, is a major public health problem in some areas of the old
world. Leishmania major is widely distributed in various populations
of rodents in arid and savannah regions. The disease is endemic in many
rural districts of Iran, in 17 out of the 30 provinces. In the current study,
natural Leishmania infection rate and seasonal variation of the infection
in Rhombomys opimus population of a hyperendemic focus of ZCL in
Iran was investigated.
Methods: The investigation was conducted over a period of 24 months
from October 2006 to October 2008 in Borkhar and Sejzi rural districts,
15−35 km, northeast and east of Esfahan City, Esfahan Province, central
Iran, respectively. Regardless of having any obvious lesions, impression
smears were prepared from the ear lobes of the animals. Nested PCR
assay was used for detection and identiﬁcation of Leishmania species
and the results were conﬁrmed using PCR-RFLP.
Results: A total of 58 R. opimus, were captured and examined by two
diagnostic techniques, direct examination and nested PCR. Fourteen out
of 58 specimens (24.1%) were positive by microscopic examination and
34 (58.6%) by the nested PCR. In 29 samples which the amastigote was
not seen by through direct examination, the nested PCR showed positive
results, and every positive smear was also found positive by nested PCR.
Twenty six out of 58 (44.8%) of the gerbils were identiﬁed to be infected
only with L. turanica, and 1 (1.7%) with L. gerbilli. A mixed natural
infection with L. major and L. turanica was seen in 12.1% of the rodents.
Pure L. turanica infection was seen throughout the year whereas mixed
infection of L. major and L. turanica was seen in all seasons except
spring. The highest (88.2%) and lowest (22.2%) Leishmania infection
rate was observed in fall and spring respectively.
Conclusion: It is concluded that L. major, L. gerbilli and L. turanica
circulate in the population of R. opimus in central part of Iran.
Leishmania turanica was the dominant species in the population of great
gerbils. Infection with L. major alone was not seen in the population
of the gerbil. Leishmania major infection usually accompanied with
L. turanica in naturally infected gerbils with the highest rate in fall.
It is recommended that the role of L. turanica in the epidemiology and
transmission of ZCL should be revisited carefully.
P2113 Single Trypanosoma cruzi antigens are differentially
recognized by Chagas patients after benznidazol treatment
A. Ferna´ndez-Villegas °, M. Pinazo, C. Maran˜o´n, M. Thomas, E. Posada,
M. Segovia, J. Gasco´n, M.C. Lo´pez (Granada, Barcelona, Murcia, ES)
Objectives: The objective of this work was to set up a panel of T. cruzi
recombinant proteins which are differentially recognized by sera from
healthy donors and Chagas disease patients at different stages of the
disease. We have also explored the dynamics of humoral recognition
of these individual antigens after benznidazole treatment, looking for
singular recognition patterns, which could be correlated with a peculiar
progression of the disease.
Methods: In this study, KMP11, HSP70 PFR2, Tgp63 recombinant
proteins and whole soluble proteins of Trypanosoma cruzi were used
to detect antiparasite antibodies by ELISA. Sera from Chagasic patients
living in Spain who were at different stages of the disease (Imported
Chagas) were collected pre and post benznidazole treatment together to
sera from non-infected subjects coming from endemic areas as a control.
Results: The recognition of all the proteins analyzed in this study was
signiﬁcatively higher by sera from chagasic patients than those from
healthy donors. When data were analyzed regarding the stage of the
disease, it was observed that indeterminate, cardiac and chronic patients
with digestive symptoms signiﬁcatively recognized the KMP11, HSP70
and PFR2 antigens compared with healthy donors. The recognition level
of the recombinant proteins by sera from 6 healthy donors did not show
any differences along one year period as an indication of the long term
stability of the detected basal antibodies.
The chagasic patients showed a signiﬁcance decrease of KMP11, HSP70
and PFR2 recognition at 3 and 6 moths after benznidazol treatment.
When humoral response in chagasic patients was sorted regarding the
stage of the disease, a relevant reduction in the KMP11 antibody level
was only observed in patients at the indeterminate stage 6 months
post-treatment. Conversely, patients with cardiac symptoms showed a
statistically signiﬁcant decrease of the antibody level speciﬁc for PFR2
and HSP70 after 3 and 6 months post-treatment, respectively.
Conclusions: These results let us to the identiﬁcation of chagasic
patients and healthy donors using a panel of recombinant proteins, and
to establish speciﬁc recognition pattern after benznidazole treatment
depending of the stage of the disease.
P2114 Detection of dengue virus in lymphoid tissues of persons
with remote dengue infections
V. Nilaratanakul °, S. Thaivanich, K. Songcharoen, K. Arunyingmongkol,
R. Plongla, M. Sriprapun, W. Kulwichit (Bangkok, TH)
Objectives: Dengue virus is thought to cause only acute infection and
then complete recovery. But some of its peer ﬂaviviruses can persistently
reside in hosts and cause diseases. Almost all adults in our country have
been infected by dengue viruses, demonstrated by neutralizing antibody
assays. Due to its tropism to mononuclear leucocytes, we conduct a study
to ﬁnd evidence of dengue virus persistence in reticuloendothelial tissues
from adults without evidence of recent dengue infection.
Methods: We enrolled autopsied cases and patients whose indicated
surgery provided tissues (liver, spleen, bone marrow and/or lymph
nodes) requiring pathological examination. After completion of each
pathological report, a fraction of remaining parafﬁn-embedded tissue was
utilised for reverse transcription-polymerase chain reaction (RT-PCR) by
dengue-speciﬁc primers. To conﬁrm that there were no acute or recent
infections, paired sera were collected just before and 1−4 weeks after
surgery for anti-dengue IgM and IgG by standard ELISA. Demographic
data and history of recent febrile illnesses were also recorded.
Results: 2 autopsied cases and 57 surgical cases were enrolled. RT-PCR
was performed on 51 lymph nodes, 23 livers, 1 bone marrow and 2
spleens. Dengue genome was detected in 2 cases (table). Neither of
them had evidence of acute or recent infection by dengue-ELISA using
paired sera. On the other hand, there was one case of asymptomatic acute
dengue infection in a 81-year-old male patient whose lymph node from
extended gastrectomy for cancer at the cardia part of stomach contained
no dengue genome. Dengue IgM in his ﬁrst and second sera, one week
apart, was 6 and 94.
Conclusions: Severe dengue infection is believed to be signiﬁcantly
associated with antibody-dependent immune enhancement in secondary
infection. In a hyperendemic area like our country, most of clinical
dengue infections are secondary; yet, these are mostly either mild or
asymptomatic. Persistence of primary dengue virus genome, defective
or complete, may play an important interactive role in clinical severity
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and dengue pathogenesis when the patient has superimposed infection
by another serotype. Our ﬁndings may be the ﬁrst step into a new area
of dengue research.
Patients with dengue genome in tissues
No. Sex Age Diagnosis Tissue DENV-EISA in
paired sera
IgM IgG
1st 2nd 1st 2nd
1 M 47 Recurrent colonic cancer
with liver metastasis
Liver 12 14 12 11
2 M 70 Lower rectal cancer Lymph node 1 0 15 6
P2115 Prevalence of Dientamoeba fragilis in adults and children
in Denmark, tested by routine real-time PCR in patients
suspected of enteroparasitic disease
D. Ro¨ser °, C.R. Stensvold, H.V. Nielsen (Copenhagen, DK)
Objectives: In recent years, Dientamoeba fragilis has become increas-
ingly recognised as an entero-pathogenic parasite associated with various
gastrointestinal symptoms. Permanent staining of faeces ﬁxed with
e.g. sodium acetate-acetic acid-formalin (SAF) has been the standard
diagnostic method in laboratories testing speciﬁcally for D. fragilis.
Diagnosis based on PCR was introduced only recently, and is not
widely used as a routine method. The objective of this study was to
ascertain the prevalence of Dientamoeba fragilis in patients suspected of
enteroparasitic disease, assessed by real-time PCR analysis of genomic
DNA extracted directly from stool samples.
Methods: Since Aug. 2007, Statens Serum Institut has as the sole
laboratory in Denmark offered routine real-time PCR analysis for
intestinal protozoa (Taqman assay targeting the SSU rRNA gene) to
hospitals and general practitioners. The analysis is performed as either a
single request (SR) analysis or as part of a diagnostic package (DP) incl.
PCR for Cryptosporidium, Entamoeba dispar, Entamoeba histolytica
and Giardia duodenalis, on genomic DNA extracted directly from faeces.
Sampling period was Aug. 07 − Jun. 09.
Results: A total of 6802 PCR’s were performed in the study period, of
which 2102 (31%) were positive for D. fragilis. The DP-group (n = 4822)
showed a lower prevalence of positives (26%) than the SR-group (42%),
one suspected reason being a higher degree of treatment control tests in
the SR-group. In the DP-group, gender distribution among positives was
55% females and 45% males. In adults (aged >16 years) the prevalence
ranged from 12% (50+ years) to 21% (31−50 years). In children (age
0−15) the prevalence was markedly higher, rising from 9% in 0−1 year
olds, to 32% in 2−3-year-olds, and to 47% in 4−10-year-olds, hereafter
declining to 39% in 11−15-year-olds.
Conclusion: This study showed a higher overall prevalence of D. fragilis
using real-time PCR (26%), than previously shown using SAF-staining
(12%), however dissimilarity between the present and earlier study in
terms of age distribution and positive prevalence within age groups have
to be considered. Compared to age groups, we found a signiﬁcantly
higher (p< 0.001) prevalence in children aged 4−10 years, and a
signiﬁcantly higher (p< 0.001) prevalence in adults aged 31−50, with
parenthood being the suspected reason for this. In general, real-time
PCR proved a reliable and feasible method for detection of D. fragilis
in stool samples.
P2116 Rickettsia hoogstraalii-like organism in the soft tick,
Ornithodoros moubata
S.J. Cutler °, J. Nikitorowicz Buniak (London, UK)
Objectives: Ornithodoros moubata complex (Argasidae) ticks collected
from human dwellings in Tanzania carry a partially characterised
Rickettsia-like organism. Subsequently others have reported a rickettsial
organism present in soft ticks feeding on seabirds. As yet we are
uncertain as to the phylogenetic position of this organism or its relevance
as a potential cause of infection. This is a realistic possibility with the
species carried by O. moubata as these ticks primarily feed on humans.
Methods: Molecular characterisation of a Rickettsia-like organism in
145 pooled O. moubata tick samples from Tanzania was undertaken
using PCR ampliﬁcation and sequence analysis. O. moubata ticks
were imported under license, and total DNA extracted using DNAeasy
kits (Qiagen) and QiaCube robot. As preliminary data suggested
this Rickettsia-like species had greatest homology with R. akari and
R. australis, we screening samples using a real-time PCR’s with
speciﬁcity for OmpB or R. felis, and a genus speciﬁc assay based upon
the citrate synthase gene citrate synthase [CS] (gltA). Samples positive
upon screening were further tested using conventional PCR for genes
gltA; OmpA; and OmpB. Twenty six rat samples collected from the
tick-infested dwellings were similarly tested.
Results: Interestingly, complete concordance between screening assays
was not observed for tick samples, with 6 samples only detected by the
R. felis assay; 8 in only the CS PCR; and 4 in both assays. Only 4 of
the rat samples were positive with 4 from tail samples and 2 from each
of ear and blood samples. Only limited amplicons were available for
sequence analysis as a result of thier signiﬁcant sequence divergence.
Greatest sequence homology was found with R. hoogstraalii, a species
described in Carios capensis soft ticks recovered from seabirds, USA,
and from the hard tick Haemaphysalis sulcata, Croatia.
Conclusions: Signiﬁcance of this Rickettsia for human health is not fully
established, but exposure is high as these ticks infest human dwellings
with man serving as their principle maintenance host. Intriguingly,
R. felis has recently been reported from signiﬁcant numbers of febrile
patients in East Africa, possibly relating to the ﬁndings reported herein.
Even if this species is not signiﬁcant as a human pathogen, exposure to
this soft-tick Rickettsia appears signiﬁcant and thus might confound the
application of rickettsial diagnostics in African settings.
P2117 Detection of Dientamoeba fragilis: a comparison between
real-time polymerase chain reaction and conventional
diagnostic assays
A. Calderaro °, C. Gorrini, S. Montecchini, F. Gargiulo, N. Manca,
G. Dettori, C. Chezzi (Parma, Brescia, IT)
Objectives: The pathogenic role of Dientamoeba fragilis has been
controversial for a long time but it was recently reassessed because
of a large number of patients with D. fragilis infection (without other
enteropathogenic agents) reporting gastro-intestinal signs and symptoms
solved by a targeted therapy. The laboratory diagnosis of dientamoebiasis
is traditionally performed by microscopic examination after permanent
staining and/or culture. The fact that conventional diagnosis is time-
consuming and requires well-trained personnel led us to evaluate the
usefulness of a real-time PCR assay compared to the methods currently
used in our laboratory for the diagnosis of infection by D. fragilis.
Methods: Conventional diagnostic methods for the detection of
intestinal parasites currently used in our laboratory (microscopic
examination of fresh and concentrated faecal material and cultivation
in Robinson’s medium, followed by acridine orange staining when
structures resembling D. fragilis were observed) were performed on 988
faecal samples belonging to 508 patients with a clinical suspicion of
intestinal parasitosis in a period of 41 months. The DNA extracted from
the same samples was used in a previously described real-time PCR
assay targeting the 5.8S rRNA gene of D. fragilis [1].
Results: Conventional methods detected D. fragilis in 72 samples of 47
patients while real-time PCR revealed the presence of the protozoan in
189 samples of 107 patients (21% of the analyzed patients). In 60 of
these cases dientamoebiasis was diagnosed by real-time PCR alone.
Discussion: In our experience, the evaluated real-time PCR assay showed
a higher diagnostic sensitivity than microscopic examination and culture
which had underestimated the number of D. fragilis infections. This
molecular assay could be a rapid and effective tool in our laboratory
to be associated with conventional ones for an accurate diagnosis of
infection by D. fragilis in faecal samples belonging to patients presenting
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with signs and symptoms and/or risk factors for intestinal parasitoses,
taking into account that dientamoebiasis is suitable to be eradicated by
a targeted therapy.
Reference(s)
[1] Verweij et al. Mol Cell Probes 2007; 21: 400–404.
P2118 The diagnosis of giardiasis by a real-time polymerase chain
reaction assay as compared to conventional assays
A. Calderaro °, C. Gorrini, S. Montecchini, F. Gargiulo, N. Manca,
G. Dettori, C. Chezzi (Parma, Brescia, IT)
Objectives: Giardia intestinalis is a world-wide distributed parasitic
agent of gastroenteritis with a higher frequency in warm climate. As
giardiasis is one of the most frequent parasitoses in our area, the aim of
this study was the evaluation of the performance and of the applicability
of a real-time PCR assay in comparison with the combination of
conventional methods used in our laboratory for the diagnosis of the
infection by G. intestinalis.
Methods: The DNA from 800 faecal samples collected in a 3-year
period and belonging to 403 patients with a clinical suspicion of
intestinal parasitosis was used in a real-time PCR assay for the
detection of G. intestinalis [1]. The same samples were analyzed
for the presence of intestinal parasites by conventional methods
(microscopic examination from fresh and concentrated faecal material
and G. intestinalis and Cryptosporidium spp. speciﬁc antigen detection
by immunocromatographic and/or immunoﬂuorescence assays).
Results: G. intestinalis was detected in 178 samples of 98 patients by
conventional methods, while the real-time PCR assay revealed the DNA
of the protozoan in 26 additional samples. In particular in 13 cases the
diagnosis was possible only by using the molecular assay evaluated in
this study. The detection limit of the real-time PCR assay was 2 cysts
per reaction. As concerns the diagnostic performance, the real-time PCR
assay showed a sensitivity and a speciﬁcity both of 100% as compared to
conventional assays for the diagnosis of the infection by G. intestinalis.
Discussion: In our experience, the evaluated real-time PCR assay
demonstrated to be a speciﬁc and sensitive tool for the detection of
G. intestinal infection. This assay could be successfully associated to
the conventional methods for the diagnosis of intestinal parasitoses in
our laboratory, in order to perform an accurate diagnosis of giardiasis,
especially in groups of selected patients such as subjects presenting with
risk factors for faecal-oral infections including immigrants and adopted
children from developing countries and travellers returning from the
same areas [2].
Reference(s)
[1] Verweij JJ. et al. J Clin Microbiol 2004; 42:1220–1223.
[2] Calderaro A. et al. Diagn Microbiol Infect Dis 2009; In press.
P2119 International travel is a signiﬁcant risk factor for acquiring
zoonotic Salmonella bacteraemia
K. Koch °, B. Kristensen, H.M. Holt, S. Ethelberg, K. Mølbak,
H.C. Schønheyder (Aalborg, Aarhus, Odense, Copenhagen, DK)
Objectives: To determine the incidence of zoonotic Salmonella
bacteraemias associated with international travel and to estimate the
relative risk according to travel destination.
Methods: We conducted a 10-year population-based cohort study in
three Danish regions 1999–2008 (population 1.6 million). Patients with
zoonotic Salmonella bacteraemias were identiﬁed in registries in local
departments of clinical microbiology. The patients’ travel history was
obtained by chart review. Statens Serum Institut is notiﬁed of all
Salmonella isolates in Denmark and information on travel is provided
on a voluntary basis; the information is recorded in the national registry
of enteric bacterial pathogens. In 2008 Statens Serum Institut undertook
a telephone-based survey of the travel history for Salmonella patients
resident in two of the regions. We computed incidence rates and
estimated the relative risk of bacteraemia compared to gastroenteritis
in the subset of patients diagnosed 2004–2008. For each geographic
region we calculated the odds ratio (OR) adjusted for age and gender by
logistic regression.
Results: We identiﬁed a total of 311 incident cases of zoonotic
Salmonella bacteraemia and 6,236 cases of gastrointestinal Salmonella
infections. Seventy six (24.4%) patients with bacteraemia had a history
of international travel within the previous two weeks and no likely
source of exposure in Denmark. The overall incidence rate of travel-
related bacteraemia was 0.5/100.000 person-years; the incidence rate
was highest in the age group 15−24 years (0.8/100.000 person-years).
Seasonal peaks differed for travel-related and domestically acquired
cases: July-August versus September-October, respectively. Two hundred
and twenty ﬁve of 1089 (20.7%) patients with gastroenteritis interviewed
by telephone had a travel history. Information collected actively and
voluntarily was comparable with regard to the distribution of travel
destinations. We found the highest risk of bacteraemia for travelling
to Sub-Saharan Africa (OR 17.7 [95%CI: 6.4–49.0]) and South East
Asia, foremost Thailand (OR 3.7 [2.0−6.9]).
Conclusion: One in four cases of zoonotic Salmonella bacteraemia
was travel-related. The incidence was highest in the young age group.
The relative risk of presenting with bacteraemia was signiﬁcantly
associated with travel to Sub-Saharan Africa and South East Asia. When
giving advice to travellers the risk of invasive salmonellosis should be
considered.
P2120 Multiplex real-time PCR for the diagnosis of malaria:
correlation with microscopy and with clinical presentation
L. Dormond, K. Jaton-Ogay, S. De Valliere, B. Genton, J. Bille,
G. Greub ° (Lausanne, CH)
Objectives: Malaria is generally diagnosed by microscopy and rapid
antigen testing. Molecular methods become more widely used. Here,
we investigated the contribution of a quantitative multiplex PCR for
malaria diagnosis. We assessed i) the agreement between PCR-based
identiﬁcation and microscopy, ii) the correlation between the parasite
load determined by this quantitative PCR and by microscopy and iii) the
correlation of parasite load with clinical severity.
Methods: For 83 patients positive by microscopy, the ﬁrst EDTA-
blood sample was tested by PCR to conﬁrm smear-based species
identiﬁcation. Number of parasites/mL of blood was assessed daily
using both microscopy and PCR. Clinical criteria of severity were
retrieved from medical ﬁles and were compared with microscopy and
PCR quantiﬁcation.
Results: Among the 83 patients tested, 1 was positive by microscopy
only and 82 were positive by microscopy and PCR. Agreement between
microscopy and PCR for the identiﬁcation at the species level was of 89%
(73/82). The 9 discordant results corresponded to co-infections with 2 or
3 species and were attributed to inaccurate phenotypic identiﬁcation of
mixed cases. The number of parasites/mL of blood generally decreased
rapidly after treatment start with similar decay curves obtained with both
microscopy and PCR. Clinical severity was signiﬁcantly correlated with
high parasite load as determined by microscopy (p = 0.0163) and PCR
(p = 0.0264).
Conclusion: Our PCR proved especially useful to identify mixed
infections. The quantiﬁcation obtained by PCR closely correlated with
microscopy-based quantiﬁcation and with disease severity.
P2121 Haematological toxicity secondary to parenteral sodium
stibogluconate in the treatment of New World cutanous
leishmaniasis
E. Wise °, D. Lockwood (London, UK)
Objectives: Systemic treatment with the pentavalent antimonial sodium
stibogluconate is advocated for New World cutaneous leishmaniasis
(CL), both to induce healing of the primary lesion and to reduce the
risk of dissemination of the parasites to the nasopharyngeal mucosa.
Signiﬁcant toxicity is associated with the parenteral administration
of the drug. Despite previous case reports of thrombocytopaenia and
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lymphopaenia associated with parenteral use of the drug, this has
yet to be adequately investigated or documented. We determined the
haematological suppressive effects of intravenous sodium stibogluconate
in a case series of patients.
Methods: Since 2003, our institution has treated ~20 returned travellers
a year for New World CL. This is done on an outpatient basis, with
21−28 doses of daily sodium stibogluconate infusions. Monitoring of
treatment is in accordance with a protocol, using the Hospital for
Tropical Diseases’ CL ‘Integrated Care Pathway’. This stipulates that
a full blood count should be performed pre-treatment and on days 1,
4, 7, 10, 13, 17, 19, 21, 24 and 28 after treatment is commenced. We
performed a retrospective case analysis of 50 patients, randomly selected,
from those with New World CL treated with the ICP between 2003 and
2008. The patients’ platelet and lymphocyte counts during treatment were
compared to baseline values. The case notes were reviewed for clinical
events suggestive of disordered haemostasis or immunocompromise.
Results: There were no documented events of abnormal bleeding or
opportunistic infections in our patient group, either during treatment or
on follow-up. Repeated blood counts demonstrated a signiﬁcant fall in
both platelet and lymphocte counts after institution of therapy (P< 0.001,
using repeated measures analysis-of-variance). Inspection of the boxplots
showed that the fall in counts was relatively small (~30%). This occurred
within a few days of commencing treatment, with no further decline
throughout the course of infusions. The Figure shows the boxplot for
lymphocyte counts up to 19 days after treatment was started. In one
exceptional case, the platelet count fell to <50,000 per ml.
Conclusion: The use of intravenous sodium stibogluconate is unlikely
to cause clinically signiﬁcant suppression of either the platelet or
lymphocyte counts. The effect on these blood elements is described by
a quadratic function, with an early moderate fall and then no further
decline over the course of treatment.
P2122 Demographic factors associated with serum IgG
anti-lipopolysaccharide for Shigella sonnei antibodies
among 147 Thai volunteers
S. Chamnanchanunt ° (Bangkok, TH)
Shigella sonnei is the most common pathogen of dysentery diarrhea in
industrialized countries. The serum IgG anti-lipopolysaccharide (LPS)
indicates previous infectious with S. sonnei. There were several studies
about serum IgG anti-LPS in infected patient, but it had not been reported
in asymptomatic individual.
Objectives: The purpose of the study was to explore the association of
demographic factors and the titer of serum IgG anti-LPS for S. sonnei.
In order to identify high-risk group of previous infection for future
prevention in un-infected group are necessary.
Methods: This study was performed in Bangkok and its periphery,
Thailand, in 2007 to 2008. All Thai volunteers were screened for
challenging of shigella vaccine study, and shown the negative result of
culture and PCR in stool. Informed consent and complete demographic
questionnaires were done at the beginning. Serum samples were tested
for serum IgG anti-LPS for S. sonnei using ELISA.
Results: Of 147 Thai volunteers aged 20−39 years. The majority were
male (63.3%) and 38.8% had high titer (>800) of anti-LPS for S. sonnei.
The highest titer was in the age group of 31−35 years. The titer for
S. sonnei was signiﬁcantly high in female (p = 0.018) and farmer groups
(p = 0.01). Moreover, in 56 (38.1%) volunteers who live outside Bangkok,
the titer were statistically higher in older age (p = 0.048) and female
groups (p = 0.046). High titer of anti-LPS for S. sonnei was not associated
with education level, family income, birth location, and current location
in Bangkok, positive of HLA-B 27, anti-HIV, HBsAg, and anti-HCV
antibodies. Finally, the logistic regression showed that two independent
factors; older age group (31−35 years); OR= 7.2 (95%CI =2.3–22.5)
and female group; OR= 2.5 (95%CI= 1.1−5.8) were associated with
high titer of anti-LPS for S. sonnei.
Conclusions: These demographic data demonstrated that older age
(between 31−35 years) and female were associated with high titer for
IgG anti-LPS for S. sonnei in Thai volunteers. In addition, farmers were
high-risk to exposure to S. sonnei organism. Therefore, these groups may
need vaccine prophylaxis.
P2123 New anti-Leishmania agents: Cymbopongon citratus and
citral triggers induction on cell-cycle arrest and apoptosis
of L. infantum, L. tropica and L. major promastigotes
M. Machado °, G. Santoro, A. Dinis, M. Santos-Rosa, V. Alves,
L. Salgueiro, C. Cavaleiro, M.C. Sousa (Coimbra, PT; Rio de Janeiro,
BR)
Leishmaniasis treatment is limited and considering toxicity, side effects,
rate of relapse, cost, length and resistance to available drugs, more
attention should be given to the search of new chemotherapeutic options.
Extracts prepared by distillation of aromatic plants, the essential oils,
are a valuable research option for anti-Leishmania leads and drugs
as they offer a huge diversity of small hydrophobic molecules, most
of them accomplishing theoretical criteria’s of druglikeness: easily
diffuse across cell membranes and consequently gain advantage in
what concerns to interactions with intracellular targets. The present
work, study the effects of Cymbopongon citratus essential oil and citral
on L. infantum, L. tropica and L. major promastigotes. Essential oil
composition were analysed by GC and GC-MS. Antileishmanial activity
was performed on promastigotes culture of L. infantum, L. tropica and
L. major. The viability was assessed by tetrazolium-dye colorimetric
method and expressed as the concentration that inhibits parasite
viability by 50% (IC50). Effects on L. infantum promastigotes were
analyzed by ﬂow cytometry in order to assess mitochondrial transmem-
brane electrochemical gradient (JC-1), to analyze phosphatidylserine
externalization (annexin V–FITC, propidium iodide) and to evaluate
cell cycle (DNase-free RNase, PI). Morphological and ultrastructural
alterations were evaluated by light, scanning and transmission electron
microscopy. Cymbopongon citratus and citral revealed activity against
promastigotes growth with IC50 values ranging from 20 to 52 microg/ml.
Modiﬁcations on normal cell shape, mitochondrial swelling, increase
number of autophagosomal structures and cytoplasmatic vacuolization,
electrondensity lost and membrane disruption were ultra-structural
alterations occurred. Apoptosis/necrosis event, mitochondrial membrane
potential and cell cycle were signiﬁcantly different in treated cells.
The leishmanicidal activity was mediated via apoptosis as evidenced by
externalization of phosphatidylserine, loss of mitochondrial membrane
potential, and cell-cycle arrest at the G(0)/G(1) phase. Taken together,
these data indicate that Cymbopongon citratus and citral has promising
anti-leishmanial activity that is mediated by programmed cell death
(PCD). No toxicity was seen on mammalian cell lines. These results
provide new perspectives on the development of drugs with activities
against Leishmania.
This work was supported FCT POCI 2010/FEDER.
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P2124 Development of a novel multiplex real-time PCR method for
simultaneous detection and differentiation of Echinococcus
granulosus and Echinococcus multilocularis from cyst
samples
A. Caner °, T. Inceboz, M. Doskaya, A. Degirmenci, F. Celebi,
M. Korkmaz, Y. Guruz (Izmir, Erzurum, TR)
Objectives: Echinococcus granulosus and Echinococcus multilocularis
cause cystic echinococcosis (CE) and alveolar echinococcosis (AE) in
human, respectively. CE most frequently involves liver followed by lungs.
CE is endemic in sheep and cattle raising endemic areas in Mediterranean
region such as Turkey, South America, Australia, and New Zeland. AE
primarily develops in the liver and metastases to other organs. Humans
acquire the CE and AE infection by ingesting the eggs present in the
dog and fox feces, respectively. To date, eight genotypes (G1−3, G6−10)
and two species (G4−5) have been identiﬁed within the former species
E. granulosus. Worldwide, sheep E. granulosus strain (G1) is the most
frequent genotype detected in humans. Parasitologically sterile cysts
or cysts without any protoscoleces and rostellar hooklets may hamper
histological differentiation of E. granulosus from E. multilocularis by
pathologists. Currently, diagnostic PCR methods have been developed
to differentiate E. granulosus and E. multilocularis from cyst biopsy
and drainage materials. In the present study, a novel multiplex Real
Time PCR method has been developed for simultaneous detection and
differentiation of E. granulosus and E. multilocularis in a single reaction
tube.
Methods: DNA extraction material obtained from the cysts diagnosed
with echinococcosis (8 samples with CE, 12 samples with AE) formerly
by serological, histological and radiological tests was used during
multiplex real time PCR method. For the simultaneous detection and
differentiation of E. granulosus and E. multilocularis by multiplex
real time PCR in a single reaction, speciﬁc primers (EchiS, EchiA),
hybridization probes (granulosus-640, multilocularis-705) and an anchor
probe (Anchor Ech-FL) were designed from the E. granulosus
genotype 1 mitochondrion and E. multilocularis mitochondrion genes.
DNA extraction material obtained from the Taenia spp., Trichinella spp.,
Toxocara spp., and Hymenolepis nana were used as negative control.
Results and Conclusion: The analyses of the ampliﬁcation curves
obtained from multiplex Real Time PCR conﬁrmed echinococcosis in 20
cysts samples (sensitivity 100%) and differentiated E. granulosus from
E. multilocularis in approximately 40 minutes. Moreover, different picks
obtained from the melting curve analysis differentiated E. granulosus
from E. multilocularis as well. The multiplex Real Time PCR didn’t
show any ampliﬁcation curve in the negative samples (speciﬁcity 100%).
P2125 Evaluation of a new immunochromatographic assay for the
detection of antibodies against Echinococcus granulosus
J.M. Delgado °, F. Soriano, A. Camacho, J. Rojas, J. Mendoza, A. Rojas
(Santa Fe, ES)
Objectives: To evaluate a new immunochromatographic rapid test for
the detection of total antibodies against E. granulosus in human serum
samples.
Methods: A new immunochromatographic assay (ICA), VIRapid
Hydatidosis, has been designed for the qualitative detection of
anti-E. granulosus in both serum and plasma samples. The new test
is based on an HPLC-puriﬁed antigen, prepared from a 5/B enriched
fraction that was obtained from hydatid ﬂuid. This antigen was used
both adsorbed on the gold conjugate and the test line to produce a
lateral ﬂow ICA. A control line was included to check the correct
performance of the test. Results were visually read out after incubation
for 20 minutes at room temperature (see attached ﬁgure). The test
performance was evaluated with 276 human serum samples: 199
negative sera from Almerı´a and Jae´n (Spain) and 77 positive sera from
different geographical areas (Spain, Turkey and France). Two CE-marked
commercial assays for hydatidosis (an IgG ELISA and an indirect
haemagglutination) were used as references to characterize the sera.
Results: 73 out of 77 positive sera showed a distinct red test line in the
ICA. 198 out of 199 negative sera showed no reactivity on the test line
in the ICA. Sensitivity, speciﬁcity, positive predictive value and negative
predictive value of the new VIRapid Hydatidosis assay were 94.7%,
99.5%, 98.6% and 98.0%, respectively.
Conclusions: The new test has proved to be able to detect anti-hydatid
antibodies in human serum samples with good sensitivity and speciﬁcity
values. Since serological assays, together with imaging techniques, are
the most frequently used techniques for the diagnosis of hydatidosis, this
test offers a new diagnostic tool that brings together good performance
characteristics with the advantages of rapid tests (easy to run, easy to
interpret and easy to store). It suits the demand of both laboratories
from developed areas with low prevalence of the disease and those from
developing regions, with more limitations in their material equipment.
